PT	AU	BA	BE	GP	AF	BF	CA	TI	SO	SE	BS	LA	DT	CT	CY	CL	SP	HO	DE	ID	AB	C1	C3	RP	EM	RI	OI	FU	FP	FX	CR	NR	TC	Z9	U1	U2	PU	PI	PA	SN	EI	BN	J9	JI	PD	PY	VL	IS	PN	SU	SI	MA	BP	EP	AR	DI	DL	D2	EA	PG	WC	WE	SC	GA	PM	OA	HC	HP	DA	UT
J	Pillaire, MJ; Selves, J; Gordien, K; Gouraud, PA; Gentil, C; Danjoux, M; Do, C; Negre, V; Bieth, A; Guimbaud, R; Trouche, D; Pasero, P; Mechali, M; Hoffmann, JS; Cazaux, C				Pillaire, M-J; Selves, J.; Gordien, K.; Gouraud, P-A; Gentil, C.; Danjoux, M.; Do, C.; Negre, V.; Bieth, A.; Guimbaud, R.; Trouche, D.; Pasero, P.; Mechali, M.; Hoffmann, J-S; Cazaux, C.			A 'DNA replication' signature of progression and negative outcome in colorectal cancer	ONCOGENE			English	Article						DNA replication; S-phase checkpoint; colorectal cancer; genetic instability; prognosis markers	MINICHROMOSOME-MAINTENANCE PROTEIN-7; CHROMOSOMAL INSTABILITY; GENOMIC INSTABILITY; POLYMERASE-LAMBDA; REPAIR; OVEREXPRESSION; PROLIFERATION; MECHANISMS; GEMININ; DAMAGE	Colorectal cancer is one of the most frequent cancers worldwide. As the tumor-node-metastasis (TNM) staging classi. cation does not allow to predict the survival of patients in many cases, additional prognostic factors are needed to better forecast their outcome. Genes involved in DNA replication may represent an underexplored source of such prognostic markers. Indeed, accidents during DNA replication can trigger 'replicative stress', one of the main features of cancer from earlier stages onward. In this study, we assessed the expression of 47 'DNA replication' genes in primary tumors and adjacent normal tissues from a homogeneous series of 74 patients. We found that genes coding for translesional (TLS) DNA polymerases, initiation of DNA replication, S-phase signaling and protection of replication forks were significantly deregulated in tumors. We also observed that the overexpression of either the MCM7 helicase or the TLS DNA polymerase POLQ (if also associated with a concomitant overexpression of. ring genes) was significantly related to poor patient survival. Our data suggest the existence of a 'DNA replication signature' that might represent a source of new prognostic markers. Such a signature could help in understanding the molecular mechanisms underlying tumor progression in colorectal cancer patients. Oncogene (2010) 29, 876-887; doi:10.1038/onc.2009.378; published online 9 November 2009	[Pillaire, M-J; Bieth, A.; Hoffmann, J-S; Cazaux, C.] Univ Toulouse 3, IPBS, Genet Instabil & Canc Grp, Dept Biol Canc,CNRS,UMR5089, F-31300 Toulouse 4, Midi Pyrenees, France; [Selves, J.; Gordien, K.; Danjoux, M.; Guimbaud, R.] Univ Toulouse 3, INSERM, U563, F-31300 Toulouse 4, Midi Pyrenees, France; [Selves, J.; Gordien, K.; Danjoux, M.; Guimbaud, R.] Univ Toulouse 3, Dept Anatomopathol, F-31300 Toulouse 4, Midi Pyrenees, France; [Gouraud, P-A; Gentil, C.; Do, C.] Univ Toulouse 3, Serv Epidemiol, Fac Med, INSERM,U558, F-31300 Toulouse 4, Midi Pyrenees, France; [Negre, V.] INSERM, U868, aCGH GSO Canceropole Platform, Montpellier, France; [Trouche, D.] Univ Toulouse 3, Lab Cellular & Mol Biol Cell Proliferat Control, CNRS, UMR 5099, F-31300 Toulouse 4, Midi Pyrenees, France; [Pasero, P.; Mechali, M.] CNRS, UPR1142, Inst Human Genet, Montpellier, France	Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); Universite de Toulouse; Universite Toulouse III - Paul Sabatier; Universite de Toulouse; Universite Toulouse III - Paul Sabatier; Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Toulouse; Universite Toulouse III - Paul Sabatier; Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Toulouse; Universite Toulouse III - Paul Sabatier; Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Montpellier; Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); Universite de Toulouse; Universite Toulouse III - Paul Sabatier; Centre National de la Recherche Scientifique (CNRS); Universite de Montpellier	Cazaux, C (corresponding author), Univ Toulouse 3, IPBS, Genet Instabil & Canc Grp, Dept Biol Canc,CNRS,UMR5089, 205 Route Narbonne, F-31300 Toulouse 4, Midi Pyrenees, France.	cazaux@ipbs.fr	Gourraud, Pierre-Antoine FD/O-3024-2015; Selves, Janick/M-7719-2014; Hoffmann, Jean-Sebastien/O-9183-2014; GUIMBAUD, Rosine/M-7503-2014; Pillaire, Marie-Jeanne/P-1579-2014; Pasero, Philippe/O-2340-2018	Hoffmann, Jean-Sebastien/0000-0003-2222-354X; Pillaire, Marie-Jeanne/0000-0001-6866-7416; Pasero, Philippe/0000-0001-5891-0822; Gourraud, Pierre-Antoine/0000-0003-1131-9554; Trouche, Didier/0000-0003-1398-6481; do, catherine/0000-0002-9796-4345	INCa (Canceropole GSO)	INCa (Canceropole GSO)(Institut National du Cancer (INCA) France)	We thank the 'GSO/3R' Consortium for helpful discussions. We thank B Orsetti for CGH experiments (GSO aCGH platform, CRLCCMontpellier). We also acknowledge JJMaoret (Q-PCR platform, IFR31, Toulouse), as well as F Viala and S Mazeres (IPBS, Toulouse) for iconography and technical assistance, respectively. This study was supported by INCa (Canceropole GSO, grant ACI 'Genetic instability as a negative outcome' 2004/07 and 2008/09 to CC; grants to JS, DT and PP).	Albertella MR, 2005, DNA REPAIR, V4, P583, DOI 10.1016/j.dnarep.2005.01.005; Arentson E, 2002, ONCOGENE, V21, P1150, DOI 10.1038/sj.onc.1205175; Bartkova J, 2006, NATURE, V444, P633, DOI 10.1038/nature05268; Bertwistle D, 1998, CURR OPIN GENET DEV, V8, P14, DOI 10.1016/S0959-437X(98)80056-7; Betous R, 2009, MOL CARCINOGEN, V48, P369, DOI 10.1002/mc.20509; Braithwaite EK, 2005, J BIOL CHEM, V280, P18469, DOI 10.1074/jbc.M411864200; Brake T, 2003, CANCER RES, V63, P8173; Brondello JM, 2008, ONCOGENE, V27, P6093, DOI 10.1038/onc.2008.212; Capp JP, 2006, NUCLEIC ACIDS RES, V34, P2998, DOI 10.1093/nar/gkl380; Cortez D, 2004, P NATL ACAD SCI USA, V101, P10078, DOI 10.1073/pnas.0403410101; Davies RJ, 2002, LANCET, V359, P1917, DOI 10.1016/S0140-6736(02)08739-1; Eisenman RN, 2001, GENE DEV, V15, P2023, DOI 10.1101/gad928101; Facoetti A, 2006, ANTICANCER RES, V26, P3513; Facoetti A, 2006, ANTICANCER RES, V26, P1071; Gonzalez MA, 2004, J PATHOL, V204, P121, DOI 10.1002/path.1625; Green BM, 2006, MOL BIOL CELL, V17, P2401, DOI 10.1091/mbc.E05-11-1043; Hanawalt PC, 2007, MOL CELL, V28, P702, DOI 10.1016/j.molcel.2007.11.014; Honeycutt KA, 2006, ONCOGENE, V25, P4027, DOI 10.1038/sj.onc.1209435; Karakaidos P, 2004, AM J PATHOL, V165, P1351, DOI 10.1016/S0002-9440(10)63393-7; Kawamura K, 2004, INT J CANCER, V109, P9, DOI 10.1002/ijc.11666; Kunkel TA, 2003, CANCER CELL, V3, P105, DOI 10.1016/S1535-6108(03)00027-8; Lemee F, 2007, ONCOGENE, V26, P3387, DOI 10.1038/sj.onc.1210116; Li JQ, 2003, INT J ONCOL, V23, P1537; Lutzmann M, 2008, MOL CELL, V31, P190, DOI 10.1016/j.molcel.2008.07.001; Lutzmann M, 2006, EMBO J, V25, P5764, DOI 10.1038/sj.emboj.7601436; Maiorano D, 2005, CELL, V120, P315, DOI 10.1016/j.cell.2004.12.010; MARRA G, 1995, J NATL CANCER I, V87, P1114, DOI 10.1093/jnci/87.15.1114; Masutani C, 1999, NATURE, V399, P700, DOI 10.1038/21447; Mattera L, 2009, ONCOGENE, V28, P1506, DOI 10.1038/onc.2008.499; McElhinny SAN, 2005, MOL CELL, V19, P357, DOI 10.1016/j.molcel.2005.06.012; McIlwraith MJ, 2005, MOL CELL, V20, P783, DOI 10.1016/j.molcel.2005.10.001; Mitchell JR, 2003, CURR OPIN CELL BIOL, V15, P232, DOI 10.1016/S0955-0674(03)00018-8; Nishihara K, 2008, INT J ONCOL, V33, P245, DOI 10.3892/ijo_00000003; Ogi T, 2006, NAT CELL BIOL, V8, P640, DOI 10.1038/ncb1417; Padmanabhan V, 2004, J CLIN PATHOL, V57, P1057, DOI 10.1136/jcp.2004.016436; Pan QR, 2005, CANCER LETT, V217, P139, DOI 10.1016/j.canlet.2004.07.021; Rey L, 2009, MOL CELL BIOL, V29, P3344, DOI 10.1128/MCB.00115-09; SANCAR A, 1994, SCIENCE, V266, P1954, DOI 10.1126/science.7801120; Seki M, 2004, EMBO J, V23, P4484, DOI 10.1038/sj.emboj.7600424; Shrestha P, 2007, CANCER-AM CANCER SOC, V109, P949, DOI 10.1002/cncr.22474; Sobol RW, 1996, NATURE, V383, P457, DOI 10.1038/383457b0; Sobol RW, 1996, NATURE, V379, P848, DOI 10.1038/379848b0; Sobol RW, 1996, NATURE, V379, P183, DOI 10.1038/379183a0; Venkatesan RN, 2007, MOL CELL BIOL, V27, P7669, DOI 10.1128/MCB.00002-07; Wang GL, 2008, JNCI-J NATL CANCER I, V100, P1815, DOI 10.1093/jnci/djn385; Wittschieben JP, 2006, CANCER RES, V66, P134, DOI 10.1158/0008-5472.CAN-05-2982; Woodward AM, 2006, J CELL BIOL, V173, P673, DOI 10.1083/jcb.200602108	47	80	87	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 11	2010	29	6					876	887		10.1038/onc.2009.378	http://dx.doi.org/10.1038/onc.2009.378			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	553WP	19901968				2022-12-25	WOS:000274397800010
J	Ohira, T; Arita, M; Omori, K; Recchiuti, A; Van Dyke, TE; Serhan, CN				Ohira, Taisuke; Arita, Makoto; Omori, Kazuhiro; Recchiuti, Antonio; Van Dyke, Thomas E.; Serhan, Charles N.			Resolvin E1 Receptor Activation Signals Phosphorylation and Phagocytosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INFLAMMATORY RESOLUTION; AIRWAY INFLAMMATION; LIPID MEDIATORS; CELLS; KINASE; GRANULOCYTES; SPECIFICITY; NEUTROPHILS; PROGRAMS; CHEMR23	Resolvins are endogenous lipid mediators that actively regulate the resolution of acute inflammation. Resolvin E1 (RvE1; (5S, 12R, 18R)-trihydroxy-6Z, 8E, 10E, 14Z, 16E-eicosapentaenoic acid) is an endogenous anti-inflammatory and pro-resolving mediator derived from eicosapentaenoic acid that regulates leukocyte migration and enhances macrophage phagocytosis of apoptotic neutrophils to resolve inflammation. In the inflammatory milieu, RvE1 mediates counter-regulatory actions initiated via specific G protein-coupled receptors. Here, we have identified RvE1-specific signaling pathways initiated by the RvE1 receptor ChemR23. RvE1 stimulated phosphorylation of Akt that was both ligand-and receptor-dependent. RvE1 regulated Akt phosphorylation in a time (0-15 min)- and dose-dependent (0.01-100 nM) manner in human ChemR23-transfected Chinese hamster ovary cells. RvE1 stimulated phosphorylation of both Akt and a 30-kDa protein, a downstream target of Akt, identified using a phospho-Akt substrate antibody. The 30-kDa protein was identified as ribosomal protein S6, a translational regulator, and its phosphorylation was inhibited by a phosphatidylinositol 3-kinase (PI3K) inhibitor (wortmannin) and an ERK inhibitor (PD98059) but not by a p38-MAPK inhibitor (SB203580). Ribosomal protein S6 is a downstream target of the PI3K/Akt signaling pathway as well as the Raf/ERK pathway. In ChemR23-expressing differentiated HL60 cells, RvE1 also stimulated the phosphorylation of ribosomal protein S6. In addition, RvE1 enhanced phagocytosis of zymosanAby human macrophages, which are inhibited by PD98059 and rapamycin (mTOR inhibitor). These results indicate that RvE1 initiates direct activation of ChemR23 and signals receptor-dependent phosphorylation. These phosphorylation-signaling pathways identified for RvE1 receptor-ligand interactions underscore the importance of endogenous pro-resolving agonists in resolving acute inflammation.	[Serhan, Charles N.] Brigham & Womens Hosp, Dept Anesthesiol Perioperat & Pain Med, Ctr Expt Therapeut & Reperfus, Boston, MA 02115 USA; [Serhan, Charles N.] Harvard Univ, Sch Med, Boston, MA 02115 USA; [Ohira, Taisuke; Omori, Kazuhiro; Van Dyke, Thomas E.] Boston Univ, Goldman Sch Dent Med, Dept Periodontol & Oral Biol, Boston, MA 02118 USA	Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School; Boston University	Serhan, CN (corresponding author), Brigham & Womens Hosp, Dept Anesthesiol Perioperat & Pain Med, Ctr Expt Therapeut & Reperfus, HIM 829,77 Ave Louis Pasteur, Boston, MA 02115 USA.	cnserhan@zeus.bwh.harvard.edu	Omori, Kazuhiro/AAX-5268-2020; Recchiuti, Antonio/K-7670-2016	Recchiuti, Antonio/0000-0002-1409-5261; Arita, Makoto/0000-0001-9902-0463	National Institutes of Health [DE-016191, DE-015566, GM38765]; NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH [R01DE015566] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [P50DE016191] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM038765, R37GM038765, R29GM038765] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	This work was supported, in whole or in part, by National Institutes of Health Grants DE-016191 (to C. N. S. and T. E. V. D.), DE-015566 (to T. E. V. D.), and GM38765 (to C. N. S.). Brigham and Women's Hospital and Boston University are assigned patents on resolvins that are licensed for clinical development and are subject to consultant agreements for Drs. Charles N. Serhan and Thomas E. Van Dyke.	Alessi DR, 1996, FEBS LETT, V399, P333, DOI 10.1016/S0014-5793(96)01370-1; Aoki H, 2008, BIOCHEM BIOPH RES CO, V367, P509, DOI 10.1016/j.bbrc.2008.01.012; Arita M, 2005, P NATL ACAD SCI USA, V102, P7671, DOI 10.1073/pnas.0409271102; Arita M, 2005, J EXP MED, V201, P713, DOI 10.1084/jem.20042031; Arita M, 2007, J IMMUNOL, V178, P3912, DOI 10.4049/jimmunol.178.6.3912; BOYUM A, 1968, SCAND J CLIN LAB INV, VS 21, P77; Campbell EL, 2007, FASEB J, V21, P3162, DOI 10.1096/fj.07-8473com; Cash JL, 2008, J EXP MED, V205, P767, DOI 10.1084/jem.20071601; Connor KM, 2007, NAT MED, V13, P868, DOI 10.1038/nm1591; Ganesan LP, 2004, J BIOL CHEM, V279, P54416, DOI 10.1074/jbc.M408188200; Gilroy DW, 2004, NAT REV DRUG DISCOV, V3, P401, DOI 10.1038/nrd1383; Gronert K, 2008, MOL INTERV, V8, P28, DOI 10.1124/mi.8.1.7; Hasturk H, 2006, FASEB J, V20, P401, DOI 10.1096/fj.05-4724fje; Haworth O, 2008, NAT IMMUNOL, V9, P873, DOI 10.1038/ni.1627; Hong S, 2008, J IMMUNOL, V180, P3512, DOI 10.4049/jimmunol.180.5.3512; Ly C, 2003, CANCER RES, V63, P5716; Maderna P, 2003, BBA-MOL BASIS DIS, V1639, P141, DOI 10.1016/j.bbadis.2003.09.004; Maudsley S, 2005, J PHARMACOL EXP THER, V314, P485, DOI 10.1124/jpet.105.083121; Ohira T, 2003, J IMMUNOL METHODS, V281, P79, DOI 10.1016/S0022-1759(03)00278-3; SAVINAINEN A, 2007, 10 INT C BIOACT LIP; Schwab JM, 2007, NATURE, V447, P869, DOI 10.1038/nature05877; Serhan CN, 2007, FASEB J, V21, P325, DOI 10.1096/fj.06-7227rev; Serhan CN, 2007, ANNU REV IMMUNOL, V25, P101, DOI 10.1146/annurev.immunol.25.022106.141647; Serhan CN, 2005, NAT IMMUNOL, V6, P1191, DOI 10.1038/ni1276; Serhan CN, 2002, J EXP MED, V196, P1025, DOI 10.1084/jem.20020760; Serhan CN, 2000, J EXP MED, V192, P1197, DOI 10.1084/jem.192.8.1197; Shimizu T, 2009, ANNU REV PHARMACOL, V49, P123, DOI 10.1146/annurev.pharmtox.011008.145616; Starosta V, 2008, J IMMUNOL, V181, P8688, DOI 10.4049/jimmunol.181.12.8688; Vassiliou EK, 2008, J IMMUNOL, V181, P4534, DOI 10.4049/jimmunol.181.7.4534; Yoshimura T, 2008, J EXP MED, V205, P2187, DOI 10.1084/jem.20081736; Zabel BA, 2006, EXP HEMATOL, V34, P1021, DOI 10.1016/j.exphem.2006.05.003	31	189	200	1	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 29	2010	285	5					3451	3461		10.1074/jbc.M109.044131	http://dx.doi.org/10.1074/jbc.M109.044131			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	546RR	19906641	hybrid, Green Published			2022-12-25	WOS:000273829000059
J	Cartier, EA; Parra, LA; Baust, TB; Quiroz, M; Salazar, G; Faundez, V; Egana, L; Torres, GE				Cartier, Etienne A.; Parra, Leonardo A.; Baust, Tracy B.; Quiroz, Marisol; Salazar, Gloria; Faundez, Victor; Egana, Loreto; Torres, Gonzalo E.			A Biochemical and Functional Protein Complex Involving Dopamine Synthesis and Transport into Synaptic Vesicles	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VESICULAR MONOAMINE TRANSPORTER-2; BOVINE CAUDATE NUCLEUS; DENSE CORE VESICLES; TYROSINE-HYDROXYLASE; ALPHA-SYNUCLEIN; PARKINSONS-DISEASE; QUANTAL SIZE; REGULATORY PROPERTIES; GTP CYCLOHYDROLASE; CYTOSOLIC DOPAMINE	Synaptic transmission depends on neurotransmitter pools stored within vesicles that undergo regulated exocytosis. In the brain, the vesicular monoamine transporter-2 (VMAT(2)) is responsible for the loading of dopamine (DA) and other mono-amines into synaptic vesicles. Prior to storage within vesicles, DA synthesis occurs at the synaptic terminal in a two-step enzymatic process. First, the rate-limiting enzyme tyrosine hydroxylase (TH) converts tyrosine to di-OH-phenylalanine. Aromatic aminoacid decarboxylase(AADC) then converts di-OH-phenylalanine into DA. Here, we provide evidence that VMAT(2) physically and functionally interacts with the enzymes responsible for DA synthesis. In rat striata, TH and AADC co-immunoprecipitate with VMAT(2), whereas in PC 12 cells, TH co-immunoprecipitates with the closely related VMAT(1) and with overexpressed VMAT(2). GST pull-down assays further identified three cytosolic domains of VMAT(2) involved in the interaction with TH and AADC. Furthermore, in vitro binding assays demonstrated that TH directly interacts with VMAT(2). Additionally, using fractionation and immunoisolation approaches, we demonstrate that TH and AADC associate with VMAT(2)-containing synaptic vesicles from rat brain. These vesicles exhibited specific TH activity. Finally, the coupling between synthesis and transport of DA into vesicles was impaired in the presence of fragments involved in the VMAT(2)/TH/AADC interaction. Taken together, our results indicate that DA synthesis can occur at the synaptic vesicle membrane, where it is physically and functionally coupled to VMAT(2)-mediated transport into vesicles.	[Egana, Loreto; Torres, Gonzalo E.] Univ Pittsburgh, Sch Med, Dept Neurobiol, Pittsburgh, PA 15261 USA; [Torres, Gonzalo E.] Univ Pittsburgh, Sch Med, Dept Pharmacol, Pittsburgh, PA 15261 USA; [Salazar, Gloria] Emory Univ, Div Cardiol, Dept Med, Atlanta, GA 30322 USA; [Faundez, Victor] Emory Univ, Dept Cell Biol, Atlanta, GA 30322 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Emory University; Emory University	Torres, GE (corresponding author), Univ Pittsburgh, Sch Med, Dept Neurobiol, Rm 6061,BST3,3501 5th Ave, Pittsburgh, PA 15261 USA.	gtorres@pitt.edu		Parra Rivas, Leonardo/0000-0002-6707-1255; Faundez, Victor/0000-0002-2114-5271				Berridge CW, 2003, BRAIN RES REV, V42, P33, DOI 10.1016/S0165-0173(03)00143-7; BERRY MD, 1994, PROG NEUROBIOL, V42, P375, DOI 10.1016/0301-0082(94)90081-7; Bowling KM, 2008, J BIOL CHEM, V283, P31449, DOI 10.1074/jbc.M802552200; Carlsson A, 2001, SCIENCE, V294, P1021, DOI 10.1126/science.1066969; Carneiro AM, 2002, J NEUROSCI, V22, P7045; Caudle WM, 2008, TRENDS NEUROSCI, V31, P303, DOI 10.1016/j.tins.2008.02.010; Caudle WM, 2007, J NEUROSCI, V27, P8138, DOI 10.1523/JNEUROSCI.0319-07.2007; Chen LN, 2008, J NEUROSCI, V28, P425, DOI 10.1523/JNEUROSCI.3602-07.2008; Chen R, 2003, J BIOMED SCI, V10, P774, DOI 10.1159/000073965; CHRISTENSON JG, 1972, P NATL ACAD SCI USA, V69, P343, DOI 10.1073/pnas.69.2.343; Edwards RH, 2007, NEURON, V55, P835, DOI 10.1016/j.neuron.2007.09.001; Erickson JD, 1996, P NATL ACAD SCI USA, V93, P5166, DOI 10.1073/pnas.93.10.5166; ERICKSON JD, 1992, P NATL ACAD SCI USA, V89, P10993, DOI 10.1073/pnas.89.22.10993; FAHN S, 1969, J NEUROCHEM, V16, P1293, DOI 10.1111/j.1471-4159.1969.tb05979.x; Funderburk CD, 2006, J BIOL CHEM, V281, P33302, DOI 10.1074/jbc.M602196200; Guo JT, 2008, CELL MOL NEUROBIOL, V28, P35, DOI 10.1007/s10571-007-9227-0; Hastings TG, 1996, ADV EXP MED BIOL, V387, P97; Hastings TG, 1996, P NATL ACAD SCI USA, V93, P1956, DOI 10.1073/pnas.93.5.1956; HAYCOCK JW, 1991, J BIOL CHEM, V266, P5650; Itagaki C, 1999, BIOCHEMISTRY-US, V38, P15673, DOI 10.1021/bi9914255; Jin H, 2003, P NATL ACAD SCI USA, V100, P4293, DOI 10.1073/pnas.0730698100; KELNER KL, 1986, P NATL ACAD SCI USA, V83, P2998, DOI 10.1073/pnas.83.9.2998; Kleppe R, 2001, J NEUROCHEM, V77, P1097, DOI 10.1046/j.1471-4159.2001.00318.x; KUCZENSKI RT, 1972, J BIOL CHEM, V247, P3114; KUHN DM, 1990, J BIOL CHEM, V265, P5780; LIU YJ, 1992, CELL, V70, P539, DOI 10.1016/0092-8674(92)90425-C; LIU YJ, 1994, J CELL BIOL, V127, P1419, DOI 10.1083/jcb.127.5.1419; Lotharius J, 2002, NAT REV NEUROSCI, V3, P932, DOI 10.1038/nrn983; Makinae K, 2000, J NEUROCHEM, V75, P1429, DOI 10.1046/j.1471-4159.2000.0751429.x; MANDELL AJ, 1972, BIOCHEM PHARMACOL, V21, P2737, DOI 10.1016/0006-2952(72)90022-6; Michelsen KA, 2008, PROG BRAIN RES, V172, P233, DOI 10.1016/S0079-6123(08)00912-6; Morciano M, 2005, J NEUROCHEM, V95, P1732, DOI 10.1111/j.1471-4159.2005.03506.x; MORITA K, 1987, J BIOL CHEM, V262, P5654; Mosharov EV, 2009, NEURON, V62, P218, DOI 10.1016/j.neuron.2009.01.033; Mosharov EV, 2006, J NEUROSCI, V26, P9304, DOI 10.1523/JNEUROSCI.0519-06.2006; NAGATSU T, 1970, EXPERIENTIA, V26, P722, DOI 10.1007/BF02232504; NAGATSU T, 1971, J NEUROCHEM, V18, P2179, DOI 10.1111/j.1471-4159.1971.tb05076.x; NIRENBERG MJ, 1995, P NATL ACAD SCI USA, V92, P8773, DOI 10.1073/pnas.92.19.8773; Nirenberg MJ, 1996, J NEUROSCI, V16, P4135; Nirenberg MJ, 1997, SYNAPSE, V26, P194; Obsilova V, 2008, PHYSIOL RES, V57, pS11, DOI 10.33549/physiolres.931598; Ostrerova N, 1999, J NEUROSCI, V19, P5782, DOI 10.1523/JNEUROSCI.19-14-05782.1999; Palmiter RD, 2008, ANN NY ACAD SCI, V1129, P35, DOI 10.1196/annals.1417.003; Perez RG, 2002, J NEUROSCI, V22, P3090, DOI 10.1523/JNEUROSCI.22-08-03090.2002; PETER D, 1995, J NEUROSCI, V15, P6179; PICKEL VM, 1975, J HISTOCHEM CYTOCHEM, V23, P1, DOI 10.1177/23.1.234988; PICKEL VM, 1976, J HISTOCHEM CYTOCHEM, V24, P792, DOI 10.1177/24.7.8567; Pothos EN, 1998, J NEUROSCI, V18, P4106; Pothos EN, 2000, J NEUROSCI, V20, P7297; Reimer RJ, 1998, CURR OPIN NEUROBIOL, V8, P405, DOI 10.1016/S0959-4388(98)80068-8; REINHARD JF, 1986, LIFE SCI, V39, P2185, DOI 10.1016/0024-3205(86)90395-4; Requena DF, 2009, J NEUROCHEM, V110, P581, DOI 10.1111/j.1471-4159.2009.06135.x; Rochet JC, 2004, J MOL NEUROSCI, V23, P23, DOI 10.1385/JMN:23:1-2:023; SCHERMAN D, 1988, NEUROSCIENCE, V27, P1029, DOI 10.1016/0306-4522(88)90207-2; SCHERMAN D, 1986, J NEUROCHEM, V47, P331; Sulzer D, 2000, P NATL ACAD SCI USA, V97, P11869, DOI 10.1073/pnas.97.22.11869; Tsudzuki T, 2004, J BIOCHEM, V136, P239, DOI 10.1093/jb/mvh113; Vermetten E, 2002, DEPRESS ANXIETY, V15, P126, DOI 10.1002/da.10016; Wang J, 2009, J BIOL CHEM, V284, P14011, DOI 10.1074/jbc.M901310200; Zhou QY, 1995, CELL, V83, P1197, DOI 10.1016/0092-8674(95)90145-0; ZIGMOND RE, 1989, ANNU REV NEUROSCI, V12, P415, DOI 10.1146/annurev.ne.12.030189.002215	61	83	86	1	16	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 15	2010	285	3					1957	1966		10.1074/jbc.M109.054510	http://dx.doi.org/10.1074/jbc.M109.054510			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	541PJ	19903816	hybrid, Green Published			2022-12-25	WOS:000273429100042
J	Kii, I; Nishiyama, T; Li, MQ; Matsumoto, K; Saito, M; Amizuka, N; Kudo, A				Kii, Isao; Nishiyama, Takashi; Li, Minqi; Matsumoto, Ken-ichi; Saito, Mitsuru; Amizuka, Norio; Kudo, Akira			Incorporation of Tenascin-C into the Extracellular Matrix by Periostin Underlies an Extracellular Meshwork Architecture	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LYSYL OXIDASE; MATRICELLULAR PROTEINS; PERIODONTAL-LIGAMENT; BINDING-SITE; CROSS-LINKS; EXPRESSION; FIBRONECTIN; COLLAGEN; MICE; CELL	Extracellular matrix (ECM) underlies a complicated multicellular architecture that is subjected to significant forces from mechanical environment. Although various components of the ECM have been enumerated, mechanisms that evolve the sophisticated ECM architecture remain to be addressed. Here we show that periostin, a matricellular protein, promotes incorporation of tenascin-C into the ECM and organizes a meshwork architecture of the ECM. We found that both periostin null mice and tenascin-C null mice exhibited a similar phenotype, confined tibial periostitis, which possibly corresponds to medial tibial stress syndrome in human sports injuries. Periostin possessed adjacent domains that bind to tenascin-C and the other ECM protein: fibronectin and type I collagen, respectively. These adjacent domains functioned as a bridge between tenascin-C and the ECM, which increased deposition of tenascin-C on the ECM. The deposition of hexabrachions of tenascin-C may stabilize bifurcations of the ECM fibrils, which is integrated into the extracellular meshwork architecture. This study suggests a role for periostin in adaptation of the ECM architecture in the mechanical environment.	[Kii, Isao; Nishiyama, Takashi; Kudo, Akira] Tokyo Inst Technol, Dept Biol Informat, Yokohama, Kanagawa 2268501, Japan; [Li, Minqi; Amizuka, Norio] Hokkaido Univ, Grad Sch Dent Med, Dept Dev Biol Hard Tissue, Div Oral Hlth Sci,Kita Ku, Sapporo, Hokkaido 0608586, Japan; [Matsumoto, Ken-ichi] Shimane Univ, Dept Biosignaling & Radioisotope Expt, Ctr Integrated Res Sci, Izumo, Shimane 6938501, Japan; [Saito, Mitsuru] Jikei Univ, Sch Med, Dept Orthopaed Surg, Minato Ku, Tokyo 1058461, Japan	Tokyo Institute of Technology; Hokkaido University; Shimane University; Jikei University		akudo@bio.titech.ac.jp	Kudo, Akira/C-7340-2015; KII, Isao/C-4117-2017; Nishiyama, Takashi/ABC-8965-2021	Kudo, Akira/0000-0001-6289-3391; KII, Isao/0000-0002-6153-6250; Nishiyama, Takashi/0000-0002-4496-240X	Ministry of Education, Science, Culture, and Sports of Japan; Japan Space Forum	Ministry of Education, Science, Culture, and Sports of Japan(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)); Japan Space Forum	This work was supported by grants-in-aid for scientific research from the Ministry of Education, Science, Culture, and Sports of Japan (to I. K. and A. K.) and by grants from the Ground-based Research Program for Space Utilization promoted by Japan Space Forum (to A. K.).	Annes JP, 2004, J CELL BIOL, V165, P723, DOI 10.1083/jcb.200312172; AUKHIL I, 1993, J BIOL CHEM, V268, P2542; BORNSTEIN P, 1995, J CELL BIOL, V130, P503, DOI 10.1083/jcb.130.3.503; Bornstein P, 2000, MATRIX BIOL, V19, P555, DOI 10.1016/S0945-053X(00)00103-7; BOUSSIF O, 1995, P NATL ACAD SCI USA, V92, P7297, DOI 10.1073/pnas.92.16.7297; Bradshaw AD, 2003, J INVEST DERMATOL, V120, P949, DOI 10.1046/j.1523-1747.2003.12241.x; Callebaut I, 2003, BIOCHEM BIOPH RES CO, V300, P619, DOI 10.1016/S0006-291X(02)02904-2; Chiquet M, 2009, BBA-MOL CELL RES, V1793, P911, DOI 10.1016/j.bbamcr.2009.01.012; Chung CY, 1997, J CELL SCI, V110, P1413; Cukierman E, 2002, CURR OPIN CELL BIOL, V14, P633, DOI 10.1016/S0955-0674(02)00364-2; Duckert P, 2004, PROTEIN ENG DES SEL, V17, P107, DOI 10.1093/protein/gzh013; FISCHER D, 1995, J BIOL CHEM, V270, P3378, DOI 10.1074/jbc.270.7.3378; Fogelgren B, 2005, J BIOL CHEM, V280, P24690, DOI 10.1074/jbc.M412979200; Gaeta M, 2005, RADIOLOGY, V235, P553, DOI 10.1148/radiol.2352040406; Hamilton DW, 2008, J CELL COMMUN SIGNAL, V2, P9, DOI 10.1007/s12079-008-0023-5; Hong HH, 2004, J CELL PHYSIOL, V200, P53, DOI 10.1002/jcp.10476; Horiuchi K, 1999, J BONE MINER RES, V14, P1239, DOI 10.1359/jbmr.1999.14.7.1239; Hsia HC, 2005, J BIOL CHEM, V280, P26641, DOI 10.1074/jbc.R500005200; Huang GR, 2009, J BIOL CHEM, V284, P25879, DOI 10.1074/jbc.M109.024125; Imanaka-Yoshida K, 2004, HISTOL HISTOPATHOL, V19, P517, DOI 10.14670/HH-19.517; Ingham KC, 2004, J BIOL CHEM, V279, P28132, DOI 10.1074/jbc.M312785200; Jang JH, 2004, J BIOL CHEM, V279, P25562, DOI 10.1074/jbc.M403170200; Kii I, 2006, BIOCHEM BIOPH RES CO, V342, P766, DOI 10.1016/j.bbrc.2006.02.016; Kim BY, 2009, J BIOL CHEM, V284, P19580, DOI 10.1074/jbc.M109.013607; Koshida S, 2005, DEV CELL, V8, P587, DOI 10.1016/j.devcel.2005.03.006; Koyama E, 1996, J ORTHOPAED RES, V14, P403, DOI 10.1002/jor.1100140310; Kudo H, 2004, DEV BIOL, V267, P473, DOI 10.1016/j.ydbio.2003.12.007; Litvin J, 2007, AM J PHYSIOL-CELL PH, V292, pC1672, DOI 10.1152/ajpcell.00153.2006; Manabe R, 1997, J CELL BIOL, V139, P295, DOI 10.1083/jcb.139.1.295; Molloy SS, 1999, TRENDS CELL BIOL, V9, P28, DOI 10.1016/S0962-8924(98)01382-8; Morita S, 2000, GENE THER, V7, P1063, DOI 10.1038/sj.gt.3301206; Niwa H, 1998, GENE DEV, V12, P2048, DOI 10.1101/gad.12.13.2048; Norris RA, 2008, DEV BIOL, V316, P200, DOI 10.1016/j.ydbio.2008.01.003; Norris RA, 2007, J CELL BIOCHEM, V101, P695, DOI 10.1002/jcb.21224; Oka T, 2007, CIRC RES, V101, P313, DOI 10.1161/CIRCRESAHA.107.149047; Pankov R, 2002, J CELL SCI, V115, P3861, DOI 10.1242/jcs.00059; Pischon N, 2005, J CELL PHYSIOL, V203, P111, DOI 10.1002/jcp.20206; Rios H, 2005, MOL CELL BIOL, V25, P11131, DOI 10.1128/MCB.25.24.11131-11144.2005; SAGA Y, 1991, GENE, V104, P177, DOI 10.1016/0378-1119(91)90248-A; SAGA Y, 1992, GENE DEV, V6, P1821, DOI 10.1101/gad.6.10.1821; Saito M, 1997, ANAL BIOCHEM, V253, P26, DOI 10.1006/abio.1997.2350; Schweitzer J, 2005, DEV DYNAM, V234, P550, DOI 10.1002/dvdy.20525; Shimazaki M, 2008, J EXP MED, V205, P295, DOI 10.1084/jem.20071297; Snider P, 2008, CIRC RES, V102, P752, DOI 10.1161/CIRCRESAHA.107.159517; Soderberg O, 2008, METHODS, V45, P227, DOI 10.1016/j.ymeth.2008.06.014; SUGIURA T, 1995, PROTEIN EXPRES PURIF, V6, P305, DOI 10.1006/prep.1995.1040; Suzuki H, 2004, ANAT REC PART A, V281A, P1264, DOI 10.1002/ar.a.20080; Takaluoma K, 2007, J BIOL CHEM, V282, P6588, DOI 10.1074/jbc.M608830200; Takayama G, 2006, J ALLERGY CLIN IMMUN, V118, P98, DOI 10.1016/j.jaci.2006.02.046; Takayama I, 2009, J BIOCHEM, V146, P713, DOI 10.1093/jb/mvp117; Tamaoki M, 2005, AM J PATHOL, V167, P71, DOI 10.1016/S0002-9440(10)62954-9; Thomas G, 2002, NAT REV MOL CELL BIO, V3, P753, DOI 10.1038/nrm934; Tweed JL, 2008, J AM PODIAT MED ASSN, V98, P107; Wang DJ, 2003, HYPERTENSION, V42, P88, DOI 10.1161/01.HYP.0000074905.22908.A6; WEBER P, 1995, J BIOL CHEM, V270, P4619, DOI 10.1074/jbc.270.9.4619; Wilde J, 2003, CELL TISSUE RES, V312, P345, DOI 10.1007/s00441-002-0664-2; Wipff PJ, 2007, J CELL BIOL, V179, P1311, DOI 10.1083/jcb.200704042; Yoshioka N, 2002, EXP CELL RES, V279, P91, DOI 10.1006/excr.2002.5590; Zhou A, 1999, J BIOL CHEM, V274, P20745, DOI 10.1074/jbc.274.30.20745	59	207	214	2	17	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 15	2010	285	3					2028	2039		10.1074/jbc.M109.051961	http://dx.doi.org/10.1074/jbc.M109.051961			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	541PJ	19887451	Green Published, hybrid			2022-12-25	WOS:000273429100048
J	Matsuura, I; Chiang, KN; Lai, CY; He, DM; Wang, GN; Ramkumar, R; Uchida, T; Ryo, A; Lu, KP; Liu, F				Matsuura, Isao; Chiang, Keng-Nan; Lai, Chen-Yu; He, Dongming; Wang, Guannan; Ramkumar, Romila; Uchida, Takafumi; Ryo, Akihide; Lu, Kunping; Liu, Fang			Pin1 Promotes Transforming Growth Factor-beta-induced Migration and Invasion	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROLYL-ISOMERASE PIN1; BREAST-CANCER CELLS; TGF-BETA; SMAD3 PHOSPHORYLATION; N-CADHERIN; ANTIPROLIFERATIVE FUNCTION; MAP KINASE; KAPPA-B; C-JUN; PATHWAYS	Transforming growth factor-beta (TGF-beta) regulates a wide variety of biological activities. It induces potent growth-inhibitory responses in normal cells but promotes migration and invasion of cancer cells. Smads mediate the TGF-beta responses. TGF-beta binding to the cell surface receptors leads to the phosphorylation of Smad2/3 in their C terminus as well as in the proline-rich linker region. The serine/threonine phosphorylation sites in the linker region are followed by the proline residue. Pin1, a peptidyl-prolyl cis/trans isomerase, recognizes phosphorylated serine/threonine-proline motifs. Here we show that Smad2/3 interacts with Pin1 in a TGF-beta-dependent manner. We further show that the phosphorylated threonine 179-proline motif in the Smad3 linker region is the major binding site for Pin1. Although epidermal growth factor also induces phosphorylation of threonine 179 and other residues in the Smad3 linker region the same as TGF-beta, Pin1 is unable to bind to the epidermal growth factor-stimulated Smad3. Further analysis suggests that phosphorylation of Smad3 in the C terminus is necessary for the interaction with Pin1. Depletion of Pin1 by small hairpin RNA does not significantly affect TGF-beta-induced growth-inhibitory responses and a number of TGF-beta/Smad target genes analyzed. In contrast, knockdown of Pin1 in human PC3 prostate cancer cells strongly inhibited TGF-beta-mediated migration and invasion. Accordingly, TGF-beta induction of N-cadherin, which plays an important role in migration and invasion, is markedly reduced when Pin1 is depleted in PC3 cells. Because Pin1 is overexpressed in many cancers, our findings highlight the importance of Pin1 in TGF-beta-induced migration and invasion of cancer cells.	[Matsuura, Isao; Chiang, Keng-Nan; Lai, Chen-Yu] Natl Hlth Res Inst, Div Mol Genom & Med, Zhunan Town 350, Miaoli County, Taiwan; [Liu, Fang] Rutgers State Univ, Ernest Mario Sch Pharm, Ctr Adv Biotechnol & Med, Piscataway, NJ 08854 USA; [Matsuura, Isao; He, Dongming; Wang, Guannan; Ramkumar, Romila; Liu, Fang] Rutgers State Univ, Ernest Mario Sch Pharm, Susan Lehman Cullman Lab Canc Res, Dept Biol Chem, Piscataway, NJ 08854 USA; [Matsuura, Isao; He, Dongming; Wang, Guannan; Ramkumar, Romila; Liu, Fang] Canc Inst New Jersey, Piscataway, NJ 08854 USA; [Uchida, Takafumi] Tohoku Univ, Grad Sch Agr Sci, Sendai, Miyagi 9818555, Japan; [Ryo, Akihide] Yokohama City Univ, Dept Microbiol, Sch Med, Yokohama, Kanagawa 2360004, Japan; [Lu, Kunping] Harvard Univ, Canc Biol Program, Div Hematol Oncol, Beth Israel Deaconess Med Ctr,Med Sch,Dept Med, Boston, MA 02105 USA	National Health Research Institutes - Taiwan; Rutgers State University New Brunswick; Rutgers State University New Brunswick; Rutgers State University New Brunswick; Rutgers State University Medical Center; Rutgers Cancer Institute of New Jersey; Tohoku University; Yokohama City University; Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School	Matsuura, I (corresponding author), Natl Hlth Res Inst, Div Mol Genom & Med, 35 Keyan Rd, Zhunan Town 350, Miaoli County, Taiwan.	imatsuura@nhri.org.tw; fangliu@cabm.rutgers.edu	Matsuura, Isao/E-3979-2010	Uchida, Takafumi/0000-0003-3665-4906	National Institutes of Health [CA93771]; National Health Research Institutes; NATIONAL CANCER INSTITUTE [R01CA093771] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); National Health Research Institutes(National Health Research Institutes, Japan); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This work was supported by National Institutes of Health Grant CA93771 (to F. L.). This work was also supported by the National Health Research Institutes (to I. M.).	Alexander NR, 2006, CANCER RES, V66, P3365, DOI 10.1158/0008-5472.CAN-05-3401; Attisano L, 2002, SCIENCE, V296, P1646, DOI 10.1126/science.1071809; Ayala G, 2003, CANCER RES, V63, P6244; Bao L, 2004, AM J PATHOL, V164, P1727, DOI 10.1016/S0002-9440(10)63731-5; BEHRENS J, 1993, BREAST CANCER RES TR, V24, P175, DOI 10.1007/BF01833258; Blanchette F, 2001, J BIOL CHEM, V276, P33986, DOI 10.1074/jbc.M100093200; Chen SY, 2006, MOL CELL BIOL, V26, P929, DOI 10.1128/MCB.26.3.929-939.2006; Cheng GZ, 2007, CANCER RES, V67, P1979, DOI 10.1158/0008-5472.CAN-06-1479; Cui Y, 2008, ONCOGENE, V27, P3122, DOI 10.1038/sj.onc.1210972; DATTO MB, 1995, P NATL ACAD SCI USA, V92, P5545, DOI 10.1073/pnas.92.12.5545; de Caestecker MP, 1998, GENE DEV, V12, P1587, DOI 10.1101/gad.12.11.1587; Denissova NG, 2000, P NATL ACAD SCI USA, V97, P6397, DOI 10.1073/pnas.090099297; Dennler S, 1998, EMBO J, V17, P3091, DOI 10.1093/emboj/17.11.3091; Derycke LDM, 2004, INT J DEV BIOL, V48, P463, DOI 10.1387/ijdb.041793ld; Derynck R, 2001, NAT GENET, V29, P117, DOI 10.1038/ng1001-117; Derynck R, 2003, NATURE, V425, P577, DOI 10.1038/nature02006; Engel ME, 1999, J BIOL CHEM, V274, P37413, DOI 10.1074/jbc.274.52.37413; Fan G, 2009, CANCER RES, V69, P4589, DOI 10.1158/0008-5472.CAN-08-4117; Feng XH, 2000, EMBO J, V19, P5178, DOI 10.1093/emboj/19.19.5178; Feng XH, 2005, ANNU REV CELL DEV BI, V21, P659, DOI 10.1146/annurev.cellbio.21.022404.142018; Funaba M, 2002, J BIOL CHEM, V277, P41361, DOI 10.1074/jbc.M204597200; Furukawa F, 2003, HEPATOLOGY, V38, P879, DOI 10.1053/jhep.2003.50384; Gianni M, 2009, CANCER RES, V69, P1016, DOI 10.1158/0008-5472.CAN-08-2603; Grimm OH, 2002, NAT CELL BIOL, V4, P519, DOI 10.1038/ncb812; Gumbiner BM, 1996, CELL, V84, P345, DOI 10.1016/S0092-8674(00)81279-9; Guo X, 2008, GENE DEV, V22, P106, DOI 10.1101/gad.1590908; HANNON GJ, 1994, NATURE, V371, P257, DOI 10.1038/371257a0; He J, 2007, LUNG CANCER, V56, P51, DOI 10.1016/j.lungcan.2006.11.024; Heldin CH, 2009, CURR OPIN CELL BIOL, V21, P166, DOI 10.1016/j.ceb.2009.01.021; Heldin CH, 1997, NATURE, V390, P465, DOI 10.1038/37284; Hu PPC, 1999, J BIOL CHEM, V274, P35381, DOI 10.1074/jbc.274.50.35381; Javelaud D, 2005, ONCOGENE, V24, P5742, DOI 10.1038/sj.onc.1208928; Jin CY, 2009, CANCER RES, V69, P735, DOI 10.1158/0008-5472.CAN-08-1463; Jonk LJC, 1998, J BIOL CHEM, V273, P21145, DOI 10.1074/jbc.273.33.21145; Kamaraju SK, 2005, J BIOL CHEM, V280, P1024, DOI 10.1074/jbc.M403960200; Kim CJ, 2005, WORLD J GASTROENTERO, V11, P5006, DOI 10.3748/wjg.v11.i32.5006; Kretzschmar M, 1999, GENE DEV, V13, P804, DOI 10.1101/gad.13.7.804; Lam PB, 2008, MOL CANCER, V7, DOI 10.1186/1476-4598-7-91; Lehmann K, 2000, GENE DEV, V14, P2610, DOI 10.1101/gad.181700; Levy L, 2006, CYTOKINE GROWTH F R, V17, P41, DOI 10.1016/j.cytogfr.2005.09.009; Lin X, 2000, J BIOL CHEM, V275, P36818, DOI 10.1074/jbc.C000580200; Liu F, 2006, CYTOKINE GROWTH F R, V17, P9, DOI 10.1016/j.cytogfr.2005.09.010; Liu F, 2005, CELL CYCLE, V4, P63, DOI 10.4161/cc.4.1.1366; Liu F, 2003, FRONT BIOSCI-LANDMRK, V8, pS1280, DOI 10.2741/1149; Lopez-Rovira T, 2000, J BIOL CHEM, V275, P28937, DOI 10.1074/jbc.M909923199; Lu KP, 1996, NATURE, V380, P544; Lu KP, 2007, NAT REV MOL CELL BIO, V8, P904, DOI 10.1038/nrm2261; Mariotti A, 2007, EXPERT OPIN INV DRUG, V16, P451, DOI 10.1517/13543784.16.4.451; Massague J, 2003, GENE DEV, V17, P2993, DOI 10.1101/gad.1167003; Massague J, 2000, CELL, V103, P295, DOI 10.1016/S0092-8674(00)00121-5; Matsuura I, 2005, BIOCHEMISTRY-US, V44, P12546, DOI 10.1021/bi050560g; Matsuura I, 2004, NATURE, V430, P226, DOI 10.1038/nature02650; Matsuzaki K, 2009, CANCER RES, V69, P5321, DOI 10.1158/0008-5472.CAN-08-4203; Millet C, 2009, J BIOL CHEM, V284, P19808, DOI 10.1074/jbc.M109.016667; Miyazono K, 2003, CANCER SCI, V94, P230, DOI 10.1111/j.1349-7006.2003.tb01425.x; Miyazono K, 2009, P JPN ACAD B-PHYS, V85, P314, DOI 10.2183/pjab.85.314; Mori S, 2004, ONCOGENE, V23, P7416, DOI 10.1038/sj.onc.1207981; Moustakas A, 1998, P NATL ACAD SCI USA, V95, P6733, DOI 10.1073/pnas.95.12.6733; Nagarajan RP, 1999, J BIOL CHEM, V274, P33412, DOI 10.1074/jbc.274.47.33412; Nakano A, 2009, J BIOL CHEM, V284, P6109, DOI 10.1074/jbc.M804659200; Pang R, 2004, ONCOGENE, V23, P4182, DOI 10.1038/sj.onc.1207493; Pang RW, 2006, J PATHOL, V210, P19, DOI 10.1002/path.2024; Pardali E, 2009, FRONT BIOSCI-LANDMRK, V14, P4848, DOI 10.2741/3573; Pardali K, 2000, J BIOL CHEM, V275, P29244, DOI 10.1074/jbc.M909467199; Price JT, 1997, CRIT REV BIOCHEM MOL, V32, P175, DOI 10.3109/10409239709082573; Roberts AB, 2003, P NATL ACAD SCI USA, V100, P8621, DOI 10.1073/pnas.1633291100; ROBERTS AB, 1990, PEPTIDE GROWTH FACTO, P419; Rustighi A, 2009, NAT CELL BIOL, V11, P133, DOI 10.1038/ncb1822; Ryo A, 2005, CLIN CANCER RES, V11, P7523, DOI 10.1158/1078-0432.CCR-05-0457; Ryo A, 2001, NAT CELL BIOL, V3, P793, DOI 10.1038/ncb0901-793; Sachdev P, 2002, J BIOL CHEM, V277, P17638, DOI 10.1074/jbc.M111575200; Sapkota G, 2007, MOL CELL, V25, P441, DOI 10.1016/j.molcel.2007.01.006; Seoane J, 2004, CELL, V117, P211, DOI 10.1016/S0092-8674(04)00298-3; Shi YG, 2003, CELL, V113, P685, DOI 10.1016/S0092-8674(03)00432-X; Takahashi K, 2008, CELL MOL LIFE SCI, V65, P359, DOI 10.1007/s00018-007-7270-0; TEN DP, 2004, TRENDS BIOCHEM SCI, V29, P265; Uchida T, 2003, CHEM BIOL, V10, P15, DOI 10.1016/S1074-5521(02)00310-1; Wang GN, 2009, J BIOL CHEM, V284, P9663, DOI 10.1074/jbc.M809281200; Wulf GM, 2001, EMBO J, V20, P3459, DOI 10.1093/emboj/20.13.3459; Xu J, 2009, CELL RES, V19, P156, DOI 10.1038/cr.2009.5; Yaffe MB, 1997, SCIENCE, V278, P1957, DOI 10.1126/science.278.5345.1957; Yamagata H, 2005, CANCER RES, V65, P157; Yang YA, 2006, CANCER CELL, V9, P445, DOI 10.1016/j.ccr.2006.04.025; Yeh ES, 2007, NAT REV CANCER, V7, P381, DOI 10.1038/nrc2107; Zhang Y, 2001, P NATL ACAD SCI USA, V98, P974, DOI 10.1073/pnas.98.3.974; Zhu SC, 2007, J BIOL CHEM, V282, P18327, DOI 10.1074/jbc.M700636200	86	81	82	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 15	2010	285	3					1754	1764		10.1074/jbc.M109.063826	http://dx.doi.org/10.1074/jbc.M109.063826			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	541PJ	19920136	Green Published, hybrid			2022-12-25	WOS:000273429100021
J	Nakamura, K; Kimple, AJ; Siderovski, DP; Johnson, GL				Nakamura, Kazuhiro; Kimple, Adam J.; Siderovski, David P.; Johnson, Gary L.			PB1 Domain Interaction of p62/Sequestosome 1 and MEKK3 Regulates NF-kappa B Activation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; SIGNALING ADAPTER P62; NERVE-GROWTH-FACTOR; IMPORTANT MEDIATOR; AUTOPHAGY; PATHWAYS; RECEPTOR; SCAFFOLD; CANCER; TUMORIGENESIS	p62/Sequestosome 1 is a scaffold protein involved in the regulation of autophagy, trafficking of proteins to the proteasome, and activation of NF-kappa B. p62 encodes an N-terminal PB1 domain in addition to the ZZ domain, TRAF6-binding domain, LC3 interaction region, and ubiquitin-associated domain, each critical for the physiological function of p62. PB1 domains have a beta-grasp topology where the front end of one PB1 domain binds the back end of a second PB1 domain. The p62 PB1 domain homodimerizes as well as heterodimerizes with other PB1 domains. The front end of the PB1 domain in p62 binds the PB1 domain of atypical protein kinases C, the MAPK kinase, MEK5, and the NBR1 protein. Other than its role in homodimerization, the rear end acidic cluster region of the p62 PB1 domain had no previous defined binding partners. Herein, we demonstrate that the rear end acidic cluster region of the p62 PB1 domain binds the front end basic region of the MAPK kinase kinase, MEKK3. p62 and MEKK3 co-localize in speckles or aggregates that are centers for organizing TRAF6-regulated NF-kappa B signaling and the assembly of polyubiquinated proteins sorting to sequestosomes and proteasomes. The p62-MEKK3 complex binds TRAF6, which regulates the ubiquitination of the IKK complex and NF-kappa B activation. p62 is required for the association of MEKK3 with TRAF6 and short hairpin RNA knockdown of p62 inhibits IL-1 and MEKK3 activation of NF-kappa B. The rear end acidic cluster of the p62 PB1 domain is used to organize cytosolic aggregates or speckles-associated TRAF6-p62-MEKK3 complex for control of NF-kappa B activation.	[Johnson, Gary L.] Univ N Carolina, Sch Med, Dept Pharmacol, Chapel Hill, NC 27599 USA; Univ N Carolina, Sch Med, Lineberger Comprehens Canc Ctr, Chapel Hill, NC 27599 USA	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine	Johnson, GL (corresponding author), Univ N Carolina, Sch Med, Dept Pharmacol, 4016 Genet Med Bldg,120 Mason Farm Rd,CB 7365, Chapel Hill, NC 27599 USA.	gary_johnson@med.unc.edu	Siderovski, David Peter/AAA-9603-2019	Siderovski, David Peter/0000-0002-0688-8210; Kimple, Adam/0000-0003-1670-8401	National Institutes of Health [GM30324, DK37871, T32 GM008719, F30 MH074266]; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK037871] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM030324, R37GM030324, R01GM068820, T32GM008719] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF MENTAL HEALTH [F30MH074266] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))	This work was supported, in whole or in part, by National Institutes of Health Grants GM30324 and DK37871.; Supported by National Institutes of Health Grant T32 GM008719 and Fellowship F30 MH074266.	Bjorkoy G, 2005, J CELL BIOL, V171, P603, DOI 10.1083/jcb.200507002; Blonska M, 2004, MOL CELL BIOL, V24, P10757, DOI 10.1128/MCB.24.24.10757-10765.2004; Di YW, 2008, CELL SIGNAL, V20, P705, DOI 10.1016/j.cellsig.2007.12.007; Duran A, 2004, DEV CELL, V6, P303, DOI 10.1016/S1534-5807(03)00403-9; Duran A, 2008, CANCER CELL, V13, P343, DOI 10.1016/j.ccr.2008.02.001; EllingerZiegelbauer H, 1997, J BIOL CHEM, V272, P2668, DOI 10.1074/jbc.272.5.2668; Hirano Y, 2004, J BIOL CHEM, V279, P31883, DOI 10.1074/jbc.M403092200; Huang QJ, 2004, NAT IMMUNOL, V5, P98, DOI 10.1038/ni1014; Kuribayashi F, 2002, EMBO J, V21, P6312, DOI 10.1093/emboj/cdf642; Lallena MJ, 1999, MOL CELL BIOL, V19, P2180; Lamark T, 2003, J BIOL CHEM, V278, P34568, DOI 10.1074/jbc.M303221200; Levine B, 2007, NATURE, V446, P745, DOI 10.1038/446745a; Martin P, 2006, EMBO J, V25, P3524, DOI 10.1038/sj.emboj.7601250; Mathew R, 2007, NAT REV CANCER, V7, P961, DOI 10.1038/nrc2254; Mathew R, 2009, CELL, V137, P1062, DOI 10.1016/j.cell.2009.03.048; Matsuda A, 2003, ONCOGENE, V22, P3307, DOI 10.1038/sj.onc.1206406; Moscat J, 2007, TRENDS BIOCHEM SCI, V32, P95, DOI 10.1016/j.tibs.2006.12.002; Moscat J, 2009, CELL, V137, P1001, DOI 10.1016/j.cell.2009.05.023; Nakamura K, 2006, MOL CELL BIOL, V26, P2065, DOI 10.1128/MCB.26.6.2065-2079.2006; Nakamura K, 2003, J BIOL CHEM, V278, P36989, DOI 10.1074/jbc.C300313200; Nakamura K, 2007, MOL CELL BIOL, V27, P4566, DOI 10.1128/MCB.00125-07; Noda Y, 2003, J BIOL CHEM, V278, P43516, DOI 10.1074/jbc.M306330200; Pankiv S, 2007, J BIOL CHEM, V282, P24131, DOI 10.1074/jbc.M702824200; Roccato E, 2003, ONCOGENE, V22, P807, DOI 10.1038/sj.onc.1206189; Rodriguez A, 2006, CELL METAB, V3, P211, DOI 10.1016/j.cmet.2006.01.011; Sanchez P, 1998, MOL CELL BIOL, V18, P3069, DOI 10.1128/MCB.18.5.3069; Sanz L, 2000, EMBO J, V19, P1576, DOI 10.1093/emboj/19.7.1576; Sanz L, 1999, EMBO J, V18, P3044, DOI 10.1093/emboj/18.11.3044; Sun WJ, 2009, CELL SIGNAL, V21, P1488, DOI 10.1016/j.cellsig.2009.05.007; Wilson MI, 2003, MOL CELL, V12, P39, DOI 10.1016/S1097-2765(03)00246-6; Wooten MW, 2005, J BIOL CHEM, V280, P35625, DOI 10.1074/jbc.C500237200; Wooten MW, 2001, J BIOL CHEM, V276, P7709, DOI 10.1074/jbc.C000869200; Wu H, 2000, EMBO J, V19, P1963, DOI 10.1093/emboj/19.9.1963; Yang JH, 2001, NAT IMMUNOL, V2, P620, DOI 10.1038/89769; Yao JH, 2007, J BIOL CHEM, V282, P6075, DOI 10.1074/jbc.M609039200	35	90	94	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 15	2010	285	3					2077	2089		10.1074/jbc.M109.065102	http://dx.doi.org/10.1074/jbc.M109.065102			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	541PJ	19903815	Green Published, hybrid			2022-12-25	WOS:000273429100052
J	Schroeder, AC; Zhu, CM; Yanamadala, SR; Cahoon, RE; Arkus, KAJ; Wachsstock, L; Bleeke, J; Krishnan, HB; Jez, JM				Schroeder, Amy C.; Zhu, Chuanmei; Yanamadala, Srinivasa Rao; Cahoon, Rebecca E.; Arkus, Kiani A. J.; Wachsstock, Leia; Bleeke, Jeremy; Krishnan, Hari B.; Jez, Joseph M.			Threonine-insensitive Homoserine Dehydrogenase from Soybean GENOMIC ORGANIZATION, KINETIC MECHANISM, AND IN VIVO ACTIVITY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MONOFUNCTIONAL ASPARTATE KINASE; ISOTOPE-EXCHANGE KINETICS; AMINO-ACID CONTENT; ESCHERICHIA-COLI; ARABIDOPSIS-THALIANA; EVOLUTIONARY RELATIONSHIPS; BIFUNCTIONAL PROTEIN; SULFUR ASSIMILATION; GENE; ASPARTOKINASE	Aspartate kinase (AK) and homoserine dehydrogenase (HSD) function as key regulatory enzymes at branch points in the aspartate amino acid pathway and are feedback-inhibited by threonine. In plants the biochemical features of AK and bifunctional AK-HSD enzymes have been characterized, but the molecular properties of the monofunctional HSD remain unexamined. To investigate the role of HSD, we have cloned the cDNA and gene encoding the monofunctional HSD (GmHSD) from soybean. Using heterologously expressed and purified GmHSD, initial velocity and product inhibition studies support an ordered bi bi kinetic mechanism in which nicotinamide cofactor binds first and leaves last in the reaction sequence. Threonine inhibition of GmHSD occurs at concentrations (K-i = 160-240 mM) more than 1000-fold above physiological levels. This is in contrast to the two AK-HSD isoforms in soybean that are sensitive to threonine inhibition (K-i similar to 150 mu M). In addition, GmHSD is not inhibited by other aspartate-derived amino acids. The ratio of threonine-resistant to threonine-sensitive HSD activity in soybean tissues varies and likely reflects different demands for amino acid biosynthesis. This is the first cloning and detailed biochemical characterization of a monofunctional feedback-insensitive HSD from any plant. Threonine-resistant HSD offers a useful biotechnology tool for manipulating the aspartate amino acid pathway to increase threonine and methionine production in plants for improved nutritional content.	[Schroeder, Amy C.; Zhu, Chuanmei; Arkus, Kiani A. J.; Jez, Joseph M.] Washington Univ, Dept Biol, St Louis, MO 63130 USA; [Schroeder, Amy C.; Cahoon, Rebecca E.; Arkus, Kiani A. J.; Wachsstock, Leia; Bleeke, Jeremy; Jez, Joseph M.] Donald Danforth Plant Sci Ctr, St Louis, MO 63132 USA; [Yanamadala, Srinivasa Rao; Krishnan, Hari B.] Univ Missouri, Plant Genet Res Unit, USDA ARS, Dept Agron, Columbia, MO 65211 USA	Washington University (WUSTL); Donald Danforth Plant Science Center; United States Department of Agriculture (USDA); University of Missouri System; University of Missouri Columbia	Jez, JM (corresponding author), WA Univ, Dept Biol, 1 Brookings Dr,Campus Box 1137, St Louis, MO 63130 USA.	jjez@biology2.wustl.edu			United States Department of Agriculture [NRI-2005-02518]; Illinois-Missouri Biotechnology Alliance [2006-4]; American Society of Plant; University of Missouri Interdisciplinary Plant Group; Pfizer-Solutia Students and Teachers as Research Scientists Internships	United States Department of Agriculture(United States Department of Agriculture (USDA)); Illinois-Missouri Biotechnology Alliance; American Society of Plant; University of Missouri Interdisciplinary Plant Group; Pfizer-Solutia Students and Teachers as Research Scientists Internships	This work was supported by United States Department of Agriculture Grant NRI-2005-02518 (to J.M.J.) and Illinois-Missouri Biotechnology Alliance Grant 2006-4 (to H.B.K. and J.M.J.).; Supported in part by an American Society of Plant Biologists Summer Research Fellowship.; Present address: Biochemistry and Molecular Biology Program, University of California, Davis, CA 95616.; Supported in part by a University of Missouri Interdisciplinary Plant Group graduate research fellowship.; Supported by Pfizer-Solutia Students and Teachers as Research Scientists Internships.	ANGELES TS, 1990, ARCH BIOCHEM BIOPHYS, V283, P96, DOI 10.1016/0003-9861(90)90617-8; ANGELES TS, 1989, BIOCHEMISTRY-US, V28, P8771, DOI 10.1021/bi00448a014; ARCHER JAC, 1991, GENE, V107, P53, DOI 10.1016/0378-1119(91)90296-N; Azevedo RA, 2006, AMINO ACIDS, V30, P143, DOI 10.1007/s00726-005-0245-2; Bareich DC, 2003, CHEM BIOL, V10, P967, DOI 10.1016/j.chembiol.2003.09.016; BLACK S, 1955, J BIOL CHEM, V213, P39; BRYAN JK, 1990, PLANT PHYSIOL, V92, P785, DOI 10.1104/pp.92.3.785; Cook P. F., 2007, ENZYME KINETICS MECH; Curien G, 2005, J BIOL CHEM, V280, P41178, DOI 10.1074/jbc.M509324200; DICAMELLI CA, 1980, PLANT PHYSIOL, V65, P176, DOI 10.1104/pp.65.2.176; FAZEL A, 1983, BIOCHEMISTRY-US, V22, P158, DOI 10.1021/bi00270a023; Frankard V, 1997, PLANT MOL BIOL, V34, P233, DOI 10.1023/A:1005863128558; Galili G, 2002, METAB ENG, V4, P3, DOI 10.1006/mben.2001.0203; Gebhardt J. S., 1999, Plant Physiology, V120, P634; GHISLAIN M, 1994, PLANT MOL BIOL, V24, P835, DOI 10.1007/BF00014439; Hacham Y, 2008, PLANT J, V54, P260, DOI 10.1111/j.1365-313X.2008.03415.x; Jacques SL, 2001, BBA-PROTEIN STRUCT M, V1544, P42, DOI 10.1016/S0167-4838(00)00202-8; Krishnan HB, 2005, CROP SCI, V45, P454, DOI 10.2135/cropsci2005.0454; LIZARDI PM, 1983, METHOD ENZYMOL, V96, P24; MUEHLBAUER GJ, 1994, PLANT PHYSIOL, V106, P1303, DOI 10.1104/pp.106.4.1303; Paris S, 2003, J BIOL CHEM, V278, P5361, DOI 10.1074/jbc.M207379200; Paris S, 2002, PROTEIN EXPRES PURIF, V24, P105, DOI 10.1006/prep.2001.1539; PARSOT C, 1988, J BIOL CHEM, V263, P14654; Phartiyal P, 2008, PHYTOCHEMISTRY, V69, P356, DOI 10.1016/j.phytochem.2007.07.013; Phartiyal P, 2006, ARCH BIOCHEM BIOPHYS, V450, P20, DOI 10.1016/j.abb.2006.03.033; Purich D L, 1980, Methods Enzymol, V64, P1; REINSCHEID DJ, 1991, J BACTERIOL, V173, P3228, DOI 10.1128/JB.173.10.3228-3230.1991; SAGHAIMAROOF MA, 1984, P NATL ACAD SCI-BIOL, V81, P8014, DOI 10.1073/pnas.81.24.8014; Sambrook J., 2002, MOL CLONING LAB MANU; SHAUL O, 1993, PLANT MOL BIOL, V23, P759, DOI 10.1007/BF00021531; SIBILLI L, 1981, J BIOL CHEM, V256, P228; Tang GL, 1997, PLANT MOL BIOL, V34, P287, DOI 10.1023/A:1005849228945; THOMAS D, 1993, FEBS LETT, V323, P289, DOI 10.1016/0014-5793(93)81359-8; Viola RE, 2001, ACCOUNTS CHEM RES, V34, P339, DOI 10.1021/ar000057q; WALTER TJ, 1979, J BIOL CHEM, V254, P1349; Wang XL, 2001, PLANT PHYSIOL, V125, P1778, DOI 10.1104/pp.125.4.1778; WEDLER FC, 1992, BIOCHIM BIOPHYS ACTA, V1119, P247, DOI 10.1016/0167-4838(92)90209-V; WEDLER FC, 1993, J BIOL CHEM, V268, P4880; WILSON BJ, 1991, PLANT PHYSIOL, V97, P1323, DOI 10.1104/pp.97.4.1323; ZhuShimoni JX, 1997, PLANT PHYSIOL, V113, P695, DOI 10.1104/pp.113.3.695	40	15	16	1	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 8	2010	285	2					827	834		10.1074/jbc.M109.068882	http://dx.doi.org/10.1074/jbc.M109.068882			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	539MH	19897476	hybrid, Green Published			2022-12-25	WOS:000273258200003
J	Henriksson, N; Nilsson, P; Wu, MS; Song, HW; Virtanen, A				Henriksson, Niklas; Nilsson, Per; Wu, Mousheng; Song, Haiwei; Virtanen, Anders			Recognition of Adenosine Residues by the Active Site of Poly(A)-specific Ribonuclease	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MAMMALIAN MESSENGER-RNA; CRYSTAL-STRUCTURE; POLY(A) BINDING; 3' EXONUCLEASE; RRM DOMAIN; CAP; DEADENYLATION; DEGRADATION; OLIGOURIDYLATION; POLYMERASES	Poly(A)-specific ribonuclease (PARN) is a mammalian 3'-exoribonuclease that degrades poly(A) with high specificity. To reveal mechanisms by which poly(A) is recognized by the active site of PARN, we have performed a kinetic analysis using a large repertoire of trinucleotide substrates. Our analysis demonstrated that PARN harbors specificity for adenosine recognition in its active site and that the nucleotides surrounding the scissile bond are critical for adenosine recognition. We propose that two binding pockets, which interact with the nucleotides surrounding the scissile bond, play a pivotal role in providing specificity for the recognition of adenosine residues by the active site of PARN. In addition, we show that PARN, besides poly(A), also quite efficiently degrades poly(U), similar to 10-fold less efficiently than poly(A). The poly(U)-degrading property of PARN could be of biological significance as oligo(U) tails recently have been proposed to play a role in RNA stabilization and destabilization.	[Henriksson, Niklas; Nilsson, Per; Virtanen, Anders] Uppsala Univ, Dept Cell & Mol Biol, SE-75124 Uppsala, Sweden; [Wu, Mousheng; Song, Haiwei] Inst Mol & Cell Biol, Singapore 138673, Singapore	Uppsala University; Agency for Science Technology & Research (A*STAR); A*STAR - Institute of Molecular & Cell Biology (IMCB)	Virtanen, A (corresponding author), Box 596, SE-75124 Uppsala, Sweden.	Virtanen@icm.uu.se	Henriksson, Niklas/A-5898-2013		Swedish Research Council; Swedish Research Council to the Uppsala RNA Research Centre; Lennanders Foundation at Uppsala University	Swedish Research Council(Swedish Research CouncilEuropean Commission); Swedish Research Council to the Uppsala RNA Research Centre; Lennanders Foundation at Uppsala University	This work was supported in part by the Swedish Research Council, the Linneus Support from the Swedish Research Council to the Uppsala RNA Research Centre, and the Lennanders Foundation at Uppsala University.	Amblar M, 2006, J MOL BIOL, V360, P921, DOI 10.1016/j.jmb.2006.05.043; Andersen KR, 2009, RNA, V15, P850, DOI 10.1261/rna.1489409; ASTROM J, 1991, EMBO J, V10, P3067, DOI 10.1002/j.1460-2075.1991.tb07858.x; ASTROM J, 1992, J BIOL CHEM, V267, P18154; Clery A, 2008, CURR OPIN STRUC BIOL, V18, P290, DOI 10.1016/j.sbi.2008.04.002; Davis JT, 2004, ANGEW CHEM INT EDIT, V43, P668, DOI 10.1002/anie.200300589; Dehlin E, 2000, EMBO J, V19, P1079, DOI 10.1093/emboj/19.5.1079; Frazao C, 2006, NATURE, V443, P110, DOI 10.1038/nature05080; Gao M, 2000, MOL CELL, V5, P479, DOI 10.1016/S1097-2765(00)80442-6; Garneau NL, 2007, NAT REV MOL CELL BIO, V8, P113, DOI 10.1038/nrm2104; Goldstrohm AC, 2008, NAT REV MOL CELL BIO, V9, P337, DOI 10.1038/nrm2370; Jonstrup AT, 2007, NUCLEIC ACIDS RES, V35, P3153, DOI 10.1093/nar/gkm178; Korner CG, 1997, J BIOL CHEM, V272, P10448; Korner CG, 1998, EMBO J, V17, P5427, DOI 10.1093/emboj/17.18.5427; Kwak JE, 2007, RNA, V13, P860, DOI 10.1261/rna.514007; Maris C, 2005, FEBS J, V272, P2118, DOI 10.1111/j.1742-4658.2005.04653.x; Martinez J, 2001, J BIOL CHEM, V276, P27923, DOI 10.1074/jbc.M102270200; Martinez J, 2000, J BIOL CHEM, V275, P24222, DOI 10.1074/jbc.M001705200; Monecke T, 2008, J MOL BIOL, V382, P827, DOI 10.1016/j.jmb.2008.07.073; Moser MJ, 1997, NUCLEIC ACIDS RES, V25, P5110, DOI 10.1093/nar/25.24.5110; Mullen TE, 2008, GENE DEV, V22, P50, DOI 10.1101/gad.1622708; Nagata T, 2008, NUCLEIC ACIDS RES, V36, P4754, DOI 10.1093/nar/gkn458; Nilsson P, 2007, J BIOL CHEM, V282, P32902, DOI 10.1074/jbc.M702375200; Nilsson P, 2006, INT J BIOL MACROMOL, V39, P95, DOI 10.1016/j.ijbiomac.2006.02.025; Parker R, 2004, NAT STRUCT MOL BIOL, V11, P121, DOI 10.1038/nsmb724; Ren YG, 2004, J BIOL CHEM, V279, P48702, DOI 10.1074/jbc.M403858200; Ren YG, 2002, J BIOL CHEM, V277, P5982, DOI 10.1074/jbc.M111515200; Rissland OS, 2008, BBA-GENE REGUL MECH, V1779, P286, DOI 10.1016/j.bbagrm.2008.03.003; Rissland OS, 2007, MOL CELL BIOL, V27, P3612, DOI 10.1128/MCB.02209-06; Rissland OS, 2009, NAT STRUCT MOL BIOL, V16, P616, DOI 10.1038/nsmb.1601; Song MG, 2007, RNA, V13, P2356, DOI 10.1261/rna.765807; Wilusz CJ, 2008, GENE DEV, V22, P1, DOI 10.1101/gad.1634508; Wu MS, 2009, STRUCTURE, V17, P276, DOI 10.1016/j.str.2008.11.012; Wu MS, 2005, EMBO J, V24, P4082, DOI 10.1038/sj.emboj.7600869; Zuo YH, 2001, NUCLEIC ACIDS RES, V29, P1017, DOI 10.1093/nar/29.5.1017	35	31	32	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 1	2010	285	1					163	170		10.1074/jbc.M109.043893	http://dx.doi.org/10.1074/jbc.M109.043893			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	536UT	19901024	Green Published, hybrid			2022-12-25	WOS:000273070100017
J	Mangialavori, I; Ferreira-Gomes, M; Pignataro, MF; Strehler, EE; Rossi, JPFC				Mangialavori, Irene; Ferreira-Gomes, Mariela; Pignataro, Maria F.; Strehler, Emanuel E.; Rossi, Juan Pablo F. C.			Determination of the Dissociation Constants for Ca2+ and Calmodulin from the Plasma Membrane Ca2+ Pump by a Lipid Probe That Senses Membrane Domain Changes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CALCIUM-PUMP; ENERGY-TRANSFER; CA-2+ PUMP; ACTIVATION; BINDING; CA2+-ATPASE; INTERACTS; CONFORMATION; PROTEINS; ATPASES	The purpose of this work was to obtain information about conformational changes of the plasma membrane Ca2+-pump (PMCA) in the membrane region upon interaction with Ca2+, calmodulin (CaM) and acidic phospholipids. To this end, we have quantified labeling of PMCA with the photoactivatable phosphatidylcholine analog [I-125]TID-PC/16, measuring the shift of conformation E-2 to the auto-inhibited conformation E1I and to the activated E(1)A state, titrating the effect of Ca2+ under different conditions. Using a similar approach, we also determined the CaM-PMCA dissociation constant. The results indicate that the PMCA possesses a high affinity site for Ca2+ regardless of the presence or absence of activators. Modulation of pump activity is exerted through the C-terminal domain, which induces an apparent auto-inhibited conformation for Ca2+ transport but does not modify the affinity for Ca2+ at the transmembrane domain. The C-terminal domain is affected by CaM and CaM-like treatments driving the auto-inhibited conformation E1I to the activated E(1)A conformation and thus modulating the transport of Ca2+. This is reflected in the different apparent constants for Ca2+ in the absence of CaM (calculated by Ca2+-ATPase activity) that sharply contrast with the lack of variation of the affinity for the Ca2+ site at equilibrium. This is the first time that equilibrium constants for the dissociation of Ca2+ and CaM ligands from PMCA complexes are measured through the change of transmembrane conformations of the pump. The data further suggest that the transmembrane domain of the PMCA undergoes major rearrangements resulting in altered lipid accessibility upon Ca2+ binding and activation.	[Mangialavori, Irene; Ferreira-Gomes, Mariela; Pignataro, Maria F.; Rossi, Juan Pablo F. C.] Univ Buenos Aires, Fac Farm & Bioquim, CONICET, Inst Quim & Fis Quim Biol, RA-1113 Buenos Aires, DF, Argentina; [Strehler, Emanuel E.] Mayo Clin, Coll Med, Dept Biochem & Mol Biol, Rochester, MN 55905 USA	Consejo Nacional de Investigaciones Cientificas y Tecnicas (CONICET); University of Buenos Aires; Mayo Clinic	Rossi, JPFC (corresponding author), Univ Buenos Aires, Fac Farm & Bioquim, CONICET, Inst Quim & Fis Quim Biol, Junin 956 1113, RA-1113 Buenos Aires, DF, Argentina.	jprossi@mail.retina.ar	Mangialavori, Irene/GLU-8182-2022	Rossi, Juan Pablo/0000-0001-7087-844X; Mangialavori, Irene/0000-0003-3187-3130	National Institutes of Health, Fogarty International Center [R03TW006837]; Agencia Nacional de Promocio n Cientifica y Tecnologica, CONICET; Universidad de Buenos Aires Ciencia y Tecnica from Argentina; FOGARTY INTERNATIONAL CENTER [R03TW006837] Funding Source: NIH RePORTER	National Institutes of Health, Fogarty International Center(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Fogarty International Center (FIC)); Agencia Nacional de Promocio n Cientifica y Tecnologica, CONICET(ANPCyTConsejo Nacional de Investigaciones Cientificas y Tecnicas (CONICET)); Universidad de Buenos Aires Ciencia y Tecnica from Argentina(University of Buenos Aires); FOGARTY INTERNATIONAL CENTER(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Fogarty International Center (FIC))	This work was supported, in whole or in part, by the National Institutes of Health, Fogarty International Center Grant R03TW006837 and by Agencia Nacional de Promocio n Cientifica y Tecnologica, CONICET, and Universidad de Buenos Aires Ciencia y Tecnica from Argentina.	BALL EH, 1986, ANAL BIOCHEM, V155, P23, DOI 10.1016/0003-2697(86)90218-6; BRUNNER J, 1981, BIOCHEMISTRY-US, V20, P7174, DOI 10.1021/bi00528a019; BRUNNER J, 1993, ANNU REV BIOCHEM, V62, P483, DOI 10.1146/annurev.bi.62.070193.002411; CANTILINA T, 1993, J BIOL CHEM, V268, P17018; CHEN PS, 1956, ANAL CHEM, V28, P1756, DOI 10.1021/ac60119a033; Corradi GR, 2007, J BIOL CHEM, V282, P35440, DOI 10.1074/jbc.M703377200; Durrer P, 1996, J BIOL CHEM, V271, P13417, DOI 10.1074/jbc.271.23.13417; ENYEDI A, 1989, J BIOL CHEM, V264, P12313; FALCHETTO R, 1992, PROTEIN SCI, V1, P1613, DOI 10.1002/pro.5560011209; FALCHETTO R, 1991, J BIOL CHEM, V266, P2930; Filomatori CV, 2003, J BIOL CHEM, V278, P22265, DOI 10.1074/jbc.M302657200; Fiske CH, 1925, J BIOL CHEM, V66, P375; Giraldo AMM, 2006, CELL BIOCHEM BIOPHYS, V44, P431, DOI 10.1385/CBB:44:3:431; Giraldo AMV, 2006, FEBS LETT, V580, P607, DOI 10.1016/j.febslet.2005.12.078; KOSKKOSICKA D, 1989, J BIOL CHEM, V264, P19495; Liyanage MR, 2009, ANAL BIOCHEM, V385, P1, DOI 10.1016/j.ab.2008.10.022; Mangialavori I, 2009, J BIOL CHEM, V284, P4823, DOI 10.1074/jbc.M806912200; Marsh D, 1998, BBA-REV BIOMEMBRANES, V1376, P267, DOI 10.1016/S0304-4157(98)00009-4; NIGGLI V, 1981, J BIOL CHEM, V256, P8588; Olesen C, 2007, NATURE, V450, P1036, DOI 10.1038/nature06418; Penheiter AR, 2003, BIOCHEMISTRY-US, V42, P12115, DOI 10.1021/bi027098+; PENNISTON JT, 1998, ADV MOL CEL A&B, V23, P249; Picard M, 2005, J BIOL CHEM, V280, P18745, DOI 10.1074/jbc.M501596200; SARKADI B, 1986, J BIOL CHEM, V261, P9552; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; Strehler EE, 2007, ANN NY ACAD SCI, V1099, P226, DOI 10.1196/annals.1387.023; Takahashi M, 2007, P NATL ACAD SCI USA, V104, P5800, DOI 10.1073/pnas.0700979104; Toyoshima C, 2004, NATURE, V430, P529, DOI 10.1038/nature02680; Toyoshima C, 2000, NATURE, V405, P647, DOI 10.1038/35015017; Toyoshima C, 2002, NATURE, V418, P605, DOI 10.1038/nature00944; WEBER T, 1995, J AM CHEM SOC, V117, P3084, DOI 10.1021/ja00116a013	31	20	20	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 1	2010	285	1					123	130		10.1074/jbc.M109.076679	http://dx.doi.org/10.1074/jbc.M109.076679			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	536UT	19892708	hybrid, Green Published			2022-12-25	WOS:000273070100013
J	Kim, K; Wang, L; Hwang, I				Kim, Kwangmi; Wang, Lin; Hwang, Inkyu			Acute Inhibition of Selected Membrane-Proximal Mouse T Cell Receptor Signaling by Mitochondrial Antagonists	PLOS ONE			English	Article							ACTIVATED PROTEIN-KINASE; DIRECT STIMULATION; ANTIGEN RECEPTOR; ATP SYNTHASE; COMPLEX-III; MECHANISMS; CA2+; PROLIFERATION; EXPRESSION; INTEGRINS	T cells absorb nanometric membrane vesicles, prepared from plasma membrane of antigen presenting cells, via dual receptor/ligand interactions of T cell receptor (TCR) with cognate peptide/major histocompatibility complex (MHC) plus lymphocyte function-associated antigen 1 (LFA-1) with intercellular adhesion molecule 1. TCR-mediated signaling for LFA-1 activation is also required for the vesicle absorption. Exploiting those findings, we had established a high throughput screening (HTS) platform and screened a library for isolation of small molecules inhibiting the vesicle absorption. Follow-up studies confirmed that treatments (1 hour) with various mitochondrial antagonists, including a class of anti-diabetic drugs (i.e., Metformin and Phenformin), resulted in ubiquitous inhibition of the vesicle absorption without compromising viability of T cells. Further studies revealed that the mitochondrial drug treatments caused impairment of specific membrane-proximal TCR signaling event(s). Thus, activation of Akt and PLC-gamma 1 and entry of extracellular Ca2+ following TCR stimulation were attenuated while polymerization of monomeric actins upon TCR triggering progressed normally after the treatments. Dynamic F-actin rearrangement concurring with the vesicle absorption was also found to be impaired by the drug treatments, implying that the inhibition by the drug treatments of downstream signaling events (and the vesicle absorption) could result from lack of directional relocation of signaling and cell surface molecules. We also assessed the potential application of mitochondrial antagonists as immune modulators by probing effects of the long-term drug treatments (24 hours) on viability of resting primary T cells and cell cycle progression of antigen-stimulated T cells. This study unveils a novel regulatory mechanism for T cell immunity in response to environmental factors having effects on mitochondrial function.			Kim, K (corresponding author), Amorepacific Corp, R&D Ctr, Yongin, Gyeonggi Do, South Korea.	inkyu@scripps.edu		Hwang, Inkyu/0000-0001-8997-6090	NIAID NIH HHS [R01 AI066146, R56 AI066146, AI066146] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R56AI066146, R01AI066146] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Acuto O, 2000, ANNU REV IMMUNOL, V18, P165, DOI 10.1146/annurev.immunol.18.1.165; Badour K, 2003, IMMUNOL REV, V192, P98, DOI 10.1034/j.1600-065X.2003.00031.x; Camello-Almaraz C, 2006, AM J PHYSIOL-CELL PH, V291, pC1082, DOI 10.1152/ajpcell.00217.2006; Childs EW, 2008, SHOCK, V29, P636, DOI 10.1097/SHK.0b013e318157f524; Chun KH, 2003, JNCI-J NATL CANCER I, V95, P291, DOI 10.1093/jnci/95.4.291; Clements JL, 1999, ANNU REV IMMUNOL, V17, P89, DOI 10.1146/annurev.immunol.17.1.89; Droge W, 2002, PHYSIOL REV, V82, P47, DOI 10.1152/physrev.00018.2001; Dustin ML, 2004, NAT IMMUNOL, V5, P363, DOI 10.1038/ni1057; Echtay KS, 2003, EMBO J, V22, P4103, DOI 10.1093/emboj/cdg412; Fang NB, 1999, J AGR FOOD CHEM, V47, P2130, DOI 10.1021/jf981188x; Ghafourifar P, 2005, TRENDS PHARMACOL SCI, V26, P190, DOI 10.1016/j.tips.2005.02.005; Gong YX, 2006, CANCER RES, V66, P4880, DOI 10.1158/0008-5472.CAN-05-4162; Guigas B, 2007, BIOCHEM J, V404, P499, DOI 10.1042/BJ20070105; Hardie DG, 2007, NAT REV MOL CELL BIO, V8, P774, DOI 10.1038/nrm2249; Hardie DG, 2007, ANNU REV PHARMACOL, V47, P185, DOI 10.1146/annurev.pharmtox.47.120505.105304; Hasbold J, 1999, IMMUNOL CELL BIOL, V77, P516, DOI 10.1046/j.1440-1711.1999.00874.x; Hogg N, 2002, IMMUNOL REV, V186, P164, DOI 10.1034/j.1600-065X.2002.18614.x; Hoth M, 2000, P NATL ACAD SCI USA, V97, P10607, DOI 10.1073/pnas.180143997; Hwang I, 2000, J EXP MED, V191, P1137, DOI 10.1084/jem.191.7.1137; Hwang IY, 2003, P NATL ACAD SCI USA, V100, P6670, DOI 10.1073/pnas.1131852100; Jin XS, 2007, STRUCTURE, V15, P1285, DOI 10.1016/j.str.2007.07.017; KANNER SB, 1993, P NATL ACAD SCI USA, V90, P7099, DOI 10.1073/pnas.90.15.7099; Kim K, 2009, J BIOL CHEM, V284, P22149, DOI 10.1074/jbc.M109.000752; Kim K, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0006044; Kovar M, 2006, P NATL ACAD SCI USA, V103, P11671, DOI 10.1073/pnas.0603466103; Kushnareva Y, 2002, BIOCHEM J, V368, P545, DOI 10.1042/BJ20021121; Leverve XM, 2003, DIABETES METAB, V29, pS88; Mahnke DK, 2005, BIOCHEMISTRY-US, V44, P5551, DOI 10.1021/bi048121p; Marrack P, 2004, ANNU REV IMMUNOL, V22, P765, DOI 10.1146/annurev.immunol.22.012703.104554; Miyadera H, 2003, P NATL ACAD SCI USA, V100, P473, DOI 10.1073/pnas.0237315100; Mor A, 2007, IMMUNOL REV, V218, P114, DOI 10.1111/j.1600-065X.2007.00538.x; Okkenhaug K, 2004, BIOCHEM SOC T, V32, P332, DOI 10.1042/BST0320332; OWEN MR, 1993, BIOCHIM BIOPHYS ACTA, V1142, P11, DOI 10.1016/0005-2728(93)90079-U; Pereira GC, 2007, J PHARMACOL EXP THER, V323, P636, DOI 10.1124/jpet.107.128017; Pribila JT, 2004, ANNU REV IMMUNOL, V22, P157, DOI 10.1146/annurev.immunol.22.012703.104649; RABINOVITCH PS, 1986, J IMMUNOL, V137, P952; Schnermann MJ, 2006, J AM CHEM SOC, V128, P11799, DOI 10.1021/ja0632862; Semenza GL, 2007, BIOCHEM J, V405, P1, DOI 10.1042/BJ20070389; SHA WC, 1988, NATURE, V335, P271, DOI 10.1038/335271a0; Smith-Garvin JE, 2009, ANNU REV IMMUNOL, V27, P591, DOI 10.1146/annurev.immunol.021908.132706; SULLIVAN JE, 1994, FEBS LETT, V353, P33, DOI 10.1016/0014-5793(94)01006-4; SYKULEV Y, 1994, P NATL ACAD SCI USA, V91, P11487, DOI 10.1073/pnas.91.24.11487; Takagi J, 2002, IMMUNOL REV, V186, P141, DOI 10.1034/j.1600-065X.2002.18613.x; Tamas P, 2006, J EXP MED, V203, P1665, DOI 10.1084/jem.20052469; Thomas R, 2007, MOL CELL BIOCHEM, V296, P35, DOI 10.1007/s11010-006-9295-3; TURRENS JF, 1985, ARCH BIOCHEM BIOPHYS, V237, P408, DOI 10.1016/0003-9861(85)90293-0; Tybulewicz VL, 2005, CURR OPIN IMMUNOL, V17, P267, DOI 10.1016/j.coi.2005.04.003; Vincenti F, 2007, ANNU REV MED, V58, P347, DOI 10.1146/annurev.med.58.080205.154004; Viollet B, 2003, BIOCHEM SOC T, V31, P216, DOI 10.1042/bst0310216; Weber J, 2006, BBA-BIOENERGETICS, V1757, P1162, DOI 10.1016/j.bbabio.2006.04.007; Zipfel PA, 2006, CURR BIOL, V16, P35, DOI 10.1016/j.cub.2005.12.024	51	3	3	0	1	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	NOV 10	2009	4	11							e7738	10.1371/journal.pone.0007738	http://dx.doi.org/10.1371/journal.pone.0007738			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	517ZU	19901985	gold, Green Submitted, Green Published			2022-12-25	WOS:000271658800005
J	Boulais, N; Pennec, JP; Lebonvallet, N; Pereira, U; Rougier, N; Dorange, G; Chesne, C; Misery, L				Boulais, Nicholas; Pennec, Jean-Pierre; Lebonvallet, Nicolas; Pereira, Ulysse; Rougier, Nathalie; Dorange, Germaine; Chesne, Christophe; Misery, Laurent			Rat Merkel Cells Are Mechanoreceptors and Osmoreceptors	PLOS ONE			English	Article							DEVELOPING NERVOUS-SYSTEM; HISTAMINE H-3 RECEPTORS; PERMEANT BLOCKER; TRPV CHANNELS; SKIN; TRANSDUCTION; ACTIVATION; LOCALIZATION; HYPERPLASIA; EXOCYTOSIS	Merkel cells (MCs) associated with nerve terminals constitute MC-neurite complexes, which are involved in slowly-adapting type I mechanoreception. Although MCs are known to express voltage-gated Ca(2+) channels and hypotonic-induced membrane deformation is known to lead to Ca(2+) transients, whether MCs initiate mechanotransduction is currently unknown. To answer to this question, rat MCs were transfected with a reporter vector, which enabled their identification. Their properties were investigated through electrophysiological studies. Voltage-gated K(+), Ca(2+) and Ca(2+)-activated K(+) (K(Ca)) channels were identified, as previously described. Here, we also report the activation of Ca(2+) channels by histamine and their inhibition by acetylcholine. As a major finding, we demonstrated that direct mechanical stimulations induced strong inward Ca(2+) currents in MCs. Depolarizations were dependent on the strength and the length of the stimulation. Moreover, touch-evoked currents were inhibited by the stretch channel antagonist gadolinium. These data confirm the mechanotransduction capabilities of MCs. Furthermore, we found that activation of the osmoreceptor TRPV4 in FM1-43-labeled MCs provoked neurosecretory granule exocytosis. Since FM1-43 blocks mechanosensory channels, this suggests that hypo-osmolarity activates MCs in the absence of mechanotransduction. Thus, mechanotransduction and osmoreception are likely distinct pathways.			Boulais, N (corresponding author), CHU Brest, EA4326, Lab Nervous Factors & Tissular Struct, European Univ Brittany,Univ Brest, F-29285 Brest, France.	laurent.misery@chu-brest.fr	Misery, Laurent/I-1186-2019; Pereira, Ulysse/ABF-6922-2020	Pereira, Ulysse/0000-0001-5677-6906; Lebonvallet, Nicolas/0000-0001-7263-1408				Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; Arrang J.-M., 2007, ANNALES PHARMACEUTIQUES FRANCAISES, V65, P275, DOI 10.1016/S0003-4509(07)90047-4; Becker D, 2005, J CELL SCI, V118, P2435, DOI 10.1242/jcs.02372; Benham CD, 2003, CELL CALCIUM, V33, P479, DOI 10.1016/S0143-4160(03)00063-0; BOULAIS N, 2008, EUR J DERMA IN PRESS, V18; Boulais N, 2007, J AM ACAD DERMATOL, V57, P147, DOI 10.1016/j.jaad.2007.02.009; Boulais N, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0006528; Brumback AC, 2004, METHODS, V33, P287, DOI 10.1016/j.ymeth.2004.01.002; Cahusac PMB, 2006, SYNAPSE, V59, P235, DOI 10.1002/syn.20236; Cannon KE, 2007, PAIN, V129, P76, DOI 10.1016/j.pain.2006.09.039; Cannon KE, 2007, PHARMACOL BIOCHEM BE, V88, P122, DOI 10.1016/j.pbb.2007.07.014; Chateau Y, 2007, J INVEST DERMATOL, V127, P979, DOI 10.1038/sj.jid.5700646; Corey DP, 2006, J PHYSIOL-LONDON, V576, P23, DOI 10.1113/jphysiol.2006.116582; Cuevas J, 1997, J NEUROPHYSIOL, V78, P1903, DOI 10.1152/jn.1997.78.4.1903; Drew LJ, 2007, MOL PAIN, V3, DOI 10.1186/1744-8069-3-1; Endoh T, 2007, NEUROREPORT, V18, P1141, DOI 10.1097/WNR.0b013e3280ba499d; Fagan BM, 2001, NEUROREPORT, V12, P341, DOI 10.1097/00001756-200102120-00032; FRYE RA, 1983, MOL PHARMACOL, V23, P547; Fukuda J, 2003, CELL TISSUE RES, V311, P325, DOI 10.1007/s00441-002-0688-7; Gale JE, 2001, J NEUROSCI, V21, P7013, DOI 10.1523/JNEUROSCI.21-18-07013.2001; GAUDILLERE A, 1994, ANN DERMATOL VENER, V121, P909; GOTTSCHALDT KM, 1981, SCIENCE, V214, P183, DOI 10.1126/science.7280690; Grando SA, 2006, J INVEST DERMATOL, V126, P1948, DOI 10.1038/sj.jid.5700151; Haeberle H, 2004, P NATL ACAD SCI USA, V101, P14503, DOI 10.1073/pnas.0406308101; Haeberle H, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0001750; HAMILL OP, 1981, PFLUG ARCH EUR J PHY, V391, P85, DOI 10.1007/BF00656997; HARTSCHUH W, 1984, PEPTIDES, V5, P239, DOI 10.1016/0196-9781(84)90213-4; Helms AW, 2000, DEVELOPMENT, V127, P1185; Hitchcock IS, 2004, NEUROSCI LETT, V362, P196, DOI 10.1016/j.neulet.2004.02.071; Johnson KO, 2001, CURR OPIN NEUROBIOL, V11, P455, DOI 10.1016/S0959-4388(00)00234-8; Kanitakis J, 1998, DERMATOLOGY, V196, P208, DOI 10.1159/000017900; Kinkelin I, 1999, EUR J NEUROSCI, V11, P3963, DOI 10.1046/j.1460-9568.1999.00822.x; Liedtke W, 2000, CELL, V103, P525, DOI 10.1016/S0092-8674(00)00143-4; Liedtke W, 2006, J ENDOCRINOL, V191, P515, DOI 10.1677/joe.1.07000; Lumpkin EA, 2003, GENE EXPR PATTERNS, V3, P389, DOI 10.1016/S1567-133X(03)00089-9; Lumpkin EA, 2007, NATURE, V445, P858, DOI 10.1038/nature05662; MEROT Y, 1989, DERMATOLOGICA, V178, P189, DOI 10.1159/000248425; MILLS LR, 1995, J NEUROCYTOL, V24, P117, DOI 10.1007/BF01181555; Nagano N, 1996, JPN J PHARMACOL, V71, P51, DOI 10.1254/jjp.71.51; O'Neil RG, 2005, PFLUG ARCH EUR J PHY, V451, P193, DOI 10.1007/s00424-005-1424-4; Pacitti E G, 1988, Prog Brain Res, V74, P37; PISKOROWSKI R, 2008, PFLUGERS ARCH; REGAZZINI R, 1995, EUR J DERMATOL, V5, P326; Righi A, 2006, INT J SURG PATHOL, V14, P206, DOI 10.1177/1066896906290053; Seino S, 2005, PHYSIOL REV, V85, P1303, DOI 10.1152/physrev.00001.2005; Senok SS, 1997, J PHYSIOL-LONDON, V500, P29, DOI 10.1113/jphysiol.1997.sp021996; Shimohira-Yamasaki M, 2006, CELL STRUCT FUNCT, V31, P39, DOI 10.1247/csf.31.39; Tachibana T, 2003, HISTOCHEM CELL BIOL, V120, P13, DOI 10.1007/s00418-003-0540-5; Talon S, 2005, J PHYSIOL-LONDON, V565, P827, DOI 10.1113/jphysiol.2005.084681; Tazaki M, 1998, NEUROSCI LETT, V243, P69, DOI 10.1016/S0304-3940(98)00066-4; Watanabe H, 2002, J BIOL CHEM, V277, P13569, DOI 10.1074/jbc.M200062200; YAMASHITA Y, 1992, J PHYSIOL-LONDON, V450, P143, DOI 10.1113/jphysiol.1992.sp019120	52	25	26	0	7	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA	1932-6203			PLOS ONE	PLoS One	NOV 9	2009	4	11							e7759	10.1371/journal.pone.0007759	http://dx.doi.org/10.1371/journal.pone.0007759			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	517ZM	19898622	Green Submitted, Green Published, gold			2022-12-25	WOS:000271658000006
J	Tatavarty, V; Kim, EJ; Rodionov, V; Yu, J				Tatavarty, Vedakumar; Kim, Eun-Ji; Rodionov, Vladimir; Yu, Ji			Investigating Sub-Spine Actin Dynamics in Rat Hippocampal Neurons with Super-Resolution Optical Imaging	PLOS ONE			English	Article							LONG-TERM POTENTIATION; DENDRITIC SPINES; LOCALIZATION MICROSCOPY; SYNAPTIC PLASTICITY; PROTRUSION; STABILITY; FILAMENT; TURNOVER	Morphological changes in dendritic spines represent an important mechanism for synaptic plasticity which is postulated to underlie the vital cognitive phenomena of learning and memory. These morphological changes are driven by the dynamic actin cytoskeleton that is present in dendritic spines. The study of actin dynamics in these spines traditionally has been hindered by the small size of the spine. In this study, we utilize a photo-activation localization microscopy (PALM)-based single-molecule tracking technique to analyze F-actin movements with similar to 30-nm resolution in cultured hippocampal neurons. We were able to observe the kinematic (physical motion of actin filaments, i.e., retrograde flow) and kinetic (F-actin turn-over) dynamics of F-actin at the single-filament level in dendritic spines. We found that F-actin in dendritic spines exhibits highly heterogeneous kinematic dynamics at the individual filament level, with simultaneous actin flows in both retrograde and anterograde directions. At the ensemble level, movements of filaments integrate into a net retrograde flow of similar to 138 nm/min. These results suggest a weakly polarized F-actin network that consists of mostly short filaments in dendritic spines.			Tatavarty, V (corresponding author), Univ Connecticut, Ctr Hlth, Ctr Cell Anal & Modeling, Farmington, CT USA.	jyu@uchc.edu			NIGMS NIH HHS [GM62290, GM085301, R01 GM085301-01A1, R01 GM085301, R01 GM062290] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM062290, R01GM085301] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Betzig E, 2006, SCIENCE, V313, P1642, DOI 10.1126/science.1127344; Bubb MR, 2000, J BIOL CHEM, V275, P5163, DOI 10.1074/jbc.275.7.5163; Chen YC, 2004, NEUROREPORT, V15, P829, DOI 10.1097/00001756-200404090-00018; Dunaevsky A, 1999, P NATL ACAD SCI USA, V96, P13438, DOI 10.1073/pnas.96.23.13438; Fischer M, 1998, NEURON, V20, P847, DOI 10.1016/S0896-6273(00)80467-5; Halpain S, 1998, J NEUROSCI, V18, P9835; HARRIS KM, 1992, J NEUROSCI, V12, P2685; HARRIS KM, 1994, ANNU REV NEUROSCI, V17, P341, DOI 10.1146/annurev.ne.17.030194.002013; Harvey CD, 2007, NATURE, V450, P1195, DOI 10.1038/nature06416; Hess ST, 2006, BIOPHYS J, V91, P4258, DOI 10.1529/biophysj.106.091116; Honkura N, 2008, NEURON, V57, P719, DOI 10.1016/j.neuron.2008.01.013; Jurado C, 2005, MOL BIOL CELL, V16, P507, DOI 10.1091/mbc.E04-10-0860; Kim CH, 1999, J NEUROSCI, V19, P4314; Le Clainche C, 2008, PHYSIOL REV, V88, P489, DOI 10.1152/physrev.00021.2007; Manley S, 2008, NAT METHODS, V5, P155, DOI 10.1038/NMETH.1176; Matsuzaki M, 2004, NATURE, V429, P761, DOI 10.1038/nature02617; Matus A, 2000, SCIENCE, V290, P754, DOI 10.1126/science.290.5492.754; MONTAGUE C, 1983, J MUSCLE RES CELL M, V4, P95, DOI 10.1007/BF00711960; Niu LL, 2008, BIOPHYS J, V95, P2009, DOI 10.1529/biophysj.108.128751; Parnass Z, 2000, HIPPOCAMPUS, V10, P561, DOI 10.1002/1098-1063(2000)10:5<561::AID-HIPO6>3.3.CO;2-O; Ponti A, 2004, SCIENCE, V305, P1782, DOI 10.1126/science.1100533; Star EN, 2002, NAT NEUROSCI, V5, P239, DOI 10.1038/nn811; Thompson RE, 2002, BIOPHYS J, V82, P2775, DOI 10.1016/S0006-3495(02)75618-X; Watanabe N, 2002, SCIENCE, V295, P1083, DOI 10.1126/science.1067470; Wiedenmann J, 2004, P NATL ACAD SCI USA, V101, P15905, DOI 10.1073/pnas.0403668101; Yildiz A, 2005, ACCOUNTS CHEM RES, V38, P574, DOI 10.1021/ar040136s; Yuste R, 2001, ANNU REV NEUROSCI, V24, P1071, DOI 10.1146/annurev.neuro.24.1.1071	27	67	68	0	13	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	NOV 9	2009	4	11							e7724	10.1371/journal.pone.0007724	http://dx.doi.org/10.1371/journal.pone.0007724			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	517ZM	19898630	Green Published, gold, Green Submitted			2022-12-25	WOS:000271658000003
J	Meng, ZQ; Liu, C; Hu, XT; Ma, YY				Meng, Zhiqiang; Liu, Chang; Hu, Xintian; Ma, Yuanye			Somatosensory Cortices Are Required for the Acquisition of Morphine-Induced Conditioned Place Preference	PLOS ONE			English	Article							COCAINE-SEEKING; CORTEX; ADDICTION; REWARD; RAT; REPRESENTATIONS; PLASTICITY; BEHAVIOR; INSULA; PROJECTIONS	Background: Sensory system information is thought to play an important role in drug addiction related responses. However, how somatic sensory information participates in the drug related behaviors is still unclear. Many studies demonstrated that drug addiction represents a pathological usurpation of neural mechanisms of learning and memory that normally relate to the pursuit of rewards. Thus, elucidate the role of somatic sensory in drug related learning and memory is of particular importance to understand the neurobiological mechanisms of drug addiction. Principal Findings: In the present study, we investigated the role of somatosensory system in reward-related associative learning using the conditioned place preference model. Lesions were made in somatosensory cortices either before or after conditioning training. We found that lesion of somatosensory cortices before, rather than after morphine conditioning impaired the acquisition of place preference. Conclusion: These results demonstrate that somatosensory cortices are necessary for the acquisition but not retention of morphine induced place preference.			Meng, ZQ (corresponding author), Chinese Acad Sci, Lab Sensory Motor Integrat Res, Kunming, Yunnan, Peoples R China.	xthu@mail.kiz.ac.cn; yuanma0716@vip.sina.com						Accolla R, 2008, P NATL ACAD SCI USA, V105, P4010, DOI 10.1073/pnas.0708927105; Bardo MT, 2000, PSYCHOPHARMACOLOGY, V153, P31, DOI 10.1007/s002130000569; Breiter HC, 1997, NEURON, V19, P591, DOI 10.1016/S0896-6273(00)80374-8; Buonomano DV, 1998, ANNU REV NEUROSCI, V21, P149, DOI 10.1146/annurev.neuro.21.1.149; Cardinal RN, 2002, NEUROSCI BIOBEHAV R, V26, P321, DOI 10.1016/S0149-7634(02)00007-6; Contreras M, 2007, SCIENCE, V318, P655, DOI 10.1126/science.1145590; Devonshire IM, 2007, NEUROSCIENCE, V146, P841, DOI 10.1016/j.neuroscience.2007.01.070; DI CG, 1999, EUR J PHARMACOL, V375, P13; Drouin C, 2004, EUR J NEUROSCI, V19, P1016, DOI 10.1111/j.0953-816X.2004.03186.x; EIKELBOOM R, 1982, PSYCHOL REV, V89, P507, DOI 10.1037/0033-295X.89.5.507; Everitt BJ, 2001, BRAIN RES REV, V36, P129, DOI 10.1016/S0165-0173(01)00088-1; Everitt BJ, 2005, NAT NEUROSCI, V8, P1481, DOI 10.1038/nn1579; Finnerty GT, 1999, NATURE, V400, P367, DOI 10.1038/22553; Fitzgerald PJ, 2004, J NEUROSCI, V24, P11193, DOI 10.1523/JNEUROSCI.3481-04.2004; Frances H, 2004, NEUROREPORT, V15, P2245, DOI 10.1097/00001756-200410050-00021; Golmayo L, 2003, NEUROSCIENCE, V119, P597, DOI 10.1016/S0306-4522(03)00031-9; Grant S, 1996, P NATL ACAD SCI USA, V93, P12040, DOI 10.1073/pnas.93.21.12040; Hearing MC, 2008, BRAIN STRUCT FUNCT, V213, P215, DOI 10.1007/s00429-008-0182-4; Hoffer ZS, 2001, J COMP NEUROL, V439, P87, DOI 10.1002/cne.1337; Hollander JA, 2008, P NATL ACAD SCI USA, V105, P19480, DOI 10.1073/pnas.0808023105; Hyman SE, 2005, AM J PSYCHIAT, V162, P1414, DOI 10.1176/appi.ajp.162.8.1414; JOHNSON SW, 1992, J NEUROSCI, V12, P483; Kalivas PW, 2003, PSYCHOPHARMACOLOGY, V168, P44, DOI 10.1007/s00213-003-1393-2; Koob GF, 2004, NEUROSCI BIOBEHAV R, V27, P739, DOI 10.1016/j.neubiorev.2003.11.007; Koob GF, 1997, SCIENCE, V278, P52, DOI 10.1126/science.278.5335.52; KOOB GF, 2009, NEUROPSYCHOPHAR 0826; Lei YL, 2005, NEUROSCI LETT, V390, P72, DOI 10.1016/j.neulet.2005.08.001; Menzel RR, 2005, CEREB CORTEX, V15, P1690, DOI 10.1093/cercor/bhi045; Naqvi NH, 2007, SCIENCE, V315, P531, DOI 10.1126/science.1135926; Naqvi NH, 2009, TRENDS NEUROSCI, V32, P56, DOI 10.1016/j.tins.2008.09.009; Paxinos G., 1998, RAT BRAIN STEROTAXIC; Shi CJ, 1998, J COMP NEUROL, V399, P469, DOI 10.1002/(SICI)1096-9861(19981005)399:4<469::AID-CNE3>3.0.CO;2-#; Siucinska E, 1996, CEREB CORTEX, V6, P506, DOI 10.1093/cercor/6.3.506; Spanagel R, 1999, TRENDS NEUROSCI, V22, P521, DOI 10.1016/S0166-2236(99)01447-2; Tzschentke TM, 2007, ADDICT BIOL, V12, P227, DOI 10.1111/j.1369-1600.2007.00070.x; Verdejo-Garcia A, 2009, NEUROPHARMACOLOGY, V56, P48, DOI 10.1016/j.neuropharm.2008.07.035; Vorel SR, 2001, SCIENCE, V292, P1175, DOI 10.1126/science.1058043; Wallace MT, 2004, P NATL ACAD SCI USA, V101, P2167, DOI 10.1073/pnas.0305697101; WEINBERGER NM, 1993, P NATL ACAD SCI USA, V90, P2394, DOI 10.1073/pnas.90.6.2394; Xiang Y, 2006, NEUROCHEM RES, V31, P1255, DOI 10.1007/s11064-006-9158-z	40	14	15	0	3	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	NOV 3	2009	4	11							e7742	10.1371/journal.pone.0007742	http://dx.doi.org/10.1371/journal.pone.0007742			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	514RY	19888465	Green Published, gold, Green Submitted			2022-12-25	WOS:000271414500011
J	Muller, IB; Bergmann, B; Groves, MR; Couto, I; Amaral, L; Begley, TP; Walter, RD; Wrenger, C				Mueller, Ingrid B.; Bergmann, Baerbel; Groves, Matthew R.; Couto, Isabel; Amaral, Leonard; Begley, Tadhg P.; Walter, Rolf D.; Wrenger, Carsten			The Vitamin B1 Metabolism of Staphylococcus aureus Is Controlled at Enzymatic and Transcriptional Levels	PLOS ONE			English	Article							PARASITE PLASMODIUM-FALCIPARUM; THIAMIN PHOSPHATE SYNTHASE; THI-BOX RIBOSWITCH; BACILLUS-SUBTILIS; CRYSTAL-STRUCTURE; MALARIA PARASITE; ANGSTROM RESOLUTION; SACCHAROMYCES-CEREVISIAE; PYROPHOSPHOKINASE CDNA; BIOSYNTHESIS	Vitamin B1 is in its active form thiamine pyrophosphate (TPP), an essential cofactor for several key enzymes in the carbohydrate metabolism. Mammals must salvage this crucial nutrient from their diet in order to complement the deficiency of de novo synthesis. In the human pathogenic bacterium Staphylococcus aureus, two operons were identified which are involved in vitamin B1 metabolism. The first operon encodes for the thiaminase type II (TenA), 4-amino-5-hydroxymethyl-2-methylpyrimidine kinase (ThiD), 5-(2-hydroxyethyl)-4-methylthiazole kinase (ThiM) and thiamine phosphate synthase (ThiE). The second operon encodes a phosphatase, an epimerase and the thiamine pyrophosphokinase (TPK). The open reading frames of the individual operons were cloned, their corresponding proteins were recombinantly expressed and biochemically analysed. The kinetic properties of the enzymes as well as the binding of TPP to the in vitro transcribed RNA of the proposed operons suggest that the vitamin B1 homeostasis in S. aureus is strongly regulated at transcriptional as well as enzymatic levels.			Muller, IB (corresponding author), Bernhard Nocht Inst Trop Med, Dept Biochem, Hamburg, Germany.	wrenger@bni-hamburg.de	Wrenger, Carsten/E-4110-2013; Amaral, Leonard/I-2112-2012; Begley, Tadhg/B-5801-2015; Couto, Isabel/I-2640-2012	Wrenger, Carsten/0000-0001-5987-1749; Amaral, Leonard/0000-0003-3127-1295; Couto, Isabel/0000-0003-3536-2733; Groves, Matthew/0000-0001-9859-5177				ACAR JF, 1978, J CLIN MICROBIOL, V8, P142; Baker LJ, 2001, STRUCTURE, V9, P539, DOI 10.1016/S0969-2126(01)00615-3; Batifoulier F, 2005, J CHROMATOGR B, V816, P67, DOI 10.1016/j.jchromb.2004.11.004; Begley TP, 1999, ARCH MICROBIOL, V171, P293, DOI 10.1007/s002030050713; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Campobasso N, 2000, BIOCHEMISTRY-US, V39, P7868, DOI 10.1021/bi0000061; Campobasso N, 1998, BIOCHEMISTRY-US, V37, P15981, DOI 10.1021/bi981673l; Cheng G, 2002, STRUCTURE, V10, P225, DOI 10.1016/S0969-2126(02)00708-6; Chiu HJ, 1999, BIOCHEMISTRY-US, V38, P6460, DOI 10.1021/bi982903z; Downs DM, 2006, ANNU REV MICROBIOL, V60, P533, DOI 10.1146/annurev.micro.60.080805.142308; Edwards TE, 2006, STRUCTURE, V14, P1459, DOI 10.1016/j.str.2006.07.008; Eschbach ML, 2006, BIOL CHEM, V387, P1583, DOI 10.1515/BC.2006.197; Fey PD, 2003, ANTIMICROB AGENTS CH, V47, P196, DOI 10.1128/AAC.47.1.196-203.2003; Grundy FJ, 2002, NUCLEIC ACIDS RES, V30, P1646, DOI 10.1093/nar/30.7.1646; Hohmann S, 1998, BBA-PROTEIN STRUCT M, V1385, P201, DOI 10.1016/S0167-4838(98)00069-7; Jenkins AH, 2007, NAT CHEM BIOL, V3, P492, DOI 10.1038/nchembio.2007.13; Jurgenson CT, 2009, ANNU REV BIOCHEM, V78, P569, DOI 10.1146/annurev.biochem.78.072407.102340; KAUFFMAN CA, 1993, AM J MED, V94, P371, DOI 10.1016/0002-9343(93)90147-H; Knockel J, 2008, MOL BIOCHEM PARASIT, V157, P241, DOI 10.1016/j.molbiopara.2007.10.010; Lawhorn BG, 2004, J BIOL CHEM, V279, P43555, DOI 10.1074/jbc.M404284200; Lee JM, 2001, J BACTERIOL, V183, P7371, DOI 10.1128/JB.183.24.7371-7380.2001; Liu JY, 2006, J BIOL CHEM, V281, P6601, DOI 10.1074/jbc.M510951200; Lowy FD, 1998, NEW ENGL J MED, V339, P520, DOI 10.1056/NEJM199808203390806; Melnick J, 2004, J BACTERIOL, V186, P3660, DOI 10.1128/JB.186.11.3660-3662.2004; Miranda-Rios J, 2001, P NATL ACAD SCI USA, V98, P9736, DOI 10.1073/pnas.161168098; MIZOTE T, 1989, BIOCHIM BIOPHYS ACTA, V991, P109, DOI 10.1016/0304-4165(89)90035-4; MOTOMIZU S, 1983, TALANTA, V30, P333, DOI 10.1016/0039-9140(83)80076-9; Muller IB, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0004406; Muller IB, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0001815; Muller IB, 2005, BIOL CHEM, V386, P117, DOI 10.1515/BC.2005.015; Nettleship Joanne E., 2008, V426, P299, DOI 10.1007/978-1-60327-058-8_19; NOSAKA K, 1993, J BIOL CHEM, V268, P17440; Nosaka K, 1999, J BIOL CHEM, V274, P34129, DOI 10.1074/jbc.274.48.34129; Nosaka K, 2001, BBA-GENE STRUCT EXPR, V1517, P293, DOI 10.1016/S0167-4781(00)00247-5; Ontiveros-Palacios N, 2008, MOL MICROBIOL, V67, P793, DOI 10.1111/j.1365-2958.2007.06088.x; Park JH, 2004, J BACTERIOL, V186, P1571, DOI 10.1128/JB.186.5.1571-1573.2004; Perkins JB, 2002, BACILLUS SUBTILIS IT, P271, DOI DOI 10.1128/9781555817992.CH20; Pohl M, 2004, CURR OPIN BIOTECH, V15, P335, DOI 10.1016/j.copbio.2004.06.002; Reddick JJ, 2001, BIOORG MED CHEM LETT, V11, P2245, DOI 10.1016/S0960-894X(01)00373-0; Reddick JJ, 2001, BIOCHEMISTRY-US, V40, P10095, DOI 10.1021/bi010267q; Rodionov DA, 2002, J BIOL CHEM, V277, P48949, DOI 10.1074/jbc.M208965200; Sambrook J., 2002, MOL CLONING LAB MANU; SAUBERLICH HE, 1984, ANNU REV NUTR, V4, P377, DOI 10.1146/annurev.nu.04.070184.002113; Shin PK, 2005, AM J PHYSIOL-CELL PH, V289, pC727, DOI 10.1152/ajpcell.00034.2005; Toms AV, 2005, BIOCHEMISTRY-US, V44, P2319, DOI 10.1021/bi0478648; VOSKOBOYEV AI, 1982, ANN NY ACAD SCI, V378, P161, DOI 10.1111/j.1749-6632.1982.tb31195.x; Wrenger C, 2008, BRAZ J MED BIOL RES, V41, P82, DOI 10.1590/S0100-879X2008005000006; Wrenger C, 2006, BIOL CHEM, V387, P41, DOI 10.1515/BC.2006.007; Zhang Y, 1997, J BACTERIOL, V179, P3030, DOI 10.1128/jb.179.9.3030-3035.1997	49	20	20	3	17	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA	1932-6203			PLOS ONE	PLoS One	NOV 3	2009	4	11							e7656	10.1371/journal.pone.0007656	http://dx.doi.org/10.1371/journal.pone.0007656			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	514RY	19888457	gold, Green Submitted, Green Published			2022-12-25	WOS:000271414500002
J	Hladik, W; Stover, J; Esiru, G; Harper, M; Tappero, J				Hladik, Wolfgang; Stover, John; Esiru, Godfrey; Harper, Malayah; Tappero, Jordan			The Contribution of Family Planning towards the Prevention of Vertical HIV Transmission in Uganda	PLOS ONE			English	Article							SINGLE-DOSE NEVIRAPINE; TO-CHILD TRANSMISSION; ZIDOVUDINE; INTRAPARTUM; LAMIVUDINE	Background: Uganda has one of the highest total fertility rates (TFR) worldwide. We compared the effects of antiretroviral (ARV) prophylaxis for the prevention of mother-to-child HIV transmission (PMTCT) to that of existing family planning (FP) use and estimated the burden of pediatric HIV disease due to unwanted fertility. Methodology/Principal Findings: Using the demographic software Spectrum, a baseline mathematical projection to estimate the current pediatric HIV burden in Uganda was compared to three hypothetical projections: 1) without ARV-PMTCT (to estimate the effect of ARV-PMTCT), 2) without contraception (effect of existing FP use), 3) without unwanted fertility (effect of unmet FP needs). Key input parameters included HIV prevalence, ARV-PMTCT uptake, MTCT probabilities, and TFR. We estimate that in 2007, an estimated 25,000 vertical infections and 17,000 pediatric AIDS deaths occurred (baseline projection). Existing ARV-PMTCT likely averted 8.1% of infections and 8.5% of deaths. FP use likely averted 19.7% of infections and 13.1% of deaths. Unwanted fertility accounted for 21.3% of infections and 13.4% of deaths. During 20082012, an estimated 131,000 vertical infections and 71,000 pediatric AIDS deaths will occur. The projected scale up of ARV-PMTCT (from 39%-57%) may avert 18.1% of infections and 24.5% of deaths. Projected FP use may avert 21.6% of infections and 18.5% of deaths. Unwanted fertility will account for 24.5% of infections and 19.8% of deaths. Conclusions: Existing FP use contributes as much or more than ARV-PMTCT in mitigating pediatric HIV in Uganda. Expanding FP services can substantially contribute towards PMTCT.			Hladik, W (corresponding author), Ctr Dis Control & Prevent, Global AIDS Program, Natl Ctr HIV Hepatitis STD & TB Prevent, Entebbe, Uganda.	wfh3@cdc.gov						[Anonymous], EP FACT SHEETS HIV A; [Anonymous], WORLD POP PROSP 2008; Brown T., 2008, SEX TRANSM INFECT S1, V84, P5; Cohen Susan, 2008, GUTTMACHER POLICY RE, V11, P2; Dabis F, 2005, AIDS, V19, P309; Feeney G, 2001, POPUL DEV REV, V27, P771, DOI 10.1111/j.1728-4457.2001.00771.x; Ghys PD, 2008, SEX TRANSM INFECT, V84, pI1, DOI 10.1136/sti.2008.032573; Iliff PJ, 2005, AIDS, V19, P699, DOI 10.1097/01.aids.0000166093.16446.c9; Jackson JB, 2003, LANCET, V362, P859, DOI 10.1016/S0140-6736(03)14341-3; KIRUNGI W, 2009, COMMUNICATION; *MIN HLTH, 2008, SIT AN REP JOINT REV; *MOH UG ORC MACRO, 2006, UG HIV AIDS SER SURV; Moodley D, 2003, J INFECT DIS, V187, P725, DOI 10.1086/367898; Musinguzi J, 2009, JAIDS-J ACQ IMM DEF, V51, P78, DOI 10.1097/QAI.0b013e3181990713; Prata N, 2008, J FAM PLAN REPROD H, V34, P219, DOI 10.1783/147118908786000406; Reynolds HW, 2006, SEX TRANSM DIS, V33, P350, DOI 10.1097/01.olq.0000194602.01058.e1; REYOLDS HW, 2008, SEX TRANSM INFECT S2, V84, P49; Robertson L, 2008, SEX TRANSM INFECT, V84, pI57, DOI 10.1136/sti.2008.029926; Singh S, 2005, INT FAM PLAN PERSPEC, V31, P183, DOI 10.1363/3118305; Stover J, 2008, SEX TRANSM INFECT, V84, pI24, DOI 10.1136/sti.2008.029868; STOVER J, 2009, AIM MANUAL COMPUTER; Sweat MD, 2004, AIDS, V18, P1661, DOI 10.1097/01.aids.0000131353.06784.8f; *UBOS MACRO INT IN, 2006, UG DEM HLTH SURV 200; *UG AIDS COMM, 2007, MOV UN ACC NAT HIV A; *UN POP FUND, 2007, PEOPL POV POSS; UNAIDS, 2008, REP GLOB AIDS EP; *UNFPA, 2004, NEW YORK CELL COMM L; *WHO INT AG TASK T, 2007, GUID GLOB SCAL UP PR; Wilcher R, 2008, SEX TRANSM INFECT, V84, pII54, DOI 10.1136/sti.2008.030098; World Health Organization, 2007, MAT MORT 2005 EST DE; World Health Organization, 2002, STRAT APPR PREV HIV; World Health Organization, 2008, UN ACC SCAL PRIOR HI	32	52	52	0	0	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	NOV 2	2009	4	11							e7691	10.1371/journal.pone.0007691	http://dx.doi.org/10.1371/journal.pone.0007691			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	514RX	19888347	Green Published, gold			2022-12-25	WOS:000271414400008
J	Kim, I; Li, Y; Muniz, P; Rao, H				Kim, Ikjin; Li, Yue; Muniz, Paulina; Rao, Hai			Usa1 Protein Facilitates Substrate Ubiquitylation through Two Separate Domains	PLOS ONE			English	Article							RETICULUM-ASSOCIATED DEGRADATION; ER-ASSOCIATED DEGRADATION; ENDOPLASMIC-RETICULUM; MISFOLDED GLYCOPROTEINS; QUALITY-CONTROL; UBIQUITIN; COMPLEX; MEMBRANE; PATHWAY; ATPASE	Background: Defects in protein folding are recognized as the root of many neurodegenerative disorders. In the endoplasmic reticulum (ER), secretory proteins are subjected to a stringent quality control process to eliminate misfolded proteins by the ER-associated degradation (ERAD) pathway. A novel ERAD component Usa1 was recently identified. However, the specific role of Usa1 in ERAD remains obscure. Methodology/Principal Findings: Here, we demonstrate that Usa1 is important for substrate ubiquitylation. Furthermore, we defined key cis-elements of Usa1 essential for its degradation function. Interestingly, a putative proteasome-binding motif is dispensable for the functioning of Usa1 in ERAD. We identify two separate cytosolic domains critical for Usa1 activity in ERAD, one of which is involved in binding to the Ub-protein ligase Hrd1/Hrd3. Usa1 may have another novel role in substrate ubiquitylation that is separate from the Hrd1 association. Conclusions/Significance: We conclude that Usa1 has two important roles in ERAD substrate ubiquitylation.			Kim, I (corresponding author), Univ Texas Hlth Sci Ctr San Antonio, Inst Biotechnol, San Antonio, TX 78229 USA.	kimi@uthscsa.edu; raoh@uthscsa.edu	Li, Yue/C-2835-2014	RAO, HAI/0000-0002-4235-2210	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM078085] Funding Source: NIH RePORTER; NIGMS NIH HHS [R01 GM078085, GM078085] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Apodaca J, 2006, BIOCHEM BIOPH RES CO, V347, P319, DOI 10.1016/j.bbrc.2006.06.078; Awasthi S, 2001, J BIOL CHEM, V276, P31004, DOI 10.1074/jbc.M100022200; Bays NW, 2001, NAT CELL BIOL, V3, P24, DOI 10.1038/35050524; Bhamidipati A, 2005, MOL CELL, V19, P741, DOI 10.1016/j.molcel.2005.07.027; Biederer T, 1997, SCIENCE, V278, P1806, DOI 10.1126/science.278.5344.1806; Biederer T, 1996, EMBO J, V15, P2069, DOI 10.1002/j.1460-2075.1996.tb00560.x; Carvalho P, 2006, CELL, V126, P361, DOI 10.1016/j.cell.2006.05.043; Ciechanover A, 2004, BBA-MOL CELL RES, V1695, P3, DOI 10.1016/j.bbamcr.2004.09.018; DeMartino GN, 1999, J BIOL CHEM, V274, P22123, DOI 10.1074/jbc.274.32.22123; Denic V, 2006, CELL, V126, P349, DOI 10.1016/j.cell.2006.05.045; Ellgaard L, 2003, NAT REV MOL CELL BIO, V4, P181, DOI 10.1038/nrm1052; Gardner RG, 2000, J CELL BIOL, V151, P69, DOI 10.1083/jcb.151.1.69; Gauss R, 2006, EMBO J, V25, P1827, DOI 10.1038/sj.emboj.7601088; Han S, 2007, J BIOL CHEM, V282, P26140, DOI 10.1074/jbc.M701969200; Hartmann-Petersen R, 2004, SEMIN CELL DEV BIOL, V15, P247, DOI 10.1016/j.semcdb.2003.12.006; Hori O, 2004, GENES CELLS, V9, P457, DOI 10.1111/j.1356-9597.2004.00735.x; Jarosch E, 2002, NAT CELL BIOL, V4, P134, DOI 10.1038/ncb746; Kim I, 2004, MOL BIOL CELL, V15, P3357, DOI 10.1091/mbc.E03-11-0835; Kim I, 2006, J CELL BIOL, V172, P211, DOI 10.1083/jcb.200507149; Kokame K, 2000, J BIOL CHEM, V275, P32846, DOI 10.1074/jbc.M002063200; Meusser B, 2005, NAT CELL BIOL, V7, P766, DOI 10.1038/ncb0805-766; Okuda-Shimizu Y, 2007, MOL CELL, V28, P544, DOI 10.1016/j.molcel.2007.09.012; Plemper RK, 1999, J CELL SCI, V112, P4123; Rabinovich E, 2002, MOL CELL BIOL, V22, P626, DOI 10.1128/MCB.22.2.626-634.2002; Romisch K, 2005, ANNU REV CELL DEV BI, V21, P435, DOI 10.1146/annurev.cellbio.21.012704.133250; Schauber C, 1998, NATURE, V391, P715, DOI 10.1038/35661; SCHNEIDER BL, 1995, YEAST, V11, P1265, DOI 10.1002/yea.320111306; Schulze A, 2005, J MOL BIOL, V354, P1021, DOI 10.1016/j.jmb.2005.10.020; Schwartz DC, 2003, TRENDS BIOCHEM SCI, V28, P321, DOI 10.1016/S0968-0004(03)00113-0; Vashist S, 2004, J CELL BIOL, V165, P41, DOI 10.1083/jcb.200309132; Vembar SS, 2008, NAT REV MOL CELL BIO, V9, P944, DOI 10.1038/nrm2546; Weissman AM, 2001, NAT REV MOL CELL BIO, V2, P169, DOI 10.1038/35056563; Ye YH, 2001, NATURE, V414, P652, DOI 10.1038/414652a	33	16	18	0	1	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA	1932-6203			PLOS ONE	PLoS One	OCT 29	2009	4	10							e7604	10.1371/journal.pone.0007604	http://dx.doi.org/10.1371/journal.pone.0007604			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	512FP	19898607	Green Published, gold, Green Submitted			2022-12-25	WOS:000271232000002
J	Espinoza, DO; Boros, LG; Crunkhorn, S; Gami, H; Patti, ME				Espinoza, Daniel O.; Boros, Laszlo G.; Crunkhorn, Sarah; Gami, Hiral; Patti, Mary-Elizabeth			Dual modulation of both lipid oxidation and synthesis by peroxisome proliferator-activated receptor-gamma coactivator-1 alpha and-1 beta in cultured myotubes	FASEB JOURNAL			English	Article						metabolomics; fatty acid metabolism; lipid metabolism	HUMAN SKELETAL-MUSCLE; INDUCED INSULIN-RESISTANCE; SATURATED FATTY-ACIDS; ERR-ALPHA; CERAMIDE SYNTHESIS; ENERGY-METABOLISM; GENE-EXPRESSION; ADIPOSE-TISSUE; OBESE SUBJECTS; PGC-1-ALPHA	The peroxisome proliferator-activated receptor gamma coactivator-1 (PGC-1) family is a key regulator of mitochondrial function, and reduced mRNA expression may contribute to muscle lipid accumulation in obesity and type 2 diabetes. To characterize the effects of PGC-1 on lipid metabolism, we overexpressed PGC-1 alpha and PGC-1 beta in C2C12 myotubes using adenoviral vectors. Both PGC-1 alpha and -1 beta increased palmitate oxidation [31% (P<0.01) and 26% (P<0.05), respectively] despite reductions in cellular uptake [by 6% (P<0.05) and 21% (P<0.001)]. Moreover, PGC-1 alpha and -1 beta increased mRNA expression of genes regulating both lipid oxidation (e.g., CPT1b and ACADL/M) and synthesis (FAS, CS, ACC1/2, and DGAT1). To determine the net effect, we assessed lipid composition in PGC-1-expressing cells. Total lipid content decreased by 42% in palmitate-loaded serum-starved cells overexpressing PGC-1 alpha (P<0.05). In contrast, in serum-replete cells, total lipid content was not significantly altered, but fatty acids C14:0, C16:0, C18:0, and C18: 1 were increased 2- to 4-fold for PGC-1 alpha/beta (P<0.05). Stable isotope-based dynamic metabolic profiling in serum-replete cells labeled with C-13 substrates revealed both increased de novo fatty acid synthesis from glucose and increased fatty acid synthesis by chain elongation with either PGC-1 alpha or -1 beta expression. These results indicate that PGC-1 can promote both lipid oxidation and synthesis, with net balance determined by the nutrient/hormonal environment.-Espinoza, D. O., Boros, L. G., Crunkhorn, S., Gami, H., Patti, M.-E. Dual Modulation of both lipid oxidation and synthesis by peroxisome proliferator-activated receptor-gamma coactivator-1 alpha and -1 beta in cultured myotubes. FASEB J. 24, 1003-1014 (2010). www.fasebj.org	[Espinoza, Daniel O.; Crunkhorn, Sarah; Gami, Hiral; Patti, Mary-Elizabeth] Joslin Diabet Ctr, Div Res, Boston, MA 02215 USA; [Espinoza, Daniel O.; Crunkhorn, Sarah; Gami, Hiral; Patti, Mary-Elizabeth] Harvard Univ, Sch Med, Boston, MA USA; [Boros, Laszlo G.] Univ Calif Los Angeles, Sch Med, Los Angeles, CA USA; [Boros, Laszlo G.] SIDMAP LLC, Los Angeles, CA USA	Harvard University; Joslin Diabetes Center, Inc.; Harvard University; Harvard Medical School; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA	Patti, ME (corresponding author), Joslin Diabet Ctr, Div Res, 1 Joslin Pl, Boston, MA 02215 USA.	mary.elizabeth.patti@joslin.harvard.edu			National Institute of Diabetes and Digestive and Kidney Diseases [DK062948]; Diabetes and Endocrinology Research Center [P30 DK36836]; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK062948, P30DK036836] Funding Source: NIH RePORTER	National Institute of Diabetes and Digestive and Kidney Diseases(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); Diabetes and Endocrinology Research Center; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))	The authors thank Dr. Bruce Spiegelman (Dana Farber Cancer Institute, Boston, MA, USA) for the gift of adenovirus constructs Ad-GFP, AdPGC-1 alpha, and AdPGC-1 beta and Drs. Masa Katic, Yuji Yamamoto, and Enxuan Jing (Joslin Diabetes Center, Boston, MA, USA) for selected primers. The authors appreciate the assistance of the Lipid Core, Mouse Metabolic Phenotyping Center, Vanderbilt University (Nashville, TN, USA). The authors gratefully acknowledge grant funding from the National Institute of Diabetes and Digestive and Kidney Diseases (DK062948) and the Diabetes and Endocrinology Research Center (P30 DK36836).	Adams JM, 2004, DIABETES, V53, P25, DOI 10.2337/diabetes.53.1.25; Arany Z, 2005, CELL METAB, V1, P259, DOI 10.1016/j.cmet.2005.03.002; Arany Z, 2007, CELL METAB, V5, P35, DOI 10.1016/j.cmet.2006.12.003; BABSON AL, 1962, CLIN CHIM ACTA, V7, P800, DOI 10.1016/0009-8981(62)90062-1; Benton CR, 2008, J BIOL CHEM, V283, P4228, DOI 10.1074/jbc.M704332200; Bodennec J, 2000, J LIPID RES, V41, P1524; Calvo JA, 2008, J APPL PHYSIOL, V104, P1304, DOI 10.1152/japplphysiol.01231.2007; Crowder CM, 2009, SCIENCE, V324, P343, DOI 10.1126/science.1173278; Crunkhorn S, 2007, J BIOL CHEM, V282, P15439, DOI 10.1074/jbc.M611214200; Dufour CR, 2007, CELL METAB, V5, P345, DOI 10.1016/j.cmet.2007.03.007; FOLLI F, 1993, J CLIN INVEST, V92, P1787, DOI 10.1172/JCI116768; Goodpaster BH, 2001, J CLIN ENDOCR METAB, V86, P5755, DOI 10.1210/jc.86.12.5755; Hammarstedt A, 2003, BIOCHEM BIOPH RES CO, V301, P578, DOI 10.1016/S0006-291X(03)00014-7; Handschin C, 2003, P NATL ACAD SCI USA, V100, P7111, DOI 10.1073/pnas.1232352100; Handschin C, 2007, J CLIN INVEST, V117, P3463, DOI 10.1172/JCI31785; Handschin C, 2007, J BIOL CHEM, V282, P30014, DOI 10.1074/jbc.M704817200; Haus JM, 2009, DIABETES, V58, P337, DOI 10.2337/db08-1228; Holland WL, 2007, CELL METAB, V5, P167, DOI 10.1016/j.cmet.2007.01.002; Itani SI, 2002, DIABETES, V51, P2005, DOI 10.2337/diabetes.51.7.2005; Jacob S, 1999, DIABETES, V48, P1113, DOI 10.2337/diabetes.48.5.1113; Jakobsson A, 2006, PROG LIPID RES, V45, P237, DOI 10.1016/j.plipres.2006.01.004; Kelley DE, 2000, DIABETES, V49, P677, DOI 10.2337/diabetes.49.5.677; Kelley DE, 2002, DIABETES, V51, P2944, DOI 10.2337/diabetes.51.10.2944; Koves TR, 2005, J BIOL CHEM, V280, P33588, DOI 10.1074/jbc.M507621200; Larrouy D, 1999, INT J OBESITY, V23, P1327, DOI 10.1038/sj.ijo.0801106; Lelliott CJ, 2006, PLOS BIOL, V4, P2042, DOI 10.1371/journal.pbio.0040369; Leone TC, 2005, PLOS BIOL, V3, P672, DOI 10.1371/journal.pbio.0030101; Lin J, 2002, NATURE, V418, P797, DOI 10.1038/nature00904; Lin JD, 2004, CELL, V119, P121, DOI 10.1016/j.cell.2004.09.013; Lin JD, 2005, CELL, V120, P261, DOI 10.1016/j.cell.2004.11.043; Michael LF, 2001, P NATL ACAD SCI USA, V98, P3820, DOI 10.1073/pnas.061035098; Montell E, 2001, AM J PHYSIOL-ENDOC M, V280, pE229, DOI 10.1152/ajpendo.2001.280.2.E229; Mootha VK, 2004, P NATL ACAD SCI USA, V101, P6570, DOI 10.1073/pnas.0401401101; Mootha VK, 2003, NAT GENET, V34, P267, DOI 10.1038/ng1180; Patti ME, 2003, P NATL ACAD SCI USA, V100, P8466, DOI 10.1073/pnas.1032913100; Petersen KF, 2004, NEW ENGL J MED, V350, P664, DOI 10.1056/NEJMoa031314; Pewzner-Jung Y, 2006, J BIOL CHEM, V281, P25001, DOI 10.1074/jbc.R600010200; Puigserver P, 2003, NATURE, V423, P550, DOI 10.1038/nature01667; Rhee J, 2003, P NATL ACAD SCI USA, V100, P4012, DOI 10.1073/pnas.0730870100; Richardson DK, 2005, J BIOL CHEM, V280, P10290, DOI 10.1074/jbc.M408985200; Russell AP, 2005, FASEB J, V19, P986, DOI 10.1096/fj.04-3168fje; Savage DB, 2007, PHYSIOL REV, V87, P507, DOI 10.1152/physrev.00024.2006; Scarpulla RC, 2002, GENE, V286, P81, DOI 10.1016/S0378-1119(01)00809-5; Schreiber SN, 2003, J BIOL CHEM, V278, P9013, DOI 10.1074/jbc.M212923200; Semple RK, 2004, INT J OBESITY, V28, P176, DOI 10.1038/sj.ijo.0802482; Simoneau JA, 1997, J APPL PHYSIOL, V83, P166, DOI 10.1152/jappl.1997.83.1.166; SONODA J, P NATL ACAD SCI US, V104, P5223; Sparks LM, 2005, DIABETES, V54, P1926, DOI 10.2337/diabetes.54.7.1926; Storey JD, 2002, J ROY STAT SOC B, V64, P479, DOI 10.1111/1467-9868.00346; Tortorella LL, 2002, AM J PHYSIOL-ENDOC M, V283, pE514, DOI 10.1152/ajpendo.00092.2002; Vega RB, 2000, MOL CELL BIOL, V20, P1868, DOI 10.1128/MCB.20.5.1868-1876.2000; Vianna CR, 2006, CELL METAB, V4, P453, DOI 10.1016/j.cmet.2006.11.003; Wende AR, 2007, J BIOL CHEM, V282, P36642, DOI 10.1074/jbc.M707006200; Wu ZD, 1999, CELL, V98, P115, DOI 10.1016/S0092-8674(00)80611-X; Yang G, 2009, AM J PHYSIOL-ENDOC M, V297, pE211, DOI 10.1152/ajpendo.91014.2008	55	45	46	0	10	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	APR	2010	24	4					1003	1014		10.1096/fj.09-133728	http://dx.doi.org/10.1096/fj.09-133728			12	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	580PV	19906680	Green Published			2022-12-25	WOS:000276462300008
J	Davidson, L; Maccario, H; Perera, NM; Yang, X; Spinelli, L; Tibarewal, P; Glancy, B; Gray, A; Weijer, CJ; Downes, CP; Leslie, NR				Davidson, L.; Maccario, H.; Perera, N. M.; Yang, X.; Spinelli, L.; Tibarewal, P.; Glancy, B.; Gray, A.; Weijer, C. J.; Downes, C. P.; Leslie, N. R.			Suppression of cellular proliferation and invasion by the concerted lipid and protein phosphatase activities of PTEN	ONCOGENE			English	Article						PTEN; PI3 kinase; phosphoinositide; cancer; TPIP; Akt	TUMOR-SUPPRESSOR; GLIOMA-CELLS; PHOSPHATIDYLINOSITOL 4,5-BISPHOSPHATE; GLIOBLASTOMA CELLS; BINDING MOTIF; NUCLEAR PTEN; GROWTH; ACTIVATION; MIGRATION; EXPRESSION	PTEN is a tumour suppressor with phosphatase activity in vitro against both lipids and proteins and other potential non-enzymatic mechanisms of action. Although the importance of PTEN's lipid phosphatase activity in regulating the PI3K signalling pathway is recognized, the significance of PTEN's other mechanisms of action is currently unclear. In this study, we describe the systematic identification of a PTEN mutant, PTEN Y138L, with activity against lipid, but not soluble substrates. Using this mutant, we provide evidence for the interfacial activation of PTEN against lipid substrates. We also show that when re-expressed at physiological levels in PTEN null U87MG glioblastoma cells, the protein phosphatase activity of PTEN is not required to regulate cellular PtdInsP(3) levels or the downstream protein kinase Akt/PKB. Finally, in three-dimensional Matrigel cultures of U87MG cells similarly re-expressing PTEN mutants, both the protein and lipid phosphatase activities were required to inhibit invasion, but either activity alone significantly inhibited proliferation, albeit only weakly for the protein phosphatase activity. Our data provide a novel tool to address the significance of PTEN's separable lipid and protein phosphatase activities and suggest that both activities suppress proliferation and together suppress invasion. Oncogene (2010) 29, 687-697; doi: 10.1038/onc.2009.384; published online 16 November 2009	[Davidson, L.; Maccario, H.; Perera, N. M.; Spinelli, L.; Tibarewal, P.; Glancy, B.; Gray, A.; Downes, C. P.; Leslie, N. R.] Univ Dundee, Div Mol Physiol, Coll Life Sci, Dundee DD1 5EH, Scotland; [Yang, X.; Weijer, C. J.] Univ Dundee, Div Cell & Dev Biol, Coll Life Sci, Dundee DD1 5EH, Scotland	University of Dundee; University of Dundee	Leslie, NR (corresponding author), Univ Dundee, Div Mol Physiol, Coll Life Sci, Dow St, Dundee DD1 5EH, Scotland.	n.r.leslie@dundee.ac.uk	Leslie, Nicholas/D-2699-2009; weijer, cornelis j/I-4538-2012	LESLIE, Nicholas/0000-0001-5131-0541; Tibarewal, Priyanka/0000-0003-3510-8428; Gray, Alexander/0000-0001-9227-0363; Weijer, Cornelis/0000-0003-2192-8150; Spinelli, Laura/0000-0002-5801-6297	Medical Research Council; Association for International Cancer Research; DSTT consortium; MRC [G0801865, G9403619] Funding Source: UKRI; Biotechnology and Biological Sciences Research Council [G18071] Funding Source: researchfish; Medical Research Council [G0801865, G9403619] Funding Source: researchfish	Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Association for International Cancer Research; DSTT consortium; MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Biotechnology and Biological Sciences Research Council(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission)	We thank Sam Swift and Paul Appleton from the Dundee Light Microscopy Facility for their help with image acquisition and analysis. We thank Hilary McLauchlan, James Hastie and their staff in the DSTT (University of Dundee) for provision of purified antibodies and recombinant protein kinases and Steven Hubbard for advice regarding data analysis. NL is an RCUK Academic Fellow. Work in the Inositol Lipid Signalling laboratory was funded by the Medical Research Council, the Association for International Cancer Research and the pharmaceutical companies of the DSTT consortium (Astra Zeneca, Boehringer Ingelheim, GlaxoSmithKline, Merck KGaA and Pfizer).	Campbell RB, 2003, J BIOL CHEM, V278, P33617, DOI 10.1074/jbc.C300296200; Cheney IW, 1998, CANCER RES, V58, P2331; Chow LML, 2006, CANCER LETT, V241, P184, DOI 10.1016/j.canlet.2005.11.042; Das S, 2003, P NATL ACAD SCI USA, V100, P7491, DOI 10.1073/pnas.0932835100; Davies MA, 1998, CANCER RES, V58, P5285; de Bouard S, 2002, J NEUROSURG, V97, P169, DOI 10.3171/jns.2002.97.1.0169; Deleu S, 2006, CELL SIGNAL, V18, P488, DOI 10.1016/j.cellsig.2005.05.017; Dey N, 2008, CANCER RES, V68, P1862, DOI 10.1158/0008-5472.CAN-07-1182; Freeman DJ, 2003, CANCER CELL, V3, P117, DOI 10.1016/S1535-6108(03)00021-7; Furnari FB, 1997, P NATL ACAD SCI USA, V94, P12479, DOI 10.1073/pnas.94.23.12479; Furnari FB, 1998, CANCER RES, V58, P5002; Gil A, 2007, CELL DEATH DIFFER, V14, P395, DOI 10.1038/sj.cdd.4402073; Gildea JJ, 2004, ONCOGENE, V23, P6788, DOI 10.1038/sj.onc.1207599; Goldbrunner RH, 1998, MICROSC RES TECHNIQ, V43, P250, DOI 10.1002/(SICI)1097-0029(19981101)43:3<250::AID-JEMT7>3.0.CO;2-C; Gray A, 2003, ANAL BIOCHEM, V313, P234, DOI 10.1016/S0003-2697(02)00607-3; Gu JG, 1999, J CELL BIOL, V146, P389, DOI 10.1083/jcb.146.2.389; Hjelmeland AB, 2005, CANCER RES, V65, P11276, DOI 10.1158/0008-5472.CAN-05-3016; Iijima M, 2004, J BIOL CHEM, V279, P16606, DOI 10.1074/jbc.M312098200; Ikeda Y, 2003, NAT BIOTECHNOL, V21, P569, DOI 10.1038/nbt815; Ji SP, 2006, NAT MED, V12, P324, DOI 10.1038/nm1349; Keniry M, 2008, ONCOGENE, V27, P5477, DOI 10.1038/onc.2008.248; Lackey J, 2007, ONCOGENE, V26, P7132, DOI 10.1038/sj.onc.1210520; Lee JO, 1999, CELL, V99, P323, DOI 10.1016/S0092-8674(00)81663-3; Leslie NR, 2008, ONCOGENE, V27, P5464, DOI 10.1038/onc.2008.243; Leslie NR, 2007, CURR BIOL, V17, P115, DOI 10.1016/j.cub.2006.12.026; Liaw D, 1997, NAT GENET, V16, P64, DOI 10.1038/ng0597-64; Maccario H, 2007, BIOCHEM J, V405, P439, DOI 10.1042/BJ20061837; Mahimainathan L, 2004, J BIOL CHEM, V279, P15258, DOI 10.1074/jbc.M314328200; McConnachie G, 2003, BIOCHEM J, V371, P947, DOI 10.1042/BJ20021848; Myers MP, 1997, P NATL ACAD SCI USA, V94, P9052, DOI 10.1073/pnas.94.17.9052; Myers MP, 1998, P NATL ACAD SCI USA, V95, P13513, DOI 10.1073/pnas.95.23.13513; Ning K, 2006, EMBO J, V25, P2377, DOI 10.1038/sj.emboj.7601118; Okumura K, 2005, P NATL ACAD SCI USA, V102, P2703, DOI 10.1073/pnas.0409370102; Orchiston EA, 2004, J BIOL CHEM, V279, P1116, DOI 10.1074/jbc.M310933200; Park MJ, 2002, CANCER RES, V62, P6318; Raftopoulou M, 2004, SCIENCE, V303, P1179, DOI 10.1126/science.1092089; Redfern RE, 2008, BIOCHEMISTRY-US, V47, P2162, DOI 10.1021/bi702114w; Salmena L, 2008, CELL, V133, P403, DOI 10.1016/j.cell.2008.04.013; Sansal I, 2004, J CLIN ONCOL, V22, P2954, DOI 10.1200/jco.2004.02.141; Shen WH, 2007, CELL, V128, P157, DOI 10.1016/j.cell.2006.11.042; Suzuki A, 2008, CANCER SCI, V99, P209, DOI 10.1111/j.1349-7006.2007.00670.x; Tamura M, 1998, SCIENCE, V280, P1614, DOI 10.1126/science.280.5369.1614; Tapparel C, 2003, GENE, V323, P189, DOI 10.1016/j.gene.2003.09.038; Trotman LC, 2007, CELL, V128, P141, DOI 10.1016/j.cell.2006.11.040; Vazquez F, 2001, J BIOL CHEM, V276, P48627, DOI 10.1074/jbc.C100556200; Vogelmann R, 2005, J CELL SCI, V118, P4901, DOI 10.1242/jcs.02594; Walker SM, 2004, BIOCHEM J, V379, P301, DOI 10.1042/BJ20031839; Walker SM, 2001, BIOCHEM J, V360, P277, DOI 10.1042/0264-6021:3600277; Yang XS, 2002, DEV CELL, V3, P425, DOI 10.1016/S1534-5807(02)00256-3	49	96	100	0	12	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 4	2010	29	5					687	697		10.1038/onc.2009.384	http://dx.doi.org/10.1038/onc.2009.384			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	551QI	19915616	Green Accepted			2022-12-25	WOS:000274223700006
J	Britt, RL; Haruta, N; Lusetti, SL; Chitteni-Pattu, S; Inman, RB; Cox, MM				Britt, Rachel L.; Haruta, Nami; Lusetti, Shelley L.; Chitteni-Pattu, Sindhu; Inman, Ross B.; Cox, Michael M.			Disassembly of Escherichia coli RecA E38K/Delta C17 Nucleoprotein Filaments Is Required to Complete DNA Strand Exchange	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROMOTED ATP HYDROLYSIS; BINDING-PROTEIN; STABLE COMPLEXES; NTP HYDROLYSIS; NUCLEOSIDE TRIPHOSPHATE; HELICAL FILAMENTS; BRANCH MIGRATION; SSB PROTEIN; C-TERMINUS; IN-VIVO	Disassembly of RecA protein subunits from a RecA filament has long been known to occur during DNA strand exchange, although its importance to this process has been controversial. An Escherichia coli RecA E38K/Delta C17 double mutant protein displays a unique and pH-dependent mutational separation of DNA pairing and extended DNA strand exchange. Single strand DNA-dependent ATP hydrolysis is catalyzed by this mutant protein nearly normally from pH 6 to 8.5. It will also form filaments on DNA and promote DNA pairing. However, below pH 7.3, ATP hydrolysis is completely uncoupled from extended DNA strand exchange. The products of extended DNA strand exchange do not form. At the lower pH values, disassembly of RecA E38K/Delta C17 filaments is strongly suppressed, even when homologous DNAs are paired and available for extended DNA strand exchange. Disassembly of RecA E38K/Delta C17 filaments improves at pH 8.5, whereas complete DNA strand exchange is also restored. Under these sets of conditions, a tight correlation between filament disassembly and completion of DNA strand exchange is observed. This correlation provides evidence that RecA filament disassembly plays a major role in, and may be required for, DNA strand exchange. A requirement for RecA filament disassembly in DNA strand exchange has a variety of ramifications for the current models linking ATP hydrolysis to DNA strand exchange.	[Britt, Rachel L.; Chitteni-Pattu, Sindhu; Inman, Ross B.; Cox, Michael M.] Univ Wisconsin, Dept Biochem, Madison, WI 53706 USA; [Haruta, Nami] Osaka Univ, Microbial Dis Res Inst, Suita, Osaka 5650871, Japan; [Lusetti, Shelley L.] New Mexico State Univ, Dept Chem & Biochem, Las Cruces, NM 88003 USA	University of Wisconsin System; University of Wisconsin Madison; Osaka University; New Mexico State University	Cox, MM (corresponding author), Univ Wisconsin, Dept Biochem, 433 Babcock Dr, Madison, WI 53706 USA.	cox@biochem.wisc.edu		Haruta, Nami/0000-0002-4232-9635	National Institutes of Health [GM32335]; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM032335, U01GM032335] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	This work was supported, in whole or in part, by National Institutes of Health Grant GM32335 (to M.M.C.).	Arenson TA, 1999, J MOL BIOL, V288, P391, DOI 10.1006/jmbi.1999.2705; Bedale WA, 1996, J BIOL CHEM, V271, P5725, DOI 10.1074/jbc.271.10.5725; Beernink HTH, 1999, TRENDS BIOCHEM SCI, V24, P385, DOI 10.1016/S0968-0004(99)01451-6; BENEDICT RC, 1988, J BIOL CHEM, V263, P15513; Bianco P R, 1998, Front Biosci, V3, pD570; BRENNER SL, 1987, J BIOL CHEM, V262, P4011; Campbell MJ, 1999, J MOL BIOL, V286, P437, DOI 10.1006/jmbi.1998.2457; Campbell MJ, 1999, J MOL BIOL, V286, P417, DOI 10.1006/jmbi.1998.2456; Chen ZC, 2008, NATURE, V453, P489, DOI 10.1038/nature06971; Churchill JJ, 2000, J MOL BIOL, V297, P537, DOI 10.1006/jmbi.2000.3590; Churchill JJ, 1999, GENE DEV, V13, P901, DOI 10.1101/gad.13.7.901; Cox JM, 2006, J BIOL CHEM, V281, P12968, DOI 10.1074/jbc.M513736200; Cox JM, 2008, J BIOL CHEM, V283, P24909, DOI 10.1074/jbc.M803934200; Cox Michael M., 2005, P369; Cox MM, 2007, NAT REV MOL CELL BIO, V8, P127, DOI 10.1038/nrm2099; Cox MM, 2003, ANNU REV MICROBIOL, V57, P551, DOI 10.1146/annurev.micro.57.030502.090953; Cox MM, 2000, PROG NUCLEIC ACID RE, V63, P311, DOI 10.1016/S0079-6603(08)60726-6; COX MM, 1995, J BIOL CHEM, V270, P26021, DOI 10.1074/jbc.270.44.26021; COX MM, 1981, P NATL ACAD SCI-BIOL, V78, P3433, DOI 10.1073/pnas.78.6.3433; COX MM, 1982, J BIOL CHEM, V257, P8523; COX MM, 1981, P NATL ACAD SCI-BIOL, V78, P6018, DOI 10.1073/pnas.78.10.6018; COX MM, 1983, J BIOL CHEM, V258, P2586; CRAIG NL, 1981, J BIOL CHEM, V256, P8039; Datta S, 2003, PROTEINS, V50, P474, DOI 10.1002/prot.10315; Eggler AL, 2003, J BIOL CHEM, V278, P16389, DOI 10.1074/jbc.M212920200; ENNIS DG, 1995, MUTAT RES-DNA REPAIR, V336, P39, DOI 10.1016/0921-8777(94)00045-8; Gruenig MC, 2008, MOL MICROBIOL, V69, P1165, DOI 10.1111/j.1365-2958.2008.06341.x; Haruta N, 2003, J BIOL CHEM, V278, P52710, DOI 10.1074/jbc.M308563200; Hobbs MD, 2007, J BIOL CHEM, V282, P11058, DOI 10.1074/jbc.M611007200; Holmes VF, 2002, J BIOL CHEM, V277, P38945, DOI 10.1074/jbc.M206962200; HOWARDFLANDERS P, 1984, NATURE, V309, P215, DOI 10.1038/309215a0; JAIN SK, 1994, J BIOL CHEM, V269, P20653; KIM JI, 1992, J BIOL CHEM, V267, P16444; KIM JI, 1992, J BIOL CHEM, V267, P16438; KOWALCZYKOWSKI SC, 1987, J MOL BIOL, V193, P97, DOI 10.1016/0022-2836(87)90630-9; KOWALCZYKOWSKI SC, 1995, P NATL ACAD SCI USA, V92, P3478, DOI 10.1073/pnas.92.8.3478; LAVERY PE, 1992, J BIOL CHEM, V267, P9315; LEE JW, 1990, BIOCHEMISTRY-US, V29, P7677, DOI 10.1021/bi00485a017; LINDSLEY JE, 1989, J MOL BIOL, V205, P695, DOI 10.1016/0022-2836(89)90315-X; LINDSLEY JE, 1990, J BIOL CHEM, V265, P9043; LOHMAN TM, 1985, J BIOL CHEM, V260, P3594; LOHMAN TM, 1986, BIOCHEMISTRY-US, V25, P21, DOI 10.1021/bi00349a004; Lusetti SL, 2002, ANNU REV BIOCHEM, V71, P71, DOI 10.1146/annurev.biochem.71.083101.133940; Lusetti SL, 2003, J BIOL CHEM, V278, P16381, DOI 10.1074/jbc.M212916200; Lusetti SL, 2003, J BIOL CHEM, V278, P16372, DOI 10.1074/jbc.M212917200; MacFarland KJ, 1997, J BIOL CHEM, V272, P17675, DOI 10.1074/jbc.272.28.17675; McGrew DA, 2003, CRIT REV BIOCHEM MOL, V38, P385, DOI 10.1080/10409230390242489; MESSING J, 1983, METHOD ENZYMOL, V101, P20; Morimatsu K, 2003, MOL CELL, V11, P1337, DOI 10.1016/S1097-2765(03)00188-6; MORRICAL SW, 1986, BIOCHEMISTRY-US, V25, P1482, DOI 10.1021/bi00355a003; MORRICAL SW, 1990, BIOCHEMISTRY-US, V29, P837, DOI 10.1021/bi00455a034; Nayak S, 1999, J BIOL CHEM, V274, P25979, DOI 10.1074/jbc.274.37.25979; NEUENDORF SK, 1986, J BIOL CHEM, V261, P8276; OGAWA T, 1993, SCIENCE, V259, P1896, DOI 10.1126/science.8456314; PUGH BF, 1988, J MOL BIOL, V203, P479, DOI 10.1016/0022-2836(88)90014-9; PUGH BF, 1987, J BIOL CHEM, V262, P1326; REGISTER JC, 1985, J BIOL CHEM, V260, P2308; REHRAUER WM, 1993, J BIOL CHEM, V268, P1292; Roca AI, 1997, PROG NUCLEIC ACID RE, V56, P129, DOI 10.1016/S0079-6603(08)61005-3; Sakai A, 2009, J BIOL CHEM, V284, P3264, DOI 10.1074/jbc.M807220200; Sandler SJ, 1996, NUCLEIC ACIDS RES, V24, P2125, DOI 10.1093/nar/24.11.2125; Schnos M, 2000, MOL BIOTECHNOL, V16, P77, DOI 10.1385/MB:16:1:77; SCHUTTE BC, 1987, BIOCHEMISTRY-US, V26, P5616, DOI 10.1021/bi00392a006; Shan Q, 1997, J MOL BIOL, V265, P519, DOI 10.1006/jmbi.1996.0748; Shan Q, 1997, J BIOL CHEM, V272, P11063; Shan Q, 1998, MOL CELL, V1, P309, DOI 10.1016/S1097-2765(00)80031-3; Shan Q, 1996, J BIOL CHEM, V271, P5712, DOI 10.1074/jbc.271.10.5712; Shan Q, 1996, J MOL BIOL, V257, P756, DOI 10.1006/jmbi.1996.0200; Sigurdsson S, 2001, J BIOL CHEM, V276, P8798, DOI 10.1074/jbc.M010011200; Spies M, 2006, MOL CELL, V21, P573, DOI 10.1016/j.molcel.2006.01.007; Stole E, 1997, BIOCHEMISTRY-US, V36, P3483, DOI 10.1021/bi962881l; STOLE E, 1994, J BIOL CHEM, V269, P7919; STOLE E, 1995, J BIOL CHEM, V270, P20322, DOI 10.1074/jbc.270.35.20322; STORY RM, 1992, NATURE, V355, P374, DOI 10.1038/355374a0; STORY RM, 1992, NATURE, V355, P318, DOI 10.1038/355318a0; SUNG P, 1994, SCIENCE, V265, P1241, DOI 10.1126/science.8066464; TATEISHI S, 1992, J MOL BIOL, V223, P115, DOI 10.1016/0022-2836(92)90720-5; UMEZU K, 1994, J BIOL CHEM, V269, P30005; WANG TCV, 1993, MUTAT RES, V294, P157, DOI 10.1016/0921-8777(93)90024-B; WEINSTOCK GM, 1981, J BIOL CHEM, V256, P8829; Yang SX, 2001, J MOL BIOL, V314, P1077, DOI 10.1006/jmbi.2000.5213; Yu X, 2001, P NATL ACAD SCI USA, V98, P8419, DOI 10.1073/pnas.111005398	82	14	14	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 29	2010	285	5					3211	3226		10.1074/jbc.M109.028951	http://dx.doi.org/10.1074/jbc.M109.028951			16	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	546RR	19910465	Green Published, hybrid			2022-12-25	WOS:000273829000036
J	Kozela, E; Pietr, M; Juknat, A; Rimmerman, N; Levy, R; Vogel, Z				Kozela, Ewa; Pietr, Maciej; Juknat, Ana; Rimmerman, Neta; Levy, Rivka; Vogel, Zvi			Cannabinoids Delta(9)-Tetrahydrocannabinol and Cannabidiol Differentially Inhibit the Lipopolysaccharide-activated NF-kappa B and Interferon-beta/STAT Proinflammatory Pathways in BV-2 Microglial Cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NITRIC-OXIDE PRODUCTION; MEDIATED INHIBITION; CB2 RECEPTOR; SIGNALING PATHWAY; BINDING PROTEIN; CUTTING EDGE; TNF-ALPHA; IN-VIVO; STAT3; MACROPHAGES	Cannabinoids have been shown to exert anti-inflammatory activities in various in vivo and in vitro experimental models as well as ameliorate various inflammatory degenerative diseases. However, the mechanisms of these effects are not completely understood. Using the BV-2 mouse microglial cell line and lipopolysaccharide (LPS) to induce an inflammatory response, we studied the signaling pathways engaged in the anti-inflammatory effects of cannabinoids as well as their influence on the expression of several genes known to be involved in inflammation. We found that the two major cannabinoids present in marijuana, Delta(9)-tetrahydrocannabinol (THC) and cannabidiol (CBD), decrease the production and release of proinflammatory cytokines, including interleukin-1 beta, interleukin-6, and interferon (IFN)beta, from LPS-activated microglial cells. The cannabinoid anti-inflammatory action does not seem to involve the CB1 and CB2 cannabinoid receptors or the abn-CBD-sensitive receptors. In addition, we found that THC and CBD act through different, although partially overlapping, mechanisms. CBD, but not THC, reduces the activity of the NF-kappa B pathway, a primary pathway regulating the expression of proinflammatory genes. Moreover, CBD, but not THC, up-regulates the activation of the STAT3 transcription factor, an element of homeostatic mechanism(s) inducing anti-inflammatory events. Following CBD treatment, but less so with THC, we observed a decreased level of mRNA for the Socs3 gene, a main negative regulator of STATs and particularly of STAT3. However, both CBD and THC decreased the activation of the LPS-induced STAT1 transcription factor, a key player in IFN beta-dependent proinflammatory processes. In summary, our observations show that CBD and THC vary in their effects on the anti-inflammatory pathways, including the NF-kappa B and IFN beta-dependent pathways.	[Kozela, Ewa; Pietr, Maciej; Rimmerman, Neta; Levy, Rivka; Vogel, Zvi] Weizmann Inst Sci, Dept Neurobiol, IL-76100 Rehovot, Israel; [Juknat, Ana; Vogel, Zvi] Tel Aviv Univ, Dr Miriam & Sheldon G Adelson Ctr Biol Addict Dis, Sackler Fac Med, IL-69978 Tel Aviv, Israel	Weizmann Institute of Science; Tel Aviv University; Sackler Faculty of Medicine	Vogel, Z (corresponding author), Weizmann Inst Sci, Dept Neurobiol, IL-76100 Rehovot, Israel.	zvi.vogel@weizmann.ac.il	Rimmerman, Neta/F-1331-2010		Dr. Miriam and Sheldon G. Adelson Center for the Biology of Addictive Diseases; Adelsons' Program for Nerve Regeneration and Repair; Nella and Leon Benoziyo Center for Neurosciences; Israeli Ministry of Health	Dr. Miriam and Sheldon G. Adelson Center for the Biology of Addictive Diseases; Adelsons' Program for Nerve Regeneration and Repair; Nella and Leon Benoziyo Center for Neurosciences; Israeli Ministry of Health	This work was supported in part by the Dr. Miriam and Sheldon G. Adelson Center for the Biology of Addictive Diseases, by the Adelsons' Program for Nerve Regeneration and Repair, by the Nella and Leon Benoziyo Center for Neurosciences, and by the Israeli Ministry of Health (to Z. V.).	Akira S, 2000, ONCOGENE, V19, P2607, DOI 10.1038/sj.onc.1203478; Baker D, 2007, BRIT J PHARMACOL, V152, P649, DOI 10.1038/sj.bjp.0707458; Barton BE, 2006, EXPERT OPIN THER TAR, V10, P459, DOI 10.1517/14728222.10.3.459; Bayewitch M, 1996, J BIOL CHEM, V271, P9902, DOI 10.1074/jbc.271.17.9902; Ben-Shabat S, 2006, J MED CHEM, V49, P1113, DOI 10.1021/jm050709m; Berdyshev EV, 2001, BIOCHEM J, V360, P67, DOI 10.1042/0264-6021:3600067; BLASI E, 1990, J NEUROIMMUNOL, V27, P229, DOI 10.1016/0165-5728(90)90073-V; BOCCHINI V, 1992, J NEUROSCI RES, V31, P616, DOI 10.1002/jnr.490310405; Borrelli F, 2009, J MOL MED, V87, P1111, DOI 10.1007/s00109-009-0512-x; Buckley  NE, 2000, EUR J PHARMACOL, V396, P141, DOI 10.1016/S0014-2999(00)00211-9; Butcher BA, 2005, J IMMUNOL, V174, P3148, DOI 10.4049/jimmunol.174.6.3148; Butovsky E, 2006, MOL CELL NEUROSCI, V31, P795, DOI 10.1016/j.mcn.2006.01.008; Cabral GA, 2001, ADV EXP MED BIOL, V493, P207; Carrier EJ, 2004, MOL PHARMACOL, V65, P999, DOI 10.1124/mol.65.4.999; Costa-Pereira AP, 2002, P NATL ACAD SCI USA, V99, P8043, DOI 10.1073/pnas.122236099; Covert MW, 2005, SCIENCE, V309, P1854, DOI 10.1126/science.1112304; Croker BA, 2008, SEMIN CELL DEV BIOL, V19, P414, DOI 10.1016/j.semcdb.2008.07.010; Curran NM, 2005, J BIOL CHEM, V280, P35797, DOI 10.1074/jbc.M507959200; De Filippis D, 2008, NEUROGASTROENT MOTIL, V20, P919, DOI 10.1111/j.1365-2982.2008.01114.x; De Filippis D, 2007, J MOL MED, V85, P635, DOI 10.1007/s00109-007-0188-z; Dheen ST, 2007, CURR MED CHEM, V14, P1189, DOI 10.2174/092986707780597961; Esposito G, 2006, NEUROSCI LETT, V399, P91, DOI 10.1016/j.neulet.2006.01.047; FELDER CC, 1992, MOL PHARMACOL, V42, P838; Franklin A, 2003, EUR J PHARMACOL, V474, P195, DOI 10.1016/S0014-2999(03)02074-0; Gallily R, 1997, J PHARMACOL EXP THER, V283, P918; Gay NJ, 2007, ANNU REV BIOCHEM, V76, P141, DOI 10.1146/annurev.biochem.76.060305.151318; Herring AC, 1999, J PHARMACOL EXP THER, V291, P1156; Hong F, 2002, J CLIN INVEST, V110, P1503, DOI 10.1172/JCI200215841; Izzo AA, 2009, TRENDS PHARMACOL SCI, V30, P515, DOI 10.1016/j.tips.2009.07.006; Jarai Z, 1999, P NATL ACAD SCI USA, V96, P14136, DOI 10.1073/pnas.96.24.14136; Jeon YJ, 1996, MOL PHARMACOL, V50, P334; Jin HJ, 2008, MOL IMMUNOL, V45, P1258, DOI 10.1016/j.molimm.2007.09.015; Kaplan BLF, 2003, J PHARMACOL EXP THER, V306, P1077, DOI 10.1124/jpet.103.051961; Kawai T, 2001, J IMMUNOL, V167, P5887, DOI 10.4049/jimmunol.167.10.5887; Kim SH, 2004, NEUROBIOL AGING, V25, P431, DOI 10.1016/S0197-4580(03)00126-X; Klein TW, 2006, J NEUROIMMUNE PHARM, V1, P50, DOI 10.1007/s11481-005-9007-x; Lacaze P, 2009, BMC GENOMICS, V10, DOI 10.1186/1471-2164-10-372; Mackie K, 2008, J NEUROENDOCRINOL, V20, P10, DOI 10.1111/j.1365-2826.2008.01671.x; MAKRIYANNIS A, 1990, BIOCHIM BIOPHYS ACTA, V1028, P31, DOI 10.1016/0005-2736(90)90262-M; Malfait AM, 2000, P NATL ACAD SCI USA, V97, P9561, DOI 10.1073/pnas.160105897; Matsukawa A, 2005, J IMMUNOL, V175, P3354, DOI 10.4049/jimmunol.175.5.3354; Mechoulam R, 2007, CHEM BIODIVERS, V4, P1678, DOI 10.1002/cbdv.200790147; Murray PJ, 2006, BIOCHEM SOC T, V34, P1028, DOI 10.1042/BST0341028; NICOLETTI I, 1991, J IMMUNOL METHODS, V139, P271, DOI 10.1016/0022-1759(91)90198-O; Nishinakamura H, 2007, INT IMMUNOL, V19, P609, DOI 10.1093/intimm/dxm026; Ock J, 2007, J NEUROSCI RES, V85, P1989, DOI 10.1002/jnr.21322; Ogawa S, 2005, CELL, V122, P707, DOI 10.1016/j.cell.2005.06.029; Pais TF, 2008, J NEUROINFLAMM, V5, DOI 10.1186/1742-2094-5-43; Panikashvili D, 2005, J CEREBR BLOOD F MET, V25, P477, DOI 10.1038/sj.jcbfm.9600047; Pertwee RG, 2008, BRIT J PHARMACOL, V153, P199, DOI 10.1038/sj.bjp.0707442; Pfaffl MW, 2001, NUCLEIC ACIDS RES, V29, DOI 10.1093/nar/29.9.e45; Pietr M, 2009, FEBS LETT, V583, P2071, DOI 10.1016/j.febslet.2009.05.028; Price TJ, 2004, BRIT J PHARMACOL, V142, P257, DOI 10.1038/sj.bjp.0705778; Puffenbarger RA, 2000, GLIA, V29, P58, DOI 10.1002/(SICI)1098-1136(20000101)29:1<58::AID-GLIA6>3.3.CO;2-N; Qing YL, 2004, J BIOL CHEM, V279, P41679, DOI 10.1074/jbc.M406413200; Rajesh M, 2008, BRIT J PHARMACOL, V153, P347, DOI 10.1038/sj.bjp.0707569; Regis G, 2008, SEMIN CELL DEV BIOL, V19, P351, DOI 10.1016/j.semcdb.2008.06.004; Roche M, 2006, J NEUROIMMUNOL, V181, P57, DOI 10.1016/j.jneuroim.2006.08.001; Romero-Sandoval EA, 2009, MOL PAIN, V5, DOI 10.1186/1744-8069-5-25; Rothwarf D M, 1999, Sci STKE, V1999, pRE1, DOI 10.1126/stke.1999.5.re1; Sacerdote P, 2005, J NEUROIMMUNOL, V159, P97, DOI 10.1016/j.jneuroim.2004.10.003; Showalter VM, 1996, J PHARMACOL EXP THER, V278, P989; Smith SR, 2000, J PHARMACOL EXP THER, V293, P136; Srivastava MD, 1998, IMMUNOPHARMACOLOGY, V40, P179, DOI 10.1016/S0162-3109(98)00041-1; Suzumura A, 2006, ANN NY ACAD SCI, V1088, P219, DOI 10.1196/annals.1366.012; Takeda K, 1999, IMMUNITY, V10, P39, DOI 10.1016/S1074-7613(00)80005-9; Tanabe Y, 2005, J IMMUNOL, V174, P609, DOI 10.4049/jimmunol.174.2.609; Thomas BF, 1998, J PHARMACOL EXP THER, V285, P285; Walter L, 2003, J NEUROSCI, V23, P1398, DOI 10.1523/JNEUROSCI.23-04-01398.2003; WATZL B, 1991, INT J IMMUNOPHARMACO, V13, P1091, DOI 10.1016/0192-0561(91)90160-9; Wesoly J, 2007, ACTA BIOCHIM POL, V54, P27, DOI 10.18388/abp.2007_3266; Wormald S, 2007, CURR OPIN HEMATOL, V14, P9, DOI 10.1097/00062752-200701000-00004; Yasukawa H, 2003, NAT IMMUNOL, V4, P551, DOI 10.1038/ni938; Zuardi AW, 2008, REV BRAS PSIQUIATR, V30, P271, DOI 10.1590/S1516-44462008000300015	74	154	158	0	27	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 15	2010	285	3					1616	1626		10.1074/jbc.M109.069294	http://dx.doi.org/10.1074/jbc.M109.069294			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	541PJ	19910459	Green Published, hybrid			2022-12-25	WOS:000273429100007
J	Olson, ML; Chalmers, S; McCarron, JG				Olson, Marnie L.; Chalmers, Susan; McCarron, John G.			Mitochondrial Ca2+ Uptake Increases Ca2+ Release from Inositol 1,4,5-Trisphosphate Receptor Clusters in Smooth Muscle Cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							XENOPUS OOCYTES; SARCOPLASMIC-RETICULUM; CALCIUM PUFFS; ENDOPLASMIC-RETICULUM; RYANODINE RECEPTOR; GATED CHANNELS; CYTOSOLIC CA2+; IP3 RECEPTORS; INTACT-CELLS; TRISPHOSPHATE	Smooth muscle activities are regulated by inositol 1,4,5-trisphosphate (InsP(3))-mediated increases in cytosolic Ca2+ concentration ([Ca2+](c)). Local Ca2+ release from an InsP(3) receptor (InsP(3)R) cluster present on the sarcoplasmic reticulum is termed a Ca2+ puff. Ca2+ released via InsP(3)R may diffuse to adjacent clusters to trigger further release and generate a cell-wide (global) Ca2+ rise. In smooth muscle, mitochondrial Ca2+ uptake maintains global InsP(3)-mediated Ca2+ release by preventing a negative feedback effect of high [Ca2+] on InsP(3)R. Mitochondria may regulate InsP(3)-mediated Ca2+ signals by operating between or within InsP(3)R clusters. In the former mitochondria could regulate only global Ca2+ signals, whereas in the latter both local and global signals would be affected. Here whether mitochondria maintain InsP(3)-mediated Ca2+ release by operating within (local) or between (global) InsP(3)R clusters has been addressed. Ca2+ puffs evoked by localized photolysis of InsP(3) in single voltage-clamped colonic smooth muscle cells had amplitudes of 0.5-4.0 F/F-0, durations of similar to 112 ms at half-maximum amplitude, and were abolished by the InsP(3)R inhibitor 2-aminoethoxydiphenyl borate. The protonophore carbonyl cyanide 3-chloropheylhydrazone and complex I inhibitor rotenone each depolarized Delta Psi(M) to prevent mitochondrial Ca2+ uptake and attenuated Ca2+ puffs by similar to 66 or similar to 60%, respectively. The mitochondrial uniporter inhibitor, RU360, attenuated Ca2+ puffs by similar to 62%. The "fast" Ca2+ chelator 1,2-bis(o-aminophenoxy) ethane-N,N,N', N'-tetraacetic acid acted like mitochondria to prolong InsP(3)-mediated Ca2+ release suggesting that mitochondrial influence is via their Ca2+ uptake facility. These results indicate Ca2+ uptake occurs quickly enough to influence InsP(3)R communication at the intra-cluster level and that mitochondria regulate both local and global InsP(3)-mediated Ca2+ signals.	[Olson, Marnie L.; Chalmers, Susan; McCarron, John G.] Univ Strathclyde, Strathclyde Inst Pharm & Biomed Sci, Glasgow G4 0NR, Lanark, Scotland	University of Strathclyde	McCarron, JG (corresponding author), Univ Strathclyde, Strathclyde Inst Pharm & Biomed Sci, John Arbuthnott Bldg, Glasgow G4 0NR, Lanark, Scotland.	john.mccarron@strath.ac.uk	Chalmers, Susan/C-1392-2009	Chalmers, Susan/0000-0002-8073-7576	Wellcome Trust [078054/Z/05/Z]; British Heart Foundation [PG/08/066]	Wellcome Trust(Wellcome TrustEuropean Commission); British Heart Foundation(British Heart Foundation)	This work was supported by Wellcome Trust Grant 078054/Z/05/Z and British Heart Foundation Grant PG/08/066.	BEZPROZVANNY I, 1991, NATURE, V351, P751, DOI 10.1038/351751a0; Boitier E, 1999, J CELL BIOL, V145, P795, DOI 10.1083/jcb.145.4.795; Boittin FX, 2000, BIOCHEM J, V349, P323, DOI 10.1042/0264-6021:3490323; Bootman M, 1997, J PHYSIOL-LONDON, V499, P307, DOI 10.1113/jphysiol.1997.sp021928; Bootman MD, 1997, CELL, V91, P367, DOI 10.1016/S0092-8674(00)80420-1; Bradley KN, 2002, J PHYSIOL-LONDON, V538, P465, DOI 10.1113/jphysiol.2001.013039; Callamaras N, 2000, EMBO J, V19, P3608, DOI 10.1093/emboj/19.14.3608; Chalmers S, 2008, J CELL SCI, V121, P75, DOI 10.1242/jcs.014522; Collins TJ, 2000, BIOCHEM J, V347, P593, DOI 10.1042/0264-6021:3470593; Csordas G, 1999, EMBO J, V18, P96, DOI 10.1093/emboj/18.1.96; Csordas G, 2006, J CELL BIOL, V174, P915, DOI 10.1083/jcb.200604016; Dai JZ, 2005, CELL CALCIUM, V37, P333, DOI 10.1016/j.ceca.2004.12.002; Dargan SL, 2003, J PHYSIOL-LONDON, V553, P775, DOI 10.1113/jphysiol.2003.054247; Drummond RM, 1999, J PHYSIOL-LONDON, V516, P139, DOI 10.1111/j.1469-7793.1999.139aa.x; Haak LL, 2002, J NEUROCHEM, V80, P405, DOI 10.1046/j.0022-3042.2001.00727.x; Hajnoczky G, 1999, J BIOL CHEM, V274, P14157, DOI 10.1074/jbc.274.20.14157; HAJNOCZKY G, 1995, CELL, V82, P415, DOI 10.1016/0092-8674(95)90430-1; Horne JH, 1997, SCIENCE, V276, P1690, DOI 10.1126/science.276.5319.1690; IINO M, 1990, J GEN PHYSIOL, V95, P1103, DOI 10.1085/jgp.95.6.1103; JOUAVILLE LS, 1995, NATURE, V377, P438, DOI 10.1038/377438a0; Landolfi B, 1998, J CELL BIOL, V142, P1235, DOI 10.1083/jcb.142.5.1235; MacMillan D, 2005, J PHYSIOL-LONDON, V569, P533, DOI 10.1113/jphysiol.2005.096529; Marchant JS, 2002, AM J PHYSIOL-CELL PH, V282, pC1374, DOI 10.1152/ajpcell.00446.2001; Marchant JS, 1998, BIOCHEM J, V334, P505, DOI 10.1042/bj3340505; McCarron JG, 2004, J BIOL CHEM, V279, P8417, DOI 10.1074/jbc.M311797200; McCarron JG, 2002, J CELL SCI, V115, P2207; McCarron JG, 1999, J PHYSIOL-LONDON, V516, P149, DOI 10.1111/j.1469-7793.1999.149aa.x; McCarron JG, 2008, J BIOL CHEM, V283, P7206, DOI 10.1074/jbc.M708923200; McCarron JG, 2008, J CELL SCI, V121, P86, DOI 10.1242/jcs.017541; MIGNERY GA, 1989, NATURE, V342, P192, DOI 10.1038/342192a0; NIXON GF, 1994, J MUSCLE RES CELL M, V15, P682, DOI 10.1007/BF00121075; Oancea E, 1996, J BIOL CHEM, V271, P17253, DOI 10.1074/jbc.271.29.17253; Parker I, 1996, J PHYSIOL-LONDON, V491, P663, DOI 10.1113/jphysiol.1996.sp021247; PARKER I, 1995, CIBA F SYMP, V188, P50; PARKER I, 1991, P ROY SOC B-BIOL SCI, V246, P269, DOI 10.1098/rspb.1991.0154; Rizzuto R, 1998, SCIENCE, V280, P1763, DOI 10.1126/science.280.5370.1763; RIZZUTO R, 1994, J CELL BIOL, V126, P1183, DOI 10.1083/jcb.126.5.1183; RIZZUTO R, 1993, SCIENCE, V262, P744, DOI 10.1126/science.8235595; Rose HJ, 2006, BIOPHYS J, V91, P4024, DOI 10.1529/biophysj.106.088872; SATOH T, 1990, J CELL BIOL, V111, P615, DOI 10.1083/jcb.111.2.615; Shuai JW, 2006, BIOPHYS J, V91, P4033, DOI 10.1529/biophysj.106.088880; Simpson PB, 1996, J BIOL CHEM, V271, P33493, DOI 10.1074/jbc.271.52.33493; Smith IF, 2009, CELL CALCIUM, V45, P65, DOI 10.1016/j.ceca.2008.06.001; Sun XP, 1998, J PHYSIOL-LONDON, V509, P67, DOI 10.1111/j.1469-7793.1998.067bo.x; Sward K, 2002, CIRC RES, V90, P792, DOI 10.1161/01.RES.0000015214.40360.84; Swillens S, 1999, P NATL ACAD SCI USA, V96, P13750, DOI 10.1073/pnas.96.24.13750; Taylor CW, 2002, CELL CALCIUM, V32, P321, DOI 10.1016/S0143416002001859; Thomas D, 1998, J BIOL CHEM, V273, P27130, DOI 10.1074/jbc.273.42.27130; YAO Y, 1995, J PHYSIOL-LONDON, V482, P533, DOI 10.1113/jphysiol.1995.sp020538	49	38	39	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 15	2010	285	3					2040	2050		10.1074/jbc.M109.027094	http://dx.doi.org/10.1074/jbc.M109.027094			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	541PJ	19889626	Green Published, hybrid			2022-12-25	WOS:000273429100049
J	Quoyer, J; Longuet, C; Broca, C; Linck, N; Costes, S; Varin, E; Bockaert, J; Bertrand, G; Dalle, S				Quoyer, Julie; Longuet, Christine; Broca, Christophe; Linck, Nathalie; Costes, Safia; Varin, Elodie; Bockaert, Joel; Bertrand, Gyslaine; Dalle, Stephane			GLP-1 Mediates Antiapoptotic Effect by Phosphorylating Bad through a beta-Arrestin 1-mediated ERK1/2 Activation in Pancreatic beta-Cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLUCAGON-LIKE PEPTIDE-1; SIGNAL-REGULATED KINASES; ELEMENT-BINDING PROTEIN; INSULIN-SECRETION; DIFFERENTIAL REGULATION; RECEPTOR; GLUCOSE; SURVIVAL; CAMP; APOPTOSIS	Strategies based on activating GLP-1 receptor (GLP-1R) are intensively developed for the treatment of type 2 diabetes. The exhaustive knowledge of the signaling pathways linked to activated GLP-1R within the beta-cells is of major importance. In beta-cells, GLP-1 activates the ERK1/2 cascade by diverse pathways dependent on either G alpha(s)/cAMP/cAMP-dependent protein kinase (PKA) or beta-arrestin 1, a scaffold protein. Using pharmacological inhibitors, beta-arrestin 1 small interfering RNA, and islets isolated from beta-arrestin 1 knock-out mice, we demonstrate that GLP-1 stimulates ERK1/2 by two temporally distinct pathways. The PKA-dependent pathway mediates rapid and transient ERK1/2 phosphorylation that leads to nuclear translocation of the activated kinases. In contrast, the beta-arrestin 1-dependent pathway produces a late ERK1/2 activity that is restricted to the beta-cell cytoplasm. We further observe that GLP-1 phosphorylates the cytoplasmic proapoptotic protein Bad at Ser-112 but not at Ser-155. We find that the beta-arrestin 1-dependent ERK1/2 activation engaged by GLP-1 mediates the Ser-112 phosphorylation of Bad, through p90RSK activation, allowing the association of Bad with the scaffold protein 14-3-3, leading to its inactivation. beta-Arrestin 1 is further found to mediate the antiapoptotic effect of GLP-1 in beta-cells through the ERK1/2-p90RSK-phosphorylation of Bad. This new regulatory mechanism engaged by activated GLP-1R involving a beta-arrestin 1-dependent spatiotemporal regulation of the ERK1/2-p90RSK activity is now suspected to participate in the protection of beta-cells against apoptosis. Such signaling mechanism may serve as a prototype to generate new therapeutic GLP-1R ligands.	[Quoyer, Julie; Broca, Christophe; Linck, Nathalie; Costes, Safia; Varin, Elodie; Bockaert, Joel; Bertrand, Gyslaine; Dalle, Stephane] Univ Montpellier I, Inst Genom Fonct, INSERM, CNRS,U661,Equipe Avenir,UMR5203, F-34094 Montpellier 5, France; [Quoyer, Julie; Broca, Christophe; Linck, Nathalie; Costes, Safia; Varin, Elodie; Bockaert, Joel; Bertrand, Gyslaine; Dalle, Stephane] Univ Montpellier 2, F-34094 Montpellier 5, France; [Longuet, Christine; Bockaert, Joel; Bertrand, Gyslaine; Dalle, Stephane] Mt Sinai Hosp, Dept Med, Samuel Lunenfeld Res Inst, Toronto, ON M5T 3L9, Canada; [Longuet, Christine; Bockaert, Joel; Bertrand, Gyslaine; Dalle, Stephane] Univ Toronto, Banting & Best Diabet Ctr, Toronto, ON M5T 3L9, Canada	Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Montpellier; Universite de Montpellier; University of Toronto; University Toronto Affiliates; Sinai Health System Toronto; Lunenfeld Tanenbaum Research Institute; University of Toronto	Dalle, S (corresponding author), Univ Montpellier I, Inst Genom Fonct, INSERM, CNRS,U661,Equipe Avenir,UMR5203, 141 Rue Cardonille, F-34094 Montpellier 5, France.	stephane.dalle@igf.cnrs.fr	Longuet, Christine/ABC-2556-2020; Dalle, Stephane/E-4552-2018; bertrand, gyslaine/AAC-6716-2020; , Costes/AAC-2820-2020	Dalle, Stephane/0000-0002-3423-4548; , Costes/0000-0001-8323-1207; Broca, Christophe/0000-0002-7715-8231; Linck, Nathalie/0000-0002-2218-239X	INSERM; Region Languedoc-Roussillon; Fondation pour la Recherche Medicale	INSERM(Institut National de la Sante et de la Recherche Medicale (Inserm)European Commission); Region Languedoc-Roussillon(Region OccitanieRegion Ile-de-France); Fondation pour la Recherche Medicale(Fondation pour la Recherche Medicale)	Supported by INSERM, the "Region Languedoc-Roussillon," and the "Fondation pour la Recherche Medicale."	Adams JM, 2007, ONCOGENE, V26, P1324, DOI 10.1038/sj.onc.1210220; Ahn S, 2004, J BIOL CHEM, V279, P7807, DOI 10.1074/jbc.C300443200; Ahn S, 2009, J BIOL CHEM, V284, P8846, DOI 10.1074/jbc.M808463200; Amori RE, 2007, JAMA-J AM MED ASSOC, V298, P194, DOI 10.1001/jama.298.2.194; Arnette D, 2003, J BIOL CHEM, V278, P32517, DOI 10.1074/jbc.M301174200; Beguin P, 1999, EMBO J, V18, P4722, DOI 10.1093/emboj/18.17.4722; Bergmann A, 2002, DEV CELL, V3, P607, DOI 10.1016/S1534-5807(02)00328-3; Bonni A, 1999, SCIENCE, V286, P1358, DOI 10.1126/science.286.5443.1358; Briaud I, 2003, DIABETES, V52, P974, DOI 10.2337/diabetes.52.4.974; Broca C, 2009, J BIOL CHEM, V284, P4332, DOI 10.1074/jbc.M807595200; Buteau J, 2003, DIABETES, V52, P124, DOI 10.2337/diabetes.52.1.124; Chang LF, 2001, NATURE, V410, P37, DOI 10.1038/35065000; Conner DA, 1997, CIRC RES, V81, P1021; Costes S, 2006, DIABETES, V55, P2220, DOI 10.2337/db05-1618; Dalle S, 2004, J BIOL CHEM, V279, P20345, DOI 10.1074/jbc.M312483200; Dalle S, 1999, J BIOL CHEM, V274, P10869, DOI 10.1074/jbc.274.16.10869; Danial NN, 2008, NAT MED, V14, P144, DOI 10.1038/nm1717; Danial NN, 2003, NATURE, V424, P952, DOI 10.1038/nature01825; Datta SR, 2000, MOL CELL, V6, P41, DOI 10.1016/S1097-2765(00)00006-X; Datta SR, 2002, DEV CELL, V3, P631, DOI 10.1016/S1534-5807(02)00326-X; DeFea KA, 2000, J CELL BIOL, V148, P1267, DOI 10.1083/jcb.148.6.1267; DeFea KA, 2000, P NATL ACAD SCI USA, V97, P11086, DOI 10.1073/pnas.190276697; DELAAGE MA, 1978, MOL BIOL PHARM CYCLI, P151; DeWire SM, 2007, ANNU REV PHYSIOL, V69, P483, DOI 10.1146/annurev.physiol.69.022405.154749; Doyle ME, 2007, PHARMACOL THERAPEUT, V113, P546, DOI 10.1016/j.pharmthera.2006.11.007; Drucker DJ, 2006, LANCET, V368, P1696, DOI 10.1016/S0140-6736(06)69705-5; Drucker DJ, 2006, CELL METAB, V3, P153, DOI 10.1016/j.cmet.2006.01.004; FRODIN M, 1995, J BIOL CHEM, V270, P7882, DOI 10.1074/jbc.270.14.7882; Frodin M, 1999, MOL CELL ENDOCRINOL, V151, P65, DOI 10.1016/S0303-7207(99)00061-1; Galandrin S, 2007, TRENDS PHARMACOL SCI, V28, P423, DOI 10.1016/j.tips.2007.06.005; Gomez E, 2002, J BIOL CHEM, V277, P48146, DOI 10.1074/jbc.M209165200; Hauge C, 2006, J CELL SCI, V119, P3021, DOI 10.1242/jcs.02950; HOLST JJ, 2007, J PHYSL REV, V87, P1409; HOLZ GG, 1993, NATURE, V361, P362, DOI 10.1038/361362a0; Hoorens A, 1996, J CLIN INVEST, V98, P1568, DOI 10.1172/JCI118950; Jorgensen R, 2007, J PHARMACOL EXP THER, V322, P148, DOI 10.1124/jpet.107.120006; Kang GX, 2003, J BIOL CHEM, V278, P8279, DOI 10.1074/jbc.M211682200; Klinger S, 2008, DIABETES, V57, P584, DOI 10.2337/db07-1414; Lawrence M, 2008, ACTA PHYSIOL, V192, P11, DOI 10.1111/j.1748-1716.2007.01785.x; Lawrence MC, 2005, J BIOL CHEM, V280, P26751, DOI 10.1074/jbc.M503158200; Lawrence MC, 2008, P NATL ACAD SCI USA, V105, P13315, DOI 10.1073/pnas.0806465105; Lawrence MC, 2007, P NATL ACAD SCI USA, V104, P11518, DOI 10.1073/pnas.0704618104; Lefkowitz RJ, 2004, CURR OPIN CELL BIOL, V16, P162, DOI 10.1016/j.ceb.2004.01.001; Leftowitz RJ, 2005, SCIENCE, V308, P512, DOI 10.1126/science.1109237; Longuet C, 2005, ENDOCRINOLOGY, V146, P643, DOI 10.1210/en.2004-0841; Luttrell LM, 2005, J MOL NEUROSCI, V26, P253, DOI 10.1385/JMN:26:2-3:253; Luttrell LM, 2001, P NATL ACAD SCI USA, V98, P2449, DOI 10.1073/pnas.041604898; Mayo KE, 2003, PHARMACOL REV, V55, P167, DOI 10.1124/pr.55.1.6; NICHOLSON DW, 1995, NATURE, V376, P37, DOI 10.1038/376037a0; Raman M, 2007, ONCOGENE, V26, P3100, DOI 10.1038/sj.onc.1210392; Reiter E, 2006, TRENDS ENDOCRIN MET, V17, P159, DOI 10.1016/j.tem.2006.03.008; Seino S, 2005, PHYSIOL REV, V85, P1303, DOI 10.1152/physrev.00001.2005; Shenoy SK, 2006, J BIOL CHEM, V281, P1261, DOI 10.1074/jbc.M506576200; Shibasaki T, 2007, P NATL ACAD SCI USA, V104, P19333, DOI 10.1073/pnas.0707054104; Sonoda N, 2008, P NATL ACAD SCI USA, V105, P6614, DOI 10.1073/pnas.0710402105; Stoffers DA, 2000, DIABETES, V49, P741, DOI 10.2337/diabetes.49.5.741; SVENSSON C, 1993, J ENDOCRINOL, V136, P289, DOI 10.1677/joe.0.1360289; THORENS B, 1992, P NATL ACAD SCI USA, V89, P8641, DOI 10.1073/pnas.89.18.8641; Tohgo AK, 2002, J BIOL CHEM, V277, P9429, DOI 10.1074/jbc.M106457200; Trumper J, 2005, DIABETOLOGIA, V48, P1534, DOI 10.1007/s00125-005-1820-5; Tsuboi T, 2003, BIOCHEM J, V369, P287, DOI 10.1042/BJ20021288; Van de Casteele M, 2003, BIOCHEM BIOPH RES CO, V312, P937, DOI 10.1016/j.bbrc.2003.11.013; Violin JD, 2007, TRENDS PHARMACOL SCI, V28, P416, DOI 10.1016/j.tips.2007.06.006; Volmat V, 2001, J CELL SCI, V114, P3433; Werry TD, 2005, TRENDS ENDOCRIN MET, V16, P26, DOI 10.1016/j.tem.2004.11.008; YANG E, 1995, CELL, V80, P285, DOI 10.1016/0092-8674(95)90411-5; Yang XP, 2005, CANCER RES, V65, P7338, DOI 10.1158/0008-5472.CAN-04-2263; Zraika S, 2006, DIABETOLOGIA, V49, P1254, DOI 10.1007/s00125-006-0212-9	68	122	129	0	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 15	2010	285	3					1989	2002		10.1074/jbc.M109.067207	http://dx.doi.org/10.1074/jbc.M109.067207			14	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	541PJ	19915011	Green Published, hybrid			2022-12-25	WOS:000273429100045
J	Redmond, TM; Poliakov, E; Kuo, S; Chander, P; Gentleman, S				Redmond, T. Michael; Poliakov, Eugenia; Kuo, Stephanie; Chander, Preethi; Gentleman, Susan			RPE65, Visual Cycle Retinol Isomerase, Is Not Inherently 11-cis-specific SUPPORT FOR A CARBOCATION MECHANISM OF RETINOL ISOMERIZATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LEBERS CONGENITAL AMAUROSIS; PIGMENT EPITHELIAL-CELLS; CATION-PI INTERACTIONS; ALL-TRANS-RETINOL; BETA-CAROTENE; VITAMIN-A; BINDING PROTEIN; ENERGY-SOURCE; GENE-THERAPY; CIS-RETINOLS	The mechanism of retinol isomerization in the vertebrate retina visual cycle remains controversial. Does the isomerase enzyme RPE65 operate via nucleophilic addition at C-11 of the all-trans substrate, or via a carbocation mechanism? To determine this, we modeled the RPE65 substrate cleft to identify residues interacting with substrate and/or intermediate. We find that wild-type RPE65 in vitro produces 13-cis and 11-cis isomers equally robustly. All Tyr-239 mutations abolish activity. Trp-331 mutations reduce activity (W331Y to similar to 75% of wild type, W331F to similar to 50%, and W331L and W331Q to 0%) establishing a requirement for aromaticity, consistent with cation-pi carbocation stabilization. Two cleft residues modulate isomerization specificity: Thr-147 is important, because replacement by Ser increases 11-cis relative to 13-cis by 40% compared with wild type. Phe-103 mutations are opposite in action: F103L and F103I dramatically reduce 11-cis synthesis relative to 13-cis synthesis compared with wild type. Thr-147 and Phe-103 thus may be pivotal in controlling RPE65 specificity. Also, mutations affecting RPE65 activity coordinately depress 11-cis and 13-cis isomer production but diverge as 11-cis decreases to zero, whereas 13-cis reaches a plateau consistent with thermal isomerization. Lastly, experiments using labeled retinol showed exchange at 13-cis-retinol C-15 oxygen, thus confirming enzymatic isomerization for both isomers. Thus, RPE65 is not inherently 11-cis-specific and can produce both 11- and 13-cis isomers, supporting a carbocation (or radical cation) mechanism for isomerization. Specific visual cycle selectivity for 11-cis isomers instead resides downstream, attributable to mass action by CRALBP, retinol dehydrogenase 5, and high affinity of opsin apoproteins for 11-cis-retinal.	[Redmond, T. Michael; Poliakov, Eugenia; Kuo, Stephanie; Chander, Preethi; Gentleman, Susan] NEI, Retinal Cell & Mol Biol Lab, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Eye Institute (NEI)	Redmond, TM (corresponding author), NEI, Retinal Cell & Mol Biol Lab, NIH, Bldg 6,Room 117A, Bethesda, MD 20892 USA.	redmond@helix.nih.gov		Redmond, T. Michael/0000-0002-1813-5291	National Institutes of Health; NATIONAL EYE INSTITUTE [ZIAEY000260] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))	This work was supported, in whole or in part, by National Institutes of Health Intramural Research Program of NEI.	Bainbridge JWB, 2008, NEW ENGL J MED, V358, P2231, DOI 10.1056/NEJMoa0802268; Borowski T, 2008, CHEM-EUR J, V14, P2264, DOI 10.1002/chem.200701344; Bouvier F, 1997, ARCH BIOCHEM BIOPHYS, V346, P53, DOI 10.1006/abbi.1997.0278; CANADA FJ, 1990, BIOCHEMISTRY-US, V29, P9690, DOI 10.1021/bi00493a026; CARLSON A, 1992, BIOCHEMISTRY-US, V31, P9056, DOI 10.1021/bi00152a049; Cideciyan AV, 2008, P NATL ACAD SCI USA, V105, P15112, DOI 10.1073/pnas.0807027105; DEIGNER PS, 1989, SCIENCE, V244, P968, DOI 10.1126/science.2727688; Dougherty DA, 1996, SCIENCE, V271, P163, DOI 10.1126/science.271.5246.163; Driessen CAGG, 2000, MOL CELL BIOL, V20, P4275, DOI 10.1128/MCB.20.12.4275-4287.2000; Fan J, 2003, P NATL ACAD SCI USA, V100, P13662, DOI 10.1073/pnas.2234461100; Golczak M, 2005, P NATL ACAD SCI USA, V102, P8162, DOI 10.1073/pnas.0503318102; Gollapalli DR, 2003, BIOCHEMISTRY-US, V42, P5809, DOI 10.1021/bi0341004; Grutter C, 2006, ANGEW CHEM INT EDIT, V45, P1126, DOI 10.1002/anie.200503123; Gu SM, 1997, NAT GENET, V17, P194, DOI 10.1038/ng1097-194; Gurzadyan GG, 2007, PHYS CHEM CHEM PHYS, V9, P288, DOI 10.1039/b609165m; HAMEL CP, 1993, J BIOL CHEM, V268, P15751; Holliday GL, 2009, J MOL BIOL, V390, P560, DOI 10.1016/j.jmb.2009.05.015; HUBBARD R, 1952, J GEN PHYSIOL, V36, P269, DOI 10.1085/jgp.36.2.269; Jenson C, 1997, J AM CHEM SOC, V119, P10846, DOI 10.1021/ja9714245; Jin MH, 2005, CELL, V122, P449, DOI 10.1016/j.cell.2005.06.042; Kiefer C, 2001, J BIOL CHEM, V276, P14110, DOI 10.1074/jbc.M011510200; Klinman JP, 2006, J BIOL CHEM, V281, P3013, DOI 10.1074/jbc.R500011200; Kloer DP, 2005, SCIENCE, V308, P267, DOI 10.1126/science.1108965; Kovaleva EG, 2007, SCIENCE, V316, P453, DOI 10.1126/science.1134697; Kuksa V, 2003, VISION RES, V43, P2959, DOI 10.1016/S0042-6989(03)00482-6; Lamb TD, 2004, PROG RETIN EYE RES, V23, P307, DOI 10.1016/j.preteyeres.2004.03.001; LANDERS GM, 1988, J CHROMATOGR, V438, P383, DOI 10.1016/S0021-9673(00)90269-3; Lesburg CA, 1998, CURR OPIN STRUC BIOL, V8, P695, DOI 10.1016/S0959-440X(98)80088-2; Lorenz B, 2008, INVEST OPHTH VIS SCI, V49, P5235, DOI 10.1167/iovs.07-1671; Maeda A, 2006, BIOCHEMISTRY-US, V45, P4210, DOI 10.1021/bi052382x; Maguire AM, 2008, NEW ENGL J MED, V358, P2240, DOI 10.1056/NEJMoa0802315; Marlhens F, 1997, NAT GENET, V17, P139, DOI 10.1038/ng1097-139; McBee JK, 2000, BIOCHEMISTRY-US, V39, P11370, DOI 10.1021/bi001061c; Mecozzi S, 1996, P NATL ACAD SCI USA, V93, P10566, DOI 10.1073/pnas.93.20.10566; Moiseyev G, 2005, P NATL ACAD SCI USA, V102, P12413, DOI 10.1073/pnas.0503460102; Moiseyev G, 2003, BIOCHEMISTRY-US, V42, P2229, DOI 10.1021/bi026911y; Morimura H, 1998, P NATL ACAD SCI USA, V95, P3088, DOI 10.1073/pnas.95.6.3088; Oberhauser V, 2008, P NATL ACAD SCI USA, V105, P19000, DOI 10.1073/pnas.0807805105; Paik J, 2001, J BIOL CHEM, V276, P32160, DOI 10.1074/jbc.M010086200; PIENTA NJ, 1992, J AM CHEM SOC, V114, P2419, DOI 10.1021/ja00033a017; Poliakov E, 2005, J BIOL CHEM, V280, P29217, DOI 10.1074/jbc.M500409200; Prigge ST, 2004, SCIENCE, V304, P864, DOI 10.1126/science.1094583; RANDO RR, 1991, BIOCHEMISTRY-US, V30, P595, DOI 10.1021/bi00217a001; RANDO RR, 1983, J AM CHEM SOC, V105, P2879, DOI 10.1021/ja00347a058; Redmond TM, 2007, MOL VIS, V13, P1813; Redmond TM, 1998, NAT GENET, V20, P344, DOI 10.1038/3813; Redmond TM, 2005, P NATL ACAD SCI USA, V102, P13658, DOI 10.1073/pnas.0504167102; Redmond TM, 2001, J BIOL CHEM, V276, P6560, DOI 10.1074/jbc.M009030200; REUTER T, 1964, NATURE, V204, P784, DOI 10.1038/204784a0; Schuttelkopf AW, 2004, ACTA CRYSTALLOGR D, V60, P1355, DOI 10.1107/S0907444904011679; Stecher H, 1999, J BIOL CHEM, V274, P8577, DOI 10.1074/jbc.274.13.8577; Thompson DA, 2000, INVEST OPHTH VIS SCI, V41, P4293; von Lintig J, 2000, J BIOL CHEM, V275, P11915, DOI 10.1074/jbc.275.16.11915; Wingerath T, 1999, ANAL BIOCHEM, V272, P232, DOI 10.1006/abio.1999.4194; Winston A, 1998, BIOCHEMISTRY-US, V37, P2044, DOI 10.1021/bi971908d	55	48	48	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 15	2010	285	3					1919	1927		10.1074/jbc.M109.027458	http://dx.doi.org/10.1074/jbc.M109.027458			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	541PJ	19920137	Green Published, hybrid			2022-12-25	WOS:000273429100038
J	Krishnan, M; Singh, AB; Smith, JJ; Sharma, A; Chen, X; Eschrich, S; Yeatman, TJ; Beauchamp, RD; Dhawan, P				Krishnan, M.; Singh, A. B.; Smith, J. J.; Sharma, A.; Chen, X.; Eschrich, S.; Yeatman, T. J.; Beauchamp, R. D.; Dhawan, P.			HDAC inhibitors regulate claudin-1 expression in colon cancer cells through modulation of mRNA stability	ONCOGENE			English	Article						tight junction; claudin-1; invasion; TSA; HDAC	HISTONE DEACETYLASE INHIBITORS; BREAST-CARCINOMA CELLS; TRICHOSTATIN-A; GENE; TUMORIGENESIS; GROWTH	Expression and cellular distribution of claudin-1, a tight junction protein, is dysregulated in colon cancer and its overexpression in colon cancer cells induced dedifferentiation and increased invasion. However, the molecular mechanism(s) underlying dysregulated claudin-1 expression in colon cancer remains poorly understood. Histone deacetylase (HDAC)-dependent histone acetylation is an important mechanism of the regulation of cancer-related genes and inhibition of HDACs induces epithelial differentiation and decreased invasion. Therefore, in this study, we examined the role of HDAC-dependent epigenetic regulation of claudin-1 in colon cancer. In this study, we show that sodium butyrate and Trichostatin A (TSA), two structurally different and widely used HDAC inhibitors, inhibited claudin-1 expression in multiple colon cancer cell lines. Further studies revealed modulation of claudin-1 mRNA stability by its 3'-UTR as the major mechanism underlying HDAC-dependent claudin-1 expression. In addition, overexpression of claudin-1 abrogated the TSA-induced inhibition of invasion in colon cancer cells suggesting functional crosstalk. Analysis of mRNA expression in colon cancer patients, showed a similar pattern of increase in claudin-1 and HDAC-2 mRNA expression throughout all stages of colon cancer. Inhibition of claudin-1 expression by HDAC-2-specific small interfering RNA further supported the role of HDAC-2 in this regulation. Taken together, we report a novel post-transcriptional regulation of claudin-1 expression in colon cancer cells and further show a functional correlation between claudin-1 expression and TSA-mediated regulation of invasion. As HDAC inhibitors are considered to be promising anticancer drugs, these new findings will have implications in both laboratory and clinical settings. Oncogene (2010) 29, 305-312; doi:10.1038/onc.2009.324; published online 2 November 2009	[Dhawan, P.] Vanderbilt Univ, Dept Surg, Med Ctr, MCN,Div Surg Oncol, Nashville, TN 37240 USA; [Smith, J. J.; Beauchamp, R. D.] Vanderbilt Univ, Med Ctr, Dept Cell & Dev Biol, Nashville, TN 37240 USA; [Chen, X.] Vanderbilt Univ, Med Ctr, Dept Biostat, Nashville, TN 37240 USA; [Eschrich, S.; Yeatman, T. J.] H Lee Moffitt Canc Ctr & Res Inst, Tampa, FL USA; [Beauchamp, R. D.; Dhawan, P.] Vanderbilt Univ, Med Ctr, Dept Canc Biol, Nashville, TN 37240 USA	Vanderbilt University; Vanderbilt University; Vanderbilt University; H Lee Moffitt Cancer Center & Research Institute; Vanderbilt University	Dhawan, P (corresponding author), Vanderbilt Univ, Dept Surg, Med Ctr, MCN,Div Surg Oncol, B-2211, Nashville, TN 37240 USA.	punita.dhawan@vanderbilt.edu	Smith, Jesse Joshua/AAN-5440-2020; Sharma, Ashok/AAE-5439-2019; Eschrich, Steven/K-6848-2013	Smith, Jesse Joshua/0000-0003-2538-5456; Sharma, Ashok/0000-0001-7505-6023; Eschrich, Steven/0000-0002-9833-2788; Beauchamp, Robert Daniel/0000-0002-8446-4114	NIH [CA119005, CA124977, DK58404]; AHA [0435471N, 5P50DK044757, P30DK058406]; Society of University Surgeons-Ethicon Scholarship Award [CA112215, DK052334, CA 069457]; GI Cancer SPORE [CA95103]; Vanderbilt-Ingram Cancer Center [P30CA68485]; NATIONAL CANCER INSTITUTE [R01CA124977, P30CA068485, R01CA069457, R21CA119005, R01CA112215, P50CA095103] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P50DK044757, P30DK058404, R01DK052334] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); AHA(American Heart Association); Society of University Surgeons-Ethicon Scholarship Award; GI Cancer SPORE; Vanderbilt-Ingram Cancer Center; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))	This work was supported by NIH grant CA119005, CA124977 (P Dhawan), and AHA Grant 0435471N, 5P50DK044757 and P30DK058406 Pilot project (AB Singh), the Society of University Surgeons-Ethicon Scholarship Award (JJS) CA112215 (TJ Yeatman), DK052334, CA 069457, the GI Cancer SPORE grant CA95103 (RD Beauchamp), the Vanderbilt-Ingram Cancer Center P30CA68485 and the NIH grant supporting the Digestive Diseases Center DK58404. We thank Christian Kis for the help in real-time quantitative reverse transcription-PCR analysis.	Abuazza G, 2006, AM J PHYSIOL-RENAL, V291, pF1132, DOI 10.1152/ajprenal.00063.2006; Chavey C, 2008, MOL PHARMACOL, V74, P1359, DOI 10.1124/mol.108.047332; Dhawan P, 2005, J CLIN INVEST, V115, P1765, DOI 10.1172/JCI24543; Dokmanovic M, 2005, J CELL BIOCHEM, V96, P293, DOI 10.1002/jcb.20532; Godman CA, 2008, CANCER BIOL THER, V7, P1570, DOI 10.4161/cbt.7.10.6561; Honda H, 2007, CANCER BIOL THER, V6, P1733, DOI 10.4161/cbt.6.11.4832; Honda H, 2006, J BIOL CHEM, V281, P21433, DOI 10.1074/jbc.M603767200; Liu PY, 2008, MOL CANCER RES, V6, P1204, DOI 10.1158/1541-7786.MCR-08-0123; Minucci S, 2006, NAT REV CANCER, V6, P38, DOI 10.1038/nrc1779; Nishikiori N, 2008, JPN J OPHTHALMOL, V52, P195, DOI 10.1007/s10384-008-0524-z; Osanai M, 2007, CANCER SCI, V98, P1557, DOI 10.1111/j.1349-7006.2007.00569.x; Osanai M, 2007, CANCER SCI, V98, P1027, DOI 10.1111/j.1349-7006.2007.00494.x; Pesole G, 2001, GENE, V276, P73, DOI 10.1016/S0378-1119(01)00674-6; Pryzbylkowski P, 2008, BREAST CANCER RES TR, V111, P15, DOI 10.1007/s10549-007-9751-0; Schefe JH, 2006, J MOL MED, V84, P901, DOI 10.1007/s00109-006-0097-6; Shiou SR, 2007, CANCER RES, V67, P1571, DOI 10.1158/0008-5472.CAN-06-1680; Wu Y, 2007, REPROD SCI, V14, P374, DOI 10.1177/1933719107302913; Yamamichi N, 2005, ONCOGENE, V24, P5471, DOI 10.1038/sj.onc.1208716; Zhang ZH, 2000, NEOPLASIA, V2, P523, DOI 10.1038/sj.neo.7900117; Zhu P, 2004, CANCER CELL, V5, P455, DOI 10.1016/S1535-6108(04)00114-X	20	73	74	1	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 14	2010	29	2					305	312		10.1038/onc.2009.324	http://dx.doi.org/10.1038/onc.2009.324			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	544IU	19881542	Green Accepted			2022-12-25	WOS:000273650000013
J	Moreno-Manzano, V; Rodriguez-Jimenez, FJ; Acena-Bonilla, JL; Fustero-Lardies, S; Erceg, S; Dopazo, J; Montaner, D; Stojkovic, M; Sanchez-Puelles, JM				Moreno-Manzano, Victoria; Rodriguez-Jimenez, Francisco J.; Acena-Bonilla, Jose L.; Fustero-Lardies, Santos; Erceg, Slaven; Dopazo, Joaquin; Montaner, David; Stojkovic, Miodrag; Sanchez-Puelles, Jose M.			FM19G11, a New Hypoxia-inducible Factor (HIF) Modulator, Affects Stem Cell Differentiation Status	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ADULT SPINAL-CORD; EMBRYONIC-DEVELOPMENT; PROLYL HYDROXYLASES; LOWERED OXYGEN; TUMOR-GROWTH; IN-VITRO; EXPRESSION; CANCER; FACTOR-1-ALPHA; IDENTIFICATION	The biology of the alpha subunits of hypoxia-inducible factors (HIF alpha) has expanded from their role in angiogenesis to their current position in the self-renewal and differentiation of stem cells. The results reported in this article show the discovery of FM19G11, a novel chemical entity that inhibits HIF alpha proteins that repress target genes of the two alpha subunits, in various tumor cell lines as well as in adult and embryonic stem cell models from rodents and humans, respectively. FM19G11 inhibits at nanomolar range the transcriptional and protein expression of Oct4, Sox2, Nanog, and Tgf-alpha undifferentiating factors, in adult rat and human embryonic stem cells, FM19G11 activity occurs in ependymal progenitor stem cells from rats (epSPC), a cell model reported for spinal cord regeneration, which allows the progression of oligodendrocyte cell differentiation in a hypoxic environment, has created interest in its characterization for pharmacological research. Experiments using small interfering RNA showed a significant depletion in Sox2 protein only in the case of HIF2 alpha silencing, but not in HIF1 alpha-mediated ablation. Moreover, chromatin immunoprecipitation data, together with the significant presence of functional hypoxia response element consensus sequences in the promoter region of Sox2, strongly validated that this factor behaves as a target gene of HIF2 alpha in epSPCs. FM19G11 causes a reduction of overall histone acetylation with significant repression of p300, a histone acetyltransferase required as a co-factor for HIF-transcription activation. Arrays carried out in the presence and absence of the inhibitor showed the predominant involvement of epigenetic-associated events mediated by the drug.	[Sanchez-Puelles, Jose M.] CSIC, Ctr Invest Biol, E-28040 Madrid, Spain; [Erceg, Slaven; Dopazo, Joaquin; Montaner, David; Stojkovic, Miodrag; Sanchez-Puelles, Jose M.] FV Ctr Invest Principe Felipe, E-46012 Valencia, Spain; [Fustero-Lardies, Santos] Univ Valencia, E-46071 Valencia, Spain	Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Centro de Investigaciones Biologicas (CIB); Prince Felipe Research Center; University of Valencia	Sanchez-Puelles, JM (corresponding author), CSIC, Ctr Invest Biol, Plaza Murillo 2, E-28040 Madrid, Spain.	jmspuelles@cib.csic.es	RODRIGUEZ-JIMENEZ, FRANCISCO JAVIER/ABC-4979-2021; Sanchez-Puelles, J. M./E-4159-2018; Dopazo, Joaquin/A-9270-2014; Aceña, José Luis/F-2453-2016; Moreno, Victoria/B-4175-2014; Erceg, Slaven/ABC-4946-2021; Montaner, David/A-9362-2014	Sanchez-Puelles, J. M./0000-0002-4283-4885; Dopazo, Joaquin/0000-0003-3318-120X; Aceña, José Luis/0000-0002-1777-8199; Moreno, Victoria/0000-0002-6035-9491; Montaner, David/0000-0002-2484-3278; Erceg, Slaven/0000-0003-3208-7705; Stojkovic, Miodrag/0000-0001-7526-6573; Fustero, Santos/0000-0002-7575-9439	Fondo de Investigaciones Sanitarias; Instituto de Salud Carlos III (Spain); Ministerio de Educacion, Ciencia y Tecnologia, and Generalitat Valenciana (Spain) [PI051973 RD06/0010/1006, SAF2007-63714, GVRE/2008/254]	Fondo de Investigaciones Sanitarias(Instituto de Salud Carlos III); Instituto de Salud Carlos III (Spain)(Instituto de Salud Carlos III); Ministerio de Educacion, Ciencia y Tecnologia, and Generalitat Valenciana (Spain)	This work was supported by the Fondo de Investigaciones Sanitarias, the Instituto de Salud Carlos III (Spain), the Ministerio de Educacion, Ciencia y Tecnologia, and Generalitat Valenciana (Spain) Projects PI051973 RD06/0010/1006, SAF2007-63714, and GVRE/2008/254.	Al-Shahrour F, 2005, NUCLEIC ACIDS RES, V33, pW460, DOI 10.1093/nar/gki456; Appelhoff RJ, 2004, J BIOL CHEM, V279, P38458, DOI 10.1074/jbc.M406026200; Avilion AA, 2003, GENE DEV, V17, P126, DOI 10.1101/gad.224503; Bertout JA, 2008, NAT REV CANCER, V8, P967, DOI 10.1038/nrc2540; Covello KL, 2006, GENE DEV, V20, P557, DOI 10.1101/gad.1399906; Covello KL, 2005, CANCER RES, V65, P2277, DOI 10.1158/0008-5472.CAN-04-3246; Dutta D, 2008, J BIOL CHEM, V283, P25404, DOI 10.1074/jbc.M804349200; Erceg S, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002122; Fedele Anthony O, 2002, Mol Interv, V2, P229, DOI 10.1124/mi.2.4.229; Fitz LJ, 1997, ONCOGENE, V15, P613, DOI 10.1038/sj.onc.1201191; Folkman J, 2007, NAT REV DRUG DISCOV, V6, P273, DOI 10.1038/nrd2115; Giaccia A, 2003, NAT REV DRUG DISCOV, V2, P803, DOI 10.1038/nrd1199; Gordan JD, 2007, CANCER CELL, V11, P335, DOI 10.1016/j.ccr.2007.02.006; Gruber M, 2007, P NATL ACAD SCI USA, V104, P2301, DOI 10.1073/pnas.0608382104; Gustafsson MV, 2005, DEV CELL, V9, P617, DOI 10.1016/j.devcel.2005.09.010; Hu Y, 2005, MOL THER, V11, P906, DOI 10.1016/j.ymthe.2005.01.016; Rodriguez-Jimenez FJ, 2008, STEM CELLS, V26, P2052, DOI 10.1634/stemcells.2007-1016; Johansson CB, 1999, CELL, V96, P25, DOI 10.1016/S0092-8674(00)80956-3; Keith B, 2007, CELL, V129, P465, DOI 10.1016/j.cell.2007.04.019; Kim JB, 2008, NATURE, V454, P646, DOI 10.1038/nature07061; Koh MY, 2008, MOL CANCER THER, V7, P90, DOI 10.1158/1535-7163.MCT-07-0463; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; Lyssiotis CA, 2007, P NATL ACAD SCI USA, V104, P14982, DOI 10.1073/pnas.0707044104; Maltepe E, 2005, DEVELOPMENT, V132, P3393, DOI 10.1242/dev.01923; Masui S, 2007, NAT CELL BIOL, V9, P625, DOI 10.1038/ncb1589; Maynard MA, 2007, CELL CYCLE, V6, P2810, DOI 10.4161/cc.6.22.4947; McCord AM, 2009, MOL CANCER RES, V7, P489, DOI 10.1158/1541-7786.MCR-08-0360; Meletis K, 2008, PLOS BIOL, V6, P1494, DOI 10.1371/journal.pbio.0060182; Metzen E, 2003, MOL BIOL CELL, V14, P3470, DOI 10.1091/mbc.e02-12-0791; Moreno-Manzano V, 2009, STEM CELLS, V27, P733, DOI 10.1002/stem.24; Ohori Y, 2006, J NEUROSCI, V26, P11948, DOI 10.1523/JNEUROSCI.3127-06.2006; Parr AM, 2008, NEUROSCIENCE, V155, P760, DOI 10.1016/j.neuroscience.2008.05.042; Pescador N, 2005, BIOCHEM J, V390, P189, DOI 10.1042/BJ20042121; Pouyssegur J, 2006, NATURE, V441, P437, DOI 10.1038/nature04871; Rankin EB, 2008, CELL DEATH DIFFER, V15, P678, DOI 10.1038/cdd.2008.21; Raval RR, 2005, MOL CELL BIOL, V25, P5675, DOI 10.1128/MCB.25.13.5675-5686.2005; Ruau D, 2008, STEM CELLS, V26, P920, DOI 10.1634/stemcells.2007-0649; Segovia KN, 2008, ANN NEUROL, V63, P520, DOI 10.1002/ana.21359; Simon MC, 2008, NAT REV MOL CELL BIO, V9, P285, DOI 10.1038/nrm2354; Studer L, 2000, J NEUROSCI, V20, P7377; Takahashi K, 2007, CELL, V131, P861, DOI 10.1016/j.cell.2007.11.019; Takahashi K, 2006, CELL, V126, P663, DOI 10.1016/j.cell.2006.07.024; Wallberg AE, 2002, MOL CELL BIOL, V22, P7812, DOI 10.1128/MCB.22.22.7812-7819.2002; Zhang CP, 2006, NEUROSIGNALS, V15, P259, DOI 10.1159/000103385	44	92	99	0	22	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 8	2010	285	2					1333	1342		10.1074/jbc.M109.008326	http://dx.doi.org/10.1074/jbc.M109.008326			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	539MH	19897487	Green Published, hybrid			2022-12-25	WOS:000273258200054
J	Sheppard, V; Poulsen, N; Kroger, N				Sheppard, Vonda; Poulsen, Nicole; Kroger, Nils			Characterization of an Endoplasmic Reticulum-associated Silaffin Kinase from the Diatom Thalassiosira pseudonana	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LACTATING MAMMARY-GLAND; APPARATUS CASEIN KINASE; CELL-WALL; GOLGI-APPARATUS; SILICA BIOMINERALIZATION; MEMBRANE-PROTEINS; TARGETING SIGNALS; IN-VITRO; PHOSPHORYLATION; PLASTIDS	The formation of SiO2-based cell walls by diatoms (a large group of unicellular microalgae) is a well established model system for the study of molecular mechanisms of biological mineral morphogenesis (biomineralization). Diatom biomineralization involves highly phosphorylated proteins (silaffins and silacidins), analogous to other biomineralization systems, which also depend on diverse sets of phosphoproteins (e. g. mammalian teeth and bone, mollusk shells, and sponge silica). The phosphate moieties on biomineralization proteins play an essential role in mineral formation, yet the kinases catalyzing the phosphorylation of these proteins have remained poorly characterized. Recent functional genomics studies on the diatom Thalassiosira pseudonana have revealed > 100 proteins potentially involved in diatom silica formation. Here we have characterized the biochemical properties and biological function of one of these proteins, tpSTK1. Multiple tpSTK1-like proteins are encoded in diatom genomes, all of which exhibit low but significant sequence similarity to kinases from other organisms. We show that tpSTK1 has serine/threonine kinase activity capable of phosphorylating silaffins but not silacidins. Cell biological and biochemical analysis demonstrated that tpSTK1 is an abundant component of the lumen of the endoplasmic reticulum. The present study provides the first molecular structure of a kinase that appears to catalyze phosphorylation of biomineral forming proteins in vivo.	Georgia Inst Technol, Sch Chem & Biochem, Atlanta, GA 30332 USA; [Kroger, Nils] Georgia Inst Technol, Sch Mat Sci & Engn, Atlanta, GA 30332 USA; [Kroger, Nils] Georgia Inst Technol, Sch Biol, Atlanta, GA 30332 USA	University System of Georgia; Georgia Institute of Technology; University System of Georgia; Georgia Institute of Technology; University System of Georgia; Georgia Institute of Technology	Kroger, N (corresponding author), 901 Atlantic Dr NW, Atlanta, GA 30332 USA.	nils.kroger@chemistry.gatech.edu		Poulsen, Nicole/0000-0002-4533-8860	National Science Foundation [DMR 0845939]; Research Corporation for Science Advancement [7492]; U.S. Department of Education Graduate Assistance in Areas of National Need (GAANN); Division Of Materials Research [0845939] Funding Source: National Science Foundation	National Science Foundation(National Science Foundation (NSF)); Research Corporation for Science Advancement(Research Corporation for Science Advancement); U.S. Department of Education Graduate Assistance in Areas of National Need (GAANN)(US Department of Education); Division Of Materials Research(National Science Foundation (NSF)NSF - Directorate for Mathematical & Physical Sciences (MPS))	This work was supported by the Georgia Institute of Technology, Grant DMR 0845939 from the National Science Foundation (to N.K.), Cottrell Scholar Award 7492 from the Research Corporation for Science Advancement (to N.K.), and a U.S. Department of Education Graduate Assistance in Areas of National Need (GAANN) fellowship (to V. S.).	Apt KE, 2002, J CELL SCI, V115, P4061, DOI 10.1242/jcs.00092; ARBER S, 1992, J CELL BIOL, V116, P113, DOI 10.1083/jcb.116.1.113; Armbrust EV, 2004, SCIENCE, V306, P79, DOI 10.1126/science.1101156; ARNON DI, 1949, PLANT PHYSIOL, V24, P15; Bauerlein E, 2003, ANGEW CHEM INT EDIT, V42, P614, DOI 10.1002/anie.200390176; Belcher AM, 1998, ACTA MATER, V46, P733, DOI 10.1016/S1359-6454(97)00253-X; BHAYA D, 1991, MOL GEN GENET, V229, P400, DOI 10.1007/BF00267462; BINGHAM EW, 1974, J BIOL CHEM, V249, P3647; BOSKEY AL, 1993, BONE MINER, V22, P147, DOI 10.1016/S0169-6009(08)80225-5; Bowler C, 2008, NATURE, V456, P239, DOI 10.1038/nature07410; Brunati AM, 2000, FEBS LETT, V471, P151, DOI 10.1016/S0014-5793(00)01378-8; BUSS JE, 1983, METHOD ENZYMOL, V99, P7; Crookes-Goodson WJ, 2008, CHEM SOC REV, V37, P2403, DOI 10.1039/b702825n; Drzymala L, 2000, BIOCHEMISTRY-US, V39, P2023, DOI 10.1021/bi9924213; Elofsson A, 2007, ANNU REV BIOCHEM, V76, P125, DOI 10.1146/annurev.biochem.76.052705.163539; Emanuelsson O, 2007, NAT PROTOC, V2, P953, DOI 10.1038/nprot.2007.131; Fischer H, 1999, J PHYCOL, V35, P113, DOI 10.1046/j.1529-8817.1999.3510113.x; Frasson M, 2009, BBA-MOL CELL RES, V1793, P239, DOI 10.1016/j.bbamcr.2008.10.001; Frigeri LG, 2006, MOL CELL PROTEOMICS, V5, P182, DOI 10.1074/mcp.M500174-MCP200; GALBRAITH DW, 1995, METHODS PLANT CELL B, P137; George A, 2008, CHEM REV, V108, P4670, DOI 10.1021/cr0782729; Goder V, 2001, FEBS LETT, V504, P87, DOI 10.1016/S0014-5793(01)02712-0; Gruber A, 2007, PLANT MOL BIOL, V64, P519, DOI 10.1007/s11103-007-9171-x; Hamm CE, 2003, NATURE, V421, P841, DOI 10.1038/nature01416; He G, 2005, J BIOL CHEM, V280, P33109, DOI 10.1074/jbc.M500159200; Hildebrand M, 2007, J PHYCOL, V43, P730, DOI 10.1111/j.1529-8817.2007.00361.x; Ishikawa HO, 2008, SCIENCE, V321, P401, DOI 10.1126/science.1158159; Kilian O, 2005, PLANT J, V41, P175, DOI 10.1111/j.1365-313X.2004.02294.x; Kroger N, 2008, ANNU REV GENET, V42, P83, DOI 10.1146/annurev.genet.41.110306.130109; Kroger N, 2002, SCIENCE, V298, P584, DOI 10.1126/science.1076221; Kroger N, 1998, PROTIST, V149, P213, DOI 10.1016/S1434-4610(98)70029-X; Kroger N, 2006, ANGEW CHEM INT EDIT, V45, P7239, DOI 10.1002/anie.200601871; Krogh A, 2001, J MOL BIOL, V305, P567, DOI 10.1006/jmbi.2000.4315; Kroth PG, 2002, INT REV CYTOL, V221, P191; Lang M, 1998, J BIOL CHEM, V273, P30973, DOI 10.1074/jbc.273.47.30973; Larkin MA, 2007, BIOINFORMATICS, V23, P2947, DOI 10.1093/bioinformatics/btm404; Lasa M, 1997, EUR J BIOCHEM, V243, P719, DOI 10.1111/j.1432-1033.1997.00719.x; Lasa M, 1997, BIOCHEM BIOPH RES CO, V240, P602, DOI 10.1006/bbrc.1997.7702; Lee SN, 2006, J BIOL CHEM, V281, P3312, DOI 10.1074/jbc.M506635200; Lowenstam HA, 1989, BIOMINERALIZATION; MANN S, 1993, NATURE, V365, P499, DOI 10.1038/365499a0; Mayer G, 2005, SCIENCE, V310, P1144, DOI 10.1126/science.1116994; Mock T, 2008, P NATL ACAD SCI USA, V105, P1579, DOI 10.1073/pnas.0707946105; Monnat J, 2000, MOL BIOL CELL, V11, P3469, DOI 10.1091/mbc.11.10.3469; PACKER L, 1997, BIOMEMBRANE, P214; Pasqualini E, 2000, BIOCHEM J, V345, P121, DOI 10.1042/0264-6021:3450121; Pfeffer SR, 2007, ANNU REV BIOCHEM, V76, P629, DOI 10.1146/annurev.biochem.76.061705.130002; Pimpl P, 2000, PLANT CELL, V12, P1517; Poulsen N, 2005, FEBS J, V272, P3413, DOI 10.1111/j.1742-4658.2005.04760.x; Poulsen N, 2004, J BIOL CHEM, V279, P42993, DOI 10.1074/jbc.M407734200; Poulsen N, 2003, P NATL ACAD SCI USA, V100, P12075, DOI 10.1073/pnas.2035131100; Poulsen N, 2007, ANGEW CHEM INT EDIT, V46, P1843, DOI 10.1002/anie.200603928; Poulsen N, 2006, J PHYCOL, V42, P1059, DOI 10.1111/j.1529-8817.2006.00269.x; Sanchez C, 2005, NAT MATER, V4, P277, DOI 10.1038/nmat1339; Simkiss K, 1989, BIOMINERALIZATION CE; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; Sumper M, 2008, CHEMBIOCHEM, V9, P1187, DOI 10.1002/cbic.200700764; Veis A, 1997, CRIT REV ORAL BIOL M, V8, P360, DOI 10.1177/10454411970080040101; Waite JH, 2001, BIOCHEMISTRY-US, V40, P2887, DOI 10.1021/bi002718x; Wenzl S, 2008, ANGEW CHEM INT EDIT, V47, P1729, DOI 10.1002/anie.200704994; Wilt FH, 2005, DEV BIOL, V280, P15, DOI 10.1016/j.ydbio.2005.01.019; Zhao H, 2005, J BIOL CHEM, V280, P42938, DOI 10.1074/jbc.M508457200	62	14	14	1	27	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 8	2010	285	2					1166	1176		10.1074/jbc.M109.039529	http://dx.doi.org/10.1074/jbc.M109.039529			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	539MH	19889629	Green Published, hybrid			2022-12-25	WOS:000273258200039
J	Hodish, I; Liu, M; Rajpal, G; Larkin, D; Holz, RW; Adams, A; Liu, L; Arvan, P				Hodish, Israel; Liu, Ming; Rajpal, Gautam; Larkin, Dennis; Holz, Ronald W.; Adams, Aaron; Liu, Leanza; Arvan, Peter			Misfolded Proinsulin Affects Bystander Proinsulin in Neonatal Diabetes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENDOPLASMIC-RETICULUM STRESS; PANCREATIC BETA-CELLS; INSULIN GENE; ER STRESS; TRANSGENIC MICE; MUTANT MICE; TYPE-2; APOPTOSIS; MUTATIONS; MELLITUS	It has previously been shown that misfolded mutant Akita proinsulin in the endoplasmic reticulum engages directly in protein complexes either with nonmutant proinsulin or with "hProCpepGFP" (human proinsulin bearing emerald-GFP within the C-peptide), impairing the trafficking of these "bystander" proinsulin molecules (Liu, M., Hodish, I., Rhodes, C. J., and Arvan, P. (2007) Proc. Natl. Acad. Sci. U.S.A. 104, 15841-15846). Herein, we generated transgenic mice, which, in addition to expressing endogenous proinsulin, exhibit beta-cell-specific expression of hProCpepGFP via the Ins1 promoter. In these mice, hProCpepGFP protein levels are physiologically regulated, and hProCpepGFP is packaged and processed to CpepGFP that is co-stored in beta-secretory granules. Visualization of CpepGFP fluorescence provides a quantifiable measure of pancreatic islet insulin content that can be followed in live animals in states of health and disease. We examined loss of pancreatic insulin in hProCpepGFP transgenic mice mated to Akita mice that develop neonatal diabetes because of the expression of misfolded proinsulin. Loss of bystander insulin in Akita animals is detected initially as a block in CpepGFP/insulin production with intracellular accumulation of the precursor, followed ultimately by loss of pancreatic beta-cells. The data support that misfolded proinsulin perturbs bystander proinsulin in the endoplasmic reticulum, leading to beta-cell failure.	[Hodish, Israel; Liu, Ming; Larkin, Dennis; Adams, Aaron; Liu, Leanza; Arvan, Peter] Univ Michigan, Div Metab Endocrinol & Diabet, Med Ctr, Ann Arbor, MI 48109 USA; [Rajpal, Gautam; Arvan, Peter] Univ Michigan, Program Cell & Mol Biol, Med Ctr, Ann Arbor, MI 48109 USA; [Holz, Ronald W.] Univ Michigan, Dept Pharmacol, Med Ctr, Ann Arbor, MI 48109 USA	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan	Arvan, P (corresponding author), Univ Michigan, Div Metab Endocrinol & Diabet, Med Ctr, 5560 MSRB2,1150 W Med Ctr Dr, Ann Arbor, MI 48109 USA.	parvan@umich.edu			National Institutes of Health [R01 DK48280, K99 DK077441A, R01 NS38129]; Michigan Diabetes Research and Training Center; University of Michigan; University of Michigan Cellular and Molecular Biology Program; University of Michigan Transgenic Mouse Core, Morphology and Image Analysis Core, and Molecular Biology and DNA Sequencing Core, NIH [P60 DK20572]; University of Michigan Cancer Center [P30 CA46592]; NATIONAL CANCER INSTITUTE [P30CA046592] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [K99DK077441, P60DK020572, R01DK048280] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007315] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS038129] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Michigan Diabetes Research and Training Center; University of Michigan(University of Michigan System); University of Michigan Cellular and Molecular Biology Program(University of Michigan System); University of Michigan Transgenic Mouse Core, Morphology and Image Analysis Core, and Molecular Biology and DNA Sequencing Core, NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); University of Michigan Cancer Center(University of Michigan System); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))	This work was supported, in whole or in part, by National Institutes of Health Grants R01 DK48280 (to P. A.), K99 DK077441A (to I. H.), and R01 NS38129 (to R. W. H.). This work was also supported by a pilot and feasibility grant from the Michigan Diabetes Research and Training Center (to M. L.), the University of Michigan (T32 Endocrinology Training Grant to L. L.), and a one-semester Rackham Regents Fellowship from the University of Michigan Cellular and Molecular Biology Program (to G. R.). This work was also supported by the University of Michigan Transgenic Mouse Core, Morphology and Image Analysis Core, and Molecular Biology and DNA Sequencing Core (these were supported in part by the NIH-funded Michigan Diabetes Research and Training Center (Grant P60 DK20572) and the University of Michigan Cancer Center (Grant P30 CA46592)).	Araki E, 2003, INTERNAL MED, V42, P7, DOI 10.2169/internalmedicine.42.7; AXELROD D, 1989, METHOD CELL BIOL, V30, P245; Babaya N, 2006, DIABETOLOGIA, V49, P1222, DOI 10.1007/s00125-006-0241-4; Bertolotti A, 2000, NAT CELL BIOL, V2, P326, DOI 10.1038/35014014; Butler AE, 2003, DIABETES, V52, P102, DOI 10.2337/diabetes.52.1.102; Colombo C, 2008, J CLIN INVEST, V118, P2148, DOI 10.1172/JCI33777; Edghill EL, 2008, DIABETES, V57, P1034, DOI 10.2337/db07-1405; Eizirik DL, 2008, ENDOCR REV, V29, P42, DOI 10.1210/er.2007-0015; FUJIWARA T, 1991, METABOLISM, V40, P1213, DOI 10.1016/0026-0495(91)90218-L; Hara M, 2003, AM J PHYSIOL-ENDOC M, V284, pE177, DOI 10.1152/ajpendo.00321.2002; Harris PE, 2008, J MOL MED, V86, P5, DOI 10.1007/s00109-007-0242-x; Herbach N, 2007, DIABETES, V56, P1268, DOI 10.2337/db06-0658; Huang CJ, 2007, DIABETES, V56, P2016, DOI 10.2337/db07-0197; Izumi T, 2003, DIABETES, V52, P409, DOI 10.2337/diabetes.52.2.409; Jeffrey KD, 2008, P NATL ACAD SCI USA, V105, P8452, DOI 10.1073/pnas.0711232105; Kayo T, 1998, J CLIN INVEST, V101, P2112, DOI 10.1172/JCI1842; Kitiphongspattana K, 2005, J BIOL CHEM, V280, P15727, DOI 10.1074/jbc.M410876200; Ladiges WC, 2005, DIABETES, V54, P1074, DOI 10.2337/diabetes.54.4.1074; Laybutt DR, 2007, DIABETOLOGIA, V50, P752, DOI 10.1007/s00125-006-0590-z; Leahy JL, 2005, ARCH MED RES, V36, P197, DOI 10.1016/j.arcmed.2005.01.003; Leroux L, 2001, DIABETES, V50, pS150, DOI 10.2337/diabetes.50.2007.S150; Leroux Loic, 2003, Int J Exp Diabesity Res, V4, P7; LIKE AA, 1970, DIABETOLOGIA, V6, P216, DOI 10.1007/BF01212232; Lin M, 2008, FRONT BIOSCI-LANDMRK, V13, P4558, DOI 10.2741/3023; Lipson KL, 2006, CELL METAB, V4, P245, DOI 10.1016/j.cmet.2006.07.007; Liu M, 2005, J BIOL CHEM, V280, P13209, DOI 10.1074/jbc.C400475200; Liu M, 2007, P NATL ACAD SCI USA, V104, P15841, DOI 10.1073/pnas.0702697104; Marchetti P, 2007, DIABETOLOGIA, V50, P2486, DOI 10.1007/s00125-007-0816-8; MATHEWS CE, 2005, JOSLINS DIABETES MEL, P1333; MAUNSBACH AB, 1964, NATURE, V202, P1131, DOI 10.1038/2021131b0; Molven A, 2008, DIABETES, V57, P1131, DOI 10.2337/db07-1467; NEERMANARBEZ M, 1993, J BIOL CHEM, V268, P16248; Ozcan U, 2006, SCIENCE, V313, P1137, DOI 10.1126/science.1128294; Oyadomari S, 2002, J CLIN INVEST, V109, P525, DOI 10.1172/JCI200214550; Oyadomari S, 2001, P NATL ACAD SCI USA, V98, P10845, DOI 10.1073/pnas.191207498; Park SY, 2009, HORM METAB RES, V41, P1, DOI 10.1055/s-0028-1087209; Poitout V, 2008, ENDOCR REV, V29, P351, DOI 10.1210/er.2007-0023; Polak M, 2008, DIABETES, V57, P1115, DOI 10.2337/db07-1358; Porter CJH, 2001, ADV DRUG DELIVER REV, V50, P1; Prentki M, 2006, J CLIN INVEST, V116, P1802, DOI 10.1172/JCI29103; Riggs AC, 2005, DIABETOLOGIA, V48, P2313, DOI 10.1007/s00125-005-1947-4; Seliverstova EV, 2007, COMP BIOCHEM PHYS A, V147, P1067, DOI 10.1016/j.cbpa.2007.03.019; Solimena M, 1996, EMBO J, V15, P2102, DOI 10.1002/j.1460-2075.1996.tb00564.x; Stoy J, 2007, P NATL ACAD SCI USA, V104, P15040, DOI 10.1073/pnas.0707291104; Takeshita S, 2006, MAMM GENOME, V17, P927, DOI 10.1007/s00335-005-0130-z; Wang HY, 2005, J CELL SCI, V118, P3905, DOI 10.1242/jcs.02513; Wang J, 1999, J CLIN INVEST, V103, P27, DOI 10.1172/JCI4431; WASADA T, 1995, METABOLISM, V44, P1194, DOI 10.1016/0026-0495(95)90015-2; Watkins S, 2002, TRAFFIC, V3, P461, DOI 10.1034/j.1600-0854.2002.30703.x; Yoshioka M, 1997, DIABETES, V46, P887, DOI 10.2337/diabetes.46.5.887	50	61	64	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 1	2010	285	1					685	694		10.1074/jbc.M109.038042	http://dx.doi.org/10.1074/jbc.M109.038042			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	536UT	19880509	Green Published, hybrid			2022-12-25	WOS:000273070100069
J	Ming, M; Han, W; Maddox, J; Soltani, K; Shea, CR; Freeman, DM; He, YY				Ming, M.; Han, W.; Maddox, J.; Soltani, K.; Shea, C. R.; Freeman, D. M.; He, Y-Y			UVB-induced ERK/AKT-dependent PTEN suppression promotes survival of epidermal keratinocytes	ONCOGENE			English	Article						PTEN; UVB; keratinocytes; AKT	NONMELANOMA SKIN-CANCER; TUMOR-SUPPRESSOR; GERMLINE MUTATIONS; GENE; APOPTOSIS; PHOSPHORYLATION; TRANSFORMATION; PROGRESSION; PTEN/MMAC1; EXPRESSION	Ultraviolet (UV) radiation in sunlight is the major environmental cause of skin cancer. PTEN (phosphatase and tensin homolog deleted on chromosome 10) is a proven critical tumor suppressor. We report here that UVB downregulates PTEN in primary human keratinocytes, human HaCaT keratinocytes and mouse skin. As compared with normal skin, PTEN levels are reduced in human actinic keratosis, a precancerous skin lesion caused by solar UV. PTEN downregulation is mediated by two mechanisms: (1) PTEN is cleaved by active caspase in apoptotic cells in which AKT activation is reduced; and (2) PTEN transcription is suppressed in surviving cells, and this suppression is independent of caspase activation and occurs in parallel with increased ERK and AKT activation. We report here that the combination of ERK and AKT activation is crucial for PTEN suppression in surviving cells following UVB irradiation. AKT activation is higher in UVB-irradiated surviving cells as compared with unirradiated cells. The ERK and AKT pathways are involved in sustaining PTEN suppression in UVB-exposed cells. Increasing PTEN expression enhances apoptosis of keratinocytes in response to UVB irradiation. Our findings indicate that (1) UVB radiation suppresses PTEN expression in keratinocytes; and (2) the ERK/AKT/PTEN axis may form a positive feedback loop following UVB irradiation. Our identification of PTEN as a critical molecular target of UVB provides new insights into the pathogenesis of skin cancer. Oncogene (2010) 29, 492-502; doi: 10.1038/onc.2009.357; published online 2 November 2009	[Ming, M.; Han, W.; Maddox, J.; Soltani, K.; Shea, C. R.; Freeman, D. M.; He, Y-Y] Univ Chicago, Dermatol Sect, Dept Med, Chicago, IL 60637 USA	University of Chicago	He, YY (corresponding author), Univ Chicago, Dermatol Sect, Dept Med, 5841 S Maryland Ave,MC5067, Chicago, IL 60637 USA.	yyhe@medicine.bsd.uchicago.edu	Shea, Christopher R./AAJ-7143-2021		Department of Medicine and the Section of Dermatology at the University of Chicago; American Skin Association to the University of Chicago Cancer Research Center [P30 CA014599]; Wendy Will Case Cancer Fund Inc.; CTSA [NIH UL1RR024999]; University of Chicago; NATIONAL CANCER INSTITUTE [P30CA014599] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [UL1RR024999] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES016936] Funding Source: NIH RePORTER	Department of Medicine and the Section of Dermatology at the University of Chicago; American Skin Association to the University of Chicago Cancer Research Center; Wendy Will Case Cancer Fund Inc.; CTSA(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS)); University of Chicago(University of Chicago); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))	This work was supported by the Department of Medicine and the Section of Dermatology at the University of Chicago, the American Skin Association to the University of Chicago Cancer Research Center (P30 CA014599), the Wendy Will Case Cancer Fund Inc., the CTSA (NIH UL1RR024999), and the University of Chicago 'Friends of Dermatology' Endowment Fund. We thank Terri Li for PTEN immunohistochemistry. We are grateful to Dr Christopher Kontos for the adenoviral PTEN vector and Dr William Sellers for the HA-PTEN plasmid.	Backman SA, 2004, P NATL ACAD SCI USA, V101, P1725, DOI 10.1073/pnas.0308217100; Birck A, 2000, J INVEST DERMATOL, V114, P277, DOI 10.1046/j.1523-1747.2000.00877.x; BODE AM, 2003, SCI STKE, pRE2; Bowden GT, 2004, NAT REV CANCER, V4, P23, DOI 10.1038/nrc1253; Byun DS, 2003, INT J CANCER, V104, P318, DOI 10.1002/ijc.10962; DATTO MB, 1995, P NATL ACAD SCI USA, V92, P5545, DOI 10.1073/pnas.92.12.5545; DIFFEY BL, 1991, CLIN PHYS PHYSIOL M, V12, P311, DOI 10.1088/0143-0815/12/4/001; DIFFEY BL, 1991, PHYS MED BIOL, V36, P299, DOI 10.1088/0031-9155/36/3/001; Erb P, 2008, ADV EXP MED BIOL, V624, P283, DOI 10.1007/978-0-387-77574-6_22; Grzanka D, 2006, NEOPLASMA, V53, P328; Harima Y, 2001, INT J ONCOL, V18, P493; He YY, 2008, PHOTOCHEM PHOTOBIOL, V84, P69, DOI 10.1111/j.1751-1097.2007.00199.x; He YY, 2008, CANCER RES, V68, P3752, DOI 10.1158/0008-5472.CAN-07-6138; He YY, 2006, ONCOGENE, V25, P3680, DOI 10.1038/sj.onc.1209384; He YY, 2006, ONCOGENE, V25, P1521, DOI 10.1038/sj.onc.1209184; He YY, 2004, J INVEST DERMATOL, V122, P533, DOI 10.1046/j.0022-202X.2003.22123.x; Hettinger K, 2007, CELL DEATH DIFFER, V14, P218, DOI 10.1038/sj.cdd.4401946; Kohno T, 1998, GENE CHROMOSOME CANC, V22, P152, DOI 10.1002/(SICI)1098-2264(199806)22:2<152::AID-GCC10>3.0.CO;2-S; Li G, 2002, DEVELOPMENT, V129, P4159; Liaw D, 1997, NAT GENET, V16, P64, DOI 10.1038/ng0597-64; Maehama T, 1998, J BIOL CHEM, V273, P13375, DOI 10.1074/jbc.273.22.13375; Marsh DJ, 1997, NAT GENET, V16, P333, DOI 10.1038/ng0897-333; Polo SE, 2006, CELL, V127, P481, DOI 10.1016/j.cell.2006.08.049; Ramos J, 2004, CANCER EPIDEM BIOMAR, V13, P2006; Rigel DS, 2008, J AM ACAD DERMATOL, V58, pS129, DOI 10.1016/j.jaad.2007.04.034; SETLOW RB, 1974, P NATL ACAD SCI USA, V71, P3363, DOI 10.1073/pnas.71.9.3363; Steck PA, 1997, NAT GENET, V15, P356, DOI 10.1038/ng0497-356; Suzuki A, 2003, CANCER RES, V63, P674; Suzuki A, 1998, CURR BIOL, V8, P1169, DOI 10.1016/S0960-9822(07)00488-5; Torres J, 2003, J BIOL CHEM, V278, P30652, DOI 10.1074/jbc.M212610200; Vasudevan KM, 2007, CANCER RES, V67, P10343, DOI 10.1158/0008-5472.CAN-07-1827; WEBB AR, 1988, J CLIN ENDOCR METAB, V67, P373, DOI 10.1210/jcem-67-2-373; Wong JW, 2000, J INVEST DERMATOL, V115, P427, DOI 10.1046/j.1523-1747.2000.00077.x	33	47	56	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN	2010	29	4					492	502		10.1038/onc.2009.357	http://dx.doi.org/10.1038/onc.2009.357			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	549WH	19881543	Green Accepted			2022-12-25	WOS:000274084600003
J	Nishida, K; Hoshino, M; Kawaguchi, Y; Murakami, F				Nishida, Kazuhiko; Hoshino, Mikio; Kawaguchi, Yoshiya; Murakami, Fujio			Ptf1a Directly Controls Expression of Immunoglobulin Superfamily Molecules Nephrin and Neph3 in the Developing Central Nervous System	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DORSAL SPINAL-CORD; SLIT DIAPHRAGM; PANCREATIC DEVELOPMENT; TRANSCRIPTION FACTORS; PROTEIN; GENE; CELLS; NEURONS; COMPLEX; BINDS	Ptf1a, a basic helix-loop-helix transcription factor, plays an indispensable role for cell fate specification of subsets of neurons in the developing central nervous system. However, downstream molecules induced by Ptf1a during neural development have not been well characterized. In the present study, we identified immunoglobulin superfamily molecules, Nephrin and Neph3, as direct downstream targets of Ptf1a. First, the expression domains of Nephrin and Neph3 closely resembled those of Ptf1a in the developing retina, hypothalamus, cerebellum, hind-brain, and spinal cord. Second, Ptf1a bound directly to a PTF-binding motif in the 5'-flanking region of Nephrin and Neph3 genes. Third, Ptf1a activated transcription driven by the 5'-flanking region of these genes. Finally, the expression of Nephrin and Neph3 was lost in Ptf1a-null mice, whereas ectopic expression of Nephrin and Neph3 was induced by forced expression of Ptf1a. We provided further evidence that Nephrin and Neph3 could interact homophilically and heterophilically, suggesting that Nephrin and Neph3 might regulate certain developmental aspects of Ptf1a-positive neurons as homo- or heterooligomers.	[Nishida, Kazuhiko; Murakami, Fujio] Osaka Univ, Grad Sch Frontier Biosci, Suita, Osaka 5650871, Japan; [Hoshino, Mikio] Natl Ctr Neurol & Psychiat, Natl Inst Neurosci, Dept Biochem & Cellular Biol, Tokyo 1878502, Japan; [Kawaguchi, Yoshiya] Kyoto Univ, Grad Sch Med, Dept Surg & Surg Basic Sci, Sakyo Ku, Kyoto 6068507, Japan	Osaka University; National Center for Neurology & Psychiatry - Japan; Kyoto University	Nishida, K (corresponding author), Osaka Univ, Grad Sch Frontier Biosci, Yamadaoka 1-3, Suita, Osaka 5650871, Japan.	nishidk@fbs.osaka-u.ac.jp; murakami@fbs.osaka-u.ac.jp		Nishida, Kazuhiko/0000-0001-8825-8441	Japan Science Technology Corporation; Japan Society for the Promotion of Science; Ministry of Education, Culture, Sports, Science, and Technology, Japan	Japan Science Technology Corporation(Japan Science & Technology Agency (JST)); Japan Society for the Promotion of Science(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of Science); Ministry of Education, Culture, Sports, Science, and Technology, Japan(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT))	This work was supported by Solution Oriented Research for Science and Technology from Japan Science Technology Corporation and grant-in-aids from the Japan Society for the Promotion of Science and Ministry of Education, Culture, Sports, Science, and Technology, Japan.	ANDREWS NC, 1991, NUCLEIC ACIDS RES, V19, P2499, DOI 10.1093/nar/19.9.2499; Barletta GM, 2003, J BIOL CHEM, V278, P19266, DOI 10.1074/jbc.M301279200; Beltcheva O, 2003, J AM SOC NEPHROL, V14, P352, DOI 10.1097/01.ASN.0000043081.65110.C4; Beres TM, 2006, MOL CELL BIOL, V26, P117, DOI 10.1128/MCB.26.1.117-130.2006; COCKELL M, 1989, MOL CELL BIOL, V9, P2464, DOI 10.1128/MCB.9.6.2464; Fischbach KF, 2009, J NEUROGENET, V23, P48, DOI 10.1080/01677060802471668; Fujitani Y, 2006, DEVELOPMENT, V133, P4439, DOI 10.1242/dev.02598; Fujiyama T, 2009, DEVELOPMENT, V136, P2049, DOI 10.1242/dev.033480; Garg P, 2007, MOL CELL BIOL, V27, P8698, DOI 10.1128/MCB.00948-07; Gerke P, 2005, J AM SOC NEPHROL, V16, P1693, DOI 10.1681/ASN.2004060439; Gerke P, 2003, J AM SOC NEPHROL, V14, P918, DOI 10.1097/01.ASN.0000057853.05686.89; Gerke P, 2006, J COMP NEUROL, V498, P466, DOI 10.1002/cne.21064; Glasgow SM, 2005, DEVELOPMENT, V132, P5461, DOI 10.1242/dev.02167; Hatanaka Y, 2002, J COMP NEUROL, V454, P1, DOI 10.1002/cne.10421; Helms AW, 2005, DEVELOPMENT, V132, P2709, DOI 10.1242/dev.01859; Henke RM, 2009, DEVELOPMENT, V136, P2945, DOI 10.1242/dev.035352; Hori K, 2008, GENE DEV, V22, P166, DOI 10.1101/gad.1628008; Hoshino M, 2005, NEURON, V47, P201, DOI 10.1016/j.neuron.2005.06.007; Huber TB, 2003, J BIOL CHEM, V278, P13417, DOI 10.1074/jbc.C200678200; Kawaguchi Y, 2002, NAT GENET, V32, P128, DOI 10.1038/ng959; Kawauchi D, 2008, DEV BIOL, V322, P345, DOI 10.1016/j.ydbio.2008.08.005; Kestila M, 1998, MOL CELL, V1, P575, DOI 10.1016/S1097-2765(00)80057-X; Khoshnoodi J, 2003, AM J PATHOL, V163, P2337, DOI 10.1016/S0002-9440(10)63590-0; Krapp A, 1998, GENE DEV, V12, P3752, DOI 10.1101/gad.12.23.3752; Li H, 2001, DEV BIOL, V240, P247, DOI 10.1006/dbio.2001.0440; Liu G, 2003, J CLIN INVEST, V112, P209, DOI 10.1172/JCI200318242; Masui T, 2007, GENE DEV, V21, P2629, DOI 10.1101/gad.1575207; Minaki Y, 2005, NEUROSCI RES, V52, P250, DOI 10.1016/j.neures.2005.03.014; Miyata T, 2001, NEURON, V31, P727, DOI 10.1016/S0896-6273(01)00420-2; Nakhai H, 2007, DEVELOPMENT, V134, P1151, DOI 10.1242/dev.02781; NIWA H, 1991, GENE, V108, P193, DOI 10.1016/0378-1119(91)90434-D; Palmen T, 2001, DIABETOLOGIA, V44, P1274, DOI 10.1007/s001250100641; Pascual M, 2007, P NATL ACAD SCI USA, V104, P5193, DOI 10.1073/pnas.0605699104; Putaala H, 2001, HUM MOL GENET, V10, P1, DOI 10.1093/hmg/10.1.1; Ristola M, 2009, BMC MOL BIOL, V10, DOI 10.1186/1471-2199-10-83; Rose SD, 2001, J BIOL CHEM, V276, P44018, DOI 10.1074/jbc.M106264200; Sellick GS, 2004, NAT GENET, V36, P1301, DOI 10.1038/ng1475; Sellin L, 2002, FASEB J, V16, P115, DOI 10.1096/fj.02-0242fje; Serizawa S, 2006, CELL, V127, P1057, DOI 10.1016/j.cell.2006.10.031; Shen K, 2004, CELL, V116, P869, DOI 10.1016/S0092-8674(04)00251-X; Shih NY, 2001, AM J PATHOL, V159, P2303, DOI 10.1016/S0002-9440(10)63080-5; Sun C, 2003, GENOMICS, V82, P130, DOI 10.1016/S0888-7543(03)00110-1; Sun YJ, 1999, J BIOCHEM, V125, P515, DOI 10.1093/oxfordjournals.jbchem.a022315; Tamura S, 2005, NEUROSCIENCE, V133, P615, DOI 10.1016/j.neuroscience.2005.03.030; Tanaka DH, 2009, J NEUROSCI, V29, P1300, DOI 10.1523/JNEUROSCI.5446-08.2009; Wagner N, 2004, J AM SOC NEPHROL, V15, P3044, DOI 10.1097/01.ASN.0000146687.99058.25; Wiebe PO, 2007, MOL CELL BIOL, V27, P4093, DOI 10.1128/MCB.01978-06; Yamada M, 2007, J NEUROSCI, V27, P10924, DOI 10.1523/JNEUROSCI.1423-07.2007; Zhu Y, 2009, DEVELOPMENT, V136, P1919, DOI 10.1242/dev.032276	49	22	24	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 1	2010	285	1					373	380		10.1074/jbc.M109.060657	http://dx.doi.org/10.1074/jbc.M109.060657			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	536UT	19887377	Green Published, hybrid			2022-12-25	WOS:000273070100039
J	Aranda, P; Agirre, X; Ballestar, E; Andreu, EJ; Roman-Gomez, J; Prieto, I; Martin-Subero, JI; Cigudosa, JC; Siebert, R; Esteller, M; Prosper, F				Aranda, Pablo; Agirre, Xabier; Ballestar, Esteban; Andreu, Enrique J.; Roman-Gomez, Jose; Prieto, Ines; Martin-Subero, Jose Ignacio; Cigudosa, Juan Cruz; Siebert, Reiner; Esteller, Manel; Prosper, Felipe			Epigenetic Signatures Associated with Different Levels of Differentiation Potential in Human Stem Cells	PLOS ONE			English	Article							ADULT PROGENITOR CELLS; ACUTE LYMPHOBLASTIC-LEUKEMIA; CHRONIC MYELOID-LEUKEMIA; GENE-EXPRESSION; DEVELOPMENTAL REGULATORS; ABERRANT METHYLATION; POLYCOMB; PLURIPOTENT; MICRORNA; GENOME				Aranda, P (corresponding author), Univ Navarra, Fdn Appl Med Res, Dept Hematol, Univ Navarra Clin, E-31080 Pamplona, Spain.	fprosper@unav.es	Agirre, Xabier/ABE-4110-2020; Esteller, Manel/L-5956-2014; Cigudosa, Juan C/E-4105-2016; Andreu, Enrique J/F-9813-2016; Prosper, Felipe/H-6859-2017; Ballestar, Esteban/ABG-8561-2020; Siebert, Reiner/A-8049-2010	Esteller, Manel/0000-0003-4490-6093; Andreu, Enrique J/0000-0001-5317-9989; Prosper, Felipe/0000-0001-6115-8790; Martin-Subero, Jose Ignacio/0000-0001-8809-5195; Ballestar, Esteban/0000-0002-1400-2440				Agirre X, 2006, ONCOGENE, V25, P1862, DOI 10.1038/sj.onc.1209236; Agirre X, 2008, MOL CANCER RES, V6, P1830, DOI 10.1158/1541-7786.MCR-08-0167; Aranguren XL, 2008, J CLIN INVEST, V118, P505, DOI [10.1172/JC131153, 10.1172/JCI31153]; Aranguren XL, 2007, BLOOD, V109, P2634, DOI 10.1182/blood-2006-06-030411; Assou S, 2007, STEM CELLS, V25, P961, DOI 10.1634/stemcells.2006-0352; Azuara V, 2006, NAT CELL BIOL, V8, P532, DOI 10.1038/ncb1403; Barski A, 2007, CELL, V129, P823, DOI 10.1016/j.cell.2007.05.009; Bernstein BE, 2006, CELL, V125, P315, DOI 10.1016/j.cell.2006.02.041; Bibikova M, 2006, GENOME RES, V16, P383, DOI 10.1101/gr.4410706; Bibikova M, 2008, CELL STEM CELL, V2, P123, DOI 10.1016/j.stem.2008.01.005; Bibikova M, 2006, GENOME RES, V16, P1075, DOI 10.1101/gr.5319906; Boyer LA, 2006, NATURE, V441, P349, DOI 10.1038/nature04733; Bracken AP, 2006, GENE DEV, V20, P1123, DOI 10.1101/gad.381706; Calvanese V, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003294; Caretti G, 2004, GENE DEV, V18, P2627, DOI 10.1101/gad.1241904; Chen JF, 2006, NAT GENET, V38, P228, DOI 10.1038/ng1725; Chen X, 2005, SCIENCE, V310, P869, DOI 10.1126/science.1118101; Dominici M, 2006, CYTOTHERAPY, V8, P315, DOI 10.1080/14653240600855905; Fouse SD, 2008, CELL STEM CELL, V2, P160, DOI 10.1016/j.stem.2007.12.011; Garrick D, 2008, BLOOD, V112, P3889, DOI 10.1182/blood-2008-06-161901; Giordano A, 2007, J CELL PHYSIOL, V211, P27, DOI 10.1002/jcp.20959; Hoffman LM, 2005, NAT BIOTECHNOL, V23, P699, DOI 10.1038/nbt1102; Ivanova NB, 2002, SCIENCE, V298, P601, DOI 10.1126/science.1073823; Jiang YH, 2002, NATURE, V418, P41, DOI 10.1038/nature00870; Jose-Eneriz ES, 2008, BRIT J HAEMATOL, V142, P571, DOI 10.1111/j.1365-2141.2008.07221.x; Josephson R, 2007, STEM CELLS, V25, P437, DOI 10.1634/stemcells.2006-0236; Kanellopoulou C, 2005, GENE DEV, V19, P489, DOI 10.1101/gad.1248505; Kim JB, 2008, NATURE, V454, P646, DOI 10.1038/nature07061; Lagarkova MA, 2006, CELL CYCLE, V5, P416, DOI 10.4161/cc.5.4.2440; Landgraf P, 2007, CELL, V129, P1401, DOI 10.1016/j.cell.2007.04.040; Laurent LC, 2008, STEM CELLS, V26, P1506, DOI 10.1634/stemcells.2007-1081; Lee TI, 2006, CELL, V125, P301, DOI 10.1016/j.cell.2006.02.043; Li QT, 2008, CELL STEM CELL, V2, P195, DOI 10.1016/j.stem.2008.02.008; Lujambio A, 2007, CANCER RES, V67, P1424, DOI 10.1158/0008-5472.CAN-06-4218; Marson A, 2008, CELL, V134, P521, DOI 10.1016/j.cell.2008.07.020; Martin-Subero JI, 2009, BLOOD, V113, P2488, DOI 10.1182/blood-2008-04-152900; Meissner A, 2008, NATURE, V454, P766, DOI 10.1038/nature07107; Mikkelsen TS, 2007, NATURE, V448, P553, DOI 10.1038/nature06008; Mohn F, 2008, MOL CELL, V30, P755, DOI 10.1016/j.molcel.2008.05.007; Morin RD, 2008, GENOME RES, V18, P610, DOI 10.1101/gr.7179508; Muller FJ, 2008, NATURE, V455, P401, DOI 10.1038/nature07213; Niwa H, 2007, GENE DEV, V21, P2071, DOI 10.1101/gad.1615707; Okita K, 2007, NATURE, V448, P313, DOI 10.1038/nature05934; Pan GJ, 2007, CELL STEM CELL, V1, P299, DOI 10.1016/j.stem.2007.08.003; Pasini D, 2007, MOL CELL BIOL, V27, P3769, DOI 10.1128/MCB.01432-06; Pittenger MF, 1999, SCIENCE, V284, P143, DOI 10.1126/science.284.5411.143; Ren XJ, 2008, MOL CELL BIOL, V28, P2884, DOI 10.1128/MCB.00949-07; Roman-Gomez J, 2007, EUR J CANCER, V43, P2736, DOI 10.1016/j.ejca.2007.10.004; ROMANGOMEZ J, 2009, J CLIN ONCOL; Schwartz RE, 2002, J CLIN INVEST, V109, P1291, DOI 10.1172/JCI200215182; Skottman H, 2006, STEM CELLS, V24, P151, DOI 10.1634/stemcells.2004-0189; Stadler BM, 2008, CELL, V132, P563, DOI 10.1016/j.cell.2008.02.005; Surani MA, 2007, CELL, V128, P747, DOI 10.1016/j.cell.2007.02.010; Takahashi K, 2007, CELL, V131, P861, DOI 10.1016/j.cell.2007.11.019; Takahashi K, 2006, CELL, V126, P663, DOI 10.1016/j.cell.2006.07.024; Tay Y, 2008, NATURE, V455, P1124, DOI 10.1038/nature07299; Tay YMS, 2008, STEM CELLS, V26, P17, DOI 10.1634/stemcells.2007-0295; Ulloa-Montoya F, 2007, GENOME BIOL, V8, DOI 10.1186/gb-2007-8-8-r163; van den Boom V, 2007, J CELL BIOL, V178, P913, DOI 10.1083/jcb.200702058; Yeo S, 2007, BIOCHEM BIOPH RES CO, V359, P536, DOI 10.1016/j.bbrc.2007.05.120; Yu JY, 2008, GENE DEV, V22, P1987, DOI 10.1101/gad.1689808; Zhao Y, 2007, CELL, V129, P303, DOI 10.1016/j.cell.2007.03.030	62	85	87	0	12	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	NOV 13	2009	4	11							e7809	10.1371/journal.pone.0007809	http://dx.doi.org/10.1371/journal.pone.0007809			14	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	518VB	19915669	Green Published, gold			2022-12-25	WOS:000271721900003
J	Antao, EM; Ewers, C; Gurlebeck, D; Preisinger, R; Homeier, T; Li, GW; Wieler, LH				Antao, Esther-Maria; Ewers, Christa; Guerlebeck, Doreen; Preisinger, Rudolf; Homeier, Timo; Li, Ganwu; Wieler, Lothar H.			Signature-Tagged Mutagenesis in a Chicken Infection Model Leads to the Identification of a Novel Avian Pathogenic Escherichia coli Fimbrial Adhesin	PLOS ONE			English	Article							TYPE-1 FIMBRIAE; EXTRAINTESTINAL INFECTIONS; BACTERIAL VIRULENCE; GENETIC-ANALYSIS; GENOME SEQUENCE; URINARY-TRACT; P-FIMBRIAE; STRAINS; APEC; PYELONEPHRITIS	The extraintestinal pathogen, avian pathogenic E. coli (APEC), known to cause systemic infections in chickens, is responsible for large economic losses in the poultry industry worldwide. In order to identify genes involved in the early essential stages of pathogenesis, namely adhesion and colonization, Signature-tagged mutagenesis (STM) was applied to a previously established lung colonization model of infection by generating and screening a total of 1,800 mutants of an APEC strain IMT5155 (O2:K1:H5; Sequence type complex 95). The study led to the identification of new genes of interest, including two adhesins, one of which coded for a novel APEC fimbrial adhesin (Yqi) not described for its role in APEC pathogenesis to date. Its gene product has been temporarily designated ExPEC Adhesin I (EA/I) until the adhesin-specific receptor is identified. Deletion of the ExPEC adhesin I gene resulted in reduced colonization ability by APEC strain IMT5155 both in vitro and in vivo. Furthermore, complementation of the adhesin gene restored its ability to colonize epithelial cells in vitro. The ExPEC adhesin I protein was successfully expressed in vitro. Electron microscopy of an afimbriate strain E. coli AAEC189 overexpressed with the putative EA/I gene cluster revealed short fimbrial-like appendages protruding out of the bacterial outer membrane. We observed that this adhesin coding gene yqi is prevalent among extraintestinal pathogenic E. coli (ExPEC) isolates, including APEC (54.4%), uropathogenic E. coli (UPEC) (65.9%) and newborn meningitic E. coli (NMEC) (60.0%), and absent in all of the 153 intestinal pathogenic E. coli strains tested, thereby validating the designation of the adhesin as ExPEC Adhesin I. In addition, prevalence of EA/I was most frequently associated with the B2 group of the EcoR classification and ST95 complex of the multi locus sequence typing (MLST) scheme, with evidence of a positive selection within this highly pathogenic complex. This is the first report of the newly identified and functionally characterized ExPEC adhesin I and its significant role during APEC infection in chickens.			Antao, EM (corresponding author), Free Univ Berlin, Inst Mikrobiol & Tierseuchen, D-1000 Berlin, Germany.	antao.em@vetmed.fu-berlin.de	Ewers, Christa/AAL-9186-2020; Li, Ganwu/AAC-7423-2020	Wieler, Lothar H./0000-0003-4365-3717; Ewers, Christa/0000-0001-6167-1340				Antao EM, 2008, MICROB PATHOGENESIS, V45, P361, DOI 10.1016/j.micpath.2008.08.005; BALCAROVASTANDER J, 1984, EMBO J, V3, P2687, DOI 10.1002/j.1460-2075.1984.tb02194.x; Blattner FR, 1997, SCIENCE, V277, P1453, DOI 10.1126/science.277.5331.1453; BLOMFIELD IC, 1991, MOL MICROBIOL, V5, P1439, DOI 10.1111/j.1365-2958.1991.tb00790.x; CHANTELOUP NK, 1991, MICROB PATHOGENESIS, V10, P271, DOI 10.1016/0882-4010(91)90011-X; Chen SL, 2006, P NATL ACAD SCI USA, V103, P5977, DOI 10.1073/pnas.0600938103; Chiang SL, 1999, ANNU REV MICROBIOL, V53, P129, DOI 10.1146/annurev.micro.53.1.129; Datsenko KA, 2000, P NATL ACAD SCI USA, V97, P6640, DOI 10.1073/pnas.120163297; Dho-Moulin M, 1999, VET RES, V30, P299; Ewers C, 2007, INT J MED MICROBIOL, V297, P163, DOI 10.1016/j.ijmm.2007.01.003; Ewers C, 2009, APPL ENVIRON MICROB, V75, P184, DOI 10.1128/AEM.01324-08; FANTINATTI F, 1994, VET MICROBIOL, V41, P75, DOI 10.1016/0378-1135(94)90137-6; Feil EJ, 2004, J BACTERIOL, V186, P1518, DOI 10.1128/JB.186.5.1518-1530.2004; Finlay BB, 1997, MICROBIOL MOL BIOL R, V61, P136, DOI 10.1128/.61.2.136-169.1997; Gophna U, 2001, INFECT IMMUN, V69, P2659, DOI 10.1128/IAI.69.4.2659-2665.2001; HANSON MS, 1988, NATURE, V332, P265, DOI 10.1038/332265a0; HENSEL M, 1995, SCIENCE, V269, P400, DOI 10.1126/science.7618105; HERZER PJ, 1990, J BACTERIOL, V172, P6175, DOI 10.1128/jb.172.11.6175-6181.1990; Janssen T, 2001, INT J MED MICROBIOL, V291, P371, DOI 10.1078/1438-4221-00143; Johnson J, 2003, J CLIN MICROBIOL, V41, P5798, DOI 10.1128/JCM.41.12.5798-5802.2003; Johnson JR, 2005, INT J MED MICROBIOL, V295, P383, DOI 10.1016/j.ijmm.2005.07.005; Johnson JR, 2002, J INFECT DIS, V186, P859, DOI 10.1086/342490; Johnson TJ, 2007, J BACTERIOL, V189, P3228, DOI 10.1128/JB.01726-06; JONES CH, 1992, INFECT IMMUN, V60, P4445, DOI 10.1128/IAI.60.11.4445-4451.1992; KAADEN OR, 1982, IN VITRO CELL DEV B, V18, P827, DOI 10.1007/BF02796323; Kariyawasam S, 2007, BMC MICROBIOL, V7, DOI 10.1186/1471-2180-7-81; KROGFELT KA, 1990, INFECT IMMUN, V58, P1995, DOI 10.1128/IAI.58.6.1995-1998.1990; KROGFELT KA, 1991, REV INFECT DIS, V13, P721; Li G, 2008, MICROBIOL-SGM, V154, P1082, DOI 10.1099/mic.0.2007/015784-0; Li GW, 2005, INFECT IMMUN, V73, P2818, DOI 10.1128/IAI.73.5.2818-2827.2005; Maiden MCJ, 1998, P NATL ACAD SCI USA, V95, P3140, DOI 10.1073/pnas.95.6.3140; Martindale J, 2000, MOL MICROBIOL, V37, P1293, DOI 10.1046/j.1365-2958.2000.02088.x; Mokady D, 2005, INT J MED MICROBIOL, V295, P455, DOI 10.1016/j.ijmm.2005.07.007; MORDHORST IL, 2009, ENV MICROBIOL; MURILLO J, 1994, PLASMID, V31, P275, DOI 10.1006/plas.1994.1029; PECHA B, 1989, J CLIN INVEST, V83, P2102, DOI 10.1172/JCI114123; Pourbakhsh SA, 1997, MICROB PATHOGENESIS, V22, P331, DOI 10.1006/mpat.1996.0116; ROBERTS JA, 1984, J UROLOGY, V131, P602, DOI 10.1016/S0022-5347(17)50513-3; Rozas J, 2003, BIOINFORMATICS, V19, P2496, DOI 10.1093/bioinformatics/btg359; Sankar TS, 2009, PLOS GENET, V5, DOI 10.1371/journal.pgen.1000405; Weissman SJ, 2006, MOL MICROBIOL, V59, P975, DOI 10.1111/j.1365-2958.2005.04985.x; Wiles TJ, 2008, EXP MOL PATHOL, V85, P11, DOI 10.1016/j.yexmp.2008.03.007; Wirth T, 2006, MOL MICROBIOL, V60, P1136, DOI 10.1111/j.1365-2958.2006.05172.x; Wizemann TM, 1999, EMERG INFECT DIS, V5, P395, DOI 10.3201/eid0503.990310; Wright KJ, 2006, FUTURE MICROBIOL, V1, P75, DOI 10.2217/17460913.1.1.75	45	39	42	0	15	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA	1932-6203			PLOS ONE	PLoS One	NOV 12	2009	4	11							e7796	10.1371/journal.pone.0007796	http://dx.doi.org/10.1371/journal.pone.0007796			14	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	518UW	19907658	Green Published, gold, Green Submitted			2022-12-25	WOS:000271721400004
J	Lund, TC; Glass, TJ; Tolar, J; Blazar, BR				Lund, Troy C.; Glass, Tiffany J.; Tolar, Jakub; Blazar, Bruce R.			Expression of Telomerase and Telomere Length Are Unaffected by either Age or Limb Regeneration in Danio rerio	PLOS ONE			English	Article							GRADUAL SENESCENCE; ZEBRAFISH; CANCER; HAPLOINSUFFICIENCY; BIOLOGY; CELLS	Background: The zebrafish is an increasingly popular model for studying many aspects of biology. Recently, ztert, the zebrafish homolog of the mammalian telomerase gene has been cloned and sequenced. In contrast to humans, it has been shown that the zebrafish maintains telomerase activity for much of its adult life and has remarkable regenerative capacity. To date, there has been no longitudinal study to assess whether this retention of telomerase activity equates to the retention of chromosome telomere length through adulthood. Methodology/Principal Findings: We have systematically analyzed individual organs of zebrafish with regard to both telomere length and telomerase activity at various time points in its adult life. Heart, gills, kidney, spleen, liver, and intestine were evaluated at 3 months, 6 months, 9 months, and 2 years of age by Southern blot analysis. We found that telomeres do not appreciably shorten throughout the lifespan of the zebrafish in any organ. In addition, there was little difference in telomere lengths between organs. Even when cells were under the highest pressure to divide after fin-clipping experiments, telomere length was unaffected. All aged ( 2 year old) tissues examined also expressed active amounts of telomerase activity as assessed by TRAP assay. Conclusions/Significance: In contrast to several other species including humans, the retention of lifelong telomerase and telomeres, as we have reported here, would be necessary in the zebrafish to maintain its tremendous regenerative capacity. The ongoing study of the zebrafish's ability to maintain telomerase activity may be helpful in unraveling the complexity involved in the maintenance ( or lack thereof) of telomeres in other species such the mouse or human.			Lund, TC (corresponding author), Univ Minnesota, Div Pediat Blood, Minneapolis, MN 55455 USA.	lundx072@umn.edu		Tolar, Jakub/0000-0002-0957-4380				Blasco MA, 1997, CELL, V91, P25, DOI 10.1016/S0092-8674(01)80006-4; Elmore LW, 2008, EXP BIOL MED, V233, P958, DOI 10.3181/0712-RM-345; Hartmann N, 2009, MECH AGEING DEV, V130, P290, DOI 10.1016/j.mad.2009.01.003; Hatakeyama H, 2008, MECH AGEING DEV, V129, P550, DOI 10.1016/j.mad.2008.05.006; Hathcock KS, 2002, P NATL ACAD SCI USA, V99, P3591, DOI 10.1073/pnas.012549799; KIPLING D, 1991, GENOMICS, V11, P235, DOI 10.1016/0888-7543(91)90128-2; KIPLING D, 1992, HUM MOL GENET, V1, P3, DOI 10.1093/hmg/1.1.3-a; Kishi S, 2004, ANN NY ACAD SCI, V1019, P521, DOI 10.1196/annals.1297.097; Kishi S, 2003, EXP GERONTOL, V38, P777, DOI 10.1016/S0531-5565(03)00108-6; Kishi S, 2008, PLOS GENET, V4, DOI 10.1371/journal.pgen.1000152; Lau BWM, 2008, J MOL NEUROSCI, V34, P63, DOI 10.1007/s12031-007-0072-x; Major Robert J, 2007, Drug Discov Today Dis Models, V4, P219, DOI 10.1016/j.ddmod.2007.09.002; McChesney PA, 2005, ZEBRAFISH, V1, P349, DOI 10.1089/zeb.2005.1.349; Meyerson M, 2000, J CLIN ONCOL, V18, P2626, DOI 10.1200/JCO.2000.18.13.2626; Modino S, 2002, INT J RADIAT BIOL, V78, P757, DOI 10.1080/09553000210146563; Morales CP, 1999, NAT GENET, V21, P115, DOI 10.1038/5063; Mozdy AD, 2006, RNA, V12, P1721, DOI 10.1261/rna.134706; Nakatani Y, 2007, DEV GROWTH DIFFER, V49, P145, DOI 10.1111/j.1440-169x.2007.00917.x; Narducci ML, 2007, J AM COLL CARDIOL, V50, P2369, DOI 10.1016/j.jacc.2007.08.048; Poss KD, 2007, SEMIN CELL DEV BIOL, V18, P36, DOI 10.1016/j.semcdb.2006.11.009; Riethman H, 2008, ANNU REV GENOM HUM G, V9, P1, DOI 10.1146/annurev.genom.8.021506.172017; Stewart SA, 2006, ANNU REV CELL DEV BI, V22, P531, DOI 10.1146/annurev.cellbio.22.010305.104518; Ulaner GA, 1997, MOL HUM REPROD, V3, P769, DOI 10.1093/molehr/3.9.769	23	50	51	0	63	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA	1932-6203			PLOS ONE	PLoS One	NOV 6	2009	4	11							e7688	10.1371/journal.pone.0007688	http://dx.doi.org/10.1371/journal.pone.0007688			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	515ND	19893630	Green Published, gold, Green Submitted			2022-12-25	WOS:000271478000001
J	Xia, YL; Yamaoka, Y; Zhu, Q; Matha, I; Gao, XL				Xia, Youlin; Yamaoka, Yoshio; Zhu, Qi; Matha, Ivan; Gao, Xiaolian			A Comprehensive Sequence and Disease Correlation Analyses for the C-Terminal Region of CagA Protein of Helicobacter pylori	PLOS ONE			English	Article							GASTRIC EPITHELIAL-CELLS; VIRULENCE FACTOR CAGA; TYROSINE PHOSPHORYLATION; PATHOGENICITY ISLAND; BIOLOGICAL-ACTIVITY; DISTINCT DIVERSITY; GENE; STRAINS; ANTIGEN; CANCER	Chronic Helicobacter pylori infection is known to be associated with the development of peptic ulcer, gastric cancer and gastric lymphoma. Currently, the bacterial factors of H. pylori are reported to be important in the development of gastroduodenal diseases. CagA protein, encoded by the cagA, is the best studied virulence factor of H. pylori. The pathogenic CagA protein contains a highly polymorphic Glu-Pro-Ile-Tyr-Ala (EPIYA) repeat region in the C-terminal. This repeat region is reported to be involved in the pathogenesis of gastroduodenal diseases. The segments containing EPIYA motifs have been designated as segments A, B, C, and D; however the classification and disease relation are still unclear. This study used 560 unique CagA sequences containing 1,796 EPIYA motifs collected from public resources, including 274 Western and 286 East Asian strains with clinical data obtained from 433 entries. Fifteen types of EPIYA or EPIYA-like sequences are defined. In addition to four previously reported major segment types, several minor segment types ( e. g., segment B', B '') and more than 30 sequence types (e.g., ABC, ABD) were defined using our classification method. We confirm that the sequences from Western and East Asian strains contain segment C and D, respectively. We also confirm that strains with two EPIYA segment C have a greater chance of developing gastric cancer than those with one segment C. Our results shed light on the relationships between the types of CagAs, the country of origin of each sequence type, and the frequency of gastric disease.			Xia, YL (corresponding author), Univ Houston, Dept Biol & Biochem, Houston, TX 77204 USA.	yyamaoka@bcm.tmc.edu; xgao@uh.edu		Yamaoka, Yoshio/0000-0002-1222-5819	NIDDK NIH HHS [R01 DK062813-05, R01 DK62813, R01 DK062813] Funding Source: Medline; NIGMS NIH HHS [R42 GM067364] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK062813] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R42GM067364] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Argent RH, 2004, GASTROENTEROLOGY, V127, P514, DOI 10.1053/j.gastro.2004.06.006; Argent RH, 2008, J MED MICROBIOL, V57, P1062, DOI 10.1099/jmm.0.2008/001818-0; Asahi M, 2000, J EXP MED, V191, P593, DOI 10.1084/jem.191.4.593; Azuma T, 2004, J CLIN MICROBIOL, V42, P2508, DOI 10.1128/JCM.42.6.2508-2517.2004; Azuma T, 2002, J INFECT DIS, V186, P1621, DOI 10.1086/345374; Backert S, 2001, MOL MICROBIOL, V42, P631, DOI 10.1046/j.1365-2958.2001.02649.x; Backert S, 2000, CELL MICROBIOL, V2, P155, DOI 10.1046/j.1462-5822.2000.00043.x; BLASER MJ, 1995, CANCER RES, V55, P2111; Censini S, 1996, P NATL ACAD SCI USA, V93, P14648, DOI 10.1073/pnas.93.25.14648; COVACCI A, 1993, P NATL ACAD SCI USA, V90, P5791, DOI 10.1073/pnas.90.12.5791; Crooks GE, 2004, GENOME RES, V14, P1188, DOI 10.1101/gr.849004; Falush D, 2003, SCIENCE, V299, P1582, DOI 10.1126/science.1080857; Ferreira AC, 2008, HELICOBACTER, V13, P28, DOI 10.1111/j.1523-5378.2008.00633.x; Franco AT, 2008, CANCER RES, V68, P379, DOI 10.1158/0008-5472.CAN-07-0824; Gressmann H, 2005, PLOS GENET, V1, P419, DOI 10.1371/journal.pgen.0010043; Hall T.A., 1999, NUCL ACIDS S SERIES, V41, P95, DOI [DOI 10.1021/BK-1999-0734.CH008, citeulike-article-id:691774, 10.12691/ajmr-6-4-3]; Hatakeyama M, 2004, NAT REV CANCER, V4, P688, DOI 10.1038/nrc1433; Hatakeyama M, 2006, INT J CANCER, V119, P1217, DOI 10.1002/ijc.21831; Hatakeyama M, 2009, J GASTROENTEROL, V44, P239, DOI 10.1007/s00535-009-0014-1; Higashi H, 2005, J BIOL CHEM, V280, P23130, DOI 10.1074/jbc.M503583200; Higashi H, 2002, P NATL ACAD SCI USA, V99, P14428, DOI 10.1073/pnas.222375399; Higashi H, 2002, SCIENCE, V295, P683, DOI 10.1126/science.1067147; Hoshino FB, 2000, J GASTROENTEROL, V35, P890, DOI 10.1007/s005350070002; Jenks PJ, 1998, GUT, V43, P752, DOI 10.1136/gut.43.6.752; Judd LM, 2004, GASTROENTEROLOGY, V126, P196, DOI 10.1053/j.gastro.2003.10.066; Kersulyte D, 2000, J BACTERIOL, V182, P3210, DOI 10.1128/JB.182.11.3210-3218.2000; Kidd M, 1999, GUT, V45, P499, DOI 10.1136/gut.45.4.499; KUIPERS EJ, 1995, J NATL CANCER I, V87, P1777, DOI 10.1093/jnci/87.23.1777; Linz B, 2007, NATURE, V445, P915, DOI 10.1038/nature05562; Moodley Y, 2009, SCIENCE, V323, P527, DOI 10.1126/science.1166083; Naito M, 2006, GASTROENTEROLOGY, V130, P1181, DOI 10.1053/j.gastro.2005.12.038; Nomura AMY, 2002, J INFECT DIS, V186, P1138, DOI 10.1086/343808; Odenbreit S, 2000, SCIENCE, V287, P1497, DOI 10.1126/science.287.5457.1497; Parsonnet J, 1997, GUT, V40, P297, DOI 10.1136/gut.40.3.297; Rizwan M, 2008, J BACTERIOL, V190, P1146, DOI 10.1128/JB.01309-07; Rota CA, 2001, J CLIN MICROBIOL, V39, P606, DOI 10.1128/JCM.39.2.606-612.2001; Satomi S, 2006, J GASTROENTEROL, V41, P668, DOI 10.1007/s00535-006-1838-6; Segal ED, 1999, P NATL ACAD SCI USA, V96, P14559, DOI 10.1073/pnas.96.25.14559; Selbach M, 2009, CELL HOST MICROBE, V5, P397, DOI 10.1016/j.chom.2009.03.004; Snider Jared L, 2009, J Carcinog, V8, P7, DOI 10.4103/1477-3163.50892; Stein M, 2000, P NATL ACAD SCI USA, V97, P1263, DOI 10.1073/pnas.97.3.1263; Suerbaum S, 2002, NEW ENGL J MED, V347, P1175, DOI 10.1056/NEJMra020542; Tammer I, 2007, GASTROENTEROLOGY, V132, P1309, DOI 10.1053/j.gastro.2007.01.050; Tebbutt NC, 2002, NAT MED, V8, P1089, DOI 10.1038/nm763; TUMMURU MKR, 1993, INFECT IMMUN, V61, P1799, DOI 10.1128/IAI.61.5.1799-1809.1993; Uchida T, 2007, CANCER SCI, V98, P521, DOI 10.1111/j.1349-7006.2007.00415.x; Uemura N, 2001, NEW ENGL J MED, V345, P784, DOI 10.1056/NEJMoa001999; UMEDA M, 2009, J BIOL CHEM     0622; Yamaoka Y, 2000, EPIDEMIOL INFECT, V124, P91, DOI 10.1017/S0950268899003209; Yamaoka Y, 1999, GASTROENTEROLOGY, V117, P342, DOI 10.1053/gast.1999.0029900342; Yamaoka Y, 2002, FEBS LETT, V517, P180, DOI 10.1016/S0014-5793(02)02617-0; Yamaoka Y, 1998, J CLIN MICROBIOL, V36, P2258, DOI 10.1128/JCM.36.8.2258-2263.1998; Yamaoka Y, 2008, INTERNAL MED, V47, P1077, DOI 10.2169/internalmedicine.47.0975; Yamazaki S, 2005, J CLIN MICROBIOL, V43, P3906, DOI 10.1128/JCM.43.8.3906-3916.2005; Zhou JC, 2004, J MED MICROBIOL, V53, P231, DOI 10.1099/jmm.0.05366-0	55	82	84	0	5	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	NOV 6	2009	4	11							e7736	10.1371/journal.pone.0007736	http://dx.doi.org/10.1371/journal.pone.0007736			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	515ND	19893742	Green Published, Green Submitted, gold			2022-12-25	WOS:000271478000011
J	Vebo, HC; Snipen, L; Nes, IF; Brede, DA				Vebo, Heidi C.; Snipen, Lars; Nes, Ingolf F.; Brede, Dag A.			The Transcriptome of the Nosocomial Pathogen Enterococcus faecalis V583 Reveals Adaptive Responses to Growth in Blood	PLOS ONE			English	Article							OXIDATIVE-STRESS-RESPONSE; GLUCOSE STARVATION RESPONSE; URINARY-TRACT-INFECTION; GROUP-A STREPTOCOCCUS; GROUP-B STREPTOCOCCUS; STAPHYLOCOCCUS-AUREUS; IN-VIVO; BIOFILM FORMATION; SERINE-PROTEASE; POLYSACCHARIDE BIOSYNTHESIS	Background: Enterococcus faecalis plays a dual role in human ecology, predominantly existing as a commensal in the alimentary canal, but also as an opportunistic pathogen that frequently causes nosocomial infections like bacteremia. A number of virulence factors that contribute to the pathogenic potential of E. faecalis have been established. However, the process in which E. faecalis gains access to the bloodstream and establishes a persistent infection is not well understood. Methodology/Principal Findings: To enhance our understanding of how this commensal bacterium adapts during a bloodstream infection and to examine the interplay between genes we designed an in vitro experiment using genome-wide microarrays to investigate what effects the presence of and growth in blood have on the transcriptome of E. faecalis strain V583. We showed that growth in both 2xYT supplemented with 10% blood and in 100% blood had a great impact on the transcription of many genes in the V583 genome. We identified several immediate changes signifying cellular processes that might contribute to adaptation and growth in blood. These include modulation of membrane fatty acid composition, oxidative and lytic stress protection, acquisition of new available substrates, transport functions including heme/iron transporters and genes associated with virulence in E. faecalis. Conclusions/Significance: The results presented here reveal that cultivation of E. faecalis in blood in vitro has a profound impact on its transcriptome, which includes a number of virulence traits. Observed regulation of genes and pathways revealed new insight into physiological features and metabolic capacities which enable E. faecalis to adapt and grow in blood. A number of the regulated genes might potentially be useful candidates for development of new therapeutic approaches for treatment of E. faecalis infections.			Vebo, HC (corresponding author), Norwegian Univ Life Sci, Lab Microbial Gene Technol & Food Microbiol Biote, As, Norway.	heidi.vebo@umb.no						Aakra A, 2005, ANTIMICROB AGENTS CH, V49, P2246, DOI 10.1128/AAC.49.6.2246-2259.2005; Andrews SC, 2003, FEMS MICROBIOL REV, V27, P215, DOI 10.1016/S0168-6445(03)00055-X; Benachour A, 2005, J BACTERIOL, V187, P1022, DOI 10.1128/JB.187.3.1022-1035.2005; Bourgogne A, 2006, J BACTERIOL, V188, P2875, DOI 10.1128/JB.188.8.2875-2884.2006; Bourgogne A, 2008, GENOME BIOL, V9, DOI 10.1186/gb-2008-9-7-r110; Brinster S, 2009, NATURE, V458, P83, DOI 10.1038/nature07772; Brooijmans R, 2009, MICROB CELL FACT, V8, DOI 10.1186/1475-2859-8-28; Brunskill EW, 1996, J BACTERIOL, V178, P5810, DOI 10.1128/jb.178.19.5810-5812.1996; Capiaux H, 2000, INT J FOOD MICROBIOL, V55, P99, DOI 10.1016/S0168-1605(00)00183-5; CHAKRABORTY T, 1992, J BACTERIOL, V174, P568, DOI 10.1128/jb.174.2.568-574.1992; Chandler JR, 2005, P NATL ACAD SCI USA, V102, P15617, DOI 10.1073/pnas.0505545102; CHOW JW, 1993, ANTIMICROB AGENTS CH, V37, P2474, DOI 10.1128/AAC.37.11.2474; Coburn PS, 2004, SCIENCE, V306, P2270, DOI 10.1126/science.1103996; Corbin BD, 2008, SCIENCE, V319, P962, DOI 10.1126/science.1152449; Deutscher J, 2006, MICROBIOL MOL BIOL R, V70, P939, DOI 10.1128/MMBR.00024-06; Diggle PJ, 2002, ANAL LONGITUDINAL DA; Duwat P, 2001, J BACTERIOL, V183, P4509, DOI 10.1128/JB.183.15.4509-4516.2001; Fabretti F, 2006, INFECT IMMUN, V74, P4164, DOI 10.1128/IAI.00111-06; Flahaut S, 1998, LETT APPL MICROBIOL, V26, P259; Gentry-Weeks C, 2003, INFECT IMMUN, V71, P1434, DOI 10.1128/IAI.71.3.1434-1441.2003; Giard JC, 2006, FEMS IMMUNOL MED MIC, V46, P410, DOI 10.1111/j.1574-695X.2005.00049.x; Giard JC, 1997, RES MICROBIOL, V148, P27, DOI 10.1016/S0923-2508(97)81897-9; Graham MR, 2005, AM J PATHOL, V166, P455, DOI 10.1016/S0002-9440(10)62268-7; Graham MR, 2002, P NATL ACAD SCI USA, V99, P13855, DOI 10.1073/pnas.202353699; Groicher KH, 2000, J BACTERIOL, V182, P1794, DOI 10.1128/JB.182.7.1794-1801.2000; GUZMAN CA, 1989, INFECT IMMUN, V57, P1834; GUZMAN CA, 1991, MICROB PATHOGENESIS, V11, P399, DOI 10.1016/0882-4010(91)90036-A; Hancock LE, 2004, J BACTERIOL, V186, P7951, DOI 10.1128/JB.186.23.7951-7958.2004; Hancock LE, 2003, J BACTERIOL, V185, P4393, DOI 10.1128/JB.185.15.4393-4401.2003; Hancock LE, 2002, P NATL ACAD SCI USA, V99, P1574, DOI 10.1073/pnas.032448299; Hechard Y, 2001, MICROBIOL-SGM, V147, P1575, DOI 10.1099/00221287-147-6-1575; Hirt H, 2002, INFECT IMMUN, V70, P716, DOI 10.1128/IAI.70.2.716-723.2002; Huebner J, 1999, INFECT IMMUN, V67, P1213, DOI 10.1128/IAI.67.3.1213-1219.1999; Hufnagel M, 2004, J INFECT DIS, V189, P420, DOI 10.1086/381150; Hutchings MI, 2009, TRENDS MICROBIOL, V17, P13, DOI 10.1016/j.tim.2008.10.001; Huycke MM, 2002, CARCINOGENESIS, V23, P529, DOI 10.1093/carcin/23.3.529; Huycke MM, 1998, EMERG INFECT DIS, V4, P239, DOI 10.3201/eid0402.980211; IKE Y, 1984, INFECT IMMUN, V45, P528, DOI 10.1128/IAI.45.2.528-530.1984; JAEGER KE, 1994, FEMS MICROBIOL REV, V15, P29, DOI 10.1016/0168-6445(94)90025-6; Jordan S, 2008, FEMS MICROBIOL REV, V32, P107, DOI 10.1111/j.1574-6976.2007.00091.x; KLEBANOFF SJ, 1980, ANN INTERN MED, V93, P480, DOI 10.7326/0003-4819-93-3-480; KREFT B, 1992, INFECT IMMUN, V60, P25, DOI 10.1128/IAI.60.1.25-30.1992; La Carbona S, 2007, MOL MICROBIOL, V66, P1148, DOI 10.1111/j.1365-2958.2007.05987.x; Le Breton Y, 2005, J APPL MICROBIOL, V98, P806, DOI 10.1111/j.1365-2672.2004.02468.x; Low YL, 2003, J MED MICROBIOL, V52, P113, DOI 10.1099/jmm.0.05039-0; LOWE AM, 1995, INFECT IMMUN, V63, P703, DOI 10.1128/IAI.63.2.703-706.1995; MACLEOD RA, 1947, J BIOL CHEM, V170, P351; MACLEOD RA, 1951, J BACTERIOL, V62, P337, DOI 10.1128/JB.62.3.337-345.1951; Mereghetti L, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003143; Mohamed JA, 2006, J INFECT DIS, V193, P231, DOI 10.1086/498871; Mohamed JA, 2004, INFECT IMMUN, V72, P3658, DOI 10.1128/IAI.72.6.3658-3663.2004; Mundy LM, 2000, CLIN MICROBIOL REV, V13, P513, DOI 10.1128/CMR.13.4.513-522.2000; MURRAY BE, 1993, J BACTERIOL, V175, P5216, DOI 10.1128/JB.175.16.5216-5223.1993; Nallapareddy SR, 2008, J INFECT DIS, V197, P1728, DOI 10.1086/588143; Nannini EC, 2005, INFECT IMMUN, V73, P7772, DOI 10.1128/IAI.73.11.7772-7774.2005; NOBLE CJ, 1978, J CLIN PATHOL, V31, P1182, DOI 10.1136/jcp.31.12.1182; Orihuela CJ, 2004, INFECT IMMUN, V72, P5582, DOI 10.1128/IAI.72.10.5582-5596.2004; Paulsen IT, 2003, SCIENCE, V299, P2071, DOI 10.1126/science.1080613; Pfaffl MW, 2001, NUCLEIC ACIDS RES, V29, DOI 10.1093/nar/29.9.e45; Portenier I, 2003, ENDOD TOP, V6, P135, DOI DOI 10.1111/j.1601-1546.2003.00040.x; Posey JE, 2000, SCIENCE, V288, P1651, DOI 10.1126/science.288.5471.1651; Qin X, 2000, INFECT IMMUN, V68, P2579, DOI 10.1128/IAI.68.5.2579-2586.2000; Qin X, 2001, J BACTERIOL, V183, P3372, DOI 10.1128/JB.183.11.3372-3382.2001; RECSEI P, 1986, MOL GEN GENET, V202, P58, DOI 10.1007/BF00330517; Riboulet E, 2007, J MOL MICROB BIOTECH, V13, P140, DOI 10.1159/000103605; Rice KC, 2005, J BACTERIOL, V187, P813, DOI 10.1128/JB.187.3.813-821.2005; Richards MJ, 2000, INFECT CONT HOSP EP, V21, P510, DOI 10.1086/501795; Rince A, 2001, J BACTERIOL, V183, P1482, DOI 10.1128/JB.183.4.1482-1488.2001; Rince A, 2000, INT J FOOD MICROBIOL, V55, P87, DOI 10.1016/S0168-1605(00)00180-X; Roberts JC, 2004, J CLIN MICROBIOL, V42, P2317, DOI 10.1128/JCM.42.5.2317-2320.2004; Rowley G, 2006, NAT REV MICROBIOL, V4, P383, DOI 10.1038/nrmicro1394; Ruiz-Garbajosa P, 2006, J CLIN MICROBIOL, V44, P2220, DOI 10.1128/JCM.02596-05; SAHM DF, 1989, ANTIMICROB AGENTS CH, V33, P1588, DOI 10.1128/AAC.33.9.1588; Schlievert PM, 1998, INFECT IMMUN, V66, P218, DOI 10.1128/IAI.66.1.218-223.1998; Shankar N, 2002, NATURE, V417, P746, DOI 10.1038/nature00802; Shepard BD, 2002, INFECT IMMUN, V70, P4344, DOI 10.1128/IAI.70.8.4344-4352.2002; Sherman JM, 1937, J BACTERIOL, V33, P275, DOI 10.1128/JB.33.3.275-282.1937; Sifri CD, 2002, INFECT IMMUN, V70, P5647, DOI 10.1128/IAI.70.10.5647-5650.2002; Singh KV, 2009, J INFECT DIS, V200, P417, DOI 10.1086/600124; Singh KV, 1998, FEMS IMMUNOL MED MIC, V21, P323, DOI 10.1016/S0928-8244(98)00087-X; Solheim M, 2007, APPL ENVIRON MICROB, V73, P5767, DOI 10.1128/AEM.00651-07; Teng F, 2005, J INFECT DIS, V191, P472, DOI 10.1086/427191; Teng F, 2002, INFECT IMMUN, V70, P2010, DOI 10.1128/IAI.70.4.2010-2015.2002; Teng F, 2002, INFECT IMMUN, V70, P1991, DOI 10.1128/IAI.70.4.1991-1996.2002; Teng F, 2009, INFECT IMMUN, V77, P3759, DOI 10.1128/IAI.00149-09; THOMAS EL, 1988, REV INFECT DIS, V10, pS450; Torres VJ, 2007, CELL HOST MICROBE, V1, P109, DOI 10.1016/j.chom.2007.03.001; Verneuil N, 2005, MICROBIOL-SGM, V151, P3997, DOI 10.1099/mic.0.28325-0; Verneuil N, 2006, MICROBIOL-SGM, V152, P2579, DOI 10.1099/mic.0.28922-0; von Wallbrunn A, 2002, APPL MICROBIOL BIOT, V60, P179, DOI 10.1007/s00253-002-1080-y; Walecka E, 2009, LETT APPL MICROBIOL, V49, P79, DOI 10.1111/j.1472-765X.2009.02629.x; WEISER JN, 1994, INFECT IMMUN, V62, P2582, DOI 10.1128/IAI.62.6.2582-2589.1994; WELLS CL, 1990, J INFECT DIS, V162, P82, DOI 10.1093/infdis/162.1.82; Wernisch L, 2003, BIOINFORMATICS, V19, P53, DOI 10.1093/bioinformatics/19.1.53; Xu Y, 1998, INFECT IMMUN, V66, P4313; Xu Y, 1997, INFECT IMMUN, V65, P4207, DOI 10.1128/IAI.65.10.4207-4215.1997; Xu Y, 2000, INFECT IMMUN, V68, P815, DOI 10.1128/IAI.68.2.815-823.2000; Yamamoto Y, 2005, MOL MICROBIOL, V56, P525, DOI 10.1111/j.1365-2958.2005.04555.x	98	67	67	0	7	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA	1932-6203			PLOS ONE	PLoS One	NOV 4	2009	4	11							e7660	10.1371/journal.pone.0007660	http://dx.doi.org/10.1371/journal.pone.0007660			14	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	514RZ	19888459	Green Published, gold, Green Submitted			2022-12-25	WOS:000271414600003
J	Engel, T; Murphy, BM; Hatazaki, S; Jimenez-Mateos, EM; Concannon, CG; Woods, I; Prehn, JHM; Henshall, DC				Engel, Tobias; Murphy, Brona M.; Hatazaki, Seiji; Jimenez-Mateos, Eva M.; Concannon, Caoimhin G.; Woods, Ina; Prehn, Jochen H. M.; Henshall, David C.			Reduced hippocampal damage and epileptic seizures after status epilepticus in mice lacking proapoptotic Puma	FASEB JOURNAL			English	Article						apoptosis; Bcl-2; BH3-only protein; epileptogenesis; kainate; p53	TEMPORAL-LOBE EPILEPSY; TUMOR-SUPPRESSOR P53; BCL-2 FAMILY-MEMBERS; CELL-DEATH; INDUCED APOPTOSIS; NEURONAL DAMAGE; KAINIC ACID; PROTECTS NEURONS; BAX ACTIVATION; DNA-DAMAGE	The functional significance of neuronal death for pathogenesis of epilepsy and the underlying molecular mechanisms thereof remain incompletely understood. The p53 transcription factor has been implicated in seizure damage, but its target genes and the influence of cell death under its control on epilepsy development are unknown. In the present study, we report that status epilepticus (SE) triggered by intra-amygdala kainic acid in mice causes rapid p53 accumulation and subsequent hippocampal damage. Expression of p53-up-regulated mediator of apoptosis (Puma), a proapoptotic Bcl-2 homology domain 3-only protein under p53 control, was increased within a few hours of SE. Induction of Puma was blocked by pharmacologic inhibition of p53, and hippocampal damage was also reduced. Puma induction was also blocked in p53-deficient mice subject to SE. Compared to Puma-expressing mice, Puma-deficient mice had significantly smaller hippocampal lesions after SE. Long-term, continuous telemetric EEG monitoring revealed a similar to 60% reduction in the frequency of epileptic seizures in the Puma-deficient mice compared to Puma-expressing mice. These are the first data showing genetic deletion of a proapoptotic protein acting acutely to influence neuronal death subsequently alters the phenotype of epilepsy in the long-term, supporting the concept that apoptotic pathway activation is a trigger of epileptogenesis.-Engel, T., Murphy, B. M., Hatazaki, S., Jimenez-Mateos, E. M., Concannon, C. G., Woods, I., Prehn, J. H. M., Henshall, D. C. Reduced hippocampal damage and epileptic seizures after status epilepticus in mice lacking proapoptotic Puma. FASEB J. 24, 853-861 (2010). www.fasebj.org	[Engel, Tobias; Murphy, Brona M.; Hatazaki, Seiji; Jimenez-Mateos, Eva M.; Concannon, Caoimhin G.; Woods, Ina; Prehn, Jochen H. M.; Henshall, David C.] Royal Coll Surgeons Ireland, Dept Physiol & Med Phys, Dublin 2, Ireland; [Hatazaki, Seiji] Mie Univ, Sch Med, Dept Neurosurg, Tsu, Mie 514, Japan	Royal College of Surgeons - Ireland; Mie University	Henshall, DC (corresponding author), Royal Coll Surgeons Ireland, Dept Physiol & Med Phys, 123 St Stephens Green, Dublin 2, Ireland.	dhenshall@rcsi.ie	Prehn, Jochen HM/A-3928-2010; Concannon, Caoimhin/B-2075-2010; Jimenez-Mateos, Eva/AAG-8072-2019; Murphy, Brona/P-2544-2019; Murphy, Brona/D-4873-2012; Henshall, David/C-3364-2012	Prehn, Jochen HM/0000-0003-3479-7794; Murphy, Brona/0000-0002-6740-8858; Murphy, Brona/0000-0002-6740-8858; Jimenez-Mateos, Eva/0000-0001-6417-6580; Henshall, David/0000-0001-6237-9632; Engel, Tobias/0000-0001-9137-0637	Health Research Board Ireland [RP/2005/24, RP/2007/37, RP/2008/69, PD/2009/31]; Wellcome Trust [GR076576]; Science Foundation Ireland [08/IN1/B1875]; Marie Curie ToK [FP-14499]; Irish Research Council for Science Engineering and Technology	Health Research Board Ireland; Wellcome Trust(Wellcome TrustEuropean Commission); Science Foundation Ireland(Science Foundation IrelandEuropean Commission); Marie Curie ToK(European Commission); Irish Research Council for Science Engineering and Technology(Irish Research Council for Science, Engineering and TechnologyCGIAR)	The authors thank Andreas Strasser (Walter and Eliza Hall Institute of Medical Research, Parkville, Australia) and Andreas Villunger (University of Innsbruck, Innsbruck, Austria) for providing Puma-deficient mice, and Genshin Mouri, Liam Tuffy and Clara Schindler for technical support. This work was supported by grants from Health Research Board Ireland (RP/2005/24, RP/2007/37, RP/2008/69, PD/2009/31), the Wellcome Trust (GR076576), Science Foundation Ireland (08/IN1/B1875), Marie Curie ToK FP-14499, and a fellowship (to T. E.) from the Irish Research Council for Science Engineering and Technology.	Akhtar RS, 2006, J NEUROSCI, V26, P7257, DOI 10.1523/JNEUROSCI.0196-06.2006; Andre V, 2000, EPILEPSY RES, V42, P7, DOI 10.1016/S0920-1211(00)00153-4; Andre V, 2000, NEUROSCIENCE, V99, P469, DOI 10.1016/S0306-4522(00)00209-8; Araki T, 2004, HIPPOCAMPUS, V14, P326, DOI 10.1002/hipo.10184; Bernasconi A, 2002, PROG BRAIN RES, V135, P297; Biagini G, 2008, J NEUROPATH EXP NEUR, V67, P687, DOI 10.1097/NEN.0b013e318181b8ae; Brandt C, 2003, NEUROSCIENCE, V118, P727, DOI 10.1016/S0306-4522(03)00027-7; Bumanglag AV, 2008, J COMP NEUROL, V510, P561, DOI 10.1002/cne.21801; Cartron PF, 2004, MOL CELL, V16, P807, DOI 10.1016/j.molcel.2004.10.028; Concannon CG, 2008, J NEUROCHEM, V105, P891, DOI 10.1111/j.1471-4159.2007.05187.x; Cregan SP, 2004, J NEUROSCI, V24, P10003, DOI 10.1523/JNEUROSCI.2114-04.2004; Culmsee C, 2001, J NEUROCHEM, V77, P220, DOI 10.1046/j.1471-4159.2001.00220.x; DEGIORGIO CM, 1992, EPILEPSIA, V33, P23, DOI 10.1111/j.1528-1157.1992.tb02278.x; Djebaili M, 2002, NEUROSCI LETT, V327, P1, DOI 10.1016/S0304-3940(02)00137-4; Djebaili M, 2001, MOL BRAIN RES, V93, P190, DOI 10.1016/S0169-328X(01)00197-8; Dube C, 2006, BRAIN, V129, P911, DOI 10.1093/brain/awl018; Endo H, 2006, J NEUROSCI, V26, P7974, DOI 10.1523/JNEUROSCI.0897-06.2006; Engel Tobias, 2009, Int J Physiol Pathophysiol Pharmacol, V1, P97; Fujikawa TG, 2000, EPILEPSIA, V41, P981, DOI 10.1111/j.1528-1157.2000.tb00283.x; Gallenne T, 2009, J CELL BIOL, V185, P279, DOI 10.1083/jcb.200809153; Gomez-Lazaro M, 2005, EXP NEUROL, V196, P96, DOI 10.1016/j.expneurol.2005.07.011; Han JW, 2001, P NATL ACAD SCI USA, V98, P11318, DOI 10.1073/pnas.201208798; Jimenez-Mateos EM, 2008, NEUROBIOL DIS, V32, P442, DOI 10.1016/j.nbd.2008.08.008; Kienzler F, 2009, J COMP NEUROL, V515, P181, DOI 10.1002/cne.22059; Komarov PG, 1999, SCIENCE, V285, P1733, DOI 10.1126/science.285.5434.1733; Li TF, 2008, J CLIN INVEST, V118, P571, DOI 10.1172/JCI33737; Liu W, 1999, MOL BRAIN RES, V63, P248, DOI 10.1016/S0169-328X(98)00285-X; Mikaeloff Y, 2006, EPILEPSY RES, V69, P67, DOI 10.1016/j.eplepsyres.2006.01.002; MIYASHITA T, 1995, CELL, V80, P293; Morrison RS, 1996, J NEUROSCI, V16, P1337; Mouri G, 2008, BRAIN RES, V1213, P140, DOI 10.1016/j.brainres.2008.03.061; Mulle C, 1998, NATURE, V392, P601, DOI 10.1038/33408; Murphy B, 2007, AM J PATHOL, V171, P1258, DOI 10.2353/ajpath.2007.070269; Nakano K, 2001, MOL CELL, V7, P683, DOI 10.1016/S1097-2765(01)00214-3; Narkilahti S, 2003, NEUROPHARMACOLOGY, V44, P1068, DOI 10.1016/S0028-3908(03)00115-1; Oda E, 2000, SCIENCE, V288, P1053, DOI 10.1126/science.288.5468.1053; Pitkanen A, 2007, EPILEPSIA, V48, P13, DOI 10.1111/j.1528-1167.2007.01063.x; Qin JZ, 2005, CANCER RES, V65, P6282, DOI 10.1158/0008-5472.CAN-05-0676; Raol YSH, 2003, ANN NEUROL, V53, P503, DOI 10.1002/ana.10490; Reimertz C, 2003, J CELL BIOL, V162, P587, DOI 10.1083/jcb.200305149; SAKHI S, 1994, P NATL ACAD SCI USA, V91, P7525, DOI 10.1073/pnas.91.16.7525; Sakhi S, 1997, EXP NEUROL, V145, P81, DOI 10.1006/exnr.1997.6451; Schauwecker PE, 1997, P NATL ACAD SCI USA, V94, P4103, DOI 10.1073/pnas.94.8.4103; Schindler CK, 2006, J CEREBR BLOOD F MET, V26, P583, DOI 10.1038/sj.jcbfm.9600219; Sedarous M, 2003, J BIOL CHEM, V278, P26031, DOI 10.1074/jbc.M302833200; Shinoda S, 2004, J NEUROSCI RES, V76, P121, DOI 10.1002/jnr.20064; Sohn D, 2009, CELL DEATH DIFFER, V16, P869, DOI 10.1038/cdd.2009.17; Steckley D, 2007, J NEUROSCI, V27, P12989, DOI 10.1523/JNEUROSCI.3400-07.2007; Tan ZQ, 2002, BRAIN RES, V929, P129, DOI 10.1016/S0006-8993(01)03360-1; Tasch E, 1999, ANN NEUROL, V45, P568, DOI 10.1002/1531-8249(199905)45:5<568::AID-ANA4>3.0.CO;2-P; Tokita Y, 1996, EUR J NEUROSCI, V8, P69, DOI 10.1111/j.1460-9568.1996.tb01168.x; Uo T, 2007, J NEUROSCI, V27, P12198, DOI 10.1523/JNEUROSCI.3222-05.2007; Villunger A, 2003, SCIENCE, V302, P1036, DOI 10.1126/science.1090072; Willis SN, 2005, CURR OPIN CELL BIOL, V17, P617, DOI 10.1016/j.ceb.2005.10.001; Xiang H, 1996, J NEUROSCI, V16, P6753; You H, 2006, J EXP MED, V203, P1657, DOI 10.1084/jem.20060353; Yu J, 2001, MOL CELL, V7, P673, DOI 10.1016/S1097-2765(01)00213-1	57	50	54	0	21	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAR	2010	24	3					853	861		10.1096/fj.09-145870	http://dx.doi.org/10.1096/fj.09-145870			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	561KE	19890018	Green Published			2022-12-25	WOS:000274974600021
J	Kim, D; Lee, J; Cheng, DH; Li, J; Carter, C; Richie, E; Bedford, MT				Kim, Daehoon; Lee, Jaeho; Cheng, Donghang; Li, Jia; Carter, Carla; Richie, Ellen; Bedford, Mark T.			Enzymatic Activity Is Required for the in Vivo Functions of CARM1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ARGININE METHYLTRANSFERASE CARM1; TRANSCRIPTIONAL COACTIVATOR; PROTEIN METHYLTRANSFERASE; ANDROGEN RECEPTOR; GENE-EXPRESSION; HISTONE H3; METHYLATION; BINDING; REGULATOR; PRMT1	CARM1 is one of nine protein arginine methyltransferases that methylate arginine residues in proteins. CARM1 is recruited by many different transcription factors as a positive regulator. Gene targeting of CARM1 in mice has been performed, and knock-out mice, which are smaller than their wild-type littermates, die just after birth. It has been proposed that CARM1 has functions that are independent of its enzymatic activity. Indeed, CARM1 is found to interact with a number of proteins and may have a scaffolding function in this context. However, CARM1 methylates histone H3, PABP1, AIB1, and a number of splicing factors, which strongly suggests that its impact on transcription and splicing is primarily through its ability to modify these substrates. To unequivocally establish the importance of CARM1 enzymatic activity in vivo, we generated an enzyme-dead knock-in of this protein arginine methyltransferase. We determined that knock-in cells and mice have defects similar to those seen in their knock-out counterparts with respect to the time of embryo lethality, T cell development, adipocyte differentiation, and transcriptional coactivator activity. CARM1 requires its enzymatic activity for all of its known cellular functions. Thus, small molecule inhibitors of CARM1 will incapacitate all of the enzyme's cellular functions.	[Kim, Daehoon; Lee, Jaeho; Cheng, Donghang; Li, Jia; Carter, Carla; Richie, Ellen; Bedford, Mark T.] Univ Texas MD Anderson Canc Ctr, Sci Pk Res Div, Smithville, TX 78957 USA	University of Texas System; UTMD Anderson Cancer Center	Bedford, MT (corresponding author), Univ Texas MD Anderson Canc Ctr, Sci Pk Res Div, Smithville, TX 78957 USA.	mtbedford@mdanderson.org	Bedford, Mark T/E-7856-2011	Richie, Ellen/0000-0003-0786-973X	NIEHS [ES07784]; NCI [CA016672]; NATIONAL CANCER INSTITUTE [P30CA016672] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P30ES007784] Funding Source: NIH RePORTER	NIEHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))	This work was supported, in whole or in part, by National Institutes of Health Grant ES07784 from NIEHS (to institutional core facilities) and National Institutes of Health Grant CA016672 from NCI (to the Genetically Engineered Mouse Facility).	An W, 2004, CELL, V117, P735, DOI 10.1016/j.cell.2004.05.009; Bedford MT, 2009, MOL CELL, V33, P1, DOI 10.1016/j.molcel.2008.12.013; Bedford MT, 2000, J BIOL CHEM, V275, P16030, DOI 10.1074/jbc.M909368199; Bu P, 2007, MOL CELL BIOL, V27, P3405, DOI 10.1128/MCB.00066-07; Chan R, 2002, MOL CELL BIOL, V22, P1073, DOI 10.1128/MCB.22.4.1073-1078.2002; Chen DG, 1999, SCIENCE, V284, P2174, DOI 10.1126/science.284.5423.2174; Cheng DH, 2007, MOL CELL, V25, P71, DOI 10.1016/j.molcel.2006.11.019; Covic M, 2005, EMBO J, V24, P85, DOI 10.1038/sj.emboj.7600500; Dacwag CS, 2009, MOL CELL BIOL, V29, P1909, DOI 10.1128/MCB.00742-08; Deng CX, 1996, CELL, V84, P911, DOI 10.1016/S0092-8674(00)81069-7; El Messaoudi S, 2006, P NATL ACAD SCI USA, V103, P13351, DOI 10.1073/pnas.0605692103; Farley FW, 2000, GENESIS, V28, P106, DOI 10.1002/1526-968X(200011/12)28:3/4<106::AID-GENE30>3.0.CO;2-T; Fauquier L, 2008, FASEB J, V22, P3337, DOI 10.1096/fj.07-104604; Feng Q, 2006, MOL CELL BIOL, V26, P7846, DOI 10.1128/MCB.00568-06; Frietze S, 2008, CANCER RES, V68, P301, DOI 10.1158/0008-5472.CAN-07-1983; Hong H, 2004, CANCER-AM CANCER SOC, V101, P83, DOI 10.1002/cncr.20327; Iberg AN, 2008, J BIOL CHEM, V283, P3006, DOI 10.1074/jbc.C700192200; Kasper LH, 2002, NATURE, V419, P738, DOI 10.1038/nature01062; Kim J, 2004, J BIOL CHEM, V279, P25339, DOI 10.1074/jbc.M402544200; Kleinschmidt MA, 2008, NUCLEIC ACIDS RES, V36, P3202, DOI 10.1093/nar/gkn166; Koh SS, 2002, J BIOL CHEM, V277, P26031, DOI 10.1074/jbc.M110865200; Koh SS, 2001, J BIOL CHEM, V276, P1089, DOI 10.1074/jbc.M004228200; Kullander K, 2001, NEURON, V29, P73, DOI 10.1016/S0896-6273(01)00181-7; Lee YH, 2004, MOL CELL BIOL, V24, P2103, DOI 10.1128/MCB.24.5.2103-2117.2004; Lupien M, 2009, MOL CELL BIOL, V29, P3413, DOI 10.1128/MCB.00020-09; Majumder S, 2006, PROSTATE, V66, P1292, DOI 10.1002/pros.20438; Monroy MA, 2003, MOL ENDOCRINOL, V17, P2519, DOI 10.1210/me.2003-0208; Naeem H, 2007, MOL CELL BIOL, V27, P120, DOI 10.1128/MCB.00815-06; Schurter BT, 2001, BIOCHEMISTRY-US, V40, P5747, DOI 10.1021/bi002631b; Weiss RS, 2000, GENE DEV, V14, P1886; Weiss VH, 2000, NAT STRUCT BIOL, V7, P1165; Xu W, 2004, GENE DEV, V18, P144, DOI 10.1101/gad.1141704; Yadav N, 2003, P NATL ACAD SCI USA, V100, P6464, DOI 10.1073/pnas.1232272100; Yadav N, 2008, EMBO REP, V9, P193, DOI 10.1038/sj.embor.7401151; Yue WW, 2007, EMBO J, V26, P4402, DOI 10.1038/sj.emboj.7601856; Zhang X, 2003, STRUCTURE, V11, P509, DOI 10.1016/S0969-2126(03)00071-6; Zhang X, 2000, EMBO J, V19, P3509, DOI 10.1093/emboj/19.14.3509	37	52	53	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 8	2010	285	2					1147	1152		10.1074/jbc.M109.035865	http://dx.doi.org/10.1074/jbc.M109.035865			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	539MH	19897492	hybrid, Green Published			2022-12-25	WOS:000273258200037
J	Qin, HN; Noberini, R; Huan, XL; Shi, JH; Pasquale, EB; Song, JX				Qin, Haina; Noberini, Roberta; Huan, Xuelu; Shi, Jiahai; Pasquale, Elena B.; Song, Jianxing			Structural Characterization of the EphA4-Ephrin-B2 Complex Reveals New Features Enabling Eph-Ephrin Binding Promiscuity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CRYSTAL-STRUCTURE; RECEPTOR; LIGAND; NMR; DOMAIN; KINASES; SYSTEM; AXONS	EphA and EphB receptors preferentially bind ephrin-A and ephrin-B ligands, respectively, but EphA4 is exceptional for its ability to bind all ephrins. Here, we report the crystal structure of the EphA4 ligand-binding domain in complex with ephrin-B2, which represents the first structure of an EphA-ephrin-B interclass complex. A loose fit of the ephrin-B2 G-H loop in the EphA4 ligand-binding channel is consistent with a relatively weak binding affinity. Additional surface contacts also exist between EphA4 residues Gln(12) and Glu(14) and ephrin-B2. Mutation of Gln(12) and Glu(14) does not cause significant structural changes in EphA4 or changes in its affinity for ephrin-A ligands. However, the EphA4 mutant has similar to 10-fold reduced affinity for ephrin-B ligands, indicating that the surface contacts are critical for interclass but not intraclass ephrin binding. Thus, EphA4 uses different strategies to bind ephrin-A or ephrin-B ligands and achieve binding promiscuity. NMR characterization also suggests that the contacts of Gln(12) and Glu(14) with ephrin-B2 induce dynamic changes throughout the whole EphA4 ligand-binding domain. Our findings shed light on the distinctive features that enable the remarkable ligand binding promiscuity of EphA4 and suggest that diverse strategies are needed to effectively disrupt different Eph-ephrin complexes.	[Noberini, Roberta; Pasquale, Elena B.] Burnham Inst Med Res, La Jolla, CA 92037 USA; [Qin, Haina; Shi, Jiahai; Song, Jianxing] Natl Univ Singapore, Fac Sci, Dept Biol Sci, Singapore 119260, Singapore; [Huan, Xuelu] Natl Univ Singapore, Grad Sch Integrat Sci & Engn, Singapore 119260, Singapore; [Song, Jianxing] Natl Univ Singapore, Dept Biochem, Yong Loo Lin Sch Med, Singapore 119260, Singapore; [Pasquale, Elena B.] Univ Calif San Diego, Dept Pathol, La Jolla, CA 92093 USA	Sanford Burnham Prebys Medical Discovery Institute; National University of Singapore; National University of Singapore; National University of Singapore; University of California System; University of California San Diego	Pasquale, EB (corresponding author), Burnham Inst Med Res, La Jolla, CA 92037 USA.	elenap@burnham.org; bchsj@nus.edu.sg	Qin, Haina/AAB-7486-2020; Shi, Jiahai/AAH-1103-2019; shi, jiahai/D-7650-2013; Song, Jianxing/J-3617-2013; Noberini, Roberta/AAP-4527-2020; Song, Jianxing/H-8026-2012	Shi, Jiahai/0000-0002-6467-8289; shi, jiahai/0000-0002-6467-8289; Noberini, Roberta/0000-0002-7267-1079; Haina, Qin/0000-0002-9175-8014; Song, Jianxing/0000-0003-0224-6322	National Institutes of Health [CA116099, HD25938]; Singapore National Medical Research Council [NMRC/1216/2009, NMRC/1126/2007]; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [P01HD025938] Funding Source: NIH RePORTER; NATIONAL CANCER INSTITUTE [R01CA116099] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Singapore National Medical Research Council(National Medical Research Council, Singapore); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This work was supported, in whole or in part, by National Institutes of Health Grants CA116099 and HD25938 (to E. B. P.). This work was also supported by Singapore National Medical Research Council Grants NMRC/1216/2009 and NMRC/1126/2007 (to J. S.).	BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Barrios A, 2003, CURR BIOL, V13, P1571, DOI 10.1016/j.cub.2003.08.030; Benson MD, 2005, P NATL ACAD SCI USA, V102, P10694, DOI 10.1073/pnas.0504021102; Bowden TA, 2008, NAT STRUCT MOL BIOL, V15, P567, DOI 10.1038/nsmb.1435; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; CHENG HJ, 1995, CELL, V82, P371, DOI 10.1016/0092-8674(95)90426-3; Chrencik JE, 2007, J BIOL CHEM, V282, P36505, DOI 10.1074/jbc.M706340200; Chrencik JE, 2006, J BIOL CHEM, V281, P28185, DOI 10.1074/jbc.M605766200; DELAGLIO F, 1995, J BIOMOL NMR, V6, P277, DOI 10.1007/BF00197809; Emsley P, 2004, ACTA CRYSTALLOGR D, V60, P2126, DOI 10.1107/S0907444904019158; Flanagan JG, 2000, METHOD ENZYMOL, V327, P19, DOI 10.1016/S0076-6879(00)27264-9; Goldgur Y, 2009, ACTA CRYSTALLOGR F, V65, P71, DOI 10.1107/S1744309108043078; Himanen JP, 1998, NATURE, V396, P486, DOI 10.1038/24904; Himanen JP, 2004, NAT NEUROSCI, V7, P501, DOI 10.1038/nn1237; Himanen JP, 2001, NATURE, V414, P933, DOI 10.1038/414933a; Himanen JP, 2009, EMBO REP, V10, P722, DOI 10.1038/embor.2009.91; Jee J, 2008, J PHYS CHEM B, V112, P6008, DOI 10.1021/jp076094h; JOHNSON BA, 1994, J BIOMOL NMR, V4, P603, DOI 10.1007/BF00404272; Kullander K, 2003, SCIENCE, V299, P1889, DOI 10.1126/science.1079641; Kullander K, 2001, GENE DEV, V15, P877, DOI 10.1101/gad.868901; Kullander K, 2001, NEURON, V29, P73, DOI 10.1016/S0896-6273(01)00181-7; Lafont V, 2007, CHEM BIOL DRUG DES, V69, P413, DOI 10.1111/j.1747-0285.2007.00519.x; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; McCoy AJ, 2005, ACTA CRYSTALLOGR D, V61, P458, DOI 10.1107/S0907444905001617; Menzel P, 2001, DEV BIOL, V230, P74, DOI 10.1006/dbio.2000.0109; Noberini R, 2008, J BIOL CHEM, V283, P29461, DOI 10.1074/jbc.M804103200; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; PACE CN, 1995, PROTEIN SCI, V4, P2411, DOI 10.1002/pro.5560041120; Pasquale EB, 2005, NAT REV MOL CELL BIO, V6, P462, DOI 10.1038/nrm1662; Pasquale EB, 2004, NAT NEUROSCI, V7, P417, DOI 10.1038/nn0504-417; Pasquale EB, 2008, CELL, V133, P38, DOI 10.1016/j.cell.2008.03.011; Prevost N, 2005, P NATL ACAD SCI USA, V102, P9820, DOI 10.1073/pnas.0404065102; Qin HN, 2008, J BIOL CHEM, V283, P29473, DOI 10.1074/jbc.M804114200; Ran XY, 2008, PROTEINS, V72, P1019, DOI 10.1002/prot.21999; Ran XY, 2005, J BIOL CHEM, V280, P19205, DOI 10.1074/jbc.M500330200; Sattler M, 1999, PROG NUCL MAG RES SP, V34, P93, DOI 10.1016/S0079-6565(98)00025-9; SHAO HN, 1994, J BIOL CHEM, V269, P26606; Smith A, 1997, CURR BIOL, V7, P561, DOI 10.1016/S0960-9822(06)00255-7; Smith FM, 2004, J BIOL CHEM, V279, P9522, DOI 10.1074/jbc.M309326200; Toth J, 2001, DEV CELL, V1, P83, DOI 10.1016/S1534-5807(01)00002-8; Velazquez-Campoy Adrian, 2004, Methods Mol Biol, V261, P35; Xu QL, 1999, NATURE, V399, P267, DOI 10.1038/20452; Yokoyama N, 2001, NEURON, V29, P85, DOI 10.1016/S0896-6273(01)00182-9	43	73	77	1	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 1	2010	285	1					644	654		10.1074/jbc.M109.064824	http://dx.doi.org/10.1074/jbc.M109.064824			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	536UT	19875447	Green Published, hybrid			2022-12-25	WOS:000273070100065
J	Kleiger, G; Hao, B; Mohl, DA; Deshaies, RJ				Kleiger, Gary; Hao, Bing; Mohl, Dane A.; Deshaies, Raymond J.			The Acidic Tail of the Cdc34 Ubiquitin-conjugating Enzyme Functions in Both Binding to and Catalysis with Ubiquitin Ligase SCFCdc4	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							F-BOX PROTEINS; SACCHAROMYCES-CEREVISIAE; CYTOCHROME-C; SUBUNIT-VI; E2 ENZYME; SCF; COMPLEX; CULLIN; YEAST; DOMAIN	Ubiquitin ligases, together with their cognate ubiquitin-conjugating enzymes, are responsible for the ubiquitylation of proteins, a process that regulates a myriad of eukaryotic cellular functions. The first cullin-RING ligase discovered, yeast SCFCdc4, functions with the conjugating enzyme Cdc34 to regulate the cell cycle. Cdc34 orthologs are notable for their highly acidic C-terminal extension. Here we confirm that the Cdc34 acidic C-terminal tail has a role in Cdc34 binding to SCFCdc4 and makes a major contribution to the submicromolar K-m of Cdc34 for SCFCdc4. Moreover, we demonstrate that a key functional property of the tail is its acidity. Our analysis also uncovers an unexpected new function for the acidic tail in promoting catalysis. We demonstrate that SCF is functional when Cdc34 is fused to the C terminus of Cul1 and that this fusion retains partial function even when the acidic tail has been deleted. The Cdc34-SCF fusion proteins that lack the acidic tail must interact in a fundamentally different manner than unfused SCF and wild type Cdc34, demonstrating that distinct mechanisms of E2 recruitment to E3, as is seen in nature, can sustain substrate ubiquitylation. Finally, a search of the yeast proteome uncovered scores of proteins containing highly acidic stretches of amino acids, hinting that electrostatic interactions may be a common mechanism for facilitating protein assembly.	[Kleiger, Gary; Mohl, Dane A.; Deshaies, Raymond J.] CALTECH, Howard Hughes Med Inst, Pasadena, CA 91125 USA; [Kleiger, Gary; Mohl, Dane A.; Deshaies, Raymond J.] CALTECH, Div Biol, Pasadena, CA 91125 USA; [Hao, Bing] Univ Connecticut, Ctr Hlth, Dept Mol Microbial & Struct Biol, Farmington, CT 06030 USA	California Institute of Technology; Howard Hughes Medical Institute; California Institute of Technology; University of Connecticut	Deshaies, RJ (corresponding author), CALTECH, Howard Hughes Med Inst, 1200 E Calif Blvd, Pasadena, CA 91125 USA.	deshaies@caltech.edu	Deshaies, Raymond/B-8354-2014	Deshaies, Raymond/0000-0002-3671-9354	National Institutes of Health Ruth Kirschstein [F32 GM074471-01]; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [F32GM074471, R01GM065997] Funding Source: NIH RePORTER	National Institutes of Health Ruth Kirschstein(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	This work was supported, in whole or in part, by National Institutes of Health Ruth Kirschstein Postdoctoral Fellowship F32 GM074471-01.	Block K, 2005, CELL CYCLE, V4, P1421, DOI 10.4161/cc.4.10.2054; Cardozo T, 2004, NAT REV MOL CELL BIO, V5, P739, DOI 10.1038/nrm1471; Creighton T. E., 1993, PROTEINS STRUCTURES, P272; Das R, 2009, MOL CELL, V34, P674, DOI 10.1016/j.molcel.2009.05.010; Deshaies RJ, 2009, ANNU REV BIOCHEM, V78, P399, DOI 10.1146/annurev.biochem.78.101807.093809; Dye BT, 2007, ANNU REV BIOPH BIOM, V36, P131, DOI 10.1146/annurev.biophys.36.040306.132820; Eletr ZM, 2005, NAT STRUCT MOL BIOL, V12, P933, DOI 10.1038/nsmb984; Feldman RMR, 1997, CELL, V91, P221, DOI 10.1016/S0092-8674(00)80404-3; Frescas D, 2008, NAT REV CANCER, V8, P438, DOI 10.1038/nrc2396; GILL G, 1990, P NATL ACAD SCI USA, V87, P2127, DOI 10.1073/pnas.87.6.2127; GILL G, 1987, CELL, V51, P121, DOI 10.1016/0092-8674(87)90016-X; Hershko A, 1998, ANNU REV BIOCHEM, V67, P425, DOI 10.1146/annurev.biochem.67.1.425; Hofmann RM, 2001, J BIOL CHEM, V276, P27936, DOI 10.1074/jbc.M103378200; Kamura T, 1999, SCIENCE, V284, P657, DOI 10.1126/science.284.5414.657; KLEIGER G, 2009, CELL IN PRESS; KOLMAN CJ, 1992, EMBO J, V11, P3081, DOI 10.1002/j.1460-2075.1992.tb05380.x; KOPPENOL WH, 1982, J BIOL CHEM, V257, P4426; Li T, 2005, METHOD ENZYMOL, V398, P125, DOI 10.1016/S0076-6879(05)98012-9; Li W, 2009, P NATL ACAD SCI USA, V106, P3722, DOI 10.1073/pnas.0808564106; Mathias N, 1998, J BIOL CHEM, V273, P4040, DOI 10.1074/jbc.273.7.4040; Nakayama KI, 2006, NAT REV CANCER, V6, P369, DOI 10.1038/nrc1881; Ohta T, 1999, MOL CELL, V3, P535, DOI 10.1016/S1097-2765(00)80482-7; Pan ZQ, 2004, ONCOGENE, V23, P1985, DOI 10.1038/sj.onc.1207414; Petroski MD, 2005, NAT REV MOL CELL BIO, V6, P9, DOI 10.1038/nrm1547; Petroski MD, 2005, CELL, V123, P1107, DOI 10.1016/j.cell.2005.09.033; Petroski MD, 2005, METHOD ENZYMOL, V398, P143, DOI 10.1016/S0076-6879(05)98013-0; POHL C, 2008, E SCHERING FDN S P, V1, P115; Ruiz A, 2004, J BIOL CHEM, V279, P34421, DOI 10.1074/jbc.M400572200; Saha A, 2008, MOL CELL, V32, P21, DOI 10.1016/j.molcel.2008.08.021; SCHOPPINK PJ, 1989, BIOCHIM BIOPHYS ACTA, V974, P192, DOI 10.1016/S0005-2728(89)80372-X; SCHREIBER G, 1993, BIOCHEMISTRY-US, V32, P5145, DOI 10.1021/bi00070a025; Schreiber G, 1996, NAT STRUCT BIOL, V3, P427, DOI 10.1038/nsb0596-427; SCHWOB E, 1994, CELL, V79, P233, DOI 10.1016/0092-8674(94)90193-7; Seol JH, 1999, GENE DEV, V13, P1614, DOI 10.1101/gad.13.12.1614; SILVER ET, 1992, EMBO J, V11, P3091, DOI 10.1002/j.1460-2075.1992.tb05381.x; Skowyra D, 1997, CELL, V91, P209, DOI 10.1016/S0092-8674(00)80403-1; Skowyra D, 1999, SCIENCE, V284, P662, DOI 10.1126/science.284.5414.662; Tan PL, 1999, MOL CELL, V3, P527, DOI 10.1016/S1097-2765(00)80481-5; Thrower JS, 2000, EMBO J, V19, P94, DOI 10.1093/emboj/19.1.94; VANLOON APGM, 1984, EMBO J, V3, P1039, DOI 10.1002/j.1460-2075.1984.tb01924.x; Willems AR, 2004, BBA-MOL CELL RES, V1695, P133, DOI 10.1016/j.bbamcr.2004.09.027; Wu K, 2002, J BIOL CHEM, V277, P516, DOI 10.1074/jbc.M108008200; Xie YM, 1999, EMBO J, V18, P6832, DOI 10.1093/emboj/18.23.6832; YANG MJ, 1994, J BIOL CHEM, V269, P1270; Zheng N, 2002, NATURE, V416, P703, DOI 10.1038/416703a	45	26	26	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 25	2009	284	52					36012	36023		10.1074/jbc.M109.058529	http://dx.doi.org/10.1074/jbc.M109.058529			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	535LT	19875449	Green Published, Green Accepted, hybrid			2022-12-25	WOS:000272970500003
J	Kobayashi, T; Murayama, T				Kobayashi, Takuya; Murayama, Takashi			Cell Cycle-Dependent Microtubule-Based Dynamic Transport of Cytoplasmic Dynein in Mammalian Cells	PLOS ONE			English	Article							LIGHT-CHAIN BINDS; INTERMEDIATE CHAIN; CHROMOSOME MOVEMENT; FLUORESCENT PROTEIN; DYNACTIN COMPLEX; MOTOR PROTEINS; SPINDLE POLES; PLUS-END; KINETOCHORE; COLOCALIZATION	Background: Cytoplasmic dynein complex is a large multi-subunit microtubule (MT)-associated molecular motor involved in various cellular functions including organelle positioning, vesicle transport and cell division. However, regulatory mechanism of the cell-cycle dependent distribution of dynein has not fully been understood. Methodology/Principal Findings: Here we report live-cell imaging of cytoplasmic dynein in HeLa cells, by expressing multifunctional green fluorescent protein (mfGFP)-tagged 74-kDa intermediate chain (IC74). IC74-mfGFP was successfully incorporated into functional dynein complex. In interphase, dynein moved bi-directionally along with MTs, which might carry cargos such as transport vesicles. A substantial fraction of dynein moved toward cell periphery together with EB1, a member of MT plus end-tracking proteins (+TIPs), suggesting +TIPs-mediated transport of dynein. In late-interphase and prophase, dynein was localized at the centrosomes and the radial MT array. In prometaphase and metaphase, dynein was localized at spindle MTs where it frequently moved from spindle poles toward chromosomes or cell cortex. +TIPs may be involved in the transport of spindle dyneins. Possible kinetochore and cortical dyneins were also observed. Conclusions and Significance: These findings suggest that cytoplasmic dynein is transported to the site of action in preparation for the following cellular events, primarily by the MT-based transport. The MT-based transport may have greater advantage than simple diffusion of soluble dynein in rapid and efficient transport of the limited concentration of the protein.			Kobayashi, T (corresponding author), Juntendo Univ, Sch Med, Dept Pharmacol, Tokyo 113, Japan.	takashim@juntendo.ac.jp						Akhmanova A, 2005, CURR OPIN CELL BIOL, V17, P47, DOI 10.1016/j.ceb.2004.11.001; Banks JD, 2001, CURR BIOL, V11, pR128, DOI 10.1016/S0960-9822(01)00059-8; Bloom K, 2001, CURR BIOL, V11, pR326, DOI 10.1016/S0960-9822(01)00176-2; Busson S, 1998, CURR BIOL, V8, P541, DOI 10.1016/S0960-9822(98)70208-8; Dujardin DL, 2002, CURR OPIN CELL BIOL, V14, P44, DOI 10.1016/S0955-0674(01)00292-7; Fumoto K, 2006, EMBO J, V25, P5670, DOI 10.1038/sj.emboj.7601459; Furuta K, 2008, CURR BIOL, V18, P152, DOI 10.1016/j.cub.2007.12.056; GILL SR, 1991, J CELL BIOL, V115, P1639, DOI 10.1083/jcb.115.6.1639; Gross SP, 2004, PHYS BIOL, V1, pR1, DOI 10.1088/1478-3967/1/2/R01; Ha JH, 2008, J CELL BIOL, V181, P1027, DOI 10.1083/jcb.200803150; Hirokawa N, 2008, PHYSIOL REV, V88, P1089, DOI 10.1152/physrev.00023.2007; Hoffman DB, 2001, MOL BIOL CELL, V12, P1995, DOI 10.1091/mbc.12.7.1995; Howell BJ, 2001, J CELL BIOL, V155, P1159, DOI 10.1083/jcb.200105093; Karata K, 1999, J BIOL CHEM, V274, P26225, DOI 10.1074/jbc.274.37.26225; KARKI S, 1995, J BIOL CHEM, V270, P28806, DOI 10.1074/jbc.270.48.28806; King JM, 2000, J CELL BIOL, V151, P739, DOI 10.1083/jcb.151.4.739; King SM, 1998, BIOCHEMISTRY-US, V37, P15033, DOI 10.1021/bi9810813; Kobayashi T, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003822; Lo KWH, 2001, J BIOL CHEM, V276, P14059, DOI 10.1074/jbc.M010320200; Merdes A, 2000, J CELL BIOL, V149, P851, DOI 10.1083/jcb.149.4.851; Mok YK, 2001, J BIOL CHEM, V276, P14067, DOI 10.1074/jbc.M011358200; Myers KR, 2007, J NEUROSCI RES, V85, P2640, DOI 10.1002/jnr.21213; O'Connell CB, 2000, MOL BIOL CELL, V11, P1765, DOI 10.1091/mbc.11.5.1765; PFARR CM, 1990, NATURE, V345, P263, DOI 10.1038/345263a0; Pfister KK, 2006, PLOS GENET, V2, P11, DOI 10.1371/journal.pgen.0020001; Pfister KK, 2005, J CELL BIOL, V171, P411, DOI 10.1083/jcb.200508078; Quintyne NJ, 2002, J CELL BIOL, V159, P245, DOI 10.1083/jcb.200203089; Schroer TA, 2004, ANNU REV CELL DEV BI, V20, P759, DOI 10.1146/annurev.cellbio.20.012103.094623; Shaner NC, 2004, NAT BIOTECHNOL, V22, P1567, DOI 10.1038/nbt1037; Sharp DJ, 2000, NAT CELL BIOL, V2, P922, DOI 10.1038/35046574; STEUER ER, 1990, NATURE, V345, P266, DOI 10.1038/345266a0; Susalka SJ, 2002, J BIOL CHEM, V277, P32939, DOI 10.1074/jbc.M205510200; TELZER BR, 1979, J CELL BIOL, V81, P484, DOI 10.1083/jcb.81.3.484; Towns WL, 2009, CELL MOTIL CYTOSKEL, V66, P80, DOI 10.1002/cm.20327; Traer CJ, 2007, NAT CELL BIOL, V9, P1370, DOI 10.1038/ncb1656; Tynan SH, 2000, J BIOL CHEM, V275, P32769, DOI 10.1074/jbc.M001537200; Valetti C, 1999, MOL BIOL CELL, V10, P4107, DOI 10.1091/mbc.10.12.4107; Vallee RB, 2004, J NEUROBIOL, V58, P189, DOI 10.1002/neu.10314; Varma D, 2008, J CELL BIOL, V182, P1045, DOI 10.1083/jcb.200710106; VAUGHAN KT, 1995, J CELL BIOL, V131, P1507, DOI 10.1083/jcb.131.6.1507; Vaughan KT, 1999, J CELL SCI, V112, P1437; Welte MA, 2004, CURR BIOL, V14, pR525, DOI 10.1016/j.cub.2004.06.045; Williams JC, 2007, P NATL ACAD SCI USA, V104, P10028, DOI 10.1073/pnas.0703614104; Wu XF, 2006, TRENDS CELL BIOL, V16, P135, DOI 10.1016/j.tcb.2006.01.004; Xiang X, 2000, CURR BIOL, V10, P603, DOI 10.1016/S0960-9822(00)00488-7	45	34	34	1	3	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA	1932-6203			PLOS ONE	PLoS One	NOV 13	2009	4	11							e7827	10.1371/journal.pone.0007827	http://dx.doi.org/10.1371/journal.pone.0007827			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	518VB	19915671	gold, Green Published, Green Submitted			2022-12-25	WOS:000271721900017
J	Spaulding, AC; Seals, RM; Page, MJ; Brzozowski, AK; Rhodes, W; Hammett, TM				Spaulding, Anne C.; Seals, Ryan M.; Page, Matthew J.; Brzozowski, Amanda K.; Rhodes, William; Hammett, Theodore M.			HIV/AIDS among Inmates of and Releasees from US Correctional Facilities, 2006: Declining Share of Epidemic but Persistent Public Health Opportunity	PLOS ONE			English	Article							HIV; INTERVENTION; EFFICACY; RISK	Because certain groups at high risk for HIV/AIDS (human immunodeficiency virus/acquired immunodeficiency syndrome) come together in correctional facilities, seroprevalence was high early in the epidemic. The share of the HIV/AIDS epidemic borne by inmates of and persons released from jails and prisons in the United States (US) in 1997 was estimated in a previous paper. While the number of inmates and releasees has risen, their HIV seroprevalence rates have fallen. We sought to determine if the share of HIV/AIDS borne by inmates and releasees in the US decreased between 1997 and 2006. We created a new model of population flow in and out of correctional facilities to estimate the number of persons released in 1997 and 2006. In 1997, approximately one in five of all HIV-infected Americans was among the 7.3 million who left a correctional facility that year. Nine years later, only one in seven (14%) of infected Americans was among the 9.1 million leaving, a 29.3% decline in the share. For black and Hispanic males, two demographic groups with heightened incarceration rates, recently released inmates comprise roughly one in five of those groups' total HIV-infected persons, a figure similar to the proportion borne by the correctional population as a whole in 1997. Decreasing HIV seroprevalence among those admitted to jails and prisons, prolonged survival and aging of the US population with HIV/AIDS beyond the crime-prone years, and success with discharge planning programs targeting HIV-infected prisoners could explain the declining concentration of the epidemic among correctional populations. Meanwhile, the number of persons with HIV/AIDS leaving correctional facilities remains virtually identical. Jails and prisons continue to be potent targets for public health interventions. The fluid nature of incarcerated populations ensures that effective interventions will be felt not only in correctional facilities but also in communities to which releasees return.			Spaulding, AC (corresponding author), Emory Univ, Rollins Sch Publ Hlth, Atlanta, GA 30322 USA.	ASpauld@emory.edu			NIAID NIH HHS [P30 AI050409] Funding Source: Medline; NICHD NIH HHS [T32 HD052460] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [T32HD052460] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [P30AI050409] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		[Anonymous], BUREAU JUSTICE STAT; [Anonymous], 2009, HIV TEST IMPL GUID C; Baillargeon J, 2009, JAMA-J AM MED ASSOC, V301, P848, DOI 10.1001/jama.2009.202; Beckwith CG, 2007, AIDS PATIENT CARE ST, V21, P41, DOI 10.1089/apc.2006.006; Campsmith M. L., 2008, Morbidity and Mortality Weekly Report, V57, P1073; *CDCP, 2009, 14 HIV AIDS CDCP; *CDCP, 2008, HIV AIDS SURV REP, V18; Centers for Disease Control and Prevention (CDC), 1999, MMWR Morb Mortal Wkly Rep, V47, P1115; Gardner LI, 2005, AIDS, V19, P423, DOI 10.1097/01.aids.0000161772.51900.eb; GILLIARD DK, 1998, BUREAU JUSTICE STAT; Glaze L. E., 2007, BUREAU JUSTICE STAT; Greenwald Jeffrey L, 2006, Curr Infect Dis Rep, V8, P125, DOI 10.1007/s11908-006-0008-6; Hammett TM, 2002, AM J PUBLIC HEALTH, V92, P1789, DOI 10.2105/AJPH.92.11.1789; HARRISON PM, 2005, BUREAU JUSTICE STAT; KIM JY, 1997, J CORRECT HEALTH CAR, V4, P5; MacGowan R, 2009, SEX TRANSM DIS, V36, pS9, DOI 10.1097/OLQ.0b013e318148b6b1; Martin SS, 2003, J PSYCHOACTIVE DRUGS, V35, P435, DOI 10.1080/02791072.2003.10400490; MARUSCHAK L, 2006, BUREAU JUSTICE STAT; Maruschak L., 2021, MED PROBLEMS REPORTE; MARUSCHAK L, 2007, BUREAU JUSTICE STAT; MARUSCHAK LM, 2001, BUREAU JUSTICE STAT; *NEW YORK CITY DEP, 1999, HIV SCROPR UPD; Sabol W. J., 2007, PRISON JAIL INMATES; SABOL WJ, 2008, BUREAU JUSTICE STAT; Spaulding A. C., 2007, Journal of Correctional Health Care, V13, P93, DOI 10.1177/1078345807301347; SPAULDING AC, 2007, J CORRECTIONAL HLTH, V12, P93; Spaulding AC, 2009, SEX TRANSM DIS, V36, pS34, DOI 10.1097/OLQ.0b013e3180959e9f; WOHL D, 2006, 16 INT AIDS C; WOHL DA, 2007, BRIGHT PROJECT BRIDG; Wolitski RJ, 2006, AM J PUBLIC HEALTH, V96, P1854, DOI 10.2105/AJPH.2004.056044	30	261	264	0	18	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	NOV 11	2009	4	11					A16	A21	e7558	10.1371/journal.pone.0007558	http://dx.doi.org/10.1371/journal.pone.0007558			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	518IX	19907649	gold, Green Published, Green Submitted			2022-12-25	WOS:000271685800002
J	Guerrera, IC; Astarita, G; Jais, JP; Sands, D; Nowakowska, A; Colas, J; Sermet-Gaudelus, I; Schuerenberg, M; Piomelli, D; Edelman, A; Ollero, M				Guerrera, Ida Chiara; Astarita, Giuseppe; Jais, Jean-Philippe; Sands, Dorota; Nowakowska, Anna; Colas, Julien; Sermet-Gaudelus, Isabelle; Schuerenberg, Martin; Piomelli, Daniele; Edelman, Aleksander; Ollero, Mario			A Novel Lipidomic Strategy Reveals Plasma Phospholipid Signatures Associated with Respiratory Disease Severity in Cystic Fibrosis Patients	PLOS ONE			English	Article							TRANSMEMBRANE CONDUCTANCE REGULATOR; FATTY-ACID DEFICIENCY; CHILDREN; SUPPLEMENTATION; ABNORMALITIES; HOMOCYSTEINE; METABOLISM; MEMBRANE; MICE; PHOSPHATIDYLCHOLINE	The aim of this study was to search for lipid signatures in blood plasma from cystic fibrosis (CF) patients using a novel MALDI-TOF-ClinProTools (TM) strategy, initially developed for protein analysis, and thin layer chromatography coupled to MALDI-TOF (TLC-MALDI). Samples from 33 CF patients and 18 healthy children were subjected to organic extraction and column chromatography separation of lipid classes. Extracts were analyzed by MALDI-TOF, ion signatures were compared by the ClinProTools (TM) software and by parallel statistical analyses. Relevant peaks were identified by LC-MSn. The ensemble of analyses provided 11 and 4 peaks differentially displayed in CF vs healthy and in mild vs severe patients respectively. Ten ions were significantly decreased in all patients, corresponding to 4 lysophosphatidylcholine ( 18: 0, 18: 2, 20: 3, and 20: 5) and 6 phosphatidylcholine ( 36: 5, O-38: 0, 38: 4, 38: 5, 38: 6, and P-40:1) species. One sphingolipid, SM(d18:0), was significantly increased in all patients. Four PC forms ( 36: 3, 36: 5, 38: 5, and 38: 6) were consistently downregulated in severe vs mild patients. These observations were confirmed by TLC-MALDI. These results suggest that plasma phospholipid signatures may be able to discriminate mild and severe forms of CF, and show for the first time MALDI-TOF-ClinProTools (TM) as a suitable methodology for the search of lipid markers in CF.			Guerrera, IC (corresponding author), Univ Paris 05, IFR94, Paris, France.	mario.ollero@inserm.fr	Sands, Dorota/T-4598-2019; Astarita, Giuseppe/AAD-1239-2019; GUERRERA, Ida Chiara/GOJ-9151-2022; Ollero, Mario/AAJ-3545-2020; Ollero, Mario/Q-6147-2018; Astarita, Giuseppe/N-7346-2014	Sands, Dorota/0000-0002-4601-5158; GUERRERA, Ida Chiara/0000-0002-4832-6793; Ollero, Mario/0000-0003-3590-706X; Astarita, Giuseppe/0000-0001-6700-301X				Astarita G., 2009, J CHROMATOGR B; Astarita G, 2008, J LIPID RES, V49, P48, DOI 10.1194/jlr.M700354-JLR200; Bensalem N, 2005, MOL CELL PROTEOMICS, V4, P1591, DOI 10.1074/mcp.M500019-MCP200; BURDGE GC, 1994, BRIT J NUTR, V71, P959, DOI 10.1079/BJN19940199; Cawood AL, 2005, CURR OPIN CLIN NUTR, V8, P153, DOI 10.1097/00075197-200503000-00008; Chen AH, 2005, AM J CLIN NUTR, V81, P686; CHRISTOPHE AB, 1994, LIPIDS, V29, P569, DOI 10.1007/BF02536629; CLANDININ MT, 1995, AM J CLIN NUTR, V62, P1268, DOI 10.1093/ajcn/62.6.1268; Davezac N, 2004, PROTEOMICS, V4, P3833, DOI 10.1002/pmic.200400850; Dombrowsky H, 2003, PEDIATR RES, V53, P447, DOI 10.1203/01.PDR.0000049937.30305.8A; Dudez T, 2008, BBA-MOL CELL RES, V1783, P779, DOI 10.1016/j.bbamcr.2008.01.007; Dyatlovitskaya EV, 2001, BIOCHEMISTRY-MOSCOW+, V66, P502, DOI 10.1023/A:1010250600604; Eidelman O, 2002, BIOCHEMISTRY-US, V41, P11161, DOI 10.1021/bi020289s; FARRELL PM, 1985, PEDIATR RES, V19, P104, DOI 10.1203/00006450-198501000-00028; Freedman SD, 1999, P NATL ACAD SCI USA, V96, P13995, DOI 10.1073/pnas.96.24.13995; Freedman SD, 2004, NEW ENGL J MED, V350, P560, DOI 10.1056/NEJMoa021218; Fuchs B, 2008, ANAL BIOANAL CHEM, V392, P849, DOI 10.1007/s00216-008-2301-8; Gaggar A, 2008, J IMMUNOL, V180, P5662, DOI 10.4049/jimmunol.180.8.5662; Gentleman RC, 2004, GENOME BIOL, V5, DOI 10.1186/gb-2004-5-10-r80; GILLJAM H, 1988, CLIN CHIM ACTA, V176, P29, DOI 10.1016/0009-8981(88)90171-4; GIROD S, 1992, PEDIATR PULM, V13, P22, DOI 10.1002/ppul.1950130107; Gray RD, 2008, AM J RESP CRIT CARE, V178, P444, DOI 10.1164/rccm.200703-409OC; Innis SM, 2008, ANNU REV NUTR, V28, P55, DOI 10.1146/annurev.nutr.27.061406.093625; Innis SM, 2007, AM J CLIN NUTR, V85, P702, DOI 10.1093/ajcn/85.3.702; Innis SM, 2006, J NUTR, V136, P2226, DOI 10.1093/jn/136.8.2226; KALUZNY MA, 1985, J LIPID RES, V26, P135; Kowalski MP, 2004, J IMMUNOL, V172, P418, DOI 10.4049/jimmunol.172.1.418; LEVY E, 1993, AM J CLIN NUTR, V57, P573, DOI 10.1093/ajcn/57.4.573; Machen TE, 2006, AM J PHYSIOL-CELL PH, V291, pC218, DOI 10.1152/ajpcell.00605.2005; Ollero M, 2006, METABOLISM, V55, P1192, DOI 10.1016/j.metabol.2006.05.002; Ollero M, 2006, PROTEOMICS, V6, P4084, DOI 10.1002/pmic.200600028; Peretti N, 2006, AM J PHYSIOL-GASTR L, V290, pG609, DOI 10.1152/ajpgi.00332.2005; ROGIERS V, 1983, EUR J PEDIATR, V141, P39, DOI 10.1007/BF00445666; Rosenstein BJ, 1998, LANCET, V351, P277, DOI 10.1016/S0140-6736(97)09174-5; Rubin BK, 2003, CHEST, V123, P1792, DOI 10.1378/chest.123.6.1792; Scambi C, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0004782; Schiller J, 2004, PROG LIPID RES, V43, P449, DOI 10.1016/j.plipres.2004.08.001; Sermet-Gaudelus I, 2005, AM J RESP CRIT CARE, V171, P1026, DOI 10.1164/rccm.200406-740OC; Sloane AJ, 2005, AM J RESP CRIT CARE, V172, P1416, DOI 10.1164/rccm.200409-1215OC; SMYTH GK, 2005, LIMMA LINEAR MODELS, P397; Srivastava M, 2006, MOL GENET METAB, V87, P303, DOI 10.1016/j.ymgme.2005.10.021; Strandvik B, 2001, J PEDIATR-US, V139, P650, DOI 10.1067/mpd.2001.118890; Team. RDC, 2007, R LANG ENV STAT COMP; Teichgraber V, 2008, NAT MED, V14, P382, DOI 10.1038/nm1748; TRUDEL S, 2009, PLOS ONE IN PRESS; ULANE MM, 1994, CLIN CHIM ACTA, V230, P109, DOI 10.1016/0009-8981(94)90263-1; VAUGHAN WJ, 1978, SCIENCE, V199, P783, DOI 10.1126/science.203033; WILKINSON MM, 1988, J CELL SCI, V91, P221; Worgall TS, 2009, CURR OPIN CLIN NUTR, V12, P105, DOI 10.1097/MCO.0b013e32832595b7; Wu YH, 2007, CELL MICROBIOL, V9, P1062, DOI 10.1111/j.1462-5822.2006.00852.x; Zhao ZW, 2007, J CLIN ONCOL, V25, P2696, DOI 10.1200/JCO.2006.08.5571	51	41	41	0	13	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA	1932-6203			PLOS ONE	PLoS One	NOV 6	2009	4	11							e7735	10.1371/journal.pone.0007735	http://dx.doi.org/10.1371/journal.pone.0007735			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	515ND	19893743	Green Published, gold			2022-12-25	WOS:000271478000010
J	Kumagai, G; Okada, Y; Yamane, J; Nagoshi, N; Kitamura, K; Mukaino, M; Tsuji, O; Fujiyoshi, K; Katoh, H; Okada, S; Shibata, S; Matsuzaki, Y; Toh, S; Toyama, Y; Nakamura, M; Okano, H				Kumagai, Gentaro; Okada, Yohei; Yamane, Junichi; Nagoshi, Narihito; Kitamura, Kazuya; Mukaino, Masahiko; Tsuji, Osahiko; Fujiyoshi, Kanehiro; Katoh, Hiroyuki; Okada, Seiji; Shibata, Shinsuke; Matsuzaki, Yumi; Toh, Satoshi; Toyama, Yoshiaki; Nakamura, Masaya; Okano, Hideyuki			Roles of ES Cell-Derived Gliogenic Neural Stem/Progenitor Cells in Functional Recovery after Spinal Cord Injury	PLOS ONE			English	Article							EMBRYONIC STEM-CELLS; RESTRICTED PRECURSOR CELLS; IN-VIVO; AXONAL REGENERATION; GENE-EXPRESSION; CONTUSION INJURIES; PROMOTE RECOVERY; PROGENITOR CELLS; HUMAN ASTROCYTES; DNA METHYLATION	Transplantation of neural stem/progenitor cells (NS/PCs) following the sub-acute phase of spinal cord injury (SCI) has been shown to promote functional recovery in rodent models. However, the types of cells most effective for treating SCI have not been clarified. Taking advantage of our recently established neurosphere-based culture system of ES cell-derived NS/PCs, in which primary neurospheres (PNS) and passaged secondary neurospheres (SNS) exhibit neurogenic and gliogenic potentials, respectively, here we examined the distinct effects of transplanting neurogenic and gliogenic NS/PCs on the functional recovery of a mouse model of SCI. ES cell-derived PNS and SNS transplanted 9 days after contusive injury at the Th10 level exhibited neurogenic and gliogenic differentiation tendencies, respectively, similar to those seen in vitro. Interestingly, transplantation of the gliogenic SNS, but not the neurogenic PNS, promoted axonal growth, remyelination, and angiogenesis, and resulted in significant locomotor functional recovery after SCI. These findings suggest that gliogenic NS/PCs are effective for promoting the recovery from SCI, and provide essential insight into the mechanisms through which cellular transplantation leads to functional improvement after SCI.			Kumagai, G (corresponding author), Keio Univ, Sch Med, Dept Physiol, Tokyo 160, Japan.	masa@sc.itc.keio.ac.jp; hidokano@sc.itc.keio.ac.jp	Okano, Hideyuki/I-7584-2019; Nakamura, Masaya/K-4111-2013; Okada, Yohei/L-1662-2013; Toh, Satoshi/K-5737-2013; Toyama, Yoshiaki/K-5743-2013; Tsuji, Osahiko/AHB-2622-2022; Shibata, Shinsuke/AAM-6620-2020	Okada, Seiji/0000-0002-5107-8209; Matsuzaki, Yumi/0000-0002-3729-2997				BAEHR M, 1990, GLIA, V3, P293, DOI 10.1002/glia.440030409; Basso DM, 2006, J NEUROTRAUM, V23, P635, DOI 10.1089/neu.2006.23.635; Beattie MS, 1997, EXP NEUROL, V148, P453, DOI 10.1006/exnr.1997.6695; Berry M, 1983, Acta Neurochir Suppl (Wien), V32, P31; Bibel M, 2004, NAT NEUROSCI, V7, P1003, DOI 10.1038/nn1301; Blondel O, 2000, J NEUROSCI, V20, P8012; BREGMAN BS, 1987, DEV BRAIN RES, V34, P265, DOI 10.1016/0165-3806(87)90214-8; Buffo A, 2008, P NATL ACAD SCI USA, V105, P3581, DOI 10.1073/pnas.0709002105; Bundesen LQ, 2003, J NEUROSCI, V23, P7789; Cao QL, 2005, J NEUROSCI, V25, P6947, DOI 10.1523/JNEUROSCI.1065-05.2005; Contag CH, 2002, ANNU REV BIOMED ENG, V4, P235, DOI 10.1146/annurev.bioeng.4.111901.093336; COUTTS M, 2007, EXP NEUROL; Cummings BJ, 2005, P NATL ACAD SCI USA, V102, P14069, DOI 10.1073/pnas.0507063102; Davis LE, 2006, LANCET NEUROL, V5, P7, DOI 10.1016/S1474-4422(05)70259-3; De Winter F, 2002, EXP NEUROL, V175, P61, DOI 10.1006/exnr.2002.7884; Fan GP, 2005, DEVELOPMENT, V132, P3345, DOI 10.1242/dev.01912; GALLO V, 1990, EXP CELL RES, V187, P211, DOI 10.1016/0014-4827(90)90084-N; Hill CE, 2004, EXP NEUROL, V190, P289, DOI 10.1016/j.expneurol.2004.05.043; Hofstetter CP, 2005, NAT NEUROSCI, V8, P346, DOI 10.1038/nn1405; Hofstetter CP, 2002, P NATL ACAD SCI USA, V99, P2199, DOI 10.1073/pnas.042678299; HOOPER M, 1987, NATURE, V326, P292, DOI 10.1038/326292a0; Iwanami A, 2005, J NEUROSCI RES, V80, P182, DOI 10.1002/jnr.20436; Kaneko S, 2006, NAT MED, V12, P1380, DOI 10.1038/nm1505; Keirstead HS, 2005, J NEUROSCI, V25, P4694, DOI 10.1523/JNEUROSCI.0311-05.2005; Kobayashi NR, 1997, J NEUROSCI, V17, P9583; Liu S, 2000, P NATL ACAD SCI USA, V97, P6126, DOI 10.1073/pnas.97.11.6126; McDonald JW, 1999, NAT MED, V5, P1410, DOI 10.1038/70986; Mense SM, 2006, PHYSIOL GENOMICS, V25, P435, DOI 10.1152/physiolgenomics.00315.2005; Moreau-Fauvarque C, 2003, J NEUROSCI, V23, P9229; Nagai T, 2002, NAT BIOTECHNOL, V20, P87, DOI 10.1038/nbt0102-87; Nakamura M, 2003, EXP NEUROL, V184, P313, DOI 10.1016/S0014-4886(03)00361-3; Niwa H, 2000, NAT GENET, V24, P372, DOI 10.1038/74199; NOBLE M, 1984, J NEUROSCI, V4, P1892; Ogawa Y, 2002, J NEUROSCI RES, V69, P925, DOI 10.1002/jnr.10341; Okada S, 2005, FASEB J, V19, P1839, DOI 10.1096/fj.05-4082fje; Okada S, 2006, NAT MED, V12, P829, DOI 10.1038/nm1425; Okada Y, 2004, DEV BIOL, V275, P124, DOI 10.1016/j.ydbio.2004.07.038; OKADA Y, 2008, STEM CELLS; Ramon-Cueto A, 1998, J NEUROSCI, V18, P3803; Rice BW, 2001, J BIOMED OPT, V6, P432, DOI 10.1117/1.1413210; Saruhashi Y, 1996, EXP NEUROL, V139, P203, DOI 10.1006/exnr.1996.0094; Scheff SW, 2003, J NEUROTRAUM, V20, P179, DOI 10.1089/08977150360547099; Shimozaki K, 2005, J NEUROCHEM, V93, P432, DOI 10.1111/j.1471-4159.2005.03031.x; Takizawa T, 2001, DEV CELL, V1, P749, DOI 10.1016/S1534-5807(01)00101-0; Tang XF, 2003, J NEUROSCI RES, V71, P427, DOI 10.1002/jnr.10523; Temple S, 2001, NATURE, V414, P112, DOI 10.1038/35102174; Wang XL, 2003, BLOOD, V102, P3478, DOI 10.1182/blood-2003-05-1432; Winkler C, 1998, MOL CELL NEUROSCI, V11, P99, DOI 10.1006/mcne.1998.0674; Yoshida H, 2002, BRAIN RES, V944, P65, DOI 10.1016/S0006-8993(02)02708-7; Zhao H, 2005, J BIOMED OPT, V10, DOI 10.1117/1.2032388	50	86	92	0	10	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	NOV 6	2009	4	11							e7706	10.1371/journal.pone.0007706	http://dx.doi.org/10.1371/journal.pone.0007706			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	515ND	19893739	Green Published, gold, Green Submitted			2022-12-25	WOS:000271478000005
J	Clay, BS; Shilling, RA; Bandukwala, HS; Moore, TV; Cannon, JL; Welcher, AA; Weinstock, JV; Sperling, AI				Clay, Bryan S.; Shilling, Rebecca A.; Bandukwala, Hozefa S.; Moore, Tamson V.; Cannon, Judy L.; Welcher, Andrew A.; Weinstock, Joel V.; Sperling, Anne I.			Inducible Costimulator Expression Regulates the Magnitude of Th2-Mediated Airway Inflammation by Regulating the Number of Th2 Cells	PLOS ONE			English	Article							CD4(+) T-CELLS; B-CELL; IMMUNE-RESPONSES; MOLECULE ICOS; CHROMOSOME 2Q; CUTTING EDGE; DIFFERENTIATION; IL-4; RECEPTOR; ASTHMA	Background: Inducible Costimulator (ICOS) is an important regulator of Th2 lymphocyte function and a potential immunotherapeutic target for allergy and asthma. A SNP in the ICOS 5' promoter in humans is associated with increased atopy and serum IgE in a founder population and increased ICOS surface expression and Th2 cytokine production from peripheral blood mononuclear cells. However, it is unknown if increased ICOS expression contributes to disease progression or is a result of disease pathology. Methodology/Principal Findings: We developed a mouse model in which ICOS surface expression levels are genetically predetermined to test our hypothesis that genetic regulation of ICOS expression controls the severity of Th2 responses in vivo. Using ICOS(+/+) and ICOS(+/-) mice in a Th2 model of airway inflammation, we found that T cells from the ICOS(+/-) mice had reduced ICOS expression and decreased Th2-mediated inflammation in vivo. Although the activation status of the T cells did not differ, T cells isolated from the lungs and draining lymph nodes of ICOS(+/-) mice at the peak of inflammation produced less Th2 cytokines upon stimulation ex vivo. Using 4get mice, which express GFP upon IL-4 transcription, we determined that the decreased Th2 cytokines in ICOS(+/-) is due to reduced percentage of Th2 cells and not a defect in their ability to produce IL-4. Conclusion: These data suggest that in both mice and humans, the level of ICOS surface expression regulates the magnitude of the in vivo Th2 response, perhaps by influencing Th2 differentiation.			Clay, BS (corresponding author), Univ Chicago, Comm Immunol, Chicago, IL 60637 USA.	asperlin@uchicago.edu	Sperling, Anne/ACZ-2351-2022	Sperling, Anne I./0000-0002-4265-9212; Cannon, Judy/0000-0003-0069-8106	NIAID NIH HHS [T32 AI007090, K08 AI059105, R01 AI50180, P01-AI56352, P01 AI056352, 5T32AI07090, R01 AI050180] Funding Source: Medline; PHS HHS [P01 A156352] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [K08AI059105, R01AI050180, T32AI007090, P01AI056352] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Beier KC, 2004, J ALLERGY CLIN IMMUN, V114, P775, DOI 10.1016/j.jaci.2004.06.024; Chen LQ, 2004, J IMMUNOL, V172, P2059, DOI 10.4049/jimmunol.172.4.2059; Cookson W, 1999, NATURE, V402, pB5, DOI 10.1038/35037002; Coyle AJ, 2000, IMMUNITY, V13, P95, DOI 10.1016/S1074-7613(00)00011-X; Ding HL, 2006, CLIN IMMUNOL, V118, P258, DOI 10.1016/j.clim.2005.10.017; Dong C, 2001, J IMMUNOL, V166, P3659, DOI 10.4049/jimmunol.166.6.3659; Dong C, 2001, NATURE, V409, P97, DOI 10.1038/35051100; Evans DM, 2004, J ALLERGY CLIN IMMUN, V114, P826, DOI 10.1016/j.jaci.2004.05.060; Gonzalo JA, 2001, NAT IMMUNOL, V2, P597, DOI 10.1038/89739; Grimbacher B, 2003, NAT IMMUNOL, V4, P261, DOI 10.1038/ni902; Hoeck J, 2001, J IMMUNOL, V166, P4507, DOI 10.4049/jimmunol.166.7.4507; Howard TD, 2002, J ALLERGY CLIN IMMUN, V110, P743, DOI 10.1067/mai.2002.128723; Hutloff A, 2004, ARTHRITIS RHEUM-US, V50, P3211, DOI 10.1002/art.20519; Koppelman GH, 2002, J ALLERGY CLIN IMMUN, V109, P498, DOI 10.1067/mai.2002.122235; Liang L, 2002, J EXP MED, V196, P97, DOI 10.1084/jem.20020298; Logue EC, 2006, J IMMUNOL, V177, P2356, DOI 10.4049/jimmunol.177.4.2356; Lohning M, 2003, J EXP MED, V197, P181, DOI 10.1084/jem.20020632; McAdam AJ, 2000, J IMMUNOL, V165, P5035, DOI 10.4049/jimmunol.165.9.5035; McAdam AJ, 2001, NATURE, V409, P102, DOI 10.1038/35051107; Mohrs K, 2005, J IMMUNOL, V175, P5306, DOI 10.4049/jimmunol.175.8.5306; Monick MM, 2007, J IMMUNOL, V179, P1648, DOI 10.4049/jimmunol.179.3.1648; Nurieva RI, 2003, IMMUNITY, V18, P801, DOI 10.1016/S1074-7613(03)00144-4; O'Connell EJ, 2004, ALLERGY, V59, P7, DOI 10.1111/j.1398-9995.2004.00563.x; Okamoto T, 2003, J RHEUMATOL, V30, P1157; ROTHENBERG ME, 1995, P NATL ACAD SCI USA, V92, P8960, DOI 10.1073/pnas.92.19.8960; Scott BG, 2004, J NEUROIMMUNOL, V153, P16, DOI 10.1016/j.jneuroim.2004.04.019; Shilling RA, 2005, J IMMUNOL, V175, P2061, DOI 10.4049/jimmunol.175.4.2061; Tafuri A, 2001, NATURE, V409, P105, DOI 10.1038/35051113; Terada N, 2001, CLIN EXP ALLERGY, V31, P1923, DOI 10.1046/j.1365-2222.2001.01152.x; Tesciuba AG, 2001, J IMMUNOL, V167, P1996, DOI 10.4049/jimmunol.167.4.1996; Venter JC, 2001, SCIENCE, V291, P1304, DOI 10.1126/science.1058040; Vinuesa CG, 2005, NATURE, V435, P452, DOI 10.1038/nature03555; Watanabe M, 2005, J IMMUNOL, V174, P1989, DOI 10.4049/jimmunol.174.4.1989; Watanabe M, 2008, J IMMUNOL, V180, P5222, DOI 10.4049/jimmunol.180.8.5222; Yagi J, 2003, J IMMUNOL, V171, P783, DOI 10.4049/jimmunol.171.2.783; Zheng Y, 2005, J IMMUNOL, V174, P3117, DOI 10.4049/jimmunol.174.5.3117; Zhou ZP, 2005, EUR J IMMUNOL, V35, P1918, DOI 10.1002/eji.200525971	37	16	16	0	3	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA	1932-6203			PLOS ONE	PLoS One	NOV 4	2009	4	11							e7525	10.1371/journal.pone.0007525	http://dx.doi.org/10.1371/journal.pone.0007525			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	514RZ	19888475	Green Published, gold, Green Submitted			2022-12-25	WOS:000271414600001
J	Abrajano, JJ; Qureshi, IA; Gokhan, S; Zheng, DY; Bergman, A; Mehler, MF				Abrajano, Joseph J.; Qureshi, Irfan A.; Gokhan, Solen; Zheng, Deyou; Bergman, Aviv; Mehler, Mark F.			Differential Deployment of REST and CoREST Promotes Glial Subtype Specification and Oligodendrocyte Lineage Maturation	PLOS ONE			English	Article							PROGENITOR-CELL RESPONSIVENESS; EMBRYONIC STEM-CELLS; SILENCER FACTOR NRSF; TARGET GENES; TRANSCRIPTION FACTORS; IN-VITRO; DEVELOPMENTAL-CHANGES; TUMOR-SUPPRESSOR; RAT-BRAIN; FATE SPECIFICATION	Background: The repressor element-1 (RE1) silencing transcription factor/neuron-restrictive silencer factor (REST/NRSF) is a master transcriptional regulator that binds to numerous genomic RE1 sites where it acts as a molecular scaffold for dynamic recruitment of modulatory and epigenetic cofactors, including corepressor for element-1-silencing transcription factor (CoREST). CoREST also acts as a hub for various cofactors that play important roles in epigenetic remodeling and transcriptional regulation. While REST can recruit CoREST to its macromolecular complex, CoREST complexes also function at genomic sites independently of REST. REST and CoREST perform a broad array of context-specific functions, which include repression of neuronal differentiation genes in neural stem cells (NSCs) and other non-neuronal cells as well as promotion of neurogenesis. Despite their involvement in multiple aspects of neuronal development, REST and CoREST are not believed to have any direct modulatory roles in glial cell maturation. Methodology/Principal Findings: We challenged this view by performing the first study of REST and CoREST in NSC-mediated glial lineage specification and differentiation. Utilizing ChIP on chip (ChIP-chip) assays, we identified distinct but overlapping developmental stage-specific profiles for REST and CoREST target genes during astrocyte (AS) and oligodendrocyte (OL) lineage specification and OL lineage maturation and myelination, including many genes not previously implicated in glial cell biology or linked to REST and CoREST regulation. Amongst these factors are those implicated in macroglial (AS and OL) cell identity, maturation, and maintenance, such as members of key developmental signaling pathways and combinatorial transcription factor codes. Conclusions/Significance: Our results imply that REST and CoREST modulate not only neuronal but also glial lineage elaboration. These factors may therefore mediate critical developmental processes including the coupling of neurogenesis and gliogenesis and neuronal-glial interactions that underlie synaptic and neural network plasticity and homeostasis in health and in specific neurological disease states.			Abrajano, JJ (corresponding author), Albert Einstein Coll Med, Inst Brain Disorders & Neural Regenerat, Bronx, NY 10467 USA.	mehler@aecom.yu.edu		Zheng, Deyou/0000-0003-4354-5337	NATIONAL INSTITUTE OF MENTAL HEALTH [R01MH066290] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS038902] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG028872, P01AG027734] Funding Source: NIH RePORTER; NIA NIH HHS [AG027734, P01 AG027734, AG028872, R01 AG028872] Funding Source: Medline; NIMH NIH HHS [R01 MH066290, MH66290] Funding Source: Medline; NINDS NIH HHS [R01 NS038902, NS38902] Funding Source: Medline	NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Ahn M, 2008, J NEUROSCI RES, V86, P992, DOI 10.1002/jnr.21561; Andres ME, 1999, P NATL ACAD SCI USA, V96, P9873, DOI 10.1073/pnas.96.17.9873; Archange C, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002475; Ballas N, 2005, CELL, V121, P645, DOI 10.1016/j.cell.2005.03.013; Ballas N, 2005, CURR OPIN NEUROBIOL, V15, P500, DOI 10.1016/j.conb.2005.08.015; BANCK M, 2009, EPIGENETICS, V4; Bao DS, 2005, J NEUROCHEM, V95, P618, DOI 10.1111/j.1471-4159.2005.03385.x; Blais A, 2007, J CELL BIOL, V179, P1399, DOI 10.1083/jcb.200705051; Broide RS, 2007, J MOL NEUROSCI, V31, P47, DOI 10.1007/BF02686117; Bruce AW, 2004, P NATL ACAD SCI USA, V101, P10458, DOI 10.1073/pnas.0401827101; BRUCE AW, 2009, GENOME RES; Butzkueven H, 2002, NAT MED, V8, P613, DOI 10.1038/nm0602-613; Cahoy JD, 2008, J NEUROSCI, V28, P264, DOI 10.1523/JNEUROSCI.4178-07.2008; Camelo S, 2005, J NEUROIMMUNOL, V164, P10, DOI 10.1016/j.jneuroim.2005.02.022; Campuzano O, 2008, J NEUROSCI RES, V86, P3170, DOI 10.1002/jnr.21751; Canzonetta C, 2008, AM J HUM GENET, V83, P388, DOI 10.1016/j.ajhg.2008.08.012; Chakrabarti SK, 2002, J BIOL CHEM, V277, P13286, DOI 10.1074/jbc.M111857200; Chen ZF, 1998, NAT GENET, V20, P136, DOI 10.1038/2431; Cheng LC, 2009, NAT NEUROSCI, V12, P399, DOI 10.1038/nn.2294; Chinnadurai G, 2009, CANCER RES, V69, P731, DOI 10.1158/0008-5472.CAN-08-3349; CHONG JHA, 1995, CELL, V80, P949, DOI 10.1016/0092-8674(95)90298-8; Cohen RI, 1996, J NEUROSCI, V16, P6433; Conaco C, 2006, P NATL ACAD SCI USA, V103, P2422, DOI 10.1073/pnas.0511041103; COPRAY S, 2009, GLIA; Cowger JJM, 2007, ONCOGENE, V26, P3378, DOI 10.1038/sj.onc.1210126; Cui XY, 2004, J BIOL CHEM, V279, P25858, DOI 10.1074/jbc.M313505200; D'Alessandro R, 2009, ANN NY ACAD SCI, V1152, P194, DOI 10.1111/j.1749-6632.2008.03988.x; Dietrich Joerg, 2006, J Biol, V5, P22, DOI 10.1186/jbiol50; Dugas JC, 2006, J NEUROSCI, V26, P10967, DOI 10.1523/JNEUROSCI.2572-06.2006; Fancy SPJ, 2009, GENE DEV, V23, P1571, DOI 10.1101/gad.1806309; Fu H, 2009, J NEUROSCI, V29, P11399, DOI 10.1523/JNEUROSCI.0160-09.2009; Gokhan S, 2005, J NEUROSCI, V25, P8311, DOI 10.1523/JNEUROSCI.1850-05.2005; Greenway DJ, 2007, STEM CELLS, V25, P354, DOI 10.1634/stemcells.2006-0207; Guan JS, 2009, NATURE, V459, P55, DOI 10.1038/nature07925; Guillemot F, 2007, PROG NEUROBIOL, V83, P37, DOI 10.1016/j.pneurobio.2007.02.009; He Y, 2007, NEURON, V55, P217, DOI 10.1016/j.neuron.2007.06.029; Hu QD, 2006, DEV NEUROSCI-BASEL, V28, P25, DOI 10.1159/000090750; Hu QD, 2003, CELL, V115, P163, DOI 10.1016/S0092-8674(03)00810-9; Huang YF, 2002, J NEUROSCI, V22, P8422; Ivkovic S, 1999, J NEUROSCI, V19, P5409; Izrael M, 2007, MOL CELL NEUROSCI, V34, P310, DOI 10.1016/j.mcn.2006.11.008; Jensen LB, 2009, CANCER BIOMARK, V5, P41, DOI 10.3233/CBM-2009-0570; Johnson DS, 2007, SCIENCE, V316, P1497, DOI 10.1126/science.1141319; Johnson R, 2009, RNA, V15, P85, DOI 10.1261/rna.1127009; Johnson R, 2008, PLOS BIOL, V6, P2205, DOI 10.1371/journal.pbio.0060256; JUNG M, 1995, EUR J NEUROSCI, V7, P1245, DOI 10.1111/j.1460-9568.1995.tb01115.x; Kalsi AS, 2004, J ANAT, V204, P475, DOI 10.1111/j.0021-8782.2004.00288.x; Kiefer JC, 2007, DEV DYNAM, V236, P2356, DOI 10.1002/dvdy.21218; Kim CS, 2008, BBA-MOL CELL RES, V1783, P1835, DOI 10.1016/j.bbamcr.2008.06.019; Kim DK, 2008, NEUROSCI LETT, V433, P259, DOI 10.1016/j.neulet.2008.01.016; KOLLER KJ, 1985, J NEUROSCI, V5, P2882; Kondo T, 2000, SCIENCE, V289, P1754, DOI 10.1126/science.289.5485.1754; Kordes U, 2005, DEV BRAIN RES, V157, P209, DOI 10.1016/j.devbrainres.2005.03.009; Koyama Y, 1999, J NEUROCHEM, V73, P1004, DOI 10.1046/j.1471-4159.1999.0731004.x; Lakowski B, 2006, J MOL NEUROSCI, V29, P227, DOI 10.1385/JMN:29:3:227; Leeds P, 2005, NEUROCHEM INT, V46, P61, DOI 10.1016/j.neuint.2004.07.001; Lin WS, 2009, NAT NEUROSCI, V12, P379, DOI 10.1038/nn.2273; Liu AX, 2003, GLIA, V44, P264, DOI 10.1002/glia.10290; Liu H, 2009, GLIA, V57, P1, DOI 10.1002/glia.20729; Liu J, 2008, BMC CANCER, V8, DOI 10.1186/1471-2407-8-261; Magin A, 2002, NEUROCHEM INT, V40, P195, DOI 10.1016/S0197-0186(01)00091-2; Majumder S, 2006, CELL CYCLE, V5, P1929, DOI 10.4161/cc.5.17.2982; Marin-Husstege M, 2002, J NEUROSCI, V22, P10333; Marin-Husstege M, 2006, GLIA, V54, P285, DOI 10.1002/glia.20385; Marmur R, 1998, J NEUROSCI, V18, P9800; Marmur R, 1998, DEV BIOL, V204, P577, DOI 10.1006/dbio.1998.9099; Mehler MF, 2000, DEV NEUROSCI-BASEL, V22, P74, DOI 10.1159/000017429; Miller RH, 2002, PROG NEUROBIOL, V67, P451, DOI 10.1016/S0301-0082(02)00058-8; Miller RH, 2007, NAT NEUROSCI, V10, P1351, DOI 10.1038/nn1995; Mortazavi A, 2006, GENOME RES, V16, P1208, DOI 10.1101/gr.4997306; Namihira M, 2008, PHILOS T R SOC B, V363, P2099, DOI 10.1098/rstb.2008.2262; Nicoilay DJ, 2007, GLIA, V55, P1287, DOI 10.1002/glia.20540; Nicolis SK, 2007, NEUROBIOL DIS, V25, P217, DOI 10.1016/j.nbd.2006.08.022; Nielsen JA, 2004, MOL CELL NEUROSCI, V25, P111, DOI 10.1016/j.mcn.2003.10.001; North BJ, 2003, MOL CELL, V11, P437, DOI 10.1016/S1097-2765(03)00038-8; Oberley MJ, 2004, METHOD ENZYMOL, V376, P315; Ohsawa R, 2005, J NEUROSCI, V25, P5857, DOI 10.1523/JNEUROSCI.4621-04.2005; Ooi L, 2007, NAT REV GENET, V8, P544, DOI 10.1038/nrg2100; Otto SJ, 2007, J NEUROSCI, V27, P6729, DOI 10.1523/JNEUROSCI.0091-07.2007; Packer AN, 2008, J NEUROSCI, V28, P14341, DOI 10.1523/JNEUROSCI.2390-08.2008; Polo JM, 2007, P NATL ACAD SCI USA, V104, P3207, DOI 10.1073/pnas.0611399104; Potzner MR, 2007, MOL CELL BIOL, V27, P5316, DOI 10.1128/MCB.00339-07; Raff M, 2001, NOVART FDN SYMP, V237, P100, DOI 10.1002/0470846666.ch9; Raff M., 2001, NOVART FDN SYMP, V237, P158; Reilly JO, 2002, MOL CELL NEUROSCI, V19, P88, DOI 10.1006/mcne.2001.1063; Relvas JB, 2001, CURR BIOL, V11, P1039, DOI 10.1016/S0960-9822(01)00292-5; Rosenbaum T, 1999, ANN NY ACAD SCI, V883, P203, DOI 10.1111/j.1749-6632.1999.tb08583.x; Saijo K, 2009, CELL, V137, P47, DOI 10.1016/j.cell.2009.01.038; Sandoval J, 2004, NUCLEIC ACIDS RES, V32, DOI 10.1093/nar/gnh091; SCHOENHERR CJ, 1995, SCIENCE, V267, P1360, DOI 10.1126/science.7871435; Shannon C, 2007, J ANAT, V210, P684, DOI 10.1111/j.1469-7580.2007.00731.x; Sorrentino E, 2007, GENE EXPR PATTERNS, V7, P714, DOI 10.1016/j.modgep.2007.02.002; Southwood CM, 2007, NEUROCHEM RES, V32, P187, DOI 10.1007/s11064-006-9127-6; Stankoff B, 2002, J NEUROSCI, V22, P9221; Stolt CC, 2004, DEVELOPMENT, V131, P2349, DOI 10.1242/dev.01114; Sun YM, 2005, MOL BIOL CELL, V16, P5630, DOI 10.1091/mbc.E05-07-0687; Sun YM, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003656; Terada N, 2002, GLIA, V40, P350, DOI 10.1002/glia.10134; Thillainadesan G, 2008, MOL CELL BIOL, V28, P6066, DOI 10.1128/MCB.00246-08; Wang SZ, 2006, DEVELOPMENT, V133, P3389, DOI 10.1242/dev.02522; Wegner M, 2008, J MOL NEUROSCI, V35, P3, DOI 10.1007/s12031-007-9008-8; Weinmann AS, 2002, METHODS, V26, P37, DOI 10.1016/S1046-2023(02)00006-3; Wen S, 2009, PROG NEUROBIOL, V87, P98, DOI 10.1016/j.pneurobio.2008.10.002; Wenning GK, 2008, ANN NEUROL, V64, P239, DOI 10.1002/ana.21465; Williams A, 2007, BRAIN, V130, P2554, DOI 10.1093/brain/awm202; Wu J, 2006, GENOME BIOL, V7, DOI 10.1186/gb-2006-7-9-r85; Wynder C, 2005, NAT CELL BIOL, V7, P1113, DOI 10.1038/ncb1312; Xu J, 2008, J NEUROSCI, V28, P4521, DOI 10.1523/JNEUROSCI.5382-07.2008; Ye F, 2009, NAT NEUROSCI, V12, P829, DOI 10.1038/nn.2333; Yokoyama A, 2008, MOL CELL BIOL, V28, P3995, DOI 10.1128/MCB.02030-07; Yung SY, 2002, P NATL ACAD SCI USA, V99, P16273, DOI 10.1073/pnas.232586699; Zheng DY, 2009, GENOME BIOL, V10, DOI 10.1186/gb-2009-10-1-r9; Zhou Y, 2006, LIFE SCI, V79, P1645, DOI 10.1016/j.lfs.2006.05.022; Zhu G, 2000, J NEUROSCI RES, V59, P312, DOI 10.1002/(SICI)1097-4547(20000201)59:3<312::AID-JNR4>3.0.CO;2-A; Zhu G, 1999, J NEUROSCI RES, V56, P131, DOI 10.1002/(SICI)1097-4547(19990415)56:2<131::AID-JNR3>3.0.CO;2-I; Zuccato C, 2007, J NEUROSCI, V27, P6972, DOI 10.1523/JNEUROSCI.4278-06.2007	117	63	64	2	6	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	NOV 3	2009	4	11							e7665	10.1371/journal.pone.0007665	http://dx.doi.org/10.1371/journal.pone.0007665			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	514RY	19888342	Green Published, Green Submitted, gold			2022-12-25	WOS:000271414500004
J	Steele, RE; Dana, CE				Steele, Robert E.; Dana, Catherine E.			Evolutionary History of the HAP2/GCS1 Gene and Sexual Reproduction in Metazoans	PLOS ONE			English	Article							CLASS-LEVEL RELATIONSHIPS; PHYLUM CNIDARIA; GENOME; GCS1	The HAP2/GCS1 gene first appeared in the common ancestor of plants, animals, and protists, and is required in the male gamete for fusion to the female gamete in the unicellular organisms Chlamydomonas and Plasmodium. We have identified a HAP2/GCS1 gene in the genome sequence of the sponge Amphimedon queenslandica. This finding provides a continuous evolutionary history of HAP2/GCS1 from unicellular organisms into the metazoan lineage. Divergent versions of the HAP2/GCS1 gene are also present in the genomes of some but not all arthropods. By examining the expression of the HAP2/GCS1 gene in the cnidarian Hydra, we have found the first evidence supporting the hypothesis that HAP2/GCS1 was used for male gamete fusion in the ancestor of extant metazoans and that it retains that function in modern cnidarians.			Steele, RE (corresponding author), Univ Calif Irvine, Dept Biol Chem, Irvine, CA 92717 USA.	resteele@uci.edu		Dana, Catherine/0000-0003-3788-7955	NIGMS NIH HHS [R24 GM080537, 1R24GM080537-01A1] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R24GM080537] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Besansky NJ, 1997, MOL BIOL EVOL, V14, P442, DOI 10.1093/oxfordjournals.molbev.a025780; Bode Hans, 2008, V469, P69, DOI 10.1007/978-1-60327-469-2_7; BOGUSKI MS, 1993, NAT GENET, V4, P332, DOI 10.1038/ng0893-332; Borges F, 2008, PLANT PHYSIOL, V148, P1168, DOI 10.1104/pp.108.125229; BRIDGE D, 1995, MOL BIOL EVOL, V12, P679; BRIDGE D, 1992, P NATL ACAD SCI USA, V89, P8750, DOI 10.1073/pnas.89.18.8750; Goodman CD, 2008, CURR BIOL, V18, pR571, DOI 10.1016/j.cub.2008.05.007; Grell K.G., 1991, MICROSCOPIC ANATOMY; Hemmrich G, 2008, BIOESSAYS, V30, P1010, DOI 10.1002/bies.20813; Hirai M, 2008, CURR BIOL, V18, P607, DOI 10.1016/j.cub.2008.03.045; King N, 2005, CURR BIOL, V15, pR113, DOI 10.1016/j.cub.2005.02.004; Liu YJ, 2008, GENE DEV, V22, P1051, DOI 10.1101/gad.1656508; Miller MA, 2000, DEV BIOL, V224, P326, DOI 10.1006/dbio.2000.9790; Mori T, 2006, NAT CELL BIOL, V8, P64, DOI 10.1038/ncb1345; Notredame C, 2000, J MOL BIOL, V302, P205, DOI 10.1006/jmbi.2000.4042; Schierwater B, 2009, PLOS BIOL, V7, P36, DOI 10.1371/journal.pbio.1000020; Signorovitch AY, 2005, P NATL ACAD SCI USA, V102, P15518, DOI 10.1073/pnas.0504031102; Srivastava M, 2008, NATURE, V454, P955, DOI 10.1038/nature07191; von Besser K, 2006, DEVELOPMENT, V133, P4761, DOI 10.1242/dev.02683; Weinstock GM, 2006, NATURE, V443, P931, DOI 10.1038/nature05260	20	37	37	0	13	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	NOV 3	2009	4	11							e7680	10.1371/journal.pone.0007680	http://dx.doi.org/10.1371/journal.pone.0007680			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	514RY	19888453	Green Submitted, Green Published, gold			2022-12-25	WOS:000271414500006
J	Tan, KS; Armugam, A; Sepramaniam, S; Lim, KY; Setyowati, KD; Wang, CW; Jeyaseelan, K				Tan, Kay Sin; Armugam, Arunmozhiarasi; Sepramaniam, Sugunavathi; Lim, Kai Ying; Setyowati, Karolina Dwi; Wang, Chee Woon; Jeyaseelan, Kandiah			Expression Profile of MicroRNAs in Young Stroke Patients	PLOS ONE			English	Article							TRANSIENT FOCAL ISCHEMIA; GENE-EXPRESSION; BLOOD; BIOMARKERS; BRAIN; HEART; RATS	Background: The methods currently available for diagnosis and prognosis of cerebral ischaemia still require further improvements. Micro-RNAs (small non-coding RNAs) have been recently reported as useful biomarkers in diseases such as cancer and diabetes. We therefore carried out microRNA (miRNA) profiling from peripheral blood to detect and identify characteristic patterns in ischaemic stroke. Methods/Principal Findings: The ischaemic stroke patients aged between 18-49 years, characterized based on World Health Organization clinical criteria were further classified according to TOAST classification, a) Large-vessel atherosclerosis [n = 8] b) Small- vessel disease [n = 3] c) Cardioembolism [n = 5] d) Undetermined cause [n = 3]. The patients' functional status at the time of blood sampling (at the outpatient clinics) was evaluated with the modified Rankin Scale (mRS). Blood samples from normal (n = 5) individuals were used as controls. Total RNA extracted from whole blood was subjected to miroRNA profiling and real-time PCR analysis. miRNAs that are implicated in the endothelial/vascular function, erythropoiesis, angiogenesis and neural function showed differential expression profile as compared to the normal control. Interestingly, miRNAs that are involved in hypoxic conditions have also been found in our miRNA profiles. Conclusion: We demonstrate that the peripheral blood miRNAs and their profiles can be developed as biomarkers in diagnosis and prognosis of cerebral ischaemic stroke. The dysregulated miRNAs have been detectable even after several months from the onset of stroke in what is usually regarded as neurologically stable patients.			Tan, KS (corresponding author), Univ Malaya, Dept Med, Kuala Lumpur, Malaysia.	bchjeya@nus.edu.sg	WANG, CHEE WOON/C-1033-2010; Wang, Chee/GQZ-3436-2022; WANG, CHEE WOON/GQZ-3715-2022; WOON, WANG CHEE/H-7458-2019; TAN, KAY SIN/B-9911-2010	Armugam, Arunmozhiarasi/0000-0002-6064-1980				Aumiller V, 2008, BBA-GENE REGUL MECH, V1779, P692, DOI 10.1016/j.bbagrm.2008.04.008; Bartel DP, 2009, CELL, V136, P215, DOI 10.1016/j.cell.2009.01.002; Bolstad BM, 2003, BIOINFORMATICS, V19, P185, DOI 10.1093/bioinformatics/19.2.185; Bushati N, 2008, CURR OPIN NEUROBIOL, V18, P292, DOI 10.1016/j.conb.2008.07.001; CARISSIMI C, 2009, AUTOIMMUN REV   0203; Chen L, 2009, J HEPATOL, V50, P358, DOI 10.1016/j.jhep.2008.09.015; Chen X, 2008, CELL RES, V18, P997, DOI 10.1038/cr.2008.282; Couzin J, 2008, SCIENCE, V319, P1782, DOI 10.1126/science.319.5871.1782; Dharap A, 2009, J CEREBR BLOOD F MET, V29, P675, DOI 10.1038/jcbfm.2008.157; Divakaran V, 2008, CIRC RES, V103, P1072, DOI 10.1161/CIRCRESAHA.108.183087; Felli N, 2005, P NATL ACAD SCI USA, V102, P18081, DOI 10.1073/pnas.0506216102; Grond-Ginsbach C, 2008, J NEUROL, V255, P723, DOI 10.1007/s00415-008-0784-z; He AB, 2007, MOL ENDOCRINOL, V21, P2785, DOI 10.1210/me.2007-0167; Jeyaseelan K, 2008, STROKE, V39, P959, DOI 10.1161/STROKEAHA.107.500736; Johnnidis JB, 2008, NATURE, V451, P1125, DOI 10.1038/nature06607; Kasner SE, 2006, LANCET NEUROL, V5, P603, DOI 10.1016/S1474-4422(06)70495-1; Kulshreshtha R, 2008, CELL DEATH DIFFER, V15, P667, DOI 10.1038/sj.cdd.4402310; Lawrie CH, 2007, INT J CANCER, V121, P1156, DOI 10.1002/ijc.22800; Li LC, 2008, RNA BIOL, V5, P61, DOI 10.4161/rna.5.2.5989; Merkerova M, 2008, EUR J HAEMATOL, V81, P304, DOI 10.1111/j.1600-0609.2008.01111.x; Mocellin S, 2009, MINI-REV MED CHEM, V9, P70, DOI 10.2174/138955709787001802; Nelson PT, 2008, BRAIN PATHOL, V18, P130, DOI 10.1111/j.1750-3639.2007.00120.x; Papadopoulos GL, 2009, BIOINFORMATICS, V25, P1991, DOI 10.1093/bioinformatics/btp299; Redell JB, 2009, J NEUROSCI RES, V87, P1435, DOI 10.1002/jnr.21945; Saeed AI, 2003, BIOTECHNIQUES, V34, P374, DOI 10.2144/03342mt01; Sucharov C, 2008, J MOL CELL CARDIOL, V45, P185, DOI 10.1016/j.yjmcc.2008.04.014; Urbich C, 2008, CARDIOVASC RES, V79, P581, DOI 10.1093/cvr/cvn156; van Rooij E, 2008, P NATL ACAD SCI USA, V105, P13027, DOI 10.1073/pnas.0805038105; Wang XH, 2009, CLIN EXP PHARMACOL P, V36, P181, DOI 10.1111/j.1440-1681.2008.05057.x; Xu HC, 2008, J CEREBR BLOOD F MET, V28, P1320, DOI 10.1038/jcbfm.2008.22	30	334	356	2	29	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	NOV 2	2009	4	11							e7689	10.1371/journal.pone.0007689	http://dx.doi.org/10.1371/journal.pone.0007689			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	514RX	19888324	Green Published, gold, Green Submitted			2022-12-25	WOS:000271414400007
J	Tanaka, H; Yi, TM				Tanaka, Hiromasa; Yi, Tau-Mu			Reverse Engineering a Signaling Network Using Alternative Inputs	PLOS ONE			English	Article							YEAST PHEROMONE RESPONSE; SACCHAROMYCES-CEREVISIAE; G-PROTEIN; CONSTITUTIVE MUTANTS; EPISTASIS ANALYSIS; INTERACTION MAP; GENE NETWORKS; BUDDING YEAST; PATHWAY; PHOSPHORYLATION	One of the goals of systems biology is to reverse engineer in a comprehensive fashion the arrow diagrams of signal transduction systems. An important tool for ordering pathway components is genetic epistasis analysis, and here we present a strategy termed Alternative Inputs (AIs) to perform systematic epistasis analysis. An alternative input is defined as any genetic manipulation that can activate the signaling pathway instead of the natural input. We introduced the concept of an "AIs-Deletions matrix'' that summarizes the outputs of all combinations of alternative inputs and deletions. We developed the theory and algorithms to construct a pairwise relationship graph from the AIs-Deletions matrix capturing both functional ordering (upstream, downstream) and logical relationships (AND, OR), and then interpreting these relationships into a standard arrow diagram. As a proof-of-principle, we applied this methodology to a subset of genes involved in yeast mating signaling. This experimental pilot study highlights the robustness of the approach and important technical challenges. In summary, this research formalizes and extends classical epistasis analysis from linear pathways to more complex networks, facilitating computational analysis and reconstruction of signaling arrow diagrams.			Tanaka, H (corresponding author), Univ Calif Irvine, Dept Dev & Cell Biol, Irvine, CA 92717 USA.	tmy@uci.edu			NIGMS NIH HHS [P50 GM076516, R01 GM075309, R01GM75309] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [P50GM076516, R01GM075309] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		[Anonymous], 1991, Methods Enzymol, V194, P1; Bansal M, 2007, MOL SYST BIOL, V3, DOI 10.1038/msb4100120; BLINDER D, 1989, CELL, V56, P479, DOI 10.1016/0092-8674(89)90250-X; CAIRNS BR, 1992, GENE DEV, V6, P1305, DOI 10.1101/gad.6.7.1305; Cho KH, 2007, IET SYST BIOL, V1, P149, DOI 10.1049/iet-syb:20060075; Collins SR, 2006, GENOME BIOL, V7, DOI 10.1186/gb-2006-7-7-r63; Dohlman HG, 2001, ANNU REV BIOCHEM, V70, P703, DOI 10.1146/annurev.biochem.70.1.703; DOLAN JW, 1989, P NATL ACAD SCI USA, V86, P5703, DOI 10.1073/pnas.86.15.5703; DOLAN JW, 1990, GENE DEV, V4, P492, DOI 10.1101/gad.4.4.492; Fiedler D, 2009, CELL, V136, P952, DOI 10.1016/j.cell.2008.12.039; GARTNER A, 1992, GENE DEV, V6, P1280, DOI 10.1101/gad.6.7.1280; Gavin AC, 2006, NATURE, V440, P631, DOI 10.1038/nature04532; Goffeau A, 1996, SCIENCE, V274, P546, DOI 10.1126/science.274.5287.546; GOFFEAU A, 1996, SCIENCE, V274, P563, DOI DOI 10.1126/SCIENCE.274.5287.546; Hughes TR, 2005, NAT GENET, V37, P457, DOI 10.1038/ng0505-457; Huh WK, 2003, NATURE, V425, P686, DOI 10.1038/nature02026; Isalan M, 2009, BIOESSAYS, V31, P1110, DOI 10.1002/bies.200900072; Ito T, 2000, P NATL ACAD SCI USA, V97, P1143, DOI 10.1073/pnas.97.3.1143; Kitano H, 2005, NAT BIOTECHNOL, V23, P961, DOI 10.1038/nbt1111; Kohn KW, 1999, MOL BIOL CELL, V10, P2703, DOI 10.1091/mbc.10.8.2703; Krogan NJ, 2006, NATURE, V440, P637, DOI 10.1038/nature04670; Pan XW, 2006, CELL, V124, P1069, DOI 10.1016/j.cell.2005.12.036; Ren B, 2000, SCIENCE, V290, P2306, DOI 10.1126/science.290.5500.2306; SCHENA M, 1995, SCIENCE, V270, P467, DOI 10.1126/science.270.5235.467; Schuldiner M, 2005, CELL, V123, P507, DOI 10.1016/j.cell.2005.08.031; Sopko R, 2006, MOL CELL, V21, P319, DOI 10.1016/j.molcel.2005.12.011; St Onge RP, 2007, NAT GENET, V39, P199, DOI 10.1038/ng1948; STEVENSON BJ, 1992, GENE DEV, V6, P1293, DOI 10.1101/gad.6.7.1293; Tanaka H, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0006946; Tong AHY, 2004, SCIENCE, V303, P808, DOI 10.1126/science.1091317; Tong AHY, 2001, SCIENCE, V294, P2364, DOI 10.1126/science.1065810; Uetz P, 2000, NATURE, V403, P623, DOI 10.1038/35001009; Van Driessche N, 2005, NAT GENET, V37, P471, DOI 10.1038/ng1545; Winzeler EA, 1999, SCIENCE, V285, P901, DOI 10.1126/science.285.5429.901; Yi TM, 2003, P NATL ACAD SCI USA, V100, P10764, DOI 10.1073/pnas.1834247100; Zupan B, 2003, BIOINFORMATICS, V19, P383, DOI 10.1093/bioinformatics/btf871	36	6	7	0	0	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	OCT 29	2009	4	10							e7622	10.1371/journal.pone.0007622	http://dx.doi.org/10.1371/journal.pone.0007622			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	512FP	19898612	Green Published, gold			2022-12-25	WOS:000271232000006
J	Bhattacharyya, S; Wei, J; Melichian, DS; Milbrandt, J; Takehara, K; Varga, J				Bhattacharyya, Swati; Wei, Jun; Melichian, Denisa S.; Milbrandt, Jeffrey; Takehara, Kazuhiko; Varga, John			The Transcriptional Cofactor Nab2 Is Induced by TGF-beta and Suppresses Fibroblast Activation: Physiological Roles and Impaired Expression in Scleroderma	PLOS ONE			English	Article							GROWTH-FACTOR-BETA; SMOOTH-MUSCLE-CELLS; COREPRESSOR NAB2; GENE-EXPRESSION; COLLAGEN GENE; A EGR-1; RESPONSES; PROTEINS; NURD; MODULATION	By stimulating collagen synthesis and myofibroblasts differentiation, transforming growth factor-beta (TGF-beta) plays a pivotal role in tissue repair and fibrosis. The early growth response-1 (Egr-1) transcription factor mediates profibrotic TGF-beta responses, and its expression is elevated in biopsies from patients with scleroderma. NGF1-A-binding protein 2 (Nab2) is a conserved transcriptional cofactor that directly binds to Egr-1 and positively or negatively modulates Egr-1 target gene transcription. Despite the recognized importance of Nab2 in governing the intensity of Egr-1-dependent responses, the regulation and function of Nab2 in the context of fibrotic TGF-beta signaling is unknown. Here we show that TGF-beta caused a time-dependent stimulation of Nab2 protein and mRNA in normal fibroblasts. Ectopic expression of Nab2 in these cells blocked Egr-1-dependent transcriptional responses, and abrogated TGF-beta-induced stimulation of collagen synthesis and myofibroblasts differentiation. These inhibitory effects of Nab2 involved recruitment of the NuRD chromatin remodeling complex to the COL1A2 promoter and were accompanied by reduced histone H4 acetylation. Mice with targeted deletion of Nab2 displayed increased collagen accumulation in the dermis, and genetic or siRNA-mediated loss of Nab2 in fibroblasts was associated with constitutively elevated collagen synthesis and accentuation of Egr-1-dependent TGF-beta responses in vitro. Expression of Nab2 was markedly up-regulated in skin biopsies from patients with scleroderma, and was localized primarily to epidermal keratinocytes. In contrast, little Nab2 could be detected in dermal fibroblasts. These results identify Nab2 as a novel endogenous negative regulator of Egr-1-dependent TGF-beta signaling responsible for setting the intensity of fibrotic responses. Defective Nab2 expression or function in dermal fibroblasts might play a role in persistent fibrotic responses in scleroderma.			Bhattacharyya, S (corresponding author), Northwestern Univ, Div Rheumatol, Feinberg Sch Med, Chicago, IL 60611 USA.	j-varga@northwestern.edu	Wei, Jun/G-3295-2012; Bhattacharyya, Swati/W-8145-2019; Varga, John/AAK-6472-2021	Milbrandt, Jeffrey/0000-0002-5477-7689	NIAMS NIH HHS [AR-04239] Funding Source: Medline	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		Abraham DJ, 2005, TRENDS IMMUNOL, V26, P587, DOI 10.1016/j.it.2005.09.004; Baloh RH, 2009, J NEUROSCI, V29, P2312, DOI 10.1523/JNEUROSCI.2168-08.2009; Becker PB, 2002, ANNU REV BIOCHEM, V71, P247, DOI 10.1146/annurev.biochem.71.110601.135400; Bhattacharyya S, 2009, ONCOGENE, V28, P1285, DOI 10.1038/onc.2008.479; Bhattacharyya S, 2008, AM J PATHOL, V173, P1085, DOI 10.2353/ajpath.2008.080382; Bowen NJ, 2004, BBA-GENE STRUCT EXPR, V1677, P52, DOI 10.1016/j.bbaexp.2003.10.010; Chen SJ, 2006, J BIOL CHEM, V281, P21183, DOI 10.1074/jbc.M603270200; Chen SJ, 2000, J CELL PHYSIOL, V183, P381, DOI 10.1002/(SICI)1097-4652(200006)183:3<381::AID-JCP11>3.0.CO;2-O; Derynck R, 2007, NAT CELL BIOL, V9, P1000, DOI 10.1038/ncb434; Desmazieres A, 2008, J NEUROSCI, V28, P5891, DOI 10.1523/JNEUROSCI.5187-07.2008; Ehrengruber MU, 2000, GENE, V258, P63, DOI 10.1016/S0378-1119(00)00445-5; Fu MG, 2003, GENE, V315, P33, DOI 10.1016/S0378-1119(03)00730-3; Fukuda T, 2007, BIOCHEM BIOPH RES CO, V353, P147, DOI 10.1016/j.bbrc.2006.12.011; GASHLER A, 1995, PROG NUCLEIC ACID RE, V50, P191, DOI 10.1016/S0079-6603(08)60815-6; GASHLER AL, 1993, MOL CELL BIOL, V13, P4556, DOI 10.1128/MCB.13.8.4556; Ghosh A, 2009, FASEB J, V23; Houston P, 2001, BIOCHEM BIOPH RES CO, V283, P480, DOI 10.1006/bbrc.2001.4810; Ihn H, 1997, J BIOL CHEM, V272, P24666, DOI 10.1074/jbc.272.39.24666; Jimenez SA, 2004, ANN INTERN MED, V140, P37, DOI 10.7326/0003-4819-140-1-200401060-00010; Kamimura M, 2004, HYPERTENSION, V44, P944, DOI 10.1161/01.HYP.0000146908.75091.99; Khachigian LM, 1998, J MOL MED-JMM, V76, P613, DOI 10.1007/s001090050258; Le N, 2005, NAT NEUROSCI, V8, P932, DOI 10.1038/nn1490; Lucerna M, 2003, J BIOL CHEM, V278, P11433, DOI 10.1074/jbc.M204937200; Mauviel A, 2005, METH MOLEC MED, V117, P69; MILBRANDT J, 1987, SCIENCE, V238, P797, DOI 10.1126/science.3672127; Mori Y, 2004, ARTHRITIS RHEUM-US, V50, P4008, DOI 10.1002/art.20658; Okano K, 2006, J BIOL CHEM, V281, P26196, DOI 10.1074/jbc.M606710200; RUSSO MW, 1995, P NATL ACAD SCI USA, V92, P6873, DOI 10.1073/pnas.92.15.6873; Schweighofer B, 2007, CLIN HEMORHEOL MICRO, V37, P57; Sevetson BR, 2000, J BIOL CHEM, V275, P9749, DOI 10.1074/jbc.275.13.9749; Silverman ES, 1999, AM J PATHOL, V155, P1311, DOI 10.1016/S0002-9440(10)65233-9; Srinivasan R, 2006, J BIOL CHEM, V281, P15129, DOI 10.1074/jbc.M600775200; Svaren J, 1996, MOL CELL BIOL, V16, P3545; Svaren J, 1998, EMBO J, V17, P6010, DOI 10.1093/emboj/17.20.6010; Swirnoff AH, 1998, MOL CELL BIOL, V18, P512, DOI 10.1128/MCB.18.1.512; Thiel G, 2002, J CELL PHYSIOL, V193, P287, DOI 10.1002/jcp.10178; Thiel G, 2000, BBA-GENE STRUCT EXPR, V1493, P289, DOI 10.1016/S0167-4781(00)00207-4; Tong JK, 1998, NATURE, V395, P917, DOI 10.1038/27699; VARGA J, 1987, BIOCHEM J, V247, P597, DOI 10.1042/bj2470597; Varga J, 2007, J CLIN INVEST, V117, P557, DOI 10.1172/JCI31139; Wu MH, 2009, AM J PATHOL, V175, P1041, DOI 10.2353/ajpath.2009.090241; Wu MH, 2009, AM J PATHOL, V174, P519, DOI 10.2353/ajpath.2009.080574; Xue YT, 1998, MOL CELL, V2, P851, DOI 10.1016/S1097-2765(00)80299-3; Zhang Y, 1999, GENE DEV, V13, P1924, DOI 10.1101/gad.13.15.1924; Zhu XJ, 2007, CARDIOVASC RES, V76, P141, DOI 10.1016/j.cardiores.2007.06.015	45	18	18	0	3	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	OCT 26	2009	4	10							e7620	10.1371/journal.pone.0007620	http://dx.doi.org/10.1371/journal.pone.0007620			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	511ER	19888474	Green Published, Green Submitted, gold			2022-12-25	WOS:000271147200018
J	Kane, MA; Folias, AE; Wang, C; Napoli, JL				Kane, Maureen A.; Folias, Alexandra E.; Wang, Chao; Napoli, Joseph L.			Ethanol elevates physiological all-trans-retinoic acid levels in select loci through altering retinoid metabolism in multiple loci: a potential mechanism of ethanol toxicity	FASEB JOURNAL			English	Article						vitamin A; alcohol dehydrogenase; short-chain dehydrogenase; retinol dehydrogenase; fetal alcohol syndrome; hippocampus	RECEPTOR MESSENGER-RNA; FETAL ALCOHOL SYNDROME; VITAMIN-A; BINDING-PROTEIN; 13-CIS-RETINOIC ACID; HIPPOCAMPAL-NEURONS; MEMBRANE-RECEPTOR; NUCLEAR RECEPTORS; RAR-ALPHA; EXPOSURE	All-trans-retinoic acid (atRA) supports embryonic development, central nervous system function, and the immune response. atRA initiates neurogenesis and dendritic growth in the hippocampus and is required for spatial memory; superphysiological atRA inhibits neurogenesis, causes teratology and/or embryo toxicity, and alters cognitive function and behavior. Because abnormal atRA shares pathological conditions with alcoholism, inhibition of retinol (vitamin A) activation into atRA has been credited widely as a mechanism of ethanol toxicity. Here, we analyze the effects of ethanol on retinoid concentrations in vivo during normal vitamin A nutriture, using sensitive and analytically robust assays. Ethanol either increased or had no effect on atRA, regardless of changes in retinol and retinyl esters. Acute ethanol (3.5 g/kg) increased atRA in adult hippocampus (1.6-fold), liver (2.4-fold), and testis (1.5-fold). Feeding dams a liquid diet with 6.5% ethanol from embryonic day 13 (e13) to e19 increased atRA in fetal hippocampus (up to 20-fold) and cortex ( up to 50-fold), depending on blood alcohol content. One-month feeding of the 6.5% ethanol diet increased atRA in adult hippocampus (20-fold), cortex (2-fold), testis (2-fold), and serum (10-fold). Tissue-specific increases in retinoid dehydrogenase mRNAs and activities, extrahepatic retinol concentrations, and atRA catabolism combined to produce site-specific effects. Because a sustained increase in atRA has deleterious effects on the central nervous system and embryo development, these data suggest that superphysiological atRA contributes to ethanol pathological conditions, including cognitive dysfunction and fetal alcohol syndrome.-Kane, M. A., Folias, A. E., Wang, C., Napoli, J. L. Ethanol elevates physiological all- trans-retinoic acid levels in select loci through altering retinoid metabolism in multiple loci: a potential mechanism of ethanol toxicity. FASEB J. 24, 823-832 (2010). www.fasebj.org	[Kane, Maureen A.; Folias, Alexandra E.; Wang, Chao; Napoli, Joseph L.] Univ Calif Berkeley, Dept Nutr Sci & Toxicol, Berkeley, CA 94720 USA	University of California System; University of California Berkeley	Napoli, JL (corresponding author), Univ Calif Berkeley, Dept Nutr Sci & Toxicol, 119 Morgan Hall,MC 3104, Berkeley, CA 94720 USA.	jna@berkeley.edu	Wang, Chao/A-4626-2016	Wang, Chao/0000-0003-0357-4096	U.S. National Institutes of Health (NIH) [AA17927, AG13566, DK061918]; NIH Kirschstein Individual Fellowship [DK066924]; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [T32DK061918, F32DK066924] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG013566] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM [R01AA017927] Funding Source: NIH RePORTER	U.S. National Institutes of Health (NIH)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NIH Kirschstein Individual Fellowship(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA))	The authors thank Na Chen for assistance with embryo dissections; Rob Griswold for assistance in refining the subcellular fractionation procedure; James Chithalen, Hua Tran, Susan Sparks, and Saverio Roberto for assistance with animal care; and Charles Krois for assistance with CrbpI preparation. This work was supported by U.S. National Institutes of Health (NIH) grants AA17927 and AG13566 (J.L.N.), NIH Kirschstein Individual Fellowship DK066924 (M. A. K.), and NIH predoctoral training grant DK061918 (A. E. F.).	Bagnardi V, 2001, ALCOHOL RES HEALTH, V25, P263; Barua AB, 1998, MOL BIOTECHNOL, V10, P167, DOI 10.1007/BF02760863; Berman RE, 2000, HIPPOCAMPUS, V10, P94, DOI 10.1002/(SICI)1098-1063(2000)10:1<94::AID-HIPO11>3.3.CO;2-K; Boerman MHEM, 1996, J BIOL CHEM, V271, P5610, DOI 10.1074/jbc.271.10.5610; Bouillet P, 1997, MECH DEVELOP, V63, P173, DOI 10.1016/S0925-4773(97)00039-7; Bremmer JD, 2008, PROG NEURO-PSYCHOPH, V32, P315, DOI 10.1016/j.pnpbp.2007.07.001; Calvert-Evers JL, 2003, MOL CELL BIOCHEM, V245, P23, DOI 10.1023/A:1022806129035; Chen N, 2008, J BIOL CHEM, V283, P20841, DOI 10.1074/jbc.M802314200; Chen N, 2008, FASEB J, V22, P236, DOI 10.1096/fj.07-8739com; Chen Y, 2009, MED ONCOL, V26, P463, DOI 10.1007/s12032-008-9147-y; Chiang MY, 1998, NEURON, V21, P1353, DOI 10.1016/S0896-6273(00)80654-6; Chung SSW, 2004, CYTOGENET GENOME RES, V105, P189, DOI 10.1159/000078189; Crandall J, 2004, P NATL ACAD SCI USA, V101, P5111, DOI 10.1073/pnas.0306336101; Deltour L, 1996, FASEB J, V10, P1050, DOI 10.1096/fasebj.10.9.8801166; DREOSTI IE, 1993, ANN NY ACAD SCI, V678, P193; Fields AL, 2007, J CELL BIOCHEM, V102, P886, DOI 10.1002/jcb.21530; FRANK O, 1976, J NUTR, V106, P606, DOI 10.1093/jn/106.5.606; FRIEDMAN H, 1989, ARCH BIOCHEM BIOPHYS, V269, P69, DOI 10.1016/0003-9861(89)90087-8; Grummer MA, 1995, ALCOHOL CLIN EXP RES, V19, P1376, DOI 10.1111/j.1530-0277.1995.tb00995.x; GRUMMER MA, 1993, ALCOHOL CLIN EXP RES, V17, P592, DOI 10.1111/j.1530-0277.1993.tb00805.x; Holson RR, 1997, NEUROTOXICOL TERATOL, V19, P335, DOI 10.1016/S0892-0362(97)00039-1; Holson RR, 1997, NEUROTOXICOL TERATOL, V19, P355, DOI 10.1016/S0892-0362(97)00041-X; HORST RL, 1995, BIOCHEMISTRY-US, V34, P1203, DOI 10.1021/bi00004a013; Kane MA, 2005, BIOCHEM J, V388, P363, DOI 10.1042/BJ20041867; Kane MA, 2008, ANAL BIOCHEM, V378, P71, DOI 10.1016/j.ab.2008.03.038; Kane MA, 2008, ANAL CHEM, V80, P1702, DOI 10.1021/ac702030f; Kawaguchi R, 2007, SCIENCE, V315, P820, DOI 10.1126/science.1136244; KIM KH, 1990, MOL ENDOCRINOL, V4, P1679, DOI 10.1210/mend-4-11-1679; Leo MA, 1999, AM J CLIN NUTR, V69, P1071; Liu C, 2002, ALCOHOL CLIN EXP RES, V26, P1703, DOI 10.1097/01.ALC.0000037135.09289.69; Liu Y, 2008, J NEUROCHEM, V106, P1104, DOI 10.1111/j.1471-4159.2008.05445.x; Mark M, 2006, ANNU REV PHARMACOL, V46, P451, DOI 10.1146/annurev.pharmtox.46.120604.141156; Molotkov A, 2002, J BIOL CHEM, V277, P22553, DOI 10.1074/jbc.M201603200; Mora JR, 2008, NAT REV IMMUNOL, V8, P685, DOI 10.1038/nri2378; Napoli JL, 1999, BBA-MOL CELL BIOL L, V1440, P139, DOI 10.1016/S1388-1981(99)00117-1; Noy N, 2000, BIOCHEM J, V348, P481, DOI 10.1042/0264-6021:3480481; Noy N, 2007, BIOCHEMISTRY-US, V46, P13461, DOI 10.1021/bi7018699; Oscar-Berman M, 2003, ALCOHOL RES HEALTH, V27, P125; POSCH KC, 1992, J BIOL CHEM, V267, P19676; Redondo C, 2008, FASEB J, V22, P1043, DOI 10.1096/fj.07-8939com; SATO M, 1981, J NUTR, V111, P2015, DOI 10.1093/jn/111.11.2015; Schug TT, 2007, CELL, V129, P723, DOI 10.1016/j.cell.2007.02.050; Shaw N, 2003, J BIOL CHEM, V278, P41589, DOI 10.1074/jbc.C300368200; Smith SM, 1997, ALCOHOL HEALTH RES W, V21, P287; Stephensen CB, 2001, ANNU REV NUTR, V21, P167, DOI 10.1146/annurev.nutr.21.1.167; Tzimas G, 1996, J NUTR, V126, P2159, DOI 10.1093/jn/126.9.2159; VORHEES CV, 1974, TERATOLOGY, V10, P269, DOI 10.1002/tera.1420100309; VORHEES CV, 1978, TERATOLOGY, V17, P271, DOI 10.1002/tera.1420170305; Wang XD, 2005, ALCOHOL, V35, P251, DOI 10.1016/j.alcohol.2005.04.006; Warren KR, 2001, ALCOHOL RES HEALTH, V25, P153; Zakhari S, 2006, ALCOHOL RES HEALTH, V29, P245	51	62	63	1	17	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	MAR	2010	24	3					823	832		10.1096/fj.09-141572	http://dx.doi.org/10.1096/fj.09-141572			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	561KE	19890016	Green Published			2022-12-25	WOS:000274974600018
J	Akech, J; Wixted, JJ; Bedard, K; van der Deen, M; Hussain, S; Guise, TA; van Wijnen, AJ; Stein, JL; Languino, LR; Altieri, DC; Pratap, J; Keller, E; Stein, GS; Lian, JB				Akech, J.; Wixted, J. J.; Bedard, K.; van der Deen, M.; Hussain, S.; Guise, T. A.; van Wijnen, A. J.; Stein, J. L.; Languino, L. R.; Altieri, D. C.; Pratap, J.; Keller, E.; Stein, G. S.; Lian, J. B.			Runx2 association with progression of prostate cancer in patients: mechanisms mediating bone osteolysis and osteoblastic metastatic lesions	ONCOGENE			English	Article						Runx2; bone metastasis; prostate cancer tissue arrays	MATRIX METALLOPROTEINASES; TRANSCRIPTION FACTORS; TUMOR-CELLS; EXPRESSION; DIFFERENTIATION; INTERLEUKIN-8; SIALOPROTEIN; OSTEOCALCIN; ACTIVATION; PROMOTE	Runx2, a bone-specific transcriptional regulator, is abnormally expressed in highly metastatic prostate cancer cells. Here, we identified the functional activities of Runx2 in facilitating tumor growth and osteolysis. Our studies show that negligible Runx2 is found in normal prostate epithelial and non-metastatic LNCaP prostate cancer cells. In the intra-tibial metastasis model, high Runx2 levels are associated with development of large tumors, increased expression of metastasis-related genes (MMP9, MMP13, VEGF, Osteopontin) and secreted bone-resorbing factors (PTHrP, IL8) promoting osteolytic disease. Runx2 siRNA treatment of PC3 cells decreased cell migration and invasion through Matrigel in vitro, and in vivo shRunx2 expression in PC3 cells blocked their ability to survive in the bone microenvironment. Mechanisms of Runx2 function were identified in co-culture studies showing that PC3 cells promote osteoclastogenesis and inhibit osteoblast activity. The clinical significance of these findings is supported by human tissue microarray studies of prostate tumors at stages of cancer progression, in which Runx2 is expressed in both adenocarcinomas and metastatic tumors. Together these findings indicate that Runx2 is a key regulator of events associated with prostate cancer metastatic bone disease. Oncogene (2010) 29, 811-821; doi:10.1038/onc.2009.389; published online 16 November 2009	[Akech, J.; Bedard, K.; van der Deen, M.; Hussain, S.; van Wijnen, A. J.; Stein, J. L.; Pratap, J.; Stein, G. S.; Lian, J. B.] Univ Massachusetts, Sch Med, Dept Cell Biol, Worcester, MA 01655 USA; [Akech, J.; Wixted, J. J.; Bedard, K.; van der Deen, M.; Hussain, S.; van Wijnen, A. J.; Stein, J. L.; Languino, L. R.; Altieri, D. C.; Pratap, J.; Stein, G. S.; Lian, J. B.] Univ Massachusetts, Sch Med, Ctr Canc, Prostate Canc Discovery & Dev Program, Worcester, MA 01655 USA; [Wixted, J. J.] Univ Massachusetts, Sch Med, Dept Orthoped Surg & Rehabil, Worcester, MA 01655 USA; [Guise, T. A.] Indiana Univ, Sch Med, Dept Internal Med, Indianapolis, IN USA; [Languino, L. R.; Altieri, D. C.] Univ Massachusetts, Sch Med, Dept Canc Biol, Worcester, MA 01655 USA; [Keller, E.] Univ Michigan, Sch Med, Dept Urol, Ann Arbor, MI USA	University of Massachusetts System; University of Massachusetts Worcester; University of Massachusetts System; University of Massachusetts Worcester; University of Massachusetts System; University of Massachusetts Worcester; Indiana University System; Indiana University-Purdue University Indianapolis; University of Massachusetts System; University of Massachusetts Worcester; University of Michigan System; University of Michigan	Lian, JB (corresponding author), Univ Massachusetts, Sch Med, Dept Cell Biol, 55 Lake Ave N, Worcester, MA 01655 USA.	jane.lian@umassmed.edu	van Wijnen, Andre J./AAG-3578-2019; Keller, Evan T/M-1446-2016	van Wijnen, Andre J./0000-0002-4458-0946; Keller, Evan T/0000-0002-7592-7535; Languino, Lucia/0000-0001-9011-7031	NIH [PO1CA082834, RO1CA89720, RO1CA090917, P01CA093900, SPORE P50CA69568, R01CA069158]; Our Danny Cancer Fund post-doctoral fellowship [ODCF 114357]; NATIONAL CANCER INSTITUTE [R01CA109874, R01CA089720, R01CA090917, R01CA069158, P01CA082834, P50CA069568, P01CA093900] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR039588, R01AR049069] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH [R37DE012528] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Our Danny Cancer Fund post-doctoral fellowship; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))	We acknowledge the following for providing us with prostate cancer cell lines: RWPE, George Barnes (Boston University School of Medicine); PC3-H and C4-2B, Leland Chung (Emory University School of Medicine). This work was supported by NIH Grants PO1CA082834 (GSS); RO1CA89720 (LRL); RO1CA090917 (DCA); P01CA093900 and SPORE P50CA69568 (EK); R01CA069158 (TAG); and Our Danny Cancer Fund post-doctoral fellowship, ODCF 114357 (JA). The contents of this article are solely the responsibility of the authors and do not necessarily represent the official views of the National Institutes of Health.	Altieri DC, 2008, ONCOGENE, V27, P6276, DOI 10.1038/onc.2008.303; Araki S, 2007, CANCER RES, V67, P6854, DOI 10.1158/0008-5472.CAN-07-1162; Armstrong AP, 2008, PROSTATE, V68, P92, DOI 10.1002/pros.20678; Barnes GL, 2004, CANCER RES, V64, P4506, DOI 10.1158/0008-5472.CAN-03-3851; Barnes GL, 2003, CANCER RES, V63, P2631; Bendre MS, 2005, CANCER RES, V65, P11001, DOI 10.1158/0008-5472.CAN-05-2630; Blyth K, 2005, NAT REV CANCER, V5, P376, DOI 10.1038/nrc1607; Brown JM, 2001, UROLOGY, V57, P611, DOI 10.1016/S0090-4295(00)01122-5; Clines GA, 2007, MOL ENDOCRINOL, V21, P486, DOI 10.1210/me.2006-0346; Dai JL, 2004, CANCER RES, V64, P994, DOI 10.1158/0008-5472.CAN-03-1382; Deryugina EI, 2006, CANCER METAST REV, V25, P9, DOI 10.1007/s10555-006-7886-9; Edwards CM, 2008, BONE, V42, P1007, DOI 10.1016/j.bone.2008.01.027; Egeblad M, 2002, NAT REV CANCER, V2, P161, DOI 10.1038/nrc745; Fornaro M, 2003, J BIOL CHEM, V278, P50402, DOI 10.1074/jbc.M307627200; Fu Z, 2006, PROSTATE, V66, P248, DOI 10.1002/pros.20319; Glinsky GV, 2006, CELL CYCLE, V5, P191, DOI 10.4161/cc.5.2.2320; Guise TA, 2006, CLIN CANCER RES, V12, p6213S, DOI 10.1158/1078-0432.CCR-06-1007; Hall CL, 2006, J CELL BIOCHEM, V97, P661, DOI 10.1002/jcb.20735; Hassan MQ, 2004, MOL CELL BIOL, V24, P9248, DOI 10.1128/MCB.24.20.9248-9261.2004; Huang WC, 2005, CANCER RES, V65, P2303, DOI 10.1158/0008-5472.CAN-04-3448; Inman CK, 2003, J BIOL CHEM, V278, P48684, DOI 10.1074/jbc.M308001200; Javed A, 2005, P NATL ACAD SCI USA, V102, P1454, DOI 10.1073/pnas.0409121102; Keller ET, 2004, J CELL BIOCHEM, V91, P718, DOI 10.1002/jcb.10662; Kingsley LA, 2007, MOL CANCER THER, V6, P2609, DOI 10.1158/1535-7163.MCT-07-0234; Li ZG, 2008, ONCOGENE, V27, P596, DOI 10.1038/sj.onc.1210694; Li ZG, 2008, J CLIN INVEST, V118, P2697, DOI 10.1172/JCI33093; Liao JH, 2006, CANCER METAST REV, V25, P559, DOI 10.1007/s10555-006-9033-z; Morgia G, 2005, UROL RES, V33, P44, DOI 10.1007/s00240-004-0440-8; Mundy GR, 2002, NAT REV CANCER, V2, P584, DOI 10.1038/nrc867; Pratap J, 2006, CANCER METAST REV, V25, P589, DOI 10.1007/s10555-006-9032-0; Pratap J, 2005, MOL CELL BIOL, V25, P8581, DOI 10.1128/MCB.25.19.8581-8591.2005; Pratap J, 2003, CANCER RES, V63, P5357; Pratap J, 2008, CANCER RES, V68, P7795, DOI 10.1158/0008-5472.CAN-08-1078; Roca H, 2008, J BIOL CHEM, V283, P25057, DOI 10.1074/jbc.M801073200; Roudier MP, 2008, J UROLOGY, V180, P1154, DOI 10.1016/j.juro.2008.04.140; Rubin MA, 2000, CLIN CANCER RES, V6, P1038; Selvamurugan N, 2006, J CELL BIOCHEM, V99, P545, DOI 10.1002/jcb.20878; Shao JS, 2005, J CLIN INVEST, V115, P1210, DOI 10.1172/JCI200524140; THALMANN GN, 1994, CANCER RES, V54, P2577; Yang QL, 2008, MATRIX BIOL, V27, P589, DOI 10.1016/j.matbio.2008.06.005; Young DW, 2007, NATURE, V445, P442, DOI 10.1038/nature05473; Zaidi SK, 2007, P NATL ACAD SCI USA, V104, P19861, DOI 10.1073/pnas.0709650104; Zaidi SK, 2007, NAT REV CANCER, V7, P454, DOI 10.1038/nrc2149; Zayzafoon M, 2004, J BIOL CHEM, V279, P3662, DOI 10.1074/jbc.M308158200	44	200	207	1	12	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 11	2010	29	6					811	821		10.1038/onc.2009.389	http://dx.doi.org/10.1038/onc.2009.389			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	553WP	19915614	Green Accepted			2022-12-25	WOS:000274397800004
J	Hammerich-Hille, S; Kaipparettu, BA; Tsimelzon, A; Creighton, CJ; Jiang, SM; Polo, JM; Melnick, A; Meyer, R; Oesterreich, S				Hammerich-Hille, Stephanie; Kaipparettu, Benny A.; Tsimelzon, Anna; Creighton, Chad J.; Jiang, Shiming; Polo, Jose M.; Melnick, Ari; Meyer, Rene; Oesterreich, Steffi			SAFB1 Mediates Repression of Immune Regulators and Apoptotic Genes in Breast Cancer Cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MATRIX ATTACHMENT REGION; MAR-BINDING PROTEIN; RECEPTOR COREPRESSOR; DISTINCT CLASSES; HET/SAF-B; EXPRESSION; ESTROGEN; TRANSCRIPTION; SATB1; CHROMATIN	The scaffold attachment factors SAFB1 and SAFB2 are paralogs, which are involved in cell cycle regulation, apoptosis, differentiation, and stress response. They have been shown to function as estrogen receptor corepressors, and there is evidence for a role in breast tumorigenesis. To identify their endogenous target genes in MCF-7 breast cancer cells, we utilized a combined approach of chromatin immunoprecipitation (ChIP)-on-chip and gene expression array studies. By performing ChIP-on-chip on microarrays containing 24,000 promoters, we identified 541 SAFB1/SAFB2-binding sites in promoters of known genes, with significant enrichment on chromosomes 1 and 6. Gene expression analysis revealed that the majority of target genes were induced in the absence of SAFB1 or SAFB2 and less were repressed. Interestingly, there was no significant overlap between the genes identified by ChIP-on-chip and gene expression array analysis, suggesting regulation through regions outside the proximal promoters. In contrast to SAFB2, which shared most of its target genes with SAFB1, SAFB1 had many unique target genes, most of them involved in the regulation of the immune system. A subsequent analysis of the estrogen treatment group revealed that 12% of estrogen-regulated genes were dependent on SAFB1, with the majority being estrogen-repressed genes. These were primarily genes involved in apoptosis, such as BBC3, NEDD9, and OPG. Thus, this study confirms the primary role of SAFB1/SAFB2 as corepressors and also uncovers a previously unknown role for SAFB1 in the regulation of immune genes and in estrogen-mediated repression of genes.	[Hammerich-Hille, Stephanie; Kaipparettu, Benny A.; Tsimelzon, Anna; Creighton, Chad J.; Jiang, Shiming; Oesterreich, Steffi] Texas Childrens Canc Ctr, Dept Med & Mol & Cellular Biol, Lester & Sue Smith Breast Ctr, Houston, TX 77030 USA; [Meyer, Rene] Texas Childrens Canc Ctr, Dept Pediat Hematol Oncol, Houston, TX 77030 USA; [Polo, Jose M.; Melnick, Ari] Albert Einstein Coll Med, Dept Dev & Mol Biol, Bronx, NY 10461 USA	Texas Children's Cancer Center; Texas Children's Cancer Center; Yeshiva University; Albert Einstein College of Medicine	Oesterreich, S (corresponding author), Baylor Coll Med, Lester & Sue Smith Breast Ctr, Houston, TX 77030 USA.	steffio@breastcenter.tmc.edu	Melnick, Ari/AAA-5763-2020	Polo, Jose M/0000-0002-2531-778X; Kaipparettu, Benny/0000-0003-3444-4307	National Institutes of Health [R01 CA9721305, P01 CA03019526, P30CA125123]; Dr. Mildred Scheel Stiftung, Deutsche Krebshilfe (German Cancer Aid); Baylor College of Medicine; NATIONAL CANCER INSTITUTE [R01CA097213, P30CA125123] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Dr. Mildred Scheel Stiftung, Deutsche Krebshilfe (German Cancer Aid)(Deutsche Krebshilfe); Baylor College of Medicine; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This work was supported, in whole or in part, by National Institutes of Health Grants R01 CA9721305 (to S. O.) and P01 CA03019526 (to S. O.). This work was also supported by Dr. Mildred Scheel Stiftung, Deutsche Krebshilfe (German Cancer Aid) (to S. H. H.).; We thank the Dan L. Duncan Cancer Center Protein Core (supported by National Institutes of Health Grant P30CA125123), Baylor College of Medicine, for generation of monoclonal SAFB1 antibodies. We also thank Dr. Adrian Lee for input and comments on the manuscript.	Acevedo ML, 2004, MOL CELL, V13, P725, DOI 10.1016/S1097-2765(04)00121-2; Alvarez JD, 2000, GENE DEV, V14, P521; Benjamini Y, 2001, BEHAV BRAIN RES, V125, P279, DOI 10.1016/S0166-4328(01)00297-2; Bergman A, 2008, BMC MED GENET, V9, DOI 10.1186/1471-2350-9-108; Britanova O, 2005, EUR J NEUROSCI, V21, P658, DOI 10.1111/j.1460-9568.2005.03897.x; Cai ST, 2006, NAT GENET, V38, P1278, DOI 10.1038/ng1913; Creighton CJ, 2006, GENOME BIOL, V7, DOI 10.1186/gb-2006-7-4-r28; De Preter K, 2008, NUCLEIC ACIDS RES, V36, DOI 10.1093/nar/gkn114; de Visser KE, 2006, NAT REV CANCER, V6, P24, DOI 10.1038/nrc1782; Debril MB, 2005, J MOL ENDOCRINOL, V35, P503, DOI 10.1677/jme.1.01856; DeNardo DG, 2005, MOL ENDOCRINOL, V19, P362, DOI 10.1210/me.2004-0267; Denegri M, 2001, MOL BIOL CELL, V12, P3502, DOI 10.1091/mbc.12.11.3502; Dennis G, 2003, GENOME BIOL, V4, DOI 10.1186/gb-2003-4-9-r60; Deroo BJ, 2006, J CLIN INVEST, V116, P561, DOI 10.1172/JCI27987; Dickinson LA, 1997, J BIOL CHEM, V272, P11463; DICKINSON LA, 1992, CELL, V70, P631, DOI 10.1016/0092-8674(92)90432-C; Dobreva G, 2003, GENE DEV, V17, P3048, DOI 10.1101/gad.1153003; Dobrzycka KM, 2006, CANCER RES, V66, P7859, DOI 10.1158/0008-5472.CAN-06-1381; Dobrzycka KM, 2003, ENDOCR-RELAT CANCER, V10, P517, DOI 10.1677/erc.0.0100517; Frasor J, 2003, ENDOCRINOLOGY, V144, P4562, DOI 10.1210/en.2003-0567; Galande S, 2007, CURR OPIN GENET DEV, V17, P408, DOI 10.1016/j.gde.2007.08.003; HAMMERICHHILLE S, 2009, BREAST CANC RES TREA; Han HJ, 2008, NATURE, V452, P187, DOI 10.1038/nature06781; Hite KC, 2009, BIOCHEM CELL BIOL, V87, P219, DOI 10.1139/O08-115; Horike S, 2005, NAT GENET, V37, P31, DOI 10.1038/ng1491; Isogai Y, 2007, GENE DEV, V21, P2936, DOI 10.1101/gad.1608807; Ivanova M, 2005, MOL CELL BIOL, V25, P2995, DOI 10.1128/MCB.25.8.2995-3006.2005; Jeffers JR, 2003, CANCER CELL, V4, P321, DOI 10.1016/S1535-6108(03)00244-7; Jiang SM, 2006, MOL ENDOCRINOL, V20, P311, DOI 10.1210/me.2005-0100; Kininis M, 2007, MOL CELL BIOL, V27, P5090, DOI 10.1128/MCB.00083-07; Kumar P, 2007, NAT CELL BIOL, V9, P45, DOI 10.1038/ncb1516; Lee YB, 2007, EXP CELL RES, V313, P3914, DOI 10.1016/j.yexcr.2007.06.023; Li C, 2001, P NATL ACAD SCI USA, V98, P31, DOI 10.1073/pnas.011404098; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; Miller BJ, 2003, AM J HUM GENET, V73, P748, DOI 10.1086/378522; Nayler O, 1998, NUCLEIC ACIDS RES, V26, P3542, DOI 10.1093/nar/26.15.3542; O'Malley BW, 2007, MOL ENDOCRINOL, V21, P1009, DOI 10.1210/me.2007-0012; Oesterreich S, 2000, MOL ENDOCRINOL, V14, P369, DOI 10.1210/me.14.3.369; Oesterreich S, 1997, J CELL BIOCHEM, V67, P275, DOI 10.1002/(SICI)1097-4644(19971101)67:2<275::AID-JCB13>3.0.CO;2-E; Oesterreich S, 2001, BRIT J CANCER, V84, P493, DOI 10.1054/bjoc.2000.1606; Polo JM, 2007, P NATL ACAD SCI USA, V104, P3207, DOI 10.1073/pnas.0611399104; Rae JM, 2005, BREAST CANCER RES TR, V92, P141, DOI 10.1007/s10549-005-1483-4; Renz A, 1996, NUCLEIC ACIDS RES, V24, P843, DOI 10.1093/nar/24.5.843; Sergeant KA, 2007, J CELL SCI, V120, P309, DOI 10.1242/jcs.03344; Szemes M, 2006, NEUROCHEM RES, V31, P237, DOI 10.1007/s11064-005-9012-8; Townson SM, 2004, J BIOL CHEM, V279, P26074, DOI 10.1074/jbc.M313726200; Townson SM, 2003, J BIOL CHEM, V278, P20059, DOI 10.1074/jbc.M212988200; Townson SM, 2000, CLIN CANCER RES, V6, P3788; Traweger A, 2003, J BIOL CHEM, V278, P2692, DOI 10.1074/jbc.M206821200; Yasui D, 2002, NATURE, V419, P641, DOI 10.1038/nature01084	50	24	24	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 5	2010	285	6					3608	3616		10.1074/jbc.M109.066431	http://dx.doi.org/10.1074/jbc.M109.066431			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	564YF	19901029	Green Published, hybrid			2022-12-25	WOS:000275254000012
J	Yamada, K; Osakabe, Y; Mizoi, J; Nakashima, K; Fujita, Y; Shinozaki, K; Yamaguchi-Shinozaki, K				Yamada, Kohji; Osakabe, Yuriko; Mizoi, Junya; Nakashima, Kazuo; Fujita, Yasunari; Shinozaki, Kazuo; Yamaguchi-Shinozaki, Kazuko			Functional Analysis of an Arabidopsis thaliana Abiotic Stress-inducible Facilitated Diffusion Transporter for Monosaccharides	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RESPONSIVE GENE-EXPRESSION; PUTATIVE SUGAR TRANSPORTER; GLUCOSE-TRANSPORTER; MESOPHYLL PROTOPLASTS; SUCROSE TRANSPORTER; VACUOLAR INVERTASE; SIEVE ELEMENTS; ABSCISIC-ACID; IDENTIFICATION; PLANTS	Sugars play indispensable roles in biological reactions and are distributed into various tissues or organelles via transporters in plants. Under abiotic stress conditions, plants accumulate sugars as a means to increase stress tolerance. Here, we report an abiotic stress-inducible transporter for monosaccharides from Arabidopsis thaliana that is termed ESL1 (ERD six-like 1). Expression of ESL1 was induced under drought and high salinity conditions and with exogenous application of abscisic acid. Promoter analyses using beta-glucuronidase and green fluorescent protein reporters revealed that ESL1 is mainly expressed in peri-cycle and xylem parenchyma cells. The fluorescence of ESL1-green fluorescent protein-fused protein was detected at tonoplast in transgenic Arabidopsis plants and tobacco BY-2 cells. Furthermore, alanine-scanning mutagenesis revealed that an N-terminal LXXXLL motif in ESL1 was essential for its localization at the tonoplast. Transgenic BY-2 cells expressing mutated ESL1, which was localized at the plasma membrane, showed an uptake ability for monosaccharides. Moreover, the value of Km for glucose uptake activity of mutated ESL1 in the transgenic BY-2 cells was extraordinarily high, and the transport activity was independent from a proton gradient. These results indicate that ESL1 is a low affinity facilitated diffusion transporter. Finally, we detected that vacuolar invertase activity was increased under abiotic stress conditions, and the expression patterns of vacuolar invertase genes were similar to that of ESL1. Under abiotic stress conditions, ESL1 might function coordinately with the vacuolar invertase to regulate osmotic pressure by affecting the accumulation of sugar in plant cells.	[Yamada, Kohji; Osakabe, Yuriko; Yamaguchi-Shinozaki, Kazuko] Univ Tokyo, Grad Sch Agr & Life Sci, Lab Plant Mol Physiol, Tokyo 1138657, Japan; [Yamada, Kohji; Mizoi, Junya; Nakashima, Kazuo; Fujita, Yasunari; Yamaguchi-Shinozaki, Kazuko] Japan Int Res Ctr Agr Sci, Biol Resources Div, Tsukuba, Ibaraki 3058686, Japan; [Shinozaki, Kazuo] RIKEN Plant Sci Ctr, Kanagawa 2030045, Japan	University of Tokyo; Japan International Research Center for Agricultural Sciences; RIKEN	Yamaguchi-Shinozaki, K (corresponding author), Univ Tokyo, Grad Sch Agr & Life Sci, Lab Plant Mol Physiol, Tokyo 1138657, Japan.	akys@mail.ecc.u-tokyo.ac.jp	Shinozaki, Kazuo/G-4202-2013; Fujita, Yasunari/P-9861-2018; Nakashima, Kazuo/ABD-9576-2021; Osakabe, Yuriko/GRI-9818-2022; Yamaguchi-Shinozaki, Kazuko/K-9004-2015; Mizoi, Junya/Y-6261-2019; Osakabe, Yuriko/Y-2507-2019; Yamada, Kohji/O-6731-2015; Shinozaki, Kazuo/AAB-4945-2019	Shinozaki, Kazuo/0000-0002-6317-9867; Fujita, Yasunari/0000-0002-5036-8319; Osakabe, Yuriko/0000-0001-5503-1427; Yamaguchi-Shinozaki, Kazuko/0000-0002-0249-8258; Mizoi, Junya/0000-0002-3383-8059; Osakabe, Yuriko/0000-0001-5503-1427; Yamada, Kohji/0000-0001-7779-9656; Shinozaki, Kazuo/0000-0002-6317-9867; Nakashima, Kazuo/0000-0001-6417-8316	Ministry of Education, Culture, Sports, Science, and Technology of Japan	Ministry of Education, Culture, Sports, Science, and Technology of Japan(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT))	This work was supported by a grant-in-aid for scientific research in priority areas from the Ministry of Education, Culture, Sports, Science, and Technology of Japan.	Aluri S, 2007, P NATL ACAD SCI USA, V104, P2537, DOI 10.1073/pnas.0610278104; Augustin R, 2005, TRAFFIC, V6, P1196, DOI 10.1111/j.1600-0854.2005.00354.x; Barth I, 2003, PLANT CELL, V15, P1375, DOI 10.1105/tpc.010967; Bonifacino JS, 2003, ANNU REV BIOCHEM, V72, P395, DOI 10.1146/annurev.biochem.72.121801.161800; BRISKIN DP, 1985, PLANT PHYSIOL, V78, P871, DOI 10.1104/pp.78.4.871; Buttner M, 2007, FEBS LETT, V581, P2318, DOI 10.1016/j.febslet.2007.03.016; Chiou TJ, 1996, PLANT PHYSIOL, V110, P511, DOI 10.1104/pp.110.2.511; HaouazineTakvorian N, 1997, GENE, V197, P239, DOI 10.1016/S0378-1119(97)00268-0; Huang SH, 2007, CELL METAB, V5, P237, DOI 10.1016/j.cmet.2007.03.006; Ibberson M, 2000, J BIOL CHEM, V275, P4607, DOI 10.1074/jbc.275.7.4607; Jaillais Y, 2008, PLANT J, V53, P237, DOI 10.1111/j.1365-313X.2007.03338.x; Janvier K, 2003, J CELL BIOL, V163, P1281, DOI 10.1083/jcb.200307157; KIYOSUE T, 1994, PLANT MOL BIOL, V25, P791, DOI 10.1007/BF00028874; Kiyosue T, 1998, BBA-BIOMEMBRANES, V1370, P187, DOI 10.1016/S0005-2736(98)00007-8; Klepek YS, 2005, PLANT CELL, V17, P204, DOI 10.1105/tpc.104.026641; Lalonde S, 2004, ANNU REV PLANT BIOL, V55, P341, DOI 10.1146/annurev.arplant.55.031903.141758; MARTINOIA E, 1987, J PLANT PHYSIOL, V131, P467, DOI 10.1016/S0176-1617(87)80289-4; Maruyama K, 2004, PLANT J, V38, P982, DOI 10.1111/j.1365-313X.2004.02100.x; MATSUOKA K, 1991, P NATL ACAD SCI USA, V88, P834, DOI 10.1073/pnas.88.3.834; Meyer S, 2004, PLANT PHYSIOL, V134, P684, DOI 10.1104/pp.103.033399; Mizuno S, 2007, PLANT J, V50, P751, DOI 10.1111/j.1365-313X.2007.03083.x; OHYAMA A, 1995, PLANT CELL PHYSIOL, V36, P369, DOI 10.1093/oxfordjournals.pcp.a078769; Osakabe Y, 2005, PLANT CELL, V17, P1105, DOI 10.1105/tpc.104.027474; Pelleschi S, 1999, PLANT MOL BIOL, V39, P373, DOI 10.1023/A:1006116310463; Petrasek J, 2006, SCIENCE, V312, P914, DOI 10.1126/science.1123542; Qin F, 2008, PLANT CELL, V20, P1693, DOI 10.1105/tpc.107.057380; RAUSCH T, 1987, PLANT PHYSIOL, V85, P996, DOI 10.1104/pp.85.4.996; Reinders A, 2005, J BIOL CHEM, V280, P1594, DOI 10.1074/jbc.M410831200; Roitsch T, 2004, TRENDS PLANT SCI, V9, P606, DOI 10.1016/j.tplants.2004.10.009; Rolland F, 2006, ANNU REV PLANT BIOL, V57, P675, DOI 10.1146/annurev.arplant.57.032905.105441; Sacchi GA, 2000, PLANT SOIL, V220, P1, DOI 10.1023/A:1004701912815; Sakuma Y, 2006, PLANT CELL, V18, P1292, DOI 10.1105/tpc.105.035881; SAUER N, 1990, EMBO J, V9, P3045, DOI 10.1002/j.1460-2075.1990.tb07500.x; Smith AM, 2005, ANNU REV PLANT BIOL, V56, P73, DOI 10.1146/annurev.arplant.56.032604.144257; Taji T, 2002, PLANT J, V29, P417, DOI 10.1046/j.0960-7412.2001.01227.x; Tang XW, 1996, PLANTA, V198, P17; Toyofuku K, 2000, PLANT CELL PHYSIOL, V41, P940, DOI 10.1093/pcp/pcd016; Trouverie J, 2004, PLANTA, V219, P894, DOI 10.1007/s00425-004-1289-3; Ueda T, 2001, EMBO J, V20, P4730, DOI 10.1093/emboj/20.17.4730; Uldry M, 2004, PFLUG ARCH EUR J PHY, V447, P480, DOI 10.1007/s00424-003-1085-0; Voitsekhovskaja OV, 2006, PLANT PHYSIOL, V140, P383, DOI 10.1104/pp.105.068312; Weise A, 2000, PLANT CELL, V12, P1345, DOI 10.1105/tpc.12.8.1345; Williams LE, 2000, TRENDS PLANT SCI, V5, P283, DOI 10.1016/S1360-1385(00)01681-2; Wormit A, 2006, PLANT CELL, V18, P3476, DOI 10.1105/tpc.106.047290; Yamaguchi-Shinozaki K, 2006, ANNU REV PLANT BIOL, V57, P781, DOI 10.1146/annurev.arplant.57.032905.105444; Yoo SD, 2007, NAT PROTOC, V2, P1565, DOI 10.1038/nprot.2007.199	46	123	137	1	39	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 8	2010	285	2					1138	1146		10.1074/jbc.M109.054288	http://dx.doi.org/10.1074/jbc.M109.054288			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	539MH	19901034	hybrid, Green Published			2022-12-25	WOS:000273258200036
J	Konishi, J; Yi, F; Chen, X; Vo, H; Carbone, DP; Dang, TP				Konishi, J.; Yi, F.; Chen, X.; Vo, H.; Carbone, D. P.; Dang, T. P.			Notch3 cooperates with the EGFR pathway to modulate apoptosis through the induction of bim	ONCOGENE			English	Article						Notch3; bim; apoptosis; lung cancer	DOWN-REGULATION; ACTIVATION; CELLS; GROWTH; BCL-2; INHIBITION; EXPRESSION; FAMILY; CANCER	Notch signaling is a highly conserved pathway important for normal embryonic development and cancer. We previously demonstrated a role for Notch3 in lung cancer pathogenesis. Notch3 inhibition resulted in tumor apoptosis and growth suppression. In vitro, these effects were enhanced when the epidermal growth factor receptor (EGFR) pathway was also inhibited, suggesting significant cross-talk between the two pathways. How Notch3 and epidermal growth factor receptor-mitogen-activated protein kinase (EGFR-MAPK) pathways cooperate in modulating apoptosis is not yet known. In this study, we provide evidence that Notch3 regulates Bim, a BH-3-only protein, via MAPK signaling. Furthermore, loss of Bim expression prevents tumor apoptosis induced by Notch3 inhibition. Using c-secretase inhibitor and erlotinib in a xenograft model, Bim induction and tumor inhibition were observed to be enhanced compared with either agent alone, consistent with our previous observation of significant synergism between Notch and EGFR-ras-MAPK signaling. Thus, our data support the hypothesis that Notch3 not only has a crucial role in lung cancer through regulating apoptosis, but also cooperates with the EGFR-MAPK pathway in modulating Bim. Oncogene (2010) 29, 589-596; doi: 10.1038/onc.2009.366; published online 2 November 2009	[Konishi, J.; Yi, F.; Chen, X.; Vo, H.; Carbone, D. P.; Dang, T. P.] Vanderbilt Ingram Canc Ctr, Div Hematol & Med Oncol, Nashville, TN 37232 USA	Vanderbilt University	Dang, TP (corresponding author), Vanderbilt Ingram Canc Ctr, Div Hematol & Med Oncol, 658 PRB,2220 Pierce Ave, Nashville, TN 37232 USA.	thao.p.dang@vanderbilt.edu	Nguyen, Phu-Huan Vo/HGF-3643-2022; Sakakibara-Konishi, Jun/G-5941-2012	Nguyen, Phu-Huan Vo/0000-0002-6326-1692; 	 [NCI 1R01 CA115707]; NATIONAL CANCER INSTITUTE [R01CA115707] Funding Source: NIH RePORTER	; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This study was supported by the Grant NCI 1R01 CA115707.	Bellavia D, 2000, EMBO J, V19, P3337, DOI 10.1093/emboj/19.13.3337; Beverly LJ, 2005, CANCER RES, V65, P7159, DOI 10.1158/0008-5472.CAN-05-1664; Biswas SC, 2007, J BIOL CHEM, V282, P29368, DOI 10.1074/jbc.M702634200; Bocchetta M, 2003, ONCOGENE, V22, P81, DOI 10.1038/sj.onc.1206097; Borner C, 2003, MOL IMMUNOL, V39, P615, DOI 10.1016/S0161-5890(02)00252-3; Campos AH, 2002, CIRC RES, V91, P999, DOI 10.1161/01.RES.0000044944.99984.25; Costa DB, 2007, PLOS MED, V4, P1669, DOI 10.1371/journal.pmed.0040315; Curry CL, 2005, ONCOGENE, V24, P6333, DOI 10.1038/sj.onc.1208783; Dang TP, 2000, J NATL CANCER I, V92, P1355, DOI 10.1093/jnci/92.16.1355; Das I, 2004, J BIOL CHEM, V279, P30771, DOI 10.1074/jbc.M309252200; Dievart A, 1999, ONCOGENE, V18, P5973, DOI 10.1038/sj.onc.1202991; Duechler M, 2005, LEUKEMIA, V19, P260, DOI 10.1038/sj.leu.2403592; Fitzgerald K, 2000, ONCOGENE, V19, P4191, DOI 10.1038/sj.onc.1203766; Gomez-Bougie P, 2005, ONCOGENE, V24, P8076, DOI 10.1038/sj.onc.1208949; Gong YX, 2007, PLOS MED, V4, P1655, DOI 10.1371/journal.pmed.0040294; Haruki N, 2005, CANCER RES, V65, P3555, DOI 10.1158/0008-5472.CAN-04-3132; Heiser PW, 2004, CELL CYCLE, V3, P270; Konishi J, 2007, CANCER RES, V67, P8051, DOI 10.1158/0008-5472.CAN-07-1022; Lewis HD, 2007, CHEM BIOL, V14, P209, DOI 10.1016/j.chembiol.2006.12.010; Qin JZ, 2004, MOL CANCER THER, V3, P895; Reedijk M, 2005, CANCER RES, V65, P8530, DOI 10.1158/0008-5472.CAN-05-1069; Roy M, 2007, CURR OPIN GENET DEV, V17, P52, DOI 10.1016/j.gde.2006.12.001; Shinjyo T, 2001, MOL CELL BIOL, V21, P854, DOI 10.1128/MCB.21.3.854-864.2001; Urbich C, 2005, FASEB J, V19, P974, DOI 10.1096/fj.04-2727fje; Wang T, 2007, CELL SIGNAL, V19, P2458, DOI 10.1016/j.cellsig.2007.07.019; Wang YF, 2007, CLIN CANCER RES, V13, P4934, DOI 10.1158/1078-0432.CCR-07-0665; Weijzen S, 2002, NAT MED, V8, P979, DOI 10.1038/nm754	27	69	72	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN	2010	29	4					589	596		10.1038/onc.2009.366	http://dx.doi.org/10.1038/onc.2009.366			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	549WH	19881544	Green Accepted			2022-12-25	WOS:000274084600011
J	Tesniere, A; Schlemmer, F; Boige, V; Kepp, O; Martins, I; Ghiringhelli, F; Aymeric, L; Michaud, M; Apetoh, L; Barault, L; Mendiboure, J; Pignon, JP; Jooste, V; van Endert, P; Ducreux, M; Zitvogel, L; Piard, F; Kroemer, G				Tesniere, A.; Schlemmer, F.; Boige, V.; Kepp, O.; Martins, I.; Ghiringhelli, F.; Aymeric, L.; Michaud, M.; Apetoh, L.; Barault, L.; Mendiboure, J.; Pignon, J-P; Jooste, V.; van Endert, P.; Ducreux, M.; Zitvogel, L.; Piard, F.; Kroemer, G.			Immunogenic death of colon cancer cells treated with oxaliplatin	ONCOGENE			English	Article						apoptosis; dendritic cells; OXP; calreticulin; HMGB1; TLR4	CALRETICULIN EXPOSURE; ANTICANCER CHEMOTHERAPY; COLORECTAL-CANCER; INDUCED APOPTOSIS; IMMUNE-SYSTEM; ANTIGEN; RECEPTOR; POLYMORPHISMS; RADIOTHERAPY; EXPRESSION	Both the pre-apoptotic exposure of calreticulin (CRT) and the post-apoptotic release of high-mobility group box 1 protein (HMGB1) are required for immunogenic cell death elicited by anthracyclins. Here, we show that both oxaliplatin (OXP) and cisplatin (CDDP) were equally efficient in triggering HMGB1 release. However, OXP, but not CDDP, stimulates pre-apoptotic CRT exposure in a series of murine and human colon cancer cell lines. Subcutaneous injection of OXP-treated colorectal cancer (CRC), CT26, cells induced an anticancer immune response that was reduced by short interfering RNA-mediated depletion of CRT or HMGB1. In contrast, CDDP-treated CT26 cells failed to induce anticancer immunity, unless recombinant CRT protein was absorbed into the cells. CT26 tumors implanted in immunocompetent mice responded to OXP treatment in vivo, and this therapeutic response was lost when CRT exposure by CT26 cells was inhibited or when CT26 cells were implanted in immunodeficient mice. The knockout of toll-like receptor 4 (TLR4), the receptor for HMGB1, also resulted in a deficient immune response against OXP-treated CT26 cells. In patients with advanced (stage IV, Duke D) CRC, who received an OXP-based chemotherapeutic regimen, the loss-of-function allele of TLR4 (Asp299Gly in linkage disequilibrium with Thr399Ile, reducing its affinity for HMGB1) was as prevalent as in the general population. However, patients carrying the TLR4 loss-of-function allele exhibited reduced progression-free and overall survival, as compared with patients carrying the normal TLR4 allele. In conclusion, OXP induces immunogenic death of CRC cells, and this effect determines its therapeutic efficacy in CRC patients. Oncogene (2010) 29, 482-491; doi: 10.1038/onc.2009.356; published online 2 November 2009	[Tesniere, A.; Schlemmer, F.; Kepp, O.; Martins, I.; Michaud, M.; Kroemer, G.] Inst Gustave Roussy, INSERM, U848, F-94805 Villejuif, France; [Tesniere, A.; Schlemmer, F.; Kepp, O.; Martins, I.; Aymeric, L.; Michaud, M.; Apetoh, L.; Ducreux, M.; Zitvogel, L.; Kroemer, G.] Univ Paris 11, Orsay, France; [Boige, V.; Ducreux, M.] Inst Gustave Roussy, Dept Med, F-94805 Villejuif, France; [Ghiringhelli, F.] INSERM CRI 866, AVENIR Team, Dijon, France; [Ghiringhelli, F.] Ctr Georges Francois Leclerc, Dijon, France; [Aymeric, L.; Apetoh, L.; Zitvogel, L.] INSERM, U805, Villejuif, France; [Barault, L.; Piard, F.] CHU, Serv Anat Pathol, Dijon, France; [Barault, L.; Piard, F.] INSERM, U866, Dijon, France; [Mendiboure, J.; Pignon, J-P] Inst Gustave Roussy, Serv Biostat & Epidemiol, F-94805 Villejuif, France; [Jooste, V.] Registre Canc Digestifs, Dijon, France; [van Endert, P.] Univ Paris 05, INSERM, U580, Paris, France; [Zitvogel, L.] Inst Gustave Roussy, CIC BT507, F-94805 Villejuif, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UNICANCER; Gustave Roussy; UDICE-French Research Universities; Universite Paris Saclay; UNICANCER; Gustave Roussy; Institut Agro; AgroSup Dijon; Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Bourgogne; UNICANCER; Centre Georges-Francois Leclerc; Institut National de la Sante et de la Recherche Medicale (Inserm); CHU Dijon Bourgogne; Institut Agro; AgroSup Dijon; Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Bourgogne; UNICANCER; Gustave Roussy; Institut Agro; AgroSup Dijon; Universite de Bourgogne; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; UNICANCER; Gustave Roussy	Kroemer, G (corresponding author), Inst Gustave Roussy, INSERM, U848, PR1 39,Rue Camille Desmoulins, F-94805 Villejuif, France.	kroemer@igr.fr	Ducreux, Michel/AAG-9415-2019; Ducreux, Michel/L-7012-2019; van Endert, Peter/R-4606-2017; Kroemer, Guido/AAY-9859-2020; Barault, Ludovic/J-2472-2016; Kepp, Oliver/GPX-8627-2022; Apetoh, Lionel/AIC-2384-2022; li, tao/B-2402-2008; Apetoh, Lionel/G-3310-2014; Jooste, Valerie/AFW-1362-2022; KROEMER, Guido/B-4263-2013; Kepp, Oliver/N-2763-2017	Ducreux, Michel/0000-0001-8649-7449; van Endert, Peter/0000-0003-3782-0750; Barault, Ludovic/0000-0001-5227-5047; Apetoh, Lionel/0000-0002-2774-438X; Apetoh, Lionel/0000-0002-2774-438X; Jooste, Valerie/0000-0002-9902-0700; KROEMER, Guido/0000-0002-9334-4405; Kepp, Oliver/0000-0002-6081-9558; ZITVOGEL, laurence/0000-0003-1596-0998; Aymeric, Laetitia/0000-0001-7459-7231; Schlemmer, Frederic/0000-0003-2113-7113; Boige, Valerie/0000-0002-7817-4663; PIGNON, Jean-Pierre/0000-0003-2047-1582; ghiringhelli, francois/0000-0002-5465-8305	INSERM; FRM; Canceropole Ile-de-France; Institut National du Cancer; Fondation de France; Association Laurette Fugain; Cent pour Sang la Vie; Agence National de la Recherche; Association for International Cancer Research (AICR); European Commission; La Ligue; ARC	INSERM(Institut National de la Sante et de la Recherche Medicale (Inserm)European Commission); FRM(Fondation pour la Recherche Medicale); Canceropole Ile-de-France(Region Ile-de-France); Institut National du Cancer(Institut National du Cancer (INCA) France); Fondation de France(Fondation de France); Association Laurette Fugain; Cent pour Sang la Vie; Agence National de la Recherche(French National Research Agency (ANR)); Association for International Cancer Research (AICR); European Commission(European CommissionEuropean Commission Joint Research Centre); La Ligue; ARC(Australian Research Council)	We thank all the investigators who participated in the FFCD 2000-05 clinical trial; Pierre Laurent Puig for help with DNA extraction and storage; and Patrick Gonin and IGR animal facility for helping with mouse breeding. This study was supported by INSERM (AT); FRM (FS); Canceropole Ile-de-France, Institut National du Cancer, Fondation de France, Association Laurette Fugain, Cent pour Sang la Vie, Agence National de la Recherche, Association for International Cancer Research (AICR), and the European Commission (ApoSys, ChemoRes, Death-Train, RIGHT) (GK); la Ligue and FRM (LA); a fellowship from La Ligue (IM); a fellowship from ARC (MM).	Agnese DM, 2002, J INFECT DIS, V186, P1522, DOI 10.1086/344893; Apetoh L, 2007, IMMUNOL REV, V220, P47, DOI 10.1111/j.1600-065X.2007.00573.x; Apetoh L, 2007, NAT MED, V13, P1050, DOI 10.1038/nm1622; Arbour NC, 2000, NAT GENET, V25, P187, DOI 10.1038/76048; Blacher NE, 2005, PLOS BIOL, V3, P1070, DOI 10.1371/journal.pbio.0030185; BOUCHE CM, 2007, J CLIN ONCOL, V25, P4069; Camus M, 2009, CANCER RES, V69, P2685, DOI 10.1158/0008-5472.CAN-08-2654; Casares N, 2005, J EXP MED, V202, P1691, DOI 10.1084/jem.20050915; Castedo M, 2006, ANN NY ACAD SCI, V1090, P35, DOI 10.1196/annals.1378.004; Ferwerda B, 2007, P NATL ACAD SCI USA, V104, P16645, DOI 10.1073/pnas.0704828104; Galon J, 2006, SCIENCE, V313, P1960, DOI 10.1126/science.1129139; Hsu WM, 2005, ANN ONCOL, V16, P314, DOI 10.1093/annonc/mdi062; Kelland L, 2007, NAT REV CANCER, V7, P573, DOI 10.1038/nrc2167; LAANE E, 2009, CELL DEATH DIFFER; Matzinger P, 2002, SCIENCE, V296, P301, DOI 10.1126/science.1071059; Mehta AM, 2008, CANCER IMMUNOL IMMUN, V57, P197, DOI 10.1007/s00262-007-0362-8; Muggia FM, 2004, J CHEMOTHERAPY, V16, P77, DOI 10.1179/joc.2004.16.Supplement-1.77; Netea-Maier RT, 2008, CANCER RES, V68, P1572, DOI 10.1158/0008-5472.CAN-07-5020; Obeid M, 2007, CELL DEATH DIFFER, V14, P1848, DOI 10.1038/sj.cdd.4402201; Obeid M, 2007, NAT MED, V13, P54, DOI 10.1038/nm1523; Pages F, 2005, NEW ENGL J MED, V353, P2654, DOI 10.1056/NEJMoa051424; Panaretakis T, 2008, CELL DEATH DIFFER, V15, P1499, DOI 10.1038/cdd.2008.67; Panaretakis T, 2009, EMBO J, V28, P578, DOI 10.1038/emboj.2009.1; Park JS, 2006, AM J PHYSIOL-CELL PH, V290, pC917, DOI 10.1152/ajpcell.00401.2005; Sancho D, 2008, J CLIN INVEST, V118, P2098, DOI 10.1172/JCI34584; Sancho D, 2009, NATURE, V458, P899, DOI 10.1038/nature07750; Savill J, 2000, NATURE, V407, P784, DOI 10.1038/35037722; Streit M, 1999, P NATL ACAD SCI USA, V96, P14888, DOI 10.1073/pnas.96.26.14888; Tesniere A, 2008, CURR OPIN IMMUNOL, V20, P504, DOI 10.1016/j.coi.2008.05.007; Toquet C, 2007, ONCOL REP, V17, P1101; Wang D, 2005, NAT REV DRUG DISCOV, V4, P307, DOI 10.1038/nrd1691; Wright CA, 2004, BIOL CHEM, V385, P763, DOI 10.1515/BC.2004.100; Zeng G, 2006, J IMMUNOL, V177, P3582, DOI 10.4049/jimmunol.177.6.3582; Zhang YN, 2006, IMMUNOL RES, V35, P151, DOI 10.1385/IR:35:1:151; Zitvogel L, 2008, J CLIN INVEST, V118, P1991, DOI 10.1172/JCI35180	35	725	754	10	109	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN	2010	29	4					482	491		10.1038/onc.2009.356	http://dx.doi.org/10.1038/onc.2009.356			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	549WH	19881547				2022-12-25	WOS:000274084600002
J	Baldassarre, M; Razinia, Z; Burande, CF; Lamsoul, I; Lutz, PG; Calderwood, DA				Baldassarre, Massimiliano; Razinia, Ziba; Burande, Clara F.; Lamsoul, Isabelle; Lutz, Pierre G.; Calderwood, David A.			Filamins Regulate Cell Spreading and Initiation of Cell Migration	PLOS ONE			English	Article							ACTIN-BINDING PROTEIN; STRUCTURAL BASIS; MOTILITY; MALFORMATIONS; COMPETITION; NEURONS; FILGAP	Mammalian filamins (FLNs) are a family of three large actin-binding proteins. FLNa, the founding member of the family, was implicated in migration by cell biological analyses and the identification of FLNA mutations in the neuronal migration disorder periventricular heterotopia. However, recent knockout studies have questioned the relevance of FLNa to cell migration. Here we have used shRNA-mediated knockdown of FLNa, FLNb or FLNa and FLNb, or, alternatively, acute proteasomal degradation of all three FLNs, to generate FLN-deficient cells and assess their ability to migrate. We report that loss of FLNa or FLNb has little effect on migration but that knockdown of FLNa and FLNb, or proteolysis of all three FLNs, impairs migration. The observed defect is primarily a deficiency in initiation of motility rather than a problem with maintenance of locomotion speed. FLN-deficient cells are also impaired in spreading. Re-expression of full length FLNa, but not re-expression of a mutated FLNa lacking immunoglobulin domains 19 to 21, reverts both the spreading and the inhibition of initiation of migration. Our results establish a role for FLNs in cell migration and spreading and suggest that compensation by other FLNs may mask phenotypes in single knockout or knockdown cells. We propose that interactions between FLNs and transmembrane or signalling proteins, mediated at least in part by immunoglobulin domains 19 to 21 are important for both cell spreading and initiation of migration.			Baldassarre, M (corresponding author), Yale Univ, Sch Med, Dept Pharmacol, New Haven, CT 06510 USA.	david.calderwood@yale.edu	Baldassarre, Massimiliano/E-6236-2011; Calderwood, David A/AAC-6954-2019; Baldassarre, Massimiliano/AAI-6581-2021; Lutz, Pierre/B-8822-2009	Baldassarre, Massimiliano/0000-0002-2498-4767; Calderwood, David A/0000-0002-0791-4142; Baldassarre, Massimiliano/0000-0002-2498-4767; Lutz, Pierre/0000-0003-0590-9101; Lamsoul, Isabelle/0000-0002-7769-5627	NIGMS NIH HHS [R01 GM068600] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM068600] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Bello NF, 2009, CELL DEATH DIFFER, V16, P921, DOI 10.1038/cdd.2009.27; Burande CF, 2009, MOL CELL PROTEOMICS, V8, P1719, DOI 10.1074/mcp.M800410-MCP200; Calderwood DA, 2001, NAT CELL BIOL, V3, P1060, DOI 10.1038/ncb1201-1060; CUNNINGHAM CC, 1992, SCIENCE, V255, P325, DOI 10.1126/science.1549777; Feng YY, 2006, P NATL ACAD SCI USA, V103, P19836, DOI 10.1073/pnas.0609628104; Feng YY, 2004, NAT CELL BIOL, V6, P1034, DOI 10.1038/ncb1104-1034; Fink JM, 1997, AM J HUM GENET, V61, P379, DOI 10.1086/514863; Flanagan LA, 2001, J CELL BIOL, V155, P511, DOI 10.1083/jcb.200105148; Fox JW, 1998, NEURON, V21, P1315, DOI 10.1016/S0896-6273(00)80651-0; GORLIN JB, 1990, J CELL BIOL, V111, P1089, DOI 10.1083/jcb.111.3.1089; Hart AW, 2006, HUM MOL GENET, V15, P2457, DOI 10.1093/hmg/ddl168; HARTWIG JH, 1980, J CELL BIOL, V87, P841, DOI 10.1083/jcb.87.3.841; Heuze ML, 2008, BLOOD, V112, P5130, DOI 10.1182/blood-2007-12-128744; Jordan M, 1996, NUCLEIC ACIDS RES, V24, P596, DOI 10.1093/nar/24.4.596; Kiema T, 2006, MOL CELL, V21, P337, DOI 10.1016/j.molcel.2006.01.011; Lad Y, 2007, EMBO J, V26, P3993, DOI 10.1038/sj.emboj.7601827; Lad Y, 2008, J BIOL CHEM, V283, P35154, DOI 10.1074/jbc.M802592200; Meyer SC, 1998, J BIOL CHEM, V273, P3013, DOI 10.1074/jbc.273.5.3013; Nagano T, 2004, J NEUROSCI, V24, P9648, DOI 10.1523/JNEUROSCI.2363-04.2004; Nagano T, 2002, NAT CELL BIOL, V4, P495, DOI 10.1038/ncb808; Nakamura F, 2007, J CELL BIOL, V179, P1011, DOI 10.1083/jcb.200707073; Ohta Y, 2006, NAT CELL BIOL, V8, P803, DOI 10.1038/ncb1437; Pollard TD, 2003, CELL, V112, P453, DOI 10.1016/S0092-8674(03)00120-X; Popowicz GM, 2006, TRENDS BIOCHEM SCI, V31, P411, DOI 10.1016/j.tibs.2006.05.006; Pudas R, 2005, STRUCTURE, V13, P111, DOI 10.1016/j.str.2004.10.014; Ridley AJ, 2003, SCIENCE, V302, P1704, DOI 10.1126/science.1092053; Sarkisian MR, 2006, NEURON, V52, P789, DOI 10.1016/j.neuron.2006.10.024; Sheen VL, 2002, HUM MOL GENET, V11, P2845, DOI 10.1093/hmg/11.23.2845; Shifrin Y, 2009, MOL BIOL CELL, V20, P1269, DOI 10.1091/mbc.E08-08-0872; Stossel TP, 2001, NAT REV MOL CELL BIO, V2, P138, DOI 10.1038/35052082; Takafuta T, 1998, J BIOL CHEM, V273, P17531, DOI 10.1074/jbc.273.28.17531; Thompson TG, 2000, J CELL BIOL, V148, P115, DOI 10.1083/jcb.148.1.115; van der Flier A, 2002, J CELL BIOL, V156, P361, DOI 10.1083/jcb.200103037; van der Flier A, 2001, BBA-MOL CELL RES, V1538, P99, DOI 10.1016/S0167-4889(01)00072-6; Vicente-Manzanares M, 2005, J CELL SCI, V118, DOI 10.1242/jcs.02662; Xie ZW, 1998, BIOCHEM BIOPH RES CO, V251, P914, DOI 10.1006/bbrc.1998.9506; Xu WF, 1998, BLOOD, V92, P1268, DOI 10.1182/blood.V92.4.1268.416k12_1268_1276; Zhou X, 2007, P NATL ACAD SCI USA, V104, P3919, DOI 10.1073/pnas.0608360104	38	91	92	0	3	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	NOV 13	2009	4	11							e7830	10.1371/journal.pone.0007830	http://dx.doi.org/10.1371/journal.pone.0007830			16	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	518VB	19915675	gold, Green Published, Green Submitted			2022-12-25	WOS:000271721900019
J	Seidelin, JB; Broom, OJ; Olsen, J; Nielsen, OH				Seidelin, Jakob Benedict; Broom, Oliver Jay; Olsen, Jorgen; Nielsen, Ole Haagen			Evidence for Impaired CARD15 Signalling in Crohn's Disease without Disease Linked Variants	PLOS ONE			English	Article							INFLAMMATORY-BOWEL-DISEASE; MURAMYL DIPEPTIDE; FRAMESHIFT MUTATION; NOD2; PEPTIDOGLYCAN; ACTIVATION; INNATE; SUSCEPTIBILITY; MACROPHAGES; EXPRESSION	Background: Sensing of muramyl dipeptide (MDP) is impaired in Crohn's disease (CD) patients with disease-linked variants of the CARD15 (caspase activation and recruitment domain 15) gene. Animal studies suggest that normal CARD15 signalling prevents inflammatory bowel disease, and may be important for disease development in CD. However, only a small fraction of CD patients carry the disease linked CARD15 variants. The aim of this study was thus to investigate if changes could be found in CARD15 signalling in patients without disease associated CARD15 variants. Methodology/Principal Findings: By mapping the response to MDP in peripheral monocytes obtained from CD patients in remission not receiving immunosuppresives, an impaired response to MDP was found in patients without disease linked CARD15 variants compared to control monocytes. This impairment was accompanied by a decreased activation of I kappa B kinase alpha/beta (IKK alpha/beta), the initial step in the nuclear factor kappa B (NF kappa B) pathway, whereas activation of mitogen-activated protein (MAP)-kinases was unaffected. MDP additionally stimulates the inflammasome which is of importance for processing of cytokines. The inflammasome was constitutively activated in CD, but unresponsive to MDP both in CD and control monocytes. Conclusions/Significance: These results suggest that inhibited MDP-dependent pathways in CD patients not carrying the disease-associated CARD15 variants might be of importance for the pathogenesis of CD. The results reveal a dysfunctional immune response in CD patients, not able to sense relevant stimuli on the one hand, and on the other hand possessing constitutively active cytokine processing.			Seidelin, JB (corresponding author), Univ Copenhagen, Herlev Hosp, Dept Gastroenterol, Med Sect, DK-1168 Copenhagen, Denmark.	jseidelin@dadlnet.dk	Nielsen, Ole Haagen/AAK-2482-2021; Seidelin, Jakob/B-7879-2013; Olsen, Jørgen/K-5355-2019	Nielsen, Ole Haagen/0000-0003-4612-8635; Seidelin, Jakob/0000-0003-3230-7966; Olsen, Jørgen/0000-0003-1974-6446				Faustin B, 2007, MOL CELL, V25, P713, DOI 10.1016/j.molcel.2007.01.032; Girardin SE, 2003, J BIOL CHEM, V278, P8869, DOI 10.1074/jbc.C200651200; Hedl M, 2007, P NATL ACAD SCI USA, V104, P19440, DOI 10.1073/pnas.0706097104; Hsu LC, 2008, P NATL ACAD SCI USA, V105, P7803, DOI 10.1073/pnas.0802726105; Hsu YMS, 2007, NAT IMMUNOL, V8, P198, DOI 10.1038/ni1426; Hugot JP, 2001, NATURE, V411, P599, DOI 10.1038/35079107; Kanneganti TD, 2007, IMMUNITY, V27, P549, DOI 10.1016/j.immuni.2007.10.002; Kim JY, 2008, J BIOL CHEM, V283, P137, DOI 10.1074/jbc.M704746200; Kobayashi K, 2002, NATURE, V416, P194, DOI 10.1038/416194a; Korzenik JR, 2007, GUT, V56, P2, DOI 10.1136/gut.2006.095588; Kramer M, 2006, J LEUKOCYTE BIOL, V79, P860, DOI 10.1189/jlb.0805484; Maeda S, 2005, SCIENCE, V307, P734, DOI 10.1126/science.1103685; Marks DJB, 2006, LANCET, V367, P668, DOI 10.1016/S0140-6736(06)68265-2; Martinon F, 2004, CURR BIOL, V14, P1929, DOI 10.1016/j.cub.2004.10.027; Martinon F, 2004, CELL, V117, P561, DOI 10.1016/j.cell.2004.05.004; McAlindon ME, 1998, GUT, V42, P214, DOI 10.1136/gut.42.2.214; Milman N, 2007, RESPIRATION, V74, P76, DOI 10.1159/000090638; Mpofu CM, 2007, GASTROENTEROLOGY, V133, P1487, DOI 10.1053/j.gastro.2007.08.004; Netea MG, 2004, EUR J IMMUNOL, V34, P2052, DOI 10.1002/eji.200425229; Netea MG, 2005, J BIOL CHEM, V280, P35859, DOI 10.1074/jbc.M504924200; Netea MG, 2005, J IMMUNOL, V174, P6518, DOI 10.4049/jimmunol.174.10.6518; Ogura Y, 2001, NATURE, V411, P603, DOI 10.1038/35079114; Peeters H, 2007, INT J IMMUNOGENET, V34, P181, DOI 10.1111/j.1744-313X.2007.00670.x; Riis L, 2007, INFLAMM BOWEL DIS, V13, P24, DOI 10.1002/ibd.20047; Seidelin JB, 2006, APMIS, V114, P508, DOI 10.1111/j.1600-0463.2006.apm_116.x; SINGER H, 1995, J EXP MED, V182, P1447; Uehori J, 2005, J IMMUNOL, V174, P7096, DOI 10.4049/jimmunol.174.11.7096; van Heel DA, 2005, LANCET, V365, P1794, DOI 10.1016/S0140-6736(05)66582-8; Waetzig GH, 2002, J IMMUNOL, V168, P5342, DOI 10.4049/jimmunol.168.10.5342; Watanabe T, 2008, J CLIN INVEST, V118, P545, DOI [10.1172/JC133145, 10.1172/JCI33145]; Wolfert MA, 2002, J BIOL CHEM, V277, P39179, DOI 10.1074/jbc.M204885200	31	16	16	0	3	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA	1932-6203			PLOS ONE	PLoS One	NOV 12	2009	4	11							e7794	10.1371/journal.pone.0007794	http://dx.doi.org/10.1371/journal.pone.0007794			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	518UW	19907652	gold, Green Published, Green Submitted			2022-12-25	WOS:000271721400003
J	Anderson, MG; Moskat, C; Ban, M; Grim, T; Cassey, P; Hauber, ME				Anderson, Michael G.; Moskat, Csaba; Ban, Miklos; Grim, Tomas; Cassey, Phillip; Hauber, Mark E.			Egg Eviction Imposes a Recoverable Cost of Virulence in Chicks of a Brood Parasite	PLOS ONE			English	Article							CUCKOO CUCULUS-CANORUS; COMMON CUCKOO; REED WARBLERS; GROWTH; HOST; NESTLINGS; YOUNG; REJECTION; BEHAVIOR; NESTS	Background: Chicks of virulent brood parasitic birds eliminate their nestmates and avoid costly competition for foster parental care. Yet, efforts to evict nest contents by the blind and naked common cuckoo Cuculus canorus hatchling are counterintuitive as both adult parasites and large older cuckoo chicks appear to be better suited to tossing the eggs and young of the foster parents. Methodology/Principal Findings: Here we show experimentally that egg tossing imposed a recoverable growth cost of mass gain in common cuckoo chicks during the nestling period in nests of great reed warbler Acrocephalus arundinaceus hosts. Growth rates of skeletal traits and morphological variables involved in the solicitation of foster parental care remained similar between evictor and non-evictor chicks throughout development. We also detected no increase in predation rates for evicting nests, suggesting that egg tossing behavior by common cuckoo hatchlings does not increase the conspicuousness of nests. Conclusion: The temporary growth cost of egg eviction by common cuckoo hatchlings is the result of constraints imposed by rejecter host adults and competitive nestmates on the timing and mechanism of parasite virulence.			Anderson, MG (corresponding author), Massey Univ, Inst Nat Sci, Ecol & Conservat Grp, Albany Campus, Auckland, New Zealand.	mark.hauber@hunter.cuny.edu	Anderson, Michael G/E-3229-2010; Anderson, Michael/AAE-6706-2019; Grim, Tomas/A-2852-2008	Cassey, Phillip/0000-0002-2626-0172; Anderson, Michael/0000-0002-6981-8199; Grim, Tomas/0000-0002-5775-6269				Alonso-Alvarez C, 2007, FUNCT ECOL, V21, P873, DOI 10.1111/j.1365-2435.2007.01300.x; Antonov A, 2006, BEHAV ECOL SOCIOBIOL, V60, P11, DOI 10.1007/s00265-005-0132-6; Antonov A, 2008, ANIM BEHAV, V76, P1893, DOI 10.1016/j.anbehav.2008.08.016; Aviles JM, 2009, AUK, V126, P431, DOI 10.1525/auk.2009.08162; Davies N.B., 2000, CUCKOOS COWBIRDS OTH; Davies NB, 1998, P ROY SOC B-BIOL SCI, V265, P673, DOI 10.1098/rspb.1998.0346; DAVIES NB, 1988, ANIM BEHAV, V36, P262, DOI 10.1016/S0003-3472(88)80269-0; DAWKINS R, 1979, PROC R SOC SER B-BIO, V205, P489, DOI 10.1098/rspb.1979.0081; Dearborn DC, 1999, AUK, V116, P448, DOI 10.2307/4089378; Fisher MO, 2006, PLOS BIOL, V4, P1462, DOI 10.1371/journal.pbio.0040251; Gil D, 2008, P R SOC B, V275, P549, DOI 10.1098/rspb.2007.1360; Grafen A., 2002, MODERN STAT LIFE SCI; Gridi-Papp M, 2006, NATURE, V442, P257, DOI 10.1038/442257b; Grim Tomas, 2006, Ornithological Science, V5, P237; Grim T, 2006, BEHAV ECOL SOCIOBIOL, V60, P716, DOI 10.1007/s00265-006-0215-z; Grim T, 2009, BEHAV ECOL, V20, P1138, DOI 10.1093/beheco/arp108; Grim T, 2009, ETHOLOGY, V115, P14, DOI 10.1111/j.1439-0310.2008.01574.x; Hansson B, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002794; Hauber ME, 2008, BEHAV ECOL, V19, P79, DOI 10.1093/beheco/arm108; Honza M, 2007, J AVIAN BIOL, V38, P385, DOI 10.1111/j.2007.0908-8857.03901.x; Hoover JP, 2006, OECOLOGIA, V149, P165, DOI 10.1007/s00442-006-0424-1; Jenner E, 1788, PHILOS T ROY SOC LON, V78, P219, DOI DOI 10.1098/RSTL.1788.0016; Kilner Rebecca M., 2006, Ornithological Science, V5, P243, DOI 10.2326/1347-0558(2006)5[243:RTGFCO]2.0.CO;2; Kilner Rebecca M., 2005, Ornithological Science, V4, P55, DOI 10.2326/osj.4.55; Kilner RM, 2004, SCIENCE, V305, P877, DOI 10.1126/science.1098487; Kilner RM, 1999, NATURE, V397, P667, DOI 10.1038/17746; Kleven O, 1999, BEHAV ECOL SOCIOBIOL, V47, P41, DOI 10.1007/s002650050647; Langmore NE, 2003, NATURE, V422, P157, DOI 10.1038/nature01460; Lepczyk CA, 2000, AUK, V117, P164, DOI 10.1642/0004-8038(2000)117[0164:EOEFRO]2.0.CO;2; Lindstrom J, 1999, TRENDS ECOL EVOL, V14, P343, DOI 10.1016/S0169-5347(99)01639-0; Martin-Galvez D, 2005, ANIM BEHAV, V70, P1313, DOI 10.1016/j.anbehav.2005.03.031; Metcalfe NB, 2001, TRENDS ECOL EVOL, V16, P254, DOI 10.1016/S0169-5347(01)02124-3; Moskat C, 2007, ANIM COGN, V10, P377, DOI 10.1007/s10071-007-0071-x; Moskat C, 2008, J AVIAN BIOL, V39, P663, DOI 10.1111/j.1600-048X.2008.04359.x; Nakagawa S, 2004, BEHAV ECOL, V15, P1044, DOI 10.1093/beheco/arh107; Nakagawa S, 2007, BIOL REV, V82, P591, DOI 10.1111/j.1469-185X.2007.00027.x; Payne RB, 1998, BEHAV ECOL, V9, P64, DOI 10.1093/beheco/9.1.64; Polacikova L, 2009, EVOL ECOL, V23, P879, DOI 10.1007/s10682-008-9278-9; Rutila J, 2002, J AVIAN BIOL, V33, P414, DOI 10.1034/j.1600-048X.2002.02937.x; Saino N, 1998, OIKOS, V81, P217, DOI 10.2307/3547043; Schulze-Hagen K, 2009, J ORNITHOL, V150, P1, DOI 10.1007/s10336-008-0340-8; SOLER JJ, 1995, BEHAV ECOL SOCIOBIOL, V36, P201, DOI 10.1007/BF00177797; Soler JJ, 2003, P ROY SOC B-BIOL SCI, V270, P241, DOI 10.1098/rspb.2002.2217; Soler M, 2002, EVOLUTION OF BEGGING: COMPETITION, COOPERATION AND COMMUNICATION, P413, DOI 10.1007/0-306-47660-6_21; Soler Manuel, 2001, Acta Ethologica, V4, P59, DOI 10.1007/s102110100047; Wyllie I., 1981, CUCKOO	46	47	47	1	18	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA	1932-6203			PLOS ONE	PLoS One	NOV 11	2009	4	11					A67	A73	e7725	10.1371/journal.pone.0007725	http://dx.doi.org/10.1371/journal.pone.0007725			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	518IX	19907639	Green Published, gold			2022-12-25	WOS:000271685800008
J	Soumahoro, MK; Gerardin, P; Boelle, PY; Perrau, J; Fianu, A; Pouchot, J; Malvy, D; Flahault, A; Favier, F; Hanslik, T				Soumahoro, Man-Koumba; Gerardin, Patrick; Boelle, Pierre-Yves; Perrau, Joelle; Fianu, Adrian; Pouchot, Jacques; Malvy, Denis; Flahault, Antoine; Favier, Francois; Hanslik, Thomas			Impact of Chikungunya Virus Infection on Health Status and Quality of Life: A Retrospective Cohort Study	PLOS ONE			English	Article							REUNION ISLAND OUTBREAK; RHEUMATIC MANIFESTATIONS; RISK-FACTORS; DISEASE; BURDEN; ALPHAVIRUSES; PREVALENCE; DISORDERS; TRAVELERS; SYMPTOMS	Background: Persistent symptoms, mainly joint and muscular pain and depression, have been reported several months after Chikungunya virus (CHIKV) infection. Their frequency and their impact on quality of life have not been compared with those of an unexposed population. In the present study, we aimed to describe the frequency of prolonged clinical manifestations of CHIKV infection and to measure the impact on quality of life and health care consumption in comparison with that of an unexposed population, more than one year after infection. Methodology/Principal Findings: In a retrospective cohort study, 199 subjects who had serologically confirmed CHIKV infection (CHIK+) were compared with 199 sero-negative subjects (CHIK-) matched for age, gender and area of residence in La Reunion Island. Following an average time of 17 months from the acute phase of infection, participants were interviewed by telephone about current symptoms, medical consumption during the last 12 months and quality of life assessed by the 12-items Short-Form Health Survey (SF-12) scale. At the time of study, 112 (56%) CHIK+ persons reported they were fully recovered. CHIK+ complained more frequently than CHIK- of arthralgia (relative risk = 1.9; 95% confidence interval: 1.6-2.2), myalgia (1.9; 1.5-2.3), fatigue (2.3; 1.8-3), depression (2.5; 1.5-4.1) and hair loss (3.8; 1.9-7.6). There was no significant difference between CHIK+ and CHIK- subjects regarding medical consumption in the past year. The mean (SD) score of the SF-12 Physical Component Summary was 46.4 (10.8) in CHIK+ versus 49.1 (9.3) in CHIK- (p = 0.04). There was no significant difference between the two groups for the Mental Component Summary. Conclusions/Significance: More than one year following the acute phase of infection, CHIK+ subjects reported more disabilities than those who were CHIK-. These persistent disabilities, however, have no significant influence on medical consumption, and the impact on quality of life is moderate.			Soumahoro, MK (corresponding author), Univ Paris 06, Unite Mixte Rech Sante 707, Paris, France.	soumahor@u707.jussieu.fr	MALVY, Denis/T-7930-2019	Soumahoro, Man-Koumba/0000-0002-6482-3917; Boelle, Pierre-Yves/0000-0002-5367-8232				Borgherini G, 2008, CLIN INFECT DIS, V47, P469, DOI 10.1086/590003; Borgherini G, 2007, CLIN INFECT DIS, V44, P1401, DOI 10.1086/517537; BRIGHTON SW, 1983, S AFR MED J, V63, P313; Carmona L, 2001, ANN RHEUM DIS, V60, P1040, DOI 10.1136/ard.60.11.1040; CONDON RJ, 1995, CLIN DIAGN VIROL, V3, P273, DOI 10.1016/S0928-0197(94)00043-3; Couderc T, 2008, PLOS PATHOG, V4, DOI 10.1371/journal.ppat.0040029; Cummings P, 2004, STATA J, V4, P274, DOI 10.1177/1536867X0400400305; Economopoulou A, 2009, EPIDEMIOL INFECT, V137, P534, DOI 10.1017/S0950268808001167; FLAHAULT A, 2007, B ACAD NATL MED, V191, P125; Flahault A, 2007, B ACAD NAT MED PARIS, V191, P113, DOI 10.1016/S0001-4079(19)33100-0; FOURIE ED, 1979, S AFR MED J, V56, P130; Gandhi SK, 2001, CLIN THER, V23, P1080, DOI 10.1016/S0149-2918(01)80093-X; Gerardin P, 2008, BMC INFECT DIS, V8, DOI 10.1186/1471-2334-8-99; Gerardin P, 2008, PLOS MED, V5, P413, DOI 10.1371/journal.pmed.0050060; Grivard P, 2007, PATHOL BIOL, V55, P490, DOI 10.1016/j.patbio.2007.07.002; Harley D, 2002, MED J AUSTRALIA, V177, P352, DOI 10.5694/j.1326-5377.2002.tb04836.x; Harley D, 2001, RHEUMATOLOGY, V40, P1319, DOI 10.1093/rheumatology/40.11.1319; Harley D, 2001, CLIN MICROBIOL REV, V14, P909, DOI 10.1128/CMR.14.4.909-932.2001; Hickie I, 2009, AUST NZ J PSYCHIAT, V43, P25, DOI 10.1080/00048670802534432; Hoffman DL, 2008, INT J CLIN PRACT, V62, P115, DOI 10.1111/j.1742-1241.2007.01638.x; Hurst NP, 1998, BRIT J RHEUMATOL, V37, P862; Josseran L, 2006, EMERG INFECT DIS, V12, P1994; Laine M, 2004, J INTERN MED, V256, P457, DOI 10.1111/j.1365-2796.2004.01413.x; Laine M, 2002, RHEUMATOLOGY, V41, P829, DOI 10.1093/rheumatology/41.7.829; Lemant J, 2008, CRIT CARE MED, V36, P2536, DOI 10.1097/CCM.0b013e318183f2d2; Lokireddy S, 2008, VIROL J, V5, DOI 10.1186/1743-422X-5-31; Mylonas AD, 2002, MED J AUSTRALIA, V177, P356, DOI 10.5694/j.1326-5377.2002.tb04837.x; Ozden S, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0000527; PARDIGON N, 2008, PATHOL BIOL PARIS; Parola P, 2007, CLIN INFECT DIS, V45, P801, DOI 10.1086/521171; Pialoux G, 2007, LANCET INFECT DIS, V7, P319, DOI 10.1016/S1473-3099(07)70107-X; Porterfield J. S., 1980, TOGAVIRUSES BIOL STR, P13; Powers AM, 2007, J GEN VIROL, V88, P2363, DOI 10.1099/vir.0.82858-0; Queyriaux B, 2008, LANCET INFECT DIS, V8, P2, DOI 10.1016/S1473-3099(07)70294-3; Ramos-e-Silva M, 2008, CLIN DERMATOL, V26, P296, DOI 10.1016/j.clindermatol.2007.10.019; Simon F, 2007, MEDICINE, V86, P123, DOI 10.1097/MD/0b013e31806010a5; Sissoko D, 2009, PLOS NEGLECT TROP D, V3, DOI 10.1371/journal.pntd.0000389; Sourisseau M, 2007, PLOS PATHOG, V3, P804, DOI 10.1371/journal.ppat.0030089; Staikowsky F, 2008, EPIDEMIOL INFECT, V136, P196, DOI 10.1017/S0950268807008424; Taubitz W, 2007, CLIN INFECT DIS, V45, pE1, DOI 10.1086/518701; Toivanen A, 2008, CURR OPIN RHEUMATOL, V20, P486, DOI 10.1097/BOR.0b013e328303220b; Urwin M, 1998, ANN RHEUM DIS, V57, P649, DOI 10.1136/ard.57.11.649; Volpe A, 2008, REUMATISMO, V60, P136, DOI 10.4081/reumatismo.2008.136; WALKER G. M., 1962, TRANS ROY SOC TROP MED AND HYG, V56, P496, DOI 10.1016/0035-9203(62)90073-1; Ware JE, 1996, MED CARE, V34, P220, DOI 10.1097/00005650-199603000-00003; Ziegler SA, 2008, AM J TROP MED HYG, V79, P133, DOI 10.4269/ajtmh.2008.79.133	46	88	93	1	6	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	NOV 11	2009	4	11					A221	A226	e7800	10.1371/journal.pone.0007800	http://dx.doi.org/10.1371/journal.pone.0007800			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	518IX	19911058	Green Published, gold, Green Submitted			2022-12-25	WOS:000271685800023
J	Mazzucchelli, RI; Warming, S; Lawrence, SM; Ishii, M; Abshari, M; Washington, AV; Feigenbaum, L; Warner, AC; Sims, DJ; Li, WQ; Hixon, JA; Gray, DHD; Rich, BE; Morrow, M; Anver, MR; Cherry, J; Naf, D; Sternberg, LR; McVicar, DW; Farr, AG; Germain, RN; Rogers, K; Jenkins, NA; Copeland, NG; Durum, SK				Mazzucchelli, Renata I.; Warming, Soren; Lawrence, Scott M.; Ishii, Masaru; Abshari, Mehrnoosh; Washington, A. Valance; Feigenbaum, Lionel; Warner, Andrew C.; Sims, Davis J.; Li, Wen Qing; Hixon, Julie A.; Gray, Daniel H. D.; Rich, Benjamin E.; Morrow, Matthew; Anver, Miriam R.; Cherry, James; Naf, Dieter; Sternberg, Lawrence R.; McVicar, Daniel W.; Farr, Andrew G.; Germain, Ronald N.; Rogers, Keith; Jenkins, Nancy A.; Copeland, Neal G.; Durum, Scott K.			Visualization and Identification of IL-7 Producing Cells in Reporter Mice	PLOS ONE			English	Article							POLYMERASE CHAIN-REACTION; CYTOKINE GENE-EXPRESSION; SEVERE COMBINED IMMUNODEFICIENCY; INTESTINAL EPITHELIAL-CELLS; HUMAN DENDRITIC CELLS; THYMIC STROMAL CELLS; EPIDERMAL T-CELLS; MESSENGER-RNA; IN-VIVO; INTERLEUKIN (IL)-7	Interleukin-7 (IL-7) is required for lymphocyte development and homeostasis although the actual sites of IL-7 production have never been clearly identified. We produced a bacterial artificial chromosome (BAC) transgenic mouse expressing ECFP in the Il7 locus. The construct lacked a signal peptide and ECFP (enhanced cyan fluorescent protein) accumulated inside IL-7-producing stromal cells in thoracic thymus, cervical thymus and bone marrow. In thymus, an extensive reticular network of IL-7-containing processes extended from cortical and medullary epithelial cells, closely contacting thymocytes. Central memory CD8 T cells, which require IL-7 and home to bone marrow, physically associated with IL-7-producing cells as we demonstrate by intravital imaging.			Mazzucchelli, RI (corresponding author), HSR TIGET, San Raffaele Telethon Inst Gene Therapy, Lab Gene Therapy & Primary Immunodeficiency, Milan, Italy.	durums@ncifcrf.gov	McVicar, Daniel/G-1970-2015; Gray, Daniel HD/A-3293-2013; Germain, Ronald N./Z-1945-2019; Warming, Soren/ABD-5729-2021; Germain, Ronald/ABE-7090-2020	Gray, Daniel HD/0000-0002-8457-8242; Abshari, Mehrnoosh/0000-0003-4217-0625; Warming, Soren/0000-0002-5721-0741; McVicar, Daniel/0000-0002-1112-5111; durum, scott/0000-0003-1307-9582	NATIONAL CANCER INSTITUTE [ZIABC009287] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [ZIAAI000545] Funding Source: NIH RePORTER; NCI NIH HHS [N01-CO-12400, N01CO12400] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Ariel A, 1997, EUR J IMMUNOL, V27, P2562, DOI 10.1002/eji.1830271015; Bradley LM, 2005, TRENDS IMMUNOL, V26, P172, DOI 10.1016/j.it.2005.01.004; de Saint-Vis B, 1998, J IMMUNOL, V160, P1666; Dooley J, 2006, J IMMUNOL, V176, P6484, DOI 10.4049/jimmunol.176.11.6484; FUNK PE, 1995, BLOOD, V86, P2661; Golden-Mason L, 2001, CYTOKINE, V14, P143, DOI 10.1006/cyto.2001.0852; GOODWIN RG, 1989, P NATL ACAD SCI USA, V86, P302, DOI 10.1073/pnas.86.1.302; Gray DHD, 2008, J IMMUNOL METHODS, V329, P56, DOI 10.1016/j.jim.2007.09.010; Gray DHD, 2002, J IMMUNOL METHODS, V260, P15, DOI 10.1016/S0022-1759(01)00493-8; GUNJI Y, 1991, BLOOD, V77, P2612; HE W, 1995, J IMMUNOL, V154, P3726; HEUFLER C, 1993, J EXP MED, V178, P1109, DOI 10.1084/jem.178.3.1109; Khaled AR, 2002, NAT REV IMMUNOL, V2, P817, DOI 10.1038/nri931; Kitazawa H, 1997, J IMMUNOL, V159, P2259; Kondrack RM, 2003, J EXP MED, V198, P1797, DOI 10.1084/jem.20030735; Kroncke R, 1996, EUR J IMMUNOL, V26, P2541, DOI 10.1002/eji.1830261040; Li WQ, 2006, J EXP MED, V203, P573, DOI 10.1084/jem.20051520; Madrigal-Estebas L, 1997, HUM IMMUNOL, V58, P83, DOI 10.1016/S0198-8859(97)00230-9; MATSUE H, 1993, J INVEST DERMATOL, V101, P537, DOI 10.1111/1523-1747.ep12365917; MATSUE H, 1993, J IMMUNOL, V151, P6012; Mazo IB, 2005, IMMUNITY, V22, P259, DOI 10.1016/j.immuni.2005.01.008; Mazzucchelli R, 2007, NAT REV IMMUNOL, V7, P144, DOI 10.1038/nri2023; MERTSCHING E, 1995, INT IMMUNOL, V7, P401, DOI 10.1093/intimm/7.3.401; MOMBAERTS P, 1992, CELL, V68, P869, DOI 10.1016/0092-8674(92)90030-G; MONTGOMERY RA, 1991, J IMMUNOL, V147, P554; Montgomery RA, 1997, CYTOKINE, V9, P717, DOI 10.1006/cyto.1997.0227; MOORE NC, 1993, EUR J IMMUNOL, V23, P922, DOI 10.1002/eji.1830230424; Murray AM, 1998, CYTOKINE, V10, P337, DOI 10.1006/cyto.1997.0302; NAMEN AE, 1988, NATURE, V333, P571, DOI 10.1038/333571a0; Napolitano LA, 2001, NAT MED, V7, P73, DOI 10.1038/83381; PESCHON JJ, 1994, J EXP MED, V180, P1955, DOI 10.1084/jem.180.5.1955; Puel A, 2000, CURR OPIN IMMUNOL, V12, P468, DOI 10.1016/S0952-7915(00)00122-9; Puel A, 1998, NAT GENET, V20, P394, DOI 10.1038/3877; Roye O, 1998, J IMMUNOL, V161, P4161; Schluns KS, 2000, NAT IMMUNOL, V1, P426, DOI 10.1038/80868; Sorg RV, 1998, IMMUNOBIOLOGY, V198, P514, DOI 10.1016/S0171-2985(98)80075-2; Soslau G, 1997, CYTOKINE, V9, P405, DOI 10.1006/cyto.1996.0182; Tagaya Y, 1996, IMMUNITY, V4, P329, DOI 10.1016/S1074-7613(00)80246-0; Takeuchi T, 1998, HISTOPATHOLOGY, V32, P383; Tan JT, 2001, P NATL ACAD SCI USA, V98, P8732, DOI 10.1073/pnas.161126098; Terszowski G, 2006, SCIENCE, V312, P284, DOI 10.1126/science.1123497; Tsuda S, 1996, J IMMUNOL, V156, P3233; VONFREEDENJEFFRY U, 1995, J EXP MED, V181, P1519, DOI 10.1084/jem.181.4.1519; Warming S, 2005, NUCLEIC ACIDS RES, V33, DOI 10.1093/nar/gni035; WATANABE M, 1995, J CLIN INVEST, V95, P2945, DOI 10.1172/JCI118002; WILES MV, 1992, EUR J IMMUNOL, V22, P1037, DOI 10.1002/eji.1830220424; Williams IR, 1997, J IMMUNOL, V159, P3044; WITTE PL, 1993, EUR J IMMUNOL, V23, P1809, DOI 10.1002/eji.1830230812; Zamisch M, 2005, J IMMUNOL, V174, P60, DOI 10.4049/jimmunol.174.1.60; Zhu J, 2007, BLOOD, V109, P3706, DOI 10.1182/blood-2006-08-041384	50	91	102	0	5	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA	1932-6203			PLOS ONE	PLoS One	NOV 10	2009	4	11							e7637	10.1371/journal.pone.0007637	http://dx.doi.org/10.1371/journal.pone.0007637			14	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	517ZU	19907640	Green Published, gold, Green Submitted			2022-12-25	WOS:000271658800002
J	Kishida, K; Tominaga, M; Matsubara, K; Taguchi, M; Noguchi, M; Tsunawake, N; Shidoji, Y				Kishida, Kunihiro; Tominaga, Mihoko; Matsubara, Kiminori; Taguchi, Masanori; Noguchi, Masanori; Tsunawake, Noriaki; Shidoji, Yoshihiro			An Association Analysis between Mitochondrial DNA A10398G Polymorphism and Temperament in Japanese Young Adults	PLOS ONE			English	Article							HEALTH	The mitochondrial (mt) DNA C5178A and A10398G polymorphisms have been reported to be associated with mental disorders such as bipolar disorder. However, the effects of these polymorphisms on temperament in healthy people are poorly understood. Evaluating healthy subjects can have the advantage of providing new strategies for maintaining psychological health and preventing mental illness. We examined the association between mtDNA polymorphisms and temperament in Japanese students. There was no significant difference in examined temperament when analysed by genotypes, 5178-10398 haplotypes, or sex. The subgroup analysis based on sex indicated that there was an interactive effect of the mtDNA A10398G polymorphism and sex on anxiety and obsession. This finding is preliminary and cannot exclude the possibility of false-positive due to small sample size (144 subjects) and multiple statistical testing. Further studies involving a larger sample size or other ethnic groups are necessary to confirm that mtDNA A10398G polymorphism can be a genetic factor for temperament.			Kishida, K (corresponding author), Nagasaki Univ, Grad Sch Human Hlth Sci, Nagasaki 852, Japan.	kunihiro@sun.ac.jp	MATSUBARA, Kiminori/N-9804-2019	Kishida, Kunihiro/0000-0001-8496-7857				Duchen MR, 2004, DIABETES, V53, pS96, DOI 10.2337/diabetes.53.2007.S96; Gong JS, 1998, J CLIN BIOCHEM NUTR, V24, P105; Kato C, 2004, AM J MED GENET B, V128B, P76, DOI 10.1002/ajmg.b.20141; Kato T, 2001, J AFFECT DISORDERS, V62, P151, DOI 10.1016/S0165-0327(99)00173-1; Kato T, 2000, BIPOLAR DISORD, V2, P180, DOI 10.1034/j.1399-5618.2000.020305.x; Kato T, 2000, AM J MED GENET, V96, P182, DOI 10.1002/(SICI)1096-8628(20000403)96:2<182::AID-AJMG12>3.3.CO;2-H; Kazuno AA, 2006, PLOS GENET, V2, P1167, DOI 10.1371/journal.pgen.0020128; Rizzuto R, 2001, CURR OPIN NEUROBIOL, V11, P306, DOI 10.1016/S0959-4388(00)00212-9; Tanaka M, 2004, GENOME RES, V14, P1832, DOI 10.1101/gr.2286304; van der Walt JM, 2004, NEUROSCI LETT, V365, P28, DOI 10.1016/j.neulet.2004.04.051; van der Walt JM, 2003, AM J HUM GENET, V72, P804, DOI 10.1086/373937; Yoshida T, 1998, PSYCHIAT CLIN NEUROS, V52, P413, DOI 10.1046/j.1440-1819.1998.00411.x	12	3	3	0	3	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	NOV 9	2009	4	11							e7763	10.1371/journal.pone.0007763	http://dx.doi.org/10.1371/journal.pone.0007763			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	517ZM	19898620	Green Published, gold, Green Submitted			2022-12-25	WOS:000271658000008
J	Antonova, I; Lu, FM; Zablow, L; Udo, H; Hawkins, RD				Antonova, Irina; Lu, Fang-Min; Zablow, Leonard; Udo, Hiroshi; Hawkins, Robert D.			Rapid and Long-Lasting Increase in Sites for Synapse Assembly during Late-Phase Potentiation in Rat Hippocampal Neurons	PLOS ONE			English	Article							LOCAL PROTEIN-SYNTHESIS; FUNCTIONAL PRESYNAPTIC BOUTONS; SINGLE DENDRITIC SPINES; TERM POTENTIATION; IN-VIVO; NITRIC-OXIDE; MORPHOLOGICAL-CHANGES; TRANSPORT PACKETS; SILENT SYNAPSES; MEMORY STORAGE	Long-term potentiation in hippocampal neurons has stages that correspond to the stages of learning and memory. Early-phase (10-30 min) potentiation is accompanied by rapid increases in clusters or puncta of presynaptic and postsynaptic proteins, which depend on actin polymerization but not on protein synthesis. We have now examined changes in pre- and postsynaptic puncta and structures during glutamate-induced late-phase ( 3 hr) potentiation in cultured hippocampal neurons. We find that ( 1) the potentiation is accompanied by long-lasting maintenance of the increases in puncta, which depends on protein synthesis, ( 2) most of the puncta and synaptic structures are very dynamic, continually assembling and disassembling at sites that are more stable than the puncta or structures themselves, ( 3) the increase in presynaptic puncta appears to be due to both rapid and more gradual increases in the number of sites where the puncta may form, and also to the stabilization of existing puncta, ( 4) under control conditions, puncta of postsynaptic proteins behave similarly to puncta of presynaptic proteins and share sites with them, and ( 5) the increase in presynaptic puncta is accompanied by a similar increase in presumably presynaptic structures, which may form at distinct as well as shared sites. The new sites could contribute to the transition between the early and late phase mechanisms of plasticity by serving as seeds for the formation and maintenance of new synapses, thus acting as local "tags'' for protein synthesis-dependent synaptic growth during late-phase plasticity.			Antonova, I (corresponding author), Columbia Univ, Dept Neurosci, New York, NY 10027 USA.	rdh1@columbia.edu			NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS045108] Funding Source: NIH RePORTER; NINDS NIH HHS [R01 NS045108, NS 045108] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Ahmari SE, 2000, NAT NEUROSCI, V3, P445, DOI 10.1038/74814; Antonova I, 2001, SCIENCE, V294, P1547, DOI 10.1126/science.1066273; Arancio O, 2001, J NEUROSCI, V21, P143, DOI 10.1523/JNEUROSCI.21-01-00143.2001; ARANCIO O, 1995, NATURE, V74, P39; BAILEY CH, 2008, LEARNING MEMORY COMP; Becker N, 2008, NEURON, V60, P590, DOI 10.1016/j.neuron.2008.09.018; Bozdagi O, 2000, NEURON, V28, P245, DOI 10.1016/S0896-6273(00)00100-8; Burette A, 2002, J NEUROSCI, V22, P8961; Calixto E, 2003, J NEUROSCI, V23, P4842; Cammalleri M, 2003, P NATL ACAD SCI USA, V100, P14368, DOI 10.1073/pnas.2336098100; Casadio A, 1999, CELL, V99, P221, DOI 10.1016/S0092-8674(00)81653-0; Colicos MA, 2001, CELL, V107, P605, DOI 10.1016/S0092-8674(01)00579-7; De Roo M, 2008, PROG BRAIN RES, V169, P199, DOI 10.1016/S0079-6123(07)00011-8; De Roo M, 2008, CEREB CORTEX, V18, P151, DOI 10.1093/cercor/bhm041; De Roo M, 2008, PLOS BIOL, V6, P1850, DOI 10.1371/journal.pbio.0060219; Engert F, 1999, NATURE, V399, P66, DOI 10.1038/19978; Fonseca R, 2006, NAT NEUROSCI, V9, P478, DOI 10.1038/nn1667; Frey U, 1997, NATURE, V385, P533, DOI 10.1038/385533a0; Friedman HV, 2000, NEURON, V27, P57, DOI 10.1016/S0896-6273(00)00009-X; Gerrow K, 2006, NEURON, V49, P547, DOI 10.1016/j.neuron.2006.01.015; Grabham PW, 2005, J NEUROBIOL, V64, P202, DOI 10.1002/neu.20133; Hofer SB, 2009, NATURE, V457, P313, DOI 10.1038/nature07487; Holtmaat A, 2006, NATURE, V441, P979, DOI 10.1038/nature04783; Hu JY, 2006, J NEUROSCI, V26, P1026, DOI 10.1523/JNEUROSCI.4258-05.2006; Huber KM, 2000, SCIENCE, V288, P1254, DOI 10.1126/science.288.5469.1254; Jourdain P, 2003, J NEUROSCI, V23, P10645; Kandel ER, 2001, SCIENCE, V294, P1030, DOI 10.1126/science.1067020; Kim JH, 2003, NEURON, V40, P151, DOI 10.1016/S0896-6273(03)00595-6; Knott GW, 2006, NAT NEUROSCI, V9, P1117, DOI 10.1038/nn1747; Krueger SR, 2003, NEURON, V40, P945, DOI 10.1016/S0896-6273(03)00729-3; Leung KM, 2006, NAT NEUROSCI, V9, P1247, DOI 10.1038/nn1775; Lohmann C, 2008, NEURON, V59, P253, DOI 10.1016/j.neuron.2008.05.025; Lucido AL, 2009, J NEUROSCI, V29, P12449, DOI 10.1523/JNEUROSCI.1381-09.2009; Ma L, 1999, NAT NEUROSCI, V2, P24, DOI 10.1038/4525; Maletic-Savatic M, 1999, SCIENCE, V283, P1923, DOI 10.1126/science.283.5409.1923; MALGAROLI A, 1992, NATURE, V357, P134, DOI 10.1038/357134a0; Malinow R, 2002, ANNU REV NEUROSCI, V25, P103, DOI 10.1146/annurev.neuro.25.112701.142758; MALINOW R, 1991, SCIENCE, V252, P722, DOI 10.1126/science.1850871; Marrs GS, 2001, NAT NEUROSCI, V4, P1006, DOI 10.1038/nn717; Martin KC, 1997, CELL, V91, P927, DOI 10.1016/S0092-8674(00)80484-5; Martin KC, 2002, NAT REV NEUROSCI, V3, P813, DOI 10.1038/nrn942; Matsuzaki M, 2004, NATURE, V429, P761, DOI 10.1038/nature02617; McAllister AM, 2007, ANNU REV NEUROSCI, V30, P425, DOI 10.1146/annurev.neuro.29.051605.112830; Meyer MP, 2006, J NEUROSCI, V26, P3604, DOI 10.1523/JNEUROSCI.0223-06.2006; Nagerl UV, 2007, J NEUROSCI, V27, P8149, DOI 10.1523/JNEUROSCI.0511-07.2007; Nagerl UV, 2004, NEURON, V44, P759, DOI 10.1016/j.neuron.2004.11.016; Niell CM, 2004, NAT NEUROSCI, V7, P254, DOI 10.1038/nn1191; Nikonenko I, 2003, J NEUROSCI, V23, P8498; Nikonenko I, 2008, J CELL BIOL, V183, P1115, DOI 10.1083/jcb.200805132; Ninan I, 2006, EMBO J, V25, P4361, DOI 10.1038/sj.emboj.7601318; ODELL TJ, 1991, P NATL ACAD SCI USA, V88, P11285, DOI 10.1073/pnas.88.24.11285; Okabe S, 2001, J NEUROSCI, V21, P6105, DOI 10.1523/JNEUROSCI.21-16-06105.2001; Okada D, 2009, SCIENCE, V324, P904, DOI 10.1126/science.1171498; Ostroff LE, 2002, NEURON, V35, P535, DOI 10.1016/S0896-6273(02)00785-7; Ramachandran B, 2009, J NEUROSCI, V29, P12167, DOI 10.1523/JNEUROSCI.2045-09.2009; Sabo SL, 2006, J NEUROSCI, V26, P10813, DOI 10.1523/JNEUROSCI.2052-06.2006; Sapoznik S, 2006, LEARN MEMORY, V13, P719, DOI 10.1101/lm.351706; Scheiffele P, 2003, ANNU REV NEUROSCI, V26, P485, DOI 10.1146/annurev.neuro.26.043002.094940; Shi SH, 1999, SCIENCE, V284, P1811, DOI 10.1126/science.284.5421.1811; Si K, 2003, CELL, V115, P893, DOI 10.1016/S0092-8674(03)01021-3; Tanaka JI, 2008, SCIENCE, V319, P1683, DOI 10.1126/science.1152864; Tang SJ, 2002, P NATL ACAD SCI USA, V99, P467, DOI 10.1073/pnas.012605299; Toni N, 1999, NATURE, V402, P421, DOI 10.1038/46574; Trachtenberg JT, 2002, NATURE, V420, P788, DOI 10.1038/nature01273; Tsokas P, 2005, J NEUROSCI, V25, P5833, DOI 10.1523/JNEUROSCI.0599-05.2005; Villareal G, 2007, CURR BIOL, V17, P2073, DOI 10.1016/j.cub.2007.10.053; Voronin LL, 2004, J PHYSIOL-LONDON, V557, P3, DOI 10.1113/jphysiol.2003.058966; Wang HG, 2005, NEURON, V45, P389, DOI 10.1016/j.neuron.2005.01.011; Washbourne P, 2002, NAT NEUROSCI, V5, P751, DOI 10.1038/nn883; Winer B.J., 1991, STAT PRINCIPLES EXPT; Wu KY, 2005, NATURE, V436, P1020, DOI 10.1038/nature03885; Zito K, 2009, NEURON, V61, P247, DOI 10.1016/j.neuron.2008.10.054	73	13	13	0	3	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	NOV 6	2009	4	11							e7690	10.1371/journal.pone.0007690	http://dx.doi.org/10.1371/journal.pone.0007690			16	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	515ND	19893634	Green Published, Green Submitted, gold			2022-12-25	WOS:000271478000002
J	Lacomble, S; Portman, N; Gull, K				Lacomble, Sylvain; Portman, Neil; Gull, Keith			A Protein-Protein Interaction Map of the Trypanosoma brucei Paraflagellar Rod	PLOS ONE			English	Article							INDUCIBLE EXPRESSION SYSTEM; RNA INTERFERENCE; AFRICAN TRYPANOSOME; INTERACTION NETWORK; GENE-FUNCTION; CHLAMYDOMONAS; PREDICTION; FLAGELLUM; TRANSPORT; MOTILITY	We have conducted a protein interaction study of components within a specific sub-compartment of a eukaryotic flagellum. The trypanosome flagellum contains a para-crystalline extra-axonemal structure termed the paraflagellar rod (PFR) with around forty identified components. We have used a Gateway cloning approach coupled with yeast two-hybrid, RNAi and 2D DiGE to define a protein-protein interaction network taking place in this structure. We define two clusters of interactions; the first being characterised by two proteins with a shared domain which is not sufficient for maintaining the interaction. The other cohort is populated by eight proteins, a number of which possess a PFR domain and sub-populations of this network exhibit dependency relationships. Finally, we provide clues as to the structural organisation of the PFR at the molecular level. This multi-strand approach shows that protein interactome data can be generated for insoluble protein complexes.			Lacomble, S (corresponding author), Univ Oxford, Sir William Dunn Sch Pathol, S Parks Rd, Oxford OX1 3RE, England.	keith.gull@path.ox.ac.uk		Portman, Neil/0000-0003-0248-0258	Biotechnology and Biological Sciences Research Council Funding Source: Medline; Wellcome Trust Funding Source: Medline	Biotechnology and Biological Sciences Research Council(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC)); Wellcome Trust(Wellcome TrustEuropean Commission)		Ahmed NT, 2008, J CELL BIOL, V183, P313, DOI 10.1083/jcb.200802025; Bastin P, 1999, J CELL SCI, V112, P3769; Bastin P, 1996, MOL BIOCHEM PARASIT, V77, P235, DOI 10.1016/0166-6851(96)02598-4; Bastin P, 1996, PARASITOL TODAY, V12, P302, DOI 10.1016/0169-4758(96)10031-4; Bastin P, 1998, NATURE, V391, P548, DOI 10.1038/35300; Bastin P, 2000, J CELL SCI, V113, P3321; Beattie P, 1997, PARASITOLOGY, V115, P47, DOI 10.1017/S0031182097001042; Berriman M, 2005, SCIENCE, V309, P416, DOI 10.1126/science.1112642; Blom N, 1999, J MOL BIOL, V294, P1351, DOI 10.1006/jmbi.1999.3310; Bologna G, 2004, PROTEOMICS, V4, P1626, DOI 10.1002/pmic.200300783; Broadhead R, 2006, NATURE, V440, P224, DOI 10.1038/nature04541; BRUN R, 1977, Acta Tropica, V34, P21; Gerdes JM, 2009, CELL, V137, P32, DOI 10.1016/j.cell.2009.03.023; Griffiths S, 2007, EUKARYOT CELL, V6, P1248, DOI 10.1128/EC.00110-07; Hamby SE, 2008, BMC BIOINFORMATICS, V9, DOI 10.1186/1471-2105-9-500; Kall L, 2004, J MOL BIOL, V338, P1027, DOI 10.1016/j.jmb.2004.03.016; Kilburn CL, 2007, J CELL BIOL, V178, P905, DOI 10.1083/jcb.200703109; LaCount DJ, 2005, NATURE, V438, P103, DOI 10.1038/nature04104; Li SM, 2004, SCIENCE, V303, P540, DOI 10.1126/science.1091403; Lucker BF, 2005, J BIOL CHEM, V280, P27688, DOI 10.1074/jbc.M505062200; Maga JA, 1999, TRENDS CELL BIOL, V9, P409, DOI 10.1016/S0962-8924(99)01635-9; Monnerat Severine, 2009, BMC Res Notes, V2, P46, DOI 10.1186/1756-0500-2-46; Morris JC, 2002, EMBO J, V21, P4429, DOI 10.1093/emboj/cdf474; Motyka SA, 2004, CURR OPIN MICROBIOL, V7, P362, DOI 10.1016/j.mib.2004.06.004; Oberholzer M, 2007, TRENDS PARASITOL, V23, P71, DOI 10.1016/j.pt.2006.12.002; Oberholzer M, 2007, FASEB J, V21, P720, DOI 10.1096/fj.06-6818com; Ogbadoyi EO, 2003, MOL BIOL CELL, V14, P1769, DOI 10.1091/mbc.E02-08-0525; Portman N, 2009, J BIOL CHEM, V284, P5610, DOI 10.1074/jbc.M808859200; Pullen TJ, 2004, MOL BIOL CELL, V15, P3257, DOI 10.1091/mbc.E04-03-0217; Ridgley E, 2000, MOL BIOCHEM PARASIT, V109, P195, DOI 10.1016/S0166-6851(00)00246-2; ROBINSON DR, 1991, NATURE, V352, P731, DOI 10.1038/352731a0; Rual JF, 2005, NATURE, V437, P1173, DOI 10.1038/nature04209; Rual JF, 2004, GENOME RES, V14, P2128, DOI 10.1101/gr.2973604; Santrich C, 1997, MOL BIOCHEM PARASIT, V90, P95, DOI 10.1016/S0166-6851(97)00149-7; Subramaniam C, 2006, EUKARYOT CELL, V5, P1539, DOI 10.1128/EC.00141-06; Tam LW, 2007, J CELL BIOL, V176, P819, DOI 10.1083/jcb.200610022; Uetz P, 2000, NATURE, V403, P623, DOI 10.1038/35001009; VICKERMAN K, 1973, J PROTOZOOL, V20, P394, DOI 10.1111/j.1550-7408.1973.tb00909.x; Walhout AJM, 2001, METHODS, V24, P297, DOI 10.1006/meth.2001.1190; Wickstead B, 2002, MOL BIOCHEM PARASIT, V125, P211, DOI 10.1016/S0166-6851(02)00238-4; Wirtz E, 1999, MOL BIOCHEM PARASIT, V99, P89, DOI 10.1016/S0166-6851(99)00002-X; Yang PF, 2006, J CELL SCI, V119, P1165, DOI 10.1242/jcs.02811; Zhang ZB, 2005, MOL CELL PROTEOMICS, V4, P914, DOI 10.1074/mcp.M400177-MCP200	43	23	23	0	1	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA	1932-6203			PLOS ONE	PLoS One	NOV 3	2009	4	11							e7685	10.1371/journal.pone.0007685	http://dx.doi.org/10.1371/journal.pone.0007685			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	514RY	19888464	Green Published, gold, Green Submitted			2022-12-25	WOS:000271414500008
J	Ghaghada, KB; Ravoori, M; Sabapathy, D; Bankson, J; Kundra, V; Annapragada, A				Ghaghada, Ketan B.; Ravoori, Murali; Sabapathy, Divya; Bankson, James; Kundra, Vikas; Annapragada, Ananth			New Dual Mode Gadolinium Nanoparticle Contrast Agent for Magnetic Resonance Imaging	PLOS ONE			English	Article							ENHANCED MR-ANGIOGRAPHY; LIPOSOMAL DOXORUBICIN; RELAXIVITY; SIZE	Background: Liposomal-based gadolinium (Gd) nanoparticles have elicited significant interest for use as blood pool and molecular magnetic resonance imaging (MRI) contrast agents. Previous generations of liposomal MR agents contained gadolinium-chelates either within the interior of liposomes (core-encapsulated gadolinium liposomes) or presented on the surface of liposomes (surface-conjugated gadolinium liposomes). We hypothesized that a liposomal agent that contained both core-encapsulated gadolinium and surface-conjugated gadolinium, defined herein as dual-mode gadolinium (Dual-Gd) liposomes, would result in a significant improvement in nanoparticle-based T1 relaxivity over the previous generations of liposomal agents. In this study, we have developed and tested, both in vitro and in vivo, such a dual-mode liposomal-based gadolinium contrast agent. Methodology/Principal Findings: Three types of liposomal agents were fabricated: core-encapsulated, surface-conjugated and dual-mode gadolinium liposomes. In vitro physico-chemical characterizations of the agents were performed to determine particle size and elemental composition. Gadolinium-based and nanoparticle-based T1 relaxivities of various agents were determined in bovine plasma. Subsequently, the agents were tested in vivo for contrast-enhanced magnetic resonance angiography (CE-MRA) studies. Characterization of the agents demonstrated the highest gadolinium atoms per nanoparticle for Dual-Gd liposomes. In vitro, surface- conjugated gadolinium liposomes demonstrated the highest T1 relaxivity on a gadolinium-basis. However, Dual-Gd liposomes demonstrated the highest T1 relaxivity on a nanoparticlebasis. In vivo, Dual-Gd liposomes resulted in the highest signal-to-noise ratio (SNR) and contrast-to-noise ratio in CE-MRA studies. Conclusions/Significance: The dual-mode gadolinium liposomal contrast agent demonstrated higher particle-based T1 relaxivity, both in vitro and in vivo, compared to either the core-encapsulated or the surface- conjugated liposomal agent. The dual-mode gadolinium liposomes could enable reduced particle dose for use in CE-MRA and increased contrast sensitivity for use in molecular imaging.			Ghaghada, KB (corresponding author), Univ Texas Hlth Sci Ctr Houston, Sch Hlth Informat Sci, Houston, TX USA.	ananth.annapragada@uth.tmc.edu	Annapragada, Ananth/GOK-1576-2022; Bankson, James A./J-9798-2014; Ghaghada, Ketan/F-6825-2012	Bankson, James A./0000-0002-8574-154X; Annapragada, Ananth/0000-0002-3156-9617	NATIONAL CANCER INSTITUTE [P30CA016672, P50CA140388] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R90DK071504] Funding Source: NIH RePORTER; NCI NIH HHS [P30 CA016672, P50 CA140388, P30-CA016672] Funding Source: Medline; NIDDK NIH HHS [R90 DK071504, R90 DK71504] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Anzalone Nicoletta, 2006, Eur Radiol, V16 Suppl 7, pM27, DOI 10.1007/s10406-006-0193-2; Ayyagari AL, 2006, MAGN RESON MED, V55, P1023, DOI 10.1002/mrm.20846; Bremerich J, 2007, EUR RADIOL, V17, P3017, DOI 10.1007/s00330-007-0712-0; Bucholz E, 2008, MAGN RESON MED, V60, P111, DOI 10.1002/mrm.21618; Choyke PL, 2003, J MAGN RESON IMAGING, V17, P509, DOI 10.1002/jmri.10304; Frias JC, 2004, J AM CHEM SOC, V126, P16316, DOI 10.1021/ja044911a; Gabizon A, 2003, CLIN PHARMACOKINET, V42, P419, DOI 10.2165/00003088-200342050-00002; Ghaghada KB, 2007, AM J NEURORADIOL, V28, P48; Ghaghada KB, 2005, J CONTROL RELEASE, V104, P113, DOI 10.1016/j.jconrel.2005.01.012; Ghaghada K, 2008, ACAD RADIOL, V15, P1259, DOI 10.1016/j.acra.2008.04.018; Hadizadeh DR, 2008, RADIOLOGY, V249, P701, DOI 10.1148/radiol.2492072033; Ishida O, 1999, INT J PHARM, V190, P49, DOI 10.1016/S0378-5173(99)00256-2; Karathanasis E, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005843; Knopp MV, 2003, J MAGN RESON IMAGING, V17, P694, DOI 10.1002/jmri.10313; Kobayashi H, 2005, ADV DRUG DELIVER REV, V57, P2271, DOI 10.1016/j.addr.2005.09.016; McNeeley KM, 2009, BIOMATERIALS, V30, P3986, DOI 10.1016/j.biomaterials.2009.04.012; Mulder WJM, 2004, BIOCONJUGATE CHEM, V15, P799, DOI 10.1021/bc049949r; Port M, 2005, INVEST RADIOL, V40, P565, DOI 10.1097/01.rli.0000175388.98721.9b; Rosen MA, 2007, CLIN CANCER RES, V13, p770S, DOI 10.1158/1078-0432.CCR-06-1921; Saul JM, 2003, J CONTROL RELEASE, V92, P49, DOI 10.1016/S0168-3659(03)00295-5; Storrs RW, 1995, JMRI-J MAGN RESON IM, V5, P719, DOI 10.1002/jmri.1880050617; Szebeni J, 2005, TOXICOLOGY, V216, P106, DOI 10.1016/j.tox.2005.07.023; TILCOCK C, 1989, RADIOLOGY, V171, P77, DOI 10.1148/radiology.171.1.2928549; Tran TD, 2007, INT J NANOMED, V2, P515; Winter PM, 2003, MAGNET RESON MED, V50, P411, DOI 10.1002/mrm.10532; Zhang HL, 2007, J MAGN RESON IMAGING, V25, P13, DOI 10.1002/jmri.20767	26	73	79	1	37	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA	1932-6203			PLOS ONE	PLoS One	OCT 29	2009	4	10							e7628	10.1371/journal.pone.0007628	http://dx.doi.org/10.1371/journal.pone.0007628			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	512FP	19893616	Green Submitted, Green Published, gold			2022-12-25	WOS:000271232000007
J	Jiang, XJ; Li, SB; Ravi, V; Venkatesh, B; Yu, WP				Jiang, Xiao-Juan; Li, Shaobing; Ravi, Vydianathan; Venkatesh, Byrappa; Yu, Wei-Ping			Identification and Comparative Analysis of the Protocadherin Cluster in a Reptile, the Green Anole Lizard	PLOS ONE			English	Article							CNR/PCDH-ALPHA GENES; GAMMA-PROTOCADHERINS; EVOLUTIONARY HISTORY; SEQUENCE-ANALYSIS; GENOMIC SEQUENCE; FAMILY; EXPRESSION; DIVERSITY; ORGANIZATION; SELECTION	Background: The vertebrate protocadherins are a subfamily of cell adhesion molecules that are predominantly expressed in the nervous system and are believed to play an important role in establishing the complex neural network during animal development. Genes encoding these molecules are organized into a cluster in the genome. Comparative analysis of the protocadherin subcluster organization and gene arrangements in different vertebrates has provided interesting insights into the history of vertebrate genome evolution. Among tetrapods, protocadherin clusters have been fully characterized only in mammals. In this study, we report the identification and comparative analysis of the protocadherin cluster in a reptile, the green anole lizard (Anolis carolinensis). Methodology/Principal Findings: We show that the anole protocadherin cluster spans over a megabase and encodes a total of 71 genes. The number of genes in the anole protocadherin cluster is significantly higher than that in the coelacanth (49 genes) and mammalian (54-59 genes) clusters. The anole protocadherin genes are organized into four subclusters: the delta, alpha, beta and gamma. This subcluster organization is identical to that of the coelacanth protocadherin cluster, but differs from the mammalian clusters which lack the delta subcluster. The gene number expansion in the anole protocadherin cluster is largely due to the extensive gene duplication in the gamma b subgroup. Similar to coelacanth and elephant shark protocadherin genes, the anole protocadherin genes have experienced a low frequency of gene conversion. Conclusions/Significance: Our results suggest that similar to the protocadherin clusters in other vertebrates, the evolution of anole protocadherin cluster is driven mainly by lineage-specific gene duplications and degeneration. Our analysis also shows that loss of the protocadherin delta subcluster in the mammalian lineage occurred after the divergence of mammals and reptiles. We present a model for the evolutionary history of the protocadherin cluster in tetrapods.			Jiang, XJ (corresponding author), Natl Inst Neurosci, Gene Regulat Lab, Singapore, Singapore.	weiping_yu@nni.com.sg	Ravi, Vydianathan/B-2759-2009	Ravi, Vydianathan/0000-0003-0807-7697; Venkatesh, Byrappa/0000-0003-3620-0277				Blank M, 2004, MOL CELL NEUROSCI, V26, P530, DOI 10.1016/j.mcn.2004.04.008; Esumi S, 2005, NAT GENET, V37, P171, DOI 10.1038/ng1500; Guindon S, 2003, SYST BIOL, V52, P696, DOI 10.1080/10635150390235520; Haas IG, 2005, J BIOL CHEM, V280, P9313, DOI 10.1074/jbc.M412909200; Hall T.A., 1999, NUCL ACIDS S SERIES, V41, P95, DOI [DOI 10.1021/BK-1999-0734.CH008, citeulike-article-id:691774, 10.12691/ajmr-6-4-3]; Hamada S, 2001, NEUROSCI RES, V41, P207, DOI 10.1016/S0168-0102(01)00281-4; Hambsch B, 2005, J BIOL CHEM, V280, P15888, DOI 10.1074/jbc.M414359200; Hasegawa S, 2008, MOL CELL NEUROSCI, V38, P66, DOI 10.1016/j.mcn.2008.01.016; Kaneko R, 2006, J BIOL CHEM, V281, P30551, DOI 10.1074/jbc.M605677200; Keane TM, 2006, BMC EVOL BIOL, V6, DOI 10.1186/1471-2148-6-29; Kohmura N, 1998, NEURON, V20, P1137, DOI 10.1016/S0896-6273(00)80495-X; Morishita H, 2006, J BIOL CHEM, V281, P33650, DOI 10.1074/jbc.M603298200; Murata Y, 2004, J BIOL CHEM, V279, P49508, DOI 10.1074/jbc.M408771200; Mutoh T, 2004, EXP CELL RES, V294, P494, DOI 10.1016/j.yexcr.2003.11.019; Noonan JP, 2004, GENOME RES, V14, P2397, DOI 10.1101/gr.2972804; Noonan JP, 2004, GENOME RES, V14, P354, DOI 10.1101/gr.2133704; Noonan JP, 2003, AM J HUM GENET, V72, P621, DOI 10.1086/368060; Phillips GR, 2003, J NEUROSCI, V23, P5096; Ribich S, 2006, P NATL ACAD SCI USA, V103, P19719, DOI 10.1073/pnas.0609445104; Senzaki K, 1999, CELL, V99, P635, DOI 10.1016/S0092-8674(00)81552-4; Serafini T, 1999, CELL, V98, P133, DOI 10.1016/S0092-8674(00)81008-9; Shapiro L, 1999, NEURON, V23, P427, DOI 10.1016/S0896-6273(00)80796-5; Sugino H, 2004, BIOCHEM BIOPH RES CO, V316, P437, DOI 10.1016/j.bbrc.2004.02.067; Tada MN, 2004, GENE, V340, P197, DOI 10.1016/j.gene.2004.07.014; THOMPSON JD, 1994, COMPUT APPL BIOSCI, V10, P19; Vanhalst K, 2001, FEBS LETT, V495, P120, DOI 10.1016/S0014-5793(01)02372-9; Wang XZ, 2002, GENE DEV, V16, P1890, DOI 10.1101/gad.1004802; Wang XZ, 2002, NEURON, V36, P843, DOI 10.1016/S0896-6273(02)01090-5; Weiner JA, 2005, P NATL ACAD SCI USA, V102, P8, DOI 10.1073/pnas.0407931101; Wernersson R, 2003, NUCLEIC ACIDS RES, V31, P3537, DOI 10.1093/nar/gkg609; Wu Q, 2001, GENOME RES, V11, P389, DOI 10.1101/gr.167301; Wu Q, 2005, GENETICS, V169, P2179, DOI 10.1534/genetics.104.037606; Wu Q, 1999, CELL, V97, P779, DOI 10.1016/S0092-8674(00)80789-8; Yanase H, 2004, GENOMICS, V83, P717, DOI 10.1016/j.ygeno.2003.09.022; Yang ZH, 1997, COMPUT APPL BIOSCI, V13, P555; Yu WP, 2008, P NATL ACAD SCI USA, V105, P3819, DOI 10.1073/pnas.0800398105; Yu WP, 2007, BMC EVOL BIOL, V7, DOI 10.1186/1471-2148-7-49; Zou C, 2007, NEUROSCIENCE, V144, P579, DOI 10.1016/j.neuroscience.2006.10.011	38	10	10	0	10	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	OCT 29	2009	4	10							e7614	10.1371/journal.pone.0007614	http://dx.doi.org/10.1371/journal.pone.0007614			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	512FP	19898614	Green Published, Green Submitted, gold			2022-12-25	WOS:000271232000005
J	Gosens, R; Baarsma, HA; Heijink, IH; Oenema, TA; Halayko, AJ; Meurs, H; Schmidt, M				Gosens, Reinoud; Baarsma, Hoeke A.; Heijink, Irene H.; Oenema, Tjitske A.; Halayko, Andrew J.; Meurs, Herman; Schmidt, Martina			De novo synthesis of beta-catenin via H-Ras and MEK regulates airway smooth muscle growth	FASEB JOURNAL			English	Article						GSK-3; airway remodeling; asthma; Wnt; proliferation	IDIOPATHIC PULMONARY-FIBROSIS; MAP KINASE ACTIVATION; CELL-PROLIFERATION; PATHWAY ACTIVATION; COLON-CANCER; WNT; EXPRESSION; CADHERIN; DISEASE; COMPLEX	beta-Catenin is a component of adherens junctions that also acts as a transcriptional coactivator when expressed in the nucleus. Growth factors are believed to regulate the nuclear expression of beta-catenin via inactivation of glycogen synthase kinase 3 (GSK-3) by phosphorylation, resulting in increased beta-catenin protein stability. Here, we report on a novel pathway that regulates the expression and nuclear presence of beta-catenin. In proliferating human airway smooth muscle cells, we observed increased expression of beta-catenin, which was required for proliferation. Interestingly, increased beta-catenin expression was accompanied by an increase in beta-catenin mRNA and was independent of beta-catenin liberation from the plasma membrane, suggesting a role for de novo synthesis. This was confirmed using actinomycin D and cycloheximide, which abrogated the induction and nuclear localization of beta-catenin protein. GSK-3 inhibition using SB216763 failed to regulate beta-catenin mRNA. However, expression of dominant negative H-Ras or pharmacological inhibition of MEK reduced serum and TGF-beta-induced beta-catenin mRNA and protein. Collectively, these data indicate that beta-catenin is an important signaling intermediate in airway smooth muscle growth and that its cellular accumulation and nuclear localization require de novo protein synthesis effected, in part, via H-Ras and MEK.-Gosens, R., Baarsma, H. A., Heijink, I. H., Oenema, T. A., Halayko, A. J., Meurs, H., Schmidt, M. De novo synthesis of beta-catenin via H-Ras and MEK regulates airway smooth muscle growth. FASEB J. 24, 757-768 (2010). www.fasebj.org	[Gosens, Reinoud; Baarsma, Hoeke A.; Oenema, Tjitske A.; Meurs, Herman; Schmidt, Martina] Univ Groningen, Dept Mol Pharmacol, NL-9713 AV Groningen, Netherlands; [Heijink, Irene H.] Univ Med Ctr Groningen, Dept Med Biol & Pathol, NL-9713 AV Groningen, Netherlands; [Halayko, Andrew J.] Univ Manitoba, Dept Physiol, Winnipeg, MB, Canada; [Halayko, Andrew J.] Univ Manitoba, Dept Internal Med, Winnipeg, MB, Canada	University of Groningen; University of Groningen; University of Manitoba; University of Manitoba	Gosens, R (corresponding author), Univ Groningen, Dept Mol Pharmacol, A Deusinglaan 1, NL-9713 AV Groningen, Netherlands.	r.gosens@rug.nl	Schmidt, Martina/C-5339-2018	Schmidt, Martina/0000-0003-3075-0630; Gosens, Reinoud/0000-0002-5595-152X; Halayko, Andrew/0000-0002-7865-4552; Baarsma, Hoeke/0000-0002-0792-0374	Dutch Organisation for Scientific Research (NWO) [916.86.036]; University of Groningen; The Netherlands Asthma Foundation [NAF 3.2.07.023]; Boehringer Ingelheim; Canada Research Chairs Program; Canadian Institutes of Health Research	Dutch Organisation for Scientific Research (NWO)(Netherlands Organization for Scientific Research (NWO)); University of Groningen; The Netherlands Asthma Foundation; Boehringer Ingelheim(Boehringer Ingelheim); Canada Research Chairs Program(Canada Research Chairs); Canadian Institutes of Health Research(Canadian Institutes of Health Research (CIHR))	This work was supported by a Veni grant (916.86.036) from the Dutch Organisation for Scientific Research (NWO) to R. G. M. S. is the recipient of a Rosalind Franklin Fellowship from the University of Groningen. H. A. B. is supported by a grant from The Netherlands Asthma Foundation (NAF 3.2.07.023). T.A.O. is supported by a grant from Boehringer Ingelheim. A.J.H. is supported by the Canada Research Chairs Program and Canadian Institutes of Health Research. We are grateful to Dr. W. T. Gerthoffer (University of Nevada-Reno, Reno, NV, USA) for preparation of the hTERT cell lines used in the study. We thank Bart G. J. Dekkers for expert technical assistance.	Almeida M, 2005, J BIOL CHEM, V280, P41342, DOI 10.1074/jbc.M502168200; An SS, 2007, EUR RESPIR J, V29, P834, DOI 10.1183/09031936.00112606; Barker N, 2006, NAT REV DRUG DISCOV, V5, P997, DOI 10.1038/nrd2154; Blankesteijn WM, 2008, TRENDS PHARMACOL SCI, V29, P175, DOI 10.1016/j.tips.2008.01.003; Bowley E, 2007, J SURG RES, V138, P141, DOI 10.1016/j.jss.2006.07.026; Brabletz T, 1999, AM J PATHOL, V155, P1033, DOI 10.1016/S0002-9440(10)65204-2; Chilosi M, 2003, AM J PATHOL, V162, P1495, DOI 10.1016/S0002-9440(10)64282-4; Clevers H, 2006, CELL, V127, P469, DOI 10.1016/j.cell.2006.10.018; De Langhe SP, 2005, DEV BIOL, V277, P316, DOI 10.1016/j.ydbio.2004.09.023; Ding QQ, 2005, MOL CELL, V19, P159, DOI 10.1016/j.molcel.2005.06.009; Doble BW, 2003, J CELL SCI, V116, P1175, DOI 10.1242/jcs.00384; Douglas IS, 2006, AM J RESP CELL MOL, V34, P274, DOI 10.1165/rcmb.2005-0277OC; George SJ, 2006, ATHEROSCLEROSIS, V188, P1, DOI 10.1016/j.atherosclerosis.2005.12.017; George SJ, 2004, TRENDS CARDIOVAS MED, V14, P100, DOI 10.1016/j.tcm.2003.12.008; Gosens R, 2008, N-S ARCH PHARMACOL, V378, P185, DOI 10.1007/s00210-008-0269-8; Gosens R, 2007, AM J PHYSIOL-LUNG C, V293, pL1348, DOI 10.1152/ajplung.00346.2007; Gosens R, 2007, AM J PHYSIOL-LUNG C, V292, pL1163, DOI 10.1152/ajplung.00471.2006; Gosens R, 2006, AM J PHYSIOL-LUNG C, V291, pL523, DOI 10.1152/ajplung.00013.2006; Gradl D, 1999, MOL CELL BIOL, V19, P5576; Hirst Stuart J, 2004, J Allergy Clin Immunol, V114, pS2, DOI 10.1016/j.jaci.2004.04.039; Howe LR, 1999, CANCER RES, V59, P1572; Hwang SG, 2005, FEBS LETT, V579, P4837, DOI 10.1016/j.febslet.2005.07.067; Iwano M, 2004, CURR OPIN NEPHROL HY, V13, P279, DOI 10.1097/00041552-200405000-00003; Jeffery PK, 2001, AM J RESP CRIT CARE, V164, pS28, DOI 10.1164/ajrccm.164.supplement_2.2106061; Jeon SH, 2007, J BIOL CHEM, V282, P14482, DOI 10.1074/jbc.M611129200; Kim D, 2007, ONCOGENE, V26, P4571, DOI 10.1038/sj.onc.1210230; Kim SE, 2007, CELL SIGNAL, V19, P1554, DOI 10.1016/j.cellsig.2007.02.003; Konigshoff M, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002142; LE FN, 2005, FASEB J, V19, P144; Li QJ, 2004, GENOMICS, V83, P231, DOI 10.1016/j.ygeno.2003.08.004; Marchetti A, 2008, CELL SIGNAL, V20, P2113, DOI 10.1016/j.cellsig.2008.08.002; Masckauchan T. Nestor H., 2005, Angiogenesis, V8, P43, DOI 10.1007/s10456-005-5612-9; Morin PJ, 1997, SCIENCE, V275, P1787, DOI 10.1126/science.275.5307.1787; Nunes RO, 2008, AM J PHYSIOL-LUNG C, V294, pL1110, DOI 10.1152/ajplung.00500.2007; Rahmani M, 2005, J BIOL CHEM, V280, P13019, DOI 10.1074/jbc.M411766200; Slater SC, 2004, ARTERIOSCL THROM VAS, V24, P1204, DOI 10.1161/01.ATV.0000130464.24599.e0; Tetsu O, 1999, NATURE, V398, P422, DOI 10.1038/18884; Thompson MD, 2007, HEPATOLOGY, V45, P1298, DOI 10.1002/hep.21651; Toualbi K, 2007, ONCOGENE, V26, P3492, DOI 10.1038/sj.onc.1210133; Tran T, 2007, AM J RESP CELL MOL, V37, P668, DOI 10.1165/rcmb.2007-0165OC; Tran T, 2006, RESP RES, V7, DOI 10.1186/1465-9921-7-117; Truant SC, 2008, J SURG RES, V150, P212, DOI 10.1016/j.jss.2007.12.800; Uglow EB, 2003, CIRC RES, V92, P1314, DOI 10.1161/01.RES.0000079027.44309.53; Wang Q, 2006, ONCOGENE, V25, P43, DOI 10.1038/sj.onc.1209004; Woodruff PG, 2004, AM J RESP CRIT CARE, V169, P1001, DOI 10.1164/rccm.200311-1529OC; Wu BB, 2007, IMMUNITY, V26, P227, DOI 10.1016/j.immuni.2006.12.007; Zhang XB, 2001, CANCER RES, V61, P6050	47	37	38	0	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	MAR	2010	24	3					757	768		10.1096/fj.09-136325	http://dx.doi.org/10.1096/fj.09-136325			12	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	561KE	19906679				2022-12-25	WOS:000274974600012
J	Bongiorno-Borbone, L; De Cola, A; Barcaroli, D; Knight, RA; Di Ilio, C; Melino, G; De Laurenzi, V				Bongiorno-Borbone, L.; De Cola, A.; Barcaroli, D.; Knight, R. A.; Di Ilio, C.; Melino, G.; De Laurenzi, V.			FLASH degradation in response to UV-C results in histone locus bodies disruption and cell-cycle arrest	ONCOGENE			English	Article						histone locus bodies; Cajal bodies; UV; FLASH	S-PHASE PROGRESSION; DNA-DAMAGE; CAJAL BODIES; GENE-EXPRESSION; E/CDK2 SUBSTRATE; TRANSCRIPTION; P220(NPAT); CHECKPOINT; G(1); BODY	Eucaryotic cell nuclei contain a number of different organelles that are highly dynamic structures and respond to a variety of stimuli. Here we investigated the effect of UV irradiation on a recently identified group of organelles, Histone Locus Bodies. Histone Locus Bodies contain at least two main proteins, FLASH and NPAT, and have been shown to be involved in replication-dependent histone gene transcription. We show that these organelles are disrupted after sublethal irradiation and both FLASH and NPAT are degraded, which in turn results in cell-cycle arrest at the S/G2 transition. The effect on the cell cycle is due to reduced transcription of histone genes and restoring normal histone protein levels by stabilizing histone mRNA allows cells to progress through the cell cycle. This provides a novel mechanism of S-phase arrest in response to DNA damage that potentially allows DNA repair before cells continue into mitosis, and thus prevents transmission of genomic alterations. Oncogene (2010) 29, 802-810; doi:10.1038/onc.2009.388; published online 16 November 2009	[De Laurenzi, V.] Univ G DAnnunzio, Dipartimento Sci Biomed, CeSI, I-66100 Chieti, Italy; [Bongiorno-Borbone, L.; De Cola, A.; Barcaroli, D.; Melino, G.] Univ Roma Tor Vergata, Dept Expt Med, IDI IRCCS Biochem Lab, Rome, Italy; [Barcaroli, D.; Di Ilio, C.; De Laurenzi, V.] Fdn G DAnnunzio, Ctr Studi SullInvecchiamento, Chieti, Italy; [Knight, R. A.; Melino, G.] Univ Leicester, MRC, Toxicol Unit, Leicester, Leics, England	G d'Annunzio University of Chieti-Pescara; University of Rome Tor Vergata; G d'Annunzio University of Chieti-Pescara; University of Leicester	De Laurenzi, V (corresponding author), Univ G DAnnunzio, Dipartimento Sci Biomed, CeSI, Via Colle Ara 1, I-66100 Chieti, Italy.	delaurenzi@unich.it	De Laurenzi, Vincenzo/K-7471-2016	De Laurenzi, Vincenzo/0000-0002-7506-1743; De Cola, Antonella/0000-0002-3202-5339	AIRC; MIUR; EU-EPISTEM; MinSan; Telethon and Alleanza Contro il Cancro; FIRC scholarship; MRC [MC_U132670600] Funding Source: UKRI; Medical Research Council [MC_U132670600] Funding Source: researchfish	AIRC(Fondazione AIRC per la ricerca sul cancro); MIUR(Ministry of Education, Universities and Research (MIUR)); EU-EPISTEM(European Commission); MinSan; Telethon and Alleanza Contro il Cancro(Fondazione Telethon); FIRC scholarship(Fondazione AIRC per la ricerca sul cancro); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission)	We thank Peter D Adams for the SLBP expression plasmid. The work was supported by grants from AIRC, MIUR to VDL, AIRC, EU-EPISTEM, FIRB, MIUR, MinSan, Telethon and Alleanza Contro il Cancro to GM. DB was supported by an FIRC scholarship.	Abraham RT, 2001, GENE DEV, V15, P2177, DOI 10.1101/gad.914401; Barcaroli D, 2006, P NATL ACAD SCI USA, V103, P14802, DOI 10.1073/pnas.0604225103; Barcaroli D, 2006, P NATL ACAD SCI USA, V103, P14808, DOI 10.1073/pnas.0604227103; Bartek J, 2004, NAT REV MOL CELL BIO, V5, P792, DOI 10.1038/nrm1493; Bongiorno-Borbone L, 2008, CELL CYCLE, V7, P2357, DOI 10.4161/cc.6344; Callegari AJ, 2007, CELL CYCLE, V6, P660, DOI 10.4161/cc.6.6.3984; Cioce M, 2006, J CELL BIOL, V175, P401, DOI 10.1083/jcb.200604099; Dellaire G, 2007, CELL CYCLE, V6, P1864, DOI 10.4161/cc.6.15.4560; Galluzzi L, 2009, CELL DEATH DIFFER, V16, P1093, DOI 10.1038/cdd.2009.44; Ghule PN, 2008, P NATL ACAD SCI USA, V105, P16964, DOI 10.1073/pnas.0809273105; Hall C, 2001, MOL CELL BIOL, V21, P1854, DOI 10.1128/MCB.21.5.1854-1865.2001; Liu JL, 2006, J CELL BIOL, V172, P875, DOI 10.1083/jcb.200511038; Ma TL, 2000, GENE DEV, V14, P2298, DOI 10.1101/gad.829500; Marti TM, 2006, P NATL ACAD SCI USA, V103, P9891, DOI 10.1073/pnas.0603779103; Matera AG, 2006, J CELL BIOL, V172, P791, DOI 10.1083/jcb.200602002; Munarriz E, 2004, MOL CELL BIOL, V24, P10593, DOI 10.1128/MCB.24.24.10593-10610.2004; Nelson DM, 2002, MOL CELL BIOL, V22, P7459, DOI 10.1128/MCB.22.21.7459-7472.2002; NICOLETTI I, 1991, J IMMUNOL METHODS, V139, P271, DOI 10.1016/0022-1759(91)90198-O; Nyberg KA, 2002, ANNU REV GENET, V36, P617, DOI 10.1146/annurev.genet.36.060402.113540; Su C, 2004, EMBO J, V23, P1133, DOI 10.1038/sj.emboj.7600120; Wang A, 2004, BIOCHEM BIOPH RES CO, V325, P1509, DOI 10.1016/j.bbrc.2004.10.198; Wei Y, 2003, MOL CELL BIOL, V23, P3669, DOI 10.1128/MCB.23.10.3669-3680.2003; Ye X, 2003, MOL CELL BIOL, V23, P8586, DOI 10.1128/MCB.23.23.8586-8600.2003; Ye XF, 2003, CELL CYCLE, V2, P185, DOI 10.4161/cc.2.3.389; Zhao JY, 2000, GENE DEV, V14, P2283, DOI 10.1101/gad.827700; Zhao JY, 2004, CELL CYCLE, V3, P695	26	20	21	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 11	2010	29	6					802	810		10.1038/onc.2009.388	http://dx.doi.org/10.1038/onc.2009.388			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	553WP	19915611				2022-12-25	WOS:000274397800003
J	Fernau, NS; Fugmann, D; Leyendecker, M; Reimann, K; Grether-Beck, S; Galban, S; Ale-Agha, N; Krutmann, J; Klotz, LO				Fernau, Niklas S.; Fugmann, Dominik; Leyendecker, Martin; Reimann, Kerstin; Grether-Beck, Susanne; Galban, Stefanie; Ale-Agha, Niloofar; Krutmann, Jean; Klotz, Lars-Oliver			Role of HuR and p38(MAPK) in Ultraviolet B-induced Post-transcriptional Regulation of COX-2 Expression in the Human Keratinocyte Cell Line HaCaT	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED PROTEIN-KINASE; MESSENGER-RNA STABILITY; EXTRACELLULAR GENERATION; P38; CYCLOOXYGENASE-2; PHOSPHORYLATION; STABILIZATION; INHIBITION; IRRADIATION; RECEPTOR	COX-2 (cyclooxygenase-2) is a pivotal player in inflammatory processes, and ultraviolet radiation is a known stimulus for COX-2 expression in skin cells. Here, an induction of COX-2 expression in HaCaT human keratinocytes was observed only upon exposure of cells to UVB (280-320 nm) but not to UVA radiation (320-400 nm), as demonstrated by reverse transcription-PCR and Western blotting. Prostaglandin E-2 levels were elevated in cell culture supernatants of HaCaT cells exposed to UVB. COX-2 mRNA stability was dramatically increased by UV Birradiation. Both the stabilization of COX-2 mRNA and the enhancement of COX-2 steady-state mRNA and protein levels caused by UVB were prevented both by inhibition and small interfering RNA-induced depletion of p38(MAPK), a kinase strongly activated upon exposure to UVB, suggesting p38MAPK-dependent mRNA stabilization as a mechanism of UVB-induced COX-2 expression. A dramatic decrease in COX-2 expression induced by UVB was elicited by small interfering RNA-based depletion of a stress-responsive mRNA stabilizing protein regulated by p38MAPK, i.e. HuR; UVB-induced elevation of COX-2 mRNA and protein levels coincided with an accumulation of HuR in the cytoplasm and was attenuated in cells depleted of HuR. Moreover, UVB-induced generation of prostaglandin E-2 by HaCaT cells was blunted by HuR depletion, suggesting that stress kinases (such as p38MAPK) as well as HuR are excellent targets for approaches aiming at interfering with induction of COX-2 expression by UVB.	[Fernau, Niklas S.; Fugmann, Dominik; Leyendecker, Martin; Reimann, Kerstin; Grether-Beck, Susanne; Galban, Stefanie; Ale-Agha, Niloofar; Krutmann, Jean; Klotz, Lars-Oliver] Leibniz Inst Umweltmed Forsch, D-40225 Dusseldorf, Germany	Leibniz Institut fur Umweltmedizinische Forschung (IUF)	Klotz, LO (corresponding author), Leibniz Inst Umweltmed Forsch, Aufm Hennekamp 50, D-40225 Dusseldorf, Germany.	LarsOliver.Klotz@uni-duesseldorf.de	Klotz, Lars Oliver/AAC-5051-2019	Klotz, Lars Oliver/0000-0002-1261-8911	Deutsche Forschungsgemeinschaft [SFB728]; Bundesministerium fur Bildung und Forschung [03NUK003C]; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM067827] Funding Source: NIH RePORTER	Deutsche Forschungsgemeinschaft(German Research Foundation (DFG)); Bundesministerium fur Bildung und Forschung(Federal Ministry of Education & Research (BMBF)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	This work was supported by Deutsche Forschungsgemeinschaft Grant SFB728 and by Bundesministerium fur Bildung und Forschung Grant 03NUK003C.	Abdelmohsen K, 2008, BIOL CHEM, V389, P243, DOI 10.1515/BC.2008.022; Abdelmohsen K, 2007, MOL CELL, V25, P543, DOI 10.1016/j.molcel.2007.01.011; Bachelor MA, 2005, MOL CANCER RES, V3, P90, DOI 10.1158/1541-7786.MCR-04-0065; Bachelor MA, 2002, ONCOGENE, V21, P7092, DOI 10.1038/sj.onc.1205855; Bain J, 2007, BIOCHEM J, V408, P297, DOI 10.1042/BJ20070797; Bollig F, 2002, EUR J BIOCHEM, V269, P5830, DOI 10.1046/j.1432-1033.2002.03300.x; BOUKAMP P, 1988, J CELL BIOL, V106, P761, DOI 10.1083/jcb.106.3.761; Brennan CM, 2001, CELL MOL LIFE SCI, V58, P266, DOI 10.1007/PL00000854; Brenneisen P, 1998, J BIOL CHEM, V273, P5279, DOI 10.1074/jbc.273.9.5279; Buckman SY, 1998, CARCINOGENESIS, V19, P723, DOI 10.1093/carcin/19.5.723; Chandrasekharan NV, 2002, P NATL ACAD SCI USA, V99, P13926, DOI 10.1073/pnas.162468699; Chen WX, 2001, ONCOGENE, V20, P3921, DOI 10.1038/sj.onc.1204530; Davies SP, 2000, BIOCHEM J, V351, P95, DOI 10.1042/0264-6021:3510095; Doller A, 2008, MOL CELL BIOL, V28, P2608, DOI 10.1128/MCB.01530-07; Doller A, 2007, MOL BIOL CELL, V18, P2137, DOI 10.1091/mbc.E06-09-0850; Fritsche E, 2007, P NATL ACAD SCI USA, V104, P8851, DOI 10.1073/pnas.0701764104; Gallouzi IE, 2001, RNA, V7, P1348, DOI 10.1017/s1355838201016089; Gowrishankar G, 2005, BIOL CHEM, V386, P1287, DOI 10.1515/BC.2005.146; GSCHWENDT M, 1994, BIOCHEM BIOPH RES CO, V199, P93, DOI 10.1006/bbrc.1994.1199; Kim HH, 2008, CELL CYCLE, V7, P3371; Kim HH, 2008, GENE DEV, V22, P1804, DOI 10.1101/gad.1645808; Klotz LO, 2002, BIOL CHEM, V383, P443, DOI 10.1515/BC.2002.047; Klotz LO, 1999, EUR J BIOCHEM, V260, P917, DOI 10.1046/j.1432-1327.1999.00255.x; Lafarga V, 2009, MOL CELL BIOL, V29, P4341, DOI 10.1128/MCB.00210-09; Mahns A, 2004, PHOTOCH PHOTOBIO SCI, V3, P257, DOI 10.1039/b309067a; Mahns A, 2003, FREE RADICAL RES, V37, P391, DOI 10.1080/1071576031000064702; MARTINYBARON G, 1993, J BIOL CHEM, V268, P9194; Rousseau S, 2002, EMBO J, V21, P6505, DOI 10.1093/emboj/cdf639; Rundhaug JE, 2008, PHOTOCHEM PHOTOBIOL, V84, P322, DOI 10.1111/j.1751-1097.2007.00261.x; Smith WL, 1996, J BIOL CHEM, V271, P33157, DOI 10.1074/jbc.271.52.33157; Subbaramaiah K, 2003, J BIOL CHEM, V278, P37637, DOI 10.1074/jbc.M301481200; Tang QB, 2001, ONCOGENE, V20, P5164, DOI 10.1038/sj.onc.1204667; von Montfort C, 2006, FREE RADICAL BIO MED, V41, P1478, DOI 10.1016/j.freeradbiomed.2006.08.005; Wang WG, 2000, MOL CELL BIOL, V20, P760, DOI 10.1128/MCB.20.3.760-769.2000; Zhang J, 2008, MOL CARCINOGEN, V47, P974, DOI 10.1002/mc.20450	35	43	45	0	8	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 5	2010	285	6					3896	3904		10.1074/jbc.M109.081430	http://dx.doi.org/10.1074/jbc.M109.081430			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	564YF	19917608	Green Published, hybrid			2022-12-25	WOS:000275254000043
J	Bommer, UA; Heng, C; Perrin, A; Dash, P; Lobov, S; Elia, A; Clemens, MJ				Bommer, U-A; Heng, C.; Perrin, A.; Dash, P.; Lobov, S.; Elia, A.; Clemens, M. J.			Roles of the translationally controlled tumour protein (TCTP) and the double-stranded RNA-dependent protein kinase, PKR, in cellular stress responses	ONCOGENE			English	Article						TCTP; PKR; p53; apoptosis; cell stress	MESSENGER-RNA; ALPHA-SUBUNIT; CALCIUM; ACTIVATION; APOPTOSIS; GENE; INITIATION; FORTILIN; TARGET; GROWTH	Translationally controlled tumour protein (TCTP) is a highly conserved protein present in all eukaryotic organisms. Various cellular functions and molecular interactions have been ascribed to this protein, many related to its growth-promoting and antiapoptotic properties. TCTP levels are highly regulated in response to various cellular stimuli and stresses. We have shown recently that the double-stranded RNA-dependent protein kinase, PKR, is involved in translational regulation of TCTP. Here we extend these studies by demonstrating that TCTP is downregulated in response to various proapoptotic treatments, in particular agents that induce Ca+ (+) stress, in a PKR-dependent manner. This regulation requires phosphorylation of protein synthesis factor eIF2 alpha. Since TCTP has been characterized as an antiapoptotic and Ca+ +- binding protein, we asked whether it is involved in protecting cells from Ca+ (+)- stress-induced apoptosis. Overexpression of TCTP partially protects cells against thapsigargin-induced apoptosis, as measured using caspase-3 activation assays, a nuclear fragmentation assay, using fluorescence-activated cell sorting analysis, and time-lapse video microscopy. TCTP also protects cells against the proapoptotic effects of tunicamycin and etoposide, but not against those of arsenite. Our results imply that cellular TCTP levels influence sensitivity to apoptosis and that PKR may exert its proapoptotic effects at least in part through downregulation of TCTP via eIF2 alpha phosphorylation. Oncogene (2010) 29, 763-773; doi: 10.1038/onc.2009.380; published online 9 November 2009	[Bommer, U-A; Heng, C.; Perrin, A.; Dash, P.; Lobov, S.; Elia, A.; Clemens, M. J.] Univ London, Div Basic Med Sci, London, England	University of London	Bommer, UA (corresponding author), Univ Wollongong, Grad Sch Med, Northfields Ave,Bldg 28, Wollongong, NSW 2522, Australia.	ubommer@uow.edu.au	Lobov, Sergei A/A-8803-2011; Elia, Androulla/AAE-6854-2021	Dash, Phil/0000-0002-6029-4560; Bommer, Ulrich/0000-0003-1110-7615	Wellcome Trust; Cancer Prevention Research Trust; Association for International Cancer Research	Wellcome Trust(Wellcome TrustEuropean Commission); Cancer Prevention Research Trust; Association for International Cancer Research	We thank Drs Charles Weissmann, Randy Kaufman and Donalyn Scheuner for cell lines; Mr Bill Newman for help in performing the initial fluorescence-activated cell sorting analysis experiments; Dr Constantina Constantinou for providing extracts from mouse erythroleukaemia cells and members of Dr Guy Whitley's laboratory for help with the cell-video microscopy facilities. This work was supported by The Wellcome Trust (UAB and MJC), the Cancer Prevention Research Trust (UAB) and the Association for International Cancer Research (MJC).	Barber GN, 2005, CELL DEATH DIFFER, V12, P563, DOI 10.1038/sj.cdd.4401643; Ben-Asouli Y, 2002, CELL, V108, P221, DOI 10.1016/S0092-8674(02)00616-5; Berkowitz O, 2008, PLANT CELL, V20, P3430, DOI 10.1105/tpc.108.061010; Bommer UA, 2002, RNA, V8, P478, DOI 10.1017/S1355838202022586; Bommer UA, 2004, INT J BIOCHEM CELL B, V36, P379, DOI 10.1016/S1357-2725(03)00213-9; Brostrom CO, 1998, PROG NUCLEIC ACID RE, V58, P79; Cans C, 2003, P NATL ACAD SCI USA, V100, P13892, DOI 10.1073/pnas.2335950100; Chen SH, 2007, MOL BIOL CELL, V18, P2525, DOI 10.1091/mbc.E07-02-0188; Chen YC, 1998, J CELL PHYSIOL, V177, P324, DOI 10.1002/(SICI)1097-4652(199811)177:2<324::AID-JCP14>3.0.CO;2-9; Constantinou C, 2007, CELL DEATH DIFFER, V14, P576, DOI 10.1038/sj.cdd.4402045; Davis S, 1996, P NATL ACAD SCI USA, V93, P508, DOI 10.1073/pnas.93.1.508; Efferth T, 2005, DRUG RESIST UPDATE, V8, P85, DOI 10.1016/j.drup.2005.04.003; Feng YG, 2007, ARCH BIOCHEM BIOPHYS, V467, P48, DOI 10.1016/j.abb.2007.08.021; Fritsch RM, 2007, J BIOL CHEM, V282, DOI 10.1074/jbc.M702673200; Gachet Y, 1999, J CELL SCI, V112, P1257; Garcia MA, 2007, BIOCHIMIE, V89, P799, DOI 10.1016/j.biochi.2007.03.001; Garcia MA, 2006, MICROBIOL MOL BIOL R, V70, P1032, DOI 10.1128/MMBR.00027-06; Gnanasekar M, 2007, PARASITOL RES, V101, P1533, DOI 10.1007/s00436-007-0671-z; Gnanasekar M, 2009, INT J ONCOL, V34, P1241, DOI 10.3892/ijo_00000252; Graidist P, 2007, BIOCHEM J, V408, P181, DOI 10.1042/BJ20070679; Harding HP, 1999, NATURE, V397, P271, DOI 10.1038/16729; Harding HP, 2000, MOL CELL, V6, P1099, DOI 10.1016/S1097-2765(00)00108-8; Hsu YC, 2007, NATURE, V445, P785, DOI 10.1038/nature05528; Ito T, 1999, J BIOL CHEM, V274, P15427, DOI 10.1074/jbc.274.22.15427; Jung J, 2004, J BIOL CHEM, V279, P49868, DOI 10.1074/jbc.M400895200; Kim JE, 2008, EXP MOL MED, V40, P709, DOI 10.3858/emm.2008.40.6.709; Kim M, 2000, ARCH PHARM RES, V23, P633, DOI 10.1007/BF02975253; Kim MJ, 2008, J MOL CELL CARDIOL, V44, P151, DOI 10.1016/j.yjmcc.2007.09.017; Koziol MJ, 2007, CURR BIOL, V17, P801, DOI 10.1016/j.cub.2007.03.062; Lee ES, 2007, FEBS LETT, V581, P4325, DOI 10.1016/j.febslet.2007.08.001; Li F, 2001, J BIOL CHEM, V276, P47542, DOI 10.1074/jbc.M108954200; Liu H, 2005, MOL CELL BIOL, V25, P3117, DOI 10.1128/MCB.25.8.3117-3126.2005; Lu LR, 2001, MOL CELL BIOL, V21, P7971, DOI 10.1128/MCB.21.23.7971-7980.2001; MA Q, 2009, J PROTEOME RES; Onuki R, 2004, EMBO J, V23, P959, DOI 10.1038/sj.emboj.7600049; Patel CV, 2000, J BIOL CHEM, V275, P37993, DOI 10.1074/jbc.M004762200; PROSTKO CR, 1995, J BIOL CHEM, V270, P6211, DOI 10.1074/jbc.270.11.6211; Rehmann H, 2008, FEBS LETT, V582, P3005, DOI 10.1016/j.febslet.2008.07.057; Scheuner D, 2006, J BIOL CHEM, V281, P21458, DOI 10.1074/jbc.M603784200; Schmidt I, 2007, FEBS J, V274, P5416, DOI 10.1111/j.1742-4658.2007.06069.x; Singh M, 2009, J MOL BIOL, V385, P457, DOI 10.1016/j.jmb.2008.10.068; Slaby O, 2009, ONCOL REP, V21, P1235, DOI 10.3892/or_00000346; SPECTOR DL, 1998, CELLS LAB MANUAL, V1; SRIVASTAVA SP, 1995, J BIOL CHEM, V270, P16619, DOI 10.1074/jbc.270.28.16619; Susini L, 2008, CELL DEATH DIFFER, V15, P1211, DOI 10.1038/cdd.2008.18; Tani T, 2007, CLONING STEM CELLS, V9, P267, DOI 10.1089/clo.2006.0072; Telerman A, 2009, NAT REV CANCER, V9, P206, DOI 10.1038/nrc2589; Tuynder M, 2004, P NATL ACAD SCI USA, V101, P15364, DOI 10.1073/pnas.0406776101; Tuynder M, 2002, P NATL ACAD SCI USA, V99, P14976, DOI 10.1073/pnas.222470799; van de Sande WWJ, 2006, J IMMUNOL, V177, P1997, DOI 10.4049/jimmunol.177.3.1997; Vonakis BM, 2008, BLOOD, V111, P1789, DOI 10.1182/blood-2007-07-104364; Wang XM, 2008, J BIOL CHEM, V283, P30482, DOI 10.1074/jbc.M803348200; Xiong ZY, 2009, ATHEROSCLEROSIS, V203, P401, DOI 10.1016/j.atherosclerosis.2008.07.041; Xu AM, 1999, BIOCHEM J, V342, P683, DOI 10.1042/0264-6021:3420683; Xu CY, 2005, J CLIN INVEST, V115, P2656, DOI 10.1172/JCI26373; Yang Y, 2005, ONCOGENE, V24, P4778, DOI 10.1038/sj.onc.1208666; Yoon CH, 2009, P NATL ACAD SCI USA, V106, P7852, DOI 10.1073/pnas.0812148106; Zhang D, 2002, J BIOL CHEM, V277, P37430, DOI 10.1074/jbc.M207413200	58	34	40	0	17	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 4	2010	29	5					763	773		10.1038/onc.2009.380	http://dx.doi.org/10.1038/onc.2009.380			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	551QI	19901967				2022-12-25	WOS:000274223700012
J	Miao, L; Song, Z; Jin, L; Zhu, YM; Wen, LP; Wu, M				Miao, L.; Song, Z.; Jin, L.; Zhu, Y. M.; Wen, L. P.; Wu, M.			ARF antagonizes the ability of Miz-1 to inhibit p53-mediated transactivation	ONCOGENE			English	Article						p53; Miz-1; p14ARF; protein/protein interaction; transcription	CELL-CYCLE ARREST; TUMOR-SUPPRESSOR; GENE-REGULATION; MYC; P53; ASSOCIATION; EXPRESSION; INK4A/ARF; P19(ARF); CANCER	Although Myc-interacting zinc-finger protein-1 (Miz-1) is known to be a poxvirus and zinc-finger (POZ) transcription factor required for Myc transcriptional repression, additional regulatory function of Miz-1 is less well understood. Using a yeast two-hybrid screen, we identified human alternate reading frame (ARF) protein as a novel interaction partner of Miz-1. The zinc-finger domain of Miz-1 is involved in its binding to ARF. In addition, we found that Miz-1 was able to interact with p53 through its DNA-binding domain, thus to diminish the binding of p53 to its target promoter and inhibit p53-mediated gene transcription. Interestingly, the Miz-1-regulated p53 transcriptional suppression does not require the presence of ARF or Mdm2. Importantly, ARF and p53 were found to competitively bind to Miz-1 in regulating p53-mediated transcription, and this conclusion was verified by both in vitro binding assay and competitive chromatin immunoprecipitation assay using a bona fide p53 endogenous Bax and Puma promoters. Thus, our study reveals that Miz-1 acts as a p53 suppressor by interfering with p53 DNA-binding ability, and ARF is able to counteract the suppression of Miz-1 on p53 by direct binding to Miz-1, suggesting that Miz-1 is a novel mediator in the ARF-p53 pathway. Oncogene (2010) 29, 711-722; doi: 10.1038/onc.2009.372; published online 9 November 2009	[Miao, L.; Jin, L.; Zhu, Y. M.; Wen, L. P.; Wu, M.] Univ Sci & Technol China, Hefei Natl Lab Phys Sci Microscale, Hefei 230027, Anhui, Peoples R China; [Miao, L.; Jin, L.; Zhu, Y. M.; Wen, L. P.; Wu, M.] Univ Sci & Technol China, Sch Life Sci, Hefei 230027, Anhui, Peoples R China; [Song, Z.] CALTECH, Div Biol, Pasadena, CA 91125 USA	Chinese Academy of Sciences; University of Science & Technology of China, CAS; Chinese Academy of Sciences; University of Science & Technology of China, CAS; California Institute of Technology	Wu, M (corresponding author), Univ Sci & Technol China, Hefei Natl Lab Phys Sci Microscale, 96 Huangshan Rd, Hefei 230027, Anhui, Peoples R China.	wumian@ustc.edu.cn	Jin, Lei/J-1896-2019; Wu, Mian/H-2494-2018	Jin, Lei/0000-0001-7187-9671; Wen, Longping/0000-0003-0384-4578; Wu, Mian/0000-0002-2714-0500	National Natural Science Foundation of China [30530200, 30728003, 30871290]; Ministry of Science and Technology of China [2006CB933300, 2006CB0N1402, 2006CB910300]; Chinese Academy of Sciences [KSCX1-YW-R-57]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Ministry of Science and Technology of China(Ministry of Science and Technology, China); Chinese Academy of Sciences(Chinese Academy of Sciences)	We thank Dr Nickie Chan for English checking and Dr Ratna B Ray for the plasmid pGL3-13-p53-Luc. This study was supported by grants from the National Natural Science Foundation of China (30530200, 30728003 and 30871290), the Ministry of Science and Technology of China (2006CB933300, 2006CB0N1402, and 2006CB910300) and the Chinese Academy of Sciences (KSCX1-YW-R-57).	Adhikary S, 2003, MOL CELL BIOL, V23, P7648, DOI 10.1128/MCB.23.21.7648-7657.2003; ALBAGLI O, 1995, CELL GROWTH DIFFER, V6, P1193; BARDWELL VJ, 1994, GENE DEV, V8, P1664, DOI 10.1101/gad.8.14.1664; Bothner B, 2001, J MOL BIOL, V314, P263, DOI 10.1006/jmbi.2001.5110; Chen DL, 2005, CELL, V121, P1071, DOI 10.1016/j.cell.2005.03.037; Collins T, 2001, MOL CELL BIOL, V21, P3609, DOI 10.1128/MCB.21.11.3609-3615.2001; Giaccia AJ, 1998, GENE DEV, V12, P2973, DOI 10.1101/gad.12.19.2973; Ha L, 2007, P NATL ACAD SCI USA, V104, P10968, DOI 10.1073/pnas.0611638104; Hershko T, 2004, J BIOL CHEM, V279, P8627, DOI 10.1074/jbc.M312866200; Honda R, 1999, EMBO J, V18, P22, DOI 10.1093/emboj/18.1.22; Kamijo T, 1998, P NATL ACAD SCI USA, V95, P8292, DOI 10.1073/pnas.95.14.8292; Kelly KF, 2006, TRENDS CELL BIOL, V16, P578, DOI 10.1016/j.tcb.2006.09.003; Korgaonkar C, 2005, MOL CELL BIOL, V25, P1258, DOI 10.1128/MCB.25.4.1258-1271.2005; LANE DP, 1992, NATURE, V358, P15, DOI 10.1038/358015a0; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; Lowe SW, 2003, CURR OPIN GENET DEV, V13, P77, DOI 10.1016/S0959-437X(02)00013-8; Midgley CA, 2000, ONCOGENE, V19, P2312, DOI 10.1038/sj.onc.1203593; Patel JH, 2007, J BIOL CHEM, V282, P5, DOI 10.1074/jbc.M609138200; Peukert K, 1997, EMBO J, V16, P5672, DOI 10.1093/emboj/16.18.5672; Pomerantz J, 1998, CELL, V92, P713, DOI 10.1016/S0092-8674(00)81400-2; QUELLE DE, 1995, CELL, V83, P993; Ruas M, 1998, BBA-REV CANCER, V1378, pF115, DOI 10.1016/S0304-419X(98)00017-1; Sakurai T, 2004, J BIOL CHEM, V279, P15505, DOI 10.1074/jbc.M310437200; Salghetti SE, 1999, EMBO J, V18, P717, DOI 10.1093/emboj/18.3.717; Schneider A, 1997, CURR TOP MICROBIOL, V224, P137; Seoane J, 2001, NAT CELL BIOL, V3, P400, DOI 10.1038/35070086; Sharpless NE, 2005, MUTAT RES-FUND MOL M, V576, P22, DOI 10.1016/j.mrfmmm.2004.08.021; Sharpless NE, 1999, CURR OPIN GENET DEV, V9, P22, DOI 10.1016/S0959-437X(99)80004-5; Sherr CJ, 2001, NAT REV MOL CELL BIO, V2, P731, DOI 10.1038/35096061; Staller P, 2001, NAT CELL BIOL, V3, P392, DOI 10.1038/35070076; Suzuki H, 2005, BIOCHEM BIOPH RES CO, V326, P242, DOI 10.1016/j.bbrc.2004.11.016; Tago K, 2005, P NATL ACAD SCI USA, V102, P7689, DOI 10.1073/pnas.0502978102; Vogelstein B, 2000, NATURE, V408, P307, DOI 10.1038/35042675; Vousden KH, 2002, NAT REV CANCER, V2, P594, DOI 10.1038/nrc864; Wanzel M, 2005, NAT CELL BIOL, V7, P30, DOI 10.1038/ncb1202; Weber JD, 2000, GENE DEV, V14, P2358, DOI 10.1101/gad.827300; Wu SQ, 2003, ONCOGENE, V22, P351, DOI 10.1038/sj.onc.1206145; Zhao NX, 2004, J CELL BIOCHEM, V92, P65, DOI 10.1002/jcb.20025; Ziegelbauer J, 2004, P NATL ACAD SCI USA, V101, P458, DOI 10.1073/pnas.0307562100	39	22	23	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 4	2010	29	5					711	722		10.1038/onc.2009.372	http://dx.doi.org/10.1038/onc.2009.372			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	551QI	19901969				2022-12-25	WOS:000274223700008
J	Ruas, JL; Berchner-Pfannschmidt, U; Malik, S; Gradin, K; Fandrey, J; Roeder, RG; Pereira, T; Poellinger, L				Ruas, Jorge L.; Berchner-Pfannschmidt, Utta; Malik, Sohail; Gradin, Katarina; Fandrey, Joachim; Roeder, Robert G.; Pereira, Teresa; Poellinger, Lorenz			Complex Regulation of the Transactivation Function of Hypoxia-inducible Factor-1 alpha by Direct Interaction with Two Distinct Domains of the CREB-binding Protein/p300	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							UBIQUITIN-PROTEASOME PATHWAY; TUMOR-SUPPRESSOR PROTEIN; HIPPEL-LINDAU PROTEIN; GENE-EXPRESSION; FACTOR 1-ALPHA; TRANSCRIPTIONAL REPRESSION; PROLYL HYDROXYLATION; STRUCTURAL BASIS; HIF-ALPHA; P53	Activation of transcription in response to low oxygen tension is mediated by the hypoxia-inducible factor-1 (HIF-1). HIF-1 is a heterodimer of two proteins: aryl hydrocarbon receptor nuclear translocator and the oxygen-regulated HIF-1 alpha. The C-terminal activation domain of HIF-1 alpha has been shown to interact with cysteine/histidine-rich region 1 (CH1) of the coactivator CBP/p300 in a hypoxia-dependent manner. However, HIF forms lacking C-terminal activation domain (naturally occurring or genetically engineered) are still able to activate transcription of target genes in hypoxia. Here, we demonstrate that the N-terminal activation domain (N-TAD) of HIF-1 alpha interacts with endogenous CBP and that this interaction facilitates its transactivation function. Our results show that interaction of HIF-1 alpha N-TAD with CBP/p300 is mediated by the CH3 region of CBP known to interact with, among other factors, p53. Using fluorescence resonance energy transfer experiments, we demonstrate that N-TAD interacts with CH3 in vivo. Coimmunoprecipitation assays using endogenous proteins showed that immunoprecipitation of CBP in hypoxia results in the recovery of a larger fraction of HIF-1 alpha than of p53. Chromatin immunoprecipitation demonstrated that at 1% O-2 CBP is recruited to a HIF-1 alpha but not to a p53 target gene. Upon activation of both pathways, lower levels of chromatin-associated CBP were detected at either target gene promoter. These results identify CBP as the coactivator directly interacting with HIF-1 alpha N-TAD and mediating the transactivation function of this domain. Thus, we suggest that in hypoxia HIF-1 alpha is a major CBP-interacting transcription factor that may compete with other CBP-dependent factors, including p53, for limiting amounts of this coactivator, underscoring the complexity in the regulation of gene expression by HIF-1 alpha.	[Ruas, Jorge L.; Gradin, Katarina; Pereira, Teresa; Poellinger, Lorenz] Karolinska Inst, Dept Cell & Mol Biol, S-17177 Stockholm, Sweden; [Berchner-Pfannschmidt, Utta; Fandrey, Joachim] Univ Duisburg Essen, Inst Physiol, D-45122 Essen, Germany; [Malik, Sohail; Roeder, Robert G.] Rockefeller Univ, Biochem & Mol Biol Lab, New York, NY 10021 USA; [Poellinger, Lorenz] Natl Univ Singapore, Canc Sci Inst Singapore, Singapore 117456, Singapore	Karolinska Institutet; University of Duisburg Essen; Rockefeller University; National University of Singapore	Poellinger, L (corresponding author), Karolinska Inst, Dept Cell & Mol Biol, Eulers Vag 3, S-17177 Stockholm, Sweden.	Lorenz.Poellinger@ki.se	Ruas, Jorge/AAE-6094-2019; Fandrey, Joachim/AAA-3524-2021; Pereira, Teresa/AAP-8197-2020	Ruas, Jorge/0000-0002-1110-2606; Pereira, Teresa/0000-0001-8654-2385; Fandrey, Joachim/0000-0001-9585-0531	National Institutes of Health [DK060764, DK071900, CA129325]; Swedish Medical Research Council; Swedish Cancer Foundation; Swedish Heart-Lung Foundation; European Union; NATIONAL CANCER INSTITUTE [R01CA129325] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK060764, R01DK071900] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Swedish Medical Research Council(Swedish Medical Research Council (SMRC)); Swedish Cancer Foundation; Swedish Heart-Lung Foundation(Swedish Heart-Lung Foundation); European Union(European Commission); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))	This work was supported, in whole or in part, by National Institutes of Health Grants DK060764 (to S. M.) and DK071900 and CA129325 (to R. G. R.). This work was also supported by grants from the Swedish Medical Research Council (to T. P. and L. P.) and from the Swedish Cancer Foundation, the Swedish Heart-Lung Foundation, and the European Union (to L. P.). 1 Supported in part by a short term grant from the Swedish Cancer Foundation. Present address: Dana-Farber Cancer Institute and Harvard Medical School, Dept. of Cancer Biology, Boston, MA 02115.	Arany Z, 1996, P NATL ACAD SCI USA, V93, P12969, DOI 10.1073/pnas.93.23.12969; Ashcroft M, 2000, MOL CELL BIOL, V20, P3224, DOI 10.1128/MCB.20.9.3224-3233.2000; Avantaggiati ML, 1997, CELL, V89, P1175, DOI 10.1016/S0092-8674(00)80304-9; Bannister AJ, 1996, NATURE, V384, P641, DOI 10.1038/384641a0; Barlev NA, 2001, MOL CELL, V8, P1243, DOI 10.1016/S1097-2765(01)00414-2; Berchner-Pfannschmidt U, 2004, J BIOL CHEM, V279, P44976, DOI 10.1074/jbc.M313995200; Blagosklonny MV, 1998, J BIOL CHEM, V273, P11995, DOI 10.1074/jbc.273.20.11995; Blobel GA, 2002, J LEUKOCYTE BIOL, V71, P545; Bruick RK, 2001, SCIENCE, V294, P1337, DOI 10.1126/science.1066373; Carrero P, 2000, MOL CELL BIOL, V20, P402, DOI 10.1128/MCB.20.1.402-415.2000; Chakravarti D, 1999, CELL, V96, P393, DOI 10.1016/S0092-8674(00)80552-8; Cockman ME, 2000, J BIOL CHEM, V275, P25733, DOI 10.1074/jbc.M002740200; Dames SA, 2002, P NATL ACAD SCI USA, V99, P5271, DOI 10.1073/pnas.082121399; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; Ema M, 1999, EMBO J, V18, P1905, DOI 10.1093/emboj/18.7.1905; Epstein ACR, 2001, CELL, V107, P43, DOI 10.1016/S0092-8674(01)00507-4; Espinosa JM, 2001, MOL CELL, V8, P57, DOI 10.1016/S1097-2765(01)00283-0; Filippi S, 2008, EMBO J, V27, P2545, DOI 10.1038/emboj.2008.180; Freedman SJ, 2002, P NATL ACAD SCI USA, V99, P5367, DOI 10.1073/pnas.082117899; Frisch SM, 2002, NAT REV MOL CELL BIO, V3, P441, DOI 10.1038/nrm827; Grossman SR, 1998, MOL CELL, V2, P405, DOI 10.1016/S1097-2765(00)80140-9; Grossman SR, 2003, SCIENCE, V300, P342, DOI 10.1126/science.1080386; Gu J, 2001, J BIOL CHEM, V276, P3550, DOI 10.1074/jbc.M009522200; Gu W, 1997, NATURE, V387, P819, DOI 10.1038/42972; Gu YZ, 1998, GENE EXPRESSION, V7, P205; Hamamori Y, 1999, CELL, V96, P405, DOI 10.1016/S0092-8674(00)80553-X; Hammond EM, 2006, MOL CELL BIOL, V26, P3492, DOI 10.1128/MCB.26.9.3492-3504.2006; Holmquist-Mengelbier L, 2006, CANCER CELL, V10, P413, DOI 10.1016/j.ccr.2006.08.026; Huang LE, 1998, P NATL ACAD SCI USA, V95, P7987, DOI 10.1073/pnas.95.14.7987; Ivan M, 2001, SCIENCE, V292, P464, DOI 10.1126/science.1059817; Jaakkola P, 2001, SCIENCE, V292, P468, DOI 10.1126/science.1059796; Kallio PJ, 1998, EMBO J, V17, P6573, DOI 10.1093/emboj/17.22.6573; Kallio PJ, 1999, J BIOL CHEM, V274, P6519, DOI 10.1074/jbc.274.10.6519; Kaluzova M, 2004, MOL CELL BIOL, V24, P5757, DOI 10.1128/MCB.24.13.5757-5766.2004; Kamura T, 2000, P NATL ACAD SCI USA, V97, P10430, DOI 10.1073/pnas.190332597; Kasper LH, 2005, EMBO J, V24, P3846, DOI 10.1038/sj.emboj.7600846; Kim WY, 2006, SEMIN ONCOL, V33, P588, DOI 10.1053/j.seminoncol.2006.06.001; Koumenis C, 2001, MOL CELL BIOL, V21, P1297, DOI 10.1128/MCB.21.4.1297-1310.2001; Kurokawa R, 1998, SCIENCE, V279, P700, DOI 10.1126/science.279.5351.700; Lando D, 2002, GENE DEV, V16, P1466, DOI 10.1101/gad.991402; Lando D, 2002, SCIENCE, V295, P858, DOI 10.1126/science.1068592; Lendahl U, 2009, NAT REV GENET, V10, P821, DOI 10.1038/nrg2665; Liu Q, 2004, P NATL ACAD SCI USA, V101, P4302, DOI 10.1073/pnas.0400265101; Mahon PC, 2001, GENE DEV, V15, P2675, DOI 10.1101/gad.924501; Metzen E, 2003, J CELL SCI, V116, P1319, DOI 10.1242/jcs.00318; Ohh M, 2000, NAT CELL BIOL, V2, P423, DOI 10.1038/35017054; Oike Y, 1999, HUM MOL GENET, V8, P387, DOI 10.1093/hmg/8.3.387; Pan Y, 2004, ONCOGENE, V23, P4975, DOI 10.1038/sj.onc.1207657; Pereira T, 2003, J BIOL CHEM, V278, P6816, DOI 10.1074/jbc.M209297200; Ravi R, 2000, GENE DEV, V14, P34; Ruas JL, 2005, SEMIN CELL DEV BIOL, V16, P514, DOI 10.1016/j.semcdb.2005.04.001; Ruas JL, 2005, J CELL SCI, V118, P301, DOI 10.1242/jcs.01617; Ruas JL, 2002, J BIOL CHEM, V277, P38723, DOI 10.1074/jbc.M205051200; Sang NL, 2002, MOL CELL BIOL, V22, P2984, DOI 10.1128/MCB.22.9.2984-2992.2002; Schmid T, 2004, BIOCHEM J, V380, P289, DOI 10.1042/BJ20031299; SIEGEL RM, 2000, SCI STKE, pPL1; Tanaka Y, 2000, MECH DEVELOP, V95, P133, DOI 10.1016/S0925-4773(00)00360-9; Tanimoto K, 2000, EMBO J, V19, P4298, DOI 10.1093/emboj/19.16.4298; Wadgaonkar R, 1999, J BIOL CHEM, V274, P13760, DOI 10.1074/jbc.274.20.13760; Yao TP, 1998, CELL, V93, P361, DOI 10.1016/S0092-8674(00)81165-4	60	43	46	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 22	2010	285	4					2601	2609		10.1074/jbc.M109.021824	http://dx.doi.org/10.1074/jbc.M109.021824			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	544YP	19880525	Green Published, hybrid			2022-12-25	WOS:000273697800039
J	Unciuleac, MC; Shuman, S				Unciuleac, Mihaela-Carmen; Shuman, Stewart			Characterization of the Mycobacterial AdnAB DNA Motor Provides Insights into the Evolution of Bacterial Motor-Nuclease Machines	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HELICASES DISPLACE STREPTAVIDIN; SINGLE-STRANDED-DNA; RECBCD ENZYME; BACILLUS-SUBTILIS; SALMONELLA VIRULENCE; REPAIR; TRANSLOCATION; BREAKS; NHEJ; OLIGONUCLEOTIDES	Mycobacterial AdnAB exemplifies a family of heterodimeric motor-nucleases involved in processing DNA double strand breaks (DSBs). The AdnA and AdnB subunits are each composed of an N-terminal UvrD-like motor domain and a C-terminal RecB-like nuclease module. Here we conducted a biochemical characterization of the AdnAB motor, using a nuclease-inactivated heterodimer. AdnAB is a vigorous single strand DNA (ssDNA)-dependent ATPase (k(cat) 415 s(-1)), and the affinity of the motor for the ssDNA cofactor increases 140-fold as DNA length is extended from 12 to 44 nucleotides. Using a streptavidin displacement assay, we demonstrate that AdnAB is a 3' -> 5' translocase on ssDNA. AdnAB binds stably to DSB ends. In the presence of ATP, the motor unwinds the DNA duplex without requiring an ssDNA loading strand. We integrate these findings into a model of DSB unwinding in which the "leading" AdnB and "lagging" AdnA motor domains track in tandem, 3' to 5', along the same DNA single strand. This contrasts with RecBCD, in which the RecB and RecD motors track in parallel along the two separated DNA single strands. The effects of 5' and 3' terminal obstacles on ssDNA cleavage by wild-type AdnAB suggest that the AdnA nuclease receives and processes the displaced 5' strand, while the AdnB nuclease cleaves the displaced 3' strand. We present evidence that the distinctive "molecular ruler" function of the ATP-dependent single strand DNase, whereby AdnAB measures the distance from the 5'-end to the sites of incision, reflects directional pumping of the ssDNA through the AdnAB motor into the AdnB nuclease. These and other findings suggest a scenario for the descent of the RecBCD-and AddAB-type DSB-processing machines from an ancestral AdnAB-like enzyme.	[Unciuleac, Mihaela-Carmen; Shuman, Stewart] Sloan Kettering Inst, Program Mol Biol, New York, NY 10065 USA	Memorial Sloan Kettering Cancer Center	Shuman, S (corresponding author), Sloan Kettering Inst, Program Mol Biol, 1275 York Ave, New York, NY 10065 USA.	s-shuman@ski.mskcc.org			National Institutes of Health [AI64693]; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI064693] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	This work was supported, in whole or in part, by National Institutes of Health Grant AI64693.	Amundsen SK, 2008, MOL MICROBIOL, V69, P994, DOI 10.1111/j.1365-2958.2008.06336.x; Aniukwu J, 2008, GENE DEV, V22, P512, DOI 10.1101/gad.1631908; Boshoff HIM, 2003, CELL, V113, P183, DOI 10.1016/S0092-8674(03)00270-8; BUCHMEIER NA, 1993, MOL MICROBIOL, V7, P933, DOI 10.1111/j.1365-2958.1993.tb01184.x; BUCHMEIER NA, 1995, J CLIN INVEST, V95, P1047, DOI 10.1172/JCI117750; Byrd AK, 2004, NAT STRUCT MOL BIOL, V11, P531, DOI 10.1038/nsmb774; Cano DA, 2002, J BACTERIOL, V184, P592, DOI 10.1128/JB.184.2.592-595.2002; Cromie GA, 2009, J BACTERIOL, V191, P5076, DOI 10.1128/JB.00254-09; Darwin KH, 2005, INFECT IMMUN, V73, P4581, DOI 10.1128/IAI.73.8.4581-4587.2005; Dillingham MS, 2008, MICROBIOL MOL BIOL R, V72, P642, DOI 10.1128/MMBR.00020-08; Dillingham MS, 2005, J BIOL CHEM, V280, P37069, DOI 10.1074/jbc.M505520200; Dillingham MS, 2003, NATURE, V423, P893, DOI 10.1038/nature01673; Farah JA, 1997, J MOL BIOL, V272, P699, DOI 10.1006/jmbi.1997.1259; Ghosh J, 2009, P NATL ACAD SCI USA, V106, P10781, DOI 10.1073/pnas.0904104106; Gong CL, 2005, NAT STRUCT MOL BIOL, V12, P304, DOI 10.1038/nsmb915; Haijema BJ, 1996, J BACTERIOL, V178, P5086, DOI 10.1128/jb.178.17.5086-5091.1996; Haijema BJ, 1996, J BACTERIOL, V178, P5130, DOI 10.1128/jb.178.17.5130-5137.1996; Moeller R, 2007, J BACTERIOL, V189, P3306, DOI 10.1128/JB.00018-07; Morris PD, 1999, BIOCHEMISTRY-US, V38, P5164, DOI 10.1021/bi9822269; Morris PD, 2002, BIOCHEMISTRY-US, V41, P2372, DOI 10.1021/bi012058b; Pitcher RS, 2007, ANNU REV MICROBIOL, V61, P259, DOI 10.1146/annurev.micro.61.080706.093354; Pitcher RS, 2007, DNA REPAIR, V6, P1271, DOI 10.1016/j.dnarep.2007.02.009; Pitcher RS, 2006, MOL CELL, V23, P743, DOI 10.1016/j.molcel.2006.07.009; Rigden DJ, 2005, BMC STRUCT BIOL, V5, DOI 10.1186/1472-6807-5-9; ROMAN LJ, 1989, BIOCHEMISTRY-US, V28, P2873, DOI 10.1021/bi00433a019; Saikrishnan K, 2008, EMBO J, V27, P2222, DOI 10.1038/emboj.2008.144; Saikrishnan K, 2009, CELL, V137, P849, DOI 10.1016/j.cell.2009.03.036; Shuman S, 2007, NAT REV MICROBIOL, V5, P852, DOI 10.1038/nrmicro1768; Singleton MR, 2004, NATURE, V432, P187, DOI 10.1038/nature02988; Sinha KM, 2007, J BIOL CHEM, V282, P15114, DOI 10.1074/jbc.M701167200; Sinha KM, 2009, GENE DEV, V23, P1423, DOI 10.1101/gad.1805709; Spies M, 2005, J BIOL CHEM, V280, P37078, DOI 10.1074/jbc.M505521200; Stephanou NC, 2007, J BACTERIOL, V189, P5237, DOI 10.1128/JB.00332-07; TAYLOR AF, 1995, J BIOL CHEM, V270, P24451, DOI 10.1074/jbc.270.41.24451; Taylor AF, 2003, NATURE, V423, P889, DOI 10.1038/nature01674; Wang ST, 2006, J MOL BIOL, V358, P16, DOI 10.1016/j.jmb.2006.01.059; Yeeles JTP, 2007, J MOL BIOL, V371, P66, DOI 10.1016/j.jmb.2007.05.053	37	28	28	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 22	2010	285	4					2632	2641		10.1074/jbc.M109.076133	http://dx.doi.org/10.1074/jbc.M109.076133			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	544YP	19920138	Green Published, hybrid			2022-12-25	WOS:000273697800042
J	Bereta, G; Wang, BL; Kiser, PD; Baehr, W; Jang, GF; Palczewski, K				Bereta, Grzegorz; Wang, Benlian; Kiser, Philip D.; Baehr, Wolfgang; Jang, Geeng-Fu; Palczewski, Krzysztof			A Functional Kinase Homology Domain Is Essential for the Activity of Photoreceptor Guanylate Cyclase 1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NATRIURETIC-PEPTIDE RECEPTOR; LEBER CONGENITAL AMAUROSIS; ACTIVATING PROTEINS GCAPS; CRYSTAL-STRUCTURE; CA2+-BINDING PROTEINS; EXTRACELLULAR DOMAIN; ADENINE-NUCLEOTIDES; MOLECULAR-CLONING; OUTER SEGMENTS; ALPHA-SUBUNIT	Phototransduction is carried out by a signaling pathway that links photoactivation of visual pigments in retinal photoreceptor cells to a change in their membrane potential. Upon photoactivation, the second messenger of phototransduction, cyclic GMP, is rapidly degraded and must be replenished during the recovery phase of phototransduction by photoreceptor guanylate cyclases (GCs) GC1 (or GC-E) and GC2 (or GC-F) to maintain vision. Here, we present data that address the role of the GC kinase homology (KH) domain in cyclic GMP production by GC1, the major cyclase in photoreceptors. First, experiments were done to test which GC1 residues undergo phosphorylation and whether such phosphorylation affects cyclase activity. Using mass spectrometry, we showed that GC1 residues Ser-530, Ser-532, Ser-533, and Ser-538, located within the KH domain, undergo light-and signal transduction-independent phosphorylation in vivo. Mutations in the putative Mg2+ binding site of the KH domain abolished phosphorylation, indicating that GC1 undergoes autophosphorylation. The dramatically reduced GC activity of these mutants suggests that a functional KH domain is essential for cyclic GMP production. However, evidence is presented that autophosphorylation does not regulate GC1 activity, in contrast to phosphorylation of other members of this cyclase family.	[Palczewski, Krzysztof] Case Western Reserve Univ, Sch Med, Dept Pharmacol, Cleveland, OH 44106 USA; [Wang, Benlian] Case Western Reserve Univ, Sch Med, Ctr Prote & Mass Spectrometry, Cleveland, OH 44106 USA; [Baehr, Wolfgang] Univ Utah, Dept Ophthalmol & Visual Sci, John A Moran Eye Ctr, Salt Lake City, UT 84132 USA; [Jang, Geeng-Fu] Roswell Pk Canc Inst, Dept Cell Stress Biol, Prote Resources Lab, Buffalo, NY 14263 USA	Case Western Reserve University; Case Western Reserve University; Utah System of Higher Education; University of Utah; Roswell Park Cancer Institute	Palczewski, K (corresponding author), Case Western Reserve Univ, Sch Med, Dept Pharmacol, 10900 Euclid Ave, Cleveland, OH 44106 USA.	kxp65@case.edu			National Institutes of Health [EY008061, EY08123, P30 EY11373]; Foundation Fighting Blindness; NATIONAL EYE INSTITUTE [R29EY008061, R01EY008061, R01EY008123, P30EY011373, T32EY007157] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Foundation Fighting Blindness(European Commission); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))	This work was supported, in whole or in part, by National Institutes of Health Grants EY008061 (to K. P.) and EY08123 (to W. B.) and Core Grant P30 EY11373. This work was also supported by the Foundation Fighting Blindness.	Adams JA, 2001, CHEM REV, V101, P2271, DOI 10.1021/cr000230w; Antos LK, 2007, AM J PHYSIOL-ENDOC M, V293, pE1756, DOI 10.1152/ajpendo.00321.2007; Aparicio JG, 1996, J BIOL CHEM, V271, P27083, DOI 10.1074/jbc.271.43.27083; Baehr W, 2007, J BIOL CHEM, V282, P8837, DOI 10.1074/jbc.M610369200; Batten ML, 2005, PLOS MED, V2, P1177, DOI 10.1371/journal.pmed.0020333; Batten ML, 2004, J BIOL CHEM, V279, P10422, DOI 10.1074/jbc.M312410200; Bodenmiller B, 2007, NAT METHODS, V4, P231, DOI 10.1038/nmeth1005; Bryan PM, 2006, BIOCHEMISTRY-US, V45, P1295, DOI 10.1021/bi051253d; Burczynska B, 2007, MOL CELL BIOCHEM, V301, P93, DOI 10.1007/s11010-006-9400-7; Calvert PD, 2000, P NATL ACAD SCI USA, V97, P13913, DOI 10.1073/pnas.250478897; CASANOVA JE, 1990, SCIENCE, V248, P742, DOI 10.1126/science.2110383; Chen CH, 2003, J PHYSIOL-LONDON, V553, P125, DOI 10.1113/jphysiol.2003.053280; CHINKERS M, 1991, J BIOL CHEM, V266, P4088; CHINKERS M, 1989, SCIENCE, V245, P1392, DOI 10.1126/science.2571188; Dizhoor A, 2002, ADV EXP MED BIOL, V514, P291; Dizhoor AM, 1999, METHODS, V19, P521, DOI 10.1006/meth.1999.0894; GIBBS CS, 1991, J BIOL CHEM, V266, P8923; GORCZYCA WA, 1994, BIOCHEMISTRY-US, V33, P3217, DOI 10.1021/bi00177a011; GORCZYCA WA, 1994, P NATL ACAD SCI USA, V91, P4014, DOI 10.1073/pnas.91.9.4014; Howes KA, 2002, EMBO J, V21, P1545, DOI 10.1093/emboj/21.7.1545; Imanishi Y, 2004, J CELL BIOL, V164, P373, DOI 10.1083/jcb.200311079; Joubert S, 2005, FEBS J, V272, P5572, DOI 10.1111/j.1742-4658.2005.04952.x; Koch KW, 2002, ADV EXP MED BIOL, V514, P349; KOLLER KJ, 1992, MOL CELL BIOL, V12, P2581, DOI 10.1128/MCB.12.6.2581; KOLLER KJ, 1993, J BIOL CHEM, V268, P5997; Krylov DM, 2001, J BIOL CHEM, V276, P30648, DOI 10.1074/jbc.M104121200; MADHUSUDAN, 1994, PROTEIN SCI, V3, P176; Mendez A, 2001, P NATL ACAD SCI USA, V98, P9948, DOI 10.1073/pnas.171308998; Mukherjee K, 2008, CELL, V133, P328, DOI 10.1016/j.cell.2008.02.036; Ogawa H, 2004, J BIOL CHEM, V279, P28625, DOI 10.1074/jbc.M313222200; Ogawa H, 2009, FEBS J, V276, P1347, DOI 10.1111/j.1742-4658.2009.06870.x; Palczewski K, 2000, BIOESSAYS, V22, P337, DOI 10.1002/(SICI)1521-1878(200004)22:4<337::AID-BIES4>3.0.CO;2-Z; PALCZEWSKI K, 1989, BIOCHEMISTRY-US, V28, P415, DOI 10.1021/bi00428a001; PALCZEWSKI K, 1989, J BIOL CHEM, V264, P15770; PALCZEWSKI K, 1994, NEURON, V13, P395, DOI 10.1016/0896-6273(94)90355-7; Palczewski K, 2006, ANNU REV BIOCHEM, V75, P743, DOI 10.1146/annurev.biochem.75.103004.142743; PEAR WS, 1993, P NATL ACAD SCI USA, V90, P8392, DOI 10.1073/pnas.90.18.8392; Perrault I, 1996, NAT GENET, V14, P461, DOI 10.1038/ng1296-461; Polans A, 1996, TRENDS NEUROSCI, V19, P547, DOI 10.1016/S0166-2236(96)10059-X; Potter LR, 2006, ENDOCR REV, V27, P47, DOI 10.1210/er.2005-0014; Potter LR, 1999, MOL BIOL CELL, V10, P1811, DOI 10.1091/mbc.10.6.1811; Potter LR, 1998, MOL CELL BIOL, V18, P2164, DOI 10.1128/MCB.18.4.2164; Ramamurthy V, 2001, J BIOL CHEM, V276, P26218, DOI 10.1074/jbc.M010495200; ROBINSON WE, 1979, NATURE, V280, P398, DOI 10.1038/280398a0; Rosenzweig DH, 2009, BIOCHEM J, V417, P803, DOI 10.1042/BJ20081513; SHYJAN AW, 1992, NEURON, V9, P727, DOI 10.1016/0896-6273(92)90035-C; Singh P, 2008, J BIOL CHEM, V283, P14053, DOI 10.1074/jbc.M708974200; Steinberg TH, 2003, PROTEOMICS, V3, P1128, DOI 10.1002/pmic.200300434; Stephen R, 2007, STRUCTURE, V15, P1392, DOI 10.1016/j.str.2007.09.013; Winger JA, 2008, BMC STRUCT BIOL, V8, DOI 10.1186/1472-6807-8-42; WONG SKF, 1992, J CLIN INVEST, V90, P299, DOI 10.1172/JCI115862; Woodruff ML, 2003, NAT GENET, V35, P158, DOI 10.1038/ng1246; Yang RB, 1999, J NEUROSCI, V19, P5889, DOI 10.1523/JNEUROSCI.19-14-05889.1999; YANG RB, 1995, P NATL ACAD SCI USA, V92, P602, DOI 10.1073/pnas.92.2.602	54	18	19	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 15	2010	285	3					1899	1908		10.1074/jbc.M109.061713	http://dx.doi.org/10.1074/jbc.M109.061713			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	541PJ	19901021	Green Published, hybrid			2022-12-25	WOS:000273429100036
J	Okuya, M; Kurosawa, H; Kikuchi, J; Furukawa, Y; Matsui, H; Aki, D; Matsunaga, T; Inukai, T; Goto, H; Altura, RA; Sugita, K; Arisaka, O; Look, AT; Inaba, T				Okuya, Mayuko; Kurosawa, Hidemitsu; Kikuchi, Jiro; Furukawa, Yusuke; Matsui, Hirotaka; Aki, Daisuke; Matsunaga, Takayuki; Inukai, Takeshi; Goto, Hiroaki; Altura, Rachel A.; Sugita, Kenich; Arisaka, Osamu; Look, A. Thomas; Inaba, Toshiya			Up-regulation of Survivin by the E2A-HLF Chimera Is Indispensable for the Survival of t(17;19)-positive Leukemia Cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							APOPTOSIS-INDUCING FACTOR; ACUTE-LYMPHOBLASTIC-LEUKEMIA; HEMATOPOIETIC PROGENITOR CELLS; PRO-B LYMPHOCYTES; TRANSCRIPTION FACTOR; IN-VIVO; ANTIAPOPTOTIC ACTIVITY; DOWNSTREAM TARGET; GENE-EXPRESSION; E2A GENE	The E2A-HLF fusion transcription factor generated by t(17;19)(q22;p13) translocation is found in a small subset of pro-B cell acute lymphoblastic leukemias (ALLs) and promotes leukemogenesis by substituting for the antiapoptotic function of cytokines. Here we show that t(17;19)(+) ALL cells express Survivin at high levels and that a dominant negative mutant of E2A-HLF suppresses Survivin expression. Forced expression of E2A-HLF in t(17;19)(-) leukemia cells up-regulated Survivin expression, suggesting that Survivin is a downstream target of E2A-HLF. Analysis using a counterflow centrifugal elutriator revealed that t(17;19)(+) ALL cells express Survivin throughout the cell cycle. Reporter assays revealed that E2A-HLF induces survivin expression at the transcriptional level likely through indirect down-regulation of a cell cycle-dependent cis element in the promoter region. Down-regulation of Survivin function by a dominant negative mutant of Survivin or reduction of Survivin expression induced massive apoptosis throughout the cell cycle in t(17;19)(+) cells mainly through caspase-independent pathways involving translocation of apoptosis-inducing factor (AIF) from mitochondria to the nucleus. AIF knockdown conferred resistance to apoptosis caused by down-regulation of Survivin function. These data indicated that reversal of AIF translocation by Survivin, which is induced by E2A-HLF throughout the cell cycle, is one of the key mechanisms in the protection of t(17;19)(+) leukemia cells from apoptosis.	[Okuya, Mayuko; Kurosawa, Hidemitsu; Matsunaga, Takayuki; Sugita, Kenich; Arisaka, Osamu] Dokkyo Med Univ, Dept Pediat, Sch Med, Mibu, Tochigi 3210293, Japan; [Matsui, Hirotaka; Aki, Daisuke; Inaba, Toshiya] Hiroshima Univ, Dept Mol Oncol, Res Inst Radiat Biol & Med, Hiroshima 7348553, Japan; [Inukai, Takeshi] Univ Yamanashi, Sch Med, Dept Pediat, Yamanashi 4093898, Japan; [Goto, Hiroaki] Yokohama City Univ, Sch Med, Dept Pediat, Kanagawa 2360004, Japan; [Altura, Rachel A.] Brown Univ, Warren Alpert Med Sch, Dept Pediat, Providence, RI 02903 USA; [Look, A. Thomas] Dana Farber Canc Inst, Dept Pediat Oncol, Boston, MA 02115 USA	Dokkyo Medical University; Hiroshima University; University of Yamanashi; Yokohama City University; Brown University; Harvard University; Dana-Farber Cancer Institute	Kurosawa, H (corresponding author), Dokkyo Med Univ, Dept Pediat, Sch Med, Mibu, Tochigi 3210293, Japan.	hidekuro@dokkyomed.ac.jp	Furukawa, Yusuke/Y-1342-2018	Furukawa, Yusuke/0000-0002-7249-6418	Japan Society for Promotion of Science [18591201]; Dokkyo Medical University	Japan Society for Promotion of Science(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of Science); Dokkyo Medical University	This work was supported by Grant-in-aid for Scientific Research (C) 18591201 from the Japan Society for Promotion of Science (to H. K.) and a young investigator award from Dokkyo Medical University (to M. O.).	Altieri DC, 2008, NAT REV CANCER, V8, P61, DOI 10.1038/nrc2293; Altieri DC, 2003, NAT REV CANCER, V3, P46, DOI 10.1038/nrc968; Ambrosini G, 1997, NAT MED, V3, P917, DOI 10.1038/nm0897-917; Carter BZ, 2003, BLOOD, V102, P4179, DOI 10.1182/blood-2003-03-0960; Croci DO, 2008, J CELL BIOCHEM, V105, P381, DOI 10.1002/jcb.21836; Fukuda S, 2006, MOL CANCER THER, V5, P1087, DOI 10.1158/1535-7163.MCT-05-0375; Gu CM, 2006, NEOPLASMA, V53, P206; Hunger SP, 1996, BLOOD, V87, P1211, DOI 10.1182/blood.V87.4.1211.bloodjournal8741211; HUNGER SP, 1992, GENE DEV, V6, P1608, DOI 10.1101/gad.6.9.1608; Ikushima S, 1997, P NATL ACAD SCI USA, V94, P2609, DOI 10.1073/pnas.94.6.2609; INABA T, 1992, SCIENCE, V257, P531, DOI 10.1126/science.1386162; Inaba T, 1996, NATURE, V382, P541, DOI 10.1038/382541a0; INABA T, 1994, MOL CELL BIOL, V14, P3403, DOI 10.1128/MCB.14.5.3403; Inoue A, 2002, CANCER CELL, V2, P279, DOI 10.1016/S1535-6108(02)00155-1; Inukai T, 2007, LEUKEMIA, V21, P288, DOI 10.1038/sj.leu.2404496; Inukai T, 1998, MOL CELL BIOL, V18, P6035, DOI 10.1128/MCB.18.10.6035; Inukai T, 1999, MOL CELL, V4, P343, DOI 10.1016/S1097-2765(00)80336-6; Kanwar JR, 2001, J NATL CANCER I, V93, P1541, DOI 10.1093/jnci/93.20.1541; Kikuchi J, 1997, BLOOD, V89, P3980, DOI 10.1182/blood.V89.11.3980; Kikuchi J, 2007, STEM CELLS, V25, P2439, DOI 10.1634/stemcells.2007-0207; KINOSHITA T, 1995, EMBO J, V14, P266, DOI 10.1002/j.1460-2075.1995.tb07000.x; Kobayashi K, 1999, P NATL ACAD SCI USA, V96, P1457, DOI 10.1073/pnas.96.4.1457; Kuribara R, 1999, MOL CELL BIOL, V19, P2754; Kurosawa H, 1999, BLOOD, V93, P321, DOI 10.1182/blood.V93.1.321.401k05_321_332; Li FZ, 2006, J CELL PHYSIOL, V208, P476, DOI 10.1002/jcp.20634; Li FZ, 2003, J CELL PHYSIOL, V197, P8, DOI 10.1002/jcp.10327; Li FZ, 1999, BIOCHEM J, V344, P305, DOI 10.1042/0264-6021:3440305; Li FZ, 1998, NATURE, V396, P580, DOI 10.1038/25141; Liu T, 2004, ONCOGENE, V23, P39, DOI 10.1038/sj.onc.1206978; Liu T, 2006, J INVEST DERMATOL, V126, P2247, DOI 10.1038/sj.jid.5700381; Matsunaga T, 2004, BLOOD, V103, P3185, DOI 10.1182/blood-2003-09-3022; Metzstein MM, 1999, MOL CELL, V4, P309, DOI 10.1016/S1097-2765(00)80333-0; Metzstein MM, 1996, NATURE, V382, P545, DOI 10.1038/382545a0; Modjtahedi N, 2006, TRENDS CELL BIOL, V16, P264, DOI 10.1016/j.tcb.2006.03.008; Moubarak RS, 2007, MOL CELL BIOL, V27, P4844, DOI 10.1128/MCB.02141-06; Rubio CA, 2003, EUR J CLIN INVEST, V33, P406, DOI 10.1046/j.1365-2362.2003.01151.x; Schimmer AD, 2004, CANCER RES, V64, P7183, DOI 10.1158/0008-5472.CAN-04-1918; Shinjyo T, 2008, TOHOKU J EXP MED, V216, P25, DOI 10.1620/tjem.216.25; Sommer KW, 2003, ONCOGENE, V22, P4266, DOI 10.1038/sj.onc.1206509; Susin SA, 1999, NATURE, V397, P441, DOI 10.1038/17135; Tamm I, 1998, CANCER RES, V58, P5315; Tu SP, 2003, CANCER RES, V63, P7724; Yu SW, 2002, SCIENCE, V297, P259, DOI 10.1126/science.1072221	43	10	11	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 15	2010	285	3					1850	1860		10.1074/jbc.M109.023762	http://dx.doi.org/10.1074/jbc.M109.023762			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	541PJ	19887369	hybrid, Green Published			2022-12-25	WOS:000273429100031
J	Webb, BN; Ballinger, JW; Kim, E; Belchik, SM; Lam, KS; Youn, B; Nissen, MS; Xun, LY; Kang, C				Webb, Brian N.; Ballinger, Jordan W.; Kim, Eunjung; Belchik, Sara M.; Lam, Ka-Sum; Youn, Buhyun; Nissen, Mark S.; Xun, Luying; Kang, ChulHee			Characterization of Chlorophenol 4-Monooxygenase (TftD) and NADH:FAD Oxidoreductase (TftC) of Burkholderia cepacia AC1100	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FMN-DEPENDENT MONOOXYGENASE; THERMUS-THERMOPHILUS HB8; CRYSTAL-STRUCTURE; 4-HYDROXYPHENYLACETATE 3-MONOOXYGENASE; STREPTOMYCES-COELICOLOR; 2,4,5-TRICHLOROPHENOXYACETIC ACID; BIOCHEMICAL-CHARACTERIZATION; ESCHERICHIA-COLI; MOLECULAR-OXYGEN; REDUCED FLAVIN	Burkholderia cepacia AC1100 completely degrades 2,4,5-trichlorophenol, in which an FADH(2)-dependent monooxygenase (TftD) and an NADH: FAD oxidoreductase (TftC) catalyze the initial steps. TftD oxidizes 2,4,5-trichlorophenol (2,4,5-TCP) to 2,5-dichloro-p-benzoquinone, which is chemically reduced to 2,5-dichloro-p-hydroquinone (2,5-DiCHQ). Then, TftD oxidizes the latter to 5-chloro-2-hydroxy-p-benzoquinone. In those processes, TftC provides all the required FADH(2). We have determined the crystal structures of dimeric TftC and tetrameric TftD at 2.0 and 2.5 angstrom resolution, respectively. The structure of TftC was similar to those of related flavin reductases. The stacked nicotinamide: isoalloxazine rings in TftC and sequential reaction kinetics suggest that the reduced FAD leaves TftC after NADH oxidation. The structure of TftD was also similar to the known structures of FADH(2)-dependent monooxygenases. Its His-289 residue in the re-side of the isoalloxazine ring is within hydrogen bonding distance with a hydroxyl group of 2,5-DiCHQ. An H289 A mutation resulted in the complete loss of activity toward 2,5-DiCHQ and a significant decrease in catalytic efficiency toward 2,4,5-TCP. Thus, His-289 plays different roles in the catalysis of 2,4,5-TCP and 2,5-DiCHQ. The results support that free FADH(2) is generated by TftC, and TftD uses FADH(2) to separately transform 2,4,5-TCP and 2,5-DiCHQ. Additional experimental data also support the diffusion of FADH(2) between TftC and TftD without direct physical interaction between the two enzymes.	[Ballinger, Jordan W.; Kim, Eunjung; Belchik, Sara M.; Lam, Ka-Sum; Youn, Buhyun; Nissen, Mark S.; Xun, Luying; Kang, ChulHee] Washington State Univ, Sch Mol Biosci, Pullman, WA 99164 USA; [Webb, Brian N.; Kang, ChulHee] Washington State Univ, Dept Chem, Pullman, WA 99164 USA	Washington State University; Washington State University	Kang, C (corresponding author), Washington State Univ, Sch Mol Biosci, Pullman, WA 99164 USA.	chkang@wsu.edu		Kang, ChulHee/0000-0002-0693-7860	National Science Foundation [MCB-0323167]; United States Department of Agriculture, Agricultural Research Service/Cooperative State Research, Education; Extension Service, American Heart Association [0850084Z]; Murdock Charitable Trust; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM008336] Funding Source: NIH RePORTER	National Science Foundation(National Science Foundation (NSF)); United States Department of Agriculture, Agricultural Research Service/Cooperative State Research, Education(United States Department of Agriculture (USDA)USDA Agricultural Research Service); Extension Service, American Heart Association(American Heart AssociationUnited States Department of Agriculture (USDA)National Institute of Food and Agriculture); Murdock Charitable Trust; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	This work was supported in part by National Science Foundation Grant MCB-0323167, the United States Department of Agriculture, Agricultural Research Service/Cooperative State Research, Education, and Extension Service, American Heart Association Grant 0850084Z, and The Murdock Charitable Trust.	Abdurachim K, 2006, J BACTERIOL, V188, P8153, DOI 10.1128/JB.00966-06; Adams PD, 2002, ACTA CRYSTALLOGR D, V58, P1948, DOI 10.1107/S0907444902016657; Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Campbell ZT, 2009, J BIOL CHEM, V284, P8322, DOI 10.1074/jbc.M808977200; Czaplicka M, 2004, SCI TOTAL ENVIRON, V322, P21, DOI 10.1016/j.scitotenv.2003.09.015; Davis IW, 2007, NUCLEIC ACIDS RES, V35, pW375, DOI 10.1093/nar/gkm216; Filisetti L, 2003, J BIOL CHEM, V278, P296, DOI 10.1074/jbc.M209689200; Galan B, 2000, J BACTERIOL, V182, P627, DOI 10.1128/JB.182.3.627-636.2000; Gao BL, 2005, BIOCHEM BIOPH RES CO, V331, P1137, DOI 10.1016/j.bbrc.2005.04.033; GIBSON QH, 1962, BIOCHEM J, V83, P368, DOI 10.1042/bj0830368; Gisi MR, 2003, J BACTERIOL, V185, P2786, DOI 10.1128/JB.185.9.2786-2792.2003; HOLM L, 1993, J MOL BIOL, V233, P123, DOI 10.1006/jmbi.1993.1489; Hubner A, 1998, APPL ENVIRON MICROB, V64, P2086; Jeffers CE, 2003, BIOCHEMISTRY-US, V42, P529, DOI 10.1021/bi026877n; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Kadiyala V, 1998, APPL ENVIRON MICROB, V64, P2479; Kantz A, 2005, ARCH BIOCHEM BIOPHYS, V442, P102, DOI 10.1016/j.abb.2005.07.020; KELLOGG ST, 1981, SCIENCE, V214, P1133, DOI 10.1126/science.7302584; KILBANE JJ, 1982, APPL ENVIRON MICROB, V44, P72, DOI 10.1128/AEM.44.1.72-78.1982; KIM JJP, 1993, P NATL ACAD SCI USA, V90, P7523, DOI 10.1073/pnas.90.16.7523; Kim SH, 2008, PROTEINS, V70, P718, DOI 10.1002/prot.21534; Kim SH, 2007, J BIOL CHEM, V282, P33107, DOI 10.1074/jbc.M703440200; Kirchner U, 2003, J BIOL CHEM, V278, P47545, DOI 10.1074/jbc.M307397200; Lawrence AD, 2008, J BIOL CHEM, V283, P10813, DOI 10.1074/jbc.M710431200; Lee JK, 2007, J BACTERIOL, V189, P8556, DOI 10.1128/JB.01050-07; Li L, 2008, J MOL BIOL, V376, P453, DOI 10.1016/j.jmb.2007.11.069; Louie TM, 2003, BIOCHEMISTRY-US, V42, P7509, DOI 10.1021/bi034092r; Louie TM, 2002, J BACTERIOL, V184, P3492, DOI 10.1128/JB.184.13.3492-3500.2002; Low JC, 2003, PHOTOCHEM PHOTOBIOL, V77, P446, DOI 10.1562/0031-8655(2003)077<0446:ETEFIV>2.0.CO;2; Malito E, 2004, P NATL ACAD SCI USA, V101, P13157, DOI 10.1073/pnas.0404538101; Martins BM, 2004, P NATL ACAD SCI USA, V101, P15645, DOI 10.1073/pnas.0403952101; MASSEY V, 1994, J BIOL CHEM, V269, P22459; MCCOLLISTER D, 1961, TOXICOL APPL PHARM, V3, P63, DOI 10.1016/0041-008X(61)90009-6; Navaza J, 2001, ACTA CRYSTALLOGR D, V57, P1367, DOI 10.1107/S0907444901012422; NEWMAN LM, 1995, BIOCHEMISTRY-US, V34, P14066, DOI 10.1021/bi00043a012; Nissen MS, 2008, J BIOL CHEM, V283, P28710, DOI 10.1074/jbc.M804535200; Okai M, 2006, BIOCHEMISTRY-US, V45, P5103, DOI 10.1021/bi052313i; Otto K, 2004, J BACTERIOL, V186, P5292, DOI 10.1128/JB.186.16.5292-5302.2004; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Pazmino DET, 2008, BIOCHEMISTRY-US, V47, P4082, DOI 10.1021/bi702296k; Perry LL, 2007, J BACTERIOL, V189, P7563, DOI 10.1128/JB.01849-06; Sucharitakul J, 2007, BIOCHEMISTRY-US, V46, P8611, DOI 10.1021/bi7006614; Terwilliger TC, 2001, ACTA CRYSTALLOGR D, V57, P1755, DOI 10.1107/S0907444901013737; Tiirola MA, 2002, APPL ENVIRON MICROB, V68, P173, DOI 10.1128/AEM.68.1.173-180.2002; Valton J, 2006, J BIOL CHEM, V281, P27, DOI 10.1074/jbc.M506146200; Valton J, 2008, J BIOL CHEM, V283, P10287, DOI 10.1074/jbc.M709730200; van den Heuvel RHH, 2004, J BIOL CHEM, V279, P12860, DOI 10.1074/jbc.M313765200; Xun LY, 1996, J BACTERIOL, V178, P2645, DOI 10.1128/jb.178.9.2645-2649.1996; Youn BY, 2005, J BIOL CHEM, V280, P12917, DOI 10.1074/jbc.M413266200	50	56	60	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 15	2010	285	3					2014	2027		10.1074/jbc.M109.056135	http://dx.doi.org/10.1074/jbc.M109.056135			14	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	541PJ	19915006	hybrid, Green Published			2022-12-25	WOS:000273429100047
J	Gach, JS; Furtmuller, PG; Quendler, H; Messner, P; Wagner, R; Katinger, H; Kunert, R				Gach, Johannes S.; Furtmueller, Paul G.; Quendler, Heribert; Messner, Paul; Wagner, Ralf; Katinger, Hermann; Kunert, Renate			Proline Is Not Uniquely Capable of Providing the Pivot Point for Domain Swapping in 2G12, a Broadly Neutralizing Antibody against HIV-1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IMMUNODEFICIENCY-VIRUS TYPE-1; ANTIIDIOTYPIC ANTIBODY; 2F5; RECOGNITION; FRAGMENT; VACCINE; BINDING; REGION; GP120; LEVEL	The human monoclonal antibody 2G12 is a member of a small group of broadly neutralizing antibodies against human immunodeficiency virus type 1. 2G12 adopts a unique variable heavy domain-exchanged dimeric configuration that results in an extensive multivalent binding surface and the ability to bind with high affinity to densely clustered high mannose oligosaccharides on the "silent" face of the gp120 envelope glycoprotein. Here, we further define the amino acids responsible for this extraordinary domain-swapping event in 2G12.	[Gach, Johannes S.; Quendler, Heribert; Katinger, Hermann; Kunert, Renate] Univ Nat Resources & Appl Life Sci, Dept Biotechnol, A-1190 Vienna, Austria; [Furtmueller, Paul G.] Univ Nat Resources & Appl Life Sci, Dept Chem, A-1190 Vienna, Austria; [Messner, Paul] Univ Nat Resources & Appl Life Sci, Ctr NanoBiotechnol, A-1190 Vienna, Austria; [Wagner, Ralf] Univ Regensburg, Inst Med Microbiol & Hyg, D-93053 Regensburg, Germany; [Gach, Johannes S.] Scripps Res Inst, Dept Immunol & Microbial Sci, La Jolla, CA 92037 USA	University of Natural Resources & Life Sciences, Vienna; University of Natural Resources & Life Sciences, Vienna; University of Natural Resources & Life Sciences, Vienna; University of Regensburg; Scripps Research Institute	Gach, JS (corresponding author), 10550 N Torrey Pines Rd, La Jolla, CA 92037 USA.	renate.kunert@boku.ac.at	Furtmüller, Paul G./Y-5819-2018; Kunert, Renate E/B-9185-2018; Messner, Paul/Q-5345-2017	Furtmüller, Paul G./0000-0002-1199-2469; Kunert, Renate E/0000-0002-3397-3621; Messner, Paul/0000-0002-3246-5801; Gach, Johannes/0000-0002-5043-5710	European Union [019052]; Austrian Science Fund [J2845-B13]	European Union(European Commission); Austrian Science Fund(Austrian Science Fund (FWF))	This work was funded by European Union Project 019052, "HIVAB," and the Austrian Science Fund J2845-B13.	Astronomo RD, 2008, J VIROL, V82, P6359, DOI 10.1128/JVI.00293-08; Bennett MJ, 2006, STRUCTURE, V14, P811, DOI 10.1016/j.str.2006.03.011; Bryson S, 2008, J MOL BIOL, V382, P910, DOI 10.1016/j.jmb.2008.07.057; Calarese DA, 2003, SCIENCE, V300, P2065, DOI 10.1126/science.1083182; Calarese DA, 2005, P NATL ACAD SCI USA, V102, P13372, DOI 10.1073/pnas.0505763102; DeLano WL, 2002, CURR OPIN STRUC BIOL, V12, P14, DOI 10.1016/S0959-440X(02)00283-X; Emsley P, 2004, ACTA CRYSTALLOGR D, V60, P2126, DOI 10.1107/S0907444904019158; Gach JS, 2007, AIDS RES HUM RETROV, V23, P1405, DOI 10.1089/aid.2007.0089; Gach JS, 2007, J BIOTECHNOL, V128, P735, DOI 10.1016/j.jbiotec.2006.12.020; Gronenborn AM, 2009, CURR OPIN STRUC BIOL, V19, P39, DOI 10.1016/j.sbi.2008.12.002; KABAT EA, 1991, J IMMUNOL, V147, P1709; Kellenberger E, 1979, UNCONVENTIONAL ELECT, P49; Kwong PD, 2009, NAT IMMUNOL, V10, P573, DOI 10.1038/ni.1746; Liu Y, 2002, PROTEIN SCI, V11, P1285, DOI 10.1110/ps.0201402; Marsche G, 2008, CARDIOVASC RES, V79, P187, DOI 10.1093/cvr/cvn051; Nelson JD, 2007, J VIROL, V81, P4033, DOI 10.1128/JVI.02588-06; Pantophlet R, 2006, ANNU REV IMMUNOL, V24, P739, DOI 10.1146/annurev.immunol.24.021605.090557; Reisinger H, 2008, APPL MICROBIOL BIOT, V81, P701, DOI 10.1007/s00253-008-1701-1; Roux KH, 2004, MOL IMMUNOL, V41, P1001, DOI 10.1016/j.molimm.2004.05.008; TRKOLA A, 1995, J VIROL, V69, P6609, DOI 10.1128/JVI.69.11.6609-6617.1995	20	10	12	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 8	2010	285	2					1122	1127		10.1074/jbc.M109.058792	http://dx.doi.org/10.1074/jbc.M109.058792			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	539MH	19903812	Green Published, hybrid, Green Accepted			2022-12-25	WOS:000273258200034
J	Gupta, MK; Atkinson, J; McGlynn, P				Gupta, Milind K.; Atkinson, John; McGlynn, Peter			DNA Structure Specificity Conferred on a Replicative Helicase by Its Loader	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI DNAB; DOUBLE-STRANDED DNA; GENE-PRODUCT; HEXAMERIC HELICASE; PROTEIN COMPLEX; NUCLEOTIDE COFACTORS; PHYSICAL-PROPERTIES; IN-VITRO; MECHANISM; FORK	Prokaryotic and eukaryotic replicative helicases can translocate along single-stranded and double-stranded DNA, with the central cavity of these multimeric ring helicases being able to accommodate both forms of DNA. Translocation by such helicases along single-stranded DNA results in the unwinding of forked DNA by steric exclusion and appears critical in unwinding of parental strands at the replication fork, whereas translocation over double-stranded DNA has no well-defined role. We have found that the accessory factor, DnaC, that promotes loading of the Escherichia coli replicative helicase DnaB onto single-stranded DNA may also act to confer DNA structure specificity on DnaB helicase. When present in excess, DnaC inhibits DnaB translocation over double-stranded DNA but not over single-stranded DNA. Inhibition of DnaB translocation over double-stranded DNA requires the ATP-bound form of DnaC, and this inhibition is relieved during translocation over single-stranded DNA indicating that stimulation of DnaC ATPase is responsible for this DNA structure specificity. These findings demonstrate that DnaC may provide the DNA structure specificity lacking in DnaB, limiting DnaB translocation to bona fide replication forks. The ability of other replicative helicases to translocate along single-stranded and double-stranded DNA raises the possibility that analogous regulatory mechanisms exist in other organisms.	[Gupta, Milind K.; Atkinson, John; McGlynn, Peter] Univ Aberdeen, Sch Med Sci, Inst Med Sci, Aberdeen AB25 2ZD, Scotland	University of Aberdeen	McGlynn, P (corresponding author), Univ Aberdeen, Sch Med Sci, Inst Med Sci, Aberdeen AB25 2ZD, Scotland.	p.mcglynn@abdn.ac.uk		McGlynn, Peter/0000-0001-8629-4713	Biotechnology and Biological Sciences Research Council [BB/E0020690]; Biotechnology and Biological Sciences Research Council [BB/E020690/1] Funding Source: researchfish; BBSRC [BB/E020690/1] Funding Source: UKRI	Biotechnology and Biological Sciences Research Council(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC)); Biotechnology and Biological Sciences Research Council(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC)); BBSRC(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC))	This work was supported by the Biotechnology and Biological Sciences Research Council (BB/E0020690).	ALLEN GC, 1991, J BIOL CHEM, V266, P22096; ARAI K, 1981, J BIOL CHEM, V256, P5253; BAKER TA, 1987, J BIOL CHEM, V262, P6877; Barcena M, 2001, EMBO J, V20, P1462, DOI 10.1093/emboj/20.6.1462; Biswas SB, 2004, BIOCHEM J, V379, P553, DOI 10.1042/BJ20031255; BRAMHILL D, 1988, CELL, V52, P743, DOI 10.1016/0092-8674(88)90412-6; Davey MJ, 2002, EMBO J, V21, P3148, DOI 10.1093/emboj/cdf308; Fang LH, 1999, MOL CELL, V4, P541, DOI 10.1016/S1097-2765(00)80205-1; FUNNELL BE, 1987, J BIOL CHEM, V262, P10327; Galletto R, 2000, BIOCHEMISTRY-US, V39, P12959, DOI 10.1021/bi0012484; Galletto R, 2004, J MOL BIOL, V343, P101, DOI 10.1016/j.jmb.2004.07.056; Galletto R, 2003, J MOL BIOL, V329, P441, DOI 10.1016/S0022-2836(03)00435-2; Hacker KJ, 1997, BIOCHEMISTRY-US, V36, P14080, DOI 10.1021/bi971644v; Heller RC, 2006, NATURE, V439, P557, DOI 10.1038/nature04329; Heller RC, 2005, J BIOL CHEM, V280, P34143, DOI 10.1074/jbc.M507224200; Jezewska MJ, 1998, BIOCHEMISTRY-US, V37, P3116, DOI 10.1021/bi972564u; Jones JM, 1999, J MOL BIOL, V289, P503, DOI 10.1006/jmbi.1999.2783; Kaplan DL, 2000, J MOL BIOL, V301, P285, DOI 10.1006/jmbi.2000.3965; Kaplan DL, 2002, MOL CELL, V10, P647, DOI 10.1016/S1097-2765(02)00642-1; Kaplan DL, 2004, MOL CELL, V15, P453, DOI 10.1016/j.molcel.2004.06.039; Kaplan DL, 2003, J BIOL CHEM, V278, P49171, DOI 10.1074/jbc.M308074200; Kim SS, 1996, CELL, V84, P643, DOI 10.1016/S0092-8674(00)81039-9; KOBORI JA, 1982, J BIOL CHEM, V257, P13770; KOBORI JA, 1982, J BIOL CHEM, V257, P13763; Learn BA, 1997, P NATL ACAD SCI USA, V94, P1154, DOI 10.1073/pnas.94.4.1154; LEBOWITZ JH, 1986, J BIOL CHEM, V261, P4738; Ludlam AV, 2001, J BIOL CHEM, V276, P27345, DOI 10.1074/jbc.M101940200; Marians KJ, 1995, METHOD ENZYMOL, V262, P507; MARSZALEK J, 1994, J BIOL CHEM, V269, P4883; McGlynn P, 1997, J MOL BIOL, V270, P212, DOI 10.1006/jmbi.1997.1120; Mott ML, 2008, CELL, V135, P623, DOI 10.1016/j.cell.2008.09.058; PARSONS CA, 1990, J BIOL CHEM, V265, P9285; Patel SS, 2000, ANNU REV BIOCHEM, V69, P651, DOI 10.1146/annurev.biochem.69.1.651; REHAKRANTZ LJ, 1978, J BIOL CHEM, V253, P4043; Roychowdhury A, 2009, BIOCHEMISTRY-US, V48, P6730, DOI 10.1021/bi9000529; Singleton MR, 2007, ANNU REV BIOCHEM, V76, P23, DOI 10.1146/annurev.biochem.76.052305.115300; SKARSTAD K, 1995, MOL MICROBIOL, V17, P825, DOI 10.1111/j.1365-2958.1995.mmi_17050825.x; WAHLE E, 1989, J BIOL CHEM, V264, P2469; WAHLE E, 1989, J BIOL CHEM, V264, P2463; WECHSLER JA, 1971, MOL GEN GENET, V113, P273, DOI 10.1007/BF00339547; WICKNER S, 1975, P NATL ACAD SCI USA, V72, P921, DOI 10.1073/pnas.72.3.921; WICKNER S, 1974, P NATL ACAD SCI USA, V71, P783, DOI 10.1073/pnas.71.3.783	42	8	8	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 8	2010	285	2					979	987		10.1074/jbc.M109.072520	http://dx.doi.org/10.1074/jbc.M109.072520			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	539MH	19880515	Green Published, hybrid			2022-12-25	WOS:000273258200018
J	Lopez-Bergami, P; Kim, H; Dewing, A; Goydos, J; Aaronson, S; Ronai, Z				Lopez-Bergami, Pablo; Kim, Hyungsoo; Dewing, Antimone; Goydos, James; Aaronson, Stuart; Ronai, Ze'ev			c-Jun Regulates Phosphoinositide-dependent Kinase 1 Transcription IMPLICATION FOR Akt AND PROTEIN KINASE C ACTIVITIES AND MELANOMA TUMORIGENESIS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EPIDERMAL-GROWTH-FACTOR; FUNCTIONAL INTERACTION; SIGNAL-TRANSDUCTION; GENE-EXPRESSION; HUMAN CANCER; ACTIVATION; PHOSPHORYLATION; PROMOTER; JNK; MUTATIONS	Mutations in N-RAS and B-RAF, which commonly occur in melanomas, result in constitutive activation of the mitogen-activated protein kinase (MAPK)/extracellular signal-regulated protein kinase (ERK) signaling. Active ERK increases expression and activity of the c-Jun transcription factor, linking ERK and Jun N-terminal kinase (JNK) cascades. Here, we show that c-Jun regulates transcription of phosphoinositide-dependent kinase 1 (PDK1) with a concomitant impact on Akt and protein kinase C (PKC) activity and related substrates. Inhibition of c-Jun reduces PDK1 expression and attenuates Akt and PKC activity, which can be restored by exogenous PDK1. c-Jun regulation of PDK1 in melanoma contributes to growth rate and the ability to form tumors in mice. Correspondingly, increased levels of c-Jun in melanoma cell lines coincide with up-regulation of PDK1 and phosphorylation of PKC and Akt. The identification of c-Jun as a transcriptional regulator of PDK1 expression highlights key mechanisms underlying c-Jun oncogenic activity, and provides new insight into the nature of up-regulated Akt and PKC in melanoma.	[Lopez-Bergami, Pablo; Kim, Hyungsoo; Dewing, Antimone; Ronai, Ze'ev] Burnham Inst Med Res, Signal Transduct Program, La Jolla, CA 92037 USA; [Lopez-Bergami, Pablo; Aaronson, Stuart] Mt Sinai Sch Med, Dept Oncol Sci, New York, NY 10029 USA; [Goydos, James] Univ Med & Dent New Jersey, Div Surg Oncol, Robert Wood Johnson Med Sch, Piscataway, NJ 08854 USA	Sanford Burnham Prebys Medical Discovery Institute; Icahn School of Medicine at Mount Sinai; Rutgers State University New Brunswick; Rutgers State University Medical Center	Ronai, Z (corresponding author), 10901 N Torrey Pines Rd, La Jolla, CA 92037 USA.	ronai@burnham.org	Goydos, James/AAR-8990-2020	Goydos, James/0000-0001-9811-939X; Kim, Hyungsoo/0000-0002-8189-5939; RONAI, ZEEV/0000-0002-3859-0400	NCI [RO1CA051995, PO1CA128814]; Roemmers Foundation; Harry J. Lloyd Charitable Trust; Agencia Nacional de Promocion Cientifica y Tecnologica (ANPCyT) [PICT-2007-01010]; NATIONAL CANCER INSTITUTE [R01CA051995, P01CA128814] Funding Source: NIH RePORTER	NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Roemmers Foundation; Harry J. Lloyd Charitable Trust; Agencia Nacional de Promocion Cientifica y Tecnologica (ANPCyT)(ANPCyT); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This work was supported, in whole or in part, by National Institutes of Health Grants RO1CA051995 and PO1CA128814 from the NCI (to Z.R.), grants from the Roemmers Foundation, The Harry J. Lloyd Charitable Trust, and Agencia Nacional de Promocion Cientifica y Tecnologica (ANPCyT) Grant PICT-2007-01010 (to P.L.B.).	Alessi DR, 1997, CURR BIOL, V7, P261, DOI 10.1016/S0960-9822(06)00122-9; Balendran A, 2000, FEBS LETT, V484, P217, DOI 10.1016/S0014-5793(00)02162-1; BASSUK AG, 1995, IMMUNITY, V3, P223, DOI 10.1016/1074-7613(95)90092-6; Behrens A, 2000, ONCOGENE, V19, P2657, DOI 10.1038/sj.onc.1203603; Bhoumik A, 2004, P NATL ACAD SCI USA, V101, P4222, DOI 10.1073/pnas.0400195101; Chan TO, 2002, CANCER CELL, V1, P181, DOI 10.1016/S1535-6108(02)00033-8; Chen BK, 2000, P NATL ACAD SCI USA, V97, P10406, DOI 10.1073/pnas.180321497; Davies H, 2002, NATURE, V417, P949, DOI 10.1038/nature00766; Eferl R, 2003, CELL, V112, P181, DOI 10.1016/S0092-8674(03)00042-4; Feldman RI, 2005, J BIOL CHEM, V280, P19867, DOI 10.1074/jbc.M501367200; Flynn P, 2000, J BIOL CHEM, V275, P11064, DOI 10.1074/jbc.275.15.11064; Gorden A, 2003, CANCER RES, V63, P3955; Huang JX, 2009, BIOCHEM SOC T, V37, P217, DOI 10.1042/BST0370217; Jiang TY, 2003, J BIOL CHEM, V278, P15789, DOI 10.1074/jbc.M212525200; Johnson R, 1996, MOL CELL BIOL, V16, P4504; Kardassis D, 1999, J BIOL CHEM, V274, P29572, DOI 10.1074/jbc.274.41.29572; Lawlor MA, 2002, EMBO J, V21, P3728, DOI 10.1093/emboj/cdf387; Logan SK, 1996, J BIOL CHEM, V271, P774, DOI 10.1074/jbc.271.2.774; Lopez-Bergami P, 2005, MOL CELL, V19, P309, DOI 10.1016/j.molcel.2005.06.025; Lopez-Bergami P, 2008, INT J BIOCHEM CELL B, V40, P1055, DOI 10.1016/j.biocel.2007.11.011; Lopez-Bergami P, 2008, PHOTOCHEM PHOTOBIOL, V84, P289, DOI 10.1111/j.1751-1097.2007.00254.x; Lopez-Bergami P, 2007, CANCER CELL, V11, P447, DOI 10.1016/j.ccr.2007.03.009; Maeno K, 2006, ONCOGENE, V25, P271, DOI 10.1038/sj.onc.1209018; MAJERUS MA, 1992, NUCLEIC ACIDS RES, V20, P2699, DOI 10.1093/nar/20.11.2699; Makris C, 2002, ONCOGENE, V21, P7891, DOI 10.1038/sj.onc.1205964; Mariani O, 2007, CANCER CELL, V11, P361, DOI 10.1016/j.ccr.2007.02.007; Matthews CP, 2007, CANCER RES, V67, P2430, DOI 10.1158/0008-5472.CAN-06-0522; Maurer M, 2009, CANCER RES, V69, P6299, DOI 10.1158/0008-5472.CAN-09-0820; Melnikova IN, 2001, J BIOL CHEM, V276, P19040, DOI 10.1074/jbc.M010735200; Mora A, 2004, SEMIN CELL DEV BIOL, V15, P161, DOI 10.1016/j.semcdb.2003.12.022; Newton AC, 2003, BIOCHEM J, V370, P361, DOI 10.1042/BJ20021626; Storz P, 2002, FRONT BIOSCI-LANDMRK, V7, pD886, DOI 10.2741/storz; Vasudevan KM, 2009, CANCER CELL, V16, P21, DOI 10.1016/j.ccr.2009.04.012; Vivanco I, 2007, CANCER CELL, V11, P555, DOI 10.1016/j.ccr.2007.04.021; Vleugel MM, 2006, HUM PATHOL, V37, P668, DOI 10.1016/j.humpath.2006.01.022; Vogt PK, 2001, ONCOGENE, V20, P2365, DOI 10.1038/sj.onc.1204443; Wang YN, 2003, J BIOL CHEM, V278, P45848, DOI 10.1074/jbc.M302630200; WASYLYK B, 1990, NATURE, V346, P191, DOI 10.1038/346191a0; Wick MJ, 2003, J BIOL CHEM, V278, P42913, DOI 10.1074/jbc.M304172200; Wick MJ, 2000, J BIOL CHEM, V275, P40400, DOI 10.1074/jbc.M003937200	40	33	34	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 8	2010	285	2					903	913		10.1074/jbc.M109.075630	http://dx.doi.org/10.1074/jbc.M109.075630			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	539MH	19910471	Green Published, hybrid			2022-12-25	WOS:000273258200010
J	Meng, XW; Heldebrant, MP; Flatten, KS; Loegering, DA; Dai, HM; Schneider, PA; Gomez, TS; Peterson, KL; Trushin, SA; Hess, AD; Smith, BD; Karp, JE; Billadeau, DD; Kaufmann, SH				Meng, Xue Wei; Heldebrant, Michael P.; Flatten, Karen S.; Loegering, David A.; Dai, Haiming; Schneider, Paula A.; Gomez, Timothy S.; Peterson, Kevin L.; Trushin, Sergey A.; Hess, Allan D.; Smith, B. Douglas; Karp, Judith E.; Billadeau, Daniel D.; Kaufmann, Scott H.			Protein Kinase C beta Modulates Ligand-induced Cell Surface Death Receptor Accumulation A MECHANISTIC BASIS FOR ENZASTAURIN-DEATH LIGAND SYNERGY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LYMPHOCYTIC-LEUKEMIA CELLS; INDUCED APOPTOSIS; SELECTIVE INHIBITOR; MEDIATED APOPTOSIS; TRAIL RESISTANCE; BCL-XL; CANCER; ACTIVATION; FADD; FAS	Although treatment with the protein kinase C (PKC) activator phorbol 12-myristate 13-acetate (PMA) is known to protect a subset of cells from induction of apoptosis by death ligands such as Fas ligand and tumor necrosis factor-alpha-related apoptosis-inducing ligand, the mechanism of this protection is unknown. This study demonstrated that protection in short term apoptosis assays and long term proliferation assays was maximal when Jurkat or HL-60 human leukemia cells were treated with 2-5 nM PMA. Immunoblotting demonstrated that multiple PKC isoforms, including PKC alpha, PKC beta, PKC epsilon, and PKC theta, translocated from the cytosol to a membrane-bound fraction at these PMA concentrations. When the ability of short hairpin RNA (shRNA) constructs that specifically down-regulated each of these isoforms was examined, PKC beta shRNA uniquely reversed PMA-induced protection against cell death. The PKC beta-selective small molecule inhibitor enzastaurin had a similar effect. Although mass spectrometry suggested that Fas is phosphorylated on a number of serines and threonines, mutation of these sites individually or collectively had no effect on Fas-mediated death signaling or PMA protection. Further experiments demonstrated that PMA diminished ligand-induced cell surface accumulation of Fas and DR5, and PKC beta shRNA or enzastaurin reversed this effect. Moreover, enzastaurin sensitized a variety of human tumor cell lines and clinical acute myelogenous leukemia isolates, which express abundant PKC beta, to tumor necrosis factor-alpha related apoptosis-inducing ligand-induced death in the absence of PMA. Collectively, these results identify a specific PKC isoform that modulates death receptor-mediated cytotoxicity as well as a small molecule inhibitor that mitigates the inhibitory effects of PKC activation on ligand-induced death receptor trafficking and cell death.	[Kaufmann, Scott H.] Mayo Clin, Div Oncol Res, Dept Mol Pharmacol & Expt Therapeut, Rochester, MN 55905 USA; [Meng, Xue Wei; Flatten, Karen S.; Loegering, David A.; Dai, Haiming; Schneider, Paula A.; Gomez, Timothy S.; Peterson, Kevin L.; Billadeau, Daniel D.; Kaufmann, Scott H.] Mayo Clin, Dept Oncol, Rochester, MN 55905 USA; [Trushin, Sergey A.; Kaufmann, Scott H.] Mayo Clin, Dept Med, Rochester, MN 55905 USA; [Billadeau, Daniel D.] Mayo Clin, Dept Immunol, Rochester, MN 55905 USA; [Hess, Allan D.; Smith, B. Douglas; Karp, Judith E.] Johns Hopkins Sidney Kimmel Canc Ctr, Div Hematol Malignancies, Baltimore, MD 21231 USA	Mayo Clinic; Mayo Clinic; Mayo Clinic; Mayo Clinic; Johns Hopkins University; Johns Hopkins Medicine	Kaufmann, SH (corresponding author), Mayo Clin, Div Oncol Res, Dept Mol Pharmacol & Expt Therapeut, Gonda 19-212,200 1st St,SW, Rochester, MN 55905 USA.	Kaufmann.scott@mayo.edu		Kaufmann, Scott/0000-0002-4900-7145; Dai, Haiming/0000-0002-0484-7407	National Institutes of Health [R01 CA69008]; Mayo Foundation; NATIONAL CANCER INSTITUTE [R01CA069008] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Mayo Foundation; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This work was supported, in whole or in part, by National Institutes of Health Grant R01 CA69008 (to S.H.K.). This work was also supported by a predoctoral fellowship (to M.P.H.) from the Mayo Foundation.	Abrams ST, 2007, BLOOD, V109, P1193, DOI 10.1182/blood-2006-03-012021; Alappat EC, 2005, MOL CELL, V19, P321, DOI 10.1016/j.molcel.2005.06.024; Ashkenazi A, 1999, CURR OPIN CELL BIOL, V11, P255, DOI 10.1016/S0955-0674(99)80034-9; Ashkenazi A, 1998, SCIENCE, V281, P1305, DOI 10.1126/science.281.5381.1305; Ashkenazi A, 2008, NAT REV DRUG DISCOV, V7, P1001, DOI 10.1038/nrd2637; BEGUINOT L, 1985, P NATL ACAD SCI USA, V82, P2774, DOI 10.1073/pnas.82.9.2774; Behbakht K, 2007, CANCER RES, V67, P3036, DOI 10.1158/0008-5472.CAN-06-3755; Bennett M, 1998, SCIENCE, V282, P290, DOI 10.1126/science.282.5387.290; BERENBAUM MC, 1989, PHARMACOL REV, V41, P93; Boatright KM, 2003, MOL CELL, V11, P529, DOI 10.1016/S1097-2765(03)00051-0; Busuttil V, 2002, ONCOGENE, V21, P3213, DOI 10.1038/sj.onc.1205433; Carducci MA, 2006, J CLIN ONCOL, V24, P4092, DOI 10.1200/JCO.2005.05.3447; Caserta TM, 2003, APOPTOSIS, V8, P345, DOI 10.1023/A:1024116916932; Chang DW, 2002, EMBO J, V21, P3704, DOI 10.1093/emboj/cdf356; Chang DW, 2003, EMBO J, V22, P4132, DOI 10.1093/emboj/cdg414; CHOU TC, 1984, ADV ENZYME REGUL, V22, P27, DOI 10.1016/0065-2571(84)90007-4; Dai HM, 2009, J BIOL CHEM, V284, P18311, DOI 10.1074/jbc.M109.004770; Dempsey EC, 2000, AM J PHYSIOL-LUNG C, V279, pL429, DOI 10.1152/ajplung.2000.279.3.L429; Doherty GJ, 2009, ANNU REV BIOCHEM, V78, P857, DOI 10.1146/annurev.biochem.78.081307.110540; Domina AM, 2004, ONCOGENE, V23, P5301, DOI 10.1038/sj.onc.1207692; Eischen CM, 1997, BLOOD, V90, P935, DOI 10.1182/blood.V90.3.935.935_935_943; Ekert PG, 2004, J CELL BIOL, V165, P835, DOI 10.1083/jcb.200312031; ENGLISH D, 1974, J IMMUNOL METHODS, V5, P249, DOI 10.1016/0022-1759(74)90109-4; Falschlehner C, 2009, IMMUNOLOGY, V127, P145, DOI 10.1111/j.1365-2567.2009.03058.x; Fedorov O, 2007, P NATL ACAD SCI USA, V104, P20523, DOI 10.1073/pnas.0708800104; Ford MGJ, 2001, SCIENCE, V291, P1051, DOI 10.1126/science.291.5506.1051; Gibson SB, 2000, MOL CELL BIOL, V20, P205, DOI 10.1128/MCB.20.1.205-212.2000; Gomez TS, 2006, IMMUNITY, V24, P741, DOI 10.1016/j.immuni.2006.03.022; Gomez-Angelats M, 2001, J BIOL CHEM, V276, P44944, DOI 10.1074/jbc.M104919200; Graff JR, 2005, CANCER RES, V65, P7462, DOI 10.1158/0008-5472.CAN-05-0071; Green LJ, 2006, CLIN CANCER RES, V12, P3408, DOI 10.1158/1078-0432.CCR-05-2231; Griner EM, 2007, NAT REV CANCER, V7, P281, DOI 10.1038/nrc2110; Guicciardi ME, 2009, FASEB J, V23, P1625, DOI 10.1096/fj.08-111005; Hackbarth JS, 2004, BIOTECHNIQUES, V37, P835; Harper N, 2003, J BIOL CHEM, V278, P44338, DOI 10.1074/jbc.M307376200; He Q, 2004, ONCOGENE, V23, P2554, DOI 10.1038/sj.onc.1207351; Hendrickson AW, 2008, J CLIN INVEST, V118, P3582, DOI 10.1172/JCI37553; Herbst RS, 2007, CLIN CANCER RES, V13, p4641S, DOI 10.1158/1078-0432.CCR-07-0538; Holmstrom TH, 2000, EMBO J, V19, P5418, DOI 10.1093/emboj/19.20.5418; Hughes MA, 2009, MOL CELL, V35, P265, DOI 10.1016/j.molcel.2009.06.012; Ito T, 1997, J BIOL CHEM, V272, P11671, DOI 10.1074/jbc.272.18.11671; Johnson TR, 2003, ONCOGENE, V22, P4953, DOI 10.1038/sj.onc.1206656; Johnstone RW, 2008, NAT REV CANCER, V8, P782, DOI 10.1038/nrc2465; Juo P, 1999, CELL GROWTH DIFFER, V10, P797; Kaufmann SH, 1997, BLOOD, V89, P2098, DOI 10.1182/blood.V89.6.2098; Kaufmann SH, 2001, ANAL BIOCHEM, V296, P283, DOI 10.1006/abio.2001.5313; Kim KH, 2000, CLIN CANCER RES, V6, P335; KISCHKEL FC, 1995, EMBO J, V14, P5579, DOI 10.1002/j.1460-2075.1995.tb00245.x; Kischkel FC, 2001, J BIOL CHEM, V276, P46639, DOI 10.1074/jbc.M105102200; Koivunen J, 2006, CANCER LETT, V235, P1, DOI 10.1016/j.canlet.2005.03.033; LEBIVIC A, 1990, J CELL BIOL, V110, P1533, DOI 10.1083/jcb.110.5.1533; Lee KH, 2006, EMBO J, V25, P1009, DOI 10.1038/sj.emboj.7601016; Martiny-Baron G, 2007, PHARMACOL RES, V55, P477, DOI 10.1016/j.phrs.2007.04.001; Matharu AL, 2001, J BIOL CHEM, V276, P30199, DOI 10.1074/jbc.M010650200; McDonald ER, 2004, P NATL ACAD SCI USA, V101, P6170, DOI 10.1073/pnas.0307459101; Medema JP, 1997, EMBO J, V16, P2794, DOI 10.1093/emboj/16.10.2794; Meng XW, 2007, J BIOL CHEM, V282, P29831, DOI 10.1074/jbc.M706110200; Meng XW, 2003, J BIOL CHEM, V278, P47326, DOI 10.1074/jbc.M304793200; Meng XW, 2002, J BIOL CHEM, V277, P3776, DOI 10.1074/jbc.M107218200; Mesner P W Jr, 1997, Adv Pharmacol, V41, P461, DOI 10.1016/S1054-3589(08)61069-8; Mesner PW, 1999, J BIOL CHEM, V274, P22635, DOI 10.1074/jbc.274.32.22635; Muzio M, 1996, CELL, V85, P817, DOI 10.1016/S0092-8674(00)81266-0; Nagata S, 1997, CELL, V88, P355, DOI 10.1016/S0092-8674(00)81874-7; NICOLETTI I, 1991, J IMMUNOL METHODS, V139, P271, DOI 10.1016/0022-1759(91)90198-O; NISHIZUKA Y, 1995, FASEB J, V9, P484, DOI 10.1096/fasebj.9.7.7737456; Panner A, 2005, MOL CELL BIOL, V25, P8809, DOI 10.1128/MCB.25.20.8809-8823.2005; Parker PJ, 2004, J CELL SCI, V117, P131, DOI 10.1242/jcs.00982; PELCHENMATTHEWS A, 1989, EMBO J, V8, P3641, DOI 10.1002/j.1460-2075.1989.tb08538.x; PIKE BL, 1970, J CELL PHYSIOL, V76, P77, DOI 10.1002/jcp.1040760111; Podar K, 2007, EXPERT OPIN INV DRUG, V16, P1693, DOI 10.1517/13543784.16.10.1693; Qin JZ, 2002, EXP DERMATOL, V11, P573, DOI 10.1034/j.1600-0625.2002.110610.x; Reyland ME, 2009, FRONT BIOSCI-LANDMRK, V14, P2386, DOI 10.2741/3385; Robertson MJ, 2007, J CLIN ONCOL, V25, P1741, DOI 10.1200/JCO.2006.09.3146; Schutze S, 2008, NAT REV MOL CELL BIO, V9, P655, DOI 10.1038/nrm2430; Scott FL, 2009, NATURE, V457, P1019, DOI 10.1038/nature07606; Shipp MA, 2002, NAT MED, V8, P68, DOI 10.1038/nm0102-68; Siegel RM, 1998, J CELL BIOL, V141, P1243, DOI 10.1083/jcb.141.5.1243; Simonian PL, 1997, BLOOD, V90, P1208, DOI 10.1182/blood.V90.3.1208.1208_1208_1216; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; Strasser A, 2009, IMMUNITY, V30, P180, DOI 10.1016/j.immuni.2009.01.001; Svingen PA, 2000, CLIN CANCER RES, V6, P237; Teicher BA, 2006, CLIN CANCER RES, V12, P5336, DOI 10.1158/1078-0432.CCR-06-0945; Thorburn A, 2008, DRUG RESIST UPDATE, V11, P17, DOI 10.1016/j.drup.2008.02.001; Ueffing N, 2009, BLOOD, V114, P572, DOI 10.1182/blood-2009-02-204230; Wagner KW, 2007, NAT MED, V13, P1070, DOI 10.1038/nm1627; Wajant H, 2006, CANC TREAT, V130, P141; Wajant H, 2004, VITAM HORM, V67, P101; Walczak H, 2000, EXP CELL RES, V256, P58, DOI 10.1006/excr.2000.4840; Wen JH, 2000, BLOOD, V96, P3900, DOI 10.1182/blood.V96.12.3900.h8003900_3900_3906; Werner MH, 2006, CELL CYCLE, V5, P2332, DOI 10.4161/cc.5.20.3385; Wu JJ, 2005, FEBS LETT, V579, P1940, DOI 10.1016/j.febslet.2005.02.041; Yoshida T, 2005, CANCER RES, V65, P5662, DOI 10.1158/0008-5472.CAN-05-0693; Yu CR, 2005, ONCOGENE, V24, P6861, DOI 10.1038/sj.onc.1208841; Yu JW, 2008, ONCOGENE, V27, P6216, DOI 10.1038/onc.2008.299; Yu JW, 2009, P NATL ACAD SCI USA, V106, P8169, DOI 10.1073/pnas.0812453106	95	15	15	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 8	2010	285	2					888	902		10.1074/jbc.M109.057638	http://dx.doi.org/10.1074/jbc.M109.057638			15	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	539MH	19887445	Green Published, hybrid			2022-12-25	WOS:000273258200009
J	Nguyen, HTT; Dalmasso, G; Yan, YT; Laroui, H; Dahan, S; Mayer, L; Sitaraman, SV; Merlin, D				Nguyen, Hang Thi Thu; Dalmasso, Guillaume; Yan, Yutao; Laroui, Hamed; Dahan, Stephanie; Mayer, Lloyd; Sitaraman, Shanthi V.; Merlin, Didier			MicroRNA-7 Modulates CD98 Expression during Intestinal Epithelial Cell Differentiation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							4F2 HEAVY-CHAIN; INFLAMMATORY BOWEL-DISEASE; AMINO-ACID TRANSPORTER; TRANSFERRIN RECEPTOR; ACTIVATION ANTIGEN; GENE-EXPRESSION; SURFACE-ANTIGEN; MESSENGER-RNA; PROTEINS; KINETICS	The transmembrane glycoprotein CD98 regulates multiple cellular functions, including extracellular signaling, epithelial cell adhesion/polarity, amino acid transport, and cell-cell interactions. MicroRNAs post-transcriptionally regulate gene expression, thereby functioning as modulators of numerous cellular processes, such as cell differentiation, proliferation, and apoptosis. Here, we investigated if microRNAs regulate CD98 expression during intestinal epithelial cell differentiation and inflammation. We found that microRNA-7 repressed CD98 expression in Caco2-BBE cells by directly targeting the 3'-untranslated region of human CD98 mRNA. Expression of CD98 was decreased, whereas that of microRNA-7 was increased in well-differentiated Caco2-BBE cells compared with undifferentiated cells. Undifferentiated crypt cells isolated from mouse jejunum showed higher CD98 levels and lower levels of mmu-microRNA-706, a murine original microRNA candidate for CD98, than well-differentiated villus cells. Importantly, microRNA-7 decreased Caco2-BBE cell attachment on laminin-1, and CD98 overexpression recovered this inhibition, suggesting that microRNA-7 modulates epithelial cell adhesion to extracellular matrix, which in turn could affect proliferation and differentiation during the migration of enterocytes across the crypt-villus axis, by regulating CD98 expression. In a pathological context, the pro-inflammatory cytokine interleukin 1-beta increased CD98 expression in Caco2-BBE cells by decreasing microRNA-7 levels. Consistent with the in vitro findings, microRNA-7 levels were decreased in actively inflamed Crohn disease colonic tissues, where CD98 expression was up-regulated, compared with normal tissues. Together, these results reveal a novel mechanism underlying regulation of CD98 expression during patho-physiological states. This study raises microRNAs as a promising target for therapeutic modulations of CD98 expression in intestinal inflammatory disorders.	[Nguyen, Hang Thi Thu; Dalmasso, Guillaume; Yan, Yutao; Laroui, Hamed; Sitaraman, Shanthi V.; Merlin, Didier] Emory Univ, Dept Med, Div Digest Dis, Sch Med, Atlanta, GA 30322 USA; [Dahan, Stephanie; Mayer, Lloyd] Mt Sinai Sch Med, Inst Immunol, New York, NY 10029 USA	Emory University; Icahn School of Medicine at Mount Sinai	Nguyen, HTT (corresponding author), Emory Univ, Dept Med, Div Digest Dis, Sch Med, 615 Michael St, Atlanta, GA 30322 USA.	hnguye9@emory.edu	Dalmasso, Guillaume/N-2443-2018; Nguyen, Hang/N-2441-2018	Dalmasso, Guillaume/0000-0002-3433-870X; Nguyen, Hang/0000-0001-7431-5126	National Institutes of Health [R24-DK-064399, R01-DK-071594, R01-DK55850]; Crohn and Colitis Foundation of America; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R24DK064399, R01DK055850, R01DK071594] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Crohn and Colitis Foundation of America; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))	This work was supported, in whole or in part, by National Institutes of Health Grants R24-DK-064399 center grant, R01-DK-071594 (to D.M.), and R01DK55850 (to S.V.S.) from the NIDDK. This work was also supported by the Crohn and Colitis Foundation of America (a research fellowship award (to G.D.) and a research career development award (to S.D.)).	Ambros V, 2004, NATURE, V431, P350, DOI 10.1038/nature02871; Bartel DP, 2004, CELL, V116, P281, DOI 10.1016/S0092-8674(04)00045-5; Cantor JM, 2008, IMMUNOL REV, V223, P236, DOI 10.1111/j.1600-065X.2008.00640.x; Chang S, 2004, NATURE, V430, P785, DOI 10.1038/nature02752; Charrier L, 2005, AM J PHYSIOL-GASTR L, V288, pG346, DOI 10.1152/ajpgi.00262.2004; Chen CZ, 2004, SCIENCE, V303, P83, DOI 10.1126/science.1091903; Chen JF, 2006, NAT GENET, V38, P228, DOI 10.1038/ng1725; COTNER T, 1983, J EXP MED, V157, P461, DOI 10.1084/jem.157.2.461; Deves R, 2000, J MEMBRANE BIOL, V173, P165, DOI 10.1007/s002320001017; Driss A, 2006, AM J PHYSIOL-GASTR L, V290, pG1228, DOI 10.1152/ajpgi.00378.2005; Esau C, 2004, J BIOL CHEM, V279, P52361, DOI 10.1074/jbc.C400438200; FAIS S, 1989, GASTROENTEROLOGY, V97, P1435, DOI 10.1016/0016-5085(89)90387-9; FERNANDEZHERRERA J, 1989, J INVEST DERMATOL, V92, P247, DOI 10.1111/1523-1747.ep12276789; FLINT N, 1991, BIOCHEM J, V280, P331, DOI 10.1042/bj2800331; GORDON JI, 1989, J CELL BIOL, V108, P1187, DOI 10.1083/jcb.108.4.1187; GOTTESDIENER KM, 1988, MOL CELL BIOL, V8, P3809, DOI 10.1128/MCB.8.9.3809; Hino K, 2008, RNA, V14, P1433, DOI 10.1261/rna.810208; Kageyama T, 2000, BRAIN RES, V879, P115, DOI 10.1016/S0006-8993(00)02758-X; Kelly AP, 2007, EMBO J, V26, P3441, DOI 10.1038/sj.emboj.7601761; Kucharzik T, 2005, LAB INVEST, V85, P932, DOI 10.1038/labinvest.3700289; LEIDEN JM, 1989, J AUTOIMMUN, V2, P67, DOI 10.1016/0896-8411(89)90118-2; LINDSTEN T, 1988, MOL CELL BIOL, V8, P3820, DOI 10.1128/MCB.8.9.3820; Liu X, 2003, J BIOL CHEM, V278, P23672, DOI 10.1074/jbc.M302777200; Merlin D, 2001, J BIOL CHEM, V276, P39282, DOI 10.1074/jbc.M105077200; Nguyen HTT, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003895; Novak DA, 1997, PLACENTA, V18, P643, DOI 10.1016/S0143-4004(97)90005-9; Ohkame H, 2001, J SURG ONCOL, V78, P265, DOI 10.1002/jso.1165; Okamoto Y, 2002, AM J PHYSIOL-CELL PH, V282, pC196, DOI 10.1152/ajpcell.2002.282.1.C196; PARMACEK MS, 1989, NUCLEIC ACIDS RES, V17, P1915, DOI 10.1093/nar/17.5.1915; Pedersen I, 2008, CYTOKINE, V43, P391, DOI 10.1016/j.cyto.2008.07.016; Poy MN, 2004, NATURE, V432, P226, DOI 10.1038/nature03076; QUACKENBUSH E, 1987, P NATL ACAD SCI USA, V84, P6526, DOI 10.1073/pnas.84.18.6526; QUACKENBUSH EJ, 1986, J IMMUNOL, V136, P118; Rossier G, 1999, J BIOL CHEM, V274, P34948, DOI 10.1074/jbc.274.49.34948; SCHREIBER S, 1991, GASTROENTEROLOGY, V101, P1020, DOI 10.1016/0016-5085(91)90729-5; Shennan DB, 2004, BBA-BIOMEMBRANES, V1664, P206, DOI 10.1016/j.bbamem.2004.05.008; Stark A, 2003, PLOS BIOL, V1, P397, DOI 10.1371/journal.pbio.0000060; TEIXEIRA S, 1991, EUR J BIOCHEM, V202, P819, DOI 10.1111/j.1432-1033.1991.tb16438.x; Wegener J, 2000, EXP CELL RES, V259, P158, DOI 10.1006/excr.2000.4919; Yan YT, 2008, BBA-GEN SUBJECTS, V1780, P1087, DOI 10.1016/j.bbagen.2008.06.007; Yan Y, 2007, AM J PHYSIOL-GASTR L, V292, pG535, DOI 10.1152/ajpgi.00385.2006	41	91	96	3	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 8	2010	285	2					1479	1489		10.1074/jbc.M109.057141	http://dx.doi.org/10.1074/jbc.M109.057141			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	539MH	19892711	Green Published, hybrid			2022-12-25	WOS:000273258200067
J	Nishimoto, Y; Ito, D; Yagi, T; Nihei, Y; Tsunoda, Y; Suzuki, N				Nishimoto, Yoshinori; Ito, Daisuke; Yagi, Takuya; Nihei, Yoshihiro; Tsunoda, Yoshiko; Suzuki, Norihiro			Characterization of Alternative Isoforms and Inclusion Body of the TAR DNA-binding Protein-43	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMYOTROPHIC-LATERAL-SCLEROSIS; FRONTOTEMPORAL LOBAR DEGENERATION; MAMMALIAN STRESS GRANULES; NUCLEAR FACTOR TDP-43; CFTR EXON-9; INTRANUCLEAR INCLUSIONS; AGGREGATE FORMATION; ALZHEIMERS-DISEASE; PROCESSING BODIES; MESSENGER-RNA	TAR DNA-binding protein-43 (TDP-43) has been recently identified as a major component of the ubiquitinated inclusions found in frontotemporal lobar degeneration with ubiquitin-positive inclusions and in amyotrophic lateral sclerosis, diseases that are collectively termed TDP-43 proteinopathies. Several amyotrophic lateral sclerosis-linked mutations of the TDP-43 gene have also been identified; however, the precise molecular mechanisms underlying the neurodegeneration remain unclear. To investigate the biochemical characteristics of TDP-43, we examined truncation, isoforms, and cytoplasmic inclusion (foci) formation using TDP-43-expressing cells. Under apoptosis, caspase-3 generates two 35-kDa (p35f) and 25-kDa (p25f) fragments. However, in caspase-3(-/-) cells, novel caspase-3-independent isoforms of these two variants (p35iso and p25iso) were also detected under normal conditions. With a deletion mutant series, the critical domains for generating both isoforms were determined and applied to in vitro transcription/translation, revealing alternate in-frame translation start sites downstream of the natural initiation codon. Subcellular localization analysis indicated that p35 (p35f and p35iso) expression leads to the formation of stress granules, cellular structures that package mRNA and RNA-binding proteins during cell stress. After applying proteasome inhibitors, aggresomes, which are aggregates of misfolded proteins, were formed in the cytoplasm of cells expressing p35. Collectively, this study demonstrates that the 35-kDa isoforms of TDP-43 assemble in stress granules, suggesting that TDP-43 plays an important role in translation, stability, and metabolism of mRNA. Our findings provide new biological and pathological insight into the development of TDP-43 proteinopathies.	[Nishimoto, Yoshinori; Ito, Daisuke; Yagi, Takuya; Nihei, Yoshihiro; Tsunoda, Yoshiko; Suzuki, Norihiro] Keio Univ, Sch Med, Dept Neurol, Shinjuku Ku, Tokyo 1608582, Japan	Keio University	Ito, D (corresponding author), Keio Univ, Sch Med, Dept Neurol, Shinjuku Ku, 35 Shinanomachi, Tokyo 1608582, Japan.	d-ito@jk9.so-net.ne.jp	Ito, Daisuke/GXF-1648-2022; Suzuki, Norihiro/J-5125-2013; Ito, Daisuke/M-3608-2013	Suzuki, Norihiro/0000-0002-0399-6590; Ito, Daisuke/0000-0002-4740-1675	Eisai Co., Ltd.; Ministry of Education, Culture, Sports, Science and Technology of Japan [18590955, 21790850]; ALS Foundation; Japan ALS Association; Keio Medical Science Fund	Eisai Co., Ltd.(Eisai Co Ltd); Ministry of Education, Culture, Sports, Science and Technology of Japan(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)); ALS Foundation; Japan ALS Association; Keio Medical Science Fund	This work was supported by Eisai Co., Ltd., the Ministry of Education, Culture, Sports, Science and Technology of Japan (Grants 18590955 and 21790850), the ALS Foundation, the Japan ALS Association, and Keio Medical Science Fund Research Grants for Life Science and Medicine.	Arai T, 2004, ANN NEUROL, V55, P72, DOI 10.1002/ana.10793; Arai T, 2006, BIOCHEM BIOPH RES CO, V351, P602, DOI 10.1016/j.bbrc.2006.10.093; Arimoto K, 2008, NAT CELL BIOL, V10, P1324, DOI 10.1038/ncb1791; Arrasate M, 2004, NATURE, V431, P805, DOI 10.1038/nature02998; Ayala YM, 2006, FEBS LETT, V580, P1339, DOI 10.1016/j.febslet.2006.01.052; Ayala YM, 2008, P NATL ACAD SCI USA, V105, P3785, DOI 10.1073/pnas.0800546105; Bose JK, 2008, J BIOL CHEM, V283, P28852, DOI 10.1074/jbc.M805376200; Buratti E, 2001, J BIOL CHEM, V276, P36337, DOI 10.1074/jbc.M104236200; Buratti E, 2001, EMBO J, V20, P1774, DOI 10.1093/emboj/20.7.1774; DiFiglia M, 1997, SCIENCE, V277, P1990, DOI 10.1126/science.277.5334.1990; Garcia-Mata R, 1999, J CELL BIOL, V146, P1239, DOI 10.1083/jcb.146.6.1239; Gilks N, 2004, MOL BIOL CELL, V15, P5383, DOI 10.1091/mbc.E04-08-0715; Gitcho MA, 2008, ANN NEUROL, V63, P535, DOI 10.1002/ana.21344; Hasegawa M, 2008, ANN NEUROL, V64, P60, DOI 10.1002/ana.21425; Hua YM, 2004, FEBS LETT, V572, P69, DOI 10.1016/j.febslet.2004.07.010; Igaz LM, 2009, J BIOL CHEM, V284, P8516, DOI 10.1074/jbc.M809462200; IGNATIUS SH, 1995, J VIROL, V69, P3584, DOI 10.1128/JVI.69.6.3584-3596.1995; Ito D, 2004, MOL CELL BIOL, V24, P9456, DOI 10.1128/MCB.24.21.9456-9469.2004; Ito D, 2008, NEUROBIOL DIS, V31, P266, DOI 10.1016/j.nbd.2008.05.004; Ito D, 2007, ANN NEUROL, V61, P237, DOI 10.1002/ana.21070; Ito D, 2009, BRAIN, V132, P8, DOI 10.1093/brain/awn216; Johnston JA, 1998, J CELL BIOL, V143, P1883, DOI 10.1083/jcb.143.7.1883; Junn E, 2002, J BIOL CHEM, V277, P47870, DOI 10.1074/jbc.M203159200; Kabashi E, 2008, NAT GENET, V40, P572, DOI 10.1038/ng.132; Kalchman MA, 1996, J BIOL CHEM, V271, P19385, DOI 10.1074/jbc.271.32.19385; Kawahara Y, 2004, NATURE, V427, P801, DOI 10.1038/427801a; Kedersha N, 2000, J CELL BIOL, V151, P1257, DOI 10.1083/jcb.151.6.1257; Kedersha N, 2005, J CELL BIOL, V169, P871, DOI 10.1083/jcb.200502088; Kedersha N, 2007, METHOD ENZYMOL, V431, P61, DOI 10.1016/S0076-6879(07)31005-7; Kopito RR, 2000, TRENDS CELL BIOL, V10, P524, DOI 10.1016/S0962-8924(00)01852-3; Mende-Mueller LM, 2001, J NEUROSCI, V21, P1830, DOI 10.1523/JNEUROSCI.21-06-01830.2001; Moisse K, 2009, BRAIN RES, V1249, P202, DOI 10.1016/j.brainres.2008.10.021; Neumann M, 2007, ARCH NEUROL-CHICAGO, V64, P1388, DOI 10.1001/archneur.64.10.1388; Neumann M, 2006, SCIENCE, V314, P130, DOI 10.1126/science.1134108; Nishimoto Y, 2008, NEUROSCI RES, V61, P201, DOI 10.1016/j.neures.2008.02.009; Nonaka T, 2009, HUM MOL GENET, V18, P3353, DOI 10.1093/hmg/ddp275; Ohn T, 2008, NAT CELL BIOL, V10, P1224, DOI 10.1038/ncb1783; Orr HT, 2004, NATURE, V431, P747, DOI 10.1038/431747a; Pagani F, 2000, J BIOL CHEM, V275, P21041, DOI 10.1074/jbc.M910165199; Rutherford NJ, 2008, PLOS GENET, V4, DOI 10.1371/journal.pgen.1000193; Selkoe DJ, 2002, SCIENCE, V298, P789, DOI 10.1126/science.1074069; Selkoe DJ, 1996, ANN NY ACAD SCI, V777, P57, DOI 10.1111/j.1749-6632.1996.tb34401.x; Shaw CE, 1998, ANN NEUROL, V43, P390, DOI 10.1002/ana.410430319; Sieradzan KA, 1999, EXP NEUROL, V156, P92, DOI 10.1006/exnr.1998.7005; SISODIA SS, 1995, FASEB J, V9, P366, DOI 10.1096/fasebj.9.5.7896005; Sreedharan J, 2008, SCIENCE, V319, P1668, DOI 10.1126/science.1154584; Tanaka M, 2004, J BIOL CHEM, V279, P4625, DOI 10.1074/jbc.M310994200; Taylor JP, 2003, HUM MOL GENET, V12, P749, DOI 10.1093/hmg/ddg074; Tourriere H, 2003, J CELL BIOL, V160, P823, DOI 10.1083/jcb.200212128; Van Deerlin VM, 2008, LANCET NEUROL, V7, P409, DOI 10.1016/S1474-4422(08)70071-1; Wellington CL, 2000, J BIOL CHEM, V275, P19831, DOI 10.1074/jbc.M001475200; Winton MJ, 2008, J BIOL CHEM, V283, P13302, DOI 10.1074/jbc.M800342200; Yokoseki A, 2008, ANN NEUROL, V63, P538, DOI 10.1002/ana.21392; Zhang HX, 2008, NEUROSCI LETT, V434, P170, DOI 10.1016/j.neulet.2008.01.060; Zhang YJ, 2007, J NEUROSCI, V27, P10530, DOI 10.1523/JNEUROSCI.3421-07.2007; Zhang YJ, 2009, P NATL ACAD SCI USA, V106, P7607, DOI 10.1073/pnas.0900688106	56	105	107	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 1	2010	285	1					608	619		10.1074/jbc.M109.022012	http://dx.doi.org/10.1074/jbc.M109.022012			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	536UT	19887443	Green Published, hybrid			2022-12-25	WOS:000273070100062
J	Sriskanthadevan, S; Lee, T; Lin, Z; Yang, DW; Siu, CH				Sriskanthadevan, Shrivani; Lee, Teresa; Lin, Zhi; Yang, Daiwen; Siu, Chi-Hung			Cell Adhesion Molecule DdCAD-1 Is Imported into Contractile Vacuoles by Membrane Invagination in a Ca2+- and Conformation-dependent Manner	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							UNCONVENTIONAL PROTEIN SECRETION; FIBROBLAST-GROWTH-FACTOR; DICTYOSTELIUM-DISCOIDEUM; PLASMA-MEMBRANE; FOLDED PROTEIN; MAMMALIAN-CELLS; BINDING PROTEIN; SIGNAL SEQUENCE; TAT PROTEIN; PATHWAY	The cadA gene in Dictyostelium encodes a Ca2+-dependent cell adhesion molecule DdCAD-1 that contains two beta-sandwich domains. DdCAD-1 is synthesized in the cytoplasm as a soluble protein and then transported by contractile vacuoles to the plasma membrane for surface presentation or secretion. DdCAD-1-green fluorescent protein (GFP) fusion protein was expressed in cadA-null cells for further investigation of this unconventional protein transport pathway. Both morphological and biochemical characterizations showed that DdCAD-1-GFP was imported into contractile vacuoles. Time-lapse microscopy of transfectants revealed the transient appearance of DdCAD-1-GFP-filled vesicular structures in the lumen of contractile vacuoles, suggesting that DdCAD-1 could be imported by invagination of contractile vacuole membrane. To assess the structural requirements in this transport process, the N-terminal and C-terminal domains of DdCAD-1 were expressed separately in cells as GFP fusion proteins. Both fusion proteins failed to enter the contractile vacuole, suggesting that the integrity of DdCAD-1 is required for import. Such a requirement was also observed in in vitro reconstitution assays using His(6)-tagged fusion proteins and purified contractile vacuoles. Import of DdCAD-1 was compromised when two of its three Ca2+-binding sites were mutated, indicating a role for Ca2+ in the import process. Spectral analysis showed that mutations in the Ca2+-binding sites resulted in subtle conformational changes. Indeed, proteins with altered conformation failed to enter the contractile vacuole, suggesting that the import signal is somehow integrated in the three-dimensional structure of DdCAD-1.	[Sriskanthadevan, Shrivani; Lee, Teresa; Siu, Chi-Hung] Univ Toronto, Banting & Best Dept Med Res, Toronto, ON M5S 1A8, Canada; [Sriskanthadevan, Shrivani; Lee, Teresa; Siu, Chi-Hung] Univ Toronto, Dept Biochem, Toronto, ON M5S 1A8, Canada; [Lin, Zhi; Yang, Daiwen] Natl Univ Singapore, Dept Biol Sci, Singapore 117543, Singapore	University of Toronto; University of Toronto; National University of Singapore	Siu, CH (corresponding author), Univ Toronto, Banting & Best Dept Med Res, 100 Coll St, Toronto, ON M5S 1A8, Canada.	chi.hung.siu@utoronto.ca	LIN, ZHI/B-1254-2016; yang, daiwen/H-8408-2012	yang, daiwen/0000-0002-6804-0071; LIN, ZHI/0000-0002-8902-4935	Canadian Institutes of Health Research Operating [FRN-6140]	Canadian Institutes of Health Research Operating(Canadian Institutes of Health Research (CIHR))	This work was supported in part by Canadian Institutes of Health Research Operating Grant FRN-6140.	Andersson D, 2001, EUR J BIOCHEM, V268, P1118, DOI 10.1046/j.1432-1327.2001.01981.x; Andrei C, 1999, MOL BIOL CELL, V10, P1463, DOI 10.1091/mbc.10.5.1463; Aubry L, 1999, ANNU REV CELL DEV BI, V15, P469, DOI 10.1146/annurev.cellbio.15.1.469; BARONDES SH, 1985, J CELL BIOL, V100, P1825, DOI 10.1083/jcb.100.6.1825; BRAR SK, 1993, J BIOL CHEM, V268, P24902; Brocard CB, 2003, TRAFFIC, V4, P74, DOI 10.1034/j.1600-0854.2003.40203.x; Clark PL, 1996, PROTEIN SCI, V5, P1108; Clark SA, 1997, MOL BIOL CELL, V8, P923, DOI 10.1091/mbc.8.5.923; Cleves AE, 1997, CURR BIOL, V7, pR318, DOI 10.1016/S0960-9822(06)00148-5; Cleves AE, 1996, J CELL BIOL, V133, P1017, DOI 10.1083/jcb.133.5.1017; Cline K, 2007, EMBO J, V26, P3039, DOI 10.1038/sj.emboj.7601759; COOPER DNW, 1990, J CELL BIOL, V110, P1681, DOI 10.1083/jcb.110.5.1681; CROWLEY TE, 1985, CELL, V43, P633, DOI 10.1016/0092-8674(85)90235-1; Denny PW, 2000, J BIOL CHEM, V275, P11017, DOI 10.1074/jbc.275.15.11017; Elliott G, 1997, CELL, V88, P223, DOI 10.1016/S0092-8674(00)81843-7; Engling A, 2002, J CELL SCI, V115, P3619, DOI 10.1242/jcs.00036; Enrich C, 1996, HEPATOLOGY, V24, P226, DOI 10.1002/hep.510240136; Flieger O, 2003, FEBS LETT, V551, P78, DOI 10.1016/S0014-5793(03)00900-1; Gerisch G, 2002, CELL BIOL INT, V26, P845, DOI 10.1006/cbir.2002.0938; HEUSER J, 1993, J CELL BIOL, V121, P1311, DOI 10.1083/jcb.121.6.1311; Kim J, 1997, J CELL BIOL, V137, P609, DOI 10.1083/jcb.137.3.609; Kinseth MA, 2007, CELL, V130, P524, DOI 10.1016/j.cell.2007.06.029; Lin Z, 2004, J BIOMOL NMR, V30, P375, DOI 10.1007/s10858-005-2336-5; Lin Z, 2006, NAT STRUCT MOL BIOL, V13, P1016, DOI 10.1038/nsmb1162; Malchow D, 2006, BMC DEV BIOL, V6, DOI 10.1186/1471-213X-6-31; MANN DA, 1991, EMBO J, V10, P1733, DOI 10.1002/j.1460-2075.1991.tb07697.x; McLaughlin S, 2005, NATURE, V438, P605, DOI 10.1038/nature04398; MELLMAN I, 1986, ANNU REV BIOCHEM, V55, P663, DOI 10.1146/annurev.biochem.55.1.663; MIGNATTI P, 1992, J CELL PHYSIOL, V151, P81, DOI 10.1002/jcp.1041510113; Moniakis J, 1999, J CELL SCI, V112, P405; Muller O, 2000, J CELL BIOL, V151, P519, DOI 10.1083/jcb.151.3.519; Nickel W, 2003, EUR J BIOCHEM, V270, P2109, DOI 10.1046/j.1432-1033.2003.03577.x; Nickel W, 2005, TRAFFIC, V6, P607, DOI 10.1111/j.1600-0854.2005.00302.x; Nickel W, 2008, ANNU REV CELL DEV BI, V24, P287, DOI 10.1146/annurev.cellbio.24.110707.175320; Nickel W, 2009, NAT REV MOL CELL BIO, V10, P148, DOI 10.1038/nrm2617; NIELSEN TB, 1987, J CELL SCI, V87, P327; ORCI L, 1991, CELL, V64, P1183; PADH H, 1989, BIOCHIM BIOPHYS ACTA, V982, P271, DOI 10.1016/0005-2736(89)90064-3; PALADE G, 1975, SCIENCE, V189, P347, DOI 10.1126/science.1096303; Pang KM, 1999, PLASMID, V41, P187, DOI 10.1006/plas.1999.1391; Pohlschroder M, 2005, ANNU REV MICROBIOL, V59, P91, DOI 10.1146/annurev.micro.59.030804.121353; Pryor PR, 2000, J CELL BIOL, V149, P1053, DOI 10.1083/jcb.149.5.1053; PUGSLEY AP, 1992, P NATL ACAD SCI USA, V89, P12058, DOI 10.1073/pnas.89.24.12058; Qu Y, 2007, J IMMUNOL, V179, P1913, DOI 10.4049/jimmunol.179.3.1913; ROTHMAN JE, 1994, NATURE, V372, P55, DOI 10.1038/372055a0; RUBARTELLI A, 1992, J BIOL CHEM, V267, P24161; RUBARTELLI A, 1990, EMBO J, V9, P1503, DOI 10.1002/j.1460-2075.1990.tb08268.x; Schafer T, 2004, J BIOL CHEM, V279, P6244, DOI 10.1074/jbc.M310500200; Schatz G, 1996, SCIENCE, V271, P1519, DOI 10.1126/science.271.5255.1519; Seelenmeyer C, 2005, J CELL BIOL, V171, P373, DOI 10.1083/jcb.200506026; Sesaki H, 1997, J CELL BIOL, V138, P939, DOI 10.1083/jcb.138.4.939; Siu CH, 2004, SEMIN CELL DEV BIOL, V15, P633, DOI 10.1016/j.semcdb.2004.09.004; SPRINGER WR, 1984, CELL, V39, P557, DOI 10.1016/0092-8674(84)90462-8; Sriskanthadevan Shrivani, 2007, Recent Research Developments in Cell Biology, V3, P9; SWAIRJO MA, 1995, NAT STRUCT BIOL, V2, P968, DOI 10.1038/nsb1195-968; Teter SA, 1999, TRENDS CELL BIOL, V9, P428, DOI 10.1016/S0962-8924(99)01652-9; Wickner W, 2005, SCIENCE, V310, P1452, DOI 10.1126/science.1113752; Wong EFS, 1996, J BIOL CHEM, V271, P16399, DOI 10.1074/jbc.271.27.16399; Yang CZ, 1997, DIFFERENTIATION, V61, P275, DOI 10.1046/j.1432-0436.1997.6150275.x; Yeung T, 2008, SCIENCE, V319, P210, DOI 10.1126/science.1152066; Yumura S, 1996, J CELL SCI, V109, P2673; ZHU QL, 1993, J CELL SCI, V104, P1119; ZHU QL, 1992, J CELL BIOL, V118, P347, DOI 10.1083/jcb.118.2.347	63	16	17	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 25	2009	284	52					36377	36386		10.1074/jbc.M109.057257	http://dx.doi.org/10.1074/jbc.M109.057257			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	535LT	19875452	Green Published, hybrid			2022-12-25	WOS:000272970500039
J	Zhang, QZ; Yamaza, T; Kelly, AP; Shi, SH; Wang, SL; Brown, J; Wang, L; French, SW; Shi, ST; Le, AD				Zhang, Qunzhou; Yamaza, Takayoshi; Kelly, A. Paul; Shi, Shihong; Wang, Songlin; Brown, Jimmy; Wang, Lina; French, Samuel W.; Shi, Songtao; Le, Anh D.			Tumor-Like Stem Cells Derived from Human Keloid Are Governed by the Inflammatory Niche Driven by IL-17/IL-6 Axis	PLOS ONE			English	Article							NF-KAPPA-B; GROWTH-FACTOR-BETA; GENE-EXPRESSION; T-CELLS; PROINFLAMMATORY CYTOKINES; DESTRUCTIVE ARTHRITIS; TELOMERASE ACTIVITY; HYPERTROPHIC SCARS; SELF-RENEWAL; BONE-MARROW	Background: Alterations in the stem cell niche are likely to contribute to tumorigenesis; however, the concept of niche promoted benign tumor growth remains to be explored. Here we use keloid, an exuberant fibroproliferative dermal growth unique to human skin, as a model to characterize benign tumor-like stem cells and delineate the role of their "pathological'' niche in the development of the benign tumor. Methods and Findings: Subclonal assay, flow cytometric and multipotent differentiation analyses demonstrate that keloid contains a new population of stem cells, named keloid derived precursor cells (KPCs), which exhibit clonogenicity, self-renewal, distinct embryonic and mesenchymal stem cell surface markers, and multipotent differentiation. KPCs display elevated telomerase activity and an inherently upregulated proliferation capability as compared to their peripheral normal skin counterparts. A robust elevation of IL-6 and IL-17 expression in keloid is confirmed by cytokine array, western blot and ELISA analyses. The altered biological functions are tightly regulated by the inflammatory niche mediated by an autocrine/paracrine cytokine IL-17/IL-6 axis. Utilizing KPCs transplanted subcutaneously in immunocompromised mice we generate for the first time a human keloid-like tumor model that is driven by the in vivo inflammatory niche and allows testing of the anti-tumor therapeutic effect of antibodies targeting distinct niche components, specifically IL-6 and IL-17. Conclusions/Significance: These findings support our hypothesis that the altered niche in keloids, predominantly inflammatory, contributes to the acquirement of a benign tumor-like stem cell phenotype of KPCs characterized by the uncontrolled self-renewal and increased proliferation, supporting the rationale for in vivo modification of the "pathological'' stem cell niche as a novel therapy for keloid and other mesenchymal benign tumors.			Zhang, QZ (corresponding author), Univ So Calif, Sch Dent, Ctr Craniofacial Mol Biol, Los Angeles, CA 90089 USA.	songtaos@usc.edu; anhle@usc.edu	Zhang, Qunzhou/X-4504-2019	Yamaza, Takayoshi/0000-0001-7055-3370	NATIONAL CENTER FOR RESEARCH RESOURCES [P20RR011145] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [S11AR047359] Funding Source: NIH RePORTER; NCRR NIH HHS [P20 RR011145, 2 P20 RR011145] Funding Source: Medline; NIAMS NIH HHS [AR47359, S11 AR047359] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		Aggarwal S, 2002, J LEUKOCYTE BIOL, V71, P1; Akino K, 2008, INT J DERMATOL, V47, P1112, DOI 10.1111/j.1365-4632.2008.03380.x; Akiyama M, 2002, CANCER RES, V62, P3876; [Anonymous], ARTHRITIS RES THER, DOI DOI 10.1186/AR1917; Bartsch G, 2005, STEM CELLS DEV, V14, P337, DOI 10.1089/scd.2005.14.337; Beltrami AR, 2007, BLOOD, V110, P3438, DOI 10.1182/blood-2006-11-055566; Bettelli E, 2006, NATURE, V441, P235, DOI 10.1038/nature04753; Bettelli E, 2008, NATURE, V453, P1051, DOI 10.1038/nature07036; Bi YM, 2007, NAT MED, V13, P1219, DOI 10.1038/nm1630; Bollrath J, 2009, CANCER CELL, V15, P91, DOI 10.1016/j.ccr.2009.01.002; Boyle M, 2007, CELL STEM CELL, V1, P470, DOI 10.1016/j.stem.2007.08.002; Cai SS, 2005, BIOMATERIALS, V26, P6054, DOI 10.1016/j.biomaterials.2005.03.012; Chen Y, 2003, J BIOL CHEM, V278, P17036, DOI 10.1074/jbc.M210429200; Coffelt SB, 2009, P NATL ACAD SCI USA, V106, P3806, DOI 10.1073/pnas.0900244106; DASILVA ML, 2006, J CELL SCI, V119, P2204, DOI DOI 10.1242/JCS.02932; De Coppi P, 2006, J SURG RES, V135, P85, DOI 10.1016/j.jss.2006.03.009; FEGHALI CA, 1994, AUTOIMMUNITY, V17, P309, DOI 10.3109/08916939409010671; Fernandes KJL, 2004, NAT CELL BIOL, V6, P1082, DOI 10.1038/ncb1181; Flores I, 2005, SCIENCE, V309, P1253, DOI 10.1126/science.1115025; Fujino S, 2003, GUT, V52, P65, DOI 10.1136/gut.52.1.65; Gang EJ, 2007, BLOOD, V109, P1743, DOI 10.1182/blood-2005-11-010504; GAULDIE J, 1987, P NATL ACAD SCI USA, V84, P7251, DOI 10.1073/pnas.84.20.7251; Ghazizadeh M, 2007, J INVEST DERMATOL, V127, P98, DOI 10.1038/sj.jid.5700564; Grivennikov S, 2009, CANCER CELL, V15, P103, DOI 10.1016/j.ccr.2009.01.001; Harrington LE, 2005, NAT IMMUNOL, V6, P1123, DOI 10.1038/ni1254; Huang F, 2007, J IMMUNOL, V179, P6504, DOI 10.4049/jimmunol.179.10.6504; Huang H, 2009, CELL DEATH DIFFER, V16, P1332, DOI 10.1038/cdd.2009.74; Hwang SY, 2004, ARTHRITIS RES THER, V6, pR120, DOI 10.1186/ar1038; Izadpanah R, 2006, J CELL BIOCHEM, V99, P1285, DOI 10.1002/jcb.20904; Jovanovic DV, 1998, J IMMUNOL, V160, P3513; Kaplanski G, 2003, TRENDS IMMUNOL, V24, P25, DOI 10.1016/S1471-4906(02)00013-3; Karnoub AE, 2007, NATURE, V449, P557, DOI 10.1038/nature06188; Kelly A Paul, 2004, Dermatol Ther, V17, P212, DOI 10.1111/j.1396-0296.2004.04022.x; KETCHUM LD, 1971, PLAST RECONSTR SURG, V48, P256, DOI 10.1097/00006534-197109000-00010; Kimura A, 2007, P NATL ACAD SCI USA, V104, P12099, DOI 10.1073/pnas.0705268104; Kolf CM, 2007, ARTHRITIS RES THER, V9, DOI 10.1186/ar2116; KOPF M, 1994, NATURE, V368, P339, DOI 10.1038/368339a0; Kovacevic-Filipovic M, 2007, J CELL PHYSIOL, V212, P68, DOI 10.1002/jcp.21003; Lee HW, 1998, NATURE, V392, P569, DOI 10.1038/33345; Lee JYY, 2004, AM J DERMATOPATH, V26, P379, DOI 10.1097/00000372-200410000-00006; Li LH, 2005, ANNU REV CELL DEV BI, V21, P605, DOI 10.1146/annurev.cellbio.21.012704.131525; Li LH, 2006, CANCER RES, V66, P4553, DOI 10.1158/0008-5472.CAN-05-3986; Lubberts E, 2005, ARTHRITIS RES THER, V7, P29, DOI 10.1186/ar1478; MACDONALD HR, 1984, EXP CELL BIOL, V52, P2; Manel N, 2008, NAT IMMUNOL, V9, P641, DOI 10.1038/ni.1610; McGeachy MJ, 2007, NAT IMMUNOL, V8, P1390, DOI 10.1038/ni1539; Mishra PJ, 2008, CANCER RES, V68, P4331, DOI 10.1158/0008-5472.CAN-08-0943; Momcilovic M, 2008, BMC IMMUNOL, V9, DOI 10.1186/1471-2172-9-47; MOON JH, 2008, STEM CELLS DEV, V17, P1; Moore KA, 2006, SCIENCE, V311, P1880, DOI 10.1126/science.1110542; Murphy CA, 2003, J EXP MED, V198, P1951, DOI 10.1084/jem.20030896; Nakae S, 2003, P NATL ACAD SCI USA, V100, P5986, DOI 10.1073/pnas.1035999100; Niessen FB, 1999, PLAST RECONSTR SURG, V104, P1435, DOI 10.1097/00006534-199910000-00031; Ogura H, 2008, IMMUNITY, V29, P628, DOI 10.1016/j.immuni.2008.07.018; Pan L, 2007, CELL STEM CELL, V1, P458, DOI 10.1016/j.stem.2007.09.010; Patel DN, 2007, J BIOL CHEM, V282, P27229, DOI 10.1074/jbc.M703250200; Pike DB, 2006, BIOMATERIALS, V27, P5242, DOI 10.1016/j.biomaterials.2006.05.018; Ruddy MJ, 2004, J BIOL CHEM, V279, P2559, DOI 10.1074/jbc.M308809200; Rudolph KL, 1999, CELL, V96, P701, DOI 10.1016/S0092-8674(00)80580-2; Sansone P, 2007, J CLIN INVEST, V117, P3988, DOI 10.1172/JCI32533; Sarin KY, 2005, NATURE, V436, P1048, DOI 10.1038/nature03836; Scadden DT, 2006, NATURE, V441, P1075, DOI 10.1038/nature04957; SCHOFIELD R, 1978, BLOOD CELLS, V4, P7; Shalom-Barak T, 1998, J BIOL CHEM, V273, P27467, DOI 10.1074/jbc.273.42.27467; Shi ST, 2002, NAT BIOTECHNOL, V20, P587, DOI 10.1038/nbt0602-587; Spaeth E, 2008, GENE THER, V15, P730, DOI 10.1038/gt.2008.39; Spaeth EL, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0004992; TAN PLJ, 1990, J RHEUMATOL, V17, P1608; Toma JG, 2001, NAT CELL BIOL, V3, P778, DOI 10.1038/ncb0901-778; Toma JG, 2005, STEM CELLS, V23, P727, DOI 10.1634/stemcells.2004-0134; Volpe E, 2008, NAT IMMUNOL, V9, P650, DOI 10.1038/ni.1613; Xie T, 2007, DEVELOPMENT, V134, P2001, DOI 10.1242/dev.002022; Xu GW, 2007, BIOCHEM BIOPH RES CO, V361, P745, DOI 10.1016/j.bbrc.2007.07.052; Xue H, 2000, J SURG RES, V89, P74, DOI 10.1006/jsre.1999.5805; Yamagiwa Y, 2006, LIFE SCI, V78, P2494, DOI 10.1016/j.lfs.2005.10.015; Yamaza T, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002615; Yang L, 2008, NATURE, V454, P350, DOI 10.1038/nature07021; YAO Z, 1995, J IMMUNOL, V155, P811; You S, 2004, EXP MOL MED, V36, P325, DOI 10.1038/emm.2004.43; Zhang QZ, 2003, J INVEST DERMATOL, V121, P1005, DOI 10.1046/j.1523-1747.2003.12564.x; Zhou LA, 2007, NAT IMMUNOL, V8, P967, DOI 10.1038/ni1488	81	75	90	0	7	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	NOV 11	2009	4	11					A192	A207	e7798	10.1371/journal.pone.0007798	http://dx.doi.org/10.1371/journal.pone.0007798			16	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	518IX	19907660	Green Published, Green Submitted, gold			2022-12-25	WOS:000271685800021
J	Disset, A; Cheval, L; Soutourina, O; Van Huyen, JPD; Li, GR; Genin, C; Tostain, J; Loupy, A; Doucet, A; Rajerison, R				Disset, Antoine; Cheval, Lydie; Soutourina, Olga; Van Huyen, Jean-Paul Duong; Li, Guorong; Genin, Christian; Tostain, Jacques; Loupy, Alexandre; Doucet, Alain; Rajerison, Rabary			Tissue Compartment Analysis for Biomarker Discovery by Gene Expression Profiling	PLOS ONE			English	Article							MOLECULAR CLASSIFICATION; LASER-MICRODISSECTION; DISEASE	Background: Although high throughput technologies for gene profiling are reliable tools, sample/tissue heterogeneity limits their outcomes when applied to identify molecular markers. Indeed, inter-sample differences in cell composition contribute to scatter the data, preventing detection of small but relevant changes in gene expression level. To date, attempts to circumvent this difficulty were based on isolation of the different cell structures constituting biological samples. As an alternate approach, we developed a tissue compartment analysis (TCA) method to assess the cell composition of tissue samples, and applied it to standardize data and to identify biomarkers. Methodology/Principal Findings: TCA is based on the comparison of mRNA expression levels of specific markers of the different constitutive structures in pure isolated structures, on the one hand, and in the whole sample on the other. TCA method was here developed with human kidney samples, as an example of highly heterogeneous organ. It was validated by comparison of the data with those obtained by histo-morphometry. TCA demonstrated the extreme variety of composition of kidney samples, with abundance of specific structures varying from 5 to 95% of the whole sample. TCA permitted to accurately standardize gene expression level amongst >100 kidney biopsies, and to identify otherwise imperceptible molecular disease markers. Conclusions/Significance: Because TCA does not require specific preparation of sample, it can be applied to all existing tissue or cDNA libraries or to published data sets, inasmuch specific operational compartments markers are available. In human, where the small size of tissue samples collected in clinical practice accounts for high structural diversity, TCA is well suited for the identification of molecular markers of diseases, and the follow up of identified markers in single patients for diagnosis/prognosis and evaluation of therapy efficiency. In laboratory animals, TCA will interestingly be applied to central nervous system where tissue heterogeneity is a limiting factor.			Disset, A (corresponding author), Univ Paris 06, Lab Genom Physiol & Physiopathol Renale, UMRS 872, Paris, France.	alain.doucet@crc.jussieu.fr	Soutourina, Olga/F-2042-2015; Loupy, Alexandre/K-8512-2019	Soutourina, Olga/0000-0001-6439-7228; CHEVAL, LYDIE/0000-0003-2957-6487				Alizadeh AA, 2000, NATURE, V403, P503, DOI 10.1038/35000501; Bittner M, 2000, NATURE, V406, P536, DOI 10.1038/35020115; Brochier C, 2008, PHYSIOL GENOMICS, V33, P170, DOI 10.1152/physiolgenomics.00125.2007; Chabardes-Garonne D, 2003, P NATL ACAD SCI USA, V100, P13710, DOI 10.1073/pnas.2234604100; Cohen CD, 2002, KIDNEY INT, V61, P125, DOI 10.1046/j.1523-1755.2002.00112.x; de Borst MH, 2008, NAT CLIN PRACT NEPHR, V4, P265, DOI 10.1038/ncpneph0785; Fenton KA, 2008, MOL IMMUNOL, V45, P3117, DOI 10.1016/j.molimm.2008.03.001; Fink L, 2006, EXP TOXICOL PATHOL, V57, P25, DOI 10.1016/j.etp.2006.02.010; Golub TR, 1999, SCIENCE, V286, P531, DOI 10.1126/science.286.5439.531; Heller RA, 1997, P NATL ACAD SCI USA, V94, P2150, DOI 10.1073/pnas.94.6.2150; Ito Y, 1998, KIDNEY INT, V53, P853, DOI 10.1046/j.1523-1755.1998.00820.x; Jiao YL, 2009, NAT GENET, V41, P258, DOI 10.1038/ng.282; Karsten S. L., 2008, CURR PROTOC NEUROSCI; Kuroda M, 2004, CLIN NEPHROL, V61, P7; Lee E, 2008, PLOS COMPUT BIOL, V4, DOI 10.1371/journal.pcbi.1000217; Malarkey DE, 2005, TOXICOL PATHOL, V33, P27, DOI 10.1080/01926230590881826; Razzaque MS, 1998, NEPHRON, V80, P434, DOI 10.1159/000045217; Schmid H, 2003, KIDNEY INT, V64, P356, DOI 10.1046/j.1523-1755.2003.00074.x; VELCULESCU VE, 1995, SCIENCE, V270, P484, DOI 10.1126/science.270.5235.484	19	7	7	0	0	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA	1932-6203			PLOS ONE	PLoS One	NOV 10	2009	4	11							e7779	10.1371/journal.pone.0007779	http://dx.doi.org/10.1371/journal.pone.0007779			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	517ZU	19901995	Green Published, Green Submitted, gold			2022-12-25	WOS:000271658800014
J	Farrugia, W; Scott, AM; Ramsland, PA				Farrugia, William; Scott, Andrew M.; Ramsland, Paul A.			A Possible Role for Metallic Ions in the Carbohydrate Cluster Recognition Displayed by a Lewis Y Specific Antibody	PLOS ONE			English	Article							GROUP-RELATED ANTIGENS; HUMANIZED MONOCLONAL-ANTIBODY; GROWTH-FACTOR RECEPTORS; HUMAN SEMINAL PLASMA; BLOOD GROUP ANTIGENS; CRYSTAL-STRUCTURE; PHASE-I; 3-DIMENSIONAL STRUCTURES; ERBB RECEPTORS; SOLID TUMORS	Background: Lewis Y (Le(y)) is a blood group-related carbohydrate that is expressed at high surface densities on the majority of epithelial carcinomas and is a promising target for antibody-based immunotherapy. A humanized Le(y)-specific antibody (hu3S193) has shown encouraging safety, pharmacokinetic and tumor-targeting properties in recently completed Phase I clinical trials. Methodology/Principal Findings: We report the three-dimensional structures for both the free (unliganded) and bound (Le(y) tetrasaccharide) hu3S193 Fab from the same crystal grown in the presence of divalent zinc ions. There is no evidence of significant conformational changes occurring in either the Le(y) carbohydrate antigen or the hu3S193 binding site, which suggests a rigid fit binding mechanism. In the crystal, the hu3S193 Fab molecules are coordinated at their protein-protein interface by two zinc ions and in solution aggregation of Fab can be initiated by zinc, but not magnesium ions. Dynamic light scattering revealed that zinc ions could initiate a sharp transition from hu3S193 Fab monomers to large multimeric aggregates in solution. Conclusions/Significance: Zinc ions can mediate interactions between hu3S193 Fab in crystals and in solution. Whether metallic ion mediated aggregation of antibody occurs in vivo is not known, but the present results suggest that similar clustering mechanisms could occur when hu3S193 binds to Le(y) on cells, particularly given the high surface densities of antigen on the target tumor cells.			Farrugia, W (corresponding author), Burnet Inst, Ctr Immunol, Melbourne, Vic, Australia.	pramsland@burnet.edu.au		Ramsland, Paul/0000-0002-2107-2738; Scott, Andrew/0000-0002-6656-295X				ALTSCHUH D, 1992, SCIENCE, V256, P92, DOI 10.1126/science.1566062; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; BASU A, 1987, CANCER RES, V47, P2531; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; BUNDLE DR, 1994, BIOCHEMISTRY-US, V33, P5183, DOI 10.1021/bi00183a023; Calarese DA, 2003, SCIENCE, V300, P2065, DOI 10.1126/science.1083182; Candelier JJ, 2000, HISTOCHEM CELL BIOL, V114, P113; Cao Y, 2001, GLYCOBIOLOGY, V11, P677, DOI 10.1093/glycob/11.8.677; Chacko S, 1996, J BIOL CHEM, V271, P12191, DOI 10.1074/jbc.271.21.12191; Chalabi S, 2002, J BIOL CHEM, V277, P32562, DOI 10.1074/jbc.M205152200; Ding YH, 1998, P NATL ACAD SCI USA, V95, P10443, DOI 10.1073/pnas.95.18.10443; Dunn MF, 2005, BIOMETALS, V18, P295, DOI 10.1007/s10534-005-3685-y; Edstrom AML, 2008, J IMMUNOL, V181, P3413, DOI 10.4049/jimmunol.181.5.3413; Esqueda AC, 2009, J AM CHEM SOC, V131, P11387, DOI 10.1021/ja901875v; Farhan H, 2006, J PHARMACOL EXP THER, V319, P1459, DOI 10.1124/jpet.106.107318; FOLIN M, 1994, BIOMETALS, V7, P75; Garcia-Vallejo JJ, 2008, MOL IMMUNOL, V45, P2359, DOI 10.1016/j.molimm.2007.11.001; Haase H, 2008, J IMMUNOL, V181, P6491, DOI 10.4049/jimmunol.181.9.6491; HELLER D S, 1990, Pediatric Pathology, V10, P681; Hemmens B, 2000, J BIOL CHEM, V275, P35786, DOI 10.1074/jbc.M005976200; HERRON JN, 1991, PROTEINS, V11, P159, DOI 10.1002/prot.340110302; Johns TG, 2007, CLIN CANCER RES, V13, P1911, DOI 10.1158/1078-0432.CCR-06-1453; Kelly MP, 2007, CLIN CANCER RES, V13, p5604S, DOI 10.1158/1078-0432.CCR-07-1071; Kim BJ, 2000, DIABETES, V49, P367, DOI 10.2337/diabetes.49.3.367; KIM YS, 1986, CANCER RES, V46, P5985; KITAMURA K, 1994, P NATL ACAD SCI USA, V91, P12957, DOI 10.1073/pnas.91.26.12957; Klinger M, 2004, CANCER RES, V64, P1087, DOI 10.1158/0008-5472.CAN-03-2435; KOPPEL DE, 1972, J CHEM PHYS, V57, P4814, DOI 10.1063/1.1678153; Krug LM, 2007, J THORAC ONCOL, V2, P947, DOI 10.1097/JTO.0b013e3181560dcc; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; Minas V, 2007, HISTOCHEM CELL BIOL, V128, P55, DOI 10.1007/s00418-007-0293-7; Moehler TM, 2008, J CELL PHYSIOL, V215, P27, DOI 10.1002/jcp.21285; MOLLICONE R, 1985, LAB INVEST, V53, P219; MORRISON B, 1979, CLIN CHEM, V25, P1799; MURATA K, 1992, AM J CLIN PATHOL, V98, P67, DOI 10.1093/ajcp/98.1.67; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Pai LH, 1996, NAT MED, V2, P350, DOI 10.1038/nm0396-350; Pai-Scherf LH, 2000, CLIN CANCER RES, V6, P1720; Pang PC, 2007, J BIOL CHEM, V282, P36593, DOI 10.1074/jbc.M705134200; Perera RM, 2007, NEOPLASIA, V9, P1099, DOI 10.1593/neo.07721; Ramsland PA, 2006, BIOCHEM J, V395, P473, DOI 10.1042/BJ20051739; Ramsland PA, 2004, J MOL BIOL, V340, P809, DOI 10.1016/j.jmb.2004.05.037; Reynolds M, 2008, MOL SIMULAT, V34, P447, DOI 10.1080/08927020701713878; RINI JM, 1992, SCIENCE, V255, P959, DOI 10.1126/science.1546293; SAKAMOTO J, 1986, CANCER RES, V46, P1553; Saleh MN, 2000, J CLIN ONCOL, V18, P2282, DOI 10.1200/JCO.2000.18.11.2282; SCHULZEGAHMEN U, 1993, J MOL BIOL, V234, P1098, DOI 10.1006/jmbi.1993.1663; Scott AM, 2000, CANCER RES, V60, P3254; Scott AM, 1997, CURR OPIN IMMUNOL, V9, P717, DOI 10.1016/S0952-7915(97)80054-4; Scott AM, 2007, CLIN CANCER RES, V13, P3286, DOI 10.1158/1078-0432.CCR-07-0284; Scott AM, 2007, P NATL ACAD SCI USA, V104, P4071, DOI 10.1073/pnas.0611693104; Stanfield RL, 2006, J MOL BIOL, V357, P1566, DOI 10.1016/j.jmb.2006.01.023; Sundstrom M, 1996, EMBO J, V15, P6832, DOI 10.1002/j.1460-2075.1996.tb01074.x; Szolar OHJ, 2006, J PHARMACEUT BIOMED, V41, P1347, DOI 10.1016/j.jpba.2006.03.026; Vagin A, 1997, J APPL CRYSTALLOGR, V30, P1022, DOI 10.1107/S0021889897006766; Vallas V, 2007, J MOL RECOGNIT, V20, P90, DOI 10.1002/jmr.814; van Liempt E, 2006, FEBS LETT, V580, P6123, DOI 10.1016/j.febslet.2006.10.009; Yin BWT, 1996, INT J CANCER, V65, P406, DOI 10.1002/(SICI)1097-0215(19960208)65:4<406::AID-IJC2>3.3.CO;2-5; Yuriev E, 2005, IMMUNOL CELL BIOL, V83, P709, DOI 10.1111/j.1440-1711.2005.01374.x	59	12	15	0	1	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA	1932-6203			PLOS ONE	PLoS One	NOV 10	2009	4	11							e7777	10.1371/journal.pone.0007777	http://dx.doi.org/10.1371/journal.pone.0007777			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	517ZU	19901987	Green Published, gold			2022-12-25	WOS:000271658800013
J	Li, HS; Pauza, CD				Li, Haishan; Pauza, C. David			Effects of 15-Deoxy-Delta(12,14)-Prostaglandin J2 (15d-PGJ2) and Rosiglitazone on Human V delta 2(+) T Cells	PLOS ONE			English	Article							ACTIVATED-RECEPTOR-GAMMA; EXPERIMENTAL ALLERGIC ENCEPHALOMYELITIS; NONPEPTIDIC MYCOBACTERIAL LIGANDS; PPAR-GAMMA; MULTIPLE-SCLEROSIS; AUTOIMMUNE INFLAMMATION; INDEPENDENT MECHANISMS; RHEUMATOID-ARTHRITIS; AIRWAY INFLAMMATION; BEHCETS-DISEASE	Background: Thiazolidinediones (TZD) class of drugs, and 15-deoxy-D12,14-prostaglandin J2 (15d-PGJ2) are immune regulators predicted to modulate human autoimmune disease. Their effects on gamma delta T cells, which are involved in animal model and human and animal autoimmune diseases, are unknown. Methodology/Principal Findings: We characterized the activity of rosiglitazone (from the TZD class of drugs) and 15d-PGJ2 in human V delta 2 T cells. We found that 15d-PGJ2 and rosiglitazone had different effects on V delta 2 T cell functions. Both 15d-PGJ2 and rosiglitazone suppressed V delta 2 T cell proliferation in response to IPP and IL2. However, only 15d-PGJ2 suppressed functional responses including cytokine production, degranulation and cytotoxicity against tumor cells. The mechanism for 15d-PGJ2 effects on V delta 2 T cells acts through inhibiting Erk activation. In contrast, rosiglitazone did not affect Erk activation but the IL2 signaling pathway, which accounts for rosiglitazone suppression of IL2-dependent, V delta 2 T cell proliferation without affecting TCR-dependent functions. Rosiglitazone and 15d-PGJ2 are designed to be peroxisome proliferator-activated receptor gamma (PPAR gamma) ligands and PPAR gamma was expressed in V delta 2 T cell. Surprisingly, when PPAR gamma levels were lowered by specific siRNA, 15d-PGJ2 and rosiglitazone were still active, suggesting their target of action induces cellular proteins other than PPAR gamma. Conclusions/Significance: The current findings expand our understanding of how the immune system is regulated by rosiglitazone and 15d-PGJ2 and will be important to evaluate these compounds as therapeutic agents in human autoimmune disease.			Li, HS (corresponding author), Univ Maryland, Sch Med, Inst Human Virol, Baltimore, MD 21201 USA.	cdpauza@ihv.umaryland.edu			NATIONAL CANCER INSTITUTE [R01CA113261, R01CA142458] Funding Source: NIH RePORTER; NCI NIH HHS [CA142458, R01 CA142458-01, R01 CA113261, CA113261, R01 CA142458] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Alexander AAZ, 2008, CLIN CANCER RES, V14, P4232, DOI 10.1158/1078-0432.CCR-07-4912; Augstein P, 2003, BIOCHEM BIOPH RES CO, V304, P378, DOI 10.1016/S0006-291X(03)00590-4; Bank I, 2003, J LAB CLIN MED, V141, P33, DOI 10.1067/mlc.2003.1; BATTISTINI L, 1995, ANN NEUROL, V37, P198, DOI 10.1002/ana.410370210; Battistini L, 2005, MICROBES INFECT, V7, P510, DOI 10.1016/j.micinf.2004.12.008; Beales PE, 1998, EUR J PHARMACOL, V357, P221, DOI 10.1016/S0014-2999(98)00574-3; Berry A, 2007, EUR J IMMUNOL, V37, P1642, DOI 10.1002/eji.200636625; Bright JJ, 2003, J IMMUNOL, V171, P5743, DOI 10.4049/jimmunol.171.11.5743; Brosnan CF, 1996, BRAIN PATHOL, V6, P243, DOI 10.1111/j.1750-3639.1996.tb00853.x; BUKOWSKI JF, 1995, J IMMUNOL, V154, P998; Cairo C, 2005, CLIN EXP IMMUNOL, V141, P116, DOI 10.1111/j.1365-2249.2005.02813.x; Carding SR, 2002, NAT REV IMMUNOL, V2, P336, DOI 10.1038/nri797; Clark RB, 2000, J IMMUNOL, V164, P1364, DOI 10.4049/jimmunol.164.3.1364; CONSTANT P, 1994, SCIENCE, V264, P267, DOI 10.1126/science.8146660; Correia DV, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005657; Cua DJ, 2003, NATURE, V421, P744, DOI 10.1038/nature01355; Evans PS, 2001, IMMUNOLOGY, V104, P19, DOI 10.1046/j.1365-2567.2001.01282.x; Fenoglio D, 2009, BLOOD, V113, P6611, DOI 10.1182/blood-2009-01-198028; Follows GA, 2006, GENOME RES, V16, P1310, DOI 10.1101/gr.5373606; FORMAN BM, 1995, CELL, V83, P803, DOI 10.1016/0092-8674(95)90193-0; Garcia VE, 1997, J IMMUNOL, V159, P1328; Hammad H, 2004, AM J PATHOL, V164, P263, DOI 10.1016/S0002-9440(10)63116-1; HOHLFELD R, 1991, NEW ENGL J MED, V324, P877, DOI 10.1056/NEJM199103283241303; Holoshitz J, 1999, MICROBES INFECT, V1, P197, DOI 10.1016/S1286-4579(99)80034-3; KLOTZ L, 2009, J EXP MED; LANG F, 1995, J IMMUNOL, V154, P5986; Leesnitzer LM, 2002, BIOCHEMISTRY-US, V41, P6640, DOI 10.1021/bi0159581; LEHMANN JM, 1995, J BIOL CHEM, V270, P12953, DOI 10.1074/jbc.270.22.12953; Li HS, 2008, J IMMUNOL, V181, P7131, DOI 10.4049/jimmunol.181.10.7131; Martin B, 2009, IMMUNITY, V31, P321, DOI 10.1016/j.immuni.2009.06.020; Mueller C, 2003, ARCH BIOCHEM BIOPHYS, V418, P186, DOI 10.1016/j.abb.2003.08.006; Murphy CA, 2003, J EXP MED, V198, P1951, DOI 10.1084/jem.20030896; Natarajan C, 2002, GENES IMMUN, V3, P59, DOI 10.1038/sj.gene.6363832; O'Brien RL, 2009, EUR J IMMUNOL, V39, P662, DOI 10.1002/eji.200839120; Ottones F, 2000, J IMMUNOL, V165, P7133, DOI 10.4049/jimmunol.165.12.7133; Pershadsingh HA, 2004, J NEUROINFLAMM, V1, DOI 10.1186/1742-2094-1-3; Phulwani NK, 2006, J NEUROCHEM, V99, P1389, DOI 10.1111/j.1471-4159.2006.04183.x; Poccia F, 1999, J INFECT DIS, V180, P858, DOI 10.1086/314925; Rajan AJ, 1996, J IMMUNOL, V157, P941; Ray DM, 2006, J IMMUNOL, V177, P5068, DOI 10.4049/jimmunol.177.8.5068; Roark CL, 2008, CURR OPIN IMMUNOL, V20, P353, DOI 10.1016/j.coi.2008.03.006; Robak E, 1999, MEDIAT INFLAMM, V8, P305, DOI 10.1080/09629359990315; Saubermann LJ, 2002, INFLAMM BOWEL DIS, V8, P330, DOI 10.1097/00054725-200209000-00004; SELMAJ K, 1991, P NATL ACAD SCI USA, V88, P6452, DOI 10.1073/pnas.88.15.6452; Shichita T, 2009, NAT MED, V15, P946, DOI 10.1038/nm.1999; Shiojiri T, 2002, EUR J PHARMACOL, V448, P231, DOI 10.1016/S0014-2999(02)01946-5; Sutton CE, 2009, IMMUNITY, V31, P331, DOI 10.1016/j.immuni.2009.08.001; Szatmari I, 2007, BLOOD, V110, P3271, DOI 10.1182/blood-2007-06-096222; Szeles L, 2007, BBA-MOL CELL BIOL L, V1771, P1014, DOI 10.1016/j.bbalip.2007.02.005; TANAKA Y, 1995, NATURE, V375, P155, DOI 10.1038/375155a0; Tikhonov I, 2006, INT IMMUNOL, V18, P1243, DOI 10.1093/intimm/dxl055; TONTONOZ P, 1995, CURR OPIN GENET DEV, V5, P571, DOI 10.1016/0959-437X(95)80025-5; TONTONOZ P, 1994, CELL, V79, P1147, DOI 10.1016/0092-8674(94)90006-X; Tzartos JS, 2008, AM J PATHOL, V172, P146, DOI 10.2353/ajpath.2008.070690; Ueki S, 2004, INT ARCH ALLERGY IMM, V134, P30, DOI 10.1159/000077790; Wiendl H, 2002, J IMMUNOL, V169, P515, DOI 10.4049/jimmunol.169.1.515; Woerly G, 2003, J EXP MED, V198, P411, DOI 10.1084/jem.20021384; Wohlfert EA, 2007, J IMMUNOL, V178, P4129, DOI 10.4049/jimmunol.178.7.4129; Yamashita N, 1997, CLIN EXP IMMUNOL, V107, P241, DOI 10.1111/j.1365-2249.1997.274-ce1159.x; Zhang X, 2004, BLOOD, V104, P3276, DOI 10.1182/blood-2004-02-0664	60	6	9	0	3	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA	1932-6203			PLOS ONE	PLoS One	NOV 4	2009	4	11							e7726	10.1371/journal.pone.0007726	http://dx.doi.org/10.1371/journal.pone.0007726			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	514RZ	19888466	Green Submitted, Green Published, gold			2022-12-25	WOS:000271414600008
J	Folkersen, L; Kyriakou, T; Goel, A; Peden, J; Malarstig, A; Paulsson-Berne, G; Hamsten, A; Franco-Cereceda, A; Gabrielsen, A; Eriksson, P; Watkins, H				Folkersen, Lasse; Kyriakou, Theodosios; Goel, Anuj; Peden, John; Malarstig, Anders; Paulsson-Berne, Gabrielle; Hamsten, Anders; Franco-Cereceda, Anders; Gabrielsen, Anders; Eriksson, Per; Watkins, Hugh		Hugh Watkins PROCARDIS Consortia	Relationship between CAD Risk Genotype in the Chromosome 9p21 Locus and Gene Expression. Identification of Eight New ANRIL Splice Variants	PLOS ONE			English	Article							CORONARY-ARTERY-DISEASE; ASSOCIATION	Background: Several genome-wide association studies have recently linked a group of single nucleotide polymorphisms in the 9p21 region with cardiovascular disease. The molecular mechanisms of this link are not fully understood. We investigated five different expression microarray datasets in order to determine if the genotype had effect on expression of any gene transcript in aorta, mammary artery, carotid plaque and lymphoblastoid cells. Methodology/Principal Findings: After multiple testing correction, no genes were found to have relation to the rs2891168 risk genotype, either on a genome-wide scale or on a regional (8 MB) scale. The neighbouring ANRIL gene was found to have eight novel transcript variants not previously known from literature and these varied by tissue type. We therefore performed a detailed probe-level analysis and found small stretches of significant relation to genotype but no consistent associations. In all investigated tissues we found an inverse correlation between ANRIL and the MTAP gene and a positive correlation between ANRIL and CDKN2A and CDKN2B. Conclusions/Significance: Investigation of relation of the risk genotype to gene expression is complicated by the transcript complexity of the locus. With our investigation of a range of relevant tissue we wish to underscore the need for careful attention to the complexity of the alternative splicing issues in the region and its implications to the design of future gene expression studies.			Folkersen, L (corresponding author), Karolinska Inst, Dept Med, Stockholm, Sweden.	lasse.folkersen@ki.se		Kyriakou, Theodosios/0000-0001-7794-8789; Folkersen, Lasse/0000-0003-0708-9530; Goel, Anuj/0000-0003-2307-4021; Watkins, Hugh/0000-0002-5287-9016; Eriksson, Per/0000-0002-5635-2692				Benovoy D, 2008, NUCLEIC ACIDS RES, V36, P4417, DOI 10.1093/nar/gkn409; Bolstad BM, 2003, BIOINFORMATICS, V19, P185, DOI 10.1093/bioinformatics/19.2.185; Broadbent HM, 2008, HUM MOL GENET, V17, P806, DOI 10.1093/hmg/ddm352; Burton PR, 2007, NATURE, V447, P661, DOI 10.1038/nature05911; DABNEY A, 2009, BIOCONDUCTOR; Edgar R, 2002, NUCLEIC ACIDS RES, V30, P207, DOI 10.1093/nar/30.1.207; FOLKERSEN L, 2009, BIOINFORMATICS; Gentleman RC, 2004, GENOME BIOL, V5, DOI 10.1186/gb-2004-5-10-r80; Gibbs RA, 2003, NATURE, V426, P789, DOI 10.1038/nature02168; Helgadottir A, 2008, NAT GENET, V40, P217, DOI 10.1038/ng.72; Helgadottir A, 2007, SCIENCE, V316, P1491, DOI 10.1126/science.1142842; Jarinova O, 2009, ARTERIOSCLER THROMB; Kent WJ, 2002, GENOME RES, V12, P996, DOI 10.1101/gr.229102; Kwan T, 2008, NAT GENET, V40, P225, DOI 10.1038/ng.2007.57; Liu Y, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005027; McPherson R, 2007, SCIENCE, V316, P1488, DOI 10.1126/science.1142447; Pasmant E, 2007, CANCER RES, V67, P3963, DOI 10.1158/0008-5472.CAN-06-2004; Samani NJ, 2007, NEW ENGL J MED, V357, P443, DOI 10.1056/NEJMoa072366; Zhang W, 2008, AM J HUM GENET, V82, P631, DOI 10.1016/j.ajhg.2007.12.015	19	124	135	0	11	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	NOV 2	2009	4	11							e7677	10.1371/journal.pone.0007677	http://dx.doi.org/10.1371/journal.pone.0007677			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	514RX	19888323	Green Published, gold, Green Submitted			2022-12-25	WOS:000271414400005
J	Ma, ZM; Kong, J; Kallen, RG				Ma, Zhongming; Kong, Jun; Kallen, Roland G.			Studies of alpha-Helicity and Intersegmental Interactions in Voltage-Gated Na+ Channels: S2D4	PLOS ONE			English	Article							SHAKER K+ CHANNEL; DEPENDENT CONFORMATIONAL-CHANGES; POTASSIUM CHANNEL; GATING CHARGE; TRANSMEMBRANE SEGMENTS; CRYSTAL-STRUCTURE; S4 SEGMENT; ELECTROSTATIC INTERACTIONS; FUNCTIONAL EXPRESSION; MOLECULAR-BASIS	Much data, including crystallographic, support structural models of sodium and potassium channels consisting of S1-S4 transmembrane segments (the "voltage-sensing domain'') clustered around a central pore-forming region (S5-S6 segments and the intervening loop). Voltage gated sodium channels have four non-identical domains which differentiates them from the homotetrameric potassium channels that form the basis for current structural models. Since potassium and sodium channels also exhibit many different functional characteristics and the fourth domain (D4) of sodium channels differs in function from other domains (D1-D3), we have explored its structure in order to determine whether segments in D4 of sodium channels differ significantly from that determined for potassium channels. We have probed the secondary and tertiary structure and the role of the individual amino acid residues of the S2D4) of Na(v)1.4 by employing cysteine-scanning mutagenesis (with tryptophan and glutamine substituted for native cysteine). A Fourier transform power spectrum of perturbations in free energy of steady-state inactivation gating (using midpoint potentials and slopes of Boltzmann equation fits of channel availability, h(infinity)-V plots) indicates a substantial amount of alpha-helical structure in S2D4 (peak at 106 degrees, alpha-Periodicity Index (alpha-PI) of 3.10), This conclusion is supported by alpha-PI values of 3.28 and 2.84 for the perturbations in rate constants of entry into (beta) and exit from (alpha) fast inactivation at 0 mV for mutant channels relative to WT channels assuming a simple two-state model for transition from the open to inactivated state. The results of cysteine substitution at the two most sensitive sites of the S2D4 alpha-helix (N1382 and E1392C) support the existence of electrostatic network interactions between S2 and other transmembrane segments within Na(v)1.4D4 similar to but not identical to those proposed for K+ channels.			Ma, ZM (corresponding author), Univ Penn, Sch Med, Dept Biochem & Biophys, Philadelphia, PA 19104 USA.	rgk@mail.med.upenn.edu			NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR041762] Funding Source: NIH RePORTER; NIAMS NIH HHS [AR 41762] Funding Source: Medline; PHS HHS [P01 08075] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		Adamian L, 2001, J MOL BIOL, V311, P891, DOI 10.1006/jmbi.2001.4908; Aggarwal SK, 1996, NEURON, V16, P1169, DOI 10.1016/S0896-6273(00)80143-9; AKABAS MH, 1992, SCIENCE, V258, P307, DOI 10.1126/science.1384130; BARCHI RL, 1991, ADV EXP MED BIOL, V308, P107; BEZANILLA F, 1994, BIOPHYS J, V66, P1011, DOI 10.1016/S0006-3495(94)80882-3; Blanchet J, 2007, BIOPHYS J, V92, P3513, DOI 10.1529/biophysj.106.090464; Boutjdir, 1996, J Cardiovasc Pharmacol Ther, V1, P149; CANNON SC, 1995, J NEUROPHYSIOL, V73, P1892, DOI 10.1152/jn.1995.73.5.1892; Cha A, 1999, NATURE, V402, P809, DOI 10.1038/45552; Cha A, 1999, NEURON, V22, P73, DOI 10.1016/S0896-6273(00)80680-7; Cha A, 1997, NEURON, V19, P1127, DOI 10.1016/S0896-6273(00)80403-1; CHAHINE M, 1994, PFLUG ARCH EUR J PHY, V427, P136, DOI 10.1007/BF00585952; Chen LQ, 1996, J GEN PHYSIOL, V108, P549, DOI 10.1085/jgp.108.6.549; Cordes MHJ, 1999, PROTEIN SCI, V8, P318; CORNETTE JL, 1987, J MOL BIOL, V195, P659, DOI 10.1016/0022-2836(87)90189-6; DeCaen PG, 2008, P NATL ACAD SCI USA, V105, P15142, DOI 10.1073/pnas.0806486105; Doyle DA, 1998, SCIENCE, V280, P69, DOI 10.1126/science.280.5360.69; Glauner KS, 1999, NATURE, V402, P813, DOI 10.1038/45561; GRANTHAM R, 1974, SCIENCE, V185, P862, DOI 10.1126/science.185.4154.862; Gregoret LM, 1998, FOLD DES, V3, P119, DOI 10.1016/S1359-0278(98)00017-0; GROS P, 1992, BIOCHEMISTRY-US, V31, P1992, DOI 10.1021/bi00122a014; HAMILL OP, 1981, PFLUG ARCH EUR J PHY, V391, P85, DOI 10.1007/BF00656997; Hille B., 2001, ION CHANNELS EXCITAB, V3rd Edn; HILLOVA J, 1975, INTERVIROLOGY, V5, P367, DOI 10.1159/000149935; Hirschberg B, 1995, J GEN PHYSIOL, V106, P1053, DOI 10.1085/jgp.106.6.1053; Islas LD, 1999, J GEN PHYSIOL, V114, P723, DOI 10.1085/jgp.114.5.723; Jiang YX, 2003, NATURE, V423, P33, DOI 10.1038/nature01580; Jiang YX, 2002, NATURE, V417, P515, DOI 10.1038/417515a; Jin WL, 1999, BIOCHEMISTRY-US, V38, P14294, DOI 10.1021/bi991206j; KALLEN RG, 1971, J AM CHEM SOC, V93, P6227, DOI 10.1021/ja00752a039; Keynes RD, 1999, P ROY SOC B-BIOL SCI, V266, P843, DOI 10.1098/rspb.1999.0714; Kuhn FJP, 1999, J GEN PHYSIOL, V114, P167, DOI 10.1085/jgp.114.2.167; Laine M, 2004, FEBS LETT, V564, P257, DOI 10.1016/S0014-5793(04)00273-X; Laine M, 2003, NEURON, V39, P467, DOI 10.1016/S0896-6273(03)00468-9; Larsson HP, 1996, NEURON, V16, P387, DOI 10.1016/S0896-6273(00)80056-2; Ledwell JL, 1999, J GEN PHYSIOL, V113, P389, DOI 10.1085/jgp.113.3.389; Li-Smerin YY, 2000, J GEN PHYSIOL, V115, P33, DOI 10.1085/jgp.115.1.33; LIWO A, 2008, CURR OPIN STRUCT BIO; Long SB, 2005, SCIENCE, V309, P897, DOI 10.1126/science.1116269; Long SB, 2005, SCIENCE, V309, P903, DOI 10.1126/science.1116270; Long SB, 2007, NATURE, V450, P376, DOI 10.1038/nature06265; Ma ZM, 2006, J GEN PHYSIOL, V127, P309, DOI 10.1085/jgp.200509421; MARGOLSKEE RF, 1993, BIOTECHNIQUES, V15, P906; McPhee JC, 1998, J BIOL CHEM, V273, P1121, DOI 10.1074/jbc.273.2.1121; Monks SA, 1999, J GEN PHYSIOL, V113, P415, DOI 10.1085/jgp.113.3.415; Neale EJ, 2007, J BIOL CHEM, V282, P37597, DOI 10.1074/jbc.M706437200; Nguyen TP, 2001, BIOPHYS J, V80, p232A; Nishida M, 2007, EMBO J, V26, P4005, DOI 10.1038/sj.emboj.7601828; OLEARY ME, 1995, J GEN PHYSIOL, V106, P641, DOI 10.1085/jgp.106.4.641; Ottschytsch N, 2005, J PHYSIOL-LONDON, V568, P737, DOI 10.1113/jphysiol.2005.090142; Ottschytsch N, 2002, P NATL ACAD SCI USA, V99, P7986, DOI 10.1073/pnas.122617999; PAKULA AA, 1989, ANNU REV GENET, V23, P289, DOI 10.1146/annurev.ge.23.120189.001445; Panaghie G, 2007, J GEN PHYSIOL, V129, P121, DOI 10.1085/jgp.200609612; Papazian DM, 1997, NEWS PHYSIOL SCI, V12, P203; PAPAZIAN DM, 1995, NEURON, V14, P1293, DOI 10.1016/0896-6273(95)90276-7; Pavlov E, 2005, BIOPHYS J, V89, P232, DOI 10.1529/biophysj.104.056994; PLANELLSCASES R, 1995, P NATL ACAD SCI USA, V92, P9422, DOI 10.1073/pnas.92.20.9422; Post MA, 1996, FEBS LETT, V399, P177, DOI 10.1016/S0014-5793(96)01316-6; REES DC, 1989, ANNU REV BIOCHEM, V58, P607; REES DC, 1989, SCIENCE, V245, P510, DOI 10.1126/science.2667138; Ren DJ, 2001, SCIENCE, V294, P2372, DOI 10.1126/science.1065635; Roden DM, 2002, ANNU REV PHYSIOL, V64, P431, DOI 10.1146/annurev.physiol.64.083101.145105; Sato Y, 2003, J BIOL CHEM, V278, P13227, DOI 10.1074/jbc.M300431200; SCHOPPA NE, 1992, SCIENCE, V255, P1712, DOI 10.1126/science.1553560; SCHREMPF H, 1995, EMBO J, V14, P5170, DOI 10.1002/j.1460-2075.1995.tb00201.x; Seoh SA, 1996, NEURON, V16, P1159, DOI 10.1016/S0896-6273(00)80142-7; Shafrir Y, 2008, BIOPHYS J, V95, P3663, DOI 10.1529/biophysj.108.135335; Smith-Maxwell CJ, 1998, J GEN PHYSIOL, V111, P399, DOI 10.1085/jgp.111.3.399; Tiwari-Woodruff SK, 2000, J GEN PHYSIOL, V115, P123, DOI 10.1085/jgp.115.2.123; TiwariWoodruff SK, 1997, BIOPHYS J, V72, P1489, DOI 10.1016/S0006-3495(97)78797-6; TRIMMER JS, 1989, NEURON, V3, P33, DOI 10.1016/0896-6273(89)90113-X; Yang NB, 1997, BIOPHYS J, V73, P2260, DOI 10.1016/S0006-3495(97)78258-4; Yang NB, 1996, NEURON, V16, P113, DOI 10.1016/S0896-6273(00)80028-8; Yang YC, 2003, J NEUROSCI, V23, P4922; ZAGOTTA WN, 1994, J GEN PHYSIOL, V103, P321, DOI 10.1085/jgp.103.2.321; ZAGOTTA WN, 1994, J GEN PHYSIOL, V103, P279, DOI 10.1085/jgp.103.2.279	76	5	5	1	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	NOV 2	2009	4	11							e7674	10.1371/journal.pone.0007674	http://dx.doi.org/10.1371/journal.pone.0007674			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	514RX	19881885	Green Published, Green Submitted, gold			2022-12-25	WOS:000271414400004
J	Hoffmann, M; Bellance, N; Rossignol, R; Koopman, WJH; Willems, PHGM; Mayatepek, E; Bossinger, O; Distelmaier, F				Hoffmann, Michael; Bellance, Nadege; Rossignol, Rodrigue; Koopman, Werner J. H.; Willems, Peter H. G. M.; Mayatepek, Ertan; Bossinger, Olaf; Distelmaier, Felix			C-elegans ATAD-3 Is Essential for Mitochondrial Activity and Development	PLOS ONE			English	Article							CAENORHABDITIS-ELEGANS; CELL-CYCLE; GENOME; GENES; INTERFERENCE; DEFICIENCY; GENERATION; NUCLEOIDS; LONGEVITY; MEMBRANE	Background: Mammalian ATAD3 is a mitochondrial protein, which is thought to play an important role in nucleoid organization. However, its exact function is still unresolved. Results: Here, we characterize the Caenorhabditis elegans (C. elegans) ATAD3 homologue (ATAD-3) and investigate its importance for mitochondrial function and development. We show that ATAD-3 is highly conserved among different species and RNA mediated interference against atad-3 causes severe defects, characterized by early larval arrest, gonadal dysfunction and embryonic lethality. Investigation of mitochondrial physiology revealed a disturbance in organellar structure while biogenesis and function, as indicated by complex I and citrate synthase activities, appeared to be unaltered according to the developmental stage. Nevertheless, we observed very low complex I and citrate synthase activities in L1 larvae populations in comparison to higher larval and adult stages. Our findings indicate that atad-3(RNAi) animals arrest at developmental stages with low mitochondrial activity. In addition, a reduced intestinal fat storage and low lysosomal content after depletion of ATAD-3 suggests a central role of this protein for metabolic activity. Conclusions: In summary, our data clearly indicate that ATAD-3 is essential for C. elegans development in vivo. Moreover, our results suggest that the protein is important for the upregulation of mitochondrial activity during the transition to higher larval stages.			Hoffmann, M (corresponding author), Univ Dusseldorf, Univ Childrens Hosp, Dept Gen Pediat, Dusseldorf, Germany.	bossinger@mac.com; felix.distelmaier@med.uni-duesseldorf.de	Willems, P.H.G.M./L-4759-2015; Koopman, Werner J.H./AAC-9668-2020; Rossignol, Rodrigue/K-7821-2014; Koopman, Werner J.H./D-3592-2009	Willems, P.H.G.M./0000-0002-0915-1599; Koopman, Werner J.H./0000-0002-5340-6747; Koopman, Werner J.H./0000-0002-5340-6747; bellance, nadege/0000-0002-8868-8596; Hoffmann, Michael/0000-0001-8677-5031				Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; Ashrafi K, 2003, NATURE, V421, P268, DOI 10.1038/nature01279; Ballard JWO, 2001, CURR OPIN GENET DEV, V11, P667, DOI 10.1016/S0959-437X(00)00251-3; Benard G, 2006, AM J PHYSIOL-CELL PH, V291, pC1172, DOI 10.1152/ajpcell.00195.2006; Benard G, 2008, ANTIOXID REDOX SIGN, V10, P1313, DOI 10.1089/ars.2007.2000; Benedetti C, 2006, GENETICS, V174, P229, DOI 10.1534/genetics.106.061580; Bogenhagen DF, 2008, J BIOL CHEM, V283, P3665, DOI 10.1074/jbc.M708444200; Bratic I, 2009, NUCLEIC ACIDS RES, V37, P1817, DOI 10.1093/nar/gkp018; BRENNER S, 1974, GENETICS, V77, P71; Chen XW, 2005, CIRC RES, V97, P1009, DOI 10.1161/01.RES.0000189270.72915.D1; Curran SP, 2004, J BIOL CHEM, V279, P54655, DOI 10.1074/jbc.M409618200; Da Cruz S, 2003, J BIOL CHEM, V278, P41566, DOI 10.1074/jbc.M304940200; Duchen Michael R., 2004, Molecular Aspects of Medicine, V25, P365, DOI 10.1016/j.mam.2004.03.001; Fire A, 1998, NATURE, V391, P806, DOI 10.1038/35888; Gires O, 2004, CELL MOL LIFE SCI, V61, P1198, DOI 10.1007/s00018-004-4045-8; Grad LI, 2004, HUM MOL GENET, V13, P303, DOI 10.1093/hmg/ddh027; He JY, 2007, J CELL BIOL, V176, P141, DOI 10.1083/jcb.200609158; Holt IJ, 2007, MITOCHONDRION, V7, P311, DOI 10.1016/j.mito.2007.06.004; Hubstenberger A, 2008, EXP CELL RES, V314, P2870, DOI 10.1016/j.yexcr.2008.06.017; Iwasaki K, 1996, J CELL BIOL, V134, P699, DOI 10.1083/jcb.134.3.699; Kamath RS, 2001, GENOME BIOL, V2, DOI 10.1186/gb-2000-2-1-research0002; Kanazawa T, 2008, PLOS GENET, V4, DOI 10.1371/journal.pgen.1000022; Kawasaki I, 2007, MECH DEVELOP, V124, P237, DOI 10.1016/j.mod.2006.11.004; Kimble Judith, 2005, WormBook, P1; Koopman WJH, 2008, METHODS, V46, P304, DOI 10.1016/j.ymeth.2008.09.018; Lee SS, 2003, NAT GENET, V33, P40, DOI 10.1038/ng1056; Linder P, 2000, CURR BIOL, V10, pR887, DOI 10.1016/S0960-9822(00)00857-5; Long XM, 2002, CURR BIOL, V12, P1448, DOI 10.1016/S0960-9822(02)01091-6; MARGULIS L, 1975, BIOSYSTEMS, V7, P266, DOI 10.1016/0303-2647(75)90034-9; Martinez-Diez M, 2006, PLOS ONE, V1, DOI 10.1371/journal.pone.0000107; Maurizi Michael R., 2001, EMBO Reports, V2, P980, DOI 10.1093/embo-reports/kve229; McGhee James D, 2007, WormBook, P1; McKay RM, 2003, DEV CELL, V4, P131, DOI 10.1016/S1534-5807(02)00411-2; Minai L, 2008, MOL GENET METAB, V94, P120, DOI 10.1016/j.ymgme.2007.12.007; Mootha VK, 2003, CELL, V115, P629, DOI 10.1016/S0092-8674(03)00926-7; Neuspiel M, 2005, J BIOL CHEM, V280, P25060, DOI 10.1074/jbc.M501599200; Piano F, 2002, CURR BIOL, V12, P1959, DOI 10.1016/S0960-9822(02)01301-5; Pilipiuk J, 2009, DEV BIOL, V327, P34, DOI 10.1016/j.ydbio.2008.11.025; PIPERNO G, 1985, J CELL BIOL, V101, P2085, DOI 10.1083/jcb.101.6.2085; POSAKONY JW, 1977, J CELL BIOL, V74, P468, DOI 10.1083/jcb.74.2.468; Sanz MA, 2003, J BIOL CHEM, V278, P32091, DOI 10.1074/jbc.M304877200; Schaffrik M, 2006, CELL MOL LIFE SCI, V63, P2162, DOI 10.1007/s00018-006-6200-x; Segbert C, 2003, MOL BIOL CELL, V14, P4458, DOI 10.1091/mbc.E03-05-0283; STROME S, 1983, CELL, V35, P15, DOI 10.1016/0092-8674(83)90203-9; Strome Susan, 2005, WormBook, P1, DOI 10.1895/wormbook.1.9.1; Suthammarak W, 2009, J BIOL CHEM, V284, P6425, DOI 10.1074/jbc.M805733200; Timmons L, 1998, NATURE, V395, P854, DOI 10.1038/27579; Wai T, 2008, NAT GENET, V40, P1484, DOI 10.1038/ng.258; Wang MC, 2008, SCIENCE, V322, P957, DOI 10.1126/science.1162011; Wood W.B., 1988, Cold Spring Harbor Monograph Series, V17, P1; Yoon YS, 2006, J CELL PHYSIOL, V209, P468, DOI 10.1002/jcp.20753	52	47	50	0	5	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	OCT 30	2009	4	10							e7644	10.1371/journal.pone.0007644	http://dx.doi.org/10.1371/journal.pone.0007644			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	514RW	19888333	Green Published, gold, Green Submitted			2022-12-25	WOS:000271414300006
J	Taylor, JM; Street, TL; Hao, LZ; Copley, R; Taylor, MS; Hayden, PJ; Stolper, G; Mott, R; Hein, J; Moffatt, MF; Cookson, WOCM				Taylor, Jennifer M.; Street, Teresa L.; Hao, Lizhong; Copley, Richard; Taylor, Martin S.; Hayden, Patrick J.; Stolper, Gina; Mott, Richard; Hein, Jotun; Moffatt, Miriam F.; Cookson, William O. C. M.			Dynamic and Physical Clustering of Gene Expression during Epidermal Barrier Formation in Differentiating Keratinocytes	PLOS ONE			English	Article							ATOPIC-DERMATITIS; HLA-G; PSORIASIS; GENOME; CORNIFICATION; MICROARRAYS; INFECTION; PROTEINS; ENVELOPE; PROTECTS	The mammalian epidermis is a continually renewing structure that provides the interface between the organism and an innately hostile environment. The keratinocyte is its principal cell. Keratinocyte proteins form a physical epithelial barrier, protect against microbial damage, and prepare immune responses to danger. Epithelial immunity is disordered in many common diseases and disordered epithelial differentiation underlies many cancers. In order to identify the genes that mediate epithelial development we used a tissue model of the skin derived from primary human keratinocytes. We measured global gene expression in triplicate at five times over the ten days that the keratinocytes took to fully differentiate. We identified 1282 gene transcripts that significantly changed during differentiation (false discovery rate < 0.01%). We robustly grouped these transcripts by K-means clustering into modules with distinct temporal expression patterns, shared regulatory motifs, and biological functions. We found a striking cluster of late expressed genes that form the structural and innate immune defences of the epithelial barrier. Gene Ontology analyses showed that undifferentiated keratinocytes were characterised by genes for motility and the adaptive immune response. We systematically identified calcium-binding genes, which may operate with the epidermal calcium gradient to control keratinocyte division during skin repair. The results provide multiple novel insights into keratinocyte biology, in particular providing a comprehensive list of known and previously unrecognised major components of the epidermal barrier. The findings provide a reference for subsequent understanding of how the barrier functions in health and disease.			Taylor, JM (corresponding author), Wellcome Trust Ctr Human Genet, Oxford, England.	wcookson@imperial.ac.uk	Taylor, Martin S/C-3825-2009; Cookson, William/HHC-1790-2022; Taylor, Jennifer M/A-1686-2010	Taylor, Martin S/0000-0001-7656-330X; Taylor, Jennifer M/0000-0003-4231-0181; Hayden, Patrick/0000-0001-8977-1845; Mott, Richard/0000-0002-1022-9330	Medical Research Council [G0801056B] Funding Source: researchfish; Wellcome Trust Funding Source: Medline	Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission); Wellcome Trust(Wellcome TrustEuropean Commission)		AHOS, 2004, J CELL BIOCHEM, V92, P1271; Ashburner M, 2001, GENOME RES, V11, P1425; Carninci P, 2005, SCIENCE, V309, P1559, DOI 10.1126/science.1112014; Christiano AM, 1997, TRENDS GENET, V13, P227, DOI 10.1016/S0168-9525(97)01104-9; CLOHESSY PA, 1995, SCAND J IMMUNOL, V42, P551, DOI 10.1111/j.1365-3083.1995.tb03695.x; Cookson W, 2004, NAT REV IMMUNOL, V4, P978, DOI 10.1038/nri1500; Cookson WOCM, 2001, NAT GENET, V27, P372, DOI 10.1038/86867; Donato R, 2001, INT J BIOCHEM CELL B, V33, P637, DOI 10.1016/S1357-2725(01)00046-2; Elias PM, 1998, J INVEST DERMATOL, V110, P399, DOI 10.1046/j.1523-1747.1998.00151.x; Freedberg IM, 2001, J INVEST DERMATOL, V116, P633, DOI 10.1046/j.1523-1747.2001.01327.x; Gautier L, 2004, BIOINFORMATICS, V20, P307, DOI 10.1093/bioinformatics/btg405; Gazit E, 2004, HUM IMMUNOL, V65, P39, DOI 10.1016/j.humimm.2003.09.019; Glaser R, 2005, NAT IMMUNOL, V6, P57, DOI 10.1038/ni1142; Gottsch JD, 1999, INFECT IMMUN, V67, P6631; Hardas BD, 1996, J INVEST DERMATOL, V106, P753, DOI 10.1111/1523-1747.ep12345807; Hennings H, 1980, Curr Probl Dermatol, V10, P3; HENNINGS H, 1983, EXP CELL RES, V143, P127, DOI 10.1016/0014-4827(83)90115-5; Holick MF, 2003, BRIT J DERMATOL, V149, P370, DOI 10.1046/j.1365-2133.2003.05437.x; Horton R, 2004, NAT REV GENET, V5, P889, DOI 10.1038/nrg1489; Huh GS, 2000, SCIENCE, V290, P2155, DOI 10.1126/science.290.5499.2155; Hurst LD, 2004, NAT REV GENET, V5, P299, DOI 10.1038/nrg1319; Khochbin S, 2001, GENE, V271, P1, DOI 10.1016/S0378-1119(01)00495-4; Lefort K, 2004, SEMIN CANCER BIOL, V14, P374, DOI 10.1016/j.semcancer.2004.04.017; Lercher MJ, 2002, NAT GENET, V31, P180, DOI 10.1038/ng887; Liu WM, 2002, BIOINFORMATICS, V18, P1593, DOI 10.1093/bioinformatics/18.12.1593; Lohman FP, 1997, EXP CELL RES, V231, P141, DOI 10.1006/excr.1996.3458; MacQueen J, 1967, P 5 BERKELEY S MATH, V1, DOI DOI 10.1007/S11665-016-2173-6; Marshall D, 2001, P NATL ACAD SCI USA, V98, P13031, DOI 10.1073/pnas.231489198; Marzluff WF, 2002, GENOMICS, V80, P487, DOI 10.1006/geno.2002.6850; Mauro T, 1998, J INVEST DERMATOL, V111, P1198, DOI 10.1046/j.1523-1747.1998.00421.x; Mischke D, 1996, J INVEST DERMATOL, V106, P989, DOI 10.1111/1523-1747.ep12338501; Nair RP, 2000, AM J HUM GENET, V66, P1833, DOI 10.1086/302932; Nicolae D, 2005, AM J HUM GENET, V76, P349, DOI 10.1086/427763; Palmer CNA, 2006, NAT GENET, V38, P441, DOI 10.1038/ng1767; Pavesi G, 2001, Bioinformatics, V17 Suppl 1, pS207; Price TS, 2005, NUCLEIC ACIDS RES, V33, P3455, DOI 10.1093/nar/gki643; Reverter D, 2004, J MOL BIOL, V338, P257, DOI 10.1016/j.jmb.2004.02.058; Roepcke S, 2005, NUCLEIC ACIDS RES, V33, pW438, DOI 10.1093/nar/gki590; ROUSSEEUW PJ, 1987, J COMPUT APPL MATH, V20, P53, DOI 10.1016/0377-0427(87)90125-7; Rustici G, 2004, NAT GENET, V36, P809, DOI 10.1038/ng1377; Sakata Y, 2004, J BIOL CHEM, V279, P5081, DOI 10.1074/jbc.M311585200; Simpson AJ, 1999, FEBS LETT, V452, P309, DOI 10.1016/S0014-5793(99)00670-5; Simpson AJ, 2001, J IMMUNOL, V167, P1778, DOI 10.4049/jimmunol.167.3.1778; South AP, 1999, J INVEST DERMATOL, V112, P910, DOI 10.1046/j.1523-1747.1999.00613.x; Sproul D, 2005, NAT REV GENET, V6, P775, DOI 10.1038/nrg1688; Tavazoie S, 1999, NAT GENET, V22, P281, DOI 10.1038/10343; Tusher VG, 2001, P NATL ACAD SCI USA, V98, P5116, DOI 10.1073/pnas.091062498; Vasilopoulos Y, 2004, J INVEST DERMATOL, V123, P62, DOI 10.1111/j.0022-202X.2004.22708.x; VEAL CD, 2002, AM J HUM GE IN PRESS, V71; Walley AJ, 2001, NAT GENET, V29, P175, DOI 10.1038/ng728	50	26	26	0	4	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	OCT 30	2009	4	10							e7651	10.1371/journal.pone.0007651	http://dx.doi.org/10.1371/journal.pone.0007651			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	514RW	19888454	Green Published, gold			2022-12-25	WOS:000271414300009
J	Pagliuca, C; Draviam, VM; Marco, E; Sorger, PK; De Wulf, P				Pagliuca, Cinzia; Draviam, Viji M.; Marco, Eugenio; Sorger, Peter K.; De Wulf, Peter			Roles for the Conserved Spc105p/Kre28p Complex in Kinetochore-Microtubule Binding and the Spindle Assembly Checkpoint	PLOS ONE			English	Article							BUDDING YEAST KINETOCHORE; MOLECULAR ARCHITECTURE; PROTEIN; ATTACHMENT; GENE; LOCALIZATION; CYTOKINESIS; INTERFACE; STABILITY; COMPONENT	Background: Kinetochores attach sister chromatids to microtubules of the mitotic spindle and orchestrate chromosome disjunction at anaphase. Although S. cerevisiae has the simplest known kinetochores, they nonetheless contain,70 subunits that assemble on centromeric DNA in a hierarchical manner. Developing an accurate picture of the DNA-binding, linker and microtubule-binding layers of kinetochores, including the functions of individual proteins in these layers, is a key challenge in the field of yeast chromosome segregation. Moreover, comparison of orthologous proteins in yeast and humans promises to extend insight obtained from the study of simple fungal kinetochores to complex animal cell kinetochores. Principal Findings: We show that S. cerevisiae Spc105p forms a heterotrimeric complex with Kre28p, the likely orthologue of the metazoan kinetochore protein Zwint-1. Through systematic analysis of interdependencies among kinetochore complexes, focused on Spc105p/Kre28p, we develop a comprehensive picture of the assembly hierarchy of budding yeast kinetochores. We find Spc105p/Kre28p to comprise the third linker complex that, along with the Ndc80 and MIND linker complexes, is responsible for bridging between centromeric heterochromatin and kinetochore MAPs and motors. Like the Ndc80 complex, Spc105p/Kre28p is also essential for kinetochore binding by components of the spindle assembly checkpoint. Moreover, these functions are conserved in human cells. Conclusions/Significance: Spc105p/Kre28p is the last of the core linker complexes to be analyzed in yeast and we show it to be required for kinetochore binding by a discrete subset of kMAPs (Bim1p, Bik1p, Slk19p) and motors (Cin8p, Kar3p), all of which are nonessential. Strikingly, dissociation of these proteins from kinetochores prevents bipolar attachment, even though the Ndc80 and DASH complexes, the two best-studied kMAPs, are still present. The failure of Spc105 deficient kinetochores to bind correctly to spindle microtubules and to recruit checkpoint proteins in yeast and human cells explains the observed severity of missegregation phenotypes.			Pagliuca, C (corresponding author), European Inst Oncol, Dept Expt Oncol, Milan, Italy.	peter.dewulf@ifom-ieo-campus.it	Marco, Eugenio/F-4583-2011	Marco, Eugenio/0000-0002-3675-263X; Draviam, Viji/0000-0001-8295-3689; Sorger, Peter/0000-0002-3364-1838; De Wulf, Peter/0000-0001-9772-5881	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM051464] Funding Source: NIH RePORTER; Associazione Italiana per la Ricerca sul Cancro Funding Source: Custom; Cancer Research UK [9787] Funding Source: Medline; NIGMS NIH HHS [R01 GM051464, GM51464] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); Associazione Italiana per la Ricerca sul Cancro(Fondazione AIRC per la ricerca sul cancro); Cancer Research UK(Cancer Research UK); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Al-Bassam J, 2006, J CELL BIOL, V172, P1009, DOI 10.1083/jcb.200511010; Bouck D, 2005, BIOCHEM CELL BIOL, V83, P696, DOI 10.1139/O05-161; Cheeseman IM, 2008, MOL BIOL CELL, V19, P587, DOI 10.1091/mbc.E07-10-1051; Cheeseman IM, 2008, NAT REV MOL CELL BIO, V9, P33, DOI 10.1038/nrm2310; Cheeseman IM, 2006, CELL, V127, P983, DOI 10.1016/j.cell.2006.09.039; Cheeseman IM, 2004, GENE DEV, V18, P2255, DOI 10.1101/gad.1234104; Chu HMA, 2005, EMBO J, V24, P3214, DOI 10.1038/sj.emboj.7600790; Cohen RL, 2008, MOL BIOL CELL, V19, P4480, DOI 10.1091/mbc.E08-03-0297; Collins KA, 2005, MOL BIOL CELL, V16, P5649, DOI 10.1091/mbc.E05-08-0771; De Wulf P, 2003, GENE DEV, V17, P2902, DOI 10.1101/gad.1144403; DeLuca JG, 2006, CELL, V127, P969, DOI 10.1016/j.cell.2006.09.047; Desai A, 2003, GENE DEV, V17, P2421, DOI 10.1101/gad.1126303; Dorn JF, 2005, BIOPHYS J, V89, P2835, DOI 10.1529/biophysj.104.058461; Draviam VM, 2006, EMBO J, V25, P2814, DOI 10.1038/sj.emboj.7601168; Fujita Y, 2007, DEV CELL, V12, P17, DOI 10.1016/j.devcel.2006.11.002; Fukagawa Tatsuo, 2009, P133, DOI 10.1007/978-0-387-69076-6_6; Gillett ES, 2004, J CELL BIOL, V164, P535, DOI 10.1083/jcb.200308100; GOH PY, 1993, J CELL BIOL, V121, P503, DOI 10.1083/jcb.121.3.503; Hayette S, 2000, ONCOGENE, V19, P4446, DOI 10.1038/sj.onc.1203789; He XW, 2001, CELL, V106, P195, DOI 10.1016/S0092-8674(01)00438-X; Janke C, 2002, EMBO J, V21, P181, DOI 10.1093/emboj/21.1.181; Janke C, 2001, EMBO J, V20, P777, DOI 10.1093/emboj/20.4.777; Joglekar AP, 2006, NAT CELL BIOL, V8, P581, DOI 10.1038/ncb1414; Joglekar AP, 2009, CURR BIOL, V19, P694, DOI 10.1016/j.cub.2009.02.056; Kerres A, 2004, MOL BIOL CELL, V15, P5255, DOI 10.1091/mbc.E04-06-0443; Kerres A, 2007, MOL BIOL CELL, V18, P2441, DOI 10.1091/mbc.E06-08-0738; Knockleby J, 2009, CELL CYCLE, V8, P2570, DOI 10.4161/cc.8.16.9267; Liu ST, 2006, J CELL BIOL, V175, P41, DOI 10.1083/jcb.200606020; Mackey AT, 2003, J BIOL CHEM, V278, P3527, DOI 10.1074/jbc.M206219200; Martin-Lluesma S, 2002, SCIENCE, V297, P2267, DOI 10.1126/science.1075596; Martinez-Exposito MJ, 1999, P NATL ACAD SCI USA, V96, P8493, DOI 10.1073/pnas.96.15.8493; Measday V, 2002, GENE DEV, V16, P101, DOI 10.1101/gad.949302; Meraldi P, 2004, DEV CELL, V7, P45, DOI 10.1016/j.devcel.2004.06.006; Meraldi P, 2006, GENOME BIOL, V7, DOI 10.1186/gb-2006-7-3-r23; Musacchio A, 2007, NAT REV MOL CELL BIO, V8, P379, DOI 10.1038/nrm2163; Nekrasov VS, 2003, MOL BIOL CELL, V14, P4931, DOI 10.1091/mbc.E03-06-0419; Norden C, 2006, CELL, V125, P85, DOI 10.1016/j.cell.2006.01.045; Ortiz J, 1999, GENE DEV, V13, P1140, DOI 10.1101/gad.13.9.1140; Pinsky BA, 2003, DEV CELL, V5, P735, DOI 10.1016/S1534-5807(03)00322-8; Pot I, 2005, CELL CYCLE, V4, P1448, DOI 10.4161/cc.4.10.2106; Pot I, 2003, MOL BIOL CELL, V14, P460, DOI 10.1091/mbc.E02-08-0517; Powers AF, 2009, CELL, V136, P865, DOI 10.1016/j.cell.2008.12.045; Przewloka MR, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0000478; Sandall S, 2006, CELL, V127, P1179, DOI 10.1016/j.cell.2006.09.049; Scharfenberger M, 2003, EMBO J, V22, P6584, DOI 10.1093/emboj/cdg636; Schittenhelm RB, 2009, EMBO J, V28, P2374, DOI 10.1038/emboj.2009.188; STOLER S, 1995, GENE DEV, V9, P573, DOI 10.1101/gad.9.5.573; Takimoto M, 2002, BRIT J CANCER, V86, P1757, DOI 10.1038/sj.bjc.6600328; Tanaka K, 2007, J CELL BIOL, V178, P269, DOI 10.1083/jcb.200702141; Tanaka TU, 2002, CELL, V108, P317, DOI 10.1016/S0092-8674(02)00633-5; Thomann D, 2002, J MICROSC-OXFORD, V208, P49, DOI 10.1046/j.1365-2818.2002.01066.x; Tytell JD, 2006, J CELL BIOL, V172, P861, DOI 10.1083/jcb.200509101; Wang PJJ, 1997, J CELL BIOL, V139, P1271, DOI 10.1083/jcb.139.5.1271; Wei RR, 2005, P NATL ACAD SCI USA, V102, P5363, DOI 10.1073/pnas.0501168102; Westermann S, 2003, J CELL BIOL, V163, P215, DOI 10.1083/jcb.200305100; Westermann S, 2005, MOL CELL, V17, P277, DOI 10.1016/j.molcel.2004.12.019; Westermann S, 2007, ANNU REV BIOCHEM, V76, P563, DOI 10.1146/annurev.biochem.76.052705.160607; Wigge PA, 2001, J CELL BIOL, V152, P349, DOI 10.1083/jcb.152.2.349	58	48	53	1	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	OCT 28	2009	4	10							e7640	10.1371/journal.pone.0007640	http://dx.doi.org/10.1371/journal.pone.0007640			15	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	511UJ	19893618	Green Published, gold, Green Submitted			2022-12-25	WOS:000271194600018
J	Morrison, JI; Borg, P; Simon, A				Morrison, Jamie I.; Borg, Paula; Simon, Andras			Plasticity and recovery of skeletal muscle satellite cells during limb regeneration	FASEB JOURNAL			English	Article						Pax7; blastema; salamander; reprogramming	SELF-RENEWAL; DEDIFFERENTIATION; EXPRESSION; ORIGIN	Salamander limb regeneration depends on local progenitors whose progeny are recruited to the new limb. We previously identified a Pax7(+) cell population in skeletal muscle whose progeny have the potential to contribute to the regenerating limb. However, the plasticity of individual Pax7(+) cells, as well as their recovery within the new limb, was unclear. Here, we show that Pax7(+) cells remain present after multiple rounds of limb amputation/regeneration. Pax7(+) cells are found exclusively within skeletal muscle in the regenerating limb and proliferate where the myofibers are growing. Pax7 is rapidly down-regulated in the blastema, and analyses of clonal derivatives show that Pax7(+) cell progeny are not restricted to skeletal muscle during limb regeneration. Our data suggest that the newt regeneration blastema is not entirely a composite of lineage-restricted progenitors. The results demonstrate that except for a transient and subsequently blunted increase, skeletal muscle satellite cells constitute a stable pool of reserve cells for multiple limb regeneration events.-Morrison, J. i., Borg, P., Simon, A. Plasticity and recovery of skeletal muscle satellite cells during limb regeneration. FASEB J. 24, 750-756 (2010). www.fasebj.org	[Morrison, Jamie I.; Borg, Paula; Simon, Andras] Karolinska Inst, Dept Cell & Mol Biol, Ctr Excellence Dev Biol Regenerat Med, S-17177 Stockholm, Sweden	Karolinska Institutet	Simon, A (corresponding author), Karolinska Inst, Dept Cell & Mol Biol, Ctr Excellence Dev Biol Regenerat Med, Eulersvag 3, S-17177 Stockholm, Sweden.	jamie.morrison@molbio.su.se; andras.simon@ki.se		Simon, Andras/0000-0002-1018-1891	Swedish Research Council; Swedish Foundation for Strategic Research; Karolinska Institute	Swedish Research Council(Swedish Research CouncilEuropean Commission); Swedish Foundation for Strategic Research(Swedish Foundation for Strategic Research); Karolinska Institute(Karolinska Institutet)	The authors thank members of the A. S. laboratory for discussions, E. Littson for help with the clonal isolations, Y. Kawakami for virus production, and M. Kirkham for help with adenovirus infections. This project was supported by grants from the Swedish Research Council, the Swedish Foundation for Strategic Research, and the Karolinska Institute to A. S.	Alvarado AS, 2006, NAT REV GENET, V7, P873, DOI 10.1038/nrg1923; Bauer S, 2005, J CELL BIOL, V171, P641, DOI 10.1083/jcb.200505072; Brockes JP, 2005, SCIENCE, V310, P1919, DOI 10.1126/science.1115200; Brockes JR, 2002, NAT REV MOL CELL BIO, V3, P566, DOI 10.1038/nrm881; Bryant SV, 2002, INT J DEV BIOL, V46, P887; CAMERON JA, 1986, NATURE, V321, P607, DOI 10.1038/321607a0; CARLSON B M, 1976, Folia Morphologica (Prague), V24, P359; Collins CA, 2005, CELL, V122, P289, DOI 10.1016/j.cell.2005.05.010; DUNIS DA, 1977, DEV BIOL, V56, P97, DOI 10.1016/0012-1606(77)90157-9; Echeverri K, 2001, DEV BIOL, V236, P151, DOI 10.1006/dbio.2001.0312; Gardiner DM, 2005, REJUV RES, V8, P141, DOI 10.1089/rej.2005.8.141; Imokawa Y, 2004, INT J DEV BIOL, V48, P285, DOI 10.1387/ijdb.031787yi; Kawakami Y, 2006, GENE DEV, V20, P3232, DOI 10.1101/gad.1475106; Kragl M, 2009, NATURE, V460, P60, DOI 10.1038/nature08152; Kuang SH, 2007, CELL, V129, P999, DOI 10.1016/j.cell.2007.03.044; Kumar A, 2004, PLOS BIOL, V2, P1168, DOI 10.1371/journal.pbio.0020218; Kumar A, 2000, DEV BIOL, V218, P125, DOI 10.1006/dbio.1999.9569; Laube F, 2006, J CELL SCI, V119, P4719, DOI 10.1242/jcs.03252; Maki N, 2009, DEV DYNAM, V238, P1613, DOI 10.1002/dvdy.21959; Meeson AP, 2004, STEM CELLS, V22, P1305, DOI 10.1634/stemcells.2004-0077; Morrison JI, 2006, J CELL BIOL, V172, P433, DOI 10.1083/jcb.200509011; MUNEOKA K, 1986, DEV BIOL, V116, P256, DOI 10.1016/0012-1606(86)90062-X; NAMENWIRTH M, 1974, DEV BIOL, V41, P42, DOI 10.1016/0012-1606(74)90281-4; POPIELA H, 1976, J EXP ZOOL, V198, P57, DOI 10.1002/jez.1401980108; ROSENBLATT JD, 1995, DEV BIOL ANIM, V31, P773; Sacco A, 2008, NATURE, V456, P502, DOI 10.1038/nature07384; Seale P, 2000, CELL, V102, P777, DOI 10.1016/S0092-8674(00)00066-0; Shinin V, 2006, NAT CELL BIOL, V8, P677, DOI 10.1038/ncb1425; Slack JMW, 2006, TRENDS CELL BIOL, V16, P273, DOI 10.1016/j.tcb.2006.04.007; Tanaka EM, 2003, CELL, V113, P559, DOI 10.1016/S0092-8674(03)00395-7; Tanaka KK, 2009, CELL STEM CELL, V4, P217, DOI 10.1016/j.stem.2009.01.016; Whited Jessica L, 2009, J Biol, V8, P5, DOI 10.1186/jbiol105	32	38	40	0	7	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAR	2010	24	3					750	756		10.1096/fj.09-134825	http://dx.doi.org/10.1096/fj.09-134825			7	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	561KE	19887652				2022-12-25	WOS:000274974600011
J	Zhu, ML; Kyprianou, N				Zhu, Meng-Lei; Kyprianou, Natasha			Role of androgens and the androgen receptor in epithelial-mesenchymal transition and invasion of prostate cancer cells	FASEB JOURNAL			English	Article						cytoskeleton reorganization; actin; talin; cofilin; metastasis; TGF-beta signaling	GROWTH-FACTOR-BETA; TUMOR PROGRESSION; TGF-BETA; NUCLEAR TRANSLOCATION; INDUCED APOPTOSIS; CATENIN; THERAPY; DEPRIVATION; ACTIVATION; PLASTICITY	Androgens are functionally required for the normal growth of the prostate gland and in prostate tumor development and progression. Epithelial-mesenchymal-transition (EMT) is an important process during normal development and in cancer cell metastasis induced by factors within the microenvironment, such as transforming growth factor-beta (TGF-beta). This study examined the ability of androgens to influence EMT of prostate cancer epithelial cells. The EMT pattern was evaluated on the basis of expression of the epithelial markers E-cadherin/beta-catenin, and the mesenchymal markers N-cadherin, as well as cytoskeleton reorganization in response to 5 alpha-dihydrotestosterone (DHT; 1 nM) and/or TGF-beta (5 ng/ml). Overexpressing and silencing approaches to regulate androgen receptor (AR) expression were conducted to determine the involvement of AR in EMT in the presence or absence of an AR antagonist. Our results demonstrate that androgens induce the EMT pattern in prostate tumor epithelial cell with Snail activation and lead to significant changes in prostate cancer cell migration and invasion potential. Expression levels of AR inversely correlated with androgen-mediated EMT in prostate tumor epithelial cells, pointing to a low AR content required for the EMT phenotype. These findings indicate the ability of androgens to induce EMT by potentially bypassing the functional involvement of TGF-beta, thus contributing to metastatic behavior of prostate cancer cells.-Zhum, M.-L., Kyprianou, N. Role of androgens and the androgen receptor in epithelial-mesenchymal transition and invasion of prostate cancer cells. FASEB J. 24, 769-777 (2010). www.fasebj.org	[Kyprianou, Natasha] Univ Kentucky, Med Ctr, Dept Toxicol, Coll Med, Lexington, KY 40536 USA; [Zhu, Meng-Lei; Kyprianou, Natasha] Univ Kentucky, Coll Med, Dept Urol Surg, Lexington, KY 40536 USA; [Kyprianou, Natasha] Univ Kentucky, Coll Med, Dept Mol Biochem, Lexington, KY 40536 USA	University of Kentucky; University of Kentucky; University of Kentucky	Kyprianou, N (corresponding author), Univ Kentucky, Med Ctr, Dept Toxicol, Coll Med, Combs Res Bldg,Rm 306, Lexington, KY 40536 USA.	nkypr2@uky.edu			U.S. National Institutes of Health [R01 CA107575-06]; NATIONAL CANCER INSTITUTE [R01CA107575] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK083761] Funding Source: NIH RePORTER	U.S. National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))	This work was supported by a U.S. National Institutes of Health R01 CA107575-06 grant (N.K.). The authors acknowledge Dr. Donald Tindall (Mayo Clinic, Rochester, MN, USA) and Dr. Scott Dehm (University of Minnesota, Minneapolis, MN, USA) for the generous gift of the plasmid pCMV5-AR; Dr. Mary Vore (Department of Toxicology, University of Kentucky, Lexington, KY, USA) for useful advice; and Lorie Howard for assistance in the submission of the manuscript.	Alimirah F, 2006, FEBS LETT, V580, P2294, DOI 10.1016/j.febslet.2006.03.041; Balk Steven P, 2008, Nucl Recept Signal, V6, pe001, DOI 10.1621/nrs.06001; Boccon-Gibod L, 2007, BJU INT, V100, P738, DOI 10.1111/j.1464-410X.2007.07053.x; Brabletz T, 2001, P NATL ACAD SCI USA, V98, P10356, DOI 10.1073/pnas.171610498; Bruckheimer EM, 2001, ENDOCRINOLOGY, V142, P2419, DOI 10.1210/en.142.6.2419; Burnstein KL, 2005, J CELL BIOCHEM, V95, P657, DOI 10.1002/jcb.20460; Calderwood DA, 2002, J BIOL CHEM, V277, P21749, DOI 10.1074/jbc.M111996200; Cinar B, 2007, J BIOL CHEM, V282, P29584, DOI 10.1074/jbc.M703310200; Cronauer MV, 2005, INT J ONCOL, V26, P1033; De Marzo AM, 1998, J UROLOGY, V160, P2381, DOI 10.1016/S0022-5347(01)62196-7; Derynck R, 2007, NAT CELL BIOL, V9, P1000, DOI 10.1038/ncb434; Eger A, 2000, J CELL BIOL, V148, P173, DOI 10.1083/jcb.148.1.173; Fuchs IB, 2002, ANTICANCER RES, V22, P3415; Ghosh M, 2004, SCIENCE, V304, P743, DOI 10.1126/science.1094561; GLEAVE ME, 1993, CANCER RES, V53, P5300; Grunert S, 2003, NAT REV MOL CELL BIO, V4, P657, DOI 10.1038/nrm1175; Guo YP, 1999, CANCER RES, V59, P1366; Guo YP, 1998, CELL GROWTH DIFFER, V9, P185; Heinlein CA, 2002, MOL ENDOCRINOL, V16, P2181, DOI 10.1210/me.2002-0070; Horiguchi K, 2009, J BIOL CHEM, V284, P245, DOI 10.1074/jbc.M804777200; Huber MA, 2005, CURR OPIN CELL BIOL, V17, P548, DOI 10.1016/j.ceb.2005.08.001; IMPERATOMCGINLEY J, 1985, ENDOCRINOLOGY, V116, P807, DOI 10.1210/endo-116-2-807; Jemal A, 2008, CA-CANCER J CLIN, V58, P71, DOI 10.3322/CA.2007.0010; Kang HY, 2002, J BIOL CHEM, V277, P43749, DOI 10.1074/jbc.M205603200; Kang HY, 2001, P NATL ACAD SCI USA, V98, P3018, DOI 10.1073/pnas.061305498; Lu X, 2004, NEOPLASIA, V6, P603, DOI 10.1593/neo.04241; Lu-Yao GL, 2008, JAMA-J AM MED ASSOC, V300, P173, DOI 10.1001/jama.300.2.173; Makhsida N, 2005, J UROLOGY, V174, P827, DOI 10.1097/01.ju.0000169490.78443.59; Martinez HD, 2008, J BIOL CHEM, V283, P29938, DOI 10.1074/jbc.M800534200; Massague J, 2008, CELL, V134, P215, DOI 10.1016/j.cell.2008.07.001; Meyer G, 2005, CELL MOL LIFE SCI, V62, P461, DOI 10.1007/s00018-004-4456-6; Mulholland DJ, 2002, J BIOL CHEM, V277, P17933, DOI 10.1074/jbc.M200135200; Nelson WJ, 2004, SCIENCE, V303, P1483, DOI 10.1126/science.1094291; Niu YJ, 2008, P NATL ACAD SCI USA, V105, P12188, DOI 10.1073/pnas.0804701105; Ozdamar B, 2005, SCIENCE, V307, P1603, DOI 10.1126/science.1105718; Peinado H, 2007, NAT REV CANCER, V7, P415, DOI 10.1038/nrc2131; Shahinian VB, 2005, NEW ENGL J MED, V352, P154, DOI 10.1056/NEJMoa041943; SIITERI PK, 1974, J CLIN ENDOCR METAB, V38, P113, DOI 10.1210/jcem-38-1-113; Suzuki H, 2008, INT J CLIN ONCOL, V13, P401, DOI 10.1007/s10147-008-0830-y; Tahmatzopoulos A, 2005, ONCOGENE, V24, P5375, DOI 10.1038/sj.onc.1208684; Tanentzapf G, 2006, NAT CELL BIOL, V8, P601, DOI 10.1038/ncb1411; Thiery JP, 2003, CURR OPIN CELL BIOL, V15, P740, DOI 10.1016/j.ceb.2003.10.006; Thiery JP, 2002, NAT REV CANCER, V2, P442, DOI 10.1038/nrc822; Thiery JP, 2006, NAT REV MOL CELL BIO, V7, P131, DOI 10.1038/nrm1835; Thuault S, 2006, J CELL BIOL, V174, P175, DOI 10.1083/jcb.200512110; Thuault S, 2008, J BIOL CHEM, V283, P33437, DOI 10.1074/jbc.M802016200; Wang G, 2008, CANCER RES, V68, P9918, DOI 10.1158/0008-5472.CAN-08-1718; Warg X, 2007, J CELL BIOCHEM, V102, P571, DOI 10.1002/jcb.21491; Zhau HE, 2008, CLIN EXP METASTAS, V25, P601, DOI 10.1007/s10585-008-9183-1; Zhu ML, 2008, ENDOCR-RELAT CANCER, V15, P841, DOI 10.1677/ERC-08-0084	50	157	164	0	8	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAR	2010	24	3					769	777		10.1096/fj.09-136994	http://dx.doi.org/10.1096/fj.09-136994			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	561KE	19901020	Green Published			2022-12-25	WOS:000274974600013
J	Zhang, Y; Gladyshev, VN				Zhang, Yan; Gladyshev, Vadim N.			General Trends in Trace Element Utilization Revealed by Comparative Genomic Analyses of Co, Cu, Mo, Ni, and Se	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; MOLYBDENUM COFACTOR; COPPER HOMEOSTASIS; EVOLUTIONARY DYNAMICS; NITRATE REDUCTASE; HEAVY-METALS; TRANSPORT; SELENIUM; PROTEIN; ZINC	Trace elements are used by all organisms and provide proteins with unique coordination and catalytic and electron transfer properties. Although many trace element-containing proteins are well characterized, little is known about the general trends in trace element utilization. We carried out comparative genomic analyses of copper, molybdenum, nickel, cobalt (in the form of vitamin B-12), and selenium (in the form of selenocysteine) in 747 sequenced organisms at the following levels: (i) transporters and transport-related proteins, (ii) cofactor biosynthesis traits, and (iii) trace element-dependent proteins. Few organisms were found to utilize all five trace elements, whereas many symbionts, parasites, and yeasts used only one or none of these elements. Investigation of metalloproteomes and selenoproteomes revealed examples of increased utilization of proteins that use copper in land plants, cobalt in Dehalococcoides and Dictyostelium, and selenium in fish and algae, whereas nematodes were found to have great diversity of copper transporters. These analyses also characterized trace element metabolism in common model organisms and suggested new model organisms for experimental studies of individual trace elements. Mismatches in the occurrence of user proteins and corresponding transport systems revealed deficiencies in our understanding of trace element biology. Biological interactions among some trace elements were observed; however, such links were limited, and trace elements generally had unique utilization patterns. Finally, environmental factors, such as oxygen requirement and habitat, correlated with the utilization of certain trace elements. These data provide insights into the general features of utilization and evolution of trace elements in the three domains of life.	[Gladyshev, Vadim N.] Harvard Univ, Sch Med, Brigham & Womens Hosp, Dept Med,Div Genet, Boston, MA 02115 USA	Harvard University; Brigham & Women's Hospital; Harvard Medical School	Gladyshev, VN (corresponding author), Harvard Univ, Sch Med, Brigham & Womens Hosp, Dept Med,Div Genet, New Res Bldg,Rm 435,77 Ave Louis Pasteur, Boston, MA 02115 USA.	vgladyshev@rics.bwh.harvard.edu	Gladyshev, Vadim N/A-9894-2013; Gladyshev, Vadim N/J-6187-2013	Gladyshev, Vadim/0000-0002-0372-7016	National Institutes of Health [GM061603]; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM061603] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	This work was supported, in whole or in part, by National Institutes of Health Grant GM061603 (to V. N. G.).	Ackland ML, 1996, BIOMETALS, V9, P29, DOI 10.1007/BF00188087; ALLEN RM, 1994, CRIT REV BIOTECHNOL, V14, P225, DOI 10.3109/07388554409079834; Altschul SF, 1998, TRENDS BIOCHEM SCI, V23, P444, DOI 10.1016/S0968-0004(98)01298-5; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; Andreini C, 2004, BIOINFORMATICS, V20, P1373, DOI 10.1093/bioinformatics/bth095; Andreini C, 2008, J PROTEOME RES, V7, P209, DOI 10.1021/pr070480u; Annesley SJ, 2009, MOL CELL BIOCHEM, V329, P73, DOI 10.1007/s11010-009-0111-8; Balamurugan K, 2006, BBA-MOL CELL RES, V1763, P737, DOI 10.1016/j.bbamcr.2006.05.001; Barbier GG, 2004, PROTEIN EXPRES PURIF, V37, P61, DOI 10.1016/j.pep.2004.05.021; Barceloux DG, 1999, J TOXICOL-CLIN TOXIC, V37, P201, DOI 10.1081/CLT-100102420; Bartsevich VV, 1996, J BIOL CHEM, V271, P26057, DOI 10.1074/jbc.271.42.26057; Bittner F, 2010, PLANT CELL MONOGR, V17, P119, DOI [10.1016/j.bbamcr.2006.03.013, 10.1007/978-3-642-10613-2_6]; BOCK A, 1991, MOL MICROBIOL, V5, P515, DOI 10.1111/j.1365-2958.1991.tb00722.x; Burke D, 2002, ANIM COGN, V5, P79, DOI 10.1007/s10071-002-0131-1; Calafato S, 2008, TOXICOL SCI, V106, P384, DOI 10.1093/toxsci/kfn180; Chapple CE, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002968; Ciccarelli FD, 2006, SCIENCE, V311, P1283, DOI 10.1126/science.1123061; COLEMAN JE, 1992, ANNU REV BIOCHEM, V61, P897, DOI 10.1146/annurev.bi.61.070192.004341; COOKSEY DA, 1994, FEMS MICROBIOL REV, V14, P381, DOI 10.1016/0168-6445(94)90056-6; DANCIS A, 1994, CELL, V76, P393, DOI 10.1016/0092-8674(94)90345-X; Degen O, 2002, J BACTERIOL, V184, P3569, DOI 10.1128/JB.184.13.3569-3577.2002; Eitinger T, 2000, ARCH MICROBIOL, V173, P1, DOI 10.1007/s002030050001; FELSENSTEIN J, 1989, CLADISTICS, V5, P166; Foster LH, 1997, CRIT REV FOOD SCI, V37, P211, DOI 10.1080/10408399709527773; Frassinetti S, 2006, J ENVIRON PATHOL TOX, V25, P597, DOI 10.1615/JEnvironPatholToxicolOncol.v25.i3.40; Galaris D, 2008, CRIT REV CL LAB SCI, V45, P1, DOI [10.1080/10408360701713104, 10.1080/10408360701713104 ]; Gold B, 2008, NAT CHEM BIOL, V4, P609, DOI 10.1038/nchembio.109; Goldhaber SB, 2003, REGUL TOXICOL PHARM, V38, P232, DOI 10.1016/S0273-2300(02)00020-X; Gonzalez-Guerrero M, 2008, P NATL ACAD SCI USA, V105, P5992, DOI 10.1073/pnas.0711446105; Grass G, 2005, J BACTERIOL, V187, P1604, DOI 10.1128/JB.187.5.1604-1611.2005; Guindon S, 2003, SYST BIOL, V52, P696, DOI 10.1080/10635150390235520; Hadaszadeh BM, 2006, PHYSIOLOGY, V21, P307, DOI 10.1152/physiol.00021.2006; Hatfield DL, 2002, MOL CELL BIOL, V22, P3565, DOI 10.1128/MCB.22.11.3565-3576.2002; HEIDER J, 1993, ADV MICROB PHYSIOL, V35, P71, DOI 10.1016/S0065-2911(08)60097-1; HIPKIN CR, 1993, J GEN MICROBIOL, V139, P473, DOI 10.1099/00221287-139-3-473; HOGSTRAND C, 1991, COMP BIOCHEM PHYS C, V100, P137, DOI 10.1016/0742-8413(91)90140-O; Kim HY, 2009, PROTEINS, V74, P1008, DOI 10.1002/prot.22212; Kobayashi M, 1999, EUR J BIOCHEM, V261, P1, DOI 10.1046/j.1432-1327.1999.00186.x; Kryukov GV, 1999, J BIOL CHEM, V274, P33888, DOI 10.1074/jbc.274.48.33888; Kuper J, 2004, NATURE, V430, P803, DOI 10.1038/nature02681; Li JX, 2005, BIOCHEM BIOPH RES CO, V337, P179, DOI 10.1016/j.bbrc.2005.09.029; Lobanov AV, 2008, GENOME BIOL, V9, DOI 10.1186/gb-2008-9-3-r62; Lobanov AV, 2007, GENOME BIOL, V8, DOI 10.1186/gb-2007-8-9-r198; Maguire Michael E., 2007, V394, P289, DOI 10.1007/978-1-59745-512-1_14; Makui H, 2000, MOL MICROBIOL, V35, P1065, DOI 10.1046/j.1365-2958.2000.01774.x; MAUPLNFURLOW JA, 1995, J BACTERIOL, V177, P4851, DOI 10.1128/jb.177.17.4851-4856.1995; MERTZ W, 1981, SCIENCE, V213, P1332, DOI 10.1126/science.7022654; Mertz W, 1998, BIOL TRACE ELEM RES, V66, P185, DOI 10.1007/BF02783137; Michel H, 1999, BIOCHEMISTRY-US, V38, P15129, DOI 10.1021/bi9910934; Millson SH, 2009, YEAST, V26, P339, DOI 10.1002/yea.1670; Morrison MS, 2007, J BIOL INORG CHEM, V12, P1129, DOI 10.1007/s00775-007-0279-x; Panina EM, 2003, P NATL ACAD SCI USA, V100, P9912, DOI 10.1073/pnas.1733691100; PATIL DS, 1994, METHOD ENZYMOL, V243, P68; Patzer SI, 1998, MOL MICROBIOL, V28, P1199, DOI 10.1046/j.1365-2958.1998.00883.x; Paulsen IT, 1997, FEMS MICROBIOL LETT, V156, P1, DOI 10.1111/j.1574-6968.1997.tb12697.x; Permina EA, 2006, BMC MICROBIOL, V6, DOI 10.1186/1471-2180-6-49; PHUNG LT, 1994, P NATL ACAD SCI USA, V91, P9651, DOI 10.1073/pnas.91.20.9651; Poole K, 2001, J MOL MICROB BIOTECH, V3, P255; Rensing C, 2003, FEMS MICROBIOL REV, V27, P197, DOI 10.1016/S0168-6445(03)00049-4; Ridge PG, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0001378; Rodionov DA, 2006, J BACTERIOL, V188, P317, DOI 10.1128/JB.188.1.317-327.2006; Rodionov DA, 2003, J BIOL CHEM, V278, P41148, DOI 10.1074/jbc.M305837200; Rodionov DA, 2006, PLOS COMPUT BIOL, V2, P1568, DOI 10.1371/journal.pcbi.0020163; Romero H, 2005, GENOME BIOL, V6, DOI 10.1186/gb-2005-6-8-r66; Ronquist F, 2003, BIOINFORMATICS, V19, P1572, DOI 10.1093/bioinformatics/btg180; Schwarz G, 2006, ANNU REV PLANT BIOL, V57, P623, DOI 10.1146/annurev.arplant.57.032905.105437; Solioz M, 2003, FEMS MICROBIOL REV, V27, P183, DOI 10.1016/S0168-6445(03)00053-6; Suliman HS, 2005, ARCH BIOCHEM BIOPHYS, V441, P56, DOI 10.1016/j.abb.2005.06.016; SUMRADA RA, 1982, J BIOL CHEM, V257, P9119; Tatusov RL, 1997, SCIENCE, V278, P631, DOI 10.1126/science.278.5338.631; Tatusov RL, 2000, NUCLEIC ACIDS RES, V28, P33, DOI 10.1093/nar/28.1.33; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; Tottey S, 2002, J BIOL CHEM, V277, P5490, DOI 10.1074/jbc.M105857200; Tottey S, 2001, J BIOL CHEM, V276, P19999, DOI 10.1074/jbc.M011243200; Tseng Tsai-Tien, 1999, Journal of Molecular Microbiology and Biotechnology, V1, P107; Valenzuela L, 2006, BIOTECHNOL ADV, V24, P197, DOI 10.1016/j.biotechadv.2005.09.004; VALLEE BL, 1990, BIOCHEMISTRY-US, V29, P5647, DOI 10.1021/bi00476a001; Van Gossum A, 1998, Curr Opin Clin Nutr Metab Care, V1, P499, DOI 10.1097/00075197-199811000-00004; VULPE CD, 1995, ANNU REV NUTR, V15, P293, DOI 10.1146/annurev.nu.15.070195.001453; Watt RK, 1999, CELL MOL LIFE SCI, V56, P604, DOI 10.1007/s000180050456; Zhang Y, 2005, BIOINFORMATICS, V21, P2580, DOI 10.1093/bioinformatics/bti400; Zhang Y, 2008, PLOS GENET, V4, DOI 10.1371/journal.pgen.1000095; Zhang Y, 2008, J MOL BIOL, V379, P881, DOI 10.1016/j.jmb.2008.03.051; Zhang Y, 2007, NUCLEIC ACIDS RES, V35, P4952, DOI 10.1093/nar/gkm514; Zhang Y, 2006, GENOME BIOL, V7, DOI 10.1186/gb-2006-7-10-r94; Zhang Y, 2009, BMC GENOMICS, V10, DOI 10.1186/1471-2164-10-78	86	87	89	6	61	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 29	2010	285	5					3393	3405		10.1074/jbc.M109.071746	http://dx.doi.org/10.1074/jbc.M109.071746			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	546RR	19887375	Green Published, hybrid			2022-12-25	WOS:000273829000054
J	Miller, SJ; Lan, ZD; Hardiman, A; Wu, J; Kordich, JJ; Patmore, DM; Hegde, RS; Cripe, TP; Cancelas, JA; Collins, MH; Ratner, N				Miller, S. J.; Lan, Z. D.; Hardiman, A.; Wu, J.; Kordich, J. J.; Patmore, D. M.; Hegde, R. S.; Cripe, T. P.; Cancelas, J. A.; Collins, M. H.; Ratner, N.			Inhibition of Eyes Absent Homolog 4 expression induces malignant peripheral nerve sheath tumor necrosis	ONCOGENE			English	Article						EYA4; MPNST; NF1; DACH1; SOX9; Ras	DETERMINATION GENE NETWORK; FATE DETERMINATION FACTOR; NEUROFIBROMATOSIS TYPE-1; SCHWANN-CELLS; SIX1 OVEREXPRESSION; BINDING-PROTEIN; BREAST-CANCER; RAS-GTP; GROWTH; SURVIVAL	Malignant peripheral nerve sheath tumors (MPNSTs) are aggressive sarcomas without effective therapeutics. Bioinformatics was used to identify potential therapeutic targets. Paired Box (PAX), Eyes Absent (EYA), Dachsund (DACH) and Sine Oculis (SIX) genes, which form a regulatory interactive network in Drosophila, were found to be dysregulated in human MPNST cell lines and solid tumors. We identified a decrease in DACH1 expression, and increases in the expressions of PAX6, EYA1, EYA2, EYA4, and SIX1-4 genes. Consistent with the observation that half of MPNSTs develop in neurofibromatosis type 1 (NF1) patients, subsequent to NF1 mutation, we found that exogenous expression of the NF1-GTPase activating protein-related domain normalized DACH1 expression. EYA4 mRNA was elevated more than 100-fold as estimated by quantitative real-time PCR in most MPNST cell lines. In vitro, suppression of EYA4 expression using short hairpin RNA reduced cell adhesion and migration and caused cellular necrosis without affecting cell proliferation or apoptotic cell death. MPNST cells expressing shEYA4 either failed to form tumors in nude mice or formed very small tumors, with extensive necrosis but similar levels of proliferation and apoptosis as control cells. Our findings identify a role of EYA4 and possibly interacting SIX and DACH proteins in MPNSTs and suggest the EYA4 pathway as a rational therapeutic target. Oncogene (2010) 29, 368-379; doi:10.1038/onc.2009.360; published online 9 November 2009	[Miller, S. J.; Lan, Z. D.; Hardiman, A.; Wu, J.; Kordich, J. J.; Patmore, D. M.; Cancelas, J. A.; Ratner, N.] Univ Cincinnati, Cincinnati Childrens Hosp Res Fdn, Div Expt Hematol & Canc Biol, Dept Pediat,Coll Med, Cincinnati, OH 45229 USA; [Hegde, R. S.] Univ Cincinnati, Coll Med, Cincinnati Childrens Hosp Res Fdn, Div Dev Biol,Dept Pediat, Cincinnati, OH 45229 USA; [Cripe, T. P.] Univ Cincinnati, Cincinnati Childrens Hosp Res Fdn, Div Hematol Oncol, Dept Pediat,Coll Med, Cincinnati, OH 45229 USA; [Collins, M. H.] Univ Cincinnati, Cincinnati Childrens Hosp Res Fdn, Div Pathol, Dept Pediat,Coll Med, Cincinnati, OH 45229 USA	Cincinnati Children's Hospital Medical Center; Cincinnati Children's Hospital Research Foundation; University System of Ohio; University of Cincinnati; Cincinnati Children's Hospital Medical Center; Cincinnati Children's Hospital Research Foundation; University System of Ohio; University of Cincinnati; Cincinnati Children's Hospital Medical Center; Cincinnati Children's Hospital Research Foundation; University System of Ohio; University of Cincinnati; Cincinnati Children's Hospital Medical Center; Cincinnati Children's Hospital Research Foundation; University System of Ohio; University of Cincinnati	Ratner, N (corresponding author), Univ Cincinnati, Cincinnati Childrens Hosp Res Fdn, Div Expt Hematol & Canc Biol, Dept Pediat,Coll Med, 3333 Burnet Ave,MLC 7013,Room S7-244, Cincinnati, OH 45229 USA.	nancy.ratner@cchmc.org	Cancelas, Jose/AAR-9324-2020	RATNER, NANCY/0000-0001-5030-9354	DAMD [DOD W81XWH-04-1-0273]; NINDS Translational Neuroscience Award [K01-NS049191-01A1]; NATIONAL EYE INSTITUTE [R01EY014648, R21EY019125] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [K01NS049191, R01NS028840] Funding Source: NIH RePORTER	DAMD; NINDS Translational Neuroscience Award(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))	Viral vectors were produced by the Viral Vector Core at the Translational Core Laboratories, Cincinnati Children's Hospital Research Foundation, Cincinnati, OH, USA. We thank Yonatan Y Mahller for assistance with the xenograft experiments. This study was supported by an award from the DAMD ( DOD W81XWH-04-1-0273) to NR and an NINDS Translational Neuroscience Award K01-NS049191-01A1 to SM.	Abdelhak S, 1997, NAT GENET, V15, P157, DOI 10.1038/ng0297-157; BASU TN, 1992, NATURE, V356, P713, DOI 10.1038/356713a0; Behbakht K, 2007, CANCER RES, V67, P3036, DOI 10.1158/0008-5472.CAN-06-3755; Borsani G, 1999, HUM MOL GENET, V8, P11, DOI 10.1093/hmg/8.1.11; Carli M, 2005, J CLIN ONCOL, V23, P8422, DOI 10.1200/JCO.2005.01.4886; Carroll SL, 2008, GLIA, V56, P1590, DOI 10.1002/glia.20776; Casella CTB, 1996, GLIA, V17, P327, DOI 10.1002/(SICI)1098-1136(199608)17:4<327::AID-GLIA7>3.0.CO;2-W; Christensen KL, 2008, ADV CANCER RES, V101, P93, DOI 10.1016/S0065-230X(08)00405-3; Coletta RD, 2008, CANCER RES, V68, P2204, DOI 10.1158/0008-5472.CAN-07-3141; Cook PJ, 2009, NATURE, V458, P591, DOI 10.1038/nature07849; DAIMARU Y, 1985, AM J SURG PATHOL, V9, P434, DOI 10.1097/00000478-198506000-00005; DECLUE JE, 1992, CELL, V69, P265, DOI 10.1016/0092-8674(92)90407-4; DIVE C, 1992, BIOCHIM BIOPHYS ACTA, V1133, P275, DOI 10.1016/0167-4889(92)90048-G; Evans DGR, 2002, J MED GENET, V39, P311, DOI 10.1136/jmg.39.5.311; Ferner RE, 2002, CANCER RES, V62, P1573; Friedman JM, 1997, AM J MED GENET, V70, P138, DOI 10.1002/(SICI)1096-8628(19970516)70:2<138::AID-AJMG7>3.0.CO;2-U; Ha HC, 1999, P NATL ACAD SCI USA, V96, P13978, DOI 10.1073/pnas.96.24.13978; He TC, 1998, P NATL ACAD SCI USA, V95, P2509, DOI 10.1073/pnas.95.5.2509; Holtkamp N, 2004, BRAIN PATHOL, V14, P258; Hsiao FC, 2001, DEV CELL, V1, P51, DOI 10.1016/S1534-5807(01)00011-9; Ikeda K, 2002, MOL CELL BIOL, V22, P6759, DOI 10.1128/MCB.22.19.6759-6766.2002; Ismat FA, 2006, J CLIN INVEST, V116, P2378, DOI 10.1172/JCI28341; Josephson R, 1998, DEVELOPMENT, V125, P3087; KIM HA, 1995, ONCOGENE, V11, P325; Klose A, 1998, HUM GENET, V102, P367, DOI 10.1007/s004390050706; Klymkowsky MW, 2009, AM J PATHOL, V174, P1588, DOI 10.2353/ajpath.2009.080545; Kobayashi M, 2001, DEV BIOL, V232, P315, DOI 10.1006/dbio.2001.0185; Kroemer G, 2009, CELL DEATH DIFFER, V16, P3, DOI 10.1038/cdd.2008.150; Krysko DV, 2008, METHOD ENZYMOL, V442, P307, DOI [10.1016/S0070-6879(08)01416-X, 10.1016/S0076-6879(08)01416-X]; Leroy K, 2001, ARCH DERMATOL, V137, P908; Li X, 2003, NATURE, V426, P247, DOI 10.1038/nature02083; Mahller YY, 2008, CANCER RES, V68, P1170, DOI 10.1158/0008-5472.CAN-07-2734; Mahller YY, 2007, MOL THER, V15, P279, DOI 10.1038/sj.mt.6300038; Mahller YY, 2006, PEDIATR BLOOD CANCER, V46, P745, DOI 10.1002/pbc.20565; Maris JM, 1997, CANCER-AM CANCER SOC, V79, P1438, DOI 10.1002/(SICI)1097-0142(19970401)79:7<1438::AID-CNCR22>3.3.CO;2-A; MCCONNELL JD, 1995, BRIT J UROL, V76, P5; Miller SJ, 2009, EMBO MOL MED, V1, P236, DOI 10.1002/emmm.200900027; Miller SJ, 2006, CANCER RES, V66, P2584, DOI 10.1158/0008-5472.CAN-05-3330; Muratovska A, 2003, ONCOGENE, V22, P7989, DOI 10.1038/sj.onc.1206766; Ng KT, 2006, BRIT J CANCER, V95, P1050, DOI 10.1038/sj.bjc.6603399; ONEILL EM, 1994, CELL, V78, P137, DOI 10.1016/0092-8674(94)90580-0; Osborn NK, 2006, CLIN GASTROENTEROL H, V4, P212, DOI 10.1016/j.cgh.2005.11.009; Ramdas L, 2001, GENOME BIOL, V2; Rasmussen SA, 2000, AM J EPIDEMIOL, V151, P33, DOI 10.1093/oxfordjournals.aje.a010118; Rayapureddi JP, 2003, NATURE, V426, P295, DOI 10.1038/nature02093; Reichenberger KJ, 2005, CANCER RES, V65, P2668, DOI 10.1158/0008-5472.CAN-04-4286; Serra E, 2000, HUM MOL GENET, V9, P3055, DOI 10.1093/hmg/9.20.3055; Sherman LS, 2000, J BIOL CHEM, V275, P30740, DOI 10.1074/jbc.M001702200; Silver SJ, 2003, MOL CELL BIOL, V23, P5989, DOI 10.1128/MCB.23.17.5989-5999.2003; Silver SJ, 2005, DEVELOPMENT, V132, P3, DOI 10.1242/dev.01539; Tootle TL, 2003, NATURE, V426, P299, DOI 10.1038/nature02097; Viskochil David, 1992, Journal of Dermatology (Tokyo), V19, P873; Vogel KS, 1999, SCIENCE, V286, P2176, DOI 10.1126/science.286.5447.2176; Waring P, 1999, CELL DEATH DIFFER, V6, P624, DOI 10.1038/sj.cdd.4400540; Watson MA, 2004, BRAIN PATHOL, V14, P297; WESTON KM, 1994, CYTOMETRY, V15, P141, DOI 10.1002/cyto.990150207; Wu KM, 2008, P NATL ACAD SCI USA, V105, P6924, DOI 10.1073/pnas.0802085105; Wu KM, 2006, MOL CELL BIOL, V26, P7116, DOI 10.1128/MCB.00268-06; Wu KM, 2009, CANCER RES, V69, P3347, DOI 10.1158/0008-5472.CAN-08-3821; Xu LZ, 1996, J BIOL CHEM, V271, P24711; Zhu CQC, 2002, DEVELOPMENT, V129, P2835; Zou HZ, 2005, CANCER EPIDEM BIOMAR, V14, P830, DOI 10.1158/1055-9965.EPI-04-0506	62	58	62	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 21	2010	29	3					368	379		10.1038/onc.2009.360	http://dx.doi.org/10.1038/onc.2009.360			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	546EO	19901965	Green Accepted			2022-12-25	WOS:000273793200006
J	Sugiura, N; Baba, Y; Kawaguchi, Y; Iwatani, T; Suzuki, K; Kusakabe, T; Yamagishi, K; Kimata, K; Kakuta, Y; Watanabe, H				Sugiura, Nobuo; Baba, Yuichi; Kawaguchi, Yoshirou; Iwatani, Toru; Suzuki, Kiyoshi; Kusakabe, Takahiro; Yamagishi, Kiwamu; Kimata, Koji; Kakuta, Yoshimitsu; Watanabe, Hideto			Glucuronyltransferase Activity of KfiC from Escherichia coli Strain K5 Requires Association of KfiA KfiC AND KfiA ARE ESSENTIAL ENZYMES FOR PRODUCTION OF K5 POLYSACCHARIDE, N-ACETYLHEPAROSAN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEPARAN-SULFATE PROTEOGLYCANS; CAPSULE GENE-CLUSTER; CHONDROITIN POLYMERASE; HYALURONAN SYNTHASES; HEPAROSAN SYNTHASE; BINDING SITES; POLYSACCHARIDE; BIOSYNTHESIS; GLYCOSYLTRANSFERASES; IDENTIFICATION	Heparan sulfate is a ubiquitous glycosaminoglycan in the extracellular matrix of most animals. It interacts with various molecules and exhibits important biological functions. K5 antigen produced by Escherichia coli strain K5 is a linear polysaccharide N-acetylheparosan consisting of GlcUA beta 1-4 and GlcNAc beta 1-4 repeating disaccharide, which forms the backbone of heparan sulfate. Region 2, located in the center of the K5-specific gene cluster, encodes four proteins, KfiA, KfiB, KfiC, and KfiD, for the biosynthesis of the K5 polysaccharide. Here, we expressed and purified the recombinant KfiA and KfiC proteins and then characterized these enzymes. Whereas the recombinant KfiC alone exhibited no GlcUA transferase activity, it did exhibit GlcUA transferase and polymerization activities in the presence of KfiA. In contrast, KfiA had GlcNAc transferase activity itself, which was unaffected by the presence of KfiC. The GlcNAc and GlcUA transferase activities were analyzed with various truncated and point mutants of KfiA and KfiC. The point mutants replacing aspartic acid of a DXD motif and lysine and glutamic acid of an ionic amino acid cluster, and the truncated mutants deleting the C-terminal and N-terminal sites, revealed the essential regions for GlcNAc and GlcUA transferase activity of KfiC and KfiA, respectively. The interaction of KfiC with KfiA is necessary for the GlcUA transferase activity of KfiC but not for the enzyme activity of KfiA. Together, these results indicate that the complex of KfiA and KfiC has polymerase activity to synthesize N-acetylheparosan, providing a useful tool toward bioengineering of defined heparan sulfate chains.	[Sugiura, Nobuo; Watanabe, Hideto] Aichi Med Univ, Inst Mol Sci Med, Aichi 4801195, Japan; [Baba, Yuichi; Kawaguchi, Yoshirou; Iwatani, Toru; Kakuta, Yoshimitsu] Kyushu Univ, Struct Biol Lab, Grad Sch Syst Life Sci, Higashi Ku, Fukuoka 8128581, Japan; [Kakuta, Yoshimitsu] Kyushu Univ, Biochem Lab, Dept Biosci & Biotechnol, Grad Sch,Fac Agr,Higashi Ku, Fukuoka 8128581, Japan; [Kusakabe, Takahiro] Kyushu Univ, Lab Silkworm Sci, Grad Sch Bioresource & Bioenvironm Sci, Higashi Ku, Fukuoka 8128581, Japan; [Suzuki, Kiyoshi; Yamagishi, Kiwamu] Seikagaku Corp, Cent Res Labs, Higashiyamato, Tokyo 2070021, Japan	Aichi Medical University; Kyushu University; Kyushu University; Kyushu University; Seikagaku Corporation	Sugiura, N (corresponding author), Aichi Med Univ, Inst Mol Sci Med, Aichi 4801195, Japan.	nsugiura@aichi-med-u.ac.jp; kakuta@agr.kyushu-u.ac.jp		Baba, Yuichi/0000-0002-6795-535X; Watanabe, Hideto/0000-0001-5291-0696; Kawaguchi, Yoshirou/0000-0003-0171-6476	New Energy and Industrial Technology Development Organization; Ministry of Education, Science, Sports and Culture	New Energy and Industrial Technology Development Organization(New Energy and Industrial Technology Development Organization (NEDO)); Ministry of Education, Science, Sports and Culture(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT))	This work was supported in part by the New Energy and Industrial Technology Development Organization and by the Ministry of Education, Science, Sports and Culture grant-in-aid (to Y. K., N. S., and H. W.).	Bernfield M, 1999, ANNU REV BIOCHEM, V68, P729, DOI 10.1146/annurev.biochem.68.1.729; Bishop JR, 2007, NATURE, V446, P1030, DOI 10.1038/nature05817; BITTER T, 1962, ANAL BIOCHEM, V4, P330, DOI 10.1016/0003-2697(62)90095-7; Boeggeman E, 2002, GLYCOBIOLOGY, V12, P395, DOI 10.1093/glycob/cwf045; Busse M, 2007, J BIOL CHEM, V282, P32802, DOI 10.1074/jbc.M703560200; Chen M, 2006, BIOCHEMISTRY-US, V45, P12358, DOI 10.1021/bi060844g; DeAngelis PL, 2004, J BACTERIOL, V186, P8529, DOI 10.1128/JB.186.24.8529-8532.2004; DeAngelis PL, 2002, GLYCOBIOLOGY, V12, p9R, DOI 10.1093/glycob/12.1.9R; Esko JD, 2002, ANNU REV BIOCHEM, V71, P435, DOI 10.1146/annurev.biochem.71.110601.135458; FINKE A, 1991, J BACTERIOL, V173, P4088, DOI 10.1128/jb.173.13.4088-4094.1991; Griffiths G, 1998, J BIOL CHEM, V273, P11752, DOI 10.1074/jbc.273.19.11752; Habuchi H, 2004, GLYCOCONJUGATE J, V21, P47, DOI 10.1023/B:GLYC.0000043747.87325.5e; Hodson N, 2000, J BIOL CHEM, V275, P27311; Itano N, 1999, J BIOL CHEM, V274, P25085, DOI 10.1074/jbc.274.35.25085; Izumikawa T, 2007, BIOCHEM J, V403, P545, DOI 10.1042/BJ20061876; Kane TA, 2006, J BIOL CHEM, V281, P33192, DOI 10.1074/jbc.M606897200; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lairson LL, 2008, ANNU REV BIOCHEM, V77, P521, DOI 10.1146/annurev.biochem.76.061005.092322; Lind T, 1998, J BIOL CHEM, V273, P26265, DOI 10.1074/jbc.273.41.26265; Minamisawa T, 2006, CARBOHYD RES, V341, P230, DOI 10.1016/J.CARRES.2005.11.013; Minamisawa T, 2006, RAPID COMMUN MASS SP, V20, P267, DOI 10.1002/rcm.2310; Ninomiya T, 2002, J BIOL CHEM, V277, P21567, DOI 10.1074/jbc.M201719200; Osawa T, 2009, BIOCHEM BIOPH RES CO, V378, P10, DOI 10.1016/j.bbrc.2008.08.121; PETIT C, 1995, MOL MICROBIOL, V17, P611, DOI 10.1111/j.1365-2958.1995.mmi_17040611.x; Rigg GP, 1998, MICROBIOL-SGM, V144, P2905, DOI 10.1099/00221287-144-10-2905; Roman E, 2003, BIOCHEM J, V374, P767, DOI 10.1042/BJ20030365; Sakai K, 2007, J BIOL CHEM, V282, P4152, DOI 10.1074/jbc.M606870200; Sobhany M, 2008, J BIOL CHEM, V283, P32328, DOI 10.1074/jbc.M804332200; Sugiura N, 2007, ANAL BIOCHEM, V365, P62, DOI 10.1016/j.ab.2007.02.023; VANN WF, 1981, EUR J BIOCHEM, V116, P359, DOI 10.1111/j.1432-1033.1981.tb05343.x; Weigel PH, 2007, J BIOL CHEM, V282, P36777, DOI 10.1074/jbc.R700036200; Whitfield C, 1999, MOL MICROBIOL, V31, P1307, DOI 10.1046/j.1365-2958.1999.01276.x	32	23	26	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 15	2010	285	3					1597	1606		10.1074/jbc.M109.023002	http://dx.doi.org/10.1074/jbc.M109.023002			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	541PJ	19915003	hybrid, Green Published			2022-12-25	WOS:000273429100005
J	Couturier, J; Morel, M; Pontcharraud, R; Gontier, V; Fauconneau, B; Paccalin, M; Page, G				Couturier, Julien; Morel, Milena; Pontcharraud, Raymond; Gontier, Virginie; Fauconneau, Bernard; Paccalin, Marc; Page, Guylene			Interaction of Double-stranded RNA-dependent Protein Kinase (PKR) with the Death Receptor Signaling Pathway in Amyloid beta (A beta)-treated Cells and in APP(SL)PS1 Knock-in Mice	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; EUKARYOTIC INITIATION FACTOR-2-ALPHA; ALZHEIMERS-DISEASE; NEURONAL DEGENERATION; NUCLEAR-LOCALIZATION; INDUCED APOPTOSIS; MOUSE MODEL; ACTIVATION; FAS; PHOSPHORYLATION	For 10 years, research has focused on signaling pathways controlling translation to explain neuronal death in Alzheimer Disease (AD). Previous studies demonstrated in different cellular and animal models and AD patients that translation is down-regulated by the activation of double-stranded RNA-dependent protein kinase (PKR). Among downstream factors of PKR, the Fas-associated protein with a death domain (FADD) and subsequent activated caspase-8 are responsible for PKR-induced apoptosis in recombinant virus-infected cells. However, no studies have reported the role of PKR in death receptor signaling in AD. The aim of this project is to determine physical and functional interactions of PKR with FADD in amyloid-beta peptide (A beta) neurotoxicity and in APP(SL)PS1 KI transgenic mice. In SH-SY5Y cells, results showed that A beta 42 induced a large increase in phosphorylated PKR and FADD levels and a physical interaction between PKR and FADD in the nucleus, also observed in the cortex of APP(SL)PS1 KI mice. However, PKR gene silencing or treatment with a specific PKR inhibitor significantly prevented the increase in pT(451)-PKR and pS(194)-FADD levels in SH-SY5Y nuclei and completely inhibited activities of caspase-3 and -8. The contribution of PKR in neurodegeneration through the death receptor signaling pathway may support the development of therapeutics targeting PKR to limit neuronal death in AD.	[Couturier, Julien; Morel, Milena; Pontcharraud, Raymond; Gontier, Virginie; Fauconneau, Bernard; Paccalin, Marc; Page, Guylene] Univ Poitiers, Res Grp Brain Aging, GReViC EA 3808, F-86034 Poitiers, France; [Paccalin, Marc] Univ Poitiers Hosp, Dept Geriatr, F-86021 Poitiers, France; [Paccalin, Marc] Univ Poitiers Hosp, Clin Invest Ctr, CIC INSERM 802, F-86021 Poitiers, France	Universite de Poitiers; CHU Poitiers; Universite de Poitiers; CHU Poitiers; Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Poitiers	Page, G (corresponding author), Univ Poitiers, Res Grp Brain Aging, GReViC EA 3808, 6 Rue Miletrie,BP 199, F-86034 Poitiers, France.	guylene.page@univ-poitiers.fr			Association Internationale pour la Recherche sur la Maladie d'Alzheimer (AIRMA); Association France Alzheimer	Association Internationale pour la Recherche sur la Maladie d'Alzheimer (AIRMA); Association France Alzheimer	This work was supported by grants from the Association Internationale pour la Recherche sur la Maladie d'Alzheimer (AIRMA) and Association France Alzheimer.	Balachandran S, 1998, EMBO J, V17, P6888, DOI 10.1093/emboj/17.23.6888; BARRIER L, 2008, NEUROBIOL A IN PRESS; Bayer TA, 2008, NEURODEGENER DIS, V5, P140, DOI 10.1159/000113684; Bennett RL, 2004, J BIOL CHEM, V279, P42687, DOI 10.1074/jbc.M403321200; Buggia-Prevot V, 2008, J BIOL CHEM, V283, P10037, DOI 10.1074/jbc.M706579200; Cantarella G, 2003, CELL DEATH DIFFER, V10, P134, DOI 10.1038/sj.cdd.4401143; Casas C, 2004, AM J PATHOL, V165, P1289, DOI 10.1016/S0002-9440(10)63388-3; Chang RCC, 2002, NEUROREPORT, V13, P2429, DOI 10.1097/00001756-200212200-00011; Chang RCC, 2002, J NEUROCHEM, V83, P1215, DOI 10.1046/j.1471-4159.2002.01237.x; Checler F, 2007, CURR ALZHEIMER RES, V4, P423, DOI 10.2174/156720507781788945; Chen GA, 2005, P NATL ACAD SCI USA, V102, P12507, DOI 10.1073/pnas.0500397102; Chiba T, 2009, MOL PSYCHIATR, V14, P206, DOI 10.1038/mp.2008.105; Christensen KD, 2008, GENET MED, V10, P207, DOI 10.1097/GIM.0b013e318164e4cf; Cuddihy AR, 1999, ONCOGENE, V18, P2690, DOI 10.1038/sj.onc.1202620; DAMJANAC M, 2009, J CELL MOL IN PRESS; Damjanac M, 2008, NEUROBIOL DIS, V29, P354, DOI 10.1016/j.nbd.2007.09.008; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; Engidawork E, 2001, BIOCHEM BIOPH RES CO, V281, P84, DOI 10.1006/bbrc.2001.4306; Garcia MA, 2006, MICROBIOL MOL BIOL R, V70, P1032, DOI 10.1128/MMBR.00027-06; GARCIABUSTOS J, 1991, BIOCHIM BIOPHYS ACTA, V1071, P83, DOI 10.1016/0304-4157(91)90013-M; Gil J, 2000, ONCOGENE, V19, P1369, DOI 10.1038/sj.onc.1203448; Gil J, 2000, ONCOGENE, V19, P3665, DOI 10.1038/sj.onc.1203710; Goh KC, 2000, EMBO J, V19, P4292, DOI 10.1093/emboj/19.16.4292; Gomez-Angelats M, 2003, CELL DEATH DIFFER, V10, P791, DOI 10.1038/sj.cdd.4401237; Guerra S, 2006, J BIOL CHEM, V281, P18734, DOI 10.1074/jbc.M511983200; Ivins KJ, 1999, NEUROBIOL DIS, V6, P440, DOI 10.1006/nbdi.1999.0268; Jammi NV, 2003, BIOCHEM BIOPH RES CO, V308, P50, DOI 10.1016/S0006-291X(03)01318-4; JEFFREY IW, 1995, EXP CELL RES, V218, P17, DOI 10.1006/excr.1995.1126; Kalai M, 2007, CELL DEATH DIFFER, V14, P1050, DOI 10.1038/sj.cdd.4402110; Lafay-Chebassier C, 2005, J NEUROCHEM, V94, P215, DOI 10.1111/j.1471-4159.2005.03187.x; NAGATA S, 1995, SCIENCE, V267, P1449, DOI 10.1126/science.7533326; NISHIMURA T, 1995, BRAIN RES, V695, P137, DOI 10.1016/0006-8993(95)00699-Q; Onuki R, 2004, EMBO J, V23, P959, DOI 10.1038/sj.emboj.7600049; Paccalin M, 2006, DEMENT GERIATR COGN, V22, P320, DOI 10.1159/000095562; Page G, 2006, NEUROSCIENCE, V139, P1343, DOI 10.1016/j.neuroscience.2006.01.047; Patel RC, 1998, EMBO J, V17, P4379, DOI 10.1093/emboj/17.15.4379; Peel AL, 2004, J NEUROPATH EXP NEUR, V63, P97, DOI 10.1093/jnen/63.2.97; Peel AL, 2003, NEUROBIOL DIS, V14, P52, DOI 10.1016/S0969-9961(03)00086-X; Pei JJ, 2008, J CELL MOL MED, V12, P2525, DOI 10.1111/j.1582-4934.2008.00509.x; Ramana CV, 2000, EMBO J, V19, P263, DOI 10.1093/emboj/19.2.263; Romano PR, 1998, MOL CELL BIOL, V18, P2282, DOI 10.1128/MCB.18.4.2282; Scaffidi C, 2000, J IMMUNOL, V164, P1236, DOI 10.4049/jimmunol.164.3.1236; Screaton RA, 2003, P NATL ACAD SCI USA, V100, P5211, DOI 10.1073/pnas.0431215100; SIMMONS LK, 1994, MOL PHARMACOL, V45, P373; Stegh AH, 1998, EMBO J, V17, P5974, DOI 10.1093/emboj/17.20.5974; Su JH, 2003, NEUROBIOL DIS, V12, P182, DOI 10.1016/S0969-9961(02)00019-0; Suen KC, 2003, J BIOL CHEM, V278, P49819, DOI 10.1074/jbc.M306503200; Uberti D, 2008, NEURODEGENER DIS, V5, P209, DOI 10.1159/000113704; Wu CK, 2005, EXP NEUROL, V195, P484, DOI 10.1016/j.expneurol.2005.06.020; Zheng LX, 2001, J BIOL CHEM, V276, P31945, DOI 10.1074/jbc.M102799200; Zhu XW, 2002, NEUROSIGNALS, V11, P270, DOI 10.1159/000067426	51	38	41	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 8	2010	285	2					1272	1282		10.1074/jbc.M109.041954	http://dx.doi.org/10.1074/jbc.M109.041954			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	539MH	19889624	Green Published, hybrid			2022-12-25	WOS:000273258200049
J	Edwards, J; Cole, LJ; Green, JB; Thomson, MJ; Wood, AJ; Whittingham, JL; Moir, JWB				Edwards, James; Cole, Lindsay J.; Green, Jasper B.; Thomson, Melanie J.; Wood, A. Jamie; Whittingham, Jean L.; Moir, James W. B.			Binding to DNA Protects Neisseria meningitidis Fumarate and Nitrate Reductase Regulator (FNR) from Oxygen	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NITRIC-OXIDE; BIOPHYSICAL CHARACTERIZATION; ESCHERICHIA-COLI; 4FE-4S CLUSTER; IN-VITRO; GENES; CONVERSION; REPRESSOR; SULFIDE; IRON	Here, we report the overexpression, purification, and characterization of the transcriptional activator fumarate and nitrate reductase regulator from the pathogenic bacterium Neisseria meningitidis (NmFNR). Like its homologue from Escherichia coli (EcFNR), NmFNR binds a 4Fe-4S cluster, which breaks down in the presence of oxygen to a 2Fe-2S cluster and subsequently to apo-FNR. The kinetics of NmFNR cluster disassembly in the presence of oxygen are 2-3x slower than those previously reported for wild-type EcFNR, but similar to constitutively active EcFNR* mutants, consistent with earlier work in which we reported that the activity of FNR-dependent promoters in N. meningitidis is only weakly inhibited by the presence of oxygen (Rock, J. D., Thomson, M. J., Read, R. C., and Moir, J. W. (2007) J. Bacteriol. 189, 1138-1144). NmFNR binds to DNA containing a consensus FNR box sequence, and this binding stabilizes the iron-sulfur cluster in the presence of oxygen. Partial degradation of the 4Fe-4S cluster to a 3Fe-4S occurs, and this form remains bound to the DNA. The 3Fe-4S cluster is converted spontaneously back to a 4Fe-4S cluster under subsequent anaerobic reducing conditions in the presence of ferrous iron. The finding that binding to DNA stabilizes FNR in the presence of oxygen such that it has a half-life of similar to 30 min on the DNA has implications for our appreciation of how oxygen switches off FNR activatable genes in vivo.	[Moir, James W. B.] Univ York, Dept Biol, Area 10, York YO10 5YW, N Yorkshire, England; [Whittingham, Jean L.] Univ York, York Struct Biol Lab, Dept Chem, York YO10 5YW, N Yorkshire, England; [Wood, A. Jamie] Univ York, York Ctr Complex Syst Anal, York YO10 5YW, N Yorkshire, England	University of York - UK; University of York - UK; University of York - UK	Moir, JWB (corresponding author), Univ York, Dept Biol, Area 10, York YO10 5YW, N Yorkshire, England.	jm46@york.ac.uk		Wood, Andrew James/0000-0002-6119-852X; Moir, James/0000-0003-2972-5235	Biotechnology and Biological Sciences Research Council [BB/F000952/1]; BBSRC [BB/F000952/1] Funding Source: UKRI	Biotechnology and Biological Sciences Research Council(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC)); BBSRC(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC))	This work was supported by Biotechnology and Biological Sciences Research Council Grant BB/F000952/1 (to J. W. B. M.).	Bartolini E, 2006, MOL MICROBIOL, V60, P963, DOI 10.1111/j.1365-2958.2006.05163.x; Bonsor D, 2006, ORG BIOMOL CHEM, V4, P1252, DOI 10.1039/b517338h; Brook I, 2003, INT J PEDIATR OTORHI, V67, P1047, DOI 10.1016/S0165-5876(03)00203-9; BRUMBY PE, 1965, J BIOL CHEM, V240, P2222; CONDON C, 1985, J BIOL CHEM, V260, P9427; Crack J, 2004, J BIOL CHEM, V279, P9278, DOI 10.1074/jbc.M309878200; Crack JC, 2006, J BIOL CHEM, V281, P18909, DOI 10.1074/jbc.C600042200; Delany I, 2004, MOL MICROBIOL, V52, P1081, DOI 10.1111/j.1365-2958.2004.04030.x; Gao-Sheridan HS, 1998, J BIOL CHEM, V273, P33692, DOI 10.1074/jbc.273.50.33692; Gorodetsky AA, 2008, P NATL ACAD SCI USA, V105, P3684, DOI 10.1073/pnas.0800093105; Green J, 1996, BIOCHEM J, V316, P887, DOI 10.1042/bj3160887; Heurlier K, 2008, J BACTERIOL, V190, P2488, DOI 10.1128/JB.01869-07; Jervis AJ, 2009, P NATL ACAD SCI USA, V106, P4659, DOI 10.1073/pnas.0804943106; Khoroshilova N, 1997, P NATL ACAD SCI USA, V94, P6087, DOI 10.1073/pnas.94.12.6087; Kiley PJ, 2003, CURR OPIN MICROBIOL, V6, P181, DOI 10.1016/S1369-5274(03)00039-0; Liu A, 2000, J BIOL CHEM, V275, P12367, DOI 10.1074/jbc.275.17.12367; MCGUINNESS BT, 1991, LANCET, V337, P514, DOI 10.1016/0140-6736(91)91297-8; McLean KJ, 2006, BIOCHEMISTRY-US, V45, P8427, DOI 10.1021/bi0601609; MELVILLE SB, 1990, J BIOL CHEM, V265, P18733; Moir JWB, 1996, BIOCHEM J, V319, P823, DOI 10.1042/bj3190823; Moore LJ, 2001, J BIOL CHEM, V276, P45744, DOI 10.1074/jbc.M106569200; Petoukhov MV, 2003, J BIOL CHEM, V278, P29933, DOI 10.1074/jbc.M304147200; Rock JD, 2005, MOL MICROBIOL, V58, P800, DOI 10.1111/j.1365-2958.2005.04866.x; Rock JD, 2007, J BACTERIOL, V189, P1138, DOI 10.1128/JB.01368-06; Sawers G, 1999, CURR OPIN MICROBIOL, V2, P181, DOI 10.1016/S1369-5274(99)80032-0; SHARROCKS AD, 1990, FEBS LETT, V270, P119, DOI 10.1016/0014-5793(90)81248-M; SPIRO S, 1990, FEMS MICROBIOL LETT, V75, P399, DOI 10.1016/0378-1097(90)90690-R; Studier FW, 2005, PROTEIN EXPRES PURIF, V41, P207, DOI 10.1016/j.pep.2005.01.016; Sutton VR, 2004, J BACTERIOL, V186, P8018, DOI 10.1128/JB.186.23.8018-8025.2004; van Deuren M, 2000, CLIN MICROBIOL REV, V13, P144, DOI 10.1128/CMR.13.1.144-166.2000; Yazdankhah SP, 2004, J MED MICROBIOL, V53, P821, DOI 10.1099/jmm.0.45529-0	31	23	24	1	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 8	2010	285	2					1105	1112		10.1074/jbc.M109.057810	http://dx.doi.org/10.1074/jbc.M109.057810			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	539MH	19917602	Green Published, hybrid			2022-12-25	WOS:000273258200032
J	Xu, GF; Tan, XJ; Wang, HM; Sun, WJ; Shi, Y; Burlingame, S; Gu, X; Cao, GW; Zhang, T; Qin, J; Yang, JH				Xu, Gufeng; Tan, Xiaojie; Wang, Hongmei; Sun, Wenjing; Shi, Yi; Burlingame, Susan; Gu, Xue; Cao, Guangwen; Zhang, Ting; Qin, Jun; Yang, Jianhua			Ubiquitin-specific Peptidase 21 Inhibits Tumor Necrosis Factor alpha-induced Nuclear Factor kappa B Activation via Binding to and Deubiquitinating Receptor-interacting Protein 1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EDITING ENZYME A20; TRANSCRIPTION FACTOR; KINASE COMPLEX; IKK-BETA; INTERLEUKIN-6 GENE; PHOSPHORYLATION; NEMO; DEUBIQUITYLATION; IDENTIFICATION; SUBUNIT	Ubiquitination and deubiquitination of receptor-interacting protein 1 (RIP1) play an important role in the positive and negative regulation of the tumor necrosis factor alpha (TNF alpha)-induced nuclear factor kappa B (NF-kappa B) activation. Using a combination of functional genomic and proteomic approaches, we have identified ubiquitin-specific peptidase 21 (USP21) as a deubiquitinase for RIP1. USP21 is constitutively associated with RIP1 and deubiquitinates RIP1 in vitro and in vivo. Notably, knockdown of USP21 in HeLa cells enhances TNF alpha-induced RIP1 ubiquitination, I kappa B kinase beta (IKK beta), and NF-kappa B phosphorylation, inhibitor of NF-kappa B alpha (I kappa B alpha) phosphorylation and ubiquitination, as well as NF-kappa B-dependent gene expression. Therefore, our results demonstrate that USP21 plays an important role in the down-regulation of TNF alpha-induced NF-kappa B activation through deubiquitinating RIP1.	[Xu, Gufeng; Tan, Xiaojie; Wang, Hongmei; Sun, Wenjing; Burlingame, Susan; Gu, Xue; Yang, Jianhua] Baylor Coll Med, Texas Childrens Canc Ctr, Dept Pediat, Dan L Duncan Canc Ctr, Houston, TX 77030 USA; [Shi, Yi; Qin, Jun] Baylor Coll Med, Ctr Mol Discovery, Verna & Marrs McLean Dept Biochem & Mol Biol, Dept Mol & Cellular Biol, Houston, TX 77030 USA; [Tan, Xiaojie; Cao, Guangwen] Second Mil Med Univ, Dept Epidemiol, Shanghai 200433, Peoples R China; [Gu, Xue; Zhang, Ting] Capital Inst Pediat, Beijing 100020, Peoples R China	Baylor College of Medicine; Texas Children's Cancer Center; Baylor College of Medicine; Naval Medical University; Capital Institute of Pediatrics (CIP)	Yang, JH (corresponding author), Baylor Coll Med, Texas Childrens Canc Ctr, Dept Pediat, Dan L Duncan Canc Ctr, 1 Baylor Plaza, Houston, TX 77030 USA.	jianhuay@bcm.edu	tan, xiao/GZL-0264-2022	Wang, Hongmei/0000-0002-5881-2488	National Institutes of Health [1R21CA106513-01A2]; American Cancer Society [RSG06- 070-01-TBE]; National Basic Research Program of China [2007CB511900]; NATIONAL CANCER INSTITUTE [R21CA106513] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK079638] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); American Cancer Society(American Cancer Society); National Basic Research Program of China(National Basic Research Program of China); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))	This work was supported, in whole or in part, by National Institutes of Health Grant 1R21CA106513-01A2 (to J.Y.), American Cancer Society Grant RSG06- 070-01-TBE (to J.Y.), and National Basic Research Program of China Grant 2007CB511900 (to T.Z.).	Ashkenazi A, 1998, SCIENCE, V281, P1305, DOI 10.1126/science.281.5381.1305; Baldwin AS, 1996, ANNU REV IMMUNOL, V14, P649, DOI 10.1146/annurev.immunol.14.1.649; Baud V, 2001, TRENDS CELL BIOL, V11, P372, DOI 10.1016/S0962-8924(01)02064-5; BEG AA, 1993, GENE DEV, V7, P2064, DOI 10.1101/gad.7.11.2064; Brummelkamp TR, 2003, NATURE, V424, P797, DOI 10.1038/nature01811; Chen GQ, 2002, SCIENCE, V296, P1634, DOI 10.1126/science.1071924; Chen ZJJ, 2005, NAT CELL BIOL, V7, P758, DOI 10.1038/ncb0805-758; Coornaert B, 2009, J BIOL CHEM, V284, P8217, DOI 10.1074/jbc.R800032200; Delhase M, 1999, SCIENCE, V284, P309, DOI 10.1126/science.284.5412.309; DiDonato JA, 1997, NATURE, V388, P548, DOI 10.1038/41493; Ea CK, 2006, MOL CELL, V22, P245, DOI 10.1016/j.molcel.2006.03.026; Enesa K, 2008, J BIOL CHEM, V283, P7036, DOI 10.1074/jbc.M708690200; Ghosh S, 2002, CELL, V109, pS81, DOI 10.1016/S0092-8674(02)00703-1; Gong LM, 2000, J BIOL CHEM, V275, P14212, DOI 10.1074/jbc.275.19.14212; Hershko A, 1998, ANNU REV BIOCHEM, V67, P425, DOI 10.1146/annurev.biochem.67.1.425; Hsu HL, 1996, IMMUNITY, V4, P387, DOI 10.1016/S1074-7613(00)80252-6; Jacque E, 2009, EMBO J, V28, P455, DOI 10.1038/emboj.2009.18; Lee EG, 2000, SCIENCE, V289, P2350, DOI 10.1126/science.289.5488.2350; LIBERMANN TA, 1990, MOL CELL BIOL, V10, P2327, DOI 10.1128/MCB.10.5.2327; Mercurio F, 1997, SCIENCE, V278, P860, DOI 10.1126/science.278.5339.860; Mu JJ, 2007, J BIOL CHEM, V282, P17330, DOI 10.1074/jbc.C700079200; Nakagawa T, 2008, GENE DEV, V22, P37, DOI 10.1101/gad.1609708; Nijman SMB, 2005, CELL, V123, P773, DOI 10.1016/j.cell.2005.11.007; O'Neill LAJ, 2009, J BIOL CHEM, V284, P8209, DOI 10.1074/jbc.R800070200; Regnier CH, 1997, CELL, V90, P373, DOI 10.1016/S0092-8674(00)80344-X; ROTHE M, 1994, CELL, V78, P681, DOI 10.1016/0092-8674(94)90532-0; Rothwarf DM, 1998, NATURE, V395, P297, DOI 10.1038/26261; Schweitzer K, 2007, EMBO J, V26, P1532, DOI 10.1038/sj.emboj.7601600; Shembade N, 2008, NAT IMMUNOL, V9, P254, DOI 10.1038/ni1563; Shembade N, 2009, EMBO J, V28, P513, DOI 10.1038/emboj.2008.285; SHIMIZU H, 1990, MOL CELL BIOL, V10, P561, DOI 10.1128/MCB.10.2.561; Sun SC, 2008, NAT REV IMMUNOL, V8, P501, DOI 10.1038/nri2337; Tzimas C, 2006, CELL SIGNAL, V18, P83, DOI 10.1016/j.cellsig.2005.03.017; VERMA IM, 1995, GENE DEV, V9, P2723, DOI 10.1101/gad.9.22.2723; Wertz IE, 2004, NATURE, V430, P694, DOI 10.1038/nature02794; Woronicz JD, 1997, SCIENCE, V278, P866, DOI 10.1126/science.278.5339.866; Wu CJ, 2006, NAT CELL BIOL, V8, P398, DOI 10.1038/ncb1384; Yamaoka S, 1998, CELL, V93, P1231, DOI 10.1016/S0092-8674(00)81466-X; Zandi E, 1997, CELL, V91, P243, DOI 10.1016/S0092-8674(00)80406-7; Zandi E, 1998, SCIENCE, V281, P1360, DOI 10.1126/science.281.5381.1360; ZHANG Y, 1990, MOL CELL BIOL, V10, P3818, DOI 10.1128/MCB.10.7.3818	41	92	95	1	14	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 8	2010	285	2					969	978		10.1074/jbc.M109.042689	http://dx.doi.org/10.1074/jbc.M109.042689			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	539MH	19910467	Green Published, hybrid			2022-12-25	WOS:000273258200017
J	Yasuhira, K; Shibata, N; Mongami, G; Uedo, Y; Atsumi, Y; Kawashima, Y; Hibino, A; Tanaka, Y; Lee, YH; Kato, D; Takeo, M; Higuchi, Y; Negoro, S				Yasuhira, Kengo; Shibata, Naoki; Mongami, Go; Uedo, Yuki; Atsumi, Yu; Kawashima, Yasuyuki; Hibino, Atsushi; Tanaka, Yusuke; Lee, Young-Ho; Kato, Dai-ichiro; Takeo, Masahiro; Higuchi, Yoshiki; Negoro, Seiji			X-ray Crystallographic Analysis of the 6-Aminohexanoate Cyclic Dimer Hydrolase CATALYTIC MECHANISM AND EVOLUTION OF AN ENZYME RESPONSIBLE FOR NYLON-6 BYPRODUCT DEGRADATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA-LACTAMASE FOLD; LYS CATALYTIC TRIAD; TRANSITION-STATE; CRYSTAL-STRUCTURE; DEGRADING ENZYME; MALONAMIDASE E2; NYLON OLIGOMERS; AMIDE HYDROLASE; GENERAL BASE; MECHANISM	We performed x-ray crystallographic analyses of the 6-aminohexanoate cyclic dimer (Acd) hydrolase (NylA) from Arthrobacter sp., an enzyme responsible for the degradation of the nylon-6 industry byproduct. The fold adopted by the 472-amino acid polypeptide generated a compact mixed alpha/beta fold, typically found in the amidase signature superfamily; this fold was especially similar to the fold of glutamyl-tRNAGln amidotransferase subunit A (z score, 49.4) and malonamidase E2 (z score, 44.8). Irrespective of the high degree of structural similarity to the typical amidase signature superfamily enzymes, the specific activity of NylA for glutamine, malonamide, and indoleacetamide was found to be lower than 0.5% of that for Acd. However, NylA possessed carboxylesterase activity nearly equivalent to the Acd hydrolytic activity. Structural analysis of the inactive complex between the activity-deficient S174A mutant of NylA and Acd, performed at 1.8 angstrom resolution, suggested the following enzyme/substrate interactions: a Ser(174)-cis-Ser(150)-Lys(72) triad constitutes the catalytic center; the backbone N in Ala(171) and Ala(172) are involved in oxyanion stabilization; Cys(316)-S-gamma forms a hydrogen bond with nitrogen (Acd-N-7) at the uncleaved amide bond in two equivalent amide bonds of Acd. A single S174A, S150A, or K72A substitution in NylA by site-directed mutagenesis decreased the Acd hydrolytic and esterolytic activities to undetectable levels, indicating that Ser(174)-cis-Ser(150)-Lys(72) is essential for catalysis. In contrast, substitutions at position 316 specifically affected Acd hydrolytic activity, suggesting that Cys(316) is responsible for Acd binding. On the basis of the structure and functional analysis, we discussed the catalytic mechanisms and evolution of NylA in comparison with other Ser-reactive hydrolases.	[Shibata, Naoki; Higuchi, Yoshiki] Hyogo Med Univ, Dept Life Sci, Grad Sch Life Sci, Kamigori, Hyogo 6781297, Japan; [Shibata, Naoki; Higuchi, Yoshiki] RIKEN Harima Inst, Spring Ctr 8, Mikazuki, Hyogo 6795148, Japan; [Lee, Young-Ho] Osaka Univ, Inst Prot Res, Suita, Osaka 5650871, Japan	University of Hyogo; RIKEN; Osaka University	Higuchi, Y (corresponding author), Hyogo Med Univ, Dept Life Sci, Grad Sch Life Sci, 3-2-1 Koto, Kamigori, Hyogo 6781297, Japan.	hig@sci.u-hyogo.ac.jp	Takeo, Masahiro/GYA-3639-2022; Shibata, Naoki/AFK-9971-2022	Shibata, Naoki/0000-0002-5096-1104; Higuchi, Yoshiki/0000-0001-8284-5709	Japan Society for Promotion of Science; Global Centers of Excellence Program; National Project on Protein Structural and Functional Analyses; Core Research for Evolutional Science and Technology Program; JST; Japan Aerospace Exploration Agency project	Japan Society for Promotion of Science(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of Science); Global Centers of Excellence Program(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)); National Project on Protein Structural and Functional Analyses(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)); Core Research for Evolutional Science and Technology Program(Core Research for Evolutional Science and Technology (CREST)); JST(Japan Science & Technology Agency (JST)); Japan Aerospace Exploration Agency project	This work was supported in part by a grant-in-aid for scientific research from the Japan Society for Promotion of Science and by grants from the Global Centers of Excellence Program, the National Project on Protein Structural and Functional Analyses, the Core Research for Evolutional Science and Technology Program, "Development of the Foundation for Nano-Interface Technology" from JST, and the Japan Aerospace Exploration Agency project.	Arpigny JL, 1999, BIOCHEM J, V343, P177, DOI 10.1042/0264-6021:3430177; Asano Y, 2008, BIOSCI BIOTECH BIOCH, V72, P2141, DOI 10.1271/bbb.80210; Bracey MH, 2002, SCIENCE, V298, P1793, DOI 10.1126/science.1076535; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Cilia E, 2005, FEBS J, V272, P4716, DOI 10.1111/j.1742-4658.2005.04887.x; Davis IW, 2007, NUCLEIC ACIDS RES, V35, pW375, DOI 10.1093/nar/gkm216; delaFortelle E, 1997, METHOD ENZYMOL, V276, P472, DOI 10.1016/S0076-6879(97)76073-7; FERSHT A, 1984, ENZYME STRUCTURE MEC, P389; Hermann JC, 2003, J AM CHEM SOC, V125, P9590, DOI 10.1021/ja034434g; Heumann S, 2009, BIOTECHNOL BIOENG, V102, P1003, DOI 10.1002/bit.22139; ITO W, 1991, GENE, V102, P67, DOI 10.1016/0378-1119(91)90539-N; KANAGAWA K, 1989, J BACTERIOL, V171, P3181, DOI 10.1128/jb.171.6.3181-3186.1989; KATO K, 1995, MICROBIOL-UK, V141, P2585, DOI 10.1099/13500872-141-10-2585; Kawashima Y, 2009, FEBS J, V276, P2547, DOI 10.1111/j.1742-4658.2009.06978.x; KINOSHITA S, 1977, EUR J BIOCHEM, V80, P489, DOI 10.1111/j.1432-1033.1977.tb11904.x; Kobayashi M, 1998, FEBS LETT, V439, P325, DOI 10.1016/S0014-5793(98)01406-9; Labahn J, 2002, J MOL BIOL, V322, P1053, DOI 10.1016/S0022-2836(02)00886-0; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; McRee D.E., 1999, PRACTICAL PROTEIN CR, V2nd ed., P91; Minasov G, 2002, J AM CHEM SOC, V124, P5333, DOI 10.1021/ja0259640; Nakamura A, 2006, SCIENCE, V312, P1954, DOI 10.1126/science.1127156; Negoro S, 2000, APPL MICROBIOL BIOT, V54, P461, DOI 10.1007/s002530000434; Negoro S, 2005, J BIOL CHEM, V280, P39644, DOI 10.1074/jbc.M505946200; Negoro S., 2002, 9 BIOPOLYMERS, P395; Negoro S, 2007, J MOL BIOL, V370, P142, DOI 10.1016/j.jmb.2007.04.043; Neu D, 2007, FEBS J, V274, P3440, DOI 10.1111/j.1742-4658.2007.05876.x; Nukaga M, 2004, J BIOL CHEM, V279, P9344, DOI 10.1074/jbc.M312356200; Ohki T, 2006, FEBS LETT, V580, P5054, DOI 10.1016/j.febslet.2006.08.031; Ohki T, 2009, PROTEIN SCI, V18, P1662, DOI 10.1002/pro.185; OKADA H, 1983, NATURE, V306, P203, DOI 10.1038/306203a0; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Schmitt E, 2005, STRUCTURE, V13, P1421, DOI 10.1016/j.str.2005.06.016; Shin S, 2002, EMBO J, V21, P2509, DOI 10.1093/emboj/21.11.2509; Silvaggi NR, 2003, BIOCHEMISTRY-US, V42, P1199, DOI 10.1021/bi0268955; TSUCHIYA K, 1989, J BACTERIOL, V171, P3187, DOI 10.1128/jb.171.6.3187-3191.1989; Valina ALB, 2004, BIOCHEMISTRY-US, V43, P15657, DOI 10.1021/bi049025r; Wagner UG, 2002, PROTEIN SCI, V11, P467, DOI 10.1110/ps.33002; Weeks CM, 2002, Z KRISTALLOGR, V217, P686, DOI 10.1524/zkri.217.12.686.20659; Wei BQQ, 2006, J BIOL CHEM, V281, P36569, DOI 10.1074/jbc.M606646200; YAMADA T, 1985, P NATL ACAD SCI USA, V82, P6522, DOI 10.1073/pnas.82.19.6522; Yasuhira K, 2007, J BIOSCI BIOENG, V104, P521, DOI 10.1263/jbb.104.521; Yasuhira K, 2007, APPL ENVIRON MICROB, V73, P7099, DOI 10.1128/AEM.00777-07; Yasuhira K, 2006, ACTA CRYSTALLOGR F, V62, P1209, DOI 10.1107/S1744309106045076; Yun YS, 2006, J BIOL CHEM, V281, P40057, DOI 10.1074/jbc.M604515200; Zawadzke LE, 1996, BIOCHEMISTRY-US, V35, P16475, DOI 10.1021/bi962242a	45	30	31	2	15	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 8	2010	285	2					1239	1248		10.1074/jbc.M109.041285	http://dx.doi.org/10.1074/jbc.M109.041285			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	539MH	19889645	Green Published, hybrid			2022-12-25	WOS:000273258200046
J	Huang, RJ; Grabarek, Z; Wang, CLA				Huang, Renjian; Grabarek, Zenon; Wang, Chih-Lueh Albert			Differential Effects of Caldesmon on the Intermediate Conformational States of Polymerizing Actin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SMOOTH-MUSCLE CALDESMON; F-ACTIN; CALMODULIN-BINDING; GIZZARD CALDESMON; CHICKEN GIZZARD; FILAMENTS; TROPOMYOSIN; COMPLEX; SITES; LOCALIZATION	The actin-binding protein caldesmon (CaD) reversibly inhibits smooth muscle contraction. In non-muscle cells, a shorter CaD isoform co-exists with microfilaments in the stress fibers at the quiescent state, but the phosphorylated CaD is found at the leading edge of migrating cells where dynamic actin filament remodeling occurs. We have studied the effect of a C-terminal fragment of CaD (H32K) on the kinetics of the in vitro actin polymerization by monitoring the fluorescence of pyrene-labeled actin. Addition of H32K or its phosphorylated form either attenuated or accelerated the pyrene emission enhancement, depending on whether it was added at the early or the late phase of actin polymerization. However, the CaD fragment had no effect on the yield of sedimentable actin, nor did it affect the actin ATPase activity. Our findings can be explained by a model in which nascent actin filaments undergo a maturation process that involves at least two intermediate conformational states. If present at early stages of actin polymerization, CaD stabilizes one of the intermediate states and blocks the subsequent filament maturation. Addition of CaD at a later phase accelerates F-actin formation. The fact that CaD is capable of inhibiting actin filament maturation provides a novel function for CaD and suggests an active role in the dynamic reorganization of the actin cytoskeleton.	[Huang, Renjian; Grabarek, Zenon; Wang, Chih-Lueh Albert] Boston Biomed Res Inst, Watertown, MA 02472 USA	Boston Biomedical Research Institute	Wang, CLA (corresponding author), Boston Biomed Res Inst, 64 Grove St, Watertown, MA 02472 USA.	wang@bbri.org		Grabarek, Zenon/0000-0002-3636-5701	National Institutes of Health [HL91162, HL92252]	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)	This work was supported, in whole or in part, by National Institutes of Health Grants HL91162 (to Z. G.) and HL92252 (to C. L. A. W.).	Beltzner CC, 2008, J BIOL CHEM, V283, P7135, DOI 10.1074/jbc.M705894200; BRETSCHER A, 1985, J CELL BIOL, V100, P1656, DOI 10.1083/jcb.100.5.1656; Brooks FJ, 2008, BIOPHYS J, V95, P1050, DOI 10.1529/biophysj.107.123125; Bursac P, 2005, NAT MATER, V4, P557, DOI 10.1038/nmat1404; CARLIER MF, 1984, J BIOL CHEM, V259, P9983; CARLIER MF, 1986, BIOCHEMISTRY-US, V25, P7789, DOI 10.1021/bi00372a001; COOKE R, 1973, BIOCHEMISTRY-US, V12, P3927, DOI 10.1021/bi00744a022; COOPER JA, 1983, J MUSCLE RES CELL M, V4, P253, DOI 10.1007/BF00712034; CROSBIE RH, 1994, BIOCHEMISTRY-US, V33, P3210, DOI 10.1021/bi00177a010; De la Cruz EM, 2000, J MOL BIOL, V295, P517, DOI 10.1006/jmbi.1999.3390; Discher DE, 2005, SCIENCE, V310, P1139, DOI 10.1126/science.1116995; Foster DB, 2004, J BIOL CHEM, V279, P53387, DOI 10.1074/jbc.M410109200; GALAZKIEWICZ B, 1985, FEBS LETT, V184, P144, DOI 10.1016/0014-5793(85)80671-2; Galinska-Rakoczy A, 2009, J MOL BIOL, V387, P869, DOI 10.1016/j.jmb.2009.02.011; Gao Y, 1999, BIOCHEMISTRY-US, V38, P15459, DOI 10.1021/bi991383k; Gerthoffer WT, 2007, CIRC RES, V100, P607, DOI 10.1161/01.RES.0000258492.96097.47; GRACEFFA P, 1987, FEBS LETT, V218, P139, DOI 10.1016/0014-5793(87)81034-7; Gunst SJ, 2003, J APPL PHYSIOL, V95, P413, DOI 10.1152/japplphysiol.00277.2003; HAYASHI T, 1962, BIOCHEM BIOPH RES CO, V8, P20, DOI 10.1016/0006-291X(62)90227-9; Hoops S, 2006, BIOINFORMATICS, V22, P3067, DOI 10.1093/bioinformatics/btl485; Huang RJ, 2006, ARCH BIOCHEM BIOPHYS, V456, P175, DOI 10.1016/j.abb.2006.07.018; Huang RJ, 2003, BIOCHEMISTRY-US, V42, P2513, DOI 10.1021/bi0268605; HUMPHREY MB, 1992, GENE, V112, P197, DOI 10.1016/0378-1119(92)90376-Z; Ichetovkin I, 2002, CURR BIOL, V12, P79, DOI 10.1016/S0960-9822(01)00629-7; Kordowska J, 2005, EXP CELL RES, V312, P95, DOI 10.1016/j.yexcr.2005.09.021; KORN ED, 1987, SCIENCE, V238, P638, DOI 10.1126/science.3672117; KOUYAMA T, 1981, EUR J BIOCHEM, V114, P33; Kudryashov DS, 2004, BIOPHYS J, V87, P1136, DOI 10.1529/biophysj.104.042242; Kueh HY, 2008, P NATL ACAD SCI USA, V105, P16531, DOI 10.1073/pnas.0807394105; Lehman W, 1992, J Muscle Res Cell Motil, V13, P582, DOI 10.1007/BF01738000; LEVINE BA, 1990, EUR J BIOCHEM, V193, P687, DOI 10.1111/j.1432-1033.1990.tb19388.x; MABUCHI K, 1991, J MUSCLE RES CELL M, V12, P145, DOI 10.1007/BF01774033; MARSTON SB, 1996, CALDESMON; Matsumura F, 1993, CURR OPIN CELL BIOL, V5, P70, DOI 10.1016/S0955-0674(05)80010-9; MILLONIG R, 1988, J CELL BIOL, V106, P785, DOI 10.1083/jcb.106.3.785; MORNET D, 1988, BIOCHEM BIOPH RES CO, V155, P808, DOI 10.1016/S0006-291X(88)80567-9; Oda T, 2009, NATURE, V457, P441, DOI 10.1038/nature07685; Orlova A, 2004, P NATL ACAD SCI USA, V101, P17664, DOI 10.1073/pnas.0407525102; Pollard TD, 2003, CELL, V112, P453, DOI 10.1016/S0092-8674(03)00120-X; Rouiller I, 2008, J CELL BIOL, V180, P887, DOI 10.1083/jcb.200709092; Seow CY, 2005, NATURE, V435, P1172, DOI 10.1038/4351172a; SMITH CWJ, 1987, J BIOL CHEM, V262, P116; SOBUE K, 1981, P NATL ACAD SCI-BIOL, V78, P5652, DOI 10.1073/pnas.78.9.5652; SPUDICH JA, 1971, J BIOL CHEM, V246, P4866; Steinmetz MO, 1997, J CELL BIOL, V138, P559, DOI 10.1083/jcb.138.3.559; VELAZ L, 1989, J BIOL CHEM, V264, P9602; WANG CLA, 1991, J BIOL CHEM, V266, P9166; WANG CLA, 1991, J BIOL CHEM, V266, P13958; Wang CLA, 2001, CELL BIOCHEM BIOPHYS, V35, P275, DOI 10.1385/CBB:35:3:275; Wang Z, 1997, P NATL ACAD SCI USA, V94, P11899, DOI 10.1073/pnas.94.22.11899; WEBB MR, 1992, P NATL ACAD SCI USA, V89, P4884, DOI 10.1073/pnas.89.11.4884; Winder SJ, 2003, CURR OPIN CELL BIOL, V15, P14, DOI 10.1016/S0955-0674(02)00002-9; Yamakita Y, 2003, J BIOL CHEM, V278, P17937, DOI 10.1074/jbc.M208739200; Zhuang SB, 1996, J BIOL CHEM, V271, P30242, DOI 10.1074/jbc.271.47.30242	54	11	11	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 1	2010	285	1					71	79		10.1074/jbc.M109.065078	http://dx.doi.org/10.1074/jbc.M109.065078			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	536UT	19889635	hybrid, Green Published			2022-12-25	WOS:000273070100008
J	Koo, BH; Apte, SS				Koo, Bon-Hun; Apte, Suneel S.			Cell-surface Processing of the Metalloprotease Pro-ADAMTS9 Is Influenced by the Chaperone GRP94/gp96	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SHOCK-PROTEIN GP96; MATRIX-METALLOPROTEINASE; FURIN INTERACTS; ACTIVATION; EXPRESSION; MATURATION; MEMBRANE; RECEPTOR; COMPLEX; GENE	A disintegrin-like and metalloprotease domain with thrombospondin type 1 motifs 9 (ADAMTS9) is a highly conserved metalloprotease that has been identified as a tumor suppressor gene and is required for normal mouse development. The secreted ADAMTS9 zymogen undergoes proteolytic excision of its N-terminal propeptide by the proprotein convertase furin. However, in contrast to other metalloproteases, propeptide excision occurs at the cell surface and leads to decreased activity of the zymogen. Here, we investigated the potential cellular mechanisms regulating ADAMTS9 biosynthesis and cell-surface processing by analysis of molecular complexes formed by a construct containing the propeptide and catalytic domain of pro-ADAMTS9 (Pro-Cat) in HEK293F cells. Cross-linking of cellular proteins bound to Pro-Cat followed by mass spectrometric analysis identified UDP-glucose: glycoprotein glucosyltransferase I, heat shock protein gp96 (GRP94), BiP (GRP78), and ERdj3 (Hsp40 homolog) as associated proteins. gp96 and BiP were present at the cell surface in an immunoprecipitable complex with pro-ADAMTS9 and furin. Treatment with geldanamycin, an inhibitor of the HSP90 alpha family (including gp96), led to decreased furin processing of pro-ADAMTS9 and accumulation of the unprocessed pro-ADAMTS9 at the cell surface. gp96 siRNA down-regulated the levels of cell-surface pro-ADAMTS9 and furin, whereas the levels of cell-surface pro-ADAMTS9, but not of cell-surface furin, were decreased upon treatment with BiP siRNA. These data identify for the first time the cellular chaperones associated with secretion of an ADAMTS protease and suggest a role for gp96 in modulating pro-ADAMTS9 processing.	[Koo, Bon-Hun; Apte, Suneel S.] Cleveland Clin, Lerner Res Inst, Dept Biomed Engn, Cleveland, OH 44195 USA; [Koo, Bon-Hun] Yonsei Univ, Coll Sci, Dept Biochem, Seoul 120749, South Korea	Cleveland Clinic Foundation; Yonsei University	Apte, SS (corresponding author), Cleveland Clin Fdn, Lerner Res Inst, Dept Biomed Engn ND20, 9500 Euclid Ave, Cleveland, OH 44195 USA.	aptes@ccf.org		Apte, Suneel/0000-0001-8441-1226	National Institutes of Health [AR49930, AR53890]; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR053890, R01AR049930, R56AR049930] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))	This work was supported, in whole or in part, by National Institutes of Health Grants AR49930 and AR53890 (to S. A.).	Apte SS, 2009, J BIOL CHEM, V284, P31493, DOI 10.1074/jbc.R109.052340; Blelloch R, 1999, NATURE, V399, P586, DOI 10.1038/21196; BRAKS JAM, 1994, CELL, V78, P263, DOI 10.1016/0092-8674(94)90296-8; Cabanes D, 2005, EMBO J, V24, P2827, DOI 10.1038/sj.emboj.7600750; Creemers JWM, 2000, J BIOL CHEM, V275, P38842, DOI 10.1074/jbc.M006758200; Dai Jie, 2003, Cancer Immun, V3, P1; DEBOER C, 1970, J ANTIBIOT, V23, P442, DOI 10.7164/antibiotics.23.442; Delpino A, 2002, BIOSCIENCE REP, V22, P407, DOI 10.1023/A:1020966008615; Demircan K, 2005, ARTHRITIS RHEUM-US, V52, P1451, DOI 10.1002/art.21010; Eustace BK, 2004, CELL CYCLE, V3, P1098; Eustace BK, 2004, NAT CELL BIOL, V6, P507, DOI 10.1038/ncb1131; Guzman-Ayala M, 2004, P NATL ACAD SCI USA, V101, P15656, DOI 10.1073/pnas.0405429101; Jang JH, 2003, PROTEOMICS, V3, P1947, DOI 10.1002/pmic.200300563; Jindadamrongwech S, 2004, ARCH VIROL, V149, P915, DOI 10.1007/s00705-003-0263-x; Joseph K, 2002, P NATL ACAD SCI USA, V99, P896, DOI 10.1073/pnas.022626899; KLIMPEL KR, 1992, P NATL ACAD SCI USA, V89, P10277, DOI 10.1073/pnas.89.21.10277; Koo BH, 2006, J BIOL CHEM, V281, P12485, DOI 10.1074/jbc.M511083200; Koo BH, 2007, J BIOL CHEM, V282, P16146, DOI 10.1074/jbc.M610161200; Kuznetsov G, 1998, NEW ENGL J MED, V339, P1688, DOI 10.1056/NEJM199812033392307; LEDUC R, 1992, J BIOL CHEM, V267, P14304; Liu B, 2003, P NATL ACAD SCI USA, V100, P15824, DOI 10.1073/pnas.2635458100; Lo PHY, 2007, ONCOGENE, V26, P148, DOI 10.1038/sj.onc.1209767; Lung HL, 2008, INT J CANCER, V123, P401, DOI 10.1002/ijc.23528; MARTENS GJM, 1994, P NATL ACAD SCI USA, V91, P5784, DOI 10.1073/pnas.91.13.5784; Mayer G, 2004, J HISTOCHEM CYTOCHEM, V52, P567, DOI 10.1177/002215540405200502; Mayer G, 2003, J CELL SCI, V116, P1763, DOI 10.1242/jcs.00394; McCulloch DR, 2009, DEV CELL, V17, P687, DOI 10.1016/j.devcel.2009.09.008; MELNICK J, 1994, NATURE, V370, P373, DOI 10.1038/370373a0; Muller L, 1999, J BIOL CHEM, V274, P21471, DOI 10.1074/jbc.274.30.21471; Nakamura H, 1999, CANCER RES, V59, P467; Picard D, 2004, NAT CELL BIOL, V6, P479, DOI 10.1038/ncb0604-479; Porter S, 2005, BIOCHEM J, V386, P15, DOI 10.1042/BJ20040424; Robert J, 1999, J IMMUNOL, V163, P4133; SATO H, 1994, NATURE, V370, P61, DOI 10.1038/370061a0; Shen Y, 2005, MOL BIOL CELL, V16, P40, DOI 10.1091/mbc.E04-05-0434; Shin BK, 2003, J BIOL CHEM, V278, P7607, DOI 10.1074/jbc.M210455200; Silver DL, 2008, PLOS GENET, V4, DOI 10.1371/journal.pgen.1000003; Somerville RPT, 2004, J BIOL CHEM, V279, P51208, DOI 10.1074/jbc.M409036200; Somerville RPT, 2004, J BIOL CHEM, V279, P35159, DOI 10.1074/jbc.M402380200; Somerville RPT, 2003, J BIOL CHEM, V278, P9503, DOI 10.1074/jbc.M211009200; Thimon V, 2006, REPRODUCTION, V132, P899, DOI 10.1530/REP-06-0077; Triantafilou K, 2002, J VIROL, V76, P633, DOI 10.1128/JVI.76.2.633-643.2002; TROMBETTA SE, 1992, J BIOL CHEM, V267, P9236; TSUNEOKA M, 1993, J BIOL CHEM, V268, P26461; Vabulas RM, 2002, J BIOL CHEM, V277, P20847, DOI 10.1074/jbc.M200425200; Wallis DD, 2003, J CELL BIOCHEM, V90, P641, DOI 10.1002/jcb.10657; Wang P, 2004, J BIOL CHEM, V279, P15434, DOI 10.1074/jbc.M312797200; WHITESELL L, 1994, P NATL ACAD SCI USA, V91, P8324, DOI 10.1073/pnas.91.18.8324; Wiest DL, 1997, P NATL ACAD SCI USA, V94, P1884, DOI 10.1073/pnas.94.5.1884; Yang Y, 2005, MOL CELLS, V20, P173; Zacchigna L, 2006, CELL, V124, P929, DOI 10.1016/j.cell.2005.12.035; Zheng H, 2001, J IMMUNOL, V167, P6731, DOI 10.4049/jimmunol.167.12.6731	52	30	32	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 1	2010	285	1					197	205		10.1074/jbc.M109.039677	http://dx.doi.org/10.1074/jbc.M109.039677			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	536UT	19875450	Green Published, hybrid			2022-12-25	WOS:000273070100021
J	Brower, CS; Varshavsky, A				Brower, Christopher S.; Varshavsky, Alexander			Ablation of Arginylation in the Mouse N-End Rule Pathway: Loss of Fat, Higher Metabolic Rate, Damaged Spermatogenesis, and Neurological Perturbations	PLOS ONE			English	Article							MEDIATED GERMLINE MOSAICISM; UBIQUITIN LIGASE; DEGRADATION; PROTEIN; MICE; CRE; PROTEASOME; EXPRESSION; APOPTOSIS; SEQUENCES	In the N-end rule pathway of protein degradation, the destabilizing activity of N-terminal Asp, Glu or (oxidized) Cys residues requires their conjugation to Arg, which is recognized directly by pathway's ubiquitin ligases. N-terminal arginylation is mediated by the Ate1 arginyltransferase, whose physiological substrates include the Rgs4, Rgs5 and Rgs16 regulators of G proteins. Here, we employed the Cre-lox technique to uncover new physiological functions of N-terminal arginylation in adult mice. We show that postnatal deletion of mouse Ate1 (its unconditional deletion is embryonic lethal) causes a rapid decrease of body weight and results in early death of similar to 15% of Ate1-deficient mice. Despite being hyperphagic, the surviving Ate1-deficient mice contain little visceral fat. They also exhibit an increased metabolic rate, ectopic induction of the Ucp1 uncoupling protein in white fat, and are resistant to diet-induced obesity. In addition, Ate1-deficient mice have enlarged brains, an enhanced startle response, are strikingly hyperkinetic, and are prone to seizures and kyphosis. Ate1-deficient males are also infertile, owing to defects in Ate1(-/-) spermatocytes. The remarkably broad range of specific biological processes that are shown here to be perturbed by the loss of N-terminal arginylation will make possible the dissection of regulatory circuits that involve Ate1 and either its known substrates, such as Rgs4, Rgs5 and Rgs16, or those currently unknown.	CALTECH, Div Biol, Pasadena, CA 91125 USA	California Institute of Technology	Brower, CS (corresponding author), CALTECH, Div Biol, Pasadena, CA 91125 USA.	avarsh@caltech.edu			National Institutes of Health [GM31530, DK39520]; American Asthma Foundation; March of Dimes Foundation; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R56DK039520, R01DK039520, R37DK039520] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM031530] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); American Asthma Foundation; March of Dimes Foundation(March of Dimes); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	This study was supported by grants to A.V. from the National Institutes of Health (GM31530 and DK39520), the American Asthma Foundation, and the March of Dimes Foundation. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Ausubel F.M., 2006, CURRENT PROTOCOLS MO; BACHMAIR A, 1989, CELL, V56, P1019, DOI 10.1016/0092-8674(89)90635-1; Boulares AH, 1999, J BIOL CHEM, V274, P22932, DOI 10.1074/jbc.274.33.22932; Dauger S, 1998, RESP PHYSIOL, V112, P215, DOI 10.1016/S0034-5687(98)00027-9; Ditzel M, 2003, NAT CELL BIOL, V5, P467, DOI 10.1038/ncb984; Eijpe M, 2003, J CELL BIOL, V160, P657, DOI 10.1083/jcb.200212080; Eisele F, 2008, FEBS LETT, V582, P4143, DOI 10.1016/j.febslet.2008.11.015; GEYER MA, 1998, CURR PROTOC NEUROSCI; Hayashi S, 2002, DEV BIOL, V244, P305, DOI 10.1006/dbio.2002.0597; Holman TJ, 2009, P NATL ACAD SCI USA, V106, P4549, DOI 10.1073/pnas.0810280106; Holzenberger M, 2000, NUCLEIC ACIDS RES, V28, DOI 10.1093/nar/28.21.e92; Hu RG, 2005, NATURE, V437, P981, DOI 10.1038/nature04027; Hu RG, 2008, P NATL ACAD SCI USA, V105, P76, DOI 10.1073/pnas.0710568105; Hu RG, 2006, J BIOL CHEM, V281, P32559, DOI 10.1074/jbc.M604355200; Hwang CS, 2009, P NATL ACAD SCI USA, V106, P2142, DOI 10.1073/pnas.0812316106; Hwang CS, 2008, P NATL ACAD SCI USA, V105, P19188, DOI 10.1073/pnas.0808891105; Joyner AL, 2000, GENE TARGETING PRACT; Karakozova M, 2006, SCIENCE, V313, P192, DOI 10.1126/science.1129344; Kiskinis E, 2007, EMBO J, V26, P4831, DOI 10.1038/sj.emboj.7601908; Kwon YT, 2003, MOL CELL BIOL, V23, P8255, DOI 10.1128/MCB.23.22.8255-8271.2003; Kwon YT, 1999, MOL CELL BIOL, V19, P182; Kwon YT, 2002, SCIENCE, V297, P96, DOI 10.1126/science.1069531; Lakso M, 1996, P NATL ACAD SCI USA, V93, P5860, DOI 10.1073/pnas.93.12.5860; Lee MJ, 2005, P NATL ACAD SCI USA, V102, P15030, DOI 10.1073/pnas.0507533102; Leneuve P, 2003, NUCLEIC ACIDS RES, V31, DOI 10.1093/nar/gng021; Mogk A, 2007, TRENDS CELL BIOL, V17, P165, DOI 10.1016/j.tcb.2007.02.001; Nagy A., 2002, MANIPULATING MOUSE E; Nair DM, 2004, J CELL BIOL, V167, P599, DOI 10.1083/jcb.200407119; Narvaez CJ, 2009, ENDOCRINOLOGY, V150, P651, DOI 10.1210/en.2008-1118; Novak I, 2008, J CELL BIOL, V180, P83, DOI 10.1083/jcb.200706136; O'Gorman S, 1997, P NATL ACAD SCI USA, V94, P14602, DOI 10.1073/pnas.94.26.14602; Prakash S, 2009, NAT CHEM BIOL, V5, P29, DOI 10.1038/nchembio.130; Rajewsky K, 1996, J CLIN INVEST, V98, P600, DOI 10.1172/JCI118828; Rao H, 2001, NATURE, V410, P955, DOI 10.1038/35073627; Ravid T, 2008, NAT REV MOL CELL BIO, V9, P679, DOI 10.1038/nrm2468; Redwine JM, 2003, P NATL ACAD SCI USA, V100, P1381, DOI 10.1073/pnas.242746599; Rousseau K, 2007, FASEB J, V21, P1844, DOI 10.1096/fj.06-7398com; Shattuck DW, 2002, MED IMAGE ANAL, V6, P129, DOI 10.1016/S1361-8415(02)00054-3; Tasaki T, 2007, TRENDS BIOCHEM SCI, V32, P520, DOI 10.1016/j.tibs.2007.08.010; Tasaki T, 2009, J BIOL CHEM, V284, P1884, DOI 10.1074/jbc.M803641200; Turner GC, 2000, NATURE, V405, P579, DOI 10.1038/35014629; Varshavsky A, 1996, P NATL ACAD SCI USA, V93, P12142, DOI 10.1073/pnas.93.22.12142; Varshavsky A, 2008, J BIOL CHEM, V283, P34469, DOI 10.1074/jbc.X800009200; Wang HQ, 2009, MOL CELL, V34, P686, DOI 10.1016/j.molcel.2009.04.032; Wasserman K, 2005, PRINCIPLES EXERCISE; Weber P, 2003, BIOL REPROD, V68, P553, DOI 10.1095/biolreprod.102.005801; Xia ZX, 2008, J BIOL CHEM, V283, P24011, DOI 10.1074/jbc.M802583200	47	57	57	0	3	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	NOV 13	2009	4	11							e7757	10.1371/journal.pone.0007757	http://dx.doi.org/10.1371/journal.pone.0007757			20	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	518VB	19915679	Green Submitted, Green Published, gold, Green Accepted			2022-12-25	WOS:000271721900002
J	Nishitsuji, H; Hayashi, T; Takahashi, T; Miyano, M; Kannagi, M; Masuda, T				Nishitsuji, Hironori; Hayashi, Takaya; Takahashi, Takuya; Miyano, Masashi; Kannagi, Mari; Masuda, Takao			Augmentation of Reverse Transcription by Integrase through an Interaction with Host Factor, SIP1/Gemin2 Is Critical for HIV-1 Infection	PLOS ONE			English	Article							IMMUNODEFICIENCY-VIRUS TYPE-1; SPINAL MUSCULAR-ATROPHY; FINGER-LIKE DOMAIN; NONDIVIDING CELLS; BINDING DOMAIN; TY3 INTEGRASE; PROTEIN; LEDGF/P75; COMPLEX; IDENTIFICATION	There has been accumulating evidence for the involvement of retroviral integrase (IN) in the reverse transcription of viral RNA. We previously identified a host factor, survival motor neuron-interacting protein 1 (SIP1/Gemin2) that binds to human immunodeficiency virus type 1 (HIV-1) IN and supports HIV-1 infection apparently at reverse transcription step. Here, we demonstrated that HIV-1 IN together with SIP1 augments reverse transcriptase (RT) activity by enhancing the assembly of RT on viral RNA in vitro. Synthetic peptides corresponding to the binding motifs within IN that inhibited the IN-SIP1 interaction abrogated reverse transcription in vitro and in vivo. Furthermore, knockdown of SIP1 reduced intracellular stability and multimer formation of IN through proteasome-mediated degradation machinery. Taken together, SIP1 appears to stabilize functional multimer forms of IN, thereby promoting the assembly of IN and RT on viral RNA to allow efficient reverse transcription, which is a prerequisite for efficient HIV-1 infection.			Nishitsuji, H (corresponding author), Chiba Inst Technol, Dept Life & Environm Sci, Chiba, Japan.	tmasu.impt@tmd.ac.jp						ADACHI A, 1986, J VIROL, V59, P284, DOI 10.1128/JVI.59.2.284-291.1986; Al-Mawsawi LQ, 2007, TRENDS PHARMACOL SCI, V28, P526, DOI 10.1016/j.tips.2007.09.005; Berthoux L, 2007, VIROLOGY, V364, P227, DOI 10.1016/j.virol.2007.02.029; Brass AL, 2008, SCIENCE, V319, P921, DOI 10.1126/science.1152725; Briggs JAG, 2004, NAT STRUCT MOL BIOL, V11, P672, DOI 10.1038/nsmb785; Buhler D, 1999, HUM MOL GENET, V8, P2351, DOI 10.1093/hmg/8.13.2351; Cai ML, 1997, NAT STRUCT BIOL, V4, P567, DOI 10.1038/nsb0797-567; Cherepanov P, 2005, NAT STRUCT MOL BIOL, V12, P526, DOI 10.1038/nsmb937; Cherepanov P, 2003, J BIOL CHEM, V278, P372, DOI 10.1074/jbc.M209278200; Cullen BR, 2001, CELL, V105, P697, DOI 10.1016/S0092-8674(01)00392-0; Devroe E, 2003, J CELL SCI, V116, P4401, DOI 10.1242/jcs.00747; Dobard CW, 2007, J VIROL, V81, P10037, DOI 10.1128/JVI.00519-07; Emiliani S, 2005, J BIOL CHEM, V280, P25517, DOI 10.1074/jbc.M501378200; ENGELMAN A, 1995, J VIROL, V69, P2729, DOI 10.1128/JVI.69.5.2729-2736.1995; Engelman A, 1997, J VIROL, V71, P3507, DOI 10.1128/JVI.71.5.3507-3514.1997; Fischer U, 1997, CELL, V90, P1023, DOI 10.1016/S0092-8674(00)80368-2; Gallay P, 1997, P NATL ACAD SCI USA, V94, P9825, DOI 10.1073/pnas.94.18.9825; Gleenberg IO, 2007, J MOL BIOL, V369, P1230, DOI 10.1016/j.jmb.2007.03.073; Goff SP, 2001, J GENE MED, V3, P517, DOI 10.1002/1521-2254(200111)3:6<517::AID-JGM234>3.0.CO;2-E; Hamamoto S, 2006, J VIROL, V80, P5670, DOI 10.1128/JVI.02471-05; Hayouka Z, 2007, P NATL ACAD SCI USA, V104, P8316, DOI 10.1073/pnas.0700781104; Hehl EA, 2004, J VIROL, V78, P5056, DOI 10.1128/JVI.78.10.5056-5067.2004; Ikeda T, 2004, J VIROL, V78, P11563, DOI 10.1128/JVI.78.21.11563-11573.2004; Jablonka S, 2001, HUM MOL GENET, V10, P497, DOI 10.1093/hmg/10.5.497; Jenkins TM, 1996, J BIOL CHEM, V271, P7712, DOI 10.1074/jbc.271.13.7712; KALPANA GV, 1994, SCIENCE, V266, P2002, DOI 10.1126/science.7801128; KATZ RA, 1994, ANNU REV BIOCHEM, V63, P133, DOI 10.1146/annurev.bi.63.070194.001025; Konig R, 2008, CELL, V135, P49, DOI 10.1016/j.cell.2008.07.032; KULKOSKY J, 1992, MOL CELL BIOL, V12, P2331, DOI 10.1128/MCB.12.5.2331; Leavitt AD, 1996, J VIROL, V70, P721, DOI 10.1128/JVI.70.2.721-728.1996; Liu Q, 1997, CELL, V90, P1013, DOI 10.1016/S0092-8674(00)80367-0; Llano M, 2004, J BIOL CHEM, V279, P55570, DOI 10.1074/jbc.M408508200; Llano M, 2006, J MOL BIOL, V360, P760, DOI 10.1016/j.jmb.2006.04.073; Lu R, 2005, J VIROL, V79, P10356, DOI 10.1128/JVI.79.16.10356-10368.2005; Maertens G, 2004, J BIOL CHEM, V279, P33421, DOI 10.1074/jbc.M404700200; Maertens G, 2003, J BIOL CHEM, V278, P33528, DOI 10.1074/jbc.M303594200; MASUDA T, 1995, J VIROL, V69, P6687, DOI 10.1128/JVI.69.11.6687-6696.1995; Meister G, 2001, NAT CELL BIOL, V3, P945, DOI 10.1038/ncb1101-945; Miyoshi H, 1998, J VIROL, V72, P8150, DOI 10.1128/JVI.72.10.8150-8157.1998; Mousnier A, 2007, P NATL ACAD SCI USA, V104, P13615, DOI 10.1073/pnas.0705162104; Nakamura T, 1997, BIOCHEM BIOPH RES CO, V239, P715, DOI 10.1006/bbrc.1997.7541; Nomura Y, 2006, J BIOCHEM, V139, P753, DOI 10.1093/jb/mvj085; Nymark-McMahon MH, 2002, J VIROL, V76, P2804, DOI 10.1128/JVI.76.6.2804-2816.2002; Nymark-McMahon MH, 1999, J VIROL, V73, P453, DOI 10.1128/JVI.73.1.453-465.1999; Ogawa C, 2007, J BIOL CHEM, V282, P11122, DOI 10.1074/jbc.M609297200; Shun MC, 2007, GENE DEV, V21, P1767, DOI 10.1101/gad.1565107; TADDEO B, 1994, J VIROL, V68, P8401, DOI 10.1128/JVI.68.12.8401-8405.1994; Tsurutani N, 2000, J VIROL, V74, P4795, DOI 10.1128/JVI.74.10.4795-4806.2000; Wang JY, 2001, EMBO J, V20, P7333, DOI 10.1093/emboj/20.24.7333; Wilkinson TA, 2009, J BIOL CHEM, V284, P7931, DOI 10.1074/jbc.M806241200; Wu XY, 1999, J VIROL, V73, P2126, DOI 10.1128/JVI.73.3.2126-2135.1999; Zhu K, 2004, J VIROL, V78, P5045, DOI 10.1128/JVI.78.10.5045-5055.2004	52	25	27	0	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	NOV 13	2009	4	11							e7825	10.1371/journal.pone.0007825	http://dx.doi.org/10.1371/journal.pone.0007825			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	518VB	19915660	gold, Green Published			2022-12-25	WOS:000271721900015
J	Gillett, A; Maratou, K; Fewings, C; Harris, RA; Jagodic, M; Aitman, T; Olsson, T				Gillett, Alan; Maratou, Klio; Fewings, Chris; Harris, Robert A.; Jagodic, Maja; Aitman, Tim; Olsson, Tomas			Alternative Splicing and Transcriptome Profiling of Experimental Autoimmune Encephalomyelitis Using Genome-Wide Exon Arrays	PLOS ONE			English	Article							MYELIN OLIGODENDROCYTE GLYCOPROTEIN; CENTRAL-NERVOUS-SYSTEM; EXPERIMENTAL ALLERGIC ENCEPHALOMYELITIS; QUANTITATIVE TRAIT LOCI; MULTIPLE-SCLEROSIS; GENE-EXPRESSION; INTERLEUKIN-7 RECEPTOR; MICROARRAY EXPERIMENTS; CEREBROSPINAL-FLUID; CONTROLLED TRIAL	Background: Multiple Sclerosis (MS) is a chronic inflammatory disease causing demyelination and nerve loss in the central nervous system. Experimental autoimmune encephalomyelitis (EAE) is an animal model of MS that is widely used to investigate complex pathogenic mechanisms. Transcriptional control through isoform selection and mRNA levels determines pathway activation and ultimately susceptibility to disease. Methodology/Principal Findings: We have studied the role of alternative splicing and differential expression in lymph node cells from EAE-susceptible Dark Agouti (DA) and EAE-resistant Piebald Virol Glaxo. AV1 (PVG) inbred rat strains using Affymetrix Gene Chip Rat Exon 1.0 ST Arrays. Comparing the two strains, we identified 11 differentially spliced and 206 differentially expressed genes at day 7 post-immunization, as well as 9 differentially spliced and 144 differentially expressed genes upon autoantigen re-stimulation. Functional clustering and pathway analysis implicate genes for glycosylation, lymphocyte activation, potassium channel activity and cellular differentiation in EAE susceptibility. Conclusions/Significance: Our results demonstrate that alternative splicing occurs during complex disease and may govern EAE susceptibility. Additionally, transcriptome analysis not only identified previously defined EAE pathways regulating the immune system, but also novel mechanisms. Furthermore, several identified genes overlap known quantitative trait loci, providing novel causative candidate targets governing EAE.			Gillett, A (corresponding author), Karolinska Hosp, Ctr Mol Med, Dept Clin Neurosci, Karolinska Inst,Neuroimmunol Unit, Solna, Sweden.	Alan.Gillett@ki.se	Harris, Robert A./I-6234-2019	Harris, Robert A./0000-0003-4990-509X; Maratou, Klio/0000-0001-6061-2322; Olsson, Tomas/0000-0002-2938-1877; Aitman, Timothy/0000-0002-7875-4502				Achiron A, 2007, ANN NY ACAD SCI, V1107, P155, DOI 10.1196/annals.1381.017; AMOR S, 1994, J IMMUNOL, V153, P4349; Arthur AT, 2008, BMC MED GENET, V9, DOI 10.1186/1471-2350-9-17; Aulchenko YS, 2008, NAT GENET, V40, P1402, DOI 10.1038/ng.251; Avasarala JR, 2008, BMC MED GENOMICS, V1, DOI 10.1186/1755-8794-1-2; Baillat D, 2005, CELL, V123, P265, DOI 10.1016/j.cell.2005.08.019; Becanovic K, 2003, EUR J IMMUNOL, V33, P1907, DOI 10.1002/eji.200323692; Behmoaras J, 2008, NAT GENET, V40, P553, DOI 10.1038/ng.137; Bemmo A, 2008, BMC GENOMICS, V9, DOI 10.1186/1471-2164-9-529; BENJAMINI Y, 1995, J R STAT SOC B, V57, P289, DOI 10.1111/j.2517-6161.1995.tb02031.x; Benovoy D, 2008, NUCLEIC ACIDS RES, V36, P4417, DOI 10.1093/nar/gkn409; Carmody RJ, 2002, J NEUROIMMUNOL, V133, P95, DOI 10.1016/S0165-5728(02)00366-1; Chen JX, 2004, GENE, V340, P61, DOI 10.1016/j.gene.2004.05.028; Compston A, 2008, LANCET, V372, P1502, DOI 10.1016/S0140-6736(08)61620-7; Cross AH, 2006, J NEUROIMMUNOL, V180, P63, DOI 10.1016/j.jneuroim.2006.06.029; De Jager PL, 2009, NAT GENET, V41, P776, DOI 10.1038/ng.401; DECOURSEY TE, 1984, NATURE, V307, P465, DOI 10.1038/307465a0; Della Beffa C, 2008, BMC GENOMICS, V9, DOI 10.1186/1471-2164-9-571; Dennis G, 2003, GENOME BIOL, V4, DOI 10.1186/gb-2003-4-9-r60; Dutta R, 2007, NEUROLOGY, V68, pS22, DOI 10.1212/01.wnl.0000275229.13012.32; Emilsson V, 2008, NATURE, V452, P423, DOI 10.1038/nature06758; Gentleman RC, 2004, GENOME BIOL, V5, DOI 10.1186/gb-2004-5-10-r80; Gregory SG, 2007, NAT GENET, V39, P1083, DOI 10.1038/ng2103; Gutcher I, 2006, NAT IMMUNOL, V7, P946, DOI 10.1038/ni1377; Hafler JP, 2009, GENES IMMUN, V10, P5, DOI 10.1038/gene.2008.82; HEDREUL MT, 2009, J NEUROIMMUNOL; Hoppenbrouwers IA, 2008, GENES IMMUN, V9, P334, DOI 10.1038/gene.2008.22; Huang DW, 2009, NAT PROTOC, V4, P44, DOI 10.1038/nprot.2008.211; Ibrahim SM, 2001, BRAIN, V124, P1927, DOI 10.1093/brain/124.10.1927; Irizarry RA, 2003, BIOSTATISTICS, V4, P249, DOI 10.1093/biostatistics/4.2.249; Jagodic M, 2005, J IMMUNOL, V174, P918, DOI 10.4049/jimmunol.174.2.918; Jagodic M, 2004, J IMMUNOL, V173, P1366, DOI 10.4049/jimmunol.173.2.1366; Jagodic M, 2006, GENOMICS, V88, P737, DOI 10.1016/j.ygeno.2006.08.013; Jiang Y, 1998, J NEUROIMMUNOL, V86, P1, DOI 10.1016/S0165-5728(98)00005-8; Judge SI, 2006, PHARMACOL THERAPEUT, V111, P224, DOI 10.1016/j.pharmthera.2005.10.006; Khademi M, 2004, J IMMUNOL, V172, P7169, DOI 10.4049/jimmunol.172.11.7169; LEE SC, 1986, J CELL BIOL, V102, P1200, DOI 10.1083/jcb.102.4.1200; Lundmark F, 2007, NAT GENET, V39, P1108, DOI 10.1038/ng2106; Marta CB, 2005, P NATL ACAD SCI USA, V102, P13992, DOI 10.1073/pnas.0504979102; Matsumoto Y, 1998, EUR J IMMUNOL, V28, P1681, DOI 10.1002/(SICI)1521-4141(199805)28:05<1681::AID-IMMU1681>3.0.CO;2-T; Millefiorini E, 1997, J NEUROL, V244, P153, DOI 10.1007/s004150050066; Miller DH, 2003, NEW ENGL J MED, V348, P15, DOI 10.1056/NEJMoa020696; Monti J, 2008, NAT GENET, V40, P529, DOI 10.1038/ng.129; Mor A, 2006, ANNU REV IMMUNOL, V24, P771, DOI 10.1146/annurev.immunol.24.021605.090723; Mueller AM, 2008, J NEUROINFLAMM, V5, DOI 10.1186/1742-2094-5-20; Nagamatsu Y, 2008, J BIOL CHEM, V283, P14532, DOI 10.1074/jbc.M801647200; O'Connor RA, 2008, J IMMUNOL, V181, P3750, DOI 10.4049/jimmunol.181.6.3750; Panyi G, 2004, P NATL ACAD SCI USA, V101, P1285, DOI 10.1073/pnas.0307421100; Parkinson H, 2007, NUCLEIC ACIDS RES, V35, pD747, DOI 10.1093/nar/gkl995; Petretto E, 2008, NAT GENET, V40, P546, DOI 10.1038/ng.134; Rubio JP, 2008, GENES IMMUN, V9, P624, DOI 10.1038/gene.2008.59; RUSSO MW, 1995, P NATL ACAD SCI USA, V92, P6873, DOI 10.1073/pnas.92.15.6873; Sanges R, 2007, BIOINFORMATICS, V23, P3406, DOI 10.1093/bioinformatics/btm469; SAWADOGO M, 1985, CELL, V43, P165, DOI 10.1016/0092-8674(85)90021-2; Sheng JR, 2005, GENETICS, V170, P283, DOI 10.1534/genetics.104.035261; Storch MK, 1998, BRAIN PATHOL, V8, P681, DOI 10.1111/j.1750-3639.1998.tb00194.x; Stromnes IM, 2008, NAT MED, V14, P337, DOI 10.1038/nm1715; Subramanian A, 2005, P NATL ACAD SCI USA, V102, P15545, DOI 10.1073/pnas.0506580102; SUN DM, 1992, CELL IMMUNOL, V145, P263, DOI 10.1016/0008-8749(92)90330-R; Walter S, 2002, J NEUROIMMUNOL, V132, P1, DOI 10.1016/S0165-5728(02)00308-9; Wang ET, 2008, NATURE, V456, P470, DOI 10.1038/nature07509; Wang G, 2008, BIOCHEM BIOPH RES CO, V374, P204, DOI 10.1016/j.bbrc.2008.07.003; Zhang BN, 1997, J EXP MED, V186, P1677, DOI 10.1084/jem.186.10.1677	63	16	17	0	4	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	NOV 10	2009	4	11							e7773	10.1371/journal.pone.0007773	http://dx.doi.org/10.1371/journal.pone.0007773			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	517ZU	19915720	Green Published, gold, Green Submitted			2022-12-25	WOS:000271658800011
J	Triana-Baltzer, GB; Gubareva, LV; Nicholls, JM; Pearce, MB; Mishin, VP; Belser, JA; Chen, LM; Chan, RWY; Chan, MCW; Hedlund, M; Larson, JL; Moss, RB; Katz, JM; Tumpey, TM; Fang, F				Triana-Baltzer, Gallen B.; Gubareva, Larisa V.; Nicholls, John M.; Pearce, Melissa B.; Mishin, Vasiliy P.; Belser, Jessica A.; Chen, Li-Mei; Chan, Renee W. Y.; Chan, Michael C. W.; Hedlund, Maria; Larson, Jeffrey L.; Moss, Ronald B.; Katz, Jacqueline M.; Tumpey, Terrence M.; Fang, Fang			Novel Pandemic Influenza A(H1N1) Viruses Are Potently Inhibited by DAS181, a Sialidase Fusion Protein	PLOS ONE			English	Article							A H5N1; OSELTAMIVIR RESISTANCE; RECEPTOR SPECIFICITY; B VIRUSES; TRANSMISSION; SENSITIVITY; DIFFERENTIATION; MORTALITY; INFECTION; TROPISM	Background: The recent emergence of a novel pandemic influenza A(H1N1) strain in humans exemplifies the rapid and unpredictable nature of influenza virus evolution and the need for effective therapeutics and vaccines to control such outbreaks. However, resistance to antivirals can be a formidable problem as evidenced by the currently widespread oseltamivir- and adamantane-resistant seasonal influenza A viruses (IFV). Additional antiviral approaches with novel mechanisms of action are needed to combat novel and resistant influenza strains. DAS181 (Fludase (TM)) is a sialidase fusion protein in early clinical development with in vitro and in vivo preclinical activity against a variety of seasonal influenza strains and highly pathogenic avian influenza strains (A/H5N1). Here, we use in vitro, ex vivo, and in vivo models to evaluate the activity of DAS181 against several pandemic influenza A( H1N1) viruses. Methods and Findings: The activity of DAS181 against several pandemic influenza A( H1N1) virus isolates was examined in MDCK cells, differentiated primary human respiratory tract culture, ex-vivo human bronchi tissue and mice. DAS181 efficiently inhibited viral replication in each of these models and against all tested pandemic influenza A( H1N1) strains. DAS181 treatment also protected mice from pandemic influenza A(H1N1)-induced pathogenesis. Furthermore, DAS181 antiviral activity against pandemic influenza A( H1N1) strains was comparable to that observed against seasonal influenza virus including the H274Y oseltamivir- resistant influenza virus. Conclusions: The sialidase fusion protein DAS181 exhibits potent inhibitory activity against pandemic influenza A( H1N1) viruses. As inhibition was also observed with oseltamivir- resistant IFV ( H274Y), DAS181 may be active against the antigenically novel pandemic influenza A( H1N1) virus should it acquire the H274Y mutation. Based on these and previous results demonstrating DAS181 broad-spectrum anti-IFV activity, DAS181 represents a potential therapeutic agent for prevention and treatment of infections by both emerging and seasonal strains of IFV.			Triana-Baltzer, GB (corresponding author), NexBio Inc, San Diego, CA USA.	ffang@nexbio.com	Chan, Renee Wan Yi/AAA-6598-2020; Chan, Renee/D-4799-2012; Chan, Michael Chi Wai/C-4212-2009; Nicholls, John Malcolm/C-4375-2009	Chan, Renee Wan Yi/0000-0001-6485-0926; Chan, Michael Chi Wai/0000-0001-8174-8405; Nicholls, John Malcolm/0000-0001-7217-7444	NIAID NIH HHS [R44 AI056786, U01 AI070281] Funding Source: Medline; PHS HHS [HHSN266200600015C] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R44AI056786, U01AI070281] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Abdel-Ghafar AN, 2008, NEW ENGL J MED, V358, P261, DOI 10.1056/NEJMra0707279; Belser JA, 2007, J INFECT DIS, V196, P1493, DOI 10.1086/522609; BELSHE RB, 2009, N ENGL J MED; *CDC, 2009, FLU VIEW WEEKL US IN; Centers for Disease Control and Prevention (CDC), 2009, MMWR Morb Mortal Wkly Rep, V58, P433; Centers for Disease Control and Prevention (CDC), 2009, MMWR Morb Mortal Wkly Rep, V58, P521; Chan KH, 2008, J CLIN VIROL, V42, P65, DOI 10.1016/j.jcv.2007.12.003; Chen LM, 2008, PLOS PATHOG, V4, DOI 10.1371/journal.ppat.1000072; Cheng PKC, 2009, EMERG INFECT DIS, V15, P966, DOI 10.3201/eid1506.081357; Cowling BJ, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002101; Cox NJ, 2000, ANNU REV MED, V51, P407, DOI 10.1146/annurev.med.51.1.407; de Jong MD, 2005, NEW ENGL J MED, V353, P2667, DOI 10.1056/NEJMoa054512; Dharan NJ, 2009, JAMA-J AM MED ASSOC, V301, P1034, DOI 10.1001/jama.2009.294; Garten RJ, 2009, SCIENCE; Gray TE, 1996, AM J RESP CELL MOL, V14, P104, DOI 10.1165/ajrcmb.14.1.8534481; Gubareva LV, 2001, J INFECT DIS, V183, P523, DOI 10.1086/318537; Gupta RK, 2006, NEW ENGL J MED, V354, P1423; Hatakeyama S, 2005, J CLIN MICROBIOL, V43, P4139, DOI 10.1128/JCM.43.8.4139-4146.2005; Hatakeyama S, 2007, JAMA-J AM MED ASSOC, V297, P1435, DOI 10.1001/jama.297.13.1435; HAYDEN FG, 1992, CURR TOP MICROBIOL, V176, P119; Hayden F, 2009, CLIN INFECT DIS, V48, pS3, DOI 10.1086/591851; Ibricevic A, 2006, J VIROL, V80, P7469, DOI 10.1128/JVI.02677-05; Ito T, 2000, MICROBIOL IMMUNOL, V44, P423, DOI 10.1111/j.1348-0421.2000.tb02516.x; Johnson NPAS, 2002, B HIST MED, V76, P105, DOI 10.1353/bhm.2002.0022; Lu XH, 1999, J VIROL, V73, P5903, DOI 10.1128/JVI.73.7.5903-5911.1999; Malakhov MP, 2006, ANTIMICROB AGENTS CH, V50, P1470, DOI 10.1128/AAC.50.4.1470-1479.2006; Matrosovich M, 2003, J VIROL, V77, P8418, DOI 10.1128/JVI.77.15.8418-8425.2003; Matrosovich MN, 2004, P NATL ACAD SCI USA, V101, P4620, DOI 10.1073/pnas.0308001101; MILLER MA, 2009, N ENGL J MED; Moscona A, 2005, NEW ENGL J MED, V353, P2633, DOI 10.1056/NEJMp058291; Moscona A, 2009, NEW ENGL J MED, V360, P953, DOI 10.1056/NEJMp0900648; Nelson MI, 2008, PLOS PATHOG, V4, DOI 10.1371/journal.ppat.1000012; Nettesheim P, 2000, J AEROSOL MED, V13, P207, DOI 10.1089/jam.2000.13.207; Nicholls JM, 2007, NAT MED, V13, P147, DOI 10.1038/nm1529; NICHOLLS JM, 2009, ANTIMICROB AGENTS CH; Nicholls JM, 2008, J ANTIMICROB CHEMOTH, V62, P426, DOI 10.1093/jac/dkn167; *NOV SWIN OR INFL, 2009, N ENGL J MED; Peiris JSM, 2003, EMERG INFECT DIS, V9, P628; Sheu TG, 2008, ANTIMICROB AGENTS CH, V52, P3284, DOI 10.1128/AAC.00555-08; SHINDE V, 2009, N ENGL J MED; Shinya K, 2006, NATURE, V440, P435, DOI 10.1038/440435a; Simonsen L, 2007, MOL BIOL EVOL, V24, P1811, DOI 10.1093/molbev/msm103; Stevens J, 2006, SCIENCE, V312, P404, DOI 10.1126/science.1124513; Stevens J, 2006, J MOL BIOL, V355, P1143, DOI 10.1016/j.jmb.2005.11.002; Stevens J, 2008, J MOL BIOL, V381, P1382, DOI 10.1016/j.jmb.2008.04.016; Suzuki Hiroshi, 2003, Journal of Infection and Chemotherapy, V9, P195; Taubenberger JK, 2006, EMERG INFECT DIS, V12, P15, DOI 10.3201/eid1209.05-0979; Thompson CI, 2006, J VIROL, V80, P8060, DOI 10.1128/JVI.00384-06; Thompson WW, 2003, JAMA-J AM MED ASSOC, V289, P179, DOI 10.1001/jama.289.2.179; Thornton DJ, 2000, AM J PHYSIOL-LUNG C, V278, pL1118, DOI 10.1152/ajplung.2000.278.6.L1118; TRIANABALTZER GB, 2009, DAS181 SIALIDA UNPUB; van Riel D, 2006, SCIENCE, V312, P399, DOI 10.1126/science.1125548	52	81	85	0	5	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	NOV 6	2009	4	11							e7788	10.1371/journal.pone.0007788	http://dx.doi.org/10.1371/journal.pone.0007788			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	515ND	19893747	Green Submitted, gold, Green Published			2022-12-25	WOS:000271478000013
J	Demers, A; Caron, V; Rodrigue-Way, A; Wahli, W; Ong, H; Tremblay, A				Demers, Annie; Caron, Veronique; Rodrigue-Way, Amelie; Wahli, Walter; Ong, Huy; Tremblay, Andre			A Concerted Kinase Interplay Identifies PPAR gamma as a Molecular Target of Ghrelin Signaling in Macrophages	PLOS ONE			English	Article							ACTIVATED-RECEPTOR-GAMMA; HORMONE-RELEASING PEPTIDE; SMOOTH-MUSCLE-CELLS; PROTEIN-KINASE; ENDOTHELIAL-CELLS; SCAVENGER RECEPTOR; DEFICIENT MICE; MEDIATED PHOSPHORYLATION; ATHEROSCLEROTIC LESIONS; CARDIOVASCULAR HEALTH	The peroxisome proliferator-activator receptor PPAR gamma plays an essential role in vascular biology, modulating macrophage function and atherosclerosis progression. Recently, we have described the beneficial effect of combined activation of the ghrelin/GHS-R1a receptor and the scavenger receptor CD36 to induce macrophage cholesterol release through transcriptional activation of PPAR gamma. Although the interplay between CD36 and PPAR gamma in atherogenesis is well recognized, the contribution of the ghrelin receptor to regulate PPAR gamma remains unknown. Here, we demonstrate that ghrelin triggers PPAR gamma activation through a concerted signaling cascade involving Erk1/2 and Akt kinases, resulting in enhanced expression of downstream effectors LXR alpha and ABC sterol transporters in human macrophages. These effects were associated with enhanced PPAR gamma phosphorylation independently of the inhibitory conserved serine-84. Src tyrosine kinase Fyn was identified as being recruited to GHS-R1a in response to ghrelin, but failure of activated Fyn to enhance PPAR gamma Ser-84 specific phosphorylation relied on the concomitant recruitment of docking protein Dok-1, which prevented optimal activation of the Erk1/2 pathway. Also, substitution of Ser-84 preserved the ghrelin-induced PPAR gamma activity and responsiveness to Src inhibition, supporting a mechanism independent of Ser-84 in PPAR gamma response to ghrelin. Consistent with this, we found that ghrelin promoted the PI3-K/Akt pathway in a G alpha(q)-dependent manner, resulting in Akt recruitment to PPAR gamma, enhanced PPAR gamma phosphorylation and activation independently of Ser-84, and increased expression of LXRa and ABCA1/G1. Collectively, these results illustrate a complex interplay involving Fyn/Dok-1/Erk and G alpha(q)/PI3-K/Akt pathways to transduce in a concerted manner responsiveness of PPAR gamma to ghrelin in macrophages.			Demers, A (corresponding author), Univ Montreal, CHU Ste Justine, Res Ctr, Montreal, PQ, Canada.	andre.tremblay.1@umontreal.ca	Wahli, Walter/I-3194-2019; Wahli, Walter/B-1398-2009	Wahli, Walter/0000-0002-5966-9089	Canadian Institutes of Health Research Funding Source: Medline	Canadian Institutes of Health Research(Canadian Institutes of Health Research (CIHR))		Adams M, 1997, J BIOL CHEM, V272, P5128, DOI 10.1074/jbc.272.8.5128; Avallone R, 2006, MOL ENDOCRINOL, V20, P3165, DOI 10.1210/me.2006-0146; Baldanzi G, 2002, J CELL BIOL, V159, P1029, DOI 10.1083/jcb.200207165; Barazzoni R, 2005, AM J PHYSIOL-ENDOC M, V288, pE228, DOI 10.1152/ajpendo.00115.2004; Bastie CC, 2007, CELL METAB, V5, P371, DOI 10.1016/j.cmet.2007.04.005; Boulay I, 2005, J IMMUNOL, V175, P4483, DOI 10.4049/jimmunol.175.7.4483; Camina JP, 2007, J CELL PHYSIOL, V213, P187, DOI 10.1002/jcp.21109; Camp HS, 1997, J BIOL CHEM, V272, P10811; Carpino N, 1997, CELL, V88, P197, DOI 10.1016/S0092-8674(00)81840-1; Castrillo A, 2004, ANNU REV CELL DEV BI, V20, P455, DOI 10.1146/annurev.cellbio.20.012103.134432; Chawla A, 2001, MOL CELL, V7, P161, DOI 10.1016/S1097-2765(01)00164-2; Chen C, 1996, J ENDOCRINOL, V148, P381, DOI 10.1677/joe.0.1480381; Chen Z, 2001, ARTERIOSCL THROM VAS, V21, P372, DOI 10.1161/01.ATV.21.3.372; Chorny A, 2008, J IMMUNOL, V180, P8369, DOI 10.4049/jimmunol.180.12.8369; Chung S, 2006, ENDOCRINOLOGY, V147, P5340, DOI 10.1210/en.2006-0536; Collins AR, 2001, ARTERIOSCL THROM VAS, V21, P365, DOI 10.1161/01.ATV.21.3.365; Demers A, 2004, BIOCHEM J, V382, P417, DOI 10.1042/BJ20040036; Demers A, 2008, PPAR RES, V2008, DOI 10.1155/2008/364784; Dixit VD, 2009, BLOOD, V113, P5202, DOI 10.1182/blood-2008-09-181255; Falls HD, 2006, J MOL ENDOCRINOL, V37, P51, DOI 10.1677/jme.1.01943; Feige JN, 2007, J BIOL CHEM, V282, P19152, DOI 10.1074/jbc.M702724200; Feige JN, 2006, PROG LIPID RES, V45, P120, DOI 10.1016/j.plipres.2005.12.002; Feuillet V, 2002, ONCOGENE, V21, P7205, DOI 10.1038/sj.onc.1205929; Filigheddu N, 2007, MOL BIOL CELL, V18, P986, DOI 10.1091/mbc.E06-05-0402; Garcia EA, 2006, CURR OPIN PHARMACOL, V6, P142, DOI 10.1016/j.coph.2005.10.006; Gnanapavan S, 2002, J CLIN ENDOCR METAB, V87, P2988, DOI 10.1210/jc.87.6.2988; Hosooka T, 2008, NAT MED, V14, P188, DOI 10.1038/nm1706; Howard AD, 1996, SCIENCE, V273, P974, DOI 10.1126/science.273.5277.974; Hu ED, 1996, SCIENCE, V274, P2100, DOI 10.1126/science.274.5295.2100; Iantorno M, 2007, AM J PHYSIOL-ENDOC M, V292, pE756, DOI 10.1152/ajpendo.00570.2006; Katugampola SD, 2001, BRIT J PHARMACOL, V134, P143, DOI 10.1038/sj.bjp.0704228; Kojima M, 1999, NATURE, V402, P656, DOI 10.1038/45230; Li AC, 2000, J CLIN INVEST, V106, P523, DOI 10.1172/JCI10370; Li AH, 2007, BIOCHEM BIOPH RES CO, V353, P238, DOI 10.1016/j.bbrc.2006.11.144; Li WG, 2004, CIRCULATION, V109, P2221, DOI 10.1161/01.CIR.0000127956.43874.F2; Lodeiro M, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0004686; Loppnow H, 2008, INNATE IMMUN-LONDON, V14, P63, DOI 10.1177/1753425908091246; Magun R, 1996, ENDOCRINOLOGY, V137, P3590, DOI 10.1210/en.137.8.3590; Marleau Sylvie, 2005, FASEB J, V19, P1869; McGarrigle D., 2007, SCI STKE, V392, pp, DOI [10.1126/stke.3922007pe35, DOI 10.1126/STKE.3922007PE35]; Muslin AJ, 2008, CLIN SCI, V115, P203, DOI 10.1042/CS20070430; Nanzer AM, 2004, EUR J ENDOCRINOL, V151, P233, DOI 10.1530/eje.0.1510233; Pasceri V, 2000, CIRCULATION, V101, P235, DOI 10.1161/01.CIR.101.3.235; Picard N, 2008, MOL ENDOCRINOL, V22, P317, DOI 10.1210/me.2007-0281; Rahaman SO, 2006, CELL METAB, V4, P211, DOI 10.1016/j.cmet.2006.06.007; Rangwala SM, 2003, DEV CELL, V5, P657, DOI 10.1016/S1534-5807(03)00274-0; Reddy MA, 2009, ARTERIOSCL THROM VAS, V29, P387, DOI 10.1161/ATVBAHA.108.179150; Ricote M, 2004, ARTERIOSCL THROM VAS, V24, P230, DOI 10.1161/01.ATV.0000103951.67680.B1; Rodrigue-Way A, 2007, ENDOCRINOLOGY, V148, P1009, DOI 10.1210/en.2006-0975; Rossi F, 2008, PEPTIDES, V29, P2046, DOI 10.1016/j.peptides.2008.07.002; Rossi F, 2009, ATHEROSCLEROSIS, V203, P97, DOI 10.1016/j.atherosclerosis.2008.06.015; Rozengurt E, 2007, J CELL PHYSIOL, V213, P589, DOI 10.1002/jcp.21246; Sanchez M, 2007, J BIOL CHEM, V282, P4830, DOI 10.1074/jbc.M607908200; Sauve K, 2009, CANCER RES, V69, P5793, DOI 10.1158/0008-5472.CAN-08-4924; Shao DL, 1998, NATURE, V396, P377, DOI 10.1038/24634; Shimizu Y, 2003, BIOCHEM BIOPH RES CO, V310, P830, DOI 10.1016/j.bbrc.2003.09.085; Shinohara H, 2004, GENES CELLS, V9, P601, DOI 10.1111/j.1356-9597.2004.00748.x; St-Laurent V, 2005, J STEROID BIOCHEM, V94, P23, DOI 10.1016/j.jsbmb.2005.02.001; Sun YT, 2005, BIOCHEMISTRY-US, V44, P14455, DOI 10.1021/bi0509090; Tesauro M, 2005, CIRCULATION, V112, P2986, DOI 10.1161/CIRCULATIONAHA.105.553883; Uto-Kondo H, 2009, J NUTR, V139, P51, DOI 10.3945/jn.108.096131; van der Lely AJ, 2004, ENDOCR REV, V25, P426, DOI 10.1210/er.2002-0029; Wettschureck N, 2005, MOL CELL BIOL, V25, P1942, DOI 10.1128/MCB.25.5.1942-1948.2005; Xu XB, 2008, ENDOCRINOLOGY, V149, P4183, DOI 10.1210/en.2008-0255; YAMANASHI Y, 1997, DOK CELL, V88, P205; Zhang B, 1996, J BIOL CHEM, V271, P31771, DOI 10.1074/jbc.271.50.31771	66	32	33	0	5	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA	1932-6203			PLOS ONE	PLoS One	NOV 4	2009	4	11							e7728	10.1371/journal.pone.0007728	http://dx.doi.org/10.1371/journal.pone.0007728			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	514RZ	19888469	gold, Green Published, Green Submitted			2022-12-25	WOS:000271414600009
J	Lopez-Bao, JV; Rodriguez, A; Palomares, F				Lopez-Bao, Jose V.; Rodriguez, Alejandro; Palomares, Francisco			Competitive Asymmetries in the Use of Supplementary Food by the Endangered Iberian Lynx (Lynx pardinus)	PLOS ONE			English	Article							ORYCTOLAGUS-CUNICULUS; ANNUAL FECUNDITY; MANAGEMENT; DISPERSAL; DONANA; CONSERVATION; INDIVIDUALS; POPULATION; ABUNDANCE; PATTERNS	Background: As a conservation tool, supplementary feeding programs may be directed to specific individuals or sectors of the target population whose productivity or survival is thought to be limited by food scarcity. However, the use of supplemental food by different sex and age classes has received little attention. We studied individual variation in the access of the endangered Iberian lynx (Lynx pardinus) to supplementary food. Methodology/Principal Findings: From 5349 pictures taken with automatic cameras placed in 25 feeding stations, we identified 28 individuals whose sex and age were known. All individuals known to live in areas subjected to supplementation regularly visited feeding stations. Food consumption was not proportional to expected variations in energy demand within sex and age classes. Food consumption by males was higher than by females, and increased with age, in agreement with a despotic distribution. Food consumption also increased with lynx body mass, and this pattern held for individuals sharing the same breeding territories. The access of inferior competitors increased with the number of feeding stations available within lynx territories. Conclusions/Significance: All lynx exposed to food supplementation made a regular use of extra food but individuals predicted to be competitively dominant visited stations more frequently than subordinates of the same breeding territory. Our results suggest that insufficient provision of supplementary food could restrict the access of juveniles, or even adult females, to feeding stations. Limited consumption by these target individuals may compromise the efficiency of the supplementary feeding programme at the population level, in endangered species that, as the Iberian lynx, exhibit marked sexual dimorphism in body size.			Lopez-Bao, JV (corresponding author), CSIC, Dept Conservat Biol, Estac Biol Donana, E-41080 Seville, Spain.	jvlb@ebd.csic.es	Rodríguez, Alejandro/E-7709-2011; Palomares, Francisco/F-5327-2016	Rodríguez, Alejandro/0000-0001-9367-3420; Palomares, Francisco/0000-0002-4655-7205; Lopez-Bao, Jose Vicente/0000-0001-9213-998X				ALDAMA JJ, 1991, J WILDLIFE MANAGE, V55, P635, DOI 10.2307/3809512; Anderson DR., 2002, PRACTICAL INFORM THE, DOI DOI 10.1007/B97636; BEKOFF M, 1977, AM NAT, V111, P715, DOI 10.1086/283201; BELTRAN JF, 1993, J MAMMAL, V74, P852, DOI 10.2307/1382423; Boland CRJ, 1997, J ANIM ECOL, V66, P683, DOI 10.2307/5921; Bose M, 2007, IBIS, V149, P490, DOI 10.1111/j.1474-919X.2007.00674.x; DELIBES M, 2000, NATURE ENV SERIES, V111, P44; Donazar JA, 1999, BEHAV ECOL SOCIOBIOL, V45, P55, DOI 10.1007/s002650050539; Elliott GP, 2001, BIOL CONSERV, V99, P121, DOI 10.1016/S0006-3207(00)00191-9; Fernandez N, 2002, J ZOOL, V258, P1, DOI 10.1017/S0952836902001140; Ferreras P, 2004, BEHAV ECOL, V15, P31, DOI 10.1093/beheco/arg097; Ferreras P, 1997, J ZOOL, V243, P163, DOI 10.1111/j.1469-7998.1997.tb05762.x; FERRERAS P, 2009, BIOL CONSERVATION WI; Funston PJ, 1998, ANIM BEHAV, V56, P1333, DOI 10.1006/anbe.1998.0884; Galindo-Leal C, 1998, J MAMMAL, V79, P1131, DOI 10.2307/1383004; GITTLEMAN JL, 1988, AM ZOOL, V28, P863, DOI 10.1093/icb/28.3.863; Gordon IJ, 2004, J APPL ECOL, V41, P1021, DOI 10.1111/j.0021-8901.2004.00985.x; Gosling L.M., 2000, BEHAV CONSERVATION, P438; Lewis RJ, 2002, Q REV BIOL, V77, P149, DOI 10.1086/343899; Littell R. C., 2006, SAS SYSTEMS MIXED MO, V2nd; Lopez-Bao JV, 2010, ANIM CONSERV, V13, P35, DOI 10.1111/j.1469-1795.2009.00300.x; Lopez-Bao JV, 2008, BIOL CONSERV, V141, P1857, DOI 10.1016/j.biocon.2008.05.002; Meretsky VJ, 1999, J WILDLIFE MANAGE, V63, P107, DOI 10.2307/3802491; MONAGHAN P, 1985, ANIM BEHAV, V33, P993, DOI 10.1016/S0003-3472(85)80033-6; MORENO S, 1995, BIOL CONSERV, V73, P81, DOI 10.1016/0006-3207(94)00106-Z; Moreno S, 2007, WILDLIFE RES, V34, P652, DOI 10.1071/WR06142; Murray DL, 2002, J ANIM ECOL, V71, P614, DOI 10.1046/j.1365-2656.2002.00632.x; Nagy LR, 2005, ECOLOGY, V86, P675, DOI 10.1890/04-0155; Palomares F, 2005, BIOL CONSERV, V122, P53, DOI 10.1016/j.biocon.2004.06.020; Palomares F, 2001, J APPL ECOL, V38, P9, DOI 10.1046/j.1365-2664.2001.00565.x; Palomares F, 2001, WILDLIFE MONOGR, P1; PARKER GA, 1986, ANIM BEHAV, V34, P1222, DOI 10.1016/S0003-3472(86)80182-8; Partridge ST, 2001, J WILDLIFE MANAGE, V65, P191, DOI 10.2307/3802897; Phillips M.K., 1988, Conservation Biology, V2, P139, DOI 10.1111/j.1523-1739.1988.tb00164.x; Preston KL, 2006, ECOLOGY, V87, P160, DOI 10.1890/05-0344; RANDALL B, 1987, BEHAVIOUR, V101, P225; REVILLA E, 2007, PROYECTOS INVESTIGAC, P307; Rode KD, 2006, ECOLOGY, V87, P2636, DOI 10.1890/0012-9658(2006)87[2636:SDRSAH]2.0.CO;2; Rodgers AR., 1998, HRE HOME RANGE EXTEN; Rodriguez A, 2002, ECOGRAPHY, V25, P314, DOI 10.1034/j.1600-0587.2002.250308.x; Ruckstuhl K.E., 2005, SEXUAL SEGREGATION V; SANDELL M, 1989, CARNIVORE BEHAV ECOL, V1, P164; Schoech SJ, 2008, BIOL CONSERV, V141, P162, DOI 10.1016/j.biocon.2007.09.009	43	17	17	0	24	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	OCT 28	2009	4	10							e7610	10.1371/journal.pone.0007610	http://dx.doi.org/10.1371/journal.pone.0007610			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	511UJ	19898611	Green Published, Green Submitted, gold			2022-12-25	WOS:000271194600010
J	Meunier, C; Cai, J; Fortin, A; Kwan, T; Marquis, JF; Turbide, C; Van der Kraak, L; Jothy, S; Beauchemin, N; Gros, P				Meunier, C.; Cai, J.; Fortin, A.; Kwan, T.; Marquis, J-F; Turbide, C.; Van der Kraak, L.; Jothy, S.; Beauchemin, N.; Gros, P.			Characterization of a major colon cancer susceptibility locus (Ccs3) on mouse chromosome 3	ONCOGENE			English	Article						colon cancer; Ccs3; genetics; azoxymethane; gene mapping	GENOME-WIDE ASSOCIATION; COPY NUMBER ANALYSIS; NF-KAPPA-B; COLORECTAL-CANCER; TUMOR SUSCEPTIBILITY; GENETIC-CONTROL; MICE; CARCINOGENESIS; AZOXYMETHANE; COMPLEX	Treatment of mice with the carcinogen azoxymethane (AOM) induces a number of lesions in the colon, including hyperplastic lesions, as well adenomas and carcinomas in situ. Inbred strains of mice show different responses to AOM-induced carcinogenesis. A/J mice are highly susceptible and develop a greater number of hyperplastic lesions and tumors (15-70 tumors per mouse) than resistant C57BL/6J mice (0-6 tumors per mouse). Susceptibility to AOM-induced tumors segregates as a co-dominant trait in (A x B6)F1 hybrids. Using a set of 23 AcB and BcA recombinant congenic mouse strains derived from A/J (susceptible) and B6 (resistant) parents, we observed that the number of hyperplastic lesions and tumors induced by AOM was under different genetic controls in AcB/BcA strains. The multiplicity of AOM-induced tumors is controlled by a major locus that we have mapped on the distal portion of chromosome 3, to which we have given the temporary designation colon cancer susceptibility locus 3 (Ccs3). B6 and A/J alleles at Ccs3 are associated with resistance and susceptibility, respectively. Haplotype analysis in key informative AcB/BcA strains restricts the size of the Ccs3 locus to a 14Mb segment that contains 94 annotated genes. The expression level of all these genes in normal colon has been established by transcript profiling with microarrays, and has led to the identification of a subset of positional candidates that are expressed at high levels in this tissue. The 4q and 1p human chromosomal segments sharing syntenic homology with the mouse Ccs3 segment are known to be associated with inflammatory bowel diseases and colorectal tumors in humans, suggesting that the study of the mouse Ccs3 locus may help further the pathogenesis of these human conditions. Oncogene (2010) 29, 647-661; doi: 10.1038/onc.2009.369; published online 16 November 2009	[Meunier, C.; Cai, J.; Fortin, A.; Marquis, J-F; Van der Kraak, L.; Beauchemin, N.; Gros, P.] McGill Univ, Dept Biochem, Quebec City, PQ H3G 0B1, Canada; [Fortin, A.] Dafra Pharma Int, Turnhout, Belgium; [Kwan, T.] McGill Univ, Genome Quebec Innovat Ctr, Quebec City, PQ H3G 0B1, Canada; [Turbide, C.; Beauchemin, N.; Gros, P.] McGill Univ, Goodman Canc Ctr, Quebec City, PQ H3G 0B1, Canada; [Jothy, S.] St Michaels Hosp, Dept Lab Med & Pathobiol, Toronto, ON M5B 1W8, Canada; [Jothy, S.] Univ Toronto, Toronto, ON M5B 1W8, Canada	McGill University; McGill University; McGill University; University of Toronto; University Toronto Affiliates; Saint Michaels Hospital Toronto; University of Toronto	Gros, P (corresponding author), McGill Univ, Dept Biochem, McGill Life Sci Complex,Bellini Pavil,Room 366,36, Quebec City, PQ H3G 0B1, Canada.	philippe.gros@mcgill.ca			National Cancer Institute of Canada; Goodman Cancer Centre	National Cancer Institute of Canada(Canadian Cancer Society (CCS)); Goodman Cancer Centre	We thank George Chountalos for his work in the haplotype mapping of the genetic interval of Ccs3 in common mouse strains. This work was supported by research grants to PG and NB from the National Cancer Institute of Canada and the Canderel Initiative Program of the Goodman Cancer Centre. PG is a James McGill professor of biochemistry.	AKAGI K, 2004, NUCLEIC ACIDS RES, V32, pD253; Angel JM, 2000, MOL CARCINOGEN, V27, P47, DOI 10.1002/(SICI)1098-2744(200001)27:1<47::AID-MC7>3.0.CO;2-7; Barrett JC, 2008, NAT GENET, V40, P955, DOI 10.1038/ng.175; Cho JH, 1998, P NATL ACAD SCI USA, V95, P7502, DOI 10.1073/pnas.95.13.7502; Cianciulli A, 2004, CANCER GENET CYTOGEN, V151, P52, DOI 10.1016/j.cancergencyto.2003.09.013; Couturier-Turpin MH, 2001, CANCER GENET CYTOGEN, V124, P47, DOI 10.1016/S0165-4608(00)00325-3; de la Chapelle A, 2004, NAT REV CANCER, V4, P769, DOI 10.1038/nrc1453; Demant P, 2003, NAT REV GENET, V4, P721, DOI 10.1038/nrg1157; DESCHNER EE, 1988, CANCER, V61, P478, DOI 10.1002/1097-0142(19880201)61:3<478::AID-CNCR2820610312>3.0.CO;2-A; Dragani TA, 2003, CANCER RES, V63, P3011; EVANS JT, 1977, CANCER RES, V37, P134; FIJNEMAN RJA, 1995, CANCER RES, V55, P3179; Fortin A, 2001, GENOMICS, V74, P21, DOI 10.1006/geno.2001.6528; Fortin Anny, 2007, Novartis Found Symp, V281, P141; Greten FR, 2004, CELL, V118, P285, DOI 10.1016/j.cell.2004.07.013; Gross O, 2008, BLOOD, V112, P2421, DOI 10.1182/blood-2007-11-123513; Herath NI, 2006, J GASTROEN HEPATOL, V21, P15, DOI 10.1111/j.1440-1746.2005.04043.x; Houlston RS, 2008, NAT GENET, V40, P1426, DOI 10.1038/ng.262; JACOBY RF, 1994, GENOMICS, V22, P381, DOI 10.1006/geno.1994.1399; Jaeger E, 2008, NAT GENET, V40, P26, DOI 10.1038/ng.2007.41; Karin M, 2008, CELL RES, V18, P334, DOI 10.1038/cr.2008.30; Kurashina K, 2008, CANCER SCI, V99, P1835, DOI 10.1111/j.1349-7006.2008.00881.x; LOTHE RA, 1995, GENE CHROMOSOME CANC, V14, P182, DOI 10.1002/gcc.2870140305; MALO D, 1994, GENOMICS, V23, P51, DOI 10.1006/geno.1994.1458; Manly KF, 2001, MAMM GENOME, V12, P930, DOI 10.1007/s00335-001-1016-3; Min-Oo G, 2003, NAT GENET, V35, P357, DOI 10.1038/ng1260; Min-Oo G, 2007, J EXP MED, V204, P511, DOI 10.1084/jem.20061252; Moen CJA, 1996, P NATL ACAD SCI USA, V93, P1082, DOI 10.1073/pnas.93.3.1082; Nambiar PR, 2003, INT J ONCOL, V22, P145; Nancarrow DJ, 2008, CANCER RES, V68, P4163, DOI 10.1158/0008-5472.CAN-07-6710; Pacifico F, 2006, BIOCHEM PHARMACOL, V72, P1142, DOI 10.1016/j.bcp.2006.07.032; Papanikolaou A, 1998, CANCER LETT, V130, P29, DOI 10.1016/S0304-3835(98)00101-3; Rajagopalan H, 2003, NAT REV CANCER, V3, P695, DOI 10.1038/nrc1165; Ruivenkamp C, 2003, ONCOGENE, V22, P3472, DOI 10.1038/sj.onc.1206246; Shih IM, 2001, CANCER RES, V61, P818; Stork PJS, 2005, BLOOD, V106, P2952, DOI 10.1182/blood-2005-03-1062; Stork PJS, 2003, TRENDS BIOCHEM SCI, V28, P267, DOI 10.1016/S0968-0004(03)00087-2; Suzui M, 2002, CANCER LETT, V183, P31, DOI 10.1016/S0304-3835(02)00114-3; Takahashi M, 2004, CANCER SCI, V95, P475, DOI 10.1111/j.1349-7006.2004.tb03235.x; Tenesa A, 2008, NAT GENET, V40, P631, DOI 10.1038/ng.133; Thome M, 2004, NAT REV IMMUNOL, V4, P348, DOI 10.1038/nri1352; Tomlinson I, 2007, NAT GENET, V39, P984, DOI 10.1038/ng2085; Tomlinson IPM, 2008, NAT GENET, V40, P623, DOI 10.1038/ng.111; Tuite A, 2005, GENES IMMUN, V6, P672, DOI 10.1038/sj.gene.6364254; vanWezel T, 1996, NAT GENET, V14, P468, DOI 10.1038/ng1296-468; Willis TG, 1999, CELL, V96, P35, DOI 10.1016/S0092-8674(00)80957-5; Wood LD, 2007, SCIENCE, V318, P1108, DOI 10.1126/science.1145720; Xue LQ, 2003, NAT IMMUNOL, V4, P857, DOI 10.1038/ni963; Zanke BW, 2007, NAT GENET, V39, P989, DOI 10.1038/ng2089	49	16	17	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 4	2010	29	5					647	661		10.1038/onc.2009.369	http://dx.doi.org/10.1038/onc.2009.369			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	551QI	19915610				2022-12-25	WOS:000274223700003
J	Oda, K; Matoba, Y; Noda, M; Kumagai, T; Sugiyama, M				Oda, Kosuke; Matoba, Yasuyuki; Noda, Masafumi; Kumagai, Takanori; Sugiyama, Masanori			Catalytic Mechanism of Bleomycin N-Acetyltransferase Proposed on the Basis of Its Crystal Structure	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RESISTANCE DETERMINANT; MYCOBACTERIUM-TUBERCULOSIS; STREPTOMYCES-VERTICILLUS; KINETIC MECHANISM; SUBSTRATE-BINDING; ESCHERICHIA-COLI; COENZYME-A; PROTEINS; COMPLEX; CLEAVAGE	Bleomycin (Bm) N-acetyltransferase, BAT, is a self-resistance determinant in Bm-producing Streptomyces verticillus ATCC15003. In our present study, we crystallized BAT under both a terrestrial and a microgravity environment in the International Space Station. In addition to substrate-free BAT, the crystal structures of BAT in a binary complex with CoA and in a ternary complex with Bm and CoA were determined. BAT forms a dimer structure via interaction of its C-terminal domains in the monomers. However, each N-terminal domain in the dimer is positioned without mutual interaction. The tunnel observed in the N-terminal domain of BAT has two entrances: one that adopts a wide funnel-like structure necessary to accommodate the metal-binding domain of Bm, and another narrow entrance that accommodates acetyl-CoA (AcCoA). A groove formed on the dimer interface of two BAT C-terminal domains accommodates the DNA-binding domain of Bm. In a ternary complex of BAT, BmA2, and CoA, a thiol group of CoA is positioned near the primary amine of Bm at the midpoint of the tunnel. This proximity ensures efficient transfer of an acetyl group from AcCoA to the primary amine of Bm. Based on the BAT crystal structure and the enzymatic kinetic study, we propose that the catalytic mode of BAT takes an ordered-like mechanism.	[Oda, Kosuke; Matoba, Yasuyuki; Noda, Masafumi; Kumagai, Takanori; Sugiyama, Masanori] Hiroshima Univ, Dept Mol Microbiol & Biotechnol, Grad Sch Biomed Sci, Minami Ku, Hiroshima 7348551, Japan	Hiroshima University	Sugiyama, M (corresponding author), Hiroshima Univ, Dept Mol Microbiol & Biotechnol, Grad Sch Biomed Sci, Minami Ku, Kasumi 1-2-3, Hiroshima 7348551, Japan.	sugi@hiroshima-u.ac.jp	ODA, KOSUKE/ABD-2610-2021		National Project on Protein Structural and Functional Analyses, Japan; Ministry of Education, Science, and Culture of Japan	National Project on Protein Structural and Functional Analyses, Japan; Ministry of Education, Science, and Culture of Japan(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT))	This work was supported by a grant from the National Project on Protein Structural and Functional Analyses, Japan (to M.S.), and a grant-in-aid for Scientific Research from the Ministry of Education, Science, and Culture of Japan (to Y.M.).	BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Bergdoll M, 1998, PROTEIN SCI, V7, P1661, DOI 10.1002/pro.5560070801; BLUM RH, 1973, CANCER, V31, P903, DOI 10.1002/1097-0142(197304)31:4<903::AID-CNCR2820310422>3.0.CO;2-N; BRUNGER AT, 1992, NATURE, V355, P472, DOI 10.1038/355472a0; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; BURGER RM, 1981, J BIOL CHEM, V256, P1636; CARTER BJ, 1990, J BIOL CHEM, V265, P4193; CARTER BJ, 1990, P NATL ACAD SCI USA, V87, P9373, DOI 10.1073/pnas.87.23.9373; De Angelis J, 1998, J BIOL CHEM, V273, P3045, DOI 10.1074/jbc.273.5.3045; delaFortelle E, 1997, METHOD ENZYMOL, V276, P472, DOI 10.1016/S0076-6879(97)76073-7; Dutnall RN, 1998, CELL, V94, P427, DOI 10.1016/S0092-8674(00)81584-6; Dyda F, 2000, ANNU REV BIOPH BIOM, V29, P81, DOI 10.1146/annurev.biophys.29.1.81; Garcia-Ruiz JM, 2002, ACTA CRYSTALLOGR D, V58, P1638, DOI 10.1107/S0907444902014464; GATIGNOL A, 1988, FEBS LETT, V230, P171, DOI 10.1016/0014-5793(88)80665-3; Hayward S, 1998, PROTEINS, V30, P144, DOI 10.1002/(SICI)1097-0134(19980201)30:2<144::AID-PROT4>3.0.CO;2-N; He HZ, 2003, J MOL BIOL, V325, P1019, DOI 10.1016/S0022-2836(02)01284-6; Hickman AB, 1999, CELL, V97, P361, DOI 10.1016/S0092-8674(00)80745-X; HOLM L, 1993, J MOL BIOL, V233, P123, DOI 10.1006/jmbi.1993.1489; KANE SA, 1994, J BIOL CHEM, V269, P10899; Kawano Y, 2000, J MOL BIOL, V295, P915, DOI 10.1006/jmbi.1999.3404; Kumagai T, 1999, FEBS LETT, V442, P34, DOI 10.1016/S0014-5793(98)01613-5; MAGLIOZZO RS, 1989, MOL PHARMACOL, V35, P428; Maruyama M, 2001, J BIOL CHEM, V276, P9992, DOI 10.1074/jbc.M009874200; Matsuo H, 1997, FEMS MICROBIOL LETT, V153, P83, DOI 10.1016/S0378-1097(97)00237-1; McRee DE, 1992, J MOL GRAPHICS, V10, P44, DOI DOI 10.1016/0263-7855(92)80022-6; MURZIN AG, 1995, J MOL BIOL, V247, P536, DOI 10.1006/jmbi.1995.0159; OPPENHEIMER NJ, 1979, BIOCHEMISTRY-US, V18, P3439, DOI 10.1021/bi00583a001; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; STUBBE J, 1987, CHEM REV, V87, P1107, DOI 10.1021/cr00081a011; Sugiyama M, 2002, J BIOL CHEM, V277, P2311, DOI 10.1074/jbc.M103278200; SUGIYAMA M, 1994, FEMS MICROBIOL LETT, V121, P81, DOI 10.1111/j.1574-6968.1994.tb07079.x; SUGIYAMA M, 1994, GENE, V151, P11; SUGIYAMA M, 1995, FEBS LETT, V362, P80, DOI 10.1016/0014-5793(95)00218-X; Tanner KG, 2000, J BIOL CHEM, V275, P22048, DOI 10.1074/jbc.M002893200; Tanner KG, 2000, BIOCHEMISTRY-US, V39, P11961, DOI 10.1021/bi001272h; Trievel RC, 1999, P NATL ACAD SCI USA, V96, P8931, DOI 10.1073/pnas.96.16.8931; UMEZAWA H, 1974, FED PROC, V33, P2296; Vetting MW, 2005, ARCH BIOCHEM BIOPHYS, V433, P212, DOI 10.1016/j.abb.2004.09.003; Vetting MW, 2003, PROTEIN SCI, V12, P1954, DOI 10.1110/ps.03153703; Vetting MW, 2002, NAT STRUCT BIOL, V9, P653, DOI 10.1038/nsb830; Wu W, 1996, J AM CHEM SOC, V118, P1281, DOI 10.1021/ja952497w; Yan Y, 2000, MOL CELL, V6, P1195, DOI 10.1016/S1097-2765(00)00116-7	42	15	16	1	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 8	2010	285	2					1446	1456		10.1074/jbc.M109.022277	http://dx.doi.org/10.1074/jbc.M109.022277			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	539MH	19889644	Green Published, hybrid			2022-12-25	WOS:000273258200064
J	Orba, Y; Suzuki, T; Makino, Y; Kubota, K; Tanaka, S; Kimura, T; Sawa, H				Orba, Yasuko; Suzuki, Tadaki; Makino, Yoshinori; Kubota, Kanako; Tanaka, Shinya; Kimura, Takashi; Sawa, Hirofumi			Large T Antigen Promotes JC Virus Replication in G(2)-arrested Cells by Inducing ATM- and ATR-mediated G(2) Checkpoint Signaling	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA-DAMAGE CHECKPOINT; PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY; BINDING-ACTIVITY; NUCLEAR-MATRIX; SV40 ORIGIN; S-PHASE; KINASE; POLYOMAVIRUS; CYCLE; P53	Large T antigen (TAg) of the human polyomavirus JC virus (JCV) possesses DNA binding and helicase activities, which, together with various cellular proteins, are required for replication of the viral genome. We now show that JCV-infected cells expressing TAg accumulate in the G(2) phase of the cell cycle as a result of the activation of ATM- and ATR-mediated G(2) checkpoint pathways. Transient transfection of cells with a TAg expression vector also induced G(2) checkpoint signaling and G(2) arrest. Analysis of TAg mutants with different subnuclear localizations suggested that the association of TAg with cellular DNA contributes to the induction of G(2) arrest. Abrogation of G(2) arrest by inhibition of ATM and ATR, Chk1, and Wee1 suppressed JCV genome replication. In addition, abrogation of the G(2)-M transition by Cdc2 depletion disabled Wee1 depletion induced suppression of JCV genome replication, suggesting that JCV replication is facilitated by G(2) arrest resulting from G(2) checkpoint signaling. Moreover, inhibition of ATM and ATR by caffeine suppressed JCV production. The observation that oligodendrocytes productively infected with JCV in vivo also undergo G(2) arrest suggests that G(2) checkpoint inhibitors such as caffeine are potential therapeutic agents for JCV infection.	[Orba, Yasuko; Suzuki, Tadaki; Makino, Yoshinori; Kimura, Takashi; Sawa, Hirofumi] Hokkaido Univ, Dept Mol Pathobiol, Res Ctr Zoonosis Control, Kita Ku, Sapporo, Hokkaido 0010020, Japan; [Kubota, Kanako] Hokkaido Univ Hosp, Dept Surg Pathol, Kita Ku, Sapporo, Hokkaido 0608648, Japan; [Tanaka, Shinya] Hokkaido Univ, Grad Sch Med, Canc Res Lab, Dept Pathol,Kita Ku, Sapporo, Hokkaido 0608638, Japan; [Orba, Yasuko; Sawa, Hirofumi] Hokkaido Univ, Global COE Program, Kita Ku, Sapporo, Hokkaido 0600818, Japan	Hokkaido University; Hokkaido University; Hokkaido University; Hokkaido University	Sawa, H (corresponding author), Hokkaido Univ, Dept Mol Pathobiol, Res Ctr Zoonosis Control, Kita Ku, N20,W10, Sapporo, Hokkaido 0010020, Japan.	h-sawa@czc.hokudai.ac.jp	Tanaka, Shinya/D-3586-2011; Sawa, Hirofumi/F-6954-2012; Suzuki, Tadaki/ABH-2661-2020; Kimura, Takashi/F-6880-2012; Orba, Yasuko/F-6888-2012; Sawa, Hirofumi/AAW-8816-2021	Sawa, Hirofumi/0000-0003-2569-2755; 	Ministry of Education, Culture, Sports, Science, and Technology (MEXT); Ministry of Health, Labor, and Welfare of Japan; Japan Health Science Foundation; Program of Founding Research Centers for Emerging and Reemerging Infectious Diseases, MEXT	Ministry of Education, Culture, Sports, Science, and Technology (MEXT)(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)); Ministry of Health, Labor, and Welfare of Japan(Ministry of Health, Labour and Welfare, Japan); Japan Health Science Foundation; Program of Founding Research Centers for Emerging and Reemerging Infectious Diseases, MEXT(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT))	This work was supported in part by grants from the Ministry of Education, Culture, Sports, Science, and Technology (MEXT) and the Ministry of Health, Labor, and Welfare of Japan, the Japan Health Science Foundation, and the Program of Founding Research Centers for Emerging and Reemerging Infectious Diseases, MEXT.	Banin S, 1998, SCIENCE, V281, P1674, DOI 10.1126/science.281.5383.1674; Bartkova J, 2006, NATURE, V444, P633, DOI 10.1038/nature05268; Berger JR, 2007, CURR NEUROL NEUROSCI, V7, P461, DOI 10.1007/s11910-007-0072-9; BULLOCK PA, 1991, MOL CELL BIOL, V11, P2350, DOI 10.1128/MCB.11.5.2350; Bunz F, 1998, SCIENCE, V282, P1497, DOI 10.1126/science.282.5393.1497; Caracciolo V, 2006, ONCOGENE, V25, P5294, DOI 10.1038/sj.onc.1209681; Chaturvedi P, 1999, ONCOGENE, V18, P4047, DOI 10.1038/sj.onc.1202925; CHEN NN, 1995, J VIROL, V69, P5843, DOI 10.1128/JVI.69.9.5843-5848.1995; CIEJEK EM, 1983, NATURE, V306, P607, DOI 10.1038/306607a0; Dahl J, 2005, J VIROL, V79, P13007, DOI 10.1128/JVI.79.20.13007-13017.2005; Davy C, 2007, VIROLOGY, V368, P219, DOI 10.1016/j.virol.2007.05.043; DEAN FB, 1987, P NATL ACAD SCI USA, V84, P16, DOI 10.1073/pnas.84.1.16; DICKMANNS A, 1994, J VIROL, V68, P5496, DOI 10.1128/JVI.68.9.5496-5508.1994; FAIRMAN MP, 1988, EMBO J, V7, P1211, DOI 10.1002/j.1460-2075.1988.tb02933.x; FRISQUE RJ, 1984, J VIROL, V51, P458, DOI 10.1128/JVI.51.2.458-469.1984; HE DC, 1990, J CELL BIOL, V110, P569, DOI 10.1083/jcb.110.3.569; Hermeking H, 1997, MOL CELL, V1, P3, DOI 10.1016/S1097-2765(00)80002-7; HIRT B, 1967, J MOL BIOL, V26, P365, DOI 10.1016/0022-2836(67)90307-5; Jiao JF, 2003, J VIROL, V77, P12720, DOI 10.1128/JVI.77.23.12720-12728.2003; Komagome R, 2002, J VIROL, V76, P12992, DOI 10.1128/JVI.76.24.12992-13000.2002; Lee JH, 2005, SCIENCE, V308, P551, DOI 10.1126/science.1108297; Lee J, 2007, J BIOL CHEM, V282, P28036, DOI 10.1074/jbc.M704635200; Lehman JM, 2000, EXP CELL RES, V258, P215, DOI 10.1006/excr.2000.4927; LEHMAN JM, 1994, CYTOMETRY, V16, P138, DOI 10.1002/cyto.990160207; LIN HJL, 1992, J VIROL, V66, P5443, DOI 10.1128/JVI.66.9.5443-5452.1992; Liu QH, 2000, GENE DEV, V14, P1448; Mu JJ, 2007, J BIOL CHEM, V282, P17330, DOI 10.1074/jbc.C700079200; NELSON WG, 1986, ANNU REV BIOPHYS BIO, V15, P457, DOI 10.1146/annurev.bb.15.060186.002325; NUKUZUMA S, 1995, J MED VIROL, V47, P370, DOI 10.1002/jmv.1890470413; NURSE P, 1990, NATURE, V344, P503, DOI 10.1038/344503a0; Okada Y, 2002, ACTA NEUROPATHOL, V104, P130, DOI 10.1007/s00401-002-0526-8; Okubo E, 2003, J VIROL, V77, P1257, DOI 10.1128/JVI.77.2.1257-1267.2003; Orba Y, 2008, VIROLOGY, V370, P173, DOI 10.1016/j.virol.2007.08.034; Paulson QX, 2008, ONCOGENE, V27, P4954, DOI 10.1038/onc.2008.138; Raleigh JM, 2000, J CELL SCI, V113, P1727; Rapic-Otrin V, 2002, NUCLEIC ACIDS RES, V30, P2588, DOI 10.1093/nar/30.11.2588; Robison JG, 2007, CELL CYCLE, V6, P2408, DOI 10.4161/cc.6.19.4773; SCHNEIDER C, 1994, MOL CELL BIOL, V14, P3176, DOI 10.1128/MCB.14.5.3176; Shi YL, 2005, J BIOL CHEM, V280, P40195, DOI 10.1074/jbc.C500400200; Shieh SY, 1997, CELL, V91, P325, DOI 10.1016/S0092-8674(00)80416-X; SIMMONS DT, 1990, J VIROL, V64, P4858, DOI 10.1128/JVI.64.10.4858-4865.1990; Sunden Y, 2006, ACTA NEUROPATHOL, V111, P379, DOI 10.1007/s00401-005-0025-9; Suzuki S, 2001, VIROLOGY, V286, P100, DOI 10.1006/viro.2001.0972; Toyoshima F, 1998, EMBO J, V17, P2728, DOI 10.1093/emboj/17.10.2728; Wang QE, 2004, CARCINOGENESIS, V25, P1033, DOI 10.1093/carcin/bgh085; Wang XW, 1999, P NATL ACAD SCI USA, V96, P3706, DOI 10.1073/pnas.96.7.3706; Wu CX, 2001, J VIROL, V75, P2839, DOI 10.1128/JVI.75.6.2839-2847.2001; Yoo HY, 2004, CELL, V117, P575, DOI 10.1016/S0092-8674(04)00417-9; Zhao RY, 2005, CELL RES, V15, P143, DOI 10.1038/sj.cr.7290279; Zou L, 2003, SCIENCE, V300, P1542, DOI 10.1126/science.1083430	50	60	62	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 8	2010	285	2					1544	1554		10.1074/jbc.M109.064311	http://dx.doi.org/10.1074/jbc.M109.064311			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	539MH	19903823	Green Published, hybrid			2022-12-25	WOS:000273258200073
J	Yang, Y; Wu, X; Gui, PC; Wu, JB; Sheng, JZ; Ling, SZ; Braun, AP; Davis, GE; Davis, MJ				Yang, Yan; Wu, Xin; Gui, Peichun; Wu, Jianbo; Sheng, Jian-Zhong; Ling, Shizhang; Braun, Andrew P.; Davis, George E.; Davis, Michael J.			alpha 5 beta 1 Integrin Engagement Increases Large Conductance, Ca2+-activated K+ Channel Current and Ca2+ Sensitivity through c-src-mediated Channel Phosphorylation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED POTASSIUM CHANNELS; VASCULAR SMOOTH-MUSCLE; RGD-CONTAINING PEPTIDE; PROTEIN-KINASE-A; EXTRACELLULAR-MATRIX; TYROSINE KINASE; ENDOTHELIAL-CELLS; INJURY; HSLO; ADHESION	Large conductance, calcium-activated K+ (BK) channels are important regulators of cell excitability and recognized targets of intracellular kinases. BK channel modulation by tyrosine kinases, including focal adhesion kinase and c-src, suggests their potential involvement in integrin signaling. Recently, we found that fibronectin, an endogenous alpha 5 beta 1 integrin ligand, enhances BK channel current through both Ca2+- and phosphorylation-dependent mechanisms in vascular smooth muscle. Here, we show that macroscopic currents from HEK 293 cells expressing murine BK channel alpha-subunits (mSlo) are acutely potentiated following alpha 5 beta 1 integrin activation. The effect occurs in a Ca2+-dependent manner, 1-3 min after integrin engagement. After integrin activation, normalized conductance-voltage relations for mSlo are left-shifted at free Ca2+ concentrations >= 1 mu M. Overexpression of human c-src with mSlo, in the absence of integrin activation, leads to similar shifts in mSlo Ca2+ sensitivity, whereas overexpression of catalytically inactive c-src blocks integrin-induced potentiation. However, neither integrin activation nor c-src overexpression potentiates current in BK channels containing a point mutation at Tyr-766. Biochemical tests confirmed the critical importance of residue Tyr-766 in integrin-induced channel phosphorylation. Thus, BK channel activity is enhanced by alpha 5 beta 1 integrin activation, likely through an intracellular signaling pathway involving c-src phosphorylation of the channel alpha-subunit at Tyr-766. The net result is increased current amplitude, enhanced Ca2+ sensitivity, and rate of activation of the BK channel, which would collectively promote smooth muscle hyperpolarization in response to integrin-extracellular matrix interactions.	[Yang, Yan; Gui, Peichun; Davis, George E.; Davis, Michael J.] Univ Missouri, Sch Med, Dept Med Pharmacol & Physiol, Columbia, MO 65212 USA; [Wu, Jianbo; Davis, Michael J.] Univ Missouri, Sch Med, Dalton CVRC, Columbia, MO 65212 USA; Texas A&M Hlth Sci Ctr, Dept Syst Biol & Translat Med, College Stn, TX 77840 USA; [Sheng, Jian-Zhong; Ling, Shizhang; Braun, Andrew P.] Univ Calgary, Sch Med, Smooth Muscle Res Grp, Calgary, AB T2N 4N1, Canada	University of Missouri System; University of Missouri Columbia; University of Missouri System; University of Missouri Columbia; Texas A&M University System; Texas A&M University College Station; Texas A&M Health Science Center; University of Calgary	Davis, MJ (corresponding author), Univ Missouri, Sch Med, Dept Med Pharmacol & Physiol, 1 Hosp Dr,Rm M451, Columbia, MO 65212 USA.	davismj@health.missouri.edu	Ling, Shizhang/J-6114-2014	Ling, Shizhang/0000-0002-6856-3577; wu, xin/0000-0002-5005-6358	National Institutes of Health [HL-72989, HL-71796, RR-017353]; Canadian Institutes of Health Research; The Heart and Stroke Foundation of Alberta; NATIONAL CENTER FOR RESEARCH RESOURCES [C06RR017353] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL072989, R01HL071796] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Canadian Institutes of Health Research(Canadian Institutes of Health Research (CIHR)); The Heart and Stroke Foundation of Alberta; NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))	This work was supported, in whole or in part, by National Institutes of Health Grants HL-72989 and HL-71796 (to M. J. D.) and RR-017353 (to University of Missouri). This work was also supported by operating grant support (to A. P. B.) from the Canadian Institutes of Health Research and The Heart and Stroke Foundation of Alberta.	Alioua A, 2002, P NATL ACAD SCI USA, V99, P14560, DOI 10.1073/pnas.222348099; Arcangeli A, 2004, BIOCHEM SOC T, V32, P826, DOI 10.1042/BST0320826; Barman SA, 2003, AM J PHYSIOL-LUNG C, V284, pL1004, DOI 10.1152/ajplung.00295.2002; Baron A, 1997, J PHYSIOL-LONDON, V504, P537, DOI 10.1111/j.1469-7793.1997.537bd.x; BRAYDEN JE, 1992, SCIENCE, V256, P532, DOI 10.1126/science.1373909; Cordes N, 2006, ONCOGENE, V25, P1378, DOI 10.1038/sj.onc.1209164; Cox DH, 1997, J GEN PHYSIOL, V110, P257, DOI 10.1085/jgp.110.3.257; Cox DH, 1997, J GEN PHYSIOL, V109, P633, DOI 10.1085/jgp.109.5.633; Cui J, 1997, J GEN PHYSIOL, V109, P647, DOI 10.1085/jgp.109.5.647; DAngelo G, 1997, AM J PHYSIOL-HEART C, V272, pH2065, DOI 10.1152/ajpheart.1997.272.4.H2065; Davis GE, 2000, AM J PATHOL, V156, P1489, DOI 10.1016/S0002-9440(10)65020-1; Davis MJ, 2002, CELL BIOCHEM BIOPHYS, V36, P41, DOI 10.1385/CBB:36:1:41; Diaz F, 1996, J GEN PHYSIOL, V107, P399, DOI 10.1085/jgp.107.3.399; Gribkoff VK, 1996, MOL PHARMACOL, V50, P206; Gui PC, 2006, J BIOL CHEM, V281, P14015, DOI 10.1074/jbc.M600433200; Hall SM, 2000, J NEUROIMMUNOL, V106, P130, DOI 10.1016/S0165-5728(00)00213-7; HAMILL OP, 1981, PFLUG ARCH EUR J PHY, V391, P85, DOI 10.1007/BF00656997; HANKS SK, 1991, METHOD ENZYMOL, V200, P38; Herrera GM, 2000, AM J PHYSIOL-REG I, V279, pR60, DOI 10.1152/ajpregu.2000.279.1.R60; Horrigan FT, 2002, J GEN PHYSIOL, V120, P267, DOI 10.1085/jgp.20028605; Horrigan FT, 1999, J GEN PHYSIOL, V114, P305, DOI 10.1085/jgp.114.2.305; Hurley BR, 1999, AM J PHYSIOL-GASTR L, V276, pG843, DOI 10.1152/ajpgi.1999.276.4.G843; Intengan HD, 2000, HYPERTENSION, V36, P312, DOI 10.1161/01.HYP.36.3.312; Jeulin C, 2008, AM J PHYSIOL-LUNG C, V295, pL489, DOI 10.1152/ajplung.90282.2008; Juliano RL, 2001, METHOD ENZYMOL, V333, P151; Kawasaki J, 2004, J BIOL CHEM, V279, P12959, DOI 10.1074/jbc.M313791200; Kim HJ, 2006, J BIOL CHEM, V281, P38573, DOI 10.1074/jbc.M604769200; Laser M, 2000, J BIOL CHEM, V275, P35624, DOI 10.1074/jbc.M006124200; Lewis A, 2002, J PHYSIOL-LONDON, V540, P771, DOI 10.1113/jphysiol.2001.013888; Lin TH, 1997, J CELL BIOL, V136, P1385, DOI 10.1083/jcb.136.6.1385; Lindsey ML, 2003, ANN MED, V35, P316, DOI 10.1080/07853890310001285; Ling SZ, 2004, AM J PHYSIOL-CELL PH, V287, pC698, DOI 10.1152/ajpcell.00030.2004; Ling SZ, 2000, J BIOL CHEM, V275, P30683, DOI 10.1074/jbc.M004292200; Lu R, 2006, J PHYSIOL-LONDON, V570, P65, DOI 10.1113/jphysiol.2005.098913; Martinez-Lemus LA, 2003, J VASC RES, V40, P211, DOI 10.1159/000071886; Meera P, 1996, FEBS LETT, V382, P84, DOI 10.1016/0014-5793(96)00151-2; NELSON MT, 1995, SCIENCE, V270, P633, DOI 10.1126/science.270.5236.633; Platts SH, 1998, AM J PHYSIOL-HEART C, V275, pH1449; Poolos NP, 1999, J NEUROSCI, V19, P5205; Rezzonico R, 2003, J BONE MINER RES, V18, P1863, DOI 10.1359/jbmr.2003.18.10.1863; Rezzonico R, 2002, J BONE MINER RES, V17, P869, DOI 10.1359/jbmr.2002.17.5.869; Sadeghi MM, 2007, TRENDS CARDIOVAS MED, V17, P5, DOI 10.1016/j.tcm.2006.07.003; SCORNIK FS, 1993, AM J PHYSIOL, V265, pH1460, DOI 10.1152/ajpheart.1993.265.4.H1460; Serini G, 2006, EXP CELL RES, V312, P651, DOI 10.1016/j.yexcr.2005.10.020; Stefani E, 1997, P NATL ACAD SCI USA, V94, P5427, DOI 10.1073/pnas.94.10.5427; Tian L, 2008, J BIOL CHEM, V283, P3067, DOI 10.1074/jbc.M706826200; Tian LJ, 2001, J PHYSIOL-LONDON, V537, P57, DOI 10.1111/j.1469-7793.2001.0057k.x; Toychiev AH, 2009, AM J PHYSIOL-CELL PH, V297, pC990, DOI 10.1152/ajpcell.00131.2009; Upadhyay J, 2003, J UROLOGY, V169, P750, DOI 10.1016/S0022-5347(05)64007-4; Vulin AI, 2005, ENDOCRINOLOGY, V146, P3535, DOI 10.1210/en.2004-1386; Wallner M, 1995, RECEPTOR CHANNEL, V3, P185; Wang HQ, 2007, EUR J CELL BIOL, V86, P51, DOI 10.1016/j.ejcb.2006.09.001; White RE, 2000, CIRC RES, V86, P897, DOI 10.1161/01.RES.86.8.897; Williams SEJ, 2004, SCIENCE, V306, P2093, DOI 10.1126/science.1105010; Wu X, 2001, J BIOL CHEM, V276, P30285, DOI 10.1074/jbc.M102436200; Wu X, 2008, J PHYSIOL-LONDON, V586, P1699, DOI 10.1113/jphysiol.2007.149500; Xu CQ, 2004, J BIOL CHEM, V279, P34562, DOI 10.1074/jbc.M312798200; Zarei MM, 2004, P NATL ACAD SCI USA, V101, P10072, DOI 10.1073/pnas.0302919101; Zhou R, 2005, CARDIOVASC RES, V68, P327, DOI 10.1016/j.cardiores.2005.06.005; Zhou XB, 2000, AM J PHYSIOL-CELL PH, V279, pC1751, DOI 10.1152/ajpcell.2000.279.6.C1751	60	35	35	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 1	2010	285	1					131	141		10.1074/jbc.M109.033506	http://dx.doi.org/10.1074/jbc.M109.033506			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	536UT	19887442	Green Published, hybrid			2022-12-25	WOS:000273070100014
J	de Vries, HS; Plantinga, TS; van Krieken, JH; Stienstra, R; van Bodegraven, AA; Festen, EAM; Weersma, RK; Crusius, JBA; Linskens, RK; Joosten, LAB; Netea, MG; de Jong, DJ				de Vries, Hilbert S.; Plantinga, Theo S.; van Krieken, J. Han; Stienstra, Rinke; van Bodegraven, Ad A.; Festen, Eleonora A. M.; Weersma, Rinse K.; Crusius, J. Bart A.; Linskens, Ronald K.; Joosten, Leo A. B.; Netea, Mihai G.; de Jong, Dirk J.			Genetic Association Analysis of the Functional c.714T > G Polymorphism and Mucosal Expression of Dectin-1 in Inflammatory Bowel Disease	PLOS ONE			English	Article							BETA-GLUCAN RECEPTOR; CROHNS-DISEASE; ULCERATIVE-COLITIS; INNATE IMMUNITY; CARD9; CELLS; NOD2; INTERLEUKIN-17; PATHOGENESIS; RECOGNITION	Background: Dectin-1 is a pattern recognition receptor (PRR) expressed by myeloid cells that specifically recognizes beta-1,3 glucan, a polysaccharide and major component of the fungal cell wall. Upon activation, dectin-1 signaling converges, similar to NOD2, on the adaptor molecule CARD9 which is associated with inflammatory bowel disease (IBD). An early stop codon polymorphism (c.714T>G) in DECTIN-1 results in a loss-of-function (p.Y238X) and impaired cytokine responses, including TNF-alpha, interleukin (IL)-1 beta and IL-17 upon in vitro stimulation with Candida albicans or beta-glucan. The aim of the present study was to test the hypothesis that the DECTIN-1 c.714T>G (p.Y238X) polymorphism is associated with lower disease susceptibility or severity in IBD and to investigate the level of dectin-1 expression in inflamed and non-inflamed colon tissue of IBD patients. Methodology: Paraffin embedded tissue samples from non-inflamed and inflamed colon of IBD patients and from diverticulitis patients were immunohistochemically stained for dectin- 1 and related to CD68 macrophage staining. Genomic DNA of IBD patients (778 patients with Crohn's disease and 759 patients with ulcerative colitis) and healthy controls (n = 772) was genotyped for the c.714T>G polymorphism and genotype-phenotype interactions were investigated. Principal Findings: Increased expression of dectin- 1 was observed in actively inflamed colon tissue, as compared to non-inflamed tissue of the same patients. Also an increase in dectin- 1 expression was apparent in diverticulitis tissue. No statistically significant difference in DECTIN-1 c.714T>G allele frequencies was observed between IBD patients and healthy controls. Furthermore, no differences in clinical characteristics could be observed related to DECTIN-1 genotype, neither alone, nor stratified for NOD2 genotype. Conclusions: Our data demonstrate that dectin- 1 expression is elevated on macrophages, neutrophils, and other immune cells involved in the inflammatory reaction in IBD. The DECTIN-1 c.714T>G polymorphism however, is not a major susceptibility factor for developing IBD.			de Vries, HS (corresponding author), Radboud Univ Nijmegen, Med Ctr, Dept Gastroenterol & Hepatol, NL-6525 ED Nijmegen, Netherlands.	D.deJong@mdl.umcn.nl	van Krieken, Joannes H J M/D-4138-2009; van Bodegraven, Ad A/L-3180-2013; Netea, Mihai/N-5155-2014; Plantinga, Theo S./A-6895-2015; van Bodegraven, Ad/ABG-4367-2020; de Jong, D.J./L-4417-2015; Festen, Eleonora A.M./S-3557-2016; Joosten, Leo AB/H-3138-2015; Stienstra, Rinke/A-4763-2015; Weersma, Rinse/ABE-3807-2021	van Krieken, Joannes H J M/0000-0001-6544-1040; Plantinga, Theo S./0000-0003-4990-6084; Joosten, Leo AB/0000-0001-6166-9830; Stienstra, Rinke/0000-0001-6729-7193; de Vries, Hilbert/0000-0003-4058-6459; Festen, Eleonora/0000-0002-3255-6930				Cho JH, 2007, GASTROENTEROLOGY, V133, P1327, DOI 10.1053/j.gastro.2007.08.032; FERWERDA B, NEW ENGLAND IN PRESS; Ferwerda G, 2008, CELL MICROBIOL, V10, P2058, DOI 10.1111/j.1462-5822.2008.01188.x; Gasche C, 2000, INFLAMM BOWEL DIS, V6, P8, DOI 10.1097/00054725-200002000-00002; Girardin SE, 2003, J BIOL CHEM, V278, P8869, DOI 10.1074/jbc.C200651200; Gross O, 2006, NATURE, V442, P651, DOI 10.1038/nature04926; Hsu YMS, 2007, NAT IMMUNOL, V8, P198, DOI 10.1038/ni1426; Inohara N, 2003, J BIOL CHEM, V278, P5509, DOI 10.1074/jbc.C200673200; LeibundGut-Landmann S, 2007, NAT IMMUNOL, V8, P630, DOI 10.1038/ni1460; Oostenbrug LE, 2006, DIGEST LIVER DIS, V38, P834, DOI 10.1016/j.dld.2006.06.042; Plantinga TS, 2009, CLIN INFECT DIS, V49, P724, DOI 10.1086/604714; Podolsky DK, 2002, NEW ENGL J MED, V347, P417, DOI 10.1056/NEJMra0804647; Quinton JF, 1998, GUT, V42, P788, DOI 10.1136/gut.42.6.788; Reid DM, 2004, J LEUKOCYTE BIOL, V76, P86, DOI 10.1189/jlb.0104031; Russell RK, 2005, INFLAMM BOWEL DIS, V11, P955, DOI 10.1097/01.MIB.0000183423.38037.f3; Sartor RB, 2008, GASTROENTEROLOGY, V134, P577, DOI 10.1053/j.gastro.2007.11.059; Seiderer J, 2008, INFLAMM BOWEL DIS, V14, P437, DOI 10.1002/ibd.20339; Silverberg MS, 2005, CAN J GASTROENTEROL, V19, p5A, DOI 10.1155/2005/269076; Standaert-Vitse A, 2006, GASTROENTEROLOGY, V130, P1764, DOI 10.1053/j.gastro.2006.02.009; Taylor PR, 2002, J IMMUNOL, V169, P3876, DOI 10.4049/jimmunol.169.7.3876; TYSK C, 1988, GUT, V29, P990, DOI 10.1136/gut.29.7.990; Underhill D, 2008, INFLAMM BOWEL DIS, V14, P1147, DOI 10.1002/ibd.20402; van Beelen AJ, 2007, IMMUNITY, V27, P660, DOI 10.1016/j.immuni.2007.08.013; Willment JA, 2001, J BIOL CHEM, V276, P43818, DOI 10.1074/jbc.M107715200; Xavier RJ, 2007, NATURE, V448, P427, DOI 10.1038/nature06005; Zhernakova A, 2008, AM J HUM GENET, V82, P1202, DOI 10.1016/j.ajhg.2008.03.016	26	35	36	0	4	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA	1932-6203			PLOS ONE	PLoS One	NOV 12	2009	4	11							e7818	10.1371/journal.pone.0007818	http://dx.doi.org/10.1371/journal.pone.0007818			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	518UW	19915667	Green Published, gold			2022-12-25	WOS:000271721400015
J	Meredith, LW; Sivakumaran, H; Major, L; Suhrbier, A; Harrich, D				Meredith, Luke W.; Sivakumaran, Haran; Major, Lee; Suhrbier, Andreas; Harrich, David			Potent Inhibition of HIV-1 Replication by a Tat Mutant	PLOS ONE			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; TRANSDOMINANT NEGATIVE MUTANT; BETA-GALACTOSIDASE; GENE-EXPRESSION; BASIC DOMAIN; NUCLEOLAR LOCALIZATION; REVERSE TRANSCRIPTION; MUTATIONAL ANALYSIS; SENSITIVE METHOD; MAMMALIAN-CELLS	Herein we describe a mutant of the two-exon HIV-1 Tat protein, termed Nullbasic, that potently inhibits multiple steps of the HIV-1 replication cycle. Nullbasic was created by replacing the entire arginine-rich basic domain of wild type Tat with glycine/alanine residues. Like similarly mutated one-exon Tat mutants, Nullbasic exhibited transdominant negative effects on Tat-dependent transactivation. However, unlike previously reported mutants, we discovered that Nullbasic also strongly suppressed the expression of unspliced and singly-spliced viral mRNA, an activity likely caused by redistribution and thus functional inhibition of HIV-1 Rev. Furthermore, HIV-1 virion particles produced by cells expressing Nullbasic had severely reduced infectivity, a defect attributable to a reduced ability of the virions to undergo reverse transcription. Combination of these inhibitory effects on transactivation, Rev-dependent mRNA transport and reverse transcription meant that permissive cells constitutively expressing Nullbasic were highly resistant to a spreading infection by HIV-1. Nullbasic and its activities thus provide potential insights into the development of potent antiviral therapeutics that target multiple stages of HIV-1 infection.			Meredith, LW (corresponding author), Univ Birmingham, HCV Res Grp, Sch Immun & Infect, Birmingham, W Midlands, England.	David.Harrich@qimr.edu.au	; Harrich, David/H-6668-2016	Suhrbier, Andreas/0000-0001-8986-9025; Harrich, David/0000-0003-3690-0150; Sivakumaran, Haran/0000-0002-4691-4989; Meredith, Luke/0000-0002-3802-8290				Apolloni A, 2003, J VIROL, V77, P9912, DOI 10.1128/JVI.77.18.9912-9921.2003; Apolloni A, 2007, CURR HIV RES, V5, P474, DOI 10.2174/157016207781662443; ARRIGO SJ, 1990, J VIROL, V64, P4585, DOI 10.1128/JVI.64.9.4585-4588.1990; BALBONI PG, 1993, J MED VIROL, V41, P289, DOI 10.1002/jmv.1890410406; BARILLARI G, 1993, P NATL ACAD SCI USA, V90, P7941, DOI 10.1073/pnas.90.17.7941; BERKHOUT B, 1989, CELL, V59, P273, DOI 10.1016/0092-8674(89)90289-4; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Caputo A, 1996, GENE THER, V3, P235; Cardarelli F, 2007, MOL THER, V15, P1313, DOI 10.1038/sj.mt.6300172; Chertova E, 2006, J VIROL, V80, P9039, DOI 10.1128/JVI.01013-06; COCHRANE AW, 1990, J VIROL, V64, P881, DOI 10.1128/JVI.64.2.881-885.1990; DAYTON AI, 1986, CELL, V44, P941, DOI 10.1016/0092-8674(86)90017-6; DUNDR M, 1995, J CELL SCI, V108, P2811; ECHETEBU CO, 1994, J ACQ IMMUN DEF SYND, V7, P655; Efthymiadis A, 1998, J BIOL CHEM, V273, P1623, DOI 10.1074/jbc.273.3.1623; EUSTICE DC, 1991, BIOTECHNIQUES, V11, P739; Felber BK, 2007, ADV PHARMACOL, V55, P161, DOI 10.1016/S1054-3589(07)55005-2; HAUBER J, 1987, P NATL ACAD SCI USA, V84, P6364, DOI 10.1073/pnas.84.18.6364; HAUBER J, 1989, J VIROL, V63, P1181, DOI 10.1128/JVI.63.3.1181-1187.1989; HOPE TJ, 1990, J VIROL, V64, P5360, DOI 10.1128/JVI.64.11.5360-5366.1990; Houzet L, 2008, NUCLEIC ACIDS RES, V36, P2311, DOI 10.1093/nar/gkn069; Jeang KT, 1999, J BIOL CHEM, V274, P28837, DOI 10.1074/jbc.274.41.28837; KIMPTON J, 1992, J VIROL, V66, P2232, DOI 10.1128/JVI.66.4.2232-2239.1992; KING J, 1971, J MOL BIOL, V62, P465, DOI 10.1016/0022-2836(71)90148-3; Li YP, 1997, J VIROL, V71, P4098, DOI 10.1128/JVI.71.5.4098-4102.1997; MACGREGOR GR, 1989, NUCLEIC ACIDS RES, V17, P2365, DOI 10.1093/nar/17.6.2365; MALIM MH, 1991, J VIROL, V65, P4248, DOI 10.1128/JVI.65.8.4248-4254.1991; MODESTI N, 1991, NEW BIOL, V3, P759; Orsini MJ, 1996, J VIROL, V70, P8055, DOI 10.1128/JVI.70.11.8055-8063.1996; PEARSON L, 1990, P NATL ACAD SCI USA, V87, P5079, DOI 10.1073/pnas.87.13.5079; Rossi C, 1997, GENE THER, V4, P1261, DOI 10.1038/sj.gt.3300522; RUBEN S, 1989, J VIROL, V63, P1; Salmon P, 2000, MOL THER, V2, P404, DOI 10.1006/mthe.2000.0141; Smulevitch S, 2006, RETROVIROLOGY, V3, DOI 10.1186/1742-4690-3-6; STAUBER R, 1995, VIROLOGY, V213, P439, DOI 10.1006/viro.1995.0016; Tritel M, 2000, J VIROL, V74, P5845, DOI 10.1128/JVI.74.13.5845-5855.2000; Truant R, 1999, MOL CELL BIOL, V19, P1210; Ulich C, 1996, J VIROL, V70, P4871, DOI 10.1128/JVI.70.7.4871-4876.1996; Vives E, 1997, J BIOL CHEM, V272, P16010, DOI 10.1074/jbc.272.25.16010; Warrilow D, 2008, J VIROL, V82, P1425, DOI 10.1128/JVI.01808-07; Wei P, 1998, CELL, V92, P451, DOI 10.1016/S0092-8674(00)80939-3; Zufferey R, 1997, NAT BIOTECHNOL, V15, P871, DOI 10.1038/nbt0997-871	42	43	44	0	1	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	NOV 10	2009	4	11							e7769	10.1371/journal.pone.0007769	http://dx.doi.org/10.1371/journal.pone.0007769			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	517ZU	19901984	gold, Green Published			2022-12-25	WOS:000271658800008
J	Ranjan, AK; Kumar, U; Hardikar, AA; Poddar, P; Nair, PD; Hardikar, AA				Ranjan, Amaresh K.; Kumar, Umesh; Hardikar, Ashutosh A.; Poddar, Pankaj; Nair, Prabha D.; Hardikar, Anandwardhan A.			Human Blood Vessel-Derived Endothelial Progenitors for Endothelialization of Small Diameter Vascular Prosthesis	PLOS ONE			English	Article							ARTERY-BYPASS SURGERY; PERCUTANEOUS CORONARY INTERVENTION; EXPANDED POLYTETRAFLUOROETHYLENE; THROMBUS GROWTH; DACRON GRAFTS; CELLS; PLATELET; DEPOSITION; COVERAGE; COLLAGEN	Background: Coronary bypass graft failure as a result of acute thrombosis and intimal hyperplasia has been the major challenge in surgical procedures involving small-diameter vascular prosthesis. Coating synthetic grafts with patients' own endothelial cells has been suggested to improve the patency rate and overall success of bypass surgeries. Methodology/Principal Findings: We isolated endothelial progenitor cells (EPCs) from leftover pieces of human saphenous vein/mammary artery. We demonstrate that EPCs can be expanded to generate millions of cells under low-density culture conditions. Exposure to high-density conditions induces differentiation to endothelial cell phenotype. EPC-derived endothelial cells show expression of CD144(high), CD31, and vWF. We then assessed the ability of differentiated endothelial cells to adhere and grow on small diameter expanded polytetrafluoroethylene (ePTFE) tubings. Since ePTFE tubings are highly hydrophobic, we optimized protocols to introduce hydrophilic groups on luminal surface of ePTFE tubings. We demonstrate here a stepwise protocol that involves introduction of hydrophilic moieties and coating with defined ECM components that support adhesion of endothelial cells, but not of blood platelets. Conclusion/Significance: Our data confirms that endothelial progenitors obtained from adult human blood vessels can be expanded in vitro under xenoprotein-free conditions, for potential use in endothelialization of small diameter ePTFE grafts. These endothelialized grafts may represent a promising treatment strategy for improving the clinical outcome of small-caliber vascular grafts in cardiac bypass surgeries.			Ranjan, AK (corresponding author), Natl Ctr Cell Sci, Stem Cells & Diabet Sect, Pune, Maharashtra, India.	anand@isletbiology.com	Hardikar, Ashutosh A/J-7638-2013; Poddar, Pankaj/G-5174-2010; Nair, Prabha/AAE-4517-2019; Kumar, Umesh/B-3737-2014; Hardikar, Anandwardhan/ACF-7730-2022; Ranjan, Amaresh/AAG-7664-2020	Hardikar, Ashutosh A/0000-0003-3558-6454; Poddar, Pankaj/0000-0002-2273-588X; Ranjan, Amaresh/0000-0002-2505-0552; Ranjan, Amaresh/0000-0001-7529-7409				Abraham S, 2009, CURR BIOL, V19, P668, DOI 10.1016/j.cub.2009.02.057; ALLEN BT, 1984, J VASC SURG, V1, P224, DOI 10.1067/mva.1984.avs0010224; Appoo J, 2004, CIRCULATION, V110, pII13, DOI 10.1161/01.CIR.0000128345.69540.ed; Asahara T, 1997, SCIENCE, V275, P964, DOI 10.1126/science.275.5302.964; AVCIADALI M, 2009, J TISSUE ENG REGEN M; Beltrami AP, 2003, CELL, V114, P763, DOI 10.1016/S0092-8674(03)00687-1; Bevilacqua S, 2009, ANN THORAC SURG, V87, P496, DOI 10.1016/j.athoracsur.2008.05.038; BUJAN J, 1992, HISTOL HISTOPATHOL, V7, P635; BULL HA, 1988, BRIT J SURG, V75, P671, DOI 10.1002/bjs.1800750716; CAMPEAU L, 1975, CIRCULATION, V52, P369, DOI 10.1161/01.CIR.52.3.369; CARR HMH, 1992, ARTIF ORGANS, V16, P342; Cho JH, 2006, BLOOD, V108, P2229, DOI 10.1182/blood-2006-02-002063; Cikirikcioglu M, 2006, INT J ARTIF ORGANS, V29, P990, DOI 10.1177/039139880602901010; Dalsing M C, 1989, Ann Vasc Surg, V3, P127, DOI 10.1016/S0890-5096(06)62005-0; Davies A H, 1996, Cardiovasc Surg, V4, P161, DOI 10.1016/0967-2109(96)82307-6; ESKIN SG, 1983, ARTIF ORGANS, V7, P31, DOI 10.1111/j.1525-1594.1983.tb04156.x; FOXALL TL, 1986, J SURG RES, V41, P158, DOI 10.1016/0022-4804(86)90021-1; Furukawa KS, 2000, ASAIO J, V46, P696, DOI 10.1097/00002480-200011000-00009; GRAHAM LM, 1991, J BIOMED MATER RES, V25, P525, DOI 10.1002/jbm.820250409; GRAHAM LM, 1980, ARCH SURG-CHICAGO, V115, P1289; Halama T, 1999, INT ARCH ALLERGY IMM, V120, P237, DOI 10.1159/000024273; Hannan EL, 2005, NEW ENGL J MED, V352, P2174, DOI 10.1056/NEJMoa040316; Ingram DA, 2005, BLOOD, V105, P2783, DOI 10.1182/blood-2004-08-3057; Jeschke MG, 1999, J VASC SURG, V29, P168, DOI 10.1016/S0741-5214(99)70358-7; Keuren JFW, 2004, ARTERIOSCL THROM VAS, V24, P613, DOI 10.1161/01.ATV.0000116026.18945.66; Keuren JFW, 2003, BIOMATERIALS, V24, P1917, DOI 10.1016/S0142-9612(02)00620-8; Kocher AA, 2001, NAT MED, V7, P430, DOI 10.1038/86498; LESECHE G, 1995, ANN VASC SURG, V9, P325, DOI 10.1007/BF02135295; Lu A, 2001, BIOMATERIALS, V22, P1439, DOI 10.1016/S0142-9612(00)00302-1; Majka SM, 2003, J CLIN INVEST, V111, P71, DOI 10.1172/JCI200316157; Matuskova J, 2006, ARTERIOSCL THROM VAS, V26, P1391, DOI 10.1161/01.ATV.0000216282.58291.c6; Murohara T, 2000, J CLIN INVEST, V105, P1527, DOI 10.1172/JCI8296; Ni HY, 2003, P NATL ACAD SCI USA, V100, P2415, DOI 10.1073/pnas.2628067100; Noishiki Y, 1996, NAT MED, V2, P90, DOI 10.1038/nm0196-90; NOISHIKI Y, 1992, J THORAC CARDIOV SUR, V104, P770; Okrainec K, 2004, AM HEART J, V148, P7, DOI 10.1016/j.ahj.2003.11.027; OZAKI CK, 1995, J BIOMED MATER RES, V29, P647; Park DW, 2008, CIRCULATION, V117, P2079, DOI 10.1161/CIRCULATIONAHA.107.750109; Pasterkamp G, 2000, CARDIOVASC RES, V45, P843, DOI 10.1016/S0008-6363(99)00377-6; Peichev M, 2000, BLOOD, V95, P952, DOI 10.1182/blood.V95.3.952.003k27_952_958; Planat-Benard V, 2004, CIRCULATION, V109, P656, DOI 10.1161/01.CIR.0000114522.38265.61; Randone B, 2005, J SURG RES, V127, P70, DOI 10.1016/j.jss.2004.09.005; Rasmussen C, 1997, EUR J CARDIO-THORAC, V12, P847, DOI 10.1016/S1010-7940(97)00268-6; Rihal CS, 2003, CIRCULATION, V108, P2439, DOI 10.1161/01.CIR.0000094405.21583.7C; SAAD EM, 1993, J VASC SURG, V18, P587, DOI 10.1016/0741-5214(93)90068-W; Sampram ESK, 2004, J VASC INTERV RADIOL, V15, P379, DOI 10.1097/01.RVI.0000121409.46920.B8; Shi Q, 1998, BLOOD, V92, P362, DOI 10.1182/blood.V92.2.362.414k38_362_367; Toes GJ, 1999, BIOMATERIALS, V20, P1951, DOI 10.1016/S0142-9612(99)00100-3; Walluscheck KP, 2005, J CARDIOVASC SURG, V46, P425; Walluscheck KP, 1996, EUR J VASC ENDOVASC, V12, P321, DOI 10.1016/S1078-5884(96)80251-6; WANG ZG, 1990, J VASC SURG, V12, P168, DOI 10.1067/mva.1990.21906; Werner N, 2003, CIRC RES, V93, pE17, DOI 10.1161/01.RES.0000083812.30141.74; Yang Zhen Kun, 2007, J Interv Cardiol, V20, P10, DOI 10.1111/j.1540-8183.2007.00222.x; Zengin E, 2006, DEVELOPMENT, V133, P1543, DOI 10.1242/dev.02315	54	49	51	0	17	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	NOV 5	2009	4	11							e7718	10.1371/journal.pone.0007718	http://dx.doi.org/10.1371/journal.pone.0007718			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	515HI	19890388	Green Published, Green Submitted, gold			2022-12-25	WOS:000271459700011
J	Bettecken, T; Trifonov, EN				Bettecken, Thomas; Trifonov, Edward N.			Repertoires of the Nucleosome-Positioning Dinucleotides	PLOS ONE			English	Article							CHROMATIN DNA; NUCLEOTIDE-SEQUENCE; IN-VITRO; GENOME; INSIGHTS; ELEGANS; REPEAT; PITCH	It is generally accepted that the organization of eukaryotic DNA into chromatin is strongly governed by a code inherent in the genomic DNA sequence. This code, as well as other codes, is superposed on the triplets coding for amino acids. The history of the chromatin code started three decades ago with the discovery of the periodic appearance of certain dinucleotides, with AA/TT and RR/YY giving the strongest signals, all with a period of 10.4 bases. Every base-pair stack in the DNA duplex has specific deformation properties, thus favoring DNA bending in a specific direction. The appearance of the corresponding dinucleotide at the distance 10.4 xn bases will facilitate DNA bending in that direction, which corresponds to the minimum energy of DNA folding in the nucleosome. We have analyzed the periodic appearances of all 16 dinucleotides in the genomes of thirteen different eukaryotic organisms. Our data show that a large variety of dinucleotides (if not all) are, apparently, contributing to the nucleosome positioning code. The choice of the periodical dinucleotides differs considerably from one organism to another. Among other 10.4 base periodicities, a strong and very regular 10.4 base signal was observed for CG dinucleotides in the genome of the honey bee A. mellifera. Also, the dinucleotide CG appears as the only periodical component in the human genome. This observation seems especially relevant since CpG methylation is well known to modulate chromatin packing and regularity. Thus, the selection of the dinucleotides contributing to the chromatin code is species specific, and may differ from region to region, depending on the sequence context.			Bettecken, T (corresponding author), Max Planck Inst Psychiat, CAGT, Munich, Germany.	bettecken@mpipsykl.mpg.de						BOLSHOY A, 1995, NAT STRUCT BIOL, V2, P446, DOI 10.1038/nsb0695-446; Cohanim AB, 2006, J BIOMOL STRUCT DYN, V23, P559, DOI 10.1080/07391102.2006.10507081; Cohanim AB, 2005, J BIOMOL STRUCT DYN, V22, P687, DOI 10.1080/07391102.2005.10507035; Costantini M, 2008, P NATL ACAD SCI USA, V105, P13971, DOI 10.1073/pnas.0803916105; Davey C, 1997, J MOL BIOL, V267, P276, DOI 10.1006/jmbi.1997.0899; Davey CS, 2004, NUCLEIC ACIDS RES, V32, P4322, DOI 10.1093/nar/gkh749; Gabdank I, 2009, J BIOMOL STRUCT DYN, V26, P403, DOI 10.1080/07391102.2009.10507255; Herzel H, 1998, J BIOMOL STRUCT DYN, V16, P341, DOI 10.1080/07391102.1998.10508251; Kato M, 2003, J MOL BIOL, V332, P111, DOI 10.1016/S0022-2836(03)00838-6; Kogan SB, 2006, J BIOMOL STRUCT DYN, V24, P43, DOI 10.1080/07391102.2006.10507097; Krueger A, 2006, BIOPHYS J, V90, P3091, DOI 10.1529/biophysj.105.078774; Manolio TA, 2008, J CLIN INVEST, V118, P1590, DOI 10.1172/JCI34772; MENGERITSKY G, 1983, NUCLEIC ACIDS RES, V11, P3833, DOI 10.1093/nar/11.11.3833; Pennings Sari, 2005, Briefings in Functional Genomics & Proteomics, V3, P351, DOI 10.1093/bfgp/3.4.351; Salih F, 2008, J BIOMOL STRUCT DYN, V26, P273, DOI 10.1080/07391102.2008.10531241; Salih F, 2008, J BIOMOL STRUCT DYN, V26, P9, DOI 10.1080/07391102.2008.10507219; Segal E, 2006, NATURE, V442, P772, DOI 10.1038/nature04979; Thastrom A, 2004, J MOL BIOL, V338, P695, DOI 10.1016/j.jmb.2004.03.032; TRIFONOV EN, 1980, NUCLEIC ACIDS RES, V8, P4041, DOI 10.1093/nar/8.17.4041; TRIFONOV EN, 1979, BIOCHEMISTRY-US, V18, P454, DOI 10.1021/bi00570a011; TRIFONOV EN, 1980, P NATL ACAD SCI-BIOL, V77, P3816, DOI 10.1073/pnas.77.7.3816; TRIFONOV EN, 1995, JERUS SYM Q, V27, P473; ULANOVSKY LE, 1983, CELL BIOPHYS, V5, P281, DOI 10.1007/BF02788626; Weinstock GM, 2006, NATURE, V443, P931, DOI 10.1038/nature05260	24	30	33	0	4	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA	1932-6203			PLOS ONE	PLoS One	NOV 2	2009	4	11							e7654	10.1371/journal.pone.0007654	http://dx.doi.org/10.1371/journal.pone.0007654			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	514RX	19888331	Green Submitted, gold, Green Published			2022-12-25	WOS:000271414400002
J	Miyamoto, T; Dubin, AE; Petrus, MJ; Patapoutian, A				Miyamoto, Takashi; Dubin, Adrienne E.; Petrus, Matt J.; Patapoutian, Ardem			TRPV1 and TRPA1 Mediate Peripheral Nitric Oxide-Induced Nociception in Mice	PLOS ONE			English	Article							SENSITIVE GUANYLYL CYCLASE; CHANNEL ACTIVATION; THERMAL HYPERALGESIA; PUNGENT COMPOUNDS; S-NITROSYLATION; INOS-DEFICIENT; PAIN; SYNTHASE; CYSTEINE; CGMP	Nitric oxide (NO) can induce acute pain in humans and plays an important role in pain sensitization caused by inflammation and injury in animal models. There is evidence that NO acts both in the central nervous system via a cyclic GMP pathway and in the periphery on sensory neurons through unknown mechanisms. It has recently been suggested that TRPV1 and TRPA1, two polymodal ion channels that sense noxious stimuli impinging on peripheral nociceptors, are activated by NO in heterologous systems. Here, we investigate the relevance of this activation. We demonstrate that NO donors directly activate TRPV1 and TRPA1 in isolated inside-out patch recordings. Cultured primary sensory neurons display both TRPV1- and TRPA1-dependent responses to NO donors. BH4, an essential co-factor for NO production, causes activation of a subset of DRG neurons as assayed by calcium imaging, and this activation is at least partly dependent on nitric oxide synthase activity. We show that BH4-induced calcium influx is ablated in DRG neurons from TRPA1/TRPV1 double knockout mice, suggesting that production of endogenous levels of NO can activate these ion channels. In behavioral assays, peripheral NO-induced nociception is compromised when TRPV1 and TRPA1 are both ablated. These results provide genetic evidence that the peripheral nociceptive action of NO is mediated by both TRPV1 and TRPA1.			Miyamoto, T (corresponding author), Scripps Res Inst, Dept Cell Biol, La Jolla, CA 92037 USA.	apatapou@gnf.org			NINDS NIH HHS [R01NS049104, R01 NS049104] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS049104] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Ahern GP, 2002, TRENDS NEUROSCI, V25, P510, DOI 10.1016/S0166-2236(02)02254-3; AKOPIAN AN, 2007, J PHYSL; Aley KO, 1998, J NEUROSCI, V18, P7008; Bae YS, 2003, MOL PHARMACOL, V63, P1043, DOI 10.1124/mol.63.5.1043; Bandell M, 2004, NEURON, V41, P849, DOI 10.1016/S0896-6273(04)00150-3; Bandell M, 2007, CURR OPIN NEUROBIOL, V17, P490, DOI 10.1016/j.conb.2007.07.014; Bautista DM, 2006, CELL, V124, P1269, DOI 10.1016/j.cell.2006.02.023; Birder LA, 2007, NAT CLIN PRACT UROL, V4, P46, DOI 10.1038/ncpuro0672; Boettger MK, 2007, EUR J PAIN, V11, P810, DOI 10.1016/j.ejpain.2006.12.008; Calabrese V, 2007, NAT REV NEUROSCI, V8, P766, DOI 10.1038/nrn2214; Cals-Grierson MM, 2004, NITRIC OXIDE-BIOL CH, V10, P179, DOI 10.1016/j.niox.2004.04.005; Caterina MJ, 2000, SCIENCE, V288, P306, DOI 10.1126/science.288.5464.306; CHIZHBEA, 2006, AM PAIN SOC M; Dhaka A, 2009, J NEUROSCI, V29, P153, DOI 10.1523/JNEUROSCI.4901-08.2009; Ford PC, 2002, CHEM REV, V102, P993, DOI 10.1021/cr0000271; FUJITA F, 2008, J CLIN INVEST; Gibson HE, 2008, NEURON, V57, P746, DOI 10.1016/j.neuron.2007.12.027; Guhring H, 2000, J NEUROSCI, V20, P6714, DOI 10.1523/JNEUROSCI.20-17-06714.2000; Hess DT, 2005, NAT REV MOL CELL BIO, V6, P150, DOI 10.1038/nrm1569; Hinman A, 2006, P NATL ACAD SCI USA, V103, P19564, DOI 10.1073/pnas.0609598103; HOLTHUSEN H, 1994, NEUROSCI LETT, V165, P71, DOI 10.1016/0304-3940(94)90712-9; HU H, 2009, NAT CHEM BIOL; HUGHES SR, 1990, EUR J PHARMACOL, V191, P481, DOI 10.1016/0014-2999(90)94184-Y; IALENTI A, 1992, EUR J PHARMACOL, V211, P177, DOI 10.1016/0014-2999(92)90526-A; Jeske NA, 2006, J BIOL CHEM, V281, P32879, DOI 10.1074/jbc.M603220200; Karashima Y, 2007, J NEUROSCI, V27, P9874, DOI 10.1523/JNEUROSCI.2221-07.2007; KITTO KF, 1992, NEUROSCI LETT, V148, P1, DOI 10.1016/0304-3940(92)90790-E; Koesling D, 2004, NEUROCHEM INT, V45, P813, DOI 10.1016/j.neuint.2004.03.011; Kwan KY, 2006, NEURON, V50, P277, DOI 10.1016/j.neuron.2006.03.042; LOWENSTEIN CJ, 1994, ANN INTERN MED, V120, P227, DOI 10.7326/0003-4819-120-3-199402010-00009; Macpherson LJ, 2007, NATURE, V445, P541, DOI 10.1038/nature05544; MAJEWSKI M, 1995, CELL TISSUE RES, V281, P445, DOI 10.1007/BF00417862; Malkia A, 2007, J PHYSIOL-LONDON, V581, P155, DOI 10.1113/jphysiol.2006.123059; Marsch R, 2007, J NEUROSCI, V27, P832, DOI 10.1523/JNEUROSCI.3303-06.2007; MELLER ST, 1992, EUR J PHARMACOL, V214, P93, DOI 10.1016/0014-2999(92)90102-A; MELLER ST, 1993, PAIN, V52, P127, DOI 10.1016/0304-3959(93)90124-8; Moqrich A, 2005, SCIENCE, V307, P1468, DOI 10.1126/science.1108609; Nilius B, 2005, J PHYSIOL-LONDON, V567, P35, DOI 10.1113/jphysiol.2005.088377; Patapoutian A, 2009, NAT REV DRUG DISCOV, V8, P55, DOI 10.1038/nrd2757; Petrus M, 2007, MOL PAIN, V3, DOI 10.1186/1744-8069-3-40; Pietrobon D, 2003, NAT REV NEUROSCI, V4, P386, DOI 10.1038/nrn1102; Salazar H, 2008, NAT NEUROSCI, V11, P255, DOI 10.1038/nn2056; Sawada Y, 2008, EUR J NEUROSCI, V27, P1131, DOI 10.1111/j.1460-9568.2008.06093.x; Schmidtko A, 2008, J NEUROSCI, V28, P8568, DOI 10.1523/JNEUROSCI.2128-08.2008; STAMLER JS, 1992, SCIENCE, V258, P1898, DOI 10.1126/science.1281928; Story GM, 2003, CELL, V112, P819, DOI 10.1016/S0092-8674(03)00158-2; Takahashi N, 2008, CHANNELS, V2, P287, DOI 10.4161/chan.2.4.6745; Taylor-Clark TE, 2008, J PHYSIOL-LONDON, V586, P3447, DOI 10.1113/jphysiol.2008.153585; TAYLORCLARK TE, 2009, MOL PHARM; Tegeder I, 2006, NAT MED, V12, P1269, DOI 10.1038/nm1490; Thomas DA, 1996, NEUROSCI LETT, V210, P124, DOI 10.1016/0304-3940(96)12670-7; Vales-Gomez Mar, 2003, BMC Immunol, V4, P4, DOI 10.1186/1471-2172-4-4; VIZZARD MA, 1995, NEUROSCIENCE, V67, P1, DOI 10.1016/0306-4522(95)00137-8; WANG S, 2008, BRAIN; Wei JY, 1998, J MOL NEUROSCI, V10, P53, DOI 10.1007/BF02737085; Xu SZ, 2008, NATURE, V451, P69, DOI 10.1038/nature06414; Yoshida T, 2006, NAT CHEM BIOL, V2, P596, DOI 10.1038/nchembio821; Zochodne DW, 2005, CELL MOL BIOL, V51, P255, DOI 10.1170/T626	58	148	150	1	14	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	OCT 29	2009	4	10							e7596	10.1371/journal.pone.0007596	http://dx.doi.org/10.1371/journal.pone.0007596			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	512FP	19893614	Green Published, Green Submitted, gold			2022-12-25	WOS:000271232000001
J	Banerji, S; Hide, BRS; James, JR; Noble, MEM; Jackson, DG				Banerji, Suneale; Hide, Branwen R. S.; James, John R.; Noble, Martin E. M.; Jackson, David G.			Distinctive Properties of the Hyaluronan-binding Domain in the Lymphatic Endothelial Receptor Lyve-1 and Their Implications for Receptor Function	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALPHA-TRYPSIN INHIBITOR; SMOOTH-MUSCLE-CELLS; LEUKOCYTE ADHESION; CD44; PROTEIN; INFLAMMATION; MECHANISM; LYMPHANGIOGENESIS; GLYCOSYLATION; DEGRADATION	The lymphatic endothelial hyaluronan (HA) receptor Lyve-1 is a member of the Link protein superfamily most similar to the leukocyte HA receptor CD44. However, the structure of Lyve-1 and the nature of its interaction with ligand are obscure. Here we present new evidence that Lyve-1 is functionally distinct from CD44. Using truncation mutagenesis we confirm that Lyve-1 in common with CD44 contains an extended HA-binding unit, comprising elements flanking the N and C termini of the consensus lectin-like Link module, bridged by a third conserved disulfide linkage that is critical for HA binding. In addition, we identify six essential residues Tyr-87, Ile-97, Arg-99, Asn-103, Lys-105, and Lys-108 that define a compact HA-binding surface on Lyve-1, encompassing the epitope for an adhesion-blocking monoclonal antibody 3A, in an analogous position to the HA-binding surface in CD44. The overtly electrostatic character of HA binding in Lyve-1 and its sensitivity to ionic strength (IC50 of 150 mM NaCl) contrast markedly with CD44 (IC50 > 2 M NaCl) in which HA binding is mediated by hydrogen bonding and hydrophobic interactions. In addition, unlike the extended Link module in CD44, which binds HA efficiently when expressed as a soluble monomer (K-d = 65.7 mu M), that of Lyve-1 requires artificial dimerization, although the full ectodomain is active as a monomer (K-d = 35.6 mu M). Finally, full-length Lyve-1 did not form stable dimers in binding-competent 293T transfectants when assessed using bioluminescent resonance energy transfer. These results reveal that elements additional to the extended Link module are required to stabilize HA binding in Lyve-1 and indicate important structural and functional differences with CD44.	[Banerji, Suneale; Hide, Branwen R. S.; Jackson, David G.] John Radcliffe Hosp, MRC, Human Immunol Unit, Oxford OX3 9DS, England; [James, John R.] John Radcliffe Hosp, Nuffield Dept Med, Weatherall Inst Mol Med, Oxford OX3 9DS, England; [Noble, Martin E. M.] Lab Mol Biophys, Oxford OX1 3QU, England	University of Oxford; University of Oxford; University of Oxford	Jackson, DG (corresponding author), John Radcliffe Hosp, MRC, Human Immunol Unit, Oxford OX3 9DS, England.	david.jackson@imm.ox.ac.uk	James, John R/B-5547-2008; James, John/AAP-3607-2021	James, John R/0000-0003-1452-7578; James, John/0000-0003-1452-7578; banerji, suneale/0000-0002-1179-3152; , david/0000-0002-4133-9364; Noble, Martin/0000-0002-3595-9807	UK Medical Research Council; Medical Research Council [G1000800c, MC_U137884182] Funding Source: researchfish; MRC [MC_U137884182] Funding Source: UKRI	UK Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))	This work was supported by grants from the UK Medical Research Council (to D. G. J.) and by a Medical Research Council D.Phil. studentship (to B. R. S. H.).	Banerji S, 1999, J CELL BIOL, V144, P789, DOI 10.1083/jcb.144.4.789; Banerji S, 1998, PROTEIN EXPRES PURIF, V14, P371, DOI 10.1006/prep.1998.0971; BANERJI S, 2005, STRUCTURE CD44 HYALU, V2, P625; Banerji S, 2007, NAT STRUCT MOL BIOL, V14, P234, DOI 10.1038/nsmb1201; Bouyain S, 2001, GLYCOBIOLOGY, V11, P989, DOI 10.1093/glycob/11.11.989; Brissett NC, 1996, FEBS LETT, V388, P211, DOI 10.1016/0014-5793(96)00576-5; Clark RA, 1996, J CELL BIOL, V134, P1075, DOI 10.1083/jcb.134.4.1075; Cole C, 2008, NUCLEIC ACIDS RES, V36, pW197, DOI 10.1093/nar/gkn238; Day AJ, 2002, J BIOL CHEM, V277, P4585, DOI 10.1074/jbc.R100036200; Day AJ, 2005, TRENDS IMMUNOL, V26, P637, DOI 10.1016/j.it.2005.09.009; de la Motte CA, 2003, AM J PATHOL, V163, P121, DOI 10.1016/S0002-9440(10)63636-X; de la Motte CA, 1999, J BIOL CHEM, V274, P30747, DOI 10.1074/jbc.274.43.30747; DOUGHERTY WG, 1988, EMBO J, V7, P1281, DOI 10.1002/j.1460-2075.1988.tb02942.x; English NM, 1998, CANCER RES, V58, P3736; FRASER JRE, 1988, BIOCHEM J, V256, P153, DOI 10.1042/bj2560153; Gee K, 2003, J BIOL CHEM, V278, P37275, DOI 10.1074/jbc.M302309200; HARDINGHAM TE, 1992, FASEB J, V6, P861, DOI 10.1096/fasebj.6.3.1740236; Harris EN, 2008, J BIOL CHEM, V283, P17341, DOI 10.1074/jbc.M710360200; HUANG L, 1993, J BIOL CHEM, V268, P26725; Jackson DG, 2001, TRENDS IMMUNOL, V22, P317, DOI 10.1016/S1471-4906(01)01936-6; Jackson DG, 2003, TRENDS CARDIOVAS MED, V13, P1, DOI 10.1016/S1050-1738(02)00189-5; Jackson DG, 2004, APMIS, V112, P526, DOI 10.1111/j.1600-0463.2004.apm11207-0811.x; JACKSON DG, 2004, GLYCOFORUM; James JR, 2006, NAT METHODS, V3, P1001, DOI 10.1038/nmeth978; Johnson LA, 2008, ANN NY ACAD SCI, V1131, P119, DOI 10.1196/annals.1413.011; Johnson LA, 2007, J BIOL CHEM, V282, DOI 10.1074/jbc.M702889200; Katoh S, 1999, J IMMUNOL, V162, P5058; KATOH S, 1995, J EXP MED, V182, P419, DOI 10.1084/jem.182.2.419; Kohda D, 1996, CELL, V86, P767, DOI 10.1016/S0092-8674(00)80151-8; Lesley J, 2000, J BIOL CHEM, V275, P26967; Majors AK, 2003, J BIOL CHEM, V278, P47223, DOI 10.1074/jbc.M304871200; Meiler J, 2003, P NATL ACAD SCI USA, V100, P12105, DOI 10.1073/pnas.1831973100; Mohamadzadeh M, 1998, J CLIN INVEST, V101, P97, DOI 10.1172/JCI1604; Nandi A, 2000, J BIOL CHEM, V275, P14939, DOI 10.1074/jbc.275.20.14939; Nightingale TD, 2009, J BIOL CHEM, V284, P3935, DOI 10.1074/jbc.M805105200; Oliver G, 2005, ANNU REV CELL DEV BI, V21, P457, DOI 10.1146/annurev.cellbio.21.012704.132338; Ponta H, 2003, NAT REV MOL CELL BIO, V4, P33, DOI 10.1038/nrm1004; Prevo R, 2001, J BIOL CHEM, V276, P19420, DOI 10.1074/jbc.M011004200; Pure E, 2001, TRENDS MOL MED, V7, P213, DOI 10.1016/S1471-4914(01)01963-3; Randolph GJ, 2005, NAT REV IMMUNOL, V5, P617, DOI 10.1038/nri1670; Siegelman MH, 1999, J LEUKOCYTE BIOL, V66, P315, DOI 10.1002/jlb.66.2.315; Sleeman J, 1996, J CELL BIOL, V135, P1139, DOI 10.1083/jcb.135.4.1139; Swartz MA, 2001, ADV DRUG DELIVER REV, V50, P3, DOI 10.1016/S0169-409X(01)00150-8; Teriete P, 2004, MOL CELL, V13, P483, DOI 10.1016/S1097-2765(04)00080-2; Torgersen D, 1998, J BIOL CHEM, V273, P6254, DOI 10.1074/jbc.273.11.6254; von Andrian UH, 2003, NAT REV IMMUNOL, V3, P867, DOI 10.1038/nri1222; Zhou B, 2002, MOL BIOL CELL, V13, P2853, DOI 10.1091/mbc.02-03-0048; Zhuo LS, 2006, J BIOL CHEM, V281, P20303, DOI 10.1074/jbc.M506703200	48	42	44	1	15	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 2	2010	285	14					10724	10735		10.1074/jbc.M109.047647	http://dx.doi.org/10.1074/jbc.M109.047647			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	578AC	19887450	Green Published, hybrid			2022-12-25	WOS:000276264600059
J	Hoashi, T; Tamaki, K; Hearing, VJ				Hoashi, Toshihiko; Tamaki, Kunihiko; Hearing, Vincent J.			The secreted form of a melanocyte membrane-bound glycoprotein (Pmel17/gp100) is released by ectodomain shedding	FASEB JOURNAL			English	Article						melanosome; glycosylation; proprotein convertase	MATRIX PROTEIN PMEL17/GP100; MONOCLONAL-ANTIBODY; MELANOSOME BIOGENESIS; ALZHEIMERS-DISEASE; PRECURSOR PROTEIN; AMYLOID FORMATION; T-LYMPHOCYTES; SILVER LOCUS; CLEAVAGE; CELLS	Ectodomain shedding is a proteolytic mechanism by which a transmembrane protein is converted into a secreted form. Pmel17/gp100 is a melanocyte-specific membrane-bound glycoprotein that has amyloid characteristics and forms fibrillar structures in melanosomes after a complex sequence of post-translational processing and trafficking events, including cleavage by a furin-like proprotein convertase (PC). A secreted form of Pmel17 (termed sPmel17) was also thought to be released due to cleavage by a PC. We used multidisciplinary approaches to demonstrate that sPmel17 is released by ectodomain shedding at the juxtamembrane and/or intramembrane motif and to show that this is independent of cleavage by a PC. We further show that sPmel17 consists of 2 fragments linked by disulfide bonds and that the shedding is inhibited at low temperature but not by metalloproteinase inhibitors. Moreover, treatment with a phorbol ester or a calmodulin inhibitor induces Pmel17 shedding. We also refine the reactivity of HMB50 and NKI/beteb, 2 monoclonal antibodies commonly used as melanoma-specific markers. The fact that those antibodies require physically separated domains of Pmel17 sheds interesting light on its 3-dimensional conformation. We conclude that sPmel17 is released by regulated proteolytic ectodomain shedding.-Hoashi, T., Tamaki, K., Hearing, V. J. The secreted form of a melanocyte membrane-bound glycoprotein (Pmel17/gp100) is released by ectodomain shedding. FASEB J. 24, 916-930 (2010). www.fasebj.org	[Hoashi, Toshihiko; Hearing, Vincent J.] NCI, Cell Biol Lab, NIH, Bethesda, MD 20892 USA; [Hoashi, Toshihiko; Tamaki, Kunihiko] Univ Tokyo, Dept Dermatol, Fac Med, Tokyo 1138655, Japan	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); University of Tokyo	Hearing, VJ (corresponding author), NCI, Cell Biol Lab, NIH, Bldg 37,Rm 2132, Bethesda, MD 20892 USA.	thoashi-tky@umin.ac.jp; hearingv@nih.gov			National Institutes of Health, National Cancer Institute; NATIONAL CANCER INSTITUTE [ZIABC010785] Funding Source: NIH RePORTER	National Institutes of Health, National Cancer Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We gratefully thank Dr. Michael S. Marks (University of Pennsylvania, Philadelphia, PA, USA) for kindly providing the Pmel17-i, Pmel17-l, and Pmel17-s vectors; Dr. Richard N. Sifers (Baylor College of Medicine, Houston, TX, USA) for the kind gift of hATM-pcDNA3.1; Dr. Donald F. Steiner (University of Chicago, Chicago, IL, USA) for the kind gift of pCMV-furin; Dr. Susan H. Garfield and Dr. Stephen M. Wincovitch for expert advice on confocal microscopy; and Dr. Motozo Yamashita for useful suggestions. This research was supported, in part, by the Intramural Research Program of the National Institutes of Health, National Cancer Institute.	ADEMA GJ, 1994, J BIOL CHEM, V269, P20126; Adema GJ, 1996, BRIT J CANCER, V73, P1044, DOI 10.1038/bjc.1996.202; Angles-Cano E, 2002, BIOL CHEM, V383, P93, DOI 10.1515/BC.2002.009; Arribas J, 2002, CHEM REV, V102, P4627, DOI 10.1021/cr010202t; Berson JF, 2003, J CELL BIOL, V161, P521, DOI 10.1083/jcb.200302072; Berson JF, 2001, MOL BIOL CELL, V12, P3451, DOI 10.1091/mbc.12.11.3451; Bosserhoff AK, 1997, CANCER RES, V57, P3149; Bycroft M, 1999, EMBO J, V18, P297, DOI 10.1093/emboj/18.2.297; Calvo PA, 1999, J BIOL CHEM, V274, P12780, DOI 10.1074/jbc.274.18.12780; Chiamenti AM, 1996, MELANOMA RES, V6, P291, DOI 10.1097/00008390-199608000-00003; de Vries TJ, 2001, J PATHOL, V193, P13; Diaz-Rodriguez E, 2000, BIOCHEM J, V346, P359, DOI 10.1042/0264-6021:3460359; Dlugosz A, 2002, J INVEST DERM SYMP P, V7, P17, DOI 10.1046/j.1523-1747.2002.19631.x; Dowdy JC, 1995, PHOTODERMATOL PHOTO, V11, P143, DOI 10.1111/j.1600-0781.1995.tb00156.x; Duguay SJ, 1997, J BIOL CHEM, V272, P6663, DOI 10.1074/jbc.272.10.6663; Elhabazi A, 2001, J IMMUNOL, V166, P4341, DOI 10.4049/jimmunol.166.7.4341; Fowler DM, 2006, PLOS BIOL, V4, P100, DOI 10.1371/journal.pbio.0040006; GOWN AM, 1986, AM J PATHOL, V123, P195; Harper DC, 2008, J BIOL CHEM, V283, P2307, DOI 10.1074/jbc.M708007200; Hearing VJ, 2005, J DERMATOL SCI, V37, P3, DOI 10.1016/j.jdermsci.2004.08.014; Hoashi T, 2005, J BIOL CHEM, V280, P14006, DOI 10.1074/jbc.M413692200; Hoashi T, 2006, J BIOL CHEM, V281, P21198, DOI 10.1074/jbc.M601643200; Honing S, 1998, EMBO J, V17, P1304, DOI 10.1093/emboj/17.5.1304; Hooper NM, 1997, BIOCHEM J, V321, P265, DOI 10.1042/bj3210265; ITO S, 1984, J CHROMATOGR, V311, P154, DOI 10.1016/S0378-4347(00)84702-7; IWATSUBO T, 1994, NEURON, V13, P45, DOI 10.1016/0896-6273(94)90458-8; JAMES P, 1995, TRENDS BIOCHEM SCI, V20, P38, DOI 10.1016/S0968-0004(00)88949-5; JARRETT JT, 1993, BIOCHEMISTRY-US, V32, P4693, DOI 10.1021/bi00069a001; Jean F, 1998, P NATL ACAD SCI USA, V95, P7293, DOI 10.1073/pnas.95.13.7293; KAPUR RP, 1992, J HISTOCHEM CYTOCHEM, V40, P207, DOI 10.1177/40.2.1552165; Kuliawat R, 2009, EUR J CELL BIOL, V88, P653, DOI 10.1016/j.ejcb.2009.07.001; Kummer MP, 2009, J BIOL CHEM, V284, P2296, DOI 10.1074/jbc.M808904200; Kushimoto T, 2001, P NATL ACAD SCI USA, V98, P10698, DOI 10.1073/pnas.191184798; KWON BS, 1991, P NATL ACAD SCI USA, V88, P9228, DOI 10.1073/pnas.88.20.9228; Lambert DW, 2008, FEBS LETT, V582, P385, DOI 10.1016/j.febslet.2007.11.085; Le Borgne R, 2001, J CELL SCI, V114, P2831; Lepage S, 2006, CANCER RES, V66, P2423, DOI 10.1158/0008-5472.CAN-05-2516; MARESH GA, 1994, ARCH BIOCHEM BIOPHYS, V311, P95, DOI 10.1006/abbi.1994.1213; MCGLINCHEY RP, 2009, P NATL ACAD SCI US; Miranda L, 1996, P NATL ACAD SCI USA, V93, P7695, DOI 10.1073/pnas.93.15.7695; Nagano O, 2004, J CELL BIOL, V165, P893, DOI 10.1083/jcb.200310024; Nichols SE, 2003, J INVEST DERMATOL, V121, P821, DOI 10.1046/j.1523-1747.2003.12474.x; Qi HL, 1999, SCIENCE, V283, P91, DOI 10.1126/science.283.5398.91; Raposo G, 2001, J CELL BIOL, V152, P809, DOI 10.1083/jcb.152.4.809; Raposo G, 2007, NAT REV MOL CELL BIO, V8, P786, DOI 10.1038/nrm2258; Robila V, 2008, J IMMUNOL, V181, P7843, DOI 10.4049/jimmunol.181.11.7843; Sadhukhan R, 1998, P NATL ACAD SCI USA, V95, P138, DOI 10.1073/pnas.95.1.138; SCANU AM, 1995, BBA-LIPID LIPID MET, V1256, P1, DOI 10.1016/0005-2760(95)00012-2; SEIJI M, 1963, NATURE, V197, P1082, DOI 10.1038/1971082a0; Skovronsky DM, 2000, J BIOL CHEM, V275, P2568, DOI 10.1074/jbc.275.4.2568; Solano F, 2000, PIGM CELL RES, V13, P118, DOI 10.1111/j.0893-5785.2000.130821.x; Swanson RA, 1996, DEV NEUROSCI-BASEL, V18, P515, DOI 10.1159/000111448; TAKAHASHI S, 1995, J BIOL CHEM, V270, P26565, DOI 10.1074/jbc.270.44.26565; Tanzi RE, 2001, NEURON, V32, P181, DOI 10.1016/S0896-6273(01)00476-7; Theos AC, 2006, DEV CELL, V10, P343, DOI 10.1016/j.devcel.2006.01.012; Theos AC, 2005, PIGM CELL RES, V18, P322, DOI 10.1111/j.1600-0749.2005.00269.x; Theos AC, 2006, MOL BIOL CELL, V17, P3598, DOI 10.1091/mbc.E06-01-0081; Thinakaran G, 2008, J BIOL CHEM, V283, P29615, DOI 10.1074/jbc.R800019200; THOMSON W, 1989, J AM ACAD DERMATOL, V21, P1280, DOI 10.1016/S0190-9622(89)70344-3; Valencia JC, 2006, J CELL SCI, V119, P1080, DOI 10.1242/jcs.02804; Valencia JC, 2007, J BIOL CHEM, V282, P11266, DOI 10.1074/jbc.M608449200; VENNEGOOR C, 1988, AM J PATHOL, V130, P179; VIJAYASARADHI S, 1995, J CELL BIOL, V130, P807, DOI 10.1083/jcb.130.4.807; VOGEL AM, 1988, CANCER RES, V48, P1286; Wolfers J, 2001, NAT MED, V7, P297, DOI 10.1038/85438; Wu Y, 2003, P NATL ACAD SCI USA, V100, P8229, DOI 10.1073/pnas.1430537100; Yasumoto K, 2004, J BIOL CHEM, V279, P28330, DOI 10.1074/jbc.M401269200	67	33	34	0	6	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAR	2010	24	3					916	930		10.1096/fj.09-140921	http://dx.doi.org/10.1096/fj.09-140921			15	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	561KE	19884326	Green Published			2022-12-25	WOS:000274974600027
J	Lagory, EL; Sitailo, LA; Denning, MF				Lagory, Edward L.; Sitailo, Leonid A.; Denning, Mitchell F.			The Protein Kinase C delta Catalytic Fragment Is Critical for Maintenance of the G(2)/M DNA Damage Checkpoint	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SQUAMOUS-CELL CARCINOMAS; UV-INDUCED APOPTOSIS; HUMAN KERATINOCYTES; PKC-DELTA; TUMOR-SUPPRESSOR; INDUCED PHOSPHORYLATION; TRANSGENIC MICE; P53 MUTATIONS; HISTONE H2AX; ACTIVATION	Protein kinase C delta (PKC delta) is an essential component of the intrinsic apoptotic program. Following DNA damage, such as exposure to UV radiation, PKC delta is cleaved in a caspase-dependent manner, generating a constitutively active catalytic fragment (PKC delta-cat), which is necessary and sufficient for keratinocyte apoptosis. We found that in addition to inducing apoptosis, expression of PKC delta-cat caused a pronounced G(2)/M cell cycle arrest in both primary human keratinocytes and immortalized HaCaT cells. Consistent with a G(2)/M arrest, PKC delta-cat induced phosphorylation of Cdk1 (Tyr(15)), a critical event in the G(2)/M checkpoint. Treatment with the ATM/ATR inhibitor caffeine was unable to prevent PKC delta-cat-induced G(2)/M arrest, suggesting that PKC delta-cat is functioning downstream of ATM/ATR in the G(2)/M checkpoint. To better understand the role of PKC delta and PKC delta-cat in the cell cycle response to DNA damage, we exposed wild-type and PKC delta null mouse embryonic fibroblasts (MEFs) to UV radiation. Wild-type MEFs underwent a pronounced G(2)/M arrest, Cdk1 phosphorylation, and induction of apoptosis following UV exposure, whereas PKC delta null MEFs were resistant to these effects. Expression of PKC delta-green fluorescent protein, but not caspase-resistant or kinase-inactive PKC delta, was able to restore G(2)/M checkpoint integrity in PKC delta null MEFs. The function of PKC delta in the DNA damage-induced G(2)/M cell cycle checkpoint may be a critical component of its tumor suppressor function.	[Sitailo, Leonid A.; Denning, Mitchell F.] Loyola Univ Chicago, Dept Pathol, Maywood, IL 60153 USA; Loyola Univ Chicago, Mol & Cellular Biochem Program, Dept Cell Biol Neurobiol & Anat, Maywood, IL 60153 USA; [Lagory, Edward L.; Sitailo, Leonid A.; Denning, Mitchell F.] Loyola Univ Chicago, Cardinal Bernardin Canc Ctr, Maywood, IL 60153 USA	Loyola University Chicago; Loyola University Chicago; Loyola University Chicago	Denning, MF (corresponding author), Loyola Univ Chicago, Dept Pathol, Rm 304,Bldg 112,2160 S 1st Ave, Maywood, IL 60153 USA.	mdennin@lumc.edu		LaGory, Edward/0000-0002-0552-1695	National Institutes of Health [CA083784]; NATIONAL CANCER INSTITUTE [R01CA083784] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This work was supported, in whole or in part, by National Institutes of Health Grant CA083784 (to M. F. D.).	AGARWAL ML, 1995, P NATL ACAD SCI USA, V92, P8493, DOI 10.1073/pnas.92.18.8493; Aziz MH, 2006, CANCER RES, V66, P713, DOI 10.1158/0008-5472.CAN-05-2684; Banin S, 1998, SCIENCE, V281, P1674, DOI 10.1126/science.281.5383.1674; Bartek J, 2007, CURR OPIN CELL BIOL, V19, P238, DOI 10.1016/j.ceb.2007.02.009; Bharti A, 1998, MOL CELL BIOL, V18, P6719, DOI 10.1128/MCB.18.11.6719; Bucher N, 2008, BRIT J CANCER, V98, P523, DOI 10.1038/sj.bjc.6604208; Bunz F, 1998, SCIENCE, V282, P1497, DOI 10.1126/science.282.5393.1497; Burma S, 2001, J BIOL CHEM, V276, P42462, DOI 10.1074/jbc.C100466200; Chan TA, 1999, NATURE, V401, P616, DOI 10.1038/44188; Chen MS, 2003, MOL CELL BIOL, V23, P7488, DOI 10.1128/MCB.23.21.7488-7497.2003; Cross T, 2000, ONCOGENE, V19, P2331, DOI 10.1038/sj.onc.1203555; D'Costa AM, 2006, ONCOGENE, V25, P378, DOI 10.1038/sj.onc.1209065; D'Costa AM, 2005, CELL DEATH DIFFER, V12, P224, DOI 10.1038/sj.cdd.4401558; Denning MF, 1998, J BIOL CHEM, V273, P29995, DOI 10.1074/jbc.273.45.29995; DeVries TA, 2002, EMBO J, V21, P6050, DOI 10.1093/emboj/cdf606; DeVries-Seimon TA, 2007, J BIOL CHEM, V282, P22307, DOI 10.1074/jbc.M703661200; Emoto Y, 1995, EMBO J, V14, P6148, DOI 10.1002/j.1460-2075.1995.tb00305.x; Fikaris AJ, 2005, J BIOL CHEM, V280, P32107, DOI 10.1074/jbc.M504432200; Heffernan TP, 2009, J INVEST DERMATOL, V129, P1805, DOI 10.1038/jid.2008.435; Hirao A, 2000, SCIENCE, V287, P1824, DOI 10.1126/science.287.5459.1824; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; Hose D, 2009, BLOOD, V113, P4331, DOI 10.1182/blood-2008-09-178350; Humphries MJ, 2006, J BIOL CHEM, V281, P9728, DOI 10.1074/jbc.M507851200; LEHMAN TA, 1993, CARCINOGENESIS, V14, P833, DOI 10.1093/carcin/14.5.833; Liu H, 2007, MOL CELL BIOL, V27, P8480, DOI 10.1128/MCB.01126-07; Liu QH, 2000, GENE DEV, V14, P1448; Lu YP, 2008, CANCER RES, V68, P2523, DOI 10.1158/0008-5472.CAN-07-5955; MITRA R, 1994, KERATINOCYTE METHODS; MUELLER PR, 1995, SCIENCE, V270, P86, DOI 10.1126/science.270.5233.86; Musacchio A, 2007, NAT REV MOL CELL BIO, V8, P379, DOI 10.1038/nrm2163; Pappa H, 1998, STRUCT FOLD DES, V6, P885, DOI 10.1016/S0969-2126(98)00090-2; PEARS CJ, 1990, EUR J BIOCHEM, V194, P89, DOI 10.1111/j.1432-1033.1990.tb19431.x; Perletti G, 2005, INT J CANCER, V113, P42, DOI 10.1002/ijc.20535; Reddig PJ, 1999, CANCER RES, V59, P5710; Ren J, 2002, J BIOL CHEM, V277, P33758, DOI 10.1074/jbc.M110667200; RUSSELL P, 1987, CELL, V49, P559, DOI 10.1016/0092-8674(87)90458-2; Sancar A, 2004, ANNU REV BIOCHEM, V73, P39, DOI 10.1146/annurev.biochem.73.011303.073723; Sarkaria JN, 1999, CANCER RES, V59, P4375; Schmidt M, 2007, DRUG RESIST UPDATE, V10, P162, DOI 10.1016/j.drup.2007.06.003; Shi MG, 2009, CELL, V136, P508, DOI 10.1016/j.cell.2008.12.021; Sitailo LA, 2004, J INVEST DERMATOL, V123, P434, DOI 10.1111/j.0022-202X.2004.23403.x; Sitailo LA, 2002, J BIOL CHEM, V277, P19346, DOI 10.1074/jbc.M200401200; Sitailo LA, 2006, J BIOL CHEM, V281, P29703, DOI 10.1074/jbc.M607351200; Takahashi A, 2006, NAT CELL BIOL, V8, P1291, DOI 10.1038/ncb1491; Tibbetts RS, 1999, GENE DEV, V13, P152, DOI 10.1101/gad.13.2.152; Tibudan SS, 2002, J INVEST DERMATOL, V119, P1282, DOI 10.1046/j.1523-1747.2002.19625.x; Ward IM, 2001, J BIOL CHEM, V276, P47759, DOI 10.1074/jbc.C100569200; WATANABE T, 1992, P NATL ACAD SCI USA, V89, P10159, DOI 10.1073/pnas.89.21.10159; Yoshida K, 2006, MOL CELL BIOL, V26, P3414, DOI 10.1128/MCB.26.9.3414-3431.2006; Yoshida K, 2006, J BIOL CHEM, V281, P5734, DOI 10.1074/jbc.M512074200; Yoshida K, 2003, EMBO J, V22, P1431, DOI 10.1093/emboj/cdg134; Yoshida K, 2007, CELL SIGNAL, V19, P892, DOI 10.1016/j.cellsig.2007.01.027	52	16	21	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 15	2010	285	3					1879	1887		10.1074/jbc.M109.055392	http://dx.doi.org/10.1074/jbc.M109.055392			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	541PJ	19917613	Green Published, hybrid			2022-12-25	WOS:000273429100034
J	Szigeti, A; Hocsak, E; Rapolti, E; Racz, B; Arpad, B; Pozsgai, E; Balazs, D; Bognar, Z; Bellyei, S; Balazs, S; Ferenc, G				Szigeti, Andras; Hocsak, Eniko; Rapolti, Edit; Racz, Boglarka; Arpad Boronkai; Pozsgai, Eva; Balazs Debreceni; Bognar, Zita; Bellyei, Szabolcs; Balazs Sumegi; Ferenc Gallyas, Jr.			Facilitation of Mitochondrial Outer and Inner Membrane Permeabilization and Cell Death in Oxidative Stress by a Novel Bcl-2 Homology 3 Domain Protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEPENDENT ANION CHANNEL; CYTOCHROME-C RELEASE; HEME-BINDING PROTEIN; FAMILY-MEMBERS; RAT-BRAIN; TRANSITION; BAX; APOPTOSIS; ACTIVATION; VDAC	We identified a sequence homologous to the Bcl-2 homology 3 (BH3) domain of Bcl-2 proteins in SOUL. Tissues expressed the protein to different extents. It was predominantly located in the cytoplasm, although a fraction of SOUL was associated with the mitochondria that increased upon oxidative stress. Recombinant SOUL protein facilitated mitochondrial permeability transition and collapse of mitochondrial membrane potential (MMP) and facilitated the release of proapoptotic mitochondrial intermembrane proteins (PMIP) at low calcium and phosphate concentrations in a cyclosporine A-dependent manner in vitro in isolated mitochondria. Suppression of endogenous SOUL by diced small interfering RNA in HeLa cells increased their viability in oxidative stress. Overexpression of SOUL in NIH3T3 cells promoted hydrogen peroxide-induced cell death and stimulated the release of PMIP but did not enhance caspase-3 activation. Despite the release of PMIP, SOUL facilitated predominantly necrotic cell death, as revealed by annexin V and propidium iodide staining. This necrotic death could be the result of SOUL-facilitated collapse of MMP demonstrated by JC-1 fluorescence. Deletion of the putative BH3 domain sequence prevented all of these effects of SOUL. Suppression of cyclophilin D prevented these effects too, indicating that SOUL facilitated mitochondrial permeability transition in vivo. Overexpression of Bcl-2 and Bcl-x(L), which can counteract the mitochondria-permeabilizing effect of BH3 domain proteins, also prevented SOUL-facilitated collapse of MMP and cell death. These data indicate that SOUL can be a novel member of the BH3 domain-only proteins that cannot induce cell death alone but can facilitate both outer and inner mitochondrial membrane permeabilization and predominantly necrotic cell death in oxidative stress.	[Szigeti, Andras; Hocsak, Eniko; Rapolti, Edit; Racz, Boglarka; Arpad Boronkai; Pozsgai, Eva; Balazs Debreceni; Bognar, Zita; Bellyei, Szabolcs; Balazs Sumegi; Ferenc Gallyas, Jr.] Univ Pecs, Dept Biochem & Med Chem, H-7624 Pecs, Hungary; [Szigeti, Andras; Arpad Boronkai; Bellyei, Szabolcs] Univ Pecs, Inst Oncotherapy, H-7624 Pecs, Hungary	University of Pecs; University of Pecs	Ferenc, G (corresponding author), Univ Pecs, Dept Biochem & Med Chem, 12 Szigeti St, H-7624 Pecs, Hungary.	ferenc.gallyas@aok.pte.hu	Szigeti, András/HGA-3522-2022; Gallyas, Ferenc/C-2272-2012	Gallyas, Ferenc/0000-0002-1906-4333; Szigeti, Andras/0000-0002-0132-5275	University of Pecs, Hungary; AOKKA [34039-1/2009, 34039-23/2009]; Hungarian Research Grants OTKA [68469, 67996, K-73738]	University of Pecs, Hungary; AOKKA; Hungarian Research Grants OTKA(Orszagos Tudomanyos Kutatasi Alapprogramok (OTKA))	This work was supported by University of Pecs, Hungary, AOKKA Grants 34039-1/2009 and 34039-23/2009 as well as Hungarian Research Grants OTKA 68469, 67996, and K-73738.	Adams JM, 1998, SCIENCE, V281, P1322, DOI 10.1126/science.281.5381.1322; Altznauer F, 2004, J BIOL CHEM, V279, P5947, DOI 10.1074/jbc.M308576200; Annis MG, 2005, EMBO J, V24, P2096, DOI 10.1038/sj.emboj.7600675; Armstrong JS, 2006, MITOCHONDRION, V6, P225, DOI 10.1016/j.mito.2006.07.006; Baines CP, 2007, NAT CELL BIOL, V9, P550, DOI 10.1038/ncb1575; Baines CP, 2005, NATURE, V434, P658, DOI 10.1038/nature03434; Banerjee J, 2004, BIOCHEM BIOPH RES CO, V323, P310, DOI 10.1016/j.bbrc.2004.08.094; Blackmon BJ, 2002, ARCH BIOCHEM BIOPHYS, V407, P196, DOI 10.1016/S0003-9861(02)00471-X; Bouillet P, 2002, J CELL SCI, V115, P1567; Brustovetsky N, 2003, J NEUROCHEM, V84, P196, DOI 10.1046/j.1471-4159.2003.01545.x; Carvalho ACP, 2004, CELL DEATH DIFFER, V11, P1265, DOI 10.1038/sj.cdd.4401508; Das S, 2008, CIRC RES, V103, P983, DOI 10.1161/CIRCRESAHA.108.178970; Deniaud A, 2008, ONCOGENE, V27, P285, DOI 10.1038/sj.onc.1210638; Epand RF, 2003, BIOCHEMISTRY-US, V42, P14576, DOI 10.1021/bi035348w; Gasz B, 2006, PEPTIDES, V27, P87, DOI 10.1016/j.peptides.2005.06.022; Gross A, 1999, GENE DEV, V13, P1899, DOI 10.1101/gad.13.15.1899; Hiller S, 2008, SCIENCE, V321, P1206, DOI 10.1126/science.1161302; HOGEBOOM GH, 1950, J BIOL CHEM, V186, P417; Hsu SY, 2000, PHYSIOL REV, V80, P593, DOI 10.1152/physrev.2000.80.2.593; Kelekar A, 1998, TRENDS CELL BIOL, V8, P324, DOI 10.1016/S0962-8924(98)01321-X; Korsmeyer SJ, 2000, CELL DEATH DIFFER, V7, P1166, DOI 10.1038/sj.cdd.4400783; Kowaltowski A, 2000, CELL DEATH DIFFER, V7, P903, DOI 10.1038/sj.cdd.4400722; Kyriakis JM, 2000, SCI STKE, V2000, DOI [DOI 10.1126/STKE.2000.63.PE1, 10.1126/stke.2000.48.pe1, DOI 10.1126/STKE.2000.48.PE1]; LATHROP JT, 1993, SCIENCE, V259, P522, DOI 10.1126/science.8424176; Lemasters JJ, 1998, BBA-BIOENERGETICS, V1366, P177, DOI 10.1016/S0005-2728(98)00112-1; Lemasters JJ, 2006, BBA-MOL BASIS DIS, V1762, P181, DOI 10.1016/j.bbadis.2005.10.006; Li T, 2008, BBA-BIOENERGETICS, V1777, P1409, DOI 10.1016/j.bbabio.2008.08.002; Lin CH, 2005, NEUROSCI LETT, V387, P22, DOI 10.1016/j.neulet.2005.06.070; Liu J, 2004, APOPTOSIS, V9, P533, DOI 10.1023/B:APPT.0000038034.16230.ea; Malia TJ, 2007, BIOCHEMISTRY-US, V46, P514, DOI 10.1021/bi061577h; Martinou JC, 2001, NAT REV MOL CELL BIO, V2, P63, DOI 10.1038/35048069; Reed JC, 1998, ONCOGENE, V17, P3225, DOI 10.1038/sj.onc.1202591; REERS M, 1991, BIOCHEMISTRY-US, V30, P4480, DOI 10.1021/bi00232a015; Rostovtseva TK, 2004, J BIOL CHEM, V279, P13575, DOI 10.1074/jbc.M310593200; Sambrook J., 1989, MOL CLONING LAB MANU, V2; Sato E, 2004, BIOCHEMISTRY-US, V43, P14189, DOI 10.1021/bi048742i; Shimizu S, 2000, P NATL ACAD SCI USA, V97, P577, DOI 10.1073/pnas.97.2.577; SHIN WS, 1994, BIOCHEM J, V304, P81, DOI 10.1042/bj3040081; Shinzawa K, 2003, J CELL BIOL, V163, P1219, DOI 10.1083/jcb.200306159; Shoshan-Barmatz V, 2008, J BIOENERG BIOMEMBR, V40, P183, DOI 10.1007/s10863-008-9147-9; Simonian PL, 1997, ONCOGENE, V15, P1871, DOI 10.1038/sj.onc.1201350; SIMS NR, 1990, J NEUROCHEM, V55, P698, DOI 10.1111/j.1471-4159.1990.tb04189.x; Smaili SS, 2001, CELL DEATH DIFFER, V8, P909, DOI 10.1038/sj.cdd.4400889; Soane L, 2005, J BIOENERG BIOMEMBR, V37, P179, DOI 10.1007/s10863-005-6590-8; Sugiyama T, 2002, ONCOGENE, V21, P4944, DOI 10.1038/sj.onc.1205621; Szigeti A, 2006, FEBS LETT, V580, P6447, DOI 10.1016/j.febslet.2006.10.067; Tafani M, 2001, CANCER RES, V61, P2459; Taketani S, 1998, J BIOL CHEM, V273, P31388, DOI 10.1074/jbc.273.47.31388; Tapodi A, 2005, J BIOL CHEM, V280, P35767, DOI 10.1074/jbc.M507075200; Terrones O, 2004, J BIOL CHEM, V279, P30081, DOI 10.1074/jbc.M313420200; Tsujimoto Y, 2007, APOPTOSIS, V12, P835, DOI 10.1007/s10495-006-0525-7; Tsujimoto Y, 2006, BBA-BIOENERGETICS, V1757, P1297, DOI 10.1016/j.bbabio.2006.03.017; Varbiro G, 2001, FREE RADICAL BIO MED, V31, P548, DOI 10.1016/S0891-5849(01)00616-5; Wang X, 2003, J BIOL CHEM, V278, P29184, DOI 10.1074/jbc.M301624200; Wu SN, 2009, J CELL PHYSIOL, V218, P603, DOI 10.1002/jcp.21636; Zylka MJ, 1999, MOL BRAIN RES, V74, P175, DOI 10.1016/S0169-328X(99)00277-6	56	26	27	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 15	2010	285	3					2140	2151		10.1074/jbc.M109.015222	http://dx.doi.org/10.1074/jbc.M109.015222			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	541PJ	19901022	hybrid, Green Published			2022-12-25	WOS:000273429100058
J	Chaudhri, VK; Kumar, D; Misra, M; Dua, R; Rao, KVS				Chaudhri, Virendra K.; Kumar, Dhiraj; Misra, Manjari; Dua, Raina; Rao, Kanury V. S.			Integration of a Phosphatase Cascade with the Mitogen-activated Protein Kinase Pathway Provides for a Novel Signal Processing Function	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RECEPTOR-TYROSINE-KINASE; MAP-KINASE; SCAFFOLD PROTEINS; SYSTEMS BIOLOGY; FEEDBACK LOOP; CELL-FATE; SPECIFICITY; TRANSDUCTION; NETWORK; RAS	We mathematically modeled the receptor-dependent mitogenactivated protein kinase (MAPK) signaling by incorporating the regulation through cellular phosphatases. Activation induced the alignment of a phosphatase cascade in parallel with the MAPK pathway. A novel regulatory motif was, thus, generated, providing for the combinatorial control of each MAPK intermediate. This ensured a non-linear mode of signal transmission with the output being shaped by the balance between the strength of input signal and the activity gradient along the phosphatase axis. Shifts in this balance yielded modulations in topology of the motif, thereby expanding the repertoire of output responses. Thus, we identify an added dimension to signal processing wherein the output response to an external stimulus is additionally filtered through indicators that define the phenotypic status of the cell.	[Chaudhri, Virendra K.; Kumar, Dhiraj; Misra, Manjari; Dua, Raina; Rao, Kanury V. S.] Int Ctr Genet Engn & Biotechnol, Immunol Grp, New Delhi 110067, India	Department of Biotechnology (DBT) India; International Center for Genetic Engineering & Biotechnology (ICGEB); International Center for Genetic Engineering & Biotechnology (ICGEB), New Delhi	Rao, KVS (corresponding author), Int Ctr Genet Engn & Biotechnol, Immunol Grp, Aruna Asaf Ali Marg, New Delhi 110067, India.	kanury@icgeb.res.in	Chaudhri, Virendra/S-9767-2019	Chaudhri, Virendra/0000-0003-3528-4667	Department of Biotechnology, Government of India; Council for Scientific and Industrial Research	Department of Biotechnology, Government of India(Department of Biotechnology (DBT) India); Council for Scientific and Industrial Research(Council of Scientific & Industrial Research (CSIR) - India)	This work was supported by a grant from Department of Biotechnology, Government of India (to K.V.S.R.).; Recipient of a Senior Research Fellowship from the Council for Scientific and Industrial Research.; Recipient of a Senior Research Fellowship from the Department of Biotechnology, Government of India.	Alon U, 2007, NAT REV GENET, V8, P450, DOI 10.1038/nrg2102; Altan-Bonnet G, 2005, PLOS BIOL, V3, P1925, DOI 10.1371/journal.pbio.0030356; Bettini ML, 2007, P NATL ACAD SCI USA, V104, P16257, DOI 10.1073/pnas.0705321104; Bhalla US, 2002, SCIENCE, V297, P1018, DOI 10.1126/science.1068873; Birtwistle MR, 2007, MOL SYST BIOL, V3, DOI 10.1038/msb4100188; Bluthgen N, 2006, FEBS J, V273, P895, DOI 10.1111/j.1742-4658.2006.05105.x; Bollen M, 2002, TRENDS CELL BIOL, V12, P138, DOI 10.1016/S0962-8924(01)02247-4; Brondello JM, 1999, SCIENCE, V286, P2514, DOI 10.1126/science.286.5449.2514; Camps M, 2000, FASEB J, V14, P6, DOI 10.1096/fasebj.14.1.6; Castelli M, 2004, J BIOL CHEM, V279, P44731, DOI 10.1074/jbc.M407669200; Chang LF, 2001, NATURE, V410, P37, DOI 10.1038/35065000; Cobb MH, 1999, PROG BIOPHYS MOL BIO, V71, P479, DOI 10.1016/S0079-6107(98)00056-X; Cyert MS, 2001, J BIOL CHEM, V276, P20805, DOI 10.1074/jbc.R100012200; Das J, 2009, CELL, V136, P337, DOI 10.1016/j.cell.2008.11.051; Dickinson RJ, 2002, MECH DEVELOP, V113, P193, DOI 10.1016/S0925-4773(02)00024-2; Dickinson RJ, 2006, J CELL SCI, V119, P4607, DOI 10.1242/jcs.03266; Ebisuya M, 2005, J CELL SCI, V118, P2997, DOI 10.1242/jcs.02505; Echevarria D, 2005, DEV BIOL, V277, P114, DOI 10.1016/j.ydbio.2004.09.011; Eungdamrong NJ, 2007, BIOPHYS J, V92, P808, DOI 10.1529/biophysj.106.093104; Ferrell JE, 1997, J BIOL CHEM, V272, P19008, DOI 10.1074/jbc.272.30.19008; Friedman A, 2006, NATURE, V444, P230, DOI 10.1038/nature05280; Hatakeyama M, 2003, BIOCHEM J, V373, P451, DOI 10.1042/BJ20021824; Heinrich R, 2002, MOL CELL, V9, P957, DOI 10.1016/S1097-2765(02)00528-2; Huang CYF, 1996, P NATL ACAD SCI USA, V93, P10078, DOI 10.1073/pnas.93.19.10078; Karlsson M, 2004, J BIOL CHEM, V279, P41882, DOI 10.1074/jbc.M406720200; Keyse SM, 2000, CURR OPIN CELL BIOL, V12, P186, DOI 10.1016/S0955-0674(99)00075-7; Kolch W, 2005, FEBS LETT, V579, P1891, DOI 10.1016/j.febslet.2005.02.002; Kumar D, 2007, MOL SYST BIOL, V3, DOI 10.1038/msb4100197; Kumar Dhiraj, 2008, BMC Res Notes, V1, P81, DOI 10.1186/1756-0500-1-81; Kurosaki T, 2000, IMMUNOL REV, V176, P19; Kurosaki T, 2000, CURR OPIN IMMUNOL, V12, P276, DOI 10.1016/S0952-7915(00)00087-X; Kurosaki T, 2002, NAT REV IMMUNOL, V2, P354, DOI 10.1038/nri801; Kurosaki T, 1999, ANNU REV IMMUNOL, V17, P555, DOI 10.1146/annurev.immunol.17.1.555; Kurosaki T, 2000, IMMUNITY, V12, P1, DOI 10.1016/S1074-7613(00)80153-3; Levchenko A, 2000, P NATL ACAD SCI USA, V97, P5818, DOI 10.1073/pnas.97.11.5818; Locasale JW, 2007, P NATL ACAD SCI USA, V104, P13307, DOI 10.1073/pnas.0706311104; MANDERS EMM, 1993, J MICROSC-OXFORD, V169, P375, DOI 10.1111/j.1365-2818.1993.tb03313.x; Muda M, 1996, J BIOL CHEM, V271, P4319; Orton RJ, 2005, BIOCHEM J, V392, P249, DOI 10.1042/BJ20050908; Qiao L, 2007, PLOS COMPUT BIOL, V3, P1819, DOI 10.1371/journal.pcbi.0030184; Raman M, 2007, ONCOGENE, V26, P3100, DOI 10.1038/sj.onc.1210392; RETH M, 1992, ANNU REV IMMUNOL, V10, P97, DOI 10.1146/annurev.iy.10.040192.000525; Rolli V, 2002, MOL CELL, V10, P1057, DOI 10.1016/S1097-2765(02)00739-6; Santos SDM, 2007, NAT CELL BIOL, V9, P324, DOI 10.1038/ncb1543; Schmidt TGM, 2007, NAT PROTOC, V2, P1528, DOI 10.1038/nprot.2007.209; Singh DK, 2005, CELL, V121, P281, DOI 10.1016/j.cell.2005.02.036; Tan PBO, 1999, TRENDS GENET, V15, P145, DOI 10.1016/S0168-9525(99)01694-7; Tian TH, 2007, NAT CELL BIOL, V9, P905, DOI 10.1038/ncb1615; UEKI K, 1994, J BIOL CHEM, V269, P15756; Widmann C, 1999, PHYSIOL REV, V79, P143, DOI 10.1152/physrev.1999.79.1.143; ZANDOMENI R, 1986, J BIOL CHEM, V261, P3414; Zhao Y, 2001, J BIOL CHEM, V276, P32382, DOI 10.1074/jbc.M103369200; Zi ZK, 2008, BMC BIOINFORMATICS, V9, DOI 10.1186/1471-2105-9-342	54	17	17	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 8	2010	285	2					1296	1310		10.1074/jbc.M109.055863	http://dx.doi.org/10.1074/jbc.M109.055863			15	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	539MH	19897477	Green Published, Green Submitted, hybrid			2022-12-25	WOS:000273258200051
J	Qi, Y; Spong, MC; Nam, K; Karplus, M; Verdine, GL				Qi, Yan; Spong, Marie C.; Nam, Kwangho; Karplus, Martin; Verdine, Gregory L.			Entrapment and Structure of an Extrahelical Guanine Attempting to Enter the Active Site of a Bacterial DNA Glycosylase, MutM	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FREE R-VALUE; MOLECULAR-DYNAMICS; SUBSTRATE-SPECIFICITY; INTRAHELICAL LESION; CROSS-VALIDATION; DUPLEX DNA; REPAIR; RECOGNITION; PROTEIN; 8-OXOGUANINE	MutM, a bacterial DNA glycosylase, protects genome integrity by catalyzing glycosidic bond cleavage of 8-oxoguanine (oxoG) lesions, thereby initiating base excision DNA repair. The process of searching for and locating oxoG lesions is especially challenging, because of the close structural resemblance of oxoG to its million-fold more abundant progenitor, G. Extrusion of the target nucleobase from the DNA double helix to an extrahelical position is an essential step in lesion recognition and catalysis by MutM. Although the interactions between the extruded oxoG and the active site of MutM have been well characterized, little is known in structural detail regarding the interrogation of extruded normal DNA bases by MutM. Here we report the capture and structural elucidation of a complex in which MutM is attempting to present an undamaged G to its active site. The structure of this MutM-extrahelical G complex provides insights into the mechanism MutM employs to discriminate against extrahelical normal DNA bases and into the base extrusion process in general.	[Qi, Yan; Verdine, Gregory L.] Harvard Univ, Sch Med, Grad Program Biophys, Boston, MA 02115 USA; [Spong, Marie C.; Nam, Kwangho; Karplus, Martin; Verdine, Gregory L.] Harvard Univ, Dept Chem & Chem Biol, Cambridge, MA 02138 USA; [Verdine, Gregory L.] Harvard Univ, Dept Mol & Cellular Biol, Cambridge, MA 02138 USA; [Verdine, Gregory L.] Harvard Univ, Dept Stem Cell & Regenerat Biol, Cambridge, MA 02138 USA; [Verdine, Gregory L.] Dana Farber Canc Inst, Chem Biol Initiat, Boston, MA 02115 USA; [Verdine, Gregory L.] Dana Farber Canc Inst, Program Canc Chem Biol, Boston, MA 02115 USA; [Karplus, Martin] Univ Strasbourg, Inst Sci & Ingn Supramol, F-67000 Strasbourg, France	Harvard University; Harvard Medical School; Harvard University; Harvard University; Harvard University; Harvard University; Dana-Farber Cancer Institute; Harvard University; Dana-Farber Cancer Institute; UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg	Verdine, GL (corresponding author), 12 Oxford St, Cambridge, MA 02138 USA.	gregory_verdine@harvard.edu			National Institutes of Health [GM044853, GM047467, CA100742, GM030804]; National Science Foundation; Howard Hughes Medical Institute; National Cancer Center; NATIONAL CANCER INSTITUTE [R01CA100742] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERING [P30EB009998] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM030804, R01GM030804, R01GM044853, P01GM047467] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); National Science Foundation(National Science Foundation (NSF)); Howard Hughes Medical Institute(Howard Hughes Medical Institute); National Cancer Center; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Biomedical Imaging & Bioengineering (NIBIB)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	This work was supported, in whole or in part, by National Institutes of Health Grants GM044853, GM047467, and CA100742 (to G.L.V.) and GM030804 (to M.K.).; Supported by a predoctoral fellowship from the National Science Foundation.; Supported by a predoctoral fellowship from the Howard Hughes Medical Institute.; Supported by a postdoctoral fellowship from the National Cancer Center.	Adams PD, 2002, ACTA CRYSTALLOGR D, V58, P1948, DOI 10.1107/S0907444902016657; Allen M.P., 1989, COMPUTER SIMULATION, P71; ANDERSEN HC, 1980, J CHEM PHYS, V72, P2384, DOI 10.1063/1.439486; Banerjee A, 2006, SCIENCE, V311, P1153, DOI 10.1126/science.1120288; Banerjee A, 2005, NATURE, V434, P612, DOI 10.1038/nature03458; Banerjee A, 2006, P NATL ACAD SCI USA, V103, P15020, DOI 10.1073/pnas.0603644103; Barnes DE, 2004, ANNU REV GENET, V38, P445, DOI 10.1146/annurev.genet.38.072902.092448; BERENDSEN HJC, 1984, J CHEM PHYS, V81, P3684, DOI 10.1063/1.448118; Blainey PC, 2006, P NATL ACAD SCI USA, V103, P5752, DOI 10.1073/pnas.0509723103; Bowman BR, 2008, STRUCTURE, V16, P1166, DOI 10.1016/j.str.2008.04.012; Brooks BR, 2009, J COMPUT CHEM, V30, P1545, DOI 10.1002/jcc.21287; BROOKS BR, 1983, J COMPUT CHEM, V4, P187, DOI 10.1002/jcc.540040211; Brunger AT, 1997, METHOD ENZYMOL, V277, P366, DOI 10.1016/S0076-6879(97)77021-6; BRUNGER AT, 1993, ACTA CRYSTALLOGR D, V49, P24, DOI 10.1107/S0907444992007352; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Cadet J, 2003, MUTAT RES-FUND MOL M, V531, P5, DOI 10.1016/j.mrfmmm.2003.09.001; Corn JE, 2007, STRUCTURE, V15, P773, DOI 10.1016/j.str.2007.05.006; DARDEN T, 1993, J CHEM PHYS, V98, P10089, DOI 10.1063/1.464397; Dornberger U, 1999, J BIOL CHEM, V274, P6957, DOI 10.1074/jbc.274.11.6957; Duguid EM, 2003, CHEM BIOL, V10, P827, DOI 10.1016/j.chembiol.2003.08.007; Emsley P, 2004, ACTA CRYSTALLOGR D, V60, P2126, DOI 10.1107/S0907444904019158; Foloppe N, 2000, J COMPUT CHEM, V21, P86, DOI 10.1002/(SICI)1096-987X(20000130)21:2<86::AID-JCC2>3.0.CO;2-G; Fromme JC, 2003, J BIOL CHEM, V278, P51543, DOI 10.1074/jbc.M307768200; Fromme JC, 2002, NAT STRUCT BIOL, V9, P544, DOI 10.1038/nsb809; GROLLMAN AP, 1993, TRENDS GENET, V9, P246, DOI 10.1016/0168-9525(93)90089-Z; Hamm ML, 2007, J AM CHEM SOC, V129, P7724, DOI 10.1021/ja0716453; Hitomi K, 2007, DNA REPAIR, V6, P410, DOI 10.1016/j.dnarep.2006.10.004; Huang HF, 1998, SCIENCE, V282, P1669, DOI 10.1126/science.282.5394.1669; Jang YH, 2002, CHEM RES TOXICOL, V15, P1023, DOI 10.1021/tx010146r; JORGENSEN WL, 1983, J CHEM PHYS, V79, P926, DOI 10.1063/1.445869; Kunkel TA, 2005, ANNU REV BIOCHEM, V74, P681, DOI 10.1146/annurev.biochem.74.082803.133243; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; LINDAHL T, 1993, NATURE, V362, P709, DOI 10.1038/362709a0; LIPSCOMB LA, 1995, P NATL ACAD SCI USA, V92, P719, DOI 10.1073/pnas.92.3.719; MacKerell AD, 2004, J AM CHEM SOC, V126, P698, DOI 10.1021/ja036959e; MacKerell AD, 1998, J PHYS CHEM B, V102, P3586, DOI 10.1021/jp973084f; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Parker JB, 2007, NATURE, V449, P433, DOI 10.1038/nature06131; Plum GE, 1995, BIOCHEMISTRY-US, V34, P16148, DOI 10.1021/bi00049a030; Priyakumar UD, 2006, J AM CHEM SOC, V128, P678, DOI 10.1021/ja056445a; Qi Y, 2009, NATURE, V462, P762, DOI 10.1038/nature08561; RYCKAERT JP, 1977, J COMPUT PHYS, V23, P327, DOI 10.1016/0021-9991(77)90098-5; Schuttelkopf AW, 2004, ACTA CRYSTALLOGR D, V60, P1355, DOI 10.1107/S0907444904011679; SHIBUTANI S, 1991, NATURE, V349, P431, DOI 10.1038/349431a0; TCHOU J, 1994, J BIOL CHEM, V269, P15318; Verdine GL, 2003, ANNU REV BIOCHEM, V72, P337, DOI 10.1146/annurev.biochem.72.121801.161447; Weiss JM, 2005, MOL CARCINOGEN, V42, P127, DOI 10.1002/mc.20067; Yang CG, 2008, NATURE, V452, P961, DOI 10.1038/nature06889; Zharkov DO, 2008, CELL MOL LIFE SCI, V65, P1544, DOI 10.1007/s00018-008-7543-2	49	44	44	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 8	2010	285	2					1468	1478		10.1074/jbc.M109.069799	http://dx.doi.org/10.1074/jbc.M109.069799			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	539MH	19889642	Green Published, hybrid			2022-12-25	WOS:000273258200066
J	Yuan, JS; Chen, JJ				Yuan, Jingsong; Chen, Junjie			MRE11-RAD50-NBS1 Complex Dictates DNA Repair Independent of H2AX	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DOUBLE-STRAND BREAKS; EARLY EMBRYONIC LETHALITY; S-PHASE CHECKPOINT; DAMAGE-RESPONSE PATHWAYS; MRE11 COMPLEX; TARGETED DISRUPTION; HISTONE H2AX; GENOMIC STABILITY; CHROMOSOMAL FRAGMENTATION; HUMAN RAD50/MRE11	DNA double-strand breaks (DSBs) represent one of the most serious forms of DNA damage that can occur in the genome. Here, we show that the DSB-induced signaling cascade and homologous recombination (HR)-mediated DSB repair pathway can be genetically separated. We demonstrate that the MRE11-RAD50-NBS1 (MRN) complex acts to promote DNA end resection and the generation of single-stranded DNA, which is critically important for HR repair. These functions of the MRN complex can occur independently of the H2AX-mediated DNA damage signaling cascade, which promotes stable accumulation of other signaling and repair proteins such as 53BP1 and BRCA1 to sites of DNA damage. Nevertheless, mild defects in HR repair are observed in H2AX-deficient cells, suggesting that the H2AX-dependent DNA damage-signaling cascade assists DNA repair. We propose that the MRN complex is responsible for the initial recognition of DSBs and works together with both CtIP and the H2AX-dependent DNA damage-signaling cascade to facilitate repair by HR and regulate DNA damage checkpoints.	[Yuan, Jingsong; Chen, Junjie] Yale Univ, Sch Med, Dept Therapeut Radiol, New Haven, CT 06520 USA	Yale University	Chen, JJ (corresponding author), Univ Texas MD Anderson Canc Ctr, Dept Expt Radiat Oncol, Houston, TX 77030 USA.	jchen8@mdanderson.org	Yuan, Jingsong/G-4527-2011		National Institutes of Health [CA100109, CA092312, CA089239]; NATIONAL CANCER INSTITUTE [R01CA089239, R01CA092312, R01CA100109] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This work was supported, in whole or in part, by a National Institutes of Health Grants CA100109, CA092312, and CA089239 (to J. C.).	Barlow C, 1996, CELL, V86, P159, DOI 10.1016/S0092-8674(00)80086-0; Bassing CH, 2003, CELL, V114, P359, DOI 10.1016/S0092-8674(03)00566-X; Bassing CH, 2002, P NATL ACAD SCI USA, V99, P8173, DOI 10.1073/pnas.122228699; Bekker-Jensen S, 2006, J CELL BIOL, V173, P195, DOI 10.1083/jcb.200510130; Bin W, 2007, P NATL ACAD SCI USA, V104, P20759, DOI 10.1073/pnas.0710061104; Borde V, 2007, CHROMOSOME RES, V15, P551, DOI 10.1007/s10577-007-1147-9; Brown EJ, 2000, GENE DEV, V14, P397; Buis J, 2008, CELL, V135, P85, DOI 10.1016/j.cell.2008.08.015; Carson CT, 2003, EMBO J, V22, P6610, DOI 10.1093/emboj/cdg630; Celeste A, 2003, NAT CELL BIOL, V5, P675, DOI 10.1038/ncb1004; Celeste A, 2002, SCIENCE, V296, P922, DOI 10.1126/science.1069398; Celeste A, 2003, CELL, V114, P371, DOI 10.1016/S0092-8674(03)00567-1; Cerosaletti K, 2004, J BIOL CHEM, V279, P38813, DOI 10.1074/jbc.M404294200; Cerosaletti K, 2006, MOL CELL BIOL, V26, P1691, DOI 10.1128/MCB.26.5.1691-1699.2006; Chapman JR, 2008, EMBO REP, V9, P795, DOI 10.1038/embor.2008.103; Chen JJ, 1998, MOL CELL, V2, P317, DOI 10.1016/S1097-2765(00)80276-2; Chen LC, 2008, J BIOL CHEM, V283, P7713, DOI 10.1074/jbc.M710245200; Chen PL, 2005, MOL CELL BIOL, V25, P3535, DOI 10.1128/MCB.25.9.3535-3542.2005; de Jager M, 2001, MOL CELL, V8, P1129, DOI 10.1016/S1097-2765(01)00381-1; de Jager M, 2002, NUCLEIC ACIDS RES, V30, P4425, DOI 10.1093/nar/gkf574; de Klein A, 2000, CURR BIOL, V10, P479, DOI 10.1016/S0960-9822(00)00447-4; Elson A, 1996, P NATL ACAD SCI USA, V93, P13084, DOI 10.1073/pnas.93.23.13084; Falck J, 2002, NAT GENET, V30, P290, DOI 10.1038/ng845; Harper JW, 2007, MOL CELL, V28, P739, DOI 10.1016/j.molcel.2007.11.015; Huen MSY, 2007, CELL, V131, P901, DOI 10.1016/j.cell.2007.09.041; Huen MS, 2008, CELL RES, V18, P8, DOI 10.1038/cr.2007.109; Jazayeri A, 2006, NAT CELL BIOL, V8, P37, DOI 10.1038/ncb1337; Jazayeri A, 2008, EMBO J, V27, P1953, DOI 10.1038/emboj.2008.128; Kolas NK, 2007, SCIENCE, V318, P1637, DOI 10.1126/science.1150034; Lavin MF, 2004, DNA REPAIR, V3, P1515, DOI 10.1016/j.dnarep.2004.07.001; Lee JH, 2004, SCIENCE, V304, P93, DOI 10.1126/science.1091496; Lee JH, 2005, SCIENCE, V308, P551, DOI 10.1126/science.1108297; Liu JS, 2006, J CELL BIOCHEM, V99, P1452, DOI 10.1002/jcb.21066; Lou ZK, 2006, MOL CELL, V21, P187, DOI 10.1016/j.molcel.2005.11.025; Lou ZK, 2003, NATURE, V421, P957, DOI 10.1038/nature01447; Lou ZK, 2003, J BIOL CHEM, V278, P13599, DOI 10.1074/jbc.C300060200; Ludwig T, 1997, GENE DEV, V11, P1226, DOI 10.1101/gad.11.10.1226; Luo GB, 1999, P NATL ACAD SCI USA, V96, P7376, DOI 10.1073/pnas.96.13.7376; Mailand N, 2007, CELL, V131, P887, DOI 10.1016/j.cell.2007.09.040; Manis JP, 2004, NAT IMMUNOL, V5, P481, DOI 10.1038/ni1067; Melander F, 2008, J CELL BIOL, V181, P213, DOI 10.1083/jcb.200708210; Moreno-Herrero F, 2005, NATURE, V437, P440, DOI 10.1038/nature03927; Myers JS, 2006, J BIOL CHEM, V281, P9346, DOI 10.1074/jbc.M513265200; Olson E, 2007, MOL CELL BIOL, V27, P6053, DOI 10.1128/MCB.00532-07; Paull TT, 2000, CURR BIOL, V10, P886, DOI 10.1016/S0960-9822(00)00610-2; Petersen S, 2001, NATURE, V414, P660, DOI 10.1038/414660a; Petrini JHJ, 2003, TRENDS CELL BIOL, V13, P458, DOI 10.1016/S0962-8924(03)00170-3; Pierce AJ, 2001, TRENDS CELL BIOL, V11, pS52, DOI 10.1016/S0962-8924(01)02149-3; Reina-San-Martin B, 2003, J EXP MED, V197, P1767, DOI 10.1084/jem.20030569; Riballo E, 2004, MOL CELL, V16, P715, DOI 10.1016/j.molcel.2004.10.029; Sartori AA, 2007, NATURE, V450, P509, DOI 10.1038/nature06337; Sharan SK, 1997, NATURE, V386, P804, DOI 10.1038/386804a0; Sobhian B, 2007, SCIENCE, V316, P1198, DOI 10.1126/science.1139516; Spycher C, 2008, J CELL BIOL, V181, P227, DOI 10.1083/jcb.200709008; Stucki M, 2005, CELL, V123, P1213, DOI 10.1016/j.cell.2005.09.038; Trujillo KM, 2003, J BIOL CHEM, V278, P48957, DOI 10.1074/jbc.M309877200; Tsuzuki T, 1996, P NATL ACAD SCI USA, V93, P6236, DOI 10.1073/pnas.93.13.6236; Uanschou C, 2007, EMBO J, V26, P5061, DOI 10.1038/sj.emboj.7601913; Ward IM, 2004, J CELL BIOL, V165, P459, DOI 10.1083/jcb.200403021; Weinstock DM, 2006, METHOD ENZYMOL, V409, P524, DOI 10.1016/S0076-6879(05)09031-2; Williams RS, 2008, CELL, V135, P97, DOI 10.1016/j.cell.2008.08.017; Wiltzius JJW, 2005, NAT STRUCT MOL BIOL, V12, P403, DOI 10.1038/nsmb928; Wood JL, 2008, TRENDS CELL BIOL, V18, P451, DOI 10.1016/j.tcb.2008.07.006; Wu LM, 2008, P NATL ACAD SCI USA, V105, P11200, DOI 10.1073/pnas.0802885105; Xiao YH, 1997, NUCLEIC ACIDS RES, V25, P2985, DOI 10.1093/nar/25.15.2985; Xie AY, 2007, MOL CELL, V28, P1045, DOI 10.1016/j.molcel.2007.12.005; Xie AY, 2004, MOL CELL, V16, P1017, DOI 10.1016/j.molcel.2004.12.007; Xu Y, 1996, GENE DEV, V10, P2411, DOI 10.1101/gad.10.19.2411; Yu XC, 2004, MOL CELL BIOL, V24, P9478, DOI 10.1128/MCB.24.21.9478-9486.2004; Yu XC, 2006, GENE DEV, V20, P1721, DOI 10.1101/gad.1431006; Zhang JR, 2005, NAT STRUCT MOL BIOL, V12, P902, DOI 10.1038/nsmb991; Zhu J, 2001, CURR BIOL, V11, P105, DOI 10.1016/S0960-9822(01)00019-7; Zou L, 2003, SCIENCE, V300, P1542, DOI 10.1126/science.1083430	73	72	73	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 8	2010	285	2					1097	1104		10.1074/jbc.M109.078436	http://dx.doi.org/10.1074/jbc.M109.078436			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	539MH	19910469	Green Published, hybrid			2022-12-25	WOS:000273258200031
J	Hockert, JA; Yeh, HJ; MacDonald, CC				Hockert, J. Andrew; Yeh, Hsiang-Jui; MacDonald, Clinton C.			The Hinge Domain of the Cleavage Stimulation Factor Protein CstF-64 Is Essential for CstF-77 Interaction, Nuclear Localization, and Polyadenylation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PRE-MESSENGER-RNA; LABELED POLYRIBOSOMAL RNA; MALE GERM-CELLS; POLYMERASE-II; TRANSCRIPTION TERMINATION; DOWNSTREAM ELEMENTS; CYTOPLASMIC POLYADENYLATION; 64-KILODALTON SUBUNIT; POLY(A) POLYMERASE; POINT MUTATIONS	Because polyadenylation is essential for cell growth, in vivo examination of polyadenylation protein function has been difficult. Here we describe a new in vivo assay that allows structure-function assays on CstF-64, a protein that binds to pre-mRNAs downstream of the cleavage site for accurate and efficient polyadenylation. In this assay (the stem-loop luciferase assay for polyadenylation, SLAP), expression of a luciferase pre-mRNA with a modified downstream sequence element was made dependent upon co-expression of an MS2-CstF-64 fusion protein. We show here that SLAP accurately reflects CstF-64-dependent polyadenylation, confirming the validity of this assay. Using SLAP, we determined that CstF-64 domains involved in RNA binding, interaction with CstF-77 (the "Hinge" domain), and coupling to transcription are critical for polyadenylation. Further, we showed that the Hinge domain is necessary for CstF-64 interaction with CstF-77 and consequent nuclear localization, suggesting that nuclear import of a preformed CstF complex is an essential step in polyadenylation.	[Hockert, J. Andrew; Yeh, Hsiang-Jui; MacDonald, Clinton C.] Texas Tech Univ, Hlth Sci Ctr, Dept Biochem & Cell Biol, Lubbock, TX 79430 USA	Texas Tech University System; Texas Tech University; Texas Tech University Health Science Center	MacDonald, CC (corresponding author), Texas Tech Univ, Hlth Sci Ctr, Dept Biochem & Cell Biol, 3601 4th St, Lubbock, TX 79430 USA.	clint.macdonald@ttuhsc.edu		MacDonald, Clinton/0000-0003-3209-1982	National Institutes of Health [R01 HD37109]; South Plains Foundation; Texas Tech University Health Sciences Center School of Medicine; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [R01HD037109] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); South Plains Foundation; Texas Tech University Health Sciences Center School of Medicine; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))	This work was supported, in whole or in part, by National Institutes of Health Grant R01 HD37109 (to C. C. M.). This work was also supported by grants from the South Plains Foundation and the Texas Tech University Health Sciences Center School of Medicine (to C. C. M.).	Bai Y, 2007, MOL CELL, V25, P863, DOI 10.1016/j.molcel.2007.01.034; Barbaux S, 1996, COMP BIOCHEM PHYS B, V114, P313, DOI 10.1016/0305-0491(96)00023-5; Barnard DC, 2004, CELL, V119, P641, DOI 10.1016/j.cell.2004.10.029; Benoit B, 2002, P NATL ACAD SCI USA, V99, P10593, DOI 10.1073/pnas.162191899; Beyer K, 1997, J BIOL CHEM, V272, P26769, DOI 10.1074/jbc.272.42.26769; BONNEAUD N, 1994, J CELL SCI, V107, P913; Buratowski S, 2005, CURR OPIN CELL BIOL, V17, P257, DOI 10.1016/j.ceb.2005.04.003; Calvo O, 2001, MOL CELL, V7, P1013, DOI 10.1016/S1097-2765(01)00236-2; Calvo O, 2003, GENE DEV, V17, P1321, DOI 10.1101/gad.1093603; Canadillas JMP, 2003, EMBO J, V22, P2821, DOI 10.1093/emboj/cdg259; Chennathukuzhi VM, 2001, MOL REPROD DEV, V58, P460, DOI 10.1002/1098-2795(20010401)58:4&lt;460::AID-MRD15&gt;3.0.CO;2-F; CHOU PY, 1974, BIOCHEMISTRY-US, V13, P222, DOI 10.1021/bi00699a002; CHOU ZF, 1994, NUCLEIC ACIDS RES, V22, P2525, DOI 10.1093/nar/22.13.2525; CHRISTOFORI G, 1988, CELL, V54, P875, DOI 10.1016/S0092-8674(88)91263-9; Colgan DF, 1997, GENE DEV, V11, P2755, DOI 10.1101/gad.11.21.2755; CONNELLY S, 1988, GENE DEV, V2, P440, DOI 10.1101/gad.2.4.440; Cui MX, 2008, P NATL ACAD SCI USA, V105, P16665, DOI 10.1073/pnas.0807104105; DARNELL JE, 1971, P NATL ACAD SCI USA, V68, P1321, DOI 10.1073/pnas.68.6.1321; Dass B, 2002, GENOMICS, V80, P509, DOI 10.1006/geno.2002.6862; Dass B, 2007, P NATL ACAD SCI USA, V104, P20374, DOI 10.1073/pnas.0707589104; Deka P, 2005, J MOL BIOL, V347, P719, DOI 10.1016/j.jmb.2005.01.046; EDMONDS M, 1971, P NATL ACAD SCI USA, V68, P1336, DOI 10.1073/pnas.68.6.1336; Edmonds M, 2002, PROG NUCLEIC ACID RE, V71, P285, DOI 10.1016/S0079-6603(02)71046-5; EDMONDS M, 1960, J BIOL CHEM, V235, P1142; EDWALDSGILBERT G, 1995, MOL CELL BIOL, V15, P6420; Erkmann JA, 2004, EXP CELL RES, V296, P12, DOI 10.1016/j.yexcr.2004.03.015; Fong N, 2001, GENE DEV, V15, P1783, DOI 10.1101/gad.889101; GILMARTIN GM, 1989, GENE DEV, V3, P2180, DOI 10.1101/gad.3.12b.2180; Glover-Cutter K, 2008, NAT STRUCT MOL BIOL, V15, P71, DOI 10.1038/nsmb1352; Hague Lisa K., 2008, V419, P171, DOI 10.1007/978-1-59745-033-1_12; Hall-Pogar T, 2007, RNA, V13, P1103, DOI 10.1261/rna.577707; Hatton LS, 2000, NUCLEIC ACIDS RES, V28, P520, DOI 10.1093/nar/28.2.520; Hernan R, 2000, BIOTECHNIQUES, V28, P789, DOI 10.2144/00284pf01; Hunt AG, 2008, BMC GENOMICS, V9, DOI 10.1186/1471-2164-9-220; Lago H, 1998, NUCLEIC ACIDS RES, V26, P1337, DOI 10.1093/nar/26.5.1337; LEE SY, 1971, P NATL ACAD SCI USA, V68, P1331, DOI 10.1073/pnas.68.6.1331; Legrand P, 2007, NUCLEIC ACIDS RES, V35, P4515, DOI 10.1093/nar/gkm458; Li L, 2006, MOL BIOL CELL, V17, P1126, DOI 10.1091/mbc.E05-08-0768; MACDONALD CC, 1994, MOL CELL BIOL, V14, P6647, DOI 10.1128/MCB.14.10.6647; Maciolek NL, 2008, VIROLOGY, V374, P468, DOI 10.1016/j.virol.2008.01.012; Mandel CR, 2008, CELL MOL LIFE SCI, V65, P1099, DOI 10.1007/s00018-007-7474-3; MANN KP, 1993, MOL CELL BIOL, V13, P2411, DOI 10.1128/MCB.13.4.2411; Martincic K, 1998, P NATL ACAD SCI USA, V95, P11095, DOI 10.1073/pnas.95.19.11095; McCracken S, 1997, NATURE, V385, P357, DOI 10.1038/385357a0; McGregor F, 1996, J VIROL, V70, P1931, DOI 10.1128/JVI.70.3.1931-1940.1996; MINVIELLESEBASTIA L, 1991, MOL CELL BIOL, V11, P3075, DOI 10.1128/MCB.11.6.3075; Mirkin N, 2008, NUCLEIC ACIDS RES, V36, P1792, DOI 10.1093/nar/gkn005; Monarez RR, 2007, BIOCHEM J, V401, P651, DOI 10.1042/BJ20061097; MOORE CL, 1988, EMBO J, V7, P3159, DOI 10.1002/j.1460-2075.1988.tb03183.x; Moreira A, 1998, GENE DEV, V12, P2522, DOI 10.1101/gad.12.16.2522; Nag A, 2007, NAT STRUCT MOL BIOL, V14, P662, DOI 10.1038/nsmb1253; NIWA M, 1992, NATURE, V360, P277, DOI 10.1038/360277a0; Qu XP, 2007, J BIOL CHEM, V282, P2101, DOI 10.1074/jbc.M609981200; Rao S, 2009, BMC CELL BIOL, V10, DOI 10.1186/1471-2121-10-51; Richardson JM, 1999, BIOCHEMISTRY-US, V38, P12869, DOI 10.1021/bi990724r; Rouget C, 2006, J BIOL CHEM, V281, P28687, DOI 10.1074/jbc.M601116200; Sadowski M, 2003, EMBO J, V22, P2167, DOI 10.1093/emboj/cdg200; Salisbury J, 2006, BMC GENOMICS, V7, DOI 10.1186/1471-2164-7-55; Schul W, 1996, EMBO J, V15, P2883, DOI 10.1002/j.1460-2075.1996.tb00649.x; Schul W, 1998, EXP CELL RES, V238, P1, DOI 10.1006/excr.1997.3808; Shankarling GS, 2009, BMC MOL BIOL, V10, DOI 10.1186/1471-2199-10-22; SHEETS MD, 1990, NUCLEIC ACIDS RES, V18, P5799, DOI 10.1093/nar/18.19.5799; Shi YS, 2009, MOL CELL, V33, P365, DOI 10.1016/j.molcel.2008.12.028; Stutz F, 2003, TRENDS CELL BIOL, V13, P319, DOI 10.1016/S0962-8924(03)00106-5; TAKAGAKI Y, 1990, GENE DEV, V4, P2112, DOI 10.1101/gad.4.12a.2112; TAKAGAKI Y, 1992, P NATL ACAD SCI USA, V89, P1403, DOI 10.1073/pnas.89.4.1403; TAKAGAKI Y, 1989, GENE DEV, V3, P1711, DOI 10.1101/gad.3.11.1711; TAKAGAKI Y, 1994, NATURE, V372, P471, DOI 10.1038/372471a0; Takagaki Y, 2000, MOL CELL BIOL, V20, P1515, DOI 10.1128/MCB.20.5.1515-1525.2000; Takagaki Y, 1996, CELL, V87, P941, DOI 10.1016/S0092-8674(00)82000-0; Uitte de Willige S, 2007, J THROMB HAEMOST, V5, P1243; Valegard K, 1997, J MOL BIOL, V270, P724, DOI 10.1006/jmbi.1997.1144; Veraldi KL, 2001, MOL CELL BIOL, V21, P1228, DOI 10.1128/MCB.21.4.1228-1238.2001; Wallace AM, 1999, P NATL ACAD SCI USA, V96, P6763, DOI 10.1073/pnas.96.12.6763; West S, 2008, NUCLEIC ACIDS RES, V36, P905, DOI 10.1093/nar/gkm1112; WICKENS M, 1984, SCIENCE, V226, P1045, DOI 10.1126/science.6208611; WILUSZ J, 1989, NUCLEIC ACIDS RES, V17, P3899, DOI 10.1093/nar/17.10.3899; WILUSZ J, 1988, CELL, V52, P221, DOI 10.1016/0092-8674(88)90510-7; Yang YS, 2009, BIOTECHNOL BIOENG, V102, P1152, DOI 10.1002/bit.22152; Yao YL, 2002, J EXP BOT, V53, P2277, DOI 10.1093/jxb/erf073; Yoshio TD, 1997, MOL CELL BIOL, V17, P3907, DOI 10.1128/MCB.17.7.3907; Zhang ZQ, 2006, MOL CELL, V21, P65, DOI 10.1016/j.molcel.2005.11.002; Zhao J, 1999, MICROBIOL MOL BIOL R, V63, P405, DOI 10.1128/MMBR.63.2.405-445.1999; Zhu ZH, 2009, ONCOGENE, V28, P41, DOI 10.1038/onc.2008.359	84	20	21	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 1	2010	285	1					695	704		10.1074/jbc.M109.061705	http://dx.doi.org/10.1074/jbc.M109.061705			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	536UT	19887456	hybrid, Green Published			2022-12-25	WOS:000273070100070
J	Rao, F; See, RY; Zhang, DW; Toh, DC; Ji, Q; Liang, ZX				Rao, Feng; See, Rui Yin; Zhang, Dongwei; Toh, Delon Chengxu; Ji, Qiang; Liang, Zhao-Xun			YybT Is a Signaling Protein That Contains a Cyclic Dinucleotide Phosphodiesterase Domain and a GGDEF Domain with ATPase Activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							C-DI-GMP; BACILLUS-SUBTILIS; PSEUDOMONAS-AERUGINOSA; DIGUANYLATE CYCLASE; ALLOSTERIC CONTROL; CYTOSOLIC EXOPOLYPHOSPHATASE; INORGANIC PYROPHOSPHATASE; SACCHAROMYCES-CEREVISIAE; CHECKPOINT PROTEIN; CRYSTAL-STRUCTURE	The cyclic dinucleotide c-di-GMP synthesized by the diadenylate cyclase domain was recently discovered as a messenger molecule for signaling DNA breaks in Bacillus subtilis. By searching bacterial genomes, we identified a family of DHH/DHHA1 domain proteins (COG3387) that co-occur with a subset of the diadenylate cyclase domain proteins. Here we report that the B. subtilis protein YybT, a member of the COG3387 family proteins, exhibits phosphodiesterase activity toward cyclic dinucleotides. The DHH/DHHA1 domain hydrolyzes c-di-AMP and c-di-GMP to generate the linear dinucleotides 5'-pApA and 5'-pGpG. The data suggest that c-di-AMP could be the physiological substrate for YybT given the physiologically relevant Michaelis-Menten constant (K-m) and the presence of YybT family proteins in the bacteria lacking c-di-GMP signaling network. The bacterial regulator ppGpp was found to be a strong competitive inhibitor of the DHH/DHHA1 domain, suggesting that YybT is under tight control during stringent response. In addition, the atypical GGDEF domain of YybT exhibits unexpected ATPase activity, distinct from the common diguanylate cyclase activity for GGDEF domains. We further demonstrate the participation of YybT in DNA damage and acid resistance by characterizing the phenotypes of the Delta yybT mutant. The novel enzymatic activity and stress resistance together point toward a role for YybT in stress signaling and response.	[Rao, Feng; See, Rui Yin; Zhang, Dongwei; Toh, Delon Chengxu; Ji, Qiang; Liang, Zhao-Xun] Nanyang Technol Univ, Sch Biol Sci, Singapore 637551, Singapore	Nanyang Technological University & National Institute of Education (NIE) Singapore; Nanyang Technological University	Liang, ZX (corresponding author), Nanyang Technol Univ, Sch Biol Sci, 60 Nanyang Dr, Singapore 637551, Singapore.	zxliang@ntu.edu.sg	Rao, Feng/AAD-4712-2019; Liang, Zhao-Xun/A-2191-2011; RAO, FENG/G-4529-2011	Rao, Feng/0000-0002-6038-6406; RAO, FENG/0000-0002-6038-6406; Liang, Zhao-Xun/0000-0002-3128-1330	Biomedical Research Council of Singapore [06/1/22/19/464]	Biomedical Research Council of Singapore(Agency for Science Technology & Research (A*STAR))	This work is supported by Biomedical Research Council of Singapore Grant 06/1/22/19/464.	Aravind L, 1998, TRENDS BIOCHEM SCI, V23, P17, DOI 10.1016/S0968-0004(97)01162-6; Arnold K, 2006, BIOINFORMATICS, V22, P195, DOI 10.1093/bioinformatics/bti770; Bejerano-Sagie M, 2006, CELL, V125, P679, DOI 10.1016/j.cell.2006.03.039; Boehm A, 2009, MOL MICROBIOL, V72, P1500, DOI 10.1111/j.1365-2958.2009.06739.x; Chan C, 2004, P NATL ACAD SCI USA, V101, P17084, DOI 10.1073/pnas.0406134101; Chatterji D, 2001, CURR OPIN MICROBIOL, V4, P160, DOI 10.1016/S1369-5274(00)00182-X; Christen B, 2006, J BIOL CHEM, V281, P32015, DOI 10.1074/jbc.M603589200; Christen M, 2005, J BIOL CHEM, V280, P30829, DOI 10.1074/jbc.M504429200; Cotter PD, 2003, MICROBIOL MOL BIOL R, V67, P429, DOI 10.1128/MMBR.67.3.429-453.2003; D'Angelo A, 2004, CANCER CELL, V5, P137, DOI 10.1016/S1535-6108(04)00021-2; De N, 2008, PLOS BIOL, V6, P601, DOI 10.1371/journal.pbio.0060067; Fabrichniy IP, 2007, J BIOL CHEM, V282, P1422, DOI 10.1074/jbc.M513161200; Fabrichniy IP, 2004, BIOCHEMISTRY-US, V43, P14403, DOI 10.1021/bi0484973; Galperin MY, 2005, BMC MICROBIOL, V5, DOI 10.1186/1471-2180-5-35; Galperin MY, 2001, FEMS MICROBIOL LETT, V203, P11, DOI 10.1111/j.1574-6968.2001.tb10814.x; Hengge R, 2009, NAT REV MICROBIOL, V7, P263, DOI 10.1038/nrmicro2109; Hickman JW, 2008, MOL MICROBIOL, V69, P376, DOI 10.1111/j.1365-2958.2008.06281.x; Holland LM, 2008, J BACTERIOL, V190, P5178, DOI 10.1128/JB.00375-08; IKEHARA K, 1984, J BIOCHEM-TOKYO, V95, P895, DOI 10.1093/oxfordjournals.jbchem.a134684; Jensen LJ, 2009, NUCLEIC ACIDS RES, V37, pD412, DOI 10.1093/nar/gkn760; Jeong KC, 2008, BMC MICROBIOL, V8, DOI 10.1186/1471-2180-8-181; Kobayashi K, 2003, P NATL ACAD SCI USA, V100, P4678, DOI 10.1073/pnas.0730515100; Larkin MA, 2007, BIOINFORMATICS, V23, P2947, DOI 10.1093/bioinformatics/btm404; Mechold U, 2007, NUCLEIC ACIDS RES, V35, P4552, DOI 10.1093/nar/gkm462; Meissner A, 2007, ENVIRON MICROBIOL, V9, P2475, DOI 10.1111/j.1462-2920.2007.01366.x; Mitic N, 2006, CHEM REV, V106, P3338, DOI 10.1021/cr050318f; Paul R, 2007, J BIOL CHEM, V282, P29170, DOI 10.1074/jbc.M704702200; Pei JM, 2001, PROTEINS, V42, P210, DOI 10.1002/1097-0134(20010201)42:2<210::AID-PROT80>3.0.CO;2-8; Pesavento C, 2009, CURR OPIN MICROBIOL, V12, P170, DOI 10.1016/j.mib.2009.01.007; PLATEAU P, 1987, J BACTERIOL, V169, P419, DOI 10.1128/jb.169.1.419-422.1987; Potrykus K, 2008, ANNU REV MICROBIOL, V62, P35, DOI 10.1146/annurev.micro.62.081307.162903; Qi YN, 2009, BIOCHEMISTRY-US, V48, P10275, DOI 10.1021/bi901121w; Rallu F, 2000, MOL MICROBIOL, V35, P517, DOI 10.1046/j.1365-2958.2000.01711.x; Rao F, 2008, J BACTERIOL, V190, P3622, DOI 10.1128/JB.00165-08; Rao F, 2009, J BACTERIOL, V191, P4722, DOI 10.1128/JB.00327-09; Rao F, 2009, ANAL BIOCHEM, V389, P138, DOI 10.1016/j.ab.2009.03.031; Romling U, 2005, MOL MICROBIOL, V57, P629, DOI 10.1111/j.1365-2958.2005.04697.x; Romling U, 2008, SCI SIGNAL, V1, DOI 10.1126/scisignal.133pe39; RUIZ A, 1989, J BACTERIOL, V171, P6703, DOI 10.1128/jb.171.12.6703-6709.1989; Ryan RP, 2006, P NATL ACAD SCI USA, V103, P6712, DOI 10.1073/pnas.0600345103; Ryjenkov DA, 2005, J BACTERIOL, V187, P1792, DOI 10.1128/JB.187.5.1792-1798.2005; Schmidt AJ, 2005, J BACTERIOL, V187, P4774, DOI 10.1128/JB.187.14.4774-4781.2005; Simm R, 2004, MOL MICROBIOL, V53, P1123, DOI 10.1111/j.1365-2958.2004.04206.x; Simm R, 2009, ANAL BIOCHEM, V386, P53, DOI 10.1016/j.ab.2008.12.013; Sinha SC, 2007, REV PHYSIOL BIOCH P, V157, P105, DOI 10.1007/112_0603; Srivatsan A, 2008, CURR OPIN MICROBIOL, V11, P100, DOI 10.1016/j.mib.2008.02.001; Tammenkoski M, 2007, J BIOL CHEM, V282, P9302, DOI 10.1074/jbc.M609423200; Tucker PA, 2007, CURR OPIN STRUC BIOL, V17, P641, DOI 10.1016/j.sbi.2007.09.012; Ugochukwu E, 2007, J MOL BIOL, V371, P1007, DOI 10.1016/j.jmb.2007.05.066; Waldron KJ, 2009, NAT REV MICROBIOL, V7, P25, DOI 10.1038/nrmicro2057; Wendrich TM, 1997, MOL MICROBIOL, V26, P65, DOI 10.1046/j.1365-2958.1997.5511919.x; Witte G, 2008, MOL CELL, V30, P167, DOI 10.1016/j.molcel.2008.02.020; Yamagata A, 2002, P NATL ACAD SCI USA, V99, P5908, DOI 10.1073/pnas.092547099; Yamagata A, 2001, NUCLEIC ACIDS RES, V29, P4617, DOI 10.1093/nar/29.22.4617; Young TW, 1998, MICROBIOL-SGM, V144, P2563, DOI 10.1099/00221287-144-9-2563	55	171	185	1	25	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 1	2010	285	1					473	482		10.1074/jbc.M109.040238	http://dx.doi.org/10.1074/jbc.M109.040238			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	536UT	19901023	hybrid, Green Published			2022-12-25	WOS:000273070100049
J	Berbey, C; Weiss, N; Legrand, C; Allard, B				Berbey, Celine; Weiss, Norbert; Legrand, Claude; Allard, Bruno			Transient Receptor Potential Canonical Type 1 (TRPC1) Operates as a Sarcoplasmic Reticulum Calcium Leak Channel in Skeletal Muscle	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DUCHENNE MUSCULAR-DYSTROPHY; MDX MICE; FIBERS; CELLS; DIFFERENTIATION; RELEASE; ENTRIES	Extensive studies performed in nonexcitable cells and expression systems have shown that type 1 transient receptor potential canonical (TRPC1) channels operate mainly in plasma membranes and open through phospholipase C-dependent processes, membrane stretch, or depletion of Ca2+ stores. In skeletal muscle, it is proposed that TRPC1 channels are involved in plasmalemmal Ca2+ influx and stimulated by store depletion or membrane stretch, but direct evidence for TRPC1 sarcolemmal channel activity is not available. We investigated here the functional role of TRPC1 using an overexpressing strategy in adult mouse muscle fibers. Immunostaining for endogenous TRPC1 revealed a striated expression pattern that matched sarcoplasmic reticulum (SR) Ca2+ pump immunolabeling. In cells expressing TRPC1-yellow fluorescent protein (YFP), the same pattern of expression was observed, compatible with a longitudinal SR localization. Resting electric properties, action potentials, and resting divalent cation influx were not altered in TRPC1-YFP-positive cells. Poisoning with the SR Ca2+ pump blocker cyclopiazonic acid elicited a contracture of the fiber at the level of the overexpression site in presence and absence of external Ca2+ which was not observed in control cells. Ca2+ measurements indicated that resting Ca2+ and the rate of Ca2+ increase induced by cyclopiazonic acid were higher in the TRPC1-YFP-positive zone than in the TRPC1-YFP-negative zone and control cells. Ca2+ transients evoked by 200-ms voltage clamp pulses decayed slower in TRPC1-YFP-positive cells. In contrast to previous hypotheses, these data demonstrate that TRPC1 operates as a SR Ca2+ leak channel in skeletal muscle.	[Berbey, Celine; Weiss, Norbert; Legrand, Claude; Allard, Bruno] Univ Lyon 1, CNRS, UMR 5123, Lab Physiol Integrat Cellulaire & Mol, F-69622 Villeurbanne, France	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Claude Bernard Lyon 1	Allard, B (corresponding author), Univ Lyon 1, CNRS, UMR 5123, Lab Physiol Integrat Cellulaire & Mol, 43 Bd 11 Novembre 1918, F-69622 Villeurbanne, France.	bruno.allard@univ-lyon1.fr	Weiss, Norbert/G-5330-2014	Weiss, Norbert/0000-0002-0040-1109; Allard, Bruno/0000-0002-7131-7828	Universite Lyon 1; Centre National de la Recherche Scientifique; Association Francaise contre les Myopathies; Agence Nationale de la Recherche	Universite Lyon 1; Centre National de la Recherche Scientifique(Centre National de la Recherche Scientifique (CNRS)); Association Francaise contre les Myopathies(Association Francaise contre les Myopathies); Agence Nationale de la Recherche(French National Research Agency (ANR))	This work was supported by grants from the Universite Lyon 1, the Centre National de la Recherche Scientifique, the Association Francaise contre les Myopathies, and the Agence Nationale de la Recherche.	Allard B, 2006, J PHYSIOL-LONDON, V575, P69, DOI 10.1113/jphysiol.2006.112367; Berbey C, 2009, BIOPHYS J, V96, P2648, DOI 10.1016/j.bpj.2009.01.008; Birnbaumer L, 2009, ANNU REV PHARMACOL, V49, P395, DOI 10.1146/annurev.pharmtox.48.113006.094928; Collet C, 1999, J PHYSIOL-LONDON, V520, P417, DOI 10.1111/j.1469-7793.1999.00417.x; Cusimano V, 2009, P NATL ACAD SCI USA, V106, P4695, DOI 10.1073/pnas.0810243106; Formigli L, 2009, J CELL SCI, V122, P1322, DOI 10.1242/jcs.035402; Gailly P, 2002, BBA-PROTEINS PROTEOM, V1600, P38, DOI 10.1016/S1570-9639(02)00442-9; Gervasio OL, 2008, J CELL SCI, V121, P2246, DOI 10.1242/jcs.032003; Louis M, 2008, J CELL SCI, V121, P3951, DOI 10.1242/jcs.037218; Matsuoka H, 2009, AM J PHYSIOL-CELL PH, V296, pC889, DOI 10.1152/ajpcell.00439.2008; Pouvreau Sandrine, 2007, V403, P185, DOI 10.1007/978-1-59745-529-9_12; Rychkov G., 2007, V179, P23; Stiber JA, 2008, MOL CELL BIOL, V28, P2637, DOI 10.1128/MCB.01601-07; TURNER PR, 1988, NATURE, V335, P735, DOI 10.1038/335735a0; Vandebrouck A, 2007, FASEB J, V21, P608, DOI 10.1096/fj.06-6683com; Vandebrouck C, 2002, J CELL BIOL, V158, P1089, DOI 10.1083/jcb.200203091; Venkatachalam K, 2007, ANNU REV BIOCHEM, V76, P387, DOI 10.1146/annurev.biochem.75.103004.142819; Woods CE, 2004, J PHYSIOL-LONDON, V557, P59, DOI 10.1113/jphysiol.2004.061291; Xin H, 2005, BIOCHEM BIOPH RES CO, V332, P756, DOI 10.1016/j.bbrc.2005.05.016	19	41	41	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 25	2009	284	52					36387	36394		10.1074/jbc.M109.073221	http://dx.doi.org/10.1074/jbc.M109.073221			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	535LT	19875453	hybrid, Green Published			2022-12-25	WOS:000272970500040
J	Pontzer, H; Allen, V; Hutchinson, JR				Pontzer, Herman; Allen, Vivian; Hutchinson, John R.			Biomechanics of Running Indicates Endothermy in Bipedal Dinosaurs	PLOS ONE			English	Article							THEROPOD DINOSAUR; SENSITIVITY-ANALYSIS; OXYGEN-CONSUMPTION; BODY TEMPERATURES; GROWTH-RATES; EVOLUTION; BIRDS; COST; ENERGETICS; PHYLOGENY	Background: One of the great unresolved controversies in paleobiology is whether extinct dinosaurs were endothermic, ectothermic, or some combination thereof, and when endothermy first evolved in the lineage leading to birds. Although it is well established that high, sustained growth rates and, presumably, high activity levels are ancestral for dinosaurs and pterosaurs (clade Ornithodira), other independent lines of evidence for high metabolic rates, locomotor costs, or endothermy are needed. For example, some studies have suggested that, because large dinosaurs may have been homeothermic due to their size alone and could have had heat loss problems, ectothermy would be a more plausible metabolic strategy for such animals. Methodology/Principal Findings: Here we describe two new biomechanical approaches for reconstructing the metabolic rate of 14 extinct bipedal dinosauriforms during walking and running. These methods, well validated for extant animals, indicate that during walking and slow running the metabolic rate of at least the larger extinct dinosaurs exceeded the maximum aerobic capabilities of modern ectotherms, falling instead within the range of modern birds and mammals. Estimated metabolic rates for smaller dinosaurs are more ambiguous, but generally approach or exceed the ectotherm boundary. Conclusions/Significance: Our results support the hypothesis that endothermy was widespread in at least larger non-avian dinosaurs. It was plausibly ancestral for all dinosauriforms (perhaps Ornithodira), but this is perhaps more strongly indicated by high growth rates than by locomotor costs. The polarity of the evolution of endothermy indicates that rapid growth, insulation, erect postures, and perhaps aerobic power predated advanced "avian" lung structure and high locomotor costs.			Pontzer, H (corresponding author), Washington Univ, Dept Anthropol, St Louis, MO 63130 USA.	hpontzer@artsci.wustl.edu	Hutchinson, John/AAH-1593-2020	Hutchinson, John/0000-0002-6767-7038; Pontzer, Herman/0000-0003-2397-6543				ALEXANDER RM, 1983, J ZOOL, V201, P135, DOI 10.1111/j.1469-7998.1983.tb04266.x; BAKKER RT, 1972, NATURE, V238, P81, DOI 10.1038/238081a0; Bennett A.F., 1976, P127; Bennett A.F., 1986, P207; BENNETT AF, 1979, SCIENCE, V206, P649, DOI 10.1126/science.493968; BIEWENER AA, 1989, SCIENCE, V245, P45, DOI 10.1126/science.2740914; Biewener AA, 2004, J APPL PHYSIOL, V97, P2266, DOI 10.1152/japplphysiol.00003.2004; Brusatte SL, 2008, J SYST PALAEONTOL, V6, P155, DOI 10.1017/S1477201907002404; Butler RJ, 2008, J SYST PALAEONTOL, V6, P1, DOI 10.1017/S1477201907002271; Carrano MT, 2008, J SYST PALAEONTOL, V6, P183, DOI 10.1017/S1477201907002246; Carrano MT, 2005, J VERTEBR PALEONTOL, V25, P835, DOI 10.1671/0272-4634(2005)025[0835:NIOSHA]2.0.CO;2; Chen PJ, 1998, NATURE, V391, P147, DOI 10.1038/34356; Chinsamy A, 1995, PALEOBIOLOGY, V21, P561, DOI 10.1017/S0094837300013543; Claessens LPAM, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0004497; Cooper A, 2001, NATURE, V409, P704, DOI 10.1038/35055536; de Ricqles AJ, 2000, ZOOL J LINN SOC-LOND, V129, P349, DOI 10.1006/zjls.1999.0239; Dyke GJ, 2004, ZOOL J LINN SOC-LOND, V141, P153, DOI 10.1111/j.1096-3642.2004.00118.x; Erickson GM, 2001, NATURE, V412, P429, DOI 10.1038/35086558; FARLOW JO, 1995, ANNU REV ECOL SYST, V26, P445, DOI 10.1146/annurev.es.26.110195.002305; Farmer CG, 2000, AM NAT, V155, P326, DOI 10.1086/303323; Farmer CG, 2003, AM NAT, V162, P826, DOI 10.1086/380922; GATESY SM, 1991, J ZOOL, V224, P577, DOI 10.1111/j.1469-7998.1991.tb03786.x; Gatesy SM, 2009, J VERTEBR PALEONTOL, V29, P535, DOI 10.1671/039.029.0213; GAUTHIER J, 1988, CLADISTICS, V4, P105, DOI 10.1111/j.1096-0031.1988.tb00514.x; Gillooly JF, 2006, PLOS BIOL, V4, P1467, DOI 10.1371/journal.pbio.0040248; Gleeson TT, 2002, COMP BIOCHEM PHYS A, V133, P259, DOI 10.1016/S1095-6433(02)00164-2; Gunga HC, 2007, NATURWISSENSCHAFTEN, V94, P623, DOI 10.1007/s00114-007-0234-2; HAUBOLD H, 1999, ZBL GEOL PALAONT 1, V7, P783; Hillenius WJ, 2004, PHYSIOL BIOCHEM ZOOL, V77, P1019, DOI 10.1086/425185; Hutchinson JR, 2007, J THEOR BIOL, V246, P660, DOI 10.1016/j.jtbi.2007.01.023; Hutchinson JR, 2009, NATURWISSENSCHAFTEN, V96, P423, DOI 10.1007/s00114-008-0488-3; Hutchinson JR, 2004, J MORPHOL, V262, P441, DOI 10.1002/jmor.10240; Hutchinson JR, 2004, J MORPHOL, V262, P421, DOI 10.1002/jmor.10241; JOHNALDER HB, 1986, PHYSIOL ZOOL, V59, P523, DOI 10.1086/physzool.59.5.30156116; Kleiber M, 1961, FIRE LIFE; KRAM R, 1990, NATURE, V346, P265, DOI 10.1038/346265a0; Langer MC, 2006, J SYST PALAEONTOL, V4, P309, DOI 10.1017/S1477201906001970; LASIEWSKI RC, 1967, CONDOR, V69, P13, DOI 10.2307/1366368; Maddison, 2019, MESQUITE MODULAR SYS; Mayr G, 2003, CLADISTICS, V19, P527, DOI [10.1016/j.cladistics.2003.10.003, 10.1111/j.1096-0031.2003.tb00387.x]; Nagy KA, 1999, ANNU REV NUTR, V19, P247, DOI 10.1146/annurev.nutr.19.1.247; Novas FE, 1996, J VERTEBR PALEONTOL, V16, P723, DOI 10.1080/02724634.1996.10011361; O'Connor PM, 2005, NATURE, V436, P253, DOI 10.1038/nature03716; OSTROM JH, 1980, COLD LOOK WARM BLOOD, P15; Owerkowicz T, 1999, SCIENCE, V284, P1661, DOI 10.1126/science.284.5420.1661; Padian K, 2004, J VERTEBR PALEONTOL, V24, P555, DOI 10.1671/0272-4634(2004)024[0555:GISDAP]2.0.CO;2; Padian K, 2001, NATURE, V412, P405, DOI 10.1038/35086500; PALADINO FV, 1990, NATURE, V344, P858, DOI 10.1038/344858a0; Paul G., 1988, PREDATORY DINOSAURS; Pontzer H, 2007, J EXP BIOL, V210, P1752, DOI 10.1242/jeb.002246; Pontzer H, 2009, J HUM EVOL, V56, P43, DOI 10.1016/j.jhevol.2008.09.001; Reid R.E.H., 1997, P449; Ricqles A. de, 1974, EVOL THEORY, V1, P51; Roberts TJ, 1998, J EXP BIOL, V201, P2753; Ruben JA, 1996, SCIENCE, V273, P1204, DOI 10.1126/science.273.5279.1204; Rubenson J, 2007, J EXP BIOL, V210, P2548, DOI 10.1242/jeb.02792; Rubenson J, 2007, J EXP BIOL, V210, P3513, DOI 10.1242/jeb.000992; Schmidt-Nielsen K, 1997, ANIMAL PHYSL ADAPTAT; Schweitzer MH, 2001, J EXP ZOOL, V291, P317, DOI 10.1002/jez.1132; Seebacher F, 2003, PALEOBIOLOGY, V29, P105, DOI 10.1666/0094-8373(2003)029<0105:DBTTOO>2.0.CO;2; Sellers WI, 2007, P ROY SOC B-BIOL SCI, V274, P2711, DOI 10.1098/rspb.2007.0846; SERENO P, 1991, J VERTEBR PALEONTOL, V2, P1; Sereno PC, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003303; Sereno PC, 1999, SCIENCE, V284, P2137, DOI 10.1126/science.284.5423.2137; Smith ND, 2007, ZOOL J LINN SOC-LOND, V151, P377, DOI 10.1111/j.1096-3642.2007.00325.x; Sockol MD, 2007, P NATL ACAD SCI USA, V104, P12265, DOI 10.1073/pnas.0703267104; SPOTILA JR, 1973, AM NAT, V107, P391, DOI 10.1086/282842; Turner AH, 2007, SCIENCE, V317, P1378, DOI 10.1126/science.1144066; Wedel M. J., 2008, J EXP ZOOL PART A, V311A, P1; Zheng XT, 2009, NATURE, V458, P333, DOI 10.1038/nature07856	70	50	50	2	88	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA	1932-6203			PLOS ONE	PLoS One	NOV 11	2009	4	11					A127	A135	e7783	10.1371/journal.pone.0007783	http://dx.doi.org/10.1371/journal.pone.0007783			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	518IX	19911059	Green Published, gold			2022-12-25	WOS:000271685800014
J	Lefkimmiatis, K; Moyer, MP; Curci, S; Hofer, AM				Lefkimmiatis, Konstantinos; Moyer, Mary Pat; Curci, Silvana; Hofer, Aldebaran M.			"cAMP Sponge": A Buffer for Cyclic Adenosine 3 ', 5 '-Monophosphate	PLOS ONE			English	Article							DEPENDENT PROTEIN-KINASE; CELLS; EPAC; PHOSPHORYLATION; COMMUNICATION; INHIBITION; ACTIVATION; INDICATORS; DYNAMICS; CHANNELS	Background: While intracellular buffers are widely used to study calcium signaling, no such tool exists for the other major second messenger, cyclic AMP (cAMP). Methods/Principal Findings: Here we describe a genetically encoded buffer for cAMP based on the high-affinity cAMP-binding carboxy-terminus of the regulatory subunit RI beta of protein kinase A (PKA). Addition of targeting sequences permitted localization of this fragment to the extra-nuclear compartment, while tagging with mCherry allowed quantification of its expression at the single cell level. This construct (named "cAMP sponge") was shown to selectively bind cAMP in vitro. Its expression significantly suppressed agonist-induced cAMP signals and the downstream activation of PKA within the cytosol as measured by FRET-based sensors in single living cells. Point mutations in the cAMP-binding domains of the construct rendered the chimera unable to bind cAMP in vitro or in situ. Cyclic AMP sponge was fruitfully applied to examine feedback regulation of gap junction-mediated transfer of cAMP in epithelial cell couplets. Conclusions: This newest member of the cAMP toolbox has the potential to reveal unique biological functions of cAMP, including insight into the functional significance of compartmentalized signaling events.			Lefkimmiatis, K (corresponding author), Brigham & Womens Hosp, VA Boston Healthcare Syst, W Roxbury, MA USA.	ahofer@rics.bwh.harvard.edu	Lefkimmiatis, Konstantinos/AAL-1647-2021; Lefkimmiatis, Konstantinos/I-1239-2016	Lefkimmiatis, Konstantinos/0000-0001-7137-7866; Lefkimmiatis, Konstantinos/0000-0001-7137-7866				Acin-Perez R, 2009, CELL METAB, V9, P265, DOI 10.1016/j.cmet.2009.01.012; Allen MD, 2006, BIOCHEM BIOPH RES CO, V348, P716, DOI 10.1016/j.bbrc.2006.07.136; Beavo JA, 2002, NAT REV MOL CELL BIO, V3, P710, DOI 10.1038/nrm911; Cheng XD, 2008, ACTA BIOCH BIOPH SIN, V40, P651, DOI 10.1111/j.1745-7270.2008.00438.x; Dao KK, 2006, J BIOL CHEM, V281, P21500, DOI 10.1074/jbc.M603116200; Enserink JM, 2002, NAT CELL BIOL, V4, P901, DOI 10.1038/ncb874; FISCHER U, 1995, CELL, V82, P475, DOI 10.1016/0092-8674(95)90436-0; Gerbino A, 2005, J CELL BIOL, V171, P303, DOI 10.1083/jcb.200507054; Guo YH, 1999, AM J PHYSIOL-LUNG C, V276, pL1018, DOI 10.1152/ajplung.1999.276.6.L1018; Hernandez VH, 2007, NAT METHODS, V4, P353, DOI 10.1038/NMETH1031; Hofer AM, 1998, J CELL BIOL, V140, P325, DOI 10.1083/jcb.140.2.325; HOFMANN F, 1977, J BIOL CHEM, V252, P1441; Kothmann WW, 2007, VISUAL NEUROSCI, V24, P363, DOI 10.1017/S095252380707037X; Lefkimmiatis K, 2009, NAT CELL BIOL, V11, P433, DOI 10.1038/ncb1850; Moyer MP, 1996, IN VITRO CELL DEV-AN, V32, P315; Neves SR, 2002, BIOESSAYS, V24, P1110, DOI 10.1002/bies.1154; Neves SR, 2002, SCIENCE, V296, P1636, DOI 10.1126/science.1071550; Ponsioen B, 2004, EMBO REP, V5, P1176, DOI 10.1038/sj.embor.7400290; Ponsioen B, 2007, EXP CELL RES, V313, P415, DOI 10.1016/j.yexcr.2006.10.029; POTTER RL, 1978, ARCH BIOCHEM BIOPHYS, V190, P174, DOI 10.1016/0003-9861(78)90265-5; SARASWAT LD, 1988, J BIOL CHEM, V263, P18241; Shaner NC, 2004, NAT BIOTECHNOL, V22, P1567, DOI 10.1038/nbt1037; STAGG RB, 1990, ENDOCR REV, V11, P302, DOI 10.1210/edrv-11-2-302; TAYLOR SS, 1990, ANNU REV BIOCHEM, V59, P971, DOI 10.1146/annurev.bi.59.070190.004543; Terrin A, 2006, J CELL BIOL, V175, P441, DOI 10.1083/jcb.200605050; TSIEN RY, 1981, NATURE, V290, P527, DOI 10.1038/290527a0; TSIEN RY, 1980, BIOCHEMISTRY-US, V19, P2396, DOI 10.1021/bi00552a018; Uchiyama T, 2002, J BIOL CHEM, V277, P8106, DOI 10.1074/jbc.M108337200; Willoughby D, 2008, NAT METHODS, V5, P29, DOI 10.1038/NMETH1135; Zhang J, 2005, NATURE, V437, P569, DOI 10.1038/nature04140; Zippin JH, 2004, J CELL BIOL, V164, P527, DOI 10.1083/jcb.200311119; Zippin JH, 2002, FASEB J, V16, P82, DOI 10.1096/fj.02-0598fje	32	28	29	0	3	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	NOV 3	2009	4	11							e7649	10.1371/journal.pone.0007649	http://dx.doi.org/10.1371/journal.pone.0007649			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	514RY	19888343	Green Published, Green Submitted, gold			2022-12-25	WOS:000271414500001
J	Katz, DA; Kiarie, JN; John-Stewart, GC; Richardson, BA; John, FN; Farquhar, C				Katz, David A.; Kiarie, James N.; John-Stewart, Grace C.; Richardson, Barbra A.; John, Francis N.; Farquhar, Carey			Male Perspectives on Incorporating Men into Antenatal HIV Counseling and Testing	PLOS ONE			English	Article							TO-CHILD TRANSMISSION; RESOURCE-POOR SETTINGS; PREGNANT-WOMEN; BURKINA-FASO; RURAL MALAWI; COTE-DIVOIRE; SCALING-UP; ACCEPTABILITY; PREVENTION; NEVIRAPINE	Background: Male partner involvement in antenatal voluntary HIV counseling and testing (VCT) has been shown to increase uptake of interventions to reduce the risk of HIV transmission in resource-limited settings. We aimed to identify methods for increasing male involvement in antenatal VCT and determine male correlates of accepting couple counseling in these settings. Methodology/Principal Findings: We invited women presenting to a Nairobi antenatal clinic to return with their male partners for individual or couples VCT. Male attitudes towards VCT and correlates of accompanying female partners to antenatal clinic and receiving couple counseling were determined. Of 1,993 women who invited their partner, 313 (16%) returned with their partners to ANC. Men attending antenatal clinic were married (>99%), employed (98%), and unlikely to report prior HIV testing (14%). Wanting an HIV test (87%) or health information (11%) were the most commonly cited reasons for attending. Most (95%) men who came to antenatal clinic accepted HIV testing and 39% elected to receive counseling as a couple. Men who received counseling with partners were younger, had fewer children, and were less knowledgeable about prevention of mother-to-child HIV transmission (PMTCT) than those who received counseling individually (p<0.05). Only 27% of men stated they would prefer HIV testing at a site other than the ANC. There was agreement between male and female reports for sociodemographic characteristics; however, men were more likely to report HIV preventive behaviors and health communication within the partnership than their partners (p<0.05). Conclusions/Significance: Offering VCT services to men at antenatal clinic with options for couple and individual counseling is an important opportunity and acceptable strategy for increasing male involvement in PMTCT and promoting male HIV testing.			Katz, DA (corresponding author), Univ Washington, Dept Epidemiol, Seattle, WA 98195 USA.	dkatz7@u.washington.edu	John-Stewart, Grace/U-3351-2019; John-Stewart, Grace/L-3650-2019	kiarie, james/0000-0003-4180-7858	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [K24HD054314] Funding Source: NIH RePORTER; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [K23HD041879] Funding Source: NIH RePORTER; FOGARTY INTERNATIONAL CENTER [D43TW000007] Funding Source: NIH RePORTER; FIC NIH HHS [D43 TW000007] Funding Source: Medline; NICHD NIH HHS [K23 HD041879, K24 HD054314] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); FOGARTY INTERNATIONAL CENTER(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Fogarty International Center (FIC)); FIC NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Fogarty International Center (FIC)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		[Anonymous], 2001, THE J, V35, P206, DOI [10.1023/A:1010484013306, DOI 10.1023/A:1010484013306, DOI 10.1023/A:1009584623712]; Baiden F, 2005, AIDS CARE, V17, P648, DOI 10.1080/09540120412331319688; Cartoux M, 1998, AIDS, V12, P2489, DOI 10.1097/00002030-199818000-00019; Cartoux M, 1998, AIDS, V12, P2337, DOI 10.1097/00002030-199817000-00016; deGraft-Johnson J, 2005, AIDS BEHAV, V9, P475, DOI 10.1007/s10461-005-9018-x; Desgrees-du-Lou A, 2002, INT J STD AIDS, V13, P462, DOI 10.1258/09564620260079617; Farquhar C, 2004, JAIDS-J ACQ IMM DEF, V37, P1620, DOI 10.1097/00126334-200412150-00016; Farquhar C, 2001, AIDS, V15, P815, DOI 10.1097/00002030-200104130-00027; Gage AJ, 2005, AIDS CARE, V17, P153, DOI 10.1080/09540120512331325635; Homsy J, 2006, JAIDS-J ACQ IMM DEF, V42, P149, DOI 10.1097/01.qai.0000225032.52766.c2; Johnson SK, 2008, LEADERSHIP QUART, V19, P1, DOI 10.1016/j.leaqua.2007.12.001; Kiarie J, 2000, AIDS, V14, P1468, DOI 10.1097/00002030-200007070-00030; Kiarie JN, 2003, AIDS, V17, P65, DOI 10.1097/00002030-200301030-00009; MACHEKANO R, 2000, AIDS BEHAV, V4, P63; Manzi M, 2005, TROP MED INT HEALTH, V10, P1242, DOI 10.1111/j.1365-3156.2005.01526.x; Meda N, 2002, AIDS, V16, P2323, DOI 10.1097/00002030-200211220-00013; Msuya SE, 2006, JAIDS-J ACQ IMM DEF, V43, P85, DOI 10.1097/01.qai.0000225016.50890.7e; Nebie Y, 2001, J ACQ IMMUN DEF SYND, V28, P367, DOI 10.1097/00126334-200112010-00010; Painter TM, 2005, INT J STD AIDS, V16, P237, DOI 10.1258/0956462053420158; Semrau K, 2005, AIDS, V19, P603, DOI 10.1097/01.aids.0000163937.07026.a0; Stringer EM, 2003, AIDS, V17, P1377, DOI 10.1097/00002030-200306130-00012; Stringer JSA, 2003, JAIDS-J ACQ IMM DEF, V32, P506, DOI 10.1097/00126334-200304150-00007; Temmerman M, 2003, AIDS, V17, P1239, DOI 10.1097/00002030-200305230-00016; Urassa P, 2005, AIDS CARE, V17, P842, DOI 10.1080/09540120500038231	24	90	90	0	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA	1932-6203			PLOS ONE	PLoS One	NOV 2	2009	4	11							e7602	10.1371/journal.pone.0007602	http://dx.doi.org/10.1371/journal.pone.0007602			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	514RX	19881884	Green Published, gold, Green Submitted			2022-12-25	WOS:000271414400001
J	Li, M; Li, S; Yuan, J; Wang, ZB; Sun, SC; Schatten, H; Sun, QY				Li, Mo; Li, Sen; Yuan, Ju; Wang, Zhen-Bo; Sun, Shao-Chen; Schatten, Heide; Sun, Qing-Yuan			Bub3 Is a Spindle Assembly Checkpoint Protein Regulating Chromosome Segregation during Mouse Oocyte Meiosis	PLOS ONE			English	Article							ANAPHASE-PROMOTING COMPLEX; MITOTIC CHECKPOINT; KINETOCHORE LOCALIZATION; CYTOSTATIC FACTOR; MAMMALIAN OOCYTES; CELL-CYCLE; CYTOPLASMIC DYNEIN; METAPHASE ARREST; VERTEBRATE EGGS; XENOPUS-OOCYTES	In mitosis, the spindle assembly checkpoint (SAC) prevents anaphase onset until all chromosomes have been attached to the spindle microtubules and aligned correctly at the equatorial metaphase plate. The major checkpoint proteins in mitosis consist of mitotic arrest-deficient (Mad) 1-3, budding uninhibited by benzimidazole (Bub) 1, Bub3, and monopolar spindle 1(Mps1). During meiosis, for the formation of a haploid gamete, two consecutive rounds of chromosome segregation occur with only one round of DNA replication. To pull homologous chromosomes to opposite spindle poles during meiosis I, both sister kinetochores of a homologue must face toward the same pole which is very different from mitosis and meiosis II. As a core member of checkpoint proteins, the individual role of Bub3 in mammalian oocyte meiosis is unclear. In this study, using overexpression and RNA interference (RNAi) approaches, we analyzed the role of Bub3 in mouse oocyte meiosis. Our data showed that overexpressed Bub3 inhibited meiotic metaphase-anaphase transition by preventing homologous chromosome and sister chromatid segregations in meiosis I and II, respectively. Misaligned chromosomes, abnormal polar body and double polar bodies were observed in Bub3 knock-down oocytes, causing aneuploidy. Furthermore, through cold treatment combined with Bub3 overexpression, we found that overexpressed Bub3 affected the attachments of microtubules and kinetochores during metaphase-anaphase transition. We propose that as a member of SAC, Bub3 is required for regulation of both meiosis I and II, and is potentially involved in kinetochore-microtubule attachment in mammalian oocytes.			Li, M (corresponding author), Chinese Acad Sci, Inst Zool, State Key Lab Reprod Biol, Beijing, Peoples R China.	sunqy@ioz.ac.cn	Holt, Janet E/B-2415-2013					Abrieu A, 2001, CELL, V106, P83, DOI 10.1016/S0092-8674(01)00410-X; Babu JR, 2003, J CELL BIOL, V160, P341, DOI 10.1083/jcb.200211048; Bhatt RR, 1999, SCIENCE, V286, P1362, DOI 10.1126/science.286.5443.1362; Brady DM, 2000, CURR BIOL, V10, P675, DOI 10.1016/S0960-9822(00)00515-7; Brunet S, 2003, REPRODUCTION, V126, P443, DOI 10.1530/rep.0.1260443; Burke DJ, 2008, DEV CELL, V14, P474, DOI 10.1016/j.devcel.2008.03.015; Cahill DP, 1998, NATURE, V392, P300, DOI 10.1038/32688; Campbell L, 2003, J CELL SCI, V116, P617, DOI 10.1242/jcs.00255; Chen RH, 2002, J CELL BIOL, V158, P487, DOI 10.1083/jcb.200204048; Cleveland DW, 2003, CELL, V112, P407, DOI 10.1016/S0092-8674(03)00115-6; Hardwick KC, 2000, J CELL BIOL, V148, P871, DOI 10.1083/jcb.148.5.871; Hassold T, 2001, NAT REV GENET, V2, P280, DOI 10.1038/35066065; Homer HA, 2005, CELL CYCLE, V4, P650, DOI 10.4161/cc.4.5.1677; Homer HA, 2005, GENE DEV, V19, P202, DOI 10.1101/gad.328105; Howell BJ, 2004, CURR BIOL, V14, P953, DOI 10.1016/j.cub.2004.05.053; HOYT MA, 1991, CELL, V66, P507, DOI 10.1016/0092-8674(81)90014-3; HUNT P, 1995, HUM MOL GENET, V4, P2007, DOI 10.1093/hmg/4.11.2007; Hunt PA, 2002, SCIENCE, V296, P2181, DOI 10.1126/science.1071907; Hwang LH, 1998, SCIENCE, V279, P1041, DOI 10.1126/science.279.5353.1041; Irniger S, 2006, CELL CYCLE, V5, P405, DOI 10.4161/cc.5.4.2476; Jin DY, 1998, CELL, V93, P81, DOI 10.1016/S0092-8674(00)81148-4; Johnson VL, 2004, J CELL SCI, V117, P1577, DOI 10.1242/jcs.01006; Kalitsis P, 2000, GENE DEV, V14, P2277, DOI 10.1101/gad.827500; Kallio M, 2000, DEV BIOL, V225, P112, DOI 10.1006/dbio.2000.9818; Kallio MJ, 2002, CURR BIOL, V12, P900, DOI 10.1016/S0960-9822(02)00887-4; Kops GJPL, 2005, NAT REV CANCER, V5, P773, DOI 10.1038/nrc1714; Lemaire-Adkins R, 1997, J CELL BIOL, V139, P1611, DOI 10.1083/jcb.139.7.1611; LI R, 1991, CELL, V66, P519, DOI 10.1016/0092-8674(81)90015-5; Lo KWH, 2007, J BIOL CHEM, V282, P11205, DOI 10.1074/jbc.M611279200; Logarinho E, 2008, MOL BIOL CELL, V19, P1798, DOI 10.1091/mbc.E07-07-0633; Lopes CS, 2005, J CELL SCI, V118, P187, DOI 10.1242/jcs.01602; Malmanche N, 2006, FEBS LETT, V580, P2888, DOI 10.1016/j.febslet.2006.03.081; Masui Y, 2001, DIFFERENTIATION, V69, P1, DOI 10.1046/j.1432-0436.2001.690101.x; MCGUINNESS BE, 2009, CURR BIOL; Meraldi P, 2004, DEV CELL, V7, P45, DOI 10.1016/j.devcel.2004.06.006; Millband DN, 2002, MOL CELL BIOL, V22, P2728, DOI 10.1128/MCB.22.8.2728-2742.2002; Morrow CJ, 2005, J CELL SCI, V118, P3639, DOI 10.1242/jcs.02487; Musacchio A, 2002, NAT REV MOL CELL BIO, V3, P731, DOI 10.1038/nrm929; Musacchio A, 2007, NAT REV MOL CELL BIO, V8, P379, DOI 10.1038/nrm2163; Nasmyth K, 2005, CELL, V120, P739, DOI 10.1016/j.cell.2005.03.006; Niault T, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0001165; Peter M, 2001, NAT CELL BIOL, V3, P83, DOI 10.1038/35050607; Peters JM, 2006, NAT REV MOL CELL BIO, V7, P644, DOI 10.1038/nrm1988; Petronczki M, 2003, CELL, V112, P423, DOI 10.1016/S0092-8674(03)00083-7; Pinsky BA, 2005, TRENDS CELL BIOL, V15, P486, DOI 10.1016/j.tcb.2005.07.005; Reimann JDR, 2002, NATURE, V416, P850, DOI 10.1038/416850a; RIEDER CL, 1981, CHROMOSOMA, V84, P145, DOI 10.1007/BF00293368; Rieder CL, 1998, TRENDS CELL BIOL, V8, P310, DOI 10.1016/S0962-8924(98)01299-9; Sakuno T, 2009, NATURE, V458, P852, DOI 10.1038/nature07876; Sakuno T, 2009, CHROMOSOME RES, V17, P239, DOI 10.1007/s10577-008-9013-y; Schmidt A, 2006, J CELL SCI, V119, P1213, DOI 10.1242/jcs.02919; Sharp-Baker H, 2001, J CELL BIOL, V153, P1239, DOI 10.1083/jcb.153.6.1239; Sotillo R, 2007, CANCER CELL, V11, P9, DOI 10.1016/j.ccr.2006.10.019; Sudakin V, 2001, J CELL BIOL, V154, P925, DOI 10.1083/jcb.200102093; Taieb FE, 2001, CURR BIOL, V11, P508, DOI 10.1016/S0960-9822(01)00145-2; Taylor SS, 2001, J CELL SCI, V114, P4385; Taylor SS, 1998, J CELL BIOL, V142, P1, DOI 10.1083/jcb.142.1.1; Tsurumi C, 2004, J CELL BIOL, V167, P1037, DOI 10.1083/jcb.200405165; Tunquist BJ, 2003, GENE DEV, V17, P683, DOI 10.1101/gad.1071303; Tunquist BJ, 2002, CURR BIOL, V12, P1027, DOI 10.1016/S0960-9822(02)00894-1; Vigneron S, 2004, MOL BIOL CELL, V15, P4584, DOI 10.1091/mbc.E04-01-0051; Vogt E, 2008, MUTAT RES-GEN TOX EN, V651, P14, DOI 10.1016/j.mrgentox.2007.10.015; Wang XS, 2001, J BIOL CHEM, V276, P26559, DOI 10.1074/jbc.M101083200; Wassmann K, 2003, CURR BIOL, V13, P1596, DOI 10.1016/j.cub.2003.08.052; Waters JC, 1998, J CELL BIOL, V141, P1181, DOI 10.1083/jcb.141.5.1181; Weiss E, 1996, J CELL BIOL, V132, P111, DOI 10.1083/jcb.132.1.111; Xiong B, 2008, BIOL REPROD, V79, P718, DOI 10.1095/biolreprod.108.069641; Yin S, 2008, CELL CYCLE, V7, P2997, DOI 10.4161/cc.7.19.6809; Yin S, 2006, CELL CYCLE, V5, P2130, DOI 10.4161/cc.5.18.3170; Yin S, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003516; Zhang D, 2004, BIOL REPROD, V71, P740, DOI 10.1095/biolreprod.104.028282; Zhang D, 2007, REPRODUCTION, V133, P685, DOI 10.1530/rep.1.01167	72	88	90	2	21	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA	1932-6203			PLOS ONE	PLoS One	NOV 2	2009	4	11							e7701	10.1371/journal.pone.0007701	http://dx.doi.org/10.1371/journal.pone.0007701			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	514RX	19888327	Green Published, gold, Green Submitted			2022-12-25	WOS:000271414400011
J	Staikowsky, F; Talarmin, F; Grivard, P; Souab, A; Schuffenecker, I; Le Roux, K; Lecuit, M; Michault, A				Staikowsky, Frederik; Talarmin, Francois; Grivard, Philippe; Souab, Abdel; Schuffenecker, Isabelle; Le Roux, Karin; Lecuit, Marc; Michault, Alain			Prospective Study of Chikungunya Virus Acute Infection in the Island of La Reunion during the 2005-2006 Outbreak	PLOS ONE			English	Article							INDIAN-OCEAN; DISEASE; DIAGNOSIS; TRAVELERS; EPIDEMIC; DENGUE; FEVER	Background: Chikungunya virus (CHIKV) is a recently re-emerged arthropod borne virus responsible for a massive outbreak in the Indian Ocean and India, and extended to Southeast Asia as well as Italy. CHIKV has adapted to Aedes albopictus, an anthropophilic mosquito species widely distributed in Asia, Europe, Africa and America. Our objective was to determine the clinical and biological features of patients at the acute phase of CHIKV infection. Methods and Findings: A prospective study enrolled 274 consecutive patients with febrile arthralgia recorded at the Emergency Department of the Groupe Hospitalier Sud-Reunion between March and May 2006. Three groups were defined: one group of 180 viremic patients ( positive CHIKV RT-PCR), one group of 34 patients with acute post-viremic infection ( negative CHIKV RT-PCR, positive anti-CHIKV IgM and negative IgG), and one group of 46 uninfected patients ( negative CHIKV RT-PCR, anti-CHIKV IgM and IgG). Bivariate analyses of clinical and biological features between groups were performed. Patients with CHIKV viremia presented typically with asymmetrical bilateral polyarthralgia (96.5%) affecting the lower (98%) and small joints (74.8%), as well as asthenia (88.6%), headache (70%), digestive trouble (63.3%), myalgia (59%), exanthems (47.8%), conjunctival hyperhemia (23%) and adenopathy (8.9%). Vertigo, cutaneous dysesthesia, pharyngitis and haemorrhages were seldom observed. So far unreported symptoms such as chondrocostal arthralgia (20%), entesopathies (1.6%), talalgia (14%) were also noted. Prurit was less frequent during the viremic than post-viremic phase (13.9% vs. 41.2%; p < 0.001), whereas lymphopenia was more frequent (87.6% vs. 39.4%; p < 0.001). Others biological abnormalities included leukopenia (38.3%), thrombocytopenia (37.3%), increased ASAT and ALAT blood levels (31.6 and 7.3%, respectively) and hypocalcemia (38.7%). Lymphopenia <1,000/mm(3) was very closely associated with viremic patients (Yule coefficient 0.82, positive predictive value 92.3%). Age under 65 was associated with a benign course, as no patients younger than 65 had to be hospitalized (Yule coefficient 0.78). Conclusions: The diagnosis of CHIKV infection in acute phase is based on commonly accepted clinical criteria ( fever and arthralgia), however clinical and biological diffrences exist in acute phase depending on whether or not the patient is within the viremic phase of the infection.			Staikowsky, F (corresponding author), Ctr Hosp Reg La Reunion, Emergency Dept, Grp Hosp Sud Reunion, St Pierre, La Reunion, France.	frederik.staikowsky@chr-reunion.fr	Lecuit, Marc/M-4126-2019; Lecuit, Marc/J-4073-2013	Lecuit, Marc/0000-0002-4491-1063; Lecuit, Marc/0000-0002-4491-1063				Borgherini G, 2007, CLIN INFECT DIS, V44, P1401, DOI 10.1086/517537; BRIGHTON SW, 1983, S AFR MED J, V63, P313; CAREY DE, 1969, T ROY SOC TROP MED H, V63, P434, DOI 10.1016/0035-9203(69)90030-3; Couderc T, 2008, PLOS PATHOG, V4, DOI 10.1371/journal.ppat.0040029; Dash PK, 2007, VECTOR-BORNE ZOONOT, V7, P519, DOI 10.1089/vbz.2007.7272; DELLER JJ, 1968, AM J TROP MED HYG, V17, P107; Endy TP, 2002, AM J EPIDEMIOL, V156, P40, DOI 10.1093/aje/kwf005; FOURIE ED, 1979, S AFR MED J, V56, P130; GARNIER PP, 2006, B SOC PATHOL EXOT, V99, P143; Gerardin P, 2008, PLOS MED, V5, P413, DOI 10.1371/journal.pmed.0050060; Grivard P, 2007, PATHOL BIOL, V55, P490, DOI 10.1016/j.patbio.2007.07.002; KENNEDY AC, 1980, J RHEUMATOL, V7, P231; Lam S K, 2001, Southeast Asian J Trop Med Public Health, V32, P447; Laurent P, 2007, CLIN CHEM, V53, P1408, DOI 10.1373/clinchem.2007.086595; Lemant J, 2008, CRIT CARE MED, V36, P2536, DOI 10.1097/CCM.0b013e318183f2d2; Maiti C R, 1978, J Indian Med Assoc, V70, P256; Martin DA, 2000, J CLIN MICROBIOL, V38, P1823, DOI 10.1128/JCM.38.5.1823-1826.2000; MARTINET O, 2006, B SOC PATHO EXOT, V99, P138; Mazaud R, 1971, Bull Soc Pathol Exot Filiales, V64, P22; OBEYESEKERE I, 1973, AM HEART J, V85, P186, DOI 10.1016/0002-8703(73)90459-6; Ozden S, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0000527; Paganin F, 2007, INTENS CARE MED, V33, P1959, DOI 10.1007/s00134-007-0776-y; Perrau J, 2007, EC REUNION, V129, P16; Ramful D, 2007, PEDIATR INFECT DIS J, V26, P811, DOI 10.1097/INF.0b013e3180616d4f; Renault P, 2007, AM J TROP MED HYG, V77, P727; Rezza G, 2007, LANCET, V370, P1840, DOI 10.1016/S0140-6736(07)61779-6; ROBINSON M C, 1955, Trans R Soc Trop Med Hyg, V49, P28, DOI [10.1016/0035-9203(57)90022-6, 10.1016/0035-9203(55)90080-8]; ROSS R. W., 1956, JOUR HYG, V54, P177; Schuffenecker I, 2006, PLOS MED, V3, P1058, DOI 10.1371/journal.pmed.0030263; Simon F, 2007, MEDICINE, V86, P123, DOI 10.1097/MD/0b013e31806010a5; Sourisseau M, 2007, PLOS PATHOG, V3, P804, DOI 10.1371/journal.ppat.0030089; Staikowsky F, 2008, EPIDEMIOL INFECT, V136, P196, DOI 10.1017/S0950268807008424; SUTTON RNP, 1984, LANCET, V1, P1243; Taubitz W, 2007, CLIN INFECT DIS, V45, pE1, DOI 10.1086/518701; Vazeille M, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0001168; WEISS HJ, 1965, P SOC EXP BIOL MED, V119, P427, DOI 10.3181/00379727-119-30201	36	88	91	0	3	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	OCT 28	2009	4	10							e7603	10.1371/journal.pone.0007603	http://dx.doi.org/10.1371/journal.pone.0007603			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	511UJ	19893613	Green Published, Green Submitted, gold			2022-12-25	WOS:000271194600008
J	Bradley, SE; Johnson, AE; Le, IP; Oosterhouse, E; Hledin, MP; Marquez, GA; Burnatowska-Hledin, M				Bradley, Shirley E.; Johnson, Alyssa E.; Le, Isabelle P.; Oosterhouse, Elizabeth; Hledin, Michael P.; Marquez, Gabriel A.; Burnatowska-Hledin, Maria			Phosphorylation of VACM-1/Cul5 by Protein Kinase A Regulates Its Neddylation and Antiproliferative Effect	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							UBIQUITIN-LIKE PROTEIN; CELL-CYCLE PROGRESSION; GENE FAMILY-MEMBER; ENDOTHELIAL-CELLS; CUL-5 GENE; DEPENDENT PHOSPHORYLATION; ADENOVIRUS E4ORF6; LIGASE ITCH; CULLIN; NEDD8	Expression of the VACM-1/cul5 gene in endothelial and in cancer cell lines in vitro inhibits cellular proliferation and decreases phosphorylation of MAPK. Structure-function analysis of the VACM-1 protein sequence identified consensus sites specific for phosphorylation by protein kinases A and C (PKA and PKC) and a Nedd8 protein modification site. Mutations at the PKA-specific site in VACM-1/Cul5 ((S730A)VACM-1) sequence resulted in increased cellular growth and the appearance of a Nedd8-modified VACM-1/Cul5. The aim of this study was to examine if PKA-dependent phosphorylation of VACM-1/Cul5 controls its neddylation status, phosphorylation by PKC, and ultimately growth. Our results indicate that in vitro transfection of rat adrenal medullary endothelial cells with anti-VACM-1-specific small interfering RNA oligonucleotides decreases endogenous VACM-1 protein concentration and increases cell growth. Western blot analysis of cell lysates immunoprecipitated with an antibody directed against a PKA-specific phosphorylation site and probed with anti-VACM-1-specific antibody showed that PKA-dependent phosphorylation of VACM-1 protein was decreased in cells transfected with (S730A)VACM-1cDNA when compared with the cytomegalovirus-transfected cells. This change was associated with increased modification of VACM-1 protein by Nedd8. Induction of PKA activity with forskolin reduced modification of VACM-1protein by Nedd8. Finally, rat adrenal medullary endothelial cells transfected with (S730A)VACM-1/cul5 cDNA and treated with phorbol 12-myristate 13-acetate (10 and 100 nM) to induce PKC activity grew significantly faster than the control cells. These results suggest that the antiproliferative effect of VACM-1/Cul5 is dependent on its posttranslational modifications and will help in the design of new anticancer therapeutics that target the Nedd8 pathway.	[Burnatowska-Hledin, Maria] Hope Coll, Ctr Sci, Dept Biol, Holland, MI 49422 USA; Hope Coll, Dept Chem, Holland, MI 49422 USA	Hope College; Hope College	Burnatowska-Hledin, M (corresponding author), Hope Coll, Ctr Sci, Dept Biol, Holland, MI 49422 USA.	hledin@hope.edu			National Institutes of Health (NIH) [RO1DK47199, R15CA104014]; Beckman Foundation; Merck Institute for Science Education; NATIONAL CANCER INSTITUTE [R15CA104014] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK047199] Funding Source: NIH RePORTER	National Institutes of Health (NIH)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Beckman Foundation; Merck Institute for Science Education; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))	This work was supported, in whole or in part, by National Institutes of Health (NIH) Grant RO1DK47199 and NIH, NCI, Grant R15CA104014. This work was also supported by a Beckman Foundation Award (to S. E. B.), a Research Experience Across Cultures at Hope program award to high school student (G. A. M.), and a Merck/American Association for the Advancement of Science Undergraduate Science Research Program Award from the Merck Institute for Science Education.	Alappat EC, 2003, J BIOL CHEM, V278, P41585, DOI 10.1074/jbc.C300385200; Buchwalter A, 2008, MICROVASC RES, V75, P155, DOI 10.1016/j.mvr.2007.08.004; Burnatowska-Hledin M, 1999, AM J PHYSIOL-RENAL, V276, pF199, DOI 10.1152/ajprenal.1999.276.2.F199; Burnatowska-Hledin M, 2000, AM J PHYSIOL-CELL PH, V279, pC266, DOI 10.1152/ajpcell.2000.279.1.C266; Burnatowska-Hledin M, 2001, ENDOTHELIUM-J ENDOTH, V8, P49, DOI 10.3109/10623320109063157; Burnatowska-Hledin MA, 2004, BIOCHEM BIOPH RES CO, V319, P817, DOI 10.1016/j.bbrc.2004.05.057; BURNATOWSKAHLEDIN MA, 1995, AM J PHYSIOL-RENAL, V268, pF1198, DOI 10.1152/ajprenal.1995.268.6.F1198; Byrd PJ, 1997, GENOME RES, V7, P71, DOI 10.1101/gr.7.1.71; Chew EH, 2007, CELL SIGNAL, V19, P1071, DOI 10.1016/j.cellsig.2006.12.002; d'Azzo A, 2005, TRAFFIC, V6, P429, DOI 10.1111/j.1600-0854.2005.00294.x; Dancey J, 2003, NAT REV DRUG DISCOV, V2, P296, DOI 10.1038/nrd1066; Denti S, 2006, J BIOL CHEM, V281, P32188, DOI 10.1074/jbc.M604746200; Dornan D, 2006, SCIENCE, V313, P1122, DOI 10.1126/science.1127335; Fang DX, 2007, J BIOL CHEM, V282, P11221, DOI 10.1074/jbc.M611871200; Gallagher E, 2006, P NATL ACAD SCI USA, V103, P1717, DOI 10.1073/pnas.0510664103; Gao M, 2004, SCIENCE, V306, P271, DOI 10.1126/science.1099414; Goyal P, 2005, J BIOL CHEM, V280, P27569, DOI 10.1074/jbc.M504448200; Herrmann J, 2004, CARDIOVASC RES, V61, P11, DOI 10.1016/j.cardiores.2003.09.033; Hori T, 1999, ONCOGENE, V18, P6829, DOI 10.1038/sj.onc.1203093; Johnson AE, 2007, MOL CELL BIOCHEM, V301, P13, DOI 10.1007/s11010-006-9392-3; Kamitani T, 1997, J BIOL CHEM, V272, P28557, DOI 10.1074/jbc.272.45.28557; Kamura T, 1999, SCIENCE, V284, P657, DOI 10.1126/science.284.5414.657; Kipreos ET, 1996, CELL, V85, P829, DOI 10.1016/S0092-8674(00)81267-2; Kurz T, 2002, SCIENCE, V295, P1294, DOI 10.1126/science.1067765; Li X, 2006, BIOCHEM J, V394, P427, DOI 10.1042/BJ20051560; Liakopoulos D, 1999, P NATL ACAD SCI USA, V96, P5510, DOI 10.1073/pnas.96.10.5510; Luo K, 2007, FASEB J, V21, P1742, DOI 10.1096/fj.06-7241com; Mathias N, 1996, MOL CELL BIOL, V16, P6634; Mohanty S, 2001, GENE DEV, V15, P1435, DOI 10.1101/gad.871101; Nishiyama K, 2007, J BIOL CHEM, V282, P17200, DOI 10.1074/jbc.M611609200; Norman JA, 2006, BIOCHEMISTRY-US, V45, P3014, DOI 10.1021/bi052435a; Pan ZQ, 2004, ONCOGENE, V23, P1985, DOI 10.1038/sj.onc.1207414; Papadimitrio E., 1993, ENDOTHELIUM-J ENDOTH, V1, P207, DOI [10.3109/10623329309102698, DOI 10.3109/10623329309102698]; Petroski MD, 2005, NAT REV MOL CELL BIO, V6, P9, DOI 10.1038/nrm1547; Querido E, 2001, GENE DEV, V15, P3104, DOI 10.1101/gad.926401; Saha A, 2008, MOL CELL, V32, P21, DOI 10.1016/j.molcel.2008.08.021; Salinas GD, 2006, J BIOL CHEM, V281, P40164, DOI 10.1074/jbc.M608194200; Sheng T, 2006, J BIOL CHEM, V281, P9, DOI 10.1074/jbc.C500300200; Shimada K, 2005, J PATHOL, V206, P423, DOI 10.1002/path.1791; Soucy TA, 2009, NATURE, V458, P732, DOI 10.1038/nature07884; Sun Y, 2003, CANCER BIOL THER, V2, P623; Tang SQ, 1997, J BIOL CHEM, V272, P28704, DOI 10.1074/jbc.272.45.28704; Tateishi K, 2001, J CELL BIOL, V155, P571, DOI 10.1083/jcb.200104035; Van Dort C, 2003, AM J PHYSIOL-CELL PH, V285, pC1386, DOI 10.1152/ajpcell.00338.2002; Wada H, 1999, BIOCHEM BIOPH RES CO, V257, P100, DOI 10.1006/bbrc.1999.0339; Yoshiji H, 1999, CANCER RES, V59, P4413; Zacchi P, 2002, NATURE, V419, P853, DOI 10.1038/nature01120	47	15	15	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 12	2010	285	7					4883	4895		10.1074/jbc.M109.085225	http://dx.doi.org/10.1074/jbc.M109.085225			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	565FN	19917606	hybrid, Green Published			2022-12-25	WOS:000275274800066
J	Hoopes, JT; Liu, XY; Xu, XM; Demeler, B; Folta-Stogniew, E; Li, C; Ha, Y				Hoopes, James T.; Liu, Xuying; Xu, Xiaomeng; Demeler, Borries; Folta-Stogniew, Ewa; Li, Chris; Ha, Ya			Structural Characterization of the E2 Domain of APL-1, a Caenorhabditis elegans Homolog of Human Amyloid Precursor Protein, and Its Heparin Binding Site	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALZHEIMERS-DISEASE; CRYSTALLOGRAPHIC ANALYSIS; SURFACE; FAMILY; APP; PH; HOMODIMERIZATION; COLOCALIZES; EXPRESSION; SCATTERING	The amyloid beta-peptide deposit found in the brain tissue of patients with Alzheimer disease is derived from a large heparin-binding protein precursor APP. The biological function of APP and its homologs is not precisely known. Here we report the x-ray structure of the E2 domain of APL-1, an APP homolog in Caenorhabditis elegans, and compare it to the human APP structure. We also describe the structure of APL-1 E2 in complex with sucrose octasulfate, a highly negatively charged disaccharide, which reveals an unexpected binding pocket between the two halves of E2. Based on the crystal structure, we are able to map, using site-directed mutagenesis, a surface groove on E2 to which heparin may bind. Our biochemical data also indicate that the affinity of E2 for heparin is influenced by pH: at pH 5, the binding appears to be much stronger than that at neutral pH. This property is likely caused by histidine residues in the vicinity of the mapped heparin binding site and could be important for the proposed adhesive function of APL-1.	[Hoopes, James T.; Liu, Xuying; Ha, Ya] Yale Univ, Sch Med, Dept Pharmacol, New Haven, CT 06520 USA; [Folta-Stogniew, Ewa] Yale Univ, Sch Med, WM Keck Fdn Biotechnol Resource Lab, New Haven, CT 06520 USA; [Xu, Xiaomeng; Li, Chris] CUNY City Coll, Dept Biol, New York, NY 10031 USA; [Demeler, Borries] Univ Texas Hlth Sci Ctr San Antonio, Ctr Analyt Ultracentrifugat Macromol Assemblies, San Antonio, TX 78229 USA	Yale University; Yale University; City University of New York (CUNY) System; City College of New York (CUNY); University of Texas System; University of Texas Health San Antonio	Ha, Y (corresponding author), Yale Univ, Sch Med, Dept Pharmacol, 333 Cedar St, New Haven, CT 06520 USA.	ya.ha@yale.edu	liu, xuying/G-7258-2012; LI, chris/HDO-6232-2022	Demeler, Borries/0000-0002-2414-9518	National Institutes of Health [GM077547]; NCRR/RCMI [G12-RR03060]; Alzheimer Association; NATIONAL CENTER FOR RESEARCH RESOURCES [G12RR003060] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERING [P30EB009998] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM077547] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [T32NS007136] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG032042] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NCRR/RCMI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); Alzheimer Association(Alzheimer's AssociationBrightFocus Foundation); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Biomedical Imaging & Bioengineering (NIBIB)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))	This work was supported, in whole or in part, by National Institutes of Health Grants GM077547 (to Y. H.) and NCRR/RCMI G12-RR03060 (City College) and by a grant from the Alzheimer Association (to C. L.).	Barnham KJ, 2003, J BIOL CHEM, V278, P17401, DOI 10.1074/jbc.M300629200; Belting M, 2003, TRENDS BIOCHEM SCI, V28, P145, DOI 10.1016/S0968-0004(03)00031-8; Borza DB, 1998, J BIOL CHEM, V273, P5493, DOI 10.1074/jbc.273.10.5493; BROOKES E, 2009, EUR BIOPHYS IN PRESS; BROWN MS, 1983, CELL, V32, P663, DOI 10.1016/0092-8674(83)90052-1; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; DAIGLE I, 1993, P NATL ACAD SCI USA, V90, P12045, DOI 10.1073/pnas.90.24.12045; Demeler B, 2008, COLLOID POLYM SCI, V286, P129, DOI 10.1007/s00396-007-1699-4; Demeler B, 2005, ANALYTICAL ULTRACENTRIFUGATION: TECHNIQUES AND METHODS, P210; Dulubova I, 2004, BIOCHEMISTRY-US, V43, P9583, DOI 10.1021/bi049041o; Faham S, 1996, SCIENCE, V271, P1116, DOI 10.1126/science.271.5252.1116; Folta-Stogniew E, 1999, J Biomol Tech, V10, P51; Fossgreen A, 1998, P NATL ACAD SCI USA, V95, P13703, DOI 10.1073/pnas.95.23.13703; Grum VL, 1999, CELL, V98, P523, DOI 10.1016/S0092-8674(00)81980-7; Herms J, 2004, EMBO J, V23, P4106, DOI 10.1038/sj.emboj.7600390; HESS ML, 1984, J MOL CELL CARDIOL, V16, P969, DOI 10.1016/S0022-2828(84)80011-5; Ho A, 2004, P NATL ACAD SCI USA, V101, P2548, DOI 10.1073/pnas.0308655100; Hornsten A, 2007, P NATL ACAD SCI USA, V104, P1971, DOI 10.1073/pnas.0603997104; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KANG J, 1987, NATURE, V325, P733, DOI 10.1038/325733a0; Keil C, 2004, ACTA CRYSTALLOGR D, V60, P1614, DOI 10.1107/S0907444904015343; Kins S, 2006, NEURODEGENER DIS, V3, P218, DOI 10.1159/000095259; KOPPEL DE, 1972, J CHEM PHYS, V57, P4814, DOI 10.1063/1.1678153; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; Lamanna JC, 1996, ADV EXP MED BIOL, V388, P283; Lomakin A, 1999, METHOD ENZYMOL, V309, P429; MELLMAN I, 1986, ANNU REV BIOCHEM, V55, P663, DOI 10.1146/annurev.biochem.55.1.663; Mello C, 1995, METHOD CELL BIOL, V48, P451; Mok SS, 1997, FEBS LETT, V415, P303, DOI 10.1016/S0014-5793(97)01146-0; Mulloy B, 2001, CURR OPIN STRUC BIOL, V11, P623, DOI 10.1016/S0959-440X(00)00257-8; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Pape T, 2004, J APPL CRYSTALLOGR, V37, P843, DOI 10.1107/S0021889804018047; Pokutta S, 2000, MOL CELL, V5, P533, DOI 10.1016/S1097-2765(00)80447-5; PUNNIAMOORTHY A, 1987, J ORAL PATHOL MED, V16, P36, DOI 10.1111/j.1600-0714.1987.tb00674.x; Rossjohn J, 1999, NAT STRUCT BIOL, V6, P327; Sabo SL, 2001, J CELL BIOL, V153, P1403, DOI 10.1083/jcb.153.7.1403; Scheuermann S, 2001, J BIOL CHEM, V276, P33923, DOI 10.1074/jbc.M105410200; Selkoe DJ, 2001, PHYSIOL REV, V81, P741, DOI 10.1152/physrev.2001.81.2.741; Shao CH, 2006, J BIOL CHEM, V281, P31689, DOI 10.1074/jbc.M604502200; Soba P, 2005, EMBO J, V24, P3624, DOI 10.1038/sj.emboj.7600824; Storey E, 1996, BRAIN RES, V735, P217, DOI 10.1016/0006-8993(96)00608-7; Svergun D, 1995, J APPL CRYSTALLOGR, V28, P768, DOI 10.1107/S0021889895007047; Wang YC, 2004, MOL CELL, V15, P343, DOI 10.1016/j.molcel.2004.06.037; WASCO W, 1993, NAT GENET, V5, P95, DOI 10.1038/ng0993-95; WASCO W, 1992, P NATL ACAD SCI USA, V89, P10758, DOI 10.1073/pnas.89.22.10758; Yamazaki T, 1997, J NEUROSCI, V17, P1004	46	20	22	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 15	2010	285	3					2165	2173		10.1074/jbc.M109.018432	http://dx.doi.org/10.1074/jbc.M109.018432			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	541PJ	19906646	Green Published, hybrid			2022-12-25	WOS:000273429100060
J	Jia, Y; Lee, KW; Swerdloff, R; Hwang, D; Cobb, LJ; Hikim, AS; Lue, Y; Cohen, P; Wang, C				Jia, Yue; Lee, Kuk-Wha; Swerdloff, Ronald; Hwang, David; Cobb, Laura J.; Hikim, Amiya Sinha; Lue, YanHe; Cohen, Pinchas; Wang, Christina			Interaction of Insulin-like Growth Factor-binding Protein-3 and BAX in Mitochondria Promotes Male Germ Cell Apoptosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYTOCHROME-C RELEASE; PEPTIDE HUMANIN; DEATH; PATHWAYS; SPERMATOGENESIS; TESTOSTERONE; IGFBP-3; FAMILY; BCL-2; HYPERTHERMIA	Germ cell apoptosis is crucial for spermatogenesis and can be triggered by various stimuli, including intratesticular hormone deprivation. This study proposes a role for insulin-like growth factor binding protein-3 (IGFBP-3) in male germ cell apoptosis. Groups of adult Sprague-Dawley male rats received one of the following treatments for 5 days: (i) daily intratesticular (IT) injections with saline (control); (ii) a single subcutaneous injection of the gonadotropin-releasing hormone antagonist (GnRHA), acyline, on day 1 and a daily IT injection of saline; (iii) daily IT injection of IGFBP-3; and (iv) a GnRH-A injection on day 1 and a daily IT injection of IGFBP-3. Germ cell apoptosis increased significantly after IGFBP-3 or GnRH-A treatment which was further enhanced by the combined treatment. After co-immunoprecipitation with BAX antibody, IGFBP-3 association with BAX was demonstrated in total and mitochondrial fractions but not in the cytosol of testis extracts. BAX-associated IGFBP-3 expression was increased in mitochondria after treatment compared with control, which was confirmed by an IGFBP-3 enzyme-linked immunosorbent assay. Dot blot studies further validated the BAX-IGFBP-3 binding in vitro. IGFBP-3 as well as BAX induced release of cytochrome c and DIABLO from isolated testicular mitochondria in vitro. IGFBP-3, when combined with an ineffective dose of BAX, triggered release of these proteins from isolated mitochondria at a 4-fold lower dose than IGFBP-3 alone. Our data demonstrate that the IGFBP-3 and BAX interaction activates germ cell apoptosis via the mitochondria-dependent pathway. This represents a novel pathway regulating germ call homeostasis that may have significance for male fertility and testicular disease.	[Wang, Christina] Harbor UCLA Med Ctr, Gen Clin Res Ctr, Div Endocrinol, Los Angeles Biomed Res Inst,Dept Med, Torrance, CA 90509 USA; [Jia, Yue; Hwang, David; Cobb, Laura J.; Cohen, Pinchas] Univ Calif Los Angeles, Div Pediat Endocrinol, Dept Pediat, David Geffen Sch Med,Mattel Childrens Hosp, Los Angeles, CA 90024 USA	University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; Lundquist Institute; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA	Wang, C (corresponding author), Harbor UCLA Med Ctr, Gen Clin Res Ctr, Div Endocrinol, Los Angeles Biomed Res Inst,Dept Med, Box 16,1000 W Carson St, Torrance, CA 90509 USA.	wang@labiomed.org	LUE, YANHE/AAN-4861-2021	LUE, YANHE/0000-0003-0458-7841				Ali O, 2003, HORM METAB RES, V35, P726; Antonsson B, 2000, BIOCHEM J, V345, P271, DOI 10.1042/0264-6021:3450271; Cohen P, 2006, ENDOCRINOLOGY, V147, P2109, DOI 10.1210/en.2006-0195; Cory S, 2002, NAT REV CANCER, V2, P647, DOI 10.1038/nrc883; Danial NN, 2004, CELL, V116, P205, DOI 10.1016/S0092-8674(04)00046-7; Eskes R, 1998, J CELL BIOL, V143, P217, DOI 10.1083/jcb.143.1.217; Franklin SL, 2003, J CLIN ENDOCR METAB, V88, P900, DOI 10.1210/jc.2002-020472; Green DR, 2000, CELL, V102, P1, DOI 10.1016/S0092-8674(00)00003-9; Hengartner MO, 2000, NATURE, V407, P770, DOI 10.1038/35037710; Hikim APS, 1997, BIOL REPROD, V57, P1193, DOI 10.1095/biolreprod57.5.1193; Hikim APS, 2003, J STEROID BIOCHEM, V85, P175, DOI 10.1016/S0960-0760(03)00193-6; Hikim APS, 2003, ENDOCRINOLOGY, V144, P3167, DOI 10.1210/en.2003-0175; Ikonen M, 2003, P NATL ACAD SCI USA, V100, P13042, DOI 10.1073/pnas.2135111100; Jia Y, 2007, BIOL REPROD, V77, P83, DOI 10.1095/biolreprod.106.058594; Jia Y, 2009, BIOL REPROD, V80, P771, DOI 10.1095/biolreprod.108.072843; Johnson C, 2008, BIOL REPROD, V79, P806, DOI 10.1095/biolreprod.108.068833; Kolluri SK, 2008, CANCER CELL, V14, P285, DOI 10.1016/j.ccr.2008.09.002; Lee KW, 2007, CARCINOGENESIS, V28, P1653, DOI 10.1093/carcin/bgm088; Lee KW, 2005, J BIOL CHEM, V280, P16942, DOI 10.1074/jbc.M412757200; Lee KW, 2002, J ENDOCRINOL, V175, P33, DOI 10.1677/joe.0.1750033; Lee KW, 2004, J BIOL CHEM, V279, P469, DOI 10.1074/jbc.M307316200; Lin BZ, 2004, CELL, V116, P527, DOI 10.1016/S0092-8674(04)00162-X; Liu BR, 2000, J BIOL CHEM, V275, P33607, DOI 10.1074/jbc.M002547200; Liu BR, 2005, CLIN CANCER RES, V11, P4851, DOI 10.1158/1078-0432.CCR-04-2160; Luciano F, 2005, J BIOL CHEM, V280, P15825, DOI 10.1074/jbc.M413062200; LUE Y, 2010, ENDOCRINOLO IN PRESS; Lue YH, 2009, BIOL REPROD, V80, P484, DOI 10.1095/biolreprod.108.070839; Lue YH, 2006, J CLIN ENDOCR METAB, V91, P539, DOI 10.1210/jc.2005-1808; Prieur A, 2004, MOL CELL BIOL, V24, P7275, DOI 10.1128/MCB.24.16.7275-7283.2004; Rajah R, 1997, J BIOL CHEM, V272, P12181, DOI 10.1074/jbc.272.18.12181; Reed JC, 2000, AM J PATHOL, V157, P1415, DOI 10.1016/S0002-9440(10)64779-7; Shimizu S, 1999, NATURE, V399, P483, DOI 10.1038/20959; SINHAHIKIM AP, 1993, ENDOCRINOLOGY, V133, P2161, DOI 10.1210/en.133.5.2161; Vera Y, 2004, BIOL REPROD, V70, P1534, DOI 10.1095/biolreprod.103.024661; Vera Y, 2006, MOL ENDOCRINOL, V20, P1597, DOI 10.1210/me.2005-0395; Wang C, 2007, J CLIN ENDOCR METAB, V92, P3292, DOI 10.1210/jc.2007-0367; Yamada PM, 2009, AM J PHYSIOL-CELL PH, V296, pC954, DOI 10.1152/ajpcell.00598.2008; Zhai DY, 2005, J BIOL CHEM, V280, P15815, DOI 10.1074/jbc.M411902200; [No title captured]	39	27	30	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 15	2010	285	3					1726	1732		10.1074/jbc.M109.046847	http://dx.doi.org/10.1074/jbc.M109.046847			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	541PJ	19887447	hybrid, Green Published			2022-12-25	WOS:000273429100018
J	Waetzig, GH; Chalaris, A; Rosenstiel, P; Suthaus, J; Holland, C; Karl, N; Uriarte, LV; Till, A; Scheller, J; Grotzinger, J; Schreiber, S; Rose-John, S; Seegert, D				Waetzig, Georg H.; Chalaris, Athena; Rosenstiel, Philip; Suthaus, Jan; Holland, Christin; Karl, Nadja; Uriarte, Lorena Valles; Till, Andreas; Scheller, Juergen; Groetzinger, Joachim; Schreiber, Stefan; Rose-John, Stefan; Seegert, Dirk			N-Linked Glycosylation Is Essential for the Stability but Not the Signaling Function of the Interleukin-6 Signal Transducer Glycoprotein 130	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LIGAND-BINDING; EXTRACELLULAR DOMAINS; BIOLOGICAL FUNCTION; DESIGNER CYTOKINE; SOLUBLE RECEPTORS; GP130; COMPLEX; MEMBRANE; ACTIVATION; EXPRESSION	N-Linked glycosylation is an important determinant of protein structure and function. The interleukin-6 signal transducer glycoprotein 130 (gp130) is a common co-receptor for cytokines of the interleukin (IL)-6 family and is N-glycosylated at 9 of 11 potential sites. Whereas N-glycosylation of the extracellular domains D1-D3 of gp130 has been shown to be dispensable for binding of the gp130 ligand IL-6 and its cognate receptor in vitro, the role of the N-linked glycans on domains D4 and D6 is still unclear. We have mutated the asparagines of all nine functional N-glycosylation sites of gp130 to glutamine and systematically analyzed the consequences of deleted N-glycosylation (dNG) in both cellular gp130 and in a soluble gp130-IgG1-Fc fusion protein (sgp130Fc). Our results show that sgp130Fc-dNG is inherently unstable and degrades rapidly under conditions that do not harm wild-type sgp130Fc. Consistently, the bulk of cellular gp130-dNG is not transported to the plasma membrane but is degraded in the proteasome. However, the small quantities of gp130-dNG, which do reach the cell surface, are still able to activate the key gp130 signaling target signal transducer and activator of transcription-3 (STAT3) upon binding of the agonistic complex of IL-6 and soluble IL-6 receptor. In conclusion, N-linked glycosylation is required for the stability but not the signal-transducing function of gp130.	[Waetzig, Georg H.; Holland, Christin; Karl, Nadja; Uriarte, Lorena Valles; Seegert, Dirk] CONARIS Res Inst AG, D-24118 Kiel, Germany; [Chalaris, Athena; Suthaus, Jan; Scheller, Juergen; Groetzinger, Joachim; Rose-John, Stefan] Univ Kiel, Inst Biochem, D-24098 Kiel, Germany; [Rosenstiel, Philip; Till, Andreas; Schreiber, Stefan] Univ Kiel, Inst Clin Mol Biol, D-24098 Kiel, Germany; [Schreiber, Stefan] Univ Hosp Schleswig Holstein, Dept Internal Med 1, D-24105 Kiel, Germany	University of Kiel; University of Kiel; University of Kiel; Schleswig Holstein University Hospital	Waetzig, GH (corresponding author), CONARIS Res Inst AG, Schauenburgerstr 116, D-24118 Kiel, Germany.	g.waetzig@conaris.de	Waetzig, Georg/AAV-7486-2021; Till, Andreas/AAO-6375-2021; Seegert, Dirk/B-8826-2011; Till, Andreas/E-9661-2013; Rose-John, Stefan/A-7998-2010; Scheller, Jürgen/K-5290-2015; Rosenstiel, Philip/A-5137-2009	Till, Andreas/0000-0002-0139-9143; Rose-John, Stefan/0000-0002-7519-3279; Rosenstiel, Philip/0000-0002-9692-8828	German Excellence Initiative; Deutsche Forschungsgemeinschaft [SFB415]	German Excellence Initiative; Deutsche Forschungsgemeinschaft(German Research Foundation (DFG))	This work was supported in part by the German Excellence Initiative (Excellence Cluster "Inflammation at Interfaces") and by Deutsche Forschungsgemeinschaft, Collaborative Research Center SFB415.	Boulanger MJ, 2003, MOL CELL, V12, P577, DOI 10.1016/S1097-2765(03)00365-4; Boulanger MJ, 2003, SCIENCE, V300, P2101, DOI 10.1126/science.1083901; Bravo J, 1998, EMBO J, V17, P1665, DOI 10.1093/emboj/17.6.1665; Chow DC, 2001, SCIENCE, V291, P2150, DOI 10.1126/science.1058308; Chow DC, 2001, BIOCHEMISTRY-US, V40, P7593, DOI 10.1021/bi010192q; DING DXH, 1995, J BIOL CHEM, V270, P24580, DOI 10.1074/jbc.270.41.24580; Fischer M, 1997, NAT BIOTECHNOL, V15, P142, DOI 10.1038/nbt0297-142; HIBI M, 1990, CELL, V63, P1149, DOI 10.1016/0092-8674(90)90411-7; Hibi M, 1996, J MOL MED-JMM, V74, P1, DOI 10.1007/BF00202068; Isaji T, 2009, J BIOL CHEM, V284, P12207, DOI 10.1074/jbc.M807920200; Jefferis R, 1998, IMMUNOL REV, V163, P59, DOI 10.1111/j.1600-065X.1998.tb01188.x; Jostock T, 2001, EUR J BIOCHEM, V268, P160, DOI 10.1046/j.1432-1327.2001.01867.x; Jung G, 2005, CHEMPHYSCHEM, V6, P1628, DOI 10.1002/cphc.200400653; Ketteler R, 2002, GENE THER, V9, P477, DOI 10.1038/sj.gt.3301653; KISHIMOTO T, 1995, BLOOD, V86, P1243, DOI 10.1182/blood.V86.4.1243.bloodjournal8641243; Kukolka F, 2004, ORG BIOMOL CHEM, V2, P2203, DOI 10.1039/b406492e; Kurth I, 2000, J IMMUNOL, V164, P273, DOI 10.4049/jimmunol.164.1.273; Meng J, 2008, J BIOL CHEM, V283, P3376, DOI 10.1074/jbc.M707640200; Mitra N, 2006, TRENDS BIOCHEM SCI, V31, P156, DOI 10.1016/j.tibs.2006.01.003; Moritz RL, 2001, J BIOL CHEM, V276, P8244, DOI 10.1074/jbc.M009979200; Mu TW, 2008, CELL, V134, P769, DOI 10.1016/j.cell.2008.06.037; NARAZAKI M, 1993, BLOOD, V82, P1120, DOI 10.1182/blood.V82.4.1120.bloodjournal8241120; Peters M, 1998, BLOOD, V92, P3495, DOI 10.1182/blood.V92.10.3495.422k47_3495_3504; Peters M, 1998, J IMMUNOL, V161, P3575; Rabe B, 2008, BLOOD, V111, P1021, DOI 10.1182/blood-2007-07-102137; Rose-John S, 2006, J LEUKOCYTE BIOL, V80, P227, DOI 10.1189/jlb.1105674; Rose-John S, 2007, EXPERT OPIN THER TAR, V11, P613, DOI 10.1517/14728222.11.5.613; ROSEJOHN S, 1994, BIOCHEM J, V300, P281, DOI 10.1042/bj3000281; Sato Y, 2009, J BIOL CHEM, V284, P11873, DOI 10.1074/jbc.M807660200; Schroers A, 2005, PROTEIN SCI, V14, P783, DOI 10.1110/ps.041117105; ShakinEshleman SH, 1996, J BIOL CHEM, V271, P6363, DOI 10.1074/jbc.271.11.6363; Skiniotis G, 2005, NAT STRUCT MOL BIOL, V12, P545, DOI 10.1038/nsmb941; SLIEKER LJ, 1985, J BIOL CHEM, V260, P687; SPRANG SR, 1993, CURR OPIN STRUC BIOL, V3, P815, DOI 10.1016/0959-440X(93)90144-A; Tenhumberg S, 2008, J BIOL CHEM, V283, P27200, DOI 10.1074/jbc.M803694200; Waetzig GH, 2002, J IMMUNOL, V168, P5342, DOI 10.4049/jimmunol.168.10.5342; Wenzel-Seifert K, 2003, BIOCHEM BIOPH RES CO, V301, P693, DOI 10.1016/S0006-291X(03)00023-8; Yanagisawa M, 2009, BIOCHEM BIOPH RES CO, V386, P101, DOI 10.1016/j.bbrc.2009.05.132; Zhou HP, 1999, ARCH BIOCHEM BIOPHYS, V369, P267, DOI 10.1006/abbi.1999.1368	39	34	39	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 15	2010	285	3					1781	1789		10.1074/jbc.M109.075952	http://dx.doi.org/10.1074/jbc.M109.075952			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	541PJ	19915009	hybrid, Green Published			2022-12-25	WOS:000273429100024
J	Adekar, SP; Klyubin, I; Macy, S; Rowan, MJ; Solomon, A; Dessain, SK; O'Nuallain, B				Adekar, Sharad P.; Klyubin, Igor; Macy, Sally; Rowan, Michael J.; Solomon, Alan; Dessain, Scott K.; O'Nuallain, Brian			Inherent Anti-amyloidogenic Activity of Human Immunoglobulin gamma Heavy Chains	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							OLIGOMERIC A-BETA; HUMAN MONOCLONAL-ANTIBODY; ALZHEIMERS-DISEASE; LIGHT-CHAINS; IN-VIVO; INDUCED NEUROTOXICITY; PASSIVE-IMMUNIZATION; SYNAPTIC PLASTICITY; FIBRIL FORMATION; MOLECULAR-BASIS	We have previously shown that a subpopulation of naturally occurring human IgGs were cross-reactive against conformational epitopes on pathologic aggregates of A beta, a peptide that forms amyloid fibrils in the brains of patients with Alzheimer disease, inhibited amyloid fibril growth, and dissociated amyloid in vivo. Here, we describe similar anti-amyloidogenic activity that is a general property of free human Ig gamma heavy chains. A gamma(1) heavy chain, F1, had nanomolar binding to an amyloid fibril-related conformational epitope on synthetic oligomers and fibrils as well as on amyloid-laden tissue sections. F1 did not bind to native A beta monomers, further indicating the conformational nature of its binding site. The inherent anti-amyloidogenic activity of Ig gamma heavy chains was demonstrated by nanomolar amyloid fibril and oligomer binding by polyclonal and monoclonal human heavy chains that were isolated from inert or weakly reactive antibodies. Most importantly, the F1 heavy chain prevented in vitro fibril growth and reduced in vivo soluble A beta oligomer-induced impairment of rodent hippocampal long term potentiation, a cellular mechanism of learning and memory. These findings demonstrate that free human Ig gamma heavy chains comprise a novel class of molecules for developing potential therapeutics for Alzheimer disease and other amyloid disorders. Moreover, establishing the molecular basis for heavy chain-amyloidogenic conformer interactions should advance understanding on the types of interactions that these pathologic assemblies have with biological molecules.	[Adekar, Sharad P.; Dessain, Scott K.] Lankenau Inst Med Res, Wynnewood, PA 19096 USA; [Klyubin, Igor; Rowan, Michael J.] Trinity Coll Dublin, Trinty Coll Inst Neurosci, Dublin 2, Ireland; [Klyubin, Igor; Rowan, Michael J.] Trinity Coll Dublin, Dept Pharmacol & Therapeut, Dublin 2, Ireland; [Macy, Sally; Solomon, Alan; O'Nuallain, Brian] Univ Tennessee, Grad Sch Med, Human Immunol & Canc Program, Dept Med, Knoxville, TN 37920 USA	Lankenau Medical Center; Lankenau Institute for Medical Research; Trinity College Dublin; Trinity College Dublin; University of Tennessee System; University of Tennessee Health Science Center	Dessain, SK (corresponding author), Lankenau Inst Med Res, R227,100 Lancester Ave, Wynnewood, PA 19096 USA.	scott.dessain@gmail.com; brian.onuallain@ucd.ie		Rowan, Michael Joseph/0000-0002-3867-9536	PMERF; Science Foundation Ireland; Sharpe-Strumia Research Foundation of the Bryn Mawr Hospital	PMERF; Science Foundation Ireland(Science Foundation IrelandEuropean Commission); Sharpe-Strumia Research Foundation of the Bryn Mawr Hospital	This work was supported by a PMERF grant (to B.O'.N.), a Principal Investigator Award from Science Foundation Ireland (to M.J.R.), and the Sharpe-Strumia Research Foundation of the Bryn Mawr Hospital (to S.K.D.).	Adekar SP, 2008, J IMMUNOL METHODS, V333, P156, DOI 10.1016/j.jim.2008.01.015; Adekar SP, 2008, HYBRIDOMA, V27, P11, DOI 10.1089/hyb.2007.0536; Bacskai BJ, 2002, J NEUROSCI, V22, P7873; Barthelemy PA, 2008, J BIOL CHEM, V283, P3639, DOI 10.1074/jbc.M708536200; CARROLL WL, 1988, MOL IMMUNOL, V25, P991, DOI 10.1016/0161-5890(88)90005-3; Cullen WK, 1997, NEUROREPORT, V8, P3213, DOI 10.1097/00001756-199710200-00006; DAVIES DR, 1975, ANNU REV BIOCHEM, V44, P639, DOI 10.1146/annurev.bi.44.070175.003231; De Genst E, 2006, P NATL ACAD SCI USA, V103, P4586, DOI 10.1073/pnas.0505379103; DeMattos RB, 2001, P NATL ACAD SCI USA, V98, P8850, DOI 10.1073/pnas.151261398; Dessain SK, 2004, J IMMUNOL METHODS, V291, P109, DOI 10.1016/j.jim.2004.05.005; Dodart JC, 2002, NAT NEUROSCI, V5, P452, DOI 10.1038/nn842; Dodel RC, 2004, J NEUROL NEUROSUR PS, V75, P1472, DOI 10.1136/jnnp.2003.033399; Du YS, 2003, BRAIN, V126, P1935, DOI 10.1093/brain/awg191; Fukuchi KI, 2006, BIOCHEM BIOPH RES CO, V344, P79, DOI 10.1016/j.bbrc.2006.03.145; Galeazzi L, 1999, AMYLOID, V6, P7, DOI 10.3109/13506129908993282; Giacomelli CE, 2005, MACROMOL BIOSCI, V5, P401, DOI 10.1002/mabi.200400189; Gilman S, 2005, NEUROLOGY, V64, P1553, DOI 10.1212/01.WNL.0000159740.16984.3C; Goedert M, 2006, SCIENCE, V314, P777, DOI 10.1126/science.1132814; Gong YS, 2003, P NATL ACAD SCI USA, V100, P10417, DOI 10.1073/pnas.1834302100; GREY HM, 1965, J EXP MED, V122, P619, DOI 10.1084/jem.122.3.619; Grimm MOW, 2005, NAT CELL BIOL, V7, P1118, DOI 10.1038/ncb1313; Gruschus JM, 2008, AMYLOID, V15, P160, DOI 10.1080/13506120802193746; HAASS C, 1992, NATURE, V359, P325; Hardy J, 2002, SCIENCE, V297, P353, DOI 10.1126/science.1072994; Henkel AW, 2007, MOL PSYCHIATR, V12, P601, DOI 10.1038/sj.mp.4001947; Istrin G, 2006, J NEUROSCI RES, V84, P434, DOI 10.1002/jnr.20886; Kaminksy W, 2006, MICRON, V37, P324, DOI 10.1016/j.micron.2005.10.014; Kayed R, 2003, SCIENCE, V300, P486, DOI 10.1126/science.1079469; Kayed R, 2007, MOL NEURODEGENER, V2, DOI 10.1186/1750-1326-2-18; Klyubin I, 2004, EUR J NEUROSCI, V19, P2839, DOI 10.1111/j.1460-9568.2004.03389.x; Klyubin I, 2008, J NEUROSCI, V28, P4231, DOI 10.1523/JNEUROSCI.5161-07.2008; Lafaye P, 2009, MOL IMMUNOL, V46, P695, DOI 10.1016/j.molimm.2008.09.008; Lambert MP, 2007, J NEUROCHEM, V100, P23, DOI 10.1111/j.1471-4159.2006.04157.x; Lee EB, 2006, J BIOL CHEM, V281, P4292, DOI 10.1074/jbc.M511018200; Lefranc MP, 2005, NUCLEIC ACIDS RES, V33, pD593, DOI 10.1093/nar/gki065; Lue LF, 1999, AM J PATHOL, V155, P853, DOI 10.1016/S0002-9440(10)65184-X; Malencik DA, 2003, AMINO ACIDS, V25, P233, DOI 10.1007/s00726-003-0014-z; MCLAUGHLIN CL, 1974, J IMMUNOL, V113, P1369; Moir RD, 2005, J BIOL CHEM, V280, P17458, DOI 10.1074/jbc.M414176200; Morgan D, 2000, NATURE, V408, P982, DOI 10.1038/35050116; Murphy CL, 2006, METHOD ENZYMOL, V412, P48, DOI 10.1016/S0076-6879(06)12004-2; NAIKI H, 1989, ANAL BIOCHEM, V177, P244, DOI 10.1016/0003-2697(89)90046-8; Nicoll JAR, 2006, J NEUROPATH EXP NEUR, V65, P1040, DOI 10.1097/01.jnen.0000240466.10758.ce; O'Nuallain B, 2002, P NATL ACAD SCI USA, V99, P1485, DOI 10.1073/pnas.022662599; O'Nuallain B, 2008, BIOCHEMISTRY-US, V47, P12254, DOI 10.1021/bi801767k; O'Nuallain B, 2007, BIOCHEMISTRY-US, V46, P13049, DOI 10.1021/bi701255m; O'Nuallain B, 2007, BIOCHEMISTRY-US, V46, P1240, DOI 10.1021/bi0616605; O'Nuallain B, 2006, METHOD ENZYMOL, V413, P34, DOI 10.1016/S0076-6879(06)13003-7; O'Nuallain B, 2006, J IMMUNOL, V176, P7071, DOI 10.4049/jimmunol.176.11.7071; PRAS M, 1968, J CLIN INVEST, V47, P924; Relkin NR, 2009, NEUROBIOL AGING, V30, P1728, DOI 10.1016/j.neurobiolaging.2007.12.021; Robert R, 2009, PROTEIN ENG DES SEL, V22, P199, DOI 10.1093/protein/gzn052; Rowan MJ, 2007, BIOCHEM SOC T, V35, P1219, DOI 10.1042/BST0351219; Shankar GM, 2008, NAT MED, V14, P837, DOI 10.1038/nm1782; Solomon A, 2003, J LAB CLIN MED, V142, P348, DOI 10.1016/S0022-2143(03)00149-5; SOLOMON A, 1985, METHOD ENZYMOL, V116, P101; Solomon B, 2007, EXPERT OPIN INV DRUG, V16, P819, DOI 10.1517/13543784.16.6.819; Solomon Beka, 2004, Current Alzheimer Research, V1, P149, DOI 10.2174/1567205043332126; Solorzano-Vargas RS, 2008, MOL IMMUNOL, V45, P881, DOI 10.1016/j.molimm.2007.08.008; Stefani M, 2004, BBA-MOL BASIS DIS, V1739, P5, DOI 10.1016/j.bbadis.2004.08.004; Tamura Y, 2005, NEUROBIOL DIS, V20, P541, DOI 10.1016/j.nbd.2005.04.007; Teplow DB, 2006, METHOD ENZYMOL, V413, P20, DOI 10.1016/S0076-6879(06)13002-5; Wall J, 1999, BIOCHEMISTRY-US, V38, P14101, DOI 10.1021/bi991131j; Walsh DM, 2007, J NEUROCHEM, V101, P1172, DOI 10.1111/j.1471-4159.2006.04426.x; Weksler ME, 2005, IMMUNOL REV, V205, P244, DOI 10.1111/j.0105-2896.2005.00264.x; Wetzel R, 2006, ACCOUNTS CHEM RES, V39, P671, DOI 10.1021/ar050069h; Yoshihara T, 2008, J BIOCHEM, V143, P475, DOI 10.1093/jb/mvm239; Zameer A, 2008, J MOL BIOL, V384, P917, DOI 10.1016/j.jmb.2008.09.068	68	17	22	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 8	2010	285	2					1066	1074		10.1074/jbc.M109.044321	http://dx.doi.org/10.1074/jbc.M109.044321			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	539MH	19889627	hybrid, Green Published			2022-12-25	WOS:000273258200027
J	Hubmacher, D; Cirulis, JT; Miao, M; Keeley, FW; Reinhardt, DP				Hubmacher, Dirk; Cirulis, Judith T.; Miao, Ming; Keeley, Fred W.; Reinhardt, Dieter P.			Functional Consequences of Homocysteinylation of the Elastic Fiber Proteins Fibrillin-1 and Tropoelastin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA-SYNTHASE DEFICIENCY; EXTRACELLULAR MICROFIBRILS; STRUCTURAL CONSEQUENCES; SELF-AGGREGATION; BINDING; HYPERHOMOCYSTEINEMIA; COACERVATION; POLYPEPTIDES; DISULFIDE; FIBULINS	Homocystinuria caused by cystathionine-beta-synthase deficiency represents a severe form of homocysteinemias, which generally result in various degrees of elevated plasma homocysteine levels. Marfan syndrome is caused by mutations in fibrillin-1, which is one of the major constituents of connective tissue microfibrils. Despite the fundamentally different origins, both diseases share common clinical symptoms in the connective tissue such as long bone overgrowth, scoliosis, and ectopia lentis, whereas they differ in others. Fibrillin-1 contains similar to 13% cysteine residues and can be modified by homocysteine. We report here that homocysteinylation affects functional properties of fibrillin-1 and tropoelastin. We used recombinant fragments spanning the entire fibrillin-1 molecule to demonstrate that homocysteinylation, but not cysteinylation leads to abnormal self-interaction, which was attributed to a reduced amount of multimerization of the fibrillin-1 C terminus. The deposition of the fibrillin-1 network by human dermal fibroblasts was greatly reduced by homocysteine, but not by cysteine. Furthermore, homocysteinylation, but not cysteinylation of elastin-like polypeptides resulted in modified coacervation properties. In summary, the results provide new insights into pathogenetic mechanisms potentially involved in cystathionine-beta-synthasedeficient homocystinuria.	McGill Univ, Fac Med, Dept Anat & Cell Biol, Montreal, PQ H3A 2B2, Canada; [Reinhardt, Dieter P.] McGill Univ, Fac Dent, Div Biomed Sci, Montreal, PQ H3A 2B2, Canada; [Cirulis, Judith T.; Miao, Ming; Keeley, Fred W.] Hosp Sick Children, Res Inst, Toronto, ON M5G 1X8, Canada	McGill University; McGill University; University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids)	Reinhardt, DP (corresponding author), 3640 Univ St, Montreal, PQ H3A 2B2, Canada.	dieter.reinhardt@mcgill.ca	Hubmacher, Dirk/AAE-1875-2020; Reinhardt, Dieter P/A-3102-2008	Reinhardt, Dieter P/0000-0001-6535-9872; Hubmacher, Dirk/0000-0003-1569-9451	Canadian Marfan Association; Canadian Institutes of Health Research [MOP-68836]; German Academic Exchange Service; Heart and Stroke Foundation of Ontario [T5451]	Canadian Marfan Association; Canadian Institutes of Health Research(Canadian Institutes of Health Research (CIHR)); German Academic Exchange Service(Deutscher Akademischer Austausch Dienst (DAAD)); Heart and Stroke Foundation of Ontario(Heart & Stroke Foundation of Ontario)	This work was supported by a grant from the Canadian Marfan Association (to D. P. R.), Canadian Institutes of Health Research Grant MOP-68836 (to D. P. R.), the German Academic Exchange Service (to D. H.), and Heart and Stroke Foundation of Ontario Grant T5451 (to F. W. K.).	Baumbach GL, 2002, CIRC RES, V91, P931, DOI 10.1161/01.RES.0000041408.64867.1D; Bellingham CM, 2001, BBA-PROTEIN STRUCT M, V1550, P6, DOI 10.1016/S0167-4838(01)00262-X; Brinckmann J, 2005, ARTHRITIS RES THER, V7, pR1221, DOI 10.1186/ar1813; BROWN PL, 1992, BIOCHEM BIOPH RES CO, V186, P549, DOI 10.1016/S0006-291X(05)80843-5; Cain SA, 2005, J BIOL CHEM, V280, P30526, DOI 10.1074/jbc.M501390200; Cain SA, 2008, J BIOL CHEM, V283, P27017, DOI 10.1074/jbc.M803373200; Carta L, 2006, J BIOL CHEM, V281, P8016, DOI 10.1074/jbc.M511599200; Charpiot P, 1998, MATRIX BIOL, V17, P559, DOI 10.1016/S0945-053X(98)90108-1; Cirulis JT, 2008, BIOCHEMISTRY-US, V47, P12601, DOI 10.1021/bi8005384; Clarke AW, 2005, BIOCHEMISTRY-US, V44, P10271, DOI 10.1021/bi050530d; Collod-Beroud G, 2003, HUM MUTAT, V22, P199, DOI 10.1002/humu.10249; Corson GM, 2004, GENOMICS, V83, P461, DOI 10.1016/j.ygeno.2003.08.023; DUERRE JA, 1966, ANAL BIOCHEM, V17, P310, DOI 10.1016/0003-2697(66)90209-0; El-Hallous E, 2007, J BIOL CHEM, V282, P8935, DOI 10.1074/jbc.M608204200; ELLMAN GL, 1959, ARCH BIOCHEM BIOPHYS, V82, P70, DOI 10.1016/0003-9861(59)90090-6; Gellekink Henkjan, 2005, Semin Vasc Med, V5, P98, DOI 10.1055/s-2005-872396; Giusti B, 2003, EUR HEART J, V24, P2038, DOI 10.1016/j.ehj.2003.08.020; Glushchenko AV, 2007, ANTIOXID REDOX SIGN, V9, P1883, DOI 10.1089/ars.2007.1809; Gupta S, 2009, FASEB J, V23, P883, DOI 10.1096/fj.08-120584; Hill CH, 2002, J NUTR, V132, P2143, DOI 10.1093/jn/132.8.2143; Hubmacher D, 2005, J BIOL CHEM, V280, P34946, DOI 10.1074/jbc.M504748200; Hubmacher D, 2008, P NATL ACAD SCI USA, V105, P6548, DOI 10.1073/pnas.0706335105; Hubmacher D, 2006, CURR TOP DEV BIOL, V75, P93, DOI 10.1016/S0070-2153(06)75004-9; Hutchinson S, 2005, J MOL BIOL, V346, P833, DOI 10.1016/j.jmb.2004.11.038; Isogai Z, 2003, J BIOL CHEM, V278, P2750, DOI 10.1074/jbc.M209256200; Jensen SA, 2001, J BIOL CHEM, V276, P39661, DOI 10.1074/jbc.M104533200; Kielty CM, 2005, ADV PROTEIN CHEM, V70, P405, DOI 10.1016/S0065-3233(04)70012-1; Lin GQ, 2002, J BIOL CHEM, V277, P50795, DOI 10.1074/jbc.M210611200; Majors AK, 2000, MOL GENET METAB, V70, P252, DOI 10.1006/mgme.2000.3024; Marson A, 2005, J BIOL CHEM, V280, P5013, DOI 10.1074/jbc.M409029200; Mecham R. P., 1994, EXTRACELLULAR MATRIX, P281; Miao M, 2005, BIOCHEMISTRY-US, V44, P14367, DOI 10.1021/bi0510173; Miao M, 2003, J BIOL CHEM, V278, P48553, DOI 10.1074/jbc.M308465200; Mithieux SM, 2005, ADV PROTEIN CHEM, V70, P437, DOI 10.1016/S0065-3233(05)70013-9; Mudd S.H., 1995, METABOLIC MOL BASES, V1, P1279; Ono RN, 2009, J BIOL CHEM, V284, P16872, DOI 10.1074/jbc.M809348200; Ramirez F, 2009, CURR OPIN CELL BIOL, V21, P616, DOI 10.1016/j.ceb.2009.05.005; Refsum H, 1998, ANNU REV MED, V49, P31, DOI 10.1146/annurev.med.49.1.31; Reinhardt DP, 2000, J BIOL CHEM, V275, P2205, DOI 10.1074/jbc.275.3.2205; Reinhardt DP, 1996, J MOL BIOL, V258, P104, DOI 10.1006/jmbi.1996.0237; SAKAI LY, 1986, J CELL BIOL, V103, P2499, DOI 10.1083/jcb.103.6.2499; Sengle G, 2008, J BIOL CHEM, V283, P13874, DOI 10.1074/jbc.M707820200; Sengupta S, 2001, J BIOL CHEM, V276, P30111, DOI 10.1074/jbc.M104324200; Sengupta S, 2001, J BIOL CHEM, V276, P46896, DOI 10.1074/jbc.M108451200; SHAPIRO SD, 1991, J CLIN INVEST, V87, P1828, DOI 10.1172/JCI115204; SKOVBY F, 2002, CONNECTIVE TISSUE IT, P627; Starcher B, 2005, EXP LUNG RES, V31, P873, DOI 10.1080/01902140600611629; Suk JY, 2004, J BIOL CHEM, V279, P51258, DOI 10.1074/jbc.M408156200; Sundaramoorthy E, 2008, PROTEINS, V71, P1475, DOI 10.1002/prot.21846; TANGEMANN K, 1995, FEBS LETT, V358, P179, DOI 10.1016/0014-5793(94)01411-S; Tiedemann K, 2005, J BIOL CHEM, V280, P11404, DOI 10.1074/jbc.M409882200; Tiedemann K, 2001, J BIOL CHEM, V276, P36035, DOI 10.1074/jbc.M104985200; Tu YD, 2008, BIOMACROMOLECULES, V9, P1739, DOI 10.1021/bm7013153; Ueland PM., 1992, ATHEROSCLEROTIC CARD, P183; Urry D W, 1977, Adv Exp Med Biol, V79, P685; Vollbrandt T, 2004, J BIOL CHEM, V279, P32924, DOI 10.1074/jbc.M405239200; Vrhovski B, 1997, EUR J BIOCHEM, V250, P92, DOI 10.1111/j.1432-1033.1997.00092.x; Wachi H, 2005, CLIN BIOCHEM, V38, P643, DOI 10.1016/j.clinbiochem.2005.04.006; Wagenseil Jessica E., 2007, Birth Defects Research, V81, P229, DOI 10.1002/bdrc.20111; ZHANG H, 1994, J CELL BIOL, V124, P855, DOI 10.1083/jcb.124.5.855	60	29	29	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 8	2010	285	2					1188	1198		10.1074/jbc.M109.021246	http://dx.doi.org/10.1074/jbc.M109.021246			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	539MH	19889633	Green Published, hybrid			2022-12-25	WOS:000273258200041
J	O'Hara, SP; Splinter, PL; Gajdos, GB; Trussoni, CE; Fernandez-Zapico, ME; Chen, XM; Larusso, NF				O'Hara, Steven P.; Splinter, Patrick L.; Gajdos, Gabriella B.; Trussoni, Christy E.; Fernandez-Zapico, Martin E.; Chen, Xian-Ming; Larusso, Nicholas F.			NF kappa B p50-CCAAT/Enhancer-binding Protein beta (C/EBP beta)-mediated Transcriptional Repression of MicroRNA let-7i following Microbial Infection	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BILIARY EPITHELIAL-CELLS; CRYPTOSPORIDIUM-PARVUM; NUCLEAR-FACTOR; C/EBP-BETA; POSTTRANSCRIPTIONAL REGULATION; HUMAN CHOLANGIOCYTES; IMMUNE-RESPONSES; BREAST-CANCER; EXPRESSION; BINDING	MicroRNAs, central players of numerous cellular processes, regulate mRNA stability or translational efficiency. Although these molecular events are established, the mechanisms regulating microRNA function and expression remain largely unknown. The microRNA let-7i regulates Toll-like receptor 4 expression. Here, we identify a novel transcriptional mechanism induced by the protozoan parasite Cryptosporidium parvum and Gram(-) bacteria-derived lipopolysaccharide (LPS) mediating let-7i promoter silencing in human biliary epithelial cells (cholangiocytes). Using cultured cholangiocytes, we show that microbial stimulus decreased let-7i expression, and promoter activity. Analysis of the mechanism revealed that microbial infection promotes the formation of a NF kappa B p50-C/EBP beta silencer complex in the regulatory sequence. Chromatin immunoprecipitation assays (ChIP) demonstrated that the repressor complex binds to the let-7i promoter following microbial stimulus and promotes histone-H3 deacetylation. Our results provide a novel mechanism of transcriptional regulation of cholangiocyte let-7i expression following microbial insult, a process with potential implications for epithelial innate immune responses in general.	[O'Hara, Steven P.; Splinter, Patrick L.; Gajdos, Gabriella B.; Trussoni, Christy E.; Fernandez-Zapico, Martin E.; Larusso, Nicholas F.] Mayo Clin, Miles & Shirley Fiterman Ctr Digest Dis, Div Gastroenterol & Hepatol, Rochester, MN 55905 USA; [Fernandez-Zapico, Martin E.] Mayo Clin, Schulze Ctr Novel Therapeut, Div Oncol Res, Rochester, MN 55905 USA; [Chen, Xian-Ming] Creighton Univ, Med Ctr, Dept Med Microbiol & Immunol, Omaha, NE 68178 USA	Mayo Clinic; Mayo Clinic; Creighton University	O'Hara, SP (corresponding author), Mayo Clin, Miles & Shirley Fiterman Ctr Digest Dis, Div Gastroenterol & Hepatol, 200 1st St SW, Rochester, MN 55905 USA.	ohara.steven@mayo.edu		Trussoni, Christy/0000-0002-4247-076X	National Institutes of Health [DK57993, DK76922, A2071321]; Mayo Foundation; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI071321] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK057993, P30DK084567, K01DK076922] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Mayo Foundation; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))	This work was supported, in whole or in part, by National Institutes of Health Grants DK57993 (to N. F. L.), DK76922 (to S. P. O.), and A2071321 (to X. C.). This work was also supported by a grant from the Mayo Foundation.	Agrawal A, 2003, IMMUNOLOGY, V108, P539, DOI 10.1046/j.1365-2567.2003.01608.x; AKIRA S, 1990, EMBO J, V9, P1897, DOI 10.1002/j.1460-2075.1990.tb08316.x; Bartel DP, 2004, CELL, V116, P281, DOI 10.1016/S0092-8674(04)00045-5; Cha-Molstad H, 2007, MOL IMMUNOL, V44, P2933, DOI 10.1016/j.molimm.2007.01.015; Chen XM, 2008, IMMUNOL CELL BIOL, V86, P497, DOI 10.1038/icb.2008.37; Chen XM, 2007, J BIOL CHEM, V282, P28929, DOI 10.1074/jbc.M702633200; Chen XM, 2000, GASTROENTEROLOGY, V118, P368, DOI 10.1016/S0016-5085(00)70219-8; Chen XM, 2005, J IMMUNOL, V175, P7447, DOI 10.4049/jimmunol.175.11.7447; Chen XM, 2001, GASTROENTEROLOGY, V120, P1774, DOI 10.1053/gast.2001.24850; Cruickshank SM, 1998, J HEPATOL, V29, P550, DOI 10.1016/S0168-8278(98)80149-9; DESCOMBES P, 1991, CELL, V67, P569, DOI 10.1016/0092-8674(91)90531-3; El-Asmar B, 2009, J MOL ENDOCRINOL, V42, P131, DOI 10.1677/JME-08-0016; Gomis RR, 2006, CANCER CELL, V10, P203, DOI 10.1016/j.ccr.2006.07.019; Grimm SL, 2003, J MAMMARY GLAND BIOL, V8, P191, DOI 10.1023/A:1025900908026; GRUBMAN SA, 1994, AM J PHYSIOL, V266, pG1060, DOI 10.1152/ajpgi.1994.266.6.G1060; Harada K, 2004, HEPATOLOGY, V40, P925, DOI 10.1002/hep.20379; JOPLIN R, 1989, IN VITRO CELL DEV B, V25, P1189; Meng F, 2008, ONCOGENE, V27, P378, DOI 10.1038/sj.onc.1210648; MORITA M, 1994, HEPATOLOGY, V19, P426; Obernosterer G, 2006, RNA, V12, P1161, DOI 10.1261/rna.2322506; Park J, 1999, HEPATOLOGY, V29, P1037, DOI 10.1002/hep.510290423; Ralph WM, 2006, J GEN VIROL, V87, P51, DOI 10.1099/vir.0.81207-0; Scholz M, 1997, TISSUE ANTIGENS, V49, P640, DOI 10.1111/j.1399-0039.1997.tb02813.x; STEIN B, 1993, MOL CELL BIOL, V13, P3964, DOI 10.1128/MCB.13.7.3964; Taganov KD, 2006, P NATL ACAD SCI USA, V103, P12481, DOI 10.1073/pnas.0605298103; Thomson JM, 2006, GENE DEV, V20, P2202, DOI 10.1101/gad.1444406; VINSON CR, 1989, SCIENCE, V246, P911, DOI 10.1126/science.2683088; Viswanathan SR, 2008, SCIENCE, V320, P97, DOI 10.1126/science.1154040; Yokoyama T, 2006, LIVER INT, V26, P467, DOI 10.1111/j.1478-3231.2006.01254.x	29	83	87	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 1	2010	285	1					216	225		10.1074/jbc.M109.041640	http://dx.doi.org/10.1074/jbc.M109.041640			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	536UT	19903813	Green Published, hybrid			2022-12-25	WOS:000273070100023
J	Seyrantepe, V; Iannello, A; Liang, F; Kanshin, E; Jayanth, P; Samarani, S; Szewczuk, MR; Ahmad, A; Pshezhetsky, AV				Seyrantepe, Volkan; Iannello, Alexandre; Liang, Feng; Kanshin, Evgeny; Jayanth, Preethi; Samarani, Suzanne; Szewczuk, Myron R.; Ahmad, Ali; Pshezhetsky, Alexey V.			Regulation of Phagocytosis in Macrophages by Neuraminidase 1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LYSOSOMAL SIALIDASE; BETA-GALACTOSIDASE; T-LYMPHOCYTES; CELL-SURFACE; ANTIGEN PRESENTATION; BINDING-PROTEIN; B-CELLS; COMPLEX; EXPRESSION; ACID	The differentiation of monocytes into macrophages and dendritic cells is accompanied by induction of cell-surface neuraminidase 1 (Neu1) and cathepsin A (CathA), the latter forming a complex with and activating Neu1. To clarify the biological importance of this phenomenon we have developed the gene-targeted mouse models of a CathA deficiency (CathA(S190A)) and a double CathA/Neu1 deficiency (CathA(S190A-Neo)). Macrophages of CathA(S190A-Neo) mice and their immature dendritic cells showed a significantly reduced capacity to engulf Gram-positive and Gram-negative bacteria and positively and negatively charged polymer beads as well as IgG-opsonized beads and erythrocytes. Properties of the cells derived from CathA(S190A) mice were indistinguishable from those of wild-type controls, suggesting that the absence of Neu1, which results in the increased sialylation of the cell surface proteins, probably affects multiple receptors for phagocytosis. Indeed, treatment of the cells with purified mouse Neu1 reduced surface sialylation and restored phagocytosis. Because Neu1-deficient cells showed reduced internalization of IgG-opsonized sheep erythrocytes whereas binding of the erythrocytes to the cells at 4 degrees C persisted, we speculate that the absence of Neu1 in particular affected transduction of signals from the Fc receptors for immunoglobulin G(Fc gamma R). Indeed the macrophages from the Neu1-deficient mice showed increased sialylation and impaired phosphorylation of Fc gamma R as well as markedly reduced phosphorylation of Syk kinase in response to treatment with IgG-opsonized beads. Altogether our data suggest that the cell surface Neu1 activates the phagocytosis in macrophages and dendritic cells through desialylation of surface receptors, thus, contributing to their functional integrity.	[Seyrantepe, Volkan; Iannello, Alexandre; Liang, Feng; Kanshin, Evgeny; Samarani, Suzanne; Ahmad, Ali; Pshezhetsky, Alexey V.] Univ Montreal, St Justine Univ Hosp Ctr, Montreal, PQ H3T 1C5, Canada; [Pshezhetsky, Alexey V.] Univ Montreal, Dept Paediat, Montreal, PQ H3T 1C5, Canada; [Ahmad, Ali] Univ Montreal, Dept Immunol, Montreal, PQ H3T 1C5, Canada; [Jayanth, Preethi; Szewczuk, Myron R.] Queens Univ, Dept Microbiol & Immunol, Kingston, ON K7L 3N6, Canada; [Pshezhetsky, Alexey V.] McGill Univ, Dept Anat & Cell Biol, Montreal, PQ H3A 2B2, Canada	Universite de Montreal; Universite de Montreal; Universite de Montreal; Queens University - Canada; McGill University	Pshezhetsky, AV (corresponding author), CHU St Justine, Serv Genet Med, 3175 Cote Ste Catherine, Montreal, PQ H3T 1C5, Canada.	alexei.pchejetski@umontreal.ca	Kanshin, Evgeny/GXM-7047-2022	Ahmad, Ali/0000-0001-7689-7115; A, Pshezhetsky/0000-0002-6612-1062	Canadian Institutes of Health Research Operating [MOP 15079, GOP 38107]; Canadian Foundation for Innovation	Canadian Institutes of Health Research Operating(Canadian Institutes of Health Research (CIHR)); Canadian Foundation for Innovation(Canada Foundation for Innovation)	This work was supported in part by Canadian Institutes of Health Research Operating Grants MOP 15079 and GOP 38107 and by an equipment grant from Canadian Foundation for Innovation (to A. V. P.).	AMITH SR, 2009, GLYCOCONJ J IN PRESS; Bagriacik EU, 1999, GLYCOBIOLOGY, V9, P267, DOI 10.1093/glycob/9.3.267; Baum LG, 1996, J BIOL CHEM, V271, P10793, DOI 10.1074/jbc.271.18.10793; Berthier R, 2000, J IMMUNOL METHODS, V239, P95, DOI 10.1016/S0022-1759(00)00186-1; Carmeliet P, 1996, NATURE, V380, P435, DOI 10.1038/380435a0; Carrillo MB, 1997, GLYCOBIOLOGY, V7, P975; Chen XP, 1997, J IMMUNOL, V158, P3070; Chen XP, 2000, CYTOKINE, V12, P972, DOI 10.1006/cyto.1999.0596; Crowley MT, 1997, J EXP MED, V186, P1027, DOI 10.1084/jem.186.7.1027; d'Azzo A., 2001, METABOLIC MOL BASES, V3, P3811; FROHMAN M, 1985, J IMMUNOL, V134, P2269; Hinek A, 2006, J BIOL CHEM, V281, P3698, DOI 10.1074/jbc.M508736200; HINEK A, 1993, J CLIN INVEST, V91, P1198, DOI 10.1172/JCI116280; Hinek A, 2008, AM J PATHOL, V173, P1042, DOI 10.2353/ajpath.2008.071081; ITOH K, 1995, J BIOL CHEM, V270, P515, DOI 10.1074/jbc.270.2.515; KEARSE KP, 1988, J IMMUNOL, V140, P1770; Kelm S, 1997, INT REV CYTOL, V175, P137, DOI 10.1016/S0074-7696(08)62127-0; KRIEGER J, 1988, J IMMUNOL, V140, P388; LANDOLFI NF, 1986, MOL IMMUNOL, V23, P297, DOI 10.1016/0161-5890(86)90057-X; LANDOLFI NF, 1985, IMMUNOGENETICS, V22, P159, DOI 10.1007/BF00563513; Liang F, 2006, J BIOL CHEM, V281, P27526, DOI 10.1074/jbc.M605633200; Lukong KE, 2001, J BIOL CHEM, V276, P46172, DOI 10.1074/jbc.M104547200; Meyers EN, 1998, NAT GENET, V18, P136, DOI 10.1038/ng0298-136; Moran JL, 1999, NATURE, V399, P742, DOI 10.1038/21560; Munday J, 1999, J LEUKOCYTE BIOL, V66, P705, DOI 10.1002/jlb.66.5.705; Nan XL, 2007, J LEUKOCYTE BIOL, V81, P284, DOI 10.1189/jlb.1105692; NARAPARAJU VR, 1994, IMMUNOL LETT, V43, P143, DOI 10.1016/0165-2478(94)90214-3; POTIER M, 1979, ANAL BIOCHEM, V94, P287, DOI 10.1016/0003-2697(79)90362-2; Pshezhetsky AV, 1996, J BIOL CHEM, V271, P28359, DOI 10.1074/jbc.271.45.28359; Pshezhetsky AV, 2001, PROG NUCLEIC ACID RE, V69, P81, DOI 10.1016/S0079-6603(01)69045-7; ROME LH, 1979, CELL, V17, P143, DOI 10.1016/0092-8674(79)90302-7; ROTH M, 1971, ANAL CHEM, V43, P880, DOI 10.1021/ac60302a020; Sedlik C, 2003, J IMMUNOL, V170, P846, DOI 10.4049/jimmunol.170.2.846; Seyrantepe V, 2008, CIRCULATION, V117, P1973, DOI 10.1161/CIRCULATIONAHA.107.733212; Stamatos NM, 2005, FEBS J, V272, P2545, DOI 10.1111/j.1742-4658.2005.04679.x; Swanson JA, 2004, J LEUKOCYTE BIOL, V76, P1093, DOI 10.1189/jlb.0804439; Thomas G.H., METABOLIC MOL BASES, V3, P3507; Uemura T, 2009, ONCOGENE, V28, P1218, DOI 10.1038/onc.2008.471; Watanabe Y, 2004, MICROBIOL IMMUNOL, V48, P875, DOI 10.1111/j.1348-0421.2004.tb03619.x; YAMAMOTO N, 1993, J IMMUNOL, V151, P2794; Yogalingam G, 2008, DEV CELL, V15, P74, DOI 10.1016/j.devcel.2008.05.005	41	62	66	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 1	2010	285	1					206	215		10.1074/jbc.M109.055475	http://dx.doi.org/10.1074/jbc.M109.055475			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	536UT	19889639	Green Published, hybrid			2022-12-25	WOS:000273070100022
J	Fontela, PS; Pai, NP; Schiller, I; Dendukuri, N; Ramsay, A; Pai, M				Fontela, Patricia Scolari; Pai, Nitika Pant; Schiller, Ian; Dendukuri, Nandini; Ramsay, Andrew; Pai, Madhukar			Quality and Reporting of Diagnostic Accuracy Studies in TB, HIV and Malaria: Evaluation Using QUADAS and STARD Standards	PLOS ONE			English	Article							GRADING QUALITY; TUBERCULOSIS; STRENGTH; TRIALS	Background: Poor methodological quality and reporting are known concerns with diagnostic accuracy studies. In 2003, the QUADAS tool and the STARD standards were published for evaluating the quality and improving the reporting of diagnostic studies, respectively. However, it is unclear whether these tools have been applied to diagnostic studies of infectious diseases. We performed a systematic review on the methodological and reporting quality of diagnostic studies in TB, malaria and HIV. Methods: We identified diagnostic accuracy studies of commercial tests for TB, malaria and HIV through a systematic search of the literature using PubMed and EMBASE (2004-2006). Original studies that reported sensitivity and specificity data were included. Two reviewers independently extracted data on study characteristics and diagnostic accuracy, and used QUADAS and STARD to evaluate the quality of methods and reporting, respectively. Findings: Ninety (38%) of 238 articles met inclusion criteria. All studies had design deficiencies. Study quality indicators that were met in less than 25% of the studies included adequate description of withdrawals (6%) and reference test execution (10%), absence of index test review bias (19%) and reference test review bias (24%), and report of uninterpretable results (22%). In terms of quality of reporting, 9 STARD indicators were reported in less than 25% of the studies: methods for calculation and estimates of reproducibility (0%), adverse effects of the diagnostic tests (1%), estimates of diagnostic accuracy between subgroups (10%), distribution of severity of disease/other diagnoses (11%), number of eligible patients who did not participate in the study (14%), blinding of the test readers (16%), and description of the team executing the test and management of indeterminate/outlier results (both 17%). The use of STARD was not explicitly mentioned in any study. Only 22% of 46 journals that published the studies included in this review required authors to use STARD. Conclusion: Recently published diagnostic accuracy studies on commercial tests for TB, malaria and HIV have moderate to low quality and are poorly reported. The more frequent use of tools such as QUADAS and STARD may be necessary to improve the methodological and reporting quality of future diagnostic accuracy studies in infectious diseases.			Fontela, PS (corresponding author), McGill Univ, Dept Epidemiol Biostat & Occupat Hlth, Montreal, PQ, Canada.	madhukar.pai@mcgill.ca	Pai, Madhukar/AAX-9901-2021; PAL, MRINAL/ABG-9676-2020; Fontela, Patricia/S-6455-2019	Pai, Madhukar/0000-0003-3667-4536; PAL, MRINAL/0000-0002-1032-272X; Pant Pai, Nitika/0000-0002-4672-0500	Canadian Institutes of Health Research [MOP-89918] Funding Source: Medline	Canadian Institutes of Health Research(Canadian Institutes of Health Research (CIHR))		Aregawi M, 2008, WORLD MALARIA REPORT; Atkins D, 2004, BMJ-BRIT MED J, V328, P1490; Bossuyt PM, 2003, ANN INTERN MED, V138, P40, DOI 10.7326/0003-4819-138-1-200301070-00010; Cot M, 2005, REV EPIDEMIOL SANTE, V53, P291, DOI 10.1016/S0398-7620(05)84606-1; DYE C, 2008, GLOBAL TUBERCULOSIS; Hopkins H, 2009, BRIT MED J, V339, DOI 10.1136/bmj.b2606; International Committee of Medical Journal Editors, 2008, BIOMEDICAL J UNPUB; *JOINT UN PROGR HI, 2008, REP GLOB AIDS EP; Lijmer JG, 1999, JAMA-J AM MED ASSOC, V282, P1061, DOI 10.1001/jama.282.11.1061; Mabey D, 2004, NAT REV MICROBIOL, V2, P231, DOI 10.1038/nrmicro841; Pai M, 2008, SEMIN RESP CRIT CARE, V29, P560, DOI 10.1055/s-0028-1085707; Pai M, 2006, EXPERT REV MOL DIAGN, V6, P509, DOI 10.1586/14737159.6.4.509; Pai M, 2009, EXPERT REV MOL DIAGN, V9, P637, DOI [10.1586/erm.09.48, 10.1586/ERM.09.48]; Pai M, 2008, PLOS MED, V5, P1043, DOI 10.1371/journal.pmed.0050156; Peeling RW, 2006, SEX TRANSM INFECT, V82, pV1, DOI 10.1136/sti.2006.024265; Peeling RW, 2006, NAT REV MICROBIOL, pS2, DOI [10.1038/nrmicro1522, 10.1038/nrmicro1568, 10.1038/nrmico1522]; Rama KRBS, 2006, CLIN ORTHOP RELAT R, P237, DOI 10.1097/01.blo.0000205906.44103.a3; REID MC, 1995, JAMA-J AM MED ASSOC, V274, P645, DOI 10.1001/jama.274.8.645; Rutjes Anne W S, 2006, CMAJ, V174, P469, DOI 10.1503/cmaj.050090; Schunemann HJ, 2008, BMJ-BRIT MED J, V336, P1106, DOI 10.1136/bmj.39500.677199.AE; Siddiqui MAR, 2005, BRIT J OPHTHALMOL, V89, P261, DOI 10.1136/bjo.2004.051862; Small PM, 2000, LANCET, V356, P1048, DOI 10.1016/S0140-6736(00)02724-0; Smidt Nynke, 2006, BMC Med Res Methodol, V6, P12, DOI 10.1186/1471-2288-6-12; *STAND REP DIAGN A, 2008, STARD STAT NEWS; Whiting Penny, 2003, BMC Med Res Methodol, V3, P25, DOI 10.1186/1471-2288-3-25; Whiting PF, 2008, BMC MED RES METHODOL, V8, DOI 10.1186/1471-2288-8-20; Whiting Penny F, 2006, BMC Med Res Methodol, V6, P9, DOI 10.1186/1471-2288-6-9; *WHO, 2007, NEW WHO POL US LIQ M; Wilczynski NL, 2008, RADIOLOGY, V248, P817, DOI 10.1148/radiol.2483072067; World Health Organization, 2008, WHO POL STAT MOL LIN	30	56	57	0	10	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	NOV 13	2009	4	11							e7753	10.1371/journal.pone.0007753	http://dx.doi.org/10.1371/journal.pone.0007753			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	518VB	19915664	Green Published, gold, Green Submitted			2022-12-25	WOS:000271721900010
J	Nemajerova, A; Palacios, G; Nowak, NJ; Matsui, SI; Petrenko, O				Nemajerova, Alice; Palacios, Gustavo; Nowak, Norma J.; Matsui, Sei-ichi; Petrenko, Oleksi			Targeted Deletion of p73 in Mice Reveals Its Role in T Cell Development and Lymphomagenesis	PLOS ONE			English	Article							COMPARATIVE GENOMIC HYBRIDIZATION; TUMOR-SUPPRESSOR FUNCTIONS; V(D)J RECOMBINATION; THYMIC LYMPHOMAS; IN-VIVO; P53-DEPENDENT APOPTOSIS; INTRAGENIC DELETIONS; DNA-DAMAGE; P53 FAMILY; MOUSE	Transcriptional silencing of the p73 gene through methylation has been demonstrated in human leukemias and lymphomas. However, the role of p73 in the malignant process remains to be explored. We show here that p73 acts as a T cell-specific tumor suppressor in a genetically defined mouse model, and that concomitant ablation of p53 and p73 predisposes mice to an increased incidence of thymic lymphomas compared to the loss of p53 alone. Our results demonstrate a causal role for loss of p73 in progression of T cell lymphomas to the stage of aggressive, disseminated disease. We provide evidence that tumorigenesis in mice lacking p53 and p73 proceeds through mechanisms involving altered patterns of gene expression, defects in early T cell development, impaired apoptosis, and the ensuing accumulation of chromosomal aberrations. Collectively, our data imply that tumor suppressive properties of p73 are highly dependent on cellular context, wherein p73 plays a major role in T cell development and neoplasia.			Nemajerova, A (corresponding author), SUNY Stony Brook, Dept Pathol, Stony Brook, NY 11794 USA.	apetrenko@notes.cc.sunysb.edu						Attardi LD, 2005, MUTAT RES-FUND MOL M, V576, P4, DOI 10.1016/j.mrfmmm.2004.08.022; Bassing CH, 2002, CELL, V109, pS45, DOI 10.1016/S0092-8674(02)00675-X; Blackburn CC, 2004, NAT REV IMMUNOL, V4, P278, DOI 10.1038/nri1331; Bogue MA, 1996, GENE DEV, V10, P553, DOI 10.1101/gad.10.5.553; Concin N, 2004, CANCER RES, V64, P2449, DOI 10.1158/0008-5472.CAN-03-1060; Corn PG, 1999, CANCER RES, V59, P3352; Cowell JK, 2004, CANCER GENET CYTOGEN, V151, P36, DOI 10.1016/j.cancergencyto.2003.09.012; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; DONEHOWER LA, 1995, MOL CARCINOGEN, V14, P16, DOI 10.1002/mc.2940140105; Flores ER, 2002, NATURE, V416, P560, DOI 10.1038/416560a; Flores ER, 2005, CANCER CELL, V7, P363, DOI 10.1016/j.ccr.2005.02.019; Guidos CJ, 1996, GENE DEV, V10, P2038, DOI 10.1101/gad.10.16.2038; Gutierrez MI, 2003, LEUKEMIA, V17, P1845, DOI 10.1038/sj.leu.2403060; Haks MC, 1999, IMMUNITY, V11, P91, DOI 10.1016/S1074-7613(00)80084-9; JACKS T, 1994, CURR BIOL, V4, P1, DOI 10.1016/S0960-9822(00)00002-6; Jost CA, 1997, NATURE, V389, P191, DOI 10.1038/38298; Kaghad M, 1997, CELL, V90, P809, DOI 10.1016/S0092-8674(00)80540-1; Kang J, 2002, EMBO J, V21, P1447, DOI 10.1093/emboj/21.6.1447; Lista F, 1997, CANCER RES, V57, P4408; Martinez-Delgado B, 2002, INT J CANCER, V102, P15, DOI 10.1002/ijc.10618; Melino G, 2002, NAT REV CANCER, V2, P605, DOI 10.1038/nrc861; Murga C, 2002, J BIOL CHEM, V277, P39156, DOI 10.1074/jbc.M203553200; Nacht M, 1996, GENE DEV, V10, P2055, DOI 10.1101/gad.10.16.2055; Nowak NJ, 2007, GENET MED, V9, P585, DOI 10.1097/GIM.0b013e3181461c4a; Ohi H, 2007, ONCOGENE, V26, P5280, DOI 10.1038/sj.onc.1210325; Osborne BA, 2007, NAT REV IMMUNOL, V7, P64, DOI 10.1038/nri1998; Pals ST, 2007, BLOOD, V110, P3102, DOI 10.1182/blood-2007-05-075176; Perez-Losada J, 2005, ONCOGENE, V24, P5521, DOI 10.1038/sj.onc.1208799; Petrenko O, 2003, MOL CELL BIOL, V23, P5540, DOI 10.1128/MCB.23.16.5540-5555.2003; Puig P, 2003, CLIN CANCER RES, V9, P5642; Ryu CJ, 2006, CANCER CELL, V9, P109, DOI 10.1016/j.ccr.2006.01.004; Sakata J, 2004, CARCINOGENESIS, V25, P1069, DOI 10.1093/carcin/bgh094; Senoo M, 2004, CANCER CELL, V6, P85, DOI 10.1016/j.ccr.2004.06.005; Stiewe T, 2004, CLIN CANCER RES, V10, P626, DOI 10.1158/1078-0432.CCR-0153-03; Stiewe T, 2007, NAT REV CANCER, V7, P165, DOI 10.1038/nrc2072; Talos F, 2007, MOL CELL, V27, P647, DOI 10.1016/j.molcel.2007.06.036; Tomasini R, 2008, GENE DEV, V22, P2677, DOI 10.1101/gad.1695308; Tsuji H, 2004, CANCER RES, V64, P8882, DOI 10.1158/0008-5472.CAN-03-1163; Tsuji H, 2009, MUTAT RES-FUND MOL M, V660, P22, DOI 10.1016/j.mrfmmm.2008.10.002; Wakabayashi Y, 2003, NAT IMMUNOL, V4, P533, DOI 10.1038/ni927; Yang A, 2000, NATURE, V404, P99, DOI 10.1038/35003607	41	15	15	0	1	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	NOV 11	2009	4	11					A136	A145	e7784	10.1371/journal.pone.0007784	http://dx.doi.org/10.1371/journal.pone.0007784			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	518IX	19907659	Green Published, gold, Green Submitted			2022-12-25	WOS:000271685800015
J	Englert, AC; Greene, MJ				Englert, Amy C.; Greene, Michael J.			Chemically-Mediated Roostmate Recognition and Roost Selection by Brazilian Free-Tailed Bats (Tadarida brasiliensis)	PLOS ONE			English	Article							SCENT RECOGNITION; CHIROPTERA; DISCRIMINATION; MOLOSSIDAE; MEXICANA; ODOR; CUES	Background: The Brazilian free-tailed bat (Tadarida brasiliensis) is an exceptionally social and gregarious species of chiropteran known to roost in assemblages that can number in the millions. Chemical recognition of roostmates within these assemblages has not been extensively studied despite the fact that an ability to chemically recognize individuals could play an important role in forming and stabilizing complex suites of social interactions. Methodology/Principal Findings: Individual bats were given a choice between three roosting pouches: one permeated with the scent of a group of roostmates, one permeated with the scent of non-roostmates, and a clean control. Subjects rejected non-roostmate pouches with greater frequency than roostmate pouches or blank control pouches. Also, bats chose to roost in the roostmate scented pouches more often than the non-roostmate or control pouches. Conclusions/Significance: We demonstrated that T. brasiliensis has the ability to chemically recognize roostmates from non-roostmates and a preference for roosting in areas occupied by roostmates. It is important to investigate these behaviors because of their potential importance in colony dynamics and roost choice.			Englert, AC (corresponding author), Univ Colorado, Dept Integrat Biol, Denver, CO 80202 USA.	michael.greene@ucdenver.edu						Bloss J, 2002, J CHEM ECOL, V28, P819, DOI 10.1023/A:1015296928423; Bloss J, 1999, ACTA CHIROPTEROL, V1, P31; Bouchard S, 2001, J ZOOL, V254, P109, DOI 10.1017/S0952836901000607; DEFANIS E, 1995, ANIM BEHAV, V49, P835; GUSTIN MK, 1987, ANIM BEHAV, V35, P13, DOI 10.1016/S0003-3472(87)80205-1; Kerth G, 2000, MOL ECOL, V9, P793, DOI 10.1046/j.1365-294x.2000.00934.x; Kerth G, 2002, MOL ECOL, V11, P1491, DOI 10.1046/j.1365-294X.2002.01528.x; LOUGHRY WJ, 1991, J MAMMAL, V72, P624, DOI 10.2307/1382150; Nielsen LT, 2006, J CAVE KARST STUD, V68, P27; Veith M, 2004, HEREDITY, V93, P342, DOI 10.1038/sj.hdy.6800509; Voigt CC, 1999, BEHAV ECOL SOCIOBIOL, V47, P29, DOI 10.1007/s002650050646	11	8	8	1	9	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA	1932-6203			PLOS ONE	PLoS One	NOV 10	2009	4	11							e7781	10.1371/journal.pone.0007781	http://dx.doi.org/10.1371/journal.pone.0007781			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	517ZU	19901986	Green Submitted, Green Published, gold			2022-12-25	WOS:000271658800016
J	Meyer, M; Rubsamen, D; Slany, R; Illmer, T; Stabla, K; Roth, P; Stiewe, T; Eilers, M; Neubauer, A				Meyer, Mona; Ruebsamen, Daniela; Slany, Robert; Illmer, Thomas; Stabla, Kathleen; Roth, Petra; Stiewe, Thorsten; Eilers, Martin; Neubauer, Andreas			Oncogenic RAS Enables DNA Damage- and p53-Dependent Differentiation of Acute Myeloid Leukemia Cells in Response to Chemotherapy	PLOS ONE			English	Article							HEMATOPOIETIC PROGENITOR CELLS; ACUTE-MYELOGENOUS-LEUKEMIA; WILD-TYPE P53; INDUCED SENESCENCE; IN-VIVO; K-RAS; ANTAGONIST NUTLIN-3; SOMATIC ACTIVATION; MUTATIONS; APOPTOSIS	Acute myeloid leukemia (AML) is a clonal disease originating from myeloid progenitor cells with a heterogeneous genetic background. High-dose cytarabine is used as the standard consolidation chemotherapy. Oncogenic RAS mutations are frequently observed in AML, and are associated with beneficial response to cytarabine. Why AML-patients with oncogenic RAS benefit most from high-dose cytarabine post-remission therapy is not well understood. Here we used bone marrow cells expressing a conditional MLL-ENL-ER oncogene to investigate the interaction of oncogenic RAS and chemotherapeutic agents. We show that oncogenic RAS synergizes with cytotoxic agents such as cytarabine in activation of DNA damage checkpoints, resulting in a p53-dependent genetic program that reduces clonogenicity and increases myeloid differentiation. Our data can explain the beneficial effects observed for AML patients with oncogenic RAS treated with higher dosages of cytarabine and suggest that induction of p53-dependent differentiation, e. g. by interfering with Mdm2-mediated degradation, may be a rational approach to increase cure rate in response to chemotherapy. The data also support the notion that the therapeutic success of cytotoxic drugs may depend on their ability to promote the differentiation of tumor-initiating cells.			Meyer, M (corresponding author), Univ Marburg, Klin Hamatol Onkol & Immunol, Marburg, Germany.	neubauer@mailer.uni-marburg.de		Eilers, Martin/0000-0002-0376-6533; Stiewe, Thorsten/0000-0003-0134-7826				Abulaiti A, 2006, CANCER RES, V66, P10505, DOI 10.1158/0008-5472.CAN-06-2351; Bacher U, 2006, BLOOD, V107, P3847, DOI 10.1182/blood-2005-08-3522; Barabe F, 2007, SCIENCE, V316, P600, DOI 10.1126/science.1139851; Bartkova J, 2005, NATURE, V434, P864, DOI 10.1038/nature03482; BOS JL, 1989, CANCER RES, V49, P4682; Braig M, 2005, NATURE, V436, P660, DOI 10.1038/nature03841; Braun BS, 2006, BLOOD, V108, P2041, DOI 10.1182/blood-2006-01-013490; Braun BS, 2004, P NATL ACAD SCI USA, V101, P597, DOI 10.1073/pnas.0307203101; Capizzi RL, 1996, INVEST NEW DRUG, V14, P249, DOI 10.1007/BF00194527; Chan IT, 2006, BLOOD, V108, P1708, DOI 10.1182/blood-2006-04-015040; Chan IT, 2004, J CLIN INVEST, V113, P528, DOI 10.1172/JCI200420476; COGHLAN DW, 1994, LEUKEMIA, V8, P1682; Collado M, 2005, NATURE, V436, P642, DOI 10.1038/436642a; Collado M, 2006, NAT REV CANCER, V6, P472, DOI 10.1038/nrc1884; Cozzio A, 2003, GENE DEV, V17, P3029, DOI 10.1101/gad.1143403; Darley RL, 1999, EXP HEMATOL, V27, P1599, DOI 10.1016/S0301-472X(99)00100-9; Di Micco R, 2006, NATURE, V444, P638, DOI 10.1038/nature05327; DIMRI GP, 1995, P NATL ACAD SCI USA, V92, P9363, DOI 10.1073/pnas.92.20.9363; Estey E, 2006, LANCET, V368, P1894, DOI 10.1016/S0140-6736(06)69780-8; Fikaris AJ, 2006, J BIOL CHEM, V281, P34759, DOI 10.1074/jbc.M606737200; Frohling S, 2005, J CLIN ONCOL, V23, P6285, DOI 10.1200/JCO.2005.05.010; GOTTLIEB E, 1994, EMBO J, V13, P1368, DOI 10.1002/j.1460-2075.1994.tb06390.x; Groth A, 2000, J BIOL CHEM, V275, P27473; Gu L, 2008, LEUKEMIA, V22, P730, DOI 10.1038/leu.2008.11; HAWLEY RG, 1995, ONCOGENE, V11, P1113; HIBI S, 1993, BLOOD, V81, P1841; HUANG CL, 1988, LEUKEMIA, V2, P518; Illmer T, 2005, CLIN CANCER RES, V11, P3217, DOI 10.1158/1078-0432.CCR-04-2232; Ivanova NB, 2002, SCIENCE, V298, P601, DOI 10.1126/science.1073823; Kamijo T, 1997, CELL, V91, P649, DOI 10.1016/S0092-8674(00)80452-3; Kojima K, 2005, BLOOD, V106, P3150, DOI 10.1182/blood-2005-02-0553; Kojima K, 2006, BLOOD, V108, P993, DOI 10.1182/blood-2005-12-5148; Komarov PG, 1999, SCIENCE, V285, P1733, DOI 10.1126/science.285.5434.1733; LARSEN J, 1992, ONCOGENE, V7, P1903; MacKenzie KL, 1999, BLOOD, V93, P2043, DOI 10.1182/blood.V93.6.2043.406k17_2043_2056; MAYER RJ, 1994, NEW ENGL J MED, V331, P896, DOI 10.1056/NEJM199410063311402; Michaloglou C, 2005, NATURE, V436, P720, DOI 10.1038/nature03890; NAGLER A, 1986, EXP HEMATOL, V14, P241; NEUBAUER A, 1994, BLOOD, V83, P1603; Neubauer A, 2008, J CLIN ONCOL, V26, P4603, DOI 10.1200/JCO.2007.14.0418; PAQUETTE RL, 1993, BLOOD, V82, P590, DOI 10.1182/blood.V82.2.590.bloodjournal822590; Parikh C, 2006, BLOOD, V108, P2349, DOI 10.1182/blood-2004-08-009498; Potenza N, 2005, EMBO REP, V6, P432, DOI 10.1038/sj.embor.7400397; RADICH JP, 1992, LEUKEMIA LYMPHOMA, V6, P325, DOI 10.3109/10428199209053564; Sarkaria JN, 1999, CANCER RES, V59, P4375; Schlenk RF, 2008, NEW ENGL J MED, V358, P1909, DOI 10.1056/NEJMoa074306; Schreiner S, 2001, CANCER RES, V61, P6480; Secchiero P, 2007, NEOPLASIA, V9, P853, DOI 10.1593/neo.07523; Serrano M, 1997, CELL, V88, P593, DOI 10.1016/S0092-8674(00)81902-9; Shen SW, 2004, EXP HEMATOL, V32, P852, DOI 10.1016/j.exphem.2004.06.001; Shen S, 2007, EXP HEMATOL, V35, P908, DOI 10.1016/j.exphem.2007.02.011; SHEN WPV, 1987, ONCOGENE, V1, P157; Subramanian A, 2005, P NATL ACAD SCI USA, V102, P15545, DOI 10.1073/pnas.0506580102; Tallman MS, 2005, BLOOD, V106, P1154, DOI 10.1182/blood-2005-01-0178; Vassilev LT, 2004, SCIENCE, V303, P844, DOI 10.1126/science.1092472; Wiederschain D, 2005, J BIOL CHEM, V280, P24315, DOI 10.1074/jbc.M412237200; WOLFEL T, 1995, SCIENCE, V269, P1281, DOI 10.1126/science.7652577; Zeisig BB, 2004, MOL CELL BIOL, V24, P617, DOI 10.1128/MCB.24.2.617-628.2004; Zeisig BB, 2003, ONCOGENE, V22, P1629, DOI 10.1038/sj.onc.1206104	59	25	25	1	5	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA	1932-6203			PLOS ONE	PLoS One	NOV 5	2009	4	11							e7768	10.1371/journal.pone.0007768	http://dx.doi.org/10.1371/journal.pone.0007768			14	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	515HI	19890398	Green Published, gold, Green Submitted			2022-12-25	WOS:000271459700020
J	Navarro, B; Pantaleo, V; Gisel, A; Moxon, S; Dalmay, T; Bisztray, G; Di Serio, F; Burgyan, J				Navarro, Beatriz; Pantaleo, Vitantonio; Gisel, Andreas; Moxon, Simon; Dalmay, Tamas; Bisztray, Gyoergy; Di Serio, Francesco; Burgyan, Jozsef			Deep Sequencing of Viroid-Derived Small RNAs from Grapevine Provides New Insights on the Role of RNA Silencing in Plant-Viroid Interaction	PLOS ONE			English	Article							SHORT INTERFERING RNAS; IN-VIVO; GENE; ARABIDOPSIS; REPLICATION; PATHWAY; GENOME; HOP; IDENTIFICATION; ACCUMULATION	Background: Viroids are circular, highly structured, non-protein-coding RNAs that, usurping cellular enzymes and escaping host defense mechanisms, are able to replicate and move through infected plants. Similarly to viruses, viroid infections are associated with the accumulation of viroid-derived 21-24 nt small RNAs (vd-sRNAs) with the typical features of the small interfering RNAs characteristic of RNA silencing, a sequence-specific mechanism involved in defense against invading nucleic acids and in regulation of gene expression in most eukaryotic organisms. Methodology/Principal Findings: To gain further insights on the genesis and possible role of vd-sRNAs in plant-viroid interaction, sRNAs isolated from Vitis vinifera infected by Hop stunt viroid (HSVd) and Grapevine yellow speckle viroid 1 (GYSVd1) were sequenced by the high-throughput platform Solexa-Illumina, and the vd-sRNAs were analyzed. The large majority of HSVd-and GYSVd1-sRNAs derived from a few specific regions (hotspots) of the genomic (+) and (2) viroid RNAs, with a prevalence of those from the (2) strands of both viroids. When grouped according to their sizes, vd-sRNAs always assumed a distribution with prominent 21-, 22- and 24-nt peaks, which, interestingly, mapped at the same hotspots. Conclusions/Significance: These findings show that different Dicer-like enzymes (DCLs) target viroid RNAs, preferentially accessing to the same viroid domains. Interestingly, our results also suggest that viroid RNAs may interact with host enzymes involved in the RNA-directed DNA methylation pathway, indicating more complex scenarios than previously thought for both vd-sRNAs genesis and possible interference with host gene expression.			Navarro, B (corresponding author), CNR, Ist Virol Vegetale, I-10126 Turin, Italy.	f.diserio@ba.ivv.cnr.it; J.burgyan@ivv.cnr.it	Navarro, Beatriz/B-9128-2015; Pantaleo, Vitantonio/C-9349-2012; Di Serio, Francesco/I-5191-2012; Dalmay, Tamas/E-1377-2011; Moxon, Simon/A-5385-2010; Pantaleo, Vitantonio/L-6543-2019; Gisel, Andreas/AAW-2335-2020; Burgyan, Jozsef/C-7511-2012	Navarro, Beatriz/0000-0001-8981-1018; Pantaleo, Vitantonio/0000-0001-6677-6504; Di Serio, Francesco/0000-0003-2822-704X; Dalmay, Tamas/0000-0003-1492-5429; Pantaleo, Vitantonio/0000-0001-6677-6504; Moxon, Simon/0000-0003-4644-1816; GISEL, ANDREAS/0000-0001-7218-9488				Adenot X, 2006, CURR BIOL, V16, P927, DOI 10.1016/j.cub.2006.03.035; Akbergenov R, 2006, NUCLEIC ACIDS RES, V34, P462, DOI 10.1093/nar/gkj447; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; Bernstein E, 2001, NATURE, V409, P363, DOI 10.1038/35053110; Blevins T, 2006, NUCLEIC ACIDS RES, V34, P6233, DOI 10.1093/nar/gkl886; Blevins T, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005932; BRANCH AD, 1988, P NATL ACAD SCI USA, V85, P9128, DOI 10.1073/pnas.85.23.9128; BRANCH AD, 1984, SCIENCE, V223, P450, DOI 10.1126/science.6197756; Brodersen P, 2008, SCIENCE, V320, P1185, DOI 10.1126/science.1159151; Carbonell A, 2008, VIROLOGY, V371, P44, DOI 10.1016/j.virol.2007.09.031; Dalmay T, 2000, CELL, V101, P543, DOI 10.1016/S0092-8674(00)80864-8; DAROS JA, 1994, P NATL ACAD SCI USA, V91, P12813, DOI 10.1073/pnas.91.26.12813; Daros JA, 2002, EMBO J, V21, P749, DOI 10.1093/emboj/21.4.749; Daros JA, 2006, EMBO REP, V7, P593, DOI 10.1038/sj.embor.7400706; Deleris A, 2006, SCIENCE, V313, P68, DOI 10.1126/science.1128214; Denti MA, 2004, PLANT J, V37, P762, DOI 10.1111/j.1365-313X.2004.02001.x; Di Serio F, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0007539; Diener TO, 2003, NAT REV MICROBIOL, V1, P75, DOI 10.1038/nrmicro736; Ding B, 1997, PLANT J, V12, P931, DOI 10.1046/j.1365-313X.1997.12040931.x; DING B, 2009, ANN REV PHYTOPATHOL; Ding B, 2007, MOL PLANT MICROBE IN, V20, P7, DOI 10.1094/MPMI-20-0007; Ding SW, 2007, CELL, V130, P413, DOI 10.1016/j.cell.2007.07.039; Donaire L, 2008, J VIROL, V82, P5167, DOI 10.1128/JVI.00272-08; Du QS, 2007, J VIROL, V81, P9142, DOI 10.1128/JVI.02885-06; Flores R, 2000, ADV VIRUS RES, V55, P271, DOI 10.1016/S0065-3527(00)55006-4; Flores R, 2005, ANNU REV PHYTOPATHOL, V43, P117, DOI 10.1146/annurev.phyto.43.040204.140243; Fusaro AF, 2006, EMBO REP, V7, P1168, DOI 10.1038/sj.embor.7400837; Gas ME, 2008, J VIROL, V82, P10321, DOI 10.1128/JVI.01229-08; Gas ME, 2007, PLOS PATHOG, V3, P1813, DOI 10.1371/journal.ppat.0030182; German MA, 2008, NAT BIOTECHNOL, V26, P941, DOI 10.1038/nbt1417; Gomez G, 2007, PLANT J, V51, P1041, DOI 10.1111/j.1365-313X.2007.03203.x; Gomez G, 2008, PLANT PHYSIOL, V148, P414, DOI 10.1104/pp.108.120808; Gomez G, 2009, TRENDS PLANT SCI, V14, P264, DOI 10.1016/j.tplants.2009.03.002; Haag JR, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0004110; Hammond SM, 2001, SCIENCE, V293, P1146, DOI 10.1126/science.1064023; Herr AJ, 2006, P NATL ACAD SCI USA, V103, P14994, DOI 10.1073/pnas.0606536103; Ho T, 2006, J VIROL METHODS, V136, P217, DOI 10.1016/j.jviromet.2006.05.016; Howell MD, 2007, PLANT CELL, V19, P926, DOI 10.1105/tpc.107.050062; HUTCHINS CJ, 1986, NUCLEIC ACIDS RES, V14, P3627, DOI 10.1093/nar/14.9.3627; Hutvagner G, 2008, NAT REV MOL CELL BIO, V9, P22, DOI 10.1038/nrm2321; Itaya A, 2001, MOL PLANT MICROBE IN, V14, P1332, DOI 10.1094/MPMI.2001.14.11.1332; Itaya A, 2007, J VIROL, V81, P2980, DOI 10.1128/JVI.02339-06; Jaillon O, 2007, NATURE, V449, P463, DOI 10.1038/nature06148; KEESE P, 1985, P NATL ACAD SCI USA, V82, P4582, DOI 10.1073/pnas.82.14.4582; Little A., 2003, Viroids, P195; Luo ZH, 2007, PLANT CELL, V19, P943, DOI 10.1105/tpc.106.045724; Machida S, 2007, J GEN VIROL, V88, P3452, DOI 10.1099/vir.0.83228-0; Margis R, 2006, FEBS LETT, V580, P2442, DOI 10.1016/j.febslet.2006.03.072; Markarian N, 2004, ARCH VIROL, V149, P397, DOI 10.1007/s00705-003-0215-5; Martin R, 2007, VIROLOGY, V367, P135, DOI 10.1016/j.virol.2007.05.011; Martinez de Alba AE, 2002, J VIROL, V76, P13094, DOI 10.1128/JVI.76.24.13094-13096.2002; Mi SJ, 2008, CELL, V133, P116, DOI 10.1016/j.cell.2008.02.034; Molnar A, 2005, J VIROL, V79, P7812, DOI 10.1128/JVI.79.12.7812-7818.2005; Navarro JA, 1999, VIROLOGY, V253, P77, DOI 10.1006/viro.1998.9497; Nykanen A, 2001, CELL, V107, P309, DOI 10.1016/S0092-8674(01)00547-5; Papaefthimiou I, 2001, NUCLEIC ACIDS RES, V29, P2395, DOI 10.1093/nar/29.11.2395; Pikaard CS, 2008, TRENDS PLANT SCI, V13, P390, DOI 10.1016/j.tplants.2008.04.008; PUCHTA H, 1988, NUCLEIC ACIDS RES, V16, P2730, DOI 10.1093/nar/16.6.2730; Qi XP, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0004971; Qi YJ, 2003, PLANT CELL, V15, P2566, DOI 10.1105/tpc.016576; Qu F, 2008, P NATL ACAD SCI USA, V105, P14732, DOI 10.1073/pnas.0805760105; Ramachandran V, 2008, SCIENCE, V321, P1490, DOI 10.1126/science.1163728; Ramachandran V, 2008, TRENDS PLANT SCI, V13, P368, DOI 10.1016/j.tplants.2008.03.008; Ruiz-Ferrer V, 2009, ANNU REV PLANT BIOL, V60, P485, DOI 10.1146/annurev.arplant.043008.092111; Sano T, 2001, VIRUS GENES, V22, P53, DOI 10.1023/A:1008182302704; Schwind N, 2009, MOL PLANT PATHOL, V10, P459, DOI [10.1111/J.1364-3703.2009.00546.X, 10.1111/j.1364-3703.2009.00546.x]; Sijen T, 2007, SCIENCE, V315, P244, DOI 10.1126/science.1136699; St-Pierre P, 2009, VIROLOGY, V383, P178, DOI 10.1016/j.virol.2008.11.008; Szittya G, 2002, PLANT CELL, V14, P359, DOI 10.1105/tpc.010366; Tabler M, 2004, TRENDS PLANT SCI, V9, P339, DOI 10.1016/j.tplants.2004.05.007; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; Turturo C, 2005, J GEN VIROL, V86, P217, DOI 10.1099/vir.0.80395-0; Vaucheret H, 2006, GENE DEV, V20, P759, DOI 10.1101/gad.1410506; Vaucheret H, 2008, TRENDS PLANT SCI, V13, P350, DOI 10.1016/j.tplants.2008.04.007; Velasco R, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0001326; Wah YFWC, 1997, J VIROL METHODS, V63, P57, DOI 10.1016/S0166-0934(96)02115-5; Wang MB, 2004, P NATL ACAD SCI USA, V101, P3275, DOI 10.1073/pnas.0400104101; Wassenegger M, 2006, TRENDS PLANT SCI, V11, P142, DOI 10.1016/j.tplants.2006.01.003; WASSENEGGER M, 1994, CELL, V76, P567, DOI 10.1016/0092-8674(94)90119-8; Xie ZX, 2004, PLOS BIOL, V2, P642, DOI 10.1371/journal.pbio.0020104; Zuker M, 2003, NUCLEIC ACIDS RES, V31, P3406, DOI 10.1093/nar/gkg595	81	96	104	0	29	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	NOV 5	2009	4	11							e7686	10.1371/journal.pone.0007686	http://dx.doi.org/10.1371/journal.pone.0007686			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	515HI	19890399	Green Published, gold, Green Submitted			2022-12-25	WOS:000271459700006
J	Lukens, JR; Dolina, JS; Kim, TS; Tacke, RS; Hahn, YS				Lukens, John R.; Dolina, Joseph S.; Kim, Taeg S.; Tacke, Robert S.; Hahn, Young S.			Liver Is Able to Activate Naive CD8(+) T Cells with Dysfunctional Anti-Viral Activity in the Murine System	PLOS ONE			English	Article							HEPATITIS-C-VIRUS; IMMUNE-RESPONSES; INFILTRATING LYMPHOCYTES; VIRAL-HEPATITIS; PD-1 EXPRESSION; DOWN-REGULATION; HCV INFECTION; CORE PROTEIN; ADENOVIRUS; TOLERANCE	The liver possesses distinct tolerogenic properties because of continuous exposure to bacterial constituents and nonpathogenic food antigen. The central immune mediators required for the generation of effective immune responses in the liver environment have not been fully elucidated. In this report, we demonstrate that the liver can indeed support effector CD8(+) T cells during adenovirus infection when the T cells are primed in secondary lymphoid tissues. In contrast, when viral antigen is delivered predominantly to the liver via intravenous (IV) adenovirus infection, intrahepatic CD8(+) T cells are significantly impaired in their ability to produce inflammatory cytokines and lyse target cells. Additionally, intrahepatic CD8(+) T cells generated during IV adenovirus infection express elevated levels of PD-1. Notably, lower doses of adenovirus infection do not rescue the impaired effector function of intrahepatic CD8(+) T cell responses. Instead, intrahepatic antigen recognition limits the generation of potent anti-viral responses at both priming and effector stages of the CD8(+) T cell response and accounts for the dysfunctional CD8+ T cell response observed during IV adenovirus infection. These results also implicate that manipulation of antigen delivery will facilitate the design of improved vaccination strategies to persistent viral infection.			Lukens, JR (corresponding author), Univ Virginia, Dept Microbiol, Beirne Carter Ctr Immunol Res, Charlottesville, VA 22908 USA.	ysh5e@virginia.edu		Dolina, Joseph/0000-0002-4602-8194; Lukens, John/0000-0002-6795-0866	NIAID NIH HHS [U19AI083024, U19 AI083024, 5T32AI10749608.] Funding Source: Medline; NIDDK NIH HHS [R01 DK063222, DK063222, P30 DK067629] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [U19AI083024] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK067629, R01DK063222] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Ajuebor MN, 2006, J IMMUNOL, V177, P2039, DOI 10.4049/jimmunol.177.4.2039; Belz GT, 1998, P NATL ACAD SCI USA, V95, P13812, DOI 10.1073/pnas.95.23.13812; Bertolino P, 2001, J IMMUNOL, V166, P5430, DOI 10.4049/jimmunol.166.9.5430; Bowen DG, 2004, J CLIN INVEST, V114, P701, DOI 10.1172/JCI200421593; Cai ZL, 1997, J EXP MED, V185, P641, DOI 10.1084/jem.185.4.641; CALNE R, 1994, LANCET, V343, P67, DOI 10.1016/S0140-6736(94)90809-5; CALNE RY, 1969, NATURE, V223, P472, DOI 10.1038/223472a0; Chisari FV, 1997, J CLIN INVEST, V99, P1472, DOI 10.1172/JCI119308; Crispe IN, 2003, NAT REV IMMUNOL, V3, P51, DOI 10.1038/nri981; Demotte N, 2008, IMMUNITY, V28, P414, DOI 10.1016/j.immuni.2008.01.011; FLEISCHER B, 1990, IMMUNOLOGY, V69, P14; Gehring AJ, 2007, J VIROL, V81, P2940, DOI 10.1128/JVI.02415-06; Golden-Mason L, 2007, J VIROL, V81, P9249, DOI 10.1128/JVI.00409-07; Grayson JM, 2006, J VIROL, V80, P8627, DOI 10.1128/JVI.00855-06; Holz LE, 2008, GASTROENTEROLOGY, V135, P989, DOI 10.1053/j.gastro.2008.05.078; HUANG L, 1994, INT IMMUNOL, V6, P533, DOI 10.1093/intimm/6.4.533; Isogawa M, 2005, IMMUNITY, V23, P53, DOI 10.1016/j.immuni.2005.05.005; Kalyuzhniy O, 2008, P NATL ACAD SCI USA, V105, P5483, DOI 10.1073/pnas.0711757105; Keating R, 2007, J IMMUNOL, V178, P2737, DOI 10.4049/jimmunol.178.5.2737; Kittlesen DJ, 2000, J CLIN INVEST, V106, P1239, DOI 10.1172/JCI10323; Klein I, 2006, J EXP MED, V203, P437, DOI 10.1084/jem.20051775; Krebs P, 2005, J IMMUNOL, V174, P4559, DOI 10.4049/jimmunol.174.8.4559; Large MK, 1999, J IMMUNOL, V162, P931; Lawrence CW, 2004, J IMMUNOL, V173, P1209, DOI 10.4049/jimmunol.173.2.1209; Lechner F, 2000, J EXP MED, V191, P1499, DOI 10.1084/jem.191.9.1499; Lukens JR, 2008, J IMMUNOL, V180, P4875, DOI 10.4049/jimmunol.180.7.4875; Maier H, 2007, J IMMUNOL, V178, P2714, DOI 10.4049/jimmunol.178.5.2714; Masopust D, 2001, SCIENCE, V291, P2413, DOI 10.1126/science.1058867; Mehal WZ, 1999, J IMMUNOL, V163, P3202; MIZUHARA H, 1994, J EXP MED, V179, P1529, DOI 10.1084/jem.179.5.1529; Nakamoto N, 2009, PLOS PATHOG, V5, DOI 10.1371/journal.ppat.1000313; Ocana-Morgner C, 2003, J EXP MED, V197, P143, DOI 10.1084/jem.20021072; Peters MG, 2002, IMMUNOL CELL BIOL, V80, P113, DOI 10.1046/j.0818-9641.2001.01059.x; Polakos NK, 2007, J IMMUNOL, V179, P201, DOI 10.4049/jimmunol.179.1.201; Radziewicz H, 2008, J VIROL, V82, P9808, DOI 10.1128/JVI.01075-08; RASMUSSEN A, 1995, TRANSPLANTATION, V59, P919, DOI 10.1097/00007890-199503270-00025; SCHOFIELD L, 1987, NATURE, V330, P664, DOI 10.1038/330664a0; Sharpe AH, 2007, NAT IMMUNOL, V8, P239, DOI 10.1038/ni1443; Shayakhmetov DM, 2005, J VIROL, V79, P7478, DOI 10.1128/JVI.79.12.7478-7491.2005; Shayakhmetov DM, 2004, J VIROL, V78, P5368, DOI 10.1128/JVI.78.10.5368-5381.2004; Spangenberg HC, 2005, HEPATOLOGY, V42, P828, DOI 10.1002/hep.20856; Stone D, 2007, J VIROL, V81, P4866, DOI 10.1128/JVI.02819-06; Takaki A, 2000, NAT MED, V6, P578, DOI 10.1038/75063; Urban BC, 2003, J EXP MED, V197, P137, DOI 10.1084/jem.20022003; Urbani S, 2006, J VIROL, V80, P11398, DOI 10.1128/JVI.01177-06; van Faassen H, 2004, J IMMUNOL, V172, P3491, DOI 10.4049/jimmunol.172.6.3491; Wack A, 1997, EUR J IMMUNOL, V27, P577, DOI 10.1002/eji.1830270302; Wherry EJ, 2003, J VIROL, V77, P4911, DOI 10.1128/JVI.77.8.4911-4927.2003; Willberg C, 2003, CELL DEATH DIFFER, V10, pS39, DOI 10.1038/sj.cdd.4401122; Wuensch SA, 2006, J IMMUNOL, V177, P1689, DOI 10.4049/jimmunol.177.3.1689; Xiao ZG, 2007, J EXP MED, V204, P2667, DOI 10.1084/jem.20062376	51	12	12	0	0	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	OCT 30	2009	4	10							e7619	10.1371/journal.pone.0007619	http://dx.doi.org/10.1371/journal.pone.0007619			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	514RW	19876399	Green Published, Green Submitted, gold			2022-12-25	WOS:000271414300005
J	Abdo, H; Derkinderen, P; Gomes, P; Chevalier, J; Aubert, P; Masson, D; Galmiche, JP; Vanden Berghe, P; Neunlist, M; Lardeux, B				Abdo, Hind; Derkinderen, Pascal; Gomes, Priya; Chevalier, Julien; Aubert, Philippe; Masson, Damien; Galmiche, Jean-Paul; Vanden Berghe, Pieter; Neunlist, Michel; Lardeux, Bernard			Enteric glial cells protect neurons from oxidative stress in part via reduced glutathione	FASEB JOURNAL			English	Article						enteric nervous system; neuronal death; neuroprotection; active caspase 3	SLOW-TRANSIT CONSTIPATION; ADULT TRANSGENIC MICE; NERVOUS-SYSTEM; MYENTERIC NEURONS; ASTROCYTES; EXPRESSION; SURVIVAL; ABLATION; DISEASE; NEUROPATHOLOGY	Enteric glial cells (EGCs) are essential in the control of gastrointestinal functions. Although lesions of EGCs are associated with neuronal degeneration in animal models, their direct neuroprotective role remains unknown. Therefore, the aims of this study were to demonstrate the direct neuroprotective effects of EGCs and to identify putative glial mediators involved. First, viral targeted ablation of EGCs in primary cultures of enteric nervous system increased neuronal death both under basal conditions and in the presence of oxidative stress (dopamine, hydrogen peroxide). Second, direct or indirect coculture experiments of EGC lines with primary cultures of enteric nervous system or neuroblastoma cell lines (SH-SY5Y) prevented neurotoxic effects induced by oxidative stress (increased membrane permeability, release of neuronal specific enolase, caspase-3 immunoreactivity, changes in [Ca(2+)](i) response). Finally, combining pharmacological inhibition and mRNA silencing methods, we demonstrated that neuroprotective effects of EGCs were mediated in part by reduced glutathione but not by oxidized glutathione or by S-nitrosoglutathione. Our study identified the neuroprotective effects of EGCs via their release of reduced glutathione, extending their critical role in physiological contexts and in enteric neuropathies.-Abdo, H., Derkinderen, P., Gomes, P., Chevalier, J., Aubert, P., Masson, D., Galmiche, J.-P., Vanden Berghe, P., Neunlist, M., Lardeux, B. Enteric glial cells protect neurons from oxidative stress in part via reduced glutathione. FASEB J. 24, 1082-1094 (2010). www.fasebj.org	[Abdo, Hind; Derkinderen, Pascal; Chevalier, Julien; Aubert, Philippe; Masson, Damien; Galmiche, Jean-Paul; Neunlist, Michel; Lardeux, Bernard] INSERM, U913, F-44093 Nantes, France; [Abdo, Hind; Derkinderen, Pascal; Chevalier, Julien; Aubert, Philippe; Masson, Damien; Galmiche, Jean-Paul; Neunlist, Michel; Lardeux, Bernard] Univ Nantes, Fac Med, Nantes, France; [Abdo, Hind; Derkinderen, Pascal; Gomes, Priya; Chevalier, Julien; Aubert, Philippe; Masson, Damien; Galmiche, Jean-Paul; Neunlist, Michel; Lardeux, Bernard] CHU Nantes, Inst Malad Appareil Digestif, F-44035 Nantes 01, France; [Derkinderen, Pascal; Neunlist, Michel] CHU Nantes, Serv Neurol, F-44035 Nantes 01, France; [Gomes, Priya; Vanden Berghe, Pieter] Katholieke Univ Leuven, Ctr Gastroenterol Res, Leuven, Belgium	Institut National de la Sante et de la Recherche Medicale (Inserm); Nantes Universite; Nantes Universite; CHU de Nantes; Nantes Universite; CHU de Nantes; KU Leuven	Lardeux, B (corresponding author), INSERM, U913, 1 Pl Alexis Ricordeau, F-44093 Nantes, France.	bernard.lardeux@univ-nantes.fr	Neunlist, Michel/K-2388-2015; Chevalier, Julien/K-2345-2015; Derkinderen, Pascal/K-2393-2015; Aubert, Philippe/K-2352-2015; Masson, Damien/K-2730-2015	Chevalier, Julien/0000-0002-7484-1457; Aubert, Philippe/0000-0001-7471-7694; Aubert, Philippe/0000-0002-3126-6202; Abdo, Hind/0000-0002-6910-9165; Vanden Berghe, Pieter/0000-0002-0009-2094	Centre National de la Recherche Scientifique (CNRS)	Centre National de la Recherche Scientifique (CNRS)(Centre National de la Recherche Scientifique (CNRS))	H. A. was supported by a grant from Inserm Pays de la Loire and SanTDige Foundation. M.N. and P.D. were supported by a contrat d'interface Inserm. B.L. is funded by the Centre National de la Recherche Scientifique (CNRS).	Anitha M, 2006, J CLIN INVEST, V116, P344, DOI 10.1172/JCI26295; Anitha M, 2006, GASTROENTEROLOGY, V131, P1164, DOI 10.1053/j.gastro.2006.07.019; Arthur JR, 2000, CELL MOL LIFE SCI, V57, P1825; Aube AC, 2006, GUT, V55, P630, DOI 10.1136/gut.2005.067595; Bassotti G, 2006, GUT, V55, P41, DOI 10.1136/gut.2005.073197; Bassotti G, 2005, J CLIN PATHOL, V58, P973, DOI 10.1136/jcp.2005.026112; Bassotti G, 2007, LAB INVEST, V87, P628, DOI 10.1038/labinvest.3700564; Bassotti G, 2006, HUM PATHOL, V37, P1252, DOI 10.1016/j.humpath.2006.04.027; Benarroch EE, 2007, NEUROLOGY, V69, P1953, DOI 10.1212/01.wnl.0000281999.56102.b5; Boulos S, 2006, BRAIN RES, V1102, P27, DOI 10.1016/j.brainres.2006.04.089; Bush TG, 1999, NEURON, V23, P297, DOI 10.1016/S0896-6273(00)80781-3; Bush TG, 1998, CELL, V93, P189, DOI 10.1016/S0092-8674(00)81571-8; Chevalier J, 2008, J PHYSIOL-LONDON, V586, P1963, DOI 10.1113/jphysiol.2007.149815; Cornet A, 2001, P NATL ACAD SCI USA, V98, P13306, DOI 10.1073/pnas.231474098; Cui W, 2001, GLIA, V34, P272, DOI 10.1002/glia.1061; Desagher S, 1996, J NEUROSCI, V16, P2553; Diaz-Hernandez JI, 2005, J BIOL CHEM, V280, P38992, DOI 10.1074/jbc.M507065200; FERRI GL, 1982, NATURE, V297, P409, DOI 10.1038/297409a0; FRANK KB, 1984, J BIOL CHEM, V259, P1566; GABELLA G, 1981, NEUROSCIENCE, V6, P425, DOI 10.1016/0306-4522(81)90135-4; Gomes P, 2009, NEUROGASTROENT MOTIL, V21, P870, DOI 10.1111/j.1365-2982.2009.01302.x; Gulbransen BD, 2009, GASTROENTEROLOGY, V136, P1349, DOI 10.1053/j.gastro.2008.12.058; HEYMAN RA, 1989, P NATL ACAD SCI USA, V86, P2698, DOI 10.1073/pnas.86.8.2698; JESSEN KR, 1980, NATURE, V286, P736, DOI 10.1038/286736a0; Koch TR, 1997, NEUROSCI LETT, V235, P77, DOI 10.1016/S0304-3940(97)00726-X; Moriez R, 2009, BIOCHEM BIOPH RES CO, V382, P577, DOI 10.1016/j.bbrc.2009.03.073; Neunlist M, 2008, J INTERN MED, V263, P577, DOI 10.1111/j.1365-2796.2008.01963.x; Neunlist M, 2007, AM J PHYSIOL-GASTR L, V292, pG231, DOI 10.1152/ajpgi.00276.2005; Neunlist M, 2003, GUT, V52, P84, DOI 10.1136/gut.52.1.84; Ruhl A, 2001, NEUROGASTROENT MOTIL, V13, P95, DOI 10.1046/j.1365-2982.2001.00246.x; Savidge TC, 2007, LAB INVEST, V87, P731, DOI 10.1038/labinvest.3700600; Savidge TC, 2007, GASTROENTEROLOGY, V132, P1344, DOI 10.1053/j.gastro.2007.01.051; Schemann M, 2004, NEUROGASTROENT MOTIL, V16, P55, DOI 10.1111/j.1743-3150.2004.00476.x; Schulz JB, 2000, EUR J BIOCHEM, V267, P4904, DOI 10.1046/j.1432-1327.2000.01595.x; Selgrad M, 2009, GUT, V58, P25, DOI 10.1136/gut.2008.152512; Shih AY, 2005, J NEUROSCI, V25, P10321, DOI 10.1523/JNEUROSCI.4014-05.2005; Shih AY, 2003, J NEUROSCI, V23, P3394, DOI 10.1523/jneurosci.23-08-03394.2003; von Boyen GBT, 2006, J NEUROENDOCRINOL, V18, P820, DOI 10.1111/j.1365-2826.2006.01478.x; Yang XG, 2000, BBA-GEN SUBJECTS, V1474, P390, DOI 10.1016/S0304-4165(00)00035-0; Zandecki M, 2006, NEUROGASTROENT MOTIL, V18, P307, DOI 10.1111/j.1365-2982.2005.00755.x	40	74	74	0	14	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	APR	2010	24	4					1082	1094		10.1096/fj.09-139519	http://dx.doi.org/10.1096/fj.09-139519			13	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	580PV	19906678	Bronze			2022-12-25	WOS:000276462300016
J	Venturini, C; Beatson, SA; Djordjevic, SP; Walker, MJ				Venturini, Carola; Beatson, Scott A.; Djordjevic, Steven P.; Walker, Mark J.			Multiple antibiotic resistance gene recruitment onto the enterohemorrhagic Escherichia coli virulence plasmid	FASEB JOURNAL			English	Article						EHEC; enterohemolysin; Tn21	ANTIMICROBIAL RESISTANCE; STRAINS; REGION; SIMILARITY; INTEGRONS; ANIMALS; SITE; IDENTIFICATION; VISUALIZATION; TRANSPOSON	Enterohemorrhagic Escherichia coli (EHEC) strains are zoonotic pathogens responsible for a range of severe human disease. The repertoire of virulence determinants promoting EHEC disease is encoded on both the main chromosome and virulence plasmid. We examined a multiply antibiotic-resistant O26 EHEC strain for carriage of resistance genes on the virulence plasmid. The EHEC virulence plasmid containing a complex antibiotic-resistance gene locus, designated as pO26-CRL, was purified from EHEC O26:H- (patient with hemorrhagic colitis) and subjected to shotgun-sequencing and bioinformatic analysis. Determination of the 111,481-bp sequence of pO26-CRL revealed genes encoding a functional enterohemolysin operon (ehxCABD), STEC-specific extracellular serine protease (espP), putative EHEC adhesin (toxB), catalase/peroxidase (katP), and myristoyl transferase (msbB) involved in lipid A synthesis. A 22,609-bp Tn21 derivative is inserted within the conjugal transfer gene traC and encodes resistance to trimethoprim, streptomycin, sulfathiozole, kanamycin, neomycin, beta-lactams, and mercuric chloride. Plasmid pO26-CRL is nonconjugative but is mobilizable. This is the first report of an EHEC virulence plasmid containing a complex antibiotic resistance locus, and raises the concern that antibiotic use will coselect for virulence determinants, leading to increased disease potential in both commensal and pathogenic E. coli populations.-Venturini, C., Beatson, S. A., Djordjevic, S. P., Walker, M. J. Multiple antibiotic resistance gene recruitment onto the enterohemorrhagic Escherichia coli virulence plasmid. FASEB J. 24, 1160-1166 (2010). www.fasebj.org	[Venturini, Carola; Walker, Mark J.] Univ Wollongong, Sch Biol Sci, Wollongong, NSW 2522, Australia; [Beatson, Scott A.; Walker, Mark J.] Univ Queensland, Sch Chem & Mol Biosci, Brisbane, Qld, Australia; [Djordjevic, Steven P.] NSW Dept Primary Ind, Menangle, NSW, Australia; [Djordjevic, Steven P.] Univ Technol Sydney, Inst Biotechnol Infect Dis, Sydney, NSW 2007, Australia	University of Wollongong; University of Queensland; NSW Department of Primary Industries; University of Technology Sydney	Walker, MJ (corresponding author), Univ Wollongong, Sch Biol Sci, Wollongong, NSW 2522, Australia.	mwalker@uow.edu.au	Djordjevic, Steven/A-2024-2013; Venturini, Carola/G-6642-2018; Walker, Mark J./F-6940-2011; Beatson, Scott/B-6985-2013; djordjevic, steven/GNP-4000-2022	Djordjevic, Steven/0000-0001-9301-5372; Venturini, Carola/0000-0003-2370-8661; Beatson, Scott/0000-0002-1806-3283; djordjevic, steven/0000-0001-9301-5372; Walker, Mark/0000-0001-7423-2769	Australian Research Council (ARC) [LP0348851]; ARC Australian Research Fellowship [DP0881247]; New South Wales (NSW) Department of Primary Industries; University of Wollongong; Australian Genome Research Foundation	Australian Research Council (ARC)(Australian Research Council); ARC Australian Research Fellowship(Australian Research Council); New South Wales (NSW) Department of Primary Industries; University of Wollongong; Australian Genome Research Foundation	The authors acknowledge the financial support of the Australian Research Council (ARC) for provision of a Ph.D.scholarship (C.V.) and research support provided through the ARC Linkage system (LP0348851).S.A.B.is supported by an ARC Australian Research Fellowship (DP0881247).The authors also acknowledge the financial support of the New South Wales (NSW) Department of Primary Industries (S.P.D.) and the University of Wollongong (M.J.W.).The authors thank Dr.Karl Bettelheim [Microbiological Diagnostic Unit (MDU), University of Melbourne, Melbourne, VIC, Australia], for the provision of E.coli strain O6877.The MDU is supported by the Victorian Department of Human Services.The authors acknowledge the technical support provided by the Australian Genome Research Foundation and by Linda Falconer (NSW Department of Primary Industries).The authors also thank Lowan Turton for photographic images.	Aldick T, 2007, MICROBES INFECT, V9, P282, DOI 10.1016/j.micinf.2006.12.001; Appleman SS, 2009, CLIN PEDIATR, V48, P99, DOI 10.1177/0009922808321901; Arias CA, 2009, NEW ENGL J MED, V360, P439, DOI 10.1056/NEJMp0804651; Bettelheim KA, 2003, J MED MICROBIOL, V52, P155, DOI 10.1099/jmm.0.04903-0; Beutin L, 2004, J CLIN MICROBIOL, V42, P1099, DOI 10.1128/JCM.42.3.1099-1108.2004; Bielaszewska M, 2005, J CLIN MICROBIOL, V43, P4225, DOI 10.1128/JCM.43.8.4225-4228.2005; Brunder W, 1996, MICROBIOL-SGM, V142, P3305, DOI 10.1099/13500872-142-11-3305; Brunder W, 1997, MOL MICROBIOL, V24, P767, DOI 10.1046/j.1365-2958.1997.3871751.x; Carattoli A, 2009, ANTIMICROB AGENTS CH, V53, P2227, DOI 10.1128/AAC.01707-08; Carver TJ, 2005, BIOINFORMATICS, V21, P3422, DOI 10.1093/bioinformatics/bti553; d'Hauteville H, 2002, J IMMUNOL, V168, P5240, DOI 10.4049/jimmunol.168.10.5240; Djafari S, 1997, MOL MICROBIOL, V25, P771, DOI 10.1046/j.1365-2958.1997.5141874.x; *EASAC REP, 2007, TACKL ANT RES EUR; Fey PD, 2000, NEW ENGL J MED, V342, P1242, DOI 10.1056/NEJM200004273421703; FURUYA N, 1991, J BACTERIOL, V173, P6612, DOI 10.1128/jb.173.20.6612-6617.1991; Guerra B, 2006, J ANTIMICROB CHEMOTH, V57, P1210, DOI 10.1093/jac/dkl127; HALL RM, 1995, MOL MICROBIOL, V15, P593, DOI 10.1111/j.1365-2958.1995.tb02368.x; Jenkins C, 2008, J APPL MICROBIOL, V104, P14, DOI 10.1111/j.1365-2672.2007.03465.x; KARCH H, 1987, INFECT IMMUN, V55, P455, DOI 10.1128/IAI.55.2.455-461.1987; KEEN NT, 1988, GENE, V70, P191, DOI 10.1016/0378-1119(88)90117-5; Kim SH, 2004, INFECT IMMUN, V72, P1174, DOI 10.1128/IAI.72.2.1174-1180.2004; KIM SR, 1993, J BACTERIOL, V175, P5035, DOI 10.1128/JB.175.16.5035-5042.1993; Levings RS, 2008, ANTIMICROB AGENTS CH, V52, P2529, DOI 10.1128/AAC.00189-08; Leyton DL, 2003, INFECT IMMUN, V71, P6307, DOI 10.1128/IAI.71.11.6307-6319.2003; Liebert CA, 1999, MICROBIOL MOL BIOL R, V63, P507, DOI 10.1128/MMBR.63.3.507-522.1999; Maidhof H, 2002, APPL ENVIRON MICROB, V68, P5834, DOI 10.1128/AEM.68.12.5834-5842.2002; Makino K, 1998, DNA Res, V5, P1, DOI 10.1093/dnares/5.1.1; Martinez JL, 2002, CLIN MICROBIOL REV, V15, P647, DOI 10.1128/CMR.15.4.647-679.2002; Miriagou V, 2005, ANTIMICROB AGENTS CH, V49, P3541, DOI 10.1128/AAC.49.8.3541-3543.2005; Newton HJ, 2009, EMERG INFECT DIS, V15, P372, DOI [10.3201/eid1502.080631, 10.3201/eid1503.080631]; Partridge SR, 2004, ANTIMICROB AGENTS CH, V48, P4250, DOI 10.1128/AAC.48.11.4250-4255.2004; Paton AW, 1998, J CLIN MICROBIOL, V36, P598, DOI 10.1128/JCM.36.2.598-602.1998; Rutherford K, 2000, BIOINFORMATICS, V16, P944, DOI 10.1093/bioinformatics/16.10.944; Sambrook J., 1989, MOL CLONING LAB MANU, V2; Schluter A, 2003, MICROBIOL-SGM, V149, P3139, DOI 10.1099/mic.0.26570-0; Schroeder CM, 2002, EMERG INFECT DIS, V8, P1409, DOI 10.3201/eid0812.0200770; Sherley M, 2004, MICROBIOL-SGM, V150, P1539, DOI 10.1099/mic.0.26773-0; Singer RS, 2003, LANCET INFECT DIS, V3, P47, DOI 10.1016/S1473-3099(03)00490-0; Singh R, 2005, J ANTIMICROB CHEMOTH, V56, P216, DOI 10.1093/jac/dki161; Sota M, 2007, J BACTERIOL, V189, P3091, DOI 10.1128/JB.01906-06; STOKES HW, 1989, MOL MICROBIOL, V3, P1669, DOI 10.1111/j.1365-2958.1989.tb00153.x; Stothard P, 2005, BIOINFORMATICS, V21, P537, DOI 10.1093/bioinformatics/bti054; Szczepanowski R, 2005, MICROBIOL-SGM, V151, P1095, DOI 10.1099/mic.0.27773-0; Tarr PI, 2005, LANCET, V365, P1073, DOI 10.1016/S0140-6736(05)71144-2; Tatsuno I, 2001, INFECT IMMUN, V69, P6660, DOI 10.1128/IAI.69.11.6660-6669.2001; Torres AG, 2005, INFECT IMMUN, V73, P18, DOI 10.1128/IAI.73.1.18-29.2005; Toukdarian A, 2004, PLASMID BIOLOGY, P259; Tozzi AE, 2003, EMERG INFECT DIS, V9, P106, DOI 10.3201/eid0901.020266; Tozzoli R, 2005, J CLIN MICROBIOL, V43, P4052, DOI 10.1128/JCM.43.8.4052-4056.2005; WALKER MJ, 1987, ARCH MICROBIOL, V146, P390, DOI 10.1007/BF00410941	50	62	64	1	22	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	APR	2010	24	4					1160	1166		10.1096/fj.09-144972	http://dx.doi.org/10.1096/fj.09-144972			7	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	580PV	19917674				2022-12-25	WOS:000276462300023
J	Wang, AX; Alimova, IN; Luo, PH; Jong, A; Triche, TJ; Wu, LT				Wang, Anxun; Alimova, Irina N.; Luo, Peihua; Jong, Ambrose; Triche, Timothy J.; Wu, Lingtao			Loss of CAK phosphorylation of RAR alpha mediates transcriptional control of retinoid-induced cancer cell differentiation	FASEB JOURNAL			English	Article						decreased CAK activity by RA; cell cycle G(1) exit; gene transcription; transcriptional repression	CDK-ACTIVATING KINASE; F9 CELLS; GRANULOCYTIC DIFFERENTIATION; SUBSTRATE-SPECIFICITY; MYELOID-LEUKEMIA; ACID RECEPTORS; G(1) ARREST; BINDING; EXPRESSION; TFIIH	Although the role of the classic retinoic acid (RA)-induced genomic pathway in cancer cell differentiation is well recognized, the underlying mechanisms remain to be dissected. Retinoic acid receptor alpha (RAR alpha) is a transcription factor activated by RA, and its serine 77 (RAR alpha S77) is the main residue phosphorylated by the cyclin-dependent kinase (CDK)-activating kinase (CAK) complex. We report here that in both human myeloid leukemia and mouse embryonic teratocarcinoma stem cells, either RA-suppressed CAK phosphorylation of RAR alpha or mutation of RAR alpha S77 to alanine (RAR alpha S77A)coordinates CAK-dependent G(1) arrest with cancer cell differentiation by transactivating RA-target genes. Both hypophosphorylated RAR alpha and RAR alpha S77A reduce binding to retinoic acid-responsive elements (RARE) in the promoters of RA-target genes while stimulating gene transcription. The enhanced transactivation and reduced RAR alpha-chromatin interaction are accompanied by RAR alpha dissociation from the transcriptional repressor N-CoR and are association with the coactivator NCoA-3. Such effects of decreased CAK phosphorylation of RAR alpha S77 on mediating RA-dependent transcriptional control of cancer cell differentiation are examined correspondingly in both RA-resistant myeloid leukemia and embryonic teratocarcinoma stem RAR alpha(-/-) cells. These studies demonstrate, for the first time, that RA couples G(1) arrest to transcriptional control of cancer cell differentiation by suppressing CAK phosphorylation of RAR alpha to release transcriptional repression.-Wang, A., Alimova, I. N., Luo, P. Jong, A., Triche, T. J., Wu, L. Loss of CAK phosphorylation of RAR alpha mediates transcriptional control of retinoid-induced cancer cell differentiation. FASEB J. 24, 833-843 (2010). www.fasebj.org	[Wu, Lingtao] Univ So Calif, Dept Pathol, Childrens Hosp Los Angeles, Keck Sch Med,Saban Res Inst, Los Angeles, CA 90027 USA; [Jong, Ambrose] Childrens Hosp Los Angeles, Saban Res Inst, Div Hematol & Oncol, Los Angeles, CA 90027 USA; [Jong, Ambrose; Triche, Timothy J.; Wu, Lingtao] Univ So Calif, Keck Sch Med, Los Angeles, CA 90027 USA	Children's Hospital Los Angeles; University of Southern California; Children's Hospital Los Angeles; University of Southern California	Wu, LT (corresponding author), Univ So Calif, Dept Pathol, Childrens Hosp Los Angeles, Keck Sch Med,Saban Res Inst, MS 103,4650 Sunset Blvd, Los Angeles, CA 90027 USA.	lingtaow@usc.edu			National Institutes of Health [R21 CA111440, R01 CA120512]; NATIONAL CANCER INSTITUTE [R21CA111440, R01CA120512] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	The authors thank Dr. Lorraine J. Gudas (Cornell University, Ithaca, NY, USA) for providing F9 RAR alpha<SUP>-/-</SUP> cells; and Dr. J. Song (University of California, Los Angeles, CA, USA) for providing beta RARE-TK-Luc plasmids. The authors acknowledge the Vector Core at Childrens Hospital Los Angeles (CHLA) and Roger Hollis for technical expertise in lentiviral-vector production. The authors thank Dr. Srinivas Somanchi for technical expertise in constructing lentiviral vector. This work was supported by grants from the National Institutes of Health (R21 CA111440 and R01 CA120512 to L. W.).	Arimura A, 2004, J BIOL CHEM, V279, P31105, DOI 10.1074/jbc.M404428200; Bastien J, 2004, GENE, V328, P1, DOI 10.1016/j.gene.2003.12.005; BOYLAN JF, 1991, J CELL BIOL, V112, P965, DOI 10.1083/jcb.112.5.965; Bruck N, 2009, EMBO J, V28, P34, DOI 10.1038/emboj.2008.256; Chambon P, 1996, FASEB J, V10, P940, DOI 10.1096/fasebj.10.9.8801176; Chambon Pierre, 1994, Seminars in Cell Biology, V5, P115, DOI 10.1006/scel.1994.1015; COLLINS SJ, 1990, MOL CELL BIOL, V10, P2154, DOI 10.1128/MCB.10.5.2154; Crowe David L, 2002, Cancer Cell Int, V2, P15, DOI 10.1186/1475-2867-2-15; DETHE H, 1990, NATURE, V343, P177, DOI 10.1038/343177a0; Epping MT, 2005, CELL, V122, P835, DOI 10.1016/j.cell.2005.07.003; FEAVER WJ, 1994, CELL, V79, P1103, DOI 10.1016/0092-8674(94)90040-X; FISHER RP, 1994, CELL, V78, P713, DOI 10.1016/0092-8674(94)90535-5; He QJ, 2004, FASEB J, V18, P1734, DOI 10.1096/fj.04-2182fje; Hoeijmakers JHJ, 1996, CURR OPIN GENET DEV, V6, P26, DOI 10.1016/S0959-437X(96)90006-4; Keriel A, 2002, CELL, V109, P125, DOI 10.1016/S0092-8674(02)00692-X; Kinjo K, 2004, EXP HEMATOL, V32, P45, DOI 10.1016/j.exphem.2003.10.009; Kopf E, 2000, J BIOL CHEM, V275, P33280, DOI 10.1074/jbc.M002840200; Lamkin TJ, 2006, AM J HEMATOL, V81, P603, DOI 10.1002/ajh.20667; Larochelle S, 2001, EMBO J, V20, P3749, DOI 10.1093/emboj/20.14.3749; LEID M, 1992, TRENDS BIOCHEM SCI, V17, P427, DOI 10.1016/0968-0004(92)90014-Z; Liao YP, 2004, J CELL SCI, V117, P2917, DOI 10.1242/jcs.01153; Losel RM, 2003, PHYSIOL REV, V83, P965, DOI 10.1152/physrev.00003.2003; Luo PH, 2007, STEM CELLS, V25, P2628, DOI 10.1634/stemcells.2007-0264; MANGELSDORF DJ, 1995, CELL, V83, P841, DOI 10.1016/0092-8674(95)90200-7; Montagne M, 2008, J MOL BIOL, V376, P141, DOI 10.1016/j.jmb.2007.11.062; Nigg EA, 1996, CURR OPIN CELL BIOL, V8, P312, DOI 10.1016/S0955-0674(96)80003-2; Park EJ, 1999, P NATL ACAD SCI USA, V96, P3519, DOI 10.1073/pnas.96.7.3519; ROBERTSON KA, 1992, BLOOD, V80, P1885; Rochette-Egly C, 2000, MOL ENDOCRINOL, V14, P1398, DOI 10.1210/me.14.9.1398; Rochette-Egly C, 2001, HISTOL HISTOPATHOL, V16, P909, DOI 10.14670/HH-16.909; RochetteEgly C, 1997, CELL, V90, P97, DOI 10.1016/S0092-8674(00)80317-7; Rosenauer A, 1996, BLOOD, V88, P2671, DOI 10.1182/blood.V88.7.2671.bloodjournal8872671; Rossignol M, 1997, EMBO J, V16, P1628, DOI 10.1093/emboj/16.7.1628; Scita G, 1996, J BIOL CHEM, V271, P6502, DOI 10.1074/jbc.271.11.6502; SOLTER D, 1978, P NATL ACAD SCI USA, V75, P5565, DOI 10.1073/pnas.75.11.5565; Song J, 2004, J BIOL CHEM, V279, P24414, DOI 10.1074/jbc.M311406200; Soprano DR, 2004, ANNU REV NUTR, V24, P201, DOI 10.1146/annurev.nutr.24.012003.132407; SPEAR BT, 1995, SOMAT CELL MOLEC GEN, V21, P19, DOI 10.1007/BF02255819; STRICKLAND S, 1978, CELL, V15, P393, DOI 10.1016/0092-8674(78)90008-9; Studzinski GP, 1999, INT REV CYTOL, V189, P1, DOI 10.1016/S0074-7696(08)61384-4; SUCOV HM, 1990, P NATL ACAD SCI USA, V87, P5392, DOI 10.1073/pnas.87.14.5392; Taneja R, 1997, EMBO J, V16, P6452, DOI 10.1093/emboj/16.21.6452; TASSAN JP, 1995, EMBO J, V14, P5608, DOI 10.1002/j.1460-2075.1995.tb00248.x; Wang JG, 2006, FASEB J, V20, P2142, DOI 10.1096/fj.06-5900fje; Wang JW, 2002, J BIOL CHEM, V277, P43369, DOI 10.1074/jbc.M206792200; Wang JX, 1998, P NATL ACAD SCI USA, V95, P10860, DOI 10.1073/pnas.95.18.10860; WEILERGUETTLER H, 1992, P NATL ACAD SCI USA, V89, P2155, DOI 10.1073/pnas.89.6.2155; Wu LT, 2001, MOL CELL BIOL, V21, P260, DOI 10.1128/MCB.21.1.260-270.2001; WU LT, 1994, ONCOGENE, V9, P2089; Yankulov KY, 1997, EMBO J, V16, P1638, DOI 10.1093/emboj/16.7.1638; Zanotto A, 2008, TOXICOL IN VITRO, V22, P1205, DOI 10.1016/j.tiv.2008.04.001; Zhang SN, 2004, CANCER RES, V64, P2977, DOI 10.1158/0008-5472.CAN-03-4018; ZHANG XK, 1992, NATURE, V358, P587, DOI 10.1038/358587a0; Zhu J, 1999, P NATL ACAD SCI USA, V96, P14807, DOI 10.1073/pnas.96.26.14807; Zhu L, 2001, CURR OPIN GENET DEV, V11, P91, DOI 10.1016/S0959-437X(00)00162-3	55	21	23	0	6	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAR	2010	24	3					833	843		10.1096/fj.09-142976	http://dx.doi.org/10.1096/fj.09-142976			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	561KE	19917671	Green Published			2022-12-25	WOS:000274974600019
J	Hsu, STD; Blaser, G; Behrens, C; Cabrita, LD; Dobson, CM; Jackson, SE				Hsu, Shang-Te Danny; Blaser, Georg; Behrens, Caroline; Cabrita, Lisa D.; Dobson, Christopher M.; Jackson, Sophie E.			Folding Study of Venus Reveals a Strong Ion Dependence of Its Yellow Fluorescence under Mildly Acidic Conditions	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SINGLE-MOLECULE FLUORESCENCE; BOUND NASCENT CHAIN; CRYSTAL-STRUCTURE; NMR-SPECTROSCOPY; FUSION PROTEIN; LIVING CELLS; GFP; DYNAMICS; COMPLEMENTATION; VISUALIZATION	Venus is a yellow fluorescent protein that has been developed for its fast chromophore maturation rate and bright yellow fluorescence that is relatively insensitive to changes in pH and ion concentrations. Here, we present a detailed study of the stability and folding of Venus in the pH range from 6.0 to 8.0 using chemical denaturants and a variety of spectroscopic probes. By following hydrogen-deuterium exchange of N-15-labeled Venus using NMR spectroscopy over 13 months, residue-specific free energies of unfolding of some highly protected amide groups have been determined. Exchange rates of less than one per year are observed for some amide groups. A super-stable core is identified for Venus and compared with that previously reported for green fluorescent protein. These results are discussed in terms of the stability and folding of fluorescent proteins. Under mildly acidic conditions, we show that Venus undergoes a drastic decrease in yellow fluorescence at relatively low concentrations of guanidinium chloride. A detailed study of this effect establishes that it is due to pH-dependent, nonspecific interactions of ions with the protein. In contrast to previous studies on enhanced green fluorescence protein variant S65T/T203Y, which showed a specific halide ion-binding site, NMR chemical shift mapping shows no evidence for specific ion binding. Instead, chemical shift perturbations are observed for many residues primarily located in both lids of the beta-barrel structure, which suggests that small scale structural rearrangements occur on increasing ionic strength under mildly acidic conditions and that these are propagated to the chromophore resulting in fluorescence quenching.	[Hsu, Shang-Te Danny; Blaser, Georg; Behrens, Caroline; Cabrita, Lisa D.; Dobson, Christopher M.; Jackson, Sophie E.] Univ Cambridge, Dept Chem, Cambridge CB2 1EW, England	University of Cambridge	Hsu, STD (corresponding author), Univ Cambridge, Dept Chem, Lensfield Rd, Cambridge CB2 1EW, England.	stdh2@cam.ac.uk; sej13@cam.ac.uk	Hsu, Shang-Te Danny/B-2324-2009; Hsu, Shang-Te Danny/L-2826-2014	Hsu, Shang-Te Danny/0000-0002-7231-0185; Cabrita, Lisa/0000-0003-2963-8078	EC [RII3-026145]; Human Frontier Science Program Long Term Fellowship [LT0798/2005]; National Science Council of the Republic of China, Taiwan [NSC97-2917-1-564-102]; Studienstiftung des Deutschen Volkes scholarship; National Health and Medical Research Council C. J. Martin Fellow; Leverhulme Trust; Biotechnology and Biological Sciences Research Council [BBF00219X1]; BBSRC [BB/F00219X/1] Funding Source: UKRI; Biotechnology and Biological Sciences Research Council [BB/F00219X/1] Funding Source: researchfish	EC(European CommissionEuropean Commission Joint Research Centre); Human Frontier Science Program Long Term Fellowship(Human Frontier Science Program); National Science Council of the Republic of China, Taiwan(Ministry of Science and Technology, Taiwan); Studienstiftung des Deutschen Volkes scholarship; National Health and Medical Research Council C. J. Martin Fellow(National Health and Medical Research Council (NHMRC) of Australia); Leverhulme Trust(Leverhulme Trust); Biotechnology and Biological Sciences Research Council(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC)); BBSRC(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC)); Biotechnology and Biological Sciences Research Council(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC))	This work was supported in part by Access to Research Infrastructures Activity in the 6th Framework Program of the EC Contract RII3-026145, EU-NMR.; Recipient of Human Frontier Science Program Long Term Fellowship LT0798/2005 and supported by the Postdoctoral Research Abroad Program of National Science Council of the Republic of China, Taiwan, Grant NSC97-2917-1-564-102. To whom correspondence may be addressed. E-mail: stdh2@cam.ac.uk.; Recipient of a Studienstiftung des Deutschen Volkes scholarship and supported by the Erasmus/Sokrates Program.; National Health and Medical Research Council C. J. Martin Fellow.; Supported by The Leverhulme Trust.; Supported by Biotechnology and Biological Sciences Research Council Grant BBF00219X1. To whom correspondence may be addressed. E-mail: sej13@cam.ac.uk.	Andrews BT, 2008, P NATL ACAD SCI USA, V105, P12283, DOI 10.1073/pnas.0804039105; Andrews BT, 2007, J MOL BIOL, V373, P476, DOI 10.1016/j.jmb.2007.07.071; Arosio D, 2007, BIOPHYS J, V93, P232, DOI 10.1529/biophysj.106.102319; Cai L, 2006, NATURE, V440, P358, DOI 10.1038/nature04599; Chang HC, 2005, J MOL BIOL, V353, P397, DOI 10.1016/j.jmb.2005.08.052; Chirico G, 2006, EUR BIOPHYS J BIOPHY, V35, P663, DOI 10.1007/s00249-006-0075-5; CUBITT AB, 1995, TRENDS BIOCHEM SCI, V20, P448, DOI 10.1016/S0968-0004(00)89099-4; Elsliger MA, 1999, BIOCHEMISTRY-US, V38, P5296, DOI 10.1021/bi9902182; Englander SW, 2007, Q REV BIOPHYS, V40, P287, DOI 10.1017/S0033583508004654; Enoki S, 2004, BIOCHEMISTRY-US, V43, P14238, DOI 10.1021/bi048733+; Enoki S, 2006, J MOL BIOL, V361, P969, DOI 10.1016/j.jmb.2006.07.009; Fukuda H, 2000, BIOCHEMISTRY-US, V39, P12025, DOI 10.1021/bi000543l; Galietta LJV, 2001, FEBS LETT, V499, P220, DOI 10.1016/S0014-5793(01)02561-3; Giepmans BNG, 2006, SCIENCE, V312, P217, DOI 10.1126/science.1124618; Goddard T.D., 2008, SPARKY NMR ASSIGNMEN; Helms V, 1999, J PHYS CHEM B, V103, P3263, DOI 10.1021/jp983120q; Hsu STD, 2007, P NATL ACAD SCI USA, V104, P16516, DOI 10.1073/pnas.0704664104; Hsu STD, 2009, J AM CHEM SOC, V131, P8366, DOI 10.1021/ja902778n; Hsu STD, 2009, BIOMOL NMR ASSIGN, V3, P67, DOI 10.1007/s12104-009-9143-y; Huang JR, 2007, J MOL BIOL, V370, P356, DOI 10.1016/j.jmb.2007.04.039; Huang JR, 2008, HFSP J, V2, P378, DOI 10.2976/1.2976660; Huang YM, 2009, BIOCHEMISTRY-US, V48, P929, DOI 10.1021/bi802027g; Jackson SE, 2006, EXPERT REV PROTEOMIC, V3, P545, DOI 10.1586/14789450.3.5.545; Jayaraman S, 2000, J BIOL CHEM, V275, P6047, DOI 10.1074/jbc.275.9.6047; Karasawa A, 2005, J BIOL CHEM, V280, P41900, DOI 10.1074/jbc.M510795200; Kerppola TK, 2006, NAT REV MOL CELL BIO, V7, P449, DOI 10.1038/nrm1929; Khan F, 2006, J AM CHEM SOC, V128, P10729, DOI 10.1021/ja060618u; Kneen M, 1998, BIOPHYS J, V74, P1591, DOI 10.1016/S0006-3495(98)77870-1; Lawrence MS, 2007, J AM CHEM SOC, V129, P10110, DOI 10.1021/ja071641y; Li CJ, 1999, J CELL SCI, V112, P1567; Mickler M, 2007, P NATL ACAD SCI USA, V104, P20268, DOI 10.1073/pnas.0705458104; Millington M, 2007, BIOPHYS CHEM, V127, P155, DOI 10.1016/j.bpc.2007.01.008; Nagai T, 2002, NAT BIOTECHNOL, V20, P87, DOI 10.1038/nbt0102-87; Nagai T, 2004, P NATL ACAD SCI USA, V101, P10554, DOI 10.1073/pnas.0400417101; Ormo M, 1996, SCIENCE, V273, P1392, DOI 10.1126/science.273.5280.1392; Orte A, 2008, J AM CHEM SOC, V130, P7898, DOI 10.1021/ja709973m; Ottmann C, 2009, BIOL CHEM, V390, P81, DOI 10.1515/BC.2009.008; Pedelacq JD, 2006, NAT BIOTECHNOL, V24, P79, DOI 10.1038/nbt1172; Reid BG, 1997, BIOCHEMISTRY-US, V36, P6786, DOI 10.1021/bi970281w; Rekas A, 2002, J BIOL CHEM, V277, P50573, DOI 10.1074/jbc.M209524200; Rucker E, 2001, PROTEIN EXPRES PURIF, V21, P220, DOI 10.1006/prep.2000.1373; Seifert MH, 2002, J AM CHEM SOC, V124, P7932, DOI 10.1021/ja0257725; Seifert MHJ, 2003, BIOCHEMISTRY-US, V42, P2500, DOI 10.1021/bi026481b; Shaner NC, 2007, J CELL SCI, V120, P4247, DOI 10.1242/jcs.005801; Shyu YJ, 2008, P NATL ACAD SCI USA, V105, P151, DOI 10.1073/pnas.0705181105; Stepanenko OV, 2004, BIOCHEMISTRY-US, V43, P14913, DOI 10.1021/bi048725t; Tsien RY, 1998, ANNU REV BIOCHEM, V67, P509, DOI 10.1146/annurev.biochem.67.1.509; VanEngelenburg SB, 2008, CURR OPIN CHEM BIOL, V12, P60, DOI 10.1016/j.cbpa.2008.01.020; Wachter RM, 2000, J MOL BIOL, V301, P157, DOI 10.1006/jmbi.2000.3905; Wang HY, 2003, P NATL ACAD SCI USA, V100, P478, DOI 10.1073/pnas.0236088100; Xie JB, 2008, BIOCHEMISTRY-US, V47, P348, DOI 10.1021/bi7011838; Yen HCS, 2008, SCIENCE, V322, P918, DOI 10.1126/science.1160489; Zacharias DA, 2002, SCIENCE, V296, P913, DOI 10.1126/science.1068539; Zapata-Hommer O, 2003, BMC BIOTECHNOL, V3, DOI 10.1186/1472-6750-3-5	54	18	19	1	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 12	2010	285	7					4859	4869		10.1074/jbc.M109.000695	http://dx.doi.org/10.1074/jbc.M109.000695			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	565FN	19901033	Green Published, hybrid			2022-12-25	WOS:000275274800064
J	Fischer, M; Bauer, T; Oberthur, A; Hero, B; Theissen, J; Ehrich, M; Spitz, R; Eils, R; Westermann, F; Brors, B; Konig, R; Berthold, F				Fischer, M.; Bauer, T.; Oberthuer, A.; Hero, B.; Theissen, J.; Ehrich, M.; Spitz, R.; Eils, R.; Westermann, F.; Brors, B.; Koenig, R.; Berthold, F.			Integrated genomic profiling identifies two distinct molecular subtypes with divergent outcome in neuroblastoma with loss of chromosome 11q	ONCOGENE			English	Article						neuroblastoma; integrative genomics; loss of 11q; gene expression; outcome; cancer	DNA COPY NUMBER; HIGH-RESOLUTION ANALYSIS; GENE-EXPRESSION; MICROARRAY ANALYSIS; 4S NEUROBLASTOMA; CANDIDATE GENES; RISK; PROGRESSION; DELETIONS; TUMORS	Imbalances in chromosome 11q occur in approximately 30% of primary neuroblastoma and are associated with poor outcome. It has been suggested that 11q loss constitutes a distinct clinico-genetic neuroblastoma subgroup by affecting expression levels of corresponding genes. This study analysed the relationship of 11q loss, clinical phenotype and global transcriptomic profiles in four clinico-genetic subgroups (11q alteration/favourable outcome, n = 7; 11q alteration/unfavourable outcome, n 14; no 11q alteration/favourable outcome, n 81; no 11q alteration/unfavourable outcome, n 8; tumours with MYCN amplification and/or 1p loss were excluded). Unsupervised and supervised comparisons of gene expression profiles consistently showed significantly different mRNA patterns between favourable and unfavourable neuroblastomas, both in the subgroups with and without 11q loss. In contrast, favourable tumours with and without 11q loss showed highly similar transcriptomic profiles. Disproportionate downregulation of 11q genes was observed only in unfavourable tumours with 11q loss. The diverging molecular profiles were neither caused by considerable differences in the size of the deleted regions nor by differential methylation patterns of 11q genes. Together, this study shows that neuroblastoma with 11q loss comprises two biological subgroups that differ both in their clinical phenotype and gene expression patterns, indicating that 11q loss is not a primary determinant of neuroblastoma tumour behaviour. Oncogene (2010) 29, 865-875; doi:10.1038/onc.2009.390; published online 9 November 2009	[Fischer, M.; Oberthuer, A.; Hero, B.; Theissen, J.; Spitz, R.; Berthold, F.] Univ Childrens Hosp, Dept Paediat Oncol, D-50924 Cologne, NRW, Germany; [Fischer, M.; Oberthuer, A.; Hero, B.; Theissen, J.; Spitz, R.; Berthold, F.] CMMC, Cologne, Germany; [Bauer, T.; Eils, R.; Koenig, R.] Inst Pharm & Mol Biotechnol, Dept Bioinformat & Funct Genom, Heidelberg, Germany; [Bauer, T.; Eils, R.; Brors, B.; Koenig, R.] German Canc Res Ctr, Dept Theoret Bioinformat, Heidelberg, Germany; [Ehrich, M.] SEQUENOM Inc, San Diego, CA USA; [Westermann, F.] German Canc Res Ctr, Dept Tumourbiol, Heidelberg, Germany	University of Cologne; University of Hamburg; University Medical Center Hamburg-Eppendorf; University of Cologne; Ruprecht Karls University Heidelberg; Helmholtz Association; German Cancer Research Center (DKFZ); Sequenom; Helmholtz Association; German Cancer Research Center (DKFZ)	Fischer, M (corresponding author), Univ Childrens Hosp, Dept Paediat Oncol, Kerpener St 62, D-50924 Cologne, NRW, Germany.	matthias.fischer@uk-koeln.de	Westermann, Frank/F-7509-2013; Eils, Roland/B-6121-2009; Brors, Benedikt/E-5620-2013	Eils, Roland/0000-0002-0034-4036; Brors, Benedikt/0000-0001-5940-3101; Bauer, Tobias/0000-0002-4961-3639	Deutsche Krebshilfe [50-2719]; Bundesministerium fur Bildung und Forschung (BMBF) through the National Genome Research Network 2 (NGFN2) [01GS0456, 01GR0450]; Competence Network Paediatric Oncology and Hematology (KPOH); Fordergesellschaft Kinderkrebs-Neuroblastom-Forschung e.V.	Deutsche Krebshilfe(Deutsche Krebshilfe); Bundesministerium fur Bildung und Forschung (BMBF) through the National Genome Research Network 2 (NGFN2)(Federal Ministry of Education & Research (BMBF)); Competence Network Paediatric Oncology and Hematology (KPOH); Fordergesellschaft Kinderkrebs-Neuroblastom-Forschung e.V.	We are grateful to Yvonne Kahlert for excellent technical assistance and to Dr Roman Thomas for critical reading of the paper. This work was supported by grants from the Deutsche Krebshilfe (Grant 50-2719), the Bundesministerium fur Bildung und Forschung (BMBF) through the National Genome Research Network 2 (NGFN2, Grants 01GS0456 and 01GR0450) and the Competence Network Paediatric Oncology and Hematology (KPOH) as well as the Fordergesellschaft Kinderkrebs-Neuroblastom-Forschung e.V.	Alaminos M, 2003, CANCER RES, V63, P4538; Ambros PF, 2001, MED PEDIATR ONCOL, V37, P492, DOI 10.1002/mpo.1242; Asgharzadeh S, 2006, JNCI-J NATL CANCER I, V98, P1193, DOI 10.1093/jnci/djj330; Attiyeh EF, 2005, NEW ENGL J MED, V353, P2243, DOI 10.1056/NEJMoa052399; Berwanger B, 2002, CANCER CELL, V2, P377, DOI 10.1016/S1535-6108(02)00179-4; Bilke S, 2005, J CLIN ONCOL, V23, P7322, DOI 10.1200/JCO.2005.03.2821; Boon K, 2001, EMBO J, V20, P1383, DOI 10.1093/emboj/20.6.1383; Brodeur GM, 2003, NAT REV CANCER, V3, P203, DOI 10.1038/nrc1014; Chen W, 2007, GENE CHROMOSOME CANC, V46, P288, DOI 10.1002/gcc.20411; Classen S, 2007, J IMMUNOL, V178, P6931, DOI 10.4049/jimmunol.178.11.6931; Cohn SL, 2009, J CLIN ONCOL, V27, P289, DOI 10.1200/JCO.2008.16.6785; Ehrich M, 2005, P NATL ACAD SCI USA, V102, P15785, DOI 10.1073/pnas.0507816102; Fischer M, 2008, KLIN PADIATR, V220, P137, DOI 10.1055/s-2008-1065345; Fischer M, 2006, CLIN CANCER RES, V12, P5118, DOI 10.1158/1078-0432.CCR-06-0985; Henrich KO, 2006, CLIN CANCER RES, V12, P131, DOI 10.1158/1078-0432.CCR-05-1431; Huang J, 2006, FEBS LETT, V580, P3571, DOI 10.1016/j.febslet.2006.05.032; Janoueix-Lerosey I, 2009, J CLIN ONCOL, V27, P1026, DOI 10.1200/JCO.2008.16.0630; Lastowska M, 2007, ONCOGENE, V26, P7432, DOI 10.1038/sj.onc.1210552; Maris JM, 2007, LANCET, V369, P2106, DOI 10.1016/S0140-6736(07)60983-0; McArdle L, 2004, CARCINOGENESIS, V25, P1599, DOI 10.1093/carcin/bgh173; Mosse YP, 2008, NATURE, V455, P930, DOI 10.1038/nature07261; Mosse YP, 2007, GENE CHROMOSOME CANC, V46, P936, DOI 10.1002/gcc.20477; Nigro JM, 2005, CANCER RES, V65, P1678, DOI 10.1158/0008-5472.CAN-04-2921; Oberthuer A, 2008, CLIN CANCER RES, V14, P6590, DOI 10.1158/1078-0432.CCR-07-4377; Oberthuer A, 2006, J CLIN ONCOL, V24, P5070, DOI 10.1200/JCO.2006.06.1879; Ohira M, 2005, CANCER CELL, V7, P337, DOI 10.1016/j.ccr.2005.03.019; Platzer P, 2002, CANCER RES, V62, P1134; Pollack JR, 2002, P NATL ACAD SCI USA, V99, P12963, DOI 10.1073/pnas.162471999; Potter N, 2008, NEOPLASIA, V10, P757, DOI 10.1593/neo.07914; Ruiz MIG, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0001722; Savelyeva L, 2001, CANCER LETT, V167, P115, DOI 10.1016/S0304-3835(01)00472-4; Spitz R, 2006, CLIN CANCER RES, V12, P3368, DOI 10.1158/1078-0432.CCR-05-2495; Spitz R, 2003, CLIN CANCER RES, V9, P52; Spitz R, 2006, GENE CHROMOSOME CANC, V45, P1130, DOI 10.1002/gcc.20376; Stallings RL, 2007, CYTOGENET GENOME RES, V118, P110, DOI 10.1159/000108291; Stallings RL, 2006, CANCER RES, V66, P3673, DOI 10.1158/0008-5472.CAN-05-4154; Tusher VG, 2001, P NATL ACAD SCI USA, V98, P5116, DOI 10.1073/pnas.091062498; Wang Q, 2006, CANCER RES, V66, P6050, DOI 10.1158/0008-5472.CAN-05-4618; Westermann F, 2008, GENOME BIOL, V9, DOI 10.1186/gb-2008-9-10-r150; Yoshimoto T, 2007, J PATHOL, V213, P392, DOI 10.1002/path.2239	40	25	26	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	FEB 11	2010	29	6					865	875		10.1038/onc.2009.390	http://dx.doi.org/10.1038/onc.2009.390			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	553WP	19901960				2022-12-25	WOS:000274397800009
J	Markova, B; Albers, C; Breitenbuecher, F; Melo, JV; Brummendorf, TH; Heidel, F; Lipka, D; Duyster, J; Huber, C; Fischer, T				Markova, B.; Albers, C.; Breitenbuecher, F.; Melo, J. V.; Bruemmendorf, T. H.; Heidel, F.; Lipka, D.; Duyster, J.; Huber, C.; Fischer, T.			Novel pathway in Bcr-Abl signal transduction involves Akt-independent, PLC-gamma 1-driven activation of mTOR/p70S6-kinase pathway	ONCOGENE			English	Article						Bcr-Abl; CML; PLC-gamma 1; signaling; mTOR; p70S6-kinase	PHOSPHOLIPASE-C-GAMMA; CHRONIC MYELOGENOUS LEUKEMIA; CHRONIC MYELOID-LEUKEMIA; RIBOSOMAL-PROTEIN S6; MAMMALIAN TARGET; TYROSINE KINASE; POSITIVE CELLS; PHOSPHATIDYLINOSITOL-3 KINASE; HEMATOPOIETIC-CELLS; IMATINIB MESYLATE	In chronic myeloid leukemia, activation of the phosphoinositide 3-kinase (PI3K)/Akt pathway is crucial for survival and proliferation of leukemic cells. Essential downstream molecules involve mammalian target of rapamycin (mTOR) and S6-kinase. Here, we present a comprehensive analysis of the molecular events involved in activation of these key signaling pathways. We provide evidence for a previously unrecognized phospholipase C-gamma 1 (PLC-gamma 1)-controlled mechanism of mTOR/p70S6-kinase activation, which operates in parallel to the classical Akt-dependent machinery. Short-term imatinib treatment of Bcr-Abl-positive cells caused dephosphorylation of p70S6K and S6-protein without inactivation of Akt. Suppression of Akt activity alone did not affect phosphorylation of p70-S6K and S6. These results suggested the existence of an alternative mechanism for mTOR/p70S6-K activation. In Bcr-Abl-expressing cells, we detected strong PLC-gamma 1 activation, which was suppressed by imatinib. Pharmacological inhibition and siRNA knockdown of PLC-gamma 1 blocked p70S6-K and S6 phosphorylation. By inhibiting the Ca-signaling, CaMK and PKCs we demonstrated participation of these molecules in the pathway. Suppression of PLC-gamma 1 led to inhibition of cell proliferation and enhanced apoptosis. The novel pathway proved to be essential for survival and proliferation of leukemic cells and almost complete cell death was observed upon combined PLC-gamma 1 and Bcr-Abl inhibition. The pivotal role of PLC-gamma 1 was further confirmed in a mouse leukemogenesis model. Oncogene (2010) 29, 739-751; doi: 10.1038/onc.2009.374; published online 2 November 2009	[Heidel, F.; Lipka, D.; Fischer, T.] Otto von Guericke Univ, Dept Hematol Oncol, Med Ctr, Magdeburg, Germany; [Markova, B.; Breitenbuecher, F.] Univ Hosp, W German Canc Ctr, Dept Med Canc Res, Essen, Germany; [Albers, C.; Duyster, J.] Tech Univ Munich, Dept Internal Med 3, Munich, Germany; [Melo, J. V.] Inst Med & Vet Sci, Dept Haematol, Adelaide, SA 5000, Australia; [Bruemmendorf, T. H.] UCCH, Dept Oncol & Hematol, Hamburg, Germany; [Markova, B.; Breitenbuecher, F.; Heidel, F.; Lipka, D.; Huber, C.; Fischer, T.] Johannes Gutenberg Univ Mainz, Dept Med 3, Mainz, Germany	Otto von Guericke University; University of Duisburg Essen; Technical University of Munich; University of Munich; Institute Medical & Veterinary Science Australia; University of Hamburg; University Medical Center Hamburg-Eppendorf; Johannes Gutenberg University of Mainz	Fischer, T (corresponding author), Univ Magdeburg, Dept Hematol Oncol, Univ Med Ctr, Leipziger Str 44, D-39120 Magdeburg, Saxony Anhalt, Germany.	thomas.fischer@med.ovgu.de		Heidel, Florian/0000-0003-2438-1955				Arvisais EW, 2006, J BIOL CHEM, V281, P26904, DOI 10.1074/jbc.M605371200; Bartolovic K, 2004, BLOOD, V103, P523, DOI 10.1182/blood-2003-05-1535; Brunn GJ, 1996, EMBO J, V15, P5256, DOI 10.1002/j.1460-2075.1996.tb00911.x; Burchert A, 2005, LEUKEMIA, V19, P1774, DOI 10.1038/sj.leu.2403898; Copland M, 2008, BLOOD, V111, P2843, DOI 10.1182/blood-2007-09-112573; Dengler J, 2005, LEUKEMIA, V19, P1835, DOI 10.1038/sj.leu.2403848; DRUKER BJ, 2001, NEW ENGL J MED, V344, P1037; Easton JB, 2006, ONCOGENE, V25, P6436, DOI 10.1038/sj.onc.1209886; Edinger AL, 2002, MOL BIOL CELL, V13, P2276, DOI 10.1091/mbc.01-12-0584; Falasca M, 1998, EMBO J, V17, P414, DOI 10.1093/emboj/17.2.414; Giles FJ, 2005, CURR MOL MED, V5, P653, DOI 10.2174/156652405774641034; GOTOH A, 1994, LEUKEMIA, V8, P115; Grandage VL, 2005, LEUKEMIA, V19, P586, DOI 10.1038/sj.leu.2403653; Hay N, 2004, GENE DEV, V18, P1926, DOI 10.1101/gad.1212704; Heidel F, 2006, BLOOD, V107, P293, DOI 10.1182/blood-2005-06-2469; Kharas NG, 2005, CANCER RES, V65, P2047, DOI 10.1158/0008-5472.CAN-04-3888; KIM HK, 1991, CELL, V65, P435, DOI 10.1016/0092-8674(91)90461-7; KIM JW, 1990, J BIOL CHEM, V265, P3940; Kindler T, 2003, LEUKEMIA, V17, P999, DOI 10.1038/sj.leu.2402940; KONOPKA JB, 1985, P NATL ACAD SCI USA, V82, P1810, DOI 10.1073/pnas.82.6.1810; Liao HJ, 2002, J BIOL CHEM, V277, P9335, DOI 10.1074/jbc.M109955200; Ly C, 2003, CANCER RES, V63, P5716; Maffucci T, 2007, BIOCHEM SOC T, V35, P229, DOI 10.1042/BST0350229; Mahon FX, 2000, BLOOD, V96, P1070, DOI 10.1182/blood.V96.3.1070.015k17_1070_1079; Marley SB, 2005, CLIN SCI, V109, P13, DOI 10.1042/CS20040336; MARTE BM, 1994, CELL GROWTH DIFFER, V5, P239; Miething C, 2006, LEUKEMIA, V20, P650, DOI 10.1038/sj.leu.2404151; Mohi MG, 2004, P NATL ACAD SCI USA, V101, P3130, DOI 10.1073/pnas.0400063101; Rameh LE, 1998, J BIOL CHEM, V273, P23750, DOI 10.1074/jbc.273.37.23750; Ren R, 2005, NAT REV CANCER, V5, P172, DOI 10.1038/nrc1567; Ren SY, 2005, EXP HEMATOL, V33, P1222, DOI 10.1016/j.exphem.2005.06.030; RHEE S, 2000, BIOL PHOSPHOINOSITID, V27; Rhee SG, 2001, ANNU REV BIOCHEM, V70, P281, DOI 10.1146/annurev.biochem.70.1.281; Richardson CJ, 2004, SEMIN CELL DEV BIOL, V15, P147, DOI 10.1016/j.semcdb.2003.12.023; Saglio G, 2004, CELL MOL LIFE SCI, V61, P2897, DOI 10.1007/s00018-004-4271-0; Sarbassov DD, 2005, CURR OPIN CELL BIOL, V17, P596, DOI 10.1016/j.ceb.2005.09.009; Shaw RJ, 2006, NATURE, V441, P424, DOI 10.1038/nature04869; Si JT, 2008, CANCER RES, V68, P3733, DOI 10.1158/0008-5472.CAN-07-2509; SKORSKI T, 1995, BLOOD, V86, P726, DOI 10.1182/blood.V86.2.726.bloodjournal862726; Skorski T, 1997, EMBO J, V16, P6151, DOI 10.1093/emboj/16.20.6151; Van Etten RA, 2002, ONCOGENE, V21, P8643, DOI 10.1038/sj.onc.1206091; Walz C, 2006, CRIT REV ONCOL HEMAT, V57, P145, DOI 10.1016/j.critrevonc.2005.06.007; Wilde JI, 2001, CELL SIGNAL, V13, P691, DOI 10.1016/S0898-6568(01)00191-7; Wing LYC, 2005, J BIOL CHEM, V280, P19937, DOI 10.1074/jbc.M411865200; Wlodarski P, 2005, CANCER RES, V65, P7800, DOI 10.1158/0008-5472.CAN-04-4180; Wullschleger S, 2006, CELL, V124, P471, DOI 10.1016/j.cell.2006.01.016	46	45	46	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 4	2010	29	5					739	751		10.1038/onc.2009.374	http://dx.doi.org/10.1038/onc.2009.374			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	551QI	19881535				2022-12-25	WOS:000274223700010
J	Lendrihas, T; Hunter, GA; Ferreira, GC				Lendrihas, Thomas; Hunter, Gregory A.; Ferreira, Gloria C.			Serine 254 Enhances an Induced Fit Mechanism in Murine 5-Aminolevulinate Synthase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MITOCHONDRIAL ASPARTATE-AMINOTRANSFERASE; HEME-BIOSYNTHESIS; ESCHERICHIA-COLI; HYDROGEN-BONDS; SWISS-MODEL; ENZYMES; ACID; STATE; DERIVATIVES; ENVIRONMENT	5-Aminolevulinate synthase (EC 2.3.1.37) (ALAS), a pyridoxal 5'-phosphate (PLP)-dependent enzyme, catalyzes the initial step of heme biosynthesis in animals, fungi, and some bacteria. Condensation of glycine and succinyl coenzyme A produces 5-aminolevulinate, coenzyme A, and carbon dioxide. X-ray crystal structures of Rhodobacter capsulatus ALAS reveal that a conserved active site serine moves to within hydrogen bonding distance of the phenolic oxygen of the PLP cofactor in the closed substrate-bound enzyme conformation and within 3-4 angstrom of the thioester sulfur atom of bound succinyl-CoA. To evaluate the role(s) of this residue in enzymatic activity, the equivalent serine in murine erythroid ALAS was substituted with alanine or threonine. Although both the K-m(SCoA) and k(cat) values of the S254A variant increased, by 25- and 2-fold, respectively, the S254T substitution decreased k(cat) without altering K-m(SCoA). Furthermore, in relation to wild-type ALAS, the catalytic efficiency of S254A toward glycine improved similar to 3-fold, whereas that of S254T diminished similar to 3-fold. Circular dichroism spectroscopy revealed that removal of the side chain hydroxyl group in the S254A variant altered the microenvironment of the PLP cofactor and hindered succinyl-CoA binding. Transient kinetic analyses of the variant-catalyzed reactions and protein fluorescence quenching upon 5-aminolevulinate binding demonstrated that the protein conformational transition step associated with product release was predominantly affected. We propose the following: 1) Ser-254 is critical for formation of a competent catalytic complex by coupling succinyl-CoA binding to enzyme conformational equilibria, and 2) the role of the active site serine should be extended to the entire alpha-oxoamine synthase family of PLP-dependent enzymes.	[Ferreira, Gloria C.] Univ S Florida, Dept Mol Med, Coll Med, Tampa, FL 33612 USA; [Ferreira, Gloria C.] Univ S Florida, Dept Chem, Tampa, FL 33612 USA; [Ferreira, Gloria C.] Univ S Florida, H Lee Moffitt Canc Ctr & Res Inst, Tampa, FL 33612 USA	State University System of Florida; University of South Florida; State University System of Florida; University of South Florida; H Lee Moffitt Cancer Center & Research Institute; State University System of Florida; University of South Florida	Ferreira, GC (corresponding author), Univ S Florida, Dept Mol Med, Coll Med, MDC 7, Tampa, FL 33612 USA.	gferreir@health.usf.edu	Ferreira, Gloria C/A-4709-2012	Ferreira, Gloria C/0000-0001-9279-2217	National Institutes of Health [DK63191]; NATIONAL CANCER INSTITUTE [R01CA008759, R37CA008759] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK054317, R01DK063191] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))	This work was supported, in whole or in part, by National Institutes of Health Grant DK63191 (to G.C.F.).	AKHTAR M, 1976, PHILOS T ROY SOC B, V273, P117, DOI 10.1098/rstb.1976.0005; ALEXANDER FW, 1994, EUR J BIOCHEM, V219, P953, DOI 10.1111/j.1432-1033.1994.tb18577.x; Astner I, 2005, EMBO J, V24, P3166, DOI 10.1038/sj.emboj.7600792; BARSHOP BA, 1983, ANAL BIOCHEM, V130, P134, DOI 10.1016/0003-2697(83)90660-7; BOTTOMLEY SS, 2004, WINTROBES CLIN HEMAT, P1012; Bottomley Sylvia S, 2006, Curr Hematol Rep, V5, P41; Cellini B, 2005, BIOCHEMISTRY-US, V44, P13970, DOI 10.1021/bi051433n; CHEN GC, 1977, ANAL LETT, V10, P1195, DOI 10.1080/00032717708067855; Christen P, 2001, CHEM REC, V1, P436, DOI 10.1002/tcr.10005; DURBIN J, 1950, BIOMETRIKA, V37, P409, DOI 10.1093/biomet/37.3-4.409; Eliot AC, 2004, ANNU REV BIOCHEM, V73, P383, DOI 10.1146/annurev.biochem.73.011303.074021; Ferreira GC, 2002, CELL MOL BIOL, V48, P827; FERREIRA GC, 1993, J BIOL CHEM, V268, P584; FUTAKI S, 1990, J BIOL CHEM, V265, P22306; GREGORET LM, 1991, PROTEINS, V9, P99, DOI 10.1002/prot.340090204; Guex N, 1997, ELECTROPHORESIS, V18, P2714, DOI 10.1002/elps.1150181505; HUNTER GA, 1995, ANAL BIOCHEM, V226, P221, DOI 10.1006/abio.1995.1217; Hunter GA, 1999, J BIOL CHEM, V274, P12222, DOI 10.1074/jbc.274.18.12222; Hunter GA, 2007, J BIOL CHEM, V282, P23025, DOI 10.1074/jbc.M609330200; Ikushiro H, 2004, BIOCHEMISTRY-US, V43, P1082, DOI 10.1021/bi035706v; JAGER J, 1994, J MOL BIOL, V239, P285, DOI 10.1006/jmbi.1994.1368; Jansonius J N, 1984, Prog Clin Biol Res, V144B, P195; JANSONIUS JN, 1984, BIOCHEM SOC T, V12, P424, DOI 10.1042/bst0120424; KALLEN RG, 1985, TRANSAMINASES, P37; Kelly SM, 2000, CURR PROTEIN PEPT SC, V1, P349, DOI 10.2174/1389203003381315; KOSHLAND DE, 1968, ANNU REV BIOCHEM, V37, P359, DOI 10.1146/annurev.bi.37.070168.002043; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lendrihas T, 2009, PROTEIN SCI, V18, P1847, DOI 10.1002/pro.195; May A, 1998, HAEMATOLOGICA, V83, P56; MAY BK, 1995, PROG NUCLEIC ACID RE, V51, P1, DOI 10.1016/S0079-6603(08)60875-2; MCPHALEN CA, 1992, J MOL BIOL, V227, P197, DOI 10.1016/0022-2836(92)90691-C; Miyazaki K, 2002, BIOTECHNIQUES, V33, P1033, DOI 10.2144/02335st03; PICOT D, 1991, EUR J BIOCHEM, V196, P329, DOI 10.1111/j.1432-1033.1991.tb15821.x; PROVENCHER SW, 1981, BIOCHEMISTRY-US, V20, P33, DOI 10.1021/bi00504a006; Rajagopal S, 2005, FEBS J, V272, P1819, DOI 10.1111/j.1742-4658.2005.04604.x; Schwede T, 2003, NUCLEIC ACIDS RES, V31, P3381, DOI 10.1093/nar/gkg520; Shoolingin-Jordan PM, 2003, BBA-PROTEINS PROTEOM, V1647, P361, DOI 10.1016/S1570-9639(03)00095-5; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; TSAI MD, 1978, BIOCHEMISTRY-US, V17, P3183, DOI 10.1021/bi00609a002; Zhang JS, 2005, PROTEIN SCI, V14, P1190, DOI 10.1110/ps.041258305; Zhang JS, 2002, J BIOL CHEM, V277, P44660, DOI 10.1074/jbc.M203584200	42	12	12	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 29	2010	285	5					3351	3359		10.1074/jbc.M109.066548	http://dx.doi.org/10.1074/jbc.M109.066548			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	546RR	19917609	Green Published, hybrid			2022-12-25	WOS:000273829000050
J	Campbell, GR; Loret, EP; Spector, SA				Campbell, Grant R.; Loret, Erwann P.; Spector, Stephen A.			HIV-1 Clade B Tat, but Not Clade C Tat, Increases X4 HIV-1 Entry into Resting but Not Activated CD4(+) T Cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VIRUS TYPE-1 HIV-1; SUBTYPE-C; DISEASE PROGRESSION; CORECEPTOR USAGE; DENDRITIC CELLS; VIRAL PHENOTYPE; LYMPH-NODES; FACTOR-I; INFECTION; CHEMOKINE	CXCR4-using human immunodeficiency virus, type 1 (HIV-1) variants emerge late in the course of infection in > 40% of individuals infected with clade B HIV-1 but are described less commonly with clade C isolates. Tat is secreted by HIV-1-infected cells where it acts on both uninfected bystander cells and infected cells. In this study, we show that clade B Tat, but not clade C Tat, increases CXCR4 surface expression on resting CD4(+) T cells through a CCR2b-dependent mechanism that does not involve de novo protein synthesis. The expression of plectin, a cytolinker protein that plays an important role as a scaffolding platform for proteins involved in cellular signaling including CXCR4 signaling and trafficking, was found to be significantly increased following B Tat but not C Tat treatment. Knockdown of plectin using RNA interference showed that plectin is essential for the B Tat-induced translocation of CXCR4 to the surface of resting CD4(+) T cells. The increased surface CXCR4 expression following B Tat treatment led to increased function of CXCR4 including increased chemoattraction toward CXCR4-using-gp120. Moreover, increased CXCR4 surface expression rendered resting CD4(+) T cells more permissive to X4 but not R5 HIV-1 infection. However, neither B Tat nor C Tat was able to up-regulate surface expression of CXCR4 on activated CD4(+) T cells, and both proteins inhibited the infection of activated CD4(+) T cells with X4 but not R5 HIV-1. Thus, B Tat, but not C Tat, has the capacity to render resting, but not activated, CD4(+) T cells more susceptible to X4 HIV-1 infection.	[Spector, Stephen A.] Univ Calif San Diego, Dept Pediat, Div Infect Dis, La Jolla, CA 92093 USA; [Spector, Stephen A.] Rady Childrens Hosp, San Diego, CA 92123 USA; [Loret, Erwann P.] Univ Aix Marseille 2, Fac Pharm, INSERM, U911, F-13385 Marseille 5, France	University of California System; University of California San Diego; Rady Childrens Hospital San Diego; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Aix-Marseille Universite	Spector, SA (corresponding author), Univ Calif San Diego, Dept Pediat, Div Infect Dis, 9500 Gilman Dr, La Jolla, CA 92093 USA.	saspector@ucsd.edu	Campbell, Grant/C-9018-2011	Campbell, Grant/0000-0003-3927-1994	National Institutes of Health [AI068632]; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [UM1AI068632, U01AI068632] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	This work was supported, in whole or in part, by National Institutes of Health Grant AI068632.	Agosto LM, 2007, VIROLOGY, V368, P60, DOI 10.1016/j.virol.2007.06.001; Albini A, 1998, J BIOL CHEM, V273, P15895, DOI 10.1074/jbc.273.26.15895; Babcock GJ, 2001, J BIOL CHEM, V276, P38433, DOI 10.1074/jbc.M106229200; Balabanian K, 2004, J IMMUNOL, V173, P7150, DOI 10.4049/jimmunol.173.12.7150; BARANY G, 1980, PEPTIDES ANAL SYNTHE, V2, P1; BARRESINOUSSI F, 1983, SCIENCE, V220, P868, DOI 10.1126/science.6189183; Bell CM, 2007, AIDS RES HUM RETROV, V23, P322, DOI 10.1089/aid.2006.0181; Berger EA, 1997, AIDS, V11, pS3; Bhoopat L, 2006, MODERN PATHOL, V19, P255, DOI 10.1038/modpathol.3800527; Bjorndal A, 1997, J VIROL, V71, P7478; Blaak H, 2000, P NATL ACAD SCI USA, V97, P1269, DOI 10.1073/pnas.97.3.1269; Campbell GR, 2005, J BIOL CHEM, V280, P38376, DOI 10.1074/jbc.M506630200; Campbell GR, 2004, J BIOL CHEM, V279, P48197, DOI 10.1074/jbc.M406195200; Campbell GR, 2008, J BIOL CHEM, V283, P30745, DOI 10.1074/jbc.M804112200; Campbell GR, 2007, VACCINE, V25, P8441, DOI 10.1016/j.vaccine.2007.09.070; Campbell GR, 2007, J VIROL, V81, P5919, DOI 10.1128/JVI.01938-06; Campbell GR, 2009, RETROVIROLOGY, V6, DOI 10.1186/1742-4690-6-50; Cecilia D, 2000, VIROLOGY, V271, P253, DOI 10.1006/viro.2000.0297; Coetzer M, 2006, VIROLOGY, V356, P95, DOI 10.1016/j.virol.2006.07.030; Correa R, 2001, AIDS, V15, P1959, DOI 10.1097/00002030-200110190-00007; Curnock AP, 2003, J IMMUNOL, V170, P4021, DOI 10.4049/jimmunol.170.8.4021; Davenport MP, 2002, TRENDS MICROBIOL, V10, P275, DOI 10.1016/S0966-842X(02)02370-3; de Mareuil J, 2005, RETROVIROLOGY, V2, DOI 10.1186/1742-4690-2-5; Ding Y, 2008, EXP CELL RES, V314, P590, DOI 10.1016/j.yexcr.2007.10.032; Eckstein DA, 2001, IMMUNITY, V15, P671, DOI 10.1016/S1074-7613(01)00217-5; Fanales-Belasio E, 2002, J IMMUNOL, V168, P197, DOI 10.4049/jimmunol.168.1.197; FINKEL TH, 1995, NAT MED, V1, P129, DOI 10.1038/nm0295-129; Ghezzi S, 2000, BIOCHEM BIOPH RES CO, V270, P992, DOI 10.1006/bbrc.2000.2523; Han YF, 2007, NAT REV MICROBIOL, V5, P95, DOI 10.1038/nrmicro1580; Hemelaar J, 2006, AIDS, V20, pW13, DOI 10.1097/01.aids.0000247564.73009.bc; Huang L, 1998, J VIROL, V72, P8952, DOI 10.1128/JVI.72.11.8952-8960.1998; Huigen MCDG, 2004, EUR J CLIN INVEST, V34, P57, DOI 10.1111/j.1365-2362.2004.01282.x; JAPOUR AJ, 1993, ANTIMICROB AGENTS CH, V37, P1095, DOI 10.1128/AAC.37.5.1095; Jeang KT, 1999, J BIOL CHEM, V274, P28837, DOI 10.1074/jbc.274.41.28837; Kaleebu P, 2007, JAIDS-J ACQ IMM DEF, V45, P28, DOI 10.1097/QAI.0b013e3180385aa0; Kinter AL, 2003, J IMMUNOL, V170, P2449, DOI 10.4049/jimmunol.170.5.2449; Koot M, 1996, J INFECT DIS, V173, P349, DOI 10.1093/infdis/173.2.349; Kumar A, 2006, IMMUNITY, V25, P213, DOI 10.1016/j.immuni.2006.06.015; Kumar M, 2006, AIDS RES HUM RETROV, V22, P1206, DOI 10.1089/aid.2006.22.1206; Lane BR, 1999, J IMMUNOL, V163, P3653; Lee B, 1998, J VIROL, V72, P7450, DOI 10.1128/JVI.72.9.7450-7458.1998; Lole KS, 1999, J VIROL, V73, P152, DOI 10.1128/JVI.73.1.152-160.1999; Mirzadegan T, 2000, J BIOL CHEM, V275, P25562, DOI 10.1074/jbc.M000692200; Ndung'u T, 2006, VIROLOGY, V347, P247, DOI 10.1016/j.virol.2005.11.047; Noraz N, 1997, AIDS, V11, P1671, DOI 10.1097/00002030-199714000-00003; Opi S, 2002, J BIOL CHEM, V277, P35915, DOI 10.1074/jbc.M204393200; Opi S, 2004, VACCINE, V22, P3105, DOI 10.1016/j.vaccine.2004.01.057; Pacyniak E, 2005, AIDS RES HUM RETROV, V21, P379, DOI 10.1089/aid.2005.21.379; Patrussi L, 2007, BLOOD, V110, P1730, DOI 10.1182/blood-2007-01-068411; Peacock JW, 1999, J IMMUNOL, V162, P215; PELCHENMATTHEWS A, 1989, EMBO J, V8, P3641, DOI 10.1002/j.1460-2075.1989.tb08538.x; Peloponese JM, 1999, J BIOL CHEM, V274, P11473, DOI 10.1074/jbc.274.17.11473; Perez-Patrigeon S, 2009, AIDS, V23, P1197, DOI 10.1097/QAD.0b013e32832c4b0a; Philpott SM, 2003, CURR HIV RES, V1, P217, DOI 10.2174/1570162033485357; Ranga U, 2004, J VIROL, V78, P2586, DOI 10.1128/JVI.78.5.2586-2590.2004; Ranjbar S, 2006, J IMMUNOL, V176, P4182, DOI 10.4049/jimmunol.176.7.4182; Regulier EG, 2004, INT REV IMMUNOL, V23, P25, DOI 10.1080/08830180490265538; Renjifo B, 2004, AIDS, V18, P1629, DOI 10.1097/01.aids.0000131392.68597.34; Riol-Blanco L, 2005, J IMMUNOL, V174, P4070, DOI 10.4049/jimmunol.174.7.4070; Roof P, 2002, VIROLOGY, V296, P77, DOI 10.1006/viro.2001.1397; Secchiero P, 1999, J IMMUNOL, V162, P2427; Smith MW, 1997, SCIENCE, V277, P959, DOI 10.1126/science.277.5328.959; Sotsios Y, 2000, IMMUNOL REV, V177, P217, DOI 10.1034/j.1600-065X.2000.17712.x; Stanners J, 1995, J BIOL CHEM, V270, P30635, DOI 10.1074/jbc.270.51.30635; van Opijnen T, 2004, J VIROL, V78, P3675, DOI 10.1128/JVI.78.7.3675-3683.2004; Vasan A, 2006, CLIN INFECT DIS, V42, P843, DOI 10.1086/499952; WAINHOBSON S, 1991, SCIENCE, V252, P961, DOI 10.1126/science.2035026; Walker PR, 2007, AIDS RES HUM RETROV, V23, P204, DOI 10.1089/aid.2006.0080; WESTENDORP MO, 1995, NATURE, V375, P497, DOI 10.1038/375497a0; Wu LJ, 1996, NATURE, V384, P179, DOI 10.1038/384179a0; Xiao H, 2000, P NATL ACAD SCI USA, V97, P11466, DOI 10.1073/pnas.97.21.11466	71	17	17	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 15	2010	285	3					1681	1691		10.1074/jbc.M109.049957	http://dx.doi.org/10.1074/jbc.M109.049957			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	541PJ	19917610	Green Published, hybrid			2022-12-25	WOS:000273429100014
J	Friedrich, N; Santos, JM; Liu, Y; Palma, AS; Leon, E; Saouros, S; Kiso, M; Blackman, MJ; Matthews, S; Feizi, T; Soldati-Favre, D				Friedrich, Nikolas; Santos, Joana M.; Liu, Yan; Palma, Angelina S.; Leon, Ester; Saouros, Savvas; Kiso, Makoto; Blackman, Michael J.; Matthews, Stephen; Feizi, Ten; Soldati-Favre, Dominique			Members of a Novel Protein Family Containing Microneme Adhesive Repeat Domains Act as Sialic Acid-binding Lectins during Host Cell Invasion by Apicomplexan Parasites	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TOXOPLASMA-GONDII; IDENTIFICATION; RECOGNITION; MEMBRANE; INSIGHTS; RECEPTOR; LOCALIZATION; MICROARRAYS; DEFICIENT; INFECTION	Numerous intracellular pathogens exploit cell surface glyco-conjugates for host cell recognition and entry. Unlike bacteria and viruses, Toxoplasma gondii and other parasites of the phylum Apicomplexa actively invade host cells, and this process critically depends on adhesins (microneme proteins) released onto the parasite surface from intracellular organelles called micronemes (MIC). The microneme adhesive repeat (MAR) domain of T. gondii MIC1 (TgMIC1) recognizes sialic acid (Sia), a key determinant on the host cell surface for invasion by this pathogen. By complementation and invasion assays, we demonstrate that TgMIC1 is one important player in Sia-dependent invasion and that another novel Sia-binding lectin, designated TgMIC13, is also involved. Using BLAST searches, we identify a family of MAR-containing proteins in enteroparasitic coccidians, a subclass of apicomplexans, including T. gondii, suggesting that all these parasites exploit sialylated glycoconjugates on host cells as determinants for enteric invasion. Furthermore, this protein family might provide a basis for the broad host cell range observed for coccidians that form tissue cysts during chronic infection. Carbohydrate microarray analyses, corroborated by structural considerations, show that TgMIC13, TgMIC1, and its homologue Neospora caninum MIC1 (NcMIC1) share a preference for alpha 2-3-over alpha 2-6-linked sialyl-N-acetyllactosamine sequences. However, the three lectins also display differences in binding preferences. Intense binding of TgMIC13 to alpha 2-9-linked disialyl sequence reported on embryonal cells and relatively strong binding to 4-O-acetylated-Sia found on gut epithelium and binding of NcMIC1 to 6' sulfo-sialyl Lewis(x) might have implications for tissue tropism.	[Liu, Yan; Palma, Angelina S.; Feizi, Ten] Univ London Imperial Coll Sci Technol & Med, Div Med, Glycosci Lab, Harrow HA1 3UJ, Middx, England; [Friedrich, Nikolas; Santos, Joana M.; Soldati-Favre, Dominique] Univ Geneva, Ctr Med Univ Geneva, Fac Med, Dept Microbiol & Mol Med, CH-1211 Geneva 4, Switzerland; [Leon, Ester; Saouros, Savvas; Matthews, Stephen] Univ London Imperial Coll Sci Technol & Med, Div Mol Biosci, London SW7 2AZ, England; [Kiso, Makoto] Gifu Univ, Dept Appl Bioorgan Chem, Gifu 50111, Japan; [Blackman, Michael J.] Natl Inst Med Res, Div Parasitol, MRC, London NW7 1AA, England	Imperial College London; University of Geneva; Imperial College London; Gifu University; MRC National Institute for Medical Research	Feizi, T (corresponding author), Univ London Imperial Coll Sci Technol & Med, Div Med, Glycosci Lab, Northwick Pk Campus, Harrow HA1 3UJ, Middx, England.	t.feizi@imperial.ac.uk; dominique.soldati-favre@unige.ch	Palma, Angelina S/D-2052-2013; Santos, Joana M/W-4149-2018; Liu, Yan/D-9117-2013	Palma, Angelina S/0000-0001-5797-6555; Matthews, Steve/0000-0003-0676-0927; Feizi, Ten/0000-0001-6495-0329; Friedrich, Nikolas/0000-0003-0694-657X; Liu, Yan/0000-0002-2566-6867	Swiss National Foundation; UK Medical Research Council; UK Research Council Basic Technology and Translational [GR/S79268, EP/G037604/1]; European [LSHP-CT-2004-503578]; Priority 1 "Life Sciences, Genomics, and Biotechnology for Health"; Biotechnology and Biological Sciences Research Council [BB/E02520X/1] Funding Source: researchfish; Engineering and Physical Sciences Research Council [EP/G037604/1, GR/S79268/02] Funding Source: researchfish; Medical Research Council [G0600512, MC_U117532063, G0800038] Funding Source: researchfish; BBSRC [BB/E02520X/1] Funding Source: UKRI; EPSRC [EP/G037604/1] Funding Source: UKRI; MRC [G0600512, MC_U117532063, G0800038] Funding Source: UKRI	Swiss National Foundation(Swiss National Science Foundation (SNSF)); UK Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); UK Research Council Basic Technology and Translational; European(European Science Foundation (ESF)); Priority 1 "Life Sciences, Genomics, and Biotechnology for Health"; Biotechnology and Biological Sciences Research Council(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC)); Engineering and Physical Sciences Research Council(UK Research & Innovation (UKRI)Engineering & Physical Sciences Research Council (EPSRC)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission); BBSRC(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC)); EPSRC(UK Research & Innovation (UKRI)Engineering & Physical Sciences Research Council (EPSRC)); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))	This work was supported in part by the Swiss National Foundation (to D. S.), the UK Medical Research Council, and UK Research Council Basic Technology Grant GR/S79268 and Translational Grant EP/G037604/1 (to T. F.). This work is part of the activities of the BioMalPar European Network of Excellence supported by a European Grant LSHP-CT-2004-503578 from the Priority 1 "Life Sciences, Genomics, and Biotechnology for Health" in the 6th Framework Programme.	Blumenschein TMA, 2007, EMBO J, V26, P2808, DOI 10.1038/sj.emboj.7601704; Brecht S, 2001, J BIOL CHEM, V276, P4119, DOI 10.1074/jbc.M008294200; Carruthers VB, 1997, EUR J CELL BIOL, V73, P114; Carruthers VB, 2000, INFECT IMMUN, V68, P4005, DOI 10.1128/IAI.68.7.4005-4011.2000; Carruthers Vern B., 2008, V47, P33; Carruthers VB, 2007, CURR OPIN MICROBIOL, V10, P82; Cerede O, 2005, J EXP MED, V201, P453, DOI 10.1084/jem.20041672; Cerede O, 2002, EMBO J, V21, P2526, DOI 10.1093/emboj/21.11.2526; Chen ZQ, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003611; Chesne-Seck ML, 2005, MOL BIOCHEM PARASIT, V144, P55, DOI 10.1016/j.molbiopara.2005.07.007; DEUTSCHER SL, 1984, CELL, V39, P295, DOI 10.1016/0092-8674(84)90007-2; Ellison SP, 2001, VET PARASITOL, V95, P251, DOI 10.1016/S0304-4017(00)00391-5; ESKO JD, 1988, SCIENCE, V241, P1092, DOI 10.1126/science.3137658; Feizi T, 2004, NAT REV MOL CELL BIO, V5, P582, DOI 10.1038/nrm1428; Fox BA, 2009, EUKARYOT CELL, V8, P520, DOI 10.1128/EC.00357-08; FUKUDA MN, 1985, J BIOL CHEM, V260, P6623; Garnett JA, 2009, PROTEIN SCI, V18, P1935, DOI 10.1002/pro.204; Gubbels MJ, 2003, ANTIMICROB AGENTS CH, V47, P309, DOI 10.1128/AAC.47.1.309-316.2003; HASEGAWA A, 1992, CARBOHYD RES, V224, P185, DOI 10.1016/0008-6215(92)84104-Z; Hemphill A, 2006, PARASITOLOGY, V133, P261, DOI 10.1017/S0031182006000485; Huynh MH, 2004, CELL MICROBIOL, V6, P771, DOI 10.1111/j.1462-5822.2004.00403.x; Huynh MH, 2009, EUKARYOT CELL, V8, P530, DOI 10.1128/EC.00358-08; Inoue S, 2003, J BIOL CHEM, V278, P8541, DOI 10.1074/jbc.M212799200; Iwersen M, 2003, BIOL CHEM, V384, P1035, DOI 10.1515/BC.2003.116; Keller N, 2002, INFECT IMMUN, V70, P3187, DOI 10.1128/IAI.70.6.3187-3198.2002; Labbe M, 2005, MOL BIOCHEM PARASIT, V140, P43, DOI 10.1016/j.molbiopara.2004.12.002; Liu Y, 2007, CHEM BIOL, V14, P847, DOI 10.1016/j.chembiol.2007.06.009; Martin MJ, 2005, P NATL ACAD SCI USA, V102, P12819, DOI 10.1073/pnas.0503819102; MATROSOVICH MN, 1992, VIROLOGY, V188, P854, DOI 10.1016/0042-6822(92)90541-V; Meissner M, 2002, J CELL SCI, V115, P563; MESSER M, 1974, BIOCHEM J, V139, P415, DOI 10.1042/bj1390415; Moire N, 2009, EXP PARASITOL, V123, P111, DOI 10.1016/j.exppara.2009.06.003; Monteiro VG, 1998, FEMS MICROBIOL LETT, V164, P323, DOI 10.1111/j.1574-6968.1998.tb13105.x; Montoya JG, 2004, LANCET, V363, P1965, DOI 10.1016/S0140-6736(04)16412-X; ORLANDI PA, 1992, J CELL BIOL, V116, P901, DOI 10.1083/jcb.116.4.901; Ortega-Barria E, 1999, J BIOL CHEM, V274, P1267, DOI 10.1074/jbc.274.3.1267; Palma AS, 2006, J BIOL CHEM, V281, P5771, DOI 10.1074/jbc.M511461200; Persson KEM, 2008, J CLIN INVEST, V118, P342, DOI 10.1172/JCI32138; Pizarro JC, 2005, SCIENCE, V308, P408, DOI 10.1126/science.1107449; Reiss M, 2001, J CELL BIOL, V152, P563, DOI 10.1083/jcb.152.3.563; Rinninger A, 2006, GLYCOCONJUGATE J, V23, P73, DOI 10.1007/s10719-006-5439-7; Saouros S, 2005, J BIOL CHEM, V280, P38583, DOI 10.1074/jbc.C500365200; Sawmynaden K, 2008, EMBO REP, V9, P1149, DOI 10.1038/embor.2008.179; SIM BKL, 1990, J CELL BIOL, V111, P1877, DOI 10.1083/jcb.111.5.1877; Soldati-Favre D, 2008, PARASITE, V15, P197, DOI 10.1051/parasite/2008153197; Takabatake N, 2007, VET PARASITOL, V148, P93, DOI 10.1016/j.vetpar.2007.06.011; Tolia NH, 2005, CELL, V122, P183, DOI 10.1016/j.cell.2005.05.033; Xia D, 2008, GENOME BIOL, V9, DOI 10.1186/gb-2008-9-7-r116	48	78	81	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 15	2010	285	3					2064	2076		10.1074/jbc.M109.060988	http://dx.doi.org/10.1074/jbc.M109.060988			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	541PJ	19901027	Green Published, hybrid			2022-12-25	WOS:000273429100051
J	Kleijn, RJ; Buescher, JM; Le Chat, L; Jules, M; Aymerich, S; Sauer, U				Kleijn, Roelco J.; Buescher, Joerg M.; Le Chat, Ludovic; Jules, Matthieu; Aymerich, Stephane; Sauer, Uwe			Metabolic Fluxes during Strong Carbon Catabolite Repression by Malate in Bacillus subtilis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BIDIRECTIONAL REACTION STEPS; ESCHERICHIA-COLI; SACCHAROMYCES-CEREVISIAE; GENE ENCODES; QUANTITATIVE METABOLOMICS; GLUCOSE-METABOLISM; MALIC ENZYME; GC-MS; MUTANTS; NETWORKS	Commonly glucose is considered to be the only preferred substrate in Bacillus subtilis whose presence represses utilization of other alternative substrates. Because recent data indicate that malate might be an exception, we quantify here the carbon source utilization hierarchy. Based on physiology and transcriptional data during co-utilization experiments with eight carbon substrates, we demonstrate that malate is a second preferred carbon source for B. subtilis, which is rapidly co-utilized with glucose and strongly represses the uptake of alternative substrates. From the different hierarchy and degree of catabolite repression exerted by glucose and malate, we conclude that both substrates might act through different molecular mechanisms. To obtain a quantitative and functional network view of how malate is (co)metabolized, we developed a novel approach to metabolic flux analysis that avoids error-prone, intuitive, and ad hoc decisions on C-13 rearrangements. In particular, we developed a rigorous approach for deriving reaction reversibilities by combining in vivo intracellular metabolite concentrations with a thermodynamic feasibility analysis. The thus-obtained analytical model of metabolism was then used for network-wide isotopologue balancing to estimate the intracellular fluxes. These C-13-flux data revealed an extraordinarily high malate influx that is primarily catabolized via the gluconeogenic reactions and toward overflow metabolism. Furthermore, a considerable NADPH-producing malic enzyme flux is required to supply the biosynthetically required NADPH in the presence of malate. Co-utilization of glucose and malate resulted in a synergistic decrease of the respiratory tricarboxylic acid cycle flux.	[Sauer, Uwe] ETH, Inst Mol Syst Biol, CH-8093 Zurich, Switzerland; [Le Chat, Ludovic; Jules, Matthieu; Aymerich, Stephane] INRA, UMR1238, CNRS, UMR2585, F-78850 Thiverval Grignon, France; [Le Chat, Ludovic; Jules, Matthieu; Aymerich, Stephane] AgroParisTech, Microbiol & Genet Mol, F-78850 Thiverval Grignon, France	Swiss Federal Institutes of Technology Domain; ETH Zurich; Centre National de la Recherche Scientifique (CNRS); INRAE; UDICE-French Research Universities; Universite Paris Saclay; AgroParisTech; UDICE-French Research Universities; Universite Paris Saclay	Sauer, U (corresponding author), ETH, Inst Mol Syst Biol, Wolfgang Pauli Str 16, CH-8093 Zurich, Switzerland.	sauer@imsb.biol.ethz.ch	Sauer, Uwe/Y-3556-2019; Jules, Matthieu/GVU-5315-2022	Jules, Matthieu/0000-0003-0817-8949; Buescher, Joerg/0000-0002-6547-0076	European Union [LSHG-CT-2006-037469]	European Union(European Commission)	This work was supported by European Union BaSysBio Program Grant LSHG-CT-2006-037469.	Alberty R. A., 2003, THERMODYNAMICS BIOCH; Asai K, 2000, MICROBIOL-UK, V146, P263, DOI 10.1099/00221287-146-2-263; AYMERICH S, 2007, GLOBAL REGULATORY NE, P39; Bais HP, 2006, ANNU REV PLANT BIOL, V57, P233, DOI 10.1146/annurev.arplant.57.032905.105159; Beard DA, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0000144; Bolten CJ, 2007, ANAL CHEM, V79, P3843, DOI 10.1021/ac0623888; Breeuwer P, 1996, APPL ENVIRON MICROB, V62, P178, DOI 10.1128/AEM.62.1.178-183.1996; Bruckner R, 2002, FEMS MICROBIOL LETT, V209, P141; Buscher JM, 2009, ANAL CHEM, V81, P2135, DOI 10.1021/ac8022857; Collier DN, 1996, RES MICROBIOL, V147, P551, DOI 10.1016/0923-2508(96)84011-3; Commichau FM, 2007, J MOL MICROB BIOTECH, V12, P106, DOI 10.1159/000096465; Cormack BP, 1996, GENE, V173, P33, DOI 10.1016/0378-1119(95)00685-0; Dauner M, 2001, BIOTECHNOL BIOENG, V76, P144, DOI 10.1002/bit.1154; Doan T, 2003, MICROBIOL-SGM, V149, P2331, DOI 10.1099/mic.0.26256-0; Ewald JC, 2009, ANAL CHEM, V81, P3623, DOI 10.1021/ac900002u; Fillinger S, 2000, J BIOL CHEM, V275, P14031, DOI 10.1074/jbc.275.19.14031; Fischer E, 2003, EUR J BIOCHEM, V270, P880, DOI 10.1046/j.1432-1033.2003.03448.x; Fischer E, 2005, NAT GENET, V37, P636, DOI 10.1038/ng1555; Fuhrer T, 2005, J BACTERIOL, V187, P1581, DOI 10.1128/JB.187.5.1581-1590.2005; Fujita Y, 2009, BIOSCI BIOTECH BIOCH, V73, P245, DOI 10.1271/bbb.80479; Galinier A, 1997, P NATL ACAD SCI USA, V94, P8439, DOI 10.1073/pnas.94.16.8439; Gorke B, 2008, NAT REV MICROBIOL, V6, P613, DOI 10.1038/nrmicro1932; Gombert AK, 2001, J BACTERIOL, V183, P1441, DOI 10.1128/JB.183.4.1441-1451.2001; HENKIN TM, 1991, MOL MICROBIOL, V5, P575, DOI 10.1111/j.1365-2958.1991.tb00728.x; JACOB F, 1961, J MOL BIOL, V3, P318, DOI 10.1016/S0022-2836(61)80072-7; Jault JM, 2000, J BIOL CHEM, V275, P1773, DOI 10.1074/jbc.275.3.1773; Jules M, 2009, J BACTERIOL, V191, P3168, DOI 10.1128/JB.01783-08; Kleijn RJ, 2005, FEBS J, V272, P4970, DOI 10.1111/j.1742-4658.2005.04907.x; Kleijn RJ, 2007, FEMS YEAST RES, V7, P216, DOI 10.1111/j.1567-1364.2006.00180.x; KRULWICH TA, 1969, J BACTERIOL, V97, P526, DOI 10.1128/JB.97.2.526-534.1969; Kummel A, 2006, MOL SYST BIOL, V2, DOI 10.1038/msb4100074; Lerondel G, 2006, J BACTERIOL, V188, P4727, DOI 10.1128/JB.00167-06; Liu JP, 2009, PLANT J, V57, P389, DOI 10.1111/j.1365-313X.2008.03696.x; Mollney M, 1999, BIOTECHNOL BIOENG, V66, P86, DOI 10.1002/(SICI)1097-0290(1999)66:2<86::AID-BIT2>3.0.CO;2-A; Oh YK, 2007, J BIOL CHEM, V282, P28791, DOI 10.1074/jbc.M703759200; Rudrappa T, 2008, PLANT PHYSIOL, V148, P1547, DOI 10.1104/pp.108.127613; Sauer U, 1999, J BACTERIOL, V181, P6679, DOI 10.1128/JB.181.21.6679-6688.1999; Sauer U, 2006, MOL SYST BIOL, V2, DOI 10.1038/msb4100109; Schilling O, 2007, APPL ENVIRON MICROB, V73, P499, DOI 10.1128/AEM.02084-06; Schmidt K, 1999, J BIOTECHNOL, V71, P175, DOI 10.1016/S0168-1656(99)00021-8; Servant P, 2005, MOL MICROBIOL, V55, P1435, DOI 10.1111/j.1365-2958.2005.04473.x; SIEGEL LS, 1977, J BACTERIOL, V129, P87, DOI 10.1128/JB.129.1.87-96.1977; Singh KD, 2008, J BACTERIOL, V190, P7275, DOI 10.1128/JB.00848-08; Tannler S, 2008, MICROB CELL FACT, V7, DOI 10.1186/1475-2859-7-19; UCKER DS, 1978, J BACTERIOL, V136, P1197, DOI 10.1128/JB.136.3.1197-1200.1978; van Winden WA, 2005, FEMS YEAST RES, V5, P559, DOI 10.1016/j.femsyr.2004.10.007; Voets T, 1999, P NATL ACAD SCI USA, V96, P5298, DOI 10.1073/pnas.96.9.5298; Warner JB, 2000, J BACTERIOL, V182, P6099, DOI 10.1128/JB.182.21.6099-6105.2000; Warner JB, 2003, FEMS MICROBIOL LETT, V220, P277, DOI 10.1016/S0378-1097(03)00126-5; Wei Y, 2000, J BIOL CHEM, V275, P30287, DOI 10.1074/jbc.M001112200; Weisskopf L, 2008, SOIL BIOL BIOCHEM, V40, P1772, DOI 10.1016/j.soilbio.2008.02.018; Wiechert W, 1999, BIOTECHNOL BIOENG, V66, P69; Wiechert W, 2001, METAB ENG, V3, P265, DOI 10.1006/mben.2001.0188; Wiechert W, 2007, BIOPHYS J, V93, P2255, DOI 10.1529/biophysj.106.099895; WOLFF JA, 1991, J BACTERIOL, V173, P4700, DOI 10.1128/jb.173.15.4700-4706.1991; Zamboni N, 2009, NAT PROTOC, V4, P878, DOI 10.1038/nprot.2009.58; Zamboni N, 2008, BMC BIOINFORMATICS, V9, DOI 10.1186/1471-2105-9-199; Zhao J, 2003, J BIOTECHNOL, V101, P101, DOI 10.1016/S0168-1656(02)00316-4	58	80	83	1	36	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 15	2010	285	3					1587	1596		10.1074/jbc.M109.061747	http://dx.doi.org/10.1074/jbc.M109.061747			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	541PJ	19917605	Green Published, hybrid			2022-12-25	WOS:000273429100004
J	Ismail, TM; Zhang, S; Fernig, DG; Gross, S; Martin-Fernandez, ML; See, V; Tozawa, K; Tynan, CJ; Wang, GZ; Wilkinson, MC; Rudland, PS; Barraclough, R				Ismail, Thamir M.; Zhang, Shu; Fernig, David G.; Gross, Stephane; Martin-Fernandez, Marisa L.; See, Violaine; Tozawa, Kaeko; Tynan, Christopher J.; Wang, Guozheng; Wilkinson, Mark C.; Rudland, Philip S.; Barraclough, Roger			Self-association of Calcium-binding Protein S100A4 and Metastasis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SQUAMOUS-CELL CARCINOMA; NONMUSCLE MYOSIN; PROGNOSTIC-SIGNIFICANCE; BREAST-CANCER; E-CADHERIN; IN-VITRO; COLORECTAL-CANCER; TUMOR-SUPPRESSOR; BLADDER-CANCER; HEAVY-CHAIN	Elevated levels of the calcium-binding protein S100A4 promote metastasis and in carcinoma cells are associated with reduced survival of cancer patients. S100A4 interacts with target proteins that affect a number of activities associated with metastatic cells. However, it is not known how many of these interactions are required for S100A4-promoted metastasis, thus hampering the design of specific inhibitors of S100A4-induced metastasis. Intracellular S100A4 exists as a homodimer through previously identified, well conserved, predominantly hydrophobic key contacts between the sub-units. Here it is shown that mutating just one key residue, phenylalanine 72, to alanine is sufficient to reduce the metastasis-promoting activity of S100A4 to 50% that of the wild type protein, and just 2 or 3 specific mutations reduces the metastasis-promoting activity of S100A4 to less than 20% that of the wild type protein. These mutations inhibit the self-association of S100A4 in vivo and reduce markedly the affinity of S100A4 for at least two of its protein targets, a recombinant fragment of non-muscle myosin heavy chain isoform A, and p53. Inhibition of the self-association of S100 proteins might be a novel means of inhibiting their metastasis-promoting activities.	[Ismail, Thamir M.; Zhang, Shu; Fernig, David G.; See, Violaine; Tozawa, Kaeko; Wang, Guozheng; Wilkinson, Mark C.; Rudland, Philip S.; Barraclough, Roger] Univ Liverpool, Sch Biol Sci, Liverpool L69 7ZB, Merseyside, England; [Gross, Stephane] Liverpool John Moores Univ, Sch Pharm & Biomol Sci, Liverpool L3 3AF, Merseyside, England; [Martin-Fernandez, Marisa L.; Tynan, Christopher J.] Rutherford Appleton Lab, Cent Laser Facil, Sci & Technol Facil Council, Didcot OX11 0QX, Oxon, England	University of Liverpool; Liverpool John Moores University; UK Research & Innovation (UKRI); Science & Technology Facilities Council (STFC); STFC Rutherford Appleton Laboratory	Barraclough, R (corresponding author), Univ Liverpool, Sch Biol Sci, Biosci Bldg,Crown St, Liverpool L69 7ZB, Merseyside, England.	brb@liverpool.ac.uk	Barraclough, Roger/AAH-6516-2020; Fernig, David G/A-3590-2008	Fernig, David G/0000-0003-4875-4293; Barraclough, Roger/0000-0002-7203-1194; Tynan, Christopher/0000-0002-4553-7018; martin-fernandez, marisa/0000-0001-5496-6300; Wilkinson, Mark/0000-0003-3109-6888; gross, stephane/0000-0002-0867-8866	North West Cancer Research Fund [CR655]; Cancer and Polio Research; David Phillips Biotechnology and Biological Sciences Research Council, Swindon, United Kingdom [BBC5204711]; Biotechnology and Biological Sciences Research Council [BB/C51464X/1] Funding Source: researchfish	North West Cancer Research Fund; Cancer and Polio Research; David Phillips Biotechnology and Biological Sciences Research Council, Swindon, United Kingdom; Biotechnology and Biological Sciences Research Council(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC))	This work was supported by North West Cancer Research Fund CR655 and the Cancer and Polio Research Fund.; Recipient of a David Phillips Biotechnology and Biological Sciences Research Council, Swindon, United Kingdom Fellowship BBC5204711.	Agerbaek M, 2006, EUR UROL, V50, P777, DOI 10.1016/j.eururo.2006.02.027; Andersen K, 2004, MODERN PATHOL, V17, P990, DOI 10.1038/modpathol.3800151; BAUDIER J, 1986, J BIOL CHEM, V261, P8192; Chen HL, 2001, BIOCHEM BIOPH RES CO, V286, P1212, DOI 10.1006/bbrc.2001.5517; DAVIES BR, 1993, ONCOGENE, V8, P999; Davies BR, 2002, J PATHOL, V196, P292, DOI 10.1002/path.1051; DUNNINGTON DJ, 1983, J NATL CANCER I, V71, P1227; Fernandez-Fernandez MR, 2005, P NATL ACAD SCI USA, V102, P4735, DOI 10.1073/pnas.0501459102; FORD HL, 1995, ONCOGENE, V11, P2067; Ford HL, 1997, BIOCHEMISTRY-US, V36, P16321, DOI 10.1021/bi971182l; FORD HL, 1995, ONCOGENE, V10, P1597; GIBBS FEM, 1994, J BIOL CHEM, V269, P18992; Gongoll S, 2002, GASTROENTEROLOGY, V123, P1478, DOI 10.1053/gast.2002.36606; Grigorian M, 2001, J BIOL CHEM, V276, P22699, DOI 10.1074/jbc.M010231200; Hemandas AK, 2006, J SURG ONCOL, V93, P498, DOI 10.1002/jso.20460; Ismail TM, 2008, CARCINOGENESIS, V29, P2259, DOI 10.1093/carcin/bgn217; Jenkinson SR, 2004, BRIT J CANCER, V90, P253, DOI 10.1038/sj.bjc.6601483; Kim EJ, 2003, J BIOL CHEM, V278, P30063, DOI 10.1074/jbc.M304909200; Kimura K, 2000, INT J ONCOL, V16, P1125; Kriajevska M, 1998, J BIOL CHEM, V273, P9852, DOI 10.1074/jbc.273.16.9852; Kriajevska M, 2002, J BIOL CHEM, V277, P5229, DOI 10.1074/jbc.M110976200; KRIAJEVSKA MV, 1994, J BIOL CHEM, V269, P19679; Lee WY, 2004, ONCOLOGY-BASEL, V66, P429, DOI 10.1159/000079496; Li ZH, 2006, CANCER RES, V66, P5173, DOI 10.1158/0008-5472.CAN-05-3087; Lloyd BH, 1998, ONCOGENE, V17, P465, DOI 10.1038/sj.onc.1201948; Malashkevich VN, 2008, BIOCHEMISTRY-US, V47, P5111, DOI 10.1021/bi702537s; Matsubara D, 2005, CANCER SCI, V96, P844, DOI 10.1111/j.1349-7006.2005.00121.x; Moriyama-Kita M, 2004, ORAL ONCOL, V40, P496, DOI 10.1016/j.oraloncology.2003.10.003; Nakamura T, 2002, INT J ONCOL, V20, P937; Ninomiya I, 2001, INT J ONCOL, V18, P715; PEDROCCHI M, 1994, BIOCHEMISTRY-US, V33, P6732, DOI 10.1021/bi00187a045; Rahmoune H, 1998, J BIOL CHEM, V273, P7303, DOI 10.1074/jbc.273.13.7303; Rudland PS, 2000, CANCER RES, V60, P1595; Semov A, 2005, J BIOL CHEM, V280, P20833, DOI 10.1074/jbc.M412653200; TAKENAGA K, 1994, J CELL BIOL, V124, P757, DOI 10.1083/jcb.124.5.757; Tarabykina S, 2001, J BIOL CHEM, V276, P24212, DOI 10.1074/jbc.M009477200; Wang GZ, 2006, CANCER RES, V66, P1199, DOI 10.1158/0008-5472.CAN-05-2605; Wang GZ, 2005, ONCOGENE, V24, P1445, DOI 10.1038/sj.onc.1208291; Yonemura Y, 2000, CLIN CANCER RES, V6, P4234; Zhang S, 2005, ONCOGENE, V24, P4401, DOI 10.1038/sj.onc.1208663; Zhang S, 2005, EUR BIOPHYS J BIOPHY, V34, P19, DOI 10.1007/s00249-004-0428-x	41	30	34	0	14	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 8	2010	285	2					914	922		10.1074/jbc.M109.010892	http://dx.doi.org/10.1074/jbc.M109.010892			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	539MH	19917604	Green Accepted, Green Published, hybrid			2022-12-25	WOS:000273258200011
J	Rao, SNR; Sharma, J; Maity, R; Jana, NR				Rao, Sudheendra N. R.; Sharma, Jaiprakash; Maity, Ranjan; Jana, Nihar Ranjan			Co-chaperone CHIP Stabilizes Aggregate-prone Malin, a Ubiquitin Ligase Mutated in Lafora Disease	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROGRESSIVE MYOCLONUS EPILEPSY; PROTEIN AGGREGATION; MOLECULAR CHAPERONES; MISFOLDED PROTEINS; GLYCOGEN-SYNTHESIS; PROTEASOME SYSTEM; UNFOLDED PROTEIN; E3 LIGASE; MUTATIONS; AGGRESOMES	Lafora disease (LD) is an autosomal recessive neurodegenerative disorder caused by mutation in either the dual specificity phosphatase laforin or ubiquitin ligase malin. A pathological hallmark of LD is the accumulation of cytoplasmic polyglucosan inclusions commonly known as Lafora bodies in both neuronal and non-neuronal tissues. How mutations in these two proteins cause disease pathogenesis is not well understood. Malin interacts with laforin and recruits to aggresomes upon proteasome inhibition and was shown to degrade misfolded proteins. Here we report that malin is spontaneously misfolded and tends to be aggregated, degraded by proteasomes, and forms not only aggresomes but also other cytoplasmic and nuclear aggregates in all transfected cells upon proteasomal inhibition. Malin also interacts with Hsp70. Several disease-causing mutants of malin are comparatively more unstable than wild type and form aggregates in most transfected cells even without the inhibition of proteasome function. These cytoplasmic and nuclear aggregates are immunoreactive to ubiquitin and 20 S proteasome. Interestingly, progressive proteasomal dysfunction and cell death is also most frequently observed in the mutant malin-overexpressed cells compared with the wild-type counterpart. Finally, we demonstrate that the co-chaperone carboxyl terminus of the Hsc70-interacting protein (CHIP) stabilizes malin by modulating the activity of Hsp70. All together, our results suggest that malin is unstable, and the aggregate-prone protein and co-chaperone CHIP can modulate its stability.	[Rao, Sudheendra N. R.; Sharma, Jaiprakash; Maity, Ranjan; Jana, Nihar Ranjan] Natl Brain Res Ctr, Mol & Cellular Neurosci Lab, Manesar 122050, Gurgaon, India	Department of Biotechnology (DBT) India; National Brain Research Centre (NBRC)	Jana, NR (corresponding author), Natl Brain Res Ctr, Mol & Cellular Neurosci Lab, Manesar 122050, Gurgaon, India.	nihar@nbrc.ac.in	Rao, Sudheendra/K-3017-2014	Rao, Sudheendra/0000-0001-7576-1718; Jana, Nihar/0000-0002-6549-4211	Department of Biotechnology, Government of India	Department of Biotechnology, Government of India(Department of Biotechnology (DBT) India)	This work was supported by the Department of Biotechnology, Government of India.	ACHARYA JN, 1993, EPILEPSIA, V34, P476, DOI 10.1111/j.1528-1157.1993.tb02588.x; Ardley HC, 2003, MOL BIOL CELL, V14, P4541, DOI 10.1091/mbc.E03-02-0078; Ballinger CA, 1999, MOL CELL BIOL, V19, P4535; Bence NF, 2001, SCIENCE, V292, P1552, DOI 10.1126/science.292.5521.1552; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Callebaut I, 1997, CELL MOL LIFE SCI, V53, P621, DOI 10.1007/s000180050082; Solaz-Fuster MC, 2008, HUM MOL GENET, V17, P667, DOI 10.1093/hmg/ddm339; CARPENTER S, 1981, NEUROLOGY, V31, P1564, DOI 10.1212/WNL.31.12.1564; Chan EM, 2003, NAT GENET, V35, P125, DOI 10.1038/ng1238; Cheng A, 2007, GENE DEV, V21, P2399, DOI 10.1101/gad.1553207; Delgado-Escueta AV, 2007, CURR NEUROL NEUROSCI, V7, P428, DOI 10.1007/s11910-007-0066-7; Fernandez-Escamilla AM, 2004, NAT BIOTECHNOL, V22, P1302, DOI 10.1038/nbt1012; Ganesh S, 2000, HUM MOL GENET, V9, P2251, DOI 10.1093/oxfordjournals.hmg.a018916; Garcia-Mata R, 2002, TRAFFIC, V3, P388, DOI 10.1034/j.1600-0854.2002.30602.x; Garyali P, 2009, HUM MOL GENET, V18, P688, DOI 10.1093/hmg/ddn398; Gentry MS, 2005, P NATL ACAD SCI USA, V102, P8501, DOI 10.1073/pnas.0503285102; Glickman MH, 2002, PHYSIOL REV, V82, P373, DOI 10.1152/physrev.00027.2001; Ianzano Leonarda, 2005, Hum Mutat, V26, P397, DOI 10.1002/humu.9376; Imai Y, 2002, MOL CELL, V10, P55, DOI 10.1016/S1097-2765(02)00583-X; Jana NR, 2005, J BIOL CHEM, V280, P11635, DOI 10.1074/jbc.M412042200; Johnston JA, 1998, J CELL BIOL, V143, P1883, DOI 10.1083/jcb.143.7.1883; Junn E, 2002, J BIOL CHEM, V277, P47870, DOI 10.1074/jbc.M203159200; Kitada T, 1998, NATURE, V392, P605, DOI 10.1038/33416; Kopito RR, 2000, TRENDS CELL BIOL, V10, P524, DOI 10.1016/S0962-8924(00)01852-3; Lafora GR, 1911, Z GESAMTE NEUROL PSY, V6, P1, DOI 10.1007/BF02863929; Lansbury PT, 2006, NATURE, V443, P774, DOI 10.1038/nature05290; Liu Y, 2009, HUM MOL GENET, V18, P2622, DOI 10.1093/hmg/ddp196; Lohi H, 2005, HUM MOL GENET, V14, P2727, DOI 10.1093/hmg/ddi306; McDonough H, 2003, CELL STRESS CHAPERON, V8, P303, DOI 10.1379/1466-1268(2003)008<0303:CALBTC>2.0.CO;2; Minassian BA, 1998, NAT GENET, V20, P171, DOI 10.1038/2470; Minassian BA, 2001, PEDIATR NEUROL, V25, P21, DOI 10.1016/S0887-8994(00)00276-9; Mittal S, 2007, HUM MOL GENET, V16, P753, DOI 10.1093/hmg/ddm006; Muchowski PJ, 2005, NAT REV NEUROSCI, V6, P11, DOI 10.1038/nrn1587; Murata S, 2001, EMBO REP, V2, P1133, DOI 10.1093/embo-reports/kve246; Murata S, 2003, INT J BIOCHEM CELL B, V35, P572, DOI 10.1016/S1357-2725(02)00394-1; NERON B, 2008, BIOOP SOURC C BOSC T; NISHIMURA RN, 1980, ANN NEUROL, V8, P409, DOI 10.1002/ana.410080412; Pickart CM, 2001, ANNU REV BIOCHEM, V70, P503, DOI 10.1146/annurev.biochem.70.1.503; Shimura H, 2000, NAT GENET, V25, P302, DOI 10.1038/77060; Singh S, 2006, J MED GENET, V43, DOI 10.1136/jmg.2005.039479; Singh S, 2009, HUM MUTAT, V30, P715, DOI 10.1002/humu.20954; Taylor JP, 2002, SCIENCE, V296, P1991, DOI 10.1126/science.1067122; Vernia S, 2009, J BIOL CHEM, V284, P8247, DOI 10.1074/jbc.M808492200; Vilchez D, 2007, NAT NEUROSCI, V10, P1407, DOI 10.1038/nn1998; Wang W, 2007, ARCH BIOCHEM BIOPHYS, V457, P264, DOI 10.1016/j.abb.2006.10.017; Wilkins MR, 1999, METH MOL B, V112, P531; Worby CA, 2008, J BIOL CHEM, V283, P4069, DOI 10.1074/jbc.M708712200	47	36	36	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 8	2010	285	2					1404	1413		10.1074/jbc.M109.006312	http://dx.doi.org/10.1074/jbc.M109.006312			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	539MH	19892702	hybrid, Green Published			2022-12-25	WOS:000273258200060
J	Anderson, LR; Sutherland, RL; Butt, AJ				Anderson, L. R.; Sutherland, R. L.; Butt, A. J.			BAG-1 overexpression attenuates luminal apoptosis in MCF-10A mammary epithelial cells through enhanced RAF-1 activation	ONCOGENE			English	Article						BAG-1; breast cancer; apoptosis; RAF-1; ERK; MCF-10A	HUMAN BREAST-CANCER; PROTEASOME PATHWAY; SIGNALING PATHWAY; PROGNOSTIC VALUE; LUMEN FORMATION; PROTEIN-KINASE; EXPRESSION; GROWTH; BIM; PROLIFERATION	Although the multi-functional, prosurvival protein, Bcl-2-associated anthanogene 1 (BAG-1) is frequently overexpressed in breast cancers, its role in the development or maintenance of the malignant state remains unclear. Here, we have used the established MCF-10A 3-dimensional (3D) model of mammary morphogenesis as a biologically relevant system to determine how BAG-1 expression may influence the development of breast cancer. When cultured in 3D, MCF-10A cells undergo a highly regulated morphogenic program leading to the development of polarized acinar structures containing a central, hollow lumen formed, in part, through the induction of BIM-dependent apoptosis. BAG-1 overexpression resulted in an attenuation of this normal apoptotic program characterized by a significantly increased number of acini with filled lumens-a phenotype commonly observed in ductal carcinoma in situ. BAG-1's effects were associated with an activation of RAF-1-a known binding partner of BAG-1, enhanced signaling through the MAP kinase pathway and a decrease in BIM expression. Reversal of the BAG-1-associated survival phenotype by the mitogen-activated kinase/ERK kinase inhibitor, U0126, implicates the RAF-1-extracellular signal-regulated kinase signaling pathway as a major mediator of BAG-1's effects in this model. As BAG-1 expression is often elevated in preinvasive breast cancers, these findings support a possible role for BAG-1 as an early contributor to the malignant process in the breast. Oncogene (2010) 29, 527-538; doi: 10.1038/onc.2009.362; published online 2 November 2009	[Anderson, L. R.; Sutherland, R. L.; Butt, A. J.] Garvan Inst Med Res, Canc Res Program, Sydney, NSW 2010, Australia; [Sutherland, R. L.; Butt, A. J.] Univ New S Wales, Fac Med, St Vincents Clin Sch, Sydney, NSW, Australia	Garvan Institute of Medical Research; University of New South Wales Sydney	Butt, AJ (corresponding author), Garvan Inst Med Res, Canc Res Program, 384 Victoria St, Sydney, NSW 2010, Australia.	abutt@garvan.org.au	Sutherland, Robert L/A-8378-2008; Anderson, Luke/D-1780-2012	Anderson, Luke/0000-0003-3654-1258; Butt, Alison/0000-0002-6216-5105	Cancer Institute NSW; Australian Postgraduate Award; National Health and Medical Research Council (Australia) [535903]; RT Hall Trust	Cancer Institute NSW; Australian Postgraduate Award(Australian Government); National Health and Medical Research Council (Australia)(National Health and Medical Research Council (NHMRC) of Australia); RT Hall Trust	We gratefully acknowledge the assistance of Drs Will Hughes and James Burchfield (Garvan Institute) with confocal microscopy, and Professor Graham Packham (University of Southampton) for useful discussions. This study was supported by Cancer Institute NSW Postgraduate Scholarship and Australian Postgraduate Award (LRA); Cancer Institute NSW Career Development and Support Fellowship (AJB); National Health and Medical Research Council (Australia) Program Grant 535903; RT Hall Trust.	Arhel NJ, 2003, INT J CANCER, V106, P364, DOI 10.1002/ijc.11257; AVRUCH J, 1994, TRENDS BIOCHEM SCI, V19, P279, DOI 10.1016/0968-0004(94)90005-1; Blagosklonny MV, 1996, BIOCHEM BIOPH RES CO, V227, P564, DOI 10.1006/bbrc.1996.1546; Brimmell M, 1999, BRIT J CANCER, V81, P1042, DOI 10.1038/sj.bjc.6690805; Brummer T, 2006, J BIOL CHEM, V281, P626, DOI 10.1074/jbc.M509567200; Caldon CE, 2008, CANCER RES, V68, P3026, DOI 10.1158/0008-5472.CAN-07-3079; Cutress RI, 2003, ONCOGENE, V22, P4973, DOI 10.1038/sj.onc.1206688; Debnath J, 2005, NAT REV CANCER, V5, P675, DOI 10.1038/nrc1695; Debnath J, 2003, METHODS, V30, P256, DOI 10.1016/S1046-2023(03)00032-X; Debnath J, 2002, CELL, V111, P29, DOI 10.1016/S0092-8674(02)01001-2; Elliott E, 2009, FEBS LETT, V583, P229, DOI 10.1016/j.febslet.2008.12.009; Froesch BA, 1998, J BIOL CHEM, V273, P11660, DOI 10.1074/jbc.273.19.11660; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; Harris J, 1999, DIS BREAST; Hohfeld J, 1998, BIOL CHEM, V379, P269; Kudoh M, 2002, CANCER RES, V62, P1904; Ley R, 2003, J BIOL CHEM, V278, P18811, DOI 10.1074/jbc.M301010200; Luciano F, 2003, ONCOGENE, V22, P6785, DOI 10.1038/sj.onc.1206792; Mailleux AA, 2008, CELL CYCLE, V7, P57, DOI 10.4161/cc.7.1.5150; Mailleux AA, 2007, DEV CELL, V12, P221, DOI 10.1016/j.devcel.2006.12.003; Meller R, 2006, J BIOL CHEM, V281, P7429, DOI 10.1074/jbc.M512138200; MILLAR EKA, 2008, BRIT J CANCER, V100, P123; Mueller H, 2000, INT J CANCER, V89, P384, DOI 10.1002/1097-0215(20000720)89:4<384::AID-IJC11>3.0.CO;2-R; Muthuswamy SK, 2001, NAT CELL BIOL, V3, P785, DOI 10.1038/ncb0901-785; Nadler Y, 2008, BREAST CANCER RES, V10, DOI 10.1186/bcr1998; Packham G, 1997, BIOCHEM J, V328, P807, DOI 10.1042/bj3280807; Reginato MJ, 2005, MOL CELL BIOL, V25, P4591, DOI 10.1128/MCB.25.11.4591-4601.2005; Salh B, 1999, ANTICANCER RES, V19, P731; Sharp Adam, 2004, Expert Reviews in Molecular Medicine, V6, P1, DOI 10.1017/S1462399404007537; Sivaraman VS, 1997, J CLIN INVEST, V99, P1478, DOI 10.1172/JCI119309; Song JW, 2001, NAT CELL BIOL, V3, P276, DOI 10.1038/35060068; Sutherland R.L., 1999, HUMAN CELL CULTURE, P79; Takayama S, 1997, EMBO J, V16, P4887, DOI 10.1093/emboj/16.16.4887; Takayama S, 1998, CANCER RES, V58, P3116; TAKAYAMA S, 1995, CELL, V80, P279, DOI 10.1016/0092-8674(95)90410-7; Townsend PA, 2003, CANCER RES, V63, P4150; Townsend PA, 2003, BBA-REV CANCER, V1603, P83, DOI 10.1016/S0304-419X(03)00002-7; Townsend PA, 2002, J PATHOL, V197, P51, DOI 10.1002/path.1081; Turner BC, 2001, J CLIN ONCOL, V19, P992, DOI 10.1200/JCO.2001.19.4.992; Wang HG, 1996, P NATL ACAD SCI USA, V93, P7063, DOI 10.1073/pnas.93.14.7063; Wang S, 1998, MOL CELL BIOL, V18, P7487, DOI 10.1128/MCB.18.12.7487; Wang XH, 2009, BRIT J CANCER, V100, P1347, DOI 10.1038/sj.bjc.6604985; Yang XL, 1999, CLIN CANCER RES, V5, P1816; ZEINER M, 1995, P NATL ACAD SCI USA, V92, P11465, DOI 10.1073/pnas.92.25.11465	45	18	21	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN	2010	29	4					527	538		10.1038/onc.2009.362	http://dx.doi.org/10.1038/onc.2009.362			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	549WH	19881545				2022-12-25	WOS:000274084600006
J	Dzamko, N; van Denderen, BJW; Hevener, AL; Jorgensen, SB; Honeyman, J; Galic, S; Chen, ZP; Watt, MJ; Campbell, DJ; Steinberg, GR; Kemp, BE				Dzamko, Nicolas; van Denderen, Bryce J. W.; Hevener, Andrea L.; Jorgensen, Sebastian Beck; Honeyman, Jane; Galic, Sandra; Chen, Zhi-Ping; Watt, Matthew J.; Campbell, Duncan J.; Steinberg, Gregory R.; Kemp, Bruce E.			AMPK beta 1 Deletion Reduces Appetite, Preventing Obesity and Hepatic Insulin Resistance	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED PROTEIN-KINASE; HUMAN SKELETAL-MUSCLE; INTERLEUKIN-6 RELEASE; CATALYTIC SUBUNIT; FOOD-INTAKE; LIVER; METABOLISM; ADIPONECTIN; DISEASE; YEAST	The AMP-activated protein kinase (AMPK) is an alpha beta gamma heterotrimer that regulates appetite and fuel metabolism. We have generated AMPK beta 1(-/-) mice on a C57Bl/6 background that are viable, fertile, survived greater than 2 years, and display no visible brain developmental defects. These mice have a 90% reduction in hepatic AMPK activity due to loss of the catalytic alpha subunits, with modest reductions of activity detected in the hypothalamus and white adipose tissue and no change in skeletal muscle or heart. On a low fat or an obesity-inducing high fat diet, beta 1(-/-) mice had reduced food intake, reduced adiposity, and reduced total body mass. Metabolic rate, physical activity, adipose tissue lipolysis, and lipogenesis were similar to wild type littermates. The reduced appetite and body mass of beta 1(-/-) mice were associated with protection from high fat diet-induced hyperinsulinemia, hepatic steatosis, and insulin resistance. We demonstrate that the loss of beta 1 reduces food intake and protects against the deleterious effects of an obesity-inducing diet.	[Dzamko, Nicolas; van Denderen, Bryce J. W.; Jorgensen, Sebastian Beck; Honeyman, Jane; Galic, Sandra; Chen, Zhi-Ping; Campbell, Duncan J.; Steinberg, Gregory R.; Kemp, Bruce E.] Univ Melbourne, St Vincents Inst Med Res, Fitzroy, Vic 3065, Australia; [Dzamko, Nicolas; van Denderen, Bryce J. W.; Jorgensen, Sebastian Beck; Honeyman, Jane; Galic, Sandra; Chen, Zhi-Ping; Campbell, Duncan J.; Steinberg, Gregory R.; Kemp, Bruce E.] Univ Melbourne, Dept Med, Fitzroy, Vic 3065, Australia; [Hevener, Andrea L.] Univ Calif Los Angeles, Dept Med, Los Angeles, CA 90095 USA; [Jorgensen, Sebastian Beck] Univ Copenhagen, Sect Human Physiol, Copenhagen Muscle Res Ctr, Dept Exercise & Sport Sci, DK-2100 Copenhagen, Denmark; [Watt, Matthew J.] Monash Univ, Dept Physiol, Clayton, Vic 3800, Australia; [Steinberg, Gregory R.] McMaster Univ, Dept Med, Hamilton, ON L8N 3Z5, Canada	St. Vincent's Institute of Medical Research; University of Melbourne; University of Melbourne; University of California System; University of California Los Angeles; University of Copenhagen; Monash University; McMaster University	Kemp, BE (corresponding author), Univ Melbourne, St Vincents Inst Med Res, 41 Victoria Parade, Fitzroy, Vic 3065, Australia.	bkemp@svi.edu.au	Watt, Matthew J/B-2089-2014; van Denderen, Bryce/AAW-5454-2021; Kemp, Bruce E/L-2633-2014; Galic, Sandra/C-6098-2014; Kemp, Bruce/G-9602-2019; Dzamko, Nicolas/AAD-6922-2019	Kemp, Bruce E/0000-0001-6735-5082; Galic, Sandra/0000-0002-7611-5619; Kemp, Bruce/0000-0001-6735-5082; Dzamko, Nicolas/0000-0002-9121-0294; Steinberg, Gregory/0000-0001-5425-8275	Australian Research Council; National Health and Medical Research Council; Diabetes Australia Research Trust; National Heart Foundation of Australia	Australian Research Council(Australian Research Council); National Health and Medical Research Council(National Health and Medical Research Council (NHMRC) of Australia); Diabetes Australia Research Trust; National Heart Foundation of Australia(National Heart Foundation of Australia)	This study was supported by grants from the Australian Research Council (to B. E. K.), the National Health and Medical Research Council (to M. J. W., D. J. C., B. E. K., and G. R. S.), the Diabetes Australia Research Trust (to G. R. S.), and the National Heart Foundation of Australia (to B. E. K. and D. J. C.).	ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; Anderson KA, 2008, CELL METAB, V7, P377, DOI 10.1016/j.cmet.2008.02.011; Andersson U, 2004, J BIOL CHEM, V279, P12005, DOI 10.1074/jbc.C300557200; Andreelli F, 2006, ENDOCRINOLOGY, V147, P2432, DOI 10.1210/en.2005-0898; Cai DS, 2005, NAT MED, V11, P183, DOI 10.1038/nm1166; CARLING D, 1994, J BIOL CHEM, V269, P11442; Chen MB, 2005, J CLIN ENDOCR METAB, V90, P3665, DOI 10.1210/jc.2004-1980; Chen ZP, 1999, FEBS LETT, V460, P343, DOI 10.1016/S0014-5793(99)01371-X; Claret M, 2007, J CLIN INVEST, V117, P2325, DOI 10.1172/JCI31516; Dasgupta B, 2009, DEV CELL, V16, P256, DOI 10.1016/j.devcel.2009.01.005; Folmes CDL, 2007, CARDIOVASC RES, V73, P278, DOI 10.1016/j.cardiores.2006.10.008; Foretz M, 2005, DIABETES, V54, P1331, DOI 10.2337/diabetes.54.5.1331; Gentry MS, 2007, J CELL BIOL, V178, P477, DOI 10.1083/jcb.200704094; Glund S, 2009, ENDOCRINOLOGY, V150, P600, DOI 10.1210/en.2008-1204; Hawley SA, 1996, J BIOL CHEM, V271, P27879, DOI 10.1074/jbc.271.44.27879; Hevener AL, 2003, NAT MED, V9, P1491, DOI 10.1038/nm956; Horike N, 2008, J BIOL CHEM, V283, P33902, DOI 10.1074/jbc.M802537200; Iseli TJ, 2005, J BIOL CHEM, V280, P13395, DOI 10.1074/jbc.M412993200; Iseli TJ, 2008, J BIOL CHEM, V283, P4799, DOI 10.1074/jbc.M708298200; Kahn BB, 2005, CELL METAB, V1, P15, DOI 10.1016/j.cmet.2004.12.003; Kemp BE, 2003, BIOCHEM SOC T, V31, P162; Kim JH, 2008, J BIOL CHEM, V283, P708, DOI 10.1074/jbc.M708568200; Klover PJ, 2003, DIABETES, V52, P2784, DOI 10.2337/diabetes.52.11.2784; Koo SH, 2005, NATURE, V437, P1109, DOI 10.1038/nature03967; Lazar MA, 2005, SCIENCE, V307, P373, DOI 10.1126/science.1104342; MacDonald C, 2003, J APPL PHYSIOL, V95, P2273, DOI 10.1152/japplphysiol.00242.2003; Minokoshi Y, 2004, NATURE, V428, P569, DOI 10.1038/nature02440; MITCHELHILL KI, 1994, J BIOL CHEM, V269, P2361; Mitchelhill KI, 1997, J BIOL CHEM, V272, P24475, DOI 10.1074/jbc.272.39.24475; Petersen KF, 2005, DIABETES, V54, P603, DOI 10.2337/diabetes.54.3.603; Scott JW, 2008, CHEM BIOL, V15, P1220, DOI 10.1016/j.chembiol.2008.10.005; Sell H, 2006, BIOCHEM BIOPH RES CO, V343, P700, DOI 10.1016/j.bbrc.2006.03.010; Shaw RJ, 2005, SCIENCE, V310, P1642, DOI 10.1126/science.1120781; Stapleton D, 1996, J BIOL CHEM, V271, P611, DOI 10.1074/jbc.271.2.611; Steinberg GR, 2006, ENDOCRINOLOGY, V147, P3906, DOI 10.1210/en.2005-1587; Steinberg GR, 2006, CELL METAB, V4, P465, DOI 10.1016/j.cmet.2006.11.005; Steinberg GR, 2009, PHYSIOL REV, V89, P1025, DOI 10.1152/physrev.00011.2008; Thornton C, 1998, J BIOL CHEM, V273, P12443, DOI 10.1074/jbc.273.20.12443; Townley R, 2007, SCIENCE, V315, P1726, DOI 10.1126/science.1137503; Ueki K, 2004, MOL CELL BIOL, V24, P5434, DOI 10.1128/MCB.24.12.5434-5446.2004; Viollet B, 2007, DIABETES METAB, V33, P395, DOI 10.1016/j.diabet.2007.10.004; Viollet B, 2003, J CLIN INVEST, V111, P91, DOI 10.1172/JCI200316567; Watt MJ, 2006, NAT MED, V12, P541, DOI 10.1038/nm1383	43	129	134	0	14	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 1	2010	285	1					115	122		10.1074/jbc.M109.056762	http://dx.doi.org/10.1074/jbc.M109.056762			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	536UT	19892703	Green Published, hybrid			2022-12-25	WOS:000273070100012
J	Kohler, S; Cirillo, LA				Kohler, Sarah; Cirillo, Lisa Ann			Stable Chromatin Binding Prevents FoxA Acetylation, Preserving FoxA Chromatin Remodeling	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTION FACTOR; DNA-BINDING; IN-VITRO; NUCLEOSOME-BINDING; CRYSTAL-STRUCTURE; GLOBULAR DOMAIN; HISTONE H5; HEPATOCYTE; PROTEIN; DIFFERENTIATION	FoxA1-3 (formerly HNF3 alpha, -beta, and -gamma), members of the FoxA subfamily of forkhead transcription factors, function as initial chromatin-binding and chromatin-remodeling factors in a variety of tissues, including liver and pancreas. Despite essential roles in development and metabolism, regulation of FoxA factors is not well understood. This study examines a potential role for acetylation in the regulation of FoxA chromatin binding and remodeling. Using in silico analysis, we have identified 11 putative p300 acetylation sites within FoxA1, five of which are located within wings 1 and 2 of its winged-helix DNA-binding domain. These polypeptide structures stabilize FoxA DNA and chromatin binding, and we have demonstrated that acetylation attenuates FoxA binding to DNA and diminishes its ability to remodel chromatin. FoxA acetylation is inhibited by chromatin binding. We propose a model whereby stable chromatin binding protects the FoxA DNA-binding domain from acetylation to preserve chromatin binding and remodeling by FoxA factors in the absence of extracellular cues.	[Kohler, Sarah; Cirillo, Lisa Ann] Med Coll Wisconsin, Dept Cell Biol Neurobiol & Anat, Milwaukee, WI 53226 USA	Medical College of Wisconsin	Cirillo, LA (corresponding author), Med Coll Wisconsin, Dept Cell Biol Neurobiol & Anat, 8701 Watertown Plank Rd, Milwaukee, WI 53226 USA.	lcirillo@mcw.edu			National Institutes of Health [R01DK073641, F32DK079649]; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [F32DK079649, R01DK073641] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))	This work was supported, in whole or in part, by National Institutes of Health Grants R01DK073641 (to L. A. C.) and F32DK079649 (to S. K.).	Bossard P, 1998, DEVELOPMENT, V125, P4909; Boyes J, 1998, NATURE, V396, P594, DOI 10.1038/25166; CASCIO S, 1991, DEVELOPMENT, V113, P217; CERF C, 1994, BIOCHEMISTRY-US, V33, P11079, DOI 10.1021/bi00203a004; Cirillo LA, 1999, MOL CELL, V4, P961, DOI 10.1016/S1097-2765(00)80225-7; Cirillo LA, 2002, MOL CELL, V9, P279, DOI 10.1016/S1097-2765(02)00459-8; Cirillo LA, 1998, EMBO J, V17, P244, DOI 10.1093/emboj/17.1.244; Cirillo LA, 2007, J MOL BIOL, V366, P720, DOI 10.1016/j.jmb.2006.11.087; CLARK KL, 1993, NATURE, V364, P412, DOI 10.1038/364412a0; COSTA RH, 1989, MOL CELL BIOL, V9, P1415, DOI 10.1128/MCB.9.4.1415; Dormeyer W, 2003, ANAL BIOANAL CHEM, V376, P994, DOI 10.1007/s00216-003-2058-z; Duncan SA, 1998, SCIENCE, V281, P692, DOI 10.1126/science.281.5377.692; Friedman JR, 2006, CELL MOL LIFE SCI, V63, P2317, DOI 10.1007/s00018-006-6095-6; Gualdi R, 1996, GENE DEV, V10, P1670, DOI 10.1101/gad.10.13.1670; Hatta M, 2009, BIOCHEM BIOPH RES CO, V379, P1005, DOI 10.1016/j.bbrc.2009.01.014; Hatta M, 2007, J BIOL CHEM, V282, P35583, DOI 10.1074/jbc.M704735200; Hernandez-Hernandez A, 2006, EMBO J, V25, P3264, DOI 10.1038/sj.emboj.7601228; Holmqvist PH, 2005, EXP CELL RES, V304, P593, DOI 10.1016/j.yexcr.2004.12.002; Howell JJ, 2009, J BIOL CHEM, V284, P24816, DOI 10.1074/jbc.M109.042135; Kaestner KH, 2000, TRENDS ENDOCRIN MET, V11, P281, DOI 10.1016/S1043-2760(00)00271-X; Kaestner KH, 2000, GENE DEV, V14, P142; Kaestner KH, 1998, MOL CELL BIOL, V18, P4245, DOI 10.1128/MCB.18.7.4245; Kalb JM, 1998, DEVELOPMENT, V125, P2171; Kim JY, 2004, MOL ENDOCRINOL, V18, P2880, DOI 10.1210/me.2004-0211; Lamonica JM, 2006, BLOOD, V108, P3736, DOI 10.1182/blood-2006-07-032847; Lee CS, 2005, NATURE, V435, P944, DOI 10.1038/nature03649; LIU JK, 1988, GENE DEV, V2, P528, DOI 10.1101/gad.2.5.528; LIU JK, 1991, MOL CELL BIOL, V11, P773, DOI 10.1128/MCB.11.2.773; Liu YN, 2005, ONCOGENE, V24, P8277, DOI 10.1038/sj.onc.1208991; MANGO SE, 1994, DEVELOPMENT, V120, P3019; Matsuzaki H, 2005, P NATL ACAD SCI USA, V102, P11278, DOI 10.1073/pnas.0502738102; McNally JG, 2000, SCIENCE, V287, P1262, DOI 10.1126/science.287.5456.1262; MCPHERSON CE, 1993, CELL, V75, P387, DOI 10.1016/0092-8674(93)80079-T; McPherson CE, 1996, NUCLEIC ACIDS RES, V24, P397, DOI 10.1093/nar/24.3.397; PANI L, 1992, MOL CELL BIOL, V12, P3723, DOI 10.1128/MCB.12.9.3723; Panowski SH, 2007, NATURE, V447, P550, DOI 10.1038/nature05837; Phair RD, 2004, MOL CELL BIOL, V24, P6393, DOI 10.1128/MCB.24.14.6393-6402.2004; RAMAKRISHNAN V, 1993, NATURE, V362, P219, DOI 10.1038/362219a0; Rausa FM, 2004, J BIOL CHEM, V279, P43070, DOI 10.1074/jbc.M407472200; Rausa FM, 2003, MOL CELL BIOL, V23, P437, DOI 10.1128/MCB.23.2.437-449.2003; Sakaguchi K, 1998, GENE DEV, V12, P2831, DOI 10.1101/gad.12.18.2831; Sekiya T, 2009, GENE DEV, V23, P804, DOI 10.1101/gad.1775509; Stafford JM, 2001, J BIOL CHEM, V276, P3811, DOI 10.1074/jbc.M009389200; Sterner DE, 2000, MICROBIOL MOL BIOL R, V64, P435, DOI 10.1128/MMBR.64.2.435-459.2000; Thompson PR, 2001, J BIOL CHEM, V276, P33721, DOI 10.1074/jbc.M104736200; Thompson PR, 2004, NAT STRUCT MOL BIOL, V11, P308, DOI 10.1038/nsmb740; Wang JCW, 2000, J BIOL CHEM, V275, P18418, DOI 10.1074/jbc.M910211199; WEIGEL D, 1989, CELL, V57, P645, DOI 10.1016/0092-8674(89)90133-5; Wolfrum C, 2003, P NATL ACAD SCI USA, V100, P11624, DOI 10.1073/pnas.1931483100; Wolfrum C, 2004, NATURE, V432, P1027, DOI 10.1038/nature03047; Wolfrum C, 2003, J CLIN INVEST, V112, P345, DOI 10.1172/JCI18698; Zhang LP, 2005, CELL METAB, V2, P141, DOI 10.1016/j.cmet.2005.07.002	52	23	23	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 1	2010	285	1					464	472		10.1074/jbc.M109.063149	http://dx.doi.org/10.1074/jbc.M109.063149			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	536UT	19897491	Green Published, hybrid			2022-12-25	WOS:000273070100048
J	Stadtmueller, BM; Ferrell, K; Whitby, FG; Heroux, A; Robinson, H; Myszka, DG; Hill, CP				Stadtmueller, Beth M.; Ferrell, Katherine; Whitby, Frank G.; Heroux, Annie; Robinson, Howard; Myszka, David G.; Hill, Christopher P.			Structural Models for Interactions between the 20S Proteasome and Its PAN/19S Activators	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							REGULATORY PARTICLE; S-PROTEASOME; ATPASES; ATP; PURIFICATION; COMPLEX; YEAST; GATE; PAN; IDENTIFICATION	Proteasome activity is regulated by sequestration of its proteolytic centers in a barrel-shaped structure that limits substrate access. Substrates enter the proteasome by means of activator complexes that bind to the end rings of proteasome alpha subunits and induce opening of an axial entrance/exit pore. The PA26 activator binds in a pocket on the proteasome surface using main chain contacts of its C-terminal residues and uses an internal activation loop to trigger gate opening by repositioning the proteasome Pro-17 reverse turn. Subunits of the unrelated PAN/19S activators bind with their C termini in the same pockets but can induce proteasome gate opening entirely from interactions of their C-terminal peptides, which are reported to cause gate opening by inducing a rocking motion of proteasome alpha subunits rather than by directly contacting the Pro-17 turn. Here we report crystal structures and binding studies of proteasome complexes with PA26 constructs that display modified C-terminal residues, including those corresponding to PAN. These findings suggest that PA26 and PAN/19S C-terminal residues bind superimposably and that both classes of activator induce gate opening by using direct contacts to residues of the proteasome Pro-17 reverse turn. In the case of the PAN and 19S activators, a penultimate tyrosine/phenylalanine residue contacts the proteasome Gly-19 carbonyl oxygen to stabilize the open conformation.	[Stadtmueller, Beth M.; Ferrell, Katherine; Whitby, Frank G.; Myszka, David G.; Hill, Christopher P.] Univ Utah, Dept Biochem, Sch Med, Salt Lake City, UT 84112 USA; [Heroux, Annie; Robinson, Howard] Brookhaven Natl Lab, Dept Biol, Upton, NY 11973 USA	Utah System of Higher Education; University of Utah; United States Department of Energy (DOE); Brookhaven National Laboratory	Hill, CP (corresponding author), Univ Utah, Dept Biochem, Sch Med, Salt Lake City, UT 84112 USA.	chris@biochem.utah.edu		Stadtmueller, Beth/0000-0003-0637-3206	National Institutes of Health [R01 GM59135]; NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERING [P30EB009998] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM059135] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Biomedical Imaging & Bioengineering (NIBIB)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	This work was supported, in whole or in part, by National Institutes of Health Grant R01 GM59135 (to C. P. H.).	Benaroudj N, 2003, MOL CELL, V11, P69, DOI 10.1016/S1097-2765(02)00775-X; Bochtler M, 1999, ANNU REV BIOPH BIOM, V28, P295, DOI 10.1146/annurev.biophys.28.1.295; Davis IW, 2007, NUCLEIC ACIDS RES, V35, pW375, DOI 10.1093/nar/gkm216; Djuranovic S, 2009, MOL CELL, V34, P580, DOI 10.1016/j.molcel.2009.04.030; DUBIEL W, 1992, J BIOL CHEM, V267, P22369; Forster A, 2003, EMBO J, V22, P4356, DOI 10.1093/emboj/cdg436; Forster A, 2005, MOL CELL, V18, P589, DOI 10.1016/j.molcel.2005.04.016; Glickman MH, 1998, MOL CELL BIOL, V18, P3149, DOI 10.1128/MCB.18.6.3149; Goldberg AL, 2007, BIOCHEM SOC T, V35, P12, DOI 10.1042/BST0350012; Groll M, 2003, J MOL BIOL, V327, P75, DOI 10.1016/S0022-2836(03)00080-9; Groll M, 1997, NATURE, V386, P463, DOI 10.1038/386463a0; HOFFMAN L, 1992, J BIOL CHEM, V267, P22362; Iwanczyk J, 2006, J MOL BIOL, V363, P648, DOI 10.1016/j.jmb.2006.08.010; Leggett DS, 2002, MOL CELL, V10, P495, DOI 10.1016/S1097-2765(02)00638-X; LOWE J, 1995, SCIENCE, V268, P533, DOI 10.1126/science.7725097; MA CP, 1994, J BIOL CHEM, V269, P3539; MA CP, 1992, J BIOL CHEM, V267, P10515; Medalia N, 2006, J STRUCT BIOL, V156, P84, DOI 10.1016/j.jsb.2006.03.015; Ortega J, 2005, J MOL BIOL, V346, P1221, DOI 10.1016/j.jmb.2004.12.049; PETERS JM, 1994, J BIOL CHEM, V269, P7709; Rabl J, 2008, MOL CELL, V30, P360, DOI 10.1016/j.molcel.2008.03.004; Rechsteiner M, 2005, TRENDS CELL BIOL, V15, P27, DOI 10.1016/j.tcb.2004.11.003; Rubin DM, 1998, EMBO J, V17, P4909, DOI 10.1093/emboj/17.17.4909; Schmidt M, 2005, NAT STRUCT MOL BIOL, V12, P294, DOI 10.1038/nsmb914; SEEMULLER E, 1995, SCIENCE, V268, P579, DOI 10.1126/science.7725107; Smith DM, 2007, MOL CELL, V27, P731, DOI 10.1016/j.molcel.2007.06.033; Smith DM, 2005, MOL CELL, V20, P687, DOI 10.1016/j.molcel.2005.10.019; UDVARDY A, 1993, J BIOL CHEM, V268, P9055; Unno M, 2002, STRUCTURE, V10, P609, DOI 10.1016/S0969-2126(02)00748-7; Ustrell V, 2002, EMBO J, V21, P3516, DOI 10.1093/emboj/cdf333; Whitby FG, 2000, NATURE, V408, P115, DOI 10.1038/35040607; Yao Y, 1999, J BIOL CHEM, V274, P33921, DOI 10.1074/jbc.274.48.33921; Zhang F, 2009, MOL CELL, V34, P473, DOI 10.1016/j.molcel.2009.04.021; Zhang ZG, 1998, P NATL ACAD SCI USA, V95, P2807, DOI 10.1073/pnas.95.6.2807; Zwickl P, 1999, J BIOL CHEM, V274, P26008, DOI 10.1074/jbc.274.37.26008; Zwickl P, 2002, ADV PROTEIN CHEM, V59, P187	36	41	48	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 1	2010	285	1					13	17		10.1074/jbc.C109.070425	http://dx.doi.org/10.1074/jbc.C109.070425			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	536UT	19889631	Green Published, hybrid			2022-12-25	WOS:000273070100003
J	Zajac, P; Oberg, C; Ahmadian, A				Zajac, Pawel; Oberg, Christine; Ahmadian, Afshin			Analysis of Short Tandem Repeats by Parallel DNA Threading	PLOS ONE			English	Article							EUKARYOTIC GENOMES; MICROSATELLITES; EVOLUTION	The majority of studies employing short tandem repeats (STRs) require investigation of several of these genetic markers. As such, we demonstrate the feasibility of the trinucleotide threading (TnT) approach for scalable analysis of STRs. The TnT method represents a parallel amplification alternative that addresses the obstacles associated with multiplex PCR. In this study, analysis of the STR fragments was performed with capillary gel electrophoresis; however, it should be possible to combine our approach with the massive 454 sequencing platform to considerably increase the number of targeted STRs.			Zajac, P (corresponding author), Royal Inst Technol KTH, Sch Biotechnol, Dept Gene Technol, Stockholm, Sweden.	afshin.ahmadian@biotech.kth.se						Arzimanoglou II, 1998, CANCER-AM CANCER SOC, V82, P1808, DOI 10.1002/(SICI)1097-0142(19980515)82:10<1808::AID-CNCR2>3.0.CO;2-J; Butler JM, 2006, J FORENSIC SCI, V51, P253, DOI 10.1111/j.1556-4029.2006.00046.x; Ellegren H, 2004, NAT REV GENET, V5, P435, DOI 10.1038/nrg1348; Everett CM, 2004, BRAIN, V127, P2385, DOI 10.1093/brain/awh278; Leclercq S, 2007, BMC BIOINFORMATICS, V8, DOI 10.1186/1471-2105-8-125; Li YC, 2004, MOL BIOL EVOL, V21, P991, DOI 10.1093/molbev/msh073; Li YC, 2002, MOL ECOL, V11, P2453, DOI 10.1046/j.1365-294X.2002.01643.x; Montelius K, 2008, FORENSIC SCI INT-GEN, V2, pE49, DOI 10.1016/j.fsigen.2007.12.005; Pettersson E, 2006, NUCLEIC ACIDS RES, V34, DOI 10.1093/nar/gkl103; Pettersson E, 2008, HUM MUTAT, V29, P323, DOI 10.1002/humu.20655; Pourmand N, 2007, P NATL ACAD SCI USA, V104, P6146, DOI 10.1073/pnas.0700921104; Rothberg JM, 2008, NAT BIOTECHNOL, V26, P1117, DOI 10.1038/nbt1485; Santana QC, 2009, BIOTECHNIQUES, V46, P217, DOI 10.2144/000113085; Sharma PC, 2007, TRENDS BIOTECHNOL, V25, P490, DOI 10.1016/j.tibtech.2007.07.013; Toth G, 2000, GENOME RES, V10, P967, DOI 10.1101/gr.10.7.967; van Belkum A, 1998, MICROBIOL MOL BIOL R, V62, P275, DOI 10.1128/MMBR.62.2.275-293.1998; Zajac P, 2008, GENOMICS, V91, P209, DOI 10.1016/j.ygeno.2007.10.012	17	4	7	0	5	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA	1932-6203			PLOS ONE	PLoS One	NOV 13	2009	4	11							e7823	10.1371/journal.pone.0007823	http://dx.doi.org/10.1371/journal.pone.0007823			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	518VB	19915680	Green Published, gold, Green Submitted			2022-12-25	WOS:000271721900014
J	Djuardi, Y; Wibowo, H; Supali, T; Ariawan, I; Bredius, RGM; Yazdanbakhsh, M; Rodrigues, LC; Sartono, E				Djuardi, Yenny; Wibowo, Heri; Supali, Taniawati; Ariawan, Iwan; Bredius, Robbert G. M.; Yazdanbakhsh, Maria; Rodrigues, Laura C.; Sartono, Erliyani			Determinants of the Relationship between Cytokine Production in Pregnant Women and Their Infants	PLOS ONE			English	Article							IMMUNE-RESPONSES; HELMINTH INFECTIONS; IN-UTERO; FETAL; REACTIVITY; CHILDHOOD; EXPOSURE; ALLERGEN; ASTHMA; GROWTH	Exposure to environmental factors during fetal life and infancy is thought to play an important role in the early development of innate and adaptive immunity. The immunological relationship between mother and infant and the effect that environmental exposures have during pregnancy and early childhood have not been studied extensively. Here the production of cytokines was measured in 146 pairs of mothers and their 2-month-old infants. The effect of place of residence, socio-economic variables, parasitic infections as well as maternal and child characteristics on measured cytokine production was determined. Mothers producing high levels of IL-10, IFN-gamma and IL-5 were more likely to have infants who also produced high levels of these cytokines either spontaneously (OR 2.6(95% CI 1.2-5.4), OR 2.9(CI 1.3-6.6), OR 11.2(CI 4.6-27.2), respectively) or in response to PHA (IL-10: OR 3.0(CI 1.4-6.6), IFN-gamma: OR 2.0(CI 1.0-4.2), respectively) even after adjustment for potential confounding variables. This was not the case for TNF-alpha. In response to LPS, place of residence was a strong determinant of infant IL-10 (OR 0.2(CI 0.1-0.9)) and TNF-alpha (OR 0.3(CI 0.1-0.9)) production. Maternal protozoan infections was independently associated with reduced infant IL10 in response to PHA and to LPS as well as reduced TNF-alpha and IFN-gamma in response to PHA. These results indicate strong relationship between maternal and infant's cellular immune responses even after taking into account many environmental influences that could affect infant's response directly or indirectly through uterine microenvironment. However, place of residence and intestinal infections may still directly affect the immune responses of the infant. Taken together, the study provides evidence for imprinted cytokine responses of an infant which may have implications for their reaction to incoming antigens, warranting further investigation into the role that genetics or epigenetics play in shaping the cytokine response by an infant to self or external antigens.			Djuardi, Y (corresponding author), Univ Indonesia, Fac Med, Dept Parasitol, Jakarta, Indonesia.	yenny_djuardi@yahoo.com	Yazdanbakhsh, Maria/AAI-3996-2020; Bredius, Robbert/AAF-2592-2019; RODRIGUES, LAURA CUNHA/AAO-4130-2021; Djuardi, Yenny/AGP-5890-2022	Yazdanbakhsh, Maria/0000-0002-7666-1441; Bredius, Robbert/0000-0001-8151-1539; Wibowo, Heri/0000-0001-7708-5135; Rodrigues, Laura Cunha/0000-0001-9008-660X				Abreu MT, 2001, J IMMUNOL, V167, P1609, DOI 10.4049/jimmunol.167.3.1609; Adegnika AA, 2008, J INFECT DIS, V198, P928, DOI 10.1086/591057; Boney CM, 2005, PEDIATRICS, V115, pE290, DOI 10.1542/peds.2004-1808; Braun-Fahrlander C, 2002, NEW ENGL J MED, V347, P869, DOI 10.1056/NEJMoa020057; Carson RT, 1999, J IMMUNOL METHODS, V227, P41, DOI 10.1016/S0022-1759(99)00069-1; Cirioni O, 1999, EUR J EPIDEMIOL, V15, P389, DOI 10.1023/A:1007551218671; de Almeida MF, 2007, REV SAUDE PUBL, V41, P35, DOI 10.1590/S0034-89102007000100006; de Jager W, 2003, CLIN DIAGN LAB IMMUN, V10, P133, DOI 10.1128/CDLI.10.1.133-139.2003; Dunstan JA, 2003, J ALLERGY CLIN IMMUN, V112, P1178, DOI 10.1016/j.jaci.2003.09.009; Eriksson M, 2007, CLIN EXP IMMUNOL, V150, P469, DOI 10.1111/j.1365-2249.2007.03515.x; Fievet N, 1996, PARASITE IMMUNOL, V18, P483, DOI 10.1046/j.1365-3024.1996.d01-19.x; Figueiredo CA, 2009, ENVIRON HEALTH PERSP, V117, P845, DOI 10.1289/ehp.0800366; Forsen T, 2000, ANN INTERN MED, V133, P176, DOI 10.7326/0003-4819-133-3-200008010-00008; Grogan JL, 1996, EUR J IMMUNOL, V26, P1365, DOI 10.1002/eji.1830260628; Jiang B, 2003, CLIN DIAGN LAB IMMUN, V10, P995, DOI 10.1128/CDLI.10.6.995-1001.2003; Jones AC, 1996, PEDIATR ALLERGY IMMU, V7, P109, DOI 10.1111/j.1399-3038.1996.tb00117.x; Kajantie E, 2008, INT J EPIDEMIOL, V37, P280, DOI 10.1093/ije/dyn012; King CL, 1998, J IMMUNOL, V160, P3578; King CL, 2002, J IMMUNOL, V168, P356, DOI 10.4049/jimmunol.168.1.356; Krauss-Etschmann S, 2008, J ALLERGY CLIN IMMUN, V121, P464, DOI 10.1016/j.jaci.2007.09.018; Malhotra I, 1997, J CLIN INVEST, V99, P1759, DOI 10.1172/JCI119340; Noakes PS, 2006, EUR RESPIR J, V28, P721, DOI 10.1183/09031936.06.00050206; Petersen E, 2007, PARASITOLOGY, V134, P1855, DOI 10.1017/S0031182007000182; Pit DSS, 2000, ALLERGY, V55, P732, DOI 10.1034/j.1398-9995.2000.00477.x; Prescott SL, 2005, CLIN EXP ALLERGY, V35, P417, DOI 10.1111/j.1365-2222.2005.02171.x; Savidge TC, 2006, PEDIATR RES, V59, P89, DOI 10.1203/01.pdr.0000195101.74184.e3; Soboslay PT, 1999, CLIN EXP IMMUNOL, V117, P130; van der Kleij D, 2004, J INFECT DIS, V189, P1044, DOI 10.1086/382089; VanDurenSchmidt K, 1997, PEDIATR RES, V41, P128, DOI 10.1203/00006450-199701000-00020; Victora CG, 1997, INT J EPIDEMIOL, V26, P224, DOI 10.1093/ije/26.1.224; Warner JA, 1998, CLIN EXP ALLERGY, V28, P35	32	30	32	0	0	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	NOV 9	2009	4	11							e7711	10.1371/journal.pone.0007711	http://dx.doi.org/10.1371/journal.pone.0007711			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	517ZM	19898617	Green Accepted, Green Submitted, gold, Green Published			2022-12-25	WOS:000271658000002
J	Nymark, M; Valle, KC; Brembu, T; Hancke, K; Winge, P; Andresen, K; Johnsen, G; Bones, AM				Nymark, Marianne; Valle, Kristin C.; Brembu, Tore; Hancke, Kasper; Winge, Per; Andresen, Kjersti; Johnsen, Geir; Bones, Atle M.			An Integrated Analysis of Molecular Acclimation to High Light in the Marine Diatom Phaeodactylum tricornutum	PLOS ONE			English	Article							PHOTOSYSTEM-II; CHLAMYDOMONAS-REINHARDTII; ARABIDOPSIS-THALIANA; ENERGY-DISSIPATION; GENE-EXPRESSION; MESSENGER-RNA; PHOTOSYNTHESIS; CHLOROPHYLL; PHOTOPROTECTION; PHOTOINHIBITION	Photosynthetic diatoms are exposed to rapid and unpredictable changes in irradiance and spectral quality, and must be able to acclimate their light harvesting systems to varying light conditions. Molecular mechanisms behind light acclimation in diatoms are largely unknown. We set out to investigate the mechanisms of high light acclimation in Phaeodactylum tricornutum using an integrated approach involving global transcriptional profiling, metabolite profiling and variable fluorescence technique. Algae cultures were acclimated to low light (LL), after which the cultures were transferred to high light (HL). Molecular, metabolic and physiological responses were studied at time points 0.5 h, 3 h, 6 h, 12 h, 24 h and 48 h after transfer to HL conditions. The integrated results indicate that the acclimation mechanisms in diatoms can be divided into an initial response phase (0-0.5 h), an intermediate acclimation phase (3-12 h) and a late acclimation phase (12-48 h). The initial phase is recognized by strong and rapid regulation of genes encoding proteins involved in photosynthesis, pigment metabolism and reactive oxygen species (ROS) scavenging systems. A significant increase in light protecting metabolites occur together with the induction of transcriptional processes involved in protection of cellular structures at this early phase. During the following phases, the metabolite profiling display a pronounced decrease in light harvesting pigments, whereas the variable fluorescence measurements show that the photosynthetic capacity increases strongly during the late acclimation phase. We show that P. tricornutum is capable of swift and efficient execution of photoprotective mechanisms, followed by changes in the composition of the photosynthetic machinery that enable the diatoms to utilize the excess energy available in HL. Central molecular players in light protection and acclimation to high irradiance have been identified.			Nymark, M (corresponding author), Norwegian Univ Sci & Technol, Dept Biol, N-7034 Trondheim, Norway.	atle.bones@bio.ntnu.no	Nymark, Marianne/H-2535-2016; Bones, Atle M/C-6202-2014; Brembu, Tore/J-7166-2015	Nymark, Marianne/0000-0002-0672-0653; Bones, Atle M/0000-0003-0544-7437; Brembu, Tore/0000-0001-5622-8037				Adir N, 2003, PHOTOSYNTH RES, V76, P343, DOI 10.1023/A:1024969518145; Andersen RA, 1997, J PHYCOL, V33, P1, DOI 10.1111/j.0022-3646.1997.00001.x; Armbrust EV, 2004, SCIENCE, V306, P79, DOI 10.1126/science.1101156; Ballottari M, 2007, J BIOL CHEM, V282, P8947, DOI 10.1074/jbc.M606417200; BARBER J, 1995, AUST J PLANT PHYSIOL, V22, P201, DOI 10.1071/PP9950201; BENJAMINI Y, 1995, J R STAT SOC B, V57, P289, DOI 10.1111/j.2517-6161.1995.tb02031.x; Bowler C, 2008, NATURE, V456, P239, DOI 10.1038/nature07410; BROWN JS, 1988, J PHYCOL, V24, P96; BRUNET C, 2009, PIGMENTS OC IN PRESS; Chen H, 2006, PLANT MOL BIOL, V61, P567, DOI 10.1007/s11103-006-0031-x; Clayton R. K., 1971, METHODS ENZYMOLOGY, V23, P696; Coesel S, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002896; Enami I, 2008, PHOTOSYNTH RES, V98, P349, DOI 10.1007/s11120-008-9343-9; Falkowski P.G., 2003, LIGHT HARVESTING ANT, P423, DOI 10.1007/978-94-017-2087-8_15; Field CB, 1998, SCIENCE, V281, P237, DOI 10.1126/science.281.5374.237; GENTY B, 1989, BIOCHIM BIOPHYS ACTA, V990, P87, DOI 10.1016/S0304-4165(89)80016-9; Gilmore AM, 1997, PHYSIOL PLANTARUM, V99, P197, DOI 10.1034/j.1399-3054.1997.990127.x; Guillard R.R.L., 1975, CULTURE MARINE INVER, P29, DOI [10.1007/978-1-4615-8714-9_3, DOI 10.1007/978-1-4615-8714-9_3]; Hancke K, 2008, J PHYCOL, V44, P501, DOI 10.1111/j.1529-8817.2008.00487.x; Hihara Y, 2001, PLANT CELL, V13, P793, DOI 10.1105/tpc.13.4.793; Horton P, 1996, ANNU REV PLANT PHYS, V47, P655, DOI 10.1146/annurev.arplant.47.1.655; HORTON P, 1992, PHOTOSYNTH RES, V34, P375, DOI 10.1007/BF00029812; Jensen PE, 2007, BBA-BIOENERGETICS, V1767, P335, DOI 10.1016/j.bbabio.2007.03.004; Johnsen G, 1997, LIMNOL OCEANOGR, V42, P1166, DOI 10.4319/lo.1997.42.5_part_2.1166; Komenda J, 2008, J BIOL CHEM, V283, P22390, DOI 10.1074/jbc.M801917200; Krieger-Liszkay A, 2008, PHOTOSYNTH RES, V98, P551, DOI 10.1007/s11120-008-9349-3; Kroth PG, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0001426; Lamkemeyer P, 2006, PLANT J, V45, P968, DOI 10.1111/j.1365-313X.2006.02665.x; Lavaud J, 2004, J PHYCOL, V40, P130, DOI 10.1046/j.1529-8817.2004.03026.x; Li Y, 2008, J INTEGR PLANT BIOL, V50, P1057, DOI 10.1111/j.1744-7909.2008.00689.x; Lohr M, 1999, P NATL ACAD SCI USA, V96, P8784, DOI 10.1073/pnas.96.15.8784; Lohr M, 2001, PLANTA, V212, P382, DOI 10.1007/s004250000403; LONG SP, 1994, ANNU REV PLANT PHYS, V45, P633, DOI 10.1146/annurev.pp.45.060194.003221; Meyer Y, 2008, BBA-MOL CELL RES, V1783, P589, DOI 10.1016/j.bbamcr.2007.10.017; Mock T, 2004, J PHYCOL, V40, P732, DOI 10.1111/j.1529-8817.2004.03224.x; Muller P, 2001, PLANT PHYSIOL, V125, P1558, DOI 10.1104/pp.125.4.1558; NAKAMURA K, 1976, BIOCHIM BIOPHYS ACTA, V423, P227, DOI 10.1016/0005-2728(76)90181-X; Nelson N, 2006, ANNU REV PLANT BIOL, V57, P521, DOI 10.1146/annurev.arplant.57.032905.105350; Niyogi KK, 1999, ANNU REV PLANT PHYS, V50, P333, DOI 10.1146/annurev.arplant.50.1.333; Oeltjen A, 2002, PLANT BIOLOGY, V4, P250, DOI 10.1055/s-2002-25737; OHAD I, 1990, J BIOL CHEM, V265, P1972; Oudot-Le Secq MP, 2007, MOL GENET GENOMICS, V277, P427, DOI 10.1007/s00438-006-0199-4; OWENS TG, 1986, PLANT PHYSIOL, V80, P739, DOI 10.1104/pp.80.3.739; PERRY MJ, 1981, MAR BIOL, V62, P91, DOI 10.1007/BF00388170; Pfaffl MW, 2002, NUCLEIC ACIDS RES, V30, DOI 10.1093/nar/30.9.e36; Plucken H, 2002, FEBS LETT, V532, P85, DOI 10.1016/S0014-5793(02)03634-7; Ramakers C, 2003, NEUROSCI LETT, V339, P62, DOI 10.1016/S0304-3940(02)01423-4; Raven JA, 2003, ADV PHOTO RESPIRAT, V14, P385; Richard C, 2000, PLANT MOL BIOL, V42, P303, DOI 10.1023/A:1006340308077; Rodriguez F, 2006, MAR BIOL, V148, P963, DOI 10.1007/s00227-005-0138-7; Roose JL, 2008, J BIOL CHEM, V283, P4044, DOI 10.1074/jbc.M708960200; Ruban AV, 2004, PHOTOSYNTH RES, V82, P165, DOI 10.1007/s11120-004-1456-1; Sakshaug E, 1997, J PLANKTON RES, V19, P1637, DOI 10.1093/plankt/19.11.1637; Savard F, 1996, PLANT MOL BIOL, V32, P461, DOI 10.1007/BF00019098; Schurmann P, 2008, ANTIOXID REDOX SIGN, V10, P1235, DOI 10.1089/ars.2007.1931; Schuster G, 1999, PLANT PHYSIOL, V120, P937, DOI 10.1104/pp.120.4.937; Shapira M, 1997, PLANT MOL BIOL, V33, P1001, DOI 10.1023/A:1005814800641; Smyth G.K., 2004, STAT APPL GENET MOL, V3, DOI DOI 10.2202/1544-6115.1027; Stolte W, 2000, J PHYCOL, V36, P529, DOI 10.1046/j.1529-8817.2000.99158.x; Tanaka R, 2007, ANNU REV PLANT BIOL, V58, P321, DOI 10.1146/annurev.arplant.57.032905.105448; VANKOOTEN O, 1990, PHOTOSYNTH RES, V25, P147, DOI 10.1007/BF00033156; Wang F, 2008, PLANT CELL ENVIRON, V31, P982, DOI 10.1111/j.1365-3040.2008.01810.x; Wilhelm C, 2006, PROTIST, V157, P91, DOI 10.1016/j.protis.2006.02.003; Yamamoto Y, 2008, PHOTOSYNTH RES, V98, P589, DOI 10.1007/s11120-008-9372-4; ZHIRONG L, 2009, ANNU REV PLANT BIOL, V60, P239; Zhu SH, 2008, ENERGY SUN, P261	66	180	180	4	57	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	NOV 3	2009	4	11							e7743	10.1371/journal.pone.0007743	http://dx.doi.org/10.1371/journal.pone.0007743			14	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	514RY	19888450	Green Published, gold, Green Submitted			2022-12-25	WOS:000271414500012
J	Trobridge, GD; Wu, RA; Beard, BC; Chiu, SY; Munoz, NM; von Laer, D; Rossi, JJ; Kiem, HP				Trobridge, Grant D.; Wu, Robert A.; Beard, Brian C.; Chiu, Sum Ying; Munoz, Nina M.; von Laer, Dorothee; Rossi, John J.; Kiem, Hans-Peter			Protection of Stem Cell-Derived Lymphocytes in a Primate AIDS Gene Therapy Model after In Vivo Selection	PLOS ONE			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; CANINE REPOPULATING CELLS; LARGE-ANIMAL MODEL; LENTIVIRAL VECTORS; NONHUMAN-PRIMATES; HIV-1 INFECTION; CD34(+) CELLS; HUMAN GENOME; MOUSE MODEL; TRANSDUCTION	Background: There is currently no effective AIDS vaccine, emphasizing the importance of developing alternative therapies. Recently, a patient was successfully transplanted with allogeneic, naturally resistant CCR5-negative (CCR5D32) cells, setting the stage for transplantation of naturally resistant, or genetically modified stem cells as a viable therapy for AIDS. Hematopoietic stem cell (HSC) gene therapy using vectors that express various anti-HIV transgenes has also been attempted in clinical trials, but inefficient gene transfer in these studies has severely limited the potential of this approach. Here we evaluated HSC gene transfer of an anti-HIV vector in the pigtailed macaque (Macaca nemestrina) model, which closely models human transplantation. Methods and Findings: We used lentiviral vectors that inhibited both HIV-1 and simian immunodeficiency virus (SIV)/HIV-1 (SHIV) chimera virus infection, and also expressed a P140K mutant methylguanine methyltransferase (MGMT) transgene to select gene-modified cells by adding chemotherapy drugs. Following transplantation and MGMT-mediated selection we demonstrated transgene expression in over 7% of stem-cell derived lymphocytes. The high marking levels allowed us to demonstrate protection from SHIV in lymphocytes derived from gene-modified macaque long-term repopulating cells that expressed an HIV-1 fusion inhibitor. We observed a statistically significant 4-fold increase of gene-modified cells after challenge of lymphocytes from one macaque that received stem cells transduced with an anti-HIV vector (p<0.02, Student's t-test), but not in lymphocytes from a macaque that received a control vector. We also established a competitive repopulation assay in a second macaque for preclinical testing of promising anti-HIV vectors. The vectors we used were HIV-based and thus efficiently transduce human cells, and the transgenes we used target HIV-1 genes that are also in SHIV, so our findings can be rapidly translated to the clinic. Conclusions: Here we demonstrate the ability to select protected HSC-derived lymphocytes in vivo in a clinically relevant nonhuman primate model of HIV/SHIV infection. This approach can now be evaluated in human clinical trials in AIDS lymphoma patients. In this patient setting, chemotherapy would not only kill malignant cells, but would also increase the number of MGMTP140K-expressing HIV-resistant cells. This approach should allow for high levels of HIV-protected cells in AIDS patients to evaluate AIDS gene therapy.			Trobridge, GD (corresponding author), Fred Hutchinson Canc Res Ctr, Div Clin Res, 1124 Columbia St, Seattle, WA 98104 USA.	hkiem@fhcrc.org		Wu, R. Alex/0000-0003-4190-4615; von Laer, Dorothee/0000-0001-5825-7237	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL053750] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R21AI063959, R01AI080326, P01AI061839] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK047754, P30DK056465] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL053750, P01 HL053750] Funding Source: Medline; NIAID NIH HHS [AI063959, R01 AI080326, P01 AI061839, R21 AI063959, AI061839] Funding Source: Medline; NIDDK NIH HHS [P30 DK047754, DK056465, DK047754, P30 DK056465] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Aagaard L, 2008, GENE THER, V15, P1566, DOI 10.1038/gt.2008.163; Amado RG, 2004, HUM GENE THER, V15, P251, DOI 10.1089/104303404322886101; An DS, 2006, MOL THER, V14, P494, DOI 10.1016/j.ymthe.2006.05.015; Bahner I, 2007, MOL THER, V15, P76, DOI 10.1038/sj.mt.6300025; Bauer G, 2000, ANN NY ACAD SCI, V918, P318; Berges BK, 2006, RETROVIROLOGY, V3, DOI 10.1186/1742-4690-3-76; Brandt S, 2007, PLOS PATHOG, V3, P518, DOI 10.1371/journal.ppat.0030054; Brennan G, 2007, J VIROL, V81, P12210, DOI 10.1128/JVI.02499-06; Buchschacher GL, 2001, HUM GENE THER, V12, P1013, DOI 10.1089/104303401750214249; Carr A, 2003, NAT REV DRUG DISCOV, V2, P624, DOI 10.1038/nrd1151; Chackerian B, 1997, J VIROL, V71, P3932, DOI 10.1128/JVI.71.5.3932-3939.1997; COLLMAN R, 1992, J VIROL, V66, P7517, DOI 10.1128/JVI.66.12.7517-7521.1992; CRONE TM, 1994, CANCER RES, V54, P6221; Davis BM, 1999, HUM GENE THER, V10, P2769, DOI 10.1089/10430349950016500; Dropulic B, 2006, HUM GENE THER, V17, P577, DOI 10.1089/hum.2006.17.577; Dull T, 1998, J VIROL, V72, P8463, DOI 10.1128/JVI.72.11.8463-8471.1998; Egelhofer M, 2004, J VIROL, V78, P568, DOI 10.1128/JVI.78.2.568-575.2004; Gerull S, 2007, HUM GENE THER, V18, P451, DOI 10.1089/hum.2006.039; Gorantla S, 2007, J VIROL, V81, P2700, DOI 10.1128/JVI.02010-06; Grimm D, 2006, NATURE, V441, P537, DOI 10.1038/nature04791; Hanawa H, 2004, BLOOD, V103, P4062, DOI 10.1182/blood-2004-01-0045; Hermann FG, 2009, HUM GENE THER, V20, P325, DOI 10.1089/hum.2006.158; Horn PA, 2004, BLOOD, V103, P3710, DOI 10.1182/blood-2003-07-2414; HOWELL DN, 1985, J IMMUNOL, V134, P971; Hutter G, 2009, NEW ENGL J MED, V360, P692, DOI 10.1056/NEJMoa0802905; Joag SV, 2000, MICROBES INFECT, V2, P223, DOI 10.1016/S1286-4579(00)00266-5; Jung CW, 2007, EXP HEMATOL, V35, P1132, DOI 10.1016/j.exphem.2007.04.004; Kiem HP, 2010, GENE THER, V17, P37, DOI 10.1038/gt.2009.118; Kiem HP, 2007, BLOOD, V109, P65, DOI 10.1182/blood-2006-04-016741; KIMPTON J, 1992, J VIROL, V66, P2232, DOI 10.1128/JVI.66.4.2232-2239.1992; Klausner RD, 2003, SCIENCE, V300, P2036, DOI 10.1126/science.1086916; Kreklau EL, 2001, J PHARMACOL EXP THER, V297, P524; Levy JA, 1996, J MED PRIMATOL, V25, P163, DOI 10.1111/j.1600-0684.1996.tb00013.x; Li MJ, 2005, METH MOL B, V309, P261; Li MJ, 2003, MOL THER, V8, P196, DOI 10.1016/S1525-0016(03)00165-5; Mautino MR, 2000, HUM GENE THER, V11, P2025, DOI 10.1089/10430340050143444; Mitsuyasu RT, 2009, NAT MED, V15, P285, DOI 10.1038/nm.1932; Miyoshi H, 1999, SCIENCE, V283, P682, DOI 10.1126/science.283.5402.682; Montini E, 2006, NAT BIOTECHNOL, V24, P687, DOI 10.1038/nbt1216; Naldini L, 1998, CURR OPIN BIOTECH, V9, P457, DOI 10.1016/S0958-1669(98)80029-3; Nathanson N, 1999, AIDS, V13, pS113; Neff T, 2005, BLOOD, V105, P997, DOI 10.1182/blood-2004-08-3169; Neff T, 2003, J CLIN INVEST, V112, P1581, DOI 10.1172/JCI200318782; Ngoi SM, 2004, CURR GENE THER, V4, P15, DOI 10.2174/1566523044578095; Rossi JJ, 2007, NAT BIOTECHNOL, V25, P1444, DOI 10.1038/nbt1367; SALTER RD, 1985, IMMUNOGENETICS, V21, P235, DOI 10.1007/BF00375376; Schroder ARW, 2002, CELL, V110, P521, DOI 10.1016/S0092-8674(02)00864-4; Strayer DS, 2002, MOL THER, V5, P33, DOI 10.1006/mthe.2001.0513; Trobridge G, 2005, HUM GENE THER, V16, P1355, DOI 10.1089/hum.2005.16.1355; Trobridge GD, 2008, BLOOD, V111, P5537, DOI 10.1182/blood-2007-09-115022; Warren J, 2002, J MED PRIMATOL, V31, P237, DOI 10.1034/j.1600-0684.2002.02010.x; Wu XL, 2003, SCIENCE, V300, P1749, DOI 10.1126/science.1083413; Xu-Welliver M, 1998, CANCER RES, V58, P1936; Yeni PG, 2002, JAMA-J AM MED ASSOC, V288, P222, DOI 10.1001/jama.288.2.222; 2008, 07 AIDS EPIDEMIC UPD; 2007, NAT MED, V13, P1389	56	50	55	0	7	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA	1932-6203			PLOS ONE	PLoS One	NOV 2	2009	4	11							e7693	10.1371/journal.pone.0007693	http://dx.doi.org/10.1371/journal.pone.0007693			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	514RX	19888329	Green Published, gold, Green Submitted			2022-12-25	WOS:000271414400009
J	Royer, DL; Meyerson, LA; Robertson, KM; Adams, JM				Royer, Dana L.; Meyerson, Laura A.; Robertson, Kevin M.; Adams, Jonathan M.			Phenotypic Plasticity of Leaf Shape along a Temperature Gradient in Acer rubrum	PLOS ONE			English	Article							MORPHOLOGICAL VARIATION; FOSSIL LEAVES; POPULATIONS; MARGIN; SIZE; CLIMATE; GROWTH; RESPONSES; INDEX	Both phenotypic plasticity and genetic determination can be important for understanding how plants respond to environmental change. However, little is known about the plastic response of leaf teeth and leaf dissection to temperature. This gap is critical because these leaf traits are commonly used to reconstruct paleoclimate from fossils, and such studies tacitly assume that traits measured from fossils reflect the environment at the time of their deposition, even during periods of rapid climate change. We measured leaf size and shape in Acer rubrum derived from four seed sources with a broad temperature range and grown for two years in two gardens with contrasting climates (Rhode Island and Florida). Leaves in the Rhode Island garden have more teeth and are more highly dissected than leaves in Florida from the same seed source. Plasticity in these variables accounts for at least 6-19 % of the total variance, while genetic differences among ecotypes probably account for at most 69-87 %. This study highlights the role of phenotypic plasticity in leaf-climate relationships. We suggest that variables related to tooth count and leaf dissection in A. rubrum can respond quickly to climate change, which increases confidence in paleoclimate methods that use these variables.			Royer, DL (corresponding author), Wesleyan Univ, Dept Earth & Environm Sci, Middletown, CT USA.	droyer@wesleyan.edu	Meyerson, Laura/K-9013-2012; Meyerson, Laura A./AAN-6688-2020; Meyerson, Laura A./S-2979-2019; Robertson, Kevin/AAT-9357-2021; Meyerson, Laura/D-4487-2013	Meyerson, Laura A./0000-0002-1283-3865; Royer, Dana/0000-0003-0976-953X				Bailey IW, 1916, AM J BOT, V3, P24, DOI 10.2307/2435109; Bailey IW, 1915, SCIENCE, V41, P831, DOI 10.1126/science.41.1066.831; Behrensmeyer Anna K., 1992, P15; Blein T, 2008, SCIENCE, V322, P1835, DOI 10.1126/science.1166168; Christophel D, 2004, NEW PHYTOL, V161, P327, DOI 10.1111/j.1469-8137.2004.00989.x; Cordell S, 1998, OECOLOGIA, V113, P188, DOI 10.1007/s004420050367; Cramer MD, 2009, OECOLOGIA, V161, P15, DOI 10.1007/s00442-009-1364-3; Dilcher DL., 1973, VEGETATION VEGETATIO, P39; Dorken ME, 2004, J ECOL, V92, P32, DOI 10.1111/j.1365-2745.2004.00857.x; Feild TS, 2005, PLANT CELL ENVIRON, V28, P1179, DOI 10.1111/j.1365-3040.2005.01354.x; Flann C, 2002, AUST SYST BOT, V15, P205, DOI 10.1071/SB01018; Godfrey RK., 1988, TREES SHRUBS WOODY V; GOSLER AG, 1994, BOT J LINN SOC, V115, P211, DOI 10.1111/j.1095-8339.1994.tb01779.x; Greenwood DR, 2005, NEW PHYTOL, V166, P355, DOI 10.1111/j.1469-8137.2005.01380.x; Greenwood DR, 2004, PALAIOS, V19, P129, DOI 10.1669/0883-1351(2004)019<0129:PEULAI>2.0.CO;2; Gregory KM, 1996, PALAEOGEOGR PALAEOCL, V124, P39, DOI 10.1016/0031-0182(96)00015-6; Groot EP, 2000, J PLANT GROWTH REGUL, V19, P77, DOI 10.1007/s003440000008; GUREVITCH J, 1988, AM J BOT, V75, P1298, DOI 10.2307/2444452; Hovenden MJ, 2004, NEW PHYTOL, V161, P585, DOI 10.1046/j.1469-8137.2003.00931.x; Hovenden MJ, 2006, NEW PHYTOL, V169, P291, DOI 10.1111/j.1469-8137.2005.01585.x; Hovenden MJ, 2001, AUST J BOT, V49, P427, DOI 10.1071/BT01001; Huff PM, 2003, PALAIOS, V18, P266, DOI 10.1669/0883-1351(2003)018<0266:DFFPEF>2.0.CO;2; Imbert E, 2000, NEW PHYTOL, V147, P601, DOI 10.1046/j.1469-8137.2000.00724.x; Lambers H., 2008, PLANT PHYSL ECOLOGY, DOI DOI 10.1007/978-0-387-78341-3_9; Morecroft MD, 1996, NEW PHYTOL, V134, P471, DOI 10.1111/j.1469-8137.1996.tb04364.x; Nicotra AB, 2008, OECOLOGIA, V154, P625, DOI 10.1007/s00442-007-0865-1; Nikovics K, 2006, PLANT CELL, V18, P2929, DOI 10.1105/tpc.106.045617; Oleksyn J, 1998, FUNCT ECOL, V12, P573, DOI 10.1046/j.1365-2435.1998.00236.x; PARKHURST DF, 1972, J ECOL, V60, P505, DOI 10.2307/2258359; Raunkiaer C, 1934, LIFE FORMS PLANTS ST; Richards PW, 1939, J ECOL, V27, P1, DOI 10.2307/2256298; Roth-Nebelsick A, 2001, PLANT CELL ENVIRON, V24, P631, DOI 10.1046/j.1365-3040.2001.00712.x; Royer DL, 2008, NEW PHYTOL, V179, P808, DOI 10.1111/j.1469-8137.2008.02496.x; Royer DL, 2006, INT J PLANT SCI, V167, P11, DOI 10.1086/497995; Royer DL, 2005, AM J BOT, V92, P1141, DOI 10.3732/ajb.92.7.1141; Sack L, 2006, AM J BOT, V93, P829, DOI 10.3732/ajb.93.6.829; Semchenko M, 2007, ANN BOT-LONDON, V100, P83, DOI 10.1093/aob/mcm074; STUCKY JM, 2001, COMMON WOODY PIEDMON; Thomas SC, 1996, AM J BOT, V83, P106, DOI 10.2307/2445962; Tsukaya H, 1997, MOL GEN GENET, V256, P231, DOI 10.1007/s004380050565; Tsukaya H, 2006, ANNU REV PLANT BIOL, V57, P477, DOI 10.1146/annurev.arplant.57.032905.105320; VOGEL S, 1970, J EXP BOT, V21, P91, DOI 10.1093/jxb/21.1.91; Wilf P, 1997, PALEOBIOLOGY, V23, P373, DOI 10.1017/S0094837300019746; Wilf P, 1998, GEOLOGY, V26, P203, DOI 10.1130/0091-7613(1998)026<0203:UFLAPI>2.3.CO;2; Wilf P, 2003, P NATL ACAD SCI USA, V100, P599, DOI 10.1073/pnas.0234701100; WILLIAMS DG, 1993, FUNCT ECOL, V7, P623, DOI 10.2307/2390140; Wing SL, 2005, SCIENCE, V310, P993, DOI 10.1126/science.1116913; WOLFE JA, 1993, US GEOL SURV B, V2040, P71; Wolfe JA, 1979, US GEOLOGICAL SURVEY, V1106, P1, DOI DOI 10.3133/PP1106	49	95	101	6	52	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	OCT 29	2009	4	10							e7653	10.1371/journal.pone.0007653	http://dx.doi.org/10.1371/journal.pone.0007653			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	512FP	19893620	gold, Green Published, Green Submitted			2022-12-25	WOS:000271232000014
J	Shi, XL; Marie, D; Jardillier, L; Scanlan, DJ; Vaulot, D				Shi, Xiao Li; Marie, Dominique; Jardillier, Ludwig; Scanlan, David J.; Vaulot, Daniel			Groups without Cultured Representatives Dominate Eukaryotic Picophytoplankton in the Oligotrophic South East Pacific Ocean	PLOS ONE			English	Article							GENETIC DIVERSITY; WIDESPREAD OCCURRENCE; MICROMONAS-PUSILLA; MEDITERRANEAN SEA; RIBOSOMAL-RNA; MARINE; PICOPLANKTON; PHYTOPLANKTON; ULTRAPHYTOPLANKTON; CYANOBACTERIA	Background: Photosynthetic picoeukaryotes (PPE) with a cell size less than 3 mm play a critical role in oceanic primary production. In recent years, the composition of marine picoeukaryote communities has been intensively investigated by molecular approaches, but their photosynthetic fraction remains poorly characterized. This is largely because the classical approach that relies on constructing 18S rRNA gene clone libraries from filtered seawater samples using universal eukaryotic primers is heavily biased toward heterotrophs, especially alveolates and stramenopiles, despite the fact that autotrophic cells in general outnumber heterotrophic ones in the euphotic zone. Methodology/Principal Findings: In order to better assess the composition of the eukaryotic picophytoplankton in the South East Pacific Ocean, encompassing the most oligotrophic oceanic regions on earth, we used a novel approach based on flow cytometry sorting followed by construction of 18S rRNA gene clone libraries. This strategy dramatically increased the recovery of sequences from putative autotrophic groups. The composition of the PPE community appeared highly variable both vertically down the water column and horizontally across the South East Pacific Ocean. In the central gyre, uncultivated lineages dominated: a recently discovered clade of Prasinophyceae (IX), clades of marine Chrysophyceae and Haptophyta, the latter division containing a potentially new class besides Prymnesiophyceae and Pavlophyceae. In contrast, on the edge of the gyre and in the coastal Chilean upwelling, groups with cultivated representatives (Prasinophyceae clade VII and Mamiellales) dominated. Conclusions/Significance: Our data demonstrate that a very large fraction of the eukaryotic picophytoplankton still escapes cultivation. The use of flow cytometry sorting should prove very useful to better characterize specific plankton populations by molecular approaches such as gene cloning or metagenomics, and also to obtain into culture strains representative of these novel groups.			Shi, XL (corresponding author), UPMC Paris 06, Roscoff, France.	vaulot@sb-roscoff.fr	Vaulot, Daniel/T-6649-2019; Scanlan, David J/G-4080-2016; Jardillier, Ludwig E/H-8486-2015	Vaulot, Daniel/0000-0002-0717-5685; Scanlan, David J/0000-0003-3093-4245; Jardillier, Ludwig E/0000-0003-4982-5807	Natural Environment Research Council [NE/C003160/1] Funding Source: researchfish	Natural Environment Research Council(UK Research & Innovation (UKRI)Natural Environment Research Council (NERC))		Andersen RA, 1999, PROTIST, V150, P71, DOI 10.1016/S1434-4610(99)70010-6; BOOTH BC, 1987, J PHYCOL, V23, P245, DOI 10.1111/j.1529-8817.1987.tb04132.x; Bravo-Sierra E, 2003, J PHYCOL, V39, P577, DOI 10.1046/j.1529-8817.2003.02181.x; Caron DA, 2009, APPL ENVIRON MICROB, V75, P5797, DOI 10.1128/AEM.00298-09; Castresana J, 2000, MOL BIOL EVOL, V17, P540, DOI 10.1093/oxfordjournals.molbev.a026334; Chambouvet A, 2008, SCIENCE, V322, P1254, DOI 10.1126/science.1164387; CHISHOLM SW, 1988, NATURE, V334, P340, DOI 10.1038/334340a0; Claustre H, 2008, BIOGEOSCIENCES, V5, P679, DOI 10.5194/bg-5-679-2008; Dawson SC, 2002, P NATL ACAD SCI USA, V99, P8324, DOI 10.1073/pnas.062169599; Diez B, 2001, APPL ENVIRON MICROB, V67, P2932, DOI 10.1128/AEM.67.7.2932-2941.2001; Foulon E, 2008, ENVIRON MICROBIOL, V10, P2433, DOI 10.1111/j.1462-2920.2008.01673.x; Fuller NJ, 2006, LIMNOL OCEANOGR, V51, P2502, DOI 10.4319/lo.2006.51.6.2502; Fuller NJ, 2006, AQUAT MICROB ECOL, V43, P79, DOI 10.3354/ame043079; Grob C, 2007, BIOGEOSCIENCES, V4, P837, DOI 10.5194/bg-4-837-2007; Guillou L, 2008, ENVIRON MICROBIOL, V10, P3349, DOI 10.1111/j.1462-2920.2008.01731.x; Guillou L, 2004, PROTIST, V155, P193, DOI 10.1078/143446104774199592; Guillou L, 1999, J PHYCOL, V35, P368, DOI 10.1046/j.1529-8817.1999.3520368.x; Katoh K, 2002, NUCLEIC ACIDS RES, V30, P3059, DOI 10.1093/nar/gkf436; Kawachi Masanobu, 2002, Phycological Research, V50, P31, DOI 10.1111/j.1440-1835.2002.tb00134.x; Klepac-Ceraj V., 2006, ONLINE J BIOINFORM, V7, P15; Komuro C, 2005, DEEP-SEA RES PT II, V52, P2206, DOI 10.1016/j.dsr2.2005.08.006; Le Gall F, 2008, BIOGEOSCIENCES, V5, P203, DOI 10.5194/bg-5-203-2008; Lepere C, 2009, ENVIRON MICROBIOL, V11, P3105, DOI 10.1111/j.1462-2920.2009.02015.x; Li WKW, 2002, NATURE, V419, P154, DOI 10.1038/nature00994; LI WKW, 1994, LIMNOL OCEANOGR, V39, P169, DOI 10.4319/lo.1994.39.1.0169; Liu H, 2009, P NATL ACAD SCI USA, V106, P12803, DOI 10.1073/pnas.0905841106; Lopez-Garcia P, 2001, NATURE, V409, P603, DOI 10.1038/35054537; Marie D, 2006, FEMS MICROBIOL ECOL, V55, P403, DOI 10.1111/j.1574-6941.2005.00058.x; MARIE D, FEMS MICROBIOL UNPUB; Masquelier S, 2008, BIOGEOSCIENCES, V5, P311, DOI 10.5194/bg-5-311-2008; Massana R, 2004, APPL ENVIRON MICROB, V70, P3528, DOI 10.1128/AEM.70.6.3528-3534.2004; Massana R, 2006, AQUAT MICROB ECOL, V45, P171, DOI 10.3354/ame045171; Massana R, 2009, ISME J, V3, P588, DOI 10.1038/ismej.2008.130; McDonald SM, 2007, AQUAT MICROB ECOL, V50, P75, DOI 10.3354/ame01148; Moon-van der Staay SY, 2000, LIMNOL OCEANOGR, V45, P98, DOI 10.4319/lo.2000.45.1.0098; Moon-van der Staay SY, 2001, NATURE, V409, P607, DOI 10.1038/35054541; Morel A, 2007, LIMNOL OCEANOGR, V52, P217, DOI 10.4319/lo.2007.52.1.0217; Not F, 2004, APPL ENVIRON MICROB, V70, P4064, DOI 10.1128/AEM.70.7.4064-4072.2004; Not F, 2007, SCIENCE, V315, P253, DOI 10.1126/science.1136264; Posada D, 1998, BIOINFORMATICS, V14, P817, DOI 10.1093/bioinformatics/14.9.817; Rappe MS, 2002, NATURE, V418, P630, DOI 10.1038/nature00917; Ras J, 2008, BIOGEOSCIENCES, V5, P353, DOI 10.5194/bg-5-353-2008; Romari K, 2004, LIMNOL OCEANOGR, V49, P784, DOI 10.4319/lo.2004.49.3.0784; SOGIN ML, 1987, ANN NY ACAD SCI, V503, P125, DOI 10.1111/j.1749-6632.1987.tb40603.x; Swofford D.L., 2002, PAUP PHYLOGENETIC AN, DOI 10.1111/j.0014-3820.2002.tb00191.x; Takano Y, 2006, MAR MICROPALEONTOL, V60, P145, DOI 10.1016/j.marmicro.2006.04.002; Vaulot D, 2008, FEMS MICROBIOL REV, V32, P795, DOI 10.1111/j.1574-6976.2008.00121.x; Viprey M, 2008, ENVIRON MICROBIOL, V10, P1804, DOI 10.1111/j.1462-2920.2008.01602.x; WATERBURY JB, 1979, NATURE, V277, P293, DOI 10.1038/277293a0; Zehr JP, 2008, SCIENCE, V322, P1110, DOI 10.1126/science.1165340; Zubkov MV, 2008, NATURE, V455, P224, DOI 10.1038/nature07236	51	122	127	2	42	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	OCT 29	2009	4	10							e7657	10.1371/journal.pone.0007657	http://dx.doi.org/10.1371/journal.pone.0007657			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	512FP	19893617	Green Published, gold, Green Submitted			2022-12-25	WOS:000271232000015
J	Perla-Kajan, J; Jakubowski, H				Perla-Kajan, Joanna; Jakubowski, Hieronim			Paraoxonase 1 protects against protein N-homocysteinylation in humans	FASEB JOURNAL			English	Article						cystathionine; beta-synthase deficiency; enzymatic activities of high-density lipoprotein; homocysteine-thiolactonase; protein modification by homocysteine-thiolactone	CYSTATHIONINE BETA-SYNTHASE; THIOLACTONASE ACTIVITY; METHYLENETETRAHYDROFOLATE REDUCTASE; PATHOLOGICAL CONSEQUENCES; POSSIBLE MECHANISM; MOLECULAR-BASIS; PON1; TOXICITY; GENE; ATHEROSCLEROSIS	Genetic or nutritional disorders in homocysteine (Hcy) or folate metabolism elevate plasma Hcy-thiolactone and lead to vascular and/or brain pathologies. Hcy-thiolactone has the ability to form isopeptide bonds with protein lysine residues, which generates N-Hcy-protein with autoimmunogenic and prothrombotic properties. Paraoxonase (PON1), carried on high-density lipoproteins (HDLs) in the blood, hydrolyzes Hcy-thiolactone and protects against the accumulation of N-Hcy-protein in vitro. To determine its role in vivo, we studied how natural variation in Hcy-thiolactonase activity of PON1 affects plasma N-Hcy-protein levels in cystathionine beta-synthase-deficient patients (n = 28). We found that plasma N-Hcy-protein was negatively correlated with serum Hcy-thiolactonase activity (r = -0.43, P = 0.01), i.e., the higher the Hcy-thiolactonase activity, the lower N-Hcy protein levels. This relation was faithfully replicated in vitro in experiments with radiolabeled Hcy-thiolactone. We also found that enzymatic activities of the PON1 protein measured with artificial substrates correlated less strongly (r = -0.36, P = 0.025 for paraoxonase activity) or did not correlate at all (phenylacetate hydrolase and TBLase activities) with plasma N-Hcy protein. These findings provide evidence that the Hcy-thiolactonase activity of PON1 is a determinant of plasma N-Hcy-protein levels and that Hcy-thiolactonase/PON1 protects proteins against N-homocysteinylation in vivo, a novel mechanism likely to contribute to atheroprotective roles of HDL in humans.-Perla-Kajan, J., Jakubowski, H. Paraoxonase 1 protects against protein N-homocysteinylation in humans. FASEB J. 24, 931-936 (2010). www.fasebj.org	[Perla-Kajan, Joanna; Jakubowski, Hieronim] UMDNJ, New Jersey Med Sch, Dept Microbiol & Mol Genet, Int Ctr Publ Hlth, Newark, NJ 07101 USA; [Perla-Kajan, Joanna; Jakubowski, Hieronim] Univ Life Sci, Dept Biochem & Biotechnol, Poznan, Poland; [Jakubowski, Hieronim] Polish Acad Sci, Inst Bioorgan Chem, Poznan, Poland	Rutgers State University New Brunswick; Rutgers State University Medical Center; Poznan University of Life Sciences; Polish Academy of Sciences; Institute of Bioorganic Chemistry of the Polish Academy of Sciences	Jakubowski, H (corresponding author), UMDNJ, New Jersey Med Sch, Dept Microbiol & Mol Genet, Int Ctr Publ Hlth, 225 Warren St, Newark, NJ 07101 USA.	jakubows@umdnj.edu	Perla-Kajan, Joanna/F-2965-2010; Jakubowski, Hieronim/AAA-6834-2019; Jakubowski, Hieronim/A-2510-2017	Perla-Kajan, Joanna/0000-0002-0791-5057; Jakubowski, Hieronim/0000-0001-5845-4409	American Heart Association [0855919D]; Ministry of Science and Higher Education, Warsaw, Poland [NN 401 230634, N401 065 32/1504, POIG.01.03.01-00-097/08]	American Heart Association(American Heart Association); Ministry of Science and Higher Education, Warsaw, Poland(Ministry of Science and Higher Education, Poland)	This work was supported in part by grants from the American Heart Association (0855919D) and the Ministry of Science and Higher Education, Warsaw, Poland (NN 401 230634, N401 065 32/1504, POIG.01.03.01-00-097/08).	Bhattacharyya T, 2008, JAMA-J AM MED ASSOC, V299, P1265, DOI 10.1001/jama.299.11.1265; Camps J, 2009, CRIT REV CL LAB SCI, V46, P83, DOI 10.1080/10408360802610878; Chwatko G, 2005, ANAL BIOCHEM, V337, P271, DOI 10.1016/j.ab.2004.11.035; Chwatko G, 2007, FASEB J, V21, P1707, DOI 10.1096/fj.06-7435com; Connelly PW, 2005, FREE RADICAL BIO MED, V38, P164, DOI 10.1016/j.freeradbiomed.2004.10.010; de las Casas CM, 2003, BIRTH DEFECTS RES A, V67, P35, DOI 10.1002/bdra.10014; Domagala TB, 2006, CELL MOL BIOL, V52, P4, DOI 10.1170/T727; Endo N, 2006, BRIT J NUTR, V95, P1088, DOI 10.1079/BJN20061764; Glowacki R, 2004, J BIOL CHEM, V279, P10864, DOI 10.1074/jbc.M313268200; Gu WJ, 2008, ADV THER, V25, P914, DOI 10.1007/s12325-008-0097-8; HARKER LA, 1974, NEW ENGL J MED, V291, P537, DOI 10.1056/NEJM197409122911101; JAKUBOWSKI H, 1993, FEBS LETT, V317, P237, DOI 10.1016/0014-5793(93)81283-6; Jakubowski H, 2000, J BIOL CHEM, V275, P3957, DOI 10.1074/jbc.275.6.3957; Jakubowski H, 2000, CIRC RES, V87, P45, DOI 10.1161/01.RES.87.1.45; Jakubowski H, 1997, J BIOL CHEM, V272, P1935; Jakubowski H, 2005, CLIN CHEM LAB MED, V43, P1011, DOI 10.1515/CCLM.2005.177; Jakubowski H, 2004, CELL MOL LIFE SCI, V61, P470, DOI 10.1007/s00018-003-3204-7; Jakubowski H, 2008, J PHYSIOL PHARMACOL, V59, P155; Jakubowski H, 2001, FEBS LETT, V491, P35, DOI 10.1016/S0014-5793(01)02143-3; Jakubowski H, 2001, BIOMED PHARMACOTHER, V55, P443, DOI 10.1016/S0753-3322(01)00085-3; Jakubowski H, 1999, FASEB J, V13, P2277, DOI 10.1096/fasebj.13.15.2277; Jakubowski H, 2000, J NUTR, V130, p377S, DOI 10.1093/jn/130.2.377S; Jakubowski H, 2008, ANAL BIOCHEM, V380, P257, DOI 10.1016/j.ab.2008.05.049; Jakubowski H, 2007, CLIN CHEM LAB MED, V45, P1704, DOI 10.1515/CCLM.2007.338; Jakubowski H, 2007, ANAL BIOCHEM, V370, P124, DOI 10.1016/j.ab.2007.05.030; Jakubowski H, 2006, J NUTR, V136, p1741S, DOI 10.1093/jn/136.6.1741S; Jakubowski H, 2008, FASEB J, V22, P4071, DOI 10.1096/fj.08-112086; Jakubowski H, 2009, FASEB J, V23, P1721, DOI 10.1096/fj.08-127548; Jarvik GP, 2000, ARTERIOSCL THROM VAS, V20, P2441, DOI 10.1161/01.ATV.20.11.2441; Kosaka T, 2005, CLIN CHIM ACTA, V359, P156, DOI 10.1016/j.cccn.2005.03.046; Lacinski M, 2004, CELL MOL BIOL, V50, P885; MACKNESS MI, 1991, FEBS LETT, V286, P152, DOI 10.1016/0014-5793(91)80962-3; Mackness Michael I, 2004, Am J Cardiovasc Drugs, V4, P211, DOI 10.2165/00129784-200404040-00002; Marathe GK, 2003, J BIOL CHEM, V278, P3937, DOI 10.1074/jbc.M211126200; MUDD SH, 2001, METABOLIC MOL BASES, V2, P2007; Perla-Kajan J, 2007, AMINO ACIDS, V32, P561, DOI 10.1007/s00726-006-0432-9; Perla-Kajan J, 2008, BIOMED PHARMACOTHER, V62, P473, DOI 10.1016/j.biopha.2008.04.001; Perla-Kajan J, 2007, BIOCHEMISTRY-US, V46, P6225, DOI 10.1021/bi602463m; Shih DM, 1998, NATURE, V394, P284, DOI 10.1038/28406; Teiber JF, 2004, J LIPID RES, V45, P2260, DOI 10.1194/jlr.M400213-JLR200; Yang X, 2006, CLIN CHIM ACTA, V364, P230, DOI 10.1016/j.cccn.2005.07.007; Yap S, 2001, ARTERIOSCL THROM VAS, V21, P2080, DOI 10.1161/hq1201.100225	42	67	70	0	7	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAR	2010	24	3					931	936		10.1096/fj.09-144410	http://dx.doi.org/10.1096/fj.09-144410			6	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	561KE	19880629				2022-12-25	WOS:000274974600028
J	Buas, MF; Kabak, S; Kadesch, T				Buas, Matthew F.; Kabak, Shara; Kadesch, Tom			The Notch Effector Hey1 Associates with Myogenic Target Genes to Repress Myogenesis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LOOP-HELIX PROTEINS; TRANSCRIPTION FACTOR; GATA3 EXPRESSION; PROGENITOR CELLS; BHLH; BINDING; DIFFERENTIATION; ACTIVATION; PROMOTER; PATHWAY	Members of the Hey family of transcriptional repressors are basic helix-loop-helix proteins that are thought to act downstream of Notch in diverse tissues. Although forced expression of Hey1, a target of Notch in myoblasts, is sufficient to recapitulate inhibitory effects of the pathway on differentiation, how Hey1 interferes with myogenic transcription has not been fully elucidated. We provide multiple lines of evidence that Hey1 does not target the intrinsic transcriptional activity of the skeletal muscle master regulator MyoD. Our results indicate instead that Hey1 is recruited to the promoter regions of myogenin and Mef2C, two genes whose induction is critical for myogenesis. Expression of Hey1 in C2C12 myoblasts correlates with reduced recruitment of MyoD to these promoters, arguing that Hey1 inhibits myogenesis by associating with and repressing expression of key myogenic targets.	[Buas, Matthew F.; Kabak, Shara; Kadesch, Tom] Univ Penn, Sch Med, Dept Genet, Philadelphia, PA 19104 USA	University of Pennsylvania	Kadesch, T (corresponding author), Univ Penn, Sch Med, Dept Genet, Philadelphia, PA 19104 USA.	kadesch@mail.med.upenn.edu		Buas, Matthew F/0000-0002-8524-3428	National Institutes of Health Training [5-T32-GM-008216-20, F32GM068394-01A1]; Muscular Dystrophy Association [MDA 3888]; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM008216, F32GM068394] Funding Source: NIH RePORTER	National Institutes of Health Training(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Muscular Dystrophy Association(Muscular Dystrophy Association); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	This work was supported, in whole or in part, by National Institutes of Health Training Grants 5-T32-GM-008216-20 (to M. B.) and F32GM068394-01A1 (NRSA; to S. K.). This work was also supported by funds from the Muscular Dystrophy Association (MDA 3888).	Amsen D, 2007, IMMUNITY, V27, P89, DOI 10.1016/j.immuni.2007.05.021; Belandia B, 2005, MOL CELL BIOL, V25, P1425, DOI 10.1128/MCB.25.4.1425-1436.2005; Berghella L, 2008, GENE DEV, V22, P2125, DOI 10.1101/gad.468508; Bergstrom DA, 2002, MOL CELL, V9, P587, DOI 10.1016/S1097-2765(02)00481-1; Berkes CA, 2004, MOL CELL, V14, P465, DOI 10.1016/S1097-2765(04)00260-6; Brack AS, 2008, CELL STEM CELL, V2, P50, DOI 10.1016/j.stem.2007.10.006; Buas MF, 2009, J CELL PHYSIOL, V218, P84, DOI 10.1002/jcp.21571; Caretti G, 2004, GENE DEV, V18, P2627, DOI 10.1101/gad.1241904; Conboy IM, 2002, DEV CELL, V3, P397, DOI 10.1016/S1534-5807(02)00254-X; Conboy IM, 2003, SCIENCE, V302, P1575, DOI 10.1126/science.1087573; Dodou E, 2003, MECH DEVELOP, V120, P1021, DOI 10.1016/S0925-4773(03)00178-3; EDMONDSON DG, 1992, MOL CELL BIOL, V12, P3665, DOI 10.1128/MCB.12.9.3665; Elagib KE, 2004, MOL CELL BIOL, V24, P7779, DOI 10.1128/MCB.24.17.7779-7794.2004; Fang TC, 2007, IMMUNITY, V27, P100, DOI 10.1016/j.immuni.2007.04.018; Fischer A, 2005, MOL CELL BIOL, V25, P8960, DOI 10.1128/MCB.25.20.8960-8970.2005; Fischer A, 2004, GENE DEV, V18, P901, DOI 10.1101/gad.291004; Fischer A, 2002, COLD SPRING HARB SYM, V67, P63, DOI 10.1101/sqb.2002.67.63; Fischer A, 2007, CIRC RES, V100, P856, DOI 10.1161/01.RES.0000260913.95642.3b; Garg V, 2005, NATURE, V437, P270, DOI 10.1038/nature03940; Gessler M, 2002, CURR BIOL, V12, P1601, DOI 10.1016/S0960-9822(02)01150-8; Ghosh B, 2006, BIOCHEM J, V393, P679, DOI 10.1042/BJ20051063; Greil F, 2006, METHOD ENZYMOL, V410, P342, DOI 10.1016/S0076-6879(06)10016-6; HASTY P, 1993, NATURE, V364, P501, DOI 10.1038/364501a0; Hayashi T, 2008, DEV BIOL, V316, P87, DOI 10.1016/j.ydbio.2008.01.006; Holderfield MT, 2006, BIOCHEM BIOPH RES CO, V346, P637, DOI 10.1016/j.bbrc.2006.05.177; Hu XY, 2008, IMMUNITY, V29, P691, DOI 10.1016/j.immuni.2008.08.016; Huang QH, 2004, P NATL ACAD SCI USA, V101, P3456, DOI 10.1073/pnas.0308562100; Iso T, 2002, J BIOL CHEM, V277, P6598, DOI 10.1074/jbc.M110495200; Iso T, 2001, MOL CELL BIOL, V21, P6080, DOI 10.1128/MCB.21.17.6080-6089.2001; Iso T, 2001, MOL CELL BIOL, V21, P6071, DOI 10.1128/MCB.21.17.6071-6079.2001; Jia JL, 2007, MOL CELL BIOL, V27, P7236, DOI 10.1128/MCB.00780-07; Kathiriya IS, 2004, J BIOL CHEM, V279, P54937, DOI 10.1074/jbc.M409879200; Kokubo H, 2005, DEV BIOL, V278, P301, DOI 10.1016/j.ydbio.2004.10.025; Kokubo H, 2007, DEVELOPMENT, V134, P747, DOI 10.1242/dev.02777; Leimeister C, 1999, MECH DEVELOP, V85, P173, DOI 10.1016/S0925-4773(99)00080-5; Lu JR, 2000, MOL CELL, V6, P233, DOI 10.1016/S1097-2765(00)00025-3; Maier MM, 2000, BIOCHEM BIOPH RES CO, V275, P652, DOI 10.1006/bbrc.2000.3354; Mal A, 2003, P NATL ACAD SCI USA, V100, P1735, DOI 10.1073/pnas.0437843100; Molkentin JD, 1995, CELL, V83, P1125, DOI 10.1016/0092-8674(95)90139-6; NABESHIMA Y, 1993, NATURE, V364, P532, DOI 10.1038/364532a0; Nakagawa O, 1999, DEV BIOL, V216, P72, DOI 10.1006/dbio.1999.9454; Nakagawa O, 2000, P NATL ACAD SCI USA, V97, P13655, DOI 10.1073/pnas.250485597; Pichon B, 2004, BBA-GENE STRUCT EXPR, V1680, P46, DOI 10.1016/j.bbaexp.2004.08.010; Reddy KL, 2008, NATURE, V452, P243, DOI 10.1038/nature06727; Rutenberg JB, 2006, DEVELOPMENT, V133, P4381, DOI 10.1242/dev.02607; Sakamoto M, 2003, J BIOL CHEM, V278, P44808, DOI 10.1074/jbc.M300448200; Schuster-Gossler K, 2007, P NATL ACAD SCI USA, V104, P537, DOI 10.1073/pnas.0608281104; SHEN CP, 1995, MOL CELL BIOL, V15, P4518; Spitz F, 1998, P NATL ACAD SCI USA, V95, P14220, DOI 10.1073/pnas.95.24.14220; Sun JX, 2001, J BIOL CHEM, V276, P18591, DOI 10.1074/jbc.M101163200; Taelman V, 2004, DEV BIOL, V276, P47, DOI 10.1016/j.ydbio.2004.08.019; Taelman V, 2006, DEVELOPMENT, V133, P2961, DOI 10.1242/dev.02458; van Steensel B, 2000, NAT BIOTECHNOL, V18, P424, DOI 10.1038/74487; van Steensel B, 2003, BIOTECHNIQUES, V35, P346; Vasyutina E, 2007, P NATL ACAD SCI USA, V104, P4443, DOI 10.1073/pnas.0610647104; Vogel MJ, 2007, NAT PROTOC, V2, P1467, DOI 10.1038/nprot.2007.148; Wang DZ, 2001, DEVELOPMENT, V128, P4623; Xu Q, 2000, J BIOL CHEM, V275, P36750, DOI 10.1074/jbc.M005030200; Zhang H, 2009, J BIOL CHEM, V284, P2867, DOI 10.1074/jbc.M807526200; Zhu BM, 2004, MOL CELL BIOL, V24, P8264, DOI 10.1128/MCB.24.18.8264-8275.2004	60	65	66	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 8	2010	285	2					1249	1258		10.1074/jbc.M109.046441	http://dx.doi.org/10.1074/jbc.M109.046441			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	539MH	19917614	hybrid, Green Published			2022-12-25	WOS:000273258200047
J	Trottier, J; Husseini, D; Perreault, M; Paquet, S; Caron, P; Bourassa, S; Verreault, M; Inaba, TT; Poirier, GG; Belanger, A; Guillemette, C; Trauner, M; Barbier, O				Trottier, Jocelyn; El Husseini, Diala; Perreault, Martin; Paquet, Sophie; Caron, Patrick; Bourassa, Sylvie; Verreault, Melanie; Inaba, Ted T.; Poirier, Guy G.; Belanger, Alain; Guillemette, Chantal; Trauner, Michael; Barbier, Olivier			The Human UGT1A3 Enzyme Conjugates Norursodeoxycholic Acid into a C-23-ester Glucuronide in the Liver	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							UDP-GLUCURONOSYLTRANSFERASE ENZYMES; BILE-ACIDS; MASS-SPECTROMETRY; SIDE-CHAIN; EXPRESSION; LOCUS; MICE; BIOTRANSFORMATION; PHARMACOGENOMICS; CHROMATOGRAPHY	Norursodeoxycholic acid (norUDCA) exhibits efficient anti-cholestatic properties in an animal model of sclerosing cholangitis. norUDCA is eliminated as a C-23-ester glucuronide (norUDCA-23G) in humans. The present study aimed at identifying the human UDP-glucuronosyltransferase (UGT) enzyme(s) involved in hepatic norUDCA glucuronidation and at evaluating the consequences of single nucleotide polymorphisms in the coding region of UGT genes on norUDCA-23G formation. The effects of norUDCA on the formation of the cholestatic lithocholic acid-glucuronide derivative and of rifampicin on hepatic norUDCA glucuronidation were also explored. In vitro glucuronidation assays were performed with microsomes from human tissues (liver and intestine) and HEK293 cells expressing human UGT enzymes and variant allozymes. UGT1A3 was identified as the major hepatic UGT enzyme catalyzing the formation of norUDCA-23G. Correlation studies using samples from a human liver bank (n = 16) indicated that the level of UGT1A3 protein is a strong determinant of in vitro norUDCA glucuronidation. Analyses of the nor UDCA-conjugating activity by 11 UGT1A3 variant allozymes identified three phenotypes with high, low, and intermediate capacity. norUDCA is also identified as a competitive inhibitor for the hepatic formation of the pro-cholestatic lithocholic acid-glucuronide derivative, whereas norUDCA glucuronidation is weakly stimulated by rifampicin. This study identifies human UGT1A3 as the major enzyme for the hepatic norUDCA glucuronidation and supports that some coding polymorphisms affecting the conjugating activity of UGT1A3 in vitro may alter the pharmacokinetic properties of norUDCA in cholestasis treatment.	[Verreault, Melanie] Univ Laval, Mol Pharmacol Lab, CHUQ Res Ctr, Quebec City, PQ G1V 4G2, Canada; [Verreault, Melanie; Guillemette, Chantal] Univ Laval, Fac Pharm, Quebec City, PQ G1V 4G2, Canada; [Bourassa, Sylvie; Poirier, Guy G.] Univ Laval, Quebec Genom Ctr, CHUQ Res Ctr, Quebec City, PQ G1V 4G2, Canada; [Bourassa, Sylvie; Poirier, Guy G.; Belanger, Alain] Univ Laval, Fac Med, Quebec City, PQ G1V 4G2, Canada; [Guillemette, Chantal] CHUL, CHUQ Res Ctr, Pharmacogenom Lab, Quebec City, PQ G1V 4G2, Canada; [Inaba, Ted T.] Univ Toronto, Dept Pharmacol, Toronto, ON M5S 1A8, Canada; [Trauner, Michael] Med Univ Graz Med, Div Gastroenterol & Hepatol, Dept Internal Med, Lab Expt & Mol Med, A-8010 Graz, Austria	Laval University; Laval University; Laval University; Laval University; Laval University; University of Toronto	Barbier, O (corresponding author), CHUL, CHUQ Res Ctr, Mol Pharmacol Lab, 2705 Laurier Blvd, Quebec City, PQ G1V 4G2, Canada.	olivier.barbier@crchul.ulaval.ca	Guillemette, Chantal/AAT-6246-2020; Guillemette, Chantal/J-6463-2012	Guillemette, Chantal/0000-0002-1113-1212; Barbier, Olivier/0000-0002-3067-1134; Trauner, Michael/0000-0002-1275-6425; Poirier, Guy/0000-0002-4869-1424	Canadian Institute of Health Research [MOP-84338]; Canadian Foundation for Innovation [10469]; Austrian Science Foundation [P19118-B05]	Canadian Institute of Health Research(Canadian Institutes of Health Research (CIHR)); Canadian Foundation for Innovation(Canada Foundation for Innovation); Austrian Science Foundation(Austrian Science Fund (FWF))	This work was supported by Canadian Institute of Health Research Grant MOP-84338, Canadian Foundation for Innovation Grant 10469, and Austrian Science Foundation Grant P19118-B05.	Barbier O, 2001, MOL PHARMACOL, V59, P636, DOI 10.1124/mol.59.3.636; Barbier O, 2009, MOL CELL BIOCHEM, V326, P3, DOI 10.1007/s11010-008-0001-5; Beaulieu M, 1996, J BIOL CHEM, V271, P22855, DOI 10.1074/jbc.271.37.22855; Belanger A, 2003, TRENDS ENDOCRIN MET, V14, P473, DOI 10.1016/j.tem.2003.10.005; Belanger AS, 2009, DRUG METAB DISPOS, V37, P1793, DOI 10.1124/dmd.109.027706; Caillier B, 2007, PHARMACOGENET GENOM, V17, P481, DOI 10.1097/FPC.0b013e32806d87a4; CAMPBELL ME, 1987, DRUG METAB DISPOS, V15, P237; Caron P, 2006, MOL PHARMACEUT, V3, P293, DOI 10.1021/mp060021l; Chouinard S, 2004, ENDOCR RES, V30, P717, DOI 10.1081/ERC-200044014; Dutton G.F., 1980, GLUCURONIDATION DRUG; Fickert P, 2006, GASTROENTEROLOGY, V130, P465, DOI 10.1053/j.gastro.2005.10.018; Gall WE, 1999, J STEROID BIOCHEM, V70, P101, DOI 10.1016/S0960-0760(99)00088-6; Gardner-Stephen D, 2004, DRUG METAB DISPOS, V32, P340, DOI 10.1124/dmd.32.3.340; Girard H, 2007, PHARMACOGENET GENOM, V17, P1077, DOI 10.1097/FPC.0b013e3282f1f118; Gong QH, 2001, PHARMACOGENETICS, V11, P357, DOI 10.1097/00008571-200106000-00011; GONG Y, 2009, COCHRANE LIB; Griffiths WJ, 2003, MASS SPECTROM REV, V22, P81, DOI 10.1002/mas.10046; Guillemette C, 2003, PHARMACOGENOMICS J, V3, P136, DOI 10.1038/sj.tpj.6500171; Halilbasic E, 2009, HEPATOLOGY, V49, P1972, DOI 10.1002/hep.22891; Hansen SH, 2004, ELECTROPHORESIS, V25, P3277, DOI 10.1002/elps.200406036; Hofmann AF, 2005, HEPATOLOGY, V42, P1391, DOI 10.1002/hep.20943; Hofmann AF, 2009, FRONT BIOSCI-LANDMRK, V14, P2584, DOI 10.2741/3399; Kaeding J, 2008, MOL CANCER THER, V7, P380, DOI 10.1158/1535-7163.MCT-07-0455; Kremer AE, 2008, DRUGS, V68, P2163, DOI 10.2165/00003495-200868150-00006; Levesque E, 2007, HEPATOLOGY, V45, P128, DOI 10.1002/hep.21464; Nagar S, 2006, ONCOGENE, V25, P1659, DOI 10.1038/sj.onc.1209375; OELBERG DG, 1984, J CLIN INVEST, V73, P1507, DOI 10.1172/JCI111356; Paumgartner G, 2008, CLIN LIVER DIS, V12, P53, DOI 10.1016/j.cld.2007.11.013; Ritter JK, 2000, CHEM-BIOL INTERACT, V129, P171, DOI 10.1016/S0009-2797(00)00198-8; SCHTEINGART CD, 1988, J LIPID RES, V29, P1387; Shipkova M, 2003, THER DRUG MONIT, V25, P1, DOI 10.1097/00007691-200302000-00001; TAKIKAWA H, 1991, BIOCHIM BIOPHYS ACTA, V1081, P39, DOI 10.1016/0005-2760(91)90247-F; Trottier J, 2006, HEPATOLOGY, V44, P1158, DOI 10.1002/hep.21362; Trottier J, 2008, HEPATOLOGY, V48, p667A; Verreault M, 2006, HEPATOLOGY, V44, P368, DOI 10.1002/hep.21259; Zollner G, 2009, BRIT J PHARMACOL, V156, P7, DOI 10.1111/j.1476-5381.2008.00030.x	36	18	18	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 8	2010	285	2					1113	1121		10.1074/jbc.M109.073908	http://dx.doi.org/10.1074/jbc.M109.073908			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	539MH	19889628	Green Published, hybrid			2022-12-25	WOS:000273258200033
J	Wayne, N; Lai, YS; Pullen, L; Bolon, DN				Wayne, Natalie; Lai, YuShuan; Pullen, Les; Bolon, Daniel N.			Modular Control of Cross-oligomerization ANALYSIS OF SUPERSTABILIZED Hsp90 HOMODIMERS IN VIVO	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HSP90 MOLECULAR CHAPERONE; HEAT-SHOCK-PROTEIN; IN-VIVO FUNCTION; CRYSTAL-STRUCTURE; ATP HYDROLYSIS; CONFORMATIONAL-CHANGES; STEROID-RECEPTOR; YEAST; BINDING; DESIGN	Homo-oligomeric proteins fulfill numerous functions in all cells. The ability to co-express subunits of these proteins that preferentially self-assemble without cross-oligomerizing provides for controlled experiments to analyze the function of mutant homo-oligomers in vivo. Hsp90 is a dimeric chaperone involved in the maturation of many kinases and steroid hormone receptors. We observed that co-expression of different Hsp90 subunits in Saccharomyces cerevisiae caused unpredictable synthetic growth defects due to cross-dimerization. We engineered superstabilized Hsp90 dimers that resisted cross-dimerization with endogenous Hsp90 and alleviated the synthetic growth defect. Superstabilized Hsp90 dimers supported robust growth of S. cerevisiae, indicating that dissociation of Hsp90 dimers could be hindered without compromising essential function. We utilized superstabilized dimers to analyze the activity of ATPase mutant homodimers in a temperature-sensitive yeast background where elevated temperature inactivated all other Hsp90 species. We found that ATP binding and hydrolysis by Hsp90 are both required for the efficient maturation of glucocorticoid receptor and v-Src, confirming the critical role of ATP hydrolysis in the maturation of steroid hormone receptors and kinases in vivo.	[Wayne, Natalie; Lai, YuShuan; Pullen, Les; Bolon, Daniel N.] Univ Massachusetts, Sch Med, Dept Biochem & Mol Pharmacol, Worcester, MA 01605 USA	University of Massachusetts System; University of Massachusetts Worcester	Bolon, DN (corresponding author), LRB 922,364 Plantat St, Worcester, MA 01605 USA.	dan.bolon@umassmed.edu		Bolon, Daniel/0000-0001-5857-6676	National Institutes of Health [R01-GM083038-01A]; American Cancer Society [RSG-08-17301-GMC]; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM083038] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); American Cancer Society(American Cancer Society); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	This work was supported, in whole or in part, by National Institutes of Health Grant R01-GM083038-01A and by American Cancer Society Grant RSG-08-17301-GMC.	Ali MMU, 2006, NATURE, V440, P1013, DOI 10.1038/nature04716; Bolon DN, 2005, P NATL ACAD SCI USA, V102, P12724, DOI 10.1073/pnas.0506124102; Bolon DN, 2004, MOL CELL, V13, P443, DOI 10.1016/S1097-2765(04)00027-9; Cox MB, 2002, TOXICOL LETT, V129, P13, DOI 10.1016/S0378-4274(01)00465-9; DELANO WL, 1994, PROTEINS, V20, P105, DOI 10.1002/prot.340200202; Floer M, 2008, P NATL ACAD SCI USA, V105, P2975, DOI 10.1073/pnas.0800053105; Ghaemmaghami S, 2003, NATURE, V425, P737, DOI 10.1038/nature02046; Grenert JP, 1999, J BIOL CHEM, V274, P17525, DOI 10.1074/jbc.274.25.17525; Havranek JJ, 2003, NAT STRUCT BIOL, V10, P45, DOI 10.1038/nsb877; Hessling M, 2009, NAT STRUCT MOL BIOL, V16, P287, DOI 10.1038/nsmb.1565; Kathuria SV, 2008, J MOL BIOL, V382, P467, DOI 10.1016/j.jmb.2008.06.054; Krukenberg KA, 2008, STRUCTURE, V16, P755, DOI 10.1016/j.str.2008.01.021; Levchenko I, 2000, SCIENCE, V289, P2354, DOI 10.1126/science.289.5488.2354; McLaughlin SH, 2004, J MOL BIOL, V344, P813, DOI 10.1016/j.jmb.2004.09.055; Mickler M, 2009, NAT STRUCT MOL BIOL, V16, P281, DOI 10.1038/nsmb.1557; Nathan DF, 1997, P NATL ACAD SCI USA, V94, P12949, DOI 10.1073/pnas.94.24.12949; NATHAN DF, 1995, MOL CELL BIOL, V15, P3917; NEMOTO T, 1995, EUR J BIOCHEM, V233, P1, DOI 10.1111/j.1432-1033.1995.001_1.x; Obermann WMJ, 1998, J CELL BIOL, V143, P901, DOI 10.1083/jcb.143.4.901; Ozbek S, 2002, EMBO J, V21, P5960, DOI 10.1093/emboj/cdf628; Panaretou B, 1998, EMBO J, V17, P4829, DOI 10.1093/emboj/17.16.4829; PICARD D, 1990, NATURE, V348, P166, DOI 10.1038/348166a0; Pratt WB, 2006, HANDB EXP PHARM, V172, P111; Pratt WB, 2003, EXP BIOL MED, V228, P111, DOI 10.1177/153537020322800201; Prodromou C, 1997, CELL, V90, P65, DOI 10.1016/S0092-8674(00)80314-1; Prodromou C, 1997, NAT STRUCT BIOL, V4, P477, DOI 10.1038/nsb0697-477; Richter K, 2001, J BIOL CHEM, V276, P33689, DOI 10.1074/jbc.M103832200; Richter K, 2008, J BIOL CHEM, V283, P17757, DOI 10.1074/jbc.M800540200; Taldone T, 2009, BIOORGAN MED CHEM, V17, P2225, DOI 10.1016/j.bmc.2008.10.087; Wandinger SK, 2008, J BIOL CHEM, V283, P18473, DOI 10.1074/jbc.R800007200; Wayne N, 2007, J BIOL CHEM, V282, P35386, DOI 10.1074/jbc.M703844200; Whitesell L, 2005, NAT REV CANCER, V5, P761, DOI 10.1038/nrc1716; Wu Y, 2007, J MOL BIOL, V366, P1624, DOI 10.1016/j.jmb.2006.12.005; Yonehara M, 1996, J BIOL CHEM, V271, P2641, DOI 10.1074/jbc.271.5.2641; Youker RT, 2004, MOL BIOL CELL, V15, P4787, DOI 10.1091/mbc.E04-07-0584; Zhao RM, 2005, CELL, V120, P715, DOI 10.1016/j.cell.2004.12.024	36	11	11	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 1	2010	285	1					234	241		10.1074/jbc.M109.060129	http://dx.doi.org/10.1074/jbc.M109.060129			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	536UT	19906642	Green Published, hybrid			2022-12-25	WOS:000273070100025
J	Delignieres, D; Torre, K; Lemoine, L				Delignieres, Didier; Torre, Kjerstin; Lemoine, Loic			Long-Range Correlation in Synchronization and Syncopation Tapping: A Linear Phase Correction Model	PLOS ONE			English	Article							SENSORIMOTOR SYNCHRONIZATION; CEREBELLAR LESIONS; DRAWING MOVEMENTS; HUMAN COGNITION; MOTOR CONTROL; TIME-SERIES; 1/F NOISE; COORDINATION; INTERVALS; EXPONENTS	We propose in this paper a model for accounting for the increase in long-range correlations observed in asynchrony series in syncopation tapping, as compared with synchronization tapping. Our model is an extension of the linear phase correction model for synchronization tapping. We suppose that the timekeeper represents a fractal source in the system, and that a process of estimation of the half-period of the metronome, obeying a random-walk dynamics, combines with the linear phase correction process. Comparing experimental and simulated series, we show that our model allows accounting for the experimentally observed pattern of serial dependence. This model complete previous modeling solutions proposed for self-paced and synchronization tapping, for a unifying framework of event-based timing.			Delignieres, D (corresponding author), Univ Montpellier 1, Motor Efficiency & Deficiency Lab, Montpellier, France.	didier.delignieres@univ-montp1.fr		Lauwereyns, Jan/0000-0003-0551-2550				Aschersleben G, 2002, BRAIN COGNITION, V48, P66, DOI 10.1006/brcg.2001.1304; Chen YQ, 1997, PHYS REV LETT, V79, P4501, DOI 10.1103/PhysRevLett.79.4501; Chen YQ, 2001, J MOTOR BEHAV, V33, P3, DOI 10.1080/00222890109601897; Delignieres D, 2004, HUM MOVEMENT SCI, V23, P87, DOI 10.1016/j.humov.2004.07.001; Delignieres D, 2008, ACTA PSYCHOL, V127, P382, DOI 10.1016/j.actpsy.2007.07.007; Eke A, 2000, PFLUG ARCH EUR J PHY, V439, P403, DOI 10.1007/s004249900135; GILDEN DL, 1995, SCIENCE, V267, P1837, DOI 10.1126/science.7892611; Huys R, 2008, UNDERST COMPLEX SYST, P77, DOI 10.1007/978-3-540-74479-5_4; Ivry RB, 1996, CURR OPIN NEUROBIOL, V6, P851, DOI 10.1016/S0959-4388(96)80037-7; Ivry RB, 2002, ANN NY ACAD SCI, V978, P302, DOI 10.1111/j.1749-6632.2002.tb07576.x; Kello CT, 2007, J EXP PSYCHOL GEN, V136, P551, DOI 10.1037/0096-3445.136.4.551; Lemoine L, 2006, CAN J EXP PSYCHOL, V60, P247, DOI 10.1037/cjep2006023; PENG CK, 1995, CHAOS, V5, P82, DOI 10.1063/1.166141; Repp BH, 2005, PSYCHON B REV, V12, P969, DOI 10.3758/BF03206433; Robertson SD, 1999, J EXP PSYCHOL HUMAN, V25, P1316, DOI 10.1037/0096-1523.25.5.1316; Schoner G, 2002, BRAIN COGNITION, V48, P31, DOI 10.1006/brcg.2001.1302; Spencer RMC, 2005, BRAIN COGNITION, V58, P84, DOI 10.1016/j.bandc.2004.09.010; Spencer RMC, 2003, SCIENCE, V300, P1437, DOI 10.1126/science.1083661; TORRE K, 2009, MOTOR CONTR IN PRESS; Torre K, 2007, BRIT J MATH STAT PSY, V60, P85, DOI 10.1348/000711005X89513; Torre K, 2008, BIOL CYBERN, V99, P159, DOI 10.1007/s00422-008-0247-8; Torre K, 2009, HUM MOVEMENT SCI, V28, P297, DOI 10.1016/j.humov.2009.01.001; Vorberg D., 1996, HDB PERCEPT ACTION, P181, DOI [10.1016/S1874-5822(06)80007-1, DOI 10.1016/S1874-5822(06)80007-1, 10.1016/S1874-5822(06)80007-1.]; Wagenmakers EJ, 2004, PSYCHON B REV, V11, P579, DOI 10.3758/BF03196615; Wagenmakers EJ, 2004, PSYCHON B REV, V11, P192, DOI 10.3758/BF03206482; WING AM, 1973, PERCEPT PSYCHOPHYS, V13, P455, DOI 10.3758/BF03205802; WING AM, 1973, PERCEPT PSYCHOPHYS, V14, P5, DOI 10.3758/BF03198607; Zelaznik HN, 2000, J MOTOR BEHAV, V32, P193, DOI 10.1080/00222890009601370; Zelaznik HN, 2002, J EXP PSYCHOL HUMAN, V28, P575, DOI 10.1037//0096-1523.28.3.575	29	23	23	1	5	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA	1932-6203			PLOS ONE	PLoS One	NOV 13	2009	4	11							e7822	10.1371/journal.pone.0007822	http://dx.doi.org/10.1371/journal.pone.0007822			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	518VB	19915658	Green Published, Green Submitted, gold			2022-12-25	WOS:000271721900013
J	Oh, WS; Jeong, PY; Joo, HJ; Lee, JE; Moon, YS; Cheon, HM; Kim, JH; Lee, YU; Shim, YH; Paik, YK				Oh, Wan-Suk; Jeong, Pan-Young; Joo, Hyoe-Jin; Lee, Jeong-Eui; Moon, Yil-Seong; Cheon, Hyang-Mi; Kim, Jung-Ho; Lee, Yong-Uk; Shim, Yhong-Hee; Paik, Young-Ki			Identification and Characterization of a Dual-Acting Antinematodal Agent against the Pinewood Nematode, Bursaphelenchus xylophilus	PLOS ONE			English	Article							TRUNK-INJECTION AGENT; WOOD NEMATODE; CAENORHABDITIS-ELEGANS; EMAMECTIN BENZOATE; WILT DISEASE; CANDIDA-ALBICANS; BLUE-STAIN; FUNGI; INHIBITION; BERBERINE	The pinewood nematode (PWN), Bursaphelenchus xylophilus, is a mycophagous and phytophagous pathogen responsible for the current widespread epidemic of the pine wilt disease, which has become a major threat to pine forests throughout the world. Despite the availability of several preventive trunk-injection agents, no therapeutic trunk-injection agent for eradication of PWN currently exists. In the characterization of basic physiological properties of B. xylophilus YB-1 isolates, we established a high-throughput screening (HTS) method that identifies potential hits within approximately 7 h. Using this HTS method, we screened 206 compounds with known activities, mostly antifungal, for antinematodal activities and identified HWY-4213 (1-n-undecyl-2-[2-fluorphenyl] methyl-3,4-dihydro-6,7-dimethoxy-isoquinolinium chloride), a highly water-soluble protoberberine derivative, as a potent nematicidal and antifungal agent. When tested on 4 year-old pinewood seedlings that were infected with YB-1 isolates, HWY-4213 exhibited a potent therapeutic nematicidal activity. Further tests of screening 39 Caenorhabditis elegans mutants deficient in channel proteins and B. xylophilus sensitivity to Ca(2+) channel blockers suggested that HWY-4213 targets the calcium channel proteins. Our study marks a technical breakthrough by developing a novel HTS method that leads to the discovery HWY-4213 as a dual-acting antinematodal and antifungal compound.			Oh, WS (corresponding author), Yonsei Univ, Yonsei Proteome Res Ctr, Seoul 120749, South Korea.	paikyk@yonsei.ac.kr	Shim, Yhong-hee/D-6691-2011; Lee, Yong-Uk/D-6703-2011	Shim, Yhong-hee/0000-0002-8660-4176; 				Baermann G., 1917, Geneeskundig Tijdschrift voor Nederlandsch-Indie Batavia, V57; BRENNER S, 1974, GENETICS, V77, P71; CHIOU WF, 1991, EUR J PHARMACOL, V204, P35; Dwinell LD, 1997, ANNU REV PHYTOPATHOL, V35, P153, DOI 10.1146/annurev.phyto.35.1.153; Espinel-Ingroff A, 2002, J CLIN MICROBIOL, V40, P3204, DOI 10.1128/JCM.40.9.3204-3208.2002; Fielding NJ, 1996, FORESTRY, V69, P35, DOI 10.1093/forestry/69.1.35; Hanawa F, 2001, PHYTOCHEMISTRY, V57, P223, DOI 10.1016/S0031-9422(00)00514-8; Hasegawa K, 2004, DEV GROWTH DIFFER, V46, P153, DOI 10.1111/j.1440-169X.2003.00734.x; Hofstetter RW, 2005, J CHEM ECOL, V31, P539, DOI 10.1007/s10886-005-2035-4; Kim S, 2008, BIOCHEM BIOPH RES CO, V368, P588, DOI 10.1016/j.bbrc.2008.01.131; *KOR MIN HLTH WELF, 2001, HMP98D10003 KOR MIN; Maehara N, 2005, NEMATOLOGY, V7, P161, DOI 10.1163/1568541054879557; MAMIYA Y, 1983, ANNU REV PHYTOPATHOL, V21, P201, DOI 10.1146/annurev.py.21.090183.001221; MOON YS, 2007, SANLIM, V192, P74; Mota MM, 1999, NEMATOLOGY, V1, P727, DOI 10.1163/156854199508757; National Committee for Clinical Laboratory Standard, 2002, M38A NAT COMM CLIN L; Park KS, 2001, J ANTIMICROB CHEMOTH, V47, P513, DOI 10.1093/jac/47.5.513; Park KS, 1999, J ANTIMICROB CHEMOTH, V43, P667, DOI 10.1093/jac/43.5.667; SanchezChapula J, 1996, BRIT J PHARMACOL, V117, P1427, DOI 10.1111/j.1476-5381.1996.tb15302.x; Santos DA, 2006, J CLIN MICROBIOL, V44, P98, DOI 10.1128/JCM.44.1.98-101.2006; Shtonda B, 2005, J EXP BIOL, V208, P2177, DOI 10.1242/jeb.01615; Song LS, 2000, BRIT J PHARMACOL, V129, P893, DOI 10.1038/sj.bjp.0703132; Steger KA, 2005, J EXP BIOL, V208, P2191, DOI 10.1242/jeb.01616; Steiner G, 1934, J AGRIC RES, V48, P0949; Suzuki K., 2002, Dendrobiology, V48, P71; Takai K, 2003, PEST MANAG SCI, V59, P365, DOI 10.1002/ps.651; Takai K, 2001, PEST MANAG SCI, V57, P463, DOI 10.1002/ps.301; Takai K, 2000, PEST MANAG SCI, V56, P937, DOI 10.1002/1526-4998(200010)56:10<937::AID-PS213>3.0.CO;2-B; Wang Y, 2005, NEMATOLOGY, V7, P459, DOI 10.1163/156854105774355545	29	15	18	2	16	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA	1932-6203			PLOS ONE	PLoS One	NOV 11	2009	4	11					A22	A30	e7593	10.1371/journal.pone.0007593	http://dx.doi.org/10.1371/journal.pone.0007593			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	518IX	19907651	Green Published, gold, Green Submitted			2022-12-25	WOS:000271685800003
J	Rex, CS; Colgin, LL; Jia, YS; Casale, M; Yanagihara, TK; Debenedetti, M; Gall, CM; Kramar, EA; Lynch, G				Rex, Christopher S.; Colgin, Laura L.; Jia, Yousheng; Casale, Malcolm; Yanagihara, Theodore K.; Debenedetti, Maria; Gall, Christine M.; Kramar, Eniko A.; Lynch, Gary			Origins of an Intrinsic Hippocampal EEG Pattern	PLOS ONE			English	Article							LONG-TERM POTENTIATION; CA3 PYRAMIDAL CELLS; ENTORHINAL CORTEX LESIONS; SPONTANEOUS SHARP WAVES; MOSSY FIBER SYNAPSE; DENTATE GYRUS; GRANULE CELLS; I-H; THETA-RHYTHM; RAT	Sharp waves (SPWs) are irregular waves that originate in field CA3 and spread throughout the hippocampus when animals are alert but immobile or as a component of the sleep EEG. The work described here used rat hippocampal slices to investigate the factors that initiate SPWs and govern their frequency. Acute transection of the mossy fibers reduced the amplitude but not the frequency of SPWs, suggesting that activity in the dentate gyrus may enhance, but is not essential for, the CA3 waves. However, selective destruction of the granule cells and mossy fibers by in vivo colchicine injections profoundly depressed SPW frequency. Reducing mossy fiber release with an mGluR2 receptor agonist or enhancing it with forskolin respectively depressed or increased the incidence of SPWs. Collectively, these results indicate that SPWs can be triggered by constitutive release from the mossy fibers. The waves were not followed by large after-hyperpolarizing potentials and their frequency was not strongly affected by blockers of various slow potassium channels. Antagonists of GABA-B mediated IPSCs also had little effect on incidence. It appears from these results that the spacing of SPWs is not dictated by slow potentials. However, modeling work suggests that the frequency and variance of large mEPSCs from the mossy boutons can account for the temporal distribution of the waves. Together, these results indicate that constitutive release from the mossy fiber terminal boutons regulates the incidence of SPWs and their contribution to information processing in hippocampus.			Rex, CS (corresponding author), Univ Calif Irvine, Dept Anat & Neurobiol, Irvine, CA 92717 USA.	glynch@uci.edu	Rex, Christopher/F-2112-2010	Colgin, Laura/0000-0002-4853-8913	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [P01NS045260, T32NS045540, R01NS051823] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [T32AG000096] Funding Source: NIH RePORTER; NIA NIH HHS [AG00096, T32 AG000096] Funding Source: Medline; NINDS NIH HHS [NS051823, T32 NS045540, P01 NS045260, R01 NS051823, NS045540, NS45260] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Amaral David G., 1995, P443; AMARAL DG, 1981, J COMP NEUROL, V195, P51, DOI 10.1002/cne.901950106; BLACKSTAD T, 1961, J COMP NEUROL, V117, P133, DOI 10.1002/cne.901170202; BRAGIN A, 1995, J NEUROPHYSIOL, V73, P1691, DOI 10.1152/jn.1995.73.4.1691; BUZSAKI G, 1986, BRAIN RES, V398, P242, DOI 10.1016/0006-8993(86)91483-6; BUZSAKI G, 1983, BRAIN RES REV, V6, P139, DOI 10.1016/0165-0173(83)90037-1; BUZSAKI G, 1992, SCIENCE, V256, P1025, DOI 10.1126/science.1589772; Buzsaki G, 2002, NEURON, V33, P325, DOI 10.1016/S0896-6273(02)00586-X; CHROBAK JJ, 1994, J NEUROSCI, V14, P6160; CLAIBORNE BJ, 1986, J COMP NEUROL, V246, P435, DOI 10.1002/cne.902460403; Colgin LL, 2005, NEUROSCI LETT, V385, P46, DOI 10.1016/j.neulet.2005.05.005; Colgin LL, 2004, J NEUROPHYSIOL, V92, P3385, DOI 10.1152/jn.00478.2004; Colgin LL, 2004, J PHYSIOL-LONDON, V558, P953, DOI 10.1113/jphysiol.2004.068080; Csicsvari J, 2000, NEURON, V28, P585, DOI 10.1016/S0896-6273(00)00135-5; Draguhn A, 2000, J CLIN NEUROPHYSIOL, V17, P361, DOI 10.1097/00004691-200007000-00003; Fan Y, 2005, NAT NEUROSCI, V8, P1542, DOI 10.1038/nn1568; Gasparini S, 1997, PFLUG ARCH EUR J PHY, V435, P99, DOI 10.1007/s004240050488; GOLDSCHMIDT RB, 1980, P NATL ACAD SCI-BIOL, V77, P3047, DOI 10.1073/pnas.77.5.3047; HALL P, 1982, J ROY STAT SOC B MET, V44, P37; Hamzei-Sichani F, 2007, P NATL ACAD SCI USA, V104, P12548, DOI 10.1073/pnas.0705281104; Henze DA, 1997, J NEUROPHYSIOL, V77, P1075, DOI 10.1152/jn.1997.77.3.1075; Henze DA, 2002, J NEUROPHYSIOL, V87, P15, DOI 10.1152/jn.00394.2001; Henze DA, 1996, J COMP NEUROL, V369, P331, DOI 10.1002/(SICI)1096-9861(19960603)369:3<331::AID-CNE1>3.0.CO;2-6; ISHIZUKA N, 1990, J COMP NEUROL, V295, P580, DOI 10.1002/cne.902950407; JONAS P, 1993, J PHYSIOL-LONDON, V472, P615, DOI 10.1113/jphysiol.1993.sp019965; Kamiya H, 1996, J PHYSIOL-LONDON, V493, P447, DOI 10.1113/jphysiol.1996.sp021395; Kirschstein T, 2004, NEUROPHARMACOLOGY, V47, P157, DOI 10.1016/j.neuropharm.2004.04.004; Klausberger T, 2003, NATURE, V421, P844, DOI 10.1038/nature01374; Klausberger T, 2004, NAT NEUROSCI, V7, P41, DOI 10.1038/nn1159; KONOPACKI J, 1987, BRAIN RES, V405, P196, DOI 10.1016/0006-8993(87)91009-2; Kramar EA, 2003, NEUROSCIENCE, V118, P387, DOI 10.1016/S0306-4522(02)00916-8; Kubota D, 2003, J NEUROPHYSIOL, V89, P81, DOI 10.1152/jn.00542.2002; LANCASTER B, 1987, J PHYSIOL-LONDON, V389, P187, DOI 10.1113/jphysiol.1987.sp016653; LARSON J, 1993, BRAIN RES, V600, P97, DOI 10.1016/0006-8993(93)90406-D; LOTHMAN EW, 1982, EXP NEUROL, V78, P293, DOI 10.1016/0014-4886(82)90048-6; Maier N, 2003, J PHYSIOL-LONDON, V550, P873, DOI 10.1113/jphysiol.2003.044602; McBain CJ, 2008, PROG BRAIN RES, V169, P225, DOI 10.1016/S0079-6123(07)00013-1; MCNAUGHTON BL, 1989, EXP BRAIN RES, V76, P485, DOI 10.1007/BF00248904; MONMAUR P, 1986, BRAIN RES, V365, P269, DOI 10.1016/0006-8993(86)91638-0; Mori M, 2007, P NATL ACAD SCI USA, V104, P7640, DOI 10.1073/pnas.0702164104; Otmakhova NA, 2004, J NEUROPHYSIOL, V92, P2027, DOI 10.1152/jn.00427.2004; Papatheodoropoulos C, 2002, BRAIN RES BULL, V57, P187, DOI 10.1016/S0361-9230(01)00738-9; Pavlidis P, 1999, J NEUROPHYSIOL, V81, P2787, DOI 10.1152/jn.1999.81.6.2787; PETSCHE H, 1962, ELECTROEN CLIN NEURO, V14, P202, DOI 10.1016/0013-4694(62)90030-5; Sah P, 1996, TRENDS NEUROSCI, V19, P150, DOI 10.1016/S0166-2236(96)80026-9; SOLIS JM, 1992, J NEUROSCI, V12, P3466; STAUBLI U, 1990, SYNAPSE, V5, P333, DOI 10.1002/syn.890050410; STEWARD O, 1992, HIPPOCAMPUS, V2, P247, DOI 10.1002/hipo.450020305; Stocker M, 1999, P NATL ACAD SCI USA, V96, P4662, DOI 10.1073/pnas.96.8.4662; SUZUKI SS, 1988, ELECTROEN CLIN NEURO, V70, P73, DOI 10.1016/0013-4694(88)90197-6; SUZUKI SS, 1988, ELECTROEN CLIN NEURO, V69, P532, DOI 10.1016/0013-4694(88)90165-4; SUZUKI SS, 1988, ELECTROEN CLIN NEURO, V69, P541, DOI 10.1016/0013-4694(88)90166-6; SWANSON LW, 1978, J COMP NEUROL, V181, P681, DOI 10.1002/cne.901810402; TallonBaudry C, 1997, J NEUROSCI, V17, P722; Urban NN, 2001, HIPPOCAMPUS, V11, P408, DOI 10.1002/hipo.1055.abs; VANDERWOLF CH, 1969, ELECTROEN CLIN NEURO, V26, P407, DOI 10.1016/0013-4694(69)90092-3; Vertes Robert P, 2004, Behav Cogn Neurosci Rev, V3, P173, DOI 10.1177/1534582304273594; Vertes RP, 1997, NEUROSCIENCE, V81, P893; Wang H, 2008, J NEUROSCI, V28, P8677, DOI 10.1523/JNEUROSCI.2440-08.2008; WHITTINGTON MA, 1995, NATURE, V373, P612, DOI 10.1038/373612a0; Yeckel MF, 1999, NAT NEUROSCI, V2, P625, DOI 10.1038/10180; YLINEN A, 1995, J NEUROSCI, V15, P30; ZALUTSKY RA, 1990, SCIENCE, V248, P1619, DOI 10.1126/science.2114039; Zhang Liang, 2006, Critical Reviews in Neurobiology, V18, P159	64	13	14	0	4	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	NOV 11	2009	4	11					A82	A94	e7761	10.1371/journal.pone.0007761	http://dx.doi.org/10.1371/journal.pone.0007761			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	518IX	19907647	Green Published, Green Submitted, gold			2022-12-25	WOS:000271685800010
J	Aujla, N; Abrams, KR; Davies, MJ; Taub, N; Skinner, TC; Khunti, K				Aujla, Navneet; Abrams, Keith R.; Davies, Melanie J.; Taub, Nick; Skinner, Timothy C.; Khunti, Kamlesh			The Prevalence of Depression in White-European and South-Asian People with Impaired Glucose Regulation and Screen-Detected Type 2 Diabetes Mellitus	PLOS ONE			English	Article							PRIMARY-CARE; RISK-FACTOR; FOLLOW-UP; SYMPTOMS; METAANALYSIS; HEALTH; ADULTS; RELIABILITY; VALIDITY; LONDON	There is a clear relationship between depression and diabetes. However, the directionality of the relationship remains unclear and very little research has considered a multi-ethnic population. The aim of this study was to determine the prevalence of depression in a White-European (WE) and South-Asian (SA) population attending a community diabetes screening programme, and to explore the association of depression with screen-detected Type 2 diabetes mellitus (T2DM) and impaired glucose regulation (IGR). Methodology/Principal Findings: Participants were recruited from general practices in Leicestershire (United Kingdom) between August 2004 and December 2007. 4682 WE (40-75 years) and 1327 SA participants (25-75 years) underwent an Oral Glucose Tolerance Test, detailed history, anthropometric measurements and completed the World Health Organisation-Five (WHO-5) Wellbeing Index. Depression was defined by a WHO-5 wellbeing score <= 13. Unadjusted prevalence of depression for people in the total sample with T2DM and IGR was 21.3% (21.6% in WE, 20.6% in SA, p = 0.75) and 26.0% (25.3% in WE, 28.9% in SA, p = 0.65) respectively. For people with normal glucose tolerance, the prevalence was 25.1% (24.9% in WE, 26.4% in SA, p = 0.86). Age-adjusted prevalences were higher for females than males. Odds ratios adjusted for age, gender, and ethnicity, showed no significant increase in prevalent depression for people with T2DM (OR = 0.95, 95% CI 0.62 to 1.45) or IGR (OR = 1.17, 95% CI 0.96 to 1.42). Conclusions: Prior to the knowledge of diagnosis, depression was not significantly more prevalent in people with screen detected T2DM or IGR. Differences in prevalent depression between WE and SA people were also not identified. In this multi-ethnic population, female gender was significantly associated with depression.			Aujla, N (corresponding author), Univ Leicester, Dept Hlth Sci, Leicester, Leics, England.	na137@le.ac.uk	Skinner, Timothy C/N-2221-2013; /ABC-9527-2021; Davies, Michael/AGX-9184-2022; Abrams, Keith/AAA-2557-2020; Davies, Michael J/H-4939-2011; Davies, Michael/GWV-2527-2022	Skinner, Timothy C/0000-0002-0018-6963; Davies, Michael/0000-0002-5196-6919; Davies, Michael J/0000-0002-5196-6919; Khunti, Kamlesh/0000-0003-2343-7099; Davies, Melanie/0000-0002-9987-9371; Abrams, Keith/0000-0002-7557-1567				Ali S, 2006, DIABETIC MED, V23, P1165, DOI 10.1111/j.1464-5491.2006.01943.x; ALI S, 2009, DIABETIC MED S1, V26, pA74; Anderson RJ, 2001, DIABETES CARE, V24, P1069, DOI 10.2337/diacare.24.6.1069; Arroyo C, 2004, DIABETES CARE, V27, P129, DOI 10.2337/diacare.27.1.129; Asghar S, 2007, DIABETIC MED, V24, P872, DOI 10.1111/j.1464-5491.2007.02136.x; Awata S, 2007, PSYCHIAT CLIN NEUROS, V61, P112, DOI 10.1111/j.1440-1819.2007.01619.x; Bech P, 2003, INT J METH PSYCH RES, V12, P85, DOI 10.1002/mpr.145; Brown LC, 2005, DIABETES CARE, V28, P1063, DOI 10.2337/diacare.28.5.1063; Carnethon MR, 2003, AM J EPIDEMIOL, V158, P416, DOI 10.1093/aje/kwg172; Chowdhury TA, 2006, POSTGRAD MED J, V82, P211, DOI 10.1136/pgmj.2005.036673; Ciechanowski PS, 2000, ARCH INTERN MED, V160, P3278, DOI 10.1001/archinte.160.21.3278; Craig CL, 2003, MED SCI SPORT EXER, V35, P1381, DOI 10.1249/01.MSS.0000078924.61453.FB; Cummins C, 1999, J PUBLIC HEALTH MED, V21, P401, DOI 10.1093/pubmed/21.4.401; *DP COMM LOC GOV, 2007, ENGL IND DEPR 2007 S; Fisher L, 2001, DIABETES CARE, V24, P1751, DOI 10.2337/diacare.24.10.1751; Henkel V, 2004, GEN HOSP PSYCHIAT, V26, P190, DOI 10.1016/j.genhosppsych.2004.02.003; Henkel V, 2003, BRIT MED J, V326, P200, DOI 10.1136/bmj.326.7382.200; Holt RIG, 2009, DIABETIC MED, V26, P641, DOI 10.1111/j.1464-5491.2009.02742.x; Icks A, 2008, DIABETIC MED, V25, P1330, DOI 10.1111/j.1464-5491.2008.02585.x; International Diabetes Federation (IDF), 2006, IDF CONS WORLDW DEF; Khunti K, 2008, DIABETIC MED, V25, P1454, DOI 10.1111/j.1464-5491.2008.02620.x; Knol MJ, 2009, DIABETOLOGIA, V52, P425, DOI 10.1007/s00125-008-1249-8; Knol MJ, 2006, DIABETOLOGIA, V49, P837, DOI 10.1007/s00125-006-0159-x; Leimkuhler AMM, 2007, J AFFECT DISORDERS, V98, P65, DOI 10.1016/j.jad.2006.07.007; Mather HM, 1998, DIABETIC MED, V15, P53, DOI 10.1002/(SICI)1096-9136(199801)15:1<53::AID-DIA521>3.0.CO;2-V; Nathan DM, 2009, DIABETES CARE, V32, P1327, DOI 10.2337/dc09-9033; National Institute for Health and Clinical Excellence, 2006, OB GUID PREV ID ASS; Rhee MK, 2008, DIABETIC MED, V25, P1361, DOI 10.1111/j.1464-5491.2008.02543.x; Rubin RR, 2006, DIABETES CARE, V29, P1249, DOI 10.2337/dc05-2494; SINGLETON N, 2001, PREVALENCE DEPRESSIO; van den Akker M, 2004, ACTA PSYCHIAT SCAND, V110, P178; World Health Organization, 2006, DEF DIAGN DIAB MELL; Zhao W, 2006, PUBLIC HEALTH, V120, P696, DOI 10.1016/j.puhe.2006.04.012	33	25	25	0	5	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	NOV 9	2009	4	11							e7755	10.1371/journal.pone.0007755	http://dx.doi.org/10.1371/journal.pone.0007755			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	517ZM	19898618	Green Published, gold, Green Submitted			2022-12-25	WOS:000271658000005
J	Ioerger, TR; Koo, S; No, EG; Chen, XH; Larsen, MH; Jacobs, WR; Pillay, M; Sturm, AW; Sacchettini, JC				Ioerger, Thomas R.; Koo, Sunwoo; No, Eun-Gyu; Chen, Xiaohua; Larsen, Michelle H.; Jacobs, William R., Jr.; Pillay, Manormoney; Sturm, A. Willem; Sacchettini, James C.			Genome Analysis of Multi- and Extensively-Drug-Resistant Tuberculosis from KwaZulu-Natal, South Africa	PLOS ONE			English	Article							LEVEL STREPTOMYCIN RESISTANCE; MYCOBACTERIUM-TUBERCULOSIS; ISONIAZID RESISTANCE; IS6110 INSERTIONS; MUTATIONS; EVOLUTION; METHYLTRANSFERASE; EMERGENCE; STRAIN; SPREAD	The KZN strain family of Mycobacterium tuberculosis is a highly virulent strain endemic to the KwaZulu-Natal region of South Africa, which has recently experienced an outbreak of extensively-drug resistant tuberculosis. To investigate the causes and evolution of drug-resistance, we determined the DNA sequences of several clinical isolates - one drug-susceptible, one multi-drug resistant, and nine extensively drug-resistant - using whole-genome sequencing. Analysis of polymorphisms among the strains is consistent with the drug-susceptibility profiles, in that well-known mutations are observed that are correlated with resistance to isoniazid, rifampicin, kanamycin, ofloxacin, ethambutol, and pyrazinamide. However, the mutations responsible for rifampicin resistance in rpoB and pyrazinamide in pncA are in different nucleotide positions in the multi-drug-resistant and extensively drug-resistant strains, clearly showing that they acquired these mutations independently, and that the XDR strain could not have evolved directly from the MDR strain (though it could have arisen from another similar MDR strain). Sequencing of eight additional XDR strains from other areas of KwaZulu-Natal shows that they have identical drug resistant mutations to the first one sequenced, including the same polymorphisms at sites associated with drug resistance, supporting the theory that this represents a case of clonal expansion.			Ioerger, TR (corresponding author), Texas A&M Univ, Dept Comp Sci & Engn, College Stn, TX 77843 USA.	ioerger@cs.tamu.edu		Jacobs, William/0000-0003-3321-3080; Koo, Sunwoo/0000-0003-2715-909X				Aubry A, 2006, ANTIMICROB AGENTS CH, V50, P104, DOI 10.1128/AAC.50.1.104-112.2006; Bifani PJ, 1996, JAMA-J AM MED ASSOC, V275, P452, DOI 10.1001/jama.275.6.452; Chan ED, 2008, NEW ENGL J MED, V359, P657, DOI 10.1056/NEJMc0706556; Cohen T, 2004, NAT MED, V10, P1117, DOI 10.1038/nm1110; Cox HS, 2008, NEW ENGL J MED, V359, P2398, DOI 10.1056/NEJMc0805644; Dover LG, 2007, ANTIMICROB AGENTS CH, V51, P1055, DOI 10.1128/AAC.01063-06; Fang Z, 2001, J BACTERIOL, V183, P5279, DOI 10.1128/JB.183.18.5279-5284.2001; Gandhi NR, 2006, LANCET, V368, P1575, DOI 10.1016/S0140-6736(06)69573-1; Gillespie SH, 2002, ANTIMICROB AGENTS CH, V46, P267, DOI 10.1128/AAC.46.2.267-274.2002; Gordon SV, 1999, MICROBIOL-SGM, V145, P881, DOI 10.1099/13500872-145-4-881; Hazbon MH, 2006, ANTIMICROB AGENTS CH, V50, P2640, DOI 10.1128/AAC.00112-06; Jassal M, 2009, LANCET INFECT DIS, V9, P19, DOI 10.1016/S1473-3099(08)70260-3; Kamerbeek J, 1997, J CLIN MICROBIOL, V35, P907, DOI 10.1128/JCM.35.4.907-914.1997; Kurtz S, 2004, GENOME BIOL, V5, DOI 10.1186/gb-2004-5-2-r12; Larsen M.H., 2007, CURRENT PROTOCOLS MI; Matsunaga I, 2004, J EXP MED, V200, P1559, DOI 10.1084/jem.20041429; Migliori GB, 2007, EMERG INFECT DIS, V13, P780, DOI 10.3201/eid1305.070200; Mlambo CK, 2008, INT J TUBERC LUNG D, V12, P99; Morlock GP, 2003, ANTIMICROB AGENTS CH, V47, P3799, DOI 10.1128/AAC.47.12.3799-3805.2003; Nishimura K, 2007, J BACTERIOL, V189, P3876, DOI 10.1128/JB.01776-06; Okamoto S, 2007, MOL MICROBIOL, V63, P1096, DOI 10.1111/j.1365-2958.2006.05585.x; Onyebujoh PC, 1999, LANCET, V354, P116, DOI 10.1016/S0140-6736(98)10448-8; Pillay M, 2007, CLIN INFECT DIS, V45, P1409, DOI 10.1086/522987; Pym AS, 2002, INFECT IMMUN, V70, P4955, DOI 10.1128/IAI.70.9.4955-4960.2002; Ramaswamy S., 1998, Tubercle and Lung Disease, V79, P3, DOI 10.1054/tuld.1998.0002; Romanowski MJ, 2002, PROTEINS, V47, P563, DOI 10.1002/prot.10121; Sampson S, 2001, J CLIN MICROBIOL, V39, P3423, DOI 10.1128/JCM.39.9.3423-3424.2001; Schrag SJ, 1996, NATURE, V381, P120, DOI 10.1038/381120b0; Shah NS, 2007, EMERG INFECT DIS, V13, P380, DOI 10.3201/eid1303.061400; Spies FS, 2008, ANTIMICROB AGENTS CH, V52, P2947, DOI 10.1128/AAC.01570-07; Sreevatsan S, 1997, ANTIMICROB AGENTS CH, V41, P1677, DOI 10.1128/AAC.41.8.1677; Sreevatsan S, 1997, ANTIMICROB AGENTS CH, V41, P636, DOI 10.1128/AAC.41.3.636; Sreevatsan S, 1996, ANTIMICROB AGENTS CH, V40, P1024, DOI 10.1128/AAC.40.4.1024; Suzuki Y, 1998, J CLIN MICROBIOL, V36, P1220, DOI 10.1128/JCM.36.5.1220-1225.1998; van Doorn HR, 2008, INT J TUBERC LUNG D, V12, P736; Victor TC, 2004, J CLIN MICROBIOL, V42, P769, DOI 10.1128/JCM.42.2.769-772.2004; ZHANG Y, 1992, NATURE, V358, P591, DOI 10.1038/358591a0	37	125	126	0	9	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA	1932-6203			PLOS ONE	PLoS One	NOV 5	2009	4	11							e7778	10.1371/journal.pone.0007778	http://dx.doi.org/10.1371/journal.pone.0007778			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	515HI	19890396	Green Published, gold, Green Submitted			2022-12-25	WOS:000271459700022
J	Ljubicic, S; Bezzi, P; Vitale, N; Regazzi, R				Ljubicic, Sanda; Bezzi, Paola; Vitale, Nicolas; Regazzi, Romano			The GTPase RalA Regulates Different Steps of the Secretory Process in Pancreatic beta-Cells	PLOS ONE			English	Article							INSULIN EXOCYTOSIS; PLASMA-MEMBRANE; EXOCYST COMPLEX; PHOSPHOLIPASE-D; ACTIVATION; ASTROCYTES; EXPRESSION; GLUTAMATE; RELEASE; FUSION	Background: RalA and RalB are multifuntional GTPases involved in a variety of cellular processes including proliferation, oncogenic transformation and membrane trafficking. Here we investigated the mechanisms leading to activation of Ral proteins in pancreatic beta-cells and analyzed the impact on different steps of the insulin- secretory process. Methodology/Principal Findings: We found that RalA is the predominant isoform expressed in pancreatic islets and insulin-secreting cell lines. Silencing of this GTPase in INS-1E cells by RNA interference led to a decrease in secretagogue-induced insulin release. Real-time measurements by fluorescence resonance energy transfer revealed that RalA activation in response to secretagogues occurs within 3-5 min and reaches a plateau after 10-15 min. The activation of the GTPase is triggered by increases in intracellular Ca(2+) and cAMP and is prevented by the L-type voltage-gated Ca(2+) channel blocker Nifedipine and by the protein kinase A inhibitor H89. Defective insulin release in cells lacking RalA is associated with a decrease in the secretory granules docked at the plasma membrane detected by Total Internal Reflection Fluorescence microscopy and with a strong impairment in Phospholipase D1 activation in response to secretagogues. RalA was found to be activated by RalGDS and to be severely hampered upon silencing of this GDP/GTP exchange factor. Accordingly, INS-1E cells lacking RalGDS displayed a reduction in hormone secretion induced by secretagogues and in the number of insulin-containing granules docked at the plasma membrane. Conclusions/Significance: Taken together, our data indicate that RalA activation elicited by the exchange factor RalGDS in response to a rise in intracellular Ca(2+) and cAMP controls hormone release from pancreatic beta-cell by coordinating the execution of different events in the secretory pathway.			Ljubicic, S (corresponding author), Univ Lausanne, Dept Cell Biol & Morphol, Lausanne, Switzerland.	Romano.Regazzi@unil.ch	Bezzi, Paola/AAP-2440-2020; Vitale, Nicolas/G-5967-2014	Vitale, Nicolas/0000-0002-4752-4907; Regazzi, Romano/0000-0002-9773-2915				Barg S, 2002, NEURON, V33, P287, DOI 10.1016/S0896-6273(02)00563-9; Bezzi P, 2004, NAT NEUROSCI, V7, P613, DOI 10.1038/nn1246; Cheviet S, 2006, J CELL SCI, V119, P2912, DOI 10.1242/jcs.03037; Clough RR, 2002, J BIOL CHEM, V277, P28972, DOI 10.1074/jbc.M201504200; Domercq M, 2006, J BIOL CHEM, V281, P30684, DOI 10.1074/jbc.M606429200; Feig LA, 2003, TRENDS CELL BIOL, V13, P419, DOI 10.1016/S0962-8924(03)00152-1; Feig LA, 1996, TRENDS BIOCHEM SCI, V21, P438, DOI 10.1016/S0968-0004(96)10058-X; Hofer F, 1998, CURR BIOL, V8, P839, DOI 10.1016/S0960-9822(98)70327-6; Hsu SC, 2004, INT REV CYTOL, V233, P243, DOI 10.1016/S0074-7696(04)33006-8; Hughes WE, 2004, J BIOL CHEM, V279, P27534, DOI 10.1074/jbc.M403012200; Jares-Erijman EA, 2003, NAT BIOTECHNOL, V21, P1387, DOI 10.1038/nbt896; Jenkins GM, 2005, CELL MOL LIFE SCI, V62, P2305, DOI 10.1007/s00018-005-5195-z; Lawrence JTR, 2003, P NATL ACAD SCI USA, V100, P13320, DOI 10.1073/pnas.2232129100; Li G, 2007, J NEUROSCI, V27, P190, DOI 10.1523/JNEUROSCI.2537-06.2007; Lilla V, 2003, ENDOCRINOLOGY, V144, P1368, DOI 10.1210/en.2002-220916; Lipschutz JH, 2002, CURR BIOL, V12, pR212, DOI 10.1016/S0960-9822(02)00753-4; Lopez JA, 2008, J BIOL CHEM, V283, P17939, DOI 10.1074/jbc.M800321200; Lovis P, 2008, BIOL CHEM, V389, P305, DOI 10.1515/BC.2008.026; Luo JQ, 1998, P NATL ACAD SCI USA, V95, P3632, DOI 10.1073/pnas.95.7.3632; Marchaland J, 2008, J NEUROSCI, V28, P9122, DOI 10.1523/JNEUROSCI.0040-08.2008; Merglen A, 2004, ENDOCRINOLOGY, V145, P667, DOI 10.1210/en.2003-1099; Moskalenko S, 2003, J BIOL CHEM, V278, P51743, DOI 10.1074/jbc.M308702200; Moskalenko S, 2002, NAT CELL BIOL, V4, P66, DOI 10.1038/ncb728; Oxford G, 2005, CANCER RES, V65, P7111, DOI 10.1158/0008-5472.CAN-04-1957; Plaisance V, 2005, J BIOL CHEM, V280, P401, DOI 10.1074/jbc.M411825200; Rebhun JF, 2000, J BIOL CHEM, V275, P13406, DOI 10.1074/jbc.C000085200; Rondaij MG, 2008, BLOOD, V112, P56, DOI 10.1182/blood-2007-07-099309; Seino S, 2005, PHYSIOL REV, V85, P1303, DOI 10.1152/physrev.00001.2005; Shipitsin M, 2004, MOL CELL BIOL, V24, P5746, DOI 10.1128/MCB.24.13.5746-5756.2004; Steyer JA, 2001, NAT REV MOL CELL BIO, V2, P268, DOI 10.1038/35067069; SUTTON R, 1986, TRANSPLANTATION, V42, P689, DOI 10.1097/00007890-198612000-00022; Takaya A, 2004, MOL BIOL CELL, V15, P2549, DOI 10.1091/mbc.E03-11-0857; Tsuboi T, 2006, DIABETES, V55, P1057, DOI 10.2337/diabetes.55.04.06.db05-1577; Tsuboi T, 2005, J BIOL CHEM, V280, P25565, DOI 10.1074/jbc.M501674200; van Dam EM, 2006, INT J BIOCHEM CELL B, V38, P1841, DOI 10.1016/j.biocel.2006.04.006; van Triest Miranda, 2004, Methods Mol Biol, V250, P97; Vitale N, 2005, J BIOL CHEM, V280, P29921, DOI 10.1074/jbc.M413748200; Wang KL, 1999, J BIOL CHEM, V274, P14525, DOI 10.1074/jbc.274.21.14525; Waselle L, 2005, MOL ENDOCRINOL, V19, P3097, DOI 10.1210/me.2004-0530; Wollheim CB, 2002, DIABETES, V51, pS37, DOI 10.2337/diabetes.51.2007.S37	40	15	16	1	6	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA	1932-6203			PLOS ONE	PLoS One	NOV 5	2009	4	11							e7770	10.1371/journal.pone.0007770	http://dx.doi.org/10.1371/journal.pone.0007770			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	515HI	19890390	Green Published, gold, Green Submitted			2022-12-25	WOS:000271459700021
J	Novitsky, V; Wang, R; Margolin, L; Baca, J; Kebaabetswe, L; Rossenkhan, R; Bonney, C; Herzig, M; Nkwe, D; Moyo, S; Musonda, R; Woldegabriel, E; van Widenfelt, E; Makhema, J; Lagakos, S; Essex, M				Novitsky, Vladimir; Wang, Rui; Margolin, Lauren; Baca, Jeannie; Kebaabetswe, Lemme; Rossenkhan, Raabya; Bonney, Caitlin; Herzig, Michaela; Nkwe, David; Moyo, Sikhulile; Musonda, Rosemary; Woldegabriel, Elias; van Widenfelt, Erik; Makhema, Joseph; Lagakos, Stephen; Essex, M.			Timing Constraints of In Vivo Gag Mutations during Primary HIV-1 Subtype C Infection	PLOS ONE			English	Article							T-CELL RESPONSES; VIRAL LOAD; LYMPHOCYTE ESCAPE; IMMUNE ESCAPE; CD8(+); REVERSION; EVOLUTION; IDENTIFICATION; TRANSMISSION; ASSOCIATIONS	Background: Aiming to answer the broad question "When does mutation occur?'' this study examined the time of appearance, dominance, and completeness of in vivo Gag mutations in primary HIV-1 subtype C infection. Methods: A primary HIV-1C infection cohort comprised of 8 acutely and 34 recently infected subjects were followed frequently up to 500 days post-seroconversion (p/s). Gag mutations were analyzed by employing single-genome amplification and direct sequencing. Gag mutations were determined in relation to the estimated time of seroconversion. Time of appearance, dominance, and completeness was compared for different types of in vivo Gag mutations. Results: Reverse mutations to the wild type appeared at a median (IQR) of 62 (44; 139) days p/s, while escape mutations from the wild type appeared at 234 (169; 326) days p/s (p<0.001). Within the subset of mutations that became dominant, reverse and escape mutations appeared at 54 (30; 78) days p/s and 104 (47; 198) days p/s, respectively (p<0.001). Among the mutations that reached completeness, reverse and escape mutations appeared at 54 (30; 78) days p/s and 90 (44; 196) days p/s, respectively (p = 0.006). Time of dominance for reverse mutations to and escape mutations from the wild type was 58 (44; 105) days p/s and 219 (90; 326) days p/s, respectively (p<0.001). Time of completeness for reverse and escape mutations was 152 (100; 176) days p/s and 243 (101; 370) days p/s, respectively (p = 0.001). Fitting a Cox proportional hazards model with frailties confirmed a significantly earlier time of appearance (hazard ratio (HR): 2.6; 95% CI: 2.3-3.0), dominance (4.8 (3.4-6.8)), and completeness (3.6 (2.3-5.5)) of reverse mutations to the wild type Gag than escape mutations from the wild type. Some complex mutational pathways in Gag included sequential series of reversions and escapes. Conclusions: The study identified the timing of different types of in vivo Gag mutations in primary HIV-1 subtype C infection in relation to the estimated time of seroconversion. Overall, the in vivo reverse mutations to the wild type occurred significantly earlier than escape mutations from the wild type. This shorter time to incidence of reverse mutations remained in the subsets of in vivo Gag mutations that reached dominance or completeness.			Novitsky, V (corresponding author), Harvard Univ, Sch Publ Hlth, AIDS Initiat, Dept Immunol & Infect Dis, 665 Huntington Ave, Boston, MA 02115 USA.	messex@hsph.harvard.edu	Moyo, Sikhulile/E-1464-2015; Wang, Rui/X-1699-2019	Moyo, Sikhulile/0000-0003-3821-4592; Wang, Rui/0000-0001-5007-193X	FOGARTY INTERNATIONAL CENTER [D43TW000004] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R37AI024643, R01AI057027] Funding Source: NIH RePORTER; FIC NIH HHS [D43 TW000004] Funding Source: Medline; NIAID NIH HHS [R37 AI024643, R01 AI057027, R37 AI24643] Funding Source: Medline	FOGARTY INTERNATIONAL CENTER(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Fogarty International Center (FIC)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); FIC NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Fogarty International Center (FIC)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Allen TM, 2005, J VIROL, V79, P12952, DOI 10.1128/JVI.79.20.12952-12960.2005; Allen TM, 2005, J VIROL, V79, P13239, DOI 10.1128/JVI.79.21.13239-13249.2005; Betts MR, 2001, J VIROL, V75, P11983, DOI 10.1128/JVI.75.24.11983-11991.2001; Boaz MJ, 2002, J IMMUNOL, V169, P6376, DOI 10.4049/jimmunol.169.11.6376; Borroto R J, 1997, Rev Panam Salud Publica, V1, P3; Boutwell CL, 2009, J VIROL, V83, P2460, DOI 10.1128/JVI.01970-08; Bredell H, 2007, AIDS RES HUM RETROV, V23, P477, DOI 10.1089/aid.2006.0232; Brockman MA, 2007, J VIROL, V81, P12608, DOI 10.1128/JVI.01369-07; Brumme ZL, 2008, J VIROL, V82, P9216, DOI 10.1128/JVI.01041-08; Brumme ZL, 2009, J EXP MED, V206, P1215, DOI 10.1084/jem.20091094; Cao JH, 2003, J IMMUNOL, V171, P3837, DOI 10.4049/jimmunol.171.7.3837; Carr JK, 1999, AIDS, V13, P1819, DOI 10.1097/00002030-199910010-00003; Chopera DR, 2008, PLOS PATHOG, V4, DOI 10.1371/journal.ppat.1000033; Crawford H, 2007, J VIROL, V81, P8346, DOI 10.1128/JVI.00465-07; Davenport MP, 2008, TRENDS MICROBIOL, V16, P561, DOI 10.1016/j.tim.2008.09.001; Duda A, 2009, J VIROL, V83, P1228, DOI 10.1128/JVI.01545-08; Dugan KA, 2002, J FORENSIC SCI, V47, P811; Edwards BH, 2002, J VIROL, V76, P2298, DOI 10.1128/JVI.76.5.2298-2305.2002; Fiebig EW, 2003, AIDS, V17, P1871, DOI 10.1097/00002030-200309050-00005; Friedrich TC, 2004, NAT MED, V10, P275, DOI 10.1038/nm998; Geels MJ, 2003, J VIROL, V77, P12430, DOI 10.1128/JVI.77.23.12430-12440.2003; Geldmacher C, 2007, J VIROL, V81, P2440, DOI 10.1128/JVI.01847-06; Goepfert PA, 2008, J EXP MED, V205, P1009, DOI 10.1084/jem.20072457; Goonetilleke N, 2009, J EXP MED, V206, P1253, DOI 10.1084/jem.20090365; Goulder PJR, 2008, NAT REV IMMUNOL, V8, P619, DOI 10.1038/nri2357; Hall T.A., 1999, NUCL ACIDS S SERIES, V41, P95, DOI [DOI 10.1021/BK-1999-0734.CH008, citeulike-article-id:691774, 10.12691/ajmr-6-4-3]; Jones NA, 2004, J EXP MED, V200, P1243, DOI 10.1084/jem.20040511; Keele BF, 2008, P NATL ACAD SCI USA, V105, P7552, DOI 10.1073/pnas.0802203105; Kelleher AD, 2001, J EXP MED, V193, P375, DOI 10.1084/jem.193.3.375; Kiepiela P, 2007, NAT MED, V13, P46, DOI 10.1038/nm1520; KOUP RA, 1994, J EXP MED, V180, P779, DOI 10.1084/jem.180.3.779; Leslie A, 2005, J EXP MED, V201, P891, DOI 10.1084/jem.20041455; Leslie AJ, 2004, NAT MED, V10, P282, DOI 10.1038/nm992; Li B, 2007, J VIROL, V81, P193, DOI 10.1128/JVI.01231-06; Liu SL, 1996, SCIENCE, V273, P415, DOI 10.1126/science.273.5274.415; Liu Y, 2006, J VIROL, V80, P9519, DOI 10.1128/JVI.00575-06; Loh L, 2008, PLOS PATHOG, V4, DOI 10.1371/journal.ppat.0040012; Martinez-Picado J, 2006, J VIROL, V80, P3617, DOI 10.1128/JVI.80.7.3617-3623.2006; Masemola A, 2004, J VIROL, V78, P3233, DOI 10.1128/JVI.78.7.3233-3243.2004; Matthews PC, 2008, J VIROL, V82, P8548, DOI 10.1128/JVI.00580-08; NDONGALA ML, 2009, CLIN IMMUNOL; Novitsky V, 2008, AIDS CARE, V20, P806, DOI 10.1080/09540120701694055; Novitsky V, 2003, J VIROL, V77, P882, DOI 10.1128/JVI.77.2.882-890.2003; NOVITSKY V, 2009, J ACQUIR IM IN PRESS; Novitsky V, 2009, JAIDS-J ACQ IMM DEF, V50, P65, DOI 10.1097/QAI.0b013e3181900141; Novitsky V, 2009, VIROLOGY, V383, P47, DOI 10.1016/j.virol.2008.09.017; Novitsky VA, 2006, VIROLOGY, V349, P142, DOI 10.1016/j.virol.2006.02.006; Palmer S, 2005, J CLIN MICROBIOL, V43, P406, DOI 10.1128/JCM.43.1.406-413.2005; Price DA, 1997, P NATL ACAD SCI USA, V94, P1890, DOI 10.1073/pnas.94.5.1890; Ramduth D, 2005, J INFECT DIS, V192, P1588, DOI 10.1086/496894; Ray S.C., 2008, MARGFREQ; Rolland M, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0001424; Rose PP, 2000, BIOINFORMATICS, V16, P400, DOI 10.1093/bioinformatics/16.4.400; Rousseau CM, 2008, J VIROL, V82, P6434, DOI 10.1128/JVI.02455-07; Salazar-Gonzalez JF, 2008, J VIROL, V82, P3952, DOI 10.1128/JVI.02660-07; Salazar-Gonzalez JF, 2009, J EXP MED, V206, P1273, DOI 10.1084/jem.20090378; Serwanga J, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0004188; Shankarappa R, 1999, J VIROL, V73, P10489, DOI 10.1128/JVI.73.12.10489-10502.1999; Zuniga R, 2006, J VIROL, V80, P3122, DOI 10.1128/JVI.80.6.3122-3125.2006	59	24	25	0	1	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	NOV 5	2009	4	11							e7727	10.1371/journal.pone.0007727	http://dx.doi.org/10.1371/journal.pone.0007727			15	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	515HI	19890401	Green Published, Green Submitted, gold			2022-12-25	WOS:000271459700014
J	Puill-Stephan, E; Willis, BL; van Herwerden, L; van Oppen, MJH				Puill-Stephan, Eneour; Willis, Bette L.; van Herwerden, Lynne; van Oppen, Madeleine J. H.			Chimerism in Wild Adult Populations of the Broadcast Spawning Coral Acropora millepora on the Great Barrier Reef	PLOS ONE			English	Article							GERM-CELL PARASITISM; NATURAL CHIMERISM; MICROSATELLITE LOCI; SOMATIC MUTATIONS; SELF-RECOGNITION; BUILDING CORAL; ALLORECOGNITION SYSTEM; BOTRYLLUS-SCHLOSSERI; CONTACT REACTIONS; GENETIC-STRUCTURE	Background: Chimeras are organisms containing tissues or cells of two or more genetically distinct individuals, and are known to exist in at least nine phyla of protists, plants, and animals. Although widespread and common in marine invertebrates, the extent of chimerism in wild populations of reef corals is unknown. Methodology/Principal Findings: The extent of chimerism was explored within two populations of a common coral, Acropora millepora, on the Great Barrier Reef, Australia, by using up to 12 polymorphic DNA microsatellite loci. At least 2% and 5% of Magnetic Island and Pelorus Island populations of A. millepora, respectively, were found to be chimeras (3% overall), based on conservative estimates. A slightly less conservative estimate indicated that 5% of colonies in each population were chimeras. These values are likely to be vast underestimates of the true extent of chimerism, as our sampling protocol was restricted to a maximum of eight branches per colony, while most colonies consist of hundreds of branches. Genotypes within chimeric corals showed high relatedness, indicating that genetic similarity is a prerequisite for long-term acceptance of non-self genotypes within coral colonies. Conclusions/Significance: While some brooding corals have been shown to form genetic chimeras in their early life history stages under experimental conditions, this study provides the first genetic evidence of the occurrence of coral chimeras in the wild and of chimerism in a broadcast spawning species. We hypothesize that chimerism is more widespread in corals than previously thought, and suggest that this has important implications for their resilience, potentially enhancing their capacity to compete for space and respond to stressors such as pathogen infection.			Puill-Stephan, E (corresponding author), James Cook Univ, AIMS JCU, Townsville, Qld 4811, Australia.	m.vanoppen@aims.gov.au	van Oppen, Madeleine JH/C-3261-2008; van Herwerden, Lynne/I-1087-2012	van Herwerden, Lynne/0000-0001-6717-8995; PUILL-STEPHAN, Eneour/0000-0003-0618-8051; van Oppen, Madeleine/0000-0003-4607-0744				Amar KO, 2008, BMC EVOL BIOL, V8, DOI 10.1186/1471-2148-8-126; BABCOCK RC, 1986, MAR BIOL, V90, P379, DOI 10.1007/BF00428562; Barki Y, 2002, MAR ECOL PROG SER, V231, P91, DOI 10.3354/meps231091; Ben-Shlomo R, 2001, MAR ECOL PROG SER, V209, P109, DOI 10.3354/meps209109; Ben-Shlomo R, 2008, GENETICA, V132, P51, DOI 10.1007/s10709-007-9148-3; BUSS LW, 1990, TRENDS ECOL EVOL, V5, P352, DOI 10.1016/0169-5347(90)90093-S; Chadwick-Furman NE, 2003, BIOL BULL-US, V205, P133, DOI 10.2307/1543234; CHADWICKFURMAN N, 1994, CORAL REEFS, V13, P57, DOI 10.1007/BF00426436; Ellegren H, 2000, TRENDS GENET, V16, P551, DOI 10.1016/S0168-9525(00)02139-9; Estoup A, 2002, MOL ECOL, V11, P1591, DOI 10.1046/j.1365-294X.2002.01576.x; FRANK U, 1994, MAR BIOL, V118, P723, DOI 10.1007/BF00347521; Frank U, 2001, J EXP ZOOL, V291, P25, DOI 10.1002/jez.3; Frank U, 1997, P ROY SOC B-BIOL SCI, V264, P99, DOI 10.1098/rspb.1997.0015; GROSBERG RK, 1988, Q REV BIOL, V63, P377, DOI 10.1086/416026; GROSBERG RK, 1986, NATURE, V322, P456, DOI 10.1038/322456a0; Hall VR, 1996, ECOLOGY, V77, P950, DOI 10.2307/2265514; HEYWARD AJ, 1985, MAR BIOL, V85, P117, DOI 10.1007/BF00397429; HIDAKA M, 1985, CORAL REEFS, V4, P111, DOI 10.1007/BF00300869; Hidaka M, 1997, CORAL REEFS, V16, P13, DOI 10.1007/s003380050054; HIDAKA M, 1985, BIOL BULL, V168, P350, DOI 10.2307/1541517; Hughes RN, 2004, EVOL DEV, V6, P431, DOI 10.1111/j.1525-142X.2004.04051.x; Hughes RN, 1989, FUNCTIONAL BIOL CLON; JACKSON JBC, 1986, B MAR SCI, V39, P588; LEWIS JB, 1974, 2ND P INT S COR REEF, P201; NEIGEL JE, 1983, EVOLUTION, V37, P437, DOI 10.1111/j.1558-5646.1983.tb05561.x; Nozawa Y, 2005, MAR ECOL PROG SER, V286, P115, DOI 10.3354/meps286115; O'Connell LM, 2004, J HERED, V95, P172, DOI 10.1093/jhered/esh024; OLIVER JK, 1987, MAR BIOL, V94, P521, DOI 10.1007/BF00431398; Orive ME, 2001, THEOR POPUL BIOL, V59, P235, DOI 10.1006/tpbi.2001.1515; Peakall R, 2006, MOL ECOL NOTES, V6, P288, DOI 10.1111/j.1471-8286.2005.01155.x; Pineda-Krch M, 2004, J EVOLUTION BIOL, V17, P1192, DOI 10.1111/j.1420-9101.2004.00815.x; Pineda-Krch M, 2004, J EVOLUTION BIOL, V17, P1167, DOI 10.1111/j.1420-9101.2004.00808.x; QUELLER DC, 1989, EVOLUTION, V43, P258, DOI 10.1111/j.1558-5646.1989.tb04226.x; Raymundo LJ, 2004, ECOL APPL, V14, P281, DOI 10.1890/02-5373; Rinkevich B, 2004, HYDROBIOLOGIA, V530, P443, DOI 10.1007/s10750-004-2686-0; Rinkevich B, 2005, J EXP MAR BIOL ECOL, V322, P93, DOI 10.1016/j.jembe.2005.02.020; Rinkevich B, 2004, J EVOLUTION BIOL, V17, P1178, DOI 10.1111/j.1420-9101.2004.00809.x; Rinkevich B, 2004, J EXP BIOL, V207, P3531, DOI 10.1242/jeb.01184; RINKEVICH B, 1985, OECOLOGIA, V66, P100, DOI 10.1007/BF00378559; Rinkevich B, 2002, BIOESSAYS, V24, P730, DOI 10.1002/bies.10123; Rinkevich B, 2001, HUM IMMUNOL, V62, P651, DOI 10.1016/S0198-8859(01)00249-X; Rinkevich B, 1999, SCAND J IMMUNOL, V50, P456; RINKEVICH B, 1992, OIKOS, V63, P119, DOI 10.2307/3545520; RINKEVICH B, 1987, SYMBIOSIS, V4, P117; Rinkevich B, 1998, HUM REPROD, V13, P455, DOI 10.1093/humrep/13.2.455; SAMMARCO PW, 1982, J EXP MAR BIOL ECOL, V61, P31, DOI 10.1016/0022-0981(82)90020-X; Santelices B, 2004, J EVOLUTION BIOL, V17, P1187, DOI 10.1111/j.1420-9101.2004.00813.x; Santelices B, 1999, J PHYCOL, V35, P1127, DOI 10.1046/j.1529-8817.1999.3561127.x; Santelices B, 1999, TRENDS ECOL EVOL, V14, P152, DOI 10.1016/S0169-5347(98)01519-5; SMITH SR, 1997, 8 INT COR REEF S, P1197; Sommerfeldt AD, 1999, MOL ECOL, V8, P885; Sommerfeldt AD, 2003, BIOL J LINN SOC, V79, P183, DOI 10.1046/j.1095-8312.2003.00179.x; STODDART JA, 1985, EVOLUTION, V39, P461, DOI 10.1111/j.1558-5646.1985.tb05682.x; Stoner DS, 1996, P NATL ACAD SCI USA, V93, P15254, DOI 10.1073/pnas.93.26.15254; Strassmann JE, 2004, J EVOLUTION BIOL, V17, P1189, DOI 10.1111/j.1420-9101.2004.00814.x; Van Oppen MJH, 2007, MOL ECOL NOTES, V7, P436, DOI 10.1111/j.1471-8286.2006.01610.x; Wang S, 2009, J HERED, V100, P329, DOI 10.1093/jhered/esn100; WHITHAM TG, 1981, OECOLOGIA, V49, P287, DOI 10.1007/BF00347587; Willis BL, 1985, OECOLOGIA, V65, P516, DOI 10.1007/BF00379666; Wilson ACC, 2004, BEHAV ECOL SOCIOBIOL, V57, P40, DOI 10.1007/s00265-004-0831-4; Wilson K, 2002, AQUACULTURE, V204, P297, DOI 10.1016/S0044-8486(01)00842-0; Zilberberg C, 2001, MAR ECOL PROG SER, V221, P125, DOI 10.3354/meps221125	63	60	60	0	33	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	NOV 4	2009	4	11							e7751	10.1371/journal.pone.0007751	http://dx.doi.org/10.1371/journal.pone.0007751			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	514RZ	19888471	gold, Green Submitted, Green Published, Green Accepted			2022-12-25	WOS:000271414600013
J	Geuking, P; Narasimamurthy, R; Lemaitre, B; Basler, K; Leulier, F				Geuking, Peter; Narasimamurthy, Rajesh; Lemaitre, Bruno; Basler, Konrad; Leulier, Francois			A Non-Redundant Role for Drosophila Mkk4 and Hemipterous/Mkk7 in TAK1-Mediated Activation of JNK	PLOS ONE			English	Article							SIGNAL-TRANSDUCTION PATHWAY; INNATE IMMUNE-RESPONSES; PROTEIN-KINASE; PEPTIDOGLYCAN RECOGNITION; GENE-EXPRESSION; KAPPA-B; BACTERIA; EIGER; TOLL	Background: The JNK pathway is a mitogen-activated protein (MAP) kinase pathway involved in the regulation of numerous physiological processes during development and in response to environmental stress. JNK activity is controlled by two MAPK kinases (MAPKK), Mkk4 and Mkk7. Mkk7 plays a prominent role upon Tumor Necrosis Factor (TNF) stimulation. Eiger, the unique TNF-superfamily ligand in Drosophila, potently activates JNK signaling through the activation of the MAPKKK Tak1. Methodology/Principal Findings: In a dominant suppressor screen for new components of the Eiger/JNK-pathway in Drosophila, we have identified an allelic series of the Mkk4 gene. Our genetic and biochemical results demonstrate that Mkk4 is dispensable for normal development and host resistance to systemic bacterial infection but plays a non-redundant role as a MAPKK acting in parallel to Hemipterous/Mkk7 in dTAK1-mediated JNK activation upon Eiger and Imd pathway activation. Conclusions/Significance: In contrast to mammals, it seems that in Drosophila both MAPKKs, Hep/Mkk7 and Mkk4, are required to induce JNK upon TNF or pro-inflammatory stimulation.			Geuking, P (corresponding author), Univ Zurich, Inst Mol Biol, Zurich, Switzerland.	konrad.basler@molbio.uzh.ch; francois.leulier@ibdml.univ-mrs.fr	Lemaitre, Bruno/T-8146-2019	Lemaitre, Bruno/0000-0001-7970-1667; Basler, Konrad/0000-0003-3534-1529				Adachi-Yamada T, 1999, NATURE, V400, P166, DOI 10.1038/22112; BASLER K, 1994, NATURE, V368, P208, DOI 10.1038/368208a0; Boutros M, 2002, DEV CELL, V3, P711, DOI 10.1016/S1534-5807(02)00325-8; Brancho D, 2003, GENE DEV, V17, P1969, DOI 10.1101/gad.1107303; BRAND AH, 1993, DEVELOPMENT, V118, P401; Chen W, 2002, J BIOL CHEM, V277, P49105, DOI 10.1074/jbc.M204934200; Clemens JC, 2000, P NATL ACAD SCI USA, V97, P6499, DOI 10.1073/pnas.110149597; Fleming Y, 2000, BIOCHEM J, V352, P145, DOI 10.1042/0264-6021:3520145; Geuking P, 2005, GENETICS, V171, P1683, DOI 10.1534/genetics.105.045534; GLISE B, 1995, CELL, V83, P451, DOI 10.1016/0092-8674(95)90123-X; Han SJ, 1998, J BIOL CHEM, V273, P369, DOI 10.1074/jbc.273.1.369; Han ZQS, 1998, MOL CELL BIOL, V18, P3527, DOI 10.1128/MCB.18.6.3527; Igaki T, 2002, EMBO J, V21, P3009, DOI 10.1093/emboj/cdf306; Leulier F, 2003, NAT IMMUNOL, V4, P478, DOI 10.1038/ni922; Michel T, 2001, NATURE, V414, P756, DOI 10.1038/414756a; Parks AL, 2004, NAT GENET, V36, P288, DOI 10.1038/ng1312; Rutschmann S, 2002, J IMMUNOL, V168, P1542, DOI 10.4049/jimmunol.168.4.1542; Schneider DS, 2007, PLOS PATHOG, V3, DOI 10.1371/journal.ppat.0030041; Silverman N, 2003, J BIOL CHEM, V278, P48928, DOI 10.1074/jbc.M304802200; Sluss HK, 1996, GENE DEV, V10, P2745, DOI 10.1101/gad.10.21.2745; Vidal S, 2001, GENE DEV, V15, P1900, DOI 10.1101/gad.203301; Wang HS, 2006, EMBO J, V25, P5783, DOI 10.1038/sj.emboj.7601461; Wang X, 2007, BBA-MOL CELL RES, V1773, P1349, DOI 10.1016/j.bbamcr.2006.10.016; Weston CR, 2007, CURR OPIN CELL BIOL, V19, P142, DOI 10.1016/j.ceb.2007.02.001; Zhuang ZH, 2006, CELL SIGNAL, V18, P441, DOI 10.1016/j.cellsig.2005.05.013	25	49	51	1	11	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA	1932-6203			PLOS ONE	PLoS One	NOV 3	2009	4	11							e7709	10.1371/journal.pone.0007709	http://dx.doi.org/10.1371/journal.pone.0007709			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	514RY	19888449	Green Published, gold, Green Submitted			2022-12-25	WOS:000271414500010
J	Fouchet, D; Leblanc, G; Sauvage, F; Guiserix, M; Poulet, H; Pontier, D				Fouchet, David; Leblanc, Guillaume; Sauvage, Frank; Guiserix, Micheline; Poulet, Herve; Pontier, Dominique			Using Dynamic Stochastic Modelling to Estimate Population Risk Factors in Infectious Disease: The Example of FIV in 15 Cat Populations	PLOS ONE			English	Article							FELINE IMMUNODEFICIENCY VIRUS; DOMESTIC CATS; TRANSMISSION; SELECTION; EPIDEMICS; INFLUENZA; INFERENCE; OUTBREAK	Background: In natural cat populations, Feline Immunodeficiency Virus (FIV) is transmitted through bites between individuals. Factors such as the density of cats within the population or the sex-ratio can have potentially strong effects on the frequency of fight between individuals and hence appear as important population risk factors for FIV. Methodology/Principal Findings: To study such population risk factors, we present data on FIV prevalence in 15 cat populations in northeastern France. We investigate five key social factors of cat populations; the density of cats, the sex-ratio, the number of males and the mean age of males and females within the population. We overcome the problem of dependence in the infective status data using sexually-structured dynamic stochastic models. Only the age of males and females had an effect (p = 0.043 and p = 0.02, respectively) on the male-to-female transmission rate. Due to multiple tests, it is even likely that these effects are, in reality, not significant. Finally we show that, in our study area, the data can be explained by a very simple model that does not invoke any risk factor. Conclusion: Our conclusion is that, in host-parasite systems in general, fluctuations due to stochasticity in the transmission process are naturally very large and may alone explain a larger part of the variability in observed disease prevalence between populations than previously expected. Finally, we determined confidence intervals for the simple model parameters that can be used to further aid in management of the disease.			Fouchet, D (corresponding author), Univ Lyon, Lyon, France.	fouchet@biomserv.univ-lyon1.fr		Pontier, Dominique/0000-0003-4700-3543				Bahi-Jaber N, 2008, J R SOC INTERFACE, V5, P1031, DOI 10.1098/rsif.2007.1326; BEGON M, 1999, P ROY SOC LOND B BIO, V266, P1339; BENDINELLI M, 1995, CLIN MICROBIOL REV, V8, P87, DOI 10.1128/CMR.8.1.87; CALLANAN JJ, 1991, VET REC, V128, P332, DOI 10.1136/vr.128.14.332; Cauchemez S, 2004, STAT MED, V23, P3469, DOI 10.1002/sim.1912; Clancy D, 2007, SCAND J STAT, V34, P259, DOI 10.1111/j.1467-9469.2006.00522.x; Cooper B, 2004, BIOSTATISTICS, V5, P223, DOI 10.1093/biostatistics/5.2.223; Cooper BS, 2008, AM J EPIDEMIOL, V168, P548, DOI 10.1093/aje/kwn176; COURCHAMP F, 1994, CR ACAD SCI III-VIE, V317, P1123; Courchamp F, 2000, WILDLIFE RES, V27, P603, DOI 10.1071/WR99049; Courchamp F, 1998, EPIDEMIOL INFECT, V121, P227, DOI 10.1017/S0950268898008875; De Jong M., 1995, EPIDEMIC MODELS THEI, P84; Eisenberg JNS, 2003, EPIDEMIOLOGY, V14, P442, DOI 10.1097/01.ede.0000071411.19255.4c; ENGELMAN C, 1972, P ACM ANN C ACM NEW, V2; Ferguson NM, 2003, NATURE, V425, P681, DOI 10.1038/nature02007; Fraser C, 2004, P NATL ACAD SCI USA, V101, P6146, DOI 10.1073/pnas.0307506101; Gibson GJ, 2004, P NATL ACAD SCI USA, V101, P12120, DOI 10.1073/pnas.0400829101; JACQUEZ JA, 1993, MATH BIOSCI, V117, P77, DOI 10.1016/0025-5564(93)90018-6; Kanzaki LIB, 2004, FRONT BIOSCI-LANDMRK, V9, P370, DOI 10.2741/1235; Krebs JR, 2002, NATURE, V415, P115, DOI 10.1038/415115a; Lipsitch M, 2003, SCIENCE, V300, P1966, DOI 10.1126/science.1086616; LUTZ H, 1988, J VET MED B, V35, P773, DOI 10.1111/j.1439-0450.1988.tb00559.x; MATTEUCCI D, 1993, J CLIN MICROBIOL, V31, P494, DOI 10.1128/JCM.31.3.494-501.1993; Natoli E, 2005, NEUROSCI BIOBEHAV R, V29, P151, DOI 10.1016/j.neubiorev.2004.06.011; Neal PJ, 2004, BIOSTATISTICS, V5, P249, DOI 10.1093/biostatistics/5.2.249; O'Neill PD, 2000, J ROY STAT SOC C-APP, V49, P517, DOI 10.1111/1467-9876.00210; O'Neill PD, 2005, STAT MED, V24, P2011, DOI 10.1002/sim.2090; Ostrowski S, 2003, J WILDLIFE DIS, V39, P696, DOI 10.7589/0090-3558-39.3.696; Ovaskainen O, 2001, J APPL PROBAB, V38, P898, DOI 10.1017/S0021900200019112; PASCAL M, 1978, TERRE VIE-REV ECOL A, V32, P529; PEDERSEN NC, 1989, VET IMMUNOL IMMUNOP, V21, P111, DOI 10.1016/0165-2427(89)90134-7; Pontier D, 1998, P ROY SOC B-BIOL SCI, V265, P167, DOI 10.1098/rspb.1998.0278; SPARGER EE, 1993, VET CLIN N AM-SMALL, V23, P173, DOI 10.1016/S0195-5616(93)50011-6; Stone P, 2008, J MATH BIOL, V56, P743, DOI 10.1007/s00285-007-0136-0; Troyer JL, 2005, J VIROL, V79, P8282, DOI 10.1128/JVI.79.13.8282-8294.2005; UELAND K, 1992, VET IMMUNOL IMMUNOP, V33, P301, DOI 10.1016/0165-2427(92)90002-8; XEMAR V, 1997, THESIS ECOLE NATL VE, P184; YAMAMOTO JK, 1989, J AM VET MED ASSOC, V194, P213; Yang Y, 2007, EMERG INFECT DIS, V13, P1348, DOI 10.3201/eid1309.070111	39	6	6	0	5	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	OCT 16	2009	4	10							e7377	10.1371/journal.pone.0007377	http://dx.doi.org/10.1371/journal.pone.0007377			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	507UN	19888418	Green Submitted, Green Published, gold			2022-12-25	WOS:000270880700003
J	Na, N; Chandel, NS; Litvan, J; Ridge, KM				Na, Ni; Chandel, Navdeep S.; Litvan, Juan; Ridge, Karen M.			Mitochondrial reactive oxygen species are required for hypoxia-induced degradation of keratin intermediate filaments	FASEB JOURNAL			English	Article						alveolar epithelial cells; superoxide dismutase; lung	EPIDERMOLYSIS-BULLOSA SIMPLEX; DESMIN CYTOSKELETON; NAD(P)H OXIDASE; PROTEIN-KINASE; PHOSPHORYLATION; ARCHITECTURE; REORGANIZATION; NA,K-ATPASE; ACTIVATION; MECHANISMS	Hypoxia can cause stress and structural changes to the epithelial cytoskeleton. The intermediate filament (IF) network is known to reorganize in response to stress. We examined whether rats exposed to hypoxia had altered keratin IF expression in their alveolar epithelial type II (ATII) cells. There was a significant decrease in keratin protein levels in hypoxic ATII cells compared with those in ATII cells isolated from normoxic rats. To define the mechanisms regulating this process we studied changes to the keratin IF network in A549 cells (an alveolar epithelial cell line) exposed to 1.5% oxygen. We observed a time-dependent disassembly-degradation of keratin 8 and 18 proteins, which was associated with an increase in reactive oxygen species (ROS). Hypoxia-treated A549 cells deficient in mitochondrial DNA or A549 cells treated with a small interfering RNA against the Rieske iron-sulfur protein of mitochondrial complex III did not have increased levels of ROS nor was the keratin IF network disassembled and degraded. The superoxide dismutase (SOD)/catalase mimetic (EUK-134) prevented the hypoxia-mediated keratin IF degradation as did the overexpression of SOD1 but not of SOD2. Accordingly, we provide evidence that hypoxia promotes the disassembly and degradation of the keratin IF network via mitochondrial complex III-generated reactive oxygen species.-Na, N., Chandel, N. S., Litvan, J., Ridge, K. M. Mitochondrial reactive oxygen species are required for hypoxia-induced degradation of keratin intermediate filaments. FASEB J. 24, 799-809 (2010). www.fasebj.org	[Na, Ni; Chandel, Navdeep S.; Litvan, Juan; Ridge, Karen M.] Northwestern Univ, Sch Med, Div Pulm & Crit Care Med, Chicago, IL 60611 USA; [Chandel, Navdeep S.; Ridge, Karen M.] Northwestern Univ, Sch Med, Dept Mol Cell Biol, Chicago, IL 60611 USA	Northwestern University; Northwestern University	Ridge, KM (corresponding author), Northwestern Univ, Sch Med, Div Pulm & Crit Care Med, 240 E Huron,McGaw 2328, Chicago, IL 60611 USA.	kridge@northwestern.edu			NHLBI NIH HHS [R01 HL079190] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL079190] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Beil M, 2003, NAT CELL BIOL, V5, P803, DOI 10.1038/ncb1037; Bell EL, 2005, MITOCHONDRION, V5, P322, DOI 10.1016/j.mito.2005.06.005; Bieberich E, 2003, J CELL BIOL, V162, P469, DOI 10.1083/jcb.200212067; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Brunelle JK, 2005, CELL METAB, V1, P409, DOI 10.1016/j.cmet.2005.05.002; Budinger GRS, 2006, P NATL ACAD SCI USA, V103, P4604, DOI 10.1073/pnas.0507604103; Budinger GRS, 1996, AM J PHYSIOL-LUNG C, V270, pL44, DOI 10.1152/ajplung.1996.270.1.L44; Budinger GRS, 1998, J BIOL CHEM, V273, P3320, DOI 10.1074/jbc.273.6.3320; Capetanaki Y, 2002, TRENDS CARDIOVAS MED, V12, P339, DOI 10.1016/S1050-1738(02)00184-6; Chandel NS, 2000, J BIOL CHEM, V275, P25130, DOI 10.1074/jbc.M001914200; Chandel NS, 1998, P NATL ACAD SCI USA, V95, P11715, DOI 10.1073/pnas.95.20.11715; Chandel NS, 2000, J APPL PHYSIOL, V88, P1880, DOI 10.1152/jappl.2000.88.5.1880; Chou YH, 2000, J CELL BIOL, V150, pF101, DOI 10.1083/jcb.150.3.F101; CHOU YH, 1990, CELL, V62, P1063, DOI 10.1016/0092-8674(90)90384-Q; Crawford LE, 1996, J BIOL CHEM, V271, P26863, DOI 10.1074/jbc.271.43.26863; Dada LA, 2003, J CLIN INVEST, V111, P1057, DOI 10.1172/JCI200316826; Duranteau J, 1998, J BIOL CHEM, V273, P11619, DOI 10.1074/jbc.273.19.11619; Emerling BM, 2005, MOL CELL BIOL, V25, P4853, DOI 10.1128/MCB.25.12.4853-4862.2005; Fuchs E, 1998, SCIENCE, V279, P514, DOI 10.1126/science.279.5350.514; Galarneau L, 2007, EXP CELL RES, V313, P179, DOI 10.1016/j.yexcr.2006.10.007; Gilbert S, 2008, APOPTOSIS, V13, P1479, DOI 10.1007/s10495-008-0274-x; Griendling KK, 2000, CIRC RES, V86, P494, DOI 10.1161/01.RES.86.5.494; He T, 2002, J BIOL CHEM, V277, P10767, DOI 10.1074/jbc.M111436200; Heberlein W, 2000, AM J PHYSIOL-LUNG C, V278, pL640, DOI 10.1152/ajplung.2000.278.4.L640; Herrmann H, 2007, NAT REV MOL CELL BIO, V8, P562, DOI 10.1038/nrm2197; Jaitovich A, 2008, J BIOL CHEM, V283, P25348, DOI 10.1074/jbc.M801635200; Killilea DW, 2000, AM J PHYSIOL-LUNG C, V279, pL408, DOI 10.1152/ajplung.2000.279.2.L408; Kim S, 2007, GENE DEV, V21, P1581, DOI 10.1101/gad.1552107; Ku NO, 1999, AM J PHYSIOL-GASTR L, V277, pG1108, DOI 10.1152/ajpgi.1999.277.6.G1108; Ku NO, 2002, J BIOL CHEM, V277, P10775, DOI 10.1074/jbc.M107623200; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Li ZL, 1996, DEV BIOL, V175, P362, DOI 10.1006/dbio.1996.0122; Linden M, 2001, J BIOENERG BIOMEMBR, V33, P333, DOI 10.1023/A:1010611408007; Litvan J, 2006, J BIOL CHEM, V281, P19892, DOI 10.1074/jbc.M602064200; Lum H, 2001, AM J PHYSIOL-CELL PH, V280, pC719; Melov S, 2000, SCIENCE, V289, P1567, DOI 10.1126/science.289.5484.1567; Milner DJ, 1996, J CELL BIOL, V134, P1255, DOI 10.1083/jcb.134.5.1255; Milner DJ, 2000, J CELL BIOL, V150, P1283, DOI 10.1083/jcb.150.6.1283; MOLL R, 1982, CELL, V31, P11, DOI 10.1016/0092-8674(82)90400-7; Morley SM, 2003, BRIT J DERMATOL, V149, P46, DOI 10.1046/j.1365-2133.2003.05493.x; Parinandi NL, 2003, AM J PHYSIOL-LUNG C, V284, pL26, DOI 10.1152/ajplung.00123.2002; Paulin D, 2004, EXP CELL RES, V301, P1, DOI 10.1016/j.yexcr.2004.08.004; Prahlad V, 1998, J CELL BIOL, V143, P159, DOI 10.1083/jcb.143.1.159; Ridge KM, 2005, J BIOL CHEM, V280, P30400, DOI 10.1074/jbc.M504239200; Sahlgren CM, 2006, EMBO J, V25, P4808, DOI 10.1038/sj.emboj.7601366; Sahlgren CM, 2003, MOL CELL BIOL, V23, P5090, DOI 10.1128/MCB.23.14.5090-5106.2003; Sanders KA, 2002, J APPL PHYSIOL, V93, P1357, DOI 10.1152/japplphysiol.00564.2001; Schweizer J, 2006, J CELL BIOL, V174, P169, DOI 10.1083/jcb.200603161; Sivaramakrishnan S, 2008, P NATL ACAD SCI USA, V105, P889, DOI 10.1073/pnas.0710728105; Turrens JF, 2003, J PHYSIOL-LONDON, V552, P335, DOI 10.1113/jphysiol.2003.049478; Uttam J, 1996, P NATL ACAD SCI USA, V93, P9079, DOI 10.1073/pnas.93.17.9079; Wagner OI, 2003, J NEUROSCI, V23, P9046; Wang HL, 2007, J IMMUNOL, V179, P1834, DOI 10.4049/jimmunol.179.3.1834; Waypa GB, 2001, CIRC RES, V88, P1259, DOI 10.1161/hh1201.091960; Waypa GB, 2002, CIRC RES, V91, P719, DOI 10.1161/01.RES.0000036751.04896.F1; Weissmann Norbert, 2006, Novartis Found Symp, V272, P196; Wolin MS, 2005, AM J PHYSIOL-LUNG C, V289, pL159, DOI 10.1152/ajplung.00060.2005; Wong P, 2003, J CELL BIOL, V163, P327, DOI 10.1083/jcb.200305032; Yoon M, 1998, J CELL BIOL, V143, P147, DOI 10.1083/jcb.143.1.147	59	26	26	1	7	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAR	2010	24	3					799	809		10.1096/fj.08-128967	http://dx.doi.org/10.1096/fj.08-128967			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	561KE	19897662	Green Published			2022-12-25	WOS:000274974600016
J	Zhang, Y; Yamada, Y; Fan, MM; Bangaru, SD; Lin, BC; Yang, J				Zhang, Yun; Yamada, Yoichi; Fan, Mingming; Bangaru, Saroja D.; Lin, Bochao; Yang, Jian			The beta Subunit of Voltage-gated Ca2+ Channels Interacts with and Regulates the Activity of a Novel Isoform of Pax6	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MESSENGER-RNA STABILITY; CALCIUM-CHANNEL; EYE DEVELOPMENT; NUCLEAR EXPORT; TRANSACTIVATION PROPERTIES; PANCREAS DEVELOPMENT; PROTEIN INTERACTIONS; ECTOPIC EYES; DNA-BINDING; GENE PAX6	Ca2+ channel beta subunits (Ca-v beta s) are essential for regulating the surface expression and gating of high voltage-activated Ca2+ channels through their interaction with Ca2+ channel alpha(1) subunits. In efforts to uncover new interacting partners and new functions for Ca-v beta, we identified a new splicing isoform of Pax6, a transcription factor crucial for the development of the eye, nose, brain, and pancreas. Pax6 contains two DNA binding domains (paired domain and homeodomain), a glycine-rich linker connecting these two domains and a C-terminal proline-, serine-, and threonine-rich transactivation domain. The protein sequence and function of Pax6 are highly conserved from invertebrate to human. The newly isolated isoform, named Pax6(S), retains the paired domain, linker, and homeodomain of Pax6, but its C terminus is composed of a truncated classic proline, serine, and threonine domain and a unique S tail. Pax6(S) shows a similar level of transcriptional activity in vitro as does Pax6, but only in primates is the protein sequence highly conserved. Its spatial-temporal expression profiles are also different from those of Pax6. These divergences suggest a noncanonical role of Pax6(S) during development. The interaction between Pax6(S) and Ca-v beta is mainly endowed by the S tail. Co-expression of Pax6(S) with a Ca2+ channel complex containing the beta(3) subunit in Xenopus oocytes does not affect channel properties. Conversely, however, beta(3) is able to suppress the transcriptional activity of Pax6(S). Furthermore, in the presence of Pax6(S), beta(3) is translocated from the cytoplasm to the nucleus. These results suggest that full-length Ca-v beta may act directly as a transcription regulator independent of its role in regulating Ca2+ channel activity.	[Zhang, Yun; Yamada, Yoichi; Fan, Mingming; Bangaru, Saroja D.; Lin, Bochao; Yang, Jian] Columbia Univ, Dept Biol Sci, New York, NY 10027 USA	Columbia University	Yang, J (corresponding author), Columbia Univ, Dept Biol Sci, 917 Fairchild Ctr,MC2462, New York, NY 10027 USA.	jy160@columbia.edu			National Institutes of Health [NS045819, NS053494]; American Heart Association; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS053494, R01NS045819] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); American Heart Association(American Heart Association); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))	This work was supported, in whole or in part, by National Institutes of Health Grants NS045819 and NS053494 (to J. Y.). This work was also supported by an Established Investigator award from the American Heart Association (to J. Y.).	Altmann CR, 1997, DEV BIOL, V185, P119, DOI 10.1006/dbio.1997.8573; Arikkath J, 2003, CURR OPIN NEUROBIOL, V13, P298, DOI 10.1016/S0959-4388(03)00066-7; Beguin P, 2006, J MOL BIOL, V355, P34, DOI 10.1016/j.jmb.2005.10.013; Beguin P, 2001, NATURE, V411, P701, DOI 10.1038/35079621; Birnbaumer L, 1998, J BIOENERG BIOMEMBR, V30, P357, DOI 10.1023/A:1021989622656; Bolognani F, 2008, J NEUROSCI RES, V86, P481, DOI 10.1002/jnr.21473; Brink C, 2003, CELL MOL LIFE SCI, V60, P1033, DOI 10.1007/s00018-003-2247-0; Callaerts P, 1997, ANNU REV NEUROSCI, V20, P483, DOI 10.1146/annurev.neuro.20.1.483; Cannell IG, 2008, BIOCHEM SOC T, V36, P1224, DOI 10.1042/BST0361224; CARRIERE C, 1995, CELL GROWTH DIFFER, V6, P1531; Chen YH, 2004, NATURE, V429, P675, DOI 10.1038/nature02641; Cheng WJ, 2005, P NATL ACAD SCI USA, V102, P19225, DOI 10.1073/pnas.0504334102; Chow RL, 1999, DEVELOPMENT, V126, P4213; Colecraft HM, 2002, J PHYSIOL-LONDON, V541, P435, DOI 10.1113/jphysiol.2002.018515; CZERNY T, 1995, MOL CELL BIOL, V15, P2858; Dahl E, 1997, BIOESSAYS, V19, P755, DOI 10.1002/bies.950190905; de Silanes IL, 2007, CELL ONCOL, V29, P1; Dohrmann C, 2000, MECH DEVELOP, V92, P47, DOI 10.1016/S0925-4773(99)00324-X; Dolphin AC, 2003, J BIOENERG BIOMEMBR, V35, P599, DOI 10.1023/B:JOBB.0000008026.37790.5a; Engel K, 1998, EMBO J, V17, P3363, DOI 10.1093/emboj/17.12.3363; Evans Thomas C, 2005, WormBook, P1, DOI 10.1895/wormbook.1.34.1; Finlin BS, 2003, P NATL ACAD SCI USA, V100, P14469, DOI 10.1073/pnas.2437756100; GLASER T, 1994, NAT GENET, V7, P463, DOI 10.1038/ng0894-463; Gonzalez-Gutierrez G, 2007, J BIOL CHEM, V282, P2156, DOI 10.1074/jbc.M609071200; Guinez C, 2005, INT J BIOCHEM CELL B, V37, P765, DOI 10.1016/j.biocel.2004.12.001; Haase H, 2005, FASEB J, V19, P1969, DOI 10.1096/fj.05-3997com; Haase H, 1999, FASEB J, V13, P2161, DOI 10.1096/fasebj.13.15.2161; Habener JF, 1998, P ASSOC AM PHYSICIAN, V110, P12; HALDER G, 1995, SCIENCE, V267, P1788, DOI 10.1126/science.7892602; He LL, 2007, BIOPHYS J, V93, P834, DOI 10.1529/biophysj.106.101691; Hibino H, 2003, P NATL ACAD SCI USA, V100, P307, DOI 10.1073/pnas.0136791100; Hidalgo P, 2007, CELL CALCIUM, V42, P389, DOI 10.1016/j.ceca.2007.05.009; Hsueh YP, 2006, CURR MED CHEM, V13, P1915, DOI 10.2174/092986706777585040; Hsueh YP, 2000, NATURE, V404, P298, DOI 10.1038/35005118; Jackson MW, 2006, J BIOL CHEM, V281, P16814, DOI 10.1074/jbc.M511617200; JANS DA, 1991, J CELL BIOL, V115, P1203, DOI 10.1083/jcb.115.5.1203; Kim EA, 2006, J BIOL CHEM, V281, P7489, DOI 10.1074/jbc.M507227200; Kiyonaka S, 2007, NAT NEUROSCI, V10, P691, DOI 10.1038/nn1904; Kozmik Z, 2005, CURR OPIN GENET DEV, V15, P430, DOI 10.1016/j.gde.2005.05.001; Kozmik Z, 2008, BRAIN RES BULL, V75, P335, DOI 10.1016/j.brainresbull.2007.10.046; Lefebvre T, 2002, J CELL BIOCHEM, V85, P208, DOI 10.1002/jcb.10119; Manuel M, 2005, BRAIN RES BULL, V66, P387, DOI 10.1016/j.brainresbull.2005.02.006; Mikkola I, 1999, J BIOL CHEM, V274, P15115, DOI 10.1074/jbc.274.21.15115; Monsigny M, 2004, BBA-GEN SUBJECTS, V1673, P94, DOI 10.1016/j.bbagen.2004.03.015; Nomura T, 2007, DEV GROWTH DIFFER, V49, P683, DOI 10.1111/j.1440-169x.2007.00965.x; Onuma Y, 2002, P NATL ACAD SCI USA, V99, P2020, DOI 10.1073/pnas.022626999; Opatowsky Y, 2004, NEURON, V42, P387, DOI 10.1016/S0896-6273(04)00250-8; Osumi N, 2008, STEM CELLS, V26, P1663, DOI 10.1634/stemcells.2007-0884; Pichaud F, 2002, CURR OPIN GENET DEV, V12, P430, DOI 10.1016/S0959-437X(02)00321-0; Pickering BM, 2005, SEMIN CELL DEV BIOL, V16, P39, DOI 10.1016/j.semcdb.2004.11.006; Sakurai K, 2008, J NEUROSCI, V28, P4604, DOI 10.1523/JNEUROSCI.5074-07.2008; Schwab MS, 1997, EUR J CELL BIOL, V73, P287; Shyu AB, 2008, EMBO J, V27, P471, DOI 10.1038/sj.emboj.7601977; Singh S, 2001, HUM MOL GENET, V10, P911, DOI 10.1093/hmg/10.9.911; Stanescu D, 2007, EYE, V21, P90, DOI 10.1038/sj.eye.6702166; Steinman RA, 2007, LEUKEMIA, V21, P1158, DOI 10.1038/sj.leu.2404656; STRACHAN T, 1994, CURR OPIN GENET DEV, V4, P427, DOI 10.1016/0959-437X(94)90032-9; TAKAHASHI K, 1993, INT J CANCER, V55, P453, DOI 10.1002/ijc.2910550322; Tang HK, 1998, J BIOL CHEM, V273, P7210, DOI 10.1074/jbc.273.13.7210; TJIAN R, 1994, CELL, V77, P5, DOI 10.1016/0092-8674(94)90227-5; TON CCT, 1991, CELL, V67, P1059, DOI 10.1016/0092-8674(91)90284-6; van der Velden AW, 1999, INT J BIOCHEM CELL B, V31, P87, DOI 10.1016/S1357-2725(98)00134-4; Van Petegem F, 2004, NATURE, V429, P671, DOI 10.1038/nature02588; WALTHER C, 1991, GENOMICS, V11, P424, DOI 10.1016/0888-7543(91)90151-4; WALTHER C, 1991, DEVELOPMENT, V113, P1435; Yan Q, 2007, J BIOL CHEM, V282, P13954, DOI 10.1074/jbc.M611476200; Yang J, 1998, GENE DEV, V12, P2131, DOI 10.1101/gad.12.14.2131; Yu K, 2008, J NEUROSCI, V28, P5660, DOI 10.1523/JNEUROSCI.0065-08.2008; Ziman MR, 2001, HISTOL HISTOPATHOL, V16, P239, DOI 10.14670/HH-16.239	69	29	29	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 22	2010	285	4					2527	2536		10.1074/jbc.M109.022236	http://dx.doi.org/10.1074/jbc.M109.022236			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	544YP	19917615	Green Published, hybrid			2022-12-25	WOS:000273697800031
J	Armishaw, CJ; Singh, N; Medina-Franco, JL; Clark, RJ; Scott, KCM; Houghten, RA; Jensen, AA				Armishaw, Christopher J.; Singh, Narender; Medina-Franco, Jose L.; Clark, Richard J.; Scott, Krystle C. M.; Houghten, Richard A.; Jensen, Anders A.			A Synthetic Combinatorial Strategy for Developing alpha-Conotoxin Analogs as Potent alpha(7) Nicotinic Acetylcholine Receptor Antagonists	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PEPTIDE LIBRARIES; MOLECULAR-DYNAMICS; CALCIUM-CHANNELS; HOMOLOG ACHBP; AMINO-ACIDS; BINDING; IMI; LIGANDS; NMR; SELECTIVITY	alpha-Conotoxins are peptide neurotoxins isolated from venomous cone snails that display exquisite selectivity for different subtypes of nicotinic acetylcholine receptors (nAChR). They are valuable research tools that have profound implications in the discovery of new drugs for a myriad of neuropharmacological conditions. They are characterized by a conserved two-disulfide bond framework, which gives rise to two intervening loops of extensively mutated amino acids that determine their selectivity for different nAChR subtypes. We have used a multistep synthetic combinatorial approach using alpha-conotoxin ImI to develop potent and selective alpha(7) nAChR antagonists. A positional scan synthetic combinatorial library was constructed based on the three residues of the n-loop of Alpha-conotoxin ImI to give a total of 10,648 possible combinations that were screened for functional activity in an alpha(7) nAChR Fluo-4/Ca2+ assay, allowing amino acids that confer antagonistic activity for this receptor to be identified. A second series of individual alpha-conotoxin analogs based on the combinations of defined active amino acid residues from positional scan synthetic combinatorial library screening data were synthesized. Several analogs exhibited significantly improved antagonist activity for the alpha(7) nAChR compared with WT-ImI. Binding interactions between the analogs and the alpha(7) nAChR were explored using a homology model of the amino-terminal domain based on a crystal structure of an acetylcholine-binding protein. Finally, a third series of refined analogs was synthesized based on modeling studies, which led to several analogs with refined pharmacological properties. Of the 96 individual alpha-conotoxin analogs synthesized, three displayed >= 10-fold increases in antagonist potency compared with WT-ImI.	[Armishaw, Christopher J.; Singh, Narender; Medina-Franco, Jose L.; Scott, Krystle C. M.; Houghten, Richard A.] Torrey Pines Inst Mol Studies, Port St Lucie, FL 34987 USA; [Clark, Richard J.] Univ Queensland, Inst Mol Biosci, Brisbane, Qld 4072, Australia; [Jensen, Anders A.] Univ Copenhagen, Dept Med Chem, Fac Pharmaceut Sci, DK-2100 Copenhagen, Denmark	Torrey Pines Institute for Molecular Studies, Florida; University of Queensland; University of Copenhagen	Armishaw, CJ (corresponding author), Torrey Pines Inst Mol Studies, 11350 SW Village Pkwy, Port St Lucie, FL 34987 USA.	carmishaw@tpims.org	Medina-Franco, Jose/AAJ-1633-2020; Jensen, Anders/AAJ-3335-2020; Clark, Richard J/G-8848-2012	Medina-Franco, Jose/0000-0003-4940-1107; Jensen, Anders/0000-0002-7927-5052; Clark, Richard J/0000-0002-6807-5426	State of Florida and the Arthritis; Chronic Pain Research Institute	State of Florida and the Arthritis; Chronic Pain Research Institute	This work was supported in part by the State of Florida and the Arthritis and Chronic Pain Research Institute.	Armishaw C, 2009, J BIOL CHEM, V284, P9498, DOI 10.1074/jbc.M806136200; Armishaw CJ, 2005, CURR PROTEIN PEPT SC, V6, P221, DOI 10.2174/1389203054065437; Azam L, 2008, J BIOL CHEM, V283, P11625, DOI 10.1074/jbc.M710288200; Azam L, 2009, ACTA PHARMACOL SIN, V30, P771, DOI 10.1038/aps.2009.47; BROOKS BR, 1983, J COMPUT CHEM, V4, P187, DOI 10.1002/jcc.540040211; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Brust A, 2007, J PEPT SCI, V13, P133, DOI 10.1002/psc.825; Bulaj G, 2008, ANTIOXID REDOX SIGN, V10, P141, DOI 10.1089/ars.2007.1856; Celie PHN, 2005, NAT STRUCT MOL BIOL, V12, P582, DOI 10.1038/nsmb951; Chenna R, 2003, NUCLEIC ACIDS RES, V31, P3497, DOI 10.1093/nar/gkg500; Clark RJ, 2006, J BIOL CHEM, V281, P23254, DOI 10.1074/jbc.M604550200; Dani JA, 2007, ANNU REV PHARMACOL, V47, P699, DOI 10.1146/annurev.pharmtox.47.120505.105214; Dooley CT, 1998, J BIOL CHEM, V273, P18848, DOI 10.1074/jbc.273.30.18848; DOOLEY CT, 1993, LIFE SCI, V52, P1509, DOI 10.1016/0024-3205(93)90113-H; Dutertre S, 2007, EMBO J, V26, P3858, DOI 10.1038/sj.emboj.7601785; Dutton JL, 2002, J BIOL CHEM, V277, P48849, DOI 10.1074/jbc.M208842200; Ellison M, 2007, CHEM REC, V7, P341, DOI 10.1002/tcr.20131; Feuerbach D, 2005, NEUROPHARMACOLOGY, V48, P215, DOI 10.1016/j.neuropharm.2004.10.003; Franco A, 2006, PROG MOLEC, V43, P83, DOI 10.1007/978-3-540-30880-5_4; Gehrmann J, 1999, J MED CHEM, V42, P2364, DOI 10.1021/jm990114p; Guntert P, 1997, J MOL BIOL, V273, P283, DOI 10.1006/jmbi.1997.1284; Halai R, 2009, J BIOL CHEM, V284, P20275, DOI 10.1074/jbc.M109.015339; Han TS, 2008, CURR PHARM DESIGN, V14, P2462, DOI 10.2174/138161208785777469; Hansen SB, 2005, EMBO J, V24, P3635, DOI 10.1038/sj.emboj.7600828; Hogg RC, 2003, J BIOL CHEM, V278, P26908, DOI 10.1074/jbc.M212628200; HOUGHTEN RA, 1985, P NATL ACAD SCI USA, V82, P5131, DOI 10.1073/pnas.82.15.5131; Houghten RA, 1999, J MED CHEM, V42, P3743, DOI 10.1021/jm990174v; Humphrey W, 1996, J MOL GRAPH MODEL, V14, P33, DOI 10.1016/0263-7855(96)00018-5; Hutchinson EG, 1996, PROTEIN SCI, V5, P212; Jacobson MP, 2004, PROTEINS, V55, P351, DOI 10.1002/prot.10613; Jensen AA, 2005, J MED CHEM, V48, P4705, DOI 10.1021/jm040219e; Jensen AA, 2007, J MED CHEM, V50, P4616, DOI 10.1021/jm070574f; Karadsheh MS, 2004, J NEUROCHEM, V91, P1138, DOI 10.1111/j.1471-4159.2004.02801.x; Kasheverov IE, 2006, FEBS J, V273, P4470, DOI 10.1111/j.1742-4658.2006.05453.x; Koradi R, 1996, J MOL GRAPHICS, V14, P51, DOI 10.1016/0263-7855(96)00009-4; Laskowski RA, 1996, J BIOMOL NMR, V8, P477, DOI 10.1007/BF00228148; Millard EL, 2009, J BIOL CHEM, V284, P4944, DOI 10.1074/jbc.M804950200; Nielsen JS, 2004, J PEPT SCI, V10, P249, DOI 10.1002/psc.531; Nino-Vasquez JJ, 2004, MOL IMMUNOL, V40, P1063, DOI 10.1016/j.molimm.2003.11.005; OSTRESH JM, 1994, BIOPOLYMERS, V34, P1681, DOI 10.1002/bip.360341212; Phillips JC, 2005, J COMPUT CHEM, V26, P1781, DOI 10.1002/jcc.20289; PINILLA C, 1992, BIOTECHNIQUES, V13, P901; Pinilla C, 2001, CANCER RES, V61, P5153; Quiram PA, 1998, J BIOL CHEM, V273, P11007, DOI 10.1074/jbc.273.18.11007; Rogers JP, 1999, BIOCHEMISTRY-US, V38, P3874, DOI 10.1021/bi9826254; Rogers JP, 2000, J MOL BIOL, V304, P911, DOI 10.1006/jmbi.2000.4247; Sasaki T, 2000, FEBS LETT, V466, P125, DOI 10.1016/S0014-5793(99)01772-X; SCHNOLZER M, 1992, INT J PEPT PROT RES, V40, P180; SCHRODINGER LLC, 2008, PRIME VERSION 2 0 11; Sollod BL, 2005, PEPTIDES, V26, P131, DOI 10.1016/j.peptides.2004.07.016; TALY A, 2009, J NAT REV DRUG DISCO, V8, P733; Ulens C, 2006, P NATL ACAD SCI USA, V103, P3615, DOI 10.1073/pnas.0507889103; Utkin YN, 1999, TOXICON, V37, P1683, DOI 10.1016/S0041-0101(99)00111-7; Xiao YX, 1998, MOL PHARMACOL, V54, P322, DOI 10.1124/mol.54.2.322	54	34	37	0	18	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 15	2010	285	3					1809	1821		10.1074/jbc.M109.071183	http://dx.doi.org/10.1074/jbc.M109.071183			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	541PJ	19901032	Green Published, hybrid			2022-12-25	WOS:000273429100027
J	Chevtzoff, C; Yoboue, ED; Galinier, A; Casteilla, L; Daignan-Fornier, B; Rigoulet, M; Devin, A				Chevtzoff, Cyrille; Yoboue, Edgar D.; Galinier, Anne; Casteilla, Louis; Daignan-Fornier, Bertrand; Rigoulet, Michel; Devin, Anne			Reactive Oxygen Species-mediated Regulation of Mitochondrial Biogenesis in the Yeast Saccharomyces cerevisiae	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEPENDENT PROTEIN-KINASE; GENE-EXPRESSION; PSEUDOHYPHAL DIFFERENTIATION; CATABOLITE REPRESSION; TRANSCRIPTION FACTOR; HEART-MITOCHONDRIA; GROWTH-YIELD; ACTIVATION; METABOLISM; CELLS	Mitochondrial biogenesis is a complex process. It necessitates the participation of both the nuclear and the mitochondrial genomes. This process is highly regulated, and mitochondrial content within a cell varies according to energy demand. In the yeast Saccharomyces cerevisiae, the cAMP pathway is involved in the regulation of mitochondrial biogenesis. An overactivation of this pathway leads to an increase in mitochondrial enzymatic content. Of the three yeast cAMP protein kinases, we have previously shown that Tpk3p is the one involved in the regulation of mitochondrial biogenesis. In this paper, we investigated the molecular mechanisms that govern this process. We show that in the absence of Tpk3p, mitochondria produce large amounts of reactive oxygen species that signal to the HAP2/3/4/5 nuclear transcription factors involved in mitochondrial biogenesis. We establish that an increase in mitochondrial reactive oxygen species production down-regulates mitochondrial biogenesis. It is the first time that a redox sensitivity of the transcription factors involved in yeast mitochondrial biogenesis is shown. Such a process could be seen as a mitochondria quality control process.	[Devin, Anne] CNRS, IBGC, Bioenerget Lab, UMR 5095, F-33077 Bordeaux, France; [Chevtzoff, Cyrille; Yoboue, Edgar D.; Daignan-Fornier, Bertrand; Rigoulet, Michel; Devin, Anne] Univ Bordeaux 2, F-33077 Bordeaux, France; [Galinier, Anne; Casteilla, Louis] Ctr Hosp Univ Rangueil, CNRS, IFR31, UMR 5241,UPS, F-31059 Toulouse 9, France; [Galinier, Anne] Ctr Hosp Univ Rangueil, Biochim Lab, F-31059 Toulouse 9, France	Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); UDICE-French Research Universities; Universite de Bordeaux; UDICE-French Research Universities; Universite de Bordeaux; Centre National de la Recherche Scientifique (CNRS); CHU de Toulouse; Universite de Toulouse; Universite Toulouse III - Paul Sabatier; CHU de Toulouse	Devin, A (corresponding author), CNRS, IBGC, Bioenerget Lab, UMR 5095, 1 Rue Camille St Saens, F-33077 Bordeaux, France.	anne.devin@ibgc.u-bordeaux2.fr	YOBOUE, Edgar D./AAA-7706-2019	Galinier, Anne/0000-0003-2454-5681; Casteilla, Louis/0000-0001-9647-3248	Agence Nationale de la Recherche [NT05-2_42268]; Conseil Regional D'Aquitaine	Agence Nationale de la Recherche(French National Research Agency (ANR)); Conseil Regional D'Aquitaine(Region Nouvelle-Aquitaine)	This work was supported in part by Agence Nationale de la Recherche Grant NT05-2_42268 and the Conseil Regional D'Aquitaine.	Beauchamp Charles, ANAL BIOCHEM, V44, P276, DOI [10.1016/0003-2697(71)90370-8, DOI 10.1016/0003-2697(71)90370-8]; BEAUVOIT B, 1993, EUR J BIOCHEM, V214, P163, DOI 10.1111/j.1432-1033.1993.tb17909.x; Bender E, 2000, FEBS LETT, V466, P130, DOI 10.1016/S0014-5793(99)01773-1; Bogacka I, 2005, J CLIN ENDOCR METAB, V90, P6650, DOI 10.1210/jc.2005-1024; Casteilla L, 2001, IUBMB LIFE, V52, P181, DOI 10.1080/15216540152845984; CHANCE B, 1979, PHYSIOL REV, V59, P527, DOI 10.1152/physrev.1979.59.3.527; Chandel NS, 1998, P NATL ACAD SCI USA, V95, P11715, DOI 10.1073/pnas.95.20.11715; Chen RM, 2004, J BIOL CHEM, V279, P26036, DOI 10.1074/jbc.M402710200; Chevtzoff C, 2005, BBA-BIOENERGETICS, V1706, P117, DOI 10.1016/j.bbabio.2004.10.001; DANG VD, 1994, YEAST, V10, P1273, DOI 10.1002/yea.320101004; Dejean L, 2000, BBA-BIOENERGETICS, V1457, P45, DOI 10.1016/S0005-2728(00)00053-0; Dejean L, 2002, BBA-BIOENERGETICS, V1554, P159, DOI 10.1016/S0005-2728(02)00240-2; Dejean L, 2002, BIOCHEM BIOPH RES CO, V293, P1383, DOI 10.1016/S0006-291X(02)00391-1; Delaunay A, 2002, CELL, V111, P471, DOI 10.1016/S0092-8674(02)01048-6; DeRisi JL, 1997, SCIENCE, V278, P680, DOI 10.1126/science.278.5338.680; Devin A, 2007, AM J PHYSIOL-CELL PH, V292, pC52, DOI 10.1152/ajpcell.00208.2006; Devin A, 2006, J BIOL CHEM, V281, P26779, DOI 10.1074/jbc.M604800200; EVANS MJ, 1989, J BIOL CHEM, V264, P14361; Fabrizio P, 2003, GENETICS, V163, P35; Fondrat C, 1996, COMPUT APPL BIOSCI, V12, P363; FORSBURG SL, 1989, GENE DEV, V3, P1166, DOI 10.1101/gad.3.8.1166; Galinier A, 2004, FEBS LETT, V578, P53, DOI 10.1016/j.febslet.2004.10.067; Gari E, 1997, YEAST, V13, P837, DOI 10.1002/(SICI)1097-0061(199707)13:9<837::AID-YEA145>3.0.CO;2-T; GRIVELL LA, 1989, NATURE, V341, P569, DOI 10.1038/341569a0; GUARENTE L, 1981, P NATL ACAD SCI-BIOL, V78, P2199, DOI 10.1073/pnas.78.4.2199; GUARENTE L, 1984, CELL, V36, P503, DOI 10.1016/0092-8674(84)90243-5; Guerin B, 1979, Methods Enzymol, V55, P149; HAHN S, 1988, MOL CELL BIOL, V8, P655, DOI 10.1128/MCB.8.2.655; KIPPERT F, 1995, FEMS MICROBIOL LETT, V128, P201, DOI 10.1016/0378-1097(95)00113-J; Larsson NG, 1998, NAT GENET, V18, P231, DOI 10.1038/ng0398-231; LEVINE RL, 1994, METHOD ENZYMOL, V233, P346; Li B, 1999, J BIOL CHEM, V274, P17534, DOI 10.1074/jbc.274.25.17534; MCNABB DS, 1995, GENE DEV, V9, P47, DOI 10.1101/gad.9.1.47; Noubhani A, 2009, J BIOL CHEM, V284, P27229, DOI 10.1074/jbc.M109.029454; OLESEN J, 1987, CELL, V51, P953, DOI 10.1016/0092-8674(87)90582-4; OSCAI LB, 1971, J BIOL CHEM, V246, P6968; Pan XW, 2002, MOL CELL BIOL, V22, P3981, DOI 10.1128/MCB.22.12.3981-3993.2002; Pan XW, 1999, MOL CELL BIOL, V19, P4874; Parrou JL, 1997, ANAL BIOCHEM, V248, P186, DOI 10.1006/abio.1997.2138; Robertson LS, 2000, P NATL ACAD SCI USA, V97, P5984, DOI 10.1073/pnas.100113397; Robertson LS, 1998, P NATL ACAD SCI USA, V95, P13783, DOI 10.1073/pnas.95.23.13783; RONNE H, 1995, TRENDS GENET, V11, P12, DOI 10.1016/S0168-9525(00)88980-5; SHIGENAGA MK, 1994, P NATL ACAD SCI USA, V91, P10771, DOI 10.1073/pnas.91.23.10771; Smith A, 1998, EMBO J, V17, P3556, DOI 10.1093/emboj/17.13.3556; Storz P, 2005, MOL CELL BIOL, V25, P8520, DOI 10.1128/MCB.25.19.8520-8530.2005; Sun H, 2003, ARCH BIOCHEM BIOPHYS, V419, P198, DOI 10.1016/j.abb.2003.08.028; Suzuki YJ, 1997, FREE RADICAL BIO MED, V22, P269, DOI 10.1016/S0891-5849(96)00275-4; Thannickal VJ, 2000, AM J PHYSIOL-LUNG C, V279, pL1005; TODA T, 1987, CELL, V50, P277, DOI 10.1016/0092-8674(87)90223-6; TURRENS JF, 1985, ARCH BIOCHEM BIOPHYS, V237, P408, DOI 10.1016/0003-9861(85)90293-0; Velot C, 1996, GENETICS, V144, P893; Votyakova TV, 2001, J NEUROCHEM, V79, P266, DOI 10.1046/j.1471-4159.2001.00548.x; Wood MJ, 2004, NATURE, V430, P917, DOI 10.1038/nature02790	53	41	44	3	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 15	2010	285	3					1733	1742		10.1074/jbc.M109.019570	http://dx.doi.org/10.1074/jbc.M109.019570			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	541PJ	19897478	Green Published, hybrid			2022-12-25	WOS:000273429100019
J	Hou, HT; Wang, Y; Kallgren, SP; Thompson, J; Yates, JR; Jia, ST				Hou, Haitong; Wang, Yu; Kallgren, Scott P.; Thompson, James; Yates, John R., III; Jia, Songtao			Histone Variant H2A.Z Regulates Centromere Silencing and Chromosome Segregation in Fission Yeast	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CENP-C; CHROMATIN-STRUCTURE; PLANT HOMEODOMAIN; PHD FINGER; HETEROCHROMATIN; KINETOCHORE; PROTEIN; GENE; METHYLATION; COMPONENT	The incorporation of histone variant H2A.Z into nucleosomes plays essential roles in regulating chromatin structure and gene expression. A multisubunit complex containing chromatin remodeling protein Swr1 is responsible for the deposition of H2A.Z in budding yeast and mammals. Here, we show that the JmjC domain protein Msc1 is a novel component of the fission yeast Swr1 complex and is required for Swr1-mediated incorporation of H2A.Z into nucleosomes at gene promoters. Loss of Msc1, Swr1, or H2A.Z results in loss of silencing at centromeres and defective chromosome segregation, although centromeric levels of CENP-A, a centromere-specific histone H3 variant that is required for setting up the chromatin structure at centromeres, remain unchanged. Intriguingly, H2A.Z is required for the expression of another centromere protein, CENP-C, and overexpression of CENP-Crescues centromere silencing defects associated with H2A.Z loss. These results demonstrate the importance of H2A.Z and CENP-C in maintaining a silenced chromatin state at centromeres.	[Jia, Songtao] Columbia Univ, Dept Biol Sci, Fairchild Ctr 1114, New York, NY 10027 USA; [Thompson, James; Yates, John R., III] Scripps Res Inst, Dept Cell Biol, La Jolla, CA 92037 USA	Columbia University; Scripps Research Institute	Jia, ST (corresponding author), Columbia Univ, Dept Biol Sci, Fairchild Ctr 1114, MC2458, New York, NY 10027 USA.	jia@biology.columbia.edu	Hou, Haitong/E-8416-2013; hou, haitong/D-5188-2019	hou, haitong/0000-0003-4493-9645; Jia, Songtao/0000-0002-7927-0227; Kallgren, Scott/0000-0002-6318-3268	National Institutes of Health [R01 GM085145]; National Center for Research Resources [P41 RR11823]; March of Dimes Foundation; NATIONAL CENTER FOR RESEARCH RESOURCES [P41RR011823] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM085145] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); National Center for Research Resources(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); March of Dimes Foundation(March of Dimes); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	This work was supported, in whole or in part, by National Institutes of Health Grant R01 GM085145 (to S. J.) and Grant P41 RR11823 from the National Center for Research Resources (to T. N. Davis). This work was also supported by a Basil O'Connor Starter Scholar Award from the March of Dimes Foundation.	Ahmed S, 2004, MOL CELL BIOL, V24, P3660, DOI 10.1128/MCB.24.9.3660-3669.2004; Ahmed S, 2007, GENETICS, V177, P1487, DOI 10.1534/genetics.107.078691; Allis C. D., 2006, EPIGENETICS; ALLSHIRE RC, 1994, CELL, V76, P157, DOI 10.1016/0092-8674(94)90180-5; Allshire RC, 2008, NAT REV GENET, V9, P923, DOI 10.1038/nrg2466; Anders A, 2008, YEAST, V25, P913, DOI 10.1002/yea.1639; Bahler J, 1998, YEAST, V14, P943, DOI 10.1002/(SICI)1097-0061(199807)14:10<943::AID-YEA292>3.0.CO;2-Y; Barski A, 2007, CELL, V129, P823, DOI 10.1016/j.cell.2007.05.009; Bernard P, 2001, SCIENCE, V294, P2539, DOI 10.1126/science.1064027; Bernstein E, 2005, GENE DEV, V19, P1635, DOI 10.1101/gad.1324305; Black BE, 2004, NATURE, V430, P578, DOI 10.1038/nature02766; Black BE, 2007, P NATL ACAD SCI USA, V104, P5008, DOI 10.1073/pnas.0700390104; Cam HP, 2005, NAT GENET, V37, P809, DOI 10.1038/ng1602; Cam HP, 2009, CELL, V136, P610, DOI 10.1016/j.cell.2009.02.004; CARR AM, 1994, MOL GEN GENET, V245, P628, DOI 10.1007/BF00282226; Cheeseman IM, 2008, NAT REV MOL CELL BIO, V9, P33, DOI 10.1038/nrm2310; Chen ES, 2008, NATURE, V451, P734, DOI 10.1038/nature06561; Chen ZZ, 2006, CELL, V125, P691, DOI 10.1016/j.cell.2006.04.024; Cleveland DW, 2003, CELL, V112, P407, DOI 10.1016/S0092-8674(03)00115-6; Dul BE, 2007, J BIOL CHEM, V282, P18397, DOI 10.1074/jbc.M700729200; Eissenberg JC, 2007, NAT STRUCT MOL BIOL, V14, P344, DOI 10.1038/nsmb1217; Fang J, 2002, CURR BIOL, V12, P1086, DOI 10.1016/S0960-9822(02)00924-7; Foltz DR, 2006, NAT CELL BIOL, V8, P458, DOI 10.1038/ncb1397; Fukagawa T, 1999, EMBO J, V18, P4196, DOI 10.1093/emboj/18.15.4196; Garcia BA, 2007, J BIOL CHEM, V282, P7641, DOI 10.1074/jbc.M607900200; Greaves IK, 2007, P NATL ACAD SCI USA, V104, P525, DOI 10.1073/pnas.0607870104; Grewal SIS, 2007, NAT REV GENET, V8, P35, DOI 10.1038/nrg2008; Guillemette B, 2005, PLOS BIOL, V3, P2100, DOI 10.1371/journal.pbio.0030384; Hayashi A, 2006, MOL BIOL CELL, V17, P5173, DOI 10.1091/mbc.E06-05-0388; Heeger S, 2005, GENE DEV, V19, P2041, DOI 10.1101/gad.347805; Holland S, 2005, CHROMOSOME RES, V13, P73, DOI 10.1007/s10577-005-7062-z; Hori T, 2008, CELL, V135, P1039, DOI 10.1016/j.cell.2008.10.019; Huarte M, 2007, J BIOL CHEM, V282, P21662, DOI 10.1074/jbc.M703897200; Iwase S, 2007, CELL, V128, P1077, DOI 10.1016/j.cell.2007.02.017; Jia ST, 2005, NAT CELL BIOL, V7, P1007, DOI 10.1038/ncb1300; Klose RJ, 2007, CELL, V128, P889, DOI 10.1016/j.cell.2007.02.013; Klose RJ, 2006, NAT REV GENET, V7, P715, DOI 10.1038/nrg1945; Kobor MS, 2004, PLOS BIOL, V2, P587, DOI 10.1371/journal.pbio.0020131; Krogan NJ, 2003, MOL CELL, V12, P1565, DOI 10.1016/S1097-2765(03)00497-0; Kwon MS, 2007, MOL BIOL CELL, V18, P2155, DOI 10.1091/mbc.E07-01-0045; Ladurner AG, 2003, MOL CELL, V11, P365, DOI 10.1016/S1097-2765(03)00035-2; Lawrence RJ, 2009, P NATL ACAD SCI USA, V106, P1163, DOI 10.1073/pnas.0811161106; Lee MG, 2007, CELL, V128, P877, DOI 10.1016/j.cell.2007.02.004; Lee N, 2007, NAT STRUCT MOL BIOL, V14, P341, DOI 10.1038/nsmb1216; Li B, 2005, P NATL ACAD SCI USA, V102, P18385, DOI 10.1073/pnas.0507975102; Li F, 2008, CELL, V135, P272, DOI 10.1016/j.cell.2008.08.036; Li HT, 2006, NATURE, V442, P91, DOI 10.1038/nature04802; Liu ST, 2006, J CELL BIOL, V175, P41, DOI 10.1083/jcb.200606020; Luk E, 2007, MOL CELL, V25, P357, DOI 10.1016/j.molcel.2006.12.015; Malik HS, 2009, CELL, V138, P1067, DOI 10.1016/j.cell.2009.08.036; Matangkasombut O, 2003, MOL CELL, V11, P353, DOI 10.1016/S1097-2765(03)00033-9; Mavrich TN, 2008, NATURE, V453, P358, DOI 10.1038/nature06929; MELUH PB, 1995, MOL BIOL CELL, V6, P793, DOI 10.1091/mbc.6.7.793; Meneghini MD, 2003, CELL, V112, P725, DOI 10.1016/S0092-8674(03)00123-5; Millar CB, 2006, GENE DEV, V20, P711, DOI 10.1101/gad.1395506; Mizuguchi G, 2004, SCIENCE, V303, P343, DOI 10.1126/science.1090701; Moore LL, 2001, J CELL BIOL, V153, P1199, DOI 10.1083/jcb.153.6.1199; Nishioka K, 2002, MOL CELL, V9, P1201, DOI 10.1016/S1097-2765(02)00548-8; Nonaka N, 2002, NAT CELL BIOL, V4, P89, DOI 10.1038/ncb739; Obuse C, 2004, GENES CELLS, V9, P105, DOI 10.1111/j.1365-2443.2004.00705.x; Okada M, 2006, NAT CELL BIOL, V8, P446, DOI 10.1038/ncb1396; Park YJ, 2005, J BIOL CHEM, V280, P1817, DOI 10.1074/jbc.M411347200; Pena PV, 2006, NATURE, V442, P100, DOI 10.1038/nature04814; Pidoux AL, 2003, J CELL BIOL, V161, P295, DOI 10.1083/jcb.200212110; POLIZZI C, 1991, J CELL BIOL, V112, P191, DOI 10.1083/jcb.112.2.191; Raisner RM, 2005, CELL, V123, P233, DOI 10.1016/j.cell.2005.10.002; Rangasamy D, 2004, NAT STRUCT MOL BIOL, V11, P650, DOI 10.1038/nsmb786; Rangasamy D, 2003, EMBO J, V22, P1599, DOI 10.1093/emboj/cdg160; Regnier V, 2005, MOL CELL BIOL, V25, P3967, DOI 10.1128/MCB.25.10.3967-3981.2005; Roguev A, 2008, SCIENCE, V322, P405, DOI 10.1126/science.1162609; Ruhl DD, 2006, BIOCHEMISTRY-US, V45, P5671, DOI 10.1021/bi060043d; SAITOH H, 1992, CELL, V70, P115, DOI 10.1016/0092-8674(92)90538-N; Secombe J, 2007, GENE DEV, V21, P537, DOI 10.1101/gad.1523007; Shevchenko A, 2008, GENOME BIOL, V9, DOI 10.1186/gb-2008-9-11-r167; Shi XB, 2006, NATURE, V442, P96, DOI 10.1038/nature04835; Shi Y, 2007, MOL CELL, V25, P1, DOI 10.1016/j.molcel.2006.12.010; TAKAHASHI K, 1992, MOL BIOL CELL, V3, P819, DOI 10.1091/mbc.3.7.819; Takahashi K, 2000, SCIENCE, V288, P2215, DOI 10.1126/science.288.5474.2215; Tanaka K, 2009, DEV CELL, V17, P334, DOI 10.1016/j.devcel.2009.08.004; TOMKIEL J, 1994, J CELL BIOL, V125, P531, DOI 10.1083/jcb.125.3.531; Wang GG, 2009, NATURE, V459, P847, DOI 10.1038/nature08036; Wang Y, 2009, MOL CELL, V33, P428, DOI 10.1016/j.molcel.2009.02.002; Washburn MP, 2001, NAT BIOTECHNOL, V19, P242, DOI 10.1038/85686; Whittle CM, 2008, PLOS GENET, V4, DOI 10.1371/journal.pgen.1000187; Wong LH, 2007, GENOME RES, V17, P1146, DOI 10.1101/gr.6022807; Wu WH, 2009, J BIOL CHEM, V284, P6200, DOI 10.1074/jbc.M808830200; Wu WH, 2005, NAT STRUCT MOL BIOL, V12, P1064, DOI 10.1038/nsmb1023; Wysocka J, 2006, NATURE, V442, P86, DOI 10.1038/nature04815; Yamane K, 2007, MOL CELL, V25, P801, DOI 10.1016/j.molcel.2007.03.001; Zhang HY, 2005, CELL, V123, P219, DOI 10.1016/j.cell.2005.08.036; Zilberman D, 2008, NATURE, V456, P125, DOI 10.1038/nature07324; Zofall M, 2009, NATURE, V461, P419, DOI 10.1038/nature08321	92	42	44	0	14	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 15	2010	285	3					1909	1918		10.1074/jbc.M109.058487	http://dx.doi.org/10.1074/jbc.M109.058487			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	541PJ	19910462	Green Published, hybrid			2022-12-25	WOS:000273429100037
J	Patel, VA; Lee, DJ; Feng, LF; Antoni, A; Lieberthal, W; Schwartz, JH; Rauch, J; Ucker, DS; Levine, JS				Patel, Vimal A.; Lee, Daniel J.; Feng, Lanfei; Antoni, Angelika; Lieberthal, Wilfred; Schwartz, John H.; Rauch, Joyce; Ucker, David S.; Levine, Jerrold S.			Recognition of Apoptotic Cells by Epithelial Cells CONSERVED VERSUS TISSUE-SPECIFIC SIGNALING RESPONSES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IMMUNE-RESPONSES; NECROTIC CELLS; MACROPHAGES; CLEARANCE; BETA; ACTIVATION; PHAGOCYTES; SURVIVAL; EVENTS; MOUSE	During apoptosis, cells acquire new activities that enable them to modulate the fate and function of interacting phagocytes, particularly macrophages (m phi). Although the best known of these activities is anti-inflammatory, apoptotic targets also influencem phi survival and proliferation by modulating proximal signaling events, such as MAPK modules and Akt. We asked whether modulation of these same signaling events extends to epithelial cells, a minimally phagocytic cell type. We used BU.MPT cells, a mouse kidney epithelial cell line, as our primary model, but we also evaluated several epithelial cell lines of distinct tissue origins. Like m phi, mouse kidney epithelial cells recognized apoptotic and necrotic targets through distinct non-competing receptors, albeit with lower binding capacity and markedly reduced phagocytosis. Also, modulation of inflammatory activity and MAPK-dependent signaling by apoptotic and necrotic targets was indistinguishable in kidney epithelial cells and m phi. In contrast, modulation of Akt-dependent signaling differed dramatically between kidney epithelial cells and m phi. In kidney epithelial cells, modulation of Akt was linked to target cell recognition, independently of phagocytosis, whereas in m phi, modulation was linked to phagocytosis. Moreover, recognition of apoptotic and necrotic targets by kidney epithelial cells elicited opposite responses; apoptotic targets inhibited whereas necrotic targets stimulated Akt activity. These data confirm that nonprofessional phagocytes recognize and respond to dying cells, albeit in a manner partially distinct from m phi. By acting as sentinels of environmental change, apoptotic and necrotic targets may permit neighboring viable cells, especially non-migratory epithelial cells, to monitor and adapt to local stresses.	[Levine, Jerrold S.] Univ Illinois, Dept Med, Nephrol Sect, Coll Med, Chicago, IL 60612 USA; [Ucker, David S.; Levine, Jerrold S.] Univ Illinois, Dept Microbiol & Immunol, Chicago, IL 60612 USA; [Patel, Vimal A.; Lee, Daniel J.; Feng, Lanfei; Levine, Jerrold S.] Jesse Brown Vet Affairs Hosp, Nephrol Sect, Dept Med, Chicago, IL 60612 USA; [Antoni, Angelika] Kutztown Univ Penn, Dept Biol, Kutztown, PA 19530 USA; [Lieberthal, Wilfred] SUNY Stony Brook, Dept Med, Nephrol Sect, Med Ctr, Stony Brook, NY 11794 USA; [Lieberthal, Wilfred] Northport Vet Affairs Hosp, Northport, NY 11768 USA; [Schwartz, John H.] Boston Univ, Dept Med, Sch Med, Renal Sect, Boston, MA 02118 USA; [Rauch, Joyce] McGill Univ, Ctr Hlth, Res Inst, Dept Med,Div Rheumatol, Montreal, PQ H3G 1A4, Canada	University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; US Department of Veterans Affairs; Veterans Health Administration (VHA); Jesse Brown VA Medical Center; Pennsylvania State System of Higher Education (PASSHE); Kutztown University - Pennsylvania; State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook; Boston University; McGill University	Levine, JS (corresponding author), Univ Illinois, Dept Med, Nephrol Sect, Coll Med, MC793,820 S Wood St, Chicago, IL 60612 USA.	jslevine@uic.edu	Schwartz, John/AAO-8158-2021	Schwartz, John/0000-0002-1660-8681	National Institutes of Health [DK071678, AG024234, DK059529]; Genzyme, Inc.; Veterans Affairs Merit Award; Pennsylvania State System of Higher Education Faculty Professional Development Grant; Canadian Institutes of Health [MOP-67101, MOP-42391]; Institute of Musculoskeletal Health and Arthritis Priority Announcement [MUS-67101]; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [K01DK071678, R01DK059529] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG029633, R21AG024234] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Genzyme, Inc.(Sanofi-AventisGenzyme Corporation); Veterans Affairs Merit Award(US Department of Veterans Affairs); Pennsylvania State System of Higher Education Faculty Professional Development Grant; Canadian Institutes of Health(Canadian Institutes of Health Research (CIHR)); Institute of Musculoskeletal Health and Arthritis Priority Announcement; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))	This work was supported, in whole or in part, by National Institutes of Health Grants DK071678(to V. A. P.), AG024234(to D. S. U.), and DK059529(to J. H. S.). This work was also supported by a GRIP Renal Innovations Program Award from Genzyme, Inc. (to J. S. L.), a Veterans Affairs Merit Award (to W. L.), a Pennsylvania State System of Higher Education Faculty Professional Development Grant (to A. L.), and Canadian Institutes of Health Research Grants MOP-67101 (to J. R.) and MOP-42391 (to J. R.) and Institute of Musculoskeletal Health and Arthritis Priority Announcement MUS-67101 (to J. R.).	Chen GY, 2009, SCIENCE, V323, P1722, DOI 10.1126/science.1168988; Cocco RE, 2001, MOL BIOL CELL, V12, P919, DOI 10.1091/mbc.12.4.919; Cvetanovic M, 2004, J IMMUNOL, V172, P880, DOI 10.4049/jimmunol.172.2.880; Cvetanovic M, 2006, J BIOL CHEM, V281, P20055, DOI 10.1074/jbc.M603920200; El-Achkar TM, 2006, NAT CLIN PRACT NEPHR, V2, P568, DOI 10.1038/ncpneph0300; Fadok VA, 1998, J CLIN INVEST, V101, P890, DOI 10.1172/JCI1112; Freire-de-Lima CG, 2006, J BIOL CHEM, V281, P38376, DOI 10.1074/jbc.M605146200; Huynh MLN, 2002, J CLIN INVEST, V109, P41, DOI 10.1172/JCI200211638; JAT PS, 1991, P NATL ACAD SCI USA, V88, P5096, DOI 10.1073/pnas.88.12.5096; Klune JR, 2008, MOL MED, V14, P476, DOI 10.2119/2008-00034.Klune; McDonald PP, 1999, J IMMUNOL, V163, P6164; Mitchell JE, 2006, J BIOL CHEM, V281, P5718, DOI 10.1074/jbc.M509775200; Monks J, 2005, CELL DEATH DIFFER, V12, P107, DOI 10.1038/sj.cdd.4401517; Parnaik R, 2000, CURR BIOL, V10, P857, DOI 10.1016/S0960-9822(00)00598-4; Patel VA, 2006, J BIOL CHEM, V281, P4663, DOI 10.1074/jbc.M508342200; Patel VA, 2007, AUTOIMMUNITY, V40, P274, DOI 10.1080/08916930701357463; Reddy SM, 2002, J IMMUNOL, V169, P702, DOI 10.4049/jimmunol.169.2.702; Savill J, 2002, NAT REV IMMUNOL, V2, P965, DOI 10.1038/nri957; Sinha D, 2005, AM J PHYSIOL-RENAL, V288, pF703, DOI 10.1152/ajprenal.00189.2004; Sinha D, 2003, AM J PHYSIOL-RENAL, V284, pF488, DOI 10.1152/ajprenal.00172.2002; THURAU K, 1976, AM J MED, V61, P308, DOI 10.1016/0002-9343(76)90365-X; Voll RE, 1997, NATURE, V390, P350, DOI 10.1038/37022; Wood W, 2000, DEVELOPMENT, V127, P5245	23	23	23	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 15	2010	285	3					1829	1840		10.1074/jbc.M109.018440	http://dx.doi.org/10.1074/jbc.M109.018440			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	541PJ	19910463	Green Published, hybrid			2022-12-25	WOS:000273429100029
J	Fish, JE; Yan, MS; Matouk, CC; Bernard, RS; Ho, JJD; Gavryushova, A; Srivastava, D; Marsden, PA				Fish, Jason E.; Yan, Matthew S.; Matouk, Charles C.; Bernard, Rosanne St.; Ho, J. J. David, Jr.; Gavryushova, Anna; Srivastava, Deepak; Marsden, Philip A.			Hypoxic Repression of Endothelial Nitric-oxide Synthase Transcription Is Coupled with Eviction of Promoter Histones	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RNA-POLYMERASE-II; CELL-SPECIFIC EXPRESSION; MISMATCH REPAIR GENE; GROWTH-FACTOR; PULMONARY-HYPERTENSION; REDUCED EXPRESSION; RESPONSE ELEMENT; HEME OXYGENASE-1; MAMMALIAN-CELLS; SWI/SNF COMPLEX	Hypoxia elicits endothelial dysfunction, in part, through reduced expression of endothelial nitric-oxide synthase (eNOS). Here we present evidence that hypoxia causes a rapid decrease in the transcription of the eNOS/NOS3 gene, accompanied by decreased acetylation and lysine 4 (histone H3) methylation of eNOS proximal promoter histones. Surprisingly, we demonstrate that histones are rapidly evicted from the eNOS proximal promoter during hypoxia. We also demonstrate endothelium-specific H2A.Z incorporation at the eNOS promoter and find that H2A.Z is also evicted by hypoxic stimulation. After longer durations of hypoxia, histones are reincorporated at the eNOS promoter, but these histones lack substantial histone acetylation. Additionally, we identify a key role for the chromatin remodeler, BRG1, in re-establishing eNOS expression following reoxygenation of hypoxic cells. We posit that post-translational histone modifications are required to maintain constitutive eNOS transcriptional activity and that histone eviction rapidly resets histone marks and is a proximal event in the hypoxic repression of eNOS. Although nucleosome eviction has been reported in models of transcriptional activation, the observation that eviction can also accompany transcriptional repression in hypoxic mammalian cells argues that eviction may be broadly relevant to both positive and negative changes in transcription.	[Marsden, Philip A.] Univ Toronto, Dept Med Biophys, Toronto, ON M5S 1A8, Canada; [Yan, Matthew S.; Matouk, Charles C.; Bernard, Rosanne St.; Ho, J. J. David, Jr.; Gavryushova, Anna; Marsden, Philip A.] St Michaels Hosp, Div Renal, Toronto, ON M5B 1W8, Canada; [Yan, Matthew S.; Matouk, Charles C.; Bernard, Rosanne St.; Ho, J. J. David, Jr.; Gavryushova, Anna; Marsden, Philip A.] St Michaels Hosp, Dept Med, Toronto, ON M5B 1W8, Canada; [Yan, Matthew S.; Matouk, Charles C.; Bernard, Rosanne St.; Ho, J. J. David, Jr.; Gavryushova, Anna; Marsden, Philip A.] Univ Toronto, Toronto, ON M5B 1W8, Canada; [Fish, Jason E.; Srivastava, Deepak] Gladstone Inst Cardiovasc Dis, San Francisco, CA 94158 USA; [Fish, Jason E.; Srivastava, Deepak] Univ Calif San Francisco, San Francisco, CA 94158 USA	University of Toronto; University of Toronto; University Toronto Affiliates; Saint Michaels Hospital Toronto; University of Toronto; University Toronto Affiliates; Saint Michaels Hospital Toronto; University of Toronto; University of California System; University of California San Francisco; The J David Gladstone Institutes; University of California System; University of California San Francisco	Marsden, PA (corresponding author), Univ Toronto, Dept Med Biophys, Rm 7358,Med Sci Bldg,1 Kings Coll Circle, Toronto, ON M5S 1A8, Canada.	p.marsden@utoronto.ca	Matouk, Charles/AAF-7694-2019; Marsden, Philip A/B-1441-2012	Fish, Jason/0000-0003-0640-7277	Canadian Institutes of Health Research (CIHR) [CIHR MOP 79475]; Natural Sciences and Engineering Research Council Canada; CIHR Frederick Banting; Charles Best Canada; Heart and Stroke Foundation of Canada	Canadian Institutes of Health Research (CIHR)(Canadian Institutes of Health Research (CIHR)); Natural Sciences and Engineering Research Council Canada(Natural Sciences and Engineering Research Council of Canada (NSERC)); CIHR Frederick Banting(Canadian Institutes of Health Research (CIHR)); Charles Best Canada; Heart and Stroke Foundation of Canada(Heart & Stroke Foundation of Canada)	This work was supported by Grant CIHR MOP 79475 from the Canadian Institutes of Health Research (CIHR).; Recipient of an Natural Sciences and Engineering Research Council Canada Graduate Scholarship.; The recipient of a CIHR Frederick Banting and Charles Best Canada Graduate Scholarship.; Recipient of a Career Investigator Award from the Heart and Stroke Foundation of Canada. To whom correspondence should be addressed: Rm. 7358, Medical Sciences Bldg., University of Toronto, 1 King's College Circle, Toronto, Ontario M5S 1A8, Canada. Tel.: 416-978-2441; Fax: 416-978-8765; E-mail: p. marsden@ utoronto. ca.	Arany Z, 1996, P NATL ACAD SCI USA, V93, P12969, DOI 10.1073/pnas.93.23.12969; Baker KM, 2003, J BIOL CHEM, V278, P17876, DOI 10.1074/jbc.M209480200; Barski A, 2007, CELL, V129, P823, DOI 10.1016/j.cell.2007.05.009; Batsche E, 2006, NAT STRUCT MOL BIOL, V13, P22, DOI 10.1038/nsmb1030; Bazett-Jones DP, 1999, MOL CELL BIOL, V19, P1470; Bentley D, 1999, CURR OPIN CELL BIOL, V11, P347, DOI 10.1016/S0955-0674(99)80048-9; Bindra RS, 2004, MOL CELL BIOL, V24, P8504, DOI 10.1128/MCB.24.19.8504-8518.2004; Castano E, 2000, P NATL ACAD SCI USA, V97, P7184, DOI 10.1073/pnas.140202297; Ceradini DJ, 2004, NAT MED, V10, P858, DOI 10.1038/nm1075; Champion HC, 2002, P NATL ACAD SCI USA, V99, P13248, DOI 10.1073/pnas.182225899; Chan GC, 2005, J IMMUNOL, V175, P3846, DOI 10.4049/jimmunol.175.6.3846; Chan Y, 2004, J BIOL CHEM, V279, P35087, DOI 10.1074/jbc.M405063200; Chen HB, 2006, CANCER RES, V66, P9009, DOI 10.1158/0008-5472.CAN-06-0101; Chen KF, 2005, NUCLEIC ACIDS RES, V33, P5190, DOI 10.1093/nar/gki839; Chen XX, 2005, MOL CELL BIOL, V25, P3209, DOI 10.1128/MCB.25.8.3209-3219.2005; Chi JT, 2006, PLOS MED, V3, P395, DOI 10.1371/journal.pmed.0030047; Choi SM, 2008, NUCLEIC ACIDS RES, V36, P6372, DOI 10.1093/nar/gkn620; Coisy M, 2004, MOL CELL, V15, P43, DOI 10.1016/j.molcel.2004.06.022; Coulet F, 2003, J BIOL CHEM, V278, P46230, DOI 10.1074/jbc.M305420200; Denko N, 2003, J BIOL CHEM, V278, P5744, DOI 10.1074/jbc.M212534200; Eltzschig HK, 2005, J EXP MED, V202, P1493, DOI 10.1084/jem.20050177; Fagan KA, 1999, J CLIN INVEST, V103, P291, DOI 10.1172/JCI3862; Fish JE, 2007, J BIOL CHEM, V282, P15652, DOI 10.1074/jbc.M608318200; Fish JE, 2006, CELL MOL LIFE SCI, V63, P144, DOI 10.1007/s00018-005-5421-8; Fish JE, 2005, J BIOL CHEM, V280, P24824, DOI 10.1074/jbc.M502115200; Flavin M, 2004, MOL CELL BIOL, V24, P7891, DOI 10.1128/MCB.24.18.7891-7901.2004; Gan YH, 2005, J BIOL CHEM, V280, P16467, DOI 10.1074/jbc.M412960200; GIAID A, 1995, NEW ENGL J MED, V333, P214, DOI 10.1056/NEJM199507273330403; Guccione E, 2006, NAT CELL BIOL, V8, P764, DOI 10.1038/ncb1434; Guillemette B, 2005, PLOS BIOL, V3, P2100, DOI 10.1371/journal.pbio.0030384; Hammond EM, 2002, MOL CELL BIOL, V22, P1834, DOI 10.1128/MCB.22.6.1834-1843.2002; Harikrishnan KN, 2005, NAT GENET, V37, P254, DOI 10.1038/ng1516; Hu CJ, 2006, J CEREBR BLOOD F MET, V26, P1519, DOI 10.1038/sj.jcbfm.9600304; Humbert M, 2004, J AM COLL CARDIOL, V43, p13S, DOI 10.1016/j.jacc.2004.02.029; Islam KN, 2006, MOL CELL BIOL, V26, P2901, DOI 10.1128/MCB.26.8.2901-2912.2006; Ivanov SV, 2007, ONCOGENE, V26, P802, DOI 10.1038/sj.onc.1209842; Jang MK, 2005, MOL CELL, V19, P523, DOI 10.1016/j.molcel.2005.06.027; Jin CY, 2009, NAT GENET, V41, P941, DOI 10.1038/ng.409; Jung JE, 2005, FASEB J, V19, P1296, DOI 10.1096/fj.04-3099fje; Karantzoulis-Fegaras F, 1999, J BIOL CHEM, V274, P3076, DOI 10.1074/jbc.274.5.3076; Karimi M, 2006, EXP CELL RES, V312, P1989, DOI 10.1016/j.yexcr.2006.03.006; Kim MS, 2001, NAT MED, V7, P437, DOI 10.1038/86507; Kitamuro T, 2003, J BIOL CHEM, V278, P9125, DOI 10.1074/jbc.M209939200; KOUREMBANAS S, 1991, J CLIN INVEST, V88, P1054, DOI 10.1172/JCI115367; KOUREMBANAS S, 1990, J CLIN INVEST, V86, P670, DOI 10.1172/JCI114759; Lemos FBC, 2003, J AM SOC NEPHROL, V14, P3278, DOI 10.1097/01.ASN.0000098683.92538.66; Li B, 2005, P NATL ACAD SCI USA, V102, P18385, DOI 10.1073/pnas.0507975102; Li Q, 2009, BIOCHIMIE, V91, P1307, DOI 10.1016/j.biochi.2009.07.001; Li ZB, 2003, EMBO J, V22, P1857, DOI 10.1093/emboj/cdg173; Linger J, 2006, EUKARYOT CELL, V5, P1780, DOI 10.1128/EC.00202-06; LIU YX, 1995, CIRC RES, V77, P638, DOI 10.1161/01.RES.77.3.638; Loyola A, 2006, MOL CELL, V24, P309, DOI 10.1016/j.molcel.2006.08.019; Mahon PC, 2001, GENE DEV, V15, P2675, DOI 10.1101/gad.924501; MARSDEN PA, 1992, FEBS LETT, V307, P287, DOI 10.1016/0014-5793(92)80697-F; Martinez-Campa C, 2004, MOL CELL, V15, P69, DOI 10.1016/j.molcel.2004.05.022; Matouk CC, 2008, CIRC RES, V102, P873, DOI 10.1161/CIRCRESAHA.107.171025; Mazure NM, 2002, CANCER RES, V62, P1158; McQuillan Lynda P., 1994, American Journal of Physiology, V267, pH1921; Mihaylova VT, 2003, MOL CELL BIOL, V23, P3265, DOI 10.1128/MCB.23.9.3265-3273.2003; Millar CB, 2006, GENE DEV, V20, P711, DOI 10.1101/gad.1395506; Moudgil R, 2005, J APPL PHYSIOL, V98, P390, DOI 10.1152/japplphysiol.00733.2004; Murphy DJ, 1999, MOL CELL BIOL, V19, P2724; Nakamura H, 2008, ONCOGENE, V27, P4200, DOI 10.1038/onc.2008.58; Ozaki M, 2001, HYPERTENSION, V37, P322, DOI 10.1161/01.HYP.37.2.322; Ozer A, 2005, P NATL ACAD SCI USA, V102, P7481, DOI 10.1073/pnas.0502716102; Pearson DL, 2001, NEW ENGL J MED, V344, P1832, DOI 10.1056/NEJM200106143442404; Pena PV, 2006, NATURE, V442, P100, DOI 10.1038/nature04814; Phelan MW, 1996, J CELL PHYSIOL, V167, P469, DOI 10.1002/(SICI)1097-4652(199606)167:3<469::AID-JCP11>3.3.CO;2-C; Raisner RM, 2005, CELL, V123, P233, DOI 10.1016/j.cell.2005.10.002; Rao SH, 2001, J IMMUNOL, V167, P4494, DOI 10.4049/jimmunol.167.8.4494; Robb GB, 2004, J BIOL CHEM, V279, P37982, DOI 10.1074/jbc.M400271200; Roberts CWM, 2004, NAT REV CANCER, V4, P133, DOI 10.1038/nrc1273; Schioppa T, 2003, J EXP MED, V198, P1391, DOI 10.1084/jem.20030267; SOBEL RE, 1995, P NATL ACAD SCI USA, V92, P1237, DOI 10.1073/pnas.92.4.1237; Strobeck MW, 2000, P NATL ACAD SCI USA, V97, P7748, DOI 10.1073/pnas.97.14.7748; Tai SC, 2004, ARTERIOSCL THROM VAS, V24, P405, DOI 10.1161/01.ATV.0000109171.50229.33; Teichert AM, 2000, AM J PHYSIOL-HEART C, V278, pH1352, DOI 10.1152/ajpheart.2000.278.4.H1352; Wang S, 2002, EMBO J, V21, P3019, DOI 10.1093/emboj/cdf302; Ward ME, 2005, J CLIN INVEST, V115, P3128, DOI 10.1172/JCI20806; Wellmann S, 2008, BIOCHEM BIOPH RES CO, V372, P892, DOI 10.1016/j.bbrc.2008.05.150; Wilcox JN, 1997, ARTERIOSCL THROM VAS, V17, P2479, DOI 10.1161/01.ATV.17.11.2479; Wysocka J, 2006, NATURE, V442, P86, DOI 10.1038/nature04815; Zhao J, 2005, MOL CELL BIOL, V25, P8985, DOI 10.1128/MCB.25.20.8985-8999.2005	83	104	106	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 8	2010	285	2					810	826		10.1074/jbc.M109.067868	http://dx.doi.org/10.1074/jbc.M109.067868			17	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	539MH	19880524	Green Published, hybrid			2022-12-25	WOS:000273258200002
J	Okemefuna, AI; Stach, L; Rana, S; Buetas, AJZ; Gor, J; Perkins, SJ				Okemefuna, Azubuike I.; Stach, Lasse; Rana, Sudeep; Buetas, Akim J. Ziai; Gor, Jayesh; Perkins, Stephen J.			C-reactive Protein Exists in an NaCl Concentration-dependent Pentamer-Decamer Equilibrium in Physiological Buffer	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMYLOID-P COMPONENT; NEOANTIGEN NEO-CRP; NEUTRON-SCATTERING; HYDRODYNAMIC PROPERTIES; SEDIMENTATION-VELOCITY; COMPLEMENT ACTIVATION; X-RAY; 3-DIMENSIONAL STRUCTURE; LAMM EQUATION; CALCIUM	C-reactive protein (CRP) is an acute phase protein of the pentraxin family that binds ligands in a Ca2+-dependent manner, and activates complement. Knowledge of its oligomeric state in solution and at surfaces is essential for functional studies. Analytical ultracentrifugation showed that CRP in 2 mM Ca2+ exhibits a rapid pentamer-decamer equilibrium. The proportion of decamer decreased with an increase in NaCl concentration. The sedimentation coefficients s(20,w)(0) of pentameric and decameric CRP were 6.4 S and in excess of 7.6 S, respectively. In the absence of Ca2+, CRP partially dissociates into its protomers and the NaCl concentration dependence of the pentamer-decamer equilibrium is much reduced. By x-ray scattering, the radius of gyration R-G values ranged from 3.7 nm for the pentamer to above 4.0 nm for the decamer. An averaged K-D value of 21 mu M in solution (140 mM NaCl, 2 mM Ca2+) was determined by x-ray scattering and modeling based on crystal structures for the pentamer and decamer. Surface plasmon resonance showed that CRP self-associates on a surface with immobilized CRP with a similar K-D value of 23 mu M (140 mM NaCl, 2 mM Ca2+), whereas CRP aggregates in low salt. It is concluded that CRP is reproducibly observed in a pentamer-decamer equilibrium in physiologically relevant concentrations both in solution and on surfaces. Both 2 mM Ca2+ and 140 mM NaCl are essential for the integrity of CRP in functional studies and understanding the role of CRP in the acute phase response.	[Okemefuna, Azubuike I.; Stach, Lasse; Rana, Sudeep; Buetas, Akim J. Ziai; Gor, Jayesh; Perkins, Stephen J.] UCL, Dept Biol Mol & Struct, London WC1E 6BT, England	University of London; University College London	Perkins, SJ (corresponding author), UCL, Dept Biol Mol & Struct, Darwin Bldg,Gower St, London WC1E 6BT, England.	s.perkins@medsch.ucl.ac.uk			Uppsala University, Sweden; University College London; Overseas Research Scholarship; Biotechnology and Biological Sciences Research Council [BB/E013104/1] Funding Source: researchfish; BBSRC [BB/E013104/1] Funding Source: UKRI	Uppsala University, Sweden; University College London(General Electric); Overseas Research Scholarship; Biotechnology and Biological Sciences Research Council(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC)); BBSRC(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC))	This work was awarded a poster prize at the 18th International Analytical Ultracentrifugation Conference, Uppsala University, Sweden (September 13-18, 2009).; Supported by a Graduate School Research Scholarship from University College London and an Overseas Research Scholarship.	Ashton AW, 1997, J MOL BIOL, V272, P408, DOI 10.1006/jmbi.1997.1271; Black S, 2004, J BIOL CHEM, V279, P48487, DOI 10.1074/jbc.R400025200; Blizniukov OP, 2003, MOL BIOL+, V37, P912, DOI 10.1023/B:MBIL.0000008361.22136.c8; Bonner A, 2007, J BIOL CHEM, V282, P16969, DOI 10.1074/jbc.M701281200; Bonner A, 2009, J BIOL CHEM, V284, P5077, DOI 10.1074/jbc.M807529200; Christopeit T, 2009, ANAL BIOCHEM, V391, P39, DOI 10.1016/j.ab.2009.04.037; CLAUS DR, 1977, J IMMUNOL, V118, P83; Cole JL, 2008, METHOD CELL BIOL, V84, P143, DOI 10.1016/S0091-679X(07)84006-4; Dam J, 2005, BIOPHYS J, V89, P651, DOI 10.1529/biophysj.105.059584; de la Torre JG, 2000, BIOPHYS J, V78, P719, DOI 10.1016/S0006-3495(00)76630-6; DEBEER FC, 1982, J IMMUNOL METHODS, V50, P17, DOI 10.1016/0022-1759(82)90300-3; DEBEER FC, 1982, J EXP MED, V156, P230, DOI 10.1084/jem.156.1.230; DELATORRE JG, 1994, BIOPHYS J, V67, P530, DOI 10.1016/S0006-3495(94)80512-0; Diehl EE, 2000, AM J MED SCI, V319, P79, DOI 10.1097/00000441-200002000-00002; EGENHOFER C, 1993, HEPATOLOGY, V18, P1216; FILEP J, 1989, LIFE SCI, V44, P517, DOI 10.1016/0024-3205(89)90613-9; Gaboriaud C, 2004, TRENDS IMMUNOL, V25, P368, DOI 10.1016/j.it.2004.04.008; Gilbert HE, 2005, J MOL BIOL, V346, P859, DOI 10.1016/j.jmb.2004.12.006; Glatter O., 1982, SMALL ANGLE X RAY SC; Hurwitz S, 1996, CRIT REV BIOCHEM MOL, V31, P41, DOI 10.3109/10409239609110575; JIANG HX, 1991, J IMMUNOL, V146, P2324; Khreiss T, 2002, J BIOL CHEM, V277, P40775, DOI 10.1074/jbc.M205378200; KINOSHITA CM, 1989, BIOCHEMISTRY-US, V28, P9840, DOI 10.1021/bi00451a044; Li KY, 2008, J MOL BIOL, V384, P137, DOI 10.1016/j.jmb.2008.08.084; Mori, 1999, SIZE EXCLUSION CHROM; Motie M, 1996, J IMMUNOL, V156, P4435; Narayanan T, 2001, NUCL INSTRUM METH A, V467, P1005, DOI 10.1016/S0168-9002(01)00553-8; NELSON SR, 1991, CLIN CHIM ACTA, V200, P191, DOI 10.1016/0009-8981(91)90090-Y; Okemefuna AI, 2010, J BIOL CHEM, V285, P1053, DOI 10.1074/jbc.M109.044529; OSMAND AP, 1977, P NATL ACAD SCI USA, V74, P739, DOI 10.1073/pnas.74.2.739; Pepys MB, 2003, J CLIN INVEST, V111, P1805, DOI 10.1172/JCI200318921; PERKINS SJ, 1986, EUR J BIOCHEM, V157, P169, DOI 10.1111/j.1432-1033.1986.tb09653.x; Perkins SJ, 2001, BIOPHYS CHEM, V93, P129, DOI 10.1016/S0301-4622(01)00216-2; PERKINS SJ, 1983, J MOL BIOL, V168, P847, DOI 10.1016/S0022-2836(83)80078-3; PERKINS SJ, 1986, PROTIDES BIOL FLUIDS, V34, P323; Perkins SJ, 2008, METHOD CELL BIOL, V84, P375, DOI 10.1016/S0091-679X(07)84013-1; POTEMPA LA, 1988, INFLAMMATION, V12, P391, DOI 10.1007/BF00915774; POTEMPA LA, 1983, MOL IMMUNOL, V20, P1165, DOI 10.1016/0161-5890(83)90140-2; POTEMPA LA, 1987, MOL IMMUNOL, V24, P531, DOI 10.1016/0161-5890(87)90028-9; Ramadan MAM, 2002, ACTA CRYSTALLOGR D, V58, P992, DOI 10.1107/S0907444902005693; REES RF, 1988, CLIN IMMUNOL IMMUNOP, V48, P95, DOI 10.1016/0090-1229(88)90160-2; ROWE IF, 1984, CLIN EXP IMMUNOL, V58, P237; SAMOLS D, 1985, BIOCHEM J, V227, P759, DOI 10.1042/bj2270759; Schuck P, 1998, BIOPHYS J, V75, P1503, DOI 10.1016/S0006-3495(98)74069-X; Schuck P, 2000, BIOPHYS J, V78, P1606, DOI 10.1016/S0006-3495(00)76713-0; SEMENYUK AV, 1991, J APPL CRYSTALLOGR, V24, P537, DOI 10.1107/S002188989100081X; Shrive AK, 1996, NAT STRUCT BIOL, V3, P346, DOI 10.1038/nsb0496-346; SIEGEL J, 1974, J EXP MED, V140, P631, DOI 10.1084/jem.140.3.631; SIEGEL J, 1975, J EXP MED, V142, P709, DOI 10.1084/jem.142.3.709; Tanious FA, 2008, METHOD CELL BIOL, V84, P53, DOI 10.1016/S009911-679X(07)84003-9; Taylor KE, 2007, IMMUNOLOGY, V120, P404, DOI 10.1111/j.1365-2567.2006.02516.x; Thompson D, 1999, STRUCTURE, V7, P169, DOI 10.1016/S0969-2126(99)80023-9; VOLANAKI.JE, 1971, P SOC EXP BIOL MED, V136, P612; VOLANAKIS JE, 1982, ANN NY ACAD SCI, V389, P235, DOI 10.1111/j.1749-6632.1982.tb22140.x; VOLANAKIS JE, 1978, J IMMUNOL METHODS, V23, P285, DOI 10.1016/0022-1759(78)90203-X; Wang HW, 2001, BIOCHEM BIOPH RES CO, V288, P75, DOI 10.1006/bbrc.2001.5733; Wu Y, 2002, BIOCHEMISTRY-MOSCOW+, V67, P1377, DOI 10.1023/A:1021862027061	57	30	31	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 8	2010	285	2					1041	1052		10.1074/jbc.M109.044495	http://dx.doi.org/10.1074/jbc.M109.044495			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	539MH	19903811	Green Published, hybrid			2022-12-25	WOS:000273258200025
J	Castellani, M; Covian, R; Kleinschroth, T; Anderka, O; Ludwig, B; Trumpower, BL				Castellani, Michela; Covian, Raul; Kleinschroth, Thomas; Anderka, Oliver; Ludwig, Bernd; Trumpower, Bernard L.			Direct Demonstration of Half-of-the-sites Reactivity in the Dimeric Cytochrome bc(1) Complex ENZYME WITH ONE INACTIVE MONOMER IS FULLY ACTIVE BUT UNABLE TO ACTIVATE THE SECOND UBIQUINOL OXIDATION SITE IN RESPONSE TO LIGAND BINDING AT THE UBIQUINONE REDUCTION SITE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BOVINE HEART-MITOCHONDRIA; IRON-SULFUR PROTEIN; ELECTRON-TRANSFER; PARACOCCUS-DENITRIFICANS; Q-CYCLE; REGULATORY INTERACTIONS; CENTER-N; MECHANISM; COMMUNICATION; KINETICS	We previously proposed that the dimeric cytochrome bc(1) complex exhibits half-of-the-sites reactivity for ubiquinol oxidation and rapid electron transfer between bc(1) monomers (Covian, R., Kleinschroth, T., Ludwig, B., and Trumpower, B. L. (2007) J. Biol. Chem. 282, 22289-22297). Here, we demonstrate the previously proposed half-of-the-sites reactivity and intermonomeric electron transfer by characterizing the kinetics of ubiquinol oxidation in the dimeric bc(1) complex from Paracoccus denitrificans that contains an inactivating Y147S mutation in one or both cytochrome b subunits. The enzyme with a Y147S mutation in one cytochrome b subunit was catalytically fully active, whereas the activity of the enzyme with a Y147S mutation in both cytochrome b subunits was only 10-16% of that of the enzyme with fully wild-type or heterodimeric cytochrome b subunits. Enzyme with one inactive cytochrome b subunit was also indistinguishable from the dimer with two wild-type cytochrome b subunits in rate and extent of reduction of cytochromes b and c(1) by ubiquinol under pre-steady-state conditions in the presence of antimycin. However, the enzyme with only one mutated cytochrome b subunit did not show the stimulation in the steady-state rate that was observed in the wildtype dimeric enzyme at low concentrations of antimycin, confirming that the half-of-the-sites reactivity for ubiquinol oxidation can be regulated in the wild-type dimer by binding of inhibitor to one ubiquinone reduction site.	[Castellani, Michela; Kleinschroth, Thomas; Anderka, Oliver; Ludwig, Bernd] Goethe Univ Frankfurt, Inst Biochem, D-60438 Frankfurt, Germany; [Castellani, Michela; Kleinschroth, Thomas; Anderka, Oliver; Ludwig, Bernd] Cluster Excellence Macromol Complexes, D-60438 Frankfurt, Germany; [Covian, Raul; Trumpower, Bernard L.] Dartmouth Med Sch, Dept Biochem, Hanover, NH 03755 USA	Goethe University Frankfurt; Dartmouth College	Ludwig, B (corresponding author), Goethe Univ Frankfurt, Inst Biochem, Max von Laue Str 9, D-60438 Frankfurt, Germany.	ludwig@em.uni-frankfurt.de; trumpower@dartmouth.edu			National Institutes of Health Research [GM 20379]; Deutsche Forschungsgemeinschaft [SFB 472]; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM020379, R01GM020379] Funding Source: NIH RePORTER	National Institutes of Health Research(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Deutsche Forschungsgemeinschaft(German Research Foundation (DFG)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	This work was supported by National Institutes of Health Research Grant GM 20379 and Deutsche Forschungsgemeinschaft Grant SFB 472.	ANDERKA O, 2005, THESIS J WOLFGANGGOE; ANTOINE R, 1992, MOL MICROBIOL, V6, P1785, DOI 10.1111/j.1365-2958.1992.tb01351.x; BERDEN JA, 1970, BIOCHIM BIOPHYS ACTA, V216, P237, DOI 10.1016/0005-2728(70)90215-X; Berry EA, 2004, PHOTOSYNTH RES, V81, P251, DOI 10.1023/B:PRES.0000036888.18223.0e; Cooley JW, 2009, BIOCHEMISTRY-US, V48, P1888, DOI 10.1021/bi802216h; Covian R, 2005, J BIOL CHEM, V280, P22732, DOI 10.1074/jbc.M413592200; Covian R, 2004, J BIOL CHEM, V279, P15040, DOI 10.1074/jbc.M400193200; Covian R, 2008, BBA-BIOENERGETICS, V1777, P1079, DOI 10.1016/j.bbabio.2008.04.022; Covian R, 2008, BBA-BIOENERGETICS, V1777, P1044, DOI 10.1016/j.bbabio.2008.04.008; Covian R, 2007, J BIOL CHEM, V282, P22289, DOI 10.1074/jbc.M702132200; Covian R, 2006, J BIOL CHEM, V281, P30925, DOI 10.1074/jbc.M604694200; Covian R, 2009, J BIOL CHEM, V284, P8605, DOI 10.1074/jbc.M808914200; Crofts AR, 2008, BBA-BIOENERGETICS, V1777, P1001, DOI 10.1016/j.bbabio.2008.04.037; Crofts AR, 2003, J BIOL CHEM, V278, P36191, DOI 10.1074/jbc.M305461200; GERHUS E, 1992, THESIS LUBECK MED U; Gutierrez-Cirlos EB, 2002, J BIOL CHEM, V277, P1195, DOI 10.1074/jbc.M109097200; Hunte C, 2000, STRUCTURE, V8, P669, DOI 10.1016/S0969-2126(00)00152-0; Margoliash E, 1967, METHOD ENZYMOL, V10, P339; Morgner N, 2007, J AM SOC MASS SPECTR, V18, P1429, DOI 10.1016/j.jasms.2007.04.013; Moser CC, 2006, BBA-BIOENERGETICS, V1757, P1096, DOI 10.1016/j.bbabio.2006.04.015; Muller FL, 2003, BIOCHEMISTRY-US, V42, P6493, DOI 10.1021/bi0342160; Pfitzner U, 1998, J BIOENERG BIOMEMBR, V30, P89, DOI 10.1023/A:1020515713103; RICH PR, 1984, BIOCHIM BIOPHYS ACTA, V768, P53, DOI 10.1016/0304-4173(84)90007-7; Saribas AS, 1995, BIOCHEMISTRY-US, V34, P16004, DOI 10.1021/bi00049a014; Schroter T, 1998, EUR J BIOCHEM, V255, P100, DOI 10.1046/j.1432-1327.1998.2550100.x; Snyder C, 1998, BBA-BIOENERGETICS, V1365, P125, DOI 10.1016/S0005-2728(98)00052-8; Solmaz SRN, 2008, J BIOL CHEM, V283, P17542, DOI 10.1074/jbc.M710126200; TRUMPOWER BL, 1979, J BIOL CHEM, V254, P8697; TRUMPOWER BL, 1990, J BIOL CHEM, V265, P11409; VONJAGOW G, 1986, METHOD ENZYMOL, V126, P253; Xia D, 1997, SCIENCE, V277, P60, DOI 10.1126/science.277.5322.60; Yang SQ, 2008, J BIOL CHEM, V283, P28767, DOI 10.1074/jbc.M803013200; Zhang ZL, 1998, NATURE, V392, P677, DOI 10.1038/33612	33	56	56	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 1	2010	285	1					502	510		10.1074/jbc.M109.072959	http://dx.doi.org/10.1074/jbc.M109.072959			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	536UT	19892700	Green Published, hybrid			2022-12-25	WOS:000273070100052
J	Chawla, B; Jhingran, A; Singh, S; Tyagi, N; Park, MH; Srinivasan, N; Roberts, SC; Madhubala, R				Chawla, Bhavna; Jhingran, Anupam; Singh, Sushma; Tyagi, Nidhi; Park, Myung Hee; Srinivasan, N.; Roberts, Sigrid C.; Madhubala, Rentala			Identification and Characterization of a Novel Deoxyhypusine Synthase in Leishmania donovani	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENZYME-SUBSTRATE INTERMEDIATE; CELL VIABILITY; AMINO-ACID; SACCHAROMYCES-CEREVISIAE; 3-DIMENSIONAL STRUCTURES; HYPUSINE FORMATION; CRYSTAL-STRUCTURE; PROTEIN; SPERMIDINE; INHIBITION	Deoxyhypusine synthase, an NAD(+)-dependent enzyme, catalyzes the first step in the post-translational synthesis of an unusual amino acid, hypusine (N-epsilon-(4-amino-2-hydroxybutyl)lysine), in the eukaryotic initiation factor 5A precursor protein. Two putative deoxyhypusine synthase (DHS) sequences have been identified in the Leishmania donovani genome, which are present on chromosomes 20: DHSL20 (DHS-like gene from chromosome 20) and DHS34 (DHS from chromosome 34). Although both sequences exhibit an overall conservation of key residues, DHSL20 protein lacks a critical lysine residue, and the recombinant protein showed no DHS activity in vitro. However, DHS34 contains the critical lysine residue, and the recombinant DHS34 effectively catalyzed deoxyhypusine synthesis. Furthermore, in vivo labeling confirmed that hypusination of eukaryotic initiation factor 5A occurs in intact Leishmania parasites. Interestingly, the DHS34 is much longer, with 601 amino acids, compared with the human DHS enzyme (369 amino acids) and contains several unique insertions. To study the physiological role of DHS34 in Leishmania, gene deletion mutations were attempted via targeted gene replacement. However, chromosomal null mutants of DHS34 could only be obtained in the presence of a DHS34-containing episome. The present data provide evidence that DHS34 is essential for L. donovani and that structural differences in the human and leishmanial DHS enzyme may be exploited for designing selective inhibitors against the parasite.	[Chawla, Bhavna; Jhingran, Anupam; Singh, Sushma; Madhubala, Rentala] Jawaharlal Nehru Univ, Sch Life Sci, New Delhi 110067, India; [Tyagi, Nidhi; Srinivasan, N.] Indian Inst Sci, Mol Biophys Unit, Bangalore 560012, Karnataka, India; [Park, Myung Hee] NIDCR, Oral & Pharyngeal Canc Branch, NIH, Bethesda, MD 20892 USA; [Roberts, Sigrid C.] Pacific Univ, Sch Pharm, Portland, OR 97123 USA	Jawaharlal Nehru University, New Delhi; Indian Institute of Science (IISC) - Bangalore; National Institutes of Health (NIH) - USA; NIH National Institute of Dental & Craniofacial Research (NIDCR)	Madhubala, R (corresponding author), Jawaharlal Nehru Univ, Sch Life Sci, New Delhi 110067, India.	madhubala@mail.jnu.ac.in	madhubala, Rentala/C-3445-2015	Tyagi, Nidhi/0000-0002-2065-9051; Singh, Sushma/0000-0002-7089-6442; madhubala, rentala/0000-0002-0034-399X	National Institutes of Health; Council of Scientific and Industrial Research, India; NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH [ZIADE000608] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Council of Scientific and Industrial Research, India(Council of Scientific & Industrial Research (CSIR) - India); NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))	This work was authored, in whole or in part, by National Institutes of Health staff. This work is supported by a grant from the Council of Scientific and Industrial Research, India ( to R. M.).	ABBRUZZESE A, 1986, J BIOL CHEM, V261, P3085; Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; Bateman A, 2004, NUCLEIC ACIDS RES, V32, pD138, DOI [10.1093/nar/gkt1223, 10.1093/nar/gkp985, 10.1093/nar/gkr1065]; Berman HM, 2000, NUCLEIC ACIDS RES, V28, P235, DOI 10.1093/nar/28.1.235; Boitz JM, 2009, INFECT IMMUN, V77, P756, DOI 10.1128/IAI.01236-08; Brochier C, 2004, GENE, V330, P169, DOI 10.1016/j.gene.2004.01.018; BYERS TL, 1994, BIOCHEM J, V303, P363, DOI 10.1042/bj3030363; CHEN KY, 1988, FEBS LETT, V229, P325, DOI 10.1016/0014-5793(88)81149-9; COOPER HL, 1983, P NATL ACAD SCI-BIOL, V80, P1854, DOI 10.1073/pnas.80.7.1854; FAIRLAMB AH, 1992, ANNU REV MICROBIOL, V46, P695, DOI 10.1146/annurev.micro.46.1.695; Gowri VS, 2006, NUCLEIC ACIDS RES, V34, pD243, DOI 10.1093/nar/gkj043; Goyard S, 2003, MOL BIOCHEM PARASIT, V130, P31, DOI 10.1016/S0166-6851(03)00142-7; HANAUSKEABEL HM, 1994, BBA-MOL CELL RES, V1221, P115, DOI 10.1016/0167-4889(94)90003-5; Hauber I, 2005, J CLIN INVEST, V115, P76, DOI 10.1172/JCI200521949; JAKUS J, 1993, J BIOL CHEM, V268, P13151; JOE YA, 1995, J BIOL CHEM, V270, P22386, DOI 10.1074/jbc.270.38.22386; Joe YA, 1997, J BIOL CHEM, V272, P32679, DOI 10.1074/jbc.272.51.32679; KANG KR, 1995, J BIOL CHEM, V270, P18408, DOI 10.1074/jbc.270.31.18408; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; Lee GH, 2001, BIOCHEM J, V355, P841, DOI 10.1042/bj3550841; Liao DI, 1998, STRUCTURE, V6, P23, DOI 10.1016/S0969-2126(98)00004-5; Marchler-Bauer A, 2003, NUCLEIC ACIDS RES, V31, P383, DOI 10.1093/nar/gkg087; MORRIS AL, 1992, PROTEINS, V12, P345, DOI 10.1002/prot.340120407; Muller S, 2001, TRENDS PARASITOL, V17, P242, DOI 10.1016/S1471-4922(01)01908-0; MURPHEY RJ, 1987, J BIOL CHEM, V262, P15033; Murray HW, 2001, ANTIMICROB AGENTS CH, V45, P2185, DOI 10.1128/AAC.45.8.2185-2197.2001; Nishimura K, 2005, BIOCHEM J, V385, P779, DOI 10.1042/BJ20041477; Ober D, 2003, J BIOL CHEM, V278, P12805, DOI 10.1074/jbc.M207112200; Park MH, 1998, J BIOL CHEM, V273, P1677, DOI 10.1074/jbc.273.3.1677; PARK MH, 1982, J BIOL CHEM, V257, P7217; PARK MH, 1994, J BIOL CHEM, V269, P27827; PARK MH, 1988, J BIOL CHEM, V263, P15264; PARK MH, 1981, P NATL ACAD SCI-BIOL, V78, P2869, DOI 10.1073/pnas.78.5.2869; Roberts SC, 2001, MOL BIOCHEM PARASIT, V115, P217, DOI 10.1016/S0166-6851(01)00293-6; Robinson KA, 2003, MOL BIOCHEM PARASIT, V128, P217, DOI 10.1016/S0166-6851(03)00079-3; SALI A, 1995, MOL MED TODAY, V1, P270, DOI 10.1016/s1357-4310(95)91170-7; Sasaki K, 1996, FEBS LETT, V384, P151, DOI 10.1016/0014-5793(96)00310-9; SCHNIER J, 1991, MOL CELL BIOL, V11, P3105, DOI 10.1128/MCB.11.6.3105; SHIBA T, 1971, BIOCHIM BIOPHYS ACTA, V244, P523, DOI 10.1016/0304-4165(71)90069-9; SIPPL MJ, 1993, PROTEINS, V17, P355, DOI 10.1002/prot.340170404; Sundar S, 2001, TROP MED INT HEALTH, V6, P849, DOI 10.1046/j.1365-3156.2001.00778.x; Sundar S, 2000, CLIN INFECT DIS, V31, P1104, DOI 10.1086/318121; Tamura K, 2007, MOL BIOL EVOL, V24, P1596, DOI 10.1093/molbev/msm092; Umland TC, 2004, J BIOL CHEM, V279, P28697, DOI 10.1074/jbc.M404095200; Wiederstein M, 2007, NUCLEIC ACIDS RES, V35, pW407, DOI 10.1093/nar/gkm290; Willert EK, 2007, P NATL ACAD SCI USA, V104, P8275, DOI 10.1073/pnas.0701111104; WOHL T, 1993, MOL GEN GENET, V241, P305; Wolff EC, 1999, YEAST, V15, P43; WOLFF EC, 1990, J BIOL CHEM, V265, P4793; Wolff EC, 1997, J BIOL CHEM, V272, P15865, DOI 10.1074/jbc.272.25.15865; Wolff EC, 2000, J BIOL CHEM, V275, P9170, DOI 10.1074/jbc.275.13.9170	51	38	42	0	3	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 1	2010	285	1					453	463		10.1074/jbc.M109.048850	http://dx.doi.org/10.1074/jbc.M109.048850			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	536UT	19880510	hybrid, Green Published			2022-12-25	WOS:000273070100047
J	Poleshko, A; Einarson, MB; Shalginskikh, N; Zhang, RG; Adams, PD; Skalka, AM; Katz, RA				Poleshko, Andrey; Einarson, Margret B.; Shalginskikh, Natalia; Zhang, Rugang; Adams, Peter D.; Skalka, Anna Marie; Katz, Richard A.			Identification of a Functional Network of Human Epigenetic Silencing Factors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HISTONE DEACETYLASE INHIBITORS; CHROMATIN MODIFICATIONS; DNA METHYLATION; BINDING MODULES; CANCER; METHYLTRANSFERASE; TRANSCRIPTION; SETDB1; CELLS; H3	Epigenetic silencing is mediated by families of factors that place, remove, read, and transmit repressive histone and DNA methylation marks on chromatin. How the roles for these functionally diverse factors are specified and integrated is the subject of intense study. To address these questions, HeLa cells harboring epigenetically silent green fluorescent protein reporter genes were interrogated with a small interference RNA library targeting 200 predicted epigenetic regulators, including potential activators, silencers, chromatin remodelers, and ancillary factors. Using this approach, individual, or combinatorial requirements for specific epigenetic silencing factors could be detected by measuring green fluorescent protein reactivation after small interference RNA-based factor knockdown. In our analyses, we identified a specific subset of 15 epigenetic factors that are candidates for participation in a functional epigenetic silencing network in human cells. These factors include histone deacetylase 1, de novo DNA methyltransferase 3A, components of the polycomb PRC1 complex (RING1 and HPH2), and the histone lysine methyltransferases KMT1E and KMT5C. Roles were also detected for two TRIM protein family members, the cohesin component Rad21, and the histone chaperone CHAF1A (CAF-1 p150). Remarkably, combinatorial knockdown of factors was not required for reactivation, indicating little functional redundancy. Consistent with this interpretation, knockdown of either KMT1E or CHAF1A resulted in a loss of multiple histone-repressive marks and concomitant gain of activation marks on the promoter during reactivation. These results reveal how functionally diverse factors may cooperate to maintain gene silencing during normal development or in disease. Furthermore, the findings suggest an avenue for discovery of new targets for epigenetic therapies.	[Poleshko, Andrey; Einarson, Margret B.; Shalginskikh, Natalia; Zhang, Rugang; Adams, Peter D.; Skalka, Anna Marie; Katz, Richard A.] Fox Chase Canc Ctr, Inst Canc Res, Philadelphia, PA 19111 USA	Fox Chase Cancer Center	Katz, RA (corresponding author), Fox Chase Canc Ctr, Inst Canc Res, 333 Cottman Ave, Philadelphia, PA 19111 USA.	Richard.Katz@fccc.edu		Poleshko, Andrey/0000-0002-6656-2941; Adams, Peter/0000-0002-0684-1770	National Institutes of Health [CA71515, CA06927, NS053666, DK082498]; Commonwealth of Pennsylvania; American Association for Cancer Research; NATIONAL CANCER INSTITUTE [R01CA071515, P30CA006927] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI040385] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK082498] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R21NS053666] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Commonwealth of Pennsylvania; American Association for Cancer Research; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))	This work was supported, in whole or in part, by National Institutes of Health Grants CA71515 and CA06927. This work was also supported by an appropriation from the Commonwealth of Pennsylvania.; Recipient of an American Association for Cancer Research Centennial Predoctoral Fellowship in Cancer Research.; Supported by the Pennsylvania Department of Health and by NIH Grants NS053666 and DK082498. Towhomcorrespondence should be addressed: Institute for Cancer Research, Fox Chase Cancer Center, 333 Cottman Ave., Philadelphia, PA 19111. Tel.: 215-728-3668; Fax: 215-728-2778; E-mail: Richard.Katz@fccc.edu.	Allis CD, 2007, CELL, V131, P633, DOI 10.1016/j.cell.2007.10.039; Berger SL, 2007, NATURE, V447, P407, DOI 10.1038/nature05915; Bernstein BE, 2007, CELL, V128, P669, DOI 10.1016/j.cell.2007.01.033; Bolden JE, 2006, NAT REV DRUG DISCOV, V5, P769, DOI 10.1038/nrd2133; Cedar H, 2009, NAT REV GENET, V10, P295, DOI 10.1038/nrg2540; Dong KB, 2008, EMBO J, V27, P2691, DOI 10.1038/emboj.2008.193; Esteller M, 2006, BRIT J CANCER, V94, P179, DOI 10.1038/sj.bjc.6602918; Feinberg AP, 2007, NATURE, V447, P433, DOI 10.1038/nature05919; Feinberg AP, 2004, NAT REV CANCER, V4, P143, DOI 10.1038/nrc1279; Fischle W, 2008, GENE DEV, V22, P3375, DOI 10.1101/gad.1759708; Frescas D, 2008, CELL CYCLE, V7, P3539, DOI 10.4161/cc.7.22.7062; Grewal SIS, 2007, NAT REV GENET, V8, P35, DOI 10.1038/nrg2008; Groothuis TAM, 2006, CELL DIV, V1, DOI 10.1186/1747-1028-1-21; Hake S B, 2007, Br J Cancer, V96 Suppl, pR31; Jones PA, 2007, CELL, V128, P683, DOI 10.1016/j.cell.2007.01.029; Katz RA, 2007, J VIROL, V81, P2592, DOI 10.1128/JVI.01643-06; Klose RJ, 2006, TRENDS BIOCHEM SCI, V31, P89, DOI 10.1016/j.tibs.2005.12.008; Kouzarides T, 2007, CELL, V128, P693, DOI 10.1016/j.cell.2007.02.005; Latham JA, 2007, NAT STRUCT MOL BIOL, V14, P1017, DOI 10.1038/nsmb1307; Li B, 2007, CELL, V128, P707, DOI 10.1016/j.cell.2007.01.015; Li HW, 2006, J BIOL CHEM, V281, P19489, DOI 10.1074/jbc.M513249200; Lieberman PM, 2006, TRENDS MICROBIOL, V14, P132, DOI 10.1016/j.tim.2006.01.001; Marks PA, 2007, NAT BIOTECHNOL, V25, P84, DOI 10.1038/nbt1272; Martin C, 2007, CURR OPIN CELL BIOL, V19, P266, DOI 10.1016/j.ceb.2007.04.002; Narezkina A, 2004, J VIROL, V78, P11656, DOI 10.1128/JVI.78.21.11656-11663.2004; Peng HZ, 2002, J MOL BIOL, V320, P629, DOI 10.1016/S0022-2836(02)00477-1; Peters JM, 2008, GENE DEV, V22, P3089, DOI 10.1101/gad.1724308; Poleshko A, 2008, J VIROL, V82, P2313, DOI 10.1128/JVI.01882-07; Quivy JP, 2008, NAT STRUCT MOL BIOL, V15, P972, DOI 10.1038/nsmb.1470; Ruthenburg AJ, 2007, NAT REV MOL CELL BIO, V8, P983, DOI 10.1038/nrm2298; Ruthenburg AJ, 2007, MOL CELL, V25, P15, DOI 10.1016/j.molcel.2006.12.014; Sarraf SA, 2004, MOL CELL, V15, P595, DOI 10.1016/j.molcel.2004.06.043; Schultz DC, 2002, GENE DEV, V16, P919, DOI 10.1101/gad.973302; Shi Y, 2007, MOL CELL, V25, P1, DOI 10.1016/j.molcel.2006.12.010; Strahl BD, 2000, NATURE, V403, P41, DOI 10.1038/47412; Taverna SD, 2007, NAT STRUCT MOL BIOL, V14, P1025, DOI 10.1038/nsmb1338; Wang HB, 2004, NATURE, V431, P873, DOI 10.1038/nature02985; Yoo CB, 2006, NAT REV DRUG DISCOV, V5, P37, DOI 10.1038/nrd1930; Zhang JH, 1999, J BIOMOL SCREEN, V4, P67, DOI 10.1177/108705719900400206	39	51	57	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 1	2010	285	1					422	433		10.1074/jbc.M109.064667	http://dx.doi.org/10.1074/jbc.M109.064667			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	536UT	19880521	Green Published, hybrid			2022-12-25	WOS:000273070100044
J	Stifanese, R; Averna, M; De Tullio, R; Pedrazzi, M; Beccaria, F; Salamino, F; Milanese, M; Bonanno, G; Pontremoli, S; Melloni, E				Stifanese, Roberto; Averna, Monica; De Tullio, Roberta; Pedrazzi, Marco; Beccaria, Francesco; Salamino, Franca; Milanese, Marco; Bonanno, Giambattista; Pontremoli, Sandro; Melloni, Edon			Adaptive Modifications in the Calpain/Calpastatin System in Brain Cells after Persistent Alteration in Ca2+ Homeostasis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMYOTROPHIC-LATERAL-SCLEROSIS; OXIDE SYNTHASE ISOFORMS; TRANSGENIC-MOUSE MODEL; SUPEROXIDE-DISMUTASE; NITRIC-OXIDE; RAT-BRAIN; CALPASTATIN LOCALIZATION; CALPAIN ACTIVATION; INACTIVE CALPAIN; ALTERED CALCIUM	Persistent dysregulation in Ca2+ homeostasis is a pervasive pathogenic mechanism in most neurodegenerative diseases, and accordingly, calpain activation has been implicated in neuronal cells dysfunction and death. In this study we examined the intracellular functional state of the calpain-calpastatin system in -G93A(+) SOD1 transgenic mice to establish if and how uncontrolled activation of calpain can be prevented in vivo during the course of prolonged [Ca2+](i) elevation. The presented data indicate that 1) calpain activation is more extensive in motor cortex, in lumbar, and sacral spinal cord segments compared with the lower or almost undetectable activation of the protease in other brain areas, 2) direct measurements of the variations of Ca2+ levels established that the degree of the protease activation is correlated to the extent of elevation of [Ca2+](i), 3) intracellular activation of calpain is always associated with diffusion of calpastatin from perinuclear aggregated forms into the cytosol and the formation of a calpain-calpastatin complex, and 4) a conservative fragmentation of calpastatin is accompanied by its increased expression and inhibitory capacity in conditions of prolonged increase in [Ca2+](i). Thus, calpastatin diffusion and formation of the calpain-calpastatin complex together with an increased synthesis of the inhibitor protein represent a cellular defense response to conditions of prolonged dysregulation in intracellular Ca2+ homeostasis. Altogether these findings provide a new understanding of the in vivo molecular mechanisms governing calpain activation that can be extended to many neurodegenerative diseases, potentially useful for the development of new therapeutic approaches.	[Stifanese, Roberto; Averna, Monica; De Tullio, Roberta; Pedrazzi, Marco; Beccaria, Francesco; Salamino, Franca; Pontremoli, Sandro; Melloni, Edon] Univ Genoa, Dept Expt Med, Biochem Sect, I-16132 Genoa, Italy; [Stifanese, Roberto; Averna, Monica; De Tullio, Roberta; Pedrazzi, Marco; Beccaria, Francesco; Salamino, Franca; Pontremoli, Sandro; Melloni, Edon] Univ Genoa, Ctr Excellence Biomed Res, I-16132 Genoa, Italy; [Milanese, Marco; Bonanno, Giambattista] Univ Genoa, Dept Expt Med, Pharmacol & Toxicol Sect, I-16147 Genoa, Italy; [Milanese, Marco; Bonanno, Giambattista] Univ Genoa, Ctr Excellence Biomed Res, I-16147 Genoa, Italy	University of Genoa; University of Genoa; University of Genoa; University of Genoa	Melloni, E (corresponding author), Univ Genoa, Dept Expt Med, Biochem Sect, Viale Benedetto XV, I-16132 Genoa, Italy.	melloni@unige.it	Milanese, Marco/C-4444-2013; AVERNA, MONICA/R-5719-2019; Bonanno, Giambattista/C-5856-2008; Averna, Maurizio/U-9527-2017; Milanese, Marco/AAB-2238-2021	Milanese, Marco/0000-0003-3384-0666; AVERNA, MONICA/0000-0002-9463-7533; Milanese, Marco/0000-0003-3384-0666; Bonanno, Giambattista/0000-0003-3744-5786	Ministero dell'Istruzione dell'Universita e della Ricerca; University of Genoa	Ministero dell'Istruzione dell'Universita e della Ricerca(Ministry of Education, Universities and Research (MIUR)); University of Genoa	This work was supported in part by grants from Ministero dell'Istruzione dell'Universita e della Ricerca and from the University of Genoa.	Appel SH, 2000, AMYOTROPH LATERAL SC, V1, P27; Araujo IM, 2005, CNS NEUROL DISORD-DR, V4, P319, DOI 10.2174/1568007054546126; Averna M, 2006, FEBS J, V273, P1660, DOI 10.1111/j.1742-4658.2006.05180.x; Averna M, 2003, CELL MOL LIFE SCI, V60, P2669, DOI 10.1007/s00018-003-3288-0; Averna M, 2001, BIOCHEM J, V354, P25, DOI 10.1042/0264-6021:3540025; Averna M, 2001, J BIOL CHEM, V276, P38426, DOI 10.1074/jbc.M101936200; Averna M, 2007, FEBS J, V274, P6116, DOI 10.1111/j.1742-4658.2007.06133.x; Averna M, 2007, J BIOL CHEM, V282, P2656, DOI 10.1074/jbc.M606919200; Averna M, 2009, J NEUROCHEM, V110, P412, DOI 10.1111/j.1471-4159.2009.06149.x; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Coligan JE, 1991, CURRENT PROTOCOL IMM; Couillard-Despres S, 1998, P NATL ACAD SCI USA, V95, P9626, DOI 10.1073/pnas.95.16.9626; CROALL DE, 1991, PHYSIOL REV, V71, P813, DOI 10.1152/physrev.1991.71.3.813; De Tullio R, 1998, FEBS LETT, V422, P113, DOI 10.1016/S0014-5793(97)01588-3; De Tullio R, 2000, FEBS LETT, V475, P17, DOI 10.1016/S0014-5793(00)01613-6; De Tullio R, 2007, ARCH BIOCHEM BIOPHYS, V465, P148, DOI 10.1016/j.abb.2007.05.007; De Tullio R, 2009, BBA-GEN SUBJECTS, V1790, P182, DOI 10.1016/j.bbagen.2008.11.002; ELLIOTT JL, 1995, NEUROREPORT, V6, P449, DOI 10.1097/00001756-199502000-00011; Goll DE, 2003, PHYSIOL REV, V83, P731, DOI 10.1152/physrev.00029.2002; GURNEY ME, 1994, SCIENCE, V264, P1772, DOI 10.1126/science.8209258; GURNEY ME, 1994, NEW ENGL J MED, V331, P1721, DOI 10.1056/NEJM199412223312516; Higgins Linda S., 1996, Methods (Orlando), V10, P384, DOI 10.1006/meth.1996.0116; Jourdi H, 2009, NEUROPHARMACOLOGY, V56, P876, DOI 10.1016/j.neuropharm.2009.01.015; Kim HJ, 2007, EXP MOL MED, V39, P574, DOI 10.1038/emm.2007.63; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Laine R, 1998, MOL PHARMACOL, V54, P305, DOI 10.1124/mol.54.2.305; Liu J, 2008, SCI SIGNAL, V1, DOI [10.1126/stke.114re1, 10.1126/scisignal.123tr3]; LOWRY OH, 1951, J BIOL CHEM, V193, P265; Mahad DJ, 2009, BRAIN, V132, P1161, DOI 10.1093/brain/awp046; MartinezZaguilan R, 1996, CELL CALCIUM, V19, P337, DOI 10.1016/S0143-4160(96)90074-3; MELLONI E, 1982, BIOCHEM BIOPH RES CO, V106, P731, DOI 10.1016/0006-291X(82)91772-7; Melloni E, 2006, J BIOL CHEM, V281, P24945, DOI 10.1074/jbc.M601449200; PALEJWALA S, 1992, P NATL ACAD SCI USA, V89, P4202, DOI 10.1073/pnas.89.9.4202; Parr T, 2004, ARCH BIOCHEM BIOPHYS, V427, P8, DOI 10.1016/j.abb.2004.04.001; PONTREMOLI S, 1988, J BIOL CHEM, V263, P1915; RASER KJ, 1995, ARCH BIOCHEM BIOPHYS, V319, P211, DOI 10.1006/abbi.1995.1284; Ray SK, 2006, CURR MED CHEM, V13, P3425, DOI 10.2174/092986706779010342; Roberts BR, 2007, J MOL BIOL, V373, P877, DOI 10.1016/j.jmb.2007.07.043; ROSEN DR, 1993, NATURE, V362, P59, DOI 10.1038/362059a0; Rowland LP, 2001, NEW ENGL J MED, V344, P1688, DOI 10.1056/NEJM200105313442207; Saez ME, 2006, DRUG DISCOV TODAY, V11, P917, DOI 10.1016/j.drudis.2006.08.009; Samantaray S, 2008, CNS NEUROL DISORD-DR, V7, P305, DOI 10.2174/187152708784936680; Sambrook J., 1989, MOL CLONING LAB MANU, V2; Shibata N, 2001, NEUROPATHOLOGY, V21, P82, DOI 10.1046/j.1440-1789.2001.00361.x; Siklos L, 1998, J NEUROPATH EXP NEUR, V57, P571, DOI 10.1097/00005072-199806000-00005; Siklos L, 1996, ANN NEUROL, V39, P203, DOI 10.1002/ana.410390210; Simon J., 2000, CALPAIN METHODS PROT, P109; Sorimachi H, 1997, BIOCHEM J, V328, P721, DOI 10.1042/bj3280721; Stifanese R, 2008, ARCH BIOCHEM BIOPHYS, V479, P145, DOI 10.1016/j.abb.2008.09.002; Stifanese R, 2006, ARCH BIOCHEM BIOPHYS, V456, P48, DOI 10.1016/j.abb.2006.09.022; Towbin H, 1992, Biotechnology, V24, P145; TULLIO RD, 1999, BIOCHEM J, V343, P467; Turner BJ, 2008, PROG NEUROBIOL, V85, P94, DOI 10.1016/j.pneurobio.2008.01.001; Vanselow BK, 2000, J PHYSIOL-LONDON, V525, P433, DOI 10.1111/j.1469-7793.2000.t01-1-00433.x; Vosler PS, 2008, MOL NEUROBIOL, V38, P78, DOI 10.1007/s12035-008-8036-x; Watson C., 2008, SPINAL CORD; Wendt A, 2004, BIOL CHEM, V385, P465, DOI 10.1515/BC.2004.054; Wootz H, 2006, EXP CELL RES, V312, P1890, DOI 10.1016/j.yexcr.2006.02.021; Wu HV, 2006, MOL NEUROBIOL, V33, P215, DOI 10.1385/MN:33:3:215; Wu HY, 2007, ACTA MED OKAYAMA, V61, P123; Zhou MO, 2009, EXP NEUROL, V218, P75, DOI 10.1016/j.expneurol.2009.04.006	61	35	35	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 1	2010	285	1					631	643		10.1074/jbc.M109.031674	http://dx.doi.org/10.1074/jbc.M109.031674			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	536UT	19880516	hybrid, Green Published			2022-12-25	WOS:000273070100064
J	Yoon, CH; Kim, MJ; Park, MJ; Park, IC; Hwang, SG; An, S; Choi, YH; Yoon, G; Lee, SJ				Yoon, Chang-Hwan; Kim, Min-Jung; Park, Myung-Jin; Park, In-Chul; Hwang, Sang-Gu; An, Sungkwan; Choi, Yung-Hyun; Yoon, Gyesoon; Lee, Su-Jae			Claudin-1 Acts through c-Abl-Protein Kinase C delta (PKC delta) Signaling and Has a Causal Role in the Acquisition of Invasive Capacity in Human Liver Cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEPATOCELLULAR-CARCINOMA; CANCER-CELLS; REDUCED EXPRESSION; GLIOMA-CELLS; IN-VITRO; METASTASIS; GROWTH; ACTIVATION; RECEPTOR; PATHWAY	Claudins are identified as members of the tetraspanin family of proteins, which are integral to the structure and function of tight junction. Recent studies showed an increase in expression of claudins during tumorigenesis, which is associated with loss of cell-cell contact, dedifferentiation, and invasiveness. However, the molecular basis for the causal relationship between claudin expression and cancer progression is not fully understood yet. In this study, we show that claudin-1 plays a causal role in the acquisition of invasive capacity in human liver cells and that c-Abl-protein kinase C delta (PKC delta) signaling is critical for the malignant progression induced by claudin-1. Overexpression of claudin-1 clearly induced expression of matrix metalloproteinase-2 (MMP-2) and cell invasion and migration in normal liver cells as well as in non-invasive human hepatocellular carcinoma (HCC) cells. Conversely, small interfering RNA targeting of claudin-1 in invasive HCC cells completely inhibited cell invasion. Both c-Abl and PKC delta are found to be activated in normal liver cell line clones that stably overexpress claudin-1. Inhibition of either c-Abl or PKC delta alone clearly attenuated MMP-2 activation and impeded cell invasion and migration in both human HCC and normal liver cells expressing claudin-1. These results indicate that claudin-1 is both necessary and sufficient to induce invasive behavior in human liver cells and that activation of c-Abl-PKC delta signaling pathway is critically required for the claudin-1-induced acquisition of the malignant phenotype. The present observations raise the possibility of exploiting claudin-1 as a potential biomarker for the spread of liver cancer and might provide pivotal points for therapeutic intervention in HCC.	[Yoon, Chang-Hwan; Kim, Min-Jung; Lee, Su-Jae] Hanyang Univ, Dept Chem, Res Inst Nat Sci, Seoul 133791, South Korea; [Park, Myung-Jin; Park, In-Chul; Hwang, Sang-Gu] Korea Inst Radiol & Med Sci, Div Radiat Canc Biol, Seoul 139706, South Korea; [An, Sungkwan] Konkuk Univ, Funct Genoproteome Res Ctr, Seoul 143701, South Korea; [Choi, Yung-Hyun] Dong Eui Univ, Dept Biochem, Coll Oriental Med, Pusan 614052, South Korea; [Yoon, Gyesoon] Ajou Univ, Sch Med, Dept Biochem & Mol Biol, Suwon 443721, South Korea	Hanyang University; Korea Institute of Radiological & Medical Sciences; Konkuk University; Dong-Eui University; Ajou University	Lee, SJ (corresponding author), Hanyang Univ, Dept Chem, Res Inst Nat Sci, 17 Haengdang Dong, Seoul 133791, South Korea.	sj0420@hanyang.ac.kr	Yoon, Changhwan/AAK-7842-2021	Yoon, Changhwan/0000-0002-8420-9818	Korea Science and Engineering Foundation; Ministry of Education, Science and Technology, Korean government; National Nuclear Technology Program; Program of Basic Atomic Energy Research Institute	Korea Science and Engineering Foundation(Korea Science and Engineering Foundation); Ministry of Education, Science and Technology, Korean government; National Nuclear Technology Program; Program of Basic Atomic Energy Research Institute	This work was supported by grants from the Korea Science and Engineering Foundation and Ministry of Education, Science and Technology, Korean government, through its National Nuclear Technology Program and Program of Basic Atomic Energy Research Institute.	AndoAkatsuka Y, 1996, J CELL BIOL, V133, P43, DOI 10.1083/jcb.133.1.43; Bartolome RA, 2006, CANCER RES, V66, P248, DOI 10.1158/0008-5472.CAN-05-2489; Bello IO, 2008, HUM PATHOL, V39, P1212, DOI 10.1016/j.humpath.2007.12.015; Besson A, 2001, ONCOGENE, V20, P7398, DOI 10.1038/sj.onc.1204899; Brenner W, 2008, INT J ONCOL, V32, P1125; Chambers AF, 2002, NAT REV CANCER, V2, P563, DOI 10.1038/nrc865; Cheung ST, 2005, CLIN CANCER RES, V11, P551; dos Reis PP, 2008, CANCER-AM CANCER SOC, V113, P3169, DOI 10.1002/cncr.23934; Fidler IJ, 2003, NAT REV CANCER, V3, P453, DOI 10.1038/nrc1098; FURUSE M, 1993, J CELL BIOL, V123, P1777, DOI 10.1083/jcb.123.6.1777; Gupta GP, 2006, CELL, V127, P679, DOI 10.1016/j.cell.2006.11.001; Hsieh YH, 2007, CANCER RES, V67, P4320, DOI 10.1158/0008-5472.CAN-06-2486; Ip YC, 2007, MOL CANCER THER, V6, P2858, DOI 10.1158/1535-7163.MCT-07-0453; Jallal H, 2007, CANCER RES, V67, P1580, DOI 10.1158/0008-5472.CAN-06-2027; Kang YB, 2004, CELL, V118, P277, DOI 10.1016/j.cell.2004.07.011; Kharait S, 2006, BIOCHEM BIOPH RES CO, V343, P848, DOI 10.1016/j.bbrc.2006.03.044; Kiley SC, 1999, CANCER RES, V59, P3230; Kim TH, 2008, HISTOPATHOLOGY, V53, P48, DOI 10.1111/j.1365-2559.2008.03052.x; Koch A, 2008, ONCOGENE, V27, P4678, DOI 10.1038/onc.2008.107; Koizumi JI, 2008, MOL PHARMACOL, V74, P432, DOI 10.1124/mol.107.043711; Leotlela PD, 2007, ONCOGENE, V26, P3846, DOI 10.1038/sj.onc.1210155; Li WQ, 2000, CANCER RES, V60, P3909; Mandil R, 2001, CANCER RES, V61, P4612; Michl P, 2003, CANCER RES, V63, P6265; Miyamori H, 2001, J BIOL CHEM, V276, P28204, DOI 10.1074/jbc.M103083200; Miyata Y, 2004, MOL CANCER THER, V3, P839; Morita K, 1999, P NATL ACAD SCI USA, V96, P511, DOI 10.1073/pnas.96.2.511; Nakashima S, 2002, J BIOCHEM, V132, P669, DOI 10.1093/oxfordjournals.jbchem.a003272; Noren NK, 2006, NAT CELL BIOL, V8, P815, DOI 10.1038/ncb1438; Oshima T, 2008, ONCOL REP, V19, P953; Park MJ, 2000, NEUROSCI LETT, V290, P201, DOI 10.1016/S0304-3940(00)01358-6; Paschoud S, 2007, MODERN PATHOL, V20, P947, DOI 10.1038/modpathol.3800835; Peter Y, 2009, MOL CARCINOGEN, V48, P488, DOI 10.1002/mc.20485; Plattner R, 1999, GENE DEV, V13, P2400, DOI 10.1101/gad.13.18.2400; Podtcheko A, 2003, J CLIN ENDOCR METAB, V88, P1889, DOI 10.1210/jc.2002-021230; Sakaguchi T, 2008, J SURG RES, V147, P123, DOI 10.1016/j.jss.2007.07.013; Soini Y, 2005, HISTOPATHOLOGY, V46, P551, DOI 10.1111/j.1365-2559.2005.02127.x; Soini Y, 2004, HUM PATHOL, V35, P1531, DOI 10.1016/j.humpath.2004.09.015; Srinivasan D, 2008, ONCOGENE, V27, P1095, DOI 10.1038/sj.onc.1210714; Suzuki J, 2007, J BIOCHEM, V141, P453, DOI 10.1093/jb/mvm059; Szmydynger-Chodobska Joanna, 2007, Cerebrospinal Fluid Res, V4, P11, DOI 10.1186/1743-8454-4-11; Usami Y, 2006, HUM PATHOL, V37, P569, DOI 10.1016/j.humpath.2005.12.018; Woodhouse EC, 1997, CANCER-AM CANCER SOC, V80, P1529, DOI 10.1002/(SICI)1097-0142(19971015)80:8+<1529::AID-CNCR2>3.0.CO;2-F	43	75	79	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 1	2010	285	1					226	233		10.1074/jbc.M109.054189	http://dx.doi.org/10.1074/jbc.M109.054189			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	536UT	19897486	Green Published, hybrid			2022-12-25	WOS:000273070100024
J	Shi, HF; Chamond, N; Djikeng, A; Tschudi, C; Ullu, E				Shi, Huafang; Chamond, Nathalie; Djikeng, Appolinaire; Tschudi, Christian; Ullu, Elisabetta			RNA Interference in Trypanosoma brucei ROLE OF THE N-TERMINAL RGG DOMAIN AND THE POLYRIBOSOME ASSOCIATION OF ARGONAUTE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN ARGININE METHYLTRANSFERASE; MESSENGER-RNAS; ARGONAUTE PROTEIN; PASSENGER-STRAND; FAMILY-MEMBERS; HUMAN-CELLS; IN-VITRO; DROSOPHILA; SIRNA; TRANSLATION	Argonaute proteins (AGOs) are central to RNA interference (RNAi) and related silencing pathways. At the core of the RNAi pathway in the ancient parasitic eukaryote Trypanosoma brucei is a single Argonaute protein, TbAGO1, with an established role in the destruction of potentially harmful retroposon transcripts. One notable feature of TbAGO1 is that a fraction sediments with polyribosomes, and this association is facilitated by an arginine/glycine-rich domain (RGG domain) at the N terminus of the protein. Here we report that reducing the size of the RGG domain and, in particular, mutating all arginine residues severely reduced the association of TbAGO1 with polyribosomes and RNAi-induced cleavage of mRNA. However, these mutations did not change the cellular localization of Argonaute and did not affect the accumulation of single-stranded siRNAs, an essential step in the activation of the RNA-induced silencing complex. We further show that mRNA on polyribosomes can be targeted for degradation, although this alliance is not a pre-requisite. Finally, sequestering tubulin mRNAs from translation with antisense morpholino oligonucleotides reduced the RNAi response indicating that mRNAs not engaged in translation may be less accessible to the RNAi machinery. We conclude that the association of the RNAi machinery and target mRNA on polyribosomes promotes an efficient RNAi response. This mechanism may represent an ancient adaptation to ensure that retroposon transcripts are efficiently destroyed, if they become associated with the translational apparatus.	[Shi, Huafang; Chamond, Nathalie; Djikeng, Appolinaire; Ullu, Elisabetta] Yale Univ, Sch Med, Dept Internal Med, New Haven, CT 06536 USA; [Tschudi, Christian] Yale Univ, Sch Med, Dept Epidemiol & Publ Hlth, New Haven, CT 06536 USA; [Ullu, Elisabetta] Yale Univ, Sch Med, Dept Cell Biol, New Haven, CT 06536 USA	Yale University; Yale University; Yale University	Tschudi, C (corresponding author), 295 Congress Ave,BCMM 136C,Box 9812, New Haven, CT 06536 USA.	christian.tschudi@yale.edu	Chamond, Nathalie/C-5907-2018	Djikeng, Appolinaire/0000-0001-9271-3419; Chamond, Nathalie/0000-0002-0518-2929	National Institutes of Health [AI28798, AI43594]; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R37AI028798, R01AI028798, R01AI043594] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	This work was supported, in whole or in part, by National Institutes of Health Grants AI28798 (to E. U.) and AI43594 (to C. T.).	BANGS JD, 1993, J CELL SCI, V105, P1101; Bedford MT, 2007, J CELL SCI, V120, P4243, DOI 10.1242/jcs.019885; Bedford MT, 2009, MOL CELL, V33, P1, DOI 10.1016/j.molcel.2008.12.013; Brahms H, 2000, J BIOL CHEM, V275, P17122, DOI 10.1074/jbc.M000300200; Brecht M, 1998, MOL BIOCHEM PARASIT, V97, P189, DOI 10.1016/S0166-6851(98)00151-0; Caudy AA, 2003, NATURE, V425, P411, DOI 10.1038/nature01956; Caudy AA, 2002, GENE DEV, V16, P2491, DOI 10.1101/gad.1025202; Cerutti H, 2006, CURR GENET, V50, P81, DOI 10.1007/s00294-006-0078-x; Darnell JC, 2001, CELL, V107, P489, DOI 10.1016/S0092-8674(01)00566-9; Djikeng A, 2003, RNA, V9, P802, DOI 10.1261/rna.5270203; Djikeng A, 2001, RNA, V7, P1522; Durand-Dubief M, 2003, BMC BIOL, V1, DOI 10.1186/1741-7007-1-2; Eulalio A, 2008, NAT STRUCT MOL BIOL, V15, P346, DOI 10.1038/nsmb.1405; Farazi TA, 2008, DEVELOPMENT, V135, P1201, DOI 10.1242/dev.005629; Gu S, 2005, RNA, V11, P38, DOI 10.1261/rna.7158605; Hammond SM, 2001, SCIENCE, V293, P1146, DOI 10.1126/science.1064023; Hammond SM, 2000, NATURE, V404, P293, DOI 10.1038/35005107; Hughes K, 2007, EMBO J, V26, P2400, DOI 10.1038/sj.emboj.7601678; Hutvagner G, 2008, NAT REV MOL CELL BIO, V9, P22, DOI 10.1038/nrm2321; Ishizuka A, 2002, GENE DEV, V16, P2497, DOI 10.1101/gad.1022002; Kennerdell JR, 2002, GENE DEV, V16, P1884, DOI 10.1101/gad.990802; Kim K, 2007, RNA, V13, P22, DOI 10.1261/rna.283207; Kinch LN, 2009, BIOL DIRECT, V4, DOI 10.1186/1745-6150-4-2; Kiriakidou M, 2007, CELL, V129, P1141, DOI 10.1016/j.cell.2007.05.016; Kirino Y, 2009, NAT CELL BIOL, V11, P652, DOI 10.1038/ncb1872; LERNER MR, 1979, P NATL ACAD SCI USA, V76, P5495, DOI 10.1073/pnas.76.11.5495; Leuschner PJF, 2006, EMBO REP, V7, P314, DOI 10.1038/sj.embor.7400637; Maiti M, 2007, GENE DEV, V21, P590, DOI 10.1101/gad.1497607; Maroney PA, 2006, NAT STRUCT MOL BIOL, V13, P1102, DOI 10.1038/nsmb1174; Matranga C, 2005, CELL, V123, P607, DOI 10.1016/j.cell.2005.08.044; Meister G, 2004, MOL CELL, V15, P185, DOI 10.1016/j.molcel.2004.07.007; Meyer WJ, 2006, PLOS GENET, V2, P1224, DOI 10.1371/journal.pgen.0020134; Miyoshi K, 2005, GENE DEV, V19, P2837, DOI 10.1101/gad.1370605; Ngo H, 1998, P NATL ACAD SCI USA, V95, P14687, DOI 10.1073/pnas.95.25.14687; Nilsen TW, 2007, TRENDS GENET, V23, P243, DOI 10.1016/j.tig.2007.02.011; Nottrott S, 2006, NAT STRUCT MOL BIOL, V13, P1108, DOI 10.1038/nsmb1173; Pasternack DA, 2007, EUKARYOT CELL, V6, P1665, DOI 10.1128/EC.00133-07; Pelletier M, 2005, MOL BIOCHEM PARASIT, V144, P206, DOI 10.1016/j.molbiopara.2005.08.015; Pham JW, 2004, CELL, V117, P83, DOI 10.1016/S0092-8674(04)00258-2; Puig O, 2001, METHODS, V24, P218, DOI 10.1006/meth.2001.1183; Ramos A, 2003, RNA, V9, P1198, DOI 10.1261/rna.5960503; Rand TA, 2005, CELL, V123, P621, DOI 10.1016/j.cell.2005.10.020; Sen GL, 2005, DIFFERENTIATION, V73, P287, DOI 10.1111/j.1432-0436.2005.00029.x; Shi HF, 2004, J BIOL CHEM, V279, P49889, DOI 10.1074/jbc.M409280200; Shi HF, 2004, MOL CELL BIOL, V24, P420, DOI 10.1128/MCB.24.1.420-427.2004; Shi HF, 2007, RNA, V13, P1132, DOI 10.1261/rna.474707; Shi H, 2006, RNA, V12, P943, DOI 10.1261/rna.20806; STIEGER J, 1984, J BIOL CHEM, V259, P4596; Stoica C, 2006, J BIOL CHEM, V281, P37646, DOI 10.1074/jbc.M604476200; Tolia NH, 2007, NAT CHEM BIOL, V3, P36, DOI 10.1038/nchembio848; Tuschl T, 1999, GENE DEV, V13, P3191, DOI 10.1101/gad.13.24.3191; Ullu E, 2002, PHILOS T ROY SOC B, V357, P65, DOI 10.1098/rstb.2001.0952; Vagin VV, 2009, GENE DEV, V23, P1749, DOI 10.1101/gad.1814809; Vasudevan S, 2007, SCIENCE, V318, P1931, DOI 10.1126/science.1149460	54	16	16	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 25	2009	284	52					36511	36520		10.1074/jbc.M109.073072	http://dx.doi.org/10.1074/jbc.M109.073072			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	535LT	19880512	hybrid, Green Published			2022-12-25	WOS:000272970500053
J	Homer, N; Merriman, B; Nelson, SF				Homer, Nils; Merriman, Barry; Nelson, Stanley F.			BFAST: An Alignment Tool for Large Scale Genome Resequencing	PLOS ONE			English	Article							HOMOLOGY SEARCH; DNA; GENERATION; SEEDS; BLAST	Background: The new generation of massively parallel DNA sequencers, combined with the challenge of whole human genome resequencing, result in the need for rapid and accurate alignment of billions of short DNA sequence reads to a large reference genome. Speed is obviously of great importance, but equally important is maintaining alignment accuracy of short reads, in the 25-100 base range, in the presence of errors and true biological variation. Methodology: We introduce a new algorithm specifically optimized for this task, as well as a freely available implementation, BFAST, which can align data produced by any of current sequencing platforms, allows for user-customizable levels of speed and accuracy, supports paired end data, and provides for efficient parallel and multi-threaded computation on a computer cluster. The new method is based on creating flexible, efficient whole genome indexes to rapidly map reads to candidate alignment locations, with arbitrary multiple independent indexes allowed to achieve robustness against read errors and sequence variants. The final local alignment uses a Smith-Waterman method, with gaps to support the detection of small indels. Conclusions: We compare BFAST to a selection of large-scale alignment tools - BLAT, MAQ, SHRiMP, and SOAP - in terms of both speed and accuracy, using simulated and real-world datasets. We show BFAST can achieve substantially greater sensitivity of alignment in the context of errors and true variants, especially insertions and deletions, and minimize false mappings, while maintaining adequate speed compared to other current methods. We show BFAST can align the amount of data needed to fully resequence a human genome, one billion reads, with high sensitivity and accuracy, on a modest computer cluster in less than 24 hours. BFAST is available at http://bfast.sourceforge.net.			Homer, N (corresponding author), Univ Calif Los Angeles, Dept Comp Sci, Los Angeles, CA 90024 USA.	barrym@ucla.edu	Nelson, Stanley F/D-4771-2009	Nelson, Stanley F/0000-0002-2082-3114	NIMH NIH HHS [R01 MH071852] Funding Source: Medline; NINDS NIH HHS [U24 NS052108] Funding Source: Medline; NATIONAL INSTITUTE OF MENTAL HEALTH [R01MH071852] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [U24NS052108] Funding Source: NIH RePORTER	NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; Bentley DR, 2006, CURR OPIN GENET DEV, V16, P545, DOI 10.1016/j.gde.2006.10.009; COX A, 2007, ELAND EFFICIENT LOCA; Holt RA, 2008, GENOME RES, V18, P839, DOI 10.1101/gr.073262.107; Homer N, 2009, BMC BIOINFORMATICS, V10, DOI 10.1186/1471-2105-10-175; Hutchison CA, 2007, NUCLEIC ACIDS RES, V35, P6227, DOI 10.1093/nar/gkm688; Ilie L, 2007, BIOINFORMATICS, V23, P2969, DOI 10.1093/bioinformatics/btm422; Kent WJ, 2002, GENOME RES, V12, P656, DOI 10.1101/gr.229202; Langmead B, 2009, GENOME BIOL, V10, DOI 10.1186/gb-2009-10-3-r25; Li H, 2008, GENOME RES, V18, P1851, DOI 10.1101/gr.078212.108; Li H, 2009, BIOINFORMATICS, V25, P1754, DOI 10.1093/bioinformatics/btp324; Li RQ, 2008, BIOINFORMATICS, V24, P713, DOI 10.1093/bioinformatics/btn025; Ma B, 2002, BIOINFORMATICS, V18, P440, DOI 10.1093/bioinformatics/18.3.440; Margulies M, 2005, NATURE, V437, P376, DOI 10.1038/nature03959; Ning ZM, 2001, GENOME RES, V11, P1725, DOI 10.1101/gr.194201; RUMBLE SM, 2008, SHRIMP SHORT READING; Rumble SM, 2009, PLOS COMPUT BIOL, V5, DOI 10.1371/journal.pcbi.1000386; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; Smith DR, 2008, GENOME RES, V18, P1638, DOI 10.1101/gr.077776.108; SMITH TF, 1981, J MOL BIOL, V147, P195, DOI 10.1016/0022-2836(81)90087-5; Sun YN, 2005, J COMPUT BIOL, V12, P847, DOI 10.1089/cmb.2005.12.847; 2008, APPL BIOSYSTEMS INCO	22	365	416	1	27	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	NOV 11	2009	4	11					A95	A106	e7767	10.1371/journal.pone.0007767	http://dx.doi.org/10.1371/journal.pone.0007767			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	518IX	19907642	gold, Green Published			2022-12-25	WOS:000271685800011
J	Kuningas, M; May, L; Tamm, R; van Bodegom, D; van den Biggelaar, AHJ; Meij, JJ; Frolich, M; Ziem, JB; Suchiman, HED; Metspalu, A; Slagboom, PE; Westendorp, RGJ				Kuningas, Maris; May, Linda; Tamm, Riin; van Bodegom, David; van den Biggelaar, Anita H. J.; Meij, Johannes J.; Froelich, Marijke; Ziem, Juventus B.; Suchiman, Helena E. D.; Metspalu, Andres; Slagboom, P. Eline; Westendorp, Rudi G. J.			Selection for Genetic Variation Inducing Pro-Inflammatory Responses under Adverse Environmental Conditions in a Ghanaian Population	PLOS ONE			English	Article							TUMOR-NECROSIS-FACTOR; INTERLEUKIN-10 TRANSCRIPTION; CYTOKINE PRODUCTION; CHILDREN; MORTALITY; RISK; POLYMORPHISMS; INFECTION; RECEPTOR; IL10	Background: Chronic inflammation is involved in the pathogenesis of chronic age-associated, degenerative diseases. Pro-inflammatory host responses that are deleterious later in life may originate from evolutionary selection for genetic variation mediating resistance to infectious diseases under adverse environmental conditions. Methodology/Principal Findings: In the Upper-East region of Ghana where infection has remained the leading cause of death, we studied the effect on survival of genetic variations at the IL10 gene locus that have been associated with chronic diseases. Here we show that an IL10 haplotype that associated with a pro-inflammatory innate immune response, characterised by low IL-10 (p = 0.028) and high TNF-alpha levels (p = 1.39 x 10(-3)), was enriched among Ghanaian elders (p = 2.46 x10(-6)). Furthermore, in an environment where the source of drinking water (wells/rivers vs. boreholes) influences mortality risks (HR 1.28, 95% CI [1.09-1.50]), we observed that carriers of the pro-inflammatory haplotype have a survival advantage when drinking from wells/rivers but a disadvantage when drinking from boreholes (p(interaction) = 0.013). Resequencing the IL10 gene region did not uncover any additional common variants in the pro-inflammatory haplotype to those SNPs that were initially genotyped. Conclusions/Significance: Altogether, these data lend strong arguments for the selection of pro-inflammatory host responses to overcome fatal infection and promote survival in adverse environments.			Kuningas, M (corresponding author), Leiden Univ, Med Ctr, Dept Gerontol & Geriatr, Leiden, Netherlands.	R.G.J.Westendorp@lumc.nl	Suchiman, H. Eka D./F-5024-2017; Slagboom, P. Eline/R-4790-2016; Meij, Johannes/ABB-6973-2021	Suchiman, H. Eka D./0000-0002-7168-5516; Slagboom, P. Eline/0000-0002-2875-4723; Ziem, Juventus/0000-0002-5130-8764; van Bodegom, David/0000-0002-5691-8342				Ates O, 2008, RHEUMATOL INT, V28, P1123, DOI 10.1007/s00296-008-0594-8; Barrett JC, 2005, BIOINFORMATICS, V21, P263, DOI 10.1093/bioinformatics/bth457; Bis JC, 2008, ATHEROSCLEROSIS, V198, P166, DOI 10.1016/j.atherosclerosis.2007.09.031; Cooke GS, 2001, NAT REV GENET, V2, P967, DOI 10.1038/35103577; Crawley E, 1999, ARTHRITIS RHEUM-US, V42, P1101, DOI 10.1002/1529-0131(199906)42:6<1101::AID-ANR6>3.0.CO;2-Y; Crimmins EM, 2006, P NATL ACAD SCI USA, V103, P498, DOI 10.1073/pnas.0501470103; Drenos F, 2006, BIOGERONTOLOGY, V7, P287, DOI 10.1007/s10522-006-9027-9; FIORENTINO DF, 1991, J IMMUNOL, V147, P3815; Franke A, 2008, NAT GENET, V40, P1319, DOI 10.1038/ng.221; GRAU GE, 1989, NEW ENGL J MED, V320, P1586, DOI 10.1056/NEJM198906153202404; Hartgers FC, 2008, PLOS NEGLECT TROP D, V2, DOI 10.1371/journal.pntd.0000227; HEISKANEN M, 2009, POLYMORPHISM IL10 PR; Hu XY, 2007, J LEUKOCYTE BIOL, V82, P237, DOI 10.1189/jlb.1206763; Jackson JA, 2009, IMMUNOLOGY, V126, P18, DOI 10.1111/j.1365-2567.2008.03010.x; KWIATKOWSKI D, 1990, LANCET, V336, P1201, DOI 10.1016/0140-6736(90)92827-5; Le Souef PN, 2000, LANCET, V356, P242; Li JCB, 2007, IMMUNOLOGY, V121, P337, DOI 10.1111/j.1365-2567.2007.02580.x; Maizels RM, 2004, IMMUNOL REV, V201, P89, DOI 10.1111/j.0105-2896.2004.00191.x; May L, 2009, CYTOKINE, V45, P184, DOI 10.1016/j.cyto.2008.12.010; Meij JJ, 2009, T ROY SOC TROP MED H, V103, P173, DOI 10.1016/j.trstmh.2008.09.015; MOLYNEUX ME, 1993, CYTOKINE, V5, P604, DOI 10.1016/S1043-4666(05)80011-0; Mosser DM, 2008, IMMUNOL REV, V226, P205, DOI 10.1111/j.1600-065X.2008.00706.x; Murray CJL, 1997, LANCET, V349, P1269, DOI 10.1016/S0140-6736(96)07493-4; Shier RP, 1996, TROP MED INT HEALTH, V1, P334, DOI 10.1046/j.1365-3156.1996.d01-55.x; Shoemaker J, 2006, J IMMUNOL, V176, P3470, DOI 10.4049/jimmunol.176.6.3470; Smith AJP, 2009, CYTOKINE GROWTH F R, V20, P43, DOI 10.1016/j.cytogfr.2008.11.006; Stephens M, 2001, AM J HUM GENET, V68, P978, DOI 10.1086/319501; Strong K, 2005, LANCET, V366, P1578, DOI 10.1016/S0140-6736(05)67341-2; Trompet S, 2007, ANN NY ACAD SCI, V1100, P189, DOI 10.1196/annals.1395.018; Van Bodegom D, 2007, ANN NY ACAD SCI, V1100, P84, DOI 10.1196/annals.1395.007; van der Pol WL, 2001, J INFECT DIS, V184, P1548, DOI 10.1086/324662; VANBODEGOM D, 2009, T R SOC TROP MED HYG; Walker RW, 2000, LANCET, V355, P1684, DOI 10.1016/S0140-6736(00)02240-6; Westendorp RGJ, 1997, LANCET, V349, P170, DOI 10.1016/S0140-6736(96)06413-6	34	32	33	0	8	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	NOV 11	2009	4	11					A174	A180	e7795	10.1371/journal.pone.0007795	http://dx.doi.org/10.1371/journal.pone.0007795			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	518IX	19907653	Green Submitted, Green Published, gold			2022-12-25	WOS:000271685800019
J	D'Avanzo, N; Pekhletski, R; Backx, PH				D'Avanzo, Nazzareno; Pekhletski, Roman; Backx, Peter H.			P-Loop Residues Critical for Selectivity in K+ Channels Fail to Confer Selectivity to Rabbit HCN4 Channels	PLOS ONE			English	Article							DIFFERENT ACTIVATION KINETICS; SHAKER POTASSIUM CHANNELS; VOLTAGE-SENSING MECHANISM; MOLECULAR-BASIS; IONIC SELECTIVITY; SINOATRIAL NODE; PACEMAKER CHANNELS; MYELINATED NERVE; ORGANIC CATIONS; SODIUM-CHANNEL	HCN channels are thought to be structurally similar to K-v channels, but show much lower selectivity for K+. The similar to 3.3 angstrom selectivity filter of K+ channels is formed by the pore-lining sequence XT(V/I)GYG, with X usually T, and is held stable by key residues in the P-loop. Differences in the P-loop sequence of HCN channels (eg. the pore- lining sequence L(478)C(479)IGYG) suggest these residues could account for differences in selectivity between these channel families. Despite being expressed, L478T/C479T HCN4 channels did not produce current. Since threonine in the second position is highly conserved in K+ channels, we also studied C479T channels. Based on permeability ratios (P-X/P-K), C479T HCN4 channels (K+(1). Rb+(0.85). Cs+(0.59). Li+(0.50)>= Na+(0.49)) were less selective than WT rabbit HCN4 (K+(1)> Rb+(0.48)>Cs+(0.31)>= Na+(0.29)>Li+(0.03)), indicating that the TIGYG sequence is insufficient to confer K+ selectivity to HCN channels. C479T HCN4 channels had an increased permeability to large organic cations than WT HCN4 channels, as well as increased unitary K+ conductance, and altered channel gating. Collectively, these results suggest that HCN4 channels have larger pores than K+ channels and replacement of the cysteine at position 479 with threonine further increases pore size. Furthermore, selected mutations in other regions linked previously to pore stability in K+ channels (ie. S475D, S475E and F471W/K472W) were also unable to confer K+ selectivity to C479T HCN4 channels. Our findings establish the presence of the TIGYG pore- lining sequence does not confer K+ selectivity to rabbit HCN4 channels, and suggests that differences in selectivity of HCN4 versus K+ channels originate from differences outside the P-loop region.			D'Avanzo, N (corresponding author), Washington Univ, Sch Med, Dept Cell Biol & Physiol, St Louis, MO 63110 USA.	p.backx@utoronto.ca			Canadian Institutes of Health Research Funding Source: Medline	Canadian Institutes of Health Research(Canadian Institutes of Health Research (CIHR))		Azene EM, 2005, BIOCHEM BIOPH RES CO, V327, P1131, DOI 10.1016/j.bbrc.2004.12.127; Azene EM, 2003, J PHYSIOL-LONDON, V547, P349, DOI 10.1113/jphysiol.2003.039768; Bell DC, 2004, J GEN PHYSIOL, V123, P5, DOI 10.1085/jgp.200308918; Berneche S, 2005, STRUCTURE, V13, P591, DOI 10.1016/j.str.2004.12.019; BEZANILLA F, 1972, J GEN PHYSIOL, V60, P588, DOI 10.1085/jgp.60.5.588; Bucchi A, 2002, J GEN PHYSIOL, V120, P1, DOI 10.1085/jgp.20028593; COHEN BN, 1992, J GEN PHYSIOL, V100, P373, DOI 10.1085/jgp.100.3.373; CORONADO R, 1980, J GEN PHYSIOL, V76, P425, DOI 10.1085/jgp.76.4.425; CORONADO R, 1987, BIOPHYS J, V51, P497, DOI 10.1016/S0006-3495(87)83371-4; Dibb KM, 2003, J BIOL CHEM, V278, P49537, DOI 10.1074/jbc.M307723200; DIFRANCESCO D, 1986, J PHYSIOL-LONDON, V377, P61, DOI 10.1113/jphysiol.1986.sp016177; DIFRANCESCO D, 1993, ANNU REV PHYSIOL, V55, P455, DOI 10.1146/annurev.physiol.55.1.455; Doyle DA, 1998, SCIENCE, V280, P69, DOI 10.1126/science.280.5360.69; DWYER TM, 1980, J GEN PHYSIOL, V75, P469, DOI 10.1085/jgp.75.5.469; Eickhorst AN, 2002, J GEN PHYSIOL, V120, P119, DOI 10.1085/jgp.20028535; EISENMAN G, 1983, J MEMBRANE BIOL, V76, P197, DOI 10.1007/BF01870364; EISENMAN G, 1962, Biophys J, V2, P259; Giorgetti A, 2005, BIOPHYS J, V89, P932, DOI 10.1529/biophysj.104.045286; Guidoni L, 1999, BIOCHEMISTRY-US, V38, P8599, DOI 10.1021/bi990540c; HEGINBOTHAM L, 1994, BIOPHYS J, V66, P1061, DOI 10.1016/S0006-3495(94)80887-2; HESTRIN S, 1987, J PHYSIOL-LONDON, V390, P319, DOI 10.1113/jphysiol.1987.sp016703; HILLE B, 1973, J GEN PHYSIOL, V61, P669, DOI 10.1085/jgp.61.6.669; HILLE B, 1971, J GEN PHYSIOL, V58, P599, DOI 10.1085/jgp.58.6.599; HILLE B, 1972, J GEN PHYSIOL, V59, P637, DOI 10.1085/jgp.59.6.637; HO WK, 1994, PFLUG ARCH EUR J PHY, V426, P68, DOI 10.1007/BF00374672; HUSH NS, 1948, AUST J SCI RES SER A, V1, P480, DOI 10.1071/CH9480480; Ishii TM, 1999, J BIOL CHEM, V274, P12835, DOI 10.1074/jbc.274.18.12835; Kaupp UB, 2001, ANNU REV PHYSIOL, V63, P235, DOI 10.1146/annurev.physiol.63.1.235; Kole MHP, 2006, J NEUROSCI, V26, P1677, DOI 10.1523/JNEUROSCI.3664-05.2006; Loboda A, 2001, BIOPHYS J, V80, P2704, DOI 10.1016/S0006-3495(01)76239-X; Ludwig A, 1998, NATURE, V393, P587, DOI 10.1038/31255; Ludwig A, 1999, EMBO J, V18, P2323, DOI 10.1093/emboj/18.9.2323; Macri V, 2002, J BIOL CHEM, V277, P35939, DOI 10.1074/jbc.M203485200; Mannikko R, 2002, NATURE, V419, P837, DOI 10.1038/nature01038; MCCLESKEY EW, 1985, P NATL ACAD SCI USA, V82, P7149, DOI 10.1073/pnas.82.20.7149; Mistrik P, 2005, J BIOL CHEM, V280, P27056, DOI 10.1074/jbc.M502696200; Much B, 2003, J BIOL CHEM, V278, P43781, DOI 10.1074/jbc.M306958200; Noskov SY, 2007, J GEN PHYSIOL, V129, P135, DOI 10.1085/jgp.200609633; Pape HC, 1996, ANNU REV PHYSIOL, V58, P299, DOI 10.1146/annurev.ph.58.030196.001503; Robinson RB, 2003, ANNU REV PHYSIOL, V65, P453, DOI 10.1146/annurev.physiol.65.092101.142734; Santoro B, 1999, ANN NY ACAD SCI, V868, P741, DOI 10.1111/j.1749-6632.1999.tb11353.x; Starkus JG, 1998, J GEN PHYSIOL, V112, P85, DOI 10.1085/jgp.112.1.85; Stieber J, 2003, J BIOL CHEM, V278, P33672, DOI 10.1074/jbc.M305318200; Sun YM, 1997, J GEN PHYSIOL, V110, P693, DOI 10.1085/jgp.110.6.693; Vemana S, 2004, J GEN PHYSIOL, V123, P21, DOI 10.1085/jgp.200308916; Voets T, 2004, J BIOL CHEM, V279, P15223, DOI 10.1074/jbc.M312076200; Wang HZ, 1997, J GEN PHYSIOL, V109, P491, DOI 10.1085/jgp.109.4.491; WOLLMUTH LP, 1992, J GEN PHYSIOL, V100, P749, DOI 10.1085/jgp.100.5.749; Yang J, 1997, P NATL ACAD SCI USA, V94, P1568, DOI 10.1073/pnas.94.4.1568; Yool AJ, 1996, BIOPHYS J, V71, P2467, DOI 10.1016/S0006-3495(96)79440-7; YOOL AJ, 1991, NATURE, V349, P700, DOI 10.1038/349700a0; Zheng J, 1997, J GEN PHYSIOL, V110, P101, DOI 10.1085/jgp.110.2.101; Zheng J, 1998, J GEN PHYSIOL, V112, P457, DOI 10.1085/jgp.112.4.457; Zhou M, 2004, J MOL BIOL, V338, P839, DOI 10.1016/j.jmb.2004.03.020; Zhou YF, 2001, NATURE, V414, P43, DOI 10.1038/35102009	55	7	7	0	3	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA	1932-6203			PLOS ONE	PLoS One	NOV 5	2009	4	11							e7712	10.1371/journal.pone.0007712	http://dx.doi.org/10.1371/journal.pone.0007712			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	515HI	19890386	Green Submitted, Green Published, gold			2022-12-25	WOS:000271459700009
J	Mucke, N; Klenin, K; Kirmse, R; Bussiek, M; Herrmann, H; Hafner, M; Langowski, J				Muecke, Norbert; Klenin, Konstantin; Kirmse, Robert; Bussiek, Malte; Herrmann, Harald; Hafner, Mathias; Langowski, Joerg			Filamentous Biopolymers on Surfaces: Atomic Force Microscopy Images Compared with Brownian Dynamics Simulation of Filament Deposition	PLOS ONE			English	Article							INTERMEDIATE-FILAMENTS; DNA; VIMENTIN; FLEXIBILITY; PROTEINS; POLYMERS; LENGTH; UNITS; HEAD; MICA	Nanomechanical properties of filamentous biopolymers, such as the persistence length, may be determined from two-dimensional images of molecules immobilized on surfaces. For a single filament in solution, two principal adsorption scenarios are possible. Both scenarios depend primarly on the interaction strength between the filament and the support: i) For interactions in the range of the thermal energy, the filament can freely equilibrate on the surface during adsorption; ii) For interactions much stronger than the thermal energy, the filament will be captured by the surface without having equilibrated. Such a 'trapping' mechanism leads to more condensed filament images and hence to a smaller value for the apparent persistence length. To understand the capture mechanism in more detail we have performed Brownian dynamics simulations of relatively short filaments by taking the two extreme scenarios into account. We then compared these 'ideal' adsorption scenarios with observed images of immobilized vimentin intermediate filaments on different surfaces. We found a good agreement between the contours of the deposited vimentin filaments on mica ('ideal' trapping) and on glass ('ideal' equilibrated) with our simulations. Based on these data, we have developed a strategy to reliably extract the persistence length of short worm-like chain fragments or network forming filaments with unknown polymer-surface interactions.			Mucke, N (corresponding author), German Canc Res Ctr, Div Biophys Macromol, D-6900 Heidelberg, Germany.	jl@dkfz.de	Langowski, Jörg/A-1843-2011	Langowski, Jörg/0000-0001-8600-0666; Mucke, Norbert/0000-0002-0683-4386				Bussiek M, 2003, NUCLEIC ACIDS RES, V31, DOI 10.1093/nar/gng137; ERMAK DL, 1978, J CHEM PHYS, V69, P1352, DOI 10.1063/1.436761; FRONTALI C, 1979, BIOPOLYMERS, V18, P1353, DOI 10.1002/bip.1979.360180604; Garcia HG, 2007, BIOPOLYMERS, V85, P115, DOI 10.1002/bip.20627; GITTES F, 1993, J CELL BIOL, V120, P923, DOI 10.1083/jcb.120.4.923; Herrmann H, 1996, J MOL BIOL, V264, P933, DOI 10.1006/jmbi.1996.0688; Herrmann H, 1999, J MOL BIOL, V286, P1403, DOI 10.1006/jmbi.1999.2528; Herrmann H, 2003, INT REV CYTOL, V223, P83; HERRMANN H, 1992, J MOL BIOL, V223, P637, DOI 10.1016/0022-2836(92)90980-X; INIESTA A, 1990, J CHEM PHYS, V92, P2015, DOI 10.1063/1.458034; Klenin K, 1998, BIOPHYS J, V74, P780, DOI 10.1016/S0006-3495(98)74003-2; KRATKY O, 1949, RECL TRAV CHIM PAY B, V68, P1106; Landau LD, 1986, THEORY ELASTICITY, DOI 10.1016/C2009-0-25521-8; Langowski J., 2004, CHROMATIN STRUCTURE, P397; Merlitz H, 1998, BIOPHYS J, V74, P773, DOI 10.1016/S0006-3495(98)74002-0; Mucke N, 2005, J STRUCT BIOL, V150, P268, DOI 10.1016/j.jsb.2005.02.012; Mucke N, 2004, J MOL BIOL, V340, P97, DOI 10.1016/j.jmb.2004.04.039; Mucke N, 2004, J MOL BIOL, V335, P1241, DOI 10.1016/j.jmb.2003.11.038; Rivetti C, 1996, J MOL BIOL, V264, P919, DOI 10.1006/jmbi.1996.0687; ROTNE J, 1969, J CHEM PHYS, V50, P4831, DOI 10.1063/1.1670977; Schulz A, 1998, J MOL BIOL, V283, P821, DOI 10.1006/jmbi.1998.2131; SUSHKO ML, 2006, SIMPLE MODEL DNA ADS, P22; Wickert U, 2005, EUR J CELL BIOL, V84, P379, DOI 10.1016/j.ejcb.2005.01.004; Wiggins PA, 2006, NAT NANOTECHNOL, V1, P137, DOI 10.1038/nnano.2006.63; YAMAKAWA H, 1972, J CHEM PHYS, V57, P2843, DOI 10.1063/1.1678675	25	21	21	0	9	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	NOV 4	2009	4	11							e7756	10.1371/journal.pone.0007756	http://dx.doi.org/10.1371/journal.pone.0007756			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	514RZ	19888472	Green Submitted, gold, Green Published			2022-12-25	WOS:000271414600014
J	Yung, GLP; Fidler, M; Albani, E; Spermon, N; Teklenburg, G; Newbury, R; Schechter, N; van den Broek, T; Prakken, B; Billetta, R; Dohil, R; Albani, S				Yung, Gisella L. Puga; Fidler, Meredith; Albani, Erika; Spermon, Naomi; Teklenburg, Gijs; Newbury, Robert; Schechter, Nicole; van den Broek, Theo; Prakken, Berent; Billetta, Rosario; Dohil, Ranjan; Albani, Salvatore			Heat Shock Protein-Derived T-Cell Epitopes Contribute to Autoimmune Inflammation in Pediatric Crohn's Disease	PLOS ONE			English	Article							MOLECULAR MIMICRY; IMMUNE-RESPONSES; ADJUVANT ARTHRITIS; BOWEL-DISEASE; HEAT-SHOCK-PROTEIN-60; PATHOGENESIS; EXPRESSION; IMMUNOTHERAPY; MYCOBACTERIUM; INHIBITION	Pediatric Crohn's disease is a chronic auto inflammatory bowel disorder affecting children under the age of 17 years. A putative etiopathogenesis of Crohn's disease (CD) is associated with disregulation of immune response to antigens commonly present in the gut microenvironment. Heat shock proteins (HSP) have been identified as ubiquitous antigens with the ability to modulate inflammatory responses associated with several autoimmune diseases. The present study tested the contribution of immune responses to HSP in the amplification of autoimmune inflammation in chronically inflamed mucosa of pediatric CD patients. Colonic biopsies obtained from normal and CD mucosa were stimulated with pairs of Pan HLA-DR binder HSP60-derived peptides (human/bacterial homologues). The modulation of RNA and protein levels of induced proinflammatory cytokines were measured. We identified two epitopes capable of sustaining proinflammatory responses, specifically TNF < and IFN (c) induction, in the inflamed intestinal mucosa in CD patients. The responses correlated positively with clinical and histological measurements of disease activity, thus suggesting a contribution of immune responses to HSP in pediatric CD site-specific mucosal inflammation.			Yung, GLP (corresponding author), Univ Hosp Geneva, Dept Internal Med, Serv Immunol & Allergy, Geneva, Switzerland.	salbani@arthritis.arizona.edu	, van den Broek T/I-9651-2019	, van den Broek T/0000-0002-2781-5731; , Gisella/0000-0002-2283-7798				Agnello D, 2002, INT IMMUNOPHARMACOL, V2, P463, DOI 10.1016/S1567-5769(01)00188-6; Albani S, 2006, ARTHRITIS RHEUM, V54, P19, DOI 10.1002/art.21520; Albani S, 1996, IMMUNOL TODAY, V17, P466, DOI 10.1016/0167-5699(96)20029-G; ALBANI S, 1995, NAT MED, V1, P448, DOI 10.1038/nm0595-448; Bason C, 2003, LANCET, V362, P1971, DOI 10.1016/S0140-6736(03)15016-7; Bouma G, 2003, NAT REV IMMUNOL, V3, P521, DOI 10.1038/nri1132; Brimnes J, 2001, EUR J IMMUNOL, V31, P23, DOI 10.1002/1521-4141(200101)31:1<23::AID-IMMU23>3.0.CO;2-2; Chauhan SK, 2004, CLIN EXP IMMUNOL, V138, P547, DOI 10.1111/j.1365-2249.2004.02644.x; Cohen IR, 2000, SEMIN IMMUNOL, V12, P215, DOI 10.1006/smim.2000.0234; COHEN IR, 2000, SEMIN IMMUNOL, V12, P257, DOI DOI 10.1006/SMIM.2000.0234; de Kleer IM, 2003, ARTHRITIS RHEUM, V48, P2001, DOI 10.1002/art.11174; FELDMAN M, 2002, SLEISENGER FORDTRANS, V41; Fiocchi C, 1998, GASTROENTEROLOGY, V115, P182, DOI 10.1016/S0016-5085(98)70381-6; Homan M, 2005, NAT CLIN PRACT GASTR, V2, P572, DOI 10.1038/ncpgasthep0338; Hu S, 2007, GASTROENTEROLOGY, V133, P1893, DOI 10.1053/j.gastro.2007.09.026; HYAMS JS, 1991, J PEDIATR GASTR NUTR, V12, P439, DOI 10.1097/00005176-199105000-00005; Kamphuis S, 2005, LANCET, V366, P50, DOI 10.1016/S0140-6736(05)66827-4; Kamradt T, 2001, NEW ENGL J MED, V344, P655, DOI 10.1056/NEJM200103013440907; KOFFEMAN EC, 2009, ARTHRITIS R IN PRESS; Linskens RK, 2001, SCAND J GASTROENTERO, V36, P29, DOI 10.1080/003655201753265082; Ludwig D, 1999, DIGEST DIS SCI, V44, P1440, DOI 10.1023/A:1026616221950; MacDonald TT, 2005, JPEN-PARENTER ENTER, V29, pS118, DOI 10.1177/01486071050290S4S118; Massa M, 2007, ARTHRITIS RHEUM, V56, P1648, DOI 10.1002/art.22567; McKaig BC, 2002, AM J PHYSIOL-CELL PH, V282, pC172, DOI 10.1152/ajpcell.00048.2001; Oldstone MBA, 1998, FASEB J, V12, P1255, DOI 10.1096/fasebj.12.13.1255; Olsen T, 2009, SCAND J GASTROENTERO, V44, P727, DOI 10.1080/00365520902803507; PEETERMANS WE, 1995, GASTROENTEROLOGY, V108, P75, DOI 10.1016/0016-5085(95)90010-1; Prakken BJ, 2001, CURR DIRECT AUTOIMMU, V3, P51; Prakken BJ, 2004, P NATL ACAD SCI USA, V101, P4228, DOI 10.1073/pnas.0400061101; Prohaszka Z, 2004, MOL IMMUNOL, V41, P29, DOI 10.1016/j.molimm.2004.02.001; Raz I, 2001, LANCET, V358, P1749, DOI 10.1016/S0140-6736(01)06801-5; Sartor RB, 1997, AM J GASTROENTEROL, V92, pS5; Southwood S, 1998, J IMMUNOL, V160, P3363; Spahn TW, 1997, DIGESTION, V58, P469, DOI 10.1159/000201485; Strober W, 2002, ANNU REV IMMUNOL, V20, P495, DOI 10.1146/annurev.immunol.20.100301.064816; SZEWCZUK MR, 1992, CLIN INVEST MED, V15, P494; van Eden W, 2005, NAT REV IMMUNOL, V5, P318, DOI 10.1038/nri1593; Viscido A, 2005, NUCL MED COMMUN, V26, P649, DOI 10.1097/01.mnm.0000169205.21377.6a; WALKER WA, 2000, PEDIAT GASTROINTESTI; Wendling U, 2000, J IMMUNOL, V164, P2711, DOI 10.4049/jimmunol.164.5.2711; Whittall T, 2006, CLIN EXP IMMUNOL, V143, P550, DOI 10.1111/j.1365-2249.2006.03010.x; WIETEN L, 2009, CELL STRESS CHAPERON; Yung GLP, 2003, INFLAMM RES, V52, P443, DOI 10.1007/s00011-003-1204-6	43	19	21	0	3	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	NOV 2	2009	4	11							e7714	10.1371/journal.pone.0007714	http://dx.doi.org/10.1371/journal.pone.0007714			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	514RX	19888320	gold, Green Submitted, Green Published			2022-12-25	WOS:000271414400014
J	Mavigner, M; Delobel, P; Cazabat, M; Dubois, M; L'Faqihi-Olive, FE; Raymond, S; Pasquier, C; Marchou, B; Massip, P; Izopet, J				Mavigner, Maud; Delobel, Pierre; Cazabat, Michelle; Dubois, Martine; L'Faqihi-Olive, Fatima-Ezzahra; Raymond, Stephanie; Pasquier, Christophe; Marchou, Bruno; Massip, Patrice; Izopet, Jacques			HIV-1 Residual Viremia Correlates with Persistent T-Cell Activation in Poor Immunological Responders to Combination Antiretroviral Therapy	PLOS ONE			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; HUMAN PERIPHERAL-BLOOD; IN-VIVO; VIRAL LOAD; REPLICATION-COMPETENT; INFECTED PATIENTS; LATENT RESERVOIR; PROGENITOR CELLS; DRUG-RESISTANCE; PLASMA VIREMIA	Background: The clinical significance and cellular sources of residual human immunodeficiency virus type 1 (HIV-1) production despite suppressive combination antiretroviral therapy (cART) remain unclear and the effect of low-level viremia on T-cell homeostasis is still debated. Methodology/Principal Findings: We characterized the recently produced residual viruses in the plasma and short-lived blood monocytes of 23 patients with various immunological responses to sustained suppressive cART. We quantified the residual HIV-1 in the plasma below 50 copies/ml, and in the CD14(high) CD16(-) and CD16(+) monocyte subsets sorted by flow cytometry, and predicted coreceptor usage by genotyping V3 env sequences. We detected residual viremia in the plasma of 8 of 10 patients with poor CD4(+) T-cell reconstitution in response to cART and in only 5 of 13 patients with good CD4(+) T-cell reconstitution. CXCR4-using viruses were frequent among the recently produced viruses in the plasma and in the main CD14(high) CD16(-) monocyte subset. Finally, the residual viremia was correlated with persistent CD4(+) and CD8(+) T-cell activation in patients with poor immune reconstitution. Conclusions: Low-level viremia could result from the release of archived viruses from cellular reservoirs and/or from ongoing virus replication in some patients. The compartmentalization of the viruses between the plasma and the blood monocytes suggests at least two origins of residual virus production during effective cART. CXCR4-using viruses might be produced preferentially in patients on cART. Our results also suggest that low-level HIV-1 production in some patients may contribute to persistent immune dysfunction despite cART.			Mavigner, M (corresponding author), Fac Med Toulouse, INSERM, U563, U317, F-31073 Toulouse, France.	izopet.j@chu-toulouse.fr	Delobel, Pierre/Q-6028-2019; Raymond, Stephanie/L-8401-2019; IZOPET, Jacques/L-5756-2014; Raymond, Stephanie/K-4507-2014; Delobel, Pierre/K-3166-2014	Delobel, Pierre/0000-0002-2874-3581; Raymond, Stephanie/0000-0002-3780-5844; Delobel, Pierre/0000-0002-2874-3581; PASQUIER, Christophe/0000-0001-9223-0150				Alexaki A, 2008, PLOS PATHOG, V4, DOI 10.1371/journal.ppat.1000215; Bailey JR, 2006, J VIROL, V80, P6441, DOI 10.1128/JVI.00591-06; Benito JM, 2004, AIDS RES HUM RETROV, V20, P227, DOI 10.1089/088922204773004950; Blaak H, 2000, P NATL ACAD SCI USA, V97, P1269, DOI 10.1073/pnas.97.3.1269; Bleul CC, 1997, P NATL ACAD SCI USA, V94, P1925, DOI 10.1073/pnas.94.5.1925; Brenchley JM, 2004, J VIROL, V78, P1160, DOI 10.1128/JVI.78.3.1160-1168.2004; Brooks DG, 2001, NAT MED, V7, P459, DOI 10.1038/86531; BUZON M, 2009, TRANSIENT INCREASE E; Chun TW, 2000, NAT MED, V6, P757, DOI 10.1038/77481; Chun TW, 1997, P NATL ACAD SCI USA, V94, P13193, DOI 10.1073/pnas.94.24.13193; Chun TW, 1998, P NATL ACAD SCI USA, V95, P8869, DOI 10.1073/pnas.95.15.8869; Crowe S, 2003, J LEUKOCYTE BIOL, V74, P635, DOI 10.1189/jlb.0503204; DAVIS BR, 1991, J VIROL, V65, P1985, DOI 10.1128/JVI.65.4.1985-1990.1991; Delobel P, 2005, JAIDS-J ACQ IMM DEF, V38, P382, DOI 10.1097/01.qai.0000152835.17747.47; Delobel P, 2007, J CLIN MICROBIOL, V45, P1572, DOI 10.1128/JCM.02090-06; Delobel P, 2006, J VIROL, V80, P10229, DOI 10.1128/JVI.00965-06; Diaz M, 2003, AIDS, V17, P1145, DOI 10.1097/00002030-200305230-00005; Dinoso JB, 2009, P NATL ACAD SCI USA, V106, P9403, DOI 10.1073/pnas.0903107106; Dion ML, 2004, IMMUNITY, V21, P757, DOI 10.1016/j.immuni.2004.10.013; Dornadula G, 1999, JAMA-J AM MED ASSOC, V282, P1627, DOI 10.1001/jama.282.17.1627; Douek DC, 2003, ANNU REV IMMUNOL, V21, P265, DOI 10.1146/annurev.immunol.21.120601.141053; Ellery PJ, 2007, J IMMUNOL, V178, P6581, DOI 10.4049/jimmunol.178.10.6581; EVERING T, 2009, SINGLE GENOME ANAL H; Finzi D, 1999, NAT MED, V5, P512, DOI 10.1038/8394; Finzi D, 1997, SCIENCE, V278, P1295, DOI 10.1126/science.278.5341.1295; Fulcher JA, 2004, J VIROL, V78, P7883, DOI 10.1128/JVI.78.15.7883-7893.2004; Furtado MR, 1999, NEW ENGL J MED, V340, P1614, DOI 10.1056/NEJM199905273402102; GANDHI R, 2009, RALTEGRAVIR INTENSIF; GARTNER S, 1986, SCIENCE, V233, P215, DOI 10.1126/science.3014648; Grage-Griebenow E, 2001, J LEUKOCYTE BIOL, V69, P11; Gunthard HF, 1999, VIROLOGY, V259, P154, DOI 10.1006/viro.1999.9774; Havlir DV, 2003, J VIROL, V77, P11212, DOI 10.1128/JVI.77.20.11212-11219.2003; Hermankova M, 2001, JAMA-J AM MED ASSOC, V286, P196, DOI 10.1001/jama.286.2.196; HO DD, 1995, NATURE, V373, P123, DOI 10.1038/373123a0; Johnston ER, 2003, J VIROL, V77, P7682, DOI 10.1128/JVI.77.13.7682-7688.2003; JONES J, 2009, DECREASE RESIDUAL VI; Kieffer TL, 2004, J INFECT DIS, V189, P1452, DOI 10.1086/382488; Kolluri SK, 1999, GENE DEV, V13, P1742, DOI 10.1101/gad.13.13.1742; Llewellyn N, 2006, J LEUKOCYTE BIOL, V80, P1118, DOI 10.1189/jlb.0306144; Maldarelli F, 2007, PLOS PATHOG, V3, P484, DOI 10.1371/journal.ppat.0030046; Martinez MA, 1999, VIROLOGY, V256, P180, DOI 10.1006/viro.1999.9601; Melby T, 2006, J INFECT DIS, V194, P238, DOI 10.1086/504693; MEURET G, 1974, BLOOD, V44, P801, DOI 10.1182/blood.V44.6.801.801; Natarajan V, 1999, LANCET, V353, P119, DOI 10.1016/S0140-6736(05)76156-0; NEAL TF, 1995, BLOOD, V86, P1749, DOI 10.1182/blood.V86.5.1749.bloodjournal8651749; Nettles RE, 2005, JAMA-J AM MED ASSOC, V293, P817, DOI 10.1001/jama.293.7.817; Nokta MA, 2002, AIDS, V16, P2119, DOI 10.1097/00002030-200211080-00003; Orenstein JM, 1997, SCIENCE, V276, P1857, DOI 10.1126/science.276.5320.1857; Ostrowski MA, 1999, J VIROL, V73, P6430, DOI 10.1128/JVI.73.8.6430-6435.1999; Ostrowski SR, 2008, SCAND J IMMUNOL, V68, P652, DOI 10.1111/j.1365-3083.2008.02184.x; Owen A, 2004, J VIROL, V78, P12022, DOI 10.1128/JVI.78.21.12022-12029.2004; Palmer S, 2003, J CLIN MICROBIOL, V41, P4531, DOI 10.1128/JCM.41.10.4531-4536.2003; Palmer S, 2008, P NATL ACAD SCI USA, V105, P3879, DOI 10.1073/pnas.0800050105; Palmisano L, 2005, AIDS, V19, P1843, DOI 10.1097/01.aids.0000188426.87538.ed; Parera M, 2004, J INFECT DIS, V189, P1444, DOI 10.1086/382485; PASSLICK B, 1989, BLOOD, V74, P2527, DOI 10.1182/blood.V74.7.2527.2527; Ramratnam B, 2000, NAT MED, V6, P82, DOI 10.1038/71577; Raymond S, 2008, AIDS, V22, pF11, DOI 10.1097/QAD.0b013e32830ebcd4; Sahu GK, 2009, J MED VIROL, V81, P9, DOI 10.1002/jmv.21366; Schmitt N, 2003, J VIROL, V77, P5784, DOI 10.1128/JVI.77.10.5784-5793.2003; Sharkey M, 2005, J VIROL, V79, P5203, DOI 10.1128/JVI.79.8.5203-5210.2005; Sharkey ME, 2000, NAT MED, V6, P76, DOI 10.1038/71569; Siliciano JD, 2003, NAT MED, V9, P727, DOI 10.1038/nm880; Sonza S, 2001, AIDS, V15, P17, DOI 10.1097/00002030-200101050-00005; Steel A, 2007, ANTIVIR THER, V12, P971; Taylor JR, 2001, J VIROL, V75, P8752, DOI 10.1128/JVI.75.18.8752-8760.2001; Tilling R, 2002, AIDS, V16, P589, DOI 10.1097/00002030-200203080-00010; Tobin NH, 2005, J VIROL, V79, P9625, DOI 10.1128/JVI.79.15.9625-9634.2005; VONLAER D, 1990, BLOOD, V76, P1281; Weber C, 2000, J LEUKOCYTE BIOL, V67, P699, DOI 10.1002/jlb.67.5.699; WEI XP, 1995, NATURE, V373, P117, DOI 10.1038/373117a0; WHITELAW DM, 1972, CELL TISSUE KINET, V5, P311, DOI 10.1111/j.1365-2184.1972.tb00369.x; Wilkin TJ, 2007, CLIN INFECT DIS, V44, P591, DOI 10.1086/511035; Wong JK, 1997, SCIENCE, V278, P1291, DOI 10.1126/science.278.5341.1291; Xu YN, 2008, J INFECT DIS, V197, P309, DOI 10.1086/524847; Zhang LQ, 2000, J CLIN INVEST, V106, P839, DOI 10.1172/JCI10565; Zhang LQ, 1999, NEW ENGL J MED, V340, P1605, DOI 10.1056/NEJM199905273402101; Zhu TF, 2002, J VIROL, V76, P707, DOI 10.1128/JVI.76.2.707-716.2002; ZieglerHeitbrock HWL, 1996, IMMUNOL TODAY, V17, P424, DOI 10.1016/0167-5699(96)10029-3	79	108	109	0	5	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA	1932-6203			PLOS ONE	PLoS One	OCT 30	2009	4	10							e7658	10.1371/journal.pone.0007658	http://dx.doi.org/10.1371/journal.pone.0007658			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	514RW	19876401	Green Published, Green Submitted, gold			2022-12-25	WOS:000271414300012
J	Astle, DE; Nobre, AC; Scerif, G				Astle, Duncan Edward; Nobre, Anna Christina; Scerif, Gaia			Applying an Attentional Set to Perceived and Remembered Features	PLOS ONE			English	Article							VISUAL WORKING-MEMORY; COGNITIVE CONTROL; ORIENTING ATTENTION; SPATIAL ATTENTION; TASK; COMPONENTS; SWITCH; ERP; MECHANISMS; INFORMATION	Previous research has examined our ability to attend selectively to particular features of perceptual objects, as well as our ability to switch from attending to one type of feature to another. This is usually done in the context of anticipatory attentional-set control, comparing the neural mechanisms involved as participants prepare to attend to the same stimulus feature as on the previous trial ("task-stay'' trials) with those required as participants prepare to attend to a different stimulus feature to that previously attended ("task-switch'' trials). We wanted to establish how participants maintain or switch attentional set retrospectively, as they attend to features of objects held in visual short-term memory (VSTM). We found that switching, relative to maintaining attentional set retrospectively, was associated with a performance cost, which can be reduced over time. This control process was mirrored by a large parietal and frontal amplitude difference in the event-related brain potentials (ERPs) and significant differences in global field power (GFP) between switch and stay trials. However, when taking into account the switch/stay GFP differences, thereby controlling for this difference in amplitude, we could not distinguish these trial types topographically. By contrast, we found clear topographic differences between preparing an anticipatory feature-based attentional set versus applying it retrospectively within VSTM. These complementary topographical and amplitude analyses suggested that anticipatory and retrospective set control recruited a qualitatively different configuration of underlying neural generators. In contrast, switch/stay differences were largely quantitative, with them differing primarily in terms of amplitude rather than topography.			Astle, DE (corresponding author), Univ Oxford, Dept Expt Psychol, S Parks Rd, Oxford OX1 3UD, England.	Duncan.astle@psy.ox.ac.uk		Nobre, Anna Christina/0000-0001-5762-2802; Astle, Duncan/0000-0002-7042-5392	ESRC [ES/F025505/1] Funding Source: UKRI; Economic and Social Research Council [ES/F025505/1] Funding Source: researchfish; Wellcome Trust Funding Source: Medline	ESRC(UK Research & Innovation (UKRI)Economic & Social Research Council (ESRC)); Economic and Social Research Council(UK Research & Innovation (UKRI)Economic & Social Research Council (ESRC)); Wellcome Trust(Wellcome TrustEuropean Commission)		ALLPORT A, 1994, ATTENTION PERFORM, V15, P421; Astle DE, 2008, EUR J NEUROSCI, V28, P1404, DOI 10.1111/j.1460-9568.2008.06439.x; Astle DE, 2006, BRAIN RES, V1125, P94, DOI 10.1016/j.brainres.2006.09.092; Astle DE, 2008, J COGNITIVE NEUROSCI, V20, P255, DOI 10.1162/jocn.2008.20015; Astle DE, 2009, FRONT HUM NEUROSCI, V3, DOI 10.3389/neuro.09.006.2009; DESIMONE R, 1995, ANNU REV NEUROSCI, V18, P193, DOI 10.1146/annurev.ne.18.030195.001205; Fabiani M, 2003, PSYCHOPHYSIOLOGY, V40, P472, DOI 10.1111/1469-8986.00049; Griffin IC, 2003, J COGNITIVE NEUROSCI, V15, P1176, DOI 10.1162/089892903322598139; Harrison SA, 2009, NATURE, V458, P632, DOI 10.1038/nature07832; JENNINGS JR, 1976, PSYCHOPHYSIOLOGY, V13, P277; Karayanidis F, 2003, PSYCHOPHYSIOLOGY, V40, P329, DOI 10.1111/1469-8986.00037; Kieffaber PD, 2005, PSYCHOPHYSIOLOGY, V42, P56, DOI 10.1111/j.1469-8986.2005.00262.x; Kuo BC, 2009, J NEUROSCI, V29, P8032, DOI 10.1523/JNEUROSCI.0952-09.2009; Landman R, 2003, VISION RES, V43, P149, DOI 10.1016/S0042-6989(02)00402-9; Lavric A, 2008, EUR J NEUROSCI, V28, P1016, DOI 10.1111/j.1460-9568.2008.06372.x; LEHMANN D, 1980, ELECTROEN CLIN NEURO, V48, P609, DOI 10.1016/0013-4694(80)90419-8; Lepsien J, 2005, NEUROIMAGE, V26, P733, DOI 10.1016/j.neuroimage.2005.02.026; Lepsien J, 2006, BRAIN RES, V1105, P20, DOI 10.1016/j.brainres.2006.03.033; Logan GD, 2003, J EXP PSYCHOL HUMAN, V29, P575, DOI 10.1037/0096-1523.29.3.575; LURIA R, 2009, J COGN NEUROSCI; Makovski T, 2008, J EXP PSYCHOL LEARN, V34, P369, DOI 10.1037/0278-7393.34.2.369; MICHEL CM, 1992, INT J PSYCHOPHYSIOL, V12, P133, DOI 10.1016/0167-8760(92)90004-U; Monsell S, 2003, TRENDS COGN SCI, V7, P134, DOI 10.1016/S1364-6613(03)00028-7; Mueller SC, 2007, BRAIN RES, V1157, P56, DOI 10.1016/j.brainres.2007.04.046; Mueller SC, 2009, NEUROIMAGE, V45, P191, DOI 10.1016/j.neuroimage.2008.11.019; Murray MM, 2008, BRAIN TOPOGR, V20, P249, DOI 10.1007/s10548-008-0054-5; Murray MM, 2006, J NEUROSCI, V26, P12043, DOI 10.1523/JNEUROSCI.3225-06.2006; Nicholson R, 2005, PSYCHOPHYSIOLOGY, V42, P540, DOI 10.1111/j.1469-8986.2005.00350.x; Nicholson R, 2006, BRAIN RES, V1095, P107, DOI 10.1016/j.brainres.2006.04.016; Nobre AC, 2008, FRONT HUM NEUROSCI, V1, DOI 10.3389/neuro.09.004.2007; PASCUALMARQUI RD, 1995, IEEE T BIO-MED ENG, V42, P658, DOI 10.1109/10.391164; ROGERS RD, 1995, J EXP PSYCHOL GEN, V124, P207, DOI 10.1037/0096-3445.124.2.207; Rushworth MFS, 2005, EXP PSYCHOL, V52, P83, DOI 10.1027/1618-3169.52.2.83; Rushworth MFS, 2002, J COGNITIVE NEUROSCI, V14, P1139, DOI 10.1162/089892902760807159; Serences JT, 2009, PSYCHOL SCI, V20, P207, DOI 10.1111/j.1467-9280.2009.02276.x; Sligte IG, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0001699; SPERLING G, 1960, PSYCHOL MONOGR, V74, P1, DOI 10.1037/h0093759; Swainson R, 2003, J COGNITIVE NEUROSCI, V15, P785, DOI 10.1162/089892903322370717; SWAINSON R, 2006, BRAIN RES; Verbruggen F, 2007, J EXP PSYCHOL LEARN, V33, P342, DOI 10.1037/0278-7393.33.2.342; Woodman GF, 2008, PSYCHON B REV, V15, P223, DOI 10.3758/PBR.15.1.223; Wylie GR, 2009, J COGNITIVE NEUROSCI, V21, P105, DOI 10.1162/jocn.2009.21009; Wylie GR, 2003, NEUROIMAGE, V20, P2322, DOI 10.1016/j.neuroimage.2003.08.010	43	10	10	0	1	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	OCT 29	2009	4	10							e7613	10.1371/journal.pone.0007613	http://dx.doi.org/10.1371/journal.pone.0007613			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	512FP	19898613	Green Published, Green Submitted, gold			2022-12-25	WOS:000271232000004
J	Odsbu, I; Morigen, KS				Odsbu, Ingvild; Morigen, Kirsten Skarstad			A Reduction in Ribonucleotide Reductase Activity Slows Down the Chromosome Replication Fork but Does Not Change Its Localization	PLOS ONE			English	Article							COLI SEQA PROTEIN; IRRADIATED ESCHERICHIA-COLI; DNA-REPLICATION; DIPHOSPHATE REDUCTASE; DEOXYRIBONUCLEOTIDE SYNTHESIS; DIVISION CYCLE; MUTANT; CELLS; HYPERSTRUCTURE; SEQUESTRATION	Background: It has been proposed that the enzymes of nucleotide biosynthesis may be compartmentalized or concentrated in a structure affecting the organization of newly replicated DNA. Here we have investigated the effect of changes in ribonucleotide reductase (RNR) activity on chromosome replication and organization of replication forks in Escherichia coli. Methodology/Principal Findings: Reduced concentrations of deoxyribonucleotides (dNTPs) obtained by reducing the activity of wild type RNR by treatment with hydroxyurea or by mutation, resulted in a lengthening of the replication period. The replication fork speed was found to be gradually reduced proportionately to moderate reductions in nucleotide availability. Cells with highly extended C periods showed a "delay'' in cell division i.e. had a higher cell mass. Visualization of SeqA structures by immunofluorescence indicated no change in organization of the new DNA upon moderate limitation of RNR activity. Severe nucleotide limitation led to replication fork stalling and reversal. Well defined SeqA structures were not found in situations of extensive replication fork repair. In cells with stalled forks obtained by UV irradiation, considerable DNA compaction was observed, possibly indicating a reorganization of the DNA into a "repair structure'' during the initial phase of the SOS response. Conclusion/Significance: The results indicate that the replication fork is slowed down in a controlled manner during moderate nucleotide depletion and that a change in the activity of RNR does not lead to a change in the organization of newly replicated DNA. Control of cell division but not control of initiation was affected by the changes in replication elongation.			Odsbu, I (corresponding author), Oslo Univ Hosp, Norwegian Radium Hosp, Inst Canc Res, Dept Cell Biol, Oslo, Norway.	kirsten.skarstad@rr-research.no						Beam CE, 2002, J BACTERIOL, V184, P6836, DOI 10.1128/JB.184.24.6836-6844.2002; Boston T, 2003, J BACTERIOL, V185, P5310, DOI 10.1128/JB.185.17.5310-5313.2003; BREMER H, 1977, J THEOR BIOL, V69, P645, DOI 10.1016/0022-5193(77)90373-3; Brendler T, 1999, EMBO J, V18, P2304, DOI 10.1093/emboj/18.8.2304; Buckstein MH, 2008, J BACTERIOL, V190, P718, DOI 10.1128/JB.01020-07; CLARK DJ, 1967, J MOL BIOL, V23, P99, DOI 10.1016/S0022-2836(67)80070-6; COOPER S, 1968, J MOL BIOL, V31, P519, DOI 10.1016/0022-2836(68)90425-7; Fossum S, 2003, MOL MICROBIOL, V47, P619, DOI 10.1046/j.1365-2958.2003.t01-1-03329.x; Fossum S, 2007, EMBO J, V26, P4514, DOI 10.1038/sj.emboj.7601871; FUCHS JA, 1972, NATURE-NEW BIOL, V238, P69, DOI 10.1038/newbio238069a0; GIBERT I, 1990, MOL GEN GENET, V220, P400, DOI 10.1007/BF00391745; Godoy VG, 2006, EMBO J, V25, P868, DOI 10.1038/sj.emboj.7600986; Gon S, 2006, EMBO J, V25, P1137, DOI 10.1038/sj.emboj.7600990; Grinberg I, 2006, J BACTERIOL, V188, P7635, DOI 10.1128/JB.00903-06; Grompone G, 2002, MOL MICROBIOL, V44, P1331, DOI 10.1046/j.1365-2958.2002.02962.x; GUARINO E, 2007, J BACTERIOL; Guarino E, 2007, J BACTERIOL, V189, P3496, DOI 10.1128/JB.01632-06; Guarne A, 2005, EMBO J, V24, P1502, DOI 10.1038/sj.emboj.7600634; GUYER MS, 1980, COLD SPRING HARB SYM, V45, P135, DOI 10.1101/SQB.1981.045.01.022; Guzman EC, 2002, MOL MICROBIOL, V43, P487, DOI 10.1046/j.1365-2958.2002.02761.x; Hiraga S, 1998, MOL CELL, V1, P381, DOI 10.1016/S1097-2765(00)80038-6; Jacobson BA, 1998, MOL MICROBIOL, V28, P1307, DOI 10.1046/j.1365-2958.1998.00896.x; JENSEN KF, 1993, J BACTERIOL, V175, P3401, DOI 10.1128/jb.175.11.3401-3407.1993; Kim J, 2005, MOL MICROBIOL, V55, P1502, DOI 10.1111/j.1365-2958.2004.04486.x; MANWARING JD, 1979, J BACTERIOL, V138, P245, DOI 10.1128/JB.138.1.245-248.1979; MATHEWS CK, 1993, PROG NUCLEIC ACID RE, V44, P167, DOI 10.1016/S0079-6603(08)60220-2; Molina F, 2004, MOL MICROBIOL, V52, P1597, DOI 10.1111/j.1365-2958.2004.04097.x; MOORE EC, 1985, PHARMACOL THERAPEUT, V27, P167; Morigen, 2001, BBA-GENE STRUCT EXPR, V1521, P73; Morigen, 2009, GENES CELLS, V14, P643, DOI 10.1111/j.1365-2443.2009.01298.x; Nordlund N, 2006, ANNU REV BIOCHEM, V75, P681, DOI 10.1146/annurev.biochem.75.103004.142443; Norris V, 2000, MOL MICROBIOL, V37, P696, DOI 10.1046/j.1365-2958.2000.02019.x; Norris V, 2007, MICROBIOL MOL BIOL R, V71, P230, DOI 10.1128/MMBR.00035-06; Odsbu I, 2005, GENES CELLS, V10, P1039, DOI 10.1111/j.1365-2443.2005.00898.x; Onogi T, 1999, MOL MICROBIOL, V31, P1775, DOI 10.1046/j.1365-2958.1999.01313.x; Ortenberg R, 2004, P NATL ACAD SCI USA, V101, P7439, DOI 10.1073/pnas.0401965101; PAYNE SM, 1982, ANAL BIOCHEM, V123, P151, DOI 10.1016/0003-2697(82)90636-4; Rudolph CJ, 2008, DNA REPAIR, V7, P1589, DOI 10.1016/j.dnarep.2008.06.012; Rudolph CJ, 2007, GENE DEV, V21, P668, DOI 10.1101/gad.417607; Seigneur M, 1998, CELL, V95, P419, DOI 10.1016/S0092-8674(00)81772-9; SEKIMIZU K, 1987, CELL, V50, P259, DOI 10.1016/0092-8674(87)90221-2; Shen RK, 2004, J BIOL CHEM, V279, P32225, DOI 10.1074/jbc.M402750200; SKARSTAD K, 1985, J BACTERIOL, V163, P661, DOI 10.1128/JB.163.2.661-668.1985; SKARSTAD K, 1986, EMBO J, V5, P1711, DOI 10.1002/j.1460-2075.1986.tb04415.x; SLATER S, 1995, CELL, V82, P927, DOI 10.1016/0092-8674(95)90272-4; Thellier M, 2006, FEBS J, V273, P4287, DOI 10.1111/j.1742-4658.2006.05425.x; Torheim NK, 2000, MOL MICROBIOL, V37, P629, DOI 10.1046/j.1365-2958.2000.02031.x; Torrents E, 2007, J BACTERIOL, V189, P5012, DOI 10.1128/JB.00440-07; WECHSLER JA, 1971, MOL GEN GENET, V113, P273, DOI 10.1007/BF00339547; Weiss DS, 1999, J BACTERIOL, V181, P508, DOI 10.1128/JB.181.2.508-520.1999	50	38	39	1	7	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	OCT 28	2009	4	10							e7617	10.1371/journal.pone.0007617	http://dx.doi.org/10.1371/journal.pone.0007617			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	511UJ	19898675	Green Submitted, Green Published, gold			2022-12-25	WOS:000271194600011
J	Fei, Z; Liu, Y; Yan, Z; Fan, DM; Alexander, A; Yang, JH				Fei, Zhou; Liu, Yang; Yan, Zhen; Fan, Daiming; Alexander, Alice; Yang, Jing-Hua			Targeting viral dsRNA for antiviral prophylaxis	FASEB JOURNAL			English	Article						apoptosis; double-stranded RNA; pathogen-associated molecular pattern	DOUBLE-STRANDED-RNA; PROTEIN-SYNTHESIS; RIG-I; ACTIVATION; PKR; INHIBITION; EXPRESSION; INTERFERENCE; PARTICLES; INFECTION	Double-stranded (ds)RNA in the infected cells is a trait shared by most if not all viruses. While humans have developed variable immune responses, viruses have also developed countermeasures to defeat dsRNA-induced antiviral strategies. Thus, we proposed a broad antiviral strategy to antagonize the countermeasures of viruses and bypass the dsRNA-induced signals that are readily defeated by viruses. By rewiring the dsRNA-binding proteins in the dsRNA complex and reconnecting them to apoptosis signaling, we created several dsRNA-dependent caspase recruiters, termed dsCAREs, to bypass dsRNA-induced antiviral signals that would otherwise be targeted by viruses. Adenovirus and vesicular stomatitis virus, representing viruses of the dsDNA and negative-stranded RNA viral groups, were used to infect HEK293 cells. The dsCARE chimera was added in medium to evaluate its antiviral activity. The truncated dsCAREs were used as controls. We demonstrate that dsCARE suppresses viral infection starting at 0.1 mu g/ml and reaches the peak at 2 mu g/ml. The EC(50) was similar to 0.2 mu g/ml. However, it had an undetectable effect on uninfected cells. Further data show that both dsRNA binding and apoptosis activation of dsCARE are essential for its antiviral activity. We conclude that dsRNA is a practical virus-associated molecular pattern that can be targeted for broad and rapid antiviral prophylaxis.-Fei, Z., Liu, Y., Yan, Z., Fan, D., Alexander, A., Yang, J.-H. Targeting viral dsRNA for antiviral prophylaxis. FASEB J. 25, 1767-1774 (2011). www.fasebj.org	[Fei, Zhou; Liu, Yang; Alexander, Alice; Yang, Jing-Hua] Boston Univ, Dept Surg, Sch Med, Boston Vet Affairs Healthcare Syst, Boston, MA 02130 USA; [Fan, Daiming] Xijing Hosp, Dept Gastroenterol, Xian, Peoples R China; [Fei, Zhou] Xijing Hosp, Dept Neurosurg, Xian, Peoples R China; [Yan, Zhen] Xijing Hosp, Dept Pharmacol, Xian, Peoples R China	Boston University; Air Force Military Medical University; Air Force Military Medical University; Air Force Military Medical University	Yang, JH (corresponding author), Boston Univ, Dept Surg, Sch Med, Boston Vet Affairs Healthcare Syst, 150 S Huntington Ave, Boston, MA 02130 USA.	jyang@bu.edu			National Institutes of Health [R01-GM-060426, K02-AI-060701]; National Science Foundation of China (NSFC) [30928031, 81071369]; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [K02AI060701] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM060426] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); National Science Foundation of China (NSFC)(National Natural Science Foundation of China (NSFC)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	This study was supported by grants from the National Institutes of Health (R01-GM-060426 and K02-AI-060701) and the National Science Foundation of China (NSFC; 30928031 and 81071369) to J.-H.Y. and a visiting scholarship from NSFC to Z.F. It is the result of work supported with resources and the use of facilities at Boston Veterans Affairs Medical Center, Boston, MA, USA. The authors declare that they have no competing financial interests.	Alexopoulou L, 2001, NATURE, V413, P732, DOI 10.1038/35099560; Bowie AG, 2007, TRENDS IMMUNOL, V28, P147, DOI 10.1016/j.it.2007.02.002; Childs KS, 2009, J VIROL, V83, P1465, DOI 10.1128/JVI.01768-08; DACQUISTO F, 2001, SCI STKE, pRE1; Dalton KP, 2001, VIROLOGY, V279, P414, DOI 10.1006/viro.2000.0736; Embury J, 2001, DIABETES, V50, P1706, DOI 10.2337/diabetes.50.8.1706; Feng ZD, 2007, J VIROL, V81, P182, DOI 10.1128/JVI.01006-06; Fujita T, 2007, BIOCHIMIE, V89, P754, DOI 10.1016/j.biochi.2007.01.013; Gainey MD, 2008, J VIROL, V82, P828, DOI 10.1128/JVI.02023-07; Gupta V, 2003, VIROLOGY, V315, P283, DOI 10.1016/S0042-6822(03)00589-0; Ho A, 2001, CANCER RES, V61, P474; Kiyosawa H, 2003, GENOME RES, V13, P1324, DOI 10.1101/gr.982903; Krasnoselskaya-Riz I, 2002, AIDS RES HUM RETROV, V18, P591, DOI 10.1089/088922202753747941; LEE JY, 1994, VIROLOGY, V200, P307, DOI 10.1006/viro.1994.1192; Li SD, 2006, VIROLOGY, V349, P13, DOI 10.1016/j.virol.2006.01.005; LIBONATI M, 1980, MOL CELL BIOCHEM, V31, P147; MARAN A, 1988, VIROLOGY, V164, P106, DOI 10.1016/0042-6822(88)90625-3; Nie YZ, 2007, J VIROL, V81, P917, DOI 10.1128/JVI.01527-06; Nie YZ, 2005, MOL CELL BIOL, V25, P6956, DOI 10.1128/MCB.25.16.6956-6963.2005; RIDER TH, 2006, Patent No. 7125839; Samuel CE, 2001, CLIN MICROBIOL REV, V14, P778, DOI 10.1128/CMR.14.4.778-809.2001; Schroder M, 2005, TRENDS IMMUNOL, V26, P462, DOI 10.1016/j.it.2005.07.002; Sioud M, 2007, ADV DRUG DELIVER REV, V59, P153, DOI 10.1016/j.addr.2007.03.006; STOLLAR BD, 1970, VIROLOGY, V42, P276, DOI 10.1016/0042-6822(70)90270-9; Strong JE, 2008, P NATL ACAD SCI USA, V105, P17982, DOI 10.1073/pnas.0809698105; TWU JS, 1988, P NATL ACAD SCI USA, V85, P252, DOI 10.1073/pnas.85.1.252; Weber F, 2004, VIRAL IMMUNOL, V17, P498, DOI 10.1089/vim.2004.17.498; Weber F, 2006, J VIROL, V80, P5059, DOI 10.1128/JVI.80.10.5059-5064.2006; Yelin R, 2003, NAT BIOTECHNOL, V21, P379, DOI 10.1038/nbt808; Yount JS, 2006, J IMMUNOL, V177, P4503, DOI 10.4049/jimmunol.177.7.4503; Zhou P, 1999, P NATL ACAD SCI USA, V96, P11265, DOI 10.1073/pnas.96.20.11265	31	7	8	1	7	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	MAY	2011	25	5					1767	1774		10.1096/fj.09-144915	http://dx.doi.org/10.1096/fj.09-144915			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	756OU	19880628	Green Published			2022-12-25	WOS:000290023800032
J	Murikinati, S; Juttler, E; Keinert, T; Ridder, DA; Muhammad, S; Waibler, Z; Ledent, C; Zimmer, A; Kalinke, U; Schwaninger, M				Murikinati, Sasidhar; Juettler, Eric; Keinert, Timo; Ridder, Dirk A.; Muhammad, Sajjad; Waibler, Zoe; Ledent, Catherine; Zimmer, Andreas; Kalinke, Ulrich; Schwaninger, Markus			Activation of cannabinoid 2 receptors protects against cerebral ischemia by inhibiting neutrophil recruitment	FASEB JOURNAL			English	Article						stroke; chemotaxis; p38; bone marrow transplantation	ADHESION MOLECULE-1 ANTIBODY; CB2 RECEPTOR; BRAIN-DAMAGE; ISCHEMIC/REPERFUSION INJURY; ARTERY OCCLUSION; VIRUS-INFECTION; CELL-DAMAGE; MOUSE MODEL; STROKE; MICE	Activation of the cannabinoid 2 receptor (CB2) reduces ischemic injury in several organs. However, the mechanisms underlying this protective action are unclear. In a mouse model of ischemic stroke, we show that the CB2 agonist JWH-133 (1 mg . kg(-1) . d(-1)) decreases the infarct size measured 3 d after onset of ischemia. The neuroprotective effect of JWH-133 was lost in CB2-deficient mice, confirming the specificity of JWH-133. Analysis of bone marrow chimeric mice revealed that bone marrow-derived cells mediate the CB2 effect on ischemic brain injury. CB2 activation reduced the number of neutrophils in the ischemic brain as shown by FACS analysis and by measuring the levels of the neutrophil marker enzyme myeloperoxidase. Indeed, we found in vitro that CB2 activation inhibits adherence of neutrophils to brain endothelial cells. JWH-133 (1 mu M) also interfered with the migration of neutrophils induced by the endogenous chemokine CXCL2 (30 ng/ml) through activation of the MAP kinase p38. This effect on neutrophils is likely responsible for the neuroprotection mediated by JWH-133 because JWH-133 was no longer protective when neutrophils were depleted. In conclusion, our data demonstrate that by activating p38 in neutrophils, CB2 agonists inhibit neutrophil recruitment to the brain and protect against ischemic brain injury.-Murikinati, S., Juttler, E., Keinert, T., Ridder, D. A., Muhammad, S., Waibler, Z., Ledent, C., Zimmer, A., Kalinke, U., Schwaninger, M. Activation of cannabinoid 2 receptors protects against cerebral ischemia by inhibiting neutrophil recruitment. FASEB J. 24, 788-798 (2010). www.fasebj.org	[Murikinati, Sasidhar; Ridder, Dirk A.; Muhammad, Sajjad; Schwaninger, Markus] Heidelberg Univ, Dept Pharmacol, D-69120 Heidelberg, Germany; [Juettler, Eric; Keinert, Timo] Heidelberg Univ, Dept Neurol, D-69120 Heidelberg, Germany; [Waibler, Zoe] Paul Ehrlich Inst, Jr Res Grp, D-6070 Langen, Germany; [Ledent, Catherine] Inst Rech Interdisciplinaire Biol Humaine & Mol, Brussels, Belgium; [Zimmer, Andreas] Univ Bonn, Inst Mol Psychiat, D-5300 Bonn, Germany; [Kalinke, Ulrich] Ctr Expt & Clin Infect Res, Inst Expt Infect Res, Hannover, Germany	Ruprecht Karls University Heidelberg; Ruprecht Karls University Heidelberg; Paul Ehrlich Institute; University of Bonn	Schwaninger, M (corresponding author), Heidelberg Univ, Dept Pharmacol, Neuenheimer Feld 366, D-69120 Heidelberg, Germany.	markus.schwaninger@pharma.uni-heidelberg.de	Zimmer, Andreas/B-8357-2009	Kalinke, Ulrich/0000-0003-0503-9564; Muhammad, Sajjad/0000-0002-6734-7979	European Union's Seventh Framework Programme [FP7/2007-2013, 201024, 202213]; Deutsche Forschungsgemeinschaft (DFG) [791]	European Union's Seventh Framework Programme; Deutsche Forschungsgemeinschaft (DFG)(German Research Foundation (DFG))	The authors thank Christina Stannek and Nadine Gehrig for expert technical assistance. The research leading to these results has received funding from the European Union's Seventh Framework Programme (FP7/2007-2013) under grant agreements 201024 and 202213 (European Stroke Network). S. M. was supported by a scholarship of the Deutsche Forschungsgemeinschaft (DFG) graduate college 791. Twincore, Centre for Experimental and Clinical Infection Research, is a joint venture between Helmholtz Centre for Infection Research (HZI; Braunschweig, Germany) and Hannover Medical School (MHH; Hannover, Germany).	Akk AM, 2008, J IMMUNOL, V180, P3535, DOI 10.4049/jimmunol.180.5.3535; Andrew DP, 1998, EUR J IMMUNOL, V28, P1959, DOI 10.1002/(SICI)1521-4141(199806)28:06<1959::AID-IMMU1959>3.0.CO;2-4; Arumugam TV, 2004, AM J PHYSIOL-HEART C, V287, pH2555, DOI 10.1152/ajpheart.00588.2004; Barone FC, 1999, J CEREBR BLOOD F MET, V19, P819, DOI 10.1097/00004647-199908000-00001; Batkai S, 2007, FASEB J, V21, P1788, DOI 10.1096/fj.06-7451com; Berger C, 2004, J NEUROCHEM, V88, P1159, DOI 10.1046/j.1471-4159.2003.02244.x; Blazquez C, 2003, FASEB J, V17, P529, DOI 10.1096/fj.02-0795fje; Brown AJ, 2007, BRIT J PHARMACOL, V152, P567, DOI 10.1038/sj.bjp.0707481; Buckley  NE, 2000, EUR J PHARMACOL, V396, P141, DOI 10.1016/S0014-2999(00)00211-9; Chamorro A, 2007, STROKE, V38, P1097, DOI 10.1161/01.STR.0000258346.68966.9d; CHEN H, 1994, ANN NEUROL, V35, P458, DOI 10.1002/ana.410350414; Connolly ES, 1996, J CLIN INVEST, V97, P209, DOI 10.1172/JCI118392; Dawson Deborah A., 1996, Keio Journal of Medicine, V45, P248; Defer N, 2009, FASEB J, V23, P2120, DOI 10.1096/fj.09-129478; Docagne F, 2007, MOL CELL NEUROSCI, V34, P551, DOI 10.1016/j.mcn.2006.12.005; Eljaschewitsch E, 2006, NEURON, V49, P67, DOI 10.1016/j.neuron.2005.11.027; Emerich DF, 2002, EXP NEUROL, V173, P168, DOI 10.1006/exnr.2001.7835; Fernandez-Lopez D, 2006, PEDIATR RES, V60, P169, DOI 10.1203/01.pdr.0000228839.00122.6c; Frangogiannis NG, 2007, THROMB HAEMOSTASIS, V97, P738, DOI 10.1160/TH07-01-0022; Furuya K, 2001, STROKE, V32, P2665, DOI 10.1161/hs3211.098535; Golech SA, 2004, MOL BRAIN RES, V132, P87, DOI 10.1016/j.molbrainres.2004.08.025; Graff G, 1998, J PHARMACOL TOXICOL, V39, P169, DOI 10.1016/S1056-8719(98)00023-9; Heit B, 2002, J CELL BIOL, V159, P91, DOI 10.1083/jcb.200202114; Heit B, 2008, NAT IMMUNOL, V9, P743, DOI 10.1038/ni.1623; Herrmann O, 2005, NAT MED, V11, P1322, DOI 10.1038/nm1323; Hillard CJ, 2008, CURR PHARM DESIGN, V14, P2347, DOI 10.2174/138161208785740054; Howlett AC, 2002, PHARMACOL REV, V54, P161, DOI 10.1124/pr.54.2.161; Huffman JW, 1999, BIOORGAN MED CHEM, V7, P2905, DOI 10.1016/S0968-0896(99)00219-9; Johns DG, 2007, BRIT J PHARMACOL, V152, P825, DOI 10.1038/sj.bjp.0707419; Juttler E, 2004, NEUROPHARMACOLOGY, V47, P580, DOI 10.1016/j.neuropharm.2004.05.009; Kataoka H, 2004, J CEREBR BLOOD F MET, V24, P668, DOI 10.1097/01.WCB.0000117812.35136.5B; Katzan IL, 2003, NEUROLOGY, V60, P620, DOI 10.1212/01.WNL.0000046586.38284.60; Khan AI, 2005, MICROCIRCULATION, V12, P421, DOI 10.1080/10739680590960368; Kim K, 2006, EUR J PHARMACOL, V542, P100, DOI 10.1016/j.ejphar.2006.05.025; Ledent C, 1999, SCIENCE, V283, P401, DOI 10.1126/science.283.5400.401; Liu QR, 2009, GENES BRAIN BEHAV, V8, P519, DOI 10.1111/j.1601-183X.2009.00498.x; Maresz K, 2007, NAT MED, V13, P492, DOI 10.1038/nm1561; Markt P, 2009, J MED CHEM, V52, P369, DOI 10.1021/jm801044g; McColl BW, 2007, J NEUROSCI, V27, P4403, DOI 10.1523/JNEUROSCI.5376-06.2007; Mestre L, 2006, BIOCHEM PHARMACOL, V72, P869, DOI 10.1016/j.bcp.2006.06.037; Mildner A, 2007, NAT NEUROSCI, V10, P1544, DOI 10.1038/nn2015; Miller AM, 2008, BRIT J PHARMACOL, V153, P299, DOI 10.1038/sj.bjp.0707523; Montecucco F, 2009, J MOL CELL CARDIOL, V46, P612, DOI 10.1016/j.yjmcc.2008.12.014; Muhammad S, 2008, J NEUROSCI, V28, P12023, DOI 10.1523/JNEUROSCI.2435-08.2008; Muthian S, 2004, NEUROSCIENCE, V129, P743, DOI 10.1016/j.neuroscience.2004.08.044; Okabe M, 1997, FEBS LETT, V407, P313, DOI 10.1016/S0014-5793(97)00313-X; Onaivi ES, 2006, ANN NY ACAD SCI, V1074, P514, DOI 10.1196/annals.1369.052; Pacher P, 2008, BRIT J PHARMACOL, V153, P252, DOI 10.1038/sj.bjp.0707582; Parmentier-Batteur S, 2002, J NEUROSCI, V22, P9771, DOI 10.1523/jneurosci.22-22-09771.2002; Prado GN, 1996, J BIOL CHEM, V271, P19186, DOI 10.1074/jbc.271.32.19186; Ramirez BG, 2005, J NEUROSCI, V25, P1904, DOI 10.1523/JNEUROSCI.4540-04.2005; Ridder DA, 2009, BRAIN RES, V1272, P3, DOI 10.1016/j.brainres.2009.03.046; Schabitz WR, 2002, STROKE, V33, P2112, DOI 10.1161/01.STR.0000023491.63693.18; Stella N, 2004, GLIA, V48, P267, DOI 10.1002/glia.20084; Tschop J, 2009, J IMMUNOL, V183, P499, DOI 10.4049/jimmunol.0900203; Van Sickle MD, 2005, SCIENCE, V310, P329, DOI 10.1126/science.1115740; Villa P, 2007, MOL MED, V13, P125, DOI 10.2119/2007-00008.Villa; Viscomi MT, 2009, J NEUROSCI, V29, P4564, DOI 10.1523/JNEUROSCI.0786-09.2009; Weston RM, 2007, J CEREBR BLOOD F MET, V27, P100, DOI 10.1038/sj.jcbfm.9600324; Yamamoto W, 2008, EUR J PHARMACOL, V583, P56, DOI 10.1016/j.ejphar.2008.01.010; Zhang M, 2008, NEUROSCIENCE, V152, P753, DOI 10.1016/j.neuroscience.2008.01.022; Zhang M, 2007, J CEREBR BLOOD F MET, V27, P1387, DOI 10.1038/sj.jcbfm.9600447; Zhang M, 2009, MICROVASC RES, V78, P86, DOI 10.1016/j.mvr.2009.03.005; ZHANG RL, 1995, STROKE, V26, P1438, DOI 10.1161/01.STR.26.8.1438	64	141	144	0	6	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAR	2010	24	3					788	798		10.1096/fj.09-141275	http://dx.doi.org/10.1096/fj.09-141275			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	561KE	19884325				2022-12-25	WOS:000274974600015
J	Kovacs, E; Toth, J; Vertessy, BG; Liliom, K				Kovacs, Erika; Toth, Judit; Vertessy, Beata G.; Liliom, Karoly			Dissociation of Calmodulin-Target Peptide Complexes by the Lipid Mediator Sphingosylphosphorylcholine IMPLICATIONS IN CALCIUM SIGNALING	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INOSITOL 1,4,5-TRISPHOSPHATE RECEPTOR; RYANODINE RECEPTOR; PLASMA-MEMBRANE; BINDING DOMAIN; HIGH-AFFINITY; RELEASE; RECOGNITION; BRAIN; CELLS; LOCALIZATION	Previously we have identified the lipid mediator sphingosylphosphorylcholine (SPC) as the first potentially endogenous inhibitor of the ubiquitous Ca2+ sensor calmodulin(CaM) (Kovacs, E., and Liliom, K. (2008) Biochem. J. 410, 427-437). Here we give mechanistic insight into CaM inhibition by SPC, based on fluorescence stopped-flow studies with the model CaM-binding domain melittin. We demonstrate that both the peptide and SPC micelles bind to CaM in a rapid and reversible manner with comparable affinities. Furthermore, we present kinetic evidence that both species compete for the same target site on CaM, and thus SPC can be considered as a competitive inhibitor of CaM-target peptide interactions. We also show that SPC disrupts the complex of CaM and the CaM-binding domain of ryanodine receptor type 1, inositol 1,4,5-trisphosphate receptor type 1, and the plasma membrane Ca2+ pump. By interfering with these interactions, thus inhibiting the negative feedback that CaM has on Ca2+ signaling, we hypothesize that SPC could lead to Ca2+ mobilization in vivo. Hence, we suggest that the action of the sphingolipid on CaM might explain the previously recognized phenomenon that SPC liberates Ca2+ from intracellular stores. Moreover, we demonstrate that unlike traditional synthetic CaM inhibitors, SPC disrupts the complex between not only the Ca2+-saturated but also the apo form of the protein and the target peptide, suggesting a completely novel regulation for target proteins that constitutively bind CaM, such as ryanodine receptors.	[Kovacs, Erika; Toth, Judit; Vertessy, Beata G.; Liliom, Karoly] Hungarian Acad Sci, Biol Res Ctr, Inst Enzymol, H-1113 Budapest, Hungary	Hungarian Academy of Sciences; Hungarian Biological Research Center; Hungarian Research Centre for Natural Sciences	Kovacs, E (corresponding author), Hungarian Acad Sci, Biol Res Ctr, Inst Enzymol, H-1113 Budapest, Hungary.	kovacs@enzim.hu	Vertessy, Beata G/H-6202-2012; Liliom, Karoly/A-6563-2011	Liliom, Karoly/0000-0002-7177-6872; Vertessy, Beata G./0000-0002-1288-2982	National Institutes of Health [1R01TW008130-01]; OTKA [61501, 72008, K68229, CK-78646]; National Development Agency [KMOP-1.1.2-07/1-20080003]; Howard Hughes Medical Institutes [55005628, 55000342]; Alexander von Humboldt Foundation; National Office for Research and Technology, Hungary [JAP_TSZ_071128_TB_INTER]; European Union [LSHG-CT-2006-031220, TEACH-SG LSSG-CT-2007-037198]; FOGARTY INTERNATIONAL CENTER [R01TW008130] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); OTKA(Orszagos Tudomanyos Kutatasi Alapprogramok (OTKA)); National Development Agency; Howard Hughes Medical Institutes(Howard Hughes Medical Institute); Alexander von Humboldt Foundation(Alexander von Humboldt Foundation); National Office for Research and Technology, Hungary(National Office for Research and Technology); European Union(European Commission); FOGARTY INTERNATIONAL CENTER(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Fogarty International Center (FIC))	This work was supported, in whole or in part, by National Institutes of Health Grant 1R01TW008130-01 (to J. T.), Hungarian Scientific Research Fund OTKA Grants 61501 (to K. L.), 72008 (to J. T.), K68229 and CK-78646 (to B. G. V.), National Development Agency Grant KMOP-1.1.2-07/1-20080003, Howard Hughes Medical Institutes Grants 55005628 and 55000342 (to B. G. V.), the Alexander von Humboldt Foundation, National Office for Research and Technology, Hungary, Grant JAP_TSZ_071128_TB_INTER, and European Union Grants FP6 SPINE2c LSHG-CT-2006-031220 and TEACH-SG LSSG-CT-2007-037198 (to B. G. V.).	Balshaw DM, 2002, J MEMBRANE BIOL, V185, P1, DOI 10.1007/s00232-001-0111-4; Beil M, 2003, NAT CELL BIOL, V5, P803, DOI 10.1038/ncb1037; Betto R, 1997, BIOCHEM J, V322, P327, DOI 10.1042/bj3220327; Brown SE, 1997, J BIOL CHEM, V272, P3389, DOI 10.1074/jbc.272.6.3389; Bunemann M, 1996, EMBO J, V15, P5527, DOI 10.1002/j.1460-2075.1996.tb00937.x; CHATTOPADHYAYA R, 1992, J MOL BIOL, V228, P1177, DOI 10.1016/0022-2836(92)90324-D; Chin D, 2000, TRENDS CELL BIOL, V10, P322, DOI 10.1016/S0962-8924(00)01800-6; Chiulli N, 2007, EUR J NEUROSCI, V26, P875, DOI 10.1111/j.1460-9568.2007.05732.x; COMTE M, 1983, BIOCHEM J, V209, P269, DOI 10.1042/bj2090269; DESAI NN, 1991, BIOCHEM BIOPH RES CO, V181, P361, DOI 10.1016/S0006-291X(05)81427-5; DETTBARN C, 1995, BRAIN RES, V669, P79, DOI 10.1016/0006-8993(94)01234-9; Di Leva F, 2008, ARCH BIOCHEM BIOPHYS, V476, P65, DOI 10.1016/j.abb.2008.02.026; ENYEDI A, 1989, J BIOL CHEM, V264, P12313; GHOSH TK, 1990, SCIENCE, V248, P1653, DOI 10.1126/science.2163543; Heringdorf DMZ, 2004, J CELL BIOCHEM, V92, P937, DOI 10.1002/jcb.20107; Heringdorf DMZ, 1998, EUR J PHARMACOL, V354, P113, DOI 10.1016/S0014-2999(98)00436-1; HERINGDORF MZ, 2002, BIOCHIM BIOPHYS ACTA, V1582, P178; Kovacs E, 2008, BIOCHEM J, V410, P427, DOI 10.1042/BJ20071019; LAPORTE DC, 1980, BIOCHEMISTRY-US, V19, P3814, DOI 10.1021/bi00557a025; Liliom K, 2001, BIOCHEM J, V355, P189, DOI 10.1042/0264-6021:3550189; Lucas JL, 2006, PHARM RES-DORDR, V23, P647, DOI 10.1007/s11095-006-9784-9; Mao CG, 1996, P NATL ACAD SCI USA, V93, P1993, DOI 10.1073/pnas.93.5.1993; Martinez-Luis S, 2007, PHYTOCHEMISTRY, V68, P1882, DOI 10.1016/j.phytochem.2007.02.025; MASSOM L, 1990, BIOCHEMISTRY-US, V29, P671, DOI 10.1021/bi00455a012; Maximciuc AA, 2006, STRUCTURE, V14, P1547, DOI 10.1016/j.str.2006.08.011; MEADOR WE, 1993, SCIENCE, V262, P1718, DOI 10.1126/science.8259515; MEADOR WE, 1992, SCIENCE, V257, P1251, DOI 10.1126/science.1519061; Mendes P, 1997, TRENDS BIOCHEM SCI, V22, P361, DOI 10.1016/S0968-0004(97)01103-1; MOLNAR A, 1995, EUR J PHARM-MOLEC PH, V291, P73; Murase T, 2002, BIOCHEMISTRY-US, V41, P1618, DOI 10.1021/bi011782r; Nixon GF, 2008, PROG LIPID RES, V47, P62, DOI 10.1016/j.plipres.2007.11.001; Okamoto R, 2003, J LIPID RES, V44, P93, DOI 10.1194/jlr.M200225-JLR200; Rhoads AR, 1997, FASEB J, V11, P331, DOI 10.1096/fasebj.11.5.9141499; Rodney GG, 2001, J BIOL CHEM, V276, P2069, DOI 10.1074/jbc.M008891200; Rodriguez-Lafrasse C, 1999, NEUROCHEM RES, V24, P199, DOI 10.1023/A:1022501702403; Schnurbus R, 2002, BIOCHEM J, V362, P183, DOI 10.1042/0264-6021:3620183; Sienaert I, 2002, BIOCHEM J, V365, P269, DOI 10.1042/BJ20020144; Turner JH, 2005, J BIOL CHEM, V280, P30741, DOI 10.1074/jbc.M501696200; Vertessy BG, 1998, BIOCHEMISTRY-US, V37, P15300, DOI 10.1021/bi980795a; YAMADA M, 1995, BIOCHEM J, V308, P83, DOI 10.1042/bj3080083	40	14	14	0	14	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 15	2010	285	3					1799	1808		10.1074/jbc.M109.053116	http://dx.doi.org/10.1074/jbc.M109.053116			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	541PJ	19910470	Green Published, hybrid			2022-12-25	WOS:000273429100026
J	Grimaldi, S; Arias-Cartin, R; Lanciano, P; Lyubenova, S; Endeward, B; Prisner, TF; Magalon, A; Guigliarelli, B				Grimaldi, Stephane; Arias-Cartin, Rodrigo; Lanciano, Pascal; Lyubenova, Sevdalina; Endeward, Burkhard; Prisner, Thomas F.; Magalon, Axel; Guigliarelli, Bruno			Direct Evidence for Nitrogen Ligation to the High Stability Semiquinone Intermediate in Escherichia coli Nitrate Reductase A	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ELECTRON-SPIN-ECHO; PRIMARY ACCEPTOR QUINONE; REACTION CENTERS; BINDING-SITE; PARAMAGNETIC-RESONANCE; RHODOBACTER-SPHAEROIDES; ENVELOPE MODULATION; A NARGHI; Q(H)(CENTER-DOT-) UBISEMIQUINONE; INHIBITOR BINDING	The membrane-bound heterotrimeric nitrate reductase A (NarGHI) catalyzes the oxidation of quinols in the cytoplasmic membrane of Escherichia coli and reduces nitrate to nitrite in the cytoplasm. The enzyme strongly stabilizes a menasemiquinone intermediate at a quinol oxidation site (Q(D)) located in the vicinity of the distal heme b(D). Here molecular details of the interaction between the semiquinone radical and the protein environment have been provided using advanced multifrequency pulsed EPR methods. N-14 and N-15 ESEEM and HYSCORE measurements carried out at X-band (similar to 9.7 GHz) on the wild-type enzyme or the enzyme uniformly labeled with N-15 nuclei reveal an interaction between the semiquinone and a single nitrogen nucleus. The isotropic hyperfine coupling constant A(iso)(N-14) similar to 0.8 MHz shows that it occurs via an H-bond to one of the quinone carbonyl group. Using N-14 ESEEM and HYSCORE spectroscopies at a lower frequency (S-band, similar to 3.4 GHz), the N-14 nuclear quadrupolar parameters of the interacting nitrogen nucleus (kappa = 0.49, eta = 0.50) were determined and correspond to those of a histidine N-delta, assigned to the heme b(D) ligand His-66 residue. Moreover S-band N-15 ESEEM spectra enabled us to directly measure the anisotropic part of the nitrogen hyperfine interaction (T(N-15) = 0.16 MHz). A distance of similar to 2.2 angstrom between the carbonyl oxygen and the nitrogen could then be calculated. Mechanistic implications of these results are discussed in the context of the peculiar properties of the menasemiquinone intermediate stabilized at the Q(D) site of NarGHI.	[Grimaldi, Stephane; Lanciano, Pascal; Guigliarelli, Bruno] CNRS, Unite Bioenerget & Ingn Prot UPR9036, Inst Microbiol Mediterrane, F-13402 Marseille 20, France; [Arias-Cartin, Rodrigo; Magalon, Axel] CNRS, Lab Chim Bacterienne UPR9043, Inst Microbiol Mediterrane, F-13402 Marseille 20, France; Aix Marseille Univ, F-13402 Marseille 20, France; [Lyubenova, Sevdalina; Endeward, Burkhard; Prisner, Thomas F.] Goethe Univ Frankfurt, Inst Phys & Theoret Chem, D-60438 Frankfurt, Germany	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Aix-Marseille Universite; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Aix-Marseille Universite; Goethe University Frankfurt	Grimaldi, S (corresponding author), CNRS, Unite Bioenerget & Ingn Prot UPR9036, Inst Microbiol Mediterrane, 31 Chemin Joseph Aiguier, F-13402 Marseille 20, France.	grimaldi@ifr88.cnrs-mrs.fr	Grimaldi, Stephane/G-9884-2013; Grimaldi, Stephane/AAF-7138-2020	Grimaldi, Stephane/0000-0002-9559-6112; Prisner, Thomas F./0000-0003-2850-9573; Magalon, Axel/0000-0002-3375-738X; Arias-Cartin, Rodrigo/0000-0001-5008-6437	CNRS; ANR; Universite de Provence; European Community [RII3-026145]; Short-Term Scientific Mission funding	CNRS(Centre National de la Recherche Scientifique (CNRS)); ANR(French National Research Agency (ANR)); Universite de Provence; European Community(European Commission); Short-Term Scientific Mission funding	This work was supported by the CNRS, the ANR(program PCV 2006), and the Universite de Provence (Aix-Marseille I). The Access to Research Infrastructures Activity in the 6th Framework Programme of the European Community (Contract RII3-026145, EU-NMR) is also acknowledged for financial support (to S. G. and P. L.), as well as COST P15 for Short-Term Scientific Mission funding (to S. G.).	ASTASHKIN AV, 1995, J CHEM PHYS, V102, P5583, DOI 10.1063/1.469289; Bertero MG, 2005, J BIOL CHEM, V280, P14836, DOI 10.1074/jbc.M410457200; Bertero MG, 2003, NAT STRUCT BIOL, V10, P681, DOI 10.1038/nsb969; Blasco F, 2001, CELL MOL LIFE SCI, V58, P179, DOI 10.1007/PL00000846; BOSCH MK, 1995, CHEM PHYS LETT, V239, P306, DOI 10.1016/0009-2614(95)00481-I; BRITO F, 1995, J BACTERIOL, V177, P3728, DOI 10.1128/jb.177.13.3728-3735.1995; Cape JL, 2007, P NATL ACAD SCI USA, V104, P7887, DOI 10.1073/pnas.0702621104; Deligiannakis Y, 1999, J AM CHEM SOC, V121, P7653, DOI 10.1021/ja984209c; Dikanov S. A., 1992, ELECT SPIN ECHO ENVE; Dikanov SA, 2004, J BIOL CHEM, V279, P15814, DOI 10.1074/jbc.M313417200; DikanovO SA, 2007, J BIOL CHEM, V282, P25831, DOI 10.1074/jbc.M702333200; EDMONDS DT, 1971, PHYS LETT A, VA 34, P325, DOI 10.1016/0375-9601(71)90894-2; Flores M, 2007, BIOPHYS J, V92, P671, DOI 10.1529/biophysj.106.092460; Fritscher J, 2006, APPL MAGN RESON, V30, P251, DOI 10.1007/BF03166200; Fritscher J, 2004, PHYS CHEM CHEM PHYS, V6, P4950, DOI 10.1039/b408764j; Giordani R, 2004, EUR J BIOCHEM, V271, P2400, DOI 10.1111/j.1432-1033.2004.04159.x; Giordani R, 1997, EUR J BIOCHEM, V250, P567, DOI 10.1111/j.1432-1033.1997.0567a.x; Grimaldi S, 2005, BIOCHEMISTRY-US, V44, P1300, DOI 10.1021/bi048009r; Grimaldi S, 2003, BIOCHEMISTRY-US, V42, P5632, DOI 10.1021/bi034010z; Grimaldi S, 2001, BIOCHEMISTRY-US, V40, P1037, DOI 10.1021/bi001641+; GRIMALDI S, 2002, THESIS GOETHE U FRAN; GUIGLIARELLI B, 1992, EUR J BIOCHEM, V207, P61, DOI 10.1111/j.1432-1033.1992.tb17020.x; Guigliarelli B, 1996, BIOCHEMISTRY-US, V35, P4828, DOI 10.1021/bi952459p; Hagerhall C, 1999, J BIOL CHEM, V274, P26157, DOI 10.1074/jbc.274.37.26157; Hanley J, 1997, BIOCHEMISTRY-US, V36, P11543, DOI 10.1021/bi971360a; Horsefield R, 2006, J BIOL CHEM, V281, P7309, DOI 10.1074/jbc.M508173200; INGLEDEW WJ, 1995, EUR J BIOCHEM, V227, P903, DOI 10.1111/j.1432-1033.1995.tb20217.x; Jormakka M, 2003, FEBS LETT, V545, P25, DOI 10.1016/S0014-5793(03)00389-2; Jormakka M, 2008, NAT STRUCT MOL BIOL, V15, P730, DOI 10.1038/nsmb.1434; LAI A, 1988, J CHEM PHYS, V89, P7161, DOI 10.1063/1.455293; Lanciano P, 2007, J PHYS CHEM B, V111, P13632, DOI 10.1021/jp075243t; Lanciano P, 2007, BIOCHEMISTRY-US, V46, P5323, DOI 10.1021/bi700074y; Lendzian F, 1996, BER BUNSEN PHYS CHEM, V100, P2036, DOI 10.1002/bbpc.19961001219; Lin MT, 2008, J AM CHEM SOC, V130, P15768, DOI 10.1021/ja805906a; Lubitz W, 1999, APPL MAGN RESON, V17, P1, DOI 10.1007/BF03162067; MacMillan F, 1995, MAGN RESON CHEM, V33, pS81, DOI 10.1002/mrc.1260331314; Magalon A, 1997, J BACTERIOL, V179, P5037, DOI 10.1128/jb.179.16.5037-5045.1997; Magalon A, 1998, J BIOL CHEM, V273, P10851, DOI 10.1074/jbc.273.18.10851; Maniatis T., 1982, MOL CLONING LAB MANU; MITCHELL P, 1979, SCIENCE, V206, P1148, DOI 10.1126/science.388618; MORPETH FF, 1985, BIOCHEMISTRY-US, V24, P40, DOI 10.1021/bi00322a007; MORTON JR, 1978, J MAGN RESON, V30, P577, DOI 10.1016/0022-2364(78)90284-6; Peloquin JM, 1999, BIOCHEMISTRY-US, V38, P2057, DOI 10.1021/bi982033l; ROBERTSON DE, 1984, J BIOL CHEM, V259, P1758; Rothery RA, 2001, J MOL MICROB BIOTECH, V3, P273; Rothery RA, 1999, BIOCHEMISTRY-US, V38, P12747, DOI 10.1021/bi990533o; Rothery RA, 2004, BIOCHEMISTRY-US, V43, P5324, DOI 10.1021/bi049938l; SATOWATANABE M, 1995, FEBS LETT, V374, P265, DOI 10.1016/0014-5793(95)01125-X; Schweiger A., 2001, PRINCIPLES PULSE ELE; Spoyalov AP, 1996, CHEM PHYS LETT, V263, P715, DOI 10.1016/S0009-2614(96)01255-9; Stowell MHB, 1997, SCIENCE, V276, P812, DOI 10.1126/science.276.5313.812; WALLACE BJ, 1977, BIOCHIM BIOPHYS ACTA, V461, P84, DOI 10.1016/0005-2728(77)90071-8; WEBER A, 1998, P 29 C AMPERE 13 ISM, V2, P1138; Yankovskaya V, 2003, SCIENCE, V299, P700, DOI 10.1126/science.1079605; Yap LL, 2006, J BIOL CHEM, V281, P16879, DOI 10.1074/jbc.M602544200; Zhao ZW, 2003, BIOCHEMISTRY-US, V42, P5403, DOI 10.1021/bi027221x	57	33	33	1	20	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 1	2010	285	1					179	187		10.1074/jbc.M109.060251	http://dx.doi.org/10.1074/jbc.M109.060251			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	536UT	19892705	hybrid, Green Published			2022-12-25	WOS:000273070100019
J	Yoon, Y; Tong, JS; Lee, PJ; Albanese, A; Bhardwaj, N; Kallberg, M; Digman, MA; Lu, H; Gratton, E; Shin, YK; Cho, W				Yoon, Youngdae; Tong, Jiansong; Lee, Park Joo; Albanese, Alexandra; Bhardwaj, Nitin; Kaellberg, Morten; Digman, Michelle A.; Lu, Hui; Gratton, Enrico; Shin, Yeon-Kyun; Cho, Wonhwa			Molecular Basis of the Potent Membrane-remodeling Activity of the Epsin 1 N-terminal Homology Domain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BAR DOMAINS; PROTEIN INTERACTIONS; ACTIN CYTOSKELETON; PLASMA-MEMBRANE; ENTH DOMAIN; CLATHRIN; CURVATURE; BINDING; INVAGINATION; MECHANISMS	The mechanisms by which cytosolic proteins reversibly bind the membrane and induce the curvature for membrane trafficking and remodeling remain elusive. The epsin N-terminal homology (ENTH) domain has potent vesicle tubulation activity despite a lack of intrinsic molecular curvature. EPR revealed that the N-terminal alpha-helix penetrates the phosphatidylinositol 4,5-bisphosphate-containing membrane at a unique oblique angle and concomitantly interacts closely with helices from neighboring molecules in an antiparallel orientation. The quantitative fluorescence microscopy showed that the formation of highly ordered ENTH domain complexes beyond a critical size is essential for its vesicle tubulation activity. The mutations that interfere with the formation of large ENTH domain complexes abrogated the vesicle tubulation activity. Furthermore, the same mutations in the intact epsin 1 abolished its endocytic activity in mammalian cells. Collectively, these results show that the ENTH domain facilitates the cellular membrane budding and fission by a novel mechanism that is distinct from that proposed for BAR domains.	[Yoon, Youngdae; Lee, Park Joo; Albanese, Alexandra; Cho, Wonhwa] Univ Illinois, Dept Chem, Chicago, IL 60607 USA; [Bhardwaj, Nitin; Kaellberg, Morten; Lu, Hui] Univ Illinois, Dept Bioengn, Chicago, IL 60607 USA; [Tong, Jiansong; Shin, Yeon-Kyun] Iowa State Univ, Dept Biochem Biophys & Mol Biol, Ames, IA 50011 USA; [Digman, Michelle A.; Gratton, Enrico] Univ Calif Irvine, Dept Biomed Engn, Irvine, CA 92697 USA	University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; Iowa State University; University of California System; University of California Irvine	Cho, W (corresponding author), Univ Illinois, Dept Chem MC 111, 845 W Taylor St, Chicago, IL 60607 USA.	wcho@uic.edu	TONG, JIANSONG/C-9232-2012; Lu, Hui/K-3264-2019	, Michelle/0000-0003-4611-7100; Lu, Hui/0000-0001-8347-0830	National Institutes of Health [GM68849, GM51290, PHS 5 P41-RR03155]; NATIONAL CENTER FOR RESEARCH RESOURCES [P41RR003155] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R29GM051290, R01GM068849, R01GM051290] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	This work was supported, in whole or in part, by National Institutes of Health Grants GM68849 (to W. C.), GM51290 (to Y.-K. S.), and PHS 5 P41-RR03155 (to E. G.).	ALTENBACH C, 1994, P NATL ACAD SCI USA, V91, P1667, DOI 10.1073/pnas.91.5.1667; Bagatolli LA, 1999, BIOPHYS J, V77, P2090, DOI 10.1016/S0006-3495(99)77050-5; Baker NA, 2001, P NATL ACAD SCI USA, V98, P10037, DOI 10.1073/pnas.181342398; Blood PD, 2008, BIOPHYS J, V95, P1866, DOI 10.1529/biophysj.107.121160; Brady RJ, 2008, J CELL SCI, V121, P3433, DOI 10.1242/jcs.032573; Chen Y, 2004, EMBO J, V23, P681, DOI 10.1038/sj.emboj.7600083; Chernomordik LV, 2003, ANNU REV BIOCHEM, V72, P175, DOI 10.1146/annurev.biochem.72.121801.161504; Cho WH, 2005, ANNU REV BIOPH BIOM, V34, P119, DOI 10.1146/annurev.biophys.33.110502.133337; Cho WW, 2001, ANAL BIOCHEM, V296, P153, DOI 10.1006/abio.2001.5225; Dawson JC, 2006, TRENDS CELL BIOL, V16, P493, DOI 10.1016/j.tcb.2006.08.004; De Camilli P, 2002, FEBS LETT, V513, P11, DOI 10.1016/S0014-5793(01)03306-3; Digman MA, 2008, BIOPHYS J, V94, P2320, DOI 10.1529/biophysj.107.114645; Farsad K, 2003, CURR OPIN CELL BIOL, V15, P372, DOI 10.1016/S0955-0674(03)00073-5; Farsad K, 2001, J CELL BIOL, V155, P193, DOI 10.1083/jcb.200107075; Ford MGJ, 2001, SCIENCE, V291, P1051, DOI 10.1126/science.291.5506.1051; Ford MGJ, 2002, NATURE, V419, P361, DOI 10.1038/nature01020; Frost A, 2008, CELL, V132, P807, DOI 10.1016/j.cell.2007.12.041; Gallop JL, 2006, EMBO J, V25, P2898, DOI 10.1038/sj.emboj.7601174; Gokhale NA, 2005, J BIOL CHEM, V280, P42831, DOI 10.1074/jbc.M508129200; Habermann B, 2004, EMBO REP, V5, P250, DOI 10.1038/sj.embor.7400105; Heath RJW, 2008, J CELL SCI, V121, P1951, DOI 10.1242/jcs.023895; Higgins MK, 2002, TRENDS BIOCHEM SCI, V27, P257, DOI 10.1016/S0968-0004(02)02089-3; Itoh T, 2005, DEV CELL, V9, P791, DOI 10.1016/j.devcel.2005.11.005; Itoh T, 2001, SCIENCE, V291, P1047, DOI 10.1126/science.291.5506.1047; Itoh T, 2006, BBA-MOL CELL BIOL L, V1761, P897, DOI 10.1016/j.bbalip.2006.06.015; KATCHALSKIKATZIR E, 1992, P NATL ACAD SCI USA, V89, P2195, DOI 10.1073/pnas.89.6.2195; Kay BK, 1999, PROTEIN SCI, V8, P435; Kweon DH, 2006, MOL CELLS, V21, P428; Kweon DH, 2003, NAT STRUCT BIOL, V10, P440, DOI 10.1038/nsb928; Kweon DH, 2002, BIOCHEMISTRY-US, V41, P5449, DOI 10.1021/bi0256476; Le Roy C, 2005, NAT REV MOL CELL BIO, V6, P112, DOI 10.1038/nrm1571; Macosko JC, 1997, J MOL BIOL, V267, P1139, DOI 10.1006/jmbi.1997.0931; Masuda M, 2006, EMBO J, V25, P2889, DOI 10.1038/sj.emboj.7601176; Mattila PK, 2007, J CELL BIOL, V176, P953, DOI 10.1083/jcb.200609176; McMahon HT, 2005, NATURE, V438, P590, DOI 10.1038/nature04396; McNiven MA, 2006, SCIENCE, V313, P1591, DOI 10.1126/science.1118133; Peter BJ, 2004, SCIENCE, V303, P495, DOI 10.1126/science.1092586; Sanner MF, 1996, BIOPOLYMERS, V38, P305, DOI 10.1002/(SICI)1097-0282(199603)38:3<305::AID-BIP4>3.3.CO;2-8; Shimada A, 2007, CELL, V129, P761, DOI 10.1016/j.cell.2007.03.040; Stahelin RV, 2004, J BIOL CHEM, V279, P29501, DOI 10.1074/jbc.M403191200; Stahelin RV, 2003, J BIOL CHEM, V278, P28993, DOI 10.1074/jbc.M302865200; Stahelin RV, 2001, BIOCHEMISTRY-US, V40, P4672, DOI 10.1021/bi0020325; Takei K, 1999, NAT CELL BIOL, V1, P33, DOI 10.1038/9004; Tsujita K, 2006, J CELL BIOL, V172, P269, DOI 10.1083/jcb.200508091; Wendland B, 1999, EMBO J, V18, P4383, DOI 10.1093/emboj/18.16.4383; Zimmerberg J, 2006, NAT REV MOL CELL BIO, V7, P9, DOI 10.1038/nrm1784	46	51	51	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 1	2010	285	1					531	540		10.1074/jbc.M109.068015	http://dx.doi.org/10.1074/jbc.M109.068015			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	536UT	19880963	Green Published, hybrid			2022-12-25	WOS:000273070100055
J	Wang, DB; Yang, RF; Zhang, ZP; Bi, LJ; You, XY; Wei, HP; Zhou, YF; Yu, ZN; Zhang, XE				Wang, Dian-Bing; Yang, Ruifu; Zhang, Zhi-Ping; Bi, Li-Jun; You, Xiang-Yu; Wei, Hong-Ping; Zhou, Ya-Feng; Yu, Ziniu; Zhang, Xian-En			Detection of B. anthracis Spores and Vegetative Cells with the Same Monoclonal Antibodies	PLOS ONE			English	Article							BACILLUS-CEREUS GROUP; GENETIC-RELATIONSHIPS; MASS-SPECTROMETRY; S-LAYER; PCR; SUBTILIS; THURINGIENSIS; COMPONENT; BACTERIA; SEQUENCE	Bacillus anthracis, the causative agent of anthrax disease, could be used as a biothreat reagent. It is vital to develop a rapid, convenient method to detect B. anthracis. In the current study, three high affinity and specificity monoclonal antibodies (mAbs, designated 8G3, 10C6 and 12F6) have been obtained using fully washed B. anthracis spores as an immunogen. These mAbs, confirmed to direct against EA1 protein, can recognize the surface of B. anthracis spores and intact vegetative cells with high affinity and species-specificity. EA1 has been well known as a major S-layer component of B. anthracis vegetative cells, and it also persistently exists in the spore preparations and bind tightly to the spore surfaces even after rigorous washing. Therefore, these mAbs can be used to build a new and rapid immunoassay for detection of both life forms of B. anthracis, either vegetative cells or spores.			Wang, DB (corresponding author), Chinese Acad Sci, Wuhan Inst Virol, State Key Lab Virol, Wuhan, Peoples R China.	x.zhang@wh.iov.cn	Wang, Dian-Bing/AFQ-6894-2022; ZHANG, Xian-En/AAJ-5579-2021	Wang, Dian-Bing/0000-0001-6225-7010; 				ASH C, 1992, FEMS MICROBIOL LETT, V23, P73; BEATTY JD, 1987, J IMMUNOL METHODS, V100, P173, DOI 10.1016/0022-1759(87)90187-6; BEYER W, 1995, MICROBIOL RES, V150, P179, DOI 10.1016/S0944-5013(11)80054-6; Castanha ER, 2006, J MICROBIOL METH, V67, P230, DOI 10.1016/j.mimet.2006.03.024; Daffonchio D, 2000, APPL ENVIRON MICROB, V66, P5460, DOI 10.1128/AEM.66.12.5460-5468.2000; Dang JL, 2001, APPL ENVIRON MICROB, V67, P3665, DOI 10.1128/AEM.67.8.3665-3670.2001; DelVecchio VG, 2006, APPL ENVIRON MICROB, V72, P6355, DOI 10.1128/AEM.00455-06; Elhanany E, 2001, RAPID COMMUN MASS SP, V15, P2110, DOI 10.1002/rcm.491; FRITZ DL, 1995, LAB INVEST, V73, P691; GREEN BD, 1985, INFECT IMMUN, V49, P291, DOI 10.1128/IAI.49.2.291-297.1985; Helgason E, 2004, APPL ENVIRON MICROB, V70, P191, DOI 10.1128/AEM.70.1.191-201.2004; HENDERSON I, 1994, INT J SYST BACTERIOL, V44, P99, DOI 10.1099/00207713-44-1-99; HENRIQUES AO, 1995, J BACTERIOL, V177, P3394, DOI 10.1128/jb.177.12.3394-3406.1995; Hill KK, 2004, APPL ENVIRON MICROB, V70, P1068, DOI 10.1128/AEM.70.2.1068-1080.2004; Keim P, 2000, J BACTERIOL, V182, P2928, DOI 10.1128/JB.182.10.2928-2936.2000; Kleine-Albers C, 1989, Zentralbl Veterinarmed B, V36, P226; KOHLER G, 1975, NATURE, V256, P495, DOI 10.1038/256495a0; Kozel TR, 2004, P NATL ACAD SCI USA, V101, P5042, DOI 10.1073/pnas.0401351101; Lai EM, 2003, J BACTERIOL, V185, P1443, DOI 10.1128/JB.185.4.1443-1454.2003; Lee MA, 1999, J APPL MICROBIOL, V87, P218, DOI 10.1046/j.1365-2672.1999.00908.x; Love TE, 2008, J IMMUNOL METHODS, V334, P1, DOI 10.1016/j.jim.2007.12.022; Mechaly A, 2008, APPL ENVIRON MICROB, V74, P818, DOI 10.1128/AEM.01244-07; Mesnage S, 1997, MOL MICROBIOL, V23, P1147, DOI 10.1046/j.1365-2958.1997.2941659.x; Mesnage S, 1998, J BACTERIOL, V180, P52, DOI 10.1128/JB.180.1.52-58.1998; MIKESELL P, 1983, INFECT IMMUN, V39, P371, DOI 10.1128/IAI.39.1.371-376.1983; Nicholson WL, 2000, MICROBIOL MOL BIOL R, V64, P548, DOI 10.1128/MMBR.64.3.548-572.2000; PEROSA F, 1990, J IMMUNOL METHODS, V128, P9, DOI 10.1016/0022-1759(90)90458-8; Qi YA, 2001, APPL ENVIRON MICROB, V67, P3720, DOI 10.1128/AEM.67.8.3720-3727.2001; SKOTTMAN T, 2007, EUR J CLIN MICROBIOL; SONENSHEIN AL, 1974, J BACTERIOL, V120, P253, DOI 10.1128/JB.120.1.253-265.1974; Swiecki MK, 2006, J IMMUNOL, V176, P6076, DOI 10.4049/jimmunol.176.10.6076; Wang SH, 2006, ANAL CHEM, V78, P997, DOI 10.1021/ac0512352; Williams DD, 2004, J BACTERIOL, V186, P566, DOI 10.1128/JB.186.2.566-569.2004; Williams DD, 2003, APPL ENVIRON MICROB, V69, P6288, DOI 10.1128/AEM.69.10.6288-6293.2003	34	28	31	0	10	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA	1932-6203			PLOS ONE	PLoS One	NOV 13	2009	4	11							e7810	10.1371/journal.pone.0007810	http://dx.doi.org/10.1371/journal.pone.0007810			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	518VB	19915677	gold, Green Published, Green Submitted			2022-12-25	WOS:000271721900004
J	Gallego-Ortega, D; de Molina, AR; Ramos, MA; Valdes-Mora, F; Barderas, MG; Sarmentero-Estrada, J; Lacal, JC				Gallego-Ortega, David; Ramirez de Molina, Ana; Angeles Ramos, Maria; Valdes-Mora, Fatima; Gonzalez Barderas, Maria; Sarmentero-Estrada, Jacinto; Carlos Lacal, Juan			Differential Role of Human Choline Kinase alpha and beta Enzymes in Lipid Metabolism: Implications in Cancer Onset and Treatment	PLOS ONE			English	Article							ETHANOLAMINE KINASE; BREAST-CANCER; RHO GTPASES; CHOLINE/ETHANOLAMINE KINASE; PHOSPHOLIPID-METABOLISM; MITOGENIC ACTIVITY; MOLECULAR-CLONING; RAT-KIDNEY; ACTIVATION; PURIFICATION	Background: The Kennedy pathway generates phosphocoline and phosphoethanolamine through its two branches. Choline Kinase (ChoK) is the first enzyme of the Kennedy branch of synthesis of phosphocholine, the major component of the plasma membrane. ChoK family of proteins is composed by ChoK alpha and ChoK beta isoforms, the first one with two different variants of splicing. Recently ChoK alpha has been implicated in the carcinogenic process, since it is over-expressed in a variety of human cancers. However, no evidence for a role of ChoK beta in carcinogenesis has been reported. Methodology/Principal Findings: Here we compare the in vitro and in vivo properties of ChoK alpha 1 and ChoK beta in lipid metabolism, and their potential role in carcinogenesis. Both ChoK alpha 1 and ChoK beta showed choline and ethanolamine kinase activities when assayed in cell extracts, though with different affinity for their substrates. However, they behave differentially when overexpressed in whole cells. Whereas ChoK beta display an ethanolamine kinase role, ChoK alpha 1 present a dual choline/ethanolamine kinase role, suggesting the involvement of each ChoK isoform in distinct biochemical pathways under in vivo conditions. In addition, while overexpression of ChoK alpha 1 is oncogenic when overexpressed in HEK293T or MDCK cells, ChoK beta overexpression is not sufficient to induce in vitro cell transformation nor in vivo tumor growth. Furthermore, a significant upregulation of ChoK alpha 1 mRNA levels in a panel of breast and lung cancer cell lines was found, but no changes in ChoK beta mRNA levels were observed. Finally, MN58b, a previously described potent inhibitor of ChoK with in vivo antitumoral activity, shows more than 20-fold higher efficiency towards ChoK alpha 1 than ChoK beta. Conclusion/Significance: This study represents the first evidence of the distinct metabolic role of ChoK alpha and ChoK beta isoforms, suggesting different physiological roles and implications in human carcinogenesis. These findings constitute a step forward in the design of an antitumoral strategy based on ChoK inhibition.	[Gallego-Ortega, David; Ramirez de Molina, Ana; Angeles Ramos, Maria; Valdes-Mora, Fatima; Sarmentero-Estrada, Jacinto; Carlos Lacal, Juan] CSIC UAM La Paz, Inst Invest Biomed, Translat Oncol Unit, Madrid, Spain; [Ramirez de Molina, Ana; Angeles Ramos, Maria; Sarmentero-Estrada, Jacinto; Carlos Lacal, Juan] Ctr Nacl Biotecnol, CD Pharma, Madrid, Spain; [Gonzalez Barderas, Maria] Hosp Nacl Paraplej, Dept Vasc Physiopathol, SESCAM, Toledo, Spain	Consejo Superior de Investigaciones Cientificas (CSIC); Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Centro Nacional de Biotecnologia (CNB); Hospital Nacional de Paraplejicos	Gallego-Ortega, D (corresponding author), CSIC UAM La Paz, Inst Invest Biomed, Translat Oncol Unit, Madrid, Spain.	jclacal@cnb.csic.es	de Molina, Ana Ramirez/AAA-3848-2019; Mora, Fatima Valdes/AAB-9728-2021; Gallego-Ortega, David/AAK-9067-2020; Lacal, Juan Carlos/AAL-2235-2020; estrada, jacinto sarmentero/C-6777-2019; Lacal, Juan Carlos/N-9064-2015	Mora, Fatima Valdes/0000-0001-7490-0114; Gallego-Ortega, David/0000-0002-2347-7835; estrada, jacinto sarmentero/0000-0002-0118-4919; Barderas, Maria G./0000-0003-4290-4721; Lacal, Juan Carlos/0000-0002-1908-2777				Aboagye EO, 1999, CANCER RES, V59, P80; Al-Saffar NMS, 2006, CANCER RES, V66, P427, DOI 10.1158/0008-5472.CAN-05-1338; Aoyama C, 2004, PROG LIPID RES, V43, P266, DOI 10.1016/j.plipres.2003.12.001; Aoyama C, 1998, BBA-LIPID LIPID MET, V1393, P179, DOI 10.1016/S0005-2760(98)00062-9; Aoyama C, 2002, BIOCHEM J, V363, P777, DOI 10.1042/0264-6021:3630777; Aznar S, 2004, CANCER LETT, V206, P181, DOI 10.1016/j.canlet.2003.08.035; Aznar S, 2001, PROG NUCLEIC ACID RE, V67, P193, DOI 10.1016/S0079-6603(01)67029-6; Banez-Coronel M, 2008, CURR CANCER DRUG TAR, V8, P709, DOI 10.2174/156800908786733432; Bell JD, 1998, NMR BIOMED, V11, P354, DOI 10.1002/(SICI)1099-1492(1998110)11:7<354::AID-NBM515>3.0.CO;2-N; Boettner B, 2002, GENE, V286, P155, DOI 10.1016/S0378-1119(02)00426-2; CARNERO A, 1994, ONCOGENE, V9, P1387; CARNERO A, 1993, J CELL BIOCHEM, V52, P440, DOI 10.1002/jcb.240520408; Cheng LL, 2005, CANCER RES, V65, P3030, DOI 10.1158/0008-5472.CAN-04-4106; CUADRADO A, 1993, ONCOGENE, V8, P2959; de Molina AR, 2002, ONCOGENE, V21, P4317, DOI 10.1038/sj.onc.1205556; de Molina AR, 2004, CANCER LETT, V206, P137, DOI 10.1016/j.canlet.2003.08.031; del Pulgar TG, 2005, BIOESSAYS, V27, P602, DOI 10.1002/bies.20238; Eliyahu G, 2007, INT J CANCER, V120, P1721, DOI 10.1002/ijc.22293; Gallego-Ortega D, 2006, INT J ONCOL, V29, P335; GIBELLINI F, 2008, BIOCH J; Glunde K, 2005, CANCER RES, V65, P11034, DOI 10.1158/0008-5472.CAN-05-1807; Glunde K, 2006, PHARMACOGENOMICS, V7, P1109, DOI 10.2217/14622416.7.7.1109; Griffin JL, 2004, NAT REV CANCER, V4, P551, DOI 10.1038/nrc1390; Hernandez-Alcoceba R, 1999, CANCER RES, V59, P3112; HernandezAlcoceba R, 1997, ONCOGENE, V15, P2289, DOI 10.1038/sj.onc.1201414; Iorio E, 2005, CANCER RES, V65, P9369, DOI 10.1158/0008-5472.CAN-05-1146; ISHIDATE K, 1985, BIOCHIM BIOPHYS ACTA, V836, P119; ISHIDATE K, 1984, J BIOL CHEM, V259, P4706; Krishnamachary B, 2009, CANCER RES, V69, P3464, DOI 10.1158/0008-5472.CAN-08-4120; Kurhanewicz J, 2000, NEOPLASIA, V2, P166, DOI 10.1038/sj.neo.7900081; Lacal J C, 2001, IDrugs, V4, P419; LACAL JC, 1987, NATURE, V330, P269, DOI 10.1038/330269a0; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; Lykidis A, 2001, J BIOL CHEM, V276, P2174, DOI 10.1074/jbc.M008794200; Malito E, 2006, J MOL BIOL, V364, P136, DOI 10.1016/j.jmb.2006.08.084; Montaner S, 1998, J BIOL CHEM, V273, P12779, DOI 10.1074/jbc.273.21.12779; Montaner S, 1999, J BIOL CHEM, V274, P8506, DOI 10.1074/jbc.274.13.8506; NEGENDANK W, 1992, NMR BIOMED, V5, P303, DOI 10.1002/nbm.1940050518; PORTER TJ, 1990, J BIOL CHEM, V265, P414; Ramirez de Molina A, 2005, CANCER RES, V65, P5647, DOI 10.1158/0008-5472.CAN-04-4416; Ramirez de Molina A, 2002, BIOCHEM BIOPH RES CO, V296, P580, DOI 10.1016/S0006-291X(02)00920-8; Ramirez de Molina A, 2004, CANCER RES, V64, P6732, DOI 10.1158/0008-5472.CAN-04-0489; Ramirez de Molina A, 2002, ONCOGENE, V21, P937, DOI 10.1038/sj.onc.1205144; Ramirez de Molina A, 2007, LANCET ONCOL, V8, P889, DOI 10.1016/S1470-2045(07)70279-6; RAMIREZ DM, 2001, BIOCHEM BIOPH RES CO, V285, P873; Rodriguez-Gonzalez A, 2005, INT J ONCOL, V26, P999; Rodriguez-Gonzalez A, 2003, ONCOGENE, V22, P8803, DOI 10.1038/sj.onc.1207062; Rodriguez-Gonzalez A, 2004, ONCOGENE, V23, P8247, DOI 10.1038/sj.onc.1208045; Rodriguez-Gonzalez Agustin, 2003, Prog Cell Cycle Res, V5, P191; Sher RB, 2006, J BIOL CHEM, V281, P4938, DOI 10.1074/jbc.M512578200; Spadaro F, 2008, CANCER RES, V68, P6541, DOI 10.1158/0008-5472.CAN-07-6763; Teichert F, 2008, PROSTATE, V68, P1035, DOI 10.1002/pros.20761; TIJBURG LBM, 1989, BIOCHIM BIOPHYS ACTA, V1004, P1, DOI 10.1016/0005-2760(89)90206-3; UCHIDA T, 1992, J BIOL CHEM, V267, P10156; UCHIDA T, 1990, BIOCHIM BIOPHYS ACTA, V1043, P281, DOI 10.1016/0005-2760(90)90028-V; WEINHOLD PA, 1974, BIOCHEMISTRY-US, V13, P5135, DOI 10.1021/bi00722a013; WU G, 2007, J BIOL CHEM; Zhou JH, 2006, P NATL ACAD SCI USA, V103, P14343, DOI 10.1073/pnas.0606480103	58	79	85	0	15	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	NOV 12	2009	4	11							e7819	10.1371/journal.pone.0007819	http://dx.doi.org/10.1371/journal.pone.0007819			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	518UW	19915674	Green Published, Green Submitted, gold			2022-12-25	WOS:000271721400016
J	Kreijtz, JHCM; Suezer, Y; de Mutsert, G; van Amerongen, G; Schwantes, A; van den Brand, JMA; Fouchier, RAM; Lower, J; Osterhaus, ADME; Sutter, G; Rimmelzwaan, GF				Kreijtz, Joost H. C. M.; Suezer, Yasemin; de Mutsert, Gerrie; van Amerongen, Geert; Schwantes, Astrid; van den Brand, Judith M. A.; Fouchier, Ron A. M.; Loewer, Johannes; Osterhaus, Albert D. M. E.; Sutter, Gerd; Rimmelzwaan, Guus F.			MVA-Based H5N1 Vaccine Affords Cross-Clade Protection in Mice against Influenza A/H5N1 Viruses at Low Doses and after Single Immunization	PLOS ONE			English	Article							PANDEMIC INFLUENZA; A VIRUS; IMMUNE-RESPONSES; RANDOMIZED-TRIAL; ANKARA; INFECTION; VECTOR; STRAIN; SAFETY; MACAQUES	Human infections with highly pathogenic avian influenza viruses of the H5N1 subtype, frequently reported since 2003, result in high morbidity and mortality. It is feared that these viruses become pandemic, therefore the development of safe and effective vaccines is desirable. MVA-based H5N1 vaccines already proved to be effective when two immunizations with high doses were used. Dose-sparing strategies would increase the number of people that can be vaccinated when the amount of vaccine preparations that can be produced is limited. Furthermore, protective immunity is induced ideally after a single immunization. Therefore the minimal requirements for induction of protective immunity with a MVA-based H5N1 vaccine were assessed in mice. To this end, mice were vaccinated once or twice with descending doses of a recombinant MVA expressing the HA gene of influenza virus A/Vietnam/1194/04. The protective efficacy was determined after challenge infection with the homologous clade 1 virus and a heterologous virus derived from clade 2.1, A/Indonesia/5/05 by assessing weight loss, virus replication and histopathological changes. It was concluded that MVA-based vaccines allowed significant dose-sparing and afford cross-clade protection, also after a single immunization, which are favorable properties for an H5N1 vaccine candidate.			Kreijtz, JHCM (corresponding author), Erasmus MC, Dept Virol, Rotterdam, Netherlands.	g.rimmelzwaan@erasmusmc.nl	Fouchier, Ron A/A-1911-2014	Fouchier, Ron A/0000-0001-8095-2869; Osterhaus, Albert/0000-0002-6074-1172; Sutter, Gerd/0000-0001-6143-082X				Belyakov IM, 1999, P NATL ACAD SCI USA, V96, P4512, DOI 10.1073/pnas.96.8.4512; Bresson JL, 2006, LANCET, V367, P1657, DOI 10.1016/S0140-6736(06)68656-X; Cosma A, 2003, VACCINE, V22, P21, DOI 10.1016/S0264-410X(03)00538-3; Crawford J, 1999, VACCINE, V17, P2265, DOI 10.1016/S0264-410X(98)00494-0; de Wit E, 2005, J VIROL, V79, P12401, DOI 10.1128/JVI.79.19.12401-12407.2005; Drexler I, 2004, CURR OPIN BIOTECH, V15, P506, DOI 10.1016/j.copbio.2004.09.001; Epstein SL, 2002, EMERG INFECT DIS, V8, P796; FRANK AL, 1980, J CLIN MICROBIOL, V12, P426, DOI 10.1128/JCM.12.3.426-432.1980; Gao WT, 2006, J VIROL, V80, P1959, DOI 10.1128/JVI.80.4.1959-1964.2006; Gomez CE, 2008, CURR GENE THER, V8, P97, DOI 10.2174/156652308784049363; Govorkova E A, 1999, Dev Biol Stand, V98, P39; Govorkova EA, 1999, DEV BIOL STAND, V8, P73; Harrop R, 2006, CLIN CANCER RES, V12, P3416, DOI 10.1158/1078-0432.CCR-05-2732; Hoelscher MA, 2006, LANCET, V367, P475, DOI 10.1016/S0140-6736(06)68076-8; Kalbfuss B, 2007, BIOTECHNOL BIOENG, V97, P73, DOI 10.1002/bit.21139; KATZ JM, 1989, J INFECT DIS, V160, P191, DOI 10.1093/infdis/160.2.191; Kistner O, 2007, VACCINE, V25, P6028, DOI 10.1016/j.vaccine.2007.05.013; Kodihalli S, 1999, J VIROL, V73, P2094, DOI 10.1128/JVI.73.3.2094-2098.1999; Kreijtz JHCM, 2009, J INFECT DIS, V199, P405, DOI 10.1086/595984; Kreijtz JHCM, 2007, J INFECT DIS, V195, P1598, DOI 10.1086/517614; Leroux-Roels I, 2007, LANCET, V370, P580, DOI 10.1016/S0140-6736(07)61297-5; Lin JT, 2006, LANCET, V368, P991, DOI 10.1016/S0140-6736(06)69294-5; Mayr A, 1978, Dev Biol Stand, V41, P225; Nerome K, 1999, Dev Biol Stand, V98, P53; Nerome K, 1999, DEV BIOL STAND, V98, P73; Nicholson KG, 2001, LANCET, V357, P1937, DOI 10.1016/S0140-6736(00)05066-2; Nicolson C, 2005, VACCINE, V23, P2943, DOI 10.1016/j.vaccine.2004.08.054; Nwe N, 2006, BMC MICROBIOL, V6, DOI 10.1186/1471-2180-6-16; Palese P, 2006, EMERG INFECT DIS, V12, P61, DOI 10.3201/eid1201.051043; PALMER D, 1975, HAEMAGGLUTINATION IN, P25; Ramirez JC, 2000, J VIROL, V74, P7651, DOI 10.1128/JVI.74.16.7651-7655.2000; Rimmelzwaan GF, 1998, J VIROL METHODS, V74, P57, DOI 10.1016/S0166-0934(98)00071-8; Rimmelzwaan GF, 2009, EXPERT REV VACCINES, V8, P447, DOI 10.1586/ERV.09.4; Ruat C, 2008, J VIROL, V82, P2565, DOI 10.1128/JVI.01928-07; Stittelaar KJ, 2001, VACCINE, V19, P3700, DOI 10.1016/S0264-410X(01)00075-5; SUTTER G, 1994, VACCINE, V12, P1032, DOI 10.1016/0264-410X(94)90341-7; Sutter Gerd, 2003, Current Drug Targets - Infectious Disorders, V3, P263, DOI 10.2174/1568005033481123; Treanor JJ, 2001, VACCINE, V19, P1732, DOI 10.1016/S0264-410X(00)00395-9; Webby RJ, 2003, SCIENCE, V302, P1519, DOI 10.1126/science.1090350; *WHO, 2009, NEW INFL A HIN1 NUMB; *WHO, 2009, 211 WHO; Yang ZY, 2003, J VIROL, V77, P799, DOI 10.1128/JVI.77.1.799-803.2003	42	39	44	0	4	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA	1932-6203			PLOS ONE	PLoS One	NOV 12	2009	4	11							e7790	10.1371/journal.pone.0007790	http://dx.doi.org/10.1371/journal.pone.0007790			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	518UW	19915662	gold, Green Published, Green Submitted			2022-12-25	WOS:000271721400002
J	Zhang, EY; Chen, AY; Zhu, BT				Zhang, Elizabeth Yan; Chen, Aaron Yun; Zhu, Bao Ting			Mechanism of Dinitrochlorobenzene-Induced Dermatitis in Mice: Role of Specific Antibodies in Pathogenesis	PLOS ONE			English	Article							CONTACT HYPERSENSITIVITY; T-CELLS; ATOPIC-DERMATITIS; IN-VITRO; ELICITATION; SUPPRESSION; RESPONSES; CD4(+); SENSITIZATION; LYMPHOCYTES	Background: Dinitrochlorobenzene-induced contact hypersensitivity is widely considered as a cell-mediated rather than antibody-mediated immune response. At present, very little is known about the role of antigen-specific antibodies and B cells in the development of dinitrochlorobenzene-induced hypersensitivity reactions, and this is the subject of the present investigation. Methodology/Principal Findings: Data obtained from multiple lines of experiments unequivocally showed that the formation of dinitrochlorobenzene-specific Abs played an important role in the development of dinitrochlorobenzene-induced contact hypersensitivity. The appearance of dinitrochlorobenzene-induced skin dermatitis matched in timing the appearance of the circulating dinitrochlorobenzene-specific antibodies. Adoptive transfer of sera containing dinitrochlorobenzene-specific antibodies from dinitrochlorobenzene-treated mice elicited a much stronger hypersensitivity reaction than the adoptive transfer of lymphocytes from the same donors. Moreover, dinitrochlorobenzene-induced contact hypersensitivity was strongly suppressed in B cell-deficient mice with no DNCB-specific antibodies. It was also observed that treatment of animals with dinitrochlorobenzene polarized Th cells into Th2 differentiation by increasing the production of Th2 cytokines while decreasing the production of Th1 cytokines. Conclusions/Significance: In striking contrast to the long-held belief that dinitrochlorobenzene-induced contact hypersensitivity is a cell-mediated immune response, the results of our present study demonstrated that the production of dinitrochlorobenzene-specific antibodies by activated B cells played an indispensible role in the pathogenesis of dinitrochlorobenzene-induced CHS. These findings may provide new possibilities in the treatment of human contact hypersensitivity conditions.			Zhang, EY (corresponding author), Univ Kansas, Med Ctr, Dept Pharmacol Toxicol & Therapeut, Sch Med, Kansas City, KS 66103 USA.	BTZhu@kumc.edu			NATIONAL CANCER INSTITUTE [R01CA097109, R01CA092391] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [P20RR021940] Funding Source: NIH RePORTER; NCI NIH HHS [CA92391, R01 CA092391, CA97109, R01 CA097109] Funding Source: Medline; NCRR NIH HHS [P20 RR021940, P20RR021940] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		Askenase PW, 2001, CLIN EXP IMMUNOL, V125, P345, DOI 10.1046/j.1365-2249.2001.01619.x; Campos RA, 2006, IMMUNOLOGY, V117, P536, DOI 10.1111/j.1365-2567.2006.02330.x; CARAPETO FJ, 1976, ARCH DERMATOL, V112, P1095, DOI 10.1001/archderm.112.8.1095; COHEN S, 1971, J EXP MED, V133, P133, DOI 10.1084/jem.133.1.133; Fei MJ, 2005, J ALLERGY CLIN IMMUN, V116, P1350, DOI 10.1016/j.jaci.2005.08.032; GARRIGUE JL, 1994, CONTACT DERMATITIS, V30, P231, DOI 10.1111/j.1600-0536.1994.tb00650.x; Grabbe S, 1998, IMMUNOL TODAY, V19, P37, DOI 10.1016/S0167-5699(97)01186-9; HSIEH CS, 1995, J EXP MED, V181, P713, DOI 10.1084/jem.181.2.713; Kehren J, 1999, J EXP MED, V189, P779, DOI 10.1084/jem.189.5.779; Kitagaki H, 1997, J IMMUNOL, V159, P2484; Larsen JM, 2007, CONTACT DERMATITIS, V57, P300, DOI 10.1111/j.1600-0536.2007.01230.x; LEUNG DYM, 1995, J ALLERGY CLIN IMMUN, V96, P302, DOI 10.1016/S0091-6749(95)70049-8; Miles SA, 2005, J EXP MED, V201, P747, DOI 10.1084/jem.20041470; Mills CD, 2000, J IMMUNOL, V164, P6166, DOI 10.4049/jimmunol.164.12.6166; Nagai H, 1999, J PHARMACOL EXP THER, V288, P43; Nagai J, 1998, J PHARMACOL EXP THER, V285, P422; Nakazawa M, 1997, J ALLERGY CLIN IMMUN, V99, P673, DOI 10.1016/S0091-6749(97)70030-7; O'Leary JG, 2006, NAT IMMUNOL, V7, P507, DOI 10.1038/ni1332; Perone MJ, 2009, J IMMUNOL, V182, P2641, DOI 10.4049/jimmunol.0800839; SHAALA AY, 1980, BRIT J DERMATOL, V103, P159, DOI 10.1111/j.1365-2133.1980.tb06585.x; STEVENS TL, 1988, NATURE, V334, P255, DOI 10.1038/334255a0; THOMSON JA, 1993, IMMUNOLOGY, V78, P185; Traidl C, 1999, J INVEST DERMATOL, V112, P476, DOI 10.1046/j.1523-1747.1999.00550.x; Tuckermann JP, 2007, J CLIN INVEST, V117, P1381, DOI 10.1172/JCI28034; Wang BH, 2000, J IMMUNOL, V165, P6783, DOI 10.4049/jimmunol.165.12.6783; Wang BH, 2001, J LEUKOCYTE BIOL, V70, P185; Wang LF, 1999, CLIN EXP ALLERGY, V29, P271; Warbrick EV, 2002, J APPL TOXICOL, V22, P1, DOI 10.1002/jat.830; Watanabe H, 2002, J INTERF CYTOK RES, V22, P407, DOI 10.1089/10799900252952181; Watanabe R, 2007, AM J PATHOL, V171, P560, DOI 10.2353/ajpath.2007.061279; Weigmann B, 1997, SCAND J IMMUNOL, V45, P308, DOI 10.1046/j.1365-3083.1997.d01-402.x; Xu H, 1997, J IMMUNOL, V158, P4721; Yamada N, 1995, J ALLERGY CLIN IMMUN, V96, P1069, DOI 10.1016/S0091-6749(95)70192-3; Yokozeki H, 2000, J EXP MED, V191, P995, DOI 10.1084/jem.191.6.995	34	47	48	0	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	NOV 5	2009	4	11							e7703	10.1371/journal.pone.0007703	http://dx.doi.org/10.1371/journal.pone.0007703			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	515HI	19890385	Green Published, gold, Green Submitted			2022-12-25	WOS:000271459700007
J	Ferhat, M; Atlan, D; Vianney, A; Lazzaroni, JC; Doublet, P; Gilbert, C				Ferhat, Mourad; Atlan, Daniele; Vianney, Anne; Lazzaroni, Jean-Claude; Doublet, Patricia; Gilbert, Christophe			The TolC Protein of Legionella pneumophila Plays a Major Role in Multi-Drug Resistance and the Early Steps of Host Invasion	PLOS ONE			English	Article							ENTERICA SEROVAR TYPHIMURIUM; PERIPLASMIC SUPEROXIDE-DISMUTASE; ESCHERICHIA-COLI; ACRAB-TOLC; EFFLUX; ACTIVATION; SECRETION; MECHANISM; MEMBRANE; MUTANTS	Pneumonia associated with Iegionnaires's disease is initiated in humans after inhalation of contaminated aerosols. In the environment, Legionella pneumophila is thought to survive and multiply as an intracellular parasite within free-living amoeba. In the genome of L. pneumophila Lens, we identified a unique gene, tolC, encoding a protein that is highly homologous to the outer membrane protein TolC of Escherichia coli. Deletion of tolC by allelic exchange in L. pneumophila caused increased sensitivity to various drugs. The complementation of the tolC mutation in trans restored drug resistance, indicating that TolC is involved in multi-drug efflux machinery. In addition, deletion of tolC caused a significant attenuation of virulence towards both amoebae and macrophages. Thus, the TolC protein appears to play a crucial role in virulence which could be mediated by its involvement in efflux pump mechanisms. These findings will be helpful in unraveling the pathogenic mechanisms of L. pneumophila as well as in developing new therapeutic agents affecting the efflux of toxic compounds.			Ferhat, M (corresponding author), Univ Lyon, Lyon, France.	gilbert@biomserv.univ-lyon1.fr	Vianney, Anne/L-9544-2014; Doublet, Patricia/L-9480-2014; Gilbert, Christophe/M-6005-2014	Doublet, Patricia/0000-0001-5848-4317; Gilbert, Christophe/0000-0003-3021-7350				Bandyopadhyay P, 2003, INFECT IMMUN, V71, P4526, DOI 10.1128/IAI.71.8.4526-4535.2003; Baucheron S, 2004, ANTIMICROB AGENTS CH, V48, P3729, DOI 10.1128/AAC.48.10.3729-3735.2004; BERGER KH, 1994, MOL MICROBIOL, V14, P809, DOI 10.1111/j.1365-2958.1994.tb01317.x; Bokma E, 2007, AMINO ACIDS, V33, pVIII; Buckley AM, 2006, CELL MICROBIOL, V8, P847, DOI 10.1111/j.1462-5822.2005.00671.x; Bunikis I, 2008, PLOS PATHOG, V4, DOI 10.1371/journal.ppat.1000009; Cazalet C, 2004, NAT GENET, V36, P1165, DOI 10.1038/ng1447; Chen DQ, 2006, PLASMID, V56, P167, DOI 10.1016/j.plasmid.2006.05.008; Cosme AM, 2008, MOL PLANT MICROBE IN, V21, P947, DOI 10.1094/MPMI-21-7-0947; DeLeo FR, 1999, J IMMUNOL, V163, P6732; Frohner IE, 2009, MOL MICROBIOL, V71, P240, DOI 10.1111/j.1365-2958.2008.06528.x; Gil H, 2006, P NATL ACAD SCI USA, V103, P12897, DOI 10.1073/pnas.0602582103; Giraud E, 2000, ANTIMICROB AGENTS CH, V44, P1223, DOI 10.1128/AAC.44.5.1223-1228.2000; Golubeva YA, 2006, J BACTERIOL, V188, P7853, DOI 10.1128/JB.00706-06; Isberg RR, 2009, NAT REV MICROBIOL, V7, P12, DOI 10.1038/nrmicro1967; Karatzas KAG, 2008, APPL ENVIRON MICROB, V74, P1508, DOI 10.1128/AEM.01931-07; Keith KE, 2007, INFECT IMMUN, V75, P2451, DOI 10.1128/IAI.01556-06; Lau SY, 2005, J BACTERIOL, V187, P7815, DOI 10.1128/JB.187.22.7815-7825.2005; Li XZ, 2004, DRUGS, V64, P159, DOI 10.2165/00003495-200464020-00004; Lobedanz S, 2007, P NATL ACAD SCI USA, V104, P4612, DOI 10.1073/pnas.0610160104; Mahamoud A, 2007, J ANTIMICROB CHEMOTH, V59, P1223, DOI 10.1093/jac/dkl493; Marchler-Bauer A, 2007, NUCLEIC ACIDS RES, V35, pD237, DOI 10.1093/nar/gkl951; Martin RG, 2008, J MOL BIOL, V380, P278, DOI 10.1016/j.jmb.2008.05.015; Molmeret M, 2004, MICROBES INFECT, V6, P129, DOI 10.1016/j.micinf.2003.11.004; Molmeret M, 2007, INFECT IMMUN, V75, P3290, DOI 10.1128/IAI.00292-07; Nishino K, 2003, ANTIMICROB AGENTS CH, V47, P3030, DOI 10.1128/AAC.47.9.3030-3033.2003; Poole K, 2004, CLIN MICROBIOL INFEC, V10, P12, DOI 10.1111/j.1469-0691.2004.00763.x; Poole Keith, 2003, Curr Opin Investig Drugs, V4, P128; POPE CD, 1994, FEMS MICROBIOL LETT, V124, P107, DOI 10.1111/j.1574-6968.1994.tb07269.x; Posadas DM, 2007, INFECT IMMUN, V75, P379, DOI 10.1128/IAI.01349-06; Seeger MA, 2008, CURR DRUG TARGETS, V9, P729, DOI 10.2174/138945008785747789; Shin S, 2008, CELL MICROBIOL, V10, P1209, DOI 10.1111/j.1462-5822.2008.01145.x; STONE BJ, 1995, MOL MICROBIOL, V17, P701, DOI 10.1111/j.1365-2958.1995.mmi_17040701.x; Sulavik MC, 2001, ANTIMICROB AGENTS CH, V45, P1126, DOI 10.1128/AAC.45.4.1126-1136.2001; SWANSON MS, 1995, INFECT IMMUN, V63, P3609, DOI 10.1128/IAI.63.9.3609-3620.1995; Tilney LG, 2001, J CELL SCI, V114, P4637; Virlogeux-Payant I, 2008, INT J MED MICROBIOL, V298, P561, DOI 10.1016/j.ijmm.2007.12.006; Viveiros M, 2008, INT J ANTIMICROB AG, V31, P458, DOI 10.1016/j.ijantimicag.2007.12.015; Yamanaka H, 2008, J BACTERIOL, V190, P7693, DOI 10.1128/JB.00853-08; Zhang A, 2008, MOL MICROBIOL, V69, P1450, DOI 10.1111/j.1365-2958.2008.06371.x	40	39	39	0	16	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	NOV 4	2009	4	11							e7732	10.1371/journal.pone.0007732	http://dx.doi.org/10.1371/journal.pone.0007732			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	514RZ	19888467	Green Submitted, Green Published, gold			2022-12-25	WOS:000271414600010
J	Martin, L; Che, A; Endy, D				Martin, Lance; Che, Austin; Endy, Drew			Gemini, a Bifunctional Enzymatic and Fluorescent Reporter of Gene Expression	PLOS ONE			English	Article							ALPHA-COMPLEMENTATION; BETA-GALACTOSIDASE; BIOLOGY; CONSTRUCTION; PROTEIN; REFINEMENT; PROGRAM; DEVICES; PARTS; CELLS	Background: The development of collections of quantitatively characterized standard biological parts should facilitate the engineering of increasingly complex and novel biological systems. The existing enzymatic and fluorescent reporters that are used to characterize biological part functions exhibit strengths and limitations. Combining both enzymatic and fluorescence activities within a single reporter protein would provide a useful tool for biological part characterization. Methodology/Principal Findings: Here, we describe the construction and quantitative characterization of Gemini, a fusion between the beta-galactosidase (beta-gal) alpha-fragment and the N-terminus of full-length green fluorescent protein (GFP). We show that Gemini exhibits functional beta-gal activity, which we assay with plates and fluorometry, and functional GFP activity, which we assay with fluorometry and microscopy. We show that the protein fusion increases the sensitivity of beta-gal activity and decreases the sensitivity of GFP. Conclusions/Significance: Gemini is therefore a bifunctional reporter with a wider dynamic range than the beta-gal alpha-fragment or GFP alone. Gemini enables the characterization of gene expression, screening assays via enzymatic activity, and quantitative single-cell microscopy or FACS via fluorescence activity. The analytical flexibility afforded by Gemini will likely increase the efficiency of research, particularly for screening and characterization of libraries of standard biological parts.			Martin, L (corresponding author), Stanford Univ, Dept Bioengn, Stanford, CA 94305 USA.	endy@stanford.edu		Endy, Drew/0000-0001-6952-8098				Anderson JC, 2007, MOL SYST BIOL, V3, DOI 10.1038/msb4100173; Baker D, 2006, SCI AM, V294, P44, DOI 10.1038/scientificamerican0606-44; Bennett MR, 2009, NAT REV GENET, V10, P628, DOI 10.1038/nrg2625; Canton B, 2008, NAT BIOTECHNOL, V26, P787, DOI 10.1038/nbt1413; Corish P, 1999, PROTEIN ENG, V12, P1035, DOI 10.1093/protein/12.12.1035; David HE, 2003, ENVIRON TOXICOL CHEM, V22, P111, DOI [10.1897/1551-5028(2003)022&lt;0111:CAEOAT&gt;2.0.CO;2, 10.1002/etc.5620220114]; Ellis T, 2009, NAT BIOTECHNOL, V27, P465, DOI 10.1038/nbt.1536; Hwang CN, 2006, BIOTECHNOL LETT, V28, P287, DOI 10.1007/s10529-005-5715-9; Juers DH, 2000, PROTEIN SCI, V9, P1685, DOI 10.1110/ps.9.9.1685; Kelly Jason R, 2009, J Biol Eng, V3, P4, DOI 10.1186/1754-1611-3-4; Marguet P, 2007, J R SOC INTERFACE, V4, P607, DOI 10.1098/rsif.2006.0206; Purnick PEM, 2009, NAT REV MOL CELL BIO, V10, P410, DOI 10.1038/nrm2698; SHETTY R, 2009, 29 BBF RFC; Tabor JJ, 2009, CELL, V137, P1272, DOI 10.1016/j.cell.2009.04.048; Tsien RY, 1998, ANNU REV BIOCHEM, V67, P509, DOI 10.1146/annurev.biochem.67.1.509; Voigt CA, 2006, CURR OPIN BIOTECH, V17, P548, DOI 10.1016/j.copbio.2006.09.001; Walhout AJM, 2001, METHODS, V24, P297, DOI 10.1006/meth.2001.1190; ZAMENHOF PJ, 1972, J BACTERIOL, V110, P171, DOI 10.1128/JB.110.1.171-178.1972; Zhang J, 2002, NAT REV MOL CELL BIO, V3, P906, DOI 10.1038/nrm976	19	26	26	1	8	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA	1932-6203			PLOS ONE	PLoS One	NOV 4	2009	4	11							e7569	10.1371/journal.pone.0007569	http://dx.doi.org/10.1371/journal.pone.0007569			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	514RZ	19888458	Green Published, Green Submitted, gold			2022-12-25	WOS:000271414600002
J	Perez, N; Trevino, J; Liu, ZY; Ho, SCM; Babitzke, P; Sumby, P				Perez, Nataly; Trevino, Jeanette; Liu, Zhuyun; Ho, Siu Chun Michael; Babitzke, Paul; Sumby, Paul			A Genome-Wide Analysis of Small Regulatory RNAs in the Human Pathogen Group A Streptococcus	PLOS ONE			English	Article							SMALL NONCODING RNAS; RECOGNITION PARTICLE PATHWAY; VIRULENCE FACTOR REGULATION; RESPONSE REGULATOR; GENETIC-LOCUS; PYOGENES; IDENTIFICATION; EXPRESSION; PREDICTION; SYSTEM	The coordinated regulation of gene expression is essential for pathogens to infect and cause disease. A recently appreciated mechanism of regulation is that afforded by small regulatory RNA (sRNA) molecules. Here, we set out to assess the prevalence of sRNAs in the human bacterial pathogen group A Streptococcus (GAS). Genome-wide identification of candidate GAS sRNAs was performed through a tiling Affymetrix microarray approach and identified 40 candidate sRNAs within the M1T1 GAS strain MGAS2221. Together with a previous bioinformatic approach this brings the number of novel candidate sRNAs in GAS to 75, a number that approximates the number of GAS transcription factors. Transcripts were confirmed by Northern blot analysis for 16 of 32 candidate sRNAs tested, and the abundance of several of these sRNAs were shown to be temporally regulated. Six sRNAs were selected for further study and the promoter, transcriptional start site, and Rho-independent terminator identified for each. Significant variation was observed between the six sRNAs with respect to their stability during growth, and with respect to their inter- and/or intra-serotype-specific levels of abundance. To start to assess the contribution of sRNAs to gene regulation in M1T1 GAS we deleted the previously described sRNA PEL from four clinical isolates. Data from genome-wide expression microarray, quantitative RT-PCR, and Western blot analyses are consistent with PEL having no regulatory function in M1T1 GAS. The finding that candidate sRNA molecules are prevalent throughout the GAS genome provides significant impetus to the study of this fundamental gene-regulatory mechanism in an important human pathogen.			Perez, N (corresponding author), Methodist Hosp, Res Inst, Ctr Mol & Translat Human Infect Dis Res, 6535 Fannin, Houston, TX 77030 USA.	psumby@tmhs.org	Babitzke, Paul/AAL-3048-2020	Babitzke, Paul/0000-0003-2481-1062; Sumby, Paul/0000-0002-0093-4159	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R21AI078159] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM059969] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Aziz RK, 2008, EMERG INFECT DIS, V14, P1511, DOI 10.3201/eid1410.071660; Barnett TC, 2007, J BACTERIOL, V189, P1866, DOI 10.1128/JB.01658-06; Beres SB, 2006, P NATL ACAD SCI USA, V103, P7059, DOI 10.1073/pnas.0510279103; Bernish B, 1999, J BIOL CHEM, V274, P4786, DOI 10.1074/jbc.274.8.4786; Betschel SD, 1998, INFECT IMMUN, V66, P1671, DOI 10.1128/IAI.66.4.1671-1679.1998; Biswas I, 2001, INFECT IMMUN, V69, P7029, DOI 10.1128/IAI.69.11.7029-7038.2001; Blount KF, 2006, NAT BIOTECHNOL, V24, P1558, DOI 10.1038/nbt1268; Cunningham MW, 2000, CLIN MICROBIOL REV, V13, P470, DOI 10.1128/CMR.13.3.470-511.2000; Eberhard T H, 2001, BMC Microbiol, V1, P33, DOI 10.1186/1471-2180-1-33; Federle MJ, 1999, J BACTERIOL, V181, P3649, DOI 10.1128/JB.181.12.3649-3657.1999; Gottesman S, 2005, TRENDS GENET, V21, P399, DOI 10.1016/j.tig.2005.05.008; Graham MR, 2005, AM J PATHOL, V166, P455, DOI 10.1016/S0002-9440(10)62268-7; Graham MR, 2002, P NATL ACAD SCI USA, V99, P13855, DOI 10.1073/pnas.202353699; Hasona A, 2005, P NATL ACAD SCI USA, V102, P17466, DOI 10.1073/pnas.0508778102; Herskovits AA, 2000, MOL MICROBIOL, V38, P927, DOI 10.1046/j.1365-2958.2000.02198.x; Huntzinger E, 2005, EMBO J, V24, P824, DOI 10.1038/sj.emboj.7600572; Keiler KC, 2007, CURR OPIN MICROBIOL, V10, P169, DOI 10.1016/j.mib.2007.03.014; Kreikemeyer B, 2003, TRENDS MICROBIOL, V11, P224, DOI 10.1016/S0966-842X(03)00098-2; Kreikemeyer B, 2001, MOL MICROBIOL, V39, P392, DOI 10.1046/j.1365-2958.2001.02226.x; Kuwayama H, 2002, NUCLEIC ACIDS RES, V30, DOI 10.1093/nar/30.2.e2; Landt SG, 2008, MOL MICROBIOL, V68, P600, DOI 10.1111/j.1365-2958.2008.06172.x; Levin JC, 1998, MOL MICROBIOL, V30, P209, DOI 10.1046/j.1365-2958.1998.01057.x; Li ZQ, 1999, J BACTERIOL, V181, P6019, DOI 10.1128/JB.181.19.6019-6027.1999; Livny J, 2007, CURR OPIN MICROBIOL, V10, P96, DOI 10.1016/j.mib.2007.03.005; Livny J, 2006, NUCLEIC ACIDS RES, V34, P3484, DOI 10.1093/nar/gkl453; Mangold M, 2004, MOL MICROBIOL, V53, P1515, DOI 10.1111/j.1365-2958.2004.04222.x; McIver KS, 2009, CONTRIB MICROBIOL, V16, P103, DOI 10.1159/000219375; Morita T, 2005, GENE DEV, V19, P2176, DOI 10.1101/gad.1330405; Nizet V, 2000, INFECT IMMUN, V68, P4245, DOI 10.1128/IAI.68.7.4245-4254.2000; Ostberg Y, 2004, J BACTERIOL, V186, P8472, DOI 10.1128/JB.186.24.8472-8477.2004; Pichon C, 2005, P NATL ACAD SCI USA, V102, P14249, DOI 10.1073/pnas.0503838102; Reichenbach B, 2008, NUCLEIC ACIDS RES, V36, P2570, DOI 10.1093/nar/gkn091; Roberts SA, 2007, MOL MICROBIOL, V66, P1506, DOI 10.1111/j.1365-2958.2007.06015.x; Roberts SA, 2007, J BACTERIOL, V189, P1459, DOI 10.1128/JB.01026-06; Romby P, 2006, CURR OPIN MICROBIOL, V9, P229, DOI 10.1016/j.mib.2006.02.005; Rosch JW, 2008, INFECT IMMUN, V76, P2612, DOI 10.1128/IAI.00239-07; Shelburne SA, 2008, P NATL ACAD SCI USA, V105, P1698, DOI 10.1073/pnas.0711767105; Shelburne SA, 2007, INFECT IMMUN, V75, P2981, DOI 10.1128/IAI.00081-07; Sorek R, 2008, NAT REV MICROBIOL, V6, P181, DOI 10.1038/nrmicro1793; Sumby P, 2005, J INFECT DIS, V192, P771, DOI 10.1086/432514; Sumby P, 2003, J BACTERIOL, V185, P6841, DOI 10.1128/JB.185.23.6841-6851.2003; Sumby P, 2006, PLOS PATHOG, V2, P41, DOI 10.1371/journal.ppat.0020005; Tjaden B, 2008, J MATH BIOL, V56, P183, DOI 10.1007/s00285-007-0079-5; Tjaden B, 2006, NUCLEIC ACIDS RES, V34, P2791, DOI 10.1093/nar/gkl356; Toledo-Arana A, 2007, CURR OPIN MICROBIOL, V10, P182, DOI 10.1016/j.mib.2007.03.004; Toledo-Arana A, 2009, NATURE, V459, P950, DOI 10.1038/nature08080; Traber KE, 2008, MICROBIOL-SGM, V154, P2265, DOI 10.1099/mic.0.2007/011874-0; Vitreschak AG, 2004, TRENDS GENET, V20, P44, DOI 10.1016/j.tig.2003.11.008; Vogel J, 2005, BIOL CHEM, V386, P1219, DOI 10.1515/BC.2005.140; Wassarman KM, 2007, CURR OPIN MICROBIOL, V10, P164, DOI 10.1016/j.mib.2007.03.008	50	72	75	0	12	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	NOV 2	2009	4	11							e7668	10.1371/journal.pone.0007668	http://dx.doi.org/10.1371/journal.pone.0007668			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	514RX	19888332	Green Submitted, Green Published, gold			2022-12-25	WOS:000271414400003
J	Pepper, ASR; Beerman, RW; Bhogal, B; Jongens, TA				Pepper, Anita S. -R.; Beerman, Rebecca W.; Bhogal, Balpreet; Jongens, Thomas A.			Argonaute2 Suppresses Drosophila Fragile X Expression Preventing Neurogenesis and Oogenesis Defects	PLOS ONE			English	Article							MENTAL-RETARDATION PROTEIN; MESSENGER-RNA; TREMOR/ATAXIA SYNDROME; INTERFERING RNAS; SOMATIC-CELLS; P-BODIES; GENE; PATHWAY; BEHAVIOR; BRAIN	Fragile X Syndrome is caused by the silencing of the Fragile X Mental Retardation gene (FMR1). Regulating dosage of FMR1 levels is critical for proper development and function of the nervous system and germ line, but the pathways responsible for maintaining normal expression levels are less clearly defined. Loss of Drosophila Fragile X protein (dFMR1) causes several behavioral and developmental defects in the fly, many of which are analogous to those seen in Fragile X patients. Overexpression of dFMR1 also causes specific neuronal and behavioral abnormalities. We have found that Argonaute2 (Ago2), the core component of the small interfering RNA (siRNA) pathway, regulates dfmr1 expression. Previously, the relationship between dFMR1 and Ago2 was defined by their physical interaction and co-regulation of downstream targets. We have found that Ago2 and dFMR1 are also connected through a regulatory relationship. Ago2 mediated repression of dFMR1 prevents axon growth and branching defects of the Drosophila neuromuscular junction (NMJ). Consequently, the neurogenesis defects in larvae mutant for both dfmr1 and Ago2 mirror those in dfmr1 null mutants. The Ago2 null phenotype at the NMJ is rescued in animals carrying an Ago2 genomic rescue construct. However, animals carrying a mutant Ago2 allele that produces Ago2 with significantly reduced endoribonuclease catalytic activity are normal with respect to the NMJ phenotypes examined. dFMR1 regulation by Ago2 is also observed in the germ line causing a multiple oocyte in a single egg chamber mutant phenotype. We have identified Ago2 as a regulator of dfmr1 expression and have clarified an important developmental role for Ago2 in the nervous system and germ line that requires dfmr1 function.			Pepper, ASR (corresponding author), Univ Penn, Sch Med, Dept Genet, Philadelphia, PA 19104 USA.	jongens@mail.med.upenn.edu	Pepper, Anita/GWC-7680-2022	Beerman, Rebecca/0000-0002-2057-4170; Bhogal, Balpreet/0000-0002-3997-7316	NATIONAL INSTITUTE OF MENTAL HEALTH [R21MH086705] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS046573] Funding Source: NIH RePORTER; NIMH NIH HHS [MH086705, R21 MH086705] Funding Source: Medline; NINDS NIH HHS [NS046573, R01 NS046573] Funding Source: Medline	NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ASHLEY CT, 1993, NAT GENET, V4, P244, DOI 10.1038/ng0793-244; Ashraf SI, 2006, CELL, V124, P191, DOI 10.1016/j.cell.2005.12.017; Barbee SA, 2006, NEURON, V52, P997, DOI 10.1016/j.neuron.2006.10.028; Berry-Kravis E, 2003, ANN NEUROL, V53, P616, DOI 10.1002/ana.10522; Beumer KJ, 1999, DEVELOPMENT, V126, P5833; Bolduc FV, 2008, NAT NEUROSCI, V11, P1143, DOI 10.1038/nn.2175; Caudy AA, 2002, GENE DEV, V16, P2491, DOI 10.1101/gad.1025202; Comery TA, 1997, P NATL ACAD SCI USA, V94, P5401, DOI 10.1073/pnas.94.10.5401; Costa A, 2005, DEV CELL, V8, P331, DOI 10.1016/j.devcel.2005.01.011; Czech B, 2008, NATURE, V453, P798, DOI 10.1038/nature07007; Deshpande G, 2005, GENE DEV, V19, P1680, DOI 10.1101/gad.1316805; Dockendorff TC, 2002, NEURON, V34, P973, DOI 10.1016/S0896-6273(02)00724-9; Eulalio A, 2007, MOL CELL BIOL, V27, P3970, DOI 10.1128/MCB.00128-07; Eulalio A, 2007, NAT REV MOL CELL BIO, V8, P9, DOI 10.1038/nrm2080; Feng Y, 1997, J NEUROSCI, V17, P1539; Gabus C, 2004, NUCLEIC ACIDS RES, V32, P2129, DOI 10.1093/nar/gkh535; Garber K, 2006, CURR OPIN GENET DEV, V16, P270, DOI 10.1016/j.gde.2006.04.010; Ghildiyal M, 2008, SCIENCE, V320, P1077, DOI 10.1126/science.1157396; Hagerman PJ, 2004, MENT RETARD DEV D R, V10, P25, DOI 10.1002/mrdd.20005; Hagerman RJ, 2001, MOL GENET METAB, V74, P89, DOI 10.1006/mgme.2001.3225; HINTON VJ, 1991, AM J MED GENET, V41, P289, DOI 10.1002/ajmg.1320410306; Hou LF, 2006, NEURON, V51, P441, DOI 10.1016/j.neuron.2006.07.005; Irwin SA, 2000, CEREB CORTEX, V10, P1038, DOI 10.1093/cercor/10.10.1038; Irwin SA, 2001, AM J MED GENET, V98, P161, DOI 10.1002/1096-8628(20010115)98:2<161::AID-AJMG1025>3.0.CO;2-B; Ishizuka A, 2002, GENE DEV, V16, P2497, DOI 10.1101/gad.1022002; Jacquemont S, 2004, AM J MENT RETARD, V109, P154, DOI 10.1352/0895-8017(2004)109<154:AIIWTF>2.0.CO;2; Jacquemont S, 2003, AM J HUM GENET, V72, P869, DOI 10.1086/374321; Kawamura Y, 2008, NATURE, V453, P793, DOI 10.1038/nature06938; Kim K, 2007, RNA, V13, P22, DOI 10.1261/rna.283207; Lee A, 2003, DEVELOPMENT, V130, P5543, DOI 10.1242/dev.00792; Leehey MA, 2003, ARCH NEUROL-CHICAGO, V60, P117, DOI 10.1001/archneur.60.1.117; Ling SC, 2004, P NATL ACAD SCI USA, V101, P17428, DOI 10.1073/pnas.0408114101; Meyer WJ, 2006, PLOS GENET, V2, P1224, DOI 10.1371/journal.pgen.0020134; Monzo K, 2006, P NATL ACAD SCI USA, V103, P18160, DOI 10.1073/pnas.0606508103; Morales J, 2002, NEURON, V34, P961, DOI 10.1016/S0896-6273(02)00731-6; Murashov AK, 2007, FASEB J, V21, P656, DOI 10.1096/fj.06-6155com; OBERLE I, 1991, SCIENCE, V252, P1097, DOI 10.1126/science.252.5009.1097; Okamura K, 2004, GENE DEV, V18, P1655, DOI 10.1101/gad.1210204; Okamura K, 2008, NAT REV MOL CELL BIO, V9, P673, DOI 10.1038/nrm2479; Okamura K, 2008, NATURE, V453, P803, DOI 10.1038/nature07015; Page SL, 2001, GENE DEV, V15, P3130, DOI 10.1101/gad.935001; Pan L, 2008, MOL CELL NEUROSCI, V37, P747, DOI 10.1016/j.mcn.2008.01.003; Pan LY, 2004, CURR BIOL, V14, P1863, DOI 10.1016/j.cub.2004.09.085; Papaceit M, 2004, GENETICS, V167, P289, DOI 10.1534/genetics.167.1.289; Peier AM, 2000, HUM MOL GENET, V9, P1145, DOI 10.1093/hmg/9.8.1145; PIERETTI M, 1991, CELL, V66, P817, DOI 10.1016/0092-8674(91)90125-I; Rehwinkel J, 2006, MOL CELL BIOL, V26, P2965, DOI 10.1128/MCB.26.8.2965-2975.2006; Rohrbough J, 2000, J NEUROSCI, V20, P6868, DOI 10.1523/JNEUROSCI.20-18-06868.2000; Schaeffer C, 2001, EMBO J, V20, P4803, DOI 10.1093/emboj/20.17.4803; Schenck A, 2002, NEUROBIOL DIS, V11, P53, DOI 10.1006/nbdi.2002.0510; Schneider MD, 2006, J CELL BIOL, V174, P349, DOI 10.1083/jcb.200512103; SIOMI H, 1993, CELL, V74, P291, DOI 10.1016/0092-8674(93)90420-U; Siomi MC, 2005, RNA, V11, P1004, DOI 10.1261/rna.2280105; Sofola O, 2008, J NEUROSCI, V28, P10200, DOI 10.1523/JNEUROSCI.2786-08.2008; Sonenberg N, 2007, MOL CELL, V28, P721, DOI 10.1016/j.molcel.2007.11.018; Wan LL, 2000, MOL CELL BIOL, V20, P8536, DOI 10.1128/MCB.20.22.8536-8547.2000; WARREN ST, 1994, JAMA-J AM MED ASSOC, V271, P536, DOI 10.1001/jama.271.7.536; Xu KY, 2004, CURR BIOL, V14, P1025, DOI 10.1016/j.cub.2004.05.055; Zarnescu DC, 2005, GENES BRAIN BEHAV, V4, P385, DOI 10.1111/j.1601-183X.2005.00136.x; Zhang YQ, 2001, CELL, V107, P591, DOI 10.1016/S0092-8674(01)00589-X; ZINSMAIER KE, 1990, J NEUROGENET, V7, P15, DOI 10.3109/01677069009084150	61	21	21	0	3	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA	1932-6203			PLOS ONE	PLoS One	OCT 27	2009	4	10							e7618	10.1371/journal.pone.0007618	http://dx.doi.org/10.1371/journal.pone.0007618			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	511ET	19888420	gold, Green Published, Green Submitted			2022-12-25	WOS:000271147400016
J	Peng, XM; Zhou, ZG; Hu, J; Fink, DJ; Mata, M				Peng, Xiangmin; Zhou, Zhigang; Hu, Jian; Fink, David J.; Mata, Marina			Soluble Nogo Receptor Down-regulates Expression of Neuronal Nogo-A to Enhance Axonal Regeneration	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SPINAL-CORD-INJURY; MYELIN-ASSOCIATED GLYCOPROTEIN; NECROSIS-FACTOR-ALPHA; HSV-MEDIATED TRANSFER; DORSAL-ROOT GANGLIA; PROTEIN-KINASE-A; RHO-KINASE; NEURITE OUTGROWTH; DEPENDENT MECHANISM; NERVOUS-SYSTEM	Nogo-A, a member of the reticulon family, is present in neurons and oligodendrocytes. Nogo-A in central nervous system (CNS) myelin prevents axonal regeneration through interaction with Nogo receptor 1, but the function of Nogo-A in neurons is less known. We found that after axonal injury, Nogo-A is increased in dorsal root ganglion (DRG) neurons unable to regenerate following a dorsal root injury or a sciatic nerve ligation-cut injury and that exposure in vitro to CNS myelin dramatically enhanced neuronal Nogo-A mRNA and protein through activation of RhoA while inhibiting neurite growth. Knocking down neuronal Nogo-A by small interfering RNA results in a marked increase of neurite outgrowth. We constructed a nonreplicating herpes simplex virus vector (QHNgSR) to express a truncated soluble fragment of Nogo receptor 1 (NgSR). NgSR released from QHNgSR prevented myelin inhibition of neurite extension by hippocampal and DRG neurons in vitro. NgSR prevents RhoA activation by myelin and decreases neuronal Nogo-A. Subcutaneous inoculation of QHNgSR to transduce DRG neurons resulted in improved regeneration of myelinated fibers in both the dorsal root and the spinal dorsal root entry zone, with concomitant improvement in sensory behavior. The results indicate that neuronal Nogo-A is an important intermediate in neurite growth dynamics and its expression is regulated by signals related to axonal injury and regeneration, that CNS myelin appears to activate signaling events that mimic axonal injury, and that NgSR released from QHNgSR may be used to improve recovery after injury.	Univ Michigan, Dept Neurol, Ann Arbor, MI 48109 USA; Ann Arbor Vet Affairs Healthcare Syst, Ann Arbor, MI 48109 USA	University of Michigan System; University of Michigan; US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Ann Arbor Healthcare System	Mata, M (corresponding author), 5027 BSRB,109 Zina Pitcher Pl, Ann Arbor, MI 48109 USA.	mmata@umich.edu			National Institutes of Health; Department of Veterans Affairs; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS038850] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Department of Veterans Affairs(US Department of Veterans Affairs); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))	This work was supported, in whole or in part, by National Institutes of Health grants (to D.J.F. and M. M.). This work was also supported by grants from the Department of Veterans Affairs (to D.J.F. and M. M.).	Aktories K, 2005, REV PHYSIOL BIOCH P, V152, P1, DOI 10.1007/s10254-004-0034-4; Alabed YZ, 2006, J NEUROCHEM, V96, P1616, DOI 10.1111/j.1471-4159.2006.03670.x; Aloy EM, 2006, BRAIN CELL BIOL, V35, P137, DOI 10.1007/s11068-007-9014-3; Arimura N, 2000, J BIOL CHEM, V275, P23973, DOI 10.1074/jbc.M001032200; Arimura N, 2005, MOL CELL BIOL, V25, P9973, DOI 10.1128/MCB.25.22.9973-9984.2005; Balasubramanian N, 2001, BIOCHEMISTRY-US, V40, P12619, DOI 10.1021/bi015624b; Bras JMA, 1998, J NEUROCHEM, V70, P1299; Cai DM, 2002, NEURON, V35, P711, DOI 10.1016/S0896-6273(02)00826-7; Cai DM, 1999, NEURON, V22, P89, DOI 10.1016/S0896-6273(00)80681-9; Chattopadhyay M, 2005, GENE THER, V12, P1377, DOI 10.1038/sj.gt.3302533; Cheatwood JL, 2008, STROKE, V39, P2091, DOI 10.1161/STROKEAHA.107.507426; Chen MS, 2000, NATURE, V403, P434, DOI 10.1038/35000219; Cheng C, 2008, EXP NEUROL, V212, P358, DOI 10.1016/j.expneurol.2008.04.023; Dodd DA, 2005, J BIOL CHEM, V280, P12494, DOI 10.1074/jbc.M411827200; Ellerbroek SM, 2003, J BIOL CHEM, V278, P19023, DOI 10.1074/jbc.M213066200; Ellezam B, 2002, PROG BRAIN RES, V137, P371; Filbin MT, 2003, NAT REV NEUROSCI, V4, P703, DOI 10.1038/nrn1195; Fournier AE, 2001, CURR OPIN NEUROBIOL, V11, P89, DOI 10.1016/S0959-4388(00)00178-1; Fournier AE, 2003, J NEUROSCI, V23, P1416, DOI 10.1523/JNEUROSCI.23-04-01416.2003; Fournier AE, 2001, NATURE, V409, P341, DOI 10.1038/35053072; Freund P, 2007, J COMP NEUROL, V502, P644, DOI 10.1002/cne.21321; Fukata Y, 2002, NAT CELL BIOL, V4, P583, DOI 10.1038/ncb825; GrandPre T, 2000, NATURE, V403, P439, DOI 10.1038/35000226; GrandPre T, 2002, NATURE, V417, P547, DOI 10.1038/417547a; HARGREAVES K, 1988, PAIN, V32, P77, DOI 10.1016/0304-3959(88)90026-7; Hasegawa T, 2005, MOL BRAIN RES, V133, P119, DOI 10.1016/j.molbrainres.2004.10.004; Huber AB, 2002, J NEUROSCI, V22, P3553; Hunt D, 2003, MOL CELL NEUROSCI, V24, P1083, DOI 10.1016/j.mcn.2003.09.002; Josephson A, 2002, J COMP NEUROL, V453, P292, DOI 10.1002/cne.10408; Kim JE, 2003, NEURON, V38, P187, DOI 10.1016/S0896-6273(03)00147-8; Kubo T, 2008, J NEUROCHEM, V105, P113, DOI 10.1111/j.1471-4159.2007.05125.x; Lee HJ, 2008, J NEUROSCI, V28, P2753, DOI 10.1523/JNEUROSCI.5586-07.2008; Li SX, 2003, J NEUROSCI, V23, P4219; Li SX, 2005, MOL CELL NEUROSCI, V29, P26, DOI 10.1016/j.mcn.2004.12.008; Li SX, 2004, J NEUROSCI, V24, P10511, DOI 10.1523/JNEUROSCI.2828-04.2004; Liebscher T, 2005, ANN NEUROL, V58, P706, DOI 10.1002/ana.20627; Liu J, 2006, BRAIN RES, V1073, P297, DOI 10.1016/j.brainres.2005.12.091; Liu J, 2004, MOL THER, V10, P57, DOI 10.1016/j.ymthe.2004.04.017; MacDermid VE, 2004, EUR J NEUROSCI, V20, P2567, DOI 10.1111/j.1460-9568.2004.03715.x; Manganello JM, 2003, J BIOL CHEM, V278, P124, DOI 10.1074/jbc.M209219200; Marklund N, 2006, EXP NEUROL, V197, P70, DOI 10.1016/j.expneurol.2005.08.029; Mata Marina, 2004, Curr Neurol Neurosci Rep, V4, P1, DOI 10.1007/s11910-004-0001-0; Meier S, 2003, FASEB J, V17, P1153, DOI 10.1096/fj.02-0453fje; Merkler D, 2001, J NEUROSCI, V21, P3665, DOI 10.1523/JNEUROSCI.21-10-03665.2001; Mi S, 2004, NAT NEUROSCI, V7, P221, DOI 10.1038/nn1188; Mimura F, 2006, J BIOL CHEM, V281, P15970, DOI 10.1074/jbc.M510934200; Montani L, 2009, J BIOL CHEM, V284, P10793, DOI 10.1074/jbc.M808297200; NORTON WT, 1973, J NEUROCHEM, V21, P749, DOI 10.1111/j.1471-4159.1973.tb07519.x; Peng XM, 2006, ANN NEUROL, V59, P843, DOI 10.1002/ana.20855; Pot C, 2002, J CELL BIOL, V159, P29, DOI 10.1083/jcb.200206068; Prinjha R, 2000, NATURE, V403, P383, DOI 10.1038/35000287; Qiao J, 2008, AM J PHYSIOL-CELL PH, V295, pC1161, DOI 10.1152/ajpcell.00139.2008; SCHNELL L, 1990, NATURE, V343, P269, DOI 10.1038/343269a0; Shao ZH, 2005, NEURON, V45, P353, DOI 10.1016/j.neuron.2004.12.050; Simonen M, 2003, NEURON, V38, P201, DOI 10.1016/S0896-6273(03)00226-5; Venkatesh K, 2005, J NEUROSCI, V25, P808, DOI 10.1523/JNEUROSCI.4464-04.2005; Wang KC, 2002, NATURE, V420, P74, DOI 10.1038/nature01176; Wang KC, 2002, NATURE, V417, P941, DOI 10.1038/nature00867; Wang R, 2008, NAT NEUROSCI, V11, P488, DOI 10.1038/nn2069; Yu PP, 2008, NEUROBIOL DIS, V32, P535, DOI 10.1016/j.nbd.2008.09.012; Zheng BH, 2005, P NATL ACAD SCI USA, V102, P1205, DOI 10.1073/pnas.0409026102; Zheng BH, 2003, NEURON, V38, P213, DOI 10.1016/S0896-6273(03)00225-3; Zhou Z, 2008, GENE THER, V15, P183, DOI 10.1038/sj.gt.3303054; Zhou ZG, 2009, MOL THER, V17, P1173, DOI 10.1038/mt.2009.52	64	23	26	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 22	2010	285	4					2783	2795		10.1074/jbc.M109.046425	http://dx.doi.org/10.1074/jbc.M109.046425			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	544YP	19901030	Green Published, hybrid			2022-12-25	WOS:000273697800055
J	Mitrofan, LM; Castells, FB; Pelkonen, J; Monkkonen, J				Mitrofan, Laura M.; Castells, Ferran B.; Pelkonen, Jukka; Monkkonen, Jukka			Lysosomal-Mitochondrial Axis in Zoledronic Acid-induced Apoptosis in Human Follicular Lymphoma Cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYTOCHROME-C RELEASE; CANCER CELLS; MEMBRANE PERMEABILIZATION; INDEPENDENT ACTIVATION; PROTEIN PRENYLATION; MEVALONATE PATHWAY; BONE-RESORPTION; BCL-XL; DEATH; BISPHOSPHONATES	Bisphosphonates (BPs) are potent inhibitors of osteoclast function, widely used to treat excessive bone resorption associated with bone metastases, that also have anti-tumor activity. Zoledronic acid (ZOL) represents a potential chemotherapeutic agent for the treatment of cancer. ZOL is the most potent nitrogen-containing BPs, and it inhibits cell growth and induces apoptosis in a variety of cancer cells. Recently we demonstrated that accumulation of isopentenyl pyrophosphate and the consequent formation of a new type of ATP analog (ApppI) after mevalonate pathway inhibition by nitrogen-containing BPs strongly correlates with ZOL-induced cell death in cancer cells in vitro. In this study we show that ZOL-induced apoptosis in HF28RA human follicular lymphoma cells occurs exclusively via the mitochondrial pathway, involves lysosomes, and is dependent on mevalonate pathway inhibition. To define the exact signaling pathway connecting them, we used modified HF28RA cell lines overexpressing either BclXL or dominant-negative caspase-9. In both mutant cells, mitochondrial and lysosomal membrane permeabilization (MMP and LMP) were totally prevented, indicating signaling between lysosomes and mitochondria and, additionally, an amplification loop for MMP and/or LMP regulated by caspase-9 in association with farnesyl pyrophosphate synthetase inhibition. Additionally, the lysosomal pathway in ZOL-induced apoptosis plays an additional/amplification role of the intrinsic pathway independently of caspase-3 activation. Moreover, we show a potential regulation by Bcl-XL and caspase-9 on cell cycle regulators of S-phase. Our findings provide a molecular basis for new strategies concomitantly targeting cell death pathways from multiple sites.	Univ Kuopio, Dept Pharmaceut, Fac Pharm, FIN-70211 Kuopio, Finland; [Pelkonen, Jukka] Univ Kuopio, Dept Clin Microbiol, Fac Med, FIN-70211 Kuopio, Finland; [Mitrofan, Laura M.; Monkkonen, Jukka] Bioctr, FIN-70211 Kuopio, Finland	University of Eastern Finland; University of Eastern Finland	Mitrofan, LM (corresponding author), POB 1627, FIN-70211 Kuopio, Finland.	laura_mitrofan@yahoo.com			NOVARTIS AG, Basel, Switzerland	NOVARTIS AG, Basel, Switzerland	This work was supported by NOVARTIS AG, Basel, Switzerland (to L. M.).	Adrain C, 2001, TRENDS BIOCHEM SCI, V26, P390, DOI 10.1016/S0968-0004(01)01844-8; Aparicio A, 1998, LEUKEMIA, V12, P220, DOI 10.1038/sj.leu.2400892; Bossy-Wetzel E, 1998, EMBO J, V17, P37, DOI 10.1093/emboj/17.1.37; Boya P, 2008, ONCOGENE, V27, P6434, DOI 10.1038/onc.2008.310; Boya P, 2003, J EXP MED, V197, P1323, DOI 10.1084/jem.20021952; Castedo M, 2002, J IMMUNOL METHODS, V265, P39, DOI 10.1016/S0022-1759(02)00069-8; Chuah C, 2005, LEUKEMIA, V19, P1896, DOI 10.1038/sj.leu.2403949; Cirman T, 2004, J BIOL CHEM, V279, P3578, DOI 10.1074/jbc.M308347200; Coleman RE, 2004, BREAST, V13, pS19, DOI 10.1016/j.breast.2004.09.004; Coxon JP, 2004, BJU INT, V94, P164, DOI 10.1111/j.1464-4096.2004.04831.x; Delmas PD, 2002, LANCET, V359, P2018, DOI 10.1016/S0140-6736(02)08827-X; Dickson PV, 2006, SURGERY, V140, P227, DOI 10.1016/j.surg.2006.02.004; Droga-Mazovec G, 2008, J BIOL CHEM, V283, P19140, DOI 10.1074/jbc.M802513200; Dunford JE, 2006, J BONE MINER RES, V21, P684, DOI 10.1359/JBMR.060118; Eeva J, 2009, APOPTOSIS, V14, P687, DOI 10.1007/s10495-009-0337-7; Evdokiou A, 2003, BONE, V33, P216, DOI 10.1016/S8756-3282(03)00223-0; Fehrenbacher N, 2005, CANCER RES, V65, P2993, DOI 10.1158/0008-5472.CAN-05-0476; Feldstein AE, 2006, AM J PHYSIOL-GASTR L, V290, pG1339, DOI 10.1152/ajpgi.00509.2005; Ferri KF, 2001, NAT CELL BIOL, V3, pE255, DOI 10.1038/ncb1101-e255; Fisher JE, 1999, P NATL ACAD SCI USA, V96, P133, DOI 10.1073/pnas.96.1.133; FLANAGAN AM, 1991, CALCIFIED TISSUE INT, V49, P407, DOI 10.1007/BF02555852; Fromigue O, 2000, J BONE MINER RES, V15, P2211, DOI 10.1359/jbmr.2000.15.11.2211; Fulda S, 2001, ONCOGENE, V20, P1063, DOI 10.1038/sj.onc.1204141; Gnant M, 2009, NEW ENGL J MED, V360, P679, DOI 10.1056/NEJMoa0806285; Green DR, 1998, SCIENCE, V281, P1309, DOI 10.1126/science.281.5381.1309; Green JR, 2003, CANCER, V97, P840, DOI 10.1002/cncr.11128; Gross A, 1999, GENE DEV, V13, P1899, DOI 10.1101/gad.13.15.1899; Gyrd-Hansen M, 2006, MOL CELL BIOL, V26, P7880, DOI 10.1128/MCB.00716-06; Hasmim M, 2007, J THROMB HAEMOST, V5, P166, DOI 10.1111/j.1538-7836.2006.02259.x; Hengartner MO, 2000, NATURE, V407, P770, DOI 10.1038/35037710; Jagdev SP, 2001, BRIT J CANCER, V84, P1126, DOI 10.1054/bjoc.2001.1727; Janumyan YM, 2003, EMBO J, V22, P5459, DOI 10.1093/emboj/cdg533; Katunuma N, 2001, ADV ENZYME REGUL, V41, P237, DOI 10.1016/S0065-2571(00)00018-2; Kim R, 2005, BIOCHEM BIOPH RES CO, V333, P336, DOI 10.1016/j.bbrc.2005.04.161; Kroemer G, 1997, NAT MED, V3, P614, DOI 10.1038/nm0697-614; Kroemer G, 2000, NAT MED, V6, P513, DOI 10.1038/74994; Leist M, 2001, NAT REV MOL CELL BIO, V2, P589, DOI 10.1038/35085008; Liu XS, 1996, CELL, V86, P147, DOI 10.1016/S0092-8674(00)80085-9; Luckman SP, 1998, J BONE MINER RES, V13, P581, DOI 10.1359/jbmr.1998.13.4.581; MASSAIA M, 2005, HAEMATOL REP, V1, P77; Mitrofan LM, 2009, BONE, V45, P1153, DOI 10.1016/j.bone.2009.08.010; Monkkonen H, 2006, BRIT J PHARMACOL, V147, P437, DOI 10.1038/sj.bjp.0706628; Morishima N, 2002, J BIOL CHEM, V277, P34287, DOI 10.1074/jbc.M204973200; NICOLETTI I, 1991, J IMMUNOL METHODS, V139, P271, DOI 10.1016/0022-1759(91)90198-O; Nuutinen U, 2009, LEUKEMIA RES, V33, P829, DOI 10.1016/j.leukres.2008.09.025; Ory B, 2007, MOL PHARMACOL, V71, P333, DOI 10.1124/mol.106.028837; Paquet C, 2005, LEUKEMIA, V19, P784, DOI 10.1038/sj.leu.2403717; Paris C, 2007, APOPTOSIS, V12, P1257, DOI 10.1007/s10495-007-0052-1; Ravagnan L, 2002, J CELL PHYSIOL, V192, P131, DOI 10.1002/jcp.10111; Roux C, 1999, DRUGS, V58, P823, DOI 10.2165/00003495-199958050-00005; Russell RGG, 2008, OSTEOPOROSIS INT, V19, P733, DOI 10.1007/s00198-007-0540-8; SCHAFER WR, 1992, ANNU REV GENET, V26, P209, DOI 10.1146/annurev.ge.26.120192.001233; Scheper MA, 2009, BRIT J HAEMATOL, V144, P667, DOI 10.1111/j.1365-2141.2008.07504.x; Schmitt E, 2007, ONCOGENE, V26, P5851, DOI 10.1038/sj.onc.1210396; Sewing L, 2008, APOPTOSIS, V13, P782, DOI 10.1007/s10495-008-0211-z; Stoka V, 2001, J BIOL CHEM, V276, P3149, DOI 10.1074/jbc.M008944200; Talanian RV, 1997, J BIOL CHEM, V272, P9677; Tassone P, 2003, BRIT J CANCER, V88, P1971, DOI 10.1038/sj.bjc.6600986; Terman Alexei, 2006, Molecular Aspects of Medicine, V27, P471, DOI 10.1016/j.mam.2006.08.006; Turk B, 2002, BIOL CHEM, V383, P1035, DOI 10.1515/BC.2002.112; van Beek E, 1999, BIOCHEM BIOPH RES CO, V264, P108, DOI 10.1006/bbrc.1999.1499; Winter MC, 2008, CANCER TREAT REV, V34, P453, DOI 10.1016/j.ctrv.2008.02.004; Zamzami N, 2000, ONCOGENE, V19, P6342, DOI 10.1038/sj.onc.1204030; ZDOLSEK JM, 1990, PHOTOCHEM PHOTOBIOL, V51, P67, DOI 10.1111/j.1751-1097.1990.tb01685.x; Zhao M, 2003, EUR J BIOCHEM, V270, P3778, DOI 10.1046/j.1432-1033.2003.03765.x	65	18	20	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 15	2010	285	3					1967	1979		10.1074/jbc.M109.038935	http://dx.doi.org/10.1074/jbc.M109.038935			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	541PJ	19875454	Green Published, hybrid			2022-12-25	WOS:000273429100043
J	Wu, BH; Yin, J; Texier, C; Roussel, M; Tan, KSW				Wu, Binhui; Yin, Jing; Texier, Catherine; Roussel, Michael; Tan, Kevin Shyong-Wei			Blastocystis Legumain Is Localized on the Cell Surface, and Specific Inhibition of Its Activity Implicates a Pro-survival Role for the Enzyme	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYTOTOXIC MONOCLONAL-ANTIBODY; CYSTEINE PROTEASES; MAMMALIAN LEGUMAIN; DEATH; ENDOPEPTIDASE; IDENTIFICATION; HOMINIS; ANTIGEN; CLAN; DEGRADATION	Programmed cell death (PCD) is crucial for cellular growth and development in multicellular organisms. Although distinct PCD features have been described for unicellular eukaryotes, homology searches have failed to reveal clear PCD-related orthologues among these organisms. Our previous studies revealed that a surface-reactive monoclonal antibody (mAb) 1D5 could induce multiple PCD pathways in the protozoan Blastocystis. In this study, we identified, by two-dimensional gel electrophoresis and mass spectrometry, the target of mAb 1D5 as a surface-localized legumain, an asparagine endopeptidase that is usually found in lysosomal/acidic compartments of other organisms. Recombinant Blastocystis legumain displayed biphasic pH optima in substrate assays, with peaks at pH 4 and 7.5. Activity of Blastocystis legumain was greatly inhibited by the legumain-specific inhibitor carbobenzyloxy-Ala-Ala-AAsn-epoxycarboxylate ethyl ester (APE-RR) (where AAsn is aza-asparagine) and moderately inhibited by mAb 1D5, cystatin, and caspase-1 inhibitor. Interestingly, inhibition of legumain activity induced PCD in Blastocystis, observed by increased externalization of phosphatidylserine residues and in situ DNA fragmentation. In contrast to plants, in which legumains have been shown to play a pro-death role, legumain appears to display a pro-survival role in Blastocystis.	[Wu, Binhui; Yin, Jing; Tan, Kevin Shyong-Wei] Natl Univ Singapore, Dept Microbiol, Yong Loo Lin Sch Med, Singapore 117597, Singapore; [Tan, Kevin Shyong-Wei] Natl Univ Singapore, Program Infect Dis, Inst Life Sci, Singapore 117597, Singapore; [Texier, Catherine; Roussel, Michael] Univ Blaise Pascal, Clermont Univ, Lab Microorganismes Genome & Environm, F-63000 Clermont Ferrand, France; [Texier, Catherine; Roussel, Michael] CNRS, UMR 6023, Lab Microorganismes Genome & Environm, F-63173 Aubiere, France	National University of Singapore; National University of Singapore; Centre National de la Recherche Scientifique (CNRS); Universite Clermont Auvergne (UCA); Centre National de la Recherche Scientifique (CNRS); CNRS - Institute of Ecology & Environment (INEE)	Tan, KSW (corresponding author), 5 Sci Dr 2, Singapore 117597, Singapore.	mictank@nus.edu.sg	Tan, Kevin/C-9653-2014		Biomedical Research Council [05/1/21/19/378]; National Medical Research Council [06May107]; Infectious Disease Program	Biomedical Research Council(Agency for Science Technology & Research (A*STAR)); National Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Infectious Disease Program	This work was supported by Biomedical Research Council Grant 05/1/21/19/378, the National Medical Research Council (06May107), and the Infectious Disease Program. Downloaded from www.jbc.org at unknown institution, on January 11, 2010	AKSOY K, 1987, HUM GENET, V76, P199, DOI 10.1007/BF00284922; Alvarez-Fernandez M, 1999, J BIOL CHEM, V274, P19195, DOI 10.1074/jbc.274.27.19195; Asgian JL, 2002, J MED CHEM, V45, P4958, DOI 10.1021/jm025581c; Beck H, 2001, EUR J IMMUNOL, V31, P3726, DOI 10.1002/1521-4141(200112)31:12<3726::AID-IMMU3726>3.0.CO;2-O; Bruchhaus I, 2007, TRENDS PARASITOL, V23, P376, DOI 10.1016/j.pt.2007.06.004; Chen JM, 1998, FEBS LETT, V441, P361, DOI 10.1016/S0014-5793(98)01574-9; Chen JM, 2001, BIOL CHEM, V382, P777, DOI 10.1515/BC.2001.093; Chen JM, 2000, BIOCHEM J, V352, P327, DOI 10.1042/0264-6021:3520327; Claveau D, 2000, BIOCHEM PHARMACOL, V60, P759, DOI 10.1016/S0006-2952(00)00381-6; Dalton JP, 1995, PARASITOLOGY, V111, P575, DOI 10.1017/S0031182000077052; Gelboin HV, 2006, J CLIN PHARMACOL, V46, P353, DOI 10.1177/0091270005285200; Hatsugai N, 2004, SCIENCE, V305, P855, DOI 10.1126/science.1099859; Iwata H, 2007, BIOSCI BIOTECH BIOCH, V71, P1279, DOI 10.1271/bbb.60682; Ju JW, 2009, PROTEOMICS, V9, P3066, DOI 10.1002/pmic.200700613; Kuroyanagi M, 2005, J BIOL CHEM, V280, P32914, DOI 10.1074/jbc.M504476200; Lam E, 2005, TRENDS CELL BIOL, V15, P124, DOI 10.1016/j.tcb.2005.01.001; Leon-Felix J, 2004, GENE, V335, P25, DOI 10.1016/j.gene.2004.03.002; Liu C, 2003, CANCER RES, V63, P2957; Maehr R, 2005, J IMMUNOL, V174, P7066, DOI 10.4049/jimmunol.174.11.7066; Manoury B, 1998, NATURE, V396, P695, DOI 10.1038/25379; MCCANN SR, 1980, J MED GENET, V17, P191, DOI 10.1136/jmg.17.3.191; Nasirudeen AMA, 2005, BIOCHIMIE, V87, P489, DOI 10.1016/j.biochi.2005.03.003; Nasirudeen AMA, 2004, EUR J CELL BIOL, V83, P477, DOI 10.1078/0171-9335-00411; Nasirudeen AMA, 2001, PARASITOL RES, V87, P559, DOI 10.1007/s004360100427; Nasirudeen AMA, 2001, PARASITOLOGY, V123, P235, DOI 10.1017/S0031182001008332; Ni DTN, 2003, J BIOL CHEM, V278, P38980, DOI 10.1074/jbc.M305930200; Oliver EM, 2006, PARASITOLOGY, V133, P237, DOI 10.1017/S0031182006000229; Puthia MK, 2008, EUKARYOT CELL, V7, P435, DOI 10.1128/EC.00371-07; Puthia MK, 2005, PARASITOL RES, V97, P386, DOI 10.1007/s00436-005-1461-0; Rotari VI, 2001, BIOL CHEM, V382, P953, DOI 10.1515/BC.2001.119; Sajid M, 2002, MOL BIOCHEM PARASIT, V120, P1, DOI 10.1016/S0166-6851(01)00438-8; Shirahama-Noda K, 2003, J BIOL CHEM, V278, P33194, DOI 10.1074/jbc.M302742200; Tan KSW, 2008, CLIN MICROBIOL REV, V21, P639, DOI 10.1128/CMR.00022-08; Tan KSW, 2005, TRENDS PARASITOL, V21, P547, DOI 10.1016/j.pt.2005.09.006; Tan KSW, 2001, PARASITOL RES, V87, P534, DOI 10.1007/s004360000365; Tan SW, 1997, INT J PARASITOL, V27, P947, DOI 10.1016/S0020-7519(97)00066-0; Tan SW, 1996, INT J PARASITOL, V26, P375, DOI 10.1016/0020-7519(96)00016-1	37	31	32	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 15	2010	285	3					1790	1798		10.1074/jbc.M109.049064	http://dx.doi.org/10.1074/jbc.M109.049064			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	541PJ	19915007	hybrid, Green Published			2022-12-25	WOS:000273429100025
J	Chang, CL; Park, JI; Hsu, SYT				Chang, Chia Lin; Park, Jae-Il; Hsu, Sheau Yu Teddy			Activation of Calcitonin Receptor and Calcitonin Receptor-like Receptor by Membrane-anchored Ligands	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-COUPLED RECEPTORS; GENE-RELATED PEPTIDE; ACTIVITY-MODIFYING PROTEINS; INTERNATIONAL UNION; TETHERED LIGANDS; HYDROPS-FETALIS; DRUG DISCOVERY; BONE-FORMATION; MICE LACKING; ADRENOMEDULLIN	G protein-coupled receptors (GPCRs) are the most important pharmaceutical targets, and more than 40% of drugs in use today modulate GPCR signaling. A major hurdle in the development of therapies targeting GPCRs is the drug candidate's nonselective actions in multiple tissues. The ability to spatially control GPCR signaling would provide a venue for developing therapies that require targeted GPCR signaling. Here, we show that the fusion of a RAMP1 co-receptor with the calcitonin gene-related peptide (CGRP), or calcitonin, transforms the RAMP1 from a co-receptor to bona fide membrane-anchored ligands (CGRP-RAMP1 and CAL-RAMP1). The CAL-RAMP1 selectively activates the calcitonin receptor (CR), whereas, the CGRP-RAMP1 activates both the calcitonin receptor-like receptor (CLR) and CR. Unlike a free peptide, which moves freely in the extracellular space and differentiates targets based on molecular affinity, the anchored CGRP-RAMP1 and CAL-RAMP1 ligands confine their activities to individual cells. In addition, our study showed that a CGRP8-37-RAMP1 chimera, but not RAMP1, functions as an antagonist for CGRP-RAMP1-mediated signaling, suggesting that the activation of CLR by CGRP-RAMP1 shares similar molecular mechanisms with the CGRP-mediated activation of CLR/RAMP1 receptor complexes. Taken together, our finding thus provides a novel class of ligands that activate CR and CLR exclusively in an autocrine manner and a proof-of-concept demonstration for future development of targeted therapies aimed at these receptors in specific cell populations.	[Chang, Chia Lin; Park, Jae-Il; Hsu, Sheau Yu Teddy] Stanford Univ, Sch Med, Dept Obstet & Gynecol, Reprod Biol & Stem Cell Res Program, Stanford, CA 94305 USA; [Chang, Chia Lin] Chang Gung Univ, Sch Med, Chang Gung Mem Hosp, Dept Obstet & Gynecol, Tao Yuan 333, Taiwan	Stanford University; Chang Gung Memorial Hospital; Chang Gung University	Hsu, SYT (corresponding author), Stanford Univ, Sch Med, Dept Obstet & Gynecol, Reprod Biol & Stem Cell Res Program, 300 Pasteur Dr,Rm A344D, Stanford, CA 94305 USA.	teddyhsu@stanford.edu			National Institutes of Health [R01 DK70652]; New Century Health Care Promotion Foundation, Taiwan [NCH-CPF-94001]; Chang Gung Memorial Hospital [CMRPG34002]; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK070652] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); New Century Health Care Promotion Foundation, Taiwan; Chang Gung Memorial Hospital(Chang Gung Memorial Hospital); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))	This work was supported, in whole or in part, by National Institutes of Health Grant R01 DK70652 (to S. Y. T. H.). This work was also supported by grants from the New Century Health Care Promotion Foundation, Taiwan (NCH-CPF-94001, to C. L. C.) and Chang Gung Memorial Hospital (CMRPG34002, to C. L. C.).	Bockaert J, 1999, EMBO J, V18, P1723, DOI 10.1093/emboj/18.7.1723; Bouschet T, 2008, TRENDS PHARMACOL SCI, V29, P633, DOI 10.1016/j.tips.2008.09.002; Caron KM, 2001, P NATL ACAD SCI USA, V98, P615, DOI 10.1073/pnas.021548898; CHIBA T, 1989, AM J PHYSIOL, V256, pE331, DOI 10.1152/ajpendo.1989.256.2.E331; Choi C, 2009, CURR BIOL, V19, P1167, DOI 10.1016/j.cub.2009.06.029; Christopoulos A, 2003, J BIOL CHEM, V278, P3293, DOI 10.1074/jbc.C200629200; Dackor RT, 2006, MOL CELL BIOL, V26, P2511, DOI 10.1128/MCB.26.7.2511-2518.2006; Dackor R, 2007, J BIOL CHEM, V282, P18094, DOI 10.1074/jbc.M703544200; Dacquin R, 2004, J CELL BIOL, V164, P509, DOI 10.1083/jcb.200312135; Drews J, 2000, SCIENCE, V287, P1960, DOI 10.1126/science.287.5460.1960; DUNNING BE, 1987, ENDOCRINOLOGY, V120, P1774, DOI 10.1210/endo-120-5-1774; Fitzsimmons TJ, 2003, J BIOL CHEM, V278, P14313, DOI 10.1074/jbc.M211946200; Flahaut M, 2003, BIOCHEMISTRY-US, V42, P10333, DOI 10.1021/bi0347508; Fortin JP, 2009, P NATL ACAD SCI USA, V106, P8049, DOI 10.1073/pnas.0900149106; Gether U, 2000, ENDOCR REV, V21, P90, DOI 10.1210/er.21.1.90; Heroux M, 2007, BIOCHEMISTRY-US, V46, P7022, DOI 10.1021/bi0622470; Hilairet S, 2001, J BIOL CHEM, V276, P29575, DOI 10.1074/jbc.M102722200; KITAMURA K, 1993, BIOCHEM BIOPH RES CO, V192, P553, DOI 10.1006/bbrc.1993.1451; Li B, 2007, NAT METHODS, V4, P169, DOI 10.1038/nmeth990; LIN HY, 1991, SCIENCE, V254, P1022, DOI 10.1126/science.1658940; Lundstrom K, 2006, CURR PROTEIN PEPT SC, V7, P465, DOI 10.2174/138920306778559403; McLatchie LM, 1998, NATURE, V393, P333, DOI 10.1038/30666; MIYAZATO M, 1991, BIOCHEM BIOPH RES CO, V181, P293, DOI 10.1016/S0006-291X(05)81416-0; Neumann JM, 2008, TRENDS BIOCHEM SCI, V33, P314, DOI 10.1016/j.tibs.2008.05.001; Nielsen SM, 2000, P NATL ACAD SCI USA, V97, P10277, DOI 10.1073/pnas.97.18.10277; Park JI, 2008, GENOME RES, V18, P974, DOI 10.1101/gr.7119108; Parnot C, 2004, NAT STRUCT MOL BIOL, V11, P691, DOI 10.1038/nsmb0804-691; Pin JP, 2007, PHARMACOL REV, V59, P5, DOI 10.1124/pr.59.1.5; Poyner DR, 2002, PHARMACOL REV, V54, P233, DOI 10.1124/pr.54.2.233; Roh J, 2004, J BIOL CHEM, V279, P7264, DOI 10.1074/jbc.M305332200; ROSENFELD MG, 1983, NATURE, V304, P129, DOI 10.1038/304129a0; Schlyer S, 2006, DRUG DISCOV TODAY, V11, P481, DOI 10.1016/j.drudis.2006.04.008; Semyonov J, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0001903; WESTERMARK P, 1987, AM J PATHOL, V127, P414; Wu CB, 1996, J BIOL CHEM, V271, P31638, DOI 10.1074/jbc.271.49.31638; Zaidi M, 2002, J CLIN INVEST, V110, P1769, DOI 10.1172/JCI200217425	36	4	5	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 8	2010	285	2					1075	1080		10.1074/jbc.M109.020040	http://dx.doi.org/10.1074/jbc.M109.020040			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	539MH	19903822	Green Published, hybrid			2022-12-25	WOS:000273258200028
J	Fujioka, Y; Noda, NN; Nakatogawa, H; Ohsumi, Y; Inagaki, F				Fujioka, Yuko; Noda, Nobuo N.; Nakatogawa, Hitoshi; Ohsumi, Yoshinori; Inagaki, Fuyuhiko			Dimeric Coiled-coil Structure of Saccharomyces cerevisiae Atg16 and Its Functional Significance in Autophagy	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN LIPIDATION; CRYSTAL-STRUCTURE; YEAST; COMPLEX; MEMBRANE; SYSTEM; CONJUGATE; DISSECTION; MECHANISMS; STATE	Atg16 interacts with the Atg12-Atg5 protein conjugate through its N-terminal domain and self-assembles through its coiled-coil domain (CCD). Formation of the Atg12-Atg5.Atg16 complex is essential for autophagy, the bulk degradation process conserved among most eukaryotes. Here, we report the crystal structures of full-length Saccharomyces cerevisiae Atg16 at 2.8 angstrom resolution and its CCD at 2.5 angstrom resolution. The CCD and full-length Atg16 each exhibit an extended alpha-helix, 90 and 130 angstrom, respectively, and form a parallel coiled-coil dimer in the crystals. Although the apparent molecular weight of Atg16 observed by gel-filtration chromatography suggests that Atg16 is tetrameric, an analytical ultracentrifugation study showed Atg16 as a dimer in solution, consistent with the crystal structure. Evolutionary conserved surface residues clustered at the C-terminal half of Atg16 CCD were shown to be crucial for autophagy. These results will give a structural basis for understanding the molecular functions and significance of Atg16 in autophagy.	[Inagaki, Fuyuhiko] Hokkaido Univ, Dept Biol Struct, Grad Sch Pharmaceut Sci, Kita Ku, Sapporo, Hokkaido 0600812, Japan; [Nakatogawa, Hitoshi; Ohsumi, Yoshinori] Tokyo Inst Technol, Integrated Res Inst, Yokohama, Kanagawa 2268503, Japan; [Nakatogawa, Hitoshi] Japan Sci & Technol Agcy, Kawaguchi, Saitama 3320012, Japan	Hokkaido University; Tokyo Institute of Technology; Japan Science & Technology Agency (JST)	Inagaki, F (corresponding author), Hokkaido Univ, Dept Biol Struct, Grad Sch Pharmaceut Sci, Kita Ku, N-12,W-6, Sapporo, Hokkaido 0600812, Japan.	finagaki@pharm.hokudai.ac.jp	Ohsumi, Yoshinori/C-6449-2009; Nakatogawa, Hitoshi/D-5155-2015; Noda, Nobuo/P-1397-2015	Ohsumi, Yoshinori/0000-0003-2384-2166; Nakatogawa, Hitoshi/0000-0002-5828-0741; Fujioka, Yuko/0000-0002-6905-0669; Noda, Nobuo/0000-0002-6940-8069	Ministry of Education, Science and Culture of Japan	Ministry of Education, Science and Culture of Japan(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT))	This work was supported by grants-in-aid for Scientific Research on Priority Areas and Targeted Proteins Research Program from the Ministry of Education, Science and Culture of Japan.	Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Burguete AS, 2008, CELL, V132, P286, DOI 10.1016/j.cell.2007.11.048; DeLano W.L., 2002, PYMOL MOL GRAPHICS S; Emsley P, 2004, ACTA CRYSTALLOGR D, V60, P2126, DOI 10.1107/S0907444904019158; Fujioka Y, 2008, ACTA CRYSTALLOGR F, V64, P1046, DOI 10.1107/S1744309108031898; Fujioka Y, 2008, J BIOL CHEM, V283, P1921, DOI 10.1074/jbc.M706214200; Fujita N, 2008, MOL BIOL CELL, V19, P2092, DOI 10.1091/mbc.E07-12-1257; Hampe J, 2007, NAT GENET, V39, P207, DOI 10.1038/ng1954; Hanada T, 2007, J BIOL CHEM, V282, P37298, DOI 10.1074/jbc.C700195200; Ichimura Y, 2000, NATURE, V408, P488, DOI 10.1038/35044114; Itoh T, 2008, MOL BIOL CELL, V19, P2916, DOI 10.1091/mbc.E07-12-1231; Kawasaki M, 2005, CURR OPIN STRUC BIOL, V15, P681, DOI 10.1016/j.sbi.2005.10.015; Kuma A, 2002, J BIOL CHEM, V277, P18619, DOI 10.1074/jbc.M111889200; Lapouge K, 2002, J BIOL CHEM, V277, P10121, DOI 10.1074/jbc.M112065200; Lupas AN, 2005, ADV PROTEIN CHEM, V70, P37, DOI 10.1016/S0065-3233(04)70003-0; Matsushita M, 2007, J BIOL CHEM, V282, P6763, DOI 10.1074/jbc.M609876200; Mizushima N, 1998, NATURE, V395, P395, DOI 10.1038/26506; Mizushima N, 2001, J CELL BIOL, V152, P657, DOI 10.1083/jcb.152.4.657; Mizushima N, 2003, J CELL SCI, V116, P1679, DOI 10.1242/jcs.00381; Mizushima N, 1999, EMBO J, V18, P3888, DOI 10.1093/emboj/18.14.3888; Mizushima N, 2007, GENE DEV, V21, P2861, DOI 10.1101/gad.1599207; Nakatogawa H, 2009, NAT REV MOL CELL BIO, V10, P458, DOI 10.1038/nrm2708; Noda NN, 2009, CHEM REV, V109, P1587, DOI 10.1021/cr800459r; NODA T, 1995, BIOCHEM BIOPH RES CO, V210, P126, DOI 10.1006/bbrc.1995.1636; Noda T, 1998, J BIOL CHEM, V273, P3963, DOI 10.1074/jbc.273.7.3963; Ohsumi Y, 2001, NAT REV MOL CELL BIO, V2, P211, DOI 10.1038/35056522; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Sato Y, 2007, P NATL ACAD SCI USA, V104, P8305, DOI 10.1073/pnas.0701550104; SEGLEN PO, 1992, EXPERIENTIA, V48, P158, DOI 10.1007/BF01923509; Shintani T, 1999, EMBO J, V18, P5234, DOI 10.1093/emboj/18.19.5234; Stagg SM, 2007, CURR OPIN STRUC BIOL, V17, P221, DOI 10.1016/j.sbi.2007.03.010; Suzuki NN, 2005, AUTOPHAGY, V1, P119, DOI 10.4161/auto.1.2.1859; TAKESHIGE K, 1992, J CELL BIOL, V119, P301, DOI 10.1083/jcb.119.2.301; Terwilliger TC, 1999, ACTA CRYSTALLOGR D, V55, P849, DOI 10.1107/S0907444999000839; Terwilliger TC, 2000, ACTA CRYSTALLOGR D, V56, P965, DOI 10.1107/S0907444900005072	35	90	95	0	22	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 8	2010	285	2					1508	1515		10.1074/jbc.M109.053520	http://dx.doi.org/10.1074/jbc.M109.053520			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	539MH	19889643	Green Published, hybrid			2022-12-25	WOS:000273258200070
J	Sahu, G; Wang, DF; Chen, CB; Zhurkin, VB; Harrington, RE; Appella, E; Hager, GL; Nagaich, AK				Sahu, Geetaram; Wang, Difei; Chen, Claudia B.; Zhurkin, Victor B.; Harrington, Rodney E.; Appella, Ettore; Hager, Gordon L.; Nagaich, Akhilesh K.			p53 Binding to Nucleosomal DNA Depends on the Rotational Positioning of DNA Response Element	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLUCOCORTICOID-RECEPTOR; TUMOR-SUPPRESSOR; CRYSTAL-STRUCTURE; TRANSCRIPTIONAL REGULATION; STRUCTURAL BASIS; DOMAIN PEPTIDES; CORE DOMAIN; COMPLEX; PROTEIN; RECOGNITION	The sequence-specific binding to DNA is crucial for the p53 tumor suppressor function. To investigate the constraints imposed on p53-DNA recognition by nucleosomal organization, we studied binding of the p53 DNA binding domain (p53DBD) and full-length wild-type p53 protein to a single p53 response element (p53RE) placed near the nucleosomal dyad in six rotational settings. We demonstrate that the strongest p53 binding occurs when the p53RE in the nucleosome is bent in the same direction as observed for the p53-DNA complexes in solution and in co-crystals. The p53RE becomes inaccessible, however, if its orientation in the core particle is changed by similar to 180 degrees. Our observations indicate that the orientation of the binding sites on a nucleosome may play a significant role in the initial p53-DNA recognition and subsequent cofactor recruitment.	[Nagaich, Akhilesh K.] US FDA, Chem Lab, Div Therapeut Prot, OBP,OPS,CDER, Bethesda, MD 20892 USA; [Wang, Difei; Zhurkin, Victor B.; Appella, Ettore] NCI, Cell Biol Lab, NIH, Bethesda, MD 20892 USA; [Hager, Gordon L.] NCI, Lab Receptor Biol & Gene Express, NIH, Bethesda, MD 20892 USA; [Harrington, Rodney E.] Arizona State Univ, Dept Microbiol, Tempe, AZ 85287 USA	US Food & Drug Administration (FDA); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Arizona State University; Arizona State University-Tempe	Nagaich, AK (corresponding author), US FDA, Chem Lab, Div Therapeut Prot, OBP,OPS,CDER, 29 Lincoln Dr, Bethesda, MD 20892 USA.	akhilesh.nagaich@fda.hhs.gov	Wang, Difei/E-7066-2010		Oak Ridge Institute for Science and Education through an intraagency agreement between the United States Department of Energy and the United States Food and Drug Administration; National Institutes of Health [R01 CA 70274]; National Cancer Institute; Center for Cancer Research; NATIONAL CANCER INSTITUTE [ZIABC005599, ZIABC010845, R01CA070274, ZIABC005450] Funding Source: NIH RePORTER	Oak Ridge Institute for Science and Education through an intraagency agreement between the United States Department of Energy and the United States Food and Drug Administration; National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); National Cancer Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Center for Cancer Research(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This work was supported, in whole or in part, by an appointment of G. Sahu to the Postgraduate Research Program at the Center for Drug Evaluation and Research administered by the Oak Ridge Institute for Science and Education through an intraagency agreement between the United States Department of Energy and the United States Food and Drug Administration. This work was also supported in part by National Institutes of Health Grant R01 CA 70274 (to R.E.H.) and by the Intramural Research Program of the National Institutes of Health, National Cancer Institute, Center for Cancer Research.	Appella E, 2001, EUR J BIOCHEM, V268, P2764, DOI 10.1046/j.1432-1327.2001.02225.x; BALAGURUMOORTHY P, 1995, P NATL ACAD SCI USA, V92, P8591, DOI 10.1073/pnas.92.19.8591; Blomquist P, 1996, J BIOL CHEM, V271, P153, DOI 10.1074/jbc.271.1.153; BROOKS BR, 1983, J COMPUT CHEM, V4, P187, DOI 10.1002/jcc.540040211; BRUKNER I, 1993, NUCLEIC ACIDS RES, V21, P1025, DOI 10.1093/nar/21.4.1025; Chen XB, 1996, GENE DEV, V10, P2438, DOI 10.1101/gad.10.19.2438; CHO YJ, 1994, SCIENCE, V265, P346, DOI 10.1126/science.8023157; Cirillo LA, 1999, MOL CELL, V4, P961, DOI 10.1016/S1097-2765(00)80225-7; CUI F, 2006, BIOMOLECULAR PATHWAY, P48; Davey CA, 2002, J MOL BIOL, V319, P1097, DOI 10.1016/S0022-2836(02)00386-8; DREW HR, 1985, J MOL BIOL, V186, P773, DOI 10.1016/0022-2836(85)90396-1; Durell SR, 1998, STRUCTURE, MOTION, INTERACTION AND EXPRESSION OF BIOLOGICAL MACROMOLECULES, VOL 2, P277; Espinosa JM, 2001, MOL CELL, V8, P57, DOI 10.1016/S1097-2765(01)00283-0; FITZGERALD DJ, 1994, J BIOL CHEM, V269, P21303; Fitzgerald DJ, 1998, NUCLEIC ACIDS RES, V26, P2526, DOI 10.1093/nar/26.11.2526; FRIEDMAN PN, 1993, P NATL ACAD SCI USA, V90, P3319, DOI 10.1073/pnas.90.8.3319; Fryer CJ, 1998, NATURE, V393, P88, DOI 10.1038/30032; Hainaut P, 2000, ADV CANCER RES, V77, P81; HAYES JJ, 1990, P NATL ACAD SCI USA, V87, P7405, DOI 10.1073/pnas.87.19.7405; Hayes JJ, 1997, METHODS, V12, P2, DOI 10.1006/meth.1997.0441; Ho WC, 2006, J BIOL CHEM, V281, P20494, DOI 10.1074/jbc.M603634200; JEFFREY PD, 1995, SCIENCE, V267, P1498, DOI 10.1126/science.7878469; Joerger AC, 2006, P NATL ACAD SCI USA, V103, P15056, DOI 10.1073/pnas.0607286103; Jordan JJ, 2008, PLOS GENET, V4, DOI 10.1371/journal.pgen.1000104; KERN SE, 1991, SCIENCE, V252, P1708, DOI 10.1126/science.2047879; Kitayner M, 2006, MOL CELL, V22, P741, DOI 10.1016/j.molcel.2006.05.015; Laptenko O, 2006, CELL DEATH DIFFER, V13, P951, DOI 10.1038/sj.cdd.4401916; Lee D, 2002, J BIOL CHEM, V277, P22330, DOI 10.1074/jbc.M111987200; LEE DY, 1993, CELL, V72, P73, DOI 10.1016/0092-8674(93)90051-Q; LI BY, 1994, J BIOL CHEM, V269, P7756; LI Q, 1993, GENE DEV, V7, P2471, DOI 10.1101/gad.7.12a.2471; LI Q, 1995, MOL CELL BIOL, V15, P4375; McKinney K, 2002, MOL CELL BIOL, V22, P6797, DOI 10.1128/MCB.22.19.6797-6808.2002; MCLACHLAN AD, 1982, ACTA CRYSTALLOGR A, V38, P871, DOI 10.1107/S0567739482001806; Murray-Zmijewski F, 2008, NAT REV MOL CELL BIO, V9, P702, DOI 10.1038/nrm2451; Nagaich AK, 1999, P NATL ACAD SCI USA, V96, P1875, DOI 10.1073/pnas.96.5.1875; Nagaich AK, 1997, J BIOL CHEM, V272, P14830, DOI 10.1074/jbc.272.23.14830; Nagaich AK, 2004, MOL CELL, V14, P163, DOI 10.1016/S1097-2765(04)00178-9; Nagaich AK, 1997, J BIOL CHEM, V272, P14842, DOI 10.1074/jbc.272.23.14842; Nishiyama M, 2009, NAT CELL BIOL, V11, P172, DOI 10.1038/ncb1831; Oh J, 2008, J BIOL CHEM, V283, P11924, DOI 10.1074/jbc.M705401200; PERLMANN T, 1988, EMBO J, V7, P3073, DOI 10.1002/j.1460-2075.1988.tb03172.x; Riley T, 2008, NAT REV MOL CELL BIO, V9, P402, DOI 10.1038/nrm2395; Rippin TM, 2002, J MOL BIOL, V319, P351, DOI 10.1016/S0022-2836(02)00326-1; SATCHWELL SC, 1986, J MOL BIOL, V191, P659, DOI 10.1016/0022-2836(86)90452-3; Speidel D, 2006, ONCOGENE, V25, P940, DOI 10.1038/sj.onc.1209126; Staples OD, 2008, SURG-J R COLL SURG E, V6, P240, DOI 10.1016/S1479-666X(08)80034-0; Studitsky VM, 1999, METH MOL B, V119, P17; TAYLOR ICA, 1991, GENE DEV, V5, P1285, DOI 10.1101/gad.5.7.1285; Toledo F, 2006, NAT REV CANCER, V6, P909, DOI 10.1038/nrc2012; TSUKIYAMA T, 1994, NATURE, V367, P525, DOI 10.1038/367525a0; Ventura A, 2007, NATURE, V445, P661, DOI 10.1038/nature05541; VetteseDadey M, 1996, EMBO J, V15, P2508, DOI 10.1002/j.1460-2075.1996.tb00608.x; WECHSLER DS, 1994, MOL CELL BIOL, V14, P4097, DOI 10.1128/MCB.14.6.4097; Xu Y, 2007, J BIOL CHEM, V282, P37429, DOI 10.1074/jbc.M706039200; Zhao KH, 2001, J BIOL CHEM, V276, P12120, DOI 10.1074/jbc.M011644200; ZHURKIN VB, 1991, P NATL ACAD SCI USA, V88, P7046, DOI 10.1073/pnas.88.16.7046	57	39	39	1	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 8	2010	285	2					1321	1332		10.1074/jbc.M109.081182	http://dx.doi.org/10.1074/jbc.M109.081182			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	539MH	19887449	Green Published, hybrid			2022-12-25	WOS:000273258200053
J	Hansson, MJ; Morota, S; Teilum, M; Mattiasson, G; Uchino, H; Elmer, E				Hansson, Magnus J.; Morota, Saori; Teilum, Maria; Mattiasson, Gustav; Uchino, Hiroyuki; Elmer, Eskil			Increased Potassium Conductance of Brain Mitochondria Induces Resistance to Permeability Transition by Enhancing Matrix Volume	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							K-ATP CHANNELS; RAT-LIVER MITOCHONDRIA; ISCHEMIC TOLERANCE; HEART-MITOCHONDRIA; REPERFUSION INJURY; INNER MEMBRANE; CYCLOSPORINE-A; CARDIAC MITOCHONDRIA; CEREBRAL-ISCHEMIA; CYCLOPHILIN-D	Modulation of K+ conductance of the inner mitochondrial membrane has been proposed to mediate preconditioning in ischemia-reperfusion injury. The mechanism is not entirely understood, but it has been linked to a decreased activation of mitochondrial permeability transition (mPT). In the present study K+ channel activity was mimicked by picomolar concentrations of valinomycin. Isolated brain mitochondria were exposed to continuous infusions of calcium. Monitoring of extramitochondrial Ca2+ and mitochondrial respiration provided a quantitative assay for mPT sensitivity by determining calcium retention capacity (CRC). Valinomycin and cyclophilin D inhibition separately and additively increased CRC. Comparable degrees of respiratory uncoupling induced by increased K+ or H+ conductance had opposite effects on mPT sensitivity. Protonophores dose-dependently decreased CRC, demonstrating that so-called mild uncoupling was not beneficial per se. The putative mitoKATP channel opener diazoxide did not mimic the effect of valinomycin. An alkaline matrix pH was required for mitochondria to retain calcium, but increased K+ conductance did not result in augmented Delta pH. The beneficial effect of valinomycin on CRC was not mediated by H2O2-induced protein kinase C epsilon activation. Rather, increased K+ conductance reduced H2O2 generation during calcium infusion. Lowering the osmolarity of the buffer induced an increase in mitochondrial volume and improved CRC similar to valinomycin without inducing uncoupling or otherwise affecting respiration. We propose that increased potassium conductance in brain mitochondria may cause a direct physiological effect on matrix volume inducing resistance to pathological calcium challenges.	[Hansson, Magnus J.; Morota, Saori; Teilum, Maria; Mattiasson, Gustav; Elmer, Eskil] Lund Univ, Expt Brain Res Lab, Mitochondrial Pathophysiol Unit, Dept Clin Sci, SE-22184 Lund, Sweden; [Uchino, Hiroyuki] Tokyo Med Univ, Dept Anesthesiol, Tokyo 1600023, Japan; [Hansson, Magnus J.] Univ Lund Hosp, Dept Clin Physiol, SE-22184 Lund, Sweden; [Elmer, Eskil] Univ Lund Hosp, Dept Clin Neurophysiol, SE-22184 Lund, Sweden	Lund University; Tokyo Medical University; Lund University; Skane University Hospital; Lund University; Skane University Hospital	Hansson, MJ (corresponding author), Lund Univ, Expt Brain Res Lab, Mitochondrial Pathophysiol Unit, Dept Clin Sci, BMC A13, SE-22184 Lund, Sweden.	magnus.hansson@med.lu.se	Elmér, Eskil/F-9341-2014; Hansson, Magnus/G-4486-2014	Elmér, Eskil/0000-0001-7901-1826; Hansson, Magnus/0000-0002-0201-0638	Swedish Research Council [2008-2634]; Japanese Ministry of Health and Labor and Welfare [18591724]; Swedish Society of Medicine; Stohne; Segerfalk; Royal Physiographic Society in Lund	Swedish Research Council(Swedish Research CouncilEuropean Commission); Japanese Ministry of Health and Labor and Welfare(Ministry of Health, Labour and Welfare, Japan); Swedish Society of Medicine; Stohne; Segerfalk; Royal Physiographic Society in Lund	This work was supported by the Swedish Research Council (reference number 2008-2634), by the Japanese Ministry of Health and Labor and Welfare Grant 18591724, by the Swedish Society of Medicine, and by the foundations of Stohne, Segerfalk, and the Royal Physiographic Society in Lund. E. Elmer is co-founder and officer of Maas Biolab, LLC and NeuroVive Pharmaceutical AB, which hold intellectual property rights and develop the use of cyclosporins as cyclophilin D inhibitors for neurological treatment.	Andrukhiv A, 2006, AM J PHYSIOL-HEART C, V291, pH2067, DOI 10.1152/ajpheart.00272.2006; Ardehali H, 2005, J MOL CELL CARDIOL, V39, P7, DOI 10.1016/j.yjmcc.2004.12.003; Baines CP, 2003, CIRC RES, V92, P873, DOI 10.1161/01.RES.0000069215.36389.8D; BAYSAL K, 1994, AM J PHYSIOL, V266, pC800, DOI 10.1152/ajpcell.1994.266.3.C800; Bernardi P, 2006, FEBS J, V273, P2077, DOI 10.1111/j.1742-4658.2006.05213.x; BERNARDI P, 1992, J BIOL CHEM, V267, P2934; Bernardi P, 1999, PHYSIOL REV, V79, P1127, DOI 10.1152/physrev.1999.79.4.1127; Brand MD, 2004, FREE RADICAL BIO MED, V37, P755, DOI 10.1016/j.freeradbiomed.2004.05.034; BRIERLEY GP, 1994, J BIOENERG BIOMEMBR, V26, P519, DOI 10.1007/BF00762736; Brustovetsky T, 2005, J PHYSIOL-LONDON, V568, P47, DOI 10.1113/jphysiol.2005.091199; Chalmers S, 2003, J BIOL CHEM, V278, P19062, DOI 10.1074/jbc.M212661200; CHOPP M, 1989, NEUROLOGY, V39, P1396, DOI 10.1212/WNL.39.10.1396; Costa ADT, 2006, AM J PHYSIOL-HEART C, V290, pH406, DOI 10.1152/ajpheart.00794.2005; Costa ADT, 2006, J BIOL CHEM, V281, P20801, DOI 10.1074/jbc.M600959200; Costa ADT, 2009, J BIOENERG BIOMEMBR, V41, P123, DOI 10.1007/s10863-009-9213-y; Crompton M, 1999, BIOCHEM J, V341, P233, DOI 10.1042/0264-6021:3410233; Das M, 2003, J PHYSIOL-LONDON, V547, P893, DOI 10.1113/jphysiol.2002.035006; Dirnagl U, 2003, TRENDS NEUROSCI, V26, P248, DOI 10.1016/S0166-2236(03)00071-7; DODGSON SJ, 1982, J BIOL CHEM, V257, P1705; Domoki F, 1999, STROKE, V30, P2713, DOI 10.1161/01.STR.30.12.2713; Dos Santos P, 2002, AM J PHYSIOL-HEART C, V283, pH284, DOI 10.1152/ajpheart.00034.2002; Drose S, 2006, J BIOL CHEM, V281, P23733, DOI 10.1074/jbc.M602570200; Empey PE, 2006, J NEUROTRAUM, V23, P109, DOI 10.1089/neu.2006.23.109; Forte M, 2007, P NATL ACAD SCI USA, V104, P7558, DOI 10.1073/pnas.0702228104; Garlid KD, 1996, J BIOL CHEM, V271, P8796, DOI 10.1074/jbc.271.15.8796; Gidday JM, 2006, NAT REV NEUROSCI, V7, P437, DOI 10.1038/nrn1927; Halestrap AP, 2009, J BIOENERG BIOMEMBR, V41, P113, DOI 10.1007/s10863-009-9206-x; HALESTRAP AP, 1991, BIOCHEM J, V278, P715, DOI 10.1042/bj2780715; HALESTRAP AP, 1989, BIOCHIM BIOPHYS ACTA, V973, P355, DOI 10.1016/S0005-2728(89)80378-0; Hanley PJ, 2005, J MOL CELL CARDIOL, V39, P17, DOI 10.1016/j.yjmcc.2005.04.002; Hansson MJ, 2004, J NEUROCHEM, V89, P715, DOI 10.1111/j.1471-4159.2004.02400.x; Hatton J, 2008, J NEUROSURG, V109, P699, DOI 10.3171/JNS/2008/109/10/0699; Hausenloy DJ, 2004, AM J PHYSIOL-HEART C, V287, pH841, DOI 10.1152/ajpheart.00678.2003; Hausenloy DJ, 2002, CARDIOVASC RES, V55, P534, DOI 10.1016/S0008-6363(02)00455-8; HAWORTH RA, 1979, ARCH BIOCHEM BIOPHYS, V195, P460, DOI 10.1016/0003-9861(79)90372-2; Holmuhamedov EL, 1999, J PHYSIOL-LONDON, V519, P347, DOI 10.1111/j.1469-7793.1999.0347m.x; HUTSON SM, 1987, J BIOL CHEM, V262, P9629; Hutter E, 2006, EXP GERONTOL, V41, P103, DOI 10.1016/j.exger.2005.09.011; Jaburek M, 1998, J BIOL CHEM, V273, P13578; Jaburek M, 2006, CIRC RES, V99, P878, DOI 10.1161/01.RES.0000245106.80628.d3; JANOFF A, 1964, Int Anesthesiol Clin, V2, P251, DOI 10.1097/00004311-196402000-00008; KITAGAWA K, 1990, BRAIN RES, V528, P21, DOI 10.1016/0006-8993(90)90189-I; Kristian T, 2001, J NEUROTRAUM, V18, P1059, DOI 10.1089/08977150152693755; Kristian T, 2007, J NEUROCHEM, V102, P1346, DOI 10.1111/j.1471-4159.2007.04626.x; Liu D, 2002, J CEREBR BLOOD F MET, V22, P431, DOI 10.1097/00004647-200204000-00007; Liu YG, 1998, CIRCULATION, V97, P2463, DOI 10.1161/01.CIR.97.24.2463; Mazzeo AT, 2008, ACTA NEUROCHIR, V150, P1019, DOI 10.1007/s00701-008-0021-7; Morota S, 2009, EXP NEUROL, V218, P353, DOI 10.1016/j.expneurol.2009.03.036; MURRY CE, 1986, CIRCULATION, V74, P1124, DOI 10.1161/01.CIR.74.5.1124; NICHOLLS DG, 1974, EUR J BIOCHEM, V50, P305, DOI 10.1111/j.1432-1033.1974.tb03899.x; Nicholls DG, 2005, CELL CALCIUM, V38, P311, DOI 10.1016/j.ceca.2005.06.011; NICHOLLS DG, 1972, FEBS LETT, V25, P61, DOI 10.1016/0014-5793(72)80454-X; Nogueira V, 2005, J BIOENERG BIOMEMBR, V37, P25, DOI 10.1007/s10863-005-4120-3; Pain T, 2000, CIRC RES, V87, P460; PETRONILLI V, 1994, BBA-BIOENERGETICS, V1187, P255, DOI 10.1016/0005-2728(94)90122-8; Ping PP, 2002, J CLIN INVEST, V109, P499, DOI 10.1172/JCI200213200; Piot C, 2008, NEW ENGL J MED, V359, P473, DOI 10.1056/NEJMoa071142; PRESSMAN BC, 1967, P NATL ACAD SCI USA, V58, P1949, DOI 10.1073/pnas.58.5.1949; Saurin AT, 2002, CARDIOVASC RES, V55, P672, DOI 10.1016/S0008-6363(02)00325-5; Schinzel AC, 2005, P NATL ACAD SCI USA, V102, P12005, DOI 10.1073/pnas.0505294102; Siemen D, 1999, BIOCHEM BIOPH RES CO, V257, P549, DOI 10.1006/bbrc.1999.0496; Sims NR, 2008, NAT PROTOC, V3, P1228, DOI 10.1038/nprot.2008.105; Szabo I, 2005, J BIOL CHEM, V280, P12790, DOI 10.1074/jbc.M413548200; WIELOCH T, 2007, HDB NEUROCHEMISTRY M, P667; Xu WH, 2002, SCIENCE, V298, P1029, DOI 10.1126/science.1074360; Yellon DM, 2003, PHYSIOL REV, V83, P1113, DOI 10.1152/physrev.00009.2003; ZOCCARATO F, 1982, EUR J BIOCHEM, V127, P333, DOI 10.1111/j.1432-1033.1982.tb06875.x; ZORATTI M, 1995, BBA-REV BIOMEMBRANES, V1241, P139, DOI 10.1016/0304-4157(95)00003-A	68	37	38	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 1	2010	285	1					741	750		10.1074/jbc.M109.017731	http://dx.doi.org/10.1074/jbc.M109.017731			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	536UT	19880514	Green Published, hybrid			2022-12-25	WOS:000273070100075
J	Kim, SY; Cho, BH; Kim, UH				Kim, Seon-Young; Cho, Baik Hwan; Kim, Uh-Hyun			CD38-mediated Ca2+ Signaling Contributes to Angiotensin II-induced Activation of Hepatic Stellate Cells ATTENUATION OF HEPATIC FIBROSIS BY CD38 ABLATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ADP-RIBOSYL CYCLASE; LIVER FIBROSIS; RECEPTOR ANTAGONIST; CYCLING ASSAY; UP-REGULATION; EXPRESSION; RELEASE; CALCIUM; NAADP; MECHANISMS	CD38 is a type II glycoprotein that is responsible for the synthesis and hydrolysis of cyclic ADP-ribose (cADPR) and nicotinic acid adenine dinucleotide phosphate (NAADP), Ca2+-mobilizing second messengers. The activation of hepatic stellate cells (HSCs) is a critical event in hepatic fibrosis because these cells are the main producers of extracellular matrix proteins in the liver. Recent evidence indicates that the renin-angiotensin system plays a major role in liver fibrosis. In this study, we showed that angiotensin II (Ang II) evoked long lasting Ca2+ rises and induced NAADP or cADPR productions via CD38 in HSCs. Inositol 1,4,5-trisphosphate as well as NAADP-induced initial Ca2+ transients were prerequisite for the production of cADPR, which was responsible for later sustained Ca2+ rises in the Ang II-treated HSCs. Ang II-mediated inositol 1,4,5-trisphosphate- and NAADP-stimulated Ca2+ signals cross-talked in a dependent manner with each other. We also demonstrated that CD38 plays an important role in Ang II-induced proliferation and overproduction of extracellular matrix proteins in HSCs, which were reduced by an antagonistic cADPR analog, 8-bromo-cADPR, or in CD38(-/-) HSCs. Moreover, we presented evidence to implicate CD38 in the bile duct ligation-induced liver fibrogenesis; infiltration of inflammatory cells and expressions of alpha-smooth muscle actin, transforming growth factor-beta 1, collagen alpha I(1), and fibronectin were reduced in CD38(-/-) mice compared with those in CD38(-/-) mice. These results demonstrate that CD38-mediated Ca2+ signals contribute to liver fibrosis via HSCs activation, suggesting that intervention of CD38 activation may help prevent hepatic fibrosis.	[Kim, Seon-Young; Kim, Uh-Hyun] Chonbuk Natl Univ, Sch Med, Dept Biochem, Jeonju 561182, South Korea; [Cho, Baik Hwan] Chonbuk Natl Univ, Sch Med, Dept Surg, Jeonju 561182, South Korea; [Kim, Uh-Hyun] Chonbuk Natl Univ, Sch Med, Inst Cardiovasc Res, Jeonju 561182, South Korea	Jeonbuk National University; Jeonbuk National University; Jeonbuk National University	Kim, UH (corresponding author), Chonbuk Natl Univ, Sch Med, Dept Biochem, Jeonju 561182, South Korea.	uhkim@chonbuk.ac.kr		Kim, Uh-Hyun/0000-0003-3304-7190	Ministry for Health, Welfare & Family Affairs, Republic of Korea [A090476]	Ministry for Health, Welfare & Family Affairs, Republic of Korea(Ministry of Health & Welfare (MOHW), Republic of Korea)	This work was supported by a grant of the Korea Healthcare Technology R&D Project, Ministry for Health, Welfare & Family Affairs, Republic of Korea (A090476; to U.-H. K.).	Aarhus R, 1996, J BIOL CHEM, V271, P8513, DOI 10.1074/jbc.271.15.8513; Abdeen SM, 2009, ACTA HISTOCHEM, V111, P520, DOI 10.1016/j.acthis.2008.04.008; Bataller R, 2005, J CLIN INVEST, V115, P209, DOI 10.1172/JCI200524282; Bataller R, 2003, GASTROENTEROLOGY, V125, P117, DOI 10.1016/S0016-5085(03)00695-4; Bataller R, 2001, SEMIN LIVER DIS, V21, P437, DOI 10.1055/s-2001-17558; BOWMAN EJ, 1988, P NATL ACAD SCI USA, V85, P7972, DOI 10.1073/pnas.85.21.7972; Breitkopf K, 2005, CYTOKINE, V31, P349, DOI 10.1016/j.cyto.2005.06.005; Calcraft PJ, 2009, NATURE, V459, P596, DOI 10.1038/nature08030; CASTILLA A, 1991, NEW ENGL J MED, V324, P933, DOI 10.1056/NEJM199104043241401; Churchill GC, 2002, CELL, V111, P703, DOI 10.1016/S0092-8674(02)01082-6; da Silva CP, 2000, BBA-MOL CELL RES, V1498, P122, DOI 10.1016/S0167-4889(00)00089-6; Foskett JK, 2007, PHYSIOL REV, V87, P593, DOI 10.1152/physrev.00035.2006; Gasser A, 2006, J BIOL CHEM, V281, P16906, DOI 10.1074/jbc.M601347200; Graeff R, 2002, BIOCHEM J, V361, P379, DOI 10.1042/bj3610379; Gressner AM, 2002, FRONT BIOSCI-LANDMRK, V7, pD793, DOI 10.2741/gressner; Gul R, 2008, AM J PHYSIOL-HEART C, V295, pH77, DOI 10.1152/ajpheart.01355.2007; Gul R, 2009, CARDIOVASC RES, V81, P582, DOI 10.1093/cvr/cvn232; Guse AH, 2008, SCI SIGNAL, V1, DOI 10.1126/scisignal.144re10; Kim SY, 2008, AM J PHYSIOL-RENAL, V294, pF982, DOI 10.1152/ajprenal.00483.2007; Kim SY, 2009, AM J PHYSIOL-RENAL, V296, pF291, DOI 10.1152/ajprenal.90381.2008; KIM UH, 1991, J BIOL CHEM, V266, P1359; Kurikawa N, 2003, BRIT J PHARMACOL, V139, P1085, DOI 10.1038/sj.bjp.0705339; Lee HC, 1997, PHYSIOL REV, V77, P1133, DOI 10.1152/physrev.1997.77.4.1133; Malavasi F, 2008, PHYSIOL REV, V88, P841, DOI 10.1152/physrev.00035.2007; Mao TK, 2002, AUTOIMMUNITY, V35, P521, DOI 10.1080/0891693021000057784; March S, 2007, AM J PATHOL, V170, P176, DOI 10.2353/ajpath.2007.051212; Marra F, 1998, HEPATOLOGY, V27, P462, DOI 10.1002/hep.510270221; Paizis G, 2002, GASTROENTEROLOGY, V123, P1667, DOI 10.1053/gast.2002.36561; Potter BVL, 2004, CURR MOL MED, V4, P303, DOI 10.2174/1566524043360744; POZZAN T, 1994, PHYSIOL REV, V74, P595, DOI 10.1152/physrev.1994.74.3.595; Russo MW, 2005, LIVER TRANSPLANT, V11, P1235, DOI 10.1002/lt.20432; Yokohama S, 2004, HEPATOLOGY, V40, P1222, DOI 10.1002/hep.20420; Yoshiji H, 2001, HEPATOLOGY, V34, P745, DOI 10.1053/jhep.2001.28231	33	49	49	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 1	2010	285	1					576	582		10.1074/jbc.M109.076216	http://dx.doi.org/10.1074/jbc.M109.076216			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	536UT	19910464	Green Published, hybrid			2022-12-25	WOS:000273070100059
J	Zhou, JS; Yi, JX; Fu, RG; Liu, ED; Siddique, T; Rios, E; Deng, HX				Zhou, Jingsong; Yi, Jianxun; Fu, Ronggen; Liu, Erdong; Siddique, Teepu; Rios, Eduardo; Deng, Han-Xiang			Hyperactive Intracellular Calcium Signaling Associated with Localized Mitochondrial Defects in Skeletal Muscle of an Animal Model of Amyotrophic Lateral Sclerosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MOUSE MOTOR TERMINALS; CA2+ SPARKS; MAMMALIAN MUSCLE; PRIMARY TARGET; UP-REGULATION; MUTANT SOD1; WILD-TYPE; MDX MICE; FIBERS; DEGENERATION	Amyotrophic lateral sclerosis (ALS) is a fatal neuromuscular disorder characterized by degeneration of motor neurons and atrophy of skeletal muscle. Mutations in the superoxide dismutase (SOD1) gene are linked to 20% cases of inherited ALS. Mitochondrial dysfunction has been implicated in the pathogenic process, but how it contributes to muscle degeneration of ALS is not known. Here we identify a specific deficit in the cellular physiology of skeletal muscle derived from an ALS mouse model (G93A) with transgenic overexpression of the human SOD1(G93A) mutant. The G93A skeletal muscle fibers display localized loss of mitochondrial inner membrane potential in fiber segments near the neuromuscular junction. These defects occur in young G93A mice prior to disease onset. Fiber segments with depolarized mitochondria show greater osmotic stress-induced Ca2+ release activity, which can include propagating Ca2+ waves. These Ca2+ waves are confined to regions of depolarized mitochondria and stop propagating shortly upon entering the regions of normal, polarized mitochondria. Uncoupling of mitochondrial membrane potential with FCCP or inhibition of mitochondrial Ca2+ uptake by Ru360 lead to cell-wide propagation of such Ca2+ release events. Our data reveal that mitochondria regulate Ca2+ signaling in skeletal muscle, and loss of this capacity may contribute to the progression of muscle atrophy in ALS.	[Zhou, Jingsong; Yi, Jianxun; Rios, Eduardo] Rush Univ, Sch Med, Dept Physiol & Mol Biophys, Chicago, IL 60612 USA; [Fu, Ronggen; Liu, Erdong; Siddique, Teepu; Deng, Han-Xiang] Northwestern Univ, Feinberg Sch Med, Dept Neurol, Chicago, IL 60611 USA	Rush University; Northwestern University; Feinberg School of Medicine	Zhou, JS (corresponding author), 1750 W Harrison St, Chicago, IL 60612 USA.	jzhou1@rush.edu	Siddique, Teepu/AAT-8166-2021	Siddique, Teepu/0000-0001-7293-9146; Deng, Han-Xiang/0000-0002-0030-8465	Muscular Dystrophy Association [MDA4351]; National Institutes of Health through NIAMS [AR032808, AR049184]; National Institutes of Health through NINDS [NS050641, NS046535, NS040308]; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR049184, R01AR032808, R01AR057404, R37AR032808] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS040308, R01NS050641, R01NS046535] Funding Source: NIH RePORTER	Muscular Dystrophy Association(Muscular Dystrophy Association); National Institutes of Health through NIAMS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); National Institutes of Health through NINDS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))	This work was supported in whole by Research Grant MDA4351 from the Muscular Dystrophy Association (to J. Z.) and in part by National Institutes of Health Grants AR032808 and AR049184 (to E. R.) through NIAMS and NS050641 and NS046535 (to T. S.) and NS040308 (to H. X. D.) through NINDS.	Appel SH, 2006, EXP NEUROL, V198, P1, DOI 10.1016/j.expneurol.2005.12.025; Bruton J, 2003, J PHYSIOL-LONDON, V551, P179, DOI 10.1113/jphysiol.2003.043927; Buntinas L, 2001, BBA-BIOENERGETICS, V1504, P248, DOI 10.1016/S0005-2728(00)00254-1; De Backer F, 2002, J PHYSIOL-LONDON, V542, P855, DOI 10.1113/jphysiol.2002.020487; Deng HX, 2006, P NATL ACAD SCI USA, V103, P7142, DOI 10.1073/pnas.0602046103; DiFranco M, 2008, P NATL ACAD SCI USA, V105, P14698, DOI 10.1073/pnas.0802217105; Dobrowolny G, 2005, J CELL BIOL, V168, P193, DOI 10.1083/jcb.200407021; Dobrowolny G, 2008, CELL METAB, V8, P425, DOI 10.1016/j.cmet.2008.09.002; Dupuis L, 2003, FASEB J, V17, P2091, DOI 10.1096/fj.02-1182fje; Fischer LR, 2004, EXP NEUROL, V185, P232, DOI 10.1016/j.expneurol.2003.10.004; Fucile S, 2004, CELL CALCIUM, V35, P1, DOI 10.1016/j.ceca.2003.08.006; FUNAKOSHI H, 1995, SCIENCE, V268, P1495, DOI 10.1126/science.7770776; GURNEY ME, 1994, SCIENCE, V264, P1772, DOI 10.1126/science.8209258; Han RZ, 2006, CELL CALCIUM, V40, P299, DOI 10.1016/j.ceca.2006.04.016; Hopf FW, 1996, AM J PHYSIOL-CELL PH, V271, pC1325, DOI 10.1152/ajpcell.1996.271.4.C1325; Kim HJ, 2007, EXP MOL MED, V39, P574, DOI 10.1038/emm.2007.63; Kirichok Y, 2004, NATURE, V427, P360, DOI 10.1038/nature02246; Kong JM, 1998, J NEUROSCI, V18, P3241; Launikonis BS, 2005, J PHYSIOL-LONDON, V567, P523, DOI 10.1113/jphysiol.2005.087973; Leclerc N, 2001, NEUROMUSCULAR DISORD, V11, P722, DOI 10.1016/S0960-8966(01)00240-1; Mahoney DJ, 2006, MUSCLE NERVE, V33, P809, DOI 10.1002/mus.20542; Martins AS, 2008, J PHYSIOL-LONDON, V586, P197, DOI 10.1113/jphysiol.2007.146571; Matlib MA, 1998, J BIOL CHEM, V273, P10223, DOI 10.1074/jbc.273.17.10223; Miller TM, 2006, P NATL ACAD SCI USA, V103, P19546, DOI 10.1073/pnas.0609411103; Nguyen KT, 2009, P NATL ACAD SCI USA, V106, P2007, DOI 10.1073/pnas.0810934106; Nguyen QT, 2000, J NEUROSCI, V20, P6077, DOI 10.1523/JNEUROSCI.20-16-06077.2000; O'Rourke B, 2009, J MOL CELL CARDIOL, V46, P767, DOI 10.1016/j.yjmcc.2008.12.011; Park KHJ, 2008, BBA-MOL BASIS DIS, V1782, P462, DOI 10.1016/j.bbadis.2008.04.001; Pasinelli P, 2006, NAT REV NEUROSCI, V7, P710, DOI 10.1038/nrn1971; Payne AM, 2009, EXP GERONTOL, V44, P261, DOI 10.1016/j.exger.2008.09.013; Rossi AE, 2009, EXERC SPORT SCI REV, V37, P29, DOI 10.1097/JES.0b013e3181911fa4; Rudolf R, 2004, J CELL BIOL, V166, P527, DOI 10.1083/jcb.200403102; Shkryl VM, 2009, PFLUG ARCH EUR J PHY, V458, P915, DOI 10.1007/s00424-009-0670-2; Siklos L, 1998, J NEUROPATH EXP NEUR, V57, P571, DOI 10.1097/00005072-199806000-00005; Teichmann MDH, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003644; Vila L, 2003, J PHYSIOL-LONDON, V549, P719, DOI 10.1113/jphysiol.2003.041905; Wang X, 2005, NAT CELL BIOL, V7, P525, DOI 10.1038/ncb1254; Weisleder N, 2006, J CELL BIOL, V174, P639, DOI 10.1083/jcb.200604166; WONG PC, 1995, NEURON, V14, P1105, DOI 10.1016/0896-6273(95)90259-7; Zhou J, 2003, J GEN PHYSIOL, V122, P95, DOI 10.1085/jgp.200308796; Zhou JS, 2006, AM J PHYSIOL-CELL PH, V290, pC539, DOI 10.1152/ajpcell.00592.2004	41	93	95	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 1	2010	285	1					705	712		10.1074/jbc.M109.041319	http://dx.doi.org/10.1074/jbc.M109.041319			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	536UT	19889637	hybrid, Green Published			2022-12-25	WOS:000273070100071
J	Maiti, A; Morgan, MT; Drohat, AC				Maiti, Atanu; Morgan, Michael T.; Drohat, Alexander C.			Role of Two Strictly Conserved Residues in Nucleotide Flipping and N-Glycosylic Bond Cleavage by Human Thymine DNA Glycosylase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BASE EXCISION-REPAIR; CRYSTAL-STRUCTURE; TRANSITION-STATE; MISMATCH RECOGNITION; MUTATIONAL ANALYSIS; CPG SITES; URACIL; METHYLATION; HYDROLYSIS; MECHANISM	Thymine DNA glycosylase (TDG) promotes genomic integrity by excising thymine from mutagenic G.T mismatches arising by deamination of 5-methylcytosine, and follow-on base excision repair enzymes restore a G.C pair. TDG cleaves the N-glycosylic bond of dT and some other nucleotides, including 5-substituted 2'-deoxyuridine analogs, once they have been flipped from the helix into its active site. We examined the role of two strictly conserved residues; Asn(140), implicated in the chemical step, and Arg(275), implicated in nucleotide flipping. The N140A variant binds substrate DNA with the same tight affinity as wild-type TDG, but it has no detectable base excision activity for a G.T substrate, and its excision rate is vastly diminished (by similar to 10(4.4)-fold) for G.U, G.FU, and G.BrU substrates. Thus, Asn(140) does not contribute substantially to substrate binding but is essential for the chemical step, where it stabilizes the transition state by similar to 6 kcal/mol (compared with 11.6 kcal/mol stabilization provided by TDG overall). Our recent crystal structure revealed that Arg(275) penetrates the DNA minor groove, filling the void created by nucleotide flipping. We found that the R275A and R275L substitutions weaken substrate binding and substantially decrease the base excision rate for G.T and G.BrU substrates. Our results indicate that Arg(275) promotes and/or stabilizes nucleotide flipping, a role that is most important for target nucleotides that are relatively large (dT and bromodeoxyuridine) and/or have a stable N-glycosylic bond (dT). Arg(275) does not contribute substantially to the binding of TDG to abasic DNA product, and it cannot account for the slow product release exhibited by TDG.	[Maiti, Atanu; Morgan, Michael T.; Drohat, Alexander C.] Univ Maryland, Sch Med, Dept Biochem & Mol Biol, Marlene & Stewart Greenebaum Canc Ctr, Baltimore, MD 21201 USA	University System of Maryland; University of Maryland Baltimore	Drohat, AC (corresponding author), Univ Maryland, Sch Med, Dept Biochem & Mol Biol, Marlene & Stewart Greenebaum Canc Ctr, 108 N Greene St, Baltimore, MD 21201 USA.	adroh001@umaryland.edu	Maiti, Atanu/E-9968-2012	Drohat, Alex/0000-0002-7458-8770; Maiti, Atanu/0000-0002-9080-1025	National Institutes of Health [R01-GM72711]; University of Maryland Marlene; Stewart Greenebaum Cancer Center; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM072711] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); University of Maryland Marlene; Stewart Greenebaum Cancer Center; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	This work was supported, in whole or in part, by National Institutes of Health Grant R01-GM72711 (to A. C. D.). This work was also supported by the University of Maryland Marlene and Stewart Greenebaum Cancer Center.	Abu M, 2003, J BIOL CHEM, V278, P8739, DOI 10.1074/jbc.M211084200; Baba D, 2005, NATURE, V435, P979, DOI 10.1038/nature03634; Barrett TE, 1999, EMBO J, V18, P6599, DOI 10.1093/emboj/18.23.6599; Barrett TE, 1998, CELL, V92, P117, DOI 10.1016/S0092-8674(00)80904-6; Bellacosa A, 1999, P NATL ACAD SCI USA, V96, P3969, DOI 10.1073/pnas.96.7.3969; Bennett MT, 2006, J AM CHEM SOC, V128, P12510, DOI 10.1021/ja0634829; Berger I, 1998, NUCLEIC ACIDS RES, V26, P2473, DOI 10.1093/nar/26.10.2473; Berti PJ, 2006, CHEM REV, V106, P506, DOI 10.1021/cr040461t; Bianchet MA, 2003, BIOCHEMISTRY-US, V42, P12455, DOI 10.1021/bi035372+; COOPER DN, 1988, HUM GENET, V78, P151, DOI 10.1007/BF00278187; Cortazar D, 2007, DNA REPAIR, V6, P489, DOI 10.1016/j.dnarep.2006.10.013; Dinner AR, 2001, NATURE, V413, P752, DOI 10.1038/35099587; Drohat AC, 1999, BIOCHEMISTRY-US, V38, P11866, DOI 10.1021/bi9910878; Emsley P, 2004, ACTA CRYSTALLOGR D, V60, P2126, DOI 10.1107/S0907444904019158; Fitzgerald ME, 2008, J BIOL CHEM, V283, P32680, DOI 10.1074/jbc.M805504200; Gallinari P, 1996, NATURE, V383, P735, DOI 10.1038/383735a0; Hardeland U, 2000, J BIOL CHEM, V275, P33449, DOI 10.1074/jbc.M005095200; Hardeland U, 2002, EMBO J, V21, P1456, DOI 10.1093/emboj/21.6.1456; Hendrich B, 1999, NATURE, V401, P301, DOI 10.1038/45843; Jiang YL, 2003, BIOCHEMISTRY-US, V42, P1922, DOI 10.1021/bi027014x; Jiang YL, 2002, J BIOL CHEM, V277, P15385, DOI 10.1074/jbc.M200634200; Jiang YL, 2002, BIOCHEMISTRY-US, V41, P11236, DOI 10.1021/bi026226r; Johnson K. A., 1992, ENZYMES, V20, P1, DOI DOI 10.1016/S1874-6047(08)60019-0; Jones PA, 2001, SCIENCE, V293, P1068, DOI 10.1126/science.1063852; Kangaspeska S, 2008, NATURE, V452, P112, DOI 10.1038/nature06640; Kunz C, 2009, PLOS BIOL, V7, P967, DOI 10.1371/journal.pbio.1000091; Leatherbarrow R, 1998, GRAFIT 5 0; LINDAHL T, 1993, NATURE, V362, P709, DOI 10.1038/362709a0; Loeb LA, 1996, MUTAT RES-FUND MOL M, V350, P279, DOI 10.1016/0027-5107(95)00117-4; Maiti A, 2008, P NATL ACAD SCI USA, V105, P8890, DOI 10.1073/pnas.0711061105; McCann JAB, 2008, J AM CHEM SOC, V130, P5789, DOI 10.1021/ja711363s; Metivier R, 2008, NATURE, V452, P45, DOI 10.1038/nature06544; Metz AH, 2007, EMBO J, V26, P2411, DOI 10.1038/sj.emboj.7601649; Millar CB, 2002, SCIENCE, V297, P403, DOI 10.1126/science.1073354; Morgan MT, 2007, J BIOL CHEM, V282, P27578, DOI 10.1074/jbc.M704253200; Parker JB, 2007, NATURE, V449, P433, DOI 10.1038/nature06131; Pearl LH, 2000, MUTAT RES-DNA REPAIR, V460, P165, DOI 10.1016/S0921-8777(00)00025-2; Pfeifer GP, 2000, MUTAT RES-FUND MOL M, V450, P155, DOI 10.1016/S0027-5107(00)00022-1; POZHARSKI E, 2009, PYITC; Privalov PL, 2007, J MOL BIOL, V365, P1, DOI 10.1016/j.jmb.2006.09.059; Przybylski JL, 2009, J PHYS CHEM B, V113, P6533, DOI 10.1021/jp810472q; Scharer OD, 1997, P NATL ACAD SCI USA, V94, P4878, DOI 10.1073/pnas.94.10.4878; SIBGHATULLAH GP, 1996, BIOCHEMISTRY-US, V35, P12926; Sjoblom T, 2006, SCIENCE, V314, P268, DOI 10.1126/science.1133427; Stivers JT, 2003, CHEM REV, V103, P2729, DOI 10.1021/cr010219b; Stivers JT, 1999, BIOCHEMISTRY-US, V38, P952, DOI 10.1021/bi9818669; Waters TR, 1998, J BIOL CHEM, V273, P20007, DOI 10.1074/jbc.273.32.20007; Waters TR, 1999, J BIOL CHEM, V274, P67, DOI 10.1074/jbc.274.1.67; Waters TR, 2000, MUTAT RES-REV MUTAT, V462, P137, DOI 10.1016/S1383-5742(00)00031-4; Werner RM, 2000, BIOCHEMISTRY-US, V39, P14054, DOI 10.1021/bi0018178; WIEBAUER K, 1989, NATURE, V339, P234, DOI 10.1038/339234a0; Wilds CJ, 2000, NUCLEIC ACIDS RES, V28, P3625, DOI 10.1093/nar/28.18.3625; Wilson DM, 2007, DNA REPAIR, V6, P544, DOI 10.1016/j.dnarep.2006.10.017	53	44	44	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 25	2009	284	52					36680	36688		10.1074/jbc.M109.062356	http://dx.doi.org/10.1074/jbc.M109.062356			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	535LT	19880517	Green Published, hybrid			2022-12-25	WOS:000272970500068
J	Grini, PE; Thorstensen, T; Alm, V; Vizcay-Barrena, G; Windju, SS; Jorstad, TS; Wilson, ZA; Aalen, RB				Grini, Paul E.; Thorstensen, Tage; Alm, Vibeke; Vizcay-Barrena, Gema; Windju, Susanne S.; Jorstad, Tommy S.; Wilson, Zoe A.; Aalen, Reidunn B.			The ASH1 HOMOLOG 2 (ASHH2) Histone H3 Methyltransferase Is Required for Ovule and Anther Development in Arabidopsis	PLOS ONE			English	Article							FLOWERING-LOCUS-C; ABORTED-MICROSPORES AMS; SET DOMAIN PROTEINS; WINTER-ANNUAL HABIT; TRANSCRIPTION FACTOR; H3K36 METHYLATION; GENE ENCODES; WILD-TYPE; THALIANA; POLLEN	Background: SET-domain proteins are histone lysine (K) methyltransferases (HMTase) implicated in defining transcriptionally permissive or repressive chromatin. The Arabidopsis ASH1 HOMOLOG 2 (ASHH2) protein (also called SDG8, EFS and CCR1) has been suggested to methylate H3K4 and/or H3K36 and is similar to Drosophila ASH1, a positive maintainer of gene expression, and yeast Set2, a H3K36 HMTase. Mutation of the ASHH2 gene has pleiotropic developmental effects. Here we focus on the role of ASHH2 in plant reproduction. Methodology/Principal Findings: A slightly reduced transmission of the ashh2 allele in reciprocal crosses implied involvement in gametogenesis or gamete function. However, the main requirement of ASHH2 is sporophytic. On the female side, close to 80% of mature ovules lack embryo sac. On the male side, anthers frequently develop without pollen sacs or with specific defects in the tapetum layer, resulting in reduction in the number of functional pollen per anther by up to similar to 90%. In consistence with the phenotypic findings, an ASHH2 promoter-reporter gene was expressed at the site of megaspore mother cell formation as well as tapetum layers and pollen. ashh2 mutations also result in homeotic changes in floral organ identity. Transcriptional profiling identified more than 300 up-regulated and 600 down-regulated genes in ashh2 mutant inflorescences, whereof the latter included genes involved in determination of floral organ identity, embryo sac and anther/pollen development. This was confirmed by real-time PCR. In the chromatin of such genes (AP1, AtDMC1 and MYB99) we observed a reduction of H3K36 trimethylation (me3), but not H3K4me3 or H3K36me2. Conclusions/Significance: The severe distortion of reproductive organ development in ashh2 mutants, argues that ASHH2 is required for the correct expression of genes essential to reproductive development. The reduction in the ashh2 mutant of H3K36me3 on down-regulated genes relevant to the observed defects, implicates ASHH2 in regulation of gene expression via H3K36 trimethylation in chromatin of Arabidopsis inflorescences.			Grini, PE (corresponding author), Univ Oslo, Dept Mol Biosci, Oslo, Norway.	reidunn.aalen@imbv.uio.no	Grini, Paul/H-9471-2016; Aalen, Reidunn B/AAE-6912-2019; Grini, Paul/N-5948-2019	Grini, Paul/0000-0003-3898-6277; Aalen, Reidunn B/0000-0001-8174-1342; Grini, Paul/0000-0003-3898-6277; Thorstensen, Tage/0000-0001-6430-3578; Wilson, Zoe A/0000-0003-0948-8770				Aarts MGM, 1997, PLANT J, V12, P615, DOI 10.1046/j.1365-313X.1997.00615.x; Adhvaryu KK, 2005, EUKARYOT CELL, V4, P1455, DOI 10.1128/EC.4.8.1455-1464.2005; ALEXANDER MP, 1969, STAIN TECHNOL, V44, P117, DOI 10.3109/10520296909063335; Alvarez-Venegas R, 2003, CURR BIOL, V13, P627, DOI 10.1016/S0960-9822(03)00243-4; Baumbusch LO, 2001, NUCLEIC ACIDS RES, V29, P4319, DOI 10.1093/nar/29.21.4319; BENJAMINI Y, 1995, J R STAT SOC B, V57, P289, DOI 10.1111/j.2517-6161.1995.tb02031.x; Cazzonelli CI, 2009, PLANT CELL, V21, P39, DOI 10.1105/tpc.108.063131; Chu YY, 2006, MOL CELL BIOL, V26, P3029, DOI 10.1128/MCB.26.8.3029-3038.2006; Clough SJ, 1998, PLANT J, V16, P735, DOI 10.1046/j.1365-313x.1998.00343.x; COEN ES, 1991, NATURE, V353, P31, DOI 10.1038/353031a0; Couteau F, 1999, PLANT CELL, V11, P1623, DOI 10.1105/tpc.11.9.1623; Curtis MD, 2003, PLANT PHYSIOL, V133, P462, DOI 10.1104/pp.103.027979; Dennis ES, 2007, CURR OPIN PLANT BIOL, V10, P520, DOI 10.1016/j.pbi.2007.06.009; Dong GF, 2008, BIOCHEM BIOPH RES CO, V373, P659, DOI 10.1016/j.bbrc.2008.06.096; Gendrel AV, 2005, NAT METHODS, V2, P213, DOI 10.1038/nmeth0305-213; Grini PE, 2002, GENETICS, V162, P1911; He YH, 2004, GENE DEV, V18, P2774, DOI 10.1101/gad.1244504; Howden R, 1998, GENETICS, V149, P621; Ito T, 2007, PLANT CELL, V19, P3549, DOI 10.1105/tpc.107.054536; JACKSON D, 1992, PLANT MOL PATHOLOGY, P163; Jenuwein T, 1998, CELL MOL LIFE SCI, V54, P80, DOI 10.1007/s000180050127; Kim HS, 2008, BIOCHEM BIOPH RES CO, V368, P419, DOI 10.1016/j.bbrc.2008.01.104; Kim SY, 2005, PLANT CELL, V17, P3301, DOI 10.1105/tpc.105.034645; Kizer KO, 2005, MOL CELL BIOL, V25, P3305, DOI 10.1128/MCB.25.8.3305-3316.2005; Klimyuk VI, 1997, PLANT J, V11, P1, DOI 10.1046/j.1365-313X.1997.11010001.x; Kouzarides T, 2007, CELL, V128, P693, DOI 10.1016/j.cell.2007.02.005; Kusnierczyk A, 2007, J EXP BOT, V58, P2537, DOI 10.1093/jxb/erm043; Mayfield JA, 2001, SCIENCE, V292, P2482, DOI 10.1126/science.1060972; Moll C, 2008, PLANT J, V56, P913, DOI 10.1111/j.1365-313X.2008.03650.x; Morris SA, 2005, EUKARYOT CELL, V4, P1446, DOI 10.1128/EC.4.8.1446-1454.2005; Pagnussat GC, 2005, DEVELOPMENT, V132, P603, DOI 10.1242/dev.01595; Park SO, 2005, DEVELOPMENT, V132, P841, DOI 10.1242/dev.01654; Pien S, 2008, PLANT CELL, V20, P580, DOI 10.1105/tpc.108.058172; R Development Core Team, 2007, R LANG ENV STAT COMP; Ratcliffe OJ, 2003, PLANT CELL, V15, P1159, DOI 10.1105/tpc.009506; Robles P, 2005, INT J DEV BIOL, V49, P633, DOI 10.1387/ijdb.052020pr; Rozovskaia T, 1999, MOL CELL BIOL, V19, P6441; Saleh A, 2008, GENE, V423, P43, DOI 10.1016/j.gene.2008.06.022; Saleh A, 2007, NUCLEIC ACIDS RES, V35, P6290, DOI 10.1093/nar/gkm464; Schiefthaler U, 1999, P NATL ACAD SCI USA, V96, P11664, DOI 10.1073/pnas.96.20.11664; Schmitz RJ, 2009, PLANT PHYSIOL, V149, P1196, DOI 10.1104/pp.108.131508; Schneitz K, 1997, DEVELOPMENT, V124, P1367; SCHNEITZ K, 1995, PLANT J, V7, P731, DOI 10.1046/j.1365-313X.1995.07050731.x; SMYTH GK, 2004, STAT APPL GENETICS M, V3; Soppe WJJ, 1999, DEVELOPMENT, V126, P4763; Sorensen AM, 2003, PLANT J, V33, P413, DOI 10.1046/j.1365-313X.2003.01644.x; Stabell M, 2007, BIOCHEM BIOPH RES CO, V359, P784, DOI 10.1016/j.bbrc.2007.05.189; Thorstensen T, 2008, PLANT MOL BIOL, V66, P47, DOI 10.1007/s11103-007-9251-y; Tompa R, 2007, GENETICS, V175, P585, DOI 10.1534/genetics.106.067751; Turner BM, 2002, CELL, V111, P285, DOI 10.1016/S0092-8674(02)01080-2; Vizcay-Barrena G, 2006, J EXP BOT, V57, P2709, DOI 10.1093/jxb/erl032; Wijeratne AJ, 2007, PLANT J, V52, P14, DOI 10.1111/j.1365-313X.2007.03217.x; Xu L, 2008, MOL CELL BIOL, V28, P1348, DOI 10.1128/MCB.01607-07; Yang C, 2007, PLANT CELL, V19, P3530, DOI 10.1105/tpc.107.054981; Zegerman P, 2002, J BIOL CHEM, V277, P11621, DOI 10.1074/jbc.C200045200; Zhao Z, 2005, NAT CELL BIOL, V7, P1256, DOI 10.1038/ncb1329	56	81	87	0	41	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA	1932-6203			PLOS ONE	PLoS One	NOV 12	2009	4	11							e7817	10.1371/journal.pone.0007817	http://dx.doi.org/10.1371/journal.pone.0007817			15	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	518UW	19915673	gold, Green Published, Green Submitted			2022-12-25	WOS:000271721400014
J	Struble, JM; Gill, RT				Struble, Julie M.; Gill, Ryan T.			Genome-Scale Identification Method Applied to Find Cryptic Aminoglycoside Resistance Genes in Pseudomonas aeruginosa	PLOS ONE			English	Article							ESCHERICHIA-COLI; ANTIBIOTIC-RESISTANCE; COMPENSATORY MUTATIONS; EVOLUTION; BINDING; HFQ; GENETICS; SITE; SALMONELLA; MECHANISMS	Background: The ability of bacteria to rapidly evolve resistance to antibiotics is a critical public health problem. Resistance leads to increased disease severity and death rates, as well as imposes pressure towards the discovery and development of new antibiotic therapies. Improving understanding of the evolution and genetic basis of resistance is a fundamental goal in the field of microbiology. Results: We have applied a new genomic method, Scalar Analysis of Library Enrichments (SCALEs), to identify genomic regions that, given increased copy number, may lead to aminoglycoside resistance in Pseudomonas aeruginosa at the genome scale. We report the result of selections on highly representative genomic libraries for three different aminoglycoside antibiotics (amikacin, gentamicin, and tobramycin). At the genome-scale, we show significant (p<0.05) overlap in genes identified for each aminoglycoside evaluated. Among the genomic segments identified, we confirmed increased resistance associated with an increased copy number of several genomic regions, including the ORF of PA5471, recently implicated in MexXY efflux pump related aminoglycoside resistance, PA4943-PA4946 (encoding a probable GTP-binding protein, a predicted host factor I protein, a delta 2-isopentenylpyrophosphate transferase, and DNA mismatch repair protein mutL), PA0960-PA0963 (encoding hypothetical proteins, a probable cold shock protein, a probable DNA-binding stress protein, and aspartyl-tRNA synthetase), a segment of PA4967 (encoding a topoisomerase IV subunit B), as well as a chimeric clone containing two inserts including the ORFs PA0547 and PA2326 (encoding a probable transcriptional regulator and a probable hypothetical protein, respectively). Conclusions: The studies reported here demonstrate the application of new a genomic method, SCALEs, which can be used to improve understanding of the evolution of antibiotic resistance in P. aeruginosa. In our demonstration studies, we identified a significant number of genomic regions that increased resistance to multiple aminoglycosides. We identified genetic regions that include open reading frames that encode for products from many functional categories, including genes related to O-antigen synthesis, DNA repair, and transcriptional and translational processes.			Struble, JM (corresponding author), Univ Colorado, Dept Chem & Biol Engn, Boulder, CO 80309 USA.	rtg@colorado.edu			NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [K25AI064338, R21AI055773] Funding Source: NIH RePORTER; NIAID NIH HHS [R21 AI055773, K25 AI064338, R21 AI055773-01] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BAKKER EP, 1992, J GEN MICROBIOL, V138, P563, DOI 10.1099/00221287-138-3-563; Baquero F, 2001, DRUG RESIST UPDATE, V4, P93, DOI 10.1054/drup.2001.0196; BENVENISTE R, 1973, ANTIMICROB AGENTS CH, V4, P402, DOI 10.1128/AAC.4.4.402; Bjorkman J, 2000, SCIENCE, V287, P1479, DOI 10.1126/science.287.5457.1479; Brown L, 1996, J BACTERIOL, V178, P3763, DOI 10.1128/jb.178.13.3763-3770.1996; Carter AP, 2000, NATURE, V407, P340, DOI 10.1038/35030019; CHANDLER PM, 1974, MUTAT RES, V23, P15, DOI 10.1016/0165-1218(74)90217-1; Choi KH, 2006, J MICROBIOL METH, V64, P391, DOI 10.1016/j.mimet.2005.06.001; Courvalin P, 1999, RES MICROBIOL, V150, P367, DOI 10.1016/S0923-2508(99)80071-0; DAVIS BD, 1986, P NATL ACAD SCI USA, V83, P6164, DOI 10.1073/pnas.83.16.6164; Finn RD, 2006, NUCLEIC ACIDS RES, V34, pD247, DOI 10.1093/nar/gkj149; Fourmy D, 1998, J MOL BIOL, V277, P347, DOI 10.1006/jmbi.1997.1552; Fourmy D, 1996, SCIENCE, V274, P1367, DOI 10.1126/science.274.5291.1367; Frangipani E, 2008, J BACTERIOL, V190, P6706, DOI 10.1128/JB.00450-08; Geissmann TA, 2004, EMBO J, V23, P396, DOI 10.1038/sj.emboj.7600058; Gottesman S, 2006, COLD SPRING HARB SYM, V71, P1, DOI 10.1101/sqb.2006.71.016; Hall BG, 2004, NAT REV MICROBIOL, V2, P430, DOI 10.1038/nrmicro888; HOLLOWAY BW, 1969, BACTERIOL REV, V33, P419, DOI 10.1128/MMBR.33.3.419-443.1969; Hopkins KL, 2005, INT J ANTIMICROB AG, V25, P358, DOI 10.1016/j.ijantimicag.2005.02.006; Horn G, 2007, CELL MOL LIFE SCI, V64, P1457, DOI 10.1007/s00018-007-6388-4; Jacoby GA, 2005, CLIN INFECT DIS, V41, pS120, DOI 10.1086/428052; Kenna DT, 2007, MICROBIOL-SGM, V153, P1852, DOI 10.1099/mic.0.2006/005082-0; Kepler TB, 1998, P NATL ACAD SCI USA, V95, P11514, DOI 10.1073/pnas.95.20.11514; Kerkhoven R, 2004, BIOINFORMATICS, V20, P1812, DOI 10.1093/bioinformatics/bth159; Kohanski MA, 2007, CELL, V130, P797, DOI 10.1016/j.cell.2007.06.049; Lawhorn BG, 2004, J BIOL CHEM, V279, P43555, DOI 10.1074/jbc.M404284200; Lee JK, 2005, INT J ANTIMICROB AG, V25, P290, DOI 10.1016/j.ijantimicag.2004.11.012; Leeb M, 2004, NATURE, V431, P892, DOI 10.1038/431892a; Levin BR, 2000, GENETICS, V154, P985; Lindgren PK, 2005, ANTIMICROB AGENTS CH, V49, P2343, DOI 10.1128/AAC.49.6.2343-2351.2005; Lynch M, 2000, SCIENCE, V290, P1151, DOI 10.1126/science.290.5494.1151; Lynch MD, 2006, BIOTECHNOL BIOENG, V94, P151, DOI 10.1002/bit.20836; Lynch MD, 2007, NAT METHODS, V4, P87, DOI 10.1038/NMETH946; Martinez JL, 2000, ANTIMICROB AGENTS CH, V44, P1771, DOI 10.1128/AAC.44.7.1771-1777.2000; Mathee K, 2008, P NATL ACAD SCI USA, V105, P3100, DOI 10.1073/pnas.0711982105; MATSUNAGA K, 1986, ANTIMICROB AGENTS CH, V30, P468, DOI 10.1128/AAC.30.3.468; Mdluli KE, 2006, ANTIMICROB AGENTS CH, V50, P2178, DOI 10.1128/AAC.00140-06; MILLER GH, 1995, J CHEMOTHERAPY, V7, P17; MINGEOTLECLERCQ M, 1999, ANTIMICROBIAL AGENTS, V43; Morita Y, 2006, J BACTERIOL, V188, P1847, DOI 10.1128/JB.188.5.1847-1855.2006; Muffler A, 1997, J BACTERIOL, V179, P445; NEIDHARDT FC, 1974, J BACTERIOL, V119, P736, DOI 10.1128/JB.119.3.736-747.1974; Normark BH, 2002, J INTERN MED, V252, P91, DOI 10.1046/j.1365-2796.2002.01026.x; NUGENT ME, 1979, NATURE, V282, P422, DOI 10.1038/282422a0; Oyamada Y, 2006, J MED MICROBIOL, V55, P1395, DOI 10.1099/jmm.0.46636-0; Poole K, 2005, ANTIMICROB AGENTS CH, V49, P479, DOI 10.1128/AAC.49.2.479-487.2005; Salipante SJ, 2003, ANTIMICROB AGENTS CH, V47, P3840, DOI 10.1128/AAC.47.12.3840-3845.2003; Schroeder R, 2000, EMBO J, V19, P1, DOI 10.1093/emboj/19.1.1; Sezonov G, 2007, J BACTERIOL, V189, P8746, DOI 10.1128/JB.01368-07; SHAW KJ, 1993, MICROBIOL REV, V57, P138, DOI 10.1128/MMBR.57.1.138-163.1993; Smith EE, 2006, P NATL ACAD SCI USA, V103, P8487, DOI 10.1073/pnas.0602138103; Struble JM, 2006, ANTIMICROB AGENTS CH, V50, P2506, DOI 10.1128/AAC.01640-05; Sun HK, 2007, INT J ANTIMICROB AG, V29, P230, DOI 10.1016/j.ijantimicag.2006.10.004; Tatusov RL, 1997, SCIENCE, V278, P631, DOI 10.1126/science.278.5338.631; Valentin-Hansen P, 2004, MOL MICROBIOL, V51, P1525, DOI 10.1111/j.1365-2958.2003.03935.x; Vytvytska O, 2000, GENE DEV, V14, P1109; Wenzel RP, 2004, NEW ENGL J MED, V351, P523, DOI 10.1056/NEJMp048093; Winsor GL, 2005, NUCLEIC ACIDS RES, V33, pD338, DOI 10.1093/nar/gki047; Yokoyama K, 2003, LANCET, V362, P1888, DOI 10.1016/S0140-6736(03)14959-8; Zhu H, 1999, NUCLEIC ACIDS RES, V27, P910, DOI 10.1093/nar/27.3.910; ZIMELIS VM, 1973, J INFECT DIS, V127, P663, DOI 10.1093/infdis/127.6.663	61	10	11	1	10	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	NOV 11	2009	4	11					A6	A15	e6576	10.1371/journal.pone.0006576	http://dx.doi.org/10.1371/journal.pone.0006576			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	518IX	19907650	Green Submitted, gold, Green Published			2022-12-25	WOS:000271685800001
J	Leu, NA; Kurosaka, S; Kashina, A				Leu, Nicolae Adrian; Kurosaka, Satoshi; Kashina, Anna			Conditional Tek Promoter-Driven Deletion of Arginyltransferase in the Germ Line Causes Defects in Gametogenesis and Early Embryonic Lethality in Mice	PLOS ONE			English	Article							RNA-PROTEIN TRANSFERASE; CYTOSKELETON; OOCYTE; ARGINYLATION; MATURATION	Posttranslational protein arginylation mediated by Ate1 is essential for cardiovascular development, actin cytoskeleton functioning, and cell migration. Ate1 plays a role in the regulation of cytoskeleton and is essential for cardiovascular development and angiogenesis-capillary remodeling driven by in-tissue migration of endothelial cells. To address the role of Ate1 in cytoskeleton-dependent processes and endothelial cell function during development, we produced a conditional mouse knockout with Ate1 deletion driven by Tek endothelial receptor tyrosine kinase promoter expressed in the endothelium and in the germ line. Contrary to expectations, Tek-Ate1 mice were viable and had no visible angiogenesis-related phenotypes; however, these mice showed reproductive defects, with high rates of embryonic lethality in the second generation, at stages much earlier than the complete Ate1 knockout strain. While some of the early lethality originated from the subpopulation of embryos with homozygous Tek-Cre transgene-a problem that has not previously been reported for this commercial mouse strain-a distinct subpopulation of embryos had lethality at early post-implantation stages that could be explained only by a previously unknown defect in gametogenesis originating from Tek-driven Ate1 deletion in premeiotic germs cells. These results demonstrate a novel role of Ate1 in germ cell development.			Leu, NA (corresponding author), Univ Penn, Sch Vet Med, Dept Anim Biol, Philadelphia, PA 19104 USA.	akashina@vet.upenn.edu			NHLBI NIH HHS [R01 HL084419-03, 5R01HL084419, R01 HL084419-02, R01 HL084419] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL084419] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BALZI E, 1990, J BIOL CHEM, V265, P7464; BEMENT WM, 1992, MICROSC RES TECHNIQ, V22, P23, DOI 10.1002/jemt.1070220105; Boiani M, 2002, GENE DEV, V16, P1209, DOI 10.1101/gad.966002; Brunet S, 2005, REPRODUCTION, V130, P801, DOI 10.1530/rep.1.00364; Coticchio G, 2004, ANN NY ACAD SCI, V1034, P132, DOI 10.1196/annals.1335.016; de Lange WJ, 2008, PHYSIOL GENOMICS, V35, P1, DOI 10.1152/physiolgenomics.90284.2008; EVANS EP, 1964, CYTOGENETICS, V3, P289, DOI 10.1159/000129818; Karakozova M, 2006, SCIENCE, V313, P192, DOI 10.1126/science.1129344; Koni PA, 2001, J EXP MED, V193, P741, DOI 10.1084/jem.193.6.741; Kwon YT, 1999, MOL CELL BIOL, V19, P182; Kwon YT, 2002, SCIENCE, V297, P96, DOI 10.1126/science.1069531; Liu PT, 2003, GENOME RES, V13, P476, DOI 10.1101/gr.749203; Patan S, 2000, J NEURO-ONCOL, V50, P1, DOI 10.1023/A:1006493130855; Rai R, 2005, P NATL ACAD SCI USA, V102, P10123, DOI 10.1073/pnas.0504500102; Rai R, 2008, DEVELOPMENT, V135, P3881, DOI 10.1242/dev.022723; Rai R, 2006, EMBO REP, V7, P800, DOI 10.1038/sj.embor.7400747; Sun QY, 2006, REPRODUCTION, V131, P193, DOI 10.1530/rep.1.00847; VANHINSBERGH VW, 2008, CARDIOVASC RES; Wong CCL, 2007, PLOS BIOL, V5, P2231, DOI 10.1371/journal.pbio.0050258; Wong CH, 2005, DEV BIOL, V286, P1, DOI 10.1016/j.ydbio.2005.08.001	20	21	22	0	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	NOV 5	2009	4	11							e7734	10.1371/journal.pone.0007734	http://dx.doi.org/10.1371/journal.pone.0007734			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	515HI	19890395	Green Published, Green Submitted, gold			2022-12-25	WOS:000271459700018
J	Tomita, H; Sugano, E; Fukazawa, Y; Isago, H; Sugiyama, Y; Hiroi, T; Ishizuka, T; Mushiake, H; Kato, M; Hirabayashi, M; Shigemoto, R; Yawo, H; Tamai, M				Tomita, Hiroshi; Sugano, Eriko; Fukazawa, Yugo; Isago, Hitomi; Sugiyama, Yuka; Hiroi, Teru; Ishizuka, Toru; Mushiake, Hajime; Kato, Megumi; Hirabayashi, Masumi; Shigemoto, Ryuichi; Yawo, Hiromu; Tamai, Makoto			Visual Properties of Transgenic Rats Harboring the Channelrhodopsin-2 Gene Regulated by the Thy-1.2 Promoter	PLOS ONE			English	Article							GANGLION-CELLS; PHOTORECEPTOR CELLS; MORPHOMETRIC-ANALYSIS; SPATIAL VISION; RETINA; EXPRESSION; DEGENERATION; ANTIGEN; ADULT; MICE	Channelrhodopsin-2 (ChR2), one of the archea-type rhodopsins from green algae, is a potentially useful optogenetic tool for restoring vision in patients with photoreceptor degeneration, such as retinitis pigmentosa. If the ChR2 gene is transferred to retinal ganglion cells (RGCs), which send visual information to the brain, the RGCs may be repurposed to act as photoreceptors. In this study, by using a transgenic rat expressing ChR2 specifically in the RGCs under the regulation of a Thy-1.2 promoter, we tested the possibility that direct photoactivation of RGCs could restore effective vision. Although the contrast sensitivities of the optomotor responses of transgenic rats were similar to those observed in the wild-type rats, they were enhanced for visual stimuli of low-spatial frequency after the degeneration of native photoreceptors. This result suggests that the visual signals derived from the ChR2-expressing RGCs were reinterpreted by the brain to form behavior-related vision.			Tomita, H (corresponding author), Tohoku Univ, Sendai, Miyagi 980, Japan.	hiroshi-tomita@iiare.tohoku.ac.jp	Hirabayashi, Masumi/C-8935-2019; Fukazawa, Yugo/H-9899-2012; Shigemoto, Ryuichi/E-3628-2013; Tomita, Hiroshi/O-2135-2018; Ishizuka, Toru/L-8191-2017; Yawo, Hiromu/I-4871-2015	Hirabayashi, Masumi/0000-0002-1059-5883; Fukazawa, Yugo/0000-0001-7436-8797; Shigemoto, Ryuichi/0000-0001-8761-9444; Tomita, Hiroshi/0000-0003-1051-2301; Ishizuka, Toru/0000-0003-4405-8792; Yawo, Hiromu/0000-0002-4299-3288; Mushiake, Hajime/0000-0002-5130-4720				BARCLAY AN, 1978, J NEUROCHEM, V31, P1375, DOI 10.1111/j.1471-4159.1978.tb06563.x; BARNSTABLE CJ, 1984, NEUROSCIENCE, V11, P847, DOI 10.1016/0306-4522(84)90195-7; Bi AD, 2006, NEURON, V50, P23, DOI 10.1016/j.neuron.2006.02.026; BRECHA NC, 1994, J COMP NEUROL, V345, P602, DOI 10.1002/cne.903450410; Caroni P, 1997, J NEUROSCI METH, V71, P3, DOI 10.1016/S0165-0270(96)00121-5; DABIN I, 1995, GLIA, V14, P23, DOI 10.1002/glia.440140105; Dowling JE, 1999, BRAIN RES BULL, V50, P317, DOI 10.1016/S0361-9230(99)00154-9; Feng GP, 2000, NEURON, V28, P41, DOI 10.1016/S0896-6273(00)00084-2; FIELDS KL, 1978, CELL, V14, P43, DOI 10.1016/0092-8674(78)90299-4; Hafezi F, 1997, EXP EYE RES, V64, P963, DOI 10.1006/exer.1997.0288; Hartong DT, 2006, LANCET, V368, P1795, DOI 10.1016/S0140-6736(06)69740-7; Hayworth CR, 2008, J TOXICOL ENV HEAL A, V71, P1582, DOI 10.1080/15287390802414190; Huang H, 2005, EXP EYE RES, V80, P727, DOI 10.1016/j.exer.2004.11.019; Humayun MS, 1999, INVEST OPHTH VIS SCI, V40, P143; Huxlin KR, 1997, J COMP NEUROL, V385, P309; Ishizuka T, 2006, NEUROSCI RES, V54, P85, DOI 10.1016/j.neures.2005.10.009; Kaldi I, 2003, MOL VIS, V9, P337; KELLEY KA, 1994, MOL BRAIN RES, V24, P261, DOI 10.1016/0169-328X(94)90139-2; Kerrison JB, 2005, INVEST OPHTH VIS SCI, V46, P2932, DOI 10.1167/iovs.04-1237; KUFFLER SW, 1953, J NEUROPHYSIOL, V16, P37, DOI 10.1152/jn.1953.16.1.37; LAVAIL MM, 1992, P NATL ACAD SCI USA, V89, P11249, DOI 10.1073/pnas.89.23.11249; Leung CKS, 2008, J NEUROSCI METH, V168, P475, DOI 10.1016/j.jneumeth.2007.10.018; Li F, 2001, EXP EYE RES, V73, P569, DOI 10.1006/exer.2001.1068; Li GY, 2007, J NEUROSCI, V27, P203, DOI 10.1523/JNEUROSCI.0445-06.2007; Lin B, 2009, EXP EYE RES, V88, P589, DOI 10.1016/j.exer.2008.11.022; Masland RH, 2001, NAT NEUROSCI, V4, P877, DOI 10.1038/nn0901-877; Masland RH, 2001, CURR OPIN NEUROBIOL, V11, P431, DOI 10.1016/S0959-4388(00)00230-0; MASON DW, 1980, BIOCHEM J, V187, P1; McGill TJ, 2004, INVEST OPHTH VIS SCI, V45, P932, DOI 10.1167/iovs.03-0964; MORRIS RJ, 1977, EUR J IMMUNOL, V7, P360, DOI 10.1002/eji.1830070607; Nagel G, 2003, P NATL ACAD SCI USA, V100, P13940, DOI 10.1073/pnas.1936192100; Nagel G, 2005, CURR BIOL, V15, P2279, DOI 10.1016/j.cub.2005.11.032; Noell W K, 1966, Invest Ophthalmol, V5, P450; PERRY VH, 1984, J NEUROCYTOL, V13, P809, DOI 10.1007/BF01148495; Prusky GT, 2004, INVEST OPHTH VIS SCI, V45, P4611, DOI 10.1167/iovs.04-0541; RAPP LM, 1992, INVEST OPHTH VIS SCI, V33, P3367; Reme CE, 1998, PROG RETIN EYE RES, V17, P443, DOI 10.1016/S1350-9462(98)00009-3; Rockhill RL, 2002, J NEUROSCI, V22, P3831; Santos A, 1997, ARCH OPHTHALMOL-CHIC, V115, P511, DOI 10.1001/archopht.1997.01100150513011; Sato H, 2005, INVEST OPHTH VIS SCI, V46, P791, DOI 10.1167/iovs.04-0867; STONE JL, 1992, ARCH OPHTHALMOL-CHIC, V110, P1634, DOI 10.1001/archopht.1992.01080230134038; Sugano E, 2005, INVEST OPHTH VIS SCI, V46, P3341, DOI 10.1167/iovs.04-1351; Takahashi R, 1999, TRANSGENIC RES, V8, P397, DOI 10.1023/A:1008910629235; Tomita H, 2005, INVEST OPHTH VIS SCI, V46, P427, DOI 10.1167/iovs.04-0946; Tomita H, 2007, INVEST OPHTH VIS SCI, V48, P3821, DOI 10.1167/iovs.06-1501; VIDAL M, 1990, EMBO J, V9, P833, DOI 10.1002/j.1460-2075.1990.tb08180.x; Yin L, 2009, J NEUROSCI, V29, P2706, DOI 10.1523/JNEUROSCI.5471-08.2009	47	106	118	1	9	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	NOV 5	2009	4	11							e7679	10.1371/journal.pone.0007679	http://dx.doi.org/10.1371/journal.pone.0007679			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	515HI	19893752	Green Published, Green Submitted, gold			2022-12-25	WOS:000271459700004
J	Sarrazin, N; Di Blasi, F; Roullot-Lacarriere, V; Rouge-Pont, F; Le Roux, A; Costet, P; Revest, JM; Piazza, PV				Sarrazin, Nadege; Di Blasi, Francesco; Roullot-Lacarriere, Valerie; Rouge-Pont, Francoise; Le Roux, Anne; Costet, Pierre; Revest, Jean-Michel; Piazza, Pier Vincenzo			Transcriptional Effects of Glucocorticoid Receptors in the Dentate Gyrus Increase Anxiety-Related Behaviors	PLOS ONE			English	Article							ELEVATED PLUS-MAZE; LONG-TERM DEPRESSION; SPATIAL MEMORY; SYNAPTIC PLASTICITY; GLUTAMATE UPTAKE; STRESS HORMONES; GENE-EXPRESSION; ANIMAL-MODELS; DNA-BINDING; HIPPOCAMPUS	The Glucocorticoid Receptor (GR) is a transcription factor ubiquitously expressed in the brain. Activation of brain GRs by high levels of glucocorticoid (GC) hormones modifies a large variety of physiological and pathological-related behaviors. Unfortunately the specific cellular targets of GR-mediated behavioral effects of GC are still largely unknown. To address this issue, we generated a mutated form of the GR called Delta GR. Delta GR is a constitutively transcriptionally active form of the GR that is localized in the nuclei and activates transcription without binding to glucocorticoids. Using the tetracycline-regulated system (Tet-OFF), we developed an inducible transgenic approach that allows the expression of the Delta GR in specific brain areas. We focused our study on a mouse line that expressed Delta GR almost selectively in the glutamatergic neurons of the dentate gyrus (DG) of the hippocampus. This restricted expression of the Delta GR increased anxiety-related behaviors without affecting other behaviors that could indirectly influence performance in anxiety-related tests. This behavioral phenotype was also associated with an up-regulation of the MAPK signaling pathway and Egr-1 protein in the DG. These findings identify glutamatergic neurons in the DG as one of the cellular substrate of stress-related pathologies.			Sarrazin, N (corresponding author), INSERM, Pathophysiol Addict Grp, Neuroctr Magendie, U862, Bordeaux, France.	jean-michel.revest@inserm.fr; pier-vincenzo.piazza@inserm.fr		Di Blasi, Francesco/0000-0001-8085-7538				Amir S, 2002, PROG BRAIN RES, V138, P191, DOI 10.1016/S0079-6123(02)38079-8; Baldwin David S, 2002, Psychopharmacol Bull, V36 Suppl 2, P158; Bannerman DM, 2004, NEUROSCI BIOBEHAV R, V28, P273, DOI 10.1016/j.neubiorev.2004.03.004; BARON U, 1995, NUCLEIC ACIDS RES, V23, P3605, DOI 10.1093/nar/23.17.3605; Boyle MP, 2006, J NEUROSCI, V26, P1971, DOI 10.1523/JNEUROSCI.2173-05.2006; Braw Y, 2006, PSYCHONEUROENDOCRINO, V31, P1105, DOI 10.1016/j.psyneuen.2006.07.003; Castagne V, 2009, EUR J PHARMACOL, V616, P128, DOI 10.1016/j.ejphar.2009.06.018; Chen JS, 1998, MOL PHARMACOL, V54, P495, DOI 10.1124/mol.54.3.495; Dalm S, 2005, NEUROENDOCRINOLOGY, V81, P372, DOI 10.1159/000089555; DANIELSEN M, 1986, EMBO J, V5, P2513, DOI 10.1002/j.1460-2075.1986.tb04529.x; de Kloet ER, 1999, TRENDS NEUROSCI, V22, P422, DOI 10.1016/S0166-2236(99)01438-1; De Kloet ER, 1998, ENDOCR REV, V19, P269, DOI 10.1210/er.19.3.269; DEROCHE V, 1993, BRAIN RES, V611, P352, DOI 10.1016/0006-8993(93)90526-S; Drapeau E, 2003, P NATL ACAD SCI USA, V100, P14385, DOI 10.1073/pnas.2334169100; Duclos M, 2009, PSYCHONEUROENDOCRINO, V34, P436, DOI 10.1016/j.psyneuen.2008.10.008; Dulawa SC, 1999, J NEUROSCI, V19, P9550; Eichenbaum H, 2000, NAT REV NEUROSCI, V1, P41, DOI 10.1038/35036213; Einat H, 2003, J NEUROSCI, V23, P7311; File SE, 2001, BEHAV BRAIN RES, V125, P151, DOI 10.1016/S0166-4328(01)00292-3; Fontella FU, 2004, NEUROCHEM RES, V29, P1703, DOI 10.1023/B:NERE.0000035805.46592.6c; FUNDER JW, 1992, J STEROID BIOCHEM, V43, P389, DOI 10.1016/0960-0760(92)90074-S; GANSS R, 1994, EMBO J, V13, P3083, DOI 10.1002/j.1460-2075.1994.tb06607.x; GILAD GM, 1990, BRAIN RES, V525, P335, DOI 10.1016/0006-8993(90)90886-G; Giraldo P, 2001, TRANSGENIC RES, V10, P83, DOI 10.1023/A:1008918913249; Hafezi-Moghadam A, 2002, NAT MED, V8, P473, DOI 10.1038/nm0502-473; Holsboer F, 2000, NEUROPSYCHOPHARMACOL, V23, P477, DOI 10.1016/S0893-133X(00)00159-7; Jovanovic JN, 2000, NAT NEUROSCI, V3, P323, DOI 10.1038/73888; KARPEN GH, 1994, CURR OPIN GENET DEV, V4, P281, DOI 10.1016/S0959-437X(05)80055-3; Kelz MB, 1999, NATURE, V401, P272, DOI 10.1038/45790; KIM JJ, 1992, SCIENCE, V256, P675, DOI 10.1126/science.1585183; Kitchener P, 2004, EUR J NEUROSCI, V19, P1837, DOI 10.1111/j.1460-9568.2004.03267.x; Kolber BJ, 2008, P NATL ACAD SCI USA, V105, P12004, DOI 10.1073/pnas.0803216105; Kolber BJ, 2009, BRAIN RES, V1293, P85, DOI 10.1016/j.brainres.2009.03.061; Krestel HE, 2001, NUCLEIC ACIDS RES, V29, DOI 10.1093/nar/29.7.e39; la Fleur SE, 2006, PHYSIOL BEHAV, V89, P110, DOI 10.1016/j.physbeh.2006.01.028; Lamprea MR, 2000, BEHAV BRAIN RES, V117, P97, DOI 10.1016/S0166-4328(00)00294-1; LOWY MT, 1993, J NEUROCHEM, V61, P1957, DOI 10.1111/j.1471-4159.1993.tb09839.x; LOWY MT, 1995, J NEUROCHEM, V65, P268; Maren S, 1996, NEURON, V16, P237, DOI 10.1016/S0896-6273(00)80041-0; Martin David I. K., 1996, Bioessays, V18, P919, DOI 10.1002/bies.950181111; Martin SJ, 2007, CELL MOL LIFE SCI, V64, P401, DOI 10.1007/s00018-007-6336-3; McEwen BS, 2000, BIOL PSYCHIAT, V48, P721, DOI 10.1016/S0006-3223(00)00964-1; McGaugh JL, 2002, CURR OPIN NEUROBIOL, V12, P205, DOI 10.1016/S0959-4388(02)00306-9; Meldrum BS, 2000, J NUTR, V130, p1007S, DOI 10.1093/jn/130.4.1007S; MOGHADDAM B, 1993, J NEUROCHEM, V60, P1650, DOI 10.1111/j.1471-4159.1993.tb13387.x; Moreira CM, 2007, BRAIN RES BULL, V71, P466, DOI 10.1016/j.brainresbull.2006.10.004; Moser MB, 1998, HIPPOCAMPUS, V8, P608, DOI 10.1002/(SICI)1098-1063(1998)8:6<608::AID-HIPO3>3.0.CO;2-7; Oitzl MS, 1997, EUR J NEUROSCI, V9, P2284, DOI 10.1111/j.1460-9568.1997.tb01646.x; Oitzl MS, 2001, P NATL ACAD SCI USA, V98, P12790, DOI 10.1073/pnas.231313998; PELLOW S, 1985, J NEUROSCI METH, V14, P149, DOI 10.1016/0165-0270(85)90031-7; PHILLIPS RG, 1992, BEHAV NEUROSCI, V106, P274, DOI 10.1037/0735-7044.106.2.274; Piazza PV, 1997, BRAIN RES REV, V25, P359, DOI 10.1016/S0165-0173(97)00025-8; Ponchel F, 2003, BMC BIOTECHNOL, V3, DOI 10.1186/1472-6750-3-18; PORSOLT RD, 1977, ARCH INT PHARMACOD T, V229, P327; Porsolt RD, 2000, REV NEUROSCIENCE, V11, P53; Reichardt HM, 2000, MOL CELL BIOL, V20, P9009, DOI 10.1128/MCB.20.23.9009-9017.2000; Revest JM, 2009, MOL PSYCHIATR, V14, P959, DOI 10.1038/mp.2009.15; Revest JM, 2005, NAT NEUROSCI, V8, P664, DOI 10.1038/nn1441; Sandi C, 1998, NEURAL PLAST, V6, P41, DOI 10.1155/NP.1998.41; Sapolsky RM, 2003, NEUROCHEM RES, V28, P1735, DOI 10.1023/A:1026021307833; Sapolsky RM, 2000, ARCH GEN PSYCHIAT, V57, P925, DOI 10.1001/archpsyc.57.10.925; Sheldon LA, 1999, MOL CELL BIOL, V19, P8146; Spiga F, 2007, J NEUROENDOCRINOL, V19, P891, DOI 10.1111/j.1365-2826.2007.01605.x; Tronche F, 1999, NAT GENET, V23, P99, DOI 10.1038/12703; Tronche F, 1998, CURR OPIN GENET DEV, V8, P532, DOI 10.1016/S0959-437X(98)80007-5; Tsetsenis T, 2007, NAT NEUROSCI, V10, P896, DOI 10.1038/nn1919; Walf AA, 2007, NAT PROTOC, V2, P322, DOI 10.1038/nprot.2007.44; Wei Q, 2004, P NATL ACAD SCI USA, V101, P11851, DOI 10.1073/pnas.0402208101; WILSON C, 1990, ANNU REV CELL BIOL, V6, P679, DOI 10.1146/annurev.cellbio.6.1.679; Wong TP, 2007, P NATL ACAD SCI USA, V104, P11471, DOI 10.1073/pnas.0702308104; Xu L, 1998, P NATL ACAD SCI USA, V95, P3204, DOI 10.1073/pnas.95.6.3204; Yang CH, 2005, J NEUROSCI, V25, P4288, DOI 10.1523/JNEUROSCI.0406-05.2005; Yang CH, 2004, J NEUROSCI, V24, P11029, DOI 10.1523/JNEUROSCI.3968-04.2004; Yun JJ, 2006, NUCLEIC ACIDS RES, V34, P6718, DOI 10.1093/nar/gkl1020	74	21	21	0	7	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	NOV 2	2009	4	11							e7704	10.1371/journal.pone.0007704	http://dx.doi.org/10.1371/journal.pone.0007704			14	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	514RX	19888328	Green Published, gold, Green Submitted			2022-12-25	WOS:000271414400012
J	Hayashi, H; Cuddy, M; Shu, VCW; Yip, KW; Madiraju, C; Diaz, P; Matsuyama, T; Kaibara, M; Taniyama, K; Vasile, S; Sergienko, E; Reed, JC				Hayashi, Hideki; Cuddy, Michael; Shu, Vincent Chih-Wen; Yip, Kenneth W.; Madiraju, Charitha; Diaz, Paul; Matsuyama, Toshifumi; Kaibara, Muneshige; Taniyama, Kohtaro; Vasile, Stefan; Sergienko, Eduard; Reed, John C.			Versatile Assays for High Throughput Screening for Activators or Inhibitors of Intracellular Proteases and Their Cellular Regulators	PLOS ONE			English	Article							SACCHAROMYCES-CEREVISIAE; DEATH DOMAIN; YEAST; APOPTOSIS; CASPASES; RECEPTOR; AUTOPHAGY; PROTEINS; FAMILY; CED-3	Background: Intracellular proteases constitute a class of promising drug discovery targets. Methods for high throughput screening against these targets are generally limited to in vitro biochemical assays that can suffer many technical limitations, as well as failing to capture the biological context of proteases within the cellular pathways that lead to their activation. Methods & Findings: We describe here a versatile system for reconstituting protease activation networks in yeast and assaying the activity of these pathways using a cleavable transcription factor substrate in conjunction with reporter gene read-outs. The utility of these versatile assay components and their application for screening strategies was validated for all ten human Caspases, a family of intracellular proteases involved in cell death and inflammation, including implementation of assays for high throughput screening (HTS) of chemical libraries and functional screening of cDNA libraries. The versatility of the technology was also demonstrated for human autophagins, cysteine proteases involved in autophagy. Conclusions: Altogether, the yeast-based systems described here for monitoring activity of ectopically expressed mammalian proteases provide a fascile platform for functional genomics and chemical library screening.			Hayashi, H (corresponding author), Burnham Inst Med Res, La Jolla, CA 92037 USA.	Reedoffice@burnham.org		Hayashi, Hideki/0000-0003-4585-6542; Shu, Chih-Wen/0000-0002-7774-0002	NIAID NIH HHS [U01 AI078048, U01-AI078048, R01 AI082629, R01-AI082629] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI082629, U01AI078048] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Bakshi P, 2005, J BIOMOL SCREEN, V10, P1, DOI 10.1177/1087057104270068; Bao Q, 2007, MOL CELL, V25, P181, DOI 10.1016/j.molcel.2006.12.013; Brachmann CB, 1998, YEAST, V14, P115; Chang CI, 2009, MOL THER, V17, P725, DOI 10.1038/mt.2008.298; CHINNAIYAN AM, 1995, CELL, V81, P505, DOI 10.1016/0092-8674(95)90071-3; CHRISTIANSON TW, 1992, GENE, V110, P119, DOI 10.1016/0378-1119(92)90454-W; Cirman T, 2004, J BIOL CHEM, V279, P3578, DOI 10.1074/jbc.M308347200; Edbauer D, 2003, NAT CELL BIOL, V5, P486, DOI 10.1038/ncb960; ESTOJAK J, 1995, MOL CELL BIOL, V15, P5820; Faustin B, 2007, MOL CELL, V25, P713, DOI 10.1016/j.molcel.2007.01.032; Hawkins CJ, 1999, P NATL ACAD SCI USA, V96, P2885, DOI 10.1073/pnas.96.6.2885; Hawkins CJ, 2001, APOPTOSIS, V6, P331, DOI 10.1023/A:1011329917895; Ho PK, 2005, FEBS J, V272, P1401, DOI 10.1111/j.1742-4658.2005.04573.x; Irmler M, 1997, NATURE, V388, P190, DOI 10.1038/40657; ITOH N, 1991, CELL, V66, P233, DOI 10.1016/0092-8674(91)90614-5; Jabbour AM, 2004, CELL DEATH DIFFER, V11, P1309, DOI 10.1038/sj.cdd.4401501; Jabbour AM, 2006, J CELL SCI, V119, P2572, DOI 10.1242/jcs.02985; Jiang XJ, 2004, ANNU REV BIOCHEM, V73, P87, DOI 10.1146/annurev.biochem.73.011303.073706; Kabeya Y, 2005, MOL BIOL CELL, V16, P2544, DOI 10.1091/mbc.e04-08-0669; Kang JJ, 1999, J BIOL CHEM, V274, P3189, DOI 10.1074/jbc.274.5.3189; Kim SY, 2004, MOL BIOTECHNOL, V27, P1, DOI 10.1385/MB:27:1:01; Kirisako T, 2000, J CELL BIOL, V151, P263, DOI 10.1083/jcb.151.2.263; Li J, 2008, ONCOGENE, V27, P6194, DOI 10.1038/onc.2008.297; Marino G, 2003, J BIOL CHEM, V278, P3671, DOI 10.1074/jbc.M208247200; Martinon F, 2007, CELL DEATH DIFFER, V14, P10, DOI 10.1038/sj.cdd.4402038; Marx J, 2006, SCIENCE, V312, P1160, DOI 10.1126/science.312.5777.1160; Mizushima N, 2008, NATURE, V451, P1069, DOI 10.1038/nature06639; MUMBERG D, 1995, GENE, V156, P119, DOI 10.1016/0378-1119(95)00037-7; Pan GH, 1997, SCIENCE, V277, P815, DOI 10.1126/science.277.5327.815; Pan GH, 1997, SCIENCE, V276, P111, DOI 10.1126/science.276.5309.111; Puryer MA, 2006, APOPTOSIS, V11, P509, DOI 10.1007/s10495-006-5114-2; Ryser S, 1999, CURR GENET, V36, P21, DOI 10.1007/s002940050468; Sheridan JP, 1997, SCIENCE, V277, P818, DOI 10.1126/science.277.5327.818; SIKORSKI RS, 1989, GENETICS, V122, P19; Silke J, 2001, EMBO J, V20, P3114, DOI 10.1093/emboj/20.12.3114; Slee EA, 1999, J CELL BIOL, V144, P281, DOI 10.1083/jcb.144.2.281; Stagljar I, 1998, P NATL ACAD SCI USA, V95, P5187, DOI 10.1073/pnas.95.9.5187; Thornberry NA, 1997, J BIOL CHEM, V272, P17907, DOI 10.1074/jbc.272.29.17907; Timmer JC, 2007, CELL DEATH DIFFER, V14, P66, DOI 10.1038/sj.cdd.4402059; Walczak H, 1997, EMBO J, V16, P5386, DOI 10.1093/emboj/16.17.5386; Westein SJ, 2008, BBA-MOL CELL RES, V1783, P448, DOI 10.1016/j.bbamcr.2007.10.003; Wright ME, 1999, FEBS LETT, V446, P9, DOI 10.1016/S0014-5793(99)00159-3; Wright ME, 2000, FEBS LETT, V481, P13, DOI 10.1016/S0014-5793(00)01962-1; Xiao F, 2007, NUCLEIC ACIDS RES, V35, DOI 10.1093/nar/gkm486; Zhang H, 2001, METHOD CELL BIOL, V66, P453	45	14	15	0	9	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	OCT 30	2009	4	10							e7655	10.1371/journal.pone.0007655	http://dx.doi.org/10.1371/journal.pone.0007655			18	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	514RW	19876397	Green Submitted, gold, Green Published			2022-12-25	WOS:000271414300011
J	Gleissman, H; Yang, R; Martinod, K; Lindskog, M; Serhan, CN; Johnsen, JI; Kogner, P				Gleissman, Helena; Yang, Rong; Martinod, Kimberly; Lindskog, Magnus; Serhan, Charles N.; Johnsen, John Inge; Kogner, Per			Docosahexaenoic acid metabolome in neural tumors: identification of cytotoxic intermediates	FASEB JOURNAL			English	Article						neuroblastoma; docosanoids; lipidomics; omega-3 fatty acids; cancer	N-3 FATTY-ACIDS; CANCER-CELL-GROWTH; IN-VIVO; COLON-CANCER; OXIDATIVE STRESS; LIPID MEDIATORS; TRANSGENIC MICE; RESOLVIN D1; APOPTOSIS; NEUROBLASTOMA	Docosahexaenoic acid (DHA) protects neural cells from stress-induced apoptosis. On the contrary, DHA exerts anticancer effects, and we have shown that DHA induces apoptosis in neuroblastoma, an embryonal tumor of the sympathetic nervous system. We now investigate the DHA metabolome in neuroblastoma using a targeted lipidomic approach in order to elucidate the mechanisms behind the DHA-induced cytotoxicity. LC-MS/MS analysis was used to identify DHA-derived lipid mediators in neuroblastoma cells. Presence of the 15-lipoxygenase enzyme was investigated using immunoblotting, and cytotoxic potency of DHA and DHA-derived compounds was compared using the MTT cell viability assay. Neuroblastoma cells metabolized DHA to 17-hydroxydocosahexaenoic acid (17-HDHA) via 17-hydroperoxydocosahexaenoic acid (17-HpDHA) through 15-lipoxygenase and autoxidation. In contrast to normal neural cells, neuroblastoma cells did not produce the anti-inflammatory and protective lipid mediators, resolvins and protectins. 17-HpDHA had significant cytotoxic potency, with an IC(50) of 3-6 mu M at 72 h, compared to 12-15 mu M for DHA. alpha-Tocopherol protected cells from 17-HpDHA-induced cytotoxicity. DHA inhibited secretion of prostaglandin-E(2) and augmented the cytotoxic potency of the cyclooxygenase-2-inhibitor celecoxib. The cytotoxic effect of DHA in neuroblastoma is mediated through production of hydroperoxy fatty acids that accumulate to toxic intracellular levels with restricted production of its products, resolvins and protectins.-Gleissman, H., Yang, R., Martinod, K., Lindskog, M., Serhan, C. N., Johnsen, J. I., Kogner, P. Docosahexaenoic acid metabolome in neural tumors: identification of cytotoxic intermediates. FASEB J. 24, 906-915 (2010). www.fasebj.org	[Gleissman, Helena; Lindskog, Magnus; Johnsen, John Inge; Kogner, Per] Astrid Lindgren Childrens Hosp, Childhood Canc Res Unit, Dept Woman & Child Hlth, Karolinska Inst, S-17176 Stockholm, Sweden; [Yang, Rong; Martinod, Kimberly; Serhan, Charles N.] Brigham & Womens Hosp, Ctr Expt Therapeut & Reperfus Injury, Dept Anesthesiol Perioperat & Pain Med, Boston, MA 02115 USA; [Yang, Rong; Martinod, Kimberly; Serhan, Charles N.] Harvard Univ, Sch Med, Boston, MA USA	Karolinska Institutet; Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School	Gleissman, H (corresponding author), Astrid Lindgren Childrens Hosp, Childhood Canc Res Unit, Dept Woman & Child Hlth, Karolinska Inst, Q6-05, S-17176 Stockholm, Sweden.	helena.gleissman@ki.se	Yang, Rong/ABA-7587-2021; Martinod, Kimberly/K-4742-2019	Martinod, Kimberly/0000-0002-1026-6107; Johnsen, John Inge/0000-0003-1277-812X; Yang, Rong/0000-0001-8837-0089; Kogner, Per/0000-0002-2202-9694	Swedish Childhood Cancer Foundation; Swedish Research Council; Swedish Cancer Society; Cystic Fibrosis Foundation; Erik and Edith Fernstrom's Foundation for Medical Research; U.S. National Institutes of Health [GM38765, DK074448, P50-DE016191]; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [P50DE016191] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK074448] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM038765, R01GM038765, R29GM038765] Funding Source: NIH RePORTER	Swedish Childhood Cancer Foundation(European Commission); Swedish Research Council(Swedish Research CouncilEuropean Commission); Swedish Cancer Society(Swedish Cancer Society); Cystic Fibrosis Foundation(Italian Cystic Fibrosis Research Foundation); Erik and Edith Fernstrom's Foundation for Medical Research; U.S. National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	The authors thank Prof. Mats Hamberg (Karolinska Institutet, Stockholm, Sweden) for critical scientific input and help with the steric analyses and Prof. Hans-Erik Claesson (Karolinska Institutet, Stockholm, Sweden) for kindly providing the 15-LOX type 1 antibody. This project was supported by the Swedish Childhood Cancer Foundation, the Swedish Research Council, the Swedish Cancer Society, the Cystic Fibrosis Foundation, Erik and Edith Fernstrom's Foundation for Medical Research, and U.S. National Institutes of Health grants GM38765, DK074448, and P50-DE016191 (C.N.S.). The authors also thank P. Pillai, S. Oh, S. Krishnamoorthy, A. Recchiuti, and L. Elfman for excellent technical assistance.	Akbar M, 2002, J NEUROCHEM, V82, P655, DOI 10.1046/j.1471-4159.2002.01015.x; Baryawno N, 2008, NEURO-ONCOLOGY, V10, P661, DOI 10.1215/15228517-2008-035; Bazan NG, 2005, MOL NEUROBIOL, V32, P89, DOI 10.1385/MN:32:1:089; Berquin IM, 2008, CANCER LETT, V269, P363, DOI 10.1016/j.canlet.2008.03.044; Brown MD, 2006, BRIT J CANCER, V94, P842, DOI 10.1038/sj.bjc.6603030; Calder PC, 2007, PROSTAG LEUKOTR ESS, V77, P327, DOI 10.1016/j.plefa.2007.10.015; Crean C, 2009, CHEM-EUR J, V15, P10634, DOI 10.1002/chem.200900500; Dommels YEM, 2003, CARCINOGENESIS, V24, P385, DOI 10.1093/carcin/24.3.385; Girotti AW, 1998, J LIPID RES, V39, P1529; Gomez-Pinilla F, 2008, NAT REV NEUROSCI, V9, P568, DOI 10.1038/nrn2421; Hanebutt FL, 2008, CLIN NUTR, V27, P685, DOI 10.1016/j.clnu.2008.05.010; Hong S, 2007, J AM SOC MASS SPECTR, V18, P128, DOI 10.1016/j.jasms.2006.09.002; Hossain Z, 2009, NUTR CANCER, V61, P123, DOI 10.1080/01635580802395725; Jahn U, 2008, ANGEW CHEM INT EDIT, V47, P5894, DOI 10.1002/anie.200705122; Jia Q, 2008, CANCER RES, V68, P3985, DOI 10.1158/0008-5472.CAN-07-6251; Johnsen JI, 2004, CANCER RES, V64, P7210, DOI 10.1158/0008-5472.CAN-04-1795; Johnsen J, 2009, APOPTOSIS, V14, P424, DOI 10.1007/s10495-009-0325-y; Jones GR, 2008, J ANAL TOXICOL, V32, P183, DOI 10.1093/jat/32.2.183; Khan NA, 2006, J LIPID RES, V47, P2306, DOI 10.1194/jlr.M600269-JLR200; Kokoglu E, 1998, Cancer Biochem Biophys, V16, P301; Koletzko B, 2007, BRIT J NUTR, V98, P873, DOI 10.1017/S0007114507764747; Krishnamoorthy Sriram, 2008, V49, P145, DOI 10.1007/978-1-4020-8831-5_6; Larsson SC, 2004, AM J CLIN NUTR, V79, P935; LEPAGE G, 1986, J LIPID RES, V27, P114; Lindskog M, 2006, INT J CANCER, V118, P2584, DOI 10.1002/ijc.21555; Liu XB, 2008, J CLIN BIOCHEM NUTR, V43, P26, DOI 10.3164/jcbn.2008040; Lu Y, 2008, MOL CANCER THER, V7, P3203, DOI 10.1158/1535-7163.MCT-08-0494; Mantovani A, 2008, NATURE, V454, P436, DOI 10.1038/nature07205; Marcheselli VL, 2003, J BIOL CHEM, V278, P43807, DOI 10.1074/jbc.M305841200; Martin DD, 1996, LIPIDS, V31, P1283, DOI 10.1007/BF02587914; Moyad MA, 2005, UROL ONCOL-SEMIN ORI, V23, P36, DOI 10.1016/j.urolonc.2005.03.001; Mukherjee PK, 2004, P NATL ACAD SCI USA, V101, P8491, DOI 10.1073/pnas.0402531101; Mukutmoni-Norris M, 2000, CANCER LETT, V150, P101, DOI 10.1016/S0304-3835(99)00380-8; Piomelli D, 2007, NAT REV NEUROSCI, V8, P743, DOI 10.1038/nrn2233; Ponthan F, 2007, CLIN CANCER RES, V13, P1036, DOI 10.1158/1078-0432.CCR-06-1908; Reynolds LM, 2001, NEUROSCI LETT, V309, P193, DOI 10.1016/S0304-3940(01)02071-7; Rose DP, 1999, INT J ONCOL, V15, P1011; Serhan CN, 2008, NAT REV IMMUNOL, V8, P349, DOI 10.1038/nri2294; Serhan CN, 2008, ANNU REV PATHOL-MECH, V3, P279, DOI 10.1146/annurev.pathmechdis.3.121806.151409; Serhan CN, 2006, AAPS J, V8, pE284; Serhan CN, 2004, LIPIDS, V39, P1125, DOI 10.1007/s11745-004-1339-7; Serhan CN, 2002, J EXP MED, V196, P1025, DOI 10.1084/jem.20020760; Serini S, 2008, APOPTOSIS, V13, P1172, DOI 10.1007/s10495-008-0246-1; Siddiqui RA, 2008, CHEM PHYS LIPIDS, V153, P47, DOI 10.1016/j.chemphyslip.2008.02.009; Sun H, 2008, CANCER RES, V68, P2912, DOI 10.1158/0008-5472.CAN-07-2305; Sun YP, 2007, J BIOL CHEM, V282, P9323, DOI 10.1074/jbc.M609212200; Sveinbjornsson B, 2008, FASEB J, V22, P3525, DOI 10.1096/fj.07-103457; Swamy MV, 2004, MOL CANCER THER, V3, P215; Wang MT, 2007, CANCER METAST REV, V26, P525, DOI 10.1007/s10555-007-9096-5; Wolk A, 2006, JAMA-J AM MED ASSOC, V296, P1371, DOI 10.1001/jama.296.11.1371; Xia SH, 2006, P NATL ACAD SCI USA, V103, P12499, DOI 10.1073/pnas.0605394103; Yin HY, 2005, J BIOL CHEM, V280, P26600, DOI 10.1074/jbc.M503088200	52	74	78	0	15	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	MAR	2010	24	3					906	915		10.1096/fj.09-137919	http://dx.doi.org/10.1096/fj.09-137919			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	561KE	19890019	Green Published			2022-12-25	WOS:000274974600026
J	Scheller, H; Tobollik, S; Kutzera, A; Eder, M; Unterlehberg, J; Pfeil, I; Jungnickel, B				Scheller, H.; Tobollik, S.; Kutzera, A.; Eder, M.; Unterlehberg, J.; Pfeil, I.; Jungnickel, B.			c-Myc overexpression promotes a germinal center-like program in Burkitt's lymphoma	ONCOGENE			English	Article						somatic hypermutation; germinal center; Burkitt's lymphoma; c-Myc	INDUCED CYTIDINE DEAMINASE; B-CELL LYMPHOMAS; SOMATIC HYPERMUTATION; IMMUNOGLOBULIN ENHANCERS; ANTIGEN RECEPTOR; ACTIVATION; GENE; EXPRESSION; BCL-6; REGION	The germinal center (GC) reaction has a pivotal function in human B-cell lymphomagenesis. Genetic aberrations occurring during somatic hypermutation and class switch recombination deregulate key factors controlling B-cell physiology and proliferation. Several human lymphoma entities are characterized by a constitutive GC phenotype and ongoing somatic hypermutation, but the molecular basis for this phenomenon is only partly understood. We have investigated the reasons for a constitutive GC-like program in Burkitt's lymphoma cells. Here, overexpression of c-Myc leads to a centroblast phenotype, promotes high constitutive expression of the key GC factors Bcl-6, E2A and activation-induced cytidine deaminase and contributes to proliferation and somatic hypermutation. Our findings elucidate how the activity of a pivotal transcription factor may freeze B-cell lymphoma cells in a constitutive GC-like state that is even maintained at an extrafollicular location. Oncogene (2010) 29, 888-897; doi:10.1038/onc.2009.377; published online 2 November 2009	[Scheller, H.; Tobollik, S.; Kutzera, A.; Eder, M.; Unterlehberg, J.; Pfeil, I.; Jungnickel, B.] German Res Ctr Environm Hlth, Helmholtz Ctr Munich, Inst Clin Mol Biol, D-81377 Munich, Germany	Helmholtz Association; Helmholtz-Center Munich - German Research Center for Environmental Health	Jungnickel, B (corresponding author), German Res Ctr Environm Hlth, Helmholtz Ctr Munich, Inst Clin Mol Biol, Marchioninistr 25, D-81377 Munich, Germany.	jungnickel@helmholtz-muenchen.de	Scheller, Henrik/AAH-4770-2020; Jungnickel, Berit/AAU-5297-2021	Scheller, Henrik/0000-0002-6702-3560; 	German Jose Carreras Leukemia Foundation [SP/03/10, R05/10v]; Wilhelm Sander foundation [2003.046.2]; Deutsche Forschungsgemeinschaft [TRR54-TPA4]	German Jose Carreras Leukemia Foundation; Wilhelm Sander foundation; Deutsche Forschungsgemeinschaft(German Research Foundation (DFG))	We thank Sabine Fischer-Burkart for expert technical assistance, Torsten Thiel for contributions to the RNAi system, Maren Mierau and Dirk Eick for discussion and support, and Ursula Zimber-Strobl, Georg Bornkamm and Ralf Kuppers for critical reading of the manuscript. This work was supported by grants from the German Jose Carreras Leukemia Foundation (SP/03/10 and R05/10v), the Wilhelm Sander foundation (2003.046.2) and the Deutsche Forschungsgemeinschaft (TRR54-TPA4).	ADAMS JM, 1985, NATURE, V318, P533, DOI 10.1038/318533a0; ADAMS JM, 1983, P NATL ACAD SCI-BIOL, V80, P1982, DOI 10.1073/pnas.80.7.1982; AIELLO A, 1990, HEMATOL ONCOL, V8, P229, DOI 10.1002/hon.2900080407; Bachl J, 1999, EUR J IMMUNOL, V29, P1383, DOI 10.1002/(SICI)1521-4141(199904)29:04<1383::AID-IMMU1383>3.3.CO;2-O; Cattoretti G, 2005, CANCER CELL, V7, P445, DOI 10.1016/j.ccr.2005.03.037; Chapman CJ, 1998, LEUKEMIA LYMPHOMA, V30, P257, DOI 10.3109/10428199809057539; Chesi M, 2008, CANCER CELL, V13, P167, DOI 10.1016/j.ccr.2008.01.007; Cole MD, 2008, NAT REV MOL CELL BIO, V9, P810, DOI 10.1038/nrm2467; DALLAFAVERA R, 1982, P NATL ACAD SCI-BIOL, V79, P7824, DOI 10.1073/pnas.79.24.7824; Dedeoglu F, 2004, INT IMMUNOL, V16, P395, DOI 10.1093/intimm/dxh042; Di Nola JM, 2007, ANNU REV BIOCHEM, V76, P1, DOI 10.1146/annurev.biochem.76.061705.090740; Faili A, 2002, NAT IMMUNOL, V3, P815, DOI 10.1038/ni826; Gavioli R, 2001, NAT CELL BIOL, V3, P283, DOI 10.1038/35060076; Honjo T, 2002, ANNU REV IMMUNOL, V20, P165, DOI 10.1146/annurev.immunol.20.090501.112049; JOHNSTON JM, 1991, BLOOD, V78, P2419; Khuda SE, 2008, J IMMUNOL, V181, P7537, DOI 10.4049/jimmunol.181.11.7537; KLEIN U, 1995, MOL MED, V1, P495, DOI 10.1007/BF03401587; Klein U, 2003, P NATL ACAD SCI USA, V100, P2639, DOI 10.1073/pnas.0437996100; Klein U, 1998, IMMUNOL REV, V162, P261; Kovalchuk AL, 2000, J EXP MED, V192, P1183, DOI 10.1084/jem.192.8.1183; Kuppers R, 1999, NEW ENGL J MED, V341, P1520; Kuppers R, 2001, ONCOGENE, V20, P5580, DOI 10.1038/sj.onc.1204640; Lee SC, 2006, MOL IMMUNOL, V43, P1965, DOI 10.1016/j.molimm.2005.11.017; Liu M, 2008, NATURE, V451, P841, DOI 10.1038/nature06547; MartinezValdez H, 1996, J EXP MED, V183, P971, DOI 10.1084/jem.183.3.971; Mierau M, 2008, NUCLEIC ACIDS RES, V36, P5591, DOI 10.1093/nar/gkn542; Niu HF, 1998, GENE DEV, V12, P1953, DOI 10.1101/gad.12.13.1953; Pajic A, 2001, INT J CANCER, V93, P810, DOI 10.1002/ijc.1404; Pasqualucci L, 2003, BLOOD, V101, P2914, DOI 10.1182/blood-2002-11-3387; Pasqualucci L, 2001, NATURE, V412, P341, DOI 10.1038/35085588; Pasqualucci L, 1998, P NATL ACAD SCI USA, V95, P11816, DOI 10.1073/pnas.95.20.11816; Polack A, 1996, P NATL ACAD SCI USA, V93, P10411, DOI 10.1073/pnas.93.19.10411; POLACK A, 1993, EMBO J, V12, P3913, DOI 10.1002/j.1460-2075.1993.tb06069.x; Rajewsky K, 1996, NATURE, V381, P751, DOI 10.1038/381751a0; Refaeli Y, 2008, PLOS BIOL, V6, P1208, DOI 10.1371/journal.pbio.0060152; Ruckerl F, 2006, MOL IMMUNOL, V43, P1645, DOI 10.1016/j.molimm.2005.09.011; Rutherford MN, 1998, AM J PATHOL, V153, P165, DOI 10.1016/S0002-9440(10)65557-5; Saito M, 2007, CANCER CELL, V12, P280, DOI 10.1016/j.ccr.2007.08.011; Sayegh CE, 2003, NAT IMMUNOL, V4, P586, DOI 10.1038/ni923; Schoetz U, 2006, J IMMUNOL, V177, P395, DOI 10.4049/jimmunol.177.1.395; Schuhmacher M, 2001, NUCLEIC ACIDS RES, V29, P397, DOI 10.1093/nar/29.2.397; Shaffer AL, 2001, IMMUNITY, V15, P375, DOI 10.1016/S1074-7613(01)00194-7; Shen HM, 1998, SCIENCE, V280, P1750, DOI 10.1126/science.280.5370.1750; Teng G, 2008, IMMUNITY, V28, P621, DOI 10.1016/j.immuni.2008.03.015; Thorley-Lawson DA, 2008, NAT REV MICROBIOL, V6, P913, DOI 10.1038/nrmicro2015; Toyama H, 2002, IMMUNITY, V17, P329, DOI 10.1016/S1074-7613(02)00387-4; Wagner SD, 2007, LEUKEMIA LYMPHOMA, V48, P1510, DOI 10.1080/10428190701458491; Wang CL, 2005, J IMMUNOL, V174, P5650, DOI 10.4049/jimmunol.174.9.5650; Yin XY, 2003, ONCOGENE, V22, P6151, DOI 10.1038/sj.onc.1206641; Yoshikawa K, 2002, SCIENCE, V296, P2033, DOI 10.1126/science.1071556; Zhang W, 2001, INT IMMUNOL, V13, P1175, DOI 10.1093/intimm/13.9.1175	51	18	18	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 11	2010	29	6					888	897		10.1038/onc.2009.377	http://dx.doi.org/10.1038/onc.2009.377			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	553WP	19881537				2022-12-25	WOS:000274397800011
J	Palencia, A; Camara-Artigas, A; Pisabarro, MT; Martinez, JC; Luque, I				Palencia, Andres; Camara-Artigas, Ana; Pisabarro, M. Teresa; Martinez, Jose C.; Luque, Irene			Role of Interfacial Water Molecules in Proline-rich Ligand Recognition by the Src Homology 3 Domain of Abl	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-PROTEIN-INTERACTION; SH3 DOMAINS; CRYSTAL-STRUCTURE; BINDING-AFFINITY; ABL-SH3 DOMAIN; FAMILY; THERMODYNAMICS; COMPLEXES; PEPTIDES; TARGETS	The interaction of Abl-Src homology 3 domain (SH3) with the high affinity peptide p41 is the most notable example of the inconsistency existing between the currently accepted description of SH3 complexes and their binding thermodynamic signature. We had previously hypothesized that the presence of interfacial water molecules is partially responsible for this thermodynamic behavior. We present here a thermodynamic, structural, and molecular dynamics simulation study of the interaction of p41 with Abl-SH3 and a set of mutants designed to alter the water-mediated interaction network. Our results provide a detailed description of the dynamic properties of the interfacial water molecules and a molecular interpretation of the thermodynamic effects elicited by the mutations in terms of the modulation of the water-mediated hydrogen bond network. In the light of these results, a new dual binding mechanism is proposed that provides a better description of proline-rich ligand recognition by Abl-SH3 and that has important implications for rational design.	[Palencia, Andres; Martinez, Jose C.; Luque, Irene] Univ Granada, Fac Sci, Dept Phys Chem, E-18071 Granada, Spain; [Palencia, Andres; Martinez, Jose C.; Luque, Irene] Univ Granada, Fac Sci, Inst Biotechnol, E-18071 Granada, Spain; [Camara-Artigas, Ana] Univ Almeria, Dept Phys Chem Biochem & Inorgan Chem, Almeria 04120, Spain; [Pisabarro, M. Teresa] BIOTEC TU Dresden, D-01307 Dresden, Germany	University of Granada; University of Granada; Universidad de Almeria; Technische Universitat Dresden	Luque, I (corresponding author), Univ Granada, Fac Sci, Dept Phys Chem, E-18071 Granada, Spain.	iluque@ugr.es	Martinez, Jose C./J-8721-2012; Pisabarro, M. Teresa/D-4270-2012; Luque, Irene/K-4758-2012; Luque, Inmaculada/K-9464-2014; Palencia, Andrés/F-4257-2017; Camara-Artigas, Ana/M-2252-2019	Martinez, Jose C./0000-0003-2657-2456; Luque, Irene/0000-0003-2757-4779; Luque, Inmaculada/0000-0003-1838-2636; Palencia, Andrés/0000-0002-1805-319X; Camara-Artigas, Ana/0000-0003-2197-726X	Spanish Ministry of Education and Sciences [BIO2006-15517-C02-01, BIO2006-15517-C02-02]; European Union [03-51-5569 INTAS]; Andalusian Government [FQM-171, BIO-292]; Klaus Tschira Stiftung; Spanish Ministry of Education and Sciences; FEBS fellowship	Spanish Ministry of Education and Sciences(Spanish Government); European Union(European Commission); Andalusian Government; Klaus Tschira Stiftung; Spanish Ministry of Education and Sciences(Spanish Government); FEBS fellowship	This work was supported in part by Grants BIO2006-15517-C02-01 and BIO2006-15517-C02-02 from the Spanish Ministry of Education and Sciences, 03-51-5569 INTAS from the European Union, grants to the research teams FQM-171 and BIO-292 from the Andalusian Government, and the Klaus Tschira Stiftung.; Supported by a predoctoral research contract from the Spanish Ministry of Education and Sciences and the recipient of a short term FEBS fellowship. Present address: European Molecular Biology Laboratory, 6 Rue Jules Horowitz, BP 181, 38042 Grenoble, France.	Arold S, 1998, BIOCHEMISTRY-US, V37, P14683, DOI 10.1021/bi980989q; Ball LJ, 2005, ANGEW CHEM INT EDIT, V44, P2852, DOI 10.1002/anie.200400618; Camara-Artigas A, 2007, ACTA CRYSTALLOGR D, V63, P646, DOI 10.1107/S0907444907011109; Casares S, 2007, BMC STRUCT BIOL, V7, DOI 10.1186/1472-6807-7-22; Dalgarno DC, 1997, BIOPOLYMERS, V43, P383; Emsley P, 2004, ACTA CRYSTALLOGR D, V60, P2126, DOI 10.1107/S0907444904019158; Feller SM, 2006, CURR PHARM DESIGN, V12, P529, DOI 10.2174/138161206775474369; Ferreon JC, 2004, BIOCHEMISTRY-US, V43, P7787, DOI 10.1021/bi049752m; Filimonov VV, 1999, BIOPHYS CHEM, V77, P195, DOI 10.1016/S0301-4622(99)00025-3; Garcia-Sosa AT, 2003, J MOL MODEL, V9, P172, DOI 10.1007/s00894-003-0129-x; GILL SC, 1989, ANAL BIOCHEM, V182, P319, DOI 10.1016/0003-2697(89)90602-7; Humphrey W, 1996, J MOL GRAPH MODEL, V14, P33, DOI 10.1016/0263-7855(96)00018-5; Kay BK, 2000, FASEB J, V14, P231, DOI 10.1096/fasebj.14.2.231; Lafont V, 2007, CHEM BIOL DRUG DES, V69, P413, DOI 10.1111/j.1747-0285.2007.00519.x; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; LEE KH, 1994, PROTEINS, V20, P68, DOI 10.1002/prot.340200108; Li Z, 2005, J PHYS CHEM B, V109, P662, DOI 10.1021/jp0477912; Luque I, 2002, PROTEINS, V49, P181, DOI 10.1002/prot.10208; Mayer BJ, 2001, J CELL SCI, V114, P1253; Musacchio A, 2003, ADV PROTEIN CHEM, V61, P211; MUSACCHIO A, 1994, NAT STRUCT BIOL, V1, P546, DOI 10.1038/nsb0894-546; Nagar B, 2003, CELL, V112, P859, DOI 10.1016/S0092-8674(03)00194-6; Oneyama C, 2003, CHEM BIOL, V10, P443, DOI 10.1016/S1074-5521(03)00101-7; Palencia A, 2004, J MOL BIOL, V336, P527, DOI 10.1016/j.jmb.2003.12.030; Pisabarro MT, 1998, J MOL BIOL, V281, P513, DOI 10.1006/jmbi.1998.1932; Pisabarro MT, 1996, BIOCHEMISTRY-US, V35, P10634, DOI 10.1021/bi960203t; Posern G, 1998, ONCOGENE, V16, P1903, DOI 10.1038/sj.onc.1201714; Raymer ML, 1997, J MOL BIOL, V265, P445, DOI 10.1006/jmbi.1996.0746; Renzoni DA, 1996, BIOCHEMISTRY-US, V35, P15646, DOI 10.1021/bi9620969; Sadqi M, 1999, BIOCHEMISTRY-US, V38, P8899, DOI 10.1021/bi990413g; Sharrow SD, 2005, PROTEIN SCI, V14, P249, DOI 10.1110/ps.04912605; Teyra J, 2006, BMC BIOINFORMATICS, V7, DOI 10.1186/1471-2105-7-104; Teyra J, 2007, PROTEINS, V67, P1087, DOI 10.1002/prot.21394; Vagin A, 1997, J APPL CRYSTALLOGR, V30, P1022, DOI 10.1107/S0021889897006766; Velazquez-Campoy A, 2005, BIOPHYS CHEM, V115, P115, DOI 10.1016/j.bpc.2004.12.015; Velazquez-Campoy A, 2001, THERMOCHIM ACTA, V380, P217, DOI 10.1016/S0040-6031(01)00671-2; Vidal M, 2001, CRIT REV ONCOL HEMAT, V40, P175, DOI 10.1016/S1040-8428(01)00142-1; VIGUERA AR, 1994, BIOCHEMISTRY-US, V33, P2142, DOI 10.1021/bi00174a022; Wang CY, 2001, J MOL BIOL, V313, P873, DOI 10.1006/jmbi.2001.5083; WITTEKIND M, 1994, BIOCHEMISTRY-US, V33, P13531, DOI 10.1021/bi00250a004	40	25	26	1	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 22	2010	285	4					2823	2833		10.1074/jbc.M109.048033	http://dx.doi.org/10.1074/jbc.M109.048033			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	544YP	19906645	Green Published, hybrid			2022-12-25	WOS:000273697800058
J	Bunch, TA				Bunch, Thomas A.			Integrin alpha IIb beta 3 Activation in Chinese Hamster Ovary Cells and Platelets Increases Clustering Rather than Affinity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BINDING-LIKE DOMAIN; CONFORMATIONAL-CHANGE; FIBRINOGEN RECEPTOR; STRUCTURAL BASIS; LIGAND-BINDING; LIVING CELLS; GPIIB-IIIA; TALIN; ALPHA(IIB)BETA(3); AGGREGATION	Integrin alpha III beta 3 affinity regulation by talin binding to the cytoplasmic tail of beta 3 is a generally accepted model for explaining activation of this integrin in Chinese hamster ovary cells and human platelets. Most of the evidence for this model comes from the use of multivalent ligands. This raises the possibility that the activation being measured is that of increased clustering of the integrin rather than affinity. Using a newly developed assay that probes integrins on the surface of cells with only monovalent ligands prior to fixation, I do not find increases in affinity of alpha III beta 3 integrins by talin head fragments in Chinese hamster ovary cells, nor do I observe affinity increases in human platelets stimulated with thrombin. Binding to a multivalent ligand does increase in both of these cases. This assay does report affinity increases induced by either Mn2+, a cytoplasmic domain mutant (D723R) in the cytoplasmic domain of beta 3, or preincubation with a peptide ligand. These results reconcile the previously observed differences between talin effects on integrin activation in Drosophila and vertebrate systems and suggest new models for talin regulation of integrin activity in human platelets.	Arizona Canc Ctr, Dept Mol & Cellular Biol, Tucson, AZ 85724 USA	Arizona Center Cancer Care	Bunch, TA (corresponding author), Arizona Canc Ctr, Dept Mol & Cellular Biol, Rm 3951A,1515 N Campbell Ave, Tucson, AZ 85724 USA.	tbunch@email.arizona.edu			National Institutes of Health [R01GM42474]; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM042474] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	This work was supported, in whole or in part, by National Institutes of Health Grant R01GM42474 (to D. Bower and T. B.).	ABRAMS C, 1994, J BIOL CHEM, V269, P18781; ALBERTS B, 2007, MOL BIOL CELL, P1172; Banno A, 2008, BIOCHEM SOC T, V36, P229, DOI 10.1042/BST0360229; Bouaouina M, 2008, J BIOL CHEM, V283, P6118, DOI 10.1074/jbc.M709527200; Brown NH, 2002, DEV CELL, V3, P569, DOI 10.1016/S1534-5807(02)00290-3; Buensuceso C, 2003, J BIOL CHEM, V278, P15217, DOI 10.1074/jbc.M213234200; Bunch TA, 2006, J BIOL CHEM, V281, P5050, DOI 10.1074/jbc.M508550200; Calderwood DA, 1999, J BIOL CHEM, V274, P28071, DOI 10.1074/jbc.274.40.28071; Calderwood DA, 2004, J CELL SCI, V117, P657, DOI 10.1242/jcs.01014; Calderwood DA, 2002, J BIOL CHEM, V277, P21749, DOI 10.1074/jbc.M111996200; Chen JF, 2003, NAT STRUCT BIOL, V10, P995, DOI 10.1038/nsb1011; Cluzel C, 2005, J CELL BIOL, V171, P383, DOI 10.1083/jcb.200503017; Critchley DR, 2005, BIOCHEM SOC T, V33, P1308, DOI 10.1042/BST0331308; DU XP, 1991, CELL, V65, P409, DOI 10.1016/0092-8674(91)90458-B; Fox JEB, 1996, J BIOL CHEM, V271, P7004, DOI 10.1074/jbc.271.12.7004; FROJMOVIC MM, 1991, BLOOD, V78, P369; Ginsberg MH, 2005, CURR OPIN CELL BIOL, V17, P509, DOI 10.1016/j.ceb.2005.08.010; Goksoy E, 2008, MOL CELL, V31, P124, DOI 10.1016/j.molcel.2008.06.011; Han JW, 2006, CURR BIOL, V16, P1796, DOI 10.1016/j.cub.2006.08.035; Hantgan RR, 1999, BIOCHEMISTRY-US, V38, P14461, DOI 10.1021/bi9907680; Hato T, 1998, J CELL BIOL, V141, P1685, DOI 10.1083/jcb.141.7.1685; Helsten TL, 2008, MOL BIOL CELL, V19, P3589, DOI 10.1091/mbc.E08-01-0085; Hughes PE, 1996, J BIOL CHEM, V271, P6571, DOI 10.1074/jbc.271.12.6571; Hynes RO, 2002, CELL, V110, P673, DOI 10.1016/S0092-8674(02)00971-6; ISENBERG WM, 1987, J CELL BIOL, V104, P1655, DOI 10.1083/jcb.104.6.1655; Konstandin MH, 2006, J IMMUNOL METHODS, V310, P67, DOI 10.1016/j.jim.2005.12.005; Litvinov RI, 2004, BLOOD, V104, P3979, DOI 10.1182/blood-2004-04-1411; Luo BH, 2005, P NATL ACAD SCI USA, V102, P3679, DOI 10.1073/pnas.0409440102; Luo BH, 2007, ANNU REV IMMUNOL, V25, P619, DOI 10.1146/annurev.immunol.25.022106.141618; MARGUERIE GA, 1980, J BIOL CHEM, V255, P154; Mould AP, 2002, J BIOL CHEM, V277, P19800, DOI 10.1074/jbc.M201571200; Nieswandt B, 2007, J EXP MED, V204, P3113, DOI 10.1084/jem.20071827; OTOOLE TE, 1994, J CELL BIOL, V124, P1047, DOI 10.1083/jcb.124.6.1047; Peerschke EIB, 1999, J LAB CLIN MED, V134, P398, DOI 10.1016/S0022-2143(99)90155-5; Petrich BG, 2007, J EXP MED, V204, P3103, DOI 10.1084/jem.20071800; SHATTIL SJ, 1985, J BIOL CHEM, V260, P1107; Simmons SR, 1997, ARTERIOSCL THROM VAS, V17, P3311, DOI 10.1161/01.ATV.17.11.3311; Tadokoro S, 2003, SCIENCE, V302, P103, DOI 10.1126/science.1086652; Takagi J, 2002, CELL, V110, P599, DOI 10.1016/S0092-8674(02)00935-2; TAUB R, 1989, J BIOL CHEM, V264, P259; Watanabe N, 2008, J CELL BIOL, V181, P1211, DOI 10.1083/jcb.200803094; Xiong JP, 2009, J CELL BIOL, V186, P589, DOI 10.1083/jcb.200905085	42	42	44	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 15	2010	285	3					1841	1849		10.1074/jbc.M109.057349	http://dx.doi.org/10.1074/jbc.M109.057349			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	541PJ	19917607	hybrid, Green Published			2022-12-25	WOS:000273429100030
J	Steinberg, F; Zhuang, L; Beyeler, M; Kalin, RE; Mullis, PE; Brandli, AW				Steinberg, Florian; Zhuang, Lei; Beyeler, Michael; Kaelin, Roland E.; Mullis, Primus E.; Braendli, Andre W.			The FGFRL1 Receptor Is Shed from Cell Membranes, Binds Fibroblast Growth Factors (FGFs), and Antagonizes FGF Signaling in Xenopus Embryos	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							WOLF-HIRSCHHORN SYNDROME; GENE-EXPRESSION; MESODERM; IDENTIFICATION; INACTIVATION; RESPONSES; FAMILY; MOUSE	FGFRL1 (fibroblast growth factor receptor like 1) is the fifth and most recently discovered member of the fibroblast growth factor receptor (FGFR) family. With up to 50% amino acid similarity, its extracellular domain closely resembles that of the four conventional FGFRs. Its intracellular domain, however, lacks the split tyrosine kinase domain needed for FGF-mediated signal transduction. During embryogenesis of the mouse, FGFRL1 is essential for the development of parts of the skeleton, the diaphragm muscle, the heart, and the metanephric kidney. Since its discovery, it has been hypothesized that FGFRL1 might act as a decoy receptor for FGF ligands. Here we present several lines of evidence that support this notion. We demonstrate that the FGFRL1 ectodomain is shed from the cell membrane of differentiating C2C12 myoblasts and from HEK293 cells by an as yet unidentified protease, which cuts the receptor in the membrane-proximal region. As determined by ligand dot blot analysis, cell-based binding assays, and surface plasmon resonance analysis, the soluble FGFRL1 ectodomain as well as the membrane-bound receptor are capable of binding to some FGF ligands with high affinity, including FGF2, FGF3, FGF4, FGF8, FGF10, and FGF22. We furthermore show that ectopic expression of FGFRL1 in Xenopus embryos antagonizes FGFR signaling during early development. Taken together, our data provide strong evidence that FGFRL1 is indeed a decoy receptor for FGFs.	[Steinberg, Florian; Zhuang, Lei; Beyeler, Michael; Braendli, Andre W.] Univ Bern, Dept Clin Res, CH-3010 Bern, Switzerland; [Braendli, Andre W.] Univ Hosp Bern, Dept Rheumatol, CH-3010 Bern, Switzerland; [Mullis, Primus E.] Univ Childrens Hosp, Dept Pediat, CH-3010 Bern, Switzerland; [Kaelin, Roland E.; Mullis, Primus E.] ETH, Dept Chem & Appl Biosci, Inst Pharmaceut Sci, CH-8093 Zurich, Switzerland	University of Bern; University of Bern; University Hospital of Bern; University of Bern; University Hospital of Bern; Swiss Federal Institutes of Technology Domain; ETH Zurich	Brandli, AW (corresponding author), Univ Bern, Dept Clin Res, CH-3010 Bern, Switzerland.	beat.trueb@dkf.unibe.ch	Trueb, Beat/AAL-9621-2020; Brandli, Andre/N-1620-2013; Kälin, Roland/AAG-9161-2020	Trueb, Beat/0000-0001-8684-6856; Brandli, Andre/0000-0002-8932-3644; 	Swiss National Science Foundation [31003A0-113806, 31003A-127046, 3100A0-101964]; European Community [LSHG-CT-2004-005085]; Swiss Foundation for Research on Muscular Diseases	Swiss National Science Foundation(Swiss National Science Foundation (SNSF)European Commission); European Community(European Commission); Swiss Foundation for Research on Muscular Diseases	This work was supported by Swiss National Science Foundation Grants 31003A0-113806, 31003A-127046, and 3100A0-101964; European Community Grant LSHG-CT-2004-005085; and funds from the Swiss Foundation for Research on Muscular Diseases.	AMAYA E, 1993, DEVELOPMENT, V118, P477; AMAYA E, 1991, CELL, V66, P257, DOI 10.1016/0092-8674(91)90616-7; Armand AS, 2006, BBA-MOL CELL RES, V1763, P773, DOI 10.1016/j.bbamcr.2006.06.005; Baertschi S, 2007, FEBS J, V274, P6241, DOI 10.1111/j.1742-4658.2007.06143.x; Beenken A, 2009, NAT REV DRUG DISCOV, V8, P235, DOI 10.1038/nrd2792; Bergemann AD, 2005, TRENDS GENET, V21, P188, DOI 10.1016/j.tig.2005.01.008; Bogdan S, 2001, CURR BIOL, V11, pR292, DOI 10.1016/S0960-9822(01)00167-1; BRANDLI AW, 1995, DEV DYNAM, V203, P119; Bushell KM, 2008, GENOME RES, V18, P622, DOI 10.1101/gr.7187808; Catela C, 2009, DIS MODEL MECH, V2, P283, DOI 10.1242/dmm.002287; Engbers H, 2009, EUR J HUM GENET, V17, P129, DOI 10.1038/ejhg.2008.168; GERBER SD, 2009, DEV BIOL IN PRESS; Grieshammer U, 2005, DEVELOPMENT, V132, P3847, DOI 10.1242/dev.01944; Hayashi S, 2004, DEV DYNAM, V230, P700, DOI 10.1002/dvdy.20040; Helbling PM, 1999, DEV DYNAM, V216, P361, DOI 10.1002/(SICI)1097-0177(199912)216:4/5<361::AID-DVDY5>3.0.CO;2-W; Hongo I, 1999, DEV BIOL, V216, P561, DOI 10.1006/dbio.1999.9515; Huovila APJ, 2005, TRENDS BIOCHEM SCI, V30, P413, DOI 10.1016/j.tibs.2005.05.006; Ibrahimi OA, 2004, HUM MOL GENET, V13, P2313, DOI 10.1093/hmg/ddh235; Itoh N, 2004, TRENDS GENET, V20, P563, DOI 10.1016/j.tig.2004.08.007; Itoh N, 2008, DEV DYNAM, V237, P18, DOI 10.1002/dvdy.21388; Kroll KL, 1996, DEVELOPMENT, V122, P3173; Kuure S, 2007, J AM SOC NEPHROL, V18, P1130, DOI 10.1681/ASN.2006111206; Lagha M, 2008, GENE DEV, V22, P1828, DOI 10.1101/gad.477908; Leibbrandt A, 2008, ANN NY ACAD SCI, V1143, P123, DOI 10.1196/annals.1443.016; Mantovani A, 2003, INT ARCH ALLERGY IMM, V132, P109, DOI 10.1159/000073711; Mantovani A, 2001, TRENDS IMMUNOL, V22, P328, DOI 10.1016/S1471-4906(01)01941-X; Miller DL, 2000, MOL CELL BIOL, V20, P2260, DOI 10.1128/MCB.20.6.2260-2268.2000; Mohammadi M, 2005, CYTOKINE GROWTH F R, V16, P107, DOI 10.1016/j.cytogfr.2005.01.008; Perantoni AO, 2005, DEVELOPMENT, V132, P3859, DOI 10.1242/dev.01945; Rieckmann T, 2008, EXP CELL RES, V314, P1071, DOI 10.1016/j.yexcr.2007.10.029; Rieckmann T, 2009, BBA-MOL BASIS DIS, V1792, P112, DOI 10.1016/j.bbadis.2008.11.006; Sleeman M, 2001, GENE, V271, P171, DOI 10.1016/S0378-1119(01)00518-2; Sugi Y, 2003, DEV BIOL, V258, P252, DOI 10.1016/S0012-1606(03)00099-X; Trueb B, 2006, INT J MOL MED, V17, P617; Trueb B, 2003, J BIOL CHEM, V278, P33857, DOI 10.1074/jbc.M300281200; von Scheven G, 2006, DEVELOPMENT, V133, P2731, DOI 10.1242/dev.02426; Wiedemann M, 2000, GENOMICS, V69, P275, DOI 10.1006/geno.2000.6332; Yu SJ, 2004, LAB INVEST, V84, P1571, DOI 10.1038/labinvest.3700187; Zhang XQ, 2006, J BIOL CHEM, V281, P15694, DOI 10.1074/jbc.M601252200	39	51	51	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 15	2010	285	3					2193	2202		10.1074/jbc.M109.058248	http://dx.doi.org/10.1074/jbc.M109.058248			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	541PJ	19920134	Green Published, hybrid			2022-12-25	WOS:000273429100063
J	Vukelic, S; Stojadinovic, O; Pastar, I; Vouthounis, C; Krzyzanowska, A; Das, S; Samuels, HH; Tomic-Canic, M				Vukelic, Sasa; Stojadinovic, Olivera; Pastar, Irena; Vouthounis, Constantinos; Krzyzanowska, Agata; Das, Sharmistha; Samuels, Herbert H.; Tomic-Canic, Marjana			Farnesyl Pyrophosphate Inhibits Epithelialization and Wound Healing through the Glucocorticoid Receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HMG-COA REDUCTASE; PERMEABILITY BARRIER DISRUPTION; MESSENGER-RNA LEVELS; BETA-CATENIN; ACTIVATION; APOPTOSIS; STATINS; PATHWAY; SKIN; PHOSPHORYLATION	Farnesyl pyrophosphate (FPP), a key intermediate in the mevalonate pathway and protein farnesylation, can act as an agonist for several nuclear hormone receptors. Here we show a novel mechanism by which FPP inhibits wound healing acting as an agonist for glucocorticoid receptor (GR). Elevation of endogenous FPP by the squalene synthetase inhibitor zaragozic acid A (ZGA) or addition of FPP to the cell culture medium results in activation and nuclear translocation of the GR, a known wound healing inhibitor. We used functional studies to evaluate the effects of FPP on wound healing. Both FPP and ZGA inhibited keratinocyte migration and epithelialization in vitro and ex vivo. These effects were independent of farnesylation and indicate that modulation of FPP levels in skin may be beneficial for wound healing. FPP inhibition of keratinocyte migration and wound healing proceeds, in part, by repression of the keratin 6 gene. Furthermore, we show that the 3-hydroxy-3-methylglutaryl-CoA-reductase inhibitor mevastatin, which blocks FPP formation, not only promotes epithelialization in acute wounds but also reverses the effect of ZGA on activation of the GR and inhibition of epithelialization. We conclude that FPP inhibits wound healing by acting as a GR agonist. Of special interest is that FPP is naturally present in cells prior to glucocorticoid synthesis and that FPP levels can be further altered by the statins. Therefore, our findings may provide a better understanding of the pleiotropic effects of statins as well as molecular mechanisms by which they may accelerate wound healing.	[Tomic-Canic, Marjana] Hosp Special Surg, Tissue Engn Regenerat & Repair Program, New York, NY 10021 USA; [Stojadinovic, Olivera; Pastar, Irena; Tomic-Canic, Marjana] Univ Miami, Miller Sch Med, Dept Dermatol & Cutaneous Surg, Wound Healing & Regenerat Med Res Program, Miami, FL 33136 USA; [Das, Sharmistha; Samuels, Herbert H.] NYU, Sch Med, Dept Pharmacol, New York, NY 10016 USA	University of Miami; New York University	Tomic-Canic, M (corresponding author), 1600 NW 10th Ave,RMSB,Rm 2023-A, Miami, FL 33136 USA.	mtcanic@med.miami.edu	Pastar, Irena/AAD-3626-2020	Pastar, Irena/0000-0003-0197-6198	National Institutes of Health [AR45974, NR08029, AG030673, DK16636]; Entertainment Industry Foundation; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR045974] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R56DK016636, R37DK016636, R01DK016636] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NURSING RESEARCH [R01NR008029] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R21AG030673] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Entertainment Industry Foundation; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF NURSING RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Nursing Research (NINR)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))	This work was supported, in whole or in part, by National Institutes of Health Grant AR45974 (to M. T.-C.), NR08029 (to M. T.-C.), AG030673 (to M. T.-C.), and DK16636 (to H. H. S.). This work was also supported by the Entertainment Industry Foundation (to H. H. S.).	Bauer DC, 2003, OSTEOPOROSIS INT, V14, P273, DOI 10.1007/s00198-002-1323-x; Bitto A, 2008, PHARMACOL RES, V57, P159, DOI 10.1016/j.phrs.2008.01.005; Brem H, 2007, EXP GERONTOL, V42, P523, DOI 10.1016/j.exger.2006.11.018; Brem H, 2007, J CLIN INVEST, V117, P1219, DOI 10.1172/JCI32169; Das S, 2007, MOL ENDOCRINOL, V21, P2672, DOI 10.1210/me.2007-0080; FEINGOLD KR, 1982, J LAB CLIN MED, V100, P405; Freedberg IM, 2001, J INVEST DERMATOL, V116, P633, DOI 10.1046/j.1523-1747.2001.01327.x; Fukuyama R, 2004, BIOCHEM BIOPH RES CO, V315, P636, DOI 10.1016/j.bbrc.2004.01.104; HANCOCK JF, 1989, CELL, V57, P1167, DOI 10.1016/0092-8674(89)90054-8; Harris IR, 1997, J INVEST DERMATOL, V109, P783, DOI 10.1111/1523-1747.ep12340962; Harris IR, 2000, J INVEST DERMATOL, V114, P83, DOI 10.1046/j.1523-1747.2000.00822.x; JACKSON SM, 1992, J LIPID RES, V33, P1307; Keller RK, 1996, BBA-LIPID LIPID MET, V1303, P169, DOI 10.1016/0005-2760(96)00081-1; Kiliccoglu SS, 2007, J TRAUMA, V63, P187, DOI 10.1097/01.TA.0000240974.07999.bc; Lahera V, 2007, CURR MED CHEM, V14, P243, DOI 10.2174/092986707779313381; Lee B, 2005, J MOL BIOL, V345, P1083, DOI 10.1016/j.jmb.2004.11.027; Li XW, 2002, J BIOL CHEM, V277, P15309, DOI 10.1074/jbc.M201253200; Liao JK, 2005, AM J CARDIOL, V96, p24F, DOI 10.1016/j.amjcard.2005.06.009; Miller AL, 2005, MOL ENDOCRINOL, V19, P1569, DOI 10.1210/me.2004-0528; Paladini RD, 1996, J CELL BIOL, V132, P381, DOI 10.1083/jcb.132.3.381; Pastar Irena, 2008, Surg Technol Int, V17, P105; PROKSCH E, 1990, J CLIN INVEST, V85, P874, DOI 10.1172/JCI114514; Rabkin SW, 2007, CARDIOVASC TOXICOL, V7, P1, DOI 10.1007/s12012-007-0003-7; Radoja N, 2000, MOL CELL BIOL, V20, P4328, DOI 10.1128/MCB.20.12.4328-4339.2000; Rego Amália Cínthia Meneses do, 2007, Acta Cir. Bras., V22, P57, DOI 10.1590/S0102-86502007000700012; Rogatsky I, 2001, EMBO J, V20, P6071, DOI 10.1093/emboj/20.21.6071; Schaaf MJM, 2002, J STEROID BIOCHEM, V83, P37, DOI 10.1016/S0960-0760(02)00263-7; Schiefelbein D, 2008, J BIOL CHEM, V283, P15479, DOI 10.1074/jbc.M709841200; Shao HW, 2008, STEM CELLS, V26, P1376, DOI 10.1634/stemcells.2007-0785; SHEARES BT, 1989, BIOCHEMISTRY-US, V28, P8129, DOI 10.1021/bi00446a025; Skoglund B, 2007, BMC MUSCULOSKEL DIS, V8, DOI 10.1186/1471-2474-8-98; Stojadinovic O, 2005, AM J PATHOL, V167, P59, DOI 10.1016/S0002-9440(10)62953-7; Stojadinovic O, 2007, J BIOL CHEM, V282, P4021, DOI 10.1074/jbc.M606262200; Takayama S, 2006, J BIOL CHEM, V281, P17856, DOI 10.1074/jbc.M602290200; Tomic-Canic M, 1998, J DERMATOL SCI, V17, P167, DOI 10.1016/S0923-1811(98)00016-4; Tomic-Canic M, 2004, DERM CLIN BAS SCI, P25; Tomic-Canic M, 2007, WOUND REPAIR REGEN, V15, P71, DOI 10.1111/j.1524-475X.2006.00187.x; Tong HX, 2005, ANAL BIOCHEM, V336, P51, DOI 10.1016/j.ab.2004.09.024; Wang Z, 2002, J BIOL CHEM, V277, P26573, DOI 10.1074/jbc.M110530200; Weber MS, 2008, CURR TOP MICROBIOL, V318, P313; Weis M, 2002, CIRCULATION, V105, P739, DOI 10.1161/hc0602.103393; Wicke C, 2000, ARCH SURG-CHICAGO, V135, P1265, DOI 10.1001/archsurg.135.11.1265; WOLDA SL, 1988, J BIOL CHEM, V263, P5997; Wu HT, 2008, J NEUROTRAUM, V25, P130, DOI 10.1089/neu.2007.0369	44	49	51	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 15	2010	285	3					1980	1988		10.1074/jbc.M109.016741	http://dx.doi.org/10.1074/jbc.M109.016741			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	541PJ	19903814	Green Published, hybrid			2022-12-25	WOS:000273429100044
J	Zhuge, R; Bao, RF; Fogarty, KE; Lifshitz, LM				ZhuGe, Ronghua; Bao, Rongfeng; Fogarty, Kevin E.; Lifshitz, Lawrence M.			Ca2+ Sparks Act as Potent Regulators of Excitation-Contraction Coupling in Airway Smooth Muscle	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CA2+-ACTIVATED CL-CHANNELS; K+ CHANNEL; CALCIUM SPARKS; BK CHANNELS; RYANODINE RECEPTORS; INWARD CURRENTS; URINARY-BLADDER; BETA-1 SUBUNIT; CELLS; MYOCYTES	Ca2+ sparks are short lived and localized Ca2+ transients resulting from the opening of ryanodine receptors in sarcoplasmic reticulum. These events relax certain types of smooth muscle by activating big conductance Ca2+-activated K+ channels to produce spontaneous transient outward currents (STOCs) and the resultant closure of voltage-dependent Ca2+ channels. But in many smooth muscles from a variety of organs, Ca2+ sparks can additionally activate Ca2+-activated Cl- channels to generate spontaneous transient inward current (STICs). To date, the physiological roles of Ca2+ sparks in this latter group of smooth muscle remain elusive. Here, we show that in airway smooth muscle, Ca2+ sparks under physiological conditions, activating STOCs and STICs, induce biphasic membrane potential transients (BiMPTs), leading to membrane potential oscillations. Paradoxically, BiMPTs stabilize the membrane potential by clamping it within a negative range and prevent the generation of action potentials. Moreover, blocking either Ca2+ sparks or hyperpolarization components of BiMPTs activates voltage-dependent Ca2+ channels, resulting in an increase in global [Ca2+](i) and cell contraction. Therefore, Ca2+ sparks in smooth muscle presenting both STICs and STOCs act as a stabilizer of membrane potential, and altering the balance can profoundly alter the status of excitability and contractility. These results reveal a novel mechanism underlying the control of excitability and contractility in smooth muscle.	[ZhuGe, Ronghua; Bao, Rongfeng] Univ Massachusetts, Sch Med, Dept Physiol, Worcester, MA 01655 USA; [ZhuGe, Ronghua; Bao, Rongfeng; Fogarty, Kevin E.; Lifshitz, Lawrence M.] Univ Massachusetts, Sch Med, Biomed Imaging Grp, Worcester, MA 01655 USA; [Fogarty, Kevin E.; Lifshitz, Lawrence M.] Univ Massachusetts, Sch Med, Program Mol Med, Worcester, MA 01655 USA	University of Massachusetts System; University of Massachusetts Worcester; University of Massachusetts System; University of Massachusetts Worcester; University of Massachusetts System; University of Massachusetts Worcester	Zhuge, R (corresponding author), Univ Massachusetts, Sch Med, Dept Physiol, 55 Lake Ave N, Worcester, MA 01655 USA.	Ronghua.zhuge@umassmed.edu			National Institutes of Health [HL73875]; American Heart Association; Charles Hood Foundation; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL073875] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); American Heart Association(American Heart Association); Charles Hood Foundation; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))	This work was supported, in whole or in part, by National Institutes of Health Grant HL73875. This work was also supported by the American Heart Association and Charles Hood Foundation.	Algara-Suarez P, 2007, AM J PHYSIOL-LUNG C, V293, pL191, DOI 10.1152/ajplung.00485.2006; Amberg GC, 2003, CIRC RES, V93, P965, DOI 10.1161/01.RES.0000100068.43006.36; Bao R, 2008, J GEN PHYSIOL, V132, P145, DOI 10.1085/jgp.200709933; BECKER PL, 1987, AM J PHYSIOL, V253, pC613, DOI 10.1152/ajpcell.1987.253.4.C613; Brenner R, 2000, NATURE, V407, P870, DOI 10.1038/35038011; Burdyga T, 2005, NATURE, V436, P559, DOI 10.1038/nature03834; Cheng HP, 2008, PHYSIOL REV, V88, P1491, DOI 10.1152/physrev.00030.2007; Chipperfield AR, 2000, PROG BIOPHYS MOL BIO, V74, P175, DOI 10.1016/S0079-6107(00)00024-9; Drummond RM, 1999, J PHYSIOL-LONDON, V516, P139, DOI 10.1111/j.1469-7793.1999.139aa.x; Eghbali M, 2003, J BIOL CHEM, V278, P45311, DOI 10.1074/jbc.M306564200; Gomez AM, 1997, SCIENCE, V276, P800, DOI 10.1126/science.276.5313.800; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; Herrera GM, 2001, AM J PHYSIOL-CELL PH, V280, pC481, DOI 10.1152/ajpcell.2001.280.3.C481; Janssen LJ, 2002, AM J PHYSIOL-LUNG C, V282, pL1161, DOI 10.1152/ajplung.00452.2001; JANSSEN LJ, 1994, PFLUG ARCH EUR J PHY, V427, P473, DOI 10.1007/BF00374263; Karkanis T, 2003, J APPL PHYSIOL, V94, P301, DOI 10.1152/japplphysiol.00660.2002; McGahon MK, 2007, CIRC RES, V100, P703, DOI 10.1161/01.RES.0000260182.36481.c9; Meredith AL, 2004, J BIOL CHEM, V279, P36746, DOI 10.1074/jbc.M405621200; NELSON MT, 1995, SCIENCE, V270, P633, DOI 10.1126/science.270.5236.633; Ohi Y, 2001, J PHYSIOL-LONDON, V534, P313, DOI 10.1111/j.1469-7793.2001.t01-3-00313.x; OTTOLIA M, 1994, BIOPHYS J, V67, P2272, DOI 10.1016/S0006-3495(94)80712-X; Pluger S, 2000, CIRC RES, V87, pE53, DOI 10.1161/01.RES.87.11.e53; Rubart M, 1996, J GEN PHYSIOL, V107, P459, DOI 10.1085/jgp.107.4.459; Sausbier M, 2007, FASEB J, V21, P812, DOI 10.1096/fj.06-7167com; Snetkov VA, 1999, EXP PHYSIOL, V84, P835, DOI 10.1111/j.1469-445X.1999.01887.x; VANHELDEN DF, 1993, J PHYSIOL-LONDON, V471, P465, DOI 10.1113/jphysiol.1993.sp019910; WANG Q, 1992, J PHYSIOL-LONDON, V451, P525, DOI 10.1113/jphysiol.1992.sp019177; Wang X, 2005, NAT CELL BIOL, V7, P525, DOI 10.1038/ncb1254; Wang YX, 1997, AM J PHYSIOL-CELL PH, V272, pC1151, DOI 10.1152/ajpcell.1997.272.4.C1151; YAGI S, 1988, P NATL ACAD SCI USA, V85, P4109, DOI 10.1073/pnas.85.11.4109; ZhuGe R, 2000, J GEN PHYSIOL, V116, P845, DOI 10.1085/jgp.116.6.845; ZhuGe R, 2002, J GEN PHYSIOL, V120, P15, DOI 10.1085/jgp.20028571; ZhuGe RH, 2004, AM J PHYSIOL-CELL PH, V287, pC1577, DOI 10.1152/ajpcell.00153.2004; ZhuGe RH, 1998, J PHYSIOL-LONDON, V513, P711, DOI 10.1111/j.1469-7793.1998.711ba.x	34	38	40	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 15	2010	285	3					2203	2210		10.1074/jbc.M109.067546	http://dx.doi.org/10.1074/jbc.M109.067546			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	541PJ	19920135	Green Published, hybrid			2022-12-25	WOS:000273429100064
J	Hammel, M; Yu, YP; Mahaney, BL; Cai, B; Ye, RQ; Phipps, BM; Rambo, RP; Hura, GL; Pelikan, M; So, S; Abolfath, RM; Chen, DJ; Lees-Miller, SP; Tainer, JA				Hammel, Michal; Yu, Yaping; Mahaney, Brandi L.; Cai, Brandon; Ye, Ruiqiong; Phipps, Barry M.; Rambo, Robert P.; Hura, Greg L.; Pelikan, Martin; So, Sairei; Abolfath, Ramin M.; Chen, David J.; Lees-Miller, Susan P.; Tainer, John A.			Ku and DNA-dependent Protein Kinase Dynamic Conformations and Assembly Regulate DNA Binding and the Initial Non-homologous End Joining Complex	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STRAND BREAK REPAIR; X-RAY-SCATTERING; CATALYTIC SUBUNIT; 3-DIMENSIONAL STRUCTURE; PHOSPHORYLATION SITES; IN-VIVO; AUTOPHOSPHORYLATION; PKCS; DOMAIN; HETERODIMER	DNA double strand break (DSB) repair by non-homologous end joining (NHEJ) is initiated by DSB detection by Ku70/80 (Ku) and DNA-dependent protein kinase catalytic subunit (DNA-PKcs) recruitment, which promotes pathway progression through poorly defined mechanisms. Here, Ku and DNA-PKcs solution structures alone and in complex with DNA, defined by x-ray scattering, reveal major structural reorganizations that choreograph NHEJ initiation. The Ku80 C-terminal region forms a flexible arm that extends from the DNA-binding core to recruit and retain DNA-PKcs at DSBs. Furthermore, Ku- and DNA-promoted assembly of a DNA-PKcs dimer facilitates transautophosphorylation at the DSB. The resulting site-specific autophosphorylation induces a large conformational change that opens DNA-PKcs and promotes its release from DNA ends. These results show how protein and DNA interactions initiate large Ku and DNA-PKcs rearrangements to control DNA-PK biological functions as a macromolecular machine orchestrating assembly and disassembly of the initial NHEJ complex on DNA.	[Hammel, Michal; Rambo, Robert P.; Hura, Greg L.] Univ Calif Berkeley, Lawrence Berkeley Lab, Dept Mol Biol, Phys Biosci Div, Berkeley, CA 94720 USA; [Tainer, John A.] Univ Calif Berkeley, Lawrence Berkeley Lab, Dept Mol Biol, Div Life Sci, Berkeley, CA 94720 USA; [Yu, Yaping; Mahaney, Brandi L.; Cai, Brandon; Ye, Ruiqiong; Phipps, Barry M.; Lees-Miller, Susan P.] Univ Calgary, Dept Biochem & Mol Biol, Calgary, AB T2N 4N1, Canada; [Yu, Yaping; Mahaney, Brandi L.; Cai, Brandon; Ye, Ruiqiong; Phipps, Barry M.; Lees-Miller, Susan P.] Univ Calgary, So Alberta Canc Res Inst, Calgary, AB T2N 4N1, Canada; [Pelikan, Martin] Univ Missouri, Dept Math & Comp Sci, St Louis, MO 63121 USA; [So, Sairei; Abolfath, Ramin M.; Chen, David J.] Univ Texas SW Med Ctr Dallas, Dept Radiat Oncol, Div Mol Radiat Biol, Dallas, TX 75390 USA; [Tainer, John A.] Scripps Res Inst, Dept Mol Biol, Skaggs Inst Chem Biol, La Jolla, CA 92037 USA	United States Department of Energy (DOE); Lawrence Berkeley National Laboratory; University of California System; University of California Berkeley; United States Department of Energy (DOE); Lawrence Berkeley National Laboratory; University of California System; University of California Berkeley; University of Calgary; University of Calgary; University of Missouri System; University of Missouri Saint Louis; University of Texas System; University of Texas Southwestern Medical Center Dallas; Scripps Research Institute	Hammel, M (corresponding author), Univ Calif Berkeley, Lawrence Berkeley Lab, Dept Mol Biol, Phys Biosci Div, Berkeley, CA 94720 USA.	mhammel@lbl.gov; leesmill@ucalgary.ca	Tainer, John/GWQ-4878-2022; Classen, Scott/AAY-8176-2020; Phipps, Barry M/F-2388-2013; Pelikan, Martin/A-8547-2012	Tainer, John/0000-0003-1659-2429; Lees-Miller, Susan/0000-0001-5809-2516; Hura, Greg/0000-0003-0501-8464; Hammel, Michal/0000-0002-5610-9289	National Institutes of Health Structural Cell Biology of DNA Repair Machines P01 [CA92584]; Canadian Institutes of Health Research [13639]; NATIONAL CANCER INSTITUTE [P01CA092584] Funding Source: NIH RePORTER	National Institutes of Health Structural Cell Biology of DNA Repair Machines P01(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Canadian Institutes of Health Research(Canadian Institutes of Health Research (CIHR)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This work was supported in whole or in part, by National Institutes of Health Structural Cell Biology of DNA Repair Machines P01 Grant CA92584 (to J.A.T., G.L.H., and S.P.L.-M.). This work was also supported by Canadian Institutes of Health Research Grant 13639 (to S.P.L.-M.).	Bernado P, 2007, J AM CHEM SOC, V129, P5656, DOI 10.1021/ja069124n; Bernstein NK, 2009, NUCLEIC ACIDS RES, V37, P6161, DOI 10.1093/nar/gkp597; Block WD, 2004, NUCLEIC ACIDS RES, V32, P4351, DOI 10.1093/nar/gkh761; Boehm MK, 1999, J MOL BIOL, V286, P1421, DOI 10.1006/jmbi.1998.2556; Boskovic J, 2003, EMBO J, V22, P5875, DOI 10.1093/emboj/cdg555; Chan DW, 2002, GENE DEV, V16, P2333, DOI 10.1101/gad.1015202; Chan DW, 1996, J BIOL CHEM, V271, P8936, DOI 10.1074/jbc.271.15.8936; Chen BPC, 2005, J BIOL CHEM, V280, P14709, DOI 10.1074/jbc.M408827200; Chiu CY, 1998, J MOL BIOL, V284, P1075, DOI 10.1006/jmbi.1998.2212; Convery E, 2005, P NATL ACAD SCI USA, V102, P1345, DOI 10.1073/pnas.0406466102; Cui XP, 2005, MOL CELL BIOL, V25, P10842, DOI 10.1128/MCB.25.24.10842-10852.2005; Datta AB, 2009, J MOL BIOL, V392, P1117, DOI 10.1016/j.jmb.2009.07.090; DeFazio LG, 2002, EMBO J, V21, P3192, DOI 10.1093/emboj/cdf299; Ding Q, 2003, MOL CELL BIOL, V23, P5836, DOI 10.1128/MCB.23.16.5836-5848.2003; Douglas P, 2002, BIOCHEM J, V368, P243, DOI 10.1042/BJ20020973; Douglas P, 2007, MOL CELL BIOL, V27, P1581, DOI 10.1128/MCB.01962-06; Falck J, 2005, NATURE, V434, P605, DOI 10.1038/nature03442; Forster F, 2008, J MOL BIOL, V382, P1089, DOI 10.1016/j.jmb.2008.07.074; Gell D, 1999, NUCLEIC ACIDS RES, V27, P3494, DOI 10.1093/nar/27.17.3494; Guinier A., 1955, SMALL ANGLE SCATTERI; Hall EJ, 2006, RADIOBIOLOGY RADIOLO, P16; Harris R, 2004, J MOL BIOL, V335, P573, DOI 10.1016/j.jmb.2003.10.047; Helleday T, 2007, DNA REPAIR, V6, P923, DOI 10.1016/j.dnarep.2007.02.006; Hopfner KP, 2002, CURR OPIN STRUC BIOL, V12, P115, DOI 10.1016/S0959-440X(02)00297-X; Hura GL, 2009, NAT METHODS, V6, P606, DOI 10.1038/nmeth.1353; Jovanovic M, 2006, NUCLEIC ACIDS RES, V34, P1112, DOI 10.1093/nar/gkj504; Leuther KK, 1999, EMBO J, V18, P1114, DOI 10.1093/emboj/18.5.1114; Lobrich M, 2007, NAT REV CANCER, V7, P861, DOI 10.1038/nrc2248; Ma YM, 2005, J BIOL CHEM, V280, P33839, DOI 10.1074/jbc.M507113200; Mahaney BL, 2009, BIOCHEM J, V417, P639, DOI 10.1042/BJ20080413; Meek K, 2007, MOL CELL BIOL, V27, P3881, DOI 10.1128/MCB.02366-06; Meek K, 2008, ADV IMMUNOL, V99, P33, DOI 10.1016/S0065-2776(08)00602-0; Merkle D, 2002, BIOCHEMISTRY-US, V41, P12706, DOI 10.1021/bi0263558; Mo XM, 2002, MOL CELL BIOL, V22, P8088, DOI 10.1128/MCB.22.22.8088-8099.2002; O'Driscoll M, 2006, NAT REV GENET, V7, P45, DOI 10.1038/nrg1746; PAILLARD S, 1993, PROTEINS, V15, P330, DOI 10.1002/prot.340150310; Pawelczak KS, 2008, NUCLEIC ACIDS RES, V36, P4022, DOI 10.1093/nar/gkn344; Pelikan M, 2009, GEN PHYSIOL BIOPHYS, V28, P174, DOI 10.4149/gpb_2009_02_174; Petoukhov MV, 2005, BIOPHYS J, V89, P1237, DOI 10.1529/biophysj.105.064154; Porod G., 1982, SMALL ANGLE XRAY SCA, P17, DOI DOI 10.1002/ACTP.1985.010360520; Putnam CD, 2007, Q REV BIOPHYS, V40, P191, DOI 10.1017/S0033583507004635; Rivera-Calzada A, 2005, STRUCTURE, V13, P243, DOI 10.1016/j.str.2004.12.006; Rivera-Calzada A, 2007, EMBO REP, V8, P56, DOI 10.1038/sj.embor.7400847; Shin DS, 2004, DNA REPAIR, V3, P863, DOI 10.1016/j.dnarep.2004.03.022; Spagnolo L, 2006, MOL CELL, V22, P511, DOI 10.1016/j.molcel.2006.04.013; Sprague BL, 2004, BIOPHYS J, V86, P3473, DOI 10.1529/biophysj.103.026765; Svergun DI, 1999, BIOPHYS J, V76, P2879, DOI 10.1016/S0006-3495(99)77443-6; SVERGUN DI, 1992, J APPL CRYSTALLOGR, V25, P495, DOI 10.1107/S0021889892001663; Svergun DI, 2001, BIOPHYS J, V80, P2946, DOI 10.1016/S0006-3495(01)76260-1; Uematsu N, 2007, J CELL BIOL, V177, P219, DOI 10.1083/jcb.200608077; Walker JR, 2001, NATURE, V412, P607, DOI 10.1038/35088000; West RB, 1998, MOL CELL BIOL, V18, P5908, DOI 10.1128/MCB.18.10.5908; Weterings E, 2008, CELL RES, V18, P114, DOI 10.1038/cr.2008.3; Williams DR, 2008, STRUCTURE, V16, P468, DOI 10.1016/j.str.2007.12.014; Williams RS, 2009, CELL, V139, P87, DOI 10.1016/j.cell.2009.07.033; Yaneva M, 1997, EMBO J, V16, P5098, DOI 10.1093/emboj/16.16.5098; Yano KI, 2008, EMBO REP, V9, P91, DOI 10.1038/sj.embor.7401137; Yoo S, 1999, NUCLEIC ACIDS RES, V27, P4679, DOI 10.1093/nar/27.24.4679; Zhang ZM, 2004, STRUCTURE, V12, P495, DOI 10.1016/j.str.2004.02.007; Zhang ZM, 2001, J BIOL CHEM, V276, P38231; Zhuang M, 2009, MOL CELL, V36, P39, DOI 10.1016/j.molcel.2009.09.022	61	157	165	1	28	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 8	2010	285	2					1414	1423		10.1074/jbc.M109.065615	http://dx.doi.org/10.1074/jbc.M109.065615			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	539MH	19893054	hybrid, Green Published, Green Submitted			2022-12-25	WOS:000273258200061
J	Liang, KW; Yang, LQ; Yin, C; Xiao, ZM; Zhang, JJ; Liu, YM; Huang, J				Liang, Kaiwei; Yang, Liuqing; Yin, Chen; Xiao, Zhimin; Zhang, Junjian; Liu, Yumin; Huang, Jian			Estrogen Stimulates Degradation of beta-Amyloid Peptide by Up-regulating Neprilysin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALZHEIMERS-DISEASE; RECEPTOR-ALPHA; A-BETA; MESSENGER-RNA; DEGRADING ENZYMES; OLDER WOMEN; RAT-BRAIN; EXPRESSION; NEURONS; CELLS	Postmenopausal estrogen depletion is a characterized risk factor for Alzheimer disease (AD), a human disorder linked to high levels of beta-amyloid peptide (A beta) in brain tissue. Previous studies suggest that estrogen negatively regulates the level of A beta in the brain, but the molecular mechanism is unknown. Here, we provide evidence that estrogen promotes A beta degradation mainly through a principal A beta degrading enzyme, neprilysin, in neuroblastoma SH-SY5Y cells. We also demonstrate that up-regulation of neprilysin by estrogen is dependent on both estrogen receptor alpha and beta (ER alpha and ER beta), and ligand-activated ER regulates expression of neprilysin through physical interactions between ER and estrogen response elements (EREs) identified in the neprilysin gene. These results were confirmed by in vitro gel shift and in vivo chromatin immunoprecipitation analyses, which demonstrate specific binding of ER alpha and ER beta to two putative EREs in the neprilysin gene. The EREs also enhance ER alpha- and ER beta-dependent reporter gene expression in a yeast model system. Therefore, the study described here provides a putative mechanism by which estrogen positively regulates expression of neprilysin to promote degradation of A beta, reducing risk for AD. These results may lead to novel approaches to prevent or treat AD.	[Liang, Kaiwei; Yang, Liuqing; Yin, Chen; Xiao, Zhimin; Huang, Jian] Wuhan Univ, Coll Life Sci, State Key Lab Virol, Zhongnan Hosp, Wuhan 430072, Hubei, Peoples R China; [Zhang, Junjian; Liu, Yumin] Wuhan Univ, Dept Neurol, Zhongnan Hosp, Wuhan 430072, Hubei, Peoples R China	Wuhan University; Wuhan University	Huang, J (corresponding author), Wuhan Univ, Coll Life Sci, Rm 5105, Wuhan 430072, Hubei, Peoples R China.	jianhuang@whu.edu.cn		Xiao, Zhimin/0000-0003-4843-9736; Liang, Kaiwei/0000-0002-6021-353X	Scientific Research Foundation for the Returned Overseas Chinese Scholars; State Education Ministry of China [2004527]; National Basic Science Foundation for Talent Education [J0630648]; National Natural Science Foundation of China [30670647, 30970914]	Scientific Research Foundation for the Returned Overseas Chinese Scholars(Scientific Research Foundation for the Returned Overseas Chinese Scholars); State Education Ministry of China(Ministry of Education, China); National Basic Science Foundation for Talent Education; National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC))	This work was supported by the Scientific Research Foundation for the Returned Overseas Chinese Scholars, State Education Ministry of China Grant 2004527, National Basic Science Foundation for Talent Education Grant J0630648, and National Natural Science Foundation of China Grants 30670647 and 30970914.	Bang OY, 2004, NEUROBIOL DIS, V16, P21, DOI 10.1016/j.nbd.2003.12.017; Bjornstrom L, 2005, MOL ENDOCRINOL, V19, P833, DOI 10.1210/me.2004-0486; Brandi ML, 1999, BIOCHEM BIOPH RES CO, V265, P335, DOI 10.1006/bbrc.1999.1665; Carroll JS, 2005, CELL, V122, P33, DOI 10.1016/j.cell.2005.05.008; Deng H, 2005, BIOCHEM BIOPH RES CO, V337, P1133, DOI 10.1016/j.bbrc.2005.09.178; Deschenes J, 2007, J BIOL CHEM, V282, P17335, DOI 10.1074/jbc.C700030200; Eckman EA, 2005, BIOCHEM SOC T, V33, P1101, DOI 10.1042/BST0331101; Farris W, 2007, AM J PATHOL, V171, P241, DOI 10.2353/ajpath.2007.070105; Fisk L, 2007, NEUROCHEM RES, V32, P1741, DOI 10.1007/s11064-007-9349-2; Gietz RD, 2002, METHOD ENZYMOL, V350, P87; Hardy J, 2002, SCIENCE, V297, P353, DOI 10.1126/science.1072994; Harrington WR, 2003, MOL CELL ENDOCRINOL, V206, P13, DOI 10.1016/S0303-7207(03)00255-7; Hellstrom-Lindahl E, 2008, NEUROBIOL AGING, V29, P210, DOI 10.1016/j.neurobiolaging.2006.10.010; Huang J, 2004, NEUROSCI LETT, V367, P85, DOI 10.1016/j.neulet.2004.05.085; Iwata N, 2000, NAT MED, V6, P143, DOI 10.1038/72237; Iwata N, 2001, SCIENCE, V292, P1550, DOI 10.1126/science.1059946; Kim H, 2001, NEUROSCI LETT, V302, P58, DOI 10.1016/S0304-3940(01)01659-7; Liang KW, 2009, MOL BIOTECHNOL, V41, P53, DOI 10.1007/s12033-008-9097-9; Marr RA, 2003, J NEUROSCI, V23, P1992; Marr RA, 2004, J MOL NEUROSCI, V22, P5, DOI 10.1385/JMN:22:1-2:5; Martins IC, 2008, EMBO J, V27, P224, DOI 10.1038/sj.emboj.7601953; Mehra RD, 2005, BRAIN RES, V1056, P22, DOI 10.1016/j.brainres.2005.06.073; Musatov S, 2006, P NATL ACAD SCI USA, V103, P10456, DOI 10.1073/pnas.0603045103; Nalivaeva NN, 2008, CURR ALZHEIMER RES, V5, P212, DOI 10.2174/156720508783954785; Pettersson K, 2001, ANNU REV PHYSIOL, V63, P165, DOI 10.1146/annurev.physiol.63.1.165; Pirskanen M, 2005, EUR J HUM GENET, V13, P1000, DOI 10.1038/sj.ejhg.5201447; Rissman EF, 2002, P NATL ACAD SCI USA, V99, P3996, DOI 10.1073/pnas.012032699; Schupf N, 2008, DEMENT GERIATR COGN, V25, P476, DOI 10.1159/000126495; Shang YF, 2000, CELL, V103, P843, DOI 10.1016/S0092-8674(00)00188-4; Shughrue PJ, 1997, J COMP NEUROL, V388, P507, DOI 10.1002/(SICI)1096-9861(19971201)388:4<507::AID-CNE1>3.0.CO;2-6; Shughrue PJ, 1998, ENDOCRINOLOGY, V139, P5267, DOI 10.1210/en.139.12.5267; Stauffer SR, 2000, J MED CHEM, V43, P4934, DOI 10.1021/jm000170m; Sun M, 2001, CANCER RES, V61, P5985; Tanzi RE, 2005, CELL, V120, P545, DOI 10.1016/j.cell.2005.02.008; Treeck O, 2007, J ENDOCRINOL, V193, P421, DOI 10.1677/JOE-07-0087; Wang DS, 2006, J BIOMED BIOTECHNOL, DOI 10.1155/JBB/2006/58406; Xu HX, 1998, NAT MED, V4, P447, DOI 10.1038/nm0498-447; Yaffe K, 2002, BIOL PSYCHIAT, V51, P677, DOI 10.1016/S0006-3223(01)01289-6; Yamaguchi-Shima N, 2007, BRAIN RES, V1155, P34, DOI 10.1016/j.brainres.2007.04.016; Yao MZ, 2008, J NEUROCHEM, V105, P2477, DOI 10.1111/j.1471-4159.2008.05341.x; Yasojima K, 2001, NEUROSCI LETT, V297, P97, DOI 10.1016/S0304-3940(00)01675-X; Zandi PP, 2002, JAMA-J AM MED ASSOC, V288, P2123, DOI 10.1001/jama.288.17.2123; Zhao LQ, 2004, BRAIN RES, V1010, P22, DOI 10.1016/j.brainres.2004.02.066	43	76	81	0	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 8	2010	285	2					935	942		10.1074/jbc.M109.051664	http://dx.doi.org/10.1074/jbc.M109.051664			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	539MH	19897485	hybrid, Green Published			2022-12-25	WOS:000273258200013
J	Kaspar, JW; Jaiswal, AK				Kaspar, James W.; Jaiswal, Anil K.			Antioxidant-induced Phosphorylation of Tyrosine 486 Leads to Rapid Nuclear Export of Bach1 That Allows Nrf2 to Bind to the Antioxidant Response Element and Activate Defensive Gene Expression	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTIONAL REPRESSOR BACH1; HEME OXYGENASE-1 GENE; LOCUS-CONTROL REGION; SMALL MAF; INDUCTION; DEGRADATION; FACTOR-2; CLONING; FAMILY	Antioxidants cause stabilization and nuclear translocation of NF-E2-related factor 2 (Nrf2), where it binds to the antioxidant response element (ARE) and induces up-regulation of defensive genes that protect cells against oxidative and electrophilic stress. Bach1, the negative regulator of Nrf2, competes with Nrf2 for binding to the ARE in the human NQO1 promoter. In this study, we demonstrate that Bach1 exits the nucleus within 1-2 h upon antioxidant treatment. Genistein, an inhibitor of tyrosine kinases, blocked nuclear export of Bach1. Site-directed mutagenesis and immunoprecipitation assays identified tyrosine 486 that was phosphorylated in response to the antioxidant and was essential for nuclear export of Bach1. Chromatin immunoprecipitation assays revealed a competitive interplay between Bach1 and Nrf2 at 1-2 and 4 h for binding to the human NQO1 ARE. Luciferase and real time PCR assays showed a significant decrease in antioxidant induction of reporter activity and mRNA levels in cells transfected with mutant Bach1 compared with wild type. This decrease was due to the absence of nuclear export of the mutant protein. Bach1 levels inside the nucleus returned to normal at 4 h after antioxidant treatment in the absence but not in the presence of protein synthesis inhibitor cycloheximide. In addition, antioxidant treatment increased the transcription of Bach1 as shown by pulse chase and real time PCR experiments. Taken together, these results indicate that increased synthesis of Bach1 restored its nuclear levels to normal at 4 h. In conclusion, antioxidant-induced tyrosine 486 phosphorylation leads to nuclear exit of Bach1, thus allowing Nrf2 access to the ARE.	[Kaspar, James W.; Jaiswal, Anil K.] Univ Maryland, Dept Pharmacol & Expt Therapeut, Sch Med, Baltimore, MD 21201 USA	University System of Maryland; University of Maryland Baltimore	Jaiswal, AK (corresponding author), Univ Maryland, Dept Pharmacol & Expt Therapeut, Sch Med, 655 W Baltimore St, Baltimore, MD 21201 USA.	ajaiswal@som.umaryland.edu			National Institutes of Health [R01 GM047466]; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM047466] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	This work was supported, in whole or in part, by National Institutes of Health Grant R01 GM047466.	CHAN JY, 1993, P NATL ACAD SCI USA, V90, P11371, DOI 10.1073/pnas.90.23.11371; CHOI SY, 1996, J PARODONTOL IMPLANT, V15, P19; Dhakshinamoorthy S, 2005, J BIOL CHEM, V280, P16891, DOI 10.1074/jbc.M500166200; Dohl Y, 2006, ANTIOXID REDOX SIGN, V8, P60, DOI 10.1089/ars.2006.8.60; Fukuda M, 1997, NATURE, V390, P308, DOI 10.1038/36894; Igarashi K, 1998, J BIOL CHEM, V273, P11783, DOI 10.1074/jbc.273.19.11783; Ishikawa M, 2005, FREE RADICAL BIO MED, V38, P1344, DOI 10.1016/j.freeradbiomed.2005.01.021; Itoh K, 1997, BIOCHEM BIOPH RES CO, V236, P313, DOI 10.1006/bbrc.1997.6943; Jain AK, 2007, J BIOL CHEM, V282, P16502, DOI 10.1074/jbc.M611336200; Jain AK, 2006, J BIOL CHEM, V281, P12132, DOI 10.1074/jbc.M511198200; Jaiswal AK, 2004, FREE RADICAL BIO MED, V36, P1199, DOI 10.1016/j.freeradbiomed.2004.02.074; Kobayashi A, 1999, J BIOL CHEM, V274, P6443, DOI 10.1074/jbc.274.10.6443; MOHLER J, 1991, MECH DEVELOP, V34, P3, DOI 10.1016/0925-4773(91)90086-L; MOI P, 1994, P NATL ACAD SCI USA, V91, P9926, DOI 10.1073/pnas.91.21.9926; Mulcahy RT, 1997, J BIOL CHEM, V272, P7445, DOI 10.1074/jbc.272.11.7445; Oyake T, 1996, MOL CELL BIOL, V16, P6083; Reichard JF, 2007, NUCLEIC ACIDS RES, V35, P7074, DOI 10.1093/nar/gkm638; Singh A, 2006, AM J RESP CELL MOL, V35, P639, DOI 10.1165/rcmb.2005-0325OC; Sun JY, 2004, P NATL ACAD SCI USA, V101, P1461, DOI 10.1073/pnas.0308083100; Sun JY, 2002, EMBO J, V21, P5216, DOI 10.1093/emboj/cdf516; Suzuki H, 2004, EMBO J, V23, P2544, DOI 10.1038/sj.emboj.7600248; Suzuki H, 2003, J BIOL CHEM, V278, P49246, DOI 10.1074/jbc.M306764200; Tembe V, 2007, CELL SIGNAL, V19, P1113, DOI 10.1016/j.cellsig.2007.03.001; Venugopal R, 1998, ONCOGENE, V17, P3145, DOI 10.1038/sj.onc.1202237; Zenke-Kawasaki Y, 2007, MOL CELL BIOL, V27, P6962, DOI 10.1128/MCB.02415-06	25	93	103	0	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 1	2010	285	1					153	162		10.1074/jbc.M109.040022	http://dx.doi.org/10.1074/jbc.M109.040022			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	536UT	19897490	Green Published, hybrid			2022-12-25	WOS:000273070100016
J	Martinez, GJ; Zhang, ZM; Chung, Y; Reynolds, JM; Lin, X; Jetten, AM; Feng, XH; Dong, C				Martinez, Gustavo J.; Zhang, Zhengmao; Chung, Yeonseok; Reynolds, Joseph M.; Lin, Xia; Jetten, Anton M.; Feng, Xin-Hua; Dong, Chen			Smad3 Differentially Regulates the Induction of Regulatory and Inflammatory T Cell Differentiation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH-FACTOR-BETA; TGF-BETA; GENERATION; PATHWAY	Transforming growth factor beta (TGF-beta) is a crucial cytokine with pleiotropic functions on immune cells. In CD4(+) T cells, TGF-beta is required for induction of both regulatory T and Th17 cells. However, the molecular mechanism underlying this differential T cell fate decision remains unclear. In this study, we have evaluated the role of Smad3 in the development of Th17 and regulatory T cells. Smad3 was found to be dispensable for natural regulatory T cell function. However, induction of Foxp3 expression by TGF-beta in naive T cells was significantly reduced in the absence of this molecule. On the contrary, Smad3 deficiency led to enhanced Th17 differentiation in vitro and in vivo. Moreover, Smad3 was found to interact with retinoid acid receptor-related orphan receptor gamma t (ROR gamma t) and decrease its transcriptional activity. These results demonstrate that Smad3 is differentially involved in the reciprocal regulatory and inflammatory T cell generation.	[Zhang, Zhengmao; Feng, Xin-Hua] Baylor Coll Med, Dept Mol & Cellular Biol, Houston, TX 77030 USA; [Martinez, Gustavo J.; Chung, Yeonseok; Reynolds, Joseph M.; Dong, Chen] MD Anderson Canc Ctr, Dept Immunol, Houston, TX 77054 USA; [Martinez, Gustavo J.; Feng, Xin-Hua] Univ Texas Hlth Sci Ctr Houston, Grad Sch Biomed Sci, Houston, TX 77030 USA; [Zhang, Zhengmao; Jetten, Anton M.] Baylor Coll Med, Michael E DeBakey Dept Surg, Houston, TX 77030 USA; [Lin, Xia] NIEHS, Cell Biol Sect, Lab Resp Biol, NIH, Res Triangle Pk, NC 27709 USA	Baylor College of Medicine; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; University of Texas Health Science Center Houston; Baylor College of Medicine; National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS)	Feng, XH (corresponding author), Baylor Coll Med, Dept Mol & Cellular Biol, Houston, TX 77030 USA.	xfeng@bcm.edu; cdong@mdanderson.org	dong, chen/B-3181-2009; Huang, Xiaoyan/N-2561-2014; Jetten, Anton/C-3736-2019; Zhang, Zhengmao/C-4566-2014	dong, chen/0000-0002-0084-9130; Jetten, Anton/0000-0003-0954-4445; Zhang, Zhengmao/0000-0002-7968-9968; Chung, Yeonseok/0000-0001-5780-4841; ZHANG, ZHENGMAO/0000-0003-4035-0331; Reynolds, Joseph/0000-0003-3490-0544; Martinez, Gustavo/0000-0003-0178-3329	National Institutes of Health Research [RO1AR050772, RC2AR059010-01, RO1AR053591, RO1CA108454, RO1DK073932]; Division of Intramural Research at the NIEHS [Z01-ES-101586]; NATIONAL CANCER INSTITUTE [R01CA108454] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR053591, R01AR050772, RC2AR059010] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK073932] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [Z01ES101586] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM063773] Funding Source: NIH RePORTER	National Institutes of Health Research(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Division of Intramural Research at the NIEHS; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	This work was supported, in whole or in part, by National Institutes of Health Research Grants RO1AR050772 and RC2AR059010-01 (to C. D.), RO1AR053591 and RO1CA108454 (to X. H. F.), RO1DK073932 (to X. L.), and by National Institutes of Health Grant Z01-ES-101586 (to A. J.) through the Division of Intramural Research at the NIEHS.	Bettelli E, 2006, NATURE, V441, P235, DOI 10.1038/nature04753; Chung Y, 2009, IMMUNITY, V30, P576, DOI 10.1016/j.immuni.2009.02.007; Datto MB, 1999, MOL CELL BIOL, V19, P2495; de Lafaille MAC, 2009, IMMUNITY, V30, P626, DOI 10.1016/j.immuni.2009.05.002; Descargues P, 2008, P NATL ACAD SCI USA, V105, P2487, DOI 10.1073/pnas.0712044105; Dong C, 2008, NAT REV IMMUNOL, V8, P337, DOI 10.1038/nri2295; Feng XH, 2000, EMBO J, V19, P5178, DOI 10.1093/emboj/19.19.5178; Feng XH, 2005, ANNU REV CELL DEV BI, V21, P659, DOI 10.1146/annurev.cellbio.21.022404.142018; He W, 2006, CELL, V125, P929, DOI 10.1016/j.cell.2006.03.045; Martinez GJ, 2008, ANN NY ACAD SCI, V1143, P188, DOI 10.1196/annals.1443.021; Nurieva R, 2007, NATURE, V448, P480, DOI 10.1038/nature05969; Ouyang W, 1998, IMMUNITY, V9, P745, DOI 10.1016/S1074-7613(00)80671-8; Wan YY, 2007, IMMUNOL REV, V220, P199, DOI 10.1111/j.1600-065X.2007.00565.x; Yang XO, 2008, IMMUNITY, V29, P44, DOI 10.1016/j.immuni.2008.05.007	14	76	78	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 18	2009	284	51					35283	35286		10.1074/jbc.C109.078238	http://dx.doi.org/10.1074/jbc.C109.078238			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	531EI	19887374	Green Published, hybrid			2022-12-25	WOS:000272645600004
J	Frank, DN; Wilson, SS; St Amand, AL; Pace, NR				Frank, Daniel N.; Wilson, Shandra S.; St Amand, Allison L.; Pace, Norman R.			Culture-Independent Microbiological Analysis of Foley Urinary Catheter Biofilms	PLOS ONE			English	Article							TRACT-INFECTION; BACTERIAL BIOFILMS; MICROBIAL DIVERSITY; COLONIZATION; PREVENTION; NUMBER; ARB; ERA	Background: Prevention of catheter-associated urinary tract infection (CAUTI), a leading cause of nosocomial disease, is complicated by the propensity of bacteria to form biofilms on indwelling medical devices [ 1,2,3,4,5]. Methodology/Principal Findings: To better understand the microbial diversity of these communities, we report the results of a culture-independent bacterial survey of Foley urinary catheters obtained from patients following total prostatectomy. Two patient subsets were analyzed, based on treatment or no treatment with systemic fluoroquinolone antibiotics during convalescence. Results indicate the presence of diverse polymicrobial assemblages that were most commonly observed in patients who did not receive systemic antibiotics. The communities typically contained both Gram-positive and Gram-negative microorganisms that included multiple potential pathogens. Conclusion/Significance: Prevention and treatment of CAUTI must take into consideration the possible polymicrobial nature of any particular infection.			Frank, DN (corresponding author), Univ Colorado, Dept Mol Cellular & Dev Biol, Boulder, CO 80309 USA.	norman.pace@colorado.edu						ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; Barford JMT, 2008, BJU INT, V102, P67, DOI 10.1111/j.1464-410X.2008.07465.x; CHAO A, 1984, SCAND J STAT, V11, P265; CHAO A, 1992, J AM STAT ASSOC, V87, P210, DOI 10.2307/2290471; Clec'h C, 2007, INFECT CONT HOSP EP, V28, P1367, DOI 10.1086/523279; COSTERTON JW, 1987, ANNU REV MICROBIOL, V41, P435, DOI 10.1146/annurev.mi.41.100187.002251; DeSantis TZ, 2006, NUCLEIC ACIDS RES, V34, pW394, DOI 10.1093/nar/gkl244; DeSantis TZ, 2006, APPL ENVIRON MICROB, V72, P5069, DOI 10.1128/AEM.03006-05; Ewing B, 1998, GENOME RES, V8, P186, DOI 10.1101/gr.8.3.186; Ewing B, 1998, GENOME RES, V8, P175, DOI 10.1101/gr.8.3.175; Frank DN, 2008, CURR OPIN GASTROEN, V24, P4, DOI 10.1097/MOG.0b013e3282f2b0e8; Frank DN, 2009, WOUND REPAIR REGEN, V17, P163, DOI 10.1111/j.1524-475X.2009.00472.x; Frank DN, 2008, BMC BIOINFORMATICS, V9, DOI 10.1186/1471-2105-9-420; Frank DN, 2003, J CLIN MICROBIOL, V41, P295, DOI 10.1128/JCM.41.1.295-303.2003; GANDERTON L, 1992, EUR J CLIN MICROBIOL, V11, P789, DOI 10.1007/BF01960877; GOOD IJ, 1953, BIOMETRIKA, V40, P237, DOI 10.2307/2333344; Huber T, 2004, BIOINFORMATICS, V20, P2317, DOI 10.1093/bioinformatics/bth226; Lane DS, 1990, NUCL ACID TECHNIQUES, P115, DOI DOI 10.1007/S00227-012-2133-0; Ludwig W, 2004, NUCLEIC ACIDS RES, V32, P1363, DOI 10.1093/nar/gkh293; Macleod SM, 2007, J MED MICROBIOL, V56, P1549, DOI 10.1099/jmm.0.47395-0; Maki DG, 2001, EMERG INFECT DIS, V7, P342, DOI 10.3201/eid0702.010240; Matsukawa M, 2005, UROLOGY, V65, P440, DOI 10.1016/j.urology.2004.10.065; NICKEL JC, 1989, UROLOGY, V34, P284; NICKEL JC, 1985, CAN J SURG, V28, P50; Nickel JC, 1985, CAN J SURG, V28, P54; Pace NR, 1997, SCIENCE, V276, P734, DOI 10.1126/science.276.5313.734; STAMM WE, 1991, AM J MED, V91, pS65, DOI 10.1016/0002-9343(91)90345-X; Stickler DJ, 2008, NAT CLIN PRACT UROL, V5, P598, DOI 10.1038/ncpuro1231; Tambyah PA, 2002, INFECT CONT HOSP EP, V23, P27, DOI 10.1086/501964; TENNEY JH, 1987, UROLOGY, V30, P444, DOI 10.1016/0090-4295(87)90376-1; Trautner BW, 2005, CURR OPIN INFECT DIS, V18, P37, DOI 10.1097/00001432-200502000-00007; WARREN JW, 1991, MED CLIN N AM, V75, P481, DOI 10.1016/S0025-7125(16)30465-5; Warren JW, 1997, INFECT DIS CLIN N AM, V11, P609, DOI 10.1016/S0891-5520(05)70376-7	33	64	65	0	11	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA	1932-6203			PLOS ONE	PLoS One	NOV 12	2009	4	11							e7811	10.1371/journal.pone.0007811	http://dx.doi.org/10.1371/journal.pone.0007811			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	518UW	19907661	gold, Green Published, Green Submitted			2022-12-25	WOS:000271721400010
J	Miragaia, M; de Lencastre, H; Perdreau-Remington, F; Chambers, HF; Higashi, J; Sullam, PM; Lin, J; Wong, KI; King, KA; Otto, M; Sensabaugh, GF; Diep, BA				Miragaia, Maria; de Lencastre, Herminia; Perdreau-Remington, Francoise; Chambers, Henry F.; Higashi, Julie; Sullam, Paul M.; Lin, Jessica; Wong, Kester I.; King, Katherine A.; Otto, Michael; Sensabaugh, George F.; Diep, Binh An			Genetic Diversity of Arginine Catabolic Mobile Element in Staphylococcus epidermidis	PLOS ONE			English	Article							ACME-ARCA GENE; AUREUS; SEQUENCE; CLONE; IDENTIFICATION; COMBINATION; RESISTANCE; VIRULENCE; USA300; MEC	Background: The methicillin-resistant Staphylococcus aureus clone USA300 contains a novel mobile genetic element, arginine catabolic mobile element ( ACME), that contributes to its enhanced capacity to grow and survive within the host. Although ACME appears to have been transferred into USA300 from S. epidermidis, the genetic diversity of ACME in the latter species remains poorly characterized. Methodology/Principal Findings: To assess the prevalence and genetic diversity of ACME, 127 geographically diverse S. epidermidis isolates representing 86 different multilocus sequence types (STs) were characterized. ACME was found in 51% (65/127) of S. epidermidis isolates. The vast majority (57/65) of ACME-containing isolates belonged to the predominant S. epidermidis clonal complex CC2. ACME was often found in association with different allotypes of staphylococcal chromosome cassette mec (SCCmec) which also encodes the recombinase function that facilities mobilization ACME from the S. epidermidis chromosome. Restriction fragment length polymorphism, PCR scanning and DNA sequencing allowed for identification of 39 distinct ACME genetic variants that differ from one another in gene content, thereby revealing a hitherto uncharacterized genetic diversity within ACME. All but one ACME variants were represented by a single S. epidermidis isolate; the singular variant, termed ACME-I.02, was found in 27 isolates, all of which belonged to the CC2 lineage. An evolutionary model constructed based on the eBURST algorithm revealed that ACME-I.02 was acquired at least on 15 different occasions by strains belonging to the CC2 lineage. Conclusions/Significance: ACME-I.02 in diverse S. epidermidis isolates were nearly identical in sequence to the prototypical ACME found in USA300 MRSA clone, providing further evidence for the interspecies transfer of ACME from S. epidermidis into USA300.			Miragaia, M (corresponding author), Univ Nova Lisboa, Inst Tecnol Quim & Biol, Mol Genet Lab, P-2780156 Oeiras, Portugal.	bdiep@medsfgh.ucsf.edu	Miragaia, Maria/J-2704-2015	Miragaia, Maria/0000-0002-1323-7184; Otto, Michael/0000-0002-2222-4115; /0000-0001-6816-8932	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [ZIAAI001080, R01AI041513, R01AI057433, R01AI070289] Funding Source: NIH RePORTER; NIAID NIH HHS [R01 AI057433, R01 AI041513, R01 AI070289] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		DELENCASTRE H, 1994, EUR J CLIN MICROBIOL, V13, P64, DOI 10.1007/BF02026129; Diep BA, 2006, LANCET, V367, P731, DOI 10.1016/S0140-6736(06)68231-7; Diep BA, 2008, J INFECT DIS, V197, P1523, DOI 10.1086/587907; Ellington MJ, 2008, J ANTIMICROB CHEMOTH, V61, P73, DOI 10.1093/jac/dkm422; GOERING RV, 2007, J CLIN MICROBIOL; JAFFE HW, 1980, J INFECT DIS, V141, P738, DOI 10.1093/infdis/141.6.738; KELLEY K, 2008, INT S STAPH STAPH IN; Kondo Y, 2007, ANTIMICROB AGENTS CH, V51, P264, DOI 10.1128/AAC.00165-06; Lina G, 2000, GRAM-POSITIVE PATHOGENS, P450; Miller LG, 2008, CLIN INFECT DIS, V46, P752, DOI 10.1086/526773; Miragaia M, 2008, J CLIN MICROBIOL, V46, P118, DOI 10.1128/JCM.01685-07; Miragaia M, 2007, J BACTERIOL, V189, P2540, DOI 10.1128/JB.01484-06; Miragaia M, 2005, MICROB DRUG RESIST, V11, P83, DOI 10.1089/mdr.2005.11.83; MONTGOMERY CP, 2009, INFECT IMMUN; NOBLE W. C., 1981, MICROBIOLOGY HUMAN S; Pi BR, 2009, J MED MICROBIOL, V58, P731, DOI 10.1099/jmm.0.007351-0; Thomas JC, 2007, J CLIN MICROBIOL, V45, P616, DOI 10.1128/JCM.01934-06; WENER KM, 2006, 44 ANN M INF DIS SOC, P118; Wielders CLC, 2001, LANCET, V357, P1674, DOI 10.1016/S0140-6736(00)04832-7; Wisplinghoff H, 2003, ANTIMICROB AGENTS CH, V47, P3574, DOI 10.1128/AAC.47.11.3574-3579.2003	20	82	85	0	7	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	NOV 6	2009	4	11							e7722	10.1371/journal.pone.0007722	http://dx.doi.org/10.1371/journal.pone.0007722			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	515ND	19893740	Green Submitted, Green Published, gold			2022-12-25	WOS:000271478000008
J	Gorres, KL; Pua, KH; Raines, RT				Gorres, Kelly L.; Pua, Khian Hong; Raines, Ronald T.			Stringency of the 2-His-1-Asp Active-Site Motif in Prolyl 4-Hydroxylase	PLOS ONE			English	Article							PROTEIN DISULFIDE-ISOMERASE; CAENORHABDITIS-ELEGANS; DIRECTED MUTAGENESIS; DIOXYGEN ACTIVATION; CRYSTAL-STRUCTURE; HALOGENASE CYTC3; IRON; COLLAGEN; ENZYMES; 2-HIS-1-CARBOXYLATE	The non-heme iron(II) dioxygenase family of enzymes contain a common 2-His-1-carboxylate iron-binding motif. These enzymes catalyze a wide variety of oxidative reactions, such as the hydroxylation of aliphatic C-H bonds. Prolyl 4-hydroxylase (P4H) is an alpha-ketoglutarate-dependent iron(II) dioxygenase that catalyzes the post-translational hydroxylation of proline residues in protocollagen strands, stabilizing the ensuing triple helix. Human P4H residues His412, Asp414, and His483 have been identified as an iron-coordinating 2-His-1-carboxylate motif. Enzymes that catalyze oxidative halogenation do so by a mechanism similar to that of P4H. These halogenases retain the active-site histidine residues, but the carboxylate ligand is replaced with a halide ion. We replaced Asp414 of P4H with alanine (to mimic the active site of a halogenase) and with glycine. These substitutions do not, however, convert P4H into a halogenase. Moreover, the hydroxylase activity of D414A P4H cannot be rescued with small molecules. In addition, rearranging the two His and one Asp residues in the active site eliminates hydroxylase activity. Our results demonstrate a high stringency for the iron-binding residues in the P4H active site. We conclude that P4H, which catalyzes an especially demanding chemical transformation, is recalcitrant to change.			Gorres, KL (corresponding author), Univ Wisconsin, Dept Biochem, 420 Henry Mall, Madison, WI 53705 USA.	rtraines@wisc.edu	Raines, Ronald T./A-5009-2013	Raines, Ronald T./0000-0001-7164-1719	NIAMS NIH HHS [R01 AR044276] Funding Source: Medline; NIGMS NIH HHS [T32 GM008505] Funding Source: Medline; FDA HHS [T32 BM008505] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR044276] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); FDA HHS; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		Blasiak LC, 2006, NATURE, V440, P368, DOI 10.1038/nature04544; Clifton IJ, 2006, J INORG BIOCHEM, V100, P644, DOI 10.1016/j.jinorgbio.2006.01.024; Costas M, 2004, CHEM REV, V104, P939, DOI 10.1021/cr020628n; Fitzpatrick PF, 2003, BIOCHEMISTRY-US, V42, P2081, DOI 10.1021/bi0271493; Friedman L, 2000, P NATL ACAD SCI USA, V97, P4736, DOI 10.1073/pnas.97.9.4736; Galonic DP, 2007, NAT CHEM BIOL, V3, P113, DOI 10.1038/nchembio856; Gorres KL, 2008, BIOCHEMISTRY-US, V47, P9447, DOI 10.1021/bi8009373; Gorres KL, 2009, ANAL BIOCHEM, V386, P181, DOI 10.1016/j.ab.2008.11.046; Grzyska PK, 2007, J INORG BIOCHEM, V101, P797, DOI 10.1016/j.jinorgbio.2007.01.011; Hoffart LM, 2006, P NATL ACAD SCI USA, V103, P14738, DOI 10.1073/pnas.0604005103; Holster T, 2007, J BIOL CHEM, V282, P2512, DOI 10.1074/jbc.M606608200; Kersteen EA, 2004, PROTEIN EXPRES PURIF, V38, P279, DOI 10.1016/j.pep.2004.09.008; Koehntop KD, 2005, J BIOL INORG CHEM, V10, P87, DOI 10.1007/s00775-005-0624-x; Koski MK, 2009, J BIOL CHEM, V284, P25290, DOI 10.1074/jbc.M109.014050; Lamberg A, 1996, J BIOL CHEM, V271, P11988, DOI 10.1074/jbc.271.20.11988; Leitgeb S, 2008, BIOCHEM SOC T, V36, P1180, DOI 10.1042/BST0361180; McGinnis K, 1996, BIOCHEMISTRY-US, V35, P3957, DOI 10.1021/bi951520n; Myllyharju J, 2003, MATRIX BIOL, V22, P15, DOI 10.1016/S0945-053X(03)00006-4; Myllyharju J, 1997, EMBO J, V16, P1173, DOI 10.1093/emboj/16.6.1173; Qiao YF, 2006, SCIENCE, V311, P1293, DOI 10.1126/science.1122224; Searls T, 2005, J LIPID RES, V46, P1660, DOI 10.1194/jlr.M500034-JLR200; Shoulders MD, 2009, ANNU REV BIOCHEM, V78, P929, DOI 10.1146/annurev.biochem.77.032207.120833; Straganz GD, 2006, CHEMBIOCHEM, V7, P1536, DOI 10.1002/cbic.200600152; TUDERMAN L, 1977, EUR J BIOCHEM, V80, P341, DOI 10.1111/j.1432-1033.1977.tb11888.x; VUORI K, 1992, P NATL ACAD SCI USA, V89, P7467, DOI 10.1073/pnas.89.16.7467; VUORI K, 1992, EMBO J, V11, P4213, DOI 10.1002/j.1460-2075.1992.tb05515.x; Winter AD, 2000, MOL CELL BIOL, V20, P4084, DOI 10.1128/MCB.20.11.4084-4093.2000; Wong C, 2009, J AM CHEM SOC, V131, P4872, DOI 10.1021/ja8097355	28	17	18	0	6	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA	1932-6203			PLOS ONE	PLoS One	NOV 5	2009	4	11							e7635	10.1371/journal.pone.0007635	http://dx.doi.org/10.1371/journal.pone.0007635			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	515HI	19890397	Green Published, gold, Green Submitted			2022-12-25	WOS:000271459700001
J	Brito, MO; Caso, LM; Balbuena, H; Bailey, RC				Brito, Maximo O.; Caso, Lilliam M.; Balbuena, Hannabell; Bailey, Robert C.			Acceptability of Male Circumcision for the Prevention of HIV/AIDS in the Dominican Republic	PLOS ONE			English	Article							HIV PREVENTION; MEN; WILLINGNESS; INFECTION; UGANDA; TRIAL; RISK; SEX	Background: Male circumcision (MC) is an effective strategy to prevent HIV infection in heterosexual men. To our knowledge, there are no studies of the acceptability of this procedure in the Dominican Republic (DR). The main objective of this study was to assess the acceptability of MC to prevent HIV transmission among men ages 18 to 50 years in the Altagracia Province in the Dominican Republic. Because differences in culture and beliefs between Haitians and Dominicans could potentially influence their acceptability of MC, we conducted a comparative analysis based on national origin. Methods: A survey was administered to a convenience sample of 368 men. The questionnaire was divided in 3 sections: 1) Background demographics (including national origin), 2) Male circumcision and 3) Sexual health. Stratified and logistic multivariate regression analyses were performed to identify factors associated with the acceptability of MC. Results: The sample consisted of 238 (65%) Dominicans and 130 (35%) Haitian immigrants. Almost all participants were uncircumcised (95%) and about half (52%) were single. The overall acceptability of MC was 29%. The number of men willing to be circumcised increased to 67% after an information session explaining the benefits of the procedure. 74% of men reported that they would be willing to circumcise their sons after hearing that information. In multivariate analysis, Haitian nationality (OR = 1.86, 95% CI 1.01-3.41), knowing that circumcision improves hygiene (OR = 2.78, 95% CI 1.29-6.0) and not believing that circumcision decreases sexual pleasure (OR = 2.18, 95% CI 1.20-3.94) were associated with a higher acceptability of the procedure. Although age was not significantly associated with the willingness to be circumcised in the multivariate analysis, stratified analysis based on national origin suggested that younger Dominicans (<30 years of age) are more likely to accept the procedure when compared to their older counterparts (OR = 2.17, 95% CI 1.14-4.12). Conclusions: An important number of sexually active men in the DR may be willing to be circumcised if educational resources detailing the benefits of the procedure are made available. These educational activities would constitute a great opportunity to teach about sexual health and reinforce safe sex practices.			Brito, MO (corresponding author), Univ Illinois, Infect Dis Sect, Chicago, IL 60607 USA.	mbrito@uic.edu	Brito, Maximo O./AAI-4905-2021	Brito, Maximo O./0000-0003-4463-514X	NIAID NIH HHS [2U01AI050440-06, U01 AI050440] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [U01AI050440] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Auvert B, 2005, PLOS MED, V2, P1112, DOI 10.1371/journal.pmed.0020298; Bailey RC, 1999, J ACQ IMMUN DEF SYND, V22, P294; Bailey RC, 2007, LANCET, V369, P643, DOI 10.1016/S0140-6736(07)60312-2; Begley EB, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002731; BRITO M, 2008, AIDS 2008 17 INT AID; *CESDEM, 2007, ENC DEM SAL; *CESDEM, 2007, ENC SOC SOBR VIH SID; Drain PK, 2006, BMC INFECT DIS, V6, DOI 10.1186/1471-2334-6-172; Gray RH, 2007, LANCET, V369, P657, DOI 10.1016/S0140-6736(07)60313-4; GUANIRA J, 2007, 4 IAS C HIV PATH TRE; Halperin D., 2006, AIDS 2006 16 INT AID; Halperin DT, 2009, JAIDS-J ACQ IMM DEF, V51, pS52, DOI 10.1097/QAI.0b013e3181a267e4; *JOINT UN PROGR HI, 2008, REP GLOB AIDS EP; Kebaabetswe P, 2003, SEX TRANSM INFECT, V79, P214, DOI 10.1136/sti.79.3.214; KRUPP K, 2008, IND AIDS 2008 17 INT; Rain-Taljaard RC, 2003, AIDS CARE, V15, P315, DOI 10.1080/0954012031000105379; Ruan YH, 2009, AIDS PATIENT CARE ST, V23, P315, DOI 10.1089/apc.2008.0199; TIEU H, 2008, AIDS 2008 17 INT AID; VIOLANTE T, 2004, 15 INT AIDS C; Westercamp N, 2007, AIDS BEHAV, V11, P341, DOI 10.1007/s10461-006-9169-4	20	35	38	0	1	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	NOV 2	2009	4	11							e7687	10.1371/journal.pone.0007687	http://dx.doi.org/10.1371/journal.pone.0007687			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	514RX	19888322	Green Published, gold, Green Submitted			2022-12-25	WOS:000271414400006
J	Chenu, O; Vuillerme, N; Demongeot, J; Payan, Y				Chenu, Olivier; Vuillerme, Nicolas; Demongeot, Jacques; Payan, Yohan			A Wireless Lingual Feedback Device to Reduce Overpressures in Seated Posture: A Feasibility Study	PLOS ONE			English	Article							PLACED TACTILE BIOFEEDBACK; ELECTROTACTILE STIMULUS ARRAY; JOINT POSITION SENSE; TONGUE; THRESHOLD; SYSTEM; ANKLE	Background: Pressure sores are localized injuries to the skin and underlying tissues and are mainly resulting from overpressure. Paraplegic peoples are particularly subjects to pressure sores because of long-time seated postures and sensory deprivation at the lower limbs. Methodology/Principal Findings: Here we report outcomes of a feasibility trial involving a biofeedback system aimed at reducing buttock overpressure whilst an individual is seated. The system consists of (1) pressure sensors, (2) a laptop coupling sensors and actuator (3) a wireless Tongue Display Unit (TDU) consisting of a circuit embedded in a dental retainer with electrodes put in contact with the tongue. The principle consists in (1) detecting overpressures in people who are seated over long periods of time, (2) estimating a postural change that could reduce these overpressures and (3) communicating this change through directional information transmitted by the TDU. Twenty-four healthy subjects voluntarily participated in this study. Twelve healthy subjects initially formed the experimental group (EG) and were seated on a chair with the wireless TDU inside their mouth. They were asked to follow TDU orders that were randomly spread throughout the session. They were evaluated during two experimental sessions during which 20 electro-stimulations were sent. Twelve other subjects, added retrospectively, formed the control group (CG). These subjects participated in one session of the same experiment without any biofeedback. Three dependent variables were computed: (1) the ability of subjects to reach target posture (EG versus CG), (2) high pressure reductions after a biofeedback (EG versus CG) and (3) the level of these reductions relative to their initial values (EG only). Results show (1) that EG reached target postures in 90.2% of the trials, against 5,3% in the CG, (2) a significant reduction in overpressures in the EG compared to the CG and (3), for the EG, that the higher the initial pressures were, the more they were decreased. Conclusions/Significance: The findings suggest that, in this trial, subjects were able to use a tongue tactile feedback system to reduce buttock overpressure while seated. Further evaluation of this system on paraplegic subjects remains to be done.			Chenu, O (corresponding author), TIMC IMAG, CNRS, UJF, UMR 5525, La Tronche, France.	olivier.chenu@imag.fr	Demongeot, Jacques/GQI-1558-2022; PAYAN, Yohan/E-3993-2013; Payan, Yohan/N-3980-2019; Demongeot, Jacques/AAZ-2539-2020; Nicolas, Vuillerme/C-6692-2009; VUILLERME, Nicolas/U-5767-2019	PAYAN, Yohan/0000-0002-6012-4123; Payan, Yohan/0000-0002-6012-4123; Demongeot, Jacques/0000-0002-8335-9240; Nicolas, Vuillerme/0000-0002-5202-4173; VUILLERME, Nicolas/0000-0003-3773-393X				BACH P, 1969, NATURE, V221, P963, DOI 10.1038/221963a0; Bach-y-Rita P, 1998, J REHABIL RES DEV, V35, P427; Bach-y-Rita P., 1972, BRAIN MECH SENSORY S; Cardenas DD, 2004, ARCH PHYS MED REHAB, V85, P1757, DOI 10.1016/j.apmr.2004.03.016; COLIN B, 2008, Patent No. 2008139099; CULLUM N, 2004, COCHRANE DATABASE SY; KACZMAREK KA, 1991, THESIS U WISCONSIN M; Linder-Ganz E, 2006, J BIOMECH, V39, P2725, DOI 10.1016/j.jbiomech.2005.08.010; Moreau-Gaudry A, 2006, STUD HEALTH TECHNOL, V124, P926; Reddy M, 2006, JAMA-J AM MED ASSOC, V296, P974, DOI 10.1001/jama.296.8.974; Robineau F, 2007, IEEE T BIO-MED ENG, V54, P711, DOI 10.1109/TBME.2006.889180; Sampaio E, 2001, BRAIN RES, V908, P204, DOI 10.1016/S0006-8993(01)02667-1; Trulsson M, 1997, J NEUROPHYSIOL, V77, P737, DOI 10.1152/jn.1997.77.2.737; Vuillerme N, 2008, NEUROSCI LETT, V431, P206, DOI 10.1016/j.neulet.2007.11.049; Vuillerme N, 2007, EXP BRAIN RES, V183, P235, DOI 10.1007/s00221-007-1039-4; Vuillerme N, 2007, EXP BRAIN RES, V181, P547, DOI 10.1007/s00221-007-0953-9; Vuillerme N, 2007, EXP BRAIN RES, V179, P409, DOI 10.1007/s00221-006-0800-4; Vuillerme N, 2006, NEUROSCI LETT, V405, P19, DOI 10.1016/j.neulet.2006.06.035	18	17	17	1	8	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA	1932-6203			PLOS ONE	PLoS One	OCT 30	2009	4	10							e7550	10.1371/journal.pone.0007550	http://dx.doi.org/10.1371/journal.pone.0007550			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	514RW	19888336	Green Published, gold, Green Submitted			2022-12-25	WOS:000271414300002
J	Deak, E; Wilson, SD; White, E; Carr, JH; Balajee, SA				Deak, Eszter; Wilson, Selwyn D.; White, Elizabeth; Carr, Janice H.; Balajee, S. Arunmozhi			Aspergillus terreus Accessory Conidia Are Unique in Surface Architecture, Cell Wall Composition and Germination Kinetics	PLOS ONE			English	Article							AMPHOTERICIN-B; CANDIDA-ALBICANS; PULMONARY ASPERGILLOSIS; ERGOSTEROL CONTENT; MURINE MODEL; FUMIGATUS; SUSCEPTIBILITY; INFECTIONS; BIOSYNTHESIS; QUANTITATION	Infection with Aspergillus terreus is more likely to result in invasive, disseminated disease when compared to other Aspergillus species; importantly this species appears to be less susceptible to the antifungal drug amphotericin B. Unique to this species is the ability to produce specialized structures denoted as accessory conidia (AC) directly on hyphae both in vitro and in vivo. With the hypothesis that production of AC by A. terreus may enhance virulence of this organism, we analyzed the phenotype, structure and metabolic potential of these conidia. Comparison of A. terreus phialidic conidia (conidia that arise from conidiophores, PC) and AC architecture by electron microscopy revealed distinct morphological differences between the two conidial forms; AC have a smoother, thicker outer cell surface with no apparent pigment-like layer. Further, AC germinated rapidly, had enhanced adherence to microspheres, and were metabolically more active compared to PC. Additionally, AC contained less cell membrane ergosterol, which correlated with decreased susceptibility to AMB as determined using a flow cytometry based analysis. Furthermore, AC exhibited surface patches of beta 1-3 glucan, suggestive of attachment scarring. Collectively, the findings of this study suggest a possible role for AC in A. terreus pathogenesis.			Deak, E (corresponding author), Ctr Dis Control & Prevent, Mycot Dis Branch, Atlanta, GA 30333 USA.	fir3@cdc.gov						AINSWORTH G. C., 1955, Veterinary Record, V67, P88; Arthington-Skaggs BA, 1999, J CLIN MICROBIOL, V37, P3332, DOI 10.1128/JCM.37.10.3332-3337.1999; Arthington-Skaggs BA, 2000, ANTIMICROB AGENTS CH, V44, P2081, DOI 10.1128/AAC.44.8.2081-2085.2000; Balajee SA, 2002, J CLIN MICROBIOL, V40, P2741, DOI 10.1128/JCM.40.8.2741-2745.2002; Bernard M, 2001, MED MYCOL, V39, P9, DOI 10.1080/mmy.39.1.9.17; CLSI/Clinical a.L.S. Institute, 2002, M38A CLSI; Dannaoui E, 2000, J MED MICROBIOL, V49, P601, DOI 10.1099/0022-1317-49-7-601; Gantner BN, 2005, EMBO J, V24, P1277, DOI 10.1038/sj.emboj.7600594; Girardin H, 1999, LETT APPL MICROBIOL, V29, P364, DOI 10.1046/j.1472-765X.1999.00643.x; Hohl TM, 2005, PLOS PATHOG, V1, P232, DOI 10.1371/journal.ppat.0010030; Iwen PC, 1998, CLIN INFECT DIS, V26, P1092, DOI 10.1086/520297; Langfelder K, 1998, MED MICROBIOL IMMUN, V187, P79, DOI 10.1007/s004300050077; Lass-Florl C, 2005, ANTIMICROB AGENTS CH, V49, P2539, DOI 10.1128/AAC.49.6.2539-2540.2005; Latge J P, 1993, Arch Med Res, V24, P269; Luther K, 2007, CELL MICROBIOL, V9, P368, DOI 10.1111/j.1462-5822.2006.00796.x; Magill SS, 2008, EXPERT OPIN PHARMACO, V9, P193, DOI 10.1517/14656566.9.2.193 ; Malani AN, 2007, DRUGS, V67, P1803, DOI 10.2165/00003495-200767130-00001; Moss BJ, 2008, BIOTECHNOL PROGR, V24, P780, DOI 10.1021/bp070334t; Raper BK., 1965, GENUS ASPERGILLUS; SANDE WV, 2009, MED MYCOL, P1; Steinbach WJ, 2004, CLIN INFECT DIS, V39, P192, DOI 10.1086/421950; Sterling TR, 1998, DRUG RESIST UPDATE, V1, P161, DOI 10.1016/S1368-7646(98)80034-4; THAU N, 1994, INFECT IMMUN, V62, P4380, DOI 10.1128/IAI.62.10.4380-4388.1994; Walsh TJ, 2004, CLIN MICROBIOL INFEC, V10, P48, DOI 10.1111/j.1470-9465.2004.00839.x; Walsh TJ, 2003, J INFECT DIS, V188, P305, DOI 10.1086/377210; Wheeler RT, 2008, PLOS PATHOG, V4, DOI 10.1371/journal.ppat.1000227	26	34	34	1	7	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	OCT 30	2009	4	10							e7673	10.1371/journal.pone.0007673	http://dx.doi.org/10.1371/journal.pone.0007673			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	514RW	19888344	Green Published, gold			2022-12-25	WOS:000271414300017
J	Mehra, R; Londono, D; Sondey, M; Lawson, C; Cadavid, D				Mehra, Rohit; Londono, Diana; Sondey, Marie; Lawson, Catherine; Cadavid, Diego			Structure-Function Investigation of Vsp Serotypes of the Spirochete Borrelia hermsii	PLOS ONE			English	Article							SURFACE PROTEIN-C; RELAPSING FEVER BORRELIOSIS; LYME-DISEASE SPIROCHETE; ANTIGENIC VARIATION; CRYSTAL-STRUCTURE; PERSISTENT INFECTION; NEUROTROPIC STRAIN; MOUSE MODEL; TURICATAE; BURGDORFERI	Background: Relapsing fever (RF) spirochetes are notable for multiphasic antigenic variation of polymorphic outer membrane lipoproteins, a phenomenon responsible for immune evasion. An additional role in tissue localization is suggested by the finding that isogenic serotypes 1 (Bt1) and 2 (Bt2) of the RF spirochete Borrelia turicatae, which differ only in the Vsp they express, exhibit marked differences in clinical disease severity and tissue localization during infection. Methodology/Principal Findings: Here we used known vsp DNA sequences encoding for B. turicatae and Borrelia hermsii Vsp proteins with variable regions and then studied whether there are differences in disease expression and tissue localization of their corresponding serotypes during mouse infection. For sequence and structural comparisons we focused exclusively on amino acid residues predicted to project away from the spirochetes surface, referred to as the Vsp dome. Disease severity and tissue localization were studied during persistent infection with individual or mixed serotypes in SCID mice. The results showed that all Vsp domes clustered into 3 main trunks, with the domes for B. turicatae Vsp1 (BtVsp1) and BtVsp2 clustering into separate ones. B. hermsii serotypes whose Vsp domes clustered with the BtVsp1 dome were less virulent but localized to the brain more. The BtVsp2 dome was the oddball among all and Bt2 was the only serotype that caused severe arthritis. Conclusion/Significance: These findings indicate that there is significant variability in Vsp dome structure, disease severity, and tissue localization among serotypes of B. hermsii.			Mehra, R (corresponding author), UMDNJ New Jersey Med Sch, Dept Neurol, Newark, NJ USA.	dcadavid@partners.org		Lawson, Catherine/0000-0002-3261-7035	NINDS NIH HHS [R21 NS057545, R21 NS057545-01A2, 1R21NS053997-01, R21 NS057545-02, R21 NS053997, 7R21NS057545-02, R21 NS057545-03] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R21NS053997, R21NS057545] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Alugupalli KR, 2003, J IMMUNOL, V170, P3819, DOI 10.4049/jimmunol.170.7.3819; BARBOUR AG, 1991, MOL MICROBIOL, V5, P489, DOI 10.1111/j.1365-2958.1991.tb02132.x; BARBOUR AG, 1986, MICROBIOL REV, V50, P381, DOI 10.1128/MMBR.50.4.381-400.1986; Barbour AG, 2000, INFECT IMMUN, V68, P7114, DOI 10.1128/IAI.68.12.7114-7121.2000; Barbour AG, 2001, INFECT IMMUN, V69, P1009, DOI 10.1128/IAI.69.2.1009-1015.2001; Barbour AG, 2006, P NATL ACAD SCI USA, V103, P18290, DOI 10.1073/pnas.0605302103; Bunikis J, 2004, EMERG INFECT DIS, V10, P1661, DOI 10.3201/eid1009.040236; Byram R, 2004, J BACTERIOL, V186, P3561, DOI 10.1128/JB.186.11.3561-3569.2004; Cadavid D, 1998, CLIN INFECT DIS, V26, P151, DOI 10.1086/516276; CADAVID D, 1994, J EXP MED, V179, P631, DOI 10.1084/jem.179.2.631; Cadavid D, 1997, INFECT IMMUN, V65, P3352, DOI 10.1128/IAI.65.8.3352-3360.1997; Cadavid D, 2001, INFECT IMMUN, V69, P3389, DOI 10.1128/IAI.69.5.3389-3397.2001; CADAVID D, 1993, J INFECT DIS, V168, P143, DOI 10.1093/infdis/168.1.143; Cadavid D, 2007, J INFECT DIS, V195, P1686, DOI 10.1086/516783; CARTER CJ, 1994, INFECT IMMUN, V62, P2792, DOI 10.1128/IAI.62.7.2792-2799.1994; Connolly SE, 2001, J IMMUNOL, V167, P3029, DOI 10.4049/jimmunol.167.6.3029; Dai QY, 2006, MOL MICROBIOL, V60, P1329, DOI 10.1111/j.1365-2958.2006.05177.x; Deitsch KW, 1997, MICROBIOL MOL BIOL R, V61, P281, DOI 10.1128/.61.3.281-293.1997; DIANA MAL, 2008, INFECT IMMUN, V77, P5508; Eicken C, 2001, J BIOL CHEM, V276, P10010, DOI 10.1074/jbc.M010062200; ENGH RA, 1991, ACTA CRYSTALLOGR A, V47, P392, DOI 10.1107/S0108767391001071; Fiser A, 2003, METHOD ENZYMOL, V374, P461, DOI 10.1016/S0076-6879(03)74020-8; FRENCH CJ, 1978, BIOCHIM BIOPHYS ACTA, V537, P386, DOI 10.1016/0005-2795(78)90523-8; Gelderblom H, 2007, J NEUROPATH EXP NEUR, V66, P208, DOI 10.1097/01.jnen.0000248556.30209.6d; Gelderblom H, 2007, AM J PATHOL, V170, P251, DOI 10.2353/ajpath.2007.060407; Grimm D, 2004, P NATL ACAD SCI USA, V101, P3142, DOI 10.1073/pnas.0306845101; Hinnebusch BJ, 1998, INFECT IMMUN, V66, P432, DOI 10.1128/IAI.66.2.432-440.1998; Kumaran D, 2001, EMBO J, V20, P971, DOI 10.1093/emboj/20.5.971; Lawson CL, 2006, J BACTERIOL, V188, P4522, DOI 10.1128/JB.00028-06; Li H, 1997, P NATL ACAD SCI USA, V94, P3584, DOI 10.1073/pnas.94.8.3584; Lin T, 2003, FEMS MICROBIOL LETT, V228, P249, DOI 10.1016/S0378-1097(03)00763-8; Londono D, 2005, INFECT IMMUN, V73, P7669, DOI 10.1128/IAI.73.11.7669-7676.2005; LONDONO D, 2008, J NEUROPATHOL EXP NE, V67; Londono D, 2008, J IMMUNOL, V181, P2076, DOI 10.4049/jimmunol.181.3.2076; Magoun L, 2000, MOL MICROBIOL, V36, P886, DOI 10.1046/j.1365-2958.2000.01906.x; Murshudov GN, 1997, ACTA CRYSTALLOGR D, V53, P240, DOI 10.1107/S0907444996012255; Pennington PM, 1997, INFECT IMMUN, V65, P285, DOI 10.1128/IAI.65.1.285-292.1997; Pennington PM, 1999, INFECT IMMUN, V67, P4637, DOI 10.1128/IAI.67.9.4637-4645.1999; Porcella SF, 2005, INFECT IMMUN, V73, P6647, DOI 10.1128/IAI.73.10.6647-6658.2005; Schwede T, 2003, NUCLEIC ACIDS RES, V31, P3381, DOI 10.1093/nar/gkg520; Sethi N, 2006, INFECT IMMUN, V74, P6408, DOI 10.1128/IAI.00538-06; STOENNER HG, 1982, J EXP MED, V156, P1297, DOI 10.1084/jem.156.5.1297; Tilly K, 2007, INFECT IMMUN, V75, P1517, DOI 10.1128/IAI.01725-06; Tilly K, 2006, INFECT IMMUN, V74, P3554, DOI 10.1128/IAI.01950-05; Zucker WR, 2001, J BIOL CHEM, V276, P457, DOI 10.1074/jbc.M008449200; Zuckert WR, 2004, INFECT IMMUN, V72, P1463, DOI 10.1128/IAI.72.3.1463-1469.2004	46	15	15	0	3	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA	1932-6203			PLOS ONE	PLoS One	OCT 30	2009	4	10							e7597	10.1371/journal.pone.0007597	http://dx.doi.org/10.1371/journal.pone.0007597			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	514RW	19888463	Green Submitted, Green Published, gold			2022-12-25	WOS:000271414300004
J	Lei, Z; Li, B; Yang, ZS; Fang, HS; Zhang, GM; Feng, ZH; Huang, B				Lei, Zhang; Li, Bo; Yang, Zhuoshun; Fang, Haoshu; Zhang, Gui-Mei; Feng, Zuo-Hua; Huang, Bo			Regulation of HIF-1 alpha and VEGF by miR-20b Tunes Tumor Cells to Adapt to the Alteration of Oxygen Concentration	PLOS ONE			English	Article							HYPOXIA-INDUCED ANGIOGENESIS; INDUCIBLE FACTOR 1-ALPHA; FACTOR-I HIF-1; INDUCED APOPTOSIS; CANCER; MICRORNAS; MICROENVIRONMENT; EXPRESSION; DIFFERENTIATION; TRANSCRIPTION	The regulation of HIF-1 alpha is considered to be realized by pVHL-mediated ubiquitin-26S proteasome pathway at a post-transcriptional level. The discovery of a class of small noncoding RNAs, called microRNAs, implies alternative mechanism of regulation of HIF-1 alpha. Here, we show that miR-20b plays an important role in fine-tuning the adaptation of tumor cells to oxygen concentration. The inhibition of miR-20b increased the protein levels of HIF-1 alpha and VEGF in normoxic tumor cells; the increase of miR-20b in hypoxic tumor cells, nevertheless, decreased the protein levels of HIF-1 alpha and VEGF. By using luciferase reporter vector system, we confirmed that miR-20b directly targeted the 3'UTR of Hif1a and Vegfa. On the other hand, the forced overexpression of HIF-1 alpha in normoxic tumor cells downregulated miR-20b expression. However, HIF-1 alpha knockdown in hypoxic tumor cells caused the increase of miR-20b. The differential expression of miR-20b has important biological significance in tumor cells, either enhancing the growth or favoring the survival of tumor cells upon the oxygen supply. Thus, we identify a novel molecular regulation mechanism through which miR-20b regulates HIF-1 alpha and VEGF and is regulated by HIF-1 alpha so to keep tumor cells adapting to different oxygen concentrations.			Lei, Z (corresponding author), Huazhong Univ Sci & Technol, Dept Biochem & Mol Biol, Tongji Med Coll, Wuhan 430074, Peoples R China.	tjhuangbo@hotmail.com						Ambros V, 2004, NATURE, V431, P350, DOI 10.1038/nature02871; Brennecke J, 2005, PLOS BIOL, V3, P404, DOI 10.1371/journal.pbio.0030085; Carmeliet P, 1998, NATURE, V394, P485, DOI 10.1038/28867; Choi KS, 2003, J BIOCHEM MOL BIOL, V36, P120; Forsythe JA, 1996, MOL CELL BIOL, V16, P4604; Giaccia AJ, 1996, SEMIN RADIAT ONCOL, V6, P46, DOI 10.1016/S1053-4296(96)80035-X; Giordano FJ, 2001, CURR OPIN GENET DEV, V11, P35, DOI 10.1016/S0959-437X(00)00153-2; Greijer AE, 2004, J CLIN PATHOL, V57, P1009, DOI 10.1136/jcp.2003.015032; Haddad JJ, 2001, FEBS LETT, V505, P269, DOI 10.1016/S0014-5793(01)02833-2; Hobert O, 2008, SCIENCE, V319, P1785, DOI 10.1126/science.1151651; Hua Z, 2006, PLOS ONE, V1, DOI 10.1371/journal.pone.0000116; Huang B, 2008, BLOOD, V112, P1269, DOI 10.1182/blood-2008-03-147033; Huang B, 2009, EMBO REP, V10, P180, DOI 10.1038/embor.2008.224; Iyer NV, 1998, GENE DEV, V12, P149, DOI 10.1101/gad.12.2.149; Ke QD, 2006, MOL PHARMACOL, V70, P1469, DOI 10.1124/mol.106.027029; Kim WY, 2004, J CLIN ONCOL, V22, P4991, DOI 10.1200/JCO.2004.05.061; Landais S, 2007, CANCER RES, V67, P5699, DOI 10.1158/0008-5472.CAN-06-4478; Liao D, 2007, CANCER METAST REV, V26, P281, DOI 10.1007/s10555-007-9066-y; Miska EA, 2005, CURR OPIN GENET DEV, V15, P563, DOI 10.1016/j.gde.2005.08.005; PEPPER MS, 1991, BIOCHEM BIOPH RES CO, V181, P902, DOI 10.1016/0006-291X(91)91276-I; Pouyssegur J, 2006, NATURE, V441, P437, DOI 10.1038/nature04871; Pugh CW, 2003, SEMIN CANCER BIOL, V13, P83, DOI 10.1016/S1044-579X(02)00103-7; RICHTER JE, 1999, CLIN PRACTICE GASTRO, V1, P1; Ruan Hangjun, 1999, Neoplasia (New York), V1, P431, DOI 10.1038/sj.neo.7900059; Sasabe E, 2005, CANCER SCI, V96, P394, DOI 10.1111/j.1349-7006.2005.00065.x; Semenza GL, 2001, J CLIN INVEST, V108, P39, DOI 10.1172/JCI13374; Semenza GL, 2003, NAT REV CANCER, V3, P721, DOI 10.1038/nrc1187; Shivdasani RA, 2006, BLOOD, V108, P3646, DOI 10.1182/blood-2006-01-030015; Sodhi A, 2000, CANCER RES, V60, P4873; Stiehl DP, 2002, FEBS LETT, V512, P157, DOI 10.1016/S0014-5793(02)02247-0; Sun Y, 2009, BREAST CANC RES TREA; Taguchi A, 2008, CANCER RES, V68, P5540, DOI 10.1158/0008-5472.CAN-07-6460; VAUPEL P, 1989, CANCER RES, V49, P6449; Weidemann A, 2008, CELL DEATH DIFFER, V15, P621, DOI 10.1038/cdd.2008.12; Wincewicz A, 2007, PATHOLOGY, V39, P334, DOI 10.1080/00313020701329765	35	155	163	0	9	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA	1932-6203			PLOS ONE	PLoS One	OCT 29	2009	4	10							e7629	10.1371/journal.pone.0007629	http://dx.doi.org/10.1371/journal.pone.0007629			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	512FP	19893619	Green Submitted, gold, Green Published			2022-12-25	WOS:000271232000008
J	Schibler, L; Gibbs, L; Benoist-Lasselin, C; Decraene, C; Martinovic, J; Loget, P; Delezoide, AL; Gonzales, M; Munnich, A; Jais, JP; Legeai-Mallet, L				Schibler, Laurent; Gibbs, Linda; Benoist-Lasselin, Catherine; Decraene, Charles; Martinovic, Jelena; Loget, Philippe; Delezoide, Anne-Lise; Gonzales, Marie; Munnich, Arnold; Jais, Jean-Philippe; Legeai-Mallet, Laurence			New Insight on FGFR3-Related Chondrodysplasias Molecular Physiopathology Revealed by Human Chondrocyte Gene Expression Profiling	PLOS ONE			English	Article							GROWTH-FACTOR RECEPTOR-3; ENDOCHONDRAL BONE-FORMATION; ACTIVATED PROTEIN-KINASE; NATRIURETIC PEPTIDE; THANATOPHORIC DYSPLASIA; SKELETAL DEVELOPMENT; ACTIN CYTOSKELETON; FGFR3 MUTATIONS; DIFFERENTIATION; PROLIFERATION	Endochondral ossification is the process by which the appendicular skeleton, facial bones, vertebrae and medial clavicles are formed and relies on the tight control of chondrocyte maturation. Fibroblast growth factor receptor ( FGFR) 3 plays a role in bone development and maintenance and belongs to a family of proteins which differ in their ligand affinities and tissue distribution. Activating mutations of the FGFR3 gene lead to craniosynostosis and multiple types of skeletal dysplasia with varying degrees of severity: thanatophoric dysplasia (TD), achondroplasia and hypochondroplasia. Despite progress in the characterization of FGFR3-mediated regulation of cartilage development, many aspects remain unclear. The aim and the novelty of our study was to examine whole gene expression differences occurring in primary human chondrocytes isolated from normal cartilage or pathological cartilage from TD-affected fetuses, using Affymetrix technology. The phenotype of the primary cells was confirmed by the high expression of chondrocytic markers. Altered expression of genes associated with many cellular processes was observed, including cell growth and proliferation, cell cycle, cell adhesion, cell motility, metabolic pathways, signal transduction, cell cycle process and cell signaling. Most of the cell cycle process genes were down-regulated and consisted of genes involved in cell cycle progression, DNA biosynthesis, spindle dynamics and cytokinesis. About eight percent of all modulated genes were found to impact extracellular matrix (ECM) structure and turnover, especially glycosaminoglycan (GAG) and proteoglycan biosynthesis and sulfation. Altogether, the gene expression analyses provide new insight into the consequences of FGFR3 mutations in cell cycle regulation, onset of pre-hypertrophic differentiation and concomitant metabolism changes. Moreover, impaired motility and ECM properties may also provide clues about growth plate disorganization. These results also suggest that many signaling pathways may be directly or indirectly altered by FGFR3 and confirm the crucial role of FGFR3 in the control of growth plate development.			Schibler, L (corresponding author), Univ Paris 05, Hop Necker, INSERM, Unite U781, Paris, France.	Laurence.legeai-mallet@inserm.fr	Legeai-Mallet, Laurence/E-6112-2016; SCHIBLER, laurent/AAQ-2630-2021	Legeai-Mallet, Laurence/0000-0003-4989-5856; BENOIST, Catherine/0000-0003-1779-0312; SCHIBLER, Laurent/0000-0003-3137-0859				Adams SL, 2007, J CELL PHYSIOL, V213, P635, DOI 10.1002/jcp.21262; Aikawa T, 2001, J BIOL CHEM, V276, P29347, DOI 10.1074/jbc.M101859200; Ambrosino C, 2003, MOL CELL BIOL, V23, P370, DOI 10.1128/MCB.23.1.370-381.2003; Aszodi A, 2003, GENE DEV, V17, P2465, DOI 10.1101/gad.277003; Benoist-Lasselin C, 2007, FEBS LETT, V581, P2593, DOI 10.1016/j.febslet.2007.04.079; Bumeister R, 2004, CURR BIOL, V14, P439, DOI 10.1016/j.cub.2004.02.037; BURGESS WH, 1989, ANNU REV BIOCHEM, V58, P575, DOI 10.1146/annurev.bi.58.070189.003043; Cheung AKL, 2008, CANCER RES, V68, P8137, DOI 10.1158/0008-5472.CAN-08-0904; Chuang PT, 1999, NATURE, V397, P617, DOI 10.1038/17611; Dailey L, 2003, J CELL BIOL, V161, P1053, DOI 10.1083/jcb.200302075; de Frutos CA, 2007, DEV CELL, V13, P872, DOI 10.1016/j.devcel.2007.09.016; Dhanasekaran DN, 2007, ONCOGENE, V26, P3185, DOI 10.1038/sj.onc.1210411; Eggenschwiler JT, 2006, DEV BIOL, V290, P1, DOI 10.1016/j.ydbio.2005.09.022; Forlino A, 2005, HUM MOL GENET, V14, P859, DOI 10.1093/hmg/ddi079; Frederick JP, 2008, P NATL ACAD SCI USA, V105, P11605, DOI 10.1073/pnas.0801182105; Gentleman RC, 2004, GENOME BIOL, V5, DOI 10.1186/gb-2004-5-10-r80; Gibbs L, 2007, BBA-MOL CELL RES, V1773, P502, DOI 10.1016/j.bbamcr.2006.12.010; Grashoff C, 2003, EMBO REP, V4, P432, DOI 10.1038/sj.embor.embor801; Greene LA, 2009, J NEUROCHEM, V108, P11, DOI 10.1111/j.1471-4159.2008.05749.x; Harrison RE, 2004, J CELL SCI, V117, P2151, DOI 10.1242/jcs.00955; Hellemans J, 2007, GENOME BIOL, V8, DOI 10.1186/gb-2007-8-2-r19; Itano N, 1999, J BIOL CHEM, V274, P25085, DOI 10.1074/jbc.274.35.25085; Karreth F, 2004, DEVELOPMENT, V131, P5717, DOI 10.1242/dev.01414; Kobayashi T, 2005, ENDOCRINOLOGY, V146, P1012, DOI 10.1210/en.2004-1343; Kurima K, 1998, P NATL ACAD SCI USA, V95, P8681, DOI 10.1073/pnas.95.15.8681; L'Hote CGM, 2005, EXP CELL RES, V304, P417, DOI 10.1016/j.yexcr.2004.11.012; Labrador JP, 2001, EMBO REP, V2, P446, DOI 10.1093/embo-reports/kve094; Lai LP, 2005, J CELL BIOCHEM, V96, P1163, DOI 10.1002/jcb.20635; Laplantine E, 2002, J CELL BIOL, V158, P741, DOI 10.1083/jcb.200205025; Legeai-Mallet L, 1998, J BIOL CHEM, V273, P13007, DOI 10.1074/jbc.273.21.13007; Legeai-Mallet L, 2004, BONE, V34, P26, DOI 10.1016/j.bone.2003.09.002; Li CY, 2007, DEVELOPMENT, V134, P167, DOI 10.1242/dev.02701; Mei W, 2005, BIOCHEM BIOPH RES CO, V328, P651, DOI 10.1016/j.bbrc.2004.11.067; Meyer AN, 2004, J BIOL CHEM, V279, P28450, DOI 10.1074/jbc.M403335200; Minina E, 2001, DEVELOPMENT, V128, P4523; Moon NS, 2008, DEV CELL, V14, P1, DOI 10.1016/j.devcel.2007.12.017; Morales TI, 2007, OSTEOARTHR CARTILAGE, V15, P861, DOI 10.1016/j.joca.2007.02.022; Murakami S, 2004, GENE DEV, V18, P290, DOI 10.1101/gad.1179104; Nojima H, 2008, NAT CELL BIOL, V10, P971, DOI 10.1038/ncb1757; Nowroozi N, 2005, HUM MOL GENET, V14, P1529, DOI 10.1093/hmg/ddi161; Ornitz DM, 2005, CYTOKINE GROWTH F R, V16, P205, DOI 10.1016/j.cytogfr.2005.02.003; Ozasa A, 2005, BONE, V36, P1056, DOI 10.1016/j.bone.2005.03.006; Park M, 2007, NAT CELL BIOL, V9, P287, DOI 10.1038/ncb1538; Pejchalova K, 2007, MOL GENET METAB, V92, P210, DOI 10.1016/j.ymgme.2007.06.014; Pombo-Suarez M, 2008, BMC MOL BIOL, V9, DOI 10.1186/1471-2199-9-17; Priore R, 2006, J CELL PHYSIOL, V207, P800, DOI 10.1002/jcp.20620; Provot S, 2006, DEVELOPMENT, V133, P651, DOI 10.1242/dev.02258; Raucci A, 2004, J BIOL CHEM, V279, P1747, DOI 10.1074/jbc.M310384200; Rousseau F, 1996, HUM MOL GENET, V5, P509, DOI 10.1093/hmg/5.4.509; ROUSSEAU F, 1994, NATURE, V371, P252, DOI 10.1038/371252a0; Rozenblatt-Rosen O, 2002, J CELL SCI, V115, P553; Sahni M, 1999, GENE DEV, V13, P1361, DOI 10.1101/gad.13.11.1361; Sahni M, 2001, DEVELOPMENT, V128, P2119; Serra R, 2008, ANAT REC, V291, P1049, DOI 10.1002/ar.20634; Settembre C, 2008, GENE DEV, V22, P2645, DOI 10.1101/gad.1711308; SMYTH GK, 2005, LIMMA LINEAR MODELS, P397; Solomon Lauren A., 2008, Birth Defects Research, V84, P123, DOI 10.1002/bdrc.20124; Tare RS, 2008, BONE, V42, P113, DOI 10.1016/j.bone.2007.08.032; Teixeira CC, 2008, DEV BIOL, V319, P171, DOI 10.1016/j.ydbio.2008.04.031; Tsumaki N, 2005, CYTOKINE GROWTH F R, V16, P279, DOI 10.1016/j.cytogfr.2005.04.001; Wang GY, 2007, DEV BIOL, V306, P612, DOI 10.1016/j.ydbio.2007.03.520; Wang IC, 2008, J BIOL CHEM, V283, P20770, DOI 10.1074/jbc.M709892200; Wang W, 2006, J BIOL CHEM, V281, P30848, DOI 10.1074/jbc.M605937200; Webster MK, 1997, TRENDS GENET, V13, P178, DOI 10.1016/S0168-9525(97)01131-1; WOODS A, 2009, J CELL MOL MED; Woods A, 2007, J CELL PHYSIOL, V213, P1, DOI 10.1002/jcp.21110; Wu S, 2007, J BIOL CHEM, V282, P33698, DOI 10.1074/jbc.M702991200; Yasoda A, 2004, NAT MED, V10, P80, DOI 10.1038/nm971; Zorn AM, 2001, CURR BIOL, V11, pR592, DOI 10.1016/S0960-9822(01)00360-8	69	20	21	0	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	OCT 29	2009	4	10							e7633	10.1371/journal.pone.0007633	http://dx.doi.org/10.1371/journal.pone.0007633			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	512FP	19898608	Green Published, Green Submitted, gold			2022-12-25	WOS:000271232000011
J	Koren, J; Jinwal, UK; Jin, Y; O'Leary, J; Jones, JR; Johnson, AG; Blair, LJ; Abisambra, JF; Chang, L; Miyata, Y; Cheng, AM; Guo, JP; Cheng, JQ; Gestwicki, JE; Dickey, CA				Koren, John, III; Jinwal, Umesh K.; Jin, Ying; O'Leary, John; Jones, Jeff R.; Johnson, Amelia G.; Blair, Laura J.; Abisambra, Jose F.; Chang, Lyra; Miyata, Yoshinari; Cheng, Anna M.; Guo, Jianping; Cheng, Jin Q.; Gestwicki, Jason E.; Dickey, Chad A.			Facilitating Akt Clearance via Manipulation of Hsp70 Activity and Levels	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEAT-SHOCK PROTEINS; HSP90 MOLECULAR CHAPERONE; BREAST-CANCER CELLS; QUALITY CONTROL; ATPASE ACTIVITY; METHYLENE-BLUE; CHIP; INHIBITOR; STRESS; APOPTOSIS	Members of the 70-kDa heat shock family can control and manipulate a host of oncogenic client proteins. This role of Hsp70 in both the folding and degradation of these client proteins makes it a potential drug target for certain forms of cancer. The phenothiazine family of compounds, as well as the flavonoid myricetin, was recently shown to inhibit Hsp70-ATPase activity, whereas members of the dihydropyrimidine family stimulated ATPase function. Akt, a major survival kinase, was found to be under the regulation of Hsp70, and when the ATPase activity of Hsp70 was increased or decreased by these compounds, Akt levels were also increased or decreased. Also, increasing Hsp70 levels concurrent with inhibition of its ATPase function synergistically reduced Akt levels to a greater extent than either manipulation alone, providing new insights about client fate decisions. Akt reductions mediated by Hsp70 inhibitors were prevented when Hsp70 expression was silenced with small interfering RNA. Inhibiting Hsp70 ATPase function produced cytotoxic events only in breast cancer cell lines where Akt dysfunction was previously shown, suggesting therapeutic specificity depending on the Hsp70 client profile. Thus, increasing Hsp70 levels combined with inhibiting its ATPase function may serve to dramatically reduce Akt levels and facilitate cell death in certain types of cancer.	[Koren, John, III; Jinwal, Umesh K.; Jin, Ying; O'Leary, John; Jones, Jeff R.; Johnson, Amelia G.; Blair, Laura J.; Abisambra, Jose F.; Cheng, Anna M.; Dickey, Chad A.] Univ S Florida, Dept Mol Med, Tampa, FL 33613 USA; [Chang, Lyra; Miyata, Yoshinari; Gestwicki, Jason E.] Univ Michigan, Dept Pathol, Inst Life Sci, Ann Arbor, MI 48109 USA; [Gestwicki, Jason E.] Univ Michigan, Dept Biol Chem, Inst Life Sci, Ann Arbor, MI 48109 USA; [Cheng, Anna M.; Guo, Jianping; Cheng, Jin Q.] H Lee Moffitt Canc Ctr & Res Inst, Dept Mol Oncol, Tampa, FL 33612 USA	State University System of Florida; University of South Florida; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; H Lee Moffitt Cancer Center & Research Institute	Dickey, CA (corresponding author), Univ S Florida, Dept Mol Med, 4001 E Fletcher Ave, Tampa, FL 33613 USA.	cdickey@health.usf.edu	Dickey, Chad A/H-4441-2011; Abisambra, Joe/AAP-3269-2020; Chang, Lyra/A-9516-2012; Abisambra, Jose/V-6860-2019	Abisambra, Jose/0000-0001-6341-679X; Jones, Jeffrey/0000-0002-7570-2571; Koren, John/0000-0002-6017-1763; Blair, Laura/0000-0002-4981-5564; Chang, Chia Yin/0000-0002-9608-4952	National Institutes of Health, NIA [R00AG031291]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS059690] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R00AG031291] Funding Source: NIH RePORTER	National Institutes of Health, NIA(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))	This work was supported by National Institutes of Health Grant R00AG031291 from NIA.	Bagatell R, 2000, CLIN CANCER RES, V6, P3312; Ballinger CA, 1999, MOL CELL BIOL, V19, P4535; Beliakoff J, 2004, ANTI-CANCER DRUG, V15, P651, DOI 10.1097/01.cad.0000136876.11928.be; Boulton DW, 1999, J PHARM PHARMACOL, V51, P353, DOI 10.1211/0022357991772367; Chang L, 2008, ANAL BIOCHEM, V372, P167, DOI 10.1016/j.ab.2007.08.020; CIOCCA DR, 1993, J NATL CANCER I, V85, P570, DOI 10.1093/jnci/85.7.570; Cyr DM, 2002, TRENDS BIOCHEM SCI, V27, P368, DOI 10.1016/S0968-0004(02)02125-4; Dai Q, 2003, EMBO J, V22, P5446, DOI 10.1093/emboj/cdg529; Dickey CA, 2008, P NATL ACAD SCI USA, V105, P3622, DOI 10.1073/pnas.0709180105; Dickey CA, 2007, J CLIN INVEST, V117, P648, DOI 10.1172/JCI29715; Dickey CA, 2006, J NEUROSCI, V26, P6985, DOI 10.1523/JNEUROSCI.0746-06.2006; Dickey Chad A., 2005, Current Alzheimer Research, V2, P231, DOI 10.2174/1567205053585927; Gabai VL, 2009, MOL CELL BIOL, V29, P559, DOI 10.1128/MCB.01041-08; Gao TY, 2002, J BIOL CHEM, V277, P31585, DOI 10.1074/jbc.M204335200; Grenert JP, 1997, J BIOL CHEM, V272, P23843, DOI 10.1074/jbc.272.38.23843; HACKETT AJ, 1977, J NATL CANCER I, V58, P1795, DOI 10.1093/jnci/58.6.1795; Havik B, 2007, ONCOL REP, V17, P1501; Jiang BM, 2009, FEBS J, V276, P2615, DOI 10.1111/j.1742-4658.2009.06989.x; Jinwal UK, 2009, J NEUROSCI, V29, P12079, DOI 10.1523/JNEUROSCI.3345-09.2009; Kelner M J, 1988, Basic Life Sci, V49, P895; Min JN, 2008, MOL CELL BIOL, V28, P4018, DOI 10.1128/MCB.00296-08; Modi S, 2007, J CLIN ONCOL, V25, P5410, DOI 10.1200/JCO.2007.11.7960; Munster PN, 2001, CANCER RES, V61, P2945; Ohnishi K, 2004, INT J RADIAT BIOL, V80, P607, DOI 10.1080/09553000412331283470; Pelicano H, 2006, LEUKEMIA, V20, P610, DOI 10.1038/sj.leu.2404140; Powers MV, 2008, CANCER CELL, V14, P250, DOI 10.1016/j.ccr.2008.08.002; Qian SB, 2006, NATURE, V440, P551, DOI 10.1038/nature04600; SALARIS SC, 1991, BIOCHEM PHARMACOL, V42, P499, DOI 10.1016/0006-2952(91)90311-R; Sharp S, 2006, ADV CANCER RES, V95, P323, DOI 10.1016/S0065-230X(06)95009-X; Sittler A, 2001, HUM MOL GENET, V10, P1307, DOI 10.1093/hmg/10.12.1307; VargasRoig LM, 1997, CANCER DETECT PREV, V21, P441; Visarius TM, 1997, FEBS LETT, V412, P157, DOI 10.1016/S0014-5793(97)00767-9; Voyer J, 2008, COMP BIOCHEM PHYS A, V151, P253, DOI 10.1016/j.cbpa.2008.07.004; Workman P, 2004, CANCER LETT, V206, P149, DOI 10.1016/j.canlet.2003.08.032; Yang L, 2004, CANCER RES, V64, P4394, DOI 10.1158/0008-5472.CAN-04-0343; Yano M, 1996, JPN J CANCER RES, V87, P908, DOI 10.1111/j.1349-7006.1996.tb02119.x; Yokota S, 2000, CANCER RES, V60, P2942; Zhang MC, 2007, CANCER LETT, V252, P244, DOI 10.1016/j.canlet.2006.12.035; Zou JY, 1998, CELL, V94, P471, DOI 10.1016/S0092-8674(00)81588-3	39	62	62	1	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 22	2010	285	4					2498	2505		10.1074/jbc.M109.057208	http://dx.doi.org/10.1074/jbc.M109.057208			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	544YP	19889640	Green Published, hybrid			2022-12-25	WOS:000273697800028
J	Demidyuk, IV; Gromova, TY; Polyakov, KM; Melik-Adamyan, WR; Kuranova, IP; Kostrov, SV				Demidyuk, Ilya V.; Gromova, Tania Yu.; Polyakov, Konstantin M.; Melik-Adamyan, William R.; Kuranova, Inna P.; Kostrov, Sergey V.			Crystal Structure of the Protealysin Precursor INSIGHTS INTO PROPEPTIDE FUNCTION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							THERMOLYSIN-LIKE PROTEASES; SUBTILIS NEUTRAL-PROTEASE; AMINO-ACID-SEQUENCE; PSEUDOMONAS-AERUGINOSA; 3-DIMENSIONAL STRUCTURE; BACILLUS-CEREUS; INTRAMOLECULAR CHAPERONE; MOLECULAR-REPLACEMENT; THERMAL-STABILITY; DIFFRACTION DATA	Protealysin (PLN) belongs to the M4 family of peptidases that are commonly known as thermolysin-like proteases (TLPs). All TLPs are synthesized as precursors containing N-terminal propeptides. According to the primary structure of the N-terminal propeptides, the family is divided into two distinct groups. Representatives of the first group including thermolysin and all TLPs with known three-dimensional structures have long prosequences (similar to 200 amino acids). Enzymes of the second group, whose prototype is protealysin, have short (similar to 50 amino acids) propeptides. Here, we present the 1.8 angstrom crystal structure of PLN precursor (proPLN), which is the first three-dimensional structure of a TLP precursor. Whereas the structure of the catalytic domain of proPLN is similar overall to previously reported structures of mature TLPs, it has specific features, including the absence of calcium-binding sites, and different structures of the N-terminal region and substrate-binding site. PLN propeptide forms a separate domain in the precursor and likely acts as an inhibitor that blocks the substrate-binding site and fixes the "open" conformation of the active site, which is unfavorable for catalysis. Furthermore the conserved PPL motif identified in our previous studies directly interacts with the S' subsites of the active center being a critical element of the propeptide-catalytic domain interface. Comparison of the primary structures of TLPs with short propeptides suggests that the specific features revealed in the proPLN crystal structure are typical for all protealysin-like enzymes. Thus, such proteins can be considered as a separate subfamily of TLPs.	[Demidyuk, Ilya V.; Gromova, Tania Yu.; Kostrov, Sergey V.] Russian Acad Sci, Inst Mol Genet, Moscow 123182, Russia; [Polyakov, Konstantin M.] Kurchatov Ctr Synchrotron Radiat & Nanotechnol, Moscow 123182, Russia; [Melik-Adamyan, William R.; Kuranova, Inna P.] Russian Acad Sci, AV Shubnikov Crystallog Inst, Moscow 119333, Russia	Russian Academy of Sciences; National Research Centre - Kurchatov Institute; Russian Academy of Sciences; FSRC Crystallography & Photonics RAS	Demidyuk, IV (corresponding author), Kurchatov Sq 2, Moscow 123182, Russia.	duk@img.ras.ru	Kostrov, Sergey/J-6612-2018; Demidyuk, Ilya V/D-1245-2009; Kuranova, Inna P/B-1349-2014	Demidyuk, Ilya V/0000-0001-8140-2287; Polyakov, Konstantin/0000-0001-7718-4336	Russian Foundation for Basic Research [09-04-00734, 09-04-00870]; Russian Academy of Sciences; Russian Scientific-Technological Complex Development [02.512.12.2050]	Russian Foundation for Basic Research(Russian Foundation for Basic Research (RFBR)); Russian Academy of Sciences(Russian Academy of Sciences); Russian Scientific-Technological Complex Development	This work was supported in part by the Russian Foundation for Basic Research (Projects 09-04-00734 and 09-04-00870), the Program for Molecular and Cell Biology of the Russian Academy of Sciences, and the Federal Program" R & D in Priority Directions of the Russian Scientific-Technological Complex Development in 2007-2012" (State Contract 02.512.12.2050).	Adekoya OA, 2009, CHEM BIOL DRUG DES, V73, P7, DOI 10.1111/j.1747-0285.2008.00757.x; [Anonymous], 1994, ACTA CRYSTALLOGR D, V50, P760; Banbula A, 1998, STRUCTURE, V6, P1185, DOI 10.1016/S0969-2126(98)00118-X; Bozhokina E, 2008, BIOCHEM BIOPH RES CO, V367, P888, DOI 10.1016/j.bbrc.2008.01.003; Braun P, 1996, MOL MICROBIOL, V19, P297, DOI 10.1046/j.1365-2958.1996.381908.x; CORBETT RJT, 1983, BIOPOLYMERS, V22, P101, DOI 10.1002/bip.360220116; Crooks GE, 2004, GENOME RES, V14, P1188, DOI 10.1101/gr.849004; DAHLQUIST FW, 1976, BIOCHEMISTRY-US, V15, P1103, DOI 10.1021/bi00650a024; Davis IW, 2007, NUCLEIC ACIDS RES, V35, pW375, DOI 10.1093/nar/gkm216; DeLano W. L., 2007, PYMOL MOL GRAPHICS S; Demidyuk IV, 2008, PROTEIN J, V27, P343, DOI 10.1007/s10930-008-9143-2; Demidyuk IV, 2006, PROTEIN EXPRES PURIF, V47, P551, DOI 10.1016/j.pep.2005.12.005; Diederichs K, 1997, NAT STRUCT BIOL, V4, P269, DOI 10.1038/nsb0497-269; Dodonov AF, 2000, EUR J MASS SPECTROM, V6, P481, DOI 10.1255/ejms.378; Emsley P, 2004, ACTA CRYSTALLOGR D, V60, P2126, DOI 10.1107/S0907444904019158; FEDER J, 1967, BIOCHEMISTRY-US, V6, P2088, DOI 10.1021/bi00859a028; FEDER J, 1970, BIOCHEMISTRY-US, V9, P2784, DOI 10.1021/bi00816a005; Gromova TY, 2008, CRYSTALLOGR REP+, V53, P793, DOI 10.1134/S1063774508050118; Gromova TY, 2009, BIOCHIMIE, V91, P639, DOI 10.1016/j.biochi.2009.03.008; Guex N, 1997, ELECTROPHORESIS, V18, P2714, DOI 10.1002/elps.1150181505; HANGAUER DG, 1984, BIOCHEMISTRY-US, V23, P5730, DOI 10.1021/bi00319a011; Hausrath AC, 2002, ACTA CRYSTALLOGR D, V58, P1002, DOI 10.1107/S090744490200584X; HOLLAND DR, 1992, BIOCHEMISTRY-US, V31, P11310, DOI 10.1021/bi00161a008; KABSCH W, 1993, J APPL CRYSTALLOGR, V26, P795, DOI 10.1107/S0021889893005588; KESSLER E, 1994, J BIOL CHEM, V269, P22726; KHAITLINA SY, 1988, FEBS LETT, V228, P172, DOI 10.1016/0014-5793(88)80610-0; Kheiker DM, 2007, CRYSTALLOGR REP+, V52, P358, DOI 10.1134/S1063774507020320; Long F, 2008, ACTA CRYSTALLOGR D, V64, P125, DOI 10.1107/S0907444907050172; Marie-Claire C, 1999, J MOL BIOL, V285, P1911, DOI 10.1006/jmbi.1998.2449; MATTHEWS BW, 1972, NATURE-NEW BIOL, V238, P37, DOI 10.1038/newbio238037a0; MATTHEWS BW, 1988, ACCOUNTS CHEM RES, V21, P333, DOI 10.1021/ar00153a003; McIver KS, 1995, MOL MICROBIOL, V18, P877, DOI 10.1111/j.1365-2958.1995.18050877.x; McKay D B, 1992, Matrix Suppl, V1, P112; Murshudov GN, 1997, ACTA CRYSTALLOGR D, V53, P240, DOI 10.1107/S0907444996012255; ODonohue MJ, 1996, J BIOL CHEM, V271, P26477, DOI 10.1074/jbc.271.43.26477; PAUPTIT RA, 1988, J MOL BIOL, V199, P525, DOI 10.1016/0022-2836(88)90623-7; RAWLINGS ND, 1995, METHOD ENZYMOL, V248, P183; Rawlings ND, 2008, NUCLEIC ACIDS RES, V36, pD320, DOI 10.1093/nar/gkm954; READ RJ, 1986, ACTA CRYSTALLOGR A, V42, P140, DOI 10.1107/S0108767386099622; ROCHE RS, 1978, CRC CR REV BIOCH MOL, V5, P1; SCHECHTER I, 1967, BIOCHEM BIOPH RES CO, V27, P157, DOI 10.1016/S0006-291X(67)80055-X; SCHNEIDER TD, 1990, NUCLEIC ACIDS RES, V18, P6097, DOI 10.1093/nar/18.20.6097; Serkina AV, 1999, FEBS LETT, V456, P215, DOI 10.1016/S0014-5793(99)00791-7; STARK W, 1992, EUR J BIOCHEM, V207, P781, DOI 10.1111/j.1432-1033.1992.tb17109.x; Tang B, 2003, BIOCHEM BIOPH RES CO, V301, P1093, DOI 10.1016/S0006-291X(03)00084-6; THAYER MM, 1991, J BIOL CHEM, V266, P2864; Thompson JD, 1997, NUCLEIC ACIDS RES, V25, P4876, DOI 10.1093/nar/25.24.4876; TITANI K, 1972, BIOCHEMISTRY-US, V11, P2427, DOI 10.1021/bi00763a007; Tsaplina OA, 2009, BIOCHEMISTRY-MOSCOW+, V74, P648, DOI 10.1134/S0006297909060091; Vagin A, 1997, J APPL CRYSTALLOGR, V30, P1022, DOI 10.1107/S0021889897006766; Veltman OR, 1998, BIOCHEMISTRY-US, V37, P5312, DOI 10.1021/bi9725879; WETMORE DR, 1992, MOL MICROBIOL, V6, P1593, DOI 10.1111/j.1365-2958.1992.tb00884.x	52	24	27	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 15	2010	285	3					2003	2013		10.1074/jbc.M109.015396	http://dx.doi.org/10.1074/jbc.M109.015396			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	541PJ	19915005	Green Published, hybrid			2022-12-25	WOS:000273429100046
J	Meyer, AE; Hoover, LA; Craig, EA				Meyer, Alison E.; Hoover, Lindsey A.; Craig, Elizabeth A.			The Cytosolic J-protein, Jjj1, and Rei1 Function in the Removal of the Pre-60 S Subunit Factor Arx1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							60S RIBOSOMAL-SUBUNIT; NUCLEAR EXPORT RECEPTOR; SACCHAROMYCES-CEREVISIAE; PRERIBOSOMAL FACTORS; MATURATION; CHAPERONE; YEAST; RNA; ASSOCIATION; NUCLEOLUS	Although the biogenesis of ribosomal subunits occurs predominantly in the nucleus, final remodeling steps take place in the cytosol. One cytosolic step has two components: 1) the removal of the maturation factor Arx1, which transits from the nucleus to the cytosol with the pre-60 S subunit, and 2) its subsequent transport back into the nucleus. Two cytosolic proteins, Rei1 and Jjj1, are required, but their individual contributions to this step are not understood. Here we report that Rei1 and Jjj1 directly interact. This interaction is mediated by a C-terminal segment of Jjj1 encompassing a region rich in charged residues, flanked by C2H2-type zinc fingers. Deletion of the charged region results in defects in 60 S subunit biogenesis in vivo. In addition, we report resolution of an apparent contradiction in the literature regarding the association of Arx1 with the pre-60 S subunit in the absence of Rei1. The association of Arx1 with ribosomes is sensitive to the concentration of magnesium ions when Rei1 is absent. At near physiological concentrations, Arx1 remains associated with the pre-60 S particle, as it does in the absence of Jjj1; at higher concentrations, Arx1 dissociates in the absence of Rei1 but not in the absence of Jjj1. As both Rei1 and Jjj1 are required for dissociation of Arx1 from the pre-60 S subunit, and the region of Jjj1 that mediates interaction with Rei1 is required in vivo for 60 S subunit biogenesis, our data support the idea that the primary role of both Rei1 and Jjj1 is the first step of the Arx1 removal/recycling process.	[Meyer, Alison E.; Hoover, Lindsey A.; Craig, Elizabeth A.] Univ Wisconsin, Dept Biochem, Madison, WI 53706 USA	University of Wisconsin System; University of Wisconsin Madison	Craig, EA (corresponding author), Univ Wisconsin, Dept Biochem, 433 Babcock Dr, Madison, WI 53706 USA.	ecraig@wisc.edu			National Institutes of Health [GM31107, T32GM0721532]; Genetech Foundation; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM031107, R37GM031107] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Genetech Foundation; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	This work was supported, in whole or in part, by National Institutes of Health Grant GM31107 (to E.A.C.) and University of Wisconsin Molecular Biosciences Training Grant T32GM0721532 from the National Institutes of Health (to L.A.H.). This work was also supported by a grant from the Genetech Foundation (to A.E.M.).	Beeler T, 1997, BBA-BIOMEMBRANES, V1323, P310, DOI 10.1016/S0005-2736(96)00199-X; Bradatsch B, 2007, MOL CELL, V27, P767, DOI 10.1016/j.molcel.2007.06.034; Craig EA, 2006, REV PHYSIOL BIOCH P, V156, P1, DOI 10.1007/s10254-005-0001-8; Demoinet E, 2007, RNA, V13, P1570, DOI 10.1261/rna.585007; ELSON D, 1979, NUCLEIC ACIDS RES, V7, P465, DOI 10.1093/nar/7.2.465; Fatica A, 2002, CURR OPIN CELL BIOL, V14, P313, DOI 10.1016/S0955-0674(02)00336-8; Fromont-Racine M, 2003, GENE, V313, P17, DOI 10.1016/S0378-1119(03)00629-2; GHYSEN A, 1970, EUR J BIOCHEM, V13, P132, DOI 10.1111/j.1432-1033.1970.tb00908.x; Hedges J, 2005, EMBO J, V24, P567, DOI 10.1038/sj.emboj.7600547; HELSER TL, 1981, MOL CELL BIOL, V1, P51, DOI 10.1128/MCB.1.1.51; Ho JHN, 2000, J CELL BIOL, V151, P1057, DOI 10.1083/jcb.151.5.1057; Huang P, 2005, NAT STRUCT MOL BIOL, V12, P497, DOI 10.1038/nsmb942; Hung NJ, 2008, MOL BIOL CELL, V19, P735, DOI 10.1091/mbc.E07-09-0968; Hung NJ, 2006, MOL CELL BIOL, V26, P3718, DOI 10.1128/MCB.26.10.3718-3727.2006; Iwase M, 2004, CELL STRUCT FUNCT, V29, P1, DOI 10.1247/csf.29.1; Lebreton A, 2006, J CELL BIOL, V173, P349, DOI 10.1083/jcb.200510080; Longtine MS, 1998, YEAST, V14, P953, DOI 10.1002/(SICI)1097-0061(199807)14:10<953::AID-YEA293>3.3.CO;2-L; Mackay JP, 1998, TRENDS BIOCHEM SCI, V23, P1, DOI 10.1016/S0968-0004(97)01168-7; Meyer AE, 2007, P NATL ACAD SCI USA, V104, P1558, DOI 10.1073/pnas.0610704104; Nissan TA, 2002, EMBO J, V21, P5539, DOI 10.1093/emboj/cdf547; Noah JW, 1998, BIOCHEMISTRY-US, V37, P15442, DOI 10.1021/bi981148m; Parnell KM, 2009, MOL CELL BIOL, V29, P4014, DOI 10.1128/MCB.01582-08; Pertschy B, 2007, MOL CELL BIOL, V27, P6581, DOI 10.1128/MCB.00668-07; Saveanu C, 2001, EMBO J, V20, P6475, DOI 10.1093/emboj/20.22.6475; Senger B, 2001, MOL CELL, V8, P1363, DOI 10.1016/S1097-2765(01)00403-8; Shenvi CL, 2005, RNA, V11, P1898, DOI 10.1261/rna.2192805; SIKORSKI RS, 1989, GENETICS, V122, P19; SPERRAZZA JM, 1983, NUCLEIC ACIDS RES, V11, P2665, DOI 10.1093/nar/11.9.2665; Tschochner H, 2003, TRENDS CELL BIOL, V13, P255, DOI 10.1016/S0962-8924(03)00054-0; Yan W, 1998, EMBO J, V17, P4809, DOI 10.1093/emboj/17.16.4809; Zamir A, 1974, Methods Enzymol, V30, P406; Zemp I, 2007, FEBS LETT, V581, P2783, DOI 10.1016/j.febslet.2007.05.013	32	40	43	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 8	2010	285	2					961	968		10.1074/jbc.M109.038349	http://dx.doi.org/10.1074/jbc.M109.038349			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	539MH	19901025	Green Published, hybrid			2022-12-25	WOS:000273258200016
J	Tomilov, AA; Bicocca, V; Schoenfeld, RA; Giorgio, M; Migliaccio, E; Ramsey, JJ; Hagopian, K; Pelicci, PG; Cortopassi, GA				Tomilov, Alexey A.; Bicocca, Vincent; Schoenfeld, Robert A.; Giorgio, Marco; Migliaccio, Enrica; Ramsey, Jon J.; Hagopian, Kevork; Pelicci, Pier Giuseppe; Cortopassi, Gino A.			Decreased Superoxide Production in Macrophages of Long-lived p66Shc Knock-out Mice	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; METHIONYL-LEUCYL-PHENYLALANINE; AMYOTROPHIC-LATERAL-SCLEROSIS; RESPIRATORY BURST OXIDASE; NEUTROPHIL NADPH OXIDASE; TRANSGENIC MOUSE MODEL; OXIDATIVE STRESS; LIFE-SPAN; ADAPTER PROTEIN; TYROSINE KINASE	A decrease in reactive oxygen species (ROS) production has been associated with extended life span in animal models of longevity. Mice deficient in the p66Shc gene are long-lived, and their cells are both resistant to oxidative stress and produce less ROS. Our microarray analysis of p66Shc(-/-) mouse tissues showed alterations in transcripts involved in heme and superoxide production and insulin signaling. Thus, we carried out analysis of ROS production by NADPH oxidase (PHOX) in macrophages of control and p66Shc knock-out mice. p66Shc(-/-) mice had a 40% reduction in PHOX-dependent superoxide production. To confirm whether the defect in superoxide production was a direct consequence of p66Shc deficiency, p66Shc was knocked down with siRNA in the macrophage cell line RAW264, and a 30% defect in superoxide generation was observed. The pathway of PHOX-dependent superoxide generation was investigated. PHOX protein levels were not decreased in mutant macrophages; however, the rate and extent of phosphorylation of p47phox was decreased in mutants, as was membrane translocation of the complex. Consistently, phosphorylation of protein kinase C delta, Akt, and ERK (the kinases responsible for phosphorylation of p47phox) was decreased. Thus, p66Shc deficiency causes a defect in activation of the PHOX complex that results in decreased superoxide production. p66Shc-deficient mice have recently been observed to be resistant to atherosclerosis and to oxidant injury in kidney and brain. Because phagocyte-derived superoxide is often a component of oxidant injury and inflammation, we suggest that the decreased superoxide production by PHOX in p66Shc-deficient mice could contribute significantly to their relative protection from oxidant injury and consequent longevity.	[Hagopian, Kevork; Cortopassi, Gino A.] Univ Calif Davis, Dept Mol Biosci, Davis, CA 95616 USA; [Giorgio, Marco; Migliaccio, Enrica; Pelicci, Pier Giuseppe] European Inst Oncol, I-20139 Milan, Italy	University of California System; University of California Davis; IRCCS European Institute of Oncology (IEO)	Cortopassi, GA (corresponding author), 1120 Haring Hall, Davis, CA 95616 USA.	gcortopassi@ucdavis.edu	Migliaccio, Enrica/AAQ-8880-2020; Giorgio, Marco/I-9425-2012; Pelicci, Pier Giuseppe/AAL-6572-2020	Giorgio, Marco/0000-0002-5842-6042; Bicocca, Vincent/0000-0002-5702-4586	National Institutes of Health [AG025532, AG16719, EY12245]; NATIONAL EYE INSTITUTE [R01EY012245] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [P01AG025532, R01AG016719] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))	This work was supported, in whole or in part, by National Institutes of Health Grants AG025532, AG16719, and EY12245.	ABO A, 1991, NATURE, V353, P668, DOI 10.1038/353668a0; Ahmed S, 1998, J BIOL CHEM, V273, P15693, DOI 10.1074/jbc.273.25.15693; Bankers-Fulbright JL, 2001, J CELL PHYSIOL, V189, P306, DOI 10.1002/jcp.10022; Bartke A, 2008, EXP GERONTOL, V43, P11, DOI 10.1016/j.exger.2007.10.009; Benard V, 1999, J BIOL CHEM, V274, P13198, DOI 10.1074/jbc.274.19.13198; Berniakovich I, 2008, J BIOL CHEM, V283, P34283, DOI 10.1074/jbc.M804362200; Berry A, 2008, EXP GERONTOL, V43, P200, DOI 10.1016/j.exger.2007.10.016; Bissonnette SA, 2008, J BIOL CHEM, V283, P2108, DOI 10.1074/jbc.M706639200; BOKOCH GM, 1995, TRENDS CELL BIOL, V5, P109, DOI 10.1016/S0962-8924(00)88960-6; Camici GG, 2007, P NATL ACAD SCI USA, V104, P5217, DOI 10.1073/pnas.0609656104; Caruso C, 2004, ANN NY ACAD SCI, V1028, P1, DOI 10.1196/annals.1322.001; Chen QD, 2003, J IMMUNOL, V170, P5302, DOI 10.4049/jimmunol.170.10.5302; Cheng N, 2007, J IMMUNOL, V179, P7720, DOI 10.4049/jimmunol.179.11.7720; Datla SR, 2007, HYPERTENSION, V50, P636, DOI 10.1161/HYPERTENSIONAHA.107.092296; Dewas C, 2000, J IMMUNOL, V165, P5238, DOI 10.4049/jimmunol.165.9.5238; Dhahbi J, 2007, EXP GERONTOL, V42, P772, DOI 10.1016/j.exger.2007.04.004; Didichenko SA, 1996, CURR BIOL, V6, P1271, DOI 10.1016/S0960-9822(02)70713-6; Draghici S, 2007, GENOME RES, V17, P1537, DOI 10.1101/gr.6202607; Durand D, 2006, BIOCHEMISTRY-US, V45, P7185, DOI 10.1021/bi060274k; ElBenna J, 1996, J BIOL CHEM, V271, P6374; Ellson C, 2006, EMBO J, V25, P4468, DOI 10.1038/sj.emboj.7601346; Erdreich-Epstein A, 1999, J LEUKOCYTE BIOL, V65, P523, DOI 10.1002/jlb.65.4.523; Finch CE, 2004, SCIENCE, V305, P1736, DOI 10.1126/science.1092556; Finch CE, 2005, NEUROBIOL AGING, V26, P281, DOI 10.1016/j.neurobiolaging.2004.03.015; Franceschi C, 2005, MECH AGEING DEV, V126, P351, DOI 10.1016/j.mad.2004.08.028; Francia P, 2004, CIRCULATION, V110, P2889, DOI 10.1161/01.CIR.0000147731.24444.4D; Fumagalli L, 2007, J IMMUNOL, V178, P3874, DOI 10.4049/jimmunol.178.6.3874; Giorgio M, 2005, CELL, V122, P221, DOI 10.1016/j.cell.2005.05.011; Gurven M, 2008, J GERONTOL A-BIOL, V63, P196, DOI 10.1093/gerona/63.2.196; HANCOCK JT, 1987, BIOCHEM J, V242, P103, DOI 10.1042/bj2420103; HARMAN D, 1956, J GERONTOL, V11, P298, DOI 10.1093/geronj/11.3.298; Hibbs ML, 2002, J EXP MED, V196, P1593, DOI 10.1084/jem.20020515; Hibbs ML, 1997, INT J BIOCHEM CELL B, V29, P397, DOI 10.1016/S1357-2725(96)00104-5; Hu YY, 2007, CELL SIGNAL, V19, P410, DOI 10.1016/j.cellsig.2006.07.017; Huang TT, 2001, FREE RADICAL BIO MED, V31, P1101, DOI 10.1016/S0891-5849(01)00694-3; Khanday FA, 2006, J CELL BIOL, V172, P817, DOI 10.1083/jcb.200506001; Khanday FA, 2006, MOL BIOL CELL, V17, P122, DOI 10.1091/mbc.e05-06-0570; Khatri P, 2004, NUCLEIC ACIDS RES, V32, pW449, DOI 10.1093/nar/gkh409; Kiaei M, 2006, J NEUROSCI, V26, P2467, DOI 10.1523/JNEUROSCI.5253-05.2006; Kiaei M, 2005, EXP NEUROL, V191, P331, DOI 10.1016/j.expneurol.2004.10.007; Kiaei M, 2005, NEURODEGENER DIS, V2, P246, DOI 10.1159/000090364; Kisielow M, 2002, BIOCHEM J, V363, P1, DOI 10.1042/0264-6021:3630001; KNAUS UG, 1991, SCIENCE, V254, P1512, DOI 10.1126/science.1660188; KNAUS UG, 1995, SCIENCE, V269, P221, DOI 10.1126/science.7618083; Lambeth JD, 2007, FREE RADICAL BIO MED, V43, P332, DOI 10.1016/j.freeradbiomed.2007.03.027; Legan SK, 2008, J BIOL CHEM, V283, P32492, DOI 10.1074/jbc.M805832200; Leitges M, 2002, MOL CELL BIOL, V22, P3970, DOI 10.1128/MCB.22.12.3970-3980.2002; LEUSEN JHW, 1996, FRONT BIOSCI, V1, P72; LI YB, 1995, NAT GENET, V11, P376, DOI 10.1038/ng1295-376; Li Z, 2000, SCIENCE, V287, P1046, DOI 10.1126/science.287.5455.1046; Luchak JM, 2007, ANN NY ACAD SCI, V1119, P260, DOI 10.1196/annals.1404.000; Martin-Padura I, 2008, ENDOTHELIUM-J ENDOTH, V15, P276, DOI 10.1080/10623320802487791; Martyn KD, 2005, BLOOD, V106, P3962, DOI 10.1182/blood-2005-03-0859; Mele J, 2006, ANTIOXID REDOX SIGN, V8, P628, DOI 10.1089/ars.2006.8.628; Menini S, 2007, DIABETOLOGIA, V50, P1997, DOI 10.1007/s00125-007-0728-7; Menini S, 2006, DIABETES, V55, P1642, DOI 10.2337/db05-1477; Migliaccio E, 1999, NATURE, V402, P309, DOI 10.1038/46311; Miura K, 2000, BLOOD, V96, P2199, DOI 10.1182/blood.V96.6.2199.h8002199_2199_2205; Morgan T. E., 2007, V35, P83; Morita M, 2008, J BIOCHEM, V143, P31, DOI 10.1093/jb/mvm190; Murakami S, 2006, EXP GERONTOL, V41, P1014, DOI 10.1016/j.exger.2006.06.061; Napoli C, 2003, P NATL ACAD SCI USA, V100, P2112, DOI 10.1073/pnas.0336359100; NAUSEEF WM, 1991, J BIOL CHEM, V266, P5911; Neptune ER, 1997, P NATL ACAD SCI USA, V94, P14489, DOI 10.1073/pnas.94.26.14489; Nishida S, 2005, INFECT IMMUN, V73, P235, DOI 10.1128/IAI.73.1.235-244.2005; OKAMURA N, 1988, BLOOD, V72, P811; Oldham WM, 2006, Q REV BIOPHYS, V39, P117, DOI 10.1017/S0033583506004306; ORR WC, 1994, SCIENCE, V263, P1128, DOI 10.1126/science.8108730; Ostan R, 2008, NEUROIMMUNOMODULAT, V15, P224, DOI 10.1159/000156466; Pace A, 2006, BBA-MOL CELL RES, V1763, P356, DOI 10.1016/j.bbamcr.2006.03.004; Perez VI, 2009, AGING CELL, V8, P73, DOI 10.1111/j.1474-9726.2008.00449.x; PTASZNIK A, 1995, J BIOL CHEM, V270, P19969, DOI 10.1074/jbc.270.34.19969; Radyuk SN, 2009, BIOCHEM J, V419, P437, DOI 10.1042/BJ20082003; Remijsen QFM, 2006, FEBS LETT, V580, P6206, DOI 10.1016/j.febslet.2006.10.024; Schadt EE, 2001, J CELL BIOCHEM, V84, P120, DOI 10.1002/jcb.10073; Schriner SE, 2005, SCIENCE, V308, P1909, DOI 10.1126/science.1106653; Sohal RS, 1996, SCIENCE, V273, P59, DOI 10.1126/science.273.5271.59; Stahelin RV, 2003, J BIOL CHEM, V278, P14469, DOI 10.1074/jbc.M212579200; STOYANOV B, 1995, SCIENCE, V269, P690, DOI 10.1126/science.7624799; Sykiotis GP, 2008, DEV CELL, V14, P76, DOI 10.1016/j.devcel.2007.12.002; Taille C, 2004, J BIOL CHEM, V279, P28681, DOI 10.1074/jbc.M310661200; Torres M, 1996, J BIOL CHEM, V271, P13244, DOI 10.1074/jbc.271.22.13244; Treuting PM, 2008, J GERONTOL A-BIOL, V63, P813, DOI 10.1093/gerona/63.8.813; Tsunawaki S, 2004, INFECT IMMUN, V72, P3373, DOI 10.1128/IAI.72.6.3373-3382.2004; Van Remmen H, 2003, PHYSIOL GENOMICS, V16, P29, DOI 10.1152/physiolgenomics.00122.2003; Welch HCE, 2002, CELL, V108, P809, DOI 10.1016/S0092-8674(02)00663-3; Wientjes FB, 2001, BIOCHEM BIOPH RES CO, V289, P382, DOI 10.1006/bbrc.2001.5982; Yamauchi A, 2004, J IMMUNOL, V173, P5971, DOI 10.4049/jimmunol.173.10.5971; Yoshida LS, 2000, BIOCHEM BIOPH RES CO, V268, P716, DOI 10.1006/bbrc.2000.2192; Zhan Y, 2002, J BIOL CHEM, V277, P4512, DOI 10.1074/jbc.M109520200; Zoja C, 2007, ARTHRITIS RHEUM, V56, P1629, DOI 10.1002/art.22593	91	48	49	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 8	2010	285	2					1153	1165		10.1074/jbc.M109.017491	http://dx.doi.org/10.1074/jbc.M109.017491			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	539MH	19892704	hybrid, Green Published			2022-12-25	WOS:000273258200038
J	Boeing, S; Rigault, C; Heidemann, M; Eick, D; Meisterernst, M				Boeing, Stefan; Rigault, Caroline; Heidemann, Martin; Eick, Dirk; Meisterernst, Michael			RNA Polymerase II C-terminal Heptarepeat Domain Ser-7 Phosphorylation Is Established in a Mediator-dependent Fashion	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PRE-MESSENGER-RNA; TRANSCRIPTIONAL ACTIVATION; PREINITIATION COMPLEX; BASAL TRANSCRIPTION; REPEAT DOMAIN; IN-VITRO; TFIIH; KINASE; CTD; RECRUITMENT	The largest subunit of RNA polymerase II (RNAPII) C-terminal heptarepeat domain (CTD) is subject to phosphorylation during initiation and elongation of transcription by RNA polymerase II. Here we study the molecular mechanisms leading to phosphorylation of Ser-7 in the human enzyme. Ser-7 becomes phosphorylated before initiation of transcription at promoter regions. We identify cyclin-dependent kinase 7 (CDK7) as one responsible kinase. Phosphorylation of both Ser-5 and Ser-7 is fully dependent on the cofactor complex Mediator. A subform of Mediator associated with an active RNAPII is critical for preinitiation complex formation and CTD phosphorylation. The Mediator-RNAPII complex independently recruits TFIIB and CDK7 to core promoter regions. CDK7 phosphorylates Ser-7 selectively in the context of an intact preinitiation complex. CDK7 is not the only kinase that can modify Ser-7 of the CTD. ChIP experiments with chemical inhibitors provide evidence that other yet to be identified kinases further phosphorylate Ser-7 in coding regions.	[Boeing, Stefan; Rigault, Caroline; Meisterernst, Michael] Univ Munster, Inst Mol Tumor Biol, D-48149 Munster, Germany; [Heidemann, Martin; Eick, Dirk] Ctr Integrated Prot Sci, Helmholtz Ctr Environm Hlth, Inst Clin Mol Biol & Tumor Genet, D-81377 Munich, Germany	University of Munster; Helmholtz Association; Helmholtz-Center Munich - German Research Center for Environmental Health; University of Munich	Meisterernst, M (corresponding author), Univ Munster, Inst Mol Tumor Biol, Robert Koch Str 43, D-48149 Munster, Germany.	meisterernst@uni-muenster.de			Bundesministerium fur Bildung und Forschung; QuantPro Grant [0313860D]; European Commission [EuTRACC 037445]; Deutsche Forschungsgemeinschaft [ME 967/2-1, SPP1356]	Bundesministerium fur Bildung und Forschung(Federal Ministry of Education & Research (BMBF)); QuantPro Grant; European Commission(European CommissionEuropean Commission Joint Research Centre); Deutsche Forschungsgemeinschaft(German Research Foundation (DFG))	This work was supported by Bundesministerium fur Bildung und Forschung Grant QuantPro Grant 0313860D, European Commission Grant EuTRACC 037445, and Deutsche Forschungsgemeinschaft Grants ME 967/2-1 and SPP1356 (to M. M.).	Akhtar MS, 2009, MOL CELL, V34, P387, DOI 10.1016/j.molcel.2009.04.016; Albert TK, 2007, P NATL ACAD SCI USA, V104, P10000, DOI 10.1073/pnas.0703490104; Baek HJ, 2006, J BIOL CHEM, V281, P15172, DOI 10.1074/jbc.M601983200; Blazek E, 2005, CHROMOSOMA, V113, P399, DOI 10.1007/s00412-005-0329-5; Bonnet F, 1999, NUCLEIC ACIDS RES, V27, P4399, DOI 10.1093/nar/27.22.4399; Buratowski S, 2005, CURR OPIN CELL BIOL, V17, P257, DOI 10.1016/j.ceb.2005.04.003; Buratowski S, 2003, NAT STRUCT BIOL, V10, P679, DOI 10.1038/nsb0903-679; Chapman RD, 2008, TRENDS GENET, V24, P289, DOI 10.1016/j.tig.2008.03.010; Chapman RD, 2007, SCIENCE, V318, P1780, DOI 10.1126/science.1145977; Cho EJ, 1997, GENE DEV, V11, P3319, DOI 10.1101/gad.11.24.3319; Deng LW, 2002, J BIOL CHEM, V277, P33922, DOI 10.1074/jbc.M111349200; Donner AJ, 2007, MOL CELL, V27, P121, DOI 10.1016/j.molcel.2007.05.026; DVIR A, 1992, P NATL ACAD SCI USA, V89, P11920, DOI 10.1073/pnas.89.24.11920; Egloff S, 2007, SCIENCE, V318, P1777, DOI 10.1126/science.1145989; Esnault C, 2008, MOL CELL, V31, P337, DOI 10.1016/j.molcel.2008.06.021; Furumoto T, 2007, GENES CELLS, V12, P119, DOI 10.1111/j.1365-2443.2007.01036.x; Gebara MM, 1997, J CELL BIOCHEM, V64, P390; Gilfillan S, 2005, J BIOL CHEM, V280, P6222, DOI 10.1074/jbc.M406343200; Gomes NP, 2006, GENE DEV, V20, P601, DOI 10.1101/gad.1398206; Guidi BW, 2004, J BIOL CHEM, V279, P29114, DOI 10.1074/jbc.M404426200; Hengartner CJ, 1998, MOL CELL, V2, P43, DOI 10.1016/S1097-2765(00)80112-4; Jenuwein T, 2001, SCIENCE, V293, P1074, DOI 10.1126/science.1063127; Kanin EI, 2007, P NATL ACAD SCI USA, V104, P5812, DOI 10.1073/pnas.0611505104; Kim M, 2004, NATURE, V432, P517, DOI 10.1038/nature03041; KIM YJ, 1994, CELL, V77, P599, DOI 10.1016/0092-8674(94)90221-6; KRETZSCHMAR M, 1994, MOL CELL BIOL, V14, P3927, DOI 10.1128/MCB.14.6.3927; LAYBOURN PJ, 1990, J BIOL CHEM, V265, P13165; Licatalosi DD, 2002, MOL CELL, V9, P1101, DOI 10.1016/S1097-2765(02)00518-X; Long JJ, 1998, MOL CELL BIOL, V18, P1467, DOI 10.1128/MCB.18.3.1467; Malik S, 2005, TRENDS BIOCHEM SCI, V30, P256, DOI 10.1016/j.tibs.2005.03.009; McCracken S, 1997, GENE DEV, V11, P3306, DOI 10.1101/gad.11.24.3306; Meinhart A, 2004, NATURE, V430, P223, DOI 10.1038/nature02679; Meinhart A, 2005, GENE DEV, V19, P1401, DOI 10.1101/gad.1318105; Mittler G, 2001, EMBO REP, V2, P808, DOI 10.1093/embo-reports/kve186; Myers LC, 1998, GENE DEV, V12, P45, DOI 10.1101/gad.12.1.45; Ng HH, 2003, MOL CELL, V11, P709, DOI 10.1016/S1097-2765(03)00092-3; Phatnani HP, 2006, GENE DEV, V20, P2922, DOI 10.1101/gad.1477006; Rossignol M, 1997, EMBO J, V16, P1628, DOI 10.1093/emboj/16.7.1628; Sato S, 2004, MOL CELL, V14, P685, DOI 10.1016/j.molcel.2004.05.006; STELZER G, 1994, MOL CELL BIOL, V14, P4712, DOI 10.1128/MCB.14.7.4712; Tirode F, 1999, MOL CELL, V3, P87, DOI 10.1016/S1097-2765(00)80177-X; Trigon S, 1998, J BIOL CHEM, V273, P6769, DOI 10.1074/jbc.273.12.6769; Uhlmann T, 2007, J BIOL CHEM, V282, P2163, DOI 10.1074/jbc.M608451200; Wu SY, 2003, MOL CELL BIOL, V23, P6229, DOI 10.1128/MCB.23.17.6229-6242.2003; Xie J, 2000, EMBO J, V19, P672, DOI 10.1093/emboj/19.4.672; Zhang XT, 2005, MOL CELL, V19, P89, DOI 10.1016/j.molcel.2005.05.015	46	43	45	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 1	2010	285	1					188	196		10.1074/jbc.M109.046565	http://dx.doi.org/10.1074/jbc.M109.046565			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	536UT	19901026	hybrid, Green Published			2022-12-25	WOS:000273070100020
J	Poulin, MB; Nothaft, H; Hug, I; Feldman, MF; Szymanski, CM; Lowary, TL				Poulin, Myles B.; Nothaft, Harald; Hug, Isabelle; Feldman, Mario F.; Szymanski, Christine M.; Lowary, Todd L.			Characterization of a Bifunctional Pyranose-Furanose Mutase from Campylobacter jejuni 11168	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							UDP-GALACTOPYRANOSE MUTASE; ESCHERICHIA-COLI O52; STD-NMR SPECTROSCOPY; O-ANTIGEN; KLEBSIELLA-PNEUMONIAE; CATALYTIC MECHANISM; CHEMICAL-STRUCTURE; GALACTOFURANOSE; BIOSYNTHESIS; LIPOPOLYSACCHARIDE	UDP-galactopyranose mutases (UGM) are the enzymes responsible for the synthesis of UDP-galactofuranose (UDP-Galf) from UDP-galactopyranose (UDP-Galp). The enzyme, encoded by the glf gene, is present in bacteria, parasites, and fungi that express Galf in their glycoconjugates. Recently, a UGM homologue encoded by the cj1439 gene has been identified in Campylobacter jejuni 11168, an organism possessing no Galf-containing glycoconjugates. However, the capsular polysaccharide from this strain contains a 2-acetamido-2-deoxy-D-galactofuranose (GalfNAc) moiety. Using an in vitro high performance liquid chromatography assay and complementation studies, we characterized the activity of this UGM homologue. The enzyme, which we have renamed UDP-N-acetylgalactopyranose mutase (UNGM), has relaxed specificity and can use either UDP-Gal or UDP-GalNAc as a substrate. Complementation studies of mutase knock-outs in C. jejuni 11168 and Escherichia coli W3110, the latter containing Galf residues in its lipopolysaccharide, demonstrated that the enzyme recognizes both UDP-Gal and UDP-GalNAc in vivo. A homology model of UNGM and site-directed mutagenesis led to the identification of two active site amino acid residues involved in the recognition of the UDP-GalNAc substrate. The specificity of UNGM was characterized using a two-substrate co-incubation assay, which demonstrated, surprisingly, that UDP-Gal is a better substrate than UDP-GalNAc.	[Nothaft, Harald; Hug, Isabelle; Feldman, Mario F.; Szymanski, Christine M.] Univ Alberta, Dept Biol Sci, Edmonton, AB T6G 2R3, Canada; [Poulin, Myles B.; Lowary, Todd L.] Univ Alberta, Dept Chem, Edmonton, AB T6G 2R3, Canada; [Poulin, Myles B.; Nothaft, Harald; Hug, Isabelle; Feldman, Mario F.; Szymanski, Christine M.; Lowary, Todd L.] Univ Alberta, Alberta Ingenu Ctr Carbohydrate Sci, Edmonton, AB T6G 2R3, Canada	University of Alberta; University of Alberta; University of Alberta	Szymanski, CM (corresponding author), Univ Alberta, Dept Biol Sci, Edmonton, AB T6G 2R3, Canada.	cszymans@ualberta.ca; tlowary@ualberta.ca	Feldman, Mario/A-2637-2014; Lowary, Todd L/F-9608-2019; Szymanski, Christine/A-3763-2014	Feldman, Mario/0000-0003-4497-0976; Lowary, Todd L/0000-0002-8331-8211; Szymanski, Christine/0000-0002-8464-1352; Hug, Isabelle/0000-0002-4524-9569; Poulin, Myles/0000-0002-3789-703X	Alberta Ingenuity Centre for Carbohydrate Science; National Sciences and Engineering Research Council of Canada	Alberta Ingenuity Centre for Carbohydrate Science; National Sciences and Engineering Research Council of Canada(Natural Sciences and Engineering Research Council of Canada (NSERC))	This work was supported in part by the Alberta Ingenuity Centre for Carbohydrate Science and National Sciences and Engineering Research Council of Canada.	Allos BM, 2001, CLIN INFECT DIS, V32, P1201, DOI 10.1086/319760; Arbatsky NP, 1998, CARBOHYD RES, V310, P85, DOI 10.1016/S0008-6215(98)00157-8; Bacon DJ, 2001, MOL MICROBIOL, V40, P769, DOI 10.1046/j.1365-2958.2001.02431.x; Bakker H, 2005, BIOL CHEM, V386, P657, DOI 10.1515/BC.2005.076; Beis K, 2005, J MOL BIOL, V348, P971, DOI 10.1016/j.jmb.2005.02.057; Belanova M, 2008, J BACTERIOL, V190, P1141, DOI 10.1128/JB.01326-07; Bernatchez S, 2005, J BIOL CHEM, V280, P4792, DOI 10.1074/jbc.M407767200; Beverley SM, 2005, EUKARYOT CELL, V4, P1147, DOI 10.1128/EC.4.6.1147-1154.2005; Bian XL, 2007, J VIROL, V81, P2899, DOI 10.1128/JVI.01850-06; BRENNAN PJ, 1995, ANNU REV BIOCHEM, V64, P29, DOI 10.1146/annurev.bi.64.070195.000333; Caravano A, 2006, BIOORG MED CHEM LETT, V16, P1123, DOI 10.1016/j.bmcl.2005.11.106; Carlson EE, 2006, CHEM BIOL, V13, P825, DOI 10.1016/j.chembiol.2006.06.007; Carrillo CD, 2004, J BIOL CHEM, V279, P20327, DOI 10.1074/jbc.M401134200; CHA S, 1968, MOL PHARMACOL, V4, P621; Chad JM, 2007, BIOCHEMISTRY-US, V46, P6723, DOI 10.1021/bi7002795; Claus H, 2009, MOL MICROBIOL, V71, P960, DOI 10.1111/j.1365-2958.2008.06580.x; DELEDERKREMER RM, 1994, J ORG CHEM, V59, P690, DOI 10.1021/jo00082a037; DELEDERKREMER RM, 1995, GLYCOBIOLOGY, V5, P547, DOI 10.1093/glycob/5.6.547; Eppe G, 2009, BIOORG MED CHEM LETT, V19, P814, DOI 10.1016/j.bmcl.2008.12.014; Errey JC, 2009, ORG BIOMOL CHEM, V7, P1009, DOI 10.1039/b815549f; Errey JC, 2004, CHEM COMMUN, P2706, DOI 10.1039/b410184g; Feldman MF, 1999, J BIOL CHEM, V274, P35129, DOI 10.1074/jbc.274.49.35129; Feng L, 2004, J BACTERIOL, V186, P4510, DOI 10.1128/JB.186.14.4510-4519.2004; Fersht A., 1999, STRUCTURE MECH PROTE, P116; Gruber TD, 2009, BIOCHEMISTRY-US, V48, P9171, DOI 10.1021/bi901437v; Gruber TD, 2009, J MOL BIOL, V391, P327, DOI 10.1016/j.jmb.2009.05.081; Guan S, 2001, J BACTERIOL, V183, P3318, DOI 10.1128/JB.183.11.3318-3327.2001; Hanniffy OM, 1999, CARBOHYD RES, V319, P124, DOI 10.1016/S0008-6215(99)00129-9; Itoh K, 2007, ORG LETT, V9, P879, DOI 10.1021/ol0631408; KALDOR J, 1984, BRIT MED J, V288, P1867, DOI 10.1136/bmj.288.6434.1867; Karlyshev AV, 2005, MOL MICROBIOL, V55, P90, DOI 10.1111/j.1365-2958.2004.04374.x; Koplin R, 1997, J BIOL CHEM, V272, P4121, DOI 10.1074/jbc.272.7.4121; Lambert C, 2002, BIOINFORMATICS, V18, P1250, DOI 10.1093/bioinformatics/18.9.1250; Lee R, 1996, ANAL BIOCHEM, V242, P1, DOI 10.1006/abio.1996.0419; Lee RE, 1997, TETRAHEDRON LETT, V38, P6733, DOI 10.1016/S0040-4039(97)01539-6; LIU D, 1994, MICROBIOL-UK, V140, P49, DOI 10.1099/13500872-140-1-49; MAROLDA CL, 1990, J BACTERIOL, V172, P3590, DOI 10.1128/jb.172.7.3590-3599.1990; Marolda Cristina L., 2006, V347, P237; Miller WG, 2000, APPL ENVIRON MICROB, V66, P5426, DOI 10.1128/AEM.66.12.5426-5436.2000; Morris GM, 1998, J COMPUT CHEM, V19, P1639, DOI 10.1002/(SICI)1096-987X(19981115)19:14<1639::AID-JCC10>3.0.CO;2-B; Nassau PM, 1996, J BACTERIOL, V178, P1047, DOI 10.1128/jb.178.4.1047-1052.1996; Nothaft H, 2009, P NATL ACAD SCI USA, V106, P15019, DOI 10.1073/pnas.0903078106; Pan F, 2001, J BACTERIOL, V183, P3991, DOI 10.1128/JB.183.13.3991-3998.2001; Parkhill J, 2000, NATURE, V403, P665, DOI 10.1038/35001088; Pedersen LL, 2003, CELL MOL LIFE SCI, V60, P259, DOI 10.1007/s000180300021; Peltier P, 2008, CARBOHYD RES, V343, P1897, DOI 10.1016/j.carres.2008.02.010; Richards MR, 2009, CHEMBIOCHEM, V10, P1920, DOI 10.1002/cbic.200900208; Rose NL, 2005, J CHEM EDUC, V82, P1846, DOI 10.1021/ed082p1846; Sanders DAR, 2001, NAT STRUCT BIOL, V8, P858, DOI 10.1038/nsb1001-858; Soltero-Higgin M, 2004, NAT STRUCT MOL BIOL, V11, P539, DOI 10.1038/nsmb772; St Michael F, 2002, EUR J BIOCHEM, V269, P5119, DOI 10.1046/j.1432-1033.2002.03201.x; STEVENSON G, 1994, J BACTERIOL, V176, P4144, DOI 10.1128/JB.176.13.4144-4156.1994; TSAI CM, 1982, ANAL BIOCHEM, V119, P115, DOI 10.1016/0003-2697(82)90673-X; Wang Q, 2008, MOL MICROBIOL, V70, P1358, DOI 10.1111/j.1365-2958.2008.06449.x; Weston A, 1998, TUBERCLE LUNG DIS, V78, P123, DOI 10.1016/S0962-8479(98)80005-1; WHITFIELD C, 1995, TRENDS MICROBIOL, V3, P178, DOI 10.1016/S0966-842X(00)88917-9; YAO RJ, 1993, GENE, V130, P127, DOI 10.1016/0378-1119(93)90355-7; Yao XH, 2009, PROTEINS, V74, P972, DOI 10.1002/prot.22206; Yuan Y, 2005, BIOCHEMISTRY-US, V44, P14080, DOI 10.1021/bi0513406; Yuan Y, 2008, J AM CHEM SOC, V130, P3157, DOI 10.1021/ja7104152; Zhang QB, 2001, J AM CHEM SOC, V123, P6756, DOI 10.1021/ja010473l; Zhang QB, 2000, J AM CHEM SOC, V122, P9065, DOI 10.1021/ja001333z	62	24	24	1	17	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 1	2010	285	1					493	501		10.1074/jbc.M109.072157	http://dx.doi.org/10.1074/jbc.M109.072157			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	536UT	19887444	Green Published, hybrid			2022-12-25	WOS:000273070100051
J	Liu, RR; Murphy, TH				Liu, Ran R.; Murphy, Timothy H.			Reversible Cyclosporin A-sensitive Mitochondrial Depolarization Occurs within Minutes of Stroke Onset in Mouse Somatosensory Cortex in Vivo A TWO-PHOTON IMAGING STUDY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PERMEABILITY TRANSITION PORE; TRANSIENT FOREBRAIN ISCHEMIA; CEREBRAL-ARTERY OCCLUSION; CEREBELLAR GRANULE CELLS; IN-VIVO; GLUTAMATE EXCITOTOXICITY; DENDRITIC STRUCTURE; LIVER-MITOCHONDRIA; OXIDATIVE STRESS; CYCLOPHILIN-D	Neuronal structure and function are rapidly damaged during global ischemia but can in part recover during reperfusion. Despite apparent recovery in the hours/days following an ischemic episode, delayed cell death can be initiated, making it important to understand how initial ischemic events affect potential mediators of apoptosis. Mitochondrial dysfunction and the opening of the mitochondrial permeability transition pore (mPTP) are proposed to link ischemic ionic imbalance to mitochondrially mediated cell death pathways. Using two-photon microscopy, we monitored mitochondrial transmembrane potential (Delta psi(m)) in vivo within the somatosensory cortex during ischemia and reperfusion in a mouse global ischemia model. Our results indicated a synchronous loss of Delta psi(m) within 1-3 min of ischemic onset that was linked to within seconds of plasma membrane potential (Delta psi(p)) depolarization. Delta psi(m) recovered rapidly upon reperfusion, and no delayed depolarization was observed over 2 h. Cyclosporin A treatment largely blocked Delta psi(m) collapse during ischemia, suggesting a role for the mPTP. Blocking Delta psi(m) depolarization did not affect structural damage to dendrites, indicating that the opening of the mPTP and damage to dendrites are separable pathways that are activated during Delta psi(p) depolarization. Our findings using in vivo imaging suggest that mitochondrial dysfunction and specifically the activation of the mPTP are early reversible events during brain ischemia that could trigger delayed cell death.	[Liu, Ran R.; Murphy, Timothy H.] Univ British Columbia, Dept Psychiat, Vancouver, BC V6T 1Z3, Canada; [Murphy, Timothy H.] Univ British Columbia, Brain Res Ctr, Vancouver, BC V6T 1Z3, Canada	University of British Columbia; University of British Columbia	Murphy, TH (corresponding author), Univ British Columbia, Dept Psychiat, 4N1-2255 Wesbrook Mall, Vancouver, BC V6T 1Z3, Canada.	thmurphy@interchange.ubc.ca	Murphy, Timothy/AAW-1975-2021; Murphy, Timothy H/I-4982-2014	Murphy, Timothy/0000-0002-0093-4490; Murphy, Timothy H/0000-0002-0093-4490	Heart and Stroke Foundation of British Columbia; Yukon; Canadian Stroke Network	Heart and Stroke Foundation of British Columbia; Yukon; Canadian Stroke Network	This work was supported by a grant-in-aid from the Heart and Stroke Foundation of British Columbia and Yukon (to T.H.M.) and grants from the Canadian Stroke Network (to T.H.M.).	Abramov AY, 2008, BBA-BIOENERGETICS, V1777, P953, DOI 10.1016/j.bbabio.2008.04.017; Abramov AY, 2007, J NEUROSCI, V27, P1129, DOI 10.1523/JNEUROSCI.4468-06.2007; Alano CC, 2002, J NEUROCHEM, V80, P531, DOI 10.1046/j.0022-3042.2001.00738.x; Andrew RD, 2007, CEREB CORTEX, V17, P787, DOI 10.1093/cercor/bhk032; Andreyev A, 1999, CELL DEATH DIFFER, V6, P825, DOI 10.1038/sj.cdd.4400565; Basso E, 2005, J BIOL CHEM, V280, P18558, DOI 10.1074/jbc.C500089200; BENEL L, 1989, BASIC APPL HISTOCHEM, V33, P71; BROEKEMEIER KM, 1989, J BIOL CHEM, V264, P7826; Brustovetsky N, 2000, J NEUROSCI, V20, P8229, DOI 10.1523/JNEUROSCI.20-22-08229.2000; Cheung ECC, 2006, EMBO J, V25, P4061, DOI 10.1038/sj.emboj.7601276; Chinopoulos C, 2003, J BIOL CHEM, V278, P27382, DOI 10.1074/jbc.M303808200; Domanska-Janik K, 2004, MOL BRAIN RES, V121, P50, DOI 10.1016/j.molbrainres.2003.11.006; Enright LE, 2007, J CEREBR BLOOD F MET, V27, P1185, DOI 10.1038/sj.jcbfm.9600428; Feng GP, 2000, NEURON, V28, P41, DOI 10.1016/S0896-6273(00)00084-2; Frantseva MV, 2001, FREE RADICAL BIO MED, V31, P1216, DOI 10.1016/S0891-5849(01)00705-5; Friberg H, 1998, J NEUROSCI, V18, P5151, DOI 10.1523/JNEUROSCI.18-14-05151.1998; Gao TM, 1998, NEUROSCIENCE, V87, P371, DOI 10.1016/S0306-4522(98)00150-X; Greenwood SM, 2007, J BIOL CHEM, V282, P26235, DOI 10.1074/jbc.M704488200; Halestrap AP, 2006, BIOCHEM SOC T, V34, P232, DOI 10.1042/BST0340232; Halestrap AP, 1997, J BIOL CHEM, V272, P3346, DOI 10.1074/jbc.272.6.3346; Hansson MJ, 2004, J NEUROCHEM, V89, P715, DOI 10.1111/j.1471-4159.2004.02400.x; Hossmann KA, 2006, CELL MOL NEUROBIOL, V26, P1057, DOI 10.1007/s10571-006-9008-1; Iyirhiaro GO, 2008, J NEUROCHEM, V105, P703, DOI 10.1111/j.1471-4159.2007.05166.x; Khaspekov L, 1999, EUR J NEUROSCI, V11, P3194, DOI 10.1046/j.1460-9568.1999.00743.x; Li P, 2008, J NEUROSCI, V28, P11970, DOI 10.1523/JNEUROSCI.3724-08.2008; Matsumoto S, 1999, J CEREBR BLOOD F MET, V19, P736, DOI 10.1097/00004647-199907000-00002; Mayevsky A, 2007, MITOCHONDRION, V7, P330, DOI 10.1016/j.mito.2007.05.001; Medvedeva YV, 2009, J NEUROSCI, V29, P1105, DOI 10.1523/JNEUROSCI.4604-08.2009; Murphy TH, 2008, J NEUROSCI, V28, P1756, DOI 10.1523/JNEUROSCI.5128-07.2008; Nicholls DG, 2000, TRENDS NEUROSCI, V23, P166, DOI 10.1016/S0166-2236(99)01534-9; Nicholls DG, 2003, CELL CALCIUM, V34, P407, DOI 10.1016/S0143-4160(03)00144-1; Precht TA, 2005, CELL DEATH DIFFER, V12, P255, DOI 10.1038/sj.cdd.4401552; Rintoul GL, 2003, J NEUROSCI, V23, P7881; Schinzel AC, 2005, P NATL ACAD SCI USA, V102, P12005, DOI 10.1073/pnas.0505294102; Sheldon C, 2002, J NEUROPHYSIOL, V87, P2209, DOI 10.1152/jn.2002.87.5.2209; Starkov AA, 2004, CELL CALCIUM, V36, P257, DOI 10.1016/j.ceca.2004.02.012; Stosiek C, 2003, P NATL ACAD SCI USA, V100, P7319, DOI 10.1073/pnas.1232232100; Uchino H, 1998, BRAIN RES, V812, P216, DOI 10.1016/S0006-8993(98)00902-0; Vergun O, 2005, BBA-BIOENERGETICS, V1709, P127, DOI 10.1016/j.bbabio.2005.07.006; Ward MW, 2000, J NEUROSCI, V20, P7208; White RJ, 1996, J NEUROSCI, V16, P5688; Yonekura I, 2004, J CEREBR BLOOD F MET, V24, P151, DOI 10.1097/01.WCB.0000096063.84070.C1; Zeng LH, 2007, J NEUROSCI, V27, P11604, DOI 10.1523/JNEUROSCI.0983-07.2007; Zhang SX, 2005, J NEUROSCI, V25, P5333, DOI 10.1523/JNEUROSCI.1085-05.2005	44	46	46	2	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 25	2009	284	52					36109	36117		10.1074/jbc.M109.055301	http://dx.doi.org/10.1074/jbc.M109.055301			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	535LT	19892710	Green Published, hybrid			2022-12-25	WOS:000272970500012
J	Mallick, B; Ghosh, Z; Chakrabarti, J				Mallick, Bibekanand; Ghosh, Zhumur; Chakrabarti, Jayprokas			MicroRNome Analysis Unravels the Molecular Basis of SARS Infection in Bronchoalveolar Stem Cells	PLOS ONE			English	Article							ACUTE RESPIRATORY SYNDROME; ANGIOTENSIN-CONVERTING ENZYME-2; CORONAVIRUS REPLICATION; NUCLEOCAPSID PROTEIN; LUNG; IDENTIFICATION; EXPRESSION; DETERMINANTS; RECEPTOR; TARGETS	Severe acute respiratory syndrome (SARS), caused by the coronavirus SARS-CoV, is an acute infectious disease with significant mortality. A typical clinical feature associated with SARS is pulmonary fibrosis and associated lung failure. In the aftermath of the SARS epidemic, although significant progress towards understanding the underlying molecular mechanism of the infection has been made, a large gap still remains in our knowledge regarding how SARS-CoV interacts with the host cell at the onset of infection. The rapidly changing viral genome adds another variable to this equation. We have focused on a novel concept of microRNA (miRNA)-mediated host-virus interactions in bronchoalveolar stem cells (BASCs) at the onset of infection by correlating the "BASC-microRNome" with their targets within BASCs and viral genome. This work encompasses miRNA array data analysis, target prediction, and miRNA-mRNA enrichment analysis and develops a complex interaction map among disease-related factors, miRNAs, and BASCs in SARS pathway, which will provide some clues for diagnostic markers to view an overall interplay leading to disease progression. Our observation reveals the BASCs (Sca-1+ CD34+ CD45- Pecam-), a subset of Oct-4+ ACE2+ epithelial colony cells at the broncho-alveolar duct junction, to be the prime target cells of SARS-CoV infection. Upregulated BASC miRNAs-17*, -574-5p, and -214 are co-opted by SARS-CoV to suppress its own replication and evade immune elimination until successful transmission takes place. Viral Nucleocapsid and Spike protein targets seem to co-opt downregulated miR-223 and miR-98 respectively within BASCs to control the various stages of BASC differentiation, activation of inflammatory chemokines, and downregulation of ACE2. All these effectively accounts for a successful viral transmission and replication within BASCs causing continued deterioration of lung tissues and apparent loss of capacity for lung repair. Overall, this investigation reveals another mode of exploitation of cellular miRNA machinery by virus to their own advantage.			Mallick, B (corresponding author), Indian Assoc Cultivat Sci, Computat Biol Grp, Kolkata 700032, W Bengal, India.	zhumurg@stanford.edu	Mallick, Bibekanand/AAT-7013-2021	Mallick, Bibekanand/0000-0003-4311-0720; Ghosh, Zhumur/0000-0002-4877-7551				Asirvatham AJ, 2008, MOL IMMUNOL, V45, P1995, DOI 10.1016/j.molimm.2007.10.035; Baltimore D, 2008, NAT IMMUNOL, V9, P839, DOI 10.1038/ni.f.209; Bartel DP, 2009, CELL, V136, P215, DOI 10.1016/j.cell.2009.01.002; Bartel DP, 2004, CELL, V116, P281, DOI 10.1016/S0092-8674(04)00045-5; Bolstad BM, 2003, BIOINFORMATICS, V19, P185, DOI 10.1093/bioinformatics/19.2.185; Bonville CA, 2003, J VIROL, V77, P1237, DOI 10.1128/JVI.77.2.1237-1244.2003; Campbell PA, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0000553; Chan CM, 2007, ARCH BIOCHEM BIOPHYS, V459, P197, DOI 10.1016/j.abb.2007.01.012; Chang J, 2000, VIROLOGY, V266, P17, DOI 10.1006/viro.1999.0077; Chen YX, 2007, J EXP MED, V204, P2529, DOI 10.1084/jem.20070462; Cinatl J, 2003, LANCET, V362, P293, DOI 10.1016/S0140-6736(03)13973-6; Donnelly CA, 2003, LANCET, V361, P1761, DOI 10.1016/S0140-6736(03)13410-1; Eramo A, 2008, CELL DEATH DIFFER, V15, P504, DOI 10.1038/sj.cdd.4402283; EVANS MJ, 1978, LAB INVEST, V38, P648; Fazi F, 2005, CELL, V123, P819, DOI 10.1016/j.cell.2005.09.023; Fehrenbach H, 2001, RESP RES, V2, P33, DOI 10.1186/rr36; Friedman RC, 2009, GENOME RES, V19, P92, DOI 10.1101/gr.082701.108; Gallagher TM, 2001, VIROLOGY, V279, P371, DOI 10.1006/viro.2000.0757; GHOSH Z, 2007, BIOCHEM BIOPH RES CO, V37, P1035; Ghosh Z, 2009, NUCLEIC ACIDS RES, V37, P1035, DOI 10.1093/nar/gkn1004; Glass WG, 2004, J IMMUNOL, V173, P4030, DOI 10.4049/jimmunol.173.6.4030; Grimson A, 2007, MOL CELL, V27, P91, DOI 10.1016/j.molcel.2007.06.017; Gu J, 2005, J EXP MED, V202, P415, DOI 10.1084/jem.20050828; Hong KU, 2004, AM J PATHOL, V164, P577, DOI 10.1016/S0002-9440(10)63147-1; Imai Y, 2008, EXP PHYSIOL, V93, P543, DOI 10.1113/expphysiol.2007.040048; Jia HP, 2005, J VIROL, V79, P14614, DOI 10.1128/JVI.79.23.14614-14621.2005; JIN DY, 2009, HONG KONG MED J S2, V15, pS37; Kim CF, 2007, AM J PHYSIOL-LUNG C, V293, pL1092, DOI 10.1152/ajplung.00015.2007; Kim CFB, 2005, CELL, V121, P823, DOI 10.1016/j.cell.2005.03.032; Ksiazek TG, 2003, NEW ENGL J MED, V348, P1953, DOI 10.1056/NEJMoa030781; Kuba K, 2005, NAT MED, V11, P875, DOI 10.1038/nm1267; Kuiken T, 2003, LANCET, V362, P263, DOI 10.1016/S0140-6736(03)13967-0; Law HKW, 2009, BMC IMMUNOL, V10, DOI 10.1186/1471-2172-10-35; Lee BN, 1997, J VIROL, V71, P3628, DOI 10.1128/JVI.71.5.3628-3635.1997; Li BJ, 2005, NAT MED, V11, P944, DOI 10.1038/nm1280; Li WH, 2003, NATURE, V426, P450, DOI 10.1038/nature02145; Li XP, 2008, AM J PHYSIOL-LUNG C, V295, pL178, DOI 10.1152/ajplung.00009.2008; Ling TY, 2006, P NATL ACAD SCI USA, V103, P9530, DOI 10.1073/pnas.0510232103; Lu M, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003420; Marra MA, 2003, SCIENCE, V300, P1399, DOI 10.1126/science.1085953; Martin U, 2008, METHODS, V45, P121, DOI 10.1016/j.ymeth.2008.05.009; McQualter JL, 2009, STEM CELLS, V27, P623, DOI 10.1634/stemcells.2008-0866; Mignone F, 2005, NUCLEIC ACIDS RES, V33, pD141, DOI 10.1093/nar/gki021; MILAN S, 2008, INFECT GENET EVOL, V8, P397; Nicholls JM, 2003, LANCET, V361, P1773, DOI 10.1016/S0140-6736(03)13413-7; Nielsen S, 1997, AM J PHYSIOL-CELL PH, V273, pC1549, DOI 10.1152/ajpcell.1997.273.5.C1549; Oudit GY, 2009, NEPHROL DIAL TRANSPL, V24, P1362, DOI 10.1093/ndt/gfp065; Poutanen SM, 2003, NEW ENGL J MED, V348, P1995, DOI 10.1056/NEJMoa030634; Prentice E, 2004, J VIROL, V78, P9977, DOI 10.1128/JVI.78.18.9977-9986.2004; Qian S, 2008, BIOCHEM BIOPH RES CO, V377, P668, DOI 10.1016/j.bbrc.2008.10.052; Rehmsmeier M, 2004, RNA, V10, P1507, DOI 10.1261/rna.5248604; Rota PA, 2003, SCIENCE, V300, P1394, DOI 10.1126/science.1085952; Shcherbata HR, 2006, CELL CYCLE, V5, P172, DOI 10.4161/cc.5.2.2343; Snijder EJ, 2003, J MOL BIOL, V331, P991, DOI 10.1016/S0022-2836(03)00865-9; Tokuda A, 2000, J IMMUNOL, V164, P2745, DOI 10.4049/jimmunol.164.5.2745; Watanabe Y, 2007, FEBS LETT, V581, P4603, DOI 10.1016/j.febslet.2007.08.049; Williams AE, 2007, DEV DYNAM, V236, P572, DOI 10.1002/dvdy.21047; Wilson L, 2004, VIROLOGY, V330, P322, DOI 10.1016/j.virol.2004.09.033; Wu CJ, 2005, ANTIVIR RES, V65, P45, DOI 10.1016/j.antiviral.2004.09.005; Wu CJ, 2004, ANTIMICROB AGENTS CH, V48, P2693, DOI 10.1128/AAC.48.7.2693-2696.2004; Xiao XD, 2003, BIOCHEM BIOPH RES CO, V312, P1159, DOI 10.1016/j.bbrc.2003.11.054; Yan XH, 2006, INT J BIOCHEM CELL B, V38, P1417, DOI 10.1016/j.biocel.2006.02.003; Ye R, 2004, J VIROL, V78, P9904, DOI 10.1128/JVI.78.18.9904-9917.2004; Yilla M, 2005, VIRUS RES, V107, P93, DOI 10.1016/j.virusres.2004.09.004; Yu ITS, 2004, NEW ENGL J MED, V350, P1731, DOI 10.1056/NEJMoa032867; Zhang BH, 2006, J CELL PHYSIOL, V209, P266, DOI 10.1002/jcp.20713; Zhao X, 2008, J BIOL CHEM, V283, P3272, DOI 10.1074/jbc.M708033200	67	86	89	0	15	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	NOV 13	2009	4	11							e7837	10.1371/journal.pone.0007837	http://dx.doi.org/10.1371/journal.pone.0007837			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	518VB	19915717	gold, Green Published, Green Submitted			2022-12-25	WOS:000271721900023
J	Shanaube, K; Sismanidis, C; Ayles, H; Beyers, N; Schaap, A; Lawrence, KA; Barker, A; Godfrey-Faussett, P				Shanaube, Kwame; Sismanidis, Charalambos; Ayles, Helen; Beyers, Nulda; Schaap, Ab; Lawrence, Katherine-Anne; Barker, Annie; Godfrey-Faussett, Peter			Annual Risk of Tuberculous Infection Using Different Methods in Communities with a High Prevalence of TB and HIV in Zambia and South Africa	PLOS ONE			English	Article							MYCOBACTERIUM-TUBERCULOSIS; SKIN-TEST; CALMETTE-GUERIN; CHILDREN; TRANSMISSION; VACCINATION; EPIDEMIC; ZAMSTAR; DESIGN; TRENDS	Background: The annual risk of tuberculous infection (ARTI) is a key epidemiological indicator of the extent of transmission in a community. Several methods have been suggested to estimate the prevalence of tuberculous infection using tuberculin skin test data. This paper explores the implications of using different methods to estimate prevalence of infection and ARTI. The effect of BCG vaccination on these estimates is also investigated. Methodology/Principal Findings: Tuberculin surveys among school children in 16 communities in Zambia and 8 in South Africa (SA) were performed in 2005, as part of baseline data collection and for randomisation purposes of the ZAMSTAR study. Infection prevalence and ARTI estimates were calculated using five methods: different cut-offs with or without adjustments for sensitivity, the mirror method, and mixture analysis. A total of 49,835 children were registered for the surveys, of which 25,048 (50%) had skin tests done and 22,563 (90%) of those tested were read. Infection prevalence was higher in the combined SA than Zambian communities. The mirror method resulted in the least difference of 7.8%, whereas that estimated by the cut-off methods varied from 12.2% to 17.3%. The ARTI in the Zambian and SA communities was between 0.8% and 2.8% and 2.5% and 4.2% respectively, depending on the method used. In the SA communities, the ARTI was higher among the younger children. BCG vaccination had little effect on these estimates. Conclusions/Significance: ARTI estimates are dependent on the calculation method used. All methods agreed that there were substantial differences in infection prevalence across the communities, with higher rates in SA. Although TB notification rates have increased over the past decades, the difference in cumulative exposure between younger and older children is less dramatic and a rise in risk of infection in parallel with the estimated incidence of active tuberculosis cannot be excluded.			Shanaube, K (corresponding author), Univ Teaching Hosp, ZAMBART Project, Lusaka, Zambia.	kshanaube@zambart.org.zm		Shanaube, Kwame/0000-0001-7899-0890; Ayles, Helen/0000-0003-4108-2842	Medical Research Council [G0700837] Funding Source: Medline; MRC [G0700837] Funding Source: UKRI	Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))		[Anonymous], 2000, MMWR Recomm Rep, V49, P1; Arnadottir T, 1996, TUBERCLE LUNG DIS, V77, P1, DOI 10.1016/S0962-8479(96)90127-6; Arnadottir T, 2001, INT J TUBERC LUNG D, V5, P391; Ayles H, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005602; Ayles HM, 2008, TRIALS, V9, DOI 10.1186/1745-6215-9-63; Bachtiar A, 2008, INT J TUBERC LUNG D, V12, P255; Bosman MCJ, 1998, INT J TUBERC LUNG D, V2, P272; Bowerman RJ, 2004, INT J TUBERC LUNG D, V8, P1228; *CENTR STAT OFF ZA, 2003, ZAMB DHS EDDATA SURV; Chadha VK, 2005, INT J TUBERC LUNG D, V9, P569; Davies GR, 2006, INT J TUBERC LUNG D, V10, P1023; *DEP ED REP S AFR, 2006, ED STAT S AFR GLANC; Dubuis M, 2004, INT J TUBERC LUNG D, V8, P1065; Egwaga SA, 2006, AIDS, V20, P915, DOI 10.1097/01.aids.0000218557.44284.83; Fine PEM, 1999, INT J TUBERC LUNG D, V3, P962; FOURIE PB, 1983, TUBERCLE, V64, P181, DOI 10.1016/0041-3879(83)90013-2; Gopi PG, 2006, INDIAN J MED RES, V124, P71; Hill PC, 2004, CLIN INFECT DIS, V38, P966, DOI 10.1086/382362; HUEBNER RE, 1993, CLIN INFECT DIS, V17, P968, DOI 10.1093/clinids/17.6.968; Kritzinger FE, 2009, TROP MED INT HEALTH, V14, P136, DOI 10.1111/j.1365-3156.2008.02213.x; Middelkoop K, 2008, CLIN INFECT DIS, V47, P349, DOI 10.1086/589750; MIGLIORI GB, 1994, EUR RESPIR J, V7, P946; Nagelkerke NJD, 2000, INT J TUBERC LUNG D, V4, P314; Neuenschwander BE, 2000, INT J TUBERC LUNG D, V4, P719; Neuenschwander BE, 2002, AM J EPIDEMIOL, V155, P654, DOI 10.1093/aje/155.7.654; Odhiambo JA, 1999, AM J PUBLIC HEALTH, V89, P1078, DOI 10.2105/AJPH.89.7.1078; Pai M, 2004, LANCET INFECT DIS, V4, P761, DOI 10.1016/S1473-3099(04)01206-X; Pai M, 2008, INT J TUBERC LUNG D, V12, P895; Pretorius C, 2009, CLIN INFECT DIS, V48, P994, DOI 10.1086/597357; Rieder H, 2005, EUR RESPIR J, V25, P181, DOI 10.1183/09031936.04.00103804; Rieder HL, 2008, CLIN INFECT DIS, V47, P356, DOI 10.1086/589751; RIEDER HL, 1995, TUBERCLE LUNG DIS, V76, P114, DOI 10.1016/0962-8479(95)90552-9; SHASHIDHAR JS, 2002, IND J TUB, V49, P147; Sismanidis C, 2008, CLIN TRIALS, V5, P316, DOI 10.1177/1740774508094747; Styblo K, 2001, INT J TUBERC LUNG D, V5, P103; Styblo K., 1985, B INT UNION TUBERC, V60, P117; STYBLO K, 1995, TSRU PROGR REPORT, V1, P140; Trebucq A, 2005, INT J TUBERC LUNG D, V9, P1097; Tupasi TE, 2000, INT J TUBERC LUNG D, V4, P216; Van Leth F, 2008, B WORLD HEALTH ORGAN, V86, P20, DOI 10.2471/BLT.06.037804; Villate JI, 2006, BMC PUBLIC HEALTH, V6, DOI 10.1186/1471-2458-6-240; Wang L, 2002, THORAX, V57, P804, DOI 10.1136/thorax.57.9.804; World Health Organization, 2008, GLOB TUB CONTR SURV	43	53	53	0	5	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	NOV 13	2009	4	11							e7749	10.1371/journal.pone.0007749	http://dx.doi.org/10.1371/journal.pone.0007749			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	518VB	19915666	Green Accepted, Green Submitted, Green Published, gold			2022-12-25	WOS:000271721900008
J	van Lunteren, E; Moyer, M				van Lunteren, Erik; Moyer, Michelle			Gene Expression Profiling in the Type 1 Diabetes Rat Diaphragm	PLOS ONE			English	Article							STREPTOZOTOCIN-TREATED RATS; SKELETAL-MUSCLE; GLUCOSE UPTAKE; FATTY-ACIDS; MICROARRAY ANALYSIS; KETONE BODIES; CONTRACTILE CHARACTERISTICS; ACTION-POTENTIALS; INSULIN-TREATMENT; NOD MICE	Background: Respiratory muscle contractile performance is impaired by diabetes, mechanisms of which included altered carbohydrate and lipid metabolism, oxidative stress and changes in membrane electrophysiology. The present study examined to what extent these cellular perturbations involve changes in gene expression. Methodology/Principal Findings: Diaphragm muscle from streptozotocin-diabetic rats was analyzed with Affymetrix gene expression arrays. Diaphragm from diabetic rats had 105 genes with at least +/- 2-fold significantly changed expression (55 increased, 50 decreased), and these were assigned to gene ontology groups based on over-representation analysis using DAVID software. There was increased expression of genes involved in palmitoyl-CoA hydrolase activity (a component of lipid metabolism) (P = 0.037, n = 2 genes, fold change 4.2 to 27.5) and reduced expression of genes related to carbohydrate metabolism (P = 0.000061, n = 8 genes, fold change -2.0 to -8.5). Other gene ontology groups among upregulated genes were protein ubiquitination (P = 0.0053, n = 4, fold change 2.2 to 3.4), oxidoreductase activity (P = 0.024, n = 8, fold change 2.1 to 6.0), and morphogenesis (P = 0.012, n = 10, fold change 2.1 to 4.3). Other downregulated gene groups were extracellular region (including extracellular matrix and collagen) (P = 0.00032, n = 13, fold change -2.2 to -3.7) and organogenesis (P = 0.032, n = 7, fold change -2.1 to -3.7). Real-time PCR confirmed the directionality of changes in gene expression for 30 of 31 genes tested. Conclusions/Significance: These data indicate that in diaphragm muscle type 1 diabetes increases expression of genes involved in lipid energetics, oxidative stress and protein ubiquitination, decreases expression of genes involved in carbohydrate metabolism, and has little effect on expression of ion channel genes. Reciprocal changes in expression of genes involved in carbohydrate and lipid metabolism may change the availability of energetic substrates and thereby directly modulate fatigue resistance, an important issue for a muscle like the diaphragm which needs to contract without rest for the entire lifetime of the organism.			van Lunteren, E (corresponding author), Louis Stokes Cleveland Dept Vet Affairs Med Ctr, Dept Med, Pulm Crit Care & Sleep Div, Cleveland, OH USA.	exv4@cwru.edu			NATIONAL CANCER INSTITUTE [P30CA043703] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL070697] Funding Source: NIH RePORTER; NCI NIH HHS [P30 CA43703, P30 CA043703] Funding Source: Medline; NHLBI NIH HHS [HL-70697, R01 HL070697] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AYTE J, 1990, P NATL ACAD SCI USA, V87, P3874, DOI 10.1073/pnas.87.10.3874; Baelde HJ, 2004, AM J KIDNEY DIS, V43, P636, DOI 10.1053/j.ajkd.2003.12.028; BEATTY CH, 1959, J BIOL CHEM, V234, P11; BELOFFCH.A, 1968, BIOCHEM J, V110, P529, DOI 10.1042/bj1100529; BELOFFCHAIN A, 1971, BIOCHEM J, V125, P97, DOI 10.1042/bj1250097; CATERSON ID, 1982, BIOCHEM J, V208, P53, DOI 10.1042/bj2080053; CHORVATHOVA V, 1981, PHYSIOL BOHEMOSLOV, V30, P259; Combaret L, 2005, AM J PHYSIOL-ENDOC M, V288, pE693, DOI 10.1152/ajpendo.00281.2004; Dehoux M, 2004, ENDOCRINOLOGY, V145, P4806, DOI 10.1210/en.2004-0406; Dennis G, 2003, GENOME BIOL, V4, DOI 10.1186/gb-2003-4-9-r60; Durgan DJ, 2006, AM J PHYSIOL-HEART C, V290, pH2480, DOI 10.1152/ajpheart.01344.2005; Eckenrode SE, 2004, DIABETES, V53, P366, DOI 10.2337/diabetes.53.2.366; Fahim MA, 1998, ANAT RECORD, V251, P240, DOI 10.1002/(SICI)1097-0185(199806)251:2<240::AID-AR13>3.0.CO;2-O; Fan QL, 2003, KIDNEY INT, V64, P1978, DOI 10.1046/j.1523-1755.2003.00312.x; Fernandes R, 2004, MOL VIS, V10, P618; FOSTER JM, 1954, J BIOL CHEM, V211, P797; GARLAND PB, 1964, BIOCHEM J, V93, P665, DOI 10.1042/bj0930665; GARLAND PB, 1964, BIOCHEM J, V93, P678, DOI 10.1042/bj0930678; Garnett KE, 2005, J MOL ENDOCRINOL, V35, P13, DOI 10.1677/jme.1.01792; Gerber LK, 2006, AM J PHYSIOL-CELL PH, V291, pC1198, DOI 10.1152/ajpcell.00246.2006; GILBERT RE, 1995, KIDNEY INT, V48, P1216, DOI 10.1038/ki.1995.405; GROSSIE J, 1982, DIABETES, V31, P194, DOI 10.2337/diabetes.31.3.194; Haufroid V, 2003, EUR J CLIN PHARMACOL, V59, P29, DOI 10.1007/s00228-003-0566-6; Hida W, 1996, AM J RESP CRIT CARE, V153, P1875, DOI 10.1164/ajrccm.153.6.8665049; Hosack DA, 2003, GENOME BIOL, V4, DOI 10.1186/gb-2003-4-10-r70; IANUZZO CD, 1982, J APPL PHYSIOL, V52, P1471, DOI 10.1152/jappl.1982.52.6.1471; Ishwaran H, 2003, J AM STAT ASSOC, V98, P438, DOI 10.1198/016214503000224; Katoh J, 1996, J INT MED RES, V24, P209, DOI 10.1177/030006059602400205; Kedar V, 2004, P NATL ACAD SCI USA, V101, P18135, DOI 10.1073/pnas.0404341102; Knoll KE, 2005, PHYSIOL GENOMICS, V21, P222, DOI 10.1152/physiolgenomics.00231.2004; Kubo E, 2005, DIABETOLOGIA, V48, P790, DOI 10.1007/s00125-005-1687-5; Laybutt DR, 2003, J BIOL CHEM, V278, P2997, DOI 10.1074/jbc.M210581200; Lecker SH, 2004, FASEB J, V18, P39, DOI 10.1096/fj.03-0610com; Lin BC, 1998, J BIOL CHEM, V273, P31656, DOI 10.1074/jbc.273.48.31656; Liu ZQ, 2000, BIOCHEM BIOPH RES CO, V276, P1255, DOI 10.1006/bbrc.2000.3609; Lopaschuk Gary D, 2002, Heart Fail Rev, V7, P149; McGuire M, 1998, EXP PHYSIOL, V83, P481, DOI 10.1113/expphysiol.1998.sp004131; McGuire M, 1999, EXP PHYSIOL, V84, P1051, DOI 10.1111/j.1469-445X.1999.01916.x; McGuire M, 2001, CLIN EXP PHARMACOL P, V28, P184, DOI 10.1046/j.1440-1681.2001.03433.x; Palsgaard J, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0006575; PAULUS SF, 1983, DIABETES, V32, P1035, DOI 10.2337/diabetes.32.11.1035; Porter JD, 2004, HUM MOL GENET, V13, P257, DOI 10.1093/hmg/ddh033; RANDLE PJ, 1964, BIOCHEM J, V93, P652, DOI 10.1042/bj0930652; Raza H, 2004, DIABETES, V53, P185, DOI 10.2337/diabetes.53.1.185; REGENSTEINER JG, 1995, MED SCI SPORT EXER, V27, P661; Rouger K, 2002, AM J PHYSIOL-CELL PH, V283, pC773, DOI 10.1152/ajpcell.00112.2002; Scano G, 2000, CHEST, V117, P960, DOI 10.1378/chest.117.4.960; Sreekumar R, 2002, DIABETES, V51, P1913, DOI 10.2337/diabetes.51.6.1913; Stavinoha MA, 2004, AM J PHYSIOL-ENDOC M, V287, pE888, DOI 10.1152/ajpendo.00190.2004; STEARNS SB, 1979, J LIPID RES, V20, P654; Suh YH, 2005, J MOL ENDOCRINOL, V34, P299, DOI 10.1677/jme.1.01679; Sullivan CJ, 2005, PHYSIOL GENOMICS, V23, P192, DOI 10.1152/physiolgenomics.00112.2005; van Lunteren E, 2006, PHYSIOL GENOMICS, V25, P85, DOI 10.1152/physiolgenomics.00226.2005; van Lunteren E, 2003, RESP PHYSIOL NEUROBI, V135, P9, DOI 10.1016/S1569-9048(03)00038-7; van Lunteren E, 2008, RESP PHYSIOL NEUROBI, V161, P41, DOI 10.1016/j.resp.2007.11.005; Van Lunteren E, 2007, AM J PHYSIOL-ENDOC M, V293, pE759, DOI 10.1152/ajpendo.00191.2007; van Lunteren E, 2007, RESP PHYSIOL NEUROBI, V156, P103, DOI 10.1016/j.resp.2006.11.007; van Lunteren E, 2006, RESP PHYSIOL NEUROBI, V153, P157, DOI 10.1016/j.resp.2005.09.015; Voss MD, 2005, DIABETOLOGIA, V48, P2622, DOI 10.1007/s00125-005-0025-2; WANKE T, 1993, AM REV RESPIR DIS, V148, P1335, DOI 10.1164/ajrccm/148.5.1335; WANKE T, 1992, RESPIRATION, V59, P233; WANKE T, 1992, DIABETIC MED, V9, P252, DOI 10.1111/j.1464-5491.1992.tb01771.x; WANKE T, 1991, AM REV RESPIR DIS, V143, P97, DOI 10.1164/ajrccm/143.1.97; Wilson KHS, 2003, DIABETES, V52, P2151, DOI 10.2337/diabetes.52.8.2151; Yokoi N, 2002, NAT GENET, V31, P391, DOI 10.1038/ng927	65	12	13	1	4	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	NOV 13	2009	4	11							e7832	10.1371/journal.pone.0007832	http://dx.doi.org/10.1371/journal.pone.0007832			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	518VB	19915678	Green Published, gold, Green Submitted			2022-12-25	WOS:000271721900021
J	Ou, GW; Rompikuntal, PK; Bitar, A; Lindmark, B; Vaitkevicius, K; Wai, SN; Hammarstrom, ML				Ou, Gangwei; Rompikuntal, Pramod Kumar; Bitar, Aziz; Lindmark, Barbro; Vaitkevicius, Karolis; Wai, Sun Nyunt; Hammarstrom, Marie-Louise			Vibrio cholerae Cytolysin Causes an Inflammatory Response in Human Intestinal Epithelial Cells That Is Modulated by the PrtV Protease	PLOS ONE			English	Article							EL-TOR HEMOLYSIN; VACCINE; STRAINS; TOXIN; ACTIVATION; LIVE; O1; PURIFICATION; VACUOLATION; EXPRESSION	Background: Vibrio cholerae is the causal intestinal pathogen of the diarrheal disease cholera. It secretes the protease PrtV, which protects the bacterium from invertebrate predators but reduces the ability of Vibrio-secreted factor(s) to induce interleukin-8 (IL-8) production by human intestinal epithelial cells. The aim was to identify the secreted component(s) of V. cholerae that induces an epithelial inflammatory response and to define whether it is a substrate for PrtV. Methodology/Principal Findings: Culture supernatants of wild type V. cholerae O1 strain C6706, its derivatives and pure V. cholerae cytolysin (VCC) were analyzed for the capacity to induce changes in cytokine mRNA expression levels, IL-8 and tumor necrosis factor-alpha (TNF-alpha) secretion, permeability and cell viability when added to the apical side of polarized tight monolayer T84 cells used as an in vitro model for human intestinal epithelium. Culture supernatants were also analyzed for hemolytic activity and for the presence of PrtV and VCC by immunoblot analysis. Conclusions/Significance: We suggest that VCC is capable of causing an inflammatory response characterized by increased permeability and production of IL-8 and TNF-alpha in tight monolayers. Pure VCC at a concentration of 160 ng/ml caused an inflammatory response that reached the magnitude of that caused by Vibrio-secreted factors, while higher concentrations caused epithelial cell death. The inflammatory response was totally abolished by treatment with PrtV. The findings suggest that low doses of VCC initiate a local immune defense reaction while high doses lead to intestinal epithelial lesions. Furthermore, VCC is indeed a substrate for PrtV and PrtV seems to execute an environment-dependent modulation of the activity of VCC that may be the cause of V. cholerae reactogenicity.			Ou, GW (corresponding author), Umea Univ, Dept Clin Microbiol Immunol, Umea, Sweden.	sun.nyunt.wai@molbiol.umu.se; marie-louise.hammarstrom@climi.umu.se	Vaitkevicius, Karolis/R-9714-2016; rompikuntal, pramod/C-6917-2015	Vaitkevicius, Karolis/0000-0001-9309-3653; rompikuntal, pramod/0000-0002-4754-4676; Wai, Sun Nyunt/0000-0003-4793-4671; Hammarstrom, Marie-Louise/0000-0001-6182-4423				ALM RA, 1991, VACCINE, V9, P588, DOI 10.1016/0264-410X(91)90247-4; Artis D, 2008, NAT REV IMMUNOL, V8, P411, DOI 10.1038/nri2316; Balsalobre C, 2006, MOL MICROBIOL, V59, P99, DOI 10.1111/j.1365-2958.2005.04938.x; Blumberg RS, 2005, J INTERF CYTOK RES, V25, P209, DOI 10.1089/jir.2005.25.209; Coelho A, 2000, INFECT IMMUN, V68, P1700, DOI 10.1128/IAI.68.3.1700-1705.2000; COSTER TS, 1995, LANCET, V345, P949, DOI 10.1016/S0140-6736(95)90698-3; Debellis L, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005074; Fahlgren A, 2003, CLIN EXP IMMUNOL, V131, P90, DOI 10.1046/j.1365-2249.2003.02035.x; Figueroa-Arredondo P, 2001, INFECT IMMUN, V69, P1613, DOI 10.1128/IAI.69.3.1613-1624.2001; Forsberg G, 2002, GASTROENTEROLOGY, V123, P667, DOI 10.1053/gast.2002.35355; Gutierrez MG, 2007, P NATL ACAD SCI USA, V104, P1829, DOI 10.1073/pnas.0601437104; Hava DL, 2001, J MICROBIOL METH, V46, P217, DOI 10.1016/S0167-7012(01)00276-7; HONDA T, 1979, INFECT IMMUN, V26, P1020, DOI 10.1128/IAI.26.3.1020-1027.1979; KAPER JB, 1984, NATURE, V308, P655, DOI 10.1038/308655a0; Levine Myron M., 1995, Papua New Guinea Medical Journal, V38, P325; Mel SF, 2000, INFECT IMMUN, V68, P6487, DOI 10.1128/IAI.68.11.6487-6492.2000; Mitra R, 2000, INFECT IMMUN, V68, P1928, DOI 10.1128/IAI.68.4.1928-1933.2000; Nagamune K, 1996, INFECT IMMUN, V64, P4655, DOI 10.1128/IAI.64.11.4655-4658.1996; Olivier V, 2007, INFECT IMMUN, V75, P5035, DOI 10.1128/IAI.00506-07; Olson R, 2005, J MOL BIOL, V350, P997, DOI 10.1016/j.jmb.2005.05.045; Ou G, 2009, SCAND J IMMUNOL, V69, P150, DOI 10.1111/j.1365-3083.2008.02208.x; Pichel M, 2003, J CLIN MICROBIOL, V41, P124, DOI 10.1128/JCM.41.1.124-134.2003; Skorupski K, 1996, GENE, V169, P47, DOI 10.1016/0378-1119(95)00793-8; TACKET CO, 1995, J INFECT DIS, V172, P883, DOI 10.1093/infdis/172.3.883; TAYLOR DN, 1994, J INFECT DIS, V170, P1518, DOI 10.1093/infdis/170.6.1518; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; Vaitkevicius K, 2008, FEBS J, V275, P3167, DOI 10.1111/j.1742-4658.2008.06470.x; Vaitkevicius K, 2006, P NATL ACAD SCI USA, V103, P9280, DOI 10.1073/pnas.0601754103; Valeva A, 2004, J BIOL CHEM, V279, P25143, DOI 10.1074/jbc.M313913200; YAMAMOTO K, 1990, INFECT IMMUN, V58, P4106, DOI 10.1128/IAI.58.12.4106-4116.1990; YAMAMOTO K, 1984, INFECT IMMUN, V45, P192, DOI 10.1128/IAI.45.1.192-196.1984; Zhou X, 2004, INFECT IMMUN, V72, P389, DOI 10.1128/IAI.72.1.389-397.2004; Zhu J, 2002, P NATL ACAD SCI USA, V99, P3129, DOI 10.1073/pnas.052694299; Zitzer A, 1997, INFECT IMMUN, V65, P1293, DOI 10.1128/IAI.65.4.1293-1298.1997	34	24	24	1	7	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA	1932-6203			PLOS ONE	PLoS One	NOV 12	2009	4	11							e7806	10.1371/journal.pone.0007806	http://dx.doi.org/10.1371/journal.pone.0007806			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	518UW	19907657	Green Published, Green Submitted, gold			2022-12-25	WOS:000271721400007
J	Doi, N; Hoshi, Y; Itokawa, M; Usui, C; Yoshikawa, T; Tachikawa, H				Doi, Nagafumi; Hoshi, Yoko; Itokawa, Masanari; Usui, Chie; Yoshikawa, Takeo; Tachikawa, Hirokazu			Persistence Criteria for Susceptibility Genes for Schizophrenia: a Discussion from an Evolutionary Viewpoint	PLOS ONE			English	Article							DIFFERENTIAL FERTILITY; REPRODUCTIVE RATES; MUTATION-RATE; PARENTAL AGE; PATERNAL AGE; ASSOCIATION; RISK; VARIANTS; DISEASE; COMMON	Background: The central paradox of schizophrenia genetics is that susceptibility genes are preserved in the human gene-pool against a strong negative selection pressure. Substantial evidence of epidemiology suggests that nuclear susceptibility genes, if present, should be sustained by mutation-selection balance without heterozygote advantage. Therefore, putative nuclear susceptibility genes for schizophrenia should meet special conditions for the persistence of the disease as well as the condition of bearing a positive association with the disease. Methodology/Principal Findings: We deduced two criteria that every nuclear susceptibility gene for schizophrenia should fulfill for the persistence of the disease under general assumptions of the multifactorial threshold model. The first criterion demands an upper limit of the case-control difference of the allele frequencies, which is determined by the mutation rate at the locus, and the prevalence and the selection coefficient of the disease. The second criterion demands an upper limit of odds ratio for a given allele frequency in the unaffected population. When we examined the top 30 genes at SZGene and the recently reported common variants on chromosome 6p with the criteria using the epidemiological data in a large-sampled Finnish cohort study, it was suggested that most of these are unlikely to confer susceptibility to schizophrenia. The criteria predict that the common disease/common variant hypothesis is unlikely to fit schizophrenia and that nuclear susceptibility genes of moderate effects for schizophrenia, if present, are limited to 'rare variants', 'very common variants', or variants with exceptionally high mutation rates. Conclusions/Significance: If we assume the nuclear DNA model for schizophrenia, it should have many susceptibility genes of exceptionally high mutation rates; alternatively, it should have many disease-associated resistance genes of standard mutation rates on different chromosomes. On the other hand, the epidemiological data show that pathogenic genes, if located in the mitochondrial DNA, could persist through sex-related mechanisms.			Doi, N (corresponding author), Ibaraki Prefectural Tomobe Hosp, Dept Psychiat, Kasama, Ibaraki, Japan.	n.doi@pref.ibaraki.lg.jp	Yoshikawa, Takeo/F-9599-2019	Itokawa, Masanari/0000-0003-4433-8030				Allen NC, 2008, NAT GENET, V40, P827, DOI 10.1038/ng.171; Bassett AS, 1996, SCHIZOPHR RES, V21, P151, DOI 10.1016/0920-9964(96)00018-7; BOOK J A, 1953, Acta Genet Stat Med, V4, P1; Brune M, 2004, NEUROSCI BIOBEHAV R, V28, P41, DOI 10.1016/j.neubiorev.2003.10.002; BUCK C, 1975, BRIT J PSYCHIAT, V127, P235, DOI 10.1192/bjp.127.3.235; Byrne M, 2003, ARCH GEN PSYCHIAT, V60, P673, DOI 10.1001/archpsyc.60.7.673; CROW TJ, 1995, BRIT J PSYCHIAT, V167, P12, DOI 10.1192/bjp.167.1.12; Doi N, 2007, AM J MED GENET B, V144B, P165, DOI 10.1002/ajmg.b.30365; Doi N, 2007, AM J MED GENET B, V144B, P1, DOI 10.1002/ajmg.b.30348; El-Saadi O, 2004, SCHIZOPHR RES, V67, P227, DOI 10.1016/S0920-9964(03)00100-2; ERLENMEYERKIMLI.L, 1978, ANN REV SCHIZOPHRENI, V5, P298; ESSENMOLLER E, 1935, ACTA PSYCHIAT NEUROL, V8, P1; FANANAS L, 1995, ACTA PSYCHIAT SCAND, V91, P202, DOI 10.1111/j.1600-0447.1995.tb09767.x; Friedman JI, 2008, MOL PSYCHIATR, V13, P261, DOI 10.1038/sj.mp.4002049; HARRISON G, 1991, BRIT J PSYCHIAT, V159, P811, DOI 10.1192/bjp.159.6.811; Haukka J, 2003, AM J PSYCHIAT, V160, P460, DOI 10.1176/appi.ajp.160.3.460; HAVERKAMP F, 1982, ARCH PSYCHIAT NERVEN, V232, P439, DOI 10.1007/BF00345599; HUXLEY J, 1964, NATURE, V204, P220, DOI 10.1038/204220a0; Jablensky A., 1995, P206; Karlsson JL, 1974, ACTA PSYCHIAT SCAND, V247, P77; Keller MC, 2006, BEHAV BRAIN SCI, V29, P385, DOI 10.1017/S0140525X06009095; Kinney DK, 2000, CREATIVITY RES J, V13, P17; Kirov G, 2009, MOL PSYCHIATR, V14, P796, DOI 10.1038/mp.2008.33; Kirov G, 2008, HUM MOL GENET, V17, P458, DOI 10.1093/hmg/ddm323; Lander ES, 1996, SCIENCE, V274, P536, DOI 10.1126/science.274.5287.536; LARSON CA, 1973, ACTA PSYCHIAT SCAND, V49, P272, DOI 10.1111/j.1600-0447.1973.tb04421.x; Lencz T, 2007, MOL PSYCHIATR, V12, P572, DOI 10.1038/sj.mp.4001983; LINDELIUS R, 1970, ACTA PSYCHIAT SCAND, P216; Mah S, 2006, MOL PSYCHIATR, V11, P471, DOI 10.1038/sj.mp.4001785; Malaspina D, 2001, ARCH GEN PSYCHIAT, V58, P361, DOI 10.1001/archpsyc.58.4.361; Marchbanks RM, 2003, SCHIZOPHR RES, V65, P33, DOI 10.1016/S0920-9964(03)00011-2; Martorell L, 2006, EUR J HUM GENET, V14, P520, DOI 10.1038/sj.ejhg.5201606; McGrath JJ, 1999, ACTA PSYCHIAT SCAND, V99, P441, DOI 10.1111/j.1600-0447.1999.tb00990.x; Munakata K, 2005, BIOL PSYCHIAT, V57, P525, DOI 10.1016/j.biopsych.2004.11.041; Nachman MW, 2000, GENETICS, V156, P297; NANKO S, 1993, ACTA PSYCHIAT SCAND, V87, P400, DOI 10.1111/j.1600-0447.1993.tb03395.x; Need AC, 2009, PLOS GENET, V5, DOI 10.1371/journal.pgen.1000373; Nimgaonkar VL, 1998, ACTA PSYCHIAT SCAND, V98, P348, DOI 10.1111/j.1600-0447.1998.tb10097.x; ODEGARD O, 1980, ACTA PSYCHIAT SCAND, V62, P212, DOI 10.1111/j.1600-0447.1980.tb00609.x; ODONOVAN MC, 2008, NAT GENET; Ohashi J, 2002, ANN HUM GENET, V66, P297, DOI [10.1046/j.1469-1809.2002.00119.x, 10.1017/S0003480002001197]; Ohashi J, 2001, ANN HUM GENET, V65, P197, DOI 10.1017/S000348000100851X; Osby U, 2001, SCHIZOPHR RES, V47, P247, DOI 10.1016/S0920-9964(00)00124-9; Pritchard JK, 2001, AM J HUM GENET, V69, P124, DOI 10.1086/321272; Pritchard JK, 2002, HUM MOL GENET, V11, P2417, DOI 10.1093/hmg/11.20.2417; Purcell SM, 2009, NATURE, V460, P748, DOI 10.1038/nature08185; Reich DE, 2001, TRENDS GENET, V17, P502, DOI 10.1016/S0168-9525(01)02410-6; Repping S, 2006, NAT GENET, V38, P463, DOI 10.1038/ng1754; RIMMER J, 1976, ACTA PSYCHIAT SCAND, V54, P161, DOI 10.1111/j.1600-0447.1976.tb00108.x; RISCH N, 1987, AM J HUM GENET, V41, P218; Risch NJ, 2000, NATURE, V405, P847, DOI 10.1038/35015718; Sanders AR, 2008, AM J PSYCHIAT, V165, P497, DOI 10.1176/appi.ajp.2007.07101573; Shaner A, 2004, SCHIZOPHR RES, V70, P101, DOI 10.1016/j.schres.2003.09.014; Shi JX, 2009, NATURE, V460, P753, DOI 10.1038/nature08192; Shifman S, 2008, PLOS GENET, V4, DOI 10.1371/journal.pgen.0040028; Siguroardottir S, 2000, AM J HUM GENET, V66, P1599, DOI 10.1086/302902; SIPOS A, 2004, BRIT MED J, DOI DOI 10.1136/BMJ938243.672396.55; SLATER E, 1971, SOC BIOL, V18, pS60; Stefansson H, 2008, NATURE, V455, P232, DOI 10.1038/nature07229; Stefansson H, 2009, NATURE, V460, P744, DOI 10.1038/nature08186; Stone JL, 2008, NATURE, V455, P237, DOI 10.1038/nature07239; Sullivan PF, 2008, MOL PSYCHIATR, V13, P570, DOI 10.1038/mp.2008.25; Svensson AC, 2007, SCHIZOPHR RES, V91, P238, DOI 10.1016/j.schres.2006.12.002; Tandon R, 2008, SCHIZOPHR RES, V102, P1, DOI 10.1016/j.schres.2008.04.011; Vogel F., 1997, HUMAN GENETICS PROBL; Walsh T, 2008, SCIENCE, V320, P539, DOI 10.1126/science.1155174; Xu B, 2008, NAT GENET, V40, P880, DOI 10.1038/ng.162; Zammit S, 2003, BRIT J PSYCHIAT, V183, P405, DOI 10.1192/bjp.183.5.405	68	20	21	0	14	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	NOV 11	2009	4	11					A208	A220	e7799	10.1371/journal.pone.0007799	http://dx.doi.org/10.1371/journal.pone.0007799			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	518IX	19911060	Green Submitted, Green Published, gold			2022-12-25	WOS:000271685800022
J	Mitterer, H; McQueen, JM				Mitterer, Holger; McQueen, James M.			Foreign Subtitles Help but Native-Language Subtitles Harm Foreign Speech Perception	PLOS ONE			English	Article							ADAPTATION	Understanding foreign speech is difficult, in part because of unusual mappings between sounds and words. It is known that listeners in their native language can use lexical knowledge (about how words ought to sound) to learn how to interpret unusual speech-sounds. We therefore investigated whether subtitles, which provide lexical information, support perceptual learning about foreign speech. Dutch participants, unfamiliar with Scottish and Australian regional accents of English, watched Scottish or Australian English videos with Dutch, English or no subtitles, and then repeated audio fragments of both accents. Repetition of novel fragments was worse after Dutch-subtitle exposure but better after English-subtitle exposure. Native-language subtitles appear to create lexical interference, but foreign-language subtitles assist speech learning by indicating which words (and hence sounds) are being spoken.			Mitterer, H (corresponding author), Max Planck Inst Psycholinguist, Nijmegen, Netherlands.	holger.mitterer@mpi.nl	McQueen, James M./B-2212-2010; Mitterer, Holger/D-1908-2010	McQueen, James M./0000-0003-3734-6286; Mitterer, Holger/0000-0003-4318-0032				ADANK P, 2009, HUMAN PERCEPTION PER, V35, P520; Bertelson P, 2003, PSYCHOL SCI, V14, P592, DOI 10.1046/j.0956-7976.2003.psci_1470.x; Best C., 2007, HONOR JAMES EMIL FLE, V1334, P1, DOI DOI 10.1075/LLLT.17.07BES; Bird SA, 2002, APPL PSYCHOLINGUIST, V23, P509, DOI 10.1017/S0142716402004022; BORRAS I, 1994, MOD LANG J, V78, P61, DOI 10.2307/329253; Bradlow AR, 2008, COGNITION, V106, P707, DOI 10.1016/j.cognition.2007.04.005; Broersma M, 2008, SYSTEM, V36, P22, DOI 10.1016/j.system.2007.11.003; Clahsen H, 2006, TRENDS COGN SCI, V10, P564, DOI 10.1016/j.tics.2006.10.002; Clarke CM, 2004, J ACOUST SOC AM, V116, P3647, DOI 10.1121/1.1815131; Clarke-Davidson CM, 2008, PERCEPT PSYCHOPHYS, V70, P604, DOI 10.3758/PP.70.4.604; Connine CM, 2009, J MEM LANG, V61, P412, DOI 10.1016/j.jml.2009.07.003; d'Ydewalle G, 1999, J PSYCHOLINGUIST RES, V28, P227, DOI 10.1023/A:1023202130625; Davis MH, 2005, J EXP PSYCHOL GEN, V134, P222, DOI 10.1037/0096-3445.134.2.222; DEBOT K, 1986, SECOND LANG RES, V2, P72; Del Toro G., 2006, LABERINTO FAUNO; Hervais-Adelman A, 2008, J EXP PSYCHOL HUMAN, V34, P460, DOI 10.1037/0096-1523.34.2.460; Jaeger TF, 2008, J MEM LANG, V59, P434, DOI 10.1016/j.jml.2007.11.007; Kraljic T, 2008, COGNITION, V107, P54, DOI 10.1016/j.cognition.2007.07.013; Kraljic T, 2008, PSYCHOL SCI, V19, P332, DOI 10.1111/j.1467-9280.2008.02090.x; LAMBERT WE, 1981, APPL PSYCHOLINGUIST, V2, P133, DOI 10.1017/S0142716400000904; Macdonald A, 1996, TRAINSPOTTING; Maye J, 2008, COGNITIVE SCI, V32, P543, DOI 10.1080/03640210802035357; MCKENNA R, 2002, KATH KIM, V1; McQueen JM, 2006, COGNITIVE SCI, V30, P1113, DOI 10.1207/s15516709cog0000_79; Mitterer H, 2008, PSYCHOL SCI, V19, P629, DOI 10.1111/j.1467-9280.2008.02133.x; Norris D, 2003, COGNITIVE PSYCHOL, V47, P204, DOI 10.1016/S0010-0285(03)00006-9; Norris D, 2006, Q J EXP PSYCHOL, V59, P1505, DOI 10.1080/17470210600739494; *OECD PISA, 2007, PISA 2006 SCI COMP T; Ullman M.T., 2001, BILING-LANG COGN, V4, P105, DOI [10.1017/S1366728901000220, DOI 10.1017/S1366728901000220]; VANDERLINDEN S, 2007, J EXPT PSYCHOL HUMAN, V33, P1483; VANORDEN GC, 1987, MEM COGNITION, V15, P181, DOI 10.3758/BF03197716; Yoshino S., 2000, LANGUAGE LAB, V37, P111; [No title captured], DOI DOI 10.1016/J.JML.2007.12.005	33	104	104	1	36	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	NOV 11	2009	4	11					A146	A150	e7785	10.1371/journal.pone.0007785	http://dx.doi.org/10.1371/journal.pone.0007785			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	518IX	19918371	gold, Green Published, Green Submitted			2022-12-25	WOS:000271685800016
J	Ikeda, M; Hirono, M; Sugiyama, T; Moriya, T; Ikeda-Sagara, M; Eguchi, N; Urade, Y; Yoshioka, T				Ikeda, Masayuki; Hirono, Moritoshi; Sugiyama, Takashi; Moriya, Takahiro; Ikeda-Sagara, Masami; Eguchi, Naomi; Urade, Yoshihiro; Yoshioka, Tohru			Phospholipase C-beta 4 Is Essential for the Progression of the Normal Sleep Sequence and Ultradian Body Temperature Rhythms in Mice	PLOS ONE			English	Article							SUPERIOR COLLICULUS; LATERAL GENICULATE; PARADOXICAL SLEEP; VISUAL RESPONSE; OREXIN; RECEPTORS; HYPOCRETIN; STATES; NOREPINEPHRINE; MODULATION	Background: The sleep sequence: i) non-REM sleep, ii) REM sleep, and iii) wakefulness, is stable and widely preserved in mammals, but the underlying mechanisms are unknown. It has been shown that this sequence is disrupted by sudden REM sleep onset during active wakefulness (i. e., narcolepsy) in orexin-deficient mutant animals. Phospholipase C (PLC) mediates the signaling of numerous metabotropic receptors, including orexin receptors. Among the several PLC subtypes, the beta 4 subtype is uniquely localized in the geniculate nucleus of thalamus which is hypothesized to have a critical role in the transition and maintenance of sleep stages. In fact, we have reported irregular theta wave frequency during REM sleep in PLC-beta 4-deficient mutant (PLC-beta 4-/-) mice. Daily behavioral phenotypes and metabotropic receptors involved have not been analyzed in detail in PLC-beta 4-/- mice, however. Methodology/Principal Findings: Therefore, we analyzed 24-h sleep electroencephalogram in PLC-beta 4-/- mice. PLC-beta 4-/- mice exhibited normal non-REM sleep both during the day and nighttime. PLC-beta 4-/- mice, however, exhibited increased REM sleep during the night, their active period. Also, their sleep was fragmented with unusual wake-to-REM sleep transitions, both during the day and nighttime. In addition, PLC-beta 4-/- mice reduced ultradian body temperature rhythms and elevated body temperatures during the daytime, but had normal homeothermal response to acute shifts in ambient temperatures (22 degrees C-4 degrees C). Within the most likely brain areas to produce these behavioral phenotypes, we found that, not orexin, but group-1 metabotropic glutamate receptor (mGluR)-mediated Ca2+ mobilization was significantly reduced in the dorsal lateral geniculate nucleus (LGNd) of PLC-beta 4-/- mice. Voltage clamp recordings revealed that group-1 mGluR-mediated currents in LGNd relay neurons (inward in wild-type mice) were outward in PLC-beta 4-/- mice. Conclusions/Significance: These lines of evidence indicate that impaired LGNd relay, possibly mediated via group-1 mGluR, may underlie irregular sleep sequences and ultradian body temperature rhythms in PLC-beta 4-/- mice.			Ikeda, M (corresponding author), Toyama Univ, Grad Sch Innovat Life Sci, Dept Chronobiol, Toyama 930, Japan.	msikeda@sci.u-toyama.ac.jp		Ikeda, Masayuki/0000-0002-6833-9495; Hirono, Moritoshi/0000-0001-6068-1045; Sugiyama, Takashi/0000-0002-7872-1540				Anderson MP, 2005, P NATL ACAD SCI USA, V102, P1743, DOI 10.1073/pnas.0409644102; Bayer L, 2002, J NEUROSCI, V22, P7835; Boutrel B, 1999, J NEUROSCI, V19, P3204; Chemelli RM, 1999, CELL, V98, P437, DOI 10.1016/S0092-8674(00)81973-X; Cox CL, 1998, NATURE, V394, P478, DOI 10.1038/28855; Deboer T, 2003, NAT NEUROSCI, V6, P1086, DOI 10.1038/nn1122; Godwin DW, 1996, J NEUROPHYSIOL, V76, P1800, DOI 10.1152/jn.1996.76.3.1800; Govindaiah G, 2006, NEUROPHARMACOLOGY, V51, P414, DOI 10.1016/j.neuropharm.2006.03.030; Hagan JJ, 1999, P NATL ACAD SCI USA, V96, P10911, DOI 10.1073/pnas.96.19.10911; Hirono M, 2001, J BIOL CHEM, V276, P45236, DOI 10.1074/jbc.M105413200; Hunsley MS, 2006, GENES BRAIN BEHAV, V5, P451, DOI 10.1111/j.1601-183X.2005.00179.x; Hunsley MS, 2003, SLEEP, V26, P521; Ikeda M, 2000, NEUROSCI LETT, V279, P185, DOI 10.1016/S0304-3940(99)00943-X; Ikeda M, 2000, NEUROREPORT, V11, P907, DOI 10.1097/00001756-200004070-00002; Jenkins TC, 2007, BRAIN RES, V1178, P83, DOI 10.1016/j.brainres.2007.07.098; Jiang HP, 1996, P NATL ACAD SCI USA, V93, P14598, DOI 10.1073/pnas.93.25.14598; JONES BE, 1991, NEUROSCIENCE, V40, P637, DOI 10.1016/0306-4522(91)90002-6; Kameyama M, 2003, BIOCHEM BIOPH RES CO, V304, P153, DOI 10.1016/S0006-291X(03)00536-9; Kim D, 1997, NATURE, V389, P290, DOI 10.1038/38508; Lee KH, 1997, NEUROSCIENCE, V77, P335, DOI 10.1016/S0306-4522(96)00481-2; Lin L, 1999, CELL, V98, P365, DOI 10.1016/S0092-8674(00)81965-0; McCarley RW, 1999, SLEEP DISORDERS MED, P21; MCCORMICK DA, 1992, P NATL ACAD SCI USA, V89, P2774, DOI 10.1073/pnas.89.7.2774; Miller AM, 1999, BEHAV NEUROSCI, V113, P755, DOI 10.1037/0735-7044.113.4.755; Miller AM, 1998, P NATL ACAD SCI USA, V95, P8957, DOI 10.1073/pnas.95.15.8957; Mochizuki T, 2004, J NEUROSCI, V24, P6291, DOI 10.1523/JNEUROSCI.0586-04.2004; Neto FL, 2000, BRAIN RES, V854, P93, DOI 10.1016/S0006-8993(99)02326-4; Parmentier R, 2002, J NEUROSCI, V22, P7695; Peyron C, 1998, J NEUROSCI, V18, P9996; Pinzar E, 2000, P NATL ACAD SCI USA, V97, P4903, DOI 10.1073/pnas.090093997; Sakurai T, 1998, CELL, V92, P573, DOI 10.1016/S0092-8674(00)80949-6; Steriade M, 2000, NEUROSCIENCE, V101, P243, DOI 10.1016/S0306-4522(00)00353-5; Sugiyama T, 1999, BIOCHEM BIOPH RES CO, V265, P473, DOI 10.1006/bbrc.1999.1628; Thakkar M M, 1999, Sleep Res Online, V2, P112; Tobler I, 1997, J NEUROSCI, V17, P1869; Vidnyanszky Z, 1996, EUR J NEUROSCI, V8, P1061, DOI 10.1111/j.1460-9568.1996.tb01273.x; White AM, 2003, BRIT J PHARMACOL, V140, P1421, DOI 10.1038/sj.bjp.0705570; Wurts SW, 2000, J NEUROSCI, V20, P4300; Zhang SW, 2007, J PHYSIOL-LONDON, V581, P649, DOI 10.1113/jphysiol.2007.129510	39	2	2	1	9	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	NOV 9	2009	4	11							e7737	10.1371/journal.pone.0007737	http://dx.doi.org/10.1371/journal.pone.0007737			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	517ZM	19898623	Green Published, gold, Green Submitted			2022-12-25	WOS:000271658000004
J	Dal Secco, V; Soldani, C; Debrat, C; Asperti-Boursin, F; Donnadieu, E; Viola, A; Sarukhan, A				Dal Secco, Valentina; Soldani, Cristiana; Debrat, Claire; Asperti-Boursin, Francois; Donnadieu, Emmanuel; Viola, Antonella; Sarukhan, Adelaida			Tunable Chemokine Production by Antigen Presenting Dendritic Cells in Response to Changes in Regulatory T Cell Frequency in Mouse Reactive Lymph Nodes	PLOS ONE			English	Article							HIGH ENDOTHELIAL VENULES; IN-VIVO; IMMUNE-RESPONSE; STEADY-STATE; MIGRATION; IMMATURE; FOXP3; RECRUITMENT; MICE; MICROENVIRONMENTS	Background: Although evidence exists that regulatory T cells (Tregs) can suppress the effector phase of immune responses, it is clear that their major role is in suppressing T cell priming in secondary lymphoid organs. Recent experiments using two photon laser microscopy indicate that dendritic cells (DCs) are central to Treg cell function and that the in vivo mechanisms of T cell regulation are more complex than those described in vitro. Principal Findings: Here we have sought to determine whether and how modulation of Treg numbers modifies the lymph node (LN) microenvironment. We found that pro-inflammatory chemokines-CCL2 (MCP-1) and CCL3 (MIP-la)-are secreted in the LN early (24 h) after T cell activation, that this secretion is dependent on antigen-specific DC-T cell interactions, and that it was inversely related to the frequency of Tregs specific for the same antigen. Furthermore, we demonstrate that Tregs modify the chemoattractant properties of antigen-presenting DCs, which, as the frequency of Tregs increases, fail to produce CCL2 and CCL3 and to attract antigen-specific T cells. Conclusions: These results substantiate a major role of Tregs in LN patterning during antigen-specific immune responses.			Dal Secco, V (corresponding author), Ist Clin Humanitas IRCCS, Milan, Italy.	antonella.viola@humanitas.it	Donnadieu, Emmanuel/P-4566-2017; Agatea, Lisa/L-8267-2016; Viola, Antonella/A-4321-2015	Soldani, Cristiana/0000-0001-5041-9588; Sarukhan, Adelaida/0000-0003-3747-6304; Viola, Antonella/0000-0002-0125-9271	Associazione Italiana per la Ricerca sul Cancro Funding Source: Custom	Associazione Italiana per la Ricerca sul Cancro(Fondazione AIRC per la ricerca sul cancro)		ALLAN SE, 2008, IMMUNOL REV, V391, P421; Allenspach EJ, 2008, IMMUNITY, V29, P795, DOI 10.1016/j.immuni.2008.08.013; Bajenoff M, 2003, J EXP MED, V198, P715, DOI 10.1084/jem.20030167; Bajenoff M, 2006, IMMUNITY, V25, P989, DOI 10.1016/j.immuni.2006.10.011; Belkaid Y, 2007, NAT REV IMMUNOL, V7, P875, DOI 10.1038/nri2189; Bennett CL, 2001, NAT GENET, V27, P20, DOI 10.1038/83713; Betts GJ, 2006, ADV DRUG DELIVER REV, V58, P948, DOI 10.1016/j.addr.2006.05.006; Brusko TM, 2008, IMMUNOL REV, V223, P371, DOI 10.1111/j.1600-065X.2008.00637.x; Castellino F, 2006, NATURE, V440, P890, DOI 10.1038/nature04651; Castellino F, 2007, J IMMUNOL, V178, P778, DOI 10.4049/jimmunol.178.2.778; CHUNG DJ, 2009, BLOOD; Cyster JG, 2005, ANNU REV IMMUNOL, V23, P127, DOI 10.1146/annurev.immunol.23.021704.115628; Dieu MC, 1998, J EXP MED, V188, P373, DOI 10.1084/jem.188.2.373; Fontenot JD, 2017, J IMMUNOL, V198, P986, DOI 10.1038/ni904; Forster R, 1999, CELL, V99, P23, DOI 10.1016/S0092-8674(00)80059-8; Gajewski TF, 2006, IMMUNOL REV, V213, P131, DOI 10.1111/j.1600-065X.2006.00442.x; Gallimore AM, 2008, ONCOGENE, V27, P5886, DOI 10.1038/onc.2008.269; Gretz JE, 2000, J EXP MED, V192, P1425, DOI 10.1084/jem.192.10.1425; Hill JA, 2007, IMMUNITY, V27, P786, DOI 10.1016/j.immuni.2007.09.010; Hokeness KL, 2005, J IMMUNOL, V174, P1549, DOI 10.4049/jimmunol.174.3.1549; Hori S, 2003, SCIENCE, V299, P1057, DOI 10.1126/science.1079490; Huang B, 2006, CANCER RES, V66, P1123, DOI 10.1158/0008-5472.CAN-05-1299; Hugues S, 2007, NAT IMMUNOL, V8, P921, DOI 10.1038/ni1495; KIRBERG J, 1994, J EXP MED, V180, P25, DOI 10.1084/jem.180.1.25; Klein L, 2003, P NATL ACAD SCI USA, V100, P8886, DOI 10.1073/pnas.1533365100; Kretschmer K, 2006, IMMUNOL REV, V212, P163, DOI 10.1111/j.0105-2896.2006.00411.x; Kurihara T, 1997, J EXP MED, V186, P1757, DOI 10.1084/jem.186.10.1757; Lanoue A, 1997, J EXP MED, V185, P405, DOI 10.1084/jem.185.3.405; Levings MK, 2006, ADV IMMUNOL, V92, P119, DOI 10.1016/S0065-2776(06)92003-3; Lu B, 1998, J EXP MED, V187, P601, DOI 10.1084/jem.187.4.601; Lund JM, 2008, SCIENCE, V320, P1220, DOI 10.1126/science.1155209; Martin-Fontecha A, 2003, J EXP MED, V198, P615, DOI 10.1084/jem.20030448; Miller MJ, 2003, P NATL ACAD SCI USA, V100, P2604, DOI 10.1073/pnas.2628040100; Nakano H, 2009, NAT IMMUNOL, V10, P394, DOI 10.1038/ni.1707; Nobile C, 2008, BLOOD, V111, P3579, DOI 10.1182/blood-2007-08-107755; Ohl L, 2004, IMMUNITY, V21, P279, DOI 10.1016/j.immuni.2004.06.014; Sozzani S, 1998, J IMMUNOL, V161, P1083; Stein JV, 2000, J EXP MED, V191, P61, DOI 10.1084/jem.191.1.61; Tadokoro CE, 2006, J EXP MED, V203, P505, DOI 10.1084/jem.20050783; Tang QZ, 2006, NAT IMMUNOL, V7, P83, DOI 10.1038/ni1289; Terme M, 2008, J IMMUNOL, V180, P4679, DOI 10.4049/jimmunol.180.7.4679; Vecchi A, 1999, J LEUKOCYTE BIOL, V66, P489, DOI 10.1002/jlb.66.3.489; Vignali DAA, 2008, NAT REV IMMUNOL, V8, P523, DOI 10.1038/nri2343; Wildin RS, 2001, NAT GENET, V27, P18, DOI 10.1038/83707	44	21	21	0	0	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA	1932-6203			PLOS ONE	PLoS One	NOV 6	2009	4	11							e7696	10.1371/journal.pone.0007696	http://dx.doi.org/10.1371/journal.pone.0007696			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	515ND	19893746	Green Published, Green Submitted, gold			2022-12-25	WOS:000271478000003
J	Chang, AYW; Chan, JYH; Chuang, YC; Chan, SHH				Chang, Alice Y. W.; Chan, Julie Y. H.; Chuang, Yao-Chung; Chan, Samuel H. H.			Brain Stem Death as the Vital Determinant for Resumption of Spontaneous Circulation after Cardiac Arrest in Rats	PLOS ONE			English	Article							ROSTRAL VENTROLATERAL MEDULLA; SYSTEMIC ARTERIAL-PRESSURE; CONFERS CARDIOVASCULAR PROTECTION; ACUTE MEVINPHOS INTOXICATION; TIME SPECTRAL-ANALYSIS; SIGNALS; HEAT-SHOCK-PROTEIN-70; APOPTOSIS; ONLINE	Background: Spontaneous circulation returns to less than half of adult cardiac arrest victims who received in-hospital resuscitation. One clue for this disheartening outcome arises from the prognosis that asystole invariably takes place, after a time lag, on diagnosis of brain stem death. The designation of brain stem death as the point of no return further suggests that permanent impairment of the brain stem cardiovascular regulatory machinery precedes death. It follows that a crucial determinant for successful revival of an arrested heart is that spontaneous circulation must resume before brain stem death commences. Here, we evaluated the hypothesis that maintained functional integrity of the rostral ventrolateral medulla (RVLM), a neural substrate that is intimately related to brain stem death and central circulatory regulation, holds the key to the vital time-window between cardiac arrest and resumption of spontaneous circulation. Methodology/Principal Findings: An animal model of brain stem death employing the pesticide mevinphos as the experimental insult in Sprague-Dawley rats was used. Intravenous administration of lethal doses of mevinphos elicited an abrupt cardiac arrest, accompanied by elevated systemic arterial pressure and anoxia, augmented neuronal excitability and enhanced microvascular perfusion in RVLM. This period represents the vital time-window between cardiac arrest and resumption of spontaneous circulation in our experimental model. Animals with restored spontaneous circulation exhibited maintained neuronal functionality in RVLM beyond this critical time-window, alongside resumption of baseline tissue oxygen and enhancement of local blood flow. Intriguingly, animals that subsequently died manifested sustained anoxia, diminished local blood flow, depressed mitochondrial electron transport activities and reduced ATP production, leading to necrotic cell death in RVLM. That amelioration of mitochondrial dysfunction and bioenergetic failure in RVLM by coenzyme Q10, the mobile electron carrier in mitochondrial respiratory chain, or oxygenation restored spontaneous circulation further established a causal relationship between functionality of RVLM and resumed spontaneous circulation after cardiac arrest. Conclusions/Significance: We conclude that whereas necrotic cell death because of bioenergetic failure triggered by anoxia in RVLM, which precipitates brain stem death, negates resuscitation of an arrested heart, maintained functional integrity of this neural substrate holds the key to resumption of spontaneous circulation after cardiac arrest in rats.			Chang, AYW (corresponding author), Chang Gung Mem Hosp, Kaohsiung Med Ctr, Ctr Translat Res Biomed Sci, Kaohsiung, Kaohsiung Cty, Taiwan.	achang@adm.cgmh.org.tw; shhchan@adm.cgmh.org.tw	Chan, Julie/X-5253-2019					[Anonymous], 1976, BMJ-BRIT MED J, V2, P1187; Chan JYH, 2007, J PHYSIOL-LONDON, V581, P1293, DOI 10.1113/jphysiol.2007.130872; Chan JYH, 2007, J BIOL CHEM, V282, P4585, DOI 10.1074/jbc.M603394200; Chan JYH, 2005, PROG NEUROBIOL, V77, P396, DOI 10.1016/j.pneurobio.2005.11.004; DEREUCK J, 1979, CLIN NEUROL NEUROSUR, V81, P247, DOI 10.1016/0303-8467(79)90029-5; Eguchi Y, 1997, CANCER RES, V57, P1835; ERNSTER L, 1995, BBA-MOL BASIS DIS, V1271, P195, DOI 10.1016/0925-4439(95)00028-3; FREI B, 1990, P NATL ACAD SCI USA, V87, P4879, DOI 10.1073/pnas.87.12.4879; HATEFI Y, 1985, ANNU REV BIOCHEM, V54, P1015, DOI 10.1146/annurev.bi.54.070185.005055; HUNG TP, 1995, J NEUROL NEUROSUR PS, V58, P75, DOI 10.1136/jnnp.58.1.75; Kroemer G, 1999, BIOCHEM SOC SYMP, V66, P1; Kuo TBJ, 1997, AM J PHYSIOL-HEART C, V272, pH485, DOI 10.1152/ajpheart.1997.272.1.H485; KUO TBJ, 1993, AM J PHYSIOL, V264, pH2208, DOI 10.1152/ajpheart.1993.264.6.H2208; Kuo TBJ, 1997, AM J PHYSIOL-HEART C, V273, pH1291, DOI 10.1152/ajpheart.1997.273.3.H1291; Leist M, 1997, J EXP MED, V185, P1481, DOI 10.1084/jem.185.8.1481; Li PL, 2001, CIRCULATION, V103, P2114; LYNN J, 1981, JAMA-J AM MED ASSOC, V246, P2184; Matthews RT, 1998, P NATL ACAD SCI USA, V95, P8892, DOI 10.1073/pnas.95.15.8892; MOHANDAS A, 1971, J NEUROSURG, V35, P211, DOI 10.3171/jns.1971.35.2.0211; PALLIS C, 1983, A B C BRAIN STEM DEA; Peberdy MA, 2003, RESUSCITATION, V58, P297, DOI 10.1016/S0300-9572(03)00215-6; Sheh YL, 2007, FREE RADICAL BIO MED, V42, P1610, DOI 10.1016/j.freeradbiomed.2007.02.019; SPYER KM, 1994, J PHYSIOL-LONDON, V474, P1; Yang CH, 1995, J PHARMACOL EXP THER, V275, P1568; YANG MW, 1995, AM J PHYSIOL-HEART C, V268, pH2329, DOI 10.1152/ajpheart.1995.268.6.H2329; Yen DHT, 2005, SHOCK, V23, P353, DOI 10.1097/01.shk.0000156673.44063.e8; Yen DHT, 2001, SHOCK, V15, P35, DOI 10.1097/00024382-200115010-00006; Yen DHT, 2000, CRIT CARE MED, V28, P2805, DOI 10.1097/00003246-200008000-00021; Yien HW, 1997, CRIT CARE MED, V25, P258, DOI 10.1097/00003246-199702000-00011	29	15	15	0	3	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	NOV 4	2009	4	11							e7744	10.1371/journal.pone.0007744	http://dx.doi.org/10.1371/journal.pone.0007744			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	514RZ	19888468	gold, Green Published			2022-12-25	WOS:000271414600011
J	Hayano-Kanashiro, C; Calderon-Vazquez, C; Ibarra-Laclette, E; Herrera-Estrella, L; Simpson, J				Hayano-Kanashiro, Corina; Calderon-Vazquez, Carlos; Ibarra-Laclette, Enrique; Herrera-Estrella, Luis; Simpson, June			Analysis of Gene Expression and Physiological Responses in Three Mexican Maize Landraces under Drought Stress and Recovery Irrigation	PLOS ONE			English	Article							HIGH-SALINITY STRESSES; ABSCISIC-ACID; PLANT-RESPONSES; CDNA MICROARRAY; ABIOTIC STRESS; CARBOHYDRATE-METABOLISM; REGULATORY NETWORKS; SIGNAL-TRANSDUCTION; MESSENGER-RNA; ABI3 GENE	Background: Drought is one of the major constraints for plant productivity worldwide. Different mechanisms of drought-tolerance have been reported for several plant species including maize. However, the differences in global gene expression between drought-tolerant and susceptible genotypes and their relationship to physiological adaptations to drought are largely unknown. The study of the differences in global gene expression between tolerant and susceptible genotypes could provide important information to design more efficient breeding programs to produce maize varieties better adapted to water limiting conditions. Methodology/Principal Findings: Changes in physiological responses and gene expression patterns were studied under drought stress and recovery in three Mexican maize landraces which included two drought tolerant (Cajete criollo and Michoacan 21) and one susceptible (85-2) genotypes. Photosynthesis, stomatal conductance, soil and leaf water potentials were monitored throughout the experiment and microarray analysis was carried out on transcripts obtained at 10 and 17 days following application of stress and after recovery irrigation. The two tolerant genotypes show more drastic changes in global gene expression which correlate with different physiological mechanisms of adaptation to drought. Differences in the kinetics and number of up-and down-regulated genes were observed between the tolerant and susceptible maize genotypes, as well as differences between the two tolerant genotypes. Interestingly, the most dramatic differences between the tolerant and susceptible genotypes were observed during recovery irrigation, suggesting that the tolerant genotypes activate mechanisms that allow more efficient recovery after a severe drought. Conclusions/Significance: A correlation between levels of photosynthesis and transcription under stress was observed and differences in the number, type and expression levels of transcription factor families were also identified under drought and recovery between the three maize landraces. Gene expression analysis suggests that the drought tolerant landraces have a greater capacity to rapidly modulate more genes under drought and recovery in comparison to the susceptible landrace. Modulation of a greater number of differentially expressed genes of different TF gene families is an important characteristic of the tolerant genotypes. Finally, important differences were also noted between the tolerant landraces that underlie different mechanisms of achieving tolerance.			Hayano-Kanashiro, C (corresponding author), Ctr Invest & Estudios Avanzados, Dept Ingn Genet Plantas, Guanajuato, Mexico.	jsimpson@ira.cinvestav.mx	Herrera-Estrella, Luis/ABC-7431-2020; Simpson, June/I-1057-2012; Herrera-Estrella, Luis/AAL-2472-2020; Calderon-Vazquez, Carlos/R-3601-2018; Estrella, Luis R Herrera/G-7351-2011	Simpson, June/0000-0002-1891-4914; Herrera-Estrella, Luis/0000-0001-7936-3856; Calderon-Vazquez, Carlos/0000-0002-6674-2504; Estrella, Luis R Herrera/0000-0001-7936-3856; Hayano-Kanashiro, Corina/0000-0001-7846-6124				Bartels D, 2005, CRIT REV PLANT SCI, V24, P23, DOI 10.1080/07352680590910410; BENJAMINI Y, 1995, J R STAT SOC B, V57, P289, DOI 10.1111/j.2517-6161.1995.tb02031.x; Bhatnagar-Mathur P, 2008, PLANT CELL REP, V27, P411, DOI 10.1007/s00299-007-0474-9; Brady SM, 2003, PLANT J, V34, P67, DOI 10.1046/j.1365-313X.2003.01707.x; Bray EA, 1997, TRENDS PLANT SCI, V2, P48, DOI 10.1016/S1360-1385(97)82562-9; Bruce WB, 2002, J EXP BOT, V53, P13, DOI 10.1093/jexbot/53.366.13; Brugiere N, 2003, PLANT PHYSIOL, V132, P1228, DOI 10.1104/pp.102.017707; Calderon-Vazquez C, 2008, J EXP BOT, V59, P2479, DOI 10.1093/jxb/ern115; Chaves MM, 2003, FUNCT PLANT BIOL, V30, P239, DOI 10.1071/FP02076; Degenkolbe T, 2009, PLANT MOL BIOL, V69, P133, DOI 10.1007/s11103-008-9412-7; Edgar R, 2002, NUCLEIC ACIDS RES, V30, P207, DOI 10.1093/nar/30.1.207; Fischer KS., 1983, BREEDING SELECTION D; Foyer CH, 1998, PLANT PHYSIOL, V117, P283, DOI 10.1104/pp.117.1.283; Garcion C, 2006, TRENDS PLANT SCI, V11, P320, DOI 10.1016/j.tplants.2006.05.009; Gibson G., 2004, GENETIC ANAL COMPLEX, P251; Vendruscolo ECG, 2007, J PLANT PHYSIOL, V164, P1367, DOI 10.1016/j.jplph.2007.05.001; Gutierrez RA, 2007, J EXP BOT, V58, P2359, DOI 10.1093/jxb/erm079; Hegeman CE, 2001, PLANT PHYSIOL, V125, P1941, DOI 10.1104/pp.125.4.1941; Ingram J, 1996, ANNU REV PLANT PHYS, V47, P377, DOI 10.1146/annurev.arplant.47.1.377; International Maize and Wheat Improvement Center (CIMMYT), 2001, CIMMYT 1999 2000 WOR; Jia JP, 2006, PLANT J, V48, P710, DOI 10.1111/j.1365-313X.2006.02905.x; Kawaguchi R, 2004, PLANT J, V38, P823, DOI 10.1111/j.1365-313X.2004.02090.x; Kishor PBK, 2005, CURR SCI INDIA, V88, P424; Koch KE, 1996, ANNU REV PLANT PHYS, V47, P509, DOI 10.1146/annurev.arplant.47.1.509; Li WX, 2008, PLANT CELL, V20, P2238, DOI 10.1105/tpc.108.059444; Mahajan S, 2005, ARCH BIOCHEM BIOPHYS, V444, P139, DOI 10.1016/j.abb.2005.10.018; Massonneau A, 2004, J EXP BOT, V55, P2549, DOI 10.1093/jxb/erh274; Mohammadi M, 2007, PLANT CELL ENVIRON, V30, P630, DOI 10.1111/j.1365-3040.2007.01645.x; Morcuende R, 2007, PLANT CELL ENVIRON, V30, P85, DOI 10.1111/j.1365-3040.2006.01608.x; MUNOZ OA, 1983, AGROCIENCIA, V51, P115; Nelson DE, 2007, P NATL ACAD SCI USA, V104, P16450, DOI 10.1073/pnas.0707193104; Oono Y, 2003, PLANT J, V34, P868, DOI 10.1046/j.1365-313X.2003.01774.x; Ozturk ZN, 2002, PLANT MOL BIOL, V48, P551, DOI 10.1023/A:1014875215580; Park JE, 2007, J BIOL CHEM, V282, P10036, DOI 10.1074/jbc.M610524200; Parry MAJ, 2005, ANN APPL BIOL, V147, P211, DOI 10.1111/j.1744-7348.2005.00032.x; Pelleschi S, 1997, PLANT CELL ENVIRON, V20, P493, DOI 10.1046/j.1365-3040.1997.d01-89.x; PEREZ JG, 1979, COMPORTAMIENTO MAICE; PHILLIPS RD, 1976, NEW PHYTOL, V77, P599, DOI 10.1111/j.1469-8137.1976.tb04652.x; Pingali P.L., 2001, M WORLD MAIZ NEEDS T; Poroyko V, 2007, J EXP BOT, V58, P279, DOI 10.1093/jxb/erl119; Rabbani MA, 2003, PLANT PHYSIOL, V133, P1755, DOI 10.1104/pp.103.025742; Reynolds M, 2007, J EXP BOT, V58, P177, DOI 10.1093/jxb/erl250; Ribaut JM, 2007, J EXP BOT, V58, P351, DOI 10.1093/jxb/erl214; Schafleitner R, 2007, PLANT PHYSIOL BIOCH, V45, P673, DOI 10.1016/j.plaphy.2007.06.003; Seki M, 2002, PLANT J, V31, P279, DOI 10.1046/j.1365-313X.2002.01359.x; Seki M, 2007, CURR OPIN PLANT BIOL, V10, P296, DOI 10.1016/j.pbi.2007.04.014; Shen QX, 2001, PLANT MOL BIOL, V45, P327, DOI 10.1023/A:1006460231978; Shinozaki K, 1997, PLANT PHYSIOL, V115, P327, DOI 10.1104/pp.115.2.327; Shinozaki K, 2007, J EXP BOT, V58, P221, DOI 10.1093/jxb/erl164; Smyth G., 2003, LIMMA LINEAR MODELS; Spollen WG, 2008, BMC PLANT BIOL, V8, DOI 10.1186/1471-2229-8-32; Sun WN, 2002, BBA-GENE STRUCT EXPR, V1577, P1, DOI 10.1016/S0167-4781(02)00417-7; Talame V, 2007, J EXP BOT, V58, P229, DOI 10.1093/jxb/erl163; Tamminen I, 2001, PLANT J, V25, P1, DOI 10.1046/j.1365-313x.2001.00927.x; Thimm O, 2004, PLANT J, V37, P914, DOI 10.1111/j.1365-313X.2004.02016.x; Tuberosa R, 2007, CROP SCI, V47, pS120, DOI 10.2135/cropsci2007.04.0001IPBS; Umezawa T, 2006, CURR OPIN BIOTECH, V17, P113, DOI 10.1016/j.copbio.2006.02.002; Vinocur B, 2005, CURR OPIN BIOTECH, V16, P123, DOI 10.1016/j.copbio.2005.02.001; Wang WX, 2003, PLANTA, V218, P1, DOI 10.1007/s00425-003-1105-5; Wasilewska A, 2008, MOL PLANT, V1, P198, DOI 10.1093/mp/ssm022; Wolfinger RD, 2001, J COMPUT BIOL, V8, P625, DOI 10.1089/106652701753307520; Xiao WY, 2000, PLANT MOL BIOL, V44, P451, DOI 10.1023/A:1026501430422; Xiong LM, 2002, PLANT CELL, V14, pS165, DOI 10.1105/tpc.000596; Xue GP, 2008, PLANT MOL BIOL, V67, P197, DOI 10.1007/s11103-008-9311-y; Yamaguchi-Shinozaki K, 2006, ANNU REV PLANT BIOL, V57, P781, DOI 10.1146/annurev.arplant.57.032905.105444; Yang YH, 2002, NUCLEIC ACIDS RES, V30, DOI 10.1093/nar/30.4.e15; Yu LX, 2003, PLANT PHYSIOL, V131, P568, DOI 10.1104/pp.014365; Zheng J, 2004, PLANT MOL BIOL, V55, P807, DOI 10.1007/s11103-005-1969-9	68	149	177	3	42	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	OCT 30	2009	4	10							e7531	10.1371/journal.pone.0007531	http://dx.doi.org/10.1371/journal.pone.0007531			19	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	514RW	19888455	Green Published, gold, Green Submitted			2022-12-25	WOS:000271414300001
J	Wirth, EK; Conrad, M; Winterer, J; Wozny, C; Carlson, BA; Roth, S; Schmitz, D; Bornkamm, GW; Coppola, V; Tessarollo, L; Schomburg, L; Kohrle, J; Hatfield, DL; Schweizer, U				Wirth, Eva K.; Conrad, Marcus; Winterer, Jochen; Wozny, Christian; Carlson, Bradley A.; Roth, Stephan; Schmitz, Dietmar; Bornkamm, Georg W.; Coppola, Vincenzo; Tessarollo, Lino; Schomburg, Lutz; Koehrle, Josef; Hatfield, Dolph L.; Schweizer, Ulrich			Neuronal selenoprotein expression is required for interneuron development and prevents seizures and neurodegeneration	FASEB JOURNAL			English	Article						selenium; parvalbumin; excitability; schizophrenia; gamma oscillation	APOLIPOPROTEIN-E RECEPTOR-2; NEUROLOGICAL DYSFUNCTION; SELENIUM DEFICIENCY; BRAIN-DEVELOPMENT; TARGET TISSUES; MICE; MOUSE; GENE; SURVIVAL; SELENOCYSTEINE	Cerebral selenium (Se) deficiency is associated with neurological phenotypes including seizures and ataxia. We wanted to define whether neurons require selenoprotein expression and which selenoproteins are most important, and explore the possible pathomechanism. Therefore, we abrogated the expression of all selenoproteins in neurons by genetic inactivation of the tRNA[Ser](Sec) gene. Cerebral expression of selenoproteins was significantly diminished in the mutants, and histological analysis revealed progressive neurodegeneration. Developing interneurons failed to specifically express parvalbumin (PV) in the mutants. Electrophysiological recordings, before overt cell death, showed normal excitatory transmission, but revealed spontaneous epileptiform activity consistent with seizures in the mutants. In developing cortical neuron cultures, the number of PV+ neurons was reduced on combined Se and vitamin E deprivation, while other markers, such as calretinin (CR) and GAD67, remained unaffected. Because of the synergism between Se and vitamin E, we analyzed mice lacking neuronal expression of the Se-dependent enzyme glutathione peroxidase 4 (GPx4). Although the number of CR+ interneurons remained normal in Gpx4-mutant mice, the number of PV+ interneurons was reduced. Since these mice similarly exhibit seizures and ataxia, we conclude that GPx4 is a selenoenzyme modulating interneuron function and PV expression. Cerebral SE deficiency may thus act via reduced GPx4 expression.-Wirth, E. K., Conrad, M., Winterer, J., Wozny, C., Carlson, B. A., Roth, S., Schmitz, D., Bornkamm, G. W., Coppola, V., Tessarollo, L., Schomburg, L., Kohrle, J., Hatfield, D. L., Schweizer, U. Neuronal selenoprotein expression is required for interneuron development and prevents seizures and neurodegeneration. FASEB J. 24, 844-852 (2010). www.fasebj.org	[Schomburg, Lutz; Koehrle, Josef; Schweizer, Ulrich] Charite, Inst Expt Endocrinol, D-13353 Berlin, Germany; [Winterer, Jochen; Wozny, Christian; Schmitz, Dietmar] Charite, Neurosci Res Ctr, D-13353 Berlin, Germany; [Conrad, Marcus; Bornkamm, Georg W.] Helmholtz Zentrum Munchen, Inst Clin Mol Biol & Tumour Genet, Munich, Germany; [Carlson, Bradley A.; Hatfield, Dolph L.] NCI, Mol Biol Selenium Sect, Lab Canc Prevent, Ctr Canc Res,NIH, Bethesda, MD 20892 USA; [Coppola, Vincenzo; Tessarollo, Lino] NCI, Neural Dev Grp, Mouse Canc Genet Program, Frederick, MD 21701 USA	Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Helmholtz Association; Helmholtz-Center Munich - German Research Center for Environmental Health; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Schweizer, U (corresponding author), Charite, Inst Expt Endocrinol, Augustenburger Pl 1, D-13353 Berlin, Germany.	ulrich.schweizer@charite.de	Köhrle, Josef/AAH-6438-2020; Schomburg, Lutz/D-8096-2013; Wozny, Christian/A-1498-2015; Conrad, Marcus/E-8792-2015; Schweizer, Ulrich/E-8105-2013; Coppola, Vincenzo/D-5352-2014; Coppola, Vincenzo/E-2917-2011	Köhrle, Josef/0000-0002-9187-9078; Schomburg, Lutz/0000-0001-9445-1555; Wozny, Christian/0000-0003-4220-2033; Conrad, Marcus/0000-0003-1140-5612; Coppola, Vincenzo/0000-0001-6163-1779; Coppola, Vincenzo/0000-0001-6163-1779; Schweizer, Ulrich/0000-0003-1380-4780; Schmitz, Dietmar/0000-0003-2741-5241; Wirth, Eva Katrin/0000-0002-0491-9941	Deutsche Forschungsgemeinschaft [Scho849/2-2, SFB 665/A7, Ko922/11-1]; Charite Universitatsmedizin Berlin; U.S. National Institutes of Health; National Cancer Institute; Center for Cancer Research; NATIONAL CANCER INSTITUTE [ZIABC005317] Funding Source: NIH RePORTER	Deutsche Forschungsgemeinschaft(German Research Foundation (DFG)); Charite Universitatsmedizin Berlin; U.S. National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); National Cancer Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Center for Cancer Research(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	The authors thank Dr. Claudia Iserhot, who performed initial physiological studies. SiJie Zhang performed some of the neuron cultures. CamK-Cre mice were generously provided by Gunther Schutz (Deutsches Krebsforschungszentrum, Heidelberg, Germany). The authors gratefully acknowledge the technical assistance of Vartiter Seher, Anita Kinne, Silke Kappler, Antje Kretschmer, and Heidi Forster. Dorette Freyer (Experimental Neurology, Charite Universitatsmedizin Berlin), initially helped with primary neuron culture. Funding for this study was provided by Deutsche Forschungsgemeinschaft Scho849/2-2, SFB 665/A7, Ko922/11-1, and Charite Universitatsmedizin Berlin and in part by the Intramural Research Program of the U.S. National Institutes of Health, National Cancer Institute, Center for Cancer Research.	Andersen JK, 2004, NAT MED, V10, pS18, DOI 10.1038/nrn1434; BEHNE D, 1988, BIOCHIM BIOPHYS ACTA, V966, P12, DOI 10.1016/0304-4165(88)90123-7; Behrens MM, 2007, SCIENCE, V318, P1645, DOI 10.1126/science.1148045; Blauwkamp MN, 2008, BMC NEPHROL, V9, DOI 10.1186/1471-2369-9-7; Breustedt J, 2003, P NATL ACAD SCI USA, V100, P12450, DOI 10.1073/pnas.2035117100; BREWER GJ, 1989, BRAIN RES, V494, P65, DOI 10.1016/0006-8993(89)90144-3; Burk RF, 2007, J NEUROSCI, V27, P6207, DOI 10.1523/JNEUROSCI.1153-07.2007; Burk RF, 2005, ANNU REV NUTR, V25, P215, DOI 10.1146/annurev.nutr.24.012003.132120; Butt SJB, 2008, NEURON, V59, P722, DOI 10.1016/j.neuron.2008.07.031; Carlson BA, 2009, BIOCHEM J, V418, P61, DOI 10.1042/BJ20081304; Casanova E, 2001, GENESIS, V31, P37, DOI 10.1002/gene.1078; Coppola V, 2004, DEVELOPMENT, V131, P5185, DOI 10.1242/dev.01383; Fisahn A, 1998, NATURE, V394, P186, DOI 10.1038/28179; Gilbert ME, 2007, ENDOCRINOLOGY, V148, P92, DOI 10.1210/en.2006-0164; Gysin R, 2007, P NATL ACAD SCI USA, V104, P16621, DOI 10.1073/pnas.0706778104; Hatfield DL, 2002, MOL CELL BIOL, V22, P3565, DOI 10.1128/MCB.22.11.3565-3576.2002; Hill KE, 2003, J BIOL CHEM, V278, P13640, DOI 10.1074/jbc.M300755200; Hill KE, 2004, J NUTR, V134, P157, DOI 10.1093/jn/134.1.157; Huang ZJ, 1999, CELL, V98, P739, DOI 10.1016/S0092-8674(00)81509-3; KAUFMAN LM, 1983, SCIENCE, V220, P1394, DOI 10.1126/science.6857258; Kinney JW, 2006, J NEUROSCI, V26, P1604, DOI 10.1523/JNEUROSCI.4722-05.2006; Kryukov GV, 2003, SCIENCE, V300, P1439, DOI 10.1126/science.1083516; Kumaraswamy E, 2003, MOL CELL BIOL, V23, P1477, DOI 10.1128/MCB.23.5.1477-1488.2003; Lewis DA, 2005, NAT REV NEUROSCI, V6, P312, DOI 10.1038/nrn1648; Olson GE, 2007, J BIOL CHEM, V282, P12290, DOI 10.1074/jbc.M611403200; Prozorovski T, 2008, NAT CELL BIOL, V10, P385, DOI 10.1038/ncb1700; RAMAEKERS VT, 1994, NEUROPEDIATRICS, V25, P217, DOI 10.1055/s-2008-1073025; Rayman MP, 2000, LANCET, V356, P233, DOI 10.1016/S0140-6736(00)02490-9; Scharpf M, 2007, J NEURAL TRANSM, V114, P877, DOI 10.1007/s00702-006-0617-0; Schomburg L, 2003, BIOCHEM J, V370, P397, DOI 10.1042/BJ20021853; SCHWARZ K, 1957, NUTRITION, V15, P255; Schweizer U, 2004, BIOCHEM J, V378, P21, DOI 10.1042/BJ20031795; Schweizer U, 2004, BRAIN RES REV, V45, P164, DOI 10.1016/j.brainresrev.2004.03.004; Schweizer U, 2005, BIOCHEM J, V386, P221, DOI 10.1042/BJ20041973; Schweizer U, 2004, J NUTR, V134, P707, DOI 10.1093/jn/134.4.707; Seiler A, 2008, CELL METAB, V8, P237, DOI 10.1016/j.cmet.2008.07.005; Smith J, 2000, P NATL ACAD SCI USA, V97, P10032, DOI 10.1073/pnas.170209797; Soerensen J, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0001813; Valentine WM, 2008, J NEUROPATH EXP NEUR, V67, P68, DOI 10.1097/NEN.0b013e318160f347; Wallis K, 2008, J NEUROSCI, V28, P1904, DOI 10.1523/JNEUROSCI.5163-07.2008; WEBER GF, 1991, LANCET, V337, P1443, DOI 10.1016/0140-6736(91)93130-2; Wirth EK, 2009, J NEUROSCI, V29, P9439, DOI 10.1523/JNEUROSCI.6055-08.2009; Wonders CP, 2006, NAT REV NEUROSCI, V7, P687, DOI 10.1038/nrn1954; Yan J, 1998, J NEUROSCI, V18, P8682; Yant LJ, 2003, FREE RADICAL BIO MED, V34, P496, DOI 10.1016/S0891-5849(02)01360-6; Zhang Y, 2008, J BIOL CHEM, V283, P2427, DOI 10.1074/jbc.M707951200	46	154	156	1	23	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAR	2010	24	3					844	852		10.1096/fj.09-143974	http://dx.doi.org/10.1096/fj.09-143974			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	561KE	19890015	Green Published			2022-12-25	WOS:000274974600020
J	Lukey, MJ; Parkin, A; Roessler, MM; Murphy, BJ; Harmer, J; Palmer, T; Sargent, F; Armstrong, FA				Lukey, Michael J.; Parkin, Alison; Roessler, Maxie M.; Murphy, Bonnie J.; Harmer, Jeffrey; Palmer, Tracy; Sargent, Frank; Armstrong, Fraser A.			How Escherichia coli Is Equipped to Oxidize Hydrogen under Different Redox Conditions	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MEMBRANE-BOUND HYDROGENASE; RALSTONIA-EUTROPHA H16; IRON-SULFUR CLUSTER; DESULFOVIBRIO-VULGARIS HILDENBOROUGH; ELECTRON-PARAMAGNETIC-RESONANCE; NICKEL-CONTAINING HYDROGENASE; DEPENDENT GENE-EXPRESSION; NIFE HYDROGENASE; CHROMATIUM-VINOSUM; ENZYME ELECTROKINETICS	The enterobacterium Escherichia coli synthesizes two H-2 uptake enzymes, Hyd-1 and Hyd-2. We show using precise electrochemical kinetic measurements that the properties of Hyd-1 and Hyd-2 contrast strikingly, and may be individually optimized to function under distinct environmental conditions. Hyd-2 is well suited for fast and efficient catalysis in more reducing environments, to the extent that in vitro it behaves as a bidirectional hydrogenase. In contrast, Hyd-1 is active for H-2 oxidation under more oxidizing conditions and cannot function in reverse. Importantly, Hyd-1 is O-2 tolerant and can oxidize H-2 in the presence of air, whereas Hyd-2 is ineffective for H-2 oxidation under aerobic conditions. The results have direct relevance for physiological roles of Hyd-1 and Hyd-2, which are expressed in different phases of growth. The properties that we report suggest distinct technological applications of these contrasting enzymes.	[Palmer, Tracy; Sargent, Frank] Univ Dundee, Coll Life Sci, Dundee DD1 5EH, Scotland; [Armstrong, Fraser A.] Univ Oxford, Dept Inorgan Chem, Oxford OX1 3QR, England	University of Dundee; University of Oxford	Sargent, F (corresponding author), Univ Dundee, Coll Life Sci, Dow St, Dundee DD1 5EH, Scotland.	F.Sargent@dundee.ac.uk; fraser.armstrong@chem.ox.ac.uk	Harmer, Jeffrey R/B-7417-2011; Harmer, Jeffrey/AAR-1851-2021; Parkin, Alison/E-4508-2011	Harmer, Jeffrey R/0000-0003-4583-2401; Harmer, Jeffrey/0000-0003-4583-2401; Parkin, Alison/0000-0003-4715-7200; Roessler, Maxie/0000-0002-5291-4328; Lukey, Michael/0000-0003-3608-3883; Sargent, Frank/0000-0002-6841-3624; Palmer, Tracy/0000-0001-9043-2592; Murphy, Bonnie/0000-0001-6341-9368	United Kingdom Biotechnology and Biological Sciences Research Council [P15018, BB/H001190/1, BB/D52222X, BB/H003878/1]; Engineering and Physical Sciences Research Council; Centre for Advanced Electron Spin Resonance [EP/D0448559/1]; Royal Society; Merton College, Oxford; Biotechnology and Biological Sciences Research Council [BB/D52222X/1, BB/H003878/1, BB/H001190/1] Funding Source: researchfish; Engineering and Physical Sciences Research Council [EP/D047943/1, EP/D048559/1] Funding Source: researchfish; Medical Research Council [G117/519] Funding Source: researchfish; BBSRC [BB/H001190/1, BB/H003878/1] Funding Source: UKRI; EPSRC [EP/D048559/1, EP/D047943/1] Funding Source: UKRI; MRC [G117/519] Funding Source: UKRI	United Kingdom Biotechnology and Biological Sciences Research Council(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC)); Engineering and Physical Sciences Research Council(UK Research & Innovation (UKRI)Engineering & Physical Sciences Research Council (EPSRC)); Centre for Advanced Electron Spin Resonance; Royal Society(Royal Society of London); Merton College, Oxford; Biotechnology and Biological Sciences Research Council(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC)); Engineering and Physical Sciences Research Council(UK Research & Innovation (UKRI)Engineering & Physical Sciences Research Council (EPSRC)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission); BBSRC(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC)); EPSRC(UK Research & Innovation (UKRI)Engineering & Physical Sciences Research Council (EPSRC)); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))	This work was supported by United Kingdom Biotechnology and Biological Sciences Research Council Grants P15018 and BB/H001190/1 (to F. S.) and BB/D52222X and BB/H003878/1 (to F. A. A.), the Engineering and Physical Sciences Research Council (Supergen V (to F. A. A.) and EP/D0448559/1 supporting the Centre for Advanced Electron Spin Resonance), the Royal Society through a University Research Fellowship (to F. S.), and a Merton College, Oxford, Junior Research Fellowship (to A. P.).	ADAMS MWW, 1979, BIOCHEM J, V183, P11, DOI 10.1042/bj1830011; ALBRACHT SPJ, 1983, BIOCHIM BIOPHYS ACTA, V724, P309, DOI 10.1016/0005-2728(83)90089-0; ALBRACHT SPJ, 1985, BIOCHIM BIOPHYS ACTA, V832, P89, DOI 10.1016/0167-4838(85)90177-3; ALBRACHT SPJ, 1984, BIOCHIM BIOPHYS ACTA, V766, P245, DOI 10.1016/0005-2728(84)90238-X; ALBRACHT SPJ, 1982, BIOCHIM BIOPHYS ACTA, V681, P330, DOI 10.1016/0005-2728(82)90041-X; Armstrong FA, 2005, CURR OPIN CHEM BIOL, V9, P110, DOI 10.1016/j.cbpa.2005.02.011; ARMSTRONG FA, 2005, PHILOS T A, V363; Atlung T, 1997, J BACTERIOL, V179, P2141, DOI 10.1128/jb.179.7.2141-2146.1997; ATLUNG T, 1989, J BACTERIOL, V171, P1683, DOI 10.1128/jb.171.3.1683-1691.1989; BALLANTINE SP, 1986, EUR J BIOCHEM, V156, P277, DOI 10.1111/j.1432-1033.1986.tb09578.x; BALLANTINE SP, 1985, J BACTERIOL, V163, P454, DOI 10.1128/JB.163.2.454-459.1985; Bard A.J., 2000, ELECTROCHEMICAL METH; Bernhard M, 1997, EUR J BIOCHEM, V248, P179, DOI 10.1111/j.1432-1033.1997.00179.x; BRONDSTED L, 1994, J BACTERIOL, V176, P5423; Brugna-Guiral M, 2003, EXTREMOPHILES, V7, P145, DOI 10.1007/s00792-002-0306-3; Buhrke T, 2005, J BIOL CHEM, V280, P23791, DOI 10.1074/jbc.M503260200; Burgdorf T, 2005, J MOL MICROB BIOTECH, V10, P181, DOI 10.1159/000091564; Caffrey SA, 2007, J BACTERIOL, V189, P6159, DOI 10.1128/JB.00747-07; CAMMACK R, 1982, FEBS LETT, V142, P289, DOI 10.1016/0014-5793(82)80154-3; CAMMACK R, 1989, EUR J BIOCHEM, V182, P363, DOI 10.1111/j.1432-1033.1989.tb14839.x; CASADABAN MJ, 1979, P NATL ACAD SCI USA, V76, P4530, DOI 10.1073/pnas.76.9.4530; Cracknell JA, 2009, P NATL ACAD SCI USA, V106, P20681, DOI 10.1073/pnas.0905959106; DerVartanian ME, 1996, BIOCHEM BIOPH RES CO, V227, P211, DOI 10.1006/bbrc.1996.1491; Dubini A, 2002, INT J HYDROGEN ENERG, V27, P1413, DOI 10.1016/S0360-3199(02)00112-X; Fontecilla-Camps JC, 2007, CHEM REV, V107, P4273, DOI 10.1021/cr050195z; Giel JL, 2006, MOL MICROBIOL, V60, P1058, DOI 10.1111/j.1365-2958.2006.05160.x; Goldet G, 2008, J AM CHEM SOC, V130, P11106, DOI 10.1021/ja8027668; HAMILTON CM, 1989, J BACTERIOL, V171, P4617, DOI 10.1128/jb.171.9.4617-4622.1989; HATCHIKIAN CE, 1990, EUR J BIOCHEM, V187, P635, DOI 10.1111/j.1432-1033.1990.tb15347.x; Jones AK, 2003, J AM CHEM SOC, V125, P8505, DOI 10.1021/ja035296y; King PW, 1999, J BACTERIOL, V181, P5250, DOI 10.1128/JB.181.17.5250-5256.1999; LALLAMAHARAJH WV, 1983, BIOCHEM J, V209, P445, DOI 10.1042/bj2090445; Lamle SE, 2004, J AM CHEM SOC, V126, P14899, DOI 10.1021/ja047939v; Larminie J, 2003, FUEL CELL SYSTEMS EX; Laurinavichene TV, 2001, FEMS MICROBIOL LETT, V202, P121, DOI 10.1111/j.1574-6968.2001.tb10790.x; Lazarus O, 2009, J AM CHEM SOC, V131, P14154, DOI 10.1021/ja905797w; Leger C, 2003, BIOCHEMISTRY-US, V42, P8653, DOI 10.1021/bi034789c; Leger C, 2002, J PHYS CHEM B, V106, P13058, DOI 10.1021/jp0265687; Leger C, 2008, CHEM REV, V108, P2379, DOI 10.1021/cr0680742; Lubitz W, 2007, CHEM REV, V107, P4331, DOI 10.1021/cr050186q; Maier RJ, 2004, INFECT IMMUN, V72, P6294, DOI 10.1128/IAI.72.11.6294-6299.2004; MENON NK, 1991, J BACTERIOL, V173, P4851, DOI 10.1128/jb.173.15.4851-4861.1991; MENON NK, 1994, J BACTERIOL, V176, P4416, DOI 10.1128/jb.176.14.4416-4423.1994; Olson JW, 2002, SCIENCE, V298, P1788, DOI 10.1126/science.1077123; Parkin A, 2008, J AM CHEM SOC, V130, P13410, DOI 10.1021/ja803657d; Reda T, 2006, J PHYS CHEM B, V110, P1394, DOI 10.1021/jp054783s; Richard DJ, 1999, MICROBIOL-SGM, V145, P2903, DOI 10.1099/00221287-145-10-2903; Romao CV, 1997, BIOCHEM BIOPH RES CO, V240, P75, DOI 10.1006/bbrc.1997.7598; Saggu M, 2009, J BIOL CHEM, V284, P16264, DOI 10.1074/jbc.M805690200; Sargent F, 1998, EUR J BIOCHEM, V255, P746, DOI 10.1046/j.1432-1327.1998.2550746.x; SAWERS G, 1994, ANTON LEEUW INT J G, V66, P57, DOI 10.1007/BF00871633; SAWERS RG, 1986, EUR J BIOCHEM, V156, P265, DOI 10.1111/j.1432-1033.1986.tb09577.x; SAWERS RG, 1985, J BACTERIOL, V164, P1324, DOI 10.1128/JB.164.3.1324-1331.1985; Stoll S, 2006, J MAGN RESON, V178, P42, DOI 10.1016/j.jmr.2005.08.013; TEIXEIRA M, 1985, J BIOL CHEM, V260, P8942; van Gastel M, 2006, J BIOL INORG CHEM, V11, P41, DOI 10.1007/s00775-005-0048-7; van Gastel M, 2005, BIOCHEM SOC T, V33, P7, DOI 10.1042/BST0330007; Vignais PM, 2007, CHEM REV, V107, P4206, DOI 10.1021/cr050196r; Vincent KA, 2005, J AM CHEM SOC, V127, P18179, DOI 10.1021/ja055160v; Vincent KA, 2007, CHEM REV, V107, P4366, DOI 10.1021/cr050191u	60	179	183	2	60	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 5	2010	285	6					3928	3938		10.1074/jbc.M109.067751	http://dx.doi.org/10.1074/jbc.M109.067751			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	564YF	19917611	hybrid, Green Published, Green Accepted			2022-12-25	WOS:000275254000046
J	Xu, X; Ehdaie, B; Ohara, N; Yoshino, T; Deng, CX				Xu, X.; Ehdaie, B.; Ohara, N.; Yoshino, T.; Deng, C-X			Synergistic action of Smad4 and Pten in suppressing pancreatic ductal adenocarcinoma formation in mice	ONCOGENE			English	Article						AKT; mTOR; Notch1; pancreas cancer; transdifferentiation	SQUAMOUS-CELL CARCINOMA; TUMOR; GENE; CANCER; EXPRESSION; INDUCTION; DISRUPTION; NOTCH; KRAS; PANCREATICODUODENECTOMY	Mutations of SMAD4/DPC4 are found in about 60% of human invasive pancreatic ductal adenocarcinomas (PDACs); yet, the manner in which SMAD4 deficiency enhances tumorigenesis remains elusive. Using a Cre-LoxP approach, we generated a mutant mouse carrying a targeted deletion of Smad4 in the pancreas. We showed that the absence of Smad4 alone did not trigger pancreas tumor formation; however, it increased the expression of an inactivated form of Pten, suggesting a role of Pten in preventing Smad4-/- cells from undergoing malignancy. To investigate this, we disrupted both Pten and Smad4. We showed that Pten deficiency initiated widespread premalignant lesions, and a low tumor incidence that was significantly accelerated by Smad4-deficiency. The absence of Smad4 in a Pten-mutant background enhanced cell proliferation and triggered transdifferentiation from acinar, centroacinar and islet cells, accompanied by activation of Notch1 signaling. We showed that all tumors developed in the Smad4/Pten-mutant pancreas exhibited high levels of pAKT and mTOR, and that about 50 and 83% of human pancreatic cancers examined showed increased pAKT and pmTOR, respectively. Besides the similarity in gene expression, the pAKT and/or pmTOR-positive human PDACs and mouse pancreatic tumors also shared some histopathological similarities. These observations indicate that Smad4/Pten-mutant mice mimic the tumor progression of human pancreatic cancers that are driven by activation of the AKT-mTOR pathway, and uncovered a synergistic action of Smad4 and Pten in repressing pancreatic tumorigenesis. Oncogene (2010) 29, 674-686; doi: 10.1038/onc.2009.375; published online 9 November 2009	[Xu, X.; Ehdaie, B.; Deng, C-X] NIDDKD, Genet Dev & Dis Branch, NIH, Bethesda, MD 20892 USA; [Ohara, N.; Yoshino, T.] Okayama Univ, Grad Sch Med & Dent, Dept Pathol, Okayama 7008530, Japan	National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK); Okayama University	Deng, CX (corresponding author), NIDDKD, Genet Dev & Dis Branch, NIH, 9000 Rockville Pike,Bldg 10 Rm 9N105, Bethesda, MD 20892 USA.	ChuxiaD@BDG10.NIDDK.NIH.Gov	deng, chuxia/N-6713-2016		National Institute of Diabetes, Digestive and Kidney Diseases, National Institutes of Health, USA	National Institute of Diabetes, Digestive and Kidney Diseases, National Institutes of Health, USA(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))	We thank Dr Douglas Melton for providing Pdx-Cre mice; Dr Hong Wu for Pten conditional mutant mice; and members of the Deng lab for critically reading the paper. This research was supported by the Intramural Research Program of the National Institute of Diabetes, Digestive and Kidney Diseases, National Institutes of Health, USA.	Aguirre AJ, 2003, GENE DEV, V17, P3112, DOI 10.1101/gad.1158703; ALMOGUERA C, 1988, CELL, V53, P549, DOI 10.1016/0092-8674(88)90571-5; Altomare DA, 2003, J CELL BIOCHEM, V88, P470, DOI 10.1002/jcb.10287; Asano T, 2004, ONCOGENE, V23, P8571, DOI 10.1038/sj.onc.1207902; Attri J, 2005, BMC GASTROENTEROL, V5, DOI 10.1186/1471-230X-5-22; Bardeesy N, 2002, NAT REV CANCER, V2, P897, DOI 10.1038/nrc949; Bardeesy N, 2002, MOL CELL BIOL, V22, P635, DOI 10.1128/MCB.22.2.635-643.2002; Deramaudt T, 2005, BBA-REV CANCER, V1756, P97, DOI 10.1016/j.bbcan.2005.08.003; Ebert MPA, 2002, BRIT J CANCER, V86, P257, DOI 10.1038/sj/bjc/6600031; Farnell MB, 2005, SURGERY, V138, P618, DOI 10.1016/j.surg.2005.06.044; Friedl W, 1999, GENE CHROMOSOME CANC, V25, P403, DOI 10.1002/(SICI)1098-2264(199908)25:4<403::AID-GCC15>3.3.CO;2-G; Gannon M, 2000, GENESIS, V26, P143, DOI 10.1002/(SICI)1526-968X(200002)26:2<143::AID-GENE13>3.0.CO;2-L; Groszer M, 2001, SCIENCE, V294, P2186, DOI 10.1126/science.1065518; Gu GQ, 2002, DEVELOPMENT, V129, P2447; Guerra C, 2007, CANCER CELL, V11, P291, DOI 10.1016/j.ccr.2007.01.012; Hahn SA, 1996, SCIENCE, V271, P350, DOI 10.1126/science.271.5247.350; Hahn SA, 2003, JNCI-J NATL CANCER I, V95, P214, DOI 10.1093/jnci/95.3.214; Hahn SA, 1996, CANCER RES, V56, P490; Hald J, 2003, DEV BIOL, V260, P426, DOI 10.1016/S0012-1606(03)00326-9; Heldin CH, 1997, NATURE, V390, P465, DOI 10.1038/37284; Hezel AF, 2006, GENE DEV, V20, P1218, DOI 10.1101/gad.1415606; Hingorani SR, 2003, CANCER CELL, V4, P437, DOI 10.1016/S1535-6108(03)00309-X; Howe JR, 1998, SCIENCE, V280, P1086, DOI 10.1126/science.280.5366.1086; Hruban RH, 2006, CANCER RES, V66, P95, DOI 10.1158/0008-5472.CAN-05-2168; Ijichi H, 2006, GENE DEV, V20, P3147, DOI 10.1101/gad.1475506; Izeradjene K, 2007, CANCER CELL, V11, P229, DOI 10.1016/j.ccr.2007.01.017; Jarriault S, 1998, MOL CELL BIOL, V18, P7423, DOI 10.1128/MCB.18.12.7423; Kang YK, 2002, HUM PATHOL, V33, P877, DOI 10.1053/hupa.2002.127444; Kim BG, 2006, NATURE, V441, P1015, DOI 10.1038/nature04846; Li WM, 2003, DEVELOPMENT, V130, P6143, DOI 10.1242/dev.00820; Maitra A, 2006, BEST PRACT RES CL GA, V20, P211, DOI 10.1016/j.bpg.2005.10.002; Maitra A, 2008, ANNU REV PATHOL-MECH, V3, P157, DOI 10.1146/annurev.pathmechdis.3.121806.154305; Massague J, 1998, ANNU REV BIOCHEM, V67, P753, DOI 10.1146/annurev.biochem.67.1.753; Michl P, 2005, Z GASTROENTEROL, V43, P1133, DOI 10.1055/s-2005-858638; Murtaugh LC, 2003, P NATL ACAD SCI USA, V100, P14920, DOI 10.1073/pnas.2436557100; Peng BL, 2002, CLIN CANCER RES, V8, P3628; Qiao W, 2006, ONCOGENE, V25, P207, DOI 10.1038/sj.onc.1209029; Roy M, 2007, CURR OPIN GENET DEV, V17, P52, DOI 10.1016/j.gde.2006.12.001; Rozenblum E, 1997, CANCER RES, V57, P1731; Sawey ET, 2007, P NATL ACAD SCI USA, V104, P19327, DOI 10.1073/pnas.0705953104; Schroeter EH, 1998, NATURE, V393, P382, DOI 10.1038/30756; Semba S, 2003, PANCREAS, V26, P250, DOI 10.1097/00006676-200304000-00008; Sirard C, 1998, GENE DEV, V12, P107, DOI 10.1101/gad.12.1.107; Soriano P, 1999, NAT GENET, V21, P70, DOI 10.1038/5007; Stanger BZ, 2005, CANCER CELL, V8, P185, DOI 10.1016/j.ccr.2005.07.015; Suto T, 2002, ANTICANCER RES, V22, P1529; Takaku K, 1999, CANCER RES, V59, P6113; Tamura G, 1996, J PATHOL, V180, P371, DOI 10.1002/(SICI)1096-9896(199612)180:4<371::AID-PATH704>3.0.CO;2-2; Teng Y, 2006, CANCER RES, V66, P6972, DOI 10.1158/0008-5472.CAN-06-0507; WARSHAW AL, 1992, NEW ENGL J MED, V326, P455, DOI 10.1056/NEJM199202133260706; Weinstein M, 2000, CYTOKINE GROWTH F R, V11, P49, DOI 10.1016/S1359-6101(99)00028-3; WEINSTEIN M, 2006, GENETIC DISRUPTIONS, V5; Xu XL, 2006, J CLIN INVEST, V116, P1843, DOI 10.1172/JCI27282; Xu XL, 2000, ONCOGENE, V19, P1868, DOI 10.1038/sj.onc.1203504; Yachida S, 2009, ARCH PATHOL LAB MED, V133, P413, DOI 10.1043/1543-2165-133.3.413; Yang LL, 2005, CANCER RES, V65, P8671, DOI 10.1158/0008-5472.CAN-05-0800; Yang X, 2002, GENESIS, V32, P80, DOI 10.1002/gene.10029; Yang X, 1998, P NATL ACAD SCI USA, V95, P3667, DOI 10.1073/pnas.95.7.3667; Yeo CJ, 2002, ANN SURG, V236, P355, DOI 10.1097/00000658-200209000-00012	59	38	40	1	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 4	2010	29	5					674	686		10.1038/onc.2009.375	http://dx.doi.org/10.1038/onc.2009.375			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	551QI	19901970				2022-12-25	WOS:000274223700005
J	Andersen, J; Olsen, L; Hansen, KB; Taboureau, O; Jorgensen, FS; Jorgensen, AM; Bang-Andersen, B; Egebjerg, J; Stromgaard, K; Kristensen, AS				Andersen, Jacob; Olsen, Lars; Hansen, Kasper B.; Taboureau, Olivier; Jorgensen, Flemming S.; Jorgensen, Anne Marie; Bang-Andersen, Benny; Egebjerg, Jan; Stromgaard, Kristian; Kristensen, Anders S.			Mutational Mapping and Modeling of the Binding Site for (S)-Citalopram in the Human Serotonin Transporter	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SPECIES-SCANNING MUTAGENESIS; HIGH-AFFINITY RECOGNITION; TRANSMEMBRANE DOMAIN-I; DEPENDENT NEUROTRANSMITTER TRANSPORTERS; ANTIDEPRESSANT BINDING; SUBSTRATE RECOGNITION; MONOAMINE TRANSPORTERS; REUPTAKE INHIBITORS; PERMEATION PATHWAY; BACTERIAL HOMOLOG	The serotonin transporter (SERT) regulates extracellular levels of the neurotransmitter serotonin (5-hydroxytryptamine) in the brain by facilitating uptake of released 5-hydroxytryptamine into neuronal cells. SERT is the target for widely used antidepressant drugs, including imipramine, fluoxetine, and (S)-citalopram, which are competitive inhibitors of the transport function. Knowledge of the molecular details of the antidepressant binding sites in SERT has been limited due to lack of structural data on SERT. Here, we present a characterization of the (S)citalopram binding pocket in human SERT (hSERT) using mutational and computational approaches. Comparative modeling and ligand docking reveal that (S)-citalopram fits into the hSERT substrate binding pocket, where (S)-citalopram can adopt a number of different binding orientations. We find, however, that only one of these binding modes is functionally relevant from studying the effects of 64 point mutations around the putative substrate binding site. The mutational mapping also identify novel hSERT residues that are crucial for (S)-citalopram binding. The model defines the molecular determinants for (S)citalopram binding to hSERT and demonstrates that the antidepressant binding site overlaps with the substrate binding site.	[Stromgaard, Kristian; Kristensen, Anders S.] Univ Copenhagen, Dept Med Chem, DK-2100 Copenhagen, Denmark; [Taboureau, Olivier] Tech Univ Denmark, Dept Syst Biol, DK-2800 Lyngby, Denmark; [Hansen, Kasper B.] Emory Univ, Sch Med, Dept Pharmacol, Atlanta, GA 30322 USA; [Jorgensen, Anne Marie; Bang-Andersen, Benny; Egebjerg, Jan] H Lundbeck & Co AS, Lundbeck Res Denmark, DK-2500 Valby, Denmark	University of Copenhagen; Technical University of Denmark; Emory University; Lundbeck Corporation	Kristensen, AS (corresponding author), Univ Copenhagen, Dept Med Chem, Univ Pk 2, DK-2100 Copenhagen, Denmark.	ask@farma.ku.dk	Hansen, Kasper B/C-4062-2008; Olsen, Lars/C-9706-2010; Kristensen, Anders Skov/B-4414-2009; Stromgaard, Kristian/E-3380-2010; Olsen, Lars/AAY-8278-2020; Bang-Andersen, Benny/D-3006-2009; Andersen, Jacob/B-7768-2016	Hansen, Kasper B/0000-0002-3303-4819; Kristensen, Anders Skov/0000-0001-8955-6790; Bang-Andersen, Benny/0000-0001-5150-7168; Andersen, Jacob/0000-0002-8067-3074; Olsen, Lars/0000-0002-7607-7130; Stromgaard, Kristian/0000-0003-2206-4737; Jorgensen, Flemming Steen/0000-0001-8040-2998	Drug Research Academy; Danish Ministry of Science, Technology and Innovation; Danish Council for Strategic Research; Danish Council for Independent Research, Medical Sciences	Drug Research Academy; Danish Ministry of Science, Technology and Innovation; Danish Council for Strategic Research(Danske Strategiske Forskningsrad (DSF)); Danish Council for Independent Research, Medical Sciences(Det Frie Forskningsrad (DFF))	This work was supported by the Drug Research Academy (Ph. D. stipend to J. A.), H. Lundbeck A/S, the Danish Ministry of Science, Technology and Innovation (Industrial Ph. D. stipend to A. M. J.), the Danish Council for Strategic Research NABIIT programme (to O. T.), and The Danish Council for Independent Research, Medical Sciences (to L. O.).	Adkins EM, 2001, MOL PHARMACOL, V59, P514, DOI 10.1124/mol.59.3.514; Andersen J, 2009, CHEM COMMUN, P3677, DOI 10.1039/b903035m; Andersen J, 2009, J BIOL CHEM, V284, P10276, DOI 10.1074/jbc.M806907200; Apparsundaram S, 2008, J PHARMACOL EXP THER, V327, P982, DOI 10.1124/jpet.108.142315; Barker EL, 1999, J NEUROSCI, V19, P4705; Barker EL, 1998, J BIOL CHEM, V273, P19459, DOI 10.1074/jbc.273.31.19459; Beuming T, 2008, NAT NEUROSCI, V11, P780, DOI 10.1038/nn.2146; Beuming T, 2006, MOL PHARMACOL, V70, P1630, DOI 10.1124/mol.106.026120; Celik L, 2008, J AM CHEM SOC, V130, P3853, DOI 10.1021/ja076403h; Chen JG, 2000, P NATL ACAD SCI USA, V97, P1044, DOI 10.1073/pnas.97.3.1044; Chen JG, 1997, J BIOL CHEM, V272, P28321, DOI 10.1074/jbc.272.45.28321; Chen NH, 2004, PFLUG ARCH EUR J PHY, V447, P519, DOI 10.1007/s00424-003-1064-5; CHENG Y, 1973, BIOCHEM PHARMACOL, V22, P3099; Forrest LR, 2008, P NATL ACAD SCI USA, V105, P10338, DOI 10.1073/pnas.0804659105; Forrest LR, 2007, P NATL ACAD SCI USA, V104, P12761, DOI 10.1073/pnas.0705600104; Gether U, 2006, TRENDS PHARMACOL SCI, V27, P375, DOI 10.1016/j.tips.2006.05.003; GRAHAM D, 1989, BIOCHEM PHARMACOL, V38, P3819, DOI 10.1016/0006-2952(89)90591-1; Henry LK, 2007, MOL INTERV, V7, P306, DOI 10.1124/mi.7.6.4; Henry LK, 2006, NEURON, V49, P791, DOI 10.1016/j.neuron.2006.03.002; Henry LK, 2006, J BIOL CHEM, V281, P2012, DOI 10.1074/jbc.M505055200; HUMPHREYS CJ, 1988, MOL PHARMACOL, V33, P657; HYTTEL J, 1992, J NEURAL TRANSM-GEN, V88, P157, DOI 10.1007/BF01244820; Jorgensen AM, 2007, CHEMMEDCHEM, V2, P827, DOI 10.1002/cmdc.200600243; Jorgensen AM, 2007, CHEMMEDCHEM, V2, P815, DOI 10.1002/cmdc.200600242; Kaufmann KW, 2009, PROTEINS, V74, P630, DOI 10.1002/prot.22178; Kristensen AS, 2004, EUR J NEUROSCI, V19, P1513, DOI 10.1111/j.1460-9568.2004.03202.x; Larsen MB, 2004, J BIOL CHEM, V279, P42147, DOI 10.1074/jbc.M405579200; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; Lin F, 1996, BIOPHYS J, V71, P3126, DOI 10.1016/S0006-3495(96)79506-1; Masson J, 1999, PHARMACOL REV, V51, P439; Moltzen EK, 2006, CURR TOP MED CHEM, V6, P1801, DOI 10.2174/156802606778249810; Mortensen OV, 2001, J NEUROCHEM, V79, P237, DOI 10.1046/j.1471-4159.2001.00587.x; Paczkowski FA, 2007, J BIOL CHEM, V282, P17837, DOI 10.1074/jbc.M610813200; Ravna AW, 2006, WORLD J BIOL PSYCHIA, V7, P99, DOI 10.1080/15622970500402144; Ravna AW, 2006, BIOORGAN MED CHEM, V14, P666, DOI 10.1016/j.bmc.2005.08.054; Ravna AW, 2003, J PHARMACOL EXP THER, V307, P34, DOI 10.1124/jpet.103.054593; Ravna AW, 2001, J MOL GRAPH MODEL, V20, P133, DOI 10.1016/S1093-3263(01)00112-7; Rudnick G, 2007, ACS CHEM BIOL, V2, P606, DOI 10.1021/cb7001818; Rudnick G, 2006, J MEMBRANE BIOL, V213, P101, DOI 10.1007/s00232-006-0878-4; SALI A, 1993, J MOL BIOL, V234, P779, DOI 10.1006/jmbi.1993.1626; Sanchez C, 2003, PSYCHOPHARMACOLOGY, V167, P353, DOI 10.1007/s00213-002-1364-z; Singh SK, 2007, NATURE, V448, P952, DOI 10.1038/nature06038; Singh SK, 2008, SCIENCE, V322, P1655, DOI 10.1126/science.1166777; TALVENHEIMO J, 1979, J BIOL CHEM, V254, P4631; Tavoulari S, 2009, J NEUROSCI, V29, P9635, DOI 10.1523/JNEUROSCI.0440-09.2009; Torres GE, 2003, NAT REV NEUROSCI, V4, P13, DOI 10.1038/nrn1008; Walline CC, 2008, J PHARMACOL EXP THER, V325, P791, DOI 10.1124/jpet.108.136200; Wein T, 2010, J MOL MODEL, V16, P155, DOI 10.1007/s00894-009-0520-3; Yamashita A, 2005, NATURE, V437, P215, DOI 10.1038/nature03978; Zhang YW, 2006, J BIOL CHEM, V281, P36213, DOI 10.1074/jbc.M605468200; Zhou YG, 2006, J BIOL CHEM, V281, P22092, DOI 10.1074/jbc.M602319200; Zhou Z, 2007, SCIENCE, V317, P1390, DOI 10.1126/science.1147614; Zhou Z, 2009, NAT STRUCT MOL BIOL, V16, P652, DOI 10.1038/nsmb.1602; Zomot E, 2007, NATURE, V449, P726, DOI 10.1038/nature06133	54	78	79	1	14	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 15	2010	285	3					2051	2063		10.1074/jbc.M109.072587	http://dx.doi.org/10.1074/jbc.M109.072587			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	541PJ	19892699	Green Published, hybrid			2022-12-25	WOS:000273429100050
J	Cao, YX; Vo, T; Millien, G; Tagne, JB; Kotton, D; Mason, RJ; Williams, MC; Ramirez, MI				Cao, Yuxia; Vo, Tiffany; Millien, Guetchyn; Tagne, Jean-Bosco; Kotton, Darrell; Mason, Robert J.; Williams, Mary C.; Ramirez, Maria I.			Epigenetic Mechanisms Modulate Thyroid Transcription Factor 1-mediated Transcription of the Surfactant Protein B Gene	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHROMATIN REMODELING COMPLEXES; MEDIATES CRITICAL INTERACTIONS; GLUCOCORTICOID-RECEPTOR; DNA METHYLATION; EPITHELIAL-CELLS; FACTOR-I; CYTOSINE METHYLATION; RESPIRATORY-DISTRESS; INCREASED EXPRESSION; LUNG MORPHOGENESIS	Epigenetic regulation of transcription plays an important role in cell-specific gene expression by altering chromatin structure and access of transcriptional regulators to DNA binding sites. Surfactant protein B (Sftpb) is a developmentally regulated lung epithelial gene critical for lung function. Thyroid transcription factor 1 (Nkx2-1) regulates Sftpb gene expression in various species. We show that Nkx2-1 binds to the mouse Sftpb (mSftpb) promoter in the lung. In a mouse lung epithelial cell line (MLE-15), Nkx2-1 knockdown reduces Sftpb expression, and mutation of Nkx2-1 cis-elements significantly reduces mSftpb promoter activity. Whether chromatin structure modulates Nkx2-1 regulation of Sftpb transcription is unknown. We found that DNA methylation of the mSftpb promoter inversely correlates with known patterns of Sftpb expression in vivo. The mSftpb promoter activity can be manipulated by altering its cytosine methylation status in vitro. Nkx2-1 activation of the mSftpb promoter is impaired by DNA methylation. The unmethylated Sftpb promoter shows an active chromatin structure enriched in the histone modification H3K4me3 (histone 3-lysine 4 trimethylated). The ATP-dependent chromatin remodeling protein Brg1 is recruited to the Sftpb promoter in Sftpb-expressing, but not in non-expressing tissues and cell lines. Brg1 knockdown in MLE-15 cells greatly decreases H3K4me3 levels at the Sftpb promoter region and expression of the Sftpb gene. Brg1 can be co-immunoprecipitated with Nkx2-1 protein. Last, Nkx2-1 and Brg1 with intact ATPase activity are required for mSftpb promoter activation in vitro. Our findings suggest that DNA methylation and chromatin modifications cooperate with Nkx2-1 to regulate Sftpb gene cell specific expression.	[Cao, Yuxia; Vo, Tiffany; Millien, Guetchyn; Tagne, Jean-Bosco; Kotton, Darrell; Williams, Mary C.; Ramirez, Maria I.] Boston Univ, Sch Med, Dept Med, Ctr Pulm, Boston, MA 02118 USA; [Mason, Robert J.] Natl Jewish Med & Res Ctr, Dept Med, Denver, CO 80206 USA	Boston University; National Jewish Health	Cao, YX (corresponding author), 80 E Concord St,R-304, Boston, MA 02118 USA.	yxcao@bu.edu		Cao, Yu-Xia/0000-0001-7396-9988; Tagne, Jean-Bosco/0000-0003-1830-9156; Kotton, Darrell/0000-0002-9604-8476; Ramirez, Maria Isabel/0000-0001-6294-4419	National Institutes of Health [P01 HL047049, HL 029891]; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL029891, P01HL047049, R37HL029891] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))	This work was supported, in whole or in part, by National Institutes of Health Grants P01 HL047049 and HL 029891.	Amin RS, 2001, J PEDIATR-US, V139, P85, DOI 10.1067/mpd.2001.114545; AVERY ME, 1959, AMA J DIS CHILD, V97, P517, DOI 10.1001/archpedi.1959.02070010519001; Berhane K, 2000, AM J PHYSIOL-LUNG C, V279, pL806, DOI 10.1152/ajplung.2000.279.5.L806; BOHINSKI RJ, 1993, J BIOL CHEM, V268, P11160; Borok Z, 1998, AM J PHYSIOL-LUNG C, V275, pL155, DOI 10.1152/ajplung.1998.275.1.L155; BRUNO MA, 1995, AM J PHYSIOL-LUNG C, V268, pL381; Cao YX, 2000, BIOCHEM J, V350, P883, DOI 10.1042/0264-6021:3500883; Cao YX, 2003, J CELL BIOCHEM, V89, P887, DOI 10.1002/jcb.10555; CLARK JC, 1995, P NATL ACAD SCI USA, V92, P7794, DOI 10.1073/pnas.92.17.7794; DAMOREBRUNO MA, 1992, AM J PHYSIOL, V262, pL40, DOI 10.1152/ajplung.1992.262.1.L40; de la Serna IL, 2005, MOL CELL BIOL, V25, P3997, DOI 10.1128/MCB.25.10.3997-4009.2005; de la Serna IL, 2006, J BIOL CHEM, V281, P20233, DOI 10.1074/jbc.M512052200; Desai TJ, 2004, DEV BIOL, V273, P402, DOI 10.1016/j.ydbio.2004.04.039; Eberharter A, 2004, J CELL SCI, V117, P3707, DOI 10.1242/jcs.01175; Floess S, 2007, PLOS BIOL, V5, P169, DOI 10.1371/journal.pbio.0050038; HAWGOOD S, 1991, ANNU REV PHYSIOL, V53, P375, DOI 10.1146/annurev.ph.53.030191.002111; Hsiao PW, 2003, MOL CELL BIOL, V23, P6210, DOI 10.1128/MCB.23.17.6210-6220.2003; Islam KN, 2008, MOL ENDOCRINOL, V22, P585, DOI 10.1210/me.2007-0412; Islam KN, 2006, MOL CELL BIOL, V26, P2901, DOI 10.1128/MCB.26.8.2901-2912.2006; John S, 2008, MOL CELL, V29, P611, DOI 10.1016/j.molcel.2008.02.010; Johnson CN, 2005, BIOCHEM CELL BIOL, V83, P405, DOI 10.1139/O05-115; Johnson TA, 2008, MOL BIOL CELL, V19, P3308, DOI 10.1091/mbc.E08-02-0123; Kangaspeska S, 2008, NATURE, V452, P112, DOI 10.1038/nature06640; Kass SU, 1997, TRENDS GENET, V13, P444, DOI 10.1016/S0168-9525(97)01268-7; Kathuria H, 2004, J BIOL CHEM, V279, P30028, DOI 10.1074/jbc.M402236200; Kathuria H, 2007, J CELL BIOCHEM, V102, P13, DOI 10.1002/jcb.21270; Kerr MH, 1999, AM J RESP CRIT CARE, V159, P1115, DOI 10.1164/ajrccm.159.4.9709065; KHAVARI PA, 1993, NATURE, V366, P170, DOI 10.1038/366170a0; Kim HP, 2007, J EXP MED, V204, P1543, DOI 10.1084/jem.20070109; Kimura S, 1999, BIOCHIMIE, V81, P321, DOI 10.1016/S0300-9084(99)80077-7; Kolla V, 2007, AM J RESP CELL MOL, V36, P213, DOI 10.1165/rcmb.2006-0207OC; Kornberg Roger D., 1999, Trends in Cell Biology, V9, pM46, DOI 10.1016/S0962-8924(99)01679-7; LAZZARO D, 1991, DEVELOPMENT, V113, P1093; LEWIS JF, 1993, AM REV RESPIR DIS, V147, P218, DOI 10.1164/ajrccm/147.1.218; Li E, 2002, NAT REV GENET, V3, P662, DOI 10.1038/nrg887; Li JY, 2007, MOL CELL BIOL, V27, P8748, DOI 10.1128/MCB.01380-07; Liu R, 2001, CELL, V106, P309, DOI 10.1016/S0092-8674(01)00446-9; Maeda Y, 2006, J BIOL CHEM, V281, P9600, DOI 10.1074/jbc.M510435200; Marmorstein R, 2001, GENE, V272, P1, DOI 10.1016/S0378-1119(01)00519-4; Metivier R, 2008, NATURE, V452, P45, DOI 10.1038/nature06544; Millien G, 2008, GENE EXPR PATTERNS, V8, P124, DOI 10.1016/j.modgep.2007.09.003; Minoo P, 1999, DEV BIOL, V209, P60, DOI 10.1006/dbio.1999.9234; Minoo P, 2008, NUCLEIC ACIDS RES, V36, P179, DOI 10.1093/nar/gkm871; Naltner A, 2000, J BIOL CHEM, V275, P56, DOI 10.1074/jbc.275.1.56; Naltner A, 2000, AM J PHYSIOL-LUNG C, V279, pL1066, DOI 10.1152/ajplung.2000.279.6.L1066; Neish AS, 1998, NUCLEIC ACIDS RES, V26, P847, DOI 10.1093/nar/26.3.847; Ni ZY, 2007, J IMMUNOL, V178, P345, DOI 10.4049/jimmunol.178.1.345; Ohkawa Y, 2006, EMBO J, V25, P490, DOI 10.1038/sj.emboj.7600943; Ohkawa Y, 2007, J BIOL CHEM, V282, P6564, DOI 10.1074/jbc.M608898200; Pedersen TA, 2001, GENE DEV, V15, P3208, DOI 10.1101/gad.209901; Pryhuber GS, 1996, AM J PHYSIOL-LUNG C, V270, pL714, DOI 10.1152/ajplung.1996.270.5.L714; Ramirez MI, 1997, J BIOL CHEM, V272, P26285, DOI 10.1074/jbc.272.42.26285; Ramirez MI, 1999, DEV DYNAM, V215, P319, DOI 10.1002/(SICI)1097-0177(199908)215:4<319::AID-AJA4>3.0.CO;2-B; Ramirez-Carrozzi VR, 2006, GENE DEV, V20, P282, DOI 10.1101/gad.1383206; Rice WR, 2002, AM J PHYSIOL-LUNG C, V283, pL256, DOI 10.1152/ajplung.00302.2001; Salinas D, 2003, AM J PHYSIOL-LUNG C, V285, pL1153, DOI 10.1152/ajplung.00084.2003; Salma N, 2004, MOL CELL BIOL, V24, P4651, DOI 10.1128/MCB.24.11.4651-4663.2004; Santangelo S, 2002, J IMMUNOL, V169, P1893, DOI 10.4049/jimmunol.169.4.1893; Saraiva M, 2005, J IMMUNOL, V175, P1041, DOI 10.4049/jimmunol.175.2.1041; Schug J, 2008, CURR PROTOC BIOINFOR; Shiota K, 2002, GENES CELLS, V7, P961, DOI 10.1046/j.1365-2443.2002.00574.x; Sif S, 2004, J CELL BIOCHEM, V91, P1087, DOI 10.1002/jcb.20005; Singh M, 2007, CHEMBIOCHEM, V8, P1308, DOI 10.1002/cbic.200600562; SMITH GJ, 1985, CELL BIOL INT REP, V9, P1115, DOI 10.1016/S0309-1651(85)80009-6; Soutoglou E, 2002, SCIENCE, V295, P1901, DOI 10.1126/science.1068356; Tredano M, 2003, AM J MED GENET A, V119A, P324, DOI 10.1002/ajmg.a.20058; Trotter KW, 2008, MOL CELL BIOL, V28, P1413, DOI 10.1128/MCB.01301-07; Trotter KW, 2007, MOL CELL ENDOCRINOL, V265, P162, DOI 10.1016/j.mce.2006.12.015; Trotter Kevin W, 2008, Nucl Recept Signal, V6, pe004, DOI 10.1621/nrs.06004; Trotter KW, 2004, MOL CELL BIOL, V24, P3347, DOI 10.1128/MCB.24.8.3347-3358.2004; Valinluck V, 2007, CANCER RES, V67, P5583, DOI 10.1158/0008-5472.CAN-07-0846; WEAVER TE, 1991, BIOCHEM J, V273, P249, DOI 10.1042/bj2730249; Wert SE, 2002, DEV BIOL, V242, P75, DOI 10.1006/dbio.2001.0540; WIKENHEISER KA, 1993, P NATL ACAD SCI USA, V90, P11029, DOI 10.1073/pnas.90.23.11029; Wunderlich S, 2008, HUM GENE THER, V19, P39, DOI 10.1089/hum.2006.0180; Xi QR, 2008, J BIOL CHEM, V283, P1146, DOI 10.1074/jbc.M707479200; Xu GL, 1997, NAT GENET, V17, P376, DOI 10.1038/ng1297-376; YAN C, 1995, J BIOL CHEM, V270, P24852, DOI 10.1074/jbc.270.42.24852; Yang L, 2004, BIOCHEMISTRY-US, V43, P12489, DOI 10.1021/bi049283o; Yang L, 2003, AM J PHYSIOL-LUNG C, V284, pL481, DOI 10.1152/ajplung.00280.2002; Zhou BY, 2008, AM J RESP CELL MOL, V38, P750, DOI 10.1165/rcmb.2007-0350OC; Zhou L, 1996, J HISTOCHEM CYTOCHEM, V44, P1183, DOI 10.1177/44.10.8813084	82	26	28	0	5	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 15	2010	285	3					2152	2164		10.1074/jbc.M109.039172	http://dx.doi.org/10.1074/jbc.M109.039172			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	541PJ	19906647	Green Published, hybrid			2022-12-25	WOS:000273429100059
J	Fazakerley, DJ; Holman, GD; Marley, A; James, DE; Stockli, J; Coster, ACF				Fazakerley, Daniel J.; Holman, Geoffrey D.; Marley, Anna; James, David E.; Stoeckli, Jacqueline; Coster, Adelle C. F.			Kinetic Evidence for Unique Regulation of GLUT4 Trafficking by Insulin and AMP-activated Protein Kinase Activators in L6 Myotubes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAT SKELETAL-MUSCLES; GLUCOSE-TRANSPORT; SURFACE GLUT4; SUBCELLULAR TRAFFICKING; STORAGE COMPARTMENTS; PLASMA-MEMBRANE; CONTRACTION; ENDOCYTOSIS; INCREASES; EXOCYTOSIS	In L6 myotubes, redistribution of a hemagglutinin (HA) epitope-tagged GLUT4 (HA-GLUT4) to the cell surface occurs rapidly in response to insulin stimulation and AMP-activated protein kinase (AMPK) activation. We have examined whether these separate signaling pathways have a convergent mechanism that leads to GLUT4 mobilization and to changes in GLUT4 recycling. HA antibody uptake on GLUT4 in the basal steady state reached a final equilibrium level that was only 81% of the insulin-stimulated level. AMPK activators (5-aminoimidazole-4-carboxyamide ribonucleoside (AICAR) and A-769662) led to a similar level of antibody uptake to that found in insulin-stimulated cells. However, the combined responses to insulin stimulation and AMPK activation led to an antibody uptake level of similar to 20% above the insulin level. Increases in antibody uptake due to insulin, but not AICAR or A-769662, treatment were reduced by both wortmannin and Akt inhibitor. The GLUT4 internalization rate constant in the basal steady state was very rapid (0.43 min(-1)) and was decreased during the steady-state responses to insulin (0.18 min(-1)), AICAR (0.16 min(-1)), and A-769662 (0.24 min(-1)). This study has revealed a nonconvergent mobilization of GLUT4 in response to activation of Akt and AMPK signaling. Furthermore, GLUT4 trafficking in L6 muscle cells is very reliant on regulated endocytosis for control of cell surface GLUT4 levels.	[Fazakerley, Daniel J.; James, David E.; Stoeckli, Jacqueline; Coster, Adelle C. F.] Garvan Inst Med Res, Diabet & Obes Program, Sydney, NSW 2010, Australia; [Fazakerley, Daniel J.; Holman, Geoffrey D.] Univ Bath, Dept Biol & Biochem, Bath BA2 7AY, Avon, England; [Coster, Adelle C. F.] Univ New S Wales, Sch Math & Stat, Sydney, NSW 2052, Australia; [Marley, Anna] AstraZeneca, Macclesfield SK10 4TG, Cheshire, England	Garvan Institute of Medical Research; University of Bath; University of New South Wales Sydney; AstraZeneca	Stockli, J (corresponding author), Garvan Inst Med Res, Diabet & Obes Program, Sydney, NSW 2010, Australia.	j.stoeckli@garvan.org.au	Stoeckli, Jacqueline/Z-4443-2019; Coster, Adelle/AAX-4829-2020; Stoeckli, Jacqueline/D-7053-2016; Fazakerley, Daniel/J-2652-2019; Coster, Adelle CF/A-7234-2013	Stoeckli, Jacqueline/0000-0002-6446-7350; Coster, Adelle/0000-0002-5572-6832; Stoeckli, Jacqueline/0000-0002-6446-7350; Fazakerley, Daniel/0000-0001-8241-2903; Coster, Adelle CF/0000-0002-5572-6832; James, David/0000-0001-5946-5257; Holman, Geoffrey/0000-0001-7045-1358	National Health and Medical Research Council of Australia; Medical Research Council United Kingdom; Wellcome Trust; AstraZeneca; Medical Research Council [G0300415, G9225018] Funding Source: researchfish; MRC [G0300415, G9225018] Funding Source: UKRI	National Health and Medical Research Council of Australia(National Health and Medical Research Council (NHMRC) of Australia); Medical Research Council United Kingdom(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Wellcome Trust(Wellcome TrustEuropean Commission); AstraZeneca(AstraZeneca); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))	This work was supported by grants from the National Health and Medical Research Council of Australia (to J. S. and D. E. J.), by grants from the Medical Research Council United Kingdom, the Wellcome Trust (to G. D. H.), and a CASE studentship from AstraZeneca (to D. J. F.).	Antonescu CN, 2008, TRAFFIC, V9, P1173, DOI 10.1111/j.1600-0854.2008.00755.x; Bergeron R, 1999, AM J PHYSIOL-ENDOC M, V276, pE938, DOI 10.1152/ajpendo.1999.276.5.E938; Blot V, 2006, EMBO J, V25, P5648, DOI 10.1038/sj.emboj.7601462; Buhl ES, 2001, DIABETES, V50, P12, DOI 10.2337/diabetes.50.1.12; Chen SA, 2008, BIOCHEM J, V409, P449, DOI 10.1042/BJ20071114; Cool B, 2006, CELL METAB, V3, P403, DOI 10.1016/j.cmet.2006.05.005; Coster ACF, 2004, TRAFFIC, V5, P763, DOI 10.1111/j.1600-0854.2004.00218.x; Fazakerley DJ, 2009, J CELL SCI, V122, P727, DOI 10.1242/jcs.041178; Fisher JS, 2002, AM J PHYSIOL-ENDOC M, V282, pE18, DOI 10.1152/ajpendo.2002.282.1.E18; GAO JP, 1994, J APPL PHYSIOL, V77, P1597, DOI 10.1152/jappl.1994.77.4.1597; Gonzalez E, 2006, MOL BIOL CELL, V17, P4484, DOI 10.1091/mbc.E06-07-0585; Govers R, 2004, MOL CELL BIOL, V24, P6456, DOI 10.1128/MCB.24.14.6456-6466.2004; Guigas B, 2009, IUBMB LIFE, V61, P18, DOI 10.1002/iub.135; Hayashi T, 1998, DIABETES, V47, P1369, DOI 10.2337/diabetes.47.8.1369; HENRIKSEN EJ, 1991, J APPL PHYSIOL, V70, P2322, DOI 10.1152/jappl.1991.70.5.2322; JHUN BH, 1992, J BIOL CHEM, V267, P17710; Karlsson HKR, 2009, DIABETES, V58, P847, DOI 10.2337/db08-1539; Karylowski O, 2004, MOL BIOL CELL, V15, P870, DOI 10.1091/mbc.E03-07-0517; Koistinen HA, 2003, DIABETES, V52, P1066, DOI 10.2337/diabetes.52.5.1066; Kramer HF, 2006, DIABETES, V55, P2067, DOI 10.2337/db06-0150; Kurth-Kraczek EJ, 1999, DIABETES, V48, P1667, DOI 10.2337/diabetes.48.8.1667; Lemieux K, 2000, DIABETES, V49, P183, DOI 10.2337/diabetes.49.2.183; Li DL, 2001, J BIOL CHEM, V276, P22883, DOI 10.1074/jbc.M010143200; Muretta JM, 2008, J BIOL CHEM, V283, P311, DOI 10.1074/jbc.M705756200; Ploug T, 1998, J CELL BIOL, V142, P1429, DOI 10.1083/jcb.142.6.1429; Randhawa VK, 2004, MOL BIOL CELL, V15, P5565, DOI 10.1091/mbc.E04-03-0266; RODNICK KJ, 1992, AM J PHYSIOL, V262, pC9, DOI 10.1152/ajpcell.1992.262.1.C9; SATOH S, 1993, J BIOL CHEM, V268, P17820; Shewan AM, 2003, MOL BIOL CELL, V14, P973, DOI 10.1091/mbc.E02-06-0315; Wijesekara N, 2006, AM J PHYSIOL-ENDOC M, V290, pE1276, DOI 10.1152/ajpendo.00573.2005; Yang J, 2005, J BIOL CHEM, V280, P4070, DOI 10.1074/jbc.M410213200; YANG J, 1993, J BIOL CHEM, V268, P4600; Yang J, 2006, ENDOCRINOLOGY, V147, P2728, DOI 10.1210/en.2005-1433	33	55	57	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 15	2010	285	3					1653	1660		10.1074/jbc.M109.051185	http://dx.doi.org/10.1074/jbc.M109.051185			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	541PJ	19915010	Green Published, hybrid			2022-12-25	WOS:000273429100011
J	Messaritou, G; Grammenoudi, S; Skoulakis, EMC				Messaritou, Georgia; Grammenoudi, Sofia; Skoulakis, Efthimios M. C.			Dimerization Is Essential for 14-3-3 zeta Stability and Function in Vivo	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LIGAND-BINDING; C-RAF; CRYSTAL-STRUCTURE; STRUCTURAL BASIS; PROTEIN; DROSOPHILA; PHOSPHORYLATION; LEONARDO; LOCALIZATION; SPECIFICITY	Members of the conserved 14-3-3 protein family spontaneously self-assemble as homo-and heterodimers via conserved sequences in the first four (alpha A-alpha D) of the nine helices that comprise them. Dimeric 14-3-3s bind conserved motifs in diverse protein targets involved in multiple essential cellular processes including signaling, intracellular trafficking, cell cycle regulation, and modulation of enzymatic activities. However, recent mostly in vitro evidence has emerged, suggesting functional and regulatory roles for monomeric 14-3-3s. We capitalized on the simplicity of the 14-3-3 family in Drosophila to investigate in vivo 14-3-3 zeta monomer properties and functionality. We report that dimerization is essential for the stability and function of 14-3-3 zeta in neurons. Moreover, we reveal the contribution of conserved amino acids in helices A and D to homo-and heterodimerization and their functional consequences on the viability of animals devoid of endogenous 14-3-3 zeta. Finally, we present evidence suggesting endogenous homeostatic adjustment of the levels of the second family member in Drosophila, D14-3-3 epsilon, to transgenic monomeric and dimerization-competent 14-3-3 zeta.	[Messaritou, Georgia; Grammenoudi, Sofia; Skoulakis, Efthimios M. C.] Alexander Fleming, Inst Mol Biol & Genet, Biomed Sci Res Ctr, Vari 16672, Greece		Skoulakis, EMC (corresponding author), 34 Fleming Str, Vari 16672, Greece.	skoulakis@fleming.gr			Research and Technology PENED [01Edelta207]; European Union [003141]	Research and Technology PENED; European Union(European Commission)	This work was supported in part by Hellenic General Secretariat for Research and Technology PENED Grant 01E Delta 207 (to S. G.) and European Union Marie Curie TOK Grant 003141 (to G. M. and E. M. C. S.).	Acevedo SF, 2007, GENETICS, V177, P239, DOI 10.1534/genetics.107.072280; Acevedo SF, 2007, MOL CELL NEUROSCI, V34, P378, DOI 10.1016/j.mcn.2006.11.011; Aitken A, 2002, BIOCHEM SOC T, V30, P351, DOI 10.1042/bst0300351; Angrand PO, 2006, MOL CELL PROTEOMICS, V5, P2211, DOI 10.1074/mcp.M600147-MCP200; BRIDGES D, 2005, SCI STKE, pRE10, DOI DOI 10.1126/STKE.2962005RE10; Broadie K, 1997, NEURON, V19, P391, DOI 10.1016/S0896-6273(00)80948-4; Chang HC, 1997, GENE DEV, V11, P1132, DOI 10.1101/gad.11.9.1132; Dougherty MK, 2004, J CELL SCI, V117, P1875, DOI 10.1242/jcs.01171; Duffy JB, 2002, GENESIS, V34, P1, DOI 10.1002/gene.10150; Gardino AK, 2006, SEMIN CANCER BIOL, V16, P173, DOI 10.1016/j.semcancer.2006.03.007; Garnett MJ, 2005, MOL CELL, V20, P963, DOI 10.1016/j.molcel.2005.10.022; Grammenoudi S, 2006, FEBS LETT, V580, P4602, DOI 10.1016/j.febslet.2006.07.045; Gu MY, 1998, J BIOL CHEM, V273, P33465, DOI 10.1074/jbc.273.50.33465; Gu YM, 2006, FEBS LETT, V580, P305, DOI 10.1016/j.febslet.2005.12.024; Hekman M, 2004, J BIOL CHEM, V279, P14074, DOI 10.1074/jbc.M309620200; Ichimura T, 1997, FEBS LETT, V413, P273, DOI 10.1016/S0014-5793(97)00910-1; Jin J, 2004, CURR BIOL, V14, P1436, DOI 10.1016/j.cub.2004.07.051; Kagan A, 2002, EMBO J, V21, P1889, DOI 10.1093/emboj/21.8.1889; Li W, 1997, DEVELOPMENT, V124, P4163; Liang XB, 2008, J BIOL CHEM, V283, P27418, DOI 10.1074/jbc.M803687200; LIN DM, 1994, NEURON, V13, P507, DOI 10.1016/0896-6273(94)90022-1; LIU D, 1995, NATURE, V376, P191, DOI 10.1038/376191a0; LUO ZJ, 1995, J BIOL CHEM, V270, P23681, DOI 10.1074/jbc.270.40.23681; McGuire SE, 2003, SCIENCE, V302, P1765, DOI 10.1126/science.1089035; Meek SEM, 2004, J BIOL CHEM, V279, P32046, DOI 10.1074/jbc.M403044200; Megidish T, 1998, J BIOL CHEM, V273, P21834, DOI 10.1074/jbc.273.34.21834; Messaritou G, 2009, FEBS LETT, V583, P2934, DOI 10.1016/j.febslet.2009.08.003; Missirlis F, 2007, GENETICS, V177, P89, DOI 10.1534/genetics.107.075150; Obsil T, 2001, CELL, V105, P257, DOI 10.1016/S0092-8674(01)00316-6; Petosa C, 1998, J BIOL CHEM, V273, P16305, DOI 10.1074/jbc.273.26.16305; Pfaffl MW, 2001, BIOTECHNOL LETT, V23, P275, DOI 10.1023/A:1005658330108; Philip N, 2001, J NEUROSCI, V21, P8417, DOI 10.1523/JNEUROSCI.21-21-08417.2001; Powell DW, 2003, MOL CELL BIOL, V23, P5376, DOI 10.1128/MCB.23.15.5376-5387.2003; Rittinger K, 1999, MOL CELL, V4, P153, DOI 10.1016/S1097-2765(00)80363-9; Rubio MP, 2004, BIOCHEM J, V379, P395, DOI 10.1042/bj20031797; Shen YH, 2003, MOL BIOL CELL, V14, P4721, DOI 10.1091/mbc.E02-12-0821; Shikano S, 2006, TRENDS CELL BIOL, V16, P370, DOI 10.1016/j.tcb.2006.05.006; Skoulakis EMC, 1996, NEURON, V17, P931, DOI 10.1016/S0896-6273(00)80224-X; Skoulakis EMC, 1998, MOL NEUROBIOL, V16, P269, DOI 10.1007/BF02741386; Tzivion G, 2000, J BIOL CHEM, V275, P29772, DOI 10.1074/jbc.M001207200; Tzivion G, 1998, NATURE, V394, P88, DOI 10.1038/27938; Tzivion G, 2002, J BIOL CHEM, V277, P3061, DOI 10.1074/jbc.R100059200; van Heusden GPH, 2005, IUBMB LIFE, V57, P623, DOI 10.1080/15216540500252666; Woodcock JM, 2003, J BIOL CHEM, V278, P36323, DOI 10.1074/jbc.M304689200; Xiao Bing, 1995, Nature (London), V376, P188, DOI 10.1038/376188a0; Yaffe MB, 2002, FEBS LETT, V513, P53, DOI 10.1016/S0014-5793(01)03288-4; Yaffe MB, 1997, CELL, V91, P961, DOI 10.1016/S0092-8674(00)80487-0; Yang XW, 2006, P NATL ACAD SCI USA, V103, P17237, DOI 10.1073/pnas.0605779103; Zhang SS, 1999, J BIOL CHEM, V274, P24865, DOI 10.1074/jbc.274.35.24865; Zhou Y, 2003, J BIOL CHEM, V278, P10073, DOI 10.1074/jbc.M211907200	50	39	40	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 15	2010	285	3					1692	1700		10.1074/jbc.M109.045989	http://dx.doi.org/10.1074/jbc.M109.045989			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	541PJ	19920133	hybrid, Green Published			2022-12-25	WOS:000273429100015
J	Damerow, S; Lamerz, AC; Haselhorst, T; Fuhring, J; Zarnovican, P; von Itzstein, M; Routier, FH				Damerow, Sebastian; Lamerz, Anne-Christin; Haselhorst, Thomas; Fuehring, Jana; Zarnovican, Patricia; von Itzstein, Mark; Routier, Francoise H.			Leishmania UDP-sugar Pyrophosphorylase THE MISSING LINK IN GALACTOSE SALVAGE?	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLUCOSE PYROPHOSPHORYLASE; TRYPANOSOMA-BRUCEI; LIGAND-BINDING; MOLECULAR ARCHITECTURE; SUBSTRATE-SPECIFICITY; NMR; TRANSPORTERS; METABOLISM; GENE; SUPPRESSION	The Leishmania parasite glycocalyx is rich in galactose-containing glycoconjugates that are synthesized by specific glycosyltransferases that use UDP-galactose as a glycosyl donor. UDP-galactose biosynthesis is thought to be predominantly a de novo process involving epimerization of the abundant nucleotide sugar UDP-glucose by the UDP-glucose 4-epimerase, although galactose salvage from the environment has been demonstrated for Leishmania major. Here, we present the characterization of an L. major UDP-sugar pyrophosphorylase able to reversibly activate galactose 1-phosphate into UDP-galactose thus proving the existence of the Isselbacher salvage pathway in this parasite. The ordered bisubstrate mechanism and high affinity of the enzyme for UTP seem to favor the synthesis of nucleotide sugar rather than their pyrophosphorolysis. Although L. major UDP-sugar pyrophosphorylase preferentially activates galactose 1-phosphate and glucose 1-phosphate, the enzyme is able to act on a variety of hexose 1-phosphates as well as pentose 1-phosphates but not hexosamine 1-phosphates and hence presents a broad in vitro specificity. The newly identified enzyme exhibits a low but significant homology with UDP-glucose pyrophosphorylases and conserved in particular is the pyrophosphorylase consensus sequence and residues involved in nucleotide and phosphate binding. Saturation transfer difference NMR spectroscopy experiments confirm the importance of these moieties for substrate binding. The described leishmanial enzyme is closely related to plant UDP-sugar pyrophosphorylases and presents a similar substrate specificity suggesting their common origin.	[Damerow, Sebastian; Lamerz, Anne-Christin; Fuehring, Jana; Zarnovican, Patricia; Routier, Francoise H.] Hannover Med Sch, Dept Cellular Chem, D-30625 Hannover, Germany; [Haselhorst, Thomas; von Itzstein, Mark] Griffith Univ, Inst Glycom, Southport, Qld 4222, Australia	Hannover Medical School; Griffith University	Routier, FH (corresponding author), Hannover Med Sch, Dept Cellular Chem, Carl Neuberg Str 1, D-30625 Hannover, Germany.	Routier.Francoise@mh-hannover.de	Haselhorst, Thomas/A-5066-2015; Routier, Francoise/O-1611-2019; von Itzstein, Mark/E-4823-2010	Haselhorst, Thomas/0000-0002-3373-8680; Routier, Francoise/0000-0002-7163-0590	Australian Research Council; National Health and Medical Research Council; National Science Foundation [0090281]	Australian Research Council(Australian Research Council); National Health and Medical Research Council(National Health and Medical Research Council (NHMRC) of Australia); National Science Foundation(National Science Foundation (NSF))	Recipient of support from the Australian Research Council and the National Health and Medical Research Council.; We thank Nikolay Nifant'ev (Zelinsky Institute of Organic Chemistry, Russian Academy of Sciences) for gift of xylose 1-phosphate. UDP-galacturonic acid and UDP-L-arabinose were purchased by CarboSource, supported in part by National Science Foundation RCN Grant 0090281.	Bakker H, 2005, BIOL CHEM, V386, P657, DOI 10.1515/BC.2005.076; Barrett MP, 1998, MOL BIOCHEM PARASIT, V91, P195, DOI 10.1016/S0166-6851(97)00192-8; Bearne SL, 2001, BIOCHEM J, V356, P223, DOI 10.1042/0264-6021:3560223; Beverley SM, 2005, EUKARYOT CELL, V4, P1147, DOI 10.1128/EC.4.6.1147-1154.2005; Burchmore RJS, 2003, P NATL ACAD SCI USA, V100, P3901, DOI 10.1073/pnas.0630165100; Capul AA, 2007, INFECT IMMUN, V75, P4629, DOI 10.1128/IAI.00735-07; Capul AA, 2007, J BIOL CHEM, V282, P14006, DOI 10.1074/jbc.M610869200; da Silva LM, 2009, P NATL ACAD SCI USA, V106, P7583, DOI 10.1073/pnas.0901698106; DATTA AK, 1995, J BIOL CHEM, V270, P1497, DOI 10.1074/jbc.270.4.1497; de Jongh WA, 2008, BIOTECHNOL BIOENG, V101, P317, DOI 10.1002/bit.21890; Duggleby RG, 1996, EUR J BIOCHEM, V235, P173, DOI 10.1111/j.1432-1033.1996.00173.x; Feng XH, 2009, MOL MICROBIOL, V71, P369, DOI 10.1111/j.1365-2958.2008.06531.x; Fridovich-Keil JL, 2006, J CELL PHYSIOL, V209, P701, DOI 10.1002/jcp.20820; Garami A, 2001, EMBO J, V20, P3657, DOI 10.1093/emboj/20.14.3657; Goodman CD, 2007, CURR DRUG TARGETS, V8, P15, DOI 10.2174/138945007779315579; Gruber TD, 2009, J MOL BIOL, V391, P327, DOI 10.1016/j.jmb.2009.05.081; Haselhorst T, 2008, ANGEW CHEM INT EDIT, V47, P1910, DOI 10.1002/anie.200704872; Haselhorst T, 2009, NAT CHEM BIOL, V5, P91, DOI 10.1038/nchembio.134; ISSELBACHER KJ, 1958, J BIOL CHEM, V232, P429; Kleczka B, 2007, J BIOL CHEM, V282, P10498, DOI 10.1074/jbc.M700023200; Kotake T, 2004, J BIOL CHEM, V279, P45728, DOI 10.1074/jbc.M408716200; Kotake T, 2007, BIOSCI BIOTECH BIOCH, V71, P761, DOI 10.1271/bbb.60605; Lamerz AC, 2006, GLYCOBIOLOGY, V16, P1143; Lamerz AC, 2006, J BIOL CHEM, V281, P16314, DOI 10.1074/jbc.M600076200; Litterer LA, 2006, PLANT PHYSIOL BIOCH, V44, P171, DOI 10.1016/j.plaphy.2006.04.004; MacRae JI, 2006, MOL BIOCHEM PARASIT, V147, P126, DOI 10.1016/j.molbiopara.2006.02.011; Maggioni A, 2008, CHEMBIOCHEM, V9, P2784, DOI 10.1002/cbic.200800526; Martz F, 2002, BIOCHEM J, V367, P295, DOI 10.1042/BJ20020772; Mayer M, 2001, J AM CHEM SOC, V123, P6108, DOI 10.1021/ja0100120; Meng M, 2008, BBA-PROTEINS PROTEOM, V1784, P967, DOI 10.1016/j.bbapap.2008.02.021; Naderer T, 2004, CURR MOL MED, V4, P649, DOI 10.2174/1566524043360069; Ohashi T, 2006, ANAL BIOCHEM, V352, P182, DOI 10.1016/j.ab.2006.02.026; Peneff C, 2001, EMBO J, V20, P6191, DOI 10.1093/emboj/20.22.6191; PENG HL, 1993, FEBS LETT, V329, P153, DOI 10.1016/0014-5793(93)80213-E; Roper JR, 2005, J BIOL CHEM, V280, P19728, DOI 10.1074/jbc.M502370200; Roper JR, 2002, P NATL ACAD SCI USA, V99, P5884, DOI 10.1073/pnas.092669999; Steiner T, 2007, J BIOL CHEM, V282, P13003, DOI 10.1074/jbc.M609984200; Tetaud E, 1997, BIOCHEM J, V325, P569, DOI 10.1042/bj3250569; Thoden JB, 2007, PROTEIN SCI, V16, P432, DOI 10.1110/ps.062626007; TURCO SJ, 1984, J BIOL CHEM, V259, P3883; Turnock DC, 2007, EUKARYOT CELL, V6, P1450, DOI 10.1128/EC.00175-07; Urbaniak MD, 2006, EUKARYOT CELL, V5, P1906, DOI 10.1128/EC.00156-06	42	44	45	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 8	2010	285	2					878	887		10.1074/jbc.M109.067223	http://dx.doi.org/10.1074/jbc.M109.067223			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	539MH	19906649	Green Published, hybrid			2022-12-25	WOS:000273258200008
J	Evans, RM; You, H; Hameed, S; Altier, C; Mezghrani, A; Bourinet, E; Zamponi, GW				Evans, Rhian M.; You, Haitao; Hameed, Shahid; Altier, Christophe; Mezghrani, Alexandre; Bourinet, Emmanuel; Zamponi, Gerald W.			Heterodimerization of ORL1 and Opioid Receptors and Its Consequences for N-type Calcium Channel Regulation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-COUPLED RECEPTOR; CENTRAL-NERVOUS-SYSTEM; NOCICEPTIN/ORPHANIN FQ; ORPHANIN FQ/NOCICEPTIN; INDUCED TRAFFICKING; INFLAMMATORY PAIN; MESSENGER-RNA; SPINAL-CORD; MU; RAT	We have investigated the heterodimerization of ORL1 receptors and classical members of the opioid receptor family. All three classes of opioid receptors could be co-immunoprecipitated with ORL1 receptors from both transfected tsA-201 cell lysate and rat dorsal root ganglia lysate, suggesting that these receptors can form heterodimers. Consistent with this hypothesis, in cells expressing either one of the opioid receptors together with ORL1, prolonged ORL1 receptor activation via nociceptin application resulted in internalization of the opioid receptors. Conversely, mu-, delta-, and kappa-opioid receptor activation with the appropriate ligands triggered the internalization of ORL1. The mu-opioid receptor/ORL1 receptor heterodimers were shown to associate with N-type calcium channels, with activation of mu-opioid receptors triggering N-type channel internalization, but only in the presence of ORL1. Furthermore, the formation of opioid receptor/ORL1 receptor heterodimers attenuated the ORL1 receptor-mediated inhibition of N-type channels, in part because of constitutive opioid receptor activity. Collectively, our data support the existence of heterodimers between ORL1 and classical opioid receptors, with profound implications for effectors such as N-type calcium channels.	[Evans, Rhian M.; You, Haitao; Hameed, Shahid; Altier, Christophe; Zamponi, Gerald W.] Univ Calgary, Dept Physiol & Pharmacol, Hotchkiss Brain Inst, Calgary, AB T2N 4N1, Canada; [Mezghrani, Alexandre; Bourinet, Emmanuel] CNRS, Inst Genom Fonctionnelle, F-34094 Montpellier, France	University of Calgary; UDICE-French Research Universities; Universite Claude Bernard Lyon 1; CHU Lyon; Centre National de la Recherche Scientifique (CNRS); Ecole Normale Superieure de Lyon (ENS de LYON); Universite de Montpellier	Zamponi, GW (corresponding author), Univ Calgary, Dept Physiol & Pharmacol, Hotchkiss Brain Inst, Calgary, AB T2N 4N1, Canada.	zamponi@ucalgary.ca		Zamponi, Gerald W./0000-0002-0644-9066	Canadian Institutes of Health Research; Agence Nationale de la Recherche [ANR Neuro 2005-031]; Alberta Heritage Foundation for Medical Research; Government of Canada	Canadian Institutes of Health Research(Canadian Institutes of Health Research (CIHR)); Agence Nationale de la Recherche(French National Research Agency (ANR)); Alberta Heritage Foundation for Medical Research(Alberta Heritage Foundation for Medical ResearchGeneral Electric); Government of Canada(CGIAR)	This work was supported by an operating grant from the Canadian Institutes of Health Research (to G.W.Z.), Agence Nationale de la Recherche Grant ANR Neuro 2005-031 (to E.B.), and an Alberta Heritage Foundation for Medical Research fellowship and a Canadian Commonwealth postdoctoral fellowship from the Government of Canada (to R.M.E.).	AbdAlla S, 2000, NATURE, V407, P94, DOI 10.1038/35024095; Altier C, 2006, NAT NEUROSCI, V9, P31, DOI 10.1038/nn1605; Beedle AM, 2004, NAT NEUROSCI, V7, P118, DOI 10.1038/nn1180; Beedle AM, 2002, J MEMBRANE BIOL, V187, P225, DOI 10.1007/s00232-001-0166-2; Bourinet E, 1996, P NATL ACAD SCI USA, V93, P1486, DOI 10.1073/pnas.93.4.1486; BUNZOW JR, 1994, FEBS LETT, V347, P284, DOI 10.1016/0014-5793(94)00561-3; Chee MJS, 2008, J BIOL CHEM, V283, P33337, DOI 10.1074/jbc.M804671200; Chen Y, 2007, J NEUROSCI RES, V85, P1478, DOI 10.1002/jnr.21272; Chen Y, 2006, J PERIPHER NERV SYST, V11, P232, DOI 10.1111/j.1529-8027.2006.0093.x; Connor M, 1998, J PHYSIOL-LONDON, V509, P47, DOI 10.1111/j.1469-7793.1998.047bo.x; Dang VC, 2009, J NEUROSCI, V29, P3322, DOI 10.1523/JNEUROSCI.4749-08.2009; George SR, 2000, J BIOL CHEM, V275, P26128, DOI 10.1074/jbc.M000345200; Gomes I, 2000, J NEUROSCI, V20, part. no., DOI 10.1523/JNEUROSCI.20-22-j0007.2000; Gouarderes C, 1999, BRAIN RES, V838, P85, DOI 10.1016/S0006-8993(99)01713-8; Gurevich VV, 2008, TRENDS PHARMACOL SCI, V29, P234, DOI 10.1016/j.tips.2008.02.004; Harding PJ, 2009, BIOPHYS J, V96, P964, DOI 10.1016/j.bpj.2008.09.054; Homberg JR, 2009, NEUROSCIENCE, V163, P308, DOI 10.1016/j.neuroscience.2009.06.021; Inoue M, 1999, J PHARMACOL EXP THER, V291, P308; Jenck F, 2000, P NATL ACAD SCI USA, V97, P4938, DOI 10.1073/pnas.090514397; Jordan BA, 1999, NATURE, V399, P697, DOI 10.1038/21441; Kaneko S, 1997, BRIT J PHARMACOL, V121, P806, DOI 10.1038/sj.bjp.0701181; Kisilevsky AE, 2008, CHANNELS, V2, P269, DOI 10.4161/chan.2.4.6402; Kisilevsky AE, 2008, NEURON, V58, P557, DOI 10.1016/j.neuron.2008.03.002; Ko MCH, 2002, BRIT J PHARMACOL, V135, P943, DOI 10.1038/sj.bjp.0704535; Kolesnikov YA, 1999, LIFE SCI, V64, P2021, DOI 10.1016/S0024-3205(99)00149-6; Kotlinska J, 2000, LIFE SCI, V66, pPL119, DOI 10.1016/S0024-3205(99)00648-7; Lipsky R, 2008, J BIOL CHEM, V283, P17221, DOI 10.1074/jbc.C800061200; Mandyam CD, 2003, J PHARMACOL EXP THER, V306, P965, DOI 10.1124/jpet.103.051599; Marker CL, 2005, J NEUROSCI, V25, P3551, DOI 10.1523/JNEUROSCI.4899-04.2005; Matsushita H, 2009, ENDOCRINOLOGY, V150, P2668, DOI 10.1210/en.2008-1515; Milligan G, 2004, MOL PHARMACOL, V66, P1, DOI 10.1124/mol.104.000497.; MOLLEREAU C, 1994, FEBS LETT, V341, P33, DOI 10.1016/0014-5793(94)80235-1; Neal CR, 1999, J COMP NEUROL, V406, P503; Neal CR, 1999, J COMP NEUROL, V412, P563; Obara I, 2009, PAIN, V141, P283, DOI 10.1016/j.pain.2008.12.006; Pettersson LME, 2002, BRAIN RES, V945, P266, DOI 10.1016/S0006-8993(02)02817-2; Polidori C, 2000, PEPTIDES, V21, P1051, DOI 10.1016/S0196-9781(00)00224-2; Puckerin A, 2006, J BIOL CHEM, V281, P31131, DOI 10.1074/jbc.M605000200; Rawls SM, 2008, NEUROPEPTIDES, V42, P229, DOI 10.1016/j.npep.2008.03.005; REINSCHEID RK, 1995, SCIENCE, V270, P792, DOI 10.1126/science.270.5237.792; RHIM H, 1994, J NEUROSCI, V14, P7608; Simen AA, 2000, MOL PHARMACOL, V57, P1064; Tedford HW, 2006, PHARMACOL REV, V58, P837, DOI 10.1124/pr.58.4.11; Tombler E, 2006, J BIOL CHEM, V281, P1827, DOI 10.1074/jbc.M508829200; Ueda H, 2000, J NEUROSCI, V20, P7640; Wang HL, 2005, J NEUROCHEM, V92, P1285, DOI 10.1111/j.1471-4159.2004.02921.x; Williams AJK, 2006, J IMMUNOL METHODS, V314, P170, DOI 10.1016/j.jim.2006.06.003; Wu ZZ, 2004, J PHARMACOL EXP THER, V311, P939, DOI 10.1124/jpet.104.073429; Zhang GH, 2009, PAIN, V143, P233, DOI 10.1016/j.pain.2009.03.007	49	63	66	0	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 8	2010	285	2					1032	1040		10.1074/jbc.M109.040634	http://dx.doi.org/10.1074/jbc.M109.040634			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	539MH	19887453	Green Published, hybrid			2022-12-25	WOS:000273258200024
J	Ohsu, T; Amino, Y; Nagasaki, H; Yamanaka, T; Takeshita, S; Hatanaka, T; Maruyama, Y; Miyamura, N; Eto, Y				Ohsu, Takeaki; Amino, Yusuke; Nagasaki, Hiroaki; Yamanaka, Tomohiko; Takeshita, Sen; Hatanaka, Toshihiro; Maruyama, Yutaka; Miyamura, Naohiro; Eto, Yuzuru			Involvement of the Calcium-sensing Receptor in Human Taste Perception	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EXTRACELLULAR CA2+-SENSING RECEPTOR; PROTEIN-COUPLED RECEPTORS; GAMMA-GLUTAMYL PEPTIDES; GASTROINTESTINAL-TRACT; GLUTATHIONE; FAMILY; CLONING; ROLES; WATER; RATS	By human sensory analyses, we found that various extracellular calcium-sensing receptor (CaSR) agonists enhance sweet, salty, and umami tastes, although they have no taste themselves. These characteristics are known as "kokumi taste" and often appear in traditional Japanese cuisine. Although GSH is a typical kokumi taste substance (taste enhancer), its mode of action is poorly understood. Here, we demonstrate how the kokumi taste is enhanced by the CaSR, a close relative of the class C G-protein-coupled receptors T1R1, T1R2, and T1R3 (sweet and umami receptors). We identified a large number of CaSR agonist gamma-glutamyl peptides, including GSH (gamma-Glu-Cys-Gly) and gamma-Glu-Val-Gly, and showed that these peptides elicit the kokumi taste. Further analyses revealed that some known CaSR agonists such as Ca2+, protamine, polylysine, L-histidine, and cinacalcet (a calcium-mimetic drug) also elicit the kokumi taste and that the CaSR-specific antagonist, NPS-2143, significantly suppresses the kokumi taste. This is the first report indicating a distinct function of the CaSR in human taste perception.	[Eto, Yuzuru] Ajinomoto Co Inc, Inst Life Sci, Kawasaki Ku, Kawasaki, Kanagawa 2108681, Japan; [Ohsu, Takeaki; Takeshita, Sen; Hatanaka, Toshihiro; Eto, Yuzuru] Pharmaceut Res Labs, Kawasaki, Kanagawa 2108681, Japan; [Amino, Yusuke] AminoSci Labs, Kawasaki, Kanagawa 2108681, Japan; [Nagasaki, Hiroaki; Yamanaka, Tomohiko; Miyamura, Naohiro] Food Prod Co, Kawasaki, Kanagawa 2108681, Japan	Ajinomoto Co Inc	Eto, Y (corresponding author), Ajinomoto Co Inc, Inst Life Sci, Kawasaki Ku, 1-1 Suzuki Cho, Kawasaki, Kanagawa 2108681, Japan.	yuzuru_eto@ajinomoto.com						Aaslyng MD, 1998, J AGR FOOD CHEM, V46, P5225, DOI 10.1021/jf9806816; Adler E, 2000, CELL, V100, P693, DOI 10.1016/S0092-8674(00)80705-9; BROWN EM, 1993, NATURE, V366, P575, DOI 10.1038/366575a0; Brown EM, 2001, PHYSIOL REV, V81, P239, DOI 10.1152/physrev.2001.81.1.239; Chandrashekar J, 2000, CELL, V100, P703, DOI 10.1016/S0092-8674(00)80706-0; Chattopadhyay N, 1997, BIOL CHEM, V378, P759; Conigrave AD, 2000, P NATL ACAD SCI USA, V97, P4814, DOI 10.1073/pnas.97.9.4814; Conigrave AD, 2006, TRENDS ENDOCRIN MET, V17, P398, DOI 10.1016/j.tem.2006.10.012; Conigrave AD, 2006, AM J PHYSIOL-GASTR L, V291, pG753, DOI 10.1152/ajpgi.00189.2006; Dunkel A, 2007, J AGR FOOD CHEM, V55, P6712, DOI 10.1021/jf071276u; Gabriel AS, 2009, BIOCHEM BIOPH RES CO, V378, P414, DOI 10.1016/j.bbrc.2008.11.060; Hebert SC, 2004, CELL CALCIUM, V35, P239, DOI 10.1016/j.ceca.2003.10.015; Hoon MA, 1999, CELL, V96, P541, DOI 10.1016/S0092-8674(00)80658-3; Ishimaru Y, 2006, P NATL ACAD SCI USA, V103, P12569, DOI 10.1073/pnas.0602702103; KANAZAWA A, 1965, BIOCHIM BIOPHYS ACTA, V111, P90, DOI 10.1016/0304-4165(65)90475-7; KRISTENSEN I, 1974, PHYTOCHEMISTRY, V13, P2803, DOI 10.1016/0031-9422(74)80245-1; Li Y, 2004, APPL MICROBIOL BIOT, V66, P233, DOI 10.1007/s00253-004-1751-y; McCaughey SA, 2005, PHYSIOL BEHAV, V84, P335, DOI 10.1016/j.physbeh.2004.12.010; MECCHI EP, 1964, J FOOD SCI, V29, P393, DOI 10.1111/j.1365-2621.1964.tb01750.x; Nelson G, 2002, NATURE, V416, P199, DOI 10.1038/nature726; Nelson G, 2001, CELL, V106, P381, DOI 10.1016/S0092-8674(01)00451-2; Reed DR, 2003, MAMM GENOME, V14, P302, DOI 10.1007/s00335-002-2170-y; Rodriguez M, 2005, AM J PHYSIOL-RENAL, V288, pF253, DOI 10.1152/ajprenal.00302.2004; ROTIN D, 1994, EMBO J, V13, P4440, DOI 10.1002/j.1460-2075.1994.tb06766.x; Rybczynska A, 2006, J ENDOCRINOL, V191, P189, DOI 10.1677/joe.1.06924; SCHEFFE H, 1952, J AM STAT ASSOC, V47, P381, DOI 10.2307/2281310; Toelstede S, 2009, J AGR FOOD CHEM, V57, P1440, DOI 10.1021/jf803376d; Tordoff MG, 2008, GENES BRAIN BEHAV, V7, P618, DOI 10.1111/j.1601-183X.2008.00398.x; Tordoff MG, 2008, PHYSIOL GENOMICS, V34, P338, DOI 10.1152/physiolgenomics.90200.2008; UEDA Y, 1990, AGR BIOL CHEM TOKYO, V54, P163, DOI 10.1080/00021369.1990.10869909; Ueda Y, 1997, BIOSCI BIOTECH BIOCH, V61, P1977, DOI 10.1271/bbb.61.1977; Wang MH, 2006, J BIOL CHEM, V281, P8864, DOI 10.1074/jbc.M512865200; Wellendorph P, 2007, GENE, V396, P257, DOI 10.1016/j.gene.2007.03.008; ZHANG YG, 1988, J AGR FOOD CHEM, V36, P992, DOI 10.1021/jf00083a022	34	174	194	7	94	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 8	2010	285	2					1016	1022		10.1074/jbc.M109.029165	http://dx.doi.org/10.1074/jbc.M109.029165			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	539MH	19892707	Green Published, hybrid			2022-12-25	WOS:000273258200022
J	Page, KM; Heblich, F; Margas, W; Pratt, WS; Nieto-Rostro, M; Chaggar, K; Sandhu, K; Davies, A; Dolphin, AC				Page, Karen M.; Heblich, Fay; Margas, Wojciech; Pratt, Wendy S.; Nieto-Rostro, Manuela; Chaggar, Kanchan; Sandhu, Kieran; Davies, Anthony; Dolphin, Annette C.			N Terminus Is Key to the Dominant Negative Suppression of Ca(V)2 Calcium Channels IMPLICATIONS FOR EPISODIC ATAXIA TYPE 2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CA2+ CHANNELS; ENDOPLASMIC-RETICULUM; TRUNCATED CONSTRUCTS; MUTATIONS; ALPHA-1B; IDENTIFICATION; TRAFFICKING; SUBUNITS; MUTANTS; GENE	Expression of the calcium channels Ca(V)2.1 and Ca(V)2.2 is markedly suppressed by co-expression with truncated constructs containing Domain I. This is the basis for the phenomenon of dominant negative suppression observed for many of the episodic ataxia type 2 mutations in Ca(V)2.1 that predict truncated channels. The process of dominant negative suppression has been shown previously to stem from interaction between the full-length and truncated channels and to result in downstream consequences of the unfolded protein response and endoplasmic reticulum-associated protein degradation. We have now identified the specific domain that triggers this effect. For both Ca(V)2.1 and Ca(V)2.2, the minimum construct producing suppression was the cytoplasmic N terminus. Suppression was enhanced by tethering the N terminus to the membrane with a CAAX motif. The 11-amino acid motif (including Arg(52) and Arg(54)) within the N terminus, which we have previously shown to be required for G protein modulation, is also essential for dominant negative suppression. Suppression is prevented by addition of an N-terminal tag (XFP) to the full-length and truncated constructs. We further show that suppression of Ca(V)2.2 currents by the N terminus-CAAX construct is accompanied by a reduction in Ca(V)2.2 protein level, and this is also prevented by mutation of Arg(52) and Arg(54) to Ala in the truncated construct. Taken together, our evidence indicates that both the extreme N terminus and the Arg(52), Arg(54) motif are involved in the processes underlying dominant negative suppression.	[Page, Karen M.; Heblich, Fay; Margas, Wojciech; Pratt, Wendy S.; Nieto-Rostro, Manuela; Chaggar, Kanchan; Sandhu, Kieran; Davies, Anthony; Dolphin, Annette C.] UCL, Dept Neurosci Physiol & Pharmacol, London WC1E 6BT, England	University of London; University College London	Dolphin, AC (corresponding author), UCL, Dept Neurosci Physiol & Pharmacol, Gower St, London WC1E 6BT, England.	a.dolphin@ucl.ac.uk	Tuluc, Petronel/C-2527-2011; Dolphin, Annette C/F-7416-2010	Dolphin, Annette C/0000-0003-4626-4856	Wellcome Trust [077883]; Medical Research Coucil [G0700368]; Medical Research Council [G0700368] Funding Source: researchfish; MRC [G0700368] Funding Source: UKRI	Wellcome Trust(Wellcome TrustEuropean Commission); Medical Research Coucil; Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))	This work was supported by Wellcome Trust Grant 077883 and Medical Research Coucil Grant G0700368.	Agler HL, 2005, NEURON, V46, P891, DOI 10.1016/j.neuron.2005.05.011; Barclay J, 2001, J NEUROSCI, V21, P6095, DOI 10.1523/JNEUROSCI.21-16-06095.2001; CAMPBELL V, 1995, FEBS LETT, V370, P135, DOI 10.1016/0014-5793(95)00813-O; Canti C, 2001, BIOPHYS J, V81, P1439, DOI 10.1016/S0006-3495(01)75799-2; Canti C, 1999, J NEUROSCI, V19, P6855, DOI 10.1523/JNEUROSCI.19-16-06855.1999; Catterall WA, 2000, ANNU REV CELL DEV BI, V16, P521, DOI 10.1146/annurev.cellbio.16.1.521; Chevet E, 2001, CURR OPIN STRUC BIOL, V11, P120, DOI 10.1016/S0959-440X(00)00168-8; Choy E, 1999, CELL, V98, P69, DOI 10.1016/S0092-8674(00)80607-8; Cormack BP, 1996, GENE, V173, P33, DOI 10.1016/0378-1119(95)00685-0; Denier C, 1999, NEUROLOGY, V52, P1816, DOI 10.1212/WNL.52.9.1816; Ertel EA, 2000, NEURON, V25, P533, DOI 10.1016/S0896-6273(00)81057-0; Jen JC, 2007, BRAIN, V130, P2484, DOI 10.1093/brain/awm126; Jeng CJ, 2008, J CELL PHYSIOL, V214, P422, DOI 10.1002/jcp.21216; Jeng CJ, 2006, AM J PHYSIOL-CELL PH, V290, pC1209, DOI 10.1152/ajpcell.00247.2005; Maquat LE, 2002, CURR BIOL, V12, pR196, DOI 10.1016/S0960-9822(02)00747-9; Mezghrani A, 2008, J NEUROSCI, V28, P4501, DOI 10.1523/JNEUROSCI.2844-07.2008; Ophoff RA, 1996, CELL, V87, P543, DOI 10.1016/S0092-8674(00)81373-2; Page KM, 2004, J NEUROSCI, V24, P5400, DOI 10.1523/JNEUROSCI.0553-04.2004; Page KM, 1998, J NEUROSCI, V18, P4815; Pietrobon D, 2002, MOL NEUROBIOL, V25, P31, DOI 10.1385/MN:25:1:031; Raghib A, 2001, J NEUROSCI, V21, P8495, DOI 10.1523/JNEUROSCI.21-21-08495.2001; Ron D, 2002, J CLIN INVEST, V110, P1383, DOI 10.1172/JCI200216784; Schwappach B, 2000, NEURON, V26, P155, DOI 10.1016/S0896-6273(00)81146-0; Tinker A, 1996, CELL, V87, P857, DOI 10.1016/S0092-8674(00)81993-5; TOMLINSON WJ, 1993, NEUROPHARMACOLOGY, V32, P1117, DOI 10.1016/0028-3908(93)90006-O; Wappl E, 2002, J BIOL CHEM, V277, P6960, DOI 10.1074/jbc.M110948200	26	38	39	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 8	2010	285	2					835	844		10.1074/jbc.M109.065045	http://dx.doi.org/10.1074/jbc.M109.065045			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	539MH	19903821	hybrid, Green Published			2022-12-25	WOS:000273258200004
J	Yuan, Q; Kaylor, JJ; Miu, A; Bassilian, S; Whitelegge, JP; Travis, GH				Yuan, Quan; Kaylor, Joanna J.; Miu, Anh; Bassilian, Sara; Whitelegge, Julian P.; Travis, Gabriel H.			Rpe65 Isomerase Associates with Membranes through an Electrostatic Interaction with Acidic Phospholipid Headgroups	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RETINAL-PIGMENT EPITHELIUM; IONIZATION MASS-SPECTROMETRY; VISUAL CYCLE; SUBCELLULAR-LOCALIZATION; BINDING-PROTEIN; ISOMEROHYDROLASE; SUBSTRATE; BIOSYNTHESIS; CARDIOLIPIN; EXPRESSION	Opsins are light-sensitive pigments in the vertebrate retina, comprising a G protein-coupled receptor and an 11-cis-retinaldehyde chromophore. Absorption of a photon by an opsin pigment induces isomerization of its chromophore to all-trans-retinaldehyde. After a brief period of activation, opsin releases all-trans-retinaldehyde and becomes insensitive to light. Restoration of light sensitivity to the apo-opsin involves the conversion of all-trans-retinaldehyde back to 11-cis-retinaldehyde via an enzyme pathway called the visual cycle. The critical isomerization step in this pathway is catalyzed by Rpe65. Rpe65 is strongly associated with membranes but contains no membrane-spanning segments. It was previously suggested that the affinity of Rpe65 for membranes is due to palmitoylation of one or more Cys residues. In this study, we re-examined this hypothesis. By two independent strategies involving mass spectrometry, we show that Rpe65 is not palmitoylated nor does it appear to undergo other post-translational modifications at significant stoichiometry. Instead, we show that Rpe65 binds the acidic phospholipids, phosphatidylserine, phosphatidylglycerol, and cardiolipin, but not phosphatidic acid. No binding of Rpe65 to basic phospholipids or neutral lipids was observed. The affinity of Rpe65 to acidic phospholipids was strongly pH-dependent, suggesting an electrostatic interaction of basic residues in Rpe65 with negatively charged phospholipid headgroups. Binding of Rpe65 to liposomes containing phosphatidylserine or phosphatidylglycerol, but not the basic or neutral phospholipids, allowed the enzyme to extract its insoluble substrate, all-trans-retinyl palmitate, from the lipid bilayer for synthesis of 11-cis-retinol. The interaction of Rpe65 with acidic phospholipids is therefore biologically relevant.	[Yuan, Quan; Kaylor, Joanna J.; Miu, Anh; Travis, Gabriel H.] Univ Calif Los Angeles, Sch Med, Jules Stein Eye Inst, Los Angeles, CA 90095 USA; [Bassilian, Sara; Whitelegge, Julian P.] Univ Calif Los Angeles, Sch Med, Pasarow Mass Spectrometry Lab, Neuropsychiat Inst,Semel Inst, Los Angeles, CA 90095 USA; [Travis, Gabriel H.] Univ Calif Los Angeles, Sch Med, Dept Biol Chem, Los Angeles, CA 90095 USA	University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA	Travis, GH (corresponding author), Univ Calif Los Angeles, Sch Med, Jules Stein Eye Inst, 100 Stein Plaza, Los Angeles, CA 90095 USA.	travis@jsei.ucla.edu	Kaylor, Joanna/Y-5184-2019; Travis, Gabriel Harvey/AIF-1062-2022; yuan, quan/GZM-5597-2022	Travis, Gabriel Harvey/0000-0003-4020-9493; 	NEI [EY01584, EY11713]; NATIONAL EYE INSTITUTE [R01EY011713] Funding Source: NIH RePORTER	NEI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))	This work was supported, in whole or in part, by National Institutes of Health Grants EY01584 and EY11713 from NEI.	BLEASDALE JE, 1985, LUNG, V163, P345, DOI 10.1007/BF02713835; BRUNE DC, 1992, ANAL BIOCHEM, V207, P285, DOI 10.1016/0003-2697(92)90013-W; Choo DW, 1998, FEBS LETT, V440, P195, DOI 10.1016/S0014-5793(98)01459-8; Gollapalli DR, 2003, BIOCHEMISTRY-US, V42, P5809, DOI 10.1021/bi0341004; Gu SM, 1997, NAT GENET, V17, P194, DOI 10.1038/ng1097-194; Guex N, 1997, ELECTROPHORESIS, V18, P2714, DOI 10.1002/elps.1150181505; GULCAN HG, 1993, INVEST OPHTH VIS SCI, V34, P3187; Hauss T, 2005, BBA-BIOENERGETICS, V1710, P57, DOI 10.1016/j.bbabio.2005.08.007; HONIG B, 1995, SCIENCE, V268, P1144, DOI 10.1126/science.7761829; Houtkooper RH, 2008, CELL MOL LIFE SCI, V65, P2493, DOI 10.1007/s00018-008-8030-5; Huang J, 2009, MOL VIS, V15, P223; JACKSON CS, 2002, CURRENT PROTOCOLS PR, V2; Jin MH, 2005, CELL, V122, P449, DOI 10.1016/j.cell.2005.06.042; Jin MH, 2007, J BIOL CHEM, V282, P20915, DOI 10.1074/jbc.M701432200; Kiser PD, 2009, P NATL ACAD SCI USA, V106, P17325, DOI 10.1073/pnas.0906600106; Kloer DP, 2005, SCIENCE, V308, P267, DOI 10.1126/science.1108965; Kuge O, 2003, J BIOCHEM, V133, P397, DOI 10.1093/jb/mvg052; Liden M, 2001, J BIOL CHEM, V276, P49251, DOI 10.1074/jbc.M107337200; Ma JX, 2001, INVEST OPHTH VIS SCI, V42, P1429; Mata NL, 2004, J BIOL CHEM, V279, P635, DOI 10.1074/jbc.M310042200; MATSUZAWA Y, 1980, J LIPID RES, V21, P202; Moise AR, 2007, J BIOL CHEM, V282, P2081, DOI 10.1074/jbc.M608315200; Moiseyev G, 2005, P NATL ACAD SCI USA, V102, P12413, DOI 10.1073/pnas.0503460102; Moiseyev G, 2003, BIOCHEMISTRY-US, V42, P2229, DOI 10.1021/bi026911y; POORTHUIS BJHM, 1976, J BIOL CHEM, V251, P4596; RANDO RR, 1991, BIOCHEMISTRY-US, V30, P595, DOI 10.1021/bi00217a001; Redmond TM, 1998, NAT GENET, V20, P344, DOI 10.1038/3813; Redmond TM, 2005, P NATL ACAD SCI USA, V102, P13658, DOI 10.1073/pnas.0504167102; Redmond TM, 2001, J BIOL CHEM, V276, P6560, DOI 10.1074/jbc.M009030200; Ruegg U T, 1977, Methods Enzymol, V47, P111; Saari JC, 2009, MOL VIS, V15, P844; Schlame M, 2000, PROG LIPID RES, V39, P257, DOI 10.1016/S0163-7827(00)00005-9; Takahashi Y, 2006, INVEST OPHTH VIS SCI, V47, P5191, DOI 10.1167/iovs.06-0614; Takahashi Y, 2009, J BIOL CHEM, V284, P3211, DOI 10.1074/jbc.M807248200; Tsilou E, 1997, ARCH BIOCHEM BIOPHYS, V346, P21, DOI 10.1006/abbi.1997.0276; Whitelegge JP, 2002, MOL CELL PROTEOMICS, V1, P816, DOI 10.1074/mcp.M200045-MCP200; Whitelegge JP, 1998, PROTEIN SCI, V7, P1423, DOI 10.1002/pro.5560070619; Whitelegge Julian P, 2004, Methods Mol Biol, V251, P323; Xie J, 2007, FEBS LETT, V581, P3545, DOI 10.1016/j.febslet.2007.06.052; Xue LL, 2004, CELL, V117, P761, DOI 10.1016/j.cell.2004.05.016	40	13	13	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 8	2010	285	2					988	999		10.1074/jbc.M109.025643	http://dx.doi.org/10.1074/jbc.M109.025643			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	539MH	19892706	Green Published, hybrid			2022-12-25	WOS:000273258200019
J	Jung, HY; Seong, HA; Manoharan, R; Ha, HJ				Jung, Haiyoung; Seong, Hyun-A; Manoharan, Ravi; Ha, Hyunjung			Serine-Threonine Kinase Receptor-associated Protein Inhibits Apoptosis Signal-regulating Kinase 1 Function through Direct Interaction	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NM23-H1 TUMOR-SUPPRESSOR; CELL-DEATH; PHYSICAL INTERACTION; ASK1; STRESS; GROWTH; ACTIVATION; PHOSPHORYLATION; STRAP; THIOREDOXIN	Serine-threonine kinase receptor-associated protein (STRAP) interacts with transforming growth factor beta (TGF-beta) receptors and inhibits TGF-beta signaling. Here, we identify STRAP as an interacting partner of ASK1 (apoptosis signal-regulating kinase 1). The association between ASK1 and STRAP is mediated through the C-terminal domain of ASK1 and the fourth and sixth WD40 repeats of STRAP. Using cysteine-to-serine amino acid substitution mutants of ASK1 (C1005S, C1351S, C1360S, and C1351S/C1360S) and STRAP (C152S, C270S, and C152S/ C270S), we demonstrated that Cys(1351) and Cys(1360) of ASK1 and Cys(152) and Cys(270) of STRAP are required for ASK1-STRAP binding. ASK1 phosphorylated STRAP at Thr(175) and Ser(179), suggesting a potential role for STRAP phosphorylation in ASK1 activity regulation. Expression of wild-type STRAP, but not STRAP mutants (C152S/C270S and T175A/S179A), inhibited ASK1-mediated signaling to both JNK and p38 kinases by stabilizing complex formation between ASK1 and its negative regulators, thioredoxin and 14-3-3, or decreasing complex formation between ASK1 and its substrate MKK3. In addition, STRAP suppressed H2O2-mediated apoptosis in a dose-dependent manner by inhibiting ASK1 activity through direct interaction. These results suggest that STRAP can act as a negative regulator of ASK1.	[Jung, Haiyoung; Seong, Hyun-A; Manoharan, Ravi; Ha, Hyunjung] Chungbuk Natl Univ, Dept Biochem, Sch Life Sci, Biotechnol Res Inst, Cheongju 361763, South Korea	Chungbuk National University	Ha, HJ (corresponding author), Chungbuk Natl Univ, Dept Biochem, Sch Life Sci, Biotechnol Res Inst, Cheongju 361763, South Korea.	hyunha@chungbuk.ac.kr	Manoharan, Ravi/AAI-4139-2021	Manoharan, Ravi/0000-0002-3494-2173	Korea Science and Engineering Foundation [R0A-2007-000-20006-0]; Chungbuk National University	Korea Science and Engineering Foundation(Korea Science and Engineering Foundation); Chungbuk National University	This work was supported by Korea Science and Engineering Foundation Grant R0A-2007-000-20006-0 and in part by Chungbuk National University Grant 2008.	Anumanthan G, 2006, CANCER RES, V66, P10824, DOI 10.1158/0008-5472.CAN-06-1599; Chang HY, 1998, SCIENCE, V281, P1860, DOI 10.1126/science.281.5384.1860; Chen ZH, 1999, ONCOGENE, V18, P173, DOI 10.1038/sj.onc.1202276; Chinnaiyan AM, 1996, J BIOL CHEM, V271, P4573; Cho SG, 2001, J BIOL CHEM, V276, P12749, DOI 10.1074/jbc.M005561200; Datta PK, 2000, MOL CELL BIOL, V20, P3157, DOI 10.1128/MCB.20.9.3157-3167.2000; Datta PK, 1998, J BIOL CHEM, V273, P34671, DOI 10.1074/jbc.273.52.34671; Fujii K, 2004, ONCOGENE, V23, P5099, DOI 10.1038/sj.onc.1207668; Garg S, 2009, BMC BIOCHEM, V10, DOI 10.1186/1471-2091-10-1; Gotoh Y, 1998, J BIOL CHEM, V273, P17477, DOI 10.1074/jbc.273.28.17477; Haider SK, 2006, CANCER RES, V66, P6156, DOI 10.1158/0008-5472.CAN-05-3261; Hatai T, 2000, J BIOL CHEM, V275, P26576, DOI 10.1074/jbc.M003412200; Ichijo H, 1997, SCIENCE, V275, P90, DOI 10.1126/science.275.5296.90; Jung HY, 2008, J BIOL CHEM, V283, P20383, DOI 10.1074/jbc.M800050200; Jung HY, 2007, J BIOL CHEM, V282, P35293, DOI 10.1074/jbc.M705181200; Jung H, 2008, J BIOL CHEM, V283, P34541, DOI 10.1074/jbc.M807219200; Kim AH, 2001, MOL CELL BIOL, V21, P893, DOI 10.1128/MCB.21.3.893-901.2001; Liu H, 2000, MOL CELL BIOL, V20, P2198, DOI 10.1128/MCB.20.6.2198-2208.2000; Liu QH, 2006, MOL CELL BIOL, V26, P3785, DOI 10.1128/MCB.26.10.3785-3797.2006; Matsuura H, 2002, J BIOL CHEM, V277, P40703, DOI 10.1074/jbc.M202004200; Morita K, 2001, EMBO J, V20, P6028, DOI 10.1093/emboj/20.21.6028; Nishitoh H, 2002, GENE DEV, V16, P1345, DOI 10.1101/gad.992302; Park HS, 2002, MOL CELL BIOL, V22, P7721, DOI 10.1128/MCB.22.22.7721-7730.2002; Patel T, 1996, FASEB J, V10, P587, DOI 10.1096/fasebj.10.5.8621058; Saitoh M, 1998, EMBO J, V17, P2596, DOI 10.1093/emboj/17.9.2596; Seong HA, 2005, J BIOL CHEM, V280, P42897, DOI 10.1074/jbc.M507539200; Seong HA, 2007, J BIOL CHEM, V282, P12272, DOI 10.1074/jbc.M609279200; Seong HA, 2007, J BIOL CHEM, V282, P12075, DOI 10.1074/jbc.M609832200; Song JJ, 2002, J BIOL CHEM, V277, P46566, DOI 10.1074/jbc.M206826200; Tobiume K, 2002, J CELL PHYSIOL, V191, P95, DOI 10.1002/jcp.10080; Wang TH, 1998, J BIOL CHEM, V273, P4928, DOI 10.1074/jbc.273.9.4928; Zhan J, 2007, MOL CELL BIOL, V27, P3530, DOI 10.1128/MCB.00086-06; Zhang LX, 1999, P NATL ACAD SCI USA, V96, P8511, DOI 10.1073/pnas.96.15.8511	33	30	35	1	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 1	2010	285	1					54	70		10.1074/jbc.M109.045229	http://dx.doi.org/10.1074/jbc.M109.045229			17	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	536UT	19880523	Green Published, hybrid			2022-12-25	WOS:000273070100007
J	Wang, RW; Ridley, J; Sun, BF; Zheng, Q; Dunn, DW; Cook, J; Shi, L; Zhang, YP; Yu, DW				Wang, Rui-Wu; Ridley, Jo; Sun, Bao-Fa; Zheng, Qi; Dunn, Derek W.; Cook, James; Shi, Lei; Zhang, Ya-Ping; Yu, Douglas W.			Interference Competition and High Temperatures Reduce the Virulence of Fig Wasps and Stabilize a Fig-Wasp Mutualism	PLOS ONE			English	Article							SEX-RATIO ADJUSTMENT; POLLINATING WASPS; MONOECIOUS FIGS; TRADE-OFF; EVOLUTIONARY CONFLICTS; PLANT MUTUALISM; HOST SANCTIONS; DIOECIOUS FIG; BODY-SIZE; ALLOCATION	Fig trees are pollinated by fig wasps, which also oviposit in female flowers. The wasp larvae gall and eat developing seeds. Although fig trees benefit from allowing wasps to oviposit, because the wasp offspring disperse pollen, figs must prevent wasps from ovipositing in all flowers, or seed production would cease, and the mutualism would go extinct. In Ficus racemosa, we find that syconia ('figs') that have few foundresses (ovipositing wasps) are underexploited in the summer (few seeds, few galls, many empty ovules) and are overexploited in the winter (few seeds, many galls, few empty ovules). Conversely, syconia with many foundresses produce intermediate numbers of galls and seeds, regardless of season. We use experiments to explain these patterns, and thus, to explain how this mutualism is maintained. In the hot summer, wasps suffer short lifespans and therefore fail to oviposit in many flowers. In contrast, cooler temperatures in the winter permit longer wasp lifespans, which in turn allows most flowers to be exploited by the wasps. However, even in winter, only in syconia that happen to have few foundresses are most flowers turned into galls. In syconia with higher numbers of foundresses, interference competition reduces foundress lifespans, which reduces the proportion of flowers that are galled. We further show that syconia encourage the entry of multiple foundresses by delaying ostiole closure. Taken together, these factors allow fig trees to reduce galling in the wasp-benign winter and boost galling (and pollination) in the wasp-stressing summer. Interference competition has been shown to reduce virulence in pathogenic bacteria. Our results show that interference also maintains cooperation in a classic, cooperative symbiosis, thus linking theories of virulence and mutualism. More generally, our results reveal how frequency-dependent population regulation can occur in the fig-wasp mutualism, and how a host species can 'set the rules of the game' to ensure mutualistic behavior in its symbionts.			Wang, RW (corresponding author), Chinese Acad Sci, Kunming Inst Zool, State Key Lab Genet Resources & Evolut, ECEC, Kunming, Yunnan, Peoples R China.	dougwyu@gmail.com	Cook, James M/D-6423-2011; Cook, James/S-2128-2019; Yu, Douglas W./D-2536-2009	Cook, James M/0000-0001-8447-6126; Cook, James/0000-0001-8447-6126; Yu, Douglas W./0000-0001-8551-5609	Natural Environment Research Council [NE/C511264/1, NE/C511305/1, NE/C511264/2] Funding Source: researchfish	Natural Environment Research Council(UK Research & Innovation (UKRI)Natural Environment Research Council (NERC))		Anstett MC, 1998, P ROY SOC B-BIOL SCI, V265, P45, DOI 10.1098/rspb.1998.0262; Anstett MC, 1996, J EVOLUTION BIOL, V9, P417, DOI 10.1046/j.1420-9101.1996.9040417.x; Anstett MC, 2001, OIKOS, V95, P476, DOI 10.1034/j.1600-0706.2001.950313.x; Anstett MC, 1997, TRENDS ECOL EVOL, V12, P94, DOI 10.1016/S0169-5347(96)10064-1; Arnold AE, 2003, P NATL ACAD SCI USA, V100, P15649, DOI 10.1073/pnas.2533483100; ASPI J, 1995, J INSECT BEHAV, V8, P67, DOI 10.1007/BF01990970; Bever JD, 2009, ECOL LETT, V12, P13, DOI 10.1111/j.1461-0248.2008.01254.x; Bronstein JL, 2001, ECOL LETT, V4, P277, DOI 10.1046/j.1461-0248.2001.00218.x; Cook JM, 2004, J EVOLUTION BIOL, V17, P238, DOI 10.1111/j.1420-9101.2003.00683.x; Cook JM, 2003, TRENDS ECOL EVOL, V18, P241, DOI 10.1016/S0169-5347(03)00062-4; COOK JM, ECOLOGICAL IN PRESS; CORNER E. J. H., 1965, GARD BULL [SINGAPORE], V21, P1; Denison RF, 2000, AM NAT, V156, P567, DOI 10.1086/316994; Dethlefsen L, 2007, NATURE, V449, P811, DOI 10.1038/nature06245; Dufay M, 2003, OIKOS, V100, P3, DOI 10.1034/j.1600-0706.2003.12053.x; Dunn DW, 2008, J ANIM ECOL, V77, P927, DOI 10.1111/j.1365-2656.2008.01416.x; Dunn DW, 2008, PLOS BIOL, V6, P490, DOI 10.1371/journal.pbio.0060059; Edwards DP, 2007, BEHAV ECOL SOCIOBIOL, V61, P1321, DOI 10.1007/s00265-007-0369-3; Edwards DP, 2007, ANIM BEHAV, V74, P377, DOI 10.1016/j.anbehav.2006.07.022; Edwards DP, 2006, P ROY SOC B-BIOL SCI, V273, P595, DOI 10.1098/rspb.2005.3273; Ferdy JB, 2002, J THEOR BIOL, V217, P219, DOI 10.1006/jtbi.2002.3018; GALIL J, 1971, NEW PHYTOL, V70, P773, DOI 10.1111/j.1469-8137.1971.tb02578.x; Ganeshaiah KN, 1999, BIOTROPICA, V31, P312, DOI 10.1111/j.1744-7429.1999.tb00143.x; GRAFEN A, 1991, P ROY SOC B-BIOL SCI, V245, P73, DOI 10.1098/rspb.1991.0090; HAMILTON WD, 1967, SCIENCE, V156, P477, DOI 10.1126/science.156.3774.477; HASSELL MP, 1969, NATURE, V223, P1133, DOI 10.1038/2231133a0; Herre EA, 1999, TRENDS ECOL EVOL, V14, P49, DOI 10.1016/S0169-5347(98)01529-8; Herre EA, 1997, P ROY SOC B-BIOL SCI, V264, P1501, DOI 10.1098/rspb.1997.0208; HERRE EA, 1989, EXPERIENTIA, V45, P637, DOI 10.1007/BF01975680; HERRE EA, 1985, SCIENCE, V228, P896, DOI 10.1126/science.228.4701.896; HERRE EA, 1997, SOCIAL COMPETITION C, V1; Herre EA, 2008, ANNU REV ECOL EVOL S, V39, P439, DOI 10.1146/annurev.ecolsys.37.091305.110232; JANZEN DH, 1979, ANNU REV ECOL SYST, V10, P13, DOI 10.1146/annurev.es.10.110179.000305; Jousselin E, 2004, INT J PLANT SCI, V165, P587, DOI 10.1086/386558; Jousselin E, 2003, OECOLOGIA, V134, P381, DOI 10.1007/s00442-002-1116-0; Jousselin E, 2001, ECOL ENTOMOL, V26, P602, DOI 10.1046/j.1365-2311.2001.00368.x; Kathuria P, 1999, OIKOS, V87, P520, DOI 10.2307/3546816; KHADARI B, 1995, AM J BOT, V82, P992, DOI 10.2307/2446228; Kiers ET, 2003, NATURE, V425, P78, DOI 10.1038/nature01931; KITANO H, 2006, MOL SYSTEMS BIOL; Kjellberg F, 2001, P ROY SOC B-BIOL SCI, V268, P1113, DOI 10.1098/rspb.2001.1633; May RM, 1976, THEORETICAL ECOLOGY; Molbo D, 2003, P NATL ACAD SCI USA, V100, P5867, DOI 10.1073/pnas.0930903100; MOORE J, 2003, ANIM BEHAV, P1101; MURRAY MG, 1985, BIOL J LINN SOC, V26, P69, DOI 10.1111/j.1095-8312.1985.tb01552.x; Nefdt RJC, 1996, J ANIM ECOL, V65, P170, DOI 10.2307/5720; PATINO S, 1994, OECOLOGIA, V100, P13, DOI 10.1007/BF00317125; PELLMYR O, 1994, NATURE, V372, P257, DOI 10.1038/372257a0; R Core Team, 2022, R LANG ENV STAT COMP; Raja S, 2008, P ROY SOC B-BIOL SCI, V275, P1603, DOI 10.1098/rspb.2008.0136; Rodriguez C, 1999, EVOLUTION, V53, P612, DOI 10.2307/2640797; Ronsted N, 2005, P ROY SOC B-BIOL SCI, V272, P2593, DOI 10.1098/rspb.2005.3249; Ruby EG, 1999, TRENDS MICROBIOL, V7, P414, DOI 10.1016/S0966-842X(99)01588-7; Ruf C, 2000, NATURWISSENSCHAFTEN, V87, P193, DOI 10.1007/s001140050702; Sachs JL, 2006, P ROY SOC B-BIOL SCI, V273, P425, DOI 10.1098/rspb.2005.3346; Schultz TR, 2008, P NATL ACAD SCI USA, V105, P5435, DOI 10.1073/pnas.0711024105; Stillman RA, 1997, J ANIM ECOL, V66, P692, DOI 10.2307/5922; Sutherland W.J., 1996, INDIVIDUAL BEHAV POP; van Baalen M, 2001, OIKOS, V95, P211, DOI 10.1034/j.1600-0706.2001.950203.x; Vigneux F, 2008, J EVOLUTION BIOL, V21, P1245, DOI 10.1111/j.1420-9101.2008.01576.x; Wall DH, 1999, BIOSCIENCE, V49, P109, DOI 10.2307/1313536; Wang RW, 2008, J ANIM ECOL, V77, P616, DOI 10.1111/j.1365-2656.2008.01359.x; Wang RW, 2005, J INTEGR PLANT BIOL, V47, P144, DOI 10.1111/j.1744-7909.2005.00034.x; Weiblen GD, 2002, ANNU REV ENTOMOL, V47, P299, DOI 10.1146/annurev.ento.47.091201.145213; Weiblen GD, 2001, P ROY SOC B-BIOL SCI, V268, P651, DOI 10.1098/rspb.2000.1389; West SA, 2002, J EVOLUTION BIOL, V15, P830, DOI 10.1046/j.1420-9101.2002.00441.x; West SA, 2002, P ROY SOC B-BIOL SCI, V269, P685, DOI 10.1098/rspb.2001.1878; WIEBES JT, 1979, ANNU REV ECOL SYST, V10, P1, DOI 10.1146/annurev.es.10.110179.000245; WILLIAMS GC, 1991, Q REV BIOL, V66, P1, DOI 10.1086/417048; YAMAMURA N, 1993, THEOR POPUL BIOL, V44, P95, DOI 10.1006/tpbi.1993.1020; Yang Da-ron, 2000, Forest Research, V13, P477; Yu DW, 2004, P ROY SOC B-BIOL SCI, V271, P1185, DOI 10.1098/rspb.2003.2630	72	40	49	5	48	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	NOV 12	2009	4	11							e7802	10.1371/journal.pone.0007802	http://dx.doi.org/10.1371/journal.pone.0007802			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	518UW	19915668	Green Published, gold, Green Submitted			2022-12-25	WOS:000271721400005
J	Campos, JL; Siegle, JH; Mohler, BJ; Bulthoff, HH; Loomis, JM				Campos, Jennifer L.; Siegle, Joshua H.; Mohler, Betty J.; Buelthoff, Heinrich H.; Loomis, Jack M.			Imagined Self-Motion Differs from Perceived Self-Motion: Evidence from a Novel Continuous Pointing Method	PLOS ONE			English	Article							MOTOR IMAGERY; MENTAL PRACTICE; IDIOTHETIC NAVIGATION; VISUAL-PERCEPTION; PATH-INTEGRATION; TRAVEL DISTANCE; NONVISUAL CUES; OPTIC FLOW; MOVEMENT; LOCOMOTION	Background: The extent to which actual movements and imagined movements maintain a shared internal representation has been a matter of much scientific debate. Of the studies examining such questions, few have directly compared actual full-body movements to imagined movements through space. Here we used a novel continuous pointing method to a) provide a more detailed characterization of self-motion perception during actual walking and b) compare the pattern of responding during actual walking to that which occurs during imagined walking. Methodology/Principal Findings: This continuous pointing method requires participants to view a target and continuously point towards it as they walk, or imagine walking past it along a straight, forward trajectory. By measuring changes in the pointing direction of the arm, we were able to determine participants' perceived/imagined location at each moment during the trajectory and, hence, perceived/imagined self-velocity during the entire movement. The specific pattern of pointing behaviour that was revealed during sighted walking was also observed during blind walking. Specifically, a peak in arm azimuth velocity was observed upon target passage and a strong correlation was observed between arm azimuth velocity and pointing elevation. Importantly, this characteristic pattern of pointing was not consistently observed during imagined self-motion. Conclusions/Significance: Overall, the spatial updating processes that occur during actual self-motion were not evidenced during imagined movement. Because of the rich description of self-motion perception afforded by continuous pointing, this method is expected to have significant implications for several research areas, including those related to motor imagery and spatial cognition and to applied fields for which mental practice techniques are common (e.g. rehabilitation and athletics).			Campos, JL (corresponding author), Toronto Rehabil Inst, iDAPT Technol Res & Dev, Toronto, ON, Canada.	campos.jennifer@torontorehab.on.ca	Bülthoff, Heinrich H/J-6579-2012; Bülthoff, Heinrich/AAC-8818-2019	Bülthoff, Heinrich H/0000-0003-2568-0607; 				Allen GL, 2004, PERCEPT PSYCHOPHYS, V66, P170, DOI 10.3758/BF03194870; Bakker M, 2007, EXP BRAIN RES, V179, P497, DOI 10.1007/s00221-006-0807-x; BERTHOZ A, 1995, SCIENCE, V269, P95, DOI 10.1126/science.7604286; Bertin RJV, 2004, EXP BRAIN RES, V154, P11, DOI 10.1007/s00221-003-1524-3; Bremmer F, 1999, EXP BRAIN RES, V127, P33, DOI 10.1007/s002210050771; Courtine G, 2004, COGNITIVE BRAIN RES, V22, P67, DOI 10.1016/j.cogbrainres.2004.07.008; DECETY J, 1989, BRAIN COGNITION, V11, P87, DOI 10.1016/0278-2626(89)90007-9; DECETY J, 1989, BEHAV BRAIN RES, V34, P35, DOI 10.1016/S0166-4328(89)80088-9; DECETY J, 1991, BEHAV BRAIN RES, V42, P1, DOI 10.1016/S0166-4328(05)80033-6; Decety J, 1996, BEHAV BRAIN RES, V77, P45, DOI 10.1016/0166-4328(95)00225-1; DECETY J, 1990, EUR ARCH PSY CLIN N, V240, P39, DOI 10.1007/BF02190091; Dichgans Johannes, 1978, PERCEPTION, P755, DOI DOI 10.1007/978-3-642-46354-9_25; Dickstein R, 2007, PHYS THER, V87, P942, DOI 10.2522/ptj.20060331; Dietrich A, 2008, METHODS, V45, P319, DOI 10.1016/j.ymeth.2008.04.004; DRISKELL JE, 1994, J APPL PSYCHOL, V79, P481, DOI 10.1037/0021-9010.79.4.481; Ellard CG, 2003, PERCEPTION, V32, P567, DOI 10.1068/p5041; ELLIOTT D, 1986, J EXP PSYCHOL HUMAN, V12, P388, DOI 10.1037/0096-1523.12.3.388; FELTZ DL, 1983, J SPORT PSYCHOL, V5, P25, DOI 10.1123/jsp.5.1.25; Frenz H, 2005, VISION RES, V45, P1679, DOI 10.1016/j.visres.2004.12.019; Frenz H, 2003, VISION RES, V43, P2173, DOI 10.1016/S0042-6989(03)00337-7; Fukusima SS, 1997, J EXP PSYCHOL HUMAN, V23, P86, DOI 10.1037/0096-1523.23.1.86; GOODALE MA, 1994, NEUROPSYCHOLOGIA, V32, P1159, DOI 10.1016/0028-3932(94)90100-7; Guillot A, 2005, BRAIN RES REV, V50, P387, DOI 10.1016/j.brainresrev.2005.09.004; Guillot A, 2005, J MOTOR BEHAV, V37, P10, DOI 10.3200/JMBR.37.1.10-20; Hall C. R., 1997, J MENTAL IMAG, V21, P143, DOI DOI 10.1037/T07979-000; Harris LR, 2000, EXP BRAIN RES, V135, P12, DOI 10.1007/s002210000504; Hettinger LJ, 2002, HUM FAC ER, P471; Howard I. P., 1986, HDB HUMAN PERCEPTION, V1, P181; Isaac A.R., 1986, J MENT IMAG, V10, P23, DOI DOI 10.1037/T07980-000; Ivanenko YP, 1997, J PHYSIOL-LONDON, V502, P223, DOI 10.1111/j.1469-7793.1997.223bl.x; Jackson PL, 2001, ARCH PHYS MED REHAB, V82, P1133, DOI 10.1053/apmr.2001.24286; Jahn K, 2004, NEUROIMAGE, V22, P1722, DOI 10.1016/j.neuroimage.2004.05.017; JEANNEROD M, 1994, BEHAV BRAIN SCI, V17, P187, DOI 10.1017/S0140525X00034026; Kallie CS, 2007, J EXP PSYCHOL HUMAN, V33, P183, DOI 10.1037/0096-1523.33.1.183; Klatzky RL, 1998, PSYCHOL SCI, V9, P293, DOI 10.1111/1467-9280.00058; Kosslyn SM, 2001, NAT REV NEUROSCI, V2, P635, DOI 10.1038/35090055; KUNZ BR, J EXP PSYCH IN PRESS; Lappe M, 2007, EXP BRAIN RES, V180, P35, DOI 10.1007/s00221-006-0835-6; Loomis Jack M., 2008, EMBODIMENT EGOSPACE; LOOMIS JM, 1992, J EXP PSYCHOL HUMAN, V18, P906, DOI 10.1037/0096-1523.18.4.906; May M, 1996, MEMORY AND PROCESSING OF VISUAL AND SPATIAL INFORMATION, P418; Mittelstaedt ML, 2001, EXP BRAIN RES, V139, P318, DOI 10.1007/s002210100735; MITTELSTAEDT ML, 1991, ZOOL JAHRB ALLG ZOOL, V95, P427; Ooi TL, 2006, PERCEPTION, V35, P605, DOI 10.1068/p5492; Papaxanthis C, 2002, BEHAV BRAIN RES, V134, P209, DOI 10.1016/S0166-4328(02)00030-X; Plumert JM., 2005, ACM T APPL PERCEPT, V2, P216, DOI [10.1145/1077399.1077402, DOI 10.1145/1077399.1077402]; Pylyshyn ZW, 2002, BEHAV BRAIN SCI, V25, P157, DOI 10.1017/S0140525X02000043; Redlick FP, 2001, VISION RES, V41, P213, DOI 10.1016/S0042-6989(00)00243-1; Riecke BE, 2002, PRESENCE-VIRTUAL AUG, V11, P443, DOI 10.1162/105474602320935810; RIESER JJ, 1990, PERCEPTION, V19, P675, DOI 10.1068/p190675; RIESER JJ, 1989, J EXP PSYCHOL LEARN, V15, P1157, DOI 10.1037/0278-7393.15.6.1157; SEGAL SJ, 1970, J EXP PSYCHOL, V83, P458, DOI 10.1037/h0028840; Seidman SH, 2008, EXP BRAIN RES, V184, P13, DOI 10.1007/s00221-007-1072-3; Sharma N, 2006, STROKE, V37, P1941, DOI 10.1161/01.STR.0000226902.43357.fc; SHOLL MJ, 1989, J EXP PSYCHOL LEARN, V15, P110, DOI 10.1037/0278-7393.15.1.110; Siegle JH, 2009, EXP BRAIN RES, V195, P429, DOI 10.1007/s00221-009-1805-6; STEENHUIS RE, 1988, J MOTOR BEHAV, V20, P399; Stevens JA, 2005, COGNITION, V95, P329, DOI 10.1016/j.cognition.2004.02.008; Sun HJ, 2004, PERCEPTION, V33, P49, DOI 10.1068/p5145; Sun HJ, 2004, EXP BRAIN RES, V154, P246, DOI 10.1007/s00221-003-1652-9; Szameitat AJ, 2007, NEUROIMAGE, V34, P702, DOI 10.1016/j.neuroimage.2006.09.033; THOMSON JA, 1983, J EXP PSYCHOL HUMAN, V9, P427, DOI 10.1037/0096-1523.9.3.427; Waller D, 2007, PSYCHOL RES-PSYCH FO, V71, P322, DOI 10.1007/s00426-006-0087-x; YAMAMOTO N, 2008, J VIS, V8, P1149; Yong NA, 2007, J NEUROPHYSIOL, V97, P1100, DOI 10.1152/jn.00694.2006	65	20	20	0	11	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	NOV 11	2009	4	11					A163	A173	e7793	10.1371/journal.pone.0007793	http://dx.doi.org/10.1371/journal.pone.0007793			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	518IX	19907655	Green Published, gold			2022-12-25	WOS:000271685800018
J	Miller, K; Kim, A; Kilimnik, G; Jo, J; Moka, U; Periwal, V; Hara, M				Miller, Kevin; Kim, Abraham; Kilimnik, German; Jo, Junghyo; Moka, Uchenna; Periwal, Vipul; Hara, Manami			Islet Formation during the Neonatal Development in Mice	PLOS ONE			English	Article							PANCREATIC BETA-CELLS; ENDOCRINE PANCREAS; REGENERATION; PROGENITORS; POLYPEPTIDE; LANGERHANS; SECRETION; GHRELIN; INVOLVE	The islet of Langerhans is a unique micro-organ within the exocrine pancreas, which is composed of insulin-secreting beta-cells, glucagon-secreting alpha-cells, somatostatin-secreting delta-cells, pancreatic polypeptide-secreting PP cells and ghrelin-secreting epsilon-cells. Islets also contain non-endocrine cell types such as endothelial cells. However, the mechanism(s) of islet formation is poorly understood due to technical difficulties in capturing this dynamic event in situ. We have developed a method to monitor beta-cell proliferation and islet formation in the intact pancreas using transgenic mice in which the beta-cells are specifically tagged with a fluorescent protein. Endocrine cells proliferate contiguously, forming branched cord-like structures in both embryos and neonates. Our study has revealed long stretches of interconnected islets located along large blood vessels in the neonatal pancreas. Alpha-cells span the elongated islet-like structures, which we hypothesize represent sites of fission and facilitate the eventual formation of discrete islets. We propose that islet formation occurs by a process of fission following contiguous endocrine cell proliferation, rather than by local aggregation or fusion of isolated beta-cells and islets. Mathematical modeling of the fission process in the neonatal islet formation is also presented.			Miller, K (corresponding author), Univ Chicago, Dept Med, 5841 S Maryland Ave, Chicago, IL 60637 USA.	mhara@midway.uchicago.edu	Periwal, Vipul/I-1728-2012; Hara, Masayuki/AAH-4361-2019; Jo, Junghyo/D-4889-2011		NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK020595, P60DK020595, R56DK081527, ZIADK075038] Funding Source: NIH RePORTER; NIDDK NIH HHS [R56 DK081527, DK-081527, P30 DK020595, P60 DK020595, DK-20595] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BAETENS D, 1978, DIABETES, V27, P1, DOI 10.2337/diabetes.27.1.1; BAETENS D, 1979, SCIENCE, V206, P1323, DOI 10.1126/science.390711; Bock T, 2003, DIABETES, V52, P1716, DOI 10.2337/diabetes.52.7.1716; BONNERWEIR S, 1988, DIABETES, V37, P616, DOI 10.2337/diabetes.37.5.616; Bouwens L, 1996, J HISTOCHEM CYTOCHEM, V44, P947, DOI 10.1177/44.9.8773559; Brennand K, 2007, PLOS BIOL, V5, P1520, DOI 10.1371/journal.pbio.0050163; Broglio F, 2006, FRONT HORM RES, V35, P102, DOI 10.1159/000094313; Dor Y, 2004, NATURE, V429, P41, DOI 10.1038/nature02520; FLOYD JC, 1980, CLIN GASTROENTEROL, V9, P657; Gromada J, 2007, ENDOCR REV, V28, P84, DOI 10.1210/er.2006-0007; Gu GQ, 2002, DEVELOPMENT, V129, P2447; Hara M, 2003, AM J PHYSIOL-ENDOC M, V284, pE177, DOI 10.1152/ajpendo.00321.2002; Hara M, 2006, AM J PHYSIOL-ENDOC M, V290, pE1041, DOI 10.1152/ajpendo.00365.2005; HERRERA PL, 1991, DEVELOPMENT, V113, P1257; Hill JT, 2009, REGUL PEPTIDES, V157, P51, DOI 10.1016/j.regpep.2009.02.013; Jensen J, 2004, DEV DYNAM, V229, P176, DOI 10.1002/dvdy.10460; Kendall M.G., 1958, DISTRIBUTION THEORY, V1; Kharouta M, 2009, DIABETES RES CLIN PR, V85, P252, DOI 10.1016/j.diabres.2009.06.021; Kim A, 2009, ISLETS, V1, P129, DOI 10.4161/isl.1.2.9480; Lammert E, 2003, MECH DEVELOP, V120, P59, DOI 10.1016/S0925-4773(02)00332-5; Lee CS, 2006, DIABETES, V55, P269; LONOVICS J, 1981, ARCH SURG-CHICAGO, V116, P1256; ORCI L, 1975, LANCET, V2, P1243, DOI 10.1016/S0140-6736(75)92078-4; PICTET R, 1972, HDB PHYSL ENDOCRINOL, V7, P25; Quesada I, 2008, J ENDOCRINOL, V199, P5, DOI 10.1677/JOE-08-0290; SAMOLS E, 1986, CLIN ENDOCRINOL META, V15, P33, DOI 10.1016/S0300-595X(86)80041-X; Teta M, 2007, DEV CELL, V12, P817, DOI 10.1016/j.devcel.2007.04.011; WEIR GC, 1990, J CLIN INVEST, V85, P983, DOI 10.1172/JCI114574; WEIR GC, 1985, ADV EXP MED BIOL, V188, P403; Xu XB, 2008, CELL, V132, P197, DOI 10.1016/j.cell.2007.12.015	30	54	58	2	6	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	NOV 6	2009	4	11							e7739	10.1371/journal.pone.0007739	http://dx.doi.org/10.1371/journal.pone.0007739			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	515ND	19893748	Green Published, gold, Green Submitted			2022-12-25	WOS:000271478000012
J	Cheng, D; Tsai, SJ; Hong, CJ; Yang, AC				Cheng, Daniel; Tsai, Shih-Jen; Hong, Chen-Jee; Yang, Albert C.			Reduced Physiological Complexity in Robust Elderly Adults with the APOE epsilon 4 Allele	PLOS ONE			English	Article							HEART-RATE-VARIABILITY; APOLIPOPROTEIN-E POLYMORPHISM; ALZHEIMERS-DISEASE; CHANGING COMPLEXITY; COGNITIVE FUNCTION; BRAIN ATROPHY; E PHENOTYPES; ASSOCIATION; GENOTYPE; DYNAMICS	Background: It is unclear whether the loss of physiological complexity during the aging process is due to genetic variations. The APOE gene has been studied extensively in regard to its relationship with aging-associated medical illness. We hypothesize that diminished physiological complexity, as measured by heart rate variability, is influenced by polymorphisms in the APOE allele among elderly individuals. Methodology/Principal Findings: A total of 102 robust, non-demented, elderly subjects with normal functions of daily activities participated in this study (97 males and 5 females, aged 79.2 +/- 4.4 years, range 72-92 years). Among these individuals, the following two APOE genotypes were represented: epsilon 4 non-carriers (n = 87, 85.3%) and epsilon 4 carriers (n = 15, 14.7%). Multi-scale entropy (MSE), an analysis used in quantifying complexity for nonlinear time series, was employed to analyze heart-rate dynamics. Reduced physiological complexity, as measured by MSE, was significantly associated with the presence of the APOE epsilon 4 allele in healthy elderly subjects, as compared to APOE epsilon 4 allele non-carriers (24.6 +/- 5.5 versus28.9 +/- 5.2, F = 9.429, p = 0.003, respectively). Conclusions/Significance: This finding suggests a role for the APOE gene in the diminished physiological complexity seen in elderly populations.			Cheng, D (corresponding author), Univ Calif Los Angeles, Dept Microbiol Immunol & Mol Genet, Los Angeles, CA 90095 USA.	ccyang@physionet.org	Tsai, Shih-Jen/AAK-7944-2020	Tsai, Shih-Jen/0000-0002-9987-022X				Bar-yam Y., 2019, DYNAMICS COMPLEX SYS; Camm AJ, 1996, CIRCULATION, V93, P1043; Chiu KM, 2007, AUTON NEUROSCI-BASIC, V132, P76, DOI 10.1016/j.autneu.2006.10.008; Christensen Helen, 2008, BMC Geriatr, V8, P14, DOI 10.1186/1471-2318-8-14; CORDER EH, 1993, SCIENCE, V261, P921, DOI 10.1126/science.8346443; Costa M, 2005, PHYS REV E, V71, DOI 10.1103/PhysRevE.71.021906; Costa M, 2002, PHYS REV LETT, V89, DOI 10.1103/PhysRevLett.89.068102; Enzinger C, 2004, ANN NEUROL, V55, P563, DOI 10.1002/ana.20027; Geroldi C, 1999, NEUROLOGY, V53, P1825, DOI 10.1212/WNL.53.8.1825; Ghebremedhin E, 2001, NEUROLOGY, V56, P1696, DOI 10.1212/WNL.56.12.1696; Goldberger AL, 2002, NEUROBIOL AGING, V23, P23, DOI 10.1016/S0197-4580(01)00266-4; Goldberger AL, 2002, P NATL ACAD SCI USA, V99, P2466, DOI 10.1073/pnas.012579499; Goldberger AL, 2000, CIRCULATION, V101, pE215, DOI 10.1161/01.CIR.101.23.e215; Goldberger JJ, 2001, CIRCULATION, V103, P1977; HALLMAN DM, 1991, AM J HUM GENET, V49, P338; Ho KKL, 1997, CIRCULATION, V96, P842; Hong CJ, 1996, NEUROLOGY, V46, P1749, DOI 10.1212/WNL.46.6.1749; Huang NE, 1998, P ROY SOC A-MATH PHY, V454, P903, DOI 10.1098/rspa.1998.0193; Isoniemi H, 2006, NEUROLOGY, V67, P756, DOI 10.1212/01.wnl.0000234140.64954.12; Jak AJ, 2007, DEMENT GERIATR COGN, V23, P382, DOI 10.1159/000101340; KATONA PG, 1975, J APPL PHYSIOL, V39, P801, DOI 10.1152/jappl.1975.39.5.801; Kirkwood TBL, 2002, NEUROBIOL AGING, V23, P21, DOI 10.1016/S0197-4580(01)00260-3; KUUSISTO J, 1994, BRIT MED J, V309, P636, DOI 10.1136/bmj.309.6955.636; Liu HC, 1999, NEUROLOGY, V53, P962, DOI 10.1212/WNL.53.5.962; Makikallio TH, 1999, AM J CARDIOL, V83, P880, DOI 10.1016/S0002-9149(98)01068-6; MALLIANI A, 1994, BRIT HEART J, V71, P1; Mietus JE, 2002, HEART, V88, P378, DOI 10.1136/heart.88.4.378; Mortensen EL, 2001, NEUROLOGY, V57, P89, DOI 10.1212/WNL.57.1.89; MYERS RH, 1996, FRAMINGHM STUDY NEUR, V46, P673; Park SK, 2006, CIRCULATION, V114, P2798, DOI 10.1161/CIRCULATIONAHA.106.643197; Peng Chung-Kang, 1994, Integrative Physiological and Behavioral Science, V29, P283, DOI 10.1007/BF02691332; POMERANZ B, 1985, AM J PHYSIOL, V248, pH151, DOI 10.1152/ajpheart.1985.248.1.H151; REED T, 1994, ARCH NEUROL-CHICAGO, V51, P1189, DOI 10.1001/archneur.1994.00540240033012; Rosvall L, 2009, NEUROBIOL AGING, V30, P1545, DOI 10.1016/j.neurobiolaging.2007.12.003; Slooter AJC, 1998, ARCH NEUROL-CHICAGO, V55, P964, DOI 10.1001/archneur.55.7.964; STENGARD JH, 1995, CIRCULATION, V91, P265, DOI 10.1161/01.CIR.91.2.265; Tapanainen JM, 2002, AM J CARDIOL, V90, P347, DOI 10.1016/S0002-9149(02)02488-8; Tsai SJ, 2008, NEUROSCI LETT, V433, P158, DOI 10.1016/j.neulet.2007.12.057; TSUJI H, 1994, CIRCULATION, V90, P878, DOI 10.1161/01.CIR.90.2.878; UTERMANN G, 1984, HUM GENET, V65, P237, DOI 10.1007/BF00286509; Vaillancourt DE, 2002, NEUROBIOL AGING, V23, P1, DOI 10.1016/S0197-4580(01)00247-0; WENHAM PR, 1991, LANCET, V337, P1158, DOI 10.1016/0140-6736(91)92823-K; WILSON PWF, 1994, JAMA-J AM MED ASSOC, V272, P1666, DOI 10.1001/jama.272.21.1666; Wu ZH, 2007, P NATL ACAD SCI USA, V104, P14889, DOI 10.1073/pnas.0701020104; Yang ACC, 2008, J AM GERIATR SOC, V56, P958, DOI 10.1111/j.1532-5415.2008.01662.x; Yeh GY, 2008, SLEEP MED, V9, P527, DOI 10.1016/j.sleep.2007.06.003; Yeh GY, 2004, AM J MED, V117, P541, DOI 10.1016/j.amjmed.2004.04.016	47	23	23	0	1	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	NOV 5	2009	4	11							e7733	10.1371/journal.pone.0007733	http://dx.doi.org/10.1371/journal.pone.0007733			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	515HI	19890394	Green Published, Green Submitted, gold			2022-12-25	WOS:000271459700017
J	Fletcher, N; Storey, EJ; Johnson, M; Reish, DJ; Hardege, JD				Fletcher, Nichola; Storey, Ellen J.; Johnson, Magnus; Reish, Donald J.; Hardege, Joergt D.			Experience Matters: Females Use Smell to Select Experienced Males for Paternal Care	PLOS ONE			English	Article							MATE CHOICE; SEXUAL SELECTION; PARENTAL CARE; REPRODUCTIVE ISOLATION; RAPID SPECIATION; FOUNDER EVENT; EVOLUTION; DOMINANT; BEHAVIOR; SUCCESS	Mate choice and mating preferences often rely on the information content of signals exchanged between potential partners. In species where a female's reproduction is the terminal event in life it is to be expected that females choose high quality males and assess males using some honest indicator of male quality. The Nereidid polychaete, Neanthes acuminata, exhibits monogamous pairing and the release of eggs by females terminates her life and larval success relies entirely on a male's ability to provide paternal care. As such females should have developed reliable, condition-dependent criteria to choose mates to guarantee survival and care for offspring. We show that females actively chose males experienced in fatherhood over others. In the absence of experienced males dominance, as evident from male-male fights, is utilized for mate selection. The preference for experienced males is not affected by previous social interactions between the individuals. We show that the choice of the partner is based on chemical signals demonstrating a 'scent of experience' to females providing evidence for the role of chemical signals in sexual selection for paternal care adding to our understanding of the mechanisms regulating condition-dependent mate choice.			Fletcher, N (corresponding author), Univ Hull, Dept Biol Sci, Kingston Upon Hull HU6 7RX, N Humberside, England.	j.d.hardege@hull.ac.uk		Johnson, Magnus/0000-0002-8163-4026				ANDERSSON M, 1982, BIOL J LINN SOC, V17, P375, DOI 10.1111/j.1095-8312.1982.tb02028.x; Bailey NW, 2008, BEHAV ECOL, V19, P960, DOI 10.1093/beheco/arn054; Brooks R, 2001, TRENDS ECOL EVOL, V16, P308, DOI 10.1016/S0169-5347(01)02147-4; COLLINS SA, 1995, ANIM BEHAV, V49, P479, DOI 10.1006/anbe.1995.0062; Cooke SJ, 2003, J THERM BIOL, V28, P445, DOI 10.1016/S0306-4565(03)00038-X; Cotton S, 2006, CURR BIOL, V16, pR755, DOI 10.1016/j.cub.2006.08.022; Darwin Charles, 1871, DESCENT MAN SEXUAL S; DRICKAMER LC, 1992, ANIM BEHAV, V43, P868, DOI 10.1016/S0003-3472(05)80212-X; Forsgren E, 1997, P ROY SOC B-BIOL SCI, V264, P1283, DOI 10.1098/rspb.1997.0177; Guevara-Fiore P, 2009, ANIM BEHAV, V77, P425, DOI 10.1016/j.anbehav.2008.10.018; Hale RE, 2008, ANIM BEHAV, V75, P1283, DOI 10.1016/j.anbehav.2007.09.034; Hardege JD, 2004, PEPTIDES, V25, P1517, DOI 10.1016/j.peptides.2003.11.029; Howard RW, 2003, J CHEM ECOL, V29, P961, DOI 10.1023/A:1022992002239; Jennions MD, 1997, BIOL REV, V72, P283, DOI 10.1017/S0006323196005014; Johansson BG, 2007, BIOL REV, V82, P265, DOI 10.1111/j.1469-185X.2007.00009.x; Johnstone RA, 1996, EVOLUTION, V50, P1382, DOI [10.2307/2410876, 10.1111/j.1558-5646.1996.tb03912.x]; KIRKPATRICK M, 1982, EVOLUTION, V36, P1, DOI 10.1111/j.1558-5646.1982.tb05003.x; Kodric-Brown A, 2001, AM NAT, V157, P316, DOI 10.1086/319191; Kokko H, 2008, CURR BIOL, V18, pR121, DOI 10.1016/j.cub.2007.11.063; Kvarnemo C, 1995, ANIM BEHAV, V50, P1455, DOI 10.1016/0003-3472(95)80002-6; Martin J, 2000, P ROY SOC B-BIOL SCI, V267, P1265, DOI 10.1098/rspb.2000.1137; Martin OY, 2003, NATURE, V423, P979, DOI 10.1038/nature01752; Moore AJ, 1999, P ROY SOC B-BIOL SCI, V266, P711, DOI 10.1098/rspb.1999.0694; Pampoulie C, 2004, BEHAV ECOL, V15, P199, DOI 10.1093/beheco/arg107; POOLE JH, 1989, ANIM BEHAV, V37, P842, DOI 10.1016/0003-3472(89)90068-7; Proulx SR, 2001, EVOLUTION, V55, P2401; Qvarnstrom A, 1998, TRENDS ECOL EVOL, V13, P498, DOI 10.1016/S0169-5347(98)01513-4; Ram JL, 2008, J EXP BIOL, V211, P757, DOI 10.1242/jeb.012773; Reburn CJ, 1999, HORM BEHAV, V35, P163, DOI 10.1006/hbeh.1998.1509; REISH D J, 1968, Bulletin Southern California Academy of Sciences, V67, P21; REISH DJ, 1985, TETHYS, V11, P335; REISH DONALD J., 1957, PACIFIC SCI, V11, P216; RIDLEY M, 1978, ANIM BEHAV, V26, P904, DOI 10.1016/0003-3472(78)90156-2; RodriguezTrelles F, 1996, EVOLUTION, V50, P457, DOI 10.1111/j.1558-5646.1996.tb04509.x; Schradin C, 1999, NEWS PHYSIOL SCI, V14, P223, DOI 10.1152/physiologyonline.1999.14.6.223; Shackleton MA, 2005, BEHAV ECOL SOCIOBIOL, V58, P1, DOI 10.1007/s00265-004-0907-1; Starczak VR, 1984, THESIS U CONNECTICUT; Sutton R, 2005, J CHEM ECOL, V31, P1865, DOI 10.1007/s10886-005-5931-8; Tallamy DW, 2001, ANNU REV ENTOMOL, V46, P139, DOI 10.1146/annurev.ento.46.1.139; Van Alphen JJM, 2001, J EVOLUTION BIOL, V14, P874, DOI 10.1046/j.1420-9101.2001.00343.x; WEINBERG JR, 1992, EVOLUTION, V46, P1214, DOI 10.1111/j.1558-5646.1992.tb00629.x; WEINBERG JR, 1990, MAR BIOL, V107, P205, DOI 10.1007/BF01319819; Wong BBM, 2004, ANIM BEHAV, V67, P583, DOI 10.1016/j.anbehav.2003.08.015; Wong BBM, 2005, BIOL REV, V80, P559, DOI 10.1017/S1464793105006809; ZEH DW, 1985, AM ZOOL, V25, P785	45	9	9	0	10	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	NOV 4	2009	4	11							e7672	10.1371/journal.pone.0007672	http://dx.doi.org/10.1371/journal.pone.0007672			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	514RZ	19888341	Green Published, Green Submitted, gold			2022-12-25	WOS:000271414600005
J	Bangham, A				Bangham, Alec			The physical chemistry of self/non-self: jigsaws, transplants and fetuses	FASEB JOURNAL			English	Editorial Material									Great Shelford, Cambridge CB2 5EG, England		Bangham, A (corresponding author), Great Shelford, 17 High Green, Cambridge CB2 5EG, England.	alecbangham@wwr.co.uk						Abramson HA, 1942, ELECTROPHORESIS PROT; Bangham AD, 2008, J LIPOSOME RES, V18, P91, DOI [10.1080/08982100801894034, 10.1080/08982100801894034 ]; BANGHAM AD, 1959, BIOCHEM J, V72, P486, DOI 10.1042/bj0720486; BANGHAM AD, 1983, BIOL CELL, V47, P1; BANGHAM AD, 1958, BIOCHEM J, V69, P12, DOI 10.1042/bj0690012; Bangham AD, 2001, J LIPOSOME RES, V11, P265; BANGHAM DH, 1949, FUEL 28, V10, P31; Calne Roy, 1998, ULTIMATE GIFT STORY; Fehr T, 2008, TRANSPL INT, V21, P1118, DOI 10.1111/j.1432-2277.2008.00783.x; Kawai T, 2008, NEW ENGL J MED, V358, P353, DOI 10.1056/NEJMoa071074; Lasic DD, 1995, STEALTH LIPOSOMES; Penn DJ, 2007, J R SOC INTERFACE, V4, P331, DOI 10.1098/rsif.2006.0182; SINGH PB, 1987, NATURE, V327, P161, DOI 10.1038/327161a0; Smith D, 2005, MASS SPECTROM REV, V24, P661, DOI 10.1002/mas.20033	14	1	1	0	2	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	NOV	2009	23	11					3644	3646		10.1096/fj.09-1102ufm	http://dx.doi.org/10.1096/fj.09-1102ufm			3	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	512TC	19875638				2022-12-25	WOS:000271272500002
J	Li, FQ; Tian, F; Wang, L; Williamson, IK; Sharifi, BG; Shah, PK				Li, Fuqiang; Tian, Fang; Wang, Lai; Williamson, Ian K.; Sharifi, Behrooz G.; Shah, Prediman K.			Pleiotrophin (PTN) is expressed in vascularized human atherosclerotic plaques: IFN-gamma/JAK/STAT1 signaling is critical for the expression of PTN in macrophages	FASEB JOURNAL			English	Article						plaque angiogenesis; neovascularization; vasculogenic mimicry	AFFIN REGULATORY PEPTIDE; GROWTH-FACTOR PLEIOTROPHIN; HUMAN CORONARY-ARTERIES; HUMAN PROSTATE-CANCER; CELL-PROLIFERATION; ENDOTHELIAL-CELLS; INTERFERON-GAMMA; GENE-EXPRESSION; VASCULOGENIC MIMICRY; UP-REGULATION	Neovascularization is critical to destabilization of atheroma. We previously reported that the angiogenic growth factor pleiotrophin (PTN) coaxes monocytes to assume the phenotype of functional endothelial cells in vitro and in vivo. In this study we show that PTN expression is colocalized with capillaries of human atherosclerotic plaques. Among the various reagents that are critical to the pathogenesis of atherosclerosis, interferon (IFN)-gamma was found to markedly induce PTN mRNA expression in a dose-dependent manner in macrophages. Mechanistic studies revealed that the Janus kinase inhibitors, WHI-P154 and ATA, efficiently blocked STAT1 phosphorylation in a concentration-and time-dependent manner. Notably, the level of phosphorylated STAT1 was found to correlate directly with the PTN mRNA levels. In addition, STAT1/STAT3/p44/42 signaling molecules were found to be phosphorylated by IFN-gamma in macrophages, and they were translocated into the nucleus. Further, PTN promoter analysis showed that a gamma-activated sequence (GAS) located at -2086 to -2078 bp is essential for IFN-gamma-regulated promoter activity. Moreover, electrophoretic mobility shift, supershift, and chromatin immunoprecipitation analyses revealed that both STAT1 and STAT3 bind to the GAS at the chromatin level in the IFN-gamma stimulated cells. Finally, to test whether the combined effect of STAT1/STAT3/p44/42 signaling is required for the expression of PTN in macrophages, gene knockdowns of these transcription factors were performed using siRNA. Cells lacking STAT1, but not STAT3 or p42, have markedly reduced PTN mRNA levels. These data suggest that PTN expression in the human plaques may be in part regulated by IFN-gamma and that PTN is involved in the adaptive immunity.-Li, F., Tian, F., Wang, L., Williamson, I. K., Sharifi, B. G., Shah, P. K. Pleiotrophin (PTN) is expressed in vascularized human atherosclerotic plaques: IFN-gamma/JAK/STAT1 signaling is critical for the expression of PTN in macrophages FASEB J.24, 810-822 (2010). www.fasebj.org	[Li, Fuqiang; Tian, Fang; Wang, Lai; Williamson, Ian K.; Sharifi, Behrooz G.; Shah, Prediman K.] Cedars Sinai Med Ctr, Div Cardiol, Atherosclerosis Res Ctr, Burns & Allen Res Inst, Los Angeles, CA 90048 USA	Cedars Sinai Medical Center	Sharifi, BG (corresponding author), Cedars Sinai Med Ctr, Div Cardiol, Atherosclerosis Res Ctr, Burns & Allen Res Inst, Davis Bldg 1016,8700 Beverly Blvd, Los Angeles, CA 90048 USA.	sharifi@cshs.org			U.S. National Institutes of Health [RO1 HL050566, RO1 HL090653]; Spielberg Research Fund; Heart Foundation; Corday Foundation; Feintech Foundation; Shapell and Guerin Foundation; United Hostesses; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL090653, R01HL050566, R01HL104068] Funding Source: NIH RePORTER	U.S. National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Spielberg Research Fund; Heart Foundation; Corday Foundation; Feintech Foundation; Shapell and Guerin Foundation; United Hostesses; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))	This work was supported by the U.S. National Institutes of Health (grants RO1 HL050566 and RO1 HL090653), the Spielberg Research Fund, the Heart Foundation, the Corday Foundation, the Feintech Foundation, the Shapell and Guerin Foundation, and United Hostesses.	Achour A., 2001, Cellular and Molecular Biology Online Papers, V47, pOL73; Arras M, 1998, J CLIN INVEST, V101, P40, DOI 10.1172/JCI119877; BARGER AC, 1984, NEW ENGL J MED, V310, P175, DOI 10.1056/NEJM198401193100307; BARGER AC, 1990, AM J CARDIOL, V66, P41; Buono C, 2003, ARTERIOSCL THROM VAS, V23, P454, DOI 10.1161/01.ATV.0000059419.11002.6E; Chang YS, 2000, P NATL ACAD SCI USA, V97, P14608, DOI 10.1073/pnas.97.26.14608; Chen HM, 2007, BLOOD, V110, P287, DOI 10.1182/blood-2006-08-042374; Chen HM, 2009, BLOOD, V113, P1992, DOI 10.1182/blood-2008-02-133751; Chen HW, 2004, HEART, V90, P927, DOI 10.1136/hrt.2002.006734; Chen HX, 2005, J BIOL CHEM, V280, P19373, DOI 10.1074/jbc.M413528200; Christman KL, 2005, BIOMATERIALS, V26, P1139, DOI 10.1016/j.biomaterials.2004.04.025; Czubayko F, 1996, P NATL ACAD SCI USA, V93, P14753, DOI 10.1073/pnas.93.25.14753; Darnell JE, 1997, SCIENCE, V277, P1630, DOI 10.1126/science.277.5332.1630; de Boer OJ, 1999, CARDIOVASC RES, V41, P443, DOI 10.1016/S0008-6363(98)00255-7; Dineen SP, 2008, CANCER RES, V68, P4340, DOI 10.1158/0008-5472.CAN-07-6705; Folberg R, 2000, AM J PATHOL, V156, P361, DOI 10.1016/S0002-9440(10)64739-6; GENG YJ, 1995, ARTERIOSCL THROM VAS, V15, P1995, DOI 10.1161/01.ATV.15.11.1995; GORDON D, 1990, P NATL ACAD SCI USA, V87, P4600, DOI 10.1073/pnas.87.12.4600; Gupta S, 1997, J CLIN INVEST, V99, P2752, DOI 10.1172/JCI119465; Hansson GK, 2001, ARTERIOSCL THROM VAS, V21, P1876, DOI 10.1161/hq1201.100220; Harvey EJ, 2005, CARDIOVASC RES, V67, P11, DOI 10.1016/j.cardiores.2005.04.019; Hatziapostolou M, 2005, PROSTATE, V65, P151, DOI 10.1002/pros.20270; Heil M, 2002, AM J PHYSIOL-HEART C, V283, pH2411, DOI 10.1152/ajpheart.01098.2001; Hendrix MJC, 2003, NAT REV CANCER, V3, P411, DOI 10.1038/nrc1092; Kano A, 2003, J EXP MED, V198, P1517, DOI 10.1084/jem.20030077; LI YS, 1992, BIOCHEM BIOPH RES CO, V184, P427, DOI 10.1016/0006-291X(92)91211-8; Masood R, 2001, BLOOD, V98, P1904, DOI 10.1182/blood.V98.6.1904; Moreno PR, 2004, CIRCULATION, V110, P2032, DOI 10.1161/01.CIR.0000143233.87854.23; Moulton KS, 2003, P NATL ACAD SCI USA, V100, P4736, DOI 10.1073/pnas.0730843100; Muramatsu T, 2002, J BIOCHEM, V132, P359, DOI 10.1093/oxfordjournals.jbchem.a003231; Niu J, 2008, J BIOL CHEM, V283, P14542, DOI 10.1074/jbc.M802139200; OBRIEN ER, 1994, AM J PATHOL, V145, P883; Polytarchou C, 2005, J BIOL CHEM, V280, P40428, DOI 10.1074/jbc.M505120200; Pufe T, 2003, ARTHRITIS RHEUM, V48, P660, DOI 10.1002/art.10839; Pugh CW, 2003, NAT MED, V9, P677, DOI 10.1038/nm0603-677; Qin MH, 2003, ARTERIOSCL THROM VAS, V23, P425, DOI 10.1161/01.ATV.0000059303.94760.5C; RIEGEL AT, 1994, BREAST CANCER RES TR, V31, P309; ROSENFELD ME, 1990, ARTERIOSCLEROSIS, V10, P680, DOI 10.1161/01.ATV.10.5.680; Sharifi BG, 2006, ARTERIOSCL THROM VAS, V26, P1273, DOI 10.1161/01.ATV.0000222017.05085.8e; STEMME S, 1995, P NATL ACAD SCI USA, V92, P3893, DOI 10.1073/pnas.92.9.3893; TAKEDA A, 1995, NEUROSCIENCE, V68, P57, DOI 10.1016/0306-4522(95)00110-5; Takeda K, 1998, J IMMUNOL, V161, P4652; Takeda K, 1999, IMMUNITY, V10, P39, DOI 10.1016/S1074-7613(00)80005-9; Vacherot F, 1999, PROSTATE, V38, P126, DOI 10.1002/(SICI)1097-0045(19990201)38:2<126::AID-PROS6>3.0.CO;2-C; Virmani R, 2005, ARTERIOSCL THROM VAS, V25, P2054, DOI 10.1161/01.ATV.0000178991.71605.18; Wallner K, 1999, CIRCULATION, V99, P1284, DOI 10.1161/01.CIR.99.10.1284; Weber D, 2000, CANCER RES, V60, P5284; Welte T, 2003, P NATL ACAD SCI USA, V100, P1879, DOI 10.1073/PNAS.0237137100; Whitman SC, 2000, AM J PATHOL, V157, P1819, DOI 10.1016/S0002-9440(10)64820-1; Yeh HJ, 1998, J NEUROSCI, V18, P3699	50	14	16	0	6	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAR	2010	24	3					810	822		10.1096/fj.09-140780	http://dx.doi.org/10.1096/fj.09-140780			13	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	561KE	19917672	Green Published, Bronze			2022-12-25	WOS:000274974600017
J	Vasilaki, E; Papadimitriou, E; Tajadura, V; Ridley, AJ; Stournaras, C; Kardassis, D				Vasilaki, Eleftheria; Papadimitriou, Elsa; Tajadura, Virginia; Ridley, Anne J.; Stournaras, Christos; Kardassis, Dimitris			Transcriptional regulation of the small GTPase RhoB gene by TGF beta-induced signaling pathways	FASEB JOURNAL			English	Article						ERK; Smad; cell migration; HaCaT; DU145; NF-Y	GROWTH-FACTOR-BETA; FUNCTIONAL INTERACTIONS; UP-REGULATION; CELLS; BINDING; PROTEIN; CANCER; ACTIVATION; EXPRESSION; MECHANISM	The purpose of the present study was to investigate the mechanism of transcriptional induction of the small GTPase RhoB gene by the transforming growth factor beta (TGF beta) signaling pathway and the role of this regulation in TGF beta-induced cell migration. To achieve our goals, we utilized a combination of siRNA-mediated gene silencing, adenovirus-mediated gene transfer receptor and MAPK inhibition, transactivation assays, and DNA-protein interaction assays in human HaCaT keratinocytes. We found that the RhoB gene is a direct transcriptional target of TGF beta. We show that TGF beta activates an early MEK/ERK pathway and that this activation is required for the recruitment of Smad3 to a novel, nonclassical, Smad binding element in the proximal RhoB promoter, in a p53-dependent manner. This element is overlapping with a CCAAT box that constitutively binds nuclear factor Y. Mutagenesis of this site abolished the Smad-mediated transactivation of the RhoB promoter. Finally, silencing of RhoB gene expression via siRNA or utilization of a dominant negative form of RhoB significantly inhibited TGF beta-induced migration of HaCaT keratinocytes and DU145 prostate cancer cells. Our findings establish RhoB as a direct transcriptional target of TGF beta in human keratinocytes and identify an important role of RhoB in TGF beta-induced cell migration.-Vasilaki, E., Papadimitriou, E., Tajadura, V., Ridley, A. J., Stournaras, C., Kardassis, D. Transcriptional regulation of the small GTPase RhoB gene by TGF beta-induced signaling pathways. FASEB J. 24, 891-905 (2010). www.fasebj.org	[Vasilaki, Eleftheria; Papadimitriou, Elsa; Stournaras, Christos; Kardassis, Dimitris] Univ Crete, Dept Biochem, Sch Med, GR-71003 Iraklion, Greece; [Vasilaki, Eleftheria; Kardassis, Dimitris] Fdn Res & Technol Hellas, Inst Mol Biol & Biotechnol, Iraklion, Greece; [Tajadura, Virginia; Ridley, Anne J.] Kings Coll London, Randall Div Cell & Mol Biophys, London WC2R 2LS, England	University of Crete; Foundation for Research & Technology - Hellas (FORTH); University of London; King's College London	Kardassis, D (corresponding author), Univ Crete, Dept Biochem, Sch Med, GR-71003 Iraklion, Greece.	kardasis@imbb.forth.gr	Vasilaki, Eleftheria/AAY-6392-2020	Ridley, Anne/0000-0001-8186-5708	Greek General Secretariat for Research and Technology [PENED-03 EDelta688]; Cancer Research U.K.; FEBS short-term fellowship; Fundacion Ramon Areces, Spain	Greek General Secretariat for Research and Technology(Greek Ministry of Development-GSRT); Cancer Research U.K.(Cancer Research UK); FEBS short-term fellowship; Fundacion Ramon Areces, Spain	The authors thank Dr. Roberto Mantovani (Department of Genetics and Biology of Microorganisms, University of Milan, Milan, Italy) for the NF-Yexpression vectors, Dr. Aris Moustakas (Ludwig Institute for Cancer Research, Uppsala, Sweden) for recombinant adenoviruses and for useful comments on this manuscript, Dr. Aris Eliopoulos (University of Crete Medical School, Heraklion, Greece) for materials, Dr. Francisco Vega for advice, and all members of the D. K., C. S., and A.J.R. laboratories for helpful discussions. This research was supported by grants from the Greek General Secretariat for Research and Technology (PENED-03 E Delta 688) to C. S. and D. K. and from Cancer Research U.K. (V. T. and A. J. R.). E. V. was supported by a FEBS short-term fellowship; V. T. was supported by a postdoctoral fellowship from the Fundacion Ramon Areces, Spain.	Adorno M, 2009, CELL, V137, P87, DOI 10.1016/j.cell.2009.01.039; Alabert C, 2006, ONCOGENE, V25, P3387, DOI 10.1038/sj.onc.1209385; Cordenonsi M, 2007, SCIENCE, V315, P840, DOI 10.1126/science.1135961; Coyle B, 2003, J BIOL CHEM, V278, P5920, DOI 10.1074/jbc.M211300200; Davies M, 2005, J CELL BIOCHEM, V95, P918, DOI 10.1002/jcb.20458; Dennler S, 1998, EMBO J, V17, P3091, DOI 10.1093/emboj/17.11.3091; Di Agostino S, 2006, CANCER CELL, V10, P191, DOI 10.1016/j.ccr.2006.08.013; Dupont S, 2004, CANCER LETT, V213, P129, DOI 10.1016/j.canlet.2004.06.008; Engel ME, 1998, J BIOL CHEM, V273, P9921, DOI 10.1074/jbc.273.16.9921; Fong YC, 2009, LUNG CANCER, V64, P13, DOI 10.1016/j.lungcan.2008.07.010; Fritz G, 2001, NUCLEIC ACIDS RES, V29, P792, DOI 10.1093/nar/29.3.792; Guzman-Ayala M, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0004268; Heinke J, 2007, CARDIOVASC RES, V76, P390, DOI 10.1016/j.cardiores.2007.08.003; Hu PPC, 1999, J BIOL CHEM, V274, P35381, DOI 10.1074/jbc.274.50.35381; Huang M, 2006, HISTOL HISTOPATHOL, V21, P213, DOI 10.14670/HH-21.213; Hutchison N, 2009, CELL SIGNAL, V21, P1522, DOI 10.1016/j.cellsig.2009.05.012; Jaffe AB, 2005, ANNU REV CELL DEV BI, V21, P247, DOI 10.1146/annurev.cellbio.21.020604.150721; JAHNER D, 1991, MOL CELL BIOL, V11, P3682; Kretzschmar M, 1999, GENE DEV, V13, P804, DOI 10.1101/gad.13.7.804; Kuo YC, 2009, INT J CANCER, V124, P2568, DOI 10.1002/ijc.24263; Kurisaki K, 2003, MOL CELL BIOL, V23, P4494, DOI 10.1128/MCB.23.13.4494-4510.2003; Lee MK, 2007, EMBO J, V26, P3957, DOI 10.1038/sj.emboj.7601818; LEHMAN TA, 1993, CARCINOGENESIS, V14, P833, DOI 10.1093/carcin/14.5.833; Mantovani R, 1998, NUCLEIC ACIDS RES, V26, P1135, DOI 10.1093/nar/26.5.1135; Massague J, 2006, FEBS LETT, V580, P2811, DOI 10.1016/j.febslet.2006.04.033; Moren A, 2000, ONCOGENE, V19, P4396, DOI 10.1038/sj.onc.1203798; Moustakas A, 2005, J CELL SCI, V118, P3573, DOI 10.1242/jcs.02554; Moustakas A, 1998, P NATL ACAD SCI USA, V95, P6733, DOI 10.1073/pnas.95.12.6733; Moustakas A, 2008, FEBS LETT, V582, P2051, DOI 10.1016/j.febslet.2008.03.027; Mucsi I, 1996, J BIOL CHEM, V271, P16567, DOI 10.1074/jbc.271.28.16567; Padua D, 2009, CELL RES, V19, P89, DOI 10.1038/cr.2008.316; Pannu J, 2007, J BIOL CHEM, V282, P10405, DOI 10.1074/jbc.M611742200; Piek E, 1999, J CELL SCI, V112, P4557; Prendergast GC, 2001, NAT REV CANCER, V1, P162, DOI 10.1038/35101096; Prokova V, 2005, NUCLEIC ACIDS RES, V33, P3708, DOI 10.1093/nar/gki679; Siegel PM, 2003, NAT REV CANCER, V3, P807, DOI 10.1038/nrc1208; SINHA S, 1995, P NATL ACAD SCI USA, V92, P1624, DOI 10.1073/pnas.92.5.1624; TEN DP, 2004, TRENDS BIOCHEM SCI, V29, P265; Thymiakou E, 2007, BIOCHEMISTRY-US, V46, P11473, DOI 10.1021/bi700994m; Vardouli L, 2005, J BIOL CHEM, V280, P11448, DOI 10.1074/jbc.M402651200; Vardouli L, 2008, FEBS J, V275, P4074, DOI 10.1111/j.1742-4658.2008.06549.x; Vasilaki E, 2009, BIOCHEMISTRY-US, V48, P8366, DOI 10.1021/bi9005489; Vega FM, 2008, FEBS LETT, V582, P2093, DOI 10.1016/j.febslet.2008.04.039; Verrecchia F, 2001, J BIOL CHEM, V276, P17058, DOI 10.1074/jbc.M100754200; Wakefield LM, 2002, CURR OPIN GENET DEV, V12, P22, DOI 10.1016/S0959-437X(01)00259-3; Wennerberg K, 2004, J CELL SCI, V117, P1301, DOI 10.1242/jcs.01118; Wheeler AP, 2007, EXP CELL RES, V313, P3505, DOI 10.1016/j.yexcr.2007.07.014; Wheeler AP, 2004, EXP CELL RES, V301, P43, DOI 10.1016/j.yexcr.2004.08.012; Xiao YQ, 2009, INVEST OPHTH VIS SCI, V50, P1698, DOI 10.1167/iovs.08-1675; Xie L, 2003, BREAST CANCER RES, V5, pR187, DOI 10.1186/bcr640; Zavadil J, 2001, P NATL ACAD SCI USA, V98, P6686, DOI 10.1073/pnas.111614398; ZUBIAGA AM, 1995, MOL CELL BIOL, V15, P2219	52	42	42	0	2	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAR	2010	24	3					891	905		10.1096/fj.09-134742	http://dx.doi.org/10.1096/fj.09-134742			15	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	561KE	19890017				2022-12-25	WOS:000274974600025
J	Beck, AH; Lee, CH; Witten, DM; Gleason, BC; Edris, B; Espinosa, I; Zhu, S; Li, R; Montgomery, KD; Marinelli, RJ; Tibshirani, R; Hastie, T; Jablons, DM; Rubin, BP; Fletcher, CD; West, RB; van de Rijn, M				Beck, A. H.; Lee, C-H; Witten, D. M.; Gleason, B. C.; Edris, B.; Espinosa, I.; Zhu, S.; Li, R.; Montgomery, K. D.; Marinelli, R. J.; Tibshirani, R.; Hastie, T.; Jablons, D. M.; Rubin, B. P.; Fletcher, C. D.; West, R. B.; van de Rijn, M.			Discovery of molecular subtypes in leiomyosarcoma through integrative molecular profiling	ONCOGENE			English	Article						sarcoma; leiomyosarcoma; integrative genomics; gene expression profiling; array comparative genomic hybridization; tissue microarrays	SOFT-TISSUE SARCOMAS; GENE-EXPRESSION ANALYSIS; TUMORS; SIGNATURE; PATTERNS; METASTASIS; SUBCLASSES; PROGNOSIS; RELEVANT; REGION	Leiomyosarcoma (LMS) is a soft tissue tumor with a significant degree of morphologic and molecular heterogeneity. We used integrative molecular pro. ling to discover and characterize molecular subtypes of LMS. Gene expression pro. ling was performed on 51 LMS samples. Unsupervised clustering showed three reproducible LMS clusters. Array comparative genomic hybridization (aCGH) was performed on 20 LMS samples and showed that the molecular subtypes defined by gene expression showed distinct genomic changes. Tumors from the 'muscle-enriched' cluster showed significantly increased copy number changes (P = 0.04). A majority of the muscle-enriched cases showed loss at 16q24, which contains Fanconi anemia, complementation group A, known to have an important role in DNA repair, and loss at 1p36, which contains PRDM16, of which loss promotes muscle differentiation. Immunohistochemistry (IHC) was performed on LMS tissue microarrays (n = 377) for five markers with high levels of messenger RNA in the muscle-enriched cluster (ACTG2, CASQ2, SLMAP, CFL2 and MYLK) and showed significantly correlated expression of the five proteins (all pairwise P<0.005). Expression of the five markers was associated with improved disease-specific survival in a multivariate Cox regression analysis (P<0.04). In this analysis that combined gene expression pro. ling, aCGH and IHC, we characterized distinct molecular LMS subtypes, provided insight into their pathogenesis, and identified prognostic biomarkers. Oncogene (2010) 29, 845-854; doi:10.1038/onc.2009.381; published online 9 November 2009	[Beck, A. H.; Edris, B.; Espinosa, I.; Zhu, S.; Li, R.; Montgomery, K. D.; West, R. B.; van de Rijn, M.] Stanford Univ, Med Ctr, Dept Pathol, Stanford, CA 94305 USA; [Lee, C-H] Vancouver Gen Hosp, Dept Pathol, Genet Pathol Evaluat Ctr, Vancouver, BC V5Z 1M9, Canada; [Lee, C-H] British Columbia Canc Agcy, Vancouver, BC V5Z 4E6, Canada; [Witten, D. M.; Tibshirani, R.; Hastie, T.] Stanford Univ, Med Ctr, Dept Stat, Stanford, CA 94305 USA; [Gleason, B. C.; Fletcher, C. D.] Brigham & Womens Hosp, Dept Pathol, Boston, MA 02115 USA; [Marinelli, R. J.] Stanford Univ, Med Ctr, Dept Biochem, Stanford, CA 94305 USA; [Jablons, D. M.] Univ Calif San Francisco, Dept Surg, San Francisco, CA 94143 USA; [Rubin, B. P.] Cleveland Clin, Dept Anat Pathol, Pathol & Lab Med Inst, Cleveland, OH 44106 USA; [Rubin, B. P.] Case Western Reserve Univ, Cleveland Clin, Lerner Coll Med, Cleveland, OH 44106 USA; [West, R. B.] Palo Alto Vet Affairs Hlth Care Syst, Dept Pathol & Lab Serv, Palo Alto, CA USA	Stanford University; University of British Columbia; British Columbia Cancer Agency; Stanford University; Harvard University; Brigham & Women's Hospital; Stanford University; University of California System; University of California San Francisco; Cleveland Clinic Foundation; Case Western Reserve University; Cleveland Clinic Foundation	van de Rijn, M (corresponding author), Stanford Univ, Med Ctr, Dept Pathol, 300 Pasteur Dr,L235, Stanford, CA 94305 USA.	mrijn@stanford.edu		van de Rijn, Matt/0000-0002-1909-9739; Hastie, Trevor/0000-0002-0164-3142; West, Robert/0000-0002-8330-8283	NIH [CA112270]; National Leiomyosarcoma Foundation; Leiomyosarcoma Direct Research Foundation; NATIONAL CANCER INSTITUTE [R01CA112270] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); National Leiomyosarcoma Foundation; Leiomyosarcoma Direct Research Foundation; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	Grant support came from NIH grant CA112270, the National Leiomyosarcoma Foundation and the Leiomyosarcoma Direct Research Foundation. The authors dedicate this paper to the memory of Suzanne Kurtz, LMS patient and founder of LMSdr. This work was supported by NIH grant CA112270, the National Leiomyosarcoma Foundation and the Leiomyosarcoma Direct Research Foundation.	ABBAS AK, 2005, ROBBINS COTRAN PATHO, V15; ACKERMAN L.V, 2004, ROSAI ACKERMANS SURG, V9th; Alizadeh AA, 2000, NATURE, V403, P503, DOI 10.1038/35000501; Baird K, 2005, CANCER RES, V65, P9226, DOI 10.1158/0008-5472.CAN-05-1699; BECK AH, 2009, VIRCHOWS ARCH; Beck AH, 2009, CLIN CANCER RES, V15, P778, DOI 10.1158/1078-0432.CCR-08-1283; Bernards R, 2002, NATURE, V418, P823, DOI 10.1038/418823a; Borden EC, 2003, CLIN CANCER RES, V9, P1941; Bullinger L, 2004, NEW ENGL J MED, V350, P1605, DOI 10.1056/NEJMoa031046; Edgar R, 2002, NUCLEIC ACIDS RES, V30, P207, DOI 10.1093/nar/30.1.207; Espinosa I, 2009, AM J PATHOL, V174, P2347, DOI 10.2353/ajpath.2009.081037; FLETCHER CDM, PATHOLOGY GENETICS T; Francis P, 2007, BMC GENOMICS, V8, DOI 10.1186/1471-2164-8-73; Helman LJ, 2003, NAT REV CANCER, V3, P685, DOI 10.1038/nrc1168; Henderson SR, 2005, GENOME BIOL, V6, DOI 10.1186/gb-2005-6-9-r76; Hernando E, 2007, NAT MED, V13, P748, DOI 10.1038/nm1560; JUN HJ, 2009, MED ONCOL; Kapp AV, 2007, BIOSTATISTICS, V8, P9, DOI 10.1093/biostatistics/kxj029; Kattan MW, 2002, J CLIN ONCOL, V20, P791, DOI 10.1200/JCO.2002.20.3.791; Kochetkova M, 2002, CANCER RES, V62, P4599; Lakhani SR, 2001, NAT REV CANCER, V1, P151, DOI 10.1038/35101087; Landis-Piwowar KR, 2008, J CELL BIOCHEM, V105, P514, DOI 10.1002/jcb.21853; Lapointe J, 2004, P NATL ACAD SCI USA, V101, P811, DOI 10.1073/pnas.0304146101; Larramendy ML, 2008, CANCER GENET CYTOGEN, V187, P1, DOI 10.1016/j.cancergencyto.2008.06.005; Lee CH, 2008, CLIN CANCER RES, V14, P1423, DOI 10.1158/1078-0432.CCR-07-1712; Lee YF, 2004, CANCER RES, V64, P7201, DOI 10.1158/0008-5472.CAN-04-1673; Lensch MW, 2003, BLOOD, V102, P7, DOI 10.1182/blood-2002-09-2781; Li LK, 2003, MOL CELL BIOL, V23, P9389, DOI 10.1128/MCB.23.24.9389-9404.2003; Meza-Zepeda LA, 2006, CANCER RES, V66, P8984, DOI 10.1158/0008-5472.CAN-06-1972; Nakayama R, 2007, MODERN PATHOL, V20, P749, DOI 10.1038/modpathol.3800794; Nielsen TO, 2002, LANCET, V359, P1301, DOI 10.1016/S0140-6736(02)08270-3; Ottone T, 2009, GENE CHROMOSOME CANC, V48, P213, DOI 10.1002/gcc.20633; Perot G, 2009, CANCER RES, V69, P2269, DOI 10.1158/0008-5472.CAN-08-1443; Pervaiz N, 2008, CANCER-AM CANCER SOC, V113, P573, DOI 10.1002/cncr.23592; Potti A, 2006, NAT MED, V12, P1294, DOI 10.1038/nm1491; Quade BJ, 2004, GENE CHROMOSOME CANC, V40, P97, DOI 10.1002/gcc.20018; Ramaswamy S, 2003, NAT GENET, V33, P49, DOI 10.1038/ng1060; Ren BG, 2003, HUM PATHOL, V34, P549, DOI 10.1016/S0046-8177(03)00014-5; RONG S, 1993, CANCER RES, V53, P5355; Sarcoma Meta-analysis Collaboration, 2000, COCHRANE DB SYST REV, DOI [10.1002/14651858.CD001419, DOI 10.1002/14651858.CD001419]; Seale P, 2008, NATURE, V454, P961, DOI 10.1038/nature07182; Segal NH, 2003, AM J PATHOL, V163, P691, DOI 10.1016/S0002-9440(10)63696-6; Shmulevich I, 2002, CANCER-AM CANCER SOC, V94, P2069, DOI 10.1002/cncr.10425; Sidransky D, 2002, NAT REV CANCER, V2, P210, DOI 10.1038/nrc755; Skubitz KM, 2003, CANCER, V98, P1029, DOI 10.1002/cncr.11586; Sorlie T, 2001, P NATL ACAD SCI USA, V98, P10869, DOI 10.1073/pnas.191367098; Sotiriou C, 2007, NAT REV CANCER, V7, P545, DOI 10.1038/nrc2173; Tibshirani R, 2002, P NATL ACAD SCI USA, V99, P6567, DOI 10.1073/pnas.082099299; Tibshirani R, 2008, BIOSTATISTICS, V9, P18, DOI 10.1093/biostatistics/kxm013; Toro JR, 2006, INT J CANCER, V119, P2922, DOI 10.1002/ijc.22239; Tusher VG, 2001, P NATL ACAD SCI USA, V98, P5116, DOI 10.1073/pnas.091062498; Wang WD, 2007, NAT REV GENET, V8, P735, DOI 10.1038/nrg2159; Weigelt B, 2005, CANCER RES, V65, P9155, DOI 10.1158/0008-5472.CAN-05-2553; Weigelt B, 2004, CELL CYCLE, V3, P756; Weiss SW, 2008, ENZINGER WEISSS SOFT, P303; Zou H, 2006, J COMPUT GRAPH STAT, V15, P265, DOI 10.1198/106186006X113430	56	91	94	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 11	2010	29	6					845	854		10.1038/onc.2009.381	http://dx.doi.org/10.1038/onc.2009.381			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	553WP	19901961	Green Submitted, Green Accepted			2022-12-25	WOS:000274397800007
J	Esselens, C; Malapeira, J; Colome, N; Casal, C; Rodriguez-Manzaneque, JC; Canals, F; Arribas, J				Esselens, Cary; Malapeira, Jordi; Colome, Nuria; Casal, Carmen; Carlos Rodriguez-Manzaneque, Juan; Canals, Francesc; Arribas, Joaquin			The Cleavage of Semaphorin 3C Induced by ADAMTS1 Promotes Cell Migration	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							E-GENE-EXPRESSION; EXTRACELLULAR-MATRIX; TUMOR PROGRESSION; PROTEIN; IDENTIFICATION; CANCER; FAMILY; GROWTH; METALLOELASTASE; DISINTEGRIN	Metastasis is a sequential process that allows cells to move from the primary tumor and grow elsewhere. Because of their ability to cleave a variety of extracellular signaling and adhesion molecules, metalloproteases have been long considered key components of the metastatic program. However, the function of certain metalloproteases, such as ADAMTS1, is not clear and seems to depend on the cellular environment and/or the stage of tumor progression. To characterize the function of ADAMTS1, we performed two alternative proteomic approaches, difference gel electrophoresis and stable isotope labeling by amino acids in cell culture, to identify novel substrates of the metalloprotease. Both techniques showed that overexpression of ADAMTS1 leads to the release of semaphorin 3C from the extracellular matrix. Although semaphorins are well known regulators of axon guidance, accumulating evidence shows that they may also participate in tumor progression. Here, we show that the cleavage of semaphorin 3C induced by ADAMTS1 promotes the migration of breast cancer cells, indicating that the co-expression of these molecules in tumors may contribute to the metastatic program.	[Canals, Francesc] Vall Hebron Univ Hosp, Med Oncol Res Program, Vall Hebron Inst Oncol, Barcelona 08035, Spain; [Colome, Nuria; Canals, Francesc] Vall Hebron Univ Hosp, Res Inst Fdn, Prote Lab, Barcelona 08035, Spain; [Arribas, Joaquin] Autonomous Univ Barcelona, Dept Biochem & Mol Biol, Bellaterra 08193, Spain; [Arribas, Joaquin] Inst Catalana Recerca & Estudis Avancats, Barcelona 08010, Spain; [Casal, Carmen; Carlos Rodriguez-Manzaneque, Juan] Genyo Pfizer Univ Granada, Andalusian Govt Ctr Genom & Oncol Res, Granada 18100, Spain	Hospital Universitari Vall d'Hebron; Vall d'Hebron Institut d'Oncologia (VHIO); Autonomous University of Barcelona; Hospital Universitari Vall d'Hebron; Vall d'Hebron Institut de Recerca (VHIR); Autonomous University of Barcelona; ICREA; Pfizer; University of Granada	Canals, F (corresponding author), Vall Hebron Univ Hosp, Med Oncol Res Program, Vall Hebron Inst Oncol, Psg Vall Hebron 119-129, Barcelona 08035, Spain.	fcanals@ir.vhebron.net; jarribas@vhio.net	Rodriguez-Manzaneque, Juan Carlos/F-3899-2012; Arribas, Joaquin/M-4482-2014; Malapeira, Jordi/I-7956-2014	Rodriguez-Manzaneque, Juan Carlos/0000-0001-5951-7029; Arribas, Joaquin/0000-0002-0504-0664; Esselens, Cary/0000-0001-8876-634X; Malapeira, Jordi/0000-0003-3503-1272; Casal Moreno, Carmen/0000-0002-4898-7671	Instituto de Salud Carlos III [PI081154]; network of cooperative cancer research [RTICC-RD06/0020/0022, CP06/00304, P1071058]; Breast Cancer Research Foundation; La Marato de TV3 [CP06/00304, PI071058]; ICREA Funding Source: Custom	Instituto de Salud Carlos III(Instituto de Salud Carlos IIIEuropean Commission); network of cooperative cancer research; Breast Cancer Research Foundation; La Marato de TV3; ICREA(ICREA)	This work was supported by grants from the Instituto de Salud Carlos III (Intrasalud PI081154 and the network of cooperative cancer research (RTICC-RD06/0020/0022)) (to J.A.) and CP06/00304 and P1071058 (to F.C.) and the Breast Cancer Research Foundation and La Marato de TV3 (to J.A.) and Grants CP06/00304 and PI071058 (to F.C.).	Adams RH, 1997, EMBO J, V16, P6077, DOI 10.1093/emboj/16.20.6077; Antelmann H, 2001, GENOME RES, V11, P1484, DOI 10.1101/gr.182801; Bachelder RE, 2003, CANCER RES, V63, P5230; Basbaum CB, 1996, CURR OPIN CELL BIOL, V8, P731, DOI 10.1016/S0955-0674(96)80116-5; Bech-Serra JJ, 2006, MOL CELL BIOL, V26, P5086, DOI 10.1128/MCB.02380-05; Beckers J, 2005, INT J CANCER, V114, P590, DOI 10.1002/ijc.20798; Blobel CP, 2005, NAT REV MOL CELL BIO, V6, P32, DOI 10.1038/nrm1548; Brinckerhoff CE, 2002, NAT REV MOL CELL BIO, V3, P207, DOI 10.1038/nrm763; Canals F, 2006, PROTEOMICS, V6, pS28, DOI 10.1002/pmic.200500446; Capparuccia L, 2009, J CELL SCI, V122, P1723, DOI 10.1242/jcs.030197; Rodriguez-Manzaneque JC, 2009, INT J BIOCHEM CELL B, V41, P800, DOI 10.1016/j.biocel.2008.08.014; Coussens LM, 2002, SCIENCE, V295, P2387, DOI 10.1126/science.1067100; De Wit J, 2005, MOL CELL NEUROSCI, V29, P40, DOI 10.1016/j.mcn.2004.12.009; Dong ZY, 1997, CELL, V88, P801, DOI 10.1016/S0092-8674(00)81926-1; Esselens CW, 2008, BIOL CHEM, V389, P1075, DOI 10.1515/BC.2008.121; Everley PA, 2005, ANN NY ACAD SCI, V1059, P1, DOI 10.1196/annals.1339.001; Galani E, 2002, ANTICANCER RES, V22, P2275; Gorrin-Rivas MJ, 2000, CLIN CANCER RES, V6, P1647; Hinck L, 2004, DEV CELL, V7, P783, DOI 10.1016/j.devcel.2004.11.002; Kang YB, 2003, CANCER CELL, V3, P537, DOI 10.1016/S1535-6108(03)00132-6; Kedrin D, 2007, J MAMMARY GLAND BIOL, V12, P143, DOI 10.1007/s10911-007-9046-4; Kersey PJ, 2004, PROTEOMICS, V4, P1985, DOI 10.1002/pmic.200300721; Kigel B, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003287; Klagsbrun M, 2005, CYTOKINE GROWTH F R, V16, P535, DOI 10.1016/j.cytogfr.2005.05.002; KOLODKIN AL, 1993, CELL, V75, P1389, DOI 10.1016/0092-8674(93)90625-Z; Kuno K, 1997, J BIOL CHEM, V272, P556, DOI 10.1074/jbc.272.1.556; Kuno K, 1998, J BIOL CHEM, V273, P13912, DOI 10.1074/jbc.273.22.13912; Kuno K, 2004, BIOCHEM BIOPH RES CO, V319, P1327, DOI 10.1016/j.bbrc.2004.05.105; Kuno K, 2000, FEBS LETT, V478, P241, DOI 10.1016/S0014-5793(00)01854-8; Lee NV, 2006, EMBO J, V25, P5270, DOI 10.1038/sj.emboj.7601400; Liu YJ, 2006, ONCOGENE, V25, P2452, DOI 10.1038/sj.onc.1209287; Lopez-Otin C, 2002, NAT REV MOL CELL BIO, V3, P509, DOI 10.1038/nrm858; Lopez-Otin C, 2007, NAT REV CANCER, V7, P800, DOI 10.1038/nrc2228; LUO YL, 1993, CELL, V75, P217, DOI 10.1016/0092-8674(93)80064-L; Luque A, 2003, J BIOL CHEM, V278, P23656, DOI 10.1074/jbc.M212964200; Martin-Satue M, 1999, J SURG ONCOL, V72, P18; Masui T, 2001, CLIN CANCER RES, V7, P3437; Neufeld G, 2008, NAT REV CANCER, V8, P632, DOI 10.1038/nrc2404; Overall CM, 2007, NAT REV MOL CELL BIO, V8, P245, DOI 10.1038/nrm2120; Porter S, 2004, CLIN CANCER RES, V10, P2429, DOI 10.1158/1078-0432.CCR-0398-3; Rocks N, 2006, BRIT J CANCER, V94, P724, DOI 10.1038/sj.bjc.6602990; Rocks N, 2008, CANCER RES, V68, P9541, DOI 10.1158/0008-5472.CAN-08-0548; Rodriguez-Manzaneque JC, 2000, J BIOL CHEM, V275, P33471, DOI 10.1074/jbc.M002599200; Sandy JD, 2001, J BIOL CHEM, V276, P13372, DOI 10.1074/jbc.M009737200; Smith GN, 1999, ARTHRITIS RHEUM, V42, P1140, DOI 10.1002/1529-0131(199906)42:6<1140::AID-ANR10>3.0.CO;2-7; STOCKER W, 1995, CURR OPIN STRUC BIOL, V5, P383, DOI 10.1016/0959-440X(95)80101-4; Tamagnone L, 2004, EMBO REP, V5, P356, DOI 10.1038/sj.embor.7400114; Torres-Collado AX, 2006, J BIOL CHEM, V281, P17827, DOI 10.1074/jbc.M513465200; Van den Bergh G, 2004, CURR OPIN BIOTECH, V15, P38, DOI 10.1016/j.copbio.2003.12.001; Varshavsky A, 2008, CANCER RES, V68, P6922, DOI 10.1158/0008-5472.CAN-07-5408; Vazquez F, 1999, J BIOL CHEM, V274, P23349, DOI 10.1074/jbc.274.33.23349; Yamada T, 1997, P NATL ACAD SCI USA, V94, P14713, DOI 10.1073/pnas.94.26.14713	52	76	81	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 22	2010	285	4					2463	2473		10.1074/jbc.M109.055129	http://dx.doi.org/10.1074/jbc.M109.055129			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	544YP	19915008	Green Published, hybrid			2022-12-25	WOS:000273697800025
J	Gonda, K; Watanabe, TM; Ohuchi, N; Higuchi, H				Gonda, Kohsuke; Watanabe, Tomonobu M.; Ohuchi, Noriaki; Higuchi, Hideo			In Vivo Nano-imaging of Membrane Dynamics in Metastatic Tumor Cells Using Quantum Dots	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BREAST-CANCER CELLS; PROTEASE-ACTIVATED RECEPTOR; PLASMA-MEMBRANE; MAMMARY-TUMORS; PROTEINS; MOLECULE; INVASION; MICE; TRACKING; MOTILITY	Changes in membrane morphology and membrane protein dynamics based on its fluidity are critical for cancer metastasis. However, this subject has remained unclear, because the spatial precision of previous in vivo imaging has been limited to the micrometer level and single molecule imaging is impossible. Here, we have imaged the membrane dynamics of tumor cells in mice with a spatial precision of 7-9 nm under a confocal microscope. A metastasis-promoting factor on the cell membrane, protease-activated receptor 1 (PAR1), was labeled with quantum dots conjugated with an anti-PAR1 antibody. Movements of cancer cells and PAR1 during metastasis were clearly observed in vivo. Images used to assess PAR1 dynamics were taken of representative cells for four stages of metastasis; i.e. cancer cells far from blood vessels in tumor, near the vessel, in the bloodstream, and adherent to the inner vascular surface in the normal tissues near tumor were photographed. The diffusion constant of PAR1 in static cells far from tumor blood vessels was smaller than in moving cells near the vessels and in the bloodstream. The diffusion constant of cells adhering to the inner vascular surface in the normal tissues was also very small. Cells formed membrane protrusion during migration. The PAR1 diffusion constant on these pseudopodia was greater than in other membrane regions in the same cell. Thus, the dynamics of PAR1 movement showed that membrane fluidity increases during intravasation, reaches a peak in the vessel, decreases during extravasation, and is also higher at locally formed pseudopodia.	[Gonda, Kohsuke; Ohuchi, Noriaki] Tohoku Univ, Grad Sch Med, Dept Nanomed Sci, Aoba Ku, Sendai, Miyagi 9808575, Japan; [Gonda, Kohsuke; Watanabe, Tomonobu M.; Higuchi, Hideo] Tohoku Univ, Biomed & Engn Res Org, Sendai, Miyagi 9808575, Japan; [Watanabe, Tomonobu M.] Osaka Univ, World Premier Int Res Ctr, Immunol Frontier Res Ctr, Suita, Osaka 5650871, Japan; [Ohuchi, Noriaki] Tohoku Univ, Grad Sch Med, Dept Surg Oncol, Aoba Ku, Sendai, Miyagi 9808574, Japan; [Higuchi, Hideo] Univ Tokyo, Dept Phys, Grad Sch Sci, Bunkyou Ku, Tokyo 1138654, Japan	Tohoku University; Tohoku University; Osaka University; Tohoku University; University of Tokyo	Gonda, K (corresponding author), Tohoku Univ, Grad Sch Med, Dept Nanomed Sci, Aoba Ku, Sendai, Miyagi 9808575, Japan.	gonda@m.tains.tohoku.ac.jp; higuchi@phys.s.u-tokyo.ac.jp	Watanabe, Tomonobu/J-4812-2013	Watanabe, Tomonobu/0000-0002-2420-4230	Japan MEXT; Ministry of Health, Labor, and Welfare of Japan [H18-Nano-001]; JST; Tohoku University Graduate School of Medicine; Tohoku University; Konica Minolta Medical Graphic, Inc.	Japan MEXT(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)); Ministry of Health, Labor, and Welfare of Japan(Ministry of Health, Labour and Welfare, Japan); JST(Japan Science & Technology Agency (JST)); Tohoku University Graduate School of Medicine; Tohoku University; Konica Minolta Medical Graphic, Inc.(Konica Minolta Science and Technology Foundation)	This work was supported by Grants-in-Aid for Scientific Research in Priority Areas from the Japan MEXT (to H. H. and K. G.), a Grants-in-aid for Research Project, Promotion of Advanced Medical Technology (H18-Nano-001) from the Ministry of Health, Labor, and Welfare of Japan (to N.O.), Special Coordination Funds for Promoting Science and Technology of JST (to K. G., T. M. W., and H. H.), Research for Promoting Technological Seeds of JST (to K. G.), and CREST of JST (to H. H.). We also acknowledge the support of the Biomedical Research Core of Tohoku University Graduate School of Medicine, the Tohoku University Global COE Program "Global Nano-Biomedical Engineering Education and Research Network Center," and Konica Minolta Medical & Graphic, Inc.	Arora P, 2007, J CELL SCI, V120, P921, DOI 10.1242/jcs.03409; Boire A, 2005, CELL, V120, P303, DOI 10.1016/j.cell.2004.12.018; Booden MA, 2004, MOL CELL BIOL, V24, P1990, DOI 10.1128/MCB.24.5.1990-1999.2004; Chambers AF, 2002, NAT REV CANCER, V2, P563, DOI 10.1038/nrc865; Chan WCW, 1998, SCIENCE, V281, P2016, DOI 10.1126/science.281.5385.2016; Condeelis J, 2003, NAT REV CANCER, V3, P921, DOI 10.1038/nrc1231; Davis ME, 2008, NAT REV DRUG DISCOV, V7, P771, DOI 10.1038/nrd2614; Even-Ram S, 1998, NAT MED, V4, P909, DOI 10.1038/nm0898-909; Geiger B, 2001, NAT REV MOL CELL BIO, V2, P793, DOI 10.1038/35099066; Guo WJ, 2004, NAT REV MOL CELL BIO, V5, P816, DOI 10.1038/nrm1490; Hoffman RM, 2005, NAT REV CANCER, V5, P796, DOI 10.1038/nrc1717; Ishijima A, 1998, CELL, V92, P161, DOI 10.1016/S0092-8674(00)80911-3; Jenkins DE, 2005, BREAST CANCER RES, V7, pR444, DOI 10.1186/bcr1026; Kurebayashi J, 1999, BRIT J CANCER, V79, P707, DOI 10.1038/sj.bjc.6690114; Kusumi A, 2005, ANNU REV BIOPH BIOM, V34, P351, DOI 10.1146/annurev.biophys.34.040204.144637; Li QS, 2008, BIOCHEM BIOPH RES CO, V374, P609, DOI 10.1016/j.bbrc.2008.07.078; Li-Shishido S, 2006, BIOCHEM BIOPH RES CO, V351, P7, DOI 10.1016/j.bbrc.2006.09.159; Lidke DS, 2004, NAT BIOTECHNOL, V22, P198, DOI 10.1038/nbt929; Mattila PK, 2008, NAT REV MOL CELL BIO, V9, P446, DOI 10.1038/nrm2406; Maxfield FR, 2005, NATURE, V438, P612, DOI 10.1038/nature04399; Melero I, 2007, NAT REV CANCER, V7, P95, DOI 10.1038/nrc2051; Morone N, 2006, J CELL BIOL, V174, P851, DOI 10.1083/jcb.200606007; Nguyen VT, 2003, EMBO J, V22, P4968, DOI 10.1093/emboj/cdg498; Pollard TD, 2003, CELL, V112, P453, DOI 10.1016/S0092-8674(03)00120-X; Sahai E, 2005, BMC BIOTECHNOL, V5, DOI 10.1186/1472-6750-5-14; Sahai E, 2007, NAT REV CANCER, V7, P737, DOI 10.1038/nrc2229; SAKO Y, 1995, J CELL BIOL, V129, P1559, DOI 10.1083/jcb.129.6.1559; Sarmiento C, 2008, J CELL BIOL, V180, P1245, DOI 10.1083/jcb.200708123; Schedin P, 2006, NAT REV CANCER, V6, P281, DOI 10.1038/nrc1839; Seeley S, 2003, CHEM BIOL, V10, P1033, DOI 10.1016/j.chembiol.2003.10.014; Tada H, 2007, CANCER RES, V67, P1138, DOI 10.1158/0008-5472.CAN-06-1185; Toba S, 2006, P NATL ACAD SCI USA, V103, P5741, DOI 10.1073/pnas.0508511103; Wang WG, 2002, CANCER RES, V62, P6278; Watanabe TM, 2007, BIOPHYS J, V92, P4109, DOI 10.1529/biophysj.106.094649; Yamaguchi H, 2005, J CELL BIOL, V168, P441, DOI 10.1083/jcb.200407076; Yamaguchi H, 2005, CURR OPIN CELL BIOL, V17, P559, DOI 10.1016/j.ceb.2005.08.002; Ybo J, 2008, EXP CELL RES, V314, P3563, DOI 10.1016/j.yexcr.2008.09.014; Zeisig R, 2007, ARCH BIOCHEM BIOPHYS, V459, P98, DOI 10.1016/j.abb.2006.09.030	38	69	72	1	33	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 22	2010	285	4					2750	2757		10.1074/jbc.M109.075374	http://dx.doi.org/10.1074/jbc.M109.075374			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	544YP	19917603	Green Published, hybrid			2022-12-25	WOS:000273697800052
J	Singh, MK; Li, Y; Li, SR; Cobb, RM; Zhou, D; Lu, MM; Epstein, JA; Morrisey, EE; Gruber, PJ				Singh, Manvendra K.; Li, Yan; Li, Shanru; Cobb, Ryan M.; Zhou, Diane; Lu, Min Min; Epstein, Jonathan A.; Morrisey, Edward E.; Gruber, Peter J.			Gata4 and Gata5 Cooperatively Regulate Cardiac Myocyte Proliferation in Mice	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CARDIOMYOCYTE CELL-CYCLE; HEART TUBE FORMATION; TRANSCRIPTION FACTOR; GENE-EXPRESSION; CARDIOVASCULAR-SYSTEM; VENTRAL MORPHOGENESIS; HEMATOPOIETIC-CELLS; MOUSE EMBRYO; DIFFERENTIATION; ZEBRAFISH	GATA5 is a member of the zinc finger transcription factor GATA family (GATA1-6) that plays a wide variety of roles in embryonic and adult development. Experiments in multiple model systems have emphasized the importance of the GATA family members 4-6 in the development of the endoderm and mesoderm. Yet despite overlapping expression patterns, there is little evidence of an important role for GATA5 in mammalian cardiac development. We have generated a new Gata5 mutant allele lacking exons 2 and 3 that encodes both zinc finger domains (Gata5(tm2Eem)), and we show that although Gata5(-/-) mice are viable, Gata4(+/-)5(-/-) mutants die at mid-gestation and exhibit profound cardiovascular defects, including abnormalities of cardiomyocyte proliferation and cardiac chamber maturation. These results demonstrate functional redundancy between Gata4 and Gata5 during cardiac development and implicate Gata5 as a candidate modifier gene for congenital heart disease.	[Zhou, Diane; Epstein, Jonathan A.; Morrisey, Edward E.] Univ Penn, Dept Med, Sch Med, Philadelphia, PA 19104 USA; [Morrisey, Edward E.] Univ Penn, Sch Med, Dept Cell & Dev Biol, Philadelphia, PA 19104 USA; [Li, Yan; Li, Shanru; Zhou, Diane; Lu, Min Min; Epstein, Jonathan A.; Morrisey, Edward E.; Gruber, Peter J.] Univ Penn, Sch Med, Penn Cardiovasc Inst, Philadelphia, PA 19104 USA; [Epstein, Jonathan A.; Morrisey, Edward E.; Gruber, Peter J.] Univ Penn, Sch Med, Inst Regenerat Med, Philadelphia, PA 19104 USA; [Singh, Manvendra K.; Cobb, Ryan M.; Gruber, Peter J.] Childrens Hosp Philadelphia, Philadelphia, PA 19104 USA	University of Pennsylvania; University of Pennsylvania; University of Pennsylvania; University of Pennsylvania; University of Pennsylvania; Pennsylvania Medicine; Childrens Hospital of Philadelphia	Morrisey, EE (corresponding author), Univ Penn, Dept Med, Sch Med, 956 BRB 2-3,421 Curie Blvd, Philadelphia, PA 19104 USA.	emorrisse@mail.med.upenn.edu; pgruber@mail.med.upenn.edu	Cobb, Ryan/L-7655-2019; Singh, Manvendra K./AHE-0676-2022	Cobb, Ryan/0000-0002-8364-7103; Singh, Manvendra K./0000-0002-2884-0074; Epstein, Jonathan/0000-0001-8637-4465	Pliezowicz Family Foundation; National Institutes of Health [R01-HL064632, R01-HL071546]; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL071546, R01HL064632] Funding Source: NIH RePORTER	Pliezowicz Family Foundation; National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))	This work was supported by grants from the Pliezowicz Family Foundation (to P. J. G.) and National Institutes of Health Grants R01-HL064632 (to E. E. M.) and R01-HL071546 (to J. A. E.).	ARCECI RJ, 1993, MOL CELL BIOL, V13, P2235, DOI 10.1128/MCB.13.4.2235; Asnagli H, 2002, J IMMUNOL, V168, P4268, DOI 10.4049/jimmunol.168.9.4268; Bicknell KA, 2007, J MOL CELL CARDIOL, V42, P706, DOI 10.1016/j.yjmcc.2007.01.006; Brewer A, 1999, J BIOL CHEM, V274, P38004, DOI 10.1074/jbc.274.53.38004; Bruneau BG, 2008, NATURE, V451, P943, DOI 10.1038/nature06801; Chen JN, 1996, DEVELOPMENT, V123, P293; Dubart A, 1996, BLOOD, V87, P3711, DOI 10.1182/blood.V87.9.3711.bloodjournal8793711; Ezoe S, 2002, BLOOD, V100, P3512, DOI 10.1182/blood-2002-04-1177; Garg V, 2003, NATURE, V424, P443, DOI 10.1038/nature01827; GREPIN C, 1994, MOL CELL BIOL, V14, P3115, DOI 10.1128/MCB.14.5.3115; Haworth KE, 2008, BMC DEV BIOL, V8, DOI 10.1186/1471-213X-8-74; HEIKINHEIMO M, 1994, DEV BIOL, V164, P361, DOI 10.1006/dbio.1994.1206; ITO E, 1993, NATURE, V362, P466, DOI 10.1038/362466a0; Koutsourakis M, 1999, DEVELOPMENT, V126, P723; Kuo CT, 1997, GENE DEV, V11, P1048, DOI 10.1101/gad.11.8.1048; LAVERRIERE AC, 1994, J BIOL CHEM, V269, P23177; MacNeill C, 1997, J BIOL CHEM, V272, P8396, DOI 10.1074/jbc.272.13.8396; Minegishi N, 1998, J BIOL CHEM, V273, P3625, DOI 10.1074/jbc.273.6.3625; Molkentin JD, 2000, J BIOL CHEM, V275, P38949, DOI 10.1074/jbc.R000029200; Molkentin JD, 1997, GENE DEV, V11, P1061, DOI 10.1101/gad.11.8.1061; Molkentin JD, 2000, MOL CELL BIOL, V20, P5256, DOI 10.1128/MCB.20.14.5256-5260.2000; Morrisey EE, 1996, DEV BIOL, V177, P309, DOI 10.1006/dbio.1996.0165; Morrisey EE, 1998, GENE DEV, V12, P3579, DOI 10.1101/gad.12.22.3579; Morrisey EE, 1997, DEV BIOL, V183, P21, DOI 10.1006/dbio.1996.8485; Muntean AG, 2007, BLOOD, V109, P5199, DOI 10.1182/blood-2006-11-059378; NAGY A, 1993, P NATL ACAD SCI USA, V90, P8424, DOI 10.1073/pnas.90.18.8424; Nemer G, 2003, DEV BIOL, V254, P131, DOI 10.1016/S0012-1606(02)00026-X; ORKIN SH, 1992, BLOOD, V80, P575; Pan XQ, 2000, J BIOCHEM, V127, P105, DOI 10.1093/oxfordjournals.jbchem.a022570; Pasumarthi KBS, 2002, CIRC RES, V90, P1044, DOI 10.1161/01.RES.0000020201.44772.67; Perlman H, 1998, J BIOL CHEM, V273, P13713, DOI 10.1074/jbc.273.22.13713; Peterkin T, 2005, SEMIN CELL DEV BIOL, V16, P83, DOI 10.1016/j.semcdb.2004.10.003; Reiter JF, 1999, GENE DEV, V13, P2983, DOI 10.1101/gad.13.22.2983; Rojas A, 2008, MOL CELL BIOL, V28, P5420, DOI 10.1128/MCB.00717-08; Rylski M, 2003, MOL CELL BIOL, V23, P5031, DOI 10.1128/MCB.23.14.5031-5042.2003; Sanchez I, 2005, SEMIN CELL DEV BIOL, V16, P311, DOI 10.1016/j.semcdb.2005.02.007; Singh MK, 2005, MECH DEVELOP, V122, P131, DOI 10.1016/j.mod.2004.10.011; Singh MK, 2005, DEVELOPMENT, V132, P2697, DOI 10.1242/dev.01854; Stainier DYR, 1996, DEVELOPMENT, V123, P285; Tipping AJ, 2009, BLOOD, V113, P2661, DOI 10.1182/blood-2008-06-161117; Trivedi CM, 2008, J BIOL CHEM, V283, P26484, DOI 10.1074/jbc.M803686200; TYBULEWICZ VLJ, 1991, CELL, V65, P1153, DOI 10.1016/0092-8674(91)90011-M; Wawersik S, 2000, METH MOL B, V137, P87; Xin M, 2006, P NATL ACAD SCI USA, V103, P11189, DOI 10.1073/pnas.0604604103; Zhao R, 2008, DEV BIOL, V317, P614, DOI 10.1016/j.ydbio.2008.03.013	45	68	71	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 15	2010	285	3					1765	1772		10.1074/jbc.M109.038539	http://dx.doi.org/10.1074/jbc.M109.038539			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	541PJ	19889636	hybrid, Green Published			2022-12-25	WOS:000273429100022
J	Beretta, M; Gorren, ACF; Wenzl, MV; Weis, R; Russwurm, M; Koesling, D; Schmidt, K; Mayer, B				Beretta, Matteo; Gorren, Antonius C. F.; Wenzl, M. Verena; Weis, Robert; Russwurm, Michael; Koesling, Doris; Schmidt, Kurt; Mayer, Bernd			Characterization of the East Asian Variant of Aldehyde Dehydrogenase-2 BIOACTIVATION OF NITROGLYCERIN AND EFFECTS OF Alda-1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NITRIC-OXIDE; GLYCERYL TRINITRATE; NITROGLYCERIN BIOACTIVATION; NITRATE TOLERANCE; GUANYLATE-CYCLASE; COENZYME BINDING; MITOCHONDRIAL; NITROPRUSSIDE; POLYMORPHISM; SPECIFICITY	The East Asian variant of mitochondrial aldehyde dehydrogenase (ALDH2) exhibits significantly reduced dehydrogenase, esterase, and nitroglycerin (GTN) denitrating activities. The small molecule Alda-1 was reported to partly restore low acetaldehyde dehydrogenase activity of this variant. In the present study we compared the wild type enzyme (ALDH2*1) with the Asian variant (ALDH2*2) regarding GTN bioactivation and the effects of Alda-1. Alda-1 increased acetaldehyde oxidation by ALDH2*1 and ALDH2*2 approximately 1.5- and 6-fold, respectively, and stimulated the esterase activities of both enzymes to similar extent as the coenzyme NAD. The effect of NAD was biphasic with pronounced inhibition occurring at >= 5 mM. In the presence of 1 mM NAD, Alda-1 stimulated ALDH2*2-catalyzed ester hydrolysis 73-fold, whereas the NAD-stimulated activity of ALDH2*1 was inhibited because of 20-fold increased inhibitory potency of NAD in the presence of the drug. Although ALDH2*2 exhibited 7-fold lower GTN denitrating activity and GTN affinity than ALDH2*1, the rate of nitric oxide formation was only reduced 2-fold, and soluble guanylate cyclase (sGC) activation was more pronounced than with wild type ALDH2 at saturating GTN. Alda-1 caused slight inhibition of GTN denitration and did not increase GTN-induced sGC activation in the presence of either variant. The present results indicate that Alda-1 stimulates established ALDH2 activities by improving NAD binding but does not improve the GTN binding affinity of the Asian variant. In addition, our data revealed an unexpected discrepancy between GTN reductase activity and sGC activation, suggesting that GTN denitration and bioactivation may reflect independent pathways of ALDH2-catalyzed GTN biotransformation.	[Beretta, Matteo; Gorren, Antonius C. F.; Wenzl, M. Verena; Schmidt, Kurt; Mayer, Bernd] Karl Franzens Univ Graz, Dept Pharmacol & Toxicol, A-8010 Graz, Austria; [Weis, Robert] Karl Franzens Univ Graz, Dept Pharmaceut Chem, A-8010 Graz, Austria; [Russwurm, Michael; Koesling, Doris] Ruhr Univ Bochum, Dept Pharmacol & Toxicol, D-44780 Bochum, Germany	University of Graz; University of Graz; Ruhr University Bochum	Mayer, B (corresponding author), Karl Franzens Univ Graz, Dept Pharmacol & Toxicol, Univ Pl 2, A-8010 Graz, Austria.	mayer@uni-graz.at	Mayer, Bernd/B-9391-2008; Beretta, Matteo/D-8573-2012	Mayer, Bernd/0000-0002-2921-3494; Gorren, Antonius Cornelis Franciscus/0000-0003-3476-6162; Weis, Robert/0000-0002-7174-6673; Beretta, Matteo/0000-0001-5564-4282	Fonds zur Forderung der Wissenschaftlichen Forschung in Austria W901 DK Molecular Enzymology [P20669, P21693]; Deutsche Forschungsgemeinschaft [KO1157/4-1]; Austrian Science Fund (FWF) [P 21693, W 901] Funding Source: researchfish	Fonds zur Forderung der Wissenschaftlichen Forschung in Austria W901 DK Molecular Enzymology(Austrian Science Fund (FWF)); Deutsche Forschungsgemeinschaft(German Research Foundation (DFG)); Austrian Science Fund (FWF)(Austrian Science Fund (FWF))	This work was supported by Fonds zur Forderung der Wissenschaftlichen Forschung in Austria W901 DK Molecular Enzymology Grants P20669 and P21693 (to B.M.) and by Deutsche Forschungsgemeinschaft Grant KO1157/4-1 (to D.K. and M.R.).	Beretta M, 2008, J BIOL CHEM, V283, P17873, DOI [10.1074/jbc.M801182200, 10.1074/jbc.M804001200]; BRIEN JF, 1986, J PHARMACOL EXP THER, V237, P608; Chen CH, 2008, SCIENCE, V321, P1493, DOI 10.1126/science.1158554; Chen ZQ, 2006, TRENDS CARDIOVAS MED, V16, P259, DOI 10.1016/j.tcm.2006.05.001; Chen ZQ, 2005, P NATL ACAD SCI USA, V102, P12159, DOI 10.1073/pnas.0503723102; Chen ZQ, 2002, P NATL ACAD SCI USA, V99, P8306, DOI 10.1073/pnas.122225199; CRABB DW, 1989, J CLIN INVEST, V83, P314, DOI 10.1172/JCI113875; Difabio J, 2003, MOL PHARMACOL, V64, P1109, DOI 10.1124/mol.64.5.1109; FARRES J, 1994, J BIOL CHEM, V269, P13854; GOEDDE HW, 1983, AM J HUM GENET, V35, P769; GRUETTER CA, 1981, J PHARMACOL EXP THER, V219, P181; HART GJ, 1978, BIOCHEM J, V175, P899, DOI 10.1042/bj1750899; KATSUKI S, 1977, J CYCLIC NUCL PROT, V3, P23; Kleschyov AL, 2003, CIRC RES, V93, pE104, DOI 10.1161/01.RES.0000100067.62876.50; Klyosov AA, 1996, BIOCHEMISTRY-US, V35, P4445, DOI 10.1021/bi9521093; Klyosov AA, 1996, BIOCHEMISTRY-US, V35, P4457, DOI 10.1021/bi9521102; Kollau A, 2005, BIOCHEM J, V385, P769, DOI 10.1042/BJ20041354; Larson HN, 2007, J BIOL CHEM, V282, P12940, DOI 10.1074/jbc.M607959200; Larson HN, 2005, J BIOL CHEM, V280, P30550, DOI 10.1074/jbc.M502345200; Li YF, 2006, J CLIN INVEST, V116, P506, DOI 10.1172/JCI26564; Mackenzie IS, 2005, ARTERIOSCL THROM VAS, V25, P1891, DOI 10.1161/01.ATV.0000179599.71086.89; Mayer B, 2008, BRIT J PHARMACOL, V155, P170, DOI 10.1038/bjp.2008.263; MAYER B, 1995, J BIOL CHEM, V270, P655, DOI 10.1074/jbc.270.2.655; Miller MR, 2008, J VASC RES, V45, P375, DOI 10.1159/000121407; MUKERJEE N, 1992, ARCH BIOCHEM BIOPHYS, V299, P23, DOI 10.1016/0003-9861(92)90239-S; Munzel T, 2005, CIRC RES, V97, P618, DOI 10.1161/01.RES.0000184694.03262.6d; Nunez C, 2005, CIRC RES, V97, P1063, DOI 10.1161/01.RES.0000190588.84680.34; Russwurm M, 2005, METHOD ENZYMOL, V396, P492, DOI 10.1016/S0076-6879(05)96041-2; Sage PR, 2000, CIRCULATION, V102, P2810; Schultz G., 1984, METHOD ENZYMAT AN, P379; Tanaka F, 1997, ALCOHOL CLIN EXP RES, V21, P596, DOI 10.1111/j.1530-0277.1997.tb03808.x; TU GC, 1988, J BIOL CHEM, V263, P1218; Wang MF, 2009, CHEM-BIOL INTERACT, V178, P36, DOI 10.1016/j.cbi.2008.10.002; Wang RS, 2002, DRUG METAB DISPOS, V30, P69, DOI 10.1124/dmd.30.1.69; Wenzel P, 2007, BRIT J PHARMACOL, V150, P526, DOI 10.1038/sj.bjp.0707116; Wenzel P, 2007, J BIOL CHEM, V282, P792, DOI 10.1074/jbc.M606477200; Wenzl MV, 2009, BRIT J PHARMACOL, V156, P1248, DOI 10.1111/j.1476-5381.2009.00126.x; Wenzl MV, 2009, J BIOL CHEM, V284, P19878, DOI 10.1074/jbc.M109.005652; Xiao Q, 1996, J CLIN INVEST, V98, P2027, DOI 10.1172/JCI119007; YOSHIDA A, 1984, P NATL ACAD SCI-BIOL, V81, P258, DOI 10.1073/pnas.81.1.258; ZHENG CF, 1993, ALCOHOL CLIN EXP RES, V17, P828, DOI 10.1111/j.1530-0277.1993.tb00849.x	41	42	44	0	14	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 8	2010	285	2					943	952		10.1074/jbc.M109.014548	http://dx.doi.org/10.1074/jbc.M109.014548			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	539MH	19906643	Green Published, hybrid			2022-12-25	WOS:000273258200014
J	Wielemans, K; Jean, C; Vissers, S; Andre, B				Wielemans, Kevin; Jean, Cathy; Vissers, Stephan; Andre, Bruno			Amino Acid Signaling in Yeast: Post-genome Duplication Divergence of the Stp1 and Stp2 Transcription Factors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSPORTER GENE BAP3; SACCHAROMYCES-CEREVISIAE; ENDOPROTEOLYTIC ACTIVATION; SENSING PATHWAY; AGP1 GENE; PROTEIN; EXPRESSION; SENSOR; INDUCTION; SEQUENCE	When yeast cells detect external amino acids via their permease-like Ssy1 sensor, the cytosolic precursor forms of Stp1 and Stp2 transcription factors are activated by endoproteolytic removal of their N-terminal domains, a reaction catalyzed by the Ssy5 endoprotease. The processed Stp factors then migrate into the nucleus, where they activate transcription of several amino acid permease genes including AGP1. We report here that the STP1 and STP2 genes most likely derive from the whole genome duplication that occurred in a yeast ancestor. Although Stp1 and Stp2 have been considered redundant, we provide evidence that they functionally diverged during evolution. Stp2 is the only factor processed when amino acids are present at low concentration, and the transcriptional activation of AGP1 promoted by Stp2 is moderate. Furthermore, only Stp2 can sustain Agp1-dependent utilization of amino acids at low concentration. In contrast, Stp1 is only processed when amino acids are present at high concentration, and it promotes higher level transcriptional activation of AGP1. Domain swapping experiments show that the N-terminal domains of Stp1 and Stp2 are responsible for these proteins being cleaved at different amino acid concentrations. Last, induction of the DIP5 permease gene by amino acids depends on Stp2 but not Stp1. We propose that post-whole genome duplication co-conservation of the STP1 and STP2 genes was favored by functional divergence of their products, likely conferring to cells an increased ability to adapt to various amino acid supply conditions.	[Wielemans, Kevin; Jean, Cathy; Vissers, Stephan; Andre, Bruno] Univ Libre Bruxelles, Lab Physiol Mol Cellule, Inst Biol & Med Mol, B-6041 Gosselies, Belgium	Universite Libre de Bruxelles	Andre, B (corresponding author), Inst Biol & Med Mol, Lab Physiol Mol Cellule CP300, 11 Rue Pr Jeener & Brachet, B-6041 Gosselies, Belgium.	bran@ulb.ac.be	André, Bruno/D-1725-2010		Communaute Francaise de Belgique [3.4.592.08.F, 04/09-307]; Region Wallonne de Belgique [716760]	Communaute Francaise de Belgique(Australian Research Council); Region Wallonne de Belgique	This work was supported by Fonds de la Recherche Scientifique Medicale Grant 3.4.592.08.F and Actions de Recherche Concertee Grant 04/09-307 of the Communaute Francaise de Belgique and by CIBLES Grant 716760 of the Region Wallonne de Belgique.	Abdel-Sater F, 2004, MOL CELL BIOL, V24, P9771, DOI 10.1128/MCB.24.22.9771-9785.2004; Abdel-Sater F, 2004, GENETICS, V166, P1727, DOI 10.1534/genetics.166.4.1727; ANDRE B, 1990, MOL GEN GENET, V220, P269; ANDRE B, 1990, NUCLEIC ACIDS RES, V18, P7136, DOI 10.1093/nar/18.23.7136; ANDRE B, 1993, MOL GEN GENET, V237, P17; Andreasson C, 2004, MOL CELL BIOL, V24, P7503, DOI 10.1128/MCB.24.17.7503-7513.2004; Andreasson C, 2002, GENE DEV, V16, P3158, DOI 10.1101/gad.239202; Andreasson C, 2006, GENE DEV, V20, P1563, DOI 10.1101/gad.374206; Barnes D, 1998, MOL MICROBIOL, V29, P297, DOI 10.1046/j.1365-2958.1998.00931.x; Bernard F, 2001, MOL MICROBIOL, V41, P489, DOI 10.1046/j.1365-2958.2001.02538.x; Bernard F, 2001, FEBS LETT, V496, P81, DOI 10.1016/S0014-5793(01)02412-7; Boban M, 2007, GENETICS, V176, P2087, DOI 10.1534/genetics.107.075077; Boles E, 2004, TOP CURR GENET, V9, P121; BRICMONT PA, 1991, MOL CELL BIOL, V11, P1161, DOI 10.1128/MCB.11.2.1161; Byrne KP, 2006, NUCLEIC ACIDS RES, V34, pD452, DOI 10.1093/nar/gkj041; Conant GC, 2008, NAT REV GENET, V9, P938, DOI 10.1038/nrg2482; COORNAERT D, 1991, GENE, V97, P163, DOI 10.1016/0378-1119(91)90048-G; de Boer M, 2000, NUCLEIC ACIDS RES, V28, P974; de Boer M, 1998, MOL MICROBIOL, V30, P603, DOI 10.1046/j.1365-2958.1998.01094.x; Didion T, 1998, MOL MICROBIOL, V27, P643, DOI 10.1046/j.1365-2958.1998.00714.x; DORRINGTON RA, 1993, NUCLEIC ACIDS RES, V21, P3777, DOI 10.1093/nar/21.16.3777; Eckert-Boulet N, 2006, EUKARYOT CELL, V5, P174, DOI 10.1128/EC.5.1.174-179.2006; Gaber RF, 2003, EUKARYOT CELL, V2, P922, DOI 10.1128/EC.2.5.922-929.2003; HEIN C, 1995, MOL MICROBIOL, V18, P77, DOI 10.1111/j.1365-2958.1995.mmi_18010077.x; Iraqui I, 1999, MOL CELL BIOL, V19, P989; JACOBS P, 1980, J MOL BIOL, V139, P691, DOI 10.1016/0022-2836(80)90055-8; Jorgensen MU, 1998, YEAST, V14, P103, DOI 10.1002/(SICI)1097-0061(19980130)14:2<103::AID-YEA203>3.0.CO;2-C; Kellis M, 2004, NATURE, V428, P617, DOI 10.1038/nature02424; Klasson H, 1999, MOL CELL BIOL, V19, P5405; Liu ZC, 2008, MOL CELL BIOL, V28, P551, DOI 10.1128/MCB.00929-07; Ljungdahl PO, 2009, BIOCHEM SOC T, V37, P242, DOI 10.1042/BST0370242; Martinez P, 2005, MOL CELL BIOL, V25, P9435, DOI 10.1128/MCB.25.21.9435-9446.2005; Nielsen PS, 2001, MOL GEN GENET, V264, P613, DOI 10.1007/s004380000347; Sabina J, 2009, J BIOL CHEM, V284, P29635, DOI 10.1074/jbc.M109.032102; Scannell DR, 2007, YEAST, V24, P929, DOI 10.1002/yea.1515; Scannell DR, 2007, P NATL ACAD SCI USA, V104, P8397, DOI 10.1073/pnas.0608218104; Sherman DJ, 2009, NUCLEIC ACIDS RES, V37, pD550, DOI 10.1093/nar/gkn859; Wach A, 1996, YEAST, V12, P259, DOI 10.1002/(SICI)1097-0061(19960315)12:3<259::AID-YEA901>3.0.CO;2-C; Wery M, 2009, RNA, V15, P406, DOI 10.1261/rna.1402709; Wolfe KH, 1997, NATURE, V387, P708, DOI 10.1038/42711; Wu BQ, 2006, J CELL BIOL, V173, P327, DOI 10.1083/jcb.200602089	41	18	21	1	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 8	2010	285	2					855	865		10.1074/jbc.M109.015263	http://dx.doi.org/10.1074/jbc.M109.015263			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	539MH	19906648	Green Published, hybrid			2022-12-25	WOS:000273258200006
J	Palmer, CD; Rahman, FZ; Sewell, GW; Ahmed, A; Ashcroft, M; Bloom, SL; Segal, AW; Smith, AM				Palmer, Christine D.; Rahman, Farooq Z.; Sewell, Gavin W.; Ahmed, Afshan; Ashcroft, Margaret; Bloom, Stuart L.; Segal, Anthony W.; Smith, Andrew M.			Diminished Macrophage Apoptosis and Reactive Oxygen Species Generation after Phorbol Ester Stimulation in Crohn's Disease	PLOS ONE			English	Article							PROTEIN-KINASE-C; INFLAMMATORY-BOWEL-DISEASE; TUMOR-NECROSIS-FACTOR; T-CELLS; PKC-DELTA; ACTIVATION; EXPRESSION; NEUTROPHIL; BAX; P53	Background: Crohn's Disease (CD) is a chronic relapsing disorder characterized by granulomatous inflammation of the gastrointestinal tract. Although its pathogenesis is complex, we have recently shown that CD patients have a systemic defect in macrophage function, which results in the defective clearance of bacteria from inflammatory sites. Methodology/Principal Findings: Here we have identified a number of additional macrophage defects in CD following diacylglycerol (DAG) homolog phorbol-12-myristate-13-acetate (PMA) activation. We provide evidence for decreased DNA fragmentation, reduced mitochondrial membrane depolarization, impaired reactive oxygen species production, diminished cytochrome c release and increased IL-6 production compared to healthy subjects after PMA exposure. The observed macrophage defects in CD were stimulus-specific, as normal responses were observed following p53 activation and endoplasmic reticulum stress. Conclusion: These findings add to a growing body of evidence highlighting disordered macrophage function in CD and, given their pivotal role in orchestrating inflammatory responses, defective apoptosis could potentially contribute to the pathogenesis of CD.			Palmer, CD (corresponding author), UCL, Dept Med, Ctr Mol Med, London, England.	andrew.m.smith@ucl.ac.uk	Palmer, Christine/GXH-4415-2022	Sewell, Gavin/0000-0002-3002-9248; Palmer, Christine Denise/0000-0003-3213-0398; Smith, Andrew/0000-0002-4691-5973; Segal, Anthony/0000-0001-7602-9043	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		AGGARWAL BB, 1985, J BIOL CHEM, V260, P2345; Atreya R, 2005, CLIN REV ALLERG IMMU, V28, P187, DOI 10.1385/CRIAI:28:3:187; Bernstein CN, 2001, CANCER-AM CANCER SOC, V91, P854, DOI 10.1002/1097-0142(20010215)91:4<854::AID-CNCR1073>3.0.CO;2-Z; Boirivant M, 1999, GASTROENTEROLOGY, V116, P557, DOI 10.1016/S0016-5085(99)70177-0; Bosca L, 2005, TOXICOLOGY, V208, P249, DOI 10.1016/j.tox.2004.11.035; Brannigan AE, 2000, SHOCK, V13, P361, DOI 10.1097/00024382-200005000-00003; Budas GR, 2007, BIOCHEM SOC T, V35, P1052, DOI 10.1042/BST0351052; Bufan B, 2009, INT IMMUNOPHARMACOL, V9, P910, DOI 10.1016/j.intimp.2009.03.016; Carol M, 2006, J LEUKOCYTE BIOL, V79, P917, DOI 10.1189/jlb.0405188; Casanova JL, 2009, J EXP MED, V206, P1839, DOI 10.1084/jem.20091683; Catarzi S, 2008, INFLAMM BOWEL DIS, V14, P819, DOI 10.1002/ibd.20397; Cenni V, 2002, BIOCHEM J, V363, P537, DOI 10.1042/0264-6021:3630537; Chan HTC, 2003, CANCER RES, V63, P5480; Di Sabatino A, 2004, GUT, V53, P70, DOI 10.1136/gut.53.1.70; Doering J, 2004, GUT, V53, P1632, DOI 10.1136/gut.2003.037911; Evan GI, 2001, NATURE, V411, P342, DOI 10.1038/35077213; Fadok VA, 1998, J CLIN INVEST, V101, P890, DOI 10.1172/JCI1112; Fong CC, 2007, TOXICOLOGY, V236, P16, DOI 10.1016/j.tox.2007.03.024; Gilroy DW, 2003, FASEB J, V17, P2269, DOI 10.1096/fj.02-1162fje; Griner EM, 2007, NAT REV CANCER, V7, P281, DOI 10.1038/nrc2110; Gutcher I, 2003, CELL MOL LIFE SCI, V60, P1061, DOI 10.1007/s00018-003-2281-y; Herman S, 2005, INFLAMM RES, V54, P273, DOI 10.1007/s00011-005-1355-8; Ina K, 1999, J IMMUNOL, V163, P1081; Issaeva N, 2004, NAT MED, V10, P1321, DOI 10.1038/nm1146; Itoh J, 2001, GUT, V49, P35, DOI 10.1136/gut.49.1.35; Kakkar P, 2007, MOL CELL BIOCHEM, V305, P235, DOI 10.1007/s11010-007-9520-8; Kikkawa U, 2002, J BIOCHEM, V132, P831, DOI 10.1093/oxfordjournals.jbchem.a003294; Kobayashi T, 2004, HISTOCHEM CELL BIOL, V122, P323, DOI 10.1007/s00418-004-0674-0; Korzenik JR, 2005, J CLIN GASTROENTEROL, V39, pS59, DOI 10.1097/01.mcg.0000155553.28348.fc; KUSUGAMI K, 1995, DIGEST DIS SCI, V40, P949, DOI 10.1007/BF02064182; Lawrence T, 2007, INT J EXP PATHOL, V88, P85, DOI 10.1111/j.1365-2613.2006.00507.x; Lugering A, 2001, GASTROENTEROLOGY, V121, P1145, DOI 10.1053/gast.2001.28702; MAEDA M, 1992, IMMUNOPHARM IMMUNOT, V14, P451, DOI 10.3109/08923979209005404; MAHIDA YR, 1991, GUT, V32, P1531, DOI 10.1136/gut.32.12.1531; Marks DJB, 2007, INFLAMM RES, V56, P168, DOI 10.1007/s00011-006-6119-6; Marks DJB, 2009, AM J GASTROENTEROL, V104, P117, DOI 10.1038/ajg.2008.72; Marks DJB, 2006, LANCET, V367, P668, DOI 10.1016/S0140-6736(06)68265-2; Mathew J, 2008, FREE RADICAL BIO MED, V45, P413, DOI 10.1016/j.freeradbiomed.2008.04.031; Mudter J, 2007, INFLAMM BOWEL DIS, V13, P1016, DOI 10.1002/ibd.20148; Pajak B, 2008, ADV MED SCI-POLAND, V53, P21, DOI 10.2478/v10039-008-0028-6; Park JK, 2008, PLACENTA, V29, P584, DOI 10.1016/j.placenta.2008.03.007; Phillips DC, 2003, BRIT J PHARMACOL, V138, P501, DOI 10.1038/sj.bjp.0705054; Podolsky DK, 2002, NEW ENGL J MED, V347, P417, DOI 10.1056/NEJMra0804647; Rahman FZ, 2008, INFLAMM BOWEL DIS, V14, P1443, DOI 10.1002/ibd.20449; Rahman FZ, 2009, IMMUNOLOGY, V128, P253, DOI 10.1111/j.1365-2567.2009.03112.x; Reinisch W, 1999, AM J GASTROENTEROL, V94, P2156; Rodenburg RJT, 2000, ARTHRITIS RHEUM, V43, P1941, DOI 10.1002/1529-0131(200009)43:9<1941::AID-ANR4>3.0.CO;2-O; Sandborn WJ, 2001, GASTROENTEROLOGY, V121, P1088, DOI 10.1053/gast.2001.28674; Shanahan F, 2002, LANCET, V359, P62, DOI 10.1016/S0140-6736(02)07284-7; Smith AM, 2009, J EXP MED, V206, P1883, DOI 10.1084/jem.20091233; Tan SL, 2003, BIOCHEM J, V376, P545, DOI 10.1042/BJ20031406; ten Hove T, 2002, GUT, V50, P206, DOI 10.1136/gut.50.2.206; THELEN M, 1993, PHYSIOL REV, V73, P797, DOI 10.1152/physrev.1993.73.4.797; Tiede I, 2003, J CLIN INVEST, V111, P1133, DOI 10.1172/JCI200316432; Van Den Brande JMH, 2003, GASTROENTEROLOGY, V124, P1774, DOI 10.1016/S0016-5085(03)00382-2; Vogelstein B, 2000, NATURE, V408, P307, DOI 10.1038/35042675; Waterhouse NJ, 2006, CELL DEATH DIFFER, V13, P607, DOI 10.1038/sj.cdd.4401772; Yang J, 2009, MOL CELL BIOL, V29, P2243, DOI 10.1128/MCB.00959-08	58	21	21	0	1	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	NOV 12	2009	4	11							e7787	10.1371/journal.pone.0007787	http://dx.doi.org/10.1371/journal.pone.0007787			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	518UW	19907654	Green Submitted, Green Published, gold			2022-12-25	WOS:000271721400001
J	Jacob, ST; Moore, CC; Banura, P; Pinkerton, R; Meya, D; Opendi, P; Reynolds, SJ; Kenya-Mugisha, N; Mayanja-Kizza, H; Scheld, WM				Jacob, Shevin T.; Moore, Christopher C.; Banura, Patrick; Pinkerton, Relana; Meya, David; Opendi, Pius; Reynolds, Steven J.; Kenya-Mugisha, Nathan; Mayanja-Kizza, Harriet; Scheld, W. Michael		PRISM-U Study Grp	Severe Sepsis in Two Ugandan Hospitals: a Prospective Observational Study of Management and Outcomes in a Predominantly HIV-1 Infected Population	PLOS ONE			English	Article							BLOOD-STREAM INFECTIONS; SEPTIC SHOCK; ADULTS; MORTALITY; BACTEREMIA; MALAWI; CARE; PREDICTORS; MEDICINE; THERAPY	Background: Sepsis likely contributes to the high burden of infectious disease morbidity and mortality in low income countries. Data regarding sepsis management in sub-Saharan Africa are limited. We conducted a prospective observational study reporting the management and outcomes of severely septic patients in two Ugandan hospitals. We describe their epidemiology, management, and clinical correlates for mortality. Methodology/Results: Three-hundred eighty-two patients fulfilled enrollment criteria for a severe sepsis syndrome. Vital signs, management and laboratory results were recorded. Outcomes measured included in-hospital and post-dischargemortality. Most patients were HIV-infected (320/377, 84.9%) with a median CD4+ T cell (CD4) count of 52 cells/mm(3) (IQR, 16-131 cells/mm(3)). Overall mortality was 43.0%, with 23.7% in-hospital mortality (90/380) and 22.3% post-discharge mortality (55/247). Significant predictors of in-hospital mortality included admission Glasgow Coma Scale and Karnofsky Performance Scale (KPS), tachypnea, leukocytosis and thrombocytopenia. Discharge KPS and early fluid resuscitation were significant predictors of post-discharge mortality. Among HIV-infected patients, CD4 count was a significant predictor of post-discharge mortality. Median volume of fluid resuscitation within the first 6 hours of presentation was 500 mLs (IQR 250-1000 mls). Fifty-two different empiric antibacterial regimens were used during the study. Bacteremic patients were more likely to die in hospital than non-bacteremic patients (OR 1.83, 95% CI = 1.01-3.33). Patients with Mycobacterium tuberculosis (MTB) bacteremia (25/249) had higher in-hospital mortality (OR 1.97, 95% CI = 1.19-327) and lower median CD4 counts (p = 0.001) than patients without MTB bacteremia. Conclusion: Patients presenting with sepsis syndromes to two Ugandan hospitals had late stage HIV infection and high mortality. Bacteremia, especially from MTB, was associated with increased in-hospital mortality. Most clinical predictors of in-hospital mortality were easily measurable and can be used for triaging patients in resource-constrained settings. Procurement of low cost and high impact treatments like intravenous fluids and empiric antibiotics may help decrease sepsis-associated mortality in resource-constrained settings.			Jacob, ST (corresponding author), Univ Washington, Dept Med, Div Allergy & Infect Dis, Seattle, WA 98195 USA.	sjacob2@uw.edu	Jacob, Shevin/CAF-0449-2022; Mayanja-Kizza, Harriet/AAM-5372-2020; Meya, David/AAO-2796-2020	Mayanja-Kizza, Harriet/0000-0002-9297-6208; Kenya Mugisha, Nathan/0000-0002-2100-1833; Reynolds, Steven/0000-0002-5403-2759; Jacob, Shevin/0000-0003-2425-9394; , David/0000-0002-8854-0321; Meya, David/0000-0002-4138-240X	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [T32AI007046, ZIAAI000361, ZIAAI001040] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Alberti C, 2003, AM J RESP CRIT CARE, V168, P77, DOI 10.1164/rccm.200208-785OC; Angus D C, 2001, Crit Care Med, V29, P1303, DOI 10.1097/00003246-200107000-00002; Anyama Norbert, 2003, Afr Health Sci, V3, P87; Archibald LK, 2001, EMERG INFECT DIS, V7, P302, DOI 10.3201/eid0702.010232; Archibald LK, 2000, J INFECT DIS, V181, P1414, DOI 10.1086/315367; Archibald LK, 1998, CLIN INFECT DIS, V26, P290, DOI 10.1086/516297; Arthur G, 2001, CLIN INFECT DIS, V33, P248, DOI 10.1086/321820; Awad AI, 2007, ANN PHARMACOTHER, V41, P1249, DOI 10.1345/aph.1K068; Becker JU, 2009, LANCET INFECT DIS, V9, P577, DOI 10.1016/S1473-3099(09)70135-5; Blomberg B, 2007, BMC INFECT DIS, V7, DOI 10.1186/1471-2334-7-43; Bochud PY, 2001, INTENS CARE MED, V27, pS33, DOI 10.1007/PL00003796; BONE RC, 1992, CHEST, V101, P1644, DOI 10.1378/chest.101.6.1644; CARCILLO JA, 1991, JAMA-J AM MED ASSOC, V266, P1242, DOI 10.1001/jama.266.9.1242; Cheng AC, 2008, PLOS MED, V5, P1173, DOI 10.1371/journal.pmed.0050175; Dellinger RP, 2008, CRIT CARE MED, V36, P296, DOI 10.1097/01.CCM.0000298158.12101.41; Dunser MW, 2006, CRIT CARE MED, V34, P1234, DOI 10.1097/01.CCM.0000208360.70835.87; Erikstrup C, 2007, JAIDS-J ACQ IMM DEF, V44, P478, DOI 10.1097/QAI.0b013e318032bbcd; Finfer S, 2009, NEW ENGL J MED, V360, P1283, DOI 10.1056/NEJMoa0810625; GILKS CF, 1990, LANCET, V336, P545, DOI 10.1016/0140-6736(90)92096-Z; Gordon MA, 2001, J INFECTION, V42, P44, DOI 10.1053/jinf.2000.0779; Gordon MA, 2008, CLIN INFECT DIS, V46, P963, DOI 10.1086/529146; Grant AD, 1997, AIDS, V11, P1357, DOI 10.1097/00002030-199711000-00010; *HLTH CTR DISTR OU, 2004, INT MAN AD AD ILLN I; *HMIS, 2008, DAT MAS REG REF HOSP; Hotchkiss RS, 2003, NEW ENGL J MED, V348, P138, DOI 10.1056/NEJMra021333; *JOINT UN PROGR HI, 2008, REP GLOB AIDS EP STA; KARNOFSKY D, 1961, CLIN PHARMACOL THER, V2, P709; Kumar A, 2006, CRIT CARE MED, V34, P1589, DOI 10.1097/01.CCM.0000217961.75225.E9; Leibovici L, 1998, J INTERN MED, V244, P379; Martin CM, 2009, CRIT CARE MED, V37, P81, DOI 10.1097/CCM.0b013e31819285f0; Martin GS, 2003, NEW ENGL J MED, V348, P1546, DOI 10.1056/NEJMoa022139; McDonald LC, 1999, LANCET, V354, P1159, DOI 10.1016/S0140-6736(98)12325-5; Moore CC, 2008, CLIN INFECT DIS, V46, P215, DOI 10.1086/524665; Moore CC, 2009, AM J TROP MED HYG, V80, P723, DOI 10.4269/ajtmh.2009.80.723; MOR V, 1984, CANCER-AM CANCER SOC, V53, P2002, DOI 10.1002/1097-0142(19840501)53:9<2002::AID-CNCR2820530933>3.0.CO;2-W; Ogwal-Okeng J W, 2004, East Afr Med J, VSuppl, pS12; Peters RPH, 2004, TROP MED INT HEALTH, V9, P928, DOI 10.1111/j.1365-3156.2004.01288.x; Petti CA, 2006, CLIN INFECT DIS, V42, P377, DOI 10.1086/499363; Rivers E, 2001, NEW ENGL J MED, V345, P1368, DOI 10.1056/NEJMoa010307; Rivers EP, 2005, CAN MED ASSOC J, V173, P1054, DOI 10.1503/cmaj.050632; Sharma B, 2007, ANAESTH INTENS CARE, V35, P874, DOI 10.1177/0310057X0703500604; Ssali FN, 1998, J ACQ IMMUN DEF SYND, V19, P484, DOI 10.1097/00042560-199812150-00007; THEODOSIS C, 2006, INT AIDS C TOR; Vincent JL, 2002, CRIT CARE, V6, pS1, DOI 10.1186/cc1860; Wanyenze R, 2006, AIDS BEHAV, V10, P361, DOI 10.1007/s10461-005-9035-9; *WHO, 2007, CLIN MAN HIV AIDS DI	46	98	103	0	3	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	NOV 11	2009	4	11					A115	A126	e7782	10.1371/journal.pone.0007782	http://dx.doi.org/10.1371/journal.pone.0007782			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	518IX	19907656	Green Published, gold, Green Submitted			2022-12-25	WOS:000271685800013
J	Skilton, RJ; Cutcliffen, LT; Barlow, D; Wang, YB; Salim, O; Lambden, PR; Clarke, IN				Skilton, Rachel J.; Cutcliffen, Lesley T.; Barlow, David; Wang, Yibing; Salim, Omar; Lambden, Paul R.; Clarke, Ian N.			Penicillin Induced Persistence in Chlamydia trachomatis: High Quality Time Lapse Video Analysis of the Developmental Cycle	PLOS ONE			English	Article							BINDING PROTEINS; GENOME SEQUENCE; CELL-CULTURE; PEPTIDOGLYCAN; INCLUSION; INFECTIVITY; MORPHOLOGY; PARADIGM; PSITTACI; CHP2	Background: Chlamydia trachomatis is a major human pathogen with a unique obligate intracellular developmental cycle that takes place inside a modified cytoplasmic structure known as an inclusion. Following entry into a cell, the infectious elementary body (EB) differentiates into a non - infectious replicative form known as a reticulate body (RB). RBs divide by binary fission and at the end of the cycle they redifferentiate into EBs. Treatment of C. trachomatis with penicillin prevents maturation of RBs which survive and enlarge to become aberrant RBs within the inclusion in a non - infective persistent state. Persistently infected individuals may be a reservoir for chlamydial infection. The C. trachomatis genome encodes the enzymes for peptidoglycan ( PG) biosynthesis but a PG sacculus has never been detected. This coupled to the action of penicillin is known as the chlamydial anomaly. We have applied video microscopy and quantitative DNA assays to the chlamydial developmental cycle to assess the effects of penicillin treatment and establish a framework for investigating penicillin induced chlamydial persistence. Principal Findings: Addition of penicillin at the time of cell infection does not prevent uptake and the establishment of an inclusion. EB to RB transition occurs but bacterial cytokinesis is arrested by the second binary fission. RBs continue to enlarge but not divide in the presence of penicillin. The normal developmental cycle can be recovered by the removal of penicillin although the large, aberrant RBs do not revert to the normal smaller size but remain present to the completion of the developmental cycle. Chromosomal and plasmid DNA replication is unaffected by the addition of penicillin but the arrest of bacterial cytokinesis under these conditions results in RBs accumulating multiple copies of the genome. Conclusions: We have applied video time lapse microscopy to the study of the chlamydial developmental cycle. Linked with accurate measures of genome replication this provides a defined framework to analyse the developmental cycle and to investigate and provide new insights into the effects of antibiotic treatments. Removal of penicillin allows recovery of the normal developmental cycle by 10-20 hrs and the process occurs by budding from aberrant RBs.			Skilton, RJ (corresponding author), Univ Southampton, Southampton Gen Hosp, Sch Med, Mol Microbiol Grp, Southampton, Hants, England.	inc@soton.ac.uk		Clarke, Ian/0000-0002-4938-1620	Wellcome Trust [080348] Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		Armstrong JA, 1967, J GEN MICROBIOL, V129, P2001; BARBOUR AG, 1982, J BACTERIOL, V151, P420, DOI 10.1128/JB.151.1.420-428.1982; BEATTY WL, 1994, MICROBIOL REV, V58, P686, DOI 10.1128/MMBR.58.4.686-699.1994; Chopra I, 1998, MICROBIOL-UK, V144, P2673, DOI 10.1099/00221287-144-10-2673; CLARK RB, 1982, MED MICROBIOL IMMUN, V171, P151, DOI 10.1007/BF02123623; Fields KA, 2002, ANNU REV CELL DEV BI, V18, P221, DOI 10.1146/annurev.cellbio.18.012502.105845; Gerbase AC, 1998, LANCET, V351, P2, DOI 10.1016/S0140-6736(98)90001-0; HACKSTADT T, 1995, P NATL ACAD SCI USA, V92, P4877, DOI 10.1073/pnas.92.11.4877; Hatch TP, 1999, CHLAMYDIA, P29; Hogan RJ, 2004, INFECT IMMUN, V72, P1843, DOI 10.1128/IAI.72.4.1843-1855.2004; JOHNSON FWA, 1977, J ANTIMICROB CHEMOTH, V3, P49, DOI 10.1093/jac/3.1.49; KRAMER MJ, 1971, INFECT IMMUN, V3, P333, DOI 10.1128/IAI.3.2.333-341.1971; Lambden PR, 2006, MICROBIOL-SGM, V152, P2573, DOI 10.1099/mic.0.29032-0; Liu BL, 2000, J VIROL, V74, P3464, DOI 10.1128/JVI.74.8.3464-3469.2000; MATSUMOTO A, 1970, J BACTERIOL, V101, P278, DOI 10.1128/JB.101.1.278-285.1970; McCoy AJ, 2006, TRENDS MICROBIOL, V14, P70, DOI 10.1016/j.tim.2005.12.004; MOULDER JW, 1993, INFECT AGENT DIS, V2, P87; O'Connell CM, 2006, MICROBIOL-SGM, V152, P1601, DOI 10.1099/mic.0.28658-0; Pavelka MS, 2007, TRENDS MICROBIOL, V15, P147, DOI 10.1016/j.tim.2007.02.003; PEELING RW, 1991, INFECT IMMUN, V59, P2624, DOI 10.1128/IAI.59.8.2624-2630.1991; PHILLIPS DM, 1984, J ULTRA MOL STRUCT R, V88, P244, DOI 10.1016/S0022-5320(84)90122-9; Pickett MA, 2005, MICROBIOL-SGM, V151, P893, DOI 10.1099/mic.0.27625-0; Rockey DD, 2000, PROKARYOTIC DEVELOPMENT, P403; SCHACHTER J, 1990, SCAND J INFECT DIS, P55; Scidmore MA, 1996, INFECT IMMUN, V64, P5366, DOI 10.1128/IAI.64.12.5366-5372.1996; Skilton RJ, 2007, J BACTERIOL, V189, P4957, DOI 10.1128/JB.00235-07; Skipp P, 2005, PROTEOMICS, V5, P1558, DOI 10.1002/pmic.200401044; Stephens RS, 1998, SCIENCE, V282, P754, DOI 10.1126/science.282.5389.754; Storey C, 2001, ANTIMICROB AGENTS CH, V45, P303, DOI 10.1128/AAC.45.1.303-305.2001; Thomson NR, 2008, GENOME RES, V18, P161, DOI 10.1101/gr.7020108; WARD ME, 1983, BRIT MED BULL, V39, P109, DOI 10.1093/oxfordjournals.bmb.a071800; Wilson DP, 2009, J BACTERIOL, V191, P5734, DOI 10.1128/JB.00293-09; Wilson DP, 2004, B MATH BIOL, V66, P523, DOI 10.1016/j.bulm.2003.09.001	33	67	72	0	4	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	NOV 6	2009	4	11							e7723	10.1371/journal.pone.0007723	http://dx.doi.org/10.1371/journal.pone.0007723			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	515ND	19893744	gold, Green Submitted, Green Accepted, Green Published			2022-12-25	WOS:000271478000009
J	Kotoula, V; Charalambous, E; Biesmans, B; Malousi, A; Vrettou, E; Fountzilas, G; Karkavelas, G				Kotoula, Vassiliki; Charalambous, Elpida; Biesmans, Bart; Malousi, Andigoni; Vrettou, Eleni; Fountzilas, George; Karkavelas, George			Targeted KRAS Mutation Assessment on Patient Tumor Histologic Material in Real Time Diagnostics	PLOS ONE			English	Article							METASTATIC COLORECTAL-CANCER; PARAFFIN-EMBEDDED TISSUES; K-RAS MUTATIONS; BREAST-CANCER; DNA PROBES; EGFR; CETUXIMAB; PCR; ASSAYS; CARCINOMA	Background: Testing for tumor specific mutations on routine formalin-fixed paraffin-embedded (FFPE) tissues may predict response to treatment in Medical Oncology and has already entered diagnostics, with KRAS mutation assessment as a paradigm. The highly sensitive real time PCR (Q-PCR) methods developed for this purpose are usually standardized under optimal template conditions. In routine diagnostics, however, suboptimal templates pose the challenge. Herein, we addressed the applicability of sequencing and two Q-PCR methods on prospectively assessed diagnostic cases for KRAS mutations. Methodology/Principal Findings: Tumor FFPE-DNA from 135 diagnostic and 75 low-quality control samples was obtained upon macrodissection, tested for fragmentation and assessed for KRAS mutations with dideoxy-sequencing and with two QPCR methods (Taqman-minor-groove-binder [TMGB] probes and DxS-KRAS-IVD). Samples with relatively well preserved DNA could be accurately analyzed with sequencing, while Q-PCR methods yielded informative results even in cases with very fragmented DNA (p<0.0001) with 100% sensitivity and specificity vs each other. However, Q-PCR efficiency (Ct values) also depended on DNA-fragmentation (p<0.0001). Q-PCR methods were sensitive to detect <= 1% mutant cells, provided that samples yielded cycle thresholds (Ct) <29, but this condition was met in only 38.5% of diagnostic samples. In comparison, FFPE samples (>99%) could accurately be analyzed at a sensitivity level of 10% (external validation of TMGB results). DNA quality and tumor cell content were the main reasons for discrepant sequencing/Q-PCR results (1.5%). Conclusions/Significance: Diagnostic targeted mutation assessment on FFPE-DNA is very efficient with Q-PCR methods in comparison to dideoxy-sequencing. However, DNA fragmentation/amplification capacity and tumor DNA content must be considered for the interpretation of Q-PCR results in order to provide accurate information for clinical decision making.			Kotoula, V (corresponding author), Aristotle Univ Thessaloniki, Dept Pathol, Papageorgiou Hosp, Sch Med, GR-54006 Thessaloniki, Greece.	vkotoula@auth.gr	Malousi, Andigoni D/A-9460-2012; Malousi, Andigoni/K-3754-2019; Fountzilas, George/ABF-2139-2020	Malousi, Andigoni D/0000-0002-1968-7020; 				Amado RG, 2008, J CLIN ONCOL, V26, P1626, DOI 10.1200/JCO.2007.14.7116; Andreassen CN, 2004, RADIOTHER ONCOL, V72, P351, DOI 10.1016/j.radonc.2004.07.006; Andreyev HJN, 1997, GUT, V41, P323, DOI 10.1136/gut.41.3.323; Andreyev HJN, 1998, J NATL CANCER I, V90, P675, DOI 10.1093/jnci/90.9.675; Ang PW, 2008, CLIN CHEM LAB MED, V46, P1117, DOI 10.1515/CCLM.2008.217; Bach PB, 2009, NEW ENGL J MED, V360, P626, DOI 10.1056/NEJMhpr0807774; Beeghly-Fadiel A, 2008, CANCER RES, V68, P6453, DOI 10.1158/0008-5472.CAN-08-0636; Benlloch S, 2006, J MOL DIAGN, V8, P540, DOI 10.2353/jmoldx.2006.060070; Brink M, 2003, CARCINOGENESIS, V24, P703, DOI 10.1093/carcin/bgg009; BURMER GC, 1991, ENVIRON HEALTH PERSP, V93, P27, DOI 10.2307/3431164; Ciardiello F, 2008, NEW ENGL J MED, V358, P1160, DOI 10.1056/NEJMra0707704; Cronin M, 2004, AM J PATHOL, V164, P35, DOI 10.1016/S0002-9440(10)63093-3; Cross J, 2008, PHARMACOGENOMICS, V9, P463, DOI 10.2217/14622416.9.4.463; Cukier HN, 2009, ANAL BIOCHEM, V386, P288, DOI 10.1016/j.ab.2008.11.040; De La Vega FA, 2005, MUTAT RES-FUND MOL M, V573, P111, DOI 10.1016/j.mrfmmm.2005.01.008; De Roock W, 2008, ANN ONCOL, V19, P508, DOI 10.1093/annonc/mdm496; Di Nicolantonio F, 2008, J CLIN ONCOL, V26, P5705, DOI 10.1200/JCO.2008.18.0786; Do H, 2008, BMC CANCER, V8, DOI 10.1186/1471-2407-8-142; *EMEA, 2007, EMEA4051132007; *EMEA, 2008, EMEACHMP2804022008; FEARON ER, 1990, CELL, V61, P759, DOI 10.1016/0092-8674(90)90186-I; Frayling IM, 2002, J CLIN PATHOL-MOL PA, V55, P73, DOI 10.1136/mp.55.2.73; Gibson NJ, 2006, CLIN CHIM ACTA, V363, P32, DOI 10.1016/j.cccn.2005.06.022; Hewitt SM, 2008, ARCH PATHOL LAB MED, V132, P1929, DOI 10.1043/1543-2165-132.12.1929; Itabashi T, 2004, INT J ONCOL, V24, P687; JIMENO A, 2009, J CLIN ONCOL; Johnson NA, 2006, LAB INVEST, V86, P968, DOI 10.1038/labinvest.3700441; Karapetis CS, 2008, NEW ENGL J MED, V359, P1757, DOI 10.1056/NEJMoa0804385; Kim S, 2007, ANNU REV BIOMED ENG, V9, P289, DOI 10.1146/annurev.bioeng.9.060906.152037; Kosel S, 2001, NEUROGENETICS, V3, P163; Kutyavin IV, 2000, NUCLEIC ACIDS RES, V28, P655, DOI 10.1093/nar/28.2.655; Legrand B, 2002, FORENSIC SCI INT, V125, P205, DOI 10.1016/S0379-0738(01)00641-7; Letertre C, 2003, MOL CELL PROBE, V17, P307, DOI 10.1016/j.mcp.2003.08.004; Lievre A, 2006, CANCER RES, V66, P3992, DOI 10.1158/0008-5472.CAN-06-0191; Lievre A, 2008, J CLIN ONCOL, V26, P374, DOI 10.1200/JCO.2007.12.5906; Lim EH, 2007, J THORAC ONCOL, V2, P387, DOI 10.1097/01.JTO.0000268671.49378.c2; Marchetti A, 2006, NEW ENGL J MED, V354, P526; Messersmith WA, 2008, NEW ENGL J MED, V359, P1834, DOI 10.1056/NEJMe0806778; Morita A, 2007, MOL CELL PROBE, V21, P171, DOI 10.1016/j.mcp.2006.10.005; Morlan J, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0004584; Nielsen K, 2008, FORENSIC SCI INT-GEN, V2, P226, DOI 10.1016/j.fsigen.2008.02.008; Ogino S, 2005, J MOL DIAGN, V7, P413, DOI 10.1016/S1525-1578(10)60571-5; Ogino S, 2009, J CLIN ONCOL, V27, P1477, DOI 10.1200/JCO.2008.18.6544; Packham D, 2009, DIAGN MOL PATHOL, V18, P62, DOI 10.1097/PDM.0b013e318182af52; Paik S, 2005, NAT CLIN PRACT ONCOL, V2, P246, DOI 10.1038/ncponc0171; PRETLOW TP, 1993, J NATL CANCER I, V85, P2004, DOI 10.1093/jnci/85.24.2004; Quach Nancy, 2004, BMC Clin Pathol, V4, P1, DOI 10.1186/1472-6890-4-1; Rauser S, 2007, CLIN CANCER RES, V13, P5115, DOI 10.1158/1078-0432.CCR-07-0465; Ruiz MIG, 2007, CELL ONCOL, V29, P257; Sartore-Bianchi A, 2009, CANCER RES, V69, P1851, DOI 10.1158/0008-5472.CAN-08-2466; Stewart DJ, 2009, J CLIN ONCOL, V27, P328, DOI 10.1200/JCO.2008.18.9621; Tol J, 2009, NEW ENGL J MED, V360, P563, DOI 10.1056/NEJMoa0808268; van Dongen JJM, 2003, LEUKEMIA, V17, P2257, DOI 10.1038/sj.leu.2403202; van Krieken JHJM, 2008, VIRCHOWS ARCH, V453, P417, DOI 10.1007/s00428-008-0665-y; von Ahlfen S, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0001261; Wang FF, 2007, J MOL DIAGN, V9, P441, DOI 10.2353/jmoldx.2007.070004; Zhu CQ, 2008, J CLIN ONCOL, V26, P4268, DOI 10.1200/JCO.2007.14.8924	57	74	76	0	4	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	NOV 4	2009	4	11							e7746	10.1371/journal.pone.0007746	http://dx.doi.org/10.1371/journal.pone.0007746			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	514RZ	19888477	Green Published, Green Submitted, gold			2022-12-25	WOS:000271414600012
J	Levinson, NM; Visperas, PR; Kuriyan, J				Levinson, Nicholas M.; Visperas, Patrick R.; Kuriyan, John			The Tyrosine Kinase Csk Dimerizes through Its SH3 Domain	PLOS ONE			English	Article							TERMINAL SRC KINASE; C-SRC; CRYSTAL-STRUCTURE; STRUCTURAL BASIS; PHOSPHATASE PEP; P50(CSK); ACTIVATION; SEQUENCE; BINDING; HCK	The Src family kinases possess two sites of tyrosine phosphorylation that are critical to the regulation of kinase activity. Autophosphorylation on an activation loop tyrosine residue (Tyr 416 in commonly used chicken c-Src numbering) increases catalytic activity, while phosphorylation of a C-terminal tyrosine (Tyr 527 in c-Src) inhibits activity. The latter modification is achieved by the tyrosine kinase Csk (C-terminal Src Kinase), but the complete inactivation of the Src family kinases also requires the dephosphorylation of the activation loop tyrosine. The SH3 domain of Csk recruits the tyrosine phosphatase PEP, allowing for the coordinated inhibition of Src family kinase activity. We have discovered that Csk forms homodimers through interactions mediated by the SH3 domain in a manner that buries the recognition surface for SH3 ligands. The formation of this dimer would therefore block the recruitment of tyrosine phosphatases and may have important implications for the regulation of Src kinase activity.			Levinson, NM (corresponding author), Univ Calif Berkeley, Dept Mol & Cell Biol, 229 Stanley Hall, Berkeley, CA 94720 USA.	kuriyan@berkeley.edu		Levinson, Nicholas/0000-0003-4338-8087	Howard Hughes Medical Institute Funding Source: Medline	Howard Hughes Medical Institute(Howard Hughes Medical Institute)		BORCHERT TV, 1994, FEBS LETT, V341, P79, DOI 10.1016/0014-5793(94)80244-0; Brown MT, 1996, BBA-REV CANCER, V1287, P121, DOI 10.1016/0304-419X(96)00003-0; Cloutier JF, 1996, EMBO J, V15, P4909, DOI 10.1002/j.1460-2075.1996.tb00871.x; Cloutier JF, 1999, J EXP MED, V189, P111, DOI 10.1084/jem.189.1.111; CLOUTIER JF, 1995, MOL CELL BIOL, V15, P5937; Davidson D, 1997, J BIOL CHEM, V272, P23455, DOI 10.1074/jbc.272.37.23455; FENG SB, 1994, SCIENCE, V266, P1241, DOI 10.1126/science.7526465; Ghose R, 2001, NAT STRUCT BIOL, V8, P998, DOI 10.1038/nsb1101-998; Gregorieff A, 1998, J BIOL CHEM, V273, P13217, DOI 10.1074/jbc.273.21.13217; Kawabuchi M, 2000, NATURE, V404, P999, DOI 10.1038/35010121; Kholodenko BN, 2000, TRENDS CELL BIOL, V10, P173, DOI 10.1016/S0962-8924(00)01741-4; Kuriyan J, 1997, ANNU REV BIOPH BIOM, V26, P259, DOI 10.1146/annurev.biophys.26.1.259; Kuriyan J, 2007, NATURE, V450, P983, DOI 10.1038/nature06524; Levinson NM, 2008, CELL, V134, P124, DOI 10.1016/j.cell.2008.05.051; LIM WA, 1994, NATURE, V372, P375, DOI 10.1038/372375a0; Moarefi I, 1997, NATURE, V385, P650, DOI 10.1038/385650a0; Ogawa A, 2002, J BIOL CHEM, V277, P14351, DOI 10.1074/jbc.C200086200; OKADA M, 1991, J BIOL CHEM, V266, P24249; SABE H, 1994, P NATL ACAD SCI USA, V91, P3984, DOI 10.1073/pnas.91.9.3984; Schindler T, 1999, MOL CELL, V3, P639, DOI 10.1016/S1097-2765(00)80357-3; Sicheri F, 1997, NATURE, V385, P602, DOI 10.1038/385602a0; Takeuchi S, 2000, J BIOL CHEM, V275, P29183, DOI 10.1074/jbc.C000326200; TAKEYA T, 1983, CELL, V32, P881, DOI 10.1016/0092-8674(83)90073-9; Xu WQ, 1997, NATURE, V385, P595, DOI 10.1038/385595a0; Xu WQ, 1999, MOL CELL, V3, P629, DOI 10.1016/S1097-2765(00)80356-1; Yamaguchi H, 1996, NATURE, V384, P484, DOI 10.1038/384484a0	26	19	21	0	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	NOV 4	2009	4	11							e7683	10.1371/journal.pone.0007683	http://dx.doi.org/10.1371/journal.pone.0007683			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	514RZ	19888460	Green Submitted, Green Published, gold			2022-12-25	WOS:000271414600006
J	Nowak, DG; Amin, EM; Rennel, ES; Hoareau-Aveilla, C; Gammons, M; Damodoran, G; Hagiwara, M; Harper, SJ; Woolard, J; Ladomery, MR; Bates, DO				Nowak, Dawid G.; Amin, Elianna Mohamed; Rennel, Emma S.; Hoareau-Aveilla, Coralie; Gammons, Melissa; Damodoran, Gopinath; Hagiwara, Masatoshi; Harper, Steven J.; Woolard, Jeanette; Ladomery, Michael R.; Bates, David O.			Regulation of Vascular Endothelial Growth Factor (VEGF) Splicing from Pro-angiogenic to Anti-angiogenic Isoforms A NOVEL THERAPEUTIC STRATEGY FOR ANGIOGENESIS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; FACTOR-I; MESSENGER-RNA; COLORECTAL-CARCINOMA; CELL CARCINOMA; BETA-II; EXPRESSION; INSULIN; VEGF(165)B; PHOSPHORYLATION	Vascular endothelial growth factor (VEGF) is produced either as a pro-angiogenic or anti-angiogenic protein depending upon splice site choice in the terminal, eighth exon. Proximal splice site selection (PSS) in exon 8 generates pro-angiogenic isoforms such as VEGF165, and distal splice site selection (DSS) results in anti-angiogenic isoforms such as VEGF165b. Cellular decisions on splice site selection depend upon the activity of RNA-binding splice factors, such as ASF/SF2, which have previously been shown to regulate VEGF splice site choice. To determine the mechanism by which the pro-angiogenic splice site choice is mediated, we investigated the effect of inhibition of ASF/SF2 phosphorylation by SR protein kinases (SRPK1/2) on splice site choice in epithelial cells and in in vivo angiogenesis models. Epithelial cells treated with insulin-like growth factor-1 (IGF-1) increased PSS and produced more VEGF165 and less VEGF165b. This down-regulation of DSS and increased PSS was blocked by protein kinase C inhibition and SRPK1/2 inhibition. IGF-1 treatment resulted in nuclear localization of ASF/SF2, which was blocked by SPRK1/2 inhibition. Pull-down assay and RNA immunoprecipitation using VEGF mRNA sequences identified an 11-nucleotide sequence required for ASF/SF2 binding. Injection of an SRPK1/2 inhibitor reduced angiogenesis in a mouse model of retinal neovascularization, suggesting that regulation of alternative splicing could be a potential therapeutic strategy in angiogenic pathologies.	[Amin, Elianna Mohamed; Ladomery, Michael R.] Univ W England, Sch Life Sci, Ctr Biomed Res, Bristol BS16 1QY, Avon, England; [Nowak, Dawid G.; Rennel, Emma S.; Hoareau-Aveilla, Coralie; Gammons, Melissa; Damodoran, Gopinath; Harper, Steven J.; Woolard, Jeanette; Bates, David O.] Univ Bristol, Sch Vet Sci, Dept Physiol & Pharmacol, Microvasc Res Labs,Bristol Heart Inst, Bristol BS2 8EJ, Avon, England; [Hagiwara, Masatoshi] Univ Tokyo, Sch Dent Med, Dept Genet, Tokyo 1138510, Japan	University of West England; University of Bristol; University of Tokyo	Ladomery, MR (corresponding author), Univ W England, Sch Life Sci, Ctr Biomed Res, Bristol BS16 1QY, Avon, England.	michael.Ladomery@uwe.ac.uk; Dave.Bates@bris.ac.uk	Hoareau-Aveilla, Coralie/G-3787-2017	Hoareau-Aveilla, Coralie/0000-0001-5506-4552; gammons, melissa/0000-0001-9661-9331; Bates, David/0000-0003-4850-2360; Woolard, Jeanette/0000-0001-5406-6847	British Heart Foundation [FS/04/09, BS/06/005]; Wellcome Trust [79633]; University of West of England; Richard Bright VEGF Research Trust, Fight for Sight, Cancer Research UK [C11392/A10484]; Skin Cancer Research Fund	British Heart Foundation(British Heart Foundation); Wellcome Trust(Wellcome TrustEuropean Commission); University of West of England; Richard Bright VEGF Research Trust, Fight for Sight, Cancer Research UK(Cancer Research UK); Skin Cancer Research Fund	This work was supported by the British Heart Foundation (FS/04/09 and BS/06/005), the Wellcome Trust (79633), a University of West of England Bristol PhD Studentship, the Richard Bright VEGF Research Trust, Fight for Sight, Cancer Research UK (C11392/A10484), and the Skin Cancer Research Fund.	Bakkour N, 2007, PLOS PATHOG, V3, P1530, DOI 10.1371/journal.ppat.0030159; Bastide A, 2008, NUCLEIC ACIDS RES, V36, P2434, DOI 10.1093/nar/gkn093; Bates DO, 2002, CANCER RES, V62, P4123; Beckert S, 2006, BIOCHEM BIOPH RES CO, V341, P67, DOI 10.1016/j.bbrc.2005.12.148; Blaustein M, 2005, NAT STRUCT MOL BIOL, V12, P1037, DOI 10.1038/nsmb1020; Blaustein M, 2004, J BIOL CHEM, V279, P21029, DOI 10.1074/jbc.M314260200; Bruno IG, 2004, HUM MOL GENET, V13, P2409, DOI 10.1093/hmg/ddh272; Colwill K, 1996, J BIOL CHEM, V271, P24569, DOI 10.1074/jbc.271.40.24569; Dieudonne SC, 2007, OPHTHALMIC RES, V39, P148, DOI 10.1159/000103234; Duh E, 1999, DIABETES, V48, P1899, DOI 10.2337/diabetes.48.10.1899; Ergorul C, 2008, MOL VIS, V14, P1517; Fukuhara T, 2006, P NATL ACAD SCI USA, V103, P11329, DOI 10.1073/pnas.0604616103; GRANT M, 1986, DIABETES, V35, P416, DOI 10.2337/diabetes.35.4.416; GRANT MB, 1993, DIABETOLOGIA, V36, P282, DOI 10.1007/BF00400229; GUI JF, 1994, NATURE, V369, P678, DOI 10.1038/369678a0; Hagiwara M, 2005, BBA-PROTEINS PROTEOM, V1754, P324, DOI 10.1016/j.bbapap.2005.09.010; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; Harper SJ, 2008, NAT REV CANCER, V8, P880, DOI 10.1038/nrc2505; Hayes GM, 2006, CANCER RES, V66, P3819, DOI 10.1158/0008-5472.CAN-05-4065; Hayes GM, 2007, CANCER RES, V67, P2072, DOI 10.1158/0008-5472.CAN-06-2969; HOUCK KA, 1991, MOL ENDOCRINOL, V5, P1806, DOI 10.1210/mend-5-12-1806; Hovhannisyan RH, 2006, NUCLEIC ACIDS RES, V34, P373, DOI 10.1093/nar/gkj407; Jang SW, 2008, CANCER RES, V68, P4559, DOI 10.1158/0008-5472.CAN-08-0021; Karni R, 2007, NAT STRUCT MOL BIOL, V14, P185, DOI 10.1038/nsmb1209; Kerbel RS, 2008, NEW ENGL J MED, V358, P2039, DOI 10.1056/NEJMra0706596; Konopatskaya O, 2006, MOL VIS, V12, P626; Lynch KW, 2000, MOL CELL BIOL, V20, P70, DOI 10.1128/MCB.20.1.70-80.2000; Ma CT, 2008, J MOL BIOL, V376, P55, DOI 10.1016/j.jmb.2007.08.029; Miele C, 2000, J BIOL CHEM, V275, P21695, DOI 10.1074/jbc.M000805200; Muraki M, 2004, J BIOL CHEM, V279, P24246, DOI 10.1074/jbc.M314298200; NAKAOHAYASHI J, 1992, ATHEROSCLEROSIS, V92, P141, DOI 10.1016/0021-9150(92)90273-J; Nowak DG, 2008, J CELL SCI, V121, P3487, DOI 10.1242/jcs.016410; Oh JS, 2002, NEOPLASIA, V4, P204, DOI 10.1038/sj.neo.7900229; Patel NA, 2005, J BIOL CHEM, V280, P14302, DOI 10.1074/jbc.M411485200; Patel NA, 2001, J BIOL CHEM, V276, P22648, DOI 10.1074/jbc.M101260200; Perrin RM, 2005, DIABETOLOGIA, V48, P2422, DOI 10.1007/s00125-005-1951-8; Pilch B, 2001, CANCER RES, V61, P6876; Poulaki V, 2003, J CLIN ENDOCR METAB, V88, P5392, DOI 10.1210/jc.2003-030389; Pritchard-Jones RO, 2007, BRIT J CANCER, V97, P223, DOI 10.1038/sj.bjc.6603839; Rennel ES, 2008, BRIT J CANCER, V98, P1250, DOI 10.1038/sj.bjc.6604309; Saleem MA, 2002, J AM SOC NEPHROL, V13, DOI 10.1681/ASN.V133630; Schumacher VA, 2007, J AM SOC NEPHROL, V18, P719, DOI 10.1681/ASN.2006020124; Shigematsu Satoshi, 1999, Endocrine Journal, V46, pS59, DOI 10.1507/endocrj.46.Suppl_S59; Slomiany MG, 2006, BIOCHEM BIOPH RES CO, V342, P851, DOI 10.1016/j.bbrc.2006.02.043; Slomiany MG, 2004, INVEST OPHTH VIS SCI, V45, P2838, DOI 10.1167/iovs.03-0565; SMITH LEH, 1994, INVEST OPHTH VIS SCI, V35, P101; Varey AHR, 2008, BRIT J CANCER, V98, P1366, DOI 10.1038/sj.bjc.6604308; Voelker RB, 2007, GENOME RES, V17, P1023, DOI 10.1101/gr.6017807; Wang HY, 1998, J CELL BIOL, V140, P737, DOI 10.1083/jcb.140.4.737; Wang YZ, 1998, PROSTATE, V35, P165; Warren RS, 1996, J BIOL CHEM, V271, P29483, DOI 10.1074/jbc.271.46.29483; Wheeler TM, 2007, J CLIN INVEST, V117, P3952, DOI 10.1172/JCI33355; Woolard J, 2004, CANCER RES, V64, P7822, DOI 10.1158/0008-5472.CAN-04-0934	53	162	173	1	36	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 19	2010	285	8					5532	5540		10.1074/jbc.M109.074930	http://dx.doi.org/10.1074/jbc.M109.074930			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	565WQ	19906640	Green Published, hybrid			2022-12-25	WOS:000275327200046
J	Ozer, BH; Wiepz, GJ; Bertics, PJ				Ozer, B. H.; Wiepz, G. J.; Bertics, P. J.			Activity and cellular localization of an oncogenic glioblastoma multiforme-associated EGF receptor mutant possessing a duplicated kinase domain	ONCOGENE			English	Article						EGF receptor (EGFR); glioblastoma multiforme; constitutive activity; duplicate kinase domains	EPIDERMAL-GROWTH-FACTOR; PROTEIN-TYROSINE KINASE; SIGNAL-TRANSDUCTION; TANDEM DUPLICATION; MALIGNANT GLIOMAS; DOWN-REGULATION; BRAIN-TUMORS; ACTIVATION; INTERNALIZATION; PHOSPHORYLATION	A mutation of the epidermal growth factor receptor (EGFR) that results in a tandem kinase domain duplication (TKD-EGFR) has been described in glioblastoma multiforme biopsies and cell lines. Although the TKD-EGFR confers tumorigenicity, little is known about the molecular underpinnings of receptor dysregulation. Therefore, we transfected B82L mouse fibroblast cells devoid of endogenous EGFR to determine the molecular mechanisms of receptor activation when expressed in cells as well as the contribution of each duplicated kinase domain to receptor phosphorylation. The TKD-EGFR displayed chronically elevated basal autophosphorylation at five known phosphotyrosine sites. The chronically phosphorylated TKD-EGFR was also resistant to competitive inhibition of ligand-binding compared with wild-type EGFR (WT-EGFR) and showed undetectable levels of basal dimerization, suggesting the TKD-EGFR escapes known mechanisms of receptor downregulation. Immunofluorescence analyses revealed a substantial portion of the TKD-EGFR resides in the cytosol in an activated state, although surface-localized subsets of the receptor retain ligand responsiveness. Kinase activity-deficient knockouts of the N-terminal or the C-terminal kinase domains generated TKD-EGFRs that recapitulate the autophosphorylation/localization patterns of a constitutively activated receptor versus a WT-like EGFR, respectively. Investigation of the molecular activity of the TKD-EGFR yields evidence for a unique mechanism of constitutive activity and dual kinase domain activation. Oncogene (2010) 29, 855-864; doi:10.1038/onc.2009.385; published online 16 November 2009	[Bertics, P. J.] Univ Wisconsin, Dept Biomol Chem, Med Sci Ctr 571A, Madison, WI 53706 USA	University of Wisconsin System; University of Wisconsin Madison	Bertics, PJ (corresponding author), Univ Wisconsin, Dept Biomol Chem, Med Sci Ctr 571A, 1300 Univ Ave, Madison, WI 53706 USA.	pbertics@wisc.edu			NIH [R33 CA122892, R01 CA108467]; NSF [DMR-0520527]; NATIONAL CANCER INSTITUTE [R33CA122892, R01CA108467] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM008692] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NSF(National Science Foundation (NSF)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	We thank MJ Ciesielski and RA Fenstermaker for generously providing the pLXIN plasmids of the TKD-EGFR mutant. In addition, we thank CR Peet for her helpful discussions and assistance in reviewing the paper and TL Becker for her advice on statistical analyses. This work was supported in part by grants from the NIH (R33 CA122892, R01 CA108467), and from the NSF (MRSEC Award DMR-0520527).	Anjum R, 2008, NAT REV MOL CELL BIO, V9, P747, DOI 10.1038/nrm2509; BERTICS PJ, 1985, J BIOL CHEM, V260, P4642; Blume-Jensen P, 2001, NATURE, V411, P355, DOI 10.1038/35077225; Bondy ML, 2008, CANCER-AM CANCER SOC, V113, P1953, DOI 10.1002/cncr.23741; Brockmann MA, 2003, NEUROSURGERY, V52, P1391, DOI 10.1227/01.NEU.0000064806.87785.AB; CHEN WS, 1987, NATURE, V328, P820, DOI 10.1038/328820a0; Chu CT, 1997, BIOCHEM J, V324, P855, DOI 10.1042/bj3240855; Ciesielski MJ, 2000, ONCOGENE, V19, P810, DOI 10.1038/sj.onc.1203409; Collins VP, 2004, J NEUROL NEUROSUR PS, V75, P2, DOI 10.1136/jnnp.2004.040337; Dummler BA, 2005, J BIOL CHEM, V280, P13304, DOI 10.1074/jbc.M408194200; Edwin Francis, 2006, V327, P1; EKSTRAND AJ, 1991, CANCER RES, V51, P2164; Fenstermaker RA, 1998, ONCOGENE, V16, P3435, DOI 10.1038/sj.onc.1202156; Fenstermaker RA, 2007, CURR GENOMICS, V8, P163, DOI 10.2174/138920207780833838; Frederick L, 2000, CANCER RES, V60, P1383; GILL GN, 1984, J BIOL CHEM, V259, P7755; Grandal MV, 2007, CARCINOGENESIS, V28, P1408, DOI 10.1093/carcin/bgm058; HONEGGER AM, 1987, CELL, V51, P199, DOI 10.1016/0092-8674(87)90147-4; Huang HJS, 1997, J BIOL CHEM, V272, P2927, DOI 10.1074/jbc.272.5.2927; Jensen RL, 1998, SURG NEUROL, V49, P189, DOI 10.1016/S0090-3019(97)00218-8; Jiang XJ, 2003, MOL BIOL CELL, V14, P858, DOI 10.1091/mbc.E02-08-0532; Jorissen RN, 2003, EXP CELL RES, V284, P31, DOI 10.1016/S0014-4827(02)00098-8; Landau M, 2004, STRUCTURE, V12, P2265, DOI 10.1016/j.str.2004.10.006; Ohgaki H, 2005, J NEUROPATH EXP NEUR, V64, P479, DOI 10.1093/jnen/64.6.479; POLLACK IF, 1991, J NEUROSURG, V75, P284, DOI 10.3171/jns.1991.75.2.0284; Poppleton HM, 1999, ARCH BIOCHEM BIOPHYS, V363, P227, DOI 10.1006/abbi.1998.1095; Riese DJ, 2007, BIOESSAYS, V29, P558, DOI 10.1002/bies.20582; Saharinen P, 2002, J BIOL CHEM, V277, P47954, DOI 10.1074/jbc.M205156200; Sato J D, 1983, Mol Biol Med, V1, P511; Sihto H, 2005, J MOL MED, V83, P976, DOI 10.1007/s00109-005-0699-4; Smith KJ, 2004, STRUCTURE, V12, P1067, DOI 10.1016/j.str.2004.02.040; Tang P, 1997, J NEURO-ONCOL, V35, P303, DOI 10.1023/A:1005824802617; Wen PY, 2008, NEW ENGL J MED, V359, P492, DOI 10.1056/NEJMra0708126; Zhang XW, 2006, CELL, V125, P1137, DOI 10.1016/j.cell.2006.05.013	34	18	19	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 11	2010	29	6					855	864		10.1038/onc.2009.385	http://dx.doi.org/10.1038/onc.2009.385			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	553WP	19915609	Green Accepted			2022-12-25	WOS:000274397800008
J	Lindahl, E; Nyman, U; Zaman, F; Palmberg, C; Cascante, A; Shafqat, J; Takigawa, M; Savendahl, L; Jorvall, H; Joseph, B				Lindahl, Emma; Nyman, Ulrika; Zaman, Farasat; Palmberg, Carina; Cascante, Anna; Shafqat, Jawed; Takigawa, Masaharu; Savendahl, Lars; Jorvall, Hans; Joseph, Bertrand			Proinsulin C-peptide Regulates Ribosomal RNA Expression	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TYPE-1 DIABETIC-NEUROPATHY; RDNA TRANSCRIPTION; INSULIN; ACETYLATION; CELLS; PROLIFERATION; METHYLATION; APOPTOSIS; CHROMATIN; MELLITUS	Proinsulin C-peptide is internalized into cells, but a function of its intracellular localization has not been established. We now demonstrate that, upon cellular entry, C-peptide is localized to the nucleoli, where it promotes transcription of genes encoding for ribosomal RNA. We find that C-peptide binds to histones and enhances acetylation of lysine residue 16 of histone H4 at the promoter region of genes for ribosomal RNA. In agreement with synchrony of ribosomal RNA synthesis and cell proliferation, we show that C-peptide stimulates proliferation in chondrocytes and HEK-293 cells. This regulation of ribosomal RNA provides a mechanism by which C-peptide can exert transcriptional effects and implies that the peptide has growth factor activity.	[Lindahl, Emma; Palmberg, Carina; Shafqat, Jawed; Jorvall, Hans] Karolinska Inst, Dept Med Biochem & Biophys, SE-17177 Stockholm, Sweden; [Nyman, Ulrika; Joseph, Bertrand] Karolinska Inst, Inst Environm Med, SE-17177 Stockholm, Sweden; [Zaman, Farasat; Savendahl, Lars] Karolinska Inst, Dept Woman & Child Hlth, Astrid Lindgren Childrens Hosp, SE-17177 Stockholm, Sweden; [Nyman, Ulrika; Joseph, Bertrand] Karolinska Inst, Dept Pathol & Oncol, SE-17177 Stockholm, Sweden; [Cascante, Anna] Karolinska Inst, Dept Neurosci, SE-17177 Stockholm, Sweden; [Takigawa, Masaharu] Okayama Univ, Grad Sch Med Dent & Pharmaceut Sci, Dept Biochem & Mol Dent, Okayama 7008525, Japan	Karolinska Institutet; Karolinska Institutet; Karolinska Institutet; Karolinska Institutet; Karolinska Institutet; Okayama University	Jorvall, H (corresponding author), Karolinska Inst, Dept Med Biochem & Biophys, SE-17177 Stockholm, Sweden.	Hans.Jornvall@ki.se	Lindahl, Emma/HHM-4459-2022; Zaman, Farasat/AAE-1144-2020; Nyman, Ulrika/D-3708-2013	Savendahl, Lars/0000-0003-1067-4976; Joseph, Bertrand/0000-0001-5655-9979; Cascante, Anna/0000-0002-8272-3098	Swedish Research Council; Ramon Areces Foundation; Swedish Cancer Society; Swedish Medical Society; Swedish Children's Cancer Foundation; Karolinska Institutet; Knut and Alice Wallenberg Foundation	Swedish Research Council(Swedish Research CouncilEuropean Commission); Ramon Areces Foundation; Swedish Cancer Society(Swedish Cancer Society); Swedish Medical Society; Swedish Children's Cancer Foundation; Karolinska Institutet(Karolinska Institutet); Knut and Alice Wallenberg Foundation(Knut & Alice Wallenberg Foundation)	This work was supported by the Swedish Research Council, the Ramon Areces Foundation, the Swedish Cancer Society, the Swedish Medical Society, the Swedish Children's Cancer Foundation, Karolinska Institutet, and the Knut and Alice Wallenberg Foundation.	Akhtar A, 2000, MOL CELL, V5, P367, DOI 10.1016/S1097-2765(00)80431-1; ANTONETTI DA, 1993, J BIOL CHEM, V268, P25277; CAHILL GF, 1973, NEW ENGL J MED, V288, P1181, DOI 10.1056/NEJM197305312882210; Calzuola I, 2005, PEPTIDES, V26, P2074, DOI 10.1016/j.peptides.2005.04.008; Chagin AS, 2006, J ENDOCRINOL, V188, P193, DOI 10.1677/joe.1.06364; Covelo G, 2006, J BIOCHEM, V140, P627, DOI 10.1093/jb/mvj197; Ekberg K, 2007, DIABETES CARE, V30, P71, DOI 10.2337/dc06-1274; Ghoshal K, 2004, J BIOL CHEM, V279, P6783, DOI 10.1074/jbc.M309393200; Grossso S, 2008, BIOCHEM BIOPH RES CO, V376, P65, DOI 10.1016/j.bbrc.2008.08.118; Grummt I, 2003, NAT REV MOL CELL BIO, V4, P641, DOI 10.1038/nrm1171; Hirschler-Laszkiewicz I, 2001, NUCLEIC ACIDS RES, V29, P4114, DOI 10.1093/nar/29.20.4114; Jagerbrink T, 2007, CELL MOL LIFE SCI, V64, P1310, DOI 10.1007/s00018-007-7136-5; Janghorbani M, 2007, AM J EPIDEMIOL, V166, P495, DOI 10.1093/aje/kwm106; Johansson BL, 2000, DIABETIC MED, V17, P181, DOI 10.1046/j.1464-5491.2000.00274.x; Joseph B, 2002, ONCOGENE, V21, P65, DOI 10.1038/sj/onc/1205018; Lawrence RJ, 2004, MOL CELL, V13, P599, DOI 10.1016/S1097-2765(04)00064-4; Li ZG, 2003, DIABETES-METAB RES, V19, P375, DOI 10.1002/dmrr.389; Lindahl E, 2007, CELL MOL LIFE SCI, V64, P479, DOI 10.1007/s00018-007-6467-6; Luppi P, 2009, DIABETOLOGIA, V52, P2218, DOI 10.1007/s00125-009-1476-7; Ohtomo Y, 1996, DIABETOLOGIA, V39, P199, DOI 10.1007/BF00403963; PAPAMARCAKI T, 1994, FEBS LETT, V345, P71, DOI 10.1016/0014-5793(94)00439-0; Pruitt K, 2006, PLOS GENET, V2, P344, DOI 10.1371/journal.pgen.0020040; Re RN, 2007, NAT CLIN PRACT CARD, V4, P549, DOI 10.1038/ncpcardio0985; RE RN, 1989, J MOL CELL CARDIOL, V21, P63, DOI 10.1016/0022-2828(89)90772-4; Rebsomen L, 2006, DIABETES METAB, V32, P223, DOI 10.1016/S1262-3636(07)70272-0; Rigler R, 1999, P NATL ACAD SCI USA, V96, P13318, DOI 10.1073/pnas.96.23.13318; RUBENSTEIN AH, 1969, NATURE, V224, P697, DOI 10.1038/224697a0; Santana RB, 2003, DIABETES, V52, P1502, DOI 10.2337/diabetes.52.6.1502; Santoro R, 2002, NAT GENET, V32, P393, DOI 10.1038/ng1010; Shafqat J, 2006, CELL MOL LIFE SCI, V63, P1805, DOI 10.1007/s00018-006-6204-6; Shogren-Knaak M, 2006, SCIENCE, V311, P844, DOI 10.1126/science.1124000; Sima AAF, 2004, EXP DIABESITY RES, V5, P65, DOI 10.1080/15438600490424541; STEINER DF, 1967, T NEW YORK ACAD SCI, V30, P60, DOI 10.1111/j.2164-0947.1967.tb02452.x; TAKIGAWA M, 1989, CANCER RES, V49, P3996; Wahren J, 2007, DIABETOLOGIA, V50, P503, DOI 10.1007/s00125-006-0559-y	35	35	39	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 29	2010	285	5					3462	3469		10.1074/jbc.M109.053587	http://dx.doi.org/10.1074/jbc.M109.053587			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	546RR	19917601	hybrid, Green Published			2022-12-25	WOS:000273829000060
J	Thomsen, T; Moeller, JB; Schlosser, A; Sorensen, GL; Moestrup, SK; Palaniyar, N; Wallis, R; Mollenhauer, J; Holmskov, U				Thomsen, Theresa; Moeller, Jesper B.; Schlosser, Anders; Sorensen, Grith L.; Moestrup, Soren K.; Palaniyar, Nades; Wallis, Russell; Mollenhauer, Jan; Holmskov, Uffe			The Recognition Unit of FIBCD1 Organizes into a Noncovalently Linked Tetrameric Structure and Uses a Hydrophobic Funnel (S1) for Acetyl Group Recognition	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MANNOSE-BINDING LECTIN; CA2+-DEPENDENT ANIMAL LECTINS; HUMAN M-FICOLIN; SWISS-MODEL; CRYSTAL-STRUCTURE; INNATE IMMUNITY; SUGAR LIGANDS; PROTEIN; MOLECULE; RECEPTOR	We have recently identified FIBCD1 (Fibrinogen C domain containing 1) as a type II transmembrane endocytic receptor located primarily in the intestinal brush border. The ectodomain of FIBCD1 comprises a coiled coil, a polycationic region, and a C-terminal FReD (fibrinogen-related domain) that assembles into disulfide-linked homotetramers. The FIBCD1-FReD binds Ca2+ dependently to acetylated structures like chitin, N-acetylated carbohydrates, and amino acids. FReDs are present in diverse innate immune pattern recognition proteins including the ficolins and horseshoe crab TL5A. Here, we use chemical cross-linking, combined with analytical ultracentrifugation and electron microscopy of the negatively stained recombinant FIBCD1-FReD to show that it assembles into noncovalent tetramers in the absence of the coiled coil. We use surface plasmon resonance, carbohydrate binding, and pulldown assays combined with site-directed mutagenesis to define the binding site involved in the interaction of FIBCD1 with acetylated structures. We show that mutations of central residues (A432V and H415G) in the hydrophobic funnel (S1) abolish the binding of FIBCD1 to acetylated bovine serum albumin and chitin. The double mutations (D393N/D395A) at the putative calcium-binding site reduce the ability of FIBCD1 to bind ligands. We conclude that the FReDs of FIBCD1 forms noncovalent tetramers and that the acetyl-binding site of FReDs of FIBCD1 is homologous to that of tachylectin 5A and M-ficolin but not to the FReD of L-ficolin. We suggest that the spatial organization of the FIBCD1-FReDs determine the molecular pattern recognition specificity and subsequent biological functions.	[Thomsen, Theresa; Moeller, Jesper B.; Schlosser, Anders; Sorensen, Grith L.; Mollenhauer, Jan; Holmskov, Uffe] Univ So Denmark, Ctr Med Biotechnol, DK-5000 Odense C, Denmark; [Moestrup, Soren K.] Univ Aarhus, Dept Med Biochem, DK-8000 Aarhus, Denmark; [Palaniyar, Nades] Hosp Sick Children, Toronto, ON M5G 2M9, Canada; [Palaniyar, Nades] Univ Toronto, Dept Lab Med & Pathobiol, Toronto, ON M5G 2M9, Canada; [Wallis, Russell] Univ Leicester, Dept Infect Immun & Inflammat, Leicester LE1 9HN, Leics, England; [Wallis, Russell] Univ Leicester, Dept Biochem, Leicester LE1 9HN, Leics, England	University of Southern Denmark; Aarhus University; University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of Toronto; University of Leicester; University of Leicester	Holmskov, U (corresponding author), Univ So Denmark, Ctr Med Biotechnol, Winsloevpk 25, DK-5000 Odense C, Denmark.	uholmskov@health.sdu.dk	Moestrup, Søren Kragh/A-1403-2014; Moestrup, Søren Kragh/AAD-1735-2019; Moeller, Jesper B/E-6377-2015; Holmskov, Uffe/AAA-3056-2022; Mollenhauer, Jan/G-4452-2012	Moestrup, Søren Kragh/0000-0003-3862-2107; Moeller, Jesper B/0000-0001-8786-8037; Holmskov, Uffe/0000-0002-2391-9445; Sorensen, Grith Lykke/0000-0002-5273-1097; Wallis, Russell/0000-0002-8705-5295; Palaniyar, Nades/0000-0002-2170-8548	Danish Council for Independent Research, Medical Sciences; Novo Nordisk Foundation; Lundbeck Foundation, Fonden; Canadian Institutes of Health Research [MOP-84312]; Lundbeck Foundation [R5-2006-446] Funding Source: researchfish; Medical Research Council [G0501425] Funding Source: researchfish; MRC [G0501425] Funding Source: UKRI	Danish Council for Independent Research, Medical Sciences(Det Frie Forskningsrad (DFF)); Novo Nordisk Foundation(Novo Nordisk FoundationNovocure Limited); Lundbeck Foundation, Fonden(Lundbeckfonden); Canadian Institutes of Health Research(Canadian Institutes of Health Research (CIHR)); Lundbeck Foundation(Lundbeckfonden); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))	This work was partially supported by the Danish Council for Independent Research, Medical Sciences; the Novo Nordisk Foundation; the Lundbeck Foundation, Fonden for L gevidenskabens Fremme; and Canadian Institutes of Health Research (MOP-84312; to N. P.).	Arnold K, 2006, BIOINFORMATICS, V22, P195, DOI 10.1093/bioinformatics/bti770; Barton WA, 2005, STRUCTURE, V13, P825, DOI 10.1016/j.str.2005.03.009; Cash HL, 2006, SCIENCE, V313, P1126, DOI 10.1126/science.1127119; Chiquet-Ehrismann R, 2004, INT J BIOCHEM CELL B, V36, P1085, DOI 10.1016/j.biocel.2004.01.007; Farrell DH, 2004, CURR OPIN HEMATOL, V11, P151, DOI 10.1097/01.moh.0000131440.02397.a4; Feinberg H, 2005, J BIOL CHEM, V280, P1327, DOI 10.1074/jbc.M409925200; Frederiksen PD, 2005, SCAND J IMMUNOL, V62, P462, DOI 10.1111/j.1365-3083.2005.01685.x; Garlatti V, 2007, J BIOL CHEM, V282, P35814, DOI 10.1074/jbc.M705741200; Garlatti V, 2007, EMBO J, V26, P623, DOI 10.1038/sj.emboj.7601500; Girija UV, 2007, J IMMUNOL, V179, P455, DOI 10.4049/jimmunol.179.1.455; Gokudan S, 1999, P NATL ACAD SCI USA, V96, P10086, DOI 10.1073/pnas.96.18.10086; Guex N, 1997, ELECTROPHORESIS, V18, P2714, DOI 10.1002/elps.1150181505; Holmskov U, 2003, ANNU REV IMMUNOL, V21, P547, DOI 10.1146/annurev.immunol.21.120601.140954; Hvidberg V, 2005, BLOOD, V106, P2572, DOI 10.1182/blood-2005-03-1185; IOBST ST, 1994, J BIOL CHEM, V269, P15512; IOBST ST, 1994, J BIOL CHEM, V269, P15505; Jones PF, 2003, J PATHOL, V201, P515, DOI 10.1002/path.1452; Kairies N, 2001, P NATL ACAD SCI USA, V98, P13519, DOI 10.1073/pnas.201523798; Kopp J, 2004, NUCLEIC ACIDS RES, V32, pD230, DOI 10.1093/nar/gkh008; Krarup A, 2005, INFECT IMMUN, V73, P1052, DOI 10.1128/IAI.73.2.1052-1060.2005; Krarup A, 2004, J BIOL CHEM, V279, P47513, DOI 10.1074/jbc.M407161200; Krarup A, 2008, IMMUNOL LETT, V118, P152, DOI 10.1016/j.imlet.2008.03.014; Kuraya M, 2005, IMMUNOBIOLOGY, V209, P689, DOI 10.1016/j.imbio.2004.11.001; Laue T.M., 1992, ANAL ULTRACENTRIFUGA, P90; Lee CG, 2008, CURR OPIN IMMUNOL, V20, P684, DOI 10.1016/j.coi.2008.10.002; Liu Y, 2005, J IMMUNOL, V175, P3150, DOI 10.4049/jimmunol.175.5.3150; Lynch NJ, 2004, J IMMUNOL, V172, P1198, DOI 10.4049/jimmunol.172.2.1198; Ma YG, 2004, J BIOL CHEM, V279, P25307, DOI 10.1074/jbc.M400701200; Matsushita M, 1996, J BIOL CHEM, V271, P2448, DOI 10.1074/jbc.271.5.2448; Matsushita M, 2000, J IMMUNOL, V164, P2281, DOI 10.4049/jimmunol.164.5.2281; NESTERENKO MV, 1994, J BIOCHEM BIOPH METH, V28, P239, DOI 10.1016/0165-022X(94)90020-5; PEITSCH MC, 1995, BIO-TECHNOL, V13, P658, DOI 10.1038/nbt0795-658; Reese TA, 2007, NATURE, V447, P92, DOI 10.1038/nature05746; Rossi V, 1998, J BIOL CHEM, V273, P1232, DOI 10.1074/jbc.273.2.1232; Runza VL, 2006, J ENDOTOXIN RES, V12, P120, DOI 10.1179/096805106X102147; Schlosser A, 2009, J IMMUNOL, V183, P3800, DOI 10.4049/jimmunol.0901526; Schuck P, 2000, BIOPHYS J, V78, P1606, DOI 10.1016/S0006-3495(00)76713-0; Schwede T, 2003, NUCLEIC ACIDS RES, V31, P3381, DOI 10.1093/nar/gkg520; Strong P, 2002, CLIN EXP ALLERGY, V32, P1794, DOI 10.1046/j.1365-2222.2002.01551.x; Tanio M, 2007, J BIOL CHEM, V282, P3889, DOI 10.1074/jbc.M608627200; Tanio M, 2009, BIOCHEM J, V417, P485, DOI 10.1042/BJ20081640; Teillet F, 2005, J IMMUNOL, V174, P2870, DOI 10.4049/jimmunol.174.5.2870; Wallis R, 1997, BIOCHEM J, V325, P391, DOI 10.1042/bj3250391; WEIS WI, 1994, STRUCTURE, V2, P1227, DOI 10.1016/S0969-2126(94)00124-3; Yee VC, 1997, STRUCTURE, V5, P125, DOI 10.1016/S0969-2126(97)00171-8; Zhang J, 2009, PLOS PATHOG, V5, DOI 10.1371/journal.ppat.1000282; Zhang PN, 2001, J BIOL CHEM, V276, P19862, DOI 10.1074/jbc.M100597200	47	25	26	1	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 8	2010	285	2					1229	1238		10.1074/jbc.M109.061523	http://dx.doi.org/10.1074/jbc.M109.061523			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	539MH	19892701	Green Published, hybrid			2022-12-25	WOS:000273258200045
J	Haimi, P; Hermansson, M; Batchu, KC; Virtanen, JA; Somerharju, P				Haimi, Perttu; Hermansson, Martin; Batchu, Krishna Chaithanya; Virtanen, Jorma A.; Somerharju, Pentti			Substrate Efflux Propensity Plays a Key Role in the Specificity of Secretory A-type Phospholipases	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TAUROCHOLATE MIXED MICELLES; TRANSITION-STATE ANALOG; MASS-SPECTROMETRY; CRYSTAL-STRUCTURE; INTERFACIAL CATALYSIS; ACTIVE-SITE; FATTY-ACID; ELECTROSPRAY-IONIZATION; VENOM PHOSPHOLIPASE-A2; UNILAMELLAR VESICLES	To better understand the principles underlying the substrate specificity of A-type phospholipases (PLAs), a high throughput mass spectrometric assay was employed to study the effect of acyl chain length and unsaturation of phospholipids on their rate of hydrolysis by three different secretory PLAs in micelles and vesicle bilayers. With micelles, each enzyme responded differently to substrate acyl chain unsaturation and double bond position, probably reflecting differences in the accommodative properties of their substrate binding sites. Experiments with saturated acyl positional isomers indicated that the length of the sn2 chain was more critical than that of the sn1 chain, suggesting tighter association of the former with the enzyme. Only the first 9-10 carbons of the sn2 acyl chain seem to interact intimately with the active site. Strikingly, no discrimination between positional isomers was observed with vesicles, and the rate of hydrolysis decreased far more with increasing chain length than with micelles, suggesting that translocation of the phospholipid substrate to the active site is rate-limiting with bilayers. Supporting this conclusion, acyl chain structure affected hydrolysis and spontaneous intervesicle transfer, which correlates with lipid efflux propensity, analogously. We conclude that substrate efflux propensity plays a more important role in the specificity of secretory PLA(2)s than commonly thought and could also be a key attribute in phospholipid homeostasis in which ( unknown) PLA2s are key players.	[Haimi, Perttu; Hermansson, Martin; Batchu, Krishna Chaithanya; Virtanen, Jorma A.; Somerharju, Pentti] Univ Helsinki, Inst Biomed, Dept Med Biochem & Dev Biol, FIN-00014 Helsinki, Finland	University of Helsinki	Hermansson, M (corresponding author), Univ Helsinki, Inst Biomed, Dept Med Biochem & Dev Biol, PL 63, FIN-00014 Helsinki, Finland.	martin.hermansson@helsinki.fi	Hermansson, Martin/B-7854-2008	Hermansson, Martin/0000-0003-3387-8365; Haimi, Perttu/0000-0002-9585-7968	Finnish Academy; University Helsinki Funds; Sigrid Juselius Foundation	Finnish Academy(Academy of Finland); University Helsinki Funds; Sigrid Juselius Foundation(Sigrid Juselius Foundation)	This work was supported by grants from the Finnish Academy, University Helsinki Funds, and Sigrid Juselius Foundation.	ALMGREN M, 1980, J AM CHEM SOC, V102, P7882, DOI 10.1021/ja00547a010; Asai K, 2003, J BIOL CHEM, V278, P8809, DOI 10.1074/jbc.M212117200; Baburina I, 1999, J BIOL CHEM, V274, P9400, DOI 10.1074/jbc.274.14.9400; Balsinde J, 1997, J BIOL CHEM, V272, P29317, DOI 10.1074/jbc.272.46.29317; BARTLETT EM, 1970, ANAL BIOCHEM, V36, P159, DOI 10.1016/0003-2697(70)90343-X; BERG OG, 1991, BIOCHEMISTRY-US, V30, P7283, DOI 10.1021/bi00243a034; BLOW D, 1991, NATURE, V351, P444, DOI 10.1038/351444a0; BURDGE GC, 1995, INT J BIOCHEM CELL B, V27, P1027, DOI 10.1016/1357-2725(95)00083-2; Burke JE, 2008, BIOCHEMISTRY-US, V47, P6451, DOI 10.1021/bi8000962; DEBOSE CD, 1985, BIOCHEMISTRY-US, V24, P1298, DOI 10.1021/bi00327a005; DENNIS EA, 1994, J BIOL CHEM, V269, P13057; Dennis EA, 1997, TRENDS BIOCHEM SCI, V22, P1, DOI 10.1016/S0968-0004(96)20031-3; Dessen A, 1999, CELL, V97, P349, DOI 10.1016/S0092-8674(00)80744-8; DIEZ E, 1994, BIOCHEM J, V301, P721, DOI 10.1042/bj3010721; Ejsing CS, 2006, ANAL CHEM, V78, P6202, DOI 10.1021/ac060545x; FOLCH J, 1957, J BIOL CHEM, V226, P497; FULLINGTON DA, 1993, BIOCHEMISTRY-US, V32, P12678, DOI 10.1021/bi00210a017; GHOMASHCHI F, 1991, BIOCHEMISTRY-US, V30, P7318, DOI 10.1021/bi00243a037; Ghosh M, 2006, PROG LIPID RES, V45, P487, DOI 10.1016/j.plipres.2006.05.003; Haimi P, 2006, ANAL CHEM, V78, P8324, DOI 10.1021/ac061390w; Hermansson M, 2005, ANAL CHEM, V77, P2166, DOI 10.1021/ac048489s; Hsu FF, 2009, J CHROMATOGR B, V877, P2673, DOI 10.1016/j.jchromb.2009.02.033; Ile KE, 2006, NAT CHEM BIOL, V2, P576, DOI 10.1038/nchembio835; Jain MK, 2006, CURR OPIN CHEM BIOL, V10, P473, DOI 10.1016/j.cbpa.2006.08.015; JAIN MK, 1993, BIOCHEMISTRY-US, V32, P8360, DOI 10.1021/bi00083a040; JONES JD, 1990, BIOCHEMISTRY-US, V29, P1593, DOI 10.1021/bi00458a034; Kainu V, 2008, J BIOL CHEM, V283, P3676, DOI 10.1074/jbc.M709176200; Kakela R, 2003, J NEUROCHEM, V84, P1051, DOI 10.1046/j.1471-4159.2003.01602.x; KUCERA GL, 1988, J BIOL CHEM, V263, P1920; Kudo I, 2002, PROSTAG OTH LIPID M, V68-9, P3, DOI 10.1016/S0090-6980(02)00020-5; Kudo N, 2008, P NATL ACAD SCI USA, V105, P488, DOI 10.1073/pnas.0709191105; KUMAR A, 1984, BIOCHIM BIOPHYS ACTA, V769, P419, DOI 10.1016/0005-2736(84)90326-2; LEWIS KA, 1990, BIOCHEMISTRY-US, V29, P9962, DOI 10.1021/bi00494a029; Lin Y, 1998, SCIENCE, V279, P1925, DOI 10.1126/science.279.5358.1925; LOMBARDO D, 1986, J BIOL CHEM, V261, P1663; MacCallum JL, 2006, J AM CHEM SOC, V128, P125, DOI 10.1021/ja0535099; Malinina L, 2006, PLOS BIOL, V4, P1996, DOI 10.1371/journal.pbio.0040362; MASSEY JB, 1984, BIOCHIM BIOPHYS ACTA, V794, P274, DOI 10.1016/0005-2760(84)90156-5; MCLEAN LR, 1984, BIOCHEMISTRY-US, V23, P4624, DOI 10.1021/bi00315a017; MERKL I, 1963, J BIOL CHEM, V238, P905; Miyamoto S, 2003, LIPIDS, V38, P641, DOI 10.1007/s11745-003-1109-6; Mousley CJ, 2007, BBA-MOL CELL BIOL L, V1771, P727, DOI 10.1016/j.bbalip.2007.04.002; NICHOLS JW, 1988, BIOCHEMISTRY-US, V27, P3925, DOI 10.1021/bi00411a006; OTTEN D, 1995, BIOPHYS J, V68, P584, DOI 10.1016/S0006-3495(95)80220-1; Pan YH, 2002, BIOCHEMISTRY-US, V41, P14790, DOI 10.1021/bi026922r; PATEL KM, 1979, LIPIDS, V14, P596, DOI 10.1007/BF02533539; PATTUS F, 1979, BIOCHEMISTRY-US, V18, P2691, DOI 10.1021/bi00580a001; PLESNIAK LA, 1995, BIOCHEMISTRY-US, V34, P4943, DOI 10.1021/bi00015a005; Pruzanski W, 2007, BBA-MOL CELL BIOL L, V1771, P5, DOI 10.1016/j.bbalip.2006.11.008; ROBERTS MF, 1978, J BIOL CHEM, V253, P1252; SCOTT DL, 1990, SCIENCE, V250, P1541, DOI 10.1126/science.2274785; SCOTT DL, 1990, SCIENCE, V250, P1563, DOI 10.1126/science.2274788; SEELIG J, 1980, Q REV BIOPHYS, V13, P19, DOI 10.1017/S0033583500000305; Sekar K, 1997, BIOCHEMISTRY-US, V36, P14186, DOI 10.1021/bi971370b; Serhan CN, 2008, NAT REV IMMUNOL, V8, P349, DOI 10.1038/nri2294; Silversand C, 1997, J CHROMATOGR B, V703, P7, DOI 10.1016/S0378-4347(97)00385-X; SILVIUS JR, 1993, BIOCHEMISTRY-US, V32, P13318, DOI 10.1021/bi00211a045; SOLTYS CE, 1994, BIOCHEMISTRY-US, V33, P11608, DOI 10.1021/bi00204a023; SOLTYS CE, 1993, BIOCHEMISTRY-US, V32, P9545, DOI 10.1021/bi00088a005; SOMERHARJU PJ, 1987, BIOCHEMISTRY-US, V26, P7193, DOI 10.1021/bi00396a048; Tatulian SA, 2005, J MOL BIOL, V351, P939, DOI 10.1016/j.jmb.2005.06.080; Thomas MJ, 1999, BBA-BIOMEMBRANES, V1417, P144, DOI 10.1016/S0005-2736(98)00254-5; THUNNISSEN MMGM, 1990, NATURE, V347, P689, DOI 10.1038/347689a0; VANDENBERG JJM, 1993, BIOCHEMISTRY-US, V32, P4962, DOI 10.1021/bi00069a035; Wee CL, 2008, BIOPHYS J, V95, P1649, DOI 10.1529/biophysj.107.123190; Wenk MR, 1997, BIOPHYS J, V72, P1719, DOI 10.1016/S0006-3495(97)78818-0; WHITE SP, 1990, SCIENCE, V250, P1560, DOI 10.1126/science.2274787; Wilkins WP, 2008, CURR DRUG TARGETS, V9, P683, DOI 10.2174/138945008785132385; Winget JM, 2006, BBA-MOL CELL BIOL L, V1761, P1260, DOI 10.1016/j.bbalip.2006.08.002; WINKLER H, 1967, BIOCHEM J, V105, pC38, DOI 10.1042/bj1050038C; Wirtz KWA, 2006, FEBS LETT, V580, P5436, DOI 10.1016/j.febslet.2006.06.065; WU SK, 1993, BIOCHEMISTRY-US, V32, P13902, DOI 10.1021/bi00213a020; Yang HC, 1999, J NEUROCHEM, V73, P1278, DOI 10.1046/j.1471-4159.1999.0731278.x; Yang K, 2009, ANAL CHEM, V81, P4356, DOI 10.1021/ac900241u; YU L, 1992, J AM CHEM SOC, V114, P8757, DOI 10.1021/ja00049a001	75	13	13	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 1	2010	285	1					751	760		10.1074/jbc.M109.061218	http://dx.doi.org/10.1074/jbc.M109.061218			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	536UT	19887372	Green Published, hybrid			2022-12-25	WOS:000273070100076
J	O'Callaghan, KM; Ayllon, V; O'Keeffe, J; Wang, YR; Cox, OT; Loughran, G; Forgac, M; O'Connor, R				O'Callaghan, Katie M.; Ayllon, Veronica; O'Keeffe, Jean; Wang, Yanru; Cox, Orla T.; Loughran, Gary; Forgac, Michael; O'Connor, Rosemary			Heme-binding Protein HRG-1 Is Induced by Insulin-like Growth Factor I and Associates with the Vacuolar H+-ATPase to Control Endosomal pH and Receptor Trafficking	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							V-ATPASE; CELL-MIGRATION; SUBUNIT; CANCER; EXPRESSION; IDENTIFICATION; TRANSPORTER; HOMEOSTASIS; GENE; INTEGRIN	Endocytosis and trafficking of receptors and nutrient transporters are dependent on an acidic intra-endosomal pH that is maintained by the vacuolar H+-ATPase (V-ATPase) proton pump. V-ATPase activity has also been associated with cancer invasiveness. Here, we report on a new V-ATPase-associated protein, which we identified in insulin-like growth factor I (IGF-I) receptor-transformed cells, and which was separately identified in Caenorhabditis elegans as HRG-1, a member of a family of heme-regulated genes. We found that HRG-1 is present in endosomes but not in lysosomes, and it is trafficked to the plasma membrane upon nutrient withdrawal in mammalian cells. Suppression of HRG-1 with small interfering RNA causes impaired endocytosis of transferrin receptor, decreased cell motility, and decreased viability of HeLa cells. HRG-1 interacts with the c subunit of the V-ATPase and enhances V-ATPase activity in isolated yeast vacuoles. Endosomal acidity and V-ATPase assembly are decreased in cells with suppressed HRG-1, whereas transferrin receptor endocytosis is enhanced in cells that over-express HRG-1. Cellular uptake of a fluorescent heme analogue is enhanced by HRG-1 in a V-ATPase-dependent manner. Our findings indicate that HRG-1 regulates V-ATPase activity, which is essential for endosomal acidification, heme binding, and receptor trafficking in mammalian cells. Thus, HRG-1 may facilitate tumor growth and cancer progression.	[O'Callaghan, Katie M.; Ayllon, Veronica; O'Keeffe, Jean; Cox, Orla T.; Loughran, Gary; O'Connor, Rosemary] Univ Coll Cork, BioSci Inst, Dept Biochem, Cell Biol Lab, Cork, Ireland; [Wang, Yanru; Forgac, Michael] Tufts Univ, Sch Med, Dept Physiol, Boston, MA 02111 USA	University College Cork; Tufts University	O'Connor, R (corresponding author), Univ Coll Cork, BioSci Inst, Dept Biochem, Cell Biol Lab, Cork, Ireland.	r.oconnor@ucc.ie	O'Connor, Rosemary/B-7902-2014; Ayllon, Veronica/L-7069-2014; Loughran, Gary/AAQ-8791-2020	O'Connor, Rosemary/0000-0002-0687-3422; Ayllon, Veronica/0000-0002-7322-9282; Loughran, Gary/0000-0002-2683-5597; Atkins, John/0000-0001-7933-0165	Science Foundation Ireland; Irish Research Council for Science, Engineering, and Technology; Health Research Board; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM034478, R37GM034478] Funding Source: NIH RePORTER	Science Foundation Ireland(Science Foundation IrelandEuropean Commission); Irish Research Council for Science, Engineering, and Technology(Irish Research Council for Science, Engineering and TechnologyCGIAR); Health Research Board; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	This work was supported by Science Foundation Ireland, the Irish Research Council for Science, Engineering, and Technology, and the Health Research Board.	ARAI H, 1987, J BIOL CHEM, V262, P11006; ARAI H, 1987, BIOCHEMISTRY-US, V26, P6632, DOI 10.1021/bi00395a011; Caswell P, 2008, TRENDS CELL BIOL, V18, P257, DOI 10.1016/j.tcb.2008.03.004; Caswell PT, 2006, TRAFFIC, V7, P14, DOI 10.1111/j.1600-0854.2005.00362.x; Cheng KW, 2004, NAT MED, V10, P1251, DOI 10.1038/nm1125; Edinger AL, 2007, BIOCHEM J, V406, P1, DOI 10.1042/BJ20070490; Forgac M, 2007, NAT REV MOL CELL BIO, V8, P917, DOI 10.1038/nrm2272; Ganapathy V, 2009, PHARMACOL THERAPEUT, V121, P29, DOI 10.1016/j.pharmthera.2008.09.005; GOLDSTEIN DJ, 1991, NATURE, V352, P347, DOI 10.1038/352347a0; Hamza I, 2006, ACS CHEM BIOL, V1, P627, DOI 10.1021/cb600442b; Hinton A, 2009, J BIOL CHEM, V284, P16400, DOI 10.1074/jbc.M901201200; Hurtado-Lorenzo A, 2006, NAT CELL BIOL, V8, P124, DOI 10.1038/ncb1348; Kepczynski M, 2002, PHOTOCHEM PHOTOBIOL, V76, P486, DOI 10.1562/0031-8655(2002)076<0486:IODMWL>2.0.CO;2; Krishnamurthy P, 2007, PHARMACOL THERAPEUT, V114, P345, DOI 10.1016/j.pharmthera.2007.02.001; Krishnamurthy PC, 2006, NATURE, V443, P586, DOI 10.1038/nature05125; Lafourcade C, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002758; Lee I, 2004, J BIOL CHEM, V279, P53007, DOI 10.1074/jbc.M405717200; Lopez T, 2002, CANCER CELL, V1, P339, DOI 10.1016/S1535-6108(02)00055-7; Loughran G, 2005, ONCOGENE, V24, P6185, DOI 10.1038/sj.onc.1208772; Loughran G, 2005, MOL BIOL CELL, V16, P1811, DOI 10.1091/mbc.E04-12-1052; Marshansky V, 2008, CURR OPIN CELL BIOL, V20, P415, DOI 10.1016/j.ceb.2008.03.015; MARTINEZZAGUILAN R, 1993, AM J PHYSIOL, V265, pC1015, DOI 10.1152/ajpcell.1993.265.4.C1015; Mauro L, 2003, J CELL PHYSIOL, V194, P108, DOI 10.1002/jcp.10207; Miaczynska M, 2004, CURR OPIN CELL BIOL, V16, P400, DOI 10.1016/j.ceb.2004.06.005; Mosesson Y, 2008, NAT REV CANCER, V8, P835, DOI 10.1038/nrc2521; Nakhoul NK, 2002, J NEPHROL, V15, pS22; Nilsson Cathrine, 2003, Methods Cell Sci, V25, P185; Rajagopal A, 2008, NATURE, V453, P1127, DOI 10.1038/nature06934; Samani AA, 2007, ENDOCR REV, V28, P20, DOI 10.1210/er.2006-0001; Sautin YY, 2005, MOL CELL BIOL, V25, P575, DOI 10.1128/MCB.25.2.575-589.2005; SELL C, 1994, MOL CELL BIOL, V14, P3604, DOI 10.1128/MCB.14.6.3604; Shayeghi M, 2005, CELL, V122, P789, DOI 10.1016/j.cell.2005.06.025; Shen HB, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002399; Smardon AM, 2007, J BIOL CHEM, V282, P26185, DOI 10.1074/jbc.M703627200; Vasilyeva E, 1996, J BIOL CHEM, V271, P12775, DOI 10.1074/jbc.271.22.12775; Wang WG, 2004, CANCER RES, V64, P8585, DOI 10.1158/0008-5472.CAN-04-1136; West AR, 2008, J GASTROEN HEPATOL, V23, P150, DOI 10.1111/j.1440-1746.2007.05047.x	37	53	57	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 1	2010	285	1					381	391		10.1074/jbc.M109.063248	http://dx.doi.org/10.1074/jbc.M109.063248			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	536UT	19875448	Green Published, hybrid			2022-12-25	WOS:000273070100040
J	Po'uha, ST; Shum, MSY; Goebel, A; Bernard, O; Kavallaris, M				Po'uha, S. T.; Shum, M. S. Y.; Goebel, A.; Bernard, O.; Kavallaris, M.			LIM-kinase 2, a regulator of actin dynamics, is involved in mitotic spindle integrity and sensitivity to microtubule-destabilizing drugs	ONCOGENE			English	Article						LIM-kinase 2; neuroblastoma; microtubule-destabilizing drugs; mitosis; drug sensitivity	PROTEIN-KINASE; COFILIN PHOSPHORYLATION; CYTOSKELETAL DYNAMICS; CHILDHOOD LEUKEMIA; CELL-MIGRATION; CANCER-CELLS; ACTIVATION; RESISTANCE; SLINGSHOT; TUBULIN	LIM-kinase 2 (LIMK2) belongs to the LIMK family of proteins, which comprises LIMK1 and LIMK2. Both proteins regulate actin polymerization through phosphorylation and inactivation of the actin depolymerizing factor cofilin. In this study, we show that the level of LIMK2 protein is increased in neuroblastoma, BE(2)-C cells, selected for resistance to microtubule-destabilizing agents, vincristine and colchicine. However, the level of phosphorylated LIMK1 and LIMK2 was similar in the resistant and parental BE(2)-C cells. In contrast, the level of phospho-cofilin was greatly increased in the drug-resistant cells. Downregulation of LIMK2 expression increases sensitivity of neuroblastoma SH-EP cells to vincristine and vinblastine but not to microtubule-stabilizing agents, while it's overexpression increased its resistance to vincristine. Its vincristine-induced mitotic arrest was moderately inhibited in the LIMK2 knockdown cells, suggesting that the increased drug sensitivity is through an alternative mechanism other then mitotic arrest and apoptosis. Moreover, downregulation of LIMK2 expression induces formation of abnormal mitotic spindles, an effect enhanced in the presence of microtubule-destabilizing agents. LIMK2 is important for normal mitotic spindle formation and altered LIMK2 expression mediates sensitivity to microtubule destabilizing agents. These findings suggest that inhibition of LIMK2 activity may be used for the treatment of tumors resistant to microtubule-destabilizing drugs. Oncogene (2010) 29, 597-607; doi: 10.1038/onc.2009.367; published online 2 November 2009	[Kavallaris, M.] Childrens Canc Inst Australia Med Res, Pharmacoprote Program, Randwick, NSW 2031, Australia; [Po'uha, S. T.; Shum, M. S. Y.] Univ New S Wales, Sydney, NSW, Australia; [Bernard, O.] St Vincents Inst Med Res, Melbourne, Vic, Australia; [Bernard, O.] St Vincents Hosp, Dept Med, Melbourne, Vic, Australia	Children's Cancer Institute; University of New South Wales Sydney; St. Vincent's Institute of Medical Research; St Vincent's Hospital Melbourne	Kavallaris, M (corresponding author), Childrens Canc Inst Australia Med Res, Pharmacoprote Program, POB 81, Randwick, NSW 2031, Australia.	m.kavallaris@ccia.unsw.edu.au	Kavallaris, Maria/J-5240-2014		Children's Cancer Institute Australia for Medical Research; New South Wales Cancer Council; NHMRC; Endeavour International; Australian Postgraduate Award	Children's Cancer Institute Australia for Medical Research; New South Wales Cancer Council(Cancer Council New South Wales); NHMRC(National Health and Medical Research Council (NHMRC) of Australia); Endeavour International; Australian Postgraduate Award(Australian Government)	We thank Professor Kensaku Mizuno, Tohoku University, Japan, for providing the LIMK2 plasmid and Professor Peter Gunning, University of New South Wales, Sydney, Australia, for gamma-actin Ab. This work was supported by the Children's Cancer Institute Australia for Medical Research, which is affiliated with the University of New South Wales and Sydney Children's Hospital, and by grants from the New South Wales Cancer Council (MK). MK is supported by a NHMRC Senior Research Fellowship, STP was supported by an Endeavour International Postgraduate Research Scholarship and MSYS is supported by an Australian Postgraduate Award. OB is a NHMRC Principal Research Fellow.	Acevedo K, 2006, J HISTOCHEM CYTOCHEM, V54, P487, DOI 10.1369/jhc.5C6813.2006; Acevedo K, 2007, EXP CELL RES, V313, P4091, DOI 10.1016/j.yexcr.2007.08.012; Amano T, 2001, BIOCHEM J, V354, P149, DOI 10.1042/0264-6021:3540149; Ambach A, 2000, EUR J IMMUNOL, V30, P3422, DOI 10.1002/1521-4141(2000012)30:12<3422::AID-IMMU3422>3.0.CO;2-J; Arber S, 1998, NATURE, V393, P805, DOI 10.1038/31729; Bhalla KN, 2003, ONCOGENE, V22, P9075, DOI 10.1038/sj.onc.1207233; Chakrabarti R, 2007, CELL CYCLE, V6, P2944, DOI 10.4161/cc.6.23.4957; Croft DR, 2006, MOL CELL BIOL, V26, P4612, DOI 10.1128/MCB.02061-05; Dan C, 2001, J BIOL CHEM, V276, P32115, DOI 10.1074/jbc.M100871200; Dan S, 2002, CANCER RES, V62, P1139; Davila M, 2007, MOL CANCER, V6, DOI 10.1186/1476-4598-6-40; Deschesnes RG, 2007, J PHARMACOL EXP THER, V320, P853, DOI 10.1124/jpet.106.110957; Don S, 2004, MOL CANCER THER, V3, P1137; Edwards DC, 1999, NAT CELL BIOL, V1, P253, DOI 10.1038/12963; Eiseler T, 2009, NAT CELL BIOL, V11, P545, DOI 10.1038/ncb1861; Gohla A, 2005, NAT CELL BIOL, V7, P21, DOI 10.1038/ncb1201; Gorovoy M, 2005, J BIOL CHEM, V280, P26533, DOI 10.1074/jbc.M502921200; Groth-Pedersen L, 2007, CANCER RES, V67, P2217, DOI 10.1158/0008-5472.CAN-06-3520; JORDAN MA, 1991, CANCER RES, V51, P2212; Kaji N, 2008, J BIOL CHEM, V283, P4983, DOI 10.1074/jbc.M708644200; Kobayashi M, 2006, EMBO J, V25, P713, DOI 10.1038/sj.emboj.7600973; LAQUAGLIA MP, 1991, J PEDIATR SURG, V26, P1107, DOI 10.1016/0022-3468(91)90684-L; MIZUNO K, 1994, ONCOGENE, V9, P1605; Niwa R, 2002, CELL, V108, P233, DOI 10.1016/S0092-8674(01)00638-9; NUNOUE K, 1995, ONCOGENE, V11, P701; Okano I, 1995, J BIOL CHEM, V270, P31321, DOI 10.1074/jbc.270.52.31321; Peterburs P, 2009, CANCER RES, V69, P5634, DOI 10.1158/0008-5472.CAN-09-0718; Sarmiere PD, 2004, J NEUROBIOL, V58, P103, DOI 10.1002/neu.10267; Soosairajah J, 2005, EMBO J, V24, P473, DOI 10.1038/sj.emboj.7600543; Sumi T, 2006, EXP CELL RES, V312, P1021, DOI 10.1016/j.yexcr.2005.12.030; Sumi T, 1999, J CELL BIOL, V147, P1519, DOI 10.1083/jcb.147.7.1519; Sumi T, 2001, J BIOL CHEM, V276, P670, DOI 10.1074/jbc.M007074200; Verrills NM, 2006, J NATL CANCER I, V98, P1363, DOI 10.1093/jnci/djj372; Verrills NM, 2006, PROTEOMICS, V6, P1681, DOI 10.1002/pmic.200500417; Verrills NM, 2005, CURR PHARM DESIGN, V11, P1719, DOI 10.2174/1381612053764706; Verrills NM, 2003, CHEM BIOL, V10, P597, DOI 10.1016/S1074-5521(03)00141-8; Yang N, 1998, NATURE, V393, P809, DOI 10.1038/31735	37	42	44	0	13	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN	2010	29	4					597	607		10.1038/onc.2009.367	http://dx.doi.org/10.1038/onc.2009.367			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	549WH	19881550				2022-12-25	WOS:000274084600012
J	Qualley, DF; Stewart-Maynard, KM; Wang, F; Mitra, M; Gorelick, RJ; Rouzina, I; Williams, MC; Musier-Forsyth, K				Qualley, Dominic F.; Stewart-Maynard, Kristen M.; Wang, Fei; Mitra, Mithun; Gorelick, Robert J.; Rouzina, Ioulia; Williams, Mark C.; Musier-Forsyth, Karin			C-terminal Domain Modulates the Nucleic Acid Chaperone Activity of Human T-cell Leukemia Virus Type 1 Nucleocapsid Protein via an Electrostatic Mechanism	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DOUBLE-STRANDED DNA; GENOMIC RNA DIMERIZATION; ZINC-FINGER STRUCTURES; INTEGRATION IN-VITRO; PRIMER BINDING-SITE; REVERSE TRANSCRIPTION; GENE-32 PROTEIN; VIRAL-RNA; STRUCTURAL DETERMINANTS; THERMODYNAMIC ANALYSIS	Retroviral nucleocapsid (NC) proteins are molecular chaperones that facilitate nucleic acid (NA) remodeling events critical in viral replication processes such as reverse transcription. Surprisingly, theNCprotein from human T-cell leukemia virus type 1 (HTLV-1) is an extremely poor NA chaperone. Using bulk and single molecule methods, we find that removal of the anionic C-terminal domain (CTD) of HTLV-1 NC results in a protein with chaperone properties comparable with that of other retroviral NCs. Increasing the ionic strength of the solution also improves the chaperone activity of full-length HTLV-1 NC. To determine how the CTD negatively modulates the chaperone activity of HTLV-1 NC, we quantified the thermodynamics and kinetics of wild-type and mutant HTLV-1 NC/NA interactions. The wild-type protein exhibits very slow dissociation kinetics, and removal of the CTD or mutations that eliminate acidic residues dramatically increase the protein/DNA interaction kinetics. Taken together, these results suggest that the anionic CTD interacts with the cationic N-terminal domain intramolecularly when HTLV-1 NC is not bound to nucleic acids, and similar interactions occur between neighboring molecules when NC is NA-bound. The intramolecular N-terminal domain-CTD attraction slows down the association of the HTLV-1 NC with NA, whereas the intermolecular interaction leads to multimerization of HTLV-1 NC on the NA. The latter inhibits both NA/NC aggregation and rapid protein dissociation from single-stranded DNA. These features make HTLV-1 NC a poor NA chaperone, despite its robust duplex destabilizing capability.	[Qualley, Dominic F.; Mitra, Mithun; Musier-Forsyth, Karin] Ohio State Univ, Ctr Retrovirus Res, Dept Chem, Columbus, OH 43210 USA; [Qualley, Dominic F.; Mitra, Mithun; Musier-Forsyth, Karin] Ohio State Univ, Ctr Retrovirus Res, Dept Biochem, Columbus, OH 43210 USA; [Qualley, Dominic F.; Mitra, Mithun; Musier-Forsyth, Karin] Ohio State Univ, Ctr RNA Biol, Columbus, OH 43210 USA; [Stewart-Maynard, Kristen M.] Univ Minnesota, Dept Chem, Minneapolis, MN 55455 USA; [Stewart-Maynard, Kristen M.] Univ Minnesota, Inst Mol Virol, Minneapolis, MN 55455 USA; [Rouzina, Ioulia] Univ Minnesota, Dept Biochem Mol Biol & Biophys, Minneapolis, MN 55455 USA; [Wang, Fei; Williams, Mark C.] Northeastern Univ, Dept Phys, Boston, MA 02115 USA; [Gorelick, Robert J.] NCI, AIDS & Canc Virus Program, Sci Applicat Int Corp Frederick Inc, NIH, Ft Detrick, MD 21702 USA	University System of Ohio; Ohio State University; University System of Ohio; Ohio State University; University System of Ohio; Ohio State University; University of Minnesota System; University of Minnesota Twin Cities; University of Minnesota System; University of Minnesota Twin Cities; University of Minnesota System; University of Minnesota Twin Cities; Northeastern University; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC)	Rouzina, I (corresponding author), Univ Minnesota, Dept Biochem Mol Biol & Biophys, 321 Church St SE, Minneapolis, MN 55455 USA.	rouzi002@umn.edu; ma.williams@neu.edu; musier@chemistry.ohio-state.edu	Mitra, Mithun/O-6711-2019; Mitra, Mithun/A-2133-2015	Williams, Mark C./0000-0003-3219-376X; Mitra, Mithun/0000-0001-8056-8963	National Institutes of Health [GM065056, GM072462]; Ruth L. Kirschstein National Service Award [GM072396]; NCI [N01-CO-12400, HHSN261200800001E]; National Science Foundation [MCB-0744456]; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM072462, F32GM072396, R01GM065056] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Ruth L. Kirschstein National Service Award(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); National Science Foundation(National Science Foundation (NSF)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	This work was supported, in whole or in part, by National Institutes of Health Grants GM065056 (to K. M. -F.) and GM072462 (to M. C. W.), Ruth L. Kirschstein National Service Award GM072396 (to K. M. S.- M.), and Contracts N01-CO-12400 and HHSN261200800001E from the NCI. This work was also supported by National Science Foundation Grant MCB-0744456 (to M. C. W.).	Askjaer P, 1998, J BIOL CHEM, V273, P11463, DOI 10.1074/jbc.273.19.11463; Beltz H, 2005, J MOL BIOL, V348, P1113, DOI 10.1016/j.jmb.2005.02.042; Bernacchi S, 2002, J MOL BIOL, V317, P385, DOI 10.1006/jmbi.2002.5429; Buckman JS, 2003, J VIROL, V77, P1469, DOI 10.1128/JVI.77.2.1469-1480.2003; Carteau S, 1999, J VIROL, V73, P6670, DOI 10.1128/JVI.73.8.6670-6679.1999; Carteau S, 1997, J VIROL, V71, P6225, DOI 10.1128/JVI.71.8.6225-6229.1997; Chan B, 1997, P NATL ACAD SCI USA, V94, P13530, DOI 10.1073/pnas.94.25.13530; Chan BD, 1999, P NATL ACAD SCI USA, V96, P459, DOI 10.1073/pnas.96.2.459; Coren LV, 2007, J VIROL, V81, P10047, DOI 10.1128/JVI.02496-06; Cristofari G, 2002, PROG NUCLEIC ACID RE, V72, P223, DOI 10.1016/S0079-6603(02)72071-0; Cruceanu M, 2006, NUCLEIC ACIDS RES, V34, P593, DOI 10.1093/nar/gkj458; Cruceanu M, 2006, J MOL BIOL, V363, P867, DOI 10.1016/j.jmb.2006.08.070; Darlix JL, 2007, ADV PHARMACOL, V55, P299, DOI 10.1016/S1054-3589(07)55009-X; DARLIX JL, 1990, J MOL BIOL, V216, P689, DOI 10.1016/0022-2836(90)90392-Y; DARLIX JL, 1995, J MOL BIOL, V254, P523, DOI 10.1006/jmbi.1995.0635; Darugar Q, 2008, J VIROL, V82, P12164, DOI 10.1128/JVI.01158-08; DEROCQUIGNY H, 1992, P NATL ACAD SCI USA, V89, P6472, DOI 10.1073/pnas.89.14.6472; Derse D, 2004, FRONT BIOSCI-LANDMRK, V9, P2495, DOI 10.2741/1411; DERSE D, 1995, J VIROL, V69, P1907, DOI 10.1128/JVI.69.3.1907-1912.1995; Derse D, 2001, J VIROL, V75, P8461, DOI 10.1128/JVI.75.18.8461-8468.2001; Derse D, 2007, P NATL ACAD SCI USA, V104, P2915, DOI 10.1073/pnas.0609444104; Feng YX, 1996, P NATL ACAD SCI USA, V93, P7577, DOI 10.1073/pnas.93.15.7577; Fisher RJ, 2006, NUCLEIC ACIDS RES, V34, P472, DOI 10.1093/nar/gkj442; FU W, 1994, J VIROL, V68, P5013, DOI 10.1128/JVI.68.8.5013-5018.1994; Gao K, 2003, J VIROL, V77, P1598, DOI 10.1128/JVI.77.2.1598-1603.2003; Goila-Gaur R, 2008, RETROVIROLOGY, V5, DOI 10.1186/1742-4690-5-51; Golinelli MP, 2001, VIROLOGY, V285, P278, DOI 10.1006/viro.2001.0970; Guo F, 2009, J VIROL, V83, P8099, DOI 10.1128/JVI.00488-09; Guo JH, 2000, J VIROL, V74, P8980, DOI 10.1128/JVI.74.19.8980-8988.2000; Hargittai MRS, 2004, J MOL BIOL, V337, P951, DOI 10.1016/j.jmb.2004.01.054; Hargittai MRS, 2001, J MOL BIOL, V312, P985, DOI 10.1006/jmbi.2001.5021; Heath MJ, 2003, J BIOL CHEM, V278, P30755, DOI 10.1074/jbc.M303819200; HENDERSON LE, 1992, J VIROL, V66, P1856, DOI 10.1128/JVI.66.4.1856-1865.1992; Holmes RK, 2007, TRENDS BIOCHEM SCI, V32, P118, DOI 10.1016/j.tibs.2007.01.004; Hong MK, 2003, J MOL BIOL, V325, P1, DOI 10.1016/S0022-2836(02)01177-4; Johnson PE, 2000, BIOCHEMISTRY-US, V39, P9084, DOI 10.1021/bi000841i; Kafaie J, 2008, VIROLOGY, V375, P592, DOI 10.1016/j.virol.2008.02.001; Kankia BI, 2005, NUCLEIC ACIDS RES, V33, P4395, DOI 10.1093/nar/gki741; Kapust RB, 2001, PROTEIN ENG, V14, P993, DOI 10.1093/protein/14.12.993; Kapust RB, 2002, BIOCHEM BIOPH RES CO, V294, P949, DOI 10.1016/S0006-291X(02)00574-0; Laughrea M, 2001, VIROLOGY, V281, P109, DOI 10.1006/viro.2000.0778; Levin JG, 2005, PROG NUCLEIC ACID RE, V80, P217, DOI 10.1016/S0079-6603(05)80006-6; Liang C, 1998, J VIROL, V72, P6629, DOI 10.1128/JVI.72.8.6629-6636.1998; Malim MH, 2009, PHILOS T R SOC B, V364, P675, DOI 10.1098/rstb.2008.0185; Martin SL, 2008, NUCLEIC ACIDS RES, V36, P5845, DOI 10.1093/nar/gkn554; Martin SL, 2005, J MOL BIOL, V348, P549, DOI 10.1016/j.jmb.2005.03.003; Mazurov D, 2006, VIROLOGY, V346, P194, DOI 10.1016/j.virol.2005.10.033; Mazurov D, 2007, J BIOL CHEM, V282, P3896, DOI 10.1074/jbc.M607322200; McCauley MJ, 2007, BIOPOLYMERS, V85, P154, DOI 10.1002/bip.20622; MCGHEE JD, 1976, BIOPOLYMERS, V15, P1345, DOI 10.1002/bip.1976.360150710; Mirambeau G, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0000669; Mirambeau G, 2006, J MOL BIOL, V364, P496, DOI 10.1016/j.jmb.2006.08.065; Morcock DR, 2000, BBA-PROTEIN STRUCT M, V1481, P381, DOI 10.1016/S0167-4838(00)00181-3; Narayanan N, 2006, BIOCHEMISTRY-US, V45, P12617, DOI 10.1021/bi060925c; Navarro F, 2005, VIROLOGY, V333, P374, DOI 10.1016/j.virol.2005.01.011; Nyborg Jennifer K, 2004, Biochem J, V381, pe3; Pant K, 2005, J MOL BIOL, V349, P317, DOI 10.1016/j.jmb.2005.03.065; Pant K, 2004, J MOL BIOL, V336, P851, DOI 10.1016/j.jmb.2003.12.025; Pant K, 2003, J MOL BIOL, V327, P571, DOI 10.1016/S0022-2836(03)00153-0; Pettit SC, 1998, AIDS RES HUM RETROV, V14, P1007, DOI 10.1089/aid.1998.14.1007; PRATS AC, 1988, EMBO J, V7, P1777, DOI 10.1002/j.1460-2075.1988.tb03008.x; Rajkowitsch L, 2007, RNA BIOL, V4, P118, DOI 10.4161/rna.4.3.5445; RECORD MT, 1978, Q REV BIOPHYS, V11, P103, DOI 10.1017/S003358350000202X; Rein A, 1998, TRENDS BIOCHEM SCI, V23, P297, DOI 10.1016/S0968-0004(98)01256-0; Rouzina I, 2005, BIOPHYS J, V89, P1941, DOI 10.1529/biophysj.105.063776; Rouzina I, 2001, BIOPHYS J, V80, P882, DOI 10.1016/S0006-3495(01)76067-5; Saadatmand J, 2009, VIROLOGY, V391, P334, DOI 10.1016/j.virol.2009.06.036; Sasada A, 2005, RETROVIROLOGY, V2, DOI 10.1186/1742-4690-2-32; Shokri L, 2008, NUCLEIC ACIDS RES, V36, P5668, DOI 10.1093/nar/gkn551; Shokri L, 2008, BIOPHYS J, V95, P1248, DOI 10.1529/biophysj.108.132688; Stewart-Maynard KM, 2008, J VIROL, V82, P10129, DOI 10.1128/JVI.01169-08; Thomas JA, 2008, VIRUS RES, V134, P39, DOI 10.1016/j.virusres.2007.12.006; Thomas JA, 2006, VIROLOGY, V353, P41, DOI 10.1016/j.virol.2006.05.014; TOYOSHIMA H, 1990, J VIROL, V64, P2825, DOI 10.1128/JVI.64.6.2825-2832.1990; TSUCHIHASHI Z, 1994, J VIROL, V68, P5863, DOI 10.1128/JVI.68.9.5863-5870.1994; Urbaneja MA, 1999, J MOL BIOL, V287, P59, DOI 10.1006/jmbi.1998.2521; Vo MN, 2006, J MOL BIOL, V363, P244, DOI 10.1016/j.jmb.2006.08.039; Vo MN, 2009, J MOL BIOL, V386, P773, DOI 10.1016/j.jmb.2008.12.073; Vo MN, 2009, J MOL BIOL, V386, P789, DOI 10.1016/j.jmb.2008.12.070; Wang HT, 2003, J VIROL, V77, P9431, DOI 10.1128/JVI.77.17.9431-9438.2003; Williams MC, 2002, ACCOUNTS CHEM RES, V35, P159, DOI 10.1021/ar010045k; Williams MC, 2002, P NATL ACAD SCI USA, V99, P8614, DOI 10.1073/pnas.132128999; Williams MC, 2002, CURR OPIN STRUC BIOL, V12, P330, DOI 10.1016/S0959-440X(02)00340-8; Williams MC, 2001, P NATL ACAD SCI USA, V98, P6121, DOI 10.1073/pnas.101033198; Zuker M, 2003, NUCLEIC ACIDS RES, V31, P3406, DOI 10.1093/nar/gkg595	85	35	35	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 1	2010	285	1					295	307		10.1074/jbc.M109.051334	http://dx.doi.org/10.1074/jbc.M109.051334			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	536UT	19887455	Green Published, hybrid			2022-12-25	WOS:000273070100031
J	Yarotskyy, V; Gao, GF; Du, L; Ganapathi, SB; Peterson, BZ; Elmslie, KS				Yarotskyy, Viktor; Gao, Guofeng; Du, Lei; Ganapathi, Sindura B.; Peterson, Blaise Z.; Elmslie, Keith S.			Roscovitine Binds to Novel L-channel (Ca(V)1.2) Sites That Separately Affect Activation and Inactivation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEPENDENT KINASE INHIBITOR; CALCIUM-CHANNELS; CA2+ CHANNELS; ANGINA-PECTORIS; R-ROSCOVITINE; CA2+-DEPENDENT INACTIVATION; ESSENTIAL-HYPERTENSION; TRANSMITTER RELEASE; GATING MECHANISMS; DRUG-BINDING	L-type (Ca(V)1.2) calcium channel antagonists play an important role in the treatment of cardiovascular disease. (R)-Roscovitine, a trisubstituted purine, has been shown to inhibit L-currents by slowing activation and enhancing inactivation. This study utilized molecular and pharmacological approaches to determine whether these effects result from (R)-roscovitine binding to a single site. Using the S enantiomer, we find that (S)-roscovitine enhances inactivation without affecting activation, which suggests multiple sites. This was further supported in studies using chimeric channels comprised of N- and L-channel domains. Those chimeras containing L-channel domains I and IV showed (R)- roscovitine-induced slowed activation like that of wild type L-channels, whereas chimeric channels containing L-channel domain I responded to (R)-roscovitine with enhanced inactivation. We conclude that (R)-roscovitine binds to distinct sites on L-type channels to slow activation and enhance inactivation. These sites appear to be unique from other calcium channel antagonist sites that reside within domains III and IV and are thus novel sites that could be exploited for future drug development. Trisubstituted purines could become a new class of drugs for the treatment of diseases related to hyperfunction of L-type channels, such as Torsades de Pointes.	[Yarotskyy, Viktor; Elmslie, Keith S.] Penn State Univ, Penn State Coll Med, Dept Anesthesiol, Hershey, PA 17033 USA; [Gao, Guofeng; Du, Lei; Peterson, Blaise Z.] Penn State Univ, Penn State Coll Med, Dept Cellular & Mol Physiol, Hershey, PA 17033 USA; [Ganapathi, Sindura B.; Elmslie, Keith S.] Penn State Univ, Penn State Coll Med, Dept Pharmacol, Hershey, PA 17033 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Penn State Health; Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Penn State Health; Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Penn State Health	Elmslie, KS (corresponding author), Penn State Coll Med, Dept Anesthesiol H187, 500 Univ Dr, Hershey, PA 17033 USA.			Elmslie, Keith/0000-0002-2988-4482	National Institutes of Health [HL074143]; American Heart Association Predoctoral Fellowship [0715336U]; Department of Anesthesiology at the Penn State College of Medicine; Pennsylvania Department of Health using Tobacco Settlement Funds; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL074143] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); American Heart Association Predoctoral Fellowship(American Heart Association); Department of Anesthesiology at the Penn State College of Medicine; Pennsylvania Department of Health using Tobacco Settlement Funds; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))	This work was supported, in whole or in part, by National Institutes of Health Grant HL074143 (to B. Z. P.). This work was also supported in part by American Heart Association Predoctoral Fellowship 0715336U (to S. B. G.), startup funds from the Department of Anesthesiology at the Penn State College of Medicine (to K. S. E.), and grants from the Pennsylvania Department of Health using Tobacco Settlement Funds (to K. S. E. and B. Z. P.).	Bai R, 2005, CLIN CARDIOL, V28, P343, DOI 10.1002/clc.4960280708; Benson C, 2007, BRIT J CANCER, V96, P29, DOI 10.1038/sj.bjc.6603509; Bers DM, 2002, CIRC RES, V90, P14, DOI 10.1161/res.90.1.14; Bourinet E, 2004, J CLIN INVEST, V113, P1382, DOI 10.1172/JCI200421815; Buraei Z, 2005, BIOPHYS J, V89, P1681, DOI 10.1529/biophysj.104.052837; Buraei Z, 2008, J NEUROCHEM, V105, P1450, DOI 10.1111/j.1471-4159.2008.05248.x; Buraei Z, 2007, NEUROPHARMACOLOGY, V52, P883, DOI 10.1016/j.neuropharm.2006.10.006; Carmeliet E, 1999, PHYSIOL REV, V79, P917, DOI 10.1152/physrev.1999.79.3.917; Cho S, 2006, EUR J NEUROSCI, V23, P3200, DOI 10.1111/j.1460-9568.2006.04849.x; Elmslie KS, 2004, J NEUROSCI RES, V75, P733, DOI 10.1002/jnr.10872; Ganapathi SB, 2009, AM J PHYSIOL-CELL PH, V296, pC701, DOI 10.1152/ajpcell.00633.2008; Glasser SP, 2003, AM J HYPERTENS, V16, P51, DOI 10.1016/S0895-7061(02)03153-9; Goo YS, 2006, J NEUROPHYSIOL, V96, P1075, DOI 10.1152/jn.01294.2005; Grabner M, 1996, NEURON, V16, P207, DOI 10.1016/S0896-6273(00)80037-9; Hockerman GH, 1997, ANNU REV PHARMACOL, V37, P361, DOI 10.1146/annurev.pharmtox.37.1.361; McClue SJ, 2002, INT J CANCER, V102, P463, DOI 10.1002/ijc.10738; Meijer L, 2003, ACCOUNTS CHEM RES, V36, P417, DOI 10.1021/ar0201198; Meijer L, 1996, TRENDS CELL BIOL, V6, P393, DOI 10.1016/0962-8924(96)10034-9; Nerbonne JM, 2005, PHYSIOL REV, V85, P1205, DOI 10.1152/physrev.00002.2005; PELLINEN TJ, 1992, ANN MED, V24, P49, DOI 10.3109/07853899209164144; Pepine CJ, 2003, JAMA-J AM MED ASSOC, V290, P2805, DOI 10.1001/jama.290.21.2805; Peterson BZ, 2000, BIOPHYS J, V78, P1906, DOI 10.1016/S0006-3495(00)76739-7; Peterson BZ, 1999, NEURON, V22, P549, DOI 10.1016/S0896-6273(00)80709-6; Raynaud FI, 2005, CLIN CANCER RES, V11, P4875, DOI 10.1158/1078-0432.CCR-04-2264; Roden DM, 2002, ANNU REV PHYSIOL, V64, P431, DOI 10.1146/annurev.physiol.64.083101.145105; Splawski I, 2004, CELL, V119, P19, DOI 10.1016/j.cell.2004.09.011; Splawski I, 2005, P NATL ACAD SCI USA, V102, P8089, DOI 10.1073/pnas.0502506102; Stotz SC, 2004, J PHYSIOL-LONDON, V554, P263, DOI 10.1113/jphysiol.2003.047068; Striessnig J, 1999, CELL PHYSIOL BIOCHEM, V9, P242, DOI 10.1159/000016320; Striessnig J, 2004, BIOCHEM BIOPH RES CO, V322, P1341, DOI 10.1016/j.bbrc.2004.08.039; Striessnig J, 1998, TRENDS PHARMACOL SCI, V19, P108, DOI 10.1016/S0165-6147(98)01171-7; Suzuki S, 2003, HYPERTENS RES, V26, P193, DOI 10.1291/hypres.26.193; Ter Keurs HEDJ, 2007, PHYSIOL REV, V87, P457, DOI 10.1152/physrev.00011.2006; Thomas G, 2007, J PHYSIOL-LONDON, V578, P85, DOI 10.1113/jphysiol.2006.121921; THOMAS MG, 1990, J CLIN PHARMACOL, V30, P24, DOI 10.1002/j.1552-4604.1990.tb03433.x; Vitali L, 2002, CANCER LETT, V180, P7, DOI 10.1016/S0304-3835(01)00827-8; Wesierska-Gadek J, 2007, J CELL BIOCHEM, V100, P865, DOI 10.1002/jcb.21211; Yan Z, 2002, J PHYSIOL-LONDON, V540, P761; Yarotskyy V, 2007, BRIT J PHARMACOL, V152, P386, DOI 10.1038/sj.bjp.0707414; Yarotskyy V, 2009, J PHYSIOL-LONDON, V587, P551, DOI 10.1113/jphysiol.2008.161737	40	27	27	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 1	2010	285	1					43	53		10.1074/jbc.M109.076448	http://dx.doi.org/10.1074/jbc.M109.076448			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	536UT	19887376	Green Published			2022-12-25	WOS:000273070100006
J	Armer, HEJ; Mariggi, G; Png, KMY; Genoud, C; Monteith, AG; Bushby, AJ; Gerhardt, H; Collinson, LM				Armer, Hannah E. J.; Mariggi, Giovanni; Png, Ken M. Y.; Genoud, Christel; Monteith, Alexander G.; Bushby, Andrew J.; Gerhardt, Holger; Collinson, Lucy M.			Imaging Transient Blood Vessel Fusion Events in Zebrafish by Correlative Volume Electron Microscopy	PLOS ONE			English	Article							EMBRYONIC-DEVELOPMENT; RECONSTRUCTION	The study of biological processes has become increasingly reliant on obtaining high-resolution spatial and temporal data through imaging techniques. As researchers demand molecular resolution of cellular events in the context of whole organisms, correlation of non-invasive live-organism imaging with electron microscopy in complex three-dimensional samples becomes critical. The developing blood vessels of vertebrates form a highly complex network which cannot be imaged at high resolution using traditional methods. Here we show that the point of fusion between growing blood vessels of transgenic zebrafish, identified in live confocal microscopy, can subsequently be traced through the structure of the organism using Focused Ion Beam/Scanning Electron Microscopy (FIB/SEM) and Serial Block Face/Scanning Electron Microscopy (SBF/SEM). The resulting data give unprecedented microanatomical detail of the zebrafish and, for the first time, allow visualization of the ultrastructure of a time-limited biological event within the context of a whole organism.			Armer, HEJ (corresponding author), Canc Res UK, London Res Inst, Electron Microscopy Unit, London, England.	lucy.collinson@cancer.org.uk	Gerhardt, Holger/G-4610-2011; Bushby, Andy/AAJ-8342-2020; Gerhardt, Holger/G-4610-2011	Gerhardt, Holger/0000-0002-3030-0384; Gerhardt, Holger/0000-0001-9228-7472; genoud, christel/0000-0002-0933-9911; Monteith, Alexander George/0000-0003-1731-0446	Engineering and Physical Sciences Research Council [EP/F019882/1] Funding Source: researchfish; EPSRC [EP/F019882/1] Funding Source: UKRI; Cancer Research UK Funding Source: Medline	Engineering and Physical Sciences Research Council(UK Research & Innovation (UKRI)Engineering & Physical Sciences Research Council (EPSRC)); EPSRC(UK Research & Innovation (UKRI)Engineering & Physical Sciences Research Council (EPSRC)); Cancer Research UK(Cancer Research UK)		Blum Y, 2008, DEV BIOL, V316, P312, DOI 10.1016/j.ydbio.2008.01.038; Briggman KL, 2006, CURR OPIN NEUROBIOL, V16, P562, DOI 10.1016/j.conb.2006.08.010; De Winter DAM, 2009, J MICROSC-OXFORD, V233, P372, DOI 10.1111/j.1365-2818.2009.03139.x; Denk W, 2004, PLOS BIOL, V2, P1900, DOI 10.1371/journal.pbio.0020329; Drobne D, 2007, MICROSC RES TECHNIQ, V70, P895, DOI 10.1002/jemt.20494; Gerhardt H, 2003, J CELL BIOL, V161, P1163, DOI 10.1083/jcb.200302047; Heymann JAW, 2006, J STRUCT BIOL, V155, P63, DOI 10.1016/j.jsb.2006.03.006; Isogai S, 2003, DEVELOPMENT, V130, P5281, DOI 10.1242/dev.00733; Jurrus E, 2009, MED IMAGE ANAL, V13, P180, DOI 10.1016/j.media.2008.05.002; Keller PJ, 2008, SCIENCE, V322, P1065, DOI 10.1126/science.1162493; KIMMEL CB, 1995, DEV DYNAM, V203, P253, DOI 10.1002/aja.1002030302; Knott G, 2008, J NEUROSCI, V28, P2959, DOI 10.1523/JNEUROSCI.3189-07.2008; Lawson ND, 2002, DEV BIOL, V248, P307, DOI 10.1006/dbio.2002.0711; Lebbink MN, 2007, J STRUCT BIOL, V158, P327, DOI 10.1016/j.jsb.2006.12.001; Lebbink MN, 2009, J STRUCT BIOL, V166, P156, DOI 10.1016/j.jsb.2009.01.006; O'Connell MK, 2008, MATRIX BIOL, V27, P171, DOI 10.1016/j.matbio.2007.10.008; Prenitzer BI, 2003, MICROSC MICROANAL, V9, P216, DOI [10.1017/S1431927603030034, 10.1017/S143192760030034]; Risau W, 1997, NATURE, V386, P671, DOI 10.1038/386671a0; White JG, 1986, PHILOS T R SOC LON B, P1, DOI [10.1098/rstb.1986.0056, DOI 10.1098/RSTB.1986.0056]	19	44	44	0	6	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA	1932-6203			PLOS ONE	PLoS One	NOV 6	2009	4	11							e7716	10.1371/journal.pone.0007716	http://dx.doi.org/10.1371/journal.pone.0007716			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	515ND	19893745	Green Published, gold, Green Submitted, Green Accepted			2022-12-25	WOS:000271478000007
J	Gotzek, D; Ross, KG				Gotzek, Dietrich; Ross, Kenneth G.			Current Status of a Model System: The Gene Gp-9 and Its Association with Social Organization in Fire Ants	PLOS ONE			English	Article							SOLENOPSIS-INVICTA HYMENOPTERA; ODORANT-BINDING PROTEIN; EXPERIMENTAL CONVERSION; PHEROMONE; EVOLUTION; COLONIES; WORKER; POPULATION; FORMICIDAE; INSECT	The Gp-9 gene in fire ants represents an important model system for studying the evolution of social organization in insects as well as a rich source of information relevant to other major evolutionary topics. An important feature of this system is that polymorphism in social organization is completely associated with allelic variation at Gp-9, such that single-queen colonies (monogyne form) include only inhabitants bearing B-like alleles while multiple-queen colonies (polygyne form) additionally include inhabitants bearing b-like alleles. A recent study of this system by Leal and Ishida ( 2008) made two major claims, the validity and significance of which we examine here. After reviewing existing literature, analyzing the methods and results of Leal and Ishida ( 2008), and generating new data from one of their study sites, we conclude that their claim that polygyny can occur in Solenopsis invicta in the U. S. A. in the absence of expression of the b-like allele Gp-9 b is unfounded. Moreover, we argue that available information on insect OBPs ( the family of proteins to which GP-9 belongs), on the evolutionary/population genetics of Gp-9, and on pheromonal/behavioral control of fire ant colony queen number fails to support their view that GP-9 plays no role in the chemosensory-mediated communication that underpins regulation of social organization. Our analyses lead us to conclude that there are no new reasons to question the existing consensus view of the Gp-9 system outlined in Gotzek and Ross ( 2007).			Gotzek, D (corresponding author), Univ Lausanne, Dept Ecol & Evolut, Lausanne, Switzerland.	GotzekD@si.edu						Benton R, 2007, TRENDS NEUROSCI, V30, P512, DOI 10.1016/j.tins.2007.07.004; Bourke A. F., 1995, SOCIAL EVOLUTION ANT; Caldera EJ, 2008, BIOL INVASIONS, V10, P1457, DOI 10.1007/s10530-008-9219-0; Cassill D, 2003, BEHAV ECOL SOCIOBIOL, V54, P441, DOI 10.1007/s00265-003-0639-7; Crozier RH, 2002, NAT GENET, V30, P4, DOI 10.1038/ng0102-4; DeHeer CJ, 1999, AM NAT, V153, P660, DOI 10.1086/303205; Fletcher D.J.C., 1986, Advances in Invertebrate Reproduction, V4, P305; FLETCHER DJC, 1981, SCIENCE, V212, P73, DOI 10.1126/science.212.4490.73; FLETCHER DJC, 1983, SCIENCE, V219, P312, DOI 10.1126/science.219.4582.312; FLETCHER DJC, 1980, ANN ENTOMOL SOC AM, V73, P658, DOI 10.1093/aesa/73.6.658; FLETCHER DJC, 1983, J COMP PHYSIOL, V153, P467, DOI 10.1007/BF00612601; Foret S, 2006, GENOME RES, V16, P1404, DOI 10.1101/gr.5075706; Fritz GN, 2006, GENETICS, V173, P207, DOI 10.1534/genetics.106.056358; GADAU J, 2009, ORG INSECT SOC GENOM; GLANCEY B M, 1973, Journal of the Georgia Entomological Society, V8, P237; Gonzalez D, 2009, INSECT MOL BIOL, V18, P395, DOI 10.1111/j.1365-2583.2009.00883.x; Goodisman MAD, 2000, J INSECT BEHAV, V13, P455, DOI 10.1023/A:1007770404496; Goodisman MAD, 1999, ANN ENTOMOL SOC AM, V92, P563, DOI 10.1093/aesa/92.4.563; Goodisman MAD, 2000, EVOLUTION, V54, P606, DOI 10.1111/j.0014-3820.2000.tb00062.x; Goodisman MAD, 2007, BIOL INVASIONS, V9, P571, DOI 10.1007/s10530-006-9059-8; Gotzek D, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0001088; Gotzek D, 2008, J INSECT BEHAV, V21, P337, DOI 10.1007/s10905-008-9130-7; Gotzek D, 2007, Q REV BIOL, V82, P201, DOI 10.1086/519965; GREENBERG L, 1985, J KANSAS ENTOMOL SOC, V58, P9; Hallar BL, 2007, GENETICA, V131, P69, DOI 10.1007/s10709-006-9114-5; Helantera H, 2009, TRENDS ECOL EVOL, V24, P341, DOI 10.1016/j.tree.2009.01.013; Holldobler B., 1990, pi; Holldobler B., 2009, SUPERORGANISM, P522; Keller L, 1998, NATURE, V394, P573, DOI 10.1038/29064; Keller L, 1999, J EVOLUTION BIOL, V12, P672, DOI 10.1046/j.1420-9101.1999.00064.x; Keller L, 2002, CURR BIOL, V12, pR180, DOI 10.1016/S0960-9822(02)00737-6; King JR, 2009, BIOL INVASIONS, V11, P373, DOI 10.1007/s10530-008-9254-x; Krieger MJB, 1999, HEREDITY, V82, P142, DOI 10.1038/sj.hdy.6884600; Krieger MJB, 2002, SCIENCE, V295, P328, DOI 10.1126/science.1065247; Krieger MJB, 2005, MOL BIOL EVOL, V22, P2090, DOI 10.1093/molbev/msi203; Krieger MJB, 2005, BIOESSAYS, V27, P91, DOI 10.1002/bies.20129; KWOK S, 1990, NUCLEIC ACIDS RES, V18, P999, DOI 10.1093/nar/18.4.999; Leal WS, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003762; Leal WS, 2005, TOP CURR CHEM, V240, P1, DOI 10.1007/b98314; Lescop E, 2009, BIOCHEMISTRY-US, V48, P2431, DOI 10.1021/bi802300k; Linksvayer TA, 2005, Q REV BIOL, V80, P317, DOI 10.1086/432266; Liu NN, 2004, GENE, V327, P81, DOI 10.1016/j.gene.2003.11.002; Mescher MC, 2003, ANN ENTOMOL SOC AM, V96, P810, DOI 10.1603/0013-8746(2003)096[0810:DOTTSF]2.0.CO;2; MESCHER MC, 2001, THESIS U GEORGIA ATH; Murphy Robert W., 1996, P51; Nagnan-Le Meillour P, 2009, J CHEM ECOL, V35, P752, DOI 10.1007/s10886-009-9663-z; PAESEN GC, 1995, INSECT BIOCHEM MOLEC, V25, P401, DOI 10.1016/0965-1748(94)00085-V; Pasteur N., 1988, PRACTICAL ISOZYME GE; Pelosi P, 2006, CELL MOL LIFE SCI, V63, P1658, DOI 10.1007/s00018-005-5607-0; Pelosi P, 2005, CHEM SENSES, V30, pI291, DOI 10.1093/chemse/bjh229; Robinson GE, 2008, SCIENCE, V322, P896, DOI 10.1126/science.1159277; Ross KG, 2008, P ROY SOC B-BIOL SCI, V275, P2231, DOI 10.1098/rspb.2008.0412; ROSS KG, 1988, BEHAV ECOL SOCIOBIOL, V23, P341, DOI 10.1007/BF00303708; Ross KG, 1997, GENETICS, V147, P643; Ross KG, 1996, P NATL ACAD SCI USA, V93, P3021, DOI 10.1073/pnas.93.7.3021; ROSS KG, 1985, BEHAV ECOL SOCIOBIOL, V17, P349, DOI 10.1007/BF00293212; ROSS KG, 1995, ANNU REV ECOL SYST, V26, P631, DOI 10.1146/annurev.es.26.110195.003215; Ross KG, 1997, GENETICS, V145, P961; Ross KG, 1998, P NATL ACAD SCI USA, V95, P14232, DOI 10.1073/pnas.95.24.14232; Ross KG, 2003, GENETICS, V165, P1853; ROSS KG, 1985, EVOLUTION, V39, P888, DOI 10.1111/j.1558-5646.1985.tb00430.x; Ross KG, 2002, BEHAV ECOL SOCIOBIOL, V51, P287, DOI [10.1007/s00265-001-0431-5, 10.1007/S00265-001-0431-5]; ROSS KG, 1988, BIOL J LINN SOC, V34, P105, DOI 10.1111/j.1095-8312.1988.tb01952.x; Sanchez-Gracia A, 2009, HEREDITY, V103, P208, DOI 10.1038/hdy.2009.55; Shanbhag SR, 2001, MICROSC RES TECHNIQ, V55, P297, DOI 10.1002/jemt.1179; Shoemaker DD, 2006, ANN ENTOMOL SOC AM, V99, P1213, DOI 10.1603/0013-8746(2006)99[1213:PGOTIF]2.0.CO;2; SHOEMAKER DD, 1992, HEREDITY, V69, P573, DOI 10.1038/hdy.1992.173; Sumner S, 2006, ANN ZOOL FENN, V43, P423; Taber SW, 2000, FIRE ANTS; Tschinkel WR., 2006, FIRE ANTS; Valles SM, 2003, INSECT SOC, V50, P199, DOI 10.1007/s00040-003-0662-8; van der Meer R.K., 1986, P201; Vander Meer RK, 2002, BEHAV ECOL SOCIOBIOL, V51, P122, DOI 10.1007/s002650100417; Vargo Edward L., 1998, P293; Vargo EL, 1999, PHYSIOL ENTOMOL, V24, P370, DOI 10.1046/j.1365-3032.1999.00153.x; VOGT RG, 2005, ENDOCRINOLOGY, V3, P753; Vogt Richard G., 2003, P391, DOI 10.1016/B978-012107151-6/50016-5; Wang J, 2008, PLOS GENET, V4, DOI 10.1371/journal.pgen.1000127; WILLER DE, 1986, PHYSIOL ENTOMOL, V11, P475, DOI 10.1111/j.1365-3032.1986.tb00441.x; Xu PX, 2005, SCIENCE, V310, P798, DOI 10.1126/science.1121249; Yang CC, 2008, INSECT SOC, V55, P54, DOI 10.1007/s00040-007-0969-y	81	26	26	0	26	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	NOV 6	2009	4	11							e7713	10.1371/journal.pone.0007713	http://dx.doi.org/10.1371/journal.pone.0007713			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	515ND	19893635	Green Published, Green Submitted, gold			2022-12-25	WOS:000271478000006
J	Gamez-Pozo, A; Sanchez-Navarro, I; Nistal, M; Calvo, E; Madero, R; Diaz, E; Camafeita, E; de Castro, J; Lopez, JA; Gonzalez-Baron, M; Espinosa, E; Vara, JAF				Gamez-Pozo, Angelo; Sanchez-Navarro, Iker; Nistal, Manuel; Calvo, Enrique; Madero, Rosario; Diaz, Esther; Camafeita, Emilio; de Castro, Javier; Antonio Lopez, Juan; Gonzalez-Baron, Manuel; Espinosa, Enrique; Fresno Vara, Juan Angel			MALDI Profiling of Human Lung Cancer Subtypes	PLOS ONE			English	Article							GLYCERALDEHYDE-3-PHOSPHATE DEHYDROGENASE GENE; IMAGING MASS-SPECTROMETRY; PROTEOMIC PATTERNS; BREAST-CANCER; CELL-LINES; EXPRESSION; CLASSIFICATION; PHOSPHOPROTEOME; REPRODUCIBILITY; ADENOCARCINOMA	Background: Proteomics is expected to play a key role in cancer biomarker discovery. Although it has become feasible to rapidly analyze proteins from crude cell extracts using mass spectrometry, complex sample composition hampers this type of measurement. Therefore, for effective proteome analysis, it becomes critical to enrich samples for the analytes of interest. Despite that one-third of the proteins in eukaryotic cells are thought to be phosphorylated at some point in their life cycle, only a low percentage of intracellular proteins is phosphorylated at a given time. Methodology/Principal Findings: In this work, we have applied chromatographic phosphopeptide enrichment techniques to reduce the complexity of human clinical samples. A novel method for high-throughput peptide profiling of human tumor samples, using Parallel IMAC and MALDI-TOF MS, is described. We have applied this methodology to analyze human normal and cancer lung samples in the search for new biomarkers. Using a highly reproducible spectral processing algorithm to produce peptide mass profiles with minimal variability across the samples, lineal discriminant-based and decision tree-based classification models were generated. These models can distinguish normal from tumor samples, as well as differentiate the various non-small cell lung cancer histological subtypes. Conclusions/Significance: A novel, optimized sample preparation method and a careful data acquisition strategy is described for high-throughput peptide profiling of small amounts of human normal lung and lung cancer samples. We show that the appropriate combination of peptide expression values is able to discriminate normal lung from non-small cell lung cancer samples and among different histological subtypes. Our study does emphasize the great potential of proteomics in the molecular characterization of cancer.	[Gamez-Pozo, Angelo; Sanchez-Navarro, Iker; Nistal, Manuel; Diaz, Esther; de Castro, Javier; Gonzalez-Baron, Manuel; Espinosa, Enrique; Fresno Vara, Juan Angel] Hosp Univ La Paz, Lab Mol Pathol & Oncol, Unidad Invest, Madrid, Spain; [Calvo, Enrique; Camafeita, Emilio; Antonio Lopez, Juan] CNIC, Unidad Proteom, Madrid, Spain; [Madero, Rosario] Hosp Univ La Paz, Unidad Bioestadist, Madrid, Spain	Hospital Universitario La Paz; Centro Nacional de Investigaciones Cardiovasculares (CNIC); Hospital Universitario La Paz	Gamez-Pozo, A (corresponding author), Hosp Univ La Paz, Lab Mol Pathol & Oncol, Unidad Invest, Madrid, Spain.	jfresnov.hulp@salud.madrid.org	Lopez, Juan Antonio/G-7750-2015; Fresno Vara, Juan Angel/F-6702-2010; Gamez-Pozo, Angelo/N-2506-2014; Vara, Juan Ángel Fresno/Y-9928-2019	Lopez, Juan Antonio/0000-0002-9097-6060; Fresno Vara, Juan Angel/0000-0003-1527-1252; Gamez-Pozo, Angelo/0000-0002-8931-0624; Vara, Juan Ángel Fresno/0000-0003-1527-1252; De Castro, Javier/0000-0002-3622-6306; Espinosa Arranz, Enrique/0000-0001-6562-7902				Abramovitz M, 2006, PROTEOME SCI, V4, DOI 10.1186/1477-5956-4-5; Albrethsen J, 2007, CLIN CHEM, V53, P852, DOI 10.1373/clinchem.2006.082644; BLOBEL GA, 1984, VIRCHOWS ARCH B, V45, P407, DOI 10.1007/BF02889883; Bodenmiller B, 2007, NAT METHODS, V4, P231, DOI 10.1038/nmeth1005; Callesen AK, 2008, RAPID COMMUN MASS SP, V22, P291, DOI 10.1002/rcm.3364; Chang TJ, 1998, ONCOL REP, V5, P469; Cohen P, 2002, NAT CELL BIOL, V4, pE127, DOI 10.1038/ncb0502-e127; Conrad DH, 2008, J GEN INTERN MED, V23, P78, DOI 10.1007/s11606-007-0411-1; Dettling M, 2003, BIOINFORMATICS, V19, P1061, DOI 10.1093/bioinformatics/btf867; Friedman J, 2000, ANN STAT, V28, P337, DOI 10.1214/aos/1016218223; Fukunaga Y, 2002, LUNG CANCER-J IASLC, V38, P31, DOI 10.1016/S0169-5002(02)00109-5; Ge GT, 2008, BMC BIOINFORMATICS, V9, DOI 10.1186/1471-2105-9-275; Groseclose MR, 2008, PROTEOMICS, V8, P3715, DOI 10.1002/pmic.200800495; Hanash S, 2003, NATURE, V422, P226, DOI 10.1038/nature01514; Herbst RS, 2008, NEW ENGL J MED, V359, P1367, DOI 10.1056/NEJMra0802714; Ishii T, 2008, TUMOR BIOL, V29, P57, DOI 10.1159/000132572; Jemal A, 2008, CA-CANCER J CLIN, V58, P71, DOI 10.3322/CA.2007.0010; Kim JW, 1998, GYNECOL ONCOL, V71, P266, DOI 10.1006/gyno.1998.5195; Makrantoni V, 2005, YEAST, V22, P401, DOI 10.1002/yea.1220; Meyerson M, 2005, J CLIN ONCOL, V23, P3219, DOI 10.1200/JCO.2005.15.511; Mountain CF, 1997, CHEST, V111, P1710, DOI 10.1378/chest.111.6.1710; Oda Y, 2001, NAT BIOTECHNOL, V19, P379, DOI 10.1038/86783; Perkins DN, 1999, ELECTROPHORESIS, V20, P3551, DOI 10.1002/(SICI)1522-2683(19991201)20:18<3551::AID-ELPS3551>3.0.CO;2-2; Persson A, 2006, CURR OPIN MOL THER, V8, P185; Pusch W, 2005, CURR PHARM DESIGN, V11, P2577, DOI 10.2174/1381612054546932; Rahman SMJ, 2005, AM J RESP CRIT CARE, V172, P1556, DOI 10.1164/rccm.200502-274OC; Revillion F, 2000, EUR J CANCER, V36, P1038, DOI 10.1016/S0959-8049(00)00051-4; Rikova K, 2007, CELL, V131, P1190, DOI 10.1016/j.cell.2007.11.025; Ruan WJ, 2007, CLIN CHIM ACTA, V385, P1, DOI 10.1016/j.cca.2007.07.003; SAVITZKY A, 1964, ANAL CHEM, V36, P1627, DOI 10.1021/ac60214a047; SCHEK N, 1988, CANCER RES, V48, P6354; Shedden K, 2008, NAT MED, V14, P822, DOI 10.1038/nm.1790; Stoeckli M, 2001, NAT MED, V7, P493, DOI 10.1038/86573; Suckau D, 2003, ANAL BIOANAL CHEM, V376, P952, DOI 10.1007/s00216-003-2057-0; TOKUNAGA K, 1987, CANCER RES, V47, P5616; Yanagisawa K, 2003, LANCET, V362, P433, DOI 10.1016/S0140-6736(03)14068-8; Zhang Xinyi, 2004, J Biomol Tech, V15, P167	37	26	26	0	14	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	NOV 5	2009	4	11							e7731	10.1371/journal.pone.0007731	http://dx.doi.org/10.1371/journal.pone.0007731			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	515HI	19890392	Green Published, Green Submitted, gold			2022-12-25	WOS:000271459700016
J	Middeldorp, J; van den Berge, SA; Aronica, E; Speijer, D; Hol, EM				Middeldorp, Jinte; van den Berge, Simone A.; Aronica, Eleonora; Speijer, Dave; Hol, Elly M.			Specific Human Astrocyte Subtype Revealed by Affinity Purified GFAP(+1) Antibody; Unpurified Serum CrossReacts with Neurofilament-L in Alzheimer	PLOS ONE			English	Article							FIBRILLARY ACIDIC PROTEIN; EXPRESSION; TANGLES; DISEASE	The human GFAP splice variants GF Delta PD164 and GF Delta PDexon6 both result in a GFAP protein isoform with a unique out-of-frame carboxy-terminus that can be detected by the GFAP(+1) antibody. We previously reported that GFAP(+1) was expressed in astrocytes and in degenerating neurons in Alzheimer's disease brains. In this study we aimed at further investigating the neuronal GFAP(+1) expression and we started by affinity purifying the GFAP(+1) antibody. The purified antibody resulted in a loss of neuronal GFAP(+1) signal, although other antibodies directed against the amino-and carboxy-terminus of GFAP alpha still revealed GFAP-immunopositive neurons, as described before. With an in-depth analysis of a western blot, followed by mass spectrometry we discovered that the previously detected neuronal GFAP(+1) expression was due to cross-reactivity of the antibody with neurofilament-L (NF-L). This was confirmed by double-label fluorescent immunohistochemistry and western blotting with the unpurified GFAP(+1) antibody and an antibody against NF-L. Our data imply that NF-L can accumulate in some tangle-like structures in Alzheimer brains. More importantly, the purified GFAP(+1) antibody clearly revealed a specific subtype of astrocytes in the adult human brain. These large astrocytes are present throughout the brain, e.g., along the subventricular zone, in the hippocampus, in the striatum and in the spinal cord of controls, Alzheimer, and Parkinson patients. The presence of a specific GFAP-isoform suggests a specialized function of these astrocytes.			Middeldorp, J (corresponding author), Inst Royal Netherlands Acad Arts & Sci, Dept Astrocyte Biol & Neurodegenerat, Netherlands Inst Neurosci, Amsterdam, Netherlands.	e.hol@nin.knaw.nl	Hol, Elly/J-2025-2019; Middeldorp, Jinte/M-2352-2016; Hol, Elly M/F-1891-2013; Speijer, Dave/AAE-4613-2019; , Jinte/AHA-6575-2022	Hol, Elly/0000-0001-5604-2603; Middeldorp, Jinte/0000-0002-9198-8020; Hol, Elly M/0000-0001-5604-2603; Speijer, Dave/0000-0002-2340-2753; , Jinte/0000-0002-9198-8020; van den Berge, Simone/0000-0003-2019-1812; Aronica, Eleonora/0000-0002-3542-3770				BEACH TG, 1989, GLIA, V2, P420, DOI 10.1002/glia.440020605; BIANCHINI D, 1992, BRAIN RES, V570, P209, DOI 10.1016/0006-8993(92)90583-U; Carotti S, 2008, LIVER TRANSPLANT, V14, P806, DOI 10.1002/lt.21436; Hainfellner JA, 2001, J NEUROPATH EXP NEUR, V60, P449, DOI 10.1093/jnen/60.5.449; Hol EM, 2003, MOL PSYCHIATR, V8, P786, DOI 10.1038/sj.mp.4001379; IKEDA K, 1992, J NEUROL, V239, P191, DOI 10.1007/BF00839138; Nakamura Y, 1997, NEUROSCI LETT, V225, P201, DOI 10.1016/S0304-3940(97)00223-1; Oberheim NA, 2006, TRENDS NEUROSCI, V29, P547, DOI 10.1016/j.tins.2006.08.004; Oberheim NA, 2009, J NEUROSCI, V29, P3276, DOI 10.1523/JNEUROSCI.4707-08.2009; OESTREICHER AB, 1983, J NEUROCHEM, V41, P331, DOI 10.1111/j.1471-4159.1983.tb04747.x; Perng MD, 2008, MOL BIOL CELL, V19, P4521, DOI 10.1091/mbc.E08-03-0284; Roelofs RF, 2005, GLIA, V52, P289, DOI 10.1002/glia.20243; Shevchenko A, 1996, ANAL CHEM, V68, P850, DOI 10.1021/ac950914h; YAMAGUCHI H, 1991, ACTA NEUROPATHOL, V81, P603, DOI 10.1007/BF00296369	14	20	20	2	7	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA	1932-6203			PLOS ONE	PLoS One	NOV 4	2009	4	11							e7663	10.1371/journal.pone.0007663	http://dx.doi.org/10.1371/journal.pone.0007663			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	514RZ	19888461	gold, Green Published, Green Submitted			2022-12-25	WOS:000271414600004
J	Gustafsson, A; Bostrom, AK; Ljungberg, B; Axelson, H; Dahlback, B				Gustafsson, Anna; Bostrom, Anna-Karin; Ljungberg, Borje; Axelson, Hakan; Dahlback, Bjorn			Gas6 and the Receptor Tyrosine Kinase Axl in Clear Cell Renal Cell Carcinoma	PLOS ONE			English	Article							ARREST-SPECIFIC GENE-6; K-DEPENDENT PROTEINS; GROWTH-ARREST; DIABETIC-NEPHROPATHY; BREAST-CANCER; EXPRESSION; LINES; HYPERTROPHY; PROGRESSION; FIBROBLASTS	Background: The molecular biology of renal cell carcinoma (RCC) is complex and not fully understood. We have recently found that the expression of the receptor tyrosine kinase Axl in the RCC tumors independently correlates with survival of the patients. Principal Findings: Here, we have investigated the role of Axl and its ligand Gas6, the vitamin-K dependent protein product of the growth arrest-specific gene 6, in clear cell RCC (ccRCC) derived cells. The Axl protein was highly expressed in ccRCC cells deficient in functional von Hippel-Lindau (VHL) protein, a tumor suppressor gene often inactivated in ccRCC. VHL reconstituted cells expressed decreased levels of Axl protein, but not Axl mRNA, suggesting VHL to regulate Axl expression. Gas6-mediated activation of Axl in ccRCC cells resulted in Axl phosphorylation, receptor down-regulation, decreased cell-viability and migratory capacity. No effects of the Gas6/Axl system could be detected on invasion. Moreover, in ccRCC tumor tissues, Axl was phosphorylated and Gas6 c-carboxylated, suggesting these molecules to be active in vivo. Significance: These results provide novel information regarding the complex function of the Gas6/Axl system in ccRCC.			Gustafsson, A (corresponding author), Lund Univ, Malmo Univ Hosp, Dept Lab Med, Sect Clin Chem, Malmo, Sweden.	bjorn.dahlback@med.lu.se		Dahlback, Bjorn/0000-0003-1546-0328; Ljungberg, Borje/0000-0002-4121-3753				Allen MP, 2002, MOL CELL BIOL, V22, P599, DOI 10.1128/MCB.22.2.599-613.2002; Angelillo-Scherrer A, 2001, NAT MED, V7, P215, DOI 10.1038/84667; Arai H, 2008, VITAM HORM, V78, P375, DOI 10.1016/S0083-6729(07)00015-5; Bellido-Martin L, 2008, VITAM HORM, V78, P185, DOI 10.1016/S0083-6729(07)00009-X; BELLOSTA P, 1995, MOL CELL BIOL, V15, P614; Berclaz G, 2001, ANN ONCOL, V12, P819, DOI 10.1023/A:1011126330233; Brown MA, 2000, J BIOL CHEM, V275, P19795, DOI 10.1074/jbc.M002298200; Budagian V, 2005, EMBO J, V24, P4260, DOI 10.1038/sj.emboj.7600874; Cohen HT, 2005, NEW ENGL J MED, V353, P2477, DOI 10.1056/NEJMra043172; CRAVEN RJ, 1995, INT J CANCER, V60, P791, DOI 10.1002/ijc.2910600611; EBERT T, 1990, CANCER RES, V50, P5531; Evenas P, 2000, THROMB HAEMOSTASIS, V84, P271, DOI 10.1055/s-0037-1614007; Fiebeler A, 2004, AM J KIDNEY DIS, V43, P286, DOI 10.1053/j.ajkd.2003.10.016; Fogh J, 1978, Natl Cancer Inst Monogr, P5; Fridell YWC, 1998, J BIOL CHEM, V273, P7123, DOI 10.1074/jbc.273.12.7123; Gallicchio M, 2005, BLOOD, V105, P1970, DOI 10.1182/blood-2004-04-1469; Goruppi S, 1996, ONCOGENE, V12, P471; GUSTAFSSON A, 2009, CLIN CANC RES, V15; Hafizi S, 2006, FEBS J, V273, P5231, DOI 10.1111/j.1742-4658.2006.05529.x; Hafizi S, 2006, CYTOKINE GROWTH F R, V17, P295, DOI 10.1016/j.cytogfr.2006.04.004; Hasanbasic I, 2005, J THROMB HAEMOST, V3, P2790, DOI 10.1111/j.1538-7836.2005.01662.x; Holland SJ, 2005, CANCER RES, V65, P9294, DOI 10.1158/0008-5472.CAN-05-0993; Hu CJ, 2003, MOL CELL BIOL, V23, P9361, DOI 10.1128/MCB.23.24.9361-9374.2003; Hutterer M, 2008, CLIN CANCER RES, V14, P130, DOI 10.1158/1078-0432.CCR-07-0862; ILIOPOULOS O, 1995, NAT MED, V1, P822, DOI 10.1038/nm0895-822; Ito T, 1999, THYROID, V9, P563, DOI 10.1089/thy.1999.9.563; JANSSEN JWG, 1991, ONCOGENE, V6, P2113; Linger RMA, 2008, ADV CANCER RES, V100, P35, DOI 10.1016/S0065-230X(08)00002-X; Ljungberg B, 2007, EUR UROL, V51, P1502, DOI 10.1016/j.eururo.2007.03.035; MANFIOLETTI G, 1993, MOL CELL BIOL, V13, P4976, DOI 10.1128/MCB.13.8.4976; Maxwell PH, 1999, NATURE, V399, P271, DOI 10.1038/20459; Mc Cormack O, 2008, BRIT J CANCER, V98, P1141, DOI 10.1038/sj.bjc.6604260; Nagai K, 2005, KIDNEY INT, V68, P552, DOI 10.1111/j.1523-1755.2005.00433.x; Nagai K, 2003, J BIOL CHEM, V278, P18229, DOI 10.1074/jbc.M213266200; Nielsen-Preiss SM, 2007, ENDOCRINOLOGY, V148, P2806, DOI 10.1210/en.2007-0039; OBRYAN JP, 1995, J BIOL CHEM, V270, P551, DOI 10.1074/jbc.270.2.551; OBRYAN JP, 1991, MOL CELL BIOL, V11, P5016, DOI 10.1128/MCB.11.10.5016; QUONG RYY, 1994, MELANOMA RES, V4, P313, DOI 10.1097/00008390-199410000-00008; Robinson DR, 2000, ONCOGENE, V19, P5548, DOI 10.1038/sj.onc.1203957; Sawabu T, 2007, MOL CARCINOGEN, V46, P155, DOI 10.1002/mc.20211; Schlessinger J, 2000, CELL, V103, P211, DOI 10.1016/j.cell.2010.06.011; Shieh YS, 2005, NEOPLASIA, V7, P1058, DOI 10.1593/neo.05640; SKINNER DG, 1971, CANCER-AM CANCER SOC, V28, P1165, DOI 10.1002/1097-0142(1971)28:5<1165::AID-CNCR2820280513>3.0.CO;2-G; Sobin LH, 2002, INT UNION CANC UICC, P193; Stenhoff J, 2004, BIOCHEM BIOPH RES CO, V319, P871, DOI 10.1016/j.bbrc.2004.05.070; Sun WS, 2004, ONCOLOGY-BASEL, V66, P450, DOI 10.1159/000079499; Tai KY, 2008, ONCOGENE, V27, P4044, DOI 10.1038/onc.2008.57; Vajkoczy P, 2006, P NATL ACAD SCI USA, V103, P5799, DOI 10.1073/pnas.0510923103; VARNUM BC, 1995, NATURE, V373, P623, DOI 10.1038/373623a0; WILLIAMS RD, 1978, IN VITRO CELL DEV B, V14, P779, DOI 10.1007/BF02617972; Wimmel A, 2001, EUR J CANCER, V37, P2264, DOI 10.1016/S0959-8049(01)00271-4; Yanagita M, 2002, J CLIN INVEST, V110, P239, DOI 10.1172/JCI200214861; Yanagita M, 2001, AM J PATHOL, V158, P1423, DOI 10.1016/S0002-9440(10)64093-X; Zhang YX, 2008, CANCER RES, V68, P1905, DOI 10.1158/0008-5472.CAN-07-2661	54	38	38	1	7	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	OCT 30	2009	4	10							e7575	10.1371/journal.pone.0007575	http://dx.doi.org/10.1371/journal.pone.0007575			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	514RW	19888345	gold, Green Published, Green Submitted			2022-12-25	WOS:000271414300003
J	Lim, JH; Davis, GE; Wang, ZS; Li, V; Wu, YP; Rue, TC; Storm, DR				Lim, Jae H.; Davis, Greg E.; Wang, Zhenshan; Li, Vicky; Wu, Yuping; Rue, Tessa C.; Storm, Daniel R.			Zicam-Induced Damage to Mouse and Human Nasal Tissue	PLOS ONE			English	Article							OLFACTORY EPITHELIUM; INTRANASAL ZINC; NEURONAL DEATH; COMMON-COLD; ANOSMIA; IRRIGATION; ZNSO4; MICE	Intranasal medications are used to treat various nasal disorders. However, their effects on olfaction remain unknown. Zicam (zinc gluconate; Matrixx Initiatives, Inc), a homeopathic substance marketed to alleviate cold symptoms, has been implicated in olfactory dysfunction. Here, we investigated Zicam and several common intranasal agents for their effects on olfactory function. Zicam was the only substance that showed significant cytotoxicity in both mouse and human nasal tissue. Specifically, Zicam-treated mice had disrupted sensitivity of olfactory sensory neurons to odorant stimulation and were unable to detect novel odorants in behavioral testing. These findings were long-term as no recovery of function was observed after two months. Finally, human nasal explants treated with Zicam displayed significantly elevated extracellular lactate dehydrogenase levels compared to saline-treated controls, suggesting severe necrosis that was confirmed on histology. Our results demonstrate that Zicam use could irreversibly damage mouse and human nasal tissue and may lead to significant smell dysfunction.			Lim, JH (corresponding author), Univ Washington, Dept Otolaryngol Head & Neck Surg, Seattle, WA 98195 USA.	dstorm@u.washington.edu	wu, Yuping/B-5104-2012		NATIONAL CENTER FOR RESEARCH RESOURCES [KL2RR025015] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS [T32DC000018, R01DC004156] Funding Source: NIH RePORTER	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD))		Alexander TH, 2006, LARYNGOSCOPE, V116, P217, DOI 10.1097/01.mlg.0000191549.17796.13; Angell M, 1998, NEW ENGL J MED, V339, P839, DOI 10.1056/NEJM199809173391210; BURD GD, 1993, MICROSC RES TECHNIQ, V24, P195, DOI 10.1002/jemt.1070240302; Calof AL, 1996, J NEUROBIOL, V30, P67; Capasso M, 2005, J ALZHEIMERS DIS, V8, P93; Chen CJ, 2003, J NEUROCHEM, V85, P443, DOI 10.1046/j.1471-4159.2003.01691.x; Doty RL, 2009, SEMIN NEUROL, V29, P74, DOI 10.1055/s-0028-1124025; Eby GA, 2006, ALTERN THER HEALTH M, V12, P34; Feron F, 1998, ARCH OTOLARYNGOL, V124, P861, DOI 10.1001/archotol.124.8.861; HARDING JW, 1978, BRAIN RES, V140, P271, DOI 10.1016/0006-8993(78)90460-2; Henion TR, 2007, J CELL PHYSIOL, V210, P290, DOI 10.1002/jcp.20888; Holbrook Eric H, 2006, Curr Opin Otolaryngol Head Neck Surg, V14, P23, DOI 10.1097/01.moo.0000193174.77321.39; Jafek BW, 2004, AM J RHINOL, V18, P137, DOI 10.1177/194589240401800302; Jones LM, 2006, CURR OPIN NEUROBIOL, V16, P420, DOI 10.1016/j.conb.2006.06.011; Kim EY, 1999, EUR J NEUROSCI, V11, P327, DOI 10.1046/j.1460-9568.1999.00437.x; Leopold Donald A, 2002, J Otolaryngol, V31 Suppl 1, pS18, DOI 10.2310/7070.2002.21263; Lund Valerie J., 1993, Rhinology (Utrecht), V31, P183; Manev H, 1997, EXP NEUROL, V146, P171, DOI 10.1006/exnr.1997.6510; MATULIONIS DH, 1975, AM J ANAT, V142, P67, DOI 10.1002/aja.1001420106; McBride K, 2003, CHEM SENSES, V28, P659, DOI 10.1093/chemse/bjg053; Mossad SB, 2003, QJM-INT J MED, V96, P35, DOI 10.1093/qjmed/hcg004; Pavlica S, 2009, TOXICOL IN VITRO, V23, P653, DOI 10.1016/j.tiv.2009.03.003; Piccirillo JF, 2002, OTOLARYNG HEAD NECK, V126, P41, DOI 10.1067/mhn.2002.121022; Sheline CT, 2000, J NEUROSCI, V20, P3139, DOI 10.1523/JNEUROSCI.20-09-03139.2000; Simon SA, 2006, NAT REV NEUROSCI, V7, P890, DOI 10.1038/nrn2006; Slotnick B, 2007, LARYNGOSCOPE, V117, P743, DOI 10.1097/MLG.0b013e318033006b; Trinh K, 2003, NAT NEUROSCI, V6, P519, DOI 10.1038/nn1039; Widdicombe J, 1997, ALLERGY, V52, P7, DOI 10.1111/j.1398-9995.1997.tb04877.x; WIDDICOMBE JG, 1986, CLIN CHEST MED, V7, P159; Wong ST, 2000, NEURON, V27, P487, DOI 10.1016/S0896-6273(00)00060-X	30	24	24	0	9	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	OCT 30	2009	4	10							e7647	10.1371/journal.pone.0007647	http://dx.doi.org/10.1371/journal.pone.0007647			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	514RW	19876403	gold, Green Published, Green Submitted			2022-12-25	WOS:000271414300008
J	Darsigny, M; Babeu, JP; Dupuis, AA; Furth, EE; Seidman, EG; Levy, E; Verdu, EF; Gendron, FP; Boudreau, F				Darsigny, Mathieu; Babeu, Jean-Philippe; Dupuis, Andree-Anne; Furth, Emma E.; Seidman, Ernest G.; Levy, Emile; Verdu, Elena F.; Gendron, Fernand-Pierre; Boudreau, Francois			Loss of Hepatocyte-Nuclear-Factor-4 alpha Affects Colonic Ion Transport and Causes Chronic Inflammation Resembling Inflammatory Bowel Disease in Mice	PLOS ONE			English	Article							INTESTINAL EPITHELIAL-CELLS; GENE-EXPRESSION; APOPTOSIS; ACTIVATION; DIFFERENTIATION; TRANSCRIPTION; PATHOGENESIS; CONTRIBUTES; PROTEINS; RECEPTOR	Background: Hnf4 alpha, an epithelial specific transcriptional regulator, is decreased in inflammatory bowel disease and protects against chemically-induced colitis in mice. However, the precise role of this factor in maintaining normal inflammatory homeostasis of the intestine remains unclear. The aim of this study was to evaluate the sole role of epithelial Hnf4 alpha in the maintenance of gut inflammatory homeostasis in mice. Methodology/Principal Findings: We show here that specific epithelial deletion of Hnf4 alpha in mice causes spontaneous chronic intestinal inflammation leading to focal areas of crypt dropout, increased cytokines and chemokines secretion, immune cell infiltrates and crypt hyperplasia. A gene profiling analysis in diseased Hnf4 alpha null colon confirms profound genetic changes in cell death and proliferative behaviour related to cancer. Among the genes involved in the immune protection through epithelial barrier function, we identify the ion transporter claudin-15 to be down-modulated early in the colon of Hnf4 alpha mutants. This coincides with a significant decrease of mucosal ion transport but not of barrier permeability in young animals prior to the manifestation of the disease. We confirm that claudin-15 is a direct Hnf4 alpha gene target in the intestinal epithelial context and is down-modulated in mouse experimental colitis and inflammatory bowel disease. Conclusion: Our results highlight the critical role of Hnf4 alpha to maintain intestinal inflammatory homeostasis during mouse adult life and uncover a novel function for Hnf4 alpha in the regulation of claudin-15 expression. This establishes Hnf4 alpha as a mediator of ion epithelial transport, an important process for the maintenance of gut inflammatory homeostasis.			Darsigny, M (corresponding author), Univ Sherbrooke, Canadian Inst Hlth Res Team Digest Epithelium, Dept Anat & Biol Cellulaire, Fac Med & Sci Sante, Sherbrooke, PQ J1K 2R1, Canada.	Francois.Boudreau@usherbrooke.ca	Gendron, Fernand-Pierre/AAN-2965-2021		Canadian Institutes of Health Research [CTP-82942, MOP-897702] Funding Source: Medline	Canadian Institutes of Health Research(Canadian Institutes of Health Research (CIHR))		Ahn SH, 2008, INFLAMM BOWEL DIS, V14, P908, DOI 10.1002/ibd.20413; Auclair BA, 2007, GASTROENTEROLOGY, V133, P887, DOI 10.1053/j.gastro.2007.06.066; Babeu JP, 2009, AM J PHYSIOL-GASTR L, V297, pG124, DOI 10.1152/ajpgi.90690.2008; Bagnat M, 2007, NAT CELL BIOL, V9, P954, DOI 10.1038/ncb1621; Battle MA, 2006, P NATL ACAD SCI USA, V103, P8419, DOI 10.1073/pnas.0600246103; Black DD, 2007, AM J PHYSIOL-GASTR L, V293, pG519, DOI 10.1152/ajpgi.00189.2007; Boudreau F, 2002, J BIOL CHEM, V277, P31909, DOI 10.1074/jbc.M204622200; Boudreau F., 2007, FASEB J; Burum-Auensen E, 2007, J CLIN PATHOL, V60, P1403, DOI 10.1136/jcp.2006.044305; CAUX C, 1994, J EXP MED, V180, P1263, DOI 10.1084/jem.180.4.1263; CHEN WS, 1994, GENE DEV, V8, P2466, DOI 10.1101/gad.8.20.2466; Chiba H, 2005, EXP CELL RES, V302, P11, DOI 10.1016/j.yexcr.2004.08.014; Edelblum KL, 2006, INFLAMM BOWEL DIS, V12, P413, DOI 10.1097/01.MIB.0000217334.30689.3e; Garrison WD, 2006, GASTROENTEROLOGY, V130, P1207, DOI 10.1053/j.gastro.2006.01.003; Grbic DM, 2008, J IMMUNOL, V180, P2659, DOI 10.4049/jimmunol.180.4.2659; Gupta RK, 2004, TRENDS MOL MED, V10, P521, DOI 10.1016/j.molmed.2004.09.004; Hayhurst GP, 2001, MOL CELL BIOL, V21, P1393, DOI 10.1128/MCB.21.4.1393-1403.2001; Ho SB, 2006, GASTROENTEROLOGY, V131, P1501, DOI 10.1053/j.gastro.2006.09.006; Huang RP, 2005, EXPERT OPIN THER TAR, V9, P601, DOI 10.1517/14728222.9.3.601; Iaquinta PJ, 2007, CURR OPIN CELL BIOL, V19, P649, DOI 10.1016/j.ceb.2007.10.006; Laubitz D, 2008, AM J PHYSIOL-GASTR L, V295, pG63, DOI 10.1152/ajpgi.90207.2008; Laukoetter MG, 2006, CURR OPIN GASTROEN, V22, P85, DOI 10.1097/01.mog.0000203864.48255.4f; Lussier CR, 2008, AM J PHYSIOL-GASTR L, V294, pG418, DOI 10.1152/ajpgi.00418.2007; MONTROSE MH, 2003, TXB GASTROENTEROLOGY, P308; Moss SF, 2005, NAT CLIN PRACT ONCOL, V2, P90, DOI 10.1038/ncponc0081; Novak JP, 2002, GENOMICS, V79, P104, DOI 10.1006/geno.2001.6675; Pan HC, 1998, MOL CELL, V2, P283, DOI 10.1016/S1097-2765(00)80273-7; Parviz F, 2003, NAT GENET, V34, P292, DOI 10.1038/ng1175; Peltekova VD, 2004, NAT GENET, V36, P471, DOI 10.1038/ng1339; Resta-Lenert SC, 2009, ANN NY ACAD SCI, V1165, P175, DOI 10.1111/j.1749-6632.2009.04042.x; Ruemmele FM, 2002, J PEDIATR GASTR NUTR, V34, P254, DOI 10.1097/00005176-200203000-00005; Schultheis PJ, 1998, NAT GENET, V19, P282, DOI 10.1038/969; Su LP, 2009, GASTROENTEROLOGY, V136, P551, DOI 10.1053/j.gastro.2008.10.081; Tamura A, 2008, GASTROENTEROLOGY, V134, P523, DOI 10.1053/j.gastro.2007.11.040; Varghese AK, 2006, GASTROENTEROLOGY, V130, P1743, DOI 10.1053/j.gastro.2006.02.007; Verdu EF, 2008, AM J PHYSIOL-GASTR L, V294, pG217, DOI 10.1152/ajpgi.00225.2007; Xavier RJ, 2007, NATURE, V448, P427, DOI 10.1038/nature06005	37	91	93	0	7	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	OCT 29	2009	4	10							e7609	10.1371/journal.pone.0007609	http://dx.doi.org/10.1371/journal.pone.0007609			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	512FP	19898610	Green Published, Green Submitted, gold			2022-12-25	WOS:000271232000003
J	Kimura, J; Abe, H; Kamitani, S; Toshima, H; Fukui, A; Miyake, M; Kamata, Y; Sugita-Konishi, Y; Yamamoto, S; Horiguchi, Y				Kimura, Jun; Abe, Hiroyuki; Kamitani, Shigeki; Toshima, Hirono; Fukui, Aya; Miyake, Masami; Kamata, Yoichi; Sugita-Konishi, Yoshiko; Yamamoto, Shigeki; Horiguchi, Yasuhiko			Clostridium perfringens Enterotoxin Interacts with Claudins via Electrostatic Attraction	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							C-TERMINAL FRAGMENT; TIGHT JUNCTION; MEMBRANE-PROTEINS; BINDING; COMPLEX; REGION; TOXIN; DETERMINANTS; MUTAGENESIS; MODULATION	Clostridium perfringens enterotoxin (CPE), a causative agent of food poisoning, is a pore-forming toxin disrupting the selective permeability of the plasma membrane of target cells, resulting in cell death. We previously identified claudin as the cell surface receptor for CPE. Claudin, a component of tight junctions, is a tetratransmembrane protein and constitutes a large family of more than 20 members, not all of which serve as the receptor for CPE. The mechanism by which the toxin distinguishes the sensitive claudins is unknown. In this study, we localized the region of claudin responsible for interaction with CPE to the C-terminal part of the second extracellular loop and found that the isoelectric point of this region in sensitive claudins was higher than insensitive claudins. Amino acid substitutions to lower the pI resulted in reduced sensitivity to CPE among sensitive claudins, whereas substitutions to raise the pI endowed CPE-insensitive claudins with sensitivity. The steric structure of the claudin-binding domain of CPE reveals an acidic cleft surrounded by Tyr(306), Tyr(310), Tyr(312), and Leu(315), which were reported to be essential for interaction with the sensitive claudins. These results imply that an electrostatic attraction between the basic claudin region and the acidic CPE cleft is involved in their interaction.	[Kimura, Jun; Abe, Hiroyuki; Kamitani, Shigeki; Toshima, Hirono; Fukui, Aya; Horiguchi, Yasuhiko] Osaka Univ, Microbial Dis Res Inst, Dept Mol Bacteriol, Suita, Osaka 5650871, Japan; [Miyake, Masami] Osaka Prefecture Univ, Dept Vet Environm Sci, Lab Vet Publ Hlth, Osaka 5988531, Japan; [Kamata, Yoichi; Sugita-Konishi, Yoshiko] Natl Inst Hlth Sci, Div Microbiol, Setagaya Ku, Tokyo 1588501, Japan; [Yamamoto, Shigeki] Natl Inst Hlth Sci, Div Biomed Food Res, Setagaya Ku, Tokyo 1588501, Japan	Osaka University; Osaka Metropolitan University; National Institute of Health Sciences - Japan; National Institute of Health Sciences - Japan	Horiguchi, Y (corresponding author), Osaka Univ, Microbial Dis Res Inst, Dept Mol Bacteriol, 3-1 Yamada Oka, Suita, Osaka 5650871, Japan.	horiguti@biken.osaka-u.ac.jp		Kamitani, Shigeki/0000-0002-1268-4652	Ministry of Education, Culture, Science, and Technology of Japan	Ministry of Education, Culture, Science, and Technology of Japan(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT))	The work was supported in part by grants-in-aid for scientific research from the Ministry of Education, Culture, Science, and Technology of Japan.	ALOUF JE, 2006, COMPREHENSIVE SOURCE, P643, DOI DOI 10.1016/B978-012088445-2/50041-X; ALOUF JE, 2006, COMPREHENSIVE SOURCE, P507; Ebihara C, 2007, BIOCHEM PHARMACOL, V73, P824, DOI 10.1016/j.bcp.2006.11.013; Fujita K, 2000, FEBS LETT, V476, P258, DOI 10.1016/S0014-5793(00)01744-0; Furuse M, 1998, J CELL BIOL, V141, P1539, DOI 10.1083/jcb.141.7.1539; HANNA PC, 1991, J BIOL CHEM, V266, P11037; HANNA PC, 1992, INFECT IMMUN, V60, P2110, DOI 10.1128/IAI.60.5.2110-2114.1992; Harada M, 2007, BIOCHEM PHARMACOL, V73, P206, DOI 10.1016/j.bcp.2006.10.002; HORIGUCHI Y, 1985, FEMS MICROBIOL LETT, V28, P131; HORIGUCHI Y, 1987, INFECT IMMUN, V55, P2912, DOI 10.1128/IAI.55.12.2912-2915.1987; Horiguchi Y, 1997, P NATL ACAD SCI USA, V94, P11623, DOI 10.1073/pnas.94.21.11623; Katahira J, 1997, J BIOL CHEM, V272, P26652, DOI 10.1074/jbc.272.42.26652; Katahira J, 1997, J CELL BIOL, V136, P1239, DOI 10.1083/jcb.136.6.1239; Kokai-Kun JF, 1999, INFECT IMMUN, V67, P5634, DOI 10.1128/IAI.67.11.5634-5641.1999; KokaiKun JF, 1997, INFECT IMMUN, V65, P1014, DOI 10.1128/IAI.65.3.1014-1022.1997; Kominsky Scott L., 2006, Expert Reviews in Molecular Medicine, V8, P1, DOI 10.1017/S1462399406000056; Kondoh M, 2005, MOL PHARMACOL, V67, P749, DOI 10.1124/mol.104.008375; Ling J, 2008, J BIOL CHEM, V283, P30585, DOI 10.1074/jbc.M803548200; McClane BA, 2001, TOXICON, V39, P1781, DOI 10.1016/S0041-0101(01)00164-7; Morin PJ, 2005, CANCER RES, V65, P9603, DOI 10.1158/0008-5472.CAN-05-2782; Piontek J, 2008, FASEB J, V22, P146, DOI 10.1096/fj.07-8319com; Rice P, 2000, TRENDS GENET, V16, P276, DOI 10.1016/S0168-9525(00)02024-2; Sonoda N, 1999, J CELL BIOL, V147, P195, DOI 10.1083/jcb.147.1.195; Takahashi A, 2005, J CONTROL RELEASE, V108, P56, DOI 10.1016/j.jconrel.2005.07.008; Takahashi A, 2008, BIOCHEM PHARMACOL, V75, P1639, DOI 10.1016/j.bcp.2007.12.016; Van Itallie CM, 2008, J BIOL CHEM, V283, P268, DOI 10.1074/jbc.M708066200; Watanabe R, 1996, J BIOL CHEM, V271, P26868, DOI 10.1074/jbc.271.43.26868; Winkler L, 2009, J BIOL CHEM, V284, P18863, DOI 10.1074/jbc.M109.008623	28	46	47	0	23	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 1	2010	285	1					401	408		10.1074/jbc.M109.051417	http://dx.doi.org/10.1074/jbc.M109.051417			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	536UT	19903817	Green Published, hybrid			2022-12-25	WOS:000273070100042
J	Kobayashi, S; Volden, P; Timm, D; Mao, K; Xu, XM; Liang, QR				Kobayashi, Satoru; Volden, Paul; Timm, Derek; Mao, Kai; Xu, Xianmin; Liang, Qiangrong			Transcription Factor GATA4 Inhibits Doxorubicin-induced Autophagy and Cardiomyocyte Death	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GENE-EXPRESSION; TRANSGENIC MICE; HEART-FAILURE; CELL-SURVIVAL; IN-VIVO; ADRIAMYCIN CARDIOMYOPATHY; CARDIAC DYSFUNCTION; HEMODYNAMIC STRESS; PATHOGENIC ROLE; APOPTOSIS	Doxorubicin (DOX) is a potent anti-tumor drug known to cause heart failure. The transcription factor GATA4 antagonizes DOX-induced cardiotoxicity. However, the protective mechanism remains obscure. Autophagy is the primary cellular pathway for lysosomal degradation of long-lived proteins and organelles, and its activation could be either protective or detrimental depending on specific pathophysiological conditions. Here we investigated the ability of GATA4 to inhibit autophagy as a potential mechanism underlying its protection against DOX toxicity in cultured neonatal rat cardiomyocytes. DOX markedly increased autophagic flux in cardiomyocytes as indicated by the difference in protein levels of LC3-II (microtubule-associated protein light chain 3 form 2) or numbers of autophagic vacuoles in the absence and presence of the lysosomal inhibitor bafilomycin A1. DOX-induced cardiomyocyte death determined by multiple assays was aggravated by a drug or genetic approach that activates autophagy, but it was attenuated by manipulations that inhibit autophagy, suggesting that autophagy contributes to DOX cardiotoxicity. DOX treatment depleted GATA4 protein levels, which predisposed cardiomyocytes to DOX toxicity. Indeed, GATA4 gene silencing triggered autophagy that rendered DOX more toxic, whereas GATA4 overexpression inhibited DOX-induced autophagy, reducing cardiomyocyte death. Mechanistically, GATA4 up-regulated gene expression of the survival factor Bcl2 and suppressed DOX-induced activation of autophagy-related genes, which may likely be responsible for the anti-apoptotic and anti-autophagic effects of GATA4. Together, these findings suggest that activation of autophagy mediates DOX cardiotoxicity, and preservation of GATA4 attenuates DOX cardiotoxicity by inhibiting autophagy through modulation of the expression of Bcl2 and autophagy-related genes.	[Kobayashi, Satoru; Volden, Paul; Timm, Derek; Mao, Kai; Xu, Xianmin; Liang, Qiangrong] Univ S Dakota, Cardiovasc Hlth Res Ctr, Sioux Falls, SD 57105 USA	University of South Dakota	Liang, QR (corresponding author), Univ S Dakota, Cardiovasc Hlth Res Ctr, Sioux Falls, SD 57105 USA.	liangq@sanfordhealth.org			National Institutes of Health [2P20RR017662-06A1]; American Heart Association; Juvenile Diabetes Research Foundation; Juvenile Diabetes Research Foundation [1-2007-741]; American Diabetes Association Career Development [1-09-CD-09]; NATIONAL CENTER FOR RESEARCH RESOURCES [P20RR017662] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); American Heart Association(American Heart Association); Juvenile Diabetes Research Foundation(Juvenile Diabetes Research Foundation); Juvenile Diabetes Research Foundation(Juvenile Diabetes Research Foundation); American Diabetes Association Career Development(American Diabetes Association); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))	This work was supported, in whole or in part, by National Institutes of Health Grant 2P20RR017662-06A1 (Project 3; National Center for Research Resources (to Q. L.)).; Supported by an American Heart Association postdoctoral fellowship and a Juvenile Diabetes Research Foundation advanced postdoctoral fellowship.; Supported by an American Heart Association predoctoral fellowship.; Supported by Juvenile Diabetes Research Foundation Research Grant 1-2007-741 and American Diabetes Association Career Development Grant 1-09-CD-09.	Agnihotri S, 2009, ONCOGENE, V28, P3033, DOI 10.1038/onc.2009.159; Akazawa H, 2004, J BIOL CHEM, V279, P41095, DOI 10.1074/jbc.M313084200; Aries A, 2004, P NATL ACAD SCI USA, V101, P6975, DOI 10.1073/pnas.0401833101; Bampton ETW, 2005, AUTOPHAGY, V1, P23, DOI 10.4161/auto.1.1.1495; Charron F, 2001, GENE DEV, V15, P2702, DOI 10.1101/gad.915701; Codogno P, 2005, CELL DEATH DIFFER, V12, P1509, DOI 10.1038/sj.cdd.4401751; Crighton D, 2006, CELL, V126, P121, DOI 10.1016/j.cell.2006.05.034; Dorr RT, 1996, SEMIN ONCOL, V23, P23; Eisenberg-Lerner A, 2009, CELL DEATH DIFFER, V16, P966, DOI 10.1038/cdd.2009.33; Kaneoka H, 2008, CYTOTECHNOLOGY, V57, P123, DOI 10.1007/s10616-007-9120-1; Kang CH, 2008, AUTOPHAGY, V4, P82, DOI 10.4161/auto.5154; Kang YJ, 1996, J BIOL CHEM, V271, P12610, DOI 10.1074/jbc.271.21.12610; Kim Y, 2003, MOL PHARMACOL, V63, P368, DOI 10.1124/mol.63.2.368; Kitta K, 2003, J BIOL CHEM, V278, P4705, DOI 10.1074/jbc.M211616200; Klionsky DJ, 2007, NAT REV MOL CELL BIO, V8, P931, DOI 10.1038/nrm2245; Kobayashi S, 2007, J BIOL CHEM, V282, P21945, DOI 10.1074/jbc.M703048200; Kobayashi S, 2006, FASEB J, V20, P800, DOI 10.1096/fj.05-5426fje; Komatsu M, 2007, CELL, V131, P1149, DOI 10.1016/j.cell.2007.10.035; Kuma A, 2004, NATURE, V432, P1032, DOI 10.1038/nature03029; Kumar D, 2001, ANTIOXID REDOX SIGN, V3, P135, DOI 10.1089/152308601750100641; Kumarapeli ARK, 2005, FASEB J, V19, P2051, DOI 10.1096/fj.05-3973fje; Kuzman JA, 2005, J MOL CELL CARDIOL, V39, P841, DOI 10.1016/j.yjmcc.2005.07.019; Ladas EJ, 2004, J CLIN ONCOL, V22, P517, DOI 10.1200/JCO.2004.03.086; LEGHA SS, 1982, ANN NY ACAD SCI, V393, P411, DOI 10.1111/j.1749-6632.1982.tb31279.x; Levine B, 2005, J CLIN INVEST, V115, P2679, DOI 10.1172/JCI26390; Li LH, 2006, CIRCULATION, V113, P535, DOI 10.1161/CIRCULATIONAHA.105.568402; Liang QR, 2001, J BIOL CHEM, V276, P30245, DOI 10.1074/jbc.M102174200; Liang QR, 2002, J MOL CELL CARDIOL, V34, P611, DOI 10.1006/jmcc.2002.2011; Liang QR, 2001, MOL CELL BIOL, V21, P7460, DOI 10.1128/MCB.21.21.7460-7469.2001; Lim CC, 2004, J BIOL CHEM, V279, P8290, DOI 10.1074/jbc.M308033200; Liu JH, 2008, AM J PHYSIOL-HEART C, V295, pH1956, DOI 10.1152/ajpheart.00407.2008; Lu LH, 2009, INT J CARDIOL, V134, P82, DOI 10.1016/j.ijcard.2008.01.043; MARCILLAT O, 1989, BIOCHEM J, V259, P181, DOI 10.1042/bj2590181; Matsui Y, 2007, CIRC RES, V100, P914, DOI 10.1161/01.RES.0000261924.76669.36; Meijer Alfred J., 2006, Molecular Aspects of Medicine, V27, P411, DOI 10.1016/j.mam.2006.08.002; Minotti G, 2004, PHARMACOL REV, V56, P185, DOI 10.1124/pr.56.2.6; Mizushima N, 2004, INT J BIOCHEM CELL B, V36, P2491, DOI 10.1016/j.biocel.2004.02.005; Mizushima N, 2004, MOL BIOL CELL, V15, P1101, DOI 10.1091/mbc.E03-09-0704; Mizushima N, 2007, AUTOPHAGY, V3, P542, DOI 10.4161/auto.4600; Molkentin JD, 2000, J BIOL CHEM, V275, P38949, DOI 10.1074/jbc.R000029200; MYERS C, 1983, SEMIN ONCOL, V10, P53; Nakai A, 2007, NAT MED, V13, P619, DOI 10.1038/nm1574; Oka T, 2006, CIRC RES, V98, P837, DOI 10.1161/01.RES.0000215985.18538.c4; Oliveira PJ, 2006, TOXICOLOGY, V220, P160, DOI 10.1016/j.tox.2005.12.009; Olson RD, 2005, CARDIOVASC TOXICOL, V5, P269, DOI 10.1385/CT:5:3:269; OLSON RD, 1990, FASEB J, V4, P3076, DOI 10.1096/fasebj.4.13.2210154; Pattingre S, 2005, CELL, V122, P927, DOI 10.1016/j.cell.2005.07.002; Pattingre S, 2008, BIOCHIMIE, V90, P313, DOI 10.1016/j.biochi.2007.08.014; Semenov DE, 2001, B EXP BIOL MED+, V131, P505, DOI 10.1023/A:1017956922385; Sengupta A, 2009, J BIOL CHEM, V284, P28319, DOI 10.1074/jbc.M109.024406; Singal PK, 1998, NEW ENGL J MED, V339, P900, DOI 10.1056/NEJM199809243391307; SIVESKIILISKOVIC N, 1995, CIRCULATION, V91, P10, DOI 10.1161/01.CIR.91.1.10; Sun XH, 2001, CANCER RES, V61, P3382; Swain SM, 2003, CANCER, V97, P2869, DOI 10.1002/cncr.11407; Tanida I, 2004, INT J BIOCHEM CELL B, V36, P2503, DOI 10.1016/j.biocel.2004.05.009; Tannous P, 2008, P NATL ACAD SCI USA, V105, P9745, DOI 10.1073/pnas.0706802105; Trainor CD, 2009, BLOOD, V114, P165, DOI 10.1182/blood-2008-10-180489; Vergne I, 2009, EMBO J, V28, P2244, DOI 10.1038/emboj.2009.159; Wei YJ, 2008, MOL CELL, V30, P678, DOI 10.1016/j.molcel.2008.06.001; Yan L, 2005, P NATL ACAD SCI USA, V102, P13807, DOI 10.1073/pnas.0506843102; Yen HC, 1996, J CLIN INVEST, V98, P1253, DOI 10.1172/JCI118909; Yuan JY, 2008, AUTOPHAGY, V4, P249, DOI 10.4161/auto.5438; Zhu HX, 2007, J CLIN INVEST, V117, P1782, DOI 10.1172/JCI27523	63	196	200	0	14	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 1	2010	285	1					793	804		10.1074/jbc.M109.070037	http://dx.doi.org/10.1074/jbc.M109.070037			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	536UT	19901028	Green Published, hybrid			2022-12-25	WOS:000273070100080
J	Li, L; Fridley, BL; Kalari, K; Jenkins, G; Batzler, A; Weinshilboum, RM; Wang, LW				Li, Liang; Fridley, Brooke L.; Kalari, Krishna; Jenkins, Gregory; Batzler, Anthony; Weinshilboum, Richard M.; Wang, Liewei			Gemcitabine and Arabinosylcytosin Pharmacogenomics: Genome-Wide Association and Drug Response Biomarkers	PLOS ONE			English	Article							ACUTE MYELOID-LEUKEMIA; ETOPOSIDE-INDUCED CYTOTOXICITY; HARDY-WEINBERG EQUILIBRIUM; GENE-EXPRESSION; CYTOSINE-ARABINOSIDE; VAV PROTEINS; LUNG-CANCER; EXACT TESTS; CELL-LINES; VARIANTS	Cancer patients show large individual variation in their response to chemotherapeutic agents. Gemcitabine (dFdC) and AraC, two cytidine analogues, have shown significant activity against a variety of tumors. We previously used expression data from a lymphoblastoid cell line-based model system to identify genes that might be important for the two drug cytotoxicity. In the present study, we used that same model system to perform a genome-wide association (GWA) study to test the hypothesis that common genetic variation might influence both gene expression and response to the two drugs. Specifically, genome-wide single nucleotide polymorphisms (SNPs) and mRNA expression data were obtained using the Illumina 550K (R) HumanHap550 SNP Chip and Affymetrix U133 Plus 2.0 GeneChip, respectively, for 174 ethnically-defined "Human Variation Panel" lymphoblastoid cell lines. Gemcitabine and AraC cytotoxicity assays were performed to obtain IC(50) values for the cell lines. We then performed GWA studies with SNPs, gene expression and IC(50) of these two drugs. This approach identified SNPs that were associated with gemcitabine or AraC IC(50) values and with the expression regulation for 29 genes or 30 genes, respectively. One SNP in IQGAP2 (rs3797418) was significantly associated with variation in both the expression of multiple genes and gemcitabine and AraC IC(50). A second SNP in TGM3 (rs6082527) was also significantly associated with multiple gene expression and gemcitabine IC50. To confirm the association results, we performed siRNA knock down of selected genes with expression that was associated with rs3797418 and rs6082527 in tumor cell and the knock down altered gemcitabine or AraC sensitivity, confirming our association study results. These results suggest that the application of GWA approaches using cell-based model systems, when combined with complementary functional validation, can provide insights into mechanisms responsible for variation in cytidine analogue response.			Li, L (corresponding author), Mayo Clin, Rochester, MN 55905 USA.	wang.liewei@mayo.edu	Fridley, Brooke L/D-8315-2015	Fridley, Brooke L/0000-0001-7739-7956; Kalari, Krishna/0000-0001-8944-8378; Li, Liang/0000-0003-1893-1965	NCI NIH HHS [R01 CA132780, K22 CA130828, CA102701, R01 CA138461, P20 CA102701, P50 CA102701] Funding Source: Medline; NIGMS NIH HHS [U01 GM061388, R01 GM28157, U19 GM061388, GM61388, R01 GM028157] Funding Source: Medline; NATIONAL CANCER INSTITUTE [K22CA130828, R01CA138461, P50CA102701, R01CA132780, P20CA102701] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [U01GM061388, R01GM028157, U19GM061388] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Alfonso J, 2005, P NATL ACAD SCI USA, V102, P17196, DOI 10.1073/pnas.0504262102; Altshuler D, 2008, SCIENCE, V322, P881, DOI 10.1126/science.1156409; Barrett JC, 2005, BIOINFORMATICS, V21, P263, DOI 10.1093/bioinformatics/bth457; Baum AE, 2008, MOL PSYCHIATR, V13, P197, DOI 10.1038/sj.mp.4002012; Bergman AM, 2005, CANCER RES, V65, P9510, DOI 10.1158/0008-5472.CAN-05-0989; Bleibel WK, 2009, HUM GENET, V125, P173, DOI 10.1007/s00439-008-0607-4; Bolstad BM, 2003, BIOINFORMATICS, V19, P185, DOI 10.1093/bioinformatics/19.2.185; Bussey KJ, 2006, MOL CANCER THER, V5, P853, DOI 10.1158/1535-7163.MCT-05-0155; Bystrykh L, 2005, NAT GENET, V37, P225, DOI 10.1038/ng1497; Campbell TB, 2000, AIDS, V14, P2109, DOI 10.1097/00002030-200009290-00006; CHOY E, 2009, PLOS GENET, V4, P1; Dimas AS, 2009, SCIENCE, V325, P1246, DOI 10.1126/science.1174148; Duan SW, 2007, CANCER RES, V67, P5425, DOI 10.1158/0008-5472.CAN-06-4431; Feng WH, 2004, J VIROL, V78, P1893, DOI 10.1128/JVI.78.4.1893-1902.2004; Feng WH, 2002, CANCER RES, V62, P1920; Gabriel SB, 2002, SCIENCE, V296, P2225, DOI 10.1126/science.1069424; Gullans SR, 2006, NEW ENGL J MED, V355, P2042, DOI 10.1056/NEJMcibr065953; GUO SW, 1992, BIOMETRICS, V48, P361, DOI 10.2307/2532296; Gwee PC, 2005, PHARMACOGENET GENOM, V15, P91, DOI 10.1097/01213011-200502000-00005; Half E, 2002, CANCER RES, V62, P1676; Hauser MA, 2003, HUM MOL GENET, V12, P671, DOI 10.1093/hmg/ddg070; HEINEMANN V, 1992, CANCER RES, V52, P533; HEINEMANN V, 1988, CANCER RES, V48, P4024; HERTEL LW, 1990, CANCER RES, V50, P4417; Hornstein I, 2004, CELL SIGNAL, V16, P1, DOI 10.1016/S0898-6568(03)00110-4; Huang RS, 2008, MOL CANCER THER, V7, P3038, DOI 10.1158/1535-7163.MCT-08-0248; Huang RS, 2007, P NATL ACAD SCI USA, V104, P9758, DOI 10.1073/pnas.0703736104; Kern W, 2006, CANCER-AM CANCER SOC, V107, P116, DOI 10.1002/cncr.21543; Kim SR, 2006, DRUG METAB PHARMACOK, V21, P248, DOI 10.2133/dmpk.21.248; Kim SR, 2008, DRUG METAB PHARMACOK, V23, P379, DOI 10.2133/dmpk.23.379; Kindler Hedy Lee, 2005, Clin Adv Hematol Oncol, V3, P420; Kwon WS, 2006, PHARMACOGENET GENOM, V16, P429, DOI 10.1097/01.fpc.0000204999.29924.da; LAGENAUR C, 1992, J NEUROBIOL, V23, P71, DOI 10.1002/neu.480230108; Li J, 2005, HUM MOL GENET, V14, pR163, DOI 10.1093/hmg/ddi267; Li L, 2008, CANCER RES, V68, P7050, DOI 10.1158/0008-5472.CAN-08-0405; Lokiec F, 2007, B CANCER, V94, pS85; Moffatt MF, 2007, NATURE, V448, P470, DOI 10.1038/nature06014; Morley M, 2004, NATURE, V430, P743, DOI 10.1038/nature02797; Mukobata S, 2002, BIOCHEM BIOPH RES CO, V297, P722, DOI 10.1016/S0006-291X(02)02284-2; Newport M, 2007, NAT GENET, V39, P1329, DOI 10.1038/ng.2007.17; Price AL, 2006, NAT GENET, V38, P904, DOI 10.1038/ng1847; Sabeti PC, 2007, NATURE, V449, P913, DOI 10.1038/nature06250; Sachidanandam R, 2001, NATURE, V409, P928, DOI 10.1038/35057149; Schadt EE, 2005, CURR OPIN BIOTECH, V16, P647, DOI 10.1016/j.copbio.2005.10.005; Schaid DJ, 2006, AM J HUM GENET, V79, P1071, DOI 10.1086/510257; Schoch C, 2001, BRIT J HAEMATOL, V112, P118, DOI 10.1046/j.1365-2141.2001.02511.x; Seve P, 2005, LUNG CANCER, V49, P363, DOI 10.1016/j.lungcan.2005.04.008; Shin BK, 2003, J BIOL CHEM, V278, P7607, DOI 10.1074/jbc.M210455200; Shukla SJ, 2008, PHARMACOGENET GENOM, V18, P253, DOI 10.1097/FPC.0b013e3282f5e605; Smid K, 2006, NUCLEOS NUCLEOT NUCL, V25, P1001, DOI 10.1080/15257770600890269; Storey JD, 2002, J ROY STAT SOC B, V64, P479, DOI 10.1111/1467-9868.00346; Storey JD, 2003, P NATL ACAD SCI USA, V100, P9440, DOI 10.1073/pnas.1530509100; Sugiyama E, 2007, J CLIN ONCOL, V25, P32, DOI 10.1200/JCO.2006.06.7405; Tomasson MH, 2008, BLOOD, V111, P4797, DOI 10.1182/blood-2007-09-113027; Trenkle T, 2000, GENE, V245, P139, DOI 10.1016/S0378-1119(00)00026-3; Turner M, 2002, NAT REV IMMUNOL, V2, P476, DOI 10.1038/nri840; Weidinger S, 2008, PLOS GENET, V4, DOI 10.1371/journal.pgen.1000166; Wigginton JE, 2005, AM J HUM GENET, V76, P887, DOI 10.1086/429864; Wu DF, 2007, J BIOL CHEM, V282, P22239, DOI 10.1074/jbc.M700941200; Wu XF, 2001, CARCINOGENESIS, V22, P923, DOI 10.1093/carcin/22.6.923; Wu ZJ, 2004, J AM STAT ASSOC, V99, P909, DOI 10.1198/016214504000000683; Yonemori K, 2005, CLIN CANCER RES, V11, P2620, DOI 10.1158/1078-0432.CCR-04-1497; [No title captured]	63	65	71	0	1	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA	1932-6203			PLOS ONE	PLoS One	NOV 9	2009	4	11							e7765	10.1371/journal.pone.0007765	http://dx.doi.org/10.1371/journal.pone.0007765			18	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	517ZM	19898621	Green Published, gold, Green Submitted			2022-12-25	WOS:000271658000009
J	Fontaine, JF; Mirebeau-Prunier, D; Raharijaona, M; Franc, B; Triau, S; Rodien, P; Goeau-Brissonniere, O; Karayan-Tapon, L; Mello, M; Houlgatte, R; Malthiery, Y; Savagner, F				Fontaine, Jean-Fred; Mirebeau-Prunier, Delphine; Raharijaona, Mahatsangy; Franc, Brigitte; Triau, Stephane; Rodien, Patrice; Goeau-Brissonniere, Olivier; Karayan-Tapon, Lucie; Mello, Marielle; Houlgatte, Remi; Malthiery, Yves; Savagner, Frederique			Increasing the Number of Thyroid Lesions Classes in Microarray Analysis Improves the Relevance of Diagnostic Markers	PLOS ONE			English	Article							GENE-EXPRESSION; TISSUE MICROARRAY; CARCINOMA; PAPILLARY; TUMORS; CANCER; CLASSIFICATION; PROFILES; METAANALYSIS; PROGRESSION	Background: Genetic markers for thyroid cancers identified by microarray analysis have offered limited predictive accuracy so far because of the few classes of thyroid lesions usually taken into account. To improve diagnostic relevance, we have simultaneously analyzed microarray data from six public datasets covering a total of 347 thyroid tissue samples representing 12 histological classes of follicular lesions and normal thyroid tissue. Our own dataset, containing about half the thyroid tissue samples, included all categories of thyroid lesions. Methodology/Principal Findings: Classifier predictions were strongly affected by similarities between classes and by the number of classes in the training sets. In each dataset, sample prediction was improved by separating the samples into three groups according to class similarities. The cross-validation of differential genes revealed four clusters with functional enrichments. The analysis of six of these genes (APOD, APOE, CLGN, CRABP1, SDHA and TIMP1) in 49 new samples showed consistent gene and protein profiles with the class similarities observed. Focusing on four subclasses of follicular tumor, we explored the diagnostic potential of 12 selected markers (CASP10, CDH16, CLGN, CRABP1, HMGB2, ALPL2, ADAMTS2, CABIN1, ALDH1A3, USP13, NR2F2, KRTHB5) by real-time quantitative RT-PCR on 32 other new samples. The gene expression profiles of follicular tumors were examined with reference to the mutational status of the Pax8-PPAR gamma, TSHR, GNAS and NRAS genes. Conclusion/Significance: We show that diagnostic tools defined on the basis of microarray data are more relevant when a large number of samples and tissue classes are used. Taking into account the relationships between the thyroid tumor pathologies, together with the main biological functions and pathways involved, improved the diagnostic accuracy of the samples. Our approach was particularly relevant for the classification of microfollicular adenomas.			Fontaine, JF (corresponding author), Max Delbruck Ctr Mol Med, Berlin, Germany.	frederique.savagner@univ-angers.fr	Prunier, Delphine/K-3301-2015; Fontaine, Jean-Fred/GNP-2904-2022; Houlgatte, Remi/P-3020-2017; Rodien, Patrice/AAT-7909-2021	Fontaine, Jean-Fred/0000-0002-1101-4091; MELLO, Marielle/0000-0002-5454-3559				Al-Shahrour F, 2005, NUCLEIC ACIDS RES, V33, pW460, DOI 10.1093/nar/gki456; Aldred MA, 2004, J CLIN ONCOL, V22, P3531, DOI 10.1200/JCO.2004.08.127; Ao A, 2008, P NATL ACAD SCI USA, V105, P7821, DOI 10.1073/pnas.0711677105; Barden CB, 2003, CLIN CANCER RES, V9, P1792; Baris O, 2004, J CLIN ENDOCR METAB, V89, P994, DOI 10.1210/jc.2003-031238; Barroeta JE, 2006, ENDOCR PATHOL, V17, P225, DOI 10.1385/EP:17:3:225; Bourasseau I, 2000, THYROID, V10, P761, DOI 10.1089/thy.2000.10.761; Carinci F, 2005, INT J IMMUNOPATH PH, V18, P513, DOI 10.1177/039463200501800311; Corvilain B, 2001, CLIN ENDOCRINOL, V55, P143, DOI 10.1046/j.1365-2265.2001.01365.x; Delys L, 2007, ONCOGENE, V26, P7894, DOI 10.1038/sj.onc.1210588; Dudoit S, 2002, GENOME BIOL, V3; Efron B, 1997, J AM STAT ASSOC, V92, P548, DOI 10.2307/2965703; Eszlinger M, 2006, J CLIN ENDOCR METAB, V91, P1934, DOI 10.1210/jc.2005-1620; Eszlinger M, 2005, J CLIN ENDOCR METAB, V90, P1163, DOI 10.1210/jc.2004-1242; Eszlinger M, 2008, J CLIN ENDOCR METAB, V93, P3286, DOI 10.1210/jc.2008-0201; Finley DJ, 2004, SURGERY, V136, P1160, DOI 10.1016/j.surg.2004.05.061; Fontaine JF, 2008, ONCOGENE, V27, P2228, DOI 10.1038/sj.onc.1210853; Franc B, 2003, HUM PATHOL, V34, P1092, DOI 10.1016/S0046-8177(03)00403-9; Fukumori T, 2006, CANCER RES, V66, P3114, DOI 10.1158/0008-5472.CAN-05-3750; Giordano TJ, 2006, CLIN CANCER RES, V12, P1983, DOI 10.1158/1078-0432.CCR-05-2039; Griffith OL, 2006, J CLIN ONCOL, V24, P5043, DOI 10.1200/JCO.2006.06.7330; Hawthorn L, 2004, HEAD NECK-J SCI SPEC, V26, P1069, DOI 10.1002/hed.20099; He HL, 2005, P NATL ACAD SCI USA, V102, P19075, DOI 10.1073/pnas.0509603102; Huang Y, 2003, INT J CANCER, V104, P735, DOI 10.1002/ijc.11006; Huang Y, 2001, P NATL ACAD SCI USA, V98, P15044, DOI 10.1073/pnas.251547398; Hundahl SA, 1998, CANCER-AM CANCER SOC, V83, P2638, DOI 10.1002/(SICI)1097-0142(19981215)83:12<2638::AID-CNCR31>3.0.CO;2-1; Jarzab B, 2005, CANCER RES, V65, P1587, DOI 10.1158/0008-5472.CAN-04-3078; Kroll TG, 2000, SCIENCE, V289, P1357, DOI 10.1126/science.289.5483.1357; Kubat M, 1998, IEEE T NEURAL NETWOR, V9, P813, DOI 10.1109/72.712154; Lacroix L, 2005, AM J PATHOL, V167, P223, DOI 10.1016/S0002-9440(10)62967-7; Lloyd RV, 2004, AM J SURG PATHOL, V28, P1336, DOI 10.1097/01.pas.0000135519.34847.f6; Netea-Maier RT, 2008, CANCER RES, V68, P1572, DOI 10.1158/0008-5472.CAN-07-5020; Nikiforova MN, 2008, J CLIN ENDOCR METAB, V93, P1600, DOI 10.1210/jc.2007-2696; Nikiforova MN, 2003, J CLIN ENDOCR METAB, V88, P2318, DOI 10.1210/jc.2002-021907; Nucera C, 2005, J ENDOCRINOL INVEST, V28, P106, DOI 10.1007/BF03345351; Porter S, 2004, CLIN CANCER RES, V10, P2429, DOI 10.1158/1078-0432.CCR-0398-3; Rhodes DR, 2004, P NATL ACAD SCI USA, V101, P9309, DOI 10.1073/pnas.0401994101; SAVIN S, 2008, HUM PATHOL IN PRESS; Schmid KW, 2006, VIRCHOWS ARCH, V448, P385, DOI 10.1007/s00428-006-0162-0; Sierra JR, 2008, J EXP MED, V205, P1673, DOI 10.1084/jem.20072602; Soiland H, 2007, CELL ONCOL, V29, P195; Stolf BS, 2005, CANCER LETT, V227, P59, DOI 10.1016/j.canlet.2004.11.050; Taylor KL, 2008, J INTERF CYTOK RES, V28, P733, DOI 10.1089/jir.2008.0030; Vasko V, 2003, J CLIN ENDOCR METAB, V88, P2745, DOI 10.1210/jc.2002-021186; Wasenius VM, 2003, CLIN CANCER RES, V9, P68; Watanabe T, 2009, CANCER, V115, P283, DOI 10.1002/cncr.24023; Wattel S, 2005, ONCOGENE, V24, P6902, DOI 10.1038/sj.onc.1208849; Weber F, 2005, J CLIN ENDOCR METAB, V90, P2512, DOI 10.1210/jc.2004-2028; Yeh MW, 2004, THYROID, V14, P207, DOI 10.1089/105072504773297885; Yukinawa N, 2006, BMC GENOMICS, V7, P1, DOI 10.1186/1471-2164-7-190	50	13	24	0	7	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA	1932-6203			PLOS ONE	PLoS One	OCT 29	2009	4	10							e7632	10.1371/journal.pone.0007632	http://dx.doi.org/10.1371/journal.pone.0007632			18	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	512FP	19893615	Green Published, gold, Green Accepted			2022-12-25	WOS:000271232000010
J	Dujka, ME; Puebla-Osorio, N; Tavana, O; Sang, M; Zhu, C				Dujka, M. E.; Puebla-Osorio, N.; Tavana, O.; Sang, M.; Zhu, C.			ATM and p53 are essential in the cell-cycle containment of DNA breaks during V(D)J recombination in vivo	ONCOGENE			English	Article						V(D)J recombination; genomic instability; ATM; cell-cycle control	DOUBLE-STRAND BREAKS; ATAXIA-TELANGIECTASIA; GENOMIC INSTABILITY; CHROMOSOME BREAKS; HISTONE H2AX; C-MYC; DEFICIENT; MICE; RECEPTOR; LOCUS	V(D)J recombination is essential for the maturation of lymphocytes. Because of the involvement of cutting and joining DNA double strands, this recombination activity is strictly contained within the noncycling phases of the cell cycle. Such containment is crucial for the maintenance of genomic integrity. The ataxia telangiectasia mutated (ATM) gene is known to have a central role in sensing general DNA damage and mediating cell-cycle checkpoint. In this study, we investigated the role of ATM and its downstream targets in the cell-cycle control of V(D) J recombination in vivo. Our results revealed the persistence of double-strand breaks (DSBs) throughout the cell cycle in ATM(-/-) and p53(-/-) thymocytes, but the cell-cycle regulation of a V(D) J recombinase, Rag-2, was normal. The histone variant H2AX, which is phosphorylated during normal V(D) J recombination, was dispensable for containing DSBs. H2AX was still phosphorylated at V(D) J loci in the absence of ATM. Therefore, V(D) J recombination, a physiological DNA rearrangement process, activates the ATM/p53 pathway to contain DNA breaks within the noncycling cells and surprisingly this pathway is not important for containing Rag-2 activity. This study shows the dynamic multiple functions of ATM in maintaining genomic stability and preventing tumorigenesis in developing lymphocytes. Oncogene (2010) 29, 957-965; doi:10.1038/onc.2009.394; published online 16 November 2009	[Dujka, M. E.; Puebla-Osorio, N.; Tavana, O.; Sang, M.; Zhu, C.] Univ Texas Houston, MD Anderson Canc Ctr, Dept Immunol, Houston, TX 77030 USA; [Dujka, M. E.; Tavana, O.; Zhu, C.] Univ Texas Houston, Grad Sch Biomed Sci Houston, Program Immunol, Houston, TX USA	University of Texas System; University of Texas Health Science Center Houston; UTMD Anderson Cancer Center; University of Texas System; University of Texas Health Science Center Houston	Zhu, C (corresponding author), Univ Texas Houston, MD Anderson Canc Ctr, Dept Immunol, 1515 Holcombe Blvd,Unit 901, Houston, TX 77030 USA.	czhu@mdanderson.org		Tavana, Omid/0000-0001-8401-4546; Puebla, Nahum/0000-0001-6498-5230	NIH [CA116933, T32 CA009598-17]; Leukemia Research Foundation; American Cancer Society; NATIONAL CANCER INSTITUTE [T32CA009598, R01CA116933] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Leukemia Research Foundation; American Cancer Society(American Cancer Society); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We acknowledge MD Anderson Flow Cytometry Core Facility for cell sorting and the Immune Imaging Core Facility for their assistance with confocal microscopy. This study was financially supported in part by NIH Grant CA116933, the Leukemia Research Foundation, the American Cancer Society-Bonnie Kies Lymphatic System Research Scholar grant (CZ) and NIH Grant T32 CA009598-17 (MED).	Bakkenist CJ, 2003, NATURE, V421, P499, DOI 10.1038/nature01368; Barlow C, 1996, CELL, V86, P159, DOI 10.1016/S0092-8674(00)80086-0; Bassing CH, 2003, CELL, V114, P359, DOI 10.1016/S0092-8674(03)00566-X; Bassing CH, 2002, P NATL ACAD SCI USA, V99, P8173, DOI 10.1073/pnas.122228699; Bassing CH, 2008, BLOOD, V111, P2163, DOI 10.1182/blood-2007-08-104760; Borghesani PR, 2000, P NATL ACAD SCI USA, V97, P3336, DOI 10.1073/pnas.050584897; Bredemeyer AL, 2008, J IMMUNOL, V181, P2620, DOI 10.4049/jimmunol.181.4.2620; Bredemeyer AL, 2006, NATURE, V442, P466, DOI 10.1038/nature04866; Callen E, 2007, CELL, V130, P63, DOI 10.1016/j.cell.2007.06.016; Celeste A, 2002, SCIENCE, V296, P922, DOI 10.1126/science.1069398; Chen HT, 2000, SCIENCE, V290, P1962, DOI 10.1126/science.290.5498.1962; Desiderio S, 1996, CURR TOP MICROBIOL, V217, P45; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; Franco S, 2006, MOL CELL, V21, P201, DOI 10.1016/j.molcel.2006.01.005; Gao YJ, 1998, IMMUNITY, V9, P367, DOI 10.1016/S1074-7613(00)80619-6; Guidos CJ, 1996, GENE DEV, V10, P2038, DOI 10.1101/gad.10.16.2038; Huang CY, 2007, J EXP MED, V204, P1371, DOI 10.1084/jem.20061460; Jankovic M, 2007, NAT IMMUNOL, V8, P801, DOI 10.1038/ni1498; Jiang H, 2005, MOL CELL, V18, P699, DOI 10.1016/j.molcel.2005.05.011; Lavin MF, 2008, NAT REV MOL CELL BIO, V9, P759, DOI 10.1038/nrm2514; Lee GS, 2004, CELL, V117, P171, DOI 10.1016/S0092-8674(04)00301-0; Lee JH, 2005, SCIENCE, V308, P551, DOI 10.1126/science.1108297; Liao MJ, 1998, MOL CELL BIOL, V18, P3495, DOI 10.1128/MCB.18.6.3495; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; Liyanage M, 2000, BLOOD, V96, P1940, DOI 10.1182/blood.V96.5.1940.h8001940_1940_1946; MCBLANE JF, 1995, CELL, V83, P387, DOI 10.1016/0092-8674(95)90116-7; Monroe RJ, 1999, IMMUNITY, V11, P201, DOI 10.1016/S1074-7613(00)80095-3; OETTINGER MA, 1990, SCIENCE, V248, P1517, DOI 10.1126/science.2360047; Perkins EJ, 2002, GENE DEV, V16, P159, DOI 10.1101/gad.956902; Robbiani DF, 2008, CELL, V135, P1028, DOI 10.1016/j.cell.2008.09.062; Rogakou EP, 1998, J BIOL CHEM, V273, P5858, DOI 10.1074/jbc.273.10.5858; Savic V, 2009, MOL CELL, V34, P298, DOI 10.1016/j.molcel.2009.04.012; SCHATZ DG, 1989, CELL, V59, P1035, DOI 10.1016/0092-8674(89)90760-5; SCHLISSEL M, 1993, GENE DEV, V7, P2520, DOI 10.1101/gad.7.12b.2520; Spilianakis CG, 2005, NATURE, V435, P637, DOI 10.1038/nature03574; Stiff T, 2004, CANCER RES, V64, P2390, DOI 10.1158/0008-5472.CAN-03-3207; Tsai AG, 2008, CELL, V135, P1130, DOI 10.1016/j.cell.2008.10.035; Vacchio MS, 2007, P NATL ACAD SCI USA, V104, P6323, DOI 10.1073/pnas.0611222104; Widrow RJ, 1997, CYTOMETRY, V27, P250, DOI 10.1002/(SICI)1097-0320(19970301)27:3<250::AID-CYTO6>3.0.CO;2-I; Winrow CJ, 2005, HUM MOL GENET, V14, P2671, DOI 10.1093/hmg/ddi301; Yan MS, 2006, FREE RADICAL BIO MED, V41, P640, DOI 10.1016/j.freeradbiomed.2006.05.008; ZHU CM, 1995, IMMUNITY, V2, P101, DOI 10.1016/1074-7613(95)90082-9	42	22	22	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 18	2010	29	7					957	965		10.1038/onc.2009.394	http://dx.doi.org/10.1038/onc.2009.394			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	556PV	19915617				2022-12-25	WOS:000274604400003
J	Zhang, J; Gonit, M; Salazar, MD; Shatnawi, A; Shemshedini, L; Trumbly, R; Ratnam, M				Zhang, J.; Gonit, M.; Salazar, M. D.; Shatnawi, A.; Shemshedini, L.; Trumbly, R.; Ratnam, M.			C/EBP alpha redirects androgen receptor signaling through a unique bimodal interaction	ONCOGENE			English	Article						androgen receptor; C/EBP alpha; prostate; prostate cancer	CCAAT/ENHANCER-BINDING-PROTEIN; PROSTATE-CANCER CELLS; GROWTH ARREST; DNA-BINDING; TRANSCRIPTIONAL COACTIVATOR; MOLECULAR-MECHANISMS; NUCLEAR RECEPTORS; MYELOID-LEUKEMIA; GENE-EXPRESSION; TERMINAL DOMAIN	Nuclear expression of CCAAT enhancer binding protein-alpha (C/EBP alpha), which supports tissue differentiation through several antiproliferative protein-protein interactions, augurs terminal differentiation of prostate epithelial cells. C/EBP alpha is also a tumor suppressor, but in many tumors its antiproliferative interactions may be attenuated by de-phosphorylation. C/EBP alpha acts as a corepressor of the classical androgen response element (ARE)-mediated gene activation by the androgen receptor (AR), but this is paradoxical as the genotropic actions of AR are crucial not only for the growth of the prostate but also for its maintenance and function. We show that DNA-bound C/EPB alpha recruits AR to activate transcription. C/EBP alpha-dependent trans-activation by AR also overrode suppression of AREs by C/EBP alpha elsewhere in a promoter. This mechanism was remarkable in that its androgen dependence was apparently for nuclear translocation of AR; it was otherwise androgen independent, flutamide insensitive and tolerant to disruption of AR dimerization. Gene response profiles and global chromatin associations in situ supported the direct bimodal regulation of AR transcriptional signaling by C/EBP alpha. This unique mechanism explains the functional coordination between AR and C/EPB alpha in the prostate and also shows that hormone-refractory AR signaling in prostate cancer could occur through receptor tethering. Oncogene (2010) 29, 723-738; doi: 10.1038/onc.2009.373; published online 9 November 2009	[Zhang, J.; Gonit, M.; Salazar, M. D.; Trumbly, R.; Ratnam, M.] Med Univ Ohio, Dept Biochem & Canc Biol, Toledo, OH 43614 USA; [Shatnawi, A.] Duke Univ, Sch Med, Dept Pharmacol & Canc Biol, Durham, NC USA; [Shemshedini, L.] Univ Toledo, Dept Biol Sci, Toledo, OH 43606 USA; [Trumbly, R.] Med Univ Ohio, Bioinformat & Proteom Genom Core Div, Toledo, OH 43614 USA	Duke University; University System of Ohio; University of Toledo	Ratnam, M (corresponding author), Med Univ Ohio, Dept Biochem & Canc Biol, Block Hlth Sci Bldg,3000 Arlington Ave, Toledo, OH 43614 USA.	manohar.ratnam@utoledo.edu	Westall, Carol A/M-9646-2013; shatnawi, Aymen/AAF-5661-2020; Trumbly, Robert/AAF-6667-2020	Trumbly, Robert/0000-0001-5618-146X	NIH [CA 103964, CA 80183]; NATIONAL CANCER INSTITUTE [R01CA080183, R01CA103964] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	Supported by NIH R01 grants CA 103964 and CA 80183 to MR.	Aarnisalo P, 1998, P NATL ACAD SCI USA, V95, P2122, DOI 10.1073/pnas.95.5.2122; Baron S, 2004, J BIOL CHEM, V279, P14579, DOI 10.1074/jbc.M306143200; BEATO M, 1995, CELL, V83, P851, DOI 10.1016/0092-8674(95)90201-5; Berrevoets CA, 1998, MOL ENDOCRINOL, V12, P1172, DOI 10.1210/me.12.8.1172; Bourguet W, 2000, TRENDS PHARMACOL SCI, V21, P381, DOI 10.1016/S0165-6147(00)01548-0; Burel SA, 2001, MOL CELL BIOL, V21, P5577, DOI 10.1128/MCB.21.16.5577-5590.2001; Chattopadhyay S, 2006, MOL ENDOCRINOL, V20, P984, DOI 10.1210/me.2005-0240; DEWINTER JAR, 1994, AM J PATHOL, V144, P735; Edwards J, 2005, BJU INT, V95, P1320, DOI 10.1111/j.1464-410X.2005.05526.x; Ettwiller L, 2007, NAT METHODS, V4, P563, DOI 10.1038/NMETH1061; Fronsdal K, 1998, J BIOL CHEM, V273, P31853, DOI 10.1074/jbc.273.48.31853; Gelmann EP, 2002, J CLIN ONCOL, V20, P3001, DOI 10.1200/JCO.2002.10.018; Gery S, 2005, CLIN CANCER RES, V11, P3184, DOI 10.1158/1078-0432.CCR-04-2625; Glass CK, 2000, GENE DEV, V14, P121; Halmos B, 2002, CANCER RES, V62, P528; Han S, 2007, ANTI-CANCER DRUG, V18, P237, DOI 10.1097/CAD.0b013e328011e67d; Harris TE, 2001, J BIOL CHEM, V276, P29200, DOI 10.1074/jbc.M011587200; HENDRICKSTAYLOR LR, 1995, NUCLEIC ACIDS RES, V23, P4726, DOI 10.1093/nar/23.22.4726; Hong H, 1996, P NATL ACAD SCI USA, V93, P4948, DOI 10.1073/pnas.93.10.4948; Jakacka M, 2001, J BIOL CHEM, V276, P13615, DOI 10.1074/jbc.M008384200; JENSTER G, 1995, J BIOL CHEM, V270, P7341, DOI 10.1074/jbc.270.13.7341; JENSTER G, 1993, BIOCHEM J, V293, P761, DOI 10.1042/bj2930761; Jia L, 2005, CANCER RES, V65, P8003, DOI 10.1158/0008-5472.CAN-04-3679; Kousteni S, 2001, CELL, V104, P719, DOI 10.1016/S0092-8674(01)00268-9; Loomis KD, 2007, CANCER RES, V67, P6768, DOI 10.1158/0008-5472.CAN-07-0139; Manolagas SC, 2001, ENDOCRINOLOGY, V142, P2200, DOI 10.1210/en.142.6.2200; McEwan IJ, 2004, ENDOCR-RELAT CANCER, V11, P281, DOI 10.1677/erc.0.0110281; McKenna NJ, 2002, CELL, V108, P465, DOI 10.1016/S0092-8674(02)00641-4; Miyamoto H, 2004, PROSTATE, V61, P332, DOI 10.1002/pros.20115; Muller C, 2004, J BIOL CHEM, V279, P7353, DOI 10.1074/jbc.M312709200; NERLOV C, 1994, GENE DEV, V8, P350, DOI 10.1101/gad.8.3.350; Osada S, 1996, J BIOL CHEM, V271, P3891; Pabst T, 2001, NAT GENET, V27, P263, DOI 10.1038/85820; Pabst T, 2001, NAT MED, V7, P444, DOI 10.1038/86515; Paltoo D, 2003, CANCER LETT, V191, P67, DOI 10.1016/S0304-3835(02)00617-1; Porse BT, 2001, CELL, V107, P247, DOI 10.1016/S0092-8674(01)00516-5; Pratt WB, 1997, ENDOCR REV, V18, P306, DOI 10.1210/er.18.3.306; QUIGLEY CA, 1995, ENDOCR REV, V16, P271, DOI 10.1210/er.16.3.271; Ramji DP, 2002, BIOCHEM J, V365, P561, DOI 10.1042/BJ20020508; Roy AK, 1999, VITAM HORM, V55, P309; SADOWSKI I, 1989, NUCLEIC ACIDS RES, V17, P7539, DOI 10.1093/nar/17.18.7539; Safe S, 2004, PROG NUCLEIC ACID RE, V77, P1, DOI 10.1016/S0079-6603(04)77001-4; Schoenmakers E, 2000, J BIOL CHEM, V275, P12290, DOI 10.1074/jbc.275.16.12290; Schuster MB, 2006, BBA-REV CANCER, V1766, P88, DOI 10.1016/j.bbcan.2006.02.003; Shaffer PL, 2004, P NATL ACAD SCI USA, V101, P4758, DOI 10.1073/pnas.0401123101; Shand RL, 2006, CURR OPIN UROL, V16, P123, DOI 10.1097/01.mou.0000193384.39351.64; Shatnawi A, 2007, MOL ENDOCRINOL, V21, P635, DOI 10.1210/me.2006-0274; Sun M, 2003, J BIOL CHEM, V278, P42992, DOI 10.1074/jbc.M306295200; Sundfeldt K, 1999, BRIT J CANCER, V79, P1240, DOI 10.1038/sj.bjc.6690199; Thomson AA, 2006, DIFFERENTIATION, V74, P382, DOI 10.1111/j.1432-0436.2006.00101.x; Timchenko NA, 1999, NUCLEIC ACIDS RES, V27, P3621, DOI 10.1093/nar/27.17.3621; Timchenko NA, 1996, GENE DEV, V10, P804, DOI 10.1101/gad.10.7.804; Timchenko NA, 1997, MOL CELL BIOL, V17, P7353, DOI 10.1128/MCB.17.12.7353; Timchenko NA, 1999, MOL CELL BIOL, V19, P2936; TSAI MJ, 1994, ANNU REV BIOCHEM, V63, P451, DOI 10.1146/annurev.biochem.63.1.451; UMEK RM, 1991, SCIENCE, V251, P288, DOI 10.1126/science.1987644; Vlahopoulos S, 2005, J BIOL CHEM, V280, P7786, DOI 10.1074/JBC.m413992200; Wang GL, 2005, MOL CELL BIOL, V25, P1325, DOI 10.1128/MCB.25.4.1325-1338.2005; Wang GL, 2004, GENE DEV, V18, P912, DOI 10.1101/gad.1183304; Wang HM, 2002, EMBO J, V21, P930, DOI 10.1093/emboj/21.5.930; Wang HM, 2001, MOL CELL, V8, P817, DOI 10.1016/S1097-2765(01)00366-5; Wang QB, 2007, MOL CELL, V27, P380, DOI 10.1016/j.molcel.2007.05.041; Watkins PJ, 1996, CANCER RES, V56, P1063; Wettenhall JM, 2006, BIOINFORMATICS, V22, P897, DOI 10.1093/bioinformatics/btl025; Xu YY, 2006, CANCER RES, V66, P7783, DOI 10.1158/0008-5472.CAN-05-4472; Yu YP, 2004, J CLIN ONCOL, V22, P2790, DOI 10.1200/JCO.2004.05.158; Zegarra-Moro OL, 2002, CANCER RES, V62, P1008; Zhang J, 2008, PROSTATE, V68, P1206, DOI 10.1002/pros.20779	68	22	23	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 4	2010	29	5					723	738		10.1038/onc.2009.373	http://dx.doi.org/10.1038/onc.2009.373			16	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	551QI	19901962	Green Accepted			2022-12-25	WOS:000274223700009
J	Hewitt, SC; Li, Y; Li, LP; Korach, KS				Hewitt, Sylvia C.; Li, Yin; Li, Leping; Korach, Kenneth S.			Estrogen-mediated Regulation of Igf1 Transcription and Uterine Growth Involves Direct Binding of Estrogen Receptor alpha to Estrogen-responsive Elements	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							I GENE-TRANSCRIPTION; BREAST-CANCER; CROSS-TALK; SIGNAL TRANSDUCERS; PROLIFERATION; EXPRESSION; STAT5A; PHOSPHORYLATION; ACTIVATOR; UTERUS	Estrogen enables uterine proliferation, which depends on synthesis of the IGF1 growth factor. This proliferation and IGF1 synthesis requires the estrogen receptor (ER), which binds directly to target DNA sequences (estrogen-responsive elements or EREs), or interacts with other transcription factors, such as AP1, to impact transcription. We observe neither uterine growth nor an increase in Igf1 transcript in a mouse with a DNA-binding mutated ER alpha (KIKO), indicating that both Igf1 regulation and uterine proliferation require the DNA binding function of the ER. We identified several potential EREs in the Igf1 gene, and chromatin immunoprecipitation analysis revealed ER alpha binding to these EREs in wild type but not KIKO chromatin. STAT5 is also reported to regulate Igf1; uterine Stat5a transcript is increased by estradiol (E-2), but not in KIKO or alpha ERKO uteri, indicating ER alpha- and ERE-dependent regulation. ER alpha binds to a potential Stat5a ERE. We hypothesize that E2 increases Stat5a transcript through ERE binding; that ER alpha, either alone or together with STAT5, then acts to increase Igf1 transcription; and that the resulting lack of IGF1 impairs KIKO uterine growth. Treatment with exogenous IGF1, alone or in combination with E2, induces proliferation in wild type but not KIKO uteri, indicating that IGF1 replacement does not rescue the KIKO proliferative response. Together, these observations suggest in contrast to previous in vitro studies of IGF-1 regulation involving AP1 motifs that direct ER alpha-DNA interaction is required to increase Igf1 transcription. Additionally, full ER alpha function is needed to mediate other cellular signals of the growth factor for uterine growth.	[Hewitt, Sylvia C.; Li, Yin; Korach, Kenneth S.] NIEHS, Receptor Biol Sect, Reprod & Dev Toxicol Lab, NIH, Res Triangle Pk, NC 27709 USA; [Li, Leping] NIEHS, Biostat Branch, NIH, Res Triangle Pk, NC 27709 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS); National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS)	Hewitt, SC (corresponding author), NIEHS, Receptor Biol Sect, Reprod & Dev Toxicol Lab, NIH, 111 Alexander Dr, Res Triangle Pk, NC 27709 USA.	curtiss@niehs.nih.gov	Li, Leping/F-6497-2019; Hewitt, Sylvia/W-8752-2019	Li, Leping/0000-0003-4208-0259; Hewitt, Sylvia/0000-0001-7713-0805; Korach, Kenneth/0000-0002-7765-418X	National Institutes of Health [Z01ES70065, Z01ES101765]; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [ZIAES101765, ZIAES070065] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))	This work was supported, in whole or in part, by National Institutes of Health Grants Z01ES70065 (to K. S. K., S. C. H., and Y. L.) and Z01ES101765 (to L. L.).	Adesanya OO, 1999, P NATL ACAD SCI USA, V96, P3287, DOI 10.1073/pnas.96.6.3287; Ahlbory-Dieker DL, 2009, MOL ENDOCRINOL, V23, P1544, DOI 10.1210/me.2009-0045; Bjornstrom L, 2001, J MOL ENDOCRINOL, V27, P93, DOI 10.1677/jme.0.0270093; Bourdeau V, 2004, MOL ENDOCRINOL, V18, P1411, DOI 10.1210/me.2003-0441; Cao JS, 2004, ENDOCRINOLOGY, V145, P1739, DOI 10.1210/en.2003-0752; Cunha GR, 2004, ARCH HISTOL CYTOL, V67, P417, DOI 10.1679/aohc.67.417; Curtis SW, 1996, P NATL ACAD SCI USA, V93, P12626, DOI 10.1073/pnas.93.22.12626; Faulds MH, 2001, MOL ENDOCRINOL, V15, P1929, DOI 10.1210/me.15.11.1929; Fox EM, 2008, MOL ENDOCRINOL, V22, P1781, DOI 10.1210/me.2007-0419; Hennighausen L, 2008, GENE DEV, V22, P711, DOI 10.1101/gad.1643908; Hewitt SC, 2006, ENDOCRINOLOGY, V147, P2203, DOI 10.1210/en.2005-1292; Hewitt SC, 2005, MOL ENDOCRINOL, V19, P657, DOI 10.1210/me.2004-0142; Hewitt SC, 2003, MOL ENDOCRINOL, V17, P2070, DOI 10.1210/me.2003-0146; Hewitt SC, 2009, MOL ENDOCRINOL, V23, P2111, DOI 10.1210/me.2009-0356; Jakacka M, 2001, J BIOL CHEM, V276, P13615, DOI 10.1074/jbc.M008384200; Jakacka M, 2002, MOL ENDOCRINOL, V16, P2188, DOI 10.1210/me.2001-0174; Jin VX, 2004, NUCLEIC ACIDS RES, V32, P6627, DOI 10.1093/nar/gkh1005; Jordan VC, 2007, NAT REV CANCER, V7, P46, DOI 10.1038/nrc2048; Kajimoto Y, 1998, ENDOCR J, V45, P1, DOI 10.1507/endocrj.45.1; Katzenellenbogen B S, 1979, Recent Prog Horm Res, V35, P259; Klotz DM, 2002, J BIOL CHEM, V277, P8531, DOI 10.1074/jbc.M109592200; Klotz DM, 2000, ENDOCRINOLOGY, V141, P3430, DOI 10.1210/en.141.9.3430; LAHOOTI H, 1994, MOL ENDOCRINOL, V8, P182, DOI 10.1210/me.8.2.182; LEROITH D, 1991, MOL CELL ENDOCRINOL, V77, pC57, DOI 10.1016/0303-7207(91)90054-V; Li LP, 2009, J COMPUT BIOL, V16, P317, DOI 10.1089/cmb.2008.16TT; LUBAHN DB, 1993, P NATL ACAD SCI USA, V90, P11162, DOI 10.1073/pnas.90.23.11162; Moyano P, 2004, GROWTH HORM IGF RES, V14, P431, DOI 10.1016/j.ghir.2004.09.001; MURPHY LJ, 1987, MOL ENDOCRINOL, V1, P445, DOI 10.1210/mend-1-7-445; O'Brien JE, 2006, J BIOL CHEM, V281, P26683, DOI 10.1074/jbc.M601522200; Pfaffl MW, 2001, NUCLEIC ACIDS RES, V29, DOI 10.1093/nar/29.9.e45; Rajkumar K, 1996, ENDOCRINOLOGY, V137, P1258, DOI 10.1210/en.137.4.1258; Ray S, 2008, MOL ENDOCRINOL, V22, P1125, DOI 10.1210/me.2007-0445; Richards RG, 1996, P NATL ACAD SCI USA, V93, P12002, DOI 10.1073/pnas.93.21.12002; Rudnik V, 2008, J CELL BIOCHEM, V103, P896, DOI 10.1002/jcb.21459; Safe S, 2008, J MOL ENDOCRINOL, V41, P263, DOI 10.1677/JME-08-0103; Santos SJ, 2008, ENDOCRINOLOGY, V149, P329, DOI 10.1210/en.2007-0594; Sato T, 2002, ENDOCRINOLOGY, V143, P2673, DOI 10.1210/en.143.7.2673; Shao WL, 2004, BREAST CANCER RES, V6, P39, DOI 10.1186/bcr742; Shavlakadze T, 2005, GROWTH HORM IGF RES, V15, P4, DOI 10.1016/j.ghir.2004.11.001; Silva CM, 2007, MOL ENDOCRINOL, V21, P1499, DOI 10.1210/me.2007-0109; Teglund S, 1998, CELL, V93, P841, DOI 10.1016/S0092-8674(00)81444-0; UMAYAHARA Y, 1994, J BIOL CHEM, V269, P16433; Wang Y, 2004, FEBS LETT, V572, P238, DOI 10.1016/j.febslet.2004.06.098; Woelfle J, 2003, J BIOL CHEM, V278, P51261, DOI 10.1074/jbc.M309486200; Woelfle J, 2003, J BIOL CHEM, V278, P22696, DOI 10.1074/jbc.M301362200; Zhu L, 2007, P NATL ACAD SCI USA, V104, P15847, DOI 10.1073/pnas.0705749104	46	93	94	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 22	2010	285	4					2676	2685		10.1074/jbc.M109.043471	http://dx.doi.org/10.1074/jbc.M109.043471			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	544YP	19920132	Green Published, hybrid			2022-12-25	WOS:000273697800046
J	Maddodi, N; Bhat, KMR; Devi, S; Zhang, SC; Setaluri, V				Maddodi, Nityanand; Bhat, Kumar M. R.; Devi, Sulochana; Zhang, Su-Chun; Setaluri, Vijayasaradhi			Oncogenic BRAF(V600E) Induces Expression of Neuronal Differentiation Marker MAP2 in Melanoma Cells by Promoter Demethylation and Down-regulation of Transcription Repressor HES1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MICROTUBULE-ASSOCIATED PROTEIN-2; EPIGENETIC REGULATION; GROWTH-FACTOR; B-RAF; NOTCH; GENE; BRAF; ACTIVATION; PATHWAY; TUMORS	MAP2 is a neuron-specific microtubule-associated protein that binds and stabilizes dendritic microtubules. Previously, we showed that MAP2 expression is (a) activated in cutaneous primary melanoma and (b) inversely associated with melanoma tumor progression. We also showed that ectopic expression of MAP2 in metastatic melanoma cells inhibits cell growth by inducing mitotic spindle defects and apoptosis. However, molecular mechanisms of regulation of MAP2 gene expression in melanoma are not understood. Here, we show that in melanoma cells MAP2 expression is induced by the demethylating agent 5-aza-2'-cytidine, and MAP2 promoter is progressively methylated during melanoma progression, indicating that epigenetic mechanisms are involved in silencing of MAP2 in melanoma. In support of this, methylation of MAP2 promoter DNA in vitro inhibits its activity. Because MAP2 promoter activity levels in melanoma cell lines also correlated with activating mutation in BRAF, a gene that is highly expressed in neurons, we hypothesized that BRAF signaling is involved in MAP2 expression. We show that hyperactivation of BRAF-MEK signaling activates MAP2 expression in melanoma cells by two independent mechanisms, promoter demethylation or down-regulation of neuronal transcription repressor HES1. Our data suggest that BRAF oncogene levels can regulate melanoma neuronal differentiation and tumor progression.	[Maddodi, Nityanand; Bhat, Kumar M. R.; Devi, Sulochana; Setaluri, Vijayasaradhi] Univ Wisconsin, Sch Med & Publ Hlth, Dept Dermatol, Madison, WI 53706 USA; [Zhang, Su-Chun] Univ Wisconsin, Sch Med & Publ Hlth, Dept Anat, Madison, WI 53706 USA	University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison	Setaluri, V (corresponding author), 1300 Univ Ave,B25, Madison, WI 53706 USA.	setaluri@wisc.edu	Bhat, Kumar/AAD-8831-2019	Bhat, Kumar/0000-0003-1805-3453	National Institutes of Health [R21CA125091, R01NS045926]; Wisconsin Alumni Research Foundation; NATIONAL CANCER INSTITUTE [R21CA125091] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS045926] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Wisconsin Alumni Research Foundation; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))	This work was supported, in whole or in part, by National Institutes of Health Grants R21CA125091 (to V.S.) and R01NS045926 ( to S.-C. Z.). This work was also supported by the Wisconsin Alumni Research Foundation.	Balint K, 2005, J CLIN INVEST, V115, P3166, DOI 10.1172/JCI25001; BARNIER JV, 1995, J BIOL CHEM, V270, P23381, DOI 10.1074/jbc.270.40.23381; Bhat KMR, 2007, CLIN CANCER RES, V13, P2849, DOI 10.1158/1078-0432.CCR-06-3040; Bhat KMR, 2006, NUCLEIC ACIDS RES, V34, P3819, DOI 10.1093/nar/gkl476; Busam KJ, 2005, ADV ANAT PATHOL, V12, P92, DOI 10.1097/01.pap.0000155071.86944.a6; Checchi PM, 2003, TRENDS PHARMACOL SCI, V24, P361, DOI 10.1016/S0165-6147(03)00161-5; Curry CL, 2006, LAB INVEST, V86, P842, DOI 10.1038/labinvest.3700442; Dai ZY, 2004, ONCOGENE, V23, P3521, DOI 10.1038/sj.onc.1207441; Davies H, 2002, NATURE, V417, P949, DOI 10.1038/nature00766; DHILLON AP, 1982, HISTOPATHOLOGY, V6, P81, DOI 10.1111/j.1365-2559.1982.tb02704.x; Dugan LL, 1999, J BIOL CHEM, V274, P25842, DOI 10.1074/jbc.274.36.25842; Fang D, 2001, AM J PATHOL, V158, P2107, DOI 10.1016/S0002-9440(10)64682-2; Frebel K, 2007, NEURODEGENER DIS, V4, P261, DOI 10.1159/000101850; GABBARA S, 1995, BIOCHEM J, V307, P87, DOI 10.1042/bj3070087; GOOVAERTS G, 1988, AM J DERMATOPATH, V10, P20, DOI 10.1097/00000372-198802000-00003; Halaban R, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0004563; Harada A, 2002, J CELL BIOL, V158, P541, DOI 10.1083/jcb.200110134; Herman JG, 1996, P NATL ACAD SCI USA, V93, P9821, DOI 10.1073/pnas.93.18.9821; Hinselwood DC, 2005, ELECTROPHORESIS, V26, P2553, DOI 10.1002/elps.200410427; Hitoshi S, 2002, GENE DEV, V16, P846, DOI 10.1101/gad.975202; Hoon DSB, 2004, ONCOGENE, V23, P4014, DOI 10.1038/sj.onc.1207505; HORRIGAN E, 2006, SURGERY, V24, P5; Howell PM, 2009, CANCER CONTROL, V16, P200, DOI 10.1177/107327480901600302; Hsieh J, 2004, CURR OPIN GENET DEV, V14, P461, DOI 10.1016/j.gde.2004.07.006; Ingram WJ, 2008, ONCOGENE, V27, P1489, DOI 10.1038/sj.onc.1210767; Jang H, 2007, J BIOL CHEM, V282, P11172, DOI 10.1074/jbc.M611199200; Kageyama R, 2000, MOL CELLS, V10, P1, DOI 10.1007/s10059-000-0001-0; Kalcheva N, 1998, CELL MOTIL CYTOSKEL, V40, P272, DOI 10.1002/(SICI)1097-0169(1998)40:3<272::AID-CM6>3.0.CO;2-F; Kao SC, 2001, J BIOL CHEM, V276, P18169, DOI 10.1074/jbc.M008870200; Khare VK, 1998, J CUTAN PATHOL, V25, P2, DOI 10.1111/j.1600-0560.1998.tb01682.x; Kohyama J, 2008, P NATL ACAD SCI USA, V105, P18012, DOI 10.1073/pnas.0808417105; Laggner U, 2007, HISTOPATHOLOGY, V50, P949, DOI 10.1111/j.1365-2559.2007.02696.x; LammerdingKoppel M, 1997, J CUTAN PATHOL, V24, P137, DOI 10.1111/j.1600-0560.1997.tb01567.x; LEE HJ, 1991, BRAIN RES, V558, P197, DOI 10.1016/0006-8993(91)90769-R; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; Michaloglou C, 2005, NATURE, V436, P720, DOI 10.1038/nature03890; Miele L, 2006, CLIN CANCER RES, V12, P1074, DOI 10.1158/1078-0432.CCR-05-2570; Minoo P, 2007, J PATHOL, V212, P124, DOI 10.1002/path.2160; Moriyama M, 2006, J CELL BIOL, V173, P333, DOI 10.1083/jcb.200509084; Nelson ED, 2008, J NEUROSCI, V28, P395, DOI 10.1523/JNEUROSCI.3796-07.2008; Nguyen HL, 1997, J CELL SCI, V110, P281; Nickoloff BJ, 2005, J INVEST DERM SYMP P, V10, P95, DOI 10.1111/j.1087-0024.2005.200404.x; Prieto VG, 1997, J CUTAN PATHOL, V24, P145, DOI 10.1111/j.1600-0560.1997.tb01568.x; Qiu MS, 1998, MECH DEVELOP, V72, P77, DOI 10.1016/S0925-4773(98)00018-5; Reed JA, 1999, AM J PATHOL, V155, P549, DOI 10.1016/S0002-9440(10)65150-4; Satyamoorthy K, 2003, CANCER RES, V63, P756; Schinstine M, 1997, EXP NEUROL, V144, P315, DOI 10.1006/exnr.1996.6370; Schmittgen TD, 2008, NAT PROTOC, V3, P1101, DOI 10.1038/nprot.2008.73; Simpson TI, 2002, BIOESSAYS, V24, P1041, DOI 10.1002/bies.10174; Smith LT, 2006, P NATL ACAD SCI USA, V103, P982, DOI 10.1073/pnas.0510171102; SMITH TW, 1993, CLIN NEUROPATHOL, V12, P335; Soltani MH, 2005, AM J PATHOL, V166, P1841, DOI 10.1016/S0002-9440(10)62493-5; Stockhausen MT, 2005, EXP CELL RES, V310, P218, DOI 10.1016/j.yexcr.2005.07.011; STORM SM, 1990, ONCOGENE, V5, P345; Tanami H, 2004, ONCOGENE, V23, P8796, DOI 10.1038/sj.onc.1208152; Vater I, 2009, BRIT J HAEMATOL, V144, P317, DOI 10.1111/j.1365-2141.2008.07443.x; Wassmann K, 2001, CURR OPIN GENET DEV, V11, P83, DOI 10.1016/S0959-437X(00)00161-1; Weinmaster G, 2000, CURR OPIN GENET DEV, V10, P363, DOI 10.1016/S0959-437X(00)00097-6; Wellbrock C, 2004, CANCER RES, V64, P2338, DOI 10.1158/0008-5472.CAN-03-3433; Wellbrock C, 2004, NAT REV MOL CELL BIO, V5, P875, DOI 10.1038/nrm1498; Wiese S, 2001, NAT NEUROSCI, V4, P137, DOI 10.1038/83960; Wittmann T, 2001, NAT CELL BIOL, V3, pE28, DOI 10.1038/35050669; Wojnowski L, 1997, NAT GENET, V16, P293, DOI 10.1038/ng0797-293; Zhiqi S, 2004, MELANOMA RES, V14, P509, DOI 10.1097/00008390-200412000-00011	64	31	34	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 1	2010	285	1					242	254		10.1074/jbc.M109.068668	http://dx.doi.org/10.1074/jbc.M109.068668			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	536UT	19880519	Green Published, hybrid			2022-12-25	WOS:000273070100026
J	Charron, CE; Chou, PC; Coutts, DJC; Kumar, V; To, M; Akashi, K; Pinhu, L; Griffiths, M; Adcock, IM; Barnes, PJ; Ito, K				Charron, Catherine E.; Chou, Pai-Chien; Coutts, David J. C.; Kumar, Vaibhav; To, Masako; Akashi, Kenichi; Pinhu, Liao; Griffiths, Mark; Adcock, Ian M.; Barnes, Peter J.; Ito, Kazuhiro			Hypoxia-inducible Factor 1 alpha Induces Corticosteroid-insensitive Inflammation via Reduction of Histone Deacetylase-2 Transcription	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NITRIC-OXIDE; RHEUMATOID-ARTHRITIS; PROTEIN; EXPRESSION; CELLS; ACETYLATION; HIF-1-ALPHA; MACROPHAGES; COMPLEX	Corticosteroids are potent anti-inflammatory agents, but corticosteroid insensitivity is a major barrier for the treatment of some chronic inflammatory diseases. Here, we show that hypoxia induces corticosteroid-insensitive inflammation via reduced transcription of histone deacetylase-2 (HDAC2) in lung epithelial and macrophage cells. HDAC2 mRNA and protein expression was reduced under hypoxic conditions (1% O-2). Hypoxia enhanced interleukin-1 beta-induced interleukin-8 (CXCL8) production in A549 cells and decreased the ability of dexamethasone to suppress the CXCL8 production. Deletion or point mutation studies revealed that binding of the transcription factor hypoxia-inducible factor (HIF) 1 alpha to a HIF response element at position -320, but not HIF-1 beta or HIF-2 alpha, results in reduced polymerase II binding at the site, leading to reduced promoter activity of HDAC2. Our results suggest that activation of HIF-1 alpha by hypoxia decreases HDAC2 levels, resulting in amplified inflammation and corticosteroid resistance.	[Charron, Catherine E.; Chou, Pai-Chien; Coutts, David J. C.; Kumar, Vaibhav; To, Masako; Akashi, Kenichi; Adcock, Ian M.; Barnes, Peter J.; Ito, Kazuhiro] Univ London Imperial Coll Sci Technol & Med, Natl Heart & Lung Inst, Sect Airway Dis, London SW3 6LY, England; [Pinhu, Liao; Griffiths, Mark] Imperial Coll Royal Brompton Hosp Campus, Crit Care Unit, London SW3 6LY, England; [Chou, Pai-Chien] Chang Gung Univ, Coll Med, Chang Gung Mem Hosp, Dept Thorac Med, Taipei 10507, Taiwan	Imperial College London; Imperial College London; Royal Brompton Hospital; Chang Gung Memorial Hospital; Chang Gung University	Charron, CE (corresponding author), Univ London Imperial Coll Sci Technol & Med, Natl Heart & Lung Inst, Sect Airway Dis, London SW3 6LY, England.	c.charron@imperial.ac.uk	Ito, Kazuhiro/AAF-5994-2019; Adcock, Ian/L-3217-2019; To, Masako/V-4051-2019; Akashi, Kenichi/AAY-6923-2021; Kumar, Vaibhav/ABG-5515-2020	Kumar, Vaibhav/0000-0002-5594-9497; Barnes, Peter/0000-0002-5122-4018; Adcock, Ian/0000-0003-2101-8843; Akashi, Kenichi/0000-0002-3867-0769; Griffiths, Mark/0000-0002-1615-1896	Wellcome Trust [076472/Z/05/Z]; Medical Research Council [G0401662]; MRC [G0401662] Funding Source: UKRI	Wellcome Trust(Wellcome Trust); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))	This work was supported by Wellcome Trust Grant 076472/Z/05/Z and Medical Research Council Grant G0401662.	Barnes PJ, 2007, PLOS MED, V4, P779, DOI 10.1371/journal.pmed.0040112; Barnes PJ, 2005, EUR RESPIR J, V25, P552, DOI 10.1183/09031936.05.00117504; Blouin CC, 2004, BLOOD, V103, P1124, DOI 10.1182/blood-2003-07-2427; Bonello S, 2007, ARTERIOSCL THROM VAS, V27, P755, DOI 10.1161/01.ATV.0000258979.92828.bc; Brindicci C, 2005, EUR RESPIR J, V26, P52, DOI 10.1183/09031936.04.00125304; Ebert BL, 1998, MOL CELL BIOL, V18, P4089, DOI 10.1128/MCB.18.7.4089; Filippin LI, 2008, CLIN EXP IMMUNOL, V152, P415, DOI 10.1111/j.1365-2249.2008.03634.x; Gerald D, 2004, CELL, V118, P781, DOI 10.1016/j.cell.2004.08.025; Guzy RD, 2005, CELL METAB, V1, P401, DOI 10.1016/j.cmet.2005.05.001; Ito K, 2000, MOL CELL BIOL, V20, P6891, DOI 10.1128/MCB.20.18.6891-6903.2000; Ito K, 2006, J EXP MED, V203, P7, DOI 10.1084/jem.20050466; Ito K, 2005, NEW ENGL J MED, V352, P1967, DOI 10.1056/NEJMoa041892; Ito K, 2002, AM J RESP CRIT CARE, V166, P392, DOI 10.1164/rccm.2110060; Kato H, 2004, J BIOL CHEM, V279, P41966, DOI 10.1074/jbc.M406320200; Kim JH, 2001, COMPOS INTERFACE, V7, P443, DOI 10.1163/156855400750262932; Kim KS, 2006, J IMMUNOL, V177, P7211, DOI 10.4049/jimmunol.177.10.7211; Komarova EA, 2005, FASEB J, V19, P1030, DOI 10.1096/fj.04-3213fje; Lee K, 2007, PHARMACOL THERAPEUT, V113, P229, DOI 10.1016/j.pharmthera.2006.08.001; Lim KH, 2008, NATURE, V452, P646, DOI 10.1038/nature06778; McDonough MA, 2006, P NATL ACAD SCI USA, V103, P9814, DOI 10.1073/pnas.0601283103; Mejlvang J, 2007, MOL BIOL CELL, V18, P4615, DOI 10.1091/mbc.E07-05-0406; Metzen E, 2003, MOL BIOL CELL, V14, P3470, DOI 10.1091/mbc.e02-12-0791; Nagy G, 2008, IMMUNOL LETT, V118, P55, DOI 10.1016/j.imlet.2008.02.009; Pluemsampant S, 2008, INT J CANCER, V122, P333, DOI 10.1002/ijc.23094; Sengupta N, 2004, J CELL BIOCHEM, V93, P57, DOI 10.1002/jcb.20179; Smith SJ, 2006, BRIT J PHARMACOL, V149, P393, DOI 10.1038/sj.bjp.0706885; Tacchini L, 2004, CARCINOGENESIS, V25, P2089, DOI 10.1093/carcin/bgh227; Thornton RD, 2000, BIOCHEM J, V350, P307, DOI 10.1042/0264-6021:3500307; Wenger Roland H, 2005, Sci STKE, V2005, pre12, DOI 10.1126/stke.3062005re12; Wyrwicz LS, 2007, ACTA BIOCHIM POL, V54, P89, DOI 10.18388/abp.2007_3273	30	39	41	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 25	2009	284	52					36047	36054		10.1074/jbc.M109.025387	http://dx.doi.org/10.1074/jbc.M109.025387			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	535LT	19880520	Green Published, hybrid			2022-12-25	WOS:000272970500006
J	Vinas, J; Tudela, S				Vinas, Jordi; Tudela, Sergi			A Validated Methodology for Genetic Identification of Tuna Species (Genus Thunnus)	PLOS ONE			English	Article							MITOCHONDRIAL-DNA SEQUENCE; PHYLOGENETIC-RELATIONSHIPS; MOLECULAR-IDENTIFICATION; HISTORICAL DEMOGRAPHY; CYTOCHROME-B; ATLANTIC; FISH; DIFFERENTIATION; DISCRIMINATION; TELEOSTEI	Background Tuna species of the genus Thunnus, such as the bluefin tunas, are some of the most important and yet most endangered trade fish in the world. Identification of these species in traded forms, however, may be difficult depending on the presentation of the products, which may hamper conservation efforts on trade control. In this paper, we validated a genetic methodology that can fully distinguish between the eight Thunnus species from any kind of processed tissue. Methodology: After testing several genetic markers, a complete discrimination of the eight tuna species was achieved using Forensically Informative Nucleotide Sequencing based primarily on the sequence variability of the hypervariable genetic marker mitochondrial DNA control region (mtDNA CR), followed, in some specific cases, by a second validation by a nuclear marker rDNA first internal transcribed spacer (ITS1). This methodology was able to distinguish all tuna species, including those belonging to the subgenus Neothunnus that are very closely related, and in consequence can not be differentiated with other genetic markers of lower variability. This methodology also took into consideration the presence of introgression that has been reported in past studies between T. thynnus, T. orientalis and T. alalunga. Finally, we applied the methodology to cross-check the species identity of 26 processed tuna samples. Conclusions: Using the combination of two genetic markers, one mitochondrial and another nuclear, allows a full discrimination between all eight tuna species. Unexpectedly, the genetic marker traditionally used for DNA barcoding, cytochrome oxidase 1, could not differentiate all species, thus its use as a genetic marker for tuna species identification is questioned.			Vinas, J (corresponding author), Univ Girona, Dept Biol, Lab Ictiol Genet, Girona, Spain.	jordi.vinas@udg.edu	Viñas, Jordi/A-5397-2010; 赵, 鹏/B-8401-2009	Viñas, Jordi/0000-0003-0193-1141; 				BARTLETT SE, 1992, BIOTECHNIQUES, V12, P408; BLOCK BA, 1993, SCIENCE, V260, P210, DOI 10.1126/science.8469974; Bottero MT, 2007, J BIOTECHNOL, V129, P575, DOI 10.1016/j.jbiotec.2007.01.032; Bremer JRA, 1998, MAR BIOL, V132, P547, DOI 10.1007/s002270050420; Bremer JRA, 1997, J FISH BIOL, V50, P540, DOI 10.1006/jfbi.1996.0321; Bremer JRA, 2005, MOL PHYLOGENET EVOL, V36, P169, DOI 10.1016/j.ympev.2004.12.011; BREMER JRA, 1994, THESIS U TORONTO TOR; Chow S, 2006, J FISH BIOL, V68, P24, DOI 10.1111/j.0022-1112.2006.00945.x; Chow S, 1995, J MOL EVOL, V41, P741, DOI 10.1007/BF00173154; Collette BB, 1999, PROCEEDINGS OF THE 5TH INDO-PACIFIC FISH CONFERENCE, P149; Collette Bruce B., 2001, Fish Physiology, V19, P1; Ely B, 2005, BMC EVOL BIOL, V5, DOI 10.1186/1471-2148-5-19; FAO, 2010, STAT WORLD FISH AQ; FELSENSTEIN J, 1985, EVOLUTION, V39, P783, DOI 10.1111/j.1558-5646.1985.tb00420.x; FINNERTY JR, 1995, FISH B-NOAA, V93, P78; Hall T.A., 1999, NUCL ACIDS S SERIES, V41, P95, DOI [DOI 10.1021/BK-1999-0734.CH008, citeulike-article-id:691774, 10.12691/ajmr-6-4-3]; Hebert PDN, 2003, P ROY SOC B-BIOL SCI, V270, pS96, DOI 10.1098/rsbl.2003.0025; KIMURA M, 1980, J MOL EVOL, V16, P111, DOI 10.1007/BF01731581; Kumar S, 2008, BRIEF BIOINFORM, V9, P299, DOI 10.1093/bib/bbn017; Lenstra J. A., 2003, Food authenticity and traceability, P34, DOI 10.1533/9781855737181.1.34; Lin WF, 2007, FOOD CONTROL, V18, P1050, DOI 10.1016/j.foodcont.2006.07.001; Lin WF, 2005, J FOOD DRUG ANAL, V13, P382; Lockley AK, 2000, J AGR FOOD CHEM, V48, P4463, DOI 10.1021/jf000387p; Mallet J, 2003, TRENDS ECOL EVOL, V18, P57, DOI 10.1016/S0169-5347(02)00061-7; Martinez P, 2006, MOL PHYLOGENET EVOL, V39, P404, DOI 10.1016/j.ympev.2005.07.022; Michelini E, 2007, J AGR FOOD CHEM, V55, P7638, DOI 10.1021/jf070902k; Moritz C, 2004, PLOS BIOL, V2, P1529, DOI 10.1371/journal.pbio.0020354; Nauen C. E., 1983, FAO FISH SYNOP, V2, P1; Nei M, 1987, MOL EVOLUTIONARY GEN; Orrell TM, 2006, B MAR SCI, V79, P505; Paine MA, 2008, ICHTHYOL RES, V55, P7, DOI 10.1007/s10228-007-0003-4; Paine MA, 2007, B MAR SCI, V80, P353; Rasmussen RS, 2008, COMPR REV FOOD SCI F, V7, P280, DOI 10.1111/j.1541-4337.2008.00046.x; ROB O, 2008, FISH FISH, V9, P462; SAITOU N, 1987, MOL BIOL EVOL, V4, P406, DOI 10.1093/oxfordjournals.molbev.a040454; *SCRS, 2008, 2008 ATL BLUEF TUN S; Smith PJ, 2001, NEW ZEAL J MAR FRESH, V35, P843, DOI 10.1080/00288330.2001.9517046; Takashima Y, 2006, FISHERIES SCI, V72, P1054, DOI 10.1111/j.1444-2906.2006.01256.x; Takeyama H, 2001, J FISH BIOL, V58, P1646, DOI 10.1111/j.1095-8649.2001.tb02319.x; Takeyama H, 2000, MAR BIOTECHNOL, V2, P309; Teletchea F, 2005, TRENDS BIOTECHNOL, V23, P359, DOI 10.1016/j.tibtech.2005.05.006; Teletchea F, 2009, REV FISH BIOL FISHER, V19, P265, DOI 10.1007/s11160-009-9107-4; Terol J, 2002, J AGR FOOD CHEM, V50, P963, DOI 10.1021/jf011032o; Vinas J, 2004, MAR BIOL, V145, P225, DOI 10.1007/s00227-004-1319-5; Ward RD, 2005, PHILOS T R SOC B, V360, P1847, DOI 10.1098/rstb.2005.1716	45	95	100	0	36	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	OCT 27	2009	4	10							e7606	10.1371/journal.pone.0007606	http://dx.doi.org/10.1371/journal.pone.0007606			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	511ET	19898615	Green Published, gold			2022-12-25	WOS:000271147400010
J	Ostenfeld, MS; Bramsen, JB; Lamy, P; Villadsen, SB; Fristrup, N; Sorensen, KD; Ulhoi, B; Borre, M; Kjems, J; Dyrskjot, L; Orntoft, TF				Ostenfeld, M. S.; Bramsen, J. B.; Lamy, P.; Villadsen, S. B.; Fristrup, N.; Sorensen, K. D.; Ulhoi, B.; Borre, M.; Kjems, J.; Dyrskjot, L.; Orntoft, T. F.			miR-145 induces caspase-dependent and -independent cell death in urothelial cancer cell lines with targeting of an expression signature present in Ta bladder tumors	ONCOGENE			English	Article						miRNA; bladder cancer; cell death; caspases; microarray	BREAST-CANCER; COLON-CANCER; PROSTATE-CANCER; MICRORNAS; TRANSLATION; DIAGNOSIS; LEUKEMIA; GROWTH; GENES; P53	Downregulation of miR-145 in a variety of cancers suggests a possible tumor suppressor function for this microRNA. Here, we show that miR-145 expression is reduced in bladder cancer and urothelial carcinoma in situ, compared with normal urothelium, using transcription profiling and in situ hybridization. Ectopic expression of miR-145 induced extensive apoptosis in urothelial carcinoma cell lines (T24 and SW780) as characterized by caspase activation, nuclear condensation and fragmentation, cellular shrinkage, and detachment. However, cell death also proceeded upon caspase inhibition by the pharmacological inhibitor zVAD-fmk and ectopic expression of anti-apoptotic Bcl-2, indicating the activation of an alternative caspase-independent death pathway. Microarray analysis of transcript levels in T24 cells, before the onset of cell death, showed destabilization of mRNAs enriched for miR-145 7mer target sites. Among these, direct targeting of CBFB, PPP3CA, and CLINT1 was confirmed by a luciferase reporter assay. Notably, a 22-gene signature targeted on enforced miR-145 expression in T24 cells was significantly (P < 0.00003) upregulated in 55 Ta bladder tumors with concomitant reduction of miR-145. Our data indicate that reduction in miR-145 expression may provide bladder cancer cells with a selective advantage by inhibition of cell death otherwise triggered in malignant cells. Oncogene (2010) 29, 1073-1084; doi:10.1038/onc.2009.395; published online 16 November 2009	[Ostenfeld, M. S.; Lamy, P.; Fristrup, N.; Sorensen, K. D.; Dyrskjot, L.; Orntoft, T. F.] Aarhus Univ Hosp, Dept Mol Med, DK-8000 Aarhus N, Denmark; [Bramsen, J. B.; Villadsen, S. B.; Kjems, J.] Univ Aarhus, Dept Mol Biol, Aarhus C, Denmark; [Lamy, P.] Univ Aarhus, Bioinformat Res Ctr, BiRC, Aarhus C, Denmark; [Ulhoi, B.] Aarhus Hosp, Inst Pathol NBG, Aarhus, Denmark; [Borre, M.] Aarhus Univ Hosp, Dept Urol, Skejby, Denmark	Aarhus University; Aarhus University; Aarhus University; Aarhus University; Aarhus University	Orntoft, TF (corresponding author), Aarhus Univ Hosp, Dept Mol Med, DK-8000 Aarhus N, Denmark.	orntoft@ki.au.dk	Kjems, Jorgen/I-3490-2016; Dyrskjot, Lars/H-4922-2012	Kjems, Jorgen/0000-0003-4128-9317; Sorensen, Karina Dalsgaard/0000-0002-4902-5490; Borre, Michael/0000-0002-1519-9185	Ministry of Technology and Science; John and Birthe Meyer Foundation; Lundbeck Foundation; Danish Cancer Society; European Community [201663]	Ministry of Technology and Science; John and Birthe Meyer Foundation; Lundbeck Foundation(Lundbeckfonden); Danish Cancer Society(Danish Cancer Society); European Community(European Commission)	We thank Gitte Hoj, Pamela Celis, Hanne Steen, Inge-Lis Thorsen, Gitte Stougard, and Conni Sorensen for technical assistance. We are grateful to M Jaattela for providing the pCEP4 Bcl-2 vector construct and to Thomas B Hansen for methylation analysis software. We thank the staff at the Departments of Urology, Clinical Biochemistry, and Pathology at Aarhus University Hospital. This work was supported by the Ministry of Technology and Science, The John and Birthe Meyer Foundation, the Lundbeck Foundation, and the Danish Cancer Society, and the European Community's Seventh framework program (FP7/2007-2013) under grant agreement no 201663.	Baek D, 2008, NATURE, V455, P64, DOI 10.1038/nature07242; Calin GA, 2004, P NATL ACAD SCI USA, V101, P2999, DOI 10.1073/pnas.0307323101; Calin GA, 2006, NAT REV CANCER, V6, P857, DOI 10.1038/nrc1997; Cordes KR, 2009, NATURE, V460, P705, DOI 10.1038/nature08195; Dyrskjot L, 2005, CLIN CANCER RES, V11, P4029, DOI 10.1158/1078-0432.CCR-04-2095; Dyrskjot L, 2009, CANCER RES, V69, P4851, DOI 10.1158/0008-5472.CAN-08-4043; Esquela-Kerscher A, 2006, NAT REV CANCER, V6, P259, DOI 10.1038/nrc1840; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; Hart SM, 2002, HAEMATOLOGICA, V87, P1307; Horrigan SK, 1996, BLOOD, V88, P2665, DOI 10.1182/blood.V88.7.2665.bloodjournal8872665; Iorio MV, 2005, CANCER RES, V65, P7065, DOI 10.1158/0008-5472.CAN-05-1783; Kagoshima H, 2007, DEVELOPMENT, V134, P3905, DOI 10.1242/dev.008276; Kedde M, 2007, CELL, V131, P1273, DOI 10.1016/j.cell.2007.11.034; Kim M, 2004, CANCER RES, V64, P4078, DOI 10.1158/0008-5472.CAN-04-0284; Kim R, 2006, J PATHOL, V208, P319, DOI 10.1002/path.1885; Kroemer G, 2009, CELL DEATH DIFFER, V16, P3, DOI 10.1038/cdd.2008.150; Lee Y, 2003, NATURE, V425, P415, DOI 10.1038/nature01957; Levine B, 2005, J CLIN INVEST, V115, P2679, DOI 10.1172/JCI26390; Litynska A, 2000, ACTA BIOCHIM POL, V47, P427; Michael MZ, 2003, MOL CANCER RES, V1, P882; Mitra AP, 2007, WORLD J UROL, V25, P563, DOI 10.1007/s00345-007-0197-0; Nakajima Go, 2006, Cancer Genomics & Proteomics, V3, P317; Nuovo GJ, 2008, METHODS, V44, P39, DOI 10.1016/j.ymeth.2007.10.008; Orom UA, 2008, MOL CELL, V30, P460, DOI 10.1016/j.molcel.2008.05.001; Ostenfeld MS, 2005, CANCER RES, V65, P8975, DOI 10.1158/0008-5472.CAN-05-0269; Ow YLP, 2008, NAT REV MOL CELL BIO, V9, P532, DOI 10.1038/nrm2434; Porkka KP, 2007, CANCER RES, V67, P6130, DOI 10.1158/0008-5472.CAN-07-0533; Rajewsky N, 2006, NAT GENET, V38, pS8, DOI 10.1038/ng1798; Sachdeva M, 2009, P NATL ACAD SCI USA, V106, P3207, DOI 10.1073/pnas.0808042106; Schepeler T, 2008, CANCER RES, V68, P6416, DOI 10.1158/0008-5472.CAN-07-6110; Selbach M, 2008, NATURE, V455, P58, DOI 10.1038/nature07228; Sempere LF, 2007, CANCER RES, V67, P11612, DOI 10.1158/0008-5472.CAN-07-5019; Shi B, 2007, J BIOL CHEM, V282, P32582, DOI 10.1074/jbc.M702806200; Tavazoie SF, 2008, NATURE, V451, P147, DOI 10.1038/nature06487; Thorsen K, 2008, MOL CELL PROTEOMICS, V7, P1214, DOI 10.1074/mcp.M700590-MCP200; Vasudevan S, 2007, SCIENCE, V318, P1931, DOI 10.1126/science.1149460; Wang XH, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002557; Yanaihara N, 2006, CANCER CELL, V9, P189, DOI 10.1016/j.ccr.2006.01.025; Yang H, 2008, CANCER RES, V68, P425, DOI 10.1158/0008-5472.CAN-07-2488; Yu L, 2004, SCIENCE, V304, P1500, DOI 10.1126/science.1096645	40	120	126	0	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	FEB 18	2010	29	7					1073	1084		10.1038/onc.2009.395	http://dx.doi.org/10.1038/onc.2009.395			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	556PV	19915607				2022-12-25	WOS:000274604400013
J	Holst, B; Nygaard, R; Valentin-Hansen, L; Bach, A; Engelstoft, MS; Petersen, PS; Frimurer, TM; Schwartz, TW				Holst, Birgitte; Nygaard, Rie; Valentin-Hansen, Louise; Bach, Anders; Engelstoft, Maja S.; Petersen, Pia S.; Frimurer, Thomas M.; Schwartz, Thue W.			A Conserved Aromatic Lock for the Tryptophan Rotameric Switch in TM-VI of Seven-transmembrane Receptors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-COUPLED RECEPTORS; METAL-ION SITE; CRYSTAL-STRUCTURE; GHRELIN RECEPTOR; TOGGLE SWITCHES; HELIX MOVEMENT; BINDING-SITE; RHODOPSIN; ACTIVATION; AGONIST	The conserved tryptophan in position 13 of TM-VI (Trp-VI:13 or Trp-6.48) of the CWXP motif located at the bottom of the main ligand-binding pocket in TM-VI is believed to function as a rotameric microswitch in the activation process of seven-transmembrane (7TM) receptors. Molecular dynamics simulations in rhodopsin demonstrated that rotation around the chi1 torsion angle of Trp-VI:13 brings its side chain close to the equally highly conserved Phe-V:13 (Phe-5.47) in TM-V. In the ghrelin receptor, engineering of high affinity metal-ion sites between these positions confirmed their close spatial proximity. Mutational analysis was performed in the ghrelin receptor with multiple substitutions and with Ala substitutions in GPR119, GPR39, and the beta(2)-adrenergic receptor as well as the NK1 receptor. In all of these cases, it was found that mutation of the Trp-VI:13 rotameric switch itself eliminated the constitutive signaling and strongly impaired agonist-induced signaling without affecting agonist affinity and potency. Ala substitution of Phe-V:13, the presumed interaction partner for Trp-VI:13, also in all cases impaired both the constitutive and the agonist-induced receptor signaling, but not to the same degree as observed in the constructs where Trp-VI:13 itself was mutated, but again without affecting agonist potency. In a proposed active receptor conformation generated by molecular simulations, where the extracellular segment of TM-VI is tilted inwards in the main ligand-binding pocket, Trp-VI:13 could rotate into a position where it obtained an ideal aromatic-aromatic interaction with Phe-V: 13. It is concluded that Phe-V:13 can serve as an aromatic lock for the proposed active conformation of the Trp-VI:13 rotameric switch, being involved in the global movement of TM-V and TM-VI in 7TM receptor activation.	[Schwartz, Thue W.] Univ Copenhagen, Dept Neurosci & Pharmacol, Mol Pharmacol Lab, DK-2200 Copenhagen, Denmark; [Nygaard, Rie; Frimurer, Thomas M.; Schwartz, Thue W.] 7TM Pharma AS, DK-5700 Horsholm, Denmark	University of Copenhagen	Holst, B (corresponding author), Univ Copenhagen, Dept Pharmacol, Mol Pharmacol Lab, Blegdamsvej 3B, DK-2200 Copenhagen, Denmark.	holst@sund.ku.dk; tws@sund.ku.dk	Nygaard, Rie/B-7351-2013	Bach, Anders/0000-0003-4305-9910; Schwartz, Thue W./0000-0002-0261-6904; Holst, Birgitte/0000-0001-7432-097X; Frimruer, Thomas/0000-0002-9682-8245	Danish Medical Research Council; NovoNordisk Foundation; Lundbeck Foundation; Alfred Benzon Foundation; Danish Diabetes Association; European Union [223057]	Danish Medical Research Council(Danish Medical Research CouncilUK Research & Innovation (UKRI)Medical Research Council UK (MRC)); NovoNordisk Foundation(Novo Nordisk Foundation); Lundbeck Foundation(Lundbeckfonden); Alfred Benzon Foundation; Danish Diabetes Association; European Union(European Commission)	This work was supported by grants from the Danish Medical Research Council, the NovoNordisk Foundation, the Lundbeck Foundation, the Alfred Benzon Foundation, the Danish Diabetes Association, and the European Union's Seventh Framework Programme (Grant Agreement 223057).	Ahuja S, 2009, J BIOL CHEM, V284, P10190, DOI 10.1074/jbc.M805725200; Ahuja S, 2009, NAT STRUCT MOL BIOL, V16, P168, DOI 10.1038/nsmb.1549; Altenbach C, 2008, P NATL ACAD SCI USA, V105, P7439, DOI 10.1073/pnas.0802515105; Cherezov V, 2007, SCIENCE, V318, P1258, DOI 10.1126/science.1150577; Colson AO, 1998, MOL PHARMACOL, V54, P968, DOI 10.1124/mol.54.6.968; Crocker E, 2006, J MOL BIOL, V357, P163, DOI 10.1016/j.jmb.2005.12.046; Dinner AR, 1999, PROTEIN ENG, V12, P909, DOI 10.1093/protein/12.11.909; Elling CE, 1999, P NATL ACAD SCI USA, V96, P12322, DOI 10.1073/pnas.96.22.12322; ELLING CE, 1995, NATURE, V374, P74, DOI 10.1038/374074a0; Elling CE, 2006, J BIOL CHEM, V281, P17337, DOI 10.1074/jbc.M512510200; Ghanouni P, 2001, P NATL ACAD SCI USA, V98, P5997, DOI 10.1073/pnas.101126198; Holst B, 2003, MOL ENDOCRINOL, V17, P2201, DOI 10.1210/me.2003-0069; Holst B, 1998, MOL PHARMACOL, V53, P166, DOI 10.1124/mol.53.1.166; Holst B, 2004, J BIOL CHEM, V279, P53806, DOI 10.1074/jbc.M407676200; Holst B, 2001, J BIOL CHEM, V276, P19793, DOI 10.1074/jbc.M100621200; Holst B, 2007, ENDOCRINOLOGY, V148, P13, DOI 10.1210/en.2006-0933; Holst B, 2009, MOL PHARMACOL, V75, P44, DOI 10.1124/mol.108.049189; Hubbell WL, 2003, ADV PROTEIN CHEM, V63, P243; Jaakola VP, 2008, SCIENCE, V322, P1211, DOI 10.1126/science.1164772; Jongejan A, 2005, NAT CHEM BIOL, V1, P98, DOI 10.1038/nchembio714; Joubert L, 2002, J BIOL CHEM, V277, P25502, DOI 10.1074/jbc.M202539200; Klein-Seetharaman J, 2004, P NATL ACAD SCI USA, V101, P3409, DOI 10.1073/pnas.0308713101; Kobilka BK, 2007, BBA-BIOMEMBRANES, V1768, P794, DOI 10.1016/j.bbamem.2006.10.021; Li J, 2004, J MOL BIOL, V343, P1409, DOI 10.1016/j.jmb.2004.08.090; Lin SW, 1996, BIOCHEMISTRY-US, V35, P11149, DOI 10.1021/bi960858u; MacKerell AD, 2001, BIOPOLYMERS, V56, P257; Marie J, 2001, J BIOL CHEM, V276, P41100, DOI 10.1074/jbc.M104875200; McAllister SD, 2004, J BIOL CHEM, V279, P48024, DOI 10.1074/jbc.M406648200; McGaughey GB, 1998, J BIOL CHEM, V273, P15458, DOI 10.1074/jbc.273.25.15458; Mirzadegan T, 2003, BIOCHEMISTRY-US, V42, P2759, DOI 10.1021/bi027224+; Nygaard R, 2009, TRENDS PHARMACOL SCI, V30, P249, DOI 10.1016/j.tips.2009.02.006; Palczewski K, 2000, SCIENCE, V289, P739, DOI 10.1126/science.289.5480.739; Park JH, 2008, NATURE, V454, P183, DOI 10.1038/nature07063; Patel AB, 2004, P NATL ACAD SCI USA, V101, P10048, DOI 10.1073/pnas.0402848101; Pellissier LP, 2009, MOL PHARMACOL, V75, P982, DOI 10.1124/mol.108.053686; Phillips JC, 2005, J COMPUT CHEM, V26, P1781, DOI 10.1002/jcc.20289; Pin JP, 2005, FEBS J, V272, P2947, DOI 10.1111/j.1742-4658.2005.04728.x; Rasmussen SGF, 2007, NATURE, V450, P383, DOI 10.1038/nature06325; Rosenbaum DM, 2007, SCIENCE, V318, P1266, DOI 10.1126/science.1150609; Rosenbaum DM, 2009, NATURE, V459, P356, DOI 10.1038/nature08144; Rosenkilde MM, 2007, MOL PHARMACOL, V71, P930, DOI 10.1124/mol.106.030031; Ruprecht JJ, 2004, EMBO J, V23, P3609, DOI 10.1038/sj.emboj.7600374; Scheerer P, 2008, NATURE, V455, P497, DOI 10.1038/nature07330; Schertler GFX, 2005, CURR OPIN STRUC BIOL, V15, P408, DOI 10.1016/j.sbi.2005.07.010; Schwartz TW, 2008, NATURE, V455, P473, DOI 10.1038/455473a; Schwartz TW, 2006, ANNU REV PHARMACOL, V46, P481, DOI 10.1146/annurev.pharmtox.46.120604.141218; Schwartz TW, 1996, TRENDS PHARMACOL SCI, V17, P213, DOI 10.1016/0165-6147(96)10017-1; Semple G, 2008, J MED CHEM, V51, P5172, DOI 10.1021/jm8006867; Shi L, 2002, J BIOL CHEM, V277, P14777, DOI 10.1074/jbc.M108967200; Sun YH, 2002, ENDOCRINOLOGY, V143, P2886, DOI 10.1210/en.143.8.2886; Swaminath G, 2004, J BIOL CHEM, V279, P686, DOI 10.1074/jbc.M310888200; Swaminath G, 2005, J BIOL CHEM, V280, P22165, DOI 10.1074/jbc.M502352200; Teller DC, 2001, BIOCHEMISTRY-US, V40, P7761, DOI 10.1021/bi0155091; Thirstrup K, 1996, J BIOL CHEM, V271, P7875, DOI 10.1074/jbc.271.14.7875; Urizar E, 2005, J BIOL CHEM, V280, P17135, DOI 10.1074/jbc.M414678200; Warne T, 2008, NATURE, V454, P486, DOI 10.1038/nature07101	56	107	108	0	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 5	2010	285	6					3973	3985		10.1074/jbc.M109.064725	http://dx.doi.org/10.1074/jbc.M109.064725			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	564YF	19920139	Green Published, hybrid			2022-12-25	WOS:000275254000051
J	Chan, PC; Sudhakar, JN; Lai, CC; Chen, HC				Chan, P-C; Sudhakar, J. N.; Lai, C-C; Chen, H-C			Differential phosphorylation of the docking protein Gab1 by c-Src and the hepatocyte growth factor receptor regulates different aspects of cell functions	ONCOGENE			English	Article						Gab1; phosphorylation; Src; Met; Crk; HGF	FACTOR-MEDIATED INTERACTION; KINASE IN-VITRO; PHOSPHATIDYLINOSITOL 3-KINASE; EPITHELIAL MORPHOGENESIS; FACTOR STIMULATION; TYROSINE KINASE; MET; ACTIVATION; IDENTIFICATION; CYTOKINE	The docking protein Grb2-associated binder1 (Gab1) has a central role in the integration of the growth-factor signaling. In this study, we aimed to examine the significance of Src-mediated Gab1 phosphorylation in the hepatocyte growth factor (HGF) signaling. Using both mutagenesis and mass spectrometry approaches, Y242, Y259, Y317, Y373 and Y627 of Gab1 were identified to be phosphorylated by c-Src. It is interesting to note that the binding of the tyrosine phosphatase SHP2 to the Y627 antagonized the effect of c-Src on the phosphorylation of the other four tyrosine residues. Moreover, the tyrosine residues predominantly phosphorylated by c-Src were different from those predominantly phosphorylated by the HGF receptor. Gab1 overexpression potentiated both mitogenic and motogenic activities of HGF. However, a Gab1 mutant with substitutions of the Src phosphorylation sites (Y242, Y259, Y317 and Y373) failed to promote HGF-induced DNA synthesis, but retained its ability to facilitate HGF-induced chemotaxis. Taken together, our results not only suggest that the phosphorylation of Gab1 by c-Src is important for HGF-induced DNA synthesis, but also provide an example to illustrate how a docking protein (for example, Gab1) is differentially phosphorylated by c-Src and a receptor tyrosine kinase to emanate full spectrum of signals to the downstream. Oncogene (2010) 29, 698-710; doi: 10.1038/onc.2009.363; published online 2 November 2009	[Chan, P-C; Chen, H-C] Natl Chung Hsing Univ, Dept Life Sci, Taichung 40227, Taiwan; [Sudhakar, J. N.; Chen, H-C] Natl Chung Hsing Univ, Inst Biomed Sci, Taichung 40227, Taiwan; [Lai, C-C] Natl Chung Hsing Univ, Inst Mol Biol, Taichung 40227, Taiwan	National Chung Hsing University; National Chung Hsing University; National Chung Hsing University	Chen, HC (corresponding author), Natl Chung Hsing Univ, Dept Life Sci, 250 Kuo Kuang Rd, Taichung 40227, Taiwan.	hcchen@nchu.edu.tw	/AGZ-4617-2022	/0000-0002-7133-8266	National Science Council, Taiwan [NSC97-3112-B-005-001, NSC97-2628-B-005-001-MY3]; National Health Research Institutes, Taiwan [NHRI-EX97-9730BI]	National Science Council, Taiwan(Ministry of Science and Technology, Taiwan); National Health Research Institutes, Taiwan(National Health Research Institutes - Taiwan)	We are indebted to Dr T Hirano (Osaka University, Osaka, Japan) for Gab1 cDNA and Gab1-null MEFs and Dr DL Wang (Academia Sinica, Taipei, Taiwan) for Flag-tagged SHP2 and its CS mutant. This work is supported by grants NSC97-3112-B-005-001 and NSC97-2628-B-005-001-MY3 from the National Science Council, Taiwan and NHRI-EX97-9730BI from the National Health Research Institutes, Taiwan.	Chan PC, 2003, J BIOL CHEM, V278, P44075, DOI 10.1074/jbc.M305745200; Chen SY, 2006, MOL CELL BIOL, V26, P5155, DOI 10.1128/MCB.02186-05; Cunnick JM, 2001, J BIOL CHEM, V276, P24380, DOI 10.1074/jbc.M010275200; DERMAN MP, 1995, AM J PHYSIOL-RENAL, V268, pF1211, DOI 10.1152/ajprenal.1995.268.6.F1211; Eulenfeld R, 2009, J CELL SCI, V122, P55, DOI 10.1242/jcs.037226; Gharahdaghi F, 1999, ELECTROPHORESIS, V20, P601, DOI 10.1002/(SICI)1522-2683(19990301)20:3<601::AID-ELPS601>3.0.CO;2-6; Gu HH, 2003, TRENDS CELL BIOL, V13, P122, DOI 10.1016/S0962-8924(03)00002-3; Gual P, 2000, ONCOGENE, V19, P1509, DOI 10.1038/sj.onc.1203514; HolgadoMadruga M, 1996, NATURE, V379, P560, DOI 10.1038/379560a0; Itoh M, 2000, MOL CELL BIOL, V20, P3695, DOI 10.1128/MCB.20.10.3695-3704.2000; Kallin A, 2004, J BIOL CHEM, V279, P17897, DOI 10.1074/jbc.M312996200; Lamorte L, 2000, ONCOGENE, V19, P5973, DOI 10.1038/sj.onc.1203977; Lehr S, 2004, BIOCHEMISTRY-US, V43, P12133, DOI 10.1021/bi049753e; Lehr S, 1999, BIOCHEMISTRY-US, V38, P151, DOI 10.1021/bi9818265; Lehr S, 2000, BIOCHEMISTRY-US, V39, P10898, DOI 10.1021/bi000982k; Machide M, 2000, J BIOL CHEM, V275, P31392, DOI 10.1074/jbc.M002817200; Maroun CR, 2000, MOL CELL BIOL, V20, P8513, DOI 10.1128/MCB.20.22.8513-8525.2000; Montagner A, 2005, J BIOL CHEM, V280, P5350, DOI 10.1074/jbc.M410012200; Nishida K, 1999, BLOOD, V93, P1809, DOI 10.1182/blood.V93.6.1809.406k35_1809_1816; Podar K, 2004, J BIOL CHEM, V279, P21658, DOI 10.1074/jbc.M305783200; Riordan SM, 2000, BIOCHEM J, V350, P925, DOI 10.1042/0264-6021:3500925; Rodrigues GA, 2000, MOL CELL BIOL, V20, P1448, DOI 10.1128/MCB.20.4.1448-1459.2000; Sachs M, 2000, J CELL BIOL, V150, P1375, DOI 10.1083/jcb.150.6.1375; Schaeper U, 2000, J CELL BIOL, V149, P1419, DOI 10.1083/jcb.149.7.1419; Schaeper U, 2007, P NATL ACAD SCI USA, V104, P15376, DOI 10.1073/pnas.0702555104; Shi ZQ, 2000, MOL CELL BIOL, V20, P1526, DOI 10.1128/MCB.20.5.1526-1536.2000; Takahashi-Tezuka M, 1998, MOL CELL BIOL, V18, P4109, DOI 10.1128/MCB.18.7.4109; Terry DE, 2004, J AM SOC MASS SPECTR, V15, P784, DOI 10.1016/j.jasms.2004.02.005; Weidner KM, 1996, NATURE, V384, P173, DOI 10.1038/384173a0; Yu CF, 2002, J BIOL CHEM, V277, P19382, DOI 10.1074/jbc.M200732200; Yu CF, 2001, J BIOL CHEM, V276, P32552, DOI 10.1074/jbc.M104493200	31	17	17	1	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 4	2010	29	5					698	710		10.1038/onc.2009.363	http://dx.doi.org/10.1038/onc.2009.363			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	551QI	19881549				2022-12-25	WOS:000274223700007
J	Lohoff, M; Giaisi, M; Kohler, R; Casper, B; Krammer, PH; Li-Weber, M				Lohoff, Michael; Giaisi, Marco; Koehler, Rebecca; Casper, Baerbel; Krammer, Peter H.; Li-Weber, Min			Early Growth Response Protein-1 (Egr-1) Is Preferentially Expressed in T Helper Type 2 (Th2) Cells and Is Involved in Acute Transcription of the Th2 Cytokine Interleukin-4	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; INTERFERON REGULATORY FACTOR-4; IMMEDIATE-EARLY GENE; HUMAN IL-4 PROMOTER; POSITIVE SELECTION; THYMIC SELECTION; NUCLEAR FACTORS; NGFI-A; BINDING; DIFFERENTIATION	The early growth response gene product Egr-1 has been shown to have great impact on growth, proliferation, and differentiation in a wide variety of cells, including T cells. In this study, we show that Egr-1 is rapidly induced upon T cell stimulation and is expressed predominantly in T helper type 2 (Th2) compared with type 1 (Th1) cells. We further investigate the role of Egr-1 in regulation of the Th2 cytokine interleukin-4 (IL-4) expression. IL-4 is a key Th2 cytokine that regulates humoral immunity and also causes allergic inflammation. Regulation of IL-4 gene transcription in Th2 cells has been shown to be controlled by multiple T cell receptor (TCR)-induced transcription factors. However, only a few transcription factors were shown to be selectively induced in differentiated Th2 cells in response to TCR stimulation. Chromatin immunoprecipitation analysis demonstrates that Egr-1 binds to the IL-4 promoter in vivo upon T cell stimulation. Ectopic expression of Egr-1 enhances endogenous IL-4 mRNA expression and elevates IL-4 promoter activity. We also show that Egr-1, nuclear factor of activated T cell, and NF-kappa B cooperatively bind to an NFAT/NF-kappa B-overlapping IL-4 enhancer element and activate the IL-4 promoter synergistically. Furthermore, we show that antisense oligonucleotides that knock down Egr-1 expression attenuate IL-4 transcription. Our study provides the first evidence that Egr-1 protein is differentially expressed in Th1 and Th2 cells and is involved in the acute phase of the IL-4 transcription in response to TCR stimulation.	[Giaisi, Marco; Koehler, Rebecca; Krammer, Peter H.; Li-Weber, Min] German Canc Res Ctr, Tumor Immunol Program D030, D-69120 Heidelberg, Germany; [Lohoff, Michael; Casper, Baerbel] Univ Marburg, Inst Med Microbiol, D-35037 Marburg, Germany	Helmholtz Association; German Cancer Research Center (DKFZ); Philipps University Marburg	Li-Weber, M (corresponding author), German Canc Res Ctr, Tumor Immunol Program G0300, Neuenheimer Feld 280, D-69120 Heidelberg, Germany.	m.li-weber@dkfz-heidelberg.de			Spitzencluster Initiative with Apogenix [BioRN-INA-10]; Deutsche Forschungsgemeinschaft [SFB TA22]	Spitzencluster Initiative with Apogenix; Deutsche Forschungsgemeinschaft(German Research Foundation (DFG))	This work was supported by the Spitzencluster Initiative with Apogenix BioRN-INA-10 (to M. L.-W.) and by Deutsche Forschungsgemeinschaft Grant SFB TA22 (to M. L.).	ABE E, 1992, P NATL ACAD SCI USA, V89, P2864, DOI 10.1073/pnas.89.7.2864; Agarwal S, 1998, IMMUNITY, V9, P765, DOI 10.1016/S1074-7613(00)80642-1; Agarwal S, 2000, IMMUNITY, V12, P643, DOI 10.1016/S1074-7613(00)80215-0; Amsen D, 2004, CELL, V117, P515, DOI 10.1016/S0092-8674(04)00451-9; Basson MA, 2000, J IMMUNOL, V165, P2444, DOI 10.4049/jimmunol.165.5.2444; Beckmann AM, 1997, NEUROCHEM INT, V31, P477, DOI 10.1016/S0197-0186(96)00136-2; Bettini M, 2002, J IMMUNOL, V169, P1713, DOI 10.4049/jimmunol.169.4.1713; Brown MA, 1997, CRIT REV IMMUNOL, V17, P1; BRUHN KW, 1993, P NATL ACAD SCI USA, V90, P9707, DOI 10.1073/pnas.90.20.9707; Chapman NR, 2000, J BIOL CHEM, V275, P4719, DOI 10.1074/jbc.275.7.4719; CHRISTY BA, 1988, P NATL ACAD SCI USA, V85, P7857, DOI 10.1073/pnas.85.21.7857; Crabtree GR, 2002, CELL, V109, pS67, DOI 10.1016/S0092-8674(02)00699-2; Decker EL, 2003, NUCLEIC ACIDS RES, V31, P911, DOI 10.1093/nar/gkg186; Decker EL, 1998, J BIOL CHEM, V273, P26923, DOI 10.1074/jbc.273.41.26923; GASHLER A, 1995, PROG NUCLEIC ACID RE, V50, P191, DOI 10.1016/S0079-6603(08)60815-6; Jankovic D, 2001, CURR OPIN IMMUNOL, V13, P403, DOI 10.1016/S0952-7915(00)00234-X; LEMAIRE P, 1988, P NATL ACAD SCI USA, V85, P4691, DOI 10.1073/pnas.85.13.4691; Li BY, 1999, EMBO J, V18, P420, DOI 10.1093/emboj/18.2.420; Li-Weber M, 2001, EUR J IMMUNOL, V31, P3694, DOI 10.1002/1521-4141(200112)31:12<3694::AID-IMMU3694>3.0.CO;2-S; Li-Weber M, 2004, EUR J IMMUNOL, V34, P1111, DOI 10.1002/eji.200324687; Li-Weber M, 2003, NAT REV IMMUNOL, V3, P534, DOI 10.1038/nri1128; Li-Weber M, 1998, J IMMUNOL, V161, P1380; Li-Weber M, 1998, J BIOL CHEM, V273, P32460, DOI 10.1074/jbc.273.49.32460; LIM RW, 1987, ONCOGENE, V1, P263; Lin JX, 1997, MOL CELL BIOL, V17, P3714, DOI 10.1128/MCB.17.7.3714; LiWeber M, 1997, J IMMUNOL, V158, P1194; Lohoff M, 2000, J EXP MED, V192, P325, DOI 10.1084/jem.192.3.325; Lohoff M, 2002, P NATL ACAD SCI USA, V99, P11808, DOI 10.1073/pnas.182425099; Luo C, 1996, MOL CELL BIOL, V16, P3955; MAGES HW, 1993, INT IMMUNOL, V5, P63, DOI 10.1093/intimm/5.1.63; MILBRANDT J, 1987, SCIENCE, V238, P797, DOI 10.1126/science.3672127; Miyazaki T, 1998, J EXP MED, V188, P715, DOI 10.1084/jem.188.4.715; Monticelli S, 2002, EUR J IMMUNOL, V32, P2971, DOI 10.1002/1521-4141(2002010)32:10<2971::AID-IMMU2971>3.0.CO;2-G; Murphy KM, 2002, NAT REV IMMUNOL, V2, P933, DOI 10.1038/nri954; NEUMANN M, 1995, EMBO J, V14, P1991, DOI 10.1002/j.1460-2075.1995.tb07191.x; NORTHROP JP, 1994, NATURE, V369, P497, DOI 10.1038/369497a0; Peng SL, 2001, IMMUNITY, V14, P13, DOI 10.1016/S1074-7613(01)00085-1; Proksch P, 2005, J IMMUNOL, V174, P7075, DOI 10.4049/jimmunol.174.11.7075; Rengarajan J, 2002, J EXP MED, V195, P1003, DOI 10.1084/jem.20011128; Ricci M, 1997, J INVEST ALLERG CLIN, V7, P144; RUSSO MW, 1993, MOL CELL BIOL, V13, P6858, DOI 10.1128/MCB.13.11.6858; Safford M, 2005, NAT IMMUNOL, V6, P472, DOI 10.1038/ni1193; SCHMITZ ML, 1991, EMBO J, V10, P3805, DOI 10.1002/j.1460-2075.1991.tb04950.x; Schnell FJ, 2005, J IMMUNOL, V175, P2270, DOI 10.4049/jimmunol.175.4.2270; SEDER RA, 1994, ANNU REV IMMUNOL, V12, P635, DOI 10.1146/annurev.iy.12.040194.003223; Shao H, 1997, J EXP MED, V185, P731, DOI 10.1084/jem.185.4.731; SKERKA C, 1995, J BIOL CHEM, V270, P22500, DOI 10.1074/jbc.270.38.22500; SUKHATME VP, 1988, CELL, V53, P37, DOI 10.1016/0092-8674(88)90485-0; SWIRNOFF AH, 1995, MOL CELL BIOL, V15, P2275; TEPPER RI, 1990, CELL, V62, P457, DOI 10.1016/0092-8674(90)90011-3; Wenner CA, 1997, J IMMUNOL, V158, P765; Worden B, 2005, CANCER RES, V65, P7071, DOI 10.1158/0008-5472.CAN-04-0989; Zelenika D, 2002, J IMMUNOL, V168, P1069, DOI 10.4049/jimmunol.168.3.1069; Zheng WP, 1997, CELL, V89, P587, DOI 10.1016/S0092-8674(00)80240-8; Zipfel PF, 1997, BBA-GENE STRUCT EXPR, V1354, P134, DOI 10.1016/S0167-4781(97)00084-5	55	29	29	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 15	2010	285	3					1643	1652		10.1074/jbc.M109.011585	http://dx.doi.org/10.1074/jbc.M109.011585			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	541PJ	19915002	Green Published, hybrid			2022-12-25	WOS:000273429100010
J	Voolstra, O; Oberhauser, V; Sumser, E; Meyer, NE; Maguire, ME; Huber, A; von Lintig, J				Voolstra, Olaf; Oberhauser, Vitus; Sumser, Emerich; Meyer, Nina E.; Maguire, Michael E.; Huber, Armin; von Lintig, Johannes			NinaB Is Essential for Drosophila Vision but Induces Retinal Degeneration in Opsin-deficient Photoreceptors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VISUAL PIGMENT CHROMOPHORE; CELL-SURFACE RECEPTOR; VITAMIN-A; BINDING-PROTEIN; BETA-CAROTENE; RHODOPSIN; CYCLE; MICE; GENE; MUTANTS	In animals, visual pigments are essential for photoreceptor function and survival. These G-protein-coupled receptors consist of a protein moiety (opsin) and a covalently bound 11-cis-retinylidene chromophore. The chromophore is derived from dietary carotenoids by oxidative cleavage and trans-to-cis isomerization of double bonds. In vertebrates, the necessary chemical transformations are catalyzed by two distinct but structurally related enzymes, the carotenoid oxygenase beta-carotenoid-15,15'-monooxygenase and the retinoid isomerase RPE65(retinal pigment epithelium protein of 65 kDa). Recently, we provided biochemical evidence that these reactions in insects are catalyzed by a single enzyme family member named NinaB. Here we show that in the fly pathway, carotenoids are mandatory precursors of the chromophore. After chromophore formation, the retinoid-binding protein Pinta acts downstream of NinaB and is required to supply photoreceptors with chromophore. Like ninaE encoding the opsin, ninaB expression is eye-dependent and is activated as a downstream target of the eyeless/pax6 and sine oculis master control genes for eye development. The requirement for coordinated synthesis of chromophore and opsin is evidenced by analysis of ninaE mutants. Retinal degeneration in opsin-deficient photoreceptors is caused by the chromophore and can be prevented by restricting its supply as seen in an opsin and chromophore-deficient double mutant. Thus, our study identifies NinaB as a key component for visual pigment production and provides evidence that chromophore in opsin-deficient photoreceptors can elicit retinal degeneration.	[Maguire, Michael E.; von Lintig, Johannes] Case Western Reserve Univ, Sch Med, Dept Pharmacol, Cleveland, OH 44160 USA; [Voolstra, Olaf; Meyer, Nina E.; Huber, Armin] Univ Hohenheim, Inst Physiol & Biosensor, D-70599 Hohenheim, Germany; [Voolstra, Olaf; Oberhauser, Vitus; Sumser, Emerich] Univ Freiburg, Inst Biol Neurobiol & Tiephysiol 1, D-79102 Freiburg, Germany	Case Western Reserve University; University Hohenheim; University of Freiburg	von Lintig, J (corresponding author), Case Western Reserve Univ, Dept Pharmacol W333, 10900 Euclid Ave, Cleveland, OH 44160 USA.	Johannes.vonlintig@case.edu	Huber, Armin/GYU-6322-2022	Huber, Armin/0000-0003-3977-089X; von Lintig, Johannes/0000-0002-2079-2143	National Institutes of Health [EY019641]; Ministry of Science and Art Baden-Wurttemberg (Germany); NATIONAL EYE INSTITUTE [R01EY019641] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Ministry of Science and Art Baden-Wurttemberg (Germany); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))	This work was supported, in whole or in part, by National Institutes of Health Grant EY019641 (to J. v. L.). This work was also supported by a grant from the Ministry of Science and Art Baden-Wurttemberg (Germany).	Blaner WS, 2007, CELL METAB, V5, P164, DOI 10.1016/j.cmet.2007.02.006; BRAND AH, 1993, DEVELOPMENT, V118, P401; Chang HY, 2000, SCIENCE, V290, P1978, DOI 10.1126/science.290.5498.1978; Daniel A, 1999, DEVELOPMENT, V126, P2945; FISCHBACH KF, 1984, DEV BIOL, V104, P219, DOI 10.1016/0012-1606(84)90050-2; Fleisch VC, 2008, J NEUROSCI, V28, P8208, DOI 10.1523/JNEUROSCI.2367-08.2008; Giovannucci DR, 1999, VISION RES, V39, P219, DOI 10.1016/S0042-6989(98)00184-9; Grimm C, 2000, NAT GENET, V25, P63, DOI 10.1038/75614; Gu G, 2004, J BIOL CHEM, V279, P18608, DOI 10.1074/jbc.M400323200; HALDER G, 1995, SCIENCE, V267, P1788, DOI 10.1126/science.7892602; HARRIS WA, 1977, NATURE, V266, P648, DOI 10.1038/266648a0; Helfrich-Forster C, 2002, J NEUROSCI, V22, P9255; Hessel S, 2007, J BIOL CHEM, V282, DOI 10.1074/jbc.M706763200; Isken A, 2008, CELL METAB, V7, P258, DOI 10.1016/j.cmet.2008.01.009; Jin MH, 2005, CELL, V122, P449, DOI 10.1016/j.cell.2005.06.042; Kiefer C, 2002, P NATL ACAD SCI USA, V99, P10581, DOI 10.1073/pnas.162182899; Kumar JP, 1997, DEV BIOL, V188, P43, DOI 10.1006/dbio.1997.8636; Kumar JP, 1995, DEVELOPMENT, V121, P4359; Maeda A, 2009, J BIOL CHEM, V284, P15173, DOI 10.1074/jbc.M900322200; Mazzoni EO, 2005, NEURON, V45, P293, DOI 10.1016/j.neuron.2004.12.038; Mendes HF, 2005, TRENDS MOL MED, V11, P177, DOI 10.1016/j.molmed.2005.02.007; Moiseyev G, 2005, P NATL ACAD SCI USA, V102, P12413, DOI 10.1073/pnas.0503460102; Oberhauser V, 2008, P NATL ACAD SCI USA, V105, P19000, DOI 10.1073/pnas.0807805105; OTOUSA JE, 1985, CELL, V40, P839, DOI 10.1016/0092-8674(85)90343-5; OTOUSA JE, 1989, J NEUROGENET, V6, P41, DOI 10.3109/01677068909107099; OZAKI K, 1993, NEURON, V10, P1113, DOI 10.1016/0896-6273(93)90059-Z; Palczewski K, 2006, ANNU REV BIOCHEM, V75, P743, DOI 10.1146/annurev.biochem.75.103004.142743; PAULSEN R, 1983, EUR J BIOCHEM, V137, P609, DOI 10.1111/j.1432-1033.1983.tb07869.x; Provencio I, 2002, NATURE, V415, P493, DOI 10.1038/415493a; Redmond TM, 1998, NAT GENET, V20, P344, DOI 10.1038/3813; Redmond TM, 2005, P NATL ACAD SCI USA, V102, P13658, DOI 10.1073/pnas.0504167102; Redmond TM, 2001, J BIOL CHEM, V276, P6560, DOI 10.1074/jbc.M009030200; Saari JC, 2001, NEURON, V29, P739, DOI 10.1016/S0896-6273(01)00248-3; Sarfare S, 2005, J BIOL CHEM, V280, P11895, DOI 10.1074/jbc.M412236200; Sparrow JR, 2005, EXP EYE RES, V80, P595, DOI 10.1016/j.exer.2005.01.007; Sprecher SG, 2007, GENE DEV, V21, P2182, DOI 10.1101/gad.1565407; Travis GH, 2007, ANNU REV PHARMACOL, V47, P469, DOI 10.1146/annurev.pharmtox.47.120505.105225; von Lintig J, 2000, J BIOL CHEM, V275, P11915, DOI 10.1074/jbc.275.16.11915; von Lintig J, 2001, ARCH BIOCHEM BIOPHYS, V385, P47, DOI 10.1006/abbi.2000.2096; Voolstra O, 2006, BIOCHEMISTRY-US, V45, P13429, DOI 10.1021/bi060701u; Wang T, 2005, J NEUROSCI, V25, P5187, DOI 10.1523/JNEUROSCI.0995-05.2005; Wang T, 2007, PFLUG ARCH EUR J PHY, V454, P821, DOI 10.1007/s00424-007-0251-1; Wang T, 2007, J CELL BIOL, V177, P305, DOI 10.1083/jcb.200610081; WASHBURN T, 1989, J BIOL CHEM, V264, P15464; Xu H, 2004, EMBO J, V23, P811, DOI 10.1038/sj.emboj.7600112; ZUKER CS, 1985, CELL, V40, P851, DOI 10.1016/0092-8674(85)90344-7	46	33	34	5	18	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 15	2010	285	3					2130	2139		10.1074/jbc.M109.056101	http://dx.doi.org/10.1074/jbc.M109.056101			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	541PJ	19889630	Green Published, hybrid			2022-12-25	WOS:000273429100057
J	George, NM; Targy, N; Evans, JJD; Zhang, LQ; Luo, X				George, Nicholas M.; Targy, Natalie; Evans, Jacquelynn J. D.; Zhang, Liqiang; Luo, Xu			Bax Contains Two Functional Mitochondrial Targeting Sequences and Translocates to Mitochondria in a Conformational Change- and Homo-oligomerization-driven Process	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BCL-2 PROTEIN FAMILY; CELL-DEATH; BH3-ONLY PROTEINS; MEMBRANE PERMEABILIZATION; CYTOCHROME-C; INTRACELLULAR-LOCALIZATION; APOPTOTIC ACTIVITY; ACTIVATION; LIFE; BH3	The apoptosis gateway protein Bax normally exists in the cytosol as a globular shaped monomer composed of nine alpha-helices. During apoptosis, Bax translocates to the mitochondria, forms homo-oligomers, and subsequently induces mitochondrial damage. The mechanism of Bax mitochondrial translocation remains unclear. Among the nine alpha-helices of Bax, helices 4, 5, 6, and 9 are capable of targeting a heterologous protein to mitochondria. However, only helices 6 and 9 can independently direct the oligomerized Bax to the mitochondria. Although Bax mitochondrial translocation can still proceed with mutations in either helix 6 or helix 9, combined mutations completely abolished mitochondrial targeting in response to activating signals. Using a proline mutagenesis scanning analysis, we demonstrated that conformational changes were sufficient to cause Bax to move from the cytosol to the mitochondria. Moreover, we found that homo-oligomerization of Bax contributed to its mitochondrial translocation. These results suggest that Bax is targeted to the mitochondria through the exposure of one or both of the two functional mitochondrial targeting sequences in a conformational change-driven and homo-oligomerization-aided process.	[George, Nicholas M.; Targy, Natalie; Evans, Jacquelynn J. D.; Zhang, Liqiang; Luo, Xu] Univ Nebraska, Med Ctr, Eppley Inst Res Canc & Allied Dis, Omaha, NE 68198 USA	University of Nebraska System; University of Nebraska Medical Center	Luo, X (corresponding author), Univ Nebraska, Med Ctr, Eppley Inst Res Canc & Allied Dis, Omaha, NE 68198 USA.	xuluo@unmc.edu	Zhang, Liqiang/B-6889-2011		National Institutes of Health [GM76237, CA009476]; NCCS [5P20RR018759]; University of Nebraska Medical Center; NATIONAL CANCER INSTITUTE [T32CA009476] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [P20RR018759] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM076237] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NCCS; University of Nebraska Medical Center; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	This work was supported, in whole or in part, by National Institutes of Health Grant GM76237. This work was also supported by a pilot grant from the Nebraska Center for Cellular Signaling (NCSS) (to X.L.).; Supported by National Institutes of Health Training Grant CA009476, Graduate Fellowship 5P20RR018759 from the NCCS, and the University of Nebraska Medical Center.	Adams JM, 2007, CURR OPIN IMMUNOL, V19, P488, DOI 10.1016/j.coi.2007.05.004; Adams JM, 2003, GENE DEV, V17, P2481, DOI 10.1101/gad.1126903; Annis MG, 2005, EMBO J, V24, P2096, DOI 10.1038/sj.emboj.7600675; Antonsson B, 2001, J BIOL CHEM, V276, P11615, DOI 10.1074/jbc.M010810200; Borner C, 2003, MOL IMMUNOL, V39, P615, DOI 10.1016/S0161-5890(02)00252-3; Cartron PF, 2003, J BIOL CHEM, V278, P11633, DOI 10.1074/jbc.M208955200; Cartron PF, 2002, FEBS LETT, V512, P95, DOI 10.1016/S0014-5793(02)02227-5; Cartron PF, 2004, MOL CELL, V16, P807, DOI 10.1016/j.molcel.2004.10.028; Certo M, 2006, CANCER CELL, V9, P351, DOI 10.1016/j.ccr.2006.03.027; Chipuk JE, 2004, SCIENCE, V303, P1010, DOI 10.1126/science.1092734; Chipuk JE, 2008, TRENDS CELL BIOL, V18, P157, DOI 10.1016/j.tcb.2008.01.007; Cory S, 2002, NAT REV CANCER, V2, P647, DOI 10.1038/nrc883; Danial NN, 2004, CELL, V116, P205, DOI 10.1016/S0092-8674(04)00046-7; Eskes R, 2000, MOL CELL BIOL, V20, P929, DOI 10.1128/MCB.20.3.929-935.2000; Fletchera JI, 2008, P NATL ACAD SCI USA, V105, P18081, DOI 10.1073/pnas.0808691105; Gavathiotis E, 2008, NATURE, V455, P1076, DOI 10.1038/nature07396; George NM, 2007, GENE DEV, V21, P1937, DOI 10.1101/gad.1553607; Goping IS, 1998, J CELL BIOL, V143, P207, DOI 10.1083/jcb.143.1.207; Green DR, 2004, SCIENCE, V305, P626, DOI 10.1126/science.1099320; Gross A, 1998, EMBO J, V17, P3878, DOI 10.1093/emboj/17.14.3878; Hsu YT, 1997, P NATL ACAD SCI USA, V94, P3668, DOI 10.1073/pnas.94.8.3668; Hsu YT, 1998, J BIOL CHEM, V273, P10777, DOI 10.1074/jbc.273.17.10777; Hu X, 2003, APOPTOSIS, V8, P277, DOI 10.1023/A:1023676906857; Huang DCS, 2000, CELL, V103, P839, DOI 10.1016/S0092-8674(00)00187-2; Jiang XJ, 2004, ANNU REV BIOCHEM, V73, P87, DOI 10.1146/annurev.biochem.73.011303.073706; Jurgensmeier JM, 1998, P NATL ACAD SCI USA, V95, P4997, DOI 10.1073/pnas.95.9.4997; Khaled AR, 1999, P NATL ACAD SCI USA, V96, P14476, DOI 10.1073/pnas.96.25.14476; Kim BJ, 2006, J BIOL CHEM, V281, P21256, DOI 10.1074/jbc.M510644200; Kim H, 2006, NAT CELL BIOL, V8, P1348, DOI 10.1038/ncb1499; Leber B, 2007, APOPTOSIS, V12, P897, DOI 10.1007/s10495-007-0746-4; Letai A, 2002, CANCER CELL, V2, P183, DOI 10.1016/S1535-6108(02)00127-7; Lindsten T, 2000, MOL CELL, V6, P1389, DOI 10.1016/S1097-2765(00)00136-2; Linseman DA, 2004, J NEUROSCI, V24, P9993, DOI 10.1523/JNEUROSCI.2057-04.2004; Lovell JF, 2008, CELL, V135, P1074, DOI 10.1016/j.cell.2008.11.010; Luo X, 1996, MOL CELL BIOL, V16, P1367; Lutter M, 2000, NAT CELL BIOL, V2, P754, DOI 10.1038/35036395; Ma YL, 2002, J BIOL CHEM, V277, P27328, DOI 10.1074/jbc.M201421200; Muchmore SW, 1996, NATURE, V381, P335, DOI 10.1038/381335a0; Nechushtan A, 1999, EMBO J, V18, P2330, DOI 10.1093/emboj/18.9.2330; Nie C, 2008, J BIOL CHEM, V283, P15359, DOI 10.1074/jbc.M800847200; Ohtsuka T, 2004, NAT CELL BIOL, V6, P121, DOI 10.1038/ncb1087; Pagliari LJ, 2005, P NATL ACAD SCI USA, V102, P17975, DOI 10.1073/pnas.0506712102; Petros AM, 2004, BBA-MOL CELL RES, V1644, P83, DOI 10.1016/j.bbamcr.2003.08.012; Ruffolo SC, 2000, CELL DEATH DIFFER, V7, P1101, DOI 10.1038/sj.cdd.4400739; Schinzel A, 2004, J CELL BIOL, V164, P1021, DOI 10.1083/jcb.200309013; Suzuki M, 2000, CELL, V103, P645, DOI 10.1016/S0092-8674(00)00167-7; Takahashi Y, 2005, MOL CELL BIOL, V25, P9369, DOI 10.1128/MCB.25.21.9369-9382.2005; Valentijn AJ, 2008, CELL DEATH DIFFER, V15, P1243, DOI 10.1038/cdd.2008.39; Valentijn AJ, 2003, J CELL BIOL, V162, P599, DOI 10.1083/jcb.200302154; Walensky LD, 2006, MOL CELL, V24, P199, DOI 10.1016/j.molcel.2006.08.020; Wei MC, 2001, SCIENCE, V292, P727, DOI 10.1126/science.1059108; Wei MC, 2000, GENE DEV, V14, P2060; Willis SN, 2007, SCIENCE, V315, P856, DOI 10.1126/science.1133289; Willis SN, 2005, GENE DEV, V19, P1294, DOI 10.1101/gad.1304105; Willis SN, 2005, CURR OPIN CELL BIOL, V17, P617, DOI 10.1016/j.ceb.2005.10.001; Wolter KG, 1997, J CELL BIOL, V139, P1281, DOI 10.1083/jcb.139.5.1281; Youle RJ, 2008, NAT REV MOL CELL BIO, V9, P47, DOI 10.1038/nrm2308	57	29	31	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 8	2010	285	2					1384	1392		10.1074/jbc.M109.049924	http://dx.doi.org/10.1074/jbc.M109.049924			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	539MH	19880508	Green Published, hybrid			2022-12-25	WOS:000273258200058
J	Lack, NA; Yam, KC; Lowe, ED; Horsman, GP; Owen, RL; Sim, E; Eltis, LD				Lack, Nathan A.; Yam, Katherine C.; Lowe, Edward D.; Horsman, Geoff P.; Owen, Robin L.; Sim, Edith; Eltis, Lindsay D.			Characterization of a Carbon-Carbon Hydrolase from Mycobacterium tuberculosis Involved in Cholesterol Metabolism	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							C-BOND HYDROLASE; POLYCHLORINATED-BIPHENYLS; DEGRADATION PATHWAY; CATALYTIC MECHANISM; L-PHOTOINTERMEDIATE; GENE-CLUSTER; BPHD; SUPERFAMILY; MACROPHAGES; SURVIVAL	In the recently identified cholesterol catabolic pathway of Mycobacterium tuberculosis, 2-hydroxy-6-oxo-6-phenylhexa-2,4-dienoate hydrolase (HsaD) is proposed to catalyze the hydrolysis of a carbon-carbon bond in 4,5-9,10-diseco-3-hydroxy-5,9,17-tri-oxoandrosta-1(10),2-diene-4-oic acid (DSHA), the cholesterol meta-cleavage product (MCP) and has been implicated in the intracellular survival of the pathogen. Herein, purified HsaD demonstrated 4-33 times higher specificity for DSHA (k(cat)/K-m = 3.3 +/- 0.3 x 10(4) M-1 s(-1)) than for the biphenyl MCP 2-hydroxy-6-oxo-6-phenylhexa-2,4-dienoic acid (HOPDA) and the synthetic analogue 8-(2-chlorophenyl)-2-hydroxy-5-methyl-6-oxoocta-2,4-dienoic acid (HOPODA), respectively. The S114A variant of HsaD, in which the active site serine was substituted with alanine, was catalytically impaired and bound DSHA with a K-d of 51 +/- 2 mu M. The S114A center dot DSHA species absorbed maximally at 456 nm, 60 nm red-shifted versus the DSHA enolate. Crystal structures of the variant in complex with HOPDA, HOPODA, or DSHA to 1.8-1.9 angstrom indicate that this shift is due to the enzyme-induced strain of the enolate. These data indicate that the catalytic serine catalyzes tautomerization. A second role for this residue is suggested by a solvent molecule whose position in all structures is consistent with its activation by the serine for the nucleophilic attack of the substrate. Finally, the alpha-helical lid covering the active site displayed a ligand-dependent conformational change involving differences in side chain carbon positions of up to 6.7 A, supporting a two-conformation enzymatic mechanism. Overall, these results provide novel insights into the determinants of specificity in a mycobacterial cholesterol-degrading enzyme as well as into the mechanism of MCP hydrolases.	[Lack, Nathan A.; Sim, Edith] Univ Oxford, Dept Pharmacol, Oxford OX1 3QT, England; [Lowe, Edward D.] Univ Oxford, Dept Mol Biophys, Oxford OX1 3QT, England; [Yam, Katherine C.; Horsman, Geoff P.; Eltis, Lindsay D.] Univ British Columbia, Dept Microbiol & Immunol, Vancouver, BC V6T 1Z3, Canada; [Owen, Robin L.] Paul Scherrer Inst, Swiss Light Source, CH-5232 Villigen, Switzerland	University of Oxford; University of Oxford; University of British Columbia; Swiss Federal Institutes of Technology Domain; Paul Scherrer Institute	Eltis, LD (corresponding author), 2350 Hlth Sci Mall, Vancouver, BC V6T 1Z3, Canada.	leltis@interchange.ubc.ca	Eltis, Lindsay D/J-8272-2015; Lowe, Edward/AAP-5381-2021; Horsman, Geoff/AAQ-2349-2020	Eltis, Lindsay D/0000-0002-6774-8158; Lowe, Edward/0000-0002-1757-0208; Horsman, Geoff/0000-0002-2023-2349	Wellcome Trust; Canadian Institutes of Health Research; Natural Sciences and Engineering Research Council of Canada; Michael Smith Foundation for Health Research; Medical Research Council [G0802079] Funding Source: researchfish; MRC [G0802079] Funding Source: UKRI	Wellcome Trust(Wellcome TrustEuropean Commission); Canadian Institutes of Health Research(Canadian Institutes of Health Research (CIHR)); Natural Sciences and Engineering Research Council of Canada(Natural Sciences and Engineering Research Council of Canada (NSERC)CGIAR); Michael Smith Foundation for Health Research(Michael Smith Foundation for Health Research); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))	This work was supported by grants from the Wellcome Trust (to E. S.) and the Canadian Institutes of Health Research (to L. D. E.).; Recipient of a studentship from the Natural Sciences and Engineering Research Council of Canada.; Recipient of studentships from the Natural Sciences and Engineering Research Council and the Michael Smith Foundation for Health Research.	Adams PD, 2002, ACTA CRYSTALLOGR D, V58, P1948, DOI 10.1107/S0907444902016657; Bhowmik S, 2007, J BIOL CHEM, V282, P36377, DOI 10.1074/jbc.M707035200; BRADY L, 1990, NATURE, V343, P767, DOI 10.1038/343767a0; Capyk JK, 2009, J BIOL CHEM, V284, P9937, DOI 10.1074/jbc.M900719200; Cornish-Bowden A., 1995, ANAL ENZYME KINETIC; Davis IW, 2007, NUCLEIC ACIDS RES, V35, pW375, DOI 10.1093/nar/gkm216; DeLano W.L., 2002, PYMOL MOL GRAPHICS S; DEREWENDA U, 1992, BIOCHEMISTRY-US, V31, P1532, DOI 10.1021/bi00120a034; Dunn G, 2005, J MOL BIOL, V346, P253, DOI 10.1016/j.jmb.2004.11.033; Dye C, 2006, LANCET, V367, P938, DOI 10.1016/S0140-6736(06)68384-0; Emsley P, 2004, ACTA CRYSTALLOGR D, V60, P2126, DOI 10.1107/S0907444904019158; ERMAN JE, 1980, J BIOL CHEM, V255, P6224; Fleming SM, 2000, BIOCHEMISTRY-US, V39, P1522, DOI 10.1021/bi9923095; Gruber K, 2004, J BIOL CHEM, V279, P20501, DOI 10.1074/jbc.M401575200; Horinouchi M, 2003, APPL ENVIRON MICROB, V69, P4421, DOI 10.1128/AEM.69.8.4421-4430.2003; Horsman GP, 2007, J BIOL CHEM, V282, P19894, DOI 10.1074/jbc.M702237200; Horsman GP, 2006, BIOCHEMISTRY-US, V45, P11071, DOI 10.1021/bi0611098; Hu JGG, 1997, BIOCHEMISTRY-US, V36, P9316, DOI 10.1021/bi970416y; Hunter RL, 2006, AM J PATHOL, V168, P1249, DOI 10.2353/ajpath.2006.050848; Lack N, 2008, ACTA CRYSTALLOGR F, V64, P2, DOI 10.1107/S1744309107065931; Lack NA, 2009, BIOCHEM J, V418, P369, DOI 10.1042/BJ20082011; Lam WWY, 1997, BIOCHEMISTRY-US, V36, P12242, DOI 10.1021/bi971115r; Lanyi JK, 2007, J MOL BIOL, V365, P1379, DOI 10.1016/j.jmb.2006.11.016; Leslie AGW, 1992, JOINT CCP4 ESF EAMCB, V26; Li C, 2005, J MOL BIOL, V346, P241, DOI 10.1016/j.jmb.2004.11.032; Li C, 2008, CHEMBIOCHEM, V9, P71, DOI 10.1002/cbic.200700428; Li JJ, 2007, ORG BIOMOL CHEM, V5, P507, DOI 10.1039/b615605c; Li JJ, 2006, BIOCHEMISTRY-US, V45, P12461, DOI 10.1021/bi0612519; Nandhagopal N, 2001, J MOL BIOL, V309, P1139, DOI 10.1006/jmbi.2001.4737; Nerdinger S, 2007, J ORG CHEM, V72, P5960, DOI 10.1021/jo062543i; OLLIS DL, 1992, PROTEIN ENG, V5, P197, DOI 10.1093/protein/5.3.197; Pagel W, 1925, VIRCHOWS ARCH A, V256, P629, DOI 10.1007/BF01891650; Pandey AK, 2008, P NATL ACAD SCI USA, V105, P4376, DOI 10.1073/pnas.0711159105; Rengarajan J, 2005, P NATL ACAD SCI USA, V102, P8327, DOI 10.1073/pnas.0503272102; Schnappinger D, 2003, J EXP MED, V198, P693, DOI 10.1084/jem.20030846; Seah SYK, 2007, J BACTERIOL, V189, P4038, DOI 10.1128/JB.01950-06; Seah SYK, 2000, J BIOL CHEM, V275, P15701, DOI 10.1074/jbc.275.21.15701; SOBEL H, 1949, J BACTERIOL, V57, P377, DOI 10.1128/JB.57.3.377-382.1949; VAGIN AA, 1994, ACTA CRYSTALLOGR D, V50, P760; Van der Geize R, 2007, P NATL ACAD SCI USA, V104, P1947, DOI 10.1073/pnas.0605728104; Williams DH., 1995, SPECTROSCOPIC METHOD, P63; Yam KC, 2009, PLOS PATHOG, V5, DOI 10.1371/journal.ppat.1000344	42	77	82	0	21	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 1	2010	285	1					434	443		10.1074/jbc.M109.058081	http://dx.doi.org/10.1074/jbc.M109.058081			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	536UT	19875455	Green Published, hybrid			2022-12-25	WOS:000273070100045
J	Qiu, LY; Pashkova, N; Walker, JR; Winistorfer, S; Allali-Hassani, A; Akutsu, M; Piper, R; Dhe-Paganon, S				Qiu, Liyan; Pashkova, Natasha; Walker, John R.; Winistorfer, Stanley; Allali-Hassani, Abdellah; Akutsu, Masato; Piper, Robert; Dhe-Paganon, Sirano			Structure and Function of the PLAA/Ufd3-p97/Cdc48 Complex	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SACCHAROMYCES-CEREVISIAE; UBIQUITIN HOMEOSTASIS; PROTEIN; CDC48; P97; BINDING; YEAST; DEGRADATION; PATHWAY; DOA1	PLAA (ortholog of yeast Doa1/Ufd3, also know as human PLAP or phospholipase A2-activating protein) has been implicated in a variety of disparate biological processes that involve the ubiquitin system. It is linked to the maintenance of ubiquitin levels, but the mechanism by which it accomplishes this is unclear. The C-terminal PUL (PLAP, Ufd3p, and Lub1p) domain of PLAA binds p97, an AAA ATPase, which among other functions helps transfer ubiquitinated proteins to the proteasome for degradation. In yeast, loss of Doa1 is suppressed by altering p97/Cdc48 function indicating that physical interaction between PLAA and p97 is functionally important. Although the overall regions of interaction between these proteins are known, the structural basis has been unavailable. We solved the high resolution crystal structure of the p97-PLAA complex showing that the PUL domain forms a 6-mer Armadillo-containing domain. Its N-terminal extension folds back onto the inner curvature forming a deep ridge that is positively charged with residues that are phylogenetically conserved. The C terminus of p97 binds in this ridge, where the side chain of p97-Tyr(805), implicated in phosphorylation-dependent regulation, is buried. Expressed in doa1 Delta null cells, point mutants of the yeast ortholog Doa1 that disrupt this interaction display slightly reduced ubiquitin levels, but unlike doa1 Delta null cells, showed only some of the growth phenotypes. These data suggest that the p97-PLAA interaction is important for a subset of PLAA-dependent biological processes and provides a framework to better understand the role of these complex molecules in the ubiquitin system.	[Pashkova, Natasha; Winistorfer, Stanley; Piper, Robert] Univ Iowa, Dept Mol Physiol & Biophys, Iowa City, IA 52242 USA; [Qiu, Liyan; Walker, John R.; Allali-Hassani, Abdellah; Akutsu, Masato; Dhe-Paganon, Sirano] Univ Toronto, Struct Genom Consortium, Toronto, ON M5G 1L7, Canada; [Qiu, Liyan; Akutsu, Masato; Dhe-Paganon, Sirano] Univ Toronto, Dept Physiol, Toronto, ON M5G 1L7, Canada	University of Iowa; University of Toronto; Structural Genomics Consortium; University of Toronto	Piper, R (corresponding author), Univ Iowa, Dept Mol Physiol & Biophys, Iowa City, IA 52242 USA.	robert-piper@uiowa.edu; sirano.dhepaganon@utoronto.ca	akutsu, masato/L-4095-2016	akutsu, masato/0000-0002-9839-3345; Piper, Robert/0000-0001-9995-5699; Pashkova, Natalya/0000-0002-2191-4683; /0000-0002-5255-895X	National Institutes of Health [RO1 GM58202]; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM058202] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	This work was supported, in whole or in part, by National Institutes of Health Grant RO1 GM58202 (to R. C. P.).	Allen MD, 2006, J BIOL CHEM, V281, P25502, DOI 10.1074/jbc.M601173200; Brandina I, 2007, FEBS LETT, V581, P4248, DOI 10.1016/j.febslet.2007.08.013; CLARK MA, 1991, P NATL ACAD SCI USA, V88, P5418, DOI 10.1073/pnas.88.12.5418; Davis IW, 2004, NUCLEIC ACIDS RES, V32, pW615, DOI 10.1093/nar/gkh398; EGERTON M, 1992, EMBO J, V11, P3533, DOI 10.1002/j.1460-2075.1992.tb05436.x; Emsley P, 2004, ACTA CRYSTALLOGR D, V60, P2126, DOI 10.1107/S0907444904019158; Ghislain M, 1996, EMBO J, V15, P4884, DOI 10.1002/j.1460-2075.1996.tb00869.x; Hatzfeld M, 1999, INT REV CYTOL, V186, P179; Holm L, 2008, BIOINFORMATICS, V24, P2780, DOI 10.1093/bioinformatics/btn507; Iyer LM, 2004, CELL CYCLE, V3, P1440, DOI 10.4161/cc.3.11.1206; Jentsch S, 2007, TRENDS BIOCHEM SCI, V32, P6, DOI 10.1016/j.tibs.2006.11.005; JOHNSON ES, 1995, J BIOL CHEM, V270, P17442, DOI 10.1074/jbc.270.29.17442; Kunze D, 2007, MICROBIOL-SGM, V153, P1026, DOI 10.1099/mic.0.2006/002741-0; Li GT, 2008, BIOCHEM BIOPH RES CO, V375, P247, DOI 10.1016/j.bbrc.2008.08.018; Lis ET, 2006, MOL CELL BIOL, V26, P4122, DOI 10.1128/MCB.01640-05; Longtine MS, 1998, YEAST, V14, P953, DOI 10.1002/(SICI)1097-0061(199807)14:10<953::AID-YEA293>3.3.CO;2-L; Madsen L, 2009, INT J BIOCHEM CELL B, V41, P2380, DOI 10.1016/j.biocel.2009.05.017; Mullally JE, 2006, MOL CELL BIOL, V26, P822, DOI 10.1128/MCB.26.3.822-830.2006; Murshudov GN, 1997, ACTA CRYSTALLOGR D, V53, P240, DOI 10.1107/S0907444996012255; Ogiso Y, 2004, MOL CELL BIOL, V24, P2324, DOI 10.1128/MCB.24.6.2324-2331.2004; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Painter J, 2006, J APPL CRYSTALLOGR, V39, P109, DOI 10.1107/S0021889805038987; Ren JH, 2008, J BIOL CHEM, V283, P21599, DOI 10.1074/jbc.M802982200; Ribardo DA, 2002, TOXICON, V40, P519, DOI 10.1016/S0041-0101(01)00247-1; Rumpf S, 2006, MOL CELL, V21, P261, DOI 10.1016/j.molcel.2005.12.014; Russell NS, 2004, BIOCHEMISTRY-US, V43, P4844, DOI 10.1021/bi035626r; Shcherbik N, 2007, MOL CELL, V25, P385, DOI 10.1016/j.molcel.2007.01.024; Terwilliger TC, 1999, ACTA CRYSTALLOGR D, V55, P849, DOI 10.1107/S0907444999000839; Terwilliger TC, 2003, ACTA CRYSTALLOGR D, V59, P38, DOI 10.1107/S0907444902018036; Tu D, 2007, P NATL ACAD SCI USA, V104, P15599, DOI 10.1073/pnas.0701369104; Wolfe D, 1999, MOL CELL BIOL, V19, P8254; Yeung HO, 2008, BIOCHEM SOC T, V36, P62, DOI 10.1042/BST0360062; Zhao G, 2007, P NATL ACAD SCI USA, V104, P8785, DOI 10.1073/pnas.0702966104; Zhao G, 2009, P NATL ACAD SCI USA, V106, P16197, DOI 10.1073/pnas.0908321106	34	23	25	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 1	2010	285	1					365	372		10.1074/jbc.M109.044685	http://dx.doi.org/10.1074/jbc.M109.044685			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	536UT	19887378	Green Published, hybrid			2022-12-25	WOS:000273070100038
J	South, PF; Fingerman, IM; Mersman, DP; Du, HN; Briggs, SD				South, Paul F.; Fingerman, Ian M.; Mersman, Douglas P.; Du, Hai-Ning; Briggs, Scott D.			A Conserved Interaction between the SDI Domain of Bre2 and the Dpy-30 Domain of Sdc1 Is Required for Histone Methylation and Gene Expression	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							H3-LYS(4) METHYLTRANSFERASE COMPLEX; ELEGANS DOSAGE COMPENSATION; CXXC FINGER PROTEIN-1; C-TERMINAL DOMAIN; SACCHAROMYCES-CEREVISIAE; LYSINE-4 METHYLATION; MOLECULAR REGULATION; H3K4 TRIMETHYLATION; ESSENTIAL COMPONENT; TRITHORAX FAMILY	In Saccharomyces cerevisiae, lysine 4 on histone H3 (H3K4) is methylated by the Set1 complex (Set1C or COMPASS). Besides the catalytic Set1 subunit, several proteins that form the Set1C (Swd1, Swd2, Swd3, Spp1, Bre2, and Sdc1) are also needed to mediate proper H3K4 methylation. Until this study, it has been unclear how individual Set1C members interact and how this interaction may impact histone methylation and gene expression. In this study, Bre2 and Sdc1 are shown to directly interact, and it is shown that the association of this heteromeric complex is needed for proper H3K4 methylation and gene expression to occur. Interestingly, mutational and biochemical analysis identified the C terminus of Bre2 as a critical protein-protein interaction domain that binds to the Dpy-30 domain of Sdc1. Using the human homologs of Bre2 and Sdc1, ASH2L and DPY-30, respectively, we demonstrate that the C terminus of ASH2L also interacts with the Dpy-30 domain of DPY-30, suggesting that this protein-protein interaction is maintained from yeast to humans. Because of the functionally conserved nature of the C terminus of Bre2 and ASH2L, this region was named the SDI (Sdc1 Dpy-30 interaction) domain. Finally, we show that the SDI-Dpy-30 domain interaction is physiologically important for the function of Set1 in vivo, because specific disruption of this interaction prevents Bre2 and Sdc1 association with Set1, resulting in H3K4 methylation defects and decreases in gene expression. Overall, these and other mechanistic studies on how H3K4 methyltransferase complexes function will likely provide insights into how human MLL and SET1-like complexes or overexpression of ASH2L leads to oncogenesis.	[Briggs, Scott D.] Purdue Univ, Dept Biochem, W Lafayette, IN 47907 USA; Purdue Univ, Ctr Canc Res, W Lafayette, IN 47907 USA	Purdue University System; Purdue University; Purdue University West Lafayette Campus; Purdue University System; Purdue University; Purdue University West Lafayette Campus	Briggs, SD (corresponding author), Purdue Univ, Dept Biochem, 175 S Univ, W Lafayette, IN 47907 USA.	sdbriggs@purdue.edu	South, Paul/AAG-2634-2020; du, hai-ning/AAE-5626-2022; South, Paul/H-2636-2017; Du, Hai-Ning/AAI-2020-2021	South, Paul/0000-0001-7885-7096; South, Paul/0000-0001-7885-7096; Du, Hai-Ning/0000-0001-8062-5411; Briggs, Scott D/0000-0003-2852-3594	National Institutes of Health [GM74183]; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM074183] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	This work was supported, in whole or in part, by National Institutes of Health Grant GM74183 (to S. D. B.).	Boa S, 2003, YEAST, V20, P827, DOI 10.1002/yea.995; Brehm A, 2004, BIOESSAYS, V26, P133, DOI 10.1002/bies.10392; Briggs SD, 2001, GENE DEV, V15, P3286, DOI 10.1101/gad.940201; Bryk M, 2002, CURR BIOL, V12, P165, DOI 10.1016/S0960-9822(01)00652-2; Carvin CD, 2004, J BIOL CHEM, V279, P33057, DOI 10.1074/jbc.M405033200; Cho YW, 2007, J BIOL CHEM, V282, P20395, DOI 10.1074/jbc.M701574200; Cui Y, 2008, MOL GENET GENOMICS, V279, P323, DOI 10.1007/s00438-007-0314-1; Dehe PM, 2006, BIOCHEM CELL BIOL, V84, P536, DOI 10.1139/O06-081; Dehe PM, 2006, J BIOL CHEM, V281, P35404, DOI 10.1074/jbc.M603099200; Demers C, 2007, MOL CELL, V27, P573, DOI 10.1016/j.molcel.2007.06.022; Dong XH, 2005, BBA-PROTEINS PROTEOM, V1753, P257, DOI 10.1016/j.bbapap.2005.08.011; Dou YL, 2006, NAT STRUCT MOL BIOL, V13, P713, DOI 10.1038/nsmb1128; Dou YL, 2005, CELL, V121, P873, DOI 10.1016/j.cell.2005.04.031; Du HN, 2008, GENE DEV, V22, P2786, DOI 10.1101/gad.1700008; Fingerman IM, 2007, GENE DEV, V21, P2018, DOI 10.1101/gad.1560607; Fingerman IM, 2005, J BIOL CHEM, V280, P28761, DOI 10.1074/jbc.C500097200; Gold MG, 2006, MOL CELL, V24, P383, DOI 10.1016/j.molcel.2006.09.006; HSU DR, 1995, DEVELOPMENT, V121, P3323; HSU DR, 1994, GENETICS, V137, P999; Hughes CM, 2004, MOL CELL, V13, P587, DOI 10.1016/S1097-2765(04)00081-4; Kelley LA, 2009, NAT PROTOC, V4, P363, DOI 10.1038/nprot.2009.2; Kinderman FS, 2006, MOL CELL, V24, P397, DOI 10.1016/j.molcel.2006.09.015; Krogan NJ, 2003, MOL CELL, V11, P721, DOI 10.1016/S1097-2765(03)00091-1; Krogan NJ, 2002, J BIOL CHEM, V277, P10753, DOI 10.1074/jbc.C200023200; Lee JH, 2008, MOL CELL BIOL, V28, P609, DOI 10.1128/MCB.01356-07; Lee JH, 2007, J BIOL CHEM, V282, P13419, DOI 10.1074/jbc.M609809200; Lee JH, 2005, J BIOL CHEM, V280, P41725, DOI 10.1074/jbc.M508312200; Luscher-Firzlaff J, 2008, CANCER RES, V68, P749, DOI 10.1158/0008-5472.CAN-07-3158; Mellor J, 2006, CELL, V126, P22, DOI 10.1016/j.cell.2006.06.028; Mersman DP, 2009, GENE DEV, V23, P951, DOI 10.1101/gad.1769209; Miller T, 2001, P NATL ACAD SCI USA, V98, P12902, DOI 10.1073/pnas.231473398; Morikis D, 2002, EUR J BIOCHEM, V269, P2040, DOI 10.1046/j.1432-1033.2002.02852.x; Mueller JE, 2006, GENETICS, V173, P557, DOI 10.1534/genetics.106.055400; Nagy PL, 2002, P NATL ACAD SCI USA, V99, P90, DOI 10.1073/pnas.221596698; Nakamura T, 2002, MOL CELL, V10, P1119, DOI 10.1016/S1097-2765(02)00740-2; Ng HH, 2003, MOL CELL, V11, P709, DOI 10.1016/S1097-2765(03)00092-3; Nislow C, 1997, MOL BIOL CELL, V8, P2421, DOI 10.1091/mbc.8.12.2421; Patel A, 2008, J BIOL CHEM, V283, P32162, DOI 10.1074/jbc.M806317200; Patel A, 2008, J BIOL CHEM, V283, P32158, DOI 10.1074/jbc.C800164200; Ponting C, 1997, TRENDS BIOCHEM SCI, V22, P193, DOI 10.1016/S0968-0004(97)01049-9; Roguev A, 2001, EMBO J, V20, P7137, DOI 10.1093/emboj/20.24.7137; Santos-Rosa H, 2002, NATURE, V419, P407, DOI 10.1038/nature01080; Schneider J, 2005, MOL CELL, V19, P849, DOI 10.1016/j.molcel.2005.07.024; Shilatifard A, 2008, CURR OPIN CELL BIOL, V20, P341, DOI 10.1016/j.ceb.2008.03.019; Simonet T, 2007, DEV BIOL, V312, P367, DOI 10.1016/j.ydbio.2007.09.035; Southall SM, 2009, MOL CELL, V33, P181, DOI 10.1016/j.molcel.2008.12.029; Steward MM, 2006, NAT STRUCT MOL BIOL, V13, P852, DOI 10.1038/nsmb1131; Subramaniam S, 1998, PROTEINS, V32, P1; Tate CM, 2009, MOL CELL BIOL, V29, P3817, DOI 10.1128/MCB.00243-09; Taverna SD, 2007, NAT STRUCT MOL BIOL, V14, P1025, DOI 10.1038/nsmb1338; Venkatasubrahmanyam S, 2007, P NATL ACAD SCI USA, V104, P16609, DOI 10.1073/pnas.0700914104; Wang XP, 2009, J MOL BIOL, V390, P530, DOI 10.1016/j.jmb.2009.05.061; Woo JS, 2006, MOL CELL, V24, P967, DOI 10.1016/j.molcel.2006.11.009; Woo JS, 2006, EMBO J, V25, P1353, DOI 10.1038/sj.emboj.7600994; Wu M, 2008, MOL CELL BIOL, V28, P7337, DOI 10.1128/MCB.00976-08; Wysocka J, 2003, GENE DEV, V17, P896, DOI 10.1101/gad.252103; Yokoyama A, 2004, MOL CELL BIOL, V24, P5639, DOI 10.1128/MCB.24.13.5639-5649.2004	57	37	42	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 1	2010	285	1					595	607		10.1074/jbc.M109.042697	http://dx.doi.org/10.1074/jbc.M109.042697			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	536UT	19897479	Green Published, hybrid			2022-12-25	WOS:000273070100061
J	Chomiak, T; Hu, B				Chomiak, Taylor; Hu, Bin			What Is the Optimal Value of the g-Ratio for Myelinated Fibers in the Rat CNS? A Theoretical Approach	PLOS ONE			English	Article							CENTRAL-NERVOUS-SYSTEM; SQUID GIANT-AXON; WHITE-MATTER; SHEATH THICKNESS; NEURONAL MORPHOLOGY; CEREBRAL-CORTEX; SURAL NERVE; CONDUCTION; REMYELINATION; OLIGODENDROCYTES	Background: The biological process underlying axonal myelination is complex and often prone to injury and disease. The ratio of the inner axonal diameter to the total outer diameter or g-ratio is widely utilized as a functional and structural index of optimal axonal myelination. Based on the speed of fiber conduction, Rushton was the first to derive a theoretical estimate of the optimal g-ratio of 0.6 [1]. This theoretical limit nicely explains the experimental data for myelinated axons obtained for some peripheral fibers but appears significantly lower than that found for CNS fibers. This is, however, hardly surprising given that in the CNS, axonal myelination must achieve multiple goals including reducing conduction delays, promoting conduction fidelity, lowering energy costs, and saving space. Methodology/Principal Findings: In this study we explore the notion that a balanced set-point can be achieved at a functional level as the micro-structure of individual axons becomes optimized, particularly for the central system where axons tend to be smaller and their myelin sheath thinner. We used an intuitive yet novel theoretical approach based on the fundamental biophysical properties describing axonal structure and function to show that an optimal g-ratio can be defined for the central nervous system (approximate to 0.77). Furthermore, by reducing the influence of volume constraints on structural design by about 40%, this approach can also predict the g-ratio observed in some peripheral fibers (approximate to 0.6). Conclusions/Significance: These results support the notion of optimization theory in nervous system design and construction and may also help explain why the central and peripheral systems have evolved different g-ratios as a result of volume constraints.			Chomiak, T (corresponding author), Univ Calgary, Dept Clin Neurosci, Calgary, AB, Canada.	tgchomia@ucalgary.ca			Canadian Institutes of Health Research Funding Source: Medline	Canadian Institutes of Health Research(Canadian Institutes of Health Research (CIHR))		ADAM A, 1988, ANAT EMBRYOL, V178, P537, DOI 10.1007/BF00305041; Arnett HA, 2001, NAT NEUROSCI, V4, P1116, DOI 10.1038/nn738; Attwell D, 2001, J CEREBR BLOOD F MET, V21, P1133, DOI 10.1097/00004647-200110000-00001; AWISZUS F, 1990, BIOL CYBERN, V64, P69, DOI 10.1007/BF00203632; Balabanov R, 2006, J NEUROSCI, V26, P5143, DOI 10.1523/JNEUROSCI.0737-06.2006; Barkovich AJ, 2000, AM J NEURORADIOL, V21, P1099; Benninger Y, 2006, J NEUROSCI, V26, P7665, DOI 10.1523/JNEUROSCI.0444-06.2006; BLAKEMORE WF, 1973, J NEUROL SCI, V20, P73, DOI 10.1016/0022-510X(73)90119-6; BLAKEMORE WF, 1974, NATURE, V249, P577, DOI 10.1038/249577a0; BLIGHT AR, 1985, NEUROSCIENCE, V15, P13, DOI 10.1016/0306-4522(85)90119-8; BLIGHT AR, 1985, NEUROSCIENCE, V15, P1, DOI 10.1016/0306-4522(85)90118-6; BOSTOCK H, 1978, J PHYSIOL-LONDON, V280, P273, DOI 10.1113/jphysiol.1978.sp012384; Brosamle C, 2000, J NEUROCYTOL, V29, P499, DOI 10.1023/A:1007297712821; Chau WK, 2000, RESTOR NEUROL NEUROS, V16, P105; Cherniak C, 1999, PHYS REV E, V59, P6001, DOI 10.1103/PhysRevE.59.6001; Cherniak C, 2004, P NATL ACAD SCI USA, V101, P1081, DOI 10.1073/pnas.0305212101; CHERNIAK C, 1995, TRENDS NEUROSCI, V18, P522, DOI 10.1016/0166-2236(95)98373-7; Chklovskii DB, 2002, NEURON, V34, P341, DOI 10.1016/S0896-6273(02)00679-7; Chklovskii DB, 2004, NEURON, V43, P609, DOI 10.1016/j.neuron.2004.08.012; Chklovskii DB, 2004, ANNU REV NEUROSCI, V27, P369, DOI 10.1146/annurev.neuro.27.070203.144226; Chomiak T, 2008, J NEUROPHYSIOL, V100, P327, DOI 10.1152/jn.90392.2008; Chomiak T, 2007, J PHYSIOL-LONDON, V579, P403, DOI 10.1113/jphysiol.2006.124057; Cole KS, 1939, J GEN PHYSIOL, V22, P671, DOI 10.1085/jgp.22.5.671; Curtis HJ, 1938, J GEN PHYSIOL, V21, P757, DOI 10.1085/jgp.21.6.757; DELORENZO AJ, 1956, ANAT REC, V124, P328; EHRLICH D, 1985, CELL TISSUE RES, V239, P661; Elder GA, 2001, J NEUROSCI RES, V65, P493, DOI 10.1002/jnr.1179; FAHRENKAMP I, 1987, ANAT EMBRYOL, V177, P115, DOI 10.1007/BF00572535; FERNANDEZMORAN H, 1959, REV MOD PHYS, V31, P319, DOI 10.1103/RevModPhys.31.319; FRAHER JP, 1992, J COMP NEUROL, V323, P551, DOI 10.1002/cne.903230407; GOLDMAN L, 1968, BIOPHYS J, V8, P596, DOI 10.1016/S0006-3495(68)86510-5; Grandis M, 2004, EXP NEUROL, V190, P213, DOI 10.1016/j.expneurol.2004.07.008; GUY J, 1989, J COMP NEUROL, V287, P446, DOI 10.1002/cne.902870404; Hamilton N, 2008, GLIA, V56, P734, DOI 10.1002/glia.20649; Ishibashi T, 2006, NEURON, V49, P823, DOI 10.1016/j.neuron.2006.02.006; Jeronimo A, 2005, J ANAT, V206, P93, DOI 10.1111/j.0021-8782.2005.00368.x; KERNS JM, 1980, J COMP NEUROL, V189, P291, DOI 10.1002/cne.901890206; Klopfleisch S, 2008, J NEUROSCI, V28, P13609, DOI 10.1523/JNEUROSCI.2765-08.2008; KOESTER J, 2000, PRINCIPLES NEURAL SC, P140; Kukley M, 2007, NAT NEUROSCI, V10, P311, DOI 10.1038/nn1850; Laughlin SB, 2003, SCIENCE, V301, P1870, DOI 10.1126/science.1089662; Laughlin SB, 1998, NAT NEUROSCI, V1, P36, DOI 10.1038/236; Lennie P, 2003, CURR BIOL, V13, P493, DOI 10.1016/S0960-9822(03)00135-0; Malik RA, 2005, DIABETOLOGIA, V48, P578, DOI 10.1007/s00125-004-1663-5; Mason JL, 2001, NEUROPATH APPL NEURO, V27, P50, DOI 10.1046/j.0305-1846.2001.00301.x; Merkler D, 2005, NMR BIOMED, V18, P395, DOI 10.1002/nbm.972; Michailov GV, 2004, SCIENCE, V304, P700, DOI 10.1126/science.1095862; MITCHISON G, 1992, TRENDS NEUROSCI, V15, P122, DOI 10.1016/0166-2236(92)90352-9; MOORE JW, 1978, BIOPHYS J, V21, P147, DOI 10.1016/S0006-3495(78)85515-5; Paus T, 2009, FRONT NEUROANAT, V3, DOI 10.3389/neuro.05.014.2009; Perge JA, 2009, J NEUROSCI, V29, P7917, DOI 10.1523/JNEUROSCI.5200-08.2009; Perrot R, 2007, J NEUROSCI, V27, P9573, DOI 10.1523/JNEUROSCI.1224-07.2007; QUARLES RH, 1978, J NEUROBIOL, V9, P217, DOI 10.1002/neu.480090304; Ramon y Cajal S., 1899, TEXTURA SISTEMA NERV; RASMINSKY M, 1978, PHYSL PATHOBIOLOGY A, P361; RUSHTON WAH, 1951, J PHYSIOL-LONDON, V115, P101, DOI 10.1113/jphysiol.1951.sp004655; Salami M, 2003, P NATL ACAD SCI USA, V100, P6174, DOI 10.1073/pnas.0937380100; Shepherd GM, 1999, FUNDAMENTAL NEUROSCI, P107; SMITH RS, 1970, AM J PHYSIOL, V219, P1256, DOI 10.1152/ajplegacy.1970.219.5.1256; Sporkel O, 2002, GLIA, V37, P19, DOI 10.1002/glia.10014; SPRUSTON N, 1994, TRENDS NEUROSCI, V17, P161, DOI 10.1016/0166-2236(94)90094-9; TASAKI I, 1955, AM J PHYSIOL, V181, P639, DOI 10.1152/ajplegacy.1955.181.3.639; THOMAS PK, 1990, ACTA NEUROPATHOL, V79, P375, DOI 10.1007/BF00308713; Wallace VCJ, 2003, J NEUROSCI, V23, P3221; Wang SSH, 2008, J NEUROSCI, V28, P4047, DOI 10.1523/JNEUROSCI.5559-05.2008; WAXMAN SG, 1972, NATURE-NEW BIOL, V238, P217, DOI 10.1038/newbio238217a0; WAXMAN SG, 1976, EXP NEUROL, V53, P115, DOI 10.1016/0014-4886(76)90287-9; WAXMAN SG, 1978, PHYSL PATHOBIOLOGY A, P169; Wen Q, 2008, J NEUROPHYSIOL, V99, P2320, DOI 10.1152/jn.00280.2007; Wen Q, 2005, PLOS COMPUT BIOL, V1, P617, DOI 10.1371/journal.pcbi.0010078; Zhang K, 2000, P NATL ACAD SCI USA, V97, P5621, DOI 10.1073/pnas.090504197	71	268	271	1	22	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	NOV 13	2009	4	11							e7754	10.1371/journal.pone.0007754	http://dx.doi.org/10.1371/journal.pone.0007754			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	518VB	19915661	Green Submitted, gold, Green Published			2022-12-25	WOS:000271721900001
J	Aghokeng, AF; Mpoudi-Ngole, E; Dimodi, H; Atem-Tambe, A; Tongo, M; Butel, C; Delaporte, E; Peeters, M				Aghokeng, Avelin F.; Mpoudi-Ngole, Eitel; Dimodi, Henriette; Atem-Tambe, Arrah; Tongo, Marcel; Butel, Christelle; Delaporte, Eric; Peeters, Martine			Inaccurate Diagnosis of HIV-1 Group M and O Is a Key Challenge for Ongoing Universal Access to Antiretroviral Treatment and HIV Prevention in Cameroon	PLOS ONE			English	Article							GENETIC DIVERSITY; INFECTION; ASSAYS; IDENTIFICATION; CHIMPANZEES; REDUCTION; ALGORITHM; STRATEGY; WINDOW	Background: Increased access to HIV testing is essential in working towards universal access to HIV prevention and treatment in resource-limited countries. We here evaluated currently used HIV diagnostic tests and algorithms in Cameroon for their ability to correctly identify HIV infections. Methods: We estimated sensitivity, specificity, and positive and negative predictive values of 5 rapid/simple tests, of which 3 were used by the national program, and 2 fourth generation ELISAs. The reference panel included 500 locally collected samples; 187 HIV-1 M, 10 HIV-1 O, 259 HIV negative and 44 HIV indeterminate plasmas. Results: None of the 5 rapid assays and only 1 ELISA reached the current WHO/UNAIDS recommendations on performance of HIV tests of at least 99% sensitivity and 98% specificity. Overall, sensitivities ranged between 94.1% and 100%, while specificities were 88.0% to 98.8%. The combination of all assays generated up to 9% of samples with indeterminate HIV status, because they reacted discordantly with at least one of the different tests. Including HIV indeterminate samples in test efficiency calculations significantly decreased specificities to a range from 77.9% to 98.0%. Finally, two rapid assays failed to detect all HIV-1 group O variants tested, with one rapid test detecting only 2 out of 10 group O specimens. Conclusion: In the era of ART scaling-up in Africa, significant proportions of false positive but also false negative results are still observed with HIV screening tests commonly used in Africa, resulting in inadequate treatment and prevention strategies. Depending on tests or algorithms used, up to 6% of HIV-1 M and 80% of HIV-1 O infected patients in Cameroon do not receive ART and adequate counseling to prevent further transmission due to low sensitivities. Also, the use of tests with low specificities could imply inclusion of up to 12% HIV negative people in ART programs and increase budgets in addition to inconveniences caused to patients.			Aghokeng, AF (corresponding author), IRD, Virol Lab IMPM, Yaounde, Cameroon.	aghokeng@ird.fr	Delaporte, Eric/J-5397-2018; Tongo, Marcel/AAB-4155-2019	Delaporte, Eric/0000-0002-1822-9853; Tongo, Marcel/0000-0002-5262-892X; AGHOKENG FOBANG, Avelin/0000-0002-1414-0237				Aghokeng AF, 2004, JAIDS-J ACQ IMM DEF, V37, P1632, DOI 10.1097/00126334-200412150-00018; [Anonymous], 2007, MANUAL ESTIMATING NA; Apetrei C, 1996, AIDS, V10, pF57, DOI 10.1097/00002030-199612000-00002; Ayouba A, 2001, EMERG INFECT DIS, V7, P466, DOI 10.3201/eid0703.017321; Constantine NT, 2005, INDIAN J MED RES, V121, P519; Corcoran C, 2008, CLIN INFECT DIS, V46, DOI 10.1086/524892; FRANSEN K, 1994, MOL CELL PROBE, V8, P317, DOI 10.1006/mcpr.1994.1043; Gautheret-Dejean A, 2008, CLIN INFECT DIS, V46, P1936, DOI 10.1086/588561; Granich RM, 2009, LANCET, V373, P48, DOI 10.1016/S0140-6736(08)61697-9; Gurtler L, 1998, J VIROL METHODS, V75, P27, DOI 10.1016/S0166-0934(98)00094-9; Klarkowski DB, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0004351; LOUSSERTAJAKA I, 1994, LANCET, V343, P1393, DOI 10.1016/S0140-6736(94)92524-0; Mahe C, 2002, INT J EPIDEMIOL, V31, P985, DOI 10.1093/ije/31.5.985; Mfinanga G S, 2007, Tanzan Health Res Bull, V9, P44; Novitsky V, 2007, CLIN INFECT DIS, V45, pE68, DOI 10.1086/520683; Rouet F, 2004, J CLIN MICROBIOL, V42, P4147, DOI 10.1128/JCM.42.9.4147-4153.2004; Simon F, 2001, AIDS RES HUM RETROV, V17, P937, DOI 10.1089/088922201750290050; Simon F, 1998, NAT MED, V4, P1032, DOI 10.1038/2017; *UNAIDS, 2008, CAM COUNTR PROGR REP; Urassa W, 2002, J VIROL METHODS, V100, P115, DOI 10.1016/S0166-0934(01)00408-6; Van Heuverswyn F, 2007, VIROLOGY, V368, P155, DOI 10.1016/j.virol.2007.06.018; Vergne L, 2003, VIROLOGY, V310, P254, DOI 10.1016/S0042-6822(03)00167-3; Weber B, 1998, J CLIN MICROBIOL, V36, P2235, DOI 10.1128/JCM.36.8.2235-2239.1998; *WHO CDC, 2001, GUID APPR EV HIV TES; Yang CF, 2000, J INFECT DIS, V181, P1791, DOI 10.1086/315439	25	56	58	0	6	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	NOV 6	2009	4	11							e7702	10.1371/journal.pone.0007702	http://dx.doi.org/10.1371/journal.pone.0007702			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	515ND	19893738	Green Published, Green Submitted, gold			2022-12-25	WOS:000271478000004
J	Heron, J; Hanson, JVM; Whitaker, D				Heron, James; Hanson, James V. M.; Whitaker, David			Effect before Cause: Supramodal Recalibration of Sensorimotor Timing	PLOS ONE			English	Article							TEMPORAL-ORDER; MOTOR ADAPTATION; TIME PERCEPTION; SELF-AGENCY; SCHIZOPHRENIA; SIMULTANEITY; DISCRIMINATION; CONSEQUENCES; MECHANISMS; JUDGMENTS	Background: Our motor actions normally generate sensory events, but how do we know which events were self generated and which have external causes? Here we use temporal adaptation to investigate the processing stage and generality of our sensorimotor timing estimates. Methodology/Principal Findings: Adaptation to artificially-induced delays between action and event can produce a startling percept-upon removal of the delay it feels as if the sensory event precedes its causative action. This temporal recalibration of action and event occurs in a quantitatively similar manner across the sensory modalities. Critically, it is robust to the replacement of one sense during the adaptation phase with another sense during the test judgment. Conclusions/Significance: Our findings suggest a high-level, supramodal recalibration mechanism. The effects are well described by a simple model which attempts to preserve the expected synchrony between action and event, but only when causality indicates it is reasonable to do so. We further demonstrate that this model successfully characterises related adaptation data from outside the sensorimotor domain.			Heron, J (corresponding author), Univ Bradford, Bradford Sch Optometry & Vis Sci, Bradford BD7 1DP, W Yorkshire, England.	j.heron2@bradford.ac.uk	Heron, James/H-1792-2012	Heron, James/0000-0003-3857-5056	EPSRC [EP/F055986/1] Funding Source: UKRI; Engineering and Physical Sciences Research Council [EP/F055986/1] Funding Source: researchfish; Wellcome Trust Funding Source: Medline	EPSRC(UK Research & Innovation (UKRI)Engineering & Physical Sciences Research Council (EPSRC)); Engineering and Physical Sciences Research Council(UK Research & Innovation (UKRI)Engineering & Physical Sciences Research Council (EPSRC)); Wellcome Trust(Wellcome TrustEuropean Commission)		Asai T, 2008, PSYCHIAT CLIN NEUROS, V62, P115, DOI 10.1111/j.1440-1819.2007.01768.x; Asai T, 2007, J MOTOR BEHAV, V39, P162, DOI 10.3200/JMBR.39.3.162-168; Bays PM, 2005, CURR BIOL, V15, P1125, DOI 10.1016/j.cub.2005.05.023; Bays PM, 2006, PLOS BIOL, V4, P281, DOI 10.1371/journal.pbio.0040028; Bedford FL, 2001, CAH PSYCHOL COGN, V20, P113; Blakemore SJ, 1999, J COGNITIVE NEUROSCI, V11, P551, DOI 10.1162/089892999563607; Bueti D, 2008, J COGNITIVE NEUROSCI, V20, P1054, DOI 10.1162/jocn.2008.20060; Burr D, 2007, NAT NEUROSCI, V10, P423, DOI 10.1038/nn1874; Chen YQ, 2002, HUM MOVEMENT SCI, V21, P515, DOI 10.1016/S0167-9457(02)00138-0; Cunningham DW, 2001, PSYCHOL SCI, V12, P532, DOI 10.1111/1467-9280.d01-17; DeWeese M, 1998, NEURAL COMPUT, V10, P1179, DOI 10.1162/089976698300017403; Eagleman DM, 2002, TRENDS COGN SCI, V6, P323, DOI 10.1016/S1364-6613(02)01945-9; Engbert K, 2007, J EXP PSYCHOL HUMAN, V33, P1261, DOI 10.1037/0096-1523.33.6.1261; Fine MS, 2007, J NEUROPHYSIOL, V98, P1392, DOI 10.1152/jn.00196.2007; Franck N, 2001, AM J PSYCHIAT, V158, P454, DOI 10.1176/appi.ajp.158.3.454; Fujisaki W, 2004, NAT NEUROSCI, V7, P773, DOI 10.1038/nn1268; Haggard P, 2002, NAT NEUROSCI, V5, P382, DOI 10.1038/nn827; Hanson JVM, 2008, EXP BRAIN RES, V185, P347, DOI 10.1007/s00221-008-1282-3; Helson H, 1964, ADAPTATION LEVEL THE; Heron J, 2007, J VISION, V7, DOI 10.1167/7.13.5; IVRY R, 1995, HUMAN PERCEPTION PEF, V21, P3; Ivry RB, 2008, TRENDS COGN SCI, V12, P273, DOI 10.1016/j.tics.2008.04.002; Johnston A, 2006, CURR BIOL, V16, P472, DOI 10.1016/j.cub.2006.01.032; Karmarkar UR, 2007, NEURON, V53, P427, DOI 10.1016/j.neuron.2007.01.006; KEELE SW, 1985, B PSYCHONOMIC SOC, V273, P273; Kennedy JS, 2009, Q J EXP PSYCHOL, V62, P453, DOI 10.1080/17470210801985235; Kording K, 2007, SCIENCE, V318, P606, DOI 10.1126/science.1142998; Korenberg AT, 2002, CAH PSYCHOL COGN, V21, P537; Lindner A, 2005, CURR BIOL, V15, P1119, DOI 10.1016/j.cub.2005.05.049; Meegan DV, 2000, NAT NEUROSCI, V3, P860, DOI 10.1038/78757; Morrone MC, 2005, NAT NEUROSCI, V8, P950, DOI 10.1038/nn1488; Nagarajan SS, 1998, J NEUROSCI, V18, P1559; Pesavento MJ, 2006, EXP BRAIN RES, V174, P435, DOI 10.1007/s00221-006-0476-9; Sato Y, 2007, NEURAL COMPUT, V19, P3335, DOI 10.1162/neco.2007.19.12.3335; Schneider KA, 2003, COGNITIVE PSYCHOL, V47, P333, DOI 10.1016/S0010-0285(03)00035-5; Shergill SS, 2005, AM J PSYCHIAT, V162, P2384, DOI 10.1176/appi.ajp.162.12.2384; Spence C, 2001, PERCEPT PSYCHOPHYS, V63, P330, DOI 10.3758/BF03194473; Stetson C, 2006, NEURON, V51, P651, DOI 10.1016/j.neuron.2006.08.006; Synofzik M, 2008, CONSCIOUS COGN, V17, P219, DOI 10.1016/j.concog.2007.03.010; Terao M, 2008, NAT NEUROSCI, V11, P541, DOI 10.1038/nn.2111; van Eijk RLJ, 2008, PERCEPT PSYCHOPHYS, V70, P955, DOI 10.3758/PP.70.6.955; Vatakis A, 2008, EXP BRAIN RES, V185, P521, DOI 10.1007/s00221-007-1168-9; Vroomen J, 2004, COGNITIVE BRAIN RES, V22, P32, DOI 10.1016/j.cogbrainres.2004.07.003; Wark B, 2009, NEURON, V61, P750, DOI 10.1016/j.neuron.2009.01.019; Waszak F, 2005, EXP BRAIN RES, V162, P346, DOI 10.1007/s00221-004-2183-8; Wei KL, 2009, J NEUROPHYSIOL, V101, P655, DOI 10.1152/jn.90545.2008; WELCH R, 1986, HDB PERCEPTION PERFO; Wenke D, 2009, EXP BRAIN RES, V196, P311, DOI 10.1007/s00221-009-1848-8; Westheimer G, 1999, EXP BRAIN RES, V129, P121, DOI 10.1007/s002210050942	49	71	74	0	25	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA	1932-6203			PLOS ONE	PLoS One	NOV 5	2009	4	11							e7681	10.1371/journal.pone.0007681	http://dx.doi.org/10.1371/journal.pone.0007681			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	515HI	19890383	Green Published, gold			2022-12-25	WOS:000271459700005
J	Hu, H; Wang, JQ; Bu, DP; Wei, HY; Zhou, LY; Li, FD; Loor, JJ				Hu, Han; Wang, Jiaqi; Bu, Dengpan; Wei, Hongyang; Zhou, Linyun; Li, Fadi; Loor, Juan J.			In Vitro Culture and Characterization of a Mammary Epithelial Cell Line from Chinese Holstein Dairy Cow	PLOS ONE			English	Article								Background: The objective of this study was to establish a culture system and elucidate the unique characteristics of a bovine mammary epithelial cell line in vitro. Methodology: Mammary tissue from a three year old lactating dairy cow (ca. 100 d relative to parturition) was used as a source of the epithelial cell line, which was cultured in collagen-coated tissue culture dishes. Fibroblasts and epithelial cells successively grew and extended from the culturing mammary tissue at the third day. Pure epithelial cells were obtained by passages culture. Principal Findings: The strong positive immunostaining to cytokeratin 18 suggested that the resulting cell line exhibited the specific character of epithelial cells. Epithelial cells cultured in the presence of 10% FBS, supraphysiologic concentrations of insulin, and hydrocortisone maintained a normal diploid chromosome modal number of 2n = 60. Furthermore, they were capable of synthesizing beta-casein (CSN2), acetyl-CoA carboxylase-alpha. (ACACA) and butyrophilin (BTN1A1). An important finding was that frozen preservation in a mixture of 90% FBS and 10% DMSO did not influence the growth characteristics, chromosome number, or protein secretion of the isolated epithelial cell line. Conclusions:The obtained mammary epithelial cell line had normal morphology, growth characteristics, cytogenetic and secretory characteristics, thus, it might represent an useful tool for studying the function of Chinese Holstein dairy cows mammary epithelial cell (CMECs).	[Hu, Han; Wang, Jiaqi; Bu, Dengpan; Wei, Hongyang; Zhou, Linyun] Chinese Acad Agr Sci, Inst Anim Sci, State Key Lab Anim Nutr, Beijing, Peoples R China; [Hu, Han; Li, Fadi] Gansu Agr Univ, Fac Anim Sci & Technol, Lanzhou, Peoples R China; [Loor, Juan J.] Univ Illinois, Dept Anim Sci, Urbana, IL 61801 USA; [Loor, Juan J.] Univ Illinois, Div Nutr Sci, Urbana, IL 61801 USA	Chinese Academy of Agricultural Sciences; Institute of Animal Science, CAAS; Gansu Agricultural University; University of Illinois System; University of Illinois Urbana-Champaign; University of Illinois System; University of Illinois Urbana-Champaign	Hu, H (corresponding author), Chinese Acad Agr Sci, Inst Anim Sci, State Key Lab Anim Nutr, Beijing, Peoples R China.	wang-jia-qi@263.net; burdenpan@gmail.com	Loor, Juan J./H-3760-2012	Loor, Juan J./0000-0003-1586-4365	Ministry of Science and Technology of China [2006BAD04A03]; National Natural Science Foundation of China [30871837]	Ministry of Science and Technology of China(Ministry of Science and Technology, China); National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC))	This work was financially supported by the Ministry of Science and Technology of China (2006BAD04A03) and the National Natural Science Foundation of China (30871837). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	CERIANI RI, 1979, IN VITRO, V135, P356; GILBOTT CA, 1991, IN VITRO CELL DEV, V27, P585; HUYNH HT, 1991, EXP CELL RES, V197, P191, DOI 10.1016/0014-4827(91)90422-Q; TAYLORPAPADIMIT.J, 1977, J NATL CANCER I, V586, P1563; ZAVIZION B, 1992, J DAIRY SCI, V75, P3367, DOI 10.3168/jds.S0022-0302(92)78113-2	5	73	97	0	26	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	NOV 3	2009	4	11							e7636	10.1371/journal.pone.0007636	http://dx.doi.org/10.1371/journal.pone.0007636			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	V11YO	19888476	gold, Green Published, Green Submitted			2022-12-25	WOS:000207567100001
J	Walia, G; Kumar, P; Surolia, A				Walia, Guneet; Kumar, Parimal; Surolia, Avadhesha			The Role of UPF0157 in the Folding of M-tuberculosis Dephosphocoenzyme A Kinase and the Regulation of the Latter by CTP	PLOS ONE			English	Article							COENZYME-A BIOSYNTHESIS; ESCHERICHIA-COLI K-12; CRYSTAL-STRUCTURE; COA SYNTHASE; PANTOTHENATE KINASE; COMPLEX; ADENYLYLTRANSFERASE; IDENTIFICATION; CALORIMETRY; PROTEINS	Background: Targeting the biosynthetic pathway of Coenzyme A (CoA) for drug development will compromise multiple cellular functions of the tubercular pathogen simultaneously. Structural divergence in the organization of the penultimate and final enzymes of CoA biosynthesis in the host and pathogen and the differences in their regulation mark out the final enzyme, dephosphocoenzyme A kinase (CoaE) as a potential drug target. Methodology/Principal Findings: We report here a complete biochemical and biophysical characterization of the M. tuberculosis CoaE, an enzyme essential for the pathogen's survival, elucidating for the first time the interactions of a dephosphocoenzyme A kinase with its substrates, dephosphocoenzyme A and ATP; its product, CoA and an intrinsic yet novel inhibitor, CTP, which helps modulate the enzyme's kinetic capabilities providing interesting insights into the regulation of CoaE activity. We show that the mycobacterial enzyme is almost 21 times more catalytically proficient than its counterparts in other prokaryotes. ITC measurements illustrate that the enzyme follows an ordered mechanism of substrate addition with DCoA as the leading substrate and ATP following in tow. Kinetic and ITC experiments demonstrate that though CTP binds strongly to the enzyme, it is unable to participate in DCoA phosphorylation. We report that CTP actually inhibits the enzyme by decreasing its Vmax. Not surprisingly, a structural homology search for the modeled mycobacterial CoaE picks up cytidylmonophosphate kinases, deoxycytidine kinases, and cytidylate kinases as close homologs. Docking of DCoA and CTP to CoaE shows that both ligands bind at the same site, their interactions being stabilized by 26 and 28 hydrogen bonds respectively. We have also assigned a role for the universal Unknown Protein Family 0157 (UPF0157) domain in the mycobacterial CoaE in the proper folding of the full length enzyme. Conclusions/Significance: In view of the evidence presented, it is imperative to assign a greater role to the last enzyme of Coenzyme A biosynthesis in metabolite flow regulation through this critical biosynthetic pathway.			Walia, G (corresponding author), Indian Inst Sci, Mol Biophys Unit, Bangalore 560012, Karnataka, India.	surolia@nii.res.in	Kumar, Parimal/AAG-9653-2019					Aghajanian S, 2002, BIOCHEM J, V365, P13, DOI 10.1042/BJ20020569; Arnold K, 2006, BIOINFORMATICS, V22, P195, DOI 10.1093/bioinformatics/bti770; Begley TP, 2006, NAT PROD REP, V23, P15, DOI 10.1039/b207131m; Begley TP, 2001, VITAM HORM, V61, P157; Bucovaz ET, 1997, BIOCHIMIE, V79, P787, DOI 10.1016/S0300-9084(97)86938-6; *CHEM COMP GROUP I, 2001, MOL OP ENV MOE VERS; Chohnan S, 1998, BIOSCI BIOTECH BIOCH, V62, P1122, DOI 10.1271/bbb.62.1122; Cole ST, 1998, NATURE, V393, P537, DOI 10.1038/31159; CUFF ME, STRUCTURE C IN PRESS; Das S, 2006, ACTA CRYSTALLOGR D, V62, P628, DOI 10.1107/S0907444906012728; Emsley P, 2004, ACTA CRYSTALLOGR D, V60, P2126, DOI 10.1107/S0907444904019158; Glickman MS, 2001, CELL, V104, P477, DOI 10.1016/S0092-8674(01)00236-7; Gu YJ, 2002, J MOL BIOL, V319, P779, DOI 10.1016/S0022-2836(02)00339-X; Hong BS, 2007, J BIOL CHEM, V282, P27984, DOI 10.1074/jbc.M701915200; JACKOWSKI S, 1981, J BACTERIOL, V148, P926, DOI 10.1128/JB.148.3.926-932.1981; Kraft L, 2002, J MOL BIOL, V318, P1057, DOI 10.1016/S0022-2836(02)00215-2; Kupke T, 2004, EUR J BIOCHEM, V271, P163, DOI 10.1046/j.1432-1033.2003.03916.x; Leavitt S, 2001, CURR OPIN STRUC BIOL, V11, P560, DOI 10.1016/S0959-440X(00)00248-7; Leonardi R, 2005, PROG LIPID RES, V44, P125, DOI 10.1016/j.plipres.2005.04.001; Manabe YC, 2000, NAT MED, V6, P1327, DOI 10.1038/82139; McKinney JD, 2000, NAT MED, V6, P1330, DOI 10.1038/82142; Mishra PK, 2001, J BACTERIOL, V183, P2774, DOI 10.1128/JB.183.9.2774-2778.2001; MURZIN AG, 1995, J MOL BIOL, V247, P536, DOI 10.1006/jmbi.1995.0159; Obmolova G, 2001, J STRUCT BIOL, V136, P119, DOI 10.1006/jsbi.2001.4428; Rock CO, 2003, J BACTERIOL, V185, P3410, DOI 10.1128/JB.185.11.3410-3415.2003; Sobolev V, 1999, BIOINFORMATICS, V15, P327, DOI 10.1093/bioinformatics/15.4.327; SONG WJ, 1994, J BIOL CHEM, V269, P27051; TAHILIANI AG, 1991, VITAM HORM, V46, P165; Todd MJ, 2001, ANAL BIOCHEM, V296, P179, DOI 10.1006/abio.2001.5218; WORRALL DM, 1985, FEBS LETT, V187, P277, DOI 10.1016/0014-5793(85)81258-8; WORRALL DM, 1983, BIOCHEM J, V215, P153, DOI 10.1042/bj2150153; Xing X, 2004, BIOCHEMISTRY-US, V43, P16142, DOI 10.1021/bi048165y; Zhyvoloup A, 2003, J BIOL CHEM, V278, P50316, DOI 10.1074/jbc.M307763200; Zhyvoloup A, 2002, J BIOL CHEM, V277, P22107, DOI 10.1074/jbc.C200195200	34	10	10	0	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	OCT 30	2009	4	10							e7645	10.1371/journal.pone.0007645	http://dx.doi.org/10.1371/journal.pone.0007645			16	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	514RW	19876400	Green Submitted, gold, Green Published			2022-12-25	WOS:000271414300007
J	Tian, MZ; Schiemann, WP				Tian, Maozhen; Schiemann, William P.			PGE2 receptor EP2 mediates the antagonistic effect of COX-2 on TGF-beta signaling during mammary tumorigenesis	FASEB JOURNAL			English	Article						angiogenesis; metastasis; prostaglandins; signal transduction	GROWTH-FACTOR-BETA; BREAST-CANCER PROGRESSION; EPITHELIAL-MESENCHYMAL TRANSITION; SKIN TUMOR-DEVELOPMENT; KAPPA-B ACTIVATION; PROSTAGLANDIN E-2; CYCLIC-AMP; CYCLOOXYGENASE-2 INDUCTION; APOPTOSIS PROTEIN; MOUSE SKIN	The molecular mechanisms that enable cyclooxygenase-2 (COX-2) and its mediator prostaglandin E2 (PGE2) to inhibit transforming growth factor-beta (TGF-beta) signaling during mammary tumorigenesis remain unknown. We show here that TGF-beta selectively stimulated the expression of the PGE2 receptor EP2, which increased normal and malignant mammary epithelial cell (MEC) invasion, anchorage-independent growth, and resistance to TGF-beta-induced cytostasis. Mechanistically, elevated EP2 expression in normal MECs inhibited the coupling of TGF-beta to Smad2/3 activation and plasminogen activator inhibitor-1 (PAI1) expression, while EP2 deficiency in these same MECs augmented Smad2/3 activation and PAI expression stimulated by TGF-beta. Along these lines, engineering malignant MECs to lack EP2 expression prevented their growth in soft agar, restored their cytostatic response to TGF-beta, decreased their invasiveness in response to TGF-beta, and potentiated their activation of Smad2/3 and expression of PAI stimulated by TGF-beta. More important, we show that COX-2 or EP2 deficiency both significantly decreased the growth, angiogenesis, and pulmonary metastasis of mammary tumors produced in mice. Collectively, this investigation establishes EP2 as a potent mediator of the anti-TGF-beta activities elicited by COX-2/PGE2 in normal and malignant MECs. Our findings also suggest that pharmacological targeting of EP2 receptors may provide new inroads to antagonize the oncogenic activities of TGF-beta during mammary tumorigenesis.-Tian, M., Schiemann, W. P. PGE2 receptor EP2 mediates the antagonistic effect of COX-2 on TGF-beta signaling during mammary tumorigenesis. FASEB J. 24, 1105-1116 (2010). www. fasebj. org	[Tian, Maozhen; Schiemann, William P.] Univ Colorado Denver, Dept Pharmacol, Aurora, CO 80045 USA	Children's Hospital Colorado; University of Colorado System; University of Colorado Anschutz Medical Campus	Schiemann, WP (corresponding author), Univ Colorado Denver, Dept Pharmacol, MS-8303,Anschutz Med Campus,RC1 S Tower,Rm L18-61, Aurora, CO 80045 USA.	bill.schiemann@ucdenver.edu	tian, maozhen/F-5457-2010		National Institutes of Health [CA-114039, CA-129359]; NATIONAL CANCER INSTITUTE [R01CA114039, R01CA129359] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	The authors thank Dr. Paul Jedlicka for pathology help and assistance. The authors also thank the members of the W. P. S. laboratory for critical comments and reading of the manuscript. W.P.S. was supported by grants from the National Institutes of Health (CA-114039 and CA-129359).	Ansari KM, 2007, CARCINOGENESIS, V28, P2063, DOI 10.1093/carcin/bgm011; Banu SK, 2009, MOL ENDOCRINOL, V23, P1291, DOI 10.1210/me.2009-0017; Boniface K, 2009, J EXP MED, V206, P535, DOI 10.1084/jem.20082293; Bradbury DA, 2003, J BIOL CHEM, V278, P49954, DOI 10.1074/jbc.M307964200; Cao Y, 2002, J CELL PHYSIOL, V190, P279, DOI 10.1002/jcp.10068; Chang SH, 2004, P NATL ACAD SCI USA, V101, P591, DOI 10.1073/pnas.2535911100; Chang SH, 2005, PROSTAG OTH LIPID M, V76, P48, DOI 10.1016/j.prostaglandins.2004.12.001; Chang SH, 2005, CANCER RES, V65, P4496, DOI 10.1158/0008-5472.CAN-05-0129; Chell S, 2006, BBA-REV CANCER, V1766, P104, DOI 10.1016/j.bbcan.2006.05.002; Cheng T, 1998, INVEST OPHTH VIS SCI, V39, P581; Chun KS, 2007, CANCER RES, V67, P2015, DOI 10.1158/0008-5472.CAN-06-3617; Dannenberg AJ, 2003, CANCER CELL, V4, P431, DOI 10.1016/S1535-6108(03)00310-6; Desai S, 2000, MOL PHARMACOL, V58, P1279, DOI 10.1124/mol.58.6.1279; DESDOUETS C, 1995, MOL CELL BIOL, V15, P3301; Eibl G, 2003, BIOCHEM BIOPH RES CO, V306, P887, DOI 10.1016/S0006-291X(03)01079-9; Fujino H, 2003, J BIOL CHEM, V278, P12151, DOI 10.1074/jbc.M212665200; Galliher AJ, 2006, BREAST CANCER RES, V8, DOI 10.1186/bcr1524; Galliher-Beckley AJ, 2008, CARCINOGENESIS, V29, P244, DOI 10.1093/carcin/bgm245; Greenhough A, 2009, CARCINOGENESIS, V30, P377, DOI 10.1093/carcin/bgp014; Hoper MM, 1997, AM J RESP CELL MOL, V17, P748; Howe LR, 2007, BREAST CANCER RES, V9, DOI 10.1186/bcr1678; Kamiyama M, 2006, ONCOGENE, V25, P7019, DOI 10.1038/sj.onc.1209694; Kuo KT, 2009, ANN SURG ONCOL, V16, P352, DOI 10.1245/s10434-008-0242-2; Lee BPL, 2009, INT IMMUNOPHARMACOL, V9, P534, DOI 10.1016/j.intimp.2009.01.023; LU XJ, 1995, P NATL ACAD SCI USA, V92, P7961, DOI 10.1073/pnas.92.17.7961; Mazhar D, 2006, BRIT J CANCER, V94, P346, DOI 10.1038/sj.bjc.6602942; Minn AJ, 2005, NATURE, V436, P518, DOI 10.1038/nature03799; Nam JS, 2008, CANCER RES, V68, P3835, DOI 10.1158/0008-5472.CAN-08-0215; Neil JR, 2008, CARCINOGENESIS, V29, P2227, DOI 10.1093/carcin/bgn202; Neil JR, 2008, CANCER RES, V68, P1462, DOI 10.1158/0008-5472.CAN-07-3094; Neil JR, 2009, J BIOL CHEM, V284, P21209, DOI 10.1074/jbc.M109.018374; Nishigaki N, 1996, MOL PHARMACOL, V50, P1031; Nishihara H, 2003, P NATL ACAD SCI USA, V100, P8921, DOI 10.1073/pnas.1533221100; Regan JW, 2003, LIFE SCI, V74, P143, DOI 10.1016/j.lfs.2003.09.031; Schiemann BJ, 2003, MOL BIOL CELL, V14, P3977, DOI 10.1091/mbc.E03-01-0001; Schiemann WP, 1999, BLOOD, V94, P2854, DOI 10.1182/blood.V94.8.2854.420k07_2854_2861; Shao JY, 2004, J BIOL CHEM, V279, P14287, DOI 10.1074/jbc.M313276200; Shao JY, 2003, CANCER RES, V63, P5218; Shaywitz AJ, 1999, ANNU REV BIOCHEM, V68, P821, DOI 10.1146/annurev.biochem.68.1.821; Sheng HM, 2001, J BIOL CHEM, V276, P18075, DOI 10.1074/jbc.M009689200; Siegel PM, 2003, NAT REV CANCER, V3, P807, DOI 10.1038/nrc1208; Singh B, 2007, ONCOGENE, V26, P3789, DOI 10.1038/sj.onc.1210154; Singh-Ranger G, 2008, BREAST CANCER RES TR, V109, P189, DOI 10.1007/s10549-007-9641-5; Sonoshita M, 2001, NAT MED, V7, P1048, DOI 10.1038/nm0901-1048; Subbaramaiah K, 2008, J BIOL CHEM, V283, P3433, DOI 10.1074/jbc.M705409200; Sugimoto Y, 2007, J BIOL CHEM, V282, P11613, DOI 10.1074/jbc.R600038200; Sung YM, 2006, ONCOGENE, V25, P5507, DOI 10.1038/sj.onc.1209538; Sung YM, 2005, CANCER RES, V65, P9304, DOI 10.1158/0008-5472.CAN-05-1015; Tian MZ, 2009, TRANSL ONCOL, V2, P174, DOI 10.1593/tlo.09145; Tian M, 2009, FUTURE ONCOL, V5, P259, DOI 10.2217/14796694.5.2.259; Wang XY, 2007, MOL CARCINOGEN, V46, P912, DOI 10.1002/mc.20320; Wilkins-Port CE, 2007, CELLS TISSUES ORGANS, V185, P116, DOI 10.1159/000101312; Williams CS, 2000, J CLIN INVEST, V105, P1589, DOI 10.1172/JCI9621; Yang L, 2003, J CLIN INVEST, V111, P727, DOI 10.1172/JCI200316492	54	47	50	0	3	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	APR	2010	24	4					1105	1116		10.1096/fj.09-141341	http://dx.doi.org/10.1096/fj.09-141341			12	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	580PV	19897661	Green Published			2022-12-25	WOS:000276462300018
J	El-Tanani, MK; Jin, D; Campbell, FC; Johnston, PG				El-Tanani, M. K.; Jin, D.; Campbell, F. C.; Johnston, P. G.			Interferon-induced transmembrane 3 binds osteopontin in vitro: expressed in vivo IFITM3 reduced OPN expression	ONCOGENE			English	Article						osteopontin; INFTM3; interferon; inhibition; breast cancer and metastasis	PROGNOSTIC-SIGNIFICANCE; TRANSCRIPTION FACTOR; METASTASIS; IDENTIFICATION; PROTEIN; GENE; CARCINOMA; FAMILY; CELLS	Osteopontin is a secreted, integrin-binding and phosphorylated acidic glycoprotein, which has an important role in tumour progression. We have shown that Wnt, Ets, AP-1, c-jun and beta-catenin/Lef-1/Tcf-1 stimulates OPN transcription in rat mammary carcinoma cells by binding to a specific promoter sequence. However, co-repressors of OPN have not been identified. In this study, we have used the bacterial two-hybrid system to isolate cDNA-encoding proteins that bind to OPN and modulate its role in malignant transformation. Using this approach we isolated interferon-induced transmembrane protein 3 gene (IFITM3) as a potential protein partner. We show that IFITM3 and OPN interact in vitro and in vivo and that IFITM3 reduces osteopontin (OPN) mRNA expression, possibly by affecting OPN mRNA stability. Stable transfection of IFITM3 inhibits OPN, which mediates anchorage-independent growth, cell adhesion and cell invasion. Northern blot analysis revealed an inverse mRNA expression pattern of IFITM3 and OPN in human mammary cell lines. Inhibition of IFITM3 by antisense RNA promoted OPN protein expression, enhanced cell invasion by parental benign non-invasive Rama 37 cells, indicating that the two proteins interact functionally as well. We also identified an IFITM3 DNA-binding domain, which interacts with OPN, deletion of which abolished its inhibitive effect on OPN. This work has shown for the first time that IFITM3 physically interacts with OPN and reduces OPN mRNA expression, which mediates cell adhesion, cell invasion, colony formation in soft agar and metastasis in a rat model system. Oncogene (2010) 29, 752-762; doi: 10.1038/onc.2009.379; published online 9 November 2009	[El-Tanani, M. K.; Jin, D.; Campbell, F. C.; Johnston, P. G.] Queens Univ Belfast, CCRCB, Belfast BT9 7LB, Antrim, North Ireland	Queens University Belfast	El-Tanani, MK (corresponding author), Queens Univ Belfast, CCRCB, 97 Lisburn Rd, Belfast BT9 7LB, Antrim, North Ireland.	m.el-tanani@qub.ac.uk		El-Tanani, Mohamed/0000-0002-4735-5445	Research and Development Office (R&D), Queen's University Belfast, Northern Ireland, United Kingdom	Research and Development Office (R&D), Queen's University Belfast, Northern Ireland, United Kingdom	We acknowledge support from Research and Development Office (R&D), Queen's University Belfast, Northern Ireland, United Kingdom.	Andreu P, 2006, CANCER RES, V66, P1949, DOI 10.1158/0008-5472.CAN-05-2731; BEHREND EI, 1994, CANCER RES, V54, P832; Brady ME, 1999, J BIOL CHEM, V274, P17599, DOI 10.1074/jbc.274.25.17599; Brem R, 2003, CELL MOL LIFE SCI, V60, P1235, DOI 10.1007/s00018-003-3016-9; Chen HJ, 1997, ONCOGENE, V14, P1581, DOI 10.1038/sj.onc.1200993; DENHARDT DT, 1993, FASEB J, V7, P1475, DOI 10.1096/fasebj.7.15.8262332; DUNNINGTON DJ, 1983, J NATL CANCER I, V71, P1227; El-Tanani M, 2001, CANCER RES, V61, P5619; El-Tanani M, 2004, J BIOL CHEM, V279, P20794, DOI 10.1074/jbc.M311131200; El-Tanani MK, 2006, J BIOL CHEM, V281, P26587, DOI 10.1074/jbc.M604403200; Euer N, 2002, ANTICANCER RES, V22, P733; EVANS SS, 1993, J IMMUNOL, V150, P736; Geissinger E, 2002, CANCER RES, V62, P4820; Green CD, 2007, MOL CANCER RES, V5, P1191, DOI 10.1158/1541-7786.MCR-07-0123; Hsieh YH, 2006, CANCER RES, V66, P7119, DOI 10.1158/0008-5472.CAN-06-1002; Jin DC, 2006, INT J ONCOL, V29, P1591; Khan SA, 2002, J CELL BIOCHEM, V85, P728, DOI 10.1002/jcb.10170; Lange U C, 2003, BMC Dev Biol, V3, P1, DOI 10.1186/1471-213X-3-1; LEWIN AR, 1991, EUR J BIOCHEM, V199, P417, DOI 10.1111/j.1432-1033.1991.tb16139.x; Liu D, 2002, BRIT J CANCER, V87, P423, DOI 10.1038/sj.bjc.6600456; Meller R, 2005, J CEREBR BLOOD F MET, V25, P217, DOI 10.1038/sj.jcbfm.9600022; Nicolini A, 2006, CYTOKINE GROWTH F R, V17, P325, DOI 10.1016/j.cytogfr.2006.07.002; Oates AJ, 1996, ONCOGENE, V13, P97; OLESEN JT, 1991, MOL CELL BIOL, V11, P611, DOI 10.1128/MCB.11.2.611; Rassart E, 2000, BBA-PROTEIN STRUCT M, V1482, P185, DOI 10.1016/S0167-4838(00)00162-X; Real SM, 2006, BMC BIOTECHNOL, V6, DOI 10.1186/1472-6750-6-38; Rittling SR, 2002, J BIOL CHEM, V277, P9175, DOI 10.1074/jbc.M109028200; Rudland PS, 2000, CANCER RES, V60, P1595; Rudland PS, 2002, CANCER RES, V62, P3417; Singhal H, 1997, CLIN CANCER RES, V3, P605; Tanaka SS, 2005, DEV CELL, V9, P745, DOI 10.1016/j.devcel.2005.10.010; Tanaka SS, 2004, DEV DYNAM, V230, P651, DOI 10.1002/dvdy.20085; Tuck AB, 1998, INT J CANCER, V79, P502, DOI 10.1002/(SICI)1097-0215(19981023)79:5<502::AID-IJC10>3.0.CO;2-3; Ue T, 1998, INT J CANCER, V79, P127, DOI 10.1002/(SICI)1097-0215(19980417)79:2<127::AID-IJC5>3.0.CO;2-V; Yang HL, 2005, BIOCHEM BIOPH RES CO, V328, P265, DOI 10.1016/j.bbrc.2004.12.159; Yang Y, 2005, CANCER LETT, V221, P191, DOI 10.1016/j.canlet.2004.08.022; Zhang JP, 2009, EXP CELL RES, V315, P304, DOI 10.1016/j.yexcr.2008.10.042	37	19	22	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 4	2010	29	5					752	762		10.1038/onc.2009.379	http://dx.doi.org/10.1038/onc.2009.379			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	551QI	19901966				2022-12-25	WOS:000274223700011
J	Zhao, LL; Jin, CJ; Chu, YJ; Varghese, C; Hua, SS; Yan, F; Miao, Y; Liu, J; Mann, D; Ding, X; Zhang, JC; Wang, ZY; Dou, Z; Yao, XB				Zhao, Lingli; Jin, Changjiang; Chu, Youjun; Varghese, Chris; Hua, Shasha; Yan, Feng; Miao, Yong; Liu, Jing; Mann, David; Ding, Xia; Zhang, Jiancun; Wang, Zhiyong; Dou, Zhen; Yao, Xuebiao			Dimerization of CPAP Orchestrates Centrosome Cohesion Plasticity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYCLE-REGULATED PROTEIN; CELL-CYCLE; BRAIN SIZE; C-ELEGANS; NEK2; KINASE; DUPLICATION; INTERACTS; CDK5RAP2; CENPJ	Centrosome cohesion and segregation are accurately regulated to prevent an aberrant separation of duplicated centrosomes and to ensure the correct formation of bipolar spindles by a tight coupling with cell cycle machinery. CPAP is a centrosome protein with five coiled-coil domains and plays an important role in the control of brain size in autosomal recessive primary microcephaly. Previous studies showed that CPAP interacts with tubulin and controls centriole length. Here, we reported that CPAP forms a homodimer during interphase, and the fifth coiled-coil domain of CPAP is required for its dimerization. Moreover, this self-interaction is required for maintaining centrosome cohesion and preventing the centrosome from splitting before the G2/M phase. Our biochemical studies show that CPAP forms homodimers in vivo. In addition, both monomeric and dimeric CPAP are required for accurate cell division, suggesting that the temporal dynamics of CPAP homodimerization is tightly regulated during the cell cycle. Significantly, our results provide evidence that CPAP is phosphorylated during mitosis, and this phosphorylation releases its intermolecular interaction. Taken together, these results suggest that cell cycle-regulated phosphorylation orchestrates the dynamics of CPAP molecular interaction and centrosome splitting to ensure genomic stability in cell division.	[Zhao, Lingli; Jin, Changjiang; Chu, Youjun; Hua, Shasha; Yan, Feng; Miao, Yong; Liu, Jing; Wang, Zhiyong; Dou, Zhen; Yao, Xuebiao] Anhui Key Lab Cellular Dynam & Chem Biol, Hefei 230027, Peoples R China; [Zhao, Lingli; Jin, Changjiang; Chu, Youjun; Hua, Shasha; Yan, Feng; Miao, Yong; Liu, Jing; Wang, Zhiyong; Dou, Zhen; Yao, Xuebiao] Hefei Natl Lab Phys Sci Nanoscale, Hefei 230027, Peoples R China; [Varghese, Chris; Yan, Feng; Mann, David; Dou, Zhen] Morehouse Sch Med, Dept Physiol, Atlanta, GA 30310 USA; [Ding, Xia] Beijing Univ Chinese Med, Dept Med, Beijing 100029, Peoples R China; [Zhang, Jiancun] Guangzhou Inst Hlth Sci, Guangzhou 510515, Guangdong, Peoples R China	Morehouse School of Medicine; Beijing University of Chinese Medicine	Dou, Z (corresponding author), Anhui Key Lab Cellular Dynam & Chem Biol, Hefei 230027, Peoples R China.	douzhen@ustc.edu.cn; yaoxb@ustc.edu.cn	Yao, Xuebiao/P-5771-2014; MIAO, YONG/D-4244-2015; DOU, ZHEN/N-2022-2013	DOU, ZHEN/0000-0003-3303-9393	National Institutes of Health [DK-56292, CA89019, CA92080, CA118948, G12RR03034]; Chinese Academy of Science [KSCX1YW-R65, KSCX2-YW-H10]; Chinese 973 Project [2002CB713700, 2006CB943600, 2007CB914503, 2010CB912103, 2006AA02A247]; Chinese Natural Science Foundation [30270654, 30070349, 90508002, 30121001, 30871236, 90813008, 30870990]; China National Key Projects for Infectious Disease [2008ZX10002-021]; American Cancer Society [RPG-99-173-01]; Georgia Cancer Coalition Breast Cancer; Atlanta Clinical and Translational Science Award Chemical Biology [P20RR011104]; NATIONAL CANCER INSTITUTE [U54CA118948, U56CA092080, P50CA089019] Funding Source: NIH RePORTER; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES [UL1TR000454] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [P20RR011104, G12RR003034] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK056292] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Chinese Academy of Science(Chinese Academy of Sciences); Chinese 973 Project(National Basic Research Program of China); Chinese Natural Science Foundation(National Natural Science Foundation of China (NSFC)); China National Key Projects for Infectious Disease; American Cancer Society(American Cancer Society); Georgia Cancer Coalition Breast Cancer; Atlanta Clinical and Translational Science Award Chemical Biology; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))	This work was supported, in whole or in part, by National Institutes of Health Grants DK-56292, CA89019, CA92080, and CA118948 and Grant G12RR03034 from the NCRR for work performed in the facilities used. This work was also supported by Chinese Academy of Science Grants KSCX1YW-R65 and KSCX2-YW-H10, Chinese 973 Project Grants 2002CB713700, 2006CB943600, 2007CB914503, and 2010CB912103, Chinese 863 Project Grant 2006AA02A247, Chinese Natural Science Foundation Grants 30270654, 30070349, 90508002, 30121001, and 30871236 (to C. J.), 90813008 (to Z. W.), and 30870990 (to X. D.), China National Key Projects for Infectious Disease Grant 2008ZX10002-021, American Cancer Society Grant RPG-99-173-01, a research grant from Georgia Cancer Coalition Breast Cancer, and Atlanta Clinical and Translational Science Award Chemical Biology Grant P20RR011104.	Bahe S, 2005, J CELL BIOL, V171, P27, DOI 10.1083/jcb.200504107; Bahmanyar S, 2008, GENE DEV, V22, P91, DOI 10.1101/gad.1596308; Barr AR, 2007, J CELL SCI, V120, P2987, DOI 10.1242/jcs.013136; Basto R, 2006, CELL, V125, P1375, DOI 10.1016/j.cell.2006.05.025; Blagden SP, 2003, NAT CELL BIOL, V5, P505, DOI 10.1038/ncb0603-505; Bond J, 2005, NAT GENET, V37, P353, DOI 10.1038/ng1539; Bornens M, 2002, CURR OPIN CELL BIOL, V14, P25, DOI 10.1016/S0955-0674(01)00290-3; Cho JH, 2006, BIOCHEM BIOPH RES CO, V339, P742, DOI 10.1016/j.bbrc.2005.11.074; Cox J, 2006, TRENDS MOL MED, V12, P358, DOI 10.1016/j.molmed.2006.06.006; Di Fiore B, 2003, J CELL SCI, V116, P3399, DOI 10.1242/jcs.00624; Doxsey S, 2005, ANNU REV CELL DEV BI, V21, P411, DOI 10.1146/annurev.cellbio.21.122303.120418; Evans PD, 2006, GENE, V375, P75, DOI 10.1016/j.gene.2006.02.019; Faragher AJ, 2003, MOL BIOL CELL, V14, P2876, DOI 10.1091/mbc.E03-02-0108; FRY AM, 1995, J BIOL CHEM, V270, P12899, DOI 10.1074/jbc.270.21.12899; Fry AM, 1998, EMBO J, V17, P470, DOI 10.1093/emboj/17.2.470; Graser S, 2007, J CELL SCI, V120, P4321, DOI 10.1242/jcs.020248; Gul A, 2006, J HUM GENET, V51, P760, DOI 10.1007/s10038-006-0017-1; Helps NR, 2000, BIOCHEM J, V349, P509, DOI 10.1042/0264-6021:3490509; Hsu WB, 2008, EXP CELL RES, V314, P2591, DOI 10.1016/j.yexcr.2008.05.012; Hung LY, 2000, MOL CELL BIOL, V20, P7813, DOI 10.1128/MCB.20.20.7813-7825.2000; Hung LY, 2004, MOL BIOL CELL, V15, P2697, DOI 10.1091/mbc.E04-02-0121; Kang JS, 2007, P NATL ACAD SCI USA, V104, P20232, DOI 10.1073/pnas.0710519105; Kirkham M, 2003, CELL, V112, P575, DOI 10.1016/S0092-8674(03)00117-X; Kleylein-Sohn J, 2007, DEV CELL, V13, P190, DOI 10.1016/j.devcel.2007.07.002; Kohlmaier G, 2009, CURR BIOL, V19, P1012, DOI 10.1016/j.cub.2009.05.018; Leidel S, 2003, DEV CELL, V4, P431, DOI 10.1016/S1534-5807(03)00062-5; Lutz W, 2001, J BIOL CHEM, V276, P20774, DOI 10.1074/jbc.M101324200; Mayor T, 2000, J CELL BIOL, V151, P837, DOI 10.1083/jcb.151.4.837; Mayor T, 1999, FEBS LETT, V452, P92, DOI 10.1016/S0014-5793(99)00534-7; Meraldi P, 2002, FEBS LETT, V521, P9, DOI 10.1016/S0014-5793(02)02865-X; Mi J, 2007, CANCER RES, V67, P1082, DOI 10.1158/0008-5472.CAN-06-3071; Nigg EA, 2007, TRENDS CELL BIOL, V17, P215, DOI 10.1016/j.tcb.2007.03.003; Peng B, 2002, MOL ENDOCRINOL, V16, P2019, DOI 10.1210/me.2002-0108; Salisbury JL, 2003, TRENDS CELL BIOL, V13, P340, DOI 10.1016/S0962-8924(03)00126-0; Schmidt TI, 2009, CURR BIOL, V19, P1005, DOI 10.1016/j.cub.2009.05.016; Tang CJC, 2009, NAT CELL BIOL, V11, P825, DOI 10.1038/ncb1889; Woods CG, 2005, AM J HUM GENET, V76, P717, DOI 10.1086/429930; Yang J, 2006, MOL BIOL CELL, V17, P1033, DOI 10.1091/mbc.E05-10-0943; Yuan K, 2007, J BIOL CHEM, V282, P27414, DOI 10.1074/jbc.M703555200; Zhu M, 2008, J BIOL CHEM, V283, P18916, DOI 10.1074/jbc.M710591200	40	16	16	0	15	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 22	2010	285	4					2488	2497		10.1074/jbc.M109.042614	http://dx.doi.org/10.1074/jbc.M109.042614			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	544YP	19889632	Green Published, hybrid			2022-12-25	WOS:000273697800027
J	Lacoste, S; Wiechec, E; Silva, AGD; Guffei, A; Williams, G; Lowbeer, M; Benedek, K; Henriksson, M; Klein, G; Mai, S				Lacoste, S.; Wiechec, E.; Silva, A. G. dos Santos; Guffei, A.; Williams, G.; Lowbeer, M.; Benedek, K.; Henriksson, M.; Klein, G.; Mai, S.			Chromosomal rearrangements after ex vivo Epstein-Barr virus (EBV) infection of human B cells	ONCOGENE			English	Article						Epstein-Barr virus; genomic instability; telomere dysfunction; nuclear organization	PROMOTES GENOMIC INSTABILITY; NEGATIVE BURKITTS-LYMPHOMA; STRONG TELOMERASE ACTIVITY; LATENT GENES; GROWTH PHENOTYPE; HODGKINS-DISEASE; TUMOR-CELLS; DNA-DAMAGE; LYMPHOCYTES; LINES	The Epstein-Barr virus (EBV) is carried by more than 90% of the adult world population and has been implicated in several human malignancies. Its ability to induce unlimited in vitro proliferation of B cells is frequently used to generate lymphoblastoid cell lines (LCLs). In this study, we have investigated the evolution of two LCLs up to 25 weeks after EBV infection. LCLs were karyotyped once a month by spectral karyotyping (SKY). LCLs but not mitogen-activated B cells showed evidence of DNA damage and DNA damage response within the first 2 weeks. After 4 weeks, the former, but not the latter, showed a high level of non-clonal structural aberrations, mainly deletions, fragments, dicentric chromosomes and unbalanced translocations. Genomic instability decreased thereafter over time. Nonrandom aneuploidy 12 weeks after infection showed clonal evolution in culture. After 25 weeks post-infection, most cells exhibited karyotypic stability. Chromosomal aberrations were compatible with telomere dysfunction, although in the absence of telomere shortening. The telomere capping protein TRF2 was partially displaced from telomeres in EBV-infected cells, suggesting an EBV-mediated uncapping problem. In conclusion, this study suggests that DNA damage and telomere dysfunction contribute to EBV-related chromosomal instability in early LCLs. Oncogene (2010) 29, 503-515; doi: 10.1038/onc.2009.359; published online 2 November 2009	[Lacoste, S.; Silva, A. G. dos Santos; Guffei, A.; Mai, S.] Univ Manitoba, Manitoba Inst Cell Biol, Dept Physiol, Winnipeg, MB R3E 0V9, Canada; [Wiechec, E.] Univ Aarhus, Dept Human Genet, Aarhus C, Denmark; [Williams, G.] Hlth Sci Ctr, Hematopathol Lab, Dept Pathol, Winnipeg, MB, Canada; [Lowbeer, M.; Benedek, K.; Henriksson, M.; Klein, G.] Karolinska Inst, Dept Microbiol Tumor & Cell Biol, Stockholm, Sweden	University of Manitoba; Aarhus University; University of Manitoba; Children's Hospital Research Institute of Manitoba; Karolinska Institutet	Mai, S (corresponding author), Univ Manitoba, Manitoba Inst Cell Biol, Dept Physiol, 675 McDermot Ave,Rm ON6046, Winnipeg, MB R3E 0V9, Canada.	smai@cc.umanitoba.ca	Mai, Sabine/E-5667-2017; Henriksson, Marie Arsenian/F-5010-2015; Silva, Amanda/G-4992-2010	Mai, Sabine/0000-0002-5797-2201; Arsenian Henriksson, Marie/0000-0001-6376-7792	Canadian Cancer Society; National Cancer Institute of Canada; Swedish Cancer Society; Canadian Institutes of Health; Manitoba Health Research Council	Canadian Cancer Society(Canadian Cancer Society (CCS)); National Cancer Institute of Canada(Canadian Cancer Society (CCS)); Swedish Cancer Society(Swedish Cancer Society); Canadian Institutes of Health(Canadian Institutes of Health Research (CIHR)); Manitoba Health Research Council	We thank Mary Cheang for statistical analyses, and Ludger Klewes, Brenda Kuschak and Sabine Hombach-Klonisch for technical help. This study was supported by the Canadian Cancer Society and the National Cancer Institute of Canada (SM), the Swedish Cancer Society (GK), the Canadian Institutes of Health Research Strategic Training Program 'Innovative Technologies in Multidisciplinary Health Research Training' fellowships (SL and EW) and by a Manitoba Health Research Council post-doctoral fellowship (SL).	Aubert G, 2008, PHYSIOL REV, V88, P557, DOI 10.1152/physrev.00026.2007; Belfiore MC, 2007, CANCER LETT, V254, P236, DOI 10.1016/j.canlet.2007.03.010; Caporali A, 2007, ONCOGENE, V26, P1398, DOI 10.1038/sj.onc.1209928; Cerimele F, 2005, P NATL ACAD SCI USA, V102, P175, DOI 10.1073/pnas.0408381102; Chuang TCY, 2004, BMC BIOL, V2, DOI 10.1186/1741-7007-2-12; CIOBANU N, 1986, MT SINAI J MED, V53, P627; COUNTER CM, 1994, J VIROL, V68, P3410, DOI 10.1128/JVI.68.5.3410-3414.1994; de Lange T, 2005, GENE DEV, V19, P2100, DOI 10.1101/gad.1346005; De Vos WH, 2009, CYTOM PART A, V75A, P428, DOI 10.1002/cyto.a.20699; Diehl V, 1977, Haematol Blood Transfus, V20, P289; Dolcetti R, 2003, J CELL PHYSIOL, V196, P207, DOI 10.1002/jcp.10263; Gargouri B, 2009, MOL CELL BIOCHEM, V324, P55, DOI 10.1007/s11010-008-9984-1; GARRONE P, 1995, J EXP MED, V182, P1265, DOI 10.1084/jem.182.5.1265; GORDON J, 1986, IMMUNOLOGY, V58, P591; Gruhne B, 2009, P NATL ACAD SCI USA, V106, P2313, DOI 10.1073/pnas.0810619106; GUNVEN P, 1970, NATURE, V228, P1053, DOI 10.1038/2281053a0; HENLE G, 1968, P NATL ACAD SCI USA, V59, P94, DOI 10.1073/pnas.59.1.94; HENLE W, 1973, NATL CANCER I MONOGR, P79; HENLE W, 1966, J BACTERIOL, V92, P269, DOI 10.1128/JB.92.1.269-271.1966; HENLE W, 1973, CANCER RES, V33, P1419; Henle W., 1979, EPSTEINBARR VIRUS, P61; Hopwood PA, 2002, TRANSPLANTATION, V74, P194, DOI 10.1097/00007890-200207270-00009; Hu BT, 1999, EUR J IMMUNOL, V29, P3745, DOI 10.1002/(SICI)1521-4141(199911)29:11<3745::AID-IMMU3745>3.0.CO;2-1; Igarashi H, 1997, BLOOD, V89, P1299, DOI 10.1182/blood.V89.4.1299; Jeon JP, 2007, CANCER GENET CYTOGEN, V173, P122, DOI 10.1016/j.cancergencyto.2006.10.010; JONCAS J, 1974, CAN MED ASSOC J, V110, P33; Jung D, 2001, IMMUNOL INVEST, V30, P157, DOI 10.1081/IMM-100104023; Kabore AF, 2006, APOPTOSIS, V11, P1175, DOI 10.1007/s10495-006-8048-9; Kamranvar SA, 2007, ONCOGENE, V26, P5115, DOI 10.1038/sj.onc.1210324; Kataoka H, 1997, DIFFERENTIATION, V62, P203; Kim SH, 2004, CYTOGENET GENOME RES, V105, P292, DOI 10.1159/000078201; Knecht H, 2009, LEUKEMIA, V23, P565, DOI 10.1038/leu.2008.314; Konishi A, 2008, GENE DEV, V22, P1221, DOI 10.1101/gad.1634008; Lassoued S, 2008, MOL CELL BIOCHEM, V313, P179, DOI 10.1007/s11010-008-9755-z; Louis SF, 2005, P NATL ACAD SCI USA, V102, P9613, DOI 10.1073/pnas.0407512102; MAI S, 2002, FISH PRACTICAL APPRO, P55; Mochida A, 2005, ARCH VIROL, V150, P2139, DOI 10.1007/s00705-005-0557-2; Nagele RG, 2001, J CELL SCI, V114, P377; NIEDERMAN JC, 1968, J AMER MED ASSOC, V203, P205; NILSSON K, 1977, INT J CANCER, V19, P337, DOI 10.1002/ijc.2910190309; Nilsson K, 1992, Hum Cell, V5, P25; NILSSON K, 1975, INT J CANCER, V15, P321, DOI 10.1002/ijc.2910150217; O'Nions J, 2004, J GEN VIROL, V85, P881, DOI 10.1099/vir.0.19704-0; Oexle K, 1997, HUM MOL GENET, V6, P905, DOI 10.1093/hmg/6.6.905; OKANO M, 1990, AM J PATHOL, V137, P517; Okubo M, 2001, CANCER GENET CYTOGEN, V129, P30, DOI 10.1016/S0165-4608(01)00420-4; PALLESEN G, 1991, LANCET, V337, P320, DOI 10.1016/0140-6736(91)90943-J; PURTILO DT, 1980, LANCET, V1, P300; RICKINSON AB, 1987, J VIROL, V61, P1310, DOI 10.1128/JVI.61.5.1310-1317.1987; ROONEY CM, 1986, BRIT J HAEMATOL, V62, P413, DOI 10.1111/j.1365-2141.1986.tb02952.x; ROWE DT, 1986, EMBO J, V5, P2599, DOI 10.1002/j.1460-2075.1986.tb04540.x; ROWE M, 1991, J EXP MED, V173, P147, DOI 10.1084/jem.173.1.147; ROWE M, 1992, J VIROL, V66, P122, DOI 10.1128/JVI.66.1.122-131.1992; ROWE M, 1989, J VIROL, V63, P1031, DOI 10.1128/JVI.63.3.1031-1039.1989; ROWE M, 1987, EMBO J, V6, P2743, DOI 10.1002/j.1460-2075.1987.tb02568.x; STEEL CM, 1977, NATURE, V270, P729, DOI 10.1038/270729a0; Sugimoto M, 1999, MECH AGEING DEV, V107, P51, DOI 10.1016/S0047-6374(98)00131-6; Tahara H, 1997, ONCOGENE, V15, P1911, DOI 10.1038/sj.onc.1201377; Takahashi T, 2003, DNA CELL BIOL, V22, P727, DOI 10.1089/104454903770946700; THOMAS JA, 1990, TRANSPLANTATION, V49, P944, DOI 10.1097/00007890-199005000-00022; THOMAS JA, 1989, LANCET, V1, P1075; Thorley-Lawson DA, 2004, NEW ENGL J MED, V350, P1328, DOI 10.1056/NEJMra032015; Thorley-Lawson DA, 2001, NAT REV IMMUNOL, V1, P75, DOI 10.1038/35095584; van Steensel B, 1998, CELL, V92, P401, DOI 10.1016/S0092-8674(00)80932-0; Verdun RE, 2006, CELL, V127, P709, DOI 10.1016/j.cell.2006.09.034; Verdun RE, 2005, MOL CELL, V20, P551, DOI 10.1016/j.molcel.2005.09.024; Vermolen BJ, 2005, CYTOM PART A, V67A, P144, DOI 10.1002/cyto.a.20159; WALTER J, 1992, INT J CANCER, V50, P265, DOI 10.1002/ijc.2910500217; WANG F, 1987, P NATL ACAD SCI USA, V84, P3452, DOI 10.1073/pnas.84.10.3452; Weierich C, 2003, CHROMOSOME RES, V11, P485, DOI 10.1023/A:1025016828544; Weng NP, 1997, P NATL ACAD SCI USA, V94, P10827, DOI 10.1073/pnas.94.20.10827; Young LS, 2003, ONCOGENE, V22, P5108, DOI 10.1038/sj.onc.1206556; YOUNG LS, 1991, LANCET, V337, P1617, DOI 10.1016/0140-6736(91)93322-Z	74	50	50	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN	2010	29	4					503	515		10.1038/onc.2009.359	http://dx.doi.org/10.1038/onc.2009.359			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	549WH	19881539				2022-12-25	WOS:000274084600004
J	Frank, E; Kessler, MS; Filiou, MD; Zhang, YY; Maccarrone, G; Reckow, S; Bunck, M; Heumann, H; Turck, CW; Landgraf, R; Hambsch, B				Frank, Elisabeth; Kessler, Melanie S.; Filiou, Michaela D.; Zhang, Yaoyang; Maccarrone, Giuseppina; Reckow, Stefan; Bunck, Mirjam; Heumann, Hermann; Turck, Christoph W.; Landgraf, Rainer; Hambsch, Boris			Stable Isotope Metabolic Labeling with a Novel N-15-Enriched Bacteria Diet for Improved Proteomic Analyses of Mouse Models for Psychopathologies	PLOS ONE			English	Article							ANXIETY-RELATED BEHAVIOR; TRAIT ANXIETY; CELL-CULTURE; GLYOXALASE-I; AMINO-ACIDS; VASOPRESSIN; MICE; IDENTIFICATION; EXTREMES; PROTEINS	The identification of differentially regulated proteins in animal models of psychiatric diseases is essential for a comprehensive analysis of associated psychopathological processes. Mass spectrometry is the most relevant method for analyzing differences in protein expression of tissue and body fluid proteomes. However, standardization of sample handling and sample-to-sample variability are problematic. Stable isotope metabolic labeling of a proteome represents the gold standard for quantitative mass spectrometry analysis. The simultaneous processing of a mixture of labeled and unlabeled samples allows a sensitive and accurate comparative analysis between the respective proteomes. Here, we describe a cost-effective feeding protocol based on a newly developed N-15 bacteria diet based on Ralstonia eutropha protein, which was applied to a mouse model for trait anxiety. Tissue from N-15-labeled vs. N-14-unlabeled mice was examined by mass spectrometry and differences in the expression of glyoxalase-1 (GLO1) and histidine triad nucleotide binding protein 2 (Hint2) proteins were correlated with the animals' psychopathological behaviors for methodological validation and proof of concept, respectively. Additionally, phenotyping unraveled an antidepressant-like effect of the incorporation of the stable isotope N-15 into the proteome of highly anxious mice. This novel phenomenon is of considerable relevance to the metabolic labeling method and could provide an opportunity for the discovery of candidate proteins involved in depression-like behavior. The newly developed N-15 bacteria diet provides researchers a novel tool to discover disease-relevant protein expression differences in mouse models using quantitative mass spectrometry.			Frank, E (corresponding author), Max Planck Inst Psychiat, Munich, Germany.	hambsch@mpipsykl.mpg.de		Filiou, Michaela/0000-0002-2991-4901; Zhang, Yaoyang/0000-0001-5363-9834				Bindschedler LV, 2008, PHYTOCHEMISTRY, V69, P1962, DOI 10.1016/j.phytochem.2008.04.007; Bunck M, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005129; DITZEN C, 2009, MOL PSYCHIAT    0113; Ditzen C, 2006, MOL CELL PROTEOMICS, V5, P1914, DOI 10.1074/mcp.M600088-MCP200; Gruhler Albrecht, 2008, V424, P101, DOI 10.1007/978-1-60327-064-9_9; Haegler K, 2009, J PROTEOMICS, V71, P601, DOI 10.1016/j.jprot.2008.10.004; HERNANDEZ M, 1981, ARCH TIERERNAHR, V31, P651, DOI 10.1080/17450398109426872; Kessler MS, 2007, EUR J NEUROSCI, V26, P2857, DOI 10.1111/j.1460-9568.2007.05917.x; Krijgsveld J, 2003, NAT BIOTECHNOL, V21, P927, DOI 10.1038/nbt848; Kromer SA, 2005, J NEUROSCI, V25, P4375, DOI 10.1523/JNEUROSCI.0115-05.2005; Landgraf R, 2007, NEUROSCI BIOBEHAV R, V31, P89, DOI 10.1016/j.neubiorev.2006.07.003; Lenglet S, 2008, ENDOCRINOLOGY, V149, P5461, DOI 10.1210/en.2008-0400; Liao LJ, 2008, J PROTEOME RES, V7, P4743, DOI 10.1021/pr8003198; McClatchy DB, 2007, GENOME RES, V17, P1378, DOI 10.1101/gr.6375007; McClatchy DB, 2007, J PROTEOME RES, V6, P2005, DOI 10.1021/pr060599n; Nelson CJ, 2007, PROTEOMICS, V7, P1279, DOI 10.1002/pmic.200600832; Ong SE, 2002, MOL CELL PROTEOMICS, V1, P376, DOI 10.1074/mcp.M200025-MCP200; PELLOW S, 1985, J NEUROSCI METH, V14, P149, DOI 10.1016/0165-0270(85)90031-7; Schaff JE, 2008, PLANT J, V56, P840, DOI 10.1111/j.1365-313X.2008.03639.x; STERU L, 1985, PSYCHOPHARMACOLOGY, V85, P367, DOI 10.1007/BF00428203; Wu CC, 2004, ANAL CHEM, V76, P4951, DOI 10.1021/ac049208j	21	55	57	0	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA	1932-6203			PLOS ONE	PLoS One	NOV 13	2009	4	11							e7821	10.1371/journal.pone.0007821	http://dx.doi.org/10.1371/journal.pone.0007821			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	518VB	19915716	Green Published, gold, Green Submitted			2022-12-25	WOS:000271721900012
J	Rahimi, F; Murakami, K; Summers, JL; Chen, CHB; Bitan, G				Rahimi, Farid; Murakami, Kazuma; Summers, Jamie L.; Chen, Chi-Hong B.; Bitan, Gal			RNA Aptamers Generated against Oligomeric A beta 40 Recognize Common Amyloid Aptatopes with Low Specificity but High Sensitivity	PLOS ONE			English	Article							IN-VITRO SELECTION; PHOTOINDUCED CROSS-LINKING; ALZHEIMERS-DISEASE; PRION-PROTEIN; BETA-PROTEIN; ANTIBODIES RECOGNIZE; FIBRIL FORMATION; DNA APTAMERS; BINDING; MECHANISM	Aptamers are useful molecular recognition tools in research, diagnostics, and therapy. Despite promising results in other fields, aptamer use has remained scarce in amyloid research, including Alzheimer's disease (AD). AD is a progressive neurodegenerative disease believed to be caused by neurotoxic amyloid beta-protein (A beta) oligomers. A beta oligomers therefore are an attractive target for development of diagnostic and therapeutic reagents. We used covalently-stabilized oligomers of the 40-residue form of A beta (A beta 40) for aptamer selection. Despite gradually increasing the stringency of selection conditions, the selected aptamers did not recognize A beta 40 oligomers but reacted with fibrils of A beta 40, A beta 42, and several other amyloidogenic proteins. Aptamer reactivity with amyloid fibrils showed some degree of protein-sequence dependency. Significant fibril binding also was found for the naive library and could not be eliminated by counter-selection using A beta 40 fibrils, suggesting that aptamer binding to amyloid fibrils was RNA-sequence-independent. Aptamer binding depended on fibrillogenesis and showed a lag phase. Interestingly, aptamers detected fibril formation with >= 15-fold higher sensitivity than thioflavin T (ThT), revealing substantial beta-sheet and fibril formation undetected by ThT. The data suggest that under physiologic conditions, aptamers for oligomeric forms of amyloidogenic proteins cannot be selected due to high, nonspecific affinity of oligonucleotides for amyloid fibrils. Nevertheless, the high sensitivity, whereby aptamers detect b-sheet formation, suggests that they can serve as superior amyloid recognition tools.			Rahimi, F (corresponding author), Univ Calif Los Angeles, David Geffen Sch Med, Dept Neurol, Los Angeles, CA 90095 USA.	gbitan@mednet.ucla.edu	Rahimi, Farid/E-6522-2018; Bitan, Gal/U-2204-2019; Murakami, Kazuma/GQA-7062-2022	Rahimi, Farid/0000-0002-0920-8188; Bitan, Gal/0000-0001-7046-3754; Murakami, Kazuma/0000-0003-3152-1784	NATIONAL INSTITUTE ON AGING [R21AG030709] Funding Source: NIH RePORTER; NIA NIH HHS [R21 AG030709, AG030709] Funding Source: Medline	NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Abramoff MD, 2004, BIOPHOTONICS INT, V11, P36, DOI DOI 10.1117/1.3589100; ARVINTE T, 1993, J BIOL CHEM, V268, P6415; BAILEY TL, 1994, P 2 INT C INT SYST M, P28; Bibby DF, 2008, J VIROL METHODS, V151, P107, DOI 10.1016/j.jviromet.2008.03.013; Bitan G, 2003, P NATL ACAD SCI USA, V100, P330, DOI 10.1073/pnas.222681699; Bitan G, 2005, AMYLOID, V12, P88, DOI 10.1080/13506120500106958; Bitan G, 2001, J BIOL CHEM, V276, P35176, DOI 10.1074/jbc.M102223200; Bitan G, 2006, METHOD ENZYMOL, V413, P217, DOI 10.1016/S0076-6879(06)13012-8; Bitan Gal, 2004, V299, P3; Bunka DHJ, 2007, J BIOL CHEM, V282, P34500, DOI 10.1074/jbc.M703679200; Bunka DHJ, 2006, NAT REV MICROBIOL, V4, P588, DOI 10.1038/nrmicro1458; Calamai M, 2003, BIOCHEMISTRY-US, V42, P15078, DOI 10.1021/bi030135s; Chen CHB, 2003, P NATL ACAD SCI USA, V100, P9226, DOI 10.1073/pnas.1332660100; Fezoui Y, 2002, J BIOL CHEM, V277, P36948, DOI 10.1074/jbc.M204168200; Georganopoulou DG, 2005, P NATL ACAD SCI USA, V102, P2273, DOI 10.1073/pnas.0409336102; Ginsberg SD, 1999, ANN NEUROL, V45, P174, DOI 10.1002/1531-8249(199902)45:2<174::AID-ANA7>3.0.CO;2-E; Ginsberg SD, 1998, ACTA NEUROPATHOL, V96, P487, DOI 10.1007/s004010050923; Gopinath SCB, 2007, ANAL BIOANAL CHEM, V387, P171, DOI 10.1007/s00216-006-0826-2; Gosal WS, 2005, J MOL BIOL, V351, P850, DOI 10.1016/j.jmb.2005.06.040; Haass C, 2007, NAT REV MOL CELL BIO, V8, P101, DOI 10.1038/nrm2101; Haller AA, 1997, P NATL ACAD SCI USA, V94, P8521, DOI 10.1073/pnas.94.16.8521; Jayasena SD, 1999, CLIN CHEM, V45, P1628; Kawas CH, 2003, NEUROLOGY, V60, P1089, DOI 10.1212/01.WNL.0000055813.36504.BF; Kayed R, 2003, SCIENCE, V300, P486, DOI 10.1126/science.1079469; Kayed R, 2007, MOL NEURODEGENER, V2, DOI 10.1186/1750-1326-2-18; Kayed R, 2006, METHOD ENZYMOL, V413, P326, DOI 10.1016/S0076-6879(06)13017-7; Khurana R, 2005, J STRUCT BIOL, V151, P229, DOI 10.1016/j.jsb.2005.06.006; King DJ, 2007, J MOL BIOL, V369, P1001, DOI 10.1016/j.jmb.2007.02.004; Kirkitadze MD, 2002, J NEUROSCI RES, V69, P567, DOI 10.1002/jnr.10328; Kouassi GK, 2007, BIOTECHNOL PROGR, V23, P1239, DOI 10.1021/bp0602101; Lacor PN, 2004, J NEUROSCI, V24, P10191, DOI 10.1523/JNEUROSCI.3432-04.2004; Lafaye P, 2009, MOL IMMUNOL, V46, P695, DOI 10.1016/j.molimm.2008.09.008; Lambert MP, 2007, J NEUROCHEM, V100, P23, DOI 10.1111/j.1471-4159.2006.04157.x; Larkin MA, 2007, BIOINFORMATICS, V23, P2947, DOI 10.1093/bioinformatics/btm404; Lee EB, 2006, J BIOL CHEM, V281, P4292, DOI 10.1074/jbc.M511018200; Lee JF, 2006, CURR OPIN CHEM BIOL, V10, P282, DOI 10.1016/j.cbpa.2006.03.015; LeVine H, 1999, METHOD ENZYMOL, V309, P274; Luhrs TT, 2006, J MOL BIOL, V357, P833, DOI 10.1016/j.jmb.2006.01.016; Mannironi C, 1997, BIOCHEMISTRY-US, V36, P9726, DOI 10.1021/bi9700633; Marcinkiewicz M, 2002, J NEUROPATH EXP NEUR, V61, P815, DOI 10.1093/jnen/61.9.915; Maury CPJ, 2009, ORIGINS LIFE EVOL B, V39, P141, DOI 10.1007/s11084-009-9165-6; Mebane-Sims I, 2009, ALZHEIMERS DEMENT, V5, P234, DOI 10.1016/j.jalz.2009.03.001; Monien BH, 2006, EXPERT REV NEUROTHER, V6, P1293, DOI 10.1586/14737175.6.9.1293; Morozova-Roche LA, 2000, J STRUCT BIOL, V130, P339, DOI 10.1006/jsbi.2000.4264; Murakami K, 2008, PRION, V2, P73, DOI 10.4161/pri.2.2.7024; Myers SL, 2006, BIOCHEMISTRY-US, V45, P2311, DOI 10.1021/bi052434i; Nestor PJ, 2004, NAT MED, V10, pS34, DOI 10.1038/nrn1433; O'Nuallain B, 2002, P NATL ACAD SCI USA, V99, P1485, DOI 10.1073/pnas.022662599; PIRTTILA T, 1994, J NEUROL SCI, V127, P90, DOI 10.1016/0022-510X(94)90140-6; Podesta A, 2006, BIOPHYS J, V90, P589, DOI 10.1529/biophysj.105.068833; Porat Y, 2004, BIOCHEMISTRY-US, V43, P14454, DOI 10.1021/bi048582a; Proske D, 2002, CHEMBIOCHEM, V3, P717, DOI 10.1002/1439-7633(20020802)3:8<717::AID-CBIC717>3.0.CO;2-C; Rahimi F, 2008, CURR ALZHEIMER RES, V5, P319, DOI 10.2174/156720508784533358; RAHIMI F, 2009, J VIS EXP, V23; Rhie A, 2003, J BIOL CHEM, V278, P39697, DOI 10.1074/jbc.M305297200; Siddiqui MAA, 2005, DRUGS, V65, P1571, DOI 10.2165/00003495-200565110-00010; Sipe JD, 2000, J STRUCT BIOL, V130, P88, DOI 10.1006/jsbi.2000.4221; Stine WB, 2003, J BIOL CHEM, V278, P11612, DOI 10.1074/jbc.M210207200; TAGLIAVINI F, 1993, P NATL ACAD SCI USA, V90, P9678, DOI 10.1073/pnas.90.20.9678; Takemura K, 2006, EXP BIOL MED, V231, P204; Ulrich H, 2006, HANDB EXP PHARM, V173, P305; Weiss S, 1997, J VIROL, V71, P8790, DOI 10.1128/JVI.71.11.8790-8797.1997; Ylera F, 2002, BIOCHEM BIOPH RES CO, V290, P1583, DOI 10.1006/bbrc.2002.6354; Zuker M, 2003, NUCLEIC ACIDS RES, V31, P3406, DOI 10.1093/nar/gkg595	64	48	52	3	43	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	NOV 10	2009	4	11							e7694	10.1371/journal.pone.0007694	http://dx.doi.org/10.1371/journal.pone.0007694			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	517ZU	19901993	gold, Green Submitted, Green Published			2022-12-25	WOS:000271658800003
J	Triana-Baltzer, GB; Gubareva, LV; Klimov, AI; Wurtman, DF; Moss, RB; Hedlund, M; Larson, JL; Belshe, RB; Fang, F				Triana-Baltzer, Gallen B.; Gubareva, Larisa V.; Klimov, Alexander I.; Wurtman, David F.; Moss, Ronald B.; Hedlund, Maria; Larson, Jeffrey L.; Belshe, Robert B.; Fang, Fang			Inhibition of Neuraminidase Inhibitor-Resistant Influenza Virus by DAS181, a Novel Sialidase Fusion Protein	PLOS ONE			English	Article							OSELTAMIVIR RESISTANCE; REDUCED SENSITIVITY; B VIRUSES; SUSCEPTIBILITY; HEMAGGLUTININ; TRANSMISSION; DRUG; GLYCOSYLATION; SEQUENCE; H1N1	Antiviral drug resistance for influenza therapies remains a concern due to the high prevalence of H1N1 2009 seasonal influenza isolates which display H274Y associated oseltamivir-resistance. Furthermore, the emergence of novel H1N1 raises the potential that additional reassortments can occur, resulting in drug resistant virus. Thus, additional antiviral approaches are urgently needed. DAS181 (Fludase (R)), a sialidase fusion protein, has been shown to have inhibitory activity against a large number of seasonal influenza strains and a highly pathogenic avian influenza ( HPAI) strain (H5N1). Here, we examine the in vitro activity of DAS181 against a panel of 2009 oseltamivir-resistant seasonal H1N1 clinical isolates. The activity of DAS181 against nine 2009, two 2007, and two 2004 clinical isolates of seasonal IFV H1N1 was examined using plaque number reduction assay on MDCK cells. DAS181 strongly inhibited all tested isolates. EC50 values remained constant against isolates from 2004, 2007, and 2009, suggesting that there was no change in DAS181 sensitivity over time. As expected, all 2007 and 2009 isolates were resistant to oseltamivir, consistent with the identification of the H274Y mutation in the NA gene of all these isolates. Interestingly, several of the 2007 and 2009 isolates also exhibited reduced sensitivity to zanamivir, and accompanying HA mutations near the sialic acid binding site were observed. DAS181 inhibits IFV that is resistant to NAIs. Thus, DAS181 may offer an alternative therapeutic option for seasonal or pandemic IFVs that become resistant to currently available antiviral drugs.			Triana-Baltzer, GB (corresponding author), NexBio Inc, San Diego, CA USA.	ffang@nexbio.com			NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [U01AI070281] Funding Source: NIH RePORTER; NIAID NIH HHS [U01 AI070281] Funding Source: Medline; PHS HHS [HHSN266200600015C] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		Abdel-Ghafar AN, 2008, NEW ENGL J MED, V358, P261, DOI 10.1056/NEJMra0707279; Abed Y, 2002, J INFECT DIS, V186, P1074, DOI 10.1086/344237; Bao YM, 2008, J VIROL, V82, P596, DOI 10.1128/JVI.02005-07; Baum EZ, 2003, ANTIVIR RES, V59, P13, DOI 10.1016/S0166-3542(03)00011-1; Baz M, 2006, CLIN INFECT DIS, V43, P1555, DOI 10.1086/508777; Belser JA, 2007, J INFECT DIS, V196, P1493, DOI 10.1086/522609; Centers for Disease Control and Prevention (CDC), 2009, MMWR Morb Mortal Wkly Rep, V58, P969; Centers for Disease Control and Prevention (CDC), 2009, MMWR Morb Mortal Wkly Rep, V58, P433; COLMAN PM, 1993, J VIROL, V67, P2972, DOI 10.1128/JVI.67.6.2972-2980.1993; de Jong MD, 2005, NEW ENGL J MED, V353, P2667, DOI 10.1056/NEJMoa054512; DeLano W.L., 2002, PYMOL MOL GRAPHICS S; Dharan NJ, 2009, JAMA-J AM MED ASSOC, V301, P1034, DOI 10.1001/jama.2009.294; Escuret V, 2008, J CLIN VIROL, V41, P25, DOI 10.1016/j.jcv.2007.10.019; Gambaryan AS, 1998, VIROLOGY, V247, P170, DOI 10.1006/viro.1998.9224; Gooskens J, 2009, JAMA-J AM MED ASSOC, V301, P1042, DOI 10.1001/jama.2009.297; Gubareva LV, 1998, J INFECT DIS, V178, P1257, DOI 10.1086/314440; Gupta RK, 2006, NEW ENGL J MED, V354, P1423; Hatakeyama S, 2007, JAMA-J AM MED ASSOC, V297, P1435, DOI 10.1001/jama.297.13.1435; HAYDEN FG, 1980, ANTIMICROB AGENTS CH, V17, P865, DOI 10.1128/AAC.17.5.865; HAYDEN FG, 1992, CURR TOP MICROBIOL, V176, P119; Hayden F, 2009, CLIN INFECT DIS, V48, pS3, DOI 10.1086/591851; Hurt AC, 2009, ANTIMICROB AGENTS CH, V53, P4433, DOI 10.1128/AAC.00334-09; Ilyushina NA, 2008, PLOS PATHOG, V4, DOI 10.1371/journal.ppat.1000043; Ison MG, 2006, J INFECT DIS, V193, P760, DOI 10.1086/500465; Ito T, 2000, MICROBIOL IMMUNOL, V44, P423, DOI 10.1111/j.1348-0421.2000.tb02516.x; Kiso M, 2004, LANCET, V364, P759, DOI 10.1016/S0140-6736(04)16934-1; Malakhov MP, 2006, ANTIMICROB AGENTS CH, V50, P1470, DOI 10.1128/AAC.50.4.1470-1479.2006; Marinina VP, 2003, MOL BIOL+, V37, P468, DOI 10.1023/A:1024207931650; Mishin VP, 2005, J VIROL, V79, P12416, DOI 10.1128/JVI.79.19.12416-12424.2005; Moscona A, 2005, NEW ENGL J MED, V353, P2633, DOI 10.1056/NEJMp058291; Moscona A, 2009, NEW ENGL J MED, V360, P953, DOI 10.1056/NEJMp0900648; Nelson MI, 2008, PLOS PATHOG, V4, DOI 10.1371/journal.ppat.1000012; Nicholls JM, 2008, J ANTIMICROB CHEMOTH, V62, P426, DOI 10.1093/jac/dkn167; Sheu TG, 2008, ANTIMICROB AGENTS CH, V52, P3284, DOI 10.1128/AAC.00555-08; Smee DF, 2001, ANTIVIR RES, V52, P251, DOI 10.1016/S0166-3542(01)00168-1; Suzuki Hiroshi, 2003, Journal of Infection and Chemotherapy, V9, P195; Tai CY, 1998, ANTIMICROB AGENTS CH, V42, P3234, DOI 10.1128/AAC.42.12.3234; Tisdale M, 2000, REV MED VIROL, V10, P45, DOI 10.1002/(SICI)1099-1654(200001/02)10:1&lt;45::AID-RMV265&gt;3.0.CO;2-R; TRIANABALTZER GB, 2009, PLOS ONE UNPUB; WANG ZM, 2000, ANTIVIRAL RES, V46; *WHO, 2009, SEAS INFL FACTSH; WINTER G, 1981, NATURE, V292, P72, DOI 10.1038/292072a0; Zambon M, 2001, ANTIVIR RES, V49, P147, DOI 10.1016/S0166-3542(01)00124-3	43	64	64	0	8	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	NOV 6	2009	4	11							e7838	10.1371/journal.pone.0007838	http://dx.doi.org/10.1371/journal.pone.0007838			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	515ND	19893749	gold, Green Published, Green Submitted			2022-12-25	WOS:000271478000014
J	Roland, CL; Lynn, KD; Toombs, JE; Dineen, SP; Udugamasooriya, DG; Brekken, RA				Roland, Christina L.; Lynn, Kristi D.; Toombs, Jason E.; Dineen, Sean P.; Udugamasooriya, D. Gomika; Brekken, Rolf A.			Cytokine Levels Correlate with Immune Cell Infiltration after Anti-VEGF Therapy in Preclinical Mouse Models of Breast Cancer	PLOS ONE			English	Article							ENDOTHELIAL GROWTH-FACTOR; REGULATORY T-CELLS; MAMMARY-CARCINOMA 4T1; TUMOR MICROENVIRONMENT; SUPPRESSOR-CELLS; INFLAMMATION; ANGIOGENESIS; EXPRESSION; MACROPHAGES; ANTAGONIST	The effect of blocking VEGF activity in solid tumors extends beyond inhibition of angiogenesis. However, no studies have compared the effectiveness of mechanistically different anti-VEGF inhibitors with respect to changes in tumor growth and alterations in the tumor microenvironment. In this study we use three distinct breast cancer models, a MDA-MB-231 xenograft model, a 4T1 syngenic model, and a transgenic model using MMTV-PyMT mice, to explore the effects of various anti-VEGF therapies on tumor vasculature, immune cell infiltration, and cytokine levels. Tumor vasculature and immune cell infiltration were evaluated using immunohistochemistry. Cytokine levels were evaluated using ELISA and electrochemiluminescence. We found that blocking the activation of VEGF receptor resulted in changes in intra-tumoral cytokine levels, specifically IL-1 beta, IL-6 and CXCL1. Modulation of the level these cytokines is important for controlling immune cell infiltration and ultimately tumor growth. Furthermore, we demonstrate that selective inhibition of VEGF binding to VEGFR2 with r84 is more effective at controlling tumor growth and inhibiting the infiltration of suppressive immune cells (MDSC, Treg, macrophages) while increasing the mature dendritic cell fraction than other anti-VEGF strategies. In addition, we found that changes in serum IL-1 beta and IL-6 levels correlated with response to therapy, identifying two possible biomarkers for assessing the effectiveness of anti-VEGF therapy in breast cancer patients.			Roland, CL (corresponding author), Univ Texas SW Med Ctr Dallas, Hamon Ctr Therapeut Oncol Res, Dept Surg, Div Surg Oncol, Dallas, TX 75390 USA.	rolf.brekken@utsouthwestern.edu	Dineen, Sean/M-3741-2013; Dineen, Sean/B-6222-2013; Dineen, Sean/K-1471-2015	Dineen, Sean/0000-0002-2012-2238	NCI NIH HHS [T32CA12433401] Funding Source: Medline	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Achen MG, 1998, P NATL ACAD SCI USA, V95, P548, DOI 10.1073/pnas.95.2.548; Amano K, 2004, J MOL CELL CARDIOL, V36, P469, DOI 10.1016/j.yjmcc.2004.01.006; Ancelin M, 2004, LAB INVEST, V84, P502, DOI 10.1038/labinvest.3700053; Aoki Y, 1999, BLOOD, V93, P4034, DOI 10.1182/blood.V93.12.4034.412k38_4034_4043; Armstrong DA, 2004, J LEUKOCYTE BIOL, V75, P641, DOI 10.1189/jlb.0803370; Astle JM, 2008, INT J PEPT RES THER, V14, P223, DOI 10.1007/s10989-008-9136-1; Balkwill F, 2001, LANCET, V357, P539, DOI 10.1016/S0140-6736(00)04046-0; Bingle L, 2002, J PATHOL, V196, P254, DOI 10.1002/path.1027; Bunt SK, 2006, J IMMUNOL, V176, P284, DOI 10.4049/jimmunol.176.1.284; Bunt SK, 2007, CANCER RES, V67, P10019, DOI 10.1158/0008-5472.CAN-07-2354; Cao YH, 1998, P NATL ACAD SCI USA, V95, P14389, DOI 10.1073/pnas.95.24.14389; Chen X, 2007, J IMMUNOL, V179, P154, DOI 10.4049/jimmunol.179.1.154; Clauss M, 1996, J BIOL CHEM, V271, P17629, DOI 10.1074/jbc.271.30.17629; Coussens LM, 2002, NATURE, V420, P860, DOI 10.1038/nature01322; Dikov MM, 2005, J IMMUNOL, V174, P215, DOI 10.4049/jimmunol.174.1.215; Dineen SP, 2008, CANCER RES, V68, P4340, DOI 10.1158/0008-5472.CAN-07-6705; Dupre SA, 2007, INT J EXP PATHOL, V88, P351, DOI 10.1111/j.1365-2613.2007.00539.x; duPre' SA, 2007, EXP MOL PATHOL, V82, P12, DOI 10.1016/j.yexmp.2006.06.007; Dvorak HF, 2002, J CLIN ONCOL, V20, P4368, DOI 10.1200/JCO.2002.10.088; Ellis LM, 2008, NAT REV CANCER, V8, P579, DOI 10.1038/nrc2403; Feng G, 2008, TRANSPLANTATION, V86, P578, DOI 10.1097/TP.0b013e3181806a60; FOLKMAN J, 1995, NAT MED, V1, P27, DOI 10.1038/nm0195-27; Folkman J, 2007, NAT REV DRUG DISCOV, V6, P273, DOI 10.1038/nrd2115; Gabrilovich DI, 2001, J IMMUNOL, V166, P5398, DOI 10.4049/jimmunol.166.9.5398; Gabrilovich DI, 2009, NAT REV IMMUNOL, V9, P162, DOI 10.1038/nri2506; GUY CT, 1992, MOL CELL BIOL, V12, P954, DOI 10.1128/MCB.12.3.954; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; Huang YH, 2007, BLOOD, V110, P624, DOI 10.1182/blood-2007-01-065714; Hurwitz H, 2004, NEW ENGL J MED, V350, P2335, DOI 10.1056/NEJMoa032691; Iwamoto M, 2003, INT J CANCER, V104, P92, DOI 10.1002/ijc.10915; Karlen Y, 2007, BMC BIOINFORMATICS, V8, DOI 10.1186/1471-2105-8-131; Ko JS, 2009, CLIN CANCER RES, V15, P2148, DOI 10.1158/1078-0432.CCR-08-1332; Konecny GE, 2004, CLIN CANCER RES, V10, P1706, DOI 10.1158/1078-0432.CCR-0951-3; Lacouture ME, 2008, ONCOLOGIST, V13, P1001, DOI 10.1634/theoncologist.2008-0131; Linehan DC, 2005, IMMUNOL RES, V32, P155, DOI 10.1385/IR:32:1-3:155; Liyanage UK, 2002, J IMMUNOL, V169, P2756, DOI 10.4049/jimmunol.169.5.2756; MANTOVANI A, 1992, FASEB J, V6, P2591, DOI 10.1096/fasebj.6.8.1592209; Maruyama K, 1999, J MOL CELL CARDIOL, V31, P607, DOI 10.1006/jmcc.1998.0895; Miller K, 2007, NEW ENGL J MED, V357, P2666, DOI 10.1056/NEJMoa072113; Murdoch C, 2008, NAT REV CANCER, V8, P618, DOI 10.1038/nrc2444; Nakao S, 2005, J CLIN INVEST, V115, P2979, DOI 10.1172/JCI23298; Ozao-Choy J, 2009, CANCER RES, V69, P2514, DOI 10.1158/0008-5472.CAN-08-4709; Pahler J, 2008, NEOPLASIA, V10, P329, DOI 10.1593/neo.07871; Pollard JW, 2004, NAT REV CANCER, V4, P71, DOI 10.1038/nrc1256; Ran S, 2003, NEOPLASIA, V5, P297, DOI 10.1016/S1476-5586(03)80023-4; Roland CL, 2009, MOL CANCER THER, V8, P1761, DOI 10.1158/1535-7163.MCT-09-0280; Roskoski R, 2007, CRIT REV ONCOL HEMAT, V62, P179, DOI 10.1016/j.critrevonc.2007.01.006; Salnikov AV, 2006, INT J CANCER, V119, P2795, DOI 10.1002/ijc.22217; Serafini P, 2004, CANCER IMMUNOL IMMUN, V53, P64, DOI 10.1007/s00262-003-0443-2; Shin JY, 2009, CELL IMMUNOL, V256, P72, DOI 10.1016/j.cellimm.2009.01.006; Tsakiri N, 2008, MOL CELL NEUROSCI, V38, P259, DOI 10.1016/j.mcn.2008.02.015; Udugamasooriya DG, 2008, BIOORG MED CHEM LETT, V18, P5892, DOI 10.1016/j.bmcl.2008.07.023; Udugamasooriya DG, 2008, J AM CHEM SOC, V130, P5744, DOI 10.1021/ja711193x; Udugamasooriya DG, 2008, BIOORGAN MED CHEM, V16, P6338, DOI 10.1016/j.bmc.2008.05.015; Vakkila J, 2004, NAT REV IMMUNOL, V4, P641, DOI 10.1038/nri1415; Whitehurst B, 2007, INT J CANCER, V121, P2181, DOI 10.1002/ijc.22937; Wilhelm SM, 2008, MOL CANCER THER, V7, P3129, DOI 10.1158/1535-7163.MCT-08-0013; Zhang Wei, 2002, Angiogenesis, V5, P35, DOI 10.1023/A:1021540120521; Zheng SG, 2007, J IMMUNOL, V178, P2018, DOI 10.4049/jimmunol.178.4.2018	59	143	150	0	17	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	NOV 3	2009	4	11							e7669	10.1371/journal.pone.0007669	http://dx.doi.org/10.1371/journal.pone.0007669			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	514RY	19888452	gold, Green Submitted, Green Published			2022-12-25	WOS:000271414500005
J	Zhu, DM; Fang, JS; Li, YX; Zhang, J				Zhu, Dongmei; Fang, Junshun; Li, Yanxin; Zhang, Jian			Mbd3, a Component of NuRD/Mi-2 Complex, Helps Maintain Pluripotency of Mouse Embryonic Stem Cells by Repressing Trophectoderm Differentiation	PLOS ONE			English	Article							CPG-BINDING DOMAINS; HISTONE DEACETYLASE; TRANSCRIPTIONAL REGULATION; DEVELOPMENTAL REGULATORS; CHROMATIN-STRUCTURE; GENE-EXPRESSION; SELF-RENEWAL; NANOG; NURD; ACETYLATION	Embryonic stem cells (ES cells) can differentiate into cells derived from all three germ layers and extraembryonic tissues. While transcription factors such as, Oct4 and Nanog are well known for their requirements for undifferentiated ES cell growth, mechanisms of epigenetic repression of germ layer specific differentiation in ES cells are not well understood. Here, we investigate functions of Mbd3, a component of nucleosome remodeling and histone deacetylation complex (NuRD/Mi-2) in mouse ES cells. We find that compared to wild type ES cells, Mbd3 knockdown cells show elevated RNA expression of trophectoderm markers, including Cdx2, Eomesodermin, and Hand1. In parallel, these cells show an increased acetylation level of histone 3 in promoters of the respective genes, suggesting Mbd3 plays a role in repression of these genes in undifferentiated ES cells. However, these changes are not sufficient for definitive differentiation to trophectoderm (TE) in chimeric embryos. When further cultured in ES medium without LIF or in trophoblast stem (TS) cell medium, Mbd3 knockdown cells differentiate into TE cells, which express Cdx2 and, at later stages, trophoblast lineage specific marker Cadherin 3. These results suggest that Mbd3 helps restrict ES cells from differentiating towards the trophectoderm lineage and is an important epigenetic player in maintaining full pluripotency of mouse ES cells.			Zhu, DM (corresponding author), Chinese Acad Sci, Inst Genet & Dev Biol, Lab Mol & Dev Biol, Beijing, Peoples R China.	jianzhang84@genetics.ac.cn						BEDDINGTON RSP, 1989, DEVELOPMENT, V105, P733; Bernstein BE, 2006, CELL, V125, P315, DOI 10.1016/j.cell.2006.02.041; Bird AP, 1999, CELL, V99, P451, DOI 10.1016/S0092-8674(00)81532-9; Boyer LA, 2006, NATURE, V441, P349, DOI 10.1038/nature04733; Chambers I, 2003, CELL, V113, P643, DOI 10.1016/S0092-8674(03)00392-1; Chambers I, 2007, NATURE, V450, P1230, DOI 10.1038/nature06403; Chew JL, 2005, MOL CELL BIOL, V25, P6031, DOI 10.1128/MCB.25.14.6031-6046.2005; Grunstein M, 1997, NATURE, V389, P349, DOI 10.1038/38664; Gu PL, 2006, MOL CELL BIOL, V26, P9471, DOI 10.1128/MCB.00898-06; Hattori N, 2004, J BIOL CHEM, V279, P17063, DOI 10.1074/jbc.M309002200; Hendrich B, 1998, MOL CELL BIOL, V18, P6538, DOI 10.1128/MCB.18.11.6538; Hendrich B, 2001, GENE DEV, V15, P710, DOI 10.1101/gad.194101; Hendrich B, 2000, CURR TOP MICROBIOL, V249, P55; HOGAN B, 1996, MANIPULATING MOUSE E; Ivanova N, 2006, NATURE, V442, P533, DOI 10.1038/nature04915; Kaji K, 2006, NAT CELL BIOL, V8, P285, DOI 10.1038/ncb1372; Kaji K, 2007, DEVELOPMENT, V134, P1123, DOI 10.1242/dev.02802; Keller G, 2005, GENE DEV, V19, P1129, DOI 10.1101/gad.1303605; KELLER GM, 1995, CURR OPIN CELL BIOL, V7, P862, DOI 10.1016/0955-0674(95)80071-9; Koutsourakis M, 1999, DEVELOPMENT, V126, P723; Kouzarides T, 1999, CURR OPIN GENET DEV, V9, P40, DOI 10.1016/S0959-437X(99)80006-9; Lee TI, 2006, CELL, V125, P301, DOI 10.1016/j.cell.2006.02.043; Li E, 2002, NAT REV GENET, V3, P662, DOI 10.1038/nrg887; Li JW, 2002, GENE DEV, V16, P687, DOI 10.1101/gad.962502; Loh YH, 2006, NAT GENET, V38, P431, DOI 10.1038/ng1760; Mitsui K, 2003, CELL, V113, P631, DOI 10.1016/S0092-8674(03)00393-3; Nichols J, 1998, CELL, V95, P379, DOI 10.1016/S0092-8674(00)81769-9; Nightingale KP, 2006, CURR OPIN GENET DEV, V16, P125, DOI 10.1016/j.gde.2006.02.015; Niwa H, 2000, NAT GENET, V24, P372, DOI 10.1038/74199; Niwa H, 2005, CELL, V123, P917, DOI 10.1016/j.cell.2005.08.040; Niwa H, 2007, DEVELOPMENT, V134, P635, DOI 10.1242/dev.02787; Saburi S, 1997, DIFFERENTIATION, V62, P1, DOI 10.1046/j.1432-0436.1997.6210001.x; Sambrook J, 2001, MOL CLONING LAB MANU; Santos F, 2002, DEV BIOL, V241, P172, DOI 10.1006/dbio.2001.0501; SCHALL TJ, 1990, CELL, V61, P361, DOI 10.1016/0092-8674(90)90816-W; SMITH AG, 1988, NATURE, V336, P688, DOI 10.1038/336688a0; Soprano DR, 2007, VITAM HORM, V75, P69, DOI 10.1016/S0083-6729(06)75003-8; Spivakov M, 2007, NAT REV GENET, V8, P263, DOI 10.1038/nrg2046; Struhl K, 1998, GENE DEV, V12, P599, DOI 10.1101/gad.12.5.599; Strumpf D, 2005, DEVELOPMENT, V132, P2093, DOI 10.1242/dev.01801; Surani MA, 2007, CELL, V128, P747, DOI 10.1016/j.cell.2007.02.010; Tanaka S, 1998, SCIENCE, V282, P2072, DOI 10.1126/science.282.5396.2072; Tolkunova E, 2006, STEM CELLS, V24, P139, DOI 10.1634/stemcells.2005-0240; Tong JK, 1998, NATURE, V395, P917, DOI 10.1038/27699; TURNER BM, 1991, J CELL SCI, V99, P13; Velkey JM, 2003, GENESIS, V37, P18, DOI 10.1002/gene.10218; Wade PA, 1998, CURR BIOL, V8, P843, DOI 10.1016/S0960-9822(98)70328-8; Wang JL, 2006, NATURE, V444, P364, DOI 10.1038/nature05284; Wang XW, 2003, NUCLEIC ACIDS RES, V31, DOI 10.1093/nar/gng154; Wobus AM, 2005, PHYSIOL REV, V85, P635, DOI 10.1152/physrev.00054.2003; Xue YT, 1998, MOL CELL, V2, P851, DOI 10.1016/S1097-2765(00)80299-3; Zhang JQ, 2006, NAT CELL BIOL, V8, P1114, DOI 10.1038/ncb1481; Zhang Y, 1999, GENE DEV, V13, P1924, DOI 10.1101/gad.13.15.1924; Zhang Y, 1998, CELL, V95, P279, DOI 10.1016/S0092-8674(00)81758-4	54	38	44	1	20	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	NOV 3	2009	4	11							e7684	10.1371/journal.pone.0007684	http://dx.doi.org/10.1371/journal.pone.0007684			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	514RY	19888462	gold, Green Published, Green Submitted			2022-12-25	WOS:000271414500007
J	Grimaldi, A; Banfi, S; Gerosa, L; Tettamanti, G; Noonan, DM; Valvassori, R; de Eguileor, M				Grimaldi, Annalisa; Banfi, Serena; Gerosa, Laura; Tettamanti, Gianluca; Noonan, Douglas M.; Valvassori, Roberto; de Eguileor, Magda			Identification, Isolation and Expansion of Myoendothelial Cells Involved in Leech Muscle Regeneration	PLOS ONE			English	Article							ENDOTHELIAL GROWTH-FACTOR; STEM-CELLS; PROGENITOR CELLS; VEGF; DIFFERENTIATION	Adult skeletal muscle in vertebrates contains myoendothelial cells that express both myogenic and endothelial markers, and which are able to differentiate into myogenic cells to contribute to muscle regeneration. In spite of intensive research efforts, numerous questions remain regarding the role of cytokine signalling on myoendothelial cell differentiation and muscle regeneration. Here we used Hirudo medicinalis (Annelid, leech) as an emerging new model to study myoendothelial cells and muscle regeneration. Although the leech has relative anatomical simplicity, it shows a striking similarity with vertebrate responses and is a reliable model for studying a variety of basic events, such as tissue repair. Double immunohistochemical analysis were used to characterize myoendothelial cells in leeches and, by injecting in vivo the matrigel biopolymer supplemented with the cytokine Vascular Endothelial Growth Factor (VEGF), we were able to isolate this specific cell population expressing myogenic and endothelial markers. We then evaluated the effect of VEGF on these cells in vitro. Our data indicate that, similar to that proposed for vertebrates, myoendothelial cells of the leech directly participate in myogenesis both in vivo and in vitro, and that VEGF secretion is involved in the recruitment and expansion of these muscle progenitor cells.			Grimaldi, A (corresponding author), Univ Insubria, Dept Biotechnol & Mol Sci, Varese, Italy.	annalisa.grimaldi@uninsubria.it	Noonan, Douglas M/A-8620-2010; Tettamanti, Gianluca/E-5465-2012; Tettamanti, Gianluca/L-8748-2019	Noonan, Douglas M/0000-0001-8058-0719; Tettamanti, Gianluca/0000-0002-0665-828X; Tettamanti, Gianluca/0000-0002-0665-828X; Grimaldi, Annalisa/0000-0002-9258-7595	Associazione Italiana per la Ricerca sul Cancro Funding Source: Custom	Associazione Italiana per la Ricerca sul Cancro(Fondazione AIRC per la ricerca sul cancro)		Arsic N, 2004, MOL THER, V10, P844, DOI 10.1016/j.ymthe.2004.08.007; Asakura A, 2003, TRENDS CARDIOVAS MED, V13, P123, DOI 10.1016/S1050-1738(03)00024-0; Beauchamp JR, 2000, J CELL BIOL, V151, P1221, DOI 10.1083/jcb.151.6.1221; CHOI J, 1990, P NATL ACAD SCI USA, V87, P7988, DOI 10.1073/pnas.87.20.7988; de Eguileor M, 2000, TISSUE CELL, V32, P437; De Eguileor M., 2001, Angiogenesis, V4, P299, DOI 10.1023/A:1016025803370; De Eguileor M, 1999, J MICROSC-OXFORD, V196, P6, DOI 10.1046/j.1365-2818.1999.00600.x; De Eguileor M, 1998, J EXP ZOOL, V281, P171, DOI 10.1002/(SICI)1097-010X(19980615)281:3&lt;171::AID-JEZ3&gt;3.0.CO;2-K; FALINI B, 1993, AM J PATHOL, V142, P1359; Gerber HP, 2003, J MOL MED, V81, P20, DOI 10.1007/s00109-002-0397-4; Germani A, 2003, AM J PATHOL, V163, P1417, DOI 10.1016/S0002-9440(10)63499-2; Grimaldi A., 2004, ISJ, V1, P38; Grimaldi A, 2006, CURR PHARM DESIGN, V12, P3033, DOI 10.2174/138161206777947443; Grimaldi A, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0001910; Hatzopoulos AK, 1998, DEVELOPMENT, V125, P1457; HUGUET G, 1994, J EXP ZOOL, V269, P23, DOI 10.1002/jez.1402690104; Huguet G, 1996, J EXP ZOOL, V275, P308, DOI 10.1002/(SICI)1097-010X(19960701)275:4&lt;308::AID-JEZ9&gt;3.0.CO;2-T; HYNES RO, 1987, CELL, V48, P549, DOI 10.1016/0092-8674(87)90233-9; Jackson KA, 1999, P NATL ACAD SCI USA, V96, P14482, DOI 10.1073/pnas.96.25.14482; Kalka C, 2000, CIRC RES, V86, P1198, DOI 10.1161/01.RES.86.12.1198; KLEINMAN HK, 1986, BIOCHEMISTRY-US, V25, P312, DOI 10.1021/bi00350a005; KOCH AE, 1994, J IMMUNOL, V152, P4149; Krause DS, 2001, CELL, V105, P369, DOI 10.1016/S0092-8674(01)00328-2; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lagasse E, 2001, IMMUNITY, V14, P425, DOI 10.1016/S1074-7613(01)00123-6; Le Grand F, 2004, EXP CELL RES, V301, P232, DOI 10.1016/j.yexcr.2004.07.028; Lee TH, 2006, INT J CANCER, V119, P839, DOI 10.1002/ijc.21916; LEGORE RS, 1971, J INVERTEBR PATHOL, V18, P40, DOI 10.1016/0022-2011(91)90006-C; MAURO A, 1961, J BIOPHYS BIOCHEM CY, V9, P493, DOI 10.1083/jcb.9.2.493; Neufeld G, 1999, FASEB J, V13, P9, DOI 10.1096/fasebj.13.1.9; Pesce M, 2003, CIRC RES, V93, pE51, DOI 10.1161/01.RES.0000090624.04507.45; SCHULTZ E, 1994, REV PHYSIOL BIOCH P, V123, P213, DOI 10.1007/BFb0030904; Seale P, 2001, DEV CELL, V1, P333, DOI 10.1016/S1534-5807(01)00049-1; Tamaki T, 2002, J CELL BIOL, V157, P571, DOI 10.1083/jcb.200112106; Tettamanti G, 2003, CYTOKINE, V22, P168, DOI 10.1016/S1043-4666(03)00176-5; Tettamanti G, 2003, TISSUE CELL, V35, P199, DOI 10.1016/S0040-8166(03)00027-2; Towbin H, 1992, Biotechnology, V24, P145; VOYTA JC, 1984, J CELL BIOL, V99, P2034, DOI 10.1083/jcb.99.6.2034; Wang SS, 2008, P NATL ACAD SCI USA, V105, P7738, DOI 10.1073/pnas.0802857105; Zhang SJ, 2006, CELL RES, V16, P577, DOI 10.1038/sj.cr.7310075; Zheng B, 2007, NAT BIOTECHNOL, V25, P1025, DOI 10.1038/nbt1334	41	12	12	1	4	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	OCT 30	2009	4	10							e7652	10.1371/journal.pone.0007652	http://dx.doi.org/10.1371/journal.pone.0007652			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	514RW	19876402	gold, Green Submitted, Green Published			2022-12-25	WOS:000271414300010
J	Czyzyk, TA; Nogueiras, R; Lockwood, JF; McKinzie, JH; Coskun, T; Pintar, JE; Hammond, C; Tschop, MH; Statnick, MA				Czyzyk, Traci A.; Nogueiras, Ruben; Lockwood, John F.; McKinzie, Jamie H.; Coskun, Tamer; Pintar, John E.; Hammond, Craig; Tschop, Matthias H.; Statnick, Michael A.			kappa-Opioid receptors control the metabolic response to a high-energy diet in mice	FASEB JOURNAL			English	Article						malonyl CoA; corticosterone; hepatocytes; energy expenditure; nonexercise activity thermogenesis	INDUCED OBESITY; MESSENGER-RNA; FOOD-INTAKE; PARAVENTRICULAR NUCLEUS; PREFRONTAL CORTEX; DEFICIENT MICE; MOUSE-BRAIN; MALONYL-COA; DYNORPHIN; RAT	General opioid receptor antagonists reduce food intake and body weight in rodents, but the contributions of specific receptor subtypes are unknown. We examined whether genetic deletion of the kappa-opioid receptor (KOR) in mice alters metabolic physiology. KOR-knockout (KO) and wild-type (WT) mice were fed a high-energy diet (HED) for 16 wk. KO mice had 28% lower body weight and 45% lower fat mass when compared to WT mice fed an HED. No differences in caloric intake were found. An HED reduced energy expenditure in WT mice, but not in KO mice. KOR deficiency led to an attenuation of triglyceride synthesis in the liver. Malonyl CoA levels were also reduced in response to an HED, thereby promoting hepatic beta-oxidation. Glycemic control was also found to be improved in KO mice. These data suggest a key role for KORs in the central nervous system regulation of the metabolic adaptation to an HED, as we were unable to detect expression of KOR in liver, white adipose tissue, or skeletal muscle in WT mice. This study provides the first evidence that KORs play an essential physiological role in the control of hepatic lipid metabolism, and KOR activation is a permissive signal toward fat storage.-Czyzyk, T. A., Nogueiras, R., Lockwood, J. F., McKinzie, J. H., Coskun, T., Pintar, J. E., Hammond, C., Tschop, M. H., Statnick, M. A. kappa-Opioid receptors control the metabolic response to a high-energy diet in mice. FASEB J. 24, 1151-1159 (2010). www.fasebj.org	[Czyzyk, Traci A.] Eli Lilly & Co, Lilly Corp Ctr, Lilly Res Labs, Indianapolis, IN 46285 USA; [Nogueiras, Ruben; Tschop, Matthias H.] Univ Cincinnati, Dept Med, Div Endocrinol, Metab Dis Inst, Cincinnati, OH 45221 USA; [Pintar, John E.] Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Dept Neurosci & Cell Biol, Piscataway, NJ 08854 USA; [Nogueiras, Ruben] Univ Santiago de Compostela, Dept Physiol, Inst Invest Sanitaria, Santiago De Compostela, Spain	Eli Lilly; University System of Ohio; University of Cincinnati; Rutgers State University New Brunswick; Rutgers State University Medical Center; Universidade de Santiago de Compostela	Czyzyk, TA (corresponding author), Eli Lilly & Co, Lilly Corp Ctr, Lilly Res Labs, DC 0403,355 E Merrill St, Indianapolis, IN 46285 USA.	czyzyk-morgantr@lilly.com; m.statnick@lilly.com	Nogueiras, Ruben/AAS-9427-2021; Coskun, Tamer/AAR-8422-2021; Tschoep, Matthias H/I-5443-2014	Nogueiras, Ruben/0000-0002-9976-9930; Tschoep, Matthias/0000-0002-4744-371X; Czyzyk, Traci/0000-0002-3888-8338	National Institutes of Health [NIDDK59630, NIDDK69987, NIDDK56863]	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)	The authors thank Aaron Showalter, Jim Baker, and Kelly Credile for their outstanding technical support and helpful advice. The authors also thank David Peake, Lawrence Goodwin, Thomas Seng, David Yurek, Rita Davidson, and MingShang Kuo for development of LC-MS/MS methods for malonyl CoA measurements. Research at the University of Cincinnati was funded by National Institutes of Health grants NIDDK59630, NIDDK69987, and NIDDK56863 (to M.H.T.). Portions of this work were presented in abstract form for the 2009 Keystone Symposia, Obesity: Novel Aspects of the Regulation of Body Weight (Banff, AB, Canada).	Ansonoff MA, 2006, J PHARMACOL EXP THER, V318, P641, DOI 10.1124/jpet.106.101998; Bodnar RJ, 2004, PEPTIDES, V25, P697, DOI 10.1016/j.peptides.2004.01.006; Brugman S, 2002, ENDOCRINOLOGY, V143, P4265, DOI 10.1210/en.2002-220230; Chang GQ, 2007, AM J PHYSIOL-ENDOC M, V292, pE561, DOI 10.1152/ajpendo.00087.2006; Chefer VI, 2005, J NEUROSCI, V25, P5029, DOI 10.1523/JNEUROSCI.0854-05.2005; Chien D, 2000, AM J PHYSIOL-ENDOC M, V279, pE259, DOI 10.1152/ajpendo.2000.279.2.E259; Chou TC, 2001, J NEUROSCI, V21, DOI 10.1523/JNEUROSCI.21-19-j0003.2001; Cooke D, 2006, NAT REV DRUG DISCOV, V5, P919, DOI 10.1038/nrd2136; CZYZYK TA, 1999, 29 ANN SOC NEUR M, V25, P179; DEPAOLI AM, 1994, MOL CELL NEUROSCI, V5, P327, DOI 10.1006/mcne.1994.1039; DICHIARA G, 1988, J PHARMACOL EXP THER, V244, P1067; FLATT JP, 1993, ANN NY ACAD SCI, V683, P122; KAPAS S, 1995, J ENDOCRINOL, V144, P503, DOI 10.1677/joe.0.1440503; Kieffer BL, 2002, PROG NEUROBIOL, V66, P285, DOI 10.1016/S0301-0082(02)00008-4; KOCH JE, 1995, NEUROSCIENCE, V66, P951, DOI 10.1016/0306-4522(95)00001-Y; Kokkotou E, 2005, AM J PHYSIOL-REG I, V289, pR117, DOI 10.1152/ajpregu.00861.2004; Lean MEJ, 2000, P NUTR SOC, V59, P331, DOI 10.1017/S0029665100000379; LEVINE AS, 1991, BRAIN RES, V566, P193, DOI 10.1016/0006-8993(91)91698-Z; MANSOUR A, 1994, MOL CELL NEUROSCI, V5, P124, DOI 10.1006/mcne.1994.1015; Maolood N, 2008, NEUROSCIENCE, V154, P1121, DOI 10.1016/j.neuroscience.2008.04.011; Margolis EB, 2006, P NATL ACAD SCI USA, V103, P2938, DOI 10.1073/pnas.0511159103; Minkler PE, 2006, ANAL BIOCHEM, V352, P24, DOI 10.1016/j.ab.2006.02.015; MORLEY JE, 1983, PEPTIDES, V4, P797, DOI 10.1016/0196-9781(83)90069-4; Ogden CL, 2006, JAMA-J AM MED ASSOC, V295, P1549, DOI 10.1001/jama.295.13.1549; Pfluger PT, 2008, P NATL ACAD SCI USA, V105, P9793, DOI 10.1073/pnas.0802917105; Pfluger PT, 2008, AM J PHYSIOL-GASTR L, V294, pG610, DOI 10.1152/ajpgi.00321.2007; Roy S, 1998, MOL BRAIN RES, V56, P281, DOI 10.1016/S0169-328X(98)00051-5; Ruderman NB, 2003, ENDOCRINOLOGY, V144, P5166, DOI 10.1210/en.2003-0849; SAHR AE, 2008, AM J PHYSIOL, V295, pR468; Sainsbury A, 2007, MOL ENDOCRINOL, V21, P1722, DOI 10.1210/me.2006-0367; SHAW WN, 1993, PHARMACOL BIOCHEM BE, V46, P653, DOI 10.1016/0091-3057(93)90557-A; SHAW WN, 1991, INT J OBESITY, V15, P387; Shuster SJ, 2000, NEUROSCIENCE, V96, P373, DOI 10.1016/S0306-4522(99)00472-8; Simonin F, 1998, EMBO J, V17, P886, DOI 10.1093/emboj/17.4.886; Smith MJ, 2001, BRAIN RES, V898, P162, DOI 10.1016/S0006-8993(01)02154-0; Statnick MA, 2003, AM J PHYSIOL-REG I, V284, pR1399, DOI 10.1152/ajpregu.00632.2002; Svingos AL, 2002, BRAIN RES, V946, P262, DOI 10.1016/S0006-8993(02)02894-9; Svingos AL, 1999, J NEUROSCI, V19, P1804; Tabarin A, 2005, DIABETES, V54, P3510, DOI 10.2337/diabetes.54.12.3510; Tataranni PA, 1996, AM J PHYSIOL-ENDOC M, V271, pE317, DOI 10.1152/ajpendo.1996.271.2.E317; Welch CC, 1996, BRAIN RES, V721, P126, DOI 10.1016/0006-8993(96)00151-5; Wittmann W, 2009, NEUROPSYCHOPHARMACOL, V34, P775, DOI 10.1038/npp.2008.142; YASUDA K, 1993, P NATL ACAD SCI USA, V90, P6736, DOI 10.1073/pnas.90.14.6736; Zuberi AR, 2008, EUR J PHARMACOL, V585, P14, DOI 10.1016/j.ejphar.2008.01.047	44	63	64	0	4	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	APR	2010	24	4					1151	1159		10.1096/fj.09-143610	http://dx.doi.org/10.1096/fj.09-143610			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	580PV	19917675	Green Published			2022-12-25	WOS:000276462300022
J	Lu, Y; Liu, P; James, M; Vikis, HG; Liu, H; Wen, W; Franklin, A; You, M				Lu, Y.; Liu, P.; James, M.; Vikis, H. G.; Liu, H.; Wen, W.; Franklin, A.; You, M.			Genetic variants cis-regulating Xrn2 expression contribute to the risk of spontaneous lung tumor	ONCOGENE			English	Article						expression; association; lung cancer; mouse	GENOME-WIDE ASSOCIATION; SUSCEPTIBILITY LOCUS; SQUAMOUS DIFFERENTIATION; SEQUENCE VARIANTS; CANCER RISK; MOUSE; NONSMOKERS; ADENOCARCINOMAS; DISEASE; CELLS	Gene expression variation is an important mechanism underlying susceptibility to complex disease. In comparison with tobacco-related lung carcinogenesis, lung cancer in nonsmokers may involve important and etiologically distinct causal pathways. In this study, we conducted a genome-wide association study on spontaneous lung tumor incidence in inbred mice and identified a major susceptibility locus on mouse chromosome 2 (rs27328255, P = 6.68 x 10(-7)). We then evaluated the correlations of polymorphisms with the transcription of positional candidate genes in normal lungs. Single-nucleotide polymorphism rs27328255 was consistently and strongly associated (P = 7.42 x 10(-9)) in cis with transcript levels of Xrn2. We further showed that Xrn2 promotes proliferation and inhibits squamous differentiation in human lung epithelial cells and polymorphisms in human homolog XRN2 are associated with human lung cancer (rs2025811, P = 1.90 x 10(-3), OR = 1.20). We conclude that genetic variants regulating Xrn2 expression in cis are determinants of spontaneous lung tumor susceptibility in mice and have genetic equivalents in lung cancer susceptibility in human beings. Identifying Xrn2 as a major candidate for spontaneous lung cancer has important implications for the diagnosis and treatment of lung cancer as well as delineation of the mechanisms underlying the genesis of lung cancer in nonsmokers. Oncogene (2010) 29, 1041-1049; doi:10.1038/onc.2009.396; published online 16 November 2009	[You, M.] Washington Univ, Sch Med, Dept Surg, St Louis, MO 63110 USA; Washington Univ, Sch Med, Alvin J Siteman Canc Ctr, St Louis, MO 63110 USA	Washington University (WUSTL); Siteman Cancer Center; Washington University (WUSTL)	You, M (corresponding author), Washington Univ, Sch Med, Dept Surg, Campus Box 8109,660 S Euclid Ave, St Louis, MO 63110 USA.	youm@wudosis.wustl.edu		James, Michael/0000-0002-8112-1108	US National Institutes of Health [CA099187, CA099147, ES012063, ES013340]; NATIONAL CANCER INSTITUTE [R01CA099147, R01CA139959, R01CA099187] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES013340, R01ES012063] Funding Source: NIH RePORTER	US National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))	We thank the Broad Institute of Harvard/Massachusetts General Hospital and Massachusetts Institute of Technology, the Wellcome Trust Center for Human Genetics at Oxford University, and Perlegen Sciences for releasing inbred laboratory mouse SNP data. We thank the Mouse Phenome Project for collecting mouse SNP data. We thank the International Agency for Research on Cancer (Lyon, France) for releasing lung cancer GWAS data. We also thank investigators for generating spontaneous lung tumor data in inbred mice. The mouse SNP and phenotype data were crucial for the key findings described in this paper. We thank the staff of The Vanderbilt Microarray Shared Resource for microarray processing. MY was supported by grants from the US National Institutes of Health (CA099187, CA099147, ES012063, and ES013340). We thank Dr Jay W Tichelaar for his critical comments on the manuscript.	Amos CI, 2008, NAT GENET, V40, P616, DOI 10.1038/ng.109; Borczuk AC, 2003, AM J PATHOL, V163, P1949, DOI 10.1016/S0002-9440(10)63553-5; Borczuk Alain C, 2007, Proc Am Thorac Soc, V4, P127, DOI 10.1513/pats.200607-143JG; Clark AG, 2005, GENOME RES, V15, P1496, DOI 10.1101/gr.4107905; Cookson W, 2009, NAT REV GENET, V10, P184, DOI 10.1038/nrg2537; Couzin J, 2007, SCIENCE, V316, P820, DOI 10.1126/science.316.5826.820; DOLL R, 1981, JNCI-J NATL CANCER I, V66, P1191, DOI 10.1093/jnci/66.6.1192; FOLEY JF, 1991, EXP LUNG RES, V17, P157, DOI 10.3109/01902149109064408; Frazer KA, 2007, NATURE, V448, P1050, DOI 10.1038/nature06067; Hung RJ, 2008, NATURE, V452, P633, DOI 10.1038/nature06885; Jemal A, 2009, CA-CANCER J CLIN, V59, P225, DOI 10.3322/caac.20006; Kang HM, 2008, GENETICS, V178, P1709, DOI 10.1534/genetics.107.080101; KE Y, 1988, DIFFERENTIATION, V38, P60, DOI 10.1111/j.1432-0436.1988.tb00592.x; Kendall J, 2007, P NATL ACAD SCI USA, V104, P16663, DOI 10.1073/pnas.0708286104; Kimura S, 1996, GENE DEV, V10, P60, DOI 10.1101/gad.10.1.60; Kuntz E, 2006, ARCH BIOCHEM BIOPHYS, V455, P48, DOI 10.1016/j.abb.2006.08.023; Kwei KA, 2008, ONCOGENE, V27, P3635, DOI 10.1038/sj.onc.1211012; Li JX, 2005, DNA SEQUENCE, V16, P143, DOI 10.1080/10425170500066771; Liu PY, 2008, JNCI-J NATL CANCER I, V100, P1326, DOI 10.1093/jnci/djn268; Liu PY, 2006, NAT GENET, V38, P888, DOI 10.1038/ng1849; Matakidou A, 2005, BRIT J CANCER, V93, P825, DOI 10.1038/sj.bjc.6602769; McKay JD, 2008, NAT GENET, V40, P1404, DOI 10.1038/ng.254; Meuwissen R, 2005, GENE DEV, V19, P643, DOI 10.1101/gad.1284505; Moffatt MF, 2007, NATURE, V448, P470, DOI 10.1038/nature06014; Morley M, 2004, NATURE, V430, P743, DOI 10.1038/nature02797; Park MH, 2007, ONCOL REP, V18, P1395; Powell CA, 2003, LUNG CANCER-J IASLC, V39, P23, DOI 10.1016/S0169-5002(02)00384-7; Rafnar T, 2009, NAT GENET, V41, P221, DOI 10.1038/ng.296; SAID JW, 1983, LAB INVEST, V49, P563; Schadt EE, 2003, NATURE, V422, P297, DOI 10.1038/nature01434; Shigematsu H, 2006, INT J CANCER, V118, P257, DOI 10.1002/ijc.21496; Smith R, 2006, CANCER CELL, V9, P405, DOI 10.1016/j.ccr.2006.04.004; Tanaka H, 2007, CANCER RES, V67, P6007, DOI 10.1158/0008-5472.CAN-06-4774; Tang H, 2008, DEV BIOL, V318, P73, DOI 10.1016/j.ydbio.2008.03.001; Thorgeirsson TE, 2008, NATURE, V452, P638, DOI 10.1038/nature06846; Thun MJ, 2006, JNCI-J NATL CANCER I, V98, P691, DOI 10.1093/jnci/djj187; Tian JM, 2006, CANCER RES, V66, P10399, DOI 10.1158/0008-5472.CAN-06-1564; Wacholder S, 2008, JNCI-J NATL CANCER I, V100, DOI 10.1093/jnci/djn380; WALTS AE, 1985, J PATHOL, V145, P329, DOI 10.1002/path.1711450406; Wang YF, 2008, NAT GENET, V40, P1407, DOI 10.1038/ng.273; Weir BA, 2007, NATURE, V450, P893, DOI 10.1038/nature06358; Wong MP, 2003, CANCER, V97, P1263, DOI 10.1002/cncr.11183; You M, 1998, HEMATOL ONCOL CLIN N, V12, P1037, DOI 10.1016/S0889-8588(05)70040-X; Zeka A, 2006, EPIDEMIOLOGY, V17, P615, DOI 10.1097/01.ede.0000239582.92495.b5	44	18	19	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 18	2010	29	7					1041	1049		10.1038/onc.2009.396	http://dx.doi.org/10.1038/onc.2009.396			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	556PV	19915612	Green Accepted			2022-12-25	WOS:000274604400010
J	Jeong, SM; Lee, C; Lee, SK; Kim, J; Seong, RH				Jeong, Seung Min; Lee, Changjin; Lee, Sung Kyu; Kim, Jieun; Seong, Rho Hyun			The SWI/SNF Chromatin-remodeling Complex Modulates Peripheral T Cell Activation and Proliferation by Controlling AP-1 Expression	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; KINASE-C-THETA; EXPERIMENTAL AUTOIMMUNE ENCEPHALOMYELITIS; GLUCOCORTICOID-INDUCED APOPTOSIS; MULTIPLE-SCLEROSIS LESIONS; TUMOR-NECROSIS-FACTOR; PKC-THETA; TRANSCRIPTION FACTORS; SRG3 EXPRESSION; BAF COMPLEX	The SWI/SNF chromatin-remodeling complex has been implicated in the activation and proliferation of T cells. After T cell receptor signaling, the SWI/SNF complex rapidly associates with chromatin and controls gene expression in T cells. However, the process by which the SWI/SNF complex regulates peripheral T cell activation has not been elucidated. In this study, we show that the SWI/SNF complex regulates cytokine production and proliferation of T cells. During T cell activation, the SWI/SNF complex is recruited to the promoter of the transcription factor AP-1, and it increases the expression of AP-1. Increased expression of the SWI/SNF complex resulted in enhanced AP-1 activity, cytokine production, and proliferation of peripheral T cells, whereas knockdown of the SWI/SNF complex expression impaired the AP-1 expression and reduced the activation and proliferation of T cells. Moreover, mice that constitutively expressed the SWI/SNF complex in T cells were much more susceptible to experimentally induced autoimmune encephalomyelitis than the normal mice were. These results suggest that the SWI/SNF complex plays a critical role during T cell activation and subsequent immune responses.	[Seong, Rho Hyun] Seoul Natl Univ, Dept Biol Sci, Inst Mol Biol & Genet, Seoul 151742, South Korea; Seoul Natl Univ, Res Ctr Funct Cellul, Seoul 151742, South Korea	Seoul National University (SNU); Seoul National University (SNU)	Seong, RH (corresponding author), Seoul Natl Univ, Dept Biol Sci, Inst Mol Biol & Genet, 599 Gwanangno, Seoul 151742, South Korea.	rhseong@snu.ac.kr		Seong, Rho/0000-0001-5699-0718	National Research Foundation of Korea; Ministry of Education, Science, and Technology; Research Center for Functional Cellulomics; Priority Research Centers Program [2009-0094022]; Ministry of Education and Human Resources Development [BK21]; Seoul Science Fellowship	National Research Foundation of Korea(National Research Foundation of Korea); Ministry of Education, Science, and Technology(Ministry of Education, Science & Technology (MEST), Republic of Korea); Research Center for Functional Cellulomics; Priority Research Centers Program; Ministry of Education and Human Resources Development(Ministry of Education & Human Resources Development (MOEHRD), Republic of Korea); Seoul Science Fellowship	This work was supported by grants from the National Research Foundation of Korea, funded by the Ministry of Education, Science, and Technology, in part through the Research Center for Functional Cellulomics and in part through the Priority Research Centers Program (2009-0094022).; Supported by the BK21 Program of the Ministry of Education and Human Resources Development.; Supported by a Seoul Science Fellowship.	Baier G, 2003, IMMUNOL REV, V192, P64, DOI 10.1034/j.1600-065X.2003.00018.x; BaierBitterlich G, 1996, MOL CELL BIOL, V16, P1842; Baldwin AS, 1996, ANNU REV IMMUNOL, V14, P649, DOI 10.1146/annurev.immunol.14.1.649; Baud V, 2001, TRENDS CELL BIOL, V11, P372, DOI 10.1016/S0962-8924(01)02064-5; Bonetti B, 1999, AM J PATHOL, V155, P1433, DOI 10.1016/S0002-9440(10)65456-9; Burgos P, 2000, J RHEUMATOL, V27, P116; Carpino N, 2004, IMMUNITY, V20, P37, DOI 10.1016/S1074-7613(03)00351-0; Chi TH, 2003, IMMUNITY, V19, P169, DOI 10.1016/S1074-7613(03)00199-7; Chi TH, 2002, NATURE, V418, P195, DOI 10.1038/nature00876; CRABTREE GR, 1994, ANNU REV BIOCHEM, V63, P1045, DOI 10.1146/annurev.biochem.63.1.1045; Cua DJ, 2003, NATURE, V421, P744, DOI 10.1038/nature01355; Eberhardt W, 2000, J IMMUNOL, V165, P5788, DOI 10.4049/jimmunol.165.10.5788; Fontenot JD, 2004, SEMIN IMMUNOL, V16, P73, DOI 10.1016/j.smim.2003.12.002; Gebuhr TC, 2003, J EXP MED, V198, P1937, DOI 10.1084/jem.20030714; Geiman TM, 2000, P NATL ACAD SCI USA, V97, P4772, DOI 10.1073/pnas.97.9.4772; Gveric D, 1998, J NEUROPATH EXP NEUR, V57, P168, DOI 10.1097/00005072-199802000-00008; Han SM, 2001, J IMMUNOL, V167, P805, DOI 10.4049/jimmunol.167.2.805; Hayashi K, 2007, PHARMACOL RES, V55, P537, DOI 10.1016/j.phrs.2007.04.009; Isakov N, 2002, ANNU REV IMMUNOL, V20, P761, DOI 10.1146/annurev.immunol.20.100301.064807; JAIN J, 1995, CURR OPIN IMMUNOL, V7, P333, DOI 10.1016/0952-7915(95)80107-3; Jeon SH, 1997, J EXP MED, V185, P1827, DOI 10.1084/jem.185.10.1827; Jeong SM, 2004, J BIOL CHEM, V279, P34373, DOI 10.1074/jbc.M403461200; JOHNSON RS, 1993, GENE DEV, V7, P1309, DOI 10.1101/gad.7.7b.1309; KARIN M, 1995, J BIOL CHEM, V270, P16483, DOI 10.1074/jbc.270.28.16483; Karin M, 1997, CURR OPIN CELL BIOL, V9, P240, DOI 10.1016/S0955-0674(97)80068-3; Kawai T, 2004, NAT IMMUNOL, V5, P1061, DOI 10.1038/ni1118; Ko M, 2004, J BIOL CHEM, V279, P21903, DOI 10.1074/jbc.M402144200; Kuchroo VK, 2002, ANNU REV IMMUNOL, V20, P101, DOI 10.1146/annurev.immunol.20.081701.141316; Langrish CL, 2005, J EXP MED, V201, P233, DOI 10.1084/jem.20041257; Lee GR, 2006, IMMUNITY, V24, P369, DOI 10.1016/j.immuni.2006.03.007; Lee KY, 2007, J IMMUNOL, V178, P7088, DOI 10.4049/jimmunol.178.11.7088; Letimier FA, 2007, EMBO J, V26, P1292, DOI 10.1038/sj.emboj.7601586; Li YQ, 2004, EMBO J, V23, P1112, DOI 10.1038/sj.emboj.7600125; Lichtinghagen R, 1999, J NEUROIMMUNOL, V99, P19, DOI 10.1016/S0165-5728(99)00094-6; McGargill MA, 2004, IMMUNITY, V21, P781, DOI 10.1016/j.immuni.2004.10.008; NORTHROP JP, 1994, NATURE, V369, P497, DOI 10.1038/369497a0; Ohashi PS, 2002, NAT REV IMMUNOL, V2, P427, DOI 10.1038/nri822; RIECKMANN P, 1995, ANN NEUROL, V37, P82, DOI 10.1002/ana.410370115; RINCON M, 1994, EMBO J, V13, P4370, DOI 10.1002/j.1460-2075.1994.tb06757.x; Sakaguchi S, 2005, NAT IMMUNOL, V6, P345, DOI 10.1038/ni1178; Seetharaman R, 1999, J IMMUNOL, V163, P1577; Smale ST, 2002, ANNU REV IMMUNOL, V20, P427, DOI 10.1146/annurev.immunol.20.100301.064739; Sohn DH, 2007, J BIOL CHEM, V282, P10614, DOI 10.1074/jbc.M610563200; Sun ZM, 2000, NATURE, V404, P402, DOI 10.1038/35006090; Tan SL, 2006, J IMMUNOL, V176, P2872, DOI 10.4049/jimmunol.176.5.2872; Tsokos GC, 2000, CURR OPIN RHEUMATOL, V12, P355, DOI 10.1097/00002281-200009000-00001; Wang WD, 1996, GENE DEV, V10, P2117, DOI 10.1101/gad.10.17.2117; Willenborg DO, 2003, ADV EXP MED BIOL, V520, P96; Zenz R, 2008, ARTHRITIS RES THER, V10, DOI 10.1186/ar2338; Zhang FP, 2006, J EXP MED, V203, P1493, DOI 10.1084/jem.20060066; Zhao KJ, 1998, CELL, V95, P625, DOI 10.1016/S0092-8674(00)81633-5	51	17	19	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 22	2010	285	4					2340	2350		10.1074/jbc.M109.026997	http://dx.doi.org/10.1074/jbc.M109.026997			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	544YP	19910461	Green Published, hybrid			2022-12-25	WOS:000273697800014
J	Frietze, S; Lan, X; Jin, VX; Farnham, PJ				Frietze, Seth; Lan, Xun; Jin, Victor X.; Farnham, Peggy J.			Genomic Targets of the KRAB and SCAN Domain-containing Zinc Finger Protein 263	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FACTOR-BINDING SITES; DNA RECOGNITION; IDENTIFICATION; WEB; BOX	Half of all human transcription factors use C2H2 zinc finger domains to specify site-specific DNA binding and yet very little is known about their role in gene regulation. Based on in vitro studies, a zinc finger code has been developed that predicts a binding motif for a particular zinc finger factor (ZNF). However, very few studies have performed genome-wide analyses of ZNF binding patterns, and thus, it is not clear if the binding code developed in vitro will be useful for identifying target genes of a particular ZNF. We performed genome-wide ChIP-seq for ZNF263, a C2H2 ZNF that contains 9 finger domains, a KRAB repression domain, and a SCAN domain and identified more than 5000 binding sites in K562 cells. Our results suggest that ZNF263 binds to a 24-nt site that differs from the motif predicted by the zinc finger code in several positions. Interestingly, many of the ZNF263 binding sites are located within the transcribed region of the target gene. Although ZNFs containing a KRAB domain are thought to function mainly as transcriptional repressors, many of the ZNF263 target genes are expressed at high levels. To address the biological role of ZNF263, we identified genes whose expression was altered by treatment of cells with ZNF263-specific small interfering RNAs. Our results suggest that ZNF263 can have both positive and negative effects on transcriptional regulation of its target genes.	[Lan, Xun; Jin, Victor X.] Ohio State Univ, Dept Biomed Informat, Columbus, OH 43210 USA; Univ Calif Davis, Dept Pharmacol, Davis, CA 95616 USA; Univ Calif Davis, Genome Ctr, Davis, CA 95616 USA	University System of Ohio; Ohio State University; University of California System; University of California Davis; University of California System; University of California Davis	Jin, VX (corresponding author), Ohio State Univ, Dept Biomed Informat, Columbus, OH 43210 USA.	Victor.Jin@osumc.edu; pjfarnham@ucdavis.edu		Lan, Xun/0000-0002-6523-046X; Farnham, Peggy/0000-0003-4469-7914	National Institutes of Health [CA45250, 1U54HG004558]; NCBI Gene Expression Omnibus [GSE19235, GSE19146]; NATIONAL CANCER INSTITUTE [R01CA045240] Funding Source: NIH RePORTER; NATIONAL HUMAN GENOME RESEARCH INSTITUTE [U54HG004558] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NCBI Gene Expression Omnibus; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HUMAN GENOME RESEARCH INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI))	This work was supported, in whole or in part, by National Institutes of Health Grants CA45250 and 1U54HG004558 (United States Public Health Service). The ChIP-seq data and the RNA expression array data of this protein can be accessed through the NCBI Gene Expression Omnibus under NCBI accession numbers GSE19235 and GSE19146.	Badis G, 2009, SCIENCE, V324, P1720, DOI 10.1126/science.1162327; Bailey TL, 1997, J COMPUT BIOL, V4, P45, DOI 10.1089/cmb.1997.4.45; Bieda M, 2006, GENOME RES, V16, P595, DOI 10.1101/gr.4887606; Carroll JS, 2005, CELL, V122, P33, DOI 10.1016/j.cell.2005.05.008; Cawley S, 2004, CELL, V116, P499, DOI 10.1016/S0092-8674(04)00127-8; Cho SY, 2008, BIOCHEM BIOPH RES CO, V369, P845, DOI 10.1016/j.bbrc.2008.02.106; Hon LS, 2006, BIOINFORMATICS, V22, P1047, DOI 10.1093/bioinformatics/btl037; Huntley S, 2006, GENOME RES, V16, P669, DOI 10.1101/gr.4842106; Iuchi S, 2001, CELL MOL LIFE SCI, V58, P625, DOI 10.1007/PL00000885; Jin VX, 2007, GENOME RES, V17, P807, DOI 10.1101/gr.6006107; Jothi R, 2008, NUCLEIC ACIDS RES, V36, P5221, DOI 10.1093/nar/gkn488; KADONAGA JT, 1986, P NATL ACAD SCI USA, V83, P5889, DOI 10.1073/pnas.83.16.5889; Kouzarides T, 2007, CELL, V128, P693, DOI 10.1016/j.cell.2007.02.005; Liu JJ, 2008, BIOINFORMATICS, V24, P1850, DOI 10.1093/bioinformatics/btn331; Mahony S, 2007, NUCLEIC ACIDS RES, V35, pW253, DOI 10.1093/nar/gkm272; Pavesi G, 2004, NUCLEIC ACIDS RES, V32, pW199, DOI 10.1093/nar/gkh465; Robertson G, 2007, NAT METHODS, V4, P651, DOI 10.1038/NMETH1068; Segal DJ, 2000, CURR OPIN CHEM BIOL, V4, P34, DOI 10.1016/S1367-5931(99)00048-4; Sripathy SP, 2006, MOL CELL BIOL, V26, P8623, DOI 10.1128/MCB.00487-06; Sui SJH, 2005, NUCLEIC ACIDS RES, V33, P3154, DOI 10.1093/nar/gki624; Tanaka K, 2002, MOL CELL BIOL, V22, P4256, DOI 10.1128/MCB.22.12.4256-4267.2002; Tupler R, 2001, NATURE, V409, P832, DOI 10.1038/35057011; Williams AJ, 1999, MOL CELL BIOL, V19, P8526; Wingender E, 2000, NUCLEIC ACIDS RES, V28, P316, DOI 10.1093/nar/28.1.316; Yokoyama M, 1997, BBA-GENE STRUCT EXPR, V1353, P13, DOI 10.1016/S0167-4781(97)00074-2	25	72	73	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 8	2010	285	2					1393	1403		10.1074/jbc.M109.063032	http://dx.doi.org/10.1074/jbc.M109.063032			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	539MH	19887448	Green Published, hybrid			2022-12-25	WOS:000273258200059
J	Nogales, A; Garcia, C; Perez, J; Callow, P; Ezquerra, TA; Gonzalez-Rodriguez, J				Nogales, Aurora; Garcia, Carolina; Perez, Javier; Callow, Phil; Ezquerra, Tiberio A.; Gonzalez-Rodriguez, Jose			Three-dimensional Model of Human Platelet Integrin alpha IIb beta 3 in Solution Obtained by Small Angle Neutron Scattering	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CRYSTAL-STRUCTURE; EXTRACELLULAR SEGMENT; GLYCOPROTEIN-IIB; STRUCTURAL BASIS; DISULFIDE BONDS; X-RAY; ACTIVATION; ALPHA(IIB)BETA(3); ALPHA-V-BETA-3; MEMBRANE	Integrin alpha IIb beta 3 is the major membrane protein and adhesion receptor at the surface of blood platelets, which after activation plays a key role in platelet plug formation in hemostasis and thrombosis. Small angle neutron scattering (SANS) and shape reconstruction algorithms allowed formation of a low resolution three-dimensional model of whole alpha IIb beta 3 in Ca2+/detergent solutions. Model projections after 90 degrees rotation along its long axis show an elongated and "arched" form (135 degrees) not observed before and a "handgun" form. This 20-nm-long structure is well defined, despite alpha IIb beta 3 multidomain nature and expected segmental flexibility, with the largest region at the top, followed by two narrower and smaller regions at the bottom. Docking of this SANS envelope into the high resolution structure of alpha IIb beta 3, reconstructed from crystallographic and NMR data, shows that the solution structure is less constrained, allows tentative assignment of the disposition of the alpha IIb and beta 3 sub-units and their domains within the model, and points out the structural analogies and differences of the SANS model with the crystallographic models of the recombinant ectodomains of alpha IIb beta 3 and alpha V beta 3 and with the cryo-electron microscopy model of whole alpha IIb beta 3. The ectodomain is in the bent configuration at the top of the model, where alpha IIb and beta 3 occupy the concave and convex sides, respectively, at the arched projection, with their bent knees at its apex. It follows the narrower transmembrane region and the cytoplasmic domains at the bottom end. alpha IIb beta 3 aggregated in Mn2+/detergent solutions, which impeded to get its SANS model.	[Garcia, Carolina; Gonzalez-Rodriguez, Jose] Consejo Super Invest Cient, Dept Biofis, Inst Quim Fis, Madrid 28006, Spain; [Nogales, Aurora; Ezquerra, Tiberio A.] Consejo Super Invest Cient, Dept Fis Macromol, Inst Estructura Mat, Madrid 28006, Spain; [Perez, Javier] Synchrotron SOLEIL, SWING, F-91192 Gif Sur Yvette, France; [Callow, Phil] Inst Max Von Laue Paul Langevin, F-38042 Grenoble 9, France	Consejo Superior de Investigaciones Cientificas (CSIC); Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Instituto de Estructura de la Materia (IEM); SOLEIL Synchrotron; Institut Laue-Langevin (ILL)	Gonzalez-Rodriguez, J (corresponding author), Consejo Super Invest Cient, Dept Biofis, Inst Quim Fis, Serrano 119, Madrid 28006, Spain.	j.gonzalez-rodriguez@iqfr.csic.es	Ezquerra, Tiberio A/N-5011-2014; Nogales, Aurora/A-8768-2008; Garcia, Carolina/E-9104-2015	Ezquerra, Tiberio A/0000-0001-9966-519X; Nogales, Aurora/0000-0002-2494-3551; Garcia, Carolina/0000-0001-5138-6191	SAF [2003-042/66]; Intramural Frontera [200680F-0083]	SAF; Intramural Frontera	This work was supported by Grants SAF 2003-042/66 (2003-2007) and Intramural Frontera 200680F-0083 (2007-2008) (to J. G.-R.).	Adair BD, 2005, J CELL BIOL, V168, P1109, DOI 10.1083/jcb.200410068; Adair BD, 2002, P NATL ACAD SCI USA, V99, P14059, DOI 10.1073/pnas.212498199; Arnaout MA, 2005, ANNU REV CELL DEV BI, V21, P381, DOI 10.1146/annurev.cellbio.21.090704.151217; Bennett JS, 2005, J CLIN INVEST, V115, P3363, DOI 10.1172/JCI26989; CALVETE JJ, 1991, BIOCHEM J, V274, P63, DOI 10.1042/bj2740063; CALVETE JJ, 1989, BIOCHEM J, V261, P561, DOI 10.1042/bj2610561; Calzada MJ, 2002, J BIOL CHEM, V277, P39899, DOI 10.1074/jbc.M205886200; Chigaev A, 2003, BIOPHYS J, V85, P3951, DOI 10.1016/S0006-3495(03)74809-7; Coutinho A, 2007, BIOPHYS CHEM, V130, P76, DOI 10.1016/j.bpc.2007.07.007; GAREWAL HS, 1973, ANAL BIOCHEM, V54, P319, DOI 10.1016/0003-2697(73)90359-X; Guinier A, 1955, SMALL ANGLE XRAY SCA; Humphries MJ, 2003, TRENDS BIOCHEM SCI, V28, P313, DOI 10.1016/S0968-0004(03)00112-9; Hunt JF, 1997, J MOL BIOL, V273, P1004, DOI 10.1006/jmbi.1997.1330; Hynes RO, 2002, CELL, V110, P673, DOI 10.1016/S0092-8674(02)00971-6; JACROT B, 1981, BIOPOLYMERS, V20, P2413, DOI 10.1002/bip.1981.360201110; Johs A, 2006, J BIOL CHEM, V281, P19732, DOI 10.1074/jbc.M601688200; Kozin MB, 2001, J APPL CRYSTALLOGR, V34, P33, DOI 10.1107/S0021889800014126; Lau TL, 2009, EMBO J, V28, P1351, DOI 10.1038/emboj.2009.63; Litvinov RI, 2004, BLOOD, V104, P3979, DOI 10.1182/blood-2004-04-1411; Luo BH, 2006, CURR OPIN CELL BIOL, V18, P579, DOI 10.1016/j.ceb.2006.08.005; MARKWELL MAK, 1978, ANAL BIOCHEM, V87, P206, DOI 10.1016/0003-2697(78)90586-9; Rivas G, 1996, J MOL RECOGNIT, V9, P31, DOI 10.1002/(SICI)1099-1352(199601)9:1<31::AID-JMR237>3.3.CO;2-F; Rivas G A, 1991, Protein Expr Purif, V2, P248, DOI 10.1016/1046-5928(91)90080-3; RIVAS GA, 1991, EUR BIOPHYS J BIOPHY, V19, P335, DOI 10.1007/BF00183324; Svergun DI, 1999, BIOPHYS J, V76, P2879, DOI 10.1016/S0006-3495(99)77443-6; SVERGUN DI, 1992, J APPL CRYSTALLOGR, V25, P495, DOI 10.1107/S0021889892001663; Svergun DI, 1998, P NATL ACAD SCI USA, V95, P2267, DOI 10.1073/pnas.95.5.2267; Takagi J, 2002, CELL, V110, P599, DOI 10.1016/S0092-8674(02)00935-2; Vinogradova O, 2002, CELL, V110, P587, DOI 10.1016/S0092-8674(02)00906-6; Volkov VV, 2003, J APPL CRYSTALLOGR, V36, P860, DOI 10.1107/S0021889803000268; WEISEL JW, 1992, J BIOL CHEM, V267, P16637; Xiao T, 2004, NATURE, V432, P59, DOI 10.1038/nature02976; Xiong JP, 2009, J CELL BIOL, V186, P589, DOI 10.1083/jcb.200905085; Xiong JP, 2004, J BIOL CHEM, V279, P40252, DOI 10.1074/jbc.C400362200; Xiong JP, 2001, SCIENCE, V294, P339, DOI 10.1126/science.1064535; Xiong JP, 2003, BLOOD, V102, P1155, DOI 10.1182/blood-2003-01-0334; Xiong JP, 2002, SCIENCE, V296, P151, DOI 10.1126/science.1069040; Yan BX, 2001, BIOCHEMISTRY-US, V40, P8861, DOI 10.1021/bi002902i; Ye F, 2008, J MOL BIOL, V378, P976, DOI 10.1016/j.jmb.2008.03.014; Zhu JH, 2008, MOL CELL, V32, P849, DOI 10.1016/j.molcel.2008.11.018	40	22	23	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 8	2010	285	2					1023	1031		10.1074/jbc.M109.050039	http://dx.doi.org/10.1074/jbc.M109.050039			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	539MH	19897481	hybrid, Green Published			2022-12-25	WOS:000273258200023
J	Seronello, S; Ito, C; Wakita, T; Choi, J				Seronello, Scott; Ito, Chieri; Wakita, Takaji; Choi, Jinah			Ethanol Enhances Hepatitis C Virus Replication through Lipid Metabolism and Elevated NADH/NAD(+)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RNA REPLICATION; ALCOHOL; LIVER; ACETALDEHYDE; INTERFERON; INFECTION; PATHWAYS; CULTURE	Ethanol has been suggested to elevate HCV titer in patients and to increase HCV RNA in replicon cells, suggesting that HCV replication is increased in the presence and absence of the complete viral replication cycle, but the mechanisms remain unclear. In this study, we use Huh7 human hepatoma cells that naturally express comparable levels of CYP2E1 as human liver to demonstrate that ethanol, at subtoxic and physiologically relevant concentrations, enhances complete HCV replication. The viral RNA genome replication is affected for both genotypes 2a and 1b. Acetaldehyde, a major product of ethanol metabolism, likewise enhances HCV replication at physiological concentrations. The potentiation of HCV replication by ethanol is suppressed by inhibiting CYP2E1 or aldehyde dehydrogenase and requires an elevated NADH/NAD(+) ratio. In addition, acetate, isopropyl alcohol, and concentrations of acetone that occur in diabetics enhance HCV replication with corresponding increases in the NADH/NAD(+). Furthermore, inhibiting the host mevalonate pathway with lovastatin or fluvastatin and fatty acid synthesis with 5-(tetradecyloxy)-2-furoic acid or cerulenin significantly attenuates the enhancement of HCV replication by ethanol, acetaldehyde, acetone, as well as acetate, whereas inhibiting beta-oxidation with beta-mercaptopropionic acid increases HCV replication. Ethanol, acetaldehyde, acetone, and acetate increase the total intracellular cholesterol content, which is attenuated with lovastatin. In contrast, both endogenous and exogenous ROS suppress the replication of HCV genotype 2a, as previously shown with genotype 1b. Conclusion: Therefore, lipid metabolism and alteration of cellular NADH/NAD(+) ratio are likely to play a critical role in the potentiation of HCV replication by ethanol rather than oxidative stress.	[Seronello, Scott; Ito, Chieri; Choi, Jinah] Univ Calif, Sch Nat Sci, Atwater, CA 95343 USA; [Wakita, Takaji] Natl Inst Infect Dis, Tokyo 1628640, Japan	National Institute of Infectious Diseases (NIID)	Choi, J (corresponding author), Univ Calif, Sch Nat Sci, 5200 N Lake Rd, Merced, CA 95343 USA.	jchoi@ucmerced.edu			University of California, Merced	University of California, Merced(University of California System)	This work was supported by start-up funds from the University of California, Merced (to J.C.).	ADACHI J, 1989, ALCOHOL CLIN EXP RES, V13, P601, DOI 10.1111/j.1530-0277.1989.tb00389.x; Adiels M, 2005, ARTERIOSCL THROM VAS, V25, P1697, DOI 10.1161/01.ATV.0000172689.53992.25; BADAWY AAB, 1977, BRIT J ALCOHOL ALCOH, V12, P120; Bader T, 2008, AM J GASTROENTEROL, V103, P1383, DOI 10.1111/j.1572-0241.2008.01876.x; Blight KJ, 2002, J VIROL, V76, P13001, DOI 10.1128/JVI.76.24.13001-13014.2002; Blight KJ, 2000, SCIENCE, V290, P1972, DOI 10.1126/science.290.5498.1972; CEDERBAUM AI, 1991, ALCOHOL ALCOHOLISM, P291; Chang T K, 1998, Methods Mol Biol, V107, P147; Choi J, 2006, FREE RADICAL BIO MED, V41, P1488, DOI 10.1016/j.freeradbiomed.2006.08.008; Choi JN, 2004, HEPATOLOGY, V39, P81, DOI 10.1002/hep.20001; Clemens DL, 2002, HEPATOLOGY, V35, P1196, DOI 10.1053/jhep.2002.32668; Cromie SL, 1996, J HEPATOL, V25, P821, DOI 10.1016/S0168-8278(96)80284-4; Eysseric H, 1997, ALCOHOL, V14, P111, DOI 10.1016/S0741-8329(96)00112-7; Gale M, 2005, NATURE, V436, P939, DOI 10.1038/nature04078; GRETCH D, 1994, J INFECT DIS, V169, P1219, DOI 10.1093/infdis/169.6.1219; Honda M, 2000, GASTROENTEROLOGY, V118, P152, DOI 10.1016/S0016-5085(00)70424-0; Hosogaya S, 2006, TRANSL RES, V148, P79, DOI 10.1016/j.trsl.2006.03.004; Huang H, 2007, P NATL ACAD SCI USA, V104, P18666, DOI 10.1073/pnas.0708423104; Jamal MM, 2003, BEST PRACT RES CL GA, V17, P649, DOI 10.1016/S1521-6918(03)00018-0; Kalapos MP, 1999, MED HYPOTHESES, V53, P236, DOI 10.1054/mehy.1998.0752; Kato T, 2005, J CLIN MICROBIOL, V43, P5679, DOI 10.1128/JCM.43.11.5679-5684.2005; Kuroki M, 2009, J VIROL, V83, P2338, DOI 10.1128/JVI.01840-08; Lieber CS, 2004, ALCOHOL, V34, P9, DOI 10.1016/j.alcohol.2004.07.008; Marshall DJ, 1997, J CLIN MICROBIOL, V35, P3156, DOI 10.1128/JCM.35.12.3156-3162.1997; McCartney EM, 2008, J INFECT DIS, V198, P1766, DOI 10.1086/593216; Moradpour D, 2007, NAT REV MICROBIOL, V5, P453, DOI 10.1038/nrmicro1645; Plumlee CR, 2005, VIROL J, V2, DOI 10.1186/1743-422X-2-89; Sagan SM, 2006, BIOCHEM CELL BIOL, V84, P67, DOI 10.1139/O05-149; Sata M, 1996, J VIRAL HEPATITIS, V3, P143, DOI 10.1111/j.1365-2893.1996.tb00005.x; Seronello S, 2007, FREE RADICAL BIO MED, V43, P869, DOI 10.1016/j.freeradbiomed.2007.05.036; Sheikh MY, 2008, HEPATOLOGY, V47, P2127, DOI 10.1002/hep.22269; Shin HR, 2005, INTERVIROLOGY, V49, P18, DOI 10.1159/000087258; Tamai T, 2000, ALCOHOL CLIN EXP RES, V24, p106S, DOI 10.1111/j.1530-0277.2000.tb00023.x; TOWLE HC, 1995, J BIOL CHEM, V270, P23235, DOI 10.1074/jbc.270.40.23235; Trujillo-Murillo K, 2007, J VIRAL HEPATITIS, V14, P608, DOI 10.1111/j.1365-2893.2006.00837.x; Wakita T, 2005, NAT MED, V11, P791, DOI 10.1038/nm1268; Yano M, 2007, ANTIMICROB AGENTS CH, V51, P2016, DOI 10.1128/AAC.01426-06; Yano M, 2009, HEPATOLOGY, V50, P678, DOI 10.1002/hep.23026; Ye J, 2007, PLOS PATHOG, V3, P1017, DOI 10.1371/journal.ppat.0030108; Zhang T, 2003, HEPATOLOGY, V38, P57, DOI 10.1053/jhep.2003.50295	40	37	37	1	16	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 8	2010	285	2					845	854		10.1074/jbc.M109.045740	http://dx.doi.org/10.1074/jbc.M109.045740			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	539MH	19910460	hybrid, Green Published			2022-12-25	WOS:000273258200005
J	Umekawa, M; Li, CS; Higashiyama, T; Huang, W; Ashida, H; Yamamoto, K; Wang, LX				Umekawa, Midori; Li, Cishan; Higashiyama, Takayuki; Huang, Wei; Ashida, Hisashi; Yamamoto, Kenji; Wang, Lai-Xi			Efficient Glycosynthase Mutant Derived from Mucor hiemalis Endo-beta-N-acetylglucosaminidase Capable of Transferring Oligosaccharide from Both Sugar Oxazoline and Natural N-Glycan	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ASPARAGINE-LINKED OLIGOSACCHARIDES; SUBSTRATE-ASSISTED CATALYSIS; TRANSGLYCOSYLATION ACTIVITY; ARTHROBACTER-PROTOPHORMIAE; CHEMOENZYMATIC SYNTHESIS; MOLECULAR-CLONING; FLAVOBACTERIUM-MENINGOSEPTICUM; COMPLEX OLIGOSACCHARIDES; CAENORHABDITIS-ELEGANS; PRIMARY SEQUENCE	Endo-M, an endo-beta-N-acetylglucosaminidase from Mucor hiemalis, is a family 85 glycoside hydrolase. This enzyme is unique in that it can transfer en bloc the oligosaccharide of various types of N-glycans onto different acceptors, and thereby it enzymatically generates diverse glycoconjugates. In this study, we performed mutational and kinetic studies focusing on a key catalytic asparagine 175 of Endo-M. We have shown that most of the Asn-175 mutants had significantly diminished hydrolysis activity but acted as glycosynthases capable of using synthetic sugar oxazoline for transglycosylation. Our results confirm the critical role of this asparagine residue in promoting the formation of an oxazolinium ion intermediate in the first step of the substrate-assisted catalysis. Interestingly, the N175Q mutant was found to possess dramatically enhanced glycosynthase-like activity with sugar oxazoline in comparison with N175A and a transglycosidase-like activity with "natural" N-glycan as well. These results also implicated the significance of amide side chain in the asparagine 175 of Endo-M for promoting oxazoline transglycosylation in the second step of the catalysis. The highly efficient syntheses of glycopeptides/glycoproteins by N175Q combined with synthetic sugar oxazolines or natural N-glycan substrates were exemplified. In addition, we also identified several previously unknown residues that seem to play a role in the catalysis of Endo-M.	[Umekawa, Midori; Higashiyama, Takayuki; Ashida, Hisashi; Yamamoto, Kenji] Kyoto Univ, Grad Sch Biostudies, Kyoto 6068502, Japan; [Li, Cishan; Huang, Wei; Wang, Lai-Xi] Univ Maryland, Sch Med, Dept Biochem & Mol Biol, Inst Human Virol, Baltimore, MD 21201 USA	Kyoto University; University System of Maryland; University of Maryland Baltimore	Yamamoto, K (corresponding author), Kyoto Univ, Grad Sch Biostudies, Kyoto 6068502, Japan.	yamamotk@kais.kyoto-u.ac.jp; LWang@som.umaryland.edu	wang, xl/Y-8251-2019; Wang, Lai-Xi/E-8790-2019; Ashida, Hisashi/HCI-0293-2022; Huang, Wei/P-9631-2017; Huang, Wei/A-2167-2011; Wang, Lai-Xi/E-8755-2019	Wang, Lai-Xi/0000-0003-4293-5819; Huang, Wei/0000-0001-6432-1848; Umekawa, Midori/0000-0002-8071-3902; Ashida, Hisashi/0000-0001-5844-4075	National Institutes of Health [R01 GM 080374, R01 GM 080374-S1]; Japan Society for the Promotion of Science [214774]; Scientific Research [20380052]; Japan Science and Technology Agency-CREST; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM080374] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Japan Society for the Promotion of Science(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of Science); Scientific Research; Japan Science and Technology Agency-CREST(Japan Science & Technology Agency (JST)Core Research for Evolutional Science and Technology (CREST)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	This work was supported in part by National Institutes of Health Grants R01 GM 080374 and R01 GM 080374-S1 (to L. X. W.) from the United States Department of Health and Human Services. This work was also supported by the Japan Society for the Promotion of Science Grants-in-aid for Research Fellowships for Young Scientists 214774 (to M. U.) and for Scientific Research (B) 20380052 (to K. Y.) and by Japan Science and Technology Agency-CREST.	Abbott DW, 2009, J BIOL CHEM, V284, P11676, DOI 10.1074/jbc.M809663200; Fujita K, 2007, J BIOCHEM, V142, P301, DOI 10.1093/jb/mvm124; Fujita K, 2006, BBA-GEN SUBJECTS, V1760, P1631, DOI 10.1016/j.bbagen.2006.09.003; Fujita M, 2001, BBA-GEN SUBJECTS, V1528, P9, DOI 10.1016/S0304-4165(01)00164-7; Hauser S, 2005, BIOCHEM BIOPH RES CO, V328, P580, DOI 10.1016/j.bbrc.2005.01.012; Heidecke CD, 2008, CHEMBIOCHEM, V9, P2045, DOI 10.1002/cbic.200800214; Huang W, 2009, J AM CHEM SOC, V131, P2214, DOI 10.1021/ja8074677; KADOWAKI S, 1991, J BIOCHEM-TOKYO, V110, P17, DOI 10.1093/oxfordjournals.jbchem.a123536; KADOWAKI S, 1990, AGR BIOL CHEM TOKYO, V54, P97, DOI 10.1080/00021369.1990.10869923; Kato T, 2002, GLYCOBIOLOGY, V12, P581, DOI 10.1093/glycob/cwf073; Kato T, 2007, J BIOL CHEM, V282, P22080, DOI 10.1074/jbc.M700805200; Li B, 2005, J AM CHEM SOC, V127, P9692, DOI 10.1021/ja051715a; Li HG, 2005, BIOORG MED CHEM LETT, V15, P895, DOI 10.1016/j.bmcl.2004.12.066; Ling ZL, 2009, J MOL BIOL, V389, P1, DOI 10.1016/j.jmb.2009.03.050; Muramatsu H, 2001, J BIOCHEM, V129, P923, DOI 10.1093/oxfordjournals.jbchem.a002938; Ochiai H, 2008, J AM CHEM SOC, V130, P13790, DOI 10.1021/ja805044x; Rich JR, 2009, NAT CHEM BIOL, V5, P206, DOI 10.1038/nchembio.148; ROBBINS PW, 1984, J BIOL CHEM, V259, P7577; Suzuki T, 2002, P NATL ACAD SCI USA, V99, P9691, DOI 10.1073/pnas.152333599; TAKEGAWA K, 1991, BIOCHEM INT, V24, P849; TAKEGAWA K, 1989, APPL ENVIRON MICROB, V55, P3107, DOI 10.1128/AEM.55.12.3107-3112.1989; TAKEGAWA K, 1995, J BIOL CHEM, V270, P3094, DOI 10.1074/jbc.270.7.3094; TARENTINO AL, 1992, J BIOL CHEM, V267, P3868; TARENTINO AL, 1993, J BIOL CHEM, V268, P9702; Umekawa M, 2008, J BIOL CHEM, V283, P4469, DOI 10.1074/jbc.M707137200; Umemura M, 2008, J MED CHEM, V51, P4496, DOI 10.1021/jm8000967; VANSCHELTINGA ACT, 1995, BIOCHEMISTRY-US, V34, P15619, DOI 10.1021/bi00048a003; Wang LX, 2004, CHEM BIOL, V11, P127, DOI 10.1016/j.chembiol.2003.12.020; Williams SJ, 2002, J BIOL CHEM, V277, P40055, DOI 10.1074/jbc.M206481200; YAMAMOTO K, 1994, BIOSCI BIOTECH BIOCH, V58, P72, DOI 10.1271/bbb.58.72; YAMAMOTO KJ, 1994, BIOCHEM BIOPH RES CO, V203, P244, DOI 10.1006/bbrc.1994.2174; Yin J, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0004658	32	114	124	1	31	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 1	2010	285	1					511	521		10.1074/jbc.M109.059832	http://dx.doi.org/10.1074/jbc.M109.059832			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	536UT	19880511	hybrid, Green Published			2022-12-25	WOS:000273070100053
J	Cadet, JL; Mccoy, MT; Cai, NS; Krasnova, IN; Ladenheim, B; Beauvais, G; Wilson, N; Wood, W; Becker, KG; Hodges, AB				Cadet, Jean Lud; Mccoy, Michael T.; Cai, Ning Sheng; Krasnova, Irina N.; Ladenheim, Bruce; Beauvais, Genevieve; Wilson, Natascha; Wood, William, III; Becker, Kevin G.; Hodges, Amber B.			Methamphetamine Preconditioning Alters Midbrain Transcriptional Responses to Methamphetamine-Induced Injury in the Rat Striatum	PLOS ONE			English	Article							THYROTROPIN-RELEASING-HORMONE; PROTEIN-TYROSINE PHOSPHATASES; DISMUTASE TRANSGENIC MICE; MESSENGER-RNA EXPRESSION; NEUROTROPHIC FACTOR; DOPAMINERGIC-NEURONS; GENE-EXPRESSION; CEREBRAL-ISCHEMIA; HEME OXYGENASE-1; FREE-RADICALS	Methamphetamine (METH) is an illicit drug which is neurotoxic to the mammalian brain. Numerous studies have revealed significant decreases in dopamine and serotonin levels in the brains of animals exposed to moderate-to-large METH doses given within short intervals of time. In contrast, repeated injections of small nontoxic doses of the drug followed by a challenge with toxic METH doses afford significant protection against monoamine depletion. The present study was undertaken to test the possibility that repeated injections of the drug might be accompanied by transcriptional changes involved in rendering the nigrostriatal dopaminergic system refractory to METH toxicity. Our results confirm that METH preconditioning can provide significant protection against METH-induced striatal dopamine depletion. In addition, the presence and absence of METH preconditioning were associated with substantial differences in the identity of the genes whose expression was affected by a toxic METH challenge. Quantitative PCR confirmed METH-induced changes in genes of interest and identified additional genes that were differentially impacted by the toxic METH challenge in the presence of METH preconditioning. These genes include small heat shock 27 kD 27 protein 2 (HspB2), thyrotropin-releasing hormone (TRH), brain derived neurotrophic factor (BDNF), c-fos, and some encoding antioxidant proteins including CuZn superoxide dismutase (CuZnSOD), glutathione peroxidase (GPx)-1, and heme oxygenase-1 (Hmox-1). These observations are consistent, in part, with the transcriptional alterations reported in models of lethal ischemic injuries which are preceded by ischemic or pharmacological preconditioning. Our findings suggest that multiple molecular pathways might work in tandem to protect the nigrostriatal dopaminergic pathway against the deleterious effects of the toxic psychostimulant. Further analysis of the molecular and cellular pathways regulated by these genes should help to provide some insight into the neuroadaptive potentials of the brain when repeatedly exposed to drugs of abuse.			Cadet, JL (corresponding author), NIDA, Mol Neuropsychiat Res Branch, DHHS, NIH,Intramural Res Program, Baltimore, MD USA.	jcadet@intra.nida.nih.gov		Becker, Kevin/0000-0002-6794-6656	NATIONAL INSTITUTE ON AGING [ZICAG000616] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON DRUG ABUSE [ZIADA000552, ZIADA000494, ZIADA000551] Funding Source: NIH RePORTER	NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission)		Andres ME, 1999, P NATL ACAD SCI USA, V96, P9873, DOI 10.1073/pnas.96.17.9873; Arikkath J, 2008, TRENDS NEUROSCI, V31, P487, DOI 10.1016/j.tins.2008.07.001; Arrigo AP, 2007, ADV EXP MED BIOL, V594, P14; BARDSLEY ME, 1981, BIOCHEM PHARMACOL, V30, P1543, DOI 10.1016/0006-2952(81)90379-8; Berry A, 2008, EXP GERONTOL, V43, P200, DOI 10.1016/j.exger.2007.10.016; Bigdeli MR, 2009, BRAIN RES, V1260, P47, DOI 10.1016/j.brainres.2008.12.065; Boger HA, 2007, J NEUROSCI, V27, P8816, DOI 10.1523/JNEUROSCI.1067-07.2007; BRADYKALNAY SM, 1993, J CELL BIOL, V122, P961, DOI 10.1083/jcb.122.4.961; BRADYKALNAY SM, 1995, J CELL BIOL, V130, P977, DOI 10.1083/jcb.130.4.977; Bruce AW, 2004, P NATL ACAD SCI USA, V101, P10458, DOI 10.1073/pnas.0401827101; Burre J, 2007, J NEUROCHEM, V101, P1448, DOI 10.1111/j.1471-4159.2007.04453.x; Cadet JL, 2007, NEUROTOX RES, V11, P183, DOI 10.1007/BF03033567; Cadet JL, 2009, NEUROTOX RES, V15, P252, DOI 10.1007/s12640-009-9026-0; Cadet J, 2009, MOL NEUROBIOL, V39, P50, DOI 10.1007/s12035-009-8051-6; Cadet JL, 1997, SYNAPSE, V25, P176; Cadet JL, 2003, FASEB J, V17, P1775, DOI 10.1096/fj.03-0073rev; Cadet JL, 2002, SYNAPSE, V44, P211, DOI 10.1002/syn.10074; CADET JL, 1994, J NEUROCHEM, V62, P380; Cadet JL, 2001, SYNAPSE, V41, P40, DOI 10.1002/syn.1058; Cadet JL, 1998, NEUROCHEM INT, V32, P117, DOI 10.1016/S0197-0186(97)00031-4; Calabrese EJ, 2008, AGEING RES REV, V7, P8, DOI 10.1016/j.arr.2007.07.001; Calabrese V, 2004, ANTIOXID REDOX SIGN, V6, P895, DOI 10.1089/1523086041798051; Canudas AM, 2005, MOL BRAIN RES, V134, P147, DOI 10.1016/j.molbrainres.2004.11.012; Cass WA, 1996, J NEUROSCI, V16, P8132; Cass WA, 2006, ANN NY ACAD SCI, V1074, P272, DOI 10.1196/annals.1369.024; Chang L, 2007, ADDICTION, V102, P16, DOI 10.1111/j.1360-0443.2006.01782.x; Chinta SJ, 2005, INT J BIOCHEM CELL B, V37, P942, DOI 10.1016/j.biocel.2004.09.009; D Kuipers S, 2006, CURR OPIN DRUG DISC, V9, P580; DADEN AI, 1999, AM J PHYSIOL, V277, pR1196; Danaceau JP, 2007, EUR J PHARMACOL, V559, P46, DOI 10.1016/j.ejphar.2006.11.045; Deng XL, 1999, J NEUROSCI, V19, P10107; Dennis KE, 2005, MOL BRAIN RES, V140, P1, DOI 10.1016/j.molbrainres.2005.06.014; DEVITO MJ, 1989, NEUROPHARMACOLOGY, V28, P1145, DOI 10.1016/0028-3908(89)90130-5; Dhodda VK, 2004, J NEUROCHEM, V89, P73, DOI 10.1111/j.1471-4159.2004.02316.x; Dirnagl U, 2003, TRENDS NEUROSCI, V26, P248, DOI 10.1016/S0166-2236(03)00071-7; DOMESICK VB, 1988, ANN NY ACAD SCI, V537, P10, DOI 10.1111/j.1749-6632.1988.tb42094.x; Dong M, 2006, NEUROSCI LETT, V400, P177, DOI 10.1016/j.neulet.2006.02.063; ENGBER TM, 1985, REGUL PEPTIDES, V12, P51, DOI 10.1016/0167-0115(85)90186-7; Engele J, 1996, NEUROSCIENCE, V73, P397, DOI 10.1016/0306-4522(96)00045-0; FADEN AI, 1981, NEW ENGL J MED, V305, P1063, DOI 10.1056/NEJM198110293051806; Ford MGJ, 2001, SCIENCE, V291, P1051, DOI 10.1126/science.291.5506.1051; Friedman SD, 1998, PHARMACOL BIOCHEM BE, V61, P35, DOI 10.1016/S0091-3057(98)00066-5; Glantz L, 2005, EXP NEUROL, V192, P117, DOI 10.1016/j.expneurol.2004.11.012; Gold MS, 2009, BIOL PSYCHIAT, V66, P118, DOI 10.1016/j.biopsych.2009.02.021; Graham DL, 2008, J NEUROCHEM, V105, P1873, DOI 10.1111/j.1471-4159.2008.05269.x; Guerra-Crespo M, 2001, EUR J NEUROSCI, V14, P483, DOI 10.1046/j.0953-816x.2001.01657.x; GUILLEMIN R, 1963, ENDOCRINOLOGY, V73, P564, DOI 10.1210/endo-73-5-564; Guo L, 2006, NAT BIOTECHNOL, V24, P1162, DOI 10.1038/nbt1238; Halliwell B, 2006, J NEUROCHEM, V97, P1634, DOI 10.1111/j.1471-4159.2006.03907.x; Hirata H, 1996, BRAIN RES, V714, P95, DOI 10.1016/0006-8993(95)01502-7; Hu ZP, 2008, J NEUROSCI RES, V86, P2125, DOI 10.1002/jnr.21682; Huang EJ, 2001, ANNU REV NEUROSCI, V24, P677, DOI 10.1146/annurev.neuro.24.1.677; HUANG YN, 2009, TOXICOL APPL PH 0702; Hung SY, 2008, MOL PHARMACOL, V74, P1564, DOI 10.1124/mol.108.048611; Ishihara H, 1998, J BIOL CHEM, V273, P8741, DOI 10.1074/jbc.273.15.8741; Itoh T, 2001, SCIENCE, V291, P1047, DOI 10.1126/science.291.5506.1047; Jaworska-Feil L, 2001, EPILEPSY RES, V43, P67, DOI 10.1016/S0920-1211(00)00178-9; Jayanthi S, 1998, ANN NY ACAD SCI, V844, P92, DOI 10.1111/j.1749-6632.1998.tb08224.x; Jayanthi S, 2005, P NATL ACAD SCI USA, V102, P868, DOI 10.1073/pnas.0404990102; Jayanthi S, 2002, MOL PHARMACOL, V61, P1124, DOI 10.1124/mol.61.5.1124; Jayanthi S, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0006092; Johnson-Davis KL, 2004, J PHARMACOL EXP THER, V309, P578, DOI 10.1124/jpet.103.062695; Johnson-Davis KL, 2003, EUR J PHARMACOL, V482, P151, DOI 10.1016/j.ejphar.2003.09.063; KALIVAS PW, 1987, NEUROPHARMACOLOGY, V26, P33, DOI 10.1016/0028-3908(87)90041-4; Kamath J, 2009, PHARMACOL THERAPEUT, V121, P20, DOI 10.1016/j.pharmthera.2008.09.004; Kamphuis W, 2007, MOL VIS, V13, P1892; Kim YT, 2009, J PSYCHIATR RES, V43, P1166, DOI 10.1016/j.jpsychires.2009.03.011; Koerner IP, 2007, ANESTHESIOLOGY, V106, P538, DOI 10.1097/00000542-200703000-00019; KRAMER JC, 1967, J AMER MED ASSOC, V201, P305, DOI 10.1001/jama.201.5.305; Krasnova IN, 2000, NEUROSCIENCE, V95, P113; Krasnova IN, 2009, BRAIN RES REV, V60, P379, DOI 10.1016/j.brainresrev.2009.03.002; Kuhn DM, 2006, ANN NY ACAD SCI, V1074, P31, DOI 10.1196/annals.1369.003; Lechan RM, 2006, PROG BRAIN RES, V153, P209, DOI 10.1016/S0079-6123(06)53012-2; Lee TH, 2008, BRAIN RES, V1187, P1, DOI 10.1016/j.brainres.2007.09.078; Li C, 2007, ANTIOXID REDOX SIGN, V9, P2227, DOI 10.1089/ars.2007.1783; Li QF, 2008, ACTA BIOCH BIOPH SIN, V40, P803, DOI 10.1111/j.1745-7270.2008.00461.x; Li QB, 2007, LIFE SCI, V80, P1087, DOI 10.1016/j.lfs.2006.11.043; LIN LFH, 1993, SCIENCE, V260, P1130, DOI 10.1126/science.8493557; Lindvall O, 1978, Adv Biochem Psychopharmacol, V19, P1; London ED, 2004, ARCH GEN PSYCHIAT, V61, P73, DOI 10.1001/archpsyc.61.1.73; Lunyak VV, 2002, SCIENCE, V298, P1747, DOI 10.1126/science.1076469; Mao YS, 2007, PFLUG ARCH EUR J PHY, V455, P5, DOI 10.1007/s00424-007-0286-3; Marini AM, 2007, AMINO ACIDS, V32, P299, DOI 10.1007/s00726-006-0414-y; Martinowich K, 2003, SCIENCE, V302, P890, DOI 10.1126/science.1090842; Miyazaki I, 2006, FASEB J, V20, P571, DOI 10.1096/fj.05-4996fje; Morrison LE, 2004, AM J PHYSIOL-HEART C, V286, pH847, DOI 10.1152/ajpheart.00715.2003; Nakagawa M, 2001, EXP CELL RES, V271, P161, DOI 10.1006/excr.2001.5362; Obrenovitch TP, 2008, PHYSIOL REV, V88, P211, DOI 10.1152/physrev.00039.2006; OLIVER C, 1974, ENDOCRINOLOGY, V95, P540, DOI 10.1210/endo-95-2-540; Paul S, 2003, CELL MOL LIFE SCI, V60, P2465, DOI 10.1007/s00018-003-3123-7; Pizzi M, 1999, EUR J PHARMACOL, V370, P133, DOI 10.1016/S0014-2999(99)00139-9; Rajeevan MS, 2001, J MOL DIAGN, V3, P26, DOI 10.1016/S1525-1578(10)60646-0; Reamon-Buettner SM, 2008, MUTAT RES-REV MUTAT, V659, P158, DOI 10.1016/j.mrrev.2008.01.003; Robinson TE, 2004, NEUROPHARMACOLOGY, V47, P33, DOI 10.1016/j.neuropharm.2004.06.025; SEIDEN LS, 1976, DRUG ALCOHOL DEPEN, V1, P215, DOI 10.1016/0376-8716(76)90030-2; Sekine Y, 2006, ARCH GEN PSYCHIAT, V63, P90, DOI 10.1001/archpsyc.63.1.90; Sekine Y, 2008, J NEUROSCI, V28, P5756, DOI 10.1523/JNEUROSCI.1179-08.2008; SEROOGY KB, 1994, J COMP NEUROL, V342, P321, DOI 10.1002/cne.903420302; SHREWSBURYGEE J, 1988, EXP BRAIN RES, V70, P342; Siamilis S, 2009, SPINAL CORD, V47, P453, DOI 10.1038/sc.2008.125; Simon SL, 2002, J ADDICT DIS, V21, P61; Stenzel-Poore MP, 2007, STROKE, V38, P680, DOI 10.1161/01.STR.0000251444.56487.4c; Stenzel-Poore MP, 2003, LANCET, V362, P1028, DOI 10.1016/S0140-6736(03)14412-1; Stoker AW, 2005, J ENDOCRINOL, V185, P19, DOI 10.1677/joe.1.06069; Sun Y, 2005, FEBS J, V272, P2613, DOI 10.1111/j.1742-4658.2005.04708.x; Suzuki A, 1998, J CELL BIOL, V140, P1113, DOI 10.1083/jcb.140.5.1113; Tang WY, 2007, REV ENDOCR METAB DIS, V8, P173, DOI 10.1007/s11154-007-9042-4; Thomas DM, 2004, J NEUROCHEM, V88, P380, DOI 10.1046/j.1471-4159.2003.02182.x; Thomas DM, 2005, J NEUROCHEM, V92, P790, DOI 10.1111/j.1471-4159.2004.02906.x; TOMAC A, 1995, NATURE, V373, P335, DOI 10.1038/373335a0; Tonks NK, 2006, NAT REV MOL CELL BIO, V7, P833, DOI 10.1038/nrm2039; Truettner J, 2002, MOL BRAIN RES, V103, P106, DOI 10.1016/S0169-328X(02)00191-2; Ubieta R, 2007, BRAIN RES, V1174, P28, DOI 10.1016/j.brainres.2007.08.026; Veronesi MC, 2007, BRAIN RES, V1128, P79, DOI 10.1016/j.brainres.2006.10.047; Volkow ND, 2001, AM J PSYCHIAT, V158, P377, DOI 10.1176/appi.ajp.158.3.377; WAGNER GC, 1979, DRUG ALCOHOL DEPEN, V4, P435, DOI 10.1016/0376-8716(79)90076-0; Wang L, 2008, CURR OPIN PHARMACOL, V8, P104, DOI 10.1016/j.coph.2007.09.005; Wang YF, 2007, P NATL ACAD SCI USA, V104, P11748, DOI 10.1073/pnas.0700019104; Wang YJ, 2004, J CELL BIOL, V167, P1005, DOI 10.1083/jcb.200408008; Weernink PAO, 2004, EUR J PHARMACOL, V500, P87, DOI 10.1016/j.ejphar.2004.07.014; Weernink PAO, 2007, BBA-BIOMEMBRANES, V1768, P888, DOI 10.1016/j.bbamem.2006.09.012; Wenk MR, 2001, NEURON, V32, P79, DOI 10.1016/S0896-6273(01)00456-1; Wu XF, 2008, INT J NEUROPSYCHOPH, V11, P1123, DOI 10.1017/S1461145708009024; Yamagata T, 1999, NEUROSCI RES, V35, P9, DOI 10.1016/S0168-0102(99)00062-0; YAMAMOTO M, 1990, EUR J PHARMACOL, V181, P207, DOI 10.1016/0014-2999(90)90080-P; Ye KQ, 2008, FRONT BIOSCI-LANDMRK, V13, P540, DOI 10.2741/2699; Zhang JH, 2002, NAT GENET, V30, P416, DOI 10.1038/ng859; Zhou Tong, 2009, V99, P325	128	42	42	0	12	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	NOV 12	2009	4	11							e7812	10.1371/journal.pone.0007812	http://dx.doi.org/10.1371/journal.pone.0007812			16	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	518UW	19915665	gold, Green Submitted, Green Published			2022-12-25	WOS:000271721400011
J	Comas, I; Homolka, S; Niemann, S; Gagneux, S				Comas, Inaki; Homolka, Susanne; Niemann, Stefan; Gagneux, Sebastien			Genotyping of Genetically Monomorphic Bacteria: DNA Sequencing in Mycobacterium tuberculosis Highlights the Limitations of Current Methodologies	PLOS ONE			English	Article							NUMBER TANDEM-REPEATS; SINGLE-NUCLEOTIDE POLYMORPHISMS; SHORT PALINDROMIC REPEATS; VARIABLE-NUMBER; YERSINIA-PESTIS; BACILLUS-ANTHRACIS; MOLECULAR EPIDEMIOLOGY; PHYLOGENETIC INFERENCE; POPULATION-STRUCTURE; MAXIMUM-LIKELIHOOD	Because genetically monomorphic bacterial pathogens harbour little DNA sequence diversity, most current genotyping techniques used to study the epidemiology of these organisms are based on mobile or repetitive genetic elements. Molecular markers commonly used in these bacteria include Clustered Regulatory Short Palindromic Repeats (CRISPR) and Variable Number Tandem Repeats (VNTR). These methods are also increasingly being applied to phylogenetic and population genetic studies. Using the Mycobacterium tuberculosis complex (MTBC) as a model, we evaluated the phylogenetic accuracy of CRISPR- and VNTR-based genotyping, which in MTBC are known as spoligotyping and Mycobacterial Interspersed Repetitive Units (MIRU)-VNTR-typing, respectively. We used as a gold standard the complete DNA sequences of 89 coding genes from a global strain collection. Our results showed that phylogenetic trees derived from these multilocus sequence data were highly congruent and statistically robust, irrespective of the phylogenetic methods used. By contrast, corresponding phylogenies inferred from spoligotyping or 15-loci-MIRU-VNTR were incongruent with respect to the sequence-based trees. Although 24-loci-MIRU-VNTR performed better, it was still unable to detect all strain lineages. The DNA sequence data showed virtually no homoplasy, but the opposite was true for spoligotyping and MIRU-VNTR, which was consistent with high rates of convergent evolution and the low statistical support obtained for phylogenetic groupings defined by these markers. Our results also revealed that the discriminatory power of the standard 24 MIRU-VNTR loci varied by strain lineage. Taken together, our findings suggest strain lineages in MTBC should be defined based on phylogenetically robust markers such as single nucleotide polymorphisms or large sequence polymorphisms, and that for epidemiological purposes, MIRU-VNTR loci should be used in a lineage-dependent manner. Our findings have implications for strain typing in other genetically monomorphic bacteria.			Comas, I (corresponding author), Natl Inst Med Res, MRC, Div Mycobacterial Res, London NW7 1AA, England.	gagneux@nimr.mrc.ac.uk	Comas, Iñaki/F-1185-2011; Comas, Iñaki/AAA-1155-2019; Gagneux, Sebastien/ABE-7909-2020; Niemann, Stefan/C-9327-2011	Comas, Iñaki/0000-0001-5504-9408; Comas, Iñaki/0000-0001-5504-9408; Gagneux, Sebastien/0000-0001-7783-9048; Niemann, Stefan/0000-0002-6604-0684	MRC [MC_U117588500] Funding Source: UKRI; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI034238] Funding Source: NIH RePORTER; Medical Research Council [MC_U117588500] Funding Source: Medline; NIAID NIH HHS [AI034238, R01 AI034238] Funding Source: Medline; PHS HHS [HHSN266200700022C] Funding Source: Medline	MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		Achtman M, 1999, P NATL ACAD SCI USA, V96, P14043, DOI 10.1073/pnas.96.24.14043; Achtman M, 2004, P NATL ACAD SCI USA, V101, P17837, DOI 10.1073/pnas.0408026101; Achtman M, 2008, ANNU REV MICROBIOL, V62, P53, DOI 10.1146/annurev.micro.62.081307.162832; AKAIKE H, 1974, IEEE T AUTOMAT CONTR, VAC19, P716, DOI 10.1109/TAC.1974.1100705; Alland D, 2003, J BACTERIOL, V185, P3392, DOI 10.1128/JB.185.11.3392-3399.2003; Allix-Beguec C, 2008, J CLIN MICROBIOL, V46, P2692, DOI 10.1128/JCM.00540-08; Andersson AF, 2008, SCIENCE, V320, P1047, DOI 10.1126/science.1157358; Baker L, 2004, EMERG INFECT DIS, V10, P1568, DOI 10.3201/eid1009.040046; Black WC, 2007, INSECT MOL BIOL, V16, P377, DOI 10.1111/j.1365-2583.2007.00736.x; Brudey K, 2006, BMC MICROBIOL, V6, DOI 10.1186/1471-2180-6-23; Caws M, 2008, PLOS PATHOG, V4, DOI 10.1371/journal.ppat.1000034; Comas I, 2009, PLOS PATHOG, V5, DOI 10.1371/journal.ppat.1000600; Cox HS, 2008, NEW ENGL J MED, V359, P2398, DOI 10.1056/NEJMc0805644; Cui YJ, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002652; de Jong BC, 2006, J INFECT DIS, V193, P1279, DOI 10.1086/502977; de Jong BC, 2008, J INFECT DIS, V198, P1037, DOI 10.1086/591504; Demangel C, 2009, NAT REV MICROBIOL, V7, P50, DOI 10.1038/nrmicro2077; Feil EJ, 2004, NAT REV MICROBIOL, V2, P483, DOI 10.1038/nrmicro904; Felsenstein J., 2004, INFERRING PHYLOGENIE, VVolume 2; Filliol I, 2006, J BACTERIOL, V188, P759, DOI 10.1128/JB.188.2.759-772.2006; Flores L, 2007, J CLIN MICROBIOL, V45, P3393, DOI 10.1128/JCM.00828-07; Foster JT, 2009, J BACTERIOL, V191, P2864, DOI 10.1128/JB.01581-08; Gagneux S, 2006, P NATL ACAD SCI USA, V103, P2869, DOI 10.1073/pnas.0511240103; Gagneux S, 2007, LANCET INFECT DIS, V7, P328, DOI 10.1016/S1473-3099(07)70108-1; Goldman N, 2000, SYST BIOL, V49, P652, DOI 10.1080/106351500750049752; Grissa I, 2008, NUCLEIC ACIDS RES, V36, pW145, DOI 10.1093/nar/gkn228; Guindon S, 2003, SYST BIOL, V52, P696, DOI 10.1080/10635150390235520; Gutacker MM, 2006, J INFECT DIS, V193, P121, DOI 10.1086/498574; Gutacker MM, 2002, GENETICS, V162, P1533; Hershberg R, 2008, PLOS BIOL, V6, P2658, DOI 10.1371/journal.pbio.0060311; Hirsh AE, 2004, P NATL ACAD SCI USA, V101, P4871, DOI 10.1073/pnas.0305627101; Holt KE, 2008, NAT GENET, V40, P987, DOI 10.1038/ng.195; HUNTER PR, 1988, J CLIN MICROBIOL, V26, P2465, DOI 10.1128/JCM.26.11.2465-2466.1988; Johansson A, 2004, J BACTERIOL, V186, P5808, DOI 10.1128/JB.186.17.5808-5818.2004; Kamerbeek J, 1997, J CLIN MICROBIOL, V35, P907, DOI 10.1128/JCM.35.4.907-914.1997; Keim P, 2000, J BACTERIOL, V182, P2928, DOI 10.1128/JB.182.10.2928-2936.2000; Kim S, 2007, ANNU REV BIOMED ENG, V9, P289, DOI 10.1146/annurev.bioeng.9.060906.152037; Klevytska AM, 2001, J CLIN MICROBIOL, V39, P3179, DOI 10.1128/JCM.39.9.3179-3185.2001; Lindstedt BA, 2005, ELECTROPHORESIS, V26, P2567, DOI 10.1002/elps.200500096; Lindstedt BA, 2004, J MICROBIOL METH, V58, P213, DOI 10.1016/j.mimet.2004.03.016; Maiden MCJ, 1998, P NATL ACAD SCI USA, V95, P3140, DOI 10.1073/pnas.95.6.3140; Mathema B, 2006, CLIN MICROBIOL REV, V19, P658, DOI 10.1128/CMR.00061-05; Mazars E, 2001, P NATL ACAD SCI USA, V98, P1901, DOI 10.1073/pnas.98.4.1901; Medini D, 2008, NAT REV MICROBIOL, V6, P419, DOI 10.1038/nrmicro1901; Monot M, 2005, SCIENCE, V308, P1040, DOI 10.1126/science/1109759; Murase Y, 2008, J MED MICROBIOL, V57, P873, DOI 10.1099/jmm.0.47564-0; NEI M, 1983, J MOL EVOL, V19, P153, DOI 10.1007/BF02300753; Nicol MP, 2008, T ROY SOC TROP MED H, V102, P955, DOI 10.1016/j.trstmh.2008.03.025; Niemann S, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0007407; Pearson T, 2004, P NATL ACAD SCI USA, V101, P13536, DOI 10.1073/pnas.0403844101; Pearson T, 2009, INFECT GENET EVOL, V9, P1010, DOI 10.1016/j.meegid.2009.05.014; Posada D, 1998, BIOINFORMATICS, V14, P817, DOI 10.1093/bioinformatics/14.9.817; Ramisse V, 2004, J CLIN MICROBIOL, V42, P5722, DOI 10.1128/JCM.42.12.5722-5730.2004; Ronquist F, 2003, BIOINFORMATICS, V19, P1572, DOI 10.1093/bioinformatics/btg180; Schmidt HA, 2002, BIOINFORMATICS, V18, P502, DOI 10.1093/bioinformatics/18.3.502; Service RF, 2006, SCIENCE, V311, P1544, DOI 10.1126/science.311.5767.1544; Shimodaira H, 1999, MOL BIOL EVOL, V16, P1114, DOI 10.1093/oxfordjournals.molbev.a026201; Smith NH, 2009, NAT REV MICROBIOL, V7, P537, DOI 10.1038/nrmicro2165; Sola C, 2003, INFECT GENET EVOL, V3, P125, DOI 10.1016/S1567-1348(03)00011-X; Sreevatsan S, 1997, P NATL ACAD SCI USA, V94, P9869, DOI 10.1073/pnas.94.18.9869; Supply P, 2003, MOL MICROBIOL, V47, P529, DOI 10.1046/j.1365-2958.2003.03315.x; SUPPLY P, 2006, J CLIN MICROBIOL, V45, P691; Swofford D.L., 2002, PAUP PHYLOGENETIC AN, DOI 10.1111/j.0014-3820.2002.tb00191.x; Tamura K., 2007, MEGA4 MOL EVOLUTIONA; Thwaites G, 2008, J CLIN MICROBIOL, V46, P1363, DOI 10.1128/JCM.02180-07; Truman R, 2004, J CLIN MICROBIOL, V42, P2558, DOI 10.1128/JCM.42.6.2558-2565.2004; Tsolaki AG, 2005, J CLIN MICROBIOL, V43, P3185, DOI 10.1128/JCM.43.7.3185-3191.2005; van Deutekom H, 2005, J CLIN MICROBIOL, V43, P4473, DOI 10.1128/JCM.43.9.4473-4479.2005; Van Ert MN, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0000461; Vogler AJ, 2009, J BACTERIOL, V191, P2474, DOI 10.1128/JB.01786-08; Wirth T, 2008, PLOS PATHOG, V4, DOI 10.1371/journal.ppat.1000160	71	321	334	0	35	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	NOV 12	2009	4	11							e7815	10.1371/journal.pone.0007815	http://dx.doi.org/10.1371/journal.pone.0007815			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	518UW	19915672	Green Published, Green Submitted, gold			2022-12-25	WOS:000271721400012
J	Ramsay, A; Cuevas, LE; Mundy, CJF; Nathanson, CM; Chirambo, P; Dacombe, R; Squire, SB; Salaniponi, FML; Munthali, S				Ramsay, Andrew; Cuevas, Luis E.; Mundy, Catherine J. F.; Nathanson, Carl-Michael; Chirambo, Petros; Dacombe, Russell; Squire, S. Bertel; Salaniponi, Felix M. L.; Munthali, Sera			New Policies, New Technologies: Modelling the Potential for Improved Smear Microscopy Services in Malawi	PLOS ONE			English	Article							PULMONARY TUBERCULOSIS; SPUTUM; FLUORESCENCE; DIAGNOSIS; OPPORTUNITY; DISTRICT; QUALITY; BACILLI	Background: To quantify the likely impact of recent WHO policy recommendations regarding smear microscopy and the introduction of appropriate low-cost fluorescence microscopy on a) case detection and b) laboratory workload. Methodology/ Principal Findings: An audit of the laboratory register in an urban hospital, Lilongwe, Malawi, and the application of a simple modelling framework. The adoption of the new definition of a smear-positive case could directly increase case detection by up to 28%. Examining Ziehl-Neelsen (ZN) sputum smears for up to 10 minutes before declaring them negative has previously been shown to increase case detection (over and above that gained by the adoption of the new case definition) by 70% compared with examination times in routine practice. Three times the number of staff would be required to adequately examine the current workload of smears using ZN microscopy. Through implementing new policy recommendations and LED-based fluorescence microscopy the current laboratory staff complement could investigate the same number of patients, examining auramine-stained smears to an extent that is equivalent to a 10 minutes ZN smear examination. Conclusions/Significance: Combined implementation of the new WHO recommendations on smear microscopy and LED-based fluorescence microscopy could result in substantial increases in smear positive case-detection using existing human resources and minimal additional equipment.			Ramsay, A (corresponding author), WHO, UNICEF, UNDP, World Bank,Special Programme Res & Training Trop, CH-1211 Geneva, Switzerland.	ramsaya@who.int	Cuevas, Luis E/I-3697-2015	Cuevas, Luis E/0000-0002-6581-0587; Squire, Stephen/0000-0001-7173-9038				Anthony RM, 2006, INT J TUBERC LUNG D, V10, P1060; BENNEDSEN J, 1966, SCAND J RESPIR DIS, V47, P114; Bonnet M, 2007, INT J TUBERC LUNG D, V11, P953; Cambanis A, 2007, INT J TUBERC LUNG D, V11, P40; Enarson DA, 1996, TUBERCULOSIS GUIDE L; FUJIKI A, 1998, TB MICROSCOPY; Hawken MP, 2001, INT J TUBERC LUNG D, V5, P360; Mabaera B, 2008, INT J TUBERC LUNG D, V12, P294; *MAL NAT TUB CONTR, 2008, ANN REP JUL 2007 JUN; Marais BJ, 2008, CLIN INFECT DIS, V47, P203, DOI 10.1086/589248; Mase SR, 2007, INT J TUBERC LUNG D, V11, P485; Mccoy D, 2008, HUM RESOUR HEALTH, V6, DOI 10.1186/1478-4491-6-16; Minion J, 2009, EXPERT REV MED DEVIC, V6, P341, DOI [10.1586/erd.09.26, 10.1586/ERD.09.26]; Mugusi F, 2006, INT J TUBERC LUNG D, V10, P663; Mundy CJF, 2002, INT J TUBERC LUNG D, V6, P47; Mundy CJF, 2003, T ROY SOC TROP MED H, V97, P403, DOI 10.1016/S0035-9203(03)90070-8; Steingart K, 2006, LANCET INFECT DIS, V6, P570, DOI 10.1016/S1473-3099(06)70578-3; Ramsay A, 2009, INT J TUBERC LUNG D, V13, P613; WELCAN UK, 1990, WORKLOAD MEASUREMENT; *WHO, 2009, STOP TB PARTN RET TA; *WHO, 2007, WHOHTMSTB200740; World Health Organization, 2008, STOP TB PARTN RET TA; World Health Organization, 2009, GLOB TUB CONTR EP ST; World Health Organization   Reginal Office for Africa, 2006, AFR REG HLTH REP HLT; World Health Organization (WHO), 1998, LAB SERVICES TUBERCU	25	16	16	0	3	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	NOV 10	2009	4	11							e7760	10.1371/journal.pone.0007760	http://dx.doi.org/10.1371/journal.pone.0007760			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	517ZU	19901989	Green Accepted, gold, Green Published			2022-12-25	WOS:000271658800006
J	Brettschneider, J; Tumani, H; Kiechle, U; Muche, R; Richards, G; Lehmensiek, V; Ludolph, AC; Otto, M				Brettschneider, Johannes; Tumani, Hayrettin; Kiechle, Ulrike; Muche, Rainer; Richards, Gayle; Lehmensiek, Vera; Ludolph, Albert C.; Otto, Markus			IgG Antibodies against Measles, Rubella, and Varicella Zoster Virus Predict Conversion to Multiple Sclerosis in Clinically Isolated Syndrome	PLOS ONE			English	Article							CENTRAL-NERVOUS-SYSTEM; MEMORY B-CELLS; CEREBROSPINAL-FLUID; OLIGOCLONAL BANDS; IMMUNE-RESPONSE; INTRATHECAL SYNTHESIS; OPTIC NEURITIS; MRI CRITERIA; DIAGNOSIS; PATTERNS	Background: Multiple sclerosis (MS) is characterized by a polyspecific B-cell response to neurotropic viruses such as measles, rubella and varicella zoster, with the corresponding antibodies measurable in CSF as the so-called "MRZ reaction'' (MRZR). We aimed to evaluate the relevance of MRZR to predict conversion of patients with clinically isolated syndrome (CIS) to MS, and to compare it to oligoclonal bands (OCB) and MRI. Methodology/Principal Findings: MRZR was determined in a prospective study over 2 years including 40 patients that remained CIS over follow-up (CIS-CIS) and 49 patients that developed MS (CIS-RRMS) using ELISA. Using logistic regression, a score (MRZS) balancing the predictive value of the antibody indices included in MRZR was defined (9 points measles, 8 points rubella, 1 point varicella zoster, cutpoint: sum of scores greater 10). MRZR and MRZS were significantly more frequent in CIS-RRMS as compared to CIS-CIS (p = 0.04 and p = 0.02). MRZS showed the best positive predictive value (PPV) of all parameters investigated (79%, 95%-CI: 54-94%), which could be further increased by combination with MRI (91%, 95%-CI: 59-99%). Conclusions/Significance: Our data indicate the relevance of MRZR to predict conversion to MS. It furthermore shows the importance of weighting the different antibody indices included in MRZR and suggest that patients with positive MRZR are candidates for an early begin of immunomodulatory therapy.			Brettschneider, J (corresponding author), Univ Ulm, Dept Neurol, D-7900 Ulm, Germany.	hayrettin.tumani@uni-ulm.de	Otto, Markus/F-4304-2015	Otto, Markus/0000-0003-4273-4267				Barkhof F, 1997, BRAIN, V120, P2059, DOI 10.1093/brain/120.11.2059; Bernasconi NL, 2002, SCIENCE, V298, P2199, DOI 10.1126/science.1076071; Bernasconi NL, 2003, BLOOD, V101, P4500, DOI 10.1182/blood-2002-11-3569; Brettschneider J, 2006, MULT SCLER J, V12, P143, DOI 10.1191/135248506ms1263oa; Corcione A, 2004, P NATL ACAD SCI USA, V101, P11064, DOI 10.1073/pnas.0402455101; FELGENHAUER K, 1992, CLIN INVESTIGATOR, V70, P28, DOI 10.1007/BF00422934; Franciotta D, 2008, J NEUROIMMUNOL, V200, P125, DOI 10.1016/j.jneuroim.2008.06.004; Franciotta D, 2008, LANCET NEUROL, V7, P852, DOI 10.1016/S1474-4422(08)70192-3; Frederiksen JL, 1998, MULT SCLER, V4, P22, DOI 10.1191/135245898678909213; GREENHOUSE JB, 1995, J COMMUN DISORD, V28, P229, DOI 10.1016/0021-9924(94)00011-N; Jarius S, 2008, J NEUROL NEUROSUR PS, V79, P1134, DOI 10.1136/jnnp.2007.133330; JARIUS S, 2008, J NEUROL SCI; Korteweg T, 2006, LANCET NEUROL, V5, P221, DOI 10.1016/S1474-4422(06)70353-2; Kuhle J, 2007, NEW ENGL J MED, V356, P371, DOI 10.1056/NEJMoa063602; Meinl E, 2006, ANN NEUROL, V59, P880, DOI 10.1002/ana.20890; Miller D, 2005, LANCET NEUROL, V4, P281, DOI 10.1016/S1474-4422(05)70071-5; NEWCOMBE RG, 1992, BRIT MED J, V304, P381, DOI 10.1136/bmj.304.6823.381-c; Polman CH, 2005, ANN NEUROL, V58, P840, DOI 10.1002/ana.20703; Reiber H, 1998, MULT SCLER, V4, P99, DOI 10.1177/135245859800400302; Reiber H, 2003, CLIN CHEM LAB MED, V41, P331, DOI 10.1515/CCLM.2003.053; Reiber H, 1998, MULT SCLER, V4, P111, DOI 10.1177/135245859800400304; Reiber H, 2001, J NEUROL SCI, V184, P101, DOI 10.1016/S0022-510X(00)00501-3; Reiber H, 2001, CLIN CHIM ACTA, V310, P173, DOI 10.1016/S0009-8981(01)00573-3; Reiber H, 2001, CLIN CHEM LAB MED, V39, P324, DOI 10.1515/CCLM.2001.051; Robinson-Agramonte M, 2007, ACTA NEUROL SCAND, V115, P312, DOI 10.1111/j.1600-0404.2006.00755.x; SINDIC CJM, 1994, J NEUROIMMUNOL, V54, P75, DOI 10.1016/0165-5728(94)90233-X; Swanton JK, 2007, LANCET NEUROL, V6, P677, DOI 10.1016/S1474-4422(07)70176-X; Thrower BW, 2007, NEUROLOGY, V68, pS12, DOI 10.1212/01.wnl.0000277704.56189.85; Tintore M, 2008, NEUROLOGY, V70, P1079, DOI 10.1212/01.wnl.0000280576.73609.c6; Tintore M, 2001, MULT SCLER, V7, P359, DOI 10.1191/135245801701567069; Tumani H, 1998, J NEUROL SCI, V155, P44, DOI 10.1016/S0022-510X(97)00272-4; WALSH MJ, 1986, J EXP MED, V163, P41, DOI 10.1084/jem.163.1.41; Whiting P, 2006, BMJ-BRIT MED J, V332, P875, DOI 10.1136/bmj.38771.583796.7C; Zipoli V, 2009, MULT SCLER J, V15, P472, DOI 10.1177/1352458508100502	34	85	89	0	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA	1932-6203			PLOS ONE	PLoS One	NOV 5	2009	4	11							e7638	10.1371/journal.pone.0007638	http://dx.doi.org/10.1371/journal.pone.0007638			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	515HI	19890384	Green Published, gold, Green Submitted			2022-12-25	WOS:000271459700002
J	Kuper, H; Atijosan, O; Rischewski, D; Simms, V; Lavy, C				Kuper, Hannah; Atijosan, Oluwarantimi; Rischewski, Dorothea; Simms, Victoria; Lavy, Chris			A Decade Later, How Much of Rwanda's Musculoskeletal Impairment Is Caused by the War in 1994 and by Related Violence?	PLOS ONE			English	Article							CROSS-SECTIONAL SURVEY; UNEXPLODED ORDNANCE; MORTALITY; TRAUMA; SUDAN; LANDMINES; INJURIES; GENOCIDE; DEATHS; HEALTH	Background: In 1994 there was a horrific genocide in Rwanda following years of tension, resulting in the murder of at least 800,000 people. Although many people were injured in addition to those killed, no attempt has been made to assess the lasting burden of physical injuries related to these events. The aim of this study was to estimate the current burden of musculoskeletal impairment (MSI) attributable to the 1994 war and related violence. Methodology/Principal Findings: A national cross-sectional survey of MSI was conducted in Rwanda. 105 clusters of 80 people were selected through probability proportionate to size sampling. Households within clusters were selected through compact segment sampling. Enumerated people answered a seven-question screening test to assess whether they might have an MSI. Those who were classed as potential cases in the screening test were examined and interviewed by a physiotherapist, using a standard protocol that recorded the site, nature, cause, and severity of the MSI. People with MSI due to trauma were asked whether this trauma occurred during the 1990-1994 war or during the episodes that preceded or followed this war. Out of 8,368 people enumerated, 6,757 were available for screening and examination (80.8%). 352 people were diagnosed with an MSI (prevalence = 5.2%, 95% CI = 4.5-5.9%). 106 cases of MSI (30.6%) were classified as resulting from trauma, based on self-report and the physiotherapist's assessment. Of these, 14 people (13.2%) reported that their trauma-related MSI occurred during the 1990-1994 war, and a further 7 (6.6%) that their trauma-related MSI occurred during the violent episodes that preceded and followed the war, giving an overall prevalence of trauma-related MSI related to the 1990-1994 war of 0.3% (95% CI = 0.2-0.4%). Conclusions/Significance: A decade on, the overall prevalence of MSI was relatively high in Rwanda but few cases appeared to be the result of the 1994 war or related violence.			Kuper, H (corresponding author), London Sch Hyg & Trop Med, Dept Epidemiol & Populat Hlth, London WC1, England.	hannah.kuper@lshtm.ac.uk	Simms, Victoria/AAU-4134-2021; Simms, Victoria/C-3278-2009	Simms, Victoria/0000-0002-4897-458X				Atijosan O, 2007, BMC MUSCULOSKEL DIS, V8, DOI 10.1186/1471-2474-8-30; Atijosan O, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002851; Bilukha OO, 2007, JAMA-J AM MED ASSOC, V298, P516, DOI 10.1001/jama.298.5.516; Bilukha OO, 2006, JAMA-J AM MED ASSOC, V296, P516, DOI 10.1001/jama.296.5.516-b; Burnham G, 2006, LANCET, V368, P1421, DOI 10.1016/S0140-6736(06)69491-9; de Jong JTVM, 2001, JAMA-J AM MED ASSOC, V286, P555, DOI 10.1001/jama.286.5.555; Depoortere E, 2004, LANCET, V364, P1315, DOI 10.1016/S0140-6736(04)17187-0; Grandesso F, 2005, JAMA-J AM MED ASSOC, V293, P1490, DOI 10.1001/jama.293.12.1490; Miller TQ, 1996, PSYCHOL BULL, V119, P322, DOI 10.1037/0033-2909.119.2.322; Neugebauer R, 2009, INT J EPIDEMIOL, V38, P1033, DOI 10.1093/ije/dyn375; Pham PN, 2004, JAMA-J AM MED ASSOC, V292, P602, DOI 10.1001/jama.292.5.602; Roberts B, 2009, BMC PSYCHIATRY, V9, DOI 10.1186/1471-244X-9-7; Spiegel PB, 2000, LANCET, V355, P2204, DOI 10.1016/S0140-6736(00)02404-1; vanderKolk BA, 1996, AM J PSYCHIAT, V153, P83; Verwimp P, 2004, POP STUD-J DEMOG, V58, P233, DOI 10.1080/0032472042000224422; WHO, 2001, WHO INT CLASS FUNCT	16	3	3	0	3	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA	1932-6203			PLOS ONE	PLoS One	NOV 5	2009	4	11							e7720	10.1371/journal.pone.0007720	http://dx.doi.org/10.1371/journal.pone.0007720			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	515HI	19890393	Green Accepted, Green Published, gold			2022-12-25	WOS:000271459700012
J	Wei, BR; Hoover, SB; Ross, MM; Zhou, WD; Meani, F; Edwards, JB; Spehalski, EI; Risinger, JI; Alvord, WG; Quinones, OA; Belluco, C; Martella, L; Campagnutta, E; Ravaggi, A; Dai, RM; Goldsmith, PK; Woolard, KD; Pecorelli, S; Liotta, LA; Petricoin, EF; Simpson, RM				Wei, Bih-Rong; Hoover, Shelley B.; Ross, Mark M.; Zhou, Weidong; Meani, Francesco; Edwards, Jennifer B.; Spehalski, Elizabeth I.; Risinger, John I.; Alvord, W. Gregory; Quinones, Octavio A.; Belluco, Claudio; Martella, Luca; Campagnutta, Elio; Ravaggi, Antonella; Dai, Ren-Ming; Goldsmith, Paul K.; Woolard, Kevin D.; Pecorelli, Sergio; Liotta, Lance A.; Petricoin, Emanuel F., III; Simpson, R. Mark			Serum S100A6 Concentration Predicts Peritoneal Tumor Burden in Mice with Epithelial Ovarian Cancer and Is Associated with Advanced Stage in Patients	PLOS ONE			English	Article							PHASE PROTEIN MICROARRAYS; CALCIUM-BINDING PROTEINS; ALBUMIN-BINDING; INCREASED EXPRESSION; SAMPLE PREPARATION; MODEL; METASTASIS; BIOMARKERS; SURVIVAL; MOUSE	Background: Ovarian cancer is the 5th leading cause of cancer related deaths in women. Five-year survival rates for early stage disease are greater than 94%, however most women are diagnosed in advanced stage with 5 year survival less than 28%. Improved means for early detection and reliable patient monitoring are needed to increase survival. Methodology and Principal Findings: Applying mass spectrometry-based proteomics, we sought to elucidate an unanswered biomarker research question regarding ability to determine tumor burden detectable by an ovarian cancer biomarker protein emanating directly from the tumor cells. Since aggressive serous epithelial ovarian cancers account for most mortality, a xenograft model using human SKOV-3 serous ovarian cancer cells was established to model progression to disseminated carcinomatosis. Using a method for low molecular weight protein enrichment, followed by liquid chromatography and mass spectrometry analysis, a human-specific peptide sequence of S100A6 was identified in sera from mice with advanced-stage experimental ovarian carcinoma. S100A6 expression was documented in cancer xenografts as well as from ovarian cancer patient tissues. Longitudinal study revealed that serum S100A6 concentration is directly related to tumor burden predictions from an inverse regression calibration analysis of data obtained from a detergent-supplemented antigen capture immunoassay and whole-animal bioluminescent optical imaging. The result from the animal model was confirmed in human clinical material as S100A6 was found to be significantly elevated in the sera from women with advanced stage ovarian cancer compared to those with early stage disease. Conclusions: S100A6 is expressed in ovarian and other cancer tissues, but has not been documented previously in ovarian cancer disease sera. S100A6 is found in serum in concentrations that correlate with experimental tumor burden and with clinical disease stage. The data signify that S100A6 may prove useful in detecting and/or monitoring ovarian cancer, when used in concert with other biomarkers.			Wei, BR (corresponding author), NCI, Mol Pathol Unit, Lab Canc Biol & Genet, Ctr Canc Res, Bethesda, MD 20892 USA.	ms43b@nih.gov	Martella, Luca/ABD-8896-2020; Ravaggi, Antonella/K-5585-2016; Meani, Francesco/GWZ-1745-2022; belluco, claudio/J-1339-2018	Martella, Luca/0000-0002-2058-1469; Ravaggi, Antonella/0000-0003-4661-9979; belluco, claudio/0000-0001-5972-9574	NATIONAL CANCER INSTITUTE [ZICBC010953] Funding Source: NIH RePORTER; Intramural NIH HHS Funding Source: Medline; NCI NIH HHS [N01-CO-12400, N01CO12400] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Intramural NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Aguilar-Mahecha A, 2009, PROTEOME SCI, V7, DOI 10.1186/1477-5956-7-15; Ahmed FE, 2009, J SEP SCI, V32, P771, DOI 10.1002/jssc.200800622; ALVORD WG, 1993, J IMMUNOL METHODS, V157, P155; BAST RC, 1985, GYNECOL ONCOL, V22, P115, DOI 10.1016/0090-8258(85)90015-0; BAST RC, 1985, EUR J OBSTET GYN R B, V19, P354, DOI 10.1016/0028-2243(85)90130-3; Bast RC., 2003, J CLIN ONCOL, V21, P200, DOI [10.1200/JCO.2003.01.068, DOI 10.1200/JCO.2003.01.068]; Besada V, 2006, PROTEOMICS, V6, P1038, DOI 10.1002/pmic.200500151; Brown LM, 2006, MOL CARCINOGEN, V45, P613, DOI 10.1002/mc.20193; Camerini S, 2007, PROTEOM CLIN APPL, V1, P176, DOI 10.1002/prca.200600618; Cannistra SA, 2004, NEW ENGL J MED, V351, P2519, DOI 10.1056/NEJMra041842; Crnogorac-Jurcevic T, 2003, J PATHOL, V201, P63, DOI 10.1002/path.1418; Cross SS, 2005, HISTOPATHOLOGY, V46, P256, DOI 10.1111/j.1365-2559.2005.02097.x; Custer MC, 2006, PROSTATE, V66, P567, DOI 10.1002/pros.20386; De Petris L, 2009, LUNG CANCER, V63, P410, DOI 10.1016/j.lungcan.2008.06.003; DELEAN A, 1978, AM J PHYSIOL, V235, pE97, DOI 10.1152/ajpendo.1978.235.2.E97; Dennis MS, 2002, J BIOL CHEM, V277, P35035, DOI 10.1074/jbc.M205854200; Donato R, 1999, BBA-MOL CELL RES, V1450, P191, DOI 10.1016/S0167-4889(99)00058-0; Donato R, 2001, INT J BIOCHEM CELL B, V33, P637, DOI 10.1016/S1357-2725(01)00046-2; Draper N.R., 1998, WILEY SERIES PROBABI, V326; Faca Vitor, 2009, V492, P309, DOI 10.1007/978-1-59745-493-3_19; Filipek A, 2006, CHEMOTHERAPY, V52, P32, DOI 10.1159/000090240; Grote T, 2008, PROTEOMICS, V8, P3051, DOI 10.1002/pmic.200700951; Hood BL, 2005, J AM SOC MASS SPECTR, V16, P1221, DOI 10.1016/j.jasms.2005.02.005; *INS CORP, 2005, S PLUS 7 0 WIND; Ito Y, 2005, HISTOPATHOLOGY, V46, P569, DOI 10.1111/j.1365-2559.2005.02137.x; Jemal A, 2008, CA-CANCER J CLIN, V58, P71, DOI 10.3322/CA.2007.0010; Juan HF, 2004, PROTEOMICS, V4, P2766, DOI 10.1002/pmic.200400785; Kelly-Spratt KS, 2008, J PROTEOME RES, V7, P3613, DOI 10.1021/pr800210b; Komatsu K, 2000, BRIT J CANCER, V83, P769, DOI 10.1054/bjoc.2000.1356; Kurtzhals P, 1995, BIOCHEM J, V312, P725, DOI 10.1042/bj3120725; KUZNICKI J, 1992, EXP CELL RES, V200, P425, DOI 10.1016/0014-4827(92)90191-A; Littell R. C., 2006, SAS SYSTEMS MIXED MO, V2nd; Luque-Garcia JL, 2007, J CHROMATOGR A, V1153, P259, DOI 10.1016/j.chroma.2006.11.054; Luu HH, 2005, CANCER LETT, V229, P135, DOI 10.1016/j.canlet.2005.02.015; Makrides SC, 1996, J PHARMACOL EXP THER, V277, P534; Milliken G. A., 2009, ANAL MESSY DATA DESI, V2nd; Nossov V, 2008, AM J OBSTET GYNECOL, V199, P215, DOI 10.1016/j.ajog.2008.04.009; Ohuchida K, 2005, CLIN CANCER RES, V11, P7785, DOI 10.1158/1078-0432.CCR-05-0714; Ohuchida K, 2007, CANCER EPIDEM BIOMAR, V16, P649, DOI 10.1158/1055-9965.EPI-06-0157; Paweletz CP, 2001, ONCOGENE, V20, P1981, DOI 10.1038/sj.onc.1204265; Petricoin EF, 2002, LANCET, V359, P572, DOI 10.1016/S0140-6736(02)07746-2; Petricoin EF, 2006, NAT REV CANCER, V6, P961, DOI 10.1038/nrc2011; Rantalainen M, 2006, J PROTEOME RES, V5, P2642, DOI 10.1021/pr060124w; Rapkiewicz AV, 2004, EUR J CANCER, V40, P2604, DOI 10.1016/j.ejca.2004.05.021; Rosen DG, 2009, FRONT BIOSCI-LANDMRK, V14, P2089, DOI 10.2741/3364; SAS Institute, 2002, SAS STAT SOFTW; Schafer BW, 1996, TRENDS BIOCHEM SCI, V21, P134, DOI 10.1016/S0968-0004(96)80167-8; Schaub MC, 2008, BIOCHEM BIOPH RES CO, V369, P247, DOI 10.1016/j.bbrc.2007.10.082; Shan WW, 2009, CELL CYCLE, V8, P731, DOI 10.4161/cc.8.5.7848; Shih IM, 2004, AM J PATHOL, V164, P1511, DOI 10.1016/S0002-9440(10)63708-X; Team RDC, 2019, R LANG ENV STAT COMP; Vimalachandran D, 2005, CANCER RES, V65, P3218, DOI 10.1158/0008-5472.CAN-04-4311; Wei BR, 2008, TOXICOL PATHOL, V36, P972, DOI 10.1177/0192623308327120; Williams TI, 2007, J PROTEOME RES, V6, P2936, DOI 10.1021/pr070041v; Young RC, 2003, JNCI-J NATL CANCER I, V95, P94, DOI 10.1093/jnci/95.2.94; Zietarska M, 2007, MOL CARCINOGEN, V46, P872, DOI 10.1002/mc.20315	56	33	37	0	8	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	OCT 30	2009	4	10							e7670	10.1371/journal.pone.0007670	http://dx.doi.org/10.1371/journal.pone.0007670			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	514RW	19888321	Green Submitted, Green Published, gold			2022-12-25	WOS:000271414300015
J	Martina, E; Degen, M; Ruegg, C; Merlo, A; Lino, MM; Chiquet-Ehrismann, R; Brellier, F				Martina, Enrico; Degen, Martin; Rueegg, Curzio; Merlo, Adrian; Lino, Maddalena M.; Chiquet-Ehrismann, Ruth; Brellier, Florence			Tenascin-W is a specific marker of glioma-associated blood vessels and stimulates angiogenesis in vitro	FASEB JOURNAL			English	Article						neovascularization; secreted glycoproteins	ENDOTHELIAL GROWTH-FACTOR; BREAST-CANCER; CELL-ADHESION; TUMOR; EXPRESSION; FIBRONECTIN; FIBROBLASTS; ANTIBODY; STROMA; RADIOIMMUNOTHERAPY	The microenvironment hosting a tumor actively participates in regulating tumor cell proliferation, migration, and invasion. Among the extracellular matrix proteins enriched in the stroma of carcinomas are the tenascin family members tenascin-C and tenascin-W. Whereas tenascin-C overexpression in gliomas is known to correlate with poor prognosis, the status of tenascin-W in brain tumors has not been investigated so far. In the present study, we analyzed protein levels of tenascin-W in 38 human gliomas and found expression of tenascin-W in 80% of the tumor samples, whereas no tenascin-W could be detected in control, nontumoral brain tissues. Double immunohistochemical staining of tenascin-W and von Willebrand factor revealed that tenascin-W is localized around blood vessels, exclusively in tumor samples. In vitro, the presence of tenascin-W increased the proportion of elongated human umbilical vein endothelial cells (HUVECs) and augmented the mean speed of cell migration. Furthermore, tenascin-W triggered sprouting of HUVEC spheroids to a similar extent as the proangio-genic factor tenascin-C. In conclusion, our study identifies tenascin-W as a candidate biomarker for brain tumor angiogenesis that could be used as a molecular target for therapy irrespective of the glioma subtype.-Martina, E., Degen, M., Ruegg, C., Merlo, A., Lino, M. M., Chiquet-Ehrismann, R., Brellier, F. Tenascin-W is a specific marker of glioma-associated blood vessels and stimulates angiogenesis in vitro. FASEB J. 24, 778-787 (2010). www.fasebj.org	[Martina, Enrico; Degen, Martin; Chiquet-Ehrismann, Ruth; Brellier, Florence] Novartis Res Fdn, Friedrich Miescher Inst Biomed Res, CH-4058 Basel, Switzerland; [Rueegg, Curzio] Univ Lausanne, CHU Vaudois, Div Expt Oncol, Ctr Pluridisciplinaire Oncol, Lausanne, Switzerland; [Rueegg, Curzio] Swiss Inst Expt Canc Res, NCCR Mol Oncol, CH-1066 Epalinges, Switzerland; [Merlo, Adrian; Lino, Maddalena M.] Univ Basel Hosp, Dept Res, Mol Neurooncol Lab, CH-4031 Basel, Switzerland	Friedrich Miescher Institute for Biomedical Research; Novartis; University of Lausanne; Centre Hospitalier Universitaire Vaudois (CHUV); Swiss Institute Experimental Cancer Research; University of Basel	Brellier, F (corresponding author), Novartis Res Fdn, Friedrich Miescher Inst Biomed Res, Maulbeerstr 66, CH-4058 Basel, Switzerland.	florence.brellier@fmi.ch	Degen, Martin/H-5791-2013	Brellier, Florence/0000-0002-0143-472X; Degen, Martin/0000-0002-4356-3714	Schweizerische National-fonds (SNF); National Center for Competence in Research; Oncosuisse [01613-12-2004, SNF 3100A0-120235]; Krebsliga beider Basel [20-2008]	Schweizerische National-fonds (SNF)(Swiss National Science Foundation (SNSF)); National Center for Competence in Research; Oncosuisse; Krebsliga beider Basel	Grant support is provided by the Schweizerische National-fonds (SNF), National Center for Competence in Research (C. R.), Oncosuisse OCS-01613-12-2004 (A. M.), SNF 3100A0-120235 (R.C.-E.), and Krebsliga beider Basel 20-2008 (F. B.). We thank Gregory Bieler (Division of Experimental Oncology, University of Lausanne, Lausanne, Switzerland) for kindly providing us early passages of HUVECs, Natsuko Imaizumi and Eveline Faes for their technical expertise with angiogenesis assays, Catherine Schiltz and Sandrine Bichet for their help with immunohistochemistry, Daniela Kenzelmann (FMi, Basel, Switzerland) for the teneurin-4 constructs, Laurent Gelman for his help with microscopy, and Clare Isacke (Institute of Cancer Research, London, UK) for the culture medium of pericytes. We also thank Remi Terranova and Richard P. Tucker for critical reading of the manuscript.	Bhowmick NA, 2004, NATURE, V432, P332, DOI 10.1038/nature03096; Bigner DD, 1998, J CLIN ONCOL, V16, P2202, DOI 10.1200/JCO.1998.16.6.2202; Brack SS, 2006, CLIN CANCER RES, V12, P3200, DOI 10.1158/1078-0432.CCR-05-2804; Bredel M, 2005, CANCER RES, V65, P8679, DOI 10.1158/0008-5472.CAN-05-1204; Brellier F, 2009, SCAND J MED SCI SPOR, V19, P511, DOI 10.1111/j.1600-0838.2009.00916.x; Cairncross JG, 1998, J CLIN ONCOL, V16, P3210, DOI 10.1200/JCO.1998.16.9.3210; Calvo A, 2008, ONCOGENE, V27, P5373, DOI 10.1038/onc.2008.155; CANFIELD AE, 1995, J CELL SCI, V108, P797; CHIQUETEHRISMANN R, 1986, CELL, V47, P131, DOI 10.1016/0092-8674(86)90374-0; De Santis R, 2003, BRIT J CANCER, V88, P996, DOI 10.1038/sj.bjc.6600818; De Wever O, 2004, FASEB J, V18, P1016, DOI 10.1096/fj.03-1110fje; Degen M, 2008, INT J CANCER, V122, P2454, DOI 10.1002/ijc.23417; Degen M, 2007, CANCER RES, V67, P9169, DOI 10.1158/0008-5472.CAN-07-0666; Fischer D, 1997, MOL BIOL CELL, V8, P2055, DOI 10.1091/mbc.8.10.2055; Giusti B, 2006, ARTHRITIS RES THER, V8, DOI 10.1186/ar2002; Herold-Mende C, 2002, INT J CANCER, V98, P362, DOI 10.1002/ijc.10233; Huang WT, 2001, CANCER RES, V61, P8586; Ishiwata T, 2005, ANTICANCER RES, V25, P489; Ivanov D, 2004, EXP CELL RES, V293, P207, DOI 10.1016/j.yexcr.2003.09.030; Kalas W, 2005, CANCER RES, V65, P8878, DOI 10.1158/0008-5472.CAN-05-1479; Kalluri R, 2006, NAT REV CANCER, V6, P392, DOI 10.1038/nrc1877; Kaspar M, 2006, INT J CANCER, V118, P1331, DOI 10.1002/IJC.21677; Kass L, 2007, INT J BIOCHEM CELL B, V39, P1987, DOI 10.1016/j.biocel.2007.06.025; Kimura H, 2007, BIOCHEM BIOPH RES CO, V356, P935, DOI 10.1016/j.bbrc.2007.03.071; Korff T, 1998, J CELL BIOL, V143, P1341, DOI 10.1083/jcb.143.5.1341; Korff T, 1999, J CELL SCI, V112, P3249; Langenfeld EM, 2004, MOL CANCER RES, V2, P141; Leins A, 2003, CANCER-AM CANCER SOC, V98, P2430, DOI 10.1002/cncr.11796; Lino M, 2009, CURR OPIN CELL BIOL, V21, P311, DOI 10.1016/j.ceb.2008.12.009; Lorusso G, 2008, HISTOCHEM CELL BIOL, V130, P1091, DOI 10.1007/s00418-008-0530-8; Marlind J, 2008, CLIN CANCER RES, V14, P6515, DOI 10.1158/1078-0432.CCR-07-5041; Orend G, 2003, ONCOGENE, V22, P3917, DOI 10.1038/sj.onc.1206618; Orend G, 2005, INT J BIOCHEM CELL B, V37, P1066, DOI 10.1016/j.biocel.2004.12.002; Orend G, 2006, CANCER LETT, V244, P143, DOI 10.1016/j.canlet.2006.02.017; PLATE KH, 1992, NATURE, V359, P845, DOI 10.1038/359845a0; Reardon DA, 2007, EXPERT REV ANTICANC, V7, P675, DOI 10.1586/14737140.7.5.675; Ren RQ, 2007, BLOOD, V109, P2847, DOI 10.1182/blood-2006-08-039743; ROMER LH, 1994, MOL BIOL CELL, V5, P349, DOI 10.1091/mbc.5.3.349; Rothhammer T, 2007, ONCOGENE, V26, P4158, DOI 10.1038/sj.onc.1210182; Saito Y, 2008, BIOL PHARM BULL, V31, P1003, DOI 10.1248/bpb.31.1003; Sauer S, 2009, BLOOD, V113, P2265, DOI 10.1182/blood-2008-06-160416; Schenk S, 1999, MOL BIOL CELL, V10, P2933, DOI 10.1091/mbc.10.9.2933; Scherberich A, 2004, J CELL SCI, V117, P571, DOI 10.1242/jcs.00867; Silacci M, 2006, PROTEIN ENG DES SEL, V19, P471, DOI 10.1093/protein/gzl033; Sivasankaran B, 2009, CANCER RES, V69, P458, DOI 10.1158/0008-5472.CAN-08-2610; Tanaka K, 2004, INT J CANCER, V108, P31, DOI 10.1002/ijc.11509; Tavazoie SF, 2008, NATURE, V451, P147, DOI 10.1038/nature06487; Tuxhorn JA, 2002, CANCER RES, V62, P6021; Zagzag D, 2002, CANCER RES, V62, P2660; Zamecnik J, 2005, ACTA NEUROPATHOL, V110, P435, DOI 10.1007/s00401-005-1078-5	50	42	46	0	9	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAR	2010	24	3					778	787		10.1096/fj.09-140491	http://dx.doi.org/10.1096/fj.09-140491			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	561KE	19884327	Green Published			2022-12-25	WOS:000274974600014
J	Liu, ZL; Zhou, SL; Liao, L; Chen, X; Meistrich, M; Xu, JM				Liu, Zhaoliang; Zhou, Suoling; Liao, Lan; Chen, Xian; Meistrich, Marvin; Xu, Jianming			Jmjd1a Demethylase-regulated Histone Modification Is Essential for cAMP-response Element Modulator-regulated Gene Expression and Spermatogenesis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MALE GERM-CELLS; METHYLATION; JHDM2A; SPERM; CREM; SPERMIOGENESIS; TRANSCRIPTION; ACTIVATION; FERTILITY; ACETYLTRANSFERASES	Spermatogenesis, a fundamental process in the male reproductive system, requires a series of tightly controlled epigenetic and genetic events in germ cells ranging from spermatogonia to spermatozoa. Jmjd1a is a key epigenetic regulator expressed in the testis. It specifically demethylates mono- and di-methylated histone H3 lysine 9 (H3K9me1 and H3K9me2) but not tri-methylated H3K9 (H3K9me3). In this study, we generated a Jmjd1a antibody for immunohistochemistry and found Jmjd1a was specifically produced in pachytene and secondary spermatocytes. Disruption of the Jmjd1a gene in mice significantly increased H3K9me1 and H3K9me2 levels in pachytene spermatocytes and early elongating spermatids without affecting H3K9me3 levels. Concurrently, the levels of histone acetylation were decreased in Jmjd1a knock-out germ cells. This suggests Jmjd1a promotes transcriptional activation by lowering histone methylation and increasing histone acetylation. Interestingly, the altered histone modifications in Jmjd1a-deficient germ cells caused diminished cAMP-response element modulator (Crem) recruitment to chromatin and decreased expression of the Crem coactivator Act and their target genes Tnp1 (transition protein 1), Tnp2, Prm1 (protamine 1), and Prm2, all of which are essential for chromatin condensation in spermatids. In agreement with these findings, Jmjd1a deficiency caused extensive germ cell apoptosis and blocked spermatid elongation, resulting in severe oligozoospermia, small testes, and infertility in male mice. These results indicate that the Jmjd1a-controlled epigenetic histone modifications are crucial for Crem-regulated gene expression and spermatogenesis.	[Liu, Zhaoliang; Zhou, Suoling; Liao, Lan; Chen, Xian; Xu, Jianming] Baylor Coll Med, Dept Mol & Cellular Biol, Houston, TX 77030 USA; [Liu, Zhaoliang; Chen, Xian; Xu, Jianming] Texas A&M Univ, Hlth Sci Ctr, Inst Biosci & Technol, Houston, TX 77030 USA; [Meistrich, Marvin] Univ Texas MD Anderson Canc Ctr, Dept Expt Radiat Oncol, Houston, TX 77030 USA; [Xu, Jianming] Luzhou Med Coll, Luzhou 646000, Sichuan, Peoples R China	Baylor College of Medicine; Texas A&M University System; Texas A&M University College Station; Texas A&M Health Science Center; University of Texas System; University of Texas Health Science Center Houston; University of Texas System; UTMD Anderson Cancer Center; Southwest Medical University	Xu, JM (corresponding author), Baylor Coll Med, Dept Mol & Cellular Biol, 1 Baylor Plaza, Houston, TX 77030 USA.	jxu@bcm.tmc.edu			National Institutes of Health [DK058242, CA112403, CA119689, DK059820]; NATIONAL CANCER INSTITUTE [R01CA119689, R01CA112403] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK058242, P01DK059820] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))	This work was supported, in whole or in part, by National Institutes of Health Grants DK058242, CA112403, CA119689, and DK059820.	Agger K, 2007, NATURE, V449, P731, DOI 10.1038/nature06145; Akimoto C, 2008, GENES CELLS, V13, P623, DOI 10.1111/j.1365-2443.2008.01193.x; Boulanger CA, 2007, P NATL ACAD SCI USA, V104, P3871, DOI 10.1073/pnas.0611637104; Chang BS, 2007, SCIENCE, V318, P444, DOI 10.1126/science.1145801; Cho C, 2001, NAT GENET, V28, P82, DOI 10.1038/ng0501-82; Couldrey C, 1999, HUM MOL GENET, V8, P2489, DOI 10.1093/hmg/8.13.2489; De Cesare D, 2003, MOL ENDOCRINOL, V17, P2554, DOI 10.1210/me.2003-0280; De Gendt K, 2004, P NATL ACAD SCI USA, V101, P1327, DOI 10.1073/pnas.0308114100; DELMAS V, 1993, MOL ENDOCRINOL, V7, P1502, DOI 10.1210/me.7.11.1502; Deng CX, 1996, CELL, V84, P911, DOI 10.1016/S0092-8674(00)81069-7; Deng W, 2002, DEV CELL, V2, P819, DOI 10.1016/S1534-5807(02)00165-X; Fimia GM, 1999, NATURE, V398, P165, DOI 10.1038/18237; Garcia-Bassets I, 2007, CELL, V128, P505, DOI 10.1016/j.cell.2006.12.038; Giorgini F, 2002, DEVELOPMENT, V129, P3669; Godmann M, 2007, BIOL REPROD, V77, P754, DOI 10.1095/biolreprod.107.062265; Govin J, 2004, EUR J BIOCHEM, V271, P3459, DOI 10.1111/j.1432-1033.2004.04266.x; Govin J, 2007, J CELL BIOL, V176, P283, DOI 10.1083/jcb.200604141; Hayashi K, 2005, NATURE, V438, P374, DOI 10.1038/nature04112; Hazzouri M, 2000, EUR J CELL BIOL, V79, P950, DOI 10.1078/0171-9335-00123; HOOG C, 1991, MOL REPROD DEV, V30, P173, DOI 10.1002/mrd.1080300302; Jeyaraj DA, 2005, STEROIDS, V70, P704, DOI 10.1016/j.steroids.2005.03.015; Klose RJ, 2006, NATURE, V442, P312, DOI 10.1038/nature04853; Ko SY, 2006, CELL STRUCT FUNCT, V31, P53, DOI 10.1247/csf.31.53; Kotaja N, 2004, P NATL ACAD SCI USA, V101, P10620, DOI 10.1073/pnas.0401947101; Lahn BT, 2002, P NATL ACAD SCI USA, V99, P8707, DOI 10.1073/pnas.082248899; Latendresse JR, 2002, TOXICOL PATHOL, V30, P524, DOI 10.1080/01926230290105721; Liu W, 2004, P NATL ACAD SCI USA, V101, P4489, DOI 10.1073/pnas.0308466101; Lockman K, 2007, CIRC RES, V101, pE115, DOI 10.1161/CIRCRESAHA.107.164178; Loh YH, 2007, GENE DEV, V21, P2545, DOI 10.1101/gad.1588207; Ma DK, 2008, STEM CELLS, V26, P2131, DOI 10.1634/stemcells.2008-0388; MALI P, 1989, REPROD FERT DEVELOP, V1, P369, DOI 10.1071/RD9890369; Mark M, 2004, P NATL ACAD SCI USA, V101, P4453, DOI 10.1073/pnas.0400234101; Martianov I, 2005, P NATL ACAD SCI USA, V102, P2808, DOI 10.1073/pnas.0406060102; Martin C, 2005, NAT REV MOL CELL BIO, V6, P838, DOI 10.1038/nrm1761; MEISTRICH ML, 1992, MOL REPROD DEV, V31, P170, DOI 10.1002/mrd.1080310303; Nantel F, 1996, NATURE, V380, P159, DOI 10.1038/380159a0; O'Carroll D, 2000, MOL CELL BIOL, V20, P9423, DOI 10.1128/MCB.20.24.9423-9433.2000; Okada Y, 2007, NATURE, V450, P119, DOI 10.1038/nature06236; Payne C, 2006, DEV BIOL, V293, P461, DOI 10.1016/j.ydbio.2006.02.013; Peters AHFM, 2001, CELL, V107, P323, DOI 10.1016/S0092-8674(01)00542-6; Pollard PJ, 2008, BIOCHEM J, V416, P387, DOI 10.1042/BJ20081238; Qin L, 2009, CANCER RES, V69, P3819, DOI 10.1158/0008-5472.CAN-08-4389; Russell LD, 1990, HISTOLOGICAL HISTOPA, P1; Sambrook J, 2001, MOL CLONING LAB MANU; Shi YJ, 2004, CELL, V119, P941, DOI 10.1016/j.cell.2004.12.012; Tachibana M, 2007, EMBO J, V26, P3346, DOI 10.1038/sj.emboj.7601767; Tanaka H, 2005, MOL CELL BIOL, V25, P7107, DOI 10.1128/MCB.25.16.7107-7119.2005; Tateishi K, 2009, NATURE, V458, P757, DOI 10.1038/nature07777; Thomas T, 2007, GENE EXPR PATTERNS, V7, P657, DOI 10.1016/j.modgep.2007.03.005; Tsukada Y, 2006, NATURE, V439, P811, DOI 10.1038/nature04433; Wellmann S, 2008, BIOCHEM BIOPH RES CO, V372, P892, DOI 10.1016/j.bbrc.2008.05.150; Wu JY, 2000, NAT GENET, V25, P448, DOI 10.1038/78153; Yamane K, 2006, CELL, V125, P483, DOI 10.1016/j.cell.2006.03.027; Yu YE, 2000, P NATL ACAD SCI USA, V97, P4683, DOI 10.1073/pnas.97.9.4683; Zhang Y, 2001, GENE DEV, V15, P2343, DOI 10.1101/gad.927301; Zhao M, 2004, BIOL REPROD, V71, P1016, DOI 10.1095/biolreprod.104.028191; Zhao M, 2001, MOL CELL BIOL, V21, P7243, DOI 10.1128/MCB.21.21.7243-7255.2001	57	100	110	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 22	2010	285	4					2758	2770		10.1074/jbc.M109.066845	http://dx.doi.org/10.1074/jbc.M109.066845			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	544YP	19910458	Green Published, hybrid			2022-12-25	WOS:000273697800053
J	Phan, J; Li, ZY; Kasprzak, A; Li, BZ; Sebti, S; Guida, W; Schonbrunn, E; Chen, JD				Phan, Jason; Li, Zhenyu; Kasprzak, Agnieszka; Li, Baozong; Sebti, Said; Guida, Wayne; Schoenbrunn, Ernst; Chen, Jiandong			Structure-based Design of High Affinity Peptides Inhibiting the Interaction of p53 with MDM2 and MDMX	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EMBRYONIC LETHALITY; MDM2-DEFICIENT MICE; ACTIVATION; PROTEIN; PATHWAY; BINDING; APOPTOSIS; RESCUE; SUPPRESSION; GROWTH	MDM2 and MDMX function as key regulators of p53 by binding to its N terminus, inhibiting its transcriptional activity, and promoting degradation. MDM2 and MDMX overexpression or hyperactivation directly contributes to the loss of p53 function during the development of nearly 50% of human cancers. Recent studies showed that disrupting p53-MDM2 and p53-MDMX interactions can lead to robust activation of p53 but also revealed a need to develop novel dual specific or MDMX-specific inhibitors. Using phage display we identified a 12-residue peptide (pDI) with inhibitory activity against MDM2 and MDMX. The co-crystal structures of the pDI and a single mutant derivative (pDI6W) liganded with the N-terminal domains of human MDMX and MDM2 served as the basis for the design of 11 distinct pDI-derivative peptides that were tested for inhibitory potential. The best derivative (termed pDIQ) contained four amino acid substitutions and exhibited a 5-fold increase in potency over the parent peptide against both MDM2 (IC50 = 8 nM) and MDMX (IC50 = 110 nM). Further structural studies revealed key molecular features enabling the high affinity binding of the pDIQ to these proteins. These include large conformational changes of the pDIQ to reach into a hydrophobic site unique to MDMX. The findings suggest new strategies toward the rational design of small molecule inhibitors efficiently targeting MDMX.	[Phan, Jason; Kasprzak, Agnieszka; Sebti, Said; Guida, Wayne; Schoenbrunn, Ernst] H Lee Moffitt Canc Ctr & Res Inst, Drug Discovery Dept, Tampa, FL 33612 USA; [Li, Zhenyu; Li, Baozong; Chen, Jiandong] H Lee Moffitt Canc Ctr & Res Inst, Dept Mol Oncol, Tampa, FL 33612 USA; [Sebti, Said; Guida, Wayne; Schoenbrunn, Ernst; Chen, Jiandong] Univ S Florida, Dept Oncol Sci, Tampa, FL 33612 USA	H Lee Moffitt Cancer Center & Research Institute; H Lee Moffitt Cancer Center & Research Institute; State University System of Florida; University of South Florida	Schonbrunn, E (corresponding author), H Lee Moffitt Canc Ctr & Res Inst, Drug Discovery Dept, 12902 Magnolia Dr, Tampa, FL 33612 USA.	Ernst.Schonbrunn@moffitt.org; Jiandong.Chen@moffitt.org	li, baozong/K-4176-2012; Li, Baozong/ABD-4742-2020	Schonbrunn, Ernst/0000-0002-3589-3510	National Institutes of Health [CA109636, CA118210]; NATIONAL CANCER INSTITUTE [R01CA109636, P01CA118210] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This work was supported, in whole or in part, by National Institutes of Health Grants CA109636 (to J.C.) and CA118210 (to S. S.).	BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Bernal F, 2007, J AM CHEM SOC, V129, P2456, DOI 10.1021/ja0693587; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; CHEN JD, 1993, MOL CELL BIOL, V13, P4107, DOI 10.1128/MCB.13.7.4107; Czarna A, 2009, CELL CYCLE, V8, P1176, DOI 10.4161/cc.8.8.8185; Fasan R, 2006, CHEMBIOCHEM, V7, P515, DOI 10.1002/cbic.200500452; Gilkes DM, 2006, EMBO J, V25, P5614, DOI 10.1038/sj.emboj.7601424; Hu B, 2007, CANCER RES, V67, P8810, DOI 10.1158/0008-5472.CAN-07-1140; Hu BL, 2006, J BIOL CHEM, V281, P33030, DOI 10.1074/jbc.C600147200; Hu WW, 2007, NATURE, V450, P721, DOI 10.1038/nature05993; JONES SN, 1995, NATURE, V378, P206, DOI 10.1038/378206a0; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KABSCH W, 1976, ACTA CRYSTALLOGR A, V32, P922, DOI 10.1107/S0567739476001873; Kapust RB, 2001, PROTEIN ENG, V14, P993, DOI 10.1093/protein/14.12.993; Kussie PH, 1996, SCIENCE, V274, P948, DOI 10.1126/science.274.5289.948; Laurie NA, 2006, NATURE, V444, P61, DOI 10.1038/nature05194; Lawrence HR, 2009, BIOORG MED CHEM LETT, V19, P3756, DOI 10.1016/j.bmcl.2009.04.124; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; LIN JY, 1994, GENE DEV, V8, P1235, DOI 10.1101/gad.8.10.1235; LUNA RMD, 1995, NATURE, V378, P203; OLINER JD, 1993, NATURE, V362, P857, DOI 10.1038/362857a0; OLINER JD, 1992, NATURE, V358, P80, DOI 10.1038/358080a0; Pan Y, 2003, MOL CELL BIOL, V23, P5113, DOI 10.1128/MCB.23.15.5113-5121.2003; Parant J, 2001, NAT GENET, V29, P92, DOI 10.1038/ng714; Patton JT, 2006, CANCER RES, V66, P3169, DOI 10.1158/0008-5472.CAN-05-3832; Pazgiera M, 2009, P NATL ACAD SCI USA, V106, P4665, DOI 10.1073/pnas.0900947106; Popowicz GM, 2008, CELL CYCLE, V7, P2441, DOI 10.4161/cc.6365; Popowicz GM, 2007, CELL CYCLE, V6, P2386, DOI 10.4161/cc.6.19.4740; Prives C, 1999, J PATHOL, V187, P112; Shangary S, 2008, P NATL ACAD SCI USA, V105, P3933, DOI 10.1073/pnas.0708917105; Sherr CJ, 2006, NAT REV CANCER, V6, P663, DOI 10.1038/nrc1954; Shvarts A, 1996, EMBO J, V15, P5349, DOI 10.1002/j.1460-2075.1996.tb00919.x; Stott FJ, 1998, EMBO J, V17, P5001, DOI 10.1093/emboj/17.17.5001; Takaoka A, 2003, NATURE, V424, P516, DOI 10.1038/nature01850; Vassilev LT, 2004, SCIENCE, V303, P844, DOI 10.1126/science.1092472; Wade M, 2008, CELL CYCLE, V7, P1973, DOI 10.4161/cc.7.13.6072; Wade M, 2006, J BIOL CHEM, V281, P33036, DOI 10.1074/jbc.M605405200; WU XW, 1993, GENE DEV, V7, P1126, DOI 10.1101/gad.7.7a.1126; Xia MX, 2008, CELL CYCLE, V7, P1604, DOI 10.4161/cc.7.11.5929; Yu GW, 2006, P NATL ACAD SCI USA, V103, P1227, DOI 10.1073/pnas.0510343103; Zhang RM, 2004, ANAL BIOCHEM, V331, P138, DOI 10.1016/j.ab.2004.03.009; Zindy F, 1998, GENE DEV, V12, P2424, DOI 10.1101/gad.12.15.2424	42	116	130	2	43	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 15	2010	285	3					2174	2183		10.1074/jbc.M109.073056	http://dx.doi.org/10.1074/jbc.M109.073056			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	541PJ	19910468	hybrid, Green Published			2022-12-25	WOS:000273429100061
J	Bhattacharyya, S; Borthakur, A; Tyagi, S; Gill, R; Chen, ML; Dudeja, PK; Tobacman, JK				Bhattacharyya, Sumit; Borthakur, Alip; Tyagi, Sangeeta; Gill, Ravinder; Chen, Mei Ling; Dudeja, Pradeep K.; Tobacman, Joanne K.			B-cell CLL/Lymphoma 10 (BCL10) Is Required for NF-kappa B Production by Both Canonical and Noncanonical Pathways and for NF-kappa B-inducing Kinase (NIK) Phosphorylation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INTESTINAL EPITHELIAL-CELLS; ACTIVATION; CARRAGEENAN; EXPRESSION; SUBUNIT; PROTEIN; IKK; T(1/14)(P22,Q32); LYMPHOTOXIN; RECEPTORS	B-cell CLL/lymphoma 10 (BCL10), the caspase recruitment domain (CARD)-containing protein involved in the etiology of the mucosa-associated lymphoid tissue (MALT) lymphomas, has been implicated in inflammatory processes in epithelial cells, as well as in immune cells. Experiments in this report indicate that BCL10 is required for activation of nuclear factor (NF)-kappa B by both canonical and noncanonical pathways, following stimulation by the sulfated polysaccharide carrageenan (CGN). In wild type and I kappa B-kinase (IKK)alpha(-/-) mouse embryonic fibroblasts, increases in phospho-I kappa B alpha, nuclear NF-kappa B p65 (RelA) and p50, and KC, the mouse analog of human interleukin-8, were markedly reduced by silencing BCL10 or by exposure to the free radical scavenger Tempol. In IKK beta(-/-) cells, BCL10 silencing, but not Tempol, reduced the CGN-induced increases in KC, phospho-NF-kappa B-inducing kinase (NIK), cytoplasmic NF-kappa B p100, and nuclear NF-kappa B p52 and RelB, suggesting a BCL10 requirement for activation of the noncanonical pathway. In NCM460 cells, derived from normal, human colonic epithelium, the CGN-induced increases in NF-kappa B family members, p65, p50, p52, and RelB, were inhibited by BCL10 silencing. Although enzyme-linked immunosorbent assay and confocal images demonstrated no change in total NIK following CGN, increases in phospho-NIK in the wild type, IKK beta(-/-) and IKK alpha(-/-) cells were inhibited by silencing BCL10. These findings indicate an upstream signaling role for BCL10, in addition to its effects on IKK gamma, the regulatory component of the IKK signalosome, and a requirement for BCL10 in both canonical and noncanonical pathways of NF-kappa B activation. Also, the commonly used food additive carrageenan can be added to the short list of known activators of both pathways.	[Bhattacharyya, Sumit; Borthakur, Alip; Tyagi, Sangeeta; Gill, Ravinder; Dudeja, Pradeep K.; Tobacman, Joanne K.] Univ Illinois, Dept Med, Chicago, IL 60612 USA; [Chen, Mei Ling] Univ Illinois, Dept Anat & Cell Biol, Chicago, IL 60612 USA; [Dudeja, Pradeep K.; Tobacman, Joanne K.] Jesse Brown Vet Affairs Med Ctr, Chicago, IL 60612 USA	University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; US Department of Veterans Affairs; Veterans Health Administration (VHA); Jesse Brown VA Medical Center	Tobacman, JK (corresponding author), Univ Illinois, Dept Med, 840 S Wood St,M-C 718,440 CSN, Chicago, IL 60612 USA.	jkt@uic.edu		Gill, Ravinder/0000-0002-5337-2567	Department of Veterans Affairs; NIDDK; National Institutes of Health [DK68324, DK54016]; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK068324, R01DK054016] Funding Source: NIH RePORTER	Department of Veterans Affairs(US Department of Veterans Affairs); NIDDK(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))	This work was supported in part by the Department of Veterans Affairs (to J. K. T.) and by NIDDK, National Institutes of Health Grants DK68324 and DK54016 (to P. K. D.).	Basak S, 2008, MOL CELL BIOL, V28, P3139, DOI 10.1128/MCB.01469-07; BHATTACHARYYA S, 2009, J NUTR BIOCH; Bhattacharyya S, 2008, BBA-GEN SUBJECTS, V1780, P973, DOI 10.1016/j.bbagen.2008.03.019; Bhattacharyya S, 2008, J BIOL CHEM, V283, P10550, DOI 10.1074/jbc.M708833200; Bhattacharyya S, 2008, J NUTR, V138, P469, DOI 10.1093/jn/138.3.469; Bhattacharyya S, 2007, J IMMUNOASS IMMUNOCH, V28, P173, DOI 10.1080/15321810701454573; Bhattacharyya S, 2007, AM J PHYSIOL-GASTR L, V293, pG429, DOI 10.1152/ajpgi.00149.2007; Bhattacharyya S, 2009, INFLAMM BOWEL DIS, V15, P673, DOI 10.1002/ibd.20821; BORTHAKUR A, 2009, INFLAM BOWEL DI 0827; Borthakur A, 2007, AM J PHYSIOL-GASTR L, V292, pG829, DOI 10.1152/ajpgi.00380.2006; Briones J, 2009, HISTOPATHOLOGY, V54, P478, DOI 10.1111/j.1365-2559.2009.03250.x; Chang HH, 2009, ORAL ONCOL, V45, P589, DOI 10.1016/j.oraloncology.2008.08.003; Dejardin E, 2006, BIOCHEM PHARMACOL, V72, P1161, DOI 10.1016/j.bcp.2006.08.007; Drew D, 2007, BIOCHEMISTRY-US, V46, P12482, DOI 10.1021/bi701137a; Endo T, 2007, BLOOD, V109, P703, DOI 10.1182/blood-2006-06-027755; EVANS SE, 2009, AM J RESP CELL  0327; Fusco AJ, 2008, J BIOL CHEM, V283, P12324, DOI 10.1074/jbc.M707898200; Fusco AJ, 2009, EMBO REP, V10, P152, DOI 10.1038/embor.2008.227; Galili U, 2005, IMMUNOL CELL BIOL, V83, P674, DOI 10.1111/j.1440-1711.2005.01366.x; Hu YL, 1999, SCIENCE, V284, P316, DOI 10.1126/science.284.5412.316; Klemm S, 2007, P NATL ACAD SCI USA, V104, P134, DOI 10.1073/pnas.0608388103; Li ZW, 1999, J EXP MED, V189, P1839, DOI 10.1084/jem.189.11.1839; Loverre A, 2004, J AM SOC NEPHROL, V15, P2675, DOI 10.1097/01.ASN.0000139932.00971.E4; Martin D, 2009, J BIOL CHEM, V284, P6038, DOI 10.1074/jbc.C800207200; McAllister-Lucas LM, 2007, P NATL ACAD SCI USA, V104, P139, DOI 10.1073/pnas.0601947103; Moyer MP, 1996, IN VITRO CELL DEV-AN, V32, P315; Myers AC, 2002, BIOCHEM BIOPH RES CO, V291, P111, DOI 10.1006/bbrc.2002.6419; Savinova OV, 2009, MOL CELL, V34, P591, DOI 10.1016/j.molcel.2009.04.033; Shiha VFS, 2009, P NATL ACAD SCI USA, V106, P9619, DOI 10.1073/pnas.0812367106; Smith C, 2001, J IMMUNOL, V167, P5895, DOI 10.4049/jimmunol.167.10.5895; ter Braak M, 2009, BBA-MOL CELL BIOL L, V1791, P357, DOI 10.1016/j.bbalip.2009.01.019; Wang DH, 2007, P NATL ACAD SCI USA, V104, P145, DOI 10.1073/pnas.0601894104; Wharry CE, 2009, CANCER BIOL THER, V8, P1567, DOI 10.4161/cbt.8.16.8961; Willis TG, 1999, CELL, V96, P35, DOI 10.1016/S0092-8674(00)80957-5; Wu CJ, 2008, P NATL ACAD SCI USA, V105, P3023, DOI 10.1073/pnas.0712313105; Yilmaz ZB, 2003, EMBO J, V22, P121, DOI 10.1093/emboj/cdg004; Zhang QG, 1999, NAT GENET, V22, P63, DOI 10.1038/8767; Zhou HL, 2004, NATURE, V427, P167, DOI 10.1038/nature02273	38	31	32	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 1	2010	285	1					522	530		10.1074/jbc.M109.050815	http://dx.doi.org/10.1074/jbc.M109.050815			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	536UT	19897484	Green Published, hybrid			2022-12-25	WOS:000273070100054
J	Lee, DY; Li, YSJ; Chang, SF; Zhou, J; Ho, HM; Chiu, JJ; Chien, S				Lee, Ding-Yu; Li, Yi-Shuan J.; Chang, Shun-Fu; Zhou, Jing; Ho, Hui-Min; Chiu, Jeng-Jiann; Chien, Shu			Oscillatory Flow-induced Proliferation of Osteoblast-like Cells Is Mediated by alpha(v)beta(3) and beta(1) Integrins through Synergistic Interactions of Focal Adhesion Kinase and Shc with Phosphatidylinositol 3-Kinase and the Akt/mTOR/p70S6K Pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FLUID SHEAR-STRESS; LOADING IN-VIVO; BONE-FORMATION; INDUCED MECHANOTRANSDUCTION; ALKALINE-PHOSPHATASE; EXTRACELLULAR-MATRIX; P85-ALPHA SUBUNIT; TYROSINE KINASES; PROTEIN-KINASE; NITRIC-OXIDE	Interstitial flow in and around bone tissue is oscillatory in nature and affects the mechanical microenvironment for bone cell growth and formation. We investigated the role of oscillatory shear stress (OSS) in modulating the proliferation of human osteoblast-like MG63 cells and its underlying mechanisms. Application of OSS (0.5 +/- 4 dynes/cm(2)) to MG63 cells induced sustained activation of phosphatidylinositol 3-kinase (PI3K)/Akt/mTOR/p70S6K (p70S6 kinase) signaling cascades and hence cell proliferation, which was accompanied by increased expression of cyclins A and D1, cyclin-dependent protein kinases-2, -4, and -6, and bone formation-related genes (c-fos, Egr-1, and Cox-2) and decreased expression of p21(CIP1) and p27(KIP1). OSS-induced activation of PI3K/Akt/mTOR/p70S6K and cell proliferation were inhibited by specific antibodies or small interference RNAs of alpha(v)beta(3) and beta(1) integrins and by dominant-negative mutants of Shc (Shc-SH2) and focal adhesion kinase (FAK) (FAK(F397Y)). Co-immunoprecipitation assay showed that OSS induces sustained increases in association of Shc and FAK with alpha(v)beta(3) and beta(1) integrins and PI3K subunit p85, which were abolished by transfecting the cells with FAK(F397Y) or Shc-SH2. OSS also induced sustained activation of ERK, which was inhibited by the specific PI3K inhibitor LY294002 and was required for OSS-induced activation of mTOR/p70S6K and proliferation in MG63 cells. Our findings provide insights into the mechanisms by which OSS induces osteoblast-like cell proliferation through activation of alpha(v)beta(3) and beta(1) integrins and synergistic interactions of FAK and Shc with PI3K, leading to the modulation of downstream ERK and Akt/mTOR/p70S6K pathways.	[Lee, Ding-Yu; Chang, Shun-Fu; Ho, Hui-Min; Chiu, Jeng-Jiann] Natl Hlth Res Inst, Div Med Engn Res, Miaoli 350, Taiwan; [Lee, Ding-Yu; Li, Yi-Shuan J.; Zhou, Jing; Chien, Shu] Univ Calif San Diego, Dept Bioengn, La Jolla, CA 91093 USA; [Lee, Ding-Yu; Li, Yi-Shuan J.; Zhou, Jing; Chien, Shu] Univ Calif San Diego, Dept Med, La Jolla, CA 91093 USA; [Lee, Ding-Yu; Li, Yi-Shuan J.; Zhou, Jing; Chien, Shu] Univ Calif San Diego, Inst Engn Med, La Jolla, CA 91093 USA; [Lee, Ding-Yu; Chiu, Jeng-Jiann] Natl Def Med Ctr, Inst Life Sci, Taipei 114, Taiwan	National Health Research Institutes - Taiwan; University of California System; University of California San Diego; University of California System; University of California San Diego; University of California System; University of California San Diego; National Defense Medical Center	Chiu, JJ (corresponding author), Natl Hlth Res Inst, Div Med Engn Res, Miaoli 350, Taiwan.	jjchiu@nhri.org.tw; shuchien@ucsd.edu	Chiu, Jeng-Jiann/E-3980-2010	Zhou, Jing/0000-0002-2211-4901	National Institutes of Health [HL080518, HL085159]; National Health Research Institutes (Taiwan) [ME-097-PP-06]; National Science Council (Taiwan) [97-3112-B-400-006, 96-2628B- 400-002-MY3]; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL085159, R01HL080518] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); National Health Research Institutes (Taiwan)(National Health Research Institutes - Taiwan); National Science Council (Taiwan)(Ministry of Science and Technology, Taiwan); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))	This work was supported, in whole or in part, by National Institutes of Health Grants HL080518 and HL085159 (to S. C.). This work was also supported by National Health Research Institutes (Taiwan) Grant ME-097-PP-06 and National Science Council (Taiwan) Grants 97-3112-B-400-006 and 96-2628B- 400-002-MY3 (to J.-J. C.).	Akagi T, 2002, MOL CELL BIOL, V22, P7015, DOI 10.1128/MCB.22.20.7015-7023.2002; Bakker AD, 2001, J BIOMECH, V34, P671, DOI 10.1016/S0021-9290(00)00231-1; Chang SF, 2008, P NATL ACAD SCI USA, V105, P3927, DOI 10.1073/pnas.0712353105; Chattopadhyay N, 2004, ENDOCRINOLOGY, V145, P3451, DOI 10.1210/en.2003-1127; Chen KD, 1999, J BIOL CHEM, V274, P18393, DOI 10.1074/jbc.274.26.18393; Chow JWM, 1998, J BONE MINER RES, V13, P1760, DOI 10.1359/jbmr.1998.13.11.1760; CLOVER J, 1994, BONE, V15, P585, DOI 10.1016/8756-3282(94)90305-0; Forwood MR, 1996, J BONE MINER RES, V11, P1688; Forwood MR, 1996, AM J PHYSIOL-ENDOC M, V270, pE419, DOI 10.1152/ajpendo.1996.270.3.E419; Gayer CP, 2009, J BIOL CHEM, V284, P2001, DOI 10.1074/jbc.M804576200; Giancotti FG, 1999, SCIENCE, V285, P1028, DOI 10.1126/science.285.5430.1028; Glantschnig H, 1996, ENDOCRINOLOGY, V137, P4536, DOI 10.1210/en.137.11.4536; Globus RK, 1998, J CELL SCI, V111, P1385; Harris Thurl E, 2003, Sci STKE, V2003, pre15; Hellyer NJ, 1998, BIOCHEM J, V333, P757, DOI 10.1042/bj3330757; HILLAM RA, 1995, J BONE MINER RES, V10, P683; Hillsley MV, 1997, CALCIFIED TISSUE INT, V60, P48, DOI 10.1007/s002239900185; HUNTER T, 1994, CELL, V79, P573, DOI 10.1016/0092-8674(94)90543-6; Jalali S, 2001, P NATL ACAD SCI USA, V98, P1042, DOI 10.1073/pnas.031562998; Jiang GL, 2002, AM J PHYSIOL-ENDOC M, V283, pE383, DOI 10.1152/ajpendo.00547.2001; Kapur S, 2004, BONE, V35, P525, DOI 10.1016/j.bone.2004.04.007; Kapur S, 2003, BONE, V32, P241, DOI 10.1016/S8756-3282(02)00979-1; KleinNulend J, 1995, BIOCHEM BIOPH RES CO, V217, P640, DOI 10.1006/bbrc.1995.2822; Kousteni S, 2003, J CLIN INVEST, V111, P1651, DOI 10.1172/JCI200317261; Kozawa O, 2001, J CELL BIOCHEM, V81, P430, DOI 10.1002/1097-4644(20010601)81:3<430::AID-JCB1056>3.0.CO;2-G; Lee DY, 2008, J BONE MINER RES, V23, P1140, DOI 10.1359/JBMR.080302; Li S, 1997, J BIOL CHEM, V272, P30455, DOI 10.1074/jbc.272.48.30455; McAllister TN, 1999, J BONE MINER RES, V14, P930, DOI 10.1359/jbmr.1999.14.6.930; MCGLADE CJ, 1992, MOL CELL BIOL, V12, P991, DOI 10.1128/MCB.12.3.991; MCMAHON AP, 1990, DEVELOPMENT, V108, P281; Miltenburger H G, 1987, Dev Biol Stand, V66, P91; MIYAMOTO S, 1995, SCIENCE, V267, P883, DOI 10.1126/science.7846531; Morinobu M, 2003, J BONE MINER RES, V18, P1706, DOI 10.1359/jbmr.2003.18.9.1706; Ogata T, 1997, J CELL PHYSIOL, V170, P27, DOI 10.1002/(SICI)1097-4652(199701)170:1<27::AID-JCP4>3.0.CO;2-N; Pavalko FM, 1998, AM J PHYSIOL-CELL PH, V275, pC1591; Plotkin LI, 2005, AM J PHYSIOL-CELL PH, V289, pC633, DOI 10.1152/ajpcell.00278.2004; Ren SY, 2005, MOL CELL BIOL, V25, P8001, DOI 10.1128/MCB.25.18.8001-8008.2005; Rubin J, 2006, GENE, V367, P1, DOI 10.1016/j.gene.2005.10.028; Scarlett A, 2008, J ENDOCRINOL, V196, P509, DOI 10.1677/JOE-07-0344; Schlaepfer DD, 1999, PROG BIOPHYS MOL BIO, V71, P435, DOI 10.1016/S0079-6107(98)00052-2; Schlaepfer DD, 1998, TRENDS CELL BIOL, V8, P151, DOI 10.1016/S0962-8924(97)01172-0; SHERR CJ, 1995, GENE DEV, V9, P1149, DOI 10.1101/gad.9.10.1149; SHERR CJ, 1993, CELL, V73, P1059, DOI 10.1016/0092-8674(93)90636-5; Shoba LNN, 2003, J CELL BIOCHEM, V88, P1247, DOI 10.1002/jcb.10474; Shyy JY, 2002, CIRC RES, V91, P769, DOI 10.1161/01.RES.0000038487.19924.18; Sikavitsas VI, 2001, BIOMATERIALS, V22, P2581, DOI 10.1016/S0142-9612(01)00002-3; Singha UK, 2008, J CELL BIOCHEM, V103, P434, DOI 10.1002/jcb.21411; Thomas G, 1997, CURR OPIN CELL BIOL, V9, P782, DOI 10.1016/S0955-0674(97)80078-6; TOYOSHIMA H, 1994, CELL, V78, P67, DOI 10.1016/0092-8674(94)90573-8; Turner C H, 1998, J Orthop Sci, V3, P346, DOI 10.1007/s007760050064; TURNER CH, 1996, ANN BIOMED ENG, V24, pS74; Wang YL, 2007, P NATL ACAD SCI USA, V104, P15941, DOI 10.1073/pnas.0707246104; Wary KK, 1996, CELL, V87, P733, DOI 10.1016/S0092-8674(00)81392-6; WEINBAUM S, 1994, J BIOMECH, V27, P339, DOI 10.1016/0021-9290(94)90010-8; Wu CC, 2006, J CELL BIOCHEM, V98, P632, DOI 10.1002/jcb.20697; Wymann MP, 1998, BBA-MOL CELL BIOL L, V1436, P127, DOI 10.1016/S0005-2760(98)00139-8; Young SRL, 2009, J BONE MINER RES, V24, P411, DOI 10.1359/JBMR.081102	57	71	74	0	22	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 1	2010	285	1					30	42		10.1074/jbc.M109.010512	http://dx.doi.org/10.1074/jbc.M109.010512			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	536UT	19889638	hybrid, Green Published			2022-12-25	WOS:000273070100005
J	Tyryshkin, A; Gorgun, FM; Fattah, EA; Mazumdar, T; Pandit, L; Zeng, SY; Eissa, NT				Tyryshkin, Alexey; Gorgun, F. Murat; Fattah, Elmoataz Abdel; Mazumdar, Tuhina; Pandit, Lavannya; Zeng, Shenyan; Eissa, N. Tony			Src Kinase-mediated Phosphorylation Stabilizes Inducible Nitric-oxide Synthase in Normal Cells and Cancer Cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POSTTRANSLATIONAL REGULATION; STRUCTURAL BASIS; LUNG-CANCER; NO; DEGRADATION; GROWTH; INOS	Src kinases are key regulators of cellular proliferation, survival, motility, and invasiveness. They play important roles in the regulation of inflammation and cancer. Overexpression or hyperactivity of c-Src has been implicated in the development of various types of cancer, including lung cancer. Src inhibition is currently being investigated as a potential therapy for non-small cell lung cancer in Phase I and II clinical trials. The mechanisms of Src implication in cancer and inflammation are linked to the ability of activated Src to phosphorylate multiple downstream targets that mediate its cellular effector functions. In this study, we reveal that inducible nitric-oxide synthase (iNOS), an enzyme also implicated in cancer and inflammation, is a downstream mediator of activated Src. We elucidate the molecular mechanisms of the association between Src and iNOS in models of inflammation induced by lipopolysaccharide and/or cytokines and in cancer cells and tissues. We identify human iNOS residue Tyr(1055) as a target for Src-mediated phosphorylation. These results are shown in normal cells and cancer cells as well as in vivo in mice. Importantly, such posttranslational modification serves to stabilize iNOS half-life. The data also demonstrate interactions and co-localization of iNOS and activated Src under inflammatory conditions and in cancer cells. This study demonstrates that phosphorylation of iNOS by Src plays an important role in the regulation of iNOS and nitric oxide production and hence could account for some Src-related roles in inflammation and cancer.	[Tyryshkin, Alexey; Gorgun, F. Murat; Fattah, Elmoataz Abdel; Mazumdar, Tuhina; Pandit, Lavannya; Zeng, Shenyan; Eissa, N. Tony] Baylor Coll Med, Dept Med, Houston, TX 77030 USA	Baylor College of Medicine	Eissa, NT (corresponding author), Baylor Coll Med, Dept Med, 1 Baylor Plaza,BCM 285 Suite 535E, Houston, TX 77030 USA.	teissa@bcm.edu			NHLBI; NIAID/National Institutes of Health; American Heart Association	NHLBI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAID/National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); American Heart Association(American Heart Association)	This work was supported by NHLBI and NIAID/National Institutes of Health and the American Heart Association.	Adler KB, 2001, AM J RESP CELL MOL, V25, P397, DOI 10.1165/ajrcmb.25.4.f214; Chen GG, 2008, CANCER, V112, P372, DOI 10.1002/cncr.23166; Fulton D, 2005, J BIOL CHEM, V280, P35943, DOI 10.1074/jbc.M504606200; Garcin ED, 2004, J BIOL CHEM, V279, P37918, DOI 10.1074/jbc.M406204200; GHOSH DK, 1995, BIOCHEMISTRY-US, V34, P801, DOI 10.1021/bi00003a013; Giaccone G, 2008, ANN ONCOL, V19, P1219, DOI 10.1093/annonc/mdn048; Grimm EA, 2008, NITRIC OXIDE-BIOL CH, V19, P133, DOI 10.1016/j.niox.2008.04.009; Guo FH, 2000, J IMMUNOL, V164, P5970, DOI 10.4049/jimmunol.164.11.5970; Hanke JH, 1996, J BIOL CHEM, V271, P695, DOI 10.1074/jbc.271.2.695; Hausel P, 2006, ONCOGENE, V25, P198, DOI 10.1038/sj.onc.1209030; Huyer G, 1997, J BIOL CHEM, V272, P843, DOI 10.1074/jbc.272.2.843; IGNARRO LJ, 1987, P NATL ACAD SCI USA, V84, P9265, DOI 10.1073/pnas.84.24.9265; Ishizawar R, 2004, CANCER CELL, V6, P209, DOI 10.1016/j.ccr.2004.09.001; Johnson LN, 1996, CELL, V85, P149, DOI 10.1016/S0092-8674(00)81092-2; Kolodziejska KE, 2005, P NATL ACAD SCI USA, V102, P4854, DOI 10.1073/pnas.0500485102; Kolodziejski PJ, 2004, P NATL ACAD SCI USA, V101, P18141, DOI 10.1073/pnas.0406711102; Kolodziejski PJ, 2002, P NATL ACAD SCI USA, V99, P12315, DOI 10.1073/pnas.192345199; Lala PK, 2001, LANCET ONCOL, V2, P149, DOI 10.1016/S1470-2045(00)00256-4; Musial A, 2001, J BIOL CHEM, V276, P24268, DOI 10.1074/jbc.M100725200; Nathan C, 1997, J CLIN INVEST, V100, P2417, DOI 10.1172/JCI119782; Page TH, 2009, CURR MOL MED, V9, P69, DOI 10.2174/156652409787314507; Pan JM, 1996, BIOCHEM J, V314, P889, DOI 10.1042/bj3140889; Pandit L, 2009, P NATL ACAD SCI USA, V106, P1211, DOI 10.1073/pnas.0810968106; Sha YB, 2009, MOL CELL BIOL, V29, P116, DOI 10.1128/MCB.00829-08; Stuehr DJ, 1999, BBA-BIOENERGETICS, V1411, P217, DOI 10.1016/S0005-2728(99)00016-X; XIE QW, 1992, SCIENCE, V256, P228; Zhang J, 2007, AM J PATHOL, V170, P366, DOI 10.2353/ajpath.2007.060706	27	28	29	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 1	2010	285	1					784	792		10.1074/jbc.M109.055038	http://dx.doi.org/10.1074/jbc.M109.055038			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	536UT	19875457	hybrid, Green Published			2022-12-25	WOS:000273070100079
J	Band, AM; Bjorklund, M; Laiho, M				Band, Arja M.; Bjorklund, Mia; Laiho, Marikki			The Phosphatidylinositol 3-Kinase/Akt Pathway Regulates Transforming Growth Factor-beta Signaling by Destabilizing Ski and Inducing Smad7	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-CYCLE PROGRESSION; KINASE B-GAMMA; TGF-BETA; C-SKI; MEDIATED PHOSPHORYLATION; CYTOPLASMIC LOCALIZATION; DEPENDENT REGULATION; TRANSCRIPTION FACTOR; NEGATIVE REGULATION; INDUCED APOPTOSIS	Ski is an oncoprotein that negatively regulates transforming growth factor (TGF)-beta signaling. It acts as a transcriptional corepressor by binding to TGF-beta signaling molecules, Smads. Efficient TGF-beta signaling is facilitated by rapid proteasome-mediated degradation of Ski by TGF-beta. Here we report that Ski is phosphorylated by Akt/PKB kinase. Akt phosphorylates Ski on a highly conserved Akt motif at threonine 458 both in vitro and in vivo. The phosphorylation of Ski at threonine 458 is induced by Akt pathway activators including insulin, insulin-like growth factor-1, and hepatocyte growth factor. The phosphorylation of Ski causes its destabilization and reduces Ski-mediated inhibition of expression of another negative regulator of TGF-beta, Smad7. Induction of Smad7 levels leads to inactivation of TGF-beta receptors and TGF-beta signaling cascade, as indicated by reduced induction of TGF-beta target p15. Therefore, Akt modulates TGF-beta signaling by temporarily adjusting the levels of two TGF-beta pathway negative regulators, Ski and Smad7. These novel findings demonstrate that Akt pathway activation directly impacts TGF-beta pathway.	[Laiho, Marikki] Johns Hopkins Univ, Sch Med, Dept Radiat Oncol & Mol Radiat Sci, Sidney Kimmel Comprehens Canc Ctr, Baltimore, MD 21231 USA; [Band, Arja M.; Bjorklund, Mia; Laiho, Marikki] Univ Helsinki, Haartman Inst, FIN-00014 Helsinki, Finland; [Band, Arja M.; Bjorklund, Mia; Laiho, Marikki] Univ Helsinki, Biomedicum Helsinki, Mol Canc Biol Program, FIN-00014 Helsinki, Finland	Johns Hopkins University; Johns Hopkins Medicine; University of Helsinki; University of Helsinki	Laiho, M (corresponding author), Johns Hopkins Univ, Sch Med, Dept Radiat Oncol & Mol Radiat Sci, Sidney Kimmel Comprehens Canc Ctr, 1550 Orleans St,Rm 444, Baltimore, MD 21231 USA.	mlaiho1@jhmi.edu			Academy of Finland Center of Excellence Program [213485]	Academy of Finland Center of Excellence Program(Academy of Finland)	This work was supported by Academy of Finland Center of Excellence Program Grant 213485.	Bakin AV, 2000, J BIOL CHEM, V275, P36803, DOI 10.1074/jbc.M005912200; Band Arja, 2008, V1, P243, DOI 10.1007/978-1-59745-292-2_15; Berk M, 1997, GENE DEV, V11, P2029, DOI 10.1101/gad.11.16.2029; Biggs WH, 1999, P NATL ACAD SCI USA, V96, P7421, DOI 10.1073/pnas.96.13.7421; Bonni S, 2001, NAT CELL BIOL, V3, P587, DOI 10.1038/35078562; BOYER PL, 1993, ONCOGENE, V8, P457; Brazil DP, 2002, CELL, V111, P293, DOI 10.1016/S0092-8674(02)01083-8; Brodbeck D, 1999, J BIOL CHEM, V274, P9133, DOI 10.1074/jbc.274.14.9133; Brunet A, 1999, CELL, V96, P857, DOI 10.1016/S0092-8674(00)80595-4; Buess M, 2004, NEOPLASIA, V6, P207, DOI 10.1593/neo.03442; Chen RH, 1998, ONCOGENE, V17, P1959, DOI 10.1038/sj.onc.1202111; COLMENARES C, 1991, J VIROL, V65, P4929, DOI 10.1128/JVI.65.9.4929-4935.1991; COLMENARES C, 1989, CELL, V59, P293, DOI 10.1016/0092-8674(89)90291-2; Conery AR, 2004, NAT CELL BIOL, V6, P366, DOI 10.1038/ncb1117; Danielpour D, 2006, CYTOKINE GROWTH F R, V17, P59, DOI 10.1016/j.cytogfr.2005.09.007; Deheuninck J, 2009, CELL RES, V19, P47, DOI 10.1038/cr.2008.324; Denissova NG, 2004, J BIOL CHEM, V279, P28143, DOI 10.1074/jbc.M404961200; Ebisawa T, 2001, J BIOL CHEM, V276, P12477, DOI 10.1074/jbc.C100008200; Fukuchi M, 2004, INT J CANCER, V108, P818, DOI 10.1002/ijc.11651; Gao DM, 2009, NAT CELL BIOL, V11, P397, DOI 10.1038/ncb1847; Hayashi H, 1997, CELL, V89, P1165, DOI 10.1016/S0092-8674(00)80303-7; Itoh S, 1998, J BIOL CHEM, V273, P29195, DOI 10.1074/jbc.273.44.29195; Itoh S, 2007, CURR OPIN CELL BIOL, V19, P176, DOI 10.1016/j.ceb.2007.02.015; Jacob C, 2008, J CELL BIOL, V182, P519, DOI 10.1083/jcb.200710161; Jang SW, 2009, J BIOL CHEM, V284, P24512, DOI 10.1074/jbc.M109.026237; Kavsak P, 2000, MOL CELL, V6, P1365, DOI 10.1016/S1097-2765(00)00134-9; Kokura K, 2003, J BIOL CHEM, V278, P20133, DOI 10.1074/jbc.M210855200; Le Scolan E, 2008, CANCER RES, V68, P3277, DOI 10.1158/0008-5472.CAN-07-6793; Lee SB, 2008, P NATL ACAD SCI USA, V105, P16584, DOI 10.1073/pnas.0807668105; Lin HK, 2009, NAT CELL BIOL, V11, P420, DOI 10.1038/ncb1849; Lonn P, 2009, CELL RES, V19, P21, DOI 10.1038/cr.2008.308; Luo KX, 1999, GENE DEV, V13, P2196, DOI 10.1101/gad.13.17.2196; Maddika S, 2008, J CELL SCI, V121, P979, DOI 10.1242/jcs.009530; Manning BD, 2002, MOL CELL, V10, P151, DOI 10.1016/S1097-2765(02)00568-3; Marcelain K, 2005, ONCOGENE, V24, P4321, DOI 10.1038/sj.onc.1208631; Massague J, 1998, ANNU REV BIOCHEM, V67, P753, DOI 10.1146/annurev.biochem.67.1.753; Massague J, 2008, CELL, V134, P215, DOI 10.1016/j.cell.2008.07.001; Masure S, 1999, EUR J BIOCHEM, V265, P353, DOI 10.1046/j.1432-1327.1999.00774.x; Nagano Y, 2007, J BIOL CHEM, V282, P20492, DOI 10.1074/jbc.M701294200; Nagata M, 2006, GENES CELLS, V11, P1267, DOI 10.1111/j.1365-2443.2006.01018.x; Nakao A, 1997, NATURE, V389, P631, DOI 10.1038/39369; Nakatani K, 1999, BIOCHEM BIOPH RES CO, V257, P906, DOI 10.1006/bbrc.1999.0559; Nomura T, 2004, J BIOL CHEM, V279, P16715, DOI 10.1074/jbc.M313069200; Prunier C, 2003, J BIOL CHEM, V278, P26249, DOI 10.1074/jbc.M304459200; Reed JA, 2001, CANCER RES, V61, P8074; Remy I, 2004, NAT CELL BIOL, V6, P358, DOI 10.1038/ncb1113; Ritter M, 2006, LEUKEMIA, V20, P437, DOI 10.1038/sj.leu.2404093; Seong HA, 2007, J BIOL CHEM, V282, P12272, DOI 10.1074/jbc.M609279200; Shi WB, 2004, J CELL BIOL, V164, P291, DOI 10.1083/jcb.200307151; Shin I, 2002, NAT MED, V8, P1145, DOI 10.1038/nm759; Shin I, 2001, MOL BIOL CELL, V12, P3328, DOI 10.1091/mbc.12.11.3328; Shinagawa T, 2001, ONCOGENE, V20, P8100, DOI 10.1038/sj.onc.1204987; Song KY, 2006, EMBO J, V25, P58, DOI 10.1038/sj.emboj.7600917; Stroschein SL, 2001, GENE DEV, V15, P2822; Stroschein SL, 1999, SCIENCE, V286, P771, DOI 10.1126/science.286.5440.771; Sun Y, 1999, MOL CELL, V4, P499, DOI 10.1016/S1097-2765(00)80201-4; SUTRAVE P, 1990, GENE DEV, V4, P1462, DOI 10.1101/gad.4.9.1462; Suzuki H, 2004, ONCOGENE, V23, P5068, DOI 10.1038/sj.onc.1207690; Tabata T, 2009, GENES CELLS, V14, P17, DOI 10.1111/j.1365-2443.2008.01246.x; Tang XL, 2007, NAT CELL BIOL, V9, P1199, DOI 10.1038/ncb1641; Tokitou F, 1999, J BIOL CHEM, V274, P4485, DOI 10.1074/jbc.274.8.4485; VLAHOS CJ, 1994, J BIOL CHEM, V269, P5241; Yaffe MB, 2001, NAT BIOTECHNOL, V19, P348, DOI 10.1038/86737; Zhang SP, 2007, MOL CELL BIOL, V27, P4488, DOI 10.1128/MCB.01636-06; Zhang YE, 2009, CELL RES, V19, P128, DOI 10.1038/cr.2008.328	65	23	23	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 18	2009	284	51					35441	35449		10.1074/jbc.M109.029488	http://dx.doi.org/10.1074/jbc.M109.029488			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	531EI	19875456	Green Published, hybrid			2022-12-25	WOS:000272645600020
J	Biasini, E; Tapella, L; Mantovani, S; Stravalaci, M; Gobbi, M; Harris, DA; Chiesa, R				Biasini, Emiliano; Tapella, Laura; Mantovani, Susanna; Stravalaci, Matteo; Gobbi, Marco; Harris, David A.; Chiesa, Roberto			Immunopurification of Pathological Prion Protein Aggregates	PLOS ONE			English	Article							AMYLOID FIBRILS; PRP; DISEASE; IDENTIFICATION; ACCUMULATION; PURIFICATION; EXPRESSION; FRAGMENT; BRAIN; CELLS	Prion diseases are fatal neurodegenerative disorders that can arise sporadically, be genetically inherited or acquired through infection. The key event in these diseases is misfolding of the cellular prion protein (PrPC) into a pathogenic isoform that is rich in beta-sheet structure. This conformational change may result in the formation of PrPSc, the prion isoform of PrP, which propagates itself by imprinting its aberrant conformation onto PrPC molecules. A great deal of effort has been devoted to developing protocols for purifying PrPSc for structural studies, and testing its biological properties. Most procedures rely on protease digestion, allowing efficient purification of PrP27-30, the protease-resistant core of PrPSc. However, protease treatment cannot be used to isolate abnormal forms of PrP lacking conventional protease resistance, such as those found in several genetic and atypical sporadic cases. Principal Findings: We developed a method for purifying pathological PrP molecules based on sequential centrifugation and immunoprecipitation with a monoclonal antibody selective for aggregated PrP. With this procedure we purified full-length PrPSc and mutant PrP aggregates at electrophoretic homogeneity. PrPSc purified from prion-infected mice was able to seed misfolding of PrPC in a protein misfolding cyclic amplification reaction, and mutant PrP aggregates from transgenic mice were toxic to cultured neurons. Significance: The immunopurification protocol described here isolates biologically active forms of aggregated PrP. These preparations may be useful for investigating the structural and chemico-physical properties of infectious and neurotoxic PrP aggregates.			Biasini, E (corresponding author), Dulbecco Telethon Inst, Milan, Italy.	roberto.chiesa@marionegri.it	Chiesa, Roberto/G-1561-2017; Biasini, Emiliano/A-3147-2011; Stravalaci, Matteo/AAB-8963-2019; Gobbi, Marco/J-2638-2016	Chiesa, Roberto/0000-0002-3842-3733; Biasini, Emiliano/0000-0002-3927-6341; Stravalaci, Matteo/0000-0002-5636-4204; Gobbi, Marco/0000-0003-1014-6225; Tapella, Laura/0000-0002-8159-1628; Harris, David/0000-0002-6985-5790; Mantovani, Susanna/0000-0001-7046-6541	NINDS NIH HHS [NS052526, NS040975, R01 NS040975, R01 NS052526] Funding Source: Medline; Telethon [TCR08005] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS052526, R01NS040975] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); Telethon(Fondazione Telethon); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Biasini E, 2008, J NEUROCHEM, V105, P2190, DOI 10.1111/j.1471-4159.2008.05306.x; Biasini E, 2008, J NEUROCHEM, V104, P1293, DOI 10.1111/j.1471-4159.2007.05082.x; Biasini E, 2006, PROTEOMICS, V6, P2823, DOI 10.1002/pmic.200500620; BOLTON DC, 1987, ARCH BIOCHEM BIOPHYS, V258, P579, DOI 10.1016/0003-9861(87)90380-8; Bonetto V, 2002, J BIOL CHEM, V277, P31327, DOI 10.1074/jbc.M203275200; Bravman T, 2006, ANAL BIOCHEM, V358, P281, DOI 10.1016/j.ab.2006.08.005; BUELER H, 1992, NATURE, V356, P577, DOI 10.1038/356577a0; Castilla J, 2005, CELL, V121, P195, DOI 10.1016/j.cell.2005.02.011; CAUGHEY BW, 1991, BIOCHEMISTRY-US, V30, P7672, DOI 10.1021/bi00245a003; CAUGHEY BW, 1991, BIOCHEMISTRY-US, V30, P10600, DOI 10.1021/bi00107a032; CHEN SG, 1995, J BIOL CHEM, V270, P19173, DOI 10.1074/jbc.270.32.19173; Chiesa R, 2003, J VIROL, V77, P7611, DOI 10.1128/JVI.77.13.7611-7622.2003; Chiesa R, 2000, P NATL ACAD SCI USA, V97, P5574, DOI 10.1073/pnas.97.10.5574; Chiesa R, 2001, NEUROBIOL DIS, V8, P743, DOI 10.1006/nbdi.2001.0433; Chiesa R, 1998, NEURON, V21, P1339, DOI 10.1016/S0896-6273(00)80653-4; Chiesa R, 2004, TECHNIQUES PRION RES, P176; Collinge J, 2001, ANNU REV NEUROSCI, V24, P519, DOI 10.1146/annurev.neuro.24.1.519; Corsaro A, 2006, INT J IMMUNOPATH PH, V19, P339, DOI 10.1177/039463200601900211; Dossena S, 2008, NEURON, V60, P598, DOI 10.1016/j.neuron.2008.09.008; Fioriti L, 2007, J NEUROSCI, V27, P1576, DOI 10.1523/JNEUROSCI.5145-06.2007; FORLONI G, 1993, NATURE, V362, P543, DOI 10.1038/362543a0; GABIZON R, 1988, P NATL ACAD SCI USA, V85, P6617, DOI 10.1073/pnas.85.18.6617; GABIZON R, 1989, P NATL ACAD SCI USA, V86, P1223; Gambetti P, 2008, ANN NEUROL, V63, P697, DOI 10.1002/ana.21420; Giese A, 1998, BRAIN PATHOL, V8, P449; HEAD MW, 2009, NEUROPATHOL APPL NEU; Hegde RS, 1998, SCIENCE, V279, P827, DOI 10.1126/science.279.5352.827; KASCSAK RJ, 1987, J VIROL, V61, P3688, DOI 10.1128/JVI.61.12.3688-3693.1987; KOCISKO DA, 1994, NATURE, V370, P471, DOI 10.1038/370471a0; Korth C, 1997, NATURE, V390, P74, DOI 10.1038/36337; LEHMANN S, 1995, J BIOL CHEM, V270, P24589, DOI 10.1074/jbc.270.41.24589; MULLER WEG, 1993, EUR J PHARM-MOLEC PH, V246, P261, DOI 10.1016/0922-4106(93)90040-G; Nazor KE, 2005, EMBO J, V24, P2472, DOI 10.1038/sj.emboj.7600717; Novitskaya V, 2006, J BIOL CHEM, V281, P13828, DOI 10.1074/jbc.M511174200; PAN KM, 1993, P NATL ACAD SCI USA, V90, P10962, DOI 10.1073/pnas.90.23.10962; PAPPIN DJC, 1993, CURR BIOL, V3, P327, DOI 10.1016/0960-9822(93)90195-T; Piccardo P, 2007, P NATL ACAD SCI USA, V104, P4712, DOI 10.1073/pnas.0609241104; Post K, 2000, ARCH VIROL, P265; PRIOLA SA, 1995, J BIOL CHEM, V270, P3299, DOI 10.1074/jbc.270.7.3299; PRUSINER SB, 1984, CELL, V38, P127, DOI 10.1016/0092-8674(84)90533-6; Raymond G. J., 2004, TECHNIQUES PRION RES, P16; Riek R, 1996, NATURE, V382, P180, DOI 10.1038/382180a0; Saa P, 2006, J BIOL CHEM, V281, P35245, DOI 10.1074/jbc.M603964200; Saborio GP, 2001, NATURE, V411, P810, DOI 10.1038/35081095; Saunders GC, 2007, RES VET SCI, V83, P157, DOI 10.1016/j.rvsc.2007.01.001; Silveira JR, 2005, NATURE, V437, P257, DOI 10.1038/nature03989; Simoneau S, 2007, PLOS PATHOG, V3, P1175, DOI 10.1371/journal.ppat.0030125; TAGLIAVINI F, 1994, CELL, V79, P695, DOI 10.1016/0092-8674(94)90554-1; Tagliavini F, 2001, J BIOL CHEM, V276, P6009, DOI 10.1074/jbc.M007062200; Tateishi J, 1996, NEUROLOGY, V46, P532, DOI 10.1212/WNL.46.2.532; Zahn R, 1997, FEBS LETT, V417, P400, DOI 10.1016/S0014-5793(97)01330-6; Zanusso G, 1998, P NATL ACAD SCI USA, V95, P8812, DOI 10.1073/pnas.95.15.8812	52	14	17	0	8	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	NOV 12	2009	4	11							e7816	10.1371/journal.pone.0007816	http://dx.doi.org/10.1371/journal.pone.0007816			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	518UW	19915706	gold, Green Published, Green Submitted			2022-12-25	WOS:000271721400013
J	Kong, SG; Fan, WL; Chen, HD; Hsu, ZT; Zhou, NJ; Zheng, B; Lee, HC				Kong, Sing-Guan; Fan, Wen-Lang; Chen, Hong-Da; Hsu, Zi-Ting; Zhou, Nengji; Zheng, Bo; Lee, Hoong-Chien			Inverse Symmetry in Complete Genomes and Whole-Genome Inverse Duplication	PLOS ONE			English	Article							STRAND COMPOSITIONAL ASYMMETRY; GENE DUPLICATION; NUCLEIC-ACIDS; DNA-SEQUENCES; REPLICATION; BACTERIAL; ORIGINS; SEPARATION; EVOLUTION; PATTERNS	The cause of symmetry is usually subtle, and its study often leads to a deeper understanding of the bearer of the symmetry. To gain insight into the dynamics driving the growth and evolution of genomes, we conducted a comprehensive study of textual symmetries in 786 complete chromosomes. We focused on symmetry based on our belief that, in spite of their extreme diversity, genomes must share common dynamical principles and mechanisms that drive their growth and evolution, and that the most robust footprints of such dynamics are symmetry related. We found that while complement and reverse symmetries are essentially absent in genomic sequences, inverse-complement plus reverse-symmetry is prevalent in complex patterns in most chromosomes, a vast majority of which have near maximum global inverse symmetry. We also discovered relations that can quantitatively account for the long observed but unexplained phenomenon of k-mer skews in genomes. Our results suggest segmental and whole-genome inverse duplications are important mechanisms in genome growth and evolution, probably because they are efficient means by which the genome can exploit its double-stranded structure to enrich its code-inventory.			Kong, SG (corresponding author), Natl Cent Univ, Grad Inst Syst Biol & Bioinformat, Chungli 32054, Taiwan.	hclee@phy.ncu.edu.tw		Chen, HongDa/0000-0002-9330-5473; Sing Guan, Kong/0000-0001-8817-781X; Zhou, Nengji/0000-0002-7530-8312				Albrecht-Buehler G, 2007, GENOMICS, V90, P297, DOI 10.1016/j.ygeno.2007.05.010; Albrecht-Buehler G, 2006, P NATL ACAD SCI USA, V103, P17828, DOI 10.1073/pnas.0605553103; Bailey JA, 2002, SCIENCE, V297, P1003, DOI 10.1126/science.1072047; Baisnee PF, 2002, BIOINFORMATICS, V18, P1021, DOI 10.1093/bioinformatics/18.8.1021; Bell SJ, 1999, J THEOR BIOL, V197, P51, DOI 10.1006/jtbi.1998.0857; BIEBRICHER CK, 1992, EMBO J, V11, P5129, DOI 10.1002/j.1460-2075.1992.tb05620.x; Blattner FR, 1997, SCIENCE, V277, P1453, DOI 10.1126/science.277.5331.1453; Chang Chang-Heng, 2005, Journal of Bioinformatics and Computational Biology, V3, P587, DOI 10.1142/S0219720005001181; CHARGAFF E, 1951, FED PROC, V10, P654; Chen HD, 2005, PHYS REV LETT, V94, DOI 10.1103/PhysRevLett.94.178103; Chen TY, 2005, COMPUT PHYS COMMUN, V169, P218, DOI 10.1016/j.cpc.2005.03.050; Christoffels A, 2004, MOL BIOL EVOL, V21, P1146, DOI 10.1093/molbev/msh114; DIXON L, 1988, COMMUN MATH PHYS, V119, P221, DOI 10.1007/BF01217740; ENQUIST M, 1994, NATURE, V372, P169, DOI 10.1038/372169a0; Forsdyke Donald R, 2004, Appl Bioinformatics, V3, P3; Forsdyke DR, 2002, BIOINFORMATICS, V18, P215, DOI 10.1093/bioinformatics/18.1.215; Freeman JM., 1998, SCIENCE, V279, P1827, DOI [10.1126/science.279.5358.1827a, DOI 10.1126/science.279.5358.1827a, DOI 10.1126/SCIENCE.279.5358.1827A]; Gilbert DM, 2001, SCIENCE, V294, P96, DOI 10.1126/science.1061724; GRAMMER K, 1994, J COMP PSYCHOL, V108, P233, DOI 10.1037/0735-7036.108.3.233; Hao BL, 2000, CHAOS SOLITON FRACT, V11, P825, DOI 10.1016/S0960-0779(98)00182-9; Hsieh LC, 2003, PHYS REV LETT, V90, DOI 10.1103/PhysRevLett.90.018101; HSU ZT, 2008, THESIS NATL CENTRAL; Jaillon O, 2004, NATURE, V431, P946, DOI 10.1038/nature03025; Jose MV, 2005, PHYSICA A, V351, P477, DOI 10.1016/j.physa.2004.11.060; Kellis M, 2004, NATURE, V428, P617, DOI 10.1038/nature02424; Kelman LM, 2004, TRENDS MICROBIOL, V12, P399, DOI 10.1016/j.tim.2004.07.001; Lobry JR, 1996, MOL BIOL EVOL, V13, P660, DOI 10.1093/oxfordjournals.molbev.a025626; Lynch M, 2002, SCIENCE, V297, P945, DOI 10.1126/science.1075472; Messer PW, 2005, PHYS REV LETT, V94, DOI 10.1103/PhysRevLett.94.138103; Mrazek J, 1998, P NATL ACAD SCI USA, V95, P3720, DOI 10.1073/pnas.95.7.3720; Muller A, 2003, SCIENCE, V300, P749, DOI 10.1126/science.1084991; NUSSINOV R, 1982, J THEOR BIOL, V95, P783, DOI 10.1016/0022-5193(82)90353-8; OCHMAN H, 2000, P NATL ACAD SCI USA, V405, P209; Ohno S., 1970, EVOLUTION GENE DUPLI; Petrillo M, 2006, BMC GENOMICS, V7, DOI 10.1186/1471-2164-7-170; Picardeau M, 2000, GENOME RES, V10, P1594, DOI 10.1101/gr.124000; Qi D, 2001, BIOINFORMATICS, V17, P557, DOI 10.1093/bioinformatics/17.6.557; Rhodes G, 2006, ANNU REV PSYCHOL, V57, P199, DOI 10.1146/annurev.psych.57.102904.190208; Rocha EPC, 2006, GENOME RES, V16, P1537, DOI 10.1101/gr.5525106; Rocha EPC, 2004, MICROBIOL-SGM, V150, P1609, DOI 10.1099/mic.0.26974-0; Rocha EPC, 2002, TRENDS MICROBIOL, V10, P393, DOI 10.1016/S0966-842X(02)02420-4; RUDNER R, 1969, P NATL ACAD SCI USA, V63, P152, DOI 10.1073/pnas.63.1.152; RUDNER R, 1968, P NATL ACAD SCI USA, V60, P921, DOI 10.1073/pnas.60.3.921; Salzberg SL, 1998, GENE, V217, P57, DOI 10.1016/S0378-1119(98)00374-6; Sanchez J, 2002, BIOCHEM BIOPH RES CO, V299, P126, DOI 10.1016/S0006-291X(02)02583-4; Volz A, 2001, IMMUNOL REV, V181, P39, DOI 10.1034/j.1600-065X.2001.1810103.x; Wapinski I, 2007, NATURE, V449, P54, DOI 10.1038/nature06107; WATSON JD, 1953, NATURE, V171, P737, DOI 10.1038/171737a0; Wolfe KH, 1997, NATURE, V387, P708, DOI 10.1038/42711; ZEE ANTHONY, 1999, FEARFUL SYMMETRY SEA; Zhang JZ, 2003, TRENDS ECOL EVOL, V18, P292, DOI 10.1016/S0169-5347(03)00033-8; Zhang LQ, 2005, MOL BIOL EVOL, V22, P135, DOI 10.1093/molbev/msh262; Zhou FF, 2008, BMC BIOINFORMATICS, V9, DOI 10.1186/1471-2105-9-546; RICE ANNOTATION PROJ; NAT CTR BIOTECHNOLOG; INVERSE SYMMETRY DAT	57	32	32	0	8	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	NOV 9	2009	4	11							e7553	10.1371/journal.pone.0007553	http://dx.doi.org/10.1371/journal.pone.0007553			15	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	517ZM	19898631	Green Published, Green Submitted, gold			2022-12-25	WOS:000271658000001
J	Stark, K; Reinhard, W; Grassl, M; Erdmann, J; Schunkert, H; Illig, T; Hengstenberg, C				Stark, Klaus; Reinhard, Wibke; Grassl, Martina; Erdmann, Jeanette; Schunkert, Heribert; Illig, Thomas; Hengstenberg, Christian			Common Polymorphisms Influencing Serum Uric Acid Levels Contribute to Susceptibility to Gout, but Not to Coronary Artery Disease	PLOS ONE			English	Article							GENOME-WIDE ASSOCIATION; CARDIOVASCULAR-DISEASE; HEART-DISEASE; RISK; MORTALITY; SLC2A9; GENE; LOCUS	Background: Recently, a large meta-analysis including over 28,000 participants identified nine different loci with association to serum uric acid (UA) levels. Since elevated serum UA levels potentially cause gout and are a possible risk factor for coronary artery disease (CAD) and myocardial infarction (MI), we performed two large case-control association analyses with participants from the German MI Family Study. In the first study, we assessed the association of the qualitative trait gout and ten single nucleotide polymorphisms (SNP) markers that showed association to UA serum levels. In the second study, the same genetic polymorphisms were analyzed for association with CAD. Methods and Findings: A total of 683 patients suffering from gout and 1,563 healthy controls from the German MI Family Study were genotyped. Nine SNPs were identified from a recently performed genome-wide meta-analysis on serum UA levels (rs12129861, rs780094, rs734553, rs2231142, rs742132, rs1183201, rs12356193, rs17300741 and rs505802). Additionally, the marker rs6855911 was included which has been associated with gout in our cohort in a previous study. SNPs rs734553 and rs6855911, located in SLC2A9, and SNP rs2231142, known to be a missense polymorphism in ABCG2, were associated with gout (p = 5.6*10(-7), p = 1.1*10(-7), and p = 1.3*10(-3), respectively). Other SNPs in the genes PDZK1, GCKR, LRRC16A, SLC17A1-SLC17A3, SLC16A9, SLC22A11 and SLC22A12 failed the significance level. None of the ten markers were associated with risk to CAD in our study sample of 1,473 CAD cases and 1,241 CAD-free controls. Conclusion: SNP markers in SLC2A9 and ABCG2 genes were found to be strongly associated with the phenotype gout. However, not all SNP markers influencing serum UA levels were also directly associated with the clinical manifestation of gout in our study sample. In addition, none of these SNPs showed association with the risk to CAD in the German MI Family Study.			Stark, K (corresponding author), Univ Klinikum Regensburg, Klin & Poliklin Innere Med 2, Regensburg, Germany.	christian.hengstenberg@klinik.uni-regensburg.de	Stark, Klaus/D-3813-2009; Hengstenberg, Christian/U-5485-2019; 王, 强/F-4212-2011; Stark, Klaus/L-7367-2013; Erdmann, Jeanette/A-4417-2009; Erdmann, Jeanette/P-7513-2014	Stark, Klaus/0000-0002-7832-1942; Stark, Klaus/0000-0002-7832-1942; Erdmann, Jeanette/0000-0002-4486-6231				ABBOTT RD, 1988, J CLIN EPIDEMIOL, V41, P237, DOI 10.1016/0895-4356(88)90127-8; Annemans L, 2008, ANN RHEUM DIS, V67, P960, DOI 10.1136/ard.2007.076232; Anzai N, 2008, J BIOL CHEM, V283, P26834, DOI 10.1074/jbc.C800156200; Baker JF, 2005, AM J MED, V118, P816, DOI 10.1016/j.amjmed.2005.03.043; Burton PR, 2007, NATURE, V447, P661, DOI 10.1038/nature05911; Campion E W, 1987, Am J Med, V82, P421, DOI 10.1016/0002-9343(87)90441-4; Caulfield MJ, 2008, PLOS MED, V5, P1509, DOI 10.1371/journal.pmed.0050197; Choi HK, 2007, CIRCULATION, V116, P894, DOI 10.1161/CIRCULATIONAHA.107.703389; Conen D, 2004, BMC PUBLIC HEALTH, V4, DOI 10.1186/1471-2458-4-9; Culleton BF, 1999, ANN INTERN MED, V131, P7, DOI 10.7326/0003-4819-131-1-199907060-00003; Dehghan A, 2008, LANCET, V372, P1953, DOI 10.1016/S0140-6736(08)61343-4; Devlin B, 1999, BIOMETRICS, V55, P997, DOI 10.1111/j.0006-341X.1999.00997.x; Doring A, 2008, NAT GENET, V40, P430, DOI 10.1038/ng.107; Enomoto A, 2002, NATURE, V417, P447, DOI 10.1038/nature742; Erdmann J, 2009, NAT GENET, V41, P280, DOI 10.1038/ng.307; Fang J, 2000, JAMA-J AM MED ASSOC, V283, P2404, DOI 10.1001/jama.283.18.2404; Faul F, 2007, BEHAV RES METHODS, V39, P175, DOI 10.3758/BF03193146; Feig DI, 2008, NEW ENGL J MED, V359, P1811, DOI 10.1056/NEJMra0800885; Helgadottir A, 2007, SCIENCE, V316, P1491, DOI 10.1126/science.1142842; Kolz M, 2009, PLOS GENET, V5, DOI 10.1371/journal.pgen.1000504; Lee WC, 2003, AM J EPIDEMIOL, V158, P397, DOI 10.1093/aje/kwg150; Li S, 2007, PLOS GENET, V3, P2156, DOI 10.1371/journal.pgen.0030194; Mandell Brian F, 2008, Cleve Clin J Med, V75 Suppl 5, pS5; Matsuo H, 2008, AM J HUM GENET, V83, P744, DOI 10.1016/j.ajhg.2008.11.001; McPherson R, 2007, SCIENCE, V316, P1488, DOI 10.1126/science.1142447; Niskanen LK, 2004, ARCH INTERN MED, V164, P1546, DOI 10.1001/archinte.164.14.1546; Purcell S, 2007, AM J HUM GENET, V81, P559, DOI 10.1086/519795; Samani NJ, 2007, NEW ENGL J MED, V357, P443, DOI 10.1056/NEJMoa072366; Stark K, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0001948; Tregouet DA, 2009, NAT GENET, V41, P283, DOI 10.1038/ng.314; Vitart V, 2008, NAT GENET, V40, P437, DOI 10.1038/ng.106; Xu JF, 2002, HUM GENET, V111, P573, DOI 10.1007/s00439-002-0819-y	32	84	93	0	11	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	NOV 5	2009	4	11							e7729	10.1371/journal.pone.0007729	http://dx.doi.org/10.1371/journal.pone.0007729			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	515HI	19890391	gold, Green Published, Green Submitted			2022-12-25	WOS:000271459700015
J	Johnson, BF; Wilson, LE; Ellis, J; Elliot, AJ; Barclay, WS; Pebody, RG; McMenamin, J; Fleming, DM; Zambon, MC				Johnson, Benjamin F.; Wilson, Louise E.; Ellis, Joanna; Elliot, Alex J.; Barclay, Wendy S.; Pebody, Richard G.; McMenamin, Jim; Fleming, Douglas M.; Zambon, Maria C.			Fatal Cases of Influenza A in Childhood	PLOS ONE			English	Article							VIRUS; HEMAGGLUTININ; CHILDREN	Background: In the northern hemisphere winter of 2003-04 antigenic variant strains (A/Fujian/411/02 -like) of influenza A H3N2 emerged. Circulation of these strains in the UK was accompanied by an unusually high number of laboratory confirmed influenza associated fatalities in children. This study was carried out to better understand risk factors associated with fatal cases of influenza in children. Methodology/Principal Findings: Case histories, autopsy reports and death registration certificates for seventeen fatal cases of laboratory confirmed influenza in children were analyzed. None had a recognized pre-existing risk factor for severe influenza and none had been vaccinated. Three cases had evidence of significant bacterial co-infection. Influenza strains recovered from fatal cases were antigenically similar to those circulating in the community. A comparison of protective antibody titres in age stratified cohort sera taken before and after winter 2003-04 showed that young children had the highest attack rate during this season (21% difference, 95% confidence interval from 0.09 to 0.33, p = 0.0009). Clinical incidences of influenza-like illness (ILI) in young age groups were shown to be highest only in the years when novel antigenic drift variants emerged. Conclusions/Significance: This work presents a rare insight into fatal influenza H3N2 in healthy children. It confirms that circulating seasonal influenza A H3N2 strains can cause severe disease and death in children in the apparent absence of associated bacterial infection or predisposing risk factors. This adds to the body of evidence demonstrating the burden of severe illness due to seasonal influenza A in childhood.			Johnson, BF (corresponding author), Hlth Protect Agcy, Ctr Infect, London, England.	maria.zambon@hpa.org.uk		Elliot, Alex/0000-0002-6414-3065; Johnson, Benjamin/0000-0001-5991-7612; Barclay, Wendy/0000-0002-3948-0895; Pebody, Richard/0000-0002-9069-2885				Bhat N, 2005, NEW ENGL J MED, V353, P2559, DOI 10.1056/NEJMoa051721; *CDC, 2009, N ENGL J MED; *CDC, 2009, TALK POINTS DEATHS C; COOKE MC, 2005, CDR SUPPLEMENT; de Jong J C, 2003, Dev Biol (Basel), V115, P63; Donaldson L, 2008, INFLUENZA IMMUNISATI; Fleming DM, 2008, EPIDEMIOL INFECT, V136, P866, DOI 10.1017/S0950268807009910; Fleming DM, 2007, EPIDEMIOL INFECT, V135, P1099, DOI 10.1017/S0950268807007881; Fleming D M, 2000, Commun Dis Public Health, V3, P32; Hackett S, 2009, LANCET, V374, P605, DOI 10.1016/S0140-6736(09)61511-7; Jin H, 2005, VIROLOGY, V336, P113, DOI 10.1016/j.virol.2005.03.010; Matrosovich M, 2003, J VIROL, V77, P8418, DOI 10.1128/JVI.77.15.8418-8425.2003; Morens DM, 2008, J INFECT DIS, V198, P962, DOI 10.1086/591708; Poehling KA, 2006, NEW ENGL J MED, V355, P31, DOI 10.1056/NEJMoa054869; Taubenberger JK, 2008, ANNU REV PATHOL-MECH, V3, P499, DOI 10.1146/annurev.pathmechdis.3.121806.154316; WILSON IA, 1990, ANNU REV IMMUNOL, V8, P737, DOI 10.1146/annurev.iy.08.040190.003513; ZAMBON M, 1998, TXB INFLUENZA	17	20	20	0	1	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA	1932-6203			PLOS ONE	PLoS One	OCT 30	2009	4	10							e7671	10.1371/journal.pone.0007671	http://dx.doi.org/10.1371/journal.pone.0007671			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	514RW	19876396	Green Published, gold, Green Submitted			2022-12-25	WOS:000271414300016
J	Pini, A; Falciani, C; Mantengoli, E; Bindi, S; Brunetti, J; Iozzi, S; Rossolini, GM; Bracci, L				Pini, Alessandro; Falciani, Chiara; Mantengoli, Elisabetta; Bindi, Stefano; Brunetti, Jlenia; Iozzi, Sara; Rossolini, Gian Maria; Bracci, Luisa			A novel tetrabranched antimicrobial peptide that neutralizes bacterial lipopolysaccharide and prevents septic shock in vivo	FASEB JOURNAL			English	Article						dendrimers; antibacterial; cystic fibrosis; gramnegative bacteria; LPS	BRANCHED PEPTIDES; SYNTHETIC PEPTIDES; POLYMYXIN-B; RESISTANCE; PATHOGENS; BINDING; DESIGN; LETHAL	We describe the nonnatural antimicrobial peptide KKIRVRLSA (M33) and its capacity to neutralize LPS-induced cytokine release, preventing septic shock in animals infected with bacterial species of clinical interest. M33 showed strong resistance to proteolytic degradation when synthesized in tetra-branched form with 4 peptides linked by a lysine core, making it suitable for use in vivo. HPLC and mass spectrometry demonstrated its stability in serum beyond 24 h. M33 was found to be very selective for gram-negative bacteria. Minimal inhibitory concentration (MIC) ranged from 0.3 to 3 mu M for multidrug resistant clinical isolates of several pathogenic species, including Pseudomonas aeruginosa, Klebsiella pneumoniae, and Acinetobacter baumannii. M33 neutralized LPS derived from P. aeruginosa and K. pneumoniae, and prevented TNF-alpha release from LPS-activated macrophages, with an EC50 of 3.8e-8 M and 2.8e-7 M, respectively, as detected by sandwich ELISA. M33 activity was also tested in sepsis animal models. It averted septic shock symptoms due to Escherichia coli and P. aeruginosa in doses compatible with clinical use (5-25 mg/kg). These properties make tetrabranched M33 peptide a good candidate for the development of a new antibacterial drug.-Pini, A., Falciani, C., Mantengoli, E., Bindi, S., Brunetti, J., Iozzi, S., Rossolini, G. M., Bracci, L. A novel tetrabranched antimicrobial peptide that neutralizes bacterial lipopolysaccharide and prevents septic shock in vivo. FASEB J. 24, 1015-1022 (2010). www.fasebj.org	[Pini, Alessandro; Falciani, Chiara; Bindi, Stefano; Brunetti, Jlenia; Iozzi, Sara; Bracci, Luisa] Univ Siena, Dept Mol Biol, Biochem Sect, I-53100 Siena, Italy; [Mantengoli, Elisabetta; Rossolini, Gian Maria] Univ Siena, Dept Mol Biol, Microbiol Sect, I-53100 Siena, Italy	University of Siena; University of Siena	Pini, A (corresponding author), Univ Siena, Dept Mol Biol, Biochem Sect, Via Fiorentina 1, I-53100 Siena, Italy.	pinia@unisi.it	Bracci, Luisa/V-9913-2018; Falciani, Chiara/R-1330-2018; Brunetti, Luisa/E-6464-2019; Pini, Alessandro/R-1359-2018	Bracci, Luisa/0000-0002-0738-5746; Falciani, Chiara/0000-0002-1027-8482; Brunetti, Luisa/0000-0001-8144-7186; Pini, Alessandro/0000-0002-3832-8349; ROSSOLINI, Gian Maria/0000-0002-9386-0434	Fondazione Italiana per la Ricerca sulla Fibrosi cistica [FFC 14/2009]	Fondazione Italiana per la Ricerca sulla Fibrosi cistica(Ministry of Health, ItalyItalian Cystic Fibrosis Research Foundation)	The authors thank Silvia Scali for technical help in peptide synthesis. Part of this work was financed by Fondazione Italiana per la Ricerca sulla Fibrosi cistica, grant FFC# 14/2009.	Arnold TM, 2007, AM J HEALTH-SYST PH, V64, P819, DOI 10.2146/ajhp060473; Bowdish DME, 2004, J IMMUNOL, V172, P3758, DOI 10.4049/jimmunol.172.6.3758; Bracci L, 2003, J BIOL CHEM, V278, P46590, DOI 10.1074/jbc.M308615200; Bracci L, 2002, BIOCHEMISTRY-US, V41, P10194, DOI 10.1021/bi0256025; Cirioni O, 2006, ANTIMICROB AGENTS CH, V50, P1672, DOI 10.1128/AAC.50.5.1672-1679.2006; Demitri MT, 1996, J ENDOTOXIN RES, V3, P445, DOI 10.1177/096805199600300602; Fabbrini M, 2009, ADV EXP MED BIOL, V611, P437, DOI 10.1007/978-0-387-73657-0_188; Falciani C, 2007, MOL CANCER THER, V6, P2441, DOI 10.1158/1535-7163.MCT-07-0164; Falciani C, 2007, CHEM BIOL DRUG DES, V69, P216, DOI 10.1111/j.1747-0285.2007.00487.x; Falciani C, 2009, EXPERT OPIN BIOL TH, V9, P171, DOI [10.1517/14712590802620501, 10.1517/14712590802620501 ]; Gordon YJ, 2005, CURR EYE RES, V30, P505, DOI 10.1080/02713680590968637; Hancock REW, 2006, NAT BIOTECHNOL, V24, P1551, DOI 10.1038/nbt1267; Lau YE, 2006, AM J RESP CELL MOL, V34, P399, DOI 10.1165/rcmb.2005-0170OC; Lozzi L, 2003, CHEM BIOL, V10, P411, DOI 10.1016/S1074-5521(03)00094-2; Marr AK, 2006, CURR OPIN PHARMACOL, V6, P468, DOI 10.1016/j.coph.2006.04.006; Michalopoulos A, 2008, CRIT CARE CLIN, V24, P377, DOI 10.1016/j.ccc.2007.12.003; Motzkus D, 2006, FASEB J, V20, P1701, DOI 10.1096/fj.05-4970fje; PECKMILLER KA, 1993, CANCER CHEMOTH PHARM, V32, P109, DOI 10.1007/BF00685612; Pini A, 2006, BIOCHEM J, V395, P157, DOI 10.1042/BJ20051747; Pini A, 2005, ANTIMICROB AGENTS CH, V49, P2665, DOI 10.1128/AAC.49.7.2665-2672.2005; Pini A, 2008, CURR PROTEIN PEPT SC, V9, P468, DOI 10.2174/138920308785915227; Pini A, 2008, PROTEIN PEPTIDE LETT, V15, P562, DOI 10.2174/092986608784966958; Pini A, 2007, J PEPT SCI, V13, P393, DOI 10.1002/psc.858; Prescott WA, 2005, PHARMACOTHERAPY, V25, P555, DOI 10.1592/phco.25.4.555.61025; Riccio ML, 2005, ANTIMICROB AGENTS CH, V49, P104, DOI 10.1128/AAC.49.1.104-110.2005; Rossetto G, 2007, NANOMED-NANOTECHNOL, V3, P198, DOI 10.1016/j.nano.2007.06.002; Rossolini GM, 2008, CLIN MICROBIOL INFEC, V14, P2, DOI 10.1111/j.1469-0691.2008.02126.x; Rossolini GM, 2008, ANTIMICROB AGENTS CH, V52, P4023, DOI 10.1128/AAC.00707-08; Rossolini GM, 2007, NEW MICROBIOL, V30, P332; TAM JP, 1988, P NATL ACAD SCI USA, V85, P5409, DOI 10.1073/pnas.85.15.5409; Walker John M., 1996, P525, DOI 10.1007/978-1-60327-259-9_88; Wong KF, 2009, PROTEIN PEPTIDE LETT, V16, P539, DOI 10.2174/092986609788167761; Yeaman MR, 2002, ANTIMICROB AGENTS CH, V46, P3883, DOI 10.1128/AAC.46.12.3883-3891.2002; Zavascki AP, 2007, J ANTIMICROB CHEMOTH, V60, P1206, DOI 10.1093/jac/dkm357; Zhang LJ, 2005, ANTIMICROB AGENTS CH, V49, P2921, DOI 10.1128/AAC.49.7.2921-2927.2005; Zhang LJ, 2006, EXPERT OPIN PHARMACO, V7, P653, DOI 10.1517/14656566.7.6.653	36	61	66	0	20	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	APR	2010	24	4					1015	1022		10.1096/fj.09-145474	http://dx.doi.org/10.1096/fj.09-145474			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	580PV	19917670				2022-12-25	WOS:000276462300009
J	Cowling, VH				Cowling, V. H.			Enhanced mRNA cap methylation increases Cyclin D1 expression and promotes cell transformation	ONCOGENE			English	Article						Cyclin D1; cell transformation; mRNA cap methylation; mRNA translation	C-MYC; CANCER; METHYLTRANSFERASE; TRANSLATION; RECRUITMENT; REPRESSION; APOPTOSIS; BINDING; EIF4E; GENE	Cap-dependent mRNA translation requires the methylation of the mRNA guanosine cap by RNA guanine-7-methyltransferase (RNMT). mRNA cap methylation was recently described to be rate-limiting for a subset of mRNAs, and to be enhanced by expression of c-Myc and E2F1, although the biological significance of this finding was not investigated. Here, it is reported that increased RNMT expression enhances cellular mRNA cap methyltransferase activity, promotes mammary epithelial cell transformation and cooperates with H-RasV12 or c-Myc to promote fibroblast cell transformation. Cyclin D1 is a prominent oncogene in epithelial tumours. A signi. cant fraction of Cyclin D1 mRNA was found to be unmethylated on the mRNA cap and thus dormant in mammary epithelial cells. Cyclin D1 expression was increased by enhanced mRNA cap methylation. In summary, this report shows that mRNA cap methylation is rate-limiting for expression of an oncogene and cell transformation. Oncogene (2010) 29, 930-936; doi:10.1038/onc.2009.368; published online 16 November 2009	Univ Dundee, Coll Life Sci, Div Cell Biol & Immunol, Dundee DD1 5EH, Scotland	University of Dundee	Cowling, VH (corresponding author), Univ Dundee, Coll Life Sci, Div Cell Biol & Immunol, Dow St, Dundee DD1 5EH, Scotland.	v.h.cowling@dundee.ac.uk		Cowling, Victoria/0000-0001-7638-4870	MRC; Tenovus Scotland Project; Medical Research Council [G0700240] Funding Source: researchfish; MRC [G0700240] Funding Source: UKRI	MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Tenovus Scotland Project; Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))	I thank Mike Cole for the generous gift of the anti-m7G antibodies, Aaron Shatkin for providing the RNMT-GFP construct, Julian Downward for providing the H-RasV12 construct and James DiRenzo for providing IMEC. I also thank all of the above and the Cowling lab for advice. This work was funded by an MRC Career Development Award and a Tenovus Scotland Project Grant.	Bentley DL, 2005, CURR OPIN CELL BIOL, V17, P251, DOI 10.1016/j.ceb.2005.04.006; Chu C, 2008, MOL CELL BIOL, V28, P5829, DOI 10.1128/MCB.00021-08; Cole MD, 2009, ONCOGENE, V28, P1169, DOI 10.1038/onc.2008.463; Cole MD, 2008, NAT REV MOL CELL BIO, V9, P810, DOI 10.1038/nrm2467; Cowling VH, 2007, MOL CELL BIOL, V27, P2059, DOI 10.1128/MCB.01828-06; Cowling VH, 2007, MOL CELL BIOL, V27, P5135, DOI 10.1128/MCB.02282-06; Cowling VH, 2006, MOL CELL BIOL, V26, P4226, DOI 10.1128/MCB.01959-05; DiRenzo J, 2002, CANCER RES, V62, P89; Furuichi Y, 2000, ADV VIRUS RES, V55, P135, DOI 10.1016/S0065-3527(00)55003-9; Gingras AC, 1999, ANNU REV BIOCHEM, V68, P913, DOI 10.1146/annurev.biochem.68.1.913; Goy A, 2006, CANCER CYTOPATHOL, V108, P10, DOI 10.1002/cncr.21500; MAO XD, 1995, MOL CELL BIOL, V15, P4167; Pandolfi PP, 2004, ONCOGENE, V23, P3134, DOI 10.1038/sj.onc.1207618; PHILIPP A, 1994, MOL CELL BIOL, V14, P4032, DOI 10.1128/MCB.14.6.4032; Pillutla RC, 1998, J BIOL CHEM, V273, P21443, DOI 10.1074/jbc.273.34.21443; Rhodes DR, 2004, NEOPLASIA, V6, P1, DOI 10.1016/S1476-5586(04)80047-2; Roy PG, 2006, BREAST, V15, P718, DOI 10.1016/j.breast.2006.02.005; Shafer B, 2005, MOL CELL BIOL, V25, P2644, DOI 10.1128/MCB.25.7.2644-2649.2005; SHATKIN AJ, 1976, CELL, V9, P645, DOI 10.1016/0092-8674(76)90128-8; Shuman S, 2002, NAT REV MOL CELL BIO, V3, P619, DOI 10.1038/nrm880; Tsai YP, 2008, FEBS LETT, V582, P4083, DOI 10.1016/j.febslet.2008.11.004; Vallat LD, 2007, BLOOD, V109, P3989, DOI 10.1182/blood-2006-09-045377; Wen YX, 2000, GENE DEV, V14, P2944, DOI 10.1101/gad.848200; Wendel HG, 2007, GENE DEV, V21, P3232, DOI 10.1101/gad.1604407; Wendel HG, 2004, NATURE, V428, P332, DOI 10.1038/nature02369; White RJ, 2008, TRENDS GENET, V24, P622, DOI 10.1016/j.tig.2008.10.003	26	31	31	1	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	FEB 11	2010	29	6					930	936		10.1038/onc.2009.368	http://dx.doi.org/10.1038/onc.2009.368			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	553WP	19915615	Green Accepted, Bronze			2022-12-25	WOS:000274397800015
J	Banci, L; Bertini, I; Cantini, F; Inagaki, S; Migliardi, M; Rosato, A				Banci, Lucia; Bertini, Ivano; Cantini, Francesca; Inagaki, Sayaka; Migliardi, Manuele; Rosato, Antonio			The Binding Mode of ATP Revealed by the Solution Structure of the N-domain of Human ATP7A	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							P-TYPE ATPASES; MAGNETIC-RESONANCE RELAXATION; COPPER-TRANSPORTING ATPASE; MENKES DISEASE; CANDIDATE GENE; BACKBONE DYNAMICS; DIPOLAR COUPLINGS; CRYSTAL-STRUCTURE; CALCIUM-PUMP; PROTEIN NMR	We report the solution NMR structures of the N-domain of the Menkes protein (ATP7A) in the ATP-free and ATP-bound forms. The structures consist of a twisted antiparallel six-stranded beta-sheet flanked by two pairs of alpha-helices. A protein loop of 50 amino acids located between beta 3 and beta 4 is disordered and mobile on the subnanosecond time scale. ATP binds with an affinity constant of (1.2 +/- 0.1) x 10(4) M-1 and exchanges with a rate of the order of 1 x 10(3) s(-1). The ATP-binding cavity is considerably affected by the presence of the ligand, resulting in a more compact conformation in the ATP-bound than in the ATP-free form. This structural variation is due to the movement of the alpha 1-alpha 2 and beta 2-beta 3 loops, both of which are highly conserved in copper(I)-transporting P-IB-type ATPases. The present structure reveals a characteristic binding mode of ATP within the protein scaffold of the copper(I)-transporting P-IB-type ATPases with respect to the other P-type ATPases. In particular, the binding cavity contains mainly hydrophobic aliphatic residues, which are involved in van der Waal's interactions with the adenine ring of ATP, and a Glu side chain, which forms a crucial hydrogen bond to the amino group of ATP.	[Banci, Lucia; Bertini, Ivano; Cantini, Francesca; Inagaki, Sayaka; Migliardi, Manuele; Rosato, Antonio] Univ Florence, Magnet Resonance Ctr, I-50019 Sesto Fiorentino, Italy; [Banci, Lucia; Bertini, Ivano; Cantini, Francesca; Rosato, Antonio] Univ Florence, Dept Chem, I-50019 Sesto Fiorentino, Italy; [Banci, Lucia] FIORGEN Fdn, I-50019 Sesto Fiorentino, Italy	University of Florence; University of Florence	Bertini, I (corresponding author), Univ Florence, Magnet Resonance Ctr, Via L Sacconi 6, I-50019 Sesto Fiorentino, Italy.	ivanobertini@cerm.unifi.it	Rosato, Antonio/M-3250-2019; Rosato, Antonio/D-8548-2011; Cantini, Francesca/O-1220-2015	Rosato, Antonio/0000-0001-6172-0368; Rosato, Antonio/0000-0001-6172-0368; Cantini, Francesca/0000-0003-0526-6732; BANCI, LUCIA/0000-0003-0562-5774	Ministero dell'Istruzione e dell' Universita e della Ricerca Fondo per gli Investimenti della Ricerca di Base-Proteomica [RBRN07BMCT]; Ente Cassa di Risparmio di Firenze Project; European Commission [SPINE2-COMPLEXES 031220]	Ministero dell'Istruzione e dell' Universita e della Ricerca Fondo per gli Investimenti della Ricerca di Base-Proteomica; Ente Cassa di Risparmio di Firenze Project(Fondazione Cassa Risparmio Firenze); European Commission(European CommissionEuropean Commission Joint Research Centre)	This work was supported by Ministero dell'Istruzione e dell' Universita e della Ricerca Fondo per gli Investimenti della Ricerca di Base-Proteomica Grant RBRN07BMCT, Ente Cassa di Risparmio di Firenze Project "Relazione varianti proteiche strutturali-malattie genetiche," and European Commission Project SPINE2-COMPLEXES 031220.	Arnesano F, 2002, GENOME RES, V12, P255, DOI 10.1101/gr.196802; Bhattacharya A, 2007, PROTEINS, V66, P778, DOI 10.1002/prot.21165; CASE DA, 2008, AMBER 10 VERSION 8 0; CHELLY J, 1993, NAT GENET, V3, P14, DOI 10.1038/ng0193-14; Cornilescu G, 1999, J BIOMOL NMR, V13, P289, DOI 10.1023/A:1008392405740; Cox DW, 2002, J BIOENERG BIOMEMBR, V34, P333, DOI 10.1023/A:1021293818125; Davis IW, 2007, NUCLEIC ACIDS RES, V35, pW375, DOI 10.1093/nar/gkm216; Dmitriev O, 2006, P NATL ACAD SCI USA, V103, P5302, DOI 10.1073/pnas.0507416103; Dosset P, 2001, J BIOMOL NMR, V20, P223, DOI 10.1023/A:1011206132740; FARROW NA, 1994, BIOCHEMISTRY-US, V33, P5984, DOI 10.1021/bi00185a040; Garrett DS, 1997, BIOCHEMISTRY-US, V36, P4393, DOI 10.1021/bi970221q; GRZESIEK S, 1993, J AM CHEM SOC, V115, P12593, DOI 10.1021/ja00079a052; Haupt M, 2006, J BIOL CHEM, V281, P9641, DOI 10.1074/jbc.M508290200; Herrmann T, 2002, J MOL BIOL, V319, P209, DOI 10.1016/S0022-2836(02)00241-3; Hilge M, 2003, NAT STRUCT BIOL, V10, P468, DOI 10.1038/nsb924; Kodama K, 1999, PEDIATR INT, V41, P430, DOI 10.1046/j.1442-200x.1999.01091.x; Koradi R, 1996, J MOL GRAPHICS, V14, P51, DOI 10.1016/0263-7855(96)00009-4; Kuhlbrandt W, 2004, NAT REV MOL CELL BIO, V5, P282, DOI 10.1038/nrm1354; Laskowski RA, 1996, J BIOMOL NMR, V8, P477, DOI 10.1007/BF00228148; LIPARI G, 1982, J AM CHEM SOC, V104, P4559, DOI 10.1021/ja00381a010; LIPARI G, 1982, J AM CHEM SOC, V104, P4546, DOI 10.1021/ja00381a009; Lutsenko S, 1997, J BIOL CHEM, V272, P18939, DOI 10.1074/jbc.272.30.18939; LUTSENKO S, 1995, BIOCHEMISTRY-US, V34, P15607, DOI 10.1021/bi00048a001; Lutsenko S, 2007, PHYSIOL REV, V87, P1011, DOI 10.1152/physrev.00004.2006; MANDEL AM, 1995, J MOL BIOL, V246, P144, DOI 10.1006/jmbi.1994.0073; MERCER JFB, 1993, NAT GENET, V3, P20, DOI 10.1038/ng0193-20; Moller JV, 1996, BBA-REV BIOMEMBRANES, V1286, P1, DOI 10.1016/0304-4157(95)00017-8; Monty JF, 2005, J NUTR, V135, P2762, DOI 10.1093/jn/135.12.2762; Morgan CT, 2004, J BIOL CHEM, V279, P36363, DOI 10.1074/jbc.M404553200; Ottiger M, 1998, J MAGN RESON, V131, P373, DOI 10.1006/jmre.1998.1361; Pedersen BP, 2007, NATURE, V450, P1111, DOI 10.1038/nature06417; Petris MJ, 2000, HUM MOL GENET, V9, P2845, DOI 10.1093/hmg/9.19.2845; Sazinsky MH, 2006, J BIOL CHEM, V281, P11161, DOI 10.1074/jbc.M510708200; Sharma S, 2009, J CHEM INF MODEL, V49, P76, DOI 10.1021/ci8002304; Solioz M, 1996, TRENDS BIOCHEM SCI, V21, P237; Toyoshima C, 2004, NATURE, V430, P529, DOI 10.1038/nature02680; Toyoshima C, 2002, NATURE, V418, P605, DOI 10.1038/nature00944; Tsuda T, 2009, EMBO J, V28, P1782, DOI 10.1038/emboj.2009.143; Voskoboinik I, 2001, J BIOL CHEM, V276, P28620, DOI 10.1074/jbc.M103532200; VRIEND G, 1990, J MOL GRAPHICS, V8, P52, DOI 10.1016/0263-7855(90)80070-V; VULPE C, 1993, NAT GENET, V3, P7, DOI 10.1038/ng0193-7; Zwahlen C, 1997, J AM CHEM SOC, V119, P6711, DOI 10.1021/ja970224q	42	21	21	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 22	2010	285	4					2537	2544		10.1074/jbc.M109.054262	http://dx.doi.org/10.1074/jbc.M109.054262			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	544YP	19917612	Green Published, hybrid			2022-12-25	WOS:000273697800032
J	Mbefo, MK; Paleologou, KE; Boucharaba, A; Oueslati, A; Schell, H; Fournier, M; Olschewski, D; Yin, GW; Zweckstetter, M; Masliah, E; Kahle, PJ; Hirling, H; Lashuel, HA				Mbefo, Martial K.; Paleologou, Katerina E.; Boucharaba, Ahmed; Oueslati, Abid; Schell, Heinrich; Fournier, Margot; Olschewski, Diana; Yin, Guowei; Zweckstetter, Markus; Masliah, Eliezer; Kahle, Philipp J.; Hirling, Harald; Lashuel, Hilal A.			Phosphorylation of Synucleins by Members of the Polo-like Kinase Family	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-SERINE/THREONINE KINASE; ALPHA-SYNUCLEIN; PARKINSONS-DISEASE; DROSOPHILA-POLO; RAT MODEL; INCLUSION FORMATION; SER-129; DOMAIN; IDENTIFICATION; LOCALIZATION	Phosphorylation of alpha-synuclein (alpha-syn) at Ser-129 is a hallmark of Parkinson disease and related synucleinopathies. However, the identity of the natural kinases and phosphatases responsible for regulating alpha-syn phosphorylation remain unknown. Here we demonstrate that three closely related members of the human Polo-like kinase (PLK) family (PLK1, PLK2, and PLK3) phosphorylate alpha-syn and beta-syn specifically at Ser-129 and Ser-118, respectively. Unlike other kinases reported to partially phosphorylate alpha-syn at Ser-129 in vitro, phosphorylation by PLK2 and PLK3 is quantitative (>95% conversion). Only PLK1 and PLK3 phosphorylate beta-syn at Ser-118, whereas no phosphorylation of gamma-syn was detected by any of the four PLKs (PLK1 to -4). PLK-mediated phosphorylation was greatly reduced in an isolated C-terminal fragment (residues 103 140) of alpha-syn, suggesting substrate recognition via the N-terminal repeats and/or the non-amyloid component domain of alpha-syn. PLKs specifically co-localized with phosphorylated Ser-129 (Ser(P)-129) alpha-syn in various subcellular compartments (cytoplasm, nucleus, and membranes) of mammalian cell lines and primary neurons as well as in alpha-syn transgenic mice, especially cortical brain areas involved in synaptic plasticity. Furthermore, we report that the levels of PLK2 are significantly increased in brains of Alzheimer disease and Lewy body disease patients. Taken together, these results provide biochemical and in vivo evidence of alpha-syn and beta-syn phosphorylation by specific PLKs. Our results suggest a need for further studies to elucidate the potential role of PLK-syn interactions in the normal biology of these proteins as well as their involvement in the pathogenesis of Parkinson disease and other synucleinopathies.	[Mbefo, Martial K.; Paleologou, Katerina E.; Oueslati, Abid; Fournier, Margot; Olschewski, Diana; Lashuel, Hilal A.] Ecole Polytech Fed Lausanne, Brain Mind Inst, Lab Mol Neurobiol & Neuroprote, CH-1015 Lausanne, Switzerland; [Boucharaba, Ahmed; Hirling, Harald] Ecole Polytech Fed Lausanne, Brain Mind Inst, Lab Cellular Neurobiol, CH-1015 Lausanne, Switzerland; [Schell, Heinrich; Kahle, Philipp J.] Univ Clin Tubingen, Lab Funct Neurogenet, Dept Neurodegenerat, Hertie Inst Clin Brain Res, D-72076 Tubingen, Germany; [Yin, Guowei; Zweckstetter, Markus] Max Planck Inst Biophys Chem, Dept NMR Based Struct Biol, D-37077 Gottingen, Germany; [Zweckstetter, Markus] Deutsch Forsch Gemeinschaft Res Ctr Mol Physiol B, D-37073 Gottingen, Germany; [Masliah, Eliezer] Univ Calif San Diego, Dept Neurosci, La Jolla, CA 92093 USA	Swiss Federal Institutes of Technology Domain; Ecole Polytechnique Federale de Lausanne; Swiss Federal Institutes of Technology Domain; Ecole Polytechnique Federale de Lausanne; Eberhard Karls University of Tubingen; Eberhard Karls University Hospital; Max Planck Society; University of California System; University of California San Diego	Lashuel, HA (corresponding author), Ecole Polytech Fed Lausanne, Brain Mind Inst, Lab Mol Neurobiol & Neuroprote, CH-1015 Lausanne, Switzerland.	hilal.lashuel@epfl.ch	Oueslati, Abid/ABG-8116-2020; Lashuel, Hilal/M-3500-2017	Oueslati, Abid/0000-0003-1122-7086; Zweckstetter, Markus/0000-0002-2536-6581; Fournier, Margot/0000-0001-8906-1907	Swiss Federal Institute of Technology Lausanne; Swiss National Science Foundation [310000-110027]; Michael J. Fox Foundation; German Science Foundation [ZW 71/2-1, ZW 71/3-1]; Helmholtz Alliance "Aging Brain"; Hertie Foundat	Swiss Federal Institute of Technology Lausanne; Swiss National Science Foundation(Swiss National Science Foundation (SNSF)European Commission); Michael J. Fox Foundation; German Science Foundation(German Research Foundation (DFG)); Helmholtz Alliance "Aging Brain"; Hertie Foundat	This work was supported by the Swiss Federal Institute of Technology Lausanne and grants to the Laboratory of Molecular Neurobiology and Neuroproteomics from the Swiss National Science Foundation (Grant 310000-110027) and the Michael J. Fox Foundation.; Supported by German Science Foundation Grant Foundation Grants ZW 71/2-1 and 3-1.; Supported by the Helmholtz Alliance "Aging Brain" and the Hertie Foundat.	Anderson JP, 2006, J BIOL CHEM, V281, P29739, DOI 10.1074/jbc.M600933200; Arawaka S, 2006, J NEUROSCI, V26, P9227, DOI 10.1523/JNEUROSCI.0341-06.2006; Bahassi ELM, 2004, ONCOGENE, V23, P2658, DOI 10.1038/sj.onc.1207425; Barr FA, 2004, NAT REV MOL CELL BIO, V5, P429, DOI 10.1038/nrm1401; Chen L, 2005, NAT NEUROSCI, V8, P657, DOI 10.1038/nn1443; CHEN L, 2009, J CLIN INVE IN PRESS; Cheng KY, 2003, EMBO J, V22, P5757, DOI 10.1093/emboj/cdg558; CLAY FJ, 1993, P NATL ACAD SCI USA, V90, P4882, DOI 10.1073/pnas.90.11.4882; da Silveira SA, 2009, HUM MOL GENET, V18, P872, DOI 10.1093/hmg/ddn417; Dai W, 2005, ONCOGENE, V24, P214, DOI 10.1038/sj.onc.1208270; Draghetti C, 2009, J BIOL CHEM, V284, P32053, DOI 10.1074/jbc.M109.009324; Ellis CE, 2001, J BIOL CHEM, V276, P3879, DOI 10.1074/jbc.M010316200; FODE C, 1994, P NATL ACAD SCI USA, V91, P6388, DOI 10.1073/pnas.91.14.6388; Fournier M, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0006629; Freichel C, 2007, NEUROBIOL AGING, V28, P1421, DOI 10.1016/j.neurobiolaging.2006.06.013; Fujiwara H, 2002, NAT CELL BIOL, V4, P160, DOI 10.1038/ncb748; GOLSTEYN RM, 1994, J CELL SCI, V107, P1509; Gorbatyuk OS, 2008, P NATL ACAD SCI USA, V105, P763, DOI 10.1073/pnas.0711053105; HAMANAKA R, 1994, CELL GROWTH DIFFER, V5, P249; Harris PLR, 2000, NEUROBIOL AGING, V21, P837, DOI 10.1016/S0197-4580(00)00218-9; Hasegawa M, 2002, J BIOL CHEM, V277, P49071, DOI 10.1074/jbc.M208046200; Hirling H, 2000, EUR J NEUROSCI, V12, P1913, DOI 10.1046/j.1460-9568.2000.00076.x; Inglis KJ, 2009, J BIOL CHEM, V284, P2598, DOI 10.1074/jbc.C800206200; JAKES R, 1994, FEBS LETT, V345, P27, DOI 10.1016/0014-5793(94)00395-5; Johnson EF, 2007, BIOCHEMISTRY-US, V46, P9551, DOI 10.1021/bi7008745; Kahle PJ, 2000, ANN NY ACAD SCI, V920, P33; Kauselmann G, 1999, EMBO J, V18, P5528, DOI 10.1093/emboj/18.20.5528; Kim EJ, 2006, J BIOL CHEM, V281, P33250, DOI 10.1074/jbc.M606147200; Kothe M, 2007, BIOCHEMISTRY-US, V46, P5960, DOI 10.1021/bi602474j; Lavedan C, 1998, GENOME RES, V8, P871, DOI 10.1101/gr.8.9.871; Lee KS, 1998, P NATL ACAD SCI USA, V95, P9301, DOI 10.1073/pnas.95.16.9301; Leung GC, 2002, NAT STRUCT BIOL, V9, P719, DOI 10.1038/nsb848; Li B, 1996, J BIOL CHEM, V271, P19402, DOI 10.1074/jbc.271.32.19402; Ma S, 2003, MOL CELL BIOL, V23, P6936, DOI 10.1128/MCB.23.19.6936-6943.2003; MAROTEAUX L, 1988, J NEUROSCI, V8, P2804; MBEFO MK, 2008, SYNUCLEIN HLTH DIS L, P21; McFarland NR, 2009, J NEUROPATH EXP NEUR, V68, P515, DOI 10.1097/NEN.0b013e3181a24b53; Nakamura T, 2001, BIOCHEM BIOPH RES CO, V280, P1085, DOI 10.1006/bbrc.2000.4253; Negro A, 2001, FASEB J, V15, P210, DOI 10.1096/fj.01-0517fje; Neumann M, 2002, J CLIN INVEST, V110, P1429, DOI 10.1172/JC1200215777; Okochi M, 2000, J BIOL CHEM, V275, P390, DOI 10.1074/jbc.275.1.390; Pak DTS, 2003, SCIENCE, V302, P1368, DOI 10.1126/science.1082475; Paleologou KE, 2008, J BIOL CHEM, V283, P16895, DOI 10.1074/jbc.M800747200; Pronin AN, 2000, J BIOL CHEM, V275, P26515, DOI 10.1074/jbc.M003542200; Schell H, 2009, NEUROSCIENCE, V160, P796, DOI 10.1016/j.neuroscience.2009.03.002; Seeburg DP, 2008, NEURON, V58, P571, DOI 10.1016/j.neuron.2008.03.021; Seeburg DP, 2005, ONCOGENE, V24, P292, DOI 10.1038/sj.onc.1208277; Smith WW, 2005, J NEUROSCI, V25, P5544, DOI 10.1523/JNEUROSCI.0482-05.2005; Spillantini MG, 1998, P NATL ACAD SCI USA, V95, P6469, DOI 10.1073/pnas.95.11.6469; Steiner P, 2002, J CELL BIOL, V157, P1197, DOI 10.1083/jcb.200202022; Takahashi M, 2003, NEUROSCI LETT, V336, P155, DOI 10.1016/S0304-3940(02)01258-2; Warnke S, 2004, CURR BIOL, V14, P1200, DOI 10.1016/j.cub.2004.06.059; WAXMAN EA, 2008, J NEUROPATH IN PRESS; Waxman EA, 2008, J NEUROPATH EXP NEUR, V67, P402, DOI 10.1097/NEN.0b013e31816fc995; Wilkins DK, 1999, BIOCHEMISTRY-US, V38, P16424, DOI 10.1021/bi991765q; Xie SQ, 2005, ONCOGENE, V24, P277, DOI 10.1038/sj.onc.1208218; Zibaee S, 2007, J MOL BIOL, V374, P454, DOI 10.1016/j.jmb.2007.09.039; Zimmerman WC, 2007, P NATL ACAD SCI USA, V104, P1847, DOI 10.1073/pnas.0610856104	58	181	186	0	19	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 22	2010	285	4					2807	2822		10.1074/jbc.M109.081950	http://dx.doi.org/10.1074/jbc.M109.081950			16	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	544YP	19889641	Green Published, hybrid			2022-12-25	WOS:000273697800057
J	Ng, Y; Ramm, G; Burchfield, JG; Coster, ACF; Stockli, J; James, DE				Ng, Yvonne; Ramm, Georg; Burchfield, James G.; Coster, Adelle C. F.; Stoeckli, Jacqueline; James, David E.			Cluster Analysis of Insulin Action in Adipocytes Reveals a Key Role for Akt at the Plasma Membrane	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AKT/PROTEIN-KINASE-B; STIMULATED GLUT4 TRANSLOCATION; 3T3-L1 ADIPOCYTES; GLUCOSE-TRANSPORTER-4 TRANSLOCATION; GLUCOSE-TRANSPORT; PROTEIN; PHOSPHORYLATION; AS160; TRAFFICKING; DOWNSTREAM	The phosphatidylinositol 3-kinase/Akt pathway regulates many biological processes, including insulin-regulated GLUT4 insertion into the plasma membrane. However, Akt operates well below its capacity to facilitate maximal GLUT4 translocation. Thus, reconciling modest changes in Akt expression or activity as a cause of metabolic dysfunction is complex. To resolve this, we examined insulin regulation of components within the signaling cascade in a quantitative kinetic and dose-response study combined with hierarchical cluster analysis. This revealed a strong relationship between phosphorylation of Akt substrates and GLUT4 translocation but not whole cell Akt phosphorylation. In contrast, Akt activity at the plasma membrane strongly correlated with GLUT4 translocation and Akt substrate phosphorylation. Additionally, two of the phosphorylated sites in the Akt substrate AS160 clustered separately, with Thr(P)-642 grouped with other Akt substrates. Further experiments suggested that atypical protein kinase C zeta phosphorylates AS160 at Ser-588 and that these two sites are mutually exclusive. These data indicate the utility of hierarchical cluster analysis for identifying functionally related biological nodes and highlight the importance of subcellular partitioning of key signaling components for biological specificity.	[Ng, Yvonne; Ramm, Georg; Burchfield, James G.; Coster, Adelle C. F.; Stoeckli, Jacqueline; James, David E.] Garvan Inst Med Res, Diabet & Obes Res Program, Sydney, NSW 2010, Australia; [Ng, Yvonne; James, David E.] Univ New S Wales, Sch Biotechnol & Biomol Sci, Sydney, NSW 2052, Australia; [Coster, Adelle C. F.] Univ New S Wales, Sch Math & Stat, Sydney, NSW 2052, Australia; [Stoeckli, Jacqueline] Univ New S Wales, Fac Med, Sydney, NSW 2052, Australia; [Ramm, Georg] Monash Univ, Sch Biomed Sci, Melbourne, Vic 3800, Australia	Garvan Institute of Medical Research; University of New South Wales Sydney; University of New South Wales Sydney; University of New South Wales Sydney; Monash University	James, DE (corresponding author), Garvan Inst Med Res, Diabet & Obes Res Program, Sydney, NSW 2010, Australia.	d.james@garvan.org.au	Stoeckli, Jacqueline/D-7053-2016; Coster, Adelle CF/A-7234-2013; Burchfield, James/C-1779-2019; Stoeckli, Jacqueline/Z-4443-2019; Coster, Adelle/AAX-4829-2020	Stoeckli, Jacqueline/0000-0002-6446-7350; Coster, Adelle CF/0000-0002-5572-6832; Burchfield, James/0000-0002-6609-6151; Stoeckli, Jacqueline/0000-0002-6446-7350; Coster, Adelle/0000-0002-5572-6832; Ramm, Georg/0000-0003-3596-2288; James, David/0000-0001-5946-5257	National Health and Medical Research Council of Australia; Swiss National Foundation; Novartis Foundation	National Health and Medical Research Council of Australia(National Health and Medical Research Council (NHMRC) of Australia); Swiss National Foundation(Swiss National Science Foundation (SNSF)); Novartis Foundation(Novartis)	This work was supported in part by grants from the National Health and Medical Research Council of Australia.; Supported by fellowships from the Swiss National Foundation and Novartis Foundation.	Adam RM, 2007, CANCER RES, V67, P6238, DOI 10.1158/0008-5472.CAN-07-0288; Biggs WH, 1999, P NATL ACAD SCI USA, V96, P7421, DOI 10.1073/pnas.96.13.7421; Cantley LC, 2002, SCIENCE, V296, P1655, DOI 10.1126/science.296.5573.1655; Cho H, 2001, SCIENCE, V292, P1728, DOI 10.1126/science.292.5522.1728; CROSS DAE, 1995, NATURE, V378, P785, DOI 10.1038/378785a0; Ding JX, 2009, MOL CELL BIOL, V29, P1459, DOI 10.1128/MCB.00754-08; Foukas LC, 2006, NATURE, V441, P366, DOI 10.1038/nature04694; Geraghty KM, 2007, BIOCHEM J, V407, P231, DOI 10.1042/BJ20070649; Gonzalez E, 2009, P NATL ACAD SCI USA, V106, P7004, DOI 10.1073/pnas.0901933106; Govers R, 2004, MOL CELL BIOL, V24, P6456, DOI 10.1128/MCB.24.14.6456-6466.2004; Gross DN, 2008, ONCOGENE, V27, P2320, DOI 10.1038/onc.2008.25; Hoehn KL, 2008, CELL METAB, V7, P421, DOI 10.1016/j.cmet.2008.04.005; Hresko RC, 2005, J BIOL CHEM, V280, P40406, DOI 10.1074/jbc.M508361200; Jiang ZY, 2003, P NATL ACAD SCI USA, V100, P7569, DOI 10.1073/pnas.1332633100; Kane S, 2002, J BIOL CHEM, V277, P22115, DOI 10.1074/jbc.C200198200; Katome T, 2003, J BIOL CHEM, V278, P28312, DOI 10.1074/jbc.M302094200; Kitamura T, 1999, MOL CELL BIOL, V19, P6286; Knight ZA, 2006, CELL, V125, P733, DOI 10.1016/j.cell.2006.03.035; Kohn AD, 1996, J BIOL CHEM, V271, P31372, DOI 10.1074/jbc.271.49.31372; Larance M, 2005, J BIOL CHEM, V280, P37803, DOI 10.1074/jbc.M503897200; Lopez JA, 2009, MOL BIOL CELL, V20, P3918, DOI 10.1091/mbc.E09-03-0187; Manning BD, 2007, CELL, V129, P1261, DOI 10.1016/j.cell.2007.06.009; Ng Y, 2008, CELL METAB, V7, P348, DOI 10.1016/j.cmet.2008.02.008; Potter CJ, 2002, NAT CELL BIOL, V4, P658, DOI 10.1038/ncb840; Ramm G, 2006, J BIOL CHEM, V281, P29174, DOI 10.1074/jbc.M603274200; Saito T, 2007, J BIOL CHEM, V282, P32280, DOI 10.1074/jbc.M704150200; Sano H, 2003, J BIOL CHEM, V278, P14599, DOI 10.1074/jbc.C300063200; Sarbassov DD, 2005, SCIENCE, V307, P1098, DOI 10.1126/science.1106148; Schenck A, 2008, CELL, V133, P486, DOI 10.1016/j.cell.2008.02.044; Shewan AM, 2003, MOL BIOL CELL, V14, P973, DOI 10.1091/mbc.E02-06-0315; Simons K, 1997, NATURE, V387, P569, DOI 10.1038/42408; Standaert ML, 1997, J BIOL CHEM, V272, P30075, DOI 10.1074/jbc.272.48.30075; Stockli J, 2008, MOL ENDOCRINOL, V22, P2703, DOI 10.1210/me.2008-0111; White MF, 1998, MOL CELL BIOCHEM, V182, P3, DOI 10.1023/A:1006806722619; Whitehead JP, 2001, J BIOL CHEM, V276, P27816, DOI 10.1074/jbc.M011590200; Whiteman EL, 2002, TRENDS ENDOCRIN MET, V13, P444, DOI 10.1016/S1043-2760(02)00662-8	36	37	37	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 22	2010	285	4					2255	2267		10.1074/jbc.M109.060236	http://dx.doi.org/10.1074/jbc.M109.060236			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	544YP	19897488	Green Published, hybrid			2022-12-25	WOS:000273697800005
J	Higuero, AM; Sanchez-Ruiloba, L; Doglio, LE; Portillo, F; Abad-Rodriguez, J; Dotti, CG; Iglesias, T				Higuero, Alonso M.; Sanchez-Ruiloba, Lucia; Doglio, Laura E.; Portillo, Francisco; Abad-Rodriguez, Jose; Dotti, Carlos G.; Iglesias, Teresa			Kidins220/ARMS Modulates the Activity of Microtubule-regulating Proteins and Controls Neuronal Polarity and Development	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLYCOGEN-SYNTHASE KINASE-3-BETA; TRANS-GOLGI NETWORK; KINASE-D; HIPPOCAMPAL-NEURONS; NERVOUS-SYSTEM; GROWING AXONS; IN-VIVO; INTRACELLULAR-LOCALIZATION; SECRETORY TRAFFICKING; PHOSPHORYLATION SITES	In order for neurons to perform their function, they must establish a highly polarized morphology characterized, in most of the cases, by a single axon and multiple dendrites. Herein we find that the evolutionarily conserved protein Kidins220 (kinase D-interacting substrate of 220-kDa), also known as ARMS (ankyrin repeat-rich membrane spanning), a downstream effector of protein kinase D and neurotrophin and ephrin receptors, regulates the establishment of neuronal polarity and development of dendrites. Kidins220/ARMS gain and loss of function experiments render severe phenotypic changes in the processes extended by hippocampal neurons in culture. Although Kidins220/ARMS early overexpression hinders neuronal development, its down-regulation by RNA interference results in the appearance of multiple longer axon-like extensions as well as aberrant dendritic arbors. Wealso find that Kidins220/ARMS interacts with tubulin and microtubule-regulating molecules whose role in neuronal morphogenesis is well established (microtubule-associated proteins 1b, 1a, and 2 and two members of the stathmin family). Importantly, neurons where Kidins220/ARMS has been knocked down register changes in the phosphorylation activity of MAP1b and stathmins. Altogether, our results indicate that Kidins220/ARMS is a key modulator of the activity of microtubule-regulating proteins known to actively regulate neuronal morphogenesis and suggest a mechanism by which it contributes to control neuronal development.	[Higuero, Alonso M.; Sanchez-Ruiloba, Lucia; Portillo, Francisco; Iglesias, Teresa] Univ Autonoma Madrid, Consejo Super Invest Cient, Inst Invest Biomed Madrid Alberto Sols, Madrid 28029, Spain; [Higuero, Alonso M.; Abad-Rodriguez, Jose] Hosp Nacl Paraplej, Membrane Biol & Axonal Repair Unit, Toledo 45071, Spain; [Doglio, Laura E.; Dotti, Carlos G.] Katholieke Univ Leuven, Dept Human Genet, B-3000 Louvain, Belgium; [Doglio, Laura E.; Dotti, Carlos G.] VIB, Dept Dev Mol Genet, B-3000 Louvain, Belgium; [Higuero, Alonso M.; Sanchez-Ruiloba, Lucia; Iglesias, Teresa] Inst Salud Carlos III, CIBERNED, Madrid 28029, Spain	Autonomous University of Madrid; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Instituto de Investigaciones Biomedicas Alberto Sols (IIBM); Hospital Nacional de Paraplejicos; KU Leuven; Flanders Institute for Biotechnology (VIB); CIBERNED; Instituto de Salud Carlos III	Iglesias, T (corresponding author), UAM, CSIC, Inst Invest Biomed Alberto Sols, C Arturo Duperier 4, Madrid 28029, Spain.	tiglesias@iib.uam.es	Dotti, Carlos G/I-5533-2015; Higuero, Alonso/L-7300-2014; Vacas, Teresa Iglesias/ABF-8663-2020; Higuero, Alonso/AAZ-8406-2021; Abad-Rodríguez, José/L-8274-2014	Dotti, Carlos G/0000-0003-4052-1719; Higuero, Alonso/0000-0003-3304-3616; Vacas, Teresa Iglesias/0000-0002-4326-9005; Higuero, Alonso/0000-0003-3304-3616; Abad-Rodríguez, José/0000-0002-0350-500X; Sanchez-Ruiloba, Lucia/0000-0001-5418-2290; Portillo Perez, Francisco/0000-0003-4922-346X	Ministerio de Ciencia e Innovacion [SAF2008-01951]; Comunidad de Madrid [CAM S-SAL-0202-2006-01]; "Instituto de Salud Carlos III" (Spain)	Ministerio de Ciencia e Innovacion(Ministry of Science and Innovation, Spain (MICINN)Instituto de Salud Carlos IIISpanish Government); Comunidad de Madrid(Comunidad de Madrid); "Instituto de Salud Carlos III" (Spain)(Instituto de Salud Carlos III)	This work was supported by "Ministerio de Ciencia e Innovacion" Grant SAF2008-01951, "Neurodegmodels" Grant CAM S-SAL-0202-2006-01 from "Comunidad de Madrid," and CIBERNED from "Instituto de Salud Carlos III" (Spain) (to T.I.).	Antonsson B, 1998, J BIOL CHEM, V273, P8439, DOI 10.1074/jbc.273.14.8439; Arevalo JC, 2004, EMBO J, V23, P2358, DOI 10.1038/sj.emboj.7600253; Arevolo JC, 2006, J BIOL CHEM, V281, P1001, DOI 10.1074/jbc.M504163200; Arimura N, 2007, NAT REV NEUROSCI, V8, P194, DOI 10.1038/nrn2056; BAAS PW, 1993, J NEUROSCI, V13, P2177; BANKER G, 1998, CULTURING NERVE CELL; Barnes AP, 2007, CELL, V129, P549, DOI 10.1016/j.cell.2007.03.025; Bisbal M, 2008, J NEUROSCI, V28, P9297, DOI 10.1523/JNEUROSCI.1879-08.2008; BLACK MM, 1994, J NEUROSCI, V14, P857; BLOOM GS, 1985, P NATL ACAD SCI USA, V82, P5404, DOI 10.1073/pnas.82.16.5404; Bondallaz P, 2006, CELL MOTIL CYTOSKEL, V63, P681, DOI 10.1002/cm.20154; Bracale A, 2007, MOL BIOL CELL, V18, P142, DOI 10.1091/mbc.E06-05-0453; Bradke F, 2000, CURR OPIN NEUROBIOL, V10, P574, DOI 10.1016/S0959-4388(00)00124-0; Bradke F, 1999, SCIENCE, V283, P1931, DOI 10.1126/science.283.5409.1931; BROWN A, 1992, J CELL BIOL, V119, P867, DOI 10.1083/jcb.119.4.867; Cabrera-Poch N, 2004, J BIOL CHEM, V279, P28592, DOI 10.1074/jbc.M312242200; CALVERT R, 1985, EMBO J, V4, P1171, DOI 10.1002/j.1460-2075.1985.tb03756.x; Czondor K, 2009, MOL BIOL CELL, V20, P2108, DOI 10.1091/mbc.E08-09-0957; Da Silva JS, 2005, NAT NEUROSCI, V8, P606, DOI 10.1038/nn1442; Da Silva JS, 2002, NAT REV NEUROSCI, V3, P694, DOI 10.1038/nrn918; Del Rio JA, 2004, CURR BIOL, V14, P840, DOI 10.1016/j.cub.2004.04.046; DHAMODHARAN R, 1995, J CELL SCI, V108, P1679; Di Paolo G, 1997, J NEUROSCI RES, V50, P1000, DOI 10.1002/(SICI)1097-4547(19971215)50:6<1000::AID-JNR10>3.0.CO;2-8; DiTella MC, 1996, J CELL SCI, V109, P467; DOTTI CG, 1988, J NEUROSCI, V8, P1454; Edelmann W, 1996, P NATL ACAD SCI USA, V93, P1270, DOI 10.1073/pnas.93.3.1270; Eiseler T, 2007, FEBS LETT, V581, P4279, DOI 10.1016/j.febslet.2007.07.079; FISCHER I, 1990, J NEUROCHEM, V55, P328, DOI 10.1111/j.1471-4159.1990.tb08855.x; Foletti DL, 1999, NEURON, V23, P641, DOI 10.1016/S0896-6273(01)80022-2; Fukata Y, 2002, NAT CELL BIOL, V4, P583, DOI 10.1038/ncb825; GARNER CC, 1990, J NEUROCHEM, V55, P146, DOI 10.1111/j.1471-4159.1990.tb08832.x; Gavet O, 1998, J CELL SCI, V111, P3333; Gavet O, 2002, J NEUROSCI RES, V68, P535, DOI 10.1002/jnr.10234; Ghanekar Y, 2005, TRENDS CELL BIOL, V15, P511, DOI 10.1016/j.tcb.2005.08.001; Gonzalez-Billault C, 2000, MOL CELL NEUROSCI, V16, P408, DOI 10.1006/mcne.2000.0880; Gonzalez-Billault C, 2005, CEREB CORTEX, V15, P1134, DOI 10.1093/cercor/bhh213; Gonzalez-Billault C, 2004, J NEUROBIOL, V58, P48, DOI 10.1002/neu.10283; Gonzalez-Billault C, 2001, MOL BIOL CELL, V12, P2087, DOI 10.1091/mbc.12.7.2087; Gonzalez-Billault C, 2002, J NEUROSCI RES, V67, P713, DOI 10.1002/jnr.10161; Goold RG, 2005, MOL CELL NEUROSCI, V28, P524, DOI 10.1016/j.mcn.2004.11.005; Goold RG, 2004, BIOCHEM SOC T, V32, P809, DOI 10.1042/BST0320809; Goold RG, 2003, J NEUROCHEM, V87, P935, DOI 10.1046/j.1471-4159.2003.02062.x; Goold RG, 2001, J CELL SCI, V114, P4273; Goold RG, 1999, J CELL SCI, V112, P3373; Gordon-Weeks PR, 2000, MICROSC RES TECHNIQ, V48, P63, DOI 10.1002/(SICI)1097-0029(20000115)48:2<63::AID-JEMT2>3.0.CO;2-1; Grenningloh G, 2004, J NEUROBIOL, V58, P60, DOI 10.1002/neu.10279; Gu YJ, 2000, J BIOL CHEM, V275, P17917, DOI 10.1074/jbc.C000179200; Hisata S, 2007, J CELL BIOL, V178, P843, DOI 10.1083/jcb.200610073; Horton AC, 2005, NEURON, V48, P757, DOI 10.1016/j.neuron.2005.11.005; Horton AC, 2003, NEURON, V40, P277, DOI 10.1016/S0896-6273(03)00629-9; Horton AC, 2004, NAT CELL BIOL, V6, P585, DOI 10.1038/ncb0704-585; Huang EJ, 2001, ANNU REV NEUROSCI, V24, P677, DOI 10.1146/annurev.neuro.24.1.677; Iglesias T, 2000, J BIOL CHEM, V275, P40048, DOI 10.1074/jbc.M005261200; Jacobson C, 2006, NEURON, V49, P797, DOI 10.1016/j.neuron.2006.02.005; Johnstone M, 1997, J NEUROCHEM, V69, P1417; Kaech S, 2006, NAT PROTOC, V1, P2406, DOI 10.1038/nprot.2006.356; Klein R, 2004, CURR OPIN CELL BIOL, V16, P580, DOI 10.1016/j.ceb.2004.07.002; Kong HY, 2001, J NEUROSCI, V21, P176, DOI 10.1523/JNEUROSCI.21-01-00176.2001; Larsson N, 1997, MOL CELL BIOL, V17, P5530, DOI 10.1128/MCB.17.9.5530; Li Y, 1996, J NEUROSCI, V16, P531; LICHTENBERGKRAAG B, 1992, P NATL ACAD SCI USA, V89, P5384, DOI 10.1073/pnas.89.12.5384; Liljedahl M, 2001, CELL, V104, P409, DOI 10.1016/S0092-8674(01)00228-8; Lopez-Menendez C, 2009, J CELL SCI, V122, P3554, DOI 10.1242/jcs.056473; Luo S, 2005, J CELL BIOL, V169, P813, DOI 10.1083/jcb.200412008; MACCIONI RB, 1995, PHYSIOL REV, V75, P835, DOI 10.1152/physrev.1995.75.4.835; Marklund U, 1996, EMBO J, V15, P5290, DOI 10.1002/j.1460-2075.1996.tb00914.x; Martinez A, 2005, BRAIN RES REV, V49, P211, DOI 10.1016/j.brainresrev.2005.02.001; Matthews SA, 1999, J BIOL CHEM, V274, P26543, DOI 10.1074/jbc.274.37.26543; Meixner A, 2000, J CELL BIOL, V151, P1169, DOI 10.1083/jcb.151.6.1169; Morii H, 2006, J NEUROBIOL, V66, P1101, DOI 10.1002/neu.20295; Ohkawa N, 2007, J CELL SCI, V120, P1447, DOI 10.1242/jcs.001461; Owen R, 2003, MOL CELL NEUROSCI, V23, P626, DOI 10.1016/S1044-7431(03)00095-2; Ozon S, 1997, EUR J BIOCHEM, V248, P794, DOI 10.1111/j.1432-1033.1997.t01-2-00794.x; Pasquale EB, 2005, NAT REV MOL CELL BIO, V6, P462, DOI 10.1038/nrm1662; Poulain FE, 2008, J NEUROSCI, V28, P7387, DOI 10.1523/JNEUROSCI.1942-08.2008; Poulain FE, 2007, MOL CELL NEUROSCI, V34, P137, DOI 10.1016/j.mcn.2006.10.012; POULAIN FE, 2009, MOL CELL NE IN PRESS; Prigozhina NL, 2004, CURR BIOL, V14, P88, DOI 10.1016/j.cub.2004.01.003; Reichardt LF, 2006, PHILOS T R SOC B, V361, P1545, DOI 10.1098/rstb.2006.1894; RIEDERER B, 1986, J NEUROCYTOL, V15, P763, DOI 10.1007/BF01625193; Riederer BM, 2007, BRAIN RES BULL, V71, P541, DOI 10.1016/j.brainresbull.2006.11.012; Rozengurt E, 2005, J BIOL CHEM, V280, P13205, DOI 10.1074/jbc.R500002200; Sanchez C, 2000, PROG NEUROBIOL, V61, P133, DOI 10.1016/S0301-0082(99)00046-5; Sanchez-Ruiloba L, 2006, J BIOL CHEM, V281, P18888, DOI 10.1074/jbc.M603044200; Takei Y, 1997, J CELL BIOL, V137, P1615, DOI 10.1083/jcb.137.7.1615; Trivedi N, 2005, J CELL SCI, V118, P993, DOI 10.1242/jcs.01697; Van Lint J, 2002, TRENDS CELL BIOL, V12, P193, DOI 10.1016/S0962-8924(02)02262-6; Watabe-Uchida M, 2006, NEURON, V51, P727, DOI 10.1016/j.neuron.2006.07.020; Witte H, 2008, J CELL BIOL, V180, P619, DOI 10.1083/jcb.200707042; Woods AJ, 2004, EMBO J, V23, P2531, DOI 10.1038/sj.emboj.7600267; Wu SH, 2009, DEV NEUROBIOL, V69, P547, DOI 10.1002/dneu.20723; Ye B, 2006, J NEUROSCI, V26, P10631, DOI 10.1523/JNEUROSCI.3271-06.2006; Yeaman C, 2004, NAT CELL BIOL, V6, P106, DOI 10.1038/ncb1090; Yin DM, 2008, J NEUROSCI, V28, P8832, DOI 10.1523/JNEUROSCI.1291-08.2008; Yoshimura T, 2005, CELL, V120, P137, DOI 10.1016/j.cell.2004.11.012; Zhou FQ, 2006, PHILOS T R SOC B, V361, P1575, DOI 10.1098/rstb.2006.1882	96	46	47	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 8	2010	285	2					1343	1357		10.1074/jbc.M109.024703	http://dx.doi.org/10.1074/jbc.M109.024703			15	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	539MH	19903810	hybrid, Green Published			2022-12-25	WOS:000273258200055
J	Hong, EH; Lee, SJ; Kim, JS; Lee, KH; Um, HD; Kim, JH; Kim, SJ; Kim, JI; Hwang, SG				Hong, Eun-Hee; Lee, Su-Jae; Kim, Jae-Sung; Lee, Kee-Ho; Um, Hong-Duck; Kim, Jae-Hong; Kim, Song-Ja; Kim, Jong-Il; Hwang, Sang-Gu			Ionizing Radiation Induces Cellular Senescence of Articular Chondrocytes via Negative Regulation of SIRT1 by p38 Kinase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED PROTEIN-KINASE; OXIDATIVE STRESS; PREMATURE SENESCENCE; HUMAN-CELLS; TRANSCRIPTION FACTORS; ENDOTHELIAL-CELLS; GROWTH ARREST; BETA-CATENIN; CYCLE ARREST; MAP KINASES	Radiotherapy is increasingly used in the treatment of joint diseases, but limited information is available on the effects of radiation on cartilage. Here, we characterize the molecular mechanisms leading to cellular senescence in irradiated primary cultured articular chondrocytes. Ionizing radiation (IR) causes activation of ERK, in turn generating intracellular reactive oxygen species (ROS) with induction of senescence-associated beta-galactosidase (SA-beta-gal) activity. ROS activate p38 kinase, which further promotes ROS generation, forming a positive feedback loop to sustain ROS-p38 kinase signaling. The ROS inhibitors, nordihydroguaiaretic acid and GSH, suppress phosphorylation of p38 and cell numbers positive for SA-beta-gal following irradiation. Moreover, inhibition of the ERK and p38 kinase pathways leads to blockage of IR-induced SA-beta-gal activity via reduction of ROS generation. Although JNK is activated by ROS, this pathway is not associated with cellular senescence of chondrocytes. Interestingly, IR triggers down-regulation of SIRT1 protein expression but not the transcript level, indicative of post-transcriptional cleavage of the protein. SIRT1 degradation is markedly blocked by SB203589 or MG132 after IR treatment, suggesting that cleavage occurs as a result of binding with p38 kinase, followed by processing via the 26 S proteasomal degradation pathway. Overexpression or activation of SIRT1 significantly reduces the IR-induced senescence phenotype, whereas inhibition of SIRT1 activity induces senescence. Based on these findings, we propose that IR induces cellular senescence of articular chondrocytes by negative post-translational regulation of SIRT1 via ROS-dependent p38 kinase activation.	[Hwang, Sang-Gu] Korea Inst Radiol & Med Sci, Div Radiat Canc Res, Seoul 139706, South Korea; [Lee, Su-Jae] Hanyang Univ, Coll Nat Sci, Dept Chem, Seoul 133791, South Korea; [Kim, Jae-Hong] Korea Univ, Grad Sch Biotechnol, Seoul 136701, South Korea; [Kim, Song-Ja] Kongju Natl Univ, Coll Nat Sci, Dept Biol Sci, Kong Ju 314701, South Korea; [Kim, Jong-Il] Seoul Womens Univ, Coll Nat Sci, Dept Food & Microbial Technol, Seoul 139774, South Korea	Korea Institute of Radiological & Medical Sciences; Hanyang University; Korea University; Kongju National University; Seoul Women's University	Hwang, SG (corresponding author), Korea Inst Radiol & Med Sci, Div Radiat Canc Res, 215-4 Gongneung Dong, Seoul 139706, South Korea.	sgh63@kcch.re.kr	Kim, Jae-Hong/B-2530-2009; Um, Hong-Duk/AAH-3733-2021	Kim, Jae-Hong/0000-0002-8019-0208; 	Korea Research Foundation [KRF-2005-041-C00344]; Korean Government	Korea Research Foundation(National Research Foundation of Korea); Korean Government(Korean Government)	This work was supported by the Korea Research Foundation Grant KRF-2005-041-C00344 and a Nuclear Research and Development Program of the Korea Science and Engineering Foundation grant funded by the Korean Government.	Aberle H, 1997, EMBO J, V16, P3797, DOI 10.1093/emboj/16.13.3797; Aigner T, 2002, CURR OPIN RHEUMATOL, V14, P578, DOI 10.1097/00002281-200209000-00018; Bardwell L, 2006, METHODS, V40, P213, DOI 10.1016/j.ymeth.2006.06.008; Breusing N, 2008, BIOL CHEM, V389, P203, DOI 10.1515/BC.2008.029; Brunet A, 2004, SCIENCE, V303, P2011, DOI 10.1126/science.1094637; Chang CI, 2002, MOL CELL, V9, P1241, DOI 10.1016/S1097-2765(02)00525-7; Chen JH, 2005, DNA REPAIR, V4, P1140, DOI 10.1016/j.dnarep.2005.06.003; Clutton SM, 1996, CARCINOGENESIS, V17, P1633, DOI 10.1093/carcin/17.8.1633; Cohen HY, 2004, SCIENCE, V305, P390, DOI 10.1126/science.1099196; Damron TA, 2004, J HISTOCHEM CYTOCHEM, V52, P157, DOI 10.1177/002215540405200203; Damron TA, 2003, J BONE JOINT SURG AM, V85A, P1302, DOI 10.2106/00004623-200307000-00017; Dantuma NP, 2002, FEBS LETT, V529, P22, DOI 10.1016/S0014-5793(02)03252-0; DIMRI GP, 1995, P NATL ACAD SCI USA, V92, P9363, DOI 10.1073/pnas.92.20.9363; Ford J, 2008, CELL CYCLE, V7, P3091, DOI 10.4161/cc.7.19.6799; GOLDWEIN JW, 1991, CLIN ORTHOP RELAT R, P101; Guyton KZ, 1996, J BIOL CHEM, V271, P4138, DOI 10.1074/jbc.271.7.3604; Han JH, 2007, TRENDS BIOCHEM SCI, V32, P364, DOI 10.1016/j.tibs.2007.06.007; Haq R, 2002, CANCER RES, V62, P5076; Hekimi S, 2003, SCIENCE, V299, P1351, DOI 10.1126/science.1082358; Honore S, 2003, EXP CELL RES, V285, P59, DOI 10.1016/S0014-4827(02)00038-1; Hristov Borislav, 2007, J Natl Compr Canc Netw, V5, P456; Hwang SG, 2005, J BIOL CHEM, V280, P29780, DOI 10.1074/jbc.M411793200; Hwang SG, 2005, J BIOL CHEM, V280, P12758, DOI 10.1074/jbc.M413367200; Hwang SG, 2004, J BIOL CHEM, V279, P26597, DOI 10.1074/jbc.M401401200; Igrashi K, 2007, EXP CELL RES, V313, P3326, DOI 10.1016/j.yexcr.2007.06.001; Iordanov M, 1997, EMBO J, V16, P1009, DOI 10.1093/emboj/16.5.1009; Jung MS, 2004, J BIOL CHEM, V279, P17765, DOI 10.1074/jbc.M305015200; Kanaar R, 1998, TRENDS CELL BIOL, V8, P483, DOI 10.1016/S0962-8924(98)01383-X; KROLL SS, 1994, ANN SURG ONCOL, V1, P473, DOI 10.1007/BF02303612; Lee YJ, 2002, CELL GROWTH DIFFER, V13, P237; Luo JY, 2001, CELL, V107, P137, DOI 10.1016/S0092-8674(01)00524-4; MATSUMURA T, 1979, J GERONTOL, V34, P328, DOI 10.1093/geronj/34.3.328; Morales A, 1998, INT J RADIAT ONCOL, V42, P191, DOI 10.1016/S0360-3016(98)00185-0; Motta MC, 2004, CELL, V116, P551, DOI 10.1016/S0092-8674(04)00126-6; Narayanan PK, 1997, CANCER RES, V57, P3963; Nebreda AR, 2000, TRENDS BIOCHEM SCI, V25, P257, DOI 10.1016/S0968-0004(00)01595-4; Oh CW, 2001, RADIAT RES, V156, P232, DOI 10.1667/0033-7587(2001)156[0232:IOASLP]2.0.CO;2; Ono K, 2000, CELL SIGNAL, V12, P1, DOI 10.1016/S0898-6568(99)00071-6; Ota H, 2007, J MOL CELL CARDIOL, V43, P571, DOI 10.1016/j.yjmcc.2007.08.008; Pateder DB, 2002, RADIAT RES, V157, P62, DOI 10.1667/0033-7587(2002)157[0062:ROPIPR]2.0.CO;2; Patel SL, 2008, DRUG-EDUC PREV POLIC, V15, P37, DOI 10.1080/09687630601138691; Picard F, 2004, NATURE, V429, P771, DOI 10.1038/nature02583; Podtcheko A, 2005, THYROID, V15, P306, DOI 10.1089/thy.2005.15.306; Reverte CG, 2001, DEV BIOL, V231, P447, DOI 10.1006/dbio.2001.0153; ROBERTSON WW, 1991, J PEDIATR ORTHOPED, V11, P284; ROGERS S, 1986, SCIENCE, V234, P364, DOI 10.1126/science.2876518; Sedelnikova OA, 2004, NAT CELL BIOL, V6, P168, DOI 10.1038/ncb1095; Serrano M, 1997, CELL, V88, P593, DOI 10.1016/S0092-8674(00)81902-9; Sharrocks AD, 2000, TRENDS BIOCHEM SCI, V25, P448, DOI 10.1016/S0968-0004(00)01627-3; Taher MM, 2000, PHOTOCHEM PHOTOBIOL, V71, P455, DOI 10.1562/0031-8655(2000)071<0455:ROTPAM>2.0.CO;2; Tateishi Y, 2008, BIOCHEM BIOPH RES CO, V366, P301, DOI 10.1016/j.bbrc.2007.11.039; Vaquero A, 2004, MOL CELL, V16, P93, DOI 10.1016/j.molcel.2004.08.031; Vaziri H, 2001, CELL, V107, P149, DOI 10.1016/S0092-8674(01)00527-X; Wang CG, 2006, NAT CELL BIOL, V8, P1025, DOI 10.1038/ncb1468; Wang WP, 2002, MOL CELL BIOL, V22, P3389, DOI 10.1128/MCB.22.10.3389-3403.2002; Wang XF, 2000, MOL CELL BIOL, V20, P4543, DOI 10.1128/MCB.20.13.4543-4552.2000; Xu H J, 1997, Adv Pharmacol, V40, P369, DOI 10.1016/S1054-3589(08)60145-3; Yeung F, 2004, EMBO J, V23, P2369, DOI 10.1038/sj.emboj.7600244; Yudoh K, 2005, ARTHRITIS RES THER, V7, pR380, DOI 10.1186/ar1499; Zhu JY, 1998, GENE DEV, V12, P2997, DOI 10.1101/gad.12.19.2997	60	124	134	0	15	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 8	2010	285	2					1283	1295		10.1074/jbc.M109.058628	http://dx.doi.org/10.1074/jbc.M109.058628			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	539MH	19887452	hybrid, Green Published			2022-12-25	WOS:000273258200050
J	Miwa, HE; Gerken, TA; Jamison, O; Tabak, LA				Miwa, Hazuki E.; Gerken, Thomas A.; Jamison, Oliver; Tabak, Lawrence A.			Isoform-specific O-Glycosylation of Osteopontin and Bone Sialoprotein by Polypeptide N-Acetylgalactosaminyltransferase-1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							N-ACETYLGALACTOSAMINYLTRANSFERASE FAMILY; MUCIN TANDEM REPEAT; UDP-GALNAC; POSTTRANSLATIONAL MODIFICATIONS; LECTIN DOMAINS; STRUCTURAL-CHARACTERIZATION; MASS-SPECTROMETRY; BINDING-SITE; AMINO-ACID; GLYCOPEPTIDE	Mucin-type O-glycan biosynthesis is regulated by the family of UDP-GalNAc polypeptide: N-acetylgalactosaminlytransfersases (ppGalNAcTs) that catalyzes the first step in the pathway by transferring GalNAc to Ser or Thr residues in a protein from the sugar donor UDP-GalNAc. Because not all Ser/Thr residues are glycosylated, rules must exist that signal which hydroyxamino acids acquire sugar. To date, no universal consensus signal has emerged. Therefore, strategies to deduce the subset of proteins that will be glycosylated by distinct ppGalNAcTs must be developed. Mucin-type O-glycoproteins are present abundantly in bone, where we found multiple ppGalNAcT isoforms, including ppGalNAcT-1, to be highly expressed. Thus, we compared glycoproteins expressed in wild-type and Galnt1-null mice to identify bone-associated proteins that were glycosylated in a ppGalNAcT-1-dependent manner. A reduction in the apparent molecular masses of two SIBLINGs (small integrin binding ligand N-linked glycoproteins), osteopontin (OPN) and bone sialoprotein (BSP) in the Galnt1-null mice relative to those of the wild-type was observed. Several synthetic peptides derived from OPN and BSP sequences were designed to include either known or predicted (in silico) glycosylation sites. In vitro glycosylation assays of these peptides with recombinant ppGalNAcT-1, ppGalNAcT-2, or ppGalNAcT-3 demonstrated that both SIBLINGs contained Thr/Ser residues that were preferentially glycosylated by ppGalNAcT-1. In addition, lysates prepared from wild-type, but not those from Galnt1-null derived osteoblasts, could glycosylate these peptides efficiently, suggesting that OPN and BSP contain sites that are specific for ppGalNAcT-1. Our study presents a novel and systematic approach for identification of isoform-specific substrates of the ppGalNAcT family and suggests ppGalNAcT-1 to be indispensable for O-glycosylation at specific sites of the bone glycoproteins OPN and BSP.	[Miwa, Hazuki E.; Tabak, Lawrence A.] NIDDK, Sect Biol Chem, NIH, Dept Hlth & Human Serv, Bethesda, MD 20892 USA; [Gerken, Thomas A.; Jamison, Oliver] Case Western Reserve Univ, Sch Med, WA Bernbaum Ctr Cyst Fibrosis Res, Dept Pediat, Cleveland, OH 44106 USA; [Gerken, Thomas A.; Jamison, Oliver] Case Western Reserve Univ, Sch Med, WA Bernbaum Ctr Cyst Fibrosis Res, Dept Biochem, Cleveland, OH 44106 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK); Case Western Reserve University; Case Western Reserve University	Tabak, LA (corresponding author), NIDDK, Sect Biol Chem, NIH, Dept Hlth & Human Serv, Bethesda, MD 20892 USA.	tabakl@mail.nih.gov			NIDDK [NCI-RO1CA-78834]; NATIONAL CANCER INSTITUTE [R01CA078834] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [ZIADK070012] Funding Source: NIH RePORTER	NIDDK(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))	This work was supported, in whole or in part, by the National Institutes of Health intramural program of NIDDK and Grant NCI-RO1CA-78834 (to T. A. G.).	ALBONE EF, 1994, J BIOL CHEM, V269, P16845; Bennett EP, 1999, J BIOL CHEM, V274, P25362, DOI 10.1074/jbc.274.36.25362; Chen YZ, 2008, BMC BIOINFORMATICS, V9, DOI 10.1186/1471-2105-9-101; Christensen B, 2005, BIOCHEM J, V390, P285, DOI 10.1042/BJ20050341; Christensen B, 2007, J BIOL CHEM, V282, P19463, DOI 10.1074/jbc.M703055200; Fedarko NS, 2004, FASEB J, V18, P734, DOI 10.1096/fj.03-0966fje; FISHER LW, 1987, J BIOL CHEM, V262, P9702; Fisher LW, 1995, ACTA ORTHOP SCAND, V66, P61, DOI 10.3109/17453679509157649; Fritz TA, 2006, J BIOL CHEM, V281, P8613, DOI 10.1074/jbc.M513590200; Fritz TA, 2004, P NATL ACAD SCI USA, V101, P15307, DOI 10.1073/pnas.0405657101; Gerken TA, 1998, J BIOL CHEM, V273, P26580, DOI 10.1074/jbc.273.41.26580; Gerken TA, 1997, J BIOL CHEM, V272, P9709; Gerken TA, 2006, J BIOL CHEM, V281, P32403, DOI 10.1074/jbc.M605149200; Gerken TA, 2008, GLYCOBIOLOGY, V18, P861, DOI 10.1093/glycob/cwn073; Guda K, 2009, P NATL ACAD SCI USA, V106, P12921, DOI 10.1073/pnas.0901454106; Hagen FK, 1997, J BIOL CHEM, V272, P13843, DOI 10.1074/jbc.272.21.13843; Ishijima M, 2001, J EXP MED, V193, P399, DOI 10.1084/jem.193.3.399; Jain A, 2008, BIOCHEMISTRY-US, V47, P5986, DOI 10.1021/bi800133n; Julenius K, 2005, GLYCOBIOLOGY, V15, P153, DOI 10.1093/glycob/cwh151; Keykhosravani M, 2005, BIOCHEMISTRY-US, V44, P6990, DOI 10.1021/bi050109p; Kingsley PD, 2000, GLYCOBIOLOGY, V10, P1317, DOI 10.1093/glycob/10.12.1317; Lu L, 2009, PEPTIDES, V30, P359, DOI 10.1016/j.peptides.2008.09.020; Malaval L, 2008, J EXP MED, V205, P1145, DOI 10.1084/jem.20071294; Midura RJ, 1996, GLYCOBIOLOGY, V6, P677, DOI 10.1093/glycob/6.7.677; MIDURA RJ, 1990, J BIOL CHEM, V265, P5285; Nehrke K, 1998, GLYCOBIOLOGY, V8, P367, DOI 10.1093/glycob/8.4.367; OCONNELL BC, 1993, ANAL BIOCHEM, V210, P423, DOI 10.1006/abio.1993.1219; Pe'er I, 2004, PROTEINS, V54, P20, DOI 10.1002/prot.10559; Perrine CL, 2009, J BIOL CHEM, V284, P20387, DOI 10.1074/jbc.M109.017236; Pratt MR, 2004, CHEM BIOL, V11, P1009, DOI 10.1016/j.chembiol.2004.05.009; Raman J, 2008, J BIOL CHEM, V283, P22942, DOI 10.1074/jbc.M803387200; Sasaki K., 2009, IPSJ T BIOINFORM, V2, P25, DOI DOI 10.2197/ipsjtbio.2.25; Seipert RR, 2009, J PROTEOME RES, V8, P493, DOI 10.1021/pr8007072; SORENSEN ES, 1995, PROTEIN SCI, V4, P2040, DOI 10.1002/pro.5560041009; Ten Hagen BG, 1998, J BIOL CHEM, V273, P27749; Ten Hagen KG, 1999, J BIOL CHEM, V274, P27867; Ten Hagen KG, 2001, J BIOL CHEM, V276, P17395, DOI 10.1074/jbc.M009638200; Tenno M, 2007, MOL CELL BIOL, V27, P8783, DOI 10.1128/MCB.01204-07; Tian E, 2007, J BIOL CHEM, V282, P606, DOI 10.1074/jbc.M606268200; Topaz O, 2004, NAT GENET, V36, P579, DOI 10.1038/ng1358; Tye CE, 2003, J BIOL CHEM, V278, P7949, DOI 10.1074/jbc.M211915200; Tye CE, 2005, J BIOL CHEM, V280, P13487, DOI 10.1074/jbc.M408923200; Wandall HH, 2007, GLYCOBIOLOGY, V17, P374, DOI 10.1093/glycob/cwl082; Wandall HH, 1997, J BIOL CHEM, V272, P23503, DOI 10.1074/jbc.272.38.23503; Wuttke M, 2001, J BIOL CHEM, V276, P36839, DOI 10.1074/jbc.M105689200; Yoshinao W, 2008, TRENDS GLYCOSCI GLYC, V20, P69; Yoshitake H, 1999, P NATL ACAD SCI USA, V96, P8156, DOI 10.1073/pnas.96.14.8156; Young WW, 2003, GLYCOBIOLOGY, V13, P549, DOI 10.1093/glycob/cwg062; Zaia J, 2001, BIOCHEMISTRY-US, V40, P12983, DOI 10.1021/bi010887r; Zara J, 1996, BIOCHEM BIOPH RES CO, V228, P38, DOI 10.1006/bbrc.1996.1613; Zhang LP, 2008, J BIOL CHEM, V283, P34076, DOI 10.1074/jbc.M804267200	51	32	32	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 8	2010	285	2					1208	1219		10.1074/jbc.M109.035436	http://dx.doi.org/10.1074/jbc.M109.035436			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	539MH	19880513	Green Published, hybrid			2022-12-25	WOS:000273258200043
J	Singh, AK; Kumar, RP; Pandey, N; Singh, N; Sinha, M; Bhushan, A; Kaur, P; Sharma, S; Singh, TP				Singh, Amit K.; Kumar, Ramasamy P.; Pandey, Nisha; Singh, Nagendra; Sinha, Mau; Bhushan, Asha; Kaur, Punit; Sharma, Sujata; Singh, Tej P.			Mode of Binding of the Tuberculosis Prodrug Isoniazid to Heme Peroxidases BINDING STUDIES AND CRYSTAL STRUCTURE OF BOVINE LACTOPEROXIDASE WITH ISONIAZID AT 2.7 angstrom RESOLUTION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ARTHROMYCES-RAMOSUS PEROXIDASE; ISONICOTINIC-ACID HYDRAZIDE; X-RAY CRYSTALLOGRAPHY; MYCOBACTERIUM-TUBERCULOSIS; SALICYLHYDROXAMIC-ACID; HORSERADISH-PEROXIDASE; HUMAN MYELOPEROXIDASE; CATALASE-PEROXIDASE; BENZHYDROXAMIC ACID; OXIDATIVE STRESS	Isoniazid (INH) is an anti-tuberculosis prodrug that is activated by mammalian lactoperoxidase and Mycobacterium tuberculosis catalase peroxidase (MtCP). We report here binding studies, an enzyme assay involving INH, and the crystal structure of the complex of bovine lactoperoxidase (LPO) with INH to illuminate binding properties and INH activation as well as the mode of diffusion and interactions together with a detailed structural and functional comparison with MtCP. The structure determination shows that isoniazid binds to LPO at the substrate binding site on the distal heme side. The substrate binding site is connected to the protein surface through a long hydrophobic channel. The acyl hydrazide moiety of isoniazid interacts with Phe(422) O, Gln(423) O-epsilon 1, and Phe(254) O. In this arrangement, pyridinyl nitrogen forms a hydrogen bond with a water molecule, W-1, which in turn forms three hydrogen bonds with Fe3+, His(109) N epsilon 2, and Gln(105) N-epsilon 2. The remaining two sides of isoniazid form hydrophobic interactions with the atoms of heme pyrrole ring A, C-beta and C-gamma atoms of Glu(258), and C-gamma and C-delta atoms of Arg(255). The binding studies indicate that INH binds to LPO with a value of 0.9 x 10(-6) M for the dissociation constant. The nitro blue tetrazolium reduction assay shows that INH is activated by the reaction of LPO-H2O2 with INH. This suggests that LPO can be used for INH activation. It also indicates that the conversion of INH into isonicotinoyl radical by LPO may be the cause of INH toxicity.	[Singh, Amit K.; Kumar, Ramasamy P.; Pandey, Nisha; Singh, Nagendra; Sinha, Mau; Bhushan, Asha; Kaur, Punit; Sharma, Sujata; Singh, Tej P.] All India Inst Med Sci, Dept Biophys, New Delhi 110029, India	All India Institute of Medical Sciences (AIIMS) New Delhi	Singh, TP (corresponding author), All India Inst Med Sci, Dept Biophys, Ansari Nagar, New Delhi 110029, India.	tpsingh.aiims@gmail.com	Ramasamy, Prem Kumar/I-6801-2019	Ramasamy, Prem Kumar/0000-0002-6555-8289; SINHA, MAU/0000-0003-3011-9160				Bertrand T, 2004, J BIOL CHEM, V279, P38991, DOI 10.1074/jbc.M402382200; BHAT TN, 1974, ACTA CRYSTALLOGR B, V30, P2921, DOI 10.1107/S0567740874008521; Blair-Johnson M, 2001, BIOCHEMISTRY-US, V40, P13990, DOI 10.1021/bi0111808; BORS W, 1978, PHOTOCHEM PHOTOBIOL, V28, P629, DOI 10.1111/j.1751-1097.1978.tb06982.x; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Cavalieri EL, 1997, P NATL ACAD SCI USA, V94, P10937, DOI 10.1073/pnas.94.20.10937; CHARLAND MB, 1995, SIGMAPLOT SCI; Davey CA, 1996, BIOCHEMISTRY-US, V35, P10967, DOI 10.1021/bi960577m; Davis IW, 2007, NUCLEIC ACIDS RES, V35, pW375, DOI 10.1093/nar/gkm216; DeLano W.L., 2002, PYMOL MOL GRAPHICS S; DEVI BG, 1975, BIOCHEM J, V149, P187, DOI 10.1042/bj1490187; DOERGE DR, 1994, CHEM RES TOXICOL, V7, P164, DOI 10.1021/tx00038a008; FERRARI RP, 1993, SPECTROCHIM ACTA A, V49, P1261, DOI 10.1016/0584-8539(93)80034-8; Gajhede M, 1997, NAT STRUCT BIOL, V4, P1032, DOI 10.1038/nsb1297-1032; Gerson C, 2000, AM J RESP CELL MOL, V22, P665, DOI 10.1165/ajrcmb.22.6.3980; Ghibaudi EM, 2000, REDOX REP, V5, P229, DOI 10.1179/135100000101535672; Henriksen A, 1998, BIOCHEMISTRY-US, V37, P8054, DOI 10.1021/bi980234j; IKEDASAITO M, 1991, J BIOL CHEM, V266, P3611; Itakura H, 1997, FEBS LETT, V412, P107, DOI 10.1016/S0014-5793(97)00751-5; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KIMURA S, 1988, PROTEINS, V3, P113, DOI 10.1002/prot.340030206; KUNISHIMA N, 1994, J MOL BIOL, V235, P331, DOI 10.1016/S0022-2836(05)80037-3; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; Metcalfe C, 2008, J BIOL CHEM, V283, P6193, DOI 10.1074/jbc.M707412200; METODIEWA D, 1989, BIOCHEM BIOPH RES CO, V160, P1183, DOI 10.1016/S0006-291X(89)80128-7; METODIEWA D, 1989, ARCH BIOCHEM BIOPHYS, V274, P601, DOI 10.1016/0003-9861(89)90475-X; Monzani E, 1997, BIOCHEMISTRY-US, V36, P1918, DOI 10.1021/bi961868y; Oakley GG, 1996, CHEM RES TOXICOL, V9, P1285, DOI 10.1021/tx960103o; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Pierattelli R, 2004, J BIOL CHEM, V279, P39000, DOI 10.1074/jbc.M402384200; POULOS TL, 1980, J BIOL CHEM, V255, P575; Ramachandran G N, 1968, Adv Protein Chem, V23, P283, DOI 10.1016/S0065-3233(08)60402-7; RAMAKRISHNA NVS, 1993, CHEM RES TOXICOL, V6, P837, DOI 10.1021/tx00036a013; Sawatdee S, 2006, MALAYS J PHARM SCI, V4, P43; Sharp KH, 2003, NAT STRUCT BIOL, V10, P303, DOI 10.1038/nsb913; Sheikh IA, 2009, J BIOL CHEM, V284, P14849, DOI 10.1074/jbc.M807644200; SHOEB HA, 1985, ANTIMICROB AGENTS CH, V27, P399, DOI 10.1128/AAC.27.3.399; Singh AK, 2009, BIOPHYS J, V96, P646, DOI 10.1016/j.bpj.2008.09.019; Singh AK, 2009, J BIOL CHEM, V284, P20311, DOI 10.1074/jbc.M109.010280; Singh AK, 2008, J MOL BIOL, V376, P1060, DOI 10.1016/j.jmb.2007.12.012; SIPE HJ, 1994, CARCINOGENESIS, V15, P2637, DOI 10.1093/carcin/15.11.2637; STEVENS FJ, 1987, MOL IMMUNOL, V24, P1055, DOI 10.1016/0161-5890(87)90073-3; Tsukamoto K, 1999, BIOCHEMISTRY-US, V38, P12558, DOI 10.1021/bi982925l; Welinder KG, 1992, CURR OPIN STRUC BIOL, V2, P388, DOI [DOI 10.1016/0959-440X(92)90230-5, 10.1016/0959-440x(92)90230-5]; Wijkstrom-Frei C, 2003, AM J RESP CELL MOL, V29, P206, DOI 10.1165/rcmb.2002-0152OC; ZENG J, 1992, J MOL BIOL, V226, P185, DOI 10.1016/0022-2836(92)90133-5; ZHANG HC, 1993, CAN J CHEM, V71, P1990, DOI 10.1139/v93-248; ZHANG Y, 1992, NATURE, V358, P591, DOI 10.1038/358591a0; Zhao XB, 2007, BIOCHEMISTRY-US, V46, P3161, DOI 10.1021/bi062218p	49	36	36	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 8	2010	285	2					1569	1576		10.1074/jbc.M109.060327	http://dx.doi.org/10.1074/jbc.M109.060327			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	539MH	19907057	Green Published, hybrid			2022-12-25	WOS:000273258200075
J	Xiao, YC; Xu, JW; Mao, CM; Jin, M; Wu, Q; Zou, J; Gu, QL; Zhang, Y; Zhang, YY				Xiao, Yichuan; Xu, Jingwei; Mao, Chaoming; Jin, Min; Wu, Qiong; Zou, Jie; Gu, Qiaoli; Zhang, Yi; Zhang, Yanyun			18 beta-Glycyrrhetinic Acid Ameliorates Acute Propionibacterium acnes-induced Liver Injury through Inhibition of Macrophage Inflammatory Protein-1 alpha	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DENDRITIC CELL PRECURSORS; FULMINANT HEPATIC-FAILURE; TOLL-LIKE RECEPTORS; NF-KAPPA-B; GLYCYRRHETINIC ACID; UP-REGULATION; TH1 RESPONSE; LYMPH-NODES; MYD88; ACTIVATION	18 beta-Glycyrrhetinic acid (GA), the major bioactive component of licorice root extract, has a protective effect on hepatic injury and exhibits antiinflammatory activity. Here, we investigate the effect of GA in Propionibacterium acnes-induced acute inflammatory liver injury. C57BL/6 mice were primed with P. acnes followed by lipopolysaccharide challenge to induce fulminant hepatitis. GA (75 mg/kg) or vehicle control was administered intraperitoneally daily 1 day after P. acnes priming, and GA significantly improved mouse mortality. Then, to investigate the underlying mechanisms of GA in this acute inflammatory liver injury model, we primed C57BL/6 mice with P. acnes only. We propose that GA ameliorates acute P. acnes-induced liver injury through reduced macrophage inflammatory protein (MIP)-1 alpha expression in Kupffer cells by down-regulating MyD88 expression and inhibiting NF-kappa B activation. Reduced MIP-1 alpha expression lowered the recruitment of CD11c(+)B22(-) dendritic cell precursors into the liver. Consequently, GA treatment inhibits the activation and proliferation of liver-infiltrating CD4(+) T cells and reduces the production of serum alanine aminotransferase and proinflammatory cytokines such as interferon-gamma and tumor necrosis factor-alpha. Moreover, anti-MIP-1 alpha treatment in P. acnes-primed mice inhibits the recruitment of dendritic cell precursors into the liver and suppresses mouse mortality as GA does. Taken together, our results suggest that GA exhibits antiinflammatory effects through inhibition of MIP-1 alpha in a mouse model of acute P. acnes-induced inflammatory liver injury.	[Xiao, Yichuan; Xu, Jingwei; Mao, Chaoming; Jin, Min; Wu, Qiong; Zou, Jie; Gu, Qiaoli; Zhang, Yanyun] Chinese Acad Sci, Key Lab Stem Cell Biol, Inst Hlth Sci, Shanghai Inst Biol Sci, Shanghai 200025, Peoples R China; [Xiao, Yichuan; Xu, Jingwei; Mao, Chaoming; Jin, Min; Wu, Qiong; Zou, Jie; Gu, Qiaoli; Zhang, Yanyun] SJTUSM, Shanghai Inst Immunol, Inst Med Sci, Shanghai 200025, Peoples R China; [Zhang, Yi] Univ Michigan, Dept Internal Med, Ann Arbor, MI 48109 USA	Chinese Academy of Sciences; Shanghai Institutes for Biological Sciences, CAS; Chinese Academy of Sciences; Shanghai Jiao Tong University; University of Michigan System; University of Michigan	Zhang, YY (corresponding author), Chinese Acad Sci, Key Lab Stem Cell Biol, Inst Hlth Sci, Shanghai Inst Biol Sci, 227 S Chongqing Rd, Shanghai 200025, Peoples R China.	yyzhang@sibs.ac.cn			Ministry of Science and Technology of China [2010CB945600, 2009ZX09503]; Chinese Academy of Sciences [KSCX1-YW-22]; National Natural Science Foundation of China [30670911, 30901317]; Shanghai Municipality Programs [074319102, 07JC14070]; Shanghai Municipal Education Commission [J50207]	Ministry of Science and Technology of China(Ministry of Science and Technology, China); Chinese Academy of Sciences(Chinese Academy of Sciences); National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Shanghai Municipality Programs; Shanghai Municipal Education Commission(Shanghai Municipal Education Commission (SHMEC))	This work was supported by the Ministry of Science and Technology of China 2010CB945600 and 2009ZX09503-24, Knowledge Innovation Project of The Chinese Academy of Sciences KSCX1-YW-22, National Natural Science Foundation of China 30670911 and 30901317, Science and Technology Commission of Shanghai Municipality Programs 074319102 and 07JC14070, and Leading Academic Discipline Project of Shanghai Municipal Education Commission J50207.	Bernhagen J, 2007, NAT MED, V13, P587, DOI 10.1038/nm1567; Debes GF, 2005, NAT IMMUNOL, V6, P889, DOI 10.1038/ni1238; Di Carlo G, 2001, TRENDS PHARMACOL SCI, V22, P292, DOI 10.1016/S0165-6147(00)01716-8; Dunne A, 2003, J BIOL CHEM, V278, P41443, DOI 10.1074/jbc.M301742200; Eisenbrand Gerhard, 2006, Mol Nutr Food Res, V50, P1087, DOI 10.1002/mnfr.200500278; Farina C, 1998, FARMACO, V53, P22, DOI 10.1016/S0014-827X(97)00013-X; He S, 2008, J LEUKOCYTE BIOL, V84, P1549, DOI 10.1189/jlb.0708420; HOOFNAGLE JH, 1995, HEPATOLOGY, V21, P240, DOI 10.1002/hep.1840210137; Hritz I, 2008, HEPATOLOGY, V48, P1342, DOI 10.1002/hep.22557; Jeong HG, 2002, PHARMACOL RES, V46, P221, DOI 10.1016/S1043-6618(02)00121-4; Juszczak GR, 2009, PROG NEURO-PSYCHOPH, V33, P181, DOI 10.1016/j.pnpbp.2008.12.014; Kang OH, 2005, INT J MOL MED, V15, P981; Kroes BH, 1997, IMMUNOLOGY, V90, P115, DOI 10.1046/j.1365-2567.1997.00131.x; Layland LE, 2005, EUR J IMMUNOL, V35, P3248, DOI 10.1002/eji.200526273; Lin G, 1999, TOXICON, V37, P1259, DOI 10.1016/S0041-0101(98)00263-3; Loiarro M, 2005, J BIOL CHEM, V280, P15809, DOI 10.1074/jbc.C400613200; Loiarro M, 2007, J LEUKOCYTE BIOL, V82, P801, DOI 10.1189/jlb.1206746; Lu JW, 2008, J HEPATOL, V48, P442, DOI 10.1016/j.jhep.2007.10.014; Matsuno K, 2000, INT REV CYTOL, V197, P83, DOI 10.1016/S0074-7696(00)97003-7; Mempel TR, 2004, NATURE, V427, P154, DOI 10.1038/nature02238; Nakayama Y, 2005, HEPATOLOGY, V42, P915, DOI 10.1002/hep.20872; PULFORD K, 1980, CLIN EXP IMMUNOL, V42, P67; Resto VA, 2008, J BIOL CHEM, V283, P15816, DOI 10.1074/jbc.M708899200; Romics L, 2004, HEPATOLOGY, V40, P555, DOI 10.1002/hep.20350; Rossi T, 2003, ANTICANCER RES, V23, P3813; Soriano ME, 2004, J BIOL CHEM, V279, P36803, DOI 10.1074/jbc.M405297200; Ukil A, 2005, J IMMUNOL, V175, P1161, DOI 10.4049/jimmunol.175.2.1161; Varrin-Doyer M, 2009, J BIOL CHEM, V284, P13265, DOI 10.1074/jbc.M807664200; Velayudham A, 2006, J HEPATOL, V45, P813, DOI 10.1016/j.jhep.2006.06.017; Wu XD, 2008, HEPATOLOGY, V47, P1905, DOI 10.1002/hep.22239; Yamamoto S, 2008, NAT MED, V14, P738, DOI 10.1038/nm1758; Yang BS, 2007, WORLD J GASTROENTERO, V13, P462, DOI 10.3748/wjg.v13.i3.462; Yoneyama H, 2001, J EXP MED, V193, P35, DOI 10.1084/jem.193.1.35; Yoneyama H, 2002, J EXP MED, V195, P1257, DOI 10.1084/jem.20011983; Zhang YY, 2004, JNCI-J NATL CANCER I, V96, P201, DOI 10.1093/jnci/djh024	35	40	46	0	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 8	2010	285	2					1128	1137		10.1074/jbc.M109.037705	http://dx.doi.org/10.1074/jbc.M109.037705			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	539MH	19897483	Green Published, hybrid			2022-12-25	WOS:000273258200035
J	Xiao, ZS; Zhang, SQ; Cao, L; Qiu, N; David, V; Quarles, LD				Xiao, Zhousheng; Zhang, Shiqin; Cao, Li; Qiu, Ni; David, Valentin; Quarles, L. Darryl			Conditional Disruption of Pkd1 in Osteoblasts Results in Osteopenia Due to Direct Impairment of Bone Formation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POLYCYSTIC KIDNEY-DISEASE; RENAL EPITHELIAL-CELLS; SIGNALING PATHWAY; GENE-PRODUCT; MICE; RECEPTOR; DIFFERENTIATION; SKELETOGENESIS; CYSTOGENESIS; EXPRESSION	PKD1 (polycystin-1), the disease-causing gene for ADPKD, is widely expressed in various cell types, including osteoblasts, where its function is unknown. Although global inactivation of Pkd1 in mice results in abnormal skeletal development, the presence of polycystic kidneys and perinatal lethality confound ascertaining the direct osteoblastic functions of PKD1 in adult bone. To determine the role of PKD1 in osteoblasts, we conditionally inactivated Pkd1 in postnatal mature osteoblasts by crossing Oc (osteocalcin)-Cre mice with floxed Pkd1 (Pkd1(flox/m1Bei)) mice to generate conditional heterozygous (Oc-Cre;Pkd1(flox/+)) and homozygous (Oc-Cre; Pkd1flox/m1Bei) Pkd1-deficient mice. Cre-mediated recombination (Pkd1(Delta flox)) occurred exclusively in bone. Compared with control mice, the conditional deletion of Pkd1 from osteoblasts resulted in a gene dose-dependent reduction in bone mineral density, trabecular bone volume, and cortical thickness. In addition, mineral apposition rates and osteoblast-related gene expression, including Runx2-II (Runt-related transcription factor 2), osteocalcin, osteopontin, and bone sialoprotein, were reduced proportionate to the reduction of Pkd1 gene dose in bone of Oc-Cre; Pkd1(flox/+) and Oc-Cre; Pkd1(flox/m1Bei) mice. Primary osteoblasts derived from Oc-Cre;Pkd1(flox/m1Bei) displayed impaired differentiation and suppressed activity of the phosphatidylinositdol 3-kinase-Akt-GSK3 beta-beta-catenin signaling pathways. The conditional deletion of Pkd1 also resulted in increased adipogenesis in bone marrow and in osteoblast cultures. Thus, PKD1 directly functions in osteoblasts to regulate bone formation.	[Xiao, Zhousheng; Zhang, Shiqin; Cao, Li; Qiu, Ni; David, Valentin; Quarles, L. Darryl] Univ Kansas, Med Ctr, Kidney Inst, Kansas City, KS 66160 USA	University of Kansas; University of Kansas Medical Center	Quarles, LD (corresponding author), Univ Kansas, Med Ctr, Kidney Inst, MS 3018,3901 Rainbow Blvd,6018 Wahl Hall E, Kansas City, KS 66160 USA.	dquarles@kumc.edu		Quarles, L. Darryl/0000-0002-5082-7896; xiao, zhousheng/0000-0002-3363-5673	National Institutes of Health [R01-AR049712, R21-AR056794]; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR049712, R21AR056794] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK083303] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))	This work was supported, in whole or in part, by National Institutes of Health Grants R01-AR049712 and R21-AR056794.	Aoki Koji, 2008, V468, P307, DOI 10.1007/978-1-59745-249-6_24; Boca M, 2007, MOL BIOL CELL, V18, P4050, DOI 10.1091/mbc.E07-02-0142; Boca M, 2006, J AM SOC NEPHROL, V17, P637, DOI 10.1681/ASN.2005050534; Boulter C, 2001, P NATL ACAD SCI USA, V98, P12174, DOI 10.1073/pnas.211191098; Chauvet V, 2002, AM J PATHOL, V160, P973, DOI 10.1016/S0002-9440(10)64919-X; David V, 2007, ENDOCRINOLOGY, V148, P2553, DOI 10.1210/en.2006-1704; DHARMARAJAN A, 2008, J MOL SIGNAL, V3, P10; Driscoll JA, 2008, CHEST, V133, P1181, DOI 10.1378/chest.07-2147; GABOW PA, 1993, NEW ENGL J MED, V329, P332, DOI 10.1056/NEJM199307293290508; Glass DA, 2005, DEV CELL, V8, P751, DOI 10.1016/j.devcel.2005.02.017; Hassane S, 2007, ARTERIOSCL THROM VAS, V27, P2177, DOI 10.1161/ATVBAHA.107.149252; Hou B, 2009, BONE, V44, P1121, DOI 10.1016/j.bone.2009.02.018; Housset C, 2005, GASTROEN CLIN BIOL, V29, P861, DOI 10.1016/S0399-8320(05)86361-4; Iwaniec UT, 2007, J BONE MINER RES, V22, P394, DOI 10.1359/JBMR.061118; Jensen CG, 2004, CELL BIOL INT, V28, P101, DOI 10.1016/j.cellbi.2003.11.007; Kawamura N, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0001058; Kim D, 2006, STEM CELLS, V24, P1798, DOI 10.1634/stemcells.2005-0480; Kim E, 1999, J BIOL CHEM, V274, P4947, DOI 10.1074/jbc.274.8.4947; Klein RF, 2004, SCIENCE, V303, P229, DOI 10.1126/science.1090985; Kolpakova-Hart E, 2008, DEV BIOL, V321, P407, DOI 10.1016/j.ydbio.2008.07.005; Kolpakova-Hart E, 2008, MATRIX BIOL, V27, P505, DOI 10.1016/j.matbio.2008.05.002; Kugimiya F, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0000837; Lantinga-van Leeuwen IS, 2006, GENESIS, V44, P225, DOI 10.1002/dvg.20207; Li Q, 2006, J BIOL CHEM, V281, P37566, DOI 10.1074/jbc.M603643200; Lian J B, 1995, Iowa Orthop J, V15, P118; Lu WN, 2001, HUM MOL GENET, V10, P2385, DOI 10.1093/hmg/10.21.2385; Mukherjee A, 2009, J CELL SCI, V122, P716, DOI 10.1242/jcs.042770; Nuttall ME, 2000, BONE, V27, P177, DOI 10.1016/S8756-3282(00)00317-3; Peczkowska M, 2004, BLOOD PRESSURE, V13, P283, DOI 10.1080/08037050410016492; Piontek KB, 2004, J AM SOC NEPHROL, V15, P3035, DOI 10.1097/01.ASN.0000144204.01352.86; Piontek K, 2007, NAT MED, V13, P1490, DOI 10.1038/nm1675; Qian F, 2002, P NATL ACAD SCI USA, V99, P16981, DOI 10.1073/pnas.252484899; Raucci A, 2008, J CELL PHYSIOL, V215, P442, DOI 10.1002/jcp.21323; Rocha VZ, 2008, CIRC RES, V103, P467, DOI 10.1161/CIRCRESAHA.108.177105; Takaoki Muneo, 2004, Biol Sci Space, V18, P181; Torra R, 1999, AM J HUM GENET, V65, P345, DOI 10.1086/302501; TURCO AE, 1993, J MED GENET, V30, P419, DOI 10.1136/jmg.30.5.419; vanDijk MA, 1995, J AM SOC NEPHROL, V6, P1670; Watnick TJ, 1998, MOL CELL, V2, P247, DOI 10.1016/S1097-2765(00)80135-5; Weimbs T, 2007, AM J PHYSIOL-RENAL, V293, pF1423, DOI 10.1152/ajprenal.00275.2007; Westendorf JJ, 2004, GENE, V341, P19, DOI 10.1016/j.gene.2004.06.044; Wilson PD, 1999, LAB INVEST, V79, P1311; Wilson PD, 2004, NEW ENGL J MED, V350, P151, DOI 10.1056/NEJMra022161; Xiao ZS, 2008, J BIOL CHEM, V283, P12624, DOI 10.1074/jbc.M710407200; Xiao ZS, 2006, J BIOL CHEM, V281, P30884, DOI 10.1074/jbc.M604772200; Xiao ZS, 2005, DEV BIOL, V283, P345, DOI 10.1016/j.ydbio.2005.04.028; Xiao ZS, 2004, J BIOL CHEM, V279, P20307, DOI 10.1074/jbc.M401109200; Xu H, 2001, DNA SEQUENCE, V12, P361, DOI 10.3109/10425170109084460; Yamaguchi T, 2004, J BIOL CHEM, V279, P40419, DOI 10.1074/jbc.M405079200; Zhang M, 2002, J BIOL CHEM, V277, P44005, DOI 10.1074/jbc.M208265200	50	47	47	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 8	2010	285	2					1177	1187		10.1074/jbc.M109.050906	http://dx.doi.org/10.1074/jbc.M109.050906			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	539MH	19887454	Green Published, hybrid			2022-12-25	WOS:000273258200040
J	Lakshmikuttyamma, A; Scott, SA; DeCoteau, JF; Geyer, CR				Lakshmikuttyamma, A.; Scott, S. A.; DeCoteau, J. F.; Geyer, C. R.			Reexpression of epigenetically silenced AML tumor suppressor genes by SUV39H1 inhibition	ONCOGENE			English	Article						p15INK4B; SUV39H1; chaetocin; histone methylation; DNA methylation	HISTONE METHYLTRANSFERASE SUV39H1; ACUTE MYELOID-LEUKEMIA; DNA METHYLATION; DEACETYLASE INHIBITION; CPG ISLAND; E-CADHERIN; HETEROCHROMATIN FORMATION; LYSINE-9 METHYLATION; POOR-PROGNOSIS; PROMOTER DNA	Reexpression of hypermethylated tumor suppressor genes using DNA methyltransferase (DNMT) and histone deacetylase inhibitors occurs by a mechanism whereby promoter demethylation is the dominant event. In support of this model, we found in acute myeloid leukemia cells with hypermethylated p15INK4B and E-cadherin promoters that the DNMT inhibitor, 5-aza-20-deoxycytidine, induced p15INK4B and E-cadherin expression, and decreased levels of DNA methylation, histone H3 lysine 9 (H3K9) methylation and SUV39H1 associated with p15INK4B and E-cadherin promoters. On the basis of these observations, we examined whether promoter demethylation was dominant to H3K9 demethylation in p15INK4B and E-cadherin reexpression. We observed that SUV39H1 short hairpin RNA and chaetocin, a SUV39H1 inhibitor, induced p15INK4B and E-cadherin expression and H3K9 demethylation without promoter demethylation. Reexpression of hypermethylated p15INK4B and E-cadherin required histone H3K9 demethylation that was achieved directly by inhibiting SUV39H1 expression or activity, or indirectly by decreasing the amount of SUV39H1 associated with the p15INK4B and E-cadherin promoters using 5-aza-20-deoxycytidine. The results from this study highlight the potential of H3K9 methyltransferases as therapeutic targets for reactivating expression of hypermethylated genes. Oncogene (2010) 29, 576-588; doi: 10.1038/onc.2009.361; published online 2 November 2009	[Geyer, C. R.] Univ Saskatchewan, Dept Pathol, Saskatchewan Canc Agcy, Canc Stem Cell Res Grp, Saskatoon, SK S7N 4H4, Canada; [Geyer, C. R.] Univ Saskatchewan, Dept Biochem, Saskatoon, SK S7N 4H4, Canada	University of Saskatchewan; University of Saskatchewan	Geyer, CR (corresponding author), Univ Saskatchewan, Dept Pathol, Saskatchewan Canc Agcy, Canc Stem Cell Res Grp, 20 Campus Dr, Saskatoon, SK S7N 4H4, Canada.	ron.geyer@usask.ca	Lakshmikuttyamma, Ashakumary/K-7164-2019	Lakshmikuttyamma, Ashakumary/0000-0001-8580-7855; Scott, Stuart/0000-0001-5720-1864	Canadian Institutes of Health Research; Canada Foundation for Innovation; Saskatchewan Health Research Foundation	Canadian Institutes of Health Research(Canadian Institutes of Health Research (CIHR)); Canada Foundation for Innovation(Canada Foundation for InnovationCGIAR); Saskatchewan Health Research Foundation	This work was supported by grants from the Canadian Institutes of Health Research, Canada Foundation for Innovation, and the Saskatchewan Health Research Foundation. CRG is a CIHR-RPP New Investigator. AL is a Rethink Breast Cancer PDF.	Bachman KE, 2003, CANCER CELL, V3, P89, DOI 10.1016/S1535-6108(02)00234-9; Bannister AJ, 2001, NATURE, V410, P120, DOI 10.1038/35065138; Baylin Stephen B, 2005, Nat Clin Pract Oncol, V2 Suppl 1, pS4, DOI 10.1038/ncponc0354; Bird A, 2002, GENE DEV, V16, P6, DOI 10.1101/gad.947102; Boultwood J, 2007, BRIT J HAEMATOL, V138, P3, DOI 10.1111/j.1365-2141.2007.06604.x; Cameron EE, 1999, NAT GENET, V21, P103, DOI 10.1038/5047; Carbone R, 2006, MOL CELL BIOL, V26, P1288, DOI 10.1128/MCB.26.4.1288-1296.2006; Cattaneo F, 2008, J CELL BIOCHEM, V105, P344, DOI 10.1002/jcb.21869; Chakraborty S, 2003, ONCOGENE, V22, P5229, DOI 10.1038/sj.onc.1206600; Christiansen DH, 2003, LEUKEMIA, V17, P1813, DOI 10.1038/sj.leu.2403054; Coombes MM, 2003, ONCOGENE, V22, P8902, DOI 10.1038/sj.onc.1207050; Dodge JE, 2001, LEUKEMIA RES, V25, P917, DOI 10.1016/S0145-2126(01)00053-4; Egger G, 2004, NATURE, V429, P457, DOI 10.1038/nature02625; Egger G, 2007, CANCER RES, V67, P346, DOI 10.1158/0008-5472.CAN-06-2845; Fahrner JA, 2002, CANCER RES, V62, P7213; Fujita N, 2003, J BIOL CHEM, V278, P24132, DOI 10.1074/jbc.M302283200; Fuks F, 2005, CURR OPIN GENET DEV, V15, P490, DOI 10.1016/j.gde.2005.08.002; Fuks F, 2003, NUCLEIC ACIDS RES, V31, P2305, DOI 10.1093/nar/gkg332; Fuks F, 2003, J BIOL CHEM, V278, P4035, DOI 10.1074/jbc.M210256200; Galm O, 2006, BLOOD REV, V20, P1, DOI 10.1016/j.blre.2005.01.006; Gilbert J, 2004, CLIN CANCER RES, V10, P4589, DOI 10.1158/1078-0432.CCR-03-0297; Gore SD, 2006, CANCER RES, V66, P6361, DOI 10.1158/0008-5472.CAN-06-0080; Gore Steven D, 2005, Nat Clin Pract Oncol, V2 Suppl 1, pS30, DOI 10.1038/ncponc0346; Greiner D, 2005, NAT CHEM BIOL, V1, P143, DOI 10.1038/nchembio721; Guldberg P, 2002, METHODS, V27, P121, DOI 10.1016/S1046-2023(02)00063-4; Herman JG, 1996, CANCER RES, V56, P722; Herman JG, 1997, CANCER RES, V57, P837; Herman JG, 2003, NEW ENGL J MED, V349, P2042, DOI 10.1056/NEJMra023075; Herman JG, 1996, P NATL ACAD SCI USA, V93, P9821, DOI 10.1073/pnas.93.18.9821; Issa Jean-Pierre, 2003, Current Opinion in Oncology, V15, P446, DOI 10.1097/00001622-200311000-00007; Jang H, 2007, J BIOL CHEM, V282, P11172, DOI 10.1074/jbc.M611199200; Jiemjit A, 2008, ONCOGENE, V27, P3615, DOI 10.1038/sj.onc.1211018; Kamoi K, 2006, RETROVIROLOGY, V3, DOI 10.1186/1742-4690-3-5; Kondo Y, 2003, MOL CELL BIOL, V23, P206, DOI 10.1128/MCB.23.1.206-215.2003; Kurokawa M, 1998, NATURE, V394, P92, DOI 10.1038/27945; Lachner M, 2001, NATURE, V410, P116, DOI 10.1038/35065132; Lehnertz B, 2003, CURR BIOL, V13, P1192, DOI 10.1016/S0960-9822(03)00432-9; Li YH, 2002, P NATL ACAD SCI USA, V99, P16462, DOI 10.1073/pnas.162371699; Liu YN, 2005, ONCOGENE, V24, P8277, DOI 10.1038/sj.onc.1208991; Macaluso M, 2003, ONCOGENE, V22, P3511, DOI 10.1038/sj.onc.1206578; Mal AK, 2006, EMBO J, V25, P3323, DOI 10.1038/sj.emboj.7601229; McGarvey KM, 2007, CANCER RES, V67, P5097, DOI 10.1158/0008-5472.CAN-06-2029; Melki JR, 2000, BLOOD, V95, P3208; Melki JR, 1999, CANCER RES, V59, P3730; Mutskov V, 2004, EMBO J, V23, P138, DOI 10.1038/sj.emboj.7600013; Narita M, 2003, CELL, V113, P703, DOI 10.1016/S0092-8674(03)00401-X; Nguyen CT, 2002, CANCER RES, V62, P6456; Nicolas E, 2003, MOL CELL BIOL, V23, P1614, DOI 10.1128/MCB.23.5.1614-1622.2003; Nielsen AL, 2001, MOL CELL, V7, P729, DOI 10.1016/S1097-2765(01)00218-0; Nielsen SJ, 2001, NATURE, V412, P561, DOI 10.1038/35087620; Ogawa M, 2007, LEUKEMIA RES, V31, P611, DOI 10.1016/j.leukres.2006.09.023; Pastural E, 2007, ONCOGENE, V26, P1586, DOI 10.1038/sj.onc.1209959; Peters AHFM, 2001, CELL, V107, P323, DOI 10.1016/S0092-8674(01)00542-6; PFEIFER GP, 1990, P NATL ACAD SCI USA, V87, P8252, DOI 10.1073/pnas.87.21.8252; Preisler HD, 2001, LEUKEMIA, V15, P1589, DOI 10.1038/sj.leu.2402211; Pruitt K, 2006, PLOS GENET, V2, P344, DOI 10.1371/journal.pgen.0020040; Rea S, 2000, NATURE, V406, P593, DOI 10.1038/35020506; Rice JC, 2003, MOL CELL, V12, P1591, DOI 10.1016/S1097-2765(03)00479-9; Scott SA, 2006, LEUKEMIA RES, V30, P69, DOI 10.1016/j.leukres.2005.05.010; Scott SA, 2007, EXP HEMATOL, V35, P263, DOI 10.1016/j.exphem.2006.10.005; Shimamoto T, 2005, LEUKEMIA RES, V29, P653, DOI 10.1016/j.leukres.2004.11.014; Spensberger D, 2008, FEBS LETT, V582, P2761, DOI 10.1016/j.febslet.2008.06.056; Suzuki H, 2002, NAT GENET, V31, P141, DOI 10.1038/ng892; Tachibana M, 2002, GENE DEV, V16, P1779, DOI 10.1101/gad.989402; Teofili L, 2003, LEUKEMIA, V17, P919, DOI 10.1038/sj.leu.2402907; Tost J, 2007, NAT PROTOC, V2, P2265, DOI 10.1038/nprot.2007.314; Vandel L, 2001, MOL CELL BIOL, V21, P6484, DOI 10.1128/MCB.21.19.6484-6494.2001; Wozniak RJ, 2007, ONCOGENE, V26, P77, DOI 10.1038/sj.onc.1209763; Wu R, 2005, MOL BIOL CELL, V16, P2872, DOI 10.1091/mbc.e04-11-0997; Yu WQ, 2008, NATURE, V451, P202, DOI 10.1038/nature06468; Zhang C, 2007, J PATHOL, V212, P134, DOI 10.1002/path.2173; Zinn RL, 2007, CANCER RES, V67, P194, DOI 10.1158/0008-5472.CAN-06-3396	72	84	92	1	15	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN	2010	29	4					576	588		10.1038/onc.2009.361	http://dx.doi.org/10.1038/onc.2009.361			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	549WH	19881540				2022-12-25	WOS:000274084600010
J	De Schutter, J; Guillabert, A; Imbault, V; Degraef, C; Erneux, C; Communi, D; Pirson, I				De Schutter, Julie; Guillabert, Aude; Imbault, Virginie; Degraef, Chantal; Erneux, Christophe; Communi, David; Pirson, Isabelle			SHIP2 (SH2 Domain-containing Inositol Phosphatase 2) SH2 Domain Negatively Controls SHIP2 Monoubiquitination in Response to Epidermal Growth Factor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							UBIQUITIN-INTERACTING MOTIFS; PHOSPHATIDYLINOSITOL 3,4,5-TRISPHOSPHATE; POLYPHOSPHATE 5-PHOSPHATASE; LIPID PHOSPHATASE; ADAPTER PROTEIN; C-CBL; TYROSINE PHOSPHORYLATION; BINDING DOMAINS; EGF RECEPTOR; STIMULATION	The SH2 domain containing inositol 5-phosphatase SHIP2 contains several interacting domains that are important for scaffolding properties. We and others have previously reported that SHIP2 interacts with the E3 ubiquitin ligase c-Cbl. Here, we identified human SHIP2 monoubiquitination on lysine 315. SHIP2 could also be polyubiquitinated but was not degraded by the 26 S proteasome. Furthermore, we identified a ubiquitin-interacting motif at the C-terminal end of SHIP2 that confers ubiquitin binding capacity. However, this ubiquitin-interacting motif is dispensable for its monoubiquitination. We showed that neither c-Cbl nor Nedd4-1 play the role of ubiquitin ligase for SHIP2. Strikingly, monoubiquitination of the Delta SH2-SHIP2 mutant (lacking the N-terminal SH2 domain) is strongly increased, suggesting an intrinsic inhibitory effect of the SHIP2 SH2 domain on its monoubiquitination. Moreover, SHIP2 monoubiquitination was increased upon 30 min of epidermal growth factor stimulation. This correlates with the loss of interaction between the SHIP2 SH2 domain and c-Cbl. In this model, c-Cbl could mask the monoubiquitination site and thereby prevent SHIP2 monoubiquitination. The present study thus reveals an unexpected and novel role of SHIP2 SH2 domain in the regulation of its newly identified monoubiquitination.	[De Schutter, Julie; Guillabert, Aude; Imbault, Virginie; Degraef, Chantal; Erneux, Christophe; Communi, David; Pirson, Isabelle] Free Univ Brussels, Sch Med, Inst Interdisciplinary Res, B-1070 Brussels, Belgium	Universite Libre de Bruxelles; Vrije Universiteit Brussel	Pirson, I (corresponding author), Free Univ Brussels, Sch Med, Inst Interdisciplinary Res, Campus Erasme,Bldg C,Route Lenn 808, B-1070 Brussels, Belgium.	ilpirson@ulb.ac.be			National Fund for Scientific Research (FNRS); Fonds pour la formation a Recherche clans l'Industrie et dans l'Agriculture; Televie, Brussels, Belgium	National Fund for Scientific Research (FNRS)(Fonds de la Recherche Scientifique - FNRS); Fonds pour la formation a Recherche clans l'Industrie et dans l'Agriculture(Fonds de la Recherche Scientifique - FNRS); Televie, Brussels, Belgium	This work was supported by a grant from the National Fund for Scientific Research (FNRS), Fonds pour la formation a Recherche clans l'Industrie et dans l'Agriculture, and Televie, Brussels, Belgium.	Aberle H, 1997, EMBO J, V16, P3797, DOI 10.1093/emboj/16.13.3797; Batty IH, 2007, BIOCHEM J, V407, P255, DOI 10.1042/BJ20070558; BAYKOV AA, 1988, ANAL BIOCHEM, V171, P266, DOI 10.1016/0003-2697(88)90484-8; Bienko M, 2005, SCIENCE, V310, P1821, DOI 10.1126/science.1120615; Blero D, 2001, BIOCHEM BIOPH RES CO, V282, P839, DOI 10.1006/bbrc.2001.4639; Campo PA, 2002, CELL GROWTH DIFFER, V13, P409; Clement S, 2001, NATURE, V409, P92, DOI 10.1038/35051094; Communi D, 2001, J BIOL CHEM, V276, P38738, DOI 10.1074/jbc.M105640200; Desterro JMP, 1998, MOL CELL, V2, P233, DOI 10.1016/S1097-2765(00)80133-1; Di Fiore PP, 2003, NAT REV MOL CELL BIO, V4, P491, DOI 10.1038/nrm1124; Drayer AL, 1996, BIOCHEM SOC T, V24, P1001, DOI 10.1042/bst0241001; Dyson JM, 2001, J CELL BIOL, V155, P1065, DOI 10.1083/jcb.200104005; Fisher RD, 2003, J BIOL CHEM, V278, P28976, DOI 10.1074/jbc.M302596200; Fouladkou F, 2008, P NATL ACAD SCI USA, V105, P8585, DOI 10.1073/pnas.0803233105; Giuriato S, 2003, BIOCHEM J, V376, P199, DOI 10.1042/BJ20030581; Habib T, 1998, J BIOL CHEM, V273, P18605, DOI 10.1074/jbc.273.29.18605; Hall AB, 2003, CURR BIOL, V13, P308, DOI 10.1016/S0960-9822(03)00086-1; Hicke L, 2005, NAT REV MOL CELL BIO, V6, P610, DOI 10.1038/nrm1701; Hicke L, 2001, CELL, V106, P527, DOI 10.1016/S0092-8674(01)00485-8; Hoege C, 2002, NATURE, V419, P135, DOI 10.1038/nature00991; Hoeller D, 2006, NAT CELL BIOL, V8, P163, DOI 10.1038/ncb1354; Hoeller D, 2007, MOL CELL, V26, P891, DOI 10.1016/j.molcel.2007.05.014; Hofmann K, 2001, TRENDS BIOCHEM SCI, V26, P347, DOI 10.1016/S0968-0004(01)01835-7; Hurley JH, 2006, BIOCHEM J, V399, P361, DOI 10.1042/BJ20061138; Ishihara H, 1999, BIOCHEM BIOPH RES CO, V260, P265, DOI 10.1006/bbrc.1999.0888; Joazeiro CAP, 1999, SCIENCE, V286, P309, DOI 10.1126/science.286.5438.309; Kalesnikoff J, 2004, REV PHYSIOL BIOCH P, V149, P87, DOI 10.1007/s10254-003-0016-y; Klapisz E, 2002, J BIOL CHEM, V277, P30746, DOI 10.1074/jbc.M203004200; Lee PSW, 1999, EMBO J, V18, P3616, DOI 10.1093/emboj/18.13.3616; Levkowitz G, 1998, GENE DEV, V12, P3663, DOI 10.1101/gad.12.23.3663; Li MY, 2003, SCIENCE, V302, P1972, DOI 10.1126/science.1091362; Lohrum MAE, 2001, MOL CELL BIOL, V21, P8521, DOI 10.1128/MCB.21.24.8521-8532.2001; McCrea HJ, 2009, PHYSIOLOGY, V24, P8, DOI 10.1152/physiol.00035.2008; Miller SLH, 2004, J BIOL CHEM, V279, P33528, DOI 10.1074/jbc.M313097200; Miyake S, 1998, P NATL ACAD SCI USA, V95, P7927, DOI 10.1073/pnas.95.14.7927; Muraille E, 2000, IMMUNOL LETT, V72, P7, DOI 10.1016/S0165-2478(00)00162-0; Muraille E, 1999, BIOCHEM J, V342, P697, DOI 10.1042/0264-6021:3420697; Oldham CE, 2002, CURR BIOL, V12, P1112, DOI 10.1016/S0960-9822(02)00900-4; Onnockx S, 2008, J CELL PHYSIOL, V214, P260, DOI 10.1002/jcp.21193; Ooms LM, 2009, BIOCHEM J, V419, P29, DOI 10.1042/BJ20081673; Paternotte N, 2005, FEBS J, V272, P6052, DOI 10.1111/j.1742-4658.2005.04996.x; Penengo L, 2006, CELL, V124, P1183, DOI 10.1016/j.cell.2006.02.020; Pesesse X, 1997, BIOCHEM BIOPH RES CO, V239, P697, DOI 10.1006/bbrc.1997.7538; Pesesse X, 2001, J BIOL CHEM, V276, P28348, DOI 10.1074/jbc.M103537200; Polo S, 2002, NATURE, V416, P451, DOI 10.1038/416451a; POLO S, 2003, SCI STKE, pRE17, DOI DOI 10.1126/STKE.2132003RE17; Prasad N, 2001, MOL CELL BIOL, V21, P1416, DOI 10.1128/MCB.21.4.1416-1428.2001; Prasad NK, 2008, CARCINOGENESIS, V29, P25, DOI 10.1093/carcin/bgm213; Prasad NK, 2009, BIOCHEMISTRY-US, V48, P6285, DOI 10.1021/bi900492d; Prasad NK, 2005, J BIOL CHEM, V280, P13129, DOI 10.1074/jbc.M410289200; Raaijmakers JH, 2007, CELL SIGNAL, V19, P1249, DOI 10.1016/j.cellsig.2006.12.015; Sanada F, 2009, HYPERTENSION, V53, P77, DOI 10.1161/HYPERTENSIONAHA.108.120725; Shevchenko A, 1996, ANAL CHEM, V68, P850, DOI 10.1021/ac950914h; SHIRAKI K, 1991, J GEN VIROL, V72, P1393, DOI 10.1099/0022-1317-72-6-1393; Sleeman MW, 2005, NAT MED, V11, P199, DOI 10.1038/nm1178; Soubeyran P, 2003, BIOCHEM J, V370, P29, DOI 10.1042/BJ20021539; Taylor V, 2000, MOL CELL BIOL, V20, P6860, DOI 10.1128/MCB.20.18.6860-6871.2000; Trotman LC, 2007, CELL, V128, P141, DOI 10.1016/j.cell.2006.11.040; vanDelft S, 1997, J CELL BIOL, V136, P811, DOI 10.1083/jcb.136.4.811; Vandenbroere I, 2003, BIOCHEM BIOPH RES CO, V300, P494, DOI 10.1016/S0006-291X(02)02894-2; Vandeput F, 2006, CELL SIGNAL, V18, P2193, DOI 10.1016/j.cellsig.2006.05.010; Wada T, 2001, MOL CELL BIOL, V21, P1633, DOI 10.1128/MCB.21.5.1633-1646.2001; Wang XJ, 2008, BIOCHEM J, V414, P221, DOI 10.1042/BJ20080674; Wang XJ, 2007, CELL, V128, P129, DOI 10.1016/j.cell.2006.11.039; Wang Y, 1996, J BIOL CHEM, V271, P17, DOI 10.1074/jbc.271.1.17; Wang YJ, 2004, J IMMUNOL, V173, P6820, DOI 10.4049/jimmunol.173.11.6820; Weissman AM, 2001, NAT REV MOL CELL BIO, V2, P169, DOI 10.1038/35056563; Woelk T, 2006, NAT CELL BIOL, V8, P1246, DOI 10.1038/ncb1484; Wu RC, 2007, CELL, V129, P1125, DOI 10.1016/j.cell.2007.04.039; Xie JW, 2008, CELL SIGNAL, V20, P1432, DOI 10.1016/j.cellsig.2008.03.010; Yang CK, 2008, BMC MOL BIOL, V9, DOI 10.1186/1471-2199-9-12; Zhuang GL, 2007, J BIOL CHEM, V282, P2683, DOI 10.1074/jbc.M608509200	72	12	13	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 25	2009	284	52					36062	36076		10.1074/jbc.M109.064923	http://dx.doi.org/10.1074/jbc.M109.064923			15	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	535LT	19880507	Green Published, hybrid			2022-12-25	WOS:000272970500008
J	Lazebnik, MB; Tussie-Luna, MI; Hinds, PW; Roy, AL				Lazebnik, Maria B.; Tussie-Luna, Maria Isabel; Hinds, Philip W.; Roy, Ananda L.			Williams-Beuren Syndrome-associated Transcription Factor TFII-I Regulates Osteogenic Marker Genes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							OSTEOBLAST DIFFERENTIATION; EMBRYONIC-DEVELOPMENT; CLEIDOCRANIAL DYSPLASIA; RETINOBLASTOMA PROTEIN; INITIATOR ELEMENT; BONE-FORMATION; EXPRESSION; BETA; CBFA1; COMPLEXES	Williams-Beuren syndrome (WBS), an autosomal dominant genetic disorder, is characterized by a unique cognitive profile and craniofacial defects. WBS results from a microdeletion at the chromosomal location 7q11.23 that encompasses the genes encoding the members of TFII-I family of transcription factors. Given that the haploinsufficiency for TFII-I is causative to the craniofacial phenotype in humans, we set out to analyze the effect of post-transcriptional silencing of TFII-I during BMP-2-driven osteoblast differentiation in the C2C12 cell line. Our results show that TFII-I plays an inhibitory role in regulating genes that are essential in osteogenesis and intersects with the bone-specific transcription factor Runx2 and the retinoblastoma protein, pRb. Identification of pathways regulated by TFII-I family transcription factors may begin to shed light on the molecular determinants of WBS.	[Lazebnik, Maria B.; Hinds, Philip W.; Roy, Ananda L.] Tufts Univ, Sch Med, Genet Program, Boston, MA 02111 USA; [Roy, Ananda L.] Tufts Univ, Sch Med, Program Immunol, Boston, MA 02111 USA; [Tussie-Luna, Maria Isabel; Roy, Ananda L.] Tufts Univ, Sch Med, Dept Pathol, Boston, MA 02111 USA; [Hinds, Philip W.] Tufts Med Ctr, Mol Oncol Res Inst, Boston, MA 02111 USA	Tufts University; Tufts University; Tufts University; Tufts Medical Center	Hinds, PW (corresponding author), Tufts Univ, Sch Med, Genet Program, Boston, MA 02111 USA.	phinds@tuftsmedicalcenter.org; ananda.roy@tufts.edu		Tussie-Luna, Maria Isabel/0000-0002-5033-408X	National Institutes of Health [AG020208, HD04603]; NATIONAL INSTITUTE ON AGING [R01AG020208] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))	This work was supported, in whole or in part, by National Institutes of Health Grants AG020208 (to P. H.) and HD04603 (to A. L. R.)	Asahina I, 1996, EXP CELL RES, V222, P38, DOI 10.1006/excr.1996.0005; Banerjee C, 1997, J CELL BIOCHEM, V66, P1, DOI 10.1002/(SICI)1097-4644(19970701)66:1<1::AID-JCB1>3.0.CO;2-V; Cheriyath V, 2002, J BIOL CHEM, V277, P22798, DOI 10.1074/jbc.M202956200; Cheriyath V, 1998, MOL CELL BIOL, V18, P4444, DOI 10.1128/MCB.18.8.4444; Choi JY, 2001, P NATL ACAD SCI USA, V98, P8650, DOI 10.1073/pnas.151236498; Crusselle-Davis VJ, 2007, FEBS J, V274, P6065, DOI 10.1111/j.1742-4658.2007.06128.x; Crusselle-Davis VJ, 2006, MOL CELL BIOL, V26, P6832, DOI 10.1128/MCB.01770-05; Desgranges ZP, 2005, MOL CELL BIOL, V25, P10940, DOI 10.1128/MCB.25.24.10940-10952.2005; DUCY P, 1995, MOL CELL BIOL, V15, P1858; Ducy P, 1997, CELL, V89, P747, DOI 10.1016/S0092-8674(00)80257-3; Ducy P, 1999, GENE DEV, V13, P1025, DOI 10.1101/gad.13.8.1025; Enkhmandakh B, 2009, P NATL ACAD SCI USA, V106, P181, DOI 10.1073/pnas.0811531106; Fujita T, 2004, J CELL BIOL, V166, P85, DOI 10.1083/jcb.200401138; Gagliardi C, 2003, J MED GENET, V40, P526, DOI 10.1136/jmg.40.7.526; Grueneberg DA, 1997, GENE DEV, V11, P2482, DOI 10.1101/gad.11.19.2482; Hakre S, 2006, MOL CELL, V24, P301, DOI 10.1016/j.molcel.2006.09.005; Hinsley TA, 2004, PROTEIN SCI, V13, P2588, DOI 10.1110/ps.04747604; Hirota H, 2003, GENET MED, V5, P311, DOI 10.1097/01.GIM.0000076975.10224.67; Hong M, 2005, J BIOL CHEM, V280, P16821, DOI 10.1074/jbc.M413753200; Jurado LAP, 1998, HUM MOL GENET, V7, P325, DOI 10.1093/hmg/7.3.325; KATAGIRI T, 1994, J CELL BIOL, V127, P1755, DOI 10.1083/jcb.127.6.1755; Komori T, 1997, CELL, V89, P755, DOI 10.1016/S0092-8674(00)80258-5; Lazebnik MB, 2008, J BIOL CHEM, V283, P11078, DOI 10.1074/jbc.C800049200; Lee JS, 2006, J BONE MINER RES, V21, P921, DOI 10.1359/JBMR.060303; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; Morris CA, 2003, AM J MED GENET A, V123A, P45, DOI 10.1002/ajmg.a.20496; Ogura Y, 2006, GENES CELLS, V11, P373, DOI 10.1111/j.1365-2443.2006.00952.x; Otto F, 1997, CELL, V89, P765, DOI 10.1016/S0092-8674(00)80259-7; Peng Y, 2004, J BIOL CHEM, V279, P32941, DOI 10.1074/jbc.M403344200; Roy AL, 2001, GENE, V274, P1, DOI 10.1016/S0378-1119(01)00625-4; Tassabehji M, 2005, SCIENCE, V310, P1184, DOI 10.1126/science.1116142; Thomas DM, 2001, MOL CELL, V8, P303, DOI 10.1016/S1097-2765(01)00327-6; Tiemann F, 1998, EMBO J, V17, P1040, DOI 10.1093/emboj/17.4.1040; Tussie-Luna MI, 2002, P NATL ACAD SCI USA, V99, P12807, DOI 10.1073/pnas.192464499; van Wijnen AJ, 2004, ONCOGENE, V23, P4209, DOI 10.1038/sj.onc.1207758; Young EJ, 2008, GENES BRAIN BEHAV, V7, P224, DOI 10.1111/j.1601-183X.2007.00343.x; Zhou G, 1999, HUM MOL GENET, V8, P2311, DOI 10.1093/hmg/8.12.2311; Zhou G, 2006, P NATL ACAD SCI USA, V103, P19004, DOI 10.1073/pnas.0605170103	38	15	15	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 25	2009	284	52					36234	36239		10.1074/jbc.C109.063115	http://dx.doi.org/10.1074/jbc.C109.063115			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	535LT	19880526	Green Published, hybrid			2022-12-25	WOS:000272970500025
J	Wang, MJ; Lin, SK				Wang, Ming Jen; Lin, Shankung			A Region within the 5 '-Untranslated Region of Hypoxia-inducible Factor-1 alpha mRNA Mediates Its Turnover in Lung Adenocarcinoma Cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRACT-BINDING-PROTEIN; FACTOR 1-ALPHA; TUMOR PROGRESSION; EXPRESSION; ANGIOGENESIS; TRANSLATION; SELECTION; INVASION; HIF-1; PTB	Previously, we showed that CL1-5 cells express more hypoxia-inducible factor-1 alpha (HIF-1 alpha) than the parental CL1 cells, which bestows CL1-5 cells a stronger invasive activity. Here, we investigated the mechanisms underlying the differential expression of HIF-1 alpha mRNA in CL1 and CL1-5 cells. Data showed that the transcription rate of HIF-1 alpha gene in CL1 cells was slightly higher than that of CL1-5 cells, suggesting that the expression of HIF-1 alpha mRNA in CL1 cells was repressed by post-transcriptional mechanisms. RNA electrophoretic mobility shift assays revealed a 61-base segment (designated as D5) within the 5'-untranslated repeat of HIF-1 alpha mRNA, with which the CL1 cell lysates formed more prominent complexes (including complex I) than did CL1-5 cell lysates. Insertion of D5 into a reporter construct reduced the half-life of the chimeric transcripts in transfected CL1 but not CL1-5 cells; conversely, overexpression of D5-containing reporter construct in CL1 cells increased HIF-1 alpha mRNA. We also identified the polypyrimidine tract-binding protein (PTB) as a required component of complex I. Deletion of the RNA recognition motif 1 (RRM1) or RRM3 of PTB abolished the formation of complex I. Our data showed that CL1 cells expressed more PTB than CL1-5 cells. Inhibition of PTB expression in CL1 cells decreased the formation of complex I, whereas overexpression of PTB in CL1-5 cells increased the levels of complex I, decreased the stability of HIF-1 alpha and D5-containing chimeric mRNAs, and decreased cell invasiveness. In sum, we have identified in lung adenocarcinoma cells a mechanism that regulates HIF-1 alpha expression by modulating HIF-1 alpha mRNA stability.	[Wang, Ming Jen; Lin, Shankung] Natl Hlth Res Inst, Inst Cellular & Syst Med, Zhunan 35053, Miaoli County, Taiwan	National Health Research Institutes - Taiwan	Lin, SK (corresponding author), Natl Hlth Res Inst, Inst Cellular & Syst Med, 35 Keyan Rd, Zhunan 35053, Miaoli County, Taiwan.	shankung@nhri.org.tw	Lin, Shan-Kung/B-1062-2010		National Science Council of Taiwan [92-2320-B-341-002]	National Science Council of Taiwan(Ministry of Science and Technology, Taiwan)	This work was supported by the National Science Council (Grant 92-2320-B-341-002 to S. L.) of Taiwan.	Auweter SD, 2008, CELL MOL LIFE SCI, V65, P516, DOI 10.1007/s00018-007-7378-2; Blagosklonny MV, 1999, BIOESSAYS, V21, P704, DOI 10.1002/(SICI)1521-1878(199908)21:8<704::AID-BIES10>3.0.CO;2-5; Chandel NS, 2000, J BIOL CHEM, V275, P25130, DOI 10.1074/jbc.M001914200; Chu YW, 1997, AM J RESP CELL MOL, V17, P353, DOI 10.1165/ajrcmb.17.3.2837; FIDLER IJ, 1994, CELL, V79, P185, DOI 10.1016/0092-8674(94)90187-2; Galban S, 2008, MOL CELL BIOL, V28, P93, DOI 10.1128/MCB.00973-07; Graeber TG, 1996, NATURE, V379, P88, DOI 10.1038/379088a0; Guillemin K, 1997, CELL, V89, P9, DOI 10.1016/S0092-8674(00)80176-2; Iyer NV, 1998, GENOMICS, V52, P159, DOI 10.1006/geno.1998.5416; Jiang BH, 1997, CANCER RES, V57, P5328; Jiang BH, 1996, AM J PHYSIOL-CELL PH, V271, pC1172, DOI 10.1152/ajpcell.1996.271.4.C1172; Kosinski PA, 2003, J IMMUNOL, V170, P979, DOI 10.4049/jimmunol.170.2.979; Krishnamachary B, 2003, CANCER RES, V63, P1138; Lang KJD, 2002, MOL BIOL CELL, V13, P1792, DOI 10.1091/mbc.02-02-0017; Lin SK, 2000, MOL CELL BIOL, V20, P7903, DOI 10.1128/MCB.20.21.7903-7913.2000; Maxwell PH, 1999, NATURE, V399, P271, DOI 10.1038/20459; Pautz A, 2006, J BIOL CHEM, V281, P32294, DOI 10.1074/jbc.M603915200; Schepens B, 2005, NUCLEIC ACIDS RES, V33, P6884, DOI 10.1093/nar/gki1000; Semenza GL, 2001, CURR OPIN CELL BIOL, V13, P167, DOI 10.1016/S0955-0674(00)00194-0; Semenza GL, 2000, CRIT REV BIOCHEM MOL, V35, P71, DOI 10.1080/10409230091169186; Shyu KG, 2007, EXP CELL RES, V313, P1181, DOI 10.1016/j.yexcr.2007.01.013; Tillmar L, 2002, MOL MED, V8, P263, DOI 10.1007/BF03402152; Wenger RH, 1997, BIOL CHEM, V378, P609; Xu MG, 2007, BIOL REPROD, V76, P1025, DOI 10.1095/biolreprod.107.060079; YANG PC, 1992, AM J RESP CELL MOL, V7, P161, DOI 10.1165/ajrcmb/7.2.161; Zagzag D, 2000, CANCER-AM CANCER SOC, V88, P2606, DOI 10.1002/1097-0142(20000601)88:11<2606::AID-CNCR25>3.0.CO;2-W; Zhong H, 1999, CANCER RES, V59, P5830; Zhong H, 2000, CANCER RES, V60, P1541	28	15	17	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 25	2009	284	52					36500	36510		10.1074/jbc.M109.008904	http://dx.doi.org/10.1074/jbc.M109.008904			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	535LT	19887373	Green Published, hybrid			2022-12-25	WOS:000272970500052
J	Troy, TC; Arabzadeh, A; Lariviere, NMK; Enikanolaiye, A; Turksen, K				Troy, Tammy-Claire; Arabzadeh, Azadeh; Lariviere, Nathalie M. K.; Enikanolaiye, Adebola; Turksen, Kursad			Dermatitis and Aging-Related Barrier Dysfunction in Transgenic Mice Overexpressing an Epidermal-Targeted Claudin 6 Tail Deletion Mutant	PLOS ONE			English	Article							PERMEABILITY BARRIER; CYTOPLASMIC TAIL; SKIN; DIFFERENTIATION; EXPRESSION; ABNORMALITIES; COMPLEXES; JUNCTIONS; PROTEINS	The barrier function of the skin protects the mammalian body against infection, dehydration, UV irradiation and temperature fluctuation. Barrier function is reduced with the skin's intrinsic aging process, however the molecular mechanisms involved are unknown. We previously demonstrated that Claudin (Cldn)-containing tight junctions (TJs) are essential in the development of the epidermis and that transgenic mice overexpressing Cldn6 in the suprabasal layers of the epidermis undergo a perturbed terminal differentiation program characterized in part by reduced barrier function. To dissect further the mechanisms by which Cldn6 acts during epithelial differentiation, we overexpressed a Cldn6 cytoplasmic tail deletion mutant in the suprabasal compartment of the transgenic mouse epidermis. Although there were no gross phenotypic abnormalities at birth, subtle epidermal anomalies were present that disappeared by one month of age, indicative of a robust injury response. However, with aging, epidermal changes with eventual chronic dermatitis appeared with a concomitant barrier dysfunction manifested in increased trans-epidermal water loss. Immunohistochemical analysis revealed aberrant suprabasal Cldn localization with marked down-regulation of Cldn1. Both the proliferative and terminal differentiation compartments were perturbed as evidenced by mislocalization of multiple epidermal markers. These results suggest that the normally robust injury response mechanism of the epidermis is lost in the aging Involucrin-Cldn6-C Delta 196 transgenic epidermis, and provide a model for evaluation of aging-related skin changes.			Troy, TC (corresponding author), Ottawa Hosp, Res Inst, Sprott Ctr Stem Cell Res, Ottawa, ON, Canada.	kturksen@ohri.ca	Enikanolaiye, Adebola/AAM-9443-2020		Canadian Institutes of Health Research [MOP 84464] Funding Source: Medline	Canadian Institutes of Health Research(Canadian Institutes of Health Research (CIHR))		Arabzadeh A, 2008, J INVEST DERMATOL, V128, P237, DOI 10.1038/sj.jid.5700966; Arabzadeh A, 2006, MOL CELL BIOL, V26, P5876, DOI 10.1128/MCB.02342-05; Arabzadeh A, 2007, BMC CANCER, V7, DOI 10.1186/1471-2407-7-196; Assemat E, 2008, BBA-BIOMEMBRANES, V1778, P614, DOI 10.1016/j.bbamem.2007.08.029; Barland CO, 2004, J INVEST DERMATOL, V122, P330, DOI 10.1046/j.0022-202X.2004.22203.x; Byrne C, 2004, METH MOL B, V289, P127; Cartlidge P, 2000, Semin Neonatol, V5, P273, DOI 10.1053/siny.2000.0013; Chiba H, 2008, BBA-BIOMEMBRANES, V1778, P588, DOI 10.1016/j.bbamem.2007.08.017; DAVIES A, 2008, BR J COMMUNITY NURS, V13, P254; DAVIES A, 2008, BR J COMMUNITY NURS, V13, P252; Davies Ann, 2008, Br J Community Nurs, V13, P254; Elias PM, 2008, J LIPID RES, V49, P697, DOI 10.1194/jlr.R800002-JLR200; Elias PM, 2005, J INVEST DERMATOL, V125, P183, DOI 10.1111/j.0022-202X.2005.23668.x; Elias PM, 2002, CLIN GERIATR MED, V18, P103, DOI 10.1016/S0749-0690(03)00037-5; FARQUHAR MG, 1963, J CELL BIOL, V17, P375, DOI 10.1083/jcb.17.2.375; Fuchs E, 2002, NAT REV GENET, V3, P199, DOI 10.1038/nrg758; FUCHS E, 1994, CURR OPIN GENET DEV, V4, P725, DOI 10.1016/0959-437X(94)90140-X; Fuchs E, 2007, NATURE, V445, P834, DOI 10.1038/nature05659; Furuse M, 2002, J CELL BIOL, V156, P1099, DOI 10.1083/jcb.200110122; Ghadially R, 1998, Am J Contact Dermat, V9, P162, DOI 10.1016/S1046-199X(98)90019-7; GHADIALLY R, 1995, J CLIN INVEST, V95, P2281, DOI 10.1172/JCI117919; Gonzalez-Mariscal L, 2003, PROG BIOPHYS MOL BIO, V81, P1, DOI 10.1016/S0079-6107(02)00037-8; Hardman MJ, 1999, J INVEST DERMATOL, V113, P1106, DOI 10.1046/j.1523-1747.1999.00800.x; Hardman MJ, 1998, DEVELOPMENT, V125, P1541; Heiskala M, 2001, TRAFFIC, V2, P92, DOI 10.1034/j.1600-0854.2001.020203.x; HOHL D, 1991, J BIOL CHEM, V266, P6626; Ivanov AI, 2004, MOL BIOL CELL, V15, P2639, DOI 10.1091/mbc.E04-02-0163; Ivanov AI, 2008, FRONT BIOSCI-LANDMRK, V13, P6662, DOI 10.2741/3180; Katoh M, 2003, INT J MOL MED, V11, P683; Kligman L H, 1989, Clin Geriatr Med, V5, P235; Koval M, 2006, CELL COMMUN ADHES, V13, P127, DOI 10.1080/15419060600726209; Krause G, 2008, BBA-BIOMEMBRANES, V1778, P631, DOI 10.1016/j.bbamem.2007.10.018; LEIGH IM, 1995, BRIT J DERMATOL, V133, P501, DOI 10.1111/j.1365-2133.1995.tb02696.x; Mack Judith A., 2005, Birth Defects Research, V75, P314, DOI 10.1002/bdrc.20055; Makrantonaki E, 2007, ANN NY ACAD SCI, V1119, P40, DOI 10.1196/annals.1404.027; McGowan K, 1998, Subcell Biochem, V31, P173; McGowan KM, 1998, J CELL BIOL, V143, P469, DOI 10.1083/jcb.143.2.469; Miyoshi J, 2008, BBA-BIOMEMBRANES, V1778, P670, DOI 10.1016/j.bbamem.2007.12.014; Paris L, 2008, BBA-BIOMEMBRANES, V1778, P646, DOI 10.1016/j.bbamem.2007.08.004; Pouillot Anne, 2008, J Cosmet Dermatol, V7, P143, DOI 10.1111/j.1473-2165.2008.00379.x; Roh MH, 2003, AM J PHYSIOL-RENAL, V285, pF377, DOI 10.1152/ajprenal.00086.2003; Ruffer C, 2004, EUR J CELL BIOL, V83, P135, DOI 10.1078/0171-9335-00366; Simard A, 2006, MECH DEVELOP, V123, P210, DOI 10.1016/j.mod.2005.12.004; Troy TC, 2007, MOL BIOTECHNOL, V36, P166, DOI 10.1007/s12033-007-0027-z; Troy TC, 2007, GENE EXPR PATTERNS, V7, P423, DOI 10.1016/j.modgep.2006.11.006; Troy TC, 2005, MECH DEVELOP, V122, P805, DOI 10.1016/j.mod.2005.03.001; Troy TC, 2005, DEV DYNAM, V232, P293, DOI 10.1002/dvdy.20223; Turksen K, 2004, J CELL SCI, V117, P2435, DOI 10.1242/jcs.01235; Turksen K, 1998, BIOCHEM CELL BIOL, V76, P889, DOI 10.1139/bcb-76-6-889; Turksen K, 2002, DEVELOPMENT, V129, P1775; Van Itallie CM, 2005, J CELL SCI, V118, P1427, DOI 10.1242/jcs.01735; Ward Sue, 2005, Br J Community Nurs, V10, P453; Williams M L, 1998, J Investig Dermatol Symp Proc, V3, P75	53	15	15	0	0	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	NOV 13	2009	4	11							e7814	10.1371/journal.pone.0007814	http://dx.doi.org/10.1371/journal.pone.0007814			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	518VB	19915705	Green Submitted, Green Published, gold			2022-12-25	WOS:000271721900011
J	Li, MY; Lai, FJ; Hsu, LJ; Lo, CP; Cheng, CL; Lin, SR; Lee, MH; Chang, JY; Subhan, D; Tsai, MS; Sze, CI; Pugazhenthi, S; Chang, NS; Chen, ST				Li, Meng-Yen; Lai, Feng-Jie; Hsu, Li-Jin; Lo, Chen-Peng; Cheng, Ching-Li; Lin, Sing-Ru; Lee, Ming-Hui; Chang, Jean-Yun; Subhan, Dudekula; Tsai, Ming-Shu; Sze, Chun-I; Pugazhenthi, Subbiah; Chang, Nan-Shan; Chen, Shur-Tzu			Dramatic Co-Activation of WWOX/WOX1 with CREB and NF-kappa B in Delayed Loss of Small Dorsal Root Ganglion Neurons upon Sciatic Nerve Transection in Rats	PLOS ONE			English	Article							DOMAIN-CONTAINING OXIDOREDUCTASE; C-JUN EXPRESSION; ELEMENT-BINDING PROTEIN; TUMOR-SUPPRESSOR WWOX; TRANSCRIPTION FACTOR; IN-VIVO; TYROSINE-33 PHOSPHORYLATION; AXONAL REGENERATION; GENE-EXPRESSION; SENSORY NEURONS	Background: Tumor suppressor WOX1 (also named WWOX or FOR) is known to participate in neuronal apoptosis in vivo. Here, we investigated the functional role of WOX1 and transcription factors in the delayed loss of axotomized neurons in dorsal root ganglia (DRG) in rats. Methodology/Principal Findings: Sciatic nerve transection in rats rapidly induced JNK1 activation and upregulation of mRNA and protein expression of WOX1 in the injured DRG neurons in 30 min. Accumulation of p-WOX1, p-JNK1, p-CREB, p-c-Jun, NF-kappa B and ATF3 in the nuclei of injured neurons took place within hours or the first week of injury. At the second month, dramatic nuclear accumulation of WOX1 with CREB (>65% neurons) and NF-kappa B (40-65%) occurred essentially in small DRG neurons, followed by apoptosis at later months. WOX1 physically interacted with CREB most strongly in the nuclei as determined by FRET analysis. Immunoelectron microscopy revealed the complex formation of p-WOX1 with p-CREB and p-c-Jun in vivo. WOX1 blocked the prosurvival CREB-, CRE-, and AP-1-mediated promoter activation in vitro. In contrast, WOX1 enhanced promoter activation governed by c-Jun, Elk-1 and NF-kappa B. WOX1 directly activated NF-kappa B-regulated promoter via its WW domains. Smad4 and p53 were not involved in the delayed loss of small DRG neurons. Conclusions/Significance: Rapid activation of JNK1 and WOX1 during the acute phase of injury is critical in determining neuronal survival or death, as both proteins functionally antagonize. In the chronic phase, concurrent activation of WOX1, CREB, and NF-kappa B occurs in small neurons just prior to apoptosis. Likely in vivo interactions are: 1) WOX1 inhibits the neuroprotective CREB, which leads to eventual neuronal death, and 2) WOX1 enhances NF-kappa B promoter activation (which turns to be proapoptotic). Evidently, WOX1 is the potential target for drug intervention in mitigating symptoms associated with neuronal injury.			Li, MY (corresponding author), Natl Cheng Kung Univ, Coll Med, Dept Cell Biol & Anat, Tainan 70101, Taiwan.	changns@mail.ncku.edu.tw	Hsu, Li-Jin/G-7822-2011		BLRD VA [I01 BX001837] Funding Source: Medline	BLRD VA		Aderca I, 2008, J HEPATOL, V49, P373, DOI 10.1016/j.jhep.2008.05.015; Alavian KN, 2008, MOVEMENT DISORD, V23, P319, DOI 10.1002/mds.21640; Aqeilan RI, 2007, J CELL PHYSIOL, V212, P307, DOI 10.1002/jcp.21099; Barrett LE, 2006, NAT METHODS, V3, P455, DOI 10.1038/NMETH885; Barron KD, 2004, J NEUROL SCI, V220, P119, DOI 10.1016/j.jns.2004.03.009; Bednarek AK, 2000, CANCER RES, V60, P2140; Bednarski BK, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0006992; Broude E, 1997, EXP NEUROL, V148, P367, DOI 10.1006/exnr.1997.6665; Buschmann T, 1998, NEUROSCIENCE, V84, P163, DOI 10.1016/S0306-4522(97)00487-9; Chang NS, 2007, TRENDS MOL MED, V13, P12, DOI 10.1016/j.molmed.2006.11.006; Chang NS, 2005, J BIOL CHEM, V280, P43100, DOI 10.1074/jbc.M505590200; Chang NS, 2005, ONCOGENE, V24, P714, DOI 10.1038/sj.onc.1208124; Chang NS, 2003, J BIOL CHEM, V278, P9195, DOI 10.1074/jbc.M208373200; Chang NS, 2001, J BIOL CHEM, V276, P3361, DOI 10.1074/jbc.M007140200; Chang YC, 2006, CURR OPIN NEUROL, V19, P141, DOI 10.1097/01.wco.0000218229.73678.a8; Chen ST, 2005, NEUROSCIENCE, V130, P397, DOI 10.1016/j.neuroscience.2004.07.054; Chen ST, 2004, NEUROSCIENCE, V124, P831, DOI 10.1016/j.neuroscience.2003.12.036; Chuang JI, 2002, NEUROCHEM INT, V40, P169, DOI 10.1016/S0197-0186(01)00075-4; DEFELIPE C, 1994, J NEUROSCI, V14, P2911; Demir O, 2008, NEUROSCI LETT, V437, P20, DOI 10.1016/j.neulet.2008.03.064; Fabbri M, 2005, P NATL ACAD SCI USA, V102, P15611, DOI 10.1073/pnas.0505485102; Gaudio E, 2006, CANCER RES, V66, P11585, DOI 10.1158/0008-5472.CAN-06-3376; Hai T, 2001, GENE, V273, P1, DOI 10.1016/S0378-1119(01)00551-0; Ham J, 2000, BIOCHEM PHARMACOL, V60, P1015, DOI 10.1016/S0006-2952(00)00372-5; Hayakawa J, 2003, J BIOL CHEM, V278, P20582, DOI 10.1074/jbc.M210992200; Herdegen T, 1998, BRAIN RES REV, V28, P370, DOI 10.1016/S0165-0173(98)00018-6; Hsu LJ, 2009, J BIOL CHEM, V284, P16049, DOI 10.1074/jbc.M806688200; JENKINS R, 1991, NEUROSCI LETT, V129, P107, DOI 10.1016/0304-3940(91)90731-8; Kenney AM, 1997, MOL BRAIN RES, V52, P53, DOI 10.1016/S0169-328X(97)00211-8; Kitagawa K, 2007, FEBS J, V274, P3210, DOI 10.1111/j.1742-4658.2007.05890.x; Lai FJ, 2005, CLIN CANCER RES, V11, P5769, DOI 10.1158/1078-0432.CCR-04-2274; Lo CP, 2008, EUR J NEUROSCI, V27, P1634, DOI 10.1111/j.1460-9568.2008.06139.x; Lonze BE, 2002, NEURON, V35, P605, DOI 10.1016/S0896-6273(02)00828-0; Lu D, 2006, J BIOL CHEM, V281, P10473, DOI 10.1074/jbc.M509278200; Mahajan NP, 2005, CANCER RES, V65, P10514, DOI 10.1158/0008-5472.CAN-05-1127; Persengiev SP, 2003, APOPTOSIS, V8, P225, DOI 10.1023/A:1023633704132; Pugazhenthi S, 1999, J BIOL CHEM, V274, P2829, DOI 10.1074/jbc.274.5.2829; Pugazhenthi S, 2000, J BIOL CHEM, V275, P10761, DOI 10.1074/jbc.275.15.10761; Qiao LY, 2005, J COMP NEUROL, V482, P142, DOI 10.1002/cne.20394; Qin HR, 2006, CANCER RES, V66, P6477, DOI 10.1158/0008-5472.CAN-06-0956; Raivich G, 2004, NEURON, V43, P57, DOI 10.1016/j.neuron.2004.06.005; Raivich G, 2006, PROG NEUROBIOL, V78, P347, DOI 10.1016/j.pneurobio.2006.03.006; Ried K, 2000, HUM MOL GENET, V9, P1651, DOI 10.1093/hmg/9.11.1651; Sarkar SA, 2009, DIABETOLOGIA, V52, P1092, DOI 10.1007/s00125-009-1331-x; Shao NS, 1998, ONCOGENE, V17, P527, DOI 10.1038/sj.onc.1201931; Smith DI, 2007, SEMIN CANCER BIOL, V17, P31, DOI 10.1016/j.semcancer.2006.10.003; Soares HD, 2001, EXP NEUROL, V167, P1, DOI 10.1006/exnr.2000.7558; Son SJ, 2007, EXP NEUROL, V204, P467, DOI 10.1016/j.expneurol.2006.09.020; Sze CI, 2004, J BIOL CHEM, V279, P30498, DOI 10.1074/jbc.M401399200; Tandrup T, 2000, J COMP NEUROL, V422, P172, DOI 10.1002/(SICI)1096-9861(20000626)422:2<172::AID-CNE2>3.0.CO;2-H; Teng FYH, 2006, J NEUROCHEM, V96, P1501, DOI 10.1111/j.1471-4159.2006.03663.x; Yi JH, 2007, NEUROCHEM INT, V50, P1014, DOI 10.1016/j.neuint.2007.04.019; Zhong SP, 2007, MOL CELL BIOL, V27, P54, DOI 10.1128/MCB.01365-06	53	42	42	0	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA	1932-6203			PLOS ONE	PLoS One	NOV 12	2009	4	11							e7820	10.1371/journal.pone.0007820	http://dx.doi.org/10.1371/journal.pone.0007820			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	518UW	19918364	Green Published, Green Submitted, gold			2022-12-25	WOS:000271721400017
J	Hough, SR; Laslett, AL; Grimmond, SB; Kolle, G; Pera, MF				Hough, Shelley R.; Laslett, Andrew L.; Grimmond, Sean B.; Kolle, Gabriel; Pera, Martin F.			A Continuum of Cell States Spans Pluripotency and Lineage Commitment in Human Embryonic Stem Cells	PLOS ONE			English	Article							GENE-EXPRESSION; PRIMITIVE ENDODERM; HUMAN BLASTOCYSTS; PROGENITOR CELLS; MOUSE; DIFFERENTIATION; CULTURE; HETEROGENEITY; TRANSCRIPTOME; INHIBITOR	Background: Commitment in embryonic stem cells is often depicted as a binary choice between alternate cell states, pluripotency and specification to a particular germ layer or extraembryonic lineage. However, close examination of human ES cell cultures has revealed significant heterogeneity in the stem cell compartment. Methodology/Principal Findings: We isolated subpopulations of embryonic stem cells using surface markers, then examined their expression of pluripotency genes and lineage specific transcription factors at the single cell level, and tested their ability to regenerate colonies of stem cells. Transcript analysis of single embryonic stem cells showed that there is a gradient and a hierarchy of expression of pluripotency genes in the population. Even cells at the top of the hierarchy generally express only a subset of the stem cell genes studied. Many cells co-express pluripotency and lineage specific genes. Cells along the continuum show a progressively decreasing likelihood of self renewal as their expression of stem cell surface markers and pluripotency genes wanes. Most cells that are positive for stem cell surface markers express Oct-4, but only those towards the top of the hierarchy express the nodal receptor TDGF-1 and the growth factor GDF3. Significance: These findings on gene expression in single embryonic stem cells are in concert with recent studies of early mammalian development, which reveal molecular heterogeneity and a stochasticity of gene expression in blastomeres. Our work indicates that only a small fraction of the population resides at the top of the hierarchy, that lineage priming ( co-expression of stem cell and lineage specific genes) characterizes pluripotent stem cell populations, and that extrinsic signaling pathways are upstream of transcription factor networks that control pluripotency.			Hough, SR (corresponding author), Univ So Calif, Keck Sch Med, Eli & Edythe Broad Ctr Regenerat Med & Stem Cell, Los Angeles, CA 90033 USA.	pera@usc.edu	Laslett, Andrew L/A-9760-2011; Grimmond, Sean M/J-5304-2016; PERA, MARTIN/A-9812-2012; Grimmond, Sean/K-3246-2019	Laslett, Andrew L/0000-0003-4729-8193; Grimmond, Sean M/0000-0002-8102-7998; PERA, MARTIN/0000-0001-6239-0428; Grimmond, Sean/0000-0002-8102-7998				Amit M, 2000, DEV BIOL, V227, P271, DOI 10.1006/dbio.2000.9912; Bahar R, 2006, NATURE, V441, P1011, DOI 10.1038/nature04844; Bernstein BE, 2006, CELL, V125, P315, DOI 10.1016/j.cell.2006.02.041; Boyer LA, 2005, CELL, V122, P947, DOI 10.1016/j.cell.2005.08.020; Chambers I, 2007, NATURE, V450, P1230, DOI 10.1038/nature06403; Chang HH, 2008, NATURE, V453, P544, DOI 10.1038/nature06965; Chang HH, 2006, BMC CELL BIOL, V7, DOI 10.1186/1471-2121-7-11; Chazaud C, 2006, DEV CELL, V10, P615, DOI 10.1016/j.devcel.2006.02.020; Chen CH, 2006, DEVELOPMENT, V133, P319, DOI 10.1242/dev.02210; Dietrich JE, 2007, DEVELOPMENT, V134, P4219, DOI 10.1242/dev.003798; Efroni S, 2008, CELL STEM CELL, V2, P437, DOI 10.1016/j.stem.2008.03.021; Enver T, 2005, HUM MOL GENET, V14, P3129, DOI 10.1093/hmg/ddi345; Enver T, 2009, CELL STEM CELL, V4, P387, DOI 10.1016/j.stem.2009.04.011; Guenther MG, 2007, CELL, V130, P77, DOI 10.1016/j.cell.2007.05.042; Hannan NRF, 2009, CLONING STEM CELLS, V11, P427, DOI 10.1089/clo.2009.0024; Hartmann CH, 2006, NUCLEIC ACIDS RES, V34, DOI 10.1093/nar/gkl740; Hayashi K, 2008, CELL STEM CELL, V3, P391, DOI 10.1016/j.stem.2008.07.027; Hu M, 1997, GENE DEV, V11, P774, DOI 10.1101/gad.11.6.774; Huang S, 2007, DEV BIOL, V305, P695, DOI 10.1016/j.ydbio.2007.02.036; Kaern M, 2005, NAT REV GENET, V6, P451, DOI 10.1038/nrg1615; Klein CA, 2002, NAT BIOTECHNOL, V20, P387, DOI 10.1038/nbt0402-387; KOLLE G, 2009, STEM CELLS; Laslett AL, 2007, BMC DEV BIOL, V7, DOI 10.1186/1471-213X-7-12; Levine AJ, 2006, DEVELOPMENT, V133, P209, DOI 10.1242/dev.02192; Mansson R, 2007, IMMUNITY, V26, P407, DOI 10.1016/j.immuni.2007.02.013; Meshorer E, 2006, DEV CELL, V10, P105, DOI 10.1016/j.devcel.2005.10.017; Murry CE, 2008, CELL, V132, P661, DOI 10.1016/j.cell.2008.02.008; Peerani R, 2007, EMBO J, V26, P4744, DOI 10.1038/sj.emboj.7601896; Pera MF, 2004, J CELL SCI, V117, P1269, DOI 10.1242/jcs.00970; Plusa B, 2008, DEVELOPMENT, V135, P3081, DOI 10.1242/dev.021519; Reubinoff BE, 2001, NAT BIOTECHNOL, V19, P1134, DOI 10.1038/nbt1201-1134; Reubinoff BE, 2000, NAT BIOTECHNOL, V18, P399, DOI 10.1038/74447; Smyth GK, 2003, METHODS, V31, P265, DOI 10.1016/S1046-2023(03)00155-5; Stadtfeld M, 2008, CELL STEM CELL, V2, P230, DOI 10.1016/j.stem.2008.02.001; Stewart MH, 2006, NAT METHODS, V3, P807, DOI 10.1038/nmeth939; Thomson JA, 1998, SCIENCE, V282, P1145, DOI 10.1126/science.282.5391.1145; Toyooka Y, 2008, DEVELOPMENT, V135, P909, DOI 10.1242/dev.017400; Watanabe K, 2007, NAT BIOTECHNOL, V25, P681, DOI 10.1038/nbt1310	38	109	113	0	15	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	NOV 5	2009	4	11							e7708	10.1371/journal.pone.0007708	http://dx.doi.org/10.1371/journal.pone.0007708			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	515HI	19890402	Green Submitted, gold, Green Published			2022-12-25	WOS:000271459700008
J	Paun, BC; Cheng, YL; Leggett, BA; Young, J; Meltzer, SJ; Mori, Y				Paun, Bogdan C.; Cheng, Yulan; Leggett, Barbara A.; Young, Joanne; Meltzer, Stephen J.; Mori, Yuriko			Screening for Microsatellite Instability Identifies Frequent 3 '-Untranslated Region Mutation of the RB1-Inducible Coiled-Coil 1 Gene in Colon Tumors	PLOS ONE			English	Article							MISMATCH REPAIR DEFICIENCY; HUMAN BREAST-CANCER; COLORECTAL-CANCER; FIP200; EXPRESSION; CELL; MICRORNA; YEAST; PATHOGENESIS; DEPENDENCE	Background: Coding region microsatellite instability (MSI) results in loss of gene products and promotion of microsatellite-unstable (MSI-H) carcinogenesis. Recent studies have indicated that MSI within 3'-untranslated regions (3'UTRs) may post-transcriptionally dysregulate gene products. Within this context, we conducted a broad mutational survey of 42 short 3'UTR microsatellites (MSs) in 45 MSI-H colorectal tumors and their corresponding normal colonic mucosae. Methodology/Principal Findings: In order to estimate the overall susceptibility of MSs to MSI in MSI-H tumors, the observed MSI frequency of each MS was correlated with its length, interspecies sequence conservation level, and distance from some genetic elements (i.e., stop codon, polyA signal, and microRNA binding sites). All MSs were stable in normal colonic mucosae. The MSI frequency at each MS in MSI-H tumors was independent of sequence conservation level and distance from other genetic elements. In contrast, MS length correlated significantly with MSI frequency in MSI-H tumors (r = 0.86, p = 7.2x10(-13)). 3'UTR MSs demonstrated MSI frequencies in MSI-H tumors higher than the 99% upper limit predicted by MS length for RB1-inducible coiled-coil 1(RB1CC1, mutation frequency 68.4%), NUAK family SNF1-like kinase 1(NUAK1, 31.0%), and Rtf1, Paf1/RNA polymerase II complex component, homolog (RTF1, 25.0%). An in silico prediction of RNA structure alterations was conducted for these MSI events to gauge their likelihood of affecting post-transcriptional regulation. RB1CC1 mutant was predicted to lose a microRNA-accessible loop structure at a putative binding site for the tumor-suppressive microRNA, miR-138. In contrast, the predicted 3'UTR structural change was minimal for NUAK1- and RTF1 mutants. Notably, real-time quantitative RT-PCR analysis revealed significant RB1CC1 mRNA overexpression vs. normal colonic mucosae in MSI-H cancers manifesting RB1CC1 3'UTR MSI (9.0-fold; p = 3.6x10(-4)). Conclusions: This mutational survey of well-characterized short 3'UTR MSs confirms that MSI incidence in MSI-H colorectal tumors correlates with MS length, but not with sequence conservation level or distance from other genetic elements. This study also identifies RB1CC1 as a novel target of frequent mutation and aberrant upregulation in MSI-H colorectal tumors. The predicted loss of a microRNA-accessible structure in mutant RB1CC1 RNA fits the hypothesis that 3'UTR MSI involves in aberrant RB1CC1 posttranscriptional upregulation. Further direct assessments are indicated to investigate this possibility.			Paun, BC (corresponding author), Johns Hopkins Univ, Sch Med, Dept Med, Div Gastroenterol, Baltimore, MD 21205 USA.	ymori3@jhmi.edu	Young, Joanne P/H-7774-2014; Young, Joanne P/B-9981-2011; Leggett, Barbara A/D-3579-2011	Leggett, Barbara/0000-0003-2062-7380; Young, Joanne/0000-0002-1514-1522	NATIONAL CANCER INSTITUTE [R01CA077057] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA077057, CA077057] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Abbi S, 2002, MOL BIOL CELL, V13, P3178, DOI 10.1091/mbc.E02-05-0295; Ariza M, 2004, CANCER-AM CANCER SOC, V100, P335, DOI 10.1002/cncr.11931; Boland CR, 1998, CANCER RES, V58, P5248; Chano T, 2002, NAT GENET, V31, P285, DOI 10.1038/ng911; Chano T, 2002, ONCOGENE, V21, P1295, DOI 10.1038/sj.onc.1205178; de Silanes IL, 2007, CELL ONCOL, V29, P1; Duval A, 2002, CANCER RES, V62, P1609; Gan B, 2008, CELL SIGNAL, V20, P787, DOI 10.1016/j.cellsig.2007.10.021; Gan BY, 2006, J CELL BIOL, V175, P121, DOI 10.1083/jcb.200604129; Grady WM, 2008, GASTROENTEROLOGY, V135, P1079, DOI 10.1053/j.gastro.2008.07.076; Halees AS, 2008, NUCLEIC ACIDS RES, V36, pD137, DOI 10.1093/nar/gkm959; Heinimann K, 2001, CANCER RES, V61, P7616; John B, 2004, PLOS BIOL, V2, P1862, DOI 10.1371/journal.pbio.0020363; Karolchik D, 2004, NUCLEIC ACIDS RES, V32, pD493, DOI 10.1093/nar/gkh103; Kertesz M, 2007, NAT GENET, V39, P1278, DOI 10.1038/ng2135; Leedham SJ, 2008, J CLIN PATHOL, V61, P164, DOI 10.1136/jcp.2006.044610; Levenberg K., 1944, Q APPL MATH, V2, P164, DOI [10.1090/qam/10666, DOI 10.1090/QAM/10666]; Lewis BP, 2005, CELL, V120, P15, DOI 10.1016/j.cell.2004.12.035; Mao G, 2008, J BIOL CHEM, V283, P3211, DOI 10.1074/jbc.M709276200; Martin N, 2008, MOL CELL BIOL, V28, P2771, DOI 10.1128/MCB.01210-07; Melkoumian ZK, 2005, CANCER RES, V65, P6676, DOI 10.1158/0008-5472.CAN-04-4142; Mitomo S, 2008, CANCER SCI, V99, P280, DOI 10.1111/j.1349-7006.2007.00666.x; Mori Y, 2001, CANCER RES, V61, P6046; Mori Y, 2006, GASTROENTEROLOGY, V131, P797, DOI 10.1053/j.gastro.2006.06.006; Pietschmann A, 2005, J CANCER RES CLIN, V131, P552, DOI 10.1007/s00432-005-0678-8; Reeder J, 2007, NUCLEIC ACIDS RES, V35, pW320, DOI 10.1093/nar/gkm258; Ruggiero T, 2003, NUCLEIC ACIDS RES, V31, P6561, DOI 10.1093/nar/gkg858; Shin JG, 2007, SURGERY, V142, P222, DOI 10.1016/j.surg.2007.04.002; Shiomi K, 2005, MOL BRAIN RES, V135, P169, DOI 10.1016/j.molbrainres.2004.12.002; Sia EA, 1997, MOL CELL BIOL, V17, P2851, DOI 10.1128/MCB.17.5.2851; Siepel A, 2005, GENOME RES, V15, P1034, DOI 10.1101/gr.3715005; Strauss BS, 1999, MUTAT RES-REV MUTAT, V437, P195, DOI 10.1016/S1383-5742(99)00066-6; Suraweera N, 2001, ONCOGENE, V20, P7472, DOI 10.1038/sj.onc.1204952; Suzuki A, 2004, MOL CELL BIOL, V24, P3526, DOI 10.1128/MCB.24.8.3526-3535.2004; Tenney K, 2006, P NATL ACAD SCI USA, V103, P11970, DOI 10.1073/pnas.0603620103; Ueda H, 2000, J CELL BIOL, V149, P423, DOI 10.1083/jcb.149.2.423; Wei HJ, 2009, J BIOL CHEM, V284, P6004, DOI 10.1074/jbc.M806375200; Wierdl M, 1997, GENETICS, V146, P769; Woerner SM, 2003, ONCOGENE, V22, P2226, DOI 10.1038/sj.onc.1206421; Woerner SM, 2001, INT J CANCER, V93, P12, DOI 10.1002/ijc.1299; Wong TS, 2008, CLIN CANCER RES, V14, P2588, DOI 10.1158/1078-0432.CCR-07-0666; Wu L, 2008, MOL CELL, V29, P1, DOI 10.1016/j.molcel.2007.12.010; Zhang HB, 2005, NUCLEIC ACIDS RES, V33, pD116, DOI 10.1093/nar/gki055	43	11	12	0	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	NOV 2	2009	4	11							e7715	10.1371/journal.pone.0007715	http://dx.doi.org/10.1371/journal.pone.0007715			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	514RX	19888451	Green Published, gold, Green Submitted			2022-12-25	WOS:000271414400015
J	Tortiglione, C; Quarta, A; Malvindi, MA; Tino, A; Pellegrino, T				Tortiglione, Claudia; Quarta, Alessandra; Malvindi, Maria Ada; Tino, Angela; Pellegrino, Teresa			Fluorescent Nanocrystals Reveal Regulated Portals of Entry into and Between the Cells of Hydra	PLOS ONE			English	Article							QUANTUM DOTS; IN-VIVO; SEMICONDUCTOR NANOCRYSTALS; HYDROPHOBIC NANOCRYSTALS; BIOLOGICAL LABELS; CRYSTAL-STRUCTURE; TARGETED PROBES; MODEL SYSTEM; LIVE CELLS; ACIDIC PH	Initially viewed as innovative carriers for biomedical applications, with unique photophysical properties and great versatility to be decorated at their surface with suitable molecules, nanoparticles can also play active roles in mediating biological effects, suggesting the need to deeply investigate the mechanisms underlying cell-nanoparticle interaction and to identify the molecular players. Here we show that the cell uptake of fluorescent CdSe/CdS quantum rods (QRs) by Hydra vulgaris, a simple model organism at the base of metazoan evolution, can be tuned by modifying nanoparticle surface charge. At acidic pH, amino-PEG coated QRs, showing positive surface charge, are actively internalized by tentacle and body ectodermal cells, while negatively charged nanoparticles are not uptaken. In order to identify the molecular factors underlying QR uptake at acidic pH, we provide functional evidence of annexins involvement and explain the QR uptake as the combined result of QR positive charge and annexin membrane insertion. Moreover, tracking QR labelled cells during development and regeneration allowed us to uncover novel intercellular trafficking and cell dynamics underlying the remarkable plasticity of this ancient organism.			Tortiglione, C (corresponding author), CNR, Ist Cibernet E Caianiello, Pozzuoli, Italy.	c.tortiglione@cib.na.cnr.it	QUARTA, ALESSANDRA/AAL-9175-2020; Tortiglione, Claudia/K-5200-2014; Pellegrino, teresa/G-6417-2010; Quarta, Alessandra/AAD-4326-2020; Tino, Angela/E-8425-2014; Tortiglione, Claudia/N-3290-2019	QUARTA, ALESSANDRA/0000-0003-1911-9864; Tortiglione, Claudia/0000-0003-1447-7611; Tino, Angela/0000-0002-9673-1064; Tortiglione, Claudia/0000-0003-1447-7611; Pellegrino, Teresa/0000-0001-5518-1134				Alivisatos P, 2004, NAT BIOTECHNOL, V22, P47, DOI 10.1038/nbt927; BARTON GJ, 1991, EUR J BIOCHEM, V198, P749, DOI 10.1111/j.1432-1033.1991.tb16076.x; Bottger A, 2007, SEMIN CANCER BIOL, V17, P134, DOI 10.1016/j.semcancer.2006.11.008; BOSCH TCG, 1984, DEV BIOL, V104, P161, DOI 10.1016/0012-1606(84)90045-9; Bruchez M, 1998, SCIENCE, V281, P2013, DOI 10.1126/science.281.5385.2013; Buzgariu W, 2008, METHOD ENZYMOL, V451, P409, DOI 10.1016/S0076-6879(08)03226-6; CAMPBELL RD, 1973, J CELL SCI, V13, P651; CAMPBELL RD, 1976, J CELL SCI, V21; Carbone L, 2007, NANO LETT, V7, P2942, DOI 10.1021/nl0717661; Carlson C, 2008, J PHYS CHEM B, V112, P13608, DOI 10.1021/jp712087m; Cartailler JP, 2000, BIOCHEMISTRY-US, V39, P2475, DOI 10.1021/bi992278d; Chera S, 2009, BBA-MOL CELL RES, V1793, P1432, DOI 10.1016/j.bbamcr.2009.03.010; Chithrani BD, 2007, NANO LETT, V7, P1542, DOI 10.1021/nl070363y; Cho SJ, 2007, LANGMUIR, V23, P1974, DOI 10.1021/la060093j; Conner SD, 2003, NATURE, V422, P37, DOI 10.1038/nature01451; Dahan M, 2003, SCIENCE, V302, P442, DOI 10.1126/science.1088525; DAVID CN, 1973, ENTW MECH ORG, P259; Deka S, 2009, J AM CHEM SOC, V131, P2948, DOI 10.1021/ja808369e; Delehanty JB, 2009, ANAL BIOANAL CHEM, V393, P1091, DOI 10.1007/s00216-008-2410-4; Di Corato R, 2008, J MATER CHEM, V18, P1991, DOI 10.1039/b717801h; Dobrovolskaia MA, 2007, NAT NANOTECHNOL, V2, P469, DOI 10.1038/nnano.2007.223; Figuerola A, 2008, J AM CHEM SOC, V130, P1477, DOI 10.1021/ja078034v; Flick K.M., 1983, P251; Fu AH, 2005, CURR OPIN NEUROBIOL, V15, P568, DOI 10.1016/j.conb.2005.08.004; Fu AH, 2007, NANO LETT, V7, P179, DOI 10.1021/nl0626434; FUJISAWA T, 1984, J CELL SCI, V68, P243; Galliot B, 2006, SEMIN CELL DEV BIOL, V17, P492, DOI 10.1016/j.semcdb.2006.05.005; Gerke V, 2005, NAT REV MOL CELL BIO, V6, P449, DOI 10.1038/nrm1661; Gerke V, 2002, PHYSIOL REV, V82, P331, DOI 10.1152/physrev.00030.2001; Hager G, 1997, DEVELOPMENT, V124, P569; Hegde BG, 2006, BIOCHEMISTRY-US, V45, P934, DOI 10.1021/bi052143+; Holdway DA, 2001, ENVIRON TOXICOL, V16, P557, DOI 10.1002/tox.10017.abs; Holstein TW, 2003, DEV DYNAM, V226, P257, DOI 10.1002/dvdy.10227; Howarth M, 2005, P NATL ACAD SCI USA, V102, P7583, DOI 10.1073/pnas.0503125102; Hunter R. J., 1988, ZETA POTENTIAL COLLO; Isas JM, 2003, J BIOL CHEM, V278, P30227, DOI 10.1074/jbc.M301228200; Isas JM, 2000, BIOCHEMISTRY-US, V39, P3015, DOI 10.1021/bi9922401; Jiang W, 2008, NAT NANOTECHNOL, V3, P145, DOI 10.1038/nnano.2008.30; Karntanut W, 2002, CHEMOSPHERE, V47, P1059, DOI 10.1016/S0045-6535(02)00050-4; Kirchner C, 2005, NANO LETT, V5, P331, DOI 10.1021/nl047996m; Kuznetsov SG, 2002, J EXP BIOL, V205, P3809; Ladokhin AS, 2005, BIOCHEMISTRY-US, V44, P3402, DOI 10.1021/bi047805u; Langen R, 1998, P NATL ACAD SCI USA, V95, P14060, DOI 10.1073/pnas.95.24.14060; Lewinski N, 2008, SMALL, V4, P26, DOI 10.1002/smll.200700595; LOOMIS WF, 1956, J EXP ZOOL, V132, P555, DOI 10.1002/jez.1401320309; LUECKE H, 1995, NATURE, V378, P512, DOI 10.1038/378512a0; Malvindi MA, 2008, SMALL, V4, P1747, DOI 10.1002/smll.200800413; Maynard AD, 2006, NATURE, V444, P267, DOI 10.1038/444267a; Maysinger D, 2007, NANO LETT, V7, P2513, DOI 10.1021/nl071611t; MCNEIL PL, 1981, J CELL SCI, V49, P311; Medintz IL, 2005, NAT MATER, V4, P435, DOI 10.1038/nmat1390; Michalet X, 2005, SCIENCE, V307, P538, DOI 10.1126/science.1104274; Mok H, 2008, BIOCONJUGATE CHEM, V19, P797, DOI 10.1021/bc700464m; Moss SE, 2004, GENOME BIOL, V5, DOI 10.1186/gb-2004-5-4-219; Murate M, 1997, J CELL SCI, V110, P1919; Nabiev I, 2007, NANO LETT, V7, P3452, DOI 10.1021/nl0719832; Pellegrino T, 2004, NANO LETT, V4, P703, DOI 10.1021/nl035172j; PRASAD K, 1988, BIOCHEMISTRY-US, V27, P6098, DOI 10.1021/bi00416a040; PRENCIPE G, 2009, J AM CHEM SOC; Quarta A, 2008, J AM CHEM SOC, V130, P10545, DOI 10.1021/ja800102v; Rescher U, 2004, J CELL SCI, V117, P2631, DOI 10.1242/jcs.01245; SCHLAEPFER DD, 1992, J CELL BIOL, V118, P911, DOI 10.1083/jcb.118.4.911; Sheng Y, 2009, BIOMATERIALS, V30, P2340, DOI 10.1016/j.biomaterials.2008.12.070; Sperling RA, 2006, ADV FUNCT MATER, V16, P943, DOI 10.1002/adfm.200500589; TECHNAU U, 1992, DEV BIOL, V151, P117, DOI 10.1016/0012-1606(92)90219-7; Tortiglione C, 2007, BIOCONJUGATE CHEM, V18, P829, DOI 10.1021/bc060355t; WILLIAMS A, 1981, CHEM REV, V81, P589, DOI 10.1021/cr00046a004; Xu G, 2008, BIOCONJUGATE CHEM, V19, P1179, DOI 10.1021/bc700477u; Yong KT, 2007, NANO LETT, V7, P761, DOI 10.1021/nl063031m	69	41	42	0	24	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA	1932-6203			PLOS ONE	PLoS One	NOV 2	2009	4	11							e7698	10.1371/journal.pone.0007698	http://dx.doi.org/10.1371/journal.pone.0007698			14	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	514RX	19888325	Green Published, Green Submitted, gold			2022-12-25	WOS:000271414400010
J	Jeru, I; Hayrapetyan, H; Duquesnoy, P; Cochet, E; Serre, JL; Feingold, J; Grateau, G; Sarkisian, T; Jeanpierre, M; Amselem, S				Jeru, Isabelle; Hayrapetyan, Hasmik; Duquesnoy, Philippe; Cochet, Emmanuelle; Serre, Jean-Louis; Feingold, Josue; Grateau, Gilles; Sarkisian, Tamara; Jeanpierre, Marc; Amselem, Serge			Involvement of the Modifier Gene of a Human Mendelian Disorder in a Negative Selection Process	PLOS ONE			English	Article							FAMILIAL-MEDITERRANEAN-FEVER; DIAGNOSTIC-VALUE; AMYLOIDOSIS; MEFV; ARMENIANS; ALLELES; SAA1	Background: Identification of modifier genes and characterization of their effects represent major challenges in human genetics. SAA1 is one of the few modifiers identified in humans: this gene influences the risk of renal amyloidosis (RA) in patients with familial Mediterranean fever (FMF), a Mendelian autoinflammatory disorder associated with mutations in MEFV. Indeed, the SAA1 alpha homozygous genotype and the p.Met694Val homozygous genotype at the MEFV locus are two main risk factors for RA. Methodology/Principal Findings: Here, we investigated Armenian FMF patients and controls from two neighboring countries: Armenia, where RA is frequent (24%), and Karabakh, where RA is rare (2.5%). Sequencing of MEFV revealed similar frequencies of p.Met694Val homozygotes in the two groups of patients. However, a major deficit of SAA1 alpha homozygotes was found among Karabakhian patients (4%) as compared to Armenian patients (24%) (p = 5.10(-5)). Most importantly, we observed deviations from Hardy-Weinberg equilibrium (HWE) in the two groups of patients, and unexpectedly, in opposite directions, whereas, in the two control populations, genotype distributions at this locus were similar and complied with (HWE). Conclusions/Significance: The excess of SAA1 alpha homozygotes among Armenian patients could be explained by the recruitment of patients with severe phenotypes. In contrast, a population-based study revealed that the deficit of alpha/alpha among Karabakhian patients would result from a negative selection against carriers of this genotype. This study, which provides new insights into the role of SAA1 in the pathophysiology of FMF, represents the first example of deviations from HWE and selection involving the modifier gene of a Mendelian disorder.			Jeru, I (corresponding author), INSERM, U933, Paris, France.	serge.amselem@trs.aphp.fr		Sarkisian, Tamara/0000-0002-4767-7567				AIVAZYAN AA, 1982, KLIN MED MOSCOW+, V60, P65; Akar N, 2003, AMYLOID, V10, P12, DOI 10.3109/13506120308995251; Aksentijevich I, 1997, CELL, V90, P797; ARMENIAN HK, 1973, LEBAN MED J, V26, P605; Bakkaloglu A, 2004, J RHEUMATOL, V31, P1139; Bernot A, 1997, NAT GENET, V17, P25; Cazeneuve C, 2000, AM J HUM GENET, V67, P1136, DOI 10.1016/S0002-9297(07)62944-9; Cazeneuve C, 1999, AM J HUM GENET, V65, P88, DOI 10.1086/302459; Cazeneuve C, 2003, ARTHRITIS RHEUM-US, V48, P2324, DOI 10.1002/art.11102; DeVry CG, 1999, J HUM GENET, V44, P275, DOI 10.1007/s100380050161; DONABEDIAN P, 1991, ARTSAKH HIST KARABAK; Gershoni-Baruch R, 2003, ARTHRITIS RHEUM, V48, P1149, DOI 10.1002/art.10944; Hartl D.L., 1997, PRINCIPLES POPULATIO, V3rd ed.; Huber M, 2006, BIOMETRICS, V62, P49, DOI 10.1111/j.1541-0420.2005.00418.x; Kang SH, 2004, HUM HERED, V58, P10, DOI 10.1159/000081452; Livneh A, 1997, ARTHRITIS RHEUM-US, V40, P1879, DOI 10.1002/art.1780401023; Luo XG, 2007, HUM MOL GENET, V16, P380, DOI 10.1093/hmg/ddl460; Medlej-Hashim Myrna, 2004, BMC Med Genet, V5, P4, DOI 10.1186/1471-2350-5-4; Nadeau JH, 2003, CURR OPIN GENET DEV, V13, P290, DOI 10.1016/S0959-437X(03)00061-3; Nadeau JH, 2001, NAT REV GENET, V2, P165, DOI 10.1038/35056009; ROGERS DB, 1989, AM J MED GENET, V34, P168, DOI 10.1002/ajmg.1320340206; Schollen E, 2000, EUR J HUM GENET, V8, P367, DOI 10.1038/sj.ejhg.5200470; SCHWABE AD, 1974, MEDICINE, V53, P453, DOI 10.1097/00005792-197411000-00005; Wahlund S, 1928, HEREDITAS, V11, P65, DOI 10.1111/j.1601-5223.1928.tb02483.x; ZEMER D, 1986, NEW ENGL J MED, V314, P1001, DOI 10.1056/NEJM198604173141601; Zuniga J, 1999, GENES IMMUN, V1, P66, DOI 10.1038/sj.gene.6363633	26	5	7	0	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	OCT 30	2009	4	10							e7676	10.1371/journal.pone.0007676	http://dx.doi.org/10.1371/journal.pone.0007676			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	514RW	19888326	Green Published, Green Submitted, gold			2022-12-25	WOS:000271414300018
J	Zheng, XM; Oancea, C; Henschler, R; Moore, MAS; Ruthardt, M				Zheng, Xiaomin; Oancea, Claudia; Henschler, Reinhard; Moore, Malcolm A. S.; Ruthardt, Martin			Reciprocal t(9;22) ABL/BCR Fusion Proteins: Leukemogenic Potential and Effects on B Cell Commitment	PLOS ONE			English	Article							CHRONIC MYELOID-LEUKEMIA; DERIVATIVE CHROMOSOME-9; SELF-RENEWAL; BCR-ABL; STEM-CELLS; EXPRESSION; GENE; DELETIONS; TRANSFORMATION; TRANSLOCATION	Background: t(9;22) is a balanced translocation, and the chromosome 22 breakpoints (Philadelphia chromosome - Ph+) determine formation of different fusion genes that are associated with either Ph+ acute lymphatic leukemia (Ph+ ALL) or chronic myeloid leukemia (CML). The "minor'' breakpoint in Ph+ ALL encodes p185(BCR/ABL) from der22 and p96(ABL/BCR) from der9. The "major'' breakpoint in CML encodes p210(BCR/ABL) and p40(ABL/BCR). Herein, we investigated the leukemogenic potential of the der9-associated p96(ABL/BCR) and p40(ABL/BCR) fusion proteins and their roles in the lineage commitment of hematopoietic stem cells in comparison to BCR/ABL. Methodology: All t(9; 22) derived proteins were retrovirally expressed in murine hematopoietic stem cells (SL cells) and human umbilical cord blood cells (UCBC). Stem cell potential was determined by replating efficiency, colony forming spleen and competitive repopulating assays. The leukemic potential of the ABL/BCR fusion proteins was assessed by in a transduction/transplantation model. Effects on the lineage commitment and differentiation were investigated by culturing the cells under conditions driving either myeloid or lymphoid commitment. Expression of key factors of the B-cell differentiation and components of the preB-cell receptor were determined by qRT-PCR. Principal Findings: Both p96(ABL/BCR) and p40(ABL/BCR) increased proliferation of early progenitors and the short term stem cell capacity of SL-cells and exhibited own leukemogenic potential. Interestingly, BCR/ABL gave origin exclusively to a myeloid phenotype independently from the culture conditions whereas p96(ABL/BCR) and to a minor extent p40(ABL/BCR) forced the B-cell commitment of SL-cells and UCBC. Conclusions/Significance: Our here presented data establish the reciprocal ABL/BCR fusion proteins as second oncogenes encoded by the t(9;22) in addition to BCR/ABL and suggest that ABL/BCR contribute to the determination of the leukemic phenotype through their influence on the lineage commitment.			Zheng, XM (corresponding author), Goethe Univ Frankfurt, Dept Hematol, Lab Tumor Stem Cell Biol, Frankfurt, Germany.	ruthardt@em.uni-frankfurt.de		Ruthardt, Martin/0000-0003-1021-3811; Chiriches, Claudia/0000-0003-3758-1892				Alberts AS, 1998, EMBO J, V17, P4075, DOI 10.1093/emboj/17.14.4075; Barnes DJ, 2006, CELL CYCLE, V5, P2862, DOI 10.4161/cc.5.24.3573; Barnes DJ, 2002, ACTA HAEMATOL-BASEL, V108, P180, DOI 10.1159/000065655; Beissert T, 2008, INT J CANCER, V122, P2744, DOI 10.1002/ijc.23467; Bug G, 2005, CANCER RES, V65, P2537, DOI 10.1158/0008-5472.CAN-04-3011; Cobaleda C, 2007, NAT IMMUNOL, V8, P463, DOI 10.1038/ni1454; de la Fuente J, 2001, BLOOD, V98, P2879, DOI 10.1182/blood.V98.9.2879; Era T, 2000, P NATL ACAD SCI USA, V97, P1737, DOI 10.1073/pnas.97.4.1737; ETTEN RAV, 2002, ONCOGENE, V21, P8643; Faderl S, 1999, NEW ENGL J MED, V341, P164, DOI 10.1056/NEJM199907153410306; Feldhahn N, 2007, J EXP MED, V204, P1157, DOI 10.1084/jem.20062662; Fu C, 1998, IMMUNITY, V9, P93, DOI 10.1016/S1074-7613(00)80591-9; Gokbuget Nicola, 2006, Hematology Am Soc Hematol Educ Program, P133; Gonda H, 2003, J EXP MED, V198, P1427, DOI 10.1084/jem.20030802; Griswold IJ, 2006, MOL CELL BIOL, V26, P6082, DOI 10.1128/MCB.02202-05; Hagman J, 2006, CURR OPIN IMMUNOL, V18, P127, DOI 10.1016/j.coi.2006.01.007; HEISTERKAMP N, 1990, NATURE, V344, P251, DOI 10.1038/344251a0; Huettner CS, 2000, NAT GENET, V24, P57, DOI 10.1038/71691; Huntly BJP, 2004, CANCER CELL, V6, P587, DOI 10.1016/j.ccr.2004.10.015; Huntly BJP, 2001, BLOOD, V98, P1732, DOI 10.1182/blood.V98.6.1732; Johnson JJ, 2003, BLOOD, V101, P3229, DOI 10.1182/blood-2002-05-1515; Jumaa H, 2005, ANNU REV IMMUNOL, V23, P415, DOI 10.1146/annurev.immunol.23.021704.115606; Kantarjian H, 2006, NEW ENGL J MED, V354, P2542, DOI 10.1056/NEJMoa055104; Klein F, 2004, J EXP MED, V199, P673, DOI 10.1084/jem.20031637; Kogan SC, 2002, BLOOD, V100, P238, DOI 10.1182/blood.V100.1.238; Kreil S, 2007, BLOOD, V110, P1283, DOI 10.1182/blood-2007-02-074252; Lavau C, 1997, EMBO J, V16, P4226, DOI 10.1093/emboj/16.14.4226; Mathas S, 2006, NAT IMMUNOL, V7, P207, DOI 10.1038/ni1285; Melo JV, 2007, NAT REV CANCER, V7, P441, DOI 10.1038/nrc2147; MELO JV, 1993, BLOOD, V81, P2488; MELO JV, 1993, BLOOD, V81, P158; Michor F, 2006, P NATL ACAD SCI USA, V103, P14931, DOI 10.1073/pnas.0607006103; Ohkawara JI, 1998, LEUKEMIA, V12, P764, DOI 10.1038/sj.leu.2401004; Orkin SH, 2008, CELL, V132, P631, DOI 10.1016/j.cell.2008.01.025; Puccetti E, 2004, LEUKEMIA, V18, P1169, DOI 10.1038/sj.leu.2403367; Radich JP., 2007, HEMATOL AM SOC HEMAT, V2007, P384, DOI [10.1182/asheducation-2007.1.384, DOI 10.1182/ASHEDUCATION-2007.1.384]; Radziwill G, 2003, MOL CELL BIOL, V23, P4663, DOI 10.1128/MCB.23.13.4663-4672.2003; Ress A, 2006, FEBS LETT, V580, P1227, DOI 10.1016/j.febslet.2006.01.034; Tokarski JS, 2006, CANCER RES, V66, P5790, DOI 10.1158/0008-5472.CAN-05-4187; VanAelst L, 1997, GENE DEV, V11, P2295, DOI 10.1101/gad.11.18.2295; Whitehead IP, 1997, BBA-REV CANCER, V1332, pF1, DOI 10.1016/S0304-419X(96)00040-6; Wilson A, 2004, GENE DEV, V18, P2747, DOI 10.1101/gad.313104; YIN JL, 1995, BRIT J HAEMATOL, V89, P539, DOI 10.1111/j.1365-2141.1995.tb08361.x; Zheng X, 2006, BMC CANCER, V6, DOI 10.1186/1471-2407-6-262; Zheng XM, 2004, BLOOD, V103, P3535, DOI 10.1182/blood-2003-09-3335	45	20	22	0	8	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	OCT 30	2009	4	10							e7661	10.1371/journal.pone.0007661	http://dx.doi.org/10.1371/journal.pone.0007661			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	514RW	19876398	Green Published, gold, Green Submitted			2022-12-25	WOS:000271414300013
J	Martin, RM; Cardoso, MC				Martin, Robert M.; Cardoso, M. Cristina			Chromatin condensation modulates access and binding of nuclear proteins	FASEB JOURNAL			English	Article						fluorescence microscopy; GFP; mitosis; photoactivation; photobleaching	MAMMALIAN-CELLS; LIVING CELLS; IN-VIVO; DYNAMICS; HETEROCHROMATIN; HP1; DNA; DOMAINS; GFP; COMPARTMENTALIZATION	The condensation level of chromatin is controlled by epigenetic modifications and associated regulatory factors and changes throughout differentiation and cell cycle progression. To test whether changes of chromatin condensation levels per se affect access and binding of proteins, we used a hypertonic cell treatment. This shift to hyperosmolar medium increased nuclear calcium concentrations and induced a reversible chromatin condensation comparable to the levels in mitosis. However, this condensation was independent of mitotic histone H3 serine 10 phosphorylation. Photobleaching and photoactivation experiments with chromatin proteins- histone H2B-GFP and GFP-HP1 alpha-before and after induced chromatin condensation demonstrated that hypercondensation reduced their dissociation rate and stabilized their chromatin binding. Finally, measuring the distribution of nucleoplasmic proteins in the size range from 30 to 230 kDa, we found that even relatively small proteins like GFP were excluded from highly condensed chromatin in living cells. These results suggest that structural changes in condensed chromatin by themselves affect chromatin access and binding of chromatin proteins independent of regulatory histone modifications.-Martin, R. M., Cardoso, M. C. Chromatin condensation modulates access and binding of nuclear proteins. FASEB J. 24, 1066-1072 (2010). www.fasebj.org	[Cardoso, M. Cristina] Tech Univ Darmstadt, Dept Biol, D-64287 Darmstadt, Germany; [Martin, Robert M.; Cardoso, M. Cristina] Max Delbruck Ctr Mol Med, Berlin, Germany	Technical University of Darmstadt; Helmholtz Association; Max Delbruck Center for Molecular Medicine	Cardoso, MC (corresponding author), Tech Univ Darmstadt, Dept Biol, Petersenstr 30, D-64287 Darmstadt, Germany.	cardoso@bio.tu-darmstadt.de	Cardoso, M. Cristina/F-5215-2011	Martin, Robert/0000-0001-5600-7525	German Research Council (DFG)	German Research Council (DFG)(German Research Foundation (DFG))	The authors thank Sabine M. Gorisch for many discussions, Jeffrey H. Stear for comments on the manuscript and Ulrike Ziebold [Max Delbruck Center for Molecular Medicine (MDC), Berlin, Germany] for the kind gift of anti-phospho H3 antibody. The authors are indebted to Heinrich Leonhardt for numerous discussions and helpful suggestions throughout the course of this project. This work was funded by grants of the German Research Council (DFG) to M.C.C.	Albiez H, 2006, CHROMOSOME RES, V14, P707, DOI 10.1007/s10577-006-1086-x; Belmont AS, 2006, CURR OPIN CELL BIOL, V18, P632, DOI 10.1016/j.ceb.2006.09.007; Belmont AS, 1999, CURR OPIN CELL BIOL, V11, P307, DOI 10.1016/S0955-0674(99)80041-6; Campbell RE, 2002, P NATL ACAD SCI USA, V99, P7877, DOI 10.1073/pnas.082243699; Cardoso MC, 1997, J CELL BIOL, V139, P579, DOI 10.1083/jcb.139.3.579; Chen DY, 2005, J CELL BIOL, V168, P41, DOI 10.1083/jcb.200407182; Cheutin T, 2003, SCIENCE, V299, P721, DOI 10.1126/science.1078572; Cremer T, 2000, CRIT REV EUKAR GENE, V10, P179; Cremer T, 2004, BIOL CELL, V96, P555, DOI 10.1016/j.biolcel.2004.07.002; Daban JR, 2003, BIOCHEM CELL BIOL, V81, P91, DOI 10.1139/o03-037; Dialynas GK, 2007, J CELL SCI, V120, P3415, DOI 10.1242/jcs.012914; Easwaran HP, 2007, BMC CELL BIOL, V8, DOI 10.1186/1471-2121-8-42; Easwaran HP, 2004, EMBO REP, V5, P1181, DOI 10.1038/sj.embor.7400295; Ellenberg J, 1999, TRENDS CELL BIOL, V9, P52, DOI 10.1016/S0962-8924(98)01420-2; Festenstein R, 2003, SCIENCE, V299, P719, DOI 10.1126/science.1078694; Francastel C, 2000, NAT REV MOL CELL BIO, V1, P137, DOI 10.1038/35040083; Gorisch SM, 2005, J CELL SCI, V118, P5825, DOI 10.1242/jcs.02689; Gorisch SM, 2003, EXP CELL RES, V289, P282, DOI 10.1016/S0014-4827(03)00265-9; Grunwald D, 2008, BIOPHYS J, V94, P2847, DOI 10.1529/biophysj.107.115014; Kanda T, 1998, CURR BIOL, V8, P377, DOI 10.1016/S0960-9822(98)70156-3; Kimura H, 2001, J CELL BIOL, V153, P1341, DOI 10.1083/jcb.153.7.1341; Kouzarides T, 2007, CELL, V128, P693, DOI 10.1016/j.cell.2007.02.005; Leonhardt H, 2000, J CELL BIOL, V149, P271, DOI 10.1083/jcb.149.2.271; Lippincott-Schwartz J, 2001, NAT REV MOL CELL BIO, V2, P444, DOI 10.1038/35073068; Martin RM, 2007, CELL CYCLE, V6, P2422, DOI 10.4161/cc.6.19.4738; Mora-Bermudez F, 2007, METHODS, V41, P158, DOI 10.1016/j.ymeth.2006.07.035; Pack C, 2006, BIOPHYS J, V91, P3921, DOI 10.1529/biophysj.106.079467; Patterson GH, 2002, SCIENCE, V297, P1873, DOI 10.1126/science.1074952; Phair RD, 2004, METHOD ENZYMOL, V375, P393; Richards EJ, 2002, CELL, V108, P489, DOI 10.1016/S0092-8674(02)00644-X; Schmiedeberg L, 2004, MOL BIOL CELL, V15, P2819, DOI 10.1091/mbc.E03-11-0827; Verschure PJ, 2005, MOL CELL BIOL, V25, P4552, DOI 10.1128/MCB.25.11.4552-4564.2005; Verschure PJ, 2003, EMBO REP, V4, P861, DOI 10.1038/sj.embor.embor922	33	50	52	1	4	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	APR	2010	24	4					1066	1072		10.1096/fj.08-128959	http://dx.doi.org/10.1096/fj.08-128959			7	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	580PV	19897663	Green Published			2022-12-25	WOS:000276462300014
J	Reeves, CV; Dufraine, J; Young, JAT; Kitajewski, J				Reeves, C. V.; Dufraine, J.; Young, J. A. T.; Kitajewski, J.			Anthrax toxin receptor 2 is expressed in murine and tumor vasculature and functions in endothelial proliferation and morphogenesis	ONCOGENE			English	Article						ANTXR2; CMG2; angiogenesis; endothelial cells	CAPILLARY MORPHOGENESIS; ANGIOGENESIS; PROTEIN-2; CELLS; IDENTIFICATION; COLLAGEN; MARKERS; CANCER; DOMAIN	The Capillary Morphogenesis Gene 2 (CMG2) gene encodes an Anthrax toxin receptor (ANTXR2), but the normal physiological function is not known. ANTXR2/CMG2 was originally identified as a result of up-regulation during capillary morphogenesis of endothelial cells (ECs) cultured in vitro. We explored the hypothesis that key steps of the angiogenic process are either dependent or are influenced by ANTXR2/CMG2 activity. We describe the expression pattern of ANTXR2/CMG2 in several murine tissues and in normal breast and breast tumors. Endothelial expression was found in all of the tissues analyzed, in cultured ECs and in breast tumor vessels; however, ANTXR2/CMG2 expression was not restricted to this cell type. To assess potential angiogenic function, we used RNA interference to achieve significant reduction of ANTXR2/CMG2 expression in cultured human umbilical venous endothelial cells (HUVECs). Reduced ANTXR2/CMG2 expression resulted in significant inhibition of proliferation and reduced capacity of ECs to form capillary-like networks in vitro, whereas overexpression of ANTXR2/CMG2 in HUVEC increased proliferation and capillary-like network formation. Little change in migration of ECs was observed on knockdown or overexpression. We conclude that ANTXR2/CMG2 functions to promote endothelial proliferation and morphogenesis during sprouting angiogenesis, consistent with the endothelial expression of ANTXR2/CMG2 in several vascular beds. Oncogene (2010) 29, 789-801; doi:10.1038/onc.2009.383; published online 9 November 2009	[Kitajewski, J.] Columbia Univ, Med Ctr, Dept Pathol, Off 926,Irving Canc Res Ctr, New York, NY 10035 USA; [Reeves, C. V.; Dufraine, J.; Kitajewski, J.] Columbia Univ, Med Ctr, OB GYN, New York, NY 10035 USA; [Young, J. A. T.] Salk Inst Biol Studies, Infect Dis Lab, La Jolla, CA 92037 USA; [Kitajewski, J.] Columbia Univ, Med Ctr, Herbert Irving Comprehens Canc Ctr, New York, NY 10035 USA	Columbia University; Columbia University; Salk Institute; Columbia University	Kitajewski, J (corresponding author), Columbia Univ, Med Ctr, Dept Pathol, Off 926,Irving Canc Res Ctr, 1130 St Nicholas Ave, New York, NY 10035 USA.	jkk9@columbia.edu		Young, John/0000-0003-1824-2561	NIH [RO1 HL62454, RO1 AI064654, DK07328, AI48489]; DOD Breast Cancer Program [X81WH-06-1-0355]; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL062454] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI064654, R01AI048489, R01AI076852] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [T32DK007328] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); DOD Breast Cancer Program(United States Department of Defense); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))	This work was supported by NIH RO1 HL62454 (JKK) and NIH RO1 AI064654 (JKK). CVR was supported by endocrinology training grant DK07328 and by a fellowship from the DOD Breast Cancer Program X81WH-06-1-0355. JY was supported by NIH grant AI48489. We thank Dr Yasuhiro Funahashi, Ayelet Spitzer, and Eunice Kim for technical support, Dr David Owens for the gift of the antibodies and critical reading of the paper, and Dr Darrell Yamashiro for help with preparation of the figures.	Adams RH, 2007, NAT REV MOL CELL BIO, V8, P464, DOI 10.1038/nrm2183; Armulik A, 2005, CIRC RES, V97, P512, DOI 10.1161/01.RES.0000182903.16652.d7; Bell SE, 2001, J CELL SCI, V114, P2755; Bonuccelli G, 2005, AM J PHYSIOL-CELL PH, V288, pC1402, DOI 10.1152/ajpcell.00582.2004; Bradley KA, 2001, NATURE, V414, P225, DOI 10.1038/n35101999; Carmeliet P, 2000, NATURE, V407, P249, DOI 10.1038/35025220; Carson-Walter EB, 2001, CANCER RES, V61, P6649; Hanks S, 2003, AM J HUM GENET, V73, P791, DOI 10.1086/378418; Hotchkiss KA, 2005, EXP CELL RES, V305, P133, DOI 10.1016/j.yexcr.2004.12.025; JAFFE EA, 1973, J CLIN INVEST, V52, P2745, DOI 10.1172/JCI107470; Li ER, 2000, EXP DERMATOL, V9, P431, DOI 10.1034/j.1600-0625.2000.009006431.x; Liu SL, 2009, P NATL ACAD SCI USA, V106, P12424, DOI 10.1073/pnas.0905409106; Mock M, 2003, CELL MICROBIOL, V5, P15, DOI 10.1046/j.1462-5822.2003.00253.x; Nanda A, 2004, CURR OPIN ONCOL, V16, P44, DOI 10.1097/00001622-200401000-00009; Nanda A, 2004, CANCER RES, V64, P817, DOI 10.1158/0008-5472.CAN-03-2408; Risau W, 1997, NATURE, V386, P671, DOI 10.1038/386671a0; Rmali KA, 2005, BIOCHEM BIOPH RES CO, V334, P231, DOI 10.1016/j.bbrc.2005.06.085; Rogers MS, 2007, CANCER RES, V67, P9980, DOI 10.1158/0008-5472.CAN-07-0829; Scobie HM, 2006, PLOS PATHOG, V2, P949, DOI 10.1371/journal.ppat.0020111; Scobie HM, 2005, J INFECT DIS, V192, P1047, DOI 10.1086/432731; Scobie HM, 2003, P NATL ACAD SCI USA, V100, P5170, DOI 10.1073/pnas.0431098100; Shimaoka M, 2002, P NATL ACAD SCI USA, V99, P16737, DOI 10.1073/pnas.252633099; St Croix B, 2000, SCIENCE, V289, P1197; Tung JJ, 2009, ANGIOGENESIS, V12, P209, DOI 10.1007/s10456-009-9139-3; Xu QF, 2007, MICROB PATHOGENESIS, V43, P37, DOI 10.1016/j.micpath.2007.03.002	25	46	47	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 11	2010	29	6					789	801		10.1038/onc.2009.383	http://dx.doi.org/10.1038/onc.2009.383			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	553WP	19901963	Green Accepted			2022-12-25	WOS:000274397800002
J	Parodi, J; Sepulveda, FJ; Roa, J; Opazo, C; Inestrosa, NC; Aguayo, LG				Parodi, Jorge; Sepulveda, Fernando J.; Roa, Jorge; Opazo, Carlos; Inestrosa, Nibaldo C.; Aguayo, Luis G.			beta-Amyloid Causes Depletion of Synaptic Vesicles Leading to Neurotransmission Failure	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LONG-TERM POTENTIATION; ALZHEIMERS-DISEASE; A-BETA; ION CHANNELS; HIPPOCAMPAL SYNAPSES; CALCIUM-CHANNELS; ALPHA-LATROTOXIN; PROTEIN; MECHANISM; NEURONS	Alzheimer disease is a progressive neurodegenerative brain disorder that leads to major debilitating cognitive deficits. It is believed that the alterations capable of causing brain circuitry dysfunctions have a slow onset and that the full blown disease may take several years to develop. Therefore, it is important to understand the early, asymptomatic, and possible reversible states of the disease with the aim of proposing preventive and disease-modifying therapeutic strategies. It is largely unknown how amyloid beta-peptide (A beta), a principal agent in Alzheimer disease, affects synapses in brain neurons. In this study, we found that similar to other pore-forming neurotoxins, A beta induced a rapid increase in intracellular calcium and miniature currents, indicating an enhancement in vesicular transmitter release. Significantly, blockade of these effects by low extracellular calcium and a peptide known to act as an inhibitor of the A beta-induced pore prevented the delayed failure, indicating that A beta blocks neurotransmission by causing vesicular depletion. This new mechanism for A beta synaptic toxicity should provide an alternative pathway to search for small molecules that can antagonize these effects of A beta.	[Aguayo, Luis G.] Univ Concepcion, Dept Physiol, Neurophysiol Lab, Concepcion, Chile; [Sepulveda, Fernando J.; Opazo, Carlos] Univ Concepcion, Dept Physiol, Lab Neurobiomet, Concepcion, Chile; [Aguayo, Luis G.] Univ Concepcion, Ctr Invest Avanzada Educ, Concepcion, Chile; [Inestrosa, Nibaldo C.] Pontificia Univ Catolica Chile, Ctr Regulac Celular & Patol Joaquin V Luco, Ctr Envejecimiento & Regenerac CARE, Millenium Inst Fundamental & Appl Biol,Fac Cienci, Santiago, Chile	Universidad de Concepcion; Universidad de Concepcion; Universidad de Concepcion; Pontificia Universidad Catolica de Chile	Aguayo, LG (corresponding author), Univ Concepcion, Dept Physiol, Neurophysiol Lab, POB 160-C, Concepcion, Chile.	laguayo@udec.cl		Opazo, Carlos/0000-0003-3473-7548; Parodi, Jorge/0000-0002-9117-5433	Fondo Nacional de Desarrollo Cientifico y Technologico [1060368]; Ring of Research Programa Bicentenario de Ciencia y Tecnologia [ACT-04, CIE-05]; Direccion de Investigacion Universidad de Concepcion [205.033.101-1.0]	Fondo Nacional de Desarrollo Cientifico y Technologico(Comision Nacional de Investigacion Cientifica y Tecnologica (CONICYT)CONICYT FONDECYT); Ring of Research Programa Bicentenario de Ciencia y Tecnologia; Direccion de Investigacion Universidad de Concepcion	This work was supported by Fondo Nacional de Desarrollo Cientifico y Technologico Grant 1060368, Ring of Research Programa Bicentenario de Ciencia y Tecnologia ACT-04, CIE-05 (to L. G. A. and C. O.) and Direccion de Investigacion Universidad de Concepcion Grant 205.033.101-1.0 (to J. R.). 1 Both authors contributed equally to this work.	Alarcon JM, 2006, PEPTIDES, V27, P95, DOI 10.1016/j.peptides.2005.07.004; Arispe N, 2004, J MEMBRANE BIOL, V197, P33, DOI 10.1007/s00232-003-0638-7; ARISPE N, 1994, ANN NY ACAD SCI, V747, P256; Arispe N, 2007, BBA-BIOMEMBRANES, V1768, P1952, DOI 10.1016/j.bbamem.2007.03.014; Ashton AC, 2001, J BIOL CHEM, V276, P44695, DOI 10.1074/jbc.M108088200; Blanchard BJ, 1997, BRAIN RES, V776, P40, DOI 10.1016/S0006-8993(97)01003-2; Bobich JA, 2004, J ALZHEIMERS DIS, V6, P243; Chauhan NB, 2002, J NEUROSCI RES, V69, P10, DOI 10.1002/jnr.10286; Cousin MA, 2000, J NEUROSCI, V20, P949, DOI 10.1523/JNEUROSCI.20-03-00949.2000; Demuro A, 2005, J BIOL CHEM, V280, P17294, DOI 10.1074/jbc.M500997200; Diaz JC, 2006, BIOL RES, V39, P447, DOI 10.4067/S0716-97602006000300007; Glabe CG, 2006, NEUROLOGY, V66, pS74, DOI 10.1212/01.wnl.0000192103.24796.42; GOODMAN LS, 2001, GOODMAN GILMANS PHAR, P203; Grace EA, 2002, NEUROSCIENCE, V114, P265, DOI 10.1016/S0306-4522(02)00241-5; Haass C, 2007, NAT REV MOL CELL BIO, V8, P101, DOI 10.1038/nrm2101; Hsia AY, 1999, P NATL ACAD SCI USA, V96, P3228, DOI 10.1073/pnas.96.6.3228; Hsieh H, 2006, NEURON, V52, P831, DOI 10.1016/j.neuron.2006.10.035; Kelly BL, 2005, J BIOL CHEM, V280, P31746, DOI 10.1074/jbc.M503259200; Kelly BL, 2006, J BIOL CHEM, V281, P28079, DOI 10.1074/jbc.M605081200; Khvotchev M, 2000, NEUROSCIENCE, V101, P793, DOI 10.1016/S0306-4522(00)00378-X; Kourie JI, 2001, CELL MOL NEUROBIOL, V21, P255, DOI 10.1023/A:1010995121153; KRIEBEL ME, 1987, NEUROSCIENCE, V23, P745, DOI 10.1016/0306-4522(87)90092-3; Lonart G, 2006, BRAIN RES, V1107, P42, DOI 10.1016/j.brainres.2006.05.092; Mattson MP, 2003, CELL CALCIUM, V34, P385, DOI 10.1016/S0143-4160(03)00128-3; Mattson MP, 1997, PHYSIOL REV, V77, P1081, DOI 10.1152/physrev.1997.77.4.1081; McLean CA, 1999, ANN NEUROL, V46, P860, DOI 10.1002/1531-8249(199912)46:6<860::AID-ANA8>3.0.CO;2-M; Nomura I, 2005, NEUROSCI LETT, V391, P1, DOI 10.1016/j.neulet.2005.08.024; Oddo S, 2003, NEURON, V39, P409, DOI 10.1016/S0896-6273(03)00434-3; Opazo C, 2002, J BIOL CHEM, V277, P40302, DOI 10.1074/jbc.M206428200; Qi JS, 2001, NEUROSCIENCE, V105, P845, DOI 10.1016/S0306-4522(01)00244-5; Quist A, 2005, P NATL ACAD SCI USA, V102, P10427, DOI 10.1073/pnas.0502066102; Ramsden M, 2001, J NEUROCHEM, V79, P699, DOI 10.1046/j.1471-4159.2001.00618.x; Reddy PH, 2005, J ALZHEIMERS DIS, V7, P103, DOI 10.3233/jad-2005-7203; RHEE JS, 1994, J NEUROPHYSIOL, V72, P1103, DOI 10.1152/jn.1994.72.3.1103; Rizzoli SO, 2005, NAT REV NEUROSCI, V6, P57, DOI 10.1038/nrn1583; Rosenmund C, 1996, NEURON, V16, P1197, DOI 10.1016/S0896-6273(00)80146-4; Ryan TA, 1996, P NATL ACAD SCI USA, V93, P5567, DOI 10.1073/pnas.93.11.5567; RYAN TA, 1995, NEURON, V14, P983, DOI 10.1016/0896-6273(95)90336-4; RYAN TA, 1993, NEURON, V11, P713, DOI 10.1016/0896-6273(93)90081-2; Schneggenburger R, 2005, CURR OPIN NEUROBIOL, V15, P266, DOI 10.1016/j.conb.2005.05.006; Selkoe DJ, 2002, SCIENCE, V298, P789, DOI 10.1126/science.1074069; Shankar GM, 2008, NAT MED, V14, P837, DOI 10.1038/nm1782; Shankar GM, 2007, J NEUROSCI, V27, P2866, DOI 10.1523/JNEUROSCI.4970-06.2007; Snyder EM, 2005, NAT NEUROSCI, V8, P1051, DOI 10.1038/nn1503; Stephan A, 2001, J NEUROSCI, V21, P5703, DOI 10.1523/JNEUROSCI.21-15-05703.2001; Tapia JC, 2001, NEUROSCIENCE, V108, P493, DOI 10.1016/S0306-4522(01)00348-7; Walsh DM, 2004, PROTEIN PEPTIDE LETT, V11, P213, DOI 10.2174/0929866043407174; Wang QW, 2004, J NEUROSCI, V24, P3370, DOI 10.1523/JNEUROSCI.1633-03.2004; Yao PJ, 1998, NEUROSCI LETT, V252, P33, DOI 10.1016/S0304-3940(98)00547-3; Ye CP, 2004, NEUROSCI LETT, V366, P320, DOI 10.1016/j.neulet.2004.05.060	50	141	143	0	14	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 22	2010	285	4					2506	2514		10.1074/jbc.M109.030023	http://dx.doi.org/10.1074/jbc.M109.030023			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	544YP	19915004	hybrid, Green Published			2022-12-25	WOS:000273697800029
J	Ribeiro, AS; Albergaria, A; Sousa, B; Correia, AL; Bracke, M; Seruca, R; Schmitt, FC; Paredes, J				Ribeiro, A. S.; Albergaria, A.; Sousa, B.; Correia, A. L.; Bracke, M.; Seruca, R.; Schmitt, F. C.; Paredes, J.			Extracellular cleavage and shedding of P-cadherin: a mechanism underlying the invasive behaviour of breast cancer cells	ONCOGENE			English	Article						P-cadherin; migration; invasion; MMPs; sP-cad	EPITHELIAL-MESENCHYMAL TRANSITION; MATRIX METALLOPROTEINASE-1; GASTRIC-CANCER; EXPRESSION; ADHESION; LINES; CARCINOMA; MOTILITY; METASTASIS; PHENOTYPE	Cell-cell adhesion is an elementary process in normal epithelial cellular architecture. Several studies have shown the role mediated by cadherins in this process, besides their role in the maintenance of cell polarity, differentiation and cell growth. However, during tumour progression, these molecules are frequently altered. In breast cancer, tumours that overexpress P-cadherin usually present a high histological grade, show decreased cell polarity and are associated with worse patient survival. However, little is known about how this protein dictates the very aggressive behaviour of these tumours. To achieve this goal, we set up two breast cancer cell models, where P-cadherin expression was differently modulated and analysed in terms of cell invasion, motility and migration. We show that P-cadherin overexpression, in breast cancer cells with wild-type E-cadherin, promotes cell invasion, motility and migration. Moreover, we found that the overexpression of P-cadherin induces the secretion of matrix metalloproteases, specifically MMP-1 and MMP-2, which then lead to P-cadherin ectodomain cleavage. Further, we showed that soluble P-cadherin fragment is able to induce in vitro invasion of breast cancer cells. Overall, our results contribute to elucidate the mechanism underlying the invasive behaviour of P-cadherin expressing breast tumours. Oncogene (2010) 29, 392-402; doi:10.1038/onc.2009.338; published online 9 November 2009	[Ribeiro, A. S.; Albergaria, A.; Sousa, B.; Correia, A. L.; Seruca, R.; Schmitt, F. C.; Paredes, J.] Univ Porto IPATIMUP, Inst Mol Pathol & Immunol, Canc Genet Grp, P-4200465 Oporto, Portugal; [Albergaria, A.] Univ Minho, Sch Hlth Sci, Life & Hlth Sci Res Inst ICVS, Braga, Portugal; [Bracke, M.] Ghent Univ Hosp, Dept Radiotherapy & Nucl Med, Lab Expt Canc Res, Ghent, Belgium; [Schmitt, F. C.] Univ Porto, Fac Med, P-4100 Oporto, Portugal	Universidade do Porto; Universidade do Minho; Ghent University; Ghent University Hospital; Universidade do Porto	Paredes, J (corresponding author), Univ Porto IPATIMUP, Inst Mol Pathol & Immunol, Canc Genet Grp, Rua Dr Roberto Frias S-N, P-4200465 Oporto, Portugal.	jparedes@ipatimup.pt	Schmitt, Fernando/A-5270-2008; Correia, Ana Luisa/E-9738-2012; Albergaria, André/J-6162-2013; Paredes, Joana/F-8224-2011; Sousa, Bárbara/K-8854-2014; Ribeiro, Ana/J-7334-2013; seruca, raquel/F-8187-2011	Schmitt, Fernando/0000-0002-3711-8681; Albergaria, André/0000-0002-2315-2360; Paredes, Joana/0000-0002-1076-1343; Sousa, Bárbara/0000-0002-0990-022X; Ribeiro, Ana/0000-0002-9698-9233; Seruca, Raquel/0000-0002-8851-4166; Schmitt, Fernando/0000-0003-1006-6946; Correia, Ana Luisa/0000-0003-2414-0131	Portuguese Science and Technology Foundation (FCT) [POCI/BIA-BCM/59252/2004, SFRH/BD/36096/2007, SFRH/BD/15316/2005]	Portuguese Science and Technology Foundation (FCT)(Portuguese Foundation for Science and Technology)	The work presented was mainly supported by a scientific project (POCI/BIA-BCM/59252/2004) financed by the Portuguese Science and Technology Foundation (FCT). FCT also provided research grants as follows: Programa Ciencia 2007 (FCT) for Joana Paredes, and PhD research grants for Ana Sofia Ribeiro (SFRH/BD/36096/2007) and Andre Albergaria (SFRH/BD/15316/2005).	Blick T, 2008, CLIN EXP METASTAS, V25, P629, DOI 10.1007/s10585-008-9170-6; Cavallaro U, 2004, NAT REV CANCER, V4, P118, DOI 10.1038/nrc1276; Charafe-Jauffret E, 2006, ONCOGENE, V25, P2273, DOI 10.1038/sj.onc.1209254; Chen HY, 1997, J CELL SCI, V110, P345; Chhabra ES, 2007, NAT CELL BIOL, V9, P1110, DOI 10.1038/ncb1007-1110; De Paul AL, 2005, J ANDROL, V26, P44; Fenteany G, 2000, CURR BIOL, V10, P831, DOI 10.1016/S0960-9822(00)00579-0; FRIXEN UH, 1991, J CELL BIOL, V113, P173, DOI 10.1083/jcb.113.1.173; Fujimoto D, 2008, ANTICANCER RES, V28, P847; Gamallo C, 2001, MODERN PATHOL, V14, P650, DOI 10.1038/modpathol.3880367; Herren B, 1998, MOL BIOL CELL, V9, P1589, DOI 10.1091/mbc.9.6.1589; Ito T, 1999, MODERN PATHOL, V12, P669; Kang YB, 2003, CANCER CELL, V3, P537, DOI 10.1016/S1535-6108(03)00132-6; Lauffenburger DA, 1996, CELL, V84, P359, DOI 10.1016/S0092-8674(00)81280-5; Lochter A, 1997, J CELL BIOL, V139, P1861, DOI 10.1083/jcb.139.7.1861; Lombaerts M, 2006, BRIT J CANCER, V94, P661, DOI 10.1038/sj.bjc.6602996; Longatto Filho A, 2005, CYTOPATHOLOGY, V16, P88, DOI 10.1111/j.1365-2303.2004.00226.x; Mannello F, 2008, CANCER SCI, V99, P2160, DOI 10.1111/j.1349-7006.2008.00921.x; Murray GI, 1998, GUT, V43, P791, DOI 10.1136/gut.43.6.791; Murray GI, 1998, J PATHOL, V185, P256; Neve RM, 2006, CANCER CELL, V10, P515, DOI 10.1016/j.ccr.2006.10.008; Noe V, 2001, J CELL SCI, V114, P111; Okuyama N, 2008, ONCOL REP, V20, P1497, DOI 10.3892/or_00000171; Oliveira MJ, 2003, EMBO J, V22, P6161, DOI 10.1093/emboj/cdg586; Paredes J, 2008, J CLIN PATHOL, V61, P856, DOI 10.1136/jcp.2007.052704; Paredes J, 2005, CLIN CANCER RES, V11, P5869, DOI 10.1158/1078-0432.CCR-05-0059; Paredes J, 2004, CANCER RES, V64, P8309, DOI 10.1158/0008-5472.CAN-04-0795; Paredes J, 2002, PATHOL RES PRACT, V198, P795, DOI 10.1078/0344-0338-00338; Paredes J, 2007, BREAST CANCER RES, V9, DOI 10.1186/bcr1774; Paredes J, 2007, CELL ONCOL, V29, P467; Remacle AG, 1998, BRIT J CANCER, V77, P926, DOI 10.1038/bjc.1998.153; Sarrio D, 2008, CANCER RES, V68, P989, DOI 10.1158/0008-5472.CAN-07-2017; Simpson KJ, 2008, NAT CELL BIOL, V10, P1027, DOI 10.1038/ncb1762; Soler AP, 1999, CANCER-AM CANCER SOC, V86, P1263, DOI 10.1002/(SICI)1097-0142(19991001)86:7<1263::AID-CNCR23>3.3.CO;2-U; Soler AP, 2002, J CELL BIOCHEM, V85, P180, DOI 10.1002/jcb.10126; Stefansson IM, 2004, J CLIN ONCOL, V22, P1242, DOI 10.1200/JCO.2004.09.034; STETLERSTEVENSON WG, 1993, ANNU REV CELL BIOL, V9, P541, DOI 10.1146/annurev.cb.09.110193.002545; Taniuchi K, 2005, CANCER RES, V65, P3092, DOI 10.1158/0008.5472.CAN-04-3646; Thiery JP, 2002, NAT REV CANCER, V2, P442, DOI 10.1038/nrc822; Van Marck V, 2005, CANCER RES, V65, P8774, DOI 10.1158/0008-5472.CAN-04-4414; Vu TH, 2000, GENE DEV, V14, P2123, DOI 10.1101/gad.815400; Yamazaki D, 2005, CANCER SCI, V96, P379, DOI 10.1111/j.1349-7006.2005.00062.x	42	84	84	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 21	2010	29	3					392	402		10.1038/onc.2009.338	http://dx.doi.org/10.1038/onc.2009.338			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	546EO	19901964	Green Published			2022-12-25	WOS:000273793200008
J	Hagiwara, Y; Sugishima, M; Khawn, H; Kinoshita, H; Inomata, K; Shang, LX; Lagarias, JC; Takahashi, Y; Fukuyama, K				Hagiwara, Yoshinori; Sugishima, Masakazu; Khawn, Htoi; Kinoshita, Hideki; Inomata, Katsuhiko; Shang, Lixia; Lagarias, J. Clark; Takahashi, Yasuhiro; Fukuyama, Keiichi			Structural Insights into Vinyl Reduction Regiospecificity of Phycocyanobilin:Ferredoxin Oxidoreductase (PcyA)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SYNECHOCYSTIS SP PCC-6803; CRYSTAL-STRUCTURE; FERREDOXIN OXIDOREDUCTASE; HEME OXYGENASE; CYANOBACTERIAL PHYCOCYANOBILIN; ESCHERICHIA-COLI; KEY ENZYME; BILIVERDIN; COMPLEX; BIOSYNTHESIS	Phycocyanobilin: ferredoxin oxidoreductase (PcyA) is the best characterized member of the ferredoxin-dependent bilin reductase family. Unlike other ferredoxin-dependent bilin reductases that catalyze a two-electron reduction, PcyA sequentially reduces D-ring (exo) and A-ring (endo) vinyl groups of biliverdin IX alpha (BV) to yield phycocyanobilin, a key pigment precursor of the light-harvesting antennae complexes of red algae, cyanobacteria, and cryptophytes. To address the structural basis for the reduction regiospecificity of PcyA, we report new high resolution crystal structures of bilin substrate complexes of PcyA from Synechocystis sp. PCC6803, all of which lack exo-vinyl reduction activity. These include the BV complex of the E76Q mutant as well as substrate-bound complexes of wild-type PcyA with the reaction intermediate 18(1),18(2)-dihydrobiliverdin IX alpha (18EtBV) and with biliverdin XIII alpha (BV13), a synthetic substrate that lacks an exo-vinyl group. Although the overall folds and the binding sites of the U-shaped substrates of all three complexes were similar with wild-type PcyA-BV, the orientation of the Glu-76 side chain, which was in close contact with the exo-vinyl group in PcyA-BV, was rotated away from the bilin D-ring. The local structures around the A-rings in the three complexes, which all retain the ability to reduce the A-ring of their bound pigments, were nearly identical with that of wild-type PcyA-BV. Consistent with the proposed proton-donating role of the carboxylic acid side chain of Glu-76 for exo-vinyl reduction, these structures reveal new insight into the reduction regiospecificity of PcyA.	[Hagiwara, Yoshinori; Fukuyama, Keiichi] Osaka Univ, Dept Biol Sci, Grad Sch Sci, Osaka 5600043, Japan; [Sugishima, Masakazu] Kurume Univ, Sch Med, Dept Med Biochem, Fukuoka 8300011, Japan; [Khawn, Htoi; Kinoshita, Hideki; Inomata, Katsuhiko] Kanazawa Univ, Grad Sch Nat Sci & Technol, Div Mat Sci, Kanazawa, Ishikawa 9201192, Japan; [Shang, Lixia; Lagarias, J. Clark] Univ Calif Davis, Sect Mol & Cellular Biol, Davis, CA 95616 USA; [Takahashi, Yasuhiro] Saitama Univ, Grad Sch Sci & Engn, Div Life Sci, Saitama 3388570, Japan	Osaka University; Kurume University; Kanazawa University; University of California System; University of California Davis; Saitama University	Fukuyama, K (corresponding author), Osaka Univ, Dept Biol Sci, Grad Sch Sci, 1-1 Machikaneyama Cho, Osaka 5600043, Japan.	fukuyama@bio.sci.osaka-u.ac.jp	Lagarias, John Clark/L-3139-2013; Sugishima, Masakazu/M-2773-2019; Takahashi, Yasuhiro/F-1119-2011; Sugishima, Masakazu/B-1049-2010	Lagarias, John Clark/0000-0002-2093-0403; Sugishima, Masakazu/0000-0002-0840-4929; Takahashi, Yasuhiro/0000-0002-0588-6045; Sugishima, Masakazu/0000-0002-0840-4929; Hagiwara, Yoshinori/0000-0002-0895-3004	Japan Society for the Promotion of Science [20370037, 18570105, 19.1065]; United States National Science Foundation [MCB-0843625]	Japan Society for the Promotion of Science(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of Science); United States National Science Foundation(National Science Foundation (NSF))	This work was supported in part by Grants-in-aid for Scientific Research 20370037 and 18570105 (to K.F.), by Grant-in-aid for Research Fellows of the Japan Society for the Promotion of Science 19.1065 (to Y.H.), and by United States National Science Foundation Grant MCB-0843625 (to Andrew J. Fisher and J.C.L.).	Afonin AV, 1996, RUSS CHEM B+, V45, P1137, DOI 10.1007/BF01431606; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; BEALE SI, 1993, CHEM REV, V93, P785, DOI 10.1021/cr00018a008; Cornejo J, 1998, PLANT J, V15, P99, DOI 10.1046/j.1365-313X.1998.00186.x; Dammeyer T, 2008, PHOTOCH PHOTOBIO SCI, V7, P1121, DOI 10.1039/b807209b; Dammeyer T, 2008, J BIOL CHEM, V283, P27547, DOI 10.1074/jbc.M803765200; Dammeyer T, 2008, CURR BIOL, V18, P442, DOI 10.1016/j.cub.2008.02.067; de Marsac NT, 2003, PHOTOSYNTH RES, V76, P197; DeLano W.L., 2002, PYMOL MOL GRAPHICS S; Frankenberg N, 2003, J BIOL CHEM, V278, P9219, DOI 10.1074/jbc.M211643200; Frankenberg N, 2001, PLANT CELL, V13, P965, DOI 10.1105/tpc.13.4.965; Frankenberg N., 2003, PORPHYRIN HDB, P211; Franklin KA, 2005, INT J DEV BIOL, V49, P653, DOI 10.1387/ijdb.051989kf; GROSSMAN AR, 1993, MICROBIOL REV, V57, P725, DOI 10.1128/MMBR.57.3.725-749.1993; Hagiwara Y, 2006, P NATL ACAD SCI USA, V103, P27, DOI 10.1073/pnas.0507266103; Hagiwara Y, 2006, FEBS LETT, V580, P3823, DOI 10.1016/j.febslet.2006.05.075; Hughes Jon, 1999, Plant Physiology (Rockville), V121, P1059, DOI 10.1104/pp.121.4.1059; Inomata K, 2008, B CHEM SOC JPN, V81, P25, DOI 10.1246/bcsj.81.25; Kakiuchi T, 1998, CHEM LETT, P1001, DOI 10.1246/cl.1998.1001; Kakiuchi T, 1999, SYNLETT, P901; KARNIOL B, 2005, PHOTOMORPHOGENESIS P, P65; Kleywegt GJ, 1998, ACTA CRYSTALLOGR D, V54, P1119, DOI 10.1107/S0907444998007100; MA JS, 1984, J HETEROCYCLIC CHEM, V21, P1005, DOI 10.1002/jhet.5570210415; McDonagh A. F., 1979, PORPHYRINS, VVI; MCDONAGH AF, 1980, BIOCHEM J, V189, P193, DOI 10.1042/bj1890193; McRee DE, 1999, J STRUCT BIOL, V125, P156, DOI 10.1006/jsbi.1999.4094; Migita CT, 2003, EUR J BIOCHEM, V270, P687, DOI 10.1046/j.1432-1033.2003.03421.x; Miroux B, 1996, J MOL BIOL, V260, P289, DOI 10.1006/jmbi.1996.0399; Murshudov GN, 1997, ACTA CRYSTALLOGR D, V53, P240, DOI 10.1107/S0907444996012255; Nakamura M, 1999, J BIOCHEM, V126, P10, DOI 10.1093/oxfordjournals.jbchem.a022409; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Potterton E, 2002, ACTA CRYSTALLOGR D, V58, P1955, DOI 10.1107/S0907444902015391; Potterton L, 2004, ACTA CRYSTALLOGR D, V60, P2288, DOI 10.1107/S0907444904023716; Rockwell NC, 2006, ANNU REV PLANT BIOL, V57, P837, DOI 10.1146/annurev.arplant.56.032604.144208; Sheldrick GM, 1997, METHOD ENZYMOL, V277, P319, DOI 10.1016/S0076-6879(97)77018-6; SHELDRICK WS, 1976, J CHEM SOC PERK T 2, P1457, DOI 10.1039/p29760001457; Stoll S, 2009, J AM CHEM SOC, V131, P1986, DOI 10.1021/ja808573f; Sugishima M, 2005, BIOCHEMISTRY-US, V44, P4257, DOI 10.1021/bi0480483; Sugishima M, 2004, EUR J BIOCHEM, V271, P4517, DOI 10.1111/j.1432-1033.2004.04411.x; Sugishima M, 2003, J BIOL CHEM, V278, P32352, DOI 10.1074/jbc.M303682200; Sugishima M, 2009, J MOL BIOL, V389, P376, DOI 10.1016/j.jmb.2009.04.017; Takahashi Y, 1999, J BIOCHEM, V126, P917, DOI 10.1093/oxfordjournals.jbchem.a022535; TERRY MJ, 1995, J BIOL CHEM, V270, P11111, DOI 10.1074/jbc.270.19.11111; Tu SL, 2007, BIOCHEMISTRY-US, V46, P1484, DOI 10.1021/bi062038f; Tu SL, 2006, J BIOL CHEM, V281, P3127, DOI 10.1074/jbc.M510126200; Tu SL, 2004, J AM CHEM SOC, V126, P8682, DOI 10.1021/ja049280z; WAGNER UG, 1995, J MOL BIOL, V247, P326, DOI 10.1006/jmbi.1994.0142; Wuthrich KL, 2000, PLANT J, V21, P189, DOI 10.1046/j.1365-313x.2000.00667.x; Zhang XH, 2005, FEBS J, V272, P1012, DOI 10.1111/j.1742-4658.2004.04535.x	49	19	20	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 8	2010	285	2					1000	1007		10.1074/jbc.M109.055632	http://dx.doi.org/10.1074/jbc.M109.055632			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	539MH	19887371	Green Published, hybrid			2022-12-25	WOS:000273258200020
J	Haller, JF; Smith, C; Liu, DL; Zheng, HY; Tornheim, K; Han, GS; Carman, GM; Zoeller, RA				Haller, Jorge F.; Smith, Conor; Liu, Dailan; Zheng, Hongying; Tornheim, Keith; Han, Gil-Soo; Carman, George M.; Zoeller, Raphael A.			Isolation of Novel Animal Cell Lines Defective in Glycerolipid Biosynthesis Reveals Mutations in Glucose-6-phosphate Isomerase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NONSPHEROCYTIC HEMOLYTIC-ANEMIA; AUTOCRINE MOTILITY FACTOR; SACCHAROMYCES-CEREVISIAE; METABOLIC SYNDROME; LIPID-METABOLISM; PHOSPHOGLUCOSE ISOMERASE; PHOSPHOHEXOSE ISOMERASE; PHOSPHATASE ENZYMES; ENZYMATIC SYNTHESIS; CRYSTAL-STRUCTURE	Glycerolipids are structural components for membranes and serve in energy storage. We describe here the use of a photodynamic selection technique to generate a population of Chinese hamster ovary cells that display a global deficiency in glycerolipid biosynthesis. One isolate from this population, GroD1, displayed a profound reduction in the synthesis of phosphatidylcholine, phosphatidylethanolamine, and triglycerides but presented high levels of phosphatidic acid and normal levels of phosphatidylinositol synthesis. This was accompanied by a reduction in phosphatidate phosphatase 1 (PAP1) activity. Expression cloning and sequencing of the cDNA obtained from GroD1 revealed a point mutation, Gly-189 -> Glu, in glucose-6-phosphate isomerase (GPI), a glycolytic enzyme involved in an inherited disorder that results in anemia and neuromuscular symptoms in humans. GPI activity was reduced by 87% in GroD1. No significant differences were found in DNA synthesis, protein synthesis, and ATP levels, whereas glycerol 3-phosphate levels were increased in the mutant. Expression of wild-type hamster GPI restored GPI activity, glycerolipid biosynthesis, and PAP1 activity in GroD1. Two additional, independently isolated GPI-deficient mutants displayed similar phenotypes with respect to PAP1 activity and glycerolipid biosynthesis. These findings uncover a novel relationship between GPI, involved in carbohydrate metabolism, and PAP1, a lipogenic enzyme. These results may also help to explain neuromuscular symptoms associated with inherited GPI deficiency.	[Haller, Jorge F.; Smith, Conor; Liu, Dailan; Zheng, Hongying; Zoeller, Raphael A.] Boston Univ, Sch Med, Dept Physiol & Biophys, Boston, MA 02118 USA; [Tornheim, Keith] Boston Univ, Sch Med, Dept Biochem, Boston, MA 02118 USA; [Han, Gil-Soo; Carman, George M.] Rutgers State Univ, Dept Food Sci, New Brunswick, NJ 08901 USA; [Han, Gil-Soo; Carman, George M.] Rutgers State Univ, Rutgers Ctr Lipid Res, New Brunswick, NJ 08901 USA	Boston University; Boston University; Rutgers State University New Brunswick; Rutgers State University New Brunswick	Zoeller, RA (corresponding author), 700 Albany St,W-317, Boston, MA 02118 USA.	rzoeller@bu.edu		Tornheim, Keith/0000-0002-6235-5128; Zoeller, Raphael/0000-0002-6560-0993	National Institutes of Health [GM-28140]; American Heart Association [GIA 0455753T]; Boston Obesity Nutrition Research Center [DK46200]; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK046200] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM028140, R01GM028140] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); American Heart Association(American Heart Association); Boston Obesity Nutrition Research Center; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	This work was supported, in whole or in part, by National Institutes of Health Grant GM-28140 (to G.M.C.). This work was also supported by American Heart Association Grant GIA 0455753T and a Pilot and Feasibility project from the Boston Obesity Nutrition Research Center (Grant DK46200) (to R.A.Z.).	AGRANOFF BW, 1958, J BIOL CHEM, V233, P1077; Balsinde J, 1996, J BIOL CHEM, V271, P31937, DOI 10.1074/jbc.271.50.31937; BAUMANN M, 1990, CANCER INVEST, V8, P351, DOI 10.3109/07357909009012053; Beutler E, 1997, BLOOD CELL MOL DIS, V23, P402, DOI 10.1006/bcmd.1997.0157; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; Brindley DN, 1998, J BIOL CHEM, V273, P24281, DOI 10.1074/jbc.273.38.24281; Carman GM, 2006, TRENDS BIOCHEM SCI, V31, P694, DOI 10.1016/j.tibs.2006.10.003; CARMAN GM, 1991, METHOD ENZYMOL, V197, P548; CHAPUT M, 1988, NATURE, V332, P454, DOI 10.1038/332454a0; Cheung O, 2008, SEMIN LIVER DIS, V28, P351, DOI 10.1055/s-0028-1091979; Chou CC, 2000, J BIOL CHEM, V275, P23154, DOI 10.1074/jbc.M002017200; Copley SD, 2003, CURR OPIN CHEM BIOL, V7, P265, DOI 10.1016/S1367-5931(03)00032-2; Donkor J, 2007, J BIOL CHEM, V282, P3450, DOI 10.1074/jbc.M610745200; ESKO JD, 1980, P NATL ACAD SCI-BIOL, V77, P5192, DOI 10.1073/pnas.77.9.5192; Ford ES, 2002, JAMA-J AM MED ASSOC, V287, P356, DOI 10.1001/jama.287.3.356; GOMM SA, 1988, BRIT J CANCER, V58, P797, DOI 10.1038/bjc.1988.312; Gracy R W, 1975, Methods Enzymol, V41, P392; Grundy SM, 2008, ARTERIOSCL THROM VAS, V28, P629, DOI 10.1161/ATVBAHA.107.151092; Gulati P, 2007, BIOCHEM SOC T, V35, P236, DOI 10.1042/BST0350236; Han GS, 2006, J BIOL CHEM, V281, P9210, DOI 10.1074/jbc.M600425200; Hanada K, 1998, J BIOL CHEM, V273, P33787, DOI 10.1074/jbc.273.50.33787; Hardie DG, 2001, BIOESSAYS, V23, P1112, DOI 10.1002/bies.10009; Huffman TA, 2002, P NATL ACAD SCI USA, V99, P1047, DOI 10.1073/pnas.022634399; James PF, 1997, J BIOL CHEM, V272, P23540, DOI 10.1074/jbc.272.38.23540; KENNEDY EP, 1956, J BIOL CHEM, V222, P193; KIYASU JY, 1963, J BIOL CHEM, V238, P2293; Koo SH, 2005, NATURE, V437, P1109, DOI 10.1038/nature03967; KUGE O, 1985, P NATL ACAD SCI USA, V82, P1926, DOI 10.1073/pnas.82.7.1926; Kugler W, 1998, HUM GENET, V103, P450, DOI 10.1007/s004390050849; Kugler W, 2000, BEST PRACT RES CL HA, V13, P89, DOI 10.1053/beha.1999.0059; LANGNER CA, 1991, J BIOL CHEM, V266, P11955; LARSSON K, 1993, MOL MICROBIOL, V10, P1101, DOI 10.1111/j.1365-2958.1993.tb00980.x; MAITRA PK, 1971, J BACTERIOL, V107, P759, DOI 10.1128/JB.107.3.759-769.1971; MERKLE S, 1993, BLOOD, V81, P206; Mittra S, 2008, DRUG DISCOV TODAY, V13, P211, DOI 10.1016/j.drudis.2008.01.006; MORGENSTERN JP, 1990, NUCLEIC ACIDS RES, V18, P3587, DOI 10.1093/nar/18.12.3587; Nadra K, 2008, GENE DEV, V22, P1647, DOI 10.1101/gad.1638008; Nanjundan M, 2003, AM J PHYSIOL-LUNG C, V284, pL1, DOI 10.1152/ajplung.00029.2002; OHTSUKA T, 1993, J BIOL CHEM, V268, P22908; PAGLIA DE, 1974, AM J CLIN PATHOL, V62, P740; PREISS J, 1986, J BIOL CHEM, V261, P8597; Read J, 2001, J MOL BIOL, V309, P447, DOI 10.1006/jmbi.2001.4680; Reue K, 2008, J LIPID RES, V49, P2493, DOI 10.1194/jlr.R800019-JLR200; RICHARDSON JS, 1988, SCIENCE, V240, P1648, DOI 10.1126/science.3381086; ROGERS TJ, 1983, METHOD ENZYMOL, V92, P237; Rumberger JM, 2003, J BIOL CHEM, V278, P28547, DOI 10.1074/jbc.M302793200; Ryu D, 2009, CELL METAB, V9, P240, DOI 10.1016/j.cmet.2009.01.007; SHALEV O, 1993, ANN HEMATOL, V67, P197, DOI 10.1007/BF01695868; Shaw RJ, 2005, SCIENCE, V310, P1642, DOI 10.1126/science.1120781; Shimizu K, 1999, FEBS LETT, V456, P295, DOI 10.1016/S0014-5793(99)00966-7; Shindou H, 2009, J BIOL CHEM, V284, P1, DOI 10.1074/jbc.R800046200; SMITH SW, 1957, J BIOL CHEM, V228, P915; ULLMAN MD, 1974, J BIOL CHEM, V249, P1506; VOELKER DR, 1986, J BIOL CHEM, V261, P1002; Watanabe H, 1996, CANCER RES, V56, P2960; WEISS SB, 1960, J BIOL CHEM, V235, P40; Xu W, 1996, BLOOD, V87, P4502, DOI 10.1182/blood.V87.11.4502.bloodjournal87114502; ZOELLER RA, 1986, P NATL ACAD SCI USA, V83, P5170, DOI 10.1073/pnas.83.14.5170; ZOELLER RA, 1988, J BIOL CHEM, V263, P11590	59	6	8	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 8	2010	285	2					866	877		10.1074/jbc.M109.068213	http://dx.doi.org/10.1074/jbc.M109.068213			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	539MH	19903819	hybrid, Green Published			2022-12-25	WOS:000273258200007
J	Zhang, J; Li, Y; Liu, Q; Lu, W; Bu, G				Zhang, J.; Li, Y.; Liu, Q.; Lu, W.; Bu, G.			Wnt signaling activation and mammary gland hyperplasia in MMTV-LRP6 transgenic mice: implication for breast cancer tumorigenesis	ONCOGENE			English	Article						LRP6; Wnt signaling; mammary gland; breast cancer	BETA-CATENIN; C-MYC; MATRIX METALLOPROTEINASES; FIBROBLASTIC CELLS; TUMOR VIRUS; HUMAN COLON; EXPRESSION; PROTEIN; GENE; PATHWAY	Although Wnt signaling activation is frequently observed in human breast cancer, mutations in genes encoding intracellular components of the Wnt signaling pathway are rare. We found that the expression of Wnt signaling co-receptor, LRP6, is upregulated in a subset of human breast cancer tissues and cell lines. To examine whether the overexpression of LRP6 in mammary epithelial cells is sufficient to activate Wnt signaling and promote cell proliferation, we generated transgenic mice overexpressing LRP6 in mammary epithelial cells driven by the mouse mammary tumor virus (MMTV) promoter. We found that mammary glands from MMTV-LRP6 mice exhibit significant Wnt activation evidenced by the translocation of beta-catenin from membrane to cytoplasmic/nuclear fractions. The expression of several Wnt target genes including Axin2, Cyclin D1 and c-Myc was also increased in MMTV-LRP6 mice. More importantly, mammary glands from virgin MMTV-LRP6 mice exhibit significant hyperplasia, a precursor to breast cancer, when compared with wild-type littermate controls. Several matrix metalloproteinases are upregulated in MMTV-LRP6 mice that could contribute to the hyperplasia phenotype. Our results suggest that Wnt signaling activation at the cell-surface receptor level can contribute to breast cancer tumorigenesis. Oncogene (2010) 29, 539-549; doi: 10.1038/onc.2009.339; published online 2 November 2009	[Zhang, J.; Li, Y.; Liu, Q.; Lu, W.; Bu, G.] Washington Univ, Sch Med, Dept Pediat, St Louis, MO 63110 USA; [Bu, G.] Washington Univ, Sch Med, Dept Cell Biol & Physiol, St Louis, MO 63110 USA; [Li, Y.; Lu, W.] So Res Inst, Dept Biochem & Mol Biol, Drug Discovery Div, Birmingham, AL 35255 USA	Washington University (WUSTL); Washington University (WUSTL)	Bu, G (corresponding author), Washington Univ, Sch Med, Dept Pediat, 660 S Euclid Ave, St Louis, MO 63110 USA.	bu@wustl.edu	Liu, Qiang/E-9245-2011		National Institutes of Health [R01CA100520, RO1CA124531]; NATIONAL CANCER INSTITUTE [R01CA100520, R01CA124531] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We are grateful to Christof Niehrs (German Cancer Research Center) for providing LRP6 cDNA, Dr Philip Leder (Harvard Medical School) for providing the MMTV-SV40-Bssk vector, Dr Gail VW Johnson (University of Rochester) for providing the GST-E-cadherin construct, and Dr Jin-Moo Lee for providing rat brain sections subjected to hypoxia-ischemia as positive controls for apoptosis. We also thank Dr Taj King for critical reading of the manuscript. This work was supported by grants from the National Institutes of Health R01CA100520 (to GB) and RO1CA124531 (to YL).	Amundadottir LT, 1996, BREAST CANCER RES TR, V39, P119, DOI 10.1007/BF01806083; Bafico A, 1998, ONCOGENE, V16, P2819, DOI 10.1038/sj.onc.1201797; Bafico A, 2004, CANCER CELL, V6, P497, DOI 10.1016/j.ccr.2004.09.032; BARTKOVA J, 1994, INT J CANCER, V57, P353, DOI 10.1002/ijc.2910570311; Blavier L, 2006, CANCER RES, V66, P2691, DOI 10.1158/0008-5472.CAN-05-2919; BU GJ, 1995, EMBO J, V14, P2269, DOI 10.1002/j.1460-2075.1995.tb07221.x; Cardiff RD, 2000, ONCOGENE, V19, P968, DOI 10.1038/sj.onc.1203277; Chenard MP, 1999, INT J CANCER, V82, P208; Crawford HC, 1999, ONCOGENE, V18, P2883, DOI 10.1038/sj.onc.1202627; Deming SL, 2000, BRIT J CANCER, V83, P1688, DOI 10.1054/bjoc.2000.1522; Egeblad M, 2002, NAT REV CANCER, V2, P161, DOI 10.1038/nrc745; Giles RH, 2003, BBA-REV CANCER, V1653, P1, DOI 10.1016/S0304-419X(03)00005-2; GILLETT C, 1994, CANCER RES, V54, P1812; He TC, 1998, SCIENCE, V281, P1509, DOI 10.1126/science.281.5382.1509; Heppner KJ, 1996, AM J PATHOL, V149, P273; Jho EH, 2002, MOL CELL BIOL, V22, P1172, DOI 10.1128/MCB.22.4.1172-1183.2002; Klopocki E, 2004, INT J ONCOL, V25, P641; Lane TF, 1997, ONCOGENE, V15, P2133, DOI 10.1038/sj.onc.1201593; Leung JY, 2002, J BIOL CHEM, V277, P21657, DOI 10.1074/jbc.M200139200; Li YH, 2004, ONCOGENE, V23, P9129, DOI 10.1038/sj.onc.1208123; Lin SY, 2000, P NATL ACAD SCI USA, V97, P4262, DOI 10.1073/pnas.060025397; Lindvall C, 2007, STEM CELL REV, V3, P157, DOI 10.1007/s12015-007-0025-3; Lindvall C, 2006, J BIOL CHEM, V281, P35081, DOI 10.1074/jbc.M607571200; Lindvall C, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005813; Lu WY, 2008, FEBS LETT, V582, P643, DOI 10.1016/j.febslet.2008.01.035; Lustig B, 2002, MOL CELL BIOL, V22, P1184, DOI 10.1128/MCB.22.4.1184-1193.2002; MCINTOSH GG, 1995, ONCOGENE, V11, P885; Moon RT, 2004, NAT REV GENET, V5, P689, DOI 10.1038/nrg1427; MOSER AR, 1993, P NATL ACAD SCI USA, V90, P8977, DOI 10.1073/pnas.90.19.8977; Nass SJ, 1997, BREAST CANCER RES TR, V44, P1, DOI 10.1023/A:1005858611585; Nielsen BS, 1997, LAB INVEST, V77, P345; Nielsen BS, 2001, CANCER RES, V61, P7091; NUSSE R, 1984, NATURE, V307, P131, DOI 10.1038/307131a0; NUSSE R, 1982, CELL, V31, P99, DOI 10.1016/0092-8674(82)90409-3; OKADA A, 1995, P NATL ACAD SCI USA, V92, P2730, DOI 10.1073/pnas.92.7.2730; PETERS G, 1983, CELL, V33, P369, DOI 10.1016/0092-8674(83)90418-X; Pinson KI, 2000, NATURE, V407, P535, DOI 10.1038/35035124; Rodriguez S, 2003, ONCOGENE, V22, P1880, DOI 10.1038/sj.onc.1206302; Shtutman M, 1999, P NATL ACAD SCI USA, V96, P5522, DOI 10.1073/pnas.96.10.5522; Sternlicht MD, 1999, CELL, V98, P137, DOI 10.1016/S0092-8674(00)81009-0; Takahashi M, 2002, ONCOGENE, V21, P5861, DOI 10.1038/sj.onc.1205755; Tamai K, 2000, NATURE, V407, P530, DOI 10.1038/35035117; Tamamura Y, 2005, J BIOL CHEM, V280, P19185, DOI 10.1074/jbc.M414275200; Tetsu O, 1999, NATURE, V398, P422, DOI 10.1038/18884; TSUKAMOTO AS, 1988, CELL, V55, P619, DOI 10.1016/0092-8674(88)90220-6; Turashvili G, 2006, PATHOBIOLOGY, V73, P213, DOI 10.1159/000098207; Ugolini F, 2001, ONCOGENE, V20, P5810, DOI 10.1038/sj.onc.1204706; WANG TC, 1994, NATURE, V369, P669, DOI 10.1038/369669a0; Wehrli M, 2000, NATURE, V407, P527, DOI 10.1038/35035110; WOLF C, 1993, P NATL ACAD SCI USA, V90, P1843, DOI 10.1073/pnas.90.5.1843; Wu BB, 2007, IMMUNITY, V26, P227, DOI 10.1016/j.immuni.2006.12.007; Yan D, 2001, P NATL ACAD SCI USA, V98, P14973, DOI 10.1073/pnas.261574498	52	74	76	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN	2010	29	4					539	549		10.1038/onc.2009.339	http://dx.doi.org/10.1038/onc.2009.339			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	549WH	19881541	Green Accepted			2022-12-25	WOS:000274084600007
J	Kim, JH; Yoon, MS; Chen, J				Kim, Jeong-Ho; Yoon, Mee-Sup; Chen, Jie			Signal Transducer and Activator of Transcription 3 (STAT3) Mediates Amino Acid Inhibition of Insulin Signaling through Serine 727 Phosphorylation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MAXIMAL ACTIVATION; S6 KINASE; RESISTANCE; METABOLISM; PROTEINS; GLUCOSE; TARGET; SUPPRESSOR; MECHANISM; RAPAMYCIN	Nutrient overload is associated with the development of obesity, insulin resistance, and type II diabetes. High plasma concentrations of amino acids have been found to correlate with insulin resistance. At the cellular level, excess amino acids impair insulin signaling, the mechanisms of which are not fully understood. Here, we report that STAT3 plays a key role in amino acid dampening of insulin signaling in hepatic cells. Excess amino acids inhibited insulin-stimulated Akt phosphorylation and glycogen synthesis in mouse primary hepatocytes as well as in human hepatocarcinoma HepG2 cells. STAT3 knockdown protected insulin sensitivity from inhibition by amino acids. Amino acids stimulated the phosphorylation of STAT3 at Ser(727), but not Tyr(705). Replacement of the endogenous STAT3 with wild-type, but not S727A, recombinant STAT3 restored the ability of amino acids to inhibit insulin signaling, suggesting that Ser(727) phosphorylation was critical for STAT3-mediated amino acid effect. Furthermore, overexpression of STAT3-S727D was sufficient to inhibit insulin signaling in the absence of excess amino acids. Our results also indicated that mammalian target of rapamycin was likely responsible for the phosphorylation of STAT3 at Ser(727) in response to excess amino acids. Finally, we found that STAT3 activity and the expression of its target gene socs3, known to be involved in insulin resistance, were both stimulated by excess amino acids and inhibited by rapamycin. In conclusion, our study reveals STAT3 as a novel mediator of nutrient signals and identifies a Ser(727) phosphorylation-dependent and Tyr(705) phosphorylation-independent STAT3 activation mechanism in the modulation of insulin signaling.	[Kim, Jeong-Ho; Yoon, Mee-Sup; Chen, Jie] Univ Illinois, Dept Cell & Dev Biol, Urbana, IL 61801 USA	University of Illinois System; University of Illinois Urbana-Champaign	Chen, J (corresponding author), 601 S Goodwin Ave,B107, Urbana, IL 61801 USA.	jiechen@illinois.edu		Chen, Jie/0000-0002-7887-3747	NIAMS/National Institutes of Health [AR48914]; American Diabetes Association; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR048914] Funding Source: NIH RePORTER	NIAMS/National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); American Diabetes Association(American Diabetes Association); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))	This work was supported by NIAMS/National Institutes of Health Grant AR48914 and by the American Diabetes Association (J.C.).	ADIBI SA, 1968, J APPL PHYSIOL, V25, P52, DOI 10.1152/jappl.1968.25.1.52; Androutsellis-Theotokis A, 2006, NATURE, V442, P823, DOI 10.1038/nature04940; Baum JI, 2005, AM J PHYSIOL-ENDOC M, V288, pE86, DOI 10.1152/ajpendo.00272.2004; Calo V, 2003, J CELL PHYSIOL, V197, P157, DOI 10.1002/jcp.10364; Decker T, 2000, ONCOGENE, V19, P2628, DOI 10.1038/sj.onc.1203481; FELIG P, 1970, NEW ENGL J MED, V282, P166; FELIG P, 1969, NEW ENGL J MED, V281, P811, DOI 10.1056/NEJM196910092811503; FELIG P, 1974, J CLIN INVEST, V53, P582, DOI 10.1172/JCI107593; Hara K, 1998, J BIOL CHEM, V273, P14484, DOI 10.1074/jbc.273.23.14484; Hay N, 2004, GENE DEV, V18, P1926, DOI 10.1101/gad.1212704; Howard JK, 2006, TRENDS ENDOCRIN MET, V17, P365, DOI 10.1016/j.tem.2006.09.007; Iiboshi Y, 1999, J BIOL CHEM, V274, P1092, DOI 10.1074/jbc.274.2.1092; Inoue H, 2006, CELL METAB, V3, P267, DOI 10.1016/j.cmet.2006.02.009; Inoue H, 2004, NAT MED, V10, P168, DOI 10.1038/nm980; Kim JH, 2008, J BIOL CHEM, V283, P708, DOI 10.1074/jbc.M708568200; Klover PJ, 2003, DIABETES, V52, P2784, DOI 10.2337/diabetes.52.11.2784; Klover PJ, 2005, ENDOCRINOLOGY, V146, P3417, DOI 10.1210/en.2004-1468; Krebs DL, 2000, J CELL SCI, V113, P2813; KREBS DL, 2003, SCI STKE, pPE6; Krebs M, 2002, DIABETES, V51, P599, DOI 10.2337/diabetes.51.3.599; Linn T, 2000, DIABETOLOGIA, V43, P1257, DOI 10.1007/s001250051521; Liu HT, 2003, BLOOD, V102, P344, DOI 10.1182/blood-2002-11-3396; Moh A, 2008, DIABETES, V57, P1227, DOI 10.2337/db06-1582; Must A, 1999, JAMA-J AM MED ASSOC, V282, P1523, DOI 10.1001/jama.282.16.1523; Newgard CB, 2009, CELL METAB, V9, P311, DOI 10.1016/j.cmet.2009.02.002; Patti ME, 1998, J CLIN INVEST, V101, P1519, DOI 10.1172/JCI1326; Peterson RT, 2000, J BIOL CHEM, V275, P7416, DOI 10.1074/jbc.275.10.7416; Qin HR, 2008, CANCER RES, V68, P7736, DOI 10.1158/0008-5472.CAN-08-1125; Rajan P, 2003, J CELL BIOL, V161, P911, DOI 10.1083/jcb.200211021; Sarbassov DD, 2005, CURR OPIN CELL BIOL, V17, P596, DOI 10.1016/j.ceb.2005.09.009; Sarbassov DD, 2005, SCIENCE, V307, P1098, DOI 10.1126/science.1106148; Schulze MB, 2003, DIABETOLOGIA, V46, P1465, DOI 10.1007/s00125-003-1220-7; Schuringa JJ, 2001, FEBS LETT, V495, P71, DOI 10.1016/S0014-5793(01)02354-7; Senn JJ, 2002, DIABETES, V51, P3391, DOI 10.2337/diabetes.51.12.3391; Senn JJ, 2003, J BIOL CHEM, V278, P13740, DOI 10.1074/jbc.M210689200; Takano T, 2001, MOL CELL BIOL, V21, P5050, DOI 10.1128/MCB.21.15.5050-5062.2001; Torisu T, 2007, GENES CELLS, V12, P143, DOI 10.1111/j.1365-2443.2007.01044.x; Tremblay F, 2005, DIABETES, V54, P2674, DOI 10.2337/diabetes.54.9.2674; Tremblay F, 2001, J BIOL CHEM, V276, P38052; Tremblay F, 2007, ANNU REV NUTR, V27, P293, DOI 10.1146/annurev.nutr.25.050304.092545; Tremblay F, 2007, P NATL ACAD SCI USA, V104, P14056, DOI 10.1073/pnas.0706517104; Ueki K, 2004, MOL CELL BIOL, V24, P5434, DOI 10.1128/MCB.24.12.5434-5446.2004; Um SH, 2006, CELL METAB, V3, P393, DOI 10.1016/j.cmet.2006.05.003; WEN ZL, 1995, CELL, V82, P241, DOI 10.1016/0092-8674(95)90311-9; Yokogami K, 2000, CURR BIOL, V10, P47, DOI 10.1016/S0960-9822(99)00268-7	45	67	71	2	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 18	2009	284	51					35425	35432		10.1074/jbc.M109.051516	http://dx.doi.org/10.1074/jbc.M109.051516			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	531EI	19875458	hybrid, Green Published			2022-12-25	WOS:000272645600018
J	Brennan, C; Momota, H; Hambardzumyan, D; Ozawa, T; Tandon, A; Pedraza, A; Holland, E				Brennan, Cameron; Momota, Hiroyuki; Hambardzumyan, Dolores; Ozawa, Tatsuya; Tandon, Adesh; Pedraza, Alicia; Holland, Eric			Glioblastoma Subclasses Can Be Defined by Activity among Signal Transduction Pathways and Associated Genomic Alterations	PLOS ONE			English	Article							GROWTH FACTOR-II; MALIGNANT GLIOMAS; MOUSE MODELS; 2 DISTINCT; MULTIFORME; SURVIVAL; SUBTYPES; CLASSIFICATION; IDENTIFICATION; PROGRESSION	Background: Glioblastoma multiforme (GBM) is an umbrella designation that includes a heterogeneous group of primary brain tumors. Several classification strategies of GBM have been reported, some by clinical course and others by resemblance to cell types either in the adult or during development. From a practical and therapeutic standpoint, classifying GBMs by signal transduction pathway activation and by mutation in pathway member genes may be particularly valuable for the development of targeted therapies. Methodology/Principal Findings: We performed targeted proteomic analysis of 27 surgical glioma samples to identify patterns of coordinate activation among glioma-relevant signal transduction pathways, then compared these results with integrated analysis of genomic and expression data of 243 GBM samples from The Cancer Genome Atlas (TCGA). In the pattern of signaling, three subclasses of GBM emerge which appear to be associated with predominance of EGFR activation, PDGFR activation, or loss of the RAS regulator NF1. The EGFR signaling class has prominent Notch pathway activation measured by elevated expression of Notch ligands, cleaved Notch receptor, and downstream target Hes1. The PDGF class showed high levels of PDGFB ligand and phosphorylation of PDGFR beta and NFKB. NF1-loss was associated with lower overall MAPK and PI3K activation and relative overexpression of the mesenchymal marker YKL40. These three signaling classes appear to correspond with distinct transcriptomal subclasses of primary GBM samples from TCGA for which copy number aberration and mutation of EGFR, PDGFRA, and NF1 are signature events. Conclusions/Significance: Proteomic analysis of GBM samples revealed three patterns of expression and activation of proteins in glioma-relevant signaling pathways. These three classes are comprised of roughly equal numbers showing either EGFR activation associated with amplification and mutation of the receptor, PDGF-pathway activation that is primarily ligand-driven, or loss of NF1 expression. The associated signaling activities correlating with these sentinel alterations provide insight into glioma biology and therapeutic strategies.			Brennan, C (corresponding author), Mem Sloan Kettering Canc Ctr, Dept Neurosurg, 1275 York Ave, New York, NY 10021 USA.	cbrennan@mskcc.org; hollande@mskcc.org	Brennan, Cameron/R-7082-2019	Brennan, Cameron/0000-0003-4064-8891	NCI NIH HHS [U54 CA126518, CA100688, U54 CA143798, CA126518, U24 CA126543, U01 CA141502, CA143798, R01 CA100688, U24 CA126543-01, CA141502] Funding Source: Medline; NATIONAL CANCER INSTITUTE [U54CA143798, U01CA141502, U54CA126518, U24CA126543, R01CA100688] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Beroukhim R, 2007, P NATL ACAD SCI USA, V104, P20007, DOI 10.1073/pnas.0710052104; Chin L, 2008, NATURE, V455, P1061, DOI 10.1038/nature07385; Choe G, 2003, CANCER RES, V63, P2742; Codeluppi S, 2009, J NEUROSCI, V29, P1093, DOI 10.1523/JNEUROSCI.4103-08.2009; Dai CK, 2005, NEOPLASIA, V7, P397, DOI 10.1593/neo.04691; Fomchenko EI, 2006, CLIN CANCER RES, V12, P5288, DOI 10.1158/1078-0432.CCR-06-0438; Freije WA, 2004, CANCER RES, V64, P6503, DOI 10.1158/0008-5472.CAN-04-0452; Furnari FB, 2007, GENE DEV, V21, P2683, DOI 10.1101/gad.1596707; Holland EC, 2000, P NATL ACAD SCI USA, V97, P6242, DOI 10.1073/pnas.97.12.6242; Huse JT, 2009, BRAIN PATHOL, V19, P132, DOI 10.1111/j.1750-3639.2008.00234.x; Lamborn KR, 2008, NEURO-ONCOLOGY, V10, P162, DOI 10.1215/15228517-2007-062; Lassman AB, 2005, CLIN CANCER RES, V11, P7841, DOI 10.1158/1078-0432.CCR-05-0421; Lee JC, 2006, PLOS MED, V3, P2264, DOI 10.1371/journal.pmed.0030485; Liang Y, 2005, P NATL ACAD SCI USA, V102, P5814, DOI 10.1073/pnas.0402870102; Louis DN, 2007, ACTA NEUROPATHOL, V114, P97, DOI 10.1007/s00401-007-0243-4; Lyustikman Y, 2008, NEOPLASIA, V10, P501, DOI 10.1593/neo.08206; Maher EA, 2001, GENE DEV, V15, P1311, DOI 10.1101/gad.891601; Maher EA, 2006, CANCER RES, V66, P11502, DOI 10.1158/0008-5472.CAN-06-2072; MEHTA MPC, 2009, PRINCIPLES PRACTICE; Mischel PS, 2003, ONCOGENE, V22, P2361, DOI 10.1038/sj.onc.1206344; Nutt CL, 2003, CANCER RES, V63, P1602; Olshen AB, 2004, BIOSTATISTICS, V5, P557, DOI 10.1093/biostatistics/kxh008; Parsons DW, 2008, SCIENCE, V321, P1807, DOI 10.1126/science.1164382; PECH M, 1989, MOL CELL BIOL, V9, P396, DOI 10.1128/MCB.9.2.396; Phillips HS, 2006, CANCER CELL, V9, P157, DOI 10.1016/j.ccr.2006.02.019; Rajasekhar VK, 2003, MOL CELL, V12, P889, DOI 10.1016/S1097-2765(03)00395-2; Rajasekhar VK, 2004, ONCOGENE, V23, P3248, DOI 10.1038/sj.onc.1207546; RAO CD, 1988, MOL CELL BIOL, V8, P284, DOI 10.1128/MCB.8.1.284; Tso CL, 2006, CANCER RES, V66, P159, DOI 10.1158/0008-5472.CAN-05-0077; VERHAAK RGW, 2009, CANC CELL IN PRESS; Wen PY, 2008, NEW ENGL J MED, V359, P492, DOI 10.1056/NEJMra0708126; Yan H, 2009, NEW ENGL J MED, V360, P765, DOI 10.1056/NEJMoa0808710	32	382	387	1	38	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA	1932-6203			PLOS ONE	PLoS One	NOV 13	2009	4	11							e7752	10.1371/journal.pone.0007752	http://dx.doi.org/10.1371/journal.pone.0007752			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	518VB	19915670	gold, Green Submitted, Green Published			2022-12-25	WOS:000271721900009
J	Kiefer, P; Buchhaupt, M; Christen, P; Kaup, B; Schrader, J; Vorholt, JA				Kiefer, Patrick; Buchhaupt, Markus; Christen, Philipp; Kaup, Bjoern; Schrader, Jens; Vorholt, Julia A.			Metabolite Profiling Uncovers Plasmid-Induced Cobalt Limitation under Methylotrophic Growth Conditions	PLOS ONE			English	Article							METHYLOBACTERIUM-EXTORQUENS AM1; RECOMBINANT ESCHERICHIA-COLI; ETHYLMALONYL-COA PATHWAY; MASS-SPECTROMETRY; NONMETHYLOTROPHIC CONDITIONS; TETRACYCLINE RESISTANCE; GENE-EXPRESSION; BETA-LACTAMASE; C1 COMPOUNDS; TRANSPORT	Background: The introduction and maintenance of plasmids in cells is often associated with a reduction of growth rate. The reason for this growth reduction is unclear in many cases. Methodology/Principal Findings: We observed a surprisingly large reduction in growth rate of about 50% of Methylobacterium extorquens AM1 during methylotrophic growth in the presence of a plasmid, pCM80 expressing the tetA gene, relative to the wild-type. A less pronounced growth delay during growth under non-methylotrophic growth conditions was observed; this suggested an inhibition of one-carbon metabolism rather than a general growth inhibition or metabolic burden. Metabolome analyses revealed an increase in pool sizes of ethylmalonyl-CoA and methylmalonyl-CoA of more than 6- and 35-fold, respectively, relative to wild type, suggesting a strongly reduced conversion of these central intermediates, which are essential for glyoxylate regeneration in this model methylotroph. Similar results were found for M. extorquens AM1 pCM160 which confers kanamycin resistance. These intermediates of the ethylmalonyl-CoA pathway have in common their conversion by coenzyme B-12-dependent mutases, which have cobalt as a central ligand. The one-carbon metabolism-related growth delay was restored by providing higher cobalt concentrations, by heterologous expression of isocitrate lyase as an alternative path for glyoxylate regeneration, or by identification and overproduction of proteins involved in cobalt import. Conclusions/Significance: This study demonstrates that the introduction of the plasmids leads to an apparent inhibition of the cobalt-dependent enzymes of the ethylmalonyl-CoA pathway. Possible explanations are presented and point to a limited cobalt concentration in the cell as a consequence of the antibiotic stress.			Kiefer, P (corresponding author), ETH, Inst Microbiol, CH-8092 Zurich, Switzerland.	vorholt@micro.biol.ethz.ch	Vorholt, Julia/K-3514-2016; Kiefer, Patrick/G-5138-2010	Vorholt, Julia/0000-0002-6011-4910; Christen, Philipp/0000-0002-3139-2874; Buchhaupt, Markus/0000-0003-2720-5973				Anthony C., 1982, BIOCH METHYLOTROPHS; Bailey J E, 1993, Adv Biochem Eng Biotechnol, V48, P29; BAILEY JE, 1986, ANN NY ACAD SCI, V469, P194, DOI 10.1111/j.1749-6632.1986.tb26498.x; BIRNBAUM S, 1991, BIOTECHNOL BIOENG, V37, P736, DOI 10.1002/bit.260370808; Bolten CJ, 2007, ANAL CHEM, V79, P3843, DOI 10.1021/ac0623888; Bosch G, 2008, PROTEOMICS, V8, P3494, DOI 10.1002/pmic.200800152; CHEAH UE, 1987, PLASMID, V18, P127, DOI 10.1016/0147-619X(87)90040-0; Chistoserdova L, 2003, J BACTERIOL, V185, P2980, DOI 10.1128/JB.185.10.2980-2987.2003; Chistoserdova L, 2009, ANNU REV MICROBIOL, V63, P477, DOI 10.1146/annurev.micro.091208.073600; Chou HH, 2009, PLOS GENET, V5, DOI 10.1371/journal.pgen.1000652; DASILVA NA, 1986, BIOTECHNOL BIOENG, V28, P741, DOI 10.1002/bit.260280514; Erb TJ, 2008, J BIOL CHEM, V283, P32283, DOI 10.1074/jbc.M805527200; Erb TJ, 2007, P NATL ACAD SCI USA, V104, P10631, DOI 10.1073/pnas.0702791104; GLICK BR, 1995, BIOTECHNOL ADV, V13, P247, DOI 10.1016/0734-9750(95)00004-A; Gonzalez-Gil G, 1999, APPL ENVIRON MICROB, V65, P1789; Guo XF, 2008, BIOTECHNOL BIOENG, V99, P929, DOI 10.1002/bit.21652; KHOSRAVI M, 1990, PLASMID, V23, P138, DOI 10.1016/0147-619X(90)90032-8; Kiefer P, 2008, ANAL BIOCHEM, V382, P94, DOI 10.1016/j.ab.2008.07.010; Korotkova N, 2004, J BIOL CHEM, V279, P13652, DOI 10.1074/jbc.M312852200; Korotkova N, 2001, J BACTERIOL, V183, P1038, DOI 10.1128/JB.183.3.1038-1046.2001; LARGE PJ, 1963, BIOCHEM J, V87, P386, DOI 10.1042/bj0870386; Laukel M, 2004, PROTEOMICS, V4, P1247, DOI 10.1002/pmic.200300713; LEADLAY PF, 1981, BIOCHEM J, V197, P413, DOI 10.1042/bj1970413; LEE SW, 1985, GENE, V39, P173, DOI 10.1016/0378-1119(85)90311-7; LEGOFFIC F, 1976, ANTIMICROB AGENTS CH, V10, P258; LEVY SB, 1978, NATURE, V276, P90, DOI 10.1038/276090a0; Marciano DC, 2007, GENETICS, V176, P2381, DOI 10.1534/genetics.106.069443; Marx CJ, 2001, MICROBIOL-SGM, V147, P2065, DOI 10.1099/00221287-147-8-2065; Mashego MR, 2004, BIOTECHNOL BIOENG, V85, P620, DOI 10.1002/bit.10907; MOYED HS, 1983, J BACTERIOL, V155, P557, DOI 10.1128/JB.155.2.557-564.1983; Nielsen J, 2005, TRENDS BIOTECHNOL, V23, P544, DOI 10.1016/j.tibtech.2005.08.005; Okubo Y, 2007, OMICS, V11, P325, DOI 10.1089/omi.2007.0027; Ow DSW, 2006, ENZYME MICROB TECH, V39, P391, DOI 10.1016/j.enzmictec.2005.11.048; Ow DSW, 2009, BIOTECHNOL PROGR, V25, P61, DOI 10.1002/btpr.51; Peyraud R, 2009, P NATL ACAD SCI USA, V106, P4846, DOI 10.1073/pnas.0810932106; Ricci JCD, 2000, CRIT REV BIOTECHNOL, V20, P79, DOI 10.1080/07388550008984167; Rodionov DA, 2006, J BACTERIOL, V188, P317, DOI 10.1128/JB.188.1.317-327.2006; Rohwerder T, 2006, APPL ENVIRON MICROB, V72, P4128, DOI 10.1128/AEM.00080-06; RYAN W, 1989, BIOTECHNOL BIOENG, V34, P309, DOI 10.1002/bit.260340306; Sambrook J, 2001, MOL CLONING LAB MANU; Schauer K, 2008, TRENDS BIOCHEM SCI, V33, P330, DOI 10.1016/j.tibs.2008.04.012; Schauer K, 2007, MOL MICROBIOL, V63, P1054, DOI 10.1111/j.1365-2958.2006.05578.x; SCHONHEIT P, 1979, ARCH MICROBIOL, V123, P105, DOI 10.1007/BF00403508; Schrader J, 2009, TRENDS BIOTECHNOL, V27, P107, DOI 10.1016/j.tibtech.2008.10.009; SEO JH, 1985, BIOTECHNOL BIOENG, V27, P156, DOI 10.1002/bit.260270209; STABLER SP, 1985, ARCH BIOCHEM BIOPHYS, V241, P252, DOI 10.1016/0003-9861(85)90381-9; Thauer RK, 1998, MICROBIOL-UK, V144, P2377, DOI 10.1099/00221287-144-9-2377; Viveiros M, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0000365; Vorholt JA, 2002, ARCH MICROBIOL, V178, P239, DOI 10.1007/s00203-002-0450-2; Vuilleumier S, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005584; Wu L, 2005, ANAL BIOCHEM, V336, P164, DOI 10.1016/j.ab.2004.09.001; YAMAGUCHI A, 1990, J BIOL CHEM, V265, P4809	52	28	29	0	6	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	NOV 13	2009	4	11							e7831	10.1371/journal.pone.0007831	http://dx.doi.org/10.1371/journal.pone.0007831			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	518VB	19915676	Green Submitted, Green Published, gold			2022-12-25	WOS:000271721900020
J	Apple, JL; Wink, M; Wills, SE; Bishop, JG				Apple, Jennifer L.; Wink, Michael; Wills, Shannon E.; Bishop, John G.			Successional Change in Phosphorus Stoichiometry Explains the Inverse Relationship between Herbivory and Lupin Density on Mount St. Helens	PLOS ONE			English	Article							BOTTOM-UP FORCES; INSECT HERBIVORES; NITROGEN; PLANT; GROWTH; TERRESTRIAL; POPULATION; IMPACT; CONSEQUENCES; LEPIDOPTERA	Background: The average nitrogen-to-phosphorus ratio (N:P) of insect herbivores is less than that of leaves, suggesting that P may mediate plant-insect interactions more often than appreciated. We investigated whether succession-related heterogeneity in N and P stoichiometry influences herbivore performance on N-fixing lupin (Lupinus lepidus) colonizing primary successional volcanic surfaces, where the abundances of several specialist lepidopteran herbivores are inversely related to lupin density and are known to alter lupin colonization dynamics. We examined larval performance in response to leaf nutritional characteristics using gelechiid and pyralid leaf-tiers, and a noctuid leaf-cutter. Methodology/Principal Findings: We conducted four studies. First, growth of larvae raised on wild-collected leaves responded positively to leaf % P and negatively to leaf carbon (% C), but there was no effect of % N or quinolizidine alkaloids (QAs). Noctuid survival was also positively related to % P. Second, we raised gelechiid larvae on greenhouse-grown lupins with factorial manipulation of competitors and soil N and P. In the presence of competition, larval mass was highest at intermediate leaf N: P and high % P. Third, survival of gelechiid larvae placed on lupins in high-density patches was greater when plant competitors were removed than on controls. Fourth, surveys of field-collected leaves in 2000, 2002, and 2003 indicated that both % P and % N were generally greater in plants from low-density areas. QAs in plants from low-density areas were equal to or higher than QAs in high-density areas. Conclusions/Significance: Our results demonstrate that declines in lupin P content under competitive conditions are associated with decreased larval growth and survival sufficient to cause the observed negative relationship between herbivore abundance and host density. The results support the theoretical finding that declines in stoichiometric resource quality (caused here by succession) have the potential to cause a decrease in consumer abundance despite very dense quantities of the resource.			Apple, JL (corresponding author), SUNY Coll Geneseo, Dept Biol, Geneseo, NY 14454 USA.	bishopj@vancouver.wsu.edu	Wink, Michael/E-3803-2012	Wink, Michael/0000-0002-7875-4510				Adamski D, 2009, P ENTOMOL SOC WASH, V111, P293, DOI 10.4289/0013-8797-111.2.293; Andersen T, 2004, ECOL LETT, V7, P884, DOI 10.1111/j.1461-0248.2004.00646.x; Ayres MP, 2000, ECOLOGY, V81, P2198, DOI 10.1890/0012-9658(2000)081[2198:NBOPFB]2.0.CO;2; Behmer ST, 2002, ECOLOGY, V83, P2489, DOI 10.1890/0012-9658(2002)083[2489:HFICHE]2.0.CO;2; Bishop JG, 2005, ECOLOGICAL RESPONSES TO THE 1980 ERUPTION OF MOUNT ST. HELENS, P151, DOI 10.1007/0-387-28150-9_11; Bishop JG, 2002, ECOLOGY, V83, P191; BISHOP JG, PLONS ONE IN PRESS; Boersma M, 2006, ECOLOGY, V87, P1325, DOI 10.1890/0012-9658(2006)87[1325:TMOAGT]2.0.CO;2; Busch JW, 1999, ECOL ENTOMOL, V24, P132, DOI 10.1046/j.1365-2311.1999.00185.x; Campo J, 2003, J TROP ECOL, V19, P525, DOI 10.1017/S0266467403003572; CAREY DB, 1994, J CHEM ECOL, V20, P849, DOI 10.1007/BF02059582; Chen Y, 2004, HORTSCIENCE, V39, P545, DOI 10.21273/HORTSCI.39.3.545; CLANCY KM, 1993, ECOLOGY, V74, P442, DOI 10.2307/1939306; Crawley MJ., 2007, R BOOK; del Moral R, 2005, PLANT ECOL, V181, P203, DOI 10.1007/s11258-005-6627-4; Denno RF, 2002, ECOLOGY, V83, P1443, DOI 10.1890/0012-9658(2002)083[1443:BUFMNE]2.0.CO;2; Elser JJ, 2006, FUNCT ECOL, V20, P846, DOI 10.1111/j.1365-2435.2006.01165.x; Elser JJ, 2000, NATURE, V408, P578, DOI 10.1038/35046058; Fagan WF, 2005, AM NAT, V166, P669, DOI 10.1086/497621; Fagan WF, 2004, ECOL ENTOMOL, V29, P398, DOI 10.1111/j.0307-6946.2004.00616.x; Fagan WF, 2000, AM NAT, V155, P238, DOI 10.1086/303320; Gill RA, 2006, OECOLOGIA, V148, P312, DOI 10.1007/s00442-006-0358-7; Gruner DS, 2004, ECOLOGY, V85, P3010, DOI 10.1890/04-0020; Halvorson JJ, 2005, ECOLOGICAL RESPONSES TO THE 1980 ERUPTION OF MOUNT ST. HELENS, P243, DOI 10.1007/0-387-28150-9_17; Houlton BZ, 2008, NATURE, V454, P327, DOI 10.1038/nature07028; Huberty AF, 2004, ECOLOGY, V85, P1383, DOI 10.1890/03-0352; Huberty AF, 2006, OECOLOGIA, V149, P444, DOI 10.1007/s00442-006-0462-8; HUNTER MD, 1991, OECOLOGIA, V86, P62, DOI 10.1007/BF00317390; JANSSEN JAM, 1994, B ENTOMOL RES, V84, P233, DOI 10.1017/S0007485300039742; JOHNSON ND, 1989, J CHEM ECOL, V15, P2425, DOI 10.1007/BF01020373; Kittler JT, 2005, P NATL ACAD SCI USA, V102, P14871, DOI 10.1073/pnas.0506653102; Kyto M, 1996, OIKOS, V75, P148, DOI 10.2307/3546238; McNeill S., 1978, BIOCH ASPECTS PLANT, P77; MORRIS WF, 1989, ECOLOGY, V70, P697, DOI 10.2307/1940220; Neumann G, 2002, TRENDS PLANT SCI, V7, P162, DOI 10.1016/S1360-1385(02)02241-0; Perkins MC, 2004, ARCH INSECT BIOCHEM, V55, P153, DOI 10.1002/arch.10133; PRICE PW, 1991, OIKOS, V62, P244, DOI 10.2307/3545270; Raubenheimer D, 2004, ECOLOGY, V85, P1203, DOI 10.1890/02-0248; RAUBENHEIMER D, 1995, FUNCT ECOL, V9, P21, DOI 10.2307/2390086; RAUBENHEIMER D, 1992, ENTOMOL EXP APPL, V62, P221, DOI 10.1007/BF00353441; RITCHIE ME, 1995, ECOLOGY, V76, P2648, DOI 10.2307/2265835; Ritchie ME, 2000, ECOLOGY, V81, P1601, DOI 10.1890/0012-9658(2000)081[1601:NLATVA]2.0.CO;2; SCHADE JD, 2003, ECOL LETT, V6, P1; SKINNER RH, 1994, ENVIRON ENTOMOL, V23, P693, DOI 10.1093/ee/23.3.693; SLANSKY F, 1977, ECOL MONOGR, V47, P209, DOI 10.2307/1942617; Sterner R.W, 2002, ECOLOGICAL STOICHIOM, DOI DOI 10.1086/382444; Stiling P, 2005, OECOLOGIA, V142, P413, DOI 10.1007/s00442-004-1739-4; Strengbom J, 2005, OECOLOGIA, V143, P241, DOI 10.1007/s00442-004-1799-5; Throop HL, 2004, ECOSYSTEMS, V7, P109, DOI 10.1007/s10021-003-0225-x; Titus JH, 1998, PLANT ECOL, V134, P13, DOI 10.1023/A:1009765502741; Vitousek PM, 2002, AMBIO, V31, P97, DOI 10.1639/0044-7447(2002)031[0097:NAN]2.0.CO;2; Waring Gwendolyn L., 1992, P167; WHITE T C R, 1969, Ecology (Washington D C), V50, P905, DOI 10.2307/1933707; White T. C. R., 1993, INADEQUATE ENV NITRO; WINK M, 1995, PHYTOCHEMISTRY, V38, P139, DOI 10.1016/0031-9422(95)91890-D; Wink M, 1992, INSECT PLANT INTERAC, P133; Woods HA, 2004, FUNCT ECOL, V18, P103, DOI 10.1111/j.1365-2435.2004.00823.x	57	31	31	1	49	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	NOV 12	2009	4	11							e7807	10.1371/journal.pone.0007807	http://dx.doi.org/10.1371/journal.pone.0007807			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	518UW	19907662	Green Published, gold			2022-12-25	WOS:000271721400008
J	Pang, YP; Vummenthala, A; Mishra, RK; Park, JG; Wang, SH; Davis, J; Millard, CB; Schmidt, JJ				Pang, Yuan-Ping; Vummenthala, Anuradha; Mishra, Rajesh K.; Park, Jewn Giew; Wang, Shaohua; Davis, Jon; Millard, Charles B.; Schmidt, James J.			Potent New Small-Molecule Inhibitor of Botulinum Neurotoxin Serotype A Endopeptidase Developed by Synthesis-Based Computer-Aided Molecular Design	PLOS ONE			English	Article							AB-INITIO CALCULATIONS; NORMAL-MODE-ANALYSIS; DYNAMICS SIMULATION; ZINC-ENDOPEPTIDASE; SUBSTRATE-SPECIFICITY; PROTEOLYTIC ACTIVITY; TOXIN; IDENTIFICATION; PROTEINS; AMBER	Botulinum neurotoxin serotype A (BoNTA) causes a life-threatening neuroparalytic disease known as botulism. Current treatment for post exposure of BoNTA uses antibodies that are effective in neutralizing the extracellular toxin to prevent further intoxication but generally cannot rescue already intoxicated neurons. Effective small-molecule inhibitors of BoNTA endopeptidase (BoNTAe) are desirable because such inhibitors potentially can neutralize the intracellular BoNTA and offer complementary treatment for botulism. Previously we reported a serotype-selective, small-molecule BoNTAe inhibitor with a K(i)(app) value of 3.8 +/- 0.8 mu M. This inhibitor was developed by lead identification using virtual screening followed by computer-aided optimization of a lead with an IC(50) value of 100 mu M. However, it was difficult to further improve the lead from micromolar to even high nanomolar potency due to the unusually large enzyme-substrate interface of BoNTAe. The enzyme-substrate interface area of 4,840 angstrom(2) for BoNTAe is about four times larger than the typical protein-protein interface area of 750-1,500 angstrom(2). Inhibitors must carry several functional groups to block the unusually large interface of BoNTAe, and syntheses of such inhibitors are therefore time-consuming and expensive. Herein we report the development of a serotype-selective, small-molecule, and competitive inhibitor of BoNTAe with a K(i) value of 760 +/- 170 nM using synthesis-based computer-aided molecular design (SBCAMD). This new approach accounts the practicality and efficiency of inhibitor synthesis in addition to binding affinity and selectivity. We also report a three-dimensional model of BoNTAe in complex with the new inhibitor and the dynamics of the complex predicted by multiple molecular dynamics simulations, and discuss further structural optimization to achieve better in vivo efficacy in neutralizing BoNTA than those of our early micromolar leads. This work provides new insight into structural modification of known small-molecule BoNTAe inhibitors. It also demonstrates that SBCAMD is capable of improving potency of an inhibitor lead by nearly one order of magnitude, even for BoNTAe as one of the most challenging protein targets. The results are insightful for developing effective small-molecule inhibitors of protein targets with large active sites.			Pang, YP (corresponding author), Mayo Clin, Comp Aided Mol Design Lab, Rochester, MN 55905 USA.	pang@mayo.edu; james.schmidt@det.amedd.army.mil		Pang, Yuan-Ping/0000-0003-0838-2560				Ariffin A, 2004, SYNTHETIC COMMUN, V34, P4439, DOI 10.1081/SCC-200043164; Arkin MR, 2004, NAT REV DRUG DISCOV, V3, P301, DOI 10.1038/nrd1343; Arnon SS, 2001, JAMA-J AM MED ASSOC, V285, P1059, DOI 10.1001/jama.285.8.1059; BERENDSEN HJC, 1984, J CHEM PHYS, V81, P3684, DOI 10.1063/1.448118; BLACK RE, 1980, AM J MED, V69, P567, DOI 10.1016/0002-9343(80)90469-6; Blommaert A, 2004, BIOORGAN MED CHEM, V12, P3055, DOI 10.1016/j.bmc.2004.03.006; Boldt GE, 2006, ORG LETT, V8, P1729, DOI 10.1021/ol0603211; Boldt GE, 2006, CHEM COMMUN, P3063, DOI 10.1039/b603099h; Breidenbach MA, 2004, NATURE, V432, P925, DOI 10.1038/nature03123; Burnett JC, 2009, BIOORG MED CHEM LETT, V19, P5811, DOI 10.1016/j.bmcl.2009.01.111; Burnett JC, 2007, J BIOL CHEM, V282, P5004, DOI 10.1074/jbc.M608166200; Case DA, 2005, J COMPUT CHEM, V26, P1668, DOI 10.1002/jcc.20290; CHENG Y, 1973, BIOCHEM PHARMACOL, V22, P3099; CIEPLAK P, 1995, J COMPUT CHEM, V16, P1357, DOI 10.1002/jcc.540161106; COREY EJ, 1988, CHEM SOC REV, V17, P111, DOI 10.1039/cs9881700111; Crowner BE, 2007, CLIN NEUROPHARMACOL, V30, P310, DOI 10.1097/WNF.0B013E31804B1A0D; DARDEN T, 1993, J CHEM PHYS, V98, P10089, DOI 10.1063/1.464397; DeLano W.L., 2002, PYMOL MOL GRAPHICS S; Ekstrom F, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005957; El Yazal J, 2000, J PHYS CHEM B, V104, P6662, DOI 10.1021/jp994283x; El Yazal J, 1999, J PHYS CHEM B, V103, P8773, DOI 10.1021/jp991787m; Eyal E, 2005, J MOL BIOL, V351, P431, DOI 10.1016/j.jmb.2005.05.066; FARNIER M, 1973, B SOC CHIM FR, P351; *FDA, 2003, BOT IMM GLOB INTR HU; Frisch M J, 1999, GAUSSIAN 98 REVISION; GARRIDO DOA, 1988, J ORG CHEM, V53, P403, DOI 10.1021/jo00237a032; HASS HB, 1949, J AM CHEM SOC, V71, P1767, DOI 10.1021/ja01173a066; Ho CY, 2005, J ORG CHEM, V70, P4873, DOI 10.1021/jo050036f; Hornak V, 2006, PROTEINS, V65, P712, DOI 10.1002/prot.21123; Johnson SL, 2008, CHEM BIOL DRUG DES, V71, P131, DOI 10.1111/j.1747-0285.2007.00617.x; JORGENSEN WL, 1983, J CHEM PHYS, V79, P926, DOI 10.1063/1.445869; Kessler KR, 1997, NEUROTOXICOLOGY, V18, P761; Larsen JC, 2009, DRUG DEVELOP RES, V70, P266, DOI 10.1002/ddr.20304; MCLACHLAN AD, 1982, ACTA CRYSTALLOGR A, V38, P871, DOI 10.1107/S0567739482001806; Moe ST, 2009, BIOORGAN MED CHEM, V17, P3072, DOI 10.1016/j.bmc.2009.03.013; MOOTOO DR, 1989, TETRAHEDRON LETT, V30, P2363, DOI 10.1016/S0040-4039(01)80399-3; Pang YP, 2000, PROTEIN SCI, V9, P1857; Pang YP, 1999, J MOL MODEL, V5, P196, DOI 10.1007/s008940050119; Pang YP, 2004, BIOORGAN MED CHEM, V12, P3063, DOI 10.1016/j.bmc.2004.02.026; Pang YP, 2001, PROTEINS, V45, P183, DOI 10.1002/prot.1138; Park JG, 2006, BIOORGAN MED CHEM, V14, P395, DOI 10.1016/j.bmc.2005.08.018; PEARLMAN DA, 1995, COMPUT PHYS COMMUN, V91, P1, DOI 10.1016/0010-4655(95)00041-D; Pires-Alves M, 2009, TOXICON, V53, P392, DOI 10.1016/j.toxicon.2008.12.016; Roxas-Duncan V, 2009, ANTIMICROB AGENTS CH, V53, P3478, DOI 10.1128/AAC.00141-09; Schmidt JJ, 2003, APPL ENVIRON MICROB, V69, P297, DOI 10.1128/AEM.69.1.297-303.2003; Schmidt JJ, 1998, FEBS LETT, V435, P61, DOI 10.1016/S0014-5793(98)01041-2; Schmidt JJ, 1997, J PROTEIN CHEM, V16, P19, DOI 10.1023/A:1026386710428; SEGEL IH, 1975, ENZYME KINETICS BEHA, V12, P109; Shao JY, 2007, J CHEM THEORY COMPUT, V3, P2312, DOI 10.1021/ct700119m; Shapiro RL, 1998, ANN INTERN MED, V129, P221, DOI 10.7326/0003-4819-129-3-199808010-00011; SHONE CC, 1994, EUR J BIOCHEM, V225, P263, DOI 10.1111/j.1432-1033.1994.00263.x; Silvaggi NR, 2008, BIOCHEMISTRY-US, V47, P5736, DOI 10.1021/bi8001067; Silvaggi NR, 2007, CHEM BIOL, V14, P533, DOI 10.1016/j.chembiol.2007.03.014; SIMPSON LL, 1981, PHARMACOL REV, V33, P155; Smith JA, 2006, ORG BIOMOL CHEM, V4, P2477, DOI 10.1039/b604692d; Smith K, 2007, J ORG CHEM, V72, P1031, DOI 10.1021/jo062024f; SPRINGEN K, 2002, NEWSWEEK, P50; Tang J, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0000761; VASILEVSKII SF, 1980, B ACAD SCI USSR CH+, V29, P1346, DOI 10.1007/BF00950586; Wang Q, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0001025; Wang Q, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0000531; Wickstrom L, 2009, BIOPHYS J, V97, P853, DOI 10.1016/j.bpj.2009.04.063; Zhang Q, 2000, J ORG CHEM, V65, P7977, DOI 10.1021/jo000978e; Zuniga JE, 2008, STRUCTURE, V16, P1588, DOI 10.1016/j.str.2008.07.011	64	40	41	0	12	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA	1932-6203			PLOS ONE	PLoS One	NOV 10	2009	4	11							e7730	10.1371/journal.pone.0007730	http://dx.doi.org/10.1371/journal.pone.0007730			18	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	517ZU	19901994	Green Published, Green Submitted, gold			2022-12-25	WOS:000271658800004
J	Holford, M; Puillandre, N; Modica, MV; Watkins, M; Collin, R; Bermingham, E; Olivera, BM				Holford, Mande; Puillandre, Nicolas; Modica, Maria Vittoria; Watkins, Maren; Collin, Rachel; Bermingham, Eldredge; Olivera, Baldomero M.			Correlating Molecular Phylogeny with Venom Apparatus Occurrence in Panamic Auger Snails (Terebridae)	PLOS ONE			English	Article							CONUS; DISCOVERY; EVOLUTION; PEPTIDE	Central to the discovery of neuroactive compounds produced by predatory marine snails of the superfamily Conoidea (cone snails, terebrids, and turrids) is identifying those species with a venom apparatus. Previous analyses of western Pacific terebrid specimens has shown that some Terebridae groups have secondarily lost their venom apparatus. In order to efficiently characterize terebrid toxins, it is essential to devise a key for identifying which species have a venom apparatus. The findings presented here integrate molecular phylogeny and the evolution of character traits to infer the presence or absence of the venom apparatus in the Terebridae. Using a combined dataset of 156 western and 33 eastern Pacific terebrid samples, a phylogenetic tree was constructed based on analyses of 16S, COI and 12S mitochondrial genes. The 33 eastern Pacific specimens analyzed represent four different species: Acus strigatus, Terebra argyosia, T. ornata, and T. cf. formosa. Anatomical analysis was congruent with molecular characters, confirming that species included in the clade Acus do not have a venom apparatus, while those in the clade Terebra do. Discovery of the association between terebrid molecular phylogeny and the occurrence of a venom apparatus provides a useful tool for effectively identifying the terebrid lineages that may be investigated for novel pharmacological active neurotoxins, enhancing conservation of this important resource, while providing supplementary information towards understanding terebrid evolutionary diversification.			Holford, M (corresponding author), City Univ New York York Coll, New York, NY USA.	mholford@york.cuny.edu	Puillandre, Nicolas/C-9208-2012; Collin, Rachel/G-2001-2010; Modica, Maria Vittoria/P-8407-2018; Collin, Rachel/Q-7100-2019	Modica, Maria Vittoria/0000-0003-2532-6763; Collin, Rachel/0000-0001-5103-4460; Holford, Mande/0000-0001-9476-2687	NIGMS NIH HHS [GM48677, P01 GM048677] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [P01GM048677] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BRATCHER T, 1987, LIVING TEREBRAS WORL; BULAJ G, 2008, CURRENT OPINION CHEM, V12, P1; Folmer O., 1994, Molecular Marine Biology and Biotechnology, V3, P294; Guindon S, 2003, SYST BIOL, V52, P696, DOI 10.1080/10635150390235520; Hall T.A., 1999, NUCL ACIDS S SERIES, V41, P95, DOI [DOI 10.1021/BK-1999-0734.CH008, citeulike-article-id:691774, 10.12691/ajmr-6-4-3]; Han TS, 2008, CURR PHARM DESIGN, V14, P2462, DOI 10.2174/138161208785777469; Holford M, 2009, TOXICON, V53, P90, DOI 10.1016/j.toxicon.2008.10.017; Holford M, 2009, MOL BIOL EVOL, V26, P15, DOI 10.1093/molbev/msn211; Huelsenbeck JP, 2001, BIOINFORMATICS, V17, P754, DOI 10.1093/bioinformatics/17.8.754; IMPERIAL J, 2007, J EXP ZOOL PART B, V308, P1; Imperial JS, 2003, TOXICON, V42, P391, DOI 10.1016/S0041-0101(03)00169-7; Imperial JS, 2007, P AM PHILOS SOC, V151, P185; KEEN AM, 1972, SEA SHELLS TROPICAL; KOHN AJ, 1959, ECOL MONOGR, V29, P47, DOI 10.2307/1948541; McIntosh JM, 2000, J BIOL CHEM, V275, P32391, DOI 10.1074/jbc.M003619200; MCINTOSH M, 1982, ARCH BIOCHEM BIOPHYS, V218, P329, DOI 10.1016/0003-9861(82)90351-4; Miljanich GP, 2004, CURR MED CHEM, V11, P3029, DOI 10.2174/0929867043363884; MILLER BA, 1975, PAC SCI, V29, P227; MILLER BA, 1970, ANN REP AM MAL UNION, V1971, P72; MILLER BA, 1970, THESIS U NEW HAMPSHI; Olivera BM, 2007, MOL INTERV, V7, P251, DOI 10.1124/mi.7.5.7; Olivera BM, 2006, J BIOL CHEM, V281, P31173, DOI 10.1074/jbc.R600020200; Palumbi S. R., 1996, MOL SYSTEMATICS, V2, P205, DOI DOI 10.1080/17451000.2014.902536; Puillandre N, 2008, MOL PHYLOGENET EVOL, V47, P1122, DOI 10.1016/j.ympev.2007.11.007; Remigio EA, 2008, MOL ECOL, V17, P1156, DOI 10.1111/j.1365-294X.2007.03627.x; SIMON C, 1991, POLYM CHAIN REACTION, P329; TAYLOR JD, 1990, MALACOLOGIA, V32, P19; Taylor John D., 1993, Bulletin of the British Museum (Natural History) Zoology, V59, P125; Terlau H, 2004, PHYSIOL REV, V84, P41, DOI 10.1152/physrev.00020.2003; TERRYN Y, 2008, TEREBRIDAE VANUATU S, V3	30	13	14	0	6	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	NOV 5	2009	4	11							e7667	10.1371/journal.pone.0007667	http://dx.doi.org/10.1371/journal.pone.0007667			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	515HI	19890382	Green Submitted, Green Published, gold			2022-12-25	WOS:000271459700003
J	Girasol, A; Albuquerque, GG; Mansour, E; Araujo, EP; Degasperi, G; Denis, RG; Carvalheira, JB; Saad, MJ; Velloso, LA				Girasol, Alessandra; Albuquerque, Gabriela G.; Mansour, Eli; Araujo, Eliana P.; Degasperi, Giovanna; Denis, Raphael G.; Carvalheira, Jose B.; Saad, Mario J.; Velloso, Licio A.			Fyn Mediates Leptin Actions in the Thymus of Rodents	PLOS ONE			English	Article							PERIPHERAL T-CELLS; IMMUNE-RESPONSE; RECEPTOR; ACTIVATION; HYPOTHALAMUS; IMMUNOLOGY; RESISTANCE; NUTRITION; PATHWAYS; P59(FYN)	Background: Several effects of leptin in the immune system rely on its capacity to modulate cytokine expression and apoptosis in the thymus. Surprisingly, some of these effects are dependent on signal transduction through the IRS1/PI3-kinase, but not on the activation of JAK2. Since all the well known effects of leptin in different cell types and tissues seem to be dependent on JAK2 activation, we hypothesized that, at least for the control of thymic function, another, unknown kinase could mediate the transduction of the leptin signal from the ObR towards the IRS1/PI3-kinase signaling cascade. Methodology/Principal Findings: Here, by employing immunoblot, real-time PCR and flow citometry we show that the tyrosine kinase, Fyn, is constitutively associated with the ObR in thymic cells. Following a leptin stimulus, Fyn undergoes an activating tyrosine phosphorylation and a transient association with IRS1. All these effects are independent of JAK2 activation and, upon Fyn inhibition, the signal transduction towards IRS1/PI3-kinase is abolished. In addition, the inhibition of Fyn significantly modifies the effects of leptin on thymic cytokine expression. Conclusion /Significance: Therefore, in the thymus, Fyn acts as a tyrosine kinase that transduces the leptin signal independently of JAK2 activation, and mediates some of the immunomodulatory effects of leptin in this tissue.			Girasol, A (corresponding author), Univ Estadual Campinas, Dept Internal Med, Campinas, SP, Brazil.	lavelloso@fcm.unicamp.br	Araujo, EP/D-9231-2013; Carvalheira, Jose B/H-8405-2012; Carvalheira, Jose Barreto Campello/E-8562-2013; Saad, Mario/ABD-8262-2020; Velloso, Licio/AAJ-3778-2020; Mansour, Eli/AAD-2841-2019; Vercesi, Aníbal E/C-8767-2012; Degasperi, G/V-3451-2018; Denis, Raphael/ABE-1758-2020	Araujo, EP/0000-0002-7539-8477; Carvalheira, Jose Barreto Campello/0000-0002-0136-0943; Mansour, Eli/0000-0001-6450-6930; Degasperi, G/0000-0002-0317-2532; Denis, Raphael/0000-0002-7677-7460				Ahluwalia N, 2004, J Nutr Health Aging, V8, P2; Banks AS, 2000, J BIOL CHEM, V275, P14563, DOI 10.1074/jbc.275.19.14563; BOYUM A, 1976, SCAND J IMMUNOL, P9, DOI 10.1111/j.1365-3083.1976.tb03851.x; Brumatti G, 2003, FEBS LETT, V541, P57, DOI 10.1016/S0014-5793(03)00299-0; Carvalheira JBC, 2001, FEBS LETT, V500, P119, DOI 10.1016/S0014-5793(01)02591-1; Chung WK, 1996, GENOME RES, V6, P431, DOI 10.1101/gr.6.5.431; Degasperi GR, 2006, EUR J PHARMACOL, V549, P179, DOI 10.1016/j.ejphar.2006.08.027; Farooqi IS, 2002, J CLIN INVEST, V110, P1093, DOI 10.1172/JCI200215693; Fernandes G, 2008, IMMUNOL RES, V40, P244, DOI 10.1007/s12026-007-0021-3; Flier JS, 1998, NAT MED, V4, P1124, DOI 10.1038/2619; Friedman JM, 1998, NATURE, V395, P763, DOI 10.1038/27376; Gasparetti AL, 2003, J PHYSIOL-LONDON, V552, P149, DOI 10.1113/jphysiol.2003.050369; Howard JK, 1999, J CLIN INVEST, V104, P1051, DOI 10.1172/JCI6762; Jiang L, 2008, J BIOL CHEM, V283, P28066, DOI 10.1074/jbc.M805545200; Kellerer M, 1997, DIABETOLOGIA, V40, P1358, DOI 10.1007/s001250050832; Kloek C, 2002, J BIOL CHEM, V277, P41547, DOI 10.1074/jbc.M205148200; La Cava A, 2004, NAT REV IMMUNOL, V4, P371, DOI 10.1038/nri1350; Lesourd BM, 1998, NUTR REV, V56, pS113; Lord GM, 1998, NATURE, V394, P897, DOI 10.1038/29795; Mansour E, 2006, ENDOCRINOLOGY, V147, P5470, DOI 10.1210/en.2006-0223; Matarese G, 2005, J IMMUNOL, V174, P3137, DOI 10.4049/jimmunol.174.6.3137; Matarese G, 2001, J IMMUNOL, V166, P5909, DOI 10.4049/jimmunol.166.10.5909; Munzberg H, 2005, NAT NEUROSCI, V8, P566, DOI 10.1038/nn1454; Myers MG, 2008, ANNU REV PHYSIOL, V70, P537, DOI 10.1146/annurev.physiol.70.113006.100707; OLSZOWY MW, 1995, J IMMUNOL, V155, P4236; Salmond RJ, 2009, IMMUNOL REV, V228, P9, DOI 10.1111/j.1600-065X.2008.00745.x; Savino W, 2007, BRIT J NUTR, V98, pS11, DOI 10.1017/S0007114507832880; STEIN PL, 1992, CELL, V70, P741, DOI 10.1016/0092-8674(92)90308-Y; Taga T, 1997, ANNU REV IMMUNOL, V15, P797, DOI 10.1146/annurev.immunol.15.1.797; Tartaglia LA, 1997, J BIOL CHEM, V272, P6093, DOI 10.1074/jbc.272.10.6093; Utting O, 1998, J IMMUNOL, V160, P5410; Valdes-Ramos R, 2007, BRIT J NUTR, V98, pS127, DOI 10.1017/S0007114507833009; Velloso LA, 2008, NEUROIMMUNOMODULAT, V15, P189, DOI 10.1159/000153423; Velloso LA, 2009, ANN NY ACAD SCI, V1153, P29, DOI 10.1111/j.1749-6632.2008.03973.x	34	10	10	0	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	NOV 3	2009	4	11							e7707	10.1371/journal.pone.0007707	http://dx.doi.org/10.1371/journal.pone.0007707			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	514RY	19888448	Green Submitted, Green Published, gold			2022-12-25	WOS:000271414500009
J	De la Fuente, IM; Vadillo, F; Perez-Pinilla, MB; Vera-Lopez, A; Veguillas, J				De la Fuente, Ildefonso M.; Vadillo, Fernando; Perez-Pinilla, Martin-Blas; Vera-Lopez, Antonio; Veguillas, Juan			The Number of Catalytic Elements Is Crucial for the Emergence of Metabolic Cores	PLOS ONE			English	Article							PANCREATIC BETA-CELL; SACCHAROMYCES-CEREVISIAE; AUTONOMOUS OSCILLATIONS; YEAST; EXPRESSION; CYCLE; CA2+; MITOCHONDRIA; ORGANIZATION; GLYCOLYSIS	Background: Different studies show evidence that several unicellular organisms display a cellular metabolic structure characterized by a set of enzymes which are always in an active state (metabolic core), while the rest of the molecular catalytic reactions exhibit on-off changing states. This self-organized enzymatic configuration seems to be an intrinsic characteristic of metabolism, common to all living cellular organisms. In a recent analysis performed with dissipative metabolic networks (DMNs) we have shown that this global functional structure emerges in metabolic networks with a relatively high number of catalytic elements, under particular conditions of enzymatic covalent regulatory activity. Methodology/Principal Findings: Here, to investigate the mechanism behind the emergence of this supramolecular organization of enzymes, we have performed extensive DMNs simulations (around 15,210,000 networks) taking into account the proportion of the allosterically regulated enzymes and covalent enzymes present in the networks, the variation in the number of substrate fluxes and regulatory signals per catalytic element, as well as the random selection of the catalytic elements that receive substrate fluxes from the exterior. The numerical approximations obtained show that the percentages of DMNs with metabolic cores grow with the number of catalytic elements, converging to 100% for all cases. Conclusions/Significance: The results show evidence that the fundamental factor for the spontaneous emergence of this global self-organized enzymatic structure is the number of catalytic elements in the metabolic networks. Our analysis corroborates and expands on our previous studies illustrating a crucial property of the global structure of the cellular metabolism. These results also offer important insights into the mechanisms which ensure the robustness and stability of living cells.			De la Fuente, IM (corresponding author), Univ Basque Country, Fac Sci & Technol, Dept Math, Vizcaya, Spain.	mtpmadei@ehu.es	Vera-López, Antonio/P-3022-2016; Pérez-Pinillla, Martín-Blas/K-9042-2017; Vadillo, Fernando/AAW-5629-2021	Pérez-Pinillla, Martín-Blas/0000-0002-3461-9990; Vadillo, Fernando/0000-0001-6524-360X; De la Fuente, Ildefonso/0000-0001-6548-7583; Vera-Lopez, Antonio/0000-0002-0351-2701				Ainscow EK, 2002, J PHYSIOL-LONDON, V544, P429, DOI 10.1113/jphysiol.2002.022434; Almaas E, 2007, J EXP BIOL, V210, P1548, DOI 10.1242/jeb.003731; Almaas E, 2005, PLOS COMPUT BIOL, V1, P557, DOI 10.1371/journal.pcbi.0010068; Chabot JR, 2007, NATURE, V450, P1249, DOI 10.1038/nature06395; Chiam KH, 2007, PHYS REV E, V75, DOI 10.1103/PhysRevE.75.061901; De La Fuente IM, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003100; De La Fuente IM, 1999, B MATH BIOL, V61, P573, DOI 10.1006/bulm.1999.0103; DIXON CJ, 1995, BIOCHEM J, V309, P145, DOI 10.1042/bj3090145; Dyachok O, 2006, NATURE, V439, P349, DOI 10.1038/nature04410; FUENTES JM, 1994, ARCH INT PHYSIOL BIO, V102, P237, DOI 10.3109/13813459409003936; Futcher B, 2006, GENOME BIOL, V7, DOI 10.1186/gb-2006-7-4-107; Garmendia-Torres C, 2007, CURR BIOL, V17, P1044, DOI 10.1016/j.cub.2007.05.032; Gavin AC, 2002, NATURE, V415, P141, DOI 10.1038/415141a; Getty L, 2000, J CLIN INVEST, V106, P421, DOI 10.1172/JCI7815; Gillette MU, 2005, SCIENCE, V309, P1196, DOI 10.1126/science.1111420; GOLDBETER A, 1972, BIOPHYS J, V12, P1302, DOI 10.1016/S0006-3495(72)86164-2; Goldbeter A, 2002, NATURE, V420, P238, DOI 10.1038/nature01259; Goldbeter A, 2007, ADV CHEM PHYS, V135, P253; Hans MA, 2003, BIOTECHNOL BIOENG, V82, P143, DOI 10.1002/bit.10553; Hartig K, 2005, PLANT BIOLOGY, V7, P33, DOI 10.1055/s-2004-830474; HEINZLE E, 1983, P 1 IFAC WORKSH MOD, P57; Hess B, 2000, NATURWISSENSCHAFTEN, V87, P199, DOI 10.1007/s001140050704; Ho Y, 2002, NATURE, V415, P180, DOI 10.1038/415180a; Holz GG, 2008, AM J PHYSIOL-CELL PH, V294, pC4, DOI 10.1152/ajpcell.00522.2007; Hungerbuehler AK, 2007, EUKARYOT CELL, V6, P473, DOI 10.1128/EC.00273-06; Ishii K, 2006, EMBO REP, V7, P390, DOI 10.1038/sj.embor.7400620; Jules M, 2005, FEBS J, V272, P1490, DOI 10.1111/j.1742-4658.2005.04588.x; Karp PD, 2001, SCIENCE, V293, P2040, DOI 10.1126/science.1064621; Kindzelskii AL, 1998, BIOPHYS J, V74, P90, DOI 10.1016/S0006-3495(98)77770-7; Kitano H, 2004, NAT REV GENET, V5, P826, DOI 10.1038/nrg1471; Klevecz RR, 2004, P NATL ACAD SCI USA, V101, P1200, DOI 10.1073/pnas.0306490101; Klevecz RR, 2001, MOL BIOL REP, V28, P73, DOI 10.1023/A:1017909012215; LANGE G, 2004, FEBS, V178, P61; LEBRUN P, 1985, BIOPHYS J, V48, P529, DOI 10.1016/S0006-3495(85)83809-1; Lloyd D, 2002, FEBS LETT, V519, P41, DOI 10.1016/S0014-5793(02)02704-7; MacDonald MJ, 2003, J BIOL CHEM, V278, P51894, DOI 10.1074/jbc.M309038200; Marquez S, 2004, FASEB J, V18, P519, DOI 10.1096/fj.03-0417fje; Mellon D, 1999, J NEUROPHYSIOL, V81, P1231, DOI 10.1152/jn.1999.81.3.1231; Moller AC, 1998, BIOPHYS CHEM, V72, P63, DOI 10.1016/S0301-4622(98)00123-9; Nielsen K, 1998, BIOPHYS CHEM, V72, P49, DOI 10.1016/S0301-4622(98)00122-7; OVADI J, 2005, CELL BIOCH, V256, P5; Pal C, 2006, NATURE, V440, P667, DOI 10.1038/nature04568; Placantonakis DG, 2001, J PHYSIOL-LONDON, V534, P123, DOI 10.1111/j.1469-7793.2001.t01-1-00123.x; Ramanujan VK, 2006, BIOPHYS J, V90, pL70, DOI 10.1529/biophysj.106.083501; Rosenspire AJ, 2001, J CELL SCI, V114, P1515; Sanchez-Armass S, 2006, AM J PHYSIOL-CELL PH, V290, pC524, DOI 10.1152/ajpcell.00290.2005; Shaul O, 1996, P NATL ACAD SCI USA, V93, P4868, DOI 10.1073/pnas.93.10.4868; Smrcinova M, 1998, INT J BIFURCAT CHAOS, V8, P2467, DOI 10.1142/S0218127498001984; Tian B, 2005, BMC GENOMICS, V6, DOI 10.1186/1471-2164-6-137; Tonozuka H, 2001, J BIOCHEM-TOKYO, V130, P589, DOI 10.1093/oxfordjournals.jbchem.a003023; Wittmann C, 2005, BIOTECHNOL BIOENG, V89, P839, DOI 10.1002/bit.20408; CYBER CELL DATABASE	54	11	11	0	5	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	OCT 19	2009	4	10							e7510	10.1371/journal.pone.0007510	http://dx.doi.org/10.1371/journal.pone.0007510			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	507UP	19888419	Green Published, gold, Green Submitted			2022-12-25	WOS:000270880900012
J	Fang, F; Lue, LF; Yan, SQ; Xu, HW; Luddy, JS; Chen, D; Walker, DG; Stern, DM; Yan, SF; Schmidt, AM; Chen, JX; Yan, SS				Fang, Fang; Lue, Lih-Fen; Yan, Shiqiang; Xu, Hongwei; Luddy, John S.; Chen, Doris; Walker, Douglas G.; Stern, David M.; Yan, Shifang; Schmidt, Ann Marie; Chen, John X.; Yan, Shirley Shidu			RAGE-dependent signaling in microglia contributes to neuroinflammation, A beta accumulation, and impaired learning/memory in a mouse model of Alzheimer's disease	FASEB JOURNAL			English	Article						A beta-binding protein; microglia/neuron interaction; cytokine; animal model	AMYLOID PRECURSOR PROTEIN; GLYCATION END-PRODUCTS; CYTOKINE UP-REGULATION; NECROSIS-FACTOR-ALPHA; APP TRANSGENIC MICE; P38 MAP KINASE; NEURODEGENERATIVE DISEASES; MITOCHONDRIAL DYSFUNCTION; SYNAPTIC DYSFUNCTION; TAU PHOSPHORYLATION	Microglia are critical for amyloid-beta peptide (A beta)-mediated neuronal perturbation relevant to Alzheimer's disease (AD) pathogenesis. We demonstrate that overexpression of receptor for advanced glycation end products (RAGE) in imbroglio exaggerates neuroinflammation, as evidenced by increased proinflammatory mediator production, A beta accumulation, impaired learning/ memory, and neurotoxicity in an A beta rich environment. Transgenic (Tg) mice expressing human mutant APP (mAPP) in neurons and RAGE in microglia displayed enhanced IL-1 beta and TNF-alpha production, increased infiltration of microglia and astrocytes, accumulation of A beta, reduced acetylcholine esterase (AChE) activity, and accelerated deterioration of spatial learning/ memory. Notably, introduction of a signal transduction- defective mutant RAGE (DN-RAGE) to microglia attenuates deterioration induced by A beta. These findings indicate that RAGE signaling in microglia contributes to the pathogenesis of an inflammatory response that ultimately impairs neuronal function and directly affects amyloid accumulation. We conclude that blockade of microglial RAGE may have a beneficial effect on A beta-mediated neuronal perturbation relevant to AD pathogenesis.-Fang, F., Lue, L.-F., Yan, S., Xu, H., Luddy, J. S., Chen, D., Walker, D. G., Stern, D. M., Yan, S., Schmidt, A. M., Chen, J. X., Yan, S. S. RAGE-dependent signaling in microglia contributes to neuroinflammation, A beta accumulation, and impaired learning/memory in a mouse model of Alzheimer's disease. FASEB J. 24, 1043-1055 (2010). www.fasebj.org	[Yan, Shirley Shidu] Columbia Univ, Coll Phys & Surg, Dept Pathol, New York, NY 10032 USA; [Fang, Fang; Yan, Shiqiang; Xu, Hongwei; Luddy, John S.; Chen, Doris; Yan, Shifang; Schmidt, Ann Marie; Yan, Shirley Shidu] Columbia Univ, Coll Phys & Surg, Dept Surg, New York, NY 10032 USA; [Yan, Shirley Shidu] Columbia Univ, Coll Phys & Surg, Taub Inst Res Alzheimers Dis & Aging Brain, New York, NY 10032 USA; [Lue, Lih-Fen; Walker, Douglas G.] Sun Hlth Res Inst, Lab Neuroinflammat, Sun City, AZ USA; [Yan, Shiqiang] Langzhou Univ, Coll Chem & Chem Engn, Langzhou, Peoples R China; [Stern, David M.] Univ Cincinnati, Coll Med, Cincinnati, OH USA; [Chen, John X.] Mem Sloan Kettering Canc Ctr, Dept Neurol, New York, NY 10021 USA	Columbia University; Columbia University; Columbia University; Banner Research; Banner Health; Banner Sun Health Research Institute; Lanzhou University; University System of Ohio; University of Cincinnati; Memorial Sloan Kettering Cancer Center	Yan, SS (corresponding author), Columbia Univ, Coll Phys & Surg, Dept Pathol, 630 W 168th St, New York, NY 10032 USA.	sdy1@columbia.edu	xu, hong/GSD-8903-2022		U.S. Public Health Service [PO1AG17490]; Arizona Alzheimer's Consortium; NATIONAL INSTITUTE ON AGING [P01AG017490] Funding Source: NIH RePORTER	U.S. Public Health Service(United States Department of Health & Human ServicesUnited States Public Health Service); Arizona Alzheimer's Consortium; NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))	This work was supported by grants from the U.S. Public Health Service (PO1AG17490). L-F. L. and D.G.W. were supported by a grant from the Arizona Alzheimer's Consortium. D.S. is a consultant of TransTech Pharma.	Akiyama H, 2000, NEUROBIOL AGING, V21, P383, DOI 10.1016/S0197-4580(00)00124-X; ANDERSEN K, 1995, NEUROLOGY, V45, P1441, DOI 10.1212/WNL.45.8.1441; Arancio O, 2004, EMBO J, V23, P4096, DOI 10.1038/sj.emboj.7600415; Blalock EM, 2005, AGEING RES REV, V4, P481, DOI 10.1016/j.arr.2005.06.006; Britschgi M, 2007, NAT MED, V13, P408, DOI 10.1038/nm0407-408; Chen X, 2007, CURR MOL MED, V7, P735; Cho HJ, 2009, FASEB J, V23, P2639, DOI 10.1096/fj.08-126383; Craft JM, 2005, J NEUROINFLAMM, V2, DOI 10.1186/1742-2094-2-15; Deane R, 2003, NAT MED, V9, P907, DOI 10.1038/nm890; Du H, 2008, NAT MED, V14, P1097, DOI 10.1038/nm.1868; Du H, 2011, NEUROBIOL AGING, V32, P398, DOI 10.1016/j.neurobiolaging.2009.03.003; DU Y.S., 1997, P NATL ACAD SCI USA, V94, P5296; Dudal S, 2004, NEUROBIOL AGING, V25, P861, DOI 10.1016/j.neurobiolaging.2003.08.008; El Khoury J, 2007, NAT MED, V13, P432, DOI 10.1038/nm1555; Farris W, 2003, P NATL ACAD SCI USA, V100, P4162, DOI 10.1073/pnas.0230450100; Ferrer I, 2004, NEUROTOX RES, V6, P469, DOI 10.1007/BF03033283; Floden AM, 2007, J NEUROSCI METH, V164, P218, DOI 10.1016/j.jneumeth.2007.04.018; Floden AM, 2005, J NEUROSCI, V25, P2566, DOI 10.1523/JNEUROSCI.4998-04.2005; Frautschy SA, 1998, AM J PATHOL, V152, P307; Giovannini MG, 2002, NEUROBIOL DIS, V11, P257, DOI 10.1006/nbdi.2002.0538; Giri R, 2002, AM J PHYSIOL-CELL PH, V283, pC895, DOI 10.1152/ajpcell.00293.2001; Giri R, 2000, AM J PHYSIOL-CELL PH, V279, pC1772, DOI 10.1152/ajpcell.2000.279.6.C1772; GIULIAN D, 1994, NEUROCHEM INT, V25, P227, DOI 10.1016/0197-0186(94)90066-3; GIULIAN D, 1995, NEUROCHEM INT, V27, P119, DOI 10.1016/0197-0186(95)00067-I; Griffin WST, 2006, J NEUROINFLAMM, V3, DOI 10.1186/1742-2094-3-5; Hadding A, 2004, BBA-MOL CELL RES, V1691, P67, DOI 10.1016/j.bbamcr.2004.01.003; Haq S, 2001, CIRCULATION, V103, P670; Heneka MT, 2005, J NEUROINFLAMM, V2, DOI 10.1186/1742-2094-2-22; Heneka MT, 2005, BRAIN, V128, P1442, DOI 10.1093/brain/awh452; Hensley K, 1999, J NEUROCHEM, V72, P2053, DOI 10.1046/j.1471-4159.1999.0722053.x; Hofmann MA, 1999, CELL, V97, P889, DOI 10.1016/S0092-8674(00)80801-6; Javadov SA, 2000, CARDIOVASC RES, V45, P360, DOI 10.1016/S0008-6363(99)00365-X; Johnson GVW, 2003, EXP NEUROL, V183, P263, DOI 10.1016/S0014-4886(03)00268-1; Li YK, 2003, J NEUROSCI, V23, P1605; Liao YF, 2004, J BIOL CHEM, V279, P49523, DOI 10.1074/jbc.M402034200; Lue LF, 2005, CNS NEUROL DISORD-DR, V4, P249, DOI 10.2174/1568007054038210; Lue LF, 2002, J NEUROSCI RES, V70, P599, DOI 10.1002/jnr.10422; Lue LF, 2001, NEUROBIOL AGING, V22, P945, DOI 10.1016/S0197-4580(01)00311-6; Lue LF, 2001, EXP NEUROL, V171, P29, DOI 10.1006/exnr.2001.7732; Lustbader JW, 2004, SCIENCE, V304, P448, DOI 10.1126/science.1091230; McGeer PL, 2006, J ALZHEIMERS DIS, V9, P271; Miller MC, 2008, BRAIN RES, V1230, P273, DOI 10.1016/j.brainres.2008.06.124; Minghetti L, 2005, CURR OPIN NEUROL, V18, P315, DOI 10.1097/01.wco.0000169752.54191.97; Morgan D, 2005, J NEUROPATH EXP NEUR, V64, P743, DOI 10.1097/01.jnen.0000178444.33972.e0; Mruthinti S, 2006, NEUROSCIENCE, V142, P463, DOI 10.1016/j.neuroscience.2006.06.010; Mruthinti S, 2004, NEUROBIOL AGING, V25, P1023, DOI 10.1016/j.neurobiolaging.2003.11.001; Mruthinti S, 2003, J MOL NEUROSCI, V20, P223, DOI 10.1385/JMN:20:3:223; Mruthinti S, 2007, CURR ALZHEIMER RES, V4, P581, DOI 10.2174/156720507783018325; Mruthinti Shyamala, 2006, Current Alzheimer Research, V3, P229, DOI 10.2174/156720506777632899; Munoz L, 2007, J NEUROINFLAMM, V4, DOI 10.1186/1742-2094-4-21; Origlia N, 2008, J NEUROSCI, V28, P3521, DOI 10.1523/JNEUROSCI.0204-08.2008; Origlia N, 2009, J ALZHEIMERS DIS, V17, P59, DOI 10.3233/JAD-2009-1045; Pei JJ, 2001, J ALZHEIMERS DIS, V3, P41, DOI 10.3233/JAD-2001-3107; Ranaivo HR, 2006, J NEUROSCI, V26, P662, DOI 10.1523/JNEUROSCI.4652-05.2006; Rong LL, 2005, RESTOR NEUROL NEUROS, V23, P355; Rong LL, 2004, FASEB J, V18, P1818, DOI 10.1096/fj.04-1900com; Sasaki N, 2001, BRAIN RES, V888, P256, DOI 10.1016/S0006-8993(00)03075-4; Savage MJ, 2002, J NEUROSCI, V22, P3376; Schieven GL, 2005, CURR TOP MED CHEM, V5, P921, DOI 10.2174/1568026054985902; Stalder M, 1999, AM J PATHOL, V154, P1673, DOI 10.1016/S0002-9440(10)65423-5; Sturchler E, 2008, J NEUROSCI, V28, P5149, DOI 10.1523/JNEUROSCI.4878-07.2008; Sun AY, 2003, EXP NEUROL, V183, P394, DOI 10.1016/S0014-4886(03)00180-8; Swatton JE, 2004, EUR J NEUROSCI, V19, P2711, DOI 10.1111/j.0953-816X.2004.03365.x; Takuma K, 2005, FASEB J, V19, P597, DOI 10.1096/fj.04-2582fje; Tarkowski E, 2003, J NEUROL NEUROSUR PS, V74, P1200, DOI 10.1136/jnnp.74.9.1200; Tesseur I, 2006, J CLIN INVEST, V116, P3060, DOI 10.1172/JCI27341; Uchihara T, 1997, STROKE, V28, P1948, DOI 10.1161/01.STR.28.10.1948; Van Eldik LJ, 2007, INT REV NEUROBIOL, V82, P277, DOI 10.1016/S0074-7742(07)82015-0; van Groen T, 2005, BRAIN RES REV, V48, P370, DOI 10.1016/j.brainresrev.2004.12.026; Vehmas AK, 2003, NEUROBIOL AGING, V24, P321, DOI 10.1016/S0197-4580(02)00090-8; Walker DG, 2005, J NEUROSCI RES, V81, P412, DOI 10.1002/jnr.20484; Weninger SC, 2001, NAT MED, V7, P527, DOI 10.1038/87839; Wilson JS, 2009, J GERONTOL A-BIOL, V64, P264, DOI 10.1093/gerona/gln002; Wyss-Coray T, 2006, NAT MED, V12, P1005, DOI 10.1038/nml1484; Yamamoto M, 2005, AM J PATHOL, V166, P1475, DOI 10.1016/S0002-9440(10)62364-4; Yamamoto M, 2007, AM J PATHOL, V170, P680, DOI 10.2353/ajpath.2007.060378; Yan SD, 2005, INT J EXP PATHOL, V86, P161, DOI 10.1111/j.0959-9673.2005.00427.x; Yan SD, 1996, NATURE, V382, P685, DOI 10.1038/382685a0; Yankner BA, 1996, NEURON, V16, P921, DOI 10.1016/S0896-6273(00)80115-4; Zhu XW, 2005, NEUROCHEM RES, V30, P791, DOI 10.1007/s11064-005-6872-x; Zhu XW, 2001, J NEUROCHEM, V79, P311, DOI 10.1046/j.1471-4159.2001.00597.x	81	222	244	1	29	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	APR	2010	24	4					1043	1055		10.1096/fj.09-139634	http://dx.doi.org/10.1096/fj.09-139634			13	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	580PV	19906677	Green Published			2022-12-25	WOS:000276462300012
J	Liu, DP; Song, H; Xu, Y				Liu, D. P.; Song, H.; Xu, Y.			A common gain of function of p53 cancer mutants in inducing genetic instability	ONCOGENE			English	Article						p53; tumorigenesis; gain of function; genetic instability	LI-FRAUMENI-SYNDROME; DNA-DAMAGE; COMPLEX; ATM; SUPPRESSOR; MUTATIONS; REVEALS; GENOME; SITES; MODEL	The critical tumor suppressor p53 is mutated in over half of all human cancers. The majority of p53 cancer mutations are missense mutations, which can be classified into contact mutations that directly disrupt the DNA-binding of p53 but have modest impact on p53 conformation and structural mutations that greatly disrupt p53 conformation. Many p53 cancer mutants, including the hot spot mutations (R175H, R248W and R273H), not only lose p53-dependent tumor-suppressor activities, but also acquire new oncogenic activities to promote cancer. Therefore, it is critical to elucidate the gain of oncogenic function of p53 cancer mutants. Using humanized p53-mutant knock-in mouse models, we have identified a gain of oncogenic function shared by the most common p53 contact mutants (R273H and R248W) and structural mutant (R175H). This gain of function inactivates Mre11/ATM-dependent DNA damage responses, leading to chromosomal translocation and defective G(2)/M checkpoint. Considering the critical roles of ATM in maintaining genetic stability and therapeutic responses to many cancer treatments, the identification of this common gain of function of p53 cancer mutants will have important implication on the drug resistance of a significant portion of human cancers that express either the contact or structural p53 cancer mutants. Oncogene (2010) 29, 949-956; doi:10.1038/onc.2009.376; published online 2 November 2009	[Liu, D. P.; Song, H.; Xu, Y.] Univ Calif San Diego, Div Biol Sci, Mol Biol Sect, La Jolla, CA 92093 USA	University of California System; University of California San Diego	Xu, Y (corresponding author), Univ Calif San Diego, Div Biol Sci, Mol Biol Sect, 9500 Gilman Dr, La Jolla, CA 92093 USA.	yangxu@ucsd.edu		Xu, Yang/0000-0001-5574-921X; Song, Hoseok/0000-0001-5723-3057	NIH [R01 CA94254]; DOD Breast Cancer Research Program [W81XWH-08-10381]; NATIONAL CANCER INSTITUTE [R01CA094254] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); DOD Breast Cancer Research Program(United States Department of Defense); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank Dr M Hollstein for the HUPKI construct. This work was supported by Grants from the NIH (R01 CA94254) and DOD Breast Cancer Research Program (W81XWH-08-10381) to YX.	Bakkenist CJ, 2003, NATURE, V421, P499, DOI 10.1038/nature01368; Bartkova J, 2005, NATURE, V434, P864, DOI 10.1038/nature03482; Bassing CH, 2003, CELL, V114, P359, DOI 10.1016/S0092-8674(03)00566-X; Carbone R, 2002, ONCOGENE, V21, P1633, DOI 10.1038/sj.onc.1205227; Chao C, 2006, EMBO J, V25, P2615, DOI 10.1038/sj.emboj.7601167; Di Agostino S, 2006, CANCER CELL, V10, P191, DOI 10.1016/j.ccr.2006.08.013; Gorgoulis VG, 2005, NATURE, V434, P907, DOI 10.1038/nature03485; Hainaut P, 2000, ADV CANCER RES, V77, P81; Kang J, 2002, EMBO J, V21, P1447, DOI 10.1093/emboj/21.6.1447; Ko LJ, 1996, GENE DEV, V10, P1054, DOI 10.1101/gad.10.9.1054; Lang GA, 2004, CELL, V119, P861, DOI 10.1016/j.cell.2004.11.006; Lavin MF, 2007, ONCOGENE, V26, P7749, DOI 10.1038/sj.onc.1210880; Li Y, 2007, ONCOGENE, V26, P2220, DOI 10.1038/sj.onc.1210311; Lista F, 1997, CANCER RES, V57, P4408; Luo JL, 2001, ONCOGENE, V20, P320, DOI 10.1038/sj.onc.1204080; Olive KP, 2004, CELL, V119, P847, DOI 10.1016/j.cell.2004.11.004; Sigal A, 2000, CANCER RES, V60, P6788; Song H, 2007, NAT CELL BIOL, V9, P573, DOI 10.1038/ncb1571; Wei CL, 2006, CELL, V124, P207, DOI 10.1016/j.cell.2005.10.043; Xu Y, 2006, NAT REV IMMUNOL, V6, P261, DOI 10.1038/nri1804	20	139	143	0	20	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 18	2010	29	7					949	956		10.1038/onc.2009.376	http://dx.doi.org/10.1038/onc.2009.376			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	556PV	19881536	Green Accepted, Bronze			2022-12-25	WOS:000274604400002
J	Khodarev, N; Ahmad, R; Rajabi, H; Pitroda, S; Kufe, T; McClary, C; Joshi, MD; MacDermed, D; Weichselbaum, R; Kufe, D				Khodarev, N.; Ahmad, R.; Rajabi, H.; Pitroda, S.; Kufe, T.; McClary, C.; Joshi, M. D.; MacDermed, D.; Weichselbaum, R.; Kufe, D.			Cooperativity of the MUC1 oncoprotein and STAT1 pathway in poor prognosis human breast cancer	ONCOGENE			English	Article						MUC1; STAT1; breast cancer; IFN gamma; auto-inductive loop; inflammation	CARCINOMA-ASSOCIATED ANTIGEN; BETA-CATENIN; TRANSCRIPTION FACTOR; C-SRC; APOPTOTIC RESPONSE; GENE-TRANSCRIPTION; DNA-DAMAGE; CELLS; ACTIVATION; EXPRESSION	Signal transducer and activator of transcription 1 (STAT1) is activated in the inflammatory response to interferons. The MUC1 oncoprotein is overexpressed in human breast cancers. Analysis of genes differentially expressed in MUC1-transformed cells has identified a network linking MUC1 and STAT1 that is associated with cellular growth and inflammation. The results further show that the MUC1-C subunit associates with STAT1 in cells and the MUC1-C cytoplasmic domain binds directly to the STAT1 DNA-binding domain. The interaction between MUC1-C and STAT1 is inducible by IFN gamma in non-malignant epithelial cells and constitutive in breast cancer cells. Moreover, the MUC1-STAT1 interaction contributes to the activation of STAT1 target genes, including MUC1 itself. Analysis of two independent databases showed that MUC1 and STAT1 are coexpressed in about 15% of primary human breast tumors. Coexpression of MUC1 and the STAT1 pathway was found to be significantly associated with decreased recurrence-free and overall survival. These findings indicate that (i) MUC1 and STAT1 function in an auto-inductive loop, and (ii) activation of both MUC1 and the STAT1 pathway in breast tumors confers a poor prognosis for patients. Oncogene (2010) 29, 920 -929; doi:10.1038/onc.2009.391; published online 16 November 2009	[Ahmad, R.; Rajabi, H.; Kufe, T.; McClary, C.; Joshi, M. D.; Kufe, D.] Harvard Univ, Sch Med, Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA; [Khodarev, N.; Pitroda, S.; MacDermed, D.; Weichselbaum, R.] Univ Chicago, Dept Radiat & Cellular Oncol, Chicago, IL 60637 USA	Harvard University; Dana-Farber Cancer Institute; Harvard Medical School; University of Chicago	Kufe, D (corresponding author), Harvard Univ, Sch Med, Dana Farber Canc Inst, Dept Med Oncol, 44 Binney St, Boston, MA 02115 USA.	donald_kufe@dfci.harvard.edu			National Cancer Institute [CA97098, CA111423]; NATIONAL CANCER INSTITUTE [R01CA097098, R01CA111423] Funding Source: NIH RePORTER	National Cancer Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This work was supported by Grants CA97098 and CA111423 awarded by the National Cancer Institute.	Ahmad R, 2007, NAT CELL BIOL, V9, P1419, DOI 10.1038/ncb1661; Ahmad R, 2009, CANCER RES, V69, P7013, DOI 10.1158/0008-5472.CAN-09-0523; Chanrion M, 2008, CLIN CANCER RES, V14, P1744, DOI 10.1158/1078-0432.CCR-07-1833; DARNELL JE, 1994, SCIENCE, V264, P1415, DOI 10.1126/science.8197455; DEBLANDRE GA, 1995, J BIOL CHEM, V270, P23860, DOI 10.1074/jbc.270.40.23860; Der SD, 1998, P NATL ACAD SCI USA, V95, P15623, DOI 10.1073/pnas.95.26.15623; Gaemers IC, 2001, J BIOL CHEM, V276, P6191, DOI 10.1074/jbc.M009449200; Huang L, 2005, CANCER RES, V65, P10413, DOI 10.1158/0008-5472.CAN-05-2474; Huang L, 2003, CANCER BIOL THER, V2, P702; Khodarev NN, 2007, CANCER RES, V67, P9214, DOI 10.1158/0008-5472.CAN-07-1019; Khodarev NN, 2009, CANCER RES, V69, P2833, DOI 10.1158/0008-5472.CAN-08-4513; Khodarev NN, 2003, GENOMICS, V81, P202, DOI 10.1016/S0888-7543(02)00042-3; Khodarev NN, 2004, P NATL ACAD SCI USA, V101, P1714, DOI 10.1073/pnas.0308102100; Kimchi ET, 2005, CANCER RES, V65, P3146, DOI 10.1158/0008-5472.CAN-04-2490; Kramer OH, 2009, GENE DEV, V23, P223, DOI 10.1101/gad.479209; Kramer OH, 2006, GENE DEV, V20, P473, DOI 10.1101/gad.364306; KUFE D, 1984, HYBRIDOMA, V3, P223, DOI 10.1089/hyb.1984.3.223; Lagow EL, 2002, J CELL BIOCHEM, V86, P759, DOI 10.1002/jcb.10261; Leng YM, 2007, J BIOL CHEM, V282, P19321, DOI 10.1074/jbc.M703222200; Levy DE, 2002, NAT REV MOL CELL BIO, V3, P651, DOI 10.1038/nrm909; Li YQ, 2003, ONCOGENE, V22, P6107, DOI 10.1038/sj.onc.1206732; Li YQ, 1998, MOL CELL BIOL, V18, P7216, DOI 10.1128/MCB.18.12.7216; Li YQ, 2001, J BIOL CHEM, V276, P35239, DOI 10.1074/jbc.C100359200; Li YQ, 2001, J BIOL CHEM, V276, P6061, DOI 10.1074/jbc.C000754200; LIGTENBERG MJL, 1992, J BIOL CHEM, V267, P6171; Loi S, 2007, J CLIN ONCOL, V25, P1239, DOI 10.1200/JCO.2006.07.1522; Macao B, 2006, NAT STRUCT MOL BIOL, V13, P71, DOI 10.1038/nsmb1035; McBride KM, 2000, EMBO J, V19, P6196, DOI 10.1093/emboj/19.22.6196; Meyer T, 2003, GENE DEV, V17, P1992, DOI 10.1101/gad.268003; Pitroda SP, 2009, P NATL ACAD SCI USA, V106, P5837, DOI 10.1073/pnas.0812029106; Raina D, 2006, EMBO J, V25, P3774, DOI 10.1038/sj.emboj.7601263; Raina D, 2009, CANCER RES, V69, P5133, DOI 10.1158/0008-5472.CAN-09-0854; Ramasamy S, 2007, MOL CELL, V27, P992, DOI 10.1016/j.molcel.2007.07.031; Ren J, 2004, CANCER CELL, V5, P163, DOI 10.1016/S1535-6108(04)00020-0; Ren J, 2006, ONCOGENE, V25, P20, DOI 10.1038/sj.onc.1209012; Ren J, 2002, J BIOL CHEM, V277, P17616, DOI 10.1074/jbc.M200436200; Schindler C, 2007, J BIOL CHEM, V282, P20059, DOI 10.1074/jbc.R700016200; Shuai K, 2000, ONCOGENE, V19, P2638, DOI 10.1038/sj.onc.1203522; Tusher VG, 2001, P NATL ACAD SCI USA, V98, P10515; Wei XL, 2007, CANCER RES, V67, P1853, DOI 10.1158/0008-5472.CAN-06-3063; Wei XL, 2005, CANCER CELL, V7, P167, DOI 10.1016/j.ccr.2005.01.008; Wei XL, 2006, MOL CELL, V21, P295, DOI 10.1016/j.molcel.2005.11.030; Weichselbaum RR, 2008, P NATL ACAD SCI USA, V105, P18490, DOI 10.1073/pnas.0809242105; Yin L, 2003, J BIOL CHEM, V278, P35458, DOI 10.1074/jbc.M301987200; Yin L, 2007, J BIOL CHEM, V282, P257, DOI 10.1074/jbc.M610156200; Yu H, 2004, NAT REV CANCER, V4, P97, DOI 10.1038/nrc1275	46	71	81	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 11	2010	29	6					920	929		10.1038/onc.2009.391	http://dx.doi.org/10.1038/onc.2009.391			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	553WP	19915608	Green Accepted			2022-12-25	WOS:000274397800014
J	Bocanegra, M; Bergamaschi, A; Kim, YH; Miller, MA; Rajput, AB; Kao, J; Langerod, A; Han, W; Noh, DY; Jeffrey, SS; Huntsman, DG; Borresen-Dale, AL; Pollack, JR				Bocanegra, M.; Bergamaschi, A.; Kim, Y. H.; Miller, M. A.; Rajput, A. B.; Kao, J.; Langerod, A.; Han, W.; Noh, D-Y; Jeffrey, S. S.; Huntsman, D. G.; Borresen-Dale, A-L; Pollack, J. R.			Focal amplification and oncogene dependency of GAB2 in breast cancer	ONCOGENE			English	Article						GAB2; DNA amplification; genomic profiling; array-based comparative genomic hybridization; breast cancer; oncogene dependency	DOCKING PROTEIN; TRANSFORMATION; PATTERNS	DNA amplifications in breast cancer are frequent on chromosome 11q, in which multiple driver oncogenes likely reside in addition to cyclin D1 (CCND1). One such candidate, the scaffolding adapter protein, GRB2-associated binding protein 2 (GAB2), functions in ErbB signaling and was recently shown to enhance mammary epithelial cell proliferation, and metastasis of ERBB2 (HER2/neu)-driven murine breast cancer. However, the amplification status and function of GAB2 in the context of amplification remain undefined. In this study, by genomic profiling of 172 breast tumors, and fluorescence in situ hybridization validation in an independent set of 210 scorable cases, we observed focal amplification spanning GAB2 (11q14.1) independent of CCND1 (11q13.2) amplification, consistent with a driver role. Further, small interfering RNA (siRNA)-mediated knockdown of GAB2 in breast cancer lines (SUM52, SUM44PE and MDA468) with GAB2 amplification revealed a dependency on GAB2 for cell proliferation, cell-cycle progression, survival and invasion, likely mediated through altered phosphatidylinositol 3-kinase (PI3K) and mitogen-activated protein kinase (MAPK) signaling. GAB2 knockdown also reduced proliferation and survival in a cell line (BT474) with ERBB2 amplification, consistent with the possibility that GAB2 can function downstream of ERBB2. Our studies implicate focal amplification of GAB2 in breast carcinogenesis, and underscore an oncogenic role of scaffolding adapter proteins, and a potential new point of therapeutic intervention. Oncogene (2010) 29, 774-779; doi: 10.1038/onc.2009.364; published online 2 November 2009	[Pollack, J. R.] Stanford Univ, Dept Pathol, Sch Med, Stanford, CA 94305 USA; [Bergamaschi, A.; Langerod, A.; Borresen-Dale, A-L] Oslo Univ Hosp, Norwegian Radium Hosp, Inst Canc Res, Dept Genet, Oslo, Norway; [Miller, M. A.; Rajput, A. B.; Huntsman, D. G.] Univ British Columbia, Dept Pathol, Vancouver, BC, Canada; [Miller, M. A.; Rajput, A. B.; Huntsman, D. G.] British Columbia Canc Agcy, Vancouver, BC V5Z 4E6, Canada; [Han, W.; Noh, D-Y] Seoul Natl Univ, Coll Med, Canc Res Inst, Seoul, South Korea; [Han, W.; Noh, D-Y] Seoul Natl Univ, Coll Med, Dept Surg, Seoul, South Korea; [Jeffrey, S. S.] Stanford Univ, Dept Surg, Stanford, CA 94305 USA; [Borresen-Dale, A-L] Univ Oslo, Fac Div, Norwegian Radium Hosp, Fac Med, Oslo, Norway	Stanford University; University of Oslo; University of British Columbia; British Columbia Cancer Agency; Seoul National University (SNU); Seoul National University (SNU); Stanford University; University of Oslo	Pollack, JR (corresponding author), Stanford Univ, Dept Pathol, Sch Med, CCSR-3245A,269 Campus Dr, Stanford, CA 94305 USA.	pollack1@stanford.edu	Huntsman, David/ABE-6082-2020; Han, Wonshik/B-3699-2008; Noh, Dong-Young/G-5531-2011; Bergamaschi, Anna/D-2022-2009	Han, Wonshik/0000-0001-7310-0764; Bergamaschi, Anna/0000-0001-8709-1766; Jeffrey, Stefanie/0000-0003-4478-2764	National Institutes of Health [CA97139, CA09302, CA130172]; Department of Defense Breast Cancer Research Program [BC073467]; California Breast Cancer Research Program [8KB-0135, 11IB-0175]; Norwegian Research Council, NFR [155218/300]; Korea Health 21 R&D Project, Ministry of Health Welfare ROK [01-PJ3-PG601GN07-0004]; Sanofi-aventis, Canada; NATIONAL CANCER INSTITUTE [F31CA130172, R01CA097139, T32CA009302] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Department of Defense Breast Cancer Research Program(United States Department of Defense); California Breast Cancer Research Program; Norwegian Research Council, NFR(Research Council of Norway); Korea Health 21 R&D Project, Ministry of Health Welfare ROK; Sanofi-aventis, Canada; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank the Stanford Functional Genomics Facility for microarray manufacture, the Stanford Microarray Database for database support and members of the Pollack lab for helpful discussion. This work was supported in part by grants from the National Institutes of Health, CA97139 (JRP), CA09302 and CA130172 (MB); the Department of Defense Breast Cancer Research Program, BC073467 (MB); the California Breast Cancer Research Program, 8KB-0135 (JRP) and 11IB-0175 (SSJ); the Norwegian Research Council, NFR, 155218/300 (ALBD); and the Korea Health 21 R&D Project, Ministry of Health & Welfare ROK, 01-PJ3-PG601GN07-0004 (WH and D-YN). AB was during this work a fellow of The Norwegian Cancer Society. DGH is a Michael Smith Foundation for Health Research Scholar. Funding for the thermomechanical analysis was provided in part by an unrestricted educational grant from Sanofi-aventis, Canada.	Bentires-Alj M, 2006, NAT MED, V12, P114, DOI 10.1038/nm1341; Bergamaschi A, 2008, MOL ONCOL, V2, P327, DOI 10.1016/j.molonc.2008.09.004; Brummer T, 2006, J BIOL CHEM, V281, P626, DOI 10.1074/jbc.M509567200; Chin K, 2006, CANCER CELL, V10, P529, DOI 10.1016/j.ccr.2006.10.009; Daly RJ, 2002, ONCOGENE, V21, P5175, DOI 10.1038/sj.onc.1205522; Gu HH, 2003, TRENDS CELL BIOL, V13, P122, DOI 10.1016/S0962-8924(03)00002-3; Hughes-Davies L, 2003, CELL, V115, P523, DOI 10.1016/S0092-8674(03)00930-9; Ischenko I, 2003, ONCOGENE, V22, P6311, DOI 10.1038/sj.onc.1206742; Jemal A, 2007, BREAST CANCER RES, V9, DOI 10.1186/bcr1672; Kao J, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0006146; KARLSEDER J, 1994, GENE CHROMOSOME CANC, V9, P42, DOI 10.1002/gcc.2870090108; Ke Y, 2007, ONCOGENE, V26, P4951, DOI 10.1038/sj.onc.1210315; Ormandy CJ, 2003, BREAST CANCER RES TR, V78, P323, DOI 10.1023/A:1023033708204; Pegram M D, 2000, Cancer Treat Res, V103, P57; Pollack JR, 2002, P NATL ACAD SCI USA, V99, P12963, DOI 10.1073/pnas.162471999; Sarmay G, 2006, IMMUNOL LETT, V104, P76, DOI 10.1016/j.imlet.2005.11.017; Sattler M, 2002, CANCER CELL, V1, P479, DOI 10.1016/S1535-6108(02)00074-0; Sorlie T, 2001, P NATL ACAD SCI USA, V98, P10869, DOI 10.1073/pnas.191367098; Tibshirani R, 2008, BIOSTATISTICS, V9, P18, DOI 10.1093/biostatistics/kxm013	19	55	61	1	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 4	2010	29	5					774	779		10.1038/onc.2009.364	http://dx.doi.org/10.1038/onc.2009.364			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	551QI	19881546				2022-12-25	WOS:000274223700013
J	Liu, X; Wang, X; Zhang, J; Lam, EKY; Shin, VY; Cheng, ASL; Yu, J; Chan, FKL; Sung, JJY; Jin, HC				Liu, X.; Wang, X.; Zhang, J.; Lam, E. K. Y.; Shin, V. Y.; Cheng, A. S. L.; Yu, J.; Chan, F. K. L.; Sung, J. J. Y.; Jin, H. C.			Warburg effect revisited: an epigenetic link between glycolysis and gastric carcinogenesis	ONCOGENE			English	Article						methylation; gastric cancer; glucose metabolism; ras	NF-KAPPA-B; PYRUVATE-KINASE; GLUCOSE-METABOLISM; II HEXOKINASE; CANCER; RAS; P53; TRANSFORMATION; TRANSCRIPTION; REPRESSION	In cancer cells, glucose is often converted into lactic acid, which is known as the 'Warburg effect'. The reason that cancer cells have a higher rate of aerobic glycolysis, but not oxidative phosphorylation, remains largely unclear. Herein, we proposed an epigenetic mechanism of the Warburg effect. Fructose-1,6-bisphosphatase-1 (FBP1), which functions to antagonize glycolysis was downregulated through NF-kappaB pathway in Ras-transformed NIH3T3 cells. Restoration of FBP1 expression suppressed anchorage-independent growth, indicating the relevance of FBP1 downregulation in carcinogenesis. Indeed, FBP1 was downregulated in gastric carcinomas (P < 0.01, n = 22) and gastric cancer cell lines (57%, 4/7). Restoration of FBP1 expression reduced growth and glycolysis in gastric cancer cells. Moreover, FBP1 downregulation was reversed by pharmacological demethylation. Its promoter was hypermethylated in gastric cancer cell lines (57%, 4/7) and gastric carcinomas (33%, 33/101). Inhibition of NF-kappaB restored FBP1 expression, partially through demethylation of FBP1 promoter. Notably, Cox regression analysis revealed FBP1 promoter methylation as an independent prognosis predicator for gastric cancer (hazard ratio: 3.60, P = 0.010). In summary, we found that NF-kappaB functions downstream of Ras to promote epigenetic downregulation of FBP1. Promoter methylation of FBP1 can be used as a new biomarker for prognosis prediction of gastric cancer. Such an important epigenetic link between glycolysis and carcinogenesis partly explains the Warburg effect. Oncogene (2010) 29, 442-450; doi:10.1038/onc.2009.332; published online 2 November 2009	[Jin, H. C.] Zhejiang Univ, Sch Med, Biomed Res Ctr, Sir Runrun Shaw Hosp,Dept Med Oncol, Hangzhou 310003, Zhejiang, Peoples R China; [Liu, X.; Zhang, J.; Lam, E. K. Y.; Shin, V. Y.; Cheng, A. S. L.; Jin, H. C.] Chinese Univ Hong Kong, Inst Digest Dis, Hong Kong, Hong Kong, Peoples R China; [Yu, J.; Chan, F. K. L.; Sung, J. J. Y.] Chinese Univ Hong Kong, Prince Wales Hosp, Dept Med & Therapeut, Hong Kong, Hong Kong, Peoples R China; Zhejiang Univ, Sch Med, Hangzhou 310003, Zhejiang, Peoples R China	Zhejiang University; Chinese University of Hong Kong; Chinese University of Hong Kong; Prince of Wales Hospital; Zhejiang University	Jin, HC (corresponding author), Zhejiang Univ, Sch Med, Biomed Res Ctr, Sir Runrun Shaw Hosp,Dept Med Oncol, Hangzhou 310003, Zhejiang, Peoples R China.	jinhc@srrsh.com	Cheng, Alfred SL/C-3327-2014; Yu, Jun/D-8569-2015; Sung, Joseph J. Y./R-3203-2018; Jin, Hongchuan/C-3686-2009; Chan, Francis K. L./F-4851-2010	Cheng, Alfred SL/0000-0003-2345-6951; Yu, Jun/0000-0001-5008-2153; Sung, Joseph J. Y./0000-0003-3125-5199; Chan, Francis K. L./0000-0001-7388-2436; Shin, Vivian Yvonne/0000-0003-1282-7593; Jin, Hongchuan/0000-0002-6697-3097; Wang, Xian/0000-0003-0041-7589	RGC-GRF [465808]; Institute of Digestive Disease, the Chinese University of Hong Kong	RGC-GRF(Hong Kong Research Grants Council); Institute of Digestive Disease, the Chinese University of Hong Kong(Chinese University of Hong Kong)	The project was supported by RGC-GRF ( Project No. 465808) granted to HJ, and Research Funding from the Institute of Digestive Disease, the Chinese University of Hong Kong.	Aarenstrup L, 2008, J INVEST DERMATOL, V128, P1095, DOI 10.1038/sj.jid.5701146; Ashburner BP, 2001, MOL CELL BIOL, V21, P7065, DOI 10.1128/MCB.21.20.7065-7077.2001; Bensaad K, 2006, CELL, V126, P107, DOI 10.1016/j.cell.2006.05.036; Bhat KP, 2008, FEBS LETT, V582, P3193, DOI 10.1016/j.febslet.2008.08.010; Cheng YY, 2008, BRIT J CANCER, V99, P2083, DOI 10.1038/sj.bjc.6604760; Christofk HR, 2008, NATURE, V452, P230, DOI 10.1038/nature06734; Dang CV, 1999, TRENDS BIOCHEM SCI, V24, P68, DOI 10.1016/S0968-0004(98)01344-9; DeBerardinis RJ, 2008, CURR OPIN GENET DEV, V18, P54, DOI 10.1016/j.gde.2008.02.003; DeBerardinis RJ, 2008, CELL METAB, V7, P11, DOI 10.1016/j.cmet.2007.10.002; DeBerardinis RJ, 2008, GENET MED, V10, P267, DOI 10.1097/GIM.0b013e31818b0d9b; Eigenbrodt E., 1992, Critical Reviews in Oncogenesis, V3, P91; Ferguson EC, 2008, TRENDS BIOCHEM SCI, V33, P359, DOI 10.1016/j.tibs.2008.05.006; Finco TS, 1997, J BIOL CHEM, V272, P24113, DOI 10.1074/jbc.272.39.24113; Fuks F, 2000, NAT GENET, V24, P88, DOI 10.1038/71750; Garber K, 2004, J NATL CANCER I, V96, P1805, DOI 10.1093/jnci/96.24.1805; Gatenby RA, 2004, NAT REV CANCER, V4, P891, DOI 10.1038/nrc1478; Green DR, 2006, CELL, V126, P30, DOI 10.1016/j.cell.2006.06.032; Jin HC, 2006, NATURE, V442, P576, DOI 10.1038/nature04856; Jurica MS, 1998, STRUCTURE, V6, P195, DOI 10.1016/S0969-2126(98)00021-5; Karnoub AE, 2008, NAT REV MOL CELL BIO, V9, P517, DOI 10.1038/nrm2438; Kawauchi K, 2008, NAT CELL BIOL, V10, P611, DOI 10.1038/ncb1724; Kondoh H, 2005, CANCER RES, V65, P177; KOSHIBA M, 1993, JPN J CANCER RES, V84, P163, DOI 10.1111/j.1349-7006.1993.tb02850.x; Lee MG, 2003, J BIOL CHEM, V278, P41047, DOI 10.1074/jbc.M307031200; Marin-Hernandez A, 2006, FEBS J, V273, P1975, DOI 10.1111/j.1742-4658.2006.05214.x; Mathupala SP, 2009, SEMIN CANCER BIOL, V19, P17, DOI 10.1016/j.semcancer.2008.11.006; Mazurek S, 2001, ONCOGENE, V20, P6891, DOI 10.1038/sj.onc.1204792; Peng SY, 2008, ONCOL REP, V19, P1045; Robertson KD, 2000, NAT GENET, V25, P338, DOI 10.1038/77124; Rountree MR, 2000, NAT GENET, V25, P269, DOI 10.1038/77023; Schwartzenberg-Bar-Yoseph F, 2004, CANCER RES, V64, P2627, DOI 10.1158/0008-5472.CAN-03-0846; TANNOCK IF, 1968, BRIT J CANCER, V22, P258, DOI 10.1038/bjc.1968.34; VanAntwerp DJ, 1996, SCIENCE, V274, P787, DOI 10.1126/science.274.5288.787; VAUPEL P, 1989, CANCER RES, V49, P6449; Wang LJ, 2009, BIOCHEM BIOPH RES CO, V379, P959, DOI 10.1016/j.bbrc.2008.12.180; WARBURG O, 1956, SCIENCE, V123, P309, DOI 10.1126/science.123.3191.309	36	150	162	1	25	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 21	2010	29	3					442	450		10.1038/onc.2009.332	http://dx.doi.org/10.1038/onc.2009.332			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	546EO	19881551				2022-12-25	WOS:000273793200013
J	Lim, ST; Miller, NLG; Nam, JO; Chen, XL; Lim, Y; Schlaepfer, DD				Lim, Ssang-Taek; Miller, Nichol L. G.; Nam, Ju-Ock; Chen, Xiao Lei; Lim, Yangmi; Schlaepfer, David D.			Pyk2 Inhibition of p53 as an Adaptive and Intrinsic Mechanism Facilitating Cell Proliferation and Survival	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FOCAL ADHESION KINASE; JUN NH2-TERMINAL KINASE; OVARIAN-CANCER; NUCLEAR TRANSLOCATION; FERM DOMAIN; FAK; ACTIVATION; PROGRESSION; MIGRATION; PROTEIN	Pyk2 is a cytoplasmic tyrosine kinase related to focal adhesion kinase (FAK). Compensatory Pyk2 expression occurs upon FAK loss in mice. However, the impact of Pyk2 up-regulation remains unclear. Previous studies showed that nuclear-localized FAK promotes cell proliferation and survival through FAK FERM domain-enhanced p53 tumor suppressor degradation (Lim, S. T., Chen, X. L., Lim, Y., Hanson, D. A., Vo, T. T., Howerton, K., Larocque, N., Fisher, S. J., Schlaepfer, D. D., and Ilic, D. (2008) Mol. Cell 29, 9-22). Here, we show that FAK knockdown triggered p53 activation and G(1) cell cycle arrest in human umbilical vein endothelial cells after 4 days. However, by 7 days elevated Pyk2 expression occurred with a reduction in p53 levels and the release of the G1 block under conditions of continued FAK knockdown. To determine whether Pyk2 regulates p53, experiments were performed in FAK(-/-)p21(-/-) mouse embryo fibroblasts expressing endogenous Pyk2 and in ID8 ovarian carcinoma cells expressing both Pyk2 and FAK. In both cell lines, Pyk2 knockdown increased p53 levels and inhibited cell proliferation associated with G1 cell cycle arrest. Pyk2 FERM domain re-expression was sufficient to reduce p53 levels and promote increased BrdUrd incorporation. Pyk2 FERM promoted Mdm2-dependent p53 ubiquitination. Pyk2 FERM effects on p53 were blocked by proteasomal inhibition or mutational-inactivation of Pyk2 FERM nuclear localization. Staurosporine stress of ID8 cells promoted endogenous Pyk2 nuclear accumulation and enhanced Pyk2 binding to p53. Pyk2 knockdown potentiated ID8 cell death upon staurosporine addition. Moreover, Pyk2 FERM expression in human fibroblasts upon FAK knockdown prevented cisplatin-mediated apoptosis. Our studies demonstrate that nuclear Pyk2 functions to limit p53 levels, thus facilitating cell growth and survival in a kinase-independent manner.	[Lim, Ssang-Taek; Miller, Nichol L. G.; Nam, Ju-Ock; Chen, Xiao Lei; Lim, Yangmi; Schlaepfer, David D.] Univ Calif San Diego, Moores Canc Ctr, Dept Reprod Med, La Jolla, CA 92093 USA	University of California System; University of California San Diego	Schlaepfer, DD (corresponding author), Univ Calif San Diego, Moores Canc Ctr, Dept Reprod Med, 0803,3855 Hlth Sci Dr, La Jolla, CA 92093 USA.	dschlaepfer@ucsd.edu		Lim, Steve/0000-0003-0323-8607	National Institutes of Health [HL093156, CA102310]; NATIONAL CANCER INSTITUTE [R01CA102310] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL093156] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))	This work was supported, in whole or in part, by National Institutes of Health Grants HL093156 and CA102310 (to D. S.).	Alfonso-De Matte MY, 2004, CANCER RES, V64, P23, DOI 10.1158/0008-5472.CAN-03-2820; Aoto H, 2002, CELL STRUCT FUNCT, V27, P47, DOI 10.1247/csf.27.47; Avraham H, 2000, CELL SIGNAL, V12, P123, DOI 10.1016/S0898-6568(99)00076-5; Behmoaram E, 2008, AM J PATHOL, V173, P1540, DOI 10.2353/ajpath.2008.080292; Cohen LA, 2005, J BIOL CHEM, V280, P8197, DOI 10.1074/jbc.M412021200; Corsi JM, 2006, BMC GENOMICS, V7, DOI 10.1186/1471-2164-7-198; Corsi JM, 2009, J BIOL CHEM, V284, P34769, DOI 10.1074/jbc.M109.067280; Essayem S, 2006, ONCOGENE, V25, P1081, DOI 10.1038/sj.onc.1209130; Faure C, 2007, J CELL SCI, V120, P3034, DOI 10.1242/jcs.009613; Gilmore AP, 2009, CURR OPIN CELL BIOL, V21, P654, DOI 10.1016/j.ceb.2009.05.009; Golubovskaya VM, 2005, J BIOL CHEM, V280, P25008, DOI 10.1074/jbc.M414172200; Iiizumi M, 2008, CANCER RES, V68, P7613, DOI 10.1158/0008-5472.CAN-07-6700; Ilic D, 2003, CIRC RES, V92, P300, DOI 10.1161/01.RES.0000055016.36679.23; Ilic Dusko, 1995, Nature (London), V377, P539, DOI 10.1038/377539a0; Iwakuma T, 2003, MOL CANCER RES, V1, P993; Klingbeil CK, 2001, J CELL BIOL, V152, P97, DOI 10.1083/jcb.152.1.97; Kohno T, 2008, BIOCHEM J, V410, P513, DOI 10.1042/BJ20070665; Landen CN, 2008, J CLIN ONCOL, V26, P995, DOI 10.1200/JCO.2006.07.9970; Lietha D, 2007, CELL, V129, P1177, DOI 10.1016/j.cell.2007.05.041; Lim ST, 2008, CELL CYCLE, V7, P2306, DOI 10.4161/cc.6367; Lim ST, 2008, MOL CELL, V29, P9, DOI 10.1016/j.molcel.2007.11.031; Lim Y, 2008, J CELL BIOL, V180, P187, DOI 10.1083/jcb.200708194; Lipinski CA, 2008, J NEURO-ONCOL, V90, P181, DOI 10.1007/s11060-008-9656-8; Lipinski CA, 2006, BIOCHEM BIOPH RES CO, V349, P939, DOI 10.1016/j.bbrc.2006.08.134; Loftus JC, 2009, MOL CANCER THER, V8, P1505, DOI 10.1158/1535-7163.MCT-08-1055; McLean GW, 2004, GENE DEV, V18, P2998, DOI 10.1101/gad.316304; Menashi EB, 2009, CELL TISSUE RES, V337, P243, DOI 10.1007/s00441-009-0807-9; Mettouchi A, 2001, MOL CELL, V8, P115, DOI 10.1016/S1097-2765(01)00285-4; Mitra SK, 2006, ONCOGENE, V25, P4429, DOI 10.1038/sj.onc.1209482; Mitra SK, 2005, NAT REV MOL CELL BIO, V6, P56, DOI 10.1038/nrm1549; Oktay M, 1999, J CELL BIOL, V145, P1461, DOI 10.1083/jcb.145.7.1461; Oren M, 2003, CELL DEATH DIFFER, V10, P431, DOI 10.1038/sj.cdd.4401183; Ossovskaya V, 2008, FEBS LETT, V582, P2402, DOI 10.1016/j.febslet.2008.06.004; Ostergaard HL, 2005, IMMUNOL RES, V31, P267, DOI 10.1385/IR:31:3:267; Parsons JT, 2003, J CELL SCI, V116, P1409, DOI 10.1242/jcs.00373; Roby KF, 2000, CARCINOGENESIS, V21, P585, DOI 10.1093/carcin/21.4.585; Schlaepfer DD, 2007, J BIOL CHEM, V282, P17450, DOI 10.1074/jbc.M610672200; Schober M, 2007, J CELL BIOL, V176, P667, DOI 10.1083/jcb.200608010; Shen TL, 2005, J CELL BIOL, V169, P941, DOI 10.1083/jcb.200411155; Sieg DJ, 1998, EMBO J, V17, P5933, DOI 10.1093/emboj/17.20.5933; Sood AK, 2004, AM J PATHOL, V165, P1087, DOI 10.1016/S0002-9440(10)63370-6; Sun CK, 2008, CARCINOGENESIS, V29, P2096, DOI 10.1093/carcin/bgn203; Vogelstein B, 2000, NATURE, V408, P307, DOI 10.1038/35042675; Vousden KH, 2002, BBA-REV CANCER, V1602, P47, DOI 10.1016/S0304-419X(02)00035-5; Weis SM, 2008, J CELL BIOL, V181, P43, DOI 10.1083/jcb.200710038; Zhao J, 2001, MOL BIOL CELL, V12, P4066, DOI 10.1091/mbc.12.12.4066	46	53	59	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 15	2010	285	3					1743	1753		10.1074/jbc.M109.064212	http://dx.doi.org/10.1074/jbc.M109.064212			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	541PJ	19880522	Green Published, hybrid			2022-12-25	WOS:000273429100020
J	Roan, NR; Sowinski, S; Munch, J; Kirchhoff, F; Greene, WC				Roan, Nadia R.; Sowinski, Stefanie; Muench, Jan; Kirchhoff, Frank; Greene, Warner C.			Aminoquinoline Surfen Inhibits the Action of SEVI (Semen-derived Enhancer of Viral Infection)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IMMUNODEFICIENCY-VIRUS TYPE-1; ACID-PHOSPHATASE; HIV-INFECTION; PREVENTION; SULFATE; FIBRILS; BINDING; FUSION	In semen, proteolytic peptide fragments from prostatic acid phosphatase can form amyloid fibrils termed SEVI (semen-derived enhancer of viral infection). These fibrils greatly enhance human immunodeficiency virus (HIV) infectivity by increasing the attachment of virions to target cells. Therefore, SEVI may have a significant impact on whether HIV is successfully transmitted during sexual contact. Here, we demonstrate that surfen, a small molecule heparan sulfate proteoglycan antagonist, inhibits both SEVI- and semen-mediated enhancement of HIV type 1 infection. Surfen interferes with the binding of SEVI to both target cells and HIV type 1 virions but does not deaggregate SEVI fibrils. Because SEVI can increase HIV infectivity by several orders of magnitude, supplementing current HIV microbicide candidates with SEVI inhibitors, such as surfen, might greatly increase their potency.	[Greene, Warner C.] Univ Calif San Francisco, Dept Microbiol & Immunol, San Francisco, CA 94158 USA; [Muench, Jan; Kirchhoff, Frank] Univ Clin Ulm, Inst Virol, D-89081 Ulm, Germany; Univ Calif San Francisco, Gladstone Inst Virol & Immunol, San Francisco, CA 94158 USA; [Greene, Warner C.] Univ Calif San Francisco, Dept Med, San Francisco, CA 94158 USA	University of California System; University of California San Francisco; Ulm University; University of California System; University of California San Francisco; The J David Gladstone Institutes; University of California System; University of California San Francisco		wgreene@gladstone.ucsf.edu		Jan, Munch/0000-0001-7316-7141	National Institutes of Health [P01 A1083050-01, 1R01AI067057-01A2, P30 AI027763]; NICHD [P01 HD40543]; Giannini Foundation; Deutsche Forschungsgemeinschaft; WHIN PPG; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [P01HD040543] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [P30AI027763, R01AI067057, P01AI083050] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NICHD(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); Giannini Foundation; Deutsche Forschungsgemeinschaft(German Research Foundation (DFG)); WHIN PPG; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	This work was supported, in whole or in part, by National Institutes of Health Grants P01 A1083050-01 (to W. C. G.), 1R01AI067057-01A2 (to F. K.), P30 AI027763 (to University of California San Francisco-GIVI CFAR), and P01 HD40543 WHIN PPG (to W. C. G.) from NICHD. This work was also supported by The Giannini Foundation fellowship (to N. R. R.), the Deutsche Forschungsgemeinschaft (to F. K.), and the WHIN PPG grant (to W. C. G.).	CALLAHAN LN, 1991, J VIROL, V65, P1543, DOI 10.1128/JVI.65.3.1543-1550.1991; Cavrois M, 2002, NAT BIOTECHNOL, V20, P1151, DOI 10.1038/nbt745; Cohen J, 2009, SCIENCE, V323, P996, DOI 10.1126/science.323.5917.996; ESKO JD, 1985, P NATL ACAD SCI USA, V82, P3197, DOI 10.1073/pnas.82.10.3197; Hong SH, 2009, J VIROL, V83, P6995, DOI 10.1128/JVI.00268-09; LANZA TJ, 1992, J MED CHEM, V35, P252, DOI 10.1021/jm00080a008; Munch J, 2007, CELL, V131, P1059, DOI 10.1016/j.cell.2007.10.014; Panchal RG, 2004, NAT STRUCT MOL BIOL, V11, P67, DOI 10.1038/nsmb711; Platt EJ, 1998, J VIROL, V72, P2855, DOI 10.1128/JVI.72.4.2855-2864.1998; Rider CC, 1997, GLYCOCONJUGATE J, V14, P639, DOI 10.1023/A:1018596728605; Roan NR, 2009, J VIROL, V83, P73, DOI 10.1128/JVI.01366-08; RONNBERG L, 1981, INT J ANDROL, V4, P372, DOI 10.1111/j.1365-2605.1981.tb00721.x; Schuksz M, 2008, P NATL ACAD SCI USA, V105, P13075, DOI 10.1073/pnas.0805862105; Skoler-Karpoff S, 2008, LANCET, V372, P1977, DOI 10.1016/S0140-6736(08)61842-5; TOYOSHIMA K, 1969, VIROLOGY, V38, P414, DOI 10.1016/0042-6822(69)90154-8; UMBER F., 1938, Klinische Wochenschrift, V17, P443, DOI 10.1007/BF01775866; Van Damme L, 2008, NEW ENGL J MED, V359, P463, DOI 10.1056/NEJMoa0707957; Wei XP, 2002, ANTIMICROB AGENTS CH, V46, P1896, DOI 10.1128/AAC.46.6.1896-1905.2002; Witvrouw M, 1997, GEN PHARMACOL-VASC S, V29, P497, DOI 10.1016/S0306-3623(96)00563-0; Zhang YJ, 2002, J VIROL, V76, P6332, DOI 10.1128/JVI.76.12.6332-6343.2002	20	60	64	1	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 15	2010	285	3					1861	1869		10.1074/jbc.M109.066167	http://dx.doi.org/10.1074/jbc.M109.066167			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	541PJ	19897482	Green Published, hybrid			2022-12-25	WOS:000273429100032
J	da Costa, KA; Rai, KS; Craciunescu, CN; Parikh, K; Mehedint, MG; Sanders, LM; McLean-Pottinger, A; Zeisel, SH				da Costa, Kerry-Ann; Rai, Kiranmai S.; Craciunescu, Corneliu N.; Parikh, Komal; Mehedint, Mihai G.; Sanders, Lisa M.; McLean-Pottinger, Audrey; Zeisel, Steven H.			Dietary Docosahexaenoic Acid Supplementation Modulates Hippocampal Development in the Pemt(-/-) Mouse	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PERINATAL CHOLINE SUPPLEMENTATION; EMBRYONIC-DEVELOPMENT ALTERS; POLYUNSATURATED FATTY-ACIDS; PROGENITOR-CELL MITOSIS; N-METHYLTRANSFERASE; GENE-EXPRESSION; PEMT GENE; AVAILABILITY ALTERS; IN-VITRO; BRAIN	The development of fetal brain is influenced by nutrients such as docosahexaenoic acid (DHA, 22: 6) and choline. Phosphatidylethanolamine-N-methyltransferase (PEMT) catalyzes the biosynthesis of phosphatidylcholine from phosphatidylethanolamine enriched in DHA and many humans have functional genetic polymorphisms in the PEMT gene. Previously, it was reported that Pemt(-/-) mice have altered hippocampal development. The present study explores whether abnormal phosphatidylcholine biosynthesis causes altered incorporation of DHA into membranes, thereby influencing brain development, and determines whether supplemental dietary DHA can reverse some of these changes. Pregnant C57BL/6 wild type (WT) and Pemt(-/-) mice were fed a control diet, or a diet supplemented with 3 g/kg of DHA, from gestational day 11 to 17. Brains from embryonic day 17 fetuses derived from Pemt(-/-) dams fed the control diet had 25-50% less phospholipid-DHA as compared with WT (p < 0.05). Also, they had 60% more neural progenitor cell proliferation (p < 0.05), 60% more neuronal apoptosis (p < 0.01), and 30% less calretinin expression (p < 0.05; a marker of neuronal differentiation) in the hippocampus compared with WT. The DHA-supplemented diet increased fetal brain Pemt(-/-) phospholipid-DHA to WT levels, and abrogated the neural progenitor cell proliferation and apoptosis differences. Although this diet did not change proliferation in the WT group, it halved the rate of apoptosis (p < 0.05). In both genotypes, the DHA-supplemented diet increased calretinin expression 2-fold (p < 0.05). These results suggest that the changes in hippocampal development in the Pemt(-/-) mouse could be mediated by altered DHA incorporation into membrane phospholipids, and that maternal dietary DHA can influence fetal brain development.	[da Costa, Kerry-Ann; Rai, Kiranmai S.; Craciunescu, Corneliu N.; Parikh, Komal; McLean-Pottinger, Audrey; Zeisel, Steven H.] Univ N Carolina, Dept Nutr, Sch Publ Hlth, Chapel Hill, NC 27599 USA; [da Costa, Kerry-Ann; Rai, Kiranmai S.; Craciunescu, Corneliu N.; Parikh, Komal; McLean-Pottinger, Audrey; Zeisel, Steven H.] Univ N Carolina, Sch Med, Chapel Hill, NC 27599 USA; [Mehedint, Mihai G.; Zeisel, Steven H.] Univ N Carolina Chapel Hill, Inst Nutr Res, Kannapolis, NC 28081 USA; [Sanders, Lisa M.] Tate & Lyle, Decatur, IL 62525 USA	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine; University of North Carolina; University of North Carolina Chapel Hill	Zeisel, SH (corresponding author), 500 Laureate Way, Kannapolis, NC 28081 USA.	steven_zeisel@unc.edu	Sanders, Lisa M./AAC-7105-2020	Sanders, Lisa M./0000-0003-1347-1533	National Institutes of Health [AG09525, DK55865, DK56350, DK034987]; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK055865, P30DK056350, P30DK034987] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [P01AG009525] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))	This work was supported, in whole or in part, by National Institutes of Health Grants AG09525, DK55865, and DK56350 (to S.H.Z.) and Grant DK034987 to the University of North Carolina Histology Core.	Akbar M, 2005, P NATL ACAD SCI USA, V102, P10858, DOI 10.1073/pnas.0502903102; Albright CD, 1999, DEV BRAIN RES, V115, P123, DOI 10.1016/S0165-3806(99)00057-7; Albright CD, 2005, DEV BRAIN RES, V159, P149, DOI 10.1016/j.devbrainres.2005.07.002; Albright CD, 2003, NUTR NEUROSCI, V6, P129, DOI 10.1080/1028415031000084418; Albright CD, 1999, DEV BRAIN RES, V113, P13, DOI 10.1016/S0165-3806(98)00183-7; BAUR FJ, 1945, J AM CHEM SOC, V67, P1899, DOI 10.1021/ja01227a007; BAZAN NG, 1990, UPSALA J MED SCI, P97; Bergmann RL, 2007, J PERINAT MED, V35, P295, DOI 10.1515/JPM.2007.085; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; Bowen RAR, 2005, BRIT J NUTR, V93, P601, DOI 10.1079/BJN20041390; Chen CT, 2008, J LIPID RES, V49, P147, DOI 10.1194/jlr.M700386-JLR200; CHERIAN G, 1992, POULTRY SCI, V71, P1658, DOI 10.3382/ps.0711658; Craciunescu CN, 2003, J NUTR, V133, P3614, DOI 10.1093/jn/133.11.3614; da Costa KA, 2006, FASEB J, V20, P1336, DOI 10.1096/fj.06-5734com; DeLong CJ, 1999, J BIOL CHEM, V274, P29683, DOI 10.1074/jbc.274.42.29683; Denkins Y, 2005, J LIPID RES, V46, P1278, DOI 10.1194/jlr.M400474-JLR200; Fan XT, 2006, P NATL ACAD SCI USA, V103, P19338, DOI 10.1073/pnas.0609663103; Fischer LM, 2007, AM J CLIN NUTR, V85, P1275; Green P, 1996, LIPIDS, V31, pS235, DOI 10.1007/BF02637082; Guo MQ, 2007, J MOL NEUROSCI, V33, P67, DOI 10.1007/s12031-007-0046-z; Harris WS, 2009, J NUTR, V139, p804S, DOI 10.3945/jn.108.101329; Innis SM, 2007, EARLY HUM DEV, V83, P761, DOI 10.1016/j.earlhumdev.2007.09.004; Innis SM, 2007, J NUTR, V137, P855, DOI 10.1093/jn/137.4.855; Institute of Medicine, 1998, DIET REF INT THIAM R, P390, DOI [DOI 10.17226/6015, 10.17226/6015]; JACOBOWITZ DM, 1998, CHEMOARCHITECTONIC A; Jones JP, 1999, DEV BRAIN RES, V118, P159, DOI 10.1016/S0165-3806(99)00103-0; Kim HY, 2007, J BIOL CHEM, V282, P18661, DOI 10.1074/jbc.R700015200; Kuan CY, 2000, TRENDS NEUROSCI, V23, P291, DOI 10.1016/S0166-2236(00)01581-2; MALLAMPALLI RK, 1994, AM J PHYSIOL-LUNG C, V267, pL641, DOI 10.1152/ajplung.1994.267.6.L641; MECK WH, 1988, DEV PSYCHOBIOL, V21, P339, DOI 10.1002/dev.420210405; Meck WH, 1997, NEUROREPORT, V8, P3053, DOI 10.1097/00001756-199709290-00010; MECK WH, 1989, BEHAV NEUROSCI, V103, P1234, DOI 10.1037/0735-7044.103.6.1234; Meck WH, 1997, NEUROREPORT, V8, P3045, DOI 10.1097/00001756-199709290-00009; Meck WH, 1999, DEV BRAIN RES, V118, P51, DOI 10.1016/S0165-3806(99)00105-4; Meck WH, 1997, NEUROREPORT, V8, P2831, DOI 10.1097/00001756-199709080-00005; Miyama S, 1997, CEREB CORTEX, V7, P678, DOI 10.1093/cercor/7.7.678; Montoya DAC, 2000, DEV BRAIN RES, V123, P25, DOI 10.1016/S0165-3806(00)00075-4; Muthayya S, 2009, EUR J CLIN NUTR, V63, P340, DOI 10.1038/sj.ejcn.1602933; Narayanan NK, 2005, INT J ONCOL, V26, P785; Niculescu MD, 2006, FASEB J, V20, P43, DOI 10.1096/fj.05-4707com; Niculescu MD, 2005, MOL BRAIN RES, V134, P309, DOI 10.1016/j.molbrainres.2004.11.001; Park JJ, 1996, J NEUROBIOL, V30, P315, DOI 10.1002/(SICI)1097-4695(199607)30:3<315::AID-NEU1>3.0.CO;2-7; Pyapali GK, 1998, J NEUROPHYSIOL, V79, P1790, DOI 10.1152/jn.1998.79.4.1790; Resseguie M, 2007, FASEB J, V21, P2622, DOI 10.1096/fj.07-8227com; RIDGWAY ND, 1992, METHOD ENZYMOL, V209, P366; RIDGWAY ND, 1988, J BIOL CHEM, V263, P16856; Shaw GM, 2006, EPIDEMIOLOGY, V17, P285, DOI 10.1097/01.ede.0000208348.30012.35; Shaw GM, 2004, AM J EPIDEMIOL, V160, P102, DOI 10.1093/aje/kwh187; SHIBATA K, 1990, EUR J BIOCHEM, V192, P87, DOI 10.1111/j.1432-1033.1990.tb19199.x; Song JN, 2005, FASEB J, V19, P1266, DOI 10.1096/fj.04-3580com; Stead LM, 2006, AM J CLIN NUTR, V83, P5; TACCONI M, 1985, J NEUROCHEM, V45, P805, DOI 10.1111/j.1471-4159.1985.tb04064.x; Tam O, 2006, DEV NEUROSCI-BASEL, V28, P222, DOI 10.1159/000091920; Tang XH, 2007, J LIPID RES, V48, P165, DOI 10.1194/jlr.M600419-JLR200; Vance JE, 2008, J LIPID RES, V49, P1377, DOI 10.1194/jlr.R700020-JLR200; Watkins SM, 2003, J NUTR, V133, P3386, DOI 10.1093/jn/133.11.3386; Zeisel SH, 2006, ANNU REV NUTR, V26, P229, DOI 10.1146/annurev.nutr.26.061505.111156; Zhu XN, 2005, MOL BRAIN RES, V134, P239, DOI 10.1016/j.molbrainres.2004.10.040; Zhu XN, 2004, DEV BRAIN RES, V149, P121, DOI 10.1016/j.devbrainres.2004.01.004	59	35	35	1	7	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 8	2010	285	2					1008	1015		10.1074/jbc.M109.017137	http://dx.doi.org/10.1074/jbc.M109.017137			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	539MH	19889625	Green Published, hybrid			2022-12-25	WOS:000273258200021
J	Duc, M; Johansen, FE; Corthesy, B				Duc, Melanie; Johansen, Finn-Eirik; Corthesy, Blaise			Antigen Binding to Secretory Immunoglobulin A Results in Decreased Sensitivity to Intestinal Proteases and Increased Binding to Cellular Fc Receptors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POLYMERIC IG RECEPTOR; ALPHA-R CD89; IMMUNE-RESPONSES; MONOCLONAL-ANTIBODIES; MUCOSAL SURFACES; M-CELLS; COMPONENT; DOMAIN; IDENTIFICATION; ASSOCIATION	In intestinal secretions, secretory IgA (SIgA) plays an important sentinel and protective role in the recognition and clearance of enteric pathogens. In addition to serving as a first line of defense, SIgA and SIgA center dot antigen immune complexes are selectively transported across Peyer's patches to underlying dendritic cells in the mucosa-associated lymphoid tissue, contributing to immune surveillance and immunomodulation. To explain the unexpected transport of immune complexes in face of the large excess of free SIgA in secretions, we postulated that SIgA experiences structural modifications upon antigen binding. To address this issue, we associated specific polymeric IgA and SIgA with antigens of various sizes and complexity (protein toxin, virus, bacterium). Compared with free antibody, we found modified sensitivity of the three antigens assayed after exposure to proteases from intestinal washes. Antigen binding further impacted on the immunoreactivity toward polyclonal antisera specific for the heavy and light chains of the antibody, as a function of the antigen size. These conformational changes promoted binding of the SIgA-based immune complex compared with the free antibody to cellular receptors (Fc alpha RI and polymeric immunoglobulin receptor) expressed on the surface of premyelocytic and epithelial cell lines. These data reveal that antigen recognition by SIgA triggers structural changes that confer to the antibody enhanced receptor binding properties. This identifies immune complexes as particular structural entities integrating the presence of bound antigens and adds to the known function of immune exclusion and mucus anchoring by SIgA.	[Duc, Melanie; Corthesy, Blaise] Univ State Hosp CHUV, Dept Immunol & Allergy, CH-1011 Lausanne, Switzerland; [Johansen, Finn-Eirik] Univ Oslo, Inst Pathol, N-0027 Oslo, Norway; [Johansen, Finn-Eirik] Univ Oslo, Ctr Immune Regulat, N-0027 Oslo, Norway	University of Oslo; University of Oslo	Corthesy, B (corresponding author), Univ State Hosp CHUV, Dept Immunol & Allergy, Rue Bugnon 46, CH-1011 Lausanne, Switzerland.	blaise.corthesy@chuv.ch			Swiss Science Research Foundation [3200-109545, 3200-122039]	Swiss Science Research Foundation(Swiss National Science Foundation (SNSF))	This work was supported by Swiss Science Research Foundation Grants 3200-109545 and 3200-122039 (to B.C.).	ALLAOUI A, 1992, MOL MICROBIOL, V6, P1605, DOI 10.1111/j.1365-2958.1992.tb00885.x; BAKOS MA, 1991, J IMMUNOL, V146, P162; Bonner A, 2009, MUCOSAL IMMUNOL, V2, P74, DOI 10.1038/mi.2008.68; Brandtzaeg P, 2007, VACCINE, V25, P5467, DOI 10.1016/j.vaccine.2006.12.001; Burns JW, 1996, SCIENCE, V272, P104, DOI 10.1126/science.272.5258.104; Carayannopoulos L, 1996, J EXP MED, V183, P1579, DOI 10.1084/jem.183.4.1579; Ciarlet M, 1999, J GEN VIROL, V80, P943, DOI 10.1099/0022-1317-80-4-943; Crottet P, 1998, J IMMUNOL, V161, P5445; Crottet P, 1999, J BIOL CHEM, V274, P31445, DOI 10.1074/jbc.274.44.31445; Favre L, 2005, J IMMUNOL, V175, P2793, DOI 10.4049/jimmunol.175.5.2793; Favre LI, 2003, J CHROMATOGR B, V786, P143, DOI 10.1016/S1570-0232(02)00723-7; Hendrickson BA, 1996, J IMMUNOL, V157, P750; Herr AB, 2003, NATURE, V423, P614, DOI 10.1038/nature01685; Hexham JM, 1999, J EXP MED, V189, P747, DOI 10.1084/jem.189.4.747; Honorio-Fransa AC, 2001, J LEUKOCYTE BIOL, V69, P289; Jerlstrom PG, 1996, INFECT IMMUN, V64, P2787; Kadaoui KA, 2007, J IMMUNOL, V179, P7751, DOI 10.4049/jimmunol.179.11.7751; Kaetzel CS, 2005, IMMUNOL REV, V206, P83, DOI 10.1111/j.0105-2896.2005.00278.x; KAETZEL CS, 1991, P NATL ACAD SCI USA, V88, P8796, DOI 10.1073/pnas.88.19.8796; Lullau E, 1996, J BIOL CHEM, V271, P16300, DOI 10.1074/jbc.271.27.16300; Mantis NJ, 2002, J IMMUNOL, V169, P1844, DOI 10.4049/jimmunol.169.4.1844; Mestecky J, 2005, MUCOSAL IMMUNOLOGY, 3RD EDITION, P1; MESTECKY J, 1987, ADV IMMUNOL, V40, P153, DOI 10.1016/S0065-2776(08)60240-0; Moura IC, 2001, J EXP MED, V194, P417, DOI 10.1084/jem.194.4.417; Muller CA, 2005, CELL MOL LIFE SCI, V62, P1297, DOI 10.1007/s00018-005-5034-2; Oortwijn BD, 2007, MOL IMMUNOL, V44, P966, DOI 10.1016/j.molimm.2006.03.014; Perrier C, 2006, J BIOL CHEM, V281, P14280, DOI 10.1074/jbc.M512958200; Phalipon A, 2002, IMMUNITY, V17, P107, DOI 10.1016/S1074-7613(02)00341-2; PHALIPON A, 1995, J EXP MED, V182, P769, DOI 10.1084/jem.182.3.769; Pleass RJ, 1999, J BIOL CHEM, V274, P23508, DOI 10.1074/jbc.274.33.23508; Ramsland PA, 2007, P NATL ACAD SCI USA, V104, P15051, DOI 10.1073/pnas.0706028104; Reterink TJF, 1997, EUR J IMMUNOL, V27, P2219, DOI 10.1002/eji.1830270915; Rey J, 2004, J IMMUNOL, V172, P3026, DOI 10.4049/jimmunol.172.5.3026; RINDISBACHER L, 1995, J BIOL CHEM, V270, P14220, DOI 10.1074/jbc.270.23.14220; Roe M, 1999, J IMMUNOL, V162, P6046; STENBERG L, 1994, J BIOL CHEM, V269, P13458; Stubbe H, 2000, J IMMUNOL, V164, P1952, DOI 10.4049/jimmunol.164.4.1952; van Spriel AB, 2002, J IMMUNOL, V169, P3831, DOI 10.4049/jimmunol.169.7.3831; Woof JM, 2002, BIOCHEM SOC T, V30, P491, DOI 10.1042/bst0300491	39	17	20	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 8	2010	285	2					953	960		10.1074/jbc.M109.059220	http://dx.doi.org/10.1074/jbc.M109.059220			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	539MH	19910466	Green Published, hybrid			2022-12-25	WOS:000273258200015
J	El Gazzar, M; Liu, TF; Yoza, BK; McCall, CE				El Gazzar, Mohamed; Liu, Tiefu; Yoza, Barbara K.; McCall, Charles E.			Dynamic and Selective Nucleosome Repositioning during Endotoxin Tolerance	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NECROSIS-FACTOR-ALPHA; HUMAN MONOCYTIC CELLS; RNA-POLYMERASE-II; NF-KAPPA-B; ASSEMBLY PROTEIN-1; TRANSCRIPTIONAL ACTIVATION; CHROMATIN-STRUCTURE; GENE ACTIVATION; HISTONE H2A.Z; DNA-SEQUENCE	Sepsis is encoded by a sequel of transcription activation and repression events that initiate, sustain, and resolve severe systemic inflammation. The repression/silencing phase occurs in blood leukocytes of animals and humans following the initiation of systemic inflammation due to developing endotoxin tolerance. We previously reported that NF-kappa B transcription factor RelB and histone H3 lysine methyltransferase G9a directly interact to induce facultative heterochromatin assembly and regulate epigenetic silencing during endotoxin tolerance, which is a major feature of sepsis. The general objective of this study was to assess whether dynamic temporal, structural, and positional changes of nucleosomes influence the sepsis phenotype. We used the THP-1 sepsis cell model to isolate mononucleosomes by rapid cell permeabilization and digestion of chromatin with micrococcal nuclease and then compared tumor necrosis factor alpha (TNF alpha) proximal promoter nucleosome alignment in endotoxin-responsive and-tolerant phenotypes. We found differential and dynamic repositioning of nucleosomes from permissive to repressive locations during the activation and silencing phases of transcription reprogramming and identified the following mechanisms that may participate in the process. 1) Two proximal nucleosomes repositioned to expose the primary NF-kappa B DNA binding site in endotoxin-responsive cells, and this "promoter opening" required the ATP-independent chaperone NAP1 to replace the core histone H2A with the H2A.Z variant. 2) During RelB-dependent endotoxin tolerance, the two nucleosomes repositioned and masked the primary NF-kappa B DNA binding site. 3) Small interfering RNA-mediated inhibition of RelB expression prevented repressive nucleosome repositioning and tolerance induction, but the "open" promoter required endotoxin-induced NF-kappa B p65 promoter binding to initiate transcription, supporting the known requirement of p65 posttranslational modifications for transactivation. 4) Sustaining the permissive promoter state after RelB knockdown required ATP-dependent nucleosome remodeler BAF complex. Moreover, we found that forced expression of RelB in responsive cells induced repressive nucleosome positioning and silenced TNF alpha transcription, demonstrating the plasticity of nucleosome remodeling and its dependence on RelB. Our data suggest that nucleosome repositioning controls both the induction and epigenetic silencing phases of TNF alpha transcription associated with sepsis.	[El Gazzar, Mohamed] Wake Forest Univ, Bowman Gray Sch Med, Dept Internal Med, Sect Mol Med, Winston Salem, NC 27157 USA; [Yoza, Barbara K.] Wake Forest Univ, Bowman Gray Sch Med, Dept Gen Surg, Winston Salem, NC 27157 USA	Wake Forest University; Wake Forest Baptist Medical Center; Wake Forest University; Wake Forest Baptist Medical Center	El Gazzar, M (corresponding author), Wake Forest Univ, Bowman Gray Sch Med, Dept Internal Med, Sect Mol Med, Med Ctr Blvd, Winston Salem, NC 27157 USA.	melgazza@wfubmc.edu			National Institutes of Health [R01AI-065791, R01AI-079144]; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI079144, R01AI065791] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	This work was supported, in whole or in part, by National Institutes of Health Grants R01AI-065791 and R01AI-079144.	Anderson JD, 2000, J MOL BIOL, V296, P979, DOI 10.1006/jmbi.2000.3531; Asahara H, 2002, MOL CELL BIOL, V22, P2974, DOI 10.1128/MCB.22.9.2974-2983.2002; Barski A, 2007, CELL, V129, P823, DOI 10.1016/j.cell.2007.05.009; BENEZRA R, 1986, CELL, V44, P697, DOI 10.1016/0092-8674(86)90835-4; Berger SL, 2007, NATURE, V447, P407, DOI 10.1038/nature05915; Bonaldi T, 2002, EMBO J, V21, P6865, DOI 10.1093/emboj/cdf692; Bondarenko VA, 2006, MOL CELL, V24, P469, DOI 10.1016/j.molcel.2006.09.009; BUCKLE R, 1991, NUCLEIC ACIDS RES, V19, P1219, DOI 10.1093/nar/19.6.1219; Cavaillon JM, 2003, SCAND J INFECT DIS, V35, P535, DOI 10.1080/00365540310015935; Chen C, 2001, MOL CELL BIOL, V21, P7682, DOI 10.1128/MCB.21.22.7682-7695.2001; Chen JG, 2006, MOL ENDOCRINOL, V20, P1, DOI 10.1210/me.2005-0192; Chen XP, 2009, J BIOL CHEM, V284, P27857, DOI 10.1074/jbc.M109.000950; Chen XX, 2005, MOL CELL BIOL, V25, P3209, DOI 10.1128/MCB.25.8.3209-3219.2005; Chi T, 2004, NAT REV IMMUNOL, V4, P965, DOI 10.1038/nri1501; Coisy M, 2004, MOL CELL, V15, P43, DOI 10.1016/j.molcel.2004.06.022; Cosgrove MS, 2004, NAT STRUCT MOL BIOL, V11, P1037, DOI 10.1038/nsmb851; Cui KR, 2004, MOL CELL BIOL, V24, P4476, DOI 10.1128/MCB.24.10.4476-4486.2004; de la Serna IL, 2006, NAT REV GENET, V7, P461, DOI 10.1038/nrg1882; El Gazzar M, 2007, INFLAMM RES, V56, P162, DOI 10.1007/s00011-006-6112-0; El Gazzar M, 2008, J BIOL CHEM, V283, P32198, DOI 10.1074/jbc.M803446200; El Gazzar M, 2007, J BIOL CHEM, V282, P26857, DOI 10.1074/jbc.M704584200; Gervais AL, 2009, BMC MOL BIOL, V10, DOI 10.1186/1471-2199-10-18; Goodbourn S, 2000, J GEN VIROL, V81, P2341, DOI 10.1099/0022-1317-81-10-2341; Goriely S, 2003, BLOOD, V101, P4894, DOI 10.1182/blood-2002-09-2851; Gottesfeld JM, 2001, BIOCHEMISTRY-US, V40, P10927, DOI 10.1021/bi0109966; Guillemette B, 2005, PLOS BIOL, V3, P2100, DOI 10.1371/journal.pbio.0030384; Hall MA, 2009, NAT STRUCT MOL BIOL, V16, P124, DOI 10.1038/nsmb.1526; Heintzman ND, 2007, NAT GENET, V39, P311, DOI 10.1038/ng1966; Jenuwein T, 2001, SCIENCE, V293, P1074, DOI 10.1126/science.1063127; Kadonaga JT, 1998, CELL, V92, P307, DOI 10.1016/S0092-8674(00)80924-1; Kireeva ML, 2005, MOL CELL, V18, P97, DOI 10.1016/j.molcel.2005.02.027; Kouzarides T, 2007, CELL, V128, P693, DOI 10.1016/j.cell.2007.02.005; Krebs JE, 2000, CRIT REV EUKAR GENE, V10, P1; Krude T, 1999, EUR J BIOCHEM, V263, P1, DOI 10.1046/j.1432-1327.1999.00508.x; LARUE KEA, 1994, J EXP MED, V180, P2269, DOI 10.1084/jem.180.6.2269; Li B, 2007, CELL, V128, P707, DOI 10.1016/j.cell.2007.01.015; Li GF, 1998, P NATL ACAD SCI USA, V95, P4772, DOI 10.1073/pnas.95.8.4772; Liu H, 2002, MOL CELL BIOL, V22, P6471, DOI 10.1128/MCB.22.18.6471-6479.2002; MATHISON JC, 1990, J CLIN INVEST, V85, P1108, DOI 10.1172/JCI114542; McCall CE, 2007, AM J RESP CRIT CARE, V175, P763, DOI 10.1164/rccm.200610-1436CP; Mito Y, 2005, NAT GENET, V37, P1090, DOI 10.1038/ng1637; Ozsolak F, 2007, NAT BIOTECHNOL, V25, P244, DOI 10.1038/nbt1279; Park YJ, 2006, P NATL ACAD SCI USA, V103, P1248, DOI 10.1073/pnas.0508002103; Park YJ, 2005, J BIOL CHEM, V280, P1817, DOI 10.1074/jbc.M411347200; Pazin MJ, 1997, SCIENCE, V276, P809, DOI 10.1126/science.276.5313.809; Placek BJ, 2005, PROTEIN SCI, V14, P514, DOI 10.1110/ps.041026405; RADMANLIVAJA M, 2009, DEV BIOL IN PRESS; Ramirez-Carrozzi VR, 2009, CELL, V138, P114, DOI 10.1016/j.cell.2009.04.020; Richmond TJ, 2003, NATURE, V423, P145, DOI 10.1038/nature01595; Rippe K, 2007, P NATL ACAD SCI USA, V104, P15635, DOI 10.1073/pnas.0702430104; Saha A, 2006, NAT REV MOL CELL BIO, V7, P437, DOI 10.1038/nrm1945; Schnitzler GR, 2008, CELL BIOCHEM BIOPHYS, V51, P67, DOI 10.1007/s12013-008-9015-6; Segal E, 2006, NATURE, V442, P772, DOI 10.1038/nature04979; Sewack GF, 1997, J BIOL CHEM, V272, P31118, DOI 10.1074/jbc.272.49.31118; Simone C, 2006, J CELL PHYSIOL, V207, P309, DOI 10.1002/jcp.20514; Sims HI, 2008, NUCLEIC ACIDS RES, V36, P6118, DOI 10.1093/nar/gkn623; Steger David J., 1996, Bioessays, V18, P875, DOI 10.1002/bies.950181106; TREDE NS, 1995, J IMMUNOL, V155, P902; Trojer P, 2007, MOL CELL, V28, P1, DOI 10.1016/j.molcel.2007.09.011; VIRCA GD, 1989, J BIOL CHEM, V264, P21951; Workman JL, 2006, GENE DEV, V20, P2009, DOI 10.1101/gad.1435706; Yao J, 1997, J BIOL CHEM, V272, P17795, DOI 10.1074/jbc.272.28.17795; Yoza BK, 2006, J IMMUNOL, V177, P4080, DOI 10.4049/jimmunol.177.6.4080; Zlatanova J, 2008, STRUCTURE, V16, P166, DOI 10.1016/j.str.2007.12.008	64	43	43	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 8	2010	285	2					1259	1271		10.1074/jbc.M109.067330	http://dx.doi.org/10.1074/jbc.M109.067330			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	539MH	19901031	Green Published, hybrid			2022-12-25	WOS:000273258200048
J	Kawasaki, Y; Jigami, T; Furukawa, S; Sagara, M; Echizen, K; Shibata, Y; Sato, R; Akiyama, T				Kawasaki, Yoshihiro; Jigami, Takafumi; Furukawa, Shiori; Sagara, Masaki; Echizen, Kanae; Shibata, Yoko; Sato, Rina; Akiyama, Tetsu			The Adenomatous Polyposis Coli-associated Guanine Nucleotide Exchange Factor Asef Is Involved in Angiogenesis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR-SUPPRESSOR APC; ENDOTHELIAL-CELLS; COLORECTAL-CANCER; GROWTH-FACTOR; ACTIVATION; CDC42; MIGRATION; RAC1; PATHWAY; IDENTIFICATION	Mutation of the tumor suppressor adenomatous polyposis coli (APC) is a key early event in the development of most colorectal tumors. APC promotes degradation of beta-catenin and thereby negatively regulates Wnt signaling, whereas mutated APCs present in colorectal tumor cells are defective in this activity. APC also stimulates the activity of the guanine nucleotide exchange factor Asef and regulates cell morphology and migration. Truncated mutant APCs constitutively activate Asef and induce aberrant migration of colorectal tumor cells. Furthermore, we have recently found that Asef and APC function downstream of hepatocyte growth factor and phosphatidylinositol 3-kinase. We show here that Asef is required for basic fibroblast growth factor-and vascular endothelial growth factor-induced endothelial cell migration. We further demonstrate that Asef is required for basic fibroblast growth factor-and vascular endothelial growth factor-induced microvessel formation. Furthermore, we show that the growth as well as vascularity of subcutaneously implanted tumors are markedly impaired in Asef(-/-) mice compared with wild-type mice. Thus, Asef plays a critical role in tumor angiogenesis and may be a promising target for cancer chemotherapy.	[Kawasaki, Yoshihiro; Jigami, Takafumi; Furukawa, Shiori; Sagara, Masaki; Echizen, Kanae; Shibata, Yoko; Sato, Rina; Akiyama, Tetsu] Univ Tokyo, Lab Mol & Genet Informat, Inst Mol & Cellular Biosci, Bunkyo Ku, Tokyo 1130032, Japan	University of Tokyo	Akiyama, T (corresponding author), 1-1-1 Yayoi,Bunkyo Ku, Tokyo 1130032, Japan.	akiyama@iam.u-tokyo.ac.jp			Ministry of Education, Culture, Sports, Science and Technology, Japan	Ministry of Education, Culture, Sports, Science and Technology, Japan(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT))	This work was supported by grants-in-aid for Scientific Research on Priority Areas and the Organization for Pharmaceutical Safety and Research and in part by Global COE Program (Integrative Life Science Based on the Study of Biosignaling Mechanisms), Ministry of Education, Culture, Sports, Science and Technology, Japan.	Akiyama T, 2006, ONCOGENE, V25, P7538, DOI 10.1038/sj.onc.1210063; Bienz M, 2000, CELL, V103, P311, DOI 10.1016/S0092-8674(00)00122-7; Birukova AA, 2007, FASEB J, V21, P2776, DOI 10.1096/fj.06-7660com; BOUT D, 1981, CELL IMMUNOL, V63, P198, DOI 10.1016/0008-8749(81)90041-1; Brembeck FH, 2006, CURR OPIN GENET DEV, V16, P51, DOI 10.1016/j.gde.2005.12.007; Cadigan KM, 1997, GENE DEV, V11, P3286, DOI 10.1101/gad.11.24.3286; Egami K, 2003, J CLIN INVEST, V112, P67, DOI 10.1172/JCI200316645; Etienne-Manneville S, 2005, J CELL BIOL, V170, P895, DOI 10.1083/jcb.200412172; Etienne-Manneville S, 2003, NATURE, V421, P753, DOI 10.1038/nature01423; Ferrara N, 2005, NATURE, V438, P967, DOI 10.1038/nature04483; Fodde R, 2001, NAT REV CANCER, V1, P55, DOI 10.1038/35094067; FOLKMAN J, 1995, NAT MED, V1, P27, DOI 10.1038/nm0195-27; Garrett TA, 2007, EXP CELL RES, V313, P3285, DOI 10.1016/j.yexcr.2007.05.027; Gavard J, 2006, NAT CELL BIOL, V8, P1223, DOI 10.1038/ncb1486; Gonzalez E, 2006, J BIOL CHEM, V281, P3210, DOI 10.1074/jbc.M510434200; Gotthardt K, 2007, BIOL CHEM, V388, P67, DOI 10.1515/BC.2007.008; Hamann MJ, 2007, MOL CELL BIOL, V27, P1380, DOI 10.1128/MCB.01608-06; Itoh RE, 2008, J CELL SCI, V121, P2635, DOI 10.1242/jcs.028647; Jimbo T, 2002, NAT CELL BIOL, V4, P323, DOI 10.1038/ncb779; Kawasaki Y, 2007, ONCOGENE, V26, P7620, DOI 10.1038/sj.onc.1210574; Kawasaki Y, 2003, NAT CELL BIOL, V5, P211, DOI 10.1038/ncb937; Kawasaki Y, 2000, SCIENCE, V289, P1194, DOI 10.1126/science.289.5482.1194; Kawasaki Y, 2009, J BIOL CHEM, V284, P22436, DOI 10.1074/jbc.M109.020768; Kinzler KW, 1996, CELL, V87, P159, DOI 10.1016/S0092-8674(00)81333-1; Lee SH, 2007, CANCER RES, V67, P11045, DOI 10.1158/0008-5472.CAN-07-0986; Lewis CE, 2006, CANCER RES, V66, P605, DOI 10.1158/0008-5472.CAN-05-4005; Li Z, 2005, PROSTAG OTH LIPID M, V76, P95, DOI 10.1016/j.prostaglandins.2005.02.002; Maffucci T, 2005, CANCER RES, V65, P8339, DOI 10.1158/0008-5472.CAN-05-0121; Miao WM, 2001, CANCER RES, V61, P7830; Mimori-Kiyosue Y, 2000, J CELL BIOL, V148, P505, DOI 10.1083/jcb.148.3.505; Mitin N, 2007, NAT STRUCT MOL BIOL, V14, P814, DOI 10.1038/nsmb1290; Murayama K, 2007, J BIOL CHEM, V282, P4238, DOI 10.1074/jbc.C600234200; Nathke IS, 1996, J CELL BIOL, V134, P165, DOI 10.1083/jcb.134.1.165; Peifer M, 2000, SCIENCE, V287, P1606, DOI 10.1126/science.287.5458.1606; Shi WB, 2000, CIRC RES, V86, P1078, DOI 10.1161/01.RES.86.10.1078; Watanabe T, 2004, DEV CELL, V7, P871, DOI 10.1016/j.devcel.2004.10.017	36	24	25	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 8	2010	285	2					1199	1207		10.1074/jbc.M109.040691	http://dx.doi.org/10.1074/jbc.M109.040691			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	539MH	19897489	Green Published, hybrid			2022-12-25	WOS:000273258200042
J	Reed, CA; Mayhew, CN; McClendon, AK; Knudsen, ES				Reed, Christopher A.; Mayhew, Christopher N.; McClendon, A. Kathleen; Knudsen, Erik S.			Unique Impact of RB Loss on Hepatic Proliferation TUMORIGENIC STRESSES UNCOVER DISTINCT PATHWAYS OF CELL CYCLE CONTROL	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RETINOBLASTOMA TUMOR-SUPPRESSOR; HUMAN HEPATOCELLULAR-CARCINOMA; LIVER-REGENERATION; GENOME INTEGRITY; DNA-DAMAGE; PROTEINS; CANCER; E2F; TRANSCRIPTION; PATHOGENESIS	The retinoblastoma (RB) tumor suppressor pathway is disrupted at high frequency in hepatocellular carcinoma. However, the mechanisms through which RB modulates physiological responses in the liver remain poorly defined. Despite the well established role of RB in cell cycle control, the deletion of RB had no impact on the kinetics of cell cycle entry or the restoration of quiescence during the course of liver regeneration. Although these findings indicated compensatory effects from the RB-related proteins p107 and p130, even the dual deletion of RB with p107 or p130 failed to deregulate hepatic proliferation. Furthermore, although these findings suggested a modest role for the RB-pathway in the context of proliferative control, RB loss had striking effects on response to the genotoxic hepatocarcinogen diethylnitrosamine. With diethylnitrosamine, RB deletion resulted in inappropriate cell cycle entry that facilitated secondary genetic damage and further uncoupling of DNA replication with mitotic entry. Analysis of the mechanism underlying the differential impact of RB status on liver biology revealed that, while liver regeneration is associated with the conventional induction of cyclin D1 expression, the RB-dependent cell cycle entry, occurring with diethylnitrosamine treatment, was independent of cyclin D1 levels and associated with the specific induction of E2F1. Combined, these studies demonstrate that RB loss has disparate effects on the response to unique tumorigenic stresses, which is reflective of distinct mechanisms of cell cycle entry.	[Knudsen, Erik S.] Thomas Jefferson Univ, Dept Canc Biol, Kimmel Canc Ctr, Philadelphia, PA 19107 USA; [Mayhew, Christopher N.] Cincinnati Childrens Hosp Res Fdn, Div Dev Biol, Cincinnati, OH 45229 USA	Jefferson University; Cincinnati Children's Hospital Medical Center; Cincinnati Children's Hospital Research Foundation	Knudsen, ES (corresponding author), Thomas Jefferson Univ, Dept Canc Biol, Kimmel Canc Ctr, 233 S 10th St, Philadelphia, PA 19107 USA.	eknudsen@kimmelcancercenter.org	Mayhew, Christopher N/AGB-4929-2022		National Cancer Institute [CA 104213]	National Cancer Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	Supported by National Cancer Institute Grant CA 104213.	ALBRECHT JH, 1995, BIOCHEM BIOPH RES CO, V209, P648, DOI 10.1006/bbrc.1995.1548; Albrecht JH, 1998, ONCOGENE, V16, P2141, DOI 10.1038/sj.onc.1201728; Azechi H, 2001, ONCOLOGY-BASEL, V60, P346, DOI 10.1159/000058531; Bioulac-Sage P, 2003, HEPATOLOGY, V37, P480, DOI 10.1053/jhep.2003.50058; Burkhart DL, 2008, NAT REV CANCER, V8, P671, DOI 10.1038/nrc2399; CAO L, 1992, NATURE, V355, P176, DOI 10.1038/355176a0; Cobrinik D, 2005, ONCOGENE, V24, P2796, DOI 10.1038/sj.onc.1208619; Cobrinik D, 1996, GENE DEV, V10, P1633, DOI 10.1101/gad.10.13.1633; DeGregori J, 2006, CURR MOL MED, V6, P739; Edamoto Y, 2003, INT J CANCER, V106, P334, DOI 10.1002/ijc.11254; FAN GS, 1995, CELL GROWTH DIFFER, V6, P1463; Farazi PA, 2006, NAT REV CANCER, V6, P674, DOI 10.1038/nrc1934; Jemal A, 2007, CA-CANCER J CLIN, V57, P43, DOI 10.3322/canjclin.57.1.43; Knudsen ES, 2008, NAT REV CANCER, V8, P714, DOI 10.1038/nrc2401; Knudsen ES, 2006, CURR MOL MED, V6, P749; Knudsen ES, 2006, EXP BIOL MED, V231, P1271; Knudsen KE, 2000, MOL CELL BIOL, V20, P7751, DOI 10.1128/MCB.20.20.7751-7763.2000; Laurent-Puig P, 2006, ONCOGENE, V25, P3778, DOI 10.1038/sj.onc.1209547; LAZAREVA MN, 1981, ONCODEV BIOL MED, V2, P89; Markey MP, 2007, ONCOGENE, V26, P6307, DOI 10.1038/sj.onc.1210450; Mayhew CN, 2007, GASTROENTEROLOGY, V133, P976, DOI 10.1053/j.gastro.2007.06.025; Mayhew CN, 2005, CANCER RES, V65, P4568, DOI 10.1158/0008-5472.CAN-04-4221; McGivern DR, 2009, ANNU REV PATHOL-MECH, V4, P399, DOI 10.1146/annurev.pathol.4.110807.092202; Munakata T, 2005, P NATL ACAD SCI USA, V102, P18159, DOI 10.1073/pnas.0505605102; Munakata T, 2007, PLOS PATHOG, V3, P1335, DOI 10.1371/journal.ppat.0030139; PAULSEN J E, 1990, Chronobiology International, V7, P271, DOI 10.3109/07420529009064632; Powell EE, 2005, HEPATOLOGY, V42, P5, DOI 10.1002/hep.20750; Rogoff HA, 2004, CELL CYCLE, V3, P845; Skawran B, 2008, MODERN PATHOL, V21, P1479, DOI 10.1038/modpathol.2008.147; Stevens C, 2003, CELL CYCLE, V2, P435, DOI 10.4161/cc.2.5.462; Thorgeirsson SS, 2002, NAT GENET, V31, P339, DOI 10.1038/ng0802-339; Wikenheiser-Brokamp KA, 2006, CELL MOL LIFE SCI, V63, P767, DOI 10.1007/s00018-005-5487-3; Yu MC, 2004, GASTROENTEROLOGY, V127, pS72, DOI 10.1016/j.gastro.2004.09.018; ZHANG X, 1994, CANCER RES, V54, P4177; ZHANG YJ, 1993, BIOCHEM BIOPH RES CO, V196, P1010, DOI 10.1006/bbrc.1993.2350	35	10	12	1	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 8	2010	285	2					1089	1096		10.1074/jbc.M109.043380	http://dx.doi.org/10.1074/jbc.M109.043380			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	539MH	19887370	Green Published, hybrid			2022-12-25	WOS:000273258200030
J	Gangolf, M; Wins, P; Thiry, M; El Moualij, B; Bettendorff, L				Gangolf, Marjorie; Wins, Pierre; Thiry, Marc; El Moualij, Benaissa; Bettendorff, Lucien			Thiamine Triphosphate Synthesis in Rat Brain Occurs in Mitochondria and Is Coupled to the Respiratory Chain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYTOSOLIC ADENYLATE KINASE; PERFORMANCE LIQUID-CHROMATOGRAPHY; PHOSPHATE-ESTERS; ADENINE-NUCLEOTIDES; ELECTRIC ORGAN; ELECTROPHORUS-ELECTRICUS; METABOLIZING ENZYMES; ALZHEIMERS-DISEASE; LIVER-MITOCHONDRIA; CHEMICAL-SYNTHESIS	In animals, thiamine deficiency leads to specific brain lesions, generally attributed to decreased levels of thiamine diphosphate, an essential cofactor in brain energy metabolism. However, another far less abundant derivative, thiamine triphosphate (ThTP), may also have a neuronal function. Here, we show that in the rat brain, ThTP is essentially present and synthesized in mitochondria. In mitochondrial preparations from brain (but not liver), ThTP can be produced from thiamine diphosphate and P-i. This endergonic process is coupled to the oxidation of succinate orNADHthrough the respiratory chain but cannot be energized by ATP hydrolysis. ThTP synthesis is strongly inhibited by respiratory chain inhibitors, such as myxothiazol and inhibitors of the H+ channel of F0F1-ATPase. It is also impaired by disruption of the mitochondria or by depolarization of the inner membrane (by protonophores or valinomycin), indicating that a proton-motive force (Delta p) is required. Collapsing Delta p after ThTP synthesis causes its rapid disappearance, suggesting that both synthesis and hydrolysis are catalyzed by a reversible H+-translocating ThTP synthase. The synthesized ThTP can be released from mitochondria in the presence of external P-i. However, ThTP probably does not accumulate in the cytoplasm in vivo, because it is not detected in the cytosolic fraction obtained from a brain homogenate. Our results show for the first time that a high energy triphosphate compound other than ATP can be produced by a chemiosmotic type of mechanism. This might shed a new light on our understanding of the mechanisms of thiamine deficiency-induced brain lesions.	[Gangolf, Marjorie; Wins, Pierre; Thiry, Marc; Bettendorff, Lucien] Univ Liege, GIGA Neurosci B36, B-4000 Liege 1, Sart Tilman, Belgium; [El Moualij, Benaissa] Univ Liege, Dept Human Histol, B-4000 Liege 1, Sart Tilman, Belgium	University of Liege; University of Liege		L.Bettendorff@ulg.ac.be			Fonds de la Recherche Fondamentale Collective; Fonds pour la Formation a la Recherche dans l'Industrie et dans l'Agriculture	Fonds de la Recherche Fondamentale Collective(Fonds de la Recherche Scientifique - FNRS); Fonds pour la Formation a la Recherche dans l'Industrie et dans l'Agriculture(Fonds de la Recherche Scientifique - FNRS)	This work was supported by the "Fonds de la Recherche Fondamentale Collective" (to F. R. F. C.) and the Fonds pour la Formation a la Recherche dans l'Industrie et dans l'Agriculture (to M. G.).	Atamna H, 2007, MITOCHONDRION, V7, P297, DOI 10.1016/j.mito.2007.06.001; BARCHI RL, 1972, J BIOL CHEM, V247, P7668; BARILE M, 1990, ARCH BIOCHEM BIOPHYS, V280, P352, DOI 10.1016/0003-9861(90)90341-U; BERGMEYER HU, 1974, METHODEN ENZYMATISCH, P607; BETTENDORFF L, 1993, J MEMBRANE BIOL, V136, P281; BETTENDORFF L, 1991, ANAL BIOCHEM, V198, P52, DOI 10.1016/0003-2697(91)90505-N; BETTENDORFF L, 1993, NEUROSCIENCE, V52, P1009, DOI 10.1016/0306-4522(93)90547-S; Bettendorff L, 2003, ANAL BIOCHEM, V322, P190, DOI 10.1016/j.ab.2003.08.013; BETTENDORFF L, 1989, J NEUROCHEM, V53, P738, DOI 10.1111/j.1471-4159.1989.tb11767.x; Bettendorff L, 1996, J NEUROCHEM, V66, P250; Bettendorff L, 1997, J NEUROCHEM, V69, P2005; BETTENDORFF L, 1989, J NEUROCHEM, V53, P80, DOI 10.1111/j.1471-4159.1989.tb07297.x; BETTENDORFF L, 1994, METAB BRAIN DIS, V9, P183, DOI 10.1007/BF01991194; BETTENDORFF L, 1987, J NEUROCHEM, V49, P495, DOI 10.1111/j.1471-4159.1987.tb02891.x; BETTENDORFF L, 1993, J NEUROCHEM, V60, P423, DOI 10.1111/j.1471-4159.1993.tb03168.x; Bettendorff L, 2007, NAT CHEM BIOL, V3, P211, DOI 10.1038/nchembio867; Bettendorff L, 2009, FEBS J, V276, P2917, DOI 10.1111/j.1742-4658.2009.07019.x; Butterworth RF, 2003, NUTR RES REV, V16, P277, DOI 10.1079/NRR200367; Calingasan NY, 2008, NEUROSCIENCE, V153, P986, DOI 10.1016/j.neuroscience.2008.02.071; Chalmers S, 2003, J BIOL CHEM, V278, P19062, DOI 10.1074/jbc.M212661200; CHERNIKEVICH I P, 1984, Biokhimiya, V49, P899; COOPER JR, 1969, SCIENCE, V164, P74, DOI 10.1126/science.164.3875.74; Davey GP, 1998, J BIOL CHEM, V273, P12753, DOI 10.1074/jbc.273.21.12753; Desjardins P, 2005, MOL NEUROBIOL, V31, P17, DOI 10.1385/MN:31:1-3:017; DUNKLEY PR, 1988, BRAIN RES, V441, P59, DOI 10.1016/0006-8993(88)91383-2; ECKERT T, 1964, H-S Z PHYSIOL CHEM, V338, P286, DOI 10.1515/bchm2.1964.338.1-2.286; EDER L, 1980, J NEUROCHEM, V35, P1278, DOI 10.1111/j.1471-4159.1980.tb08999.x; EGI Y, 1986, BIOCHEM INT, V12, P385; ELIASSON SG, 1976, NEUROCHEM RES, V1, P191, DOI 10.1007/BF00966110; Frederich M, 2009, FEBS J, V276, P3256, DOI 10.1111/j.1742-4658.2009.07040.x; Gigliobianco T, 2008, BMC MICROBIOL, V8, DOI 10.1186/1471-2180-8-16; Hazell AS, 2009, ALCOHOL ALCOHOLISM, V44, P141, DOI 10.1093/alcalc/agn120; HILL M, 1987, METHOD ENZYMOL, V148, P132; Hill RL, 1969, METHOD ENZYMOL, V8, P91, DOI 10.1016/0076-6879(69)13021-9; ISHII K, 1979, J NUTR SCI VITAMINOL, V25, P517, DOI 10.3177/jnsv.25.517; ITOKAWA Y, 1970, BIOCHIM BIOPHYS ACTA, V196, P274, DOI 10.1016/0005-2736(70)90015-5; IWATA H, 1988, J CHROMATOGR, V450, P317, DOI 10.1016/S0021-9673(01)83586-X; Ji HF, 2009, EUR J NEUROSCI, V29, P1883, DOI 10.1111/j.1460-9568.2009.06735.x; Johnson DT, 2007, AM J PHYSIOL-CELL PH, V292, pC689, DOI 10.1152/ajpcell.00108.2006; Karuppagounder SS, 2009, NEUROBIOL AGING, V30, P1587, DOI 10.1016/j.neurobiolaging.2007.12.013; Lakaye B, 2004, INT J BIOCHEM CELL B, V36, P1348, DOI 10.1016/j.biocel.2003.11.013; Lakaye B, 2004, J BIOL CHEM, V279, P17142, DOI 10.1074/jbc.M313569200; Lakaye B, 2002, J BIOL CHEM, V277, P13771, DOI 10.1074/jbc.M111241200; Lazarowski ER, 2004, J BIOL CHEM, V279, P36855, DOI 10.1074/jbc.M405367200; LEVITT B, 1984, ANAL BIOCHEM, V137, P93, DOI 10.1016/0003-2697(84)90352-X; Lindhurst MJ, 2006, P NATL ACAD SCI USA, V103, P15927, DOI 10.1073/pnas.0607661103; Makarchikov AF, 2003, CELL MOL LIFE SCI, V60, P1477, DOI 10.1007/s00018-003-3098-4; MAKARCHIKOV AF, 1992, BIOCHIM BIOPHYS ACTA, V1117, P326, DOI 10.1016/0304-4165(92)90032-P; Makarchikov AF, 2002, BBA-MOL CELL RES, V1592, P117, DOI 10.1016/S0167-4889(02)00277-X; Makarchikov Alexander F., 2007, BMC Biochemistry, V8, P17, DOI 10.1186/1471-2091-8-17; Marobbio CMT, 2002, EMBO J, V21, P5653, DOI 10.1093/emboj/cdf583; Mastrogiacomo F, 1996, ANN NEUROL, V39, P585, DOI 10.1002/ana.410390507; MIYOSHI K, 1990, J BIOCHEM-TOKYO, V108, P267, DOI 10.1093/oxfordjournals.jbchem.a123192; Nghiem HO, 2000, FASEB J, V14, P543, DOI 10.1096/fasebj.14.3.543; NISHINO K, 1983, J BIOL CHEM, V258, P1871; Panov A, 2007, AM J PHYSIOL-CELL PH, V292, pC708, DOI 10.1152/ajpcell.00202.2006; PETERSON GL, 1977, ANAL BIOCHEM, V83, P346, DOI 10.1016/0003-2697(77)90043-4; REINHART PH, 1982, BIOCHEM J, V204, P731, DOI 10.1042/bj2040731; RINDI G, 1961, BIOCHEM J, V78, P602, DOI 10.1042/bj0780602; ROSENTHAL RE, 1987, J CEREBR BLOOD F MET, V7, P752, DOI 10.1038/jcbfm.1987.130; SHIKATA H, 1989, BIOCHEM INT, V18, P933; SHIODA T, 1991, BIOCHIM BIOPHYS ACTA, V1115, P30, DOI 10.1016/0304-4165(91)90007-4; SIMS NR, 1990, J NEUROCHEM, V55, P698, DOI 10.1111/j.1471-4159.1990.tb04189.x; Starkov AA, 2001, BIOCHEM BIOPH RES CO, V281, P645, DOI 10.1006/bbrc.2001.4409; Szyniarowski P, 2005, BBA-GEN SUBJECTS, V1725, P93, DOI 10.1016/j.bbagen.2005.05.026; Tahara EB, 2009, FREE RADICAL BIO MED, V46, P1283, DOI 10.1016/j.freeradbiomed.2009.02.008; Vergara R, 2003, J PHYSIOL-LONDON, V553, P169, DOI 10.1113/jphysiol.2003.050799; VOSKOBOEV A I, 1985, Biokhimiya, V50, P1421	68	38	39	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 1	2010	285	1					583	594		10.1074/jbc.M109.054379	http://dx.doi.org/10.1074/jbc.M109.054379			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	536UT	19906644	hybrid, Green Published			2022-12-25	WOS:000273070100060
J	Stanford, KI; Wang, LC; Castagnola, J; Song, DY; Bishop, JR; Brown, JR; Lawrence, R; Bai, XM; Habuchi, H; Tanaka, M; Cardoso, WV; Kimata, K; Esko, JD				Stanford, Kristin I.; Wang, Lianchun; Castagnola, Jan; Song, Danyin; Bishop, Joseph R.; Brown, Jillian R.; Lawrence, Roger; Bai, Xaiomei; Habuchi, Hiroko; Tanaka, Masakazu; Cardoso, Wellington V.; Kimata, Koji; Esko, Jeffrey D.			Heparan Sulfate 2-O-Sulfotransferase Is Required for Triglyceride-rich Lipoprotein Clearance	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LOW-DENSITY-LIPOPROTEIN; RECEPTOR-RELATED PROTEIN; PROTEOGLYCAN-BINDING-SITE; APOLIPOPROTEIN-E; LDL RECEPTOR; HEPATIC LIPASE; REMNANT LIPOPROTEINS; CHYLOMICRON REMNANTS; MICE LACKING; SUBSTRATE-SPECIFICITY	Hepatic clearance of triglyceride-rich lipoproteins depends on heparan sulfate and low density lipoprotein receptors expressed on the basal membrane of hepatocytes. Binding and uptake of the lipoproteins by way of heparan sulfate depends on the degree of sulfation of the chains based on accumulation of plasma triglycerides and delayed clearance of triglyceride-rich lipoproteins in mice bearing a hepatocyte-specific alteration of N-acetylglucosamine (GlcNAc) N-deacetylase-N-sulfotransferase 1 (Ndst1) (MacArthur, J. M., Bishop, J. R., Stanford, K. I., Wang, L., Bensadoun, A., Witztum, J. L., and Esko, J. D. (2007) J. Clin. Invest. 117, 153-164). Inactivation of Ndst1 led to decreased overall sulfation of heparan sulfate due to coupling of uronyl 2-O-sulfation and glucosaminyl 6-O-sulfation to initial N-deacetylation and N-sulfation of GlcNAc residues. To determine whether lipoprotein clearance depends on 2-O-and 6-O-sulfation, we evaluated plasma triglyceride levels in mice containing loxP-flanked conditional alleles of uronyl 2-O-sulfotransferase (Hs2st(f/f)) and glucosaminyl 6-O-sulfotransferase-1 (Hs6st1(f/f)) and the bacterial Cre recombinase expressed in hepatocytes from the rat albumin (Alb) promoter. We show that Hs2st(f/f) AlbCre(+) mice accumulated plasma triglycerides and exhibited delayed clearance of intestinally derived chylomicrons and injected human very low density lipoproteins to the same extent as observed in Ndst1(f/f) AlbCre(+) mice. In contrast, Hs6st1(f/f) AlbCre(+) mice did not exhibit any changes in plasma triglycerides. Chemically modified heparins lacking N-sulfate and 2-O-sulfate groups did not block very low density lipoprotein binding and uptake in isolated hepatocytes, whereas heparin lacking 6-O-sulfate groups was as active as unaltered heparin. Our findings show that plasma lipoprotein clearance depends on specific subclasses of sulfate groups and not on overall charge of the chains.	[Stanford, Kristin I.; Wang, Lianchun; Castagnola, Jan; Song, Danyin; Bishop, Joseph R.; Brown, Jillian R.; Lawrence, Roger; Bai, Xaiomei; Esko, Jeffrey D.] Univ Calif San Diego, Dept Cellular & Mol Med, La Jolla, CA 92093 USA; [Stanford, Kristin I.; Wang, Lianchun; Castagnola, Jan; Song, Danyin; Bishop, Joseph R.; Brown, Jillian R.; Lawrence, Roger; Bai, Xaiomei; Esko, Jeffrey D.] Univ Calif San Diego, Glycobiol Res & Training Ctr, La Jolla, CA 92093 USA; [Stanford, Kristin I.] Univ Calif San Diego, Biomed Sci Grad Program, La Jolla, CA 92093 USA; [Habuchi, Hiroko; Tanaka, Masakazu; Kimata, Koji] Aichi Med Univ, Aichi 4801195, Japan; [Cardoso, Wellington V.] Boston Univ, Dept Med, Boston, MA 02118 USA	University of California System; University of California San Diego; University of California System; University of California San Diego; University of California System; University of California San Diego; Aichi Medical University; Boston University	Esko, JD (corresponding author), Univ Calif San Diego, Dept Cellular & Mol Med, La Jolla, CA 92093 USA.	jesko@ucsd.edu		Cardoso, Wellington/0000-0002-2550-3697	National Institutes of Health [HL57345, GM33063]; American Heart Association [0735038N]; NATIONAL CENTER FOR RESEARCH RESOURCES [P41RR005351] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL093339, P01HL057345] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM033063, R37GM033063, P41GM103390] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); American Heart Association(American Heart Association); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	This work was supported, in whole or in part, by National Institutes of Health Grants HL57345 and GM33063 (to J.D.E.). This work was also supported by American Heart Association Grant 0735038N (to J.R.B.).	AlHaideri M, 1997, BIOCHEMISTRY-US, V36, P12766, DOI 10.1021/bi9631024; Bai XM, 1996, J BIOL CHEM, V271, P17711, DOI 10.1074/jbc.271.30.17711; BAME KJ, 1991, J BIOL CHEM, V266, P10287; Bazin HG, 2002, BIOCHEMISTRY-US, V41, P8203, DOI 10.1021/bi025817e; Beigneux AP, 2009, ARTERIOSCL THROM VAS, V29, P956, DOI 10.1161/ATVBAHA.109.186577; Belting M, 2003, TRENDS BIOCHEM SCI, V28, P145, DOI 10.1016/S0968-0004(03)00031-8; Bernfield M, 1999, ANNU REV BIOCHEM, V68, P729, DOI 10.1146/annurev.biochem.68.1.729; Bethea HN, 2008, P NATL ACAD SCI USA, V105, P18724, DOI 10.1073/pnas.0806975105; Boren J, 1998, J CLIN INVEST, V101, P2658, DOI 10.1172/JCI2265; Bullock SL, 1998, GENE DEV, V12, P1894, DOI 10.1101/gad.12.12.1894; Bulow HE, 2004, NEURON, V41, P723, DOI 10.1016/S0896-6273(04)00084-4; CARDIN AD, 1989, ARTERIOSCLEROSIS, V9, P21, DOI 10.1161/01.ATV.9.1.21; Conrad H. E., 1998, HEPARIN BINDING PROT; Dong J, 2001, BIOCHEMISTRY-US, V40, P2826, DOI 10.1021/bi002417n; DULBECCO R, 1954, J EXP MED, V99, P167, DOI 10.1084/jem.99.2.167; Elson-Schwab L, 2007, J BIOL CHEM, V282, P13585, DOI 10.1074/jbc.M700463200; Esko JD, 2002, ANNU REV BIOCHEM, V71, P435, DOI 10.1146/annurev.biochem.71.110601.135458; Esko JD, 2001, J CLIN INVEST, V108, P169, DOI 10.1172/JCI200113530; Flood C, 2002, J BIOL CHEM, V277, P32228, DOI 10.1074/jbc.M204053200; Fuki IV, 2000, J BIOL CHEM, V275, P25742, DOI 10.1074/jbc.M909173199; Fuki IV, 2003, J BIOL CHEM, V278, P34331, DOI 10.1074/jbc.M302181200; Fuki IV, 1997, J CLIN INVEST, V100, P1611, DOI 10.1172/JCI119685; Goldberg IJ, 1998, J BIOL CHEM, V273, P35355, DOI 10.1074/jbc.273.52.35355; Grobe K, 2005, DEVELOPMENT, V132, P3777, DOI 10.1242/dev.01935; Habuchi H, 2007, J BIOL CHEM, V282, P15578, DOI 10.1074/jbc.M607434200; HAVEL RJ, 2001, METABOLIC MOL BASES, P2705; Horton JD, 1999, J CLIN INVEST, V103, P1067, DOI 10.1172/JCI6246; Ishibashi S, 1996, J BIOL CHEM, V271, P22422, DOI 10.1074/jbc.271.37.22422; ISHIHARA M, 1993, GLYCOBIOLOGY, V3, P83, DOI 10.1093/glycob/3.1.83; Izvolsky KI, 2008, GENESIS, V46, P8, DOI 10.1002/dvg.20355; Jakel H, 2006, ANN MED, V38, P2, DOI 10.1080/07853890500407488; Jaye M, 1999, NAT GENET, V21, P424, DOI 10.1038/7766; JI ZS, 1994, J BIOL CHEM, V269, P13421; JI ZS, 1994, J BIOL CHEM, V269, P13429; JI ZS, 1993, J BIOL CHEM, V268, P10160; Ji ZS, 1997, J BIOL CHEM, V272, P31285, DOI 10.1074/jbc.272.50.31285; JI ZS, 1995, J LIPID RES, V36, P583; JI ZS, 1994, ARTERIOSCLER THROMB, V14, P2025, DOI 10.1161/01.ATV.14.12.2025; Kamimura K, 2006, J CELL BIOL, V174, P773, DOI 10.1083/jcb.200603129; Kreuger J, 2006, J CELL BIOL, V174, P323, DOI 10.1083/jcb.200604035; KUSCHE M, 1990, J BIOL CHEM, V265, P15403; LARNKJAER A, 1995, BIOCHEM J, V307, P205, DOI 10.1042/bj3070205; Lawrence R, 2008, NAT METHODS, V5, P291, DOI 10.1038/nmeth0408-291; Ledin J, 2004, J BIOL CHEM, V279, P42732, DOI 10.1074/jbc.M405382200; Libeu CP, 2001, J BIOL CHEM, V276, P39138, DOI 10.1074/jbc.M104746200; Lookene A, 2005, J BIOL CHEM, V280, P25383, DOI 10.1074/jbc.M501589200; MacArthur JM, 2007, J CLIN INVEST, V117, P153, DOI 10.1172/JCI29154; Mahley RW, 1999, J LIPID RES, V40, P1; MERCHANT ZM, 1986, ATHEROSCLEROSIS, V62, P151, DOI 10.1016/0021-9150(86)90061-4; Merry CLR, 2001, J BIOL CHEM, V276, P35429, DOI 10.1074/jbc.M100379200; MORTIMER BC, 1995, J BIOL CHEM, V270, P28767, DOI 10.1074/jbc.270.48.28767; ORBAN PC, 1992, P NATL ACAD SCI USA, V89, P6861, DOI 10.1073/pnas.89.15.6861; Otarod Jila Kaberi, 2004, Curr Atheroscler Rep, V6, P335, DOI 10.1007/s11883-004-0043-4; PARTHASARATHY N, 1994, J BIOL CHEM, V269, P22391; Postic C, 2000, GENESIS, V26, P149, DOI 10.1002/(SICI)1526-968X(200002)26:2<149::AID-GENE16>3.0.CO;2-V; Ringvall M, 2000, J BIOL CHEM, V275, P25926, DOI 10.1074/jbc.C000359200; Rong JH, 2001, BIOCHEMISTRY-US, V40, P5548, DOI 10.1021/bi002926p; SALACINSKI PRP, 1981, ANAL BIOCHEM, V117, P136, DOI 10.1016/0003-2697(81)90703-X; Sendak RA, 2000, J LIPID RES, V41, P260; Spillmann D, 2006, J BIOL CHEM, V281, P23405, DOI 10.1074/jbc.M604702200; Toyoda H, 2000, J BIOL CHEM, V275, P21856, DOI 10.1074/jbc.M003540200; van Dijk KW, 2004, CURR OPIN LIPIDOL, V15, P239, DOI [10.1097/01.mol.00001300096.77252.1f, 10.1097/00041433-200406000-00002]; VARKI A, 2009, ESSENTIALS GLYCOBIOL, P12; Williams K J, 2001, Methods Mol Biol, V171, P457; Williams KJ, 1997, CURR OPIN LIPIDOL, V8, P253; WILLIAMS KJ, 1992, J BIOL CHEM, V267, P13284; Wilsie LC, 2003, J BIOL CHEM, V278, P15758, DOI 10.1074/jbc.M208786200; Windler E, 1996, HEPATOLOGY, V24, P344; YOUNG SG, 1986, CLIN CHEM, V32, P1484; Yu W, 2006, BIOCHEM BIOPH RES CO, V343, P659, DOI 10.1016/j.bbrc.2006.02.175; Zeng BJ, 1998, J LIPID RES, V39, P845	71	65	66	1	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 1	2010	285	1					286	294		10.1074/jbc.M109.063701	http://dx.doi.org/10.1074/jbc.M109.063701			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	536UT	19889634	hybrid, Green Published			2022-12-25	WOS:000273070100030
J	van der Wijst, J; Glaudemans, B; Venselaar, H; Nair, AV; Forst, AL; Hoenderop, JGJ; Bindels, RJM				van der Wijst, Jenny; Glaudemans, Bob; Venselaar, Hanka; Nair, Anil V.; Forst, Anna-Lena; Hoenderop, Joost G. J.; Bindels, Rene J. M.			Functional Analysis of the Kv1.1 N255D Mutation Associated with Autosomal Dominant Hypomagnesemia	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POTASSIUM CHANNEL GENE; EPISODIC ATAXIA TYPE-1; MAMMALIAN K+ CHANNEL; GATED ION CHANNELS; KCNA1; INACTIVATION; EXPRESSION; DIVERSITY; RESIDUES; EPILEPSY	Mutations in the voltage-gated K+ channel Kv1.1 have been linked with a mixed phenotype of episodic ataxia and/or myokymia. Recently, we presented autosomal dominant hypomagnesemia as a new phenotypic characteristic associated with a mutation in Kv1.1 (N255D) (Glaudemans, B., van der Wijst, J., Scola, R. H., Lorenzoni, P. J., Heister, A., van der Kemp, A. W., Knoers, N.V., Hoenderop, J. G., and Bindels, R. J. (2009) J. Clin. Invest. 119, 936-942). A conserved asparagine at position 255 in the third transmembrane segment was converted into an aspartic acid, resulting in a non-functional channel. In this study, we explored the functional consequence of this conserved residue by substitution with other hydrophobic, polar, or charged amino acids (N255E, N255Q, N255A, N255V, N255T, and N255H). Upon overexpression in human embryonic kidney (HEK293) cells, cell surface biotinylation revealed plasma membrane expression of all mutant channels. Next, we used the whole-cell patch clamp technique to demonstrate that the N255E and N255Q mutants were non-functional. Substitution of Asn-255 with other amino acids (N255A, N255V, N255T, and N255H) did not prevent ion conduction, and these mutant channels activated at more negative potentials when compared with wild-type channels, -41.5 +/- 1.6, -45.5 +/- 2.0, -50.5 +/- 1.9, and -33.8 +/- 1.3 mV to -29.4 +/- 1.1 mV, respectively. The time constant of activation was significantly faster for the two most hydrophobic mutations, N255A (6.2 +/- 0.2 ms) and N255V (5.2 +/- 0.3 ms), and the hydrophilic mutant N255T (9.8 +/- 0.4 ms) in comparison with wild type (13.0 +/- 0.9 ms). Furthermore, the voltage dependence of inactivation was shifted similar to 13 mV to more negative potentials in all mutant channels except for N255H. Taken together, our data showed that an asparagine at position 255 in Kv1.1 is required for normal voltage dependence and kinetics of channel gating.	[van der Wijst, Jenny; Glaudemans, Bob; Nair, Anil V.; Forst, Anna-Lena; Hoenderop, Joost G. J.; Bindels, Rene J. M.] Radboud Univ Nijmegen, Med Ctr, Dept Physiol, NL-6500 HB Nijmegen, Netherlands; [Venselaar, Hanka] Radboud Univ Nijmegen, Med Ctr, Ctr Mol & Biomol Informat, NL-6500 HB Nijmegen, Netherlands	Radboud University Nijmegen; Radboud University Nijmegen	Bindels, RJM (corresponding author), Radboud Univ Nijmegen, Med Ctr, Dept Physiol, 286 Physiol,POB 9101, NL-6500 HB Nijmegen, Netherlands.	r.bindels@fysiol.umcn.nl	Forst, Anna-Lena/K-1909-2015; van der Wijst, Jenny/D-9726-2016; Hoenderop, Joost G.J./H-8047-2014; Venselaar, Hanka/D-2009-2016; Bindels, René JM/B-9824-2013; van der Wijst, Jenny/T-1620-2019	van der Wijst, Jenny/0000-0002-1547-516X; Hoenderop, Joost G.J./0000-0002-1816-8544; Venselaar, Hanka/0000-0001-9824-6559; Bindels, René JM/0000-0003-1167-1339; van der Wijst, Jenny/0000-0002-1547-516X	Netherlands Organization for Scientific Research [ZonMw 9120.6110, NWO-CW 700.55.302, ZonMw 9120.8026]; European Science Foundation; Dutch Kidney foundation [C03.6017, C08.2252]	Netherlands Organization for Scientific Research(Netherlands Organization for Scientific Research (NWO)); European Science Foundation(European Science Foundation (ESF)European Commission); Dutch Kidney foundation	This work was supported by grants from the Netherlands Organization for Scientific Research (Grants ZonMw 9120.6110, NWO-CW 700.55.302, and ZonMw 9120.8026), a European Young Investigator award from the European Science Foundation, and the Dutch Kidney foundation (Grants C03.6017 and C08.2252).	Aggarwal SK, 1996, NEURON, V16, P1169, DOI 10.1016/S0896-6273(00)80143-9; Armstrong Clay M, 2003, Sci STKE, V2003, pre10, DOI 10.1126/stke.2003.188.re10; ARMSTRONG CM, 1974, J GEN PHYSIOL, V63, P533, DOI 10.1085/jgp.63.5.533; Armstrong CM, 1998, NEURON, V20, P371, DOI 10.1016/S0896-6273(00)80981-2; BROWNE DL, 1994, NAT GENET, V8, P136, DOI 10.1038/ng1094-136; Chang Q, 2005, SCIENCE, V310, P490, DOI 10.1126/science.1114245; Chen HJ, 2007, NEUROGENETICS, V8, P131, DOI 10.1007/s10048-006-0071-z; Christie MJ, 1995, CLIN EXP PHARMACOL P, V22, P944, DOI 10.1111/j.1440-1681.1995.tb02331.x; Dolly JO, 1996, J BIOENERG BIOMEMBR, V28, P231, DOI 10.1007/BF02110698; Eunson LH, 2000, ANN NEUROL, V48, P647; Gkika D, 2006, EMBO J, V25, P4707, DOI 10.1038/sj.emboj.7601357; Glaudemans B, 2009, J CLIN INVEST, V119, P936, DOI 10.1172/JCI36948; Grottesi A, 2005, CURR BIOL, V15, pR771, DOI 10.1016/j.cub.2005.08.054; Gulbis JM, 2002, NOVART FDN SYMP, V245, P127; Hille B., 2001, ION CHANNELS EXCITAB, P131; Joosten RP, 2009, ACTA CRYSTALLOGR D, V65, P176, DOI 10.1107/S0907444908037591; Klein A, 2004, NEUROPEDIATRICS, V35, P147, DOI 10.1055/s-2004-817921; Krieger E, 2002, PROTEINS, V47, P393, DOI 10.1002/prot.10104; Lee Hane, 2004, Hum Mutat, V24, P536, DOI 10.1002/humu.9295; LIMAN ER, 1991, NATURE, V353, P752, DOI 10.1038/353752a0; Long SB, 2005, SCIENCE, V309, P897, DOI 10.1126/science.1116269; Long SB, 2007, NATURE, V450, P376, DOI 10.1038/nature06265; O'Grady SM, 2005, INT J BIOCHEM CELL B, V37, P1578, DOI 10.1016/j.biocel.2005.04.002; PANYI G, 1995, BIOPHYS J, V69, P896, DOI 10.1016/S0006-3495(95)79963-5; Pathak MM, 2007, NEURON, V56, P124, DOI 10.1016/j.neuron.2007.09.023; PLANELLSCASES R, 1995, P NATL ACAD SCI USA, V92, P9422, DOI 10.1073/pnas.92.20.9422; SANDER C, 1991, PROTEINS, V9, P56, DOI 10.1002/prot.340090107; Sands Z, 2005, CURR BIOL, V15, pR44, DOI 10.1016/j.cub.2004.12.050; Shook SJ, 2008, MUSCLE NERVE, V37, P399, DOI 10.1002/mus.20904; SIGWORTH FJ, 1994, Q REV BIOPHYS, V27, P1, DOI 10.1017/S0033583500002894; Smart SL, 1998, NEURON, V20, P809, DOI 10.1016/S0896-6273(00)81018-1; Sokolov MV, 2007, NEUROPHARMACOLOGY, V53, P272, DOI 10.1016/j.neuropharm.2007.05.008; Swartz KJ, 2004, NAT REV NEUROSCI, V5, P905, DOI 10.1038/nrn1559; YELLEN G, 1994, BIOPHYS J, V66, P1068, DOI 10.1016/S0006-3495(94)80888-4; Zerr P, 1998, J NEUROSCI, V18, P2842; Zhu J, 2003, J BIOL CHEM, V278, P25558, DOI 10.1074/jbc.M207984200; Zuberi SM, 1999, BRAIN, V122, P817, DOI 10.1093/brain/122.5.817; [No title captured]	38	34	35	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 1	2010	285	1					171	178		10.1074/jbc.M109.041517	http://dx.doi.org/10.1074/jbc.M109.041517			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	536UT	19903818	Green Published, hybrid			2022-12-25	WOS:000273070100018
J	Lin, CH; Lin, C; Tanaka, H; Fero, ML; Eisenman, RN				Lin, Chin-Hsing; Lin, ChenWei; Tanaka, Hisashi; Fero, Matthew L.; Eisenman, Robert N.			Gene Regulation and Epigenetic Remodeling in Murine Embryonic Stem Cells by c-Myc	PLOS ONE			English	Article							SELF-RENEWAL; DEVELOPMENTAL REGULATORS; TRANSCRIPTIONAL NETWORK; GENOMIC TARGETS; RIBOSOMAL DNA; PLURIPOTENCY; CHROMATIN; POLYCOMB; ACTIVATION; DIFFERENTIATION	Background: The Myc oncoprotein, a transcriptional regulator involved in the etiology of many different tumor types, has been demonstrated to play an important role in the functions of embryonic stem (ES) cells. Nonetheless, it is still unclear as to whether Myc has unique target and functions in ES cells. Methodology/Principal Findings: To elucidate the role of c-Myc in murine ES cells, we mapped its genomic binding sites by chromatin-immunoprecipitation combined with DNA microarrays (ChIP-chip). In addition to previously identified targets we identified genes involved in pluripotency, early development, and chromatin modification/structure that are bound and regulated by c-Myc in murine ES cells. Myc also binds and regulates loci previously identified as Polycomb (PcG) targets, including genes that contain bivalent chromatin domains. To determine whether c-Myc influences the epigenetic state of Myc-bound genes, we assessed the patterns of trimethylation of histone H3-K4 and H3-K27 in mES cells containing normal, increased, and reduced levels of c-Myc. Our analysis reveals widespread and surprisingly diverse changes in repressive and activating histone methylation marks both proximal and distal to Myc binding sites. Furthermore, analysis of bulk chromatin from phenotypically normal c-myc null E7 embryos demonstrates a 70-80% decrease in H3-K4me3, with little change in H3-K27me3, compared to wild-type embryos indicating that Myc is required to maintain normal levels of histone methylation. Conclusions/Significance: We show that Myc induces widespread and diverse changes in histone methylation in ES cells. We postulate that these changes are indirect effects of Myc mediated by its regulation of target genes involved in chromatin remodeling. We further show that a subset of PcG-bound genes with bivalent histone methylation patterns are bound and regulated in response to altered c-Myc levels. Our data indicate that in mES cells c-Myc binds, regulates, and influences the histone modification patterns of genes involved in chromatin remodeling, pluripotency, and differentiation.			Lin, CH (corresponding author), Fred Hutchinson Canc Res Ctr, Div Basic Sci, 1124 Columbia St, Seattle, WA 98104 USA.	eisenman@fhcrc.org		Tanaka, Hisashi/0000-0001-9223-4186; Fero, Matthew/0000-0002-9967-4659	NATIONAL CANCER INSTITUTE [R01CA020525] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA20525, R01 CA020525] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Adhikary S, 2005, NAT REV MOL CELL BIO, V6, P635, DOI 10.1038/nrm1703; Arabi A, 2005, NAT CELL BIOL, V7, P303, DOI 10.1038/ncb1225; Arnold I, 2001, CURR BIOL, V11, P558, DOI 10.1016/S0960-9822(01)00154-3; Avilion AA, 2003, GENE DEV, V17, P126, DOI 10.1101/gad.224503; Azuara V, 2006, NAT CELL BIOL, V8, P532, DOI 10.1038/ncb1403; Bechard M, 2009, MOL CELL BIOL, V29, P2092, DOI 10.1128/MCB.01405-08; Bernstein BE, 2006, CELL, V125, P315, DOI 10.1016/j.cell.2006.02.041; Boyer LA, 2006, NATURE, V441, P349, DOI 10.1038/nature04733; Boyer LA, 2005, CELL, V122, P947, DOI 10.1016/j.cell.2005.08.020; Bracken AP, 2006, GENE DEV, V20, P1123, DOI 10.1101/gad.381706; Cartwright P, 2005, DEVELOPMENT, V132, P885, DOI 10.1242/dev.01670; Chambers I, 2003, CELL, V113, P643, DOI 10.1016/S0092-8674(03)00392-1; Chen X, 2008, CELL, V133, P1106, DOI 10.1016/j.cell.2008.04.043; Cole MD, 2006, CURR TOP MICROBIOL, V302, P33; Cotterman R, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005799; DAVIS AC, 1993, GENE DEV, V7, P671, DOI 10.1101/gad.7.4.671; Dubois NC, 2008, DEVELOPMENT, V135, P2455, DOI 10.1242/dev.022707; Efroni S, 2008, CELL STEM CELL, V2, P437, DOI 10.1016/j.stem.2008.03.021; Eisenman RN, 2001, GENE DEV, V15, P2023, DOI 10.1101/gad928101; Fernandez PC, 2003, GENE DEV, V17, P1115, DOI 10.1101/gad.1067003; Frank SR, 2003, EMBO REP, V4, P575, DOI 10.1038/sj.embor.embor861; Gandarillas A, 1997, GENE DEV, V11, P2869, DOI 10.1101/gad.11.21.2869; Garcia-Bassets I, 2007, CELL, V128, P505, DOI 10.1016/j.cell.2006.12.038; Gaspar-Maia A, 2009, NATURE, V460, P863, DOI 10.1038/nature08212; Gomez-Roman N, 2003, NATURE, V421, P290, DOI 10.1038/nature01327; Goodliffe JM, 2005, GENE DEV, V19, P2941, DOI 10.1101/gad.1352305; Goodliffe JM, 2007, BMC MOL BIOL, V8, DOI 10.1186/1471-2199-8-40; Grandori C, 2005, NAT CELL BIOL, V7, P311, DOI 10.1038/ncb1224; Guccione E, 2006, NAT CELL BIOL, V8, P764, DOI 10.1038/ncb1434; Habib T, 2007, J CELL BIOL, V179, P717, DOI 10.1083/jcb.200704173; Henikoff S, 2008, NAT REV GENET, V9, P15, DOI 10.1038/nrg2206; Hooker CW, 2006, J CELL SCI, V119, P208, DOI 10.1242/jcs.02815; Ivanova NB, 2002, SCIENCE, V298, P601, DOI 10.1126/science.1073823; Jaenisch R, 2008, CELL, V132, P567, DOI 10.1016/j.cell.2008.01.015; Kidder BL, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003932; Kim JW, 2008, CELL, V132, P1049, DOI 10.1016/j.cell.2008.02.039; Kleine-Kohlbrecher D, 2006, CURR TOP MICROBIOL, V302, P51; Knoepfler PS, 2006, EMBO J, V25, P2723, DOI 10.1038/sj.emboj.7601152; Laurenti E, 2008, CELL STEM CELL, V3, P611, DOI 10.1016/j.stem.2008.09.005; Lawlor ER, 2006, CANCER RES, V66, P4591, DOI 10.1158/0008-5472.CAN-05-3826; Lee TI, 2006, CELL, V125, P301, DOI 10.1016/j.cell.2006.02.043; Li F, 2005, MOL CELL BIOL, V25, P6225, DOI 10.1128/MCB.25.14.6225-6234.2005; Li ZR, 2003, P NATL ACAD SCI USA, V100, P8164, DOI 10.1073/pnas.1332764100; LIN CH, 2009, EMBO J IN PRESS; Loh YH, 2006, NAT GENET, V38, P431, DOI 10.1038/ng1760; Loh YH, 2007, GENE DEV, V21, P2545, DOI 10.1101/gad.1588207; Maherali N, 2007, CELL STEM CELL, V1, P55, DOI 10.1016/j.stem.2007.05.014; Mao DYL, 2003, CURR BIOL, V13, P882, DOI 10.1016/S0960-9822(03)00297-5; Martinato F, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003650; MEISSNER A, 2007, NAT BIOTECHNOL; Meshorer E, 2006, DEV CELL, V10, P105, DOI 10.1016/j.devcel.2005.10.017; Meshorer E, 2006, NAT REV MOL CELL BIO, V7, P540, DOI 10.1038/nrm1938; Mikkelsen TS, 2007, NATURE, V448, P553, DOI 10.1038/nature06008; Mitsui K, 2003, CELL, V113, P631, DOI 10.1016/S0092-8674(03)00393-3; Morrish F, 2008, CELL CYCLE, V7, P1054, DOI 10.4161/cc.7.8.5739; Murphy MJ, 2005, TRENDS CELL BIOL, V15, P128, DOI 10.1016/j.tcb.2005.01.008; NAKAGAWA M, 2007, NAT BIOTECHNOL; Nichols J, 1998, CELL, V95, P379, DOI 10.1016/S0092-8674(00)81769-9; Niwa H, 2007, GENE DEV, V21, P2071, DOI 10.1101/gad.1615707; Orian A, 2003, GENE DEV, V17, P1101, DOI 10.1101/gad.1066903; Pan GJ, 2007, CELL STEM CELL, V1, P299, DOI 10.1016/j.stem.2007.08.003; Park IH, 2008, NATURE, V451, P141, DOI [10.1038/nature06534, 10.1038/natureO6534]; Pasini D, 2007, MOL CELL BIOL, V27, P3769, DOI 10.1128/MCB.01432-06; Patel JH, 2004, NAT REV CANCER, V4, P562, DOI 10.1038/nrc1393; Reik W, 2007, NATURE, V447, P425, DOI 10.1038/nature05918; Scacheri PC, 2006, METHOD ENZYMOL, V411, P270, DOI 10.1016/S0076-6879(06)11014-9; Scacheri PC, 2006, PLOS GENET, V2, P406, DOI 10.1371/journal.pgen.0020051; Schoeftner S, 2006, EMBO J, V25, P3110, DOI 10.1038/sj.emboj.7601187; Secombe J, 2007, GENE DEV, V21, P537, DOI 10.1101/gad.1523007; Shilatifard A, 2006, ANNU REV BIOCHEM, V75, P243, DOI 10.1146/annurev.biochem.75.103004.142422; Silva J, 2008, CELL, V132, P532, DOI 10.1016/j.cell.2008.02.006; Takahashi K, 2007, CELL, V131, P861, DOI 10.1016/j.cell.2007.11.019; Takahashi K, 2006, CELL, V126, P663, DOI 10.1016/j.cell.2006.07.024; Thomas PD, 2003, GENOME RES, V13, P2129, DOI 10.1101/gr.772403; Wernig M, 2008, CELL STEM CELL, V2, P10, DOI 10.1016/j.stem.2007.12.001; Wernig M, 2007, NATURE, V448, P318, DOI 10.1038/nature05944; Wilson A, 2004, GENE DEV, V18, P2747, DOI 10.1101/gad.313104; Wong DJ, 2008, CELL STEM CELL, V2, P333, DOI 10.1016/j.stem.2008.02.009; Yu JY, 2007, SCIENCE, V318, P1917, DOI 10.1126/science.1151526; Zeller KI, 2006, P NATL ACAD SCI USA, V103, P17834, DOI 10.1073/pnas.0604129103; Zhao XD, 2007, CELL STEM CELL, V1, P286, DOI 10.1016/j.stem.2007.08.004; Zhong JF, 2005, P NATL ACAD SCI USA, V102, P2448, DOI 10.1073/pnas.0409459102	82	59	60	0	7	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	NOV 13	2009	4	11							e7839	10.1371/journal.pone.0007839	http://dx.doi.org/10.1371/journal.pone.0007839			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	518VB	19915707	Green Submitted, Green Published, gold			2022-12-25	WOS:000271721900024
J	Fredholm, H; Eaker, S; Frisell, J; Holmberg, L; Fredriksson, I; Lindman, H				Fredholm, Hanna; Eaker, Sonja; Frisell, Jan; Holmberg, Lars; Fredriksson, Irma; Lindman, Henrik			Breast Cancer in Young Women: Poor Survival Despite Intensive Treatment	PLOS ONE			English	Article							AGE 30 YEARS; PROGNOSTIC-FACTOR; CONSERVING THERAPY; LESS-THAN-35 YEARS; LOCAL RECURRENCE; RISK-FACTORS; STAGE-I; CARCINOMA; DIAGNOSIS; FEATURES	Background: Breast cancer is uncommon in young women and correlates with a less favourable prognosis; still it is the most frequent cancer in women under 40, accounting for 30-40% of all incident female cancer. The aim of this study was to study prognosis in young women, quantifying how much stage at diagnosis and management on the one hand, and tumour biology on the other; each contribute to the worse prognosis seen in this age group. Methodology/Principal Findings: In a registry based cohort of women aged 20-69 (n = 22 017) with a primary diagnosis of invasive breast cancer (1992-2005), women aged 20-34 (n = 471), 35-39 (n = 858) and 40-49 (n = 4789) were compared with women aged 50-69 years (n = 15 899). The cumulative 5-year relative survival ratio and the relative excess mortality (RER) were calculated. The cumulative 5-year relative survival ratio was lowest in women aged 20-34. The RER was 2.84 for women aged 20-34 and decreased with increasing age (RER 1.76 and 1.17 for women aged 35-39 and 40-49, respectively). The excess risk was, however, present only in disease stages I and II. For women aged 20-34 with stage I disease RER was 4.63, and 6.70 in the subgroup with tumour size 1-10 mm. The absolute difference in stage I between the youngest and the reference groups amounted to nearly 8%, with a 90% 5-year survival in women aged 20-34. In stages IIa and IIb, the relative excess risk was not as dramatic, but the absolute differences approached 15%. The youngest women with small tumours generally received more aggressive treatment than women in older age groups. Conclusions: After correction for stage, tumour characteristics and treatment, age remained an independent risk factor for breast cancer death in women,35 years of age. The excess risk for young women was only seen in early stages of disease and was most pronounced in women with small tumours. Young women affected by breast cancer have a high risk of dying compared to their middle-aged counterparts even if diagnosed early and receiving an intense treatment.			Fredholm, H (corresponding author), Karolinska Univ Hosp, Karolinska Inst, Dept Mol Med & Surg, Stockholm, Sweden.	hanna.fredholm@ki.se		Fredriksson, Irma/0000-0001-7811-9317				Abe O, 2005, LANCET, V366, P2087; ADAMI HO, 1986, NEW ENGL J MED, V315, P559, DOI 10.1056/NEJM198608283150906; ADAMI HO, 1985, CANCER-AM CANCER SOC, V56, P898, DOI 10.1002/1097-0142(19850815)56:4<898::AID-CNCR2820560433>3.0.CO;2-L; Aebi S, 2000, LANCET, V355, P1869, DOI 10.1016/S0140-6736(00)02292-3; Ahn SH, 2007, J CLIN ONCOL, V25, P2360, DOI 10.1200/JCO.2006.10.3754; Anders CK, 2008, J CLIN ONCOL, V26, P3324, DOI 10.1200/JCO.2007.14.2471; ASPEGREN K, 1988, BRIT J SURG, V75, P807, DOI 10.1002/bjs.1800750829; BARLOW L, 2008, ACTA ONCOL, P1; BOFFETTA P, 1993, CANCER CAUSE CONTROL, V4, P209; BONNIER P, 1995, INT J CANCER, V62, P138, DOI 10.1002/ijc.2910620205; BOTTOM O, 2006, NIH PUB; Brenner H, 2004, J CLIN ONCOL, V22, P432, DOI 10.1200/JCO.2004.04.067; Brinton LA, 2008, JNCI-J NATL CANCER I, V100, P1643, DOI 10.1093/jnci/djn344; Chung M, 1996, CANCER, V77, P97, DOI 10.1002/(SICI)1097-0142(19960101)77:1<97::AID-CNCR16>3.3.CO;2-T; Colleoni M, 2002, ANN ONCOL, V13, P273, DOI 10.1093/annonc/mdf039; DELAROCHEFORDIERE A, 1993, LANCET, V341, P1039, DOI 10.1016/0140-6736(93)92407-K; Dickman PW, 2004, STAT MED, V23, P51, DOI 10.1002/sim.1597; Eaker S, 2006, PLOS MED, V3, P321, DOI 10.1371/journal.pmed.0030025; EDERER FRED, 1961, NATL CANCER INST MONOGR, V6, P101; FOWBLE BL, 1994, INT J RADIAT ONCOL, V30, P23, DOI 10.1016/0360-3016(94)90515-0; Fredriksson I, 2003, BRIT J SURG, V90, P1093, DOI 10.1002/bjs.4206; Gajdos C, 2000, J AM COLL SURGEONS, V190, P523, DOI 10.1016/S1072-7515(00)00257-X; Goldhirsch A, 1998, J NATL CANCER I, V90, P1601, DOI 10.1093/jnci/90.21.1601; Goldhirsch A, 2001, J Natl Cancer Inst Monogr, P44; HOST H, 1986, CANCER-AM CANCER SOC, V57, P2217, DOI 10.1002/1097-0142(19860601)57:11<2217::AID-CNCR2820571124>3.0.CO;2-T; KEMETLI L, 2008, TEMPORAL TRENDS USE, P1; Krag D, 1998, NEW ENGL J MED, V339, P941, DOI 10.1056/NEJM199810013391401; Kroman N, 2000, BRIT MED J, V320, P474, DOI 10.1136/bmj.320.7233.474; Liebens FP, 2007, EUR J CANCER, V43, P238, DOI 10.1016/j.ejca.2006.07.019; Maggard MA, 2003, J SURG RES, V113, P109, DOI 10.1016/S0022-4804(03)00179-3; Mariotto Angela B, 2006, J Natl Cancer Inst Monogr, P7, DOI 10.1093/jncimonographs/lgj003; Marrett Loraine D, 2002, Chronic Dis Can, V23, P58; Maru D, 2005, CANCER-AM CANCER SOC, V103, P900, DOI 10.1002/cncr.20850; MATTSSON B, 1984, ACTA RADIOL ONCOL, V23, P305, DOI 10.3109/02841868409136026; NIXON AJ, 1994, J CLIN ONCOL, V12, P888, DOI 10.1200/JCO.1994.12.5.888; Paik S, 2004, NEW ENGL J MED, V351, P2817, DOI 10.1056/NEJMoa041588; Ries L., 2005, SEER CANC STAT REV 1; Sant M, 1998, INT J CANCER, V77, P679, DOI 10.1002/(SICI)1097-0215(19980831)77:5<679::AID-IJC3>3.0.CO;2-S; SIEGEL BM, 1990, ARCH SURG-CHICAGO, V125, P1144; Sobin, 2009, UICC TNM CLASSIFICAT; *STAT SWED, 2008, POP STAT SWED; Tabar L, 2004, CANCER-AM CANCER SOC, V101, P1745, DOI 10.1002/cncr.20582; Tai P, 2005, BMC CANCER, V5, DOI 10.1186/1471-2407-5-130; Tataru D, 2006, J PUBLIC HEALTH, V28, P215, DOI 10.1093/pubmed/fdl011; Voogd AC, 2001, J CLIN ONCOL, V19, P1688, DOI 10.1200/JCO.2001.19.6.1688; Vrieling C, 2003, EUR J CANCER, V39, P932, DOI 10.1016/S0959-8049(03)00123-0; Walker RA, 1996, BRIT J CANCER, V74, P1796, DOI 10.1038/bjc.1996.632; Winchester DP, 1996, CANCER-AM CANCER SOC, V78, P1838, DOI 10.1002/(SICI)1097-0142(19961015)78:8<1838::AID-CNCR27>3.0.CO;2-Y; Xiong QH, 2001, CANCER, V92, P2523, DOI 10.1002/1097-0142(20011115)92:10<2523::AID-CNCR1603>3.0.CO;2-6	49	308	315	1	18	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	NOV 11	2009	4	11					A38	A46	e7695	10.1371/journal.pone.0007695	http://dx.doi.org/10.1371/journal.pone.0007695			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	518IX	19907646	Green Submitted, gold, Green Published			2022-12-25	WOS:000271685800005
J	Haghighi, HR; Read, LR; Haeryfar, SMM; Behboudi, S; Sharif, S				Haghighi, Hamid R.; Read, Leah R.; Haeryfar, S. M. Mansour; Behboudi, Shahriar; Sharif, Shayan			Identification of a Dual-Specific T Cell Epitope of the Hemagglutinin Antigen of an H5 Avian Influenza Virus in Chickens	PLOS ONE			English	Article							CYTOKINE GENE-EXPRESSION; MHC CLASS-I; MAREKS-DISEASE; A VIRUS; FOWLPOX VIRUS; INFECTION; CD4(+); PROTECTION; PEPTIDE; VACCINE	Avian influenza viruses (AIV) of the H5N1 subtype have caused morbidity and mortality in humans. Although some migratory birds constitute the natural reservoir for this virus, chickens may play a role in transmission of the virus to humans. Despite the importance of avian species in transmission of AIV H5N1 to humans, very little is known about host immune system interactions with this virus in these species. The objective of the present study was to identify putative T cell epitopes of the hemagglutinin (HA) antigen of an H5 AIV in chickens. Using an overlapping peptide library covering the HA protein, we identified a 15-mer peptide, H5(246-260), within the HA1 domain which induced activation of T cells in chickens immunized against the HA antigen of an H5 virus. Furthermore, H5(246-260) epitope was found to be presented by both major histocompatibility complex (MHC) class I and II molecules, leading to activation of CD4+ and CD8+ T cell subsets, marked by proliferation and expression of interferon (IFN)-gamma by both of these cell subsets as well as the expression of granzyme A by CD8+ T cells. This is the first report of a T cell epitope of AIV recognized by chicken T cells. Furthermore, this study extends the previous finding of the existence of dual-specific epitopes in other species to chickens. Taken together, these results elucidate some of the mechanisms of immune response to AIV in chickens and provide a platform for creation of rational vaccines against AIV in this species.			Haghighi, HR (corresponding author), Univ Guelph, Dept Pathobiol, Guelph, ON N1G 2W1, Canada.	shayan@uoguelph.ca		behboudi, shahriar/0000-0001-6455-4086				Abdul-Careem MF, 2006, VIRAL IMMUNOL, V19, P167, DOI 10.1089/vim.2006.19.167; Abdul-Careem MF, 2007, VACCINE, V25, P424, DOI 10.1016/j.vaccine.2006.08.006; ADAMS SC, 2009, MOL IMMUNOL; Ayaru L, 2007, J IMMUNOL, V178, P1914, DOI 10.4049/jimmunol.178.3.1914; Ben-Yedidia T, 1999, INT IMMUNOL, V11, P1043, DOI 10.1093/intimm/11.7.1043; BENNINK JR, 1988, J EXP MED, V168, P1935, DOI 10.1084/jem.168.5.1935; Brincks EL, 2008, J IMMUNOL, V181, P4918, DOI 10.4049/jimmunol.181.7.4918; Brisbin JT, 2008, DEV COMP IMMUNOL, V32, P563, DOI 10.1016/j.dci.2007.09.003; Brown DM, 2004, SEMIN IMMUNOL, V16, P171, DOI 10.1016/j.smim.2004.02.004; Bui HH, 2007, P NATL ACAD SCI USA, V104, P246, DOI 10.1073/pnas.0609330104; Crowe SR, 2006, VACCINE, V24, P452, DOI 10.1016/j.vaccine.2005.07.090; Crowe SR, 2005, J IMMUNOL, V174, P696, DOI 10.4049/jimmunol.174.2.696; Falchetti R, 1996, CELL IMMUNOL, V170, P222, DOI 10.1006/cimm.1996.0155; Fomsgaard A, 1999, VACCINE, V18, P681, DOI 10.1016/S0264-410X(99)00279-0; Gelder C, 1998, INT IMMUNOL, V10, P211, DOI 10.1093/intimm/10.2.211; Homann D, 2007, VIROLOGY, V363, P113, DOI 10.1016/j.virol.2006.12.025; Kodihalli S, 1997, J VIROL, V71, P3391, DOI 10.1128/JVI.71.5.3391-3396.1997; LAWSON CM, 1994, J VIROL, V68, P3505, DOI 10.1128/JVI.68.6.3505-3511.1994; Lee LYH, 2008, J CLIN INVEST, V118, P3478, DOI 10.1172/JCI32460; Miller MM, 2004, IMMUNOGENETICS, V56, P261, DOI 10.1007/s00251-004-0682-1; Odunsi K, 2007, P NATL ACAD SCI USA, V104, P12837, DOI 10.1073/pnas.0703342104; Peiris JSM, 2007, CLIN MICROBIOL REV, V20, P243, DOI 10.1128/CMR.00037-06; Pfaffl MW, 2002, NUCLEIC ACIDS RES, V30, DOI 10.1093/nar/30.9.e36; Roti M, 2008, J IMMUNOL, V180, P1758, DOI 10.4049/jimmunol.180.3.1758; Sarson AJ, 2008, VIRAL IMMUNOL, V21, P267, DOI 10.1089/vim.2007.0094; Seo SH, 2002, J VIROL, V76, P4886, DOI 10.1128/JVI.76.10.4886-4890.2002; Seo SH, 2001, J VIROL, V75, P2516, DOI 10.1128/JVI.75.6.2516-2525.2001; Shams H, 2004, J IMMUNOL, V173, P1966, DOI 10.4049/jimmunol.173.3.1966; SHAPIRA M, 1984, P NATL ACAD SCI-BIOL, V81, P2461, DOI 10.1073/pnas.81.8.2461; Stevens J, 2006, SCIENCE, V312, P404, DOI 10.1126/science.1124513; Suarez DL, 2000, DEV COMP IMMUNOL, V24, P269, DOI 10.1016/S0145-305X(99)00078-6; Swain SL, 2006, IMMUNOL REV, V211, P8, DOI 10.1111/j.0105-2896.2006.00388.x; Swayne DE, 1997, AVIAN DIS, V41, P910, DOI 10.2307/1592346; Swayne DE, 2000, VACCINE, V18, P1088, DOI 10.1016/S0264-410X(99)00369-2; SWEETSER MT, 1989, NATURE, V342, P180, DOI 10.1038/342180a0; TAKAHASHI H, 1990, J EXP MED, V171, P571, DOI 10.1084/jem.171.2.571; Thomas PG, 2006, EMERG INFECT DIS, V12, P48, DOI 10.3201/eid1201.051237; Topham DJ, 1997, J IMMUNOL, V159, P5197; TRIPATHY DN, 1991, AVIAN DIS, V35, P186, DOI 10.2307/1591312; Ullenhag GJ, 2004, CANCER IMMUNOL IMMUN, V53, P331, DOI 10.1007/s00262-003-0441-4; van den Berg T, 2008, COMP IMMUNOL MICROB, V31, P121, DOI 10.1016/j.cimid.2007.07.004; Wang JH, 2001, P NATL ACAD SCI USA, V98, P10799, DOI 10.1073/pnas.191124098; Webby RJ, 2003, SCIENCE, V302, P1519, DOI 10.1126/science.1090350; WEBSTER RG, 1991, VACCINE, V9, P303, DOI 10.1016/0264-410X(91)90055-B	44	23	25	0	3	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA	1932-6203			PLOS ONE	PLoS One	NOV 10	2009	4	11							e7772	10.1371/journal.pone.0007772	http://dx.doi.org/10.1371/journal.pone.0007772			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	517ZU	19901990	Green Published, gold, Green Submitted			2022-12-25	WOS:000271658800010
J	Kumar, K; Tharad, M; Ganapathy, S; Ram, G; Narayan, A; Khan, JA; Pratap, R; Ghosh, A; Samuchiwal, SK; Kumar, S; Bhalla, K; Gupta, D; Natarajan, K; Singh, Y; Ranganathan, A				Kumar, Krishan; Tharad, Megha; Ganapathy, Swetha; Ram, Geeta; Narayan, Azeet; Khan, Jameel Ahmad; Pratap, Rana; Ghosh, Anamika; Samuchiwal, Sachin Kumar; Kumar, Sushil; Bhalla, Kuhulika; Gupta, Deepti; Natarajan, Krishnamurthy; Singh, Yogendra; Ranganathan, Anand			Phenylalanine-Rich Peptides Potently Bind ESAT6, a Virulence Determinant of Mycobacterium tuberculosis, and Concurrently Affect the Pathogen's Growth	PLOS ONE			English	Article							DE-NOVO PROTEINS; CULTURE FILTRATE; MYCOLIC ACIDS; BOVIS BCG; SECRETED PROTEIN; CFP-10; BIOSYNTHESIS; ANTIGENS; SYSTEM; ELECTROPHORESIS	Background: The secretory proteins of Mycobacterium tuberculosis (M. tuberculosis) have been known to be involved in the virulence, pathogenesis as well as proliferation of the pathogen. Among this set, many proteins have been hypothesized to play a critical role at the genesis of the onset of infection, the primary site of which is invariably the human lung. Methodology/Principal Findings: During our efforts to isolate potential binding partners of key secretory proteins of M. tuberculosis from a human lung protein library, we isolated peptides that strongly bound the virulence determinant protein Esat6. All peptides were less than fifty amino acids in length and the binding was confirmed by in vivo as well as in vitro studies. Curiously, we found all three binders to be unusually rich in phenylalanine, with one of the three peptides a short fragment of the human cytochrome c oxidase-3 (Cox-3). The most accessible of the three binders, named Hcl1, was shown also to bind to the Mycobacterium smegmatis (M. smegmatis) Esat6 homologue. Expression of hcl1 in M. tuberculosis H37Rv led to considerable reduction in growth. Microarray analysis showed that Hcl1 affects a host of key cellular pathways in M. tuberculosis. In a macrophage infection model, the sets expressing hcl1 were shown to clear off M. tuberculosis in much greater numbers than those infected macrophages wherein the M. tuberculosis was not expressing the peptide. Transmission electron microscopy studies of hcl1 expressing M. tuberculosis showed prominent expulsion of cellular material into the matrix, hinting at cell wall damage. Conclusions/Significance: While the debilitating effects of Hcl1 on M. tuberculosis are unrelated and not because of the peptide's binding to Esat6-as the latter is not an essential protein of M. tuberculosis-nonetheless, further studies with this peptide, as well as a closer inspection of the microarray data may shed important light on the suitability of such small phenylalanine-rich peptides as potential drug-like molecules against this pathogen.			Kumar, K (corresponding author), Int Ctr Genet Engn & Biotechnol, Recombinant Gene Prod Grp, New Delhi, India.	anand@icgeb.res.in	Samuchiwal, Sachin/AAL-2904-2021; Gupta, Deepti/U-1777-2019; Bhalla, Kuhulika/P-3280-2019; KUMAR, SUSHIL/T-8493-2017	Gupta, Deepti/0000-0001-7931-0017; Bhalla, Kuhulika/0000-0002-6608-2120; KUMAR, KRISHAN/0000-0003-3957-2084; Narayan, Azeet/0000-0003-1820-7934; SAMUCHIWAL, SACHIN/0000-0001-6232-5650; KUMAR, SUSHIL/0000-0001-8481-9221				ABOUZEID C, 1988, INFECT IMMUN, V56, P3046, DOI 10.1128/IAI.56.12.3046-3051.1988; ANDERSEN P, 1991, INFECT IMMUN, V59, P1905, DOI 10.1128/IAI.59.6.1905-1910.1991; Aravinda S, 2003, J AM CHEM SOC, V125, P5308, DOI 10.1021/ja0341283; BACKLOCK JWS, 1947, BRIT MED J, V24, P707; Barry CE, 1998, PROG LIPID RES, V37, P143, DOI 10.1016/S0163-7827(98)00008-3; Berthet FX, 1998, MICROBIOL-UK, V144, P3195, DOI 10.1099/00221287-144-11-3195; Bhatt A, 2007, P NATL ACAD SCI USA, V104, P5157, DOI 10.1073/pnas.0608654104; Brodin P, 2006, INFECT IMMUN, V74, P88, DOI 10.1128/IAI.74.1.88-98.2006; Cheadle C, 2003, J MOL DIAGN, V5, P73, DOI 10.1016/S1525-1578(10)60455-2; de Jonge MI, 2007, J BACTERIOL, V189, P6028, DOI 10.1128/JB.00469-07; Derrick SC, 2007, CELL MICROBIOL, V9, P1547, DOI 10.1111/j.1462-5822.2007.00892.x; Dubnau E, 2000, MOL MICROBIOL, V36, P630, DOI 10.1046/j.1365-2958.2000.01882.x; Dye C, 1999, JAMA-J AM MED ASSOC, V282, P677, DOI 10.1001/jama.282.7.677; Harboe M, 1996, INFECT IMMUN, V64, P16, DOI 10.1128/IAI.64.1.16-22.1996; Hsu T, 2003, P NATL ACAD SCI USA, V100, P12420, DOI 10.1073/pnas.1635213100; Jain A, 2008, FEMS IMMUNOL MED MIC, V53, P145, DOI 10.1111/j.1574-695X.2008.00400.x; Khatri GR, 2002, NEW ENGL J MED, V347, P1420, DOI 10.1056/NEJMsa020098; Lee IH, 1997, COMP BIOCHEM PHYS B, V118, P515, DOI 10.1016/S0305-0491(97)00109-0; Majlessi L, 2005, J IMMUNOL, V174, P3570, DOI 10.4049/jimmunol.174.6.3570; Miller J.H., 1972, EXPT MOL GENETICS; Mondal R, 2007, EMERG INFECT DIS, V13, P1429, DOI 10.3201/eid1309.070443; NAGAI S, 1991, INFECT IMMUN, V59, P372, DOI 10.1128/IAI.59.1.372-382.1991; Ojha A, 2005, CELL, V123, P861, DOI 10.1016/j.cell.2005.09.012; PEAKE P, 1993, INFECT IMMUN, V61, P4828, DOI 10.1128/IAI.61.11.4828-4834.1993; Provvedi R, 2009, MICROBIOL-SGM, V155, P1093, DOI 10.1099/mic.0.024802-0; Pym AS, 2002, MOL MICROBIOL, V46, P709, DOI 10.1046/j.1365-2958.2002.03237.x; Qamra R, 2005, TUBERCULOSIS, V85, P385, DOI 10.1016/j.tube.2005.08.014; Rao A, 2005, J BIOL CHEM, V280, P23605, DOI 10.1074/jbc.M503056200; Rao A, 2007, APPL ENVIRON MICROB, V73, P1320, DOI 10.1128/AEM.02461-06; Renshaw PS, 2002, J BIOL CHEM, V277, P21598, DOI 10.1074/jbc.M201625200; Renshaw PS, 2005, EMBO J, V24, P2491, DOI 10.1038/sj.emboj.7600732; Sassetti CM, 2003, P NATL ACAD SCI USA, V100, P12989, DOI 10.1073/pnas.2134250100; Sassetti CM, 2003, MOL MICROBIOL, V48, P77, DOI 10.1046/j.1365-2958.2003.03425.x; Schmittgen TD, 2008, NAT PROTOC, V3, P1101, DOI 10.1038/nprot.2008.73; Schumann G, 2006, CENT EUR J BIOL, V1, P183, DOI 10.2478/s11535-006-0018-2; Schwebach JR, 2001, J CLIN MICROBIOL, V39, P769, DOI 10.1128/JCM.39.2.769-771.2001; Sonnenberg MG, 1997, INFECT IMMUN, V65, P4515, DOI 10.1128/IAI.65.11.4515-4524.1997; Stanley SA, 2003, P NATL ACAD SCI USA, V100, P13001, DOI 10.1073/pnas.2235593100; Volmink J, 1997, BMJ-BRIT MED J, V315, P1403, DOI 10.1136/bmj.315.7120.1403; Wards BJ, 2000, TUBERCLE LUNG DIS, V80, P185, DOI 10.1054/tuld.2000.0244; Weldingh K, 1998, INFECT IMMUN, V66, P3492, DOI 10.1128/IAI.66.8.3492-3500.1998; Yew WW, 2008, AM J RESP CRIT CARE, V177, P479, DOI 10.1164/rccm.200710-1561UP; YUAN Y, 1995, P NATL ACAD SCI USA, V92, P6630, DOI 10.1073/pnas.92.14.6630	43	15	17	0	3	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA	1932-6203			PLOS ONE	PLoS One	NOV 10	2009	4	11							e7615	10.1371/journal.pone.0007615	http://dx.doi.org/10.1371/journal.pone.0007615			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	517ZU	19901982	Green Submitted, Green Published, gold			2022-12-25	WOS:000271658800001
J	Hausmann, L; von Campenhausen, M; Endler, F; Singheiser, M; Wagner, H				Hausmann, Laura; von Campenhausen, Mark; Endler, Frank; Singheiser, Martin; Wagner, Hermann			Improvements of Sound Localization Abilities by the Facial Ruff of the Barn Owl (Tyto alba) as Demonstrated by Virtual Ruff Removal	PLOS ONE			English	Article							INTERAURAL TIME DIFFERENCE; AUDITORY SPACE; SPECTRAL CUES; EXTERNAL-EAR; HEADPHONE SIMULATION; LEVEL DIFFERENCE; HEAD; FREQUENCY; DECORRELATION; ORIENTATION	Background: When sound arrives at the eardrum it has already been filtered by the body, head, and outer ear. This process is mathematically described by the head-related transfer functions (HRTFs), which are characteristic for the spatial position of a sound source and for the individual ear. HRTFs in the barn owl (Tyto alba) are also shaped by the facial ruff, a specialization that alters interaural time differences (ITD), interaural intensity differences (ILD), and the frequency spectrum of the incoming sound to improve sound localization. Here we created novel stimuli to simulate the removal of the barn owl's ruff in a virtual acoustic environment, thus creating a situation similar to passive listening in other animals, and used these stimuli in behavioral tests. Methodology/Principal Findings: HRTFs were recorded from an owl before and after removal of the ruff feathers. Normal and ruff-removed conditions were created by filtering broadband noise with the HRTFs. Under normal virtual conditions, no differences in azimuthal head-turning behavior between individualized and non-individualized HRTFs were observed. The owls were able to respond differently to stimuli from the back than to stimuli from the front having the same ITD. By contrast, such a discrimination was not possible after the virtual removal of the ruff. Elevational head-turn angles were (slightly) smaller with non-individualized than with individualized HRTFs. The removal of the ruff resulted in a large decrease in elevational head-turning amplitudes. Conclusions/Significance: The facial ruff a) improves azimuthal sound localization by increasing the ITD range and b) improves elevational sound localization in the frontal field by introducing a shift of iso-ILD lines out of the midsagittal plane, which causes ILDs to increase with increasing stimulus elevation. The changes at the behavioral level could be related to the changes in the binaural physical parameters that occurred after the virtual removal of the ruff. These data provide new insights into the function of external hearing structures and open up the possibility to apply the results on autonomous agents, creation of virtual auditory environments for humans, or in hearing aids.			Hausmann, L (corresponding author), Rhein Westfal TH Aachen, Inst Biol 2, D-5100 Aachen, Germany.	laura@bio2.rwth-aachen.de	Wagner, Hermann/G-5454-2012	Hausmann, Laura/0000-0003-0174-7248				Aytekin M, 2004, J ACOUST SOC AM, V116, P3594, DOI 10.1121/1.1811412; Bala ADS, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0000675; Blauert J., 1997, SPATIAL HEARING PSYC, DOI [10.7551/mitpress/6391.001.0001, DOI 10.7551/MITPRESS/6391.001.0001]; BRAINARD MS, 1992, J ACOUST SOC AM, V91, P1015, DOI 10.1121/1.402627; Calmes L, 2007, J ACOUST SOC AM, V121, P2034, DOI 10.1121/1.2709866; COLES RB, 1988, J COMP PHYSIOL A, V163, P117, DOI 10.1007/BF00612002; Dietz M, 2009, J ACOUST SOC AM, V125, P1622, DOI 10.1121/1.3076045; Egnor SER, 2001, J COMP PHYSIOL A, V187, P589; Euston DR, 2002, J NEUROSCI, V22, P284, DOI 10.1523/JNEUROSCI.22-01-00284.2002; GARDNER MB, 1973, J ACOUST SOC AM, V53, P400, DOI 10.1121/1.1913336; Heffner RS, 1996, HEARING RES, V99, P13, DOI 10.1016/S0378-5955(96)00074-3; Hill PA, 2000, J ACOUST SOC AM, V108, P2901, DOI 10.1121/1.1323235; Huang AY, 1996, J ACOUST SOC AM, V100, P2341, DOI 10.1121/1.417943; Hwang S, 2008, ACTA ACUST UNITED AC, V94, P965, DOI 10.3813/AAA.918113; JAY FJ, 1990, COMP PERCEPTION BASI, P351; Keller CH, 1998, HEARING RES, V118, P13, DOI 10.1016/S0378-5955(98)00014-8; Kim SM, 2005, J ACOUST SOC AM, V117, P3657, DOI 10.1121/1.1921548; King AJ, 2001, AUDIOL NEURO-OTOL, V6, P182, DOI 10.1159/000046829; KNUDSEN EI, 1978, SCIENCE, V200, P795, DOI 10.1126/science.644324; KNUDSEN EI, 1979, J COMP PHYSIOL, V133, P13, DOI 10.1007/BF00663106; KNUDSEN EI, 1981, SCI AM, V245, P113; KNUDSEN EI, 1979, J COMP PHYSIOL, V133, P1, DOI 10.1007/BF00663105; Koka K, 2008, J ACOUST SOC AM, V123, P4297, DOI 10.1121/1.2916587; Kulkarni A, 1998, NATURE, V396, P747, DOI 10.1038/25526; Langendijk EHA, 2002, J ACOUST SOC AM, V112, P1583, DOI 10.1121/1.1501901; Macpherson EA, 2002, J ACOUST SOC AM, V111, P2219, DOI 10.1121/1.1471898; May BJ, 1996, J ACOUST SOC AM, V100, P1059, DOI 10.1121/1.416292; Middlebrooks JC, 1999, J ACOUST SOC AM, V106, P1493, DOI 10.1121/1.427147; MOISEFF A, 1981, J NEUROSCI, V1, P40, DOI 10.1523/JNEUROSCI.01-01-00040.1981; MOISEFF A, 1989, J COMP PHYSIOL A, V164, P637, DOI 10.1007/BF00614506; MOISEFF A, 1989, J COMP PHYSIOL A, V164, P629, DOI 10.1007/BF00614505; Mrsic-Flogel TD, 2001, J NEUROPHYSIOL, V86, P1043, DOI 10.1152/jn.2001.86.2.1043; MUSICANT AD, 1990, J ACOUST SOC AM, V87, P757, DOI 10.1121/1.399545; Nodal FR, 2008, NEUROSCIENCE, V154, P397, DOI 10.1016/j.neuroscience.2007.12.022; Parsons CH, 1999, J NEUROPHYSIOL, V82, P2294, DOI 10.1152/jn.1999.82.5.2294; Phillips DP, 2008, HEARING RES, V238, P124, DOI 10.1016/j.heares.2007.09.007; Poganiatz I, 2001, J COMP PHYSIOL A, V187, P225, DOI 10.1007/s003590100193; Poganiatz I, 2001, JARO, V2, P1; Populin LC, 1998, J NEUROSCI, V18, P2147; Populin LC, 2008, EXP BRAIN RES, V190, P11, DOI 10.1007/s00221-008-1445-2; Saberi K, 2002, JARO, V3, P80, DOI 10.1007/s101620020006; Saberi K, 1999, NAT NEUROSCI, V2, P656, DOI 10.1038/10212; Saberi K, 1998, NEURON, V21, P789, DOI 10.1016/S0896-6273(00)80595-4; TAKAHASHI T, 1984, J NEUROSCI, V4, P1781; Takahashi TT, 2003, BIOL CYBERN, V89, P378, DOI 10.1007/s00422-003-0443-5; Tollin DJ, 2009, J ACOUST SOC AM, V125, P980, DOI 10.1121/1.3058630; Van Wanrooij MM, 2004, J NEUROSCI, V24, P4163, DOI 10.1523/JNEUROSCI.0048-04.2004; von Campenhausen M, 2006, J COMP PHYSIOL A, V192, P1073, DOI 10.1007/s00359-006-0139-0; WAGNER H, 1993, J NEUROSCI, V13, P371; Wagner H, 2007, J NEUROSCI, V27, P4191, DOI 10.1523/JNEUROSCI.5250-06.2007; Walker BN, 2006, HUM FACTORS, V48, P265, DOI 10.1518/001872006777724507; Wenzel E, 1988, J ACOUST SOC AM, V84, pS79, DOI [DOI 10.1121/1.2026486, 10.1121/1.2026486]; WENZEL EM, 1993, J ACOUST SOC AM, V94, P111, DOI 10.1121/1.407089; WIGHTMAN FL, 1989, J ACOUST SOC AM, V85, P868, DOI 10.1121/1.397558; WIGHTMAN FL, 1989, J ACOUST SOC AM, V85, P858, DOI 10.1121/1.397557; WOTTON JM, 1995, J ACOUST SOC AM, V98, P1423, DOI 10.1121/1.413410; Zahorik P, 2006, J ACOUST SOC AM, V120, P343, DOI 10.1121/1.2208429	57	40	40	0	29	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	NOV 5	2009	4	11							e7721	10.1371/journal.pone.0007721	http://dx.doi.org/10.1371/journal.pone.0007721			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	515HI	19890389	Green Published, Green Submitted, gold			2022-12-25	WOS:000271459700013
J	Mauduit, M; Gruner, AC; Tewari, R; Depinay, N; Kayibanda, M; Chavatte, JM; Franetich, JF; Crisanti, A; Mazier, D; Snounou, G; Renia, L				Mauduit, Marjorie; Gruener, Anne Charlotte; Tewari, Rita; Depinay, Nadya; Kayibanda, Michele; Chavatte, Jean-Marc; Franetich, Jean-Francois; Crisanti, Andrea; Mazier, Dominique; Snounou, Georges; Renia, Laurent			A Role for Immune Responses against Non-CS Components in the Cross-Species Protection Induced by Immunization with Irradiated Malaria Sporozoites	PLOS ONE			English	Article							CIRCUMSPOROZOITE PROTEIN VACCINE; PLASMODIUM-FALCIPARUM INFECTION; T-CELLS RECOGNIZE; YOELII; EFFICACY; BERGHEI; PARASITES; PEPTIDE; STAGE; MICE	Immunization with irradiated Plasmodium sporozoites induces sterile immunity in rodents, monkeys and humans. The major surface component of the sporozoite the circumsporozoite protein ( CS) long considered as the antigen predominantly responsible for this immunity, thus remains the leading candidate antigen for vaccines targeting the parasite's preerythrocytic (PE) stages. However, this role for CS was questioned when we recently showed that immunization with irradiated sporozoites (IrrSpz) of a P. berghei line whose endogenous CS was replaced by that of P. falciparum still conferred sterile protection against challenge with wild type P. berghei sporozoites. In order to investigate the involvement of CS in the cross-species protection recently observed between the two rodent parasites P. berghei and P. yoelii, we adopted our gene replacement approach for the P. yoelii CS and exploited the ability to conduct reciprocal challenges. Overall, we found that immunization led to sterile immunity irrespective of the origin of the CS in the immunizing or challenge sporozoites. However, for some combinations, immune responses to CS contributed to the acquisition of protective immunity and were dependent on the immunizing IrrSpz dose. Nonetheless, when data from all the cross-species immunization/challenges were considered, the immune responses directed against non-CS parasite antigens shared by the two parasite species played a major role in the sterile protection induced by immunization with IrrSpz. This opens the perspective to develop a single vaccine formulation that could protect against multiple parasite species.			Mauduit, M (corresponding author), ASTAR, Singapore Immunol Network SIgN, Biopolis, Singapore.	renia_laurent@immunol.a-star.edu.sg	Franetich, Jean-François/GZA-9674-2022; Tewari, Rita/M-5698-2014; Renia, Laurent/E-2117-2011; Snounou, Georges/F-3352-2011; Gruner, Anne Charlotte/C-1841-2012	Renia, Laurent/0000-0003-0349-1557; Snounou, Georges/0000-0002-6133-6398; Crisanti, Andrea/0000-0002-2406-4426; Chavatte, Jean-Marc/0000-0002-0003-541X; Tewari, Rita/0000-0003-3943-1847				Abdulla S, 2008, NEW ENGL J MED, V359, P2533, DOI 10.1056/NEJMoa0807773; Alonso PL, 2004, LANCET, V364, P1411, DOI 10.1016/S0140-6736(04)17223-1; Bejon P, 2008, NEW ENGL J MED, V359, P2521, DOI 10.1056/NEJMoa0807381; Belnoue E, 2004, J IMMUNOL, V172, P2487, DOI 10.4049/jimmunol.172.4.2487; Belnoue E, 2008, J IMMUNOL, V181, P8552, DOI 10.4049/jimmunol.181.12.8552; Bojang KA, 2001, LANCET, V358, P1927, DOI 10.1016/S0140-6736(01)06957-4; Bruna-Romero O, 2001, INT J PARASITOL, V31, P1499, DOI 10.1016/S0020-7519(01)00265-X; CLYDE DF, 1973, AM J MED SCI, V266, P169, DOI 10.1097/00000441-197309000-00002; Druilhe P., 1998, MALARIA PARASITE BIO; Franke-Fayard B, 2004, MOL BIOCHEM PARASIT, V137, P23, DOI 10.1016/j.molbiopara.2004.04.007; GRILLOT D, 1990, EUR J IMMUNOL, V20, P1215, DOI 10.1002/eji.1830200604; Gruner AC, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0001371; Hoffman SL, 2002, J INFECT DIS, V185, P1155, DOI 10.1086/339409; Hoffman SL, 2006, NATURE, V444, P824, DOI 10.1038/nature05409; Hulier E, 1996, MOL BIOCHEM PARASIT, V77, P127, DOI 10.1016/0166-6851(96)02584-4; JANSE CJ, 1985, PARASITOLOGY, V91, P19, DOI 10.1017/S0031182000056481; Kester KE, 2001, J INFECT DIS, V183, P640, DOI 10.1086/318534; Kester KE, 2008, VACCINE, V26, P2191, DOI 10.1016/j.vaccine.2008.02.048; Kumar KA, 2006, NATURE, V444, P937, DOI 10.1038/nature05361; LOPEZ JA, 1996, VACCINES COLD SPRING, V96, P255; Luke TC, 2003, J EXP BIOL, V206, P3803, DOI 10.1242/jeb.00644; Marussig M, 1997, INT IMMUNOL, V9, P1817, DOI 10.1093/intimm/9.12.1817; MIGLIORINI P, 1993, EUR J IMMUNOL, V23, P582, DOI 10.1002/eji.1830230245; Mikolajczak SA, 2007, CURR OPIN INFECT DIS, V20, P461, DOI 10.1097/QCO.0b013e3282ef6172; Mueller AK, 2005, NATURE, V433, P164, DOI 10.1038/nature03188; NARDIN EH, 1982, J EXP MED, V156, P20, DOI 10.1084/jem.156.1.20; NUSSENZWEIG RS, 1972, AM J TROP MED HYG, V21, P722, DOI 10.4269/ajtmh.1972.21.722; Preiser PR, 2002, SCIENCE, V295, P342, DOI 10.1126/science.1064938; RENIA L, 1990, EUR J IMMUNOL, V20, P1445, DOI 10.1002/eji.1830200706; RENIA L, 1988, J IMMUNOL METHODS, V112, P201, DOI 10.1016/0022-1759(88)90358-4; RENIA L, 1993, J IMMUNOL, V150, P1471; Renia L, 2006, EXPERT REV VACCINES, V5, P473, DOI 10.1586/14760584.5.4.473; RODRIGUES MM, 1991, INT IMMUNOL, V3, P579, DOI 10.1093/intimm/3.6.579; ROMERO P, 1989, NATURE, V341, P323, DOI 10.1038/341323a0; Sedegah M, 2007, PARASITE IMMUNOL, V29, P559, DOI 10.1111/j.1365-3024.2007.00976.x; SEDEGAH M, 1994, P NATL ACAD SCI USA, V91, P9866, DOI 10.1073/pnas.91.21.9866; Silvie O, 2006, CELL MICROBIOL, V8, P1134, DOI 10.1111/j.1462-5822.2006.00697.x; Snounou G, 2005, TRENDS PARASITOL, V21, P456, DOI 10.1016/j.pt.2005.08.002; Stoute JA, 1997, NEW ENGL J MED, V336, P86, DOI 10.1056/NEJM199701093360202; Tewari R, 2005, CELL MICROBIOL, V7, P699, DOI 10.1111/j.1462-5822.2005.00503.x; van Dijk MR, 2005, P NATL ACAD SCI USA, V102, P12194, DOI 10.1073/pnas.0500925102; WEISS WR, 1992, J IMMUNOL, V149, P2103; WEISS WR, 1990, J EXP MED, V171, P763, DOI 10.1084/jem.171.3.763; ZAVALA F, 1987, J EXP MED, V166, P1591, DOI 10.1084/jem.166.5.1591; ZAVALA F, 1986, J IMMUNOL METHODS, V93, P55, DOI 10.1016/0022-1759(86)90432-1	45	30	31	0	4	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	NOV 5	2009	4	11							e7717	10.1371/journal.pone.0007717	http://dx.doi.org/10.1371/journal.pone.0007717			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	515HI	19890387	Green Submitted, Green Published, gold			2022-12-25	WOS:000271459700010
J	Szmaragd, C; Wilson, AJ; Carpenter, S; Wood, JLN; Mellor, PS; Gubbins, S				Szmaragd, Camille; Wilson, Anthony J.; Carpenter, Simon; Wood, James L. N.; Mellor, Philip S.; Gubbins, Simon			A Modeling Framework to Describe the Transmission of Bluetongue Virus within and between Farms in Great Britain	PLOS ONE			English	Article							CULICOIDES-VARIIPENNIS SONORENSIS; SOUTHERN CALIFORNIA DAIRY; H5N1 AVIAN INFLUENZA; MOUTH EPIDEMIC; VACCINATION STRATEGIES; NORTHERN EUROPE; MIDGES DIPTERA; CASE-FATALITY; BITING RATES; 2001 FOOT	Background: Recently much attention has been given to developing national-scale micro-simulation models for livestock diseases that can be used to predict spread and assess the impact of control measures. The focus of these models has been on directly transmitted infections with little attention given to vector-borne diseases such as bluetongue, a viral disease of ruminants transmitted by Culicoides biting midges. Yet BT has emerged over the past decade as one of the most important diseases of livestock. Methodology/Principal Findings: We developed a stochastic, spatially-explicit, farm-level model to describe the spread of bluetongue virus (BTV) within and between farms. Transmission between farms was modeled by a generic kernel, which includes both animal and vector movements. Once a farm acquired infection, the within-farm dynamics were simulated based on the number of cattle and sheep kept on the farm and on local temperatures. Parameter estimates were derived from the published literature and using data from the outbreak of bluetongue in northern Europe in 2006. The model was validated using data on the spread of BTV in Great Britain during 2007. The sensitivity of model predictions to the shape of the transmission kernel was assessed. Conclusions/Significance: The model is able to replicate the dynamics of BTV in Great Britain. Although uncertainty remains over the precise shape of the transmission kernel and certain aspects of the vector, the modeling approach we develop constitutes an ideal framework in which to incorporate these aspects as more and better data become available. Moreover, the model provides a tool with which to examine scenarios for the spread and control of BTV in Great Britain.			Szmaragd, C (corresponding author), Univ Bristol, Sch Clin Vet Sci, Bristol, Avon, England.	Camille.Szmaragd@bristol.ac.uk	Carpenter, Simon T/C-2718-2013; Wood, James/A-1626-2008	Carpenter, Simon T/0000-0001-5775-045X; Wood, James/0000-0002-0258-3188; Wilson, Anthony/0000-0002-2000-2914; Gubbins, Simon/0000-0003-0538-4173	Biotechnology and Biological Sciences Research Council [IAH1320, BBS/B/00654, BBS/B/00603, BBS/E/I/00001409, BBS/E/I/00001320] Funding Source: Medline; BBSRC [BBS/E/I/00001320, BBS/E/I/00001409] Funding Source: UKRI	Biotechnology and Biological Sciences Research Council(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC)); BBSRC(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC))		Backer JA, 2009, J R SOC INTERFACE, V6, P849, DOI 10.1098/rsif.2008.0408; Baylis M, 2008, MED VET ENTOMOL, V22, P228, DOI 10.1111/j.1365-2915.2008.00732.x; BIRLEY MH, 1982, J ANIM ECOL, V51, P135, DOI 10.2307/4315; BRAVERMAN Y, 1985, J MED ENTOMOL, V22, P476, DOI 10.1093/jmedent/22.5.476; Braverman Y., 2003, Israel Journal of Veterinary Medicine, V58, P46; Carpenter S, 2008, VET REC, V163, P589, DOI 10.1136/vr.163.20.589; Carpenter S, 2006, J MED ENTOMOL, V43, P73, DOI 10.1603/0022-2585(2006)043[0073:OSTBVO]2.0.CO;2; Carpenter S, 2008, J APPL ECOL, V45, P1237, DOI 10.1111/j.1365-2664.2008.01511.x; Carpenter S, 2009, TRENDS MICROBIOL, V17, P172, DOI 10.1016/j.tim.2009.01.001; *DEP ENV FOOD RUR, DECL PROT ZON SURV Z; *DEP ENV FOOD RUR, 2008, REP DISTR BLUET INF; Elbers ARW, 2008, PREV VET MED, V87, P31, DOI 10.1016/j.prevetmed.2008.06.003; *EUR FOOD STAND AU, 2007, EP AN 2006 BLUET VIR; Evans M., 1993, STAT DISTRIBUTIONS, V2nd; Ferguson NM, 2001, NATURE, V413, P542, DOI 10.1038/35097116; Ferguson NM, 2001, SCIENCE, V292, P1155, DOI 10.1126/science.1061020; Gerbier G, 2008, PREV VET MED, V87, P119, DOI 10.1016/j.prevetmed.2008.06.012; Gerbier G, 2002, PREV VET MED, V56, P33, DOI 10.1016/S0167-5877(02)00122-8; Gerry AC, 2000, J MED ENTOMOL, V37, P675, DOI 10.1603/0022-2585-37.5.675; Gerry AC, 2001, J MED ENTOMOL, V38, P197, DOI 10.1603/0022-2585-38.2.197; Gerry AC, 2009, J MED ENTOMOL, V46, P615, DOI 10.1603/033.046.0329; Gloster J, 2008, VET REC, V162, P298, DOI 10.1136/vr.162.10.298; GOLDSMIT L, 1975, AUST VET J, V51, P190, DOI 10.1111/j.1751-0813.1975.tb00053.x; Gubbins S, 2005, PREV VET MED, V69, P175, DOI 10.1016/j.prevetmed.2004.12.009; Gubbins S, 2005, PREV VET MED, V67, P143, DOI 10.1016/j.prevetmed.2004.08.007; Gubbins S, 2008, J R SOC INTERFACE, V5, P363, DOI 10.1098/rsif.2007.1110; HARTEMINK N, 2009, EPIDEMICS IN PRESS, DOI DOI 10.1016/J.EPIDEM.2009.05.004; Hendrickx G, 2008, PREV VET MED, V87, P162, DOI 10.1016/j.prevetmed.2008.06.009; Jewell CP, 2009, PREV VET MED, V91, P19, DOI 10.1016/j.prevetmed.2009.05.019; Keeling MJ, 2001, SCIENCE, V294, P813, DOI 10.1126/science.1065973; Keeling MJ, 2003, NATURE, V421, P136, DOI 10.1038/nature01343; Lewis MA, 2000, J MATH BIOL, V41, P387, DOI 10.1007/s002850000050; Mellor PS, 2008, PREV VET MED, V87, P4, DOI 10.1016/j.prevetmed.2008.06.002; Melville LF, 1995, ACIAR PROC, P245; MOLLISON D, 1991, MATH BIOSCI, V107, P255, DOI 10.1016/0025-5564(91)90009-8; Mullens BA, 1998, J MED ENTOMOL, V35, P245, DOI 10.1093/jmedent/35.3.245; Mullens BA, 2004, VETER ITAL SER, V40, P160; NELVILLE EM, 1979, J S AFRIC VET ASS, V49, P129; Nunamaker RA, 1997, J MED ENTOMOL, V34, P24, DOI 10.1093/jmedent/34.1.24; Purse BV, 2004, MED VET ENTOMOL, V18, P90, DOI 10.1111/j.0269-283X.2004.00492.x; Purse BV, 2005, NAT REV MICROBIOL, V3, P171, DOI 10.1038/nrmicro1090; Savini G, 2005, VET REC, V157, P133, DOI 10.1136/vr.157.5.133; Schley D, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005481; Sharkey KJ, 2008, P ROY SOC B-BIOL SCI, V275, P19, DOI 10.1098/rspb.2007.1100; Ster IC, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0000502; Ster IC, 2009, EPIDEMICS-NETH, V1, P21, DOI 10.1016/j.epidem.2008.09.001; Szmaragd C, 2007, VET REC, V161, P571, DOI 10.1136/vr.161.16.571-e; Tatem AJ, 2003, VET MICROBIOL, V97, P13, DOI 10.1016/j.vetmic.2003.08.009; Taylor W P, 1986, Rev Sci Tech, V5, P351, DOI 10.20506/rst.5.2.256; Tildesley MJ, 2006, NATURE, V440, P83, DOI 10.1038/nature04324; Truscott JE, 2009, EPIDEMIOL INFECT, V137, P775, DOI 10.1017/S0950268808001064; Truscott J, 2007, P ROY SOC B-BIOL SCI, V274, P2287, DOI 10.1098/rspb.2007.0542; *UK MET OFF, 2009, MIDAS LAND SURF STAT; Veronesi E, 2005, VACCINE, V23, P5509, DOI 10.1016/j.vaccine.2005.07.039; Wilson A, 2008, PARASITOL RES, V103, pS69, DOI 10.1007/s00436-008-1053-x; Wittmann EJ, 2002, MED VET ENTOMOL, V16, P147, DOI 10.1046/j.1365-2915.2002.00357.x	56	84	85	0	31	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	NOV 5	2009	4	11							e7741	10.1371/journal.pone.0007741	http://dx.doi.org/10.1371/journal.pone.0007741			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	515HI	19890400	Green Published, gold, Green Submitted			2022-12-25	WOS:000271459700019
J	Quaranta, A; Bellantuono, V; Cassano, G; Lippe, C				Quaranta, Angelo; Bellantuono, Vito; Cassano, Giuseppe; Lippe, Claudio			Why Amphibians Are More Sensitive than Mammals to Xenobiotics	PLOS ONE			English	Article							PIG EAR SKIN; ANURAN AMPHIBIANS; ATRAZINE; EXTINCTION; ABSORPTION; EXPOSURE; PENETRATION; HERBICIDE; TRANSPORT; JUNCTIONS	Dramatic declines in amphibian populations have been described all over the world since the 1980s. The evidence that the sensitivity to environmental threats is greater in amphibians than in mammals has been generally linked to the observation that amphibians are characterized by a rather permeable skin. Nevertheless, a numerical comparison of data of percutaneous (through the skin) passage between amphibians and mammals is lacking. Therefore, in this investigation we have measured the percutaneous passage of two test molecules (mannitol and antipyrine) and three heavily used herbicides (atrazine, paraquat and glyphosate) in the skin of the frog Rana esculenta ( amphibians) and of the pig ear (mammals), by using the same experimental protocol and a simple apparatus which minimizes the edge effect, occurring when the tissue is clamped in the usually used experimental device. The percutaneous passage (P) of each substance is much greater in frog than in pig. LogP is linearly related to logK(ow) (logarithm of the octanol-water partition coefficient). The measured P value of atrazine was about 134 times larger than that of glyphosate in frog skin, but only 12 times in pig ear skin. The FoD value (P(frog)/P(pig)) was 302 for atrazine, 120 for antipyrine, 66 for mannitol, 29 for paraquat, and 26 for glyphosate. The differences in structure and composition of the skin between amphibians and mammals are discussed.			Quaranta, A (corresponding author), Univ Bari, Dept Anim Prod, I-70121 Bari, Italy.	a.quaranta@veterinaria.uniba.it		Quaranta, Angelo/0000-0001-7835-2485; CASSANO, Giuseppe/0000-0003-3698-3355				Anderson JM, 2001, NEWS PHYSIOL SCI, V16, P126; BirdLife International, 2004, STAT WORLDS BIRDS IN; BLAUSTEIN AR, 1990, TRENDS ECOL EVOL, V5, P203, DOI 10.1016/0169-5347(90)90129-2; Boone MD, 2003, ENVIRON TOXICOL CHEM, V22, P2695, DOI 10.1897/02-401; Carrer DC, 2008, J CONTROL RELEASE, V132, P12, DOI 10.1016/j.jconrel.2008.08.006; Cassano G, 2006, ENVIRON TOXICOL CHEM, V25, P509, DOI 10.1897/05-141R.1; Dalton R, 2002, NATURE, V416, P665, DOI 10.1038/416665a; DICK IP, 1992, J PHARM PHARMACOL, V44, P640, DOI 10.1111/j.2042-7158.1992.tb05485.x; FARQUHAR MG, 1965, J CELL BIOL, V26, P263, DOI 10.1083/jcb.26.1.263; HADLEY NF, 1991, ADV LIPID RES, V24, P303; Hansch C., 1995, EXPLORING QSAR HYDRO; HELMAN SI, 1974, AM J PHYSIOL, V226, P1198, DOI 10.1152/ajplegacy.1974.226.5.1198; Herkenne C, 2006, PHARM RES-DORDR, V23, P1850, DOI 10.1007/s11095-006-9011-8; IUCN - The World Conservation Union, 2001, IUCN RED LIST CAT CR; IUCN - World Conservation Union, 2003, IUCN RED LIST THREAT; Langerveld AJ, 2009, ENVIRON RES, V109, P379, DOI 10.1016/j.envres.2009.01.006; Lillywhite HB, 2006, J EXP BIOL, V209, P202, DOI 10.1242/jeb.02007; LILLYWHITE HB, 2007, KOSMETISCHE MED, V5, P220; Moody RP, 2000, TOXICOL IN VITRO, V14, P467, DOI 10.1016/S0887-2333(00)00038-2; Nemes Z, 1999, EXP MOL MED, V31, P5, DOI 10.1038/emm.1999.2; Nielsen JB, 2000, OCCUP ENVIRON MED, V57, P734, DOI 10.1136/oem.57.11.734; OECD, 2004, OECD GUID TEST CHEM; Pimm SL, 2000, NATURE, V403, P843, DOI 10.1038/35002708; Rowe CL, 2003, AMPHIBIAN DECLINE: AN INTEGRATED ANALYSIS OF MULTIPLE STRESSOR EFFECTS, P9; Sangster J, 2006, LOGKOW DATABANK EVAL; Schaefer H., 1996, SKIN BARRIER PRINCIP, P118; Sodhi NS, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0001636; Stuart SN, 2004, SCIENCE, V306, P1783, DOI 10.1126/science.1103538; Suzawa M, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002117; Thomas CD, 2004, NATURE, V427, P145, DOI 10.1038/nature02121; Uchiyama M, 2006, GEN COMP ENDOCR, V147, P54, DOI 10.1016/j.ygcen.2005.12.018; Vallet V, 2007, TOXICOL IN VITRO, V21, P1182, DOI 10.1016/j.tiv.2007.03.007; Willens S, 2006, ENVIRON TOXICOL PHAR, V22, P255, DOI 10.1016/j.etap.2006.04.010; WITHERS PC, 1984, J EXP ZOOL, V232, P11, DOI 10.1002/jez.1402320103; Young BE, 2001, CONSERV BIOL, V15, P1213, DOI 10.1046/j.1523-1739.2001.00218.x	35	85	89	7	64	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA	1932-6203			PLOS ONE	PLoS One	NOV 4	2009	4	11							e7699	10.1371/journal.pone.0007699	http://dx.doi.org/10.1371/journal.pone.0007699			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	514RZ	19888346	gold, Green Published, Green Submitted			2022-12-25	WOS:000271414600007
J	Jonsdottir, IH; Hagg, DA; Glise, K; Ekman, R				Jonsdottir, Ingibjorg H.; Hagg, Daniel A.; Glise, Kristina; Ekman, Rolf			Monocyte Chemotactic Protein-1 (MCP-1) and Growth Factors Called into Question as Markers of Prolonged Psychosocial Stress	PLOS ONE			English	Article							C-REACTIVE PROTEIN; TERM SICKNESS ABSENCE; CARDIOVASCULAR-DISEASE; RHEUMATOID-ARTHRITIS; GENERAL-POPULATION; DEPRESSION SCALE; HOSPITAL ANXIETY; BURNOUT; WOMEN; INFLAMMATION	Background: Psychosocial stress is becoming a major contributor to increased mental ill-health and sick leave in many countries. Valid markers of chronic stress would be valuable for diagnostic and prognostic purposes. A recent study suggested monocyte chemotactic protein-1 (MCP-1), epidermal growth factor (EGF) and vascular endothelial growth factor (VEGF) as markers of chronic stress. We aimed to confirm these potential biomarkers of prolonged psychosocial stress in female patients. Methodology/Principal Findings: Circulating levels of MCP-1, EGF and VEGF, along with several other cytokines, were measured in plasma from 42 female patients suffering from exhaustion due to prolonged psychosocial stress and 42 control subjects, using a protein biochip immunoassay. There were no significant differences between patients and controls in any of the cytokines or growth factors analyzed. Furthermore, when using a different protein bioassay and reanalyzing MCP-1 and VEGF in the same samples, markedly different levels were obtained. To further explore if inflammation is present in patients with exhaustion, the classical inflammatory marker C-reactive protein (CRP) was measured in another group of patients (n = 89) and controls (n = 88) showing a small but significant increase of CRP levels in the patients. Conclusions/Significance: MCP-1, EGF and VEGF may not be suitable markers of prolonged psychosocial stress as previously suggested. Furthermore, significant differences were obtained when using two different protein assays measuring the same samples, indicating that comparing studies where different analytic techniques have been used might be difficult. Increased levels of CRP indicate that low-grade inflammation might be present in patients with exhaustion due to prolonged stress exposure but this inflammation does not seem to be reflected by increase in circulating MCP-1 or other cytokines measured.			Jonsdottir, IH (corresponding author), Inst Stress Med, Gothenburg, Sweden.	inga.jonsdottir@stressmedicin.com	Hägg, Daniel/K-8027-2019					[Anonymous], 2005, FAC CHALL BUILD SOL; Asberg M, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0003590; Bellingrath S, 2009, STRESS, V12, P37, DOI 10.1080/10253890802042041; Bjelland I, 2002, J PSYCHOSOM RES, V52, P69, DOI 10.1016/S0022-3999(01)00296-3; Black PH, 2002, J PSYCHOSOM RES, V52, P1, DOI 10.1016/S0022-3999(01)00302-6; BLAND JM, 1986, LANCET, V1, P307, DOI 10.1016/s0140-6736(86)90837-8; Bultmann U, 2005, J OCCUP ENVIRON MED, V47, P941; CUSHING SD, 1990, P NATL ACAD SCI USA, V87, P5134, DOI 10.1073/pnas.87.13.5134; FitzGerald SP, 2005, CLIN CHEM, V51, P1165, DOI 10.1373/clinchem.2005.049429; Grossi G, 2003, J PSYCHOSOM RES, V55, P309, DOI 10.1016/S0022-3999(02)00633-5; Haus E, 2001, CHRONOBIOL INT, V18, P709, DOI 10.1081/CBI-100106083; Hayashi M, 2007, BIOL PHARM BULL, V30, P621, DOI 10.1248/bpb.30.621; Henderson M, 2005, BMJ-BRIT MED J, V330, P802, DOI 10.1136/bmj.330.7495.802; Henningsson S, 2008, BEHAV BRAIN FUNCT, V4, DOI 10.1186/1744-9081-4-16; Hetland ML, 2008, DIS MARKERS, V24, P1; Howren MB, 2009, PSYCHOSOM MED, V71, P171, DOI 10.1097/PSY.0b013e3181907c1b; KOCH AE, 1992, J CLIN INVEST, V90, P772, DOI 10.1172/JCI115950; Kudielka B M, 2006, G Ital Med Lav Ergon, V28, P34; Kuo HK, 2005, LANCET NEUROL, V4, P371, DOI 10.1016/S1474-4422(05)70099-5; Maslach C, 2001, ANNU REV PSYCHOL, V52, P397, DOI 10.1146/annurev.psych.52.1.397; MELAMED S, 1992, BEHAV MED, V18, P53, DOI 10.1080/08964289.1992.9935172; Melamed S, 2006, PSYCHOL BULL, V132, P327, DOI 10.1037/0033-2909.132.3.327; Panagiotakos DB, 2004, EUR HEART J, V25, P492, DOI 10.1016/j.ehj.2004.01.018; Rajagopalan S, 2001, AM J CARDIOL, V88, P196, DOI 10.1016/S0002-9149(01)01623-X; Ranjit N, 2007, ARCH INTERN MED, V167, P174, DOI 10.1001/archinte.167.2.174; Rink L, 1998, MECH AGEING DEV, V102, P199, DOI 10.1016/S0047-6374(97)00153-X; Rovin BH, 1999, BIOCHEM BIOPH RES CO, V259, P344, DOI 10.1006/bbrc.1999.0796; Stansfeld S, 2006, SCAND J WORK ENV HEA, V32, P443, DOI 10.5271/sjweh.1050; Stenlund T, 2007, SCAND J PUBLIC HEALT, V35, P516, DOI 10.1080/14034940701271874; Sutcigil L, 2007, CLIN DEV IMMUNOL, DOI 10.1155/2007/76396; Toker S, 2005, J OCCUP HEALTH PSYCH, V10, P344, DOI 10.1037/1076-8998.10.4.344; Wener MH, 2000, J RHEUMATOL, V27, P2351; Zhang ZF, 2008, EXP BIOL MED, V233, P1171, DOI 10.3181/0712-RM-328; ZIGMOND AS, 1983, ACTA PSYCHIAT SCAND, V67, P361, DOI 10.1111/j.1600-0447.1983.tb09716.x	34	37	37	0	3	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA	1932-6203			PLOS ONE	PLoS One	NOV 3	2009	4	11							e7659	10.1371/journal.pone.0007659	http://dx.doi.org/10.1371/journal.pone.0007659			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	514RY	19888340	Green Published, Green Submitted, gold			2022-12-25	WOS:000271414500003
J	Hirsch, ML; Storici, F; Li, CW; Choi, VW; Samulski, J				Hirsch, Matthew L.; Storici, Francesca; Li, Chengwen; Choi, Vivian W.; Samulski, Jude			AAV Recombineering with Single Strand Oligonucleotides	PLOS ONE			English	Article							RECOMBINANT ADENOASSOCIATED VIRUS; PACKAGING CAPACITY; GENE-THERAPY; DNA-DAMAGE; REPAIR; TRANSDUCTION; REPLICATION; VECTORS; CELLS; GENOMES	Adeno-associated virus (AAV) transduction initiates a signaling cascade that culminates in a transient DNA damage response. During this time, host DNA repair proteins convert the linear single-strand AAV genomes to double-strand circular monomers and concatemers in processes stimulated by the AAV inverted terminal repeats (ITRs). As the orientation of AAV genome concatemerization appears unbiased, the likelihood of concatemerization in a desired orientation is low (less than 1 in 6). Using a novel recombineering method, Oligo-Assisted AAV Genome Recombination (OAGR), this work demonstrates the ability to direct concatemerization specifically to a desired orientation in human cells. This was achieved by a single-strand DNA oligonucleotide (oligo) displaying homology to distinct AAV genomes capable of forming an intermolecular bridge for recombination. This DNA repair process results in concatemers with genomic junctions corresponding to the sequence of oligo homology. Furthermore, OAGR was restricted to single-strand, not duplexed, AAV genomes suggestive of replication-dependent recombination. Consistent with this process, OAGR demonstrated oligo polarity biases in all tested configurations except when a portion of the oligo targeted the ITR. This approach, in addition to being useful for the elucidation of intermolecular homologous recombination, may find eventual relevance for AAV mediated large gene therapy.			Hirsch, ML (corresponding author), Univ N Carolina, UNC Gene Therapy Ctr, Chapel Hill, NC 27599 USA.	RJS@med.unc.edu	Xue, Fu-Shan/ADO-0664-2022	Choi, Vivian/0000-0003-4787-0735	NHLBI NIH HHS [P01 HL051818, HL066973, HL051818, P01 HL066973] Funding Source: Medline; NIAID NIH HHS [R01 AI072176, AI072176] Funding Source: Medline; NIGMS NIH HHS [GM0529299] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL051818, P01HL066973] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI072176] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Choi VW, 2006, J VIROL, V80, P10346, DOI 10.1128/JVI.00841-06; Choi VW, 2005, J VIROL, V79, P6801, DOI 10.1128/JVI.79.11.6801-6807.2005; Duan DS, 1998, J VIROL, V72, P8568, DOI 10.1128/JVI.72.11.8568-8577.1998; Duan DS, 2001, MOL THER, V4, P383, DOI 10.1006/mthe.2001.0456; Ellis HM, 2001, P NATL ACAD SCI USA, V98, P6742, DOI 10.1073/pnas.121164898; Ferrari FK, 1996, J VIROL, V70, P3227, DOI 10.1128/JVI.70.5.3227-3234.1996; Ghosh A, 2008, MOL THER, V16, P124, DOI 10.1038/sj.mt.6300322; Grieger JC, 2006, NAT PROTOC, V1, P1412, DOI 10.1038/nprot.2006.207; Halbert CL, 2002, NAT BIOTECHNOL, V20, P697, DOI 10.1038/nbt0702-697; Hermanns J, 1997, J VIROL, V71, P6020, DOI 10.1128/JVI.71.8.6020-6027.1997; Huen MSY, 2006, NUCLEIC ACIDS RES, V34, P6183, DOI 10.1093/nar/gkl852; Inagaki K, 2007, J VIROL, V81, P11304, DOI 10.1128/JVI.01225-07; Jasin M, 1996, TRENDS GENET, V12, P224, DOI 10.1016/0168-9525(96)10019-6; Jurvansuu J, 2005, J VIROL, V79, P569, DOI 10.1128/JVI.79.1.569-580.2005; Jurvansuu J, 2007, J MOL BIOL, V372, P397, DOI 10.1016/j.jmb.2007.06.077; King JA, 2001, EMBO J, V20, P3282, DOI 10.1093/emboj/20.12.3282; Kreuzer KN, 2005, ANNU REV MICROBIOL, V59, P43, DOI 10.1146/annurev.micro.59.030804.121255; Liu L, 2002, MOL CELL BIOL, V22, P3852, DOI 10.1128/MCB.22.11.3852-3863.2002; Nakai H, 2000, J VIROL, V74, P9451, DOI 10.1128/JVI.74.20.9451-9463.2000; Radecke F, 2006, MOL THER, V14, P798, DOI 10.1016/j.ymthe.2006.06.008; Radecke S, 2006, J GENE MED, V8, P217, DOI 10.1002/jgm.828; Raj K, 2001, NATURE, V412, P914, DOI 10.1038/35091082; SAMULSKI RJ, 1989, J VIROL, V63, P3822, DOI 10.1128/JVI.63.9.3822-3828.1989; SAMULSKI RJ, 1983, CELL, V33, P135, DOI 10.1016/0092-8674(83)90342-2; Schwartz RA, 2007, J VIROL, V81, P12936, DOI 10.1128/JVI.01523-07; SRIVASTAVA A, 1983, J VIROL, V45, P555, DOI 10.1128/JVI.45.2.555-564.1983; Storici F, 2003, P NATL ACAD SCI USA, V100, P14994, DOI 10.1073/pnas.2036296100; Storici F, 2006, MOL CELL BIOL, V26, P7645, DOI 10.1128/MCB.00672-06; Wu ZJ, 2006, MOL THER, V14, P316, DOI 10.1016/j.ymthe.2006.05.009; Xu ZP, 2004, HUM GENE THER, V15, P896, DOI 10.1089/1043034041839253; YAMAMOTO T, 1992, GENETICS, V131, P811; Zolotukhin S, 1999, GENE THER, V6, P973, DOI 10.1038/sj.gt.3300938	32	22	22	1	4	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	NOV 2	2009	4	11							e7705	10.1371/journal.pone.0007705	http://dx.doi.org/10.1371/journal.pone.0007705			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	514RX	19888330	Green Published, gold			2022-12-25	WOS:000271414400013
J	Sareen, D; McMillan, E; Ebert, AD; Shelley, BC; Johnson, JA; Meisner, LF; Svendsen, CN				Sareen, Dhruv; McMillan, Erin; Ebert, Allison D.; Shelley, Brandon C.; Johnson, Julie A.; Meisner, Lorraine F.; Svendsen, Clive N.			Chromosome 7 and 19 Trisomy in Cultured Human Neural Progenitor Cells	PLOS ONE			English	Article							EMBRYONIC STEM-CELLS; EPIDERMAL-GROWTH-FACTOR; SPINAL-CORD-INJURY; RAT MODEL; GLIOBLASTOMA-MULTIFORME; SUBVENTRICULAR ZONE; PARKINSONS-DISEASE; DOPAMINE NEURONS; PRECURSOR CELLS; IN-VITRO	Background: Stem cell expansion and differentiation is the foundation of emerging cell therapy technologies. The potential applications of human neural progenitor cells (hNPCs) are wide ranging, but a normal cytogenetic profile is important to avoid the risk of tumor formation in clinical trials. FDA approved clinical trials are being planned and conducted for hNPC transplantation into the brain or spinal cord for various neurodegenerative disorders. Although human embryonic stem cells (hESCs) are known to show recurrent chromosomal abnormalities involving 12 and 17, no studies have revealed chromosomal abnormalities in cultured hNPCs. Therefore, we investigated frequently occurring chromosomal abnormalities in 21 independent fetal-derived hNPC lines and the possible mechanisms triggering such aberrations. Methods and Findings: While most hNPC lines were karyotypically normal, G-band karyotyping and fluorescent in situ hybridization (FISH) analyses revealed the emergence of trisomy 7 (hNPC(+7)) and trisomy 19 (hNPC(+19)), in 24% and 5% of the lines, respectively. Once detected, subsequent passaging revealed emerging dominance of trisomy hNPCs. DNA microarray and immunoblotting analyses demonstrate epidermal growth factor receptor (EGFR) overexpression in hNPC(+7) and hNPC(+19) cells. We observed greater levels of telomerase (hTERT), increased proliferation (Ki67), survival (TUNEL), and neurogenesis (beta(III)-tubulin) in hNPC(+7) and hNPC(+19), using respective immunocytochemical markers. However, the trisomy lines underwent replicative senescence after 50-60 population doublings and never showed neoplastic changes. Although hNPC(+7) and hNPC(+19) survived better after xenotransplantation into the rat striatum, they did not form malignant tumors. Finally, EGF deprivation triggered a selection of trisomy 7 cells in a diploid hNPC line. Conclusions: We report that hNPCs are susceptible to accumulation of chromosome 7 and 19 trisomy in long-term cell culture. These results suggest that micro-environmental cues are powerful factors in the selection of specific hNPC aneuploidies, with trisomy of chromosome 7 being the most common. Given that a number of stem cell based clinical trials are being conducted or planned in USA and a recent report in PLoS Medicine showing the dangers of grafting an inordinate number of cells, these data substantiate the need for careful cytogenetic evaluation of hNPCs (fetal or hESC-derived) before their use in clinical or basic science applications.			Sareen, D (corresponding author), Univ Wisconsin, Dept Neurol, Sch Med & Publ Hlth, WIMR, Madison, WI 53706 USA.	cnsvendsen@wisc.edu			NINDS NIH HHS [P01NS057778, P01 NS057778] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [P01NS057778] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Amariglio N, 2009, PLOS MED, V6, P221, DOI 10.1371/journal.pmed.1000029; Amon A, 1999, CURR OPIN GENET DEV, V9, P69, DOI 10.1016/S0959-437X(99)80010-0; Andrews PW, 2006, NAT BIOTECHNOL, V24, P325, DOI 10.1038/nbt0306-325; Bailey KJ, 2004, AGING CELL, V3, P391, DOI 10.1111/j.1474-9728.2004.00128.x; Baker DEC, 2007, NAT BIOTECHNOL, V25, P207, DOI 10.1038/nbt1285; Briand P, 1996, CANCER RES, V56, P2039; Cesetti T, 2009, STEM CELLS, V27, P1443, DOI 10.1002/stem.74; Cui W, 2002, J BIOL CHEM, V277, P38531, DOI 10.1074/jbc.M205981200; Damelin M, 2005, CANCER CELL, V8, P479, DOI 10.1016/j.ccr.2005.11.004; Danilov AI, 2009, GLIA, V57, P136, DOI 10.1002/glia.20741; Draper JS, 2004, NAT BIOTECHNOL, V22, P53, DOI 10.1038/nbt922; Ebert AD, 2008, EXP NEUROL, V209, P213, DOI 10.1016/j.expneurol.2007.09.022; Emlet DR, 1997, J BIOL CHEM, V272, P4079, DOI 10.1074/jbc.272.7.4079; Englund U, 2002, EXP NEUROL, V173, P1, DOI 10.1006/exnr.2001.7750; Englund U, 2002, DEV BRAIN RES, V134, P123, DOI 10.1016/S0165-3806(01)00330-3; Gilbertson RJ, 2007, NAT REV CANCER, V7, P733, DOI 10.1038/nrc2246; Hoffman LM, 2005, NAT BIOTECHNOL, V23, P699, DOI 10.1038/nbt1102; Hoffman SMG, 1997, GENOMICS, V43, P109, DOI 10.1006/geno.1997.4792; Huhn SL, 1999, CLIN CANCER RES, V5, P1435; Jakel RJ, 2004, NAT REV GENET, V5, P136, DOI 10.1038/nrg1268; Keirstead HS, 2005, J NEUROSCI, V25, P4694, DOI 10.1523/JNEUROSCI.0311-05.2005; Keirstead HS, 2005, TRENDS NEUROSCI, V28, P677, DOI 10.1016/j.tins.2005.09.008; Kingsbury MA, 2005, P NATL ACAD SCI USA, V102, P6143, DOI 10.1073/pnas.0408171102; KOCH P, 2009, P NATL ACAD SCI US; Lim DA, 2007, NEURO-ONCOLOGY, V9, P424, DOI 10.1215/15228517-2007-023; Lopez-Gines C, 2005, CLIN NEUROPATHOL, V24, P209; Masutomi K, 2003, CELL, V114, P241, DOI 10.1016/S0092-8674(03)00550-6; McBride JL, 2004, J COMP NEUROL, V475, P211, DOI 10.1002/cne.20176; McIntyre A, 2008, GENE CHROMOSOME CANC, V47, P547, DOI 10.1002/gcc.20562; Meisner LF, 2008, METHODS, V45, P133, DOI 10.1016/j.ymeth.2008.03.005; Morshead CM, 2002, NAT MED, V8, P268, DOI 10.1038/nm0302-268; Nelson AD, 2008, STEM CELLS, V26, P348, DOI 10.1634/stemcells.2007-0299; Ostenfeld T, 2000, EXP NEUROL, V164, P215, DOI 10.1006/exnr.2000.7427; Ostenfeld T, 2002, J NEUROSCI RES, V69, P955, DOI 10.1002/jnr.10396; Palmer RD, 2007, BRIT J CANCER, V96, P667, DOI 10.1038/sj.bjc.6603602; Puceat M, 2007, CLIN PHARMACOL THER, V82, P337, DOI 10.1038/sj.clpt.6100298; Pyle AD, 2006, NAT BIOTECHNOL, V24, P344, DOI 10.1038/nbt1189; Rousseau E, 2007, MOL CANCER, V6, DOI 10.1186/1476-4598-6-47; Shay JW, 2005, CARCINOGENESIS, V26, P867, DOI 10.1093/carcin/bgh296; Sherr CJ, 2000, CELL, V102, P407, DOI 10.1016/S0092-8674(00)00046-5; Spits C, 2008, NAT BIOTECHNOL, V26, P1361, DOI 10.1038/nbt.1510; Stewart SA, 2003, NAT GENET, V33, P492, DOI 10.1038/ng1127; Sugawara A, 2006, COMPARATIVE MED, V56, P31; SUH Y, 2009, MOL CELL NEUROSCI; Sun Y, 2008, MOL CELL NEUROSCI, V38, P245, DOI 10.1016/j.mcn.2008.02.014; Suzuki M, 2008, TRENDS NEUROSCI, V31, P192, DOI 10.1016/j.tins.2008.01.006; Suzuki M, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0000689; Svendsen CN, 2004, NAT MED, V10, P224, DOI 10.1038/nm0304-224; Svendsen CN, 1998, J NEUROSCI METH, V85, P141, DOI 10.1016/S0165-0270(98)00126-5; Svendsen CN, 1997, EXP NEUROL, V148, P135, DOI 10.1006/exnr.1997.6634; Tamaki S, 2002, J NEUROSCI RES, V69, P976, DOI 10.1002/jnr.10412; Taupin P, 2006, CURR OPIN MOL THER, V8, P156; Vroemen M, 2003, EUR J NEUROSCI, V18, P743, DOI 10.1046/j.1460-9568.2003.02804.x; Wang SM, 2008, INVEST OPHTH VIS SCI, V49, P3201, DOI 10.1167/iovs.08-1831; Werbowetski-Ogilvie TE, 2009, NAT BIOTECHNOL, V27, P91, DOI 10.1038/nbt.1516; Westra JW, 2008, J COMP NEUROL, V507, P1944, DOI 10.1002/cne.21648; Wong RWC, 2004, CYTOKINE GROWTH F R, V15, P147, DOI 10.1016/j.cytogfr.2004.01.004; Wright LS, 2006, EXP CELL RES, V312, P2107, DOI 10.1016/j.yexcr.2006.03.012; Yurov YB, 2005, J HISTOCHEM CYTOCHEM, V53, P385, DOI 10.1369/jhc.4A6430.2005; Zhao CM, 2008, CELL, V132, P645, DOI 10.1016/j.cell.2008.01.033; 2009, GERON RECEIVES FDA C; 2009, STUDY SAFETY PRELIMI	62	51	60	1	10	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	OCT 29	2009	4	10							e7630	10.1371/journal.pone.0007630	http://dx.doi.org/10.1371/journal.pone.0007630			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	512FP	19898616	Green Submitted, Green Published, gold			2022-12-25	WOS:000271232000009
J	Jarmalavicius, S; Trefzer, U; Walden, P				Jarmalavicius, Saulius; Trefzer, Uwe; Walden, Peter			Differential arginine methylation of the G-protein pathway suppressor GPS-2 recognized by tumor-specific T cells in melanoma	FASEB JOURNAL			English	Article						cancer; immunology; major histocompatibility complex; mass spectrometry; post-translational modification; protein arginine methylation; T lymphocytes	MASS-SPECTROMETRY; POSTTRANSLATIONAL MODIFICATIONS; SYMMETRIC DIMETHYLARGININE; CANCER-IMMUNOTHERAPY; PEPTIDE; METHYLTRANSFERASE; RESIDUES; IDENTIFICATION; EPITOPES; COMPLEX	The aim of the study was to identify as potential therapeutic targets specific molecular alterations in tumor cells recognized by the immune system. To identify such targets, we analyzed the human leukocyte antigen (HLA) peptidomes of human melanoma cells by 2-dimensional nano-HPLC/mass spectrometry and tested the immunological significance of the peptides by ex vivo ELISpot assays with lymphocytes from melanoma patients. The peptide SQNPRFYHK was identified as derived from the regulator of the nuclear corepressor complex (NCoR) G-protein pathway suppressor 2 (GPS-2) and to be differentially unmethylated, monomethylated or asymmetrically dimethylated at the arginine. The methylation state was specifically recognized by the immune system in that only the monomethylated variant induced T-cell responses and significantly stronger responses in patients than in healthy controls. The methylations were confirmed with synthetic analogues and in vitro radiolabeling assays with recombinant GPS-2 and synthetic peptides. The immunity of the 3 variants of GPS-2 was tested in T-cell assays with T lymphocytes of melanoma patients compared with healthy donors. The results show for the first time that GPS-2 is differentially methylated at a site that lacks known methylation motifs and that the methylation state is detected by the immune system.-Jarmalavicius, S., Trefzer, U., Walden, P. Differential arginine methylation of the G-protein pathway suppressor GPS-2 recognized by tumor-specific T cells in melanoma. FASEB J. 24, 937-946 (2010). www.fasebj.org	[Walden, Peter] Humboldt Univ, Dept Dermatol, Charite Univ Med Berlin, Clin Res Grp Tumor Immunol, D-10117 Berlin, Germany	Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin	Walden, P (corresponding author), Humboldt Univ, Dept Dermatol, Charite Univ Med Berlin, Clin Res Grp Tumor Immunol, Charitepl 1, D-10117 Berlin, Germany.	peter.walden@charite.de			German Research Council (DFG) [KFO50, FOR299/2-1,2]; EU [10132690]	German Research Council (DFG)(German Research Foundation (DFG)); EU(European Commission)	We thank Stefanie Gross (Charite-Universitatsmedizin Berlin) for providing the melanoma cell lines, Anne Bredenbeck for her help in establishing the T-cell analysis, Arthur O'Connor for technical assistance, and Patricia Zambon for help in preparing this manuscript. The work was supported in part with funds of the German Research Council (DFG; KFO50 and FOR299/2-1,2) and the EU Regional Fund for Berlin ProFit (10132690). The protocol for the use of human materials had been reviewed and approved by the institutional ethics committee of the Charite-Universitatsmedizin Berlin (EA1/206/05).	BACHMAIR A, 1986, SCIENCE, V234, P179, DOI 10.1126/science.3018930; Bedford MT, 1998, P NATL ACAD SCI USA, V95, P10602, DOI 10.1073/pnas.95.18.10602; BIEMANN K, 1990, METHOD ENZYMOL, V193, P886, DOI 10.1016/0076-6879(90)93460-3; Boulanger MC, 2005, J VIROL, V79, P124, DOI 10.1128/JVI.79.1.124-131.2005; Branscombe TL, 2001, J BIOL CHEM, V276, P32971, DOI 10.1074/jbc.M105412200; Bredenbeck A, 2005, J IMMUNOL, V174, P6716, DOI 10.4049/jimmunol.174.11.6716; Cheng DH, 2007, MOL CELL, V25, P71, DOI 10.1016/j.molcel.2006.11.019; Cook JR, 2006, BIOCHEM BIOPH RES CO, V342, P472, DOI 10.1016/j.bbrc.2006.01.167; Degenhardt YY, 2001, J VIROL, V75, P151, DOI 10.1128/JVI.75.1.151-160.2001; Demine R, 2005, J BIOL CHEM, V280, P17573, DOI 10.1074/jbc.M501233200; Demine R, 2004, RAPID COMMUN MASS SP, V18, P907, DOI 10.1002/rcm.1420; Demine R, 2003, MOL BIOTECHNOL, V25, P71, DOI 10.1385/MB:25:1:71; Diederichs S, 2004, J BIOL CHEM, V279, P33727, DOI 10.1074/jbc.M401708200; Engelhard VH, 2006, CURR OPIN IMMUNOL, V18, P92, DOI 10.1016/j.coi.2005.11.015; Fuchs SY, 2005, CANCER METAST REV, V24, P329, DOI 10.1007/s10555-005-1581-0; Gary JD, 1998, PROG NUCLEIC ACID RE, V61, P65, DOI 10.1016/S0079-6603(08)60825-9; Gehrig PM, 2004, J AM SOC MASS SPECTR, V15, P142, DOI 10.1016/j.jasms.2003.10.002; Hughes RM, 2006, J AM CHEM SOC, V128, P12735, DOI 10.1021/ja061656g; Jin DY, 1997, J BIOL CHEM, V272, P25816, DOI 10.1074/jbc.272.41.25816; Kessler Jan H, 2004, Curr Protoc Immunol, VChapter 18, DOI 10.1002/0471142735.im1812s61; Kessler JH, 2003, HUM IMMUNOL, V64, P245, DOI 10.1016/S0198-8859(02)00787-5; Kim S, 1997, BIOCHEMISTRY-US, V36, P5185, DOI 10.1021/bi9625509; Lee J, 2005, J BIOL CHEM, V280, P32890, DOI 10.1074/jbc.M506944200; Lee JH, 2005, J BIOL CHEM, V280, P3656, DOI 10.1074/jbc.M405295200; Lee TH, 2006, DNA REPAIR, V5, P32, DOI 10.1016/j.dnarep.2005.07.004; McBride AE, 2001, CELL, V106, P5, DOI 10.1016/S0092-8674(01)00423-8; Milner E, 2006, MOL CELL PROTEOMICS, V5, P357, DOI 10.1074/mcp.M500241-MCP200; Mowen KA, 2001, CELL, V104, P731, DOI 10.1016/S0092-8674(02)08085-6; Pahlich S, 2006, BBA-PROTEINS PROTEOM, V1764, P1890, DOI 10.1016/j.bbapap.2006.08.008; Peng YC, 2000, J VIROL, V74, P5872, DOI 10.1128/JVI.74.13.5872-5879.2000; Peng YC, 2001, MOL CELL BIOL, V21, P5913, DOI 10.1128/MCB.21.17.5913-5924.2001; Princiotta MF, 2003, IMMUNITY, V18, P343, DOI 10.1016/S1074-7613(03)00051-7; Rappsilber J, 2003, ANAL CHEM, V75, P3107, DOI 10.1021/ac026283q; Smith JJ, 1999, J BIOL CHEM, V274, P13229, DOI 10.1074/jbc.274.19.13229; Strahl BD, 2001, CURR BIOL, V11, P996, DOI 10.1016/S0960-9822(01)00294-9; Swiercz R, 2005, BIOCHEM J, V386, P85, DOI 10.1042/BJ20041466; Tang J, 2000, J BIOL CHEM, V275, P7723, DOI 10.1074/jbc.275.11.7723; Varshavsky A, 1996, P NATL ACAD SCI USA, V93, P12142, DOI 10.1073/pnas.93.22.12142; Yague J, 2000, PROTEIN SCI, V9, P2210, DOI 10.1110/ps.9.11.2210; Yewdell JW, 1996, J IMMUNOL, V157, P1823; Zarling AL, 2006, P NATL ACAD SCI USA, V103, P14889, DOI 10.1073/pnas.0604045103; Zhang JS, 2002, MOL CELL, V9, P611, DOI 10.1016/S1097-2765(02)00468-9; Zobel-Thropp P, 1998, J BIOL CHEM, V273, P29283, DOI 10.1074/jbc.273.45.29283; Zou Y, 2005, BIOCHEMISTRY-US, V44, P6293, DOI 10.1021/bi0475525	44	11	12	0	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAR	2010	24	3					937	946		10.1096/fj.09-136283	http://dx.doi.org/10.1096/fj.09-136283			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	561KE	19917673				2022-12-25	WOS:000274974600029
J	Kahlfeldt, N; Vahedi-Faridi, A; Koo, SJ; Schafer, JG; Krainer, G; Keller, S; Saenger, W; Krauss, M; Haucke, V				Kahlfeldt, Nina; Vahedi-Faridi, Ardeschir; Koo, Seong Joo; Schaefer, Johannes G.; Krainer, Georg; Keller, Sandro; Saenger, Wolfram; Krauss, Michael; Haucke, Volker			Molecular Basis for Association of PIPKI gamma-p90 with Clathrin Adaptor AP-2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOSPHATIDYLINOSITOL PHOSPHATE KINASE; ENDOCYTIC SORTING ADAPTER; GAMMA; CARGO; AP2; COMPLEX; BINDING; PHOSPHORYLATION; RECOGNITION; MOTIFS	Phosphatidylinositol 4,5-bisphosphate (PI(4,5)P-2) is an essential determinant in clathrin-mediated endocytosis (CME). In mammals three type I phosphatidylinositol-4-phosphate 5-kinase (PIPK) enzymes are expressed, with the I gamma-p90 isoform being highly expressed in the brain where it regulates synaptic vesicle (SV) exo-/endocytosis at nerve terminals. How precisely PI(4,5)P-2 metabolism is controlled spatially and temporally is still uncertain, but recent data indicate that direct interactions between type I PIPK and components of the endocytic machinery, in particular the AP-2 adaptor complex, are involved. Here we demonstrated that PIPKI gamma-p90 associates with both the mu and beta 2 subunits of AP-2 via multiple sites. Crystallographic data show that a peptide derived from the splice insert of the human PIPKI gamma-p90 tail binds to a cognate recognition site on the sandwich subdomain of the beta 2 appendage. Partly overlapping aromatic and hydrophobic residues within the same peptide also can engage the C-terminal sorting signal binding domain of AP-2 mu, thereby potentially competing with the sorting of conventional YXXempty set motif-containing cargo. Biochemical and structure-based mutagenesis analysis revealed that association of the tail domain of PIPKI gamma-p90 with AP-2 involves both of these sites. Accordingly the ability of overexpressed PIPKI gamma tail to impair endocytosis of SVs in primary neurons largely depends on its association with AP-2 beta and AP-2 mu. Our data also suggest that interactions between AP-2 and the tail domain of PIPKI gamma-p90 may serve to regulate complex formation and enzymatic activity. We postulate a model according to which multiple interactions between PIPKI gamma-p90 and AP-2 lead to spatiotemporally controlled PI(4,5)P-2 synthesis during clathrin-mediated SV endocytosis.	[Kahlfeldt, Nina; Vahedi-Faridi, Ardeschir; Koo, Seong Joo; Schaefer, Johannes G.; Krainer, Georg; Saenger, Wolfram; Krauss, Michael; Haucke, Volker] Free Univ Berlin, Inst Chem & Biochem, Dept Membrane Biochem, D-14195 Berlin, Germany; [Kahlfeldt, Nina; Vahedi-Faridi, Ardeschir; Koo, Seong Joo; Schaefer, Johannes G.; Krainer, Georg; Saenger, Wolfram; Krauss, Michael; Haucke, Volker] Free Univ Berlin, Dept Prot Crystallog, D-14195 Berlin, Germany; [Haucke, Volker] Charite, D-14195 Berlin, Germany; [Krainer, Georg; Keller, Sandro; Haucke, Volker] Leibniz Inst Mol Pharmacol, D-13125 Berlin, Germany	Free University of Berlin; Free University of Berlin; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Leibniz Forschungsinstitut furr Molekulare Pharmakologie (FMP)	Krauss, M (corresponding author), Free Univ Berlin, Inst Chem & Biochem, Dept Membrane Biochem, Takustr 6, D-14195 Berlin, Germany.	mkrauss@chemie.fu-berlin.de; volker.haucke@fu-berlin.de	Keller, Sandro/G-7202-2016; Krainer, Georg/AAW-4764-2020; Keller, Sandro/T-3487-2019	Keller, Sandro/0000-0001-5469-8772; Krainer, Georg/0000-0002-9626-7636; Keller, Sandro/0000-0001-5469-8772; Krauss, Michael/0000-0003-1010-9723; Haucke, Volker/0000-0003-3119-6993	German Research Foundation (DFG) [HA2686/2-1, HA2686/2-2]; Exc 257-Neurocure;  [FG 806];  [SFB 449];  [TP A11];  [TP Z3]	German Research Foundation (DFG)(German Research Foundation (DFG)); Exc 257-Neurocure; ; ; ; 	This work was supported by German Research Foundation (DFG) Grants HA2686/2-1, -/2-2, and FG 806 (to V. H.), SFB 449: TP A11 (to V. H.), TP Z3 (to W. S.), and Exc 257-Neurocure.	Anggono V, 2006, NAT NEUROSCI, V9, P752, DOI 10.1038/nn1695; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Bairstow SF, 2006, J BIOL CHEM, V281, P20632, DOI 10.1074/jbc.M601465200; Collins BM, 2002, CELL, V109, P523, DOI 10.1016/S0092-8674(02)00735-3; Cremona O, 1999, CELL, V99, P179, DOI 10.1016/S0092-8674(00)81649-9; Di Paolo G, 2004, NATURE, V431, P415, DOI 10.1038/nature02896; Di Paolo G, 2002, NATURE, V420, P85, DOI 10.1038/nature01147; Di Paolo G, 2006, NATURE, V443, P651, DOI 10.1038/nature05185; Diril MK, 2006, DEV CELL, V10, P233, DOI 10.1016/j.devcel.2005.12.011; Doherty GJ, 2009, ANNU REV BIOCHEM, V78, P857, DOI 10.1146/annurev.biochem.78.081307.110540; Edeling MA, 2006, DEV CELL, V10, P329, DOI 10.1016/j.devcel.2006.01.016; Emsley P, 2004, ACTA CRYSTALLOGR D, V60, P2126, DOI 10.1107/S0907444904019158; Gaidarov I, 1999, J CELL BIOL, V146, P755, DOI 10.1083/jcb.146.4.755; GALLI T, 2004, SCI STKE, pRE19; Harris TW, 2000, J CELL BIOL, V150, P589, DOI 10.1083/jcb.150.3.589; Honing S, 2005, MOL CELL, V18, P519, DOI 10.1016/j.molcel.2005.04.019; Jung N, 2007, J CELL BIOL, V179, P1497, DOI 10.1083/jcb.200708107; Jung N, 2007, TRAFFIC, V8, P1129, DOI 10.1111/j.1600-0854.2007.00595.x; Kelly BT, 2008, NATURE, V456, P976, DOI 10.1038/nature07422; Kittler JT, 2008, P NATL ACAD SCI USA, V105, P3616, DOI 10.1073/pnas.0707920105; Krauss M, 2006, P NATL ACAD SCI USA, V103, P11934, DOI 10.1073/pnas.0510306103; Krissinel E, 2007, J MOL BIOL, V372, P774, DOI 10.1016/j.jmb.2007.05.022; Lee SY, 2005, J CELL BIOL, V168, P789, DOI 10.1083/jcb.200409028; Ling K, 2003, J CELL BIOL, V163, P1339, DOI 10.1083/jcb.200310067; Ling K, 2002, NATURE, V420, P89, DOI 10.1038/nature01082; Ling K, 2007, J CELL BIOL, V176, P343, DOI 10.1083/jcb.200606023; LINSTEDT AD, 1991, NEURON, V7, P309, DOI 10.1016/0896-6273(91)90269-6; Loerke D, 2009, PLOS BIOL, V7, P628, DOI 10.1371/journal.pbio.1000057; Mao YS, 2009, J CELL BIOL, V184, P281, DOI 10.1083/jcb.200806121; McPherson PS, 2005, MOL NEUROBIOL, V32, P73, DOI 10.1385/MN:32:1:073; Mellman DL, 2008, NATURE, V451, P1013, DOI 10.1038/nature06666; Milosevic I, 2005, J NEUROSCI, V25, P2557, DOI 10.1523/JNEUROSCI.3761-04.2005; Murshudov GN, 1997, ACTA CRYSTALLOGR D, V53, P240, DOI 10.1107/S0907444996012255; Nakano-Kobayashi A, 2007, EMBO J, V26, P1105, DOI 10.1038/sj.emboj.7601573; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Rohde G, 2002, J CELL BIOL, V158, P209, DOI 10.1083/jcb.200203103; Schmid EM, 2006, PLOS BIOL, V4, P1532, DOI 10.1371/journal.pbio.0040262; Thieman JR, 2009, J BIOL CHEM, V284, P13924, DOI 10.1074/jbc.M901017200; Traub LM, 2003, J CELL BIOL, V163, P203, DOI 10.1083/jcb.200309175; Voglmaier SM, 2006, NEURON, V51, P71, DOI 10.1016/j.neuron.2006.05.027; Wenk MR, 2001, NEURON, V32, P79, DOI 10.1016/S0896-6273(01)00456-1	42	22	22	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 22	2010	285	4					2734	2749		10.1074/jbc.M109.074906	http://dx.doi.org/10.1074/jbc.M109.074906			16	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	544YP	19903820	Green Published			2022-12-25	WOS:000273697800051
J	Brown, CR; Dunton, D; Chiang, HL				Brown, C. Randell; Dunton, Danielle; Chiang, Hui-Ling			The Vacuole Import and Degradation Pathway Utilizes Early Steps of Endocytosis and Actin Polymerization to Deliver Cargo Proteins to the Vacuole for Degradation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHAPERONE-MEDIATED AUTOPHAGY; HEAT-SHOCK-PROTEIN; SACCHAROMYCES-CEREVISIAE; BUDDING YEAST; MOLECULAR MACHINERY; ENDOSOME FUNCTION; TARGETING SIGNAL; SELECTIVE UPTAKE; VID VESICLES; AMINO-ACIDS	When glucose is added to yeast cells that are starved for 3 days, fructose-1,6-bisphosphatase (FBPase) and malate dehydrogenase 2 are degraded in the vacuole via the vacuole import and degradation (Vid) pathway. In this study, we examined the distribution of FBPase at the ultrastructural level. FBPase was observed in areas close to the plasma membrane and in cytoplasmic structures that are heterogeneous in size and density. We have isolated these intracellular structures that contain FBPase, the Vid vesicle marker Vid24p, and the endosomal marker Pep12p. They appeared irregular in size and shape. In yeast, actin polymerization plays an important role in early steps of endocytosis. Mutants that affect actin polymerization inhibited FBPase degradation, suggesting that actin polymerization is important for FBPase degradation. Both FBPase and malate dehydrogenase 2 were associated with actin patches. Vid vesicle proteins such as Vid24p or Sec28p were also at actin patches, although they dissociated from these structures at later time points. We propose that Vid24p and Sec28p are present at actin patches during glucose starvation. Cargo proteins arrive at these sites following the addition of glucose, and the endocytic vesicles then pinch off from the plasma membrane. Following the fusion of endosomes with the vacuole, cargo proteins are then degraded in the vacuole.	[Brown, C. Randell; Dunton, Danielle; Chiang, Hui-Ling] Penn State Univ, Coll Med, Dept Cellular & Mol Physiol, Hershey, PA 17033 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Penn State Health	Chiang, HL (corresponding author), Penn State Univ, Coll Med, Dept Cellular & Mol Physiol, 500 Univ Dr, Hershey, PA 17033 USA.	hlchiang@psu.edu			National Institutes of Health [R01 GM 59480]; Pennsylvania Tobacco Settlement Fund; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM059480] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Pennsylvania Tobacco Settlement Fund; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	This work was supported, in whole or in part, by National Institutes of Health Grant R01 GM 59480 (to H.-L.C.). This work was also supported by a grant from the Pennsylvania Tobacco Settlement Fund (to H.-L.C.). S The on-line version of this article (availableat http://www.jbc.org) contains supplemental Fig. S1.	ADAMS AEM, 1984, J CELL BIOL, V98, P934, DOI 10.1083/jcb.98.3.934; Aniento F, 1996, J CELL BIOL, V133, P29, DOI 10.1083/jcb.133.1.29; Brown CR, 2008, J BIOL CHEM, V283, P26116, DOI 10.1074/jbc.M709922200; Brown CR, 2001, J BIOL CHEM, V276, P48017, DOI 10.1074/jbc.M109222200; Brown CR, 2002, J CELL SCI, V115, P655; Brown CR, 2000, J CELL BIOL, V150, P65, DOI 10.1083/jcb.150.1.65; Bryant NJ, 1998, MICROBIOL MOL BIOL R, V62, P230, DOI 10.1128/MMBR.62.1.230-247.1998; Cecconi F, 2008, DEV CELL, V15, P344, DOI 10.1016/j.devcel.2008.08.012; CHIANG HL, 1988, J BIOL CHEM, V263, P6797; CHIANG HL, 1991, NATURE, V350, P313, DOI 10.1038/350313a0; Chiang HL, 1996, J BIOL CHEM, V271, P9934, DOI 10.1074/jbc.271.17.9934; CHIANG HL, 1989, SCIENCE, V246, P382, DOI 10.1126/science.2799391; Chiang MC, 1998, J CELL BIOL, V140, P1347, DOI 10.1083/jcb.140.6.1347; Cuervo AM, 2000, J BIOL CHEM, V275, P31505, DOI 10.1074/jbc.M002102200; Cuervo AM, 2004, TRENDS CELL BIOL, V14, P70, DOI 10.1016/j.tcb.2003.12.002; Cuervo AM, 1996, SCIENCE, V273, P501, DOI 10.1126/science.273.5274.501; Daro E, 1997, J CELL BIOL, V139, P1747, DOI 10.1083/jcb.139.7.1747; Dewar H, 2002, MOL BIOL CELL, V13, P3646, DOI 10.1091/mbc.E02-05-0262; Dice JF, 2007, AUTOPHAGY, V3, P295, DOI 10.4161/auto.4144; DUNN WA, 1990, J CELL BIOL, V110, P1923, DOI 10.1083/jcb.110.6.1923; Engqvist-Goldstein AEY, 2003, ANNU REV CELL DEV BI, V19, P287, DOI 10.1146/annurev.cellbio.19.111401.093127; Evangelista M, 2000, J CELL BIOL, V148, P353, DOI 10.1083/jcb.148.2.353; Gabriely G, 2007, MOL CELL BIOL, V27, P526, DOI 10.1128/MCB.00577-06; Geli MI, 1996, SCIENCE, V272, P533, DOI 10.1126/science.272.5261.533; Goldberg AL, 2007, BIOCHEM SOC T, V35, P12, DOI 10.1042/BST0350012; Gu F, 1997, J CELL BIOL, V139, P1183, DOI 10.1083/jcb.139.5.1183; Hanna J, 2007, FEBS LETT, V581, P2854, DOI 10.1016/j.febslet.2007.03.053; Hoffman M, 1996, GENETICS, V143, P1555; Howard JP, 2002, J CELL BIOL, V157, P315, DOI 10.1083/jcb.200110027; Huang PH, 1997, J CELL BIOL, V136, P803, DOI 10.1083/jcb.136.4.803; Huang WP, 2002, CELL STRUCT FUNCT, V27, P409, DOI 10.1247/csf.27.409; Hung GC, 2004, J BIOL CHEM, V279, P49138, DOI 10.1074/jbc.M404544200; JONES EW, 1991, J BIOL CHEM, V266, P7963; Kaksonen M, 2003, CELL, V115, P475, DOI 10.1016/S0092-8674(03)00883-3; Kaksonen M, 2005, CELL, V123, P305, DOI 10.1016/j.cell.2005.09.024; Klionsky DJ, 2005, J CELL SCI, V118, P7, DOI 10.1242/jcs.01620; KLIONSKY DJ, 1990, MICROBIOL REV, V54, P266, DOI 10.1128/MMBR.54.3.266-292.1990; KUBLER E, 1993, EMBO J, V12, P2855, DOI 10.1002/j.1460-2075.1993.tb05947.x; Mizushima N, 2008, NATURE, V451, P1069, DOI 10.1038/nature06639; Mizushima N, 2007, ANNU REV NUTR, V27, P19, DOI 10.1146/annurev.nutr.27.061406.093749; MORTIMORE GE, 1983, P NATL ACAD SCI-BIOL, V80, P2179, DOI 10.1073/pnas.80.8.2179; MORTIMORE GE, 1973, BIOCHEM BIOPH RES CO, V54, P89, DOI 10.1016/0006-291X(73)90892-9; NEELY AN, 1977, J BIOL CHEM, V252, P6948; Piguet V, 1999, CELL, V97, P63, DOI 10.1016/S0092-8674(00)80715-1; Rajawat YS, 2009, AGEING RES REV, V8, P199, DOI 10.1016/j.arr.2009.05.001; Reggiori F, 2005, CURR OPIN CELL BIOL, V17, P415, DOI 10.1016/j.ceb.2005.06.007; ROBINSON JS, 1988, MOL CELL BIOL, V8, P4936, DOI 10.1128/MCB.8.11.4936; ROTHMAN JH, 1986, CELL, V47, P1041, DOI 10.1016/0092-8674(86)90819-6; Rubinsztein DC, 2006, NATURE, V443, P780, DOI 10.1038/nature05291; Sarkar S, 2008, FEBS J, V275, P4263, DOI 10.1111/j.1742-4658.2008.06562.x; Seglen P O, 1990, Semin Cell Biol, V1, P441; Shieh HL, 1998, J BIOL CHEM, V273, P3381, DOI 10.1074/jbc.273.6.3381; Shieh HL, 2001, J BIOL CHEM, V276, P10398, DOI 10.1074/jbc.M001767200; Sun YD, 2006, DEV CELL, V11, P33, DOI 10.1016/j.devcel.2006.05.008; Toret CP, 2006, J CELL SCI, V119, P4585, DOI 10.1242/jcs.03251; Toshima JY, 2006, P NATL ACAD SCI USA, V103, P5793, DOI 10.1073/pnas.0601042103; TUTTLE DL, 1995, J CELL SCI, V108, P25; Varshavsky A, 2005, TRENDS BIOCHEM SCI, V30, P283, DOI 10.1016/j.tibs.2005.04.005; VIDA TA, 1995, J CELL BIOL, V128, P779, DOI 10.1083/jcb.128.5.779; Wang CW, 2003, MOL MED, V9, P65, DOI 10.1007/BF03402040; Warren DT, 2002, J CELL SCI, V115, P1703; WHITNEY JA, 1995, CELL, V83, P703; Wieland F, 1999, CURR OPIN CELL BIOL, V11, P440, DOI 10.1016/S0955-0674(99)80063-5; Yang HC, 2002, P NATL ACAD SCI USA, V99, P751, DOI 10.1073/pnas.022462899	65	24	24	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 8	2010	285	2					1516	1528		10.1074/jbc.M109.028241	http://dx.doi.org/10.1074/jbc.M109.028241			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	539MH	19892709	Green Published, hybrid			2022-12-25	WOS:000273258200071
J	Gao, WT; Kang, JH; Liao, Y; Ding, WX; Gambotto, AA; Watkins, SC; Liu, YJ; Stolz, DB; Yin, XM				Gao, Wentao; Kang, Jeong Han; Liao, Yong; Ding, Wen-Xing; Gambotto, Andrea A.; Watkins, Simon C.; Liu, Yong-Jian; Stolz, Donna B.; Yin, Xiao-Ming			Biochemical Isolation and Characterization of the Tubulovesicular LC3-positive Autophagosomal Compartment	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MAMMALIAN-CELLS; ENDOPLASMIC-RETICULUM; ENDOCYTIC PATHWAYS; PROTEIN; MEMBRANE; VACUOLES; MACROAUTOPHAGY; MATURATION; YEAST; ATG9	Autophagosomes and their precursors are best defined by electron microscopy but may also be traced in living cells based on the distribution of specific autophagy molecules. LC3, the most commonly examined autophagy marker in mammalian cells, labels structures that are frequently manifested as dots or rings using light microscopy; however, the nature of these structures is not entirely clear. We reported here a novel approach to examine the LC3-positive compartment in cell-free lysates, which revealed that they were actually tubulovesicular structures with considerable heterogeneity. Using affinity purification, we isolated these membranes for electron microscopy, which indicated that they possessed ultrastructural features consistent with autophagosomal membranes at various maturation stages. Further biochemical and proteomics analyses demonstrated the presence of multiple autophagy-related and other functional molecules. The different distribution patterns of Atg5, Atg16, Atg9, and p62/SQSTM1 on the LC3-positive compartment provided new clues on how these molecules might be involved in the dynamics of the autophagosomal membranes. Finally, several morphologically unique groups of LC3-positive membranes were categorized. Their topological configurations suggested that double-membrane vesicles could be derived from single membrane compartments via different means, including tubule-to-vesicle conversion, whose presence was supported by live cell imaging. These findings thus provide new information on the dynamics of the autophagosomal compartment.	[Yin, Xiao-Ming] Univ Pittsburgh, Sch Med, Dept Pathol, Pittsburgh, PA 15261 USA; [Gambotto, Andrea A.] Univ Pittsburgh, Sch Med, Dept Surg, Pittsburgh, PA 15261 USA; [Watkins, Simon C.; Stolz, Donna B.] Univ Pittsburgh, Sch Med, Dept Cell Biol & Physiol, Pittsburgh, PA 15261 USA; [Liu, Yong-Jian] Univ Pittsburgh, Sch Med, Dept Neurobiol, Pittsburgh, PA 15261 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Yin, XM (corresponding author), Univ Pittsburgh, Sch Med, Dept Pathol, Pittsburgh, PA 15261 USA.	xmyin@pitt.edu	Kang, Jeong-Han/J-3541-2019; Liu, Yongjian/J-7852-2018; Watkins, Simon/ABG-2590-2021	Kang, Jeong-Han/0000-0002-9693-0696; Watkins, Simon/0000-0003-4092-1552	National Institutes of Health [CA111456, CA83817, NS058463]; NATIONAL CANCER INSTITUTE [R01CA111456, R01CA083817] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R21NS058463] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))	This work was supported, in whole or in part, by National Institutes of Health Grants CA111456 and CA83817 (to X.M.Y.) and NS058463 (to Y.J.L.).	Axe EL, 2008, J CELL BIOL, V182, P685, DOI 10.1083/jcb.200803137; Bjorkoy G, 2005, J CELL BIOL, V171, P603, DOI 10.1083/jcb.200507002; Chan EYW, 2009, MOL CELL BIOL, V29, P157, DOI 10.1128/MCB.01082-08; DEDUVE C, 1966, ANNU REV PHYSIOL, V28, P435, DOI 10.1146/annurev.ph.28.030166.002251; Demarchi F, 2006, J CELL BIOL, V175, P595, DOI 10.1083/jcb.200601024; Ding WX, 2007, J BIOL CHEM, V282, P4702, DOI 10.1074/jbc.M609267200; Eskelinen EL, 2005, AUTOPHAGY, V1, P1, DOI 10.4161/auto.1.1.1270; Fader CM, 2008, TRAFFIC, V9, P230, DOI 10.1111/j.1600-0854.2007.00677.x; Fengsrud M, 2004, AUTOPHAGY, P11; Fujita N, 2008, MOL BIOL CELL, V19, P2092, DOI 10.1091/mbc.E07-12-1257; Gao WT, 2008, AUTOPHAGY, V4, P754, DOI 10.4161/auto.6360; Gohla A, 2007, P NATL ACAD SCI USA, V104, P3003, DOI 10.1073/pnas.0611434104; GORDON PB, 1988, BIOCHEM BIOPH RES CO, V151, P40, DOI 10.1016/0006-291X(88)90556-6; Gutierrez MG, 2004, J CELL SCI, V117, P2687, DOI 10.1242/jcs.01114; He CC, 2008, MOL BIOL CELL, V19, P5506, DOI 10.1091/mbc.E08-05-0544; Itoh T, 2008, MOL BIOL CELL, V19, P2916, DOI 10.1091/mbc.E07-12-1231; Jager S, 2004, J CELL SCI, V117, P4837, DOI 10.1242/jcs.01370; Kabeya Y, 2000, EMBO J, V19, P5720, DOI 10.1093/emboj/19.21.5720; Kang JH, 2006, PROTEOMICS, V6, P1261, DOI 10.1002/pmic.200500290; Kanki T, 2009, DEV CELL, V17, P98, DOI 10.1016/j.devcel.2009.06.014; Kirisako T, 1999, J CELL BIOL, V147, P435, DOI 10.1083/jcb.147.2.435; Klionsky DJ, 2008, AUTOPHAGY, V4, P151, DOI 10.4161/auto.5338; Kochl R, 2006, TRAFFIC, V7, P129, DOI 10.1111/j.1600-0854.2005.00368.x; Komatsu M, 2007, CELL, V131, P1149, DOI 10.1016/j.cell.2007.10.035; Kundu M, 2008, ANNU REV PATHOL-MECH, V3, P427, DOI 10.1146/annurev.pathmechdis.2.010506.091842; Levine B, 2004, DEV CELL, V6, P463, DOI 10.1016/S1534-5807(04)00099-1; Liang CY, 2008, NAT CELL BIOL, V10, P776, DOI 10.1038/ncb1740; Liou W, 1997, J CELL BIOL, V136, P61, DOI 10.1083/jcb.136.1.61; Meijer AJ, 2004, INT J BIOCHEM CELL B, V36, P2445, DOI 10.1016/j.biocel.2004.02.002; Mizushima N, 2001, J CELL BIOL, V152, P657, DOI 10.1083/jcb.152.4.657; Mizushima N, 2003, J CELL SCI, V116, P1679, DOI 10.1242/jcs.00381; Mizushima N, 2007, GENE DEV, V21, P2861, DOI 10.1101/gad.1599207; Nakatogawa H, 2007, CELL, V130, P165, DOI 10.1016/j.cell.2007.05.021; NEUHOFF V, 1988, ELECTROPHORESIS, V9, P255, DOI 10.1002/elps.1150090603; Okamoto K, 2009, DEV CELL, V17, P87, DOI 10.1016/j.devcel.2009.06.013; Overbye A, 2007, AUTOPHAGY, V3, P300, DOI 10.4161/auto.3910; Ravikumar B, 2008, J CELL SCI, V121, P1649, DOI 10.1242/jcs.025726; Reggiori F, 2005, AUTOPHAGY, V1, P101, DOI 10.4161/auto.1.2.1840; SEGLEN PO, 1992, EXPERIENTIA, V48, P158, DOI 10.1007/BF01923509; Stromhaug PE, 1998, BIOCHEM J, V335, P217, DOI 10.1042/bj3350217; Suzuki K, 2007, FEBS LETT, V581, P2156, DOI 10.1016/j.febslet.2007.01.096; Xie ZP, 2007, NAT CELL BIOL, V9, P1102, DOI 10.1038/ncb1007-1102; Yamada T, 2005, J BIOL CHEM, V280, P18283, DOI 10.1074/jbc.M413957200; Young ARJ, 2006, J CELL SCI, V119, P3888, DOI 10.1242/jcs.03172; Yue Z, 2007, AUTOPHAGY, V3, P139, DOI 10.4161/auto.3602; Zheng JY, 1998, J CELL SCI, V111, P1061	46	69	73	1	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 8	2010	285	2					1371	1383		10.1074/jbc.M109.054197	http://dx.doi.org/10.1074/jbc.M109.054197			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	539MH	19910472	hybrid, Green Published			2022-12-25	WOS:000273258200057
J	Pruessmeyer, J; Martin, C; Hess, FM; Schwarz, N; Schmidt, S; Kogel, T; Hoettecke, N; Schmidt, B; Sechi, A; Uhlig, S; Ludwig, A				Pruessmeyer, Jessica; Martin, Christian; Hess, Franz M.; Schwarz, Nicole; Schmidt, Sven; Kogel, Tanja; Hoettecke, Nicole; Schmidt, Boris; Sechi, Antonio; Uhlig, Stefan; Ludwig, Andreas			A Disintegrin and Metalloproteinase 17 (ADAM17) Mediates Inflammation-induced Shedding of Syndecan-1 and-4 by Lung Epithelial Cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALPHA-CONVERTING-ENZYME; TNF-ALPHA; TRANSMEMBRANE CHEMOKINES; SOLUBLE SYNDECAN-1; REGULATED RELEASE; GROWTH-FACTOR; ADHESION; MATRIX; ECTODOMAINS; MIGRATION	Syndecans are cell surface proteoglycans that bind and modulate various proinflammatory mediators and can be proteolytically shed from the cell surface. Within the lung, syndecan-1 and -4 are expressed as transmembrane proteins on epithelial cells and released in the bronchoalveolar fluid during inflammation. We here characterize the mechanism leading to the generation of soluble syndecan-1 and -4 in cultured epithelial cells and murine lung tissue. We show that the bladder carcinoma epithelial cell line ECV304, the lung epithelial cell line A459 and primary alveolar epithelial cells express and constitutively release syndecan-1 and -4. This release involves the activity of the disintegrin-like metalloproteinase ADAM17 as demonstrated by use of specific inhibitors and lentivirally transduced shRNA. Stimulation of epithelial cells with PMA, thrombin, or proinflammatory cytokines (TNF alpha/IFN gamma) led to the down-regulation of surface-expressed syndecan-1 and -4, which was associated with a significant increase of soluble syndecans and cell-associated cleavage fragments. The enhanced syndecan release was not related to gene induction of syndecans or ADAM17, but rather due to increased ADAM17 activity. Soluble syndecan-1 and -4 were also released into the bronchoalveolar fluid of mice. Treatment with TNF alpha/IFN gamma increased ADAM17 activity and syndecan release in murine lungs. Both constitutive and induced syndecan shedding was prevented by the ADAM17 inhibitor. ADAM17 may therefore be an important regulator of syndecan functions on inflamed lung epithelium.	[Pruessmeyer, Jessica; Martin, Christian; Hess, Franz M.; Schwarz, Nicole; Schmidt, Sven; Kogel, Tanja; Uhlig, Stefan; Ludwig, Andreas] Rhein Westfal TH Aachen, Inst Pharmacol & Toxicol, D-52074 Aachen, Germany; [Pruessmeyer, Jessica; Kogel, Tanja; Ludwig, Andreas] Rhein Westfal TH Aachen, Fac Med, Interdisciplinary Ctr Clin Res Biomat, D-52074 Aachen, Germany; [Hoettecke, Nicole; Schmidt, Boris] Tech Univ Darmstadt, Clemens Schopf Inst Chem & Biochem, D-64287 Darmstadt, Germany; [Sechi, Antonio] Rhein Westfal TH Aachen, Fac Med, Inst Biomed Engn, D-52074 Aachen, Germany	RWTH Aachen University; RWTH Aachen University; Technical University of Darmstadt; RWTH Aachen University	Ludwig, A (corresponding author), Rhein Westfal TH Aachen, Inst Pharmacol & Toxicol, Pauwelsstr 30, D-52074 Aachen, Germany.	aludwig@ukaachen.de	Ludwig, Andreas/I-5685-2012; Schmidt, Boris/D-3293-2009; Schwarz, Nicole/ABC-8096-2020; Sechi, Antonio S/A-5595-2009; Uhlig, Stefan/A-7290-2014; Schmidt, Boris/M-7886-2019	Ludwig, Andreas/0000-0001-8536-4986; Schmidt, Boris/0000-0003-1662-2392; Sechi, Antonio S/0000-0002-1374-1794; Uhlig, Stefan/0000-0003-2332-1280; Schmidt, Boris/0000-0003-1662-2392; Schwarz, Nicole/0000-0001-7888-6970	RWTH Aachen;  [SFB 542]	RWTH Aachen; 	This work was supported in part by IZKF BioMAT of the RWTH Aachen and by SFB 542 Projects A12 and C16.	Abel S, 2004, J IMMUNOL, V172, P6362, DOI 10.4049/jimmunol.172.10.6362; Amour A, 2000, FEBS LETT, V473, P275, DOI 10.1016/S0014-5793(00)01528-3; Amour A, 1998, FEBS LETT, V435, P39, DOI 10.1016/S0014-5793(98)01031-X; Bartlett AH, 2007, MOL CELLS, V24, P153; Bass MD, 2007, J CELL BIOL, V177, P527, DOI 10.1083/jcb.200610076; Black RA, 2003, BIOCHEM SOC SYMP, V70, P39, DOI 10.1042/bss0700039; Brule S, 2006, GLYCOBIOLOGY, V16, P488, DOI 10.1093/glycob/cwj098; Chen P, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0006565; DE SB, 1999, NATURE, V398, P518; Dijkstra A, 2009, VIRCHOWS ARCH, V454, P441, DOI 10.1007/s00428-009-0748-4; Elenius V, 2004, J BIOL CHEM, V279, P41928, DOI 10.1074/jbc.M404506200; Endo K, 2003, J BIOL CHEM, V278, P40764, DOI 10.1074/jbc.M306736200; Fitzgerald ML, 2000, J CELL BIOL, V148, P811, DOI 10.1083/jcb.148.4.811; Hasegawa M, 2007, RESPIROLOGY, V12, P140, DOI 10.1111/j.1440-1843.2006.00967.x; Hayashida K, 2008, J BIOL CHEM, V283, P19895, DOI 10.1074/jbc.M801614200; Hayashida K, 2009, BLOOD, V114, P3033, DOI 10.1182/blood-2009-02-204966; Held HD, 2000, AM J RESP CRIT CARE, V162, P1547, DOI 10.1164/ajrccm.162.4.9912079; Holen I, 2001, BRIT J HAEMATOL, V114, P414, DOI 10.1046/j.1365-2141.2001.02963.x; Hundhausen C, 2003, BLOOD, V102, P1186, DOI 10.1182/blood-2002-12-3775; Hundhausen C, 2007, J IMMUNOL, V178, P8064, DOI 10.4049/jimmunol.178.12.8064; Iba K, 2000, J CELL BIOL, V149, P1143, DOI 10.1083/jcb.149.5.1143; Joensuu H, 2002, CANCER RES, V62, P5210; KIM CW, 1994, MOL BIOL CELL, V5, P797, DOI 10.1091/mbc.5.7.797; Koenen RR, 2009, BLOOD, V113, P4799, DOI 10.1182/blood-2008-04-152330; Li QL, 2002, CELL, V111, P635, DOI 10.1016/S0092-8674(02)01079-6; Ludwig A, 2005, COMB CHEM HIGH T SCR, V8, P161, DOI 10.2174/1386207053258488; Maretzky T, 2005, P NATL ACAD SCI USA, V102, P9182, DOI 10.1073/pnas.0500918102; Okamoto I, 2001, J CELL BIOL, V155, P755, DOI 10.1083/jcb.200108159; Penc SF, 1998, J BIOL CHEM, V273, P28116, DOI 10.1074/jbc.273.43.28116; Pruessmeyer J, 2009, SEMIN CELL DEV BIOL, V20, P164, DOI 10.1016/j.semcdb.2008.09.005; Salmon Patrick, 2006, Curr Protoc Neurosci, VChapter 4, DOI 10.1002/0471142301.ns0421s37; Scholz F, 2007, J INVEST DERMATOL, V127, P1444, DOI 10.1038/sj.jid.5700751; Schulte A, 2007, BIOCHEM BIOPH RES CO, V358, P233, DOI 10.1016/j.bbrc.2007.04.100; Seidel C, 2000, BLOOD, V95, P388, DOI 10.1182/blood.V95.2.388; Su G, 2008, CANCER RES, V68, P9558, DOI 10.1158/0008-5472.CAN-08-1645; Subramanian SV, 1997, J BIOL CHEM, V272, P14713, DOI 10.1074/jbc.272.23.14713; Wang ZH, 2005, BIOCHEMISTRY-US, V44, P12355, DOI 10.1021/bi050620i; Wiznerowicz M, 2003, J VIROL, V77, P8957, DOI 10.1128/JVI.77.16.8957-8951.2003; Zhang YH, 2004, INT IMMUNOPHARMACOL, V4, P1845, DOI 10.1016/j.intimp.2004.08.003	39	120	124	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 1	2010	285	1					555	564		10.1074/jbc.M109.059394	http://dx.doi.org/10.1074/jbc.M109.059394			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	536UT	19875451	hybrid, Green Published			2022-12-25	WOS:000273070100057
J	Wang, P; Wu, F; Ma, YP; Li, L; Lai, R; Young, LC				Wang, Peng; Wu, Fang; Ma, Yupo; Li, Liang; Lai, Raymond; Young, Leah C.			Functional Characterization of the Kinase Activation Loop in Nucleophosmin (NPM)-Anaplastic Lymphoma Kinase (ALK) Using Tandem Affinity Purification and Liquid Chromatography-Mass Spectrometry	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NPM-ALK; ANAPLASTIC LYMPHOMA; TYROSINE KINASE; PROTEIN; IDENTIFICATION; DIGESTION; DOMAIN; GENE; PHOSPHORYLATION; FUSION	Previous studies have shown that the kinase activation loop (KAL) of the oncogenic fusion protein NPM-ALK regulates its overall tyrosine phosphorylation status and tumorigenicity. Using tandem affinity purification-mass spectrometry, we assessed how the KAL of NPM-ALK regulates the phosphorylation status of its individual tyrosines. Using the lysates of GP293 cells transfected with NPM-ALK, our highly reproducible results showed evidence of phosphorylation in all 3 tyrosines in KAL and 8 tyrosines outside KAL. We created 7 KAL mutants, each of which carried a Tyr-to-Phe mutation of >= 1 of the 3 tyrosines in KAL. A complete loss of the 8 phosphotyrosines outside KAL was found in 3 KAL mutants, and their oncogenicity (assessed by cell viability, colony formation, and the ability to phosphorylate effector proteins) was abrogated. A partial loss of the 8 phosphotyrosines was found in 4 KAL mutants, but their oncogenicity did not show simple correlation with the number of residual phosphotyrosines. Tyr-to-Phe mutations of each of the 8 phosphotyrosines outside KAL did not result in a significant decrease in the oncogenicity. In conclusion, we have provided details of how the KAL in NPM-ALK regulates its tyrosine phosphorylation pattern. Our results challenge some of the current concepts regarding the relationship between the tyrosine phosphorylation and oncogenicity of NPM-ALK.	[Lai, Raymond] Univ Alberta, Dept Lab Med & Pathol, Cross Canc Inst, Edmonton, AB T6G 1Z2, Canada; [Wu, Fang; Li, Liang] Univ Alberta, Dept Chem, Edmonton, AB T6G 2Z2, Canada; [Ma, Yupo] Nevada Canc Inst, Div Lab Med, Las Vegas, NV 89135 USA	University of Alberta; University of Alberta; University of California System; University of California San Diego	Lai, R (corresponding author), Univ Alberta, Dept Lab Med & Pathol, Cross Canc Inst, Edmonton, AB T6G 1Z2, Canada.	rlai@ualberta.ca	Young, Leah/AAN-3579-2020; Young, Leah C/B-9051-2012; Li, Liang/D-1822-2011	Young, Leah C/0000-0001-7156-1006; 	Canadian Institutes of Health Research; Alberta Cancer Research Institute; Natural Sciences and Engineering Research Council of Canada; Canada Research Chairs Program	Canadian Institutes of Health Research(Canadian Institutes of Health Research (CIHR)); Alberta Cancer Research Institute; Natural Sciences and Engineering Research Council of Canada(Natural Sciences and Engineering Research Council of Canada (NSERC)CGIAR); Canada Research Chairs Program(Canada Research Chairs)	This work was supported by the Canadian Institutes of Health Research and the Alberta Cancer Research Institute (to R. L.). This work was also supported by the Natural Sciences and Engineering Research Council of Canada and the Canada Research Chairs Program (to L. L.).	Amin HM, 2007, BLOOD, V110, P2259, DOI 10.1182/blood-2007-04-060715; Bai RY, 1998, MOL CELL BIOL, V18, P6951, DOI 10.1128/MCB.18.12.6951; Bard JD, 2008, LEUKEMIA, V22, P1595, DOI 10.1038/leu.2008.129; Boccalatte FE, 2009, BLOOD, V113, P2776, DOI 10.1182/blood-2008-06-161018; Delsol G, 2001, WHO CLASSIFICATION T, P230; Donella-Deana A, 2005, BIOCHEMISTRY-US, V44, P8533, DOI 10.1021/bi0472954; Doucette A, 2003, J AM SOC MASS SPECTR, V14, P203, DOI 10.1016/S1044-0305(02)00909-1; Doucette A, 2000, ANAL CHEM, V72, P3355, DOI 10.1021/ac000176j; Falini B, 2007, HAEMATOLOGICA, V92, P519, DOI 10.3324/haematol.11007; Fujimoto J, 1996, P NATL ACAD SCI USA, V93, P4181, DOI 10.1073/pnas.93.9.4181; Han YJ, 2006, BLOOD, V108, P2796, DOI 10.1182/blood-2006-04-017434; HUBBARD SR, 1994, NATURE, V372, P746, DOI 10.1038/372746a0; Kaiser Peter, 2008, V439, P309, DOI 10.1007/978-1-59745-188-8_21; Leventaki V, 2007, BLOOD, V110, P1621, DOI 10.1182/blood-2006-11-059451; LEVINE BA, 1991, J BIOL CHEM, V266, P3565; Marzec M, 2007, ONCOGENE, V26, P5606, DOI 10.1038/sj.onc.1210346; Marzec M, 2007, ONCOGENE, V26, P813, DOI 10.1038/sj.onc.1209843; MORRIS SW, 1994, SCIENCE, V263, P1281, DOI 10.1126/science.8122112; Piva R, 2006, BLOOD, V107, P689, DOI 10.1182/blood-2005-05-2125; Rush J, 2005, NAT BIOTECHNOL, V23, P94, DOI 10.1038/nbt1046; Slupianek A, 2004, EXP HEMATOL, V32, P1265, DOI 10.1016/j.exphem.2004.11.002; Slupianek A, 2001, CANCER RES, V61, P2194; Tagwerker C, 2006, MOL CELL PROTEOMICS, V5, P737, DOI 10.1074/mcp.M500368-MCP200; Tartari CJ, 2008, J BIOL CHEM, V283, P3743, DOI 10.1074/jbc.M706067200; Turner SD, 2007, CELL SIGNAL, V19, P740, DOI 10.1016/j.cellsig.2006.09.007; Wan WH, 2006, BLOOD, V107, P1617, DOI 10.1182/blood-2005-08-3254; Wang N, 2008, ANAL CHEM, V80, P4696, DOI 10.1021/ac800260w; Wang N, 2007, J PROTEOME RES, V6, P263, DOI 10.1021/pr060367o; Wang P, 2009, J PROTEOME RES, V8, P3403, DOI 10.1021/pr9000477; Wu F, 2009, AM J PATHOL, V174, P361, DOI 10.2353/ajpath.2009.080521; ZHANG B, 1991, J BIOL CHEM, V266, P990	31	14	14	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 1	2010	285	1					95	103		10.1074/jbc.M109.059758	http://dx.doi.org/10.1074/jbc.M109.059758			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	536UT	19887368	Green Published, hybrid			2022-12-25	WOS:000273070100010
J	Zhao, CX; Matveeva, EA; Ren, QS; Whiteheart, SW				Zhao, Chunxia; Matveeva, Elena A.; Ren, Qiansheng; Whiteheart, Sidney W.			Dissecting the N-Ethylmaleimide-sensitive Factor REQUIRED ELEMENTS OF THE N AND D1 DOMAINS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEPENDENT PROTEASE FTSH; AAA PLUS PROTEINS; CRYSTAL-STRUCTURE; FUSION PROTEIN; ATPASE ACTIVITY; CONFORMATIONAL-CHANGES; TERMINAL DOMAIN; IN-VIVO; P97/VALOSIN-CONTAINING PROTEIN; CONSERVED ARGININE	N-Ethylmaleimide-sensitive factor (NSF) is a homo-hexameric member of the AAA(+) (ATPases associated with various cellular activities plus) family. It plays an essential role in most intracellular membrane trafficking through its binding to and disassembly of soluble NSF attachment protein (SNAP) receptor (SNARE) complexes. Each NSF protomer contains an N-terminal domain (NSF-N) and two AAA domains, a catalytic NSF-D1 and a structural NSF-D2. This study presents detailed mutagenesis analyses of NSF-N and NSF-D1, dissecting their roles in ATP hydrolysis, SNAP.SNARE binding, and complex disassembly. Our results show that a positively charged surface on NSF-N, bounded by Arg(67) and Lys(105), and the conserved residues in the central pore of NSF-D1 (Tyr(296) and Gly(298)) are involved in SNAP.SNARE binding but not basal ATP hydrolysis. Mutagenesis of Sensor 1 (Thr(373)-Arg(375)), Sensor 2 (Glu(440)-Glu(442)), and Arginine Fingers (Arg(385) and Arg(388)) in NSF-D1 shows that each region plays a discrete role. Sensor 1 is important for basal ATPase activity and nucleotide binding. Sensor 2 plays a role in ATP-and SNAP-dependent SNARE complex binding and disassembly but does so in cis and not through inter-protomer interactions. Arginine Fingers are important for SNAP.SNARE complex-stimulated ATPase activity and complex disassembly. Mutants at these residues have a dominant-negative phenotype in cells, suggesting that Arginine Fingers function in trans via inter-protomer interactions. Taken together, these data establish functional roles for many of the structural elements of the N domain and of the D1 ATP-binding site of NSF.	[Zhao, Chunxia; Matveeva, Elena A.; Ren, Qiansheng; Whiteheart, Sidney W.] Univ Kentucky, Med Ctr, Dept Mol & Cellular Biochem, Lexington, KY 40536 USA	University of Kentucky	Whiteheart, SW (corresponding author), 741 S Limestone,BBSRB B261, Lexington, KY 40536 USA.	whitehe@uky.edu		Whiteheart, Sidney/0000-0001-5577-0473	National Institutes of Health [NS046242]; American Heart Association Predoctoral Fellowship [065238B]	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); American Heart Association Predoctoral Fellowship(American Heart Association)	This work was supported, in whole or in part, by National Institutes of Health Grant NS046242 (to S. W. W.). This work was also supported by a Steckler award (to C. Z.) and American Heart Association Predoctoral Fellowship 065238B (to Q. R.).	Aker J, 2007, PLANT PHYSIOL, V145, P339, DOI 10.1104/pp.107.103986; Babor SM, 1999, P NATL ACAD SCI USA, V96, P14759, DOI 10.1073/pnas.96.26.14759; Barnard RJO, 1996, MOL BIOL CELL, V7, P693, DOI 10.1091/mbc.7.5.693; Besche H, 2004, FEBS LETT, V574, P161, DOI 10.1016/j.febslet.2004.08.021; Beuron F, 2006, EMBO J, V25, P1967, DOI 10.1038/sj.emboj.7601055; Brunger AT, 2003, FEBS LETT, V555, P126, DOI 10.1016/S0014-5793(03)01107-4; Dalal S, 2004, MOL BIOL CELL, V15, P637, DOI 10.1091/mbc.E03-02-0097; DeLaBarre B, 2005, J MOL BIOL, V347, P437, DOI 10.1016/j.jmb.2005.01.060; DeLaBarre B, 2003, NAT STRUCT BIOL, V10, P856, DOI 10.1038/nsb972; DeLaBarre B, 2006, MOL CELL, V22, P451, DOI 10.1016/j.molcel.2006.03.036; Dreveny I, 2004, EMBO J, V23, P1030, DOI 10.1038/sj.emboj.7600139; Erzberger JP, 2006, ANNU REV BIOPH BIOM, V35, P93, DOI 10.1146/annurev.biophys.35.040405.101933; Furst J, 2003, EMBO J, V22, P4365, DOI 10.1093/emboj/cdg420; Gerega A, 2005, J BIOL CHEM, V280, P42856, DOI 10.1074/jbc.M510592200; Gonciarz MD, 2008, J MOL BIOL, V384, P878, DOI 10.1016/j.jmb.2008.09.066; Hanson PI, 2005, NAT REV MOL CELL BIO, V6, P519, DOI 10.1038/nrm1684; Hanson PI, 1997, CELL, V90, P523, DOI 10.1016/S0092-8674(00)80512-7; Hattendorf DA, 2002, P NATL ACAD SCI USA, V99, P2732, DOI 10.1073/pnas.261693199; Hattendorf DA, 2002, EMBO J, V21, P12, DOI 10.1093/emboj/21.1.12; Haynes LP, 1998, FEBS LETT, V436, P1, DOI 10.1016/S0014-5793(98)01088-6; Hishida T, 2004, P NATL ACAD SCI USA, V101, P9573, DOI 10.1073/pnas.0403584101; Hohl TM, 1998, MOL CELL, V2, P539, DOI 10.1016/S1097-2765(00)80153-7; Horsnell WGC, 2002, BIOCHEMISTRY-US, V41, P5230, DOI 10.1021/bi0160359; Huynh H, 2004, NAT CELL BIOL, V6, P831, DOI 10.1038/ncb1164; Inoue M, 2008, TRAFFIC, V9, P2180, DOI 10.1111/j.1600-0854.2008.00831.x; Isaacson RL, 2007, J BIOL CHEM, V282, P21361, DOI 10.1074/jbc.M610069200; Jeruzalmi D, 2001, CELL, V106, P429, DOI 10.1016/S0092-8674(01)00463-9; KAISER CA, 1990, CELL, V61, P723, DOI 10.1016/0092-8674(90)90483-U; Karata K, 1999, J BIOL CHEM, V274, P26225, DOI 10.1074/jbc.274.37.26225; Kawakami H, 2005, J BIOL CHEM, V280, P27420, DOI 10.1074/jbc.M502764200; Kawakami H, 2006, MOL MICROBIOL, V62, P1310, DOI 10.1111/j.1365-2958.2006.05450.x; Lee S, 2003, CELL, V115, P229, DOI 10.1016/S0092-8674(03)00807-9; Lenzen CU, 1998, CELL, V94, P525, DOI 10.1016/S0092-8674(00)81593-7; Li CS, 2006, ARCH BIOCHEM BIOPHYS, V450, P176, DOI 10.1016/j.abb.2006.04.002; Littleton JT, 1998, NEURON, V21, P401, DOI 10.1016/S0896-6273(00)80549-8; Martin A, 2008, NAT STRUCT MOL BIOL, V15, P1147, DOI 10.1038/nsmb.1503; Matias PM, 2006, J BIOL CHEM, V281, P38918, DOI 10.1074/jbc.M605625200; Matsushita K, 2003, CELL, V115, P139, DOI 10.1016/S0092-8674(03)00803-1; Matveeva EA, 2002, BIOCHEMISTRY-US, V41, P530, DOI 10.1021/bi015632s; May AP, 1999, NAT CELL BIOL, V1, P175, DOI 10.1038/11097; Mogk A, 2003, J BIOL CHEM, V278, P17615, DOI 10.1074/jbc.M209686200; Mogk A, 2008, BIOCHEM SOC T, V36, P120, DOI 10.1042/BST0360120; Moreau MJ, 2007, MOL CELL, V28, P304, DOI 10.1016/j.molcel.2007.08.013; NAGIEC EE, 1995, J BIOL CHEM, V270, P29182, DOI 10.1074/jbc.270.49.29182; Neuwald AF, 1999, GENOME RES, V9, P27; Ogura T, 2004, J STRUCT BIOL, V146, P106, DOI 10.1016/j.jsb.2003.11.008; Putnam CD, 2001, J MOL BIOL, V311, P297, DOI 10.1006/jmbi.2001.4852; Rothballer A, 2007, FEBS LETT, V581, P1197, DOI 10.1016/j.febslet.2007.02.031; Scheffzek K, 1997, SCIENCE, V277, P333, DOI 10.1126/science.277.5324.333; Schumacher J, 2007, J BIOL CHEM, V282, P9825, DOI 10.1074/jbc.M611532200; Scott A, 2005, EMBO J, V24, P3658, DOI 10.1038/sj.emboj.7600818; Shiozawa K, 2006, FEBS J, V273, P4959, DOI 10.1111/j.1742-4658.2006.05494.x; Sorensen JB, 2006, EMBO J, V25, P955, DOI 10.1038/sj.emboj.7601003; Steel GJ, 2000, MOL BIOL CELL, V11, P1345, DOI 10.1091/mbc.11.4.1345; Suno R, 2006, MOL CELL, V22, P575, DOI 10.1016/j.molcel.2006.04.020; TAGAYA M, 1993, J BIOL CHEM, V268, P2662; Takahashi N, 2002, J BIOL CHEM, V277, P16033, DOI 10.1074/jbc.M108615200; Takehara M, 2008, BIOCHEM J, V413, P535, DOI 10.1042/BJ20070484; Wang Q, 2005, J BIOL CHEM, V280, P40515, DOI 10.1074/jbc.M509636200; Weber T, 1998, CELL, V92, P759, DOI 10.1016/S0092-8674(00)81404-X; Weibezahn J, 2004, CELL, V119, P653, DOI 10.1016/j.cell.2004.11.027; Wendler P, 2007, CELL, V131, P1366, DOI 10.1016/j.cell.2007.10.047; Whiteheart SW, 2001, INT REV CYTOL, V207, P71; WHITEHEART SW, 1994, J CELL BIOL, V126, P945, DOI 10.1083/jcb.126.4.945; WHITEHEART SW, 1993, NATURE, V362, P353, DOI 10.1038/362353a0; Yeung HO, 2008, BIOCHEM SOC T, V36, P62, DOI 10.1042/BST0360062; Yu RC, 1999, MOL CELL, V4, P97, DOI 10.1016/S1097-2765(00)80191-4; Yu RC, 1998, NAT STRUCT BIOL, V5, P803, DOI 10.1038/1843; Zhang XD, 2000, MOL CELL, V6, P1473, DOI 10.1016/S1097-2765(00)00143-X; Zhao CX, 2007, FEBS LETT, V581, P2140, DOI 10.1016/j.febslet.2007.03.032	70	34	34	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 1	2010	285	1					761	772		10.1074/jbc.M109.056739	http://dx.doi.org/10.1074/jbc.M109.056739			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	536UT	19887446	Green Published, hybrid			2022-12-25	WOS:000273070100077
J	Lai, YP; Lin, CC; Liao, WJ; Tang, CY; Chen, SC				Lai, Yo-Ping; Lin, Chia-Ching; Liao, Wan-Jung; Tang, Chih-Yung; Chen, Shu-Ching			CD4+ T Cell-Derived IL-2 Signals during Early Priming Advances Primary CD8(+) T Cell Responses	PLOS ONE			English	Article							ANTIGEN-PRESENTING CELLS; RAPID COLORIMETRIC ASSAY; IN-VIVO; B-CELL; SECONDARY EXPANSION; DENDRITIC CELLS; CUTTING EDGE; MEMORY; CD4(+); ACTIVATION	Stimulating naive CD8(+) T cells with specific antigens and costimulatory signals is insufficient to induce optimal clonal expansion and effector functions. In this study, we show that the activation and differentiation of CD8(+) T cells require IL-2 provided by activated CD4(+) T cells at the initial priming stage within 0-2.5 hours after stimulation. This critical IL-2 signal from CD4(+) cells is mediated through the IL-2R beta gamma of CD8(+) cells, which is independent of IL-2R alpha. The activation of IL-2 signaling advances the restriction point of the cell cycle, and thereby expedites the entry of antigen-stimulated CD8(+) T-cell into the S phase. Besides promoting cell proliferation, IL-2 stimulation increases the amount of IFN gamma and granzyme B produced by CD8(+) T cells. Furthermore, IL-2 at priming enhances the ability of P14 effector cells generated by antigen activation to eradicate B16.gp33 tumors in vivo. Therefore, our studies demonstrate that a full CD8(+) T-cell response is elicited by a critical temporal function of IL-2 released from CD4(+) T cells, providing mechanistic insights into the regulation of CD8(+) T cell activation and differentiation.			Lai, YP (corresponding author), Natl Taiwan Univ Hosp, Dept Internal Med, Taipei 100, Taiwan.	mdchensc@ntu.edu.tw		/0000-0002-9904-8199; Chen, Shu-Ching/0000-0001-9112-1526; TANG, CHIH-YUNG/0000-0003-1065-2865				BABCOCK SK, 1987, TRANSPLANT P, V19, P303; Bennett SRM, 1998, NATURE, V393, P478, DOI 10.1038/30996; Beuneu H, 2006, J IMMUNOL, V177, P1406, DOI 10.4049/jimmunol.177.3.1406; BEVERLY B, 1992, INT IMMUNOL, V4, P661, DOI 10.1093/intimm/4.6.661; Bourgeois C, 2002, SCIENCE, V297, P2060, DOI 10.1126/science.1072615; BULLER RML, 1987, NATURE, V328, P77, DOI 10.1038/328077a0; Castellino F, 2006, NATURE, V440, P890, DOI 10.1038/nature04651; COUSENS LP, 1995, J IMMUNOL, V155, P5690; Curtsinger JM, 1999, J IMMUNOL, V162, P3256; DENIZOT F, 1986, J IMMUNOL METHODS, V89, P271, DOI 10.1016/0022-1759(86)90368-6; Gattinoni L, 2005, J CLIN INVEST, V115, P1616, DOI 10.1172/JCI24480; Hammers HJ, 2002, J IMMUNOL METHODS, V264, P89, DOI 10.1016/S0022-1759(02)00082-0; HANSEN MB, 1989, J IMMUNOL METHODS, V119, P203, DOI 10.1016/0022-1759(89)90397-9; HOFFMANN MK, 1977, J EXP MED, V146, P1640, DOI 10.1084/jem.146.6.1640; JANEWAY CA, 1987, J IMMUNOL, V138, P1051; Janssen EM, 2003, NATURE, V421, P852, DOI 10.1038/nature01441; Janssen EM, 2005, NATURE, V434, P88, DOI 10.1038/nature03337; JENKINS MK, 1987, J EXP MED, V165, P302, DOI 10.1084/jem.165.2.302; Julia V, 1996, SCIENCE, V274, P421, DOI 10.1126/science.274.5286.421; KAKIUCHI T, 1983, J IMMUNOL, V131, P109; KEENE JA, 1982, J EXP MED, V155, P768, DOI 10.1084/jem.155.3.768; Kim HP, 2005, J BIOL CHEM, V280, P34042, DOI 10.1074/jbc.M505833200; Klebanoff CA, 2005, P NATL ACAD SCI USA, V102, P9571, DOI 10.1073/pnas.0503726102; KNEITZ B, 1995, EUR J IMMUNOL, V25, P2572, DOI 10.1002/eji.1830250925; Lee BO, 2003, J EXP MED, V198, P1759, DOI 10.1084/jem.20031440; Lenschow DJ, 1996, ANNU REV IMMUNOL, V14, P233, DOI 10.1146/annurev.immunol.14.1.233; Lord JD, 2000, J IMMUNOL, V164, P2533, DOI 10.4049/jimmunol.164.5.2533; MITCHISON NA, 1987, EUR J IMMUNOL, V17, P1579, DOI 10.1002/eji.1830171109; MOSMANN T, 1983, J IMMUNOL METHODS, V65, P55, DOI 10.1016/0022-1759(83)90303-4; MOSMANN TR, 1987, J IMMUNOL, V138, P1813; Muller J, 2008, CHEMBIOCHEM, V9, P723, DOI 10.1002/cbic.200700701; Nakamura M, 1993, Semin Immunol, V5, P309, DOI 10.1006/smim.1993.1037; Odenbreit S, 2000, SCIENCE, V287, P1497, DOI 10.1126/science.287.5457.1497; PFEIFFER C, 1995, J EXP MED, V181, P1569, DOI 10.1084/jem.181.4.1569; Plas DR, 2002, NAT IMMUNOL, V3, P515, DOI 10.1038/ni0602-515; Prevost-Blondel A, 1998, J IMMUNOL, V161, P2187; RAHEMTULLA A, 1991, NATURE, V353, P180, DOI 10.1038/353180a0; Ridge JP, 1998, NATURE, V393, P474, DOI 10.1038/30989; ROSENBERG AS, 1987, J EXP MED, V165, P1296, DOI 10.1084/jem.165.5.1296; Schoenberger SP, 1998, NATURE, V393, P480, DOI 10.1038/31002; Smith CM, 2004, NAT IMMUNOL, V5, P1143, DOI 10.1038/ni1129; SMITH KA, 1988, SCIENCE, V240, P1169, DOI 10.1126/science.3131876; Sojka DK, 2004, J IMMUNOL, V172, P6136, DOI 10.4049/jimmunol.172.10.6136; Sun JC, 2004, J IMMUNOL, V172, P3385, DOI 10.4049/jimmunol.172.6.3385; WILLERFORD DM, 1995, IMMUNITY, V3, P521, DOI 10.1016/1074-7613(95)90180-9; Williams MA, 2006, NATURE, V441, P890, DOI 10.1038/nature04790; WU Y, 1994, CURR BIOL, V4, P499, DOI 10.1016/S0960-9822(00)00110-X; Yang L, 2004, EUR J IMMUNOL, V34, P1617, DOI 10.1002/eji.200424939; Zinkernagel RM, 1996, SCIENCE, V271, P173, DOI 10.1126/science.271.5246.173	49	26	28	0	1	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA	1932-6203			PLOS ONE	PLoS One	NOV 10	2009	4	11							e7766	10.1371/journal.pone.0007766	http://dx.doi.org/10.1371/journal.pone.0007766			14	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	517ZU	19901991	Green Submitted, Green Published, gold			2022-12-25	WOS:000271658800007
J	Zhang, HH; Huang, JX; Duvel, K; Boback, B; Wu, SL; Squillace, RM; Wu, CL; Manning, BD				Zhang, Hui H.; Huang, Jingxiang; Duevel, Katrin; Boback, Bernard; Wu, Shulin; Squillace, Rachel M.; Wu, Chin-Lee; Manning, Brendan D.			Insulin Stimulates Adipogenesis through the Akt-TSC2-mTORC1 Pathway	PLOS ONE			English	Article								Background: The signaling pathways imposing hormonal control over adipocyte differentiation are poorly understood. While insulin and Akt signaling have been found previously to be essential for adipogenesis, the relative importance of their many downstream branches have not been defined. One direct substrate that is inhibited by Akt-mediated phosphorylation is the tuberous sclerosis complex 2 (TSC2) protein, which associates with TSC1 and acts as a critical negative regulator of the mammalian target of rapamycin (mTOR) complex 1 (mTORC1). Loss of function of the TSC1-TSC2 complex results in constitutive mTORC1 signaling and, through mTORC1-dependent feedback mechanisms and loss of mTORC2 activity, leads to a concomitant block of Akt signaling to its other downstream targets. Methodology/Principal Findings: We find that, despite severe insulin resistance and the absence of Akt signaling, TSC2-deficient mouse embryo fibroblasts and 3T3-L1 pre-adipocytes display enhanced adipocyte differentiation that is dependent on the elevated mTORC1 activity in these cells. Activation of mTORC1 causes a robust increase in the mRNA and protein expression of peroxisome proliferator-activated receptor gamma (PPAR gamma), which is the master transcriptional regulator of adipocyte differentiation. In examining the requirements for different Akt-mediated phosphorylation sites on TSC2, we find that only TSC2 mutants lacking all five previously identified Akt sites fully block insulin-stimulated mTORC1 signaling in reconstituted Tsc2 null cells, and this mutant also inhibits adipogenesis. Finally, renal angiomyolipomas from patients with tuberous sclerosis complex contain both adipose and smooth muscle-like components with activated mTORC1 signaling and elevated PPAR gamma expression. Conclusions/Significance: This study demonstrates that activation of mTORC1 signaling is a critical step in adipocyte differentiation and identifies TSC2 as a primary target of Akt driving this process. Therefore, the TSC1-TSC2 complex regulates the differentiation of mesenchymal cell lineages, at least in part, through its control of mTORC1 activity and PPAR gamma expression.			Zhang, HH (corresponding author), Harvard Univ, Sch Publ Hlth, Dept Genet & Complex Dis, 665 Huntington Ave, Boston, MA 02115 USA.	bmanning@hsph.harvard.edu	Huang, Jingxiang/B-4515-2008; Manning, Brendan/ABD-6528-2021	Manning, Brendan/0000-0003-3895-5956; Qu, Liang-Hu/0000-0003-3657-2863; Zhou, Hui/0000-0001-9157-3792; Zhang, Hua/0000-0001-9731-2737	NATIONAL CANCER INSTITUTE [R01CA122617, P01CA120964] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA122617-04, R01 CA122617, CA120964, CA122617, P01 CA120964] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Armoni M, 2006, J BIOL CHEM, V281, P19881, DOI 10.1074/jbc.M600320200; Baudry A, 2006, J CELL SCI, V119, P889, DOI 10.1242/jcs.02792; Bell A, 2000, OBES RES, V8, P249, DOI 10.1038/oby.2000.29; Berg CE, 2002, BIOCHEM BIOPH RES CO, V293, P1021, DOI 10.1016/S0006-291X(02)00333-9; Bhaskar PT, 2007, DEV CELL, V12, P487, DOI 10.1016/j.devcel.2007.03.020; Brady MJ, 1999, J BIOL CHEM, V274, P27497, DOI 10.1074/jbc.274.39.27497; Brugarolas J, 2004, GENE DEV, V18, P2893, DOI 10.1101/gad.1256804; Brugarolas JB, 2003, CANCER CELL, V4, P147, DOI 10.1016/S1535-6108(03)00187-9; Cai SL, 2006, J CELL BIOL, V173, P279, DOI 10.1083/jcb.200507119; Carsillo T, 2000, P NATL ACAD SCI USA, V97, P6085, DOI 10.1073/pnas.97.11.6085; Cho HJ, 2004, BIOCHEM BIOPH RES CO, V321, P942, DOI 10.1016/j.bbrc.2004.07.050; Crino PB, 2006, NEW ENGL J MED, V355, P1345, DOI 10.1056/NEJMra055323; El-Chaar D, 2004, INT J OBESITY, V28, P191, DOI 10.1038/sj.ijo.0802554; Fasshauer M, 2001, MOL CELL BIOL, V21, P319, DOI 10.1128/MCB.21.1.319-329.2001; Fonseca BD, 2007, J BIOL CHEM, V282, P24514, DOI 10.1074/jbc.M704406200; Gagnon A, 2001, J CELL PHYSIOL, V189, P14, DOI 10.1002/jcp.1132; Garami A, 2003, MOL CELL, V11, P1457, DOI 10.1016/S1097-2765(03)00220-X; Garofalo RS, 2003, J CLIN INVEST, V112, P197, DOI 10.1172/JCI200316885; GARVEY WT, 1991, J CLIN INVEST, V87, P1072, DOI 10.1172/JCI115068; GARVEY WT, 1989, SCIENCE, V245, P60, DOI 10.1126/science.2662408; Hahn-Windgassen A, 2005, J BIOL CHEM, V280, P32081, DOI 10.1074/jbc.M502876200; Harrington LS, 2005, TRENDS BIOCHEM SCI, V30, P35, DOI 10.1016/j.tibs.2004.11.003; Harrington LS, 2004, J CELL BIOL, V166, P213, DOI 10.1083/jcb.200403069; Haruta T, 2000, MOL ENDOCRINOL, V14, P783, DOI 10.1210/me.14.6.783; HUANG J, 2008, MOL CELL BIOL, V28; Huang JX, 2009, BIOCHEM SOC T, V37, P217, DOI 10.1042/BST0370217; Huang SH, 2007, CELL METAB, V5, P237, DOI 10.1016/j.cmet.2007.03.006; Inoki K, 2002, NAT CELL BIOL, V4, P648, DOI 10.1038/ncb839; Inoki K, 2003, GENE DEV, V17, P1829, DOI 10.1101/gad.1110003; Jaeschke A, 2002, J CELL BIOL, V159, P217, DOI 10.1083/jcb.jcb.200206108; Karbowniczek M, 2003, AM J PATHOL, V162, P491, DOI 10.1016/S0002-9440(10)63843-6; Kim JE, 2004, DIABETES, V53, P2748, DOI 10.2337/diabetes.53.11.2748; Kohn AD, 1996, J BIOL CHEM, V271, P31372, DOI 10.1074/jbc.271.49.31372; Kovacina KS, 2003, J BIOL CHEM, V278, P10189, DOI 10.1074/jbc.M210837200; Kwiatkowski DJ, 2002, HUM MOL GENET, V11, P525, DOI 10.1093/hmg/11.5.525; Le Bacquer O, 2007, J CLIN INVEST, V117, P387, DOI 10.1172/JCI29528; Li JP, 1999, J BIOL CHEM, V274, P9351, DOI 10.1074/jbc.274.14.9351; Li XH, 2005, ACTA PHARMACOL SIN, V26, P1081, DOI 10.1111/j.1745-7254.2005.00161.x; Manning BD, 2005, GENE DEV, V19, P1773, DOI 10.1101/gad.1314605; Manning BD, 2002, MOL CELL, V10, P151, DOI 10.1016/S1097-2765(02)00568-3; Manning BD, 2007, CELL, V129, P1261, DOI 10.1016/j.cell.2007.06.009; Miki H, 2001, MOL CELL BIOL, V21, P2521, DOI 10.1128/MCB.21.7.2521-2532.2001; Nakae J, 2003, DEV CELL, V4, P119, DOI 10.1016/S1534-5807(02)00401-X; Nakamura N, 2000, MOL CELL BIOL, V20, P8969, DOI 10.1128/MCB.20.23.8969-8982.2000; Oshiro N, 2007, J BIOL CHEM, V282, P20329, DOI 10.1074/jbc.M702636200; PEDERSEN O, 1992, J CLIN INVEST, V89, P1964, DOI 10.1172/JCI115804; Pederson T, 2000, BIOCHEM BIOPH RES CO, V276, P162, DOI 10.1006/bbrc.2000.3429; Peng XD, 2003, GENE DEV, V17, P1352, DOI 10.1101/gad.1089403; Polak P, 2008, CELL METAB, V8, P399, DOI 10.1016/j.cmet.2008.09.003; Potter CJ, 2002, NAT CELL BIOL, V4, P658, DOI 10.1038/ncb840; Rosen ED, 2002, GENE DEV, V16, P22, DOI 10.1101/gad.948702; Rosen ED, 2001, J BIOL CHEM, V276, P37731, DOI 10.1074/jbc.R100034200; Rosen ED, 2006, NAT REV MOL CELL BIO, V7, P885, DOI 10.1038/nrm2066; Rui LY, 2001, J BIOL CHEM, V276, P40362, DOI 10.1074/jbc.M105332200; Sancak Y, 2007, MOL CELL, V25, P903, DOI 10.1016/j.molcel.2007.03.003; Sarbassov DD, 2006, MOL CELL, V22, P159, DOI 10.1016/j.molcel.2006.03.029; Sarbassov DD, 2005, SCIENCE, V307, P1098, DOI 10.1126/science.1106148; Saucedo LJ, 2003, NAT CELL BIOL, V5, P566, DOI 10.1038/ncb996; Shah OJ, 2006, MOL CELL BIOL, V26, P6425, DOI 10.1128/MCB.01254-05; Shah OJ, 2004, CURR BIOL, V14, P1650, DOI 10.1016/j.cub.2004.08.026; Shepherd PR, 1999, NEW ENGL J MED, V341, P248, DOI 10.1056/NEJM199907223410406; SMITH PJ, 1988, J BIOL CHEM, V263, P9402; Stocker H, 2003, NAT CELL BIOL, V5, P559, DOI 10.1038/ncb995; Takano T, 2001, MOL CELL BIOL, V21, P5050, DOI 10.1128/MCB.21.15.5050-5062.2001; Tee AR, 2003, CURR BIOL, V13, P1259, DOI 10.1016/S0960-9822(03)00506-2; Thedieck K, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0001217; Um SH, 2004, NATURE, V431, P200, DOI 10.1038/nature02866; Vander Haar E, 2007, NAT CELL BIOL, V9, P316, DOI 10.1038/ncb1547; Wang L, 2008, J BIOL CHEM, V283, P15619, DOI 10.1074/jbc.M800723200; Wang LF, 2007, J BIOL CHEM, V282, P20036, DOI 10.1074/jbc.M702376200; [王志刚 WANG Zhigang], 2008, [东北师大学报. 自然科学版, Journal of Northeast Normal University], V40, P1; Wullschleger S, 2006, CELL, V124, P471, DOI 10.1016/j.cell.2006.01.016; Xu JF, 2004, J BIOL CHEM, V279, P35914, DOI 10.1074/jbc.M402297200; YEH WC, 1995, P NATL ACAD SCI USA, V92, P11086, DOI 10.1073/pnas.92.24.11086; Yun SJ, 2008, BIOCHEM BIOPH RES CO, V371, P138, DOI 10.1016/j.bbrc.2008.04.029; Zhang HB, 2003, J CLIN INVEST, V112, P1223, DOI 10.1172/JCI200317222; Zhang HH, 2006, MOL CELL, V24, P185, DOI 10.1016/j.molcel.2006.09.019; Zhang Y, 2003, NAT CELL BIOL, V5, P578, DOI 10.1038/ncb999	78	286	295	1	33	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUL 10	2009	4	7							e6189	10.1371/journal.pone.0006189	http://dx.doi.org/10.1371/journal.pone.0006189			14	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	471DN	19915715	Green Published, Green Submitted, gold			2022-12-25	WOS:000268035300005
J	Chen, GJ; Han, GC; Feng, JN; Wang, JA; Wang, RX; Xu, RN; Shen, BF; Qian, JH; Li, Y				Chen, Guojiang; Han, Gencheng; Feng, Jiannan; Wang, Jianan; Wang, Renxi; Xu, Ruonan; Shen, Beifen; Qian, Jiahua; Li, Yan			Glutamic Acid Decarboxylase-Derived Epitopes with Specific Domains Expand CD4(+)CD25(+) Regulatory T Cells	PLOS ONE			English	Article								Background: CD4(+)CD25(+) regulatory T cell (Treg)-based immunotherapy is considered a promising regimen for controlling the progression of autoimmune diabetes. In this study, we tested the hypothesis that the therapeutic effects of Tregs in response to the antigenic epitope stimulation depend on the structural properties of the epitopes used. Methodology/Principal Findings: Splenic lymphocytes from nonobese diabetic (NOD) mice were stimulated with different glutamic acid decarboxylase (GAD)-derived epitopes for 7-10 days and the frequency and function of Tregs was analyzed. We found that, although all expanded Tregs showed suppressive functions in vitro, only p524 (GAD524-538)-expanded CD4(+)CD25(+) T cells inhibited diabetes development in the co-transfer models, while p509 (GAD509-528)- or p530 (GAD530-543)-expanded CD4(+)CD25(+) T cells had no such effects. Using computer-guided molecular modeling and docking methods, the differences in structural characteristics of these epitopes and the interaction mode (including binding energy and identified domains in the epitopes) between the above-mentioned epitopes and MHC class II I-A(g7) were analyzed. The theoretical results showed that the epitope p524, which induced protective Tregs, possessed negative surface-electrostatic potential and bound two chains of MHC class II I-A(g7), while the epitopes p509 and p530 which had no such ability exhibited positive surface-electrostatic potential and bound one chain of I-A(g7). Furthermore, p524 bound to I-A(g7) more stably than p509 and p530. Of importance, we hypothesized and subsequently confirmed experimentally that the epitope (GAD570-585, p570), which displayed similar characteristics to p524, was a protective epitope by showing that p570-expanded CD4(+)CD25(+) T cells suppressed the onset of diabetes in NOD mice. Conclusions/Significance: These data suggest that molecular modeling-based structural analysis of epitopes may be an instrumental tool for prediction of protective epitopes to expand functional Tregs.			Chen, GJ (corresponding author), Chinese Acad Med Sci, Inst Basic Med Sci, Dept Mol Immunol, Beijing 100730, Peoples R China.	liyan62033@yahoo.com.cn	Wang, Renxi/AAM-1326-2020	Wang, Renxi/0000-0003-4130-3334; Han, George/0000-0003-3302-5098; Friedman, Adam/0000-0001-8925-1620				Arneson LS, 2000, J IMMUNOL, V165, P2059, DOI 10.4049/jimmunol.165.4.2059; ATKINSON MA, 1992, LANCET, V339, P458, DOI 10.1016/0140-6736(92)91061-C; Barthlott T, 2003, J EXP MED, V197, P451, DOI 10.1084/jem.20021387; Bayer AL, 2007, J IMMUNOL, V178, P4062, DOI 10.4049/jimmunol.178.7.4062; Bommireddy R, 2007, TRENDS MOL MED, V13, P492, DOI 10.1016/j.molmed.2007.08.005; Chen C, 2003, J IMMUNOL, V171, P733, DOI 10.4049/jimmunol.171.2.733; Chen ZB, 2005, P NATL ACAD SCI USA, V102, P14735, DOI 10.1073/pnas.0507014102; Corper AL, 2000, SCIENCE, V288, P505, DOI 10.1126/science.288.5465.505; Dai YD, 2008, EUR J IMMUNOL, V38, P968, DOI 10.1002/eji.200737703; Deng L, 2007, NAT IMMUNOL, V8, P398, DOI 10.1038/ni1447; Di Lorenzo TP, 2007, CLIN EXP IMMUNOL, V148, P1, DOI 10.1111/j.1365-2249.2006.03244.x; Ellis TM, 1996, NAT MED, V2, P148, DOI 10.1038/nm0296-148; Fanelli F, 1998, METHODS, V14, P302, DOI 10.1006/meth.1998.0586; Fisson S, 2006, EUR J IMMUNOL, V36, P817, DOI 10.1002/eji.200535445; Fontenot JD, 2017, J IMMUNOL, V198, P986, DOI 10.1038/ni904; Garnier J, 1996, METHOD ENZYMOL, V266, P540; Geng LP, 1998, P NATL ACAD SCI USA, V95, P10055, DOI 10.1073/pnas.95.17.10055; Han GC, 2005, J IMMUNOL, V174, P4516, DOI 10.4049/jimmunol.174.8.4516; Herman AE, 2004, J EXP MED, V199, P1479, DOI 10.1084/jem.20040179; HOPP TP, 1981, P NATL ACAD SCI-BIOL, V78, P3824, DOI 10.1073/pnas.78.6.3824; Hori S, 2003, SCIENCE, V299, P1057, DOI 10.1126/science.1079490; Huang CT, 2004, IMMUNITY, V21, P503, DOI 10.1016/j.immuni.2004.08.010; JANIN J, 1979, NATURE, V277, P491, DOI 10.1038/277491a0; KAUFMAN DL, 1993, NATURE, V366, P69, DOI 10.1038/366069a0; Kukreja A, 2002, J CLIN INVEST, V109, P131, DOI 10.1172/JCI13605; Masteller EL, 2005, J IMMUNOL, V175, P3053, DOI 10.4049/jimmunol.175.5.3053; Nicholson MJ, 2005, IMMUNITY, V23, P351, DOI 10.1016/j.immuni.2005.09.009; Ochoa-Reparaz J, 2007, J IMMUNOL, V178, P1791, DOI 10.4049/jimmunol.178.3.1791; Ortiz AR, 1999, PROTEINS, P177; Pop SM, 2005, J EXP MED, V201, P1333, DOI 10.1084/jem.20042398; Quinn A, 2001, J IMMUNOL, V166, P2982, DOI 10.4049/jimmunol.166.5.2982; Roncarolo MG, 2006, IMMUNOL REV, V212, P28; Sakaguchi S, 2004, ANNU REV IMMUNOL, V22, P531, DOI 10.1146/annurev.immunol.21.120601.141122; Salomon B, 2001, ANNU REV IMMUNOL, V19, P225, DOI 10.1146/annurev.immunol.19.1.225; Severe S, 2007, MOL IMMUNOL, V44, P2950, DOI 10.1016/j.molimm.2007.01.008; Shimizu J, 2002, NAT IMMUNOL, V3, P135, DOI 10.1038/ni759; Song L, 2004, GENE THER, V11, P1487, DOI 10.1038/sj.gt.3302327; Stockinger B, 2001, NAT IMMUNOL, V2, P757, DOI 10.1038/ni0901-757; Tang QZ, 2004, J EXP MED, V199, P1455, DOI 10.1084/jem.20040139; Tarbell KV, 2007, J EXP MED, V204, P191, DOI 10.1084/jem.20061631; Tarbell KV, 2004, J EXP MED, V199, P1467, DOI 10.1084/jem.20040180; Tarbell KV, 2002, J EXP MED, V196, P481, DOI 10.1084/jem.20011845; Tian JD, 1996, J EXP MED, V183, P1561, DOI 10.1084/jem.183.4.1561; Tisch R, 1998, DIABETES, V47, P894, DOI 10.2337/diabetes.47.6.894; TISCH R, 1993, NATURE, V366, P72, DOI 10.1038/366072a0; WELLING GW, 1985, FEBS LETT, V188, P215, DOI 10.1016/0014-5793(85)80374-4; Yamanouchi J, 2007, NAT GENET, V39, P329, DOI 10.1038/ng1958; Yoon JW, 1999, SCIENCE, V284, P1183, DOI 10.1126/science.284.5417.1183; Zekzer D, 1998, J CLIN INVEST, V101, P68, DOI 10.1172/JCI119878; Zhao YL, 2008, BIOCHEM BIOPH RES CO, V372, P346, DOI 10.1016/j.bbrc.2008.05.046; Zheng Y, 2007, NAT IMMUNOL, V8, P457, DOI 10.1038/ni1455	51	31	33	0	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA	1932-6203			PLOS ONE	PLoS One	SEP 13	2009	4	9							e7034	10.1371/journal.pone.0007034	http://dx.doi.org/10.1371/journal.pone.0007034			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	494FM	19759824	Green Published, Green Submitted, gold			2022-12-25	WOS:000269796100001
